<SEC-DOCUMENT>0001193125-23-302158.txt : 20231222
<SEC-HEADER>0001193125-23-302158.hdr.sgml : 20231222
<ACCEPTANCE-DATETIME>20231222163210
ACCESSION NUMBER:		0001193125-23-302158
CONFORMED SUBMISSION TYPE:	S-1
PUBLIC DOCUMENT COUNT:		165
FILED AS OF DATE:		20231222
DATE AS OF CHANGE:		20231222

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Spyre Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001636282
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				464312787
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-1
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-276251
		FILM NUMBER:		231510307

	BUSINESS ADDRESS:	
		STREET 1:		221 CRESCENT STREET
		STREET 2:		BUILDING 23, SUITE 105
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02453
		BUSINESS PHONE:		6176515940

	MAIL ADDRESS:	
		STREET 1:		221 CRESCENT STREET
		STREET 2:		BUILDING 23, SUITE 105
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02453

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Aeglea BioTherapeutics, Inc.
		DATE OF NAME CHANGE:	20150311
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1
<SEQUENCE>1
<FILENAME>d518298ds1.htm
<DESCRIPTION>S-1
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:agle="http://www.spy.com/20230930" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2023" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>S-1</title>
<meta content="text/html; charset=UTF-8" http-equiv="Content-Type"/>
</head>
<body style="max-width: auto"><div style='display: none'><ix:header><ix:hidden><ix:nonNumeric name="dei:EntityAddressStateOrProvince" id="hidden95764034" contextRef="P01_01_2023To09_30_2023">MA</ix:nonNumeric><ix:nonNumeric name="dei:EntityAddressStateOrProvince" id="hidden95764035" contextRef="P01_01_2023To09_30_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">MA</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="P01_01_2023To09_30_2023">0001636282</ix:nonNumeric><ix:nonNumeric name="dei:AmendmentFlag" contextRef="P01_01_2023To09_30_2023">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="agle-20230930.xsd" /></ix:references><ix:resources><xbrli:context id="PAsOn12_31_2022" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2023To09_30_2023" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-07-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To09_30_2022" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To09_30_2023" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2023To04_30_2023" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-04-01</xbrli:startDate> <xbrli:endDate>2023-04-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2023To06_30_2023" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-04-01</xbrli:startDate> <xbrli:endDate>2023-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2023" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P06_22_2023To06_22_2023" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-06-22</xbrli:startDate> <xbrli:endDate>2023-06-22</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_22_2023" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-06-22</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn04_30_2019" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-04-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To04_30_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2020-04-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_01_2019To02_28_2019" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-02-01</xbrli:startDate> <xbrli:endDate>2019-02-28</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2019To04_30_2019" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-04-01</xbrli:startDate> <xbrli:endDate>2019-04-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn04_30_2023" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-04-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2023" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn08_07_2023" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-08-07</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_31_2022" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-05-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2022To06_30_2022" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-04-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P05_01_2022To05_31_2022" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-05-01</xbrli:startDate> <xbrli:endDate>2022-05-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_31_2017" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2017-01-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P09_08_2023To09_08_2023" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-09-08</xbrli:startDate> <xbrli:endDate>2023-09-08</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_01_2019To05_31_2022" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-02-01</xbrli:startDate> <xbrli:endDate>2022-05-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_MinimumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:ComputerEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_PurchasedSoftwareMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >agle:PurchasedSoftwareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_LaboratoryEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >agle:LaboratoryEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_USGovernmentAgenciesDebtSecuritiesMemberusgaapFinancialInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_ReimbursableCostsUnderParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >us-gaap:RelatedPartyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >agle:ReimbursableCostsUnderParagonAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >us-gaap:RelatedPartyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_ParapyreOptionObligationMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >us-gaap:RelatedPartyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >agle:ParapyreOptionObligationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CommercialPaperMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:CommercialPaperMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CommercialPaperMemberusgaapFairValueByAssetClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:CommercialPaperMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapCashAndCashEquivalentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis" >us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapCashAndCashEquivalentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis" >us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapCashAndCashEquivalentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis" >us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapCashAndCashEquivalentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis" >us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CommercialPaperMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:CommercialPaperMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CommercialPaperMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:CommercialPaperMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CorporateBondSecuritiesMemberusgaapInvestmentTypeAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CorporateBondSecuritiesMemberusgaapInvestmentTypeAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CorporateBondSecuritiesMemberusgaapInvestmentTypeAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CorporateBondSecuritiesMemberusgaapInvestmentTypeAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis" >us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis" >us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis" >us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis" >us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CommercialPaperMemberusgaapFinancialInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >us-gaap:CommercialPaperMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFinancialInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_MoneyMarketFundsMemberusgaapFinancialInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CorporateBondSecuritiesMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CommercialPaperMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:CommercialPaperMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >agle:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FebruaryTwoThousandNinteenMemberusgaapAwardDateAxis_WarrantMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis" >agle:FebruaryTwoThousandNinteenMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:WarrantMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AprilTwoThousandTwentyMemberusgaapAwardDateAxis_WarrantMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:WarrantMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis" >agle:AprilTwoThousandTwentyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_MayTwoThousandTwentyTwoMemberusgaapAwardDateAxis_WarrantMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:WarrantMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis" >agle:MayTwoThousandTwentyTwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_WarrantMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:WarrantMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" >us-gaap:DomesticCountryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" >us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_USBankingInstitutionMemberusgaapFinancialInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >agle:USBankingInstitutionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >agle:TwoThousandAndSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >agle:TwoThousandAndSixteenEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_TwoThousandAndEighteenEquityInducementPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >agle:TwoThousandAndEighteenEquityInducementPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >agle:ImmedicaPharmaABMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_EmployeesAndNonEmployeesMembersrtTitleOfIndividualAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >agle:EmployeesAndNonEmployeesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_LicenseAgreementsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_UniversityOfTexasAtAustinMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >agle:UniversityOfTexasAtAustinMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" >agle:LicenseAgreementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2023_FebruaryEightTwoThousandNinteenMemberusgaapAwardDateAxis_WarrantMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:WarrantMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis" >agle:FebruaryEightTwoThousandNinteenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2023_AprilThirtyTwoThousandTwentyMemberusgaapAwardDateAxis_WarrantMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:WarrantMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis" >agle:AprilThirtyTwoThousandTwentyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2023_MayTwentyTwoThousandTwentyTwoMemberusgaapAwardDateAxis_WarrantMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:WarrantMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis" >agle:MayTwentyTwoThousandTwentyTwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2023_USGovernmentAgenciesDebtSecuritiesMemberusgaapFinancialInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2023_MaximumMembersrtRangeAxis_OwnershipInterestMemberusgaapRelatedPartyTransactionAxis_ParagonTherapeuticsIncMembersrtOwnershipAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:OwnershipAxis" >agle:ParagonTherapeuticsIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >agle:OwnershipInterestMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >us-gaap:RelatedPartyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2023_FairmountFundsManagementLlcMembersrtOwnershipAxis_MinimumMembersrtRangeAxis_OwnershipInterestMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >agle:OwnershipInterestMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >us-gaap:RelatedPartyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:OwnershipAxis" >agle:FairmountFundsManagementLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2023_ReimbursableCostsUnderParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >us-gaap:RelatedPartyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >agle:ReimbursableCostsUnderParagonAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2023_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >us-gaap:RelatedPartyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2023_ParapyreOptionObligationMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >us-gaap:RelatedPartyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >agle:ParapyreOptionObligationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2023_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis" >us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis" >us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2023_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis" >us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2023_CommercialPaperMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:CommercialPaperMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2023_CommercialPaperMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:CommercialPaperMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2023_CorporateBondSecuritiesMemberusgaapInvestmentTypeAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2023_CorporateBondSecuritiesMemberusgaapInvestmentTypeAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2023_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2023_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2023_CorporateBondSecuritiesMemberusgaapInvestmentTypeAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2023_CorporateBondSecuritiesMemberusgaapInvestmentTypeAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis" >us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2023_CommercialPaperMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:CommercialPaperMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2023_CommercialPaperMemberusgaapFairValueByAssetClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:CommercialPaperMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_ParapyreOptionObligationMemberusgaapFairValueByLiabilityClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis" >agle:ParapyreOptionObligationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2023_ContingentValueRightLiabilityMemberusgaapFairValueByLiabilityClassAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis" >agle:ContingentValueRightLiabilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2023_ContingentValueRightLiabilityMemberusgaapFairValueByLiabilityClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis" >agle:ContingentValueRightLiabilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2023_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_ParapyreOptionObligationMemberusgaapFairValueByLiabilityClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis" >agle:ParapyreOptionObligationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_ParapyreOptionObligationMemberusgaapFairValueByLiabilityClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis" >agle:ParapyreOptionObligationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2023_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_ParapyreOptionObligationMemberusgaapFairValueByLiabilityClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis" >agle:ParapyreOptionObligationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2023_ContingentValueRightLiabilityMemberusgaapFairValueByLiabilityClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis" >agle:ContingentValueRightLiabilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2023_ContingentValueRightLiabilityMemberusgaapFairValueByLiabilityClassAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis" >agle:ContingentValueRightLiabilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2023_ContingentValueRightLiabilityMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputProabilityOfSuccessMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >agle:ContingentValueRightLiabilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >agle:MeasurementInputProabilityOfSuccessMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2023_ContingentValueRightLiabilityMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MaximumMembersrtRangeAxis_MeasurementInputProabilityOfSuccessMemberusgaapMeasurementInputTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >agle:ContingentValueRightLiabilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >agle:MeasurementInputProabilityOfSuccessMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2023_ContingentValueRightLiabilityMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >agle:ContingentValueRightLiabilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2023_ContingentValueRightLiabilityMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MaximumMembersrtRangeAxis_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >agle:ContingentValueRightLiabilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2023_MoneyMarketFundsMemberusgaapFinancialInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2023_CommercialPaperMemberusgaapFinancialInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >us-gaap:CommercialPaperMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2023_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2023_CorporateBondSecuritiesMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2023_CommercialPaperMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:CommercialPaperMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >agle:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2023_AppointOfBoardMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >agle:AppointOfBoardMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >us-gaap:RelatedPartyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2023_WarrantMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:WarrantMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2023_MaximumMembersrtRangeAxis_USBankingInstitutionMemberusgaapFinancialInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >agle:USBankingInstitutionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2023_USBankingInstitutionMemberusgaapFinancialInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >agle:USBankingInstitutionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2023_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2023_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFinancialInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2023_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >agle:TwoThousandAndSixteenEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2023_ParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >agle:ParagonAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >us-gaap:RelatedPartyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2023_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >agle:ImmedicaPharmaABMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2023_ParapyreOptionObligationMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >agle:ParapyreOptionObligationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_SeriesAConvertiblePreferredStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >agle:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >agle:TwoThousandAndSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >agle:TwoThousandAndSixteenEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_ReimbursableCostsUnderParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >us-gaap:RelatedPartyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >agle:ReimbursableCostsUnderParagonAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >us-gaap:RelatedPartyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_ForwardContractsMemberusgaapDerivativeInstrumentRiskAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis" >us-gaap:ForwardContractsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_ContingentValueRightLiabilityMemberusgaapDerivativeInstrumentRiskAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis" >agle:ContingentValueRightLiabilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_USGovernmentAgenciesDebtSecuritiesMemberusgaapFinancialInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_PeaceTrialAndBLAPackageMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" >agle:PeaceTrialAndBLAPackageMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >agle:ImmedicaPharmaABMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_ParapyreOptionObligationMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >agle:ParapyreOptionObligationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To09_30_2022_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To09_30_2022_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To09_30_2022_SeriesAConvertiblePreferredStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >agle:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To09_30_2022_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To09_30_2022_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To09_30_2022_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >agle:TwoThousandAndSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To09_30_2022_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >agle:TwoThousandAndSixteenEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To09_30_2022_ReimbursableCostsUnderParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >us-gaap:RelatedPartyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >agle:ReimbursableCostsUnderParagonAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To09_30_2022_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >us-gaap:RelatedPartyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To09_30_2022_ForwardContractsMemberusgaapDerivativeInstrumentRiskAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis" >us-gaap:ForwardContractsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To09_30_2022_USGovernmentAgenciesDebtSecuritiesMemberusgaapFinancialInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To09_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To09_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To09_30_2022_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_PeaceTrialAndBLAPackageMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" >agle:PeaceTrialAndBLAPackageMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >agle:ImmedicaPharmaABMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To09_30_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To09_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To09_30_2022_ParapyreOptionObligationMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >agle:ParapyreOptionObligationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To09_30_2023_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To09_30_2023_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To09_30_2023_SeriesAConvertiblePreferredStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >agle:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To09_30_2023_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To09_30_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To09_30_2023_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >agle:TwoThousandAndSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To09_30_2023_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >agle:TwoThousandAndSixteenEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To09_30_2023_TwoThousandAndEighteenEquityInducementPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >agle:TwoThousandAndEighteenEquityInducementPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To09_30_2023_ReimbursableCostsUnderParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >us-gaap:RelatedPartyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >agle:ReimbursableCostsUnderParagonAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To09_30_2023_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >us-gaap:RelatedPartyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To09_30_2023_ForwardContractsMemberusgaapDerivativeInstrumentRiskAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis" >us-gaap:ForwardContractsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To09_30_2023_ContingentValueRightLiabilityMemberusgaapDerivativeInstrumentRiskAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis" >agle:ContingentValueRightLiabilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To09_30_2023_USGovernmentAgenciesDebtSecuritiesMemberusgaapFinancialInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To09_30_2023_SeveranceLiabilityMemberusgaapRestructuringCostAndReserveAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis" >agle:SeveranceLiabilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To09_30_2023_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_StockCompensationAndResearchAndDevelopmentExpenseMemberusgaapRelatedPartyTransactionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >us-gaap:RelatedPartyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >agle:StockCompensationAndResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To09_30_2023_MilestonePaymentsMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >agle:MilestonePaymentsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >us-gaap:RelatedPartyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To09_30_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis" >dei:BusinessContactMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To09_30_2023_ParapyreOptionObligationMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >agle:ParapyreOptionObligationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To09_30_2023_ParagonTherapeuticsIncMembersrtCounterpartyNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis" >agle:ParagonTherapeuticsIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To09_30_2023_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_PeacePhase3TrialAndDrugSupplyMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" >agle:PeacePhase3TrialAndDrugSupplyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >agle:ImmedicaPharmaABMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To09_30_2023_ParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >agle:ParagonAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >us-gaap:RelatedPartyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To09_30_2023_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >agle:TwoThousandAndSixteenEquityIncentivePlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2023To09_30_2023_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-07-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2023To09_30_2023_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-07-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2023To09_30_2023_SeriesAConvertiblePreferredStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >agle:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-07-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2023To09_30_2023_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-07-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2023To09_30_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-07-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2023To09_30_2023_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >agle:TwoThousandAndSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-07-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2023To09_30_2023_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >agle:TwoThousandAndSixteenEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-07-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2023To09_30_2023_ReimbursableCostsUnderParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >us-gaap:RelatedPartyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >agle:ReimbursableCostsUnderParagonAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-07-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2023To09_30_2023_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >us-gaap:RelatedPartyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-07-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2023To09_30_2023_ForwardContractsMemberusgaapDerivativeInstrumentRiskAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis" >us-gaap:ForwardContractsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-07-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2023To09_30_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >agle:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-07-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2023To09_30_2023_USGovernmentAgenciesDebtSecuritiesMemberusgaapFinancialInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-07-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2023To09_30_2023_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_StockCompensationAndResearchAndDevelopmentExpenseMemberusgaapRelatedPartyTransactionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >us-gaap:RelatedPartyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >agle:StockCompensationAndResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-07-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2023To09_30_2023_MilestonePaymentsMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >us-gaap:RelatedPartyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >agle:MilestonePaymentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-07-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2023To09_30_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-07-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2023To09_30_2023_ParapyreOptionObligationMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >agle:ParapyreOptionObligationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-07-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2023To09_30_2023_ParagonTherapeuticsIncMembersrtCounterpartyNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis" >agle:ParagonTherapeuticsIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-07-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2023To09_30_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-07-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2023To09_30_2023_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_PeacePhase3TrialAndDrugSupplyMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" >agle:PeacePhase3TrialAndDrugSupplyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >agle:ImmedicaPharmaABMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-07-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2023To09_30_2023_ContingentValueRightLiabilityMemberusgaapFairValueByLiabilityClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis" >agle:ContingentValueRightLiabilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-07-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2023To09_30_2023_ParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >agle:ParagonAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >us-gaap:RelatedPartyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-07-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2023To09_30_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-07-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2023To09_30_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-07-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2023To06_30_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_RestructuringActivitiesMemberusgaapRestructuringCostAndReserveAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis" >agle:RestructuringActivitiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-04-01</xbrli:startDate> <xbrli:endDate>2023-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2023To06_30_2023_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_RestructuringActivitiesMemberusgaapRestructuringCostAndReserveAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis" >agle:RestructuringActivitiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-04-01</xbrli:startDate> <xbrli:endDate>2023-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2023To06_30_2023_RestructuringActivitiesMemberusgaapRestructuringCostAndReserveAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis" >agle:RestructuringActivitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-04-01</xbrli:startDate> <xbrli:endDate>2023-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2023To06_30_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >agle:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-04-01</xbrli:startDate> <xbrli:endDate>2023-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2023To06_30_2023_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-04-01</xbrli:startDate> <xbrli:endDate>2023-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2023To06_30_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-04-01</xbrli:startDate> <xbrli:endDate>2023-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2023To06_30_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-04-01</xbrli:startDate> <xbrli:endDate>2023-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2023To06_30_2023_ContingentValueRightLiabilityMemberusgaapFairValueByLiabilityClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis" >agle:ContingentValueRightLiabilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-04-01</xbrli:startDate> <xbrli:endDate>2023-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2023To06_30_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-04-01</xbrli:startDate> <xbrli:endDate>2023-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2023To06_30_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-04-01</xbrli:startDate> <xbrli:endDate>2023-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2023To06_30_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-04-01</xbrli:startDate> <xbrli:endDate>2023-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:ComputerEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_PurchasedSoftwareMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >agle:PurchasedSoftwareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_LaboratoryEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >agle:LaboratoryEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_USGovernmentAgenciesDebtSecuritiesMemberusgaapFinancialInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CommercialPaperMemberusgaapFairValueByAssetClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:CommercialPaperMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CorporateBondSecuritiesMemberusgaapInvestmentTypeAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CorporateBondSecuritiesMemberusgaapInvestmentTypeAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis" >us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis" >us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CommercialPaperMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:CommercialPaperMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_MoneyMarketFundsMemberusgaapFinancialInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CommercialPaperMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:CommercialPaperMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CorporateBondSecuritiesMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" >us-gaap:DomesticCountryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" >us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CommercialPaperMemberusgaapFinancialInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >us-gaap:CommercialPaperMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_EmployeesAndNonEmployeesMembersrtTitleOfIndividualAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >agle:EmployeesAndNonEmployeesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >agle:ImmedicaPharmaABMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2022To06_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-04-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2022To06_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-04-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2022To06_30_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-04-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2022To06_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-04-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P06_22_2023To06_22_2023_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis" >agle:SpyreTherapeuticsIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-06-22</xbrli:startDate> <xbrli:endDate>2023-06-22</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P06_22_2023To06_22_2023_CommonStockMemberusgaapEquityInterestIssuedOrIssuableByTypeAxis_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis" >agle:SpyreTherapeuticsIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-06-22</xbrli:startDate> <xbrli:endDate>2023-06-22</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P06_22_2023To06_22_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >agle:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis" >agle:SpyreTherapeuticsIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-06-22</xbrli:startDate> <xbrli:endDate>2023-06-22</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P06_22_2023To06_22_2023_ParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >us-gaap:RelatedPartyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >agle:ParagonAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-06-22</xbrli:startDate> <xbrli:endDate>2023-06-22</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P06_22_2023To06_22_2023_AssetAcquisitionMemberusgaapAssetAcquisitionAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >agle:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis" >agle:AssetAcquisitionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-06-22</xbrli:startDate> <xbrli:endDate>2023-06-22</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P06_22_2023To06_22_2023_Spyre2023EquityIncentivePlanMemberusgaapPlanNameAxis_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >agle:Spyre2023EquityIncentivePlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis" >agle:SpyreTherapeuticsIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-06-22</xbrli:startDate> <xbrli:endDate>2023-06-22</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P06_22_2023To06_22_2023_MinimumMembersrtRangeAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >agle:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-06-22</xbrli:startDate> <xbrli:endDate>2023-06-22</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P06_22_2023To06_22_2023_MaximumMembersrtRangeAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >agle:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-06-22</xbrli:startDate> <xbrli:endDate>2023-06-22</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P06_22_2023To06_22_2023_AssetAcquisitionMemberusgaapAssetAcquisitionAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis" >agle:AssetAcquisitionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-06-22</xbrli:startDate> <xbrli:endDate>2023-06-22</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P06_22_2023To06_22_2023_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >us-gaap:RelatedPartyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-06-22</xbrli:startDate> <xbrli:endDate>2023-06-22</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P06_22_2023To06_22_2023_AssetAcquisitionMemberusgaapAssetAcquisitionAxis_Spyre2023EquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >agle:Spyre2023EquityIncentivePlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis" >agle:AssetAcquisitionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-06-22</xbrli:startDate> <xbrli:endDate>2023-06-22</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P06_22_2023To06_22_2023_ParapyreOptionObligationMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >agle:ParapyreOptionObligationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-06-22</xbrli:startDate> <xbrli:endDate>2023-06-22</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P06_22_2023To06_22_2023_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >agle:TwoThousandAndSixteenEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-06-22</xbrli:startDate> <xbrli:endDate>2023-06-22</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_22_2023_MaximumMembersrtRangeAxis_OwnershipInterestMemberusgaapRelatedPartyTransactionAxis_ParagonAndParapyreHoldingLlcMembersrtOwnershipAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >us-gaap:RelatedPartyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >agle:OwnershipInterestMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:OwnershipAxis" >agle:ParagonAndParapyreHoldingLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-06-22</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_22_2023_FairmountFundsManagementLlcMembersrtOwnershipAxis_MinimumMembersrtRangeAxis_OwnershipInterestMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:OwnershipAxis" >agle:FairmountFundsManagementLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >us-gaap:RelatedPartyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >agle:OwnershipInterestMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-06-22</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_22_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >agle:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-06-22</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_22_2023_ForwardContractsMemberusgaapDerivativeInstrumentRiskAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis" >us-gaap:ForwardContractsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-06-22</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_22_2023_AssetAcquisitionMemberusgaapAssetAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis" >agle:AssetAcquisitionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-06-22</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_22_2023_ParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >us-gaap:RelatedPartyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >agle:ParagonAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-06-22</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_22_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >agle:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis" >agle:SpyreTherapeuticsIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-06-22</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_22_2023_CommonStockMemberusgaapEquityInterestIssuedOrIssuableByTypeAxis_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis" >agle:SpyreTherapeuticsIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-06-22</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_22_2023_AssetAcquisitionMemberusgaapAssetAcquisitionAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >agle:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis" >agle:AssetAcquisitionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-06-22</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_22_2023_ParapyreOptionObligationMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >agle:ParapyreOptionObligationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-06-22</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_22_2023_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis" >agle:SpyreTherapeuticsIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-06-22</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_22_2023_USBankingInstitutionMemberusgaapFinancialInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >agle:USBankingInstitutionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-06-22</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_22_2023_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >agle:TwoThousandAndSixteenEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-06-22</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P06_26_2023To06_26_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >agle:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-06-26</xbrli:startDate> <xbrli:endDate>2023-06-26</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P06_26_2023To06_26_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >agle:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:PrivatePlacementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-06-26</xbrli:startDate> <xbrli:endDate>2023-06-26</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_26_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:PrivatePlacementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >agle:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-06-26</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P07_07_2023To07_07_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >agle:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-07-07</xbrli:startDate> <xbrli:endDate>2023-07-07</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_07_2023To07_07_2023_AssetAcquisitionMemberusgaapBusinessAcquisitionAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >agle:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >agle:AssetAcquisitionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-07-07</xbrli:startDate> <xbrli:endDate>2023-07-07</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_07_2023To07_07_2023_CommonStockMemberusgaapEquityInterestIssuedOrIssuableByTypeAxis_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis" >agle:SpyreTherapeuticsIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-07-07</xbrli:startDate> <xbrli:endDate>2023-07-07</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_07_2023To07_07_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis" >agle:SpyreTherapeuticsIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >agle:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-07-07</xbrli:startDate> <xbrli:endDate>2023-07-07</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P06_23_2023To06_30_2023_ForwardContractsMemberusgaapDerivativeInstrumentRiskAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis" >us-gaap:ForwardContractsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-06-23</xbrli:startDate> <xbrli:endDate>2023-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_31_2023To12_31_2023_ParapyreOptionObligationMemberusgaapPlanNameAxis_ScenarioForecastMembersrtStatementScenarioAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >agle:ParapyreOptionObligationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementScenarioAxis" >srt:ScenarioForecastMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-12-31</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_31_2023_MaximumMembersrtRangeAxis_ParagonTherapeuticsIncMembersrtOwnershipAxis_Spy001LicenseAgreementMemberusgaapRelatedPartyTransactionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:OwnershipAxis" >agle:ParagonTherapeuticsIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >agle:Spy001LicenseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-07-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_31_2023_ParapyreOptionObligationMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >agle:ParapyreOptionObligationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-05-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P07_12_2023To07_12_2023_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_Spy001LicenseAgreementMemberusgaapRelatedPartyTransactionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >us-gaap:RelatedPartyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >agle:Spy001LicenseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-07-12</xbrli:startDate> <xbrli:endDate>2023-07-12</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_12_2023_MaximumMembersrtRangeAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_Spy001LicenseAgreementMemberusgaapRelatedPartyTransactionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >us-gaap:RelatedPartyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >agle:Spy001LicenseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-07-12</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P05_01_2022To05_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-05-01</xbrli:startDate> <xbrli:endDate>2022-05-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-05-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_31_2022_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-05-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P02_01_2019To05_31_2022_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-02-01</xbrli:startDate> <xbrli:endDate>2022-05-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2016To12_31_2016_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >agle:TwoThousandAndSixteenEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2016-01-01</xbrli:startDate> <xbrli:endDate>2016-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To07_31_2020_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >agle:TwoThousandAndSixteenEquityIncentivePlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2020-07-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To09_30_2023_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >agle:TwoThousandAndSixteenEquityIncentivePlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_01_2022_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >agle:TwoThousandAndSixteenEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-01-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_01_2022_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >agle:TwoThousandAndSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-01-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_01_2023_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >agle:TwoThousandAndSixteenEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-01-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P03_21_2021To03_21_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >agle:ImmedicaPharmaABMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-03-21</xbrli:startDate> <xbrli:endDate>2021-03-21</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P03_21_2021To03_21_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >agle:ImmedicaPharmaABMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-03-21</xbrli:startDate> <xbrli:endDate>2021-03-21</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_21_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_LicenseMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:LicenseMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >agle:ImmedicaPharmaABMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-21</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2021To07_31_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >agle:ImmedicaPharmaABMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-07-01</xbrli:startDate> <xbrli:endDate>2021-07-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2021To07_31_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_PIPTrialMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" >agle:PIPTrialMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >agle:ImmedicaPharmaABMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-07-01</xbrli:startDate> <xbrli:endDate>2021-07-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2021To07_31_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_PeaceTrialAndBLAPackageMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" >agle:PeaceTrialAndBLAPackageMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >agle:ImmedicaPharmaABMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-07-01</xbrli:startDate> <xbrli:endDate>2021-07-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_27_2023To07_27_2023_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberusgaapDisposalGroupClassificationAxis_GlobalRightsToPegzilarginaseMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis" >us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" >agle:GlobalRightsToPegzilarginaseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-07-27</xbrli:startDate> <xbrli:endDate>2023-07-27</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_27_2023_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberusgaapDisposalGroupClassificationAxis_GlobalRightsToPegzilarginaseMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis" >us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" >agle:GlobalRightsToPegzilarginaseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-07-27</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_EmployeesMembersrtTitleOfIndividualAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >agle:TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >agle:EmployeesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_NonEmployeesMembersrtTitleOfIndividualAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >agle:TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >agle:NonEmployeesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_EmployeesMembersrtTitleOfIndividualAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >agle:TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >agle:EmployeesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_NonEmployeesMembersrtTitleOfIndividualAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >agle:TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >agle:NonEmployeesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_EmployeesMembersrtTitleOfIndividualAxis_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >agle:TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >agle:EmployeesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_NonEmployeesMembersrtTitleOfIndividualAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >agle:TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >agle:NonEmployeesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >agle:TwoThousandAndSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_PropertyPlantAndEquipmentMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_LicenseMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:LicenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_DevelopmentFeeMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >agle:DevelopmentFeeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" >us-gaap:DomesticCountryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" >us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_LicenseAgreementsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" >agle:LicenseAgreementsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >agle:ImmedicaPharmaABMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis_NonEmployeesMembersrtTitleOfIndividualAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >agle:NonEmployeesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_NonEmployeesMembersrtTitleOfIndividualAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >agle:NonEmployeesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_LicenseAgreementsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_UniversityOfTexasAtAustinMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >agle:UniversityOfTexasAtAustinMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" >agle:LicenseAgreementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_EmployeesMembersrtTitleOfIndividualAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >agle:TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >agle:EmployeesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_NonEmployeesMembersrtTitleOfIndividualAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >agle:TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >agle:NonEmployeesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_EmployeesMembersrtTitleOfIndividualAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >agle:TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >agle:EmployeesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_NonEmployeesMembersrtTitleOfIndividualAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >agle:TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >agle:NonEmployeesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_EmployeesMembersrtTitleOfIndividualAxis_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >agle:TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >agle:EmployeesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_NonEmployeesMembersrtTitleOfIndividualAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >agle:TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >agle:NonEmployeesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >agle:TwoThousandAndSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_ForeignCountryMemberusgaapIncomeTaxAuthorityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" >us-gaap:ForeignCountryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_PropertyPlantAndEquipmentMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_LicenseMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:LicenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_DevelopmentFeeMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >agle:DevelopmentFeeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_USGovernmentAgenciesDebtSecuritiesMemberusgaapFinancialInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" >us-gaap:DomesticCountryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" >us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_LicenseAgreementsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >agle:ImmedicaPharmaABMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" >agle:LicenseAgreementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_PeaceTrialAndBLAPackageMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >agle:ImmedicaPharmaABMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" >agle:PeaceTrialAndBLAPackageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis_NonEmployeesMembersrtTitleOfIndividualAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >agle:NonEmployeesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_NonEmployeesMembersrtTitleOfIndividualAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >agle:NonEmployeesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_LicenseAgreementsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_UniversityOfTexasAtAustinMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >agle:UniversityOfTexasAtAustinMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" >agle:LicenseAgreementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_EmployeesMembersrtTitleOfIndividualAxis_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >agle:TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >agle:EmployeesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_NonEmployeesMembersrtTitleOfIndividualAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >agle:TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >agle:NonEmployeesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_EmployeesMembersrtTitleOfIndividualAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >agle:TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >agle:EmployeesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_NonEmployeesMembersrtTitleOfIndividualAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >agle:TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >agle:NonEmployeesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_EmployeesMembersrtTitleOfIndividualAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >agle:TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >agle:EmployeesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_NonEmployeesMembersrtTitleOfIndividualAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >agle:TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >agle:NonEmployeesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >agle:TwoThousandAndSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ForeignCountryMemberusgaapIncomeTaxAuthorityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" >us-gaap:ForeignCountryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_PropertyPlantAndEquipmentMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_FebruaryTwoThousandNinteenMemberusgaapAwardDateAxis_WarrantMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:WarrantMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis" >agle:FebruaryTwoThousandNinteenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_AprilTwoThousandTwentyMemberusgaapAwardDateAxis_WarrantMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:WarrantMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis" >agle:AprilTwoThousandTwentyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_MayTwoThousandTwentyTwoMemberusgaapAwardDateAxis_WarrantMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:WarrantMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis" >agle:MayTwoThousandTwentyTwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_EmployeesMembersrtTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >agle:EmployeesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_LicenseMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:LicenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_DevelopmentFeeMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >agle:DevelopmentFeeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_USGovernmentAgenciesDebtSecuritiesMemberusgaapFinancialInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" >us-gaap:DomesticCountryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" >us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_TwoThousandAndFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >agle:TwoThousandAndFifteenEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_EarliestTaxYearMemberusgaapTaxPeriodAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis" >us-gaap:EarliestTaxYearMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >agle:TwoThousandAndSixteenEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_PeaceTrialAndBLAPackageMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" >agle:PeaceTrialAndBLAPackageMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >agle:ImmedicaPharmaABMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis_NonEmployeesMembersrtTitleOfIndividualAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >agle:NonEmployeesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_NonEmployeesMembersrtTitleOfIndividualAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >agle:NonEmployeesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_LicenseAgreementsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_UniversityOfTexasAtAustinMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >agle:UniversityOfTexasAtAustinMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" >agle:LicenseAgreementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_MinimumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >agle:ImmedicaPharmaABMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >agle:ImmedicaPharmaABMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_EmployeesAndNonEmployeesMembersrtTitleOfIndividualAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >agle:EmployeesAndNonEmployeesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn04_30_2019_LetterOfCreditMemberusgaapShortTermDebtTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis" >us-gaap:LetterOfCreditMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-04-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn04_30_2019_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-04-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P02_01_2019To02_28_2019_CommonStockMemberusgaapStatementEquityComponentsAxis_FollowOnPublicOfferingMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >agle:FollowOnPublicOfferingMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-02-01</xbrli:startDate> <xbrli:endDate>2019-02-28</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_01_2019To02_28_2019_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-02-01</xbrli:startDate> <xbrli:endDate>2019-02-28</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_28_2019_CommonStockMemberusgaapStatementEquityComponentsAxis_FollowOnPublicOfferingMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >agle:FollowOnPublicOfferingMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-02-28</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_28_2019_CommonStockMemberusgaapStatementEquityComponentsAxis_FollowOnPublicOfferingMemberusgaapSubsidiarySaleOfStockAxis_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >agle:FollowOnPublicOfferingMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-02-28</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To04_30_2020_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2020-04-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To04_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_FollowOnPublicOfferingMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >agle:FollowOnPublicOfferingMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2020-04-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To04_30_2020_AtTheMarketSalesAgreementMemberusgaapSubsidiarySaleOfStockAxis_JonesTradingInstitutionalServicesLimitedLiabilityCompanyMemberusgaapRelatedPartyTransactionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >agle:AtTheMarketSalesAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >agle:JonesTradingInstitutionalServicesLimitedLiabilityCompanyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2020-04-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn04_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_FollowOnPublicOfferingMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >agle:FollowOnPublicOfferingMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-04-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn04_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_FollowOnPublicOfferingMemberusgaapSubsidiarySaleOfStockAxis_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >agle:FollowOnPublicOfferingMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-04-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P10_01_2020To12_31_2020_AtTheMarketSalesAgreementMemberusgaapSubsidiarySaleOfStockAxis_JonesTradingInstitutionalServicesLimitedLiabilityCompanyMemberusgaapRelatedPartyTransactionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >agle:AtTheMarketSalesAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >agle:JonesTradingInstitutionalServicesLimitedLiabilityCompanyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-10-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To03_31_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >agle:ImmedicaPharmaABMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To03_31_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >agle:ImmedicaPharmaABMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To03_31_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_PeaceTrialAndBLAPackageMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >agle:ImmedicaPharmaABMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" >agle:PeaceTrialAndBLAPackageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To03_31_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_PIPTrialMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >agle:ImmedicaPharmaABMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" >agle:PIPTrialMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P06_01_2021To06_30_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_LicenseAgreementsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" >agle:LicenseAgreementsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >agle:ImmedicaPharmaABMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-06-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2017To01_31_2017_LicenseAgreementsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_MinimumMembersrtRangeAxis_UniversityOfTexasAtAustinMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >agle:UniversityOfTexasAtAustinMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" >agle:LicenseAgreementsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2017-01-01</xbrli:startDate> <xbrli:endDate>2017-01-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2017To01_31_2017_LicenseAgreementsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_MaximumMembersrtRangeAxis_UniversityOfTexasAtAustinMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >agle:UniversityOfTexasAtAustinMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" >agle:LicenseAgreementsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2017-01-01</xbrli:startDate> <xbrli:endDate>2017-01-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2017To01_31_2017_LicenseAgreementsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_UniversityOfTexasAtAustinMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >agle:UniversityOfTexasAtAustinMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" >agle:LicenseAgreementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2017-01-01</xbrli:startDate> <xbrli:endDate>2017-01-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P03_01_2015To03_31_2015_MinimumMembersrtRangeAxis_TwoThousandAndFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >agle:TwoThousandAndFifteenEquityIncentivePlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2015-03-01</xbrli:startDate> <xbrli:endDate>2015-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P03_01_2015To03_31_2015_MaximumMembersrtRangeAxis_StockOptionMemberusgaapAwardTypeAxis_TwoThousandAndFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >agle:TwoThousandAndFifteenEquityIncentivePlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:StockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2015-03-01</xbrli:startDate> <xbrli:endDate>2015-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P03_01_2015To03_31_2015_TwoThousandAndFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >agle:TwoThousandAndFifteenEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2015-03-01</xbrli:startDate> <xbrli:endDate>2015-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn04_30_2016_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >agle:TwoThousandAndSixteenEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2016-04-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn04_30_2016_TwoThousandAndFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >agle:TwoThousandAndFifteenEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2016-04-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn04_30_2016_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >agle:TwoThousandAndSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2016-04-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P10_01_2018To10_31_2018_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >agle:TwoThousandAndSixteenEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-10-01</xbrli:startDate> <xbrli:endDate>2018-10-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_01_2020_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >agle:TwoThousandAndSixteenEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-01-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_01_2020_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >agle:TwoThousandAndSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-01-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_01_2021_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >agle:TwoThousandAndSixteenEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-01-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_01_2021_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >agle:TwoThousandAndSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-01-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_28_2018_TwoThousandAndEighteenEquityInducementPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >agle:TwoThousandAndEighteenEquityInducementPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-02-28</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P11_01_2022To11_30_2022_NewChiefExecutiveOfficerMembersrtTitleOfIndividualAxis_NonQualifiedStockOptionsMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >agle:NonQualifiedStockOptionsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >agle:NewChiefExecutiveOfficerMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-11-01</xbrli:startDate> <xbrli:endDate>2022-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2016To04_30_2016_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >agle:TwoThousandAndSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2016-04-01</xbrli:startDate> <xbrli:endDate>2016-04-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2016To04_30_2016_MaximumMembersrtRangeAxis_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >agle:TwoThousandAndSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2016-04-01</xbrli:startDate> <xbrli:endDate>2016-04-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P06_01_2018To06_30_2018_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >agle:TwoThousandAndSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-06-01</xbrli:startDate> <xbrli:endDate>2018-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_01_2023To02_28_2023_MaximumMembersrtRangeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >agle:TwoThousandAndSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-02-01</xbrli:startDate> <xbrli:endDate>2023-02-28</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P09_08_2023To09_08_2023_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-09-08</xbrli:startDate> <xbrli:endDate>2023-09-08</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P09_08_2023To09_08_2023_MaximumMembersrtRangeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-09-08</xbrli:startDate> <xbrli:endDate>2023-09-08</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P09_08_2023To09_08_2023_MinimumMembersrtRangeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-09-08</xbrli:startDate> <xbrli:endDate>2023-09-08</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_08_2023_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-08</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P09_29_2023To09_29_2023_ParapyreOptionObligationMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >agle:ParapyreOptionObligationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-09-29</xbrli:startDate> <xbrli:endDate>2023-09-29</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P09_29_2023To09_29_2023_ParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >agle:ParagonAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >us-gaap:RelatedPartyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-09-29</xbrli:startDate> <xbrli:endDate>2023-09-29</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P09_29_2023To09_29_2023_ParapyreOptionObligationMemberusgaapPlanNameAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >agle:ParapyreOptionObligationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-09-29</xbrli:startDate> <xbrli:endDate>2023-09-29</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_01_2018To02_28_2018_ServiceBasedAwardsMemberusgaapAwardTypeAxis_TwoThousandAndFifteenAndTwoThousandAndSixteenEquityIncentivePlanAndTwoThousandAndEighteenEquityInducementPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >agle:TwoThousandAndFifteenAndTwoThousandAndSixteenEquityIncentivePlanAndTwoThousandAndEighteenEquityInducementPlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >agle:ServiceBasedAwardsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-02-01</xbrli:startDate> <xbrli:endDate>2018-02-28</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_01_2018To02_28_2018_MaximumMembersrtRangeAxis_ServiceBasedAwardsMemberusgaapAwardTypeAxis_TwoThousandAndFifteenAndTwoThousandAndSixteenEquityIncentivePlanAndTwoThousandAndEighteenEquityInducementPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >agle:TwoThousandAndFifteenAndTwoThousandAndSixteenEquityIncentivePlanAndTwoThousandAndEighteenEquityInducementPlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >agle:ServiceBasedAwardsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-02-01</xbrli:startDate> <xbrli:endDate>2018-02-28</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2023To07_31_2023_LicensingAgreementsMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >us-gaap:LicensingAgreementsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >us-gaap:RelatedPartyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-07-01</xbrli:startDate> <xbrli:endDate>2023-07-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P09_01_2021To09_30_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_LicenseAgreementsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" >agle:LicenseAgreementsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >agle:ImmedicaPharmaABMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-09-01</xbrli:startDate> <xbrli:endDate>2021-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_SeveranceLiabilityMemberusgaapRestructuringCostAndReserveAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis" >agle:SeveranceLiabilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_ContingentValueRightLiabilityMemberusgaapDerivativeInstrumentRiskAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis" >agle:ContingentValueRightLiabilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_EmployeesMembersrtTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >agle:EmployeesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2023_SeveranceLiabilityMemberusgaapRestructuringCostAndReserveAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis" >agle:SeveranceLiabilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2023_ContingentValueRightLiabilityMemberusgaapDerivativeInstrumentRiskAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis" >agle:ContingentValueRightLiabilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2023_ForwardContractsMemberusgaapDerivativeInstrumentRiskAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis" >us-gaap:ForwardContractsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >agle:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >agle:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >agle:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2023_ForwardContractsMemberusgaapDerivativeInstrumentRiskAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis" >us-gaap:ForwardContractsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_EmployeesMembersrtTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >agle:EmployeesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >agle:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >agle:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >agle:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:unit id="Unit_USD" > <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_shares" > <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Year" > <xbrli:measure>utr:Year</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_pure" > <xbrli:measure>xbrli:pure</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Day" > <xbrli:measure>utr:Day</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Month" > <xbrli:measure>utr:Month</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_sqft" > <xbrli:measure>utr:sqft</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_USD_per_Share" > <xbrli:divide> <xbrli:unitNumerator> <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unitNumerator> <xbrli:unitDenominator> <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unitDenominator> </xbrli:divide> </xbrli:unit><xbrli:unit id="Unit_SEGMENT" > <xbrli:measure>agle:SEGMENT</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_BOARDSEAT" > <xbrli:measure>agle:BOARDSEAT</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_SUBSIDARY" > <xbrli:measure>agle:SUBSIDARY</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_bank" > <xbrli:measure>agle:bank</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_PROGRAMOPTION" > <xbrli:measure>agle:PROGRAMOPTION</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_VOTE" > <xbrli:measure>agle:VOTE</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_employee" > <xbrli:measure>agle:employee</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_EUR_per_Share" > <xbrli:divide> <xbrli:unitNumerator> <xbrli:measure>iso4217:EUR</xbrli:measure> </xbrli:unitNumerator> <xbrli:unitDenominator> <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unitDenominator> </xbrli:divide> </xbrli:unit><xbrli:unit id="Unit_LICENSEAGREEMENT" > <xbrli:measure>agle:LICENSEAGREEMENT</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_USD_LICENSEAGREEMENT" > <xbrli:divide> <xbrli:unitNumerator> <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unitNumerator> <xbrli:unitDenominator> <xbrli:measure>agle:LICENSEAGREEMENT</xbrli:measure> </xbrli:unitDenominator> </xbrli:divide> </xbrli:unit></ix:resources></ix:header></div><div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: medium; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; text-align: center;"><div style="width: 8.5in; text-align: left; margin-left: auto; margin-right: auto;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">As filed with the Securities and Exchange Commission on December&#160;22, 2023</div></div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; text-align: right;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Registration No.&#160;333-&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="line-height: 1pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="line-height: 3pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="margin-top: 4pt; margin-bottom: 0pt; font-size: 16pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 16pt; letter-spacing: 0px; top: 0px;;display:inline;">UNITED STATES</div></div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 16pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 16pt; letter-spacing: 0px; top: 0px;;display:inline;">SECURITIES AND EXCHANGE COMMISSION</div></div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">WASHINGTON, D.C. 20549</div></div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center;"><div style="line-height: 6pt; margin: 0pt auto 2pt; border-bottom: 1pt solid rgb(0, 0, 0); width: 171.359px; text-align: center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 16pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">FORM<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:DocumentType" contextRef="P01_01_2023To09_30_2023">S-1</ix:nonNumeric></div></div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 16pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 16pt; letter-spacing: 0px; top: 0px;;display:inline;">REGISTRATION STATEMENT</div></div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">UNDER</div></div></div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">THE SECURITIES ACT OF 1933</div></div></div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center;"><div style="line-height: 6pt; margin: 0pt auto 2pt; border-bottom: 1pt solid rgb(0, 0, 0); width: 171.359px; text-align: center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 18pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="P01_01_2023To09_30_2023">Spyre Therapeutics, Inc.</ix:nonNumeric></div></div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">(Exact name of registrant as specified in its charter)</div></div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center;"><div style="line-height: 6pt; margin: 0pt auto 2pt; border-bottom: 1pt solid rgb(0, 0, 0); width: 171.359px; text-align: center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: &quot;Times New Roman&quot;; font-size: 8pt; width: 816px; border: 0px; margin: 0px auto; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 412.125px;"></td>
<td style="vertical-align: bottom; width: 8.23438px;"></td>
<td style="width: 395.641px;"></td></tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 8.5pt;">
<td style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="P01_01_2023To09_30_2023" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="P01_01_2023To09_30_2023">46-4312787</ix:nonNumeric></div></div></div></td></tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 8pt;">
<td style="vertical-align: top;;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(State or other jurisdiction of</div></div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">incorporation or organization)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(I.R.S. Employer</div></div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Identification No.)</div></div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="P01_01_2023To09_30_2023">221 Crescent Street</ix:nonNumeric></div></div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="P01_01_2023To09_30_2023">Building 23</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine3" contextRef="P01_01_2023To09_30_2023">Suite 105</ix:nonNumeric></div></div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="P01_01_2023To09_30_2023">Waltham</ix:nonNumeric>, <div style="display:inline;"><span style="-sec-ix-hidden:hidden95764034">MA</span></div> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="P01_01_2023To09_30_2023">02453</ix:nonNumeric></div></div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(<ix:nonNumeric name="dei:CityAreaCode" contextRef="P01_01_2023To09_30_2023">617</ix:nonNumeric>)<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="P01_01_2023To09_30_2023">651-5940</ix:nonNumeric></div></div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(Address, including zip code, and telephone number, including area code, of registrant&#8217;s principal executive offices)</div></div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center;"><div style="line-height: 6pt; margin: 0pt auto 2pt; border-bottom: 1pt solid rgb(0, 0, 0); width: 171.359px; text-align: center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:ContactPersonnelName" contextRef="P01_01_2023To09_30_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">Heidy King-Jones</ix:nonNumeric></div></div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Chief Legal Officer and Corporate Secretary</div></div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Spyre Therapeutics, Inc.</div></div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="P01_01_2023To09_30_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">221 Crescent Street</ix:nonNumeric></div></div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="P01_01_2023To09_30_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">Building 23</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine3" contextRef="P01_01_2023To09_30_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">Suite 105</ix:nonNumeric></div></div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="P01_01_2023To09_30_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">Waltham</ix:nonNumeric>, <div style="display:inline;"><span style="-sec-ix-hidden:hidden95764035">MA</span></div> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="P01_01_2023To09_30_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">02453</ix:nonNumeric></div></div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(<ix:nonNumeric name="dei:CityAreaCode" contextRef="P01_01_2023To09_30_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">617</ix:nonNumeric>)<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="P01_01_2023To09_30_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">651-5940</ix:nonNumeric></div></div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(Name, address, including zip code, and telephone number, including area code, of agent for service)</div></div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center;"><div style="line-height: 6pt; margin: 0pt auto 2pt; border-bottom: 1pt solid rgb(0, 0, 0); width: 171.359px; text-align: center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Copies to:</div></div></div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Ryan A. Murr</div></div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Branden C. Berns</div></div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Gibson, Dunn&#160;&amp; Crutcher LLP</div></div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">One Embarcadero Center, Suite 2600</div></div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">San Francisco, CA 94111</div></div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(415)<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">393-8373</div></div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center;"><div style="line-height: 6pt; margin: 0pt auto 2pt; border-bottom: 1pt solid rgb(0, 0, 0); width: 171.359px; text-align: center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: 'Times New Roman';"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Approximate date of commencement of proposed sale to the public</div></div>: From time to time after the effective date of this Registration Statement.</div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: 'Times New Roman';"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">If any of the securities being registered on this form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box.&#160;&#160;&#9746;</div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: 'Times New Roman';"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">If this form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&#160;&#160;&#9744;</div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: 'Times New Roman';"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">If this form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&#160;&#160;&#9744;</div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: 'Times New Roman';"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">If this form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&#160;&#160;&#9744;</div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: 'Times New Roman';">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-accelerated</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12b-2</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>of the Exchange Act.</div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; width: 816px; border: 0px; margin: 0px auto; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 138.719px;"></td>
<td style="vertical-align: bottom; width: 8.15625px;"></td>
<td style="width: 465.125px;"></td>
<td style="vertical-align: bottom; width: 8.15625px;"></td>
<td style="width: 171.359px;"></td>
<td style="vertical-align: bottom; width: 8.15625px;"></td>
<td style="width: 16.3281px;"></td></tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 8.5pt;">
<td style="vertical-align: bottom;">Large&#160;accelerated&#160;filer</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#9744;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Accelerated&#160;filer</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#9744;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td></tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 8.5pt;">
<td style="vertical-align: bottom;"><ix:nonNumeric name="dei:EntityFilerCategory" contextRef="P01_01_2023To09_30_2023" format="ixt-sec:entityfilercategoryen">Non-accelerated filer</ix:nonNumeric></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#9746;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Smaller&#160;reporting&#160;company</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><ix:nonNumeric name="dei:EntitySmallBusiness" contextRef="P01_01_2023To09_30_2023" format="ixt:fixed-true">&#9746;</ix:nonNumeric></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td></tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 8.5pt;">
<td style="vertical-align: bottom; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Emerging&#160;growth&#160;company</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="P01_01_2023To09_30_2023" format="ixt:fixed-false">&#9744;</ix:nonNumeric></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: 'Times New Roman';"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;7(a)(2)(B) of the Securities Act.&#160;&#160;<div style="display:inline;">&#9744;</div></div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center;"><div style="line-height: 6pt; margin: 0pt auto 2pt; border-bottom: 1pt solid rgb(0, 0, 0); width: 171.359px; text-align: center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">The Registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment that specifically states that this registration statement shall thereafter become effective in accordance with Section&#160;8(a) of the Securities Act of 1933, as amended, or until this registration statement shall become effective on such date as the Commission, acting pursuant to said Section&#160;8(a), may determine.</div></div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="line-height: 1pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="line-height: 3pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><br/> </div></div></div>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial Narrow"><span style="color:#ff4338"><span style="font-weight:bold">The information in this prospectus is not complete and may be changed. The selling stockholders named in this prospectus may not sell these securities until the registration statement filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) is effective. This prospectus is not an offer to sell these securities, and it is not soliciting an offer to buy these securities, in any jurisdiction where the offer or sale is not permitted. </span></span></p> <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="color:#ff4338"><span style="font-weight:bold">SUBJECT TO COMPLETION, DATED DECEMBER&#160;22, 2023 </span></span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">PRELIMINARY PROSPECTUS </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g518298g81i79.jpg" alt="LOGO" />
 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center">Spyre Therapeutics, Inc. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">12,000,000 Shares </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman;font-weight:bold;text-align:center">Common Stock </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman;font-weight:bold;text-align:center">Offered by the Selling Stockholders </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus relates to the proposed resale or other disposition by the selling stockholders identified herein (the &#8220;Selling Stockholders&#8221;) of up to (i) 6,000,000 shares (the &#8220;Private Placement Common Shares&#8221;) of our common stock, par value $0.0001 per share (&#8220;Common Stock&#8221;) and (ii) 6,000,000 shares of Common Stock (the &#8220;Private Placement Conversion Shares&#8221;) issuable upon the conversion of 150,000 shares (the &#8220;Private Placement Preferred Shares&#8221;) of Series B preferred stock, par value $0.0001 (the &#8220;Series B Preferred Stock&#8221;). Subject to receiving the requisite stockholder approval and certain beneficial ownership limitations set by each preferred stockholder, each share of Series B Preferred Stock will automatically convert upon the requisite stockholder approval into an aggregate of 40 shares of Common Stock. The shares of Common Stock registered by this prospectus are referred to herein as the &#8220;Resale Shares.&#8221; </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Private Placement Preferred Shares were issued and sold to accredited investors in a private placement (the &#8220;December 2023 PIPE&#8221;), which closed on December&#160;11, 2023. We are not selling any Resale Shares under this prospectus and will not receive any of the proceeds from the sale or other disposition of Resale Shares by the Selling Stockholders. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Selling Stockholders may sell the Resale Shares on any national securities exchange or quotation service on which the securities may be listed or quoted at the time of sale, on the <span style="white-space:nowrap"><span style="white-space:nowrap">over-the-counter</span></span> market, in one or more transactions otherwise than on these exchanges or systems, such as privately negotiated transactions, or using a combination of these methods, and at fixed prices, at prevailing market prices at the time of the sale, at varying prices determined at the time of sale, or at negotiated prices. See the disclosure under the heading &#8220;Plan of Distribution&#8221; elsewhere in this prospectus for more information about how the Selling Stockholders may sell or otherwise dispose of their Resale Shares hereunder. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Selling Stockholders may sell any, all or none of the securities offered by this prospectus and we do not know when or in what amount the Selling Stockholders may sell their Resale Shares hereunder following the effective date of the registration statement of which this prospectus forms a part. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You should carefully read this prospectus and any applicable prospectus supplement before you invest in any of the securities being offered. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Common Stock is traded on The Nasdaq Capital Market under the symbol &#8220;SYRE.&#8221; On December&#160;21, 2023, the last reported sale price for our Common Stock was $17.22 per share. </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:6pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold">An investment in our securities involves a high degree of risk. You should carefully consider the information under the heading &#8220;<a href="#tx518298_5">Risk Factors</a>&#8221; beginning on page 11 of this prospectus and any applicable prospectus supplement. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">We are a &#8220;smaller reporting company&#8221; as defined by Rule <span style="white-space:nowrap">12b-2</span> of the Exchange Act and are subject to reduced public company reporting requirements. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Neither the SEC nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">The date of this prospectus is &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2024 </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc">TABLE OF CONTENTS </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:94%"></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">PAGE</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx518298_1">ABOUT THIS PROSPECTUS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx518298_2">CAUTIONARY STATEMENT CONCERNING FORWARD-LOOKING STATEMENTS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx518298_3">PROSPECTUS SUMMARY</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx518298_4">RISK FACTOR SUMMARY</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx518298_5">RISK FACTORS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx518298_6">USE OF PROCEEDS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">47</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx518298_7">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">48</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx518298_8">CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">64</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx518298_9">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">65</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx518298_10">BUSINESS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">66</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx518298_11">MANAGEMENT</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">93</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx518298_12">EXECUTIVE COMPENSATION</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">99</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx518298_13">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">112</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx518298_14">CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">115</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx518298_15">SELLING STOCKHOLDERS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">117</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx518298_16">PLAN OF DISTRIBUTION</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">124</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx518298_17">DESCRIPTION OF CAPITAL STOCK</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">127</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx518298_18">LEGAL MATTERS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">132</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx518298_19">EXPERTS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">133</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx518298_20">WHERE YOU CAN FIND MORE INFORMATION</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">134</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx518298_21">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="white-space:nowrap">F-1</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx518298_1">ABOUT THIS PROSPECTUS </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement that we filed with the SEC using a &#8220;shelf&#8221; registration process. Under this shelf registration process, the Selling Stockholders may, from time to time, sell the securities described in this prospectus in one or more offerings. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus contains information that you should consider when making your investment decision. Neither we, nor the Selling Stockholders, have authorized anyone to give any information or to make any representation other than those contained in this prospectus. The Selling Stockholders are offering to sell, and seeking offers to buy, our securities only in jurisdictions where it is lawful to do so. We have not authorized anyone to provide you with different information. This prospectus and any accompanying prospectus supplement do not constitute an offer to sell or the solicitation of an offer to buy any securities other than the securities described in any accompanying prospectus supplement or an offer to sell or the solicitation of an offer to buy such securities in any circumstances in which such offer or solicitation is unlawful. You should assume that the information appearing in this prospectus, any prospectus supplement and any related free writing prospectus is accurate only as of their respective dates. Our business, financial condition, results of operations and prospects may have changed materially since those dates. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In this prospectus, unless the context otherwise requires, the terms &#8220;Spyre,&#8221; &#8220;Aeglea BioTherapeutics, Inc.,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to Spyre Therapeutics, Inc., a Delaware corporation, and its consolidated subsidiaries. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus contains trade names, trademarks and service marks of others, which are the property of their respective owners. Solely for convenience, trademarks and trade names referred to in this prospectus may appear without the <sup style="font-size:75%; vertical-align:top">&#174;</sup> or TM symbols. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All references to &#8220;our product candidates,&#8221; &#8220;our programs&#8221; and &#8220;our pipeline&#8221; in this prospectus refer to the research programs with respect to which we have exercised the option to acquire intellectual property license rights to or have the option to acquire intellectual property license rights to pursuant to that certain antibody discovery and option agreement, dated May&#160;25, 2023 and subsequently amended and restated on September&#160;29, 2023, by and among Spyre Therapeutics, LLC, Paragon Therapeutics, Inc. (&#8220;Paragon&#8221;) and Parapyre Holding LLC (&#8220;Parapyre&#8221;) (the &#8220;Paragon Agreement&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Please be advised that on September&#160;8, 2023, we effected a reverse stock split of our Common Stock at a ratio of <span style="white-space:nowrap"><span style="white-space:nowrap">1-for-25</span></span> (the &#8220;Reverse Split&#8221;). Except as indicated otherwise, all share numbers related to our Common Stock disclosed in this prospectus have been adjusted on a post-Reverse Split basis. In addition, on November&#160;28, 2023, we changed our name from &#8220;Aeglea Biotherapeutics, Inc.&#8221; to &#8220;Spyre Therapeutics, Inc.&#8221; </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">1 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx518298_2">CAUTIONARY STATEMENT CONCERNING FORWARD-LOOKING STATEMENTS </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus contains &#8220;forward-looking statements&#8221; within the meaning of Section&#160;27A of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and Section&#160;21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). These forward-looking statements involve a number of risks and uncertainties. We caution readers that any forward-looking statement is not a guarantee of future performance and that actual results could differ materially from those contained in the forward-looking statement. These statements are based on current expectations of future events. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All statements, other than statements of historical facts contained in this prospectus, including, without limitation, statements regarding: stockholder approval of the conversion rights of the Series B Preferred Stock; any future payouts under the CVR (as defined herein); our ability to achieve the expected benefits or opportunities and related timing with respect to our acquisition of Spyre Therapeutics, Inc. <span style="white-space:nowrap">(&#8220;Pre-Merger</span> Spyre&#8221;) or to monetize any of our legacy assets, our future results of operations and financial position, business strategy, the length of time that we believe our existing cash resources will fund our operations, our market size, our potential growth opportunities, our preclinical and future clinical development activities, the efficacy and safety profile of our product candidates, the potential therapeutic benefits and economic value of our product candidates, the timing and results of preclinical studies and clinical trials, the expected impact of macroeconomic conditions, including inflation, increasing interest rates and volatile market conditions, current or potential bank failures, as well as global events, including the ongoing military conflict in Ukraine, conflict in Israel and surrounding areas, and geopolitical tensions in China on our operations, and the receipt and timing of potential regulatory designations, approvals and commercialization of product candidates. Forward-looking statements generally relate to future events or our future financial or operating performance. Forward-looking statements generally relate to future events or our future financial or operating performance. The words &#8220;believe,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;potentially,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;anticipate,&#8221; &#8220;predict,&#8221; &#8220;target,&#8221; &#8220;intend,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;project,&#8221; &#8220;plan,&#8221; &#8220;expect,&#8221; and similar expressions that convey uncertainty of future events or outcomes are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These forward-looking statements are subject to a number of risks, uncertainties and assumptions. Moreover, we operate in a very competitive and rapidly changing environment, and new risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. Factors that might cause such a difference are disclosed in the sections titled &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221; You should evaluate all forward-looking statements made in this prospectus in the context of these risks and uncertainties. We caution you that the risks, uncertainties and other factors referred to in this prospectus may not contain all of the risks, uncertainties and other factors that may affect our future results and operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based on information available to us as of the date of this prospectus. While we believe that such information provides a reasonable basis for these statements, such information may be limited or incomplete. Our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely on these statements. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All subsequent written or oral forward-looking statements attributable to us or any person acting on our behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. We do not undertake any obligation to release publicly any revisions to these forward-looking statements to reflect events or circumstances after the date of this prospectus or to reflect the occurrence of unanticipated events, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">2 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
except as may be required under applicable U.S. securities laws. If we do update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">3 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx518298_3">PROSPECTUS SUMMARY </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">This summary may not contain all the information that you should consider before investing in securities. You should read the entire prospectus carefully, including the sections titled &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; and our consolidated financial statements and the related notes included elsewhere in this prospectus, before making an investment decision. </span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Company Overview </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&#160;22, 2023, we completed the Asset Acquisition pursuant to the Acquisition Agreement (as defined under the section titled &#8220;<span style="font-style:italic">Recent Developments</span>&#8221; below). <span style="white-space:nowrap">Pre-Merger</span> Spyre was a <span style="white-space:nowrap">pre-clinical</span> stage biotechnology company that was incorporated on April&#160;28, 2023 under the direction of Peter Harwin, a Managing Member of Fairmount Funds Management LLC (&#8220;Fairmount&#8221;), for the purpose of holding rights to certain intellectual property being developed by Paragon. Fairmount is a founder of Paragon. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Through the Asset Acquisition, we received the option to acquire the intellectual property rights related to four research programs (collectively, the &#8220;Option&#8221;) pursuant to the Paragon Agreement. On July&#160;12, 2023, we exercised the Option with respect to one of these research programs to exclusively license intellectual property rights related to such research program directed to antibodies that selectively bind to &#945;4&#223;7 integrin and methods of using these antibodies, including methods of treating inflammatory bowel disease (&#8220;IBD&#8221;) using the SPY001 program. If this research program is pursued <span style="white-space:nowrap">non-provisionally</span> and matures into issued patents, we would expect those patents to expire no earlier than 2044 subject to any disclaimers or extensions. On December&#160;14, 2023, we exercised the Option under the Paragon Agreement to be granted an exclusive license to all of Paragon&#8217;s rights, title and interest in and to intellectual property rights, including inventions, patents, sequence information and results, under SPY002, Spyre&#8217;s TL1A program, to develop and commercialize antibodies and products worldwide in all therapeutics disorders. The license agreements pertaining to such research programs are currently being finalized. Furthermore, as of the date of this registration statement, the Option remains unexercised with respect to the intellectual property rights related to the two remaining research programs under the Paragon Agreement. For more information on the Paragon Agreement, see discussion under the heading &#8220;<span style="font-style:italic">Paragon Agreement</span>&#8221; below. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&#160;27, 2023, we announced that we entered into an agreement to sell the global rights to pegzilarginase, an investigational treatment for the rare metabolic disease Arginase 1 Deficiency, to Immedica Pharma AB (&#8220;Immedica&#8221;) for $15.0&#160;million in upfront cash proceeds and up to $100.0&#160;million in contingent milestone payments (the &#8220;Immedica APA&#8221;). The sale of pegzilarginase to Immedica supersedes and terminates the license agreement between us and Immedica dated March 2021. See the section titled &#8220;<span style="font-style:italic">Recent Developments</span>&#8221; below for more information regarding the Immedica APA. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following the Asset Acquisition and the entry into the Immedica APA, we have significantly reshaped the business into a preclinical stage biotechnology company focused on developing next generation therapeutics for patients living with IBD, including ulcerative colitis (&#8220;UC&#8221;) and Crohn&#8217;s disease (&#8220;CD&#8221;). Through the Paragon Agreement, our portfolio of novel and proprietary monoclonal antibody product candidates has the potential to address unmet needs in IBD care by improving efficacy, safety, and/or dosing convenience relative to products currently available or product candidates in development. We have purposely engineered our product candidates to bind potently and selectively to target epitopes with extended half-lives. We plan to use combinations of our proprietary antibodies and patient enrichment strategies via companion diagnostics to enhance efficacy. We intend to deliver our product candidates through convenient, infrequently self-administered, subcutaneous (&#8220;SC&#8221;) injection as a <span style="white-space:nowrap">pre-filled</span> pen. </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">4 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Recent Developments </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">On September 8<sup style="font-size:75%; vertical-align:top">th</sup>, 2023, we effected the Reverse Split, which resulted in the reverse split of our Common Stock at a ratio of <span style="white-space:nowrap"><span style="white-space:nowrap">1-for-25.</span></span> Readers should note that, except as indicated otherwise, all share numbers related to our Common Stock disclosed in this &#8220;Recent Developments&#8221; section have been adjusted on a post-Reverse Split basis. </span></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&#160;22, 2023, we acquired in accordance with the terms of the Agreement and Plan of Merger (the &#8220;Acquisition Agreement&#8221;), by and among the Company, Aspen Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of the Company, Sequoia Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of the Company, and <span style="white-space:nowrap">Pre-Merger</span> Spyre, the assets of <span style="white-space:nowrap">Pre-Merger</span> Spyre, a privately held biotechnology company advancing a pipeline of antibody therapeutics through the Paragon Agreement. <span style="white-space:nowrap">Pre-Merger</span> Spyre was incorporated on April&#160;28, 2023, for the purpose of holding rights to certain intellectual property being developed by Paragon. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Asset Acquisition was structured as a <span style="white-space:nowrap"><span style="white-space:nowrap">stock-for-stock</span></span> transaction pursuant to which all of <span style="white-space:nowrap">Pre-Merger</span> Spyre&#8217;s outstanding equity interests were exchanged based on a fixed exchange ratio of 0.5494488 to 1 for consideration from the Company of 517,809 shares of Common Stock and 364,887 shares of Series A Preferred Stock (convertible on a 40 to 1 basis) in addition to the assumption of outstanding and unexercised stock options to purchase 2,734 shares of Common Stock from the Amended and Restated Spyre 2023 Equity Incentive Plan. The Common Stock and the Series A Preferred Stock related to the Asset Acquisition were issued to <span style="white-space:nowrap">Pre-Merger</span> Spyre stockholders on July&#160;7, 2023. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Concurrently with the Asset Acquisition, we entered into a definitive agreement (the &#8220;June 2023 SPA&#8221;) for a PIPE investment (the &#8220;June 2023 PIPE&#8221; and, together with the Asset Acquisition, the &#8220;June 2023 Transactions&#8221;) with existing and new investors (the &#8220;June 2023 Investors&#8221;) to raise approximately $210&#160;million in which the June 2023 Investors were issued 721,452 shares of Series A Preferred Stock at a price of $291.08 per share. The Asset Acquisition was approved by our board of directors and the board of directors and stockholders of <span style="white-space:nowrap">Pre-Merger</span> Spyre. The closings of the June 2023 Transactions were not subject to the approval of the Company&#8217;s stockholders. Following receipt of stockholder approval of the conversion of Series A Preferred Stock, each share of Series A Preferred Stock automatically converted into 40 shares of Common Stock, subject to certain beneficial ownership limitations set by each holder. Except as otherwise required by law (e.g. voting on a change to the authorized shares of Series A <span style="white-space:nowrap">Non-Voting</span> Preferred Stock or the rights of such shares as required by Delaware General Corporation Law) and Spyre&#8217;s Certificate of Designation of Series A <span style="white-space:nowrap">Non-Voting</span> Convertible Preferred Stock (the &#8220;Series A Certificate of Designation&#8221;), the Series A Preferred Stock does not have voting rights. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the execution of the Acquisition Agreement, Spyre and <span style="white-space:nowrap">Pre-Merger</span> Spyre entered into stockholder support agreements (the &#8220;Support Agreements&#8221;) with certain of Spyre&#8217;s officers and directors, which collectively own an aggregate of less than 1% of the outstanding shares of the Common Stock. The Support Agreements provide that, among other things, each of the parties thereto would vote or cause to be voted all of the shares of Common Stock owned by such stockholder in favor of the approval of the conversion of shares of the Series A Preferred Stock into shares of Common Stock in accordance with Nasdaq Stock Market Rules at Spyre&#8217;s stockholders&#8217; meeting held in connection therewith. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Concurrently and in connection with the execution of the Acquisition Agreement, certain <span style="white-space:nowrap">Pre-Merger</span> Spyre stockholders as of immediately prior to the Asset Acquisition, and certain of the directors and officers of Spyre as of immediately prior to the Asset Acquisition entered into <span style="white-space:nowrap">lock-up</span> agreements with Spyre and <span style="white-space:nowrap">Pre-Merger</span> Spyre, pursuant to which each such stockholder was subject to a <span style="white-space:nowrap">180-day</span> lockup on the sale or transfer of shares of Common Stock held by each such stockholder at the closing of the Asset Acquisition, including those shares received by such <span style="white-space:nowrap">Pre-Merger</span> Spyre stockholders in the Asset Acquisition. </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">5 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Asset Acquisition, a <span style="white-space:nowrap">non-transferrable</span> contingent value right (a &#8220;CVR&#8221;) was distributed to Spyre stockholders of record as of the close of business on July&#160;3, 2023, but was not distributed to holders of shares of Common Stock or Series A Preferred Stock issued to the June 2023 Investors or former stockholders of Pre- Merger Spyre in connection with the June 2023 Transactions. Holders of the CVRs will be entitled to receive cash payments from proceeds received by Spyre for a three-year period, if any, related to the disposition or monetization of certain legacy assets owned by us prior to the Asset Acquisition (the &#8220;Legacy Assets&#8221;) for a period of one year following the closing of the Asset Acquisition. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&#160;27, 2023, we announced that we entered the Immedica APA. The sale of pegzilarginase to Immedica supersedes and terminates the license agreement between the us and Immedica dated March 2021. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The milestone payments under the Immedica APA are contingent on formal reimbursement decisions by national authorities in key European markets and pegzilarginase approval by the United States Food and Drug Administration (the &#8220;FDA&#8221;), among other events. The upfront payment has been paid and distributed and contingent milestone payments if paid, net of expenses and adjustments, will be distributed to holders of Spyre&#8217;s CVR pursuant to the CVR Agreement that was entered into in connection with the Asset Acquisition. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&#160;7, 2023, we entered into a definitive agreement (the &#8220;December 2023 SPA&#8221;) for a PIPE investment with existing and new investors (the &#8220;December 2023 Investors&#8221;) to raise $180&#160;million in which the December 2023 Investors were issued an aggregate of 6,000,000 shares of Common Stock at a price of $15.00 per share and 150,000 shares of Series B Preferred Stock at a price of $600.00 per share. The closing of the December 2023 PIPE was not subject to Spyre stockholder approval. Subject to Spyre stockholder approval and certain beneficial ownership limitations set by each holder, each share of Series B Preferred Stock will automatically convert into 40 shares of Common Stock. We will file a definitive proxy statement with the SEC to solicit such stockholder approval, among other matters, at the 2024 annual meeting of stockholders. Except as otherwise required by law (e.g. voting on a change to the authorized shares of Series B <span style="white-space:nowrap">Non-Voting</span> Preferred Stock or the rights of such shares as required by Delaware General Corporation Law) and Spyre&#8217;s Certificate of Designation of Series B <span style="white-space:nowrap">Non-Voting</span> Convertible Preferred Stock (&#8220;Series B Certificate of Designation&#8221;), the Series B Preferred Stock does not have voting rights. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Corporation Information </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We were formed as a limited liability company under the laws of the State of Delaware in December 2013 and converted to a Delaware corporation in March 2015. On June&#160;22, 2023, we completed the Asset Acquisition, pursuant to which all of <span style="white-space:nowrap">Pre-Merger</span> Spyre&#8217;s outstanding equity interests were exchanged based on a fixed exchange ratio of 0.5494488 to 1 for consideration from Spyre of 517,809 shares of Common Stock and 364,887 shares of Series A Preferred Stock in addition to the assumption of outstanding and unexercised stock options to purchase 2,734 shares of Common Stock from the Amended and Restated Spyre 2023 Equity Incentive Plan. On November&#160;28, 2023, we changed our name from &#8220;Aeglea Biotherapeutics, Inc.&#8221; to &#8220;Spyre Therapeutics, Inc.&#8221; and our Nasdaq ticker symbol from &#8220;AGLE&#8221; to &#8220;SYRE&#8221;. Our principal executive offices are located at 221 Crescent Street, Building 23, Suite 105, Waltham, MA 02453, and our telephone number is (617) <span style="white-space:nowrap">651-5940.</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&#160;8, 2023, we effected a reverse stock split of our Common Stock at a ratio of <span style="white-space:nowrap"><span style="white-space:nowrap">1-for-25.</span></span> Except as indicated otherwise, all share numbers related to our Common Stock disclosed in this prospectus have been adjusted on a post-Reverse Split basis. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Implications of Being a Smaller Reporting Company </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a &#8220;smaller reporting company,&#8221; meaning that the market value of our Common Stock held by <span style="white-space:nowrap">non-affiliates</span> is less than $700.0&#160;million and our annual revenue is less than $100.0&#160;million during the most </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">6 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
recently completed fiscal year. We may continue to be a smaller reporting company after this offering if either (i)&#160;the market value of our Common Stock held by <span style="white-space:nowrap">non-affiliates</span> is less than $250.0&#160;million or (ii)&#160;our annual revenue is less than $100.0&#160;million during the most recently completed fiscal year and the market value of our Common Stock held by <span style="white-space:nowrap">non-affiliates</span> is less than $700.0&#160;million. As a smaller reporting company we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on Form <span style="white-space:nowrap">10-K</span> and smaller reporting companies have reduced disclosure obligations regarding executive compensation. </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">7 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">The Offering </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="vertical-align:TOP">
<td style="width:38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Shares Offered by the Selling Securityholders </p></td>
<td>Up to (i) 6,000,000 shares of Common Stock and (ii) 6,000,000 shares of Common Stock issuable upon the conversion of 150,000 shares of Series B Preferred Stock. </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="vertical-align:TOP">
<td style="width:38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Terms of the Offering </p></td>
<td>The selling securityholders will determine when and how they will dispose of the shares of Common Stock and shares of Common Stock issuable upon conversion of Series B Preferred Stock registered under this prospectus for resale. </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="vertical-align:TOP">
<td style="width:38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Shares Outstanding </p></td>
<td>As of December&#160;11, 2023, the closing date of the December 2023 PIPE, there were 36,021,007 shares of our Common Stock, 437,037 shares of Series A Preferred Stock and 150,000 shares of Series B Preferred Stock outstanding. </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="vertical-align:TOP">
<td style="width:38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Use of Proceeds </p></td>
<td>We will not receive any proceeds from the sale of the Resale Shares offered by the Selling Stockholders under this prospectus. The net proceeds from the sale of the Resale Shares offered by this prospectus will be received by the Selling Stockholders. See the section titled &#8220;Use of Proceeds.&#8221; </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="vertical-align:TOP">
<td style="width:38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Risk Factors </p></td>
<td>See the section titled &#8220;Risk Factors&#8221; and other information included in this prospectus for a discussion of factors that you should consider carefully before deciding to invest in our securities. </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="vertical-align:TOP">
<td style="width:38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Trading Markets and Ticker Symbols </p></td>
<td>Our Common Stock is listed on The Nasdaq Capital Market under the symbol &#8220;SYRE.&#8221; </td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The number of issued and outstanding shares of Common Stock does not include the following, as of December&#160;11, 2023: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">17,481,480 shares of Common Stock issuable upon the conversion of 437,037 shares of Series A Preferred Stock; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">6,000,000 shares of Common Stock issuable upon the conversion of 150,000 shares of Series B Preferred Stock; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">3,029 shares of Common Stock reserved for issuance under our 2015 Equity Incentive Plan; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">4,968,578 shares of Common Stock reserved for issuance under our Amended and Restated 2016 Equity Incentive Plan; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">6,044,000 shares of Common Stock reserved for issuance under our 2018 Equity Inducement Plan, as amended; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">72,404 shares of Common Stock reserved for issuance pursuant to our 2016 Employee Stock Purchase Plan; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">250,000 shares of Common Stock reserved for issuance upon the exercise of 250,000 <span style="white-space:nowrap">pre-funded</span> warrants to acquire shares of Common Stock; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">121,871 shares of Common Stock reserved for issuance under the Spyre 2023 Equity Incentive Plan, as amended and assumed by us. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as indicated otherwise, all share numbers related to our Common Stock disclosed in this prospectus have been adjusted on a post-Reverse Split basis. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For additional information concerning the offering, see the section titled &#8220;<span style="font-style:italic">Plan of Distribution</span>.&#8221; </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">8 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx518298_4">RISK FACTOR SUMMARY </p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following summarizes the principal factors that make an investment in the Company speculative or risky, all of which are more fully described in the Risk Factors section below. This summary should be read in conjunction with the Risk Factors section and should not be relied upon as an exhaustive summary of the material risks facing our business. The occurrence of any of these risks could harm our business, financial condition, results of operations and/or growth prospects or cause our actual results to differ materially from those contained in forward-looking statements we have made in this prospectus and those we may make from time to time. You should consider all of the risk factors described in our public filings when evaluating our business. </p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to Our Financial Condition and Capital Requirements </p> <p style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">There is no guarantee that our acquisition of <span style="white-space:nowrap">Pre-Merger</span> Spyre will increase stockholder value. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We will not be able to continue as a going concern if we are unable to raise additional capital when needed. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We have never generated any revenue from product sales and may never be profitable. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We anticipate that we will continue to incur significant losses for the foreseeable future. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We may not be able to raise the capital that we need to support our business plans and raising additional capital may cause dilution to our stockholders and restrict our operations. </p></td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to the Discovery, Development and Commercialization </p> <p style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We face competition from companies that have developed or may develop competing programs. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Our programs are in preclinical stages of development and may fail in development or suffer delays. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We are substantially dependent on the success of the SPY001 and SPY002 programs. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We may fail to achieve our projected development goals in the time frames we announce and expect. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We may not be successful in our efforts to build a pipeline of programs with commercial value. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Our studies and trials may not be sufficient to support regulatory approval of any of our programs. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We may encounter difficulties enrolling patients in our future clinical trials. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Preliminary or &#8220;topline&#8221; data from our clinical trials may change as more data becomes available. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Our future clinical trials may reveal significant adverse events or side effects. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We may fail to capitalize on more profitable or potentially successful programs than those we pursue. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Any of our future approved products may not achieve regulatory approval, market acceptance or commercial success. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Certain of our programs may compete with our other programs. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The FDA may not accept data from clinical trials we conduct at sites outside the United States. </p></td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to Government Regulation </p> <p style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">FDA and comparable foreign regulatory approval processes are lengthy and time-consuming and we may not be able to obtain or may be delayed in obtaining regulatory approvals for our programs. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We may not be able to meet requirements for chemistry, manufacturing and control of our programs. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Our programs may face competition sooner than anticipated. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Even if we receive regulatory approval, we will be subject to extensive ongoing regulatory obligations. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We may face difficulties from healthcare legislative reform measures. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Our operations and arrangements with third-parties are subject to healthcare regulatory laws. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We may be unable to offer programs at competitive prices. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We may face criminal liability or other consequences for violations of U.S. and foreign trade regulations. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Foreign governments may impose strict price controls, which may adversely affect our revenue. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Any Fast Track Designation we may pursue may not hasten development or regulatory review. </p></td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to Our Intellectual Property </p> <p style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Our ability to protect our patents and other proprietary rights is uncertain. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We may fail in obtaining or maintaining necessary rights to our programs. </p></td></tr></table>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">9 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We may be subject to patent infringement claims or may need to file such claims. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We may subject to claims of wrongful hiring of employees or wrongful use of confidential information. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Our patents and our ability to protect our products may be impaired by changes to patent laws. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Our patent protection could be reduced or eliminated for <span style="white-space:nowrap">non-compliance</span> with regulatory requirements. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We may fail to identify or interpret relevant third-party patents. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We may become subject to claims challenging the inventorship or ownership of our intellectual property. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Patent terms may be inadequate to protect our competitive position of our programs. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Our technology licensed from various third parties may be subject to retained rights. </p></td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to Our Reliance on Third Parties </p> <p style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We may fail to maintain collaborations and licensing arrangements with third parties that we rely on. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Third-parties we rely on for preclinical studies and clinical trials may fail to carry out their contractual duties. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We may be unable to use third-party manufacturing sites or our third-party manufacturers may encounter difficulties in production. </p></td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to Employee Matters, Managing Growth and Other Risks Related to Our Business </p> <p style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We may experience difficulties in managing the growth of our organization. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We may fail to attract or retain highly qualified personnel. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Our ability to operate in foreign markets is subject to regulatory burdens, risks and uncertainties. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Our employees or third-parties may engage in misconduct or other improper activities. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We may be impacted by security or data breaches or other improper access to our data. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We may fail to comply with privacy and data security regulations. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We may fail to comply with environmental, health and safety laws and regulations. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We may be subject to adverse legislative or regulatory tax changes. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We may fail to realize the benefits of our business or product acquisitions or our strategic alliances. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We may be impacted by the failure of financial institutions. </p></td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to Our Common Stock </p> <p style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We may fail to obtain stockholder approval of the conversion of our Series B Preferred Stock. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Our certificate of incorporation, Delaware law and certain contracts include anti-takeover provisions. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Our certificate of incorporation and bylaws contain exclusive forum provisions. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We do not anticipate paying any dividends in the foreseeable future. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Future sales of shares by existing stockholders could cause our stock price to decline. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Future sales and issuances of equity and debt could result in additional dilution to our stockholders. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Our principal stockholders own a significant percentage of our stock. </p></td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">General Risk Factors </p> <p style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The market price of our Common Stock has historically been volatile and may drop in the future. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We incur significant costs as associated with complying with public company reporting requirements. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">A lack of analyst coverage may cause a decline in our stock price or trading volume. We may fail to maintain proper and effective internal controls. </p></td></tr></table>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">10 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx518298_5">RISK FACTORS </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to Our Financial Condition and Capital Requirements </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">There is no guarantee that our Asset Acquisition will increase stockholder value. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2023, we acquired <span style="white-space:nowrap">Pre-Merger</span> Spyre. We cannot guarantee that implementing the Asset Acquisition and related transactions will not impair stockholder value or otherwise adversely affect our business. The Asset Acquisition poses significant integration challenges between our businesses and management teams which could result in management and business disruptions, any of which could harm our results of operation, business prospects, and impair the value of the Asset Acquisition to our stockholders. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We will need to raise additional capital, and if we are unable to do so when needed, we will not be able to continue as a going concern. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our most recent Quarterly Report on Form <span style="white-space:nowrap">10-Q</span> filed on November&#160;9, 2023 includes disclosures regarding our management&#8217;s substantial doubt assessment of our ability to continue as a going concern. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Developing our product candidates requires a substantial amount of capital. We expect our research and development expenses to increase in connection with our ongoing activities, particularly as we advance our product candidates through clinical trials. We will need to raise additional capital to fund our operations and such funding may not be available to us on acceptable terms, or at all, and such funding may become even more difficult to obtain due to rising interest rates and the current downturn in the U.S. capital markets and the biotechnology sector in general. Competition for additional capital among biotechnology companies may be particularly intense during this present economic downturn. We may be unable to raise capital through public offerings of our Common Stock and may need to turn to alternative financing arrangements. Such arrangements, if we pursue them, could involve issuances of one or more types of securities, including Common Stock, Preferred Stock, convertible debt, warrants to acquire Common Stock or other securities. These securities could be issued at or below the then prevailing market price for our Common Stock. In addition, if we issue debt securities, the holders of the debt would have a claim to our assets that would be superior to the rights of stockholders until the principal, accrued and unpaid interest and any premium or make-whole has been paid. Interest on any newly-issued debt securities and/or newly-incurred borrowings would increase our operating costs and reduce our net income (or increase our net loss), and these impacts may be material. If the issuance of new securities results in diminished rights to holders of our Common Stock, the market price of our Common Stock could be materially and adversely affected. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not currently have any products approved for sale and do not generate any revenue from product sales. Accordingly, we expect to rely primarily on equity and/or debt financings to fund our continued operations. Our ability to raise additional funds will depend, in part, on the success of our preclinical studies and clinical trials and other product development activities, regulatory events, our ability to identify and enter into licensing or other strategic arrangements, and other events or conditions that may affect our value or prospects, as well as factors related to financial, economic and market conditions, many of which are beyond our control. There can be no assurances that sufficient funds will be available to us when required or on acceptable terms, if at all. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we are unable to raise additional capital when required or on acceptable terms, we may be required to: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">significantly delay, scale back, or discontinue the development or commercialization of our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">seek strategic partnerships, or amend existing partnerships, for research and development programs at an earlier stage than otherwise would be desirable or that we otherwise would have sought to develop independently, or on terms that are less favorable than might otherwise be available in the future; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">dispose of technology assets, or relinquish or license on unfavorable terms, our rights to technologies or any of our product candidates that we otherwise would seek to develop or commercialize ourselves; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">11 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">pursue the sale of our company to a third party at a price that may result in a loss on investment for our stockholders; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">file for bankruptcy or cease operations altogether (and face any related legal proceedings). </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any of these events could have a material adverse effect on our business, operating results, and prospects. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even if successful in raising new capital, we could be limited in the amount of capital we raise due to investor demand restrictions placed on the amount of capital we raise or other reasons. For example, we are currently subject to the limitations set forth in Instruction I.B.6 of Form <span style="white-space:nowrap">S-3.</span></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, any capital raising efforts are subject to significant risks and contingencies, as described in more detail under the risk factor titled &#8220;<span style="font-style:italic">Raising additional capital may cause dilution to our stockholders, restrict our operations, or require us to relinquish rights.</span>&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We have never generated any revenue from product sales and may never be profitable. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have no products approved for commercialization and have never generated any revenue from product sales. Our ability to generate revenue and achieve profitability depends on our ability, alone or with strategic collaborators, to successfully complete the development of, and obtain the regulatory and marketing approvals necessary to commercialize one or more of our product candidates. We do not anticipate generating revenue from product sales for the foreseeable future. Our ability to generate future revenue from product sales depends heavily on our success in many areas, including but not limited to: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">completing research and development of our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">obtaining regulatory and marketing approvals for our product candidates for which we complete clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">manufacturing product candidates and establishing and maintaining supply and manufacturing relationships with third parties that are commercially feasible, meet regulatory requirements and our supply needs in sufficient quantities to meet market demand for our product candidates, if approved; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">qualify for adequate coverage and reimbursement by government and third-party payors for any product candidates for which we obtain regulatory and marketing approval; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">marketing, launching, and commercializing product candidates for which we obtain regulatory and marketing approval, either directly or with a collaborator or distributor; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">gaining market acceptance of our product candidates as treatment options; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">addressing any competing products and technological and market developments; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">implementing internal systems and infrastructure, as needed; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">protecting and enforcing our intellectual property rights, including patents, trade secrets, and <span style="white-space:nowrap">know-how;</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">negotiating favorable terms in any collaboration, licensing, or other arrangements into which we may enter; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">obtaining coverage and adequate reimbursement from third-party payors and maintaining pricing for our product candidates that supports profitability; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">attracting, hiring, and retaining qualified personnel. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even if one or more of the product candidates that we develop is approved for commercial sale, we anticipate incurring significant costs associated with commercializing any approved product candidate. Our expenses could </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">12 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
increase beyond expectations if we are required by regulatory authorities to perform clinical and other studies in addition to those that we anticipate. Even if we are able to generate revenues from the sale of any approved products, we may not become profitable and may need to obtain additional funding to continue operations. Portions of the research programs with respect to which we have exercised the Option to acquire intellectual property license rights to or have the Option to acquire intellectual property license rights to pursuant to the Paragon Agreement may be <span style="white-space:nowrap">in-licensed</span> from third parties, which make the commercial sale of such <span style="white-space:nowrap">in-licensed</span> products potentially subject to additional royalty and milestone payments to such third parties. We will also have to develop or acquire manufacturing capabilities or continue to contract with contract manufacturers in order to continue development and potential commercialization of our product candidates. For instance, if the costs of manufacturing our drug product are not commercially feasible, we will need to develop or procure our drug product in a commercially feasible manner in order to successfully commercialize a future approved product, if any. Additionally, if we are not able to generate revenue from the sale of any approved products, we may never become profitable. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We have historically incurred losses, have a limited operating history on which to assess our business, and anticipate that we will continue to incur significant losses for the foreseeable future. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a biopharmaceutical company with a limited operating history. Since inception, we have incurred significant operating losses. For the three and nine months ended September&#160;30, 2023, we reported a net loss of $40.1&#160;million and $275.6&#160;million, respectively. For the years ended December&#160;31, 2022 and 2021, we reported a net loss of $83.8&#160;million and $65.8&#160;million, respectively. As of September&#160;30, 2023, we had an accumulated deficit of $701.2&#160;million. We will need to raise substantial additional capital to continue to fund our operations in the future. If our stockholders do not timely approve the conversion of our Series B Preferred Stock, then the holders of our Series B Preferred Stock may be entitled to require us to settle their shares of Series B Preferred Stock for cash at a price per share equal to the fair value of the Series B Preferred Stock, as described in our Series B Certificate of Designation relating to the Series B Preferred Stock. The cash redemption is not under our control and raises substantial doubt about our ability to continue as a going concern. The consolidated financial statements included in this prospectus assume the Company will continue as a going concern through the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Failure to raise capital as and when needed, on favorable terms or at all, would have a negative impact on our financial condition and our ability to develop our product candidates. Changing circumstances may cause us to consume capital significantly faster or slower than we currently anticipate. If we are unable to acquire additional capital or resources, we will be required to modify our operational plans to complete future milestones and we may be required to delay, limit, reduce or eliminate development or future commercialization efforts of product candidates and/or programs. We have based these estimates on assumptions that may prove to be wrong, and we could exhaust our available financial resources sooner than we currently anticipate. We may be forced to reduce our operating expenses and raise additional funds to meet our working capital needs, principally through the additional sales of our securities or debt financings or entering into strategic collaborations. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have devoted substantially all of our financial resources to identify, acquire, and develop our product candidates, including conducting clinical trials and providing general and administrative support for our operations. To date, we have funded our operations primarily from the sale and issuance of convertible preferred and common equity securities, <span style="white-space:nowrap">pre-funded</span> warrants, the collection of grant proceeds, and the licensing of our product rights for commercialization of pegzilarginase in Europe and certain countries in the Middle East. The amount of our future net losses will depend, in part, on the rate of our future expenditures and our ability to obtain funding through equity or debt financings, strategic collaborations, or grants. Biopharmaceutical product development is a highly speculative undertaking and involves a substantial degree of risk. We expect our losses to increase as our product candidates enter more advanced clinical trials. It may be several years, if ever, before we complete pivotal clinical trials or have a product candidate approved for commercialization. We expect to invest significant funds into the research and development of our current product candidates to determine the potential to advance these product candidates to regulatory approval. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">13 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we obtain regulatory approval to market a product candidate, our future revenue will depend upon the size of any markets in which our product candidates may receive approval, and our ability to achieve sufficient market acceptance, pricing, coverage and adequate reimbursement from third-party payors, and adequate market share for our product candidates in those markets. Even if we obtain adequate market share for our product candidates, because the potential markets in which our product candidates may ultimately receive regulatory approval could be very small, we may never become profitable despite obtaining such market share and acceptance of our products. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future and our expenses will increase substantially if and as we: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">continue the preclinical development and initiate the clinical development of our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">continue efforts to discover and develop new product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">continue the manufacturing of our product candidates or increase volumes manufactured by third parties; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">advance our product candidates into larger, more expensive clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">initiate additional preclinical studies or clinical trials for our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">seek regulatory and marketing approvals and reimbursement for our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">establish a sales, marketing, and distribution infrastructure to commercialize any products for which we may obtain marketing approval and market for ourselves; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">seek to identify, assess, acquire, and/or develop other product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">make milestone, royalty, or other payments under third-party license agreements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">seek to maintain, protect, and expand our intellectual property portfolio; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">pay penalties under our registration rights agreement for failing to timely register the applicable securities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">seek to attract and retain skilled personnel; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">experience any delays or encounter issues with the development and potential for regulatory approval of our clinical and product candidates such as safety issues, manufacturing delays, clinical trial accrual delays, longer <span style="white-space:nowrap">follow-up</span> for planned studies or trials, additional major studies or trials, or supportive trials necessary to support marketing approval. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, the net losses we incur may fluctuate significantly from quarter to quarter and year to year, such that a <span style="white-space:nowrap"><span style="white-space:nowrap">period-to-period</span></span> comparison of our results of operations may not be a good indication of our future performance. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Raising additional capital may cause dilution to our stockholders, restrict our operations, or require us to relinquish rights. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Until such time, if ever, as we can generate substantial revenue from the sale of our product candidates, we expect to finance our cash needs through a combination of equity offerings, debt financings and license and development agreements. To the extent that we raise additional capital through the sale of equity securities or convertible debt securities, the ownership interest of our stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a holder of Common Stock. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">14 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may be required to relinquish valuable rights to our research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings or other arrangements with third parties when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to third parties to develop and market product candidates that we would otherwise prefer to develop and market ourselves. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the extent that we raise additional capital through the sale of equity, including pursuant to any sales under convertible debt or other securities convertible into equity, the ownership interest of our stockholders will be diluted, and the terms of these new securities may include liquidation or other preferences that adversely affect the rights of our stockholders. For instance, in December 2023, we sold an aggregate of 6,000,000 shares of Common Stock and 150,000 shares of our Series B Preferred Stock in the December 2023 PIPE to the December 2023 Investors for gross proceeds of $180.0&#160;million. Subject to receiving the requisite stockholder approval and certain beneficial ownership limitations set by each holder of Series B Preferred Stock, each share of Series B Preferred Stock will automatically convert into an aggregate of 40 shares of our Common Stock. We are required to solicit the consent of our stockholders with regard to conversion of the shares of our Series B Preferred Stock, which will be voted on at our 2024 annual meeting of stockholders. If our stockholders fail to approve such matters, we may be subject to financial penalties that could materially harm our business, including the forced settlement of shares of Series B Preferred Stock for cash, as described in our Series B Certificate of Designation. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Debt financing, if available, would likely involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, making additional product acquisitions, or declaring dividends. If we raise additional funds through strategic collaborations or licensing arrangements with third parties, we may have to relinquish valuable rights to our product candidates or future revenue streams or grant licenses on terms that are not favorable to us. We cannot be assured that we will be able to obtain additional funding if and when necessary to fund our entire portfolio of product candidates to meet our projected plans. If we are unable to obtain funding on a timely basis, we may be required to delay or discontinue one or more of our development programs or the commercialization of any product candidates or be unable to expand our operations or otherwise capitalize on potential business opportunities, which could materially harm our business, financial condition, and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to Discovery, Development and Commercialization </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We face competition from entities that have developed or may develop programs for the diseases addressed by our programs. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The development and commercialization of drugs is highly competitive. Our programs, if approved, will face significant competition and our failure to effectively compete may prevent us from achieving significant market penetration. We compete with a variety of multinational biopharmaceutical companies, specialized biotechnology companies and emerging biotechnology companies, as well as academic institutions, governmental agencies, and public and private research institutions, among others. Many of the companies with which we are currently competing or will complete against in the future have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals, and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industry may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites, patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">15 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our competitors have developed, are developing or will develop programs and processes competitive with our programs and processes. Competitive therapeutic treatments include those that have already been approved and accepted by the medical community and any new treatments. Our success will depend partially on our ability to develop and commercialize products that have a competitive safety, efficacy, dosing and/or presentation profile. Our commercial opportunity and success will be reduced or eliminated if competing products are safer, more effective, have a more attractive dosing profile or presentation or are less expensive than the products we develop, or if our competitors develop competing products or if biosimilars enter the market more quickly than we do and are able to gain market acceptance. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, because of the competitive landscape for inflammatory and immunology (&#8220;I&amp;I&#8221;) indications, we may also face competition for clinical trial enrollment. Patient enrollment will depend on many factors, including if potential clinical trial patients choose to undergo treatment with approved products or enroll in competitors&#8217; ongoing clinical trials for programs that are under development for the same indications as our programs. An increase in the number of approved products for the indications we are targeting with our programs may further exacerbate this competition. Our inability to enroll a sufficient number of patients could, among others, delay our development timeline, which may further harm our competitive position. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our programs are in preclinical stages of development and may fail in development or suffer delays that materially and adversely affect their commercial viability. If we or our current or future collaborators are unable to complete development of, or commercialize our programs, or experience significant delays in doing so, our business will be materially harmed. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have no products on the market and all of our programs are in preclinical stages of development and have not been tested in humans. As a result, we expect it will be many years before we commercialize any program, if ever. Our ability to achieve and sustain profitability depends on obtaining regulatory approvals for, and successfully commercializing, our programs, either alone or with third parties, and we cannot guarantee you that we will ever obtain regulatory approval for any of our programs. We have not yet demonstrated our ability to initiate or complete any clinical trials, obtain regulatory approvals, manufacture a clinical development or commercial scale product or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful product commercialization. Before obtaining regulatory approval for the commercial distribution of our programs, we or an existing or future collaborator must conduct extensive preclinical tests and clinical trials to demonstrate the safety and efficacy in humans of our programs and future product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We or our collaborators may experience delays in initiating or completing clinical trials. We or our collaborators also may experience numerous unforeseen events during, or as a result of, any current or future clinical trials that we could conduct that could delay or prevent our ability to receive marketing approval or commercialize our current programs or any future programs, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">regulators or institutional review boards (&#8220;IRBs&#8221;), the FDA or ethics committees may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we may experience delays in reaching, or fail to reach, agreement on acceptable terms with prospective trial sites and prospective contract research organizations (&#8220;CROs&#8221;), the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">clinical trial sites deviating from trial protocol or dropping out of a trial; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">clinical trials of any programs may fail to show safety or efficacy, produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional preclinical studies or clinical trials or we may decide to abandon product development programs; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the number of subjects required for clinical trials of any programs may be larger than we anticipate, especially if regulatory bodies require completion of <span style="white-space:nowrap">non-inferiority</span> or superiority trials, enrollment in </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">16 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
these clinical trials may be slower than we anticipate or subjects may drop out of these clinical trials or fail to return for post-treatment <span style="white-space:nowrap">follow-up</span> at a higher rate than we anticipate; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all, or may deviate from the clinical trial protocol or drop out of the trial, which may require that we add new clinical trial sites or investigators; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we may elect to, or regulators, IRBs or ethics committees may require that we or our investigators, suspend or terminate clinical research or trials for various reasons, including noncompliance with regulatory requirements or a finding that the participants in our trials are being exposed to unacceptable health risks; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the cost of clinical trials of any of our programs may be greater than we anticipate; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the quality of our programs or other materials necessary to conduct clinical trials of our programs may be inadequate to initiate or complete a given clinical trial; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our inability to manufacture sufficient quantities of our programs for use in clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reports from clinical testing of other therapies may raise safety or efficacy concerns about our programs; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our failure to establish an appropriate safety profile for a program based on clinical or preclinical data for such programs as well as data emerging from other therapies in the same class as our programs; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the FDA or other regulatory authorities may require us to submit additional data such as long-term toxicology studies, or impose other requirements before permitting us to initiate a clinical trial. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Commencing clinical trials in the United States is subject to acceptance by the FDA of an investigational new drug application (&#8220;IND&#8221;), biologics license application (&#8220;BLA&#8221;) or similar application and finalizing the trial design based on discussions with the FDA and other regulatory authorities. In the event that the FDA requires us to complete additional preclinical studies or we are required to satisfy other FDA requests prior to commencing clinical trials, the start of our first clinical trials may be delayed. Even after we receive and incorporate guidance from these regulatory authorities, the FDA or other regulatory authorities could disagree that we have satisfied their requirements to commence any clinical trial or change their position on the acceptability of our trial design or the clinical endpoints selected, which may require us to complete additional preclinical studies or clinical trials, delay the enrollment of our clinical trials or impose stricter approval conditions than we currently expect. There are equivalent processes and risks applicable to clinical trial applications in other countries, including countries in the European Union (&#8220;EU&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may not have the financial resources to continue development of, or to modify existing or enter into new collaborations for, a program if we experience any issues that delay or prevent regulatory approval of, or our ability to commercialize, our programs. We or our current or future collaborators&#8217; inability to complete development of, or commercialize our programs, or significant delays in doing so, could have a material and adverse effect on our business, financial condition, results of operations and prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We are substantially dependent on the success of our two most advanced programs, SPY001 and SPY002, and our anticipated clinical trials of such programs may not be successful. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our future success is substantially dependent on our ability to timely obtain marketing approval for, and then successfully commercialize, our two most advanced programs, SPY001 and SPY002. We exercised our Option with respect to the SPY001 and SPY002 programs on July&#160;12, 2023 and December&#160;14, 2023, respectively. We are investing a majority of our efforts and financial resources into the research and development of these programs. We anticipate initiating a Phase 1 clinical trial in healthy volunteers of SPY001 in the first half of 2024 and of SPY002 in the second half of 2024, each subject to the filing of an IND or foreign equivalent and regulatory approval. The success of our programs is dependent on observing a longer half-life of our programs in </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">17 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
humans than other mAbs currently marketed and in development as we believe this longer half-life has the potential to result in a more favorable dosing schedule for our programs, assuming they successfully complete clinical development and obtain marketing approval. This is based in part on the assumption that the longer half-life we have observed in <span style="white-space:nowrap">non-human</span> primates (&#8220;NHPs&#8221;) will translate into an extended half-life of our programs in humans. To the extent we do not observe this extended half-life when we dose humans with our programs, it would significantly and adversely affect the clinical and commercial potential of our programs. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our programs will require additional clinical development, evaluation of clinical, preclinical and manufacturing activities, marketing approval in multiple jurisdictions, substantial investment and significant marketing efforts before we generate any revenues from product sales. We are not permitted to market or promote these programs, or any other programs, before we receive marketing approval from the FDA and comparable foreign regulatory authorities, and we may never receive such marketing approvals. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The success of our programs will depend on a variety of factors. We do not have complete control over many of these factors, including certain aspects of clinical development and the regulatory submission process, potential threats to our intellectual property rights and the manufacturing, marketing, distribution and sales efforts of any future collaborator. Accordingly, we cannot assure you that we will ever be able to generate revenue through the sale of these programs, even if approved. If we are not successful in commercializing our SPY001 or SPY002 programs, or are significantly delayed in doing so, our business will be materially harmed. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we do not achieve our projected development goals in the time frames we announce and expect, the commercialization of our programs may be delayed and our expenses may increase and, as a result, our stock price may decline. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From time to time, we estimate the timing of the anticipated accomplishment of various scientific, clinical, regulatory and other product development goals, which we sometimes refer to as milestones. These milestones may include the commencement or completion of scientific studies and clinical trials, such as the expected timing for the anticipated commencement of our Phase 1 clinical trials in IBD, as well as the submission of regulatory filings. From time to time, we may publicly announce the expected timing of some of these milestones. All of these milestones are and will be based on numerous assumptions. The actual timing of these milestones can vary dramatically compared to our estimates, in some cases for reasons beyond our control. If we do not meet these milestones as publicly announced, or at all, the commercialization of our programs may be delayed or never achieved and, as a result, our stock price may decline. Additionally, delays relative to our projected timelines are likely to cause overall expenses to increase, which may require us to raise additional capital sooner than expected and prior to achieving targeted development milestones. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our approach to the discovery and development of our programs is unproven, and we may not be successful in our efforts to build a pipeline of programs with commercial value. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our approach to the discovery and development of the research programs with respect to which we have exercised the Option to acquire intellectual property license rights to or have the Option to acquire intellectual property license rights to pursuant to the Paragon Agreement leverages clinically validated mechanisms of action and incorporates advanced antibody engineering to optimize half-life and other properties designed to overcome limitations of existing therapies. Our programs are purposefully designed to improve upon existing product candidates and products while maintaining the same, well-established mechanisms of action. However, the scientific research that forms the basis of our efforts to develop programs using half-life extension technologies, including YTE and LS amino acid substitutions, is ongoing and may not result in viable programs. We have limited clinical data on product candidates utilizing YTE and LS half-life extension technologies, especially in I&amp;I indications, demonstrating whether they are safe or effective for long-term treatment in humans. The long-term safety and efficacy of these technologies and the extended half-life and exposure profile of our programs compared to currently approved products is unknown. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">18 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may ultimately discover that utilizing half-life extension technologies for our specific targets and indications and any programs resulting therefrom do not possess certain properties required for therapeutic effectiveness. We currently have only preclinical data regarding the increased half-life properties of our programs and the same results may not be seen in humans. In addition, programs using half-life extension technologies may demonstrate different chemical and pharmacological properties in patients than they do in laboratory studies. This technology and any programs resulting therefrom may not demonstrate the same chemical and pharmacological properties in humans and may interact with human biological systems in unforeseen, ineffective or harmful ways. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, we may in the future seek to discover and develop programs that are based on novel targets and technologies that are unproven. If our discovery activities fail to identify novel targets or technologies for drug discovery, or such targets prove to be unsuitable for treating human disease, we may not be able to develop viable additional programs. We and our existing or future collaborators may never receive approval to market and commercialize any program. Even if we or an existing or future collaborator obtains regulatory approval, the approval may be for targets, disease indications or patient populations that are not as broad as we intended or desired or may require labeling that includes significant use or distribution restrictions or safety warnings. If the products resulting from the research programs with respect to which we have exercised the Option to acquire intellectual property license rights to or have the Option to acquire intellectual property license rights to pursuant to the Paragon Agreement prove to be ineffective, unsafe or commercially unviable, such programs would have little, if any, value, which would have a material and adverse effect on our business, financial condition, results of operations and prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Preclinical and clinical development involves a lengthy and expensive process that is subject to delays and with uncertain outcomes, and results of earlier studies and trials may not be predictive of future clinical trial results. If our preclinical studies and clinical trials are not sufficient to support regulatory approval of any of our programs, we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development of such program. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Before obtaining marketing approval from regulatory authorities for the sale of any program, we must complete preclinical studies and then conduct extensive clinical trials to demonstrate the safety and efficacy of our program in humans. Our clinical trials may not be conducted as planned or completed on schedule, if at all, and failure can occur at any time during the preclinical study or clinical trial process. For example, we depend on the availability of NHPs to conduct certain preclinical studies that we are required to complete prior to submitting an IND and initiating clinical development. There is currently a global shortage of NHPs available for drug development. This could cause the cost of obtaining NHPs for our future preclinical studies to increase significantly and, if the shortage continues, could also result in delays to our development timelines. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Furthermore, a failure of one or more clinical trials can occur at any stage of testing. The outcome of preclinical studies and early-stage clinical trials may not be predictive of the success of later clinical trials. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their programs performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their programs. In addition, we expect to rely on patients to provide feedback on measures such as measures of quality of life, which are subjective and inherently difficult to evaluate. These measures can be influenced by factors outside of our control, and can vary widely from day to day for a particular patient, and from patient to patient and from site to site within a clinical trial. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We cannot be sure that the FDA will agree with our clinical development plan. We plan to use the data from our planned Phase 1 trials of our SPY001 and SPY002 programs in healthy volunteers to support Phase 2 trials in IBD and other I&amp;I indications. If the FDA requires us to conduct additional trials or enroll additional patients, our development timelines may be delayed. We cannot be sure that submission of an IND, BLA or similar application will result in the FDA or comparable foreign regulatory authorities, as applicable, allowing clinical trials to begin in a timely manner, if at all. Moreover, even if these trials begin, issues may arise that could cause regulatory authorities to suspend or terminate such clinical trials. Events that may prevent successful or timely </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">19 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
initiation or completion of clinical trials include: inability to generate sufficient preclinical, toxicology or other <span style="font-style:italic">in vivo </span>or <span style="font-style:italic">in vitro </span>data to support the initiation or continuation of clinical trials; delays in reaching a consensus with regulatory authorities on study design or implementation of the clinical trials; delays or failure in obtaining regulatory authorization to commence a trial; delays in reaching agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical trial sites; delays in identifying, recruiting and training suitable clinical investigators; delays in obtaining required IRB approval at each clinical trial site; delays in manufacturing, testing, releasing, validating or importing/exporting sufficient stable quantities of our programs for use in clinical trials or the inability to do any of the foregoing; failure by our CROs, other third parties or us to adhere to clinical trial protocols; failure to perform in accordance with the FDA&#8217;s or any other regulatory authority&#8217;s good clinical practice requirements (&#8220;GCPs&#8221;) or applicable regulatory guidelines in other countries; changes to the clinical trial protocols; clinical sites deviating from trial protocol or dropping out of a trial; changes in regulatory requirements and guidance that require amending or submitting new clinical protocols; selection of clinical endpoints that require prolonged periods of observation or analyses of resulting data; transfer of manufacturing processes to larger-scale facilities operated by a contract manufacturing organization (&#8220;CMO&#8221;) and delays or failure by our CMOs or us to make any necessary changes to such manufacturing process; and third parties being unwilling or unable to satisfy their contractual obligations to us. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We could also encounter delays if a clinical trial is suspended or terminated by us, by the IRBs of the institutions in which such clinical trials are being conducted, by the Data Safety Monitoring Board, if any, for such clinical trial or by the FDA or comparable foreign regulatory authorities. Such authorities may suspend or terminate a clinical trial due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical trial protocols, inspection of the clinical trial operations or trial site by the FDA or comparable foreign regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from the programs, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. If we are required to conduct additional clinical trials or other testing of our programs beyond those that we currently contemplate, if we are unable to successfully complete clinical trials of our programs, if the results of these trials are not positive or are only moderately positive or if there are safety concerns, our business and results of operations may be adversely affected and we may incur significant additional costs. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we encounter difficulties enrolling patients in our future clinical trials, our clinical development activities could be delayed or otherwise adversely affected. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may experience difficulties in patient enrollment in our future clinical trials for a variety of reasons. The timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of patients who remain in the trial until its conclusion. The enrollment of patients in future trials for any of our programs will depend on many factors, including if patients choose to enroll in clinical trials, rather than using approved products, or if our competitors have ongoing clinical trials for programs that are under development for the same indications as our programs, and patients instead enroll in such clinical trials. Additionally, the number of patients required for clinical trials of our programs may be larger than we anticipate, especially if regulatory bodies require the completion of <span style="white-space:nowrap">non-inferiority</span> or superiority trials. Even if we are able to enroll a sufficient number of patients for our future clinical trials, we may have difficulty maintaining patients in our clinical trials. Our inability to enroll or maintain a sufficient number of patients would result in significant delays in completing clinical trials or receipt of marketing approvals and increased development costs or may require us to abandon one or more clinical trials altogether. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Preliminary, &#8220;topline&#8221; or interim data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From time to time, we may publicly disclose preliminary or topline data from our preclinical studies and clinical trials, which are based on a preliminary analysis of then-available data, and the results and related findings and </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">20 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
conclusions are subject to change following a more comprehensive review of the data. We also make assumptions, estimations, calculations and conclusions as part of our analyses of these data without the opportunity to fully and carefully evaluate complete data. As a result, the preliminary or topline results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated or subsequently made subject to audit and verification procedures. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any preliminary or topline data should be viewed with caution until the final data are available. From time to time, we may also disclose interim data from our preclinical studies and clinical trials. Interim data are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available or as patients from our clinical trials continue other treatments. Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular program and our company in general. In addition, the information we choose to publicly disclose regarding a particular preclinical study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is material or otherwise appropriate information to include in our disclosure. If the preliminary, topline or interim data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our programs may be harmed, which could harm our business, operating results, prospects or financial condition. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our future clinical trials or those of our future collaborators may reveal significant adverse events or undesirable side effects not seen in our preclinical studies and may result in a safety profile that could halt clinical development, inhibit regulatory approval or limit commercial potential or market acceptance of any of our programs. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Results of our clinical trials could reveal a high and unacceptable severity and prevalence of side effects, adverse events or unexpected characteristics. While our preclinical studies in NHPs have not shown any such characteristics to date, we have not yet initiated any clinical trials in humans. If significant adverse events or other side effects are observed in any of our future clinical trials, we may have difficulty recruiting patients to such trials, patients may drop out of our trials, or we may be required to abandon the trials or our development efforts of one or more programs altogether. We, the FDA or other applicable regulatory authorities, or an IRB, may suspend any clinical trials of any program at any time for various reasons, including a belief that subjects or patients in such trials are being exposed to unacceptable health risks or adverse side effects. Some potential products developed in the biotechnology industry that initially showed therapeutic promise in early-stage studies and trials have later been found to cause side effects that prevented their further development. Other potential products have shown side effects in preclinical studies, which side effects do not present themselves in clinical trials in humans. Even if the side effects do not preclude the program from obtaining or maintaining marketing approval, undesirable side effects may inhibit market acceptance of the approved product due to its tolerability versus other therapies. In addition, an extended half-life could prolong the duration of undesirable side effects, which could also inhibit market acceptance. Treatment-emergent adverse events could also affect patient recruitment or the ability of enrolled subjects to complete our clinical trials or could result in potential product liability claims. Potential side effects associated with our programs may not be appropriately recognized or managed by the treating medical staff, as toxicities resulting from our programs may not be normally encountered in the general patient population and by medical personnel. Any of these occurrences could harm our business, financial condition, results of operations and prospects significantly. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, even if we successfully advance our programs or any future program through clinical trials, such trials will only include a limited number of patients and limited duration of exposure to our programs. As a result, we cannot be assured that adverse effects of our programs will not be uncovered when a significantly larger number of patients are exposed to the program after approval. Further, any clinical trials may not be sufficient to determine the effect and safety consequences of using our programs over a multi-year period. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">21 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If any of the foregoing events occur or if one or more of the research programs with respect to which we have exercised the Option to acquire intellectual property license rights to or have the Option to acquire intellectual property license rights to pursuant to the Paragon Agreement prove to be unsafe, our entire pipeline could be affected, which would have a material adverse effect on our business, financial condition, results of operations and prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may expend our limited resources to pursue a particular program and fail to capitalize on programs that may be more profitable or for which there is a greater likelihood of success. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because we have limited financial and managerial resources, we focus our research and development efforts on certain selected programs. For example, we are initially focused on our most advanced programs, SPY001 and SPY002. As a result, we may forgo or delay pursuit of opportunities with other programs that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs for specific indications may not yield any commercially viable programs. If we do not accurately evaluate the commercial potential or target market for a particular program, we may relinquish valuable rights to that program through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such program. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Any approved products resulting from our current programs or any future program may not achieve adequate market acceptance among clinicians, patients, healthcare third-party payors and others in the medical community necessary for commercial success and we may not generate any future revenue from the sale or licensing of such products. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even if regulatory approval is obtained for a product candidate resulting from one of our current or future programs, they may not gain market acceptance among physicians, patients, healthcare payors or the medical community. We may not generate or sustain revenue from sales of the product due to factors such as whether the product can be sold at a competitive cost and whether it will otherwise be accepted in the market. There are several approved products and product candidates in later stages of development for the treatment of IBD. However, our programs incorporate advanced antibody engineering to optimize the half-life and formulation of antibodies; to date, no such antibody has been approved by the FDA for the treatment of IBD. Market participants with significant influence over acceptance of new treatments, such as clinicians and third-party payors, may not adopt a biologic that incorporates half-life extension for our targeted indications, and we may not be able to convince the medical community and third-party payors to accept and use, or to provide favorable reimbursement for, any programs developed by us or our existing or future collaborators. An extended half-life may make it more difficult for patients to change treatments and there is a perception that half-life extension could exacerbate side effects, each of which may adversely affect our ability to gain market acceptance. Market acceptance of our programs will depend on many factors, including factors that are not within our control. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sales of medical products also depend on the willingness of clinicians to prescribe the treatment. We cannot predict whether clinicians, clinicians&#8217; organizations, hospitals, other healthcare providers, government agencies or private insurers will determine that our product is safe, therapeutically effective, cost effective or less burdensome as compared with competing treatments. If any current or future program is approved but does not achieve an adequate level of acceptance by such parties, we may not generate or derive sufficient revenue from that program and may not become or remain profitable. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Certain of our programs may compete with our other programs, which could negatively impact our business and reduce our future revenue. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are developing product candidates for the same indication: IBD, and may in the future develop our programs for other I&amp;I indications. Each such program targets a different mechanism of action. However, developing </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">22 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
multiple programs for a single indication may negatively impact our business if the programs compete with each other. For example, if multiple programs are conducting clinical trials at the same time, they could compete for the enrollment of patients. In addition, if multiple programs are approved for the same indication, they may compete for market share, which could limit our future revenue. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We plan to conduct clinical trials for programs at sites outside the United States, and the FDA may not accept data from trials conducted in such locations. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may choose to conduct one or more of our future clinical trials outside the United States. Although the FDA may accept data from clinical trials conducted outside the United States, acceptance of this data is subject to conditions imposed by the FDA. For example, the clinical trial must be well designed and conducted and performed by qualified investigators in accordance with ethical principles. The trial population must also adequately represent the U.S. population, and the data must be applicable to the U.S. population and U.S. medical practice in ways that the FDA deems clinically meaningful. In addition, while these clinical trials are subject to the applicable local laws, FDA acceptance of the data will depend on its determination that the trials also complied with all applicable U.S. laws and regulations. If the FDA does not accept the data from any trial that we conduct outside the United States, it would likely result in the need for additional trials, which would be costly and time-consuming and would delay or permanently halt our development of the applicable product candidates. Even if the FDA accepted such data, it could require us to modify our planned clinical trials to receive clearance to initiate such trials in the United States or to continue such trials once initiated. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, conducting international clinical trials presents additional risks that may delay completion of our clinical trials. These risks include the failure of enrolled patients in foreign countries to adhere to clinical protocol as a result of differences in healthcare services or cultural customs that could restrict or limit our ability to conduct our clinical trials, the administrative burdens of conducting clinical trials under multiple sets of foreign regulations, foreign exchange fluctuations, diminished protection of intellectual property in some countries, as well as political and economic risks relevant to foreign countries. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to Government Regulation </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The regulatory approval processes of the FDA and other comparable foreign regulatory authorities are lengthy, time-consuming and inherently unpredictable. If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals for our programs, we will not be able to commercialize, or will be delayed in commercializing, our programs, and our ability to generate revenue will be materially impaired. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The process of obtaining regulatory approvals, both in the United States and abroad, is unpredictable, expensive and typically takes many years following commencement of clinical trials, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the programs involved. We cannot commercialize programs in the United States without first obtaining regulatory approval from the FDA. Similarly, we cannot commercialize programs outside of the United States without obtaining regulatory approval from comparable foreign regulatory authorities. Before obtaining regulatory approvals for the commercial sale of our programs, including our most advanced programs, SPY001 and SPY002, we must demonstrate through lengthy, complex and expensive preclinical studies and clinical trials that our programs are both safe and effective for each targeted indication. Securing regulatory approval also requires the submission of information about the drug manufacturing process to, and inspection of manufacturing facilities by, the relevant regulatory authority. Further, our programs may not be effective, may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude our obtaining marketing approval. The FDA and comparable foreign regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical, clinical or other data. Our programs could be delayed in receiving, or fail to receive, regulatory approval for many reasons, including: the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials; we may be unable to </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">23 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that a program is safe and effective for its proposed indication; the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval; serious and unexpected drug-related side effects may be experienced by participants in our clinical trials or by individuals using drugs similar to our programs; we may be unable to demonstrate that a program&#8217;s clinical and other benefits outweigh its safety risks; the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials; the data collected from clinical trials of our programs may not be acceptable or sufficient to support the submission of an NDA or other submission or to obtain regulatory approval in the United States or elsewhere, and we may be required to conduct additional clinical trials; the FDA or the applicable foreign regulatory authority may disagree regarding the formulation, labeling and/or the specifications of our programs; the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Of the large number of drugs in development, only a small percentage successfully complete the FDA or foreign regulatory approval processes and are commercialized. The lengthy approval process as well as the unpredictability of future clinical trial results may result in our failing to obtain regulatory approval to market our programs, which would significantly harm our business, results of operations and prospects. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we were to obtain approval, regulatory authorities may approve any of our programs for fewer or more limited indications than we request, including failing to approve the most commercially promising indications, may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve a program with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that program. If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals for our programs, we will not be able to commercialize, or will be delayed in commercializing, our programs and our ability to generate revenue will be materially impaired. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may not be able to meet requirements for the chemistry, manufacturing and control of our programs. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to receive approval of our products by the FDA and comparable foreign regulatory authorities, we must show that we and our contract manufacturing partners are able to characterize, control and manufacture our drug products safely and in accordance with regulatory requirements. This includes synthesizing the active ingredient, developing an acceptable formulation, performing tests to adequately characterize the formulated product, documenting a repeatable manufacturing process, and demonstrating that our drug products meet stability requirements. Meeting these chemistry, manufacturing and control requirements is a complex task that requires specialized expertise. If we are not able to meet the chemistry, manufacturing and control requirements, we may not be successful in getting our products approved. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our programs for which we intend to seek approval as biologics may face competition sooner than anticipated. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Patient Protection and Affordable Act, as amended by the Healthcare and Education Reconciliation Act (the &#8220;ACA&#8221;), includes a subtitle called the Biologics Price Competition and Innovation Act of 2009 (&#8220;BPCIA&#8221;), which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an <span style="white-space:nowrap">FDA-licensed</span> reference biological product. Under the BPCIA, an application for a highly similar or &#8220;biosimilar&#8221; product may not be submitted to the FDA until four years following the date that the reference product was first approved by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first approved. During this <span style="white-space:nowrap">12-year</span> period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing the sponsor&#8217;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of their product. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">24 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe that any of our programs approved as biologics under a BLA should qualify for the <span style="white-space:nowrap">12-year</span> period of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider our programs to be reference products for competing products, potentially creating the opportunity for competition sooner than anticipated. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. Moreover, the extent to which a biosimilar, once approved, will be substituted for any reference products in a way that is similar to traditional generic substitution for <span style="white-space:nowrap">non-biological</span> products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Even if we receive regulatory approval of our programs, we will be subject to extensive ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our programs. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any regulatory approvals that we may receive for our programs will require the submission of reports to regulatory authorities and surveillance to monitor the safety and efficacy of the program, may contain significant limitations related to use restrictions for specified age groups, warnings, precautions or contraindications, and may include burdensome post-approval study or risk management requirements. For example, the FDA may require a risk evaluation and mitigation strategy (&#8220;REMS&#8221;) in order to approve our programs, which could entail requirements for a medication guide, physician training and communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA or comparable foreign regulatory authorities approve our programs, our programs and the activities associated with their development and commercialization, including their design, testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale, distribution, import and export will be subject to comprehensive regulation by the FDA and other regulatory agencies in the United States and by comparable foreign regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as <span style="white-space:nowrap">on-going</span> compliance with current cGMPs and GCPs for any clinical trials that we conduct following approval. In addition, manufacturers of drug products and their facilities are subject to continual review and periodic, unannounced inspections by the FDA and other regulatory authorities for compliance with cGMPs. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we or a regulatory authority discover previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facilities where the product is manufactured, a regulatory authority may impose restrictions on that product, the manufacturing facility or us, including requiring recall or withdrawal of the product from the market or suspension of manufacturing. restrictions on our ability to conduct clinical trials, including full or partial clinical holds on ongoing or planned trials, restrictions on the manufacturing process, warning or untitled letters, civil and criminal penalties, injunctions, product seizures, detentions or import bans, voluntary or mandatory publicity requirements and imposition of restrictions on operations, including costly new manufacturing requirements. The occurrence of any event or penalty described above may inhibit our ability to commercialize our programs and generate revenue and could require us to expend significant time and resources in response and could generate negative publicity. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may face difficulties from healthcare legislative reform measures. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Existing regulatory policies may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our programs. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">25 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers will be subject to applicable healthcare regulatory laws, which could expose us to penalties. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations. These laws may constrain the business or financial arrangements and relationships through which we conduct our operations, including how we research, market, sell and distribute our programs, if approved. Ensuring that our internal operations and future business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. If our operations are found to be in violation of any of these laws or any other governmental laws and regulations that may apply to us, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, exclusion from government-funded healthcare programs, integrity oversight and reporting obligations to resolve allegations of <span style="white-space:nowrap">non-compliance,</span> disgorgement, individual imprisonment, contractual damages, reputational harm, diminished profits and the curtailment or restructuring of our operations. Further, defending against any such actions can be costly and time-consuming and may require significant personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Even if we are able to commercialize any programs, due to unfavorable pricing regulations and/or third-party coverage and reimbursement policies, we may not be able to offer such programs at competitive prices which would seriously harm our business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We intend to seek approval to market our programs in both the United States and in selected foreign jurisdictions. If we obtain approval in one or more foreign jurisdictions for our programs, we will be subject to rules and regulations in those jurisdictions. Our ability to successfully commercialize any programs that we may develop will depend in part on the extent to which reimbursement for these programs and related treatments will be available from government health administration authorities, private health insurers and other organizations. Government authorities and other third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. Government authorities and other third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. These entities may create preferential access policies for a competitor&#8217;s product, including a branded or generic/biosimilar product, over our products in an attempt to reduce their costs, which may reduce our commercial opportunity. Additionally, if any of our programs are approved and we are found to have improperly promoted off- label uses of those programs, we may become subject to significant liability, which would materially adversely affect our business and financial condition. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We are subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws, and anti-money laundering laws and regulations. We can face criminal liability and other serious consequences for violations, which can harm our business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are subject to export control and import laws and regulations, including the U.S. Export Administration Regulations, U.S. Customs regulations, various economic and trade sanctions regulations administered by the U.S. Treasury Department&#8217;s Office of Foreign Assets Controls, the U.S. Foreign Corrupt Practices Act of 1977, as amended, the U.S. domestic bribery statute contained in 18 U.S.C. &#167; 201, the U.S. Travel Act, the USA PATRIOT Act, and other state and national anti-bribery and anti-money laundering laws in the countries in which we conduct activities. Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, contractors, and other collaborators from authorizing, promising, offering, or providing, directly or indirectly, improper payments or anything else of value to or from recipients in the public or private sector. We may engage third parties to sell our products outside the United States, to conduct clinical trials, and/ or to obtain necessary permits, licenses, patent registrations, and other regulatory approvals. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">26 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
universities, and other organizations. We can be held liable for the corrupt or other illegal activities of our employees, agents, contractors, and other collaborators, even if we do not explicitly authorize or have actual knowledge of such activities. Any violations of the laws and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and other consequences. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Governments outside the United States tend to impose strict price controls, which may adversely affect our revenue, if any. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In some countries, particularly member states of the EU, the pricing of prescription drugs is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after receipt of marketing approval for a therapeutic. In addition, there can be considerable pressure by governments and other stakeholders on prices and reimbursement levels, including as part of cost containment measures. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various EU member states and parallel distribution, or arbitrage between <span style="white-space:nowrap">low-priced</span> and high-priced member states, can further reduce prices. To obtain coverage and reimbursement or pricing approvals in some countries, we or current or future collaborators may be required to conduct a clinical trial or other studies that compare the cost-effectiveness of our programs to other available therapies in order to obtain or maintain reimbursement or pricing approval. Publication of discounts by third-party payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If reimbursement of any program approved for marketing is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business, financial condition, results of operations or prospects could be materially and adversely affected. Brexit could lead to legal uncertainty and potentially divergent national laws and regulations, including those related to the pricing of prescription pharmaceuticals, as the United Kingdom (&#8220;UK&#8221;) determines which EU laws to replicate or replace. If the UK were to significantly alter its regulations affecting the pricing of prescription pharmaceuticals, we could face significant new costs. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we decide to pursue a Fast Track Designation by the FDA, it may not lead to a faster development or regulatory review or approval process. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may seek Fast Track Designation for one or more of our programs. If a drug is intended for the treatment of a serious or life-threatening condition and the drug demonstrates the potential to address unmet medical needs for this condition, the product sponsor may apply for FDA Fast Track Designation. The FDA has broad discretion whether or not to grant this designation, so even if we believe a particular program is eligible for this designation, we cannot assure you that the FDA would decide to grant it. Even if we do receive Fast Track Designation, we may not experience a faster development process, review or approval compared to conventional FDA procedures. The FDA may withdraw Fast Track Designation if it believes that the designation is no longer supported by data from our clinical development program. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to Our Intellectual Property </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our ability to protect our patents and other proprietary rights is uncertain, exposing us to the possible loss of competitive advantage. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We rely upon a combination of patents, trademarks, trade secret protection, confidentiality agreements and the Paragon Agreement to protect the intellectual property related to our programs and technologies and to prevent third parties from competing with us. Our success depends in large part on our ability to obtain and maintain patent protection for our platform technologies, programs and their uses, as well as our ability to operate without infringing on or violating the proprietary rights of others. We own and have licensed rights to pending patent applications and expect to continue to file patent applications in the United States and abroad related to our novel discoveries and technologies that are important to our business. However, we may not be able to protect our </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">27 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
intellectual property rights throughout the world and the legal systems in certain countries may not favor enforcement or protection of patents, trade secrets and other intellectual property. Filing, prosecuting and defending patents on programs worldwide would be prohibitively expensive and our intellectual property rights in some foreign jurisdictions can be less extensive than those in the United States. As such, we may not have patents in all countries or all major markets and may not be able to obtain patents in all jurisdictions even if we apply for them. Our competitors may operate in countries where we do not have patent protection and can freely use our technologies and discoveries in such countries to the extent such technologies and discoveries are publicly known or disclosed in countries where we do have patent protection or pending patent applications. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our pending and future patent applications may not result in patents being issued. Any issued patents may not afford sufficient protection of our programs or their intended uses against competitors, nor can there be any assurance that the patents issued will not be infringed, designed around, invalidated by third parties, or effectively prevent others from commercializing competitive technologies, products or programs. Even if these patents are granted, they may be difficult to enforce. Further, any issued patents that we may license or own covering our programs could be narrowed or found invalid or unenforceable if challenged in court or before administrative bodies in the United States or abroad, including the United States Patent and Trademark Office (&#8220;USPTO&#8221;). Further, if we encounter delays in our clinical trials or delays in obtaining regulatory approval, the period of time during which we could market our programs under patent protection would be reduced. Thus, the patents that we may own and license may not afford us any meaningful competitive advantage. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to seeking patents for some of our technology and programs, we may also rely on trade secrets, including unpatented <span style="white-space:nowrap">know-how,</span> technology and other proprietary information, to maintain our competitive position. Any disclosure, either intentional or unintentional, by our employees, the employees of third parties with whom we share our facilities or third-party consultants and vendors that we engage to perform research, clinical trials or manufacturing activities, or misappropriation by third parties (such as through a cybersecurity breach) of our trade secrets or proprietary information could enable competitors to duplicate or surpass our technological achievements, thus eroding our competitive position in our market. In order to protect our proprietary technology and processes, we rely in part on confidentiality agreements with our collaborators, employees, consultants, outside scientific collaborators and sponsored researchers and other advisors. These agreements may not effectively prevent disclosure of confidential information and may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. We may need to share our proprietary information, including trade secrets, with future business partners, collaborators, contractors and others located in countries at heightened risk of theft of trade secrets, including through direct intrusion by private parties or foreign actors and those affiliated with or controlled by state actors. In addition, while the company undertakes efforts to protect its trade secrets and other confidential information from disclosure, others may independently discover trade secrets and proprietary information, and in such cases, we may not be able to assert any trade secret rights against such party. Costly and time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights and failure to obtain or maintain trade secret protection could adversely affect our competitive business position. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lastly, if our trademarks and trade names are not registered or adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may not be successful in obtaining or maintaining necessary rights to our programs through acquisitions and <span style="white-space:nowrap">in-licenses.</span></span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because our development programs currently do and may in the future require the use of proprietary rights held by third parties, the growth of our business may depend in part on our ability to acquire, <span style="white-space:nowrap">in-license,</span> or use these third-party proprietary rights. We may be unable to acquire or <span style="white-space:nowrap">in-license</span> any compositions, methods of use, processes or other third-party intellectual property rights from third parties that we identify as necessary for our programs. The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies may pursue strategies to license or acquire third-party intellectual </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">28 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
property rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, capital resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment or at all. If we are unable to successfully obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have, we may have to abandon development of the relevant program, which could have a material adverse effect on our business, financial condition, results of operations, and prospects. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While we normally seek to obtain the right to control prosecution, maintenance and enforcement of the patents relating to our programs, there may be times when the filing and prosecution activities for patents and patent applications relating to our programs are controlled by our current and future licensors or collaboration partners. If any of our current and future licensors or collaboration partners fail to prosecute, maintain and enforce such patents and patent applications in a manner consistent with the best interests of our business, including by payment of all applicable fees for patents covering our programs, we could lose our rights to the intellectual property or our exclusivity with respect to those rights, our ability to develop and commercialize those programs may be adversely affected and we may not be able to prevent competitors from making, using and selling competing products. In addition, even where we have the right to control patent prosecution of patents and patent applications we have licensed to and from third parties, we may still be adversely affected or prejudiced by actions or inactions of our licensees, our current and future licensors and their counsel that took place prior to the date upon which we assumed control over patent prosecution. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our current and future licensors may rely on third-party consultants or collaborators or on funds from third parties such that our current and future licensors are not the sole and exclusive owners of the patents we <span style="white-space:nowrap">in-license.</span> If other third parties have ownership rights to our current and future <span style="white-space:nowrap">in-licensed</span> patents, they may be able to license such patents to our competitors, and our competitors could market competing products and technology. This could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It is possible that we may be unable to obtain licenses at a reasonable cost or on reasonable terms, if at all. Even if we are able to obtain a license, it may be <span style="white-space:nowrap">non-exclusive,</span> thereby giving our competitors access to the same technologies licensed to us. In that event, we may be required to expend significant time and resources to redesign our technology, programs, or the methods for manufacturing them or to develop or license replacement technology, all of which may not be feasible on a technical or commercial basis. If we are unable to do so, we may be unable to develop or commercialize the affected programs, which could harm our business, financial condition, results of operations, and prospects significantly. We cannot provide any assurances that third-party patents do not exist which might be enforced against our current technology, manufacturing methods, programs, or future methods or products resulting in either an injunction prohibiting our manufacture or future sales, or, with respect to our future sales, an obligation on our part to pay royalties and/or other forms of compensation to third parties, which could be significant. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Disputes may arise between us and our current and future licensors regarding intellectual property subject to a license agreement, including: the scope of rights granted under the license agreement and other interpretation-related issues; whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement; our right to sublicense patents and other rights to third parties; our right to transfer or assign the license; the inventorship and ownership of inventions and <span style="white-space:nowrap">know-how</span> resulting from the joint creation or use of intellectual property by our current and future licensors and us and our partners; and the priority of invention of patented technology. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">29 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may be subject to patent infringement claims or may need to file claims to protect our intellectual property, which could result in substantial costs and liability and prevent us from commercializing our potential products. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because the intellectual property landscape in the biotechnology industry is rapidly evolving and interdisciplinary, it is difficult to conclusively assess our freedom to operate and guarantee that we can operate without infringing on or violating third party rights. If certain of our programs are ultimately granted regulatory approval, patent rights held by third parties, if found to be valid and enforceable, could be alleged to render one or more of our programs infringing. If a third party successfully brings a claim against us, we may be required to pay substantial damages, be forced to abandon any affected program and/or seek a license from the patent holder. In addition, any intellectual property claims (e.g. patent infringement or trade secret theft) brought against us, whether or not successful, may cause us to incur significant legal expenses and divert the attention of our management and key personnel from other business concerns. We cannot be certain that patents owned or licensed by us will not be challenged by others in the course of litigation. Some of our competitors may be able to sustain the costs of complex intellectual property litigation more effectively than we can because they have substantially greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise funds and on the market price of our Common Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Competitors may infringe or otherwise violate our patents, trademarks, copyrights or other intellectual property. To counter infringement or other violations, we may be required to file claims, which can be expensive and time-consuming. Any such claims could provoke these parties to assert counterclaims against us, including claims alleging that we infringe their patents or other intellectual property rights. In addition, in a patent infringement proceeding, a court or administrative body may decide that one or more of the patents we assert is invalid or unenforceable, in whole or in part, construe the patent&#8217;s claims narrowly or refuse to prevent the other party from using the technology at issue on the grounds that our patents do not cover the technology. Similarly, if we assert trademark infringement claims, a court or administrative body may determine that the marks we have asserted are invalid or unenforceable or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In such a case, we could ultimately be forced to cease use of such marks. In any intellectual property litigation, even if we are successful, any award of monetary damages or other remedy we receive may not be commercially valuable. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, we may be required to protect our patents through procedures created to attack the validity of a patent at the USPTO. An adverse determination in any such submission or proceeding could reduce the scope or enforceability of, or invalidate, our patent rights, which could adversely affect our competitive position. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in United States federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, if our programs are found to infringe the intellectual property rights of third parties, these third parties may assert infringement claims against our future licensees and other parties with whom we have business relationships and we may be required to indemnify those parties for any damages they suffer as a result of these claims, which may require us to initiate or defend protracted and costly litigation on behalf of licensees and other parties regardless of the merits of such claims. If any of these claims succeed, we may be forced to pay damages on behalf of those parties or may be required to obtain licenses for the products they use. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or other legal proceedings relating to our intellectual property rights, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation or other proceedings. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">30 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may be subject to claims that we have wrongfully hired an employee from a competitor or that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As is common in the biotechnology industry, in addition to our employees, we engage the services of consultants to assist us in the development of our programs. Many of these consultants, and many of our employees, were previously employed at, or may have previously provided or may be currently providing consulting services to, other biotechnology or pharmaceutical companies including our competitors or potential competitors. We could in the future be subject to claims that we or our employees have inadvertently or otherwise used or disclosed alleged trade secrets or other confidential information of former employers or competitors. Although we try to ensure that our employees and consultants do not use the intellectual property, proprietary information, <span style="white-space:nowrap">know-how</span> or trade secrets of others in their work for us, we may become subject to claims that we caused an employee to breach the terms of his or her <span style="white-space:nowrap">non-competition</span> or <span style="white-space:nowrap">non-solicitation</span> agreement, or that we or these individuals have, inadvertently or otherwise, used or disclosed the alleged trade secrets or other proprietary information of a former employer or competitor. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While we may litigate to defend ourselves against these claims, even if we are successful, litigation could result in substantial costs and could be a distraction to management. If our defenses to these claims fail, in addition to requiring us to pay monetary damages, a court could prohibit us from using technologies or features that are essential to our programs, if such technologies or features are found to incorporate or be derived from the trade secrets or other proprietary information of the former employers. Moreover, any such litigation or the threat thereof may adversely affect our reputation, our ability to form strategic alliances or sublicense our rights to collaborators, engage with scientific advisors or hire employees or consultants, each of which would have an adverse effect on our business, results of operations and financial condition. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Changes to patent laws in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Changes in either the patent laws or interpretation of patent laws in the United States, including patent reform legislation such as the Leahy-Smith America Invents Act (the &#8220;Leahy-Smith Act&#8221;) could increase the uncertainties and costs surrounding the prosecution of our owned and <span style="white-space:nowrap">in-licensed</span> patent applications and the maintenance, enforcement or defense of our owned and <span style="white-space:nowrap">in-licensed</span> issued patents. The Leahy-Smith Act includes a number of significant changes to United States patent law. These changes include provisions that affect the way patent applications are prosecuted, redefine prior art, provide more efficient and cost-effective avenues for competitors to challenge the validity of patents, and enable third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent at USPTO-administered post-grant proceedings, including post-grant review, inter partes review and derivation proceedings. Assuming that other requirements for patentability are met, prior to March 2013, in the United States, the first to invent the claimed invention was entitled to the patent, while outside the United States, the first to file a patent application was entitled to the patent. After March 2013, under the Leahy-Smith Act, the United States transitioned to a <span style="white-space:nowrap"><span style="white-space:nowrap">first-to-file</span></span> system in which, assuming that the other statutory requirements for patentability are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. As such, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the patent positions of companies in the development and commercialization of biologics and pharmaceuticals are particularly uncertain. U.S. Supreme Court and U.S. Court of Appeals for the Federal Circuit rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations, including in the antibody arts. This combination of events has created </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">31 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
uncertainty with respect to the validity and enforceability of patents once obtained. Depending on future actions by the U.S. Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could have a material adverse effect on our patent rights and our ability to protect, defend and enforce our patent rights in the future. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Geopolitical instability in the United States and in foreign countries could increase the uncertainties and costs surrounding the prosecution or maintenance of patent applications and the maintenance, enforcement or defense of issued patents. For example, the United States and foreign government actions related to Russia&#8217;s invasion of Ukraine may limit or prevent filing, prosecution and maintenance of patent applications in Russia. Government actions may also prevent maintenance of issued patents in Russia. These actions could result in abandonment or lapse of patents or patent applications, resulting in partial or complete loss of patent rights in Russia. If such an event were to occur, it could have a material adverse effect on our business. In addition, a decree was adopted by the Russian government in March 2022, allowing Russian companies and individuals to exploit inventions owned by patentees that have citizenship or nationality in, are registered in, or have predominately primary place of business or profit-making activities in the United States and other countries that Russia has deemed unfriendly without consent or compensation. Consequently, we would not be able to prevent third parties from practicing our inventions in Russia or from selling or importing products made using our inventions in and into Russia. Accordingly, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be adversely affected. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, a European Unified Patent Court (&#8220;UPC&#8221;) entered into force on June&#160;1, 2023. The UPC is a common patent court that hears patent infringement and revocation proceedings effective for member states of the EU. This could enable third parties to seek revocation of a European patent in a single proceeding at the UPC rather than through multiple proceedings in each of the jurisdictions in which the European patent is validated. Although we do not currently own any European patents or applications, if we obtain such patents and applications in the future, any such revocation and loss of patent protection could have a material adverse impact on our business and our ability to commercialize or license our technology and products. Moreover, the controlling laws and regulations of the UPC will develop over time, and may adversely affect our ability to enforce or defend the validity of any European patents we may obtain. We may decide to opt out from the UPC any future European patent applications that we may file and any patents we may obtain. If certain formalities and requirements are not met, however, such European patents and patent applications could be challenged for <span style="white-space:nowrap">non-compliance</span> and brought under the jurisdiction of the UPC. We cannot be certain that future European patents and patent applications will avoid falling under the jurisdiction of the UPC, if we decide to opt out of the UPC. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Obtaining and maintaining patent protection depends on compliance with various procedural, document submissions, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for <span style="white-space:nowrap">non-compliance</span> with these requirements. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Periodic maintenance fees, renewal fees, annuities fees and various other governmental fees on patents and/or patent applications are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patent and/or patent application. The USPTO and various foreign governmental patent agencies also require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. <span style="white-space:nowrap">Non-compliance</span> events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, <span style="white-space:nowrap">non-payment</span> of fees and failure to properly legalize and submit formal documents. If we fail to maintain the patents and patent applications covering our programs, our competitive position would be adversely affected. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">32 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might adversely affect our ability to develop and market our products. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We cannot guarantee that any of our patent searches or analyses, including the identification of relevant patents, the scope of patent claims or the expiration of relevant patents, are complete or thorough, nor can we be certain that we have identified each and every third-party patent and pending application in the United States and abroad that is relevant to or necessary for the commercialization of our programs in any jurisdiction. The scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent&#8217;s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect. For example, we may incorrectly determine that our products are not covered by a third-party patent or may incorrectly predict whether a third-party&#8217;s pending application will issue with claims of relevant scope. Our determination of the expiration date of any patent in the United States or abroad that we consider relevant may be incorrect. Our failure to identify and correctly interpret relevant patents may negatively impact our ability to develop and market our products. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, because some patent applications in the United States may be maintained in secrecy until the patents are issued, patent applications in the United States and many foreign jurisdictions are typically not published until 18 months after filing, and publications in the scientific literature often lag behind actual discoveries, we cannot be certain that others have not filed patent applications for technology covered by our issued patents or our pending applications, or that we were the first to invent the technology. Our competitors may have filed, and may in the future file, patent applications covering our products or technology similar to ours. Any such patent application may have priority over our patent applications or patents, which could require us to obtain rights to issued patents covering such technologies. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may become subject to claims challenging the inventorship or ownership of our patents and other intellectual property. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may be subject to claims that former employees, collaborators or other third parties have an interest in our patents or other intellectual property as an inventor or <span style="white-space:nowrap">co-inventor.</span> The failure to name the proper inventors on a patent application can result in the patents issuing thereon being unenforceable. Inventorship disputes may arise from conflicting views regarding the contributions of different individuals named as inventors, the effects of foreign laws where foreign nationals are involved in the development of the subject matter of the patent, conflicting obligations of third parties involved in developing our programs or as a result of questions regarding <span style="white-space:nowrap">co-ownership</span> of potential joint inventions. Litigation may be necessary to resolve these and other claims challenging inventorship and/or ownership. Alternatively, or additionally, we may enter into agreements to clarify the scope of our rights in such intellectual property. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our current and future licensors may have relied on third-party consultants or collaborators or on funds from third parties, such as the U.S. government, such that our licensors are not the sole and exclusive owners of the patents we <span style="white-space:nowrap">in-licensed.</span> For example, certain intellectual property we license from the University of Texas at Austin includes inventions that were made with U.S. government support. The U.S. government therefore has certain rights in such inventions under the applicable funding agreements and under applicable law. If other third parties have ownership rights or other rights to our <span style="white-space:nowrap">in-licensed</span> patents, they may be able to license such patents to our competitors, and our competitors could market competing products and technology. This could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">33 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Patent terms may be inadequate to protect the competitive position of our programs for an adequate amount of time. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest United States <span style="white-space:nowrap">non-provisional</span> filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our programs are obtained, once the patent life has expired, we may be open to competition from competitive products, including generics or biosimilars. Given the amount of time required for the development, testing and regulatory review of new programs, patents protecting such programs might expire before or shortly after such programs are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our technology licensed from various third parties may be subject to retained rights. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our current or future licensors may retain certain rights under the relevant agreements with us, including the right to use the underlying technology for noncommercial academic and research use, to publish general scientific findings from research related to the technology, and to make customary scientific and scholarly disclosures of information relating to the technology. It is difficult to monitor whether our licensors limit their use of the technology to these uses, and we could incur substantial expenses to enforce our rights to our licensed technology in the event of misuse. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to Our Reliance on Third Parties </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We rely on collaborations and licensing arrangements with third parties, including our arrangement with Paragon. If we are unable to maintain these collaborations or licensing arrangements, or if these collaborations or licensing arrangements are not successful, our business could be negatively impacted. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We currently rely on our collaborations and licensing arrangements with third parties, including Paragon, for a substantial portion of our discovery capabilities and <span style="white-space:nowrap">in-licenses.</span></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Collaborations or licensing arrangements that we enter into may not be successful, and any success will depend heavily on the efforts and activities of such collaborators or licensors. If any of our collaborators or licensors experiences delays in performance of, or fails to perform its obligations under their agreement with us, disagrees with our interpretation of the terms of such agreement or terminates their agreement with us, the research programs with respect to which we have exercised the Option to acquire intellectual property license rights to or have the Option to acquire intellectual property license rights to pursuant to the Paragon Agreement and development timeline could be adversely affected. If we fail to comply with any of the obligations under our collaborations or license agreements, including payment terms and diligence terms, our collaborators or licensors may have the right to terminate such agreements, in which event we may lose intellectual property rights and may not be able to develop, manufacture, market or sell the products covered by our agreements or may face other penalties under our agreements. Our collaborators and licensors may also fail to properly maintain or defend the intellectual property we have licensed from them, if required by our agreement with them, or even infringe upon, our intellectual property rights, leading to the potential invalidation of our intellectual property or subjecting us to litigation or arbitration, any of which would be time-consuming and expensive and could harm our ability to commercialize our programs. In addition, collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our programs and products if the collaborators believe that the competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As part of our strategy, we plan to evaluate additional opportunities to enhance our capabilities and expand our development pipeline or provide development or commercialization capabilities that complement our own. We may not realize the benefits of such collaborations, alliances or licensing arrangements. Any of these relationships may require us to incur <span style="white-space:nowrap">non-recurring</span> and other charges, increase our near and long-term expenditures, issue securities that dilute our existing stockholders or disrupt our management and business. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">34 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may face significant competition in attracting appropriate collaborators, and more established companies may also be pursuing strategies to license or acquire third-party intellectual property rights that we consider attractive. These companies may have a competitive advantage over us due to their size, financial resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. Whether we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. Collaborations are complex and time-consuming to negotiate, document and execute. In addition, consolidation among large pharmaceutical and biotechnology companies has reduced the number of potential future collaborators. We may not be able to negotiate additional collaborations on a timely basis, on acceptable terms or at all. If we fail to enter into collaborations and do not have sufficient funds or expertise to undertake the necessary development and commercialization activities, we may not be able to further develop our programs or bring them to market. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We currently rely, and plan to rely in the future, on third parties to conduct and support our preclinical studies and clinical trials. If these third parties do not properly and successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval of or commercialize our programs. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have utilized and plan to continue to utilize and depend upon independent investigators and collaborators, such as medical institutions, CROs, contract testing labs and strategic partners, to conduct and support our preclinical studies and clinical trials under agreements with us. We will rely heavily on these third parties over the course of our preclinical studies and clinical trials, and we control only certain aspects of their activities. As a result, we will have less direct control over the conduct, timing and completion of these preclinical studies and clinical trials and the management of data developed through preclinical studies and clinical trials than would be the case if we were relying entirely upon our own staff. Nevertheless, we are responsible for ensuring that each of our studies and trials is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards, and our reliance on these third parties does not relieve us of our regulatory responsibilities. We and our third-party contractors and CROs are required to comply with GCP regulations, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for all of our programs in clinical development. If we or any of these third parties fail to comply with applicable GCP regulations, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP regulations. In addition, our clinical trials must be conducted with products produced under cGMP regulations. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process. Moreover, our business may be implicated if any of these third parties violates federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security laws. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any third parties conducting our clinical trials will not be our employees and, except for remedies available to us under our agreements with such third parties, we cannot control whether they devote sufficient time and resources to our programs. These third parties may be involved in mergers, acquisitions or similar transactions and may have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other product development activities, which could negatively affect their performance on our behalf and the timing thereof and could lead to products that compete directly or indirectly with our current or future programs. If these third parties do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to complete development of, obtain regulatory approval of or successfully commercialize our programs. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">35 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We currently rely and expect to rely in the future on the use of manufacturing suites in third-party facilities or on third parties to manufacture our programs, and we may rely on third parties to produce and process our products, if approved. Our business could be adversely affected if we are unable to use third-party manufacturing suites or if the third-party manufacturers encounter difficulties in production. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not currently own any facility that may be used as our clinical-scale manufacturing and processing facility and must currently rely on CMOs to manufacture our programs. We have not yet caused our programs to be manufactured on a commercial scale and may not be able to do so for any of our programs, if approved. We currently have a sole source relationship for our supply of the SPY001 program. If there should be any disruption in such supply arrangement, including any adverse events affecting our sole supplier, it could have a negative effect on the clinical development of our programs and other operations while we work to identify and qualify an alternate supply source. We may not control the manufacturing process of, and may be completely dependent on, our contract manufacturing partners for compliance with cGMP requirements and any other regulatory requirements of the FDA or comparable foreign regulatory authorities for the manufacture of our programs. Beyond periodic audits, we have no control over the ability of our CMOs to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of our programs or if it withdraws any approval in the future, we may need to find alternative manufacturing facilities, which would require the incurrence of significant additional costs and materially adversely affect our ability to develop, obtain regulatory approval for or market our programs, if approved. Similarly, our failure, or the failure of our CMOs, to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of programs or drugs, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our programs or drugs and harm our business and results of operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moreover, our CMOs may experience manufacturing difficulties due to resource constraints, supply chain issues, or as a result of labor disputes or unstable political environments. If any CMOs on which we will rely fail to manufacture quantities of our programs at quality levels necessary to meet regulatory requirements and at a scale sufficient to meet anticipated demand at a cost that allows us to achieve profitability, our business, financial condition and prospects could be materially and adversely affected. In addition, our CMOs are responsible for transporting temperature controlled materials that can be inadvertently degraded during transport due to several factors, rendering certain batches unsuitable for trial use for failure to meet, among others, our integrity and purity specifications. We and any of our CMOs may also face product seizure or detention or refusal to permit the import or export of products. Our business could be materially adversely affected by business disruptions to our third-party providers that could materially adversely affect our anticipated timelines, potential future revenue and financial condition and increase our costs and expenses. Each of these risks could delay or prevent the completion of our preclinical studies and clinical trials or the approval of any of our programs by the FDA, result in higher costs or adversely impact commercialization of our programs. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to Employee Matters, Managing Growth and Other Risks Related to Our Business </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">In order to successfully implement our plans and strategies, we will need to grow the size of our organization and we may experience difficulties in managing this growth. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect to experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of preclinical and clinical drug development, technical operations, clinical operations, regulatory affairs and, potentially, sales and marketing. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial personnel and systems, expand our facilities and continue to recruit and train additional qualified personnel. Due to our limited financial resources and the limited experience of our management team working together in managing a company with such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">36 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We are highly dependent on our key personnel and anticipate hiring new key personnel. If we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a preclinical stage biotechnology company with a limited operating history, and, as of December&#160;11, 2023, we had 30 employees. We have been and will continue to be highly dependent on the research and development, clinical and business development expertise of our executive officers, as well as the other principal members of our management, scientific and clinical team. Any of our management team members may terminate their employment with us at any time. We do not maintain &#8220;key person&#8221; insurance for any of our executives or other employees. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attracting and retaining qualified personnel will also be critical to our success, including with respect to any strategic transaction that we may pursue. The loss of the services of our executive officers or other key employees could impede the achievement of our research, development and commercialization objectives and seriously harm our ability to successfully implement our business strategy. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop, facilitate regulatory approval of and commercialize product candidates. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our discovery and nonclinical and clinical development and commercialization strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. If we are unable to continue to attract and retain high quality personnel, our ability to pursue our growth strategy will be limited. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our future growth may depend, in part, on our ability to operate in foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our future growth may depend, in part, on our ability to develop and commercialize our programs in foreign markets for which we may rely on collaboration with third parties. We are not permitted to market or promote any of our programs before we receive regulatory approval from the applicable foreign regulatory authority, and may never receive such regulatory approval for any of our programs. To obtain separate regulatory approval in many other countries, we must comply with numerous and varying regulatory requirements of such countries regarding safety and efficacy and governing, among other things, clinical trials and commercial sales, pricing and distribution of our programs, and we cannot predict success in these jurisdictions. If we fail to comply with the regulatory requirements in international markets and receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our programs will be harmed and our business will be adversely affected. Moreover, even if we obtain approval of our programs and ultimately commercialize our programs in foreign markets, we would be subject to the risks and uncertainties, including the burden of complying with complex and changing foreign regulatory, tax, accounting and legal requirements and reduced protection of intellectual property rights in some foreign countries. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs, CMOs, suppliers and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are exposed to the risk that our employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs, CMOs, suppliers and vendors acting for or on our behalf may engage in </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">37 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
misconduct or other improper activities. We have adopted a code of conduct and ethics, but it is not always possible to identify and deter misconduct by these parties and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our internal computer systems, or those of any of our CROs, manufacturers, other contractors or consultants, third party service providers, or potential future collaborators, may fail or suffer security or data privacy breaches or other unauthorized or improper access to, use of, or destruction of our proprietary or confidential data, employee data or personal data, which could result in additional costs, loss of revenue, significant liabilities, harm to our brand and material disruption of our operations. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Despite the implementation of security measures in an effort to protect systems that store our information, given their size and complexity and the increasing amounts of information maintained on our internal information technology systems and those of our third-party CROs, other contractors (including sites performing our clinical trials), third party service providers and supply chain companies, and consultants, these systems are potentially vulnerable to breakdown or other damage or interruption from service interruptions, system malfunction, natural disasters, terrorism, war and telecommunication and electrical failures, as well as security breaches from inadvertent or intentional actions by our employees, contractors, consultants, business partners and/or other third parties, or from cyber-attacks by malicious third parties, which may compromise our system infrastructure or lead to the loss, destruction, alteration or dissemination of, or damage to, our data. To the extent that any disruption or security breach were to result in loss, destruction, unavailability, alteration or dissemination of, or damage to, our data or applications, or for it to be believed or reported that any of these occurred, we could incur liability and reputational damage and the development and commercialization of our programs could be delayed. Further, our insurance policies may not be adequate to compensate us for the potential losses arising from any such disruption in, or failure or security breach of, our systems or third-party systems where information important to our business operations or commercial development is stored. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our fully-remote workforce may create additional risks for our information technology systems and data because our employees work remotely and utilize network connections, computers, and devices working at home, while in transit and in public locations. Additionally, business transactions (such as acquisitions or integrations) could expose us to additional cybersecurity risks and vulnerabilities, as our systems could be negatively affected by vulnerabilities present in acquired or integrated entities&#8217; systems and technologies. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While we have implemented security measures designed to protect against security incidents, there can be no assurance that these measures will be effective. We may be unable in the future to detect vulnerabilities in our information technology systems because such threats and techniques change frequently, are often sophisticated in nature, and may not be detected until after a security incident has occurred. Further, we may experience delays in developing and deploying remedial measures designed to address any such identified vulnerabilities. Applicable data privacy and security obligations may require us to notify relevant stakeholders of security incidents. Such disclosures are costly, and the disclosure or the failure to comply with such requirements could lead to adverse consequences. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We rely on third-party service providers and technologies to operate critical business systems to process sensitive information in a variety of contexts. Our ability to monitor these third parties&#8217; information security practices is limited, and these third parties may not have adequate information security measures in place. If our third-party service providers experience a security incident or other interruption, we could experience adverse consequences. While we may be entitled to damages if our third-party service providers fail to satisfy their privacy or security-related obligations to us, any award may be insufficient to cover our damages, or we may be unable to recover such award. In addition, supply-chain attacks have increased in frequency and severity, and we cannot guarantee that third parties&#8217; infrastructure in our supply chain or our third-party partners&#8217; supply chains have not been compromised. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">38 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we (or a third party upon whom we rely) experience a security incident or are perceived to have experienced a security incident, we may experience adverse consequences, such as government enforcement actions (for example, investigations, fines, penalties, audits, and inspections); additional reporting requirements and/or oversight; restrictions on processing sensitive information (including personal data); litigation (including class claims); indemnification obligations; negative publicity; reputational harm; monetary fund diversions; interruptions in our operations (including availability of data); financial loss; and other similar harms. Security incidents and attendant consequences may cause stakeholders (including investors and potential customers) to stop supporting our platform, deter new customers from products, and negatively impact our ability to grow and operate our business. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our contracts may not contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in our contracts are sufficient to protect us from liabilities, damages, or claims related to our data privacy and security obligations. We cannot be sure that our insurance coverage will be adequate or sufficient to protect us from or to mitigate liabilities arising out of our privacy and security practices, that such coverage will continue to be available on commercially reasonable terms or at all, or that such coverage will pay future claims. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under Section&#160;382 of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), if a corporation undergoes an &#8220;ownership change,&#8221; generally defined as a greater than 50% change (by value) in its equity ownership over a three-year period, the corporation&#8217;s ability to use its <span style="white-space:nowrap">pre-change</span> net operating loss carryforwards, or NOLs, and other <span style="white-space:nowrap">pre-change</span> tax attributes (such as research tax credits) to offset its post-change income or taxes may be limited. Upon certain events since our conversion from a Delaware limited liability company to a Delaware corporation in 2015, it is possible that we may have triggered an &#8220;ownership change&#8221; limitation. We may also experience ownership changes in the future as a result of subsequent shifts in our stock ownership (some of which are outside of our control). As a result, if we earn net taxable income, our ability to use our <span style="white-space:nowrap">pre-change</span> NOLs and other <span style="white-space:nowrap">pre-change</span> tax attributes to offset U.S. federal taxable income or taxes may be subject to limitations, which could potentially result in increased future tax liability to us. Our NOLs and other tax attributes arising before our conversion from a Delaware limited liability company to a Delaware corporation in 2015 also may be limited by the Separate Return Limitation Year rule, which could increase our U.S. federal tax liability. In addition, at the state level, there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We are subject to stringent and changing laws, regulations and standards, and contractual obligations relating to privacy, data protection, and data security. The actual or perceived failure to comply with such obligations could lead to government enforcement actions (which could include civil or criminal penalties), fines and sanctions, private litigation and/or adverse publicity and could negatively affect our operating results and business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We, and third parties who we work with are or may become subject to numerous domestic and foreign laws, regulations, and standards relating to privacy, data protection, and data security, the scope of which is changing, subject to differing applications and interpretations, and may be inconsistent among countries, or conflict with other rules. We are or may become subject to the terms of contractual obligations related to privacy, data protection and data security. Our obligations may also change or expand as our business grows. The actual or perceived failure by us or third parties related to us to comply with such laws, regulations and obligations could increase our compliance and operational costs, expose us to regulatory scrutiny, actions, fines and penalties, result in reputational harm, lead to a loss of customers, result in litigation and liability, and otherwise cause a material adverse effect on our business, financial condition, and results of operations. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">39 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations may involve the use of hazardous and flammable materials, including chemicals and biological and radioactive materials. In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or commercialization efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may be subject to adverse legislative or regulatory tax changes that could negatively impact our financial condition. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The rules dealing with U.S. federal, state and local income taxation are constantly under review by persons involved in the legislative process and by the Internal Revenue Service and the U.S. Treasury Department. Changes to tax laws (which changes may have retroactive application) could adversely affect our stockholders or us. We assess the impact of various tax reform proposals and modifications to existing tax treaties in all jurisdictions where we have operations to determine the potential effect on our business and any assumptions we have made about our future taxable income. We cannot predict whether any specific proposals will be enacted, the terms of any such proposals or what effect, if any, such proposals would have on our business if they were to be enacted. For example, the United States recently enacted the Inflation Reduction Act of 2022, which implements, among other changes, a 1% excise tax on certain stock buybacks. In addition, beginning in 2022, the Tax Cuts and Jobs Act eliminated the previously available option to deduct research and development expenditures and requires taxpayers to amortize them generally over five years for research activities conducted in the United States and over 15 years for research activities conducted outside the United States. The U.S. Congress is considering legislation that would restore the current deductibility of research and development expenditures; however, we have no assurance that the provision will be repealed or otherwise modified. Such changes, among others, may adversely affect our effective tax rate, results of operation and general business condition. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may acquire businesses or products, or form strategic alliances, in the future, and may not realize the benefits of such acquisitions. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may acquire additional businesses or products, form strategic alliances, or create joint ventures with third parties that we believe will complement or augment our existing business. If we acquire businesses with promising markets or technologies, we may not be able to realize the benefit of acquiring such businesses if we are unable to successfully integrate them with our existing operations and company culture. We may encounter numerous difficulties in developing, manufacturing and marketing any new programs or products resulting from a strategic alliance or acquisition that delay or prevent us from realizing their expected benefits or enhancing our business. There is no assurance that, following any such acquisition, we will achieve the synergies expected in order to justify the transaction, which could result in a material adverse effect on our business and prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We maintain our cash at financial institutions, often in balances that exceed federally-insured limits. The failure of financial institutions could adversely affect our ability to pay our operational expenses or make other payments. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our cash held in <span style="white-space:nowrap">non-interest-bearing</span> and interest-bearing accounts exceeds the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) insurance limits. If such banking institutions were to fail, we could lose all or a portion of those amounts held in excess of such insurance limitations. For example, the FDIC took control of Silicon Valley Bank on March&#160;10, 2023. The Federal Reserve subsequently announced that account holders would be made whole. However, the FDIC may not make all account holders whole in the event of future bank failures. In </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">40 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
addition, even if account holders are ultimately made whole with respect to a future bank failure, account holders&#8217; access to their accounts and assets held in their accounts may be substantially delayed. Any material loss that we may experience in the future or inability for a material time period to access our cash and cash equivalents could have an adverse effect on our ability to pay our operational expenses or make other payments, which could adversely affect our business. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to Our Common Stock </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Pursuant to the terms of the December 2023 SPA, we are required to recommend that our stockholders approve the conversion of all outstanding shares of our Series B Preferred Stock into shares of our Common Stock. We cannot guarantee that our stockholders will approve this matter, and if they fail to do so, we may be required to settle such shares in cash and our operations may be materially harmed. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the terms of the December 2023 SPA, we agreed to use best efforts to obtain the requisite approval for the conversion of all outstanding shares of Series B Preferred Stock issued in the December 2023 PIPE into shares of our Common Stock, as required by the Nasdaq listing rules, at the Company&#8217;s 2024 annual meeting of stockholders and, if such approval is not obtained at that meeting, to seek to obtain such approval at a stockholders meeting to be held at least every 90 days thereafter until such approval is obtained, which would be time consuming and costly. Additionally, if our stockholders do not timely approve the conversion of our Series B Preferred Stock, then the holders of our Series B Preferred Stock may be entitled to require us to settle their shares of Series B Preferred Stock for cash at a price per share equal to the fair value of the Series B Preferred Stock at such time, as described in our Series B Certificate of Designation relating to the Series B Preferred Stock. If we are forced to settle a significant amount of the Series B Preferred Stock, it could materially affect our results of operations, including raising a substantial doubt about our ability to continue as a going concern within one year from the date of this registration statement. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Anti-takeover provisions in our charter documents and under Delaware law and the terms of some of our contracts could make an acquisition of us more difficult and may prevent attempts by our stockholders to replace or remove our management. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Provisions in our Certificate of Incorporation and Bylaws may delay or prevent an acquisition or a change in management. These provisions include a prohibition on actions by written consent of our stockholders and the ability of our board of directors to issue Preferred Stock without stockholder approval. In addition, because we are incorporated in Delaware, we are governed by the provisions of Section&#160;203 of the Delaware General Corporation Law (the &#8220;DGCL&#8221;), which prohibits stockholders owning in excess of 15% of our outstanding voting stock from merging or combining with us. Although we believe these provisions collectively will provide for an opportunity to receive higher bids by requiring potential acquirers to negotiate with our board of directors, they would apply even if the offer may be considered beneficial by some stockholders. In addition, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove then current management by making it more difficult for stockholders to replace members of the board of directors, which is responsible for appointing the members of management. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the Series A Certificate of Designation relating to our Series A Preferred Stock may delay or prevent a change in control of our company. At any time while at least 30% of the originally issued Series A Preferred Stock remains issued and outstanding, we may not consummate a Fundamental Transaction (as defined in the Series Certificate of Designation) or any merger or consolidation of the Company with or into another entity or any stock sale to, or other business combination in which our stockholders immediately before such transaction do not hold at least a majority of our capital stock immediately after such transaction, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series A Preferred Stock. This provision of the Series A Certificate of Designation may make it more difficult for us to enter into any of the aforementioned transactions. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">41 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our Certificate of Incorporation provides that the Court of Chancery of the State of Delaware is the exclusive forum certain types of actions and proceedings that may be initiated by our stockholders, and our Bylaws designate the federal courts of the United States as the exclusive forum for actions arising under the Securities Act, each of which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, employees or agents. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Certificate of Incorporation provides that, unless we consent in writing to an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for any derivative action or proceeding brought on our behalf, any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers, employees or agents to us or our stockholders, any action asserting a claim arising pursuant to any provision of the DGCL, our Certificate of Incorporation or our Bylaws or any action asserting a claim that is governed by the internal affairs doctrine, in each case subject to the Court of Chancery having personal jurisdiction over the indispensable parties named as defendants therein and the claim not being one which is vested in the exclusive jurisdiction of a court or forum other than the Court of Chancery or for which the Court of Chancery does not have subject matter jurisdiction. Any person purchasing or otherwise acquiring any interest in any shares of our capital stock shall be deemed to have notice of and to have consented to this provision of our Certificate of Incorporation. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Bylaws provide that the federal district courts of the United States of America will, to the fullest extent permitted by law, be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act (a &#8220;Federal Forum Provision&#8221;). Our decision to adopt a Federal Forum Provision followed a decision by the Supreme Court of the State of Delaware holding that such provisions are facially valid under Delaware law. While there can be no assurance that federal or state courts will follow the holding of the Delaware Supreme Court or determine that the Federal Forum Provision should be enforced in a particular case, application of the Federal Forum Provision means that suits brought by our stockholders to enforce any duty or liability created by the Securities Act must be brought in federal court and cannot be brought in state court. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These choice of forum provisions may limit our stockholders&#8217; ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers, employees or agents, which may discourage such lawsuits against us and our directors, officers, employees and agents even though an action, if successful, might benefit our stockholders. Stockholders who do bring a claim in the specified courts could face additional litigation costs in pursuing any such claim. The specified courts may also reach different judgments or results than would other courts, including courts where a stockholder considering an action may be located or would otherwise choose to bring the action, and such judgments or results may be more favorable to us than to our stockholders. Alternatively, if a court were to find these provisions of our governance documents inapplicable to, or unenforceable in respect of, one or more of the specified types of actions or proceedings, we may incur additional costs associated with resolving such matters in other jurisdictions, which could have a material adverse effect on our business, financial condition or results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We do not anticipate that we will pay any cash dividends in the foreseeable future. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The current expectation is that we will retain our future earnings, if any, to fund the development and growth of our business. As a result, capital appreciation, if any, of our Common Stock will be your sole source of gain, if any, for the foreseeable future. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Future sales of shares by existing stockholders could cause our stock price to decline. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&#160;7, 2023, we entered into a registration rights agreement (the &#8220;December 2023 RRA&#8221;) with the December 2023 Investors. Pursuant to the December 2023 RRA, we agreed to file a resale registration statement to register the Registrable Securities (as defined in the December 2023 RRA) (the &#8220;Registration Statement&#8221;). This registration statement is being filed in order to satisfy our obligations under the December 2023 RRA. We have agreed to file with the SEC the Registration Statement on or prior to the 30<sup style="font-size:75%; vertical-align:top">th</sup> calendar day following the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">42 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
closing of the December 2023 PIPE and will use our commercially reasonable efforts to cause this Registration Statement to be declared effective by the SEC as soon as practicable. If, following receipt of approval of the Series B Conversion Proposal (as defined in the section titled &#8220;<span style="font-style:italic">Description Of Capital Stock &#8211; Preferred Stock &#8211; Series B Preferred Stock</span>&#8221; below), this Registration Statement is not declared effective prior to, subject to certain limited exceptions pursuant to the December 2023 RRA, the 90<sup style="font-size:75%; vertical-align:top">th</sup> calendar day following the closing date of the December 2023 PIPE (or, in the event the SEC reviews and has written comments to this Registration Statement, the 120<sup style="font-size:75%; vertical-align:top">th</sup> calendar day following such closing date), among other events (each event, a &#8220;Registration Failure&#8221;), then we will be required to make pro rata payments to each Investor of the then outstanding Registrable Securities in an amount equal to one percent of the aggregate amount invested by such December 2023 Investor for the Registrable Securities then held by such December 2023 Investor for the initial day of a Registration Failure and for each 30 day period thereafter until the Registration Failure is cured. If this Registration Statement is declared effective, the shares subject to this Registration Statement will no longer constitute restricted securities and may be sold freely in the public markets, subject to lapse on any related contractual restrictions related thereto of any December 2023 Investor and, for shares of Common Stock issuable upon the conversion of Series B Preferred Stock, the approval of our stockholders of such conversion. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If our stockholders sell, or indicate an intention to sell, substantial amounts of our Common Stock in the public market after legal restrictions on resale lapse, the trading price of our Common Stock could decline. In addition, shares of our Common Stock that are subject to our outstanding options will become eligible for sale in the public market to the extent permitted by the provisions of various vesting agreements and Rules 144 and 701 under the Securities Act. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Future sales and issuances of equity and debt could result in additional dilution to our stockholders. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect that we will need significant additional capital to fund our current and future operations, including to complete potential clinical trials for our product candidates. To raise capital, we may sell Common Stock, convertible securities, or other equity securities in one or more transactions at prices and in a manner we determine from time to time. As a result, our stockholders may experience additional dilution, which could cause our stock price to fall. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to our equity incentive plans, we may grant equity awards and issue additional shares of our Common Stock to our employees, directors and consultants, and the number of shares of our Common Stock reserved for future issuance under certain of these plans will be subject to automatic annual increases in accordance with the terms of the plans. To the extent that new options are granted and exercised, or we issue additional shares of Common Stock in the future, our stockholders may experience additional dilution, which could cause our stock price to fall. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our principal stockholders own a significant percentage of our stock and are able to exert significant control over matters subject to stockholder approval. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our directors, officers, 5% stockholders, and their affiliates currently beneficially own a substantial portion of our outstanding voting stock. Therefore, these stockholders have the ability and may continue to have the ability to influence us through this ownership position. These stockholders may be able to determine some or all matters requiring stockholder approval. For example, these stockholders, acting together, may be able to control elections of directors, amendments of organizational documents, or approval of any merger, sale of assets, or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our Common Stock that you may believe are in your best interest as one of our stockholders. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">43 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">General Risk Factors </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The market price of our Common Stock has historically been volatile, and the market price of our Common Stock may decline in the future. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The market price of our Common Stock has been, and may continue to be, subject to significant fluctuations. Market prices for securities of early-stage pharmaceutical, biotechnology, and other life sciences companies have historically been particularly volatile. Some of the factors that may cause the market price of our Common Stock to fluctuate include: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to obtain regulatory approvals for our product candidates, and delays or failures to obtain such approvals; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">failure of any of our product candidates, if approved, to achieve commercial success; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">failure to maintain our existing third-party license and supply agreements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">changes in laws or regulations applicable to our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any inability to obtain adequate supply of our product candidates or the inability to do so at acceptable prices; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">adverse regulatory authority decisions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">introduction of new products, services, or technologies by our competitors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">failure to meet or exceed financial and development projections we may provide to the public and the investment community; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the perception of the pharmaceutical industry by the public, legislatures, regulators, and the investment community; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">announcements of significant acquisitions, strategic collaborations, joint ventures, or capital commitments by us or our competitors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">disputes or other developments relating to proprietary rights, including patents, litigation matters, and our ability to obtain patent protection for our technologies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">additions or departures of key personnel; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">significant lawsuits, including patent or stockholder litigation; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">if securities or industry analysts do not publish research or reports about our business, or if they issue an adverse or misleading opinion regarding our business and stock; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">changes in the market valuations of similar companies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">general market or macroeconomic conditions, including global inflationary pressures, rising interest rates, general economic slowdown or a recession, changes in monetary policy, instability in financial institutions and the prospect of a shutdown of the U.S. federal government; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">geopolitical instability, including the ongoing military conflict in Ukraine, conflict in Israel and surrounding areas, and geopolitical tensions in China; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">sales of our Common Stock by us or our stockholders in the future; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">trading volume of our Common Stock; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">announcements by commercial partners or competitors of new commercial products, clinical progress or the lack thereof, significant contracts, commercial relationships, or capital commitments; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the introduction of technological innovations or new therapies that compete with our potential products; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">44 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">changes in the structure of health care payment systems; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="white-space:nowrap"><span style="white-space:nowrap">period-to-period</span></span> fluctuations in our financial results. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moreover, the capital markets in general have experienced substantial volatility that has often been unrelated to the operating performance of individual companies. These broad market fluctuations may also adversely affect the trading price of our Common Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the past, following periods of volatility in the market price of a company&#8217;s securities, stockholders have often instituted class action securities litigation against those companies. Such litigation, if instituted, could result in substantial costs and diversion of management attention and resources, which could significantly harm our profitability and reputation. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We incur costs and demands upon management as a result of complying with the laws and regulations regulating public companies. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We incur significant legal, accounting, and other expenses associated with public company reporting requirements. We also incur costs associated with corporate governance requirements, including requirements under the Sarbanes-Oxley Act, as well as rules implemented by the SEC and Nasdaq. These rules and regulations increase our legal and financial compliance costs and make some activities more time-consuming and costly. These rules and regulations may also make it difficult and expensive for us to obtain directors&#8217; and officers&#8217; liability insurance. As a result, it may be more difficult for us to attract and retain qualified individuals to serve on our board of directors or as our executive officers, which may adversely affect investor confidence and could cause our business or stock price to suffer. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business, or our market, our stock price and trading volume could decline. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The trading market for our Common Stock is influenced by the research and reports that equity research analysts publish about us and our business. Equity research analysts may elect not to provide research coverage of our Common Stock and such lack of research coverage may adversely affect the market price of our Common Stock. In the event we do have equity research analyst coverage, we will not have any control over the analysts or the content and opinions included in their reports. The price of our Common Stock could decline if one or more equity research analysts downgrade our stock or issue other unfavorable commentary or research. If one or more equity research analysts ceases coverage of us or fails to publish reports on us regularly, demand for our Common Stock could decrease, which in turn could cause our stock price or trading volume to decline. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we fail to maintain proper and effective internal controls, our ability to produce accurate financial statements on a timely basis could be impaired, investors may lose confidence in the accuracy and completeness of our financial reports and the market price of our Common Stock may be negatively affected. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act, and the rules and regulations of Nasdaq. The Sarbanes-Oxley Act requires, among other things, that we maintain effective disclosure controls and procedures and internal control over financial reporting. We must perform system and process evaluation and testing of our internal control over financial reporting to allow management to report on the effectiveness of our internal controls over financial reporting in our annual report filing for that year, as required by Section&#160;404 of the Sarbanes-Oxley Act. This requires that we incur substantial professional fees and internal costs to expand our accounting and finance functions and that we expend significant management efforts. We may experience difficulty in meeting these reporting requirements in a timely manner for each period. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may or any subsequent testing by our independent registered public accounting firm may discover weaknesses in our system of internal financial and accounting controls and procedures that could result in a </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">45 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
material misstatement of our financial statements. Our internal control over financial reporting will not prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud will be detected. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we are not able to comply with the requirements of Section&#160;404 of the Sarbanes-Oxley Act, or if we are unable to maintain proper and effective internal controls, it could result in a material misstatement of our financial statements that would not be prevented or detected on a timely basis, which could require a restatement, cause us to be subject to sanctions or investigations by Nasdaq, the SEC, or other regulatory authorities, cause investors to lose confidence in our financial information, or cause our stock price to decline. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a public company, we incur significant legal, accounting, insurance, and other expenses, and our management and other personnel have and will need to continue to devote a substantial amount of time to compliance initiatives resulting from operating as a public company. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">46 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx518298_6">USE OF PROCEEDS </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are not selling any securities under this prospectus and we will not receive any proceeds from the sale of the Resale Shares covered hereby. The net proceeds from the sale of the Resale Shares offered by this prospectus will be received by the Selling Stockholders. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to limited exceptions, the Selling Stockholders will pay any underwriting discounts and commissions and expenses incurred by the Selling Stockholders for brokerage, accounting, tax or legal services or any other expenses incurred by the Selling Stockholders in disposing of any of the Resale Shares. We will bear the costs, fees and expenses incurred in effecting the registration of the Resale Shares covered by this prospectus, including all registration and filing fees, Nasdaq listing fees and fees and expenses of our counsel and our independent registered public accounting firm. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">47 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx518298_7">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">You should read the following discussion of our financial condition and results of operations in conjunction with the consolidated financial statements and the related notes thereto and other financial information included elsewhere in this prospectus. This discussion contains forward-looking statements based upon current beliefs, plans and expectations related to future events and our future financial performance that involve risks, uncertainties and assumptions. Our actual results could differ materially from those discussed in these forward-looking statements as a result of various factors. Factors that could cause or contribute to these differences include, but are not limited to, those discussed below and elsewhere in this prospectus, particularly in the section titled &#8220;Risk Factors.&#8221; Please also see the section titled &#8220;Special Note Regarding Forward-Looking Statements.&#8221; As used in this prospectus, unless the context suggests otherwise, &#8220;we&#8221;, &#8220;us&#8221;, &#8220;our&#8221;, &#8220;the Company&#8221;. &#8220;Aeglea BioTherapeutics, Inc.&#8221; or &#8220;Spyre&#8221; refers to Spyre Therapeutics, Inc. and its subsidiaries, including Spyre Therapeutics, LLC. </span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Acquisition of <span style="white-space:nowrap">Pre-Merger</span> Spyre </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&#160;22, 2023, we acquired <span style="white-space:nowrap">Pre-Merger</span> Spyre pursuant to the Acquisition Agreement, by and among the Company, Aspen Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (&#8220;First Merger Sub&#8221;), Sequoia Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of the Company (&#8220;Second Merger Sub&#8221;), and <span style="white-space:nowrap">Pre-Merger</span> Spyre. Pursuant to the Acquisition Agreement, First Merger Sub merged with and into <span style="white-space:nowrap">Pre-Merger</span> Spyre, pursuant to which <span style="white-space:nowrap">Pre-Merger</span> Spyre was the surviving corporation and became a wholly owned subsidiary of the Company (the &#8220;First Merger&#8221;). Immediately following the First Merger, <span style="white-space:nowrap">Pre-Merger</span> Spyre merged with and into Second Merger Sub, pursuant to which Second Merger Sub became the surviving entity. <span style="white-space:nowrap">Pre-Merger</span> Spyre was a <span style="white-space:nowrap">pre-clinical</span> stage biotechnology company that was incorporated on April&#160;28, 2023 under the direction of Peter Harwin, a Managing Member of Fairmount, for the purpose of holding rights to certain intellectual property being developed by Paragon. Fairmount is a founder of Paragon. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Through the Asset Acquisition, we received the Option to license the <span style="white-space:nowrap">in-process</span> and research development (&#8220;IPR&amp;D&#8221;) related to four research programs. On July&#160;12, 2023 we exercised the Option with respect to one of these research programs to exclusively license intellectual property rights related to such research program directed to antibodies that selectively bind to &#945;4&#223;7 integrin and methods of using these antibodies, including methods of treating inflammatory bowel disease (&#8220;IBD&#8221;) using SPY001. If this research program is pursued <span style="white-space:nowrap">non-provisionally</span> and matures into issued patents, we would expect those patents to expire no earlier than 2044, subject to any disclaimers or extensions. On December&#160;14, 2023, we exercised the Option under the Paragon Agreement to be granted an exclusive license to all of Paragon&#8217;s rights, title and interest in and to intellectual property rights, including inventions, patents, sequence information and results, under SPY002, Spyre&#8217;s TL1A program, to develop and commercialize antibodies and products worldwide in all therapeutics disorders. The license agreements pertaining to such research programs are currently being finalized on previously agreed terms. Furthermore, as of the date of the filing of this prospectus, the Option remains unexercised with respect to the IPR&amp;D related to the two remaining research programs under the Paragon Agreement. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Overview </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following the Asset Acquisition, we have significantly reshaped the business into a preclinical stage biotechnology company focused on developing next generation therapeutics for patients living with IBD, including ulcerative colitis (&#8220;UC&#8221;) and Crohn&#8217;s disease (&#8220;CD&#8221;). Through the Paragon Agreement, our portfolio of novel and proprietary monoclonal antibody product candidates has the potential to address unmet needs in IBD care by improving efficacy, safety, and/or dosing convenience relative to products currently available or product candidates in development. We have engineered our product candidates with the aim to bind potently and selectively to their target epitopes and to exhibit extended pharmacokinetic half-lives. We plan to use </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">48 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
combinations of our proprietary antibodies and patient enrichment strategies via patient selection approaches to enhance efficacy. We intend to deliver our product candidates through convenient, infrequently self-administered, subcutaneous (&#8220;SC&#8221;) injections as a <span style="white-space:nowrap">pre-filled</span> pen. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In accordance with ASC <span style="white-space:nowrap">205-40,</span> Going Concern, we have evaluated and determined that there are conditions and events, considered in the aggregate, that raise substantial doubt about our ability to continue as a going concern within one year after the date the consolidated financial statements included in this prospectus were issued. If our stockholders do not timely approve the conversion of our Series B Preferred Stock, then the holders of our Series B Preferred Stock may be entitled to require us to settle their shares of Series B Preferred Stock for cash at a price per share equal to the fair value of the Series B Preferred Stock, as described in our Series B Certificate of Designation relating to the Series B Preferred Stock. The cash redemption is not under our control and raises substantial doubt about our ability to continue as a going concern. The consolidated financial statements included in this prospectus assume the Company will continue as a going concern through the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Our Relationship with Paragon and Parapyre </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Paragon and Parapyre each beneficially owns less than 5% of our capital stock through their respective holdings of our Common Stock. Fairmount beneficially owns more than 5% of our capital stock, has two seats on our board of directors and beneficially owns more than 5% of Paragon, which is a joint venture between Fairmount and Fair Journey Biologics. Fairmount appointed Paragon&#8217;s board of directors and has the contractual right to approve the appointment of any executive officers. Parapyre is an entity formed by Paragon as a vehicle to hold equity in <span style="white-space:nowrap">Pre-Merger</span> Spyre in order to share profits with certain employees of Paragon. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Asset Acquisition, Spyre assumed the rights and obligations of <span style="white-space:nowrap">Pre-Merger</span> Spyre under the Paragon Agreement. Under the Paragon Agreement, Spyre is obligated to compensate Paragon on a quarterly basis for its services performed under each research program based on the actual costs incurred with <span style="white-space:nowrap">mark-up</span> costs pursuant to the terms of the Paragon Agreement. As of the date of the Asset Acquisition, <span style="white-space:nowrap">Pre-Merger</span> Spyre had incurred total expenses of $19.0&#160;million under the Paragon Agreement since inception, inclusive of a $3.0&#160;million research initiation fee that was due upon signing of the Paragon Agreement and $16.0&#160;million of reimbursable expenses under the Paragon Agreement for historical costs owed to Paragon. As of the acquisition date, $19.0&#160;million was unpaid and was assumed by Spyre through the Asset Acquisition. As of September&#160;30, 2023, $0.5&#160;million of the assumed Paragon liability remained unpaid. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the three and nine months ended September&#160;30, 2023, we recognized $19.4&#160;million and $20.8&#160;million, respectively, in research and development expenses that are due to Paragon under the Paragon Agreement. As of September&#160;30, 2023, $16.8&#160;million was unpaid and owed to Paragon under the Paragon Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In July 2023 and December 2023, we exercised our Option for the SPY001 and SPY002 programs, respectively, and the remaining two options for the SPY003 and SPY004 programs remain outstanding. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Asset Acquisition, we assumed the Parapyre Option Obligation which provided for an annual equity grant of options to purchase 1% of the then outstanding shares of <span style="white-space:nowrap">Pre-Merger</span> Spyre&#8217;s common stock, on a fully diluted basis, on the last business day of each calendar year during the term of the Paragon Agreement, at the fair market value determined by the board of directors of <span style="white-space:nowrap">Pre-Merger</span> Spyre. As a result of the Asset Acquisition the Parapyre Option Obligation shall continue and Parapyre shall be entitled to receive equivalent shares from us with the same terms. As of September&#160;30, 2023, the <span style="white-space:nowrap">pro-rated</span> estimated fair value of the options was approximately $3.0&#160;million, of which $0.1&#160;million was recognized as part of the liabilities assumed with the Asset Acquisition. For the three and nine months ended September&#160;30, 2023, $2.7&#160;million and $2.9&#160;million, respectively, was recognized as stock compensation expense related to the Parapyre Option Obligation. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">49 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Corporate Developments </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In July 2023, we announced that we had entered into an agreement to sell the global rights to pegzilarginase, an investigational treatment for the rare metabolic disease Arginase 1 Deficiency, to Immedica for $15&#160;million in upfront cash proceeds and up to $100&#160;million in contingent milestone payments. The sale of pegzilarginase to Immedica superseded and terminated the previous license agreement between us and Immedica. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&#160;30, 2023, our board of directors appointed Scott Burrows to succeed Jonathan Alspaugh as our Chief Financial Officer effective September&#160;1, 2023. Mr.&#160;Burrows also succeeded Mr.&#160;Alspaugh as our principal financial officer and principal accounting officer on the effective date. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&#160;1, 2023, Heidy Abreu King-Jones was appointed as Chief Legal Officer and Corporate Secretary. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&#160;6, 2023, our board of directors appointed Dr.&#160;Cameron Turtle, our then-current Chief Operating Officer, as our principal executive officer effective the same day. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&#160;22, 2023, Dr.&#160;Turtle was promoted from Chief Operating Officer to Chief Executive Officer and was appointed to our board of directors. In addition, Jeffrey W. Albers and Laurie Stelzer were appointed to our board of directors to fill the vacancies resulting from the resignations of Hunter Smith and Ivana Magov&#269;evi&#263;-Liebisch, each of which was effective that same day. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&#160;28, 2023, we changed our name from &#8220;Aeglea Biotherapeutics, Inc.&#8221; to &#8220;Spyre Therapeutics, Inc.&#8221; and our Nasdaq ticker symbol from &#8220;AGLE&#8221; to &#8220;SYRE&#8221;. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Restructuring </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the second quarter of 2023, we implemented a restructuring plan based on the review of the inconclusive interim results from our Phase 1/2 clinical trial of pegtarviliase for the treatment of classical homocystinuria and other business considerations, as well as our plan to explore strategic alternatives. Under the restructuring plan, our workforce was reduced by 83%, various lab equipment, consumables, and furniture and fixtures were sold, and our corporate headquarters lease in Austin, TX was abandoned. All charges related to the restructuring activities was recognized during the second quarter of 2023. No further restructuring charges will be incurred under the restructuring plan. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Critical Accounting Policies and Estimates </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our consolidated financial statements are prepared in accordance with generally accepted accounting principles in the United States. The preparation of these condensed consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, costs and expenses, and related disclosures. These estimates form the basis for judgments we make about the carrying values of our assets, liabilities and equity and the amount of revenues and expenses, which are not readily apparent from other sources. We base our estimates on historical experience and on various other assumptions that we believe are reasonable under the circumstances. On an ongoing basis, we evaluate our estimates and assumptions. Our actual results may differ materially from these estimates under different assumptions or conditions. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our critical accounting policies are those policies which require the most significant judgments and estimates in the preparation of our condensed consolidated financial statements. The most significant estimates and assumptions that management considers in the preparation of our financial statements relate to accrued research and development costs; the valuation of consideration transferred in acquiring IPR&amp;D; the discount rate, probabilities of success, and timing of estimated cash flows in the valuation of the CVR liability; inputs used in the Black-Scholes model for stock-based compensation expense; estimated future cash flows used in calculating the impairment of <span style="white-space:nowrap"><span style="white-space:nowrap">right-of-use</span></span> lease assets; and estimated cost to complete performance obligations related to </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">50 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
revenue recognition. The consideration transferred in acquiring IPR&amp;D in connection with the acquisition of <span style="white-space:nowrap">Pre-Merger</span> Spyre was comprised of our Common Stock and shares of Series A Preferred Stock. To determine the fair value of the equity transferred, we considered the per share value of the June 2023 PIPE, which was a financing involving a group of accredited investors. Our significant accounting policies are more fully described in Note 2 to our audited consolidated financial statements as of December&#160;31, 2022 and 2021 and for each of the three years in the period ended December&#160;31, 2022 (the &#8220;2022 Annual Financials&#8221;) and Note 2 to our condensed consolidated financial statements as of and for the three and nine months ended September&#160;30, 2023 appearing elsewhere in this prospectus. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Revenue recognition </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We enter into license agreements related to our technologies that we have determined are within the scope of Accounting Standards Codification 606. Based on the terms and conditions of our agreements, we identify the goods and services that we promise to transfer to the customer, which may consist of the licensing of technologies, the performance of research and development activities, and/or the supply of products related to our technologies. Based on the nature of the goods and services provided and the customer&#8217;s intended benefit of the arrangement, we evaluate which of the promised goods and services are distinct and, therefore, represent a performance obligation, which may require us to combine certain promised goods and services that are determined to not be distinct from one another. We also evaluate whether an agreement provides the customer an option to purchase future goods or services at a discounted price, or a material right, which would also represent a performance obligation. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In exchange for the performance obligations, we estimate the amount of consideration promised by the customer, or transaction price, which may include both fixed and variable consideration. Variable consideration, which may consist of various milestone payments based upon the achievement of certain events or conditions, sales-based royalties, or payments contingent on the performance of research and development services, are included in the transaction price only if we expect to receive such consideration and determine it is likely that the inclusion of the variable consideration will not result in a significant reversal in the cumulative amount of revenue recognized under the arrangement. Sales-based royalty and milestone payments that we determine are predominantly related to the license of our intellectual property are excluded from the transaction price we expect to receive until the underlying sales occur. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We allocate the estimated transaction price to the identified performance obligations based on the relative estimated stand-alone selling price, or SSP, of each performance. SSP is based on the observable price of our goods and services, or when SSP is not directly observable, we estimate SSP based on factors such as forecasted revenues or costs, development timelines, discount rates, probabilities of technical and regulatory success, and considerations such as market conditions and entity-specific factors. We recognize revenue allocated to each performance obligation either at a <span style="white-space:nowrap"><span style="white-space:nowrap">point-in-time</span></span> or over time in a manner that depicts the transfer of control of the promised goods and services to the customer. For performance obligations that are recognized over time, we estimate the measure of progress associated with the satisfaction of the performance obligation based on an input or output method, which may be based on factors such as costs incurred, labor hours expended, time elapsed, among other measures based on the nature of the performance obligation. The estimates made on an input or output method are subject to change and may result in material changes to revenue that could materially affect our results of operations. Please refer to Note 9, Strategic License Agreements, to our 2022 Annual Financials included elsewhere in this prospectus. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Accrued research and development costs </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We record the costs associated with research nonclinical studies, clinical trials, and manufacturing development as incurred. These costs are a significant component of our research and development expenses, with a substantial portion of our <span style="white-space:nowrap">on-going</span> research and development activities conducted by third-party service providers, including CROs and CMOs. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">51 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We accrue for expenses resulting from obligations under agreements with CROs, CMOs, and other outside service providers for which payment flows do not match the periods over which materials or services are provided to us. We record accruals based on estimates of services received and efforts expended pursuant to agreements established with CROs, CMOs, and other outside service providers. These estimates are typically based on contracted amounts applied to the proportion of work performed and determined through analysis with internal personnel and external service providers as to the progress or stage of completion of the services. We make significant judgments and estimates in determining the accrual balance in each reporting period. In the event advance payments are made to a CRO, CMO, or outside service provider, the payments will be recorded as a prepaid asset which will be amortized as the contracted services are performed. As actual costs become known, we adjust our accruals. Inputs, such as the services performed, the number of patients enrolled, or the study duration, may vary from our estimates, resulting in adjustments to research and development expense in future periods. Changes in these estimates that result in material changes to our accruals could materially affect our results of operations. However, there have been no material changes in estimates for the periods presented. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Impairment of ROU Assets and Leasehold Improvements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are required to test for impairment of our long-lived assets when events arise that would call into question the recoverability of an asset group. We determined that the abandonment of our leased office space in Austin, Texas would meet this criteria. Accordingly, we tested for impairment using a discounted future cash flow model using estimated cash flows that could be obtained through a hypothetical <span style="white-space:nowrap">sub-letting</span> of the leased space. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Convertible Preferred Stock Issued through PIPE </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We record shares of convertible preferred stock at their respective fair values on the dates of issuance, net of issuance costs. The Company has applied the guidance in ASC <span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap">480-10-S99-3A,</span></span></span> SEC Staff Announcement: Classification and Measurement of Redeemable Securities, and therefore classified the Series A Preferred Stock outside of stockholders&#8217; (deficit) equity because, if conversion to common stock was not approved by the stockholders, the Series A Preferred Stock would have been redeemable at the option of the holders for cash equal to the closing price of the common stock on the last trading day prior to the holder&#8217;s redemption request. We determined that the conversion and redemption were outside of our control. Additionally, we determined the conversion and redemption features did not require bifurcation as derivatives. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Contingent Value Rights Liability </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&#160;3, 2023, we issued a CVR to Legacy Stockholders, but these were not issued to holders of shares of common stock or preferred stock issued to former stockholders of <span style="white-space:nowrap">Pre-Merger</span> Spyre or the Investors in connection with the Transactions. Each CVR entitles the holder thereof to receive cash payments in the future calculated on the monetization or disposal of Legacy Assets within the CVR period. Certain contingent payments under the CVR Agreement qualify as derivatives under ASC 815, Derivatives and Hedging, and are recorded as a liability on the balance sheet as of September&#160;30, 2023. The CVR liability is considered a Level&#160;3 instrument that is initially measured at its estimated fair value on the transaction date and subsequently remeasured at each reporting date with changes recorded in the consolidated statement of operations. The determination of the initial and subsequent fair value of the CVR liability requires significant judgment by management. Changes in any of the inputs not related to facts and circumstances existing as of the transaction date may result in a significant fair value adjustment, which can impact the results of operations in the period in which the adjustment is made. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">52 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Results of Operations </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Comparison of the Three Months Ended September&#160;30, 2023 and 2022 </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes our results of operations for the three months ended September&#160;30, 2023 and 2022, together with the changes in those items in dollars and as a percentage: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">


<tr>

<td style="width:60%"></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Three Months Ended<br />September&#160;30,</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" rowspan="2">&#160;&#160;</td>
<td colspan="2" rowspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Dollar<br />Change</span></td>
<td style="vertical-align:bottom" rowspan="2">&#160;</td>
<td style="vertical-align:bottom" rowspan="2">&#160;&#160;</td>
<td colspan="2" rowspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">%<br />Change</span></td>
<td style="vertical-align:bottom" rowspan="2">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2023</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2022</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="10" align="center"><span style="font-weight:bold">(dollars in thousands)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Development fee and royalty</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">174</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(174</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(100</td>
<td style="white-space:nowrap;vertical-align:bottom">)%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenue</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">174</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(174</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(100</td>
<td style="white-space:nowrap;vertical-align:bottom">)%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses (income):</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">24,660</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11,977</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12,683</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">106</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8,584</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,952</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,632</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">23</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquired <span style="white-space:nowrap">in-process</span> research and development</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(298</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(298</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">*&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain on sale of <span style="white-space:nowrap">in-process</span> research and development asset</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(14,609</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(14,609</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">*&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">18,337</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">18,929</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(592</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">*&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(18,337</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(18,755</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">418</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">*&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,251</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">288</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">963</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">*&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of forward contract liability</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(25,360</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(25,360</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">*&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income, net</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,342</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">24</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,318</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">*&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss before income tax expense</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(40,104</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(18,443</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(21,661</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">*&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax (expense) benefit</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(3</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">209</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(212</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">*&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(40,107</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(18,234</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(21,873</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">*&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:2%;vertical-align:top" align="left">*</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Percentage not meaningful </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Development Fee and Royalty Revenue.</span> For the three months ended September&#160;30, 2023, we did not recognize any revenue in connection with the our exclusive license and supply agreement with Immedica Pharma AB (the &#8220;Immedica Agreement&#8221;). For the three months ended September&#160;30, 2022, we recognized $0.2&#160;million of development fee revenue in connection with the Immedica Agreement, which was attributable to the PEACE Phase 3 trial and BLA package. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Research and Development Expenses</span>. Our Research and development expenses incurred during the three months ended September&#160;30, 2023 primarily related to costs associated with advancing our IBD pipeline and with winding down the legacy rare disease clinical studies conducted by us prior to the Asset Acquisition (the &#8220;Legacy Pipeline&#8221;). Wind down costs include final patient visits, collection and analysis of final patient data, the creation and submission of final research reports, site and pharmacy closeouts, and formally closing the studies with regulatory agencies. Research and development expenses increased by $12.7&#160;million, or 106%, to $24.7&#160;million for the three months ended September&#160;30, 2023, from $12.0&#160;million for the three months ended September&#160;30, 2022. The change in research and development expenses was primarily due to a $22.4&#160;million increase in preclinical development and manufacturing expenses for our IBD pipeline, partially offset by a $10.0&#160;million decrease in expenses associated with the Legacy Pipeline. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">General and Administrative Expenses.</span> General and administrative expenses increased by $1.6&#160;million, or 23%, to $8.6&#160;million for the three months ended September&#160;30, 2023, from $7.0&#160;million for the three months ended September&#160;30, 2022. The increase in general and administrative expenses was primarily due to a $1.1&#160;million increase in legal costs and a $0.6&#160;million increase in employee separation costs. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">53 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Gain on Sale of <span style="white-space:nowrap">In-Process</span> Research and Development Asset</span>. Gain on sale of <span style="white-space:nowrap">in-process</span> research and development asset during the three months ended September&#160;30, 2023 was due to the gain recognized on the sale of pegzilarginase to Immedica. There was no similar gain or loss during the three months ended September&#160;30, 2022. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Change in Fair Value of Forward Contract Liability</span>. <span style="white-space:nowrap">Non-cash</span> expenses associated with the change in fair value of the forward contract liability were $25.4&#160;million for the three months ended September&#160;30, 2023. This expense was due to the change in fair value of the underlying Series A Preferred Stock between June&#160;30, 2023 and the forward contract&#8217;s settlement on July&#160;7, 2023. There was no similar expense during the three months ended September&#160;30, 2022. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Comparison of the Nine Months Ended September&#160;30, 2023 and 2022 </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes our results of operations for the nine months ended September&#160;30, 2023 and 2022, together with the changes in those items in dollars and as a percentage: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">


<tr>

<td style="width:58%"></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Nine Months Ended<br />September&#160;30,</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" rowspan="2">&#160;&#160;</td>
<td colspan="2" rowspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Dollar<br />Change</span></td>
<td style="vertical-align:bottom" rowspan="2">&#160;</td>
<td style="vertical-align:bottom" rowspan="2">&#160;&#160;</td>
<td colspan="2" rowspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">%<br />Change</span></td>
<td style="vertical-align:bottom" rowspan="2">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2023</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2022</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="10" align="center"><span style="font-weight:bold">(dollars in thousands)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Development fee and royalty</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">886</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,161</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1,275</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(59</td>
<td style="white-space:nowrap;vertical-align:bottom">)%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenue</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">886</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,161</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1,275</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(59</td>
<td style="white-space:nowrap;vertical-align:bottom">)%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses (income):</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">55,822</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">44,328</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11,494</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">26</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">25,874</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">23,452</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,422</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquired <span style="white-space:nowrap">in-process</span> research and development</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">130,188</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">130,188</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">*&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain on sale of <span style="white-space:nowrap">in-process</span> research and development asset</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(14,609</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(14,609</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">*&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">197,275</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">67,780</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">129,495</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">*&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(196,389</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(65,619</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(130,770</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">*&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,021</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">427</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,594</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">*&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of forward contract liability</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(83,530</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(83,530</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">*&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income, net</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,262</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">25</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,237</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">*&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss before income tax expense</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(275,636</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(65,167</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(210,469</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">*&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax benefit</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">26</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">174</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(148</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">*&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(275,610</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(64,993</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(210,617</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">*&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:2%;vertical-align:top" align="left">*</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Percentage not meaningful </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Development Fee and Royalty Revenue.</span> For the nine months ended September&#160;30, 2023, we recognized $0.9&#160;million of revenue in connection with the Immedica Agreement. The revenue generated was attributable to the PEACE Phase 3 trial and drug supply and royalties from an early access program in France. For the nine months ended September&#160;30, 2022, we recognized $2.2&#160;million of development fee revenue in connection with the Immedica Agreement, which was attributable to the PEACE Phase 3 trial and BLA package. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Research and Development Expenses</span>. Our research and development expenses incurred during the nine months ended September&#160;30, 2023 were primarily related to clinical study costs associated with our Legacy Assets, costs associated with the wind down of those Legacy Assets, and costs associated with furthering our IBD pipeline candidates. Wind down costs included final patient visits, collection and analysis of final patient data, the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">54 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
creation and submission of final research reports, site and pharmacy closeouts, and formally closing the studies with regulatory agencies. Research and development expenses increased by $11.5&#160;million, or 26%, to $55.8&#160;million for the nine months ended September&#160;30, 2023, from $44.3&#160;million for the nine months ended September&#160;30, 2022. The change in research and development expenses was primarily due to: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a $23.6&#160;million increase in preclinical development and manufacturing expenses for our IBD pipeline; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a $2.4&#160;million increase in restructuring costs net of savings; partially offset by </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a $14.5&#160;million decrease in activities associated with the Legacy Pipeline. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">General and Administrative Expenses.</span> General and administrative expenses increased by $2.4&#160;million, or 10%, to $25.9&#160;million for the nine months ended September&#160;30, 2023, from $23.5&#160;million for the nine months ended September&#160;30, 2022. The increase in general and administrative expenses was primarily due to a $2.6&#160;million increase in restructuring costs, net of restructuring savings, coupled with a $1.1&#160;million increase in legal fees and a $0.5&#160;million increase in employee separation costs, partially offset by a $1.8&#160;million decrease in legacy commercial readiness activities. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Gain on Sale of <span style="white-space:nowrap">In-Process</span> Research and Development Asset</span>. Gain on sale of <span style="white-space:nowrap">in-process</span> research and development asset during the nine months ended September&#160;30, 2023 was due to the gain recognized on the sale of pegzilarginase to Immedica. There was no similar gain or loss during the nine months ended September&#160;30, 2022. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Acquired <span style="white-space:nowrap">In-process</span> Research and Development Expenses</span>. Acquired <span style="white-space:nowrap">in-process</span> research and development expenses were $130.2&#160;million for the nine months ended September&#160;30, 2023, as the <span style="white-space:nowrap">Pre-Merger</span> Spyre transaction was determined by management to be an asset acquisition, in accordance with U.S. GAAP as the product candidates were determined to have no alternative future use. There was no similar expense during the nine months ended September&#160;30, 2022. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Change in Fair Value of Forward Contract Liability</span>. <span style="white-space:nowrap">Non-cash</span> expenses associated with the change in fair value of the forward contract liability were $83.5&#160;million for the nine months ended September&#160;30, 2023. This expense was due to the change in fair value of the underlying Series A Preferred Stock between June&#160;22, 2023 and the forward contract&#8217;s settlement on July&#160;7, 2023. There was no similar expense during the nine months ended September&#160;30, 2022. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">55 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Comparison of the Years Ended December&#160;31, 2022 and 2021 </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes our results of operations for the years ended December&#160;31, 2022 and 2021, together with the changes in those items in dollars and as a percentage: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">


<tr>

<td style="width:60%"></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="6" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Year&#160;Ended&#160;December&#160;31,</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" rowspan="2">&#160;&#160;</td>
<td colspan="2" rowspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Dollar<br />Change</span></td>
<td style="vertical-align:bottom" rowspan="2">&#160;</td>
<td style="vertical-align:bottom" rowspan="2">&#160;&#160;</td>
<td colspan="2" rowspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">%<br />Change</span></td>
<td style="vertical-align:bottom" rowspan="2">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2022</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2021</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="14" align="center"><span style="font-weight:bold">(in thousands)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">License</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(12,000</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">*&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Development fee</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,329</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,739</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(4,410</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">-65</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenue</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,329</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">18,739</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(16,410</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">-88</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">58,579</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">57,069</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,510</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">28,531</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">27,319</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,212</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">87,110</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">84,388</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,722</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(84,781</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(65,649</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(19,132</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">29</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">837</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">111</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">726</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">*&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expense, net</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(7</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(122</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">115</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">-94</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss before income tax expense</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(83,951</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(65,660</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(18,291</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">28</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax benefit (expense)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">136</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(141</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">277</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">-196</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(83,815</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(65,801</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(18,014</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">27</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:2%;vertical-align:top" align="left">*</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Percentage not meaningful </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">License and Development Fee Revenue. </span>For the year ended December&#160;31, 2022, we recognized $2.3&#160;million of development fee revenue allocated to the PEACE Phase 3 trial and BLA package of the Immedica Agreement. For the year ended December&#160;31, 2021, we recognized $18.7&#160;million of license and development fee revenue in connection with the Immedica Agreement. The total revenue generated was attributable to $12.0&#160;million allocated to the license and $6.7&#160;million allocated to the PEACE Phase 3 trial and BLA package. Please refer to Note 9, Strategic License Agreements, to the 2022 Annual Financials included elsewhere in this prospectus for additional disclosures around revenue recognition. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Research and Development Expenses</span>. Research and development expenses increased $1.5&#160;million, or 3%, to $58.6&#160;million for the year ended December&#160;31, 2022 from $57.1&#160;million for the year ended December&#160;31, 2021. The change in research and development expenses was due to: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a $1.1&#160;million increase in expenses associated with pegzilarginase primarily due to a $1.4&#160;million increase related to activities involved in closing the PEACE trial and ramping up the new open-label extension trial for the treatment of patients with Arginase 1 Deficiency, partially offset by a $0.3&#160;million decrease in professional services to support the pegzilarginase program; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a $2.8&#160;million increase in expense associated with <span style="white-space:nowrap">IND-enabling</span> activities of <span style="white-space:nowrap">AGLE-325</span> for the treatment of patients with Cystinuria; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a $0.6&#160;million increase in personnel-related expenses, primarily driven by an increase of headcount expenses; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a $1.5&#160;million decrease in expenses primarily associated with the completion of <span style="white-space:nowrap">non-clinical</span> toxicology studies in the prior year for pegtarviliase for the treatment of patients with Homocystinuria; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a $0.6&#160;million decrease due to reduction in preclinical lab work; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a $0.9&#160;million decrease in other research and development expenses, primarily related to a reduction of consulting and recruiting activities. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">56 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">General and Administrative Expenses</span>. General and administrative expenses increased by $1.2&#160;million, or 4%, to $28.5&#160;million for the year ended December&#160;31, 2022 from $27.3&#160;million for the year ended December&#160;31, 2021. The increase in general and administrative expenses was primarily due to a $0.8&#160;million increase in expense related to our commercial capabilities and infrastructure and $0.4&#160;million increase in expenses related to financing activities. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Comparison of the Years Ended December&#160;31, 2021 and 2020 </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes our results of operations for the years ended December&#160;31, 2021 and 2020, together with the changes in those items in dollars and as a percentage: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">


<tr>

<td style="width:58%"></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Year Ended<br />December&#160;31,</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" rowspan="2">&#160;&#160;</td>
<td colspan="2" rowspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Dollar<br />Change</span></td>
<td style="vertical-align:bottom" rowspan="2">&#160;</td>
<td style="vertical-align:bottom" rowspan="2">&#160;&#160;</td>
<td colspan="2" rowspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">%&#160;Change</span></td>
<td style="vertical-align:bottom" rowspan="2">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2021</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2020</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="6" align="center"><span style="font-weight:bold">(dollars in thousands)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">License</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">*&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Development fee</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,739</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,739</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">*&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenue</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">18,739</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">18,739</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">*&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">57,069</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">59,638</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(2,569</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">27,319</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">21,843</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,476</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">25</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">84,388</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">81,481</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,907</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(65,649</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(81,481</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">15,832</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">19</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">111</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">593</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(482</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">81</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expense, net</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(122</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(5</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(117</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">*&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss before income tax expense</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(65,660</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(80,893</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">15,233</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">19</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(141</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(141</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">*&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(65,801</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(80,893</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">15,092</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">19</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:2%;vertical-align:top" align="left">*</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Percentage not meaningful </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">License and Development Fee Revenue. </span>For the year ended December&#160;31, 2021, we recognized $18.7&#160;million of license and development fee revenue in connection with the Immedica Agreement. The total revenue generated of $18.7&#160;million was attributable to $12.0&#160;million allocated to the license and $6.7&#160;million allocated to the PEACE Phase 3 trial and BLA package. We did not recognize any revenue for the year ended December&#160;31, 2020. Please refer to Note 9, Strategic License Agreements, to the 2022 Annual Financials included elsewhere in this prospectus for additional disclosures around revenue recognition. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Research and Development Expenses</span>. Research and development expenses decreased by $2.6&#160;million, or 4%, to $57.1&#160;million for the year ended December&#160;31, 2021 from $59.6&#160;million for the year ended December&#160;31, 2020. The change in research and development expenses was due to: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">lower manufacturing expenses, which decreased by $12.4&#160;million as a result of completing certain <span style="white-space:nowrap">pre-commercial</span> manufacturing activities for pegzilarginase and formulation, characterization, and stability studies for <span style="white-space:nowrap">AGLE-177;</span> offset by </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">higher clinical development expenses, which increased by $5.1&#160;million as a result of <span style="white-space:nowrap">ramping-up</span> and completing enrollment in our PEACE Phase 3 trial of pegzilarginase for the treatment of patients with Arginase 1 Deficiency, and preparing and initiating dosing in our Phase 1/2 trial of <span style="white-space:nowrap">AGLE-177</span> for the treatment of Homocystinuria; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">57 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">higher nonclinical development expenses, which increased by $2.5&#160;million as a result of additional laboratory costs, BLA development activities, and toxicology costs incurred to support our Phase 1/2 trial of <span style="white-space:nowrap">AGLE-177</span> for the treatment of patients with Homocystinuria; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">higher personnel-related expenses, which increased by $2.2&#160;million as a result of changes to employee headcount and additional compensation to support our clinical and research development capabilities. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">General and Administrative Expenses</span>. General and administrative expenses increased by $5.5&#160;million, or 25%, to $27.3&#160;million for the year ended December&#160;31, 2021 from $21.8&#160;million for the year ended December&#160;31, 2020. The increase in general and administrative expenses was primarily due to a $3.6&#160;million increase in compensation and other personnel expenses, including $1.3&#160;million in <span style="white-space:nowrap">non-cash</span> stock compensation, driven by additional headcount to establish and execute our commercial planning activities, and $1.9&#160;million of expenses to <span style="white-space:nowrap">ramp-up</span> our commercial infrastructure and capabilities. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Liquidity and Capital Resources </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Sources of Liquidity </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a preclinical stage biotechnology company with a limited operating history, and due to our significant research and development expenditures, we have generated operating losses since our inception and have not generated any revenue from the sale of any products. Since our inception and through September&#160;30, 2023, we have funded our operations primarily by raising an aggregate of approximately $716.2&#160;million of gross proceeds from the sale and issuance of convertible preferred stock and common stock, <span style="white-space:nowrap">pre-funded</span> warrants, the collection of grant proceeds, and the licensing of our product rights for commercialization of pegzilarginase in Europe and certain countries in the Middle East. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In March 2021, we entered into the Immedica Agreement, pursuant to which Immedica licensed from us the product rights for commercialization of pegzilarginase in the European Economic Area, United Kingdom, Switzerland, Andorra, Monaco, San Marino, Vatican City, Turkey, Saudi Arabia, United Arab Emirates, Qatar, Kuwait, Bahrain, and Oman. In April 2021, we received an upfront payment of $21.5&#160;million from Immedica. Under the terms of the Immedica Agreement, we were also eligible to receive regulatory and commercial milestone payments and entitled to receive royalties in the <span style="white-space:nowrap">mid-20%</span> range on the net sales of the product in countries included in the Immedica Agreement. In July 2021, the Immedica Agreement was modified to include additional development services of up to $3.0&#160;million, to support the PEACE Phase 3 trial and the BLA package performance obligation. On July&#160;27, 2023, we announced that we had entered into an agreement to sell the global rights to pegzilarginase to Immedica for $15.0&#160;million in upfront cash proceeds and up to $100.0&#160;million in contingent milestone payments. The sale of the global rights to pegzilarginase to Immedica superseded and terminated the previous license agreement between us and Immedica. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May 2022, we sold 430,107 shares of common stock and <span style="white-space:nowrap">pre-funded</span> warrants to purchase up to 694,892 shares of common stock in a registered direct offering (the &#8220;2022 RDO&#8221;), for gross proceeds of $45.0&#160;million, resulting in net proceeds of $42.9&#160;million after deducting placement agent fees and offering costs. The shares of common stock and <span style="white-space:nowrap">pre-funded</span> warrants sold in the 2022 RDO were offered pursuant to a shelf registration statement on Form <span style="white-space:nowrap">S-3</span> that we filed and the SEC declared effective in July 2020. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Asset Acquisition, in June 2023, we completed a PIPE transaction under which we sold shares of Series A Preferred Stock to a group of Investors. We sold an aggregate of 721,452 shares of Series A Preferred Stock for an aggregate purchase price of approximately $210.0&#160;million, before deducting placement agent and other offering expenses of approximately $12.7&#160;million. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our primary use of cash is to fund the development of our product candidates, and advance our pipeline. This includes both the research and development costs and the general and administrative expenses required to </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">58 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
support those operations. Since we are a preclinical stage biotechnology company, we have incurred significant operating losses since our inception and we anticipate such losses, in absolute dollar terms, to increase as we pursue clinical development of our product candidates, prepare for the potential commercialization of our product candidates, and expand our development efforts in our pipeline of nonclinical candidates. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Future Funding Requirements and Operational Plan </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Due to our significant research and development expenditures, we have generated substantial losses in each period since inception. We have an accumulated deficit of $701.2&#160;million as of September&#160;30, 2023. We anticipate that we will continue to generate losses into the foreseeable future as we develop our product candidates, seek regulatory approval of those candidates and begin to commercialize any approved products. Until such time as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity or debt financings, research grants, collaborations, license and development agreements, or other sources. We currently have no debt, credit facility or additional committed capital. To the extent that we raise additional equity, the ownership interest of our stockholders will be diluted. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on our available cash, cash equivalents, and marketable securities of $203.6&#160;million as of September&#160;30, 2023, we have evaluated and determined that there are conditions and events, considered in the aggregate, that raise substantial doubt about our ability to continue as a going concern within one year after the date the condensed consolidated financial statements as of and for the three and nine months ended September&#160;30, 2023 included in this prospectus were issued. Our Series A Preferred Stock agreement requires us to seek stockholder approval for the conversion of the Series A Preferred Stock to Common Stock. We have agreed to hold a stockholders&#8217; meeting to submit this matter to our stockholders for their consideration. In connection with this, we filed with the SEC a definitive proxy statement and other relevant materials. The special meeting of stockholders is scheduled for November&#160;21, 2023. If our stockholders do not timely approve the conversion of our Series A Preferred Stock, then the holders of our Series A Preferred Stock may be entitled to require us to settle their shares of Series A Preferred Stock for cash at a price per share equal to the fair value of the Series A Preferred Stock, as described in the Certificate of Designation relating to the Series A Preferred Stock. The cash redemption is not under our control and raises substantial doubt about our ability to continue as a going concern. The consolidated financial statements included in this prospectus assume we will continue as a going concern through the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Recent Developments </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&#160;21, 2023, our stockholders approved the issuance of shares of our Common Stock upon conversion of Series A Preferred Stock, eliminating the potential requirement to settle shares of Series A Preferred Stock in cash. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">59 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Cash Flows for the Nine Months Ended September&#160;30, 2023 and 2022 </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes our cash flows for the periods indicated (in thousands): </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:72%"></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Nine Months Ended<br />September&#160;30,</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2023</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2022</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash, cash equivalents, and restricted cash (used in) provided by:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating activities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(68,874</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(62,004</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investing activities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(73,121</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">43,008</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financing activities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">197,471</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">42,686</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effect of exchange rate on cash, cash equivalents, and restricted cash</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(152</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net increase in cash, cash equivalents, and restricted cash</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">55,483</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">23,538</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Cash Used in Operating Activities </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash used in operating activities for the nine months ended September&#160;30, 2023 was $68.9&#160;million and reflected a net loss of $275.6&#160;million. Our net loss was offset in part by <span style="white-space:nowrap">non-cash</span> expenses of $130.2&#160;million for acquired IPR&amp;D, $83.5&#160;million change in fair value of forward contract liability, $8.4&#160;million in stock-based compensation, $2.6&#160;million impairment loss on lease abandonment, $1.0&#160;million in depreciation and amortization, and a $0.9&#160;million loss on disposal of long-lived assets. The net change in operating assets and liabilities of $1.2&#160;million was primarily due to a $2.3&#160;million decrease in operating lease liabilities primarily due to the termination of the Las Cimas lease, a $4.0&#160;million decrease in accrued and other liabilities and a $2.1&#160;million decrease in related party payable, partially offset by a $3.3&#160;million increase in prepaid expenses and other assets, a $1.0&#160;million increase in accounts payable, a $0.6&#160;million increase in deferred revenue, and a $0.2&#160;million increase in development receivables. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash used in operating activities for the nine months ended September&#160;30, 2022 was $62.0&#160;million and reflected a net loss of $65.0&#160;million. Our net loss was offset in part by <span style="white-space:nowrap">non-cash</span> expense of $5.7&#160;million for stock-based compensation and $1.5&#160;million for depreciation and amortization. The net change in operating assets and liabilities of $4.3&#160;million was primarily related to a $2.9&#160;million increase in prepaid expenses and other assets and a $1.3&#160;million decrease in accrued and other liabilities. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Cash Provided by Investing Activities </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash used in investing activities for the nine months ended September&#160;30, 2023 was $73.1&#160;million and primarily consisted of $112.6&#160;million in purchases of marketable securities, partially offset by $21.0&#160;million in maturities and sales of marketable securities, $15.0&#160;million in proceeds from the sale of <span style="white-space:nowrap">in-process</span> research&#160;&amp; development asset, and $3.0&#160;million cash assumed from the Asset Acquisition. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash provided by investing activities for the nine months ended September&#160;30, 2022 was $43.0&#160;million and consisted of $78.0&#160;million in maturities and sales of marketable securities, partially offset by $35.0&#160;million in purchases of marketable securities. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Cash Provided by Financing Activities </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash provided by financing activities for the nine months ended September&#160;30, 2023 was $197.5&#160;million, which primarily consisted of the net proceeds from the issuance of the Series A Preferred Stock in the June 2023 PIPE. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">60 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash provided by financing activities for the nine months ended September&#160;30, 2022 was $42.7&#160;million, which primarily consisted of $42.9&#160;million from the registered direct offering of our Common Stock and <span style="white-space:nowrap">pre-funded</span> warrants in May 2022, net of placement agent fees and offering costs, and $0.2&#160;million from the sale of Common Stock under our 2016 Employee Stock Purchase Plan, partially offset by $0.4&#160;million in principal payments made on our finance lease obligations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Cash flows for the Years Ended December&#160;31, 2022 and 2021 </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes our cash flows for the periods indicated (in thousands): </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:72%"></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Year&#160;Ended&#160;December&#160;31,</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2022</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2021</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash and cash equivalents (used in) provided by:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating activities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(80,144</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(53,716</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investing activities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">57,008</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(22,619</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financing activities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">42,678</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,393</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effect of exchange rate on cash, cash equivalents, and restricted cash</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(106</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(15</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net increase (decrease) in cash and cash equivalents</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">19,436</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(74,957</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Cash used in operating activities </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash used in operating activities for the year ended December&#160;31, 2022 was $80.1&#160;million and reflected a net loss of $83.8&#160;million. The cash impact of our net loss was offset by <span style="white-space:nowrap">non-cash</span> expenses of $7.1&#160;million for stock-based compensation, $1.6&#160;million for depreciation and amortization, $0.4&#160;million for operating lease expense, and $0.1&#160;million for net premium purchase and amortization on marketable securities. The net decrease in operating assets and liabilities of $5.5&#160;million was primarily related to a $2.6&#160;million decrease in accounts payable, a $1.1&#160;million increase in prepaid expenses and other assets, a $0.9&#160;million decrease in deferred revenue due to receiving payments under the Immedica Agreement offset by the recognition of revenue allocated to the license, PEACE Phase 3 trial and BLA filing, a $0.9&#160;million decrease in accrued expenses and other liabilities, and a $0.4&#160;million decrease in operating lease liabilities due to lease payments made during the year, partially offset by a $0.4&#160;million increase in accounts receivable for incremental services provided to Immedica and not yet paid. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash used in operating activities for the year ended December&#160;31, 2021 was $53.7&#160;million and reflected a net loss of $65.8&#160;million. The cash impact of our net loss was offset by <span style="white-space:nowrap">non-cash</span> expenses of $8.0&#160;million for stock-based compensation, $1.6&#160;million for depreciation and amortization, $0.4&#160;million for operating lease expense, and $0.2&#160;million for net premium purchase and amortization on marketable securities. The net change in operating assets and liabilities of $1.8&#160;million was primarily related to a $3.6&#160;million increase in deferred revenue due to receiving a $21.5&#160;million upfront payment under the Immedica Agreement offset by the recognition of revenue allocated to the license, PEACE Phase 3 trial and BLA submission. Additional offsets included a $1.2&#160;million increase in prepaid expenses and other assets due to advance payments for the Phase 1/2 trial of pegtarviliase and manufacturing activities for the Arginase 1 Deficiency program, a $0.8&#160;million increase in license and development receivable for incremental services provided to Immedica and not yet paid, and a $0.4&#160;million decrease in operating lease liabilities due to lease payments made during the year. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Cash used in investing activities </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash used in investing activities for the year ended December&#160;31, 2022 was $57.0&#160;million and consisted of $39.5&#160;million in purchases of marketable securities offset by $96.5&#160;million in maturities of marketable securities. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">61 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash used in investing activities for the year ended December&#160;31, 2021 was $22.6&#160;million and consisted of $133.1&#160;million in purchases of marketable securities and $0.5&#160;million in purchases of property and equipment offset by $111.0&#160;million in maturities of marketable securities. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Cash provided by financing activities </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash provided by financing activities for the year ended December&#160;31, 2022 was $42.7&#160;million, which consisted of $42.9&#160;million from issuance of common stock and <span style="white-space:nowrap">pre-funded</span> warrants in a registered direct offering, the 2022 RDO, net of offering costs and $0.2&#160;million sale of common stock under our 2016 Employee Stock Purchase Plan offset by $0.4&#160;million in principal payments made on finance lease obligations. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash provided by financing activities for the year ended December&#160;31, 2021 was $1.4&#160;million, which consisted of $1.9&#160;million in stock option exercises and sale of common stock under our 2016 Employee Stock Purchase Plan offset by $0.5&#160;million in principal payments made on finance lease obligations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Cash flows for the Years Ended December&#160;31, 2021 and 2020 </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes our cash flows for the periods indicated (in thousands): </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:72%"></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Year&#160;Ended&#160;December&#160;31,</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2021</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2020</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash and cash equivalents (used in) provided by:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating activities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(53,716</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(75,775</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investing activities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(22,619</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(7,604</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financing activities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,393</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">154,512</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effect of exchange rate on cash, cash equivalents, and restricted cash</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(15</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">51</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net (decrease) increase in cash and cash equivalents</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(74,957</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">71,184</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Cash used in operating activities </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash used in operating activities for the year ended December&#160;31, 2021 was $53.7&#160;million and reflected a net loss of $65.8&#160;million. The cash impact of our net loss was offset by <span style="white-space:nowrap">non-cash</span> expenses of $8.0&#160;million for stock-based compensation, $1.6&#160;million for depreciation and amortization, $0.4&#160;million for operating lease expense, and $0.2&#160;million for net premium purchase and amortization on marketable securities. The net change in operating assets and liabilities of $1.8&#160;million was primarily related to a $3.6&#160;million increase in deferred revenue due to receiving a $21.5&#160;million upfront payment under the Immedica Agreement offset by the recognition of revenue allocated to the license, PEACE Phase 3 trial and BLA filing. Additional offsets included a $1.2&#160;million increase in prepaid expenses and other assets due to advance payments for the Phase 1/2 trial of <span style="white-space:nowrap">AGLE-177</span> and manufacturing activities for the Arginase 1 Deficiency program, a $0.8&#160;million increase in license and development receivable for incremental services provided to Immedica and not yet paid, and a $0.4&#160;million decrease in operating lease liabilities due to lease payments made during the year. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash used in operating activities for the year ended December&#160;31, 2020 was $75.8&#160;million and reflected a net loss of $80.9&#160;million. The cash impact of our net loss was offset by <span style="white-space:nowrap">non-cash</span> expenses of $6.3&#160;million for stock-based compensation, $1.0&#160;million for depreciation and amortization, and $0.6&#160;million for operating lease expense. The net change in operating assets and liabilities of $2.5&#160;million was primarily related to a $1.7&#160;million decrease in accrued liabilities and accounts payable due to payments for manufacturing and a $1.1&#160;million increase in prepaid expenses and other assets due to advanced payments associated with manufacturing for Arginase 1 Deficiency and nonclinical studies for Homocystinuria. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">62 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Cash used in investing activities </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash used in investing activities for the year ended December&#160;31, 2021 was $22.6&#160;million and consisted of $133.1&#160;million in purchases of marketable securities and $0.5&#160;million in purchases of property and equipment offset by $111.0&#160;million in maturities of marketable securities. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash used in investing activities for the year ended December&#160;31, 2020 was $7.6&#160;million and consisted of $129.0&#160;million in purchases of marketable securities and $4.3&#160;million in purchases of property and equipment offset by $125.7&#160;million in maturities of marketable securities. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Cash provided by financing activities </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash provided by financing activities for the year ended December&#160;31, 2021 was $1.4&#160;million, which consisted of $1.9&#160;million in stock option exercises and sale of common stock under our 2016 Employee Stock Purchase Plan offset by $0.5&#160;million in principal payments made on finance lease obligations. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash provided by financing activities for the year ended December&#160;31, 2020 was $154.5&#160;million, which consisted of $138.0&#160;million from the public offering of our common stock, offset by $9.0&#160;million in paid underwriting and offering costs, $25.3&#160;million from the sale of our common stock under an <span style="white-space:nowrap"><span style="white-space:nowrap">at-the-market</span></span> program, offset by $0.7 million in paid underwriting and offering costs, and $0.8&#160;million in proceeds received from stock option exercises and sale of common stock under our 2016 Employee Stock Purchase Plan. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Contractual Obligations and Other Commitments </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Through the Asset Acquisition, we received the Option to license the IPR&amp;D related to four research programs. On July&#160;12, 2023, we exercised the Option with respect to one of these research programs. The exercise of the Option obligates us to pay Paragon up to $22.0&#160;million based on specific clinical and regulatory milestones. As of September&#160;30, 2023, none of the $22.0&#160;million obligation was accrued for since the likelihood of achieving those milestones was not determined to be probable. As of the date of the filing of this prospectus, the Option remains unexercised with respect to the three remaining research programs under the Paragon Agreement. Should the Option for these research programs be exercised, we would be obligated to pay Paragon up to $22.0&#160;million per research program based on certain clinical and regulatory milestones. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have entered into agreements in the normal course of business with contract research organizations for clinical trials and contract manufacturing organizations, and with vendors for nonclinical research studies and other services and products for operating purposes. These contractual obligations are cancelable at any time by us, generally upon 30 to 60 days&#8217; prior written notice to the vendor. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Recently Adopted Accounting Pronouncements </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We early adopted the Financial Accounting Standards Board&#8217;s Accounting Standards Update <span style="white-space:nowrap">2020-06,</span> Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity (&#8220;ASU <span style="white-space:nowrap">2020-06&#8221;),</span> effective as of January&#160;1, 2023, using the modified retrospective method. Among other amendments, ASU <span style="white-space:nowrap">2020-06</span> eliminates the cash conversion and beneficial conversion feature models in ASC <span style="white-space:nowrap">470-20</span> that required an issuer of certain convertible debt and preferred stock to separately account for embedded conversion features as a component of equity, as well as changes the accounting for diluted <span style="white-space:nowrap"><span style="white-space:nowrap">earnings-per-share</span></span> for convertible instruments and contracts that may be settled in cash or stock. Additionally, ASU <span style="white-space:nowrap">2020-06</span> requires the <span style="white-space:nowrap">if-converted</span> method, which is more dilutive than the treasury stock method, be used for all convertible instruments. We applied ASU <span style="white-space:nowrap">2020-06</span> to all Series A Preferred Stock during fiscal year 2023, and, accordingly, we did not apply the cash conversion or beneficial conversion feature models in our analysis of the Series A Preferred Stock. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">63 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx518298_8">CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">64 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx518298_9">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are exposed to market risks in the ordinary course of our business. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of United States interest rates, particularly because our investments are in marketable securities. Our marketable securities are subject to interest rate risk and could fall in value if market interest rates increase. However, we believe that our exposure to interest rate risk is not significant as the majority of our investments are short-term in duration and have a low risk profile. A hypothetical 10% change in interest rates is not expected to have a material effect on the total market value of our investment portfolio. We have the ability to hold our marketable securities until maturity, and therefore, we would not expect our operating results or cash flows to be materially impacted by a change in market interest rates on our investments. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">As of December&#160;31, 2022 </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2022, we held $57.3&#160;million in cash, cash equivalents, marketable securities, and restricted cash, all of which was denominated in U.S. dollars, and consisted primarily of investments in money market funds, commercial paper, and corporate bonds. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">As of September&#160;30, 2023 </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of September&#160;30, 2023, we held $203.6&#160;million in cash, cash equivalents, and marketable securities, predominantly all of which was denominated in U.S. dollars, and consisted primarily of investments in money market funds, commercial paper, and corporate bonds. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are also exposed to market risk related to changes in foreign currency exchange rates as a result of our entering into transactions denominated in currencies other than U.S. dollars. Due to the uncertain timing of expected payments in foreign currencies, we do not utilize any forward exchange contracts. All foreign transactions settle on the applicable spot exchange basis at the time such payments are made. For the year ended December&#160;31, 2022 and for the nine months ended September&#160;30, 2023, a majority of our expenditures were denominated in U.S. dollars. A hypothetical 10% change in foreign exchange rates during any of the periods presented would not have had a material impact on our consolidated financial statements. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">65 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx518298_10">BUSINESS </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Company Overview </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&#160;22, 2023, we completed the Asset Acquisition pursuant to the Acquisition Agreement. <span style="white-space:nowrap">Pre-Merger</span> Spyre was a <span style="white-space:nowrap">pre-clinical</span> stage biotechnology company that was incorporated on April&#160;28, 2023 under the direction of Peter Harwin, a Managing Member of Fairmount, for the purpose of holding rights to certain intellectual property being developed by Paragon. Fairmount is a founder of Paragon. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Through the Asset Acquisition, we received the Option pursuant to the Paragon Agreement. On July&#160;12, 2023, we exercised the Option with respect to one of these research programs to exclusively license intellectual property rights related to such research program directed to antibodies that selectively bind to &#945;4&#223;7 integrin and methods of using these antibodies, including methods of treating IBD using the SPY001 program. If this research program is pursued <span style="white-space:nowrap">non-provisionally</span> and matures into issued patents, we would expect those patents to expire no earlier than 2044 subject to any disclaimers or extensions. On December&#160;14, 2023, we exercised the Option under the Paragon Agreement to be granted an exclusive license to all of Paragon&#8217;s rights, title and interest in and to intellectual property rights, including inventions, patents, sequence information and results, under SPY002, Spyre&#8217;s TL1A program, to develop and commercialize antibodies and products worldwide in all therapeutics disorders. The license agreements pertaining to such research programs are currently being finalized. Furthermore, as of the date of this registration statement, the Option remains unexercised with respect to the intellectual property rights related to the three remaining research programs under the Paragon Agreement. For more information on the Paragon Agreement, see discussion under the heading &#8220;<span style="font-style:italic">Paragon Agreement</span>&#8221; below. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&#160;27, 2023, we announced that we entered into an agreement to sell the global rights to pegzilarginase, an investigational treatment for the rare metabolic disease Arginase 1 Deficiency, to Immedica for $15.0&#160;million in upfront cash proceeds and up to $100.0&#160;million in contingent milestone payments. The sale of pegzilarginase to Immedica supersedes and terminates the license agreement between us and Immedica dated March 2021. See the section titled &#8220;<span style="font-style:italic">Recent Developments</span>&#8221; below for more information regarding the Immedica APA. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following the Asset Acquisition and the entry into the Immedica APA, we have significantly reshaped the business into a preclinical stage biotechnology company focused on developing next generation therapeutics for patients living with IBD, including UC and CD. Through the Paragon Agreement, our portfolio of novel and proprietary monoclonal antibody product candidates has the potential to address unmet needs in IBD care by improving efficacy, safety, and/or dosing convenience relative to products currently available or product candidates in development. We have purposely engineered our product candidates to bind potently and selectively to target epitopes with extended half-lives. We plan to use combinations of our proprietary antibodies and patient enrichment strategies via companion diagnostics to enhance efficacy. We intend to deliver our product candidates through convenient, infrequently self-administered, SC injection as a <span style="white-space:nowrap">pre-filled</span> pen. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Our Strategy </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our goal is to develop next-generation therapeutics for the treatment of IBD, relying on three strategic pillars: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Advancing novel, potentially <span style="white-space:nowrap"><span style="white-space:nowrap">best-in-class,</span></span> long-acting antibodies against validated IBD targets, </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Evaluating rational therapeutic combinations of potentially <span style="white-space:nowrap"><span style="white-space:nowrap">best-in-class</span></span> antibodies, and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Developing genetic- or biomarker-based companion diagnostics to match treatment targets to IBD <span style="white-space:nowrap">sub-populations.</span></p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Inflammatory Bowel Disease </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IBD is a chronic condition characterized by inflammation within the gastrointestinal tract. It encompasses two main disorders: UC and CD. UC primarily affects the colon and the rectum. Inflammation occurs in the innermost lining of the colon leading to ulcers. Symptoms include bloody diarrhea, abdominal pain, bowel urgency, and frequent bowel movements. CD can affect any part of the gastrointestinal tract, from the mouth to the anus. It is characterized by inflammation that extends through multiple layers of the bowel wall. Symptoms </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">66 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
include abdominal pain, diarrhea, weight loss, fatigue, and complications such as strictures or fistulas. Both conditions can significantly impact patients&#8217; quality of life in terms of physical health, emotional well-being, and the unpredictability of symptom onset. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IBD affects millions of individuals worldwide, with increasing prevalence and incidence in both developed and developing countries. In the United States, it is estimated that approximately 2.4&#160;million individuals currently have IBD, with approximately 70,000 patients newly diagnosed every year. The prevalence of UC in the United States is approximately 900,000 individuals, and the prevalence of CD in the United States is approximately 800,000 individuals. Based on research from the Crohn&#8217;s and Colitis Foundation of America, the market for IBD therapeutics is expected to experience steady growth, driven by rising disease prevalence, increasing diagnosis rates, and evolving treatment paradigms. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A range of pharmaceutical options exists, including anti-inflammatory drugs, immunosuppressants, and biologics. Treatment plans are often tailored to the individual patient&#8217;s disease severity, location, and response to therapy. In some cases, surgical interventions such as bowel resection or ostomy formation may be necessary to manage complications or improve quality of life. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Despite available treatments, there remain substantial unmet needs in IBD management, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Inadequate response or loss of response to existing therapies, </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Side effects and safety concerns associated with long-term medication use, </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Limited options for patients with refractory or severe disease, and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Adherence to frequent and/or inconvenient dosing regimens. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Our Portfolio </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are advancing a broad pipeline of potentially <span style="white-space:nowrap"><span style="white-space:nowrap">best-in-class</span></span> monoclonal antibodies (&#8220;mAbs&#8221;) for the treatment of IBD in connection with the research programs with respect to which we have exercised the Option to exclusively license all of Paragon&#8217;s right, title, and interest in, including all intellectual property license rights to, or have the Option to acquire such intellectual property and other rights to pursuant to the Paragon Agreement and plan to develop patient selection approaches for each program. The following table summarizes these programs: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g518298g29e61.jpg" alt="LOGO" />
 </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><sup style="font-size:75%; vertical-align:top">1</sup>&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="font-style:italic">We exercised our Option to license worldwide rights from Paragon for the SPY001 and SPY002 programs. We continue to hold the Option to license similar rights from Paragon for certain other programs. We expect the SPY003 license to be restricted to IBD, and we expect other potential program licenses related to the Option to be indication agnostic.</span> </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">67 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although we hold the Option to acquire intellectual property license rights related to the SPY003 and SPY004 programs, such Option remains unexercised. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For a discussion of the risks associated with our portfolio, see the section of this prospectus entitled &#8220;Risk Factors.&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">SPY001 &#8211; anti-</span><span style="font-style:italic"></span>&#945;<span style="font-style:italic"></span><span style="font-style:italic">4</span><span style="font-style:italic">&#223;</span><span style="font-style:italic">7 mAb </span> </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our most advanced product candidate, SPY001, is a highly potent, highly selective, and fully human monoclonal immunoglobulin G1 antibody designed to bind selectively to the &#945;4&#223;7 integrin. The &#945;4&#223;7 integrin is a protein found on the surface of immune cells known as lymphocytes. This integrin regulates the migration of lymphocytes to the gut where they contribute to the inflammatory process in IBD. By selectively binding to the &#945;4&#223;7 integrin, SPY001 is designed to prevent the interaction of these lymphocytes with <span style="white-space:nowrap">MAdCAM-1,</span> a molecule expressed on endothelial cells lining the blood vessels in the gut. This interaction is responsible for guiding lymphocytes from the bloodstream into the gut tissue, where they cause inflammation. By blocking the interaction between &#945;4&#223;7 integrin and <span style="white-space:nowrap">MAdCAM-1,</span> SPY001 aims to reduce the recruitment of lymphocytes to the gut, leading to a decrease in inflammation. Since it specifically targets the gut immune system, SPY001 is designed to help minimize systemic immunosuppressive effects unrelated to IBD pathology. SPY001 is currently progressing through <span style="white-space:nowrap">IND-enabling</span> studies and is expected to enter <span style="white-space:nowrap"><span style="white-space:nowrap">first-in-human</span></span> (&#8220;FIH&#8221;) studies in the first half of 2024. Interim data from a healthy volunteer study are expected by the end of 2024. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">SPY002 &#8211; anti-TL1A mAb </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our <span style="white-space:nowrap">co-lead</span> product candidate, SPY002, is a highly potent, highly selective, and fully human mAb designed to bind to tumor necrosis factor-like ligand 1A (&#8220;TL1A&#8221;). TL1A is a protein that plays a role in regulating the immune system and is elevated in the gut tissue of individuals with IBD. TL1A interacts with its receptor, death receptor 3 (&#8220;DR3&#8221;), which is expressed in various immune cells, including T cells. This interaction triggers signaling pathways that contribute to inflammation and immune system activation, leading to IBD symptomology. SPY002 has been designed to block the interaction between TL1A and DR3 and thereby inhibit the downstream signaling events and dampen the inflammatory response. By neutralizing TL1A, we believe SPY002 has the potential to modulate the immune response in IBD patients, potentially reducing disease activity and promoting mucosal healing. Our extensive discovery campaign has identified lead clones which bind TL1A monomers and trimers with picomolar affinity and exhibit extended pharmacokinetic half-lives relative to competitive molecules in clinical development. We expect to begin FIH studies of the SPY002 program in the second half of 2024 with healthy volunteer interim data expected in the first half of 2025. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">SPY003 &#8211; <span style="white-space:nowrap"><span style="white-space:nowrap">anti-IL-23</span></span> mAb </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our third program, SPY003, is a discovery stage program designed to bind to Interleukin 23 <span style="white-space:nowrap">(&#8220;IL-23&#8221;).</span> <span style="white-space:nowrap">IL-23</span> is a cytokine that is produced by immune cells and is involved in immune response regulation. <span style="white-space:nowrap">IL-23</span> promotes the survival, expansion, and activity of Th17 cells. Th17 cells produce other inflammatory cytokines, such as <span style="white-space:nowrap">IL-17,</span> which contribute to the inflammation seen in IBD. <span style="white-space:nowrap">IL-23</span> also helps in the recruitment and activation of other immune cells, such as neutrophils, which further contribute to tissue damage in the gut. We are continuing our preclinical development efforts with the SPY003 program. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">SPY004 &#8211; novel MOA mAb </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SPY004 is an undisclosed novel mechanism of action (&#8220;MOA&#8221;) and incorporates half-life extension modifications. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">68 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Our combination programs &#8211; SPY120, SPY130, and SPY230 </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We aim to advance certain rational combinations of our therapeutic antibodies into clinical studies. SPY120 combines SPY001 (&#945;4&#223;7) and SPY002 (TL1A), SPY130 combines SPY001 (&#945;4&#223;7) and SPY003 <span style="white-space:nowrap">(IL-23),</span> and SPY230 combines SPY002 (TL1A) and SPY003 <span style="white-space:nowrap">(IL-23).</span> We believe these combinations target orthogonal biology and could lead to greater remission rates in IBD. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Our Precision Immunology Approach </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We aim to develop genetic- or biomarker-based patient selection approaches across our portfolio of therapeutics to aid patients and physicians in selecting the optimal treatment regimen. We are in discussions with potential partners with access to large scale IBD biobanks to support CDx development across our portfolio. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Employees and Human Capital Resources </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;11, 2023, we had 30 employees, all of whom were employed full time. We also engage temporary employees and consultants to augment our existing workforce. None of our employees are represented by a labor union or covered under a collective bargaining agreement. We consider our relationship with our employees to be good. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are committed to providing our employees with a work environment that is free of unlawful discrimination, including any harassment on the basis of any legally protected status. Accordingly, we do not and will not tolerate any form of unlawful harassment against our employees, whether by executives, managers, <span style="white-space:nowrap">co-workers,</span> or by third parties, such as vendors, or other third parties with whom our employees interact. In addition, we provide equal employment opportunity to all employees and applicants for employment and do not discriminate on any basis prohibited by law, including race, color, sex, gender, sexual orientation, pregnancy, age, religion, national origin, disability, marital status, and veteran status. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We recognize that attracting, motivating, and retaining talent at all levels is vital to continuing our success. We invest in our employees through high-quality benefits and various health and wellness initiatives and offer competitive compensation packages (base salary and incentive plans), ensuring fairness in internal compensation practices. The principal purposes of our incentive plans (bonus and equity) are to align with the long-term interests of our stakeholders and stockholders. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To further engage and incentivize our workforce, we offer a wide range of opportunities to support professional development and growth. For our talent pipeline assessment and development, we work closely with individual business functional leaders to identify our high-performing and high-potential employees, by conducting a company-wide talent assessment utilizing a Performance/Potential Matrix assessment tool. This assessment is completed annually to ensure we tie together our incentives, development, and recognition to retain and attract the people we need to drive our success. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Commercial </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Should any of our product candidates be approved for commercialization, we intend to develop a plan to commercialize them in the United States and other key markets, through internal infrastructure and/or external partnerships in a manner that will enable us to realize the full commercial value of our programs. Given our stage of development, we have not yet established a commercial organization or distribution capabilities. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Manufacturing </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not currently own or operate facilities for product manufacturing, testing, storage, and distribution. We are currently in the process of novating certain agreements with third parties for the performance of future clinical </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">69 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
manufacturing and toxicology activities from Paragon to us. The initial forms of these agreements are generally non-specific master services agreements that allow an entity to begin the process of future manufacturing or toxicology services, respectively. As clinical development activities are commenced by us, the agreements will be revised to provide for the specific deliverables and associated costs that are needed under our development plan. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to a Novation Agreement dated September&#160;19, 2023 (the &#8220;Novation Agreement&#8221;), by and between us, Paragon and WuXi Biologics (Hong Kong) Limited (&#8220;WuXi Biologics&#8221;), we novated (i)&#160;a Biologics Master Services Agreement (the &#8220;WuXi Biologics MSA&#8221;) and (ii)&#160;a Cell Line License Agreement (the &#8220;Cell Line License Agreement&#8221;). </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Biologics Master Services Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In April 2023, Paragon and WuXi Biologics entered into the WuXi Biologics MSA, which was subsequently novated to us by Paragon on September&#160;19, 2023 pursuant to the Novation Agreement. The WuXi Biologics MSA governs certain development activities and GMP manufacturing and testing for the SPY001 program, as well as potential future programs, on a work order basis. Under the WuXi Biologics MSA, we are obligated to pay WuXi Biologics a service fee and all <span style="white-space:nowrap">non-cancellable</span> obligations in the amount specified in each work order associated with the agreement for the provision of services. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The WuXi Biologics MSA terminates on the later of (i)&#160;June&#160;20, 2027 or (ii)&#160;the completion of services under all work orders executed by the parties prior to June&#160;20, 2027, unless terminated earlier. The term of each work order terminates upon completion of the services under such work order, unless terminated earlier. We can terminate the WuXi Biologics MSA or any work order at any time upon 30 days&#8217; prior written notice and immediately upon written notice if WuXi Biologics fails to obtain or maintain required material governmental licenses or approvals. Either party may terminate a work order (i)&#160;at any time upon six months&#8217; prior notice with reasonable cause, provided however that if WuXi Biologics terminates a work order in such manner, no termination or cancellation fees shall be paid by us and (ii)&#160;immediately for cause upon (a)&#160;the other party&#8217;s material breach that remains uncured for 30 days after notice of such breach, (b)&#160;the other party&#8217;s bankruptcy or (c)&#160;a force majeure event that prevents performance for a period of at least 90 days. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Cell Line License Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In April 2023, Paragon and WuXi Biologics entered into the Cell Line License Agreement, which was subsequently novated to us by Paragon pursuant to the Novation Agreement. Under the Cell Line License Agreement, we received a <span style="white-space:nowrap">non-exclusive,</span> worldwide, sublicensable license to certain of WuXi Biologics&#8217;s <span style="white-space:nowrap">know-how,</span> cell line, biological materials (the &#8220;WuXi Biologics Licensed Technology&#8221;) and media and feeds to make, have made, use, sell and import certain therapeutic products produced through the use of the cell line licensed by WuXi Biologics under the Cell Line License Agreement (the &#8220;WuXi Biologics Licensed Products&#8221;). Specifically, the WuXi Biologics Licensed Technology is used in certain manufacturing activities in support of the SPY001 program. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In consideration for the license, we agreed to pay WuXi Biologics a <span style="white-space:nowrap">non-refundable</span> license fee of $150,000. Additionally, if we manufacture all of our commercial supplies of bulk drug product with a manufacturer other than WuXi Biologics or its affiliates, we are required to make royalty payments to WuXi Biologics in an amount equal to a less than one percent of global net sales of WuXi Biologics Licensed Products manufactured by a third-party manufacturer (the &#8220;Royalty&#8221;). If we manufacture part of our commercial supplies of the WuXi Biologics Licensed Products with WuXi Biologics or its affiliates, then the Royalty will be reduced accordingly on a pro rata basis. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Cell Line License Agreement will continue indefinitely unless terminated (i)&#160;by us upon six months&#8217; prior written notice and our payment of all undisputed amounts due to WuXi Biologics through the effective date of </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">70 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
termination, (ii)&#160;by WuXi Biologics for a material breach by us that remains uncured for 60 days after written notice, (iii)&#160;by WuXi Biologics if we fail to make a payment and such failure continues for 30 days after receiving notice of such failure, or (iv)&#160;by either party upon the other party&#8217;s bankruptcy. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Competition </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect to face intense competition from other biopharmaceutical companies that are developing agents for the treatment of inflammatory diseases. If approved for the treatment of patients with <span style="white-space:nowrap"><span style="white-space:nowrap">moderate-to-severe</span></span> IBD, our portfolio of products would compete with TNF antibodies including Humira (AbbVie), Remicade (Johnson&#160;&amp; Johnson), and Simponi (Johnson&#160;&amp; Johnson); <span style="white-space:nowrap">IL-12/23</span> and <span style="white-space:nowrap">IL-23</span> antibodies including Stelara (Johnson&#160;&amp; Johnson) and Skyrizi (AbbVie); &#945;4&#223;7 antibody Entyvio (Takeda); JAK inhibitors including Xeljanz (Pfizer), Rinvoq (AbbVie); and S1P1 receptor modulating therapies including Zeposia (Bristol Myers Squibb). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are aware of several companies with product candidates in development for the treatment of patients with IBD, including Merck&#8217;s <span style="white-space:nowrap">MK-7240,</span> Roivant&#8217;s <span style="white-space:nowrap">RVT-3101,</span> and Teva&#8217;s <span style="white-space:nowrap">TEV-48574</span> TL1A antibodies; additional <span style="white-space:nowrap">IL-23s</span> including Tremfya (Johnson&#160;&amp; Johnson) and mirikizumab (Lilly); additional S1P1 modulator etrasimod (Pfizer); and oral anti-integrin agents including Morphic Therapeutic&#8217;s <span style="white-space:nowrap">MORF-057,</span> and Gilead&#8217;s <span style="white-space:nowrap">GS-1427,</span> and a discovery program at Dice Therapeutics (Lilly). </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Government Regulation </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA and other regulatory authorities at federal, state and local levels, as well as in foreign countries, extensively regulate, among other things, the research, development, testing, manufacture, quality control, import, export, safety, effectiveness, labeling, packaging, storage, distribution, record keeping, approval, advertising, promotion, marketing, post-approval monitoring and post-approval reporting of biologics such as those we are developing. We, along with our third-party contractors, will be required to navigate the various preclinical, clinical and commercial approval requirements of the governing regulatory agencies of the countries in which we wish to conduct studies or seek approval or licensure of our product candidates. Failure to comply with the applicable United States requirements at any time during the product development process, approval process or post-market may subject an applicant to administrative or judicial sanctions. These sanctions could include, among other actions, the FDA&#8217;s refusal to approve pending applications, withdrawal of an approval, a clinical hold, untitled or warning letters, product recalls or market withdrawals, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement and civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">United States Biologics Regulation </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the United States, biological products are subject to regulation under the Federal Food, Drug, and Cosmetic Act (&#8220;FDCA&#8221;) and the Public Health Service Act (&#8220;PHSA&#8221;) and their implementing regulations, as well as other federal, state, local, and foreign statutes and regulations. The process required by the FDA before biologic product candidates may be marketed in the United States generally involves the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">completion of preclinical laboratory tests and animal studies performed in accordance with applicable regulations, including the FDA&#8217;s current Good Laboratory Practices; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">submission to the FDA of an IND, which must become effective before clinical trials may begin and must be updated annually or when significant changes are made; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">approval by an independent IRB, or ethics committee at each clinical site before the trial may be commenced; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">manufacture of the proposed biologic candidate in accordance with current Good Manufacturing Practices (&#8220;cGMPs&#8221;); </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">71 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">performance of adequate and well-controlled human clinical trials in accordance with applicable IND regulations, current Good Clinical Practice (&#8220;cGCP&#8221;) requirements and other clinical-trial related regulations to establish the safety, purity and potency of the proposed biologic product candidate for its intended purpose; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">preparation of and submission to the FDA of a BLA, after completion of all pivotal clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">satisfactory completion of an FDA Advisory Committee review, if applicable; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a determination by the FDA within 60 days of its receipt of a BLA to file the application for review; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">satisfactory completion of an FDA <span style="white-space:nowrap">pre-approval</span> inspection of the manufacturing facility or facilities at which the proposed product is produced to assess compliance with cGMPs, and to assure that the facilities, methods and controls are adequate to preserve the biological product&#8217;s continued safety, purity and potency, and potential audit of selected clinical investigation sites to assess compliance with cGCPs; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">payment of user fees for FDA review of the BLA, unless a waiver is applicable; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">FDA review and approval of a BLA to permit commercial marketing of the product for a particular indication(s) for use in the United States. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Preclinical and Clinical Development </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to beginning the first clinical trial with a product candidate, in the United States, we must submit an IND to the FDA. An IND is a request for authorization from the FDA to administer an investigational new drug product to humans. The central focus of an IND submission is on the general investigational plan and the protocol or protocols for preclinical studies and clinical trials. The IND also includes results of animal and in vitro studies assessing the toxicology, pharmacokinetics, pharmacology and pharmacodynamic characteristics of the product, chemistry, manufacturing and controls information, and any available human data or literature to support the use of the investigational product. An IND must become effective before human clinical trials may begin. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the <span style="white-space:nowrap">30-day</span> period, raises safety concerns or questions about the proposed clinical trial. In such a case, the IND may be placed on clinical hold and the IND sponsor and the FDA must resolve any outstanding concerns or questions before the clinical trial can begin. Submission of an IND therefore may or may not result in FDA authorization to begin a clinical trial. Similar processes exist in countries outside the United States that we will be required to follow if we choose to execute trials in other countries. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance with cGCPs, which include the requirement that all research subjects provide their informed consent for their participation in any clinical study. Clinical trials are conducted under protocols detailing, among other things, the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A separate submission to the existing IND must be made for each successive clinical trial conducted during product development and for any subsequent protocol amendments. Furthermore, an independent IRB for each site proposing to conduct the clinical trial must review and approve the plan for any clinical trial and its informed consent form before the clinical trial begins at that site, and must monitor the study until completed. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Regulatory authorities, the IRB or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable health risk or that the trial is unlikely to meet its stated objectives. Some studies also include oversight by an independent group of qualified experts organized by the clinical study sponsor, known as a data safety monitoring board, which provides authorization for whether or not a study may move forward at designated check points based on access to certain data from the study and may recommend halting the clinical trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy. There are also requirements governing the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">72 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
reporting of ongoing preclinical studies and clinical trials and clinical study results to public registries. Sponsors of clinical trials of <span style="white-space:nowrap">FDA-regulated</span> products, including biological products, are required to register and disclose certain clinical trial information, which is publicly available at www.clinicaltrials.gov. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A sponsor who wishes to conduct a clinical trial outside of the United States may, but need not, obtain FDA authorization to conduct the clinical trial under an IND. If a foreign clinical trial is not conducted under an IND, the sponsor may submit data from the clinical trial to the FDA in support of a BLA. The FDA will accept a well-designed and well-conducted foreign clinical trial not conducted under an IND if the trial was conducted in accordance with cGCP requirements and the FDA is able to validate the data through an onsite inspection if deemed necessary. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the purposes of BLA approval, human clinical trials are typically conducted in three sequential phases that may overlap. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Phase 1. The investigational product is initially introduced into healthy human subjects or patients with the target disease or condition. These studies are designed to test the safety, dosage tolerance, absorption, metabolism and distribution of the investigational product in humans, and the side effects associated with increasing doses, and, if possible, to gain early evidence on effectiveness. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Phase 2. The investigational product is administered to a limited patient population with a specified disease or condition to evaluate the preliminary efficacy, optimal dosages and dosing schedule and to identify possible adverse side effects and safety risks. Multiple Phase 2 clinical trials may be conducted to obtain information prior to beginning larger and more expensive Phase 3 clinical trials. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Phase 3. The investigational product is administered to an expanded patient population to further evaluate dosage, to provide statistically significant evidence of clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of the investigational product and to provide an adequate basis for product approval. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In some cases, the FDA may require, or companies may voluntarily pursue, additional clinical trials after a product is approved to gain more information about the product. These <span style="white-space:nowrap">so-called</span> Phase 4 studies may be made a condition to approval of the BLA. Concurrent with clinical trials, companies may complete additional animal studies and develop additional information about the biological characteristics of the product candidate and must finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, must develop methods for testing the identity, strength, quality and purity of the final product, or for biologics, the safety, purity and potency. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During all phases of clinical development, regulatory agencies require extensive monitoring and auditing of all clinical activities, clinical data and clinical study investigators. Written IND safety reports must be promptly submitted to the FDA and the investigators for serious and unexpected suspected adverse events, any findings from other studies, tests in laboratory animals or in vitro testing that suggest a significant risk for human subjects, or any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. The sponsor must submit an IND safety report within 15 calendar days after the sponsor determines that the information qualifies for reporting. The sponsor also must notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction within seven calendar days after the sponsor&#8217;s initial receipt of the information. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">BLA Submission and Review </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product development, preclinical studies and clinical trials are submitted to the FDA as part of a </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">73 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
BLA requesting approval to market the product for one or more indications. FDA approval of a BLA must be obtained before a biologic may be marketed in the United States. The BLA must include all relevant data available from pertinent preclinical studies and clinical trials, including negative or ambiguous results as well as positive findings, together with detailed information relating to the product&#8217;s chemistry, manufacturing, controls, and proposed labeling, among other things. Data can come from company-sponsored clinical studies intended to test the safety and effectiveness of the product, or from a number of alternative sources, including studies initiated and sponsored by investigators. The submission of a BLA requires payment of a substantial application user fee to the FDA, unless a waiver or exemption applies. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, under the Pediatric Research Equity Act (&#8220;PREA&#8221;), a BLA or supplement to a BLA must contain data to assess the safety and effectiveness of the biological product candidate for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The Food and Drug Administration Safety and Innovation Act requires that a sponsor who is planning to submit a marketing application for a biological product that includes a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration submit an initial pediatric study plan (&#8220;PSP&#8221;) within sixty days after an <span style="white-space:nowrap"><span style="white-space:nowrap">end-of-Phase</span></span> 2 meeting or, if there is no such meeting, as early as practicable before the initiation of the Phase 3 or Phase 2/3 study as may be agreed between the sponsor and FDA. The initial PSP must include an outline of the pediatric study or studies that the sponsor plans to conduct, including study objectives and design, age groups, relevant endpoints and statistical approach, or a justification for not including such detailed information, and any request for a deferral of pediatric assessments or a full or partial waiver of the requirement to provide data from pediatric studies along with supporting information. The FDA and the sponsor must reach an agreement on the PSP. A sponsor can submit amendments to an agreed-upon initial PSP at any time if changes to the pediatric plan need to be considered based on data collected from preclinical studies, early phase clinical trials and/or other clinical development programs. Unless otherwise required by regulation, PREA does not apply to any biological product for an indication for which orphan designation has been granted. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Within 60 days following submission of the application, the FDA reviews the BLA to determine if it is substantially complete before the agency accepts it for filing. The FDA may refuse to file any BLA that it deems incomplete or not properly reviewable at the time of submission and may request additional information. In this event, the BLA must be resubmitted with additional information. Once a BLA has been accepted for filing, the FDA&#8217;s goal is to review standard applications within ten months after the filing date, or, if the application qualifies for priority review, six months after the FDA accepts the application for filing. In both standard and priority reviews, the review process may also be extended by FDA requests for additional information or clarification. The FDA reviews a BLA to determine, among other things, whether a product is safe, pure and potent and the facility in which it is manufactured, processed, packed or held meets standards designed to assure the product&#8217;s continued safety, purity and potency. The FDA may convene an advisory committee to provide clinical insight on application review questions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Before approving a BLA, the FDA will typically inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving a BLA, the FDA will typically inspect one or more clinical sites to assure compliance with cGCPs. If the FDA determines that the application, manufacturing process or manufacturing facilities are not acceptable, it typically will outline the deficiencies in the submission and often will request additional testing or information. Notwithstanding the submission of any requested additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After the FDA evaluates a BLA and conducts inspections of manufacturing facilities where the investigational product and/or its drug substance will be produced, the FDA may issue an approval letter or a Complete </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">74 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Response Letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A Complete Response Letter will describe all of the deficiencies that the FDA has identified in the BLA, except that where the FDA determines that the data supporting the application are inadequate to support approval, the FDA may issue the Complete Response Letter without first conducting required inspections, testing submitted product lots and/or reviewing proposed labeling. In issuing the Complete Response Letter, the FDA may recommend actions that the applicant might take to place the BLA in condition for approval, including requests for additional information or clarification. If a Complete Response Letter is issued, the applicant may either resubmit the BLA, addressing all of the deficiencies identified in the letter, or withdraw the application or request an opportunity for a hearing. The FDA may delay or refuse approval of a BLA if applicable regulatory criteria are not satisfied, require additional testing or information and/or require post-marketing testing and surveillance to monitor safety or efficacy of a product. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If regulatory approval of a product is granted, such approval will be granted for particular indications and may entail limitations on the indicated uses for which such product may be marketed. For example, the FDA may approve the BLA with a REMS to ensure the benefits of the product outweigh its risks. A REMS is a safety strategy to manage a known or potential serious risk associated with a product and to enable patients to have continued access to such medicines by managing their safe use, and could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. The FDA also may condition approval on, among other things, changes to proposed labeling or the development of adequate controls and specifications. Once approved, the FDA may withdraw the product approval if compliance with <span style="white-space:nowrap">pre-</span> and post-marketing requirements is not maintained or if problems occur after the product reaches the marketplace. The FDA may require one or more Phase 4 post-market studies and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization, and may limit further marketing of the product based on the results of these post-marketing studies. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Expedited Development and Review Programs </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA offers several expedited development and review programs for qualifying product candidates. The Fast Track program is intended to expedite or facilitate the process for reviewing new products that meet certain criteria. Specifically, new products are eligible for Fast Track designation if they are intended to treat a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. Fast Track designation applies to the combination of the product and the specific indication for which it is being studied. The sponsor of a Fast Track product has opportunities for more frequent interactions with the review team during product development and, once a BLA is submitted, the product may be eligible for priority review. A Fast Track product may also be eligible for rolling review, where the FDA may consider for review sections of the BLA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the BLA, the FDA agrees to accept sections of the BLA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the BLA. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A product intended to treat a serious or life-threatening disease or condition may also be eligible for Breakthrough Therapy designation to expedite its development and review. A product can receive Breakthrough Therapy designation if preliminary clinical evidence indicates that the product, alone or in combination with one or more other drugs or biologics, may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation includes all of the Fast Track program features, as well as more intensive FDA interaction and guidance beginning as early as Phase 1 and an organizational commitment to expedite the development and review of the product, including involvement of senior managers. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any marketing application for a biologic submitted to the FDA for approval, including a product with a Fast Track designation and/or Breakthrough Therapy designation, may be eligible for other types of FDA programs </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">75 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
intended to expedite the FDA review and approval process, such as priority review and accelerated approval. A product is eligible for priority review if it has the potential to provide a significant improvement in the treatment, diagnosis or prevention of a serious disease or condition. For original BLAs, priority review designation means the FDA&#8217;s goal is to take action on the marketing application within six months of the <span style="white-space:nowrap">60-day</span> filing date (as compared to ten months under standard review). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, products studied for their safety and effectiveness in treating serious or life-threatening diseases or conditions may receive accelerated approval upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of accelerated approval, the FDA will generally require the sponsor to perform adequate and well-controlled post-marketing clinical studies with due diligence to verify and describe the anticipated effect on irreversible morbidity or mortality or other clinical benefit. Under the Food and Drug Omnibus Reform Act of 2022 (&#8220;FDORA&#8221;) the FDA may require, as appropriate, that such studies be underway prior to approval or within a specific time period after the date of approval for a product granted accelerated approval. Under FDORA, the FDA has increased authority for expedited procedures to withdraw approval of a product or indication approved under accelerated approval if the sponsor fails to conduct the required post-marketing studies or if such studies fail to verify the predicted clinical benefit. In addition, the FDA currently requires as a condition for accelerated approval <span style="white-space:nowrap">pre-approval</span> of promotional materials, which could adversely impact the timing of the commercial launch of the product. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Fast Track designation, Breakthrough Therapy designation and priority review do not change the standards for approval but may expedite the development or approval process. Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Post-Approval Requirements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any products manufactured or distributed by us pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to record-keeping, reporting of adverse experiences, periodic reporting, product sampling and distribution, and advertising and promotion of the product. As part of the manufacturing process, the manufacturer is required to perform certain tests on each lot of the product before it is released for distribution. After a BLA is approved for a biological product, the product also may be subject to official lot release. If the product is subject to official release by the FDA, the manufacturer submits samples of each lot of product to the FDA together with a release protocol showing a summary of the history of manufacture of the lot and the results of all of the manufacturer&#8217;s tests performed on the lot. The FDA also may perform certain confirmatory tests on lots of some products before releasing the lots for distribution by the manufacturer. In addition, the FDA conducts laboratory research related to the regulatory standards on the safety, purity, potency and effectiveness of biologics. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing user fee requirements, under which the FDA assesses an annual program fee for each product identified in an approved BLA. Biologic manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMPs, which impose certain procedural and documentation requirements upon us and our third-party manufacturers. Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMPs and impose reporting requirements upon us and any third-party manufacturers that we may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMPs and other aspects of regulatory compliance. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">76 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical studies to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">restrictions on the marketing or manufacturing of a product, complete withdrawal of the product from the market or product recalls; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">fines, warning letters or holds on post-approval clinical studies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of existing product approvals; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">product seizure or detention, or refusal of the FDA to permit the import or export of products; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">consent decrees, corporate integrity agreements, debarment or exclusion from federal healthcare programs; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">mandated modification of promotional materials and labeling and the issuance of corrective information; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the issuance of safety alerts, Dear Healthcare Provider letters, press releases and other communications containing warnings or other safety information about the product; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">injunctions or the imposition of civil or criminal penalties. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA closely regulates the marketing, labeling, advertising and promotion of biologics. A company can make only those claims relating to safety and efficacy, purity and potency that are approved by the FDA and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of <span style="white-space:nowrap">off-label</span> uses. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties. Physicians may prescribe legally available products for uses that are not described in the product&#8217;s labeling and that differ from those tested by us and approved by the FDA. Such <span style="white-space:nowrap">off-label</span> uses are common across medical specialties. Physicians may believe that such <span style="white-space:nowrap">off-label</span> uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer&#8217;s communications on the subject of <span style="white-space:nowrap">off-label</span> use of their products. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Biosimilars and Reference Product Exclusivity </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ACA, includes a subtitle called the BPCIA, which created an abbreviated approval pathway for biological products that are highly similar, or &#8220;biosimilar,&#8221; to or interchangeable with an <span style="white-space:nowrap">FDA-approved</span> reference biological product. The FDA has issued several guidance documents outlining an approach to review and approval of biosimilars. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Biosimilarity, which requires that there be no clinically meaningful differences between the biological product and the reference product in terms of safety, purity, and potency, is generally shown through analytical studies, animal studies, and a clinical study or studies. Interchangeability requires that a product is biosimilar to the reference product and the product must demonstrate that it can be expected to produce the same clinical results as the reference product in any given patient and, for products that are administered multiple times to an individual, the biologic and the reference biologic may be alternated or switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic. A product shown to be biosimilar or interchangeable with an <span style="white-space:nowrap">FDA-approved</span> reference biological product may rely in part on the FDA&#8217;s previous determination of safety and effectiveness for the reference product for </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">77 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
approval, which can potentially reduce the cost and time required to obtain approval to market the product. Complexities associated with the larger, and often more complex, structures of biological products, as well as the processes by which such products are manufactured, pose significant hurdles to implementation of the abbreviated approval pathway that are still being worked out by the FDA. In September 2021, the FDA issued two guidance documents intended to inform prospective applicants and facilitate the development of proposed biosimilars and interchangeable biosimilars, as well as to describe the FDA&#8217;s interpretation of certain statutory requirements added by the BPCIA. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this <span style="white-space:nowrap">12-year</span> period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing that applicant&#8217;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of its product. The BPCIA also created certain exclusivity periods for biosimilars approved as interchangeable products. <span style="white-space:nowrap">FDA-approved</span> interchangeable biosimilars may be substituted for the reference product without the intervention of the prescribing health care provider, subject to state laws, which differ by state. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A biological product can also obtain pediatric market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to existing exclusivity periods and patent terms. This <span style="white-space:nowrap">six-month</span> exclusivity, which runs from the end of other exclusivity protection or patent term, may be granted based on the voluntary completion of a pediatric study in accordance with an <span style="white-space:nowrap">FDA-issued</span> &#8220;Written Request&#8221; for such a study. The BPCIA is complex and continues to be interpreted and implemented by the FDA. In July 2018, the FDA announced an action plan to encourage the development and efficient review of biosimilars, including the establishment of a new office within the agency that will focus on therapeutic biologics and biosimilars. On December&#160;20, 2020, Congress amended the PHSA as part of the <span style="white-space:nowrap">COVID-19</span> relief bill to further simplify the biosimilar review process by making it optional to show that conditions of use proposed in labeling have been previously approved for the reference product, which used to be a requirement of the application. In addition, government proposals have sought to reduce the <span style="white-space:nowrap">12-year</span> reference product exclusivity period. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. As a result, the ultimate impact, implementation, and impact of the BPCIA is subject to significant uncertainty. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As discussed below, the Inflation Reduction Act of 2022 (&#8220;IRA&#8221;) is a significant new law that intends to foster generic and biosimilar competition and to lower drug and biologic costs. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Other Healthcare Laws and Compliance Requirements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pharmaceutical companies are subject to additional healthcare regulation and enforcement by the federal government and by authorities in the states and foreign jurisdictions in which they conduct their business. Such laws include, without limitation: the federal Anti-Kickback Statute (&#8220;AKS&#8221;); the federal False Claims Act (&#8220;FCA&#8221;); the Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;) and similar foreign, federal and state fraud, abuse and transparency laws. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The AKS prohibits, among other things, persons and entities from knowingly and willfully soliciting, receiving, offering or paying remuneration, to induce, or in return for, either the referral of an individual, or the purchase, lease, order, arrangement, or recommendation of an item or service for which payment may be made under any federal healthcare program. The term remuneration has been interpreted broadly to include anything of value. The AKS has been interpreted to apply to arrangements between pharmaceutical manufacturers on one hand, and prescribers and purchasers on the other. The government often takes the position that to violate the AKS, only one purpose of the remuneration need be to induce referrals, even if there are other legitimate purposes for the remuneration. There are a number of statutory exceptions and regulatory safe harbors protecting some common </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">78 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
activities from AKS prosecution, but they are drawn narrowly and practices that involve remuneration, such as consulting agreements, that may be alleged to be intended to induce prescribing, purchasing or recommending may be subject to scrutiny if they do not qualify for an exception or safe harbor. Our practices may not in all cases meet all of the criteria for protection under a statutory exception or regulatory safe harbor. Failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the AKS. Instead, the legality of the arrangement will be evaluated on a <span style="white-space:nowrap"><span style="white-space:nowrap">case-by-case</span></span> basis based on a cumulative review of all of its facts and circumstances. Violations are subject to civil and criminal fines and penalties for each violation, plus up to three times the remuneration involved, imprisonment, and exclusion from government healthcare programs. In addition, the government may assert that a claim including items or services resulting from a violation of the AKS constitutes a false or fraudulent claim for purposes of the FCA or federal civil monetary penalties. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Civil and criminal false claims laws, including the FCA, and civil monetary penalty laws, which impose criminal and civil penalties and can be enforced through civil whistleblower or qui tam actions, prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment of federal government funds, including in federal healthcare programs, that are false or fraudulent; knowingly making, using or causing to be made or used, a false statement of record material to a false or fraudulent claim or obligation to pay or transmit money or property to the federal government or knowingly concealing or knowingly and improperly avoiding or decreasing an obligation to pay money to the federal government. Pharmaceutical and other healthcare companies have been prosecuted under these laws for engaging in a variety of different types of conduct that &#8220;caused&#8221; the submission of false claims to federal healthcare programs. Under the AKS, for example, a claim resulting from a violation of the AKS is deemed to be a false or fraudulent claim for purposes of the FCA. The FCA also permits a private individual acting as a &#8220;whistleblower&#8221; to bring actions on behalf of the federal government alleging violations of the FCA and to share in any monetary recovery. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">HIPAA created additional federal criminal statutes that prohibit, among other things, executing a scheme to defraud any healthcare benefit program, including private third-party payors, and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false statements or representations relating to healthcare matters. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDCA addresses, among other things, the design, production, labeling, promotion, manufacturing, and testing of drugs, biologics and medical devices, and prohibits such acts as the introduction into interstate commerce of adulterated or misbranded drugs or devices. The PHSA also prohibits the introduction into interstate commerce of unlicensed or mislabeled biological products. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The United States federal Physician Payments Sunshine Act requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with specific exceptions, to annually report to the Centers for Medicaid&#160;&amp; Medicare Services (&#8220;CMS&#8221;) information related to payments or other transfers of value made to various healthcare professionals including physicians, certain other licensed health care practitioners, and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. Beginning on January&#160;1, 2023, California Assembly Bill 1278 requires California physicians and surgeons to notify patients of the Open Payments database established under the federal Physician Payments Sunshine Act. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are also subject to additional similar United States state and foreign law equivalents of each of the above federal laws, which, in some cases, differ from each other in significant ways, and may not have the same effect, thus complicating compliance efforts. If our operations are found to be in violation of any of such laws or any other governmental regulations that apply, we may be subject to penalties, including, without limitation, civil, criminal and administrative penalties, damages, fines, exclusion from government-funded healthcare programs, such as Medicare and Medicaid or similar programs in other countries or jurisdictions, integrity oversight and reporting obligations to resolve allegations of <span style="white-space:nowrap">non-compliance,</span> disgorgement, individual imprisonment, contractual damages, reputational harm, diminished profits and the curtailment or restructuring of our operations. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">79 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Data Privacy and Security </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Numerous state, federal, and foreign laws govern the collection, dissemination, use, access to, confidentiality, and security of personal information, including health-related information. In the United States, numerous federal and state laws and regulations, including state data breach notification laws, state health information privacy laws, and federal and state consumer protection laws and regulations, govern the collection, use, disclosure, and protection of health-related and other personal information could apply to our operations or the operations of our partners. For example, HIPAA, as amended by the Health Information Technology for Economic and Clinical Health, and their respective implementing regulations imposes privacy, security, and breach notification obligations on certain health care providers, health plans, and health care clearinghouses, known as covered entities, as well as their business associates and their covered subcontractors that perform certain services that involve using, disclosing, creating, receiving, maintaining, or transmitting individually identifiable health information for or on behalf of such covered entities. Entities that are found to be in violation of HIPAA may be subject to significant civil, criminal, and administrative fines and penalties and/or additional reporting and oversight obligations if required to enter into a resolution agreement and corrective action plan with the U.S. Department of Health and Human Services (&#8220;HHS&#8221;) to settle allegations of HIPAA <span style="white-space:nowrap">non-compliance.</span> Further, entities that knowingly obtain, use, or disclose individually identifiable health information maintained by a HIPAA covered entity in a manner that is not authorized or permitted by HIPAA may be subject to criminal penalties. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even when HIPAA does not apply, according to the FTC, violating consumers&#8217; privacy rights or failing to take appropriate steps to keep consumers&#8217; personal information secure may constitute unfair acts or practices in or affecting commerce in violation of Section&#160;5(a) of the Federal Trade Commission Act. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, state laws govern the privacy and security of personal information, including health-related information, in certain circumstances. Failure to comply with these laws, where applicable, can result in the imposition of significant civil and/or criminal penalties and private litigation. For example, the California Consumer Privacy Act, which went into effect on January&#160;1, 2020, has created new data privacy obligations for covered companies and provided new privacy rights to California residents. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Coverage and Reimbursement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the United States and markets in other countries, patients generally rely on third-party payors to reimburse all or part of the costs associated with their treatment. Adequate coverage and reimbursement from governmental healthcare programs, such as Medicare and Medicaid, and commercial payors is critical to new product acceptance. Our ability to successfully commercialize our product candidates will depend in part on the extent to which coverage and adequate reimbursement for these products and related treatments will be available from government health administration authorities, private health insurers and other organizations. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize a sufficient return on our investment. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Significant uncertainty exists as to the coverage and reimbursement status of any pharmaceutical or biological product for which we obtain regulatory approval. Sales of any product, if approved, depend, in part, on the extent to which such product will be covered by third-party payors, such as federal, state, and foreign government healthcare programs, commercial insurance and managed healthcare organizations, and the level of reimbursement, if any, for such product by third-party payors. Decisions regarding whether to cover any of our product candidates, if approved, the extent of coverage and amount of reimbursement to be provided are made on a <span style="white-space:nowrap"><span style="white-space:nowrap">plan-by-plan</span></span> basis. Further, no uniform policy for coverage and reimbursement exists in the United States, and coverage and reimbursement can differ significantly from payor to payor. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement rates, but also have their </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">80 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
own methods and approval process apart from Medicare determinations. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our product candidates to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Factors payors consider in determining reimbursement are based on whether the product is: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a covered benefit under its health plan; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">safe, effective and medically necessary; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">appropriate for the specific patient; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">cost-effective; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">neither experimental nor investigational. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Third-party payors are increasingly challenging the prices charged for medical products and services, examining the medical necessity and reviewing the cost effectiveness of pharmaceutical or biological products, medical devices and medical services, in addition to questioning safety and efficacy. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit sales of any product that receives approval. Decreases in third-party reimbursement for any product or a decision by a third-party not to cover a product could reduce physician usage and patient demand for the product. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs. Additionally, separate reimbursement for the product itself or the treatment or procedure in which the product is used may not be available, which may impact physician utilization. In addition, companion diagnostic tests require coverage and reimbursement separate and apart from the coverage and reimbursement for their companion pharmaceutical or biological products. Similar challenges to obtaining coverage and reimbursement, applicable to pharmaceutical or biological products, will apply to companion diagnostics. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. We cannot be sure that reimbursement will be available for any product candidate that we commercialize and, if reimbursement is available, the level of reimbursement. In addition, many pharmaceutical manufacturers must calculate and report certain price reporting metrics to the government, such as average sales price, and best price. Penalties may apply in some cases when such metrics are not submitted accurately and timely. Further, these prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Finally, in some foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing vary widely from country to country. For example, the EU provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. To obtain reimbursement or pricing approval, some of these countries may require the completion of clinical trials that compare the cost effectiveness of a particular product candidate to currently available therapies. A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of its product candidates. Historically, products launched in the EU do not follow price structures of the United States and generally prices tend to be significantly lower. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">81 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Healthcare reform </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The United States and some foreign jurisdictions are considering or have enacted a number of reform proposals to change the healthcare system. There is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by federal and state legislative initiatives, including those designed to limit the pricing, coverage, and reimbursement of pharmaceutical and biopharmaceutical products, especially under government-funded health care programs, and increased governmental control of drug pricing. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ACA, which was enacted in 2010, substantially changed the way healthcare is financed by both governmental and private insurers in the United States, and significantly affected the pharmaceutical industry. The ACA contains a number of provisions of particular import to the pharmaceutical and biotechnology industries, including, but not limited to, those governing enrollment in federal healthcare programs. Since its enactment, there have been judicial and Congressional challenges to certain aspects of the ACA, and we expect there will be additional challenges and amendments to the ACA in the future. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other legislative changes have been proposed and adopted since the ACA was enacted. For example, the Budget Control Act of 2011 and subsequent legislation, among other things, created measures for spending reductions by Congress that include aggregate reductions of Medicare payments to providers of 2% per fiscal year, which remain in effect through 2032. Due to the Statutory <span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap">Pay-As-You-Go</span></span></span> Act of 2010, estimated budget deficit increases resulting from the American Rescue Plan Act of 2021, and subsequent legislation, Medicare payments to providers will be further reduced starting in 2025 absent further legislation. The United States American Taxpayer Relief Act of 2012 further reduced Medicare payments to several types of providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the Bipartisan Budget Act of 2018, among other things, amended the Medicare Act (as amended by the ACA) to increase the <span style="white-space:nowrap"><span style="white-space:nowrap">point-of-sale</span></span> discounts that manufacturers must agree to offer under the Medicare Part D coverage discount program to 70% off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs being covered under Medicare Part D. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moreover, there has recently been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted federal and state measures designed to, among other things, reduce the cost of prescription drugs, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. For example, in May 2019, CMS adopted a final rule allowing Medicare Advantage Plans the option to use step therapy for Part B drugs, permitting Medicare Part D plans to apply certain utilization controls to new starts of five of the six protected class drugs, and requiring the Explanation of Benefits for Part D beneficiaries to disclose drug price increases and lower cost therapeutic alternatives. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the United States government, state legislatures and foreign governments have continued implementing cost-containment programs, including price controls, restrictions on coverage and reimbursement and requirements for substitution of generic products. The IRA includes several provisions that may impact our business to varying degrees, including provisions that reduce the <span style="white-space:nowrap"><span style="white-space:nowrap">out-of-pocket</span></span> spending cap for Medicare Part D beneficiaries from $7,050 to $2,000 starting in 2025, thereby effectively eliminating the coverage gap; impose new manufacturer financial liability on certain drugs under Medicare Part D, allow the United States government to negotiate Medicare Part B and Part D price caps for certain high-cost drugs and biologics without generic or biosimilar competition; require companies to pay rebates to Medicare for certain drug prices that increase faster than inflation; and delay until January&#160;1, 2032 the implementation of the HHS rebate rule that would have limited the fees that pharmacy benefit managers can charge. Further, under the IRA, orphan drugs are exempted from the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">82 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Medicare drug price negotiation program, but only if they have one rare disease designation and for which the only approved indication is for that disease or condition. If a product receives multiple rare disease designations or has multiple approved indications, it may not qualify for the orphan drug exemption. These provisions will take effect progressively starting in fiscal year 2023, although the Medicare drug price negotiation program is currently subject to legal challenges. The effects of the IRA on its business and the healthcare industry in general is not yet known. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">President Biden has also issued multiple executive orders that have sought to reduce prescription drug costs. In February 2023, HHS also issued a proposal in response to an October 2022 executive order from President Biden that includes a proposed prescription drug pricing model that will test whether targeted Medicare payment adjustments will sufficiently incentivize manufacturers to complete confirmatory trials for drugs approved through FDA&#8217;s accelerated approval pathway. Although a number of these and other proposed measures may require authorization through additional legislation to become effective, and the Biden administration may reverse or otherwise change these measures, both the Biden administration and Congress have indicated that they will continue to seek new legislative measures to control drug costs. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding the IRA and President Biden&#8217;s executive orders, continued legislative and enforcement interest exists in the United States with respect to specialty drug pricing practices. Specifically, we expect regulators to continue pushing for transparency to drug pricing, reducing the cost of prescription drugs under Medicare, reviewing the relationship between pricing and manufacturer patient programs, and reforming government program reimbursement methodologies for drugs. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Individual states in the United States have also become increasingly active in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain drug access and marketing cost disclosure and transparency measures, and designed to encourage importation from other countries and bulk purchasing. Legally mandated price controls on payment amounts by third-party payors or other restrictions could harm our business, financial condition, results of operations and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. This could reduce the ultimate demand for our drugs or put pressure on our drug pricing, which could negatively affect our business, financial condition, results of operations and prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Other Government and Regulation Outside of the United States </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to regulations in the United States, we are subject to a variety of regulations in other jurisdictions governing, among other things, research and development, clinical trials, testing, manufacturing, safety, efficacy, quality control, labeling, packaging, storage, record keeping, distribution, reporting, export and import, advertising, marketing and other promotional practices involving biological products as well as authorization, approval as well as post-approval monitoring and reporting of our products. Because biologically sourced raw materials are subject to unique contamination risks, their use may be restricted in some countries. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Whether or not we obtain FDA approval for a product, we must obtain the requisite approvals from regulatory authorities in foreign countries prior to the commencement of clinical trials or marketing of the product in those countries. Certain countries outside of the United States have a similar process that requires the submission of a clinical trial application much like an IND prior to the commencement of human clinical trials. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The requirements and process governing the conduct of clinical trials, including requirements to conduct additional clinical trials, product licensing, safety reporting, post-authorization requirements, marketing and promotion, interactions with healthcare professionals, pricing and reimbursement may vary widely from country to country. No action can be taken to market any product in a country until an appropriate approval application has been approved by the regulatory authorities in that country. The current approval process varies from country </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">83 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to country, and the time spent in gaining approval varies from that required for FDA approval. In certain countries, the sales price of a product must also be approved. The pricing review period often begins after market approval is granted. Even if a product is approved by a regulatory authority, satisfactory prices may not be approved for such product, which would make launch of such products commercially unfeasible in such countries. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Regulation in the European Union </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The collection and use of personal health data and other personal data regarding individuals in the EEA is governed by the provisions of the European General Data Protection Regulation (EU) 2016/679 (&#8220;EU GDPR&#8221;) and related data protection laws in individual EEA member states, including additional requirements relating to health, genetic and biometric data implemented through national legislation. Similar processing of personal health data and other personal data regarding individuals in the UK is governed by the UK General Data Protection Regulation (&#8220;UK GDPR&#8221;) and the UK Data Protection Act 2018. In this document, &#8220;GDPR&#8221; refers to both the EU GDPR and the UK GDPR, unless specified otherwise. The GDPR imposes a number of strict obligations and restrictions on the ability to process, including collecting, analyzing and transferring, personal data of individuals, in particular with respect to health data from clinical trials and adverse event reporting. The GDPR includes requirements relating to the legal basis of the processing (such as consent of the individuals to whom the personal data relates), the information provided to the individuals prior to processing their personal data, the notification obligations to the national data protection authorities, and the security and confidentiality of the personal data. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the GDPR imposes specific restrictions on the transfer of personal data to countries outside of the EEA/UK that are not considered by the European Commission (&#8220;EC&#8221;) and the UK government as providing an adequate level of data protection (third countries), including the United States. Appropriate safeguards are required to enable such transfers. Among the appropriate safeguards that can be used, the data exporter may use the EC approved standard contractual clauses (&#8220;SCCs&#8221;) and the UK International Data Transfer Agreement/Addendum (&#8220;UK IDTA&#8221;). Where relying on the SCCs or UK IDTA for data transfers, we may also be required to carry out transfer impact assessments to assess whether the recipient is subject to local laws which allow public authority access to personal data. The international transfer obligations under the EEA/UK data protection regimes will require effort and cost and may result in us needing to make strategic considerations around where EEA/UK personal data is located and which service providers we can utilize for the processing of EEA/UK personal data. Although the UK is regarded as a third country under the EU GDPR, the EC has issued a decision recognizing the UK as providing adequate protection under the EU GDPR (&#8220;Adequacy Decision&#8221;) and, therefore, transfers of personal data originating in the EEA to the UK remain unrestricted. The UK government has confirmed that personal data transfers from the UK to the EEA remain free flowing. The UK government has also now introduced a Data Protection and Digital Information Bill (&#8220;UK Data Protection Bill&#8221;) into the UK legislative process with the intention for this bill to reform the UK&#8217;s data protection regime following Brexit. If passed, the final version of the UK Data Protection Bill may have the effect of further altering the similarities between the UK and EU data protection regime. This may lead to additional compliance costs and could increase our overall risk. The respective provisions and enforcement of the EU GDPR and UK GDPR may further diverge in the future and create additional regulatory challenges and uncertainties. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&#160;25, 2022, the EC and the United States announced that they have agreed in principle on a new Trans-Atlantic Data Privacy Framework. Following this statement, on October&#160;7, 2022, President Biden signed an Executive Order on &#8216;Enhancing Safeguards for United States Signals Intelligence Activities&#8217;, which implemented the agreement in principle. On that basis, the EC prepared a draft Adequacy Decision and launched its adoption procedure. While this new <span style="white-space:nowrap">EU-United</span> States privacy framework is expected to enter into force in 2023, there is still some uncertainty around the new framework. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Failure to comply with the requirements of the GDPR and the related national data protection laws of the EEA member states/UK may result in significant monetary fines for noncompliance of up to &#8364;20&#160;million </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">84 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(&#163;17.5&#160;million for the UK) or 4% of the annual global revenues of the noncompliant company, whichever is greater, other administrative penalties and a number of criminal offenses (punishable by uncapped fines) for organizations and, in certain cases, their directors and officers, as well as civil liability claims from individuals whose personal data was processed. Data protection authorities from the different EEA member states/UK may still implement certain variations, enforce the GDPR and national data protection laws differently, and introduce additional national regulations and guidelines, which adds to the complexity of processing personal data subject to the EEA/UK data protection regimes. Guidance developed at both the EU level and at the national level in individual EU member states concerning implementation and compliance practices are often updated or otherwise revised. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Compliance with the GDPR is a rigorous and time-intensive process that may increase our cost of doing business or require us to change our business practices, and despite those efforts, there is a risk that we may be subject to fines, penalties and litigation in connection with European activities, which could in turn have a negative effect on our reputation and materially harm our business. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Furthermore, there is a growing trend towards the required public disclosure of clinical trial data in the EU, which adds to the complexity of obligations relating to processing health data from clinical trials. Such public disclosure obligations are provided in the new EU Clinical Trials Regulation (EU) No.&#160;536/2014 (the &#8220;CTR&#8221;), European Medical Agency (&#8220;EMA&#8221;) disclosure initiatives and voluntary commitments by industry. Failure to comply with these obligations could lead to government enforcement actions and significant penalties against us, harm to our reputation, and adversely impact our business and operating results. The uncertainty regarding the interplay between different regulatory frameworks, such as the CTR and the GDPR, further adds to the complexity that we face with regard to data protection regulation. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Drug and Biologic Development Process </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Regardless of where they are conducted, all clinical trials included in applications for marketing authorization for human medicines in the EU must have been carried out in accordance with EU regulations. This means that clinical trials conducted in the EU have to comply with EU clinical trial legislation but also that clinical trials conducted outside the EU have to comply with ethical principles equivalent to those set out in the EU, including adhering to international good clinical practice and the Declaration of Helsinki. The conduct of clinical trials in the EU is governed by the CTR, which entered into force on January&#160;31, 2022. The CTR replaced the Clinical Trials Directive 2001/20/EC, (&#8220;Clinical Trials Directive&#8221;) and introduced a complete overhaul of the existing regulation of clinical trials for medicinal products in the EU. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the former regime, which will expire after a transition period of one or three years, respectively, as outlined below in more detail, before a clinical trial can be initiated it must be approved in each EU member state where there is a site at which the clinical trial is to be conducted. The approval must be obtained from two separate entities: the national competent authority in the applicable EU member state(s) and one or more ethics committees. The national competent authority of all EU member states in which the clinical trial will be conducted must authorize the conduct of the trial, and the independent ethics committee must grant a positive opinion in relation to the conduct of the clinical trial in the relevant EU member state before the commencement of the trial. Any substantial changes to the trial protocol or other information submitted with the clinical trial applications must be submitted to or approved by the relevant national competent authorities and ethics committees. Under the current regime all suspected unexpected serious adverse reactions to the investigated drug that occur during the clinical trial must be reported to the national competent authority and to the ethics committees of the EU member state where they occur. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A more unified procedure applies under the CTR. A sponsor can submit a single application for approval of a clinical trial through a centralized EU clinical trials portal (the &#8220;CTIS&#8221;). One national competent authority (the reporting EU member state proposed by the applicant) will take the lead in validating and evaluating the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">85 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
application, and will consult and coordinate with the other concerned EU member states. If an application is rejected, it may be amended and resubmitted through the EU clinical trials portal. If an approval is issued, the sponsor may start the clinical trial in all concerned EU member states. However, a concerned EU member state may in limited circumstances declare an <span style="white-space:nowrap">&#8220;opt-out&#8221;</span> from an approval and prevent the clinical trial from being conducted in such member state. The CTR also aims to streamline and simplify the rules on safety reporting, and introduces enhanced transparency requirements such as mandatory submission of a summary of the clinical trial results to the EU database. The CTR foresees a three-year transition period. On January&#160;31, 2023, submission of initial clinical trial applications via CTIS became mandatory, and by January&#160;31, 2025, all ongoing trials approved under the former Clinical Trials Directive will need to comply with the CTR and have to be transitioned to CTIS. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under both the former regime and the CTR, national laws, regulations, and the applicable Good Clinical Practice and Good Laboratory Practice standards must also be respected during the conduct of the trials, including the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use guidelines on Good Clinical Practice and the ethical principles that have their origin in the Declaration of Helsinki. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the development of a medicinal product, the EMA and national regulators within the EU provide the opportunity for dialogue and guidance on the development program. At the EMA level, this is usually done in the form of scientific advice, which is given by the Committee for Medicinal Products for Human Use (&#8220;CHMP&#8221;) on the recommendation of the Scientific Advice Working Party. A fee is incurred with each scientific advice procedure, but is significantly reduced for designated orphan medicines. Advice from the EMA is typically provided based on questions concerning, for example, quality (chemistry, manufacturing and controls testing), nonclinical testing and clinical studies, and pharmacovigilance plans and risk-management programs. Advice is not legally binding with regard to any future marketing authorization application (&#8220;MAA&#8221;) for the product concerned. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Drug Marketing Authorization </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the EU, medicinal products are subject to extensive <span style="white-space:nowrap">pre-</span> and post-market regulation by regulatory authorities at both the EU and national levels. To obtain regulatory approval of a product under the EU regulatory systems, we must submit an MAA under either the EU centralized procedure, or one of the national procedures in the EU. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Centralized Authorization Procedure </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The centralized procedure provides for the grant of a single marketing authorization (&#8220;MA&#8221;) that is issued by the EC following the scientific assessment of the application by the EMA and that is valid for all EU member states as well as in the three additional EEA member states (Norway, Iceland and Liechtenstein). The centralized procedure is compulsory for certain types of medicinal products, including for medicines developed by means of certain biotechnological processes, products designated as orphan medicinal products, advanced therapy medicinal products (gene therapy, somatic cell therapy or tissue-engineered medicines)and medicinal products with a new active substance indicated for the treatment of certain diseases (HIV/AIDS, cancer, neurodegenerative disorders, diabetes, auto-immune and other immune dysfunctions and viral diseases). The centralized procedures is option for medicinal products containing a new active substance not yet authorized in the EU, or for products that constitute a significant therapeutic, scientific or technical innovation or for which the grant of an MA through the centralized procedure would be in the interest of public health at EU level. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the centralized procedure, the CHMP established at the EMA, is responsible for conducting the initial assessment of a drug. The CHMP is also responsible for several post-authorization and maintenance activities, such as the assessment of modifications or extensions to an existing marketing authorization. Under the centralized procedure, the timeframe for the evaluation of an MAA by the EMA&#8217;s CHMP is, in principle, 210 </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">86 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
days from receipt of a valid MAA. However, this timeline excludes clock stops, when additional written or oral information is to be provided by the applicant in response to questions asked by the CHMP, so the overall process typically takes a year or more, unless the application is eligible for an accelerated assessment. Accelerated evaluation might be granted by the CHMP in exceptional cases, when a medicinal product is expected to be of a major public health interest, particularly from the point of view of therapeutic innovation. Upon request, the CHMP can reduce the time frame to 150 days if the applicant provides sufficient justification for an accelerated assessment. The CHMP will provide a positive opinion regarding the application only if it meets certain quality, safety and efficacy requirements. This opinion is then transmitted to the EC, which has the ultimate authority for granting the MA within 67 days after receipt of the CHMP opinion. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Decentralized and Mutual Recognition Procedures </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Medicines that fall outside the mandatory scope of the centralized procedure can be authorized under a decentralized procedure where an applicant applies for simultaneous authorization in more than one EU member state, or they can be authorized in an EU member state in accordance with that state&#8217;s national procedures and then be authorized in other EU countries by a procedure whereby the countries concerned agree to recognize the validity of the original, national marketing authorization (mutual recognition procedure). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The decentralized procedure permits companies to file identical MA applications for a medicinal product to the competent authorities in various EU member states simultaneously if such medicinal product has not received marketing approval in any EU member state before. The competent authority of a single EU member state, the reference member state, is appointed to review the application and provide an assessment report. The competent authorities of the other EU member states, the concerned member states, are subsequently required to grant a marketing authorization for their territories on the basis of this assessment. The only exception to this is where the competent authority of an EU member state considers that there are concerns of potential serious risk to public health, the disputed points are subject to a dispute resolution mechanism and may eventually be referred to the EC, whose decision is binding for all EU member states. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Risk Management Plan </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All new MAAs must include a Risk Management Plan (&#8220;RMP&#8221;) describing the risk management system that the company will put in place and documenting measures to prevent or minimize the risks associated with the product. RMPs are continually modified and updated throughout the lifetime of the medicine as new information becomes available. An updated RMP must be submitted: (i)&#160;at the request of EMA or a national competent authority, or (ii)&#160;whenever the risk-management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit-risk profile or as a result of an important pharmacovigilance or risk-minimization milestone being reached. The regulatory authorities may also impose specific obligations as a condition of the MA. RMPs and Periodic Safety Update Reports (&#8220;PSURs&#8221;) are routinely available to third parties requesting access, subject to limited redactions. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">MA Validity Period </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the EU, an MA has an initial duration of five years. After these five years, the authorization may subsequently be renewed on the basis of a reevaluation of the risk-benefit balance. Once renewed, the MA is valid for an unlimited period unless the EC or the national competent authority decides, on justified grounds relating to pharmacovigilance, to proceed with only one additional five-year renewal. Applications for renewal must be made to the EMA at least nine months before the five-year period expires. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Exceptional Circumstances/Conditional Approval </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Similar to accelerated approval regulations in the United States, conditional Mas can be granted in the EU for medicines intended for treating, preventing or diagnosing seriously debilitating or life-threatening diseases, or in </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">87 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
a public health emergency. A conditional MA can be granted for medicinal products where, although comprehensive clinical data referring to the safety and efficacy of the medicinal product have not been supplied, the following criteria are fulfilled: (i)&#160;the benefit/risk balance of the product is positive, (ii)&#160;it is likely that the applicant will be in a position to provide the comprehensive clinical data post-authorization, (iii)&#160;unmet medical needs will be fulfilled by the grant of the MA and (iv)&#160;the benefit to public health of the immediate availability on the market of the medicinal product concerned outweighs the risk inherent in the fact that additional data are still required. Once a conditional MA has been granted, the MA holder must fulfill specific obligations within defined timelines. A conditional MA must be renewed annually, but can be converted into a standard MA once the MA holder fulfills the obligations imposed and the complete data confirm that the medicine&#8217;s benefits continue to outweigh its risks. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Data and Market Exclusivity </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As in the United States, it may be possible to obtain a period of market and / or data exclusivity in the EU that would have the effect of postponing the entry into the marketplace of a competitor&#8217;s generic, hybrid or biosimilar product (even if the pharmaceutical product has already received a MA) and prohibiting another applicant from relying on the MA holder&#8217;s pharmacological, toxicological and clinical data in support of another MA for the purposes of submitting an application, obtaining an MA or placing the product on the market. Innovative medicinal products (sometimes referred to as new chemical entities (&#8220;NCEs&#8221;)) approved in the EU generally qualify for eight years of data exclusivity and 10 years of marketing exclusivity. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If granted, the data exclusivity period begins on the date of the product&#8217;s first MA in the EU and prevents generic or biosimilar applicants from referencing the innovator&#8217;s preclinical and clinical trial data contained in the dossier of the reference product when applying for a generic or biosimilar marketing authorization in the EU. After eight years, a generic product application may be submitted and generic companies may rely on the MA holder&#8217;s data. However, a generic product cannot launch until two years later (or a total of 10 years after the first MA in the EU of the innovator product). An additional <span style="white-space:nowrap">one-year</span> period of marketing exclusivity is possible if, during the data exclusivity period (the first eight years of the <span style="white-space:nowrap">10-year</span> marketing exclusivity period), the MA holder obtains an authorization for one or more new therapeutic indications that are deemed to bring a significant clinical benefit compared to existing therapies. Additionally, a standalone <span style="white-space:nowrap">one-year</span> period of data exclusivity can be granted where an application is made for a new indication for a well-established substance, provided that significant <span style="white-space:nowrap">pre-clinical</span> or clinical studies were carried out in relation to the new indication. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Where a change of classification of a pharmaceutical product has been authorized on the basis of significant <span style="white-space:nowrap">pre-trial</span> tests or clinical trials, when examining an application by another applicant for or holder of an MA for a change of classification of the same substance the competent authority will not refer to the results of those tests or trials for one year after the initial change was authorized. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Products may not be granted data exclusivity since there is no guarantee that a product will be considered by the EU&#8217;s regulatory authorities to include a NCE. Even if a compound is considered to be a NCE and the MA applicant is able to gain the prescribed period of data exclusivity, another company nevertheless could also market another version of the medicinal product if such company can complete a full MAA with their own complete database of pharmaceutical tests, preclinical studies and clinical trials and obtain MA of its product. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Pediatric Development </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the EU, companies developing a new medicinal product are obligated to study their product in children and must therefore submit a pediatric investigation plan (&#8220;PIP&#8221;) together with a request for agreement to the EMA, unless the EMA has granted a product-specific waiver, a class waiver, or a deferral for one or more of the measures included in the PIP. The EMA issues a decision on the PIP based on an opinion of the EMA&#8217;s Pediatric Committee. Companies must conduct pediatric clinical trials in accordance with the PIP approved by the EMA, unless a deferral (e.g. until enough information to demonstrate its effectiveness and safety in adults is available) </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">88 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or waiver (e.g. because the relevant disease or condition occurs only in adults) has been granted by the EMA. The MAA for the medicinal product must include the results of all pediatric clinical trials performed and details of all information collected in compliance with the approved PIP, unless such a waiver or a deferral has been granted. Medicinal products that are granted an MA on the basis of the pediatric clinical trials conducted in accordance with the approved PIP are eligible for a six month extension of the protection under a supplementary protection certificate (&#8220;SPC&#8221;), provided an application for such extension is made at the same time as filing the SPC application for the product, or at any point up to two years before the SPC expires, or, in the case of orphan medicinal products, a two year extension of the orphan market exclusivity. This pediatric reward is subject to specific conditions and is not automatically available when data in compliance with the approved PIP are developed and submitted. An approved PIP is also required when an MA holder wants to add a new indication, medicinal form or route of administration for a medicine that is already authorized and covered by intellectual property rights. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">PRIME Designation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In March 2016, the EMA launched an initiative to facilitate development of product candidates in indications, often rare, for which few or no therapies currently exist. The Priority Medicines (&#8220;PRIME&#8221;) scheme is intended to encourage drug development in areas of unmet medical need and provides accelerated assessment of products representing substantial innovation reviewed under the centralized procedure. Products from small- and <span style="white-space:nowrap">medium-sized</span> enterprises may qualify for earlier entry into the PRIME scheme than larger companies on the basis of compelling <span style="white-space:nowrap">non-clinical</span> data and tolerability data from initial clinical trials. Many benefits accrue to sponsors of product candidates with PRIME designation, including but not limited to, early and proactive regulatory dialogue with the EMA, frequent discussions on clinical trial designs and other development program elements, and potentially accelerated marketing authorization application assessment once a dossier has been submitted. Importantly, once a candidate medicine has been selected for the PRIME scheme, a dedicated contact point and rapporteur from the CHMP or from the Committee for Advanced Therapeutics (&#8220;CAT&#8221;) are appointed facilitating increased understanding of the product at EMA&#8217;s Committee level. A <span style="white-space:nowrap">kick-off</span> meeting with the CHMP/CAT rapporteur initiates these relationships and includes a team of multidisciplinary experts to provide guidance on the overall development plan and regulatory strategy. PRIME eligibility does not change the standards for product approval, and there is no assurance that any such designation or eligibility will result in expedited review or approval. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Post-Approval Regulation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Similar to the United States, both MA holders and manufacturers of medicinal products are subject to comprehensive regulatory oversight by the EMA, the EC and/or the competent regulatory authorities of the EU member states. This oversight applies both before and after grant of manufacturing licenses and marketing authorizations. It includes control of compliance with EU good manufacturing practices rules, manufacturing authorizations, pharmacovigilance rules and requirements governing advertising, promotion, sale, and distribution, recordkeeping, importing and exporting of medicinal products. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Failure by us or by any of our third-party partners, including suppliers, manufacturers and distributors to comply with EU laws and the related national laws of individual EU member states governing the conduct of clinical trials, manufacturing approval, MA of medicinal products and marketing of such products, both before and after grant of MA, statutory health insurance, bribery and anti-corruption or other applicable regulatory requirements may result in administrative, civil or criminal penalties. These penalties could include delays or refusal to authorize the conduct of clinical trials or to grant an MA, product withdrawals and recalls, product seizures, suspension, withdrawal or variation of the MA, total or partial suspension of production, distribution, manufacturing or clinical trials, operating restrictions, injunctions, suspension of licenses, fines and criminal penalties. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">89 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The holder of an MA for a medicinal product must also comply with EU pharmacovigilance legislation and its related regulations and guidelines, which entail many requirements for conducting pharmacovigilance, or the assessment and monitoring of the safety of medicinal products. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MA holders must establish and maintain a pharmacovigilance system and appoint an individual qualified person for pharmacovigilance, who is responsible for oversight of that system. Key obligations include expedited reporting of suspected serious adverse reactions and submission of PSURs in relation to medicinal products for which they hold Mas. The EMA reviews PSURs for medicinal products authorized through the centralized procedure. If the EMA has concerns that the risk benefit profile of a product has varied, it can adopt an opinion advising that the existing MA for the product be suspended, withdrawn or varied. The EMA can advise that the MA holder be obliged to conduct post-authorization Phase IV safety studies. If the EC agrees with the opinion, it can adopt a decision varying the existing MA. Failure by the MA holder to fulfill the obligations for which the EC&#8217;s decision provides can undermine the ongoing validity of the MA. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">More generally, <span style="white-space:nowrap">non-compliance</span> with pharmacovigilance obligations can lead to the variation, suspension or withdrawal of the MA for the product or imposition of financial penalties or other enforcement measures. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The manufacturing process for pharmaceutical products in the EU is highly regulated and regulators may shut down manufacturing facilities that they believe do not comply with regulations. Manufacturing requires a manufacturing authorization, and the manufacturing authorization holder must comply with various requirements set out in the applicable EU laws, regulations and guidance, including Directive 2001/83/EC, Directive 2003/94/EC, Regulation (EC) No 726/2004 and the European Commission Guidelines for Good Manufacturing Practice (&#8220;GMP&#8221;). These requirements include compliance with GMP standards when manufacturing pharmaceutical products and active pharmaceutical ingredients, including the manufacture of active pharmaceutical ingredients outside of the EU with the intention to import the active pharmaceutical ingredients into the EU. Similarly, the distribution of pharmaceutical products into and within the EU is subject to compliance with the applicable EU laws, regulations and guidelines, including the requirement to hold appropriate authorizations for distribution granted by the competent authorities of the EU member states. The manufacturer or importer must have a qualified person who is responsible for certifying that each batch of product has been manufactured in accordance with GMP, before releasing the product for commercial distribution in the EU or for use in a clinical trial. Manufacturing facilities are subject to periodic inspections by the competent authorities for compliance with GMP. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Sales and Marketing Regulations </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The advertising and promotion of our products is also subject to EU laws concerning promotion of medicinal products, interactions with physicians, misleading and comparative advertising and unfair commercial practices. In addition, other national legislation of individual EU member states may apply to the advertising and promotion of medicinal products and may differ from one country to another. These laws require that promotional materials and advertising in relation to medicinal products comply with the product&#8217;s Summary of Product Characteristics (&#8220;SmPC&#8221;) as approved by the national competent authorities. The SmPC is the document that provides information to physicians concerning the safe and effective use of the medicinal product. It forms an intrinsic and integral part of the marketing authorization granted for the medicinal product. Promotion of a medicinal product that does not comply with the SmPC is considered to constitute <span style="white-space:nowrap">off-label</span> promotion, which is prohibited in the EU. <span style="white-space:nowrap"><span style="white-space:nowrap">Direct-to-consumer</span></span> advertising of prescription-only medicines is also prohibited in the EU. Violations of the rules governing the promotion of medicinal products in the EU could be penalized by administrative measures, fines and imprisonment. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Anti-Corruption Legislation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the EU, interactions between pharmaceutical companies and physicians are also governed by strict laws, regulations, industry self-regulation codes of conduct and physicians&#8217; codes of professional conduct both at EU </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">90 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
level and in the individual EU member states. The provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is prohibited in the EU. The provision of benefits or advantages to physicians is also governed by the national anti-bribery laws of the EU member states. Violation of these laws could result in substantial fines and imprisonment. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Payments made to physicians in certain EU member states also must be publicly disclosed. Moreover, agreements with physicians must often be the subject of prior notification and approval by the physician&#8217;s employer, his/her regulatory professional organization, and/or the competent authorities of the individual EU member states. These requirements are provided in the national laws, industry codes, or professional codes of conduct, applicable in the individual EU member states. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Other Markets </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The UK formally left the EU on January&#160;31, 2020 and the transition period, during which EU laws continued to apply to the UK, expired on December&#160;31, 2020. This means EU laws now only apply to the UK in respect of Northern Ireland as laid out in the Northern Ireland Protocol. Following the end of the transition period, the EU and the UK concluded a trade and cooperation agreement (&#8220;TCA&#8221;), which applied provisionally from January&#160;1, 2021 and entered into force on May&#160;1, 2021. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The TCA includes specific provisions concerning pharmaceuticals, which include the mutual recognition of GMP, inspections of manufacturing facilities for medicinal products and GMP documents issued but does not provide for wholesale mutual recognition of UK and EU pharmaceutical regulations. At present, Great Britain has implemented EU legislation on the marketing, promotion and sale of medicinal products through the Human Medicines Regulations 2012 (as amended). Except in respect of the new CTR, the regulatory regime in Great Britain therefore largely aligns with current EU medicines regulations, however it is possible that these regimes will diverge more significantly in future now that Great Britain&#8217;s regulatory system is independent from the EU and the TCA does not provide for mutual recognition of UK and EU pharmaceutical legislation. However, notwithstanding that there is no wholesale recognition of EU pharmaceutical legislation under the TCA, under a new framework which will be put in place by the Medicines and Healthcare products Regulatory Agency (&#8220;MHRA&#8221;), from January&#160;1, 2024, the MHRA has stated that it will take into account decisions on the approval of marketing authorizations from the EMA (and certain other regulators) when considering an application for a Great Britain marketing authorization. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&#160;27, 2023, the UK government and the EC announced a political agreement in principle to replace the Northern Ireland Protocol with a new set of arrangements, known as the &#8220;Windsor Framework&#8221;. This new framework fundamentally changes the existing system under the Northern Ireland Protocol, including with respect to the regulation of medicinal products in the UK. In particular, the MHRA will be responsible for approving all medicinal products destined for the UK market (i.e., Great Britain and Northern Ireland), and the EMA will no longer have any role in approving medicinal products destined for Northern Ireland. A single <span style="white-space:nowrap">UK-wide</span> marketing authorization will be granted by the MHRA for all medicinal products to be sold in the UK, enabling products to be sold in a single pack and under a single authorization throughout the UK. The Windsor Framework was approved by the <span style="white-space:nowrap">EU-</span> UK Joint Committee on March&#160;24, 2023, so the UK government and the EU will enact legislative measures to bring it into law. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For other countries outside of the EU, such as countries in Eastern Europe, Latin America or Asia, the requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country. In all cases, again, the clinical trials must be conducted in accordance with cGCPs and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">91 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension of clinical trials, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Properties and Facilities </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a fully remote company and do not maintain physical corporate offices. Our employees work remotely. We believe these arrangements support our current needs. We maintain a mailing address at 221 Crescent St., Building 23, Suite 105, Waltham, MA. As we expand, we believe that suitable additional alternative spaces will be available in the future on commercially reasonable terms, if required. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Legal Proceedings </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From time to time, we may become involved in legal proceedings relating to claims arising from the ordinary course of business. Our management believes that there are currently no claims or actions pending against us, the ultimate disposition of which could have a material adverse effect on our results of operations, financial condition or cash flows. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">92 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx518298_11">MANAGEMENT </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Directors </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our board of directors currently consists of eight directors and is divided into three classes. Each class serves for three years, with the terms of office of the respective classes expiring in successive years. Directors in Class&#160;I will stand for election at our Annual Meeting expected to be held in June 2026. The terms of office of directors in Class&#160;II and Class&#160;III do not expire until the annual meetings of stockholders held in 2024 and 2025, respectively. Peter Harwin and Tomas Kiselak were designated by entities affiliated with Fairmount. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our current directors, and their ages, occupations and length of board service as of December&#160;11, 2023, are provided in the table below. Additional biographical descriptions of each director are set forth in the text below the table. These descriptions include the primary individual experience, qualifications, qualities and skills of each of our directors. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:35%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td style="width:53%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-weight:bold">Name of Director</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center"><span style="font-weight:bold">Age</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center"><span style="font-weight:bold">Principal Occupation</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center"><span style="font-weight:bold">Director<br />Since</span></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="5"><span style="font-weight:bold">Class&#160;I Directors:</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Alison Lawton (1)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">62</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Director, ProQR Therapeutics N.V; Director, Magenta Therapeutics, Inc; Director X4 Pharmaceuticals Inc.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">2020</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Cameron Turtle</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">33</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Chief Executive Officer of Spyre Therapeutics, Inc.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">2023</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Laurie Stelzer (1)(2)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">56</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Chief Financial Officer of ReNAgade Therapeutics, Inc.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">2023</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><span style="font-weight:bold">Class&#160;II Directors:</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Russell J. Cox (3)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">60</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">President and Chief Executive Officer, Epirium Bio, Inc.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">2015</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Jeffrey W. Albers (2)(3)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">52</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Chairman of Blueprint Medicines Corporation and Venture Partner at Atlas Venture</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">2023</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Tomas Kiselak (3)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">37</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Managing Member, Fairmount Funds Management LLC; Director, Dianthus Therapeutics, Inc.; Director, Viridian Therapeutics, Inc.; Director, Apogee Therapeutics, Inc.; and Director, Paragon Therapeutics, Inc.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">2023</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><span style="font-weight:bold">Class&#160;III Directors:</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Peter Harwin (1)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">37</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Managing Member, Fairmount Funds Management LLC; Director, Cogent Biosciences, Inc.; Director, Viridian Therapeutics, Inc.; Director, Apogee Therapeutics, Inc.; and Director, Paragon Therapeutics, Inc.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">2023</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Michael Henderson (2)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">34</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Chief Executive Officer of Apogee Therapeutics, Inc.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">2023</td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Member of the nominating and corporate governance committee. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Member of the audit committee. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Member of the compensation committee. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Cameron Turtle, Dphil</span>. Dr.&#160;Turtle joined the Company as Chief Operating Officer in June 2023, and was appointed as Chief Executive Officer and director of the Company in November 2023. Prior to joining the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">93 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Company, Dr.&#160;Turtle was an advisor to <span style="white-space:nowrap">Pre-Merger</span> Spyre from May 2023 to June 2023. Previously, he served as Venture Partner at Foresite Labs, a life sciences investment firm, from July 2022 to May 2023; Chief Strategy Officer of BridgeBio Pharma (NASDAQ: BBIO), a biotechnology company, from January 2021 to April 2022; and Chief Business Officer of Eidos Therapeutics (NASDAQ: EIDX), a biopharmaceutical company, from November 2018 to January 2021, where he led business development, investor relations, and multiple operational functions as the company advanced an investigational medicine for a form of heart failure. Prior to joining BridgeBio and Eidos, he was a consultant at McKinsey&#160;&amp; Company, where he worked with pharmaceutical and medical device companies on topics including M&amp;A, growth strategy, clinical trial strategy, and sales force optimization. Dr.&#160;Turtle received his B.S. with honors in Bioengineering from the University of Washington and his D.Phil. in Cardiovascular Medicine from the University of Oxford, St. John&#8217;s College. He is the recipient of several awards, including a Rhodes Scholarship, Goldwater Scholarship, Forbes 30 Under 30, San Francisco Business Times 40 Under 40, and the Biocom Life Sciences Catalyst Award. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe Dr.&#160;Turtle is qualified to serve on our board of directors due to his experience as a leader in building, financing, and shaping biopharma organizations from preclinical development to late-stage clinical trials and commercialization. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Russell J. Cox</span>. Mr.&#160;Cox has served as a director since June 2015 and has served as Chair of our board of directors since January 2019. Mr.&#160;Cox has served as President and Chief Executive Officer of Epirium Bio, Inc. since July 2019. Mr.&#160;Cox previously served as Chief Executive Officer at Vital Therapies, Inc. from January 2018 to January 2019. Additionally, Mr.&#160;Cox served as Executive Vice President and Chief Operating Officer at Jazz </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pharmaceuticals plc, a publicly traded biopharmaceutical company, from May 2014 to January 2018, where he also served as Executive Vice President and Chief Commercial Officer from March 2012 to May 2014 and as Senior Vice President, Sales and Marketing from July 2010 until February 2012. Prior to that, Mr.&#160;Cox served in a variety of senior management roles since joining Jazz Pharmaceuticals, Inc. (the predecessor to Jazz Pharmaceuticals plc) in July 2010. From January 2009 to January 2010, he served as Senior Vice President and Chief Commercial Officer of Ipsen Group, a publicly traded pharmaceutical company, and from 2007 until December 2008, he served as Vice President of Marketing at Tercica, Inc. (acquired by Ipsen Group), a biotechnology company. From 2003 to 2007, Mr.&#160;Cox was with Scios Inc. (acquired by Johnson and Johnson in 2003), where he also served as Vice President, Marketing. Prior to 2003, Mr.&#160;Cox was with Genentech, Inc. for 12 years, where he was a Product Team Leader responsible for the Growth Hormone franchise and led numerous product launches as a Group Product Manager. Mr.&#160;Cox currently serves on the boards of directors of Epirium Bio, Inc. and Gossamer Bio, Inc. Mr.&#160;Cox received a B.S. in Biomedical Science from Texas A&amp;M University. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe Mr.&#160;Cox is qualified to serve on our board of directors due to his commercial and operating experience in the biopharmaceutical industry. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Jeffrey W. Albers</span>. Mr.&#160;Albers has over 25 years of experience working in the biopharmaceutical industry and bringing important new medicines to patients with cancer and rare diseases. He is currently Chairman of Blueprint Medicines Corporation (Nasdaq: BPMC), a global precision therapy company, since January 2023, and Venture Partner at Atlas Venture, a venture capital firm focused on investment in biotechnology companies, since January 2023. Mr.&#160;Albers served as Chief Executive Officer, President and Chairman of Blueprint Medicines from June 2021 to April 2022, Executive Chairman from April 2022 to December 2022 and as Chief Executive Officer, President and Director from July 2014 to June 2021. Prior to joining Blueprint Medicines in July 2014, Mr.&#160;Albers was President of Algeta ASA, a Norwegian biotechnology company from January 2012 to April 2014, where he oversaw the commercial and business functions. Prior to Algeta ASA, from July 2005 to November 2011, Mr.&#160;Albers was at Genzyme Corporation, a biotechnology company that is now a wholly-owned subsidiary of Sanofi S.A., most recently as Vice President of the U.S. hematology and oncology business unit. In addition to Blueprint Medicines, Mr.&#160;Albers serves on the board of directors of Kymera Therapeutics, Inc. (Nasdaq: KYMR) and several private companies, and previously served on the board of directors of Magenta Therapeutics, Inc. (which later became Dianthus Therapeutics, Inc. (Nasdaq: DNTH)) from July 2017 to </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">94 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
September 2023. Mr.&#160;Albers received a B.S. from Indiana University and an M.B.A. and a J.D. from Georgetown University. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe that Mr.&#160;Albers is qualified to serve on our board of directors due to his extensive leadership experience in the biopharmaceutical industry. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Alison Lawton</span>. Ms.&#160;Lawton has served as a director since December 2020. Ms.&#160;Lawton served as a special advisor at Kaleido Biosciences, Inc. from June 2020 to December 2020. Ms.&#160;Lawton previously served as President and Chief Executive Officer of Kaleido Biosciences, Inc. from August 2018 to June 2020, and served as President and Chief Operating Officer from December 2017 to August 2018. Prior to joining Kaleido Biosciences, Inc., Ms.&#160;Lawton served as Chief Operating Officer at Aura Biosciences, Inc., an oncology therapeutics company, from January 2015 until December 2017, and, prior to joining Aura, served as a consultant to Aura from March 2014 to December 2014. From January 2013 to January 2014, Ms.&#160;Lawton served as Chief Operating Officer at OvaScience Inc., a life sciences company. From 2014 to 2017, Ms.&#160;Lawton served as a biotech consultant for various companies, including as Chief Operating Officer consultant at X4 Pharmaceuticals Inc. Prior to that, Ms.&#160;Lawton spent more than 20 years in various positions of increasing responsibility including Senior VP and General Manager of Biosurgery and prior to that, Senior VP of Market Access at Genzyme Corporation, a global biopharmaceutical company, and subsequently at Sanofi S.A., also a global biopharmaceutical company, following the acquisition of Genzyme by Sanofi in 2011. Additionally, Ms.&#160;Lawton previously served two terms as the industry representative on the U.S. Food&#160;&amp; Drug Administration&#8217;s Cell&#160;&amp; Gene Therapy Advisory Committee and as Chair of the Board of the Regulatory Affairs Professional Society. Ms.&#160;Lawton currently serves on the boards of directors of ProQR Therapeutics N.V., Magenta Therapeutics, Inc., X4 Pharmaceuticals and three other private companies. Ms.&#160;Lawton previously served on the boards of directors of Kaleido Biosciences, Verastem, Inc., CoLucid Pharmaceuticals, Inc., Cubist Pharmaceuticals, Inc. Ms.&#160;Lawton received a B.Sc. in pharmacology from Kings College, University of London. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe that Ms.&#160;Lawton is qualified to serve on our board of directors due to her extensive commercial and operating experience in the biopharmaceutical industry. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Laurie Stelzer</span>. Ms.&#160;Stelzer has served as Chief Financial Officer of ReNAgade Therapeutics, Inc., a biotechnology company focused on RNA therapeutics, since September 2023. Prior to joining ReNAgade, Ms.&#160;Stelzer served as Chief Financial Officer of Mirati Therapeutics, Inc. (Nasdaq: MRTX), a commercial-stage targeted oncology company (&#8220;Mirati&#8221;), from May 2022 to September 2023. Prior to joining Mirati Therapeutics, Ms.&#160;Stelzer served as Executive Vice President and Chief Financial Officer of Arena Pharmaceuticals, Inc. (acquired by Pfizer Inc.), a biopharmaceutical company, from March 2020 until the completion of Pfizer&#8217;s acquisition in March 2022. Prior to joining Arena Pharmaceuticals, Ms.&#160;Stelzer served as Chief Financial Officer at Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharma technology platform company, from June 2015 to March 2020, where she led the Finance, Information Technology, Business Development, Project Management and Site Operations organizations. Prior to joining Halozyme Therapeutics, Ms.&#160;Stelzer held senior management roles at Shire Plc (acquired by Takeda Pharmaceutical), including Senior Vice President of Finance, Division Chief Financial Officer for the Regenerative Medicine Division and Head of Investor Relations. Previously, she also worked at Amgen, Inc. (Nasdaq: AMGN), a global biopharmaceutical company, for 15 years, serving in positions of increasing responsibility in the areas of Finance, Treasury, Global Accounting and International/Emerging Markets. Ms.&#160;Stelzer has served as a member of the board of directors of PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company, since 2020, Surface Oncology, Inc. (Nasdaq: SURF), a clinical-stage 88mmune-oncology company, from 2018 until its acquisition by Coherus in September 2023 and Longboard Pharmaceuticals, a clinical-stage neurology company from 2020 to 2021 . Ms.&#160;Stelzer received her B.S. in Accounting from Arizona State University and her M.B.A. from University of California, Los Angeles, Anderson School of Management. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe Ms.&#160;Stelzer is qualified to serve on our board of directors because of her financial expertise and experience within the biopharmaceutical industry. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">95 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Peter Harwin</span>. Peter Harwin has served as a director since June 2023. Mr.&#160;Harwin is a Managing Member at Fairmount Funds Management LLC, a healthcare investment firm he <span style="white-space:nowrap">co-founded</span> in April 2016. Prior to Fairmount, Mr.&#160;Harwin was a member of the investment team at Boxer Capital, LLC, an investment fund that was part of the Tavistock Group, based in San Diego. Mr.&#160;Harwin also serves as chairman of the board of directors of Cogent Biosciences, Inc. (Nasdaq: COGT) and is a director of Viridian Therapeutics, Inc. (Nasdaq: VRDN), Apogee Therapeutics, Inc. (Nasdaq: APGE) and Paragon Therapeutics, Inc. Mr.&#160;Harwin holds a B.B.A. from Emory University. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe Mr.&#160;Harwin is qualified to serve on our board of directors because of his experience serving as a director of biotechnology companies and as a manager of funds specializing in the area of life sciences. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Tomas Kiselak</span>. Tomas Kiselak has served as a director since June 2023. Mr.&#160;Kiselak is a Managing Member at Fairmount Funds Management LLC, a healthcare investment firm he <span style="white-space:nowrap">co-founded</span> in April 2016. Prior to Fairmount, Mr.&#160;Kiselak was a managing director at RA Capital Management, LLC, a healthcare and life science investment firm. Mr.&#160;Kiselak currently serves as the chairman of the board of directors of Viridian Therapeutics, Inc. (Nasdaq: VRDN) and as a director for Apogee Therapeutics, Inc. (Nasdaq: APGE), Dianthus Therapeutics, Inc. (Nasdaq: DNTH) as well as several private companies. He received a B.S. in neuroscience and economics from Amherst College. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe Mr.&#160;Kiselak is qualified to serve on our board of directors because of his experience advising biotechnology companies and as a manager of funds specializing in the area of life sciences. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Michael Henderson, M.D</span>. Michael Henderson, M.D. has served as a director since June 2023. Dr.&#160;Henderson is Chief Executive Officer of Apogee Therapeutics, Inc. (Nasdaq: APGE), a biotechnology company, since September 2022 as well as a member of its board of directors since June 2023. Dr.&#160;Henderson is an experienced biotechnology executive with expertise in business leadership, drug development, and commercial strategy. He has overseen the creation of multiple companies, launched a significant number of drug development programs, and led teams to two FDA approvals, to date. Prior to joining Apogee, Dr.&#160;Henderson served as Chief Business Officer of BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company, from January 2020 to September 2022, where he was responsible for furthering the overarching strategy of BridgeBio, identifying and investing in new technologies and running business development and operations. Prior to holding that position, he spent two years serving as BridgeBio&#8217;s Senior Vice President, Asset Acquisition, Strategy and Operations, where he was responsible for business development, strategy and operations. Dr.&#160;Henderson joined BridgeBio as Vice President of Asset Acquisition, Strategy and Operations in April 2016. Dr.&#160;Henderson also served as the Chief Executive Officer of a number of BridgeBio&#8217;s subsidiaries. Prior to BridgeBio, Dr.&#160;Henderson worked at McKinsey&#160;&amp; Company, a global management consulting firm, from January 2015 to April 2016 and prior to that, he <span style="white-space:nowrap">co-founded</span> PellePharm, Inc., a biotechnology company, in August 2011. Dr.&#160;Henderson has served on the board of directors of ARYA Sciences Acquisition Corp IV (Nasdaq: ARYD), a special purpose acquisition company focused on the healthcare industry, since February 2021. Dr.&#160;Henderson received his B.A. in global health from Harvard University and his M.D. from Stanford University. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe Dr.&#160;Henderson is qualified to serve on our board of directors because of his experience in business leadership, drug development, and commercial strategy in the area of life sciences. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Director Independence </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our board of directors determines the independence of our directors by applying the applicable rules, regulations and listing standards of Nasdaq. These provide that a director is independent only if the board affirmatively determines that the director does not have a relationship with the company which, in the opinion of the board of directors, would interfere with the exercise of his or her independent judgment in carrying out the responsibilities of a director. They also specify various relationships that preclude a determination of director independence. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">96 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Such relationships may include employment, commercial, accounting, family and other business, professional and personal relationships. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Applying these standards, the board reviews the independence of our directors, taking into account all relevant facts and circumstances. After considering the foregoing factors, our board of directors has determined that the following members of our board are currently independent as determined under applicable rules, regulations and listing standards of Nasdaq: Mr.&#160;Russell Cox, Ms.&#160;Laurie Stelzer, Ms.&#160;Alison Lawton, Mr.&#160;Jeffrey&#160;W. Albers, Mr.&#160;Peter Harwin, Mr.&#160;Tomas Kiselak and Dr.&#160;Michael Henderson. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All members of our audit committee, compensation committee and nominating and corporate governance committee must be independent directors under the applicable rules, regulations and listing standards of Nasdaq. Members of the audit committee also must satisfy the independence criteria set forth in Rule <span style="white-space:nowrap">10A-3</span> under the Exchange Act. Members of the compensation committee also must satisfy the independence criteria set forth in Rule 10C under the Exchange Act, and related Nasdaq listing standards with respect to their affiliation with Spyre and any consulting, advisory or other fees they may have received from Spyre. Our board of directors has determined that all members of our audit committee, compensation committee and nominating and corporate governance committee are independent and satisfy the relevant SEC, Exchange Act and Nasdaq independence requirements for such committees. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Executive Officers </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The names of our current executive officers, their ages as of December&#160;11, 2023, and their positions are shown below. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:35%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td style="width:59%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-weight:bold">Name</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center"><span style="font-weight:bold">Age</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">Position</span></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Cameron Turtle, Dphil(1)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">33</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Chief Operating Officer</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Scott Burrows</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">46</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Chief Financial Officer</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Heidy King-Jones</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">41</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Chief Legal Officer and Corporate Secretary</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt" colspan="5"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="5"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(1)&#8194;&#8201;&#8202;For Dr.&#160;Turtle&#8217;s biographical information, see &#8220;Directors&#8221; above.</p></td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our board of directors chooses executive officers, who then serve at the board&#8217;s discretion. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Scott Burrows.</span> Mr.&#160;Burrows joined as our Chief Financial Officer in September 2023. Prior to becoming Chief Financial Officer, Mr.&#160;Burrows most recently served as the Chief Financial Officer of Arcutis Biotherapeutics, Inc. (&#8220;Arcutis&#8221;) (Nasdaq: ARQT) where he helped lead Arcutis through a successful initial public offering, several further equity and debt financings, and the transition to a fully integrated commercial-stage company. Prior to Arcutis, Mr.&#160;Burrows was the head of international investor relations for Shire, plc based in Switzerland. Earlier in his career, he spent 15 years at Amgen, Inc. in roles of increasing responsibility across financial planning and analysis, treasury and investor relations. Mr.&#160;Burrows began his career at Arthur Andersen as a consultant. He earned his B.A. and M.B.A. from the University of California, Los Angeles, and is a licensed C.P.A. (inactive). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Heidy King-Jones.</span> Ms.&#160;King-Jones joined as our Chief Legal Officer and Corporate Secretary in September 2023. Ms.&#160;King-Jones most recently served as the Chief Legal Officer and Corporate Secretary at Provention Bio, Inc. through various financings, the approval of Tzield<sup style="font-size:75%; vertical-align:top">&#174;</sup>, the companies successful transition from clinical-stage to commercial-stage as well as its acquisition by Sanofi in April 2023. Prior to her leadership role at Provention Bio, she was a Senior Vice President, General Counsel and Corporate Secretary at Axcella Health Inc. where she was responsible for Axcella&#8217;s corporate legal function and strategy. From 2013 to 2018, she held positions of increasing responsibility in the legal department at Sarepta Therapeutics, Inc., including overseeing all Corporate Law matters as Senior Director, Corporate Law. While at Sarepta, she served as a member of the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">97 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
company&#8217;s commercial readiness working group and was responsible for the development of the compliance program, contract and other legal work for the launch of its first product, Exondys 51<sup style="font-size:75%; vertical-align:top">&#174;</sup>. Ms.&#160;King-Jones began her legal career in the Securities&#160;&amp; Public Companies Practice Group at Ropes&#160;&amp; Gray LLP, where she represented private and publicly traded companies in the pharmaceutical, utility and technology industries. She holds a J.D. and LL.M in International and Comparative Law from Cornell Law School, and a B.A. from Dartmouth College. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Family Relationships </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are no family relationships among our directors and executive officers. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">98 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx518298_12">EXECUTIVE COMPENSATION </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All of the information contained in the sections below generally relates to compensation for our fiscal year 2022 and was included in our proxy statement for the 2023 annual meeting of stockholders (the &#8220;2023 Annual Proxy&#8221;) filed with the SEC on April&#160;17, 2023. Such information has not been adjusted to reflect the effects of the Reverse Split. Since the date of the 2023 Annual Proxy, there have been several changes to senior management, including the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Jeffrey Goldberg&#8217;s termination as President and Chief Executive Officer, effective May&#160;16, 2023; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Jim Kastenmayer&#8217;s termination as General Counsel and Corporate Secretary, effective May&#160;16, 2023; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Jonathan Alspaugh&#8217;s termination as President and Chief Financial Officer, effective August&#160;31, 2023; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Cameron Turtle&#8217;s appointment as Chief Operating Officer, effective June&#160;22, 2023 and transition to Chief Executive Officer, effective November&#160;22, 2023; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Scott Burrows&#8217; appointment as Chief Financial Officer, effective September&#160;1, 2023; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Heidy King-Jones&#8217; appointment as Chief Legal Officer and Corporate Secretary, effective September&#160;1, 2023. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Overview </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This section provides an overview of the material components of our executive compensation program for our Chief Executive Officer, including anyone who served as Chief Executive Officer during any part of fiscal year 2022, and each of our two other most highly compensated executive officers (our &#8220;Named Executive Officers&#8221;) during fiscal year 2022. The compensation provided to our Named Executive Officers for fiscal year 2022 is set forth in detail in the Summary Compensation Table and other tables that follow in this section, as well as the accompanying footnotes and narratives relating to those tables. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Named Executive Officers for fiscal year 2022 were: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Jeffrey M. Goldberg, our Former President and Chief Executive Officer; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Jim Kastenmayer, our Former General Counsel, Corporate Secretary and Interim Chief Executive Officer; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Anthony G. Quinn, M.B Ch.B, Ph.D., our Former President and Chief Executive Officer; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Jonathan Alspaugh, our Former Chief Financial Officer; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Leslie Sloan, Ph.D., our Former Chief Operating Officer. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">99 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Summary Compensation Table </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table provides information regarding all plan and <span style="white-space:nowrap">non-plan</span> compensation awarded to, earned by or paid to each of our Named Executive Officers for the fiscal years ended December&#160;31, 2022 and 2021. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:52%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom"></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-weight:bold">Name and Principal Position</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Year</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Salary<br />($)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Nonequity<br />Incentive Plan<br />Compensation<br />($) (1)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Option<br />Awards<br />($) (2)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">All Other<br />Compensation<br />($)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Total<br />($)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Jeffrey M. Goldberg (4)<br /><span style="font-style:italic">Former </span><span style="font-style:italic">President and Chief Executive Officer</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">2022</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">54,616</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">1,774,952</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">2,917</td>
<td style="white-space:nowrap;vertical-align:top">(3)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">1,832,485</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Jim Kastenmayer (4)(6)<br /><span style="font-style:italic">Former General Counsel, Corporate Secretary and Interim Chief Executive Officer</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">2022</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">443,943</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">155,694</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">253,948</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">12,200</td>
<td style="white-space:nowrap;vertical-align:top">(3)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">865,785</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Anthony G. Quinn, M.B Ch.B, Ph.D. (4)<br /><span style="font-style:italic">Former President and Chief Executive Officer</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;<br /></td>
<td style="white-space:nowrap;vertical-align:top" align="right">2022<br />2021</td>
<td style="white-space:nowrap;vertical-align:top">&#160;<br />&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;<br /></td>
<td style="white-space:nowrap;vertical-align:top" align="right">424,429<br />560,000</td>
<td style="white-space:nowrap;vertical-align:top">&#160;<br />&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;<br /></td>
<td style="white-space:nowrap;vertical-align:top" align="right">&#8212;&#160;&#160;<br />332,000</td>
<td style="white-space:nowrap;vertical-align:top">&#160;<br />&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;<br /></td>
<td style="white-space:nowrap;vertical-align:top" align="right">779,625<br />1,701,525</td>
<td style="white-space:nowrap;vertical-align:top">&#160;<br />&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;<br /> <p style="margin-bottom:1pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman"></p></td>
<td style="white-space:nowrap;vertical-align:top" align="right">1,188,200<br /> <p style="margin-bottom:1pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;text-align:right">29,661</p></td>
<td style="white-space:nowrap;vertical-align:top">(3)(5)&#160;<br /> <p style="margin-bottom:1pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman">&#160;</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;<br /></td>
<td style="white-space:nowrap;vertical-align:top" align="right">2,392,254<br />2,623,186</td>
<td style="white-space:nowrap;vertical-align:top">&#160;<br />&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Jonathan Alspaugh (7)<br /><span style="font-style:italic">Former Chief Financial Officer</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">2022</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">425,001</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">130,560</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">443,285</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">12,994</td>
<td style="white-space:nowrap;vertical-align:top">(3)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">1,011,840</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Leslie Sloan, Ph.D. (8)<br /><span style="font-style:italic">Former Chief Operating Officer</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;<br /></td>
<td style="white-space:nowrap;vertical-align:top" align="right">2022<br />2021</td>
<td style="white-space:nowrap;vertical-align:top">&#160;<br />&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;<br /></td>
<td style="white-space:nowrap;vertical-align:top" align="right">435,000<br />410,000</td>
<td style="white-space:nowrap;vertical-align:top">&#160;<br />&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;<br /></td>
<td style="white-space:nowrap;vertical-align:top" align="right">174,000<br />200,000</td>
<td style="white-space:nowrap;vertical-align:top">&#160;<br />&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;<br /></td>
<td style="white-space:nowrap;vertical-align:top" align="right">465,560<br />822,496</td>
<td style="white-space:nowrap;vertical-align:top">&#160;<br />&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;<br /> <p style="margin-bottom:1pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman"></p></td>
<td style="white-space:nowrap;vertical-align:top" align="right">13,323<br /> <p style="margin-bottom:1pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;text-align:right">16,940</p></td>
<td style="white-space:nowrap;vertical-align:top">(3)&#160;<br /> <p style="margin-bottom:1pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman">&#160;</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;<br /></td>
<td style="white-space:nowrap;vertical-align:top" align="right">1,087,882<br />1,449,436</td>
<td style="white-space:nowrap;vertical-align:top">&#160;<br />&#160;</td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:left">Cash bonuses earned in 2022 and paid in 2023, based in part on achievement of specified milestones and performance objectives. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:left">The amounts reported in this column represent the aggregate grant date fair value of the awards granted to our Named Executive Officers during the year ended December&#160;31, 2022, as computed in accordance with Accounting Standards Codification Topic 718 (&#8220;ASC 718&#8221;). The assumptions used in calculating the grant date fair value of the awards reported in the Option Awards column are set forth in Note 10 to our 2022 Annual Financials included elsewhere in this prospectus. Note that the amounts reported in this column reflect the aggregate accounting cost for these awards, and do not necessarily correspond to the actual economic value that may be received by the Named Executive Officers from the awards. As of the date of grant, the achievement of the performance goals applicable to the performance-based options granted to Dr.&#160;Quinn during the year ended December&#160;31, 2022 was not deemed to be probable, and therefore, the grant date fair value ascribed to such options in accordance with ASC 718, and reported in this column, is $0. The maximum grant date fair value of such performance-based options, assuming full achievement of the performance conditions to which such options are subject, is $78,066.61. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:left">For Mr.&#160;Goldberg, represents housing allowance. For each of our other Named Executive Officers, primarily represents matching 401(k) or other retirement plan contributions paid by us on their behalf in the amount of $12,200. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(4)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:left">On August&#160;23, 2022, Dr.&#160;Quinn transitioned from our President and Chief Executive Officer to a <span style="white-space:nowrap">non-employee</span> consultant of Spyre until September&#160;1, 2023. Our board of directors appointed Mr.&#160;Kastenmayer, who served as our General Counsel and Corporate Secretary, to serve as our interim Chief Executive Officer from August&#160;23, 2022 until the appointment of Mr.&#160;Goldberg as our President and Chief Executive Officer on November&#160;29, 2022. Mr.&#160;Goldberg&#8217;s employment with us terminated on May&#160;16, 2023. Under SEC rules, as each of Dr.&#160;Quinn, Mr.&#160;Kastenmayer and Mr.&#160;Goldberg served as Spyre&#8217;s principal executive officer during a portion of 2022, each is considered to be a Named Executive Officer for 2022. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(5)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:left">Includes severance payment of $1,176,000 in connection with Dr.&#160;Quinn&#8217;s termination of employment. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(6)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:left">Because Mr.&#160;Kastenmayer was not a Named Executive Officer in 2021, SEC rules do not require his compensation for that year to be reported. Mr.&#160;Kastenmayer&#8217;s employment with us terminated on May&#160;16, 2023. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(7)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:left">Because Mr.&#160;Alspaugh was not a Named Executive officer in 2021, SEC rules do not require his compensation for that year to be reported. Mr.&#160;Alspaugh&#8217;s employment with us terminated on August&#160;31, 2023. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(8)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:left">Dr.&#160;Sloan&#8217;s employment with us terminated on January&#160;5, 2023. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">100 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Outstanding Equity Awards at December&#160;31, 2022 </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table presents, for our Named Executive Officers, information regarding outstanding equity awards held as of December&#160;31, 2022. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:28%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="22" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Option Awards</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="10" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Stock Awards</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-weight:bold">Name</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Grant date</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number of<br />securities<br />underlying<br />unexercised<br />options (#)<br />exercisable</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number of<br />securities<br />underlying<br />unexercised<br />options (#)<br />unexercisable</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Equity<br />Incentive<br />Plan<br />Awards:<br />Number of<br />securities<br />underlying<br />unexercised<br />unearned<br />options (#)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Option<br />exercise<br />price<br />($)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Option<br />expiration<br />date</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Grant<br />date</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Equity<br />Incentive<br />Plan<br />Awards:<br />Number<br />of<br />unearned<br />shares,<br />units or<br />other<br />rights<br />that have<br />not<br />vested<br />(#)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Equity<br />Incentive<br />Plan<br />Awards:<br />Market<br />or<br />payout<br />value of<br />unearned<br />shares,<br />units or<br />other<br />rights<br />that<br />have not<br />vested<br />($) (2)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Jeffrey M. Goldberg</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11/28/2022</td>
<td style="white-space:nowrap;vertical-align:bottom">(1)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,884,838</td>
<td style="white-space:nowrap;vertical-align:bottom">(5)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1.27</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11/27/2032</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Jim Kastenmayer</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7/6/2021</td>
<td style="white-space:nowrap;vertical-align:bottom">(1)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">46,041</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">83,959</td>
<td style="white-space:nowrap;vertical-align:bottom">(5)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7.03</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7/5/2031</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2/17/2022</td>
<td style="white-space:nowrap;vertical-align:bottom">(1)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">17,708</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">67,292</td>
<td style="white-space:nowrap;vertical-align:bottom">(3)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3.17</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2/16/2032</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8/23/2022</td>
<td style="white-space:nowrap;vertical-align:bottom">(1)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10,833</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">119,167</td>
<td style="white-space:nowrap;vertical-align:bottom">(3)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.68</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8/22/2032</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Anthony G. Quinn, M.B Ch.B, Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2/20/2018</td>
<td style="white-space:nowrap;vertical-align:bottom">(1)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">119,914</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">(3)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6.31</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2/19/2028</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7/18/2018</td>
<td style="white-space:nowrap;vertical-align:bottom">(1)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">160,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">(3)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9.36</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7/17/2028</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10/8/2018</td>
<td style="white-space:nowrap;vertical-align:bottom">(1)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">140,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">(3)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9.36</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7/18/2028</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2/28/2019</td>
<td style="white-space:nowrap;vertical-align:bottom">(1)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">268,333</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11,667</td>
<td style="white-space:nowrap;vertical-align:bottom">(3)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8.36</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2/27/2029</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2/14/2020</td>
<td style="white-space:nowrap;vertical-align:bottom">(1)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">213,208</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">87,792</td>
<td style="white-space:nowrap;vertical-align:bottom">(3)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8.15</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2/13/2030</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7/15/2020</td>
<td style="white-space:nowrap;vertical-align:bottom">(1)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">55,000</td>
<td style="white-space:nowrap;vertical-align:bottom">(4)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8.13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7/15/2030</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2/17/2021</td>
<td style="white-space:nowrap;vertical-align:bottom">(1)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">151,250</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">178,750</td>
<td style="white-space:nowrap;vertical-align:bottom">(3)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7.35</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2/16/2031</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2/17/2022</td>
<td style="white-space:nowrap;vertical-align:bottom">(1)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">72,916</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">277,084</td>
<td style="white-space:nowrap;vertical-align:bottom">(3)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3.17</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2/16/2032</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4/18/2022</td>
<td style="white-space:nowrap;vertical-align:bottom">(1)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">40,000</td>
<td style="white-space:nowrap;vertical-align:bottom">(4)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1.90</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4/18/2032</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7/15/2020</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">55,000</td>
<td style="white-space:nowrap;vertical-align:bottom">(6)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">24,750</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Jonathan Alspaugh</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7/6/2021</td>
<td style="white-space:nowrap;vertical-align:bottom">(1)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">56,666</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">103,334</td>
<td style="white-space:nowrap;vertical-align:bottom">(5)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7.03</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7/5/2031</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2/17/2022</td>
<td style="white-space:nowrap;vertical-align:bottom">(1)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">35,416</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">134,584</td>
<td style="white-space:nowrap;vertical-align:bottom">(3)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3.17</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2/16/2032</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8/23/2022</td>
<td style="white-space:nowrap;vertical-align:bottom">(1)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10,833</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">119,167</td>
<td style="white-space:nowrap;vertical-align:bottom">(3)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.68</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8/22/2032</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Leslie Sloan, Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10/10/2017</td>
<td style="white-space:nowrap;vertical-align:bottom">(1)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">55,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">(5)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5.98</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10/9/2027</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2/20/2018</td>
<td style="white-space:nowrap;vertical-align:bottom">(1)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">80,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">(3)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6.31</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2/19/2028</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2/28/2019</td>
<td style="white-space:nowrap;vertical-align:bottom">(1)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">69,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,000 </td>
<td style="white-space:nowrap;vertical-align:bottom">(3)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8.36</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2/27/2029</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3/6/2019</td>
<td style="white-space:nowrap;vertical-align:bottom">(1)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">33,750</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,250 </td>
<td style="white-space:nowrap;vertical-align:bottom">(3)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8.06</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3/5/2029</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2/14/2020</td>
<td style="white-space:nowrap;vertical-align:bottom">(1)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">70,833</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">29,167</td>
<td style="white-space:nowrap;vertical-align:bottom">(3)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8.15</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2/13/2030</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7/15/2020</td>
<td style="white-space:nowrap;vertical-align:bottom">(1)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">20,000</td>
<td style="white-space:nowrap;vertical-align:bottom">(4)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8.13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7/15/2030</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2/17/2021</td>
<td style="white-space:nowrap;vertical-align:bottom">(1)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">73,333</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">86,667</td>
<td style="white-space:nowrap;vertical-align:bottom">(3)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7.35</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2/16/2031</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2/17/2022</td>
<td style="white-space:nowrap;vertical-align:bottom">(1)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">37,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">142,500</td>
<td style="white-space:nowrap;vertical-align:bottom">(3)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3.17</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2/16/2032</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8/23/2022</td>
<td style="white-space:nowrap;vertical-align:bottom">(1)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10,833</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">119,167</td>
<td style="white-space:nowrap;vertical-align:bottom">(3)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.68</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8/22/2032</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7/15/2020</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">20,000</td>
<td style="white-space:nowrap;vertical-align:bottom">(6)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Equity award was granted under our 2016 Plan. For Mr.&#160;Goldberg, equity award was granted as an inducement award. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">101 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The market value was determined by multiplying the number of shares by $0.45, the closing price of our Common Stock as reported on the Nasdaq Global Market on December&#160;30, 2022, the last trading day of the year. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">1/48<sup style="font-size:75%; vertical-align:top">th</sup> of the options vests on each monthly anniversary of the applicable vesting commencement date, subject to the executive&#8217;s continued service. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(4)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The options vest and become exercisable contingent upon achievement of certain product development, regulatory, or stock price milestones, which have not been met as of December&#160;31, 2022. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(5)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">1/4<sup style="font-size:75%; vertical-align:top">th</sup> of the options vest on the one year anniversary of the applicable vesting commencement date and an additional 1/48<sup style="font-size:75%; vertical-align:top">th</sup> vests monthly thereafter, subject to the executive&#8217;s continued service. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(6)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The restricted stock units vest contingent upon achievement of certain product development or regulatory milestones, which have not been met as of December&#160;31, 2022. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Narrative to Summary Compensation Table </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our compensation committee has historically determined our executive compensation and determines the compensation of our Named Executive Officers. Our compensation committee typically reviews and discusses management&#8217;s proposed compensation with the Chief Executive Officer for all executives other than the Chief Executive Officer. Based on those discussions and its discretion, our compensation committee then approves the compensation of each executive officer after discussions without members of management present. We generally do not provide perquisites or personal benefits, except in situations where we believe it is appropriate to assist an individual in the performance of his or her duties, to make our executive officers more efficient and effective, and for recruitment and retention purposes. See &#8220;&#8211; <span style="font-style:italic">Employment Arrangements with Our Named Executive Officers</span>&#8221; below for additional information. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Welfare and Health Benefits </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Named Executive Officers are eligible to participate in all of our benefit plans, such as the 401(k) plan (see description under &#8220;&#8211; <span style="font-style:italic">Retirement Benefits</span>&#8221; below), medical, dental, vision, short-term disability, long-term disability and group life insurance, in each case generally on the same basis as other employees. We do not currently have qualified or nonqualified defined benefit plans or nonqualified deferred compensation plans, nor do we offer pension or other retirement benefits other than our 401(k) plan. Our board of directors may elect to adopt such plans in the future if it determines that doing so is in our best interests. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Retirement Benefits </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We maintain a <span style="white-space:nowrap">tax-qualified</span> retirement plan that provides eligible U.S. employees, including our Named Executive Officers, with an opportunity to save for retirement on a <span style="white-space:nowrap">tax-advantaged</span> basis. Eligible employees may make voluntary contributions from their eligible pay, up to certain applicable annual limits set by the Code. The 401(k) plan is intended to be qualified under Section&#160;401(a) of the Code with the 401(k) plan&#8217;s related trust intended to be tax exempt under Section&#160;501(a) of the Code. We match our employee contributions in an amount equal to 100% of the first 3% of eligible compensation, and 50% of the next 2% of eligible compensation. All such employee contributions and matching contributions are immediately and fully vested. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Employment Arrangements with Our Named Executive Officers </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Jeffrey M. Goldberg </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to an offer letter dated November&#160;28, 2022, Mr.&#160;Goldberg served as our President and Chief Executive Officer until May&#160;16, 2023. Mr.&#160;Goldberg&#8217;s offer letter set forth the principal terms and conditions of his employment, including his initial annual base salary of $600,000, an annual target bonus opportunity of 50% of his base salary (which bonus is earned based on our achievement of specified milestones and performance objectives, as well as Mr.&#160;Goldberg&#8217;s performance relative to one or more performance objectives established by </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">102 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
our board of directors, the achievement of which is evaluated by our board of directors) and an annual housing allowance of $35,000. Mr.&#160;Goldberg&#8217;s offer letter provides for an option grant for the purchase of 1,884,838 shares of our Common Stock, which vests over a <span style="white-space:nowrap">48-month</span> period with 25% of the options vesting on the <span style="white-space:nowrap">one-year</span> anniversary of his employment as Chief Executive Officer and the remainder vesting in equal monthly installments thereafter, subject to Mr.&#160;Goldberg&#8217;s continued service to us on each monthly vesting date. Pursuant to the terms of his severance agreement, Mr.&#160;Goldberg received the severance benefits described in &#8220;<span style="font-style:italic">Termination or Change in Control Arrangements with Our Named Executive Officers</span>&#8221; below. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Jim Kastenmayer </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to an offer letter dated June&#160;8, 2021, Mr.&#160;Kastenmayer served as our General Counsel and Corporate Secretary until May&#160;16, 2023, and from August 2022 to November 2022, served as our Interim Chief Executive Officer. Mr.&#160;Kastenmayer&#8217;s offer letter set forth the principal terms and conditions of his employment, including his initial annual base salary of $365,000 and an annual target bonus opportunity of 40% of his base salary (which bonus is earned based on our achievement of specified financial performance objectives, as well as Mr.&#160;Kastenmayer&#8217;s performance relative to one or more performance objectives established by our board of directors, the achievement of which is evaluated by our board of directors). Mr.&#160;Kastenmayer&#8217;s offer letter provides for an option grant for the purchase of 130,000 shares of our Common Stock, which vests over a <span style="white-space:nowrap">48-month</span> period with 25% of the options vesting on the <span style="white-space:nowrap">one-year</span> anniversary of his employment as General Counsel and Corporate Secretary and the remainder vesting in equal monthly installments thereafter, subject to Mr.&#160;Kastenmayer&#8217;s continued service to us on each monthly vesting date. In connection with Mr.&#160;Kastenmayer&#8217;s appointment as Interim Chief Executive Officer, in August 2022, our board of directors approved certain adjustments to Mr.&#160;Kastenmayer&#8217;s compensation terms for such position, which included an increase in base salary to $588,000 and an increase in target bonus amount to 50%. The adjustments to Mr.&#160;Kastenmayer&#8217;s compensation in relation to his appointment as Interim Chief Executive Officer was prorated for time served. Pursuant to the terms of his severance agreement, Mr.&#160;Kastenmayer received the severance benefits described in &#8220;<span style="font-style:italic">Termination or Change in Control Arrangements with Our Named Executive Officers</span>&#8221; below. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Anthony G. Quinn, M.B Ch.B, Ph.D. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to an offer letter dated July&#160;18, 2018, Dr.&#160;Quinn served as our President and Chief Executive Officer until August&#160;24, 2022. Dr.&#160;Quinn&#8217;s offer letter set forth the principal terms and conditions of his employment, including his initial annual base salary of $507,000, an annual target bonus opportunity of 50% of his base salary (which bonus is earned based on our achievement of specified milestones and performance objectives, as well as Dr.&#160;Quinn&#8217;s performance relative to one or more performance objectives established by our board of directors, the achievement of which is evaluated by our board of directors). Dr.&#160;Quinn&#8217;s offer letter provides for (i)&#160;an option grant for the purchase of 300,000 shares of our Common Stock, which vests over a <span style="white-space:nowrap">48-month</span> period subject to Dr.&#160;Quinn&#8217;s continued service to us on each monthly vesting date, and (ii)&#160;three options to purchase an aggregate of 200,000 shares of our Common Stock, which will vest based on the achievement of certain performance objectives set by our board of directors. Pursuant to the terms of his severance agreement, Dr.&#160;Quinn received the severance benefits described in &#8220;<span style="font-style:italic">Termination or Change in Control Arrangements with Our Named Executive Officers</span>&#8221; below. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Jonathan Alspaugh </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to an offer letter dated June&#160;14, 2021, Mr.&#160;Alspaugh served as our Chief Financial Officer until August&#160;31, 2023. Mr.&#160;Alspaugh&#8217;s offer letter set forth the principal terms and conditions of his employment as Chief Financial Officer, including his annual base salary and an annual target bonus opportunity (which bonus is earned based on our achievement of specified milestones and performance objectives, as well as Mr.&#160;Alspaugh&#8217;s performance relative to one or more performance objectives established by our board of directors, the achievement of which is evaluated by our board of directors). Mr.&#160;Alspaugh&#8217;s base salary and annual bonus are </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">103 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
set forth in the &#8220;Summary Compensation Table&#8221; above. Mr.&#160;Alspaugh&#8217;s offer letter also provides for an additional option grant for the purchase of 160,000 shares of Common Stock, which vests over a <span style="white-space:nowrap">48-month</span> period subject to Mr.&#160;Alspaugh&#8217;s continued service to us on each monthly vesting date. Mr.&#160;Alspaugh is entitled to severance benefits described in &#8220;<span style="font-style:italic">Termination or Change in Control Arrangements with Our Named Executive Officers</span>&#8221; below. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Leslie Sloan, Ph.D. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to an offer letter dated March&#160;13, 2020, Dr.&#160;Sloan served as our Chief Operating Officer until January 2023. Dr.&#160;Sloan&#8217;s offer letter set forth the principal terms and conditions of her employment as Chief Operating Officer, including her annual base salary of $355,000 and an annual target bonus opportunity of 40% of her base salary (which bonus is earned based on our achievement of specified milestones and performance objectives, as well as Dr.&#160;Sloan&#8217;s performance relative to one or more performance objectives established by our board of directors, the achievement of which is evaluated by our board of directors). Dr.&#160;Sloan&#8217;s offer letter also provided for an additional option grant for the purchase of 108,000 shares of Common Stock, which vests over a <span style="white-space:nowrap">48-month</span> period subject to Dr.&#160;Sloan&#8217;s continued service to us on each monthly vesting date. Pursuant to the terms of her severance agreement, Dr.&#160;Sloan received the severance benefits described in &#8220;<span style="font-style:italic">Termination or Change in Control Arrangements with Our Named Executive Officers</span>&#8221; below. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Termination or Change in Control Arrangements with Our Named Executive Officers </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Jeffrey M. Goldberg </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Effective May&#160;16, 2023, Mr.&#160;Goldberg was terminated from his position as President and Chief Executive Officer. Pursuant to his severance agreement, entered into as of November&#160;29, 2022, Mr.&#160;Goldberg received the following benefits: (i)&#160;a severance payment equal to 12 months of his annual salary; (ii)&#160;a lump sum bonus payment equal to his annual target bonus; (iii)&#160;payment of COBRA premiums to maintain group healthcare coverage for 12 months; and (iv)&#160;acceleration of vesting of Mr.&#160;Goldberg&#8217;s outstanding option awards with respect to the number of shares that would have vested if Mr.&#160;Goldberg had remained in service through an additional 12 months beyond the date of his termination. In addition, in recognition of his service to the Company during our previously announced process of pursuing strategic alternatives, our board of directors approved an additional severance payment to Mr.&#160;Goldberg of $50,000. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Jim Kastenmayer </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Effective May&#160;16, 2023, Mr.&#160;Kastenmayer was terminated from his position as General Counsel. Pursuant to his severance agreement, entered into as of July&#160;6, 2021, Mr.&#160;Kastenmayer received the following benefits: (i)&#160;a severance payment equal to 12 months of his annual salary; (ii)&#160;a lump sum bonus payment equal to his annual target bonus; (iii)&#160;payment of COBRA premiums to maintain group healthcare coverage for 12 months; and (iv)&#160;acceleration of vesting of Mr.&#160;Kastenmayer&#8217;s outstanding option awards with respect to the number of shares that would have vested if Mr.&#160;Kastenmayer had remained in service through an additional 12 months beyond the date of his termination. In addition, in recognition of his service to the Company during our previously announced process of pursuing strategic alternatives, our board of directors approved an additional severance payment to Mr.&#160;Kastenmayer of $34,167. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Anthony G. Quinn, M.B Ch.B, Ph.D. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&#160;24, 2022, we entered into a certain transition and separation agreement with Dr.&#160;Quinn in connection with his departure as our President and Chief Executive Officer (the &#8220;Transition Agreement&#8221;). We also entered into a consulting agreement (the &#8220;Consulting Agreement&#8221;) with Dr.&#160;Quinn, pursuant to which Dr.&#160;Quinn agreed </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">104 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to serve as a <span style="white-space:nowrap">non-employee</span> consultant to us until September&#160;1, 2023 (such transition term end date, the &#8220;Consultancy End Date&#8221;). Subject to Dr.&#160;Quinn&#8217;s execution of a general release of claims, the terms of the Transition Agreement and the terms of the Consulting Agreement, Dr.&#160;Quinn will be entitled to receive the following benefits: (i)&#160;a severance payment of $882,000, equal to 18 months of his annual salary; (ii)&#160;a lump sum bonus payment of $294,000; and (iii)&#160;the amount of COBRA premiums he would be required to pay to maintain group healthcare coverage as in effect on September&#160;1, 2022 for 18 months. In exchange for providing consulting services to us through the Consultancy End Date, Dr.&#160;Quinn also will be entitled to receive the following benefits: (x)&#160;continued vesting in his outstanding option awards with respect to the number of shares that would have vested if Dr.&#160;Quinn had remained in service through the Consultancy End Date; and (y)&#160;acceleration of vesting of Dr.&#160;Quinn&#8217;s outstanding option awards with respect to the number of shares that would have vested if Dr.&#160;Quinn had remained in service through an additional 12 months beyond the Consultancy End Date. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Jonathan Alspaugh </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Effective August&#160;31, 2023, Mr.&#160;Alspaugh was terminated from his position as Chief Financial Officer. Pursuant to his separation and consulting agreement and general release of claims (the &#8220;Separation Agreement&#8221;), Mr.&#160;Alspaugh is entitled to receive the following benefits as consideration for his general release of claims in favor of us: (i)&#160;aggregate severance payments of $623,000 payable in installments over 12 months; (ii)&#160;fully subsidized COBRA coverage for up to 12 months; (iii)&#160;a lump sum bonus payment of $168,247; (iv) accelerated vesting of all stock options that were scheduled to vest during the <span style="white-space:nowrap">12-month</span> period following the last day on which Mr.&#160;Alspaugh provides consulting services to us; (v)&#160;extension of the post-termination exercise period of outstanding stock options to six months; and (vi)&#160;potential transaction bonuses in the event we consummate any sale, licensing, disposition or monetization transaction relating to pegtarviliase or any of our development-stage Legacy Pipeline assets prior to June&#160;23, 2024. The Separation Agreement provides that Mr.&#160;Alspaugh will provide consulting services to us through February&#160;29, 2024 (which consulting period may be extended by mutual agreement of the parties or may be earlier terminated by Mr.&#160;Alspaugh, by us for cause or as a result of Mr.&#160;Alspaugh&#8217;s death or disability). During the consulting period, Mr.&#160;Alspaugh will receive a consulting fee of $500 per hour and will continue to vest in any outstanding stock options. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Leslie Sloan, Ph.D. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&#160;5, 2023, Dr.&#160;Sloan resigned from her position as Chief Operating Officer. Pursuant to her severance agreement, entered into as of August&#160;7, 2019, Dr.&#160;Sloan received the following benefits: (i)&#160;a severance payment of $435,000, equal to 12 months of her annual salary; (ii)&#160;a lump sum bonus payment of $174,000; (iii) payment of COBRA premiums to maintain group healthcare coverage for 12 months; and (iv)&#160;acceleration of vesting of Dr.&#160;Sloan&#8217;s outstanding option awards with respect to the number of shares that would have vested if Dr.&#160;Sloan had remained in service through an additional 12 months beyond the date of her termination. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">105 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Director Compensation </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table provides information for the fiscal year ended December&#160;31, 2022 regarding all compensation awarded to, earned by or paid to each person who served as a <span style="white-space:nowrap">non-employee</span> director for some portion of 2022. Mr.&#160;Goldberg, our former President and Chief Executive Officer, received compensation solely as an employee of Spyre in 2022. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:65%"></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-weight:bold">Name</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Fees<br />Earned<br />or Paid<br />in&#160;Cash<br />($)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Option<br />Awards<br />($) (1)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Total<br />($)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alison Lawton</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">50,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">21,268</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">71,268</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Armen Shanafelt, Ph.D. (2)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">45,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">21,268</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">66,268</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hunter C. Smith</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">58,167</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">21,268</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">79,435</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ivana Magovcevic-Liebisch, Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">57,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">21,268</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">78,768</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marcio Souza (2)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">51,847</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">21,268</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">73,115</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Russell J. Cox</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">90,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">21,268</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">111,268</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">V. Bryan Lawlis, Ph.D. (2)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">50,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">21,268</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">71,268</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sandesh Mahatme (3)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">24,556</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">21,268</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">45,824</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sarah Brownstein (4)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,875</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,875</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The amounts reported in this column represent the aggregate grant date fair value of the awards granted to our <span style="white-space:nowrap">non-employee</span> directors during the year ended December&#160;31, 2022, as computed in accordance with ASC 718. The assumptions used in calculating the grant date fair value of the awards reported in the Option Awards column are set forth in Note 10 to our 2022 Annual Financials included elsewhere in this prospectus. Note that the amounts reported in this column reflect the aggregate accounting cost for these awards, and do not necessarily correspond to the actual economic value that may be received by the <span style="white-space:nowrap">non-employee</span> directors from the awards. For information regarding the number of stock options and restricted common stock held by each <span style="white-space:nowrap">non-employee</span> director as of December&#160;31, 2022, see the table below. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Dr.&#160;Shanafelt, Mr.&#160;Souza and Dr.&#160;Lawlis each resigned from our board of directors in June 2023. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Mr.&#160;Mahatme resigned from our board of directors in July 2022. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(4)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Ms.&#160;Brownstein resigned from our board of directors in February 2022. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2022, our <span style="white-space:nowrap">non-employee</span> directors held the following number of outstanding stock options. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">


<tr>

<td style="width:85%"></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-weight:bold">Name</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Option<br />Awards<br />(#)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alison Lawton</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">130,200</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hunter C. Smith</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">103,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ivana Magovcevic-Liebisch, Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">160,300</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael Henderson, M.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Peter Harwin</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Russell J. Cox</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">205,709</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tomas Kiselak</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="white-space:nowrap">Non-Employee</span> Director Compensation Arrangements </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our <span style="white-space:nowrap">non-employee</span> directors received the following compensation pursuant to a program adopted by our board of directors: </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Cash Compensation.</span> The program provides an annual cash retainer of $40,000 to each of our <span style="white-space:nowrap">non-employee</span> directors and an additional $35,000 to the chair of the board. The chair of our audit committee, compensation committee and nominating and corporate governance committee receives annual retainers of $20,000, $15,000 </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">106 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and $10,000, respectively. Each <span style="white-space:nowrap">non-chairperson</span> member of our audit committee, compensation committee and nominating and corporate governance committee receives an annual cash retainer of $10,000, $7,500 and $5,000, respectively. We do not pay fees to directors for attendance at meetings of our board of directors and its committees. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Equity Compensation.</span> Each new, <span style="white-space:nowrap">non-employee</span> director who joins our board of directors will receive an initial option grant for the purchase of 65,000 shares of our Common Stock upon election to our board of directors. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On the date of each annual meeting of stockholders, each <span style="white-space:nowrap">non-employee</span> director who continues to serve on our board of directors immediately following such meeting will receive an option grant for the purchase of 43,000 shares of our Common Stock, or such other amount as determined by our board of directors. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Equity awards for new directors will vest in equal monthly installments for three years after the grant date if the director has served continuously as a member of our board of directors through the applicable vesting date. Annual equity grants for directors will vest in equal monthly installments for one year after the grant date if the director has served continuously as a member of our board of directors through the applicable vesting date. In addition, equity awards for <span style="white-space:nowrap">non-employee</span> directors will vest in full in the event that we are subject to a change in control or upon certain other events. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">Non-employee</span> directors receive no other form of remuneration, perquisites or benefits, but are reimbursed for their reasonable travel expenses incurred in attending board and committee meetings. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="white-space:nowrap">Pay-Versus-Performance</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our compensation committee approves and administers our executive compensation program to align executive compensation with stockholder interests by linking pay to performance. Our overall compensation program includes a mix of short-term and long-term components through our annual incentive plan and equity awards. During fiscal year 2022, there was a change to our executive management team when our tenured Chief Executive Officer, Dr.&#160;Quinn (&#8220;PEO 2&#8221;) resigned on August&#160;23, 2022 and transitioned to an advisory role. Upon this transition, Mr.&#160;Kastenmayer (&#8220;PEO 3&#8221;) was appointed our interim Chief Executive Officer until Mr.&#160;Goldberg (&#8220;PEO 1&#8221;) was appointed on November&#160;29, 2022. We provide the compensation actually paid during fiscal year 2022 for all three individuals providing service as Chief Executive Officer during fiscal year 2022 in the following tables. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As required by Item 402(v) of Regulation <span style="white-space:nowrap">S-K,</span> we are providing the following information about the relationship between the compensation actually paid to our Named Executive Officers and certain aspects of our financial performance. We are a smaller reporting company pursuant to Rule 405 of the Securities Act and, as such, are only required to include information for the past two fiscal years in the table below. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><span style="white-space:nowrap">Pay-Versus-Performance</span> Table </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:19%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman;font-weight:bold">Year</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman;font-weight:bold">(a)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Summary<br />Compensation<br />Table Total<br />for PEO 1<br />(b) (1)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Compensation<br />Actually Paid<br />to PEO 1<br />(c) (2)(5)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Summary<br />Compensation<br />Table Total<br />for PEO 2<br />(b) (1)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Compensation<br />Actually Paid<br />to PEO 2<br />(c) (2)(5)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Summary<br />Compensation<br />Table Total<br />for PEO 3<br />(b) (1)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Compensation<br />Actually Paid<br />to PEO 3<br />(c) (2)(5)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Average<br />Summary<br />Compensation<br />Table Total<br />for <span style="white-space:nowrap">Non-PEO</span><br />NEOs<br />(d) (3)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Average<br />Compensation<br />Actually Paid<br />to <span style="white-space:nowrap">Non-PEO</span><br />NEOs<br />(e) (4)(5)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Total<br />Stockholder<br />Return<br />Based<br />on Initial<br />Fixed $100<br />Investment<br />(f) (6)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Net<br />Income<br />(in<br />thousands)<br />(g) (7)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman;font-weight:bold">2022</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,832,485</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">564,676</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,392,254</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">431,085</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">865,785</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">318,380</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,049,862</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">202,299</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">($</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">83,815</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman;font-weight:bold">2021</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">N/A</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">N/A</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,623,186</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">361,504</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">N/A</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">N/A</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,365,778</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">712,689</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">62</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">($</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">65,801</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The dollar amounts reported in column (b)&#160;represent the amount of total compensation reported for Mr.&#160;Goldberg, Dr.&#160;Quinn and Mr.&#160;Kastenmayer (collectively, our &#8220;PEOs&#8221;) for each covered fiscal year in the &#8220;Total&#8221; column of the Summary Compensation Table for each applicable year. Please refer to &#8220;<span style="font-style:italic">Executive Compensation &#8211; Summary Compensation Table&#8221;</span> above. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">107 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The dollar amounts reported in column (c)&#160;represent the amount of &#8220;compensation actually paid&#8221; to our PEOs, as computed in accordance with Item 402(v) of Regulation <span style="white-space:nowrap">S-K,</span> for each covered fiscal year. The dollar amounts do not reflect the actual amount of compensation earned or received by or paid to the PEOs during the applicable fiscal year. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">a.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The equity award adjustments for each covered fiscal year include the addition (or subtraction, as applicable) of the following: (i)&#160;the <span style="white-space:nowrap">year-end</span> fair value of all equity awards granted during the covered fiscal year that are outstanding and unvested as of the end of the covered fiscal year; (ii)&#160;the amount equal to the change as of the end of the covered fiscal year (from the end of the prior fiscal year) in fair value of any equity awards granted in any prior fiscal year that are outstanding and unvested as of the end of the covered fiscal year; (iii)&#160;for equity awards that are granted and vest in same covered fiscal year, the fair value as of the vesting date; (iv)&#160;for equity awards granted in any prior fiscal year for which all applicable vesting conditions were satisfied at the end of or during the covered fiscal year, the amount equal to the change as of the vesting date (from the end of the prior fiscal year) in fair value; (v)&#160;for equity awards granted in any prior fiscal year that fail to meet the applicable vesting conditions during the covered fiscal year, the amount equal to the fair value at the end of the prior fiscal year; and (vi)&#160;the dollar value of any dividends or other earnings paid on stock or option awards in the covered fiscal year prior to the vesting date that are not otherwise included in the total compensation for the covered fiscal year. </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:47%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="4" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">PEO 1</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">PEO 2</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="4" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">PEO 3</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2021</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2022</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2021</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2022</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2021</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2022</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Summary Compensation Table &#8211; Total Compensation</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(a)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">N/A</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,832,485</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,623,186</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,392,254</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">N/A</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">865,785</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- Grant Date Fair Value of Option Awards Granted in Fiscal Year</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(b)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">N/A</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,774,952</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,701,525</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">779,625</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">N/A</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">253,948</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">+ Fair Value at Fiscal <span style="white-space:nowrap">Year-End</span> of Outstanding and Unvested Stock Awards and Option Awards Granted in Fiscal Year</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(c)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">N/A</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">507,143</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">706,475</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">58,188</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">N/A</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">48,564</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">+ Change in Fair Value of Outstanding and Unvested Stock Awards and Option Awards Granted in Prior Fiscal Years</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(d)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">N/A</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">($</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,323,528</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">($</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">794,439</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">N/A</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">($</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">238,617</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">+ Fair Value at Vesting of Stock Awards and Option Awards Granted in Fiscal Year that Vested During Fiscal Year</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(e)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">N/A</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">299,983</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">36,311</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">N/A</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13,519</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">+ Change in Fair Value as of Vesting Date of Stock Awards and Option Awards Granted in Prior Fiscal Years For Which Applicable Vesting Conditions Were Satisfied During Fiscal Year</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(f)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">N/A</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">($</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">243,087</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">($</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">481,604</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">N/A</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">($</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">116,923</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- Fiscal Value as of Prior Fiscal <span style="white-space:nowrap">Year-End</span> of Stock Awards and Option Awards Granted in Prior Fiscal Years that Failed to Meet Applicable Vesting Conditions During Fiscal Year</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(g)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">N/A</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">N/A</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">= Compensation Actually Paid</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">N/A</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">564,676</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">361,504</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">431,085</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">N/A</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">318,380</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">108 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The dollar amounts reported in column (d)&#160;represent the average of the amounts of total compensation reported for our NEOs as a group (excluding our PEOs) for each covered fiscal year in the &#8220;Total&#8221; column of the Summary Compensation Table for each applicable year. The names of each NEO (excluding our PEOs) included for purposes of calculating the average amounts of total compensation in each covered fiscal year are as follows: </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">a.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">For fiscal year 2022, Jonathan Alspaugh (our former Chief Financial Officer) and Leslie Sloan (our former Chief Operating Officer); and </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">b.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">For fiscal year 2021, Michael Hanley (our former Chief Business Officer) and Leslie Sloan (our former Chief Operating Officer). </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(4)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The dollar amounts reported in column (e)&#160;represent the average amount of &#8220;compensation actually paid&#8221; to our NEOs as a group (excluding our PEOs), as computed in accordance with Item 402(v) of Regulation <span style="white-space:nowrap">S-K</span> for each covered fiscal year. The dollar amounts do not reflect the actual average amount of compensation earned or received by or paid to our NEOs as a group (excluding our PEOs) during the applicable fiscal year. In accordance with the requirements of Item 402(v) of Regulation <span style="white-space:nowrap">S-K,</span> the following adjustments were made to the average total compensation for each covered fiscal year to determine the &#8220;compensation actually paid&#8221; to our NEOs as a group (excluding our PEOs) for such fiscal year, using the methodology described in Note 2 above: </p></td></tr></table> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><span style="white-space:nowrap">Non-PEO</span> NEO Average </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:73%"></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2021</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2022</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Summary Compensation Table &#8211; Total Compensation</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(a</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,365,778</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,049,862</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- Grant Date Fair Value of Option Awards Granted in Fiscal Year</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(b</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">763,599</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">454,423</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">+ Fair Value at Fiscal <span style="white-space:nowrap">Year-End</span> of Outstanding and Unvested Stock Awards and Option Awards Granted in Fiscal Year</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(c</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">315,773</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">61,231</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">+ Change in Fair Value of Outstanding and Unvested Stock Awards and Option Awards Granted in Prior Fiscal Years</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(d</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">($</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">287,121</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">($</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">318,632</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">+ Fair Value at Vesting of Stock Awards and Option Awards Granted in Fiscal Year that Vested During Fiscal Year</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(e</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">134,082</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">22,857</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">+ Change in Fair Value as of Vesting Date of Stock Awards and Option Awards Granted in Prior Fiscal Years for which Applicable Vesting Conditions were Satisfied During Fiscal Year</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(f</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">($</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">52,224</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">($</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">158,597</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- Fair Value as of Prior Fiscal <span style="white-space:nowrap">Year-End</span> of Stock Awards and Option Awards Granted in Prior Fiscal Years that Failed to Meet Applicable Vesting Conditions During Fiscal Year</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(g</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">= Compensation Actually Paid</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">712,689</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">202,299</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(5)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Stock option grant date fair values are calculated based on the Black-Scholes option pricing model as of date of grant. The valuation assumptions used to calculate the fair values of the stock options held by our PEOs and other NEOs on average that vested during or were outstanding as of the end of each covered fiscal year materially differed from those valuation assumptions disclosed at the time of grant primarily based on the differing option value assumptions: fiscal year 2021 <span style="white-space:nowrap">year-end</span> calculations were based on an expected life range of 3.1 to 6.51, volatility of 77.8% to 81.2%, and risk-free rate of 1.0% to 1.4%; fiscal year 2022 <span style="white-space:nowrap">year-end</span> calculations were based on an expected life of 3.1 to 6.91, volatility of 77.8% to 88.6%, and risk-free rate of 3.9% to 4.2%. More tenured executives (Dr.&#160;Quinn, Ms.&#160;Sloan and Mr.&#160;Hanley) had significant decreases in year-over-year stock option valuations while compensation of more recently hired executives (Mr.&#160;Goldberg, Mr.&#160;Kastenmayer and Mr.&#160;Alspaugh) had less dynamic changes. Performance-based options used a different Monte Carlo valuation at fiscal year 2021 and fiscal year 2022 year-ends than the grant date valuation based on updated probability of achievement. Performance-based RSU award grant date fair values are calculated using the stock price as of date of grant assuming target performance. The performance-based RSU awards held by Dr.&#160;Quinn, Ms.&#160;Sloan and Mr.&#160;Hanley that were outstanding as of the end of each covered fiscal year were deemed to have a de minimis chance of approval and are included as unachieved. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">109 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(6)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Cumulative total stockholder return (&#8220;TSR&#8221;) is calculated by dividing the sum of the cumulative amount of dividends during the measurement period, assuming dividend reinvestment, and the difference between our stock price at the end of the applicable measurement period and the beginning of the measurement period (December 31, 2020) by our stock price at the beginning of the measurement period. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(7)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The dollar amounts reported represent the amount of net income (loss) reflected in our audited financial statements for each covered fiscal year. </p></td></tr></table> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Analysis of Information Presented in the Pay Versus Performance Table </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In accordance with Item 402(v) of Regulation <span style="white-space:nowrap">S-K,</span> we are providing the following descriptions of the relationships between information presented in the Pay Versus Performance table above. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><span style="text-decoration:underline">Compensation Actually Paid and Company TSR </span></span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g518298g01q73.jpg" alt="LOGO" />
 </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">110 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><span style="text-decoration:underline">Compensation Actually Paid and Net Income </span></span></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following graph displays our compensation actually paid compared to our net income. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g518298g94u77.jpg" alt="LOGO" />
 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All information provided above under the <span style="white-space:nowrap">&#8220;Pay-Versus-Performance&#8221;</span> heading will not be deemed to be incorporated by reference into any of our filings under the Securities Act or the Exchange Act, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing, except to the extent we specifically incorporates such information by reference. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">111 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx518298_13">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth information, to the extent known by us or ascertainable from public filings, with respect to the beneficial ownership of our Common Stock as of December&#160;11, 2023 by: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">each of our directors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">each of our named executive officers; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">all of our directors and executive officers as a group; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">each person, or group of affiliated persons, who is known by us to beneficially owner of greater than 5.0% of our Common Stock. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The column entitled &#8220;Shares Beneficially Owned&#8221; is based on a total of 36,021,007 shares of our Common Stock outstanding as of December&#160;11, 2023. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Beneficial ownership is determined in accordance with the rules and regulations of the SEC and includes voting or investment power with respect to our Common Stock. Shares of our Common Stock subject to options that are currently exercisable or exercisable within 60 days of December&#160;11, 2023 are considered outstanding and beneficially owned by the person holding the options for the purpose of calculating the percentage ownership of that person but not for the purpose of calculating the percentage ownership of any other person. Due to the conversion limitations on the Series A Preferred Stock and Series B Preferred Stock, shares of underlying Common Stock have been excluded from beneficial ownership set forth below. Except as otherwise noted, the persons and entities in this table have sole voting and investing power with respect to all of the shares of our Common Stock beneficially owned by them, subject to community property laws, where applicable. Except as otherwise indicated in the table below, addresses of named beneficial owners are in care of Spyre Therapeutics, Inc., 221 Crescent Street, Building 23, Suite 105, Waltham, MA 02453. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:72%"></td>

<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Shares&#160;beneficially&#160;owned</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<td style="vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Name and address of beneficial owner</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Percentage</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><span style="font-weight:bold"></span><span style="font-weight:bold"><span style="font-style:italic">5% Stockholders:</span></span><span style="font-weight:bold"></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Entities associated with Fairmount Funds Management<br />LLC (1)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,813,901</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10.6</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Entities associated with FMR LLC (Fidelity) (2)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,734,826</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10.4</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Perceptive Life Sciences Master Fund, Ltd. (3)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,606,679</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7.2</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Entities associated with Venrock Healthcare Capital<br />Partners (4)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,372,714</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6.6</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Entities associated with RTW Investments, LP (5)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,232,760</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6.2</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Deep Track Biotechnology Master Fund, Ltd. (6)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,952,760</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5.4</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Commodore Capital Master LP (7)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,834,084</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5.1</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><span style="font-weight:bold"></span><span style="font-weight:bold"><span style="font-style:italic">Named Executive Officers and Directors:</span></span><span style="font-weight:bold"></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Jonathan Alspaugh (8)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">307,645</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Jeffrey M. Goldberg</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Jim Kastenmayer</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Anthony G. Quinn, M.B Ch.B, Ph.D. (9)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">66,367</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Leslie Sloan, Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Russell J. Cox (10)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">54,008</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Jeffrey W. Albers (11)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">37,137</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Laurie Stelzer (12)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,777</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Alison Lawton (13)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">50,708</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Peter Harwin (1)(14)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,859,401</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10.7</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Tomas Kiselak (1)(15)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,859,401</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10.7</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Michael Henderson, M.D. (16)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">45,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Cameron Turtle, DPhil (17)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,022,407</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2.8</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">All current executive officers and directors as a group<br />(10 persons) (18)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,117,438</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14.2</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">*</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents beneficial ownership of less than one percent. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">112 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Based on our records and on a Schedule 13D/A filed by Fairmount Funds Management LLC (&#8220;Fairmount&#8221;) on December&#160;11, 2023 with the SEC. Represents shares of Common Stock held by Fairmount Healthcare Fund LP (&#8220;Fairmount I&#8221;), Fairmount Healthcare Fund II LP (&#8220;Fairmount II&#8221;) and Fairmount Healthcare <span style="white-space:nowrap">Co-Invest</span> LP (together with Fairmount I and Fairmount II, the &#8220;Fairmount Funds&#8221;), which may be deemed to be indirectly beneficially owned by Fairmount. Fairmount serves as investment manager for each of the Fairmount Funds and may be deemed a beneficial owner of any of our securities of held by each of the Fairmount Funds. The general partner of Fairmount is Fairmount Funds Management GP LLC (&#8220;Fairmount GP&#8221;). As managing members of Fairmount GP, Peter Harwin and Tomas Kiselak may be deemed beneficial owners of any of our securities beneficially owned by Fairmount. The address of Fairmount is 200 Barr Harbor Drive, Suite 400, West Conshohocken, PA 19428. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Based on our records and on information provided by FMR LLC as of December&#160;14, 2023. Represents shares of Common Stock held by Fidelity Select Portfolios: Pharmaceuticals Portfolio, Fidelity Select Portfolios: Biotechnology Portfolio, Fidelity Advisor Series VII: Fidelity Advisor Biotechnology Fund, Fidelity Mt. Vernon Street Trust: Fidelity Series Growth Company Fund, Fidelity Mt. Vernon Street Trust: Fidelity Growth Company Fund, Fidelity Growth Company Commingled Pool, and Fidelity Mt. Vernon Street Trust: Fidelity Growth Company K6 Fund. These funds and accounts are managed by direct or indirect subsidiaries of FMR LLC. Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders&#8217; voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders&#8217; voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. The address of these funds and accounts is 245 Summer Street, Boston, MA 02210. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Based on our records and on information provided by Perceptive Life Sciences Master Fund, Ltd (&#8220;Perceptive Fund&#8221;) as of December&#160;14, 2023. Represents shares of Common Stock held by Perceptive Fund. The address of Perceptive Fund is 51 Astor Place, 10th Floor, New York, NY 10003. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(4)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Based on our records and on information provided byVenrock Healthcare Capital Partners III, LP (&#8220;VHCP III&#8221;) as of December 12, 2023. Represents shares of Common Stock held by VHCP III, VHCP III Co-Investment Holdings III, LLC (&#8220;VHCP III Co&#8221;) and Venrock Healthcare Capital Partners EG, L.P. (&#8220;VHCP EG&#8221;). VHCP Management III, LLC (&#8220;VHCPM&#8221;) is the sole general partner of VHCP III and the sole manager of VHCP III Co. VHCP Management EG, LLC (&#8220;VHCPM EG&#8221;) is the sole general partner of VHCP EG. Dr. Bong Koh and Nimish Shah are the voting members of VHCPM and VHCPM EG. The address of each of these persons and entities is 7 Bryant Park, 23rd Floor, New York, NY 10018. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(5)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Based on our records and on information provided by RTW Investments, LP (&#8220;RTW Investments&#8221;) as of December 13, 2023. Represents shares of Common Stock held by RTW Investments. The address of RTW Investments is 40 10th Avenue, Floor 7, New York, NY 10014. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(6)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Based on our records and on information provided by Deep Track Biotechnology Master Fund, Ltd. (&#8220;Deep Track&#8221;) as of December&#160;13, 2023. Represents shares of Common Stock held by Deep Track. David Kroin is the voting member of Deep Track. The address of person and entity is 200 Greenwich Avenue, 3rd Floor, Greenwich, CT 06830. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(7)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Based on records and on information provided by Commodore Capital Master LP (&#8220;Commodore Capital&#8221;) as of December&#160;14, 2023. Represents shares of Common Stock held by Commodore Capital. Commodore Capital LP is the investment manager to Commodore Capital and may be deemed to beneficially own the shares held by Commodore Capital. Michael Kramarz and Robert Egen Atkinson are the managing partners of Commodore Capital LP and exercise investment discretion with respect to these shares. The address of Commodore Capital LP and Commodore Capital Master LP is 444 Madison Avenue, 35th Floor, New York, NY 10022. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(8)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents (i) 7,254 shares of Common Stock held by Mr.&#160;Alspaugh and (ii)&#160;options exercisable for 300,391 shares of Common Stock within 60 days of December&#160;11, 2023. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">113 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(9)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents (i) 489 shares of Common Stock held by Dr.&#160;Quinn and (ii)&#160;options exercisable for 66,367 shares of Common Stock within 60 days of December&#160;11, 2023. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(10)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents (i) 280 shares of Common Stock held by Mr.&#160;Cox and (ii)&#160;options exercisable for 53,728 shares of Common Stock within 60 days of December&#160;11, 2023. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(11)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents (i) 34,360 shares of Common Stock held by Sessions LLC, , which may be deemed to be indirectly beneficially owned by Mr.&#160;Albers, and (ii)&#160;options exercisable for 2,777 shares of Common Stock within 60 days of December&#160;11, 2023. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(12)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents options exercisable for 2,777 shares of Common Stock within 60 days of December&#160;11, 2023. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(13)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents options exercisable for 50,708 shares of Common Stock within 60 days of December&#160;11, 2023. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(14)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents (i) 3,813,901 shares held by the Fairmount Funds that may be deemed to be beneficially owned by Mr.&#160;Harwin and (ii)&#160;options exercisable for 45,500 shares of Common Stock within 60 days of December&#160;11, 2023. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(15)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents (i) 3,813,901 shares held by the Fairmount Funds that may be deemed to be beneficially owned by Mr.&#160;Kiselak and (ii)&#160;options exercisable for 45,500 shares of Common Stock within 60 days of December&#160;11, 2023. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(16)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents options exercisable for 45,500 shares of Common Stock within 60 days of December&#160;11, 2023. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(17)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents (i) 746,507 shares of Common Stock held by Dr.&#160;Turtle and (ii)&#160;options exercisable for 275,900 shares of Common Stock within 60 days of December&#160;11, 2023. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(18)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents (i) 4,595,048 shares of Common Stock and (ii)&#160;options exercisable for 522,390 shares of Common Stock within 60 days of December&#160;11, 2023. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">114 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx518298_14">CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As discussed in the &#8220;Related Party Transactions&#8221; section of our 2023 Annual Proxy, below we describe the transactions to which we were a party since January&#160;1, 2021, in which the amount involved exceeded the lesser of $120,000 and 1% of the average of our total assets at <span style="white-space:nowrap">year-end</span> for the prior two completed fiscal years and in which our directors, executive officers, former directors, former executive officers, director nominees and holders of more than 5% of our Common Stock, or other persons as may be required to be disclosed pursuant to Item 404 of Regulation <span style="white-space:nowrap">S-K,</span> had a direct or indirect material interest: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">On May&#160;5, 2022, we entered into a placement agent agreement with JonesTrading Institutional Services LLC, as placement agent, relating to a registered direct offering of an aggregate of 430,107 shares of our Common Stock at a public purchase price of $40.00 per share and <span style="white-space:nowrap">pre-funded</span> warrants to purchase up to 694,892 shares of our Common Stock at a public purchase price of $39.99 per <span style="white-space:nowrap">pre-funded</span> warrant with an exercise price of $0.0025 per share. This registered direct offering closed on May&#160;9, 2022. Pursuant to this offering, on the closing date: </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">i.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Baker Brothers Life Sciences, L.P. and 667, L.P. (together, the &#8220;Baker Funds&#8221;) purchased 251,351 and 29,898 <span style="white-space:nowrap">pre-funded</span> warrants to purchase Common Stock, respectively, for an aggregate purchase price of approximately $11.2&#160;million; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">ii.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Averill Master Fund, Ltd., an entity affiliated with Suvretta, purchased 250,000 <span style="white-space:nowrap">pre-funded</span> warrants to purchase Common Stock for an aggregate purchase price of approximately $10.0&#160;million; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">iii.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Entities affiliated with Nantahala purchased 132,071 <span style="white-space:nowrap">pre-funded</span> warrants to purchase Common Stock for an aggregate purchase price of approximately $5.3&#160;million. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">On March&#160;16, 2021, we entered into a registration rights agreement (the &#8220;Baker RRA&#8221;) with the Baker Funds, pursuant to which the Baker Funds are entitled to certain resale registration rights with respect to shares of our Common Stock held by the Baker Funds (the &#8220;Baker Registrable Securities&#8221;). Under the Baker RRA, following a request by the Baker Funds, we are obligated to file a resale registration statement on Form <span style="white-space:nowrap">S-3,</span> or other appropriate form, covering Baker Registrable Securities. Under the Baker RRA, the Baker Funds also have the right to up to two underwritten public offerings or block trades per calendar year, but no more than three underwritten public offerings and eight block trades in total, to effect the sale or distribution of their Baker Registrable Securities, subject to specified exceptions, conditions and limitations. The Baker RRA also includes customary indemnification obligations in connection with registrations conducted pursuant to the Baker RRA. The rights of the Baker Funds under the Baker RRA terminate automatically upon the earlier to occur of the following events: (i)&#160;all Baker Registrable Securities covered by the Baker RRA have been sold pursuant to an effective registration statement; (ii)&#160;all Baker Registrable Securities covered by the Baker RRA have been sold pursuant to Rule 144 under the Securities Act (&#8220;Rule 144&#8221;), or other similar rule; (iii)&#160;at any time after the Baker Funds are no longer our affiliate, all Baker Registrable Securities covered by the Baker RRA may be resold by the Baker Funds without limitations as to volume or manner of sale pursuant to Rule 144; or (iv)&#160;ten (10) years after the date of the Baker RRA. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, other than the executive officer and director compensation arrangements discussed above under &#8220;Executive Compensation,&#8221; below we describe the transactions to which we were a party since the date of our 2023 Annual Proxy, in which the amount involved exceeded the lesser of $120,000 and 1% of the average of our total assets at <span style="white-space:nowrap">year-end</span> for the prior two completed fiscal years and in which our directors, executive officers, former directors, former executive officers, director nominees and holders of more than 5% of our Common Stock, or other persons as may be required to be disclosed pursuant to Item 404 of Regulation <span style="white-space:nowrap">S-K,</span> had a direct or indirect material interest. </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">In connection with the Asset Acquisition, we assumed the rights and obligations of <span style="white-space:nowrap">Pre-Merger</span> Spyre under the Paragon Agreement. Under the Paragon Agreement, we are obligated to compensate Paragon on a quarterly basis for its services performed under each research program based on the actual costs incurred with <span style="white-space:nowrap">mark-up</span> costs pursuant to the terms of the Paragon Agreement. As of the date of the Asset Acquisition, </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">115 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
<span style="white-space:nowrap">Pre-Merger</span> Spyre had incurred total expenses of $19.0&#160;million under the Paragon Agreement since inception, inclusive of a $3.0&#160;million research initiation fee that was due upon signing of the Paragon Agreement and $16.0&#160;million of reimbursable expenses under the Paragon Agreement for historical costs incurred by Paragon. As of the acquisition date, $19.0&#160;million was unpaid and was assumed by us through the Asset Acquisition. Furthermore, following our amendment and restatement of the Paragon Agreement on September&#160;29, 2023, we are obligated to provide certain equity grants to Parapyre pursuant to the Parapyre Option Obligation. For additional detail regarding our arrangements with Paragon and Parapyre, see the sections titled &#8220;<span style="font-style:italic">Paragon Agreement</span>&#8221; and &#8220;<span style="font-style:italic">Our Relationship with Paragon and Parapyre</span>.&#8221; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">In July 2023 and December 2023, we exercised our option available under the Paragon Agreement with respect to the SPY001 and SPY002 research programs, respectively, and expect to enter into the SPY001 License Agreement and the SPY002 License Agreement. Our option available under the Paragon Agreement with respect to the SPY003 and SPY004 programs remains unexercised. Following the execution of each of the SPY001 License Agreement and SPY002 License Agreement, we expect to be obligated to pay Paragon up to $22.0&#160;million upon the achievement of specific development and clinical milestones for the first product under each of the SPY001 License Agreement and SPY002 License Agreement, respectively, that achieves such specified milestones. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">In connection with the June 2023 Transactions, we issued to Fairmount (i) 378,421 shares of Common Stock and 265,263 shares of Series A Preferred Stock in exchange for shares of <span style="white-space:nowrap">Pre-Merger</span> Spyre based on a fixed exchange ratio of 0.5494488 to 1 pursuant to the Asset Acquisition and (ii) 257,661 shares of Series A Preferred Stock at a price of $291.08 per share pursuant to the June 2023 PIPE. On June&#160;22, 2023, we also entered into a registration rights agreement (the &#8220;June 2023 RRA&#8221;) with the June 2023 Investors, including Fairmount, pursuant to which the June 2023 Investors are entitled to certain resale registration rights with respect to shares of our Common Stock held by such investors. For additional detail regarding the June 2023 Transactions, see &#8220;<span style="font-style:italic">Prospectus Summary &#8211; Recent Developments.</span>&#8221; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">In connection with the December 2023 PIPE, we issued to Fairmount 16,667 shares of Series B Preferred Stock at a price of $600.00 per share. On December&#160;7, 2023, we also entered into the December 2023 RRA with the December 2023 Investors, including Fairmount, pursuant to which the December 2023 Investors are entitled to certain resale registration rights with respect to shares of our Common Stock held by such investors. For additional detail regarding the December 2023 PIPE and the December 2023 RRA, see &#8220;<span style="font-style:italic">Prospectus Summary &#8211; Recent Developments</span>&#8221; and &#8220;<span style="font-style:italic">Risk Factors&#8212;Future sales of shares by existing stockholders could cause our stock price to decline</span>,&#8221; respectively. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Review, Approval or Ratification of Transactions with Related Parties </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our board of directors has adopted a written related person transactions policy. Under this policy, our executive officers, directors, nominees for election as a director, beneficial owners of more than 5% of our Common Stock, and any members of the immediate family of and any entity affiliated with any of the foregoing persons, are not permitted to enter into a material related person transaction with us without the review and approval of our audit committee, or a committee composed solely of independent directors in the event it is inappropriate for our audit committee to review such transaction due to a conflict of interest. The policy provides that any request for us to enter into a transaction with an executive officer, director, nominee for election as a director, beneficial owner of more than 5% of our Common Stock or with any of their immediate family members or affiliates in which the amount involved exceeds $120,000, or 1% of the average of our total assets at <span style="white-space:nowrap">year-end</span> for the prior two completed fiscal years, will be presented to our audit committee for review, consideration and approval. In approving or rejecting any such proposal, our audit committee will consider the relevant facts and circumstances available and deemed relevant to the audit committee, including, but not limited to, whether the transaction is on terms no less favorable than terms generally available to an unaffiliated third party under the same or similar circumstances and the extent of the related person&#8217;s interest in the transaction. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">116 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx518298_15">SELLING STOCKHOLDERS </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus covers the resale or other disposition from time to time by the Selling Stockholders identified in the table below of up to an aggregate of 12,000,000 shares of our Common Stock. The Selling Stockholders may from time to time offer and sell any or all of the Resale Shares set forth below pursuant to this prospectus and any accompanying prospectus supplement. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&#160;7, 2023, we entered into the December 2023 SPA, pursuant to which we sold an aggregate of 6,000,000 shares of our Common Stock and 150,000 shares of our Series B Preferred Stock, which will automatically convert into 40 shares of Common Stock, subject to stockholder approval and certain beneficial ownership limitations set by each holder, pursuant to the Series B Certificate of Designation, at an aggregate purchase price of $180&#160;million. This prospectus covers the resale or other disposition by the Selling Stockholders or their pledgees, donees, transferees or other <span style="white-space:nowrap"><span style="white-space:nowrap">successors-in-interest</span></span> that receive their shares after the date of this prospectus of up to the total number of shares of Common Stock and shares of Common Stock issuable upon the conversion of the Series B Preferred Stock sold to the Selling Stockholders pursuant to the December 2023 SPA. This prospectus covers the resale or other disposition by the Selling Stockholders or their transferees of up to the total number of Private Placement Common Shares and Private Placement Conversion Shares issued to the Selling Stockholders upon conversion of the Private Placement Preferred Shares issued pursuant to the December 2023 SPA. Throughout this prospectus, when we refer to the &#8220;Selling Stockholders,&#8221; we are referring to the purchasers under the December 2023 SPA listed in the table below. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are registering the Resale Shares to permit the Selling Stockholders and their pledgees, donees, transferees or other <span style="white-space:nowrap">successors-in</span> interest that receive their shares after the date of this prospectus to resell or otherwise dispose of the shares in the manner contemplated under &#8220;Plan of Distribution&#8221; herein. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as otherwise disclosed herein, the Selling Stockholders do not have, and within the past three years have not had, any position, office or other material relationship with us. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth the names of the Selling Stockholders, the number of shares of our Common Stock owned by the Selling Stockholders, the number of shares of our Common Stock that may be offered under this prospectus and the number of shares of our Common Stock that will be owned after this offering by the Selling Stockholders assuming all of the shares registered for resale hereby are sold. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Selling Stockholders may sell some, all or none of their Resale Shares. We do not know how long the Selling Stockholders will hold the Resale Shares before selling them, and we currently have no agreements, arrangements or understandings with the Selling Stockholders regarding the sale or other disposition of any of the Resale Shares. The Resale Shares covered hereby may be offered from time to time by the Selling Stockholders, provided that Resale Shares issued upon conversion of Series B Preferred Stock may only be offered after such shares of Series B Preferred Stock are converted to Common Stock pursuant to the terms of the Series B Certificate of Designation. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information set forth below is based upon information obtained from the Selling Stockholders and upon information in our possession regarding the issuance of the Series B Preferred Stock and Private Placement Common Shares in connection with the December 2023 PIPE. The percentages of Common Stock owned after the offering by each Selling Stockholder below are based on 36,021,007 shares of Common Stock outstanding as of December&#160;11, 2023, and, for each Selling Stockholder, assumes the conversion of only the Series B Preferred Stock owned by such Selling Stockholder but not the Series B Preferred Stock owned by any other Selling Stockholder. The numbers of shares of Common Stock beneficially owned before and after the offering presented in the table below do not give effect to any Beneficial Ownership Limitations with respect to the Series B Preferred Stock. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">117 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:62%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of Selling<br />Stockholders(1)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Common<br />Stock<br />Beneficially<br />Owned<br />Before<br />Offering&#160;(2)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Common<br />Stock that<br />May<br />Be Offered<br />Pursuant&#160;to<br />Prospectus</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Common Stock<br />Beneficially<br />Owned After<br />Offering (2)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Percentage<br />(%)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities associated with Fairmount Funds Management<br />LLC (3)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,480,581</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">666,680</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,813,901</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10.4</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities associated with Venrock Healthcare Capital<br />Partners (4)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,789,394</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,666,680</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,122,714</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5.7</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Perceptive Life Sciences Master Fund, Ltd. (5)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,329,999</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,433,320</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,896,679</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5.2</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities associated with RTW Investments, LP (6)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,717,760</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,000,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,717,760</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4.7</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deep Track Capital, LP (7)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,184,440</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">466,680</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,717,760</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4.7</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commodore Capital Master LP (8)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,934,084</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">100,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,834,084</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5.1</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fidelity Growth Company Commingled Pool (9)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,376,763</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">460,763</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">916,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2.5</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cormorant Global Healthcare Master Fund, LP (10)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,153,760</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">466,680</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">687,080</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1.9</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fidelity Mt. Vernon Street Trust: Fidelity Growth Company Fund (9)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,070,184</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">366,184</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">704,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2.9</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Braidwell Partners Master Fund LP (11)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,000,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,000,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Polar Capital LLP (12)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">500,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">233,320</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">266,680</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fidelity Advisor Series VII: Fidelity Advisor Biotechnology Fund (9)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">479,168</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">455,168</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">24,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Boxer Capital, LLC (13)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">466,680</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">466,680</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fidelity Mt. Vernon Street Trust : Fidelity Growth Company K6 Fund (9)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">332,531</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">116,531</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">216,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fidelity Mt. Vernon Street Trust: Fidelity Series Growth Company Fund (9)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">294,104</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">98,104</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">196,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities associated with Great Point Partners LLC (14)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">233,320</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">233,320</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CDK Associates, L.L.C. (15)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">187,980</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">187,980</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fidelity Select Portfolios: Pharmaceuticals Portfolio (9)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">148,742</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">136,582</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12,160</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Blackstone Annex Master Fund L.P. (16)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">133,320</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">133,320</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Woodline Master Fund LP (17)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">100,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">100,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fidelity Series Portfolios: Biotechnology Portfolio (9)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">33,334</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">33,334</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Third Street Holdings LLC (18)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12,020</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12,020</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">*</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Less than 1% </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To our knowledge, unless otherwise indicated, all persons named in the table above have sole voting and investment power with respect to their shares of Common Stock. Unless an address is provided below, the address for the holder is 221 Crescent Street, Building 23, Suite 105, Waltham MA 02453. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">&#8220;Beneficial ownership&#8221; is a term broadly defined by the SEC in Rule <span style="white-space:nowrap">13d-3</span> under the Exchange Act, and includes more than the typical form of stock ownership, that is, stock held in the person&#8217;s name. The term also includes what is referred to as &#8220;indirect ownership,&#8221; meaning ownership of shares as to which a person has or shares investment power. Notwithstanding the foregoing, the beneficial ownership amounts assume the sale of all Common Stock that may be offered pursuant to this prospectus without taking into account certain limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series A Preferred Stock into shares of Common Stock (i)&#160;prior to the affirmative vote of the holders of a majority of the then outstanding shares of the Series A Preferred Stock, or (ii)&#160;if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (established by the holder between 0.00% and 19.99%) (the &#8220;Beneficial Ownership Limitation&#8221;) of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">118 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (i) 666,680 shares of Common Stock issuable upon the conversion of Series B Preferred Stock held by Fairmount Healthcare Fund II L.P. (&#8220;Fund II&#8221;); (ii) 367,378 shares of Common Stock held by Fund II; (iii) 11,043 shares of Common Stock held by Fairmount Healthcare Fund L.P. (&#8220;Fund I&#8221;); and (iv) 3,435,480 shares of Common Stock held by Fairmount Healthcare <span style="white-space:nowrap">Co-Invest</span> L.P. <span style="white-space:nowrap">(&#8220;Co-Invest&#8221;).</span> Fairmount Funds Management LLC (&#8220;Fairmount&#8221;) serves as investment manager for Fund I, Fund II and <span style="white-space:nowrap">Co-Invest</span> and may be deemed a beneficial owner of any of the securities of the Company held by Fund I, Fund II and <span style="white-space:nowrap">Co-Invest.</span> Fund I, Fund II and <span style="white-space:nowrap">Co-Invest</span> have delegated to Fairmount the sole power to vote and the sole power to dispose of all securities held in Fund I&#8217;s, Fund II&#8217;s and <span style="white-space:nowrap">Co-Invest&#8217;s</span> portfolio. Because Fund I, Fund II and <span style="white-space:nowrap">Co-Invest</span> have divested themselves of voting and investment power over the securities they hold and may not revoke that delegation on less than 61 days&#8217; notice, Fund I, Fund II and <span style="white-space:nowrap">Co-Invest</span> disclaim beneficial ownership of the securities they hold. The general partner of Fairmount is Fairmount Funds Management GP LLC (&#8220;Fairmount GP&#8221;). As managing members of Fairmount GP, Peter Harwin and Tomas Kiselak may be deemed beneficial owners of any of our securities beneficially owned by Fairmount. The address of the beneficial owners is 200 Barr Harbor Drive, Suite 400, West Conshohocken, PA 19428. The shares of Common Stock issuable upon the conversion of the shares of Preferred Stock held by each of Fund I, Fund II and <span style="white-space:nowrap">Co-Invest</span> are subject to a Beneficial Ownership Limitation of 0.00%, 0.00% and 19.99%, respectively. Shares of Series A Preferred Stock held by Fund I and Fund II are omitted from this footnote because the conversion of such shares is subject to a Beneficial Ownership Limitation of 0.00%. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(4)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (i) 1,403,560 shares of Common Stock issuable upon the conversion of Series B Preferred Stock held by Venrock Healthcare Capital Partners EG, L.P. (&#8220;VHCP EG&#8221;), (ii) 1,756,456 shares of Common Stock held by VHCP EG, (iii) 11,960 shares of Common Stock issuable upon the conversion of Series B Preferred Stock held by Venrock Healthcare Capital Partners III, L.P. (&#8220;VHCP III&#8221;), (iv) 560,171 shares of Common Stock held by VHCP III, (v) 1,160 shares of Common Stock issuable upon the conversion of Series B Preferred Stock held by VHCP <span style="white-space:nowrap">Co-Investment</span> Holdings III, LLC (&#8220;VHCP III Co&#8221;), and (vi) 56,087 shares of Common Stock held by VHCP III Co. VHCP Management III, LLC (&#8220;VHCPM&#8221;) is the sole general partner of VHCP III and the sole manager of VHCP III Co. VHCP Management EG, LLC (&#8220;VHCPM EG&#8221;) is the sole general partner of VHCP EG. Dr.&#160;Bong Koh and Nimish Shah are the voting members of VHCPM and VHCPM EG. The address of each of these persons and entities is 7 Bryant Park, 23rd Floor, New York, NY 10018. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by VHCP EG, VHCP III, and VHCP III Co are subject to a Beneficial Ownership Limitation of 9.99%. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(5)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (i) 723,320 shares of Common Stock issuable upon the conversion of Series B Preferred Stock held by Perceptive Life Sciences Master Fund, Ltd (&#8220;Perceptive Fund&#8221;) and (ii) 2,606,679 shares of Common Stock held by Perceptive Fund. Perceptive Advisors LLC (&#8220;Perceptive Advisors&#8221;) is the investment advisor of Perceptive Fund and may be deemed to have beneficial ownership of the shares beneficially owned thereby. Joseph Edelman is the controlling person of each of Perceptive Fund and Perceptive Advisors and, accordingly, may be deemed to have beneficial ownership of the shares beneficially owned by each of Perceptive Fund and Perceptive Advisors. Mr.&#160;Edelman disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. The address of Perceptive is 51 Astor Place, 10th Floor, New York, NY 10003. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by Perceptive Life Sciences Master Fund, Ltd. are subject to a Beneficial Ownership Limitation of 9.99%. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(6)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of an aggregate of (i) 485,000 shares of Common Stock issuable upon the conversion of Series B Preferred Stock held by RTW Master Fund, Ltd., RTW Innovation Master Fund, Ltd. and RTW Biotech Opportunities LTD (collectively, the &#8220;RTW Funds&#8221;) and (ii) 2,232,760 shares of Common Stock held by RTW Funds. RTW Investments, LP (&#8220;RTW&#8221;), in its capacity as the investment manager of the RTW Funds, has the power to vote and the power to direct the disposition of the shares held by the RTW Funds. Accordingly, RTW may be deemed to be the beneficial owner of such securities. Roderick Wong, M.D., as the Managing Partner of RTW, has the power to direct the vote and disposition of the securities held by RTW. Dr.&#160;Wong disclaims beneficial ownership of the shares held by the RTW Funds, except to the extent of his pecuniary interest therein. The address and principal office of RTW Investments, LP is 40 10th </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">119 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td align="left" style="vertical-align:top">
Avenue, Floor 7, New York, NY 10014, and the address of Dr.&#160;Wong and each of the RTW Funds is c/o RTW Investments, LP, 40 10th Avenue, Floor 7, New York, NY 10014. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by the RTW Funds are subject to a Beneficial Ownership Limitation of 9.99%. </td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(7)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (i) 231,680 shares of Common Stock issuable upon the conversion of Series B Preferred Stock held by Deep Track Biotechnology Master Fund, Ltd. (&#8220;Deep Track Biotech&#8221;) and (ii) 1,952,760 shares of Common Stock held by Deep Track Biotech. Deep Track Capital, LP (&#8220;Deep Track Capital&#8221;) and David Kroin have shared voting power and shared dispositive power over the shares held by the Deep Track Biotech. Mr.&#160;Kroin may be considered a control person for Deep Track Capital. The address of Deep Track Capital and Mr.&#160;Kroin is 200 Greenwich Ave, 3rd Floor, Greenwich, CT 06830, and the address for Deep Track Biotech is 190 Elgin Avenue, George Town, <span style="white-space:nowrap">KY1-9001,</span> Cayman Islands. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by Deep Track Biotech are subject to a Beneficial Ownership Limitation of 9.99%. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(8)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (i) 50,000 shares of Common Stock issuable upon the conversion of Series B Preferred Stock held by Commodore Capital Master LP and (ii) 1,884,084 shares of Common Stock held by Commodore Capital Master LP. Commodore Capital LP is the investment manager to Commodore Capital Master LP and may be deemed to beneficially own the shares held by Commodore Capital Master LP. Michael Kramarz and Robert Egen Atkinson are the managing partners of Commodore Capital LP and exercise investment discretion with respect to these shares. Commodore Capital LP and Commodore Capital Master LP have shared voting and dispositive power with respect to these shares. The address of Commodore Capital LP and Commodore Capital Master LP is 444 Madison Avenue, 35th Floor, New York, NY 10022. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by Commodore Capital Master LP are subject to a Beneficial Ownership Limitation of 9.99%. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(9)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">These funds and accounts are managed by direct or indirect subsidiaries of FMR LLC. Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders&#8217; voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders&#8217; voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. The address of these funds and accounts is 245 Summer Street, Boston, MA 02210. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(10)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (i) 216,680 shares of Common Stock issuable upon the conversion of Series B Preferred Stock held by Cormorant Global Healthcare Master Fund, LP (&#8220;Cormorant Global Healthcare&#8221;) and (ii) 937,080 shares of Common Stock held by Cormorant Global Healthcare. Cormorant Global Healthcare GP, LLC (&#8220;Global Healthcare GP&#8221;) is the general partner of Cormorant Global Healthcare. Cormorant Asset Management, LP serves as the investment manager to Cormorant Global Healthcare. Bihua Chen serves as the managing member of both Global Healthcare GP and Cormorant Asset Management, LP and accordingly may be deemed to have voting and dispositive power with respect to shares held by Cormorant Global Healthcare. Each of Global Healthcare GP, Cormorant Asset Management, LP and Ms.&#160;Chen disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. The principal address for the Cormorant Asset Management, LP entities is 200 Clarendon Street 52nd Floor, Boston, MA 02116. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by Cormorant Global Healthcare are subject to a Beneficial Ownership Limitation of 9.99%. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(11)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (i) 485,000 shares of Common Stock issuable upon the conversion of Series B Preferred Stock held by Braidwell Partners Master Fund LP (&#8220;Braidwell Partners&#8221;) and (ii) 515,000 shares of Common Stock held by Braidwell Partners. Braidwell LP is the investment manager of Braidwell Partners. The address of Braidwell Partners is c/o Maples Corporate Services Limited, P.O Box 309, Ugland House, Grand Cayman, <span style="white-space:nowrap">KY1-1104</span> Cayman Islands. The shares of Common Stock issuable upon the conversion of </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">120 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td align="left" style="vertical-align:top">
the shares of Series B Preferred Stock held by Braidwell Fund is subject to a Beneficial Ownership Limitation of 9.99%. </td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(12)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (i) 108,320 shares of Common Stock issuable upon the conversion of Series B Preferred Stock held by Polar Capital Funds plc &#8211; Biotechnology Fund, Polar Capital Funds plc is a company with variable capital and segregated liability between <span style="white-space:nowrap">sub-funds</span> incorporated in Ireland and authorized by the Central Bank of Ireland pursuant to the European Communities (Undertakings for Investment in Transferable Securities) Regulations 2011, as amended and with the address George&#8217;s Court, <span style="white-space:nowrap">54-62</span> Townsend Street, Dublin 2, Ireland and (ii) 391,680 shares of Common Stock held by Polar Capital Funds plc &#8211; Biotechnology Fund. The investment manager of Polar Capital Funds plc is Polar Capital LLP, an FCA and SEC regulated fund manager/investment advisor, which has the ability to make decisions with respect to the voting and disposition of the shares and has overall responsibility for directing the investments of the entities in accordance with their investment objectives, policies and limitations. Polar Capital LLP is 100% owned by Polar Capital Partners Ltd, which is in turn 100% owned by Polar Capital Holdings plc, a London AIM listed holding company. Certain directors/employees are beneficial owners of Polar Capital Holdings plc but each such individual disclaims any beneficial ownership of the reported shares, other than to the extent they may or may not hold shares directly of the entities. The address for the investment manager is 16 Palace Street, London, United Kingdom, SW1E 5JD. The shares of Common Stock issuable upon the conversion of the shares of Series B Preferred Stock held by Polar Capital Funds plc &#8211; Biotechnology Fund is subject to a Beneficial Ownership Limitation of 9.99%. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(13)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (i) 216,680 shares of Common Stock issuable upon the conversion of Series B Preferred Stock held by Boxer Capital, LLC (&#8220;Boxer Capital&#8221;) and (ii) 250,000 shares of Common Stock held by Boxer Capital. Boxer Asset Management Inc. (&#8220;Boxer Asset Management&#8221;) is the managing member of Boxer Capital. Joseph C. Lewis, as the sole indirect owner of Boxer Asset Management, may be deemed to have shared power to vote (or direct vote) and/or to dispose (or direct the disposition) of the securities held by Boxer Capital. Boxer Asset Management and Joseph C. Lewis disclaim beneficial ownership over the shares owned by Boxer Capital except to the extent of their pecuniary interests therein. The principal address for Boxer Capital is 12860 El Camino Real, Ste 300, San Diego, CA 92130 and the principal address for Boxer Asset Management Inc. and Mr.&#160;Lewis is Cay House, EP Taylor Drive N7776, Lyford Cay, New Providence, Bahamas. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by Boxer Capital are subject to a Beneficial Ownership Limitation of 4.99%.&#160;&#160;&#160;&#160; </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(14)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (i) 61,520 shares of Common Stock issuable upon the conversion of Series B Preferred Stock held by Biomedical Value Fund, L.P. (&#8220;BMVF&#8221;), (ii) 71,000 shares of Common Stock held by BMVF, (iii) 39,440 shares of Common Stock issuable upon the conversion of Series B Preferred Stock held by Biomedical Offshore Value Fund, Ltd. (&#8220;BOVF&#8221;), (iv) 45,500 shares of Common Stock held by BOVF, (v) 7,360 shares of Common Stock issuable upon the conversion of Series B Preferred Stock held by Cheyne Select Master Fund ICAV &#8211; Cheyne Global Equity Fund (&#8220;CGEF&#8221; and together with BMVF and BOVF, the &#8220;GPP Entities&#8221;), and (vi) 8,500 shares of Common Stock held by CGEF. Great Point Partners LLC (&#8220;GPP LLC&#8221;) is the investment manager of BMVF and BMOVF and the <span style="white-space:nowrap">sub-advisor</span> to CGEF, and by virtue of such status may be deemed to be the beneficial owner of the securities held by the GPP Entities. Each of Dr.&#160;Jeffrey&#160;R. Jay, M.D., as Senior Managing Member of GPP LLC, and Mr.&#160;Ortav Yehudai, as Managing Director of GPP LLC, has voting and investment power with respect to securities held by the GPP Entities, and therefore may be deemed to be the beneficial owner of the securities held by the GPP Entities. Notwithstanding the above, GPP LLC, Dr.&#160;Jay and Mr.&#160;Yehudai disclaim beneficial ownership of the securities held by the GPP Entities except to the extent of their respective pecuniary interests. The address of the GPP Entities is 165 Mason Street, 3rd Floor, Greenwich, CT 06830. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by each of the GPP Entities are subject to a Beneficial Ownership Limitation of 9.99%. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(15)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (i) 89,280 shares of Common Stock issuable upon the conversion of Series B Preferred Stock held by CDK Associates, L.L.C (&#8220;CDK&#8221;) and (ii) 98,700 shares of Common Stock held by CDK. Bruce Kovner has voting and/or dispositive power over the holdings of CDK. The address of CDK is c/o CAM Capital 731 Alexander Road, Bldg 2, Suite 500, Princeton, NJ 08540. The shares of Common Stock issuable </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">121 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td align="left" style="vertical-align:top">
upon conversion of the shares of Series B Preferred Stock held by CDK is subject to a Beneficial Ownership Limitation of 4.90%. </td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(16)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (i) 63,320 shares of Common Stock issuable upon the conversion of Series B Preferred Stock held by Blackstone Annex Master Fund L.P. (&#8220;Annex Fund&#8221;) and (ii) 70,000 shares of Common Stock held by Annex Fund. Blackstone Holdings II L.P. is the sole member of Blackstone Alternative Asset Management Associates LLC. Blackstone Holdings I/II GP L.L.C. is the general partner of Blackstone Holdings II L.P. Blackstone Inc. is the sole member of Blackstone Holdings I/II GP L.L.C. Blackstone Group Management L.L.C. is the sole holder of the Series II preferred stock of Blackstone Inc. Blackstone Group Management L.L.C. is wholly owned by its senior managing directors and controlled by its founder, Stephen A. Schwarzman. Each of such Blackstone entities and Mr.&#160;Schwarzman may be deemed to beneficially own the securities beneficially owned by Annex Fund directly or indirectly controlled by it or him, but each (other than the Annex Fund to the extent of its direct holdings) disclaims beneficial ownership of such securities. The address of each of the entities listed is c/o Blackstone Inc., 345 Park Avenue, New York, New York 10154. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by Annex Fund is subject to a Beneficial Ownership Limitation of 4.90%.&#160;&#160;&#160;&#160; </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(17)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (i) 50,000 shares of Common Stock issuable upon the conversion of Series B Preferred Stock held by Woodline Master Fund LP (the &#8220;Woodline Fund&#8221;), and (ii) 50,000 shares of Common Stock held by Woodline Fund. Woodline Partners LP serves as the investment manager of Woodline Fund and may be deemed to be the beneficial owner of the shares. Woodline Partners LP disclaims any beneficial ownership of these shares. The address of this fund and account is 4 Embarcadero Center, Suite 34590, San Francisco, CA 94111. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by Woodline Fund is subject to a Beneficial Ownership Limitation of 9.99%. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(18)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (i) 5,720 shares of Common Stock issuable upon the conversion of Series B Preferred Stock held by Third Street Holdings LLC (&#8220;Third Street&#8221;) and (ii) 6,300 shares of Common Stock held by CDK. Peter P. D&#8217;Angelo has voting and/or dispositive power over the holdings of Third Street Holdings, LLC. The address of Third Street is c/o CAM Capital 731 Alexander Road, Bldg 2, Suite 500, Princeton, NJ 08540. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by Third Street is subject to a Beneficial Ownership Limitation of 4.90%.&#160;&#160;&#160;&#160; </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Relationship with the Selling Stockholders </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to the December 2023 SPA, in connection with the December 2023 PIPE, we entered into the December 2023 RRA on December&#160;7, 2023 with the Selling Stockholders. Certain of the December 2023 Investors were, immediately prior to the closing of the December 2023 PIPE, or became holders of more than 5% of our Common Stock and were parties to the June 2023 SPA and the June 2023 RRA. See &#8220;<span style="font-style:italic">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</span>&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Registration Rights Agreements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of our June 2023 RRA, we agreed to prepare and file with the SEC a registration statement that permits the resale or other disposition, by purchasers under the June 2023 SPA, certain of the securityholders under the Acquisition Agreement and certain of our employees (collectively, the &#8220;Previous Selling Stockholders&#8221;), including certain Selling Stockholders, of shares of Common Stock issued upon conversion of the Series A Preferred Stock issued to such investors pursuant to the June 2023 SPA and Acquisition Agreement and, subject to certain exceptions, use commercially reasonable efforts to keep the registration statement of which this prospectus forms a part effective under the Securities Act for so long as such securities registered for resale thereunder retain their character as Registrable Securities (as defined in the June 2023 RRA). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of our December 2023 RRA, we agreed to prepare and file with the SEC a registration statement that permits the resale or other disposition of the Selling Stockholders&#8217; shares of Common Stock issued and shares of Common Stock issued upon conversion of the Series B Preferred Stock issued to such Selling Stockholders pursuant to the December 2023 SPA and, subject to certain exceptions, use commercially </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">122 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
reasonable efforts to keep the registration statement of which this prospectus forms a part effective under the Securities Act for so long as such securities registered for resale thereunder retain their character as Registrable Securities (as defined in the December 2023 RRA). This registration statement is being filed in order to satisfy our obligations under the December 2023 RRA. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have also agreed, among other things, to indemnify the Previous Selling Stockholders and the Selling Stockholders and each of their respective officers, directors, members, employees, partners, managers, stockholders, affiliates, investment advisors and agents, each person who controls any such Previous Selling Stockholder or Selling Stockholder and the officers, directors, members, employees, partners, managers, stockholders, affiliates, investment advisors and agents of each such controlling person from certain liabilities and pay all fees and expenses (excluding any legal fees of the selling holder(s), and any underwriting discounts and selling commissions) incident to our obligations under the June 2023 RRA and the December 2023 RRA, respectively. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">123 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx518298_16">PLAN OF DISTRIBUTION </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are registering the Resale Shares issued to the Selling Stockholders to permit the sale, transfer or other disposition of these shares by the Selling Stockholders or their donees, pledgees, transferees or other <span style="white-space:nowrap"><span style="white-space:nowrap">successors-in-interest</span></span> from time to time after the date of this prospectus. We will not receive any of the proceeds from the sale by the Selling Stockholders of the Resale Shares. We will, or will procure to, bear all fees and expenses incident to our obligation to register the Resale Shares. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Selling Stockholders may sell all or a portion of the Resale Shares beneficially owned by them and offered hereby from time to time, and in the case of the Private Placement Conversion Shares, may only be offered after such shares are converted to Common Stock pursuant to the terms of the Series B Certificate of Designation, directly or through one or more underwriters, broker-dealers or agents. If the Resale Shares are sold through underwriters or broker-dealers, the Selling Stockholders will be responsible for underwriting discounts (it being understood that the Selling Stockholders shall not be deemed to be underwriters solely as a result of their participation in this offering) or commissions or agent&#8217;s commissions. The Resale Shares may be sold on any national securities exchange or quotation service on which the securities may be listed or quoted at the time of sale, in the <span style="white-space:nowrap"><span style="white-space:nowrap">over-the-counter</span></span> market or in transactions otherwise than on these exchanges or systems or in the <span style="white-space:nowrap"><span style="white-space:nowrap">over-the-counter</span></span> market and in one or more transactions at fixed prices, at prevailing market prices at the time of the sale, at varying prices determined at the time of sale, or at negotiated prices. These sales may be effected in transactions, which may involve crosses or block transactions. The Selling Stockholders may use any one or more of the following methods when selling Resale Shares: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">block trades in which the broker-dealer will attempt to sell the shares as agent but may position and resell a portion of the block as principal to facilitate the transaction; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">to or through underwriters or purchases by a broker-dealer as principal and resale by the broker-dealer for its account; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">an exchange distribution in accordance with the rules of the applicable exchange; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">privately negotiated transactions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">settlement of short sales entered into after the effective date of the registration statement of which this prospectus is a part; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">broker-dealers may agree with the Selling Stockholders to sell a specified number of such shares at a stipulated price per share; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">through the writing or settlement of options or other hedging transactions, whether such options are listed on an options exchange or otherwise; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a combination of any such methods of sale; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any other method permitted pursuant to applicable law. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Selling Stockholders also may resell all or a portion of the Resale Shares in open market transactions in reliance upon Rule 144, as permitted by that rule, or Section&#160;4(a)(1) under the Securities Act, if available, rather than under this prospectus, provided that they meet the criteria and conform to the requirements of those provisions. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Broker-dealers engaged by the Selling Stockholders may arrange for other broker-dealers to participate in sales. If the Selling Stockholders effect such transactions by selling Resale Shares to or through underwriters, broker-dealers or agents, such underwriters, broker-dealers or agents may receive commissions in the form of discounts, concessions or commissions from the Selling Stockholders or commissions from purchasers of the Resale Shares for whom they may act as agent or to whom they may sell as principal. Such commissions will be in amounts to </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">124 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
be negotiated, but, except as set forth in a supplement to this prospectus, in the case of an agency transaction will not be in excess of a customary brokerage commission in compliance with FINRA Rule 2121; and in the case of a principal transaction a markup or markdown in compliance with FINRA <span style="white-space:nowrap">IM-2121.01.</span></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with sales of the Resale Shares or otherwise, the Selling Stockholders may enter into hedging transactions with broker-dealers or other financial institutions, which may in turn engage in short sales of the Resale Shares in the course of hedging in positions they assume. The Selling Stockholders may also sell Resale Shares short and if such short sale takes place after the date that this registration statement is declared effective by the SEC, the Selling Stockholders may deliver Resale Shares covered by this prospectus to close out short positions and to return borrowed Resale Shares in connection with such short sales. The Selling Stockholders may also loan or pledge Resale Shares to broker-dealers that in turn may sell such shares, to the extent permitted by applicable law. The Selling Stockholders may also enter into option or other transactions with broker-dealers or other financial institutions or the creation of one or more derivative securities which require the delivery to such broker-dealer or other financial institution of shares offered by this prospectus, which shares such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction). Notwithstanding the foregoing, the Selling Stockholders have been advised that they may not use Resale Shares the resale of which has been registered on this registration statement to cover short sales of our Common Stock made prior to the date the registration statement, of which this prospectus forms a part, has been declared effective by the SEC. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Selling Stockholders may, from time to time, pledge or grant a security interest in some or all of the Resale Shares owned by them and, if they default in the performance of their secured obligations, the pledgees or secured parties may offer and sell the Resale Shares from time to time pursuant to this prospectus or any amendment to this prospectus under Rule 424(b)(3) or other applicable provision of the Securities Act, amending, if necessary, the list of Selling Stockholders to include the pledgee, transferee or other successors in interest as Selling Stockholders under this prospectus. The Selling Stockholders also may transfer and donate the Resale Shares in other circumstances in which case the transferees, donees, pledgees or other successors in interest will be the selling beneficial owners for purposes of this prospectus. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Selling Stockholders and any broker-dealer or agents participating in the distribution of the Resale Shares may be deemed to be &#8220;underwriters&#8221; within the meaning of Section&#160;2(11) of the Securities Act in connection with such sales. In such event, any commissions paid, or any discounts or concessions allowed to, any such broker-dealer or agent and any profit on the resale of the shares purchased by them may be deemed to be underwriting commissions or discounts under the Securities Act. Selling Stockholders who are &#8220;underwriters&#8221; within the meaning of Section&#160;2(11) of the Securities Act will be subject to the applicable prospectus delivery requirements of the Securities Act including Rule 172 thereunder and may be subject to certain statutory liabilities of, including but not limited to, Sections 11, 12 and 17 of the Securities Act and Rule <span style="white-space:nowrap">10b-5</span> under the Exchange Act. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each Selling Stockholder has informed the Company that it is not a registered broker-dealer and does not have any written or oral agreement or understanding, directly or indirectly, with any person to distribute the Resale Shares. Upon the Company being notified in writing by a Selling Stockholder that any material arrangement has been entered into with a broker-dealer for the sale of Common Stock through a block trade, special offering, exchange distribution or secondary distribution or a purchase by a broker or dealer, a supplement to this prospectus will be filed, if required, pursuant to Rule 424(b) under the Securities Act, disclosing (i)&#160;the name of each such Selling Stockholder and of the participating broker-dealer(s), (ii) the number of Resale Shares involved, (iii)&#160;the price at which such the Resale Shares were sold, (iv)&#160;the commissions paid or discounts or concessions allowed to such broker-dealer(s), where applicable, (v)&#160;that such broker-dealer(s) did not conduct any investigation to verify the information set out in this prospectus, and (vi)&#160;other facts material to the transaction. In no event shall any broker-dealer receive fees, commissions and markups, which, in the aggregate, would exceed eight percent (8.0%). </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">125 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the securities laws of some U.S. states, the Resale Shares may be sold in such states only through registered or licensed brokers or dealers. In addition, in some U.S. states the Resale Shares may not be sold unless such shares have been registered or qualified for sale in such state or an exemption from registration or qualification is available and is complied with. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There can be no assurance that any Selling Stockholder will sell any or all of the Resale Shares registered pursuant to the shelf registration statement, of which this prospectus forms a part. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each Selling Stockholder and any other person participating in such distribution will be subject to applicable provisions of the Exchange Act and the rules and regulations thereunder, including, without limitation, to the extent applicable, Regulation M of the Exchange Act, which may limit the timing of purchases and sales of any of the Resale Shares by the Selling Stockholder and any other participating person. To the extent applicable, Regulation M may also restrict the ability of any person engaged in the distribution of the Resale Shares to engage in market-making activities with respect to the Resale Shares. All of the foregoing may affect the marketability of the Resale Shares and the ability of any person or entity to engage in market-making activities with respect to the Resale Shares. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will pay all expenses of the registration of the Resale Shares pursuant to the December 2023 RRA, including, without limitation, SEC filing fees and expenses of compliance with state securities or &#8220;blue sky&#8221; laws; provided, however, that each Selling Stockholder will pay all underwriting discounts and selling commissions, if any and any related legal expenses incurred by it. We will indemnify the Selling Stockholders against certain liabilities, including some liabilities under the Securities Act, in accordance with the December 2023 RRA, or the Selling Stockholders will be entitled to contribution. We may be indemnified by the Selling Stockholders against certain civil liabilities set forth in the December 2023 RRA, including liabilities under the Securities Act, that may arise from any written information furnished to us by the Selling Stockholders specifically for use in this prospectus, in accordance with the related registration rights agreements, or we may be entitled to contribution. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">126 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx518298_17">DESCRIPTION OF CAPITAL STOCK </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">General </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our authorized capital stock consists of 400,000,000 shares of Common Stock, $0.0001 par value per share, and 10,000,000 shares of preferred stock (&#8220;Preferred Stock&#8221;), of which 1,086,341 shares have been designated as Series A Preferred Stock, $0.0001 par value per share and 150,000 shares have been designated as Series B Preferred Stock, $0.0001 par value per share. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;11, 2023, there were 36,021,007 shares of our Common Stock, 437,037 shares of Series A Preferred Stock and 150,000 shares of Series B Preferred Stock outstanding. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following description summarizes the most important terms of our capital stock. Because it is only a summary, it does not contain all the information that may be important to you. For a complete description, you should refer to our Certificate of Incorporation (the &#8220;Certificate of Incorporation&#8221;) and Bylaws (the &#8220;Bylaws&#8221;), which are included as exhibits to this prospectus, and to the applicable provisions of Delaware law. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Common Stock </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Dividend rights </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to preferences that may apply to any shares of Preferred Stock outstanding at the time, the holders of our Common Stock are entitled to receive dividends out of funds legally available if our board of directors, in its discretion, determines to issue dividends and then only at the times and in the amounts that our board of directors may determine. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Voting rights </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Holders of our Common Stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders. We have not provided for cumulative voting for the election of directors in our Certificate of Incorporation. Accordingly, pursuant to our Certificate of Incorporation, holders of a majority of the shares of our Common Stock are able to elect all of our directors. Our Certificate of Incorporation establishes a classified board of directors, divided into three classes with staggered three-year terms. Only one class of directors will be elected at each annual meeting of our stockholders, with the other classes continuing for the remainder of their respective three-year terms. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">No preemptive or similar rights </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Common Stock is not entitled to preemptive rights, and is not subject to conversion, redemption or sinking fund provisions. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Right to receive liquidation distributions </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon our liquidation, dissolution or <span style="white-space:nowrap">winding-up,</span> the assets legally available for distribution to our stockholders would be distributable ratably among the holders of our Common Stock and any participating Preferred Stock outstanding at that time, subject to prior satisfaction of all outstanding debt and liabilities and the preferential rights of and the payment of liquidation preferences, if any, on any outstanding shares of Preferred Stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Preferred Stock </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our board of directors is authorized, subject to limitations prescribed by Delaware law, to issue Preferred Stock in one or more series, to establish from time to time the number of shares to be included in each series and to fix the designation, powers, preferences and rights of the shares of each series and any of their qualifications, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">127 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
limitations or restrictions, in each case without further vote or action by our stockholders. Subject to the Certificate of Designation, our board of directors can also increase or decrease the number of shares of any series of Preferred Stock, but not below the number of shares of that series then outstanding, without any further vote or action by our stockholders. Our board of directors may authorize the issuance of Preferred Stock with voting or conversion rights that could adversely affect the voting power or other rights of the holders of our Common Stock. The issuance of Preferred Stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, could, among other things, have the effect of delaying, deferring or preventing a change in control of our company and might adversely affect the market price of our Common Stock and the voting and other rights of the holders of our Common Stock. We have no current plan to issue any shares of Preferred Stock other than the shares of our Series A Preferred Stock and shares of our Series B Preferred Stock that were issued in connection with the June 2023 Transactions and the December 2023 PIPE, respectively. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Series A Preferred Stock </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Holders of Series A Preferred Stock are entitled to receive dividends on shares of Series A Preferred Stock equal to, on an <span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap">as-if-converted-to-common-stock</span></span></span></span> basis, and in the same form as dividends actually paid on shares of our Common Stock. Except as provided in the Series A Certificate of Designation or as otherwise required by law, the Series A Preferred Stock does not have voting rights. However, as long as any shares of Series A Preferred Stock are outstanding, we will not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series A Preferred Stock: (a)&#160;alter or change adversely the powers, preferences or rights given to the Series A Preferred Stock, or alter or amend the Certificate of Designation, amend or repeal any provision of, or add any provision to, the Company&#8217;s Certificate of Incorporation or its Bylaws, or file any articles of amendment, certificate of designations, preferences, limitations and relative rights of any series of Preferred Stock, if such action would adversely alter or change the preferences, rights, privileges or powers of, or restrictions provided for the benefit of the Series A Preferred Stock, regardless of whether any of the foregoing actions will be by means of amendment to the Certificate of Incorporation or by merger, consolidation, recapitalization, reclassification, conversion or otherwise, (b)&#160;issue further shares of Series A Preferred Stock or increase or decrease (other than by conversion) the number of authorized shares of Series A Preferred Stock, (c)&#160;prior to the stockholder approval of the conversion of the Series A Preferred Stock into shares of Common Stock in accordance with Nasdaq Stock Market Rules (the &#8220;Series A Conversion Proposal&#8221;) or at any time while at least 30% of the originally issued Series A Preferred Stock remains issued and outstanding, consummate (x)&#160;any Fundamental Transaction (as defined in the Series A Certificate of Designation) or (y)&#160;any merger or consolidation of the Company with or into another entity or any stock sale to, or other business combination in which the stockholders of the Company immediately before such transaction do not hold at least a majority of the capital stock of the Company immediately after such transaction or (d)&#160;enter into any agreement with respect to any of the foregoing. The Series A Preferred Stock does not have a preference upon any liquidation, dissolution or <span style="white-space:nowrap">winding-up</span> of the Company. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following stockholder approval of the Series A Conversion Proposal, each share of Series A Preferred Stock automatically converted into 40 shares of Common Stock, subject to certain limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series A Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (established by the holder between 0% and 19.99%) of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Series B Preferred Stock </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Holders of Series B Preferred Stock are entitled to receive dividends on shares of Series B Preferred Stock equal to, on an <span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap">as-if-converted-to-common-stock</span></span></span></span> basis, and in the same form as dividends actually paid on shares of our Common Stock. Except as provided in the Series B Certificate of Designation or as otherwise required by law, the Series B Preferred Stock does not have voting rights. However, as long as any shares of Series B Preferred Stock are outstanding, we will not, without the affirmative vote of the holders of a majority of the then </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">128 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
outstanding shares of the Series B Preferred Stock alter or change adversely the powers, preferences or rights given to the Series B Preferred Stock, or alter or amend the Series B Certificate of Designation, amend or repeal any provision of, or add any provision to, the Company&#8217;s Certificate of Incorporation or its Bylaws, or file any articles of amendment, certificate of designations, preferences, limitations and relative rights of any series of Preferred Stock, if such action would adversely alter or change the preferences, rights, privileges or powers of, or restrictions provided for the benefit of the Series B Preferred Stock, regardless of whether any of the foregoing actions will be by means of amendment to the Certificate of Incorporation or by merger, consolidation, recapitalization, reclassification, conversion or otherwise. The Series B Preferred Stock does not have a preference upon any liquidation, dissolution or <span style="white-space:nowrap">winding-up</span> of the Company. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following stockholder approval of the conversion of the Series B Preferred Stock into shares of Common Stock in accordance with Nasdaq Stock Market Rules (the &#8220;Series B Conversion Proposal&#8221;), each share of Series B Preferred Stock will automatically convert into 40 shares of Common Stock, subject to certain limitations, including that a holder of Series B Preferred Stock is prohibited from converting shares of Series B Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (established by the holder between 0% and 19.99%) of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Registration Rights </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Holders of our Series A Preferred Stock and Series B Preferred Stock are entitled to certain rights with respect to the registration of such securities as further provided under the heading &#8220;<span style="font-style:italic">Selling Stockholders &#8211; Registration Rights Agreements</span>.&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Anti-Takeover Provisions </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The provisions of Delaware law, our Certificate of Incorporation and our Bylaws could have the effect of delaying, deferring or discouraging another person from acquiring control of our company. These provisions, which are summarized below, may have the effect of discouraging takeover bids. They are also designed, in part, to encourage persons seeking to acquire control of us to negotiate first with our board of directors. We believe that the benefits of increased protection of our potential ability to negotiate with an unfriendly or unsolicited acquirer outweigh the disadvantages of discouraging a proposal to acquire us because negotiation of these proposals could result in an improvement of their terms. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Delaware law </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are subject to the provisions of Section&#160;203 of the Delaware General Corporation Law (the &#8220;DGCL&#8221;) regulating corporate takeovers. In general, Section&#160;203 prohibits a publicly-held Delaware corporation from engaging in a business combination with an interested stockholder for a period of three years following the date on which the person became an interested stockholder unless: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">prior to the date of the transaction, the board of directors of the corporation approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder; </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">upon completion of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding upon consummation of the transaction, excluding for purposes of determining the voting stock outstanding, but not the outstanding voting stock owned by the interested stockholder, (1)&#160;shares owned by persons who are directors and also officers and (2)&#160;shares owned by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">129 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">At or subsequent to the date of the transaction, the business combination is approved by the board of directors of the corporation and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least 66 2/3% of the outstanding voting stock which is not owned by the interested stockholder. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Certificate of Incorporation and Bylaw Provisions </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Certificate of Incorporation and our Bylaws include a number of provisions that could deter hostile takeovers or delay or prevent changes in control of our company, including the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold"><span style="font-style:italic">Board of Directors vacancies</span></span>. Our Certificate of Incorporation and Bylaws authorize our board of directors to fill vacant directorships, including newly created seats unless the board of directors determines that any such vacancies shall be filled by the stockholders. In addition, the number of directors constituting our board of directors is permitted to be set only by a resolution adopted by a majority vote of our entire board of directors. These provisions prevent a stockholder from increasing the size of our board of directors and then gaining control of our board of directors by filling the resulting vacancies with its own nominees. This makes it more difficult to change the composition of our board of directors but promotes continuity of management. </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold"><span style="font-style:italic">Classified board</span></span><span style="font-style:italic">. </span>Our Certificate of Incorporation and Bylaws provide that our board is classified into three classes of directors, each with staggered three-year terms. A third party may be discouraged from making a tender offer or otherwise attempting to obtain control of us as it is more difficult and time consuming for stockholders to replace a majority of the directors on a classified board of directors. </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold"><span style="font-style:italic">Stockholder action; special meetings of stockholders</span></span><span style="font-style:italic">. </span>Our Certificate of Incorporation provides that our stockholders may not take action by written consent, but may only take action at annual or special meetings of our stockholders. As a result, a holder controlling a majority of our capital stock would not be able to amend our Bylaws or remove directors without holding a meeting of our stockholders called in accordance with our Bylaws. Further, our Bylaws provide that special meetings of our stockholders may be called only by a majority of our board of directors, the chairperson of our board of directors, our Chief Executive Officer or our President, thus prohibiting a stockholder from calling a special meeting. These provisions might delay the ability of our stockholders to force consideration of a proposal or for stockholders controlling a majority of our capital stock to take any action, including the removal of directors. </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold"><span style="font-style:italic">Advance notice requirements for stockholder proposals and director nominations</span></span><span style="font-style:italic">. </span>Our Bylaws provide advance notice procedures for stockholders seeking to bring business before our annual meeting of stockholders or to nominate candidates for election as directors at our annual meeting of stockholders. Our Bylaws also specify certain requirements regarding the form and content of a stockholder&#8217;s notice. These provisions might preclude our stockholders from bringing matters before our annual meeting of stockholders or from making nominations for directors at our annual meeting of stockholders if the proper procedures are not followed. We expect that these provisions might also discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer&#8217;s own slate of directors or otherwise attempting to obtain control of our company. </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold"><span style="font-style:italic">No cumulative voting</span></span>. The DGCL provides that stockholders are not entitled to the right to cumulate votes in the election of directors unless a corporation&#8217;s certificate of incorporation provides otherwise. Our Certificate of Incorporation and Bylaws do not provide for cumulative voting. </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold"><span style="font-style:italic">Directors removed only for cause</span></span>. Our Certificate of Incorporation provides that stockholders may remove directors only for cause. </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold"><span style="font-style:italic">Amendment of charter provisions</span></span>. Any amendment of the above provisions in our Certificate of Incorporation requires approval by holders of at least <span style="white-space:nowrap">two-thirds</span> of our outstanding Common Stock, </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">130 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
provided that if <span style="white-space:nowrap">two-thirds</span> of our board of directors approves such an amendment, then only the approval of a majority of holders is required. </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold"><span style="font-style:italic">Issuance of Preferred Stock</span></span>. Our board of directors has the authority, without further action by the stockholders, to issue up to 10,000,000 shares of Preferred Stock with rights and preferences, including voting rights, designated from time to time by our board of directors. The existence of authorized but unissued shares of Preferred Stock enables our board of directors to render more difficult or to discourage an attempt to obtain control of us by merger, tender offer, proxy contest or other means. </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold"><span style="font-style:italic">Choice of forum</span></span>. Our Certificate of Incorporation provides that the Court of Chancery of the State of Delaware is the sole and exclusive forum for any derivative action or proceeding brought on our behalf; any action asserting a breach of fiduciary duty; any action asserting a claim against us arising pursuant to the DGCL, our Certificate of Incorporation or our Bylaws; or any action asserting a claim against us that is governed by the internal affairs doctrine. In addition, our Bylaws also provide that the federal district courts of the United States is the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Transfer Agent and Registrar </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The transfer agent and registrar for our Common Stock is Equiniti Trust Company, LLC (previously known as American Stock Transfer&#160;&amp; Trust Company LLC). The transfer agent&#8217;s address is 6201 15th Avenue, Brooklyn, New York 11219, and its telephone number is (800) <span style="white-space:nowrap">937-5449.</span> </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Exchange Listing </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Common Stock is listed on The Nasdaq Capital Market under the symbol &#8220;SYRE.&#8221; </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">131 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx518298_18">LEGAL MATTERS </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain legal matters, including the legality of the securities offered, has been passed upon for us by Gibson, Dunn&#160;&amp; Crutcher LLP, San Francisco, California. Additional legal matters may be passed upon for us or any underwriters, dealers or agents, by counsel that we will name in the applicable prospectus supplement. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">132 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx518298_19">EXPERTS </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The financial statements of Aeglea BioTherapeutics, Inc. as of December&#160;31, 2022 and 2021 and for each of the three years in the period ended December&#160;31, 2022 included in this prospectus have been so included in reliance on the report (which contains an explanatory paragraph relating to the Company&#8217;s ability to continue as a going concern as described in Note 1 to the financial statements) of PricewaterhouseCoopers LLP, an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The audited Statement of Assets Acquired and Liabilities Assumed from Spyre Therapeutics, Inc. by Aeglea BioTherapeutics, Inc., as of June&#160;22, 2023 included in this prospectus have been so included in reliance on the report (which contains an emphasis of matter relating to the basis of presentation as described in Note 1 and an explanatory paragraph relating to the Company&#8217;s ability to continue as a going concern as described in Note 1 to the financial statement) of PricewaterhouseCoopers LLP, an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">133 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx518298_20">WHERE YOU CAN FIND MORE INFORMATION </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are subject to the informational requirements of the Exchange Act and are required to file annual, quarterly and other reports, proxy statements and other information with the SEC. The SEC maintains an Internet site (<span style="text-decoration:underline">http://www.sec.gov</span>) that contains reports, proxy and information statements, and various other information about us. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Information about us is also available at our website at http://www.aeglea.com. You may access these materials free of charge as soon as reasonably practicable after they are electronically filed with, or furnished to, the SEC. However, the information on our website is not a part of this prospectus and is not incorporated by reference into this prospectus. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have filed a registration statement on Form <span style="white-space:nowrap">S-1</span> with the SEC relating to the securities covered by this prospectus. This prospectus is a part of the registration statement and does not contain all of the information in the registration statement. Whenever a reference is made in this prospectus to a contract or other document of ours, please be aware that the reference is only a summary and that you should refer to the exhibits that are part of the registration statement for a copy of the contract or other document. You may review a copy of the registration statement through the SEC&#8217;s website or our website. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">134 </p>

</div></div>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" /><div style='display: none'><ix:header><ix:hidden><ix:nonNumeric name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="hidden95765451" contextRef="PAsOn12_31_2022_MinimumMembersrtRangeAxis">P3Y</ix:nonNumeric><ix:nonNumeric name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" id="hidden95765421" contextRef="P01_01_2022To12_31_2022_FebruaryTwoThousandNinteenMemberusgaapAwardDateAxis_WarrantMemberusgaapStatementEquityComponentsAxis">2019-02-28</ix:nonNumeric><ix:nonNumeric name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" id="hidden95765422" contextRef="P01_01_2022To12_31_2022_AprilTwoThousandTwentyMemberusgaapAwardDateAxis_WarrantMemberusgaapStatementEquityComponentsAxis">2020-04-30</ix:nonNumeric><ix:nonNumeric name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" id="hidden95765423" contextRef="P01_01_2022To12_31_2022_MayTwoThousandTwentyTwoMemberusgaapAwardDateAxis_WarrantMemberusgaapStatementEquityComponentsAxis">2022-05-31</ix:nonNumeric><ix:nonNumeric name="us-gaap:LesseeFinanceLeaseRenewalTerm1" id="hidden95765453" contextRef="PAsOn12_31_2022_MinimumMembersrtRangeAxis">P3Y</ix:nonNumeric><ix:nonNumeric name="us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList" id="hidden95764124" contextRef="P07_01_2023To09_30_2023">http://www.spy.com/20230930#DevelopmentFeeAndRoyaltyMember</ix:nonNumeric><ix:nonNumeric name="us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList" id="hidden95764125" contextRef="P07_01_2022To09_30_2022">http://www.spy.com/20230930#DevelopmentFeeAndRoyaltyMember</ix:nonNumeric><ix:nonNumeric name="us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList" id="hidden95764126" contextRef="P01_01_2023To09_30_2023">http://www.spy.com/20230930#DevelopmentFeeAndRoyaltyMember</ix:nonNumeric><ix:nonNumeric name="us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList" id="hidden95764127" contextRef="P01_01_2022To09_30_2022">http://www.spy.com/20230930#DevelopmentFeeAndRoyaltyMember</ix:nonNumeric><ix:nonNumeric name="us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="hidden95765537" contextRef="PAsOn12_31_2022">http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric name="us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="hidden95765538" contextRef="PAsOn12_31_2021">http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonFraction name="agle:RateOfRevenueShare" id="hidden95765599" contextRef="P01_01_2021To03_31_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis" unitRef="Unit_pure" decimals="4">0.2500</ix:nonFraction><ix:nonNumeric name="us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="hidden95765544" contextRef="PAsOn12_31_2022">http://fasb.org/us-gaap/2023#AccruedLiabilitiesAndOtherLiabilities</ix:nonNumeric><ix:nonNumeric name="us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="hidden95765545" contextRef="PAsOn12_31_2021">http://fasb.org/us-gaap/2023#AccruedLiabilitiesAndOtherLiabilities</ix:nonNumeric><ix:nonFraction name="us-gaap:CommonStockSharesIssued" id="hidden95764152" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="INF">2614014</ix:nonFraction><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" id="hidden95764153" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="INF">2614014</ix:nonFraction><ix:nonNumeric name="us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="hidden95765511" contextRef="PAsOn12_31_2021">http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric name="us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="hidden95765401" contextRef="PAsOn12_31_2022">http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonFraction name="agle:NumberOfLicenseAgreements" id="hidden95765449" contextRef="PAsOn01_31_2017" unitRef="Unit_LICENSEAGREEMENT" decimals="0">1</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="agle-20230930.xsd" /></ix:references></ix:header></div><div><div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: medium; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; text-align: center;"><div style="width: 8.5in; text-align: left; margin-left: auto; margin-right: auto;"><div id="index" style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AEGLEA BIOTHERAPEUTICS, INC.</div></div></div><div id="tx518298_21" style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 816px; border: 0px; margin: 0px auto; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 774.438px;"></td>
<td style="vertical-align: bottom; width: 16.3125px;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 8pt;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Page</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt;">
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Consolidated Financial Statements for each of the three years in the period ended December&#160;31, 2022</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt;">
<td style="vertical-align: top;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin518298_22">Report of Independent Registered Public Accounting Firm (ID 238 PricewaterhouseCoopers LLP)</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-2</div></td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt;">
<td style="vertical-align: top;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin518298_23">Consolidated Balance Sheets</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-4</div></td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt;">
<td style="vertical-align: top;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin518298_24">Consolidated Statements of Operations</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-5</div></td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt;">
<td style="vertical-align: top;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin518298_25">Consolidated Statements of Comprehensive Loss</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-6</div></td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt;">
<td style="vertical-align: top;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin518298_26">Consolidated Statements of Changes in Stockholders&#8217; Equity</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-7</div></td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt;">
<td style="vertical-align: top;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin518298_27">Consolidated Statements of Cash Flows</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-8</div></td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt;">
<td style="vertical-align: top;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin518298_28">Notes to Consolidated Financial Statements</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-9</div></td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="margin-top: 24pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">INDEX TO STATEMENT OF ASSETS ACQUIRED AND LIABILITIES ASSUMED FROM SPYRE THERAPEUTICS, INC. BY AEGLEA BIOTHERAPEUTICS, INC.</div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 816px; border: 0px; margin: 0px auto; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 775.188px;"></td>
<td style="vertical-align: bottom; width: 8.15625px;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 8pt;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Page</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt;">
<td style="vertical-align: top;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Statement of Assets Acquired and Liabilities Assumed from Spyre Therapeutics, Inc. by Aeglea BioTherapeutics, Inc. as of June&#160;22, 2023</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt;">
<td style="vertical-align: top;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin518298_29">Report of Independent Registered Public Accounting Firm (ID 238 PricewaterhouseCoopers LLP)</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-33</div></td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt;">
<td style="vertical-align: top;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin518298_30">Statement of Assets Acquired and Liabilities Assumed from Spyre Therapeutics, Inc. by Aeglea BioTherapeutics, Inc.</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-35</div></td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt;">
<td style="vertical-align: top;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin518298_31">Notes to Statement of Assets Acquired and Liabilities Assumed from Spyre Therapeutics, Inc. by Aeglea BioTherapeutics, Inc.</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-36</div></td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="margin-top: 24pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">INDEX TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 816px; border: 0px; margin: 0px auto; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 775.188px;"></td>
<td style="vertical-align: bottom; width: 8.15625px;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 8pt;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Page</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt;">
<td style="vertical-align: top;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Unaudited Condensed Consolidated Financial Statements for the three and nine months ended September&#160;30, 2023</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt;">
<td style="vertical-align: top;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin518298_32">Condensed Consolidated Balance Sheets</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-41</div></td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt;">
<td style="vertical-align: top;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin518298_33">Condensed Consolidated Statements of Operations</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-42</div></td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt;">
<td style="vertical-align: top;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin518298_34">Condensed Consolidated Statements of Comprehensive Loss</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-43</div></td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt;">
<td style="vertical-align: top;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin518298_35">Condensed Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders&#8217; (Deficit) Equity</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-44</div></td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt;">
<td style="vertical-align: top;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin518298_36">Condensed Consolidated Statements of Cash Flows</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-46</div></td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt;">
<td style="vertical-align: top;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin518298_37">Notes to Unaudited Condensed Consolidated Financial Statements</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-47</div></td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: 'Times New Roman'; text-align: center;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-1</div></div></div></div><div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: medium; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; margin-top: 1em; margin-bottom: 0em; break-before: page;"></div><hr style="font-family: 'Times New Roman'; font-size: medium; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; color: rgb(153, 153, 153); height: 3px; width: 1841px;"/><div style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: medium; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; text-align: center;"><div style="width: 8.5in; text-align: left; margin-left: auto; margin-right: auto;"><div id="fin518298_22" style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Report of Independent Registered Public Accounting Firm</div></div></div><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: 'Times New Roman';"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To the Board of Directors and Stockholders of Aeglea BioTherapeutics, Inc.</div></div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Opinion on the Financial Statements</div></div></div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: 'Times New Roman';"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have audited the accompanying consolidated balance sheets of Aeglea BioTherapeutics, Inc. and its subsidiaries (the &#8220;Company&#8221;) as of December&#160;31, 2022 and 2021, and the related consolidated statements of operations, of comprehensive loss, of changes in stockholders&#8217; equity and of cash flows for each of the three years in the period ended December&#160;31, 2022, including the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December&#160;31, 2022 and 2021, and the results of its operations and its cash flows for each of the three years in the period ended December&#160;31, 2022 in conformity with accounting principles generally accepted in the United States of America.</div></div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: 'Times New Roman';"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Substantial Doubt About the Company&#8217;s Ability to Continue as a Going Concern</div></div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: 'Times New Roman';"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the consolidated financial statements, the Company has not generated any product revenues and has not achieved profitable operations. These conditions raise substantial doubt about the Company&#8217;s ability to continue as a going concern. Management&#8217;s plans in regard to these matters are also described in Note 1. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</div></div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basis for Opinion</div></div></div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: 'Times New Roman';"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</div></div><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: 'Times New Roman';"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We conducted our audits of these consolidated financial statements in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</div></div><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: 'Times New Roman';"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</div></div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Critical Audit Matters</div></div></div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: 'Times New Roman';"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that (i)&#160;relates to accounts or disclosures that are material to the consolidated financial statements and</div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: 'Times New Roman'; text-align: center;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-2</div></div></div></div><div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: medium; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; margin-top: 1em; margin-bottom: 0em; break-before: page;"></div><hr style="font-family: 'Times New Roman'; font-size: medium; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; color: rgb(153, 153, 153); height: 3px; width: 1841px;"/><div style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: medium; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; text-align: center;"><div style="width: 8.5in; text-align: left; margin-left: auto; margin-right: auto;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: 'Times New Roman';"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(ii)&#160;involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</div></div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: 'Times New Roman';"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Accrued Contracted Research and Development Costs</div></div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: 'Times New Roman';"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As described in Notes 2 and 6 to the consolidated financial statements, the Company has entered into various agreements with contract research organizations (CROs), contract manufacturing organizations (CMOs), and other outside service providers. Management records accruals based on estimates of services received and efforts expended pursuant to agreements established with CROs, CMOs, and other outside service providers. These estimates are typically based on contracted amounts applied to the proportion of work performed and determined through analysis with internal personnel and external service providers as to the progress or stage of completion of the services. The Company&#8217;s research and development expense for the year ended December&#160;31, 2022 was $59&#160;million, a portion of which relates to contracted research and development costs. Within accrued and other current liabilities, management has accrued $7&#160;million of contracted research and development costs as of December&#160;31, 2022.</div></div><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: 'Times New Roman';"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The principal consideration for our determination that performing procedures relating to accrued contracted research and development costs is a critical audit matter is a high degree of auditor effort in performing procedures related to management&#8217;s estimate of the accrued contracted research and development costs.</div></div><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: 'Times New Roman';"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures also included, among others (i)&#160;testing management&#8217;s process for estimating accrued contracted research and development costs, (ii)&#160;testing the completeness and accuracy of the data used to develop the estimate, (iii)&#160;testing the completeness and accuracy of costs incurred, on a sample basis, by tracing information to the underlying contracts, purchase orders, invoices and information received from certain third party service providers, where applicable, and (iv)&#160;evaluating the reasonableness of the estimated costs incurred for the services which have not been invoiced by tracing to underlying supporting documentation, such as underlying contracts, purchase orders and information received from certain third party service, providers, where applicable.</div></div><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: 'Times New Roman';"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ PricewaterhouseCoopers LLP</div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: 'Times New Roman';"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Austin, Texas</div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: 'Times New Roman';"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">March&#160;2, 2023, except for the effects of the reverse stock split discussed in Note 14 to the consolidated financial statements, as to which the date is November&#160;15, 2023</div></div><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: 'Times New Roman';"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have served as the Company&#8217;s auditor since 2014.</div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: 'Times New Roman'; text-align: center;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-3</div></div></div></div><div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: medium; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; margin-top: 1em; margin-bottom: 0em; break-before: page;"></div><hr style="font-family: 'Times New Roman'; font-size: medium; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; color: rgb(153, 153, 153); height: 3px; width: 1841px;"/><div style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a><br/> </div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Aeglea BioTherapeutics, Inc. </div></div><div id="fin518298_23" style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Consolidated Balance Sheets </div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(In thousands, except share and per share amounts) </div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:81%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td colspan="8" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">ASSETS</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">CURRENT ASSETS</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash and cash equivalents</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">34,863</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">15,142</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">20,848</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">77,986</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Development receivable</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:NontradeReceivablesCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">375</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:NontradeReceivablesCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">815</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Prepaid expenses and other current assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,172</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,948</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total current assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">62,258</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">98,891</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Restricted cash</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RestrictedCashNoncurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,553</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RestrictedCashNoncurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,838</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Property and equipment, net</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,220</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,549</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,430</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,806</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">683</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">842</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">TOTAL ASSETS</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">71,144</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">109,926</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td colspan="8" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">CURRENT LIABILITIES</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accounts payable</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableTradeCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">677</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableTradeCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,319</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">625</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">436</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred revenue</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredRevenueCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">517</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredRevenueCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,359</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued and other current liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">12,837</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">14,030</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total current liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">14,656</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">20,144</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div> operating lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,004</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,608</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred revenue, net of current portion</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,179</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,217</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">16</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">TOTAL LIABILITIES</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">20,839</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">25,985</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commitments and Contingencies (Note 9)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">STOCKHOLDERS&#8217; EQUITY</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Preferred stock, $<ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2021" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2022" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">10,000,000</ix:nonFraction></ix:nonFraction> shares authorized as of December&#160;31, 2022 and 2021; <ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn12_31_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding as of December&#160;31, 2022 and 2021</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Common stock, $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2021" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2022" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">20,000,000</ix:nonFraction></ix:nonFraction> shares authorized as of December&#160;31, 2022 and 2021, <span style="-sec-ix-hidden:hidden95764152"><span style="-sec-ix-hidden:hidden95764153">2,614,01</span>3</span> shares and <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">1,974,205</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of December&#160;31, 2022 and 2021, respectively</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">475,971</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">425,765</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accumulated other comprehensive (loss) income</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">48</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">20</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accumulated deficit</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">425,624</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">341,809</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">TOTAL STOCKHOLDERS&#8217; EQUITY</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">50,305</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">83,941</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">71,144</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">109,926</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">The accompanying notes are an integral part of these consolidated financial statements. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-4 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Aeglea BioTherapeutics, Inc. </div></div><div id="fin518298_24" style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Consolidated Statements of Operations </div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(In thousands, except share and per share amounts) </div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:67%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Revenue:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">License</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To12_31_2022_LicenseMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To12_31_2021_LicenseMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">12,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2020To12_31_2020_LicenseMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Development fee</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To12_31_2022_DevelopmentFeeMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,329</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To12_31_2021_DevelopmentFeeMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,739</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2020To12_31_2020_DevelopmentFeeMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total revenue</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,329</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">18,739</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating expenses:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">58,579</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">57,069</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">59,638</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">General and administrative</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">28,531</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">27,319</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">21,843</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total operating expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">87,110</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">84,388</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">81,481</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Loss from operations</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">84,781</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">65,649</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">81,481</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other income (expense):</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Interest income</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentIncomeNet" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">837</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentIncomeNet" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">111</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentIncomeNet" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">593</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other expense, net</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">7</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">122</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">5</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total other income (expense)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">830</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">11</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">588</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Loss before income tax expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">83,951</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">65,660</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">80,893</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Income tax benefit (expense)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">136</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">141</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">83,815</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">65,801</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">80,893</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss per share, basic and diluted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">24.86</ix:nonFraction></ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">25.02</ix:nonFraction></ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">37.89</ix:nonFraction></ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted-average common shares outstanding, basic and diluted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">3,371,231</ix:nonFraction></ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">2,629,784</ix:nonFraction></ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">2,134,869</ix:nonFraction></ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">The accompanying notes are an integral part of these consolidated financial statements. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-5 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div> <div> <div style="line-height:normal;background-color:white;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Aeglea BioTherapeutics, Inc. </div></div> <div id="fin518298_25" style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Consolidated Statements of Comprehensive Loss </div></div> <div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(In thousands) </div></div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:73%"></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">83,815</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">65,801</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">80,893</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other comprehensive income (loss):</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Foreign currency translation adjustment</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">35</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">19</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unrealized gain (loss) on marketable securities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">30</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">59</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total comprehensive loss</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">83,843</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">65,832</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">80,933</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">The accompanying notes are an integral part of these consolidated financial statements. </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-6 </div> </div> </div> </div> <div></div> </div> <div> <div style="line-height:normal;background-color:white;display: inline;"> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> </div> </div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Aeglea BioTherapeutics, Inc. </div></div><div id="fin518298_26" style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Consolidated Statements of Changes in Stockholders&#8217; Equity </div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(In thousands) </div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:51%"></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Common<br/> Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Additional<br/> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Paid-in</div><br/> Capital</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated<br/> Other<br/> Comprehensive<br/> (Loss) Income</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated<br/> Deficit</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total<br/> Stockholders&#8217;<br/> Equity</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balances&#8212;December 31, 2019</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,163</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">255,142</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2019_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">51</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">195,115</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">60,081</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of common stock and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants in connection with public and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">at-the-market</div></div> offerings, net of offering costs</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="agle:StockIssuedDuringPeriodSharesCommonStockAndPreFundedWarrants" contextRef="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">747</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="agle:StockIssuedDuringPeriodValueCommonStockAndPreFundedWarrants" contextRef="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="agle:StockIssuedDuringPeriodValueCommonStockAndPreFundedWarrants" contextRef="P01_01_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">153,570</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="agle:StockIssuedDuringPeriodValueCommonStockAndPreFundedWarrants" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">153,572</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of common stock in connection with exercise of stock options</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">5</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P01_01_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">490</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">490</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of common stock in connection with employee stock purchase plan</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" contextRef="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">3</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="P01_01_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">366</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">366</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock-based compensation expense</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="P01_01_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,256</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,256</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Foreign currency translation adjustment</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" contextRef="P01_01_2020To12_31_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">19</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">19</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unrealized loss on marketable securities</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="P01_01_2020To12_31_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">59</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">59</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2020To12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">80,893</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">80,893</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balances&#8212;December 31, 2020</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,918</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">415,824</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">11</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">276,008</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">139,832</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of common stock in connection with exercise of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="agle:IssuanceOfCommonStockInConnectionWithExerciseOfPreFundedWarrants" contextRef="P01_01_2021To12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">40</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of common stock in connection with exercise of stock options</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="P01_01_2021To12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">13</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P01_01_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,449</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,449</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of common stock in connection with employee stock purchase plan</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" contextRef="P01_01_2021To12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">3</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="P01_01_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">454</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">454</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock-based compensation expense</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="P01_01_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,038</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,038</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Foreign currency translation adjustment</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" contextRef="P01_01_2021To12_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unrealized loss on marketable securities</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="P01_01_2021To12_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">30</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">30</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">65,801</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">65,801</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balances&#8212;December 31, 2021</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,974</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">425,765</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">20</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">341,809</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">83,941</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of common stock and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants in connection with registered direct offering, net of offering costs</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="agle:IssuanceOfCommonStockAndPreFundedWarrantsSharesInConnectionWithRegisteredDirectOfferingNetOfOfferingCosts" contextRef="P01_01_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">430</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="agle:IssuanceOfCommonStockAndPreFundedWarrantsValueInConnectionWithRegisteredDirectOfferingNetOfOfferingCosts" contextRef="P01_01_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="agle:IssuanceOfCommonStockAndPreFundedWarrantsValueInConnectionWithRegisteredDirectOfferingNetOfOfferingCosts" contextRef="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">42,873</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="agle:IssuanceOfCommonStockAndPreFundedWarrantsValueInConnectionWithRegisteredDirectOfferingNetOfOfferingCosts" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">42,874</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of common stock in connection with exercise of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="agle:IssuanceOfCommonStockInConnectionWithExerciseOfPreFundedWarrants" contextRef="P01_01_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">204</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of common stock in connection with employee stock purchase plan</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" contextRef="P01_01_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">6</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">222</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">222</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock-based compensation expense</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,111</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,111</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Foreign currency translation adjustment</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" contextRef="P01_01_2022To12_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">35</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">35</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unrealized gain (loss) on marketable securities</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="P01_01_2022To12_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">83,815</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">83,815</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balances&#8212;December 31, 2022</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,614</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">475,971</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">48</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">425,624</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">50,305</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">The accompanying notes are an integral part of these consolidated financial statements. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-7 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Aeglea BioTherapeutics, Inc. </div></div><div id="fin518298_27" style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Consolidated Statements of Cash Flows </div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(In thousands) </div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:73%"></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">CASH FLOWS FROM OPERATING ACTIVITIES</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">83,815</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">65,801</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">80,893</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Adjustments to reconcile net loss to net cash used in operating activities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock-based compensation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,111</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,038</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,256</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Depreciation and amortization</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,567</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,576</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">996</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Purchase net (premium) discount on marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="agle:PaymentForDiscountPremiumOnInvestmentsNet" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">428</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="agle:PaymentForDiscountPremiumOnInvestmentsNet" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">344</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="agle:PaymentForDiscountPremiumOnInvestmentsNet" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">286</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net amortization of premium (accretion of discount) on marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">327</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">548</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">73</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-cash</div> operating lease expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="agle:NonCashOperatingLeaseExpense" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">397</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="agle:NonCashOperatingLeaseExpense" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">425</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="agle:NonCashOperatingLeaseExpense" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">628</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherNoncashIncomeExpense" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherNoncashIncomeExpense" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">9</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherNoncashIncomeExpense" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">9</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Changes in operating assets and liabilities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Development receivable</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">440</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">815</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accounts payable</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">2,641</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,065</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">544</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Prepaid expenses and other assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,144</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,216</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,101</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred revenue</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">880</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,576</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="agle:IncreaseDecreaseInOperatingLeaseLiabilities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">435</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="agle:IncreaseDecreaseInOperatingLeaseLiabilities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">404</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="agle:IncreaseDecreaseInOperatingLeaseLiabilities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">251</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued and other liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">843</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">373</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1,146</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net cash used in operating activities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">80,144</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">53,716</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">75,775</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">CASH FLOWS FROM INVESTING ACTIVITIES</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Purchases of property and equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">38</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">573</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,280</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Purchases of marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">39,500</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">133,079</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">129,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Proceeds from maturities and sales of marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">96,546</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">111,033</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">125,676</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net cash provided by (used in) investing activities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">57,008</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">22,619</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">7,604</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">CASH FLOWS FROM FINANCING ACTIVITIES</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Proceeds from issuance of common stock and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants in registered direct offering, net of offering costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="agle:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfOfferingCosts" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">42,874</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="agle:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfOfferingCosts" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="agle:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfOfferingCosts" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">153,716</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Proceeds from employee stock plan purchases and stock option exercises</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">222</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,903</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">816</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Principal payments on finance lease obligation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:FinanceLeasePrincipalPayments" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">418</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:FinanceLeasePrincipalPayments" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">510</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:FinanceLeasePrincipalPayments" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">20</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net cash provided by financing activities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">42,678</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,393</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">154,512</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Effect of exchange rate on cash, cash equivalents, and restricted cash</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">106</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">15</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">51</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">NET (DECREASE) INCREASE IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">19,436</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">74,957</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">71,184</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">CASH, CASH EQUIVALENTS, AND RESTRICTED CASH</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Beginning of period</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">16,980</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">91,937</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">20,753</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">End of period</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">36,416</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">16,980</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">91,937</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Supplemental Disclosure of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Cash</div> Investing and Financing Information:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Leased assets obtained in exchange for lease obligations</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="agle:LeasedAssetsObtainedInExchangeForLeaseObligations" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">21</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="agle:LeasedAssetsObtainedInExchangeForLeaseObligations" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">872</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="agle:LeasedAssetsObtainedInExchangeForLeaseObligations" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">172</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unpaid amounts related to purchase of property and equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">224</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">The accompanying notes are an integral part of these consolidated financial statements. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-8 </div></div></div></div><div></div></div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Aeglea BioTherapeutics, Inc. </div></div><div id="fin518298_28" style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Notes to Consolidated Financial Statements </div></div><ix:nonNumeric name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">1. The Company and Basis of Presentation </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Aeglea BioTherapeutics, Inc. (&#8220;Aeglea&#8221; or the &#8220;Company&#8221;) is a clinical-stage biotechnology company developing human enzyme therapeutics to benefit people with rare metabolic diseases. The Company was formed as a Limited Liability Company (LLC) in Delaware on December&#160;16, 2013 under the name Aeglea BioTherapeutics Holdings, LLC and was converted from a Delaware LLC to a Delaware corporation on March&#160;10, 2015. The Company operates in <ix:nonFraction name="us-gaap:NumberOfOperatingSegments" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_SEGMENT" decimals="0" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction> segment and has its principal offices in Austin, Texas. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Liquidity </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2022, the Company had working capital of $<ix:nonFraction name="agle:WorkingCapital" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">47.6</ix:nonFraction>&#160;million, an accumulated deficit of $<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal">425.6</ix:nonFraction>&#160;million, and cash, cash equivalents, marketable securities, and restricted cash of $<ix:nonFraction name="agle:CashCashEquivalentsMarketableSecuritiesAndRestrictedCash" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">57.3</ix:nonFraction>&#160;million. The Company has not generated any product revenues and has not achieved profitable operations. There is no assurance that profitable operations will ever be achieved, and, if achieved, could be sustained on a continuing basis. In addition, development activities, clinical and nonclinical testing, and commercialization of the Company&#8217;s products will require significant additional financing. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is subject to a number of risks similar to other life science companies, including, but not limited to, risks related to the successful discovery, development, and commercialization of product candidates, raising additional capital, development of competing drugs and therapies, protection of proprietary technology and market acceptance of the Company&#8217;s products. As a result of these and other factors and the related uncertainties, there can be no assurance of the Company&#8217;s future success. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">205-40,</div> Going Concern, the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date the financial statements included in this Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> are issued. Based upon the Company&#8217;s current operating plans, the Company believes that it has sufficient resources to fund operations into the fourth quarter of 2023 with its existing cash, cash equivalents, and marketable securities. Accordingly, based on its recurring losses from operations incurred since inception, the expectation of continued operating losses, and the need to raise additional capital to finance its future operations, the Company determined that there is substantial doubt about the Company&#8217;s ability to continue as a going concern within twelve months of the issuance date of these financial statements. The accompanying consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty and assumes the Company will continue as a going concern through the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business. The Company plans to address this condition through the sale of common stock in public offerings and/or private placements, debt financings, or through other capital sources, including collaborations with other companies or other strategic transactions. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although the Company has been successful in raising capital in the past, there is no assurance that it will be successful in obtaining such additional financing on terms acceptable to the Company, if at all, nor is it considered probable under the accounting standards. If the Company is unable to obtain sufficient funding on acceptable terms, it could be forced to delay, reduce or eliminate some or all of its research and development programs or commercialization activities, which could materially adversely affect its business prospects or its ability to continue operations. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Basis of Presentation </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States (&#8220;U.S. GAAP&#8221;) as defined by the Financial Accounting Standards Board (&#8220;FASB&#8221;) and include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. </div></ix:nonNumeric><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-9 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:nonNumeric name="us-gaap:SignificantAccountingPoliciesTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_95763961"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">2. Summary of Significant Accounting Policies </div></div><ix:nonNumeric name="us-gaap:UseOfEstimates" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Use of Estimates </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances, the results of which form the basis for making judgements about the carrying value of assets, liabilities, and equity and the amount of revenues and expenses. Estimates are used in accounting for, among other items, accrued research and development costs and revenue recognition. Actual results could differ materially from those estimates. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Cash and Cash Equivalents </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company considers all highly liquid investments with original maturities of three months or less from the date of purchase to be cash equivalents. Cash equivalents consist of money market funds and debt securities and are stated at fair value. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:MarketableSecuritiesPolicy" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Marketable Securities </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All investments have been classified as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> and are carried at estimated fair value as determined based upon quoted market prices or pricing models for similar securities. Management determines the appropriate classification of its investments in debt securities at the time of purchase. The Company may hold securities with stated maturities greater than <ix:nonNumeric name="agle:MarketableSecuritiesMaturityPeriod" contextRef="P01_01_2022To12_31_2022_MaximumMembersrtRangeAxis" format="ixt-sec:durwordsen">one year</ix:nonNumeric> until maturity. All <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> securities are considered available to support current operations and are classified as current assets. The Company presents credit losses as an allowance rather than as a reduction in the amortized cost of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> securities. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> debt securities in an unrealized loss position, the Company first assesses whether it intends to sell, or it is more likely than not that it will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security&#8217;s amortized cost basis is written down to fair value and recognized in other income (expense) in the results of operations. For <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> debt securities that do not meet the aforementioned criteria, the Company evaluates whether the decline in fair value has resulted from credit losses or other factors. In making this assessment, management considers the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and adverse conditions specifically related to the security, among other factors. If this assessment indicates that a credit loss exists, an allowance is recorded for the difference between the present value of cash flows expected to be collected and the amortized cost basis of the security. Impairment losses attributable to credit loss factors are charged against the allowance when management believes an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> security is uncollectible or when either of the criteria regarding intent or requirement to sell is met. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any unrealized losses from declines in fair value below the amortized cost basis as a result of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-credit</div> loss factors is recognized as a component of accumulated other comprehensive (loss) income, along with unrealized gains. Realized gains and losses and declines in fair value, if any, on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> securities are included in other income (expense) in the results of operations. The cost of securities sold is based on the specific-identification method. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Restricted Cash </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Restricted cash consists of money market accounts held by financial institutions as collateral for the Company&#8217;s obligations under a credit agreement and a facility lease for the Company&#8217;s corporate headquarters in Austin, Texas. </div></ix:nonNumeric><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-10</ix:exclude> </div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_95763961" continuedAt="TextSelectionAppend_95763961_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_95763961_1" continuedAt="TextSelectionAppend_95763961_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_95763961_2" continuedAt="TextSelectionAppend_95763961_3"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_95763961_3" continuedAt="TextSelectionAppend_95763961_4"><ix:nonNumeric name="us-gaap:ConcentrationRiskCreditRisk" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Concentration of Credit Risk </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash, cash equivalents, marketable securities, and restricted cash. The Company&#8217;s investment policy limits investments to high credit quality securities issued by the U.S. government, U.S. government-sponsored agencies, highly rated banks, and corporate issuers, subject to certain concentration limits and restrictions on maturities. The Company&#8217;s cash, cash equivalents, marketable securities, and restricted cash are held by financial institutions that management believes are of high credit quality. Amounts on deposit may at times exceed federally insured limits. The Company has not experienced any losses on its deposits of cash, cash equivalents, and restricted cash and its accounts are monitored by management to mitigate risk. The Company is exposed to credit risk in the event of default by the financial institutions holding its cash, cash equivalents, and restricted cash, and bond issuers. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Property and Equipment </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Property and equipment are stated at cost, net of accumulated depreciation and amortization. Depreciation and amortization are computed using the straight-line method over the estimated useful lives of the assets. Repairs and maintenance that do not extend the life or improve an asset are expensed as incurred. Upon retirement or sale, the cost of disposed assets and their related accumulated depreciation and amortization are removed from the balance sheet. Any gain or loss is credited or charged to operations. </div><ix:nonNumeric name="agle:ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The useful lives of the property and equipment are as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:39%"></td>
<td style="vertical-align:bottom;width:2%"></td>
<td style="width:59%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Laboratory equipment</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="PAsOn12_31_2022_LaboratoryEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" format="ixt-sec:duryear">5</ix:nonNumeric> years</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Furniture and office equipment</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="PAsOn12_31_2022_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" format="ixt-sec:duryear">5</ix:nonNumeric> years</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Computer equipment</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="PAsOn12_31_2022_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" format="ixt-sec:duryear">3</ix:nonNumeric> years</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Software</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="PAsOn12_31_2022_PurchasedSoftwareMemberusgaapPropertyPlantAndEquipmentByTypeAxis" format="ixt-sec:duryear">3</ix:nonNumeric> years</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Leasehold improvements</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentBasisOfValuation" contextRef="P01_01_2022To12_31_2022_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">Shorter of remaining lease term or estimated useful life</ix:nonNumeric></td></tr></table></ix:nonNumeric></ix:nonNumeric><ix:nonNumeric name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Impairment of Long-Lived Assets </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Long-lived assets are reviewed for indications of possible impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amounts to the future undiscounted cash flows attributable to these assets. An impairment loss is recognized to the extent an asset group is not recoverable, and the carrying amount exceeds the fair value. There were <ix:nonFraction name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> impairments of long-lived assets for the years ended December&#160;31, 2022, 2021, and 2020. </div></ix:nonNumeric><ix:nonNumeric name="agle:AccruedResearchAndDevelopmentExpensePolicyTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_95764340"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Accrued Research and Development Costs </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company records the costs associated with research nonclinical studies, clinical trials, and manufacturing development as incurred. These costs are a significant component of the Company&#8217;s research and development expenses, with a substantial portion of the Company&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">on-going</div> research and development activities conducted by third-party service providers, including contract research and manufacturing organizations. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company accrues for expenses resulting from obligations under agreements with contract research organizations (&#8220;CROs&#8221;), contract manufacturing organizations (&#8220;CMOs&#8221;), and other outside service providers for which payment flows do not match the periods over which materials or services are provided to the Company. Accruals are recorded based on estimates of services received and efforts expended pursuant to agreements established with CROs, CMOs, and other outside service providers. These estimates are typically based on contracted amounts applied to the proportion of work performed and determined through analysis with internal personnel and external service providers as to the progress or stage of completion of the services. The Company </div><ix:exclude><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-11 </div></ix:exclude></ix:nonNumeric></ix:continuation></div></div><ix:continuation id="TextSelection_95764340" continuedAt="TextSelectionAppend_95764340_1"><ix:continuation id="TextSelectionAppend_95763961_4" continuedAt="TextSelectionAppend_95763961_5"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_95763961_5" continuedAt="TextSelectionAppend_95763961_6"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_95763961_6" continuedAt="TextSelectionAppend_95763961_7"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_95763961_7" continuedAt="TextSelectionAppend_95763961_8"><ix:continuation id="TextSelectionAppend_95764340_1"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">makes significant judgments and estimates in determining the accrual balance in each reporting period. In the event advance payments are made to a CRO, CMO, or outside service provider, the payments will be recorded as a prepaid asset which will be amortized as the contracted services are performed. As actual costs become known, the Company adjusts its accruals. Inputs, such as the services performed, the number of patients enrolled, or the study duration, may vary from the Company&#8217;s estimates, resulting in adjustments to research and development expense in future periods. Changes in these estimates that result in material changes to the Company&#8217;s accruals could materially affect the Company&#8217;s results of operations. Historically, the Company has not <div style="display:inline;">experienced </div>any material deviations between accrued and actual research and development expenses. </div></ix:continuation><ix:nonNumeric name="us-gaap:LesseeLeasesPolicyTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Leases </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company determines if an arrangement is a lease at inception. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Right-of-use</div></div> (&#8220;ROU&#8221;) assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. The classification of the Company&#8217;s leases as operating or finance leases along with the initial measurement and recognition of the associated ROU assets and lease liabilities is performed at the lease commencement date. The measurement of lease liabilities is based on the present value of future lease payments over the lease term. As the Company&#8217;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of future lease payments. To determine the incremental borrowing rate, the Company uses the lease-term appropriate current treasury bond rates adjusted for collateral and inflation risks combined with quoted bank financing rates. The ROU asset is based on the measurement of the lease liability and also includes any lease payments made prior to or on lease commencement and excludes lease incentives and initial direct costs incurred, as applicable. The lease terms may include options to extend or terminate the lease when it is reasonably certain the Company will exercise any such options. Rent expense for the Company&#8217;s operating leases is recognized on a straight-line basis over the lease term. Amortization expense for the ROU asset associated with its finance leases is recognized on a straight-line basis over the term of the lease and interest expense associated with its finance leases is recognized on the balance of the lease liability using the effective interest method based on the estimated incremental borrowing rate. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has lease agreements with lease and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components. As allowed under Topic 842, the Company has elected to not separate lease and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components for any leases involving real estate and office equipment classes of assets and, as a result, accounts for the lease and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components as a single lease component. The Company has also elected to not apply the recognition requirement of Topic 842 to leases with a term of 12 months or less for all classes of assets. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:FairValueOfFinancialInstrumentsPolicy" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_95764342"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Fair Value of Financial Instruments </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company uses fair value measurements to record fair value adjustments to certain financial and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-financial</div> assets and liabilities and to determine fair value disclosures. The accounting standards define fair value, establish a framework for measuring fair value, and require disclosures about fair value measurements. Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required to be recorded at fair value, the principal or most advantageous market in which the Company would transact are considered along with assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accounting standard for fair value establishes a fair value hierarchy based on three levels of inputs, the first two of which are considered observable and the last unobservable, that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. A financial instrument&#8217;s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-12</ix:exclude> </div></ix:nonNumeric></ix:continuation></div></div><ix:continuation id="TextSelection_95764342" continuedAt="TextSelectionAppend_95764342_1"><ix:continuation id="TextSelectionAppend_95763961_8" continuedAt="TextSelectionAppend_95763961_9"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_95763961_9" continuedAt="TextSelectionAppend_95763961_10"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_95763961_10" continuedAt="TextSelectionAppend_95763961_11"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></ix:continuation></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_95763961_11" continuedAt="TextSelectionAppend_95763961_12"><ix:continuation id="TextSelectionAppend_95764342_1"><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The three levels of inputs that may be used to measure fair value are as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:9%"></td>
<td style="vertical-align:bottom;width:2%"></td>
<td style="width:90%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Level&#160;1:</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Observable inputs, such as quoted prices in active markets for identical assets or liabilities.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td colspan="2" style="height:6pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Level&#160;2:</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Observable inputs other than Level&#160;1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td colspan="2" style="height:6pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Level&#160;3:</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Valuations based on unobservable inputs to the valuation methodology and including data about assumptions that market participants would use in pricing the asset or liability based on the best information available under the circumstances.</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Financial instruments carried at fair value include cash, cash equivalents, marketable securities, and restricted cash. The carrying amounts of accounts payable and accrued liabilities approximate fair value due to their relatively short maturities. </div></ix:continuation><ix:nonNumeric name="us-gaap:RevenueRecognitionPolicyTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_95764343"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Revenue Recognition </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under ASC Topic 606, &#8220;Revenue from Contracts with Customers&#8221; (&#8220;Topic 606&#8221;), an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of Topic 606, the entity performs the following five steps: (i)&#160;identify the contract(s) with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price, including variable consideration, if any; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the entity satisfies a performance obligation. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company assesses its license arrangements within the scope of Topic 606 in accordance with this framework as follows: </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">License revenue </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company assesses whether the goods or services promised within each contract are distinct to identify those that are performance obligations. This assessment involves subjective determinations and requires management to make judgments about the individual promised goods or services and whether such are separable from the other aspects of the contractual relationship. In assessing whether a promised good or service is distinct, and therefore a performance obligation, the Company considers factors such as the research, stage of development of the licensed product, manufacturing and commercialization capabilities of the customer and the availability of the associated expertise in the general marketplace. The Company also considers the intended benefit of the contract in assessing whether a promised good or service is separately identifiable from other promises in the contract. If a promised good or service is not distinct, the Company is required to combine that good or service with other promised goods or services until it identifies a bundle of goods or services that is distinct. Arrangements that include rights to additional goods or services that are exercisable at a customer&#8217;s discretion are generally considered options. The Company assesses if these options provide a material right to the customer and if so, they are considered performance obligations. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transaction price is determined and allocated to the identified performance obligations in proportion to their stand-alone selling prices (&#8220;SSP&#8221;) on a relative SSP basis. SSP is based on observable prices of the performance obligations or, when such prices are not observable, are estimated. The estimation of SSP may include factors such as forecasted revenues or costs, development timelines, discount rates, probabilities of technical and regulatory success, and considerations such as market conditions and entity-specific factors. In certain circumstances, the Company may apply the residual method to determine the SSP of a good or service if the SSP is considered highly variable or uncertain. The Company validates the SSP for performance obligations </div><ix:exclude><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-13 </div></ix:exclude></ix:nonNumeric></ix:continuation></div></div><ix:continuation id="TextSelection_95764343" continuedAt="TextSelectionAppend_95764343_1"><ix:continuation id="TextSelectionAppend_95763961_12" continuedAt="TextSelectionAppend_95763961_13"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_95763961_13" continuedAt="TextSelectionAppend_95763961_14"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_95763961_14" continuedAt="TextSelectionAppend_95763961_15"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_95764343_1" continuedAt="TextSelectionAppend_95764343_2"><ix:continuation id="TextSelectionAppend_95763961_15" continuedAt="TextSelectionAppend_95763961_16"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">by evaluating whether changes in the key assumptions used to determine the SSP will have a significant effect on the allocation of arrangement consideration between multiple performance obligations. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the consideration promised in a contract includes a variable amount, the Company estimates the amount of consideration to which it will be entitled in exchange for transferring the promised goods or services to a customer. The Company determines the amount of variable consideration by using the expected value method or the most likely amount method. The Company includes the amount of estimated variable consideration in the transaction price to the extent that it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-evaluates</div> the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">catch-up</div> basis in the period of adjustment. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an arrangement includes development, regulatory or commercial milestone payments, the Company evaluates whether the milestones are considered likely of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant cumulative revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company&#8217;s control or the licensee&#8217;s control, such as regulatory approvals, are generally not considered likely of being achieved until those approvals are received. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In determining the transaction price, the Company adjusts consideration for the effects of the time value of money if the timing of payments provides the Company with a significant benefit of financing. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the licensee and the transfer of the promised goods or services to the licensees will be one year or less. For arrangements with licenses of intellectual property that include sales-based royalties, including milestone payments based on the level of sales, and if the license is deemed to be the predominant item to which the royalties relate, the Company recognizes royalty revenue and sales-based milestones at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which the royalty has been allocated has been satisfied. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied at a point in time or over time, and if over time, recognition is based on the use of an output or input method. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#8217;s contracts may be modified for changes in the customer&#8217;s requirements. If contract modifications are for additional goods and services that are distinct from the existing contract, the modification will be accounted for as either a separate contract or a termination of the existing contract, depending on whether the additional goods or services reflects the SSP. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the additional goods or services in a contract modification are not distinct from the existing contract, they are accounted for as if they were part of the original contract. The effect of the contract modification on the transaction price and the measure of progress for the performance obligation to which it relates is recognized as an adjustment to revenue on a cumulative <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">catch-up</div> basis. The cumulative <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">catch-up</div> adjustment is calculated using an updated measure of progress applied to the sum of (1)&#160;the remaining consideration allocated to the partially satisfied performance obligation and (2)&#160;the revenue already recognized on that performance obligation. The revenue recognized for fully satisfied goods or services and distinct from the remaining performance obligations is not altered by the modification. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Collaborative arrangements </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company analyzes its license arrangements to assess whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-14</ix:exclude> </div></ix:continuation></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_95764343_2" continuedAt="TextSelectionAppend_95764343_3"><ix:continuation id="TextSelectionAppend_95763961_16" continuedAt="TextSelectionAppend_95763961_17"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_95763961_17" continuedAt="TextSelectionAppend_95763961_18"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_95763961_18" continuedAt="TextSelectionAppend_95763961_19"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></ix:continuation></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_95763961_19" continuedAt="TextSelectionAppend_95763961_20"><ix:continuation id="TextSelectionAppend_95764343_3"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">and rewards dependent on the commercial success of such activities and therefore within the scope of ASC Topic 808, Collaborative Arrangements (&#8220;Topic 808&#8221;). This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. For arrangements within the scope of Topic 808 that contain multiple elements, the Company first determines which elements of the collaboration are deemed to be within the scope of Topic 808 and which elements of the collaboration are more reflective of a vendor-customer relationship and therefore within the scope of Topic 606. For elements of collaboration arrangements that are accounted for pursuant to Topic 808, an appropriate recognition method is determined and applied consistently, either by analogy to authoritative accounting literature or by applying a reasonable and rational policy election. For those elements of the arrangement that are accounted for pursuant to Topic 606, the Company applies the five-step model described <div style="display:inline;">above</div>. </div></ix:continuation><ix:nonNumeric name="us-gaap:ResearchAndDevelopmentExpensePolicy" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Research and Development Costs </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development costs are expensed as incurred. Research and development costs include, but are not limited to, salaries, benefits, travel, stock-based compensation, consulting costs, contract research service costs, laboratory supplies and facilities, contract manufacturing costs, and costs paid to other third parties that conduct research and development activities on the Company&#8217;s behalf. Amounts incurred in connection with license agreements are also included in research and development expense. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Advance payments for goods or services to be rendered in the future for use in research and development activities are recorded as a prepaid asset and expensed as the related goods are delivered or the services are performed. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Stock-Based Compensation </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognizes the cost of stock-based awards granted to employees and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employees</div> based on the estimated grant-date fair values of the awards. The fair values of stock options are estimated on the date of grant using the Black-Scholes option pricing model. The fair values of restricted stock units (&#8220;RSUs&#8221;) are based on the fair value of the Company&#8217;s common stock on the date of the grant. The value of the award is recognized as compensation expense on a straight-line basis over the requisite service period. Forfeitures are recognized when they occur, which may result in the reversal of compensation costs in subsequent periods as the forfeitures arise. Compensation expense for employee and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> share-based payment awards with performance conditions is recognized when the performance condition is deemed probable. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:IncomeTaxPolicyTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Income Taxes </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company and its <ix:nonFraction name="agle:NumberOfSubsidiaryCorporationsOwned" contextRef="PAsOn12_31_2022" unitRef="Unit_SUBSIDARY" decimals="0" scale="0" format="ixt-sec:numwordsen">ten</ix:nonFraction> wholly owned subsidiary corporations use the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial statements and the tax bases of assets and liabilities. Additionally, any changes in income tax laws are immediately recognized in the year of enactment. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A valuation allowance is established against the deferred tax assets to reduce their carrying value to an amount that is more likely than not to be realized. The deferred tax assets and liabilities are classified as noncurrent along with the related valuation allowance. Due to a lack of earnings history, the net deferred tax assets have been fully offset by a valuation allowance. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognizes benefits of uncertain tax positions if it is more likely than not that such positions will be sustained upon examination based solely on the technical merits, as the largest amount of benefits that is more likely than not to be realized upon the ultimate settlement. The Company&#8217;s policy is to recognize interest and penalties related to the unrecognized tax benefits as a component of income tax expense, if applicable. As of December&#160;31, 2022 and 2021, the Company had <ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> unrecognized tax benefits and there were <ix:nonFraction name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> interest or penalties incurred by the Company in the years ended December&#160;31, 2022, 2021, or 2020. </div></ix:nonNumeric><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-15</ix:exclude> </div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_95763961_20" continuedAt="TextSelectionAppend_95763961_21"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_95763961_21" continuedAt="TextSelectionAppend_95763961_22"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_95763961_22" continuedAt="TextSelectionAppend_95763961_23"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_95763961_23"><ix:nonNumeric name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Comprehensive Loss </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Comprehensive loss is the change in stockholders&#8217; equity from transactions and other events and circumstances other than those resulting from investments by stockholders and distributions to stockholders. The Company&#8217;s other comprehensive income (loss) is currently comprised of changes in unrealized losses and gains on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> securities and foreign currency translation adjustments reflecting the cumulative effect of changes in exchange rates between the foreign entity&#8217;s functional currency and the reporting currency. </div></ix:nonNumeric></ix:continuation><ix:nonNumeric name="us-gaap:FairValueDisclosuresTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">3. Fair Value Measurements </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company measures and reports certain financial instruments as assets and liabilities at fair value on a recurring basis. <ix:nonNumeric name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_95763983">The following tables sets forth the fair value of the Company&#8217;s financial assets and liabilities at fair value on a recurring basis based on the three-tier fair value hierarchy (in thousands): </ix:nonNumeric></div><ix:continuation id="TextSelection_95763983"><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:63%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Financial Assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Money market funds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">15,250</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">15,250</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial paper</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">23,641</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapFairValueByAssetClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">23,641</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">U.S. government securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapCashAndCashEquivalentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,230</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapCashAndCashEquivalentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,230</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate bonds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2022_CorporateBondSecuritiesMemberusgaapInvestmentTypeAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,732</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2022_CorporateBondSecuritiesMemberusgaapInvestmentTypeAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,732</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total financial assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">15,250</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">31,603</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">46,853</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:64%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Financial Assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Money market funds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,888</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,888</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial paper</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2021_CommercialPaperMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">65,412</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2021_CommercialPaperMemberusgaapFairValueByAssetClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">65,412</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate bonds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2021_CorporateBondSecuritiesMemberusgaapInvestmentTypeAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">12,574</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2021_CorporateBondSecuritiesMemberusgaapInvestmentTypeAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">12,574</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total financial assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,888</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">77,986</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">86,874</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:continuation><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company measures the fair value of money market funds on quoted prices in active markets for identical asset or liabilities. The Level&#160;2 assets include U.S. government agency securities, commercial paper and corporate bonds, and are valued based on quoted prices for similar assets in active markets and inputs other than quoted prices that are derived from observable market data. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company evaluates transfers between levels at the end of each reporting period. There were <ix:nonFraction name="agle:FairValueAssetsLevel1ToLevel2TransfersAmount1" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="agle:FairValueAssetsLevel1ToLevel2TransfersAmount1" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> transfers between Level&#160;1 and Level&#160;2 during the periods presented. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_95763958"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">4. Cash Equivalents and Marketable Securities </div></div><ix:nonNumeric name="us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_95763966"><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following tables summarize the estimated fair value of the Company&#8217;s cash equivalents and marketable securities and the gross unrealized gains and losses (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:57%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amortized<br/> Cost</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross<br/> Unrealized<br/> Gains</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross<br/> Unrealized<br/> Losses</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Estimated<br/> Fair<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash equivalents:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Money market funds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2022_MoneyMarketFundsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">15,250</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="PAsOn12_31_2022_MoneyMarketFundsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">15,250</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial paper</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,021</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="agle:CashEquivalentsUnrealizedGains" contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="agle:CashEquivalentsUnrealizedLosses" contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,020</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">U.S. government securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2022_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,736</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="agle:CashEquivalentsUnrealizedLosses" contextRef="PAsOn12_31_2022_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="PAsOn12_31_2022_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,735</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total cash equivalents</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">26,007</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="agle:CashEquivalentsUnrealizedGains" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="agle:CashEquivalentsUnrealizedLosses" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">26,005</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-16</ix:exclude> </div></ix:nonNumeric></ix:nonNumeric></div></div><ix:continuation id="TextSelection_95763966" continuedAt="TextSelectionAppend_95763966_1"><ix:continuation id="TextSelection_95763958" continuedAt="TextSelectionAppend_95763958_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_95763958_1" continuedAt="TextSelectionAppend_95763958_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_95763958_2" continuedAt="TextSelectionAppend_95763958_3"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></ix:continuation></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_95763958_3" continuedAt="TextSelectionAppend_95763958_4"><ix:continuation id="TextSelectionAppend_95763966_1">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:56%"></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amortized<br/> Cost</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross<br/> Unrealized<br/> Gains</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross<br/> Unrealized<br/> Losses</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Estimated<br/> Fair&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Marketable securities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial paper</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">16,644</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">25</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">16,621</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate bonds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="PAsOn12_31_2022_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,738</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="PAsOn12_31_2022_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="PAsOn12_31_2022_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,732</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">U.S. government securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="PAsOn12_31_2022_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">495</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="PAsOn12_31_2022_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">495</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">20,877</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">31</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">20,848</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:57%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amortized<br/> Cost</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross<br/> Unrealized<br/> Gains</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross<br/> Unrealized<br/> Losses</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Estimated<br/> Fair&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash equivalents:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Money market funds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2021_MoneyMarketFundsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,888</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="agle:CashEquivalentsUnrealizedLosses" contextRef="PAsOn12_31_2021_MoneyMarketFundsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="PAsOn12_31_2021_MoneyMarketFundsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,888</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total cash equivalents</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,888</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="agle:CashEquivalentsUnrealizedLosses" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,888</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Marketable securities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial paper</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="PAsOn12_31_2021_CommercialPaperMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">65,443</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="PAsOn12_31_2021_CommercialPaperMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="PAsOn12_31_2021_CommercialPaperMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">34</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="PAsOn12_31_2021_CommercialPaperMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">65,412</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate bonds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="PAsOn12_31_2021_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">12,581</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="PAsOn12_31_2021_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="PAsOn12_31_2021_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">12,574</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">78,024</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">41</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">77,986</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:continuation><ix:nonNumeric name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> securities in an unrealized loss position for which an allowance for credit losses has <ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" contextRef="PAsOn12_31_2021_USGovernmentAgenciesDebtSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" contextRef="PAsOn12_31_2022_USGovernmentAgenciesDebtSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction>t been recorded as of December&#160;31, 2022 and 2021, aggregated by major security type and length of time in a continuous unrealized loss position: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:46%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="22" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Less Than 12 Months</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">12&#160;Months&#160;or&#160;Longer</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Losses</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Losses</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Losses</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial paper</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">17,699</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">27</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">17,699</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">27</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">U.S. government securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" contextRef="PAsOn12_31_2022_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,735</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" contextRef="PAsOn12_31_2022_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" contextRef="PAsOn12_31_2022_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,735</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" contextRef="PAsOn12_31_2022_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate bonds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" contextRef="PAsOn12_31_2022_CorporateBondSecuritiesMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,732</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" contextRef="PAsOn12_31_2022_CorporateBondSecuritiesMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" contextRef="PAsOn12_31_2022_CorporateBondSecuritiesMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,732</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" contextRef="PAsOn12_31_2022_CorporateBondSecuritiesMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">25,166</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">34</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">25,166</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">34</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:46%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="22" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Less Than 12 Months</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">12&#160;Months&#160;or&#160;Longer</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Losses</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Losses</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Losses</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial paper</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" contextRef="PAsOn12_31_2021_CommercialPaperMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">47,425</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" contextRef="PAsOn12_31_2021_CommercialPaperMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">34</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" contextRef="PAsOn12_31_2021_CommercialPaperMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">47,425</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" contextRef="PAsOn12_31_2021_CommercialPaperMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">34</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate bonds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" contextRef="PAsOn12_31_2021_CorporateBondSecuritiesMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">12,573</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" contextRef="PAsOn12_31_2021_CorporateBondSecuritiesMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" contextRef="PAsOn12_31_2021_CorporateBondSecuritiesMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">12,573</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" contextRef="PAsOn12_31_2021_CorporateBondSecuritiesMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">59,998</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">41</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">59,998</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">41</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company evaluated its securities for credit losses and considered the decline in market value to be primarily attributable to current economic and market conditions and not to a credit loss or other factors. Additionally, the Company does <ix:nonFraction name="agle:ImpairmentOfMarketableSecurities" contextRef="P01_01_2022To12_31_2022_USGovernmentAgenciesDebtSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="agle:ImpairmentOfMarketableSecurities" contextRef="P01_01_2021To12_31_2021_USGovernmentAgenciesDebtSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction>t intend to sell the securities in an unrealized loss position and does not expect they will be required to sell the securities before recovery of the unamortized cost basis. As of December&#160;31, 2022 and 2021, an allowance for credit losses had not been recognized. Given the Company&#8217;s intent and ability to hold such securities until recovery, and the lack of significant change in credit risk of these investments, the Company does <ix:nonFraction name="agle:ImpairmentOfMarketableSecurities" contextRef="P01_01_2022To12_31_2022_USGovernmentAgenciesDebtSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="agle:ImpairmentOfMarketableSecurities" contextRef="P01_01_2021To12_31_2021_USGovernmentAgenciesDebtSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction>t consider these marketable securities to be impaired as of December&#160;31, 2022 and 2021. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-17</ix:exclude> </div></ix:continuation></div></div></div><ix:continuation id="TextSelectionAppend_95763958_4" continuedAt="TextSelectionAppend_95763958_5"><div></div></ix:continuation></div><div><div style="line-height:normal;background-color:white;display: inline;"><ix:continuation id="TextSelectionAppend_95763958_5" continuedAt="TextSelectionAppend_95763958_6"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_95763958_6" continuedAt="TextSelectionAppend_95763958_7"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_95763958_7" continuedAt="TextSelectionAppend_95763958_8"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_95763958_8"><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There were <ix:nonFraction name="us-gaap:MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments" contextRef="P01_01_2022To12_31_2022_USGovernmentAgenciesDebtSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments" contextRef="P01_01_2021To12_31_2021_USGovernmentAgenciesDebtSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen">no </ix:nonFraction></ix:nonFraction>realized gains or losses on marketable securities for the years ended December&#160;31, 2022 and 2021. Interest on marketable securities is included in interest income. Accrued interest receivable on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> debt securities totaled $<ix:nonFraction name="us-gaap:InterestReceivable" contextRef="PAsOn12_31_2022_USGovernmentAgenciesDebtSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.1</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:InterestReceivable" contextRef="PAsOn12_31_2021_USGovernmentAgenciesDebtSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.1</ix:nonFraction>&#160;million as of December&#160;31, 2022 and 2021, respectively, and is excluded from the estimate of credit losses. </div><ix:nonNumeric name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the contractual maturities of the Company&#8217;s marketable securities at estimated fair value (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:74%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Due in one year or less</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">20,848</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">77,986</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Due in 1 &#8211; 2 years</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">20,848</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">77,986</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company may sell investments at any time for use in current operations even if they have not yet reached maturity. As a result, the <div style="letter-spacing: 0px; top: 0px;;display:inline;">Company </div>classifies marketable securities, including securities with maturities beyond twelve months as current assets. </div></ix:continuation><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">5. Property and Equipment, Net </div></div><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Property and equipment, net consist of the following (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:76%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Laboratory equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2022_LaboratoryEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,257</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2021_LaboratoryEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,245</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Furniture and office equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2022_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">520</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2021_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">520</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Computer equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2022_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">73</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2021_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">54</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Software</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2022_PurchasedSoftwareMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">121</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2021_PurchasedSoftwareMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">139</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Leasehold improvements</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2022_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,393</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2021_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,393</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Property and equipment, gross</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,364</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,351</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: Accumulated depreciation and amortization</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,144</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,802</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Property and equipment, net</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,220</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,549</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depreciation and amortization expense for the years ended December&#160;31, 2022, 2021, and 2020 was $<ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="P01_01_2022To12_31_2022_PropertyPlantAndEquipmentMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.4</ix:nonFraction>&#160;million, $<ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="P01_01_2021To12_31_2021_PropertyPlantAndEquipmentMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.4</ix:nonFraction>&#160;million, and $<ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="P01_01_2020To12_31_2020_PropertyPlantAndEquipmentMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.0</ix:nonFraction>&#160;million, respectively. All of the Company&#8217;s long-lived assets are located in the United States. </div></ix:nonNumeric><ix:nonNumeric name="agle:AccruedAndOtherCurrentLiabilitiesTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">6. Accrued and Other Current Liabilities </div></div><ix:nonNumeric name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accrued and other current liabilities consist of the following (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:74%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued compensation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccruedSalariesCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,589</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccruedSalariesCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,988</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued contracted research and development costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="agle:AccruedContractedResearchAndDevelopmentCosts" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,972</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="agle:AccruedContractedResearchAndDevelopmentCosts" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,995</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued professional and consulting fees</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">946</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,264</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">330</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">783</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total accrued and other current liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">12,837</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">14,030</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric></ix:nonNumeric><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-18 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:nonNumeric name="agle:LesseeOperatingAndFinanceLeasesDisclosureTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_95765392"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">7. Leases </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company leases certain office space, laboratory facilities, and equipment. These leases require monthly lease payments that may be subject to annual increases throughout the lease term. Certain of these leases also include renewal options at the election of the Company to renew or extend the lease for an additional <span style="-sec-ix-hidden:hidden95765451"><span style="-sec-ix-hidden:hidden95765453">thre</span>e</span> to <ix:nonNumeric name="us-gaap:LesseeFinanceLeaseRenewalTerm1" contextRef="PAsOn12_31_2022_MaximumMembersrtRangeAxis" format="ixt-sec:durwordsen"><ix:nonNumeric name="us-gaap:LesseeOperatingLeaseRenewalTerm" contextRef="PAsOn12_31_2022_MaximumMembersrtRangeAxis" format="ixt-sec:durwordsen">five years</ix:nonNumeric></ix:nonNumeric>. These optional periods have not been considered in the determination of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets or lease liabilities associated with these leases as the Company did not consider it reasonably certain it would exercise the options. The Company performed evaluations of its contracts and determined it has both operating and finance leases. Variable lease expense for these leases primarily consists of common area maintenance and other operating costs. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2019, the Company entered into a lease agreement (the &#8220;Las Cimas Lease&#8221;) for its corporate headquarters and laboratory space located in Austin, Texas. The Las Cimas Lease includes approximately <ix:nonFraction name="us-gaap:AreaOfLand" contextRef="PAsOn04_30_2019" unitRef="Unit_sqft" decimals="INF" scale="0" format="ixt:num-dot-decimal">30,000</ix:nonFraction> square feet and commenced on April&#160;30, 2019, with an expiration on <ix:nonNumeric name="us-gaap:LeaseExpirationDate1" contextRef="P04_01_2019To04_30_2019" format="ixt:date-monthname-day-year-en">April 30, 2028</ix:nonNumeric>. The Company posted a customary letter of credit in the amount of $<ix:nonFraction name="us-gaap:LineOfCredit" contextRef="PAsOn04_30_2019_LetterOfCreditMemberusgaapShortTermDebtTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.5</ix:nonFraction>&#160;million as security, which is subject to automatic reductions per the terms of the Las Cimas Lease. A tenant allowance of up to $<ix:nonFraction name="us-gaap:TenantImprovements" contextRef="PAsOn04_30_2019_MaximumMembersrtRangeAxis" unitRef="Unit_USD" decimals="INF" scale="6" format="ixt:num-dot-decimal">1.0</ix:nonFraction>&#160;million was provided by the lessor and fully reimbursed to the Company. </div><ix:nonNumeric name="agle:ScheduleOfOperatingAndFinancingLeasesPresentedInBalanceSheetTableTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the Company&#8217;s recognition of its operating and finance leases (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:31%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td style="width:50%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Classification</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Assets</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,430</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,806</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><span style="-sec-ix-hidden:hidden95765537">Finan</span><span style="-sec-ix-hidden:hidden95765538">ce</span></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> assets</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FinanceLeaseRightOfUseAsset" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">597</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FinanceLeaseRightOfUseAsset" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">798</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td colspan="3" style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total leased assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="agle:OperatingAndFinanceLeaseRightOfUseAsset" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,027</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="agle:OperatingAndFinanceLeaseRightOfUseAsset" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,604</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Leases</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Current</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Operating lease liabilities</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">625</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">436</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><span style="-sec-ix-hidden:hidden95765544">Fin</span><span style="-sec-ix-hidden:hidden95765545">ance</span></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Accrued and other current liabilities</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">16</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">418</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div> operating lease liabilities</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,004</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,608</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><span style="-sec-ix-hidden:hidden95765401"><span style="-sec-ix-hidden:hidden95765511">Finan</span>ce</span></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> liabilities</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityNoncurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">16</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td colspan="3" style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="agle:OperatingAndFinanceLeaseLiabilities" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,645</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="agle:OperatingAndFinanceLeaseLiabilities" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,478</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><ix:nonNumeric name="agle:SummaryOfWeightedAverageRemainingLeaseTermAndDiscountRatesOfOperatingAndFinanceLeasesTableTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the weighted-average remaining lease term and discount rates for the Company&#8217;s operating and finance leases: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:83%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Lease term (years)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating leases</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="PAsOn12_31_2022" format="ixt-sec:duryear">5.3</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="PAsOn12_31_2021" format="ixt-sec:duryear">6.3</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Finance leases</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" contextRef="PAsOn12_31_2022" format="ixt-sec:duryear">0.6</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" contextRef="PAsOn12_31_2021" format="ixt-sec:duryear">0.5</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Discount rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating leases</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="PAsOn12_31_2022" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">10.6</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="PAsOn12_31_2021" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">10.7</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Finance leases</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" contextRef="PAsOn12_31_2022" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">10.2</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" contextRef="PAsOn12_31_2021" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">6.7</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr></table></ix:nonNumeric><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-19</ix:exclude> </div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_95765392" continuedAt="TextSelectionAppend_95765392_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_95765392_1" continuedAt="TextSelectionAppend_95765392_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_95765392_2" continuedAt="TextSelectionAppend_95765392_3"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_95765392_3"><ix:nonNumeric name="us-gaap:LeaseCostTableTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the lease costs pertaining to the Company&#8217;s operating leases (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:70%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease cost</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">910</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">991</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,258</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Variable lease cost</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:VariableLeaseCost" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">472</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:VariableLeaseCost" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">519</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:VariableLeaseCost" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">665</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total lease cost</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LeaseCost" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,382</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LeaseCost" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,510</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LeaseCost" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,923</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cash paid for amounts included in the measurement of operating lease liabilities during the years ended December&#160;31, 2022 and 2021 was $<ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.9</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.1</ix:nonFraction>&#160;million, respectively, and was included within net cash used in operating activities in the cash flows. </div><ix:nonNumeric name="agle:ScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesTableTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The maturities of the Company&#8217;s operating and finance lease liabilities as of December&#160;31, 2022 were as follows (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:76%"></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Operating</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Leases</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Finance</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Leases</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,078</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">16</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2024</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,103</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2025</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,129</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2026</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,163</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2027</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,198</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Thereafter</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">403</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total lease payments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,074</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsDue" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">16</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Imputed interest</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,445</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,629</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FinanceLeaseLiability" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">16</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric></ix:continuation><ix:nonNumeric name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_95765407"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">8. Stockholders&#8217; Equity </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is authorized to issue <ix:nonFraction name="agle:SharesAuthorized" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">30,000,000</ix:nonFraction> shares of capital stock of which <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">20,000,000</ix:nonFraction> shares are designated as common stock and <ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">10,000,000</ix:nonFraction> shares are designated as preferred stock, all with a par value of $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2022" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2022" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction> per share. <ix:nonNumeric name="us-gaap:CommonStockVotingRights" contextRef="P01_01_2022To12_31_2022">Each holder of common stock is entitled to <ix:nonFraction name="agle:NumberOfCommonStockVotingRightsHeldPerShare" contextRef="PAsOn12_31_2022" unitRef="Unit_VOTE" decimals="0" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction> vote for each share of common stock held</ix:nonNumeric>. The Company&#8217;s common stock is not entitled to preemptive rights, and is not subject to conversion, redemption or sinking fund provisions. Subject to preferences that may apply to any shares of preferred stock outstanding at the time, the holders of common stock are entitled to receive dividends out of funds legally available if the board of directors, in its discretion, determines to issue dividends and then only at the times and in the amounts that the board of directors may determine. As of December&#160;31, 2022 and 2021, <ix:nonFraction name="us-gaap:DividendsCommonStock" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:DividendsCommonStock" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> common stock dividends had been declared by the board of directors and there were <ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2021" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> shares of preferred stock outstanding. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Registered Direct Offering </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May 2022, the Company issued and sold <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P05_01_2022To05_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">430,107</ix:nonFraction> shares of common stock at an offering price of $<ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="PAsOn05_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">40.00</ix:nonFraction> per share and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants to purchase up to <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn05_31_2022_MaximumMembersrtRangeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">694,892</ix:nonFraction> shares of common stock at an offering price of $<ix:nonFraction name="agle:ClassOfWarrantOrRightOfferingPriceOfWarrantsOrRights" contextRef="PAsOn05_31_2022" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">39.9975</ix:nonFraction> per warrant (representing the price per share of common stock sold in the offering minus the $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn05_31_2022" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal">0.0025</ix:nonFraction> exercise price per warrant) in a registered direct offering pursuant to a shelf registration statement on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-3.</div> The net proceeds to the Company from this offering were approximately $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="P05_01_2022To05_31_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">42.9</ix:nonFraction>&#160;million, after deducting placement agent fees and offering costs of $<ix:nonFraction name="agle:PlacementAgentFeesAndOfferingCosts" contextRef="P05_01_2022To05_31_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.1</ix:nonFraction>&#160;million. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-20</ix:exclude> </div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_95765407" continuedAt="TextSelectionAppend_95765407_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_95765407_1" continuedAt="TextSelectionAppend_95765407_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_95765407_2" continuedAt="TextSelectionAppend_95765407_3"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_95765407_3"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Follow-on</div> Public Offerings </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2019, the Company issued and sold <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P02_01_2019To02_28_2019_CommonStockMemberusgaapStatementEquityComponentsAxis_FollowOnPublicOfferingMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">185,000</ix:nonFraction> shares of common stock at a public offering price of $<ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="PAsOn02_28_2019_CommonStockMemberusgaapStatementEquityComponentsAxis_FollowOnPublicOfferingMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">200.00</ix:nonFraction> per share and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants to purchase up to <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn02_28_2019_CommonStockMemberusgaapStatementEquityComponentsAxis_FollowOnPublicOfferingMemberusgaapSubsidiarySaleOfStockAxis_MaximumMembersrtRangeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">160,000</ix:nonFraction> shares of common stock at a public offering price of $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn02_28_2019_CommonStockMemberusgaapStatementEquityComponentsAxis_FollowOnPublicOfferingMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">199.9975</ix:nonFraction> per warrant in an underwritten public offering pursuant to a shelf registration statement on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-3.</div> This includes the full exercise by the underwriters of their option to purchase up to <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P02_01_2019To02_28_2019_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">45,000</ix:nonFraction> additional shares of common stock. The net proceeds to the Company from this public offering were $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="P02_01_2019To02_28_2019" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">64.5</ix:nonFraction>&#160;million, after deducting underwriting discounts and commissions of $<ix:nonFraction name="us-gaap:ExpenseRelatedToDistributionOrServicingAndUnderwritingFees" contextRef="P02_01_2019To02_28_2019" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">4.1</ix:nonFraction>&#160;million and offering costs of $<ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="P02_01_2019To02_28_2019" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.4</ix:nonFraction>&#160;million. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2020, the Company issued and sold <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P04_01_2020To04_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_FollowOnPublicOfferingMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">617,692</ix:nonFraction> shares of common stock at a public offering price of $<ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="PAsOn04_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_FollowOnPublicOfferingMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">118.75</ix:nonFraction> per share and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants to purchase up to <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn04_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_FollowOnPublicOfferingMemberusgaapSubsidiarySaleOfStockAxis_MaximumMembersrtRangeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">544,413</ix:nonFraction> shares of common stock at a public offering price of $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn04_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_FollowOnPublicOfferingMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">118.7475</ix:nonFraction> per warrant in an underwritten public offering pursuant to a shelf registration statement on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-3.</div> This includes the full exercise by the underwriters of their option to purchase up to <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P04_01_2020To04_30_2020_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">151,578</ix:nonFraction> additional shares of common stock. The net proceeds to the Company from this public offering were $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="P04_01_2020To04_30_2020" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">129.0</ix:nonFraction>&#160;million, after deducting underwriting discounts and commissions of $<ix:nonFraction name="us-gaap:ExpenseRelatedToDistributionOrServicingAndUnderwritingFees" contextRef="P04_01_2020To04_30_2020" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">8.2</ix:nonFraction>&#160;million and offering costs of $<ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="P04_01_2020To04_30_2020" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.8</ix:nonFraction>&#160;million. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Funded</div> Warrants </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2019, April 2020 and May 2022, the Company issued <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants to purchase the Company&#8217;s common stock in underwritten public offerings at the offering price of the common stock, less the $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn12_31_2022" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal">0.0025</ix:nonFraction> per share exercise price of each warrant. The warrants were recorded as a component of stockholders&#8217; equity within additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital and have no expiration date. Per the terms of the warrant agreements, the outstanding warrants to purchase shares of common stock may not be exercised if the holder&#8217;s ownership of the Company&#8217;s common stock would exceed <ix:nonFraction name="agle:MaximumOwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercised" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:num-dot-decimal">4.99</ix:nonFraction>% (&#8220;Maximum Ownership Percentage&#8221;) or <ix:nonFraction name="agle:OwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercisedToCertainHolders" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:num-dot-decimal">9.99</ix:nonFraction>% for certain holders. By written notice to the Company, each holder may increase or decrease the Maximum Ownership Percentage to any other percentage (not in excess of <ix:nonFraction name="agle:MaximumOwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercised" contextRef="P01_01_2022To12_31_2022_MaximumMembersrtRangeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">19.99</ix:nonFraction>% for the majority of such warrants). <ix:nonNumeric name="agle:PeriodAfterNoticeReceivedByCompanyMaximumOwnershipPercentageToBeEffectiveDescription" contextRef="P01_01_2022To12_31_2022">The revised Maximum Ownership Percentage would be effective 61 days after the notice is received by the Company.</ix:nonNumeric> </div><ix:nonNumeric name="us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2022, the following <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants to purchase common stock were issued and outstanding: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:46%"></td>
<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Issue Date</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Expiration&#160;Date</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Exercise&#160;Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of&#160;Warrants</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Outstanding</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><span style="-sec-ix-hidden:hidden95765421">February 2019</span></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="agle:WarrantExpirationDate" contextRef="P01_01_2022To12_31_2022_FebruaryTwoThousandNinteenMemberusgaapAwardDateAxis_WarrantMemberusgaapStatementEquityComponentsAxis">None</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn12_31_2022_FebruaryTwoThousandNinteenMemberusgaapAwardDateAxis_WarrantMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal">0.0025</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn12_31_2022_FebruaryTwoThousandNinteenMemberusgaapAwardDateAxis_WarrantMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">150,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><span style="-sec-ix-hidden:hidden95765422">April 2020</span></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="agle:WarrantExpirationDate" contextRef="P01_01_2022To12_31_2022_AprilTwoThousandTwentyMemberusgaapAwardDateAxis_WarrantMemberusgaapStatementEquityComponentsAxis">None</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn12_31_2022_AprilTwoThousandTwentyMemberusgaapAwardDateAxis_WarrantMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal">0.0025</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn12_31_2022_AprilTwoThousandTwentyMemberusgaapAwardDateAxis_WarrantMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">474,413</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><span style="-sec-ix-hidden:hidden95765423">May 2022</span></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="agle:WarrantExpirationDate" contextRef="P01_01_2022To12_31_2022_MayTwoThousandTwentyTwoMemberusgaapAwardDateAxis_WarrantMemberusgaapStatementEquityComponentsAxis">None</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn12_31_2022_MayTwoThousandTwentyTwoMemberusgaapAwardDateAxis_WarrantMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal">0.0025</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn12_31_2022_MayTwoThousandTwentyTwoMemberusgaapAwardDateAxis_WarrantMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">531,250</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn12_31_2022_WarrantMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">1,155,663</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">At-The-Market</div></div> Offering </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2020, the Company entered into a new sales agreement with JonesTrading Institutional Services LLC, as sales agent, to issue and sell shares of its common stock for an aggregate offering price of $<ix:nonFraction name="agle:AggregateOfferingPriceOfCommonStock" contextRef="P04_01_2020To04_30_2020_AtTheMarketSalesAgreementMemberusgaapSubsidiarySaleOfStockAxis_JonesTradingInstitutionalServicesLimitedLiabilityCompanyMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">60.0</ix:nonFraction>&#160;million under an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">at-the-market</div></div> (&#8220;2020 ATM&#8221;) offering program. In the fourth quarter of 2020, the Company issued and sold <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P10_01_2020To12_31_2020_AtTheMarketSalesAgreementMemberusgaapSubsidiarySaleOfStockAxis_JonesTradingInstitutionalServicesLimitedLiabilityCompanyMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">129,803</ix:nonFraction> shares of common stock under the 2020 ATM for gross proceeds of $<ix:nonFraction name="agle:ProceedsFromIssuanceOfCommonStockGross" contextRef="P10_01_2020To12_31_2020_AtTheMarketSalesAgreementMemberusgaapSubsidiarySaleOfStockAxis_JonesTradingInstitutionalServicesLimitedLiabilityCompanyMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">25.3</ix:nonFraction>&#160;million, resulting in net proceeds of $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="P10_01_2020To12_31_2020_AtTheMarketSalesAgreementMemberusgaapSubsidiarySaleOfStockAxis_JonesTradingInstitutionalServicesLimitedLiabilityCompanyMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">24.6</ix:nonFraction>&#160;million, after deducting underwriting discounts, commissions, and offering costs. </div></ix:continuation><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-21 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:nonNumeric name="agle:StrategicLicenseAgreementTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_95764038"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">9. Strategic License Agreements </div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Immedica Pharma AB License and Development Agreement </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On <ix:nonNumeric name="agle:LicenseAndSupplyAgreementDate" contextRef="P03_21_2021To03_21_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis" format="ixt:date-monthname-day-year-en">March 21, 2021</ix:nonNumeric>, the Company entered into an exclusive license and supply agreement with Immedica Pharma AB (&#8220;Immedica&#8221;). By entering into this agreement, the Company agreed to provide Immedica the following goods and services: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">i.</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Deliver an exclusive, sublicensable, license and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> (the &#8220;License&#8221;) to develop and commercialize pegzilarginase (the &#8220;Product&#8221;) in the territory comprising the members states of the European Economic Area, United Kingdom, Switzerland, Andorra, Monaco, San Marino, Vatican City, Turkey, Saudi Arabia, United Arab Emirates, Qatar, Kuwait, Bahrain, and Oman (the &#8220;Territory&#8221;); </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">ii.</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Complete the global pivotal PEACE (Pegzilarginase Effect on Arginase 1 Deficiency Clinical Endpoints) Phase 3 trial (&#8220;PEACE Trial&#8221;) and related Biologics License Application (&#8220;BLA&#8221;) package to file with the United States Food and Drug Administration (&#8220;FDA&#8221;), which will be leveraged by Immedica in obtaining the necessary regulatory approvals in the Territory; and </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">iii.</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Perform a Pediatric Investigation Plan trial (&#8220;PIP Trial&#8221;) in order for Immedica to be able to receive certain regulatory approvals within the Territory. </div></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the Company and Immedica formed a Joint Steering Committee (&#8220;JSC&#8221;) to provide oversight to the activities performed under the agreement; however, the substance of the Company&#8217;s participation in the JSC does not represent an additional promised service, but rather, a right of the Company to protect its own interests in the arrangement. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, the Company agreed to supply to Immedica, and Immedica agreed to purchase from the Company, substantially all commercial requirements of the Product. The terms of the agreement do not provide for either (i)&#160;an option to Immedica to purchase the Product from the Company at a discount from the standalone selling price or (ii)&#160;minimum purchase quantities. Finally, Immedica will bear (i)&#160;all costs and expenses for any development or commercialization of the Product in the Territory subject to the License exclusive of the Company&#8217;s promised goods and services summarized above and (ii)&#160;all costs and fees associated with applying for regulatory approval of the Product in the Territory. In July 2021, the Company modified the agreement with Immedica to provide certain additional services in relation to the PEACE Phase 3 Trial and BLA package performance obligation in exchange for the reimbursement of up to $<ix:nonFraction name="us-gaap:ReimbursementFromLimitedPartnershipInvestment" contextRef="P07_01_2021To07_31_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">3.0</ix:nonFraction>&#160;million of the actual costs incurred in relation to such incremental services. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company received a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-refundable</div> payment of $<ix:nonFraction name="agle:NonRefundablePaymentReceived" contextRef="P01_01_2021To03_31_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">21.5</ix:nonFraction>&#160;million and Immedica agreed to provide payment of <ix:nonFraction name="agle:PercentageOfPaymentForCostIncurredInPIPTrial" contextRef="P01_01_2021To03_31_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_MaximumMembersrtRangeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">50</ix:nonFraction>% of the Company&#8217;s costs incurred in performing the PIP Trial up to a maximum of $<ix:nonFraction name="agle:CostsIncurredInPerformingTheTrial" contextRef="P01_01_2021To03_31_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_MaximumMembersrtRangeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.8</ix:nonFraction>&#160;million. In addition, the Company has the ability to receive additional payments under the agreement of up to approximately $<ix:nonFraction name="agle:AdditionalUpfrontPaymentAbilityToReceived" contextRef="P01_01_2021To03_31_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">120.8</ix:nonFraction>&#160;million in regulatory and commercial milestone payments, assuming an exchange rate of $<ix:nonFraction name="agle:MilestonePaymentsExchangeRate" contextRef="P01_01_2022To12_31_2022_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_MinimumMembersrtRangeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">1.07</ix:nonFraction> to &#8364;<ix:nonFraction name="agle:MilestonePaymentsExchangeRate" contextRef="P01_01_2022To12_31_2022_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_MaximumMembersrtRangeAxis" unitRef="Unit_EUR_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">1.00</ix:nonFraction>. The Company is also entitled to receive royalties in the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="display:inline;"><span style="-sec-ix-hidden:hidden95765599">mid-20</span></div>&#160;percent</div> range on net sales of the Product in the Territory. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company concluded that Immedica meets the definition to be accounted for as a customer because the Company is delivering intellectual property and other services within the Company&#8217;s normal course of business, in which the parties are not jointly sharing the risks and rewards. Therefore, the Company concluded that the promises summarized above represent transactions with a customer within the scope of ASC 606. The Company determined that the following promises represent distinct promised services, and therefore, performance obligations: (i)&#160;the License, (ii)&#160;the PEACE Trial and BLA package, and (iii)&#160;the PIP Trial. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Specifically, in making these determinations, the Company considered the following factors: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">As of inception of the agreement, the Company had completed the Phase 1/2 clinical trial related to the Product and were conducting the ongoing PEACE Trial. Accordingly, the Company is not promising, </div></td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-22</ix:exclude> </div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_95764038" continuedAt="TextSelectionAppend_95764038_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_95764038_1" continuedAt="TextSelectionAppend_95764038_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_95764038_2" continuedAt="TextSelectionAppend_95764038_3"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_95764038_3" continuedAt="TextSelectionAppend_95764038_4">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; line-height: normal;">nor expecting, to perform additional research and development activities pursuant to the agreement that would either significantly modify, customize or be considered highly interdependent or interrelated with pegzilarginase. </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">The License represents functional intellectual property given the functionality of the License is not expected to change substantially as a result of the company&#8217;s ongoing activities. </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">The services necessary to complete the PEACE Trial, BLA package and PIP Trial could be performed by other parties. </div></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Given that Immedica is not obligated to purchase any minimum amount or quantities of the Product, the supply of the Product for commercial use to Immedica was determined to be an option for Immedica, rather than a performance obligation of the Company at contract inception and will be accounted for if and when exercised. The Company also determined that Immedica&#8217;s option to purchase the Product does not create a material right as the expected pricing is not at a discount. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company determined that the upfront fixed payment amount of $<ix:nonFraction name="agle:UpfrontPayment" contextRef="P01_01_2021To03_31_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">21.5</ix:nonFraction>&#160;million must be included in the transaction price. Additionally, the Company determined at inception of the arrangement that <ix:nonFraction name="agle:PercentageOfPaymentForCostIncurredInPIPTrial" contextRef="P01_01_2021To03_31_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_MaximumMembersrtRangeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">50</ix:nonFraction>% of the estimated costs to be incurred in relation to the PIP Trial exceeded $<ix:nonFraction name="agle:CostsIncurredInPerformingTheTrial" contextRef="P01_01_2021To03_31_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_MaximumMembersrtRangeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.8</ix:nonFraction>&#160;million and included the full reimbursement amount of $<ix:nonFraction name="agle:CostsIncurredInPerformingTheTrial" contextRef="P01_01_2021To03_31_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_MaximumMembersrtRangeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.8</ix:nonFraction>&#160;million in the transaction price. Upon subsequent <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-evaluation</div> due to changing facts and circumstances, the Company determined the estimated costs are now less than the maximum allowable reimbursement and a portion of the variable consideration was constrained, which did not materially impact the revenue recognized to date. Additionally, upon the modification of the agreement in July 2021, the Company determined that the estimated costs to perform the additional services related to the PEACE Trial and BLA package exceeds the maximum allowable reimbursement of $<ix:nonFraction name="us-gaap:ReimbursementFromLimitedPartnershipInvestment" contextRef="P07_01_2021To07_31_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">3.0</ix:nonFraction>&#160;million. Therefore, the Company included an estimated total of $<ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" contextRef="P07_01_2021To07_31_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">3.6</ix:nonFraction>&#160;million that will be due in relation to the PIP Trial, PEACE Trial, and BLA package in the transaction price and it is probable that a significant reversal will not occur in the future. In total, the modified transaction price was determined to be $<ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="P07_01_2021To07_31_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">25.1</ix:nonFraction>&#160;million. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has allocated $<ix:nonFraction name="agle:AllocatedAmountOfTransactionPrice" contextRef="P01_01_2021To03_31_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_PeaceTrialAndBLAPackageMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">9.6</ix:nonFraction>&#160;million and $<ix:nonFraction name="agle:AllocatedAmountOfTransactionPrice" contextRef="P01_01_2021To03_31_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_PIPTrialMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">3.5</ix:nonFraction>&#160;million of the modified transaction price to the PEACE Trial and BLA package and PIP Trial performance obligations, respectively, based on the stand-alone selling prices (&#8220;SSP&#8221;), which was based on the estimated costs that a third-party would charge in performing such services on a stand-alone basis. The SSP for the License was established at inception of the arrangement using a residual value approach due to the uniqueness of and lack of observable data related to the License, and without a specific analog from which to make reliable estimates, resulting in an allocation of $<ix:nonFraction name="agle:AllocationPriceTotal" contextRef="P01_01_2021To03_31_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">12.0</ix:nonFraction>&#160;million. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The potential regulatory milestone payments that the Company is eligible to receive were excluded from the transaction price, as the milestone amounts were fully constrained based on the probability of achievement, since the milestones relate to successful achievement of certain regulatory approvals, which might not be achieved. The Company determined that the royalties and commercial milestone payments relate predominantly to the license of intellectual property and are therefore excluded from the transaction price under the sales- or usage-based royalty exception of ASC 606. The Company will reevaluate the transaction price, including all constrained amounts, at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur, the Company will adjust its estimate of the transaction price as necessary. The Company will recognize the royalties and commercial milestone payments as revenue when the associated sales occur, and relevant sales-based thresholds are met. The Company assessed the arrangement with Immedica and concluded that a significant financing component does not exist. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognized revenue allocated to the License performance obligation at a point in time and upon transfer of the License. The Company completed the transfer of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> necessary for Immedica to benefit from the License in June 2021 and recognized $<ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P06_01_2021To06_30_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_LicenseAgreementsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">12.0</ix:nonFraction>&#160;million of revenue at that time. The development fee allocated to the PEACE Trial, BLA package and PIP Trial performance obligations will be recognized over time using an input method of costs incurred related to the performance obligations. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-23</ix:exclude> </div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_95764038_4" continuedAt="TextSelectionAppend_95764038_5"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_95764038_5" continuedAt="TextSelectionAppend_95764038_6"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_95764038_6" continuedAt="TextSelectionAppend_95764038_7"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_95764038_7"><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December&#160;31, 2022, the Company recognized revenue of $<ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To12_31_2022_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_PeaceTrialAndBLAPackageMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.3</ix:nonFraction>&#160;million related to the PEACE Trial and BLA package performance obligation using a cost to cost model. The Company recognized revenue of $<ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To12_31_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_PeaceTrialAndBLAPackageMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">6.7</ix:nonFraction>&#160;million related to the PEACE Trial and BLA package performance obligation using a cost to cost model and $<ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To12_31_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_LicenseAgreementsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">12.0</ix:nonFraction>&#160;million related to the transfer of the License for the year ended December&#160;31, 2021 and <ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2020To12_31_2020_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_LicenseAgreementsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen">no</ix:nonFraction> revenue for the year ended December&#160;31, 2020. As of December&#160;31, 2022, the Company has recorded deferred revenue of $<ix:nonFraction name="us-gaap:DeferredRevenue" contextRef="PAsOn12_31_2022_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.7</ix:nonFraction>&#160;million associated with the license and supply agreement with Immedica, of which $<ix:nonFraction name="us-gaap:DeferredRevenueCurrent" contextRef="PAsOn12_31_2022_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.5</ix:nonFraction>&#160;million is classified as current. As of December&#160;31, 2021, the Company had recorded deferred revenue of $<ix:nonFraction name="us-gaap:DeferredRevenue" contextRef="PAsOn12_31_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">3.6</ix:nonFraction>&#160;million associated with the license and supply agreement with Immedica, of which $<ix:nonFraction name="us-gaap:DeferredRevenueCurrent" contextRef="PAsOn12_31_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.4</ix:nonFraction>&#160;million was classified as current. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Contract Balances from Customer Contract </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The timing of revenue recognition, billings and cash collections results in contract assets and contract liabilities on the balance sheets. The Company recognizes license and development receivables based on billed services, which are derecognized upon reimbursement. When consideration is received, or such consideration is unconditionally due, from a customer prior to transferring goods or services to the customer under the terms of a contract, a contract liability is recorded. Contract liabilities are recognized as revenue after control of the goods or services is transferred to the customer and all revenue recognition criteria have been met. </div><ix:nonNumeric name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents changes in the Company&#8217;s contract liabilities for the periods presented (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:51%"></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Additions</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Deductions</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Contract liabilities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred revenue</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,576</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="agle:ContractWithCustomerLiabilityRevenueRecognizedIncludingAdditions" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,449</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="agle:ContractWithCustomerLiabilityDeductionsThroughContractsAcquired" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,329</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,696</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table></ix:nonNumeric><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company had <ix:nonFraction name="us-gaap:ContractWithCustomerAssetNet" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:ContractWithCustomerAssetNet" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:ContractWithCustomerAssetNet" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> contract assets during the years ended December&#160;31, 2022, 2021 and 2020 and <ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen">no</ix:nonFraction> contract liabilities during the year ended December&#160;31, 2020. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">University of Texas at Austin License Agreement </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In <ix:nonNumeric name="agle:ResearchAgreementDate" contextRef="P01_01_2022To12_31_2022_LicenseAgreementsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_UniversityOfTexasAtAustinMemberusgaapTypeOfArrangementAxis" format="ixt:date-monthname-year-en">December 2013</ix:nonNumeric>, two of the Company&#8217;s wholly owned subsidiaries AECase, Inc. and AEMase, Inc. each entered into an exclusive, worldwide license agreement, including the right to grant sublicenses, with the University of Texas at Austin (the &#8220;University&#8221;) for certain intellectual property owned by the University related to cystinase and methioninase. In January 2017, the Company and the University entered into an Amended and Restated Patent License Agreement (the &#8220;Restated License&#8221;), which <span style="-sec-ix-hidden:hidden95765449">consolidated</span> the <ix:nonFraction name="agle:NumberOfLicenseAgreements" contextRef="PAsOn12_31_2022_LicenseAgreementsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_UniversityOfTexasAtAustinMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD_LICENSEAGREEMENT" decimals="0" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction> license agreements, revised certain obligations, and licensed additional patent applications and invention disclosures to us. The Restated License was amended in August 2017, December 2017, and December 2018 to revise diligence milestones and license additional patent applications, including our program candidates under the pegtarviliase and Cystinuria Programs. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the Restated License, the Company may be required to pay the University up to $<ix:nonFraction name="agle:MaximumFutureContingentLicensePayment" contextRef="P01_01_2017To01_31_2017_LicenseAgreementsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_UniversityOfTexasAtAustinMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">6.4</ix:nonFraction>&#160;million in milestone payments based on the achievement of certain development milestones, including clinical trials and regulatory approvals, the majority of which are due upon the achievement of later development milestones, including a $<ix:nonFraction name="agle:AggregatePotentialMilestonePaymentsForReceiptOfRegulatoryApproval" contextRef="P01_01_2017To01_31_2017_LicenseAgreementsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_UniversityOfTexasAtAustinMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">5.0</ix:nonFraction>&#160;million payment due on regulatory approval of a product and a $<ix:nonFraction name="agle:AggregatePotentialMilestonePaymentsForFinalRegulatoryApprovalOfSecondIndication" contextRef="P01_01_2017To01_31_2017_LicenseAgreementsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_UniversityOfTexasAtAustinMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.5</ix:nonFraction>&#160;million payment payable on final regulatory approval of a product for a second indication. In addition, the Company is required to pay the University a low single-digit royalty on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">worldwide-net</div> sales of products covered under the Restated License, together with a revenue share on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-royalty</div> consideration received from sublicensees. The rate of the revenue share ranges from <ix:nonFraction name="agle:RateOfRevenueShare" contextRef="P01_01_2017To01_31_2017_LicenseAgreementsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_MinimumMembersrtRangeAxis_UniversityOfTexasAtAustinMemberusgaapTypeOfArrangementAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:num-dot-decimal">6.5</ix:nonFraction>% to <ix:nonFraction name="agle:RateOfRevenueShare" contextRef="P01_01_2017To01_31_2017_LicenseAgreementsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_MaximumMembersrtRangeAxis_UniversityOfTexasAtAustinMemberusgaapTypeOfArrangementAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:num-dot-decimal">25</ix:nonFraction>% depending on the date the sublicense agreement is signed. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the year ended December&#160;31, 2022, the Company paid $<ix:nonFraction name="agle:PaymentOfMilestone" contextRef="P01_01_2022To12_31_2022_LicenseAgreementsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_UniversityOfTexasAtAustinMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.1</ix:nonFraction>&#160;million in milestone payments pursuant to the Restated License. For the years ended December&#160;31, 2021 and 2020, the Company paid $<ix:nonFraction name="agle:PaymentOfAnnualLicenseFees" contextRef="P01_01_2021To12_31_2021_LicenseAgreementsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_UniversityOfTexasAtAustinMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal"><ix:nonFraction name="agle:PaymentOfAnnualLicenseFees" contextRef="P01_01_2020To12_31_2020_LicenseAgreementsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_UniversityOfTexasAtAustinMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.1</ix:nonFraction></ix:nonFraction>&#160;million in license fees annually. </div></ix:continuation><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-24 </div></div></div></div><div></div></div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:nonNumeric name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_95764052"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">10. Stock-Based Compensation </div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">2015 Equity Incentive Plan </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2015, the Company adopted the 2015 Equity Incentive Plan (&#8220;2015 Plan&#8221;), administered by the board of directors, and provides for the Company to sell or issue common stock or restricted common stock, or to grant incentive stock options or nonqualified stock options for the purchase of common stock, to employees, members of the board of directors and consultants of the Company. Under the terms of the 2015 Plan, the exercise prices, vesting and other restrictions may be determined at the discretion of the board of directors, or their committee if so delegated, except that the exercise price per share of stock options may not be less than <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" contextRef="P03_01_2015To03_31_2015_MinimumMembersrtRangeAxis_TwoThousandAndFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction>% of the fair market value of the share of common stock on the date of grant, the term of stock options may not be greater than <ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" contextRef="P03_01_2015To03_31_2015_MaximumMembersrtRangeAxis_StockOptionMemberusgaapAwardTypeAxis_TwoThousandAndFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" format="ixt-sec:durwordsen">ten years</ix:nonNumeric> for all grants, and for grantees holding more than <ix:nonFraction name="agle:GranteesWithMoreThanFiveYearsVestingTermPercent" contextRef="P03_01_2015To03_31_2015_TwoThousandAndFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:num-dot-decimal">10</ix:nonFraction>% of the total combined voting power of all classes of stock, the term may not be greater than <ix:nonNumeric name="agle:MaximumVestingTermForMoreThanTenPercentGrantees" contextRef="P03_01_2015To03_31_2015_TwoThousandAndFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" format="ixt-sec:durwordsen">five years</ix:nonNumeric>. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company granted options under the 2015 Plan until April 2016 when it was terminated as to future awards, although it continues to govern the terms of options that remain outstanding under the 2015 Plan. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2022, a total of <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" contextRef="P01_01_2022To12_31_2022_TwoThousandAndFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">3,785</ix:nonFraction> shares of common stock are subject to options outstanding under the 2015 Plan and will become available under the 2016 Equity Incentive Plan (&#8220;2016 Plan&#8221;) to the extent the options are forfeited or lapse unexercised. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">2016 Equity Incentive Plan </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2016 Plan became effective in April 2016 and serves as the successor to the 2015 Plan. Under the 2016 Plan, the Company may grant stock options, stock appreciation rights, restricted stock awards, restricted stock units, performance awards, and stock bonuses. The 2016 Plan provides for an initial reserve of <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="PAsOn04_30_2016_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">44,000</ix:nonFraction> shares of common stock, plus <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="PAsOn04_30_2016_TwoThousandAndFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">20,394</ix:nonFraction> shares of common stock remaining under the 2015 Plan, and any share awards that subsequently are forfeited or lapse unexercised under the 2015 Plan. The shares reserved exclude shares of common stock reserved for issuance under the 2015 Plan. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2018, the 2016 plan was amended to increase the number of shares of common stock reserved for issuance thereunder by <ix:nonFraction name="agle:IncreaseInCommonStockCapitalSharesReservedForFutureIssuance" contextRef="P10_01_2018To10_31_2018_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">70,384</ix:nonFraction> shares, extend the term of the 2016 Plan through <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" contextRef="P10_01_2018To10_31_2018_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis" format="ixt:date-monthname-day-year-en">August 7, 2028</ix:nonNumeric>, and provide for an automatic increase in the number of shares reserved for issuance thereunder on January&#160;1 of each year for the remaining term of the plan equal to (a) <ix:nonFraction name="agle:AnnualPercentageOfAdditionalSharesWhichEqualsToIssuedAndOutstandingShares" contextRef="P01_01_2022To12_31_2022_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">4.0</ix:nonFraction>% of the number of issued and outstanding shares of common stock on December&#160;31 of the immediately preceding year, or (b)&#160;a lesser amount as approved by the board each year. As a result of the operation of each of these provisions, on January&#160;1, 2022, 2021, and 2020, an additional <ix:nonFraction name="agle:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant" contextRef="PAsOn01_01_2022_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">78,968</ix:nonFraction>, <ix:nonFraction name="agle:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant" contextRef="PAsOn01_01_2021_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">76,734</ix:nonFraction>, and <ix:nonFraction name="agle:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant" contextRef="PAsOn01_01_2020_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">46,535</ix:nonFraction> shares, respectively, became available for issuance under the 2016 Plan. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2022, the total number of shares reserved for issuance under the 2016 Plan was <ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn12_31_2022_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">432,725</ix:nonFraction>, of which <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn12_31_2022_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">319,122</ix:nonFraction> shares were subject to outstanding option awards and restricted unit awards. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">2018 Equity Inducement Plan </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2018, the board of directors approved and adopted the 2018 Equity Inducement Plan (&#8220;2018 Plan&#8221;), which became effective on the same date. The board of directors approved an initial reserve of <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="PAsOn02_28_2018_TwoThousandAndEighteenEquityInducementPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">44,000</ix:nonFraction> shares of common stock to be used exclusively for individuals who were not previously employees or directors, or following a bona fide period of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employment,</div> as an inducement material to the individual entering into employment with the Company. Nonqualified stock options or restricted stock units may be granted under the 2018 Plan at the discretion of the Compensation Committee or the board of directors. The Company did not seek stockholder approval of the 2018 Plan pursuant to Nasdaq Rule 5635(c)(4). </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2022, the total number of shares reserved for issuance under the 2018 Plan was <ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn12_31_2022_TwoThousandAndEighteenEquityInducementPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">44,000</ix:nonFraction>, of which <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn12_31_2022_TwoThousandAndEighteenEquityInducementPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">12,440</ix:nonFraction> shares were subject to outstanding option awards. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-25</ix:exclude> </div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_95764052" continuedAt="TextSelectionAppend_95764052_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_95764052_1" continuedAt="TextSelectionAppend_95764052_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_95764052_2" continuedAt="TextSelectionAppend_95764052_3"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_95764052_3" continuedAt="TextSelectionAppend_95764052_4"><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the 2016 Plan and 2018 Plan, the Company may grant stock-based awards with service conditions (&#8220;service-based&#8221; awards), performance conditions (&#8220;performance-based&#8221; awards), and market conditions (&#8220;market-based&#8221; awards). Service-based awards granted under the 2018 Plan, 2016 Plan, and 2015 Plan generally vest over <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="P02_01_2018To02_28_2018_ServiceBasedAwardsMemberusgaapAwardTypeAxis_TwoThousandAndFifteenAndTwoThousandAndSixteenEquityIncentivePlanAndTwoThousandAndEighteenEquityInducementPlanMemberusgaapPlanNameAxis" format="ixt-sec:durwordsen">four years</ix:nonNumeric> and expire after <ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" contextRef="P02_01_2018To02_28_2018_ServiceBasedAwardsMemberusgaapAwardTypeAxis_TwoThousandAndFifteenAndTwoThousandAndSixteenEquityIncentivePlanAndTwoThousandAndEighteenEquityInducementPlanMemberusgaapPlanNameAxis" format="ixt-sec:durwordsen">ten years</ix:nonNumeric>, although awards have been granted with vesting terms less than <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="P02_01_2018To02_28_2018_MaximumMembersrtRangeAxis_ServiceBasedAwardsMemberusgaapAwardTypeAxis_TwoThousandAndFifteenAndTwoThousandAndSixteenEquityIncentivePlanAndTwoThousandAndEighteenEquityInducementPlanMemberusgaapPlanNameAxis" format="ixt-sec:durwordsen">four years</ix:nonNumeric>. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">CEO Inducement Grant </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November 2022, the Company granted <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="P11_01_2022To11_30_2022_NewChiefExecutiveOfficerMembersrtTitleOfIndividualAxis_NonQualifiedStockOptionsMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="-6" scale="6" format="ixt:num-dot-decimal">75,393</ix:nonFraction> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-qualified</div> stock options to the new Chief Executive Officer in a stand alone inducement grant. The first 25% of these options vest on the <ix:nonNumeric name="agle:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodOfFirstTwentyFivePercent" contextRef="P11_01_2022To11_30_2022_NewChiefExecutiveOfficerMembersrtTitleOfIndividualAxis_NonQualifiedStockOptionsMemberusgaapAwardTypeAxis" format="ixt-sec:durwordsen">one year</ix:nonNumeric> anniversary of the grant, and the remaining 75% vest in equal amounts over <ix:nonNumeric name="agle:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodOfRemainingSeventyFivePercent" contextRef="P11_01_2022To11_30_2022_NewChiefExecutiveOfficerMembersrtTitleOfIndividualAxis_NonQualifiedStockOptionsMemberusgaapAwardTypeAxis" format="ixt-sec:durmonth">48</ix:nonNumeric> months following the one year anniversary date and are exercisable for a term of <ix:nonNumeric name="agle:ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsGrantedExercisablePeriod" contextRef="P11_01_2022To11_30_2022_NewChiefExecutiveOfficerMembersrtTitleOfIndividualAxis_NonQualifiedStockOptionsMemberusgaapAwardTypeAxis" format="ixt-sec:durwordsen">ten years</ix:nonNumeric>. </div><ix:nonNumeric name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes employee and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> stock option activity for the year ended December&#160;31, 2022: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:55%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Issuable</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Under</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Options</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Average</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Exercise<br/> Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Average</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Remaining</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Contractual</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Term</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Aggregate</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Intrinsic</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(in years)</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(in&#160;thousands)</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Outstanding as of December&#160;31, 2021</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn12_31_2021" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">264,303</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2021" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">189.00</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="P01_01_2021To12_31_2021" format="ixt-sec:duryear">7.90</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">328</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Granted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">235,199</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">45.00</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercised</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD_per_Share" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Forfeited</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">94,421</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">153.50</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Outstanding as of December&#160;31, 2022</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">405,081</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2022" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">113.75</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="P01_01_2022To12_31_2022" format="ixt-sec:duryear">6.72</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Options vested and expected to vest as of December&#160;31, 2022</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">397,772</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2022" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">112.50</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" contextRef="P01_01_2022To12_31_2022" format="ixt-sec:duryear">6.78</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Options exercisable as of December&#160;31, 2022</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">163,450</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="PAsOn12_31_2022" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">171.00</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" contextRef="P01_01_2022To12_31_2022" format="ixt-sec:duryear">4.93</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr></table></ix:nonNumeric><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aggregate intrinsic value of options outstanding, exercisable, vested and expected to vest were calculated as the difference between the exercise price of the options and the fair value of the Company&#8217;s common stock as of the reporting date. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the years ended December&#160;31, 2022, 2021, and 2020, the weighted-average grant date fair value of options granted was $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="P01_01_2022To12_31_2022_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">45.00</ix:nonFraction>, $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">124.00</ix:nonFraction>, and $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">117.00</ix:nonFraction>, respectively. <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="P01_01_2022To12_31_2022_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt-sec:numwordsen">No</ix:nonFraction> options were exercised in the year ended December&#160;31, 2022. The total intrinsic value of options exercised during the years ended December&#160;31, 2021, and 2020 was $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.7</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.4</ix:nonFraction>&#160;million, respectively. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There were <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" contextRef="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis_NonEmployeesMembersrtTitleOfIndividualAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" contextRef="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis_NonEmployeesMembersrtTitleOfIndividualAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" contextRef="P01_01_2022To12_31_2022_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis_NonEmployeesMembersrtTitleOfIndividualAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> stock options issued to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employees</div> during the years ended December&#160;31, 2022, 2021, and 2020. For the year ended December&#160;31, 2020, <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis_NonEmployeesMembersrtTitleOfIndividualAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">66</ix:nonFraction> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> stock options vested in the period. For the years ended December&#160;31, 2022 and 2021, <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis_NonEmployeesMembersrtTitleOfIndividualAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="P01_01_2022To12_31_2022_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis_NonEmployeesMembersrtTitleOfIndividualAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> stock options vested in the period. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">2016 Employee Stock Purchase Plan </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2016 Employee Stock Purchase Plan (&#8220;2016 ESPP&#8221;) became effective in April 2016. A total of <ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn04_30_2016_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">6,600</ix:nonFraction> shares of common stock were reserved for issuance under the 2016 ESPP. Eligible employees may purchase shares of common stock under the 2016 ESPP at <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" contextRef="P04_01_2016To04_30_2016_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">85</ix:nonFraction>% of the lower of the fair market value of the Company&#8217;s common stock as of the first or the last day of each offering period. Employees are limited to contributing <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" contextRef="PAsOn04_30_2016_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">15</ix:nonFraction>% of the employee&#8217;s eligible compensation and may not purchase more than $<ix:nonFraction name="agle:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAnnualFairMarketValuePerEmployee" contextRef="P04_01_2016To04_30_2016_MaximumMembersrtRangeAxis_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">25,000</ix:nonFraction> of stock during any calendar year. The 2016 ESPP will terminate ten years from the first purchase date under the plan, unless terminated earlier by the board of directors. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-26</ix:exclude> </div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_95764052_4" continuedAt="TextSelectionAppend_95764052_5"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_95764052_5" continuedAt="TextSelectionAppend_95764052_6"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_95764052_6" continuedAt="TextSelectionAppend_95764052_7"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_95764052_7" continuedAt="TextSelectionAppend_95764052_8"><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2018, the 2016 ESPP was amended to provide for an automatic annual increase in the number of shares reserved for issuance thereunder on January&#160;1 of each year for the remaining term of the year equal to (a) <ix:nonFraction name="agle:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalAnnualPercentageIncrease" contextRef="P06_01_2018To06_30_2018_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">1.0</ix:nonFraction>% of the number of issued and outstanding shares of common stock on December&#160;31 of the immediately preceding year, or (b)&#160;a lesser amount as approved by the board of directors each year. As a result of the operation of this provision, on January&#160;1, 2022, 2021 and 2020, an additional <ix:nonFraction name="agle:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant" contextRef="PAsOn01_01_2022_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">19,742</ix:nonFraction>, <ix:nonFraction name="agle:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant" contextRef="PAsOn01_01_2021_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">19,183</ix:nonFraction>, and <ix:nonFraction name="agle:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant" contextRef="PAsOn01_01_2020_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">11,633</ix:nonFraction> shares, respectively, became available for issuance under the 2016 ESPP. As of December&#160;31, 2022, the reserve remaining and available for future issuance under the 2016 ESPP was <ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn12_31_2022_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">48,665</ix:nonFraction> shares. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2023, the 2016 ESPP was amended to increase the maximum shares purchased during any one period from <ix:nonFraction name="agle:MaximumNumberOfSharesPurchasedUnderEmployeeStockPurchasePlan" contextRef="P04_01_2016To04_30_2016_MaximumMembersrtRangeAxis_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">80</ix:nonFraction> shares to <ix:nonFraction name="agle:MaximumNumberOfSharesPurchasedUnderEmployeeStockPurchasePlan" contextRef="P02_01_2023To02_28_2023_MaximumMembersrtRangeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">400</ix:nonFraction> shares or a lesser amount determined by the board of directors. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Restricted Common Stock Units </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company granted <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="P01_01_2020To12_31_2020_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">9,128</ix:nonFraction> restricted stock units (&#8220;RSUs&#8221;) during the year ended December&#160;31, 2020 to certain employees with regulatory, commercial, and clinical milestones in addition to a service condition. There were <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="P01_01_2022To12_31_2022_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="P01_01_2021To12_31_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> RSUs granted for the years ended December&#160;31, 2022 and 2021. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2022, the performance conditions of the granted RSUs were not probable of being achieved. If and when the performance milestones are deemed probable of being achieved within the required time frame, the Company may recognize up to $<ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" contextRef="PAsOn12_31_2022_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.2</ix:nonFraction>&#160;million of stock-based compensation for the remaining unvested RSUs as of December&#160;31, 2022. </div><ix:nonNumeric name="us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes employee restricted stock activity for the year ended December&#160;31, 2022: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:71%"></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average&#160;Grant<br/> Date&#160;Fair&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Unvested restricted stock units as of December&#160;31, 2021</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="PAsOn12_31_2021_EmployeesMembersrtTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">7,600</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="PAsOn12_31_2021_EmployeesMembersrtTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">203.25</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Granted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="P01_01_2022To12_31_2022_EmployeesMembersrtTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="P01_01_2022To12_31_2022_EmployeesMembersrtTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Vested</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="P01_01_2022To12_31_2022_EmployeesMembersrtTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="P01_01_2022To12_31_2022_EmployeesMembersrtTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Forfeited</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="P01_01_2022To12_31_2022_EmployeesMembersrtTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">1,940</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="P01_01_2022To12_31_2022_EmployeesMembersrtTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">203.25</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Unvested restricted stock units as of December&#160;31, 2022</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="PAsOn12_31_2022_EmployeesMembersrtTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">5,660</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="PAsOn12_31_2022_EmployeesMembersrtTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">203.25</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr></table></ix:nonNumeric><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There were <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="P01_01_2021To12_31_2021_NonEmployeesMembersrtTitleOfIndividualAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="P01_01_2020To12_31_2020_NonEmployeesMembersrtTitleOfIndividualAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="P01_01_2022To12_31_2022_NonEmployeesMembersrtTitleOfIndividualAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> RSUs granted to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employees</div> during the years ended December&#160;31, 2022, 2021, and 2020. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Stock-Based Compensation Expense </div></div></div><ix:nonNumeric name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Total stock-based compensation expense recognized from the Company&#8217;s equity incentive plans, 2018 Plan, and the 2016 ESPP for the years ended December&#160;31, 2022, 2021, and 2020 was as follows (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:47%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="22" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Employees</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Non-</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Employees</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Employees</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Non-</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Employees</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Employees</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Non-</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Employees</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2022To12_31_2022_EmployeesMembersrtTitleOfIndividualAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,591</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2022To12_31_2022_NonEmployeesMembersrtTitleOfIndividualAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2021To12_31_2021_EmployeesMembersrtTitleOfIndividualAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,723</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2021To12_31_2021_NonEmployeesMembersrtTitleOfIndividualAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2020To12_31_2020_EmployeesMembersrtTitleOfIndividualAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,168</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2020To12_31_2020_NonEmployeesMembersrtTitleOfIndividualAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">36</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">General and administrative</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2022To12_31_2022_EmployeesMembersrtTitleOfIndividualAxis_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,520</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2022To12_31_2022_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_NonEmployeesMembersrtTitleOfIndividualAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2021To12_31_2021_EmployeesMembersrtTitleOfIndividualAxis_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,315</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2021To12_31_2021_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_NonEmployeesMembersrtTitleOfIndividualAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2020To12_31_2020_EmployeesMembersrtTitleOfIndividualAxis_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,052</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2020To12_31_2020_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_NonEmployeesMembersrtTitleOfIndividualAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total stock-based compensation expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2022To12_31_2022_EmployeesMembersrtTitleOfIndividualAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,111</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2022To12_31_2022_NonEmployeesMembersrtTitleOfIndividualAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2021To12_31_2021_EmployeesMembersrtTitleOfIndividualAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,038</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2021To12_31_2021_NonEmployeesMembersrtTitleOfIndividualAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2020To12_31_2020_EmployeesMembersrtTitleOfIndividualAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,220</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2020To12_31_2020_NonEmployeesMembersrtTitleOfIndividualAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">36</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><ix:exclude><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-27 </div></ix:exclude></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_95764052_8" continuedAt="TextSelectionAppend_95764052_9"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_95764052_9" continuedAt="TextSelectionAppend_95764052_10"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_95764052_10" continuedAt="TextSelectionAppend_95764052_11"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_95764052_11" continuedAt="TextSelectionAppend_95764052_12"><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen">No</ix:nonFraction></ix:nonFraction></ix:nonFraction> related tax benefits were recognized for the years ended December&#160;31, 2022, 2021, and 2020 (see Note 11). </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The employee and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> awards contain both performance and service-based vesting conditions. <ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="PAsOn12_31_2021_EmployeesAndNonEmployeesMembersrtTitleOfIndividualAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="PAsOn12_31_2020_EmployeesAndNonEmployeesMembersrtTitleOfIndividualAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="PAsOn12_31_2022_EmployeesAndNonEmployeesMembersrtTitleOfIndividualAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen">No</ix:nonFraction></ix:nonFraction></ix:nonFraction> expense was recognized for the unvested employee and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> awards with only a performance condition for the years ended December&#160;31, 2022, 2021, and 2020. The performance-based vesting conditions represent specific performance targets. Compensation expense for employee and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> share-based payment awards with performance conditions is recognized when the performance condition is deemed probable of achievement. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2022, the Company had an aggregate of $<ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="PAsOn12_31_2022_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">11.6</ix:nonFraction>&#160;million of unrecognized stock-based compensation expense for options outstanding, which is expected to be recognized over a weighted average period of <ix:nonNumeric name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="P01_01_2022To12_31_2022_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis" format="ixt-sec:duryear">1.6</ix:nonNumeric> years. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In determining the fair value of the stock-based awards, the Company uses the Black-Scholes option-pricing model and assumptions discussed below. Each of these inputs is subjective and generally requires significant judgment to determine. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Expected Term </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#8217;s expected term represents the period that the Company&#8217;s stock-based awards are expected to be outstanding and is determined using the simplified method (based on the midpoint between the vesting date and the end of the contractual term). The Company utilizes this method due to lack of historical exercise data and the plain-vanilla nature of the Company&#8217;s stock-based awards. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Expected Volatility </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since the Company was privately held through April 2016, it alone does not have the relevant company-specific historical data to support its expected volatility. As such, the Company has used an average of expected volatilities based on the volatilities of a representative group of publicly traded biopharmaceutical companies over a period equal to the expected term of the stock option grants. Subsequent to the Company&#8217;s initial public offering, it began to consider the Company&#8217;s own historic volatility. However, due to its limited history as a public company, the Company still uses peer company data to assist in this analysis. For purposes of identifying comparable companies, the Company selected companies with comparable characteristics to it, including enterprise value, risk profiles, position within the industry, and with historical share price information sufficient to meet the expected life of the stock-based awards. The historical volatility data was computed using the daily closing prices for the selected companies&#8217; shares during the equivalent period of the calculated expected term of the stock-based awards. The Company intends to consistently apply this process using the same or similar comparable entities until a sufficient amount of historical information regarding the volatility of the Company&#8217;s own share price becomes available. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Risk-Free Interest Rate </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of option. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Expected Dividend </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has never paid dividends on its common stock and has no plans to pay dividends on its common stock. Therefore, the Company used an expected dividend yield of <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="0" scale="-2" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="0" scale="-2" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_pure" decimals="0" scale="-2" format="ixt-sec:numwordsen">zero</ix:nonFraction></ix:nonFraction></ix:nonFraction>. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-28</ix:exclude> </div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_95764052_12" continuedAt="TextSelectionAppend_95764052_13"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_95764052_13" continuedAt="TextSelectionAppend_95764052_14"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_95764052_14" continuedAt="TextSelectionAppend_95764052_15"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_95764052_15"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Valuation of Stock Options and 2016 ESPP </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fair value of the stock options granted under the 2018 Plan, 2016 Plan, 2015 Plan and the CEO inducement grant, as well as the shares available for purchase under the 2016 ESPP were determined using the Black-Scholes option-pricing model. <ix:nonNumeric name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_95765418">The following table summarizes the weighted-average assumptions used in calculating the fair value of the awards: </ix:nonNumeric></div><ix:continuation id="TextSelection_95765418"><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:78%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Stock Options Granted</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected term (in years)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2022To12_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis" format="ixt-sec:duryear">6.00</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis" format="ixt-sec:duryear">5.99</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis" format="ixt-sec:duryear">6.10</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected volatility</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P01_01_2022To12_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">84</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">83</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">76</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Risk-free interest</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2022To12_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">2.93</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">0.88</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">1.06</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Dividend yield</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P01_01_2022To12_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:num-dot-decimal">0</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:num-dot-decimal">0</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:num-dot-decimal">0</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">2016 ESPP</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected term (in years)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2022To12_31_2022_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" format="ixt-sec:duryear">0.49</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2021To12_31_2021_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" format="ixt-sec:duryear">0.50</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2020To12_31_2020_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" format="ixt-sec:duryear">0.50</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected volatility</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P01_01_2022To12_31_2022_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">84</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P01_01_2021To12_31_2021_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">86</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P01_01_2020To12_31_2020_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">76</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Risk-free interest</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2022To12_31_2022_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">1.95</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2021To12_31_2021_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">0.08</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2020To12_31_2020_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">0.75</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Dividend yield</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P01_01_2022To12_31_2022_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:num-dot-decimal">0</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P01_01_2021To12_31_2021_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:num-dot-decimal">0</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P01_01_2020To12_31_2020_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:num-dot-decimal">0</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr></table></ix:continuation></ix:continuation><ix:nonNumeric name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">11. Defined Contribution Plan </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company sponsors a 401(k) retirement plan in which substantially all of its full-time employees are eligible to participate. Participants may contribute a percentage of their annual compensation to this plan, subject to statutory limitations. During the years ended December&#160;31, 2022, 2021, 2020, the Company provided $<ix:nonFraction name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.6</ix:nonFraction>&#160;million, $<ix:nonFraction name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.6</ix:nonFraction>&#160;million, and $<ix:nonFraction name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.5</ix:nonFraction>&#160;million, respectively, in contributions to the plan. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:IncomeTaxDisclosureTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_95764351"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">12. Income Taxes </div></div><ix:nonNumeric name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the (loss) income before income tax expense by jurisdiction for the periods indicated: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:64%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Domestic</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">84,113</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">65,940</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">80,893</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Foreign</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">162</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">280</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Loss before income tax expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">83,951</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">65,660</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">80,893</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-29</ix:exclude> </div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_95764351" continuedAt="TextSelectionAppend_95764351_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_95764351_1" continuedAt="TextSelectionAppend_95764351_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_95764351_2" continuedAt="TextSelectionAppend_95764351_3"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_95764351_3" continuedAt="TextSelectionAppend_95764351_4"><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December&#160;31, 2022, the Company recognized an income tax expense of $<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2022To12_31_2022_ForeignCountryMemberusgaapIncomeTaxAuthorityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.1</ix:nonFraction>&#160;million, related to foreign subsidiaries refund from research client and foreign subsidiaries income tax expense. For the year ended December&#160;31, 2021, the Company recognized an income tax expense of $<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2021To12_31_2021_ForeignCountryMemberusgaapIncomeTaxAuthorityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.1</ix:nonFraction>&#160;million, related to foreign subsidiaries income tax expense and the Texas margins tax. For the year ended December&#160;31, 2020, the Company recognized <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt-sec:numwordsen">no</ix:nonFraction> provision or benefit from income taxes. <ix:nonNumeric name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_95764357">The difference between the Company&#8217;s provision for income taxes and the amounts computed by applying the statutory federal income tax rate to income before income taxes is as follows (in thousands): </ix:nonNumeric></div><ix:continuation id="TextSelection_95764357"><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:64%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Tax provision derived by applying the federal statutory rate to income before income taxes</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">17,630</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">13,789</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">16,988</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Permanent differences and other</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,042</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,002</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">482</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Federal tax credits</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="agle:IncomeTaxReconciliationTaxCostCredit" contextRef="P01_01_2022To12_31_2022_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">3,559</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="agle:IncomeTaxReconciliationTaxCostCredit" contextRef="P01_01_2021To12_31_2021_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">3,815</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="agle:IncomeTaxReconciliationTaxCostCredit" contextRef="P01_01_2020To12_31_2020_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">3,905</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">State tax credits</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="agle:IncomeTaxReconciliationTaxCostCredit" contextRef="P01_01_2022To12_31_2022_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">640</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="agle:IncomeTaxReconciliationTaxCostCredit" contextRef="P01_01_2021To12_31_2021_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">152</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="agle:IncomeTaxReconciliationTaxCostCredit" contextRef="P01_01_2020To12_31_2020_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">251</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Effect of tax rate on foreign jurisdiction</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationOtherAdjustments" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">42</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationOtherAdjustments" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">5</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationOtherAdjustments" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in the valuation allowance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">20,609</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">16,900</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">20,662</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Income tax (benefit) expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">136</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">141</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:continuation><ix:nonNumeric name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The components of the deferred tax assets and liabilities consist of the following (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:70%"></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred tax assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net operating loss carryforward</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">68,917</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">64,531</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Intangible assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">11,149</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">57</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred revenue</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsDeferredIncome" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">566</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsDeferredIncome" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">668</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">846</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock-based compensation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,293</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,767</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Federal tax credits</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" contextRef="PAsOn12_31_2022_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">21,914</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" contextRef="PAsOn12_31_2021_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">18,579</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">State tax credits</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" contextRef="PAsOn12_31_2022_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,631</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" contextRef="PAsOn12_31_2021_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">991</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">190</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">220</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total deferred tax assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">108,328</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">87,991</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred tax liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Depreciable assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">676</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">948</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total deferred tax liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">676</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">948</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: Valuation allowance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">107,652</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">87,043</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred tax assets, net</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has established a full federal and state valuation allowance equal to the net deferred tax assets due to uncertainties regarding the realization of the deferred tax asset based on the Company&#8217;s lack of earnings history. The valuation allowance increased by $<ix:nonFraction name="agle:IncreaseInValuationPrimarilyDueToOperationLosses" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">20.6</ix:nonFraction>&#160;million, $<ix:nonFraction name="agle:IncreaseInValuationPrimarilyDueToOperationLosses" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">16.9</ix:nonFraction>&#160;million, and $<ix:nonFraction name="agle:IncreaseInValuationPrimarilyDueToOperationLosses" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">20.7</ix:nonFraction>&#160;million during the years ended December&#160;31, 2022, 2021, and 2020, respectively, primarily due to continuing loss from operations. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2022 and 2021, the Company had U.S. net operating loss carryforwards (&#8220;NOL&#8221;) of $<ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">328.2</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">307.3</ix:nonFraction>&#160;million, respectively. As of December&#160;31, 2022 and 2021, the Company had U.S. tax credit carryforwards of $<ix:nonFraction name="us-gaap:TaxCreditCarryforwardAmount" contextRef="PAsOn12_31_2022_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">21.9</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:TaxCreditCarryforwardAmount" contextRef="PAsOn12_31_2021_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">18.6</ix:nonFraction>&#160;million, respectively, and state tax credit carryforwards of $<ix:nonFraction name="us-gaap:TaxCreditCarryforwardAmount" contextRef="PAsOn12_31_2022_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.6</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:TaxCreditCarryforwardAmount" contextRef="PAsOn12_31_2021_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.0</ix:nonFraction>&#160;million, respectively. Of the net operating loss and tax credit carryforwards, $<ix:nonFraction name="agle:NetOperatingLossAndCreditCarryforwards" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">58.4</ix:nonFraction>&#160;million and $<ix:nonFraction name="agle:NetOperatingLossAndCreditCarryforwards" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">21.9</ix:nonFraction>&#160;million, respectively, will expire in <ix:nonNumeric name="agle:TaxCreditCarryforwardExpirationYear" contextRef="P01_01_2022To12_31_2022_EarliestTaxYearMemberusgaapTaxPeriodAxis"><ix:nonNumeric name="agle:OperatingLossCarryforwardsExpirationYear" contextRef="P01_01_2022To12_31_2022_EarliestTaxYearMemberusgaapTaxPeriodAxis">2033</ix:nonNumeric></ix:nonNumeric>, if not utilized. Any remaining net operating loss will carry forward indefinitely and can be utilized to offset up to <ix:nonFraction name="agle:PercentageOfNetOperatingLossUtilizedToOffsetTaxableIncome" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">80</ix:nonFraction>% of the taxable income in any tax year. The net </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-30</ix:exclude> </div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_95764351_4" continuedAt="TextSelectionAppend_95764351_5"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_95764351_5" continuedAt="TextSelectionAppend_95764351_6"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_95764351_6" continuedAt="TextSelectionAppend_95764351_7"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></div></div></div> <div><ix:continuation id="TextSelectionAppend_95764351_7" continuedAt="TextSelectionAppend_95764351_8"><div><div></div></div></ix:continuation><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_95764351_8"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">operating loss and credit carryforwards are subject to Internal Revenue Service adjustments until the statute closes on the year the net operating loss or tax credits are utilized. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has not completed a study to assess whether an ownership change has occurred or whether there have been multiple ownership changes since the Company&#8217;s formation due to the complexity and cost associated with such a study, and the fact that there may be additional such ownership changes in the future. If the Company has experienced an ownership change at any time since its formation, utilization of the NOL or research and development credit carryforwards would be subject to an annual limitation under Section&#160;<div style="display:inline;">382</div> or 383 of the Internal Revenue Code, which is determined by first multiplying the value of the Company&#8217;s stock at the time of the ownership change by the applicable long-term, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">tax-exempt</div> rate, and then could be subject to additional adjustments, as required. Additionally, the separate return limitation year (&#8220;SRLY&#8221;) rules may apply to losses of the Company&#8217;s eight wholly owned U.S. subsidiary corporations. The SRLY rules limit the consolidated group&#8217;s use of a subsidiary corporation&#8217;s net operating losses to the amount of income generated by the subsidiary corporation after it becomes a member of the group. Any limitation may result in expiration of a portion of the NOL or research and development credit carryforwards before utilization. Further, until a study is completed and any limitation known, <ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction> amounts are being considered as an uncertain tax position or disclosed as an unrecognized tax benefit. Additionally, the Company does not expect any unrecognized tax benefits to change significantly over the next twelve months. Due to the existence of the valuation allowance, future changes in the Company&#8217;s unrecognized tax benefits will not impact its effective tax rate. Any carryforwards that will expire prior to utilization as a result of such limitations will be removed from deferred tax assets with a corresponding reduction of the valuation allowance. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is subject to examination by taxing authorities in its significant jurisdictions for the 2018 and subsequent years. However, due to NOL and tax attribute carryovers, the taxing authorities have the ability to adjust the NOLs and other tax attributes related to closed years. As of December&#160;31, 2022 and 2021, there were <ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction> amounts recorded for uncertain tax positions. As of December&#160;31, 2022, undistributed earnings of the Company&#8217;s newly incorporated foreign subsidiaries are immaterial. Under the Global Intangible <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Low-Taxed</div> Income (&#8220;GILTI&#8221;) provisions of the 2017 Tax Cuts and Jobs Act, U.S. income taxes have been incurred on the undistributed earnings of the foreign subsidiaries and therefore, the tax impact upon distribution is limited to state income and withholding taxes and is not material. </div></ix:continuation><ix:nonNumeric name="us-gaap:EarningsPerShareTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_95764841"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">13. Net Loss Per Share </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per share is computed by dividing net loss by the weighted-average number of common stock and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants outstanding during the period. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants are included in the computation of basic net loss per share as the exercise price is negligible and they are fully vested and exercisable. For periods in which the Company generated a net loss, the Company does not include the potential impact of dilutive securities in diluted net loss per share, as the impact of these items is anti-dilutive. </div><ix:nonNumeric name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following weighted-average equity instruments were excluded from the calculation of diluted net loss per share because their effect would have been anti-dilutive for the periods presented: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:84%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:67%"></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Options to purchase common stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2022To12_31_2022_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">346,331</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">264,858</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">201,977</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unvested restricted stock units</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2022To12_31_2022_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">6,982</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2021To12_31_2021_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">7,975</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2020To12_31_2020_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">4,239</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table></ix:nonNumeric><ix:exclude><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-31 </div></ix:exclude></ix:nonNumeric></div></div><ix:continuation id="TextSelection_95764841" continuedAt="TextSelectionAppend_95764841_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_95764841_1" continuedAt="TextSelectionAppend_95764841_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_95764841_2" continuedAt="TextSelectionAppend_95764841_3"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_95764841_3"><ix:nonNumeric name="us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a reconciliation of the shares used as the denominator for the calculation of basic and diluted net loss per share: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:61%"></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average common shares</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">2,307,668</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">1,956,933</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">1,608,952</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="agle:WeightedAverageNumberOfSharesPreFundedWarrants" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">1,063,563</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="agle:WeightedAverageNumberOfSharesPreFundedWarrants" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">672,851</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="agle:WeightedAverageNumberOfSharesPreFundedWarrants" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">525,917</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total basic and diluted weighted average shares</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">3,371,231</ix:nonFraction></ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">2,629,784</ix:nonFraction></ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">2,134,869</ix:nonFraction></ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric></ix:continuation><ix:nonNumeric name="agle:ReverseStockSplitTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">14. Reverse Stock Split </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&#160;8, 2023, the Company effected a reverse stock split of its common stock at a ratio of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="us-gaap:StockholdersEquityReverseStockSplit" contextRef="P09_08_2023To09_08_2023">1-for-25</ix:nonNumeric></div></div> (the &#8220;Reverse Split&#8221;). Upon the effectiveness of the Reverse Split, (i)&#160;every <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits" contextRef="P09_08_2023To09_08_2023" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">25</ix:nonFraction> shares of outstanding common stock were reclassified and combined into one share of common stock, (ii)&#160;the number of shares of common stock for which each outstanding option and warrant to purchase common stock is exercisable was proportionally decreased and the exercise price of each outstanding option and warrant to purchase common stock proportionally increased, and (iii)&#160;the total number of authorized shares of common stock was proportionally decreased. No fractional shares were issued as a result of the Reverse Split. Accordingly, all share and per share amounts for all periods presented in these financial statements and notes thereto have been adjusted retroactively, where applicable, to reflect the Reverse Split and adjustment of the exercise price of each outstanding option and warrant as if the transaction had occurred as of the beginning of the earliest period presented. </div></ix:nonNumeric><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-32 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div id="fin518298_29" style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Report of Independent Registered Public Accounting Firm </div></div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the Board of Directors of Aeglea BioTherapeutics, Inc. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Opinion </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have audited the accompanying statement of assets acquired and liabilities assumed from Spyre Therapeutics, Inc. (&#8220;Spyre&#8221;) by Aeglea BioTherapeutics, Inc. (&#8220;Aeglea&#8221;) as of June&#160;22, 2023, including the related notes (collectively referred to as the &#8220;financial statement&#8221;). </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In our opinion, the accompanying financial statement presents fairly, in all material respects, the assets acquired and liabilities assumed from Spyre by Aeglea as of June&#160;22, 2023 in accordance with accounting principles generally accepted in the United States of America. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Basis for Opinion </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We conducted our audit in accordance with auditing standards generally accepted in the United States of America (US GAAS). Our responsibilities under those standards are further described in the Auditors&#8217; Responsibilities for the Audit of the Financial Statement section of our report. We are required to be independent of Aeglea and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Substantial Doubt about the Company&#8217;s Ability to Continue as a Going Concern </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying financial statement has been prepared assuming that Aeglea will continue as a going concern. As discussed in Note 1 to the financial statement, holders of Aeglea Series A Preferred Stock are entitled to require Aeglea to settle their shares of Series A Preferred Stock for cash, and the cash redemption is not in Aeglea&#8217;s control, and Aeglea has stated that substantial doubt exists about it&#8217;s ability to continue as a going concern. Management&#8217;s evaluation of the events and conditions and management&#8217;s plans regarding these matters are also described in Note 1. The financial statement does not include any adjustments that might result from the outcome of the uncertainty. Our opinion is not modified with respect to this matter. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Emphasis of Matter </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As described in Note 1 to the accompanying financial statement, the financial statement was prepared in connection with Aeglea&#8217;s acquisition of Spyre in accordance with a Securities and Exchange Commission (SEC) waiver received by Aeglea, for the purpose of Aeglea complying with Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-05</div> of the SEC&#8217;s Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-X.</div> The financial statement is not intended to be a complete presentation of the financial position, results of operations, or cash flows of Spyre. Our opinion is not modified with respect to this matter. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Responsibilities of Management for the Financial Statement </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Management is responsible for the preparation and fair presentation of the financial statement in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of the financial statement that is free from material misstatement, whether due to fraud or error. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In preparing the financial statement, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about Aeglea&#8217;s ability to continue as a going concern for one year after the date the financial statement is available to be issued. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-33 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Auditors&#8217; Responsibilities for the Audit of the Financial Statement </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our objectives are to obtain reasonable assurance about whether the financial statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditors&#8217; report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with US GAAS will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statement. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In performing an audit in accordance with US GAAS, we: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">Exercise professional judgment and maintain professional skepticism throughout the audit. </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">Identify and assess the risks of material misstatement of the financial statement, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statement. </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of Aeglea&#8217;s internal control. Accordingly, no such opinion is expressed. </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statement. </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about Aeglea&#8217;s ability to continue as a going concern for a reasonable period of time. </div></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit. </div><div style="margin-top:12pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">/s/ PricewaterhouseCoopers LLP </div><div style="margin-top:12pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Austin, Texas </div><div style="margin-top:0pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">October&#160;6, 2023 </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-34 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Aeglea BioTherapeutics, Inc. </div></div><div id="fin518298_30" style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Statement of Assets Acquired and Liabilities Assumed </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">from Spyre Therapeutics, Inc. by Aeglea BioTherapeutics, Inc. </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(in thousands) </div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:88%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;of&#160;June&#160;22,<br/>2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">ASSETS ACQUIRED</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Current assets:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash and cash equivalents</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" contextRef="PAsOn06_22_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,035</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total current assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" contextRef="PAsOn06_22_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,035</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total assets acquired</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" contextRef="PAsOn06_22_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,035</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">LIABILITIES ASSUMED</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Current liabilities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" contextRef="PAsOn06_22_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">20,047</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total current liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" contextRef="PAsOn06_22_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">20,047</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total liabilities assumed</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" contextRef="PAsOn06_22_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">20,047</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Net liabilities assumed</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" contextRef="PAsOn06_22_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">17,012</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">See accompanying notes to the Statement of Assets Acquired and Liabilities Assumed from Spyre Therapeutics, Inc. by Aeglea BioTherapeutics, Inc. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-35 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Aeglea BioTherapeutics, Inc. </div></div><div id="fin518298_31" style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Notes to Statement of Assets Acquired and Liabilities Assumed </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">from Spyre Therapeutics, Inc. by Aeglea BioTherapeutics, Inc. </div></div><ix:nonNumeric name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" contextRef="P06_22_2023To06_22_2023" escape="true" continuedAt="TextSelection_95763840"><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">1. Description of the Business and Summary of Significant Accounting Policies </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;22, 2023, Aeglea BioTherapeutics, Inc. (&#8220;Aeglea&#8221;, the &#8220;Company&#8221;, and &#8220;our&#8221;) acquired, in accordance with the terms of the Agreement and Plan of Merger (the &#8220;Acquisition Agreement&#8221;), the assets from Spyre Therapeutics, Inc (&#8220;Spyre&#8221;), a privately held biotechnology company advancing a pipeline of antibody therapeutics through a research and development option agreement (&#8220;Paragon Agreement&#8221;) with Paragon Therapeutics (&#8220;Paragon&#8221;). Spyre was incorporated on April&#160;28, 2023, for the purpose of holding rights to certain intellectual property being developed by Paragon. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&#160;8, 2023, Aeglea effected a reverse stock split of its Common Stock at a ratio of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="us-gaap:StockholdersEquityReverseStockSplit" contextRef="P09_08_2023To09_08_2023">1-for-25</ix:nonNumeric></div></div> (the &#8220;Reverse Split&#8221;). Except as indicated otherwise, all share numbers related to our Common Stock disclosed in this statement have been adjusted on a post-Reverse Split basis. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transaction (the &#8220;Asset Acquisition&#8221;) was structured as a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">stock-for-stock</div></div> transaction pursuant to which all of Spyre&#8217;s outstanding equity interests were exchanged based on a fixed exchange ratio of <ix:nonFraction name="agle:FixedExchangeRatio" contextRef="PAsOn06_22_2023_AssetAcquisitionMemberusgaapAssetAcquisitionAxis" unitRef="Unit_pure" decimals="9" scale="-2" format="ixt:num-dot-decimal">0.5494488</ix:nonFraction> to 1 for consideration from Aeglea of <ix:nonFraction name="agle:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares" contextRef="P06_22_2023To06_22_2023_AssetAcquisitionMemberusgaapAssetAcquisitionAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">517,809</ix:nonFraction> shares of common stock and <ix:nonFraction name="agle:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares" contextRef="P06_22_2023To06_22_2023_AssetAcquisitionMemberusgaapAssetAcquisitionAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">364,887</ix:nonFraction> shares of Series A <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-voting</div> convertible preferred stock, par value of $<ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn06_22_2023_AssetAcquisitionMemberusgaapAssetAcquisitionAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction> per share (&#8220;Series A Preferred Stock&#8221;) (convertible on a <ix:nonFraction name="us-gaap:PreferredStockConvertibleConversionRatio" contextRef="PAsOn06_22_2023_AssetAcquisitionMemberusgaapAssetAcquisitionAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_pure" decimals="0" scale="0" format="ixt:num-dot-decimal">40</ix:nonFraction> to 1 basis) in addition to the assumption of outstanding and unexercised stock options to purchase <ix:nonFraction name="agle:OutstandingAndUnexercisedStockOptions" contextRef="P06_22_2023To06_22_2023_AssetAcquisitionMemberusgaapAssetAcquisitionAxis_Spyre2023EquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">2,734</ix:nonFraction> shares of common stock from the Amended and Restated Spyre 2023 Equity Incentive Plan. The Aeglea common stock and the Aeglea Series A Preferred Stock related to the Asset Acquisition were issued to the Spyre stockholders on July&#160;7, 2023. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company concluded that the arrangement meets the definition of an asset acquisition rather than a business combination, as substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset, Spyre&#8217;s option (the &#8220;Option&#8221;) to exclusively license certain <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development (&#8220;IPR&amp;D&#8221;). The Company determined that the Option to license IPR&amp;D was a single asset as the Company&#8217;s strategy relies on developing a portfolio of combination treatments that simultaneously address different mechanisms of irritable bowel disease. The Company also determined that the pipeline candidates within the portfolio are similar in nature and risk profile. In addition, the Company did not obtain any substantive processes, assembled workforce, or employees capable of producing outputs in connection with the Asset Acquisition. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company determined that the cost to acquire the asset was $<ix:nonFraction name="us-gaap:AssetAcquisitionConsiderationTransferred" contextRef="P06_22_2023To06_22_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">113.2</ix:nonFraction>&#160;million, which was recorded as acquired IPR&amp;D. The fair value of the consideration issued consisted of the <ix:nonFraction name="agle:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares" contextRef="P06_22_2023To06_22_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">364,887</ix:nonFraction> shares of Series A Preferred Stock (<ix:nonFraction name="agle:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableSharesOfCommonStockOnAnAsConvertedBasis" contextRef="P06_22_2023To06_22_2023_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">14,595,480</ix:nonFraction> shares of common stock on an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">as-converted</div> basis) and <ix:nonFraction name="agle:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares" contextRef="P06_22_2023To06_22_2023_CommonStockMemberusgaapEquityInterestIssuedOrIssuableByTypeAxis_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">517,809</ix:nonFraction> shares of common stock, valued at $<ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="PAsOn06_22_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">291.08</ix:nonFraction> per share and $<ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="PAsOn06_22_2023_CommonStockMemberusgaapEquityInterestIssuedOrIssuableByTypeAxis_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD_per_Share" decimals="3" scale="0" format="ixt:num-dot-decimal">7.277</ix:nonFraction> per share, respectively. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Paragon Agreement provided for an annual equity grant of options to purchase <ix:nonFraction name="agle:PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock" contextRef="PAsOn06_22_2023_ParapyreOptionObligationMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">1</ix:nonFraction>% of the then outstanding shares of Spyre&#8217;s common stock, on a fully diluted basis, on the last business day of each calendar year during the term of the Option, at the fair market value determined by the board of directors of Spyre (the &#8220;Parapyre Option Obligation&#8221;). In connection with the Asset Acquisition, the Company assumed the rights and obligations of Spyre under the Paragon Agreement, including the Parapyre Option Obligation. As a result, the Parapyre Option Obligation shall continue and Parapyre shall be entitled to receive the equivalent shares of common stock of the Company on the same terms. For additional information, see Note&#160;3. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-36</ix:exclude> </div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_95763840" continuedAt="TextSelectionAppend_95763840_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_95763840_1" continuedAt="TextSelectionAppend_95763840_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_95763840_2" continuedAt="TextSelectionAppend_95763840_3"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_95763840_3" continuedAt="TextSelectionAppend_95763840_4"><ix:nonNumeric name="us-gaap:AssetAcquisitionTableTextBlock" contextRef="P06_22_2023To06_22_2023" escape="true"><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Asset Acquisition costs are shown on the following table (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:80%"></td>
<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;of&#160;June&#160;22,<br/>2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Consideration transferred in Series A Preferred Stock and common stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" contextRef="P06_22_2023To06_22_2023_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">109,979</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Transaction costs incurred by Aeglea</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetAcquisitionConsiderationTransferredTransactionCost" contextRef="P06_22_2023To06_22_2023_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,197</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total cost to acquire asset</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetAcquisitionConsiderationTransferred" contextRef="P06_22_2023To06_22_2023_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">113,176</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#8217;s allocation of the purchase price to net assets acquired is as follows (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:80%"></td>
<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;of&#160;June&#160;22,<br/>2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Acquired <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="agle:AcquiredInProcessResearchAndDevelopment" contextRef="P06_22_2023To06_22_2023_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">130,188</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash acquired</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashAcquiredFromAcquisition" contextRef="P06_22_2023To06_22_2023_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,035</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="PAsOn06_22_2023_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">20,047</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total cost to acquire asset</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetAcquisitionConsiderationTransferred" contextRef="P06_22_2023To06_22_2023_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">113,176</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">730-10-25-2(c),</div></div></div> intangible assets used in research and developmental activities acquired in an asset acquisition should be expensed at the acquisition date if there is no alternative future use in other R&amp;D projects or otherwise (i.e., if they have no economic value). The Company determined that product candidates pertaining to Spyre had no alternative future use at the time of acquisition and recorded $<ix:nonFraction name="agle:AcquiredInProcessResearchAndDevelopment" contextRef="P06_22_2023To06_22_2023_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">130.2</ix:nonFraction>&#160;million to Acquired <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">In-process</div> Research and Development Expenses as of the date of acquisition. The difference between this amount and the $<ix:nonFraction name="us-gaap:AssetAcquisitionConsiderationTransferred" contextRef="P06_22_2023To06_22_2023_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">113.2</ix:nonFraction>&#160;million cost to acquire Spyre represents the net liabilities assumed of $<ix:nonFraction name="agle:AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet" contextRef="P06_22_2023To06_22_2023_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">17.0</ix:nonFraction>&#160;million. </div><ix:nonNumeric name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" contextRef="P06_22_2023To06_22_2023" escape="true" continuedAt="TextSelection_95763841"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Basis of Presentation</div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result of acquiring Spyre, and based on the criteria in Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-05</div> of the Securities and Exchange Commission&#8217;s (the &#8220;SEC&#8221;) Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-X,</div> the Company would ordinarily be required to file certain historical audited financial statements for Spyre and corresponding pro forma financial information pursuant to Article 11 of Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-X.</div> Further, the historical financial statements could require the inclusion of predecessor entity information, if warranted. However, because the Company believes that Spyre&#8217;s full financial statements are not material to the Company&#8217;s shareholders and would be of limited value to investors, the Company requested relief from the SEC from the requirements under Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-05</div> and Article 11 of Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-X</div> to file audited financial statements and pro forma financial information in connection with the acquisition of Spyre. In response to the waiver request, the SEC provided the Company with a waiver that it could file an audited Statement of Assets Acquired and Liabilities Assumed from Spyre Therapeutics, Inc. on the basis of the allocation of the Company&#8217;s purchase price as of the acquisition date of June&#160;22, 2023. Stand-alone full financial statements related to the assets acquired have not been prepared previously. This financial statement is not intended to be a complete presentation of the financial position, results of operations, or cash flows of Spyre. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company determined that it was the acquirer of Spyre under ASC 805 due to the relative voting rights in the combined entity, the composition of the governing body of the combined entity, and the composition of the senior management of the combined entity remaining relatively the same before and after the consummation of the transaction. The Company determined that the future conversion of the Series A Preferred Stock, if approved by the Company&#8217;s voting shareholders, was an independent event based on it being outside of the control of the Company and therefore substantive. The Company did not succeed to substantially all of Paragon&#8217;s business nor acquire from Paragon any separately identifiable line of business, the Company concluded that Paragon did not meet the definition of predecessor. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-37</ix:exclude> </div></ix:nonNumeric></ix:continuation></div></div><ix:continuation id="TextSelection_95763841" continuedAt="TextSelectionAppend_95763841_1"><ix:continuation id="TextSelectionAppend_95763840_4" continuedAt="TextSelectionAppend_95763840_5"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_95763840_5" continuedAt="TextSelectionAppend_95763840_6"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_95763840_6" continuedAt="TextSelectionAppend_95763840_7"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_95763841_1" continuedAt="TextSelectionAppend_95763841_2"><ix:continuation id="TextSelectionAppend_95763840_7" continuedAt="TextSelectionAppend_95763840_8"><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company evaluates acquisitions of assets and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first applying a screen test to determine whether substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If so, the transaction is accounted for as an asset acquisition. If not, further determination is required as to whether or not the Company has acquired inputs and processes that have the ability to create outputs, which would meet the definition of a business. Significant judgment is required in the application of the screen test to determine whether an acquisition is a business combination or an acquisition of assets. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company concluded that the arrangement meets the definition of an asset acquisition rather than a business combination, as substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset, Spyre&#8217;s option to exclusively license IPR&amp;D. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company measures and recognizes asset acquisitions that are not deemed to be business combinations based on the cost to acquire the assets, which includes <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-acquisition</div> direct costs recorded in accrued professional and consulting fees. Goodwill is not recognized in asset acquisitions. When a transaction accounted for as an asset acquisition includes an IPR&amp;D asset, the IPR&amp;D asset is only capitalized if it has an alternative future use other than in a particular research and development project. Otherwise, the cost allocated to acquire an IPR&amp;D asset with no alternative future use is charged to expense at the acquisition date. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has not generated any product revenues and has not achieved profitable operations. There is no assurance that profitable operations will ever be achieved, and, if achieved, could be sustained on a continuing basis. In addition, development activities, clinical and nonclinical testing, and commercialization of the Company&#8217;s product candidates will require significant additional financing before a commercial drug can be produced and marketed. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is subject to a number of risks similar to other life science companies, including, but not limited to, risks related to the successful discovery, development, and commercialization of product candidates, raising additional capital, development of competing drugs and therapies, protection of proprietary technology and market acceptance of the Company&#8217;s product candidates. As a result of these and other factors and the related uncertainties, there can be no assurance of the Company&#8217;s future success. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2023, the Board of Directors approved a restructuring of the Company&#8217;s workforce pursuant to which the Company&#8217;s workforce was reduced by approximately <ix:nonFraction name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" contextRef="P04_01_2023To04_30_2023" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">83</ix:nonFraction>%, retaining approximately <ix:nonFraction name="agle:NumberOfEmployeesRetained" contextRef="P04_01_2023To04_30_2023" unitRef="Unit_employee" decimals="0" scale="0" format="ixt:num-dot-decimal">10</ix:nonFraction> employees. Additionally, the Company announced interim results from its ongoing Phase 1/2 clinical trial of pegtarviliase for the treatment of classical homocystinuria. Following a review of the interim results and other business considerations, the Company explored strategic alternatives with the goal of maximizing stockholder value, including possible business combinations and/or a divestiture of the Company&#8217;s clinical programs. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;22, 2023, the Company acquired the net liabilities from Spyre. Additionally, on June&#160;26, 2023, the Company completed a private placement of shares of Series A Preferred Stock and sold an aggregate of <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn06_26_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">721,452</ix:nonFraction> shares of Series A Preferred Stock for an aggregate purchase price of approximately $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="P06_26_2023To06_26_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">210.0</ix:nonFraction>&#160;million before deducting approximately $<ix:nonFraction name="agle:PlacementAgentAndOtherOfferingExpenses" contextRef="P06_26_2023To06_26_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">12.7</ix:nonFraction>&#160;million placement agent and other offering expenses. In accordance with ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">205-40,</div> Going Concern, in connection with the preparation of the statement of assets acquired and liabilities assumed of Spyre, the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date the financial statement is available to be issued. Our Series A Preferred Stock agreement requires us to seek stockholder approval for the conversion of the Series A Preferred Stock to Common Stock. The Company has agreed to hold a stockholders&#8217; meeting to submit this matter to its stockholders for their consideration. In connection with this, the Company filed with the SEC a preliminary proxy statement and other relevant materials. The stockholder meeting has not occurred as of October&#160;6, 2023. If our stockholders do not timely approve the conversion of our Series A Preferred Stock, then the holders of our Series A Preferred Stock </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-38</ix:exclude> </div></ix:continuation></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_95763841_2" continuedAt="TextSelectionAppend_95763841_3"><ix:continuation id="TextSelectionAppend_95763840_8" continuedAt="TextSelectionAppend_95763840_9"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_95763840_9" continuedAt="TextSelectionAppend_95763840_10"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_95763840_10" continuedAt="TextSelectionAppend_95763840_11"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></ix:continuation></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_95763840_11"><ix:continuation id="TextSelectionAppend_95763841_3"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">are entitled to require us to settle their shares of Series A Preferred Stock for cash at a price per share equal to the fair value of the Series A Preferred Stock, as described in our Certificate of Designation relating to the Series&#160;A Preferred Stock. The cash redemption is not in our control and raises substantial doubt about our ability to continue as a going concern. The accompanying financial statement assumes the Company will continue as a going concern through the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business. </div></ix:continuation><ix:nonNumeric name="us-gaap:UseOfEstimates" contextRef="P06_22_2023To06_22_2023" escape="true"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Use of Estimates</div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and certain financial statement disclosures. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets, liabilities, and equity and the amount of revenues and expenses. Actual results could differ significantly from those estimates. Key estimates that management considers in the preparation of the Company&#8217;s financial statements relate to accrued option costs payable to Paragon and the valuation of consideration transferred. The consideration transferred in acquiring IPR&amp;D in connection with the acquisition of Spyre was comprised of the Company&#8217;s common stock and shares of Series A preferred stock. To determine the fair value of the equity transferred, the Company considered the per share value of its concurrent private financing transaction, which was an over-subscribed financing event involving a group of investors. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" contextRef="P06_22_2023To06_22_2023" escape="true"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Cash and Cash Equivalents</div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June&#160;22, 2023, Spyre held $<ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn06_22_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">3.0</ix:nonFraction>&#160;million in cash and cash equivalents, which consisted of a single deposit account denominated in U.S. dollars. At June&#160;22, 2023, U.S. cash deposits in excess of the Federal Deposit Insurance Corporation&#8217;s insured limit were $<ix:nonFraction name="us-gaap:Cash" contextRef="PAsOn06_22_2023_USBankingInstitutionMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.8</ix:nonFraction>&#160;million. </div></ix:nonNumeric><ix:nonNumeric name="agle:AccruedLiabilitiesPolicyTextBlock" contextRef="P06_22_2023To06_22_2023" escape="true"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Accrued Liabilities</div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accrued liabilities primarily consist of research initiation fees, reimbursable expenses under the Paragon Agreement for historical costs incurred by Paragon, professional and consulting fees, and the fair of assumed Parapyre Option Obligation. </div></ix:nonNumeric></ix:continuation><ix:nonNumeric name="agle:AccruedLiabilitiesTextBlock" contextRef="P06_22_2023To06_22_2023" escape="true"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">2. Accrued liabilities </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Asset Acquisition, the Company assumed the rights and obligations of Spyre under the Paragon Agreement. Under the Paragon Agreement, Spyre is obligated to compensate Paragon on a quarterly basis for its services performed under each research program based on the actual costs incurred with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mark-up</div> costs pursuant to the terms of the Paragon Agreement. As of the date of the Asset Acquisition, Spyre had incurred total expenses of $<ix:nonFraction name="agle:RelatedPartyExpensesIncurredPriorToAssetAcquisition" contextRef="P06_22_2023To06_22_2023_ParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">19.0</ix:nonFraction>&#160;million under the Paragon Agreement since inception, inclusive of a $<ix:nonFraction name="agle:ResearchInitiationFees" contextRef="P06_22_2023To06_22_2023_ParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">3.0</ix:nonFraction>&#160;million research initiation fee that was due upon signing of the Paragon Agreement and $<ix:nonFraction name="agle:ReimbursableResearchCosts" contextRef="P06_22_2023To06_22_2023_ParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">16.0</ix:nonFraction>&#160;million of historical reimbursable expenses owed to Paragon. As of June&#160;22, 2023, $<ix:nonFraction name="agle:RelatedPartyExpensesUnpaidPriorToAssetAcquisition" contextRef="PAsOn06_22_2023_ParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">19.0</ix:nonFraction>&#160;million was unpaid and was assumed by the Company through the Asset Acquisition. </div><ix:nonNumeric name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" contextRef="P06_22_2023To06_22_2023" escape="true"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accrued liabilities consist of the following (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:80%"></td>
<td style="vertical-align:bottom;width:11%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;of&#160;June&#160;22,<br/>2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued option cost payable to Paragon</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="agle:AccruedOptionCostPayable" contextRef="PAsOn06_22_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">18,987</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued professional and consulting fees</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="PAsOn06_22_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">917</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Fair value of assumed Parapyre Option Obligation (Note&#160;3)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProgramRightsObligations" contextRef="PAsOn06_22_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">143</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" contextRef="PAsOn06_22_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">20,047</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric></ix:nonNumeric><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-39 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:nonNumeric name="us-gaap:AssetAcquisitionTextBlock" contextRef="P06_22_2023To06_22_2023" escape="true"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">3. Parapyre Option Obligation </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;22, 2023, in connection with the Asset Acquisition, the Company assumed the Parapyre Option Obligation which provided for an annual equity grant of options for Parapyre to purchase <ix:nonFraction name="agle:PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock" contextRef="PAsOn06_22_2023_ParapyreOptionObligationMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">1</ix:nonFraction>% of the then outstanding shares of Spyre&#8217;s common stock, on a fully diluted basis, on the last business day of each calendar year during the term of the Paragon Agreement, at the fair market value determined by the board of directors of Spyre. As a result of the Asset Acquisition the Parapyre Option Obligation shall continue and Parapyre shall be entitled to receive the equivalent shares of the Company with the same terms. The Parapyre Option Obligation is considered a Level&#160;2 liability based on observable market data for substantially the full term of the liabilities. The Parapyre Option Obligation is measured each period using a Black-Scholes model to estimate the fair value of the option grant. Changes in the fair value of the Parapyre Option Obligation are recorded as stock-based compensation within Research and development expenses for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employees</div> who provided <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> testing services within Research and development expenses. As of June&#160;22, 2023, the estimated liability of the Parapyre Option Obligation was $<ix:nonFraction name="us-gaap:AssetAcquisitionContingentConsiderationLiabilityCurrent" contextRef="PAsOn06_22_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.1</ix:nonFraction>&#160;million and was included in accrued liabilities. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" contextRef="P06_22_2023To06_22_2023" escape="true"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">4. Related Party Transactions </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Paragon and Parapyre Holding LLC each beneficially owns less than <ix:nonFraction name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" contextRef="PAsOn06_22_2023_MaximumMembersrtRangeAxis_OwnershipInterestMemberusgaapRelatedPartyTransactionAxis_ParagonAndParapyreHoldingLlcMembersrtOwnershipAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">5</ix:nonFraction>% of the Company&#8217;s capital stock through their respective holdings of Common Stock and Series A Preferred Stock of the Company. Fairmount Funds Management LLC (&#8220;Fairmount&#8221;) beneficially owns more than <ix:nonFraction name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" contextRef="PAsOn06_22_2023_FairmountFundsManagementLlcMembersrtOwnershipAxis_MinimumMembersrtRangeAxis_OwnershipInterestMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">5</ix:nonFraction>% of our capital stock, has <ix:nonFraction name="agle:RelatedPartyTransactionNumberOfBoardSeats" contextRef="PAsOn06_22_2023" unitRef="Unit_BOARDSEAT" decimals="0" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction> seats on the Company&#8217;s board of directors and beneficially owns more than <ix:nonFraction name="agle:MinorityInterestOwnershipPercentageByNoncontrollingOwnersHeldInThirdParty" contextRef="PAsOn06_22_2023_FairmountFundsManagementLlcMembersrtOwnershipAxis_MinimumMembersrtRangeAxis_OwnershipInterestMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">5</ix:nonFraction>% of Paragon, which is a joint venture between Fairmount and Fair Journey Biologics. Fairmount has appointed Paragon&#8217;s board of directors and has the contractual right to approve the appointment of any executive officers. Parapyre is an entity formed by Paragon as a vehicle to hold equity in Spyre in order to share profits with certain employees of Paragon. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:SubsequentEventsTextBlock" contextRef="P06_22_2023To06_22_2023" escape="true"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">5. Subsequent Events </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#8217;s management has evaluated subsequent events up to October&#160;6, 2023, the date the Statement of Assets Acquired and Liabilities Assumed from Spyre, Inc. was available to be issued. There have been no subsequent events that require recognition or disclosure in this financial statement except for the following described below. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&#160;7, 2023, the Company issued <ix:nonFraction name="agle:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares" contextRef="P07_07_2023To07_07_2023_CommonStockMemberusgaapEquityInterestIssuedOrIssuableByTypeAxis_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">517,809</ix:nonFraction> shares of common stock and <ix:nonFraction name="agle:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares" contextRef="P07_07_2023To07_07_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">364,887</ix:nonFraction> shares of Series&#160;A Preferred Stock as part of its consideration transferred in connection with the Asset Acquisition. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August&#160;8, 2023, the Company filed a preliminary proxy statement with the SEC to solicit approval of the conversion of the Series A Preferred Stock into shares of Common Stock in connection with the Asset acquisition, among other matters, at a special meeting of stockholders. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&#160;8, 2023, the Company&#8217;s Board of Directors approved a reverse stock split of the Company&#8217;s common stock, par value $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn09_08_2023_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction> per share, at a ratio of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="us-gaap:StockholdersEquityReverseStockSplit" contextRef="P09_08_2023To09_08_2023_SubsequentEventMemberusgaapSubsequentEventTypeAxis">1-for-25</ix:nonNumeric></div></div> and a reduction in the total number of authorized shares of Common Stock from <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits" contextRef="P09_08_2023To09_08_2023_MaximumMembersrtRangeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">500,000,000</ix:nonFraction> shares to <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits" contextRef="P09_08_2023To09_08_2023_MinimumMembersrtRangeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">20,000,000</ix:nonFraction> shares. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&#160;29, 2023, the Company amended the Paragon Agreement to amend and restate certain terms of the option grant pertaining to the Parapyre Option Obligation, including but not limited to (i)&#160;defining that the annual equity grant of options is based on the outstanding shares of Aeglea&#8217;s common stock, (ii)&#160;establishing the grant date as the last business day of each applicable calendar year, and (iii)&#160;defining the term of the options granted is <ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" contextRef="P09_29_2023To09_29_2023_ParapyreOptionObligationMemberusgaapPlanNameAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" format="ixt-sec:durwordsen">ten years</ix:nonNumeric>. The liability related to the Parapyre Option Obligation will be recorded pursuant to the amended Paragon Agreement on a go forward basis. The Company determined that these amendments would not have materially impacted the liability as of June&#160;22, 2023. </div></ix:nonNumeric><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-40 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Aeglea BioTherapeutics, Inc. </div><div id="fin518298_32" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Condensed Consolidated Balance Sheets </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">(Unaudited, in thousands, except share and per share amounts) </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:79%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">September&#160;30,<br/> 2023</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">December&#160;31,<br/> 2022</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt;background-color:#cceeff">
<td style="vertical-align:top;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;">ASSETS</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">CURRENT ASSETS</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash and cash equivalents</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">90,592</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">34,863</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="PAsOn09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">113,007</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">20,848</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Development receivables</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:NontradeReceivablesCurrent" contextRef="PAsOn09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">163</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:NontradeReceivablesCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">375</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Prepaid expenses and other current assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="PAsOn09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,187</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,172</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total current assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">205,949</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">62,258</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Restricted cash</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RestrictedCashNoncurrent" contextRef="PAsOn09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,307</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RestrictedCashNoncurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,553</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Property and equipment, net</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,220</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,430</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="PAsOn09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">9</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">683</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">TOTAL ASSETS</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">207,265</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">71,144</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt;background-color:#cceeff">
<td style="vertical-align:top;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">CURRENT LIABILITIES</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accounts payable</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableTradeCurrent" contextRef="PAsOn09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,678</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableTradeCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">677</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">CVR liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="PAsOn09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,510</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">625</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred revenue</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredRevenueCurrent" contextRef="PAsOn09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredRevenueCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">517</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued and other current liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" contextRef="PAsOn09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">15,861</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">12,837</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Related party accounts payable</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableOtherCurrent" contextRef="PAsOn09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">19,823</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableOtherCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total current liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">44,872</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">14,656</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div> CVR liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" contextRef="PAsOn09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">20,690</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div> operating lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,004</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred revenue, net of current portion</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="PAsOn09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,179</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">TOTAL LIABILITIES</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">65,562</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">20,839</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commitments and Contingencies (Note&#160;11)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="PAsOn09_30_2023" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Series A <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-voting</div> convertible preferred stock, $<ix:nonFraction name="us-gaap:TemporaryEquityParOrStatedValuePerShare" contextRef="PAsOn12_31_2022_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:TemporaryEquityParOrStatedValuePerShare" contextRef="PAsOn09_30_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction name="us-gaap:TemporaryEquitySharesAuthorized" contextRef="PAsOn09_30_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">1,086,341</ix:nonFraction> and <ix:nonFraction name="us-gaap:TemporaryEquitySharesAuthorized" contextRef="PAsOn12_31_2022_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction> shares authorized as of September&#160;30, 2023 and December&#160;31, 2022, respectively; <ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="PAsOn09_30_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:TemporaryEquitySharesIssued" contextRef="PAsOn09_30_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">1,086,339</ix:nonFraction></ix:nonFraction> and <ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="PAsOn12_31_2022_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:TemporaryEquitySharesIssued" contextRef="PAsOn12_31_2022_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of September&#160;30, 2023 and December&#160;31, 2022, respectively</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="PAsOn09_30_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">387,105</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="PAsOn12_31_2022_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">STOCKHOLDERS&#8217; (DEFICIT) EQUITY</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Preferred stock, $<ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2022" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn09_30_2023" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn09_30_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">8,913,659</ix:nonFraction> shares and <ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">10,000,000</ix:nonFraction> authorized as of September&#160;30, 2023 and December&#160;31, 2022; <ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn09_30_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn09_30_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding as of September&#160;30, 2023 and December&#160;31, 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="PAsOn09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Common stock, $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2022" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn09_30_2023" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn09_30_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">20,000,000</ix:nonFraction></ix:nonFraction> shares authorized as of September&#160;30, 2023 and December&#160;31, 2022; <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn09_30_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn09_30_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">4,048,687</ix:nonFraction></ix:nonFraction> shares and <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">2,614,014</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of September&#160;30, 2023 and December&#160;31, 2022, respectively</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="PAsOn09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">455,957</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">475,971</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accumulated other comprehensive income (loss)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">132</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">48</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accumulated deficit</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">701,234</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">425,624</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">TOTAL STOCKHOLDERS&#8217; (DEFICIT) EQUITY</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">245,402</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">50,305</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">TOTAL LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#8217; (DEFICIT) EQUITY</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">207,265</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">71,144</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">The accompanying notes are an integral part of these condensed consolidated financial statements. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-41 </div></div></div></div><div></div></div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Aeglea BioTherapeutics, Inc. </div><div id="fin518298_33" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Condensed Consolidated Statements of Operations </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">(Unaudited, in thousands, except share and per share amounts) </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:59%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Three Months Ended<br/> September&#160;30,</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Nine Months Ended<br/> September&#160;30,</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">2023</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">2022</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">2023</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">2022</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Revenue:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><span style="-sec-ix-hidden:hidden95764124"><span style="-sec-ix-hidden:hidden95764125"><span style="-sec-ix-hidden:hidden95764126"><span style="-sec-ix-hidden:hidden95764127">Development fee and roya</span>l</span>t</span>y</span></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P07_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P07_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">174</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">886</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,161</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total revenue</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P07_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P07_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">174</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">886</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,161</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating expenses (income):</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development <div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">(1)</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="P07_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">24,660</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="P07_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">11,977</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">55,822</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">44,328</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">General and administrative</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P07_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,584</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P07_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,952</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">25,874</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">23,452</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Acquired <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="agle:AcquiredInProcessResearchAndDevelopment" contextRef="P07_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">298</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="agle:AcquiredInProcessResearchAndDevelopment" contextRef="P07_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="agle:AcquiredInProcessResearchAndDevelopment" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">130,188</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="agle:AcquiredInProcessResearchAndDevelopment" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Gain on sale of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development asset</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" contextRef="P07_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">14,609</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" contextRef="P07_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">14,609</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total operating expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P07_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">18,337</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P07_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">18,929</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">197,275</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">67,780</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Loss from operations</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P07_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">18,337</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P07_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">18,755</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">196,389</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">65,619</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other (expense) income:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Interest income</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentIncomeNet" contextRef="P07_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,251</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentIncomeNet" contextRef="P07_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">288</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentIncomeNet" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,021</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentIncomeNet" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">427</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value of forward contract liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="P07_01_2023To09_30_2023_ForwardContractsMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">25,360</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="P07_01_2022To09_30_2022_ForwardContractsMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="P01_01_2023To09_30_2023_ForwardContractsMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">83,530</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="P01_01_2022To09_30_2022_ForwardContractsMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other income, net</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="P07_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,342</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="P07_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">24</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,262</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">25</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total other (expense) income</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="P07_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">21,767</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="P07_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">312</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">79,247</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">452</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Loss before income tax expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P07_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">40,104</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P07_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">18,443</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">275,636</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">65,167</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Income tax (expense) benefit</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P07_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P07_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">209</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">26</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">174</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P07_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">40,107</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P07_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">18,234</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">275,610</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">64,993</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss per share, basic and diluted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P07_01_2023To09_30_2023" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P07_01_2023To09_30_2023" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">9.34</ix:nonFraction></ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P07_01_2022To09_30_2022" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P07_01_2022To09_30_2022" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">4.84</ix:nonFraction></ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">69.57</ix:nonFraction></ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">20.17</ix:nonFraction></ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted-average common shares outstanding, basic and diluted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P07_01_2023To09_30_2023" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P07_01_2023To09_30_2023" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">4,293,812</ix:nonFraction></ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P07_01_2022To09_30_2022" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P07_01_2022To09_30_2022" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">3,767,918</ix:nonFraction></ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">3,961,546</ix:nonFraction></ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">3,222,987</ix:nonFraction></ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Includes $<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="P07_01_2023To09_30_2023_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">19.4</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="P01_01_2023To09_30_2023_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">20.8</ix:nonFraction>&#160;million in related party expenses for the three and nine months ended September&#160;30, 2023, respectively and <ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="P01_01_2022To09_30_2022_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="P07_01_2022To09_30_2022_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> related party expenses for the three and nine months ended September&#160;30, 2022. </div></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">The accompanying notes are an integral part of these condensed consolidated financial statements. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-42 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Aeglea BioTherapeutics, Inc. </div><div id="fin518298_34" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Condensed Consolidated Statements of Comprehensive Loss </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">(Unaudited, in thousands) </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:63%"></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Three Months Ended<br/> September&#160;30,</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Nine Months Ended<br/> September&#160;30,</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">2023</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">2022</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">2023</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">2022</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P07_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">40,107</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P07_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">18,234</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">275,610</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">64,993</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other comprehensive (loss) income:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Foreign currency translation adjustment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" contextRef="P07_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">29</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" contextRef="P07_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">38</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">87</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unrealized (loss) gain on marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="P07_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">114</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="P07_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">74</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">83</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">77</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total comprehensive loss</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="P07_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">40,250</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="P07_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">18,198</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">275,694</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">65,157</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">The accompanying notes are an integral part of these condensed consolidated financial statements. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-43 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Aeglea BioTherapeutics, Inc. </div><div id="fin518298_35" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Condensed Consolidated Statements of Changes in </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Convertible Preferred Stock and Stockholders&#8217; (Deficit) Equity </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">(Unaudited, in thousands) </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:45%"></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="30" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Nine Months Ended September&#160;30, 2023</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Series A<br/> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Voting</div><br/> Convertible<br/> Preferred Stock</td>
<td style="border-right: 0.75pt solid rgb(0, 0, 0); vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Common Stock</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Additional<br/> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Paid-In</div><br/> Capital</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Accumulated<br/> Other<br/> Comprehensive<br/> Income (Loss)</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Accumulated<br/> Deficit</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Total<br/> Stockholders&#8217;<br/> Equity<br/> (Deficit)</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Shares</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Amount</td>
<td style="border-right: 0.75pt solid rgb(0, 0, 0); vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Shares</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Amount</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balances &#8211; December 31, 2022</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="PAsOn12_31_2022_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="PAsOn12_31_2022_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,614</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">475,971</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">48</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">425,624</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">50,305</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of common stock in connection with employee stock purchase plan</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" contextRef="P01_01_2023To03_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">2</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="P01_01_2023To03_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">18</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">18</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock-based compensation expense</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="P01_01_2023To03_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,709</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,709</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Foreign currency translation adjustment</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" contextRef="P01_01_2023To03_31_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">10</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">10</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unrealized gain on marketable securities</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="P01_01_2023To03_31_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">32</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">32</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2023To03_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">18,422</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">18,422</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style=" BORDER-LEFT:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balances &#8211; March 31, 2023</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="PAsOn03_31_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="PAsOn03_31_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn03_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,616</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">477,698</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">6</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">444,046</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">33,652</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style=" BORDER-LEFT:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of Series A <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-voting</div> convertible preferred stock in connection with private placement, net of financing costs</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="agle:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" contextRef="P04_01_2023To06_30_2023" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">721</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" contextRef="P04_01_2023To06_30_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">197,323</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of common stock forward in connection with the asset acquisition of Spyre</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets" contextRef="P04_01_2023To06_30_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,768</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets" contextRef="P04_01_2023To06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,768</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of common stock in connection with exercise of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="P04_01_2023To06_30_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">624</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">CVR distribution to common stockholders</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="agle:ContingentValueRightDistributionToCommonStockholders" contextRef="P04_01_2023To06_30_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">29,500</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="agle:ContingentValueRightDistributionToCommonStockholders" contextRef="P04_01_2023To06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">29,500</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock-based compensation expense</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="P04_01_2023To06_30_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,775</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="P04_01_2023To06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,775</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Foreign currency translation adjustment</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" contextRef="P04_01_2023To06_30_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">18</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" contextRef="P04_01_2023To06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">18</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unrealized loss on marketable securities</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="P04_01_2023To06_30_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="P04_01_2023To06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P04_01_2023To06_30_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">217,081</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P04_01_2023To06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">217,081</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style=" BORDER-LEFT:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balances &#8211; June 30, 2023</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="PAsOn06_30_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">721</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="PAsOn06_30_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">197,323</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn06_30_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,240</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn06_30_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn06_30_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">453,741</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn06_30_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">11</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn06_30_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">661,127</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">207,369</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style=" BORDER-LEFT:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of Series A <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-voting</div> convertible preferred stock in connection with the asset acquisition of Spyre and settlement of related forward contract</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="agle:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" contextRef="P07_01_2023To09_30_2023" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">365</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" contextRef="P07_01_2023To09_30_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">189,741</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Settlement of financing costs in connection with private placement of Series A <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-voting</div> convertible preferred stock</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="agle:TemporaryEquityFinancingCosts" contextRef="P07_01_2023To09_30_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">41</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of common stock in connection with the asset acquisition of Spyre and settlement of related forward contract</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" contextRef="P07_01_2023To09_30_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="3" format="ixt:num-dot-decimal">518</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="P07_01_2023To09_30_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="P07_01_2023To09_30_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of common stock in connection with exercise of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="P07_01_2023To09_30_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">281</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of common stock in connection with exercise of stock options and employee stock purchase plan</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style=" BORDER-LEFT:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="agle:StockIssuedDuringPeriodSharesOptionsExercisedAndEmployeeStockOwnershipPlan" contextRef="P07_01_2023To09_30_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">10</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="agle:StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan" contextRef="P07_01_2023To09_30_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">105</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="agle:StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan" contextRef="P07_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">105</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock-based compensation expense</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="P07_01_2023To09_30_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,112</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="P07_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,112</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Foreign currency translation adjustment</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" contextRef="P07_01_2023To09_30_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">29</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" contextRef="P07_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">29</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unrealized loss on marketable securities</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="P07_01_2023To09_30_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">114</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="P07_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">114</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P07_01_2023To09_30_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">40,107</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P07_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">40,107</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style=" BORDER-LEFT:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balances &#8211; September 30, 2023</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="PAsOn09_30_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,086</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="PAsOn09_30_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">387,105</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn09_30_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">4,049</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn09_30_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn09_30_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">455,957</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn09_30_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">132</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn09_30_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">701,234</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">245,402</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style=" BORDER-LEFT:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-44 </div></div></div></div><div></div></div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:49%"></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="30" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Nine Months Ended September&#160;30, 2022</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Series A<br/> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Voting</div><br/> Convertible<br/> Preferred Stock</td>
<td style="border-right: 0.75pt solid rgb(0, 0, 0); vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Common Stock</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Additional<br/> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Paid-In</div><br/> Capital</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Accumulated<br/> Other<br/> Comprehensive<br/> Income (Loss)</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Accumulated<br/> Deficit</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Total<br/> Stockholders&#8217;<br/> Equity</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Shares</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Amount</td>
<td style="border-right: 0.75pt solid rgb(0, 0, 0); vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Shares</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Amount</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balances&#8212; December 31, 2021</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="PAsOn12_31_2021_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="PAsOn12_31_2021_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,974</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">425,765</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">20</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">341,809</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">83,941</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of common stock in connection with employee stock purchase plan</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" contextRef="P01_01_2022To03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">3</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="P01_01_2022To03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">184</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">184</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock-based compensation expense</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="P01_01_2022To03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,101</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,101</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Foreign currency translation adjustment</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" contextRef="P01_01_2022To03_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">13</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">13</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unrealized loss on marketable securities</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="P01_01_2022To03_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">120</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">120</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2022To03_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">24,436</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">24,436</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balances&#8212; March 31, 2022</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="PAsOn03_31_2022_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="PAsOn03_31_2022_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,977</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">428,050</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">153</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">366,245</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">61,657</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of common stock and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants in connection with registered direct offering, net of offering costs</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="agle:StockIssuedDuringPeriodSharesCommonStockAndPreFundedWarrantsRegisteredDirectOffering" contextRef="P04_01_2022To06_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">430</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="agle:StockIssuedDuringPeriodValueCommonStockAndPreFundedWarrantsRegisteredDirectOffering" contextRef="P04_01_2022To06_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="agle:StockIssuedDuringPeriodValueCommonStockAndPreFundedWarrantsRegisteredDirectOffering" contextRef="P04_01_2022To06_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">42,872</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="agle:StockIssuedDuringPeriodValueCommonStockAndPreFundedWarrantsRegisteredDirectOffering" contextRef="P04_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">42,873</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of common stock in connection with exercise of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="P04_01_2022To06_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">40</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock-based compensation expense</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="P04_01_2022To06_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,017</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="P04_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,017</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Foreign currency translation adjustment</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" contextRef="P04_01_2022To06_30_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">36</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" contextRef="P04_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">36</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unrealized loss on marketable securities</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="P04_01_2022To06_30_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">31</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="P04_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">31</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P04_01_2022To06_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">22,323</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P04_01_2022To06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">22,323</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balances&#8212; June 30, 2022</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="PAsOn06_30_2022_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="PAsOn06_30_2022_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn06_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,447</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn06_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn06_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">472,939</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn06_30_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">220</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn06_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">388,568</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">84,157</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of common stock and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants in connection with registered direct offering, net of offering costs</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="agle:StockIssuedDuringPeriodSharesCommonStockAndPreFundedWarrantsRegisteredDirectOffering" contextRef="P07_01_2022To09_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">10</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of common stock in connection with exercise of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="P07_01_2022To09_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">8</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="P07_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">8</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of common stock in connection with employee stock purchase plan</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" contextRef="P07_01_2022To09_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="3" format="ixt:num-dot-decimal">3</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="P07_01_2022To09_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">38</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="P07_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">38</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock-based compensation expense</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="P07_01_2022To09_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,566</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="P07_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,566</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Foreign currency translation adjustment</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" contextRef="P07_01_2022To09_30_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">38</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" contextRef="P07_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">38</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unrealized loss on marketable securities</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="P07_01_2022To09_30_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">74</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="P07_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">74</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P07_01_2022To09_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">18,234</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P07_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">18,234</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balances&#8212; September 30, 2022</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="PAsOn09_30_2022_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="PAsOn09_30_2022_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn09_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,460</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn09_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn09_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">474,535</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn09_30_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">184</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn09_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">406,802</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">67,555</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">The accompanying notes are an integral part of these condensed consolidated financial statements. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-45 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Aeglea BioTherapeutics, Inc. </div><div id="fin518298_36" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Condensed Consolidated Statements of Cash Flows </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">(Unaudited, in thousands) </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:83%"></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Nine Months Ended<br/> September&#160;30,</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">2023</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">2022</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">CASH FLOWS FROM OPERATING ACTIVITIES</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">275,610</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">64,993</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Adjustments to reconcile net loss to net cash used in operating activities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Depreciation and amortization</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">744</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,182</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock-based compensation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,405</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,684</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Acquired <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="agle:AcquiredInProcessResearchAndDevelopment" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">130,188</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="agle:AcquiredInProcessResearchAndDevelopment" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value of CVR liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="P01_01_2023To09_30_2023_ContingentValueRightLiabilityMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,300</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="P01_01_2022To09_30_2022_ContingentValueRightLiabilityMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value of forward contract liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="P01_01_2023To09_30_2023_ForwardContractsMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">83,530</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="P01_01_2022To09_30_2022_ForwardContractsMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Gain on sale of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development asset</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">14,609</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Lease ROU asset and leasehold improvement impairment loss</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetImpairmentCharges" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,580</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetImpairmentCharges" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Loss on disposal of long-lived assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">915</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Amortization of operating lease assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">220</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">292</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net accretion of discount on marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">612</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">175</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherNoncashIncomeExpense" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">18</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherNoncashIncomeExpense" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">351</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Changes in operating assets and liabilities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Prepaid expenses and other assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">3,310</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,863</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accounts payable</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,001</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">859</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred revenue</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">575</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">897</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Development receivables</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">212</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">146</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">2,326</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">297</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued and other liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">4,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1,293</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Related party payable</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherAccountsPayable" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">2,115</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherAccountsPayable" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net cash used in operating activities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">68,874</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">62,004</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">CASH FLOWS FROM INVESTING ACTIVITIES</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash assumed from asset acquisition of Spyre</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashAcquiredFromAcquisition" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,035</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashAcquiredFromAcquisition" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Proceeds from sale of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research&#160;&amp; development asset</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromSaleOfIntangibleAssets" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">15,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromSaleOfIntangibleAssets" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Purchases of property and equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">38</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Proceeds from sale of property and equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">475</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Purchases of marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">112,631</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">35,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Proceeds from maturities and sales of marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">21,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">78,046</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net cash (used in) and provided by investing activities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">73,121</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">43,008</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">CASH FLOWS FROM FINANCING ACTIVITIES</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Proceeds from issuance of Series A <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-voting</div> convertible preferred stock in connection with private placement, net of placement and other offering costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">197,364</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Proceeds from issuance of common stock and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants in registered direct offering, net of offering costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="agle:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfOfferingCosts" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="agle:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfOfferingCosts" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">42,874</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Proceeds from employee stock plan purchases and stock option exercises</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">123</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">222</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Principal payments on finance lease obligation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:FinanceLeasePrincipalPayments" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">16</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:FinanceLeasePrincipalPayments" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">410</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net cash provided by financing activities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">197,471</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">42,686</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Effect of exchange rate on cash, cash equivalents, and restricted cash</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">152</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">NET INCREASE IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">55,483</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">23,538</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">CASH, CASH EQUIVALENTS, AND RESTRICTED CASH</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Beginning of period</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">36,416</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">16,980</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">End of period</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">91,899</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">40,518</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Supplemental Disclosure of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Cash</div> Investing and Financing Information:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Settlement of forward contract liability and issuance of Series A <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-voting</div> convertible preferred stock in connection with the asset acquisition of Spyre</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssued1" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">189,741</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssued1" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">The accompanying notes are an integral part of these condensed consolidated financial statements. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-46 </div></div></div></div><div></div></div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Aeglea BioTherapeutics, Inc. </div><div id="fin518298_37" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Notes to Unaudited Condensed Consolidated Financial Statements </div><ix:nonNumeric name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" contextRef="P01_01_2023To09_30_2023" escape="true" continuedAt="TextSelection_95763949"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1. The Company and Basis of Presentation </div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Aeglea BioTherapeutics, Inc. (&#8220;Aeglea&#8221; or the &#8220;Company&#8221;) is a preclinical stage biotechnology company focused on developing next generation therapeutics for patients living with inflammatory bowel disease. The Company was formed as a Limited Liability Company (&#8220;LLC&#8221;) in Delaware on December&#160;16, 2013 under the name Aeglea BioTherapeutics Holdings, LLC and was converted from a Delaware LLC to a Delaware corporation on March&#160;10, 2015. The Company operates in <ix:nonFraction name="us-gaap:NumberOfOperatingSegments" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_SEGMENT" decimals="0" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction> segment and has its principal offices in Waltham, Massachusetts. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&#160;12, 2023, based on the review of the inconclusive interim results from the Company&#8217;s Phase 1/2 clinical trial of pegtarviliase for the treatment of classical homocystinuria and other business considerations, the Company announced that it had initiated a process to explore strategic alternatives to maximize stockholder value and engaged an independent exclusive financial advisor to support this process. In April 2023, the Company implemented a restructuring plan resulting in an approximate <ix:nonFraction name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" contextRef="P04_01_2023To04_30_2023" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">83</ix:nonFraction>% reduction of the Company&#8217;s existing headcount. On September&#160;8, 2023, Aeglea effected a reverse stock split of its common stock at a ratio of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">1-for-25</div></div> (the &#8220;Reverse Split&#8221;). All share numbers related to the Company&#8217;s common stock disclosed in these financial statements have been adjusted on a post-Reverse Split basis. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;22, 2023, the Company acquired, in accordance with the terms of the Agreement and Plan of Merger (the &#8220;Acquisition Agreement&#8221;), the assets from Spyre Therapeutics, Inc. (&#8220;Spyre&#8221;), as disclosed in Notes 7 and 8, a privately held biotechnology company advancing a pipeline of antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease through a research and development option agreement (&#8220;Paragon Agreement&#8221;) with Paragon Therapeutics (&#8220;Paragon&#8221;). The transaction was structured as a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">stock-for-stock</div></div> transaction pursuant to which all of Spyre&#8217;s outstanding equity interests were exchanged based on a fixed exchange ratio of <ix:nonFraction name="agle:FixedExchangeRatio" contextRef="PAsOn06_22_2023_AssetAcquisitionMemberusgaapAssetAcquisitionAxis" unitRef="Unit_pure" decimals="9" scale="-2" format="ixt:num-dot-decimal">0.5494488</ix:nonFraction> to 1 for consideration from Aeglea of <ix:nonFraction name="agle:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares" contextRef="P06_22_2023To06_22_2023_AssetAcquisitionMemberusgaapAssetAcquisitionAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">517,809</ix:nonFraction> shares of common stock and <ix:nonFraction name="agle:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares" contextRef="P06_22_2023To06_22_2023_AssetAcquisitionMemberusgaapAssetAcquisitionAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">364,887</ix:nonFraction> shares of Series A <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-voting</div> convertible preferred stock, par value of $<ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn06_22_2023_AssetAcquisitionMemberusgaapAssetAcquisitionAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction> per share (&#8220;Series A Preferred Stock&#8221;) (convertible on a <ix:nonFraction name="us-gaap:PreferredStockConvertibleConversionRatio" contextRef="PAsOn06_22_2023_AssetAcquisitionMemberusgaapAssetAcquisitionAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_pure" decimals="0" scale="0" format="ixt:num-dot-decimal">40</ix:nonFraction> to 1 basis) in addition to the assumption of outstanding and unexercised stock options to purchase <ix:nonFraction name="agle:OutstandingAndUnexercisedStockOptions" contextRef="P06_22_2023To06_22_2023_AssetAcquisitionMemberusgaapAssetAcquisitionAxis_Spyre2023EquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">2,734</ix:nonFraction> shares of common stock from the Amended and Restated Spyre 2023 Equity Incentive Plan (the &#8220;Asset Acquisition&#8221;). The Aeglea common stock and Aeglea Series A Preferred Stock related to the Asset Acquisition were issued to the Spyre stockholders on July&#160;7, 2023. For additional information, see Notes 7 and 8. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Asset Acquisition, on June&#160;26, 2023, the Company completed a private placement of shares of Series A Preferred Stock (the &#8220;PIPE&#8221;) to a group of investors (the &#8220;Investors&#8221;). The Company sold an aggregate of <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn06_26_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">721,452</ix:nonFraction> shares of Series A Preferred Stock for an aggregate purchase price of approximately $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="P06_26_2023To06_26_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">210.0</ix:nonFraction>&#160;million before deducting approximately $<ix:nonFraction name="agle:PlacementAgentAndOtherOfferingExpenses" contextRef="P06_26_2023To06_26_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">12.7</ix:nonFraction>&#160;million in placement agent and other offering expenses (together with the Asset Acquisition, the &#8220;Transactions&#8221;). For additional information, see Note 9. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Asset Acquisition and pursuant to a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-transferable</div> contingent value right (&#8220;CVR&#8221;) agreement (the &#8220;CVR Agreement&#8221;) a CVR was distributed to each Aeglea stockholder of record as of the close of business on July&#160;3, 2023 (the &#8220;Legacy Stockholders&#8221;), but was not distributed to the holders of shares of common stock or Series A Preferred Stock issued to the former stockholders of Spyre or Investors in the Transactions. Holders of the CVRs will be entitled to receive cash payments from proceeds received by Aeglea for a <ix:nonNumeric name="agle:AssetAcquisitionStockholderPaymentPeriod" contextRef="P06_22_2023To06_22_2023_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis" format="ixt-sec:durwordsen">three-year</ix:nonNumeric> period, if any, related to the disposition or monetization of its legacy assets for a period of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="agle:AssetAcquisitionCashPaymentThresholdPeriod" contextRef="P06_22_2023To06_22_2023_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis" format="ixt-sec:durwordsen">one-year</ix:nonNumeric></div> following the closing of the Asset Acquisition. For additional information see Note 3. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Liquidity </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of September&#160;30, 2023, the Company had an accumulated deficit of $<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn09_30_2023" unitRef="Unit_USD" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal">701.2</ix:nonFraction>&#160;million, and cash, cash equivalents, and marketable securities of $<ix:nonFraction name="us-gaap:CashCashEquivalentsAndShortTermInvestments" contextRef="PAsOn09_30_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">203.6</ix:nonFraction>&#160;million. The Company has not generated any product revenues </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-47</ix:exclude> </div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_95763949" continuedAt="TextSelectionAppend_95763949_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_95763949_1" continuedAt="TextSelectionAppend_95763949_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_95763949_2" continuedAt="TextSelectionAppend_95763949_3"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_95763949_3" continuedAt="TextSelectionAppend_95763949_4"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">and has not achieved profitable operations. There can be no assurance that profitable operations will ever be achieved, and, if achieved, whether it can be sustained on a continuing basis. In addition, development activities, clinical and nonclinical testing, and commercialization of the Company&#8217;s product candidates will require significant additional financing before a commercial drug can be produced and marketed. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is subject to a number of risks similar to other life science companies, including, but not limited to, risks related to the successful discovery, development, and commercialization of product candidates, raising additional capital, development of competing drugs and therapies, protection of proprietary technology and market acceptance of the Company&#8217;s product candidates. As a result of these and other factors and uncertainties, there can be no assurance of the Company&#8217;s future success. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2023, the Board of Directors (the &#8220;Board&#8221;) approved a restructuring of the Company&#8217;s workforce pursuant to which the Company&#8217;s workforce was reduced by approximately <ix:nonFraction name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" contextRef="P04_01_2023To04_30_2023" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">83</ix:nonFraction>% and the Company retained approximately <ix:nonFraction name="agle:NumberOfEmployeesRetained" contextRef="P04_01_2023To04_30_2023" unitRef="Unit_employee" decimals="0" scale="0" format="ixt:num-dot-decimal">10</ix:nonFraction> employees. Following a review of the interim results from its ongoing Phase 1/2 clinical trial of pegtarviliase for the treatment of classical homocystinuria and other business considerations, the Company explored strategic alternatives with the goal of maximizing stockholder value, including possible business combinations and/or a divestiture of the Company&#8217;s clinical programs. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;22, 2023, the Company acquired, in accordance with the terms of the Acquisition Agreement, the net assets of Spyre, as disclosed in Notes 7 and 8. Additionally, the Company completed the PIPE. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with Accounting Standards Codification (&#8220;ASC&#8221;) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">205-40,</div> Going Concern, the Company has evaluated and determined that there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date the accompanying condensed consolidated financial statements included in this Quarterly Report are issued. The Company&#8217;s Series A Preferred Stock agreement requires it to seek stockholder approval for the conversion of the Series A Preferred Stock to common stock. The Company has agreed to hold a stockholders&#8217; meeting to submit this matter to its stockholders for their consideration. In connection with this, the Company filed with the Securities and Exchange Commission (&#8220;SEC&#8221;) a definitive proxy statement and other relevant materials. The special meeting of stockholders is scheduled for November&#160;21, 2023. If the Company&#8217;s stockholders do not timely approve the conversion of its Series A Preferred Stock into common stock, then the holders of its Series A Preferred Stock are entitled to require the Company to settle their shares of Series A Preferred Stock for cash at a price per share equal to the fair value of the Series A Preferred Stock, as described in the Certificate of Designation relating to the Series A Preferred Stock (see Note 9). The cash redemption is not in the Company&#8217;s control and raises substantial doubt about the Company&#8217;s ability to continue as a going concern. The accompanying condensed consolidated financial statements assume the Company will continue as a going concern through the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Unaudited Interim Financial Information </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The interim condensed consolidated financial statements included in this Quarterly Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q</div> are unaudited. The unaudited interim financial statements have been prepared on the same basis as the annual financial statements and reflect, in the opinion of management, all adjustments of a normal and recurring nature that are necessary for a fair statement of the Company&#8217;s financial position as of September&#160;30, 2023, and its results of operations for the three and nine months ended September&#160;30, 2023 and 2022, changes in convertible preferred stock and stockholders&#8217; (deficit) equity for the three and nine months ended September&#160;30, 2023 and 2022, and cash flows for the nine months ended September&#160;30, 2023 and 2022. The results of operations for the three and nine months ended September&#160;30, 2023, are not necessarily indicative of the results to be expected for the year ending December&#160;31, 2023 or for any other future annual or interim period. The December&#160;31, 2022 balance sheet was derived from audited financial statements, but does not include all disclosures required by accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;). These financial statements should </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-48</ix:exclude> </div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_95763949_4" continuedAt="TextSelectionAppend_95763949_5"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_95763949_5" continuedAt="TextSelectionAppend_95763949_6"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_95763949_6" continuedAt="TextSelectionAppend_95763949_7"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_95763949_7"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">be read in conjunction with the audited financial statements included in the Company&#8217;s Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> for the year ended December&#160;31, 2022 (the &#8220;Annual Report&#8221;) as filed with <div style="display:inline;">the </div>SEC. </div></ix:continuation><ix:nonNumeric name="us-gaap:SignificantAccountingPoliciesTextBlock" contextRef="P01_01_2023To09_30_2023" escape="true" continuedAt="TextSelection_95763969"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2. Summary of Significant Accounting Policies </div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other than policies noted below, there have been no significant changes from the significant accounting policies and estimates disclosed in Note 2 of the &#8220;Notes to Consolidated Financial Statements&#8221; included in our Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> for the year ended December&#160;31, 2022. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These interim condensed consolidated financial statements have been prepared in accordance with U.S. GAAP and SEC instructions for interim financial information, and should be read in conjunction with the Company&#8217;s Annual Report. Significant accounting policies and other disclosures normally provided have been omitted since such items are disclosed in the Company&#8217;s Annual Report. The Company uses the same accounting policies in preparing quarterly and annual financial statements. </div><ix:nonNumeric name="agle:ConvertiblePreferredStockIssuedThroughPipePolicyTextBlock" contextRef="P01_01_2023To09_30_2023" escape="true"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Convertible Preferred Stock Issued through PIPE </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company records shares of convertible preferred stock at their respective fair values on the dates of issuance, net of issuance costs. The Company has applied the guidance in ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">480-10-S99-3A</div></div></div> as well as SEC Staff Announcement, Classification and Measurement of Redeemable Securities, and has therefore classified the Series A Preferred Stock outside of stockholders&#8217; (deficit) equity because, if conversion to common stock is not approved by the stockholders, the Series A Preferred Stock will be redeemable at the option of the holders for cash equal to the closing price of the common stock on the last trading day prior to the holder&#8217;s redemption request. The Company has determined that the conversion and redemption are outside of the Company&#8217;s control. Additionally, the Company has determined the conversion and redemption features do not require bifurcation as derivatives. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:BusinessCombinationsPolicy" contextRef="P01_01_2023To09_30_2023" escape="true"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Acquisitions </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company evaluates acquisitions of assets and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first applying a screen test to determine whether substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If so, the transaction is accounted for as an asset acquisition. If not, further determination is required as to whether or not the Company has acquired inputs and processes that have the ability to create outputs, which would meet the definition of a business. Significant judgment is required in the application of the test to determine whether an acquisition is a business combination or an acquisition of assets. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Acquisitions meeting the definition of business combinations are accounted for using the acquisition method of accounting, which requires that the purchase price be allocated to the net assets acquired at their respective fair values. In a business combination, any excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company measures and recognizes asset acquisitions that are not deemed to be business combinations based on the cost to acquire the assets, which includes <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-acquisition</div> direct costs recorded in accrued professional and consulting fees. Goodwill is not recognized in asset acquisitions. When a transaction accounted for as an asset acquisition includes an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development (&#8220;IPR&amp;D&#8221;) asset, the IPR&amp;D asset is only capitalized if it has an alternative future use other than in a particular research and development project. Otherwise, the cost allocated to acquire an IPR&amp;D asset with no alternative future use is charged to expense at the acquisition date. </div></ix:nonNumeric><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-49</ix:exclude> </div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_95763969" continuedAt="TextSelectionAppend_95763969_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_95763969_1" continuedAt="TextSelectionAppend_95763969_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_95763969_2" continuedAt="TextSelectionAppend_95763969_3"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_95763969_3" continuedAt="TextSelectionAppend_95763969_4"><ix:nonNumeric name="us-gaap:DerivativesPolicyTextBlock" contextRef="P01_01_2023To09_30_2023" escape="true"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Contingent Value Rights </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company evaluates its contracts to determine if those contracts qualify as derivatives under ASC 815, Derivatives and Hedging (&#8220;ASC 815&#8221;). For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-valued</div> at each reporting date. Any changes in fair value are recorded as other income or expense for each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> based on whether or not <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">net-cash</div> settlement of the derivative instrument is probable within the next 12 months from the balance sheet date. The Company determined that certain contingent payments under the CVR Agreement qualified as derivatives under ASC 815, and as such, were recorded as a liability on the balance sheet. This value is then remeasured for future expected payout as well as the increase in fair value due to the time value of money. These gains or losses, if any, are recognized in the consolidated statements of operations and comprehensive loss within Other (expense) income, net. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company applies a scenario-based method and weighs them based on the possible achievement of certain milestones. The milestone payments are contingent on formal reimbursement decisions by national authorities in key European markets and pegzilarginase approval by the U.S. Food and Drug Administration (&#8220;FDA&#8221;), among other events. This fair value measurement is based on significant inputs not observable in the market and thus represents a Level&#160;3 measurement as defined in ASC 820, Fair Value Measurement. The key assumptions used include the discount rate, probability of regulatory success, and reimbursement rates from certain government agencies. The estimated value of the CVR consideration is based upon available information and certain assumptions which the Company&#8217;s management believes are reasonable under the circumstances. The ultimate payout under the CVRs may differ materially from the assumptions used in determining the fair value of the CVR consideration. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:UseOfEstimates" contextRef="P01_01_2023To09_30_2023" escape="true"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets, liabilities, and equity and the amount of revenues and expenses. Actual results could differ significantly from those estimates. The most significant estimates and assumptions that management considers in the preparation of the Company&#8217;s financial statements relate to the valuation of consideration transferred in acquiring IPR&amp;D; the discount rate, probabilities of success, and timing of estimated cash flows in the valuation of the CVR liability; inputs used in the Black-Scholes model for stock-based compensation expense; estimated future cash flows used in calculating the impairment of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> lease assets; and estimated cost to complete performance obligations related to revenue recognition. The consideration transferred in acquiring IPR&amp;D in connection with the acquisition of Spyre was comprised of shares of the Company&#8217;s common stock and shares of Series A Preferred Stock. To determine the fair value of the equity transferred, the Company considered the per share value of the PIPE, which was an over-subscribed financing event involving a group of accredited investors. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="P01_01_2023To09_30_2023" escape="true" continuedAt="TextSelection_95763974"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Recently Adopted Accounting Pronouncement </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company early adopted the Financial Accounting Standards Board&#8217;s Accounting Standards Update <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06,</div> Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity (&#8220;ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06&#8221;),</div> effective as of January&#160;1, 2023 using the modified retrospective method. Among other amendments, ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06</div> eliminates the cash conversion and beneficial conversion feature models in ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">470-20</div> that required an issuer of certain convertible debt and preferred stock to separately account for embedded conversion features as a component of equity, as well as changes the accounting for diluted <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">earnings-per-share</div></div> for convertible instruments and contracts that may be settled in cash or stock. Additionally, ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06</div> requires the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">if-converted</div> method, </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-50</ix:exclude> </div></ix:nonNumeric></ix:continuation></div></div><ix:continuation id="TextSelection_95763974" continuedAt="TextSelectionAppend_95763974_1"><ix:continuation id="TextSelectionAppend_95763969_4" continuedAt="TextSelectionAppend_95763969_5"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_95763969_5" continuedAt="TextSelectionAppend_95763969_6"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_95763969_6" continuedAt="TextSelectionAppend_95763969_7"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></ix:continuation></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_95763969_7"><ix:continuation id="TextSelectionAppend_95763974_1"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">which is more dilutive than the treasury stock method, be used for all convertible instruments. The Company applied ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06</div> to all Series A Preferred Stock during fiscal year 2023, and, accordingly, the Company did not apply the cash conversion or beneficial conversion feature models in its analysis of the Series A <div style="display:inline;"><div style="display:inline;">Preferred </div></div>Stock. </div></ix:continuation></ix:continuation><ix:nonNumeric name="us-gaap:FairValueDisclosuresTextBlock" contextRef="P01_01_2023To09_30_2023" escape="true" continuedAt="TextSelection_95763988"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3. Fair Value Measurements </div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company measures and reports certain financial instruments as assets and liabilities at fair value on a recurring basis. <ix:nonNumeric name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" contextRef="P01_01_2023To09_30_2023" escape="true" continuedAt="TextSelection_95763990">The following tables set forth the fair value of the Company&#8217;s financial assets and liabilities at fair value on a recurring basis based on the three-tier fair value hierarchy (in thousands): </ix:nonNumeric></div><ix:continuation id="TextSelection_95763990"><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:56%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">September&#160;30, 2023</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Level&#160;1</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Level&#160;2</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Level&#160;3</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Total</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Financial Assets:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Money market funds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn09_30_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">55,451</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn09_30_2023_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn09_30_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn09_30_2023_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">55,451</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial paper</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn09_30_2023_CommercialPaperMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn09_30_2023_CommercialPaperMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">107,093</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn09_30_2023_CommercialPaperMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn09_30_2023_CommercialPaperMemberusgaapFairValueByAssetClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">107,093</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate bonds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn09_30_2023_CorporateBondSecuritiesMemberusgaapInvestmentTypeAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn09_30_2023_CorporateBondSecuritiesMemberusgaapInvestmentTypeAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">22,828</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn09_30_2023_CorporateBondSecuritiesMemberusgaapInvestmentTypeAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn09_30_2023_CorporateBondSecuritiesMemberusgaapInvestmentTypeAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">22,828</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total financial assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn09_30_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">55,451</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn09_30_2023_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">129,921</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn09_30_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn09_30_2023_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">185,372</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Liabilities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Parapyre Option Obligation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn09_30_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_ParapyreOptionObligationMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn09_30_2023_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_ParapyreOptionObligationMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,952</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn09_30_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_ParapyreOptionObligationMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn09_30_2023_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_ParapyreOptionObligationMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,952</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">CVR liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn09_30_2023_ContingentValueRightLiabilityMemberusgaapFairValueByLiabilityClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn09_30_2023_ContingentValueRightLiabilityMemberusgaapFairValueByLiabilityClassAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn09_30_2023_ContingentValueRightLiabilityMemberusgaapFairValueByLiabilityClassAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">28,200</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn09_30_2023_ContingentValueRightLiabilityMemberusgaapFairValueByLiabilityClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">28,200</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn09_30_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn09_30_2023_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,952</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn09_30_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">28,200</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn09_30_2023_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">31,152</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td colspan="16" style="height:12pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">December&#160;31, 2022</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Level&#160;1</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Level&#160;2</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Level&#160;3</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Total</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Financial Assets:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Money market funds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">15,250</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">15,250</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial paper</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">23,641</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapFairValueByAssetClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">23,641</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">U.S. government securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapCashAndCashEquivalentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapCashAndCashEquivalentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,230</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapCashAndCashEquivalentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapCashAndCashEquivalentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,230</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate bonds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2022_CorporateBondSecuritiesMemberusgaapInvestmentTypeAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2022_CorporateBondSecuritiesMemberusgaapInvestmentTypeAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,732</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2022_CorporateBondSecuritiesMemberusgaapInvestmentTypeAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2022_CorporateBondSecuritiesMemberusgaapInvestmentTypeAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,732</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total financial assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">15,250</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">31,603</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">46,853</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:continuation><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company measures the fair value of money market funds on quoted prices in active markets for identical assets or liabilities. The Level&#160;2 assets include commercial paper, U.S. government securities and corporate bonds and are valued based on quoted prices for similar assets in active markets and inputs other than quoted prices that are derived from observable market data. The Company evaluates transfers between levels at the end of each reporting period. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Parapyre Option Obligation (as defined in Note 6) is considered a Level&#160;2 liability based on observable market data for substantially the full term of the liability. The Parapyre Option Obligation is measured each period using a Black-Scholes model to estimate the fair value of the option grant. Changes in the fair value of the Parapyre Option Obligation are recorded as stock-based compensation within Research and development expenses for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employees</div> who provided <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> testing services. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The CVR liability value is based on significant inputs not observable in the market such as estimated cash flows, estimated probabilities of success, and risk-adjusted discount rates, which represent a Level&#160;3 liability. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2022, the Company had <ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction> financial liabilities outstanding measured at fair value. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Forward Contract Liability </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Asset Acquisition, the Company entered into a contract for the issuance of <ix:nonFraction name="agle:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares" contextRef="P06_22_2023To06_22_2023_AssetAcquisitionMemberusgaapAssetAcquisitionAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">364,887</ix:nonFraction> shares of Series A Preferred Stock as part of the consideration transferred. This forward contract was classified as </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-51</ix:exclude> </div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_95763988" continuedAt="TextSelectionAppend_95763988_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_95763988_1" continuedAt="TextSelectionAppend_95763988_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_95763988_2" continuedAt="TextSelectionAppend_95763988_3"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_95763988_3" continuedAt="TextSelectionAppend_95763988_4"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">a liability because the underlying preferred shares were contingently redeemable. Further, the forward contract liability was considered a Level&#160;2 liability based on observable market data for substantially the full term of the liability and was initially measured at its estimated fair value on the transaction date based on the underlying price per share on an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">as-converted</div> basis of the Series A Preferred Stock issued in the PIPE. Subsequent remeasurement of the fair value of the forward contract liability through its settlement date was based on the market price of the Company&#8217;s common stock, which represents the redemption value of the Series A Preferred Stock. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fair value of the forward contract at the transaction date, June&#160;22, 2023, was $<ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn06_22_2023_ForwardContractsMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">106.2</ix:nonFraction>&#160;million. The liability was settled with the issuance of the Series A Preferred Stock on July&#160;7, 2023 for $<ix:nonFraction name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" contextRef="P07_07_2023To07_07_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">189.7</ix:nonFraction>&#160;million. For the three and nine months ended September&#160;30, 2023, $<ix:nonFraction name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="P07_01_2023To09_30_2023_ForwardContractsMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_USD" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal">25.4</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="P01_01_2023To09_30_2023_ForwardContractsMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_USD" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal">83.5</ix:nonFraction>&#160;million, respectively, was recorded as Other (expense) income in the consolidated statements of operations in connection with the change in fair value of the forward contract liability. </div><ix:nonNumeric name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" contextRef="P01_01_2023To09_30_2023" escape="true" continuedAt="TextSelection_95763993"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents changes in the forward contract liability for the periods presented (in millions): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:86%"></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Forward<br/> Contract<br/> Liability</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Beginning balance as of June&#160;22, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn06_22_2023_ForwardContractsMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">106.2</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="P06_23_2023To06_30_2023_ForwardContractsMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_USD" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal">58.1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Ending balance as of June&#160;30, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn06_30_2023_ForwardContractsMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">164.3</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="P07_01_2023To09_30_2023_ForwardContractsMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_USD" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal">25.4</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of Series A Preferred Stock on July&#160;7, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" contextRef="P07_01_2023To09_30_2023_ForwardContractsMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">189.7</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Ending balance as of September&#160;30, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn09_30_2023_ForwardContractsMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Parapyre Option Obligation </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;22, 2023, in connection with the Asset Acquisition, the Company assumed the Parapyre Option Obligation which provided for an annual equity grant of options for Parapyre Holding LLC (&#8220;Parapyre&#8221;) to purchase <ix:nonFraction name="agle:PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock" contextRef="PAsOn06_22_2023_ParapyreOptionObligationMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">1</ix:nonFraction>% of the then outstanding shares of Spyre&#8217;s common stock, on a fully diluted basis, on the last business day of each calendar year during the term of the Paragon Agreement, at the fair market value determined by the board of directors of Spyre. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&#160;29, 2023, the Company amended the Paragon Agreement to amend and restate certain terms of the option grant pertaining to the Parapyre Option Obligation, including but not limited to (i)&#160;defining that the annual equity grant of options is based on the outstanding shares of Aeglea&#8217;s common stock, (ii)&#160;establishing the grant date as the last business day of each applicable calendar year, and (iii)&#160;defining the term of the options granted as <ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" contextRef="P09_29_2023To09_29_2023_ParapyreOptionObligationMemberusgaapPlanNameAxis" format="ixt-sec:durwordsen">ten years</ix:nonNumeric>. The liability related to the Parapyre Option Obligation will be recorded pursuant to the amended Paragon Agreement. As of September&#160;30, 2023, the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pro-rated</div> estimated fair value of the options to be granted on December&#160;31, 2023, was approximately $<ix:nonFraction name="agle:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodFairValue" contextRef="P12_31_2023To12_31_2023_ParapyreOptionObligationMemberusgaapPlanNameAxis_ScenarioForecastMembersrtStatementScenarioAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">3.0</ix:nonFraction>&#160;million, of which $<ix:nonFraction name="us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration" contextRef="P06_22_2023To06_22_2023_ParapyreOptionObligationMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.1</ix:nonFraction>&#160;million was recognized as part of the liabilities assumed with the Asset Acquisition on June&#160;22, 2023. For the three and nine months ended September&#160;30, 2023, $<ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P07_01_2023To09_30_2023_ParapyreOptionObligationMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.7</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2023To09_30_2023_ParapyreOptionObligationMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.9</ix:nonFraction>&#160;million, respectively, was recognized as stock compensation expense related to the Parapyre Option Obligation. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">CVR Liability </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Asset Acquisition, a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-transferable</div> contingent value right (a &#8220;CVR&#8221;) was distributed to Aeglea stockholders of record as of the close of business on July&#160;3, 2023, but was not distributed to holders of shares of Common Stock or Series A Preferred Stock issued to the Investors or former stockholders of Spyre in connection with the Transactions. Holders of the CVR will be entitled to receive certain cash payments from proceeds received by the Company for a <ix:nonNumeric name="agle:AssetAcquisitionStockholderPaymentPeriod" contextRef="P06_22_2023To06_22_2023_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis" format="ixt-sec:durwordsen">three-year</ix:nonNumeric> period, if any, related to the disposition or monetization of Aeglea&#8217;s legacy assets for a period of <ix:nonNumeric name="agle:AssetAcquisitionCashPaymentThresholdPeriod" contextRef="P06_22_2023To06_22_2023_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis" format="ixt-sec:durwordsen">one year</ix:nonNumeric> following the closing of the Asset Acquisition. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-52</ix:exclude> </div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_95763988_4" continuedAt="TextSelectionAppend_95763988_5"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_95763988_5" continuedAt="TextSelectionAppend_95763988_6"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_95763988_6" continuedAt="TextSelectionAppend_95763988_7"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_95763988_7"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of the CVR liability was determined using the probability weighted discounted cash flow method to estimate future cash flows associated with the sale of the legacy assets. Analogous to a dividend being declared/approved in one period and paid out in another, the liability was recorded at the date of approval, June&#160;22, 2023, as a common stock dividend, returning capital to the Legacy Stockholders. Changes in fair value of the liability will be recognized as a component of Other income (expense) in the condensed consolidated statement of operations and comprehensive loss in each reporting period. The liability value is based on significant inputs not observable in the market such as estimated cash flows, estimated probabilities of success, and risk-adjusted discount rates, which represent a Level&#160;3 measurement within the fair value hierarchy. <ix:nonNumeric name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" contextRef="P01_01_2023To09_30_2023" escape="true" continuedAt="TextSelection_95763994">The significant inputs used to estimate the fair value of the CVR liability were as follows: </ix:nonNumeric></div></div></div><ix:continuation id="TextSelection_95763994"><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 67%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td style="width: 29%;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">September&#160;30, 2023</div></div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Estimated cash flow dates</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="display:inline;">11/28/23 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">-</div> 06/22/26</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Estimated probability of success</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="display:inline;"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextRef="PAsOn09_30_2023_ContingentValueRightLiabilityMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputProabilityOfSuccessMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:num-dot-decimal">27</ix:nonFraction>% - <ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextRef="PAsOn09_30_2023_ContingentValueRightLiabilityMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MaximumMembersrtRangeAxis_MeasurementInputProabilityOfSuccessMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction>%</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-adjusted discount rates</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="display:inline;"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextRef="PAsOn09_30_2023_ContingentValueRightLiabilityMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:num-dot-decimal">7.14</ix:nonFraction>% - <ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextRef="PAsOn09_30_2023_ContingentValueRightLiabilityMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MaximumMembersrtRangeAxis_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:num-dot-decimal">7.57</ix:nonFraction>%</div></td></tr></table></ix:continuation><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The change in fair value between June&#160;30, 2023 and September&#160;30, 2023 was a $<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="P04_01_2023To06_30_2023_ContingentValueRightLiabilityMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="P07_01_2023To09_30_2023_ContingentValueRightLiabilityMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.3</ix:nonFraction></ix:nonFraction>&#160;million decrease, and was primarily driven by changes in the likelihood of a successful disposition of pegtarviliase, changes in the expected timing of achievement of certain milestones, updates to expenses and deductions, partially offset by changes in the likelihood of certain milestones related to the favorable Committee for Medicinal Products Human Use (&#8220;CHMP&#8221;) opinion received by Immedica Pharma AB (&#8220;Immedica&#8221;). </div></div></div><ix:continuation id="TextSelection_95763993"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents changes in the CVR liability for the periods presented (in thousands): </div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:85%"></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">CVR<br/> Liability</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Beginning balance as of December&#160;31, 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn12_31_2022_ContingentValueRightLiabilityMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Fair value at CVR issuance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" contextRef="P01_01_2023To09_30_2023_ContingentValueRightLiabilityMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">29,500</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Changes in the fair value of the CVR liability since issuance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="P01_01_2023To09_30_2023_ContingentValueRightLiabilityMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,300</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Ending Balance as of September&#160;30, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn09_30_2023_ContingentValueRightLiabilityMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">28,200</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:continuation></ix:continuation><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-53 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:nonNumeric name="us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock" contextRef="P01_01_2023To09_30_2023" escape="true" continuedAt="TextSelection_95763959"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4. Cash Equivalents and Marketable Securities </div><ix:nonNumeric name="us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" contextRef="P01_01_2023To09_30_2023" escape="true"><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following tables summarize the estimated fair value of the Company&#8217;s cash equivalents and marketable securities and the gross unrealized gains and losses (in thousands): </div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:57%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">September&#160;30, 2023</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Amortized<br/> Cost</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Gross<br/> Unrealized<br/> Gains</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Gross<br/> Unrealized<br/> Losses</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Estimated<br/> Fair Value</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash equivalents:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Money market funds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="PAsOn09_30_2023_MoneyMarketFundsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">55,451</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="agle:CashEquivalentsUnrealizedGains" contextRef="PAsOn09_30_2023_MoneyMarketFundsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="agle:CashEquivalentsUnrealizedLosses" contextRef="PAsOn09_30_2023_MoneyMarketFundsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="PAsOn09_30_2023_MoneyMarketFundsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">55,451</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial paper</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="PAsOn09_30_2023_CommercialPaperMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">16,911</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="agle:CashEquivalentsUnrealizedGains" contextRef="PAsOn09_30_2023_CommercialPaperMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="agle:CashEquivalentsUnrealizedLosses" contextRef="PAsOn09_30_2023_CommercialPaperMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="PAsOn09_30_2023_CommercialPaperMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">16,914</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total cash equivalents</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="PAsOn09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">72,362</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="agle:CashEquivalentsUnrealizedGains" contextRef="PAsOn09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="agle:CashEquivalentsUnrealizedLosses" contextRef="PAsOn09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="PAsOn09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">72,365</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Marketable securities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial paper</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="PAsOn09_30_2023_CommercialPaperMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">90,272</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="PAsOn09_30_2023_CommercialPaperMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="PAsOn09_30_2023_CommercialPaperMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">93</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="PAsOn09_30_2023_CommercialPaperMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">90,179</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate bonds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="PAsOn09_30_2023_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">22,849</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="PAsOn09_30_2023_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="PAsOn09_30_2023_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">22</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="PAsOn09_30_2023_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">22,828</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">U.S. government securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="PAsOn09_30_2023_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="PAsOn09_30_2023_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="PAsOn09_30_2023_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="PAsOn09_30_2023_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="PAsOn09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">113,121</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="PAsOn09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="PAsOn09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">115</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="PAsOn09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">113,007</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="16" style="height:12pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">December&#160;31, 2022</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Amortized<br/> Cost</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Gross<br/> Unrealized<br/> Gains</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Gross<br/> Unrealized<br/> Losses</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Estimated<br/> Fair&#160;Value</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash equivalents:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Money market funds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2022_MoneyMarketFundsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">15,250</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="agle:CashEquivalentsUnrealizedGains" contextRef="PAsOn12_31_2022_MoneyMarketFundsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="agle:CashEquivalentsUnrealizedLosses" contextRef="PAsOn12_31_2022_MoneyMarketFundsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="PAsOn12_31_2022_MoneyMarketFundsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">15,250</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial paper</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,021</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="agle:CashEquivalentsUnrealizedGains" contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="agle:CashEquivalentsUnrealizedLosses" contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,020</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">U.S. government securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2022_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,736</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="agle:CashEquivalentsUnrealizedGains" contextRef="PAsOn12_31_2022_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="agle:CashEquivalentsUnrealizedLosses" contextRef="PAsOn12_31_2022_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="PAsOn12_31_2022_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,735</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total cash equivalents</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">26,007</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="agle:CashEquivalentsUnrealizedGains" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="agle:CashEquivalentsUnrealizedLosses" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">26,005</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Marketable securities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial paper</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">16,644</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">25</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">16,621</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate bonds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="PAsOn12_31_2022_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,738</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="PAsOn12_31_2022_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="PAsOn12_31_2022_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="PAsOn12_31_2022_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,732</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">U.S. government securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="PAsOn12_31_2022_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">495</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="PAsOn12_31_2022_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="PAsOn12_31_2022_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="PAsOn12_31_2022_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">495</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">20,877</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">31</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">20,848</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-54</ix:exclude> </div></ix:nonNumeric></div></div></div><ix:continuation id="TextSelection_95763959" continuedAt="TextSelectionAppend_95763959_1"><div></div></ix:continuation></div><ix:continuation id="TextSelectionAppend_95763959_1" continuedAt="TextSelectionAppend_95763959_2"><div><div style="line-height:normal;background-color:white;display: inline;"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></div></div></ix:continuation></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_95763959_2" continuedAt="TextSelectionAppend_95763959_3"><ix:nonNumeric name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" contextRef="P01_01_2023To09_30_2023" escape="true"><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> securities in an unrealized loss position for which an allowance for credit losses has not been recorded as of September&#160;30, 2023 and December&#160;31, 2022, aggregated by major security type and length of time in a continuous unrealized loss position: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:56%"></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="22" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">September&#160;30, 2023</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Less Than 12 Months</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">12 Months or<br/> Longer</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Total</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Fair<br/> Value</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Unrealized<br/> Losses</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Fair<br/> Value</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Unrealized<br/> Losses</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Fair<br/> Value</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Unrealized<br/> Losses</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial paper</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" contextRef="PAsOn09_30_2023_CommercialPaperMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">78,820</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" contextRef="PAsOn09_30_2023_CommercialPaperMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">93</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" contextRef="PAsOn09_30_2023_CommercialPaperMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" contextRef="PAsOn09_30_2023_CommercialPaperMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" contextRef="PAsOn09_30_2023_CommercialPaperMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">78,820</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" contextRef="PAsOn09_30_2023_CommercialPaperMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">93</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">U.S. government securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" contextRef="PAsOn09_30_2023_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" contextRef="PAsOn09_30_2023_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" contextRef="PAsOn09_30_2023_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" contextRef="PAsOn09_30_2023_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" contextRef="PAsOn09_30_2023_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" contextRef="PAsOn09_30_2023_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate bonds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" contextRef="PAsOn09_30_2023_CorporateBondSecuritiesMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">18,373</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" contextRef="PAsOn09_30_2023_CorporateBondSecuritiesMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">22</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" contextRef="PAsOn09_30_2023_CorporateBondSecuritiesMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" contextRef="PAsOn09_30_2023_CorporateBondSecuritiesMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" contextRef="PAsOn09_30_2023_CorporateBondSecuritiesMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">18,373</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" contextRef="PAsOn09_30_2023_CorporateBondSecuritiesMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">22</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" contextRef="PAsOn09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">97,193</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" contextRef="PAsOn09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">115</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" contextRef="PAsOn09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" contextRef="PAsOn09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" contextRef="PAsOn09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">97,193</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" contextRef="PAsOn09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">115</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td colspan="24" style="height:12pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="22" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">December&#160;31, 2022</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Less Than 12 Months</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">12 Months or<br/> Longer</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Total</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Fair<br/> Value</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Unrealized<br/> Losses</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Fair<br/> Value</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Unrealized<br/> Losses</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Fair<br/> Value</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Unrealized<br/> Losses</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial paper</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">17,699</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">27</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">17,699</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">27</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">U.S. government securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" contextRef="PAsOn12_31_2022_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,735</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" contextRef="PAsOn12_31_2022_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" contextRef="PAsOn12_31_2022_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" contextRef="PAsOn12_31_2022_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" contextRef="PAsOn12_31_2022_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,735</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" contextRef="PAsOn12_31_2022_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate bonds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" contextRef="PAsOn12_31_2022_CorporateBondSecuritiesMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,732</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" contextRef="PAsOn12_31_2022_CorporateBondSecuritiesMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" contextRef="PAsOn12_31_2022_CorporateBondSecuritiesMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" contextRef="PAsOn12_31_2022_CorporateBondSecuritiesMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" contextRef="PAsOn12_31_2022_CorporateBondSecuritiesMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,732</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" contextRef="PAsOn12_31_2022_CorporateBondSecuritiesMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">25,166</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">34</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">25,166</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">34</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company evaluated its securities for credit losses and considered the decline in market value to be primarily attributable to current economic and market conditions and not to a credit loss or other factors. Additionally, the Company does not intend to sell the securities in an unrealized loss position and does not expect it will be required to sell the securities before recovery of the unamortized cost basis. As of September&#160;30, 2023 and December&#160;31, 2022, an allowance for credit losses had <ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" contextRef="PAsOn09_30_2023_USGovernmentAgenciesDebtSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" contextRef="PAsOn12_31_2022_USGovernmentAgenciesDebtSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction>t been recognized. Given the Company&#8217;s intent and ability to hold such securities until recovery, and the lack of significant change in credit risk of these investments, the Company does <ix:nonFraction name="agle:ImpairmentOfMarketableSecurities" contextRef="P01_01_2023To09_30_2023_USGovernmentAgenciesDebtSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="agle:ImpairmentOfMarketableSecurities" contextRef="P01_01_2022To12_31_2022_USGovernmentAgenciesDebtSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction>t consider these marketable securities to be impaired as of September&#160;30, 2023 and December&#160;31, 2022. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The financial instruments that potentially subject the Company to a concentration of credit risk consist principally of cash deposits. Accounts at each of our <ix:nonFraction name="agle:NumberOfDomesticBankingInstitutions" contextRef="PAsOn09_30_2023" unitRef="Unit_bank" decimals="0" scale="0" format="ixt-sec:numwordsen">three</ix:nonFraction> U.S. banking institutions are insured by the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) up to $<ix:nonFraction name="us-gaap:CashFDICInsuredAmount" contextRef="PAsOn09_30_2023_MaximumMembersrtRangeAxis_USBankingInstitutionMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">250,000</ix:nonFraction> per depositor. At September&#160;30, 2023 and December&#160;31, 2022, the Company had $<ix:nonFraction name="us-gaap:Cash" contextRef="PAsOn09_30_2023_USBankingInstitutionMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">16.9</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:Cash" contextRef="PAsOn12_31_2022_USBankingInstitutionMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">23.5</ix:nonFraction>&#160;million, respectively, of U.S. cash deposits in excess of the FDIC insured limit. Uninsured foreign cash deposits were immaterial for both periods. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There were <ix:nonFraction name="us-gaap:MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments" contextRef="P01_01_2023To09_30_2023_USGovernmentAgenciesDebtSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments" contextRef="P07_01_2022To09_30_2022_USGovernmentAgenciesDebtSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments" contextRef="P01_01_2022To09_30_2022_USGovernmentAgenciesDebtSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments" contextRef="P07_01_2023To09_30_2023_USGovernmentAgenciesDebtSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen">no </ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>realized gains or losses on marketable securities for the three and nine months ended September&#160;30, 2023 and 2022. Interest on marketable securities is included in interest income. Accrued interest receivable on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> debt securities at September&#160;30, 2023 and December&#160;31, 2022 was $<ix:nonFraction name="us-gaap:InterestReceivable" contextRef="PAsOn09_30_2023_USGovernmentAgenciesDebtSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.4</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:InterestReceivable" contextRef="PAsOn12_31_2022_USGovernmentAgenciesDebtSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.1</ix:nonFraction>&#160;million, respectively. </div><ix:nonNumeric name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" contextRef="P01_01_2023To09_30_2023" escape="true"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the contractual maturities of the Company&#8217;s marketable securities at estimated fair value (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:67%"></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">September&#160;30,<br/> 2023</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">December&#160;31,<br/> 2022</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Due in one year or less</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" contextRef="PAsOn09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">102,518</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">20,848</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Due thereafter</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="agle:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne" contextRef="PAsOn09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,489</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="agle:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="PAsOn09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">113,007</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">20,848</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-55</ix:exclude> </div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_95763959_3" continuedAt="TextSelectionAppend_95763959_4"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_95763959_4" continuedAt="TextSelectionAppend_95763959_5"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_95763959_5" continuedAt="TextSelectionAppend_95763959_6"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_95763959_6"><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company may sell investments at any time for use in current operations even if they have not yet reached maturity. As a result, the Company classifies marketable securities, including securities with maturities beyond twelve months as current <div style="display:inline;">assets</div>. </div></ix:continuation><ix:nonNumeric name="agle:AccruedAndOtherCurrentLiabilitiesTextBlock" contextRef="P01_01_2023To09_30_2023" escape="true"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5. Accrued and Other Current Liabilities </div><ix:nonNumeric name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" contextRef="P01_01_2023To09_30_2023" escape="true"><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accrued and other current liabilities consist of the following (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:66%"></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">September&#160;30,<br/> 2023</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">December&#160;31,<br/> 2022</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued compensation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccruedSalariesCurrent" contextRef="PAsOn09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,368</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccruedSalariesCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,589</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued contracted research and development costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="agle:AccruedContractedResearchAndDevelopmentCosts" contextRef="PAsOn09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,669</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="agle:AccruedContractedResearchAndDevelopmentCosts" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,972</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued professional and consulting fees</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="PAsOn09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,484</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">946</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued other</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="PAsOn09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">340</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">330</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total accrued and other current liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" contextRef="PAsOn09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">15,861</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">12,837</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric></ix:nonNumeric><ix:nonNumeric name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" contextRef="P01_01_2023To09_30_2023" escape="true" continuedAt="TextSelection_95764042"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6. Related Party Transactions </div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Paragon and Parapyre Holding LLC each beneficially owns less than <ix:nonFraction name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" contextRef="PAsOn09_30_2023_MaximumMembersrtRangeAxis_OwnershipInterestMemberusgaapRelatedPartyTransactionAxis_ParagonTherapeuticsIncMembersrtOwnershipAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">5</ix:nonFraction>% of the Company&#8217;s capital stock through their respective holdings of the Company&#8217;s common stock and Series A Preferred Stock. Fairmount Funds Management LLC (&#8220;Fairmount&#8221;) beneficially owns more than <ix:nonFraction name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" contextRef="PAsOn09_30_2023_FairmountFundsManagementLlcMembersrtOwnershipAxis_MinimumMembersrtRangeAxis_OwnershipInterestMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">5</ix:nonFraction>% of the Company&#8217;s capital stock, has <ix:nonFraction name="agle:RelatedPartyTransactionNumberOfBoardSeats" contextRef="PAsOn09_30_2023_AppointOfBoardMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_BOARDSEAT" decimals="0" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction> seats on the Board and beneficially owns more than <ix:nonFraction name="agle:MinorityInterestOwnershipPercentageByNoncontrollingOwnersHeldInThirdParty" contextRef="PAsOn09_30_2023_FairmountFundsManagementLlcMembersrtOwnershipAxis_MinimumMembersrtRangeAxis_OwnershipInterestMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">5</ix:nonFraction>% of Paragon, which is a joint venture between Fairmount and Fair Journey Biologics. Fairmount appointed Paragon&#8217;s board of directors and has the contractual right to approve the appointment of any executive officers. Parapyre is an entity formed by Paragon as a vehicle to hold equity in Spyre in order to share profits with certain employees of Paragon. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Asset Acquisition, the Company assumed the rights and obligations of Spyre under the Paragon Agreement. Under the Paragon Agreement, Spyre is obligated to compensate Paragon for its services performed under each research program based on the actual costs incurred with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mark-up</div> costs pursuant to the terms of the Paragon Agreement. As of the date of the Asset Acquisition, Spyre had incurred total expenses of $<ix:nonFraction name="agle:RelatedPartyExpensesIncurredPriorToAssetAcquisition" contextRef="P06_22_2023To06_22_2023_ParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">19.0</ix:nonFraction>&#160;million under the Paragon Agreement since inception, inclusive of a $<ix:nonFraction name="agle:ResearchInitiationFees" contextRef="P06_22_2023To06_22_2023_ParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">3.0</ix:nonFraction>&#160;million research initiation fee that was due upon signing of the Paragon Agreement and $<ix:nonFraction name="agle:ReimbursableResearchCosts" contextRef="P06_22_2023To06_22_2023_ParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">16.0</ix:nonFraction>&#160;million of reimbursable expenses under the Paragon Agreement for historical costs owed to Paragon. As of the acquisition date, $<ix:nonFraction name="agle:RelatedPartyExpensesUnpaidPriorToAssetAcquisition" contextRef="PAsOn06_22_2023_ParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">19.0</ix:nonFraction>&#160;million was unpaid and was assumed by the Company through the Asset Acquisition. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the three and nine months ended September&#160;30, 2023, the Company recognized expenses related to services provided by Paragon subsequent to the Asset Acquisition totaling $<ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="P07_01_2023To09_30_2023_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_StockCompensationAndResearchAndDevelopmentExpenseMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">19.4</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="P01_01_2023To09_30_2023_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_StockCompensationAndResearchAndDevelopmentExpenseMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">20.8</ix:nonFraction>&#160;million, respectively, which were recorded as Research and development expenses in the consolidated statements of operations. As of September&#160;30, 2023, $<ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="PAsOn09_30_2023_ReimbursableCostsUnderParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">16.8</ix:nonFraction>&#160;million was unpaid and was included in Related party payable on the Company&#8217;s consolidated balance sheets. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the three and nine months ended September&#160;30, 2023, the Company made payments totaling $<ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="P07_01_2023To09_30_2023_MilestonePaymentsMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="P01_01_2023To09_30_2023_MilestonePaymentsMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">20.0</ix:nonFraction></ix:nonFraction>&#160;million to Paragon. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July 2023, the Company exercised its option for the SPY001 program with the remaining <ix:nonFraction name="agle:RelatedPartyTransactionNumberOfProgramOptionsOutstanding" contextRef="P07_01_2023To07_31_2023_LicensingAgreementsMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_PROGRAMOPTION" decimals="0" scale="0" format="ixt-sec:numwordsen">three</ix:nonFraction> options for the SPY002, SPY003, SPY004 programs remaining outstanding. Following the execution of the license agreement with respect to the SPY001 program (the &#8220;SPY001 License Agreement&#8221;), the Company will be obligated to pay Paragon up to $<ix:nonFraction name="agle:AmountToBePaidUnderAgreement" contextRef="PAsOn07_31_2023_MaximumMembersrtRangeAxis_ParagonTherapeuticsIncMembersrtOwnershipAxis_Spy001LicenseAgreementMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">22.0</ix:nonFraction>&#160;million upon the achievement of specific development and clinical milestones for the first product under the SPY001 License Agreement that achieves such specified milestones. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-56</ix:exclude> </div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_95764042" continuedAt="TextSelectionAppend_95764042_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_95764042_1" continuedAt="TextSelectionAppend_95764042_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_95764042_2" continuedAt="TextSelectionAppend_95764042_3"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_95764042_3"><ix:nonNumeric name="us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock" contextRef="P01_01_2023To09_30_2023" escape="true"><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is the summary of expenses related to the Paragon Agreement, which were ultimately settled in cash (in millions): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:52%"></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Three Months<br/> Ended<br/> September&#160;30,</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Nine Months<br/> Ended<br/> September&#160;30,</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">2023</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">2022</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">2023</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">2022</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Financial&#160;Statement&#160;Line&#160;Item</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Reimbursable costs under the Paragon Agreement</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="agle:RelatedPartyTransactionReimbursableCosts" contextRef="P07_01_2023To09_30_2023_ReimbursableCostsUnderParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">16.7</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="agle:RelatedPartyTransactionReimbursableCosts" contextRef="P07_01_2022To09_30_2022_ReimbursableCostsUnderParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="agle:RelatedPartyTransactionReimbursableCosts" contextRef="P01_01_2023To09_30_2023_ReimbursableCostsUnderParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">17.9</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="agle:RelatedPartyTransactionReimbursableCosts" contextRef="P01_01_2022To09_30_2022_ReimbursableCostsUnderParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Research&#160;and&#160;development</td></tr></table></ix:nonNumeric><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Parapyre Option Obligation </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Paragon Agreement provided for an annual equity grant of options to purchase <ix:nonFraction name="agle:PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock" contextRef="PAsOn09_30_2023_ParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">1</ix:nonFraction>% of the then outstanding shares of Spyre&#8217;s common stock, on a fully diluted basis, on the last business day of each calendar year, at the fair market value determined by the board of directors of Spyre (the &#8220;Parapyre Option Obligation&#8221;). </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Asset Acquisition, the Company assumed the rights and obligations of Spyre under the Paragon Agreement, including the Parapyre Option Obligation. As a result, the Parapyre Option Obligation shall continue and Parapyre shall be entitled to receive the equivalent shares of the Company with the same terms. On September&#160;29, 2023, the Company amended the Paragon Agreement to amend and restate certain terms of the option grant pertaining to the Parapyre Option Obligation, including but not limited to (i)&#160;defining that the annual equity grant of options is based on the outstanding shares of Aeglea&#8217;s common stock, (ii)&#160;establishing the grant date as the last business day of each applicable calendar year, and (iii)&#160;defining the term of the options granted as <ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" contextRef="P09_29_2023To09_29_2023_ParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" format="ixt-sec:durwordsen">ten years</ix:nonNumeric>. See Notes 3 and 10 for disclosures related to the Parapyre Option Obligation. For the three and nine months ended September&#160;30, 2023, $<ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P07_01_2023To09_30_2023_ParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.7</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2023To09_30_2023_ParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.9</ix:nonFraction>&#160;million, respectively, was recognized as stock compensation expense related to the Parapyre Option Obligation. </div><ix:nonNumeric name="agle:ScheduleOfBalancesDueToAffiliatesTableTextBlock" contextRef="P01_01_2023To09_30_2023" escape="true"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is the summary of Related party accounts payable (in millions): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:67%"></td>
<td style="vertical-align:bottom;width:12%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:12%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">September&#160;30,<br/> 2023</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">December&#160;31,<br/> 2022</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Reimbursable costs under the Paragon Agreement</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="PAsOn09_30_2023_ReimbursableCostsUnderParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">16.8</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="PAsOn12_31_2022_ReimbursableCostsUnderParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Parapyre Option Obligation liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="PAsOn09_30_2023_ParapyreOptionObligationMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">3.0</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="PAsOn12_31_2022_ParapyreOptionObligationMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total related party accounts payable</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="PAsOn09_30_2023_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">19.8</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="PAsOn12_31_2022_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric></ix:continuation><ix:nonNumeric name="us-gaap:AssetAcquisitionTextBlock" contextRef="P01_01_2023To09_30_2023" escape="true" continuedAt="TextSelection_95764050"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7. Asset Acquisition </div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;22, 2023, the Company acquired Spyre pursuant to the Acquisition Agreement, by and among the Company, Aspen Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (&#8220;First Merger Sub&#8221;), Sequoia Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of the Company (&#8220;Second Merger Sub&#8221;), and Spyre. Pursuant to the Acquisition Agreement, First Merger Sub merged with and into Spyre, pursuant to which Spyre was the surviving corporation and became a wholly owned subsidiary of the Company (the &#8220;First Merger&#8221;). Immediately following the First Merger, Spyre merged with and into Second Merger Sub, pursuant to which Second Merger Sub became the surviving entity. Spyre was a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> stage biotechnology company that was incorporated on April&#160;28, 2023 under the direction of Peter Harwin, a Managing Member of Fairmount, for the purpose of holding rights to certain intellectual property being developed by Paragon. Fairmount is a founder of Paragon. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company completed the Asset Acquisition of Spyre, in accordance with the terms of the Acquisition Agreement. Under the terms of the Acquisition Agreement, the Company issued <ix:nonFraction name="agle:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares" contextRef="P06_22_2023To06_22_2023_CommonStockMemberusgaapEquityInterestIssuedOrIssuableByTypeAxis_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">517,809</ix:nonFraction> shares of common stock and <ix:nonFraction name="agle:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares" contextRef="P06_22_2023To06_22_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">364,887</ix:nonFraction> shares of Series A Preferred Stock to former Spyre security holders. In addition, outstanding and unexercised stock options to purchase <ix:nonFraction name="agle:OutstandingAndUnexercisedStockOptions" contextRef="P06_22_2023To06_22_2023_Spyre2023EquityIncentivePlanMemberusgaapPlanNameAxis_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">2,734</ix:nonFraction> shares of common stock were assumed from the Amended and Restated Spyre 2023 Equity Incentive Plan. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-57</ix:exclude> </div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_95764050" continuedAt="TextSelectionAppend_95764050_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_95764050_1" continuedAt="TextSelectionAppend_95764050_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_95764050_2" continuedAt="TextSelectionAppend_95764050_3"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_95764050_3"><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the acquisition date, the Company recorded forward contracts to represent the obligation to issue shares of the Company&#8217;s common stock and shares of Series A Preferred Stock, respectively. The forward contract related to the common stock was recorded as Additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital as the instrument is indexed to the Company&#8217;s common stock. The forward contract related to the Series A Preferred Stock was recorded as a liability, as the underlying stock has a cash redemption feature. On July&#160;7, 2023, both the shares of common stock and Series A Preferred Stock were issued and the forward contract liability associated with the Series A Preferred Stock was settled accordingly. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company concluded that the arrangement meets the definition of an asset acquisition rather than a business combination, as substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset, Spyre&#8217;s option (the &#8220;Option&#8221;) to exclusively license IPR&amp;D. The Company determined that the Option to license IPR&amp;D was a single asset as the Company&#8217;s strategy relies on developing the entire portfolio of individual treatments to create combination treatments that simultaneously address different mechanisms of irritable bowel disease with a single treatment. The Company also determined that the pipeline candidates within the portfolio are similar in nature and risk profile. In addition, the Company did not obtain any substantive processes, assembled workforce, or employees capable of producing outputs in connection with the Asset Acquisition. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company determined that the cost to acquire the asset was $<ix:nonFraction name="us-gaap:AssetAcquisitionConsiderationTransferred" contextRef="P06_22_2023To06_22_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">113.2</ix:nonFraction>&#160;million which was recorded as acquired IPR&amp;D. The fair value of the consideration issued consisted of the <ix:nonFraction name="agle:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares" contextRef="P06_22_2023To06_22_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">364,887</ix:nonFraction> shares of Series A Preferred Stock (<ix:nonFraction name="agle:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableSharesOfCommonStockOnAnAsConvertedBasis" contextRef="P06_22_2023To06_22_2023_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">14,595,480</ix:nonFraction> shares of common stock on an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">as-converted</div> basis) and <ix:nonFraction name="agle:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares" contextRef="P06_22_2023To06_22_2023_CommonStockMemberusgaapEquityInterestIssuedOrIssuableByTypeAxis_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">517,809</ix:nonFraction> shares of common stock, valued at $<ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="PAsOn06_22_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">291.08</ix:nonFraction> per share and $<ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="PAsOn06_22_2023_CommonStockMemberusgaapEquityInterestIssuedOrIssuableByTypeAxis_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD_per_Share" decimals="3" scale="0" format="ixt:num-dot-decimal">7.277</ix:nonFraction> per share, respectively. </div><ix:nonNumeric name="us-gaap:AssetAcquisitionTableTextBlock" contextRef="P01_01_2023To09_30_2023" escape="true"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Asset Acquisition Costs are shown on the following table (in millions): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:87%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">June&#160;22,<br/> 2023</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Consideration transferred in Series A Preferred Stock and common stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" contextRef="P06_22_2023To06_22_2023_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">110.0</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Transaction costs incurred by Aeglea</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetAcquisitionConsiderationTransferredTransactionCost" contextRef="P06_22_2023To06_22_2023_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">3.2</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total cost to acquire asset</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetAcquisitionConsiderationTransferred" contextRef="P06_22_2023To06_22_2023_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">113.2</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The allocation of the purchase price to net assets acquired is as a follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:87%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">June&#160;22,<br/> 2023</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Acquired <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="agle:AcquiredInProcessResearchAndDevelopment" contextRef="P06_22_2023To06_22_2023_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">130.2</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash acquired</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashAcquiredFromAcquisition" contextRef="P06_22_2023To06_22_2023_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">3.0</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Assumed liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="agle:AssumedLiabilities" contextRef="P06_22_2023To06_22_2023_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">20.0</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total cost to acquire asset</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetAcquisitionConsiderationTransferred" contextRef="P06_22_2023To06_22_2023_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">113.2</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric></ix:continuation><ix:nonNumeric name="agle:OptionAgreementTextBlock" contextRef="P01_01_2023To09_30_2023" escape="true" continuedAt="TextSelection_95764058"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">8. Paragon Agreement </div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May 2023, Spyre entered into the Paragon Agreement with Paragon and Parapyre. In consideration for the Option granted under the Paragon Agreement, Spyre was obligated to pay Paragon an upfront cash amount of $<ix:nonFraction name="agle:ResearchInitiationFees" contextRef="P06_22_2023To06_22_2023_ParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">3.0</ix:nonFraction>&#160;million in research initiation fees. In addition, Spyre was obligated to compensate Paragon on a quarterly basis for its services performed under each research program based on the actual costs incurred with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mark-up</div> costs pursuant to the terms of the Paragon Agreement. As of the date of the Asset Acquisition, Spyre had incurred total expenses of $<ix:nonFraction name="agle:RelatedPartyExpensesIncurredPriorToAssetAcquisition" contextRef="P06_22_2023To06_22_2023_ParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">19.0</ix:nonFraction>&#160;million under the Paragon Agreement since inception, which included the $<ix:nonFraction name="agle:ResearchInitiationFees" contextRef="P06_22_2023To06_22_2023_ParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">3.0</ix:nonFraction>&#160;million research initiation fee and $<ix:nonFraction name="agle:ReimbursableResearchCosts" contextRef="P06_22_2023To06_22_2023_ParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">16.0</ix:nonFraction>&#160;million of historical reimbursable expenses owed to Paragon. As of June&#160;22, 2023, $<ix:nonFraction name="agle:RelatedPartyExpensesUnpaidPriorToAssetAcquisition" contextRef="PAsOn06_22_2023_ParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">19.0</ix:nonFraction>&#160;million was unpaid and was assumed by the Company through the Asset Acquisition. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-58</ix:exclude> </div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_95764058" continuedAt="TextSelectionAppend_95764058_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_95764058_1" continuedAt="TextSelectionAppend_95764058_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_95764058_2" continuedAt="TextSelectionAppend_95764058_3"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_95764058_3"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Furthermore, the Paragon Agreement provided for an annual equity grant of options to purchase <ix:nonFraction name="agle:PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock" contextRef="PAsOn05_31_2023_ParapyreOptionObligationMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">1</ix:nonFraction>% of the then outstanding shares of Spyre&#8217;s common stock, on a fully diluted basis, on the last business day of each calendar year, during the term of the Paragon Agreement, at the fair market value determined by the board of directors of Spyre. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result of the Asset Acquisition, the Company assumed the rights and obligations of Spyre under the Paragon Agreement, including the Parapyre Option Obligation. Pursuant to the Paragon Agreement, on a research <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">program-by-research</div></div> program basis following the finalization of the research plan for each respective research program, the Company is required to pay Paragon a nonrefundable fee in cash of $<ix:nonFraction name="agle:NonrefundableResearchInitiationFeeForOneProgramPaidInCash" contextRef="P06_22_2023To06_22_2023_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.8</ix:nonFraction>&#160;million. For the three and nine months ended September&#160;30, 2023, the Company incurred $<ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="P07_01_2023To09_30_2023_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_StockCompensationAndResearchAndDevelopmentExpenseMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">19.4</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="P01_01_2023To09_30_2023_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_StockCompensationAndResearchAndDevelopmentExpenseMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">20.8</ix:nonFraction>&#160;million, respectively, in costs reimbursable to Paragon, which were recorded as Research and development expenses in the consolidated statements of operations. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the three and nine months ended September&#160;30, 2023, the Company made payments totaling $<ix:nonFraction name="agle:LicenseAgreementMilestonePayments" contextRef="P07_01_2023To09_30_2023_ParagonTherapeuticsIncMembersrtCounterpartyNameAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal"><ix:nonFraction name="agle:LicenseAgreementMilestonePayments" contextRef="P01_01_2023To09_30_2023_ParagonTherapeuticsIncMembersrtCounterpartyNameAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">20.0</ix:nonFraction></ix:nonFraction>&#160;million to Paragon. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&#160;12, 2023, the Company exercised its Option available under the Paragon Agreement with respect to the SPY001 research program and expects to enter into a SPY001 license agreement (the &#8220;SPY001 License Agreement&#8221;). The Company&#8217;s Option available under the Paragon Agreement with respect to the SPY002, SPY003 and SPY004 programs remains unexercised. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the execution of the SPY001 License Agreement, the Company will be obligated to pay Paragon up to $<ix:nonFraction name="agle:AmountToBePaidUnderAgreement" contextRef="PAsOn07_12_2023_MaximumMembersrtRangeAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_Spy001LicenseAgreementMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">22.0</ix:nonFraction>&#160;million upon the achievement of specific development and clinical milestones for the first product under the SPY001 License Agreement that achieves such specified milestones. Upon execution of the SPY001 License Agreement, the Company expects to pay Paragon a $<ix:nonFraction name="agle:NominationFee" contextRef="P07_12_2023To07_12_2023_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_Spy001LicenseAgreementMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.5</ix:nonFraction>&#160;million fee for nomination of a development candidate, and the Company expects to be obligated to make a further milestone payment of $<ix:nonFraction name="agle:PaymentOfMilestone" contextRef="P07_12_2023To07_12_2023_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_Spy001LicenseAgreementMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.5</ix:nonFraction>&#160;million upon the first dosing of a human patient in a Phase 1 trial. Subject to the execution of the Option with respect to the SPY002, SPY003 or SPY004 research programs, the Company expects to be obligated to make similar payments upon and following the execution of license agreements with respect to the these research programs, respectively. </div></ix:continuation><ix:nonNumeric name="us-gaap:PreferredStockTextBlock" contextRef="P01_01_2023To09_30_2023" escape="true" continuedAt="TextSelection_95764037"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">9. Series A <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Voting</div> Convertible Preferred Stock </div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;22, 2023, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of the Series A Preferred Stock with the Secretary of State of the State of Delaware (the &#8220;Certificate of Designation&#8221;) in connection with the Asset Acquisition and the PIPE. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Certificate of Designation, holders of Series A Preferred Stock are entitled to receive dividends on shares of Series A Preferred Stock equal to, on an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">as-if-converted-to-common-stock</div></div></div></div> basis, and in the same form as, dividends actually paid on shares of the Company&#8217;s common stock. Except as provided in the Certificate of Designation or as otherwise required by law, the Series A Preferred Stock does not have voting rights. However, as long as any shares of Series A Preferred Stock are outstanding, the Company will not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series A Preferred Stock: (a)&#160;alter or change adversely the powers, preferences or rights given to the Series A Preferred Stock, or alter or amend the Certificate of Designation, amend or repeal any provision of, or add any provision to, the Company&#8217;s Certificate of Incorporation or its Bylaws, or file any articles of amendment, certificate of designations, preferences, limitations and relative rights of any series of Preferred Stock, if such action would adversely alter or change the preferences, rights, privileges or powers of, or restrictions provided for the benefit of the Series A Preferred Stock, regardless of whether any of the foregoing actions will be by means of amendment to the Certificate of Incorporation or by merger, consolidation, recapitalization, reclassification, conversion or otherwise, (b)&#160;issue further shares of Series A Preferred Stock or increase or decrease (other than by conversion) the number of authorized shares of Series A Preferred Stock, (c)&#160;prior to the stockholder approval of the conversion of the Series A Preferred Stock into shares of Common Stock in accordance with Nasdaq Stock </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-59</ix:exclude> </div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_95764037" continuedAt="TextSelectionAppend_95764037_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_95764037_1" continuedAt="TextSelectionAppend_95764037_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_95764037_2" continuedAt="TextSelectionAppend_95764037_3"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_95764037_3"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Market Rules (the &#8220;Conversion Proposal&#8221;) or at any time while at least <ix:nonFraction name="agle:PreferredStockRemainsIssuedAndOutstandingPercentage" contextRef="PAsOn06_22_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">30</ix:nonFraction>% of the originally issued Series A Preferred Stock remains issued and outstanding, consummate (x)&#160;any Fundamental Transaction (as defined in the Certificate of Designation) or (y)&#160;any merger or consolidation of the Company with or into another entity or any stock sale to, or other business combination in which our stockholders immediately before such transaction do not hold at least a majority of our capital stock immediately after such transaction or (d)&#160;enter into any agreement with respect to any of the foregoing. The Series A Preferred Stock does not have a preference upon any liquidation, dissolution or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">winding-up</div> of the Company. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has agreed to hold a stockholders&#8217; meeting to submit the following matters to its stockholders for their consideration: (i)&#160;the approval of the Conversion Proposal, and (ii)&#160;if deemed necessary or appropriate by the Company or as otherwise required by law or contract, the approval of an amendment to the Certificate of Incorporation to authorize sufficient shares of common stock for the conversion of the Series A Preferred Stock issued pursuant to the Acquisition Agreement. In connection with these matters, the Company filed with the SEC a definitive proxy statement and other relevant materials. The stockholder meeting has not occurred as of September&#160;30, 2023. The Series A Preferred Stock is recorded outside of stockholders&#8217; (deficit) equity because, if conversion to common stock is not approved by the stockholders, the Series A Preferred Stock will be redeemable at the option of the holders for cash equal to the closing price of the common stock per share of common stock underlying the Series A Preferred Stock, on the last trading day prior to the holder&#8217;s redemption request. As of September&#160;30, 2023, the redemption value of the Company&#8217;s outstanding Series A Preferred Stock was $<ix:nonFraction name="us-gaap:PreferredStockRedemptionAmount" contextRef="PAsOn09_30_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">532.3</ix:nonFraction>&#160;million based on the closing stock price of the Company&#8217;s common stock on September&#160;30, 2023 of $<ix:nonFraction name="us-gaap:PreferredStockRedemptionPricePerShare" contextRef="PAsOn09_30_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">12.25</ix:nonFraction> per share. The Company has determined that the conversion and redemption features of the Series A Preferred Stock do not require bifurcation as derivatives. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following stockholder approval of the Conversion Proposal, each share of Series A Preferred Stock will automatically convert into <ix:nonFraction name="us-gaap:PreferredStockConvertibleConversionRatio" contextRef="PAsOn06_22_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_pure" decimals="0" scale="0" format="ixt:num-dot-decimal">40</ix:nonFraction> shares of common stock, subject to certain limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series A Preferred Stock into shares of common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (established by the holder between <ix:nonFraction name="agle:BeneficiallyHoldersOwnedPercentage" contextRef="P06_22_2023To06_22_2023_MinimumMembersrtRangeAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">0</ix:nonFraction>% and <ix:nonFraction name="agle:BeneficiallyHoldersOwnedPercentage" contextRef="P06_22_2023To06_22_2023_MaximumMembersrtRangeAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">19.99</ix:nonFraction>%) of the total number of shares of common stock issued and outstanding immediately after giving effect to such conversion. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;26, 2023, the Company completed a private placement of <ix:nonFraction name="agle:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" contextRef="P06_26_2023To06_26_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">721,452</ix:nonFraction> shares of Series A Preferred Stock in exchange for gross proceeds of $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="P06_26_2023To06_26_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">210.0</ix:nonFraction>&#160;million, or net proceeds of $<ix:nonFraction name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" contextRef="P06_26_2023To06_26_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">197.3</ix:nonFraction>&#160;million, after deducting placement agent and other offering costs. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&#160;7, 2023, the Company issued <ix:nonFraction name="agle:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares" contextRef="P07_07_2023To07_07_2023_AssetAcquisitionMemberusgaapBusinessAcquisitionAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">364,887</ix:nonFraction> shares of Series A Preferred Stock as part of its consideration transferred in connection with the Asset Acquisition that closed on June&#160;22, 2023 which settled the related forward contract liability. For additional information, see Note 3. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&#160;27, 2023, the Company filed a definitive proxy statement with the SEC to solicit approval of the Conversion Proposal, among other matters, at a special meeting of stockholders to be held on November&#160;21, 2023. </div></ix:continuation><ix:nonNumeric name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" contextRef="P01_01_2023To09_30_2023" escape="true" continuedAt="TextSelection_95764053"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">10. Liabilities, Convertible Preferred Stock and Stockholders&#8217; (Deficit) Equity </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Registered Direct Offering </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May 2022, the Company issued and sold <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P05_01_2022To05_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">430,107</ix:nonFraction> shares of common stock at an offering price of $<ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="PAsOn05_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">40.00</ix:nonFraction> per share and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants to purchase up to <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn05_31_2022" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">694,892</ix:nonFraction> shares of common stock at an offering price of $<ix:nonFraction name="agle:ClassOfWarrantOrRightOfferingPriceOfWarrantsOrRights" contextRef="PAsOn05_31_2022" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal">39.9975</ix:nonFraction> per warrant (representing the price per share of common stock sold in the offering minus the $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn05_31_2022" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal">0.0025</ix:nonFraction> exercise price per warrant) in a registered direct offering pursuant to a shelf registration statement on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-3.</div> The net proceeds to the Company from this offering were approximately $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="P05_01_2022To05_31_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">42.9</ix:nonFraction>&#160;million, after deducting placement agent fees and offering costs of $<ix:nonFraction name="agle:PlacementAgentFeesAndOfferingCosts" contextRef="P05_01_2022To05_31_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.1</ix:nonFraction>&#160;million. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-60</ix:exclude> </div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_95764053" continuedAt="TextSelectionAppend_95764053_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_95764053_1" continuedAt="TextSelectionAppend_95764053_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_95764053_2" continuedAt="TextSelectionAppend_95764053_3"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_95764053_3" continuedAt="TextSelectionAppend_95764053_4"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Funded</div> Warrants </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2019, April 2020 and May 2022, the Company issued <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants to purchase the Company&#8217;s common stock in underwritten public offerings at the offering price of the common stock, less the $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn05_31_2022" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal">0.0025</ix:nonFraction> per share exercise price of each warrant. The warrants were recorded as a component of stockholders&#8217; (deficit) equity within additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital and have no expiration date. Per the terms of the warrant agreements, the outstanding warrants to purchase shares of common stock may not be exercised if the holder&#8217;s ownership of the Company&#8217;s common stock would exceed <ix:nonFraction name="agle:OwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercised" contextRef="P02_01_2019To05_31_2022" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">4.99</ix:nonFraction>% (&#8220;Maximum Ownership Percentage&#8221;), or <ix:nonFraction name="agle:OwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercisedToCertainHolders" contextRef="P02_01_2019To05_31_2022" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">9.99</ix:nonFraction>% for certain holders. By written notice to the Company, each holder may increase or decrease the Maximum Ownership Percentage to any other percentage (not in excess of <ix:nonFraction name="agle:OwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercised" contextRef="P02_01_2019To05_31_2022_MaximumMembersrtRangeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">19.99</ix:nonFraction>% for the majority of such warrants). The revised Maximum Ownership Percentage would be effective <ix:nonNumeric name="agle:ClassOfWarrantOrRightRevisedOwnershipPercentagePeriodToTakeEffectAfterNotice" contextRef="P02_01_2019To05_31_2022" format="ixt-sec:durday">61</ix:nonNumeric> days after the notice is received by the Company. </div><ix:nonNumeric name="us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" contextRef="P01_01_2023To09_30_2023" escape="true"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of September&#160;30, 2023, the following <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants for common stock were issued and outstanding: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:48%"></td>
<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">Issue Date</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Expiration&#160;Date</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Exercise&#160;Price</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Number&#160;of&#160;Warrants<br/> Outstanding</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">February&#160;8, 2019</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">None</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn09_30_2023_FebruaryEightTwoThousandNinteenMemberusgaapAwardDateAxis_WarrantMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal">0.0025</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn09_30_2023_FebruaryEightTwoThousandNinteenMemberusgaapAwardDateAxis_WarrantMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">April&#160;30, 2020</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">None</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn09_30_2023_AprilThirtyTwoThousandTwentyMemberusgaapAwardDateAxis_WarrantMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal">0.0025</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn09_30_2023_AprilThirtyTwoThousandTwentyMemberusgaapAwardDateAxis_WarrantMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">May&#160;20, 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">None</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn09_30_2023_MayTwentyTwoThousandTwentyTwoMemberusgaapAwardDateAxis_WarrantMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal">0.0025</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn09_30_2023_MayTwentyTwoThousandTwentyTwoMemberusgaapAwardDateAxis_WarrantMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">250,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn09_30_2023_WarrantMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">250,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stock-Based Compensation </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2016 Equity Incentive Plan </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2016 Equity Incentive Plan (&#8220;2016 Plan&#8221;) provides for an automatic increase in the number of shares reserved for issuance thereunder on January&#160;<div style="display:inline;">1</div> of each year for the remaining term of the plan (through 2028) equal to (a) <ix:nonFraction name="agle:AnnualPercentageOfAdditionalSharesWhichEqualsToIssuedAndOutstandingShares" contextRef="P01_01_2016To12_31_2016_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">4.0</ix:nonFraction>% of the number of issued and outstanding shares of common stock on December&#160;31 of the immediately preceding year, or (b)&#160;a lesser amount as approved by the Board each year. As a result of this provision, on January&#160;1, 2023 and January&#160;1, 2022, an additional <ix:nonFraction name="agle:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant" contextRef="PAsOn01_01_2023_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">104,560</ix:nonFraction> and <ix:nonFraction name="agle:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant" contextRef="PAsOn01_01_2022_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">78,968</ix:nonFraction> shares, respectively, became available for issuance under the 2016 Plan. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July 2020, the Company granted <div style="display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="P07_01_2020To07_31_2020_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">9,128</ix:nonFraction></div> restricted stock units (&#8220;RSUs&#8221;) to certain employees, with vesting terms subject to regulatory, commercial, and clinical milestones, in addition to a service condition. As of September&#160;30, 2023, <div style="display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="P07_01_2020To09_30_2023_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen">none</ix:nonFraction></div> of these RSUs had vested and all RSUs were forfeited since the performance milestones were not met within the required time frame. <div style="display:inline;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2023To09_30_2023_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen">No</ix:nonFraction></div> stock-based compensation expense was recognized on these awards. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;22, 2023, concurrent with the closing of the Asset Acquisition, the Board approved an amendment of the 2016 Plan to eliminate the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">per-participant</div> annual award limits originally intended to comply with the qualified performance-based compensation exception set forth in Section&#160;162(m) of the Internal Revenue Code, in light of the repeal of such exception pursuant to the Tax Cuts and Jobs Act of 2017. In addition, the Company approved <div style="display:inline;"><ix:nonFraction name="agle:StockOptionsGrantedToCertainMembersOfBoardOfDirectorsContingentOnStockholderApproval" contextRef="P06_22_2023To06_22_2023_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">2,720,033</ix:nonFraction></div> options contingent on stockholder approval to certain members of the Board, legacy Aeglea employees and consultants under the 2016 Plan. These awards are in excess of the shares available for issuance under the 2016 Plan and require stockholder approval before being granted. Accordingly, <div style="display:inline;"><ix:nonFraction name="agle:StockBasedCompensationExpenseOnContingentAwards" contextRef="PAsOn06_22_2023_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></div> expense has been recognized on these contingent awards since they are contingent on stockholder approval. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of September&#160;30, 2023, the 2016 Plan had <div style="display:inline;"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn09_30_2023_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">293,497</ix:nonFraction></div> shares available for future issuance. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-61</ix:exclude> </div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_95764053_4" continuedAt="TextSelectionAppend_95764053_5"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_95764053_5" continuedAt="TextSelectionAppend_95764053_6"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_95764053_6" continuedAt="TextSelectionAppend_95764053_7"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_95764053_7" continuedAt="TextSelectionAppend_95764053_8"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2018 Equity Inducement Plan </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the nine months ended September&#160;30, 2023, the Board approved an increase of <div style="display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" contextRef="P01_01_2023To09_30_2023_TwoThousandAndEighteenEquityInducementPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">2,800,000</ix:nonFraction></div> in the number of shares reserved for issuance to the 2018 Equity Inducement Plan and granted <div style="display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="P01_01_2023To09_30_2023_TwoThousandAndEighteenEquityInducementPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">3,583,880</ix:nonFraction></div> inducement awards to new hires. The grant-date fair value of these inducement awards will be recognized as expense on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pro-rata</div> basis over the vesting period. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The awards have an exercise price equal to the grant date closing price of the Company&#8217;s common stock, vest ratably over <div style="display:inline;"><ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="P01_01_2023To09_30_2023_TwoThousandAndEighteenEquityInducementPlanMemberusgaapPlanNameAxis" format="ixt-sec:durwordsen">four years</ix:nonNumeric></div>, and have a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="display:inline;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" contextRef="P01_01_2023To09_30_2023_TwoThousandAndEighteenEquityInducementPlanMemberusgaapPlanNameAxis" format="ixt-sec:durwordsen">ten-year</ix:nonNumeric></div></div> exercise period from the grant date. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Spyre 2023 Equity Incentive Plan </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;22, 2023, in connection with the Asset Acquisition, the Company assumed the Amended and Restated Spyre 2023 Equity Incentive Plan (the &#8220;Spyre Equity Plan&#8221;) and its outstanding and unexercised stock options, which were converted to options to purchase <div style="display:inline;"><ix:nonFraction name="agle:OutstandingAndUnexercisedStockOptions" contextRef="P06_22_2023To06_22_2023_AssetAcquisitionMemberusgaapAssetAcquisitionAxis_Spyre2023EquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">2,734</ix:nonFraction></div> shares of Aeglea common stock. The acquisition-date fair value of these grants will be recognized as an expense on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pro-rata</div> basis over the vesting period. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Parapyre Option Obligation </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;22, 2023, in connection with the Asset Acquisition, the Company assumed the Parapyre Option Obligation which provided for an annual equity grant of options to purchase <ix:nonFraction name="agle:AnnualPercentageOfAdditionalSharesWhichEqualsToIssuedAndOutstandingShares" contextRef="P06_22_2023To06_22_2023_ParapyreOptionObligationMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">1</ix:nonFraction>% of the then outstanding shares of Spyre&#8217;s common stock, on a fully diluted basis, on the last business day of each calendar year during the term of the Paragon Agreement, at the fair market value determined by the board of directors of Spyre. As a result of the Asset Acquisition the Parapyre Option Obligation shall continue and Parapyre shall be entitled to receive the equivalent shares of the Company with the same terms. As of September&#160;30, 2023, the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pro-rated</div> estimated fair value of the options to be granted on December&#160;31, 2023, was approximately $<ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="P12_31_2023To12_31_2023_ParapyreOptionObligationMemberusgaapPlanNameAxis_ScenarioForecastMembersrtStatementScenarioAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">3.0</ix:nonFraction>&#160;million, of which $<ix:nonFraction name="us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration" contextRef="P06_22_2023To06_22_2023_ParapyreOptionObligationMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.1</ix:nonFraction>&#160;million was recognized as part of the liabilities assumed with the Asset Acquisition. For the three and nine months ended September&#160;30, 2023, $<ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P07_01_2023To09_30_2023_ParapyreOptionObligationMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.7</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2023To09_30_2023_ParapyreOptionObligationMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.9</ix:nonFraction>&#160;million, respectively, was recognized as stock compensation expense related to the Parapyre Option Obligation. As of September&#160;30, 2023, the unamortized expense related to the Parapyre Option Obligation was $<ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="PAsOn09_30_2023_ParapyreOptionObligationMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.1</ix:nonFraction>&#160;million. </div><ix:nonNumeric name="us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock" contextRef="P01_01_2023To09_30_2023" escape="true"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the Company&#8217;s stock awards granted under all plans for each of the periods indicated: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:34%"></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Three Months Ended September&#160;30,</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Nine Months Ended September&#160;30,</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">2023</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">2022</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">2023</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">2022</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Grants</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Weighted<br/> Average<br/> Grant<br/> Date Fair<br/> Value</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Grants</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Weighted<br/> Average<br/> Grant<br/> Date Fair<br/> Value</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Grants</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Weighted<br/> Average<br/> Grant<br/> Date Fair<br/> Value</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Grants</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Weighted<br/> Average<br/> Grant<br/> Date Fair<br/> Value</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock options</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="P07_01_2023To09_30_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">1,044,667</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="P07_01_2023To09_30_2023" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">14.50</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="P07_01_2022To09_30_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">50,806</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="P07_01_2022To09_30_2022" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">16.75</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">3,867,366</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">9.65</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">153,686</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">52.50</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table></ix:nonNumeric><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2016 Employee Stock Purchase Plan </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Company&#8217;s 2016 Employee Stock Purchase Plan (&#8220;2016 ESPP&#8221;), the Company issued and sold <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" contextRef="P01_01_2023To09_30_2023_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">2,496</ix:nonFraction> shares for aggregate cash proceeds of less than $<ix:nonFraction name="us-gaap:ProceedsFromStockPlans" contextRef="P01_01_2023To09_30_2023_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.1</ix:nonFraction>&#160;million during the nine months ended September&#160;30, 2023. There were <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" contextRef="P01_01_2022To09_30_2022_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">6,073</ix:nonFraction> shares issued and sold under the 2016 ESPP for aggregate cash proceeds of $<ix:nonFraction name="us-gaap:ProceedsFromStockPlans" contextRef="P01_01_2022To09_30_2022_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.2</ix:nonFraction>&#160;million during the nine months ended September&#160;30, 2022. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-62</ix:exclude> </div></ix:continuation></div></div></div><ix:continuation id="TextSelectionAppend_95764053_8" continuedAt="TextSelectionAppend_95764053_9"><div></div></ix:continuation></div><ix:continuation id="TextSelectionAppend_95764053_9" continuedAt="TextSelectionAppend_95764053_10"><div><div style="line-height:normal;background-color:white;display: inline;"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></div></div></ix:continuation></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_95764053_10"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stock-based Compensation Expense </div></div></div><ix:nonNumeric name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" contextRef="P01_01_2023To09_30_2023" escape="true"><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Total stock-based compensation expense related to all plans was as follows (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:64%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Three&#160;Months&#160;Ended<br/> September&#160;30,</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Nine Months Ended<br/> September&#160;30,</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">2023</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">2022</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">2023</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">2022</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development <div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">(1)</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P07_01_2023To09_30_2023_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,965</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P07_01_2022To09_30_2022_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">639</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2023To09_30_2023_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,136</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2022To09_30_2022_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,031</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">General and administrative</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P07_01_2023To09_30_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,820</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P07_01_2022To09_30_2022_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">926</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2023To09_30_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,269</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2022To09_30_2022_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,653</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total stock-based compensation expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P07_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,785</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P07_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,565</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,405</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,684</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">(1)</div>&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">For the three and nine months ended September&#160;30, 2023, $<ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P07_01_2023To09_30_2023_ParapyreOptionObligationMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.7</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2023To09_30_2023_ParapyreOptionObligationMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.9</ix:nonFraction>&#160;million, respectively, was recognized as stock compensation expense related to the Parapyre Option Obligation. There were <ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2022To09_30_2022_ParapyreOptionObligationMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P07_01_2022To09_30_2022_ParapyreOptionObligationMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> such expenses for the three and nine months ended September&#160;30, 2022. </div></td></tr></table></ix:nonNumeric><ix:nonNumeric name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" contextRef="P01_01_2023To09_30_2023" escape="true"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the weighted-average Black-Scholes option pricing model assumptions used to estimate the fair value of stock options granted under the Company&#8217;s 2016 Plan, and the shares purchasable under the 2016 ESPP during the periods presented: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:67%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Three&#160;Months&#160;Ended<br/> September&#160;30,</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Nine&#160;Months&#160;Ended<br/> September&#160;30,</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">2023</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">2022</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">2023</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">2022</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2016 Plan</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected term (in years)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P07_01_2023To09_30_2023_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis" format="ixt-sec:duryear">6.08</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P07_01_2022To09_30_2022_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis" format="ixt-sec:duryear">6.02</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2023To09_30_2023_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis" format="ixt-sec:duryear">6.04</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2022To09_30_2022_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis" format="ixt-sec:duryear">5.96</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected volatility</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P07_01_2023To09_30_2023_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">101</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P07_01_2022To09_30_2022_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">85</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P01_01_2023To09_30_2023_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">111</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P01_01_2022To09_30_2022_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">83</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Risk-free interest</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P07_01_2023To09_30_2023_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">4.28</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P07_01_2022To09_30_2022_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">3.16</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2023To09_30_2023_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">4.07</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2022To09_30_2022_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">2.43</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Dividend yield</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P07_01_2023To09_30_2023_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="0" scale="-2" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P07_01_2022To09_30_2022_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="0" scale="-2" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P01_01_2023To09_30_2023_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="0" scale="-2" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P01_01_2022To09_30_2022_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="0" scale="-2" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2016 ESPP</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected term (in years)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P07_01_2023To09_30_2023_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" format="ixt-sec:duryear">0.50</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P07_01_2022To09_30_2022_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" format="ixt-sec:duryear">0.50</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2023To09_30_2023_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" format="ixt-sec:duryear">0.49</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2022To09_30_2022_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" format="ixt-sec:duryear">0.49</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected volatility</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P07_01_2023To09_30_2023_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">222</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P07_01_2022To09_30_2022_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">95</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P01_01_2023To09_30_2023_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">181</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P01_01_2022To09_30_2022_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">84</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Risk-free interest</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P07_01_2023To09_30_2023_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">5.29</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P07_01_2022To09_30_2022_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">3.26</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2023To09_30_2023_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">4.99</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2022To09_30_2022_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">1.95</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Dividend yield</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P07_01_2023To09_30_2023_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="0" scale="-2" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P07_01_2022To09_30_2022_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="0" scale="-2" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P01_01_2023To09_30_2023_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="0" scale="-2" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P01_01_2022To09_30_2022_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="0" scale="-2" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table></ix:nonNumeric></ix:continuation><ix:nonNumeric name="agle:StrategicLicenseAgreementTextBlock" contextRef="P01_01_2023To09_30_2023" escape="true" continuedAt="TextSelection_95763844"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">11. Strategic License Agreements </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&#160;21, 2021, the Company entered into an exclusive license and supply agreement with Immedica (the &#8220;Immedica Agreement&#8221;). By entering into this agreement, the Company agreed to provide Immedica the following goods and services: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">i.</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Deliver an exclusive, sublicensable, license and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> (the &#8220;License&#8221;) to develop and commercialize pegzilarginase (the &#8220;Product&#8221;) in the territory comprising the members states of the European Economic Area (&#8220;EEA&#8221;), United Kingdom (&#8220;UK&#8221;), Switzerland, Andorra, Monaco, San Marino, Vatican City, Turkey, Saudi Arabia, United Arab Emirates, Qatar, Kuwait, Bahrain, and Oman (the &#8220;Territory&#8221;); </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">ii.</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Complete the global pivotal PEACE (Pegzilarginase Effect on Arginase 1 Deficiency Clinical Endpoints) Phase 3 trial (&#8220;PEACE Trial&#8221;) and related Biologics License Application (&#8220;BLA&#8221;) package to file with the FDA, which will be leveraged by Immedica in obtaining the necessary regulatory approvals in the Territory; and </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">iii.</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Perform a Pediatric Investigation Plan trial (&#8220;PIP Trial&#8221;) in order for Immedica to be able to receive certain regulatory approvals within the Territory. </div></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the Company and Immedica formed a Joint Steering Committee (&#8220;JSC&#8221;) to provide oversight to the activities performed under the agreement; however, the substance of the Company&#8217;s participation in the JSC </div><ix:exclude><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-63 </div></ix:exclude></ix:nonNumeric></div></div><ix:continuation id="TextSelection_95763844" continuedAt="TextSelectionAppend_95763844_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_95763844_1" continuedAt="TextSelectionAppend_95763844_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_95763844_2" continuedAt="TextSelectionAppend_95763844_3"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_95763844_3" continuedAt="TextSelectionAppend_95763844_4"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">did not represent an additional promised service, but rather, a right of the Company to protect its own interests in the arrangement. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, the Company agreed to supply to Immedica, and Immedica agreed to purchase from the Company, substantially all commercial requirements of the Product. The terms of the agreement did not provide for either (i)&#160;an option to Immedica to purchase the Product from the Company at a discount from the standalone selling price or (ii)&#160;minimum purchase quantities. Immedica was expected to bear (i)&#160;all costs and expenses for any development or commercialization of the Product in the Territory subject to the License exclusive of the Company&#8217;s promised goods and services summarized above and (ii)&#160;all costs and fees associated with applying for regulatory approval of the Product in the Territory. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company received a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-refundable</div> payment of $<ix:nonFraction name="agle:NonRefundablePaymentReceived" contextRef="P03_21_2021To03_21_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">21.5</ix:nonFraction>&#160;million and Immedica agreed to provide payment of <ix:nonFraction name="agle:PercentageOfPaymentForCostIncurredInPIPTrial" contextRef="P03_21_2021To03_21_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">50</ix:nonFraction>% of the Company&#8217;s costs incurred in performing the PIP Trial up to a maximum of $<ix:nonFraction name="agle:CostsIncurredInPerformingTheTrial" contextRef="P03_21_2021To03_21_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_MaximumMembersrtRangeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.8</ix:nonFraction>&#160;million. In addition, the Company had the ability to receive regulatory and commercial milestone payments. The Company was also entitled to receive royalties in the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mid-20%</div> range on net sales of the Product in the Territory. In July 2021, the Company modified the agreement with Immedica to provide certain additional services in relation to the PEACE Trial and BLA package performance obligation in exchange for the reimbursement of up to $<ix:nonFraction name="us-gaap:ReimbursementFromLimitedPartnershipInvestment" contextRef="P07_01_2021To07_31_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">3.0</ix:nonFraction>&#160;million of the actual costs incurred in relation to such incremental services. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company concluded that Immedica met the definition to be accounted for as a customer because the Company was delivering intellectual property and other services within the Company&#8217;s normal course of business, in which the parties are not jointly sharing the risks and rewards. Therefore, the Company concluded that the promises summarized above represent transactions with a customer within the scope of ASC 606. The Company determined that the following promises represent distinct promised services, and therefore, performance obligations: (i)&#160;the License, (ii)&#160;the PEACE Trial and BLA package, and (iii)&#160;the PIP Trial. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Specifically, in making these determinations, the Company considered the following factors: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">As of inception of the agreement, the Company had completed the Phase 1/2 clinical trial related to the Product and was conducting the PEACE Trial. Accordingly, the Company was not promising, nor expecting, to perform additional research and development activities pursuant to the agreement that would either significantly modify, customize or be considered highly interdependent or interrelated with pegzilarginase. </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">The License represented functional intellectual property given the functionality of the License was not expected to change substantially as a result of the company&#8217;s ongoing activities. </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">The services necessary to complete the PEACE Trial, BLA package and PIP Trial could have been performed by other parties. </div></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Given that Immedica was not obligated to purchase any minimum amount or quantities of Product, the supply of Product for commercial use to Immedica was determined to be an option for Immedica, rather than a performance obligation of the Company at contract inception and will be accounted for if and when exercised. The Company also determined that Immedica&#8217;s option to purchase the Product did not create a material right as the expected pricing is not at a discount. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company determined that the upfront fixed payment amount of $<ix:nonFraction name="agle:UpfrontPayment" contextRef="P03_21_2021To03_21_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">21.5</ix:nonFraction>&#160;million should be included in the transaction price. Additionally, the Company determined at inception of the arrangement that <ix:nonFraction name="agle:PercentageOfPaymentForCostIncurredInPIPTrial" contextRef="P03_21_2021To03_21_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">50</ix:nonFraction>% of the probable estimated costs to be incurred in relation to the PIP Trial exceeded $<ix:nonFraction name="agle:CostsIncurredInPerformingTheTrial" contextRef="P03_21_2021To03_21_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_MaximumMembersrtRangeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.8</ix:nonFraction>&#160;million and included the full reimbursement amount of $<ix:nonFraction name="agle:ContractWithCustomerFullReimbursementOfCostsIncludedLiability" contextRef="PAsOn03_21_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_LicenseMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.8</ix:nonFraction>&#160;million in the transaction price. Upon subsequent <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-evaluation</div> due to changing facts and circumstances, the Company determined the probable estimated costs were less than the maximum allowable reimbursement and a portion of the variable consideration was constrained, which did not materially impact the revenue recognized as of September&#160;30, 2023. Additionally, upon the modification of the agreement </div><ix:exclude><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-64 </div></ix:exclude></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_95763844_4" continuedAt="TextSelectionAppend_95763844_5"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_95763844_5" continuedAt="TextSelectionAppend_95763844_6"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_95763844_6" continuedAt="TextSelectionAppend_95763844_7"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_95763844_7" continuedAt="TextSelectionAppend_95763844_8"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">in July 2021, the Company determined that the probable estimated costs to perform the additional services related to the PEACE Trial and BLA package exceeded the maximum allowable reimbursement of $<ix:nonFraction name="us-gaap:ReimbursementFromLimitedPartnershipInvestment" contextRef="P07_01_2021To07_31_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">3.0</ix:nonFraction>&#160;million. Therefore, the Company included an estimated total of $<ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" contextRef="P07_01_2021To07_31_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">3.6</ix:nonFraction>&#160;million that was due in relation to the PIP Trial, PEACE Trial, and BLA package in the transaction price and concluded that it is probable that a significant reversal will not occur in the future. In total, the modified transaction price was determined to be $<ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="P07_01_2021To07_31_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">25.1</ix:nonFraction>&#160;million. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company allocated $<ix:nonFraction name="agle:AllocatedAmountOfTransactionPrice" contextRef="P07_01_2021To07_31_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_PeaceTrialAndBLAPackageMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">9.6</ix:nonFraction>&#160;million and $<ix:nonFraction name="agle:AllocatedAmountOfTransactionPrice" contextRef="P07_01_2021To07_31_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_PIPTrialMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">3.5</ix:nonFraction>&#160;million of the modified transaction price to the PEACE Trial and BLA package and PIP Trial performance obligations, respectively, based on the stand-alone selling prices (&#8220;SSP&#8221;), which were based on the estimated costs that a third-party would charge in performing such services on a stand-alone basis. The SSP for the License was established at inception of the arrangement using a residual value approach due to the uniqueness of and lack of observable data related to the License, and without a specific analog from which to make reliable estimates, resulting in an allocation of $<ix:nonFraction name="agle:AllocationPriceTotal" contextRef="P07_01_2021To07_31_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">12.0</ix:nonFraction>&#160;million. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The potential regulatory milestone payments that the Company was eligible to receive were excluded from the transaction price, as the milestone amounts were fully constrained based on the probability of achievement, since the milestones related to successful achievement of certain regulatory approvals, which might not have been achieved. The Company determined that the royalties and commercial milestone payments related predominantly to the license of intellectual property and therefore should be excluded from the transaction price under the sales- or usage-based royalty exception under ASC 606. The Company intends to reevaluate the transaction price, including all constrained amounts, at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur, the Company intends to adjust its estimate of the transaction price as necessary. The Company recognized the royalties and commercial milestone payments as revenue when the associated sales occurred, and relevant sales-based thresholds were met. The Company also assessed the arrangement with Immedica and concluded that a significant financing component does not exist. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognized revenue allocated to the License performance obligation at a point in time and upon transfer of the License. The Company completed the transfer of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> necessary for Immedica to benefit from the License in September 2021 and recognized $<ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P09_01_2021To09_30_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_LicenseAgreementsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">12.0</ix:nonFraction>&#160;million of revenue at that time. The development fee allocated to the PEACE Trial, BLA package and PIP Trial performance obligations is recognized over time using an input method of costs incurred related to the performance obligations. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognized revenue of $<ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2023To09_30_2023_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_PeacePhase3TrialAndDrugSupplyMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.9</ix:nonFraction>&#160;million under the Immedica Agreement for the nine months ended September&#160;30, 2023. There was <ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P07_01_2023To09_30_2023_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_PeacePhase3TrialAndDrugSupplyMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction> such revenue for the three months ended September&#160;30, 2023. The total revenue generated in the nine months ended September&#160;30, 2023 was attributable to the PEACE Phase 3 and PIP trials, drug supply, and royalties from an early access program in France. For the three and nine months ended September&#160;30, 2022, the Company recognized revenue of $<ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P07_01_2022To09_30_2022_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_PeaceTrialAndBLAPackageMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.2</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To09_30_2022_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_PeaceTrialAndBLAPackageMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.2</ix:nonFraction>&#160;million, respectively, related to the PEACE Trial and BLA package performance obligation. As of December&#160;31, 2022, the Company recorded deferred revenue of $<ix:nonFraction name="us-gaap:ContractWithCustomerLiability" contextRef="PAsOn12_31_2022_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">3.6</ix:nonFraction>&#160;million associated with the Immedica Agreement, of which $<ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="PAsOn12_31_2022_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.4</ix:nonFraction>&#160;million was classified as current. There was <ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="PAsOn09_30_2023_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction> such revenue associated with the Immedica Agreement as of September&#160;30, 2023. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&#160;27, 2023, the Company announced that it had entered into an agreement to sell the global rights to pegzilarginase to Immedica and concurrently terminated the Immedica Agreement. Remaining deferred revenue was recognized as part of the gain on disposal of the assets. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Contract Balances from Customer Contract </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The timing of revenue recognition, billings and cash collections results in contract assets and contract liabilities on the Company&#8217;s balance sheets. The Company recognizes license and development receivables based on billed services, which are derecognized upon reimbursement. When consideration is received, or such consideration is unconditionally due, from a customer prior to transferring goods or services to the customer under the terms of a contract, a contract liability is recorded. Contract liabilities are recognized as revenue after control of the goods or services is transferred to the customer and all revenue recognition criteria have been met. </div><ix:exclude><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-65 </div></ix:exclude></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_95763844_8" continuedAt="TextSelectionAppend_95763844_9"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_95763844_9" continuedAt="TextSelectionAppend_95763844_10"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_95763844_10" continuedAt="TextSelectionAppend_95763844_11"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_95763844_11"><ix:nonNumeric name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" contextRef="P01_01_2023To09_30_2023" escape="true"><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents changes in the Company&#8217;s contract liabilities for the periods presented (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:52%"></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">Nine Months Ended September&#160;30, 2023</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">December&#160;31,<br/> 2022</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Additions</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Deductions</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">September&#160;30,<br/> 2023</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Contract liabilities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred revenue</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ContractWithCustomerLiability" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,696</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="agle:ContractWithCustomerLiabilityAdditions" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">575</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">3,271</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ContractWithCustomerLiability" contextRef="PAsOn09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table></ix:nonNumeric><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company had <ix:nonFraction name="us-gaap:ContractWithCustomerAssetNet" contextRef="PAsOn09_30_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:ContractWithCustomerAssetNet" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> contract assets during the nine months ended September&#160;30, 2023 and 2022. </div></ix:continuation><ix:nonNumeric name="us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" contextRef="P01_01_2023To09_30_2023" escape="true"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">12. Sale of Pegzilarginase to Immedica </div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&#160;27, 2023, the Company announced that it had entered into an agreement to sell the global rights to pegzilarginase, an investigational treatment for the rare metabolic disease Arginase 1 Deficiency, to Immedica for $<ix:nonFraction name="us-gaap:ProceedsFromSaleOfIntangibleAssets" contextRef="P07_27_2023To07_27_2023_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberusgaapDisposalGroupClassificationAxis_GlobalRightsToPegzilarginaseMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">15.0</ix:nonFraction>&#160;million in upfront cash proceeds and up to $<ix:nonFraction name="agle:DisposalGroupIncludingDiscontinuedOperationContingentConsideration" contextRef="PAsOn07_27_2023_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberusgaapDisposalGroupClassificationAxis_GlobalRightsToPegzilarginaseMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">100.0</ix:nonFraction>&#160;million in contingent milestone payments. The sale of pegzilarginase to Immedica superseded and terminated the previous license agreement between the Company and Immedica. On July&#160;27, 2023, the carrying value of the asset was <ix:nonFraction name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation" contextRef="PAsOn07_27_2023_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberusgaapDisposalGroupClassificationAxis_GlobalRightsToPegzilarginaseMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt-sec:numwordsen">zero</ix:nonFraction> as it was internally developed. Accordingly the Company recognized a $<ix:nonFraction name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" contextRef="P07_27_2023To07_27_2023_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberusgaapDisposalGroupClassificationAxis_GlobalRightsToPegzilarginaseMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">14.6</ix:nonFraction>&#160;million gain within operating expenses, which is the full $<ix:nonFraction name="us-gaap:ProceedsFromSaleOfIntangibleAssets" contextRef="P07_27_2023To07_27_2023_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberusgaapDisposalGroupClassificationAxis_GlobalRightsToPegzilarginaseMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">15.0</ix:nonFraction>&#160;million in upfront cash proceeds, net of transaction costs and the derecognition of pegzilarginase related nonfinancial assets and liabilities. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The milestone payments are contingent on formal reimbursement decisions by national authorities in key European markets and pegzilarginase approval by the FDA, among other events. The upfront payment and contingent milestone payments if paid, net of expenses and adjustments, will be distributed to holders of Aeglea&#8217;s CVR pursuant to the CVR Agreement resulting from the Asset Acquisition. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:EarningsPerShareTextBlock" contextRef="P01_01_2023To09_30_2023" escape="true" continuedAt="TextSelection_95764843"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">13. Net Loss Per Share </div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company computes net loss attributable per common stockholder using the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-class</div> method required for participating securities. The Company considers convertible. preferred stock to be participating securities. In the event that the Company paid out distributions, holders of convertible preferred stock would participate in the distribution. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-class</div> method is an earnings (loss) allocation method under which earnings (loss) per share is calculated for common stock and participating security considering a participating security&#8217;s rights to undistributed earnings (loss) as if all such earnings (loss) had been distributed during the period. The holders of Series A Preferred Stock do not have an obligation to fund losses and therefore the Series A Preferred Stock was excluded from the calculation of basic net loss per share. The Company included in the calculation of basic net loss per share, contingently issuable common shares related to the Asset Acquisition because they will be issued for no consideration due to the consideration already having been satisfied as of September&#160;30, 2023. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per share is computed by dividing the net loss by the weighted-average number of common stock and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants outstanding during the period, without consideration of potential dilutive securities. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants are included in the computation of basic net loss per share as the exercise price is negligible and they are fully vested and exercisable. For periods in which the Company generated a net loss, the Company does not include the potential impact of dilutive securities in diluted net loss per share, as the impact of these items is anti-dilutive. The Company has generated a net loss for all periods presented, therefore diluted net loss per share is the same as basic net loss per share since the inclusion of potentially dilutive securities would be anti-dilutive. </div><ix:exclude><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-66 </div></ix:exclude></ix:nonNumeric></div></div><ix:continuation id="TextSelection_95764843" continuedAt="TextSelectionAppend_95764843_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_95764843_1" continuedAt="TextSelectionAppend_95764843_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_95764843_2" continuedAt="TextSelectionAppend_95764843_3"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_95764843_3"><ix:nonNumeric name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" contextRef="P01_01_2023To09_30_2023" escape="true"><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following weighted-average equity instruments were excluded from the calculation of diluted net loss per share because their effect would have been anti-dilutive for the periods presented: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:54%"></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Three Months Ended<br/> September&#160;30,</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Nine Months Ended<br/> September&#160;30,</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">2023</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">2022</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">2023</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">2022</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Options to purchase common stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P07_01_2023To09_30_2023_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">3,135,672</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P07_01_2022To09_30_2022_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">351,533</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2023To09_30_2023_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">1,426,224</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2022To09_30_2022_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">335,395</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unvested restricted stock units</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P07_01_2023To09_30_2023_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P07_01_2022To09_30_2022_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">6,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2023To09_30_2023_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">252</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2022To09_30_2022_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">7,315</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Series A Preferred Stock (on an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">as-converted</div> basis)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P07_01_2023To09_30_2023_SeriesAConvertiblePreferredStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">42,501,681</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P07_01_2022To09_30_2022_SeriesAConvertiblePreferredStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2023To09_30_2023_SeriesAConvertiblePreferredStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">14,851,447</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2022To09_30_2022_SeriesAConvertiblePreferredStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table></ix:nonNumeric></ix:continuation><ix:nonNumeric name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" contextRef="P01_01_2023To09_30_2023" escape="true" continuedAt="TextSelection_95764029"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">14. Restructuring Charges </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Severance and Stock Compensation </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&#160;12, 2023, based on the review of the inconclusive interim results from the Company&#8217;s Phase 1/2 clinical trial of pegtarviliase for the treatment of classical homocystinuria and other business considerations, the Company announced that it had initiated a process to explore strategic alternatives to maximize stockholder value and engaged an independent exclusive financial advisor to support this process. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result, the Company implemented a restructuring plan resulting in an approximate <ix:nonFraction name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" contextRef="P04_01_2023To06_30_2023" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" contextRef="P04_01_2023To04_30_2023" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">83</ix:nonFraction></ix:nonFraction>% reduction of the Company&#8217;s existing headcount by June&#160;30, 2023. The Company recognized restructuring expenses consisting of cash severance payments and other employee-related costs of nil and $<ix:nonFraction name="us-gaap:SeveranceCosts1" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">6.4</ix:nonFraction>&#160;million during the three and nine months ended September&#160;30, 2023, respectively. Cash payments for employee related restructuring charges of $<ix:nonFraction name="us-gaap:PaymentsForRestructuring" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">4.5</ix:nonFraction>&#160;million were paid as of September&#160;30, 2023. In addition, the Company recognized $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.0</ix:nonFraction>&#160;million in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> stock-based compensation expense related to the accelerated vesting of stock-based awards for certain employees. The Company recorded these restructuring charges based on each employee&#8217;s role to the respective research and development and general and administrative operating expense categories on its condensed consolidated statements of operations and comprehensive loss. </div><ix:nonNumeric name="us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock" contextRef="P01_01_2023To09_30_2023" escape="true"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the changes in the Company&#8217;s accrued restructuring balance (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:45%"></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Beginning&#160;Balance<br/> December&#160;31,&#160;2022</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Charges</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Payments</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Ending&#160;Balance<br/> September&#160;30,&#160;2023</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Severance liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RestructuringReserve" contextRef="PAsOn12_31_2022_SeveranceLiabilityMemberusgaapRestructuringCostAndReserveAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RestructuringCharges" contextRef="P01_01_2023To09_30_2023_SeveranceLiabilityMemberusgaapRestructuringCostAndReserveAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,448</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsForRestructuring" contextRef="P01_01_2023To09_30_2023_SeveranceLiabilityMemberusgaapRestructuringCostAndReserveAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,527</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RestructuringReserve" contextRef="PAsOn09_30_2023_SeveranceLiabilityMemberusgaapRestructuringCostAndReserveAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,921</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table></ix:nonNumeric><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Sale of Assets </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the second quarter of 2023, the Company sold various lab equipment, consumables, and furniture and fixtures for total consideration of $<ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration" contextRef="PAsOn06_30_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.5</ix:nonFraction>&#160;million. After recording the disposal of all property and equipment net of proceeds, the Company recorded a $<ix:nonFraction name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="P04_01_2023To06_30_2023_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal">0.7</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="P04_01_2023To06_30_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal">0.2</ix:nonFraction>&#160;million loss on disposal of long lived assets which is included in Research and development and General and administrative expenses, respectively. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Right-of-use</div></div> Asset and Leasehold Improvement Impairment </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Effective June&#160;30, 2023, the Company abandoned its leased office space in Austin, Texas. As a result, the Company recognized an impairment loss of $<ix:nonFraction name="us-gaap:OperatingLeaseImpairmentLoss" contextRef="P04_01_2023To06_30_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.9</ix:nonFraction>&#160;million related to the operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> asset and $<ix:nonFraction name="us-gaap:ImpairmentOfLeasehold" contextRef="P04_01_2023To06_30_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.7</ix:nonFraction>&#160;million related to leasehold improvements. On August&#160;7, 2023, the Company terminated its building lease in Austin, Texas. The negotiated termination agreement obligated the Company to pay the lessor a $<ix:nonFraction name="agle:OperatingLeaseTerminationFeeAmount" contextRef="PAsOn08_07_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.0</ix:nonFraction>&#160;million termination fee in exchange for releasing the Company of all further obligations under the lease. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-67</ix:exclude> </div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_95764029" continuedAt="TextSelectionAppend_95764029_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_95764029_1" continuedAt="TextSelectionAppend_95764029_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_95764029_2" continuedAt="TextSelectionAppend_95764029_3"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_95764029_3"><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All charges related to the restructuring activities were recognized during the second quarter of 2023. No further restructuring charges will be incurred under the restructuring plan. <ix:nonNumeric name="us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock" contextRef="P01_01_2023To09_30_2023" escape="true" continuedAt="TextSelection_95764033">A summary of the charges related to the restructuring activities is as follows (in thousands): </ix:nonNumeric></div><ix:continuation id="TextSelection_95764033"><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:33%"></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Severance&#160;Related<br/> Expenses</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Stock&#160;Compensation<br/> Expenses</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Loss&#160;on&#160;Disposal&#160;of<br/> Long Lived Assets</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Lease&#160;Asset<br/> Impairment</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Total&#160;Restructuring&#160;Costs</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SeveranceCosts1" contextRef="P04_01_2023To06_30_2023_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_RestructuringActivitiesMemberusgaapRestructuringCostAndReserveAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,182</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P04_01_2023To06_30_2023_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_RestructuringActivitiesMemberusgaapRestructuringCostAndReserveAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">123</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="P04_01_2023To06_30_2023_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_RestructuringActivitiesMemberusgaapRestructuringCostAndReserveAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">749</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseImpairmentLoss" contextRef="P04_01_2023To06_30_2023_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_RestructuringActivitiesMemberusgaapRestructuringCostAndReserveAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,405</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RestructuringCosts" contextRef="P04_01_2023To06_30_2023_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_RestructuringActivitiesMemberusgaapRestructuringCostAndReserveAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,459</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">General and administrative</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SeveranceCosts1" contextRef="P04_01_2023To06_30_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_RestructuringActivitiesMemberusgaapRestructuringCostAndReserveAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,266</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P04_01_2023To06_30_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_RestructuringActivitiesMemberusgaapRestructuringCostAndReserveAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">870</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="P04_01_2023To06_30_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_RestructuringActivitiesMemberusgaapRestructuringCostAndReserveAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">182</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseImpairmentLoss" contextRef="P04_01_2023To06_30_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_RestructuringActivitiesMemberusgaapRestructuringCostAndReserveAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,175</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RestructuringCosts" contextRef="P04_01_2023To06_30_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_RestructuringActivitiesMemberusgaapRestructuringCostAndReserveAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,493</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SeveranceCosts1" contextRef="P04_01_2023To06_30_2023_RestructuringActivitiesMemberusgaapRestructuringCostAndReserveAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,448</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P04_01_2023To06_30_2023_RestructuringActivitiesMemberusgaapRestructuringCostAndReserveAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">993</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="P04_01_2023To06_30_2023_RestructuringActivitiesMemberusgaapRestructuringCostAndReserveAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">931</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseImpairmentLoss" contextRef="P04_01_2023To06_30_2023_RestructuringActivitiesMemberusgaapRestructuringCostAndReserveAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,580</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RestructuringCosts" contextRef="P04_01_2023To06_30_2023_RestructuringActivitiesMemberusgaapRestructuringCostAndReserveAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,952</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:continuation></ix:continuation><ix:nonNumeric name="us-gaap:CommitmentsDisclosureTextBlock" contextRef="P01_01_2023To09_30_2023" escape="true" continuedAt="TextSelection_95764036"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">15. Novation of Manufacturing Agreements </div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to a Novation Agreement dated September&#160;19, 2023 (the &#8220;Novation Agreement&#8221;), by and between the Company, Paragon and WuXi Biologics (Hong Kong) Limited (&#8220;WuXi Biologics&#8221;), the Company novated (i)&#160;a Biologics Master Services Agreement (the &#8220;WuXi Biologics MSA&#8221;) and (ii)&#160;a Cell Line License Agreement (the &#8220;Cell Line License Agreement&#8221;). </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Biologics Master Services Agreement </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2023, Paragon and WuXi Biologics entered into the WuXi Biologics MSA, which was subsequently novated to the Company by Paragon on September&#160;19, 2023 pursuant to the Novation Agreement. The WuXi Biologics MSA governs certain development activities and GMP manufacturing and testing for the SPY001 program, as well as potential future programs, on a work order basis. Under the WuXi Biologics MSA, the Company is obligated to pay WuXi Biologics a service fee and all <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cancellable</div> obligations in the amount specified in each work order associated with the agreement for the provision of services. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The WuXi Biologics MSA terminates on the later of (i)&#160;June&#160;20, 2027 or (ii)&#160;the completion of services under all work orders executed by the parties prior to June&#160;20, 2027, unless terminated earlier. The term of each work order terminates upon completion of the services under such work order, unless terminated earlier. The Company can terminate the WuXi Biologics MSA or any work order at any time upon <ix:nonNumeric name="agle:OtherCommitmentRightToTerminateAgreementOrWorkOrderPriorWrittenNoticePeriod" contextRef="P04_01_2023To04_30_2023" format="ixt-sec:durday">30</ix:nonNumeric> days&#8217; prior written notice and immediately upon written notice if WuXi Biologics fails to obtain or maintain required material governmental licenses or approvals. Either party may terminate a work order (i)&#160;at any time upon <ix:nonNumeric name="agle:OtherCommitmentRightToTerminateWorkOrderReasonableCausePriorWrittenNoticePeriod" contextRef="P04_01_2023To04_30_2023" format="ixt-sec:durwordsen">six months</ix:nonNumeric>&#8217; prior notice with reasonable cause, provided however that if WuXi Biologics terminates a work order in such manner, <ix:nonFraction name="agle:OtherCommitmentRightToTerminateWorkOrderByCounterpartyReasonableCauseTerminationAmountPayable" contextRef="PAsOn04_30_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction> termination or cancellation fees shall be paid by the Company and (ii)&#160;immediately for cause upon (a)&#160;the other party&#8217;s material breach that remains uncured for <ix:nonNumeric name="agle:OtherCommitmentRightToTerminateWorkOrderMaterialBreachUncuredPeriod" contextRef="P04_01_2023To04_30_2023" format="ixt-sec:durday">30</ix:nonNumeric> days after notice of such breach, (b)&#160;the other party&#8217;s bankruptcy or (c)&#160;a force majeure event that prevents performance for a period of at least <ix:nonNumeric name="agle:OtherCommitmentRightToTerminateWorkOrderUnusualOrInfrequentCausePeriod" contextRef="P04_01_2023To04_30_2023" format="ixt-sec:durday">90</ix:nonNumeric> days. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cell Line License Agreement </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2023, Paragon and WuXi Biologics entered into the Cell Line License Agreement, which was subsequently novated to the Company by Paragon pursuant to the Novation Agreement. Under the Cell Line License Agreement, the Company received a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-exclusive,</div> worldwide, sublicensable license to certain of WuXi Biologics&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how,</div> cell line, biological materials (the &#8220;WuXi Biologics Licensed Technology&#8221;) and media and feeds to make, have made, use, sell and import certain therapeutic products produced through the use of the cell line licensed by WuXi Biologics under the Cell Line License Agreement (the &#8220;WuXi Biologics Licensed Products&#8221;). Specifically, the WuXi Biologics Licensed Technology is used in certain manufacturing activities in support of the SPY001 program. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In consideration for the license, the Company agreed to pay WuXi Biologics a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-refundable</div> license fee of $<ix:nonFraction name="agle:OtherCommitmentNonRefundableLicenseFeeAmount" contextRef="PAsOn04_30_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.2</ix:nonFraction>&#160;million. Additionally, if the Company manufactures all of its commercial supplies of bulk drug product with a manufacturer other than WuXi Biologics or its affiliates, the Company is required to make royalty payments to WuXi Biologics of less than <ix:nonFraction name="agle:OtherCommitmentRoyaltyPercentage" contextRef="PAsOn04_30_2023" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt-sec:numwordsen">one</ix:nonFraction> percent of global net sales of WuXi Biologics Licensed Products manufactured </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-68</ix:exclude> </div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_95764036" continuedAt="TextSelectionAppend_95764036_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_95764036_1" continuedAt="TextSelectionAppend_95764036_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_95764036_2" continuedAt="TextSelectionAppend_95764036_3"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></div></div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_95764036_3"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">by a third-party manufacturer (the &#8220;Royalty&#8221;). If the Company manufactures part of its commercial supplies of the WuXi Biologics Licensed Products with WuXi Biologics or its affiliates, then the Royalty will be reduced accordingly on a pro rata basis. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Cell Line License Agreement will continue indefinitely unless terminated (i)&#160;by the Company upon <ix:nonNumeric name="agle:OtherCommitmentRightToTerminateAgreementPriorWrittenNoticePeriod" contextRef="P04_01_2023To04_30_2023" format="ixt-sec:durwordsen">six months</ix:nonNumeric>&#8217; prior written notice and our payment of all undisputed <div style="display:inline;">amounts </div>due to WuXi Biologics through the effective date of termination, (ii)&#160;by WuXi Biologics for a material breach by the Company that remains uncured for <ix:nonNumeric name="agle:OtherCommitmentRightToTerminateAgreementByCounterpartyMaterialBreachUncuredPeriod" contextRef="P04_01_2023To04_30_2023" format="ixt-sec:durday">60</ix:nonNumeric> days after written notice, (iii)&#160;by WuXi Biologics if the Company fails to make a payment and such failure continues for <ix:nonNumeric name="agle:OtherCommitmentRightToTerminateAgreementByCounterpartyPaymentsNotReceivedPeriod" contextRef="P04_01_2023To04_30_2023" format="ixt-sec:durday">30</ix:nonNumeric> days after receiving notice of such failure, or (iv)&#160;by either party upon the other party&#8217;s bankruptcy. </div></ix:continuation><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-69 </div></div></div></div></div></div>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">PART II </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">INFORMATION NOT REQUIRED IN PROSPECTUS </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;13.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Other Expenses of Issuance and Distribution </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The expenses payable by us in connection with the issuance and distribution of the securities being registered hereunder on Form <span style="white-space:nowrap">S-1</span> (other than underwriting discounts and commissions, if any) are set forth below. The Selling Stockholders will not bear any portion of such expenses. Each item listed is estimated, except for the SEC registration fee: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">


<tr>

<td style="width:83%"></td>

<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SEC registration fee</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">26,816</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Printing and engraving</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">25,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal fees and expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">50,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounting fees and expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">50,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Miscellaneous expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,184</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">105,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;14.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Indemnification of Officers and Directors </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&#160;145 of the DGCL authorizes a court to award, or a corporation&#8217;s board of directors to grant, indemnity to directors and officers under certain circumstances and subject to certain limitations. The terms of Section&#160;145 of the DGCL are sufficiently broad to permit indemnification under certain circumstances for liabilities, including reimbursement of expenses incurred, arising under the Securities Act. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As permitted by the DGCL, the Registrant&#8217;s Certificate of Incorporation contains provisions that eliminate the personal liability of its directors for monetary damages for any breach of fiduciary duties as a director, except liability for the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any breach of the director&#8217;s duty of loyalty to the Registrant or its stockholders; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">under Section&#160;174 of the DGCL (regarding unlawful dividends and stock purchases); or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any transaction from which the director derived an improper personal benefit. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As permitted by the DGCL, the Registrant&#8217;s Bylaws provide that: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the Registrant is required to indemnify its directors and executive officers to the fullest extent permitted by the DGCL, subject to very limited exceptions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the Registrant may indemnify its other employees and agents as set forth in the DGCL; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the Registrant is required to advance expenses, as incurred, to its directors and executive officers in connection with a legal proceeding to the fullest extent permitted by the DGCL, subject to very limited exceptions; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the rights conferred in the Bylaws are not exclusive. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Registrant has entered, and intends to continue to enter, into separate indemnification agreements with its directors and executive officers to provide these directors and executive officers additional contractual assurances regarding the scope of the indemnification set forth in the Registrant&#8217;s Certificate of Incorporation and Bylaws and to provide additional procedural protections. At present, there is no pending litigation or proceeding involving a director or executive officer of the Registrant regarding which indemnification is sought. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-1 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
The indemnification provisions in the Registrant&#8217;s Certificate of Incorporation, Bylaws and the indemnification agreements entered into or to be entered into between the Registrant and each of its directors and executive officers may be sufficiently broad to permit indemnification of the Registrant&#8217;s directors and executive officers for liabilities arising under the Securities Act. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Registrant currently carries liability insurance for its directors and officers. Two of the Registrant&#8217;s directors, Peter Harwin and Tomas Kiselak, are also indemnified by their employer with regard to their service on the Registrant&#8217;s board of directors. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;15.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Recent Sales of Unregistered Securities </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&#160;22, 2023, we entered into the June 2023 SPA, pursuant to which we sold an aggregate of 721,452 shares of our Series A Preferred Stock, which will automatically convert into 40 shares of Common Stock, subject to stockholder approval and certain beneficial ownership limitations set by each holder, pursuant to the Series A Certificate of Designation, at an aggregate purchase price of approximately $210&#160;million. The shares issued pursuant to the June 2023 SPA were offered and sold in transactions exempt from registration under the Securities Act, in reliance on Section&#160;4(a)(2) thereof and Rule 506 of Regulation D thereunder. Each of the June 2023 Investors represented that it was an &#8220;accredited investor,&#8221;; as defined in Regulation D, and acquired the securities for investment only and not with a view towards, or for resale in connection with, the public sale or distribution thereof. The shares of Series A Preferred Stock issued pursuant to the June 2023 SPA have not been registered under the Securities Act and such securities may not be offered or sold in the United States absent registration or an exemption from registration under the Securities Act and any applicable state securities laws. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Also on June&#160;22, 2023, we completed our acquisition of <span style="white-space:nowrap">Pre-Merger</span> Spyre in accordance with the Acquisition Agreement, pursuant to which we issued an aggregate of 517,809 shares of Common Stock and 364,887 shares of Series A Preferred Stock to certain of the Previous Selling Stockholders. Such issuances were exempt from registration pursuant to Section&#160;4(a)(2) of the Securities Act and Regulation D promulgated thereunder. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&#160;7, 2023, we entered into the December 2023 SPA, pursuant to which we sold an aggregate of 6,000,000 shares of our Common Stock and 150,000 shares of our Series B Preferred Stock, which will automatically convert into 40 shares of Common Stock, subject to stockholder approval and certain beneficial ownership limitations set by each holder, pursuant to the Series B Certificate of Designation, at an aggregate purchase price of $180.0&#160;million. The Private Placement Preferred Shares were offered and sold in transactions exempt from registration under the Securities Act, in reliance on Section&#160;4(a)(2) thereof and Rule 506 of Regulation D thereunder. Each of the December 2023 Investors represented that it was an &#8220;accredited investor,&#8221;; as defined in Regulation D, and acquired the securities for investment only and not with a view towards, or for resale in connection with, the public sale or distribution thereof. The Private Placement Preferred Shares have not been registered under the Securities Act and such securities may not be offered or sold in the United States absent registration or an exemption from registration under the Securities Act and any applicable state securities laws. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;16.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Exhibits and Financial Statement Schedules </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left"><span style="font-weight:bold">(a)</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="font-weight:bold">Exhibits</span> </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:8%"></td>
<td style="width:88%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">EXHIBIT<br />NUMBER</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">DESCRIPTION OF EXHIBIT</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;2.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d518298dex21.htm">Agreement and Plan of Merger, dated June&#160;22, 2023, by and among the Company, Aspen Merger Sub I, Inc., Sequoia Merger Sub II, LLC and Spyre Therapeutics, Inc. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;3.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d518298dex31.htm">Amended and Restated Certificate of Incorporation </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;3.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d518298dex32.htm">Amended and Restated Bylaws </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;3.3</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d518298dex33.htm">Certificate of Designations of Series A <span style="white-space:nowrap">Non-Voting</span> Convertible Preferred Stock </a></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-2 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td style="width:88%"></td></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">EXHIBIT<br />NUMBER</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">DESCRIPTION OF EXHIBIT</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;&#160;&#160;3.4</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d518298dex34.htm">Certificate of Designations of Series B <span style="white-space:nowrap">Non-Voting</span> Convertible Preferred Stock </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;&#160;&#160;4.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d518298dex41.htm">Form of Registration Rights Agreement (December 2023 PIPE) </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;&#160;&#160;4.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d518298dex42.htm">Form of Common Stock Certificate </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;&#160;&#160;4.3</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d518298dex43.htm">Securities Purchase Agreement, dated December&#160;7, 2023, by and among Spyre Therapeutics, Inc. and each purchaser identified on Annex A thereto </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;&#160;&#160;4.4</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d518298dex44.htm">Form of Registration Rights Agreement, by and among the Company and certain purchasers (June 2023 PIPE) </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;&#160;&#160;4.5</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d518298dex45.htm">Form of <span style="white-space:nowrap">Pre-Funded</span> Warrants 2022 </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;&#160;&#160;5.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d518298dex51.htm">Opinion of Gibson, Dunn&#160;&amp; Crutcher LLP </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.1#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d518298dex101.htm">Biologics Master Services Agreement, effective June&#160;20, 2022, by and between Paragon Therapeutics, Inc. and WuXi Biologics (Hong Kong) Limited</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.2#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d518298dex102.htm">Cell Line License Agreement, effective June&#160;20, 2022, by and between Paragon Therapeutics, Inc. and WuXi Biologics (Hong Kong) Limited </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.3</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d518298dex103.htm">Novation Agreement, dated September&#160;19, 2023, by and between Paragon Therapeutics, Inc., the Company and WuXi Biologics (Hong Kong) Limited </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.4&#8224;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d518298dex104.htm">Amended and Restated Offer Letter, dated November&#160;22, 2023, by and between the Company and Cameron Turtle </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.5#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d518298dex105.htm">Amended and Restated Antibody Discovery and Option agreement, dated September&#160;29, 2023, by and between Paragon Therapeutics, Inc., Parapyre Holding LLC and Spyre Therapeutics, LLC</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.6</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d518298dex106.htm">Form of Amended and Restated Indemnification Agreement </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.7&#8224;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d518298dex107.htm">2015 Equity Incentive Plan and forms of award agreements </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.8&#8224;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d518298dex108.htm">Spyre Therapeutics, Inc. 2016 Equity Incentive Plan, As Amended and Restated Effective November&#160;21, 2023 </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.9&#8224;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d518298dex109.htm">2016 Employee Stock Purchase Plan and forms of award agreements, as amended </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.10&#8224;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d518298dex1010.htm">Spyre Therapeutics, Inc. 2018 Equity Inducement Plan and the First Amendment, Second Amendment, Third Amendment and Fourth Amendment thereto </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.11&#8224;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d518298dex1011.htm">Form of Stock Option Agreement under the Amended and Restated 2018 Equity Inducement Plan </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.12&#8224;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d518298dex1012.htm">Spyre Therapeutics, Inc. 2023 Equity Incentive Plan </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.13&#8224;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d518298dex1013.htm">Form of Stock Restriction Agreement </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.14&#8224;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d518298dex1014.htm">Form of Severance Agreement </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.15&#8224;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d518298dex1015.htm">Separation and Consulting Agreement and General Release of Claims by and between the Company and Jonathan Alspaugh, dated as of September&#160;22, 2023 </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.16&#8224;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d518298dex1016.htm">Offer Letter, dated August&#160;10, 2023, by and between the Company and Scott Burrows </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.17</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d518298dex1017.htm">Asset Purchase Agreement, dated July&#160;27, 2023, by and between the Company and Immedica Pharma AB </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.18</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d518298dex1018.htm">Lease Termination Agreement dated August&#160;7, 2023, between the Company and Las Cimas Owner LP </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;21.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d518298dex211.htm">Subsidiaries of the Registrant </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;23.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d518298dex231.htm">Consent of PricewaterhouseCoopers LLP </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;23.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d518298dex232.htm">Consent of PricewaterhouseCoopers LLP </a></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-3 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td style="width:88%"></td></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">EXHIBIT<br />NUMBER</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">DESCRIPTION OF EXHIBIT</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;23.3</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d518298dex51.htm">Consent of Gibson, Dunn&#160;&amp; Crutcher LLP (included in Exhibit 5.1) </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;24.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d518298ds1.htm#sig">Power of Attorney (included on the signature page to the registration statement) </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.INS</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Instance Document.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.SCH</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Taxonomy Extension Schema Document.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.CAL</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.DEF</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Taxonomy Extension Definition Linkbase Document.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.LAB</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Taxonomy Extension Labels Linkbase Document.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.PRE</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</p></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">107</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d518298dexfilingfees.htm">Filing Fee Table </a></td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">&#8224;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Indicates a management contract or compensatory plan. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">#</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Portions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation <span style="white-space:nowrap">S-K.</span> </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left"><span style="font-weight:bold">(b)</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial statement schedules </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;17.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Undertakings </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) The undersigned Registrant hereby undertakes: </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement: </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(i) to include any prospectus required by Section&#160;10(a)(3) of the Securities Act; </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(ii) to reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20&#160;percent change in the maximum aggregate offering price set forth in the &#8220;Filing Fee Table&#8221; in the effective registration statement; and </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(iii) to include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement; </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial <span style="font-style:italic">bona fide</span> offering thereof. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-4 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(4) That, for the purpose of determining liability under the Securities Act to any purchaser, each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness. <span style="font-style:italic">Provided, however</span>, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(5) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers, and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer, or controlling person of the Registrant in the successful defense of any action, suit, or proceeding) is asserted by such director, officer, or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-5 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="sig">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act, the Registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Waltham, Commonwealth of Massachusetts, on December&#160;22, 2023. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border:0;margin-left:auto">


<tr>

<td style="width:7%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:92%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">SPYRE THERAPEUTICS, INC.</p></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</p></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">/s/ Cameron Turtle, DPhil</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cameron Turtle, DPhil</p> <p style="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Executive Officer</p></td></tr>
</table></div> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">POWER OF ATTORNEY </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">KNOW ALL PERSONS BY THESE PRESENTS</span>, that each person whose signature appears below hereby constitutes and appoints Dr. Cameron Turtle and Mr. Scott Burrows, as his or her true and lawful attorneys-in-fact, proxies and agents, each with full power of substitution, for him or her in any and all capacities, to sign any and all amendments to this registration statement (including post-effective amendments or any abbreviated registration statement and any amendments thereto filed pursuant to Rule 462(b) increasing the number of securities for which registration is sought), and to file the same, with all exhibits thereto and other documents in connection therewith, with the SEC, granting unto said <span style="white-space:nowrap"><span style="white-space:nowrap">attorneys-in-fact,</span></span> proxies and agents full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that <span style="white-space:nowrap"><span style="white-space:nowrap">said&#160;attorneys-in-fact,</span></span> proxies and agents, or their or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act, this registration statement has been signed by the following persons in the capacities and on the dates indicated. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:45%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:35%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td style="width:18%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom" align="center"><span style="font-weight:bold">Signature</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center"><span style="font-weight:bold">Title</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="center"><span style="font-weight:bold">Date</span></td></tr>


<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman;text-align:center">/s/ Cameron Turtle, DPhil</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">Cameron Turtle, DPhil</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Chief Executive Officer&#160;&amp; Director</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">(Principal Executive Officer)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">December&#160;22, 2023</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman;text-align:center">/s/ Scott Burrows</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">Scott Burrows</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Chief Financial Officer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">(Principal Financial Officer and Principal Accounting Officer)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">December&#160;22, 2023</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman;text-align:center">/s/ Russell J. Cox</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">Russell J. Cox</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">Chairman of the Board</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">December&#160;22, 2023</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman;text-align:center">/s/ Jeffrey W. Albers</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">Jeffrey W. Albers</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">Director</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">December&#160;22, 2023</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman;text-align:center">/s/ Peter Harwin</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">Peter Harwin</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">Director</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">December&#160;22, 2023</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman;text-align:center">/s/ Michael Henderson, M.D.</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">Michael Henderson, M.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">Director</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">December&#160;22, 2023</td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-6 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:45%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:35%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td style="width:18%"></td></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom" align="center"><span style="font-weight:bold">Signature</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center"><span style="font-weight:bold">Title</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="center"><span style="font-weight:bold">Date</span></td></tr>


<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman;text-align:center">/s/ Tomas Kiselak</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">Tomas Kiselak</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">Director</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">December&#160;22, 2023</p></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman;text-align:center">/s/ Alison Lawton</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">Alison Lawton</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">Director</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">December&#160;22, 2023</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman;text-align:center">/s/ Laurie Stelzer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">Laurie Stelzer</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">Director</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">December&#160;22, 2023</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">*** </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-7 </p>

</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2.1
<SEQUENCE>2
<FILENAME>d518298dex21.htm
<DESCRIPTION>EX-2.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-2.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 2.1 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><I>Execution Version</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AGREEMENT AND PLAN OF MERGER </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">by and among: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AEGLEA
BIOTHERAPEUTICS, INC., </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">a Delaware corporation; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ASPEN MERGER SUB I, INC., </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">a Delaware corporation; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEQUOIA MERGER SUB II, LLC, </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">a Delaware limited liability company; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPYRE THERAPEUTICS, INC.,
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">a Delaware corporation </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Dated as of June&nbsp;22, 2023 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;1.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">DESCRIPTION OF TRANSACTION</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>The Merger</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Effects of the Merger</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Closing; First Effective Time; Second Effective Time</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Certificate of Designation; Certificate of Incorporation and Bylaws; Directors and Officers</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Merger Consideration; Effect of Merger on Company Capital Stock</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Conversion of Shares</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Closing of the Company&#146;s Transfer Books</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.8</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Exchange of Shares</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.9</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Company Options</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.10</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Contingent Value Right</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.11</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Further Action</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.12</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Withholding</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;2.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">REPRESENTATIONS AND WARRANTIES OF THE COMPANY</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Due Organization; Subsidiaries</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Organizational Documents</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Authority; Binding Nature of Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Vote Required</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="white-space:nowrap">Non-Contravention;</FONT> Consents</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Capitalization</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Financial Statements</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.8</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Absence of Changes</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.9</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Absence of Undisclosed Liabilities</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.10</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Title to Assets</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.11</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Real Property; Leasehold</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.12</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Intellectual Property</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.13</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Agreements, Contracts and Commitments</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.14</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Compliance; Permits; Restrictions</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.15</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Legal Proceedings; Orders</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.16</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Tax Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.17</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Employee and Labor Matters; Benefit Plans</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.18</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Environmental Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.19</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Insurance</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.20</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>No Financial Advisors</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.21</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Transactions with Affiliates</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.22</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Anti-Bribery</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.23</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Disclaimer of Other Representations or Warranties</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;3.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">REPRESENTATIONS AND WARRANTIES OF PARENT AND MERGER SUBS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Due Organization; Subsidiaries</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Organizational Documents</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Authority; Binding Nature of Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Vote Required</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="white-space:nowrap">Non-Contravention;</FONT> Consents</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Capitalization</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(continued) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>SEC Filings; Financial Statements</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.8</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Absence of Changes</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.9</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Absence of Undisclosed Liabilities</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.10</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Title to Assets</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.11</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Real Property; Leasehold</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.12</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Intellectual Property</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.13</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Agreements, Contracts and Commitments</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.14</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Compliance; Permits</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.15</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Legal Proceedings; Orders</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.16</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Tax Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.17</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Employee and Labor Matters; Benefit Plans</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.18</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Environmental Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.19</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Transactions with Affiliates</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.20</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Insurance</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.21</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Opinion of Financial Advisor</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.22</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>No Financial Advisors</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.23</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Anti-Bribery</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.24</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Valid Issuance</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.25</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Disclaimer of Other Representations or Warranties</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;4.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">ADDITIONAL AGREEMENTS OF THE PARTIES</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Parent Stockholders&#146; Meeting</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Proxy Statement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Reservation of Parent Common Stock; Issuance of Shares of Parent Common Stock</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Employee Benefits</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Indemnification of Officers and Directors</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Additional Agreements</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Listing</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.8</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Tax Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.9</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Legends</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.10</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Directors and Officers</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.11</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section&nbsp;16 Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.12</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Cooperation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.13</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Closing Certificates</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.14</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Takeover Statutes</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.15</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Obligations of Merger Subs</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.16</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Private Placement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;5.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">CONDITIONS PRECEDENT TO OBLIGATIONS OF EACH PARTY</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>No Restraints</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Certificate of Designation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Parent Financing</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;6.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">CLOSING DELIVERIES OF THE COMPANY</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Documents</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>FIRPTA Certificate</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Company <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(continued) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;7.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">CLOSING DELIVERIES OF PARENT</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Documents</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Parent <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;8.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">MISCELLANEOUS PROVISIONS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="white-space:nowrap">Non-Survival</FONT> of Representations and Warranties</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Amendment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Waiver</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Entire Agreement; Counterparts; Exchanges by Electronic Transmission</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Applicable Law; Jurisdiction</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Attorneys&#146; Fees</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Assignability</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.8</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Notices</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.9</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Cooperation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.10</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Severability</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.11</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Other Remedies; Specific Performance</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.12</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>No Third-Party Beneficiaries</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.13</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Construction</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.14</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Expenses</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">iii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exhibits: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Exhibit&nbsp;A</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Definitions</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">A-1</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Exhibit B</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Form of <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">B-1</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Exhibit C</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Form of Certificate of Designation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">C-1</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Exhibit D</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Form of CVR Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">D-1</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Exhibit E</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Form of Parent Support Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">E-1</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">iv </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AGREEMENT AND PLAN OF MERGER </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">THIS AGREEMENT AND PLAN OF MERGER is made and entered into as of June&nbsp;22, 2023, by and among <B>AEGLEA BIOTHERAPEUTICS, INC.</B>, a
Delaware corporation (&#147;<B><I>Parent</I></B>&#148;), <B>ASPEN MERGER SUB I, INC.</B>, a Delaware corporation and wholly owned subsidiary of Parent (&#147;<B><I>First </I></B><B><I>Merger Sub</I></B>&#148;), <B>SEQUOIA MERGER SUB II, LLC</B>, a
Delaware limited liability company and wholly owned subsidiary of Parent (&#147;<B><I>Second </I></B><B><I>Merger Sub</I></B>&#148; and together with First Merger Sub, &#147;<B><I>Merger Subs</I></B>&#148;), and <B>SPYRE THERAPEUTICS, INC.</B>, a
Delaware corporation (the &#147;<B><I>Company</I></B>&#148;). Certain capitalized terms used in this Agreement are defined in <B>Exhibit A</B>. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A. Parent and
the Company desire to enter into a business combination as contemplated by this Agreement based on the mutually agreed values of each Parent and the Company, and following the Closing, the aggregate percentage ownership will be based upon an agreed
valuation for the Company of $110&nbsp;million and an agreed valuation for Parent of $35&nbsp;million, assuming certain minimum cash of Target at the Closing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">B. Parent and the Company intend to effect a merger of First Merger Sub with and into the Company (the &#147;<B><I>First Merger</I></B>&#148;)
in accordance with this Agreement and the DGCL. Upon consummation of the First Merger, First Merger Sub will cease to exist and the Company will become a wholly owned subsidiary of Parent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">C. Immediately following the First Merger and as part of the same overall transaction as the First Merger, the Company will merge with and
into Second Merger Sub (the&nbsp;&#147;<B><I>Second Merger</I></B>&#148; and, together with the First Merger, the &#147;<B><I>Merger</I></B>&#148;), with Second Merger Sub being the surviving entity of the Second Merger; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">D. The Parties intend that, (i)&nbsp;the First Merger and the Second Merger, taken together, will constitute an integrated transaction
described in Rev. Rul. <FONT STYLE="white-space:nowrap">2001-46,</FONT> <FONT STYLE="white-space:nowrap">2001-2</FONT> C.B. 321 that qualifies as a &#147;reorganization&#148; within the meaning of Section&nbsp;368(a) of the Code, and (ii)&nbsp;this
Agreement will constitute, and is hereby adopted as, a plan of reorganization within the meaning of Treasury Regulations Sections 1.368-2(g) and 1.368-3(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">E. The Parent Board has (i)&nbsp;determined that the Contemplated Transactions are fair to, advisable and in the best interests of Parent and
its stockholders, (ii)&nbsp;approved and declared advisable this Agreement and the Contemplated Transactions, including the issuance of the Parent Common Stock Payment Shares and the Parent Preferred Stock Payment Shares to the stockholders of the
Company pursuant to the terms of this Agreement, and (iii)&nbsp;determined to recommend, upon the terms and subject to the conditions set forth in this Agreement, that the stockholders of the Parent vote to approve the Parent Stockholder Matters at
the Parent Stockholders&#146; Meeting to be convened following the Closing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">F. The First Merger Sub Board has (i)&nbsp;determined that
the Contemplated Transactions are fair to, advisable, and in the best interests of First Merger Sub and its sole stockholder, (ii)&nbsp;approved and declared advisable this Agreement and the Contemplated Transactions and (iii)&nbsp;determined to
recommend, upon the terms and subject to the conditions set forth in this Agreement, that the stockholder of First Merger Sub votes to adopt this Agreement and thereby approve the Contemplated Transactions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">G. The sole member of the Second Merger Sub has (i)&nbsp;determined that the Contemplated
Transactions are fair to, advisable, and in the best interests of Second Merger Sub and its sole member, (ii) approved and declared advisable this Agreement and the Contemplated Transactions and (iii)&nbsp;determined to recommend, upon the terms and
subject to the conditions set forth in this Agreement, that the sole member of Second Merger Sub votes to adopt this Agreement and thereby approve the Contemplated Transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">H. The Company Board has (i)&nbsp;determined that the Contemplated Transactions are fair to, advisable and in the best interests of the
Company and its stockholders, (ii)&nbsp;approved and declared advisable this Agreement and the Contemplated Transactions and (iii)&nbsp;recommended, upon the terms and subject to the conditions set forth in this Agreement, that the stockholders of
the Company vote to approve the Company Stockholder Matters (the &#147;<B><I>Board Approval</I></B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I. Subsequent to the Board
Approval, but prior to the execution and delivery of this Agreement, the requisite Company stockholders by written consent and in accordance with the Company&#146;s certificate of incorporation, the Company&#146;s bylaws and the DGCL
(i)&nbsp;approved and adopted this Agreement and the Contemplated Transactions, (ii)&nbsp;acknowledged that the approval given thereby is irrevocable and that such stockholder is aware of its rights to demand appraisal for its shares pursuant to
Section&nbsp;262 of the DGCL, a true and correct copy of which was attached thereto, and that such stockholder has received and read a copy of Section&nbsp;262 of the DGCL, and (iii)&nbsp;acknowledged that by its approval of the Merger it is not
entitled to appraisal rights with respect to its shares in connection with the Merger and thereby waives any rights to receive payment of the fair value of its capital stock under the DGCL (such matters, the &#147;<B><I>Company Stockholder
Matters</I></B>&#148; and the consent, the &#147;<B><I>Stockholder Written Consent</I></B>&#148;), and the Stockholder Written Consent is to become effective by its terms immediately following the execution of this Agreement by the parties hereto.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">J. Concurrently with the execution and delivery of this Agreement and as a condition and inducement to each of Parent and the
Company&#146;s willingness to enter into this Agreement, all of the directors, all of the officers and the stockholders of Parent listed in <U>Section <FONT STYLE="white-space:nowrap">A-1</FONT></U> of the Parent Disclosure Schedule (solely in their
capacity as stockholders of Parent) (the &#147;<B><I>Parent Signatories</I></B>&#148;) and the stockholders of the Company listed in <U>Section A</U> of the Company Disclosure Schedule (the &#147;<B><I>Company Signatories</I></B>&#148;) (solely in
their capacity as stockholders of the Company) are executing <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements in substantially the form attached as <B>Exhibit B</B><B> </B>(each, a
&#147;<B><I><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement</I></B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">K. Concurrently with the execution and delivery of
this Agreement, certain investors have executed a Securities Purchase Agreement among Parent and the Persons named therein (representing an aggregate commitment no less than the Concurrent Investment Amount of $150,000,000), pursuant to which such
Persons will have agreed to purchase the number of shares of Parent Convertible Preferred Stock set forth therein concurrently with the Closing in connection with the Parent Financing (the &#147;<B><I>Securities Purchase Agreement</I></B>&#148;).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">L. Concurrently with the execution and delivery of this Agreement and as a condition and inducement to the Company&#146;s willingness to
enter into this Agreement, certain stockholders set forth on <U>Section <FONT STYLE="white-space:nowrap">A-2</FONT></U> of the Parent Disclosure Schedule (solely in their capacity as stockholders) are executing support agreements in favor of the
Company in substantially the form attached hereto as <B>Exhibit E</B> (the &#147;<B>Parent</B> <B>Stockholder Support Agreement</B>&#148;), pursuant to which such Persons have, subject to the terms and conditions set forth therein, agreed to vote
all of their shares of capital stock of Parent in favor of the Parent Stockholder Matters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">M. Immediately following the execution and
delivery of this Agreement, but prior to the filing of the Certificate of Merger, Parent will file the Certificate of Designation with the office of the Secretary of State of the State of Delaware. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Parties, intending to be legally bound, agree as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;1. DESCRIPTION OF TRANSACTION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.1 <B><U>The Merger</U></B>. Upon the terms and subject to the conditions set forth in this Agreement, at the First Effective Time, First
Merger Sub shall be merged with and into the Company, and the separate existence of First Merger Sub shall cease. As a result of the First Merger, the Company will continue as the surviving corporation in the First Merger (the &#147;<B><I>First
Step</I></B> <B><I>Surviving Corporation</I></B>&#148;). Upon the terms and subject to the conditions set forth in this Agreement, at the Second Effective Time, the First Step Surviving Corporation will merge with and into Second Merger Sub, and the
separate existence of the First Step Surviving Corporation shall cease. As a result of the Second Merger, Second Merger Sub will continue as the surviving entity in the Second Merger (the &#147;<B><I>Surviving Entity</I></B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.2 <B><U>Effects of the Merger</U></B>. At and after the First Effective Time, the First Merger shall have the effects set forth in this
Agreement, the First Certificate of Merger and in the applicable provisions of the DGCL. As a result of the First Merger, the First Step Surviving Corporation will become a wholly owned subsidiary of Parent. At and after the Second Effective Time,
the Second Merger shall have the effects set forth in this Agreement, the Second Certificate of Merger and in the applicable provisions of the DGCL and the DLLCA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.3 <B><U>Closing; First Effective Time</U></B><B><U>; Second Effective Time</U></B>. The consummation of the Merger (the
&#147;<B><I>Closing</I></B>&#148;) is being consummated remotely via the electronic exchange of documents and signatures substantially simultaneously with the execution and delivery of this Agreement, or at such other time, date and place as Parent
and the Company may mutually agree in writing. The date on which the Closing actually takes place is referred to as the &#147;<B><I>Closing Date</I></B>.&#148; At the Closing, (i)&nbsp;the Parties shall cause the First Merger to be consummated by
executing and filing with the Secretary of State of the State of Delaware a certificate of merger with respect to the First Merger, satisfying the applicable requirements of the DGCL and in form and substance to be agreed upon by the Parties (the
&#147;<B><I>First</I></B><B><I></I></B><B><I>&nbsp;Certificate of Merger</I></B>&#148;) and (ii)&nbsp;the Parties shall cause the Second Merger to be consummated by executing and filing with the Secretary of State of the State of Delaware a
certificate of merger with respect to the Second Merger, satisfying the applicable requirements of the DGCL and the DLLCA and in form and substance to be agreed upon by the Parties (the &#147;<B><I>Second</I></B><B><I></I></B><B><I>&nbsp;Certificate
of Merger</I></B>&#148; and together with the First Certificate of Merger, the &#147;<B><I>Certificates of Merger</I></B>&#148;). The First Merger shall become effective at the time of the filing of such First Certificate of Merger with the
Secretary of State of the State of Delaware or at such later time as may be specified in such First Certificate of Merger with the consent of Parent and the Company (the time as of which the First Merger becomes effective being referred to as the
&#147;<B><I>First</I></B><B><I></I></B><B><I>&nbsp;Effective Time</I></B>&#148;). The Second Merger shall become effective at the time of the filing of such Second Certificate of Merger with the Secretary of State of the State of Delaware or at such
later time as may be specified in such Second Certificate of Merger with the consent of Parent and the Company (the time as of which the Second Merger becomes effective being referred to as the
&#147;<B><I>Second</I></B><B><I></I></B><B><I>&nbsp;Effective Time</I></B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.4 <B><U>Certificate of Designation; Certificate of
Incorporation and Bylaws; Directors and Officers</U></B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) Prior to the First Effective Time, Parent will file the Certificate of
Designation with the office of the Secretary of State of the State of Delaware. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) At the First Effective Time: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(i) the certificate of incorporation of the First Step Surviving Corporation shall be amended and restated as set forth in an exhibit to the
First Certificate of Merger, until thereafter amended as provided by the DGCL and such certificate of incorporation; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(ii) the bylaws of
the First Step Surviving Corporation shall be amended and restated in their entirety to read identically to the bylaws of the Company as in effect immediately prior to the First Effective Time, until thereafter amended as provided by the DGCL and
such bylaws; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(iii) the directors and officers of the First Step Surviving Corporation, each to hold office in accordance with the
certificate of incorporation and bylaws of the First Step Surviving Corporation, shall be such persons as shall be mutually agreed upon by Parent and the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) At the Second Effective Time: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(i) the certificate of formation of the Surviving Entity shall be the certificate of formation of Second Merger Sub as in effect immediately
prior to the Second Effective Time, until thereafter amended as provided by the DLLCA and such certificate of formation; <I>provided</I>, <I>however</I>, that at the Second Effective Time (as part of the Second Certificate of Merger), the
certificate of formation shall be amended to (A)&nbsp;change the name of the Surviving Entity to &#147;Spyre Therapeutics, LLC,&#148; (B) comply with <U>Section</U><U></U><U>&nbsp;4.5</U>, and (C)&nbsp;make such other changes as are mutually agreed
to by Parent and the Company; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(ii) the limited liability company agreement of the Surviving Entity shall be amended and restated in its
entirety to read identically to the limited liability company agreement of Second Merger Sub as in effect immediately prior to the Second Effective Time, until thereafter amended as provided by the DLLCA and such limited liability company agreement;
<I>provided</I>, <I>however</I>, that following the Second Effective Time (but as soon thereafter as practicable), the limited liability company agreement shall be amended to (A)&nbsp;comply with <U>Section</U><U></U><U>&nbsp;4.5</U> and
(B)&nbsp;change the name of the Surviving Entity to &#147;Spyre Therapeutics, LLC&#148;; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(iii) the managers and officers of the
Surviving Entity, each to hold office in accordance with the certificate of formation and limited liability company agreement of the Surviving Entity, shall be such persons as shall be mutually agreed upon by Parent and the Company; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(iv) the certificate of incorporation of Parent shall be identical to the certificate of incorporation of Parent immediately prior to the
Second Effective Time, until thereafter amended as provided by the DGCL and such certificate of incorporation, <I>provided</I>, <I>however</I>, that following the Second Effective Time, the certificate of incorporation shall be amended to
(A)&nbsp;change the corporate name of Parent to &#147;Spyre Therapeutics, Inc.&#148;, (B) effect the Nasdaq Reverse Split, if deemed necessary, and (C)&nbsp;make such other changes as are mutually agreed to by Parent and the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.5 <B><U>Merger Consideration; Effect of Merger on Company Capital Stock</U></B>. The aggregate merger consideration (the &#147;<B><I>Merger
Consideration</I></B>&#148;) to be paid by Parent for all of the outstanding shares of Company Capital Stock at the Closing and amounts reserved for Company Options shall be (a) 13,013,636 shares of Parent Common Stock (&#147;<B><I>Parent Common
Stock Payment Shares</I></B>&#148;), which shares shall represent a number of shares equal to no more than 19.9% of the outstanding shares of Parent Common Stock as of immediately before the First Effective Time (the &#147;<B><I>Parent Common Stock
Consideration Cap</I></B>&#148;), and (b)&nbsp;in the event the aggregate number of shares of Parent Common Stock Payment Shares issued to any Company stockholder at Closing would result in the issuance of shares of Parent Common Stock in an amount
in excess of the Parent Common Stock Consideration Cap, Parent shall issue to such Company stockholders shares of Parent Common Stock up to the Parent Common Stock Consideration Cap and shall </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
issue the remaining balance to such stockholders a total of 364,889 shares of Parent Convertible Preferred Stock (&#147;<B><I>Parent Preferred Stock Payment Shares</I></B>&#148;). Each Parent
Preferred Stock Payment Share shall be convertible into 1,000 shares of Parent Common Stock, subject to and contingent upon the affirmative vote of a majority of the Parent Common Stock present or represented and entitled to vote at a meeting of
stockholders of Parent to approve, for purposes of the Nasdaq Stock Market Rules, the issuance of shares of Parent Common Stock to the stockholders of the Company upon conversion of any and all shares of Parent Convertible Preferred Stock in
accordance with the terms of the Certificate of Designation in substantially the form attached hereto as <B>Exhibit C</B> (the &#147;<B><I>Preferred Stock Conversion Proposal</I></B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.6 <B><U>Conversion of Shares</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) At the First Effective Time, by virtue of the First Merger and without any further action on the part of Parent, Merger Subs, the Company
or any stockholder of the Company or Parent: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(i) any shares of Company Common Stock held as treasury stock or held or owned by the
Company or any wholly owned Subsidiary of the Company immediately prior to the First Effective Time shall be canceled and retired and shall cease to exist, and no consideration shall be delivered in exchange therefor; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(ii) subject to <U>Section</U><U></U><U>&nbsp;1.5</U> and <U>Section</U><U></U><U>&nbsp;1.6(c)</U>, each share of Company Capital Stock
outstanding immediately prior to the First Effective Time (excluding shares to be canceled pursuant to <U>Section</U><U></U><U>&nbsp;1.6(a)(i)</U> and excluding Dissenting Shares) shall be automatically converted solely into the right to receive a
number of Parent Common Stock Payment Shares equal to the Exchange Ratio as set forth on the Allocation Certificate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) If any shares
of Company Common Stock outstanding immediately prior to the First Effective Time are subject to a repurchase option or a risk of forfeiture under any applicable restricted stock purchase agreement or other similar agreement with the Company, such
shares of Company Common Stock shall no longer be subject to any right of repurchase, risk of forfeiture or other such conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c)
No fractional shares of Parent Common Stock and Parent Convertible Preferred Stock shall be issued in connection with the First Merger, and no certificates or scrip for any such fractional shares shall be issued and no cash shall be paid for any
such fractional shares. Any fractional shares of Parent Common Stock that a holder of Company Common Stock would otherwise be entitled to receive shall be aggregated with all fractional shares of Parent Common Stock issuable to such holder) or a
fraction of a share of Parent Convertible Preferred Stock issuable to such holder and any remaining fractional shares shall be rounded up to the nearest whole share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) At the First Effective Time, by virtue of the First Merger and without any further action on the part of Parent, Merger Subs, the Company
or any member of the Company or stockholder of Parent, each share of common stock of First Merger Sub issued and outstanding immediately prior to the First Effective Time shall be converted into and exchanged for one share of common stock of the
First Step Surviving Corporation. If applicable, each stock certificate of First Merger Sub evidencing ownership of any such shares shall, as of the First Effective Time, evidence ownership of such shares of common stock of the First Step Surviving
Corporation.</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) If, between the date of this Agreement and the First Effective Time, the outstanding
shares of Company Common Stock or Parent Common Stock or Parent Convertible Preferred Stock shall have been changed into, or exchanged for, a different number of shares or a different class, by reason of any stock dividend, subdivision,
reclassification, recapitalization, split, combination or exchange of shares or other like change, the Exchange Ratio shall, to the extent necessary, be equitably adjusted to reflect such change to the extent necessary to provide the holders of
Company Common Stock and Parent Common Stock and Parent Convertible Preferred Stock, with the same economic effect as contemplated by this Agreement prior to such stock dividend, subdivision, reclassification, recapitalization, split, combination or
exchange of shares or other like change; <I>provided</I>,<I> however</I>, that nothing herein will be construed to permit the Company or Parent to take any action with respect to Company Common Stock or Parent Common Stock or Parent Convertible
Preferred Stock, respectively, that is prohibited or not expressly permitted by the terms of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f) At the Second Effective
Time, by virtue of the Second Merger and without any action on the part of Parent, the First Step Surviving Corporation, Second Merger Sub or their respective stockholders, each share of the First Step Surviving Corporation issued and outstanding
immediately prior to the Second Effective Time shall be canceled and extinguished without any conversion thereof and no payment or distribution shall be made with respect thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.7 <B><U>Closing of the Company</U></B><B><U>&#146;</U></B><B><U>s Transfer Books</U></B>. At the First Effective Time: (a) all holders of
(i)&nbsp;certificates representing shares of Company Capital Stock and (ii)&nbsp;book-entry shares representing shares of Company Capital Stock (&#147;<B><I>Book-Entry Shares</I></B>&#148;), in each case, that were outstanding immediately prior to
the First Effective Time shall cease to have any rights as stockholders of the Company; and (b)&nbsp;the stock transfer books of the Company shall be closed with respect to all shares of Company Capital Stock outstanding immediately prior to the
First Effective Time. No further transfer of any such shares of Company Capital Stock shall be made on such stock transfer books after the First Effective Time. If, after the first Effective Time, a valid certificate previously representing any
shares of Company Capital Stock outstanding immediately prior to the First Effective Time (a &#147;<B><I>Company Stock Certificate</I></B>&#148;) is presented to the Exchange Agent or to the Surviving Entity, such Company Stock Certificate shall be
canceled and shall be exchanged as provided in <U>Sections</U><U></U><U>&nbsp;1.6</U> and <U>1.8</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.8 <B><U>Exchange of
Shares</U></B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) On or prior to the Closing Date, Parent and the Company shall agree upon and select a reputable bank, transfer agent
or trust company to act as exchange agent in the Merger (the &#147;<B><I>Exchange Agent</I></B>&#148;). At the First Effective Time, Parent shall deposit with the Exchange Agent certificates or evidence of book-entry shares representing the Parent
Common Stock and Parent Convertible Preferred Stock issuable pursuant to <U>Section</U><U></U><U>&nbsp;1.6(a)</U>. The Parent Common Stock and Parent Convertible Preferred Stock so deposited with the Exchange Agent, together with any dividends or
distributions received by the Exchange Agent with respect to such shares, are referred to collectively as the &#147;<B><I>Exchange Fund</I></B>.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) As soon as reasonably practicable after the record date for the CVR, the Exchange Agent shall issue book-entry shares representing the
Merger Consideration (in a number of whole shares of Parent Common Stock and Parent Convertible Preferred Stock) that each holder of Company Common Stock has the right to receive pursuant to the provisions of <U>Section</U><U></U><U>&nbsp;1.6(a)</U>
and each Company Stock Certificate or Book-Entry Share formerly held by each such holder shall be deemed, from and after the First Effective Time, to represent only the right to receive book-entry shares of Parent Common Stock and Parent Convertible
Preferred Stock representing the Merger Consideration and, following issuance of book-entry shares representing the Merger Consideration, shall be canceled. The Merger Consideration and any dividends or other distributions as are payable pursuant to
<U>Section</U><U></U><U>&nbsp;1.8(d)</U> shall be deemed to have been in full satisfaction of all rights pertaining to Company Capital Stock formerly represented by such Company Stock Certificates or Book-Entry Shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) No dividends or other distributions declared or made with respect to Parent Common
Stock or Parent Convertible Preferred Stock with a record date on or after the First Effective Time shall be paid to the holder of any unsurrendered Company Stock Certificate or Book-Entry Shares with respect to the shares of Parent Common Stock
and/or Parent Convertible Preferred Stock that such holder has the right to receive in the Merger until such holder surrenders such Company Stock Certificate or transfers such Book-Entry Shares or provides an affidavit of loss or destruction in lieu
thereof in accordance with this <U>Section</U><U></U><U>&nbsp;1.8</U> (at which time (or, if later, on the applicable payment date) such holder shall be entitled, subject to the effect of applicable abandoned property, escheat or similar Laws, to
receive all such dividends and distributions, without interest); provided, however, that in no event shall holders of Company Capital Stock receiving the Merger Consideration be entitled to receive the CVR. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) Any portion of the Exchange Fund that remains unclaimed by holders of shares of Company Capital Stock as of the date that is one year
after the Closing Date shall be delivered to Parent upon demand, and any holders of Company Stock Certificates or Book-Entry Shares who have not theretofore surrendered their Company Stock Certificates or transferred their Book-Entry Shares in
accordance with this Section&nbsp;1.8 shall thereafter look only to Parent as general creditors for satisfaction of their claims for Parent Common Stock and Parent Convertible Preferred Stock and any dividends or distributions with respect to shares
of Parent Common Stock and Parent Convertible Preferred Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) No Party shall be liable to any holder of any shares of Company
Capital Stock or to any other Person with respect to any shares of Parent Common Stock or Parent Convertible Preferred Stock (or dividends or distributions with respect thereto) or for any cash amounts delivered to any public official pursuant to
any applicable abandoned property Law, escheat Law or similar Law. Any portion of the Exchange Fund that remains unclaimed by holders of shares of Company Capital Stock as of the date that is two years after the Closing Date (or immediately prior to
such earlier date on which the related Exchange Funds (and all dividends or other distributions in respect thereof) would otherwise escheat to or become the property of any Governmental Body) shall, to the extent permitted by applicable Law, become
the property of the Surviving Entity, free and clear of all claims or interest of any Person previously entitled thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.9
<B><U>Company Options</U></B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) At the First Effective Time, each Company Option that is outstanding and unexercised immediately
prior to the First Effective Time under the Company Plan, whether or not vested, shall be converted into and become an option to purchase Parent Common Stock, and Parent shall assume the Company Plan and each such Company Option in accordance with
the terms (as in effect as of the date of this Agreement) of the Company Plan and the terms of the stock option agreement by which such Company Option is evidenced (but with changes to such documents as Parent in good faith determines are necessary
to reflect the substitution of the Company Options by Parent to purchase shares of Parent Common Stock). All rights with respect to Company Common Stock under Company Options assumed by Parent shall thereupon be converted into rights with respect to
Parent Common Stock. Accordingly, from and after the First Effective Time: (i) each Company Option assumed by Parent may be exercised solely for shares of Parent Common Stock; (ii)&nbsp;the number of shares of Parent Common Stock subject to each
Company Option assumed by Parent shall be determined by multiplying (A)&nbsp;the number of shares of Company Common Stock that were subject to such Company Option, as in effect immediately prior to the First Effective Time, by (B)&nbsp;the Exchange
Ratio, and rounding the resulting number down to the nearest whole number of shares of Parent Common Stock; (iii)&nbsp;the per share exercise price for the Parent Common Stock issuable upon exercise of each Company Option assumed by Parent shall be
determined by dividing (A)&nbsp;the per share exercise price of Company Common Stock subject to such Company Option, as in effect immediately prior to the First Effective Time, by (B)&nbsp;the Exchange Ratio and rounding the resulting exercise price
up to the nearest whole cent; and (iv)&nbsp;any restriction on the exercise of any Company Option assumed by Parent shall continue in full force and effect and the term, exercisability, vesting schedule and other
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
provisions of such Company Option shall otherwise remain unchanged; <I>provided</I>, that, (I)&nbsp;in the case of any Company Option to which Section&nbsp;421 of the Code applies as of the First
Effective Time by reason of its qualification under Section&nbsp;422 of the Code, the exercise price, the number of shares of Parent Common Stock subject to such option and the terms and conditions of exercise of such option shall be determined in a
manner consistent with the requirements of Section&nbsp;424(a) of the Code; and (II)&nbsp;the exercise price, the number of shares of Parent Common Stock subject to, and the terms and conditions of exercise of each option to purchase Parent Common
Stock shall also be determined in a manner consistent with the requirements of Section&nbsp;409A of the Code; <I>provided, further</I>, that: (x) Parent may amend the terms of the Company Options and the Company Plan as may be necessary to reflect
Parent&#146;s substitution of the Company Options with options to purchase Parent Common Stock (such as by making any change in control or similar definition relate to Parent and having any provision that provides for the adjustment of Company
Options upon the occurrence of certain corporate events relate to corporate events that relate to Parent and/or Parent Common Stock); and (y)&nbsp;the Parent Board or a committee thereof shall succeed to the authority and responsibility of the
Company Board or any committee thereof with respect to each Company Option assumed by Parent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) Parent shall file with the SEC,
promptly after the First Effective Time (and in any evert, not later than thirty (30)&nbsp;days thereafter), a registration statement on Form <FONT STYLE="white-space:nowrap">S-8</FONT> (or any successor form), if available for use by Parent,
relating to the shares of Parent Common Stock issuable with respect to Company Options assumed by Parent in accordance with Section&nbsp;1.10. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.10 <B><U>Contingent Value Right</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) Holders of Parent Common Stock of record as of immediately prior to the First Effective Time shall be entitled to one contractual
contingent value right (a &#147;<B><I>CVR</I></B>&#148;) issued by Parent subject to and in accordance with the terms and conditions of the CVR Agreement, attached hereto as <B>Exhibit </B><B>D </B>(the &#147;<B><I>CVR Agreement</I></B>&#148;), for
each share of Parent Common Stock held by such holders (less applicable withholding Taxes). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) Within thirty (30)&nbsp;days of the
First Effective Time, Parent shall authorize and duly adopt, execute and deliver, and will ensure that Exchange Agent executes and delivers, the CVR Agreement, subject to any reasonable revisions to the CVR Agreement that are requested by such
Exchange Agent (<I>provided</I> that such revisions are not, individually or in the aggregate, detrimental or adverse, taken as a whole, to any holder of a CVR). Parent and the Company shall cooperate, including by making changes to the form of CVR
Agreement, as necessary to ensure that the CVRs are not subject to registration under the Securities Act, the Exchange Act or any applicable state securities or &#147;blue sky&#148; laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) Parent and the Exchange Agent shall, within thirty (30)&nbsp;days of the First Effective Time, duly authorize, execute and deliver the
CVR Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.11 <B><U>Further Action</U></B>. If, at any time after the First Effective Time, any further action is determined by the
Surviving Entity to be necessary or desirable to carry out the purposes of this Agreement or to vest the Surviving Entity with full right, title and possession of and to all rights and property of the Company, then the officers and directors of the
Surviving Entity shall be fully authorized, and shall use their and its reasonable best efforts (in the name of the Company, in the name of Merger Subs, in the name of the Surviving Entity and otherwise) to take such action. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.12 <B><U>Withholding</U></B>. The Parties and the Exchange Agent (each, a &#147;<B><I>Withholding Agent</I></B>&#148;) shall be entitled to
deduct and withhold from the consideration otherwise payable pursuant to this Agreement (including the CVR Agreement) to any holder of Company Capital Stock or any other Person such amounts as such Party or the Exchange Agent is required to deduct
and withhold under the Code or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
any other Law with respect to the making of such payment; provided, however, that if a Withholding Agent determines that any payment to any stockholder of the Company hereunder is subject to
deduction and/or withholding, then, except with respect to compensatory payments, or as a result of a failure to deliver the certificate described in Section&nbsp;6.2, such Withholding Agent shall (i)&nbsp;provide notice to such stockholder as soon
as reasonably practicable after such determination (and no later than three (3)&nbsp;Business Days prior to undertaking such deduction and/or withholding), and (ii)&nbsp;use commercially reasonable efforts to cooperate with such stockholder prior to
Closing to reduce or eliminate any such deduction and/or withholding. To the extent that amounts are so withheld and paid over to the appropriate Governmental Body, such withheld amounts shall be treated for all purposes of this Agreement as having
been paid to the Person in respect of whom such deduction and withholding was made. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;2. REPRESENTATIONS AND WARRANTIES OF
THE COMPANY </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Subject to <U>Section</U><U></U><U>&nbsp;8.13(h)</U>, except as set forth in the disclosure schedule delivered by the
Company to Parent (the &#147;<B><I>Company Disclosure Schedule</I></B>&#148;), the Company represents and warrants to Parent and Merger Subs as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.1 <B><U>Due Organization; Subsidiaries</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) The Company is a corporation duly incorporated, validly existing and in good standing under the Laws of Delaware and has all necessary
corporate power and authority: (i) to conduct its business in the manner in which its business is currently being conducted; (ii)&nbsp;to own or lease and use its property and assets in the manner in which its property and assets are currently owned
or leased and used; and (iii)&nbsp;to perform its obligations under all Contracts by which it is bound. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) The Company is duly licensed
and qualified to do business, and is in good standing (to the extent applicable in such jurisdiction), under the Laws of all jurisdictions where the nature of its business requires such licensing or qualification other than in jurisdictions where
the failure to be so qualified individually or in the aggregate would not be reasonably expected to have a Company Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) The Company has no Subsidiaries and the Company does not own any capital stock of, or any equity, ownership or profit-sharing interest of
any nature in, or controls directly or indirectly, any other Entity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) The Company is not nor has ever been, directly or indirectly, a
party to, member of or participant in any partnership, joint venture or similar business entity. The Company has not agreed to, and is not obligated to make, nor is bound by any Contract under which it may become obligated to make, any future
investment in or capital contribution to any other Entity. The Company has not, at any time, been a general partner of, or has otherwise been liable for any of the debts or other obligations of, any general partnership, limited partnership or other
Entity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.2 <B><U>Organizational Documents</U></B>. The Company has made available to Parent accurate and complete copies of the
Organizational Documents of the Company in effect as of the date of this Agreement. The Company is not in breach or violation of its respective Organizational Documents. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.3 <B><U>Authority; Binding Nature of Agreement</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) The Company has all necessary corporate power and authority to enter into and to perform its obligations under this Agreement and,
subject to receipt of the Required Company Stockholder Vote, to consummate the Contemplated Transactions. The Company Board (at meetings duly called and held or by unanimous written consent) has (i)&nbsp;determined that the Contemplated Transactions
are fair to, advisable and in the best interests of the Company and its stockholders, (ii)&nbsp;authorized, approved and declared advisable this Agreement and the Contemplated Transactions and (iii)&nbsp;determined to recommend, upon the terms and
subject to the conditions set forth in this Agreement, that the stockholders of the Company vote in favor of the Company Stockholder Matters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) This Agreement has been duly executed and delivered by the Company and, assuming the due authorization, execution and delivery by Parent
and Merger Subs, constitutes the legal, valid and binding obligation of the Company, enforceable against the Company in accordance with its terms, subject to the Enforceability Exceptions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.4 <B><U>Vote Required</U></B>. The affirmative vote (or written consent) of the holders of a majority of the shares of Company Common Stock
outstanding on the record date for the Stockholder Written Consent and entitled to vote thereon, voting as a single class (the &#147;<B><I>Required Company Stockholder Vote</I></B>&#148;), is the only vote (or written consent) of the holders of any
class or series of Company Capital Stock necessary to adopt and approve this Agreement and approve the Contemplated Transactions. The Stockholder Written Consent became effective upon the execution of this Agreement by the parties hereto and
provided the Required Company Stockholder Vote. No other corporate proceedings by the Company are necessary to authorize this Agreement or to consummate the Contemplated Transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.5 <B><U><FONT STYLE="white-space:nowrap">Non-Contravention;</FONT> Consents</U></B>.<B> </B>Subject to obtaining the required Company
Stockholder Vote, the filing of the Certificates of Merger required by the DGCL, and the filing of the Certificate of Designation, neither (x)&nbsp;the execution, delivery or performance of this Agreement by the Company, nor (y)&nbsp;the
consummation of the Contemplated Transactions, will directly or indirectly (with or without notice or lapse of time): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) contravene,
conflict with or result in a violation of any of the provisions of the Company&#146;s Organizational Documents; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) contravene, conflict
with or result in a violation of, or give any Governmental Body or other Person the right to challenge the Contemplated Transactions or to exercise any remedy or obtain any relief under, any Law or any order, writ, injunction, judgment or decree to
which the Company, or any of the assets owned or used by the Company, is subject, except as would not reasonably be expected to be material to the Company or its business; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) contravene, conflict with or result in a violation of any of the terms or requirements of, or give any Governmental Body the right to
revoke, withdraw, suspend, cancel, terminate or modify, any Governmental Authorization that is held by the Company, except as would not reasonably be expected to be material to the Company or its business; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) contravene, conflict with or result in a violation or breach of, or result in a default under, any provision of any Company Material
Contract, or give any Person the right to: (i) declare a default or exercise any remedy under any Company Material Contract; (ii)&nbsp;any material payment, rebate, chargeback, penalty or change in delivery schedule under any Company Material
Contract; (iii)&nbsp;accelerate the maturity or performance of any Company Material Contract; or (iv)&nbsp;cancel, terminate or modify any term of any Company Material Contract, except in the case of any
<FONT STYLE="white-space:nowrap">non-material</FONT> breach, default, penalty or modification; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) result in the imposition or
creation of any Encumbrance upon or with respect to any asset owned or used by the Company (except for Permitted Encumbrances). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except for (i)&nbsp;any Consent set forth in <U>Section</U><U></U><U>&nbsp;2.5</U> of the
Company Disclosure Schedule under any Company Contract, (ii)&nbsp;the Required Company Stockholder Vote, (iii)&nbsp;the filing of the Certificates of Merger with the Secretary of State of the State of Delaware pursuant to the DGCL, (iv)&nbsp;the
filing of the Certificate of Designation with the Secretary of State of the State of Delaware pursuant to the DGCL and (v)&nbsp;such consents, waivers, approvals, orders, authorizations, registrations, declarations and filings as may be required
under applicable federal and state securities Laws, the Company is not required to make any filing with or give any notice to, or to obtain any Consent from, any Person in connection with (A)&nbsp;the execution, delivery or performance of this
Agreement, or (B)&nbsp;the consummation of the Contemplated Transactions. The Company Board has taken and will take all actions necessary to ensure that the restrictions applicable to business combinations contained in Section&nbsp;203 of the DGCL
are, and will be, inapplicable to the execution, delivery and performance of this Agreement, the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements and to the consummation of the Contemplated Transactions. No other state takeover statute or
similar Law applies or purports to apply to the Merger, this Agreement, the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements or any of the Contemplated Transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.6 <B><U>Capitalization</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) The authorized Company Capital Stock as of the date of this Agreement consists of (i) 47,728,480 shares of Company Common Stock, par
value $0.001 per share, of which 7,506,651 shares have been issued and are outstanding as of the date of this Agreement, and (ii) 20,000,000 shares of Preferred Stock, par value $0.001<B> </B>per share (the &#147;<B><I>Company Preferred
Stock</I></B>&#148;), of which 20,000,000 shares have been designated &#145;Series A Preferred Stock&#146; all of which have been issued and are outstanding as of the date of this Agreement. The Company does not hold any shares of its capital stock
in its treasury. <U>Section</U><U></U><U>&nbsp;2.6(a)</U> of the Company Disclosure Schedule lists, as of the date of this Agreement, each record holder of issued and outstanding Company Capital Stock and the number and type of shares of Company
Capital Stock held by such holder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) All of the outstanding shares of Company Common Stock and Company Preferred Stock have been duly
authorized and validly issued, and are fully paid and nonassessable. Except as set forth in the Investor Agreements, none of the outstanding shares of Company Capital Stock is entitled or subject to any preemptive right, right of participation,
right of maintenance or any similar right and none of the outstanding shares of Company Capital Stock is subject to any right of first refusal in favor of the Company. Except as contemplated herein or as set forth in the Investor Agreements, there
is no Company Contract relating to the voting or registration of, or restricting any Person from purchasing, selling, pledging or otherwise disposing of (or granting any option or similar right with respect to), any shares of Company Capital Stock.
The Company is not under any obligation, nor is it bound by any Contract pursuant to which it may become obligated, to repurchase, redeem or otherwise acquire any outstanding shares of Company Capital Stock or other securities.
<U>Section</U><U></U><U>&nbsp;2.6(b)</U> of the Company Disclosure Schedule accurately and completely lists all repurchase rights held by the Company with respect to shares of Company Capital Stock (including shares issued pursuant to the exercise
of stock options) and specifies which of those repurchase rights are currently exercisable and whether the holder of such shares of Company Capital Stock timely filed an election with the relevant Governmental Bodies under Section&nbsp;83(b) of the
Code with respect to such shares. Each share of Company Preferred Stock is convertible into one share of Company Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c)
Except for the Company&#146;s 2023 Equity Incentive Plan (the &#147;<B><I>Company Plan</I></B>&#148;), the Company does not have any stock option plan or any other plan, program, agreement or arrangement providing for any equity-based compensation
for any Person. As of the date of this Agreement, the Company has reserved 2,049,133 shares of Company Common Stock for issuance under the Company Plan, of which 1,827,304 shares have been issued and are currently outstanding, 5,000 shares have been
reserved for issuance upon exercise of Company Options previously granted and currently outstanding </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
under the Company Plan, and 216,829 shares of Company Common Stock remain available for future issuance of awards pursuant to the Company Plan. <U>Section</U><U></U><U>&nbsp;2.6(c)</U> of the
Company Disclosure Schedule sets forth the following information with respect to each Company Option outstanding as of the date of this Agreement: (i) the name of the optionee; (ii)&nbsp;the number of shares of Company Common Stock subject to such
Company Option at the time of grant; (iii)&nbsp;the number of shares of Company Common Stock subject to such Company Option as of the date of this Agreement; (iv)&nbsp;the exercise price of such Company Option; (v)&nbsp;the date on which such
Company Option was granted; (vi)&nbsp;the applicable vesting schedule, including the number of vested and unvested shares as of the date of this Agreement and any acceleration provisions; (vii)&nbsp;the date on which such Company Option expires;
(viii)&nbsp;whether such Company Option is intended to constitute an &#147;incentive stock option&#148; (as defined in the Code) or a <FONT STYLE="white-space:nowrap">non-qualified</FONT> stock option; and (ix)&nbsp;whether such Company Option is
&#147;early exercisable.&#148; The Company has made available to Parent an accurate and complete copy of the Company Plan and a form of stock option agreement that is consistent in all material respects with the stock option agreements evidencing
outstanding Company Options granted thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) Except for Company Options set forth in <U>Section</U><U></U><U>&nbsp;2.6(c)</U> of
the Company Disclosure Schedule, there is no: (i) outstanding subscription, option, call, warrant or right (whether or not currently exercisable) to acquire any shares of the capital stock or other securities of the Company; (ii)&nbsp;outstanding
security, instrument or obligation that is or may become convertible into or exchangeable for any shares of the capital stock or other securities of the Company; or (iii)&nbsp;condition or circumstance that could be reasonably likely to give rise to
or provide a basis for the assertion of a claim by any Person to the effect that such Person is entitled to acquire or receive any shares of capital stock or other securities of the Company. There are no outstanding or authorized stock appreciation,
phantom stock, profit participation or other similar rights with respect to the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) All outstanding shares of Company Common
Stock, Company Preferred Stock, Company Options, and other securities of the Company have been issued and granted in material compliance with (i)&nbsp;the Organizational Documents of the Company in effect as of the relevant time and all applicable
securities Laws and other applicable Law, and (ii)&nbsp;all requirements set forth in applicable Contracts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f) All distributions,
dividends, repurchases and redemptions of the Company Capital Stock or other equity interests of the Company were undertaken in material compliance with (i)&nbsp;the Organizational Documents of the Company in effect as of the relevant time and all
applicable securities Laws and other applicable Laws, and (ii)&nbsp;all requirements set forth in applicable Contract. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.7
<B><U>Financial Statements</U></B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) Concurrently with the execution hereof, the Company has provided to Parent true and complete
copies of the Company Unaudited Interim Balance Sheet, together with the unaudited statements of operations and cash flows of the Company for the period reflected in the Company Unaudited Interim Balance Sheet (collectively, the &#147;<B><I>Company
Financials</I></B>&#148;). The Company Financials were prepared in accordance with GAAP (except as may be indicated in the notes to such financial statements and except that the unaudited financial statements may not contain footnotes and are
subject to normal and recurring <FONT STYLE="white-space:nowrap">year-end</FONT> adjustments, none of which is material) and fairly present, in all material respects, the financial position and operating results of the Company as of the dates and
for the periods indicated therein. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) The Company maintains accurate books and records reflecting its assets and liabilities
and maintains a system of internal accounting controls designed to provide reasonable assurance that: (i)&nbsp;transactions are executed in accordance with management&#146;s general or specific authorizations; (ii)&nbsp;transactions are recorded as
necessary to permit preparation of the financial statements of the Company in accordance with GAAP and to maintain accountability of the Company&#146;s assets; (iii)&nbsp;access to the Company&#146;s assets is permitted only in accordance with
management&#146;s general or specific authorization; (iv)&nbsp;the recorded accountability for the Company&#146;s assets is compared with the existing assets at regular intervals and appropriate action is taken with respect to any differences; and
(v)&nbsp;accounts, notes and other receivables and inventory are recorded accurately, and proper and adequate procedures are implemented which are designed to effect the collection thereof on a current and timely basis. The Company maintains
internal controls consistent with the practices of similarly situated private companies over financial reporting that provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for
external purposes in accordance with GAAP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) <U>Section</U><U></U><U>&nbsp;2.7(c)</U> of the Company Disclosure Schedule lists, and
the Company has delivered to Parent accurate and complete copies of the documentation creating or governing, all securitization transactions and <FONT STYLE="white-space:nowrap">&#147;off-balance</FONT> sheet arrangements&#148; (as defined in Item
303(c) of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> under the Exchange Act) effected by the Company since the Company&#146;s inception. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) Since the Company&#146;s inception, there have been no formal internal investigations regarding financial reporting or accounting
policies and practices discussed with, reviewed by or initiated at the direction of the chief executive officer, chief financial officer or general counsel of the Company, the Company Board or any committee thereof. Since the Company&#146;s
inception, neither the Company nor its independent auditors have identified (i)&nbsp;any significant deficiency or material weakness in the design or operation of the system of internal accounting controls utilized by the Company, (ii)&nbsp;any
fraud, whether or not material, that involves the Company, the Company&#146;s management or other employees who have a role in the preparation of financial statements or the internal accounting controls utilized by the Company or (iii)&nbsp;any
claim or allegation regarding any of the foregoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.8 <B><U>Absence of Changes</U></B>. Except as set forth in
<U>Section</U><U></U><U>&nbsp;2.8</U> of the Company Disclosure Schedule, after the date of the Company Unaudited Interim Balance Sheet, the Company has conducted its business only in the Ordinary Course of Business (except for the execution and
performance of this Agreement and the discussions, negotiations and transactions related thereto) and there has not been any (a)&nbsp;Company Material Adverse Effect and (b)&nbsp;the Company has not done any of the following: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) declared, accrued, set aside or paid any dividend or made any other distribution in respect of any shares of its capital stock; or
repurchased, redeemed or otherwise reacquired any shares of its capital stock or other securities (except for shares of Company Common Stock from terminated employees, directors or consultants of the Company or in connection with the payment of the
exercise price and/or withholding Taxes incurred upon the exercise, settlement or vesting of any award granted under the Company Plan); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) sold, issued, granted, pledged or otherwise disposed of or encumbered or authorized any of the foregoing with respect to: (A) any capital
stock or other security of the Company; (B)&nbsp;any option, warrant or right to acquire any capital stock or any other security, other than option grants to employees and service providers in the Ordinary Course of Business; or (C)&nbsp;any
instrument convertible into or exchangeable for any capital stock or other security of the Company; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) except as required to give
effect to anything in contemplation of the Closing, amended any of its Organizational Documents, or effected or been a party to any merger, consolidation, share exchange, business combination, recapitalization, reclassification of shares, stock
split, reverse stock split or similar transaction except, for the avoidance of doubt, the Contemplated Transactions; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) formed any Subsidiary or acquired any equity interest or other interest in any other
Entity or entered into a joint venture with any other Entity; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;(i) lent money to any Person (except for the advance of
reasonable business expenses to employees, directors and consultants in the Ordinary Course of Business), (ii) incurred or guaranteed any indebtedness for borrowed money, or (iii)&nbsp;guaranteed any debt securities of others; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f) other than as required by applicable Law or the terms of any Company Benefit Plan as in effect on the date of this Agreement and other
than the Company Plan or any Company Option: (A) adopted, terminated, established or entered into any Company Benefit Plan; (B)&nbsp;caused or permitted any Company Benefit Plan to be amended in any material respect; (C)&nbsp;paid any material bonus
or distributed any profit-sharing account balances or similar payment to, or, other than in the Ordinary Course of Business, increased the amount of the wages, salary, commissions, benefits or other compensation or remuneration payable to, any of
its directors, officers or employees; (D)&nbsp;increased the severance or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">change-of-control</FONT></FONT> benefits offered to any current, former or new employees, directors or
consultants or (E)&nbsp;hired, terminated or gave notice of termination (other than for cause) to, any (x)&nbsp;officer or (y)&nbsp;employee whose annual base salary is or is expected to be more than $125,000 per year; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(g) entered into any collective bargaining agreement or similar agreement with any labor union or similar labor organization; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(h) entered into any material transaction other than (A)&nbsp;in the Ordinary Course of Business or (B)&nbsp;in connection with the
Contemplated Transactions; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) acquired any material asset or sold, leased or otherwise irrevocably disposed of any of its assets or
properties, or granted any Encumbrance (other than Permitted Encumbrances) with respect to such assets or properties, except in the Ordinary Course of Business; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(j) sold, assigned, transferred, licensed, sublicensed or otherwise disposed of any material Company IP (other than pursuant to <FONT
STYLE="white-space:nowrap">non-exclusive</FONT> licenses in the Ordinary Course of Business); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(k) made, changed or revoked any material
Tax election, failed to pay any income or other material Tax as such Tax becomes due and payable, filed any amendment making any material change to any Tax Return, settled or compromised any income or other material Tax liability, entered into any
Tax allocation, sharing, indemnification or other similar agreement or arrangement (including any &#147;closing agreement&#148; described in Section&nbsp;7121 of the Code (or any similar Law) with any Governmental Body, but excluding customary
commercial Contracts entered into in the Ordinary Course of Business the principal subject matter of which is not Taxes), requested or consented to any extension or waiver of any limitation period with respect to any claim or assessment for any
income or other material Taxes (other than pursuant to an extension of time to file any Tax Return granted in the Ordinary Course of Business of not more than six months), or adopted or changed any material accounting method in respect of Taxes;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(l) made any expenditures, incurred any Liabilities or discharged or satisfied any Liabilities, in each case, in amounts that exceed
$300,000; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(m) other than as required by Law or GAAP, taken any action to change accounting policies or procedures; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(n) initiated or settled any Legal Proceeding; or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(o) agreed, resolved or committed to do any of the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.9 <B><U>Absence of Undisclosed Liabilities</U></B>. As of the date hereof, the Company has no any liability, indebtedness, obligation or
expense of any kind, whether accrued, absolute, contingent, matured or unmatured (whether or not required to be reflected in the financial statements in accordance with GAAP) (each a &#147;<B><I>Liability</I></B>&#148;), individually or in the
aggregate, of a type required to be recorded or reflected on a balance sheet or disclosed in the footnotes thereto under GAAP, except for: (a) Liabilities disclosed, reflected or reserved against in the Company Unaudited Interim Balance Sheet;
(b)&nbsp;Liabilities that have been incurred by the Company since the date of the Company Unaudited Interim Balance Sheet in the Ordinary Course of Business; (c)&nbsp;Liabilities for performance of obligations under Company Contracts in the Ordinary
Course of Business; (d)&nbsp;Liabilities incurred in connection with the Contemplated Transactions; (e)&nbsp;Liabilities which would not, individually or in the aggregate, reasonably be expected to be material to the Company; and
(f)&nbsp;Liabilities described in <U>Section</U><U></U><U>&nbsp;2.9</U> of the Company Disclosure Schedule. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.10 <B><U>Title to
Assets</U></B>. The Company owns, and has good and valid title to, or, in the case of leased properties and assets, valid leasehold interests in, all tangible properties or tangible assets and equipment used or held for use in its business or
operations or purported to be owned by it that are material to the Company or its business, including: (a) all tangible assets reflected on the Company Unaudited Interim Balance Sheet; and (b)&nbsp;all other tangible assets reflected in the books
and records of the Company as being owned by the Company. All of such assets are owned or, in the case of leased assets, leased by the Company free and clear of any Encumbrances, other than Permitted Encumbrances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.11 <B><U>Real Property; Leasehold</U></B>. The Company does not own, nor has ever owned, any real property. The Company has made available
to Parent (a)&nbsp;an accurate and complete list of all real properties with respect to which the Company directly or indirectly holds a valid leasehold interest as well as any other real estate that is in the possession of, or occupied or leased
by, the Company and (b)&nbsp;copies of all leases under which any such real property is possessed, occupied or leased (the &#147;<B><I>Company Real Estate Leases</I></B>&#148;), each of which is in full force and effect, with no existing material
default thereunder by the Company, or to the Knowledge of the Company, any other party thereto. The Company&#146;s possession, occupancy, lease, use and/or operation of each such leased property conforms to all applicable Laws in all material
respects, and the Company has exclusive possession of each such leased property and leasehold interest and has not granted any occupancy rights to tenants or licensees with respect to such leased property or leasehold interest. In addition, each
such leased property and leasehold interest is free and clear of all Encumbrances other than Permitted Encumbrances. The Company has not received any written notice from its landlords or any Governmental Body that: (i)&nbsp;relates to violations of
building, zoning, safety or fire ordinances or regulations; (ii)&nbsp;claims any defect or deficiency with respect to any of such properties; or (iii)&nbsp;requests the performance of any repairs, alterations or other work to such properties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.12 <B><U>Intellectual Property</U></B><B><U>; Privacy</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) <U>Section</U><U></U><U>&nbsp;2.12(a)</U> of the Company Disclosure Schedule identifies each item of material Registered IP owned in
whole or in part by the Company, including, with respect to each application and registration: (i)&nbsp;the name of the applicant or registrant and any other <FONT STYLE="white-space:nowrap">co-owner,</FONT> (ii)&nbsp;the jurisdiction of application
or registration, and (iii)&nbsp;the application or registration number. To the Knowledge of the Company, each of the patents and patent applications included in <U>Section</U><U></U><U>&nbsp;2.12(a)</U> of the Company Disclosure Schedule properly
identifies by name each and every inventor of the inventions claimed therein as determined in accordance with applicable Laws of the United States. As of the date of this Agreement, no cancellation, interference, opposition, reissue, reexamination
or other proceeding of any nature (other than office actions or similar communications issued by any Governmental Body in the ordinary course of prosecution of any pending applications for registration) is pending or, to the Knowledge
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of the Company, threatened in writing, in which the scope, validity, enforceability or ownership of any Company IP is being or has been contested or challenged. To the Knowledge of the Company,
each item of Company IP is valid and enforceable, and with respect to the Company&#146;s Registered IP, subsisting. There are no actions that must be taken within ninety (90)&nbsp;days of the Closing, the failure of which will result in the
abandonment, lapse or cancellation of any material Registered IP owned in whole or in part by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) Except as has not had and
would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect, the Company exclusively own, are the sole assignee of, or have exclusively licensed all material Company IP (other than as disclosed in
<U>Section</U><U></U><U>&nbsp;2.12(b)</U> of the Company Disclosure Schedule), free and clear of all Encumbrances other than Permitted Encumbrances. The Company IP and the Intellectual Property Rights licensed to the Company pursuant to a valid,
enforceable written agreement constitute all Intellectual Property Rights used in, material to or otherwise necessary for the operation of the Company&#146;s business as currently conducted. Each Company Associate involved in the creation or
development of any material Company IP, pursuant to such Company Associate&#146;s activities on behalf of the Company, has signed a valid and enforceable written agreement containing an assignment of such Company Associate&#146;s rights in such
Company IP to the Company. Each Company Associate who has or has had access to the Company&#146;s trade secrets or confidential information has signed a valid and enforceable written agreement containing confidentiality provisions protecting the
Company IP, trade secrets and confidential information. The Company has taken commercially reasonable steps to protect and preserve the confidentiality of its trade secrets and confidential information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) To the Knowledge of the Company, no funding, facilities or personnel of any Governmental Body or any university, college, research
institute or other educational institution has been used to create Company IP, except for any such funding or use of facilities or personnel that does not result in such Governmental Body or institution owning such Company IP as of the date of this
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) <U>Section</U><U></U><U>&nbsp;2.12(d)</U> of the Company Disclosure Schedule sets forth each license agreement pursuant
to which the Company (i)&nbsp;is granted a license under any material Intellectual Property Right owned by any third party that is used by the Company in its business as currently conducted (each a &#147;<B><I>Company
<FONT STYLE="white-space:nowrap">In-bound</FONT> License</I></B>&#148;) or (ii)&nbsp;grants to any third party a license under any material Company IP or material Intellectual Property Right licensed to the Company under a Company <FONT
STYLE="white-space:nowrap">In-bound</FONT> License (each a &#147;<B><I>Company</I></B> <B><I><FONT STYLE="white-space:nowrap">Out-bound</FONT> License</I></B>&#148;) (<I>provided</I>, that, Company <FONT STYLE="white-space:nowrap">In-bound</FONT>
Licenses shall not include, when entered into in the Ordinary Course of Business, material transfer agreements, clinical trial agreements, agreements with Company Associates, services agreements,
<FONT STYLE="white-space:nowrap">non-disclosure</FONT> agreements, commercially available <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Software-as-a-Service</FONT></FONT></FONT> offerings, or <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">off-the-shelf</FONT></FONT> software licenses; and Company <FONT STYLE="white-space:nowrap">Out-bound</FONT> Licenses shall not include, when entered into in the Ordinary Course of
Business, material transfer agreements, clinical trial agreements, services agreements, <FONT STYLE="white-space:nowrap">non-disclosure</FONT> agreements, or <FONT STYLE="white-space:nowrap">non-exclusive</FONT> outbound licenses). All Company <FONT
STYLE="white-space:nowrap">In-bound</FONT> Licenses and Company <FONT STYLE="white-space:nowrap">Out-bound</FONT> Licenses are in full force and effect and are valid, enforceable and binding obligations of the Company and, to the Knowledge of
Company, each other party to such Company <FONT STYLE="white-space:nowrap">In-bound</FONT> Licenses or Company <FONT STYLE="white-space:nowrap">Out-bound</FONT> Licenses. Neither the Company, nor to the Knowledge of the Company, any other party to
such Company <FONT STYLE="white-space:nowrap">In-bound</FONT> Licenses or Company <FONT STYLE="white-space:nowrap">Out-bound</FONT> Licenses, is in material breach under any Company <FONT STYLE="white-space:nowrap">In-bound</FONT> Licenses or
Company <FONT STYLE="white-space:nowrap">Out-bound</FONT> Licenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) To the Knowledge of the Company: (i)&nbsp;the operation of the
business of the Company as currently conducted does not infringe, misappropriate or otherwise violate any Intellectual Property Rights of any other Person and (ii)&nbsp;no other Person is infringing, misappropriating or otherwise violating any
Company IP. No Legal Proceeding is pending (or, to the Knowledge of the Company, is threatened in writing) (A)&nbsp;against the Company alleging that the operation of the business of the Company </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
infringes or constitutes the misappropriation or other violation of any Intellectual Property Rights of another Person or (B)&nbsp;by the Company alleging that another Person has infringed,
misappropriated or otherwise violated any of the Company IP. Since the Company&#146;s inception, the Company has not received any written notice or other written communication alleging that the operation of the business of the Company infringes or
constitutes the misappropriation or other violation of any Intellectual Property Right of another Person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f) None of the Company IP
owned by the Company or, to the Knowledge of the Company, none of the material Intellectual Property Rights exclusively licensed to the Company is subject to any pending or outstanding injunction, directive, order, judgment or other disposition of
dispute that adversely and materially restricts the use, transfer, registration or licensing by the Company of any such Company IP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(g)
To the Knowledge of the Company, the Company and the operation of the Company&#146;s business are and since December&nbsp;31, 2020 has been, in material compliance with Privacy and Data Processing Requirements. To the knowledge of the Company, the
Company has at all applicable times provided all notices, and obtained and maintained all rights, consents, and authorizations, to Process Company Data as Processed by or for the Company. Since the Company&#146;s inception, there have been
(i)&nbsp;no loss or theft or security breach relating to Company Data, (ii)&nbsp;no violation of any security policy of the Company regarding any such Company Data, and (iii)&nbsp;no unauthorized access to, or unauthorized, unintended, or improper
use disclosure, or other Processing of any Company Data. The Company has taken commercially reasonable steps and implemented reasonable disaster recovery and security plans and procedures to protect the information technology systems used in,
material to or necessary for operation of the Company&#146;s business as currently conducted and Company Data from unauthorized use access, or other Processing. To the Knowledge of the Company, there have been no (i)&nbsp;material malfunctions or
unauthorized intrusions or breaches of the information technology systems used in, material to or necessary for the operation of the Company&#146;s business or (ii)&nbsp;material unauthorized access to, or other processing of, Company Data. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.13 <B><U>Agreements, Contracts and Commitments</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) <U>Section</U><U></U><U>&nbsp;2.13(a)</U> of the Company Disclosure Schedule lists the following Company Contracts in effect as of the
date of this Agreement other than any Company Benefit Plans (each, a &#147;<B><I>Company Material Contract</I></B>&#148; and collectively, the &#147;<B><I>Company Material Contracts</I></B>&#148;): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(i) each Company Contract relating to any agreement of indemnification or guaranty not entered into in the Ordinary Course of Business; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(ii) each Company Contract containing (A)&nbsp;any covenant limiting the freedom of the Company or the Surviving Entity to engage in any line
of business or compete with any Person, (B)&nbsp;any most-favored nation or other preferred pricing arrangement in favor of a Person other than the Company or any similar term by which any Person is or could become entitled to any benefit, right or
privilege that must be at least as favorable to such Person as those offered to any other Person, (C)&nbsp;any exclusivity provision, right of first refusal or right of first negotiation or similar covenant in favor of a Person other than the
Company, or (D)&nbsp;any <FONT STYLE="white-space:nowrap">non-solicitation</FONT> provision not entered into the Ordinary Course of Business; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(iii) each Company Contract relating to capital expenditures and requiring payments after the date of this Agreement in excess of $100,000
pursuant to its express terms and not cancelable without penalty; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(iv) each Company Contract relating to the disposition or acquisition of material assets or
any ownership interest in any Entity, except as contemplated hereby; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(v) each Company Contract relating to any mortgages, indentures,
loans, notes or credit agreements, security agreements or other agreements or instruments relating to the borrowing of money or extension of credit or creating any material Encumbrances with respect to any assets of the Company or any loans or debt
obligations with officers or directors of the Company; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(vi) each Company Contract requiring payment by or to the Company after the date
of this Agreement in excess of $100,000 in the aggregate in the current calendar year or any future calendar year pursuant to its express terms relating to: (A) any distribution agreement (identifying any that contain exclusivity provisions); (B)
any agreement involving provision of services or products with respect to any <FONT STYLE="white-space:nowrap">pre-clinical</FONT> or clinical development activities of the Company; (C)&nbsp;any dealer, distributor, joint marketing, alliance, joint
venture, cooperation, development or other agreement currently in force under which the Company has continuing obligations to develop or market any product, technology or service, or any agreement pursuant to which the Company has continuing
obligations to develop any Intellectual Property Rights that will not be owned, in whole or in part, by the Company; or (D)&nbsp;any Contract with any third party providing any services relating to the manufacture or production of any product,
service or technology of the Company or any Contract to sell, distribute or commercialize any products or service of the Company; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(vii)
each Company Contract with any financial advisor, broker, finder, investment banker or other similar Person providing financial advisory services to the Company in connection with the Contemplated Transactions; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(viii) each Company Real Estate Lease; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(ix) each Company Contract with any Governmental Body; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(x) each Company <FONT STYLE="white-space:nowrap">Out-bound</FONT> License and Company <FONT STYLE="white-space:nowrap">In-bound</FONT>
License, and each Company Contract containing a covenant not to sue or otherwise enforce any Intellectual Property Rights; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(xi) each
Company Contract requiring the payment of any royalty, dividend or similar arrangement based on the revenues or profits of the Company; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(xii) each Company Contract, offer letter, employment agreement, or independent contractor agreement with any employee, independent
contractor or other natural person service provider whose annual compensation equals or exceeds $125,000 that (A)&nbsp;is not immediately terminable at will by the Company without notice, severance or other cost or payment, except as required under
applicable Law, or (B)&nbsp;provides for retention payments, change of control payments, severance, accelerated vesting, or any similar payment or benefit that may or will become due as a result of the Merger; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(xiii) each Company Contract providing any option to receive a license or other right, any right of first negotiation, any right of first
refusal or any similar right to any Person related to any material Company IP or material Intellectual Property Right licensed to the Company under a Company <FONT STYLE="white-space:nowrap">In-bound</FONT> License; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(xiv) each Company Contract entered into in settlement of any Legal Proceeding or other dispute; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(xv) any other Company Contract that is not terminable at will (with no penalty or payment
or requirement for prior notice, except as required by applicable law) by the Company and (A)&nbsp;which involves payment or receipt by the Company after the date of this Agreement under any such agreement, Contract or commitment of more than
$100,000 in the aggregate, or obligations after the date of this Agreement in excess of $100,000 in the aggregate, or (B)&nbsp;that is material to the business or operations of the Company taken as a whole. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) The Company has delivered or made available to Parent accurate and complete copies of all Company Material Contracts, including all
amendments thereto. Except as set forth in <U>Section</U><U></U><U>&nbsp;2.13(b)</U> of the Company Disclosure Schedule, there are no Company Material Contracts that are not in written form. Neither the Company nor, to the Company&#146;s Knowledge,
as of the date of this Agreement any other party to a Company Material Contract, has breached, violated or defaulted under, or received notice that it breached, violated or defaulted under, any of the terms or conditions of any Company Material
Contract in such manner as would permit any other party to cancel or terminate any such Company Material Contract, or would permit any other party to seek damages which would reasonably be expected to be material to the Company or its business. As
to the Company, as of the date of this Agreement, each Company Material Contract is valid, binding, enforceable and in full force and effect, subject to the Enforceability Exceptions. No Person is renegotiating, or has a right pursuant to the terms
of any Company Material Contract to change, any material amount paid or payable to the Company under any Company Material Contract or any other material term or provision of any Company Material Contract, and no Person has indicated in writing to
the Company that it desires to renegotiate, modify, not renew or cancel any Company Material Contract. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.14 <B><U>Compliance; Permits;
Restrictions</U></B>. The Company holds all required Governmental Authorizations which are material to the operation of the business of the Company as currently conducted (the &#147;<B><I>Company Permits</I></B>&#148;).
<U>Section</U><U></U><U>&nbsp;2.14(b)</U> of the Company Disclosure Schedule identifies each Company Permit. Each such Company Permit is valid and in full force and effect, and the Company is in material compliance with the terms of the Company
Permits. No Legal Proceeding is pending or, to the Knowledge of the Company, threatened, which seeks to revoke, limit, suspend, or materially modify any Company Permit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.15 <B><U>Legal Proceedings; Orders</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) As of the date of this Agreement, there is no material pending Legal Proceeding and, to the Knowledge of the Company, no Person has
threatened in writing to commence any Legal Proceeding: (i)&nbsp;that involves (A)&nbsp;the Company, (B)&nbsp;any Company Associate (in his or her capacity as such) or (C)&nbsp;any of the material assets owned or used by the Company; or
(ii)&nbsp;that challenges, or that would have the effect of preventing, delaying, making illegal or otherwise interfering with, the Contemplated Transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) Except as set forth in Section&nbsp;2.15(b) of the Company Disclosure Schedule, since the Company&#146;s inception through the date of
this Agreement, no Legal Proceeding has been pending against the Company that resulted in material liability to the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) There
is no order, writ, injunction, judgment or decree to which the Company, or any of the material assets owned or used by the Company, is subject. To the Knowledge of the Company, no officer or employees of the Company is subject to any order, writ,
injunction, judgment or decree that prohibits such officer or employee from engaging in or continuing any conduct, activity or practice relating to the business of the Company or to any material assets owned or used by the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.16 <B><U>Tax Matters</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) The Company has timely filed all income and other material Tax Returns that were required to be filed by or with respect to it under
applicable Law. All such Tax Returns are correct and complete in all material respects and have been prepared in compliance with all applicable Law. No written claim has ever been made by any Governmental Body in any jurisdiction where the Company
does not file a particular Tax Return or pay a particular Tax that the Company or such Subsidiary is subject to taxation by that jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) All income and other material Taxes due and owing by the Company on or before the date hereof (whether or not shown on any Tax Return)
have been fully and timely paid. The unpaid Taxes of the Company did not, as of the date of the Company Unaudited Interim Balance Sheet, materially exceed the reserve for Tax liability (excluding any reserve for deferred Taxes established to reflect
timing differences between book and Tax items) set forth on the face of the Company Unaudited Interim Balance Sheet. Since the date of the Company Unaudited Interim Balance Sheet, the Company has not incurred any material Liability for Taxes outside
the Ordinary Course of Business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) All Taxes that the Company is or was required by Law to withhold or collect have been duly and
timely withheld or collected in all material respects on behalf of its respective employees, independent contractors, stockholders, lenders, customers or other third parties and have been timely paid to the proper Governmental Body or other Person
or properly set aside in accounts for this purpose. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) There are no Encumbrances for material Taxes (other than Taxes not yet due and
payable) upon any of the assets of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) No deficiencies for a material amount of Taxes with respect to the Company have been
claimed, proposed or assessed by any Governmental Body in writing. There are no pending or ongoing and, to the Knowledge of the Company, no threatened audits, assessments or other actions for or relating to any liability in respect of a material
amount of Taxes of the Company. The Company nor any of its predecessors has waived any statute of limitations or agreed to any extension of time with respect to any income or other material Tax assessment or deficiency. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f) The Company has not been a United States real property holding corporation within the meaning of Section&nbsp;897(c)(2) of the Code
during the applicable period specified in Section&nbsp;897(c)(1)(A)(ii) of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(g) The Company is not a party to any Tax
allocation agreement, Tax sharing agreement, Tax indemnity agreement, or similar agreement or arrangement, other than customary commercial Contracts entered into in the Ordinary Course of Business the principal subject matter of which is not Taxes.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(h) The Company (nor Parent as a result of the Mergers) will not be required to include any item of income in, or exclude any item of
deduction from, taxable income for any Tax period (or portion thereof) ending after the Closing Date as a result of any: (i)&nbsp;change in method of accounting for Tax purposes for a Tax period ending on or prior to the Closing Date; (ii)&nbsp;use
of an improper method of accounting for a Tax period ending on or prior to the Closing Date; (iii) &#147;closing agreement&#148; as described in Section&nbsp;7121 of the Code (or any similar provision of state, local or foreign Law) executed on or
prior to the Closing Date; (iv)&nbsp;intercompany transaction or excess loss account described in Treasury Regulations under Section&nbsp;1502 of the Code (or any similar provision of state, local or foreign Law); (v) installment sale or open
transaction disposition made on or prior to the Closing Date; or (vi)&nbsp;prepaid amount, advance payment or deferred revenue received or accrued on or prior to the Closing Date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) The Company has not ever been (i)&nbsp;a member of a consolidated, combined or unitary
Tax group (other than such a group the common parent of which is the Company) or (ii)&nbsp;a party to any joint venture, partnership, or other arrangement that is treated as a partnership for U.S. federal income Tax purposes. The Company has no
Liability for any material Taxes of any Person (other than the Company) under Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.1502-6</FONT> (or any similar provision of state, local, or foreign Law), as a transferee or
successor, by Contract (other than a Contract entered into in the Ordinary Course of Business the principal subject matter of which is not Taxes) or otherwise by operation of law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(j) The Company has not ever distributed stock of another Person, or had its stock distributed by another Person, in a transaction that was
purported or intended to be governed in whole or in part by Section&nbsp;355 of the Code or Section&nbsp;361 of the Code (or any similar provisions of state, local or foreign Law). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(k) The Company has not had a permanent establishment (within the meaning of an applicable Tax treaty) or otherwise had an office or fixed
place of business in a country other than the country in which it is organized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(l) The Company has not participated in or been a party
to a transaction that, as of the date of this Agreement, constitutes a &#147;listed transaction&#148; within the meaning of Section&nbsp;6707A(c)(2) of the Code and Treasury Regulations
<FONT STYLE="white-space:nowrap">Section&nbsp;1.6011-4(b)(2).</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(m) Section&nbsp;2.16(n) of the Company Disclosure Schedule sets
forth the entity classification of the Company for U.S. federal income tax purposes. The Company has not made an election or taken any other action to change its federal and state income tax classification from such classification. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of this <U>Section</U><U></U><U>&nbsp;2.16</U>, each reference to the Company shall be deemed to include any Person that was
liquidated into, merged with, or is otherwise a predecessor to, the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.17 <B><U>Employee and Labor Matters; Benefit
Plans</U></B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) Section&nbsp;2.17(a) of the Company Disclosure Schedule is a list of all material Company Benefit Plans, other than <FONT
STYLE="white-space:nowrap">at-will</FONT> employment offer letters on the Company&#146;s standard form and other than individual compensatory equity award agreements made pursuant to the Company&#146;s standard forms, in which case only
representative standard forms of such agreements shall be scheduled. &#147;<B><I>Company Benefit Plan</I></B>&#148; means each (i) &#147;employee benefit plan&#148; as defined in Section&nbsp;3(3) of ERISA and (ii)&nbsp;other pension, retirement,
deferred compensation, excess benefit, profit-sharing, bonus, incentive, equity or equity-based, phantom equity, employment, consulting, severance, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">change-of-control,</FONT></FONT>
retention, health, life, disability, group insurance, paid time off, holiday, welfare and fringe benefit plan, program, agreement, Contract, or arrangement (whether written or unwritten, qualified or nonqualified, funded or unfunded, subject or not
subject to ERISA and including any that have been frozen), in each case, sponsored, maintained, administered, contributed to, or required to be contributed to, by the Company for the benefit of any current or former employee, director, officer or
independent contractor of the Company (or beneficiary thereof) or under which the Company has any actual or contingent liability (including, without limitation, by reason of having a Company ERISA Affiliate). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) As applicable with respect to each material Company Benefit Plan, the Company has made available to Parent, true and complete copies of
(i)&nbsp;each material Company Benefit Plan, including all amendments thereto, and in the case of an unwritten material Company Benefit Plan, a written description thereof, (ii)&nbsp;all current trust documents, investment management Contracts,
custodial agreements, administrative services agreements and insurance and annuity Contracts relating thereto, (iii)&nbsp;the current summary plan description and each summary of material modifications thereto, (iv)&nbsp;the most
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
recently filed annual reports with any Governmental Body (<I>e.g.</I>,<I> </I>Form 5500 and all schedules thereto), (v) the most recent IRS determination, opinion or advisory letter,
(vi)&nbsp;the most recent summary annual reports, nondiscrimination testing reports, actuarial reports, financial statements and trustee reports, and (vii)&nbsp;all notices and filings from the IRS or Department of Labor or other Governmental Body
concerning audits or investigations, or &#147;prohibited transactions&#148; within the meaning of Section&nbsp;406 of ERISA or Section&nbsp;4975 of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) Each Company Benefit Plan has been maintained, operated and administered in compliance in all material respects with its terms and the
applicable provisions of ERISA, the Code and all other Laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) The Company Benefit Plans which are &#147;employee pension benefit
plans&#148; within the meaning of Section&nbsp;3(2) of ERISA and which are intended to meet the qualification requirements of Section&nbsp;401(a) of the Code have received determination or opinion letters from the IRS on which they may currently
rely to the effect that such plans are qualified under Section&nbsp;401(a) of the Code and the related trusts are exempt from federal income Taxes under Section&nbsp;501(a) of the Code, respectively, and nothing has occurred that would reasonably be
expected to materially adversely affect the qualification of such Company Benefit Plan or the tax exempt status of the related trust. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) Neither the Company nor any Company ERISA Affiliate maintains, contributes to, is required to contribute to, or has any actual or
contingent liability with respect to, (i)&nbsp;any &#147;employee pension benefit plan&#148; (within the meaning of Section&nbsp;3(2) of ERISA) that is subject to Title IV or Section&nbsp;302 of ERISA or Section&nbsp;412 of the Code, (ii)&nbsp;any
&#147;multiemployer plan&#148; (within the meaning of Section&nbsp;3(37) of ERISA), (iii) any &#147;multiple employer plan&#148; (within the meaning of Section&nbsp;413 of the Code) or (iv)&nbsp;any &#147;multiple employer welfare arrangement&#148;
(within the meaning of Section&nbsp;3(40) of ERISA). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f) There are no pending audits or investigations by any Governmental Body
involving any Company Benefit Plan, and no pending or, to the Knowledge of the Company, threatened claims (except for routine individual claims for benefits payable in the normal operation of the Company Benefit Plans), suits or proceedings
involving any Company Benefit Plan, or, to the Knowledge of the Company, any fiduciary thereof or service provider thereto, in any case except as would not be reasonably expected to result in material liability to the Company. All contributions and
premium payments required to have been made under any of the Company Benefit Plans or by applicable Law (without regard to any waivers granted under Section&nbsp;412 of the Code), have been timely made and the Company has no material liability for
any unpaid contributions with respect to any Company Benefit Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(g) None of the Company, any Company ERISA Affiliate or, to the
Knowledge of the Company, any fiduciary, trustee or administrator of any Company Benefit Plan, has engaged in, or in connection with the Contemplated Transactions will engage in, any transaction with respect to any Company Benefit Plan which would
subject any such Company Benefit Plan, the Company, or Parent to a material Tax, material penalty or material liability for a &#147;prohibited transaction&#148; under Section&nbsp;406 of ERISA or Section&nbsp;4975 of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(h) No Company Benefit Plan provides death, medical, dental, vision, life insurance or other welfare benefits beyond termination of service
or retirement other than coverage mandated by Law and, to the Knowledge of the Company, the Company has not made a written representation promising the same. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) Neither the execution of this Agreement, nor the performance of the Contemplated
Transactions (either alone or when combined with the occurrence of any other event, including without limitation, a termination of employment), will: (i)&nbsp;result in any payment becoming due to any current or former employee, director, officer,
or independent contractor of the Company thereof, pursuant to any Company Benefit Plan (ii)&nbsp;increase any amount of compensation or benefits otherwise payable under any Company Benefit Plan, (iii)&nbsp;result in the acceleration of the time of
payment, funding or vesting of any benefits under any Company Benefit Plan, (iv)&nbsp;require any contribution or payment to fund any obligation under any Company Benefit Plan or (v)&nbsp;limit the right to merge, amend or terminate any Company
Benefit Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(j) Except as set forth in Section&nbsp;2.17(a) of the Company Disclosure Schedule, neither the execution of this
Agreement, nor the consummation of the Contemplated Transactions (either alone or when combined with the occurrence of any other event, including without limitation, a termination of employment) will result in the receipt or retention by any person
who is a &#147;disqualified individual&#148; (within the meaning of Code Section&nbsp;280G) with respect to the Company of any payment or benefit that is or could be characterized as a &#147;parachute payment&#148; (within the meaning of Code
Section&nbsp;280G), determined without regard to the application of Code Section&nbsp;280G(b)(5). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(k) No current or former employee,
officer, director or independent contractor of the Company has any &#147;gross up&#148; agreements with the Company or other assurance of reimbursement by the Company for any Taxes imposed under Code Section&nbsp;409A or Code Section&nbsp;4999. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(l) The Company does not maintain any Company Benefit Plan for the benefit of any service providers located outside of the United States.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(m) The Company has provided to Parent a true and correct list, as of the date of this Agreement, containing the names of all current
full-time, part-time or temporary employees and independent contractors (and indication as such), and, as applicable: (i)&nbsp;the annual dollar amount of all cash compensation in the form of wages, salary, fees, commissions, or director&#146;s fees
payable to each person; (ii)&nbsp;dates of employment or service; (iii)&nbsp;title and, with respect to independent contractors, a current written description of such person&#146;s contracting services; (iv)&nbsp;visa status, if applicable; and
(v)&nbsp;with respect to employees, (A)&nbsp;a designation of whether they are classified as exempt or <FONT STYLE="white-space:nowrap">non-exempt</FONT> for purposes of the Fair Labor Standards Act, as amended (&#147;<B><I>FLSA</I></B>&#148;) and
any similar state law and (B)&nbsp;whether such an employee is on leave and, if so, the expected return date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(n) The Company is not and
has never been a party to, bound by, or has a duty to bargain under, any collective bargaining agreement or other Contract with a labor union or similar labor organization representing any of its employees, and there is no labor union or similar
labor organization representing or, to the Knowledge of the Company, purporting to represent or seeking to represent any employees of the Company, including through the filing of a petition for representation election. There is not and has not been
in the past five years, nor, to the Knowledge of the Company, is there or has there been since the Company&#146;s inception any threat of, any strike, slowdown, work stoppage, lockout, union election petition, demand for recognition, or any similar
activity or dispute or any union organizing activity, affecting the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(o) The Company is, and since the Company&#146;s inception
has been, in material compliance with all applicable Laws respecting labor, employment, employment practices, and terms and conditions of employment, including worker classification, discrimination, harassment and retaliation, equal employment
opportunities, fair employment practices, meal and rest periods, immigration, employee safety and health, payment of wages (including overtime wages), unemployment and workers&#146; compensation, leaves of absence, and hours of work. Except as would
not be reasonably likely to result in a material liability to the Company, with respect to employees of the Company, the Company, since the Company&#146;s inception, has withheld and reported all amounts required by Law to be withheld and reported
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
with respect to wages, salaries and other payments, benefits, or compensation to employees. There is no material Legal Proceeding pending or, to the Knowledge of the Company, threatened or
reasonably anticipated against the Company relating to any current or former employee, applicant for employment, or consultant of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(p) Within the preceding two years, the Company has complied in all material respects with the WARN Act, and no action that could trigger the
WARN Act will be implemented before the Closing Date without advance notification to and approval of Parent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.18 <B><U>Environmental
Matters</U></B>.<B> </B>The Company is and since inception has complied with all applicable Environmental Laws, which compliance includes the possession by the Company of all permits and other Governmental Authorizations required under applicable
Environmental Laws and compliance with the terms and conditions thereof, except for any failure to be in such compliance that, either individually or in the aggregate, would not reasonably be expected to be material to the Company or its business.
The Company has not received since inception any written notice or other communication (in writing or otherwise), whether from a Governmental Body or other Person, that alleges that the Company is not in compliance with or has liability pursuant to
any Environmental Law and, to the Knowledge of the Company, there are no circumstances that would reasonably be expected to prevent or interfere with the Company&#146;s compliance in any material respects with any Environmental Law, except where
such failure to comply would not reasonably be expected to be material to the Company or its business. No current or (during the time a prior property was leased or controlled by the Company) prior property leased or controlled by the Company has
had a release of or exposure to Hazardous Materials in material violation of or as would reasonably be expected to result in any material liability of the Company pursuant to Environmental Law. No consent, approval or Governmental Authorization of
or registration or filing with any Governmental Body is required by Environmental Laws in connection with the execution and delivery of this Agreement or consummation of the Contemplated Transactions by the Company. Prior to the date hereof, the
Company has provided or otherwise made available to Parent true and correct copies of all material environmental reports, assessments, studies and audits in the possession or control of the Company with respect to any property leased or controlled
by the Company or any business operated by it. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.19 <B><U>Insurance</U></B>. The Company has delivered or made available to Parent
accurate and complete copies of all material insurance policies and all material self-insurance programs and arrangements relating to the business, assets, liabilities and operations of the Company. Each of such insurance policies is in full force
and effect and the Company is in compliance in all material respects with the terms thereof. Other than customary end of policy notifications from insurance carriers, since the Company&#146;s inception, the Company has not received any notice or
other communication regarding any actual or possible: (a)&nbsp;cancellation or invalidation of any insurance policy; or (b)&nbsp;refusal or denial of any coverage, reservation of rights or rejection of any material claim under any insurance policy.
The Company has provided timely written notice to the appropriate insurance carrier(s) of each Legal Proceeding that is currently pending against the Company for which the Company has insurance coverage, and no such carrier has issued a denial of
coverage or a reservation of rights with respect to any such Legal Proceeding, or informed the Company of its intent to do so. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.20
<B><U>No Financial Advisors</U></B>. Except as set forth in <U>Section</U><U></U><U>&nbsp;2.20</U> of the Company Disclosure Schedule, no broker, finder or investment banker is entitled to any brokerage fee, finder&#146;s fee, opinion fee, success
fee, transaction fee or other fee or commission in connection with the Contemplated Transactions based upon arrangements made by or on behalf of the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.21 <B><U>Transactions with Affiliates</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) <U>Section</U><U></U><U>&nbsp;2.21(a)</U> of the Company Disclosure Schedule describes any material transactions or relationships, since
the Company&#146;s inception, between, on one hand, the Company and, on the other hand, any (i)&nbsp;officer or director of the Company or, to the Knowledge of the Company, any of such officer&#146;s or director&#146;s immediate family members,
(ii)&nbsp;owner of more than 5% of the voting power of the outstanding Company Capital Stock or (iii)&nbsp;to the Knowledge of the Company, any &#147;related person&#148; (within the meaning of Item 404 of Regulation
<FONT STYLE="white-space:nowrap">S-K</FONT> under the Securities Act) of any such officer, director or owner (other than the Company) in the case of each of (i), (ii) or (iii)&nbsp;that is of the type that would be required to be disclosed under
Item 404 of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> under the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b)
<U>Section</U><U></U><U>&nbsp;2.21(b)</U> of the Company Disclosure Schedule lists each stockholders agreement, voting agreement, registration rights agreement, <FONT STYLE="white-space:nowrap">co-sale</FONT> agreement or other similar Contract
between the Company and any holders of Company Capital Stock, including any such Contract granting any Person investor rights, rights of first refusal, rights of first offer, registration rights, director designation rights or similar rights
(collectively, the &#147;<B><I>Investor Agreements</I></B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.22 <B><U>Anti-Bribery</U></B>. None of the Company nor any of its
directors, officers, employees or, to the Company&#146;s Knowledge, agents or any other Person acting on their behalf (in each in their respective capacities as such) has directly or indirectly made any bribes, rebates, payoffs, influence payments,
kickbacks, illegal payments, illegal political contributions, or other payments, in the form of cash, gifts, or otherwise, or taken any other action, in violation of the Foreign Corrupt Practices Act of 1977, the UK Bribery Act of 2010 or any other
anti-bribery or anti-corruption Law (collectively, the &#147;<B><I>Anti-Bribery Laws</I></B>&#148;). The Company is not, nor has ever been, the subject of any investigation or inquiry by any Governmental Body with respect to potential violations of
Anti-Bribery Laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.23 <B><U>Disclaimer of Other Representations or Warranties</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) Except as previously set forth in this <U>Section</U><U></U><U>&nbsp;2</U> or in any certificate delivered by the Company to Parent
and/or Merger Subs pursuant to this Agreement, the Company makes no representation or warranty, express or implied, at law or in equity, with respect to it or any of its assets, liabilities or operations, and any such other representations or
warranties are hereby expressly disclaimed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) The Company acknowledges and agrees that, except for the representations and warranties
of Parent and Merger Subs set forth in <U>Section</U><U></U><U>&nbsp;3</U> or in any certificate delivered by Parent and/or Merger Subs to the Company pursuant to this Agreement, none of Parent, Merger Subs or any of their respective Representatives
is relying on any other representation or warranty of Parent or any other Person made outside of <U>Section</U><U></U><U>&nbsp;3</U> or such certificate, including regarding the accuracy or completeness of any such other representations or
warranties or the omission of any material information, whether express or implied, in each case, with respect to the Contemplated Transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;3. REPRESENTATIONS AND WARRANTIES OF PARENT AND MERGER SUBS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Subject to <U>Section</U><U></U><U>&nbsp;8.13(h)</U>, except (a)&nbsp;as set forth in the disclosure schedule delivered by Parent to the
Company (the &#147;<B><I>Parent Disclosure Schedule</I></B>&#148;) or (b)&nbsp;as disclosed in the Parent SEC Documents filed with the SEC after December&nbsp;31, 2020 and prior to the date hereof and publicly available on the SEC&#146;s Electronic
Data Gathering Analysis and Retrieval system (but (i)&nbsp;without giving effect to any amendment thereof filed with, or furnished to the SEC on or after the date hereof and (ii)&nbsp;excluding any disclosures contained under the heading &#147;Risk
Factors&#148; and any disclosure of risks included in any &#147;forward-looking statements&#148; disclaimer or in any other section to the extent they are forward-looking statements or cautionary, predictive or forward-looking in nature), it being
understood that any matter disclosed in the Parent SEC Documents (x)&nbsp;shall not be deemed disclosed for purposes of <U>Section</U><U></U><U>&nbsp;3.1</U><U>,</U> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<U>Section</U><U></U><U>&nbsp;3.2</U>, <U>Section</U><U></U><U>&nbsp;3.3</U>, <U>Section</U><U></U><U>&nbsp;3.4</U>, <U>Section</U><U></U><U>&nbsp;3.5</U>, <U>Section</U><U></U><U>&nbsp;3.6</U>,
and <U>Section</U><U></U><U>&nbsp;3.7</U> and (y)&nbsp;shall be deemed to be disclosed in a section of the Parent Disclosure Schedule only to the extent that it is readily apparent from a reading of such Parent SEC Documents that is applicable to
such section of the Parent Disclosure Schedule, Parent and Merger Sub represent and warrant to the Company as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.1 <B><U>Due
Organization; Subsidiaries</U></B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) Each of Parent, First Merger Sub and Second Merger Sub is a corporation duly incorporated,
validly existing and in good standing under the Laws of the jurisdiction of its incorporation, and has all necessary corporate power and authority: (i) to conduct its business in the manner in which its business is currently being conducted;
(ii)&nbsp;to own or lease and use its property and assets in the manner in which its property and assets are currently owned or leased and used; and (iii)&nbsp;to perform its obligations under all Contracts by which it is bound. Since their
respective date of incorporation, no Merger Sub has engaged in any activities other than activities incident to its formation or in connection with or as contemplated by this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) Parent is duly licensed and qualified to do business, and is in good standing (to the extent applicable in such jurisdiction), under the
Laws of all jurisdictions where the nature of its business requires such licensing or qualification other than in jurisdictions where the failure to be so qualified individually or in the aggregate would not be reasonably expected to have a Parent
Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) Parent has no Subsidiaries, except for the Entities identified in <U>Section</U><U></U><U>&nbsp;3.1(c)</U>
of the Parent Disclosure Schedule; and neither Parent nor any of the Entities identified in <U>Section</U><U></U><U>&nbsp;3.1(c)</U> of the Company Disclosure Schedule owns any capital stock of, or any equity, ownership or profit-sharing interest of
any nature in, or controls directly or indirectly, any other Entity other than the Entities identified in <U>Section</U><U></U><U>&nbsp;3.1(c)</U> of the Company Disclosure Schedule. Each of Parent&#146;s Subsidiaries is a corporation or other legal
entity duly organized, validly existing and, if applicable, in good standing under the Laws of the jurisdiction of its organization and has all necessary corporate or other power and authority: (i) to conduct its business in the manner in which its
business is currently being conducted; (ii)&nbsp;to own or lease and use its property and assets in the manner in which its property and assets are currently owned or leased and used; and (iii)&nbsp;to perform its obligations under all Contracts by
which it is bound. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) Neither the Parent nor any of its Subsidiaries is or has otherwise been, directly or indirectly, a party to,
member of or participant in any partnership, joint venture or similar business Entity. Neither the Parent nor any of its Subsidiaries has agreed or is obligated to make, or is bound by any Contract under which it may become obligated to make, any
future investment in or capital contribution to any other Entity. Neither the Parent nor any of its Subsidiaries has, at any time, been a general partner of, or has otherwise been liable for, any of the debts or other obligations of, any general
partnership, limited partnership or other Entity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.2 <B><U>Organizational Documents</U></B>.<B> </B>Parent has made available to the
Company accurate and complete copies of the Organizational Documents or Parent and each of its Subsidiaries in effect as of the date of this Agreement. Neither Parent nor any of its Subsidiaries is in breach or violation of its respective
Organizational Documents. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.3 <B><U>Authority; Binding Nature of Agreement</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) The Parent and each of its Subsidiaries (including the Merger Subs) have all necessary corporate power and authority to enter into and to
perform its obligations under this Agreement and, subject, with respect to Parent, to receipt of the Required Parent Stockholder Vote and, with respect to Merger Subs, the adoption of this Agreement by Parent in its capacity as sole stockholder of
Merger Subs, to perform its obligations hereunder and to consummate the Contemplated Transactions. The Parent Board (at meetings duly called and held) has: (i) determined that the Contemplated Transactions are fair to, advisable and in the best
interests of Parent and its stockholders; (ii)&nbsp;authorized, approved and declared advisable this Agreement and the Contemplated Transactions, including the issuance of Parent Common Stock Payment Shares and Parent Preferred Stock Payment Shares
to the stockholders of the Company pursuant to the terms of this Agreement and the treatment of the Company Options pursuant to this Agreement; and (iii)&nbsp;determined to recommend, upon the terms and subject to the conditions set forth in this
Agreement, that the stockholders of Parent vote to approve the Parent Stockholder Matters. The First Merger Sub Board (by unanimous written consent) has: (A) determined that the Contemplated Transactions are fair to, advisable, and in the best
interests of First Merger Sub and its sole stockholder; (B)&nbsp;authorized, approved and declared advisable this Agreement and the Contemplated Transactions; and (C)&nbsp;determined to recommend, upon the terms and subject to the conditions set
forth in this Agreement, that the stockholder of First Merger Sub vote to adopt this Agreement and thereby approve the Contemplated Transactions. The Second Merger Sub Board (by unanimous written consent) has: (A) determined that the Contemplated
Transactions are fair to, advisable, and in the best interests of Second Merger Sub and its sole member; (B)&nbsp;authorized, approved and declared advisable this Agreement and the Contemplated Transactions; and (C)&nbsp;determined to recommend,
upon the terms and subject to the conditions set forth in this Agreement, that the member of Second Merger Sub vote to adopt this Agreement and thereby approve the Contemplated Transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) This Agreement has been duly executed and delivered by Parent and each Merger Sub and, assuming the due authorization, execution and
delivery by the Company, constitutes the legal, valid and binding obligation of Parent and Merger Subs, enforceable against each of Parent and Merger Subs in accordance with its terms, subject to the Enforceability Exceptions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.4 <B><U>Vote Required</U></B>. The approval of holders of Parent Common Stock is not required in order to approve this Agreement or, except
with respect to Parent Stockholder Matters, the transactions contemplated hereby. The affirmative vote of a majority of the votes cast at the Parent Stockholders&#146; Meeting by the holders of Parent Common Stock (other than the Parent Common Stock
Payment Shares to be issued at Closing pursuant to this Agreement) are the only vote of the holders of any class or series of Parent&#146;s capital stock necessary to approve the proposal described in <U>Section</U><U></U><U>&nbsp;4.2(a)(i)</U><U>
</U>(<B>&#147;</B><B><I>Required Parent Stockholder Vote</I></B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.5
<B><U><FONT STYLE="white-space:nowrap">Non-Contravention;</FONT> Consents</U></B>. Subject to obtaining the Required Parent Stockholder Vote, the filing of the Certificates of Merger required by the DGCL and the filing of the Certificate of
Designation, neither (x)&nbsp;the execution, delivery or performance of this Agreement by Parent or Merger Subs, nor (y)&nbsp;the consummation of the Contemplated Transactions, will directly or indirectly (with or without notice or lapse of time):
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) contravene, conflict with or result in a violation of any of the provisions of the Organizational Documents of Parent or Merger Subs;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) contravene, conflict with or result in a violation of, give any Governmental Body or other Person the right to challenge the
Contemplated Transactions or to exercise any remedy or obtain any relief under, any Law or any order, writ, injunction, judgment or decree to which Parent or its Subsidiaries, or any of the assets owned or used by Parent or its Subsidiaries, is
subject, except as would not reasonably be expected to be material to Parent or its business; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) contravene, conflict with or result in
a violation of any of the terms or requirements of, or give any Governmental Body the right to revoke, withdraw, suspend, cancel, terminate or modify, any Governmental Authorization that is held by Parent, except as would not reasonably be expected
to be material to Parent or its business; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) contravene, conflict with or result in a violation or breach of, or result in a default
under, any provision of any Parent Material Contract, or give any Person the right to: (i) declare a default or exercise any remedy under any Parent Material Contract; (ii)&nbsp;any material payment, rebate, chargeback, penalty or change in delivery
schedule under any Parent Material Contract; (iii)&nbsp;accelerate the maturity or performance of any Parent Material Contract; or (iv)&nbsp;cancel, terminate or modify any term of any Parent Material Contract, except in the case of any <FONT
STYLE="white-space:nowrap">non-material</FONT> breach, default, penalty or modification; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) result in the imposition or creation of
any Encumbrance upon or with respect to any asset owned or used by Parent (except for Permitted Encumbrances). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except for (i)&nbsp;any
Consent set forth in <U>Section</U><U></U><U>&nbsp;3.5</U> of the Parent Disclosure Schedule under any Parent Contract, (ii)&nbsp;the Required Parent Stockholder Vote, (iii)&nbsp;the filing of the Certificates of Merger with the Secretary of State
of the State of Delaware pursuant to the DGCL, (iv)&nbsp;the filing of the Certificate of Designation with the Secretary of State of the State of Delaware pursuant to the DGCL and (v)&nbsp;such consents, waivers, approvals, orders, authorizations,
registrations, declarations and filings as may be required under applicable federal and state securities Laws, neither Parent nor any of its Subsidiaries is or will be required to make any filing with or give any notice to, or to obtain any Consent
from, any Person in connection with (A)&nbsp;the execution, delivery or performance of this Agreement, or (B)&nbsp;the consummation of the Contemplated Transactions. The Parent Board and the First Merger Sub Board and the Second Merger Sub Board
have taken and will take all actions necessary to ensure that the restrictions applicable to business combinations contained in Section&nbsp;203 of the DGCL (or analogous provisions) are, and will be, inapplicable to the execution, delivery and
performance of this Agreement, the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements and to the consummation of the Contemplated Transactions. No other state takeover statute or similar Law applies or purports to apply to the Merger, this
Agreement or any of the other Contemplated Transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.6 <B><U>Capitalization</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) The authorized capital stock of Parent as of the date of this Agreement consists of 500,000,000 shares of Parent Common Stock, par value
$0.0001 per share, of which 65,395,159 shares have been issued and are outstanding as of the close of business on the Reference Date and 10,000,000 shares of preferred stock of Parent, par value $0.0001 per share, of which no shares have been issued
and are outstanding as of the date of this Agreement.&nbsp;Parent does not hold any shares of its capital stock in its treasury. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) All
of the outstanding shares of Parent Common Stock have been duly authorized and validly issued, and are fully paid and nonassessable. None of the outstanding shares of Parent Common Stock are entitled or subject to any preemptive right, right of
participation, right of maintenance or any similar right and none of the outstanding shares of Parent Common Stock is subject to any right of first refusal in favor of Parent. Except as contemplated herein, there is no Parent Contract relating to
the voting or registration of, or restricting any Person from purchasing, selling, pledging or otherwise disposing of (or granting any option or similar right with respect to), any shares of Parent Common Stock. Parent is not under any obligation,
nor is it bound by any Contract pursuant to which it may become obligated, to repurchase, redeem or otherwise acquire any outstanding shares of Parent Common Stock or other securities. <U>Section</U><U></U><U>&nbsp;3.6(b)</U> of the Parent
Disclosure Schedule accurately and completely lists all repurchase rights held by Parent with respect to shares of Parent Common Stock (including shares issued pursuant to the exercise of stock options) and specifies which of those repurchase rights
are currently exercisable and whether the holder of such shares of Parent Common Stock timely filed an election with the relevant Governmental Bodies under Section&nbsp;83(b) of the Code with respect to such shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) Except for the Parent Stock Plans, and except as set forth in Section&nbsp;3.6(c) of
the Parent Disclosure Schedule, Parent does not have any stock option plan or any other plan, program, agreement or arrangement providing for any equity-based compensation for any Person. As of the close of business on the Reference Date,
(i)&nbsp;Parent has reserved 15,700,776 shares of Parent Common Stock for issuance under the Parent Stock Plans, of which Parent RSUs and Parent Options to purchase a total of 10,162,453 shares, in the aggregate, have been issued and are currently
outstanding of, which no shares are subject to Parent&#146;s right of repurchase, of which (1) 10,160,786 shares have been reserved for issuance upon exercise of Parent Options previously granted and currently outstanding under the Parent Stock
Plans, (2) 1,667 shares have been reserved for issuance upon the settlement of Parent RSUs granted under the Parent Stock Plans that are outstanding as of the close of business on the Reference Date, and (3) 5,538,323 shares remain available for
future issuance pursuant to the Parent Stock Plans; and (ii) 2,323,888 shares have been reserved and available for purchase under the Parent ESPP, of which 498,554 shares have been issued under the Parent ESPP and 1,825,334 shares remain available
for future purchase under the Parent ESPP. Section&nbsp;3.6(c) of the Parent Disclosure Schedule sets forth the following information with respect to each Parent Option and Parent RSU outstanding as of the Reference Date: (i)&nbsp;the name of the
holder; (ii)&nbsp;the number of shares of Parent Common Stock subject to such Parent Option or Parent RSU at the time of grant; (iii)&nbsp;the number of shares of Parent Common Stock subject to such Parent Option or Parent RSU as of the close of
business on the Reference Date; (iv)&nbsp;the exercise price of such Parent Option; (v)&nbsp;the date on which such Parent Option or Parent RSU was granted; (vi)&nbsp;the applicable vesting schedule, including the number of vested and unvested
shares as of the close of business on the Reference Date and any acceleration provisions; (vii)&nbsp;the date on which such Parent Option or Parent RSU expires; (viii)&nbsp;whether such Parent Option is intended to constitute an &#147;incentive
stock option&#148; (as defined in the Code) or a <FONT STYLE="white-space:nowrap">non-qualified</FONT> stock option and (ix)&nbsp;whether such Parent Option is &#147;early exercisable&#148;. Parent has made available to the Company accurate and
complete copies of the Parent Stock Plans and the form of the stock option agreements and restricted stock unit agreements evidencing outstanding Parent Options and Parent RSUs granted thereunder. No vesting of Parent Options or Parent RSUs will be
accelerated in connection with the closing of the Contemplated Transactions other than as set forth on such Section&nbsp;3.6(c) of the Parent Disclosure Schedule. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) Except for the Parent Options and the Parent RSUs granted pursuant to the Parent Stock Plans, and as otherwise set forth in
<U>Section</U><U></U><U>&nbsp;3.6(d)</U> of the Parent Disclosure Schedule, there is no: (i) outstanding subscription, option, call, warrant or right (whether or not currently exercisable) to acquire any shares of the capital stock or other
securities of Parent or any of its Subsidiaries; (ii)&nbsp;outstanding security, instrument or obligation that is or may become convertible into or exchangeable for any shares of the capital stock or other securities of Parent or any of its
Subsidiaries; or (iii)&nbsp;condition or circumstance that could be reasonably likely to give rise to or provide a basis for the assertion of a claim by any Person to the effect that such Person is entitled to acquire or receive any shares of
capital stock or other securities of Parent or any of its Subsidiaries (it being understood that Parent intends to issue prior to (but contingent upon) the Closing restricted stock units to certain employees of the Company identified in the Company
Disclosure Schedule). There are no outstanding or authorized stock appreciation, phantom stock, profit participation or other similar rights with respect to Parent or any of its Subsidiaries. In addition, there are no stockholder rights plans (or
similar plan commonly referred to as a &#147;poison pill&#148;) or bonds, debentures, notes or other indebtedness of Parent having the right to vote (or convertible into, or exchangeable for, securities having the right to vote) on any matters on
which stockholders of Parent may vote. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) All outstanding shares of Parent Common Stock, Parent Options, Parent RSUs and other
securities of Parent have been issued and granted in material compliance with (i)&nbsp;the Organizational Documents of Parent in effect as of the relevant time and all applicable securities Laws and other applicable Law, and (ii)&nbsp;all
requirements set forth in applicable Contracts. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f) All distributions, dividends, repurchases and redemptions of Parent Common Stock or
other equity interests of Parent were undertaken in material compliance with (i)&nbsp;the Organizational Documents of Parent in effect as of the relevant time and all applicable securities Laws and other applicable Laws, and (ii)&nbsp;all
requirements set forth in applicable Contracts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.7 <B><U>SEC Filings; Financial Statements</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) Parent has delivered or made available to the Company accurate and complete copies of all registration statements, proxy statements,
Certifications (as defined below) and other statements, reports, schedules, forms and other documents filed by Parent with the SEC since December&nbsp;31, 2020 (the &#147;<B><I>Parent SEC Documents</I></B>&#148;), other than such documents that can
be obtained on the SEC&#146;s website at <U>www.sec.gov</U>. Since December&nbsp;31, 2020, all material statements, reports, schedules, forms and other documents required to have been filed by Parent or its officers with the SEC have been so filed
on a timely basis. As of the time it was filed with the SEC (or, if amended or superseded by a filing prior to the date of this Agreement, then on the date of such filing), each of the Parent SEC Documents complied in all material respects with the
applicable requirements of the Securities Act or the Exchange Act (as the case may be) and, as of the time they were filed, or if amended or superseded by a filing prior to the date of this Agreement, on the date of the last such amendment or
superseding filing prior to the date of this Agreement, none of the Parent SEC Documents contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements
therein, in the light of the circumstances under which they were made, not misleading. The certifications and statements required by (i)&nbsp;Rule <FONT STYLE="white-space:nowrap">13a-14</FONT> under the Exchange Act and (ii) 18 U.S.C. &#167;1350
(Section 906 of the Sarbanes-Oxley Act) relating to the Parent SEC Documents (collectively, the &#147;<B><I>Certifications</I></B>&#148;) are accurate and complete and comply as to form and content with all applicable Laws, and no current or former
executive officer of Parent has failed to make the Certifications required of him or her. Parent has made available to the Company true and complete copies of all correspondence, other than transmittal correspondence or general communications by the
SEC not specifically addressed to Parent, between the SEC, on the one hand, and Parent, on the other, since December&nbsp;31, 2020, including all SEC comment letters and responses to such comment letters and responses to such comment letters by or
on behalf of Parent except for such comment letters and responses to such comment letters that are publicly accessible through EDGAR. As of the date of this Agreement, there are no outstanding unresolved comments in comment letters received from the
SEC or Nasdaq with respect to Parent SEC Documents. To the Knowledge of Parent, none of the Parent SEC Documents is the subject of ongoing SEC review and there are no inquiries or investigations by the SEC or any internal investigations pending or
threatened, including with regards to any accounting practices of Parent. As used in this <U>Section</U><U></U><U>&nbsp;3.7</U>, the term &#147;file&#148; and variations thereof shall be broadly construed to include any manner in which a document or
information is filed, furnished, supplied or otherwise made available to the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) The financial statements (including any related
notes) contained or incorporated by reference in the Parent SEC Documents: (i) complied as to form in all material respects with the published rules and regulations of the SEC applicable thereto; (ii)&nbsp;were prepared in accordance with GAAP
(except as may be indicated in the notes to such financial statements or, in the case of unaudited financial statements, except as permitted by Form <FONT STYLE="white-space:nowrap">10-Q</FONT> of the SEC, and except that the unaudited financial
statements may not contain footnotes and are subject to normal and recurring <FONT STYLE="white-space:nowrap">year-end</FONT> adjustments) applied on a consistent basis unless otherwise noted therein throughout the periods indicated; and
(iii)&nbsp;fairly present, in all material respects, the financial position of Parent and its consolidated Subsidiaries as of the respective dates thereof and the results of operations and cash flows of Parent for the periods covered thereby. Other
than as expressly disclosed in the Parent SEC Documents filed prior to the date hereof, there has been no material change in Parent&#146;s accounting methods or principles that would be required to be disclosed in Parent&#146;s financial statements
in accordance with GAAP. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) Parent&#146;s independent registered public accounting firm has at all times since the
date of enactment of the Sarbanes-Oxley Act been: (i) a registered public accounting firm (as defined in Section&nbsp;2(a)(12) of the Sarbanes-Oxley Act); (ii) to the Knowledge of Parent, &#147;independent&#148; with respect to Parent within the
meaning of Regulation <FONT STYLE="white-space:nowrap">S-X</FONT> under the Exchange Act; and (iii)&nbsp;to the Knowledge of Parent, in compliance with subsections (g)&nbsp;through (l) of Section&nbsp;10A of the Exchange Act and the rules and
regulations promulgated by the SEC and the Public Company Accounting Oversight Board thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) Since December&nbsp;31, 2020,
through the date of this Agreement, Parent has not received any comment letter from the SEC or the staff thereof or any correspondence from officials of Nasdaq or the staff thereof relating to the delisting or maintenance of listing of the Parent
Common Stock on Nasdaq. As of the date of this Agreement, Parent has timely responded to all comment letters of the staff of the SEC relating to the Parent SEC Documents, and the SEC has not advised Parent that any final responses are inadequate,
insufficient or otherwise <FONT STYLE="white-space:nowrap">non-responsive.</FONT> Parent has made available to the Company true, correct and complete copies or all comment letters, written inquiries and enforcement correspondences between the SEC,
on the one hand, and Parent, on the other hand, occurring since December&nbsp;31, 2020 and will, reasonably promptly following the receipt thereof, make available to the Company any such correspondence sent or received after the date of this
Agreement. To the Knowledge of Parent, as of the date of this Agreement, none of the Parent SEC Documents is the subject of an ongoing SEC report or outstanding SEC comment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) Since December&nbsp;31, 2020, there have been no formal investigations regarding financial reporting or accounting policies and practices
discussed with, reviewed by or initiated at the direction of the chief executive officer, chief financial officer, principal accounting officer or general counsel of Parent, the Parent Board or any committee thereof, other than ordinary course
audits or reviews of accounting policies and practices or internal controls required by the Sarbanes-Oxley Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f) Parent is and since
its first date of listing on Nasdaq, has been, in compliance in all material respects with the applicable current listing and governance rules and regulations of Nasdaq. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(g) Parent maintains, and at all times since December&nbsp;31, 2020, has maintained, a system of internal control over financial reporting
(as defined in Rules <FONT STYLE="white-space:nowrap">13a-15(f)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(f)</FONT> of the Exchange Act) that is designed to provide reasonable assurance regarding the reliability of financial reporting and
the preparation of financial statements for external purposes in accordance with GAAP and to provide reasonable assurance (i)&nbsp;that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP,
(ii)&nbsp;that receipts and expenditures are made only in accordance with authorizations of management and the Parent Board, (iii)&nbsp;regarding prevention or timely detection of the unauthorized acquisition, use or disposition of Parent&#146;s
assets that could have a material effect on Parent&#146;s financial statements and (iv)&nbsp;that Parent maintains records in reasonable detail which accurately and fairly reflect the transactions and dispositions of the assets of Parent and any of
its Subsidiaries. Parent has evaluated the effectiveness of Parent&#146;s internal control over financial reporting as of December&nbsp;31, 2020, and, to the extent required by applicable Law, presented in any applicable Parent SEC Document that is
a report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> or Form <FONT STYLE="white-space:nowrap">10-Q</FONT> (or any amendment thereto) its conclusions about the effectiveness of the internal control over financial reporting as of the end of
the period covered by such report or amendment based on such evaluation. Parent has disclosed, based on its most recent evaluation of internal control over financial reporting, to Parent&#146;s auditors and audit committee (and has described in
<U>Section</U><U></U><U>&nbsp;3.7(g)</U> of the Parent Disclosure Schedule)&nbsp;(A) all material weaknesses and all </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
significant deficiencies, if any, in the design or operation of internal control over financial reporting that are reasonably likely to adversely affect Parent&#146;s ability to record, process,
summarize and report financial information and (B)&nbsp;any fraud, whether or not material, that involves Parent, any of its Subsidiaries, Parent&#146;s management or other employees who have a role in the preparation of financial statements or the
internal accounting controls utilized by the Parent and its Subsidiaries or (C)&nbsp;any claim or allegation regarding any of the foregoing. Parent has not identified, based on its most recent evaluation of internal control over financial reporting,
any significant deficiencies or material weaknesses in the design or operation of Parent&#146;s internal control over financial reporting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(h) Parent maintains &#147;disclosure controls and procedures&#148; (as defined in Rules <FONT STYLE="white-space:nowrap">13a-15(e)</FONT>
and <FONT STYLE="white-space:nowrap">15d-15(e)</FONT> of the Exchange Act) that are reasonably designed to ensure that information required to be disclosed by Parent in the periodic reports that it files or submits under the Exchange Act is
recorded, processed, summarized and reported within the required time periods, and that all such information is accumulated and communicated to Parent&#146;s management as appropriate to allow timely decisions regarding required disclosure and to
make the Certifications. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) <U>Section</U><U></U><U>&nbsp;3.7(i)</U> to the Parent Disclosure Schedule sets forth an accurate statement
of Parent&#146;s cash and cash equivalents as of the close of business on the Business Day preceding the date of this Agreement, and there has been no material change in the amount thereof from such statement through the date of this Agreement. The
cash forecast set forth in <U>Section</U><U></U><U>&nbsp;3.7(i)</U> to the Parent Disclosure Schedule: (i) has been prepared by Parent in good faith, (ii)&nbsp;is based on assumptions that Parent considers to be reasonable, and (iii)&nbsp;fairly
reflects Parent&#146;s reasonably anticipated rate of cash usage for the periods covered therein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(j) Parent has not been and is not
currently a &#147;shell company&#148; as defined under Section&nbsp;12b-2 of the Exchange Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.8 <B><U>Absence of Changes</U></B>.
Except as set forth in <U>Section</U><U></U><U>&nbsp;3.8</U> of the Parent Disclosure Schedule, after the date of the Parent Balance Sheet, Parent and its Subsidiaries have conducted its business only in the Ordinary Course of Business (except for
the execution and performance of this Agreement and the discussions, negotiations and transactions related thereto) and there has not been any (a)&nbsp;Parent Material Adverse Effect and (b)&nbsp;neither Parent nor any of its Subsidiaries has done
any of the following: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) declared, accrued, set aside or paid any dividend or made any other distribution in respect of any shares of
its capital stock or repurchased, redeemed or otherwise reacquired any shares of its capital stock or other securities (except in connection with the payment of the exercise price and/or withholding Taxes incurred upon the exercise, settlement or
vesting of any award granted under the Parent Stock Plans); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) sold, issued, granted, pledged or otherwise disposed of or encumbered or
authorized any of the foregoing with respect to: (A) any capital stock or other security of Parent (except for Parent Common Stock issued upon the valid exercise of outstanding Parent Options); (B) any option, warrant or right to acquire any capital
stock or any other security, other than option grants to employees in the Ordinary Course of Business; or (C)&nbsp;any instrument convertible into or exchangeable for any capital stock or other security of Parent; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) except as required to give effect to anything in contemplation of the Closing, amended any of its Organizational Documents, or effected
or been a party to any merger, consolidation, share exchange, business combination, recapitalization, reclassification of shares, stock split, reverse stock split or similar transaction except, for the avoidance of doubt, the Contemplated
Transactions; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) formed any Subsidiary or acquired any equity interest or other interest in any other
Entity or entered into a joint venture with any other Entity; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;(A) lent money to any Person (except for the advance of
reasonable business expenses to employees, directors and consultants in the Ordinary Course of Business), (B) incurred or guaranteed any indebtedness for borrowed money, or (C)&nbsp;guaranteed any debt securities of others; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f) other than as required by applicable Law or the terms of any Parent Benefit Plan as in effect on the date of this Agreement: (A) adopted,
terminated, established or entered into any Parent Benefit Plan; (B)&nbsp;caused any Parent Benefit Plan to be amended in any material respect; (C)&nbsp;paid any material bonus or distributed any profit-sharing account balances or similar payment
to, or, other than in the Ordinary Course of Business, increased the amount of the wages, salary, commissions, benefits or other compensation or remuneration payable to, any of its directors, officers or employees; (D)&nbsp;increased the severance
or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">change-of-control</FONT></FONT> benefits offered to any current, former or new employees, directors or consultants or (E)&nbsp;hired, terminated or gave notice of termination
(other than for cause) to any (x)&nbsp;officer or (y)&nbsp;employee whose annual base salary is or is expected to be more than $125,000 per year; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(g) entered into any collective bargaining agreement or similar agreement with any labor union, or similar labor organization; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(h) entered into any material transaction other than (A)&nbsp;in the Ordinary Course of Business or (B)&nbsp;in connection with the
Contemplated Transactions; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) acquired any material asset or sold, leased or otherwise irrevocably disposed of any of its assets or
properties, or granted any Encumbrance with respect to such assets or properties, except in the Ordinary Course of Business; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(j) sold,
assigned, transferred, licensed, sublicensed or otherwise disposed of any material Parent IP (other than pursuant to <FONT STYLE="white-space:nowrap">non-exclusive</FONT> licenses in the Ordinary Course of Business); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(k) made, changed or revoked any material Tax election, failed to pay any income or other material Tax as such Tax becomes due and payable,
filed any amendment making any material change to any Tax Return, settled or compromised any income or other material Tax liability, entered into any Tax allocation, sharing, indemnification or other similar agreement or arrangement (including any
&#147;closing agreement&#148; described in Section&nbsp;7121 of the Code (or any similar Law) with any Governmental Body, but excluding customary commercial Contracts entered into in the Ordinary Course of Business the principal subject matter of
which is not Taxes), requested or consented to any extension or waiver of any limitation period with respect to any claim or assessment for any income or other material Taxes (other than pursuant to an extension of time to file any Tax Return
granted in the Ordinary Course of Business of not more than six months), or adopted or changed any material accounting method in respect of Taxes; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(l) made any expenditures, incurred any Liabilities or discharged or satisfied any Liabilities, in each case, in amounts that exceed the
aggregate amount of $300,000; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(m) other than as required by Law or GAAP, taken any action to change accounting policies or procedures;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(n) initiated or settled any Legal Proceeding; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(o) agreed, resolved or committed to do any of the foregoing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.9 <B><U>Absence of Undisclosed Liabilities</U></B>.<B> </B>As of the date hereof, neither
Parent nor any of its Subsidiaries has any Liability, individually or in the aggregate, of a type required to be recorded or reflected on a balance sheet or disclosed in the footnotes thereto under GAAP except for: (a) Liabilities disclosed,
reflected or reserved against in the Parent Balance Sheet; (b)&nbsp;Liabilities that have been incurred by Parent or its Subsidiaries since the date of the Parent Balance Sheet in the Ordinary Course of Business; (c)&nbsp;Liabilities for performance
of obligations of Parent or any of its Subsidiaries under Parent Contracts in the Ordinary Course of Business; (d)&nbsp;Liabilities incurred in connection with the Contemplated Transactions; (e)&nbsp;Liabilities which would not, individually or in
the aggregate, reasonably be expected to be material to the Parent; and (f)&nbsp;Liabilities described in <U>Section</U><U></U><U>&nbsp;3.9</U> of the Parent Disclosure Schedule. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.10 <B><U>Title to Assets</U></B>. Each of Parent and its Subsidiaries owns, and has good and valid title to, or, in the case of leased
properties and assets, valid leasehold interests in, all tangible properties or tangible assets and equipment used or held for use in its business or operations or purported to be owned by it, including: (a) all tangible assets reflected on the
Parent Balance Sheet; and (b)&nbsp;all other tangible assets reflected in the books and records of Parent or any of its Subsidiaries as being owned by Parent or such Subsidiary. All of such assets are owned or, in the case of leased assets, leased
by Parent or its Subsidiaries free and clear of any Encumbrances, other than Permitted Encumbrances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.11 <B><U>Real Property;
Leasehold</U></B>. Neither Parent nor any of its Subsidiaries own or ever have owned any real property. Parent has made available to the Company (a)&nbsp;an accurate and complete list of all real properties with respect to which Parent directly or
indirectly holds a valid leasehold interest as well as any other real estate that is in the possession of, or occupied or leased by, Parent or any of its Subsidiaries, and (b)&nbsp;copies of all leases under which any such real property is
possessed, occupied or leased (the &#147;<B><I>Parent Real Estate Leases</I></B>&#148;), each of which is in full force and effect, with no existing material default thereunder by Parent or any of its Subsidiaries, or to the Knowledge of Parent, any
other party thereto. Parent&#146;s possession, occupancy, lease, use and/or operation of each such leased property conforms to all applicable Laws in all material respects, and Parent has exclusive possession of each such leased property and
leasehold interest and has not granted any occupancy rights to tenants or licensees with respect to such leased property or leasehold interest. In addition, each such leased property and leasehold interest is free and clear of all Encumbrances other
than Permitted Encumbrances. Parent has not received any written notice from its landlords or any Governmental Body that: (i)&nbsp;relates to violations of building, zoning, safety or fire ordinances or regulations; (ii)&nbsp;claims any defect or
deficiency with respect to any of such properties; or (iii)&nbsp;requests the performance of any repairs, alterations or other work to such properties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.12 <B><U>Intellectual Property</U></B><B><U>; Privacy</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) Section&nbsp;3.12(a) of the Parent Disclosure Schedule identifies each item of material Registered IP owned in whole or in part by the
Parent or its Subsidiaries, including, with respect to each application and registration: (i)&nbsp;the name of the applicant/registrant and any other <FONT STYLE="white-space:nowrap">co-owners,</FONT> (ii)&nbsp;the jurisdiction of application or
registration, and (iii)&nbsp;the application or registration number. To the Knowledge of Parent, each of the U.S. patents included in Section&nbsp;3.12(a) of the Parent Disclosure Schedule properly identifies by name each and every inventor of the
inventions claimed therein as determined in accordance with applicable Laws of the United States. As of the date of this Agreement, no cancellation, interference, opposition, reissue, reexamination or other proceeding of any nature (other than
office actions or similar communications issued by any Governmental Body in the ordinary course of prosecution of any pending applications for registration) is pending or, to the Knowledge of Parent, threatened in writing, in which the scope,
validity, enforceability or ownership of any Parent IP is being or has been contested or challenged. To the Knowledge of Parent, each item of Parent IP is valid and enforceable, and with respect to the Parent&#146;s material Registered IP,
subsisting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) There are no actions that must be taken within ninety (90)&nbsp;days of the Closing,
the failure of which will result in the abandonment, lapse or cancellation of any of the Registered IP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) Except as has not had and
would not reasonably be expected to have, individually or in the aggregate, a Parent Material Adverse Effect, Parent or its Subsidiaries exclusively own, are the sole assignee of, or have exclusively licensed all of material Parent IP, free and
clear of all Encumbrances other than Permitted Encumbrances. The Parent IP constitute all Intellectual Property Rights used in, material to or otherwise necessary for the operation of Parent&#146;s and any of its Subsidiaries&#146; business as
currently conducted. Each Parent Associate involved in the creation or development of any material Parent IP, pursuant to such Parent Associate&#146;s activities on behalf of Parent or any of its Subsidiaries, has signed a valid and enforceable
written agreement containing an assignment of such Parent Associate&#146;s rights in such Parent IP to Parent or its Subsidiaries. Each Parent Associate who has or has had access to Parent&#146;s or any of its Subsidiaries&#146; trade secrets or
confidential information has signed a valid and enforceable written agreement containing confidentiality provisions protecting the Parent IP, trade secrets and confidential information. Parent has taken commercially reasonable steps to protect and
preserve the confidentiality of its trade secrets and confidential information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) To the Knowledge of Parent, no funding, facilities
or personnel of any Governmental Body or any university, college, research institute or other educational institution has been used to create Parent IP, except for any such funding or use of facilities or personnel that does not result in such
Governmental Body or institution obtaining ownership rights or a license to such Parent IP or the right to receive royalties for the practice of such Parent IP. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) Section&nbsp;3.12(d) of Parent Disclosure Schedule sets forth each license agreement pursuant to which Parent (i)&nbsp;is granted a
license under any material Intellectual Property Right owned by any third party that is used by Parent or its Subsidiaries in its business as currently conducted (each a &#147;<B><I>Parent <FONT STYLE="white-space:nowrap">In-bound</FONT>
License</I></B>&#148;) or (ii)&nbsp;grants to any third party a license under any material Parent IP (each a &#147;<B><I>Parent <FONT STYLE="white-space:nowrap">Out-bound</FONT> License</I></B>&#148;) (<I>provided</I>, that, Parent <FONT
STYLE="white-space:nowrap">In-bound</FONT> Licenses shall not include, when entered into in the Ordinary Course of Business, material transfer agreements, services agreements, clinical trial agreements, agreements with Parent Associates, <FONT
STYLE="white-space:nowrap">non-disclosure</FONT> agreements, commercially available <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Software-as-a-Service</FONT></FONT></FONT> offerings, or <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">off-the-shelf</FONT></FONT> software licenses; and Parent <FONT STYLE="white-space:nowrap">Out-bound</FONT> Licenses shall not include, when entered into in the Ordinary Course of Business,
material transfer agreements, clinical trial agreements, services agreements, <FONT STYLE="white-space:nowrap">non-disclosure</FONT> agreements, or <FONT STYLE="white-space:nowrap">non-exclusive</FONT> outbound licenses). All Parent <FONT
STYLE="white-space:nowrap">In-bound</FONT> Licenses and Parent <FONT STYLE="white-space:nowrap">Out-bound</FONT> Licenses are in full force and effect and are valid, enforceable and binding obligations of Parent and, to the Knowledge of Parent, each
other party to such Parent <FONT STYLE="white-space:nowrap">In-bound</FONT> Licenses or Parent <FONT STYLE="white-space:nowrap">Out-bound</FONT> Licenses. Neither Parent, nor, to the Knowledge of Parent, any other party to such Parent <FONT
STYLE="white-space:nowrap">In-bound</FONT> Licenses or Parent <FONT STYLE="white-space:nowrap">Out-bound</FONT> Licenses, is in material breach under any Parent <FONT STYLE="white-space:nowrap">In-bound</FONT> Licenses or Parent <FONT
STYLE="white-space:nowrap">Out-bound</FONT> Licenses. Except as set forth in Section&nbsp;3.12(d) of the Parent Disclosure Schedule, none of the terms or conditions of any Parent <FONT STYLE="white-space:nowrap">In-Bound</FONT> License or any Parent
<FONT STYLE="white-space:nowrap">Out-bound</FONT> License requires Parent or any of its Subsidiaries or any of their Affiliates to maintain, develop or prosecute any Intellectual Property Rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f) To the Knowledge of Parent: (i)&nbsp;the operation of the business of Parent and its Subsidiaries as currently conducted does not
infringe, misappropriate or otherwise violate any Intellectual Property Rights of any other Person and (ii)&nbsp;no other Person is infringing, misappropriating or otherwise violating any Parent IP. No Legal Proceeding is pending (or, to the
Knowledge of Parent, is threatened in writing)&nbsp;(A) against Parent or its Subsidiaries alleging that the operation of the business of Parent or its Subsidiaries infringes or constitutes the misappropriation or other violation of any Intellectual
Property Rights of another Person or (B)&nbsp;by Parent or its Subsidiaries alleging that another Person has infringed, misappropriated or otherwise violated any of the Parent IP. Since May&nbsp;18, 2020, neither Parent nor its Subsidiaries have
received any written notice or other written communication alleging that the operation of the business of Parent or its Subsidiaries infringes or constitutes the misappropriation or other violation of any Intellectual Property Right of another
Person. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(g) None of the Parent IP or, to the Knowledge of Parent, any material Intellectual
Property Rights exclusively licensed by Parent or its Subsidiaries, is subject to any pending or outstanding injunction, directive, order, judgment or other disposition of dispute, that adversely and materially restricts the use, transfer,
registration or licensing by Parent or its Subsidiaries of any such Parent IP or material Intellectual Property Rights exclusively licensed to Parent or its Subsidiaries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(h) To the Knowledge of Parent, Parent and the operation of Parent&#146;s and its Subsidiaries&#146; business are, and have at all times
been, in material compliance with all Privacy and Data Processing Requirements. To the knowledge of Parent, Parent and its Subsidiaries have at all applicable times provided all notices, and obtained and maintained all rights, consents, and
authorizations, to Process Parent Data as Processed by or for Parent or its Subsidiaries. Since Parent&#146;s inception, there have been (i)&nbsp;no loss or theft of, or security breach relating to. Parent Data, (ii)&nbsp;no violation of any
security policy of Parent or its Subsidiaries regarding any such Parent Data, and (iii)&nbsp;no unauthorized access to, or unauthorized, unintended, or improper use, disclosure, or other Processing of, any Parent Data. Parent and its Subsidiaries
have taken commercially reasonable steps and implemented reasonable disaster recovery and security plans and procedures to protect the information technology systems used in, material to or necessary for operation of Parent&#146;s or its
Subsidiaries business as currently conducted and Parent Data from unauthorized use, access, or other Processing. To the Knowledge of Parent, there have been no (i)&nbsp;material malfunctions or unauthorized intrusions or breaches of the information
technology systems used in, material to or necessary for the operation of Parent&#146;s or its Subsidiaries&#146; business or (ii)&nbsp;material unauthorized access to, or other processing of, Parent Data. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.13 <B><U>Agreements, Contracts and Commitments</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) Section&nbsp;3.13 of the Parent Disclosure Schedule lists the following Parent Contracts in effect as of the date of this Agreement other
than any Parent Benefit Plans (each, a &#147;<B><I>Parent Material Contract</I></B>&#148; and collectively, the &#147;<B><I>Parent Material Contracts</I></B>&#148;): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(i) a material Contract as defined in Item 601(b)(10) of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> as promulgated under the
Securities Act; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(ii) each Parent Contract relating to any agreement of indemnification or guaranty not entered into in the Ordinary
Course of Business; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(iii) each Parent Contract containing (A)&nbsp;any covenant limiting in any material respect the freedom of Parent
or its Subsidiaries to engage in any line of business or compete with any Person, (B)&nbsp;any most-favored nation or other preferred pricing arrangement in favor of a Person other than Parent or any similar term by which any Person is or could
become entitled to any benefit, right or privilege that must be at least as favorable to such Person as those offered to any other Person, (C)&nbsp;any exclusivity provision, option to receive a license, right of first refusal or right of first
negotiation or similar covenant in favor of a Person other than Parent, or (D)&nbsp;any <FONT STYLE="white-space:nowrap">non-solicitation</FONT> provision not entered into in the Ordinary Course of Business; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(iv) each Parent Contract relating to capital expenditures and requiring payments after the date of this Agreement in excess of $100,000
pursuant to its express terms and not cancelable without penalty; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(v) each Parent Contract relating to the disposition or acquisition of material assets or
any ownership interest in any Entity; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(vi) each Parent Contract relating to any mortgages, indentures, loans, notes or credit
agreements, security agreements or other agreements or instruments relating to the borrowing of money or extension of credit or creating any material Encumbrances with respect to any assets of Parent or its Subsidiaries or any loans or debt
obligations with officers or directors of Parent; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(vii) each Parent Contract requiring payment by or to Parent after the date of this
Agreement in excess of $100,000 in the aggregate in the current calendar year or any future calendar year pursuant to its express terms relating to: (A)&nbsp;any distribution agreement (identifying any that contain exclusivity provisions); (B) any
agreement involving provision of services or products with respect to any <FONT STYLE="white-space:nowrap">pre-clinical</FONT> or clinical development activities of Parent; (C)&nbsp;any dealer, distributor, joint marketing, alliance, joint venture,
cooperation, development or other agreement currently in force under which Parent has continuing obligations to develop or market any product, technology or service, or any agreement pursuant to which Parent has continuing obligations to develop any
Intellectual Property Rights that will not be owned, in whole or in part, by Parent; or (D)&nbsp;any Parent Contract with any third party providing any services relating to the manufacture or production of any product, service or technology of
Parent or any Parent Contract to sell, distribute or commercialize any products or service of Parent; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(viii) each Parent Contract with
any financial advisor, broker, finder, investment banker or other similar Person providing financial advisory services to Parent in connection with the Contemplated Transactions; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(ix) each Parent Real Estate Lease; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(x) each Parent Contract with any Governmental Body; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(xi) each Parent <FONT STYLE="white-space:nowrap">Out-bound</FONT> License and Parent <FONT STYLE="white-space:nowrap">In-bound</FONT>
License, and each Parent Contract containing a covenant not to sue or otherwise enforce any Intellectual Property Rights; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(xii) each
Parent Contract requiring the payment of any royalty, dividend or similar arrangement based on the revenues or profits of Parent or its Subsidiaries; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(xiii) each Parent Contract, offer letter, employment agreement, or independent contractor agreement with any employee, independent
contractor or other natural person service provider whose annual compensation equals or exceeds $125,000 that (A)&nbsp;is not immediately terminable by Parent without notice, severance, or other cost or liability, except as required under applicable
Law, or (B)&nbsp;provides for retention payments, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">change-of-control</FONT></FONT> payments, severance, accelerated vesting, or any similar payment or benefit that may or will become
due as a result of the Merger; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(xiv) any other Contract that is not terminable at will (with no penalty or payment or requirement for
prior notice, except as required by applicable law) by Parent or its Subsidiaries, as applicable, and (A)&nbsp;which involves payment or receipt by Parent or its Subsidiaries after the date of this Agreement under any such agreement, Contract or
commitment of more than $100,000 in the aggregate, or obligations after the date of this Agreement in excess of $100,000 in the aggregate, or (B)&nbsp;that is material to the business or operations of Parent and its Subsidiaries, taken as a whole;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(xv) each Parent Contract entered into in settlement of any Legal Proceeding or other dispute; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(xvi) each Parent Contract providing any option to receive a license or other right, any
right of first negotiation, any right of first refusal or any similar right to any Person related to any material Parent IP or material Intellectual Property Right licensed to Parent under a Parent <FONT STYLE="white-space:nowrap">In-bound</FONT>
License; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(xvii) each Parent Contract entered into in settlement of any Legal Proceeding or other dispute. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) Parent has delivered or made available to the Company accurate and complete copies of all Parent Material Contracts, including all
amendments thereto. There are no Parent Material Contracts that are not in written form. Neither Parent nor any of its Subsidiaries has, nor, to Parent&#146;s Knowledge, as of the date of this Agreement, has any other party to a Parent Material
Contract, breached, violated or defaulted under, or received notice that it breached, violated or defaulted under, any of the terms or conditions of any Parent Material Contract in such manner as would permit any other party to cancel or terminate
any such Parent Material Contract, or would permit any other party to seek damages which would reasonably be expected to be material to Parent or its business. As to Parent and its Subsidiaries, as of the date of this Agreement, each Parent Material
Contract is valid, binding, enforceable and in full force and effect, subject to the Enforceability Exceptions. No Person is renegotiating, or has a right pursuant to the terms of any Parent Material Contract to change, any material amount paid or
payable to Parent under any Parent Material Contract or any other material term or provision of any Parent Material Contract, and no Person has indicated in writing to Parent that it desires to renegotiate, modify, not renew or cancel any Parent
Material Contract. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.14 <B><U>Compliance; Permits</U></B>. Parent or its Subsidiaries hold all required Governmental Authorizations which
are material to the operation of the business of Parent or such Subsidiary as currently conducted (the &#147;<B><I>Parent Permits</I></B>&#148;). Section&nbsp;3.14(b) of the Parent Disclosure Schedule identifies each Parent Permit. Each such Parent
Permit is valid and in full force and effect, and Parent is in material compliance with the terms of the Parent Permits. No Legal Proceeding is pending or, to the Knowledge of Parent, threatened, which seeks to revoke, limit, suspend, or materially
modify any Parent Permit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.15 <B><U>Legal Proceedings; Orders</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) As of the date of this Agreement, there is no material pending Legal Proceeding and, to the Knowledge of Parent, no Person has threatened
in writing to commence any Legal Proceeding: (i) that involves (A)&nbsp;Parent, (B) any of its Subsidiaries, (C)&nbsp;any Parent Associate (in his or her capacity as such) or (D)&nbsp;any of the material assets owned or used by Parent or its
Subsidiaries; or (ii)&nbsp;that challenges, or that would have the effect of preventing, delaying, making illegal or otherwise interfering with, the Contemplated Transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) Except as set forth in <U>Section</U><U></U><U>&nbsp;3.15(b)</U> of the Parent Disclosure Schedule, since January&nbsp;1, 2019 through
the date of this Agreement, no Legal Proceeding has been pending against Parent that resulted in material liability to Parent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) There
is no order, writ, injunction, judgment or decree to which Parent or any of its Subsidiaries, or any of the material assets owned or used by Parent or any of its Subsidiaries, is subject. To the Knowledge of Parent, no officer of Parent or any of
its Subsidiaries is subject to any order, writ, injunction, judgment or decree that prohibits such officer or employee from engaging in or continuing any conduct, activity or practice relating to the business of Parent or any of its Subsidiaries or
to any material assets owned or used by Parent or any of its Subsidiaries. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.16 <B><U>Tax Matters</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) Parent and each of its Subsidiaries have filed all income and other material Tax Returns that were required to be filed by or with
respect to it under applicable Law. All such Tax Returns are correct and complete in all material respects and have been prepared in compliance with all applicable Law. No written claim has ever been made by any Governmental Body in any jurisdiction
where Parent or any of its Subsidiaries does not file a particular Tax Return or pay a particular Tax that Parent or such Subsidiary is subject to taxation by that jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) All income and other material Taxes due and owing by Parent or any of its Subsidiaries on or before the date hereof (whether or not shown
on any Tax Return) have been fully and timely paid. The unpaid Taxes of Parent and its Subsidiaries did not, as of the date of the Parent Balance Sheet, materially exceed the reserve for Tax liability (excluding any reserve for deferred Taxes
established to reflect timing differences between book and Tax items) set forth on the face of the Parent Balance Sheet. Since the Parent Balance Sheet Date, neither Parent nor any of its Subsidiaries has incurred any material Liability for Taxes
outside the Ordinary Course of Business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) All Taxes that Parent and each of its Subsidiaries is or was required by Law to withhold or
collect have been duly and timely withheld or collected in all material respects on behalf of its respective employees, independent contractors, stockholders, lenders, customers or other third parties and have been timely paid to the proper
Governmental Body or other Person or properly set aside in accounts for this purpose. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) There are no Encumbrances for material Taxes
(other than Taxes not yet due and payable) upon any of the assets of Parent or any of its Subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) No deficiencies for a
material amount of Taxes with respect to Parent or any of its Subsidiaries have been claimed, proposed or assessed by any Governmental Body in writing. There are no pending or ongoing and, to the Knowledge of Parent, threatened audits, assessments
or other actions for or relating to any liability in respect of a material amount of Taxes of Parent. Neither Parent nor any of its Subsidiaries (or predecessors thereof) has waived any statute of limitations or agreed to any extension of time with
respect to any income or other material Tax assessment or deficiency. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f) Neither Parent nor any of its Subsidiaries has been a United
States real property holding corporation within the meaning of Section&nbsp;897(c)(2) of the Code during the applicable period specified in Section&nbsp;897(c)(1)(A)(ii) of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(g) Neither Parent nor any of its Subsidiaries is a party to any Tax allocation agreement, Tax sharing agreement, Tax indemnity agreement, or
similar agreement or arrangement, other than customary commercial Contracts entered into in the Ordinary Course of Business the principal subject matter of which is not Taxes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(h) Neither Parent nor any of its Subsidiaries will be required to include any item of income in, or exclude any item of deduction from,
taxable income for any Tax period (or portion thereof) ending after the Closing Date as a result of any: (i) change in method of accounting for Tax purposes for a Tax period ending on or prior to the Closing Date; (ii)&nbsp;use of an improper method
of accounting for a Tax period ending on or prior to the Closing Date; (iii) &#147;closing agreement&#148; as described in Section&nbsp;7121 of the Code (or any similar provision of state, local or foreign Law) executed on or prior to the Closing
Date; (iv)&nbsp;intercompany transaction or excess loss account described in Treasury Regulations under Section&nbsp;1502 of the Code (or any similar provision of state, local or foreign Law); (v) installment sale or open transaction disposition
made on or prior to the Closing Date; (vi)&nbsp;prepaid amount, advance payment or deferred revenue received or accrued on or prior to the Closing Date; (vii)&nbsp;application of Section&nbsp;367(d) of the Code to any transfer of intangible property
on or prior to the Closing Date; or (viii)&nbsp;application of Sections 951 or 951A of the Code (or any similar provision of state, local or foreign Law) to any income received or accrued on or prior to the Closing Date. Parent has not made any
election under Section&nbsp;965(h) of the Code. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) Neither Parent nor any of its Subsidiaries has ever been (i)&nbsp;a member of a
consolidated, combined or unitary Tax group (other than such a group the common parent of which is Parent) or (ii)&nbsp;a party to any joint venture, partnership, or other arrangement that is treated as a partnership for U.S. federal income Tax
purposes. Parent has no Liability for any material Taxes of any Person (other than Parent and any of its Subsidiaries) under Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.1502-6</FONT> (or any similar provision of state,
local, or foreign Law), as a transferee or successor, by Contract (other than a Contract entered into in the Ordinary Course of Business the principal subject matter of which is not Taxes) or otherwise by operation of Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(j) Neither Parent nor any of its Subsidiaries has distributed stock of another Person, or had its stock distributed by another Person, in a
transaction that was purported or intended to be governed in whole or in part by Section&nbsp;355 of the Code or Section&nbsp;361 of the Code (or any similar provisions of state, local or foreign Law). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(k) Parent has never had a permanent establishment (within the meaning of an applicable Tax treaty) or otherwise had an office or fixed place
of business in a country other than the country in which it is organized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(l) Neither Parent nor any of its Subsidiaries has
participated in or been a party to a transaction that, as of the date of this Agreement, constitutes a &#147;listed transaction&#148; within the meaning of Section&nbsp;6707A(c)(2) of the Code and Treasury Regulations
<FONT STYLE="white-space:nowrap">Section&nbsp;1.6011-4(b)(2).</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(m) <U>Section</U><U></U><U>&nbsp;3.16(n)</U> of the Parent
Disclosure Schedule sets forth the entity classification of Parent and each of its Subsidiaries for U.S. federal income tax purposes. Neither Parent nor any of its Subsidiaries has made an election or taken any other action to change its federal and
state income tax classification from such classification. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of this <U>Section</U><U></U><U>&nbsp;3.16</U>, each reference to
Parent or any of its Subsidiaries shall be deemed to include any Person that was liquidated into, merged with, or is otherwise a predecessor to, Parent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.17 <B><U>Employee and Labor Matters; Benefit Plans</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) <U>Section</U><U></U><U>&nbsp;3.17(a)</U> of the Parent Disclosure Schedule is a list of all material Parent Benefit Plans, other than
employment offer letters on Parent&#146;s standard form and other than individual Parent Options or other compensatory equity award agreements made pursuant to the Parent&#146;s standard forms, in which case only representative standard forms of
such agreements shall be scheduled. &#147;<B><I>Parent</I></B> <B><I>Benefit Plan</I></B>&#148; means each (i) &#147;employee benefit plan&#148; as defined in Section&nbsp;3(3) of ERISA and (ii)&nbsp;other pension, retirement, deferred compensation,
excess benefit, profit sharing, bonus, incentive, equity or equity-based, phantom equity, employment, consulting, severance, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">change-of-control,</FONT></FONT> retention, health, life,
disability, group insurance, paid time off, holiday, welfare and fringe benefit plan, program, agreement, Contract, or arrangement (whether written or unwritten, qualified or nonqualified, funded or unfunded, subject or not subject to ERISA and
including any that have been frozen), in each case, sponsored, maintained, administered, contributed to, or required to be contributed to, by Parent or any of its Subsidiaries for the benefit of any current or former employee, director, officer or
independent contractor of Parent or any of its Subsidiaries or under which Parent or any of its Subsidiaries has any actual or contingent liability (including, without limitation, by reason of having a Parent ERISA Affiliate). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) As applicable with respect to each material Parent Benefit Plan, Parent has made
available to the Company true and complete copies of (i)&nbsp;each material Parent Benefit Plan, including all amendments thereto, and in the case of an unwritten material Parent Benefit Plan, a written description thereof, (ii)&nbsp;all current
trust documents, investment management Contracts, custodial agreements, administrative services agreements and insurance and annuity Contracts relating thereto, (iii)&nbsp;the current summary plan description and each summary of material
modifications thereto, (iv)&nbsp;the most recently filed annual reports with any Governmental Body (<I>e.g.</I>,<I> </I>Form 5500 and all schedules thereto), (v) the most recent IRS determination, opinion or advisory letter, (vi)&nbsp;the most
recent summary annual reports, nondiscrimination testing reports, actuarial reports, financial statements and trustee reports, and (vii)&nbsp;all notices and filings from the IRS or Department of Labor or other Governmental Body concerning audits or
investigations, or &#147;prohibited transactions&#148; within the meaning of Section&nbsp;406 of ERISA or Section&nbsp;4975 of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) Each Parent Benefit Plan has been maintained, operated and administered in compliance in all material respects with its terms and the
applicable provisions of ERISA, the Code and all other Laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) The Parent Benefit Plans which are &#147;employee pension benefit
plans&#148; within the meaning of Section&nbsp;3(2) of ERISA and which are intended to meet the qualification requirements of Section&nbsp;401(a) of the Code have received determination or opinion letters from the IRS on which they may currently
rely to the effect that such plans are qualified under Section&nbsp;401(a) of the Code and the related trusts are exempt from federal income Taxes under Section&nbsp;501(a) of the Code, respectively, and nothing has occurred that would reasonably be
expected to materially adversely affect the qualification of such Parent Benefit Plan or the tax exempt status of the related trust. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e)
Neither Parent, any of its Subsidiaries nor any Parent ERISA Affiliate maintains, contributes to, is required to contribute to, or has any actual or contingent liability with respect to, (i)&nbsp;any &#147;employee pension benefit plan&#148; (within
the meaning of Section&nbsp;3(2) of ERISA) that is subject to Title IV or Section&nbsp;302 of ERISA or Section&nbsp;412 of the Code, (ii)&nbsp;any &#147;multiemployer plan&#148; (within the meaning of Section&nbsp;3(37) of ERISA), (iii) any
&#147;multiple employer plan&#148; (within the meaning of Section&nbsp;413 of the Code) or (iv)&nbsp;any &#147;multiple employer welfare arrangement&#148; (within the meaning of Section&nbsp;3(40) of ERISA). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f) There are no pending audits or investigations by any Governmental Body involving any Parent Benefit Plan, and no pending or, to the
Knowledge of Parent, threatened claims (except for routine individual claims for benefits payable in the normal operation of the Parent Benefit Plans), suits or proceedings involving any Parent Benefit Plan, or, to the Knowledge of Parent, any
fiduciary thereof or service provider thereto, in any case except as would not be reasonably expected to result in material liability to Parent or any of its Subsidiaries. All contributions and premium payments required to have been made under any
of the Parent Benefit Plans or by applicable Law (without regard to any waivers granted under Section&nbsp;412 of the Code), have been timely made and neither Parent nor any Parent ERISA Affiliate has any material liability for any unpaid
contributions with respect to any Parent Benefit Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(g) None of Parent, any of its Subsidiaries or any Parent ERISA Affiliates, or to
the Knowledge of Parent, any fiduciary, trustee or administrator of any Parent Benefit Plan, has engaged in, or in connection with the Contemplated Transactions will engage in, any transaction with respect to any Parent Benefit Plan which would
subject any such Parent Benefit Plan, Parent, any of its Subsidiaries or Parent ERISA Affiliates to a material Tax, material penalty or material liability for a &#147;prohibited transaction&#148; under Section&nbsp;406 of ERISA or Section&nbsp;4975
of the Code. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(h) No Parent Benefit Plan provides death, medical, dental, vision, life insurance or other
welfare benefits beyond termination of service or retirement other than coverage mandated by Law and to the Knowledge of Parent, neither Parent nor any of its Subsidiaries has made a written representation promising the same. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) Except as set forth in <U>Section</U><U></U><U>&nbsp;3.17(i)</U> of the Parent Disclosure Schedule, neither the execution of this
Agreement, nor the performance of the Contemplated Transactions (either alone or when combined with the occurrence of any other event, including without limitation, a termination of employment) will: (i)&nbsp;result in any payment becoming due to
any current or former employee, director, officer, or independent contractor of Parent or any Subsidiary thereof pursuant to any Parent Benefit Plan, (ii)&nbsp;increase any amount of compensation or benefits otherwise payable under any Parent
Benefit Plan, (iii)&nbsp;result in the acceleration of the time of payment, funding or vesting of any benefits under any Parent Benefit Plan, (iv)&nbsp;require any contribution or payment to fund any obligation under any Parent Benefit Plan or
(v)&nbsp;limit the right to merge, amend or terminate any Parent Benefit Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(j) Except as set forth in
<U>Section</U><U></U><U>&nbsp;3.17(j)</U> of the Parent Disclosure Schedule, neither the execution of, nor the consummation of the Contemplated Transactions (either alone or when combined with the occurrence of any other event, including without
limitation, a termination of employment) will result in the receipt or retention by any person who is a &#147;disqualified individual&#148; (within the meaning of Code Section&nbsp;280G) with respect to Parent and its Subsidiaries of any payment or
benefit that is or could be characterized as a &#147;parachute payment&#148; (within the meaning of Code Section&nbsp;280G), determined without regard to the application of Code Section&nbsp;280G(b)(5). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(k) No current or former employee, officer, director or independent contractor of Parent or any of its Subsidiaries has any &#147;gross
up&#148; agreements with the Parent or any of its Subsidiaries or other assurance of reimbursement by the Parent or any of its Subsidiaries for any Taxes imposed under Code Section&nbsp;409A or Code Section&nbsp;4999. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(l) Each Parent Benefit Plan maintained for the benefit of service providers located outside of the United States (each, a &#147;<B><I>Parent
Foreign Plan</I></B>&#148;) has obtained from the Governmental Body having jurisdiction with respect to such plan any required determinations that such plan is in compliance with the Laws of any such Governmental Body. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(m) The assets of each of the Parent Foreign Plans that is similar to an employee pension benefit plan (as defined in Section&nbsp;3(2) of
ERISA (whether or not subject to ERISA)) or that otherwise provides retirement, medical or life insurance benefits following retirement or other termination of service or employment are at least equal to the liabilities of such plans. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(n) Parent has provided to the Company a true and correct list, as of the date of this Agreement, containing the names of all current
full-time, part-time or temporary employees and independent contractors (and indication as such), and, as applicable: (i) the annual dollar amount of all cash compensation in the form of wages, salary, fees, commissions, or director&#146;s fees
payable to each person; (ii)&nbsp;dates of employment or service; (iii)&nbsp;title and, with respect to independent contractors, a current written description of such person&#146;s contracting services; (iv)&nbsp;visa status, if applicable; and
(v)&nbsp;with respect to employees, (A)&nbsp;a designation of whether they are classified as exempt or <FONT STYLE="white-space:nowrap">non-exempt</FONT> for purposes of FLSA and any similar state, federal or Foreign law and (B)&nbsp;whether such an
employee is on leave, and if so, the expected return date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(o) Neither Parent nor any of its Subsidiaries is or has ever been a party to, bound by, or
has a duty to bargain under, any collective bargaining agreement or other Contract with a labor union or similar labor organization representing any of its employees, and there is no labor union or similar labor organization representing or, to the
Knowledge of Parent, purporting to represent or seeking to represent any employees of Parent or its Subsidiaries, including through the filing of a petition for representation election. There is not and has not been in the past five years, nor, to
the Knowledge of Parent, is there or has there been in the past five years any threat of, any strike, slowdown, work stoppage, lockout, union election petition, demand for recognition, or any similar activity or dispute, or any union organizing
activity, against Parent or any of its Subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(p) Parent and each of its Subsidiaries is, and since December&nbsp;31, 2020 has
been, in material compliance with all applicable Laws respecting labor, employment, employment practices, and terms and conditions of employment, including worker classification, discrimination, harassment and retaliation, equal employment
opportunities, fair employment practices, meal and rest periods, immigration, employee safety and health, payment of wages (including overtime wages), unemployment and workers&#146; compensation, leaves of absence, and hours of work. Except as would
not be reasonably likely to result in a material liability to Parent or any of its Subsidiaries, with respect to employees of Parent and its Subsidiaries, each of Parent and its Subsidiaries, since December&nbsp;31, 2020, has withheld and reported
all amounts required by Law to be withheld and reported with respect to wages, salaries and other payments, benefits, or compensation to employees. There is no material Legal Proceeding pending or, to the Knowledge of Parent, threatened or
reasonably anticipated against Parent or any of its Subsidiaries relating to any current or former employee, applicant for employment, or consultant of Parent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(q) Within the preceding two years, Parent has complied in all material respects with the WARN Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.18 <B><U>Environmental Matters</U></B><B>. </B>Parent and each of its Subsidiaries are in compliance and since December&nbsp;31, 2020 have
complied with all applicable Environmental Laws, which compliance includes the possession by Parent of all permits and other Governmental Authorizations required under applicable Environmental Laws and compliance with the terms and conditions
thereof, except for any failure to be in such compliance that, either individually or in the aggregate, would not reasonably be expected to be material to Parent or its business. Neither Parent nor any of its Subsidiaries has received since
December&nbsp;31, 2020 (or prior to that time, which is pending and unresolved), any written notice or other communication (in writing or otherwise), whether from a Governmental Body or other Person, that alleges that Parent or any of its
Subsidiaries is not in compliance with or has liability pursuant to any Environmental Law and, to the Knowledge of Parent, there are no circumstances that would reasonably be expected to prevent or interfere with Parent&#146;s or any of its
Subsidiaries&#146; compliance in any material respects with any Environmental Law, except where such failure to comply would not reasonably be expected to be material to Parent or its business. No current or (during the time a prior property was
leased or controlled by Parent or any of its Subsidiaries) prior property leased or controlled by Parent or any of its Subsidiaries has had a release of or exposure to Hazardous Materials in material violation of or as would reasonably be expected
to result in any material liability of Parent or any of its Subsidiaries pursuant to Environmental Law. No consent, approval or Governmental Authorization of or registration or filing with any Governmental Body is required by Environmental Laws in
connection with the execution and delivery of this Agreement or the consummation of the Contemplated Transactions by Parent or Merger Subs. Prior to the date hereof, Parent has provided or otherwise made available to the Company true and correct
copies of all material environmental reports, assessments, studies and audits in the possession or control of Parent or any of its Subsidiaries with respect to any property leased or controlled by Parent or any of its Subsidiaries or any business
operated by them. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.19 <B><U>Transactions with Affiliates</U></B>. Except as set forth in the Parent SEC Documents filed prior to the
date of this Agreement, since the date of Parent&#146;s last proxy statement filed in April 2023 with the SEC, no event has occurred that would be required to be reported by Parent pursuant to Item 404 of Regulation
<FONT STYLE="white-space:nowrap">S-K.</FONT> <U>Section</U><U></U><U>&nbsp;3.19</U> of the Parent Disclosure Schedule identifies each Person who is (or who may be deemed to be) an Affiliate of Parent as of the date of this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.20 <B><U>Insurance</U></B>. Parent has delivered or made available to the Company accurate
and complete copies of all material insurance policies and all material self-insurance programs and arrangements relating to the business, assets, liabilities and operations of Parent and each of its Subsidiaries. Each of such insurance policies is
in full force and effect and Parent and each of its Subsidiaries is in compliance in all material respects with the terms thereof. Other than customary end of policy notifications from insurance carriers, since January&nbsp;1, 2020, neither Parent
nor any of its Subsidiaries has received any notice or other communication regarding any actual or possible: (a)&nbsp;cancellation or invalidation of any insurance policy; or (b)&nbsp;refusal or denial of any coverage, reservation of rights or
rejection of any material claim under any insurance policy. Parent and each of its Subsidiaries has provided timely written notice to the appropriate insurance carrier(s) of each Legal Proceeding that is currently pending against Parent or any of
its Subsidiaries for which Parent or such Subsidiary has insurance coverage, and no such carrier has issued a denial of coverage or a reservation of rights with respect to any such Legal Proceeding, or informed Parent or any of its Subsidiaries of
its intent to do so. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.21 <B><U>Opinion of Financial Advisor</U></B>. The Parent Board has received an opinion of Houlihan Lokey Capital
Inc., dated on or about the date of the Agreement, to the effect that, as of the date of such opinion and subject to the assumptions, qualifications, limitations and other matters set forth therein, the Exchange Ratio (as specified in such opinion)
is fair, from a financial point of view, to Parent. It is agreed and understood that such opinion is furnished solely for the use of the Parent Board and may not be relied upon by the Company or any other party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.22 <B><U>No Financial Advisors</U></B>. No broker, finder or investment banker, other than Wedbush Securities Inc. and Houlihan Lokey
Capital Inc., is entitled to any brokerage fee, finder&#146;s fee, opinion fee, success fee, transaction fee or other fee or commission in connection with the Contemplated Transactions based upon arrangements made by or on behalf of Parent or any of
its Subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.23 <B><U>Anti-Bribery</U></B>. None of Parent or any of its Subsidiaries nor any of their respective directors,
officers, employees or, to Parent&#146;s Knowledge, agents or any other Person acting on its behalf has directly or indirectly made any bribes, rebates, payoffs, influence payments, kickbacks, illegal payments, illegal political contributions, or
other payments, in the form of cash, gifts, or otherwise, or taken any other action, in violation of Anti-Bribery Laws. Neither Parent nor any of its Subsidiaries is or has been the subject of any investigation or inquiry by any Governmental Body
with respect to potential violations of Anti-Bribery Laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.24 <B><U>Valid Issuance</U></B>. The Parent Common Stock and Parent
Convertible Preferred Stock to be issued in the Merger will, when issued in accordance with the provisions of this Agreement, be validly issued, fully paid and nonassessable. To the Knowledge of Parent as of the date of this Agreement, no &#147;bad
actor&#148; disqualifying event described in Rule 506(d)(1)(i)&#150;(viii) of the Securities Act (a &#147;<B><I>Disqualifying Event</I></B>&#148;) is applicable to Parent or, to Parent&#146;s Knowledge, any Parent Covered Person, except for a
Disqualifying Event as to which Rule 506(d)(2)(ii)&#150;(iv) or (d)(3) of the Securities Act is applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.25 <B><U>Disclaimer of
Other Representations or Warranties</U></B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) Except as previously set forth in this <U>Section</U><U></U><U>&nbsp;3</U> or in any
certificate delivered by Parent or Merger Subs to the Company pursuant to this Agreement, neither Parent nor any Merger Sub makes any representation or warranty, express or implied, at law or in equity, with respect to it or any of its assets,
liabilities or operations, and any such other representations or warranties are hereby expressly disclaimed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) Each of Parent, First Merger Sub and Second Merger Sub acknowledges and agrees that,
except for the representations and warranties of the Company set forth in <U>Section</U><U></U><U>&nbsp;2</U> or in any certificate delivered by the Company to Parent or the Merger Subs pursuant to this Agreement, none of the Company or any of their
respective Representatives is relying on any other representation or warranty of the Company or any other Person made outside of <U>Section</U><U></U><U>&nbsp;2</U> or such certificates, including regarding the accuracy or completeness of any such
other representations or warranties or the omission of any material information, whether express or implied, in each case, with respect to the Contemplated Transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;4. ADDITIONAL AGREEMENTS OF THE PARTIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.1 <B><U>Parent Stockholders</U></B><B><U>&#146;</U></B><B><U> Meeting</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) As promptly as practicable following the execution of this Agreement, Parent shall take all action necessary under applicable Law to
call, give notice of and hold a meeting of the holders of Parent Common Stock for the purpose of seeking: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(i) approval of the Preferred
Stock Conversion Proposal; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(ii) if deemed necessary or appropriate by Parent or as otherwise required by applicable Law or Contract, to
authorize the amendment of Parent&#146;s certificate of incorporation to authorize sufficient Parent Common Stock in Parent&#146;s certificate of incorporation for the conversion of the Parent Convertible Preferred Stock issued pursuant to this
Agreement and/or to effectuate the Nasdaq Reverse Split (the &#147;<B><I>Charter Amendment Proposal</I></B>&#148;) (the matters contemplated by the clauses 4.2(a)(i)&#150;(iii) are referred to as the &#147;<B><I>Parent Stockholder
Matters</I></B>,&#148; and such meeting, the &#147;<B><I>Parent Stockholders</I></B><B><I>&#146;</I></B><B><I> Meeting</I></B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) Parent agrees to use reasonable best efforts to call and hold the Parent Stockholders&#146; Meeting as soon as practicable after the date
hereof. If the approval of the Parent Stockholder Matters is not obtained at the Parent Stockholders&#146; Meeting or if on a date preceding the Parent Stockholders&#146; Meeting, Parent reasonably believes that (i)&nbsp;it will not receive proxies
sufficient to obtain the Required Parent Stockholder Vote, whether or not quorum would be present or (ii)&nbsp;it will not have sufficient shares of Parent Common Stock represented (whether in person or by proxy) to constitute a quorum necessary to
conduct the business of the Parent Stockholders&#146; Meeting, then, in each case, Parent will use its reasonable best efforts to adjourn the Parent Stockholders&#146; Meeting one or more times to a date or dates no more than 30 days after the
scheduled date for such meeting, and to obtain such approvals at such time. If the Parent Stockholders&#146; Meeting is not so adjourned, and/or if the approval of the Parent Stockholder Matters is not then obtained, Parent will&nbsp;use its
reasonable best efforts to&nbsp;obtain such approvals as soon as practicable thereafter, and in any event to obtain such approvals at the next occurring annual meeting of the stockholders of Parent or, if such annual meeting is not scheduled to be
held within six months after the Parent Stockholders&#146; Meeting, a special meeting of the stockholders of Parent to be held within six months after the Parent Stockholders&#146; Meeting. Parent will hold an annual meeting or special meeting of
its stockholders, at which a vote of the stockholders of Parent to approve the Parent Stockholder Matters will be solicited and taken, at least once every six months until Parent obtains approval of the Parent Stockholder Matters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) Parent agrees that: (i) the Parent Board shall recommend that the holders of Parent Common Stock vote to approve the Parent Stockholder
Matters and shall use its reasonable best efforts to solicit and obtain such approval within the time frames set forth in <U>Section</U><U></U><U>&nbsp;4.2(b)</U>, and (ii)&nbsp;the Proxy Statement shall include a statement to the effect that the
Parent Board recommends that the Parent&#146;s stockholders vote to approve the Parent Stockholder Matters. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) The Company and Parent acknowledge that, under the Nasdaq Stock Market Rules, the
Parent Common Stock Payment Shares and the Parent Preferred Stock Payment Shares will not be entitled to vote on the Preferred Stock Conversion Proposal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.2 <B><U>Proxy Statement</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) As promptly as practicable after the Closing Date, Parent shall prepare and file with the SEC a proxy statement relating to the Parent
Stockholders&#146; Meeting to be held in connection with the Parent Stockholder Matters (together with any amendments thereof or supplements thereto, the &#147;<B><I>Proxy Statement</I></B>&#148;). Parent shall use its commercially reasonable
efforts to (i)&nbsp;cause the Proxy Statement to comply with applicable rules and regulations promulgated by the SEC and (ii)&nbsp;respond promptly to any comments or requests of the SEC or its staff related to the Proxy Statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) Parent covenants and agrees that the Proxy Statement (and the letters to stockholders, notice of meeting and form of proxy included
therewith) will (i)&nbsp;comply as to form in all material respects with the requirements of applicable U.S. federal securities Laws and the DGCL, and (ii)&nbsp;will not contain any untrue statement of a material fact or omit to state any material
fact required to be stated therein or necessary in order to make the statements made therein, in light of the circumstances under which they were made, not misleading. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) Parent shall use commercially reasonable efforts to cause the Proxy Statement to be mailed to Parent&#146;s stockholders as promptly as
practicable after the Proxy Statement has been filed with the SEC and either (i)&nbsp;the SEC has indicated that it does not intend to review the Proxy Statement or that its review of the Proxy Statement has been completed or (ii)&nbsp;at least ten
(10)&nbsp;days shall have passed since the Proxy Statement was filed with the SEC without receiving any correspondence from the SEC commenting upon, or indicating that it intends to review, the Proxy Statement, all in compliance with applicable U.S.
federal securities laws and the DGCL. If Parent, First Merger Sub, Second Merger Sub or the Surviving Entity (A)&nbsp;become aware of any event or information that, pursuant to the Securities Act or the Exchange Act, should be disclosed in an
amendment or supplement to the Proxy Statement, (B)&nbsp;receives notice of any SEC request for an amendment or supplement to the Proxy Statement or for additional information related thereto, or (C)&nbsp;receives SEC comments on the Proxy
Statement, as the case may be, then such Party, as the case may be, shall promptly inform the other Parties thereof and shall cooperate with such other Parties in Parent filing such amendment or supplement with the SEC and, if appropriate, in
mailing such amendment or supplement to the Parent stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.3 <B><U>Reservation of Parent Common Stock; Issuance of Shares of
Parent Common Stock</U></B>. For as long as any Parent Preferred Stock Payment Shares remain outstanding, Parent shall at all times reserve and keep available, free from preemptive rights, out of its authorized but unissued Parent Common Stock or
shares of Parent Common Stock held in treasury by Parent, for the purpose of effecting the conversion of the Parent Preferred Stock Payment Shares, the full number of shares of Parent Common Stock then issuable upon the conversion of all Parent
Preferred Stock Payment Shares then outstanding. All shares of Parent Common Stock delivered upon conversion of the Parent Preferred Stock Payment Shares shall be newly issued shares or shares held in treasury by Parent, shall have been duly
authorized and validly issued and shall be fully paid and nonassessable, and shall be free from preemptive rights and free of any Encumbrance. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.4 <B><U>Employee Benefits</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) For purposes of vesting, eligibility to participate, and level of benefits (other than for purposes of determining awards under an equity
incentive plan or accrued benefits under any defined benefit pension plan) under the benefit plans, programs, Contracts or arrangements of Parent or any of its Subsidiaries (including, following the Closing, the Surviving Entity and its
Subsidiaries) (the &#147;<B><I>Post-Closing Plans</I></B>&#148;), Parent shall use reasonable best efforts to cause each employee of the Company who remains employed by Parent or the Surviving Entity, or any of their respective Subsidiaries
following the Closing, (together, the &#147;<B><I>Continuing Employees</I></B>&#148;) to be credited with his or her years of service with the Company or any of its predecessors; <I>provided</I> that the foregoing shall not apply to the extent that
its application would result in a duplication of benefits. In addition, and without limiting the generality of the foregoing, for purposes of each Post-Closing Plan providing medical, dental, pharmaceutical and/or vision benefits to a Continuing
Employee, Parent shall use reasonable best efforts to cause all <FONT STYLE="white-space:nowrap">pre-existing</FONT> condition exclusions and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">actively-at-work</FONT></FONT>
requirements of such Post-Closing Plan to be waived for such Continuing Employee and his or her covered dependents to the extent and unless such conditions would have been waived or satisfied under the employee benefit plan whose coverage is being
replaced under the Post-Closing Plan, and Parent shall use its best efforts to cause any eligible expenses incurred by a Continuing Employee and his or her covered dependents during the portion of such plan year in which coverage is replaced with
coverage under a Post-Closing Plan to be taken into account under such Post-Closing Plan with respect to the plan year in which participation in such Post-Closing Plan begins for purposes of satisfying all deductible, coinsurance and maximum <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> requirements applicable to such Continuing Employee and his or her covered dependents for such plan year as if such amounts had been paid in accordance with such
Post-Closing Plan. For employees of Parent who are not Continuing Employees and who are entitled to severance under their applicable employment agreements, Parent shall prepay for medical, dental, pharmaceutical and/or vision benefits for such
employees, if the provider of such benefits is under an individual plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) Parent shall, or shall cause one of its Affiliates to,
(i)&nbsp;provide Continuing Employees with base salary or hourly wage rate, as applicable, that are no less than the base salary or hourly wage rate, as applicable, in effect as of immediately prior to the First Effective Time through
December&nbsp;31, 2023 and, (ii)&nbsp;at all times from the First Effective Time through December&nbsp;31, 2023, honor all severance commitments of Parent in effect as of immediately prior to the First Effective Time that pertain to the Continuing
Employees (the &#147;<B><I>Existing Severance Plan</I></B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) The provisions of this <U>Section</U><U></U><U>&nbsp;4.4</U> are
for the sole benefit of Parent and the Company and no provision of this Agreement shall (i)&nbsp;create any third-party beneficiary or other rights in any Person, including rights in respect of any benefits that may be provided, directly or
indirectly, under any Company Benefit Plan, Parent Benefit Plan or Post-Closing Plan or rights to continued employment or service with the Company or the Parent (or any Subsidiary thereof), (ii) be construed as an amendment, waiver or creation of or
limitation on the ability to terminate any Company Benefit Plan, Parent Benefit Plan or Post-Closing Plan, or (iii)&nbsp;limit the ability of the Parent to terminate the employment of any Continuing Employee or modify the <FONT
STYLE="white-space:nowrap">at-will</FONT> status of any Continuing Employees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.5 <B><U>Indemnification of Officers and
Directors</U></B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) From the First Effective Time through the sixth anniversary of the date on which the First Effective Time occurs,
each of Parent and the Surviving Entity shall indemnify and hold harmless each person who is now, or has been at any time prior to the date hereof, or who becomes prior to the First Effective Time, a director or officer of Parent or the Company or
any of their respective Subsidiaries, respectively (the &#147;<B><I>D&amp;O Indemnified Parties</I></B>&#148;), against all claims, losses, liabilities, damages, judgments, fines and reasonable fees, costs and expenses, including attorneys&#146;
fees and disbursements, incurred in connection with any claim, action, suit, proceeding or investigation, whether civil, criminal, administrative or investigative, arising out of or pertaining to the fact that the D&amp;O Indemnified Party is or
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
was a director or officer of Parent or of the Company, or any Subsidiary thereof, asserted or claimed prior to the First Effective Time, in each case, to the fullest extent permitted under
applicable Law. Except in the case of fraud, each D&amp;O Indemnified Party will be entitled to advancement of expenses incurred in the defense of any such claim, action, suit, proceeding or investigation from each of Parent and the Surviving
Entity, jointly and severally, upon receipt by Parent or the Surviving Entity from the D&amp;O Indemnified Party of a request therefor; <I>provided</I> that any such person to whom expenses are advanced provides an undertaking to Parent, to the
extent then required by the DGCL or DLLCA, as applicable, to repay such advances if it is ultimately determined that such person is not entitled to indemnification. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) The provisions of the certificate of incorporation and bylaws of Parent with respect to indemnification, advancement of expenses and
exculpation of present and former directors and officers of Parent that are presently set forth in the certificate of incorporation and bylaws of Parent shall not be amended, modified or repealed for a period of six years from the First Effective
Time in a manner that would adversely affect the rights thereunder of individuals who, at or prior to the First Effective Time, were officers or directors of Parent, unless such modification is required by applicable Law. The certificate of
formation and limited liability company agreement of the Surviving Entity shall contain, and Parent shall cause the certificate of formation and limited liability company agreement of the Surviving Entity to so contain, provisions no less favorable
with respect to indemnification, advancement of expenses and exculpation of present and former directors and officers as those presently set forth in the certificate of incorporation and bylaws of Parent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) From and after the First Effective Time, (i)&nbsp;the Surviving Entity shall fulfill and honor in all respects the obligations of the
Company to its D&amp;O Indemnified Parties as of immediately prior to the Closing pursuant to any indemnification provisions under the Company&#146;s Organizational Documents and pursuant to any indemnification agreements between the Company and
such D&amp;O Indemnified Parties, with respect to claims arising out of matters occurring at or prior to the First Effective Time and (ii)&nbsp;Parent shall fulfill and honor in all respects the obligations of Parent to its D&amp;O Indemnified
Parties as of immediately prior to the Closing pursuant to any indemnification provisions under Parent&#146;s Organizational Documents and pursuant to any indemnification agreements between Parent and such D&amp;O Indemnified Parties, with respect
to claims arising out of matters occurring at or prior to the First Effective Time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) From and after the First Effective Time, Parent
shall continue to maintain directors&#146; and officers&#146; liability insurance policies, with an effective date as of the Closing Date, on commercially available terms and conditions and with coverage limits customary for U.S. public companies
similarly situated to Parent. From and after the First Effective Time, Parent shall pay all expenses, including reasonable attorneys&#146; fees, that are incurred by the persons referred to in this <U>Section</U><U></U><U>&nbsp;4.5</U> in connection
with their successful enforcement of the rights provided to such persons in this <U>Section</U><U></U><U>&nbsp;4.5</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) The
provisions of this <U>Section</U><U></U><U>&nbsp;4.5</U> are intended to be in addition to the rights otherwise available to the current and former officers and directors of Parent and the Company by Law, charter, statute, bylaw or agreement, and
shall operate for the benefit of, and shall be enforceable by, each of the D&amp;O Indemnified Parties, their heirs and their representatives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f) In the event Parent or the Surviving Entity or any of their respective successors or assigns (i)&nbsp;consolidates with or merges into
any other Person and shall not be the continuing or surviving corporation or entity of such consolidation or merger, or (ii)&nbsp;transfers all or substantially all of its properties and assets to any Person, then, and in each such case, proper
provision shall be made so that the successors and assigns of Parent or the Surviving Entity, as the case may be, shall succeed to the obligations set forth in this <U>Section</U><U></U><U>&nbsp;4.5</U>. Parent shall cause the Surviving Entity to
perform all of the obligations of the Surviving Entity under this <U>Section</U><U></U><U>&nbsp;4.5</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.6 <B><U>Additional Agreements</U></B>. The Parties shall use reasonable best efforts to
cause to be taken all actions necessary to consummate the Contemplated Transactions. Without limiting the generality of the foregoing, each Party to this Agreement: (a) shall make all filings and other submissions (if any) and give all notices (if
any) required to be made and given by such Party in connection with the Contemplated Transactions; (b)&nbsp;shall use reasonable best efforts to obtain each Consent (if any) reasonably required to be obtained (pursuant to any applicable Law or
Contract, or otherwise) by such Party in connection with the Contemplated Transactions or for such Contract to remain in full force and effect; (c)&nbsp;shall use reasonable best efforts to lift any injunction prohibiting, or any other legal bar to,
the Contemplated Transactions; and (d)&nbsp;shall use reasonable best efforts to satisfy the conditions precedent to the consummation of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.7 <B><U>Listing</U></B>. Parent shall use its reasonable best efforts to (a)&nbsp;maintain its existing listing on Nasdaq; (b)&nbsp;prepare
and submit to Nasdaq a notification form for the listing of the shares of Parent Common Stock Payment Shares and the Parent Common Stock to be issued upon conversion of the Parent Preferred Stock Payment Shares to be issued in connection with the
Contemplated Transactions, to cause such shares to be approved for listing (subject to official notice of issuance); (c) effect the Nasdaq Reverse Split and (d)&nbsp;to the extent required by Nasdaq rules and regulations, file an initial listing
application for the Parent Common Stock on Nasdaq (the &#147;<B><I>Nasdaq Listing Application</I></B>&#148;), which Nasdaq Listing Application shall be prepared in cooperation with the Company, and to cause such Nasdaq Listing Application to be
conditionally approved prior to the First Effective Time. The Parties will use reasonable best efforts to coordinate with respect to compliance with Nasdaq rules and regulations. Each Party will promptly inform the other Party of all verbal or
written communications between Nasdaq and such Party or its representatives. The Company will cooperate with Parent as reasonably requested by Parent with respect to the Nasdaq Listing Application and promptly furnish to Parent all information
concerning the Company and its stockholders that may be required or reasonably requested in connection with any action contemplated by this Section&nbsp;4.8. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.8 <B><U>Tax Matters</U></B>. For U.S. federal income Tax purposes, (i)&nbsp;the Parties intend that the First Merger and the Second Merger,
taken together, constitute an integrated transaction described in Rev. Rul. <FONT STYLE="white-space:nowrap">2001-46,</FONT> <FONT STYLE="white-space:nowrap">2001-2</FONT> C.B. 321 that qualifies as a &#147;reorganization&#148; within the meaning of
Section&nbsp;368(a) of the Code and the Treasury Regulations promulgated thereunder (the &#147;<B><I>Intended Tax Treatment</I></B>&#148;), and (ii)&nbsp;this Agreement is intended to be, and is hereby adopted as, a &#147;plan of
reorganization&#148; for purposes of Sections 354 and 361 of the Code and Treasury Regulations Sections 1.368-2(g) and 1.368-3(a), to which the Parent, Merger Subs and the Company are parties under Section&nbsp;368(b) of the Code. The Parties shall
treat and shall not take any tax reporting position (including during the course of any audit, litigation or other proceeding with respect to Taxes) inconsistent with the treatment of the Merger as a reorganization within the meaning of
Section&nbsp;368(a) of the Code for U.S. federal, state and other relevant Tax purposes, unless otherwise required pursuant to a &#147;determination&#148; within the meaning of Section&nbsp;1313(a) of the Code. The Parties shall (and shall cause
their Affiliates to) will not take any action or cause any action to be taken, or fail to take or cause to be taken any action, which action or failure to act would reasonably be expected to prevent the Merger from qualifying, for the Intended Tax
Treatment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.9 <B><U>Legends</U></B>. Parent shall be entitled to place appropriate legends, including the legend noted in
<U>Section</U><U></U><U>&nbsp;4.18</U>, on the book entries and/or certificates evidencing any shares of Parent Common Stock or Parent Convertible Preferred Stock to be received in the Merger by equity holders of the Company who may be considered
&#147;affiliates&#148; of Parent for purposes of Rules 144 and 145 under the Securities Act reflecting the restrictions set forth in Rules 144 and 145 and to issue appropriate stop transfer instructions to the transfer agent for Parent Common Stock
and Parent Convertible Preferred Stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.10 <B><U>Directors and Officers</U></B>. The Parties shall take all necessary action so
that immediately after the Second Effective Time, (a)&nbsp;the Parent Board is comprised of six members, with four such members designated by Parent (one of whom shall be an independent board member acceptable to the Company, such acceptance not to
be unreasonably withheld), and two such members designated by the Company and set forth on Section&nbsp;4.11(a) of the Parent Disclosure Schedule and (b)&nbsp;the Persons set forth on Section&nbsp;4.11(b) of the Parent Disclosure Schedule under the
heading &#147;Officers&#148; are elected or appointed, as applicable, to the positions of officers of Parent and the Surviving Entity, as set forth therein, to serve in such positions effective as of the Second Effective Time until successors are
duly appointed and qualified in accordance with applicable Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.11 <B><U>Section</U></B><B><U></U></B><B><U>&nbsp;16</U></B><B><U>
Matters</U></B>. Prior to the First Effective Time, Parent and the Company shall take all such steps as may be required (to the extent permitted under applicable Laws) to cause any acquisitions of Parent Common Stock, restricted stock awards to
acquire Parent Common Stock and any Parent Options to purchase Parent Common Stock in connection with the Contemplated Transactions, by each individual who is reasonably expected to become subject to the reporting requirements of Section&nbsp;16(a)
of the Exchange Act with respect to Parent, to be exempt under Rule <FONT STYLE="white-space:nowrap">16b-3</FONT> promulgated under the Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.12 <B><U>Cooperation</U></B>. Each Party shall cooperate reasonably with the other Party and shall provide the other Party with such
assistance as may be reasonably requested for the purpose of facilitating the performance by each Party of its respective obligations under this Agreement and to enable the combined entity to continue to meet its obligations following the First
Effective Time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.13 <B><U>Closing Certificates</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) The Company will prepare and deliver to Parent prior to the Closing a certificate signed by the President of the Company in a form
reasonably acceptable to Parent setting forth, as of immediately prior to the First Effective Time (i)&nbsp;each holder of Company Common Stock, Company Preferred Stock and Company Options, (ii)&nbsp;such holder&#146;s name and address,
(iii)&nbsp;the number and type of Company Common Stock held and/or underlying the Company Options as of immediately prior to the First Effective Time for each such holder, and the number and type of Company Preferred Stock held, and (v)&nbsp;the
number of shares of Parent Common Stock and/or Parent Convertible Preferred Stock to be issued to such holder, or to underlie any Parent Option to be issued to such holder, pursuant to this Agreement in respect of the Company Capital Stock, Company
Preferred Stock or Company Options held by such holder as of immediately prior to the First Effective Time (the &#147;<B><I>Allocation Certificate</I></B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) Parent will prepare and deliver to the Company prior to the Closing a certificate signed by the Chief Financial Officer of Parent in a
form reasonably acceptable to the Company, setting forth, as of immediately prior to the Reference Date (A)&nbsp;the number of Parent Common Stock outstanding and (B)&nbsp;(i) each record holder of Parent Common Stock, Parent Options or Parent RSUs,
(ii)&nbsp;such record holder&#146;s name and address, (iii)&nbsp;the number of shares of Parent Common Stock underlying the Parent Options or Parent RSUs as of the First Effective Time for such holder (the &#147;<B><I>Parent Outstanding Shares
Certificate</I></B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.14 <B><U>Takeover Statutes</U></B>. If any Takeover Statute is or may become applicable to the Contemplated
Transactions, each of the Company, the Company Board, Parent and the Parent Board, as applicable, shall grant such approvals and take such actions as are necessary so that the Contemplated Transactions may be consummated as promptly as practicable
on the terms contemplated by this Agreement and otherwise act to eliminate or minimize the effects of such statute or regulation on the Contemplated Transactions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.15 <B><U>Obligations of Merger Subs</U></B>. Parent will take all action necessary to
cause Merger Subs to perform their obligations under this Agreement and to consummate the Merger on the terms and conditions set forth in this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.16 <B><U>Private Placement</U></B>. Each of the Company and Parent shall take all reasonably necessary action on its part such that the
issuance of Parent Common Stock Payment Shares and Parent Preferred Stock Payment Shares pursuant to this Agreement constitutes a transaction exempt from registration under the Securities Act in compliance with Rule 506 of Regulation D promulgated
thereunder. Each certificate representing Parent Common Stock Payment Shares and the Parent Preferred Stock Payment Shares comprising Merger Consideration shall, until such time that such shares are not so restricted under the Securities Act, bear a
legend identical or similar in effect to the following legend (together with any other legend or legends required by applicable state securities applicable Law or otherwise, if any): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 (THE &#145;<B><I>ACT</I></B>&#146;)
AND MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, ASSIGNED, PLEDGED OR HYPOTHECATED UNLESS REGISTERED UNDER THE ACT OR UNLESS AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE ACT IS AVAILABLE.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;5. CONDITIONS PRECEDENT TO OBLIGATIONS OF EACH PARTY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The obligations of each Party to effect the Merger and otherwise consummate the Contemplated Transactions to be consummated at the Closing are
subject to the satisfaction or, to the extent permitted by applicable Law, the written waiver by each of the Parties, at or prior to the Closing Date, of each of the following conditions: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.1 <B><U>No Restraints</U></B>. No temporary restraining order, preliminary or permanent injunction or other order preventing the consummation
of the Contemplated Transactions shall have been issued by any court of competent jurisdiction or other Governmental Body of competent jurisdiction and remain in effect and there shall not be any Law which has the effect of making the consummation
of the Contemplated Transactions illegal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.2 <B><U>Certificate of Designation</U></B>. Parent shall have filed the Certificate of
Designation with the Secretary of State of the State of Delaware. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.3 <B><U>Parent Financing</U></B>. The Securities Purchase Agreement
shall be in full force and effect and cash proceeds not less than the Concurrent Investment Amount shall have been received by Parent, or will be received by Parent substantially simultaneously with the Closing, in connection with the consummation
of the transactions contemplated by the Securities Purchase Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;6. CLOSING DELIVERIES OF THE COMPANY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The obligations of Parent and Merger Subs to effect the Merger and otherwise consummate the transactions to be consummated at the Closing are
subject to the satisfaction or the written waiver by Parent, at or prior to the Closing, of each of the following conditions: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.1
<B><U>Documents</U></B>. Parent shall have received the following documents, each of which shall be in full force and effect: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) a
written resignation, in a form reasonably satisfactory to Parent, dated as of the Closing Date and effective as of the Closing, executed by each of the directors of the Company listed in <U>Section</U><U></U><U>&nbsp;7.1(a)</U> of the Company
Disclosure Schedule; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) the Allocation Certificate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.2 <B><U>FIRPTA Certificate</U></B>. Parent shall have received (i)&nbsp;an original signed statement from the Company that the Company is
not, and has not been at any time during the applicable period specified in Section&nbsp;897(c)(1)(A)(ii) of the Code, a &#147;United States real property holding corporation,&#148; as defined in Section&nbsp;897(c)(2) of the Code, conforming to the
requirements of Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.1445-2(c)(3)</FONT> and 1.897-2(h), and (ii)&nbsp;an original signed notice to be delivered to the IRS in accordance with the provisions of Treasury Regulations
Section&nbsp;1.897-2(h)(2), together with written authorization for Parent to deliver such notice to the IRS on behalf of the Company following the Closing, each dated as of the Closing Date, duly executed by an authorized officer of the Company,
and in form and substance reasonably acceptable to Parent; <I>provided</I>, that the Parent&#146;s sole remedy for the Company&#146;s failure to deliver such documentation shall be to withhold pursuant to <U>Section</U><U></U><U>&nbsp;1.12</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.3 <B><U>Company <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements</U></B>. Parent shall have received the <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Agreements duly executed by each of the Company Signatories, each of which shall be in full force and effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;7. CLOSING DELIVERIES OF PARENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The obligations of the Company to effect the Merger and otherwise consummate the transactions to be consummated at the Closing are subject to
the satisfaction or the written waiver by the Company, at or prior to the Closing, of each of the following conditions: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.1
<B><U>Documents</U></B>. The Company shall have received the following documents, each of which shall be in full force and effect: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a)
the Parent Outstanding Shares Certificate; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) a written resignation, in a form reasonably satisfactory to the Company, dated as of the
Closing Date and effective as of the Closing, executed by each of the officers and directors of Parent who are not to continue as officers or directors, as the case may be, of Parent after the Closing pursuant to
<U>Section</U><U></U><U>&nbsp;4.11</U> hereof; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) certified copies of the resolutions duly adopted by the Parent Board and in full
force and effect as of the Closing authorizing the appointment of the directors and officers set forth in<U> Section</U><U></U><U>&nbsp;4.11</U><B>.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.2 <B><U>Parent <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements</U></B>. The Company shall have received the <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Agreements duly executed by each of the Parent Signatories, each of which shall be in full force and effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;8. MISCELLANEOUS PROVISIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.1 <B><U><FONT STYLE="white-space:nowrap">Non-Survival</FONT> of Representations and Warranties</U></B>. The representations and warranties
of the Company, Parent and Merger Subs contained in this Agreement or any certificate or instrument delivered pursuant to this Agreement shall terminate at the First Effective Time, and only the covenants that by their terms survive the First
Effective Time and this <U>Section</U><U></U><U>&nbsp;8</U> shall survive the First Effective Time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.2 <B><U>Amendment</U></B>. This Agreement may be amended with the approval of the
respective boards of directors (or managers as applicable) of the Surviving Entity and Parent at any time; <I>provided</I>, <I>however</I>, that after any such approval of this Agreement by a Party&#146;s stockholders, no amendment shall be made
which by Law requires further approval of such stockholders without the further approval of such stockholders. This Agreement may not be amended except by an instrument in writing signed on behalf of each of the Surviving Entity and Parent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.3 <B><U>Waiver</U></B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a)
No failure on the part of any Party to exercise any power, right, privilege or remedy under this Agreement, and no delay on the part of any Party in exercising any power, right, privilege or remedy under this Agreement, shall operate as a waiver of
such power, right, privilege or remedy; and no single or partial exercise of any such power, right, privilege or remedy shall preclude any other or further exercise thereof or of any other power, right, privilege or remedy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) No Party shall be deemed to have waived any claim arising out of this Agreement, or any power, right, privilege or remedy under this
Agreement, unless the waiver of such claim, power, right, privilege or remedy is expressly set forth in a written instrument duly executed and delivered on behalf of such Party and any such waiver shall not be applicable or have any effect except in
the specific instance in which it is given. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.4 <B><U>Entire Agreement; Counterparts; Exchanges by Electronic Transmission</U></B>. This
Agreement and the other schedules, exhibits, certificates, instruments and agreements referred to in this Agreement constitute the entire agreement and supersede all prior agreements and understandings, both written and oral, among or between any of
the Parties with respect to the subject matter hereof and thereof; <I>provided</I>, <I>however</I>, that the Confidentiality Agreement shall not be superseded and shall remain in full force and effect in accordance with its terms. This Agreement may
be executed in several counterparts, each of which shall be deemed an original and all of which shall constitute one and the same instrument. Counterparts may be delivered via electronic mail (including pdf or any electronic signature complying with
the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.5 <B><U>Applicable Law; Jurisdiction</U></B>. This Agreement shall be governed by, and construed in accordance with, the Laws of the State
of Delaware, regardless of the Laws that might otherwise govern under applicable principles of conflicts of laws. In any action or proceeding between any of the Parties arising out of or relating to this Agreement or any of the Contemplated
Transactions, each of the Parties: (a) irrevocably and unconditionally consents and submits to the exclusive jurisdiction and venue of the Court of Chancery of the State of Delaware or, to the extent such court does not have subject matter
jurisdiction, the United States District Court for the District of Delaware or, to the extent that neither of the foregoing courts has jurisdiction, the Superior Court of the State of Delaware; (b)&nbsp;agrees that all claims in respect of such
action or proceeding shall be heard and determined exclusively in accordance with clause (a)&nbsp;of this <U>Section</U><U></U><U>&nbsp;8.5</U>; (c) waives any objection to laying venue in any such action or proceeding in such courts;
(d)&nbsp;waives any objection that such courts are an inconvenient forum or do not have jurisdiction over any Party; (e)&nbsp;agrees that service of process upon such Party in any such action or proceeding shall be effective if notice is given in
accordance with <U>Section</U><U></U><U>&nbsp;8.8</U> of this Agreement; and (f)&nbsp;irrevocably and unconditionally waives the right to trial by jury. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.6 <B><U>Attorneys</U></B><B><U>&#146;</U></B><B><U> Fees</U></B>. In any action at law or
suit in equity to enforce this Agreement or the rights of any of the Parties, the prevailing Party in such action or suit (as determined by a court of competent jurisdiction) shall be entitled to recover its reasonable
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> attorneys&#146; fees and all other reasonable costs and expenses incurred in such action or suit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.7 <B><U>Assignability</U></B>. This Agreement shall be binding upon, and shall be enforceable by and inure solely to the benefit of, the
Parties and their respective successors and permitted assigns; <I>provided</I>, <I>however</I>, that neither this Agreement nor any of a Party&#146;s rights or obligations hereunder may be assigned or delegated by such Party without the prior
written consent of the other Party, and any attempted assignment or delegation of this Agreement or any of such rights or obligations by such Party without the other Party&#146;s prior written consent shall be void and of no effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.8 <B><U>Notices</U></B>. All notices and other communications hereunder shall be in writing and shall be deemed to have been duly delivered
and received hereunder (a)&nbsp;one Business Day after being sent for next Business Day delivery, fees prepaid, via a reputable international overnight courier service, (b)&nbsp;upon delivery in the case of delivery by hand, or (c)&nbsp;on the date
delivered in the place of delivery if sent by email (with a written or electronic confirmation of delivery) prior to 5:00 p.m. Pacific Time, otherwise on the next succeeding Business Day, in each case to the intended recipient as set forth below:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">if to Parent or Merger Subs: </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Aeglea Biotherapeutics, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">805
Las Cimas Parkway </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Suite 100 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Austin, TX 78746 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention:
Jonathan Alspaugh </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Email Address: <U>jalspaugh@aeglea.com</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">with a copy to (which shall not constitute notice): </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Cooley&nbsp;LLP </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">55 Hudson Yards
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">New York, NY 10001 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention: William Sorabella; Matthew Silverman </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Email Address: wsorabella@cooley.com; msilverman@cooley.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">if to the Company: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Spyre
Therapeutics, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">221 Crescent Street, Building 17, Suite 102B </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Waltham, MA 02453 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention:
Evan Thompson </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Email Address: evan.thompson@paragontherapeutics.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">with a copy to (which shall not constitute notice): </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Gibson, Dunn&nbsp;&amp; Crutcher LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">555 Mission St., Suite 3000 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">San
Francisco, CA 94105 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention: Ryan Murr, Branden Berns, Chris Trester </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Email Address: rmurr@gibsondunn.com; bberns@gibsondunn.com; </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">ctrester@gibsondunn.com </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.9 <B><U>Cooperation</U></B>. Each Party agrees to cooperate fully with the other Party and
to execute and deliver such further documents, certificates, agreements and instruments and to take such other actions as may be reasonably requested by the other Party to evidence or reflect the Contemplated Transactions and to carry out the intent
and purposes of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.10 <B><U>Severability</U></B>. Any term or provision of this Agreement that is invalid or unenforceable
in any situation in any jurisdiction shall not affect the validity or enforceability of the remaining terms and provisions of this Agreement or the validity or enforceability of the offending term or provision in any other situation or in any other
jurisdiction. If a final judgment of a court of competent jurisdiction declares that any term or provision of this Agreement is invalid or unenforceable, the Parties agree that the court making such determination shall have the power to limit such
term or provision, to delete specific words or phrases or to replace such term or provision with a term or provision that is valid and enforceable and that comes closest to expressing the intention of the invalid or unenforceable term or provision,
and this Agreement shall be valid and enforceable as so modified. In the event such court does not exercise the power granted to it in the prior sentence, the Parties agree to replace such invalid or unenforceable term or provision with a valid and
enforceable term or provision that will achieve, to the extent possible, the economic, business and other purposes of such invalid or unenforceable term or provision. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.11 <B><U>Other Remedies; Specific Performance</U></B>. Except as otherwise provided herein, any and all remedies herein expressly conferred
upon a Party will be deemed cumulative with and not exclusive of any other remedy conferred hereby, or by law or equity upon such Party, and the exercise by a Party of any one remedy will not preclude the exercise of any other remedy. The Parties
agree that irreparable damage for which monetary damages, even if available, would not be an adequate remedy, would occur in the event that any Party does not perform the provisions of this Agreement (including failing to take such actions as are
required of it hereunder to consummate this Agreement) in accordance with its specified terms or otherwise breaches such provisions. Accordingly, the Parties acknowledge and agree that the Parties shall be entitled to an injunction, specific
performance and other equitable relief to prevent breaches of this Agreement and to enforce specifically the terms and provisions hereof, in addition to any other remedy to which they are entitled at law or in equity. Each of the Parties agrees that
it will not oppose the granting of an injunction, specific performance or other equitable relief on the basis that any other Party has an adequate remedy at law or that any award of specific performance is not an appropriate remedy for any reason at
law or in equity. Any Party seeking an injunction or injunctions to prevent breaches of this Agreement shall not be required to provide any bond or other security in connection with any such order or injunction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.12 <B><U>No Third-Party Beneficiaries</U></B>. Nothing in this Agreement, express or implied, is intended to or shall confer upon any Person
(other than the Parties and the D&amp;O Indemnified Parties to the extent of their respective rights pursuant to <U>Section</U><U></U><U>&nbsp;4.5</U>) any right, benefit or remedy of any nature whatsoever under or by reason of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.13 <B><U>Construction</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) References to &#147;cash,&#148; &#147;dollars&#148; or &#147;$&#148; are to U.S. dollars. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) For purposes of this Agreement, whenever the context requires: the singular number shall include the plural, and vice versa; the
masculine gender shall include the feminine and neuter genders; the feminine gender shall include the masculine and neuter genders; and the neuter gender shall include masculine and feminine genders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) The Parties have participated jointly in the negotiating and drafting of this Agreement
and agree that any rule of construction to the effect that ambiguities are to be resolved against the drafting Party shall not be applied in the construction or interpretation of this Agreement, and no presumption or burden of proof shall arise
favoring or disfavoring any Party by virtue of the authorship of any provision of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) As used in this Agreement, the
words &#147;include&#148; and &#147;including,&#148; and variations thereof, shall not be deemed to be terms of limitation, but rather shall be deemed to be followed by the words &#147;without limitation.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) Except as otherwise indicated, all references in this Agreement to &#147;Sections,&#148; &#147;Exhibits&#148; and &#147;Schedules&#148;
are intended to refer to Sections of this Agreement and Exhibits and Schedules to this Agreement, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f) Any reference to
legislation or to any provision of any legislation shall include any modification, amendment, <FONT STYLE="white-space:nowrap">re-enactment</FONT> thereof, any legislative provision substituted therefore and all rules, regulations, and statutory
instruments issued or related to such legislations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(g) The bold-faced headings and table of contents contained in this Agreement are
for convenience of reference only, shall not be deemed to be a part of this Agreement and shall not be referred to in connection with the construction or interpretation of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(h) The inclusion of any information in the Company Disclosure Schedule or Parent Disclosure Schedule shall not be deemed an admission or
acknowledgment to any third party, in and of itself and solely by virtue of the inclusion of such information in the Company Disclosure Schedule or Parent Disclosure Schedule, as applicable, that such information is required to be listed in the
Company Disclosure Schedule or Parent Disclosure Schedule, as applicable, that such items are material to the Company and its Subsidiaries, taken as a whole, or Parent and its Subsidiaries, taken as a whole, as the case may be, or that such items
have resulted in a Company Material Adverse Effect or a Parent Material Adverse Effect. The Parties agree that each of the Company Disclosure Schedule and the Parent Disclosure Schedule shall be arranged in sections and subsections corresponding to
the numbered and lettered sections and subsections contained in this Agreement. The disclosures in any section or subsection of the Company Disclosure Schedule or the Parent Disclosure Schedule shall qualify other sections and subsections in this
Agreement to the extent it is readily apparent on its face from a reading of the disclosure that such disclosure is applicable to such other sections and subsections. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) Each of &#147;delivered&#148; or &#147;made available&#148; means, with respect to any documentation, that (i)&nbsp;prior to 11:59 p.m.
(Pacific Time) on the date that is two Business Days prior to the date of this Agreement (A)&nbsp;a copy of such material has been posted to and made available by a Party to the other Party and its Representatives in the electronic data room
maintained by such disclosing Party or (B)&nbsp;such material is disclosed in the Parent SEC Documents filed with the SEC prior to the date hereof and publicly made available on the SEC&#146;s Electronic Data Gathering Analysis and Retrieval system
or (ii)&nbsp;delivered by or on behalf of a Party or its Representatives via electronic mail or in hard copy form prior to the execution of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(j) Whenever the last day for the exercise of any privilege or the discharge of any duty hereunder shall fall upon a Saturday, Sunday, or any
date on which banks in San Francisco, California, are authorized or obligated by Law to be closed, the Party having such privilege or duty may exercise such privilege or discharge such duty on the next succeeding day which is a regular Business Day.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.14 <B><U>Expenses</U></B>. Except as otherwise expressly provided in this Agreement, all
expenses incurred in connection with this Agreement and the Contemplated Transactions will be paid by the Party incurring such expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(<I>Remainder of page intentionally left blank</I>) </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF,</B> the Parties have caused this Agreement to be executed as of the
date first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"><B>AEGLEA BIOTHERAPEUTICS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jonathan Alspaugh</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Jonathan Alspaugh</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">President and Chief Financial Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"><B>ASPEN MERGER SUB I, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jonathan Alspaugh</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Jonathan Alspaugh</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"><B>SEQUOIA MERGER SUB II, LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jonathan Alspaugh</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Jonathan Alspaugh</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"><B>SPYRE THERAPEUTICS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ K. Evan Thompson</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">K. Evan Thompson</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">President</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT A </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTAIN DEFINITIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">a)
For purposes of this Agreement (including this <B>Exhibit A</B>) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>ACT</I></B>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;4.18.</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Affiliate</I></B>&#148; of a Person means any other Person that directly or
indirectly, through one or more intermediaries, controls, is controlled by, or is under common control with, such Person. The term &#147;control&#148; (including the terms &#147;controlled by&#148; and &#147;under common control with&#148;) means
the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership of voting securities, by Contract or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Agreement</I></B>&#148; means the Agreement and Plan of Merger to which this <B>Exhibit A</B> is attached, as it may be amended
from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Allocation Certificate</I></B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;4.14.</U>
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Anti-Bribery Laws</I></B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;2.22.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Board Approval</I></B>&#148; has the meaning set forth in the Recitals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Book-Entry Shares</I></B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;1.7.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Business Day</I></B>&#148; means any day other than a Saturday, Sunday or other day on which banks in San Francisco, California,
are authorized or obligated by Law to be closed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Certificate of Designation</I></B>&#148; means the Certificate of
Designation of Preferences, Rights and Limitations of Parent Convertible Preferred Stock in the form attached hereto as <B>Exhibit C</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Certificates of Merger</I></B>&#148; has the meaning set forth in Section&nbsp;1.3. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Certifications</I></B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;3.7(a).</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Charter Amendment Proposal</I></B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;4.2(a)(iii).</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Closing</I></B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;1.3.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Closing Date</I></B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;1.3.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Code</I></B>&#148; means the Internal Revenue Code of 1986, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Company</I></B>&#148; has the meaning set forth in the Preamble. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Company Associate</I></B>&#148; means any current or former employee, independent contractor, officer or director of the Company.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Company Benefit Plan</I></B>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;2.17(a)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Company Board</I></B>&#148; means the board of directors of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Company Capital Stock</I></B>&#148; means the Company Common Stock and the Company Preferred Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Company Common Stock</I></B>&#148; means the Common Stock, $0.0001 par value per share, of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Company Contract</I></B>&#148; means any Contract: (a) to which the Company or any of its Subsidiaries is a Party; (b)&nbsp;by
which the Company or any of its Subsidiaries or any Company IP or any other asset of the Company or its Subsidiaries is or may become bound or under which the Company or any of its Subsidiaries has, or may become subject to, any obligation; or
(c)&nbsp;under which the Company or any of its Subsidiaries has or may acquire any right or interest. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Company
Data</I></B>&#148; means all data and information Processed by or for the Company or any of its Subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Company
Disclosure Schedule</I></B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;2</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Company</I></B>
<B><I>ERISA Affiliate</I></B>&#148; means any corporation or trade or business (whether or not incorporated) which is (or at any relevant time was) treated with the Company as a single employer within the meaning of Section&nbsp;414 of the Code.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Company Financials</I></B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;2.7(a).</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Company IP</I></B>&#148; means all Intellectual Property Rights that are owned or purported to be owned by, assigned to, or
exclusively licensed by, the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Company <FONT STYLE="white-space:nowrap">In-bound</FONT> License</I></B>&#148; has the
meaning set forth in <U>Section</U><U></U><U>&nbsp;2.12(d)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Company Material Adverse Effect</I></B>&#148; means any
Effect that, considered together with all other Effects that have occurred prior to the date of determination of the occurrence of a Company Material Adverse Effect, has or would reasonably be expected to have a material adverse effect on the
business, condition (financial or otherwise), assets, liabilities or results of operations of the Company, taken as a whole; <I>provided</I>, <I>however</I>, that Effects arising or resulting from the following shall not be taken into account in
determining whether there has been a Company Material Adverse Effect: (a) general business or economic conditions affecting the industry in which the Company and its Subsidiaries operate, (b)&nbsp;acts of war, armed hostilities or terrorism, acts of
God or comparable events, epidemic, pandemic or disease outbreak (including the <FONT STYLE="white-space:nowrap">COVID-19</FONT> virus) or any worsening of the foregoing, or any declaration of martial law, quarantine or similar directive, policy or
guidance or Law or other action by any Governmental Body in response thereto, (c)&nbsp;changes in financial, banking or securities markets, (d)&nbsp;any change in, or any compliance with or action taken for the purpose of complying with, any Law or
GAAP (or interpretations of any Law or GAAP), (e) resulting from the announcement of this Agreement or the pendency of the Contemplated Transactions; <I>provided</I>, that this clause (e)&nbsp;shall not apply to any representation or warranty (or
condition to the consummation of the Mergers relating to such representation or warranty) to the extent the representation and warranty expressly addresses the consequences resulting from the execution and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
delivery of this Agreement or the consummation of the Contemplated Transactions, or (f)&nbsp;resulting from the taking of any action required to be taken by this Agreement; except in each case
with respect to clauses (a)&nbsp;through (c), to the extent disproportionately affecting the Company, taken as a whole, relative to other similarly situated companies in the industries in which the Company operates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Company Material Contract(s)</I></B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;2.13(a).</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Company Options</I></B>&#148; means options or other rights to purchase shares of Company Common Stock issued by the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Company <FONT STYLE="white-space:nowrap">Out-bound</FONT> License</I></B>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;2.12(d).</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Company Permits</I></B>&#148; has the meaning set forth in Section&nbsp;2.14(b).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Company Plan</I></B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;2.6(c).</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Company Preferred Stock</I></B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;2.6(a).</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Company Real Estate Leases</I></B>&#148; has the meaning set forth in Section&nbsp;2.11. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Company Signatories</I></B>&#148; has the meaning set forth in the Recitals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Company Stock Certificate</I></B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;1.7.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Company Stockholder Matters</I></B>&#148; has the meaning set forth in the Recitals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Company Unaudited Interim Balance Sheet</I></B>&#148; means the unaudited balance sheet of the Company as of April&nbsp;30, 2023
provided to Parent prior to the date of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Concurrent Investment Amount</I></B>&#148; means $150,000,000 as
contemplated by the Securities Purchase Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Confidentiality Agreement</I></B>&#148; means that certain mutual letter
agreement, dated as of April&nbsp;27, 2023, between the Company and Parent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Consent</I></B>&#148; means any approval,
consent, ratification, permission, waiver or authorization (including any Governmental Authorization). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Contemplated
Transactions</I></B>&#148; means the Merger, the Nasdaq Reverse Split, Parent Stockholder Support Agreements, the CVR Agreement and the other transactions and actions contemplated by this Agreement to be consummated at or prior to the Closing (but
not, for the avoidance of doubt, the actions proposed to be taken as the Parent Stockholders&#146; Meeting following the Closing pursuant to <U>Section</U><U></U><U>&nbsp;4.2</U>). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Continuing Employees</I></B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;4.4(a).</U> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Contract</I></B>&#148; means, with respect to any Person, any written or oral
agreement, contract, subcontract, lease (whether for real or personal property), mortgage, license, sublicense or other legally binding commitment or undertaking of any nature to which such Person is a party or by which such Person or any of its
assets are bound or affected under applicable Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Data Processing Policy</I></B>&#148; means each policy, statement,
representation, or notice of the Company, Parent or their respective Subsidiaries relating to the Processing of Company Data or Parent Data (as applicable), privacy, data protection, or security. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>DGCL</I></B>&#148; means the General Corporation Law of the State of Delaware. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>DLLCA</I></B>&#148; means the Delaware Limited Liability Company Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>D&amp;O Indemnified Parties</I></B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;4.5(a)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Disqualifying Event</I></B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;3.24.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Dissenting Shares</I></B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;1.9(a).</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Effect</I></B>&#148; means any effect, change, event, circumstance, or development. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Encumbrance</I></B>&#148; means any lien, pledge, hypothecation, charge, mortgage, security interest, lease, license, option,
easement, reservation, servitude, adverse title, claim, infringement, interference, option, right of first refusal, preemptive right, community property interest or restriction or encumbrance of any nature (including any restriction on the voting of
any security, any restriction on the transfer of any security or other asset, any restriction on the receipt of any income derived from any asset, any restriction on the use of any asset and any restriction on the possession, exercise or transfer of
any other attribute of ownership of any asset). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Enforceability Exceptions</I></B>&#148; means the (a)&nbsp;Laws of general
application relating to bankruptcy, insolvency and the relief of debtors; and (b)&nbsp;rules of law governing specific performance, injunctive relief and other equitable remedies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Entity</I></B>&#148; means any corporation (including any <FONT STYLE="white-space:nowrap">non-profit</FONT> corporation),
partnership (including any general partnership, limited partnership or limited liability partnership), joint venture, estate, trust, company (including any company limited by shares, limited liability company or joint stock company), firm, society
or other enterprise, association, organization or entity, and each of its successors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Environmental Law</I></B>&#148; means
any federal, state, local or foreign Law relating to pollution or protection of human health (as it relates to exposure to Hazardous Materials) or the environment (including ambient air, surface water, ground water, land surface or subsurface
strata), including any Law or regulation relating to emissions, discharges, releases or threatened releases of Hazardous Materials, or otherwise relating to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or
handling of Hazardous Materials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>ERISA</I></B>&#148; means the Employee Retirement Income Security Act of 1974, as amended.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Exchange Act</I></B>&#148; means the Securities Exchange Act of 1934. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Exchange Agent</I></B>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;1.8.</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Exchange Fund</I></B>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;1.8.</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Exchange Ratio</I></B>&#148; means, 13.73622. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Existing Severance Plan</I></B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;4.4(b).</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>First Certificate of Merger</I></B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;1.3.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>First Effective Time</I></B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;1.3.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>First Merger</I></B>&#148; has the meaning set forth in the Recitals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>First Merger Sub</I></B>&#148; has the meaning set forth in the Preamble. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>First Merger Sub Board</I></B>&#148; means the board of directors of First Merger Sub. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>First Step Surviving Corporation</I></B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;1.1</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>FLSA</I></B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;2.17(m).</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>GAAP</I></B>&#148; means generally accepted accounting principles and practices in effect from time to time within the United
States applied consistently throughout the period involved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Governmental Authorization</I></B>&#148; means any:
(a)&nbsp;permit, license, certificate, franchise, permission, variance, exception, approval, exemption, order, clearance, registration, qualification or authorization issued, granted, given or otherwise made available by or under the authority of
any Governmental Body or pursuant to any Law; or (b)&nbsp;right under any Contract with any Governmental Body. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Governmental
Body</I></B>&#148; means any: (a) nation, state, commonwealth, province, territory, county, municipality, district or other jurisdiction of any nature; (b)&nbsp;federal, state, local, municipal, foreign or other government; (c)&nbsp;governmental or
quasi-governmental authority of any nature (including any governmental division, department, agency, commission, bureau, instrumentality, official, ministry, fund, foundation, center, organization, unit, body or Entity and any court or other
tribunal, and for the avoidance of doubt, any taxing authority); or (d)&nbsp;self-regulatory organization (including Nasdaq). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Hazardous Materials</I></B>&#148; means any pollutant, chemical, substance and any toxic, infectious, carcinogenic, reactive,
corrosive, ignitable or flammable chemical, or chemical compound, or hazardous substance, material or waste, whether solid, liquid or gas, that is subject to regulation, control or remediation under any Environmental Law, including without
limitation, crude oil or any fraction thereof, and petroleum products or byproducts. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Intellectual Property Rights</I></B>&#148; means and includes all intellectual
property or other proprietary rights under the laws of any jurisdiction in the world, including, without limitation: (a)&nbsp;rights associated with works of authorship, including exclusive exploitation rights, copyrights, moral rights, software,
databases, and mask works; (b)&nbsp;trademarks, service marks, trade dress, logos, trade names and other source identifiers, domain names and URLs and similar rights and any goodwill associated therewith; (c)&nbsp;rights associated with trade
secrets, know how, inventions, invention disclosures, methods, processes, protocols, specifications, techniques and other forms of technology; (d)&nbsp;patents and industrial property rights; (e)&nbsp;other similar proprietary rights in intellectual
property of every kind and nature; (f)&nbsp;rights of privacy and publicity; and (g)&nbsp;all registrations, renewals, extensions, statutory invention registrations, provisionals, continuations, <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">continuations-in-part,</FONT></FONT> provisionals, divisions, or reissues of, and applications for, any of the rights referred to in clauses (a)&nbsp;through (f) above (whether or not in tangible form and including all
tangible embodiments of any of the foregoing, such as samples, studies and summaries), along with all rights to prosecute and perfect the same through administrative prosecution, registration, recordation or other administrative proceeding, and all
causes of action and rights to sue or seek other remedies arising from or relating to the foregoing, including for past, present or future infringement of any of the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Intended Tax Treatment</I></B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;4.9(a).</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Investor Agreements</I></B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;2.21(b).</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>IRS</I></B>&#148; means the United States Internal Revenue Service. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Knowledge</I></B>&#148; means, with respect to an individual, that such individual is actually aware of the relevant fact or such
individual would reasonably be expected to know such fact in the ordinary course of the performance of such individual&#146;s employment responsibilities. Any Person that is an Entity shall have Knowledge if any officer or director of such Person as
of the date such knowledge is imputed has Knowledge of such fact or other matter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Law</I></B>&#148; means any federal, state,
national, foreign, material local or municipal or other law, statute, constitution, principle of common law, resolution, ordinance, code, edict, decree, rule, regulation, ruling or requirement issued, enacted, adopted, promulgated, implemented or
otherwise put into effect by or under the authority of any Governmental Body (including under the authority of Nasdaq or the Financial Industry Regulatory Authority). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Legal Proceeding</I></B>&#148; means any action, suit, litigation, arbitration, proceeding (including any civil, criminal,
administrative, investigative or appellate proceeding), hearing, inquiry, audit, examination or investigation commenced, brought, conducted or heard by or before, or otherwise involving, any court or other Governmental Body or any arbitrator or
arbitration panel. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Liability</I></B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;2.9</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement</I></B>&#148; has the meaning set forth in the Recitals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Merger</I></B>&#148; has the meaning set forth in the Recitals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Merger Consideration</I></B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;1.5.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Merger Subs</I></B>&#148; has the meaning set forth in the Preamble. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Nasdaq</I></B>&#148; means the Nasdaq Stock Market, including the Nasdaq Global
Select Market or such other Nasdaq market on which shares of Parent Common Stock are then listed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Nasdaq Listing
Application</I></B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;4.8</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Nasdaq Reverse
Split</I></B>&#148; means a reverse stock split of all outstanding shares of Parent Common Stock at a reverse stock split ratio to be reasonably determined by Parent for the purpose of maintaining compliance with Nasdaq listing standards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Ordinary Course of Business</I></B>&#148; means, in the case of each of the Company and Parent, such actions taken in the ordinary
course of its normal operations and consistent with its past practices. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Organizational Documents</I></B>&#148; means, with
respect to any Person (other than an individual), (a) the certificate or articles of association or incorporation or organization or limited partnership or limited liability company, and any joint venture, limited liability company, operating or
partnership agreement and other similar documents adopted or filed in connection with the creation, formation or organization of such Person and (b)&nbsp;all bylaws, regulations and similar documents or agreements relating to the organization or
governance of such Person, in each case, as amended or supplemented. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Parent</I></B>&#148; has the meaning set forth in the
Preamble. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Parent Associate</I></B>&#148; means any current or former employee, independent contractor, officer or director of
Parent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Parent Balance Sheet</I></B>&#148; means the unaudited balance sheet of Parent as of March&nbsp;31, 2023 (the
&#147;<B><I>Parent Balance Sheet Date</I></B>&#148;) provided to the Company prior to the date of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Parent
Benefit Plan</I></B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;3.17(a)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Parent Board</I></B>&#148;
means the board of directors of Parent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Parent Common Stock</I></B>&#148; means the Common Stock, $0.0001 par value per
share, of Parent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Parent Common Stock Consideration Cap</I></B>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;1.5</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Parent Common Stock Consideration Cap</I></B>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;1.5</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Parent Common Stock Payment Shares</I></B>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;1.5</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Parent Contract</I></B>&#148; means any Contract: (a) to which Parent or any of its
Subsidiaries is a party; (b)&nbsp;by which Parent or any of its Subsidiaries or any Parent IP or any other asset of Parent or any of its Subsidiaries is or may become bound or under which Parent or any of its Subsidiaries has, or may become subject
to, any obligation; or (c)&nbsp;under which Parent or any of its Subsidiaries has or may acquire any right or interest. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Parent Convertible Preferred Stock</I></B>&#148; means Parent&#146;s <FONT
STYLE="white-space:nowrap">non-voting</FONT> convertible preferred stock, par value $0.0001 per share, with the rights, preferences, powers and privileges specified in the Certificate of Designation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Parent Covered Person</I></B>&#148; means, with respect to Parent as an &#147;issuer&#148; for purposes of Rule 506 promulgated
under the Securities Act, any Person listed in the first paragraph of Rule 506(d)(1). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Parent Data</I></B>&#148; means all
data and information Processed by or for Parent or any of its Subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Parent Disclosure Schedule</I></B>&#148; has the
meaning set forth in <U>Section</U><U></U><U>&nbsp;3</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Parent</I></B> <B><I>ERISA Affiliate</I></B>&#148; means any
corporation or trade or business (whether or not incorporated) which is (or at any relevant time was) treated with Parent or any of its Subsidiaries as a single employer within the meaning of Section&nbsp;414 of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Parent ESPP</I></B>&#148; means Parent&#146;s 2016 Employee Stock Purchase Plan, as may be amended from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Parent Financing</I></B>&#148; means an acquisition of shares of Parent Convertible Preferred Stock to be consummated concurrently
with the Closing pursuant to the Securities Purchase Agreement with aggregate gross cash proceeds to Parent of at least the Concurrent Investment Amount. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Parent Foreign Plan</I></B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;3.17(l)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Parent <FONT STYLE="white-space:nowrap">In-bound</FONT> License</I></B>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;3.12(d)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Parent IP</I></B>&#148; means all Intellectual Property Rights that are owned or
purported to be owned by, assigned to, or exclusively licensed by, Parent or its Subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Parent Material Adverse
Effect</I></B>&#148; means any Effect that, considered together with all other Effects that have occurred prior to the date of determination of the occurrence of a Parent Material Adverse Effect, has or would reasonably be expected to have a
material adverse effect on the business, condition (financial or otherwise), assets, liabilities or results of operations of Parent; <I>provided</I>, <I>however</I>, that Effects arising or resulting from the following shall not be taken into
account in determining whether there has been a Parent Material Adverse Effect: (a) general business or economic conditions affecting the industry in which Parent operates, (b)&nbsp;acts of war, armed hostilities or terrorism, acts of God or
comparable events, epidemic, pandemic or disease outbreak (including the <FONT STYLE="white-space:nowrap">COVID-19</FONT> virus) or any worsening of the foregoing, or any declaration of martial law, quarantine or similar directive, policy or
guidance or Law or other action by any Governmental Body in response thereto, (c)&nbsp;changes in financial, banking or securities markets, (d)&nbsp;the taking of any action required to be taken by this Agreement, (e)&nbsp;any change in the stock
price or trading volume of Parent Common Stock (it being understood, however, that any Effect causing or contributing to any change in stock price or trading volume of Parent Common Stock may be taken into account in determining whether a Parent
Material Adverse Effect has occurred, unless such Effects are otherwise excepted from this definition); (f) any change in, or any compliance with or action taken for the purpose of complying with, any Law or GAAP (or interpretations of any Law or
GAAP); (g) resulting from the announcement of this Agreement or the pendency of the Contemplated Transactions; <I>provided</I>, that this clause (e)&nbsp;shall not apply to any representation or warranty (or condition to the consummation of the
Mergers relating to such representation or warranty) to the extent the representation and warranty expressly </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
addresses the consequences resulting from the execution and delivery of this Agreement or the consummation of the Contemplated Transactions; or (h)&nbsp;resulting from the taking of any action or
the failure to take any action, by Parent that is required to be taken by this Agreement, except in each case with respect to clauses (a)&nbsp;through (c), to the extent disproportionately affecting Parent relative to other similarly situated
companies in the industries in which Parent operates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Parent Material Contract(s)</I></B>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;3.13(a)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Parent Options</I></B>&#148; means options or other rights to purchase shares of
Parent Common Stock issued by Parent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Parent <FONT STYLE="white-space:nowrap">Out-bound</FONT> License</I></B>&#148; has the
meaning set forth in <U>Section</U><U></U><U>&nbsp;3.12(d)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Parent Outstanding Shares Certificate</I></B>&#148; has the
meaning set forth in <U>Section</U><U></U><U>&nbsp;4.14(b)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Parent Permits</I></B>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;3.14(b). </U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Parent Preferred Stock Payment Shares</I></B>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;1.5</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Parent Real Estate Leases</I></B>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;3.11</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Parent RSUs</I></B>&#148; means any restricted stock unit award granted pursuant to
the Parent Stock Plans. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Parent SEC Documents</I></B>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;3.7(a)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Parent Signatories</I></B>&#148; has the meaning set forth in the Recitals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B><I>&#147;</I></B><B><I>Parent Stock Plans</I></B>&#148; means collectively, Parent&#146;s 2015 Equity Incentive Plan, 2016 Equity Incentive
Plan, 2016 Employee Stock Purchase Plan and 2018 Equity Incentive Plan, each as may be amended from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Parent
Stockholder Matters</I></B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;4.2(a)(iii)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Parent
Stockholders&#146; Meeting</I></B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;4.2(a)(iii)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Party</I></B>&#148; or &#147;<B><I>Parties</I></B>&#148; means the Company, First Merger Sub, Second Merger Sub and Parent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Permitted Encumbrance</I></B>&#148; means: (a) any Encumbrance for current Taxes not yet due and payable or for Taxes that are
being contested in good faith and, in each case, for which adequate reserves have been made on the Company Unaudited Interim Balance Sheet or the Parent Balance Sheet, as applicable, in accordance with GAAP; (b)&nbsp;minor liens that have arisen in
the Ordinary Course of Business and that do not (in any case or in the aggregate) materially detract from the value of the assets or properties subject thereto or materially impair the operations of the Company or any of its Subsidiaries or Parent,
as applicable; (c)&nbsp;liens to secure obligations to landlords, lessors or renters under leases or rental agreements; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(d) deposits or pledges made in connection with, or to secure payment of, workers&#146; compensation, unemployment insurance or similar programs mandated by Law;
<FONT STYLE="white-space:nowrap">(e)&nbsp;non-exclusive</FONT> licenses of Intellectual Property Rights granted by the Company or any of its Subsidiaries or Parent, as applicable, in the Ordinary Course of Business and that do not (in any case or in
the aggregate) materially detract from the value of the Intellectual Property Rights subject thereto; and (f)&nbsp;statutory liens in favor of carriers, warehousemen, mechanics and materialmen, to secure claims for labor, materials or supplies the
payment for which is not delinquent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Person</I></B>&#148; means any individual, Entity or Governmental Body. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Post-Closing Plans</I></B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;4.4(a)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Preferred Stock Conversion Proposal</I></B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;1.5</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Privacy and Data Processing Requirements</I></B>&#148; means any applicable (i)&nbsp;Law relating to privacy, data protection, or
security, (ii)&nbsp;Data Processing Policy, or (iii)&nbsp;requirement of any self-regulatory organization, industry standard (including, as applicable, the Payment Card Industry Data Security Standard), or Contract by which the Company, Parent or
their respective Subsidiaries are bound relating to the Processing of Company Data or Parent Data (as applicable), privacy, data protection, or security, including, in each case of (i)&nbsp;through (iii), in connection with direct marketing or the
initiation, transmission, monitoring, interception, recording, or receipt of communications. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Process</I></B>&#148; means,
with respect to any data, information, or information technology system, any operation or set of operations performed thereon, whether or not by automated means, including access, adaptation, alignment, alteration, collection, combination,
compilation, consultation, creation, derivation, destruction, disclosure, disposal, dissemination, erasure, interception, maintenance, making available, organization, recording, restriction, retention, retrieval, storage, structuring, transmission,
and use, and security measures with respect thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Proxy Statement</I></B>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;4.7(a)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Reference Date</I></B>&#148; means June&nbsp;19, 2023. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Registered IP</I></B>&#148; means all Intellectual Property Rights that are registered or issued under the authority of, with or
by any Governmental Body, including all patents, registered copyrights, registered mask works, and registered trademarks, service marks and trade dress, and all applications for any of the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Representatives</I></B>&#148; means directors, officers, employees, agents, attorneys, accountants, investment bankers, advisors
and representatives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Required Company Stockholder Vote</I></B>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;2.4</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Required Parent Stockholder Vote</I></B>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;3.4</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Sarbanes-Oxley Act</I></B>&#148; means the Sarbanes-Oxley Act of 2002. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>SEC</I></B>&#148; means the United States Securities and Exchange Commission.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Second Certificate of Merger</I></B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;1.3</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Second Effective Time</I></B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;1.3</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Second Merger</I></B>&#148; has the meaning set forth in the Recitals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Second Merger Sub</I></B>&#148; has the meaning set forth in the Preamble. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Second Merger Sub Board</I></B>&#148; means the board of managers of Second Merger Sub. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Securities Act</I></B>&#148; means the Securities Act of 1933, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Stockholder Written Consent</I></B>&#148; has the meaning set forth in the Recitals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Subsidiary</I></B>&#148; An entity shall be deemed to be a &#145;subsidiary&#146; of a Person if such Person directly or
indirectly owns or purports to own, beneficially or of record, (a)&nbsp;an amount of voting securities or other interests in such entity that is sufficient to enable such Person to elect at least a majority of the members of such entity&#146;s board
of directors or other governing body, or (b)&nbsp;at least 50% of the outstanding equity, voting, beneficial or financial interests in such Entity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Surviving Entity</I></B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;1.1</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Takeover Statute</I></B>&#148; means any &#147;fair price,&#148; &#147;moratorium,&#148; &#147;control share acquisition&#148; or
other similar anti-takeover Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Tax</I></B>&#148; means any (i)&nbsp;federal, state, local, foreign or other tax, including
any income, capital gain, gross receipts, capital stock, profits, transfer, estimated, registration, stamp, premium, escheat, unclaimed property, customs duty, ad valorem, occupancy, occupation, alternative,
<FONT STYLE="white-space:nowrap">add-on,</FONT> windfall profits, value added, severance, property, business, production, sales, use, license, excise, franchise, employment, payroll, social security, disability, unemployment, workers&#146;
compensation, national health insurance, withholding or other taxes, duties, fees, assessments or governmental charges, surtaxes or deficiencies thereof in the nature of a tax, however denominated (whether imposed directly or through withholding and
whether or not disputed), and including any fine, penalty, addition to tax, or interest or additional amount imposed by a Governmental Body with respect thereto (or attributable to the nonpayment thereof) and (ii)&nbsp;any liability for payment of
amounts described in clause (i)&nbsp;whether as a result of transferee or successor liability, of being a member of an affiliated, consolidated, combined or unitary group for any period, pursuant to a Contract, through operation of Law or otherwise.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Tax Return</I></B>&#148; means any return (including any information return), report, statement, declaration, claim for
refund, estimate, schedule, notice, notification, form, election, certificate or other document, and any amendment or supplement to any of the foregoing, filed with or submitted to, or required to be filed with or submitted to, any Governmental Body
(or provided to a payee) in connection with the determination, assessment, collection or payment of any Tax or in connection with the administration, implementation or enforcement of or compliance with any Law relating to any Tax. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Treasury Regulations</I></B>&#148; means the United States Treasury regulations
promulgated under the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>WARN Act</I></B>&#148; means the Worker Adjustment Retraining and Notification Act of 1988, as
amended, or any similar state or local plant closing mass layoff statute, rule or regulation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Withholding Agent</I></B>&#148;
has the meaning set forth in <U>Section</U><U></U><U>&nbsp;1.12. </U> </P> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Exhibit B </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Form of <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement </U></B></P>
<P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><I>Privileged and Confidential </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><I>Final Form </I></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF <FONT
STYLE="white-space:nowrap">LOCK-UP</FONT> AGREEMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">June [_], 2023 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aeglea Biotherapetuics, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">805 Las Cimas Parkway </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Suite 100 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Austin, TX 78746 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned
signatory of this <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement (this &#147;<B><I><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement</I></B>&#148;) understands that Aeglea Biotherapetuics, Inc. a Delaware corporation (including
any successor thereto, &#147;<B><I>Parent</I></B>&#148;), has entered into an Agreement and Plan of Merger, dated as of June [_], 2023 (as the same may be amended from time to time, the &#147;<B><I>Merger Agreement</I></B>&#148;) with Aspen Merger
Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of Parent, Sequoia Merger Sub II, LLC, a Delaware limited liability company and a wholly owned subsidiary of Parent, and Spyre Therapeutics, Inc, a Delaware corporation (the
&#147;<B><I>Company</I></B>&#148;). Capitalized terms used but not otherwise defined herein shall have the respective meanings ascribed to such terms in the Merger Agreement.<SUP STYLE="font-size:75%; vertical-align:top"> </SUP> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.</B> As a condition and material inducement to each of the parties to enter into the Merger Agreement and to consummate the Contemplated Transactions,
and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the undersigned hereby irrevocably agrees that, subject to the exceptions set forth herein, without the prior written consent of Parent and,
solely prior to the Closing, the Company, the undersigned will not, during the period commencing upon the Closing and ending on the date that is 180 days after the Closing Date (the &#147;<B><I>Restricted Period</I></B>&#148;): </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any
option, right or warrant to purchase, lend or otherwise transfer or dispose of, directly or indirectly, any shares of Parent Common Stock, Parent Convertible Preferred Stock or any securities convertible into or exercisable or exchangeable for
Parent Common Stock (including without limitation, Parent Common Stock or such other securities which may be deemed to be beneficially owned by the undersigned in accordance with the rules and regulations of the SEC and securities of Parent which
may be issued upon exercise of Parent Options or settlement of Parent RSUs) that are currently or hereafter owned by the undersigned (collectively, the &#147;<B><I>Undersigned&#146;s Shares</I></B>&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> enter into any swap, short sale, hedge or other agreement that transfers, in whole or in part, any of the economic consequences of
ownership of the Undersigned&#146;s Shares regardless of whether any such transaction described in clause (i)&nbsp;above or this clause (ii)&nbsp;is to be settled by delivery of Parent Common Stock, Parent Convertible Preferred Stock or other
securities, in cash or otherwise; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> make any demand for, or exercise any right with respect to, the registration of any shares
of Parent Common Stock, Parent Convertible Preferred Stock or any security convertible into or exercisable or exchangeable for Parent Common Stock (other than such rights set forth in the Merger Agreement); or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> publicly disclose the intention to do any of the foregoing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.</B> The restrictions and obligations contemplated by this
<FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement shall not apply to: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> transfers of the Undersigned&#146;s Shares: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> if the undersigned is a natural person, (A)&nbsp;to any person related to the undersigned (or to an ultimate beneficial owner of
the undersigned) by blood or adoption who is an immediate family member of the undersigned, or by marriage or domestic partnership (a &#147;<B><I>Family Member</I></B>&#148;), or to a trust formed for the benefit of the undersigned or any of the
undersigned&#146;s Family Members, (B)&nbsp;to the undersigned&#146;s estate, following the death of the undersigned, by will, intestacy or other operation of Law, (C)&nbsp;as a bona fide charitable gift or contribution, (D)&nbsp;by operation of Law
pursuant to a qualified domestic order or in connection with a divorce settlement or (E)&nbsp;to any partnership, corporation or limited liability company which is controlled by or under common control with the undersigned and/or by any such Family
Member(s); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> if the undersigned is a corporation, partnership or<I> </I>other Entity, (A)&nbsp;to another corporation,
partnership, or other Entity that is an affiliate (as defined under Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Exchange Act) of the undersigned, including investment funds or other entities under common control or management with the
undersigned, (B)&nbsp;as a distribution or dividend to equity holders, current or former general or limited partners, members or managers (or to the estates of any of the foregoing), as applicable, of the undersigned (including upon the liquidation
and dissolution of the undersigned pursuant to a plan of liquidation approved by the undersigned&#146;s equity holders), (C) as a bona fide charitable gift or contribution or otherwise to a trust or other entity for the direct or indirect benefit of
an immediate family member of a beneficial owner (as defined in Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> of the Exchange Act) of the Undersigned&#146;s Shares or (D)&nbsp;transfers or dispositions not involving a change in beneficial
ownership; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> if the undersigned is a trust, to any grantors or beneficiaries of the trust; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>provided that</U></I>, in the case of any transfer or distribution pursuant to this clause (a), such transfer is not for value and each donee, heir,
beneficiary or other transferee or distributee shall sign and deliver to Parent a <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement in the form of this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement with respect to the shares of
Parent Common Stock, Parent Convertible Preferred Stock or such other securities that have been so transferred or distributed; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>
the exercise of Parent Options (including a net or cashless exercise of a Parent Option), and any related transfer of shares of Parent Common Stock to Parent for the purpose of paying the exercise price of such options or for paying taxes (including
estimated taxes) due as a result of the exercise of such options; <I><U>provided that</U></I>, for the avoidance of doubt, the underlying shares of Parent Common Stock shall continue to be subject to the restrictions on transfer set forth in this <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Agreement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> the disposition (including a forfeiture or repurchase) to Parent of any
shares of restricted stock granted pursuant to the terms of any employee benefit plan or restricted stock purchase agreement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B>
transfers to Parent in connection with the net settlement of any Parent RSU or other equity award that represents the right to receive in the future shares of Parent Common Stock settled in Parent Common Stock to pay any tax withholding obligations;
<I><U>provided that</U></I>, for the avoidance of doubt, the underlying shares of Parent Common Stock shall continue to be subject to the restrictions on transfer set forth in this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> the establishment of a trading plan pursuant to Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange Act for the
transfer of Parent Common Stock; <I><U>provided that</U></I> such plan does not provide for any transfers of Parent Common Stock during the Restricted Period; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> transfers by the undersigned of shares of Parent Common Stock purchased by the
undersigned on the open market or in a public offering by Parent, in each case following the Closing Date; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(g)</B> pursuant to a
bona-fide third party tender offer, merger, consolidation or other similar transaction made to all holders of Parent&#146;s capital stock involving a change of control of Parent, <I><U>provided that</U></I> in the event that such tender offer,
merger, consolidation or other such transaction is not completed, the Undersigned&#146;s Shares shall remain subject to the restrictions contained in this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(h)</B> pursuant to an order of a court or regulatory agency; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">and <I><U>provided</U></I><I>, </I><I><U>further</U></I><U>,</U> that, with respect to each of (a), (b), (c), (d) and (e)&nbsp;above, no filing by any party
(including any donor, donee, transferor, transferee, distributor or distributee) under Section&nbsp;16 of the Exchange Act or other public announcement shall be required or shall be made voluntarily in connection with such transfer or disposition
during the Restricted Period (other than (i)&nbsp;any exit filings or public announcements that may be required under applicable federal and state securities Laws or (ii)&nbsp;in respect of a required filing under the Exchange Act in connection with
the exercise of an option to purchase Parent Common Stock or in connection with the net settlement of any RSU or other equity award that represents the right to receive in the future shares of Parent Common Stock settled in Parent Common Stock that
would otherwise expire during the Restricted Period, <I><U>provided that</U></I> (i)&nbsp;reasonable notice shall be provided to Parent prior to any such filing) and (ii)&nbsp;such filing, report or announcement shall clearly indicate in the
footnotes therein, in reasonable detail, a description of the circumstances of the transfer and that the shares remain subject to the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement, &#147;change of control&#148; shall mean the transfer (whether by tender
offer, merger, consolidation or other similar transaction), in one transaction or a series of related transactions, to a person or group of affiliated persons, of Parent&#146;s voting securities if, after such transfer, Parent&#146;s stockholders as
of immediately prior to such transfer do not hold a majority of the outstanding voting securities of Parent (or the surviving entity) other than the Contemplated Transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3.</B> Any attempted transfer in violation of this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement will be of no effect and null and void,
regardless of whether the purported transferee has any actual or constructive knowledge of the transfer restrictions set forth in this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement, and will not be recorded on the share register of
Parent. In furtherance of the foregoing, the undersigned agrees that Parent and any duly appointed transfer agent for the registration or transfer of the securities described herein are hereby authorized to decline to make any transfer of securities
if such transfer would constitute a violation or breach of this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement. Parent may cause the legend set forth below, or a legend substantially equivalent thereto, to be placed upon any
certificate(s) or other documents, ledgers or instruments evidencing the undersigned&#146;s ownership of Parent Common Stock, Parent Convertible Preferred Stock or any securities convertible into or exercisable or exchangeable for Parent Common
Stock: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO AND MAY ONLY BE TRANSFERRED IN COMPLIANCE WITH A <FONT
STYLE="white-space:nowrap">LOCK-UP</FONT> AGREEMENT, A COPY OF WHICH IS ON FILE AT THE PRINCIPAL OFFICE OF THE COMPANY. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4.</B> The undersigned hereby
represents and warrants that the undersigned has full power and authority to enter into this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement. All authority herein conferred or agreed to be conferred and any obligations of the undersigned
shall be binding upon the successors, assigns, heirs or personal representatives of the undersigned. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5.</B> The undersigned understands that if the Merger Agreement is terminated for any reason, the
undersigned shall be released from all obligations under this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement. The undersigned understands that Parent and the Company are proceeding with the Contemplated Transactions in reliance upon this <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6.</B> Any and all remedies herein expressly conferred upon Parent or the Company will be deemed
cumulative with and not exclusive of any other remedy conferred hereby, or by Law or equity, and the exercise by Parent or the Company of any one remedy will not preclude the exercise of any other remedy. The undersigned agrees that irreparable
damage for which monetary damages, even if available, would not be an adequate remedy, would occur to Parent and/or the Company in the event that any provision of this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement were not performed in
accordance with its specific terms or were otherwise breached. It is accordingly agreed that Parent and the Company shall be entitled to an injunction or injunctions to prevent breaches of this <FONT STYLE="white-space:nowrap">Lock-Up</FONT>
Agreement and to enforce specifically the terms and provisions hereof in any court of the United States or any state having jurisdiction, this being in addition to any other remedy to which Parent or the Company is entitled at Law or in equity, and
the undersigned waives any bond, surety or other security that might be required of Parent or the Company with respect thereto. Each of the parties further agrees that it will not oppose the granting of an injunction, specific performance or other
equitable relief on the basis that any other party has an adequate remedy at law or that any award of specific performance is not an appropriate remedy for any reason at law or in equity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7.</B> In the event that any holder of securities of Parent that are subject to a substantially similar agreement entered into by such holder, other than
the undersigned, is permitted by Parent to sell or otherwise transfer or dispose of shares of Parent Common Stock, Parent Convertible Preferred Stock or any securities convertible into or exercisable or exchangeable for Parent Common Stock for value
other than as permitted by this or a substantially similar agreement entered into by such holder (whether in one or multiple releases or waivers), the same percentage of shares of Parent Common Stock, Parent Convertible Preferred Stock or any
securities convertible into or exercisable or exchangeable for Parent Common Stock held by the undersigned on the date of such release or waiver as the percentage of the total number of outstanding shares of such securities held by such holder on
the date of such release or waiver that are the subject of such release or waiver shall be immediately and fully released on the same terms from any remaining restrictions set forth herein (the &#147;<B><I>Pro Rata Release</I></B>&#148;); provided,
however, that such Pro Rata Release shall not be applied unless and until permission has been granted by Parent to an equity holder or equity holders to sell or otherwise transfer or dispose of all or a portion of such equity holders shares of
Parent Common Stock in an aggregate amount in excess of 1% of the number of shares of Parent Common Stock originally subject to a substantially similar agreement. In the event of any <FONT STYLE="white-space:nowrap">Pro-Rata</FONT> Release, the
Company shall promptly (and in any event within two (2)&nbsp;business days of such release) inform each relevant holder of Parent Common Stock, Parent Convertible Preferred Stock or any securities convertible into or exercisable or exchangeable for
Parent Common Stock of the terms of such <FONT STYLE="white-space:nowrap">Pro-Rata</FONT> Release. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8.</B> Upon the release of any of the
Undersigned&#146;s Shares from this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement, Parent will cooperate with the undersigned to facilitate the timely preparation and delivery of certificates or the establishment of book-entry positions
at Parent&#146;s transfer agent representing the Undersigned&#146;s Shares without the restrictive legend above or the withdrawal of any stop transfer instructions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9.</B> The undersigned understands that this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement is irrevocable and is binding upon the
undersigned&#146;s heirs, legal representatives, successors and assigns. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10.</B> This <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement shall
be governed by, and construed in accordance with, the Laws of the state of Delaware, regardless of the Laws that might otherwise govern under applicable principles of conflicts of Laws. In any action or Legal Proceeding between any of the parties
arising out of or relating to this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement, each of the parties: (i)&nbsp;irrevocably and unconditionally consents and submits to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the exclusive jurisdiction and venue of the Court of Chancery of the state of Delaware or to the extent such court does not have subject matter jurisdiction, the Superior Court of the State of
Delaware or the United States District Court for the District of Delaware, (ii)&nbsp;agrees that all claims in respect of such action or Legal Proceeding shall be heard and determined exclusively in accordance with clause (i)&nbsp;of this
<U>Section</U><U></U><U>&nbsp;10</U>, (iii) waives any objection to laying venue in any such action or Legal Proceeding in such courts, (iv)&nbsp;waives any objection that such courts are an inconvenient forum or do not have jurisdiction over any
party, and (v)&nbsp;agrees that service of process upon such party in any such action or Legal Proceeding shall be effective if notice is given in accordance with <U>Section</U><U></U><U>&nbsp;11</U> of this
<FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement. This <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement constitutes the entire agreement between the parties to this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement and
supersedes all other prior agreements, arrangements and understandings, both written and oral, among the parties with respect to the subject matter hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THE PARTIES HERETO HEREBY WAIVE ANY RIGHT TO TRIAL BY JURY WITH RESPECT TO ANY ACTION OR LEGAL PROCEEDING RELATED TO OR ARISING OUT OF THIS <FONT
STYLE="white-space:nowrap">LOCK-UP</FONT> AGREEMENT, ANY DOCUMENT EXECUTED IN CONNECTION HEREWITH AND THE MATTERS CONTEMPLATED HEREBY AND THEREBY. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11.</B> All notices and other communications hereunder shall be in writing and shall be deemed given if delivered personally or sent by overnight courier
(providing proof of delivery), by electronic transmission (providing confirmation of transmission) to the Company or Parent, as the case may be, in accordance with [Section 8.8] of the Merger Agreement and to the undersigned at his, her or its
address or email address (providing confirmation of transmission) set forth on the signature page hereto (or at such other address for a party as shall be specified by like notice). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12.</B> This <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement may be executed in several counterparts, each of which shall be deemed an original
and all of which shall constitute one and the same instrument. The exchange of a fully executed <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement (in counterparts or otherwise) by Parent, the Company and the undersigned by electronic
transmission in .pdf format shall be sufficient to bind such parties to the terms and conditions of this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(Signature Page Follows) </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="60%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Very truly yours,</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[&nbsp;&nbsp;&nbsp;&nbsp;]</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Signature&nbsp;(for&nbsp;individuals):</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Print&nbsp;Name&nbsp;of&nbsp;Stockholder:</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Email:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Address:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Signature (for entities):</P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Email:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><U>Address:</U></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> L<SMALL>OCK</SMALL><FONT
STYLE="white-space:nowrap">-U</FONT><SMALL>P</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Accepted and Agreed</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>by
AEGLEA BIOTHERAPETUICS, INC.:</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="right">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Accepted and Agreed</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>by
SPYRE THERAPEUTICS, INC.:</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="right">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="right">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> L<SMALL>OCK</SMALL><FONT
STYLE="white-space:nowrap">-U</FONT><SMALL>P</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Exhibit C </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Form of Certificate of Designation </U></B></P> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><I>Final Form </I></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AEGLEA BIOTHERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATE OF DESIGNATION OF PREFERENCES, </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RIGHTS AND LIMITATIONS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SERIES A <FONT
STYLE="white-space:nowrap">NON-VOTING</FONT> CONVERTIBLE PREFERRED STOCK </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Pursuant to Section&nbsp;151 of the </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">General Corporation Law of the State of Delaware </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">THE UNDERSIGNED DOES HEREBY CERTIFY, on behalf of Aeglea BioTherapeutics, Inc., a Delaware corporation (the &#147;<B><I>Corporation</I></B>&#148;), that the
following resolution was duly adopted by the Board of Directors of the Corporation (the &#147;<B><I>Board of Directors</I></B>&#148;), in accordance with the provisions of Section&nbsp;151 of the General Corporation Law of the State of Delaware (the
&#147;<B><I>DGCL</I></B>&#148;), at a meeting duly called and held on June&nbsp;21, 2023, which resolution provides for the creation of a series of the Corporation&#146;s Preferred Stock, par value $0.0001 per share, which is designated as
&#147;Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Convertible Preferred Stock,&#148; with the preferences, rights and limitations set forth therein relating to dividends, conversion, redemption, dissolution and distribution of assets
of the Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>: the Restated Certificate of Incorporation of the Corporation (the &#147;<B><I>Certificate of
Incorporation</I></B>&#148;), provides for a class of its authorized stock known as Preferred Stock, consisting of 10,000,000 shares, $0.0001 par value per share (the &#147;<B><I>Preferred Stock</I></B>&#148;), issuable from time to time in one or
more series. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>RESOLVED</B>: that, pursuant to authority conferred upon the Board of Directors by the Certificate of Incorporation,
(i)&nbsp;a series of Preferred Stock of the Corporation be, and hereby is authorized by the Board of Directors, (ii)&nbsp;the Board of Directors hereby authorizes the issuance of 1,086,341 shares of &#147;Series A
<FONT STYLE="white-space:nowrap">Non-Voting</FONT> Convertible Preferred Stock&#148; pursuant to the terms of (a)&nbsp;the Securities Purchase Agreement, dated as of the date hereof, by and among the Corporation and the initial Holders (as defined
below) (the &#147;<B><I>Purchase Agreement</I></B>&#148;) and (b)&nbsp;the Agreement and Plan of Merger, dated as of the date hereof, by and among the Corporation, Aspen Merger Sub I, Inc., a Delaware corporation and wholly owned subsidiary of
Parent, Sequoia Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of Parent and Spyre Therapeutics, Inc. (the &#147;<B><I>Merger Agreement</I></B>&#148;), and (iii)&nbsp;the Board of Directors hereby fixes the
designations, powers, preferences and relative, participating, optional or other special rights, and the qualifications, limitations or restrictions thereof, of such shares of Preferred Stock, in addition to any provisions set forth in the
Certificate of Incorporation that are applicable to the Preferred Stock of all classes and series, as follows: </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TERMS OF SERIES A <FONT
STYLE="white-space:nowrap">NON-VOTING</FONT> CONVERTIBLE PREFERRED STOCK </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1. <U>Definitions</U>. For the purposes hereof, the
following terms shall have the following meanings: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Business Day</I></B>&#148; means any day except any Saturday, any Sunday,
any day which is a federal legal holiday in the United States or any day on which banking institutions in the State of New York are authorized or required by law or other governmental action to&nbsp;close. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I><FONT STYLE="white-space:nowrap">Buy-In</FONT></I></B>&#148; shall have the meaning set forth in
<U>Section</U><U></U><U>&nbsp;6.5.4</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Closing Sale Price</I></B>&#148; means, for any security as of any date, the last
closing trade price for such security immediately prior to 4:00 p.m., New York City time, on the principal Trading Market where such security is listed or traded, as reported by Bloomberg, L.P. (or an equivalent, reliable reporting service), or if
the foregoing do not apply, the last trade price of such security in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market on the electronic bulletin board for such
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
security as reported by Bloomberg, L.P., or, if no last trade price is reported for such security by Bloomberg, L.P., the average of the bid prices of any market makers for such security as
reported on the OTC Pink Market by OTC Markets Group, Inc. If the Closing Sale Price cannot be calculated for a security on a particular date on any of the foregoing bases, the Closing Sale Price of such security on such date shall be the fair
market value as determined in good faith by the Board of Directors of the Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Commission</I></B>&#148; means the
United States Securities and Exchange Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Common Stock</I></B>&#148; means the Corporation&#146;s common stock, par
value $0.0001 per share, and stock of any other class of securities into which such securities may hereafter be reclassified or changed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Conversion Shares</I></B>&#148; means, collectively, the shares of Common Stock issuable upon conversion of the shares of Series A
<FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock in accordance with the terms hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Exchange
Act</I></B>&#148; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Holder</I></B>&#148; means a holder of shares of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Person</I></B>&#148; means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint
venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Trading Day</I></B>&#148; means a day on which the principal Trading Market is open for business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Trading Market</I></B>&#148; means any of the following markets or exchanges on which the Common Stock is listed or quoted for
trading on the date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, or the New York Stock Exchange (or any successors to any of the foregoing). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2. <U>Designation, Amount and Par Value</U>. The series of Preferred Stock shall be designated as the Corporation&#146;s Series A <FONT
STYLE="white-space:nowrap">Non-Voting</FONT> Convertible Preferred Stock (the &#147;<B><I>Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock</I></B>&#148;) and the number of shares so designated shall be 1,086,341. Each
share of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock shall have a par value of $0.0001 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.
<U>Dividends</U>. Holders shall be entitled to receive, and the Corporation shall pay, dividends on shares of the Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock (on an <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">as-if-converted-to-Common-Stock</FONT></FONT></FONT></FONT> basis, without regard to the Beneficial Ownership Limitation (as defined below)) equal to and in
the same form, and in the same manner, as dividends (other than dividends on shares of the Common Stock payable in the form of Common Stock) actually paid on shares of the Common Stock when, as and if such dividends (other than dividends payable in
the form of Common Stock) are paid on shares of the Common Stock; provided, however, in no event shall Holders of Series A Non-Voting Preferred Stock be entitled to receive the &#147;rights&#148; distributed pursuant to that certain Contingent Value
Rights Agreement dated as of June 22, 2023 by and between the Corporation and American Stock Transfer &amp; Trust Company, LLC, as may be amended from time to time (the &#147;CVR Agreement&#148;), or any amounts paid under the CVR Agreement. Other
than as set forth in the previous sentence, no other dividends shall be paid on shares of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock, and the Corporation shall pay no dividends (other than dividends payable in the
form of Common Stock) on shares of the Common Stock unless it simultaneously complies with the previous sentence. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4. <U>Voting
Rights</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.1 Except as otherwise provided herein or as otherwise required by the DGCL, the Series A
<FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock shall have no voting rights. However, as long as any shares of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock are outstanding, the Corporation shall not,
without the affirmative vote of the holders of a majority of the then outstanding shares of the Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock: (i)&nbsp;alter or change adversely
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the powers, preferences or rights given to the Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock or alter or amend this Certificate of Designation, amend or repeal any
provision of, or add any provision to, the Certificate of Incorporation or Amended and Restated Bylaws of the Corporation, or file any articles of amendment, certificate of designations, preferences, limitations and relative rights of any series of
Preferred Stock, if such action would adversely alter or change the preferences, rights, privileges or powers of, or restrictions provided for the benefit of the Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock, regardless
of whether any of the foregoing actions shall be by means of amendment to the Certificate of Incorporation or by merger, consolidation, recapitalization, reclassification, conversion or otherwise, (ii)&nbsp;issue further shares of Series A <FONT
STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock or increase or decrease (other than by conversion) the number of authorized shares of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock, (iii)&nbsp;prior to the
Stockholder Approval (as defined below) or at any time while at least 30% of the originally issued Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock remains issued and outstanding, consummate either: (A)&nbsp;any
Fundamental Transaction (as defined below) or (B)&nbsp;any merger or consolidation of the Corporation with or into another entity or any stock sale to, or other business combination in which the stockholders of the Corporation immediately before
such transaction do not hold at least a majority of the capital stock of the Corporation immediately after such transaction or (iv)&nbsp;enter into any agreement with respect to any of the foregoing. Holders of shares of Common Stock acquired upon
the conversion of shares of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock shall be entitled to the same voting rights as each other holder of Common Stock, except that such holders may not vote such shares upon the
proposal for Stockholder Approval in accordance with Rule 5635 of the listing rules of The Nasdaq Stock Market LLC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.2 Any vote
required or permitted under <U>Section</U><U></U><U>&nbsp;4.1</U> may be taken at a meeting of the Holders or through the execution of an action by written consent in lieu of such meeting, provided that the consent is executed by Holders
representing a majority of the outstanding shares of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.
<U>Rank; Liquidation</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">5.1 The Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock shall rank on parity with
the Common Stock as to distributions of assets upon liquidation, dissolution or winding up of the Corporation, whether voluntarily or involuntarily. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">5.2 Upon any liquidation, dissolution or <FONT STYLE="white-space:nowrap">winding-up</FONT> of the Corporation, whether voluntary or
involuntary (a &#147;<B><I>Liquidation</I></B>&#148;), each Holder shall be entitled to receive out of the assets, whether capital or surplus, of the Corporation the same amount that a holder of Common Stock would receive if the Series A <FONT
STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock were fully converted (disregarding for such purpose any Beneficial Ownership Limitations) to Common Stock which amounts shall be paid <I>pari</I><I> </I><I>passu</I> with all holders of
Common Stock, plus an additional amount equal to any dividends declared on but unpaid to such shares. If, upon any such Liquidation, the assets of the Corporation shall be insufficient to pay the Holders of shares of the Series A <FONT
STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock the amount required under the preceding sentence, then all remaining assets of the Corporation shall be distributed ratably to the Holders and the holders of Common Stock in accordance
with the respective amounts that would be payable on all such securities if all amounts payable thereon were paid in full. For the avoidance of any doubt, a Fundamental Transaction shall not be deemed a Liquidation unless the Corporation expressly
declares that such Fundamental Transaction shall be treated as if it were a Liquidation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6. <U>Conversion</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">6.1 <U>Automatic Conversion on Stockholder Approval</U>. Effective as of 5:00 p.m. Eastern time on the third Business Day after the date that
the Corporation&#146;s stockholders approve the conversion of the Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock into shares of Common Stock in accordance with the listing rules of the Nasdaq Stock Market, as set forth
in Section&nbsp;4.1 of the Merger Agreement (the &#147;<B><I>Stockholder Approval</I></B>&#148;), each share of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock then outstanding shall automatically convert into a number of
shares of Common Stock equal to the Conversion Ratio (as defined below), subject to the Beneficial Ownership Limitation (the &#147;<B><I>Automatic Conversion</I></B>&#148;). The Corporation shall inform each Holder of the occurrence of the
Stockholder </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Approval within one Business Day of such Stockholder Approval. In determining the application of the Beneficial Ownership Limitations solely with respect to the Automatic Conversion, the
Corporation shall calculate beneficial ownership for each Holder assuming beneficial ownership by such Holder of: (x)&nbsp;the number of shares of Common Stock issuable to such Holder in such Automatic Conversion, plus (y)&nbsp;any additional shares
of Common Stock for which a Holder has provided the Corporation with prior written notice of beneficial ownership within 30 days prior to the date of Stockholder Approval (a &#147;<B><I>Beneficial Ownership Statement</I></B>&#148;) and assuming the
conversion of all shares of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock held by all other Holders less the aggregate number of shares of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock held
by all other Holders that will not convert into shares of Common Stock on account of the application of any Beneficial Ownership Limitations applicable to any such other Holders. If a Holder fails to provide the Corporation with a Beneficial
Ownership Statement within 30 days prior to the date of Stockholder Approval, then the Corporation shall presume the Holder&#146;s beneficial ownership of Common Stock (excluding the Conversion Shares) to be zero. The shares of Series A <FONT
STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock that are converted in the Automatic Conversion are referred to as the &#147;<B><I>Converted Stock</I></B>&#148;. The Conversion Shares shall be issued as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">6.1.1 Converted Stock that is registered in book entry form shall be automatically cancelled upon the Automatic Conversion and converted into
the corresponding Conversion Shares, which shares shall be issued in book entry form and without any action on the part of the Holders and shall be delivered to the Holders within one Business Day of the effectiveness of the Automatic Conversion.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">6.1.2 Converted Stock that is issued in certificated form shall be deemed converted into the corresponding Conversion Shares on the date
of Automatic Conversion and the Holder&#146;s rights as a holder of such shares of Converted Stock shall cease and terminate on such date, excepting only the right to receive the Conversion Shares upon the Holder tendering to the Corporation (or its
designated agent) the stock certificate(s) (duly endorsed) representing such certificated Converted Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">6.1.3 Notwithstanding the
cancellation of the Converted Stock upon the Automatic Conversion, Holders of Converted Stock shall continue to have any remedies provided herein or otherwise available at law or in equity to such Holder because of a failure by the Corporation to
comply with the terms of this Certificate of Designation. In all cases, the Holder shall retain all of its rights and remedies for the Corporation&#146;s failure to convert the Converted Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">6.2 <U>Conversion at Option of Holder</U>. Subject to <U>Section</U><U></U><U>&nbsp;6.1</U>, <U>Section</U><U></U><U>&nbsp;6.4</U> and
<U>Section</U><U></U><U>&nbsp;6.5.3</U>, each share of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock then outstanding shall be convertible, at any time and from time to time following 5:00 p.m. Eastern time on the third
Business Day after the date that the Stockholder Approval is obtained by the Corporation, at the option of the Holder thereof, into a number of shares of Common Stock equal to the Conversion Ratio, subject to the Beneficial Ownership Limitation
(each, an &#147;<B><I>Optional Conversion</I></B>&#148;). Holders shall effect conversions by providing the Corporation with the form of conversion notice attached hereto as <B><U>Annex A</U></B> (a &#147;<B><I>Notice of Conversion</I></B>&#148;),
duly completed and executed. Provided the Corporation&#146;s transfer agent is participating in the Depository Trust Company (&#147;<B><I>DTC</I></B>&#148;) Fast Automated Securities Transfer program, the Notice of Conversion may specify, at the
Holder&#146;s election, whether the applicable Conversion Shares shall be credited to the account of the Holder&#146;s prime broker with DTC through its Deposit Withdrawal Agent Commission system (a &#147;<B><I>DWAC Delivery</I></B>&#148;). The date
on which an Optional Conversion shall be deemed effective (the &#147;<B><I>Conversion Date</I></B>&#148;) shall be the Trading Day that the Notice of Conversion, completed and executed, is sent via email to, and received during regular business
hours by, the Corporation; provided, that the original certificate(s) (if any) representing such shares of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock being converted, duly endorsed, and the accompanying Notice of
Conversion, are received by the Corporation within two (2)&nbsp;Trading Days thereafter. In all other cases, the Conversion Date shall be defined as the Trading Day on which the original certificate(s) (if any) representing such shares of Series A <FONT
STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock being converted, duly endorsed, and the accompanying Notice of Conversion, are received by the Corporation. The calculations set forth in the Notice of Conversion shall control in the
absence of manifest or mathematical error. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">6.3 <U>Conversion Ratio</U>. The &#147;<B><I>Conversion Ratio</I></B>&#148; for each share
of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock shall be 1,000 shares of Common Stock issuable upon the conversion (the &#147;<B><I>Conversion</I></B>&#148;) of each share of Series A
<FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock (corresponding to a ratio of 1,000:1), subject to adjustment as provided herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">6.4 <U>Beneficial Ownership Limitation</U>. Notwithstanding anything herein to the contrary, the Corporation shall not effect any conversion
of any share of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock, including pursuant to Section&nbsp;6.1, and a Holder shall not have the right to convert any portion of the Series A
<FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock pursuant to Section&nbsp;6.2, to the extent that, after giving effect to such attempted conversion set forth on an applicable Notice of Conversion (as defined in the Certificate of
Designation) with respect to the Series A Preferred Stock, such Holder (or any of such Holder&#146;s Affiliates or any other Person who would be a beneficial owner of Common Stock beneficially owned by the Holder for purposes of Section&nbsp;13(d)
or Section&nbsp;16 of the Exchange Act and the applicable rules and regulations of the Commission, including any &#147;group&#148; of which the Holder is a member (the foregoing, &#147;<B><I>Attribution Parties</I></B>&#148;)) would beneficially own
a number of shares of Common Stock in excess of the Beneficial Ownership Limitation. For purposes of the foregoing sentence, the aggregate number of shares of Common Stock beneficially owned by such Holder and its Attribution Parties shall include
the number of shares of Common Stock issuable upon conversion of the Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock subject to the Notice of Conversion or the Automatic Conversion, as applicable, with respect to which
such determination is being made, but shall exclude the number of shares of Common Stock which are issuable upon (A)&nbsp;conversion of the remaining, unconverted Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock
beneficially owned by such Holder or any of its Attribution Parties, and (B)&nbsp;exercise or conversion of the unexercised or unconverted portion of any other securities of the Corporation (including any warrants) beneficially owned by such Holder
or any of its Attribution Parties that are subject to and would exceed a limitation on conversion or exercise similar to the limitation contained herein. Except as set forth in the preceding sentence, for purposes of this
<U>Section</U><U></U><U>&nbsp;6.4</U>, beneficial ownership shall be calculated in accordance with Section&nbsp;13(d) of the Exchange Act and the applicable rules and regulations of the Commission, and the terms &#147;beneficial ownership&#148; and
&#147;beneficially own&#148; have the meanings ascribed to such terms therein. In addition, for purposes hereof, &#147;group&#148; has the meaning set forth in Section&nbsp;13(d) of the Exchange Act and the applicable rules and regulations of the
Commission. For purposes of this <U>Section</U><U></U><U>&nbsp;6.4</U>, in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as stated in the most recent of the
following: (A)&nbsp;the Corporation&#146;s most recent periodic or annual filing with the Commission, as the case may be, (B)&nbsp;a more recent public announcement by the Corporation that is filed with the Commission, or (C)&nbsp;a more recent
notice by the Corporation or the Corporation&#146;s transfer agent to the Holder setting forth the number of shares of Common Stock then outstanding. Upon the written request of a Holder (which may be by email), the Corporation shall, within two
(2)&nbsp;Trading Days thereof, confirm in writing to such Holder (which may be via email) the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to
any actual conversion or exercise of securities of the Corporation, including shares of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock, by such Holder or its Attribution Parties since the date as of which such number of
outstanding shares of Common Stock was last publicly reported or confirmed to the Holder. The &#147;<B><I>Beneficial Ownership Limitation</I></B>&#148; shall initially be set at the discretion of each Holder to a percentage designated by such Holder
on its signature page to the Purchase Agreement between 0% and 19.9% of the number of shares of the Common Stock outstanding or deemed to be outstanding as of the applicable measurement date, and such percentage shall be set at 19.9% for any Holder
that does not make such designation in the Purchase Agreement. The Corporation shall be entitled to rely on representations made to it by the Holder in any Notice of Conversion regarding its Beneficial Ownership Limitation. Notwithstanding the
foregoing, by written notice to the Corporation, (i)&nbsp;the Holder may reset the Beneficial Ownership Limitation percentage to a higher percentage, not to exceed 19.9%, which increase will not be effective until the sixty-first (61st) day after
such written notice is delivered to the Corporation, and (ii)&nbsp;the Holder may reset the Beneficial Ownership Limitation percentage to a lower percentage provided that such decrease shall not become effective until the later of (x) 5:00 p.m.
Eastern time on the third Business Day after the date of the Stockholder Approval and (y)&nbsp;if Stockholder Approval is not obtained within six months after the initial issuance of the Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT>
Preferred Stock, the date that is three Business Days after the date that is six months after the initial issuance of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock. Upon such a change by a Holder of the Beneficial Ownership Limitation, not to exceed 19.9%, the Beneficial Ownership
Limitation may not be further amended by such Holder without first providing the minimum notice required by this <U>Section</U><U></U><U>&nbsp;6.4</U>. Notwithstanding the foregoing, at any time following notice of a Fundamental Transaction, the
Holder may waive and/or change the Beneficial Ownership Limitation effective immediately upon written notice to the Corporation and may reinstitute a Beneficial Ownership Limitation at any time thereafter effective immediately upon written notice to
the Corporation. The provisions of this <U>Section</U><U></U><U>&nbsp;6.4 </U>shall be construed, corrected and implemented in a manner so as to effectuate the intended Beneficial Ownership Limitation herein contained and the shares of Common Stock
underlying the Securities in excess of the Beneficial Ownership Limitation shall not be deemed to be beneficially owned by the Purchaser for any purpose including for purposes of Section&nbsp;13(d) or Rule
<FONT STYLE="white-space:nowrap">16a-1(a)(1)</FONT> of the Exchange Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">6.5 <U>Mechanics of Conversion</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">6.5.1 <U>Delivery of Certificate or Electronic Issuance</U>. Upon Conversion not later than two (2)&nbsp;Trading Days after the applicable
Conversion Date, or if the Holder requests the issuance of physical certificate(s), two (2)&nbsp;Trading Days after receipt by the Corporation of the original certificate(s) representing such shares of Series A
<FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock being converted, duly endorsed, and the accompanying Notice of Conversion (the &#147;<B><I>Share Delivery Date</I></B>&#148;), the Corporation shall either: (a)&nbsp;deliver, or
cause to be delivered, to the converting Holder a physical certificate or certificates representing the number of Conversion Shares being acquired upon the conversion of shares of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred
Stock, or (b)&nbsp;in the case of a DWAC Delivery (if so requested by the Holder), electronically transfer such Conversion Shares by crediting the account of the Holder&#146;s prime broker with DTC through its DWAC system. If in the case of any
Notice of Conversion such certificate or certificates for the Conversion Shares are not delivered to or as directed by or, in the case of a DWAC Delivery, such shares are not electronically delivered to or as directed by, the applicable Holder by
the Share Delivery Date, the applicable Holder shall be entitled to elect to rescind such Notice of Conversion by written notice to the Corporation at any time on or before its receipt of such certificate or certificates for Conversion Shares or
electronic receipt of such shares, as applicable, in which event the Corporation shall promptly return to such Holder any original Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock certificate delivered to the Corporation
and such Holder shall promptly return to the Corporation any Common Stock certificates or otherwise direct the return of any shares of Common Stock delivered to the Holder through the DWAC system, representing the shares of Series A <FONT
STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock unsuccessfully tendered for conversion to the Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">6.5.2
<U>Obligation Absolute</U>. Subject to <U>Section</U><U></U><U>&nbsp;6.4</U> and subject to Holder&#146;s right to rescind a Notice of Conversion pursuant to <U>Section</U><U></U><U>&nbsp;6.5.1</U>, the Corporation&#146;s obligation to issue and
deliver the Conversion Shares upon conversion of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock in accordance with the terms hereof are absolute and unconditional, irrespective of any action or inaction by a Holder to
enforce the same, any waiver or consent with respect to any provision hereof, the recovery of any judgment against any Person or any action to enforce the same, or any setoff, counterclaim, recoupment, limitation or termination, or any breach or
alleged breach by such Holder or any other Person of any obligation to the Corporation or any violation or alleged violation of law by such Holder or any other Person, and irrespective of any other circumstance which might otherwise limit such
obligation of the Corporation to such Holder in connection with the issuance of such Conversion Shares. Subject to <U>Section</U><U></U><U>&nbsp;6.4</U> and subject to Holder&#146;s right to rescind a Notice of Conversion pursuant to
<U>Section</U><U></U><U>&nbsp;6.5.1</U>, in the event a Holder shall elect to convert any or all of its Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock, the Corporation may not refuse conversion based on any claim that
such Holder or anyone associated or affiliated with such Holder has been engaged in any violation of law, agreement or for any other reason, unless an injunction from a court, on notice to Holder, restraining and/or enjoining conversion of all or
part of the Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock of such Holder shall have been sought and obtained by the Corporation, and the Corporation posts a surety bond for the benefit of such Holder in the amount of
150% of the value of the Conversion Shares into which would be converted the Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock which is subject to such injunction, which bond shall remain in effect until the completion of
arbitration/litigation of the underlying dispute and the proceeds of which shall be payable to such Holder to the extent it obtains judgment. In the absence of such injunction, the Corporation shall, subject to <U>Section </U><U>6.4</U> and subject
to Holder&#146;s right to rescind a Notice of Conversion pursuant to <U>Section</U><U></U><U>&nbsp;6.5.1</U>, issue Conversion Shares upon a properly noticed conversion. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">6.5.3 <U>Cash Settlement</U>. If, at any time after the earlier of Stockholder Approval or
six months after the initial issuance of the Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock, the Corporation fails to deliver to a Holder such certificate or certificates, or electronically deliver (or cause its transfer
agent to electronically deliver) such shares in the case of a DWAC Delivery, pursuant to <U>Section</U><U></U><U>&nbsp;6.5.1</U> on or prior to the third (3rd) Trading Day after the Share Delivery Date applicable to such conversion (other than a
failure caused by (i)&nbsp;materially incorrect or incomplete information provided by Holder to the Corporation or (ii)&nbsp;the application of the Beneficial Ownership Limitation after Stockholder Approval (but, prior to the Stockholder Approval,
disregarding for such purpose any Beneficial Ownership Limitation), then, unless the Holder has rescinded the applicable Notice of Conversion pursuant to <U>Section</U><U></U><U>&nbsp;6.5.1</U>, the Corporation shall, at the request of the Holder,
pay an amount equal to the Fair Value (as defined below) of such undelivered shares, with such payment to be made within two Business Days from the date of request by the Holder, whereupon the Corporation&#146;s obligations to deliver such shares
underlying the Notice of Conversion shall be extinguished upon payment in full of the Fair Value of such undelivered shares; provided, however that such request shall be presumed to have been made by such Holder if Stockholder Approval shall not
have been obtained prior to the date on which the Notice of Conversion is delivered to the Corporation. For purposes of this <U>Section</U><U></U><U>&nbsp;6.5.3</U>, the &#147;Fair Value&#148; of shares shall be fixed with reference to the last
reported Closing Sale Price on the principal Trading Market on which the Common Stock is listed as of the Trading Day immediately prior to the date on which the Notice of Conversion is delivered to the Corporation. For the avoidance of doubt, the
cash settlement provisions set forth in this <U>Section</U><U></U><U>&nbsp;6.5.3</U> shall be available irrespective of the reason for the Corporation&#146;s failure to timely deliver Conversion Shares (other than a failure caused by
(i)&nbsp;materially incorrect or incomplete information provided by Holder to the Corporation or (ii)&nbsp;the application of the Beneficial Ownership Limitation after Stockholder Approval (but, prior to the Stockholder Approval, disregarding for
such purpose any Beneficial Ownership Limitation)), including due to limitations set forth in <U>Section</U><U></U><U>&nbsp;6.5.6</U>, the lack of obtaining Stockholder Approval, or due to applicable Trading Market rules. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">6.5.4 <U><FONT STYLE="white-space:nowrap">Buy-In</FONT> on Failure to Timely Deliver Certificates</U>. If the Corporation fails to deliver to
a Holder the applicable certificate or certificates or to effect a DWAC Delivery, as applicable, by the Share Delivery Date pursuant to <U>Section</U><U></U><U>&nbsp;6.5.1</U> (other than a failure caused by materially incorrect or incomplete
information provided by Holder to the Corporation or the application of the Beneficial Ownership Limitation), and if after such Share Delivery Date such Holder is required by its brokerage firm to purchase (in an open market transaction or
otherwise), or the Holder&#146;s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by such Holder of the Conversion Shares which such Holder was entitled to receive upon the conversion relating to such
Share Delivery Date (a &#147;<B><I><FONT STYLE="white-space:nowrap">Buy-In</FONT></I></B>&#148;), then the Corporation shall (A)&nbsp;pay in cash to such Holder (in addition to any other remedies available to or elected by such Holder) the amount by
which (x)&nbsp;such Holder&#146;s total purchase price (including any brokerage commissions) for the shares of Common Stock so purchased exceeds (y)&nbsp;the product of (1)&nbsp;the aggregate number of shares of Common Stock that such Holder was
entitled to receive from the conversion at issue multiplied by (2)&nbsp;the actual sale price at which the sell order giving rise to such purchase obligation was executed (including any brokerage commissions) and (B)&nbsp;at the option of such
Holder, either reissue (if surrendered) the shares of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock equal to the number of shares of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock submitted
for conversion or deliver to such Holder the number of shares of Common Stock that would have been issued if the Corporation had timely complied with its delivery requirements under <U>Section</U><U></U><U>&nbsp;6.5.1</U>. For example, if a Holder
purchases shares of Common Stock having a total purchase price of $11,000 to cover a <FONT STYLE="white-space:nowrap">Buy-In</FONT> with respect to an attempted conversion of shares of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT>
Preferred Stock with respect to which the actual sale price (including any brokerage commissions) giving rise to such purchase obligation was a total of $10,000 under clause (A)&nbsp;of the immediately preceding sentence, the Corporation shall be
required to pay such Holder $1,000. The Holder shall provide the Corporation written notice, within three (3)&nbsp;Trading Days after the occurrence of a <FONT STYLE="white-space:nowrap">Buy-In,</FONT> indicating the amounts payable to such Holder
in respect of such <FONT STYLE="white-space:nowrap">Buy-In</FONT> together with applicable confirmations and other evidence reasonably requested by the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Corporation. Nothing herein shall limit a Holder&#146;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific
performance and/or injunctive relief with respect to the Corporation&#146;s failure to timely deliver certificates representing shares of Common Stock upon conversion of the shares of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT>
Preferred Stock as required pursuant to the terms hereof or the cash settlement remedy set forth in <U>Section</U><U></U><U>&nbsp;6.5.3</U>; provided, however, that the Holder shall not be entitled to both (i)&nbsp;require the reissuance of the
shares of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock submitted for conversion for which such conversion was not timely honored and (ii)&nbsp;receive the number of shares of Common Stock that would have been issued if
the Corporation had timely complied with its delivery requirements under <U>Section</U><U></U><U>&nbsp;6.5.1</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">6.5.5 <U>Reservation
of Shares Issuable Upon Conversion</U>. The Corporation covenants that at all times it will reserve and keep available out of its authorized and unissued shares of Common Stock for the sole purpose of issuance upon conversion of the Series A <FONT
STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock, free from preemptive rights or any other actual contingent purchase rights of Persons other than the Holders of the Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred
Stock, not less than such aggregate number of shares of the Common Stock as shall be issuable (taking into account the adjustments of <U>Section</U><U></U><U>&nbsp;7</U>) upon the conversion of all outstanding shares of Series A <FONT
STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock. The Corporation covenants that all shares of Common Stock that shall be so issuable shall, upon issue, be duly authorized, validly issued, fully paid and
<FONT STYLE="white-space:nowrap">non-assessable.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">6.5.6 <U>Fractional Shares</U>. No fractional shares of Common Stock shall be
issued upon conversion of the Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock, no certificates or scrip for any such fractional shares shall be issued and no cash shall be paid for any such fractional shares. Any
fractional shares of Common Stock that a Holder of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock would otherwise be entitled to receive shall be aggregated with all fractional shares of Common Stock issuable to such
Holder and any remaining fractional shares shall be rounded up to the nearest whole share. Whether or not fractional shares would be issuable upon such conversion shall be determined on the basis of the total number of shares of Series A <FONT
STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock the Holder is at the time converting into Common Stock and the aggregate number of shares of Common Stock issuable upon such conversion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">6.5.7 <U>Transfer Taxes</U>. The issuance of certificates for shares of the Common Stock upon conversion of the Series A <FONT
STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock shall be made without charge to any Holder for any documentary stamp or similar taxes that may be payable in respect of the issue or delivery of such certificates, provided that the
Corporation shall not be required to pay any tax that may be payable in respect of any transfer involved in the issuance and delivery of any such certificate upon conversion in a name other than that of the registered Holder(s) of such shares of
Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock and the Corporation shall not be required to issue or deliver such certificates unless or until the Person or Persons requesting the issuance thereof shall have paid to the
Corporation the amount of such tax or shall have established to the satisfaction of the Corporation that such tax has been paid. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">6.6
<U>Status as Stockholder</U>. Upon each Conversion Date, (i)&nbsp;the shares of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock being converted shall be deemed converted into shares of Common Stock and (ii)&nbsp;the
Holder&#146;s rights as a holder of such converted shares of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock shall cease and terminate, excepting only the right to receive certificates for such shares of Common Stock and
to any remedies provided herein or otherwise available at law or in equity to such Holder because of a failure by the Corporation to comply with the terms of this Certificate of Designation. In all cases, the Holder shall retain all of its rights
and remedies for the Corporation&#146;s failure to convert Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock. In no event shall the Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock convert into
shares of Common Stock prior to the Stockholder Approval. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7. <U>Certain Adjustments</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">7.1 <U>Stock Dividends and Stock Splits</U>. If the Corporation, at any time while this Series A
<FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock is outstanding: (A)&nbsp;pays a stock dividend or otherwise makes a distribution or distributions payable in shares of Common Stock (which, for avoidance of doubt, shall not include
any shares of Common Stock issued by the Corporation upon conversion of this Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock) with respect to the then outstanding shares of Common Stock; (B)&nbsp;subdivides outstanding
shares of Common Stock into a larger number of shares; or (C)&nbsp;combines (including by way of a reverse stock split) outstanding shares of Common Stock into a smaller number of shares, then the Conversion Ratio shall be multiplied by a fraction
of which the numerator shall be the number of shares of Common Stock (excluding any treasury shares of the Corporation) outstanding immediately after such event and of which the denominator shall be the number of shares of Common Stock outstanding
immediately before such event (excluding any treasury shares of the Corporation). Any adjustment made pursuant to this <U>Section</U><U></U><U>&nbsp;7.1</U> shall become effective immediately after the record date for the determination of
stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision or combination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">7.2 <U>Fundamental Transaction</U>. If, at any time while this Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock is
outstanding, (A)&nbsp;the Corporation effects any merger or consolidation of the Corporation with or into another Person or any stock sale to, or other business combination (including, without limitation, a reorganization, recapitalization, <FONT
STYLE="white-space:nowrap">spin-off,</FONT> share exchange or scheme of arrangement) with or into another Person (other than such a transaction in which the Corporation is the surviving or continuing entity and its Common Stock is not exchanged for
or converted into other securities, cash or property), (B) the Corporation effects any sale, lease, transfer or exclusive license of all or substantially all of its assets in one transaction or a series of related transactions, (C)&nbsp;any tender
offer or exchange offer (whether by the Corporation or another Person) is completed pursuant to which more than 50% of the Common Stock not held by the Corporation or such Person is exchanged for or converted into other securities, cash or property,
or (D)&nbsp;the Corporation effects any reclassification of the Common Stock or any compulsory share exchange pursuant (other than as a result of a dividend, subdivision or combination covered by <U>Section</U><U></U><U>&nbsp;7.1</U>) to which the
Common Stock is effectively converted into or exchanged for other securities, cash or property (in any such case, a &#147;<B><I>Fundamental Transaction</I></B>&#148;), then, upon any subsequent conversion of this Series A <FONT
STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock the Holders shall have the right to receive, in lieu of the right to receive Conversion Shares, for each Conversion Share that would have been issuable upon such conversion immediately
prior to the occurrence of such Fundamental Transaction, the same kind and amount of securities, cash or property as it would have been entitled to receive upon the occurrence of such Fundamental Transaction if it had been, immediately prior to such
Fundamental Transaction, the holder of one share of Common Stock (the &#147;<B><I>Alternate Consideration</I></B>&#148;). For purposes of any such subsequent conversion, the determination of the Conversion Ratio shall be appropriately adjusted to
apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Corporation shall adjust the Conversion Ratio in a reasonable manner
reflecting the relative value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holders shall be
given the same choice as to the Alternate Consideration it receives upon any conversion of this Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock following such Fundamental Transaction. To the extent necessary to effectuate
the foregoing provisions, any successor to the Corporation or surviving entity in such Fundamental Transaction shall file a new certificate of designations with the same terms and conditions and issue to the Holders new preferred stock consistent
with the foregoing provisions and evidencing the Holders&#146; right to convert such preferred stock into Alternate Consideration. The terms of any agreement to which the Corporation is a party and pursuant to which a Fundamental Transaction is
effected shall include terms requiring any such successor or surviving entity to comply with the provisions of this <U>Section</U><U></U><U>&nbsp;7.2</U> and insuring that this Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred
Stock (or any such replacement security) will be similarly adjusted upon any subsequent transaction analogous to a Fundamental Transaction. The Corporation shall cause to be delivered to each Holder, at its last address as it shall appear upon the
stock books of the Corporation, written notice of any Fundamental Transaction at least 20 calendar days prior to the date on which such Fundamental Transaction is expected to become effective or close. Notwithstanding anything to the contrary
herein, the Corporation&#146;s disposition of certain assets pursuant to the CVR Agreement shall not constitute a Fundamental Transaction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">7.3 <U>Calculations</U>. All calculations under this <U>Section</U><U></U><U>&nbsp;7</U>
shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes of this <U>Section</U><U></U><U>&nbsp;7</U>, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be
the sum of the number of shares of Common Stock (excluding any treasury shares of the Corporation) issued and outstanding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.
<U>Redemption</U>. The shares of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock shall not be redeemable; provided, however, that the foregoing shall not limit the ability of the Corporation to purchase or otherwise deal
in such shares to the extent otherwise permitted hereby and by law, nor shall the foregoing limit the Holder&#146;s rights under <U>Section</U><U></U><U>&nbsp;6.5.3</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9. <U>Transfer</U>. A Holder may transfer any shares of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock together
with the accompanying rights set forth herein, held by such holder without the consent of the Corporation; provided that such transfer is in compliance with applicable securities laws. The Corporation shall in good faith (i)&nbsp;do and perform, or
cause to be done and performed, all such further acts and things, and (ii)&nbsp;execute and deliver all such other agreements, certificates, instruments and documents, in each case, as any holder of Series A
<FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock may reasonably request in order to carry out the intent and accomplish the purposes of this <U>Section</U><U></U><U>&nbsp;9</U>. The transferee of any shares of Series A <FONT
STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock shall be subject to the Beneficial Ownership Limitation applicable to the transferor as of the time of such transfer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">10. <U>Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock Register</U>. The Corporation shall maintain at its
principal executive offices (or such other office or agency of the Corporation as it may designate by notice to the Holders in accordance with <U>Section</U><U></U><U>&nbsp;11</U>), a register for the Series A
<FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock, in which the Corporation shall record (i)&nbsp;the name, address, and electronic mail address of each holder in whose name the shares of Series A
<FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock have been issued and (ii)&nbsp;the name, address, and electronic mail address of each transferee of any shares of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT>
Preferred Stock. The Corporation may deem and treat the registered Holder of shares of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock as the absolute owner thereof for the purpose of any conversion thereof and for all
other purposes. The Corporation shall keep the register open and available at all times during business hours for inspection by any holder of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock or his, her or its legal
representatives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">11. <U>Notices</U>. Any notice required or permitted by the provisions of this Certificate of Designation to be given to
a Holder of shares of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock shall be mailed, postage prepaid, to the post office address last shown on the records of the Corporation, or given by electronic communication in
compliance with the provisions of the Delaware General Corporation Law, and shall be deemed sent upon such mailing or electronic transmission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">12. <U>Book-Entry; Certificates</U>. The Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock will be issued in
book-entry form; provided that, if a Holder requests that such Holder&#146;s shares of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock be issued in certificated form, the Corporation will instead issue a stock certificate
to such Holder representing such Holder&#146;s shares of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock. To the extent that any shares of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock are
issued in book-entry form, references herein to &#147;certificates&#148; shall instead refer to the book-entry notation relating to such shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">13. <U>Waiver</U>. Any waiver by the Corporation or a Holder of a breach of any provision of this Certificate of Designation shall not operate
as or be construed to be a waiver of any other breach of such provision or of any breach of any other provision of this Certificate of Designation or a waiver by any other Holders. The failure of the Corporation or a Holder to insist upon strict
adherence to any term of this Certificate of Designation on one or more occasions shall not be considered a waiver or deprive that party (or any other Holder) of the right thereafter to insist upon strict adherence to that term or any other term of
this Certificate of Designation. Any waiver by the Corporation or a Holder must be in writing. Notwithstanding any provision in this Certificate of Designation to the contrary, any provision contained herein and any right of the Holders of Series A <FONT
STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
granted hereunder may be waived as to all shares of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock (and the Holders thereof) upon the written consent of the Holders
of not less than a majority of the shares of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock then outstanding, provided, however, that the Beneficial Ownership Limitation applicable to a Holder, and any provisions
contained herein that are related to such Beneficial Ownership Limitation, cannot be modified, waived or terminated without the consent of such Holder, provided further, that any proposed waiver that would, by its terms, have a disproportionate and
materially adverse effect on any Holder shall require the consent of such Holder(s). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">14. <U>Severability</U>. Whenever possible, each
provision hereof shall be interpreted in a manner as to be effective and valid under applicable law, but if any provision hereof is held to be prohibited by or invalid under applicable law, then such provision shall be ineffective only to the extent
of such prohibition or invalidity, without invalidating or otherwise adversely affecting the remaining provisions hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">15. <U>Status
of Converted Series </U><U>A</U><U> <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock</U>. If any shares of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock shall be converted or redeemed by the
Corporation, such shares shall, to the fullest extent permitted by applicable law, be retired and cancelled upon such acquisition, and shall not be reissued as a share of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock.
Any share of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock so acquired shall, upon its retirement and cancellation, and upon the taking of any action required by applicable law, resume the status of authorized but
unissued shares of preferred stock and shall no longer be designated as Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Remainder of Page Intentionally Left Blank</I>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, Aeglea BioTherapeutics, Inc. has caused this Certificate of
Designation of Preferences, Rights and Limitations of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Convertible Preferred Stock to be duly executed by its Chief Executive Officer on June&nbsp;22, 2023. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>AEGLEA BIOTHERAPEUTICS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ANNEX A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">NOTICE OF CONVERSION </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(TO BE
EXECUTED BY THE REGISTERED HOLDER IN ORDER TO CONVERT SHARES OF SERIES A <FONT STYLE="white-space:nowrap">NON-VOTING</FONT> CONVERTIBLE PREFERRED STOCK) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned Holder hereby irrevocably elects to convert the number of shares of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred
Stock indicated below, represented in book-entry form, into shares of common stock, par value $0.0001 per share (the &#147;<B><I>Common Stock</I></B>&#148;), of Aeglea BioTherapeutics, Inc., a Delaware corporation (the
&#147;<B><I>Corporation</I></B>&#148;), as of the date written below. If securities are to be issued in the name of a Person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto. Capitalized terms
utilized but not defined herein shall have the meaning ascribed to such terms in that certain Certificate of Designation of Preferences, Rights and Limitations of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Convertible Preferred
Stock (the &#147;<B><I>Certificate of Designation</I></B>&#148;) filed by the Corporation with the Secretary of State of the State of Delaware on June&nbsp;22, 2023. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of the date hereof, the number of shares of Common Stock beneficially owned by the undersigned Holder (together with such Holder&#146;s Attribution
Parties), including the number of shares of Common Stock issuable upon conversion of the Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock subject to this Notice of Conversion, but excluding the number of shares of Common
Stock which are issuable upon (A)&nbsp;conversion of the remaining, unconverted Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock beneficially owned by such Holder or any of its Attribution Parties, and (B)&nbsp;exercise or
conversion of the unexercised or unconverted portion of any other securities of the Corporation (including any warrants) beneficially owned by such Holder or any of its Attribution Parties that are subject to a limitation on conversion or exercise
similar to the limitation contained in <U>Section</U><U></U><U>&nbsp;6.4</U> of the Certificate of Designation, is _____. For purposes hereof, beneficial ownership shall be calculated in accordance with Section&nbsp;13(d) of the Exchange Act and the
applicable regulations of the Commission. In addition, for purposes hereof, &#147;group&#148; has the meaning set forth in Section&nbsp;13(d) of the Exchange Act and the applicable regulations of the Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CONVERSION CALCULATIONS: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Date to Effect Conversion:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Number of shares of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock
owned prior to Conversion:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Number of shares of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock to
be Converted:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Number of shares of Common Stock to be Issued:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Address for delivery of physical certificates:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For DWAC Delivery, please provide the following: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Broker No.: ________________ </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Account No.: _______________ </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">[HOLDER]</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Exhibit D </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Form of CVR Agreement </U></B></P> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><I>Privileged and Confidential </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><I>Final Form </I></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONTINGENT VALUE RIGHTS AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>THIS CONTINGENT VALUE RIGHTS AGREEMENT </B>(this &#147;<B>Agreement</B>&#148;), dated as of [&#149;], 2023, is entered into by and between
Aeglea BioTherapeutics, Inc., a Delaware corporation (the &#147;<B>Company</B>&#148;), and American Stock Transfer&nbsp;&amp; Trust Company LLC, a Delaware limited liability company, as Rights Agent (as defined herein). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>,
the Company, Aspen Merger Sub I, Inc., a Delaware corporation and wholly owned subsidiary of the Company (&#147;<B>First Merger Sub</B>&#148;), Sequoia Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of the
Company (&#147;<B>Second Merger Sub</B>&#148;), and <B>SPYRE THERAPEUTICS, INC.</B>, a Delaware corporation (&#147;<B>Spyre</B>&#148;), have entered into an Agreement and Plan of Merger, dated as of [&#149;], 2023 (the &#147;<B>Merger
Agreement</B>&#148;), pursuant to which First Merger Sub will merge with and into Spyre (the &#147;<B>First Merger</B>&#148;), with Spyre surviving the First Merger as a wholly-owned subsidiary of the Company and immediately following the First
Merger and as part of the same overall transaction, Spyre will merge with and into Second Merger Sub (the &#147;<B>Second Merger</B>&#148; and together with the First Merger, the &#147;<B>Merger</B>&#148;), with Second Merger Sub surviving the
Second Merger as a wholly owned subsidiary of the Company (the &#147;<B>Surviving Company</B>&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, pursuant to the
Merger Agreement, and in accordance with the terms and conditions thereof, the Company has agreed to provide to the Holders (as defined herein) contingent value rights as hereinafter described; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, the parties have done all things reasonably necessary to make the contingent value rights, when issued pursuant to the Merger
Agreement and hereunder, the valid obligations of the Company and to make this Agreement a valid and binding agreement of the Company, in accordance with its terms; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NOW, THEREFORE</B>, in consideration of the premises and the consummation of the transactions referred to above, it is mutually covenanted
and agreed, for the proportionate benefit of all Holders, as follows: </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 1. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DEFINITIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;1.1</B> <B>Definitions</B>. Capitalized terms used but not otherwise defined herein have the meanings ascribed
thereto in the Merger Agreement. The following terms have the meanings ascribed to them as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Acting Holders</B>&#148;
means, at the time of determination, the Holders of at least 30% of the outstanding CVRs, as reflected on the CVR Register. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Adjustment Amount</B>&#148; means the amount (negative or positive) of any assets
or Liabilities existing or incurred during the CVR Term that would have been required to be included in the calculation of Net Cash to the extent not taken account in the calculation of Net Cash in connection with calculating the Exchange Ratio
provided that such assets or Liabilities shall not exceed $1,000,000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Assignee</B>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;7.5</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Calendar Quarter</B>&#148; means the successive periods of three (3)&nbsp;consecutive
calendar months ending on March&nbsp;31, June&nbsp;30, September&nbsp;30 or December&nbsp;31, for so long as this Agreement is in effect; <I><U>provided</U></I>, <I><U>however</U></I> that (a)&nbsp;the first Calendar Quarter shall commence on the
date of this Agreement and shall end on the first September&nbsp;30 thereafter, and (b)&nbsp;the last Calendar Quarter shall commence on the first day after the full Calendar Quarter immediately preceding the effective date of the termination or
expiration of this Agreement and shall end on the effective date of the termination or expiration of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Common
Stock</B>&#148; means the common stock, $0.0001 par value, of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company Legacy Business</B>&#148; means the business
of the Company as conducted at any time prior to the date of this Agreement, including but not limited to business related to the Potentially Transferable Assets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>CVR</B>&#148; means a contingent contractual right of Holders to receive CVR Payments pursuant to the Merger Agreement and this
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>CVR Cash Payment</B>&#148; means the Net Proceeds, plus the Adjustment Amount, received by the Company in a given
Calendar Quarter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>CVR Fees</B>&#148; means all fees and other amounts associated with the execution, delivery and performance of
this Agreement or otherwise associated with any action contemplated by Section&nbsp;1.10 of the Merger Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>CVR
Payment</B>&#148; means any CVR Cash Payment; provided that the Company, in its reasonable discretion as resolved by the Company&#146;s Board of Directors, may withhold up to 15% of any CVR Cash Payment to provide for the satisfaction of
(i)&nbsp;indemnity obligations under any Disposition Agreement in excess of any escrow fund established therein, in each case to the extent not already deducted as Permitted Deductions, and (ii)&nbsp;any Loss arising out of any third-party claims,
demands, actions, or other proceedings relating to or in connection with any Potentially Transferable Assets during the CVR Term; provided, further, that any such withheld amount shall be distributed (net of any Permitted Deductions satisfied
therefrom) to the Holders no later than three (3)&nbsp;years following the date such amount would have otherwise been distributed to the Holders in the CVR Payment from which such amount was deducted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>CVR Payment Amount</B>&#148; means with respect to each CVR Payment and each Holder, an amount equal to such CVR Payment divided by
the total number of CVRs and then multiplied by the total number of CVRs held by such Holder as reflected on the CVR Register. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>CVR Payment Period</B>&#148; means a period equal to a Calendar Quarter ending at
any time after the effective date of a Disposition Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>CVR Payment Statement</B>&#148; means, for a given CVR Payment
Period during the CVR Term, a written statement of the Company, signed on behalf of the Company, setting forth in reasonable detail the calculation of the applicable CVR Payment for such CVR Payment Period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;CVR Register</B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;2.3(b)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>CVR Term</B>&#148; means the period beginning on the Closing and ending upon the third anniversary of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Disposition</B>&#148; means the sale, license, transfer or disposition of any Potentially Transferable Asset (including any such sale
or disposition of equity securities in any Subsidiary established by the Company to hold any right, title or interest in or to any Potentially Transferable Asset), in each case during the Disposition Period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Disposition Agreement</B>&#148; means a definitive written agreement providing for a transaction or series of transactions between
the Company or its Affiliates and any Person who is not an Affiliate of the Company regarding a Disposition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Disposition
Period</B>&#148; means the period beginning on the execution date of the Merger Agreement and ending on the first anniversary of the Closing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>DTC</B>&#148; means The Depository Trust Company or any successor thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Gross Proceeds</B>&#148; means, without duplication, the sum of all cash consideration and the value of any marketable securities
actually received by the Company or its Affiliates during the CVR Term in consideration for a Disposition pursuant to a Disposition Agreement. The value of any marketable securities (whether debt or equity) shall be equal to the volume weighted
average of their closing market prices for the thirty (30)&nbsp;trading days ending the day prior to the date of payment to, or receipt by, the Company or its relevant Affiliate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Holder</B>&#148; means, at the relevant time, a Person in whose name CVRs are registered in the CVR Register. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Loss</B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;3.2(g)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Net Cash</B>&#148; means unrestricted free cash and cash equivalents, plus (i)&nbsp;all prepaid expenses and receivables expected to
provide benefit to the combined company within 12 months of Closing, minus (ii)&nbsp;total short and long term liabilities accrued at Closing, minus (iii)&nbsp;fees and expenses incurred with respect to the Contemplated Transactions, including for
the avoidance of doubt, the Transaction Expenses of Parent to the extent unpaid as of the Closing and any Black Scholes make-whole payments to warrant holders, minus (iv)&nbsp;the cash cost of change in control and severance payments arising in
connection with the Merger (including any Black Scholes make-whole payments to warrant holders), minus (v)&nbsp;wind-down costs associated with the Company Legacy Business, including lease liabilities and the termination of any ongoing clinical
trials. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Net Proceeds</B>&#148; means, for any CVR Payment Period, the Gross Proceeds minus
Permitted Deductions for such CVR Payment Period, all as calculated, to the extent in accordance with GAAP, in a manner consistent with the Company&#146;s accounting practices and the most recently filed annual audited financial statements with the
SEC, except as otherwise set forth herein. For clarity, to the extent Permitted Deductions exceed Gross Proceeds for any CVR Payment Period, any excess Permitted Deductions shall be applied against Gross Proceeds in subsequent CVR Payment Periods.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Notice</B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;7.1</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Officer&#146;s Certificate</B>&#148; means a certificate signed by the chief executive officer and the chief financial officer of the
Company, in their respective official capacities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Party</B>&#148; means the Company or the Rights Agent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Permitted Deductions</B>&#148; means the sum of, without duplication: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> any applicable Taxes (including any applicable value added or sales taxes) imposed on Gross Proceeds and payable by the Company or
any of its Affiliates (regardless of whether the due date for such Taxes arises during or after the Disposition Period) and, without duplication, any income or other similar Taxes payable by the Company or any of its Affiliates that would not have
been incurred by the Company or any of its Affiliates but for the Gross Proceeds; provided that, for purposes of calculating income Taxes incurred by the Company or its Affiliates in respect of the Gross Proceeds, any such income Taxes shall be
computed based on the gain recognized by the Company or its Affiliates from the Disposition after reduction for any net operating loss carryforwards or other Tax attributes of the Company or its Affiliates as of the Closing Date that are available
to offset such gain after taking into account any limits of the usability of such attributes, including under Section&nbsp;382 of the Code as determined by the Company&#146;s tax advisers; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> any reasonable out of pocket expenses incurred by the Company or any of its Affiliates in respect of its performance of this
Agreement following the Closing Date or in respect of its performance of any Contract in connection with any Potentially Transferable Asset, including any costs related to the prosecution, maintenance or enforcement by the Company or any of its
Subsidiaries of intellectual property rights (but excluding any costs related to a breach of this Agreement, including costs incurred in litigation in respect of the same); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> any reasonable out of pocket expenses incurred or accrued by the Company or any of its Affiliates in connection with the
negotiation, entry into and closing of any Disposition of any Potentially Transferable Asset, including any brokerage fee, finder&#146;s fee, opinion fee, success fee, transaction fee, service fee or other fee, commission or expense owed to any
broker, finder, investment bank, auditor, accountant, counsel, advisor or other third party in relation thereto; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> any Losses
incurred or reasonably expected to be incurred by the Company or any of its Affiliates arising out of any third-party claims, demands, actions, or other proceedings relating to or in connection with any Disposition, including indemnification
obligations of the Company or any of its Affiliates set forth in any Disposition Agreement; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> any Liabilities borne by the Company or any of its Affiliates pursuant to
Contracts related to Potentially Transferable Assets, including costs arising from the termination thereof; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> any fees
required to be paid pursuant to <U>Section</U><U></U><U>&nbsp;3.1(h)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Permitted Transfer</B>&#148; means a transfer of CVRs
(a)&nbsp;upon death of a Holder by will or intestacy; (b)&nbsp;pursuant to a court order; (c)&nbsp;by operation of law (including by consolidation or merger) or without consideration in connection with the dissolution, liquidation or termination of
any corporation, limited liability company, partnership or other entity; (d)&nbsp;in the case of CVRs held in book-entry or other similar nominee form, from a nominee to a beneficial owner and, if applicable, through an intermediary, to the extent
allowable by DTC; or (e)&nbsp;as provided in <U>Section</U><U></U><U>&nbsp;2.6</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Potentially Transferable Assets</B>&#148;
means the tangible and intangible assets (including intellectual property) primarily used in or primarily related to the research and development programs of the Company, including pegtarviliase for Homocystinuria and pegzilarginase for Arginase 1
Deficiency. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Rights Agent</B>&#148; means the Rights Agent named in the first paragraph of this Agreement, until a successor
Rights Agent will have become the Rights Agent pursuant to the applicable provisions of this Agreement, and thereafter &#147;Rights Agent&#148; will mean such successor Rights Agent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Transaction Expenses</B>&#148; means, without duplication, with respect to a Party, the aggregate amount (without duplication) of all
costs, fees and expenses incurred by such Party or any of its Subsidiaries (including Merger Subs), or for which such Party or any of its Subsidiaries are or may become liable in connection with the Contemplated transactions and the negotiation,
preparation and execution of the Merger Agreement or any other agreement, document, instrument, filing, certificate, schedule, exhibit, letter or other document prepared or executed in connection with the Contemplated Transactions, including
(a)&nbsp;any fees and expenses of legal counsel and accountants, the maximum amount of fees and expenses payable to financial advisors, investment bankers, brokers, consultants, tax advisors and other advisors of such Party and (b)&nbsp;the CVR
Fees. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 2. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONTINGENT VALUE RIGHTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;2.1 Holders of CVRs; Appointment of Rights Agent. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> The CVRs represent the rights of Holders to receive CVR Payments pursuant to this Agreement. The initial Holders will be the
holders of Common Stock as of immediately prior to the First Effective Time. One CVR will be issued with respect to each share of Common Stock that is outstanding as of immediately prior to the First Effective Time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> The Company hereby appoints the Rights Agent to act as Rights Agent for the Company in accordance with the express terms and
conditions set forth in this Agreement, and the Rights Agent hereby accepts such appointment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;2.2</B>
<B><FONT STYLE="white-space:nowrap">Non-transferable</FONT></B>. The CVRs may not be sold, assigned, transferred, pledged, encumbered or in any other manner transferred or disposed of, in whole or in part, other than through a Permitted Transfer.
The CVRs will not be listed on any quotation system or traded on any securities exchange. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;2.3</B> <B>No
Certificate; Registration; Registration of Transfer; Change of Address</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> The CVRs will be issued in book-entry form only
and will not be evidenced by a certificate or other instrument. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> The Rights Agent shall create and maintain a register (the
&#147;<B>CVR Register</B>&#148;) for the purpose of registering CVRs and Permitted Transfers. The CVR Register will be created, and CVRs will be distributed, pursuant to written instructions to the Rights Agent from the Company. The CVR Register
will initially show one position for Cede&nbsp;&amp; Co. representing shares of Common Stock held by DTC on behalf of the street holders of the shares of Common Stock held by such holders as of immediately prior to the First Effective Time. The
Rights Agent will have no responsibility whatsoever directly or indirectly to the street name holders with respect to transfers of CVRs. With respect to any payments or issuances to be made under <U>Section</U><U></U><U>&nbsp;2.4</U> below, the
Rights Agent will accomplish the payment to any former street name holders of shares of Common Stock by sending one <FONT STYLE="white-space:nowrap">lump-sum</FONT> payment or issuance to DTC. The Rights Agent will have no responsibilities
whatsoever with regard to the distribution of payments or shares of Common Stock by DTC to such street name holders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> Subject
to the restrictions on transferability set forth in <U>Section</U><U></U><U>&nbsp;2.2</U>, every request made to transfer a CVR must be in writing and accompanied by a written instrument of transfer in form reasonably satisfactory to the Rights
Agent pursuant to its guidelines or procedures, including a guaranty of signature by an &#147;eligible guarantor institution&#148; that is a member or participant in the Securities Transfer Agents Medallion Program, duly executed by the Holder
thereof, the Holder&#146;s attorney duly authorized in writing, the Holder&#146;s personal representative or the Holder&#146;s survivor, and setting forth in reasonable detail the circumstances relating to the transfer. Upon receipt of such written
notice, the Rights Agent shall, subject to its reasonable determination that the transfer instrument is in proper form and the transfer otherwise complies with the other terms and conditions of this Agreement (including the provisions of
<U>Section</U><U></U><U>&nbsp;2.2</U>), register the transfer of the CVRs in the CVR Register. The Company and Rights Agent may require evidence of payment of a sum sufficient to cover any stamp, documentary, registration, or other Tax or
governmental charge that is imposed in connection with any such registration of transfer (or evidence that such Taxes and charges are not applicable). All duly transferred CVRs registered in the CVR Register will be the valid obligations of the
Company and will entitle the transferee to the same benefits and rights under this Agreement as those held immediately prior to the transfer by the transferor. No transfer of a CVR will be valid until registered in the CVR Register. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> A Holder may make a written request to the Rights Agent to change such Holder&#146;s address of record in the CVR Register. The
written request must be duly executed by the Holder. Upon receipt of such written notice, the Rights Agent shall, subject to its reasonable determination that the transfer instrument is in proper form, promptly record the change of address
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in the CVR Register. The Acting Holders may, without duplication, make a written request to the Rights Agent for a list containing the names, addresses and number of CVRs of the Holders that are
registered in the CVR Register. Upon receipt of such written request from the Acting Holders, the Rights Agent shall promptly deliver a copy of such list to the Acting Holders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> The Company will provide written instructions to the Rights Agent for the distribution of CVRs to holders of Common Stock as of
immediately prior to the First Effective Time (the &#147;<B>Record Time</B>&#148;). Subject to the terms and conditions of this Agreement and the Company&#146;s prompt confirmation of the First Effective Time, the Rights Agent shall effect the
distribution of the CVRs, less any applicable tax withholding, to each holder of Common Stock as of the Record Time by the mailing of a statement of holding reflecting such CVRs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;2.4</B> <B>Payment Procedures</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> No later than forty-five (45)&nbsp;days following the end of each Calendar Quarter during the CVR Term beginning with the Calendar
Quarter ending on September&nbsp;30, 2023, commencing with the first CVR Payment Period in which the Company or its Affiliates receives Gross Proceeds, the Company shall deliver to the Rights Agent a CVR Payment Statement for such CVR Payment
Period. Concurrent with the delivery of each CVR Payment Statement, on the terms and conditions of this Agreement, the Company shall pay the Rights Agent in U.S. dollars an amount equal to ninety percent (90%) of the CVR Payment plus the Adjustment
Amount, if applicable (subject to the proviso in the definition of the term &#147;CVR Payment&#148;), for the applicable CVR Payment Period. Such CVR Payment will be transferred by wire transfer of immediately available funds to an account
designated in writing by the Rights Agent not less than twenty (20)&nbsp;Business Days prior to the date of the applicable payment. Upon receipt of the wire transfer referred to in the foregoing sentence, the Rights Agent shall promptly (and in any
event, within ten (10)&nbsp;Business Days) pay, by check mailed, first-class postage prepaid, to the address of each Holder set forth in the CVR Register at such time, an amount equal to such Holder&#146;s CVR Payment Amount. The Rights Agent shall
promptly, and in any event within ten (10)&nbsp;Business Days after receipt of a CVR Payment Statement under this <U>Section</U><U></U><U>&nbsp;2.4(a)</U>, send each Holder at its registered address a copy of such statement. For the avoidance of
doubt the Company shall have no further liability in respect of the relevant CVR Payment upon delivery of such CVR Payment in accordance with this <U>Section</U><U></U><U>&nbsp;2.4(a)</U> and the satisfaction of each of the Company&#146;s
obligations set forth in this <U>Section</U><U></U><U>&nbsp;2.4(a)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> The Rights Agent shall solicit from each Holder an IRS
Form <FONT STYLE="white-space:nowrap">W-9</FONT> or applicable IRS Form <FONT STYLE="white-space:nowrap">W-8</FONT> at such time or times as is necessary to permit any payment under this Agreement to be made without U.S. federal backup withholding.
That notwithstanding, the Company shall be entitled to deduct and withhold, and hereby authorizes the Rights Agent to deduct and withhold, any tax or similar governmental charge or levy, that is required to be deducted or withheld under applicable
law from any amounts payable pursuant to this Agreement (&#147;<B>Withholding Taxes</B>&#148;). To the extent the amounts are so withheld by the Company or the Rights Agent, as the case may be, and paid over to the appropriate Governmental Body,
such withheld amounts shall be treated for all purposes of this Agreement as having been paid to the person in respect of whom such deduction and withholding was made. In the event the Company becomes aware that a payment under this Agreement is
subject to Withholding Taxes (other than U.S. federal backup withholding), the Company shall use commercially reasonable efforts to provide </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
written notice to the Rights Agent and the Rights Agent shall use commercially reasonable efforts to provide written notice of such Withholding Taxes to the applicable Holders and the parties
shall use commercially reasonable efforts to cooperate with one another to minimize taxes required by applicable law to be withheld or deducted from any payments made under this Agreement. For the avoidance of doubt, in the event that notice has
been provided to an applicable Holder pursuant to this <U>Section</U><U></U><U>&nbsp;2.4(b)</U>, no further notice shall be required to be given for any future payments of such Withholding Tax. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> Any portion of a CVR Payment that remains undistributed to the Holders six (6)&nbsp;months after the applicable Calendar Quarter
end (including by means of uncashed checks or invalid addresses on the CVR Register) will be delivered by the Rights Agent to the Company or a person nominated in writing by the Company (with written notice thereof from the Company to the Rights
Agent), and any Holder will thereafter look only to the Company for payment of such CVR Payment (which shall be without interest). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> If any CVR Payment (or portion thereof) remains unclaimed by a Holder two (2)&nbsp;years after the applicable Calendar Quarter end
(or immediately prior to such earlier date on which such CVR Payment would otherwise escheat to or become the property of any Governmental Authority), such CVR Payment (or portion thereof) will, to the extent permitted by applicable Law, become the
property of the Company and will be transferred to the Company or a person nominated in writing by the Company (with written notice thereof from the Company to the Rights Agent), free and clear of all claims or interest of any Person previously
entitled thereto, and no consideration or compensation shall be payable therefor. Neither the Company nor the Rights Agent will be liable to any Person in respect of a CVR Payment delivered to a public official pursuant to any applicable abandoned
property, escheat or similar legal requirement under applicable Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;2.5</B> <B>No Voting, Dividends or
Interest; No Equity or Ownership Interest</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> The CVRs will not have any voting or dividend rights, and interest will not
accrue on any amounts payable in respect of CVRs to any Holder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> The CVRs will not represent any equity or ownership interest
in the Company or in any constituent company to the Merger. It is hereby acknowledged and agreed that a CVR shall not constitute a security of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> Nothing contained in this Agreement shall be construed as conferring upon any Holder, by virtue of the CVRs, any rights or
obligations of any kind or nature whatsoever as a stockholder or member of the Company or any of its subsidiaries either at law or in equity. The rights of any Holder and the obligations of the Company and its Affiliates and their respective
officers, directors and controlling Persons are contract rights limited to those expressly set forth in this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> It is
hereby acknowledged and agreed that the CVRs and the possibility of any payment hereunder with respect thereto are highly speculative and subject to numerous factors outside of the Company&#146;s control, and there is no assurance that Holders will
receive any payments under this Agreement or in connection with the CVRs. Each Holder acknowledges that it is highly </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
possible that no Disposition will occur prior to the expiration of the Disposition Period and that there will not be any Gross Proceeds that may be the subject of a CVR Payment Amount. It is
further acknowledged and agreed that neither the Company nor its Affiliates owe, by virtue of their obligations under this Agreement, a fiduciary duty or any implied duties to the Holders and the parties hereto, and the Company and its Affiliates
intend solely the express provisions of this Agreement to govern their contractual relationship with respect to the CVRs. It is acknowledged and agreed that this <U>Section</U><U></U><U>&nbsp;2.5(d)</U> is an essential and material term of this
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;2.6</B> <B>Ability to Abandon CVR</B>. A Holder may at any time, at such Holder&#146;s option,
abandon all of such Holder&#146;s remaining rights represented by CVRs by transferring such CVRs to the Company or a Person nominated in writing by the Company (with written notice thereof from the Company to the Rights Agent) without consideration
in compensation therefor, and such rights will be cancelled, with the Rights Agent being promptly notified in writing by the Holder of such transfer and cancellation. Nothing in this Agreement is intended to prohibit the Company or its Affiliates
from offering to acquire or acquiring CVRs, in private transactions or otherwise, for consideration in its sole discretion. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 3.
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THE RIGHTS AGENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;3.1</B> <B>Certain Duties and Responsibilities</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> The Rights Agent will not have any liability for any actions taken or not taken in connection with this Agreement, except to the
extent such liability arises as a result of the willful misconduct, fraud, bad faith or gross negligence of the Rights Agent (in each case as determined by a final <FONT STYLE="white-space:nowrap">non-appealable</FONT> judgment of court of competent
jurisdiction). Notwithstanding anything in this Agreement to the contrary, any liability of the Rights Agent under this Agreement will be limited to the amount of annual fees paid by the Company to the Rights Agent in connection with this Agreement
(but not including reimbursable expenses and other charges). Anything to the contrary notwithstanding, in no event will the Rights Agent be liable for special, punitive, indirect, incidental or consequential loss or damages of any kind whatsoever
(including, without limitation, lost profits), even if the Rights Agent has been advised of the likelihood of such loss or damages, and regardless of the form of action. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> The Rights Agent shall not have any duty or responsibility in the case of the receipt of any written demand from any Holder with
respect to any action or default by any person or entity, including, without limiting the generality of the foregoing, any duty or responsibility to initiate or attempt to initiate any proceedings at law or otherwise or to make any demand upon the
Company or Spyre. The Rights Agent may (but shall not be required to) enforce all rights of action under this Agreement and any related claim, action, suit, audit, investigation or proceeding instituted by the Rights Agent may be brought in its name
as the Rights Agent and any recovery in connection therewith will be for the proportionate benefit of all the Holders, as their respective rights or interests may appear on the CVR Register. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;3.2</B> <B>Certain Rights of Rights Agent</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> The Rights Agent undertakes to perform such duties and only such duties as are specifically set forth in this Agreement, and no
implied covenants or obligations will be read into this Agreement against the Rights Agent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> The Rights Agent may rely and will
be protected by the Company in acting or refraining from acting upon any resolution, certificate, statement, instrument, opinion, report, notice, request, direction, consent, order or other paper or document reasonably believed by it in the absence
of bad faith to be genuine and to have been signed or presented by or on behalf of the Company or with respect to <U>Section</U><U></U><U>&nbsp;2.3(d)</U>, the Acting Holders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> Whenever the Rights Agent deems it desirable that a matter be proved or established prior to taking or omitting any action
hereunder, the Rights Agent may rely upon an Officer&#146;s Certificate, which certificate shall be full authorization and protection to the Rights Agent, and the Rights Agent shall, in the absence of bad faith, gross negligence or willful
misconduct (each as determined by a final <FONT STYLE="white-space:nowrap">non-appealable</FONT> judgment of a court of competent jurisdiction) on its part, incur no liability and be held harmless by the Company for or in respect of any action taken
or omitted to be taken by it under the provisions of this Agreement in reliance upon such Officer&#146;s Certificate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> The
Rights Agent may engage and consult with counsel of its selection, and the advice or opinion of such counsel will, in the absence of bad faith, fraud, gross negligence or willful misconduct (in each case, as determined by a final, <FONT
STYLE="white-space:nowrap">non-appealable</FONT> judgment of a court of competent jurisdiction) on the part of the Rights Agent, be full and complete authorization and protection in respect of any action taken or not taken by the Rights Agent in
reliance thereon. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> Any permissive rights of the Rights Agent hereunder will not be construed as a duty. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> The Rights Agent will not be required to give any note or surety in respect of the execution of its powers or otherwise under this
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(g)</B> The Company agrees to indemnify the Rights Agent for, and to hold the Rights Agent harmless from and against, any
loss, liability, damage, judgment, fine, penalty, cost or expense (each, a &#147;<B>Loss</B>&#148;) suffered or incurred by the Rights Agent and arising out of or in connection with the Rights Agent&#146;s performance of its obligations under this
Agreement, including the reasonable and documented costs and expenses of defending the Rights Agent against any claims, charges, demands, actions or suits arising out of or in connection in connection with the execution, acceptance, administration,
exercise and performance of its duties under this Agreement, including the costs and expenses of defending against any claim of liability arising therefrom, directly or indirectly, or enforcing its rights hereunder, except to the extent such Loss
has been determined by a final <FONT STYLE="white-space:nowrap">non-appealable</FONT> decision of a court of competent jurisdiction to have resulted from the Rights Agent&#146;s gross negligence, bad faith or willful misconduct; provided that this
<U>Section</U><U></U><U>&nbsp;3.2(g)</U> shall not apply with respect to income, receipt, franchise or similar Taxes imposed with respect to payments to the Rights Agent for its services pursuant to this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(h)</B> The Company agrees (i)&nbsp;to pay the fees of the Rights Agent in connection
with the Rights Agent&#146;s performance of its obligations hereunder, as agreed upon in writing by the Rights Agent and the Company on or prior to the date of this Agreement, and (ii)&nbsp;to reimburse the Rights Agent for all reasonable and
documented <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses and other disbursements incurred in the preparation, delivery, negotiation, amendment, administration and execution of this Agreement
and the exercise and performance of its duties hereunder, including all stamp and transfer Taxes (and excluding for the avoidance of doubt, any income, receipt, franchise or similar Taxes on payments to the Rights Agent for its services pursuant to
this Agreement) and governmental charges, incurred by the Rights Agent in the performance of its obligations under this Agreement, except that the Company will have no obligation to pay the fees of the Rights Agent or reimburse the Rights Agent for
the fees of counsel in connection with any lawsuit initiated by the Rights Agent on behalf of itself or the Holders, except in the case of any suit enforcing the provisions of <U>Section</U><U></U><U>&nbsp;2.4(a)</U> and
<U>Section</U><U></U><U>&nbsp;3.2(g)</U>, if the Company is found by a court of competent jurisdiction to be liable to the Rights Agent or the Holders, as applicable in such suit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> No provision of this Agreement shall require the Rights Agent to expend or risk its own funds or otherwise incur any financial
liability in the performance of any of its duties hereunder or in the exercise of any of its rights or powers if it believes that repayment of such funds or adequate indemnification against such risk or liability is not reasonably assured to it.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(j)</B> The Rights Agent shall not be subject to, nor be required to comply with, or determine if any Person has complied with, the
Merger Agreement or any other agreement between or among any of the Company, Spyre or Holders, even though reference thereto may be made in this Agreement, or to comply with any notice, instruction, direction, request or other communication, paper
or document other than as expressly set forth in this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(k)</B> In the event the Rights Agent reasonably believes any
ambiguity or uncertainty exists hereunder or in any notice, instruction, direction, request or other communication, paper or document received by the Rights Agent hereunder, the Rights Agent shall, as soon as practicable, provide notice to the
Company, and the Rights Agent may, in its sole discretion, refrain from taking any action, and shall be fully protected and shall not be liable in any way to the Company or any Holder or any other Person for refraining from taking such action,
unless the Rights Agent receives written instructions from the Company or such Holder or other Person which eliminate such ambiguity or uncertainty to the reasonable satisfaction of the Rights Agent; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(l)</B> The Rights Agent may execute and exercise any of the rights or powers hereby vested in it or perform any duty hereunder either
itself or by or through its attorney or agents and the Rights Agent shall not be answerable or accountable for any act, default, neglect or misconduct of any such attorney or agents or for any loss to the Company or Spyre resulting from any such
act, default, neglect or misconduct, absent gross negligence, bad faith or willful misconduct (each as determined by a final <FONT STYLE="white-space:nowrap">non-appealable</FONT> judgment of a court of competent jurisdiction) in the selection and
continued employment thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(m)</B> The Rights Agent shall not be liable for or by reason of any of the statements of fact or
recitals contained in this Agreement (except its countersignature thereof) or be required to verify the same, and all such statements and recitals are and shall be deemed to have been made by the Company only. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(n)</B> The Rights Agent shall act hereunder solely as agent for the Company and shall
not assume any obligations or relationship of agency or trust with any of the owners or holders of the CVRs. The Rights Agent shall not have any duty or responsibility in the case of the receipt of any written demand from any Holders with respect to
any action or default by the Company, including, without limiting the generality of the foregoing, any duty or responsibility to initiate or attempt to initiate any proceedings at law or otherwise or to make any demand upon the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(o)</B> The Rights Agent may rely on and be fully authorized and protected in acting or failing to act upon (i)&nbsp;any guaranty of
signature by an &#147;eligible guarantor institution&#148; that is a member or participant in the Securities Transfer Agents Medallion Program or other comparable &#147;signature guarantee program&#148; or insurance program in addition to, or in
substitution for, the foregoing; or (ii)&nbsp;any law, act, regulation or any interpretation of the same even though such law, act, or regulation may thereafter have been altered, changed, amended or repealed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(p)</B> The Rights Agent shall not be liable or responsible for any failure of the Company to comply with any of its obligations relating
to any registration statement filed with the Securities and Exchange Commission or this Agreement, including without limitation obligations under applicable regulation or law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(q)</B> The obligations of the Company and the rights of the Rights Agent under this <U>Section</U><U></U><U>&nbsp;3.2</U>,
<U>Section</U><U></U><U>&nbsp;3.1</U> and <U>Section</U><U></U><U>&nbsp;2.4</U> shall survive the expiration of the CVRs and the termination of this Agreement and the resignation, replacement or removal of the Rights Agent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;3.3</B> <B>Resignation and Removal; Appointment of Successor</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> The Rights Agent may resign at any time by written notice to the Company. Any such resignation notice shall specify the date on
which such resignation will take effect (which shall be at least thirty (30)&nbsp;days following the date that such resignation notice is delivered), and such resignation will be effective on the earlier of (x)&nbsp;the date so specified and
(y)&nbsp;the appointment of a successor Rights Agent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> The Company will have the right to remove the Rights Agent at any time
by written notice to the Rights Agent, specifying the date on which such removal will take effect. Such notice will be given at least thirty (30)&nbsp;days prior to the date so specified (or, if earlier, the appointment of the successor Rights
Agent). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> If the Rights Agent resigns, is removed or becomes incapable of acting, the Company will promptly appoint a qualified
successor Rights Agent. Notwithstanding the foregoing, if the Company fails to make such appointment within a period of thirty (30)&nbsp;days after giving notice of such removal or after it has been notified in writing of such resignation or
incapacity by the resigning or incapacitated Rights Agent, then the incumbent Rights Agent may apply to any court of competent jurisdiction for the appointment of a new Rights Agent. The successor Rights Agent so appointed will, upon its acceptance
of such appointment in accordance with this <U>Section</U><U></U><U>&nbsp;3.3(c)</U> and<U> Section</U><U></U><U>&nbsp;3.4</U>, become the Rights Agent for all purposes hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> The Company will give notice to the Holders of each resignation or removal of the Rights Agent and each appointment of a successor
Rights Agent in accordance with<U> Section</U><U></U><U>&nbsp;7.2</U>. Each notice will include the name and address of the successor Rights Agent. If the Company fails to send such notice within ten (10)&nbsp;Business Days after acceptance of
appointment by a successor Rights Agent, the successor Rights Agent will cause the notice to be mailed at the expense of the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> Notwithstanding anything to the contrary in this
<U>Section</U><U></U><U>&nbsp;3.3</U>, unless consented to in writing by the Acting Holders, the Company will not appoint as a successor Rights Agent any Person that is not a stock transfer agent of national reputation or the corporate trust
department of a commercial bank. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> The Rights Agent will reasonably cooperate with the Company and any successor Rights Agent in
connection with the transition of the duties and responsibilities of the Rights Agent to the successor Rights Agent, including the transfer of all relevant data, including the CVR Register, to the successor Rights Agent, but such predecessor Rights
Agent shall not be required to make any additional expenditure or assume any additional liability in connection with the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;3.4</B> <B>Acceptance of Appointment by Successor</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Every successor Rights Agent appointed hereunder will, at or prior to such appointment, execute, acknowledge and deliver to the Company and to
the resigning or removed Rights Agent an instrument accepting such appointment and a counterpart of this Agreement, and such successor Rights Agent, without any further act, deed or conveyance, will become vested with all the rights, powers, trusts
and duties of the Rights Agent; <I><U>provided</U></I> that upon the request of the Company or the successor Rights Agent, such resigning or removed Rights Agent will execute and deliver an instrument transferring to such successor Rights Agent all
the rights, powers and trusts of such resigning or removed Rights Agent. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 4. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COVENANTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.1</B> <B>List of Holders</B>. The Company will furnish or cause to be furnished to the Rights Agent, in such
form as the Company receives from the Company&#146;s transfer agent (or other agent performing similar services for the Company), the names and addresses of the Holders within ten (10)&nbsp;Business Days following the Closing Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.2</B> <B>No Obligations of Public Company</B>. Notwithstanding anything herein to the contrary, and for the
avoidance of doubt, (a)&nbsp;during the Disposition Period, the Company shall use commercially reasonable efforts to monetize the tangible and intangible assets (including intellectual property) primarily used in or primarily related to the
pegtarviliase for Homocystinuria and pegzilarginase for Arginase 1 Deficiency programs, (b)&nbsp;none of the Company or any of its Affiliates (or any directors, officer, employee, or other representative of the foregoing) owes any fiduciary duty or
similar duty to any Holder in respect of the Potentially Transferable Assets, and (c)&nbsp;following the Disposition Period, the Company shall be permitted to take any action in respect of the Potentially Transferable Assets in order to satisfy any
wind-down and termination Liabilities of the Potentially Transferable Assets. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.3</B> <B>Prohibited Actions</B>. Unless approved by the
Acting Holders, prior to the end of the Disposition Period, the Company shall not grant any lien, security interest, pledge or similar interest in any Potentially Transferable Assets or any Net Proceeds or the Adjustment Amount. Unless approved by
the Acting Holders, prior to end of the Disposition Period, the Company shall not, and shall not permit its Affiliates to, grant, assign, transfer or otherwise convey any Potentially Transferable Assets (including any option to obtain rights) to any
third party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.4</B> <B>Books and Records</B>. Until the end of the CVR Term, the Company shall, and shall
cause its Affiliates to, keep true, complete and accurate records in sufficient detail to enable the Rights Agent to confirm each CVR Payment payable hereunder in accordance with the terms specified in this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.5</B> <B>Audits</B>. Until the expiration of this Agreement and for a period of one (1)&nbsp;year thereafter,
the Company shall keep complete and accurate records in sufficient detail to permit the Rights Agent to confirm the accuracy of the payments due hereunder. The Rights Agent or the Acting Holders, without duplication, shall each have the right to
cause an independent accounting firm reasonably acceptable to the Company to audit such records for the sole purpose of confirming payments for a period covering not more than the date commencing with the first CVR Payment Period in which the
Company or its Affiliates receives Gross Proceeds and ending on the last day of the CVR Term. The Company may require such accounting firm to execute a reasonable confidentiality agreement with the Company prior to commencing the audit. The
accounting firm shall disclose to Rights Agent or the Acting Holders, as applicable, only whether the reports are correct or not and the specific details concerning any discrepancies. No other information shall be shared. Such audits may be
conducted during normal business hours upon reasonable prior written notice to the Company, but no more than frequently than once per year. No accounting period of the Company shall be subject to audit more than one time by the Rights Agent or the
Acting Holders, as applicable, unless after an accounting period has been audited by the Rights Agent or the Acting Holders, as applicable, the Company restates its financial results for such accounting period, in which event the Rights Agent or the
Acting Holders, as applicable, may conduct a second audit of such accounting period in accordance with this <U>Section</U><U></U><U>&nbsp;4.5</U>. Adjustments (including remittances of underpayments or overpayments disclosed by such audit) shall be
made by the Parties to reflect the results of such audit, which adjustments shall be paid promptly following receipt of an invoice therefor. The Rights Agent or the Acting Holders, as applicable, shall bear the full cost and expense of such audit
unless such audit discloses an underpayment by the Company of twenty percent (20%) or more of the CVR Payments due under this Agreement for the audited period, in which case the Company shall bear the full cost and expense of such audit. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 5. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5.1</B> <B>Amendments Without Consent of Holders or Rights Agent</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> The Company, at any time and from time to time, may (without the consent of any Person, other than the Rights Agent with such
consent not to be unreasonably withheld, conditioned or delayed) enter into one or more amendments to this Agreement for any of the following purposes: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(</B><B>i</B><B>)</B> to evidence the appointment of another Person as a successor Rights Agent and the assumption by any successor Rights
Agent of the covenants and obligations of the Rights Agent herein in accordance with the provisions hereof; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> subject to
<U>Section</U><U></U><U>&nbsp;6.1</U>, to evidence the succession of another person to the Company and the assumption of any such successor of the covenants of the Company outlined herein in a transaction contemplated by
<U>Section</U><U></U><U>&nbsp;6.1;</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> to add to the covenants of the Company such further covenants, restrictions,
conditions or provisions as the Company and the Rights Agent will consider to be for the protection and benefit of the Holders; <I><U>provided</U></I> that in each case, such provisions do not adversely affect the interests of the Holders; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> to cure any ambiguity, to correct or supplement any provision in this Agreement that may be defective or inconsistent with any
other provision in this Agreement, or to make any other provisions with respect to matters or questions arising under this Agreement; <I><U>provided</U></I> that, in each case, such provisions do not adversely affect the interests of the Holders;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(v)</B> as may be necessary or appropriate to ensure that the CVRs are not subject to registration under the Securities Act or the
Exchange Act and the rules and regulations promulgated thereunder, or any applicable state securities or &#147;blue sky&#148; laws; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(vi)</B> as may be necessary or appropriate to ensure that the Company is not required to produce a prospectus or an admission document in
order to comply with applicable Law; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(vii)</B> to cancel the applicable CVRs (i)&nbsp;in the event that any Holder has abandoned its
rights in accordance with <U>Section</U><U></U><U>&nbsp;2.6</U>, or (ii)&nbsp;following a transfer of such CVRs to the Company or its Affiliates in accordance with <U>Section</U><U></U><U>&nbsp;2.2</U> or <U>Section</U><U></U><U>&nbsp;2.3</U>; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(viii)</B> as may be necessary or appropriate to ensure that the Company complies with applicable Law; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ix)</B> to effect any other amendment to this Agreement for the purpose of adding, eliminating or changing any provisions of this
Agreements, <I><U>provided</U></I> that, in each case, such additions, eliminations or changes do not adversely affect the interests of the Holders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> Promptly after the execution by the Company of any amendment pursuant to this
<U>Section</U><U></U><U>&nbsp;5.1</U>, the Company will (or will cause the Rights Agent to) notify the Holders in general terms of the substance of such amendment in accordance with <U>Section</U><U></U><U>&nbsp;7.2</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5.2</B> <B>Amendments with Consent of Holders</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> In addition to any amendments to this Agreement that may be made by the Company without the consent of any Holder pursuant to
<U>Section</U><U></U><U>&nbsp;5.1</U>, with the consent of the Acting Holders (whether evidenced in a writing or taken at a meeting of the Holders), the Company and the Rights Agent may enter into one or more amendments to this Agreement for the
purpose of adding, eliminating or amending any provisions of this Agreement, even if such addition, elimination or amendment is adverse to the interests of the Holders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> Promptly after the execution by the Company and the Rights Agent of any amendment pursuant to the provisions of this
<U>Section</U><U></U><U>&nbsp;5.2</U>, the Company will (or will cause the Rights Agent to) notify the Holders in general terms of the substance of such amendment in accordance with <U>Section</U><U></U><U>&nbsp;7.2</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5.3</B> <B>Effect of Amendments</B>. Upon the execution of any amendment under this <U>ARTICLE 5</U> this
Agreement will be modified in accordance therewith, such amendment will form a part of this Agreement for all purposes and every Holder will be bound thereby. Upon the delivery of a certificate from an appropriate officer of the Company which states
that the proposed supplement or amendment is in compliance with the terms of this <U>ARTICLE 5</U>, the Rights Agent shall execute such supplement or amendment. Notwithstanding anything in this Agreement to the contrary, the Rights Agent shall not
be required to execute any supplement or amendment to this Agreement that it has determined would adversely affect its own rights, duties, obligations or immunities under this Agreement. No supplement or amendment to this Agreement shall be
effective unless duly executed by the Rights Agent. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 6. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSOLIDATION, MERGER, SALE OR CONVEYANCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;6.1</B> <B>The Company May Not Consolidate, Etc</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the CVR Term, the Company shall not consolidate with or merge into any other Person or convey, transfer or lease its properties and
assets substantially as an entirety to any Person, unless: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> The Person formed by such consolidation or into which the Company
is merged or the Person that acquires by conveyance or transfer, or that leases, the properties and assets of the Company substantially as an entirety (the &#147;<B>Surviving Person</B>&#148;) shall expressly assume payment of amounts on all CVRs
(when and as due hereunder) and the performance of every duty and covenant of this Agreement on the part of the Company to be performed or observed; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> The Company has delivered to the Rights Agent an Officer&#146;s Certificate, stating that such consolidation, merger, conveyance,
transfer or lease complies with this <U>ARTICLE </U><U>6</U> and that all conditions precedent herein provided for relating to such transaction have been complied with. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;6.2</B> <B>Successor Substituted</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon any consolidation of or merger by the Company with or into any other Person, or any conveyance, transfer or lease of the properties and
assets substantially as an entirety to any Person in accordance with <U>Section</U><U></U><U>&nbsp;6.1</U>, the Surviving Person shall succeed to, and be substituted for, and may exercise every right and power of, and shall assume all of the
obligations of the Company under this Agreement with the same effect as if the Surviving Person had been named as the Company herein. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 7. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MISCELLANEOUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;7.1</B> <B>Notices to Rights Agent and to the Company</B>. All notices and other communications hereunder shall
be in writing and shall be deemed to have been duly delivered and received hereunder (a)&nbsp;one Business Day after being sent for next Business Day delivery, fees prepaid, via a reputable international overnight courier service, (b)&nbsp;upon
delivery in the case of delivery by hand, or (c)&nbsp;on the date delivered in the place of delivery if sent by email (with a written or electronic confirmation of delivery) prior to 5:00 p.m. Pacific Time, otherwise on the next succeeding Business
Day, in each case to the intended recipient as set forth below: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">if to the Rights Agent, to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">American Stock Transfer&nbsp;&amp; Trust Company LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">1010 El Camino Real &#150; Suite 360 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Menlo Park, CA 94025 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attn:
[&#149;] </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Email: [&#149;] </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">if to the Company, to: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Aeglea
BioTherapeutics, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">805 Las Cimas Parkway </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Suite 100 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Austin, TX 78746
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: Jonathan Alspaugh </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Email Address: jalspaugh@aeglea.com </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">with a copy, which shall not constitute notice, to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">With a copy to: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Gibson,
Dunn&nbsp;&amp; Crutcher LLP </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">555 Mission St., Suite 3000 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">San Francisco, CA 94105 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: Ryan Murr, Branden Berns, Chris Trester </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Email Address: rmurr@gibsondunn.com; bberns@gibsondunn.com; ctrester@gibsondunn.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">or to such other address or email address as such Party may hereafter specify for the purpose by notice to the other Party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;7.2</B> <B>Notice to Holders</B>. All Notices required to be given to the Holders will be given (unless
otherwise herein expressly provided) in writing and mailed, first-class postage prepaid, to each Holder at such Holder&#146;s address as set forth in the CVR Register, not later than the latest date, and not earlier than the earliest date,
prescribed for the sending of such Notice, if any, and will be deemed given on the date of mailing. In any case where notice to the Holders is given by mail, neither the failure to mail such Notice, nor any defect in any Notice so mailed, to any
particular Holder will affect the sufficiency of such Notice with respect to other Holders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;7.3</B>
<B>Entire Agreement</B>. As between the Company and the Rights Agent, this Agreement constitutes the entire agreement between the parties with respect to the subject matter of this Agreement, notwithstanding the reference to any other agreement
herein, and supersedes all prior agreements and understandings, both written and oral, among or between any of the parties with respect to the subject matter of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;7.4</B> <B>Merger or Consolidation or Change of Name of Rights Agent</B>. Any Person into which the Rights Agent
or any successor Rights Agent may be merged or with which it may be consolidated, or Person resulting from any merger or consolidation to which the Rights Agent or any successor Rights Agent shall be a party, or any Person succeeding to the stock
transfer or other shareholder services business of the Rights Agent or any successor Rights Agent, shall be the successor to the Rights Agent under this Agreement without the execution or filing of any paper or any further act on the part of any of
the parties hereto, provided that such Person would be eligible for appointment as a successor Rights Agent under the provisions of <U>Section</U><U></U><U>&nbsp;3.3</U>. The purchase of all or substantially all of the Rights Agent&#146;s assets
employed in the performance of transfer agent activities shall be deemed a merger or consolidation for purposes of this <U>Section</U><U></U><U>&nbsp;7.4</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;7.5</B> <B>Successors and Assigns</B>. This Agreement will be binding upon, and will be enforceable by and inure
solely to the benefit of, the Holders, the Company and the Rights Agent and their respective successors and assigns. Except for assignments pursuant to <U>Section</U><U></U><U>&nbsp;7.4</U>, the Rights Agent may not assign this Agreement without the
Company&#146;s prior written consent. Subject to <U>Section</U><U></U><U>&nbsp;5.1(a)(ii) </U>and <U>ARTICLE 6</U> hereof, the Company may assign, in its sole discretion and without the consent of any other party, any or all of its rights, interests
and obligations hereunder to one or more of its Affiliates or to any Person with whom the Company is merged or consolidated, or any entity resulting from any merger or consolidation to which the Company shall be a party (each, an
&#147;<B>Assignee</B>&#148;); <I><U>provided</U></I>, that in connection with any assignment to an Assignee, the Company shall agree to remain liable for the performance by the Company of its obligations hereunder (to the extent the Company exists
following such assignment). The Company or an Assignee may not otherwise assign this Agreement without the prior consent of the Acting Holders (such consent not to be unreasonably withheld, conditioned or delayed). Any attempted assignment of this
Agreement in violation of this <U>Section</U><U></U><U>&nbsp;7.5</U> will be void <I>ab initio</I> and of no effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;7.6</B> <B>Benefits of Agreement; Action by Acting
Holders</B>. Nothing in this Agreement, express or implied, will give to any Person (other than the Company, the Rights Agent, the Holders and their respective permitted successors and assigns hereunder) any benefit or any legal or equitable right,
remedy or claim under this Agreement or under any covenant or provision herein contained, all such covenants and provisions being for the sole benefit of the Company, the Rights Agent, the Holders and their permitted successors and assigns. The
Holders will have no rights hereunder except as are expressly set forth herein. Except for the rights of the Rights Agent set forth herein, the Acting Holders will have the sole right, on behalf of all Holders, by virtue of or under any provision of
this Agreement, to institute any action or proceeding at law or in equity with respect to this Agreement, and no individual Holder or other group of Holders will be entitled to exercise such rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;7.7</B> <B>Governing Law</B>. This Agreement and the CVRs will be governed by, and construed in accordance with,
the laws of the State of Delaware, regardless of the Laws that might otherwise govern under applicable principles of conflicts of laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;7.8</B> <B>Jurisdiction</B>. In any action or proceeding between any of the parties hereto arising out of or
relating to this Agreement or any of the transactions contemplated hereby, each of the parties hereto: (a)&nbsp;irrevocably and unconditionally consents and submits to the exclusive jurisdiction and venue of the Chancery Court of the State of
Delaware, County of New Castle, or, if under applicable Law exclusive jurisdiction is vested in the Federal courts, the United States District Court for the District of Delaware (and appellate courts thereof); (b) agrees that all claims in respect
of such action or proceeding shall be heard and determined exclusively in accordance with clause (a)&nbsp;of this <U>Section</U><U></U><U>&nbsp;7.8</U>; (c) waives any objection to laying venue in any such action or proceeding in such courts;
(d)&nbsp;waives any objection that such courts are an inconvenient forum or do not have jurisdiction over any Party; and (e)&nbsp;agrees that service of process upon such Party in any such action or proceeding shall be effective if notice is given
in accordance with <U>Section</U><U></U><U>&nbsp;7.1</U> or <U>Section</U><U></U><U>&nbsp;7.2</U> of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;7.9
WAIVER OF JURY TRIAL. EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY WAIVES ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATED TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY. EACH PARTY CERTIFIES AND
ACKNOWLEDGES THAT (I)&nbsp;NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER, (II)&nbsp;EACH PARTY
UNDERSTANDS AND HAS CONSIDERED THE IMPLICATION OF THIS WAIVER, (III)&nbsp;EACH PARTY MAKES THIS WAIVER VOLUNTARILY, AND (IV)&nbsp;EACH PARTY HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS
IN THIS <U>SECTION</U><U></U><U>&nbsp;7.9</U>. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;7.10</B> <B>Severability Clause</B>. Any term or
provision of this Agreement that is invalid or unenforceable in any situation in any jurisdiction shall not affect the validity or enforceability of the remaining terms and provisions of this Agreement or the validity or enforceability of the
offending term or provision in any other situation or in any other jurisdiction. If a final judgment of a court of competent jurisdiction declares that any term or provision of this </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Agreement is invalid or unenforceable, the parties agree that the court making such determination shall have the power to limit such term or provision, to delete specific words or phrases or to
replace such term or provision with a term or provision that is valid and enforceable and that comes closest to expressing the intention of the invalid or unenforceable term or provision, and this Agreement shall be valid and enforceable as so
modified. In the event such court does not exercise the power granted to it in the prior sentence, the parties agree to replace such invalid or unenforceable term or provision with a valid and enforceable term or provision that will achieve, to the
extent possible, the economic, business and other purposes of such invalid or unenforceable term or provision. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;7.11</B> <B>Counterparts; Effectiveness</B>. This Agreement may be executed in several counterparts, each of
which shall be deemed an original and all of which shall constitute one and the same instrument. Counterparts may be delivered via electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g.,
www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. This Agreement will become effective when each party hereto will
have received a counterpart hereof signed by the other party hereto. Until and unless each party has received a counterpart hereof signed by the other party hereto, this Agreement will have no effect and no party will have any right or obligation
hereunder (whether by virtue of any oral or written agreement or any other communication). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;7.12</B>
<B>Termination</B>. This Agreement will automatically terminate and be of no further force or effect and, except as provided in <U>Section</U><U></U><U>&nbsp;3.2</U>, the parties hereto will have no further liability hereunder, and the CVRs will
expire without any consideration or compensation therefor, upon the expiration of the CVR Term. The termination of this Agreement will not affect or limit the right of Holders to receive the CVR Payments under <U>Section</U><U></U><U>&nbsp;2.4</U>
to the extent earned prior to the termination of this Agreement, and the provisions applicable thereto will survive the expiration or termination of this Agreement until such CVR Payments have been made, if applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;7.13</B> <B>Construction</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> For purposes of this Agreement, whenever the context requires: the singular number shall include the plural, and vice versa; the
masculine gender shall include the feminine and neuter genders; the feminine gender shall include the masculine and neuter genders; and the neuter gender shall include masculine and feminine genders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> As used in this Agreement, the words &#147;include&#148; and &#147;including,&#148; and variations thereof, shall not be deemed to
be terms of limitation, but rather shall be deemed to be followed by the words &#147;without limitation.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> The headings
contained in this Agreement are for convenience of reference only, will not be deemed to be a part of this Agreement and will not be referred to in connection with the construction or interpretation of this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> Unless stated otherwise, &#147;Article&#148; and &#147;Section&#148; followed by
a number or letter mean and refer to the specified Article or Section of this Agreement. The term &#147;Agreement&#148; and any reference in this Agreement to this Agreement or any other agreement or document includes, and is a reference to, this
Agreement or such other agreement or document as it may have been, or may from time to time be, amended, restated, replaced, supplemented or novated and includes all schedules to it. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> A period of time is to be computed as beginning on the day following the event that began the period and ending at 4:30 p.m.
(Pacific Time) on the last day of the period, if the last day of the period is a Business Day, or at 4:30 p.m. (Pacific Time) on the next Business Day if the last day of the period is not a Business Day. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> Any reference in this Agreement to a date or time shall be deemed to be such date or time in San Francisco, California, United
States, unless otherwise specified. The parties hereto and the Company have participated jointly in the negotiation and drafting of this Agreement. In the event an ambiguity or question of intent or interpretation arises, this Agreement shall be
construed as if drafted jointly by the parties and the Company and no presumption or burden of proof shall arise favoring or disfavoring any Person by virtue of the authorship of any provision of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(g)</B> References to &#147;cash,&#148; &#147;dollars&#148; or &#147;$&#148; are to U.S. dollars. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Remainder of page intentionally left blank] </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, each of the parties has caused this Agreement to be executed as
of the day and year first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">AEGLEA BIOTHERAPEUTICS, INC.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">AMERICAN STOCK TRANSFER&nbsp;&amp; TRUST COMPANY LLC</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to
Contingent Value Rights Agreement] </I></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Exhibit E </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Form of Parent Support Agreement </U></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">E-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><I>Privileged and Confidential</I> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><I>Final Form</I> </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF
PARENT STOCKHOLDER SUPPORT AGREEMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AEGLEA BIOTHERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SUPPORT AGREEMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>THIS SUPPORT
AGREEMENT</B> (this &#147;<B><I>Agreement</I></B>&#148;), dated as of June [&nbsp;&nbsp;&nbsp;&nbsp;], 2023, is made by and among Aeglea BioTherapeutics, Inc., a Delaware corporation (&#147;<B><I>Parent</I></B>&#148;), Spyre Therapeutics,Inc., a
Delaware corporation (the &#147;<B><I>Company</I></B>&#148;), and the undersigned holder (&#147;<B><I>Stockholder</I></B>&#148;) of shares of capital stock (the &#147;<B><I>Shares</I></B>&#148;) of Parent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, Parent, Aspen Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (&#147;<B><I>First Merger
Sub</I></B>&#148;), Sequoia Merger Sub II, LLC, a Delaware limited liability company and a wholly owned subsidiary of Parent (&#147;<B><I>Second Merger Sub</I></B>&#148;), and the Company, have entered into an Agreement and Plan of Merger, dated of
even date herewith (the &#147;<B><I>Merger Agreement</I></B>&#148;), providing for the merger of First Merger Sub with and into the Company (the &#147;<B><I>First Merger</I></B>&#148;) and the merger of the Company with and into Second Merger Sub
(the &#147;<B><I>Second Merger</I></B>&#148; and, together with the First Merger, the &#147;<B><I>Merger</I></B>&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>,
Stockholder beneficially owns and has sole or shared voting power with respect to the number of Shares, and holds options to purchase shares of Parent Common Stock (&#147;<B><I>Parent Options</I></B>&#148;) and/or restricted stock units to acquire
shares of Parent Common Stock (&#147;<B><I>Parent Restricted Stock Units</I></B>&#148;), in each case in the number of Shares indicated opposite Stockholder&#146;s name on <U>Schedule 1</U> attached hereto; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, as an inducement and a condition to the willingness of Parent, First Merger Sub, Second Merger Sub and the Company to enter
into the Merger Agreement, and in consideration of the substantial expenses incurred and to be incurred by them in connection therewith, Stockholder has agreed to enter into and perform this Agreement; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, all capitalized terms used in this Agreement without definition herein shall have the meanings ascribed to them in the Merger
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>NOW, THEREFORE</B>, in consideration of, and as a condition to, Parent, First Merger Sub, Second Merger Sub and the
Company&#146;s entering into the Merger Agreement and proceeding with the transactions contemplated thereby, and in consideration of the substantial expenses incurred and to be incurred by them in connection therewith, Stockholder, Parent and the
Company agree as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Agreement to Vote Shares</U>. Stockholder agrees that, prior to the Expiration Date (as defined in
<U>Section</U><U></U><U>&nbsp;2</U> below), at any meeting of the stockholders of Parent or any adjournment or postponement thereof, or in connection with any written consent of the stockholders of Parent, with respect to the Parent Stockholder
Matters, Stockholder shall, or shall cause the holder of record on any applicable record date to: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">appear at such meeting or otherwise cause the Shares and any New Shares (as defined in
<U>Section</U><U></U><U>&nbsp;3</U> below) to be counted as present thereat (in person or by proxy) for purposes of calculating a quorum; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">from and after the date hereof until the Expiration Date, vote (or cause to be voted), or deliver a written
consent (or cause a written consent to be delivered) covering all of the Shares and any New Shares that Stockholder shall be entitled to so vote: (i)&nbsp;in favor of the Parent Stockholder Matters and any matter that could reasonably be expected to
facilitate the Parent Stockholder Matters; (ii)&nbsp;against any proposal to remove the limitation initially set at the discretion of holders of Parent Convertible Preferred Stock between 4.99% and 19.99% of the number of shares of Parent Common
Stock outstanding immediately after giving effect to the issuance of shares of Parent Common Stock upon conversion (the &#147;<B><I>Beneficial Ownership Limitation</I></B>&#148;) restricting such holders from beneficially owning a number of shares
of Parent Common Stock in excess of the Beneficial Ownership Limitation or any agreement, transaction or other matter that is intended to, or would reasonably be expected to, impede, interfere with, delay, postpone, discourage or materially and
adversely affect the consummation of the Parent Stockholder Matters; and (iii)&nbsp;to approve any proposal to adjourn or postpone the meeting to a later date, if there are not sufficient votes for the approval of the Parent Stockholder Matters on
the date on which such meeting is held. Stockholder shall not take or commit or agree to take any action inconsistent with the foregoing. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">E-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Expiration Date</U>. As used in this Agreement, the term &#147;<B><I>Expiration Date</I></B>&#148; shall
mean the earlier to occur of (a)&nbsp;the effective time of the approval of the Parent Stockholder Matters, (b)&nbsp;upon mutual written agreement of the Company, the Parent and Stockholder to terminate this Agreement or (c)&nbsp;nine (9) months
following the date of this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Additional Purchases</U>. Stockholder agrees that any shares of capital stock or other equity securities of
Parent that Stockholder purchases or with respect to which Stockholder otherwise acquires sole or shared voting power (including any proxy) after the execution of this Agreement and prior to the Expiration Date, whether by the exercise of any Parent
Options, settlement of Parent Restricted Stock Units or otherwise, including, without limitation, by gift, succession, in the event of a stock split or as a dividend or distribution of any Shares (&#147;<B><I>New</I></B><B>
</B><B><I>Shares</I></B>&#148;), shall be subject to the terms and conditions of this Agreement to the same extent as if they constituted the Shares. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Share Transfers</U>. From and after the date hereof until the Expiration Date, Stockholder shall not,
directly or indirectly, (a)&nbsp;sell, assign, transfer, tender, or otherwise dispose of (including, without limitation, by the creation of any Liens (as defined in <U>Section</U><U></U><U>&nbsp;5(c)</U> below)) any Shares or any New Shares
acquired, (b)&nbsp;deposit any Shares or New Shares into a voting trust or enter into a voting agreement or similar arrangement with respect to such Shares or New Shares or grant any proxy or power of attorney with respect thereto (other than this
Agreement), (c) enter into any Contract, option, commitment or other arrangement or understanding with respect to the direct or indirect sale, transfer, assignment or other disposition of (including, without limitation, by the creation of any Liens)
any Shares or New Shares, or (d)&nbsp;take any action that would make any representation or warranty of Stockholder contained herein untrue or incorrect or have the effect of preventing or disabling Stockholder from performing Stockholder&#146;s
obligations under this Agreement. Notwithstanding the foregoing, Stockholder may make (1)&nbsp;transfers by will or by operation of Law or other transfers for estate-planning purposes, in which case this Agreement shall bind the transferee,
(2)&nbsp;with respect to Stockholder&#146;s Parent Options which expire on or prior to the Expiration Date, transfers, sale, or other disposition of Shares or New Shares to Parent as payment for the (i)&nbsp;exercise price of Stockholder&#146;s
Parent Options and (ii)&nbsp;taxes applicable to the exercise of Stockholder&#146;s Parent Options, (3)&nbsp;with respect to Stockholder&#146;s Parent Restricted Stock Units, (i)&nbsp;transfers for the net settlement of Stockholder&#146;s Parent
Restricted Stock Units settled in Shares or New Shares (to pay any tax withholding obligations) or (ii)&nbsp;transfers for receipt upon settlement of Stockholder&#146;s Parent Restricted Stock Units, and the sale of a sufficient number of such
Shares acquired upon settlement of such securities as would generate sales proceeds sufficient to pay the aggregate taxes payable by Stockholder as a result of such settlement, (4)&nbsp;if Stockholder is a partnership or limited liability company, a
transfer to one or more partners or members of Stockholder or to an Affiliated corporation, trust or other Entity under common control with Stockholder, or if Stockholder is a trust, a transfer to a beneficiary, <I><U>provided</U></I><U>
</U><I><U>that</U></I>, in each such case the applicable transferee has signed a voting agreement in substantially the form hereof, (5)&nbsp;transfers to another holder of the capital stock of the Company that has signed a voting agreement in
substantially the form hereof, and (6)&nbsp;transfers, sales or other dispositions as the Company may otherwise agree in writing in its sole discretion. If any voluntary or involuntary transfer of any Shares or New Shares covered hereby shall occur
(including a transfer or disposition permitted by <U>Section</U><U></U><U>&nbsp;4(1)</U> through <U>Section</U><U></U><U>&nbsp;4(6)</U>, sale by a Stockholder&#146;s trustee in bankruptcy, or a sale to a purchaser at any creditor&#146;s or court
sale), (x) the transferee (which term, as used herein, shall include any and all transferees and subsequent transferees of the initial transferee) shall take and hold such Shares or New Shares subject to all of the restrictions, Liabilities and
rights under this Agreement, which shall continue in full force and effect, and the transferee shall agree in writing to be bound by the terms and conditions of this Agreement and either the Stockholder or the transferee provides the Company with a
copy of such agreement promptly upon consummation of any such transfer. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Representations and Warranties of Stockholder</U>. Stockholder hereby represents and warrants to Parent and
the Company as follows: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If Stockholder is an Entity: (i)&nbsp;Stockholder is duly organized, validly existing and in good standing
under the laws of the jurisdiction in which it is incorporated, organized or constituted, (ii)&nbsp;Stockholder has all necessary power and authority to execute and deliver this Agreement, to perform Stockholder&#146;s obligations hereunder
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">E-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
and to consummate the transactions contemplated hereby, and (iii)&nbsp;the execution and delivery of this Agreement, performance of Stockholder&#146;s obligations hereunder and the consummation
of the transactions contemplated hereby by Stockholder have been duly authorized by all necessary action on the part of Stockholder and no other proceedings on the part of Stockholder are necessary to authorize this Agreement, or to consummate the
transactions contemplated hereby. If Stockholder is an individual, Stockholder has the legal capacity to execute and deliver this Agreement, to perform Stockholder&#146;s obligations hereunder and to consummate the transactions contemplated hereby;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">this Agreement has been duly executed and delivered by or on behalf of Stockholder and, assuming this Agreement
constitutes a valid and binding agreement of the Company and Parent, constitutes a valid and binding agreement with respect to Stockholder, enforceable against Stockholder in accordance with its terms, except as enforcement may be limited by general
principles of equity whether applied in a court of Law or a court of equity and by bankruptcy, insolvency and similar Laws affecting creditors&#146; rights and remedies generally; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Stockholder beneficially owns the number of Shares indicated opposite Stockholder&#146;s name on <U>Schedule
1</U>, and will own any New Shares, free and clear of any liens, claims, charges or other encumbrances or restrictions of any kind whatsoever (&#147;<B><I>Liens</I></B>&#148;), and has sole or shared, and otherwise unrestricted, voting power with
respect to such Shares or New Shares and none of the Shares or New Shares is subject to any voting trust or other agreement, arrangement or restriction with respect to the voting of the Shares or the New Shares, except as contemplated by this
Agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the execution and delivery of this Agreement by Stockholder does not, and the performance by Stockholder of
his, her or its obligations hereunder and the compliance by Stockholder with any provisions hereof will not, violate or conflict with, result in a material breach of or constitute a default (or an event that with notice or lapse of time or both
would become a material default) under, or give to others any rights of termination, amendment, acceleration or cancellation of, or result in the creation of any Liens on any Shares or New Shares pursuant to, any agreement, instrument, note, bond,
mortgage, Contract, lease, license, permit or other obligation or any order, arbitration award, judgment or decree to which Stockholder is a party or by which Stockholder is bound, or any Law, statute, rule or regulation to which Stockholder is
subject or, in the event that Stockholder is a corporation, partnership, trust or other Entity, any bylaw or other Organizational Document of Stockholder; except for any of the foregoing as would not reasonably be expected to prevent or delay the
performance by Stockholder of his, her or its obligations under this Agreement in any material respect; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the execution and delivery of this Agreement by Stockholder does not, and the performance of this Agreement by
Stockholder does not and will not, require any consent, approval, authorization or permit of, or filing with or notification to, any Governmental Body or regulatory authority by Stockholder except for applicable requirements, if any, of the Exchange
Act, and except where the failure to obtain such consents, approvals, authorizations or permits, or to make such filings or notifications, would not prevent or delay the performance by Stockholder of his, her or its obligations under this Agreement
in any material respect; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">no investment banker, broker, finder or other intermediary is entitled to a fee or commission from Parent or
the Company in respect of this Agreement based upon any Contract made by or on behalf of Stockholder; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">as of the date of this Agreement, there is no Legal Proceeding pending or, to the knowledge of Stockholder,
threatened against Stockholder that would reasonably be expected to prevent or delay the performance by Stockholder of his, her or its obligations under this Agreement in any material respect. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Irrevocable Proxy</U>. Subject to the final sentence of this <U>Section</U><U></U><U>&nbsp;6</U>, by
execution of this Agreement, Stockholder does hereby appoint the Company and any of its designees with full power of substitution and resubstitution, as Stockholder&#146;s true and lawful attorney and irrevocable proxy, to the fullest extent of
Stockholder&#146;s rights with respect to the Shares or New Shares, to vote and exercise all voting and related rights, including the right to sign Stockholder&#146;s name (solely in its capacity as a stockholder) to any stockholder consent, if
Stockholder is unable to perform or otherwise does not perform his, her or its obligations under this Agreement, with respect to such </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">E-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Shares solely with respect to the matters set forth in <U>Section</U><U></U><U>&nbsp;1</U> hereof. Stockholder intends this proxy to be irrevocable and coupled with an interest hereunder until
the Expiration Date, hereby revokes any proxy previously granted by Stockholder with respect to the Shares or New Shares and represents that none of such previously-granted proxies are irrevocable. The irrevocably proxy and power of attorney granted
herein shall survive the death or incapacity of Stockholder and the obligations of Stockholder shall be binding on Stockholder&#146;s heirs, personal representatives, successors, transferees and assigns. Stockholder hereby agrees not to grant any
subsequent powers of attorney or proxies with respect to any Shares or New Shares with respect to the matters set forth in <U>Section</U><U></U><U>&nbsp;1</U> until after the Expiration Date. The Stockholder hereby affirms that the proxy set forth
in this Section&nbsp;6 is given in connection with and granted in consideration of and as an inducement to the Company, Parent, First Merger Sub and Second Merger Sub to enter into the Merger Agreement and that such proxy is given to secure the
obligations of the Stockholder under Section&nbsp;1. Notwithstanding anything contained herein to the contrary, this irrevocable proxy shall automatically terminate upon the Expiration Date. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Other Remedies; Specific Performance</U>. Except as otherwise provided herein, any and all remedies herein
expressly conferred upon a party will be deemed cumulative with, and not exclusive of, any other remedy conferred hereby, or by Law or equity upon such party, and the exercise by a party of any one remedy will not preclude the exercise of any other
remedy. The parties hereto agree that irreparable damage would occur in the event that any of the provisions of this Agreement were not performed in accordance with their specific terms or were otherwise breached. It is accordingly agreed that the
parties shall be entitled to an injunction or injunctions to prevent breaches of this Agreement and to enforce specifically the terms and provisions hereof without the need of posting bond in any court of the United States or any state having
jurisdiction, this being in addition to any other remedy to which they are entitled at Law or in equity. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Directors and Officers</U>. This Agreement shall apply to Stockholder solely in Stockholder&#146;s capacity
as a stockholder of Parent and/or holder of Parent Options and/or Parent Restricted Stock Units and not in Stockholder&#146;s capacity as a director, officer or employee of Parent or any of its Subsidiaries or in Stockholder&#146;s capacity as a
trustee or fiduciary of any employee benefit plan or trust. Notwithstanding any provision of this Agreement to the contrary, nothing in this Agreement shall (or require Stockholder to attempt to) limit or restrict a director and/or officer of Parent
in the exercise of his or her fiduciary duties as a director and/or officer of Parent or in his or her capacity as a trustee or fiduciary of any employee benefit plan or trust or prevent or be construed to create any obligation on the part of any
director and/or officer of Parent or any trustee or fiduciary of any employee benefit plan or trust from taking any action in his or her capacity as such director, officer, trustee and/or fiduciary. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>No Ownership Interest</U>. Nothing contained in this Agreement shall be deemed to vest in the Company any
direct or indirect ownership or incidence of ownership of or with respect to any Shares or New Shares. All rights, ownership and economic benefits of and relating to the Shares or New Shares shall remain vested in and belong to Stockholder, and the
Company does not have authority to manage, direct, superintend, restrict, regulate, govern, or administer any of the policies or operations of Parent or exercise any power or authority to direct Stockholder in the voting of any of the Shares or New
Shares, except as otherwise provided herein. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">10)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Termination</U>. This Agreement shall terminate and shall have no further force or effect as of the
Expiration Date. Notwithstanding the foregoing, upon termination or expiration of this Agreement, no party shall have any further obligations or liabilities under this Agreement; <I><U>provided</U></I>, <I><U>however</U></I>, nothing set forth in
this <U>Section</U><U></U><U>&nbsp;10</U> or elsewhere in this Agreement shall relieve any party from liability for any fraud or for any willful and material breach of this Agreement prior to termination hereof. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">11)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Further Assurances</U>. Stockholder shall, from time to time, execute and deliver, or cause to be executed
and delivered, such additional or further consents, documents and other instruments as the Company or Parent may reasonably request for the purpose of effectively carrying out the transactions contemplated by this Agreement and the Contemplated
Transactions. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">12)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Disclosure</U>. Stockholder hereby agrees that Parent and the Company may publish and disclose in any
registration statement, any prospectus filed with any regulatory authority in connection with the Contemplated Transactions and any related documents filed with such regulatory authority and as otherwise required by Law, Stockholder&#146;s identity
and ownership of Shares and the nature of Stockholder&#146;s commitments, arrangements and understandings </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">E-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
under this Agreement and may further file this Agreement as an exhibit to any registration statement or prospectus or in any other filing made by Parent or the Company as required by Law or the
terms of the Merger Agreement, including with the SEC or other regulatory authority, relating to the Contemplated Transactions, all subject to prior review and an opportunity to comment by Stockholder&#146;s counsel. Prior to the Closing,
Stockholder shall not, and shall use its reasonable best efforts to cause its representatives not to, directly or indirectly, make any press release, public announcement or other public communication that criticizes or disparages this Agreement or
the Merger Agreement or any of the Contemplated Transactions, without the prior written consent of Parent and the Company, <I><U>provided</U></I><U> </U><I><U>that</U></I><I>, </I>the foregoing shall not limit or affect any actions taken by
Stockholder (or any affiliated officer or director of Stockholder) that would be permitted to be taken by Stockholder, Parent or the Company pursuant to the Merger Agreement; <I><U>provided</U></I>, <I><U>further</U></I>, that the foregoing shall
not effect any actions of Stockholder the prohibition of which would be prohibited under applicable Law. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">13)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Notice</U>. All notices and other communications hereunder shall be in writing and shall be deemed given if
delivered personally or sent by overnight courier (providing proof of delivery), by electronic transmission (providing confirmation of transmission) to the Company or Parent, as the case may be, in accordance with Section&nbsp;8.8 of the Merger
Agreement and to Stockholder at his, her or its address or email address (providing confirmation of transmission) set forth on <U>Schedule 1</U> attached hereto (or at such other address for a party as shall be specified by like notice).
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">14)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Severability</U>. Any term or provision of this Agreement that is invalid or unenforceable in any situation
in any jurisdiction shall not affect the validity or enforceability of the remaining terms and provisions of this Agreement or the validity or enforceability of the offending term or provision in any other situation or in any other jurisdiction. If
a final judgment of a court of competent jurisdiction declares that any term or provision of this Agreement is invalid or unenforceable, the parties hereto agree that the court making such determination shall have the power to limit such term or
provision, to delete specific words or phrases or to replace such term or provision with a term or provision that is valid and enforceable and that comes closest to expressing the intention of the invalid or unenforceable term or provision, and this
Agreement shall be valid and enforceable as so modified. In the event such court does not exercise the power granted to it in the prior sentence, the parties hereto agree to replace such invalid or unenforceable term or provision with a valid and
enforceable term or provision that will achieve, to the extent possible, the economic, business and other purposes of such invalid or unenforceable term or provision. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">15)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Assignability</U>. This Agreement shall be binding upon, and shall be enforceable by and inure solely to the
benefit of, the parties hereto and their respective successors and assigns; <I><U>provided</U></I><I>, </I><I><U>however</U></I>, that neither this Agreement nor any of a party&#146;s rights or obligations hereunder may be assigned or delegated by
such party without the prior written consent of the other parties hereto, and any attempted assignment or delegation of this Agreement or any of such rights or obligations by such party without the other party&#146;s prior written consent shall be
void and of no effect. Nothing in this Agreement, express or implied, is intended to or shall confer upon any Person (other than the parties hereto) any right, benefit or remedy of any nature whatsoever under or by reason of this Agreement.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">16)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>No Waivers</U>. No waivers of any breach of this Agreement extended by the Company or Parent to Stockholder
shall be construed as a waiver of any rights or remedies of the Company or Parent, as applicable, with respect to any other stockholder of Parent who has executed an agreement substantially in the form of this Agreement with respect to Shares or New
Shares held or subsequently held by such stockholder or with respect to any subsequent breach of Stockholder or any other stockholder of Parent. No waiver of any provisions hereof by any party shall be deemed a waiver of any other provisions hereof
by any such party, nor shall any such waiver be deemed a continuing waiver of any provision hereof by such party. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">17)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Applicable Law; Jurisdiction</U>. This Agreement shall be governed by, and construed in accordance with, the
Laws of the state of Delaware, regardless of the Laws that might otherwise govern under applicable principles of conflicts of Laws. In any action or Legal Proceeding between any of the parties arising out of or relating to this Agreement, each of
the parties: (i)&nbsp;irrevocably and unconditionally consents and submits to the exclusive jurisdiction and venue of the Court of Chancery of the state of Delaware or to the extent such court does not have subject matter jurisdiction, the Superior
Court of the State of Delaware or the United States District Court for the District of Delaware, (ii)&nbsp;agrees that all claims in respect of such action or Legal Proceeding shall be heard and determined exclusively in accordance with clause
(i)&nbsp;of this <U>Section</U><U></U><U>&nbsp;17,</U> (iii) waives any objection to laying venue </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">E-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
in any such action or Legal Proceeding in such courts, (iv)&nbsp;waives any objection that such courts are an inconvenient forum or do not have jurisdiction over any party, and (v)&nbsp;agrees
that service of process upon such party in any such action or Legal Proceeding shall be effective if notice is given in accordance with <U>Section</U><U></U><U>&nbsp;13</U> of this Agreement. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">18)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Waiver of Jury Trial</U>. THE PARTIES HERETO HEREBY WAIVE ANY RIGHT TO TRIAL BY JURY WITH RESPECT TO ANY
ACTION OR LEGAL PROCEEDING RELATED TO OR ARISING OUT OF THIS AGREEMENT, ANY DOCUMENT EXECUTED IN CONNECTION HEREWITH AND THE MATTERS CONTEMPLATED HEREBY AND THEREBY. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">19)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>No Agreement Until Executed</U>. Irrespective of negotiations among the parties or the exchanging of drafts
of this Agreement, this Agreement shall not constitute or be deemed to evidence a Contract, agreement, arrangement or understanding between the parties hereto unless and until (a)&nbsp;the Parent Board has approved, for purposes of any applicable
anti-takeover Laws and regulations and any applicable provision of the certificate of incorporation of Parent, the Merger Agreement and the Contemplated Transactions, (b)&nbsp;the Merger Agreement is executed by all parties thereto, and
(c)&nbsp;this Agreement is executed by all parties hereto. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">20)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Entire Agreement; Counterparts; Exchanges by Electronic Transmission</U>. This Agreement and the other
agreements referred to in this Agreement constitute the entire agreement and supersede all prior agreements and understandings, both written and oral, among or between any of the parties with respect to the subject matter hereof and thereof. This
Agreement may be executed in several counterparts, each of which shall be deemed an original and all of which shall constitute one and the same instrument. The exchange of a fully executed Agreement (in counterparts or otherwise) by all parties by
electronic transmission via &#147;.pdf&#148; shall be sufficient to bind the parties to the terms and conditions of this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">21)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Amendment</U>. This Agreement may not be amended, supplemented or modified, and no provisions hereof may be
modified or waived, except by an instrument in writing signed on behalf of each party hereto; <I><U>provided</U></I>, <I><U>however</U></I>, that the rights or obligations of any Stockholder may be waived, amended or otherwise modified in a writing
signed by Parent (for the avoidance of doubt, with the prior written approval required by Section&nbsp;4.1 of Parent&#146;s Certificate of Designation of Preferences, Rights and Limitations of Series A
<FONT STYLE="white-space:nowrap">Non-Voting</FONT> Convertible Preferred Stock), the Company and Stockholder. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">22)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Fees and Expenses</U>. Except as otherwise specifically provided herein, the Merger Agreement or any other
agreement contemplated by the Merger Agreement to which a party hereto is a party, each party hereto shall bear its own expenses in connection with this Agreement and the transactions contemplated hereby. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">23)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Voluntary Execution of Agreement</U>. This Agreement is executed voluntarily and without any duress or undue
influence on the part or behalf of the parties. Each of the parties hereby acknowledges, represents and warrants that (i)&nbsp;it has read and fully understood this Agreement and the implications and consequences thereof; (ii)&nbsp;it has been
represented in the preparation, negotiation, and execution of this Agreement by legal counsel of its own choice, or it has made a voluntary and informed decision to decline to seek such counsel; and (iii)&nbsp;it is fully aware of the legal and
binding effect of this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">24)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Construction</U>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For purposes of this Agreement, whenever the context requires: the singular number shall include the plural,
and vice versa; the masculine gender shall include the feminine and neuter genders; the feminine gender shall include the masculine and neuter genders; and the neuter gender shall include masculine and feminine genders. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The parties hereto agree that any rule of construction to the effect that ambiguities are to be resolved
against the drafting party shall not be applied in the construction or interpretation of this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As used in this Agreement, the words &#147;include&#148; and &#147;including,&#148; and variations thereof,
shall not be deemed to be terms of limitation, but rather shall be deemed to be followed by the words &#147;without limitation.&#148; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">E-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Except as otherwise indicated, all references in this Agreement to &#147;Sections,&#148; and
&#147;Schedules&#148; are intended to refer to Sections of this Agreement and Schedules to this Agreement, respectively. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The underlined headings contained in this Agreement are for convenience of reference only, shall not be deemed
to be a part of this Agreement and shall not be referred to in connection with the construction or interpretation of this Agreement. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Remainder of Page has Intentionally Been Left Blank</I>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">E-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EXECUTED as of the date first above written. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>[STOCKHOLDER]</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Signature:
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name (if an Entity):</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title (if an Entity):</P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I></I>[<I>Signature Page
to Support Agreement</I>]<I> </I></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EXECUTED as of the date first above written. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>AEGLEA BIOTHERAPEUTICS, INC.</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to
Support Agreement</I>] </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EXECUTED as of the date first above written. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>SPYRE THERAPEUTICS, INC.</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I></I>[<I>Signature Page
to Support Agreement</I>]<I> </I></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Name, Address and Email Address of Stockholder</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Shares&nbsp;of&nbsp;Parent</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Parent&nbsp;Options</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Parent&nbsp;Restricted</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Stock Units</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>3
<FILENAME>d518298dex31.htm
<DESCRIPTION>EX-3.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-3.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 3.1 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AEGLEA BIOTHERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED AND RESTATED CERTIFICATE OF INCORPORATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Aeglea BioTherapeutics, Inc. (the &#147;<B>Corporation</B>&#148;), a corporation organized and existing under and by virtue of the provisions
of the General Corporation Law of the State of Delaware (the &#147;<B>General Corporation Law</B>&#148;), does hereby certify as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. The current name of the Corporation is Aeglea BioTherapeutics, Inc. The Corporation was first formed on December&nbsp;16, 2013 under the
name Aeglea BioTherapeutics Holdings, LLC, a Delaware limited liability company. Aeglea BioTherapeutics Holdings, LLC converted into Aeglea BioTherapeutics, Inc. on March&nbsp;10, 2015. The date of filing of the original Certificate of Incorporation
of Aeglea BioTherapeutics, Inc. with the Secretary of State was March&nbsp;10, 2015 under the name Aeglea BioTherapeutics, Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. The
Amended and Restated Certificate of Incorporation of the Corporation attached hereto as <U>Exhibit &#147;A&#148;</U>, which is incorporated herein by this reference, only restates and integrates and does not further amend (except to change the name
of the Corporation as permitted under Sections 242(a)(1) and 242(d)(1)(A) of the General Corporation Law) the provisions of the Restated Certificate of Incorporation of the Corporation as theretofore amended or supplemented and there is no
discrepancy between those provisions and the provisions of the Amended and Restated Certificate of Incorporation, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. The Amended and
Restated Certificate of Incorporation has been duly adopted by the Board of Directors of the Corporation in accordance with Sections 242 and 245 of the Delaware General Corporation Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. This Amended and Restated Certificate of Incorporation shall become effective on November&nbsp;28, 2023 at 12:01 a.m. Eastern Time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, this Corporation has caused this Amended and Restated Certificate of Incorporation to be signed by a duly
authorized officer of this Corporation on this 27<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> day of&nbsp;November, 2023. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Cameron Turtle</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Cameron Turtle</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT &#147;A&#148; </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPYRE THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED AND RESTATED CERTIFICATE OF INCORPORATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE I: NAME </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The name of the
corporation is Spyre Therapeutics, Inc. (the &#147;<B><I>Corporation</I></B>&#148;). </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE II: AGENT FOR SERVICE OF PROCESS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The address of the Corporation&#146;s registered office in the State of Delaware is 1521 Concord Pike Suite 201, City of Wilmington, County of New Castle,
Delaware 19803. The name of the registered agent of the Corporation at that address is Corporate Creations Network Inc. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE III:
PURPOSE </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The purpose of the Corporation is to engage in any lawful act or activity for which corporations may be organized under the General
Corporation Law of the State of Delaware. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE IV: AUTHORIZED STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.</B><B></B><B><U>&nbsp;Total Authorized</U></B><B>.</B>&nbsp;The total number of shares of all classes of stock that the Corporation has authority to
issue is Four Hundred and Ten Million (410,000,000) shares, consisting of two classes: Four Hundred Million (400,000,000) shares of Common Stock, $0.0001 par value per share (&#147;<B><I>Common Stock</I></B>&#148;), and Ten Million (10,000,000)
shares of Preferred Stock, $0.0001 par value per share (&#147;<B><I>Preferred Stock</I></B>&#148;). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.<U>&nbsp;Designation of Additional
Series.</U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2.1. The Board of Directors of the Corporation (the &#147;<B><I>Board</I></B>&#148;) is authorized, subject to any limitations prescribed
by the law of the State of Delaware, to provide for the issuance of the shares of Preferred Stock in one or more series, and, by filing a Certificate of Designation pursuant to the applicable law of the State of Delaware, to establish from time to
time the number of shares to be included in each such series, to fix the designation, vesting, powers, preferences and relative, participating, optional or other rights, if any, of the shares of each such series and any qualifications, limitations
or restrictions thereof, and to increase (but not above the total number of authorized shares of the class) or decrease (but not below the number of shares of such series then outstanding) the number of shares of any such series. The number of
authorized shares of Preferred Stock may also be increased or decreased (but not below the number of shares thereof then outstanding) by the affirmative vote of the holders <FONT STYLE="white-space:nowrap">of&nbsp;two-thirds&nbsp;of</FONT> the
voting power of all then outstanding shares of capital stock of the Corporation entitled to vote generally in the election of directors, without a vote of the holders of the Preferred Stock, unless a vote of any other holders is required pursuant to
a Certificate or Certificates establishing a series of Preferred Stock;<I><U>&nbsp;provided</U></I>, that <FONT STYLE="white-space:nowrap">if&nbsp;two-thirds&nbsp;of</FONT> the Whole Board has approved such increase or decrease of the number of
authorized shares of Preferred Stock, then only the affirmative vote of the holders of a majority of the voting power of all of the then outstanding shares of the capital stock of the Corporation entitled to vote generally in the election of
directors, voting together as a single class, without a vote of the holders of the Preferred Stock (unless a vote of any other holders is required pursuant to a Certificate or Certificates establishing a series of Preferred Stock), shall be required
to effect such increase or decrease. For purposes of this Certificate of Incorporation, the term &#147;<B><I>Whole Board</I></B>&#148; shall mean the total number of authorized directors whether or not there exist any vacancies in previously
authorized directorships. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2.2 Except as otherwise expressly provided in any Certificate of Designation designating any series of
Preferred Stock pursuant to the foregoing provisions of this Article IV, any new series of Preferred Stock may be designated, fixed and determined as provided herein by the Board without approval of the holders of Common Stock or the holders of
Preferred Stock, or any series thereof, and any such new series may have powers, preferences and rights, including, without limitation, voting rights, dividend rights, liquidation rights, redemption rights and conversion rights, senior to, junior to
or pari passu with the rights of the Common Stock, the Preferred Stock or any future class or series of Preferred Stock or Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2.3 Each
outstanding share of Common Stock shall entitle the holder thereof to one vote on each matter properly submitted to the stockholders of the Corporation for their vote;<I><U>&nbsp;provided</U></I><I>,</I><I></I><I><U>&nbsp;however</U></I>, that,
except as otherwise required by law, holders of Common Stock shall not be entitled to vote on any amendment to this Certificate of Incorporation (including any Certificate of Designation relating to any series of Preferred Stock) that relates solely
to the terms of one or more outstanding series of Preferred Stock if the holders of such affected series are entitled, either separately or together as a class with the holders of one or more other such series, to vote thereon pursuant to this
Certificate of Incorporation (including any Certificate of Designation relating to any series of Preferred Stock). </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE V: AMENDMENT
OF BYLAWS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board shall have the power to adopt, amend or repeal the Bylaws of the Corporation. Any adoption, amendment or repeal of the Bylaws of
the Corporation by the Board shall require the approval of a majority of the Whole Board. For purposes of this Certificate of Incorporation, the term &#147;<B><I>Whole Board</I></B>&#148; shall mean the total number of authorized directors whether
or not there exist any vacancies in previously authorized directorships. The stockholders shall also have power to adopt, amend or repeal the Bylaws of the Corporation;<I><U>&nbsp;provided</U></I>,<I><U>&nbsp;however</U></I>, that in addition to any
vote of the holders of any class or series of stock of the Corporation required by law or by this Certificate of Incorporation (including any Preferred Stock issued pursuant to a Certificate of Designation), the affirmative vote of the holders of at
<FONT STYLE="white-space:nowrap">least&nbsp;two-thirds&nbsp;of</FONT> the voting power of all of the then outstanding shares of the capital stock of the Corporation entitled to vote generally in the election of directors, voting together as a single
class, shall be required to adopt, amend or repeal any provision of the Bylaws;<I><U>&nbsp;provided further</U></I>, that <FONT STYLE="white-space:nowrap">if&nbsp;two-thirds&nbsp;of</FONT> the Whole Board has approved such adoption, amendment or
repeal of any provisions of the Bylaws, then only the affirmative vote of the holders of a majority of the voting power of all of the then-outstanding shares of the capital stock of the Corporation entitled to vote generally in the election of
directors, voting together as a single class, shall be required to adopt, amend or repeal any provision of the Bylaws. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VI:
MATTERS RELATING TO THE BOARD OF DIRECTORS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.</B><B></B><B><U>&nbsp;Director Powers</U></B>. The conduct of the affairs of the Corporation shall
be managed by or under the direction of the Board. In addition to the powers and authority expressly conferred upon them by statute or by this Certificate of Incorporation or the Bylaws of the Corporation, the directors are hereby empowered to
exercise all such powers and do all such acts and things as may be exercised or done by the Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.</B><B></B><B><U>&nbsp;Number of
Directors</U></B>. Subject to the rights of the holders of any series of Preferred Stock to elect additional directors under specified circumstances, the number of directors shall be fixed from time to time exclusively by resolution adopted by a
majority of the Whole Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3.</B><B></B><B><U>&nbsp;Classified Board</U></B>. Subject to the rights of the holders of any series of Preferred Stock
to elect additional directors under specified circumstances, the directors shall be divided, with respect to the time for which they severally hold office, into three classes designated as Class&nbsp;I, Class&nbsp;II and Class&nbsp;III, respectively
(the &#147;<B><I>Classified Board</I></B>&#148;). The Board may assign members of the Board already in office to the Classified Board, which assignments shall become effective at the same time the Classified Board becomes effective. Directors shall
be assigned to each class in accordance with a resolution or resolutions adopted by the Board, with the number of directors in each class to be divided as nearly equal as reasonably possible. The initial term of office of the Class&nbsp;I directors
shall expire at the Corporation&#146;s first annual meeting of stockholders following the closing of the Corporation&#146;s initial public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended,
relating to the offer and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
sale of Common Stock to the public (the &#147;<B><I>Initial Public Offering</I></B>&#148;), the initial term of office of the Class&nbsp;II directors shall expire at the Corporation&#146;s second
annual meeting of stockholders following the closing of the Initial Public Offering and the initial term of office of the Class&nbsp;III directors shall expire at the Corporation&#146;s third annual meeting of stockholders following the closing of
the Initial Public Offering. At each annual meeting of stockholders following the closing of the Initial Public Offering, directors elected to succeed those directors of the class whose terms then expire shall be elected for a term of office to
expire at the third succeeding annual meeting of stockholders after their election. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4.</B><B></B><B><U>&nbsp;Term and Removal</U></B>. Each director
shall hold office until such director&#146;s successor is elected and qualified, or until such director&#146;s earlier death, resignation or removal. Any director may resign at any time upon notice to the Corporation given in writing or by any
electronic transmission permitted in the Corporation&#146;s Bylaws. Subject to the rights of the holders of any series of Preferred Stock, no director may be removed except for cause and only by the affirmative vote of the holders of at <FONT
STYLE="white-space:nowrap">least&nbsp;two-thirds&nbsp;of</FONT> the voting power of the then-outstanding shares of capital stock of the Corporation then entitled to vote at an election of directors voting together as a single class. In the event of
any increase or decrease in the authorized number of directors, (a)&nbsp;each director then serving as such shall nevertheless continue as a director of the class of which he or she is a member and (b)&nbsp;the newly created or eliminated
directorships resulting from such increase or decrease shall be apportioned by the Board among the classes of directors so as to ensure that no one class has more than one director more than any other class. To the extent possible, consistent with
the foregoing rule, any newly created directorships shall be added to those classes whose terms of office are to expire at the latest dates following such allocation, and any newly eliminated directorships shall be subtracted from those classes
whose terms of office are to expire at the earliest dates following such allocation, unless otherwise provided from time to time by resolution adopted by the Board. No decrease in the authorized number of directors shall shorten the term of any
incumbent director. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5.</B><B></B><B><U>&nbsp;Board Vacancies</U></B>. Subject to the rights of the holders of any series of Preferred Stock, any
vacancy occurring in the Board for any cause, and any newly created directorship resulting from any increase in the authorized number of directors, shall, unless (a)&nbsp;the Board determines by resolution that any such vacancies or newly created
directorships shall be filled by the stockholders or (b)&nbsp;as otherwise provided by law, be filled only by the affirmative vote of a majority of the directors then in office, although less than a quorum, or by a sole remaining director, and not
by the stockholders. Any director elected in accordance with the preceding sentence shall hold office for a term expiring at the annual meeting of stockholders at which the term of office of the class to which the director has been assigned expires
or until such director&#146;s successor shall have been duly elected and qualified, or until such director&#146;s earlier death, resignation or removal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6.</B><B></B><B><U>&nbsp;Vote by Ballot</U></B>. Election of directors need not be by written ballot unless the Bylaws of the Corporation shall so provide.
</P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VII: DIRECTOR LIABILITY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.</B><B></B><B><U>&nbsp;Limitation of Liability</U></B>. To the fullest extent permitted by law, no director of the Corporation shall be personally liable
for monetary damages for breach of fiduciary duty as a director. Without limiting the effect of the preceding sentence, if the Delaware General Corporation Law is hereafter amended to authorize the further elimination or limitation of the liability
of a director, then the liability of a director of the Corporation shall be eliminated or limited to the fullest extent permitted by the Delaware General Corporation Law, as so amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.</B><B></B><B><U>&nbsp;Change in Rights</U></B>. Neither any amendment nor repeal of this&nbsp;Article VII, nor the adoption of any provision of this
Certificate of Incorporation inconsistent with this&nbsp;Article VII, shall eliminate, reduce or otherwise adversely affect any limitation on the personal liability of a director of the Corporation existing at the time of such amendment, repeal or
adoption of such an inconsistent provision. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VIII: MATTERS RELATING TO STOCKHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.</B><B></B><B><U>&nbsp;No Action by Written Consent of Stockholders</U></B>. Subject to the rights of any series of Preferred Stock, no action shall be
taken by the stockholders of the Corporation except at a duly called annual or special meeting of stockholders and no action shall be taken by the stockholders by written consent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.</B><B></B><B><U>&nbsp;Special Meeting of Stockholders</U></B><B>.</B><B></B>&nbsp;Special meetings of the stockholders of the Corporation may be called
only by the Chairperson of the Board, the Chief Executive Officer, the President or the Board acting pursuant to a resolution adopted by a majority of the Whole Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3.</B><B></B><B><U>&nbsp;Advance Notice of Stockholder Nominations and Business Transacted at Special Meetings</U></B>. Advance notice of stockholder
nominations for the election of directors of the Corporation and of business to be brought by stockholders before any meeting of stockholders of the Corporation shall be given in the manner provided in the Bylaws of the Corporation. Business
transacted at special meetings of stockholders shall be confined to the purpose or purposes stated in the notice of meeting. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE
IX: CHOICE OF FORUM </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless the Corporation consents in writing to the selection of an alternative forum, the Court of Chancery in the State of
Delaware shall be the sole and exclusive forum for any stockholder (including a beneficial owner) to bring (i)&nbsp;any derivative action or proceeding brought on behalf of the Corporation, (ii)&nbsp;any action asserting a claim of breach of
fiduciary duty owed by, or other wrongdoing by, any director, officer or other employee of the Corporation to the Corporation or the Corporation&#146;s stockholders, (iii)&nbsp;any action asserting a claim against the Corporation, its directors,
officers or employees arising pursuant to any provision of the Delaware General Corporation Law or the Corporation&#146;s certificate of incorporation or bylaws or (iv)&nbsp;any action asserting a claim against the Corporation, its directors,
officers or employees governed by the internal affairs doctrine, except for, as to each of (i)&nbsp;through (iv) above, any claim as to which the Court of Chancery determines that there is an indispensable party not subject to the jurisdiction of
the Court of Chancery (and the indispensable party does not consent to the personal jurisdiction of the Court of Chancery within ten days following such determination), which is vested in the exclusive jurisdiction of a court or forum other than the
Court of Chancery, or for which the Court of Chancery does not have subject matter jurisdiction. If any provision or provisions of this&nbsp;Article IX&nbsp;shall be held to be invalid, illegal or unenforceable as applied to any person or entity or
circumstance for any reason whatsoever, then, to the fullest extent permitted by law, the validity, legality and enforceability of such provisions in any other circumstance and of the remaining provisions of this&nbsp;Article IX&nbsp;(including,
without limitation, each portion of any sentence of this&nbsp;Article IX&nbsp;containing any such provision held to be invalid, illegal or unenforceable that is not itself held to be invalid, illegal or unenforceable) and the application of such
provision to other persons or entities and circumstances shall not in any way be affected or impaired thereby. Any person or entity purchasing or otherwise acquiring any interest in shares of capital stock of the Corporation shall be deemed to have
notice of and to have consented to the provisions of this&nbsp;Article IX. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE X: AMENDMENT OF CERTIFICATE OF INCORPORATION
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If any provision of this Certificate of Incorporation becomes or is declared on any ground by a court of competent jurisdiction to be illegal,
unenforceable or void, portions of such provision, or such provision in its entirety, to the extent necessary, shall be severed from this Certificate of Incorporation, and the court will replace such illegal, void or unenforceable provision of this
Certificate of Incorporation with a valid and enforceable provision that most accurately reflects the Corporation&#146;s intent, in order to achieve, to the maximum extent possible, the same economic, business and other purposes of the illegal, void
or unenforceable provision. The balance of this Certificate of Incorporation shall be enforceable in accordance with its terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Corporation reserves
the right to amend or repeal any provision contained in this Certificate of Incorporation in the manner prescribed by the laws of the State of Delaware and all rights conferred upon stockholders are granted subject to this
reservation;<I><U>&nbsp;provided</U></I>,<I><U>&nbsp;however</U></I>, that, notwithstanding any other provision of this Certificate of Incorporation or any provision of law that might otherwise permit a lesser vote or no vote, but in addition to any
vote of the holders of any class or series of the stock of the Corporation required by law or by this Certificate of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Incorporation, the affirmative vote of the holders of at <FONT STYLE="white-space:nowrap">least&nbsp;two-thirds&nbsp;of</FONT> the voting power of all of the then-outstanding shares of the
capital stock of the Corporation entitled to vote generally in the election of directors, voting together as a single class, shall be required to amend or repeal any provision of this Certificate of Incorporation; provided, further, that <FONT
STYLE="white-space:nowrap">if&nbsp;two-thirds&nbsp;of</FONT> the Whole Board has approved such amendment or repeal of any provisions of this Certificate of Incorporation, then only the affirmative vote of the holders of at least a majority of the
voting power of all of the then-outstanding shares of the capital stock of the Corporation entitled to vote generally in the election of directors, voting together as a single class, shall be required to amend or repeal such provisions of this
Certificate of Incorporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>* * * * * * * * * * * </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.2
<SEQUENCE>4
<FILENAME>d518298dex32.htm
<DESCRIPTION>EX-3.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-3.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 3.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AEGLEA BIOTHERAPEUTICS, INC., </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">a Delaware Corporation </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>AMENDED AND RESTATED BYLAWS </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">As Amended and Restated on December&nbsp;15, 2022 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AEGLEA BIOTHERAPEUTICS, INC., </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">a Delaware Corporation </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>AMENDED AND RESTATED BYLAWS </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">As Amended and Restated on December&nbsp;15, 2022 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE I: STOCKHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Section</U></B><B><U></U></B><B><U>&nbsp;1.1</U></B><B>: </B><B><U>Annual Meetings</U></B><B>.</B> An annual meeting of stockholders shall be held for
the election of directors at such date and time as the Board of Directors of the Corporation (the &#147;<B><I>Board</I></B>&#148;) shall each year fix. The meeting may be held either at a place, within or without the State of Delaware as permitted
by the Delaware General Corporation Law (the &#147;<B><I>DGCL</I></B>&#148;), or by means of remote communication as the Board in its sole discretion may determine. Any proper business may be transacted at the annual meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Section</U></B><B><U></U></B><B><U>&nbsp;1.2</U></B><B>: </B><B><U>Special Meetings</U></B><B>.</B> Special meetings of stockholders for any purpose or
purposes may be called at any time by the Chairperson of the Board, the Chief Executive Officer, the President or the Board acting pursuant to a resolution adopted by a majority of the &#147;<B><I>Whole Board</I></B>,&#148; which shall mean the
total number of authorized directors, whether or not there exist any vacancies in previously authorized directorships. Special meetings may not be called by any other person or persons. The special meeting may be held either at a place, within or
without the State of Delaware, or by means of remote communication as the Board in its sole discretion may determine. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Section</U></B><B><U></U></B><B><U>&nbsp;1.3</U></B><B>: </B><B><U>Notice of Meetings</U></B><B>.</B> Notice of all meetings of stockholders shall be
given in accordance with applicable law (including, without limitation, as set forth in Section&nbsp;7.1 of these Bylaws) stating the date, time and place, if any, of the meeting, the means of remote communications, if any, by which stockholders and
proxyholders may be deemed to be present in person and vote at such meeting and, in the case of a special meeting, the purpose or purposes for which the meeting is called. Unless otherwise required by applicable law or the Certificate of
Incorporation of the Corporation (the &#147;<B><I>Certificate of Incorporation</I></B>&#148;), such notice shall be given not less than ten (10), nor more than sixty (60), days before the date of the meeting to each stockholder of record entitled to
vote at such meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Section</U></B><B><U></U></B><B><U>&nbsp;1.4</U></B><B>: </B><B><U>Adjournments</U></B><B>.</B> The person presiding over the
meeting shall have the power to adjourn the meeting to another time, date and place (if any). Any meeting of stockholders may adjourn from time to time (including an adjournment taken to address a technical failure to convene or continue a meeting
using remote communication), and notice need not be given of any such adjourned meeting if the time, date and place (if any) thereof and the means of remote communications (if any) by which stockholders and proxy holders may be deemed to be present
in person and vote at such adjourned meeting are (i)&nbsp;announced at the meeting at which the adjournment is taken, (ii)&nbsp;displayed, during the time scheduled for the meeting, on the same electronic network used to enable stockholders and
proxy holders to participate in the meeting by means of remote communication or (iii)&nbsp;set forth in the notice of meeting given in accordance with Section&nbsp;222(a) of the DGCL; <I><U>provided</U></I><I>, </I><I><U>however</U></I>, that if the
adjournment is for more than thirty (30)&nbsp;days, or if a new record date is fixed for the adjourned meeting, then a notice of the adjourned meeting shall be given to each stockholder of record entitled to vote at the meeting. At the adjourned
meeting the Corporation may transact any business that might have been transacted at the original meeting. To the fullest extent permitted by law, the Board may postpone or reschedule any previously scheduled special or annual meeting of
stockholders before it is to be held, in which case notice shall be provided to the stockholders of the new date, time and place, if any, of the meeting as provided in Section&nbsp;1.3 above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Section</U></B><B><U></U></B><B><U>&nbsp;1.5</U></B><B>: </B><B><U>Quorum</U></B><B>.</B> At each meeting of stockholders the holders of a majority of
the voting power of the shares of stock entitled to vote at the meeting, present in person or represented by proxy, shall constitute a quorum for the transaction of business, unless otherwise required by applicable law. Where a separate vote by a
class or classes or series is required, a majority of the voting power of the shares of such class or classes or series present in person or represented by proxy shall constitute a quorum entitled to take action with respect to that vote on that
matter. If a quorum shall fail to attend any meeting, the chairperson of the meeting or the holders of a majority of the shares entitled to vote who are present, in person or by proxy, at the meeting may adjourn the meeting. A quorum, once
established at a meeting, shall not be broken by the withdrawal of enough votes to leave less than the quorum. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Section</U></B><B><U></U></B><B><U>&nbsp;1.6</U></B><B>: </B><B><U>Organization</U></B><B>.</B>
Meetings of stockholders shall be presided over by such person as the Board may designate, or, in the absence of such a person, the Chairperson of the Board, or, in the absence of such person, the President of the Corporation, or, in the absence of
such person, such person as may be chosen by the holders of a majority of the voting power of the shares entitled to vote who are present, in person or by proxy, at the meeting. Such person shall be chairperson of the meeting and, subject to
Section&nbsp;1.10 hereof, shall determine the order of business and the procedure at the meeting, including such regulation of the manner of voting and the conduct of discussion as seems to him or her to be in order. The Secretary of the Corporation
shall act as secretary of the meeting, but in such person&#146;s absence the chairperson of the meeting may appoint any person to act as secretary of the meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Section</U></B><B><U></U></B><B><U>&nbsp;1.7</U></B><B>: </B><B><U>Voting; Proxies</U></B><B>.</B> Each stockholder entitled to vote at a meeting of
stockholders may authorize another person or persons to act for such stockholder by proxy. Such a proxy may be prepared, transmitted and delivered in any manner permitted by applicable law. Except as may be required in the Certificate of
Incorporation, directors shall be elected by a plurality of the votes cast. Unless otherwise provided by applicable law, the rules of any stock exchange upon which the Corporation&#146;s securities are listed, the Certificate of Incorporation or
these Bylaws, every matter other than the election of directors shall be decided by a majority of the affirmative votes cast for or against the matter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any stockholder directly or indirectly soliciting proxies from other stockholders must use a proxy card color other than white, which shall be
reserved for exclusive use by the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Section</U></B><B><U></U></B><B><U>&nbsp;1.8</U></B><B>: </B><B><U>Fixing Date for Determination of
Stockholders of Record</U></B><B>.</B> In order that the Corporation may determine the stockholders entitled to notice of or to vote at any meeting of stockholders or entitled to receive payment of any dividend or other distribution or allotment of
any rights, or entitled to exercise any rights in respect of any change, conversion or exchange of stock or for the purpose of any other lawful action, unless otherwise required by law, the Board may fix, in advance, a record date, which shall not
precede the date upon which the resolution fixing the record date is adopted by the Board and which shall not be more than sixty (60), nor less than ten (10), days before the date of such meeting, nor more than sixty (60)&nbsp;days prior to any
other action. If no record date is fixed by the Board, then the record date shall be as provided by applicable law. To the fullest extent permitted by law, a determination of stockholders of record entitled to notice of or to vote at a meeting of
stockholders shall apply to any adjournment of the meeting; <I><U>provided</U></I><I>, </I><I><U>however</U></I>, that the Board may fix a new record date for the adjourned meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Section</U></B><B><U></U></B><B><U>&nbsp;1.9</U></B><B>: </B><B><U>List of Stockholders Entitled to Vote</U></B><B>.</B> The Corporation shall prepare,
no later than the tenth (10th) day before each meeting of stockholders, a complete list of stockholders entitled to vote at the meeting (<I><U>provided</U></I>, <I><U>however</U></I>, if the record date for determining the stockholders entitled to
vote is less than ten (10)&nbsp;days before the date of the meeting, the list shall reflect the stockholders entitled to vote as of the tenth (10th) day before the meeting date), arranged in alphabetical order and showing the address of each
stockholder and the number of shares registered in the name of each stockholder. Nothing in this Section&nbsp;1.9 shall require the Corporation to include electronic mail addresses or other electronic contact information on such list. Such list
shall be open to the examination of any stockholder, for any purpose germane to the meeting, during ordinary business hours, for a period of ten (10)&nbsp;days ending on the day before the meeting date, either on a reasonably accessible electronic
network as permitted by law (provided that the information required to gain access to the list is provided with the notice of the meeting) or during ordinary business hours at the principal place of business of the Corporation
(<I><U>provided</U></I>, <I><U>however</U></I>, if the record date for determining the stockholders entitled to vote is less than ten (10)&nbsp;days before the date of the meeting, the list shall reflect the stockholders entitled to vote as of the
tenth (10th) day before the meeting date), arranged in alphabetical order and showing the address of each stockholder and the number of shares registered in the name of each stockholder. In the event that the Corporation determines to make the list
available on an electronic network, the Corporation may take reasonable steps to ensure that such information is available only to stockholders of the Corporation. Except as otherwise provided by law, the stock ledger shall be the only evidence as
to who are the stockholders entitled to examine the list of stockholders required by this Section&nbsp;1.9 or to vote in person or by proxy at any meeting of stockholders. Notwithstanding the foregoing, the Corporation may maintain and authorize
examination of the list of stockholders in any manner expressly permitted by the DGCL at the time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Section</U><U></U><U>&nbsp;1.10</U>: <U>Inspectors of Elections</U>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.10.1 <U>Applicability</U>. Unless otherwise required by the Certificate of Incorporation or by the DGCL, the following provisions of this Section&nbsp;1.10
shall apply only if and when the Corporation has a class of voting stock that is: (a)&nbsp;listed on a national securities exchange; (b)&nbsp;authorized for quotation on an interdealer quotation system of a registered national securities
association; or (c)&nbsp;held of record by more than two thousand (2,000) stockholders. In all other cases, observance of the provisions of this Section&nbsp;1.10 shall be optional, and at the discretion of the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.10.2 <U>Appointment</U>. The Corporation shall, in advance of any meeting of stockholders, appoint one or more inspectors of election to act at the meeting
and make a written report thereof. The Corporation may designate one or more persons as alternate inspectors to replace any inspector who fails to act. If no inspector or alternate is able to act at a meeting of stockholders, the person presiding at
the meeting shall appoint one or more inspectors to act at the meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.10.3 <U>Inspector&#146;s Oath</U>. Each inspector of election, before entering
upon the discharge of his duties, shall take and sign an oath faithfully to execute the duties of inspector with strict impartiality and according to the best of such inspector&#146;s ability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.10.4 <U>Duties of Inspectors</U>. At a meeting of stockholders, the inspectors of election shall (a)&nbsp;ascertain the number of shares outstanding and the
voting power of each share, (b)&nbsp;determine the shares represented at a meeting and the validity of proxies and ballots, (c)&nbsp;count all votes and ballots, (d)&nbsp;determine and retain for a reasonable period of time a record of the
disposition of any challenges made to any determination by the inspectors, and (e)&nbsp;certify their determination of the number of shares represented at the meeting, and their count of all votes and ballots. The inspectors may appoint or retain
other persons or entities to assist the inspectors in the performance of the duties of the inspectors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.10.5 <U>Opening and Closing of Polls</U>. The
date and time of the opening and the closing of the polls for each matter upon which the stockholders will vote at a meeting shall be announced at the meeting. No ballot, proxies or votes, nor any revocations thereof or changes thereto, shall be
accepted by the inspectors after the closing of the polls unless the Court of Chancery of the State of Delaware upon application by a stockholder shall determine otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.10.6 <U>Determinations</U>. In determining the validity and counting of proxies and ballots, the inspectors shall be limited to an examination of the
proxies, any envelopes submitted with those proxies, any information pursuant to Section&nbsp;211(a)(2)(b)(i) or (iii)&nbsp;of the DGCL, or Sections 211(e) or 212(c)(2) of the DGCL, ballots and the regular books and records of the Corporation,
except that the inspectors may consider other reliable information for the limited purpose of reconciling proxies and ballots submitted by or on behalf of banks, brokers, their nominees or similar persons which represent more votes than the holder
of a proxy is authorized by the record owner to cast or more votes than the stockholder holds of record. If the inspectors consider other reliable information for the limited purpose permitted herein, the inspectors at the time they make their
certification of their determinations pursuant to this Section&nbsp;1.10 shall specify the precise information considered by them, including the person or persons from whom they obtained the information, when the information was obtained, the means
by which the information was obtained and the basis for the inspectors&#146; belief that such information is accurate and reliable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Section</U></B><B><U></U></B><B><U>&nbsp;1.11</U></B><B>: </B><B><U>Conduct of Meetings</U></B><B>.</B> The Board may adopt by resolution such rules and
regulations for the conduct of the meeting of stockholders as it shall deem appropriate. Except to the extent inconsistent with such rules and regulations as adopted by the Board, the person presiding over any meeting of stockholders shall have the
right and authority to convene and (for any or no reason) to recess and/or adjourn the meeting, to prescribe such rules, regulations and procedures and to do all such acts as, in the judgment of such presiding person, are appropriate for the proper
conduct of the meeting. Such rules, regulations or procedures, whether adopted by the Board or prescribed by the presiding person of the meeting, may include, without limitation, the following: (a)&nbsp;the establishment of an agenda or order of
business for the meeting, (b)&nbsp;rules and procedures for maintaining order at the meeting and the safety of those present, (c)&nbsp;limitations on attendance at or participation in the meeting to stockholders entitled to vote at the meeting,
their duly authorized and constituted proxies or such other persons as </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the presiding person of the meeting or the Board shall determine, (d)&nbsp;restrictions on entry to the meeting after the time fixed for the commencement thereof, (e)&nbsp;limitations on the time
allotted to questions or comments by participants, (f)&nbsp;restricting the use of audio/video recording devices and cell phones, (g)&nbsp;complying with any state and local laws and regulations concerning safety and security, (h)&nbsp;procedures
(if any) requiring attendees to provide the Corporation advance notice of their intent to attend the meeting; and (i)&nbsp;any additional attendance or other procedures or requirements for proponents submitting a proposal pursuant to Rule <FONT
STYLE="white-space:nowrap">14a-8</FONT> promulgated under the Exchange Act (defined below).The presiding person at any meeting of stockholders, in addition to making any other determinations that may be appropriate to the conduct of the meeting,
shall, if the facts warrant, determine and declare to the meeting that a matter or business was not properly brought before the meeting and if such presiding person should so determine, such presiding person shall so declare to the meeting and any
such matter or business not properly brought before the meeting shall not be transacted or considered. Unless and to the extent determined by the Board or the person presiding over the meeting, meetings of stockholders shall not be required to be
held in accordance with the rules of parliamentary procedure.<B><U> </U></B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Section</U><U></U><U>&nbsp;1.12</U>: <U>Notice of Stockholder
Business; Nominations</U>. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.12.1 <U>Annual Meeting of Stockholders</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)Nominations of persons for election to the Board and the proposal of business to be considered by the stockholders shall be made at an
annual meeting of stockholders (i)&nbsp;pursuant to the Corporation&#146;s notice of such meeting, (ii)&nbsp;by or at the direction of the Board or (iii)&nbsp;by any stockholder of the Corporation who was a stockholder of record at the time of
giving of the notice provided for in this Section&nbsp;1.12 (the &#147;<B><I>Record Stockholder</I></B>&#148;), who is entitled to vote at such meeting and who complies with the notice procedures set forth in this Section&nbsp;1.12. For the
avoidance of doubt, the foregoing clause (iii)&nbsp;shall be the exclusive means for a stockholder to make nominations or propose business (other than business included in the Corporation&#146;s proxy materials pursuant to Rule <FONT
STYLE="white-space:nowrap">14a-8</FONT> under the Securities Exchange Act of 1934, as amended (such act, and the rules and regulations promulgated thereunder, the &#147;<B><I>Exchange Act</I></B>&#148;)), at an annual meeting of stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)For nominations or other business to be properly brought before an annual meeting by a Record Stockholder pursuant to
Section&nbsp;1.12.1(a): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) the Record Stockholder must have given timely notice thereof in writing to the Secretary of the Corporation
and provide any updates or supplements to such notice at the time and in the forms required by this Section&nbsp;1.12; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) such other
business must otherwise be a proper matter for stockholder action; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;(A) if the Proposing Person (as defined below) has provided
the Corporation with a Solicitation Notice, as that term is defined in this Section, in the case of a proposal other than the nomination of persons for election to the Board, such Proposing Person must have delivered a proxy statement and form of
proxy to holders of at least the percentage of the Corporation&#146;s voting shares required under applicable law to carry any such proposal and must have included in such materials the Solicitation Notice, or (B)&nbsp;if the Proposing Person has
delivered a notice of nomination or nominations, such Proposing Person must certify to the Corporation in writing, that it has complied with and will comply with the requirements of Rule <FONT STYLE="white-space:nowrap">14a-19</FONT> promulgated
under the Exchange Act (as such rule and regulations may be amended from time to time by the Securities and Exchange Commission, including any Securities and Exchange Commission Staff interpretations relating thereto) (&#147;<B><I>Rule <FONT
STYLE="white-space:nowrap">14a-19</FONT></I></B>&#148;), if applicable, and the Proposing Person shall deliver, no later than five (5)&nbsp;business days prior to the annual meeting or any adjournment, rescheduling, postponement or other delay
thereof, reasonable evidence that it has complied with such requirements; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iv) in the case of a proposal other than the nomination of
persons for election to the Board, if no Solicitation Notice relating thereto has been timely provided pursuant to this Section, the Proposing Person proposing such business must not have solicited a number of proxies sufficient to have required the
delivery of such a Solicitation Notice under this Section. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">To be timely, (i)&nbsp;a Record Stockholder&#146;s notice must be delivered to the Secretary
at the principal executive offices of the Corporation not later than the close of business on the seventy-fifth (75th) day nor earlier than the close of business on the one hundred and fifth (105th) day prior to the first anniversary of the
preceding year&#146;s annual meeting; <I><U>provided</U></I><I>, </I><I><U>however</U></I>, that in the event that the date of the annual meeting is more than thirty (30)&nbsp;days before or more than sixty (60)&nbsp;days after such anniversary
date, or if no annual meeting was held in the preceding year, notice by the Record Stockholder to be timely must be so delivered (A)&nbsp;no earlier than the close of business on the one hundred and fifth (105th) day prior to currently proposed
annual meeting and (B)&nbsp;no later than the close of business on the later of the seventy-fifth (75th) day prior to such annual meeting or the close of business on the tenth (10th) day following the day on which Public Announcement (as defined
below) of the date of such meeting is first made by the Corporation, (ii)&nbsp;in the case of a proposal for the nomination of persons for election to the Board, the Record Stockholder shall have complied in all respects with the requirements of
Section&nbsp;14 of the Exchange Act, including, without limitation, if applicable, the requirements of Rule <FONT STYLE="white-space:nowrap">14a-19</FONT> and (iii)&nbsp;in the case of a proposal for the nomination of persons for election to the
Board, the Board or an executive officer designated thereby shall have determined that the Record Stockholder has satisfied the requirements of this Section&nbsp;1.12. In no event shall an adjournment, postponement or rescheduling (or the Public
Announcement thereof) of an annual meeting for which notice has been given or a Public Announcement of the meeting date has been made commence a new time period (or extend any time period) for providing the stockholder&#146;s notice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Such Record Stockholder&#146;s notice shall set forth: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(x) as to each person whom the Record Stockholder proposes to nominate for election or reelection as a director, all information relating to
such person that would be required to be disclosed in solicitations of proxies for election of directors, or would be otherwise required, in each case pursuant to Regulation 14A under the Exchange Act, including such person&#146;s written consent to
being named as a nominee in any proxy materials relating to the Corporation&#146;s next meeting, to the public disclosure of information regarding or related to such person provided to the Corporation by such person or otherwise pursuant to this
Section&nbsp;1.12 and to serving as a director if elected (<I><U>provided</U></I>, that the Corporation may require any proposed nominee to furnish such other information as it may reasonably require to determine the eligibility of such proposed
nominee to serve as a director of the Corporation and to determine the independence of such director under the Exchange Act and rules and regulations thereunder and applicable stock exchange rules); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(y) as to any other business that the Record Stockholder proposes to bring before the meeting, a brief description of the business desired to
be brought before the meeting, the reasons for conducting such business at the meeting and any material interest in such business of such Proposing Person; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(z) as to each Proposing Person giving the notice (aa) the name and address of such Proposing Person, as they appear on the Corporation&#146;s
books, (bb)&nbsp;(i) the class and number of shares of the Corporation that are owned beneficially and held of record by such Proposing Person and (ii)&nbsp;a certification regarding whether such Proposing Person has complied with all applicable
federal, state and other legal requirements in connection with such Proposing Person&#146;s acquisition of shares of capital stock or other securities of the Corporation and/or such Proposing Person&#146;s acts or omissions as a stockholder of the
Corporation, (cc)&nbsp;a description of any agreement, arrangement or understanding with respect to the nomination or proposal between or among such Proposing Person, any of its affiliates or associates, and any others Acting in Concert (as defined
below) with any of the foregoing, (dd) a description of any agreement, arrangement or understanding (including any derivative or short positions, profit interests, options, warrants, stock appreciation or similar rights, hedging transactions, and
borrowed or loaned shares) that has been entered into as of the date of the stockholder&#146;s notice by, or on behalf of, such Proposing Persons, the effect or intent of which is to mitigate loss to, manage risk or benefit of share price changes
for, or increase or decrease the voting power of, such Proposing Person, with respect to shares of stock of the Corporation, (ee) a representation that the Proposing Person is a holder of record of stock of the Corporation entitled to vote at such
meeting and intends to appear in person (including virtually in the case of a meeting conducted solely by means of remote communication) or by proxy at the meeting to propose such business or nomination, (ff) any other information relating to such
Proposing Person that would be required to be disclosed in proxy materials or other filings required to be made in connection with solicitations of proxies or consents by such Proposing Person in support of the business or nomination proposed to be
brought before the meeting pursuant to Section&nbsp;14(a) (or any successor provision) under the Exchange Act and the rules and regulations thereunder, (gg) in the case of a proposal other than the nomination of persons for election to the Board,
whether such Proposing Person intends to deliver a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
proxy statement and form of proxy to holders of at least the percentage of the Corporation&#146;s voting shares required under applicable law to carry the proposal (an affirmative statement of
such intent being a &#147;<B><I>Solicitation Notice</I></B>&#148;) and (hh) in the case of a nomination or nominations of persons for election to the Board, a representation that such Proposing Person intends to solicit the holders of shares
representing at least 67% of the voting power of the shares entitled to vote on the election of directors in support of director nominees other than the Corporation&#146;s nominees in accordance with Rule
<FONT STYLE="white-space:nowrap">14a-19,</FONT> and the name of each participant (as defined in Item 4 of Exchange Act Schedule 14A) in such solicitation. If requested by the Corporation, the information required under clauses (bb), (cc) and (dd) of
this subparagraph (z)&nbsp;shall be supplemented by such Record Stockholder not later than 10 days after the record date for the meeting to disclose such information as of the record date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)Notwithstanding anything in the second sentence of Section&nbsp;1.12.1(b) to the contrary, in the event that the number of directors to be
elected to the Board is increased and there is no Public Announcement by the Corporation naming all of the nominees for director or specifying the size of the increased Board at least seventy five (75)&nbsp;days prior to the first anniversary of the
preceding year&#146;s annual meeting (or, if the annual meeting is held more than thirty (30)&nbsp;days before or sixty (60)&nbsp;days after such anniversary date, at least seventy five (75)&nbsp;days prior to such annual meeting), a
stockholder&#146;s notice required by this Section&nbsp;1.12 shall also be considered timely, but only with respect to nominees for any new positions created by such increase, if it shall be delivered to the Secretary of the Corporation at the
principal executive office of the Corporation no later than the close of business on the tenth (10th) day following the day on which such Public Announcement is first made by the Corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) A Record Stockholder providing written notice required by this Section&nbsp;1.12 shall update such notice, and any other information
provided to the Corporation, in writing, so that the information provided or required to be provided in such notice is true and correct in all material respects as of (i)&nbsp;the record date for determining the stockholders entitled to notice of
the meeting and (ii)&nbsp;the close of business on the tenth (10th) business day prior to the meeting or any adjournment, postponement or rescheduling thereof. In the case of an update pursuant to clause (i)&nbsp;of the foregoing sentence, such
update shall be received by the Secretary of the Corporation at the principal executive office of the Corporation not later than five (5)&nbsp;business days after the record date for determining the stockholders entitled to notice of the meeting,
and in the case of an update and supplement pursuant to clause (ii)&nbsp;of the foregoing sentence, such update and supplement shall be received by the Secretary of the Corporation at the principal executive office of the Corporation not later than
eight (8)&nbsp;business days prior to the date for the meeting and, if practicable, any adjournment, postponement or rescheduling thereof (and, if not practicable, on the first practicable date prior to the date to which the meeting has been
adjourned, postponed or rescheduled). Notwithstanding the foregoing, if a Proposing Person no longer plans to solicit proxies in accordance with its representation pursuant to clause (hh) of subparagraph (z)&nbsp;above, the Record Stockholder shall
inform the Corporation of this change by delivering a writing to the Secretary at the principal executive offices of the Corporation no later than two (2)&nbsp;business days after the occurrence of such change. A Record Stockholder shall also update
its notice so that the information required by clause (gg) of subparagraph (z)&nbsp;above is current through the date of the meeting or any adjournment, postponement, or rescheduling thereof, and such update shall be delivered in writing to the
Secretary at the principal executive offices of the Corporation no later than two (2)&nbsp;business days after the occurrence of any material change to the information previously disclosed pursuant to clause (gg) of subparagraph (z)&nbsp;above. For
the avoidance of doubt, the obligation to update as set forth in this paragraph shall not limit the Corporation&#146;s rights with respect to any deficiencies in any notice provided by a Record Stockholder, extend any applicable deadlines hereunder
or enable or be deemed to permit a stockholder who has previously submitted notice hereunder to amend or update any proposal or nomination or to submit any new proposal, including by changing or adding nominees, matters, business and/or resolutions
proposed to be brought before a meeting of the stockholders. If a Record Stockholder providing written notice required by this Section&nbsp;1.12 fails to provide any written update in accordance with this Section&nbsp;1.12, the information as to
which such written update relates may be deemed not to have been provided in accordance with these Bylaws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) If any information
submitted pursuant to this Section&nbsp;1.12 is inaccurate or incomplete in any material respect (as determined by the Board or a committee thereof), such information shall be deemed not to have been provided in accordance with these Bylaws. A
Record Stockholder shall notify the Secretary in writing at the principal executive offices of the Corporation of any inaccuracy or change in any information submitted within two (2)&nbsp;business days after becoming aware of such inaccuracy or
change, and any such notification shall clearly identify the inaccuracy or change, it being understood that no such notification will cure any deficiencies or inaccuracies with respect to any prior submission by such Record Stockholder. Upon written
request of the Secretary on behalf of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Board (or a duly authorized committee thereof), the Record Stockholder shall provide, within seven (7)&nbsp;business days after delivery of such request (or such longer period as may be
specified in such request), (1) written verification, reasonably satisfactory to the Board, any committee thereof, or any authorized officer of the Corporation, to demonstrate the accuracy of any information submitted and (2)&nbsp;a written
affirmation of any information submitted as of an earlier date. If the Record Stockholder fails to provide such written verification or affirmation within such period, the information as to which written verification or affirmation was requested may
be deemed not to have been provided in accordance with these Bylaws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.12.2 <U>Submission of Questionnaire, Representation and Agreement</U>. To be
eligible to be a nominee of any stockholder for election or reelection as a director of the Corporation, the person proposed to be nominated must deliver (in accordance with the time periods prescribed for delivery of notice under Section&nbsp;1.12
of these Bylaws) to the Secretary of the Corporation at the principal executive offices of the Corporation all completed and signed questionnaires in the forms required by the Corporation (which form the stockholder shall request in writing from the
Secretary of the Corporation and which the Secretary of the Corporation shall provide to such stockholder within ten (10)&nbsp;days of receiving such request) with respect to the background and qualification of such person to serve as a director of
the Corporation and the background of any other person or entity on whose behalf, directly or indirectly, the nomination is being made and a signed representation and agreement (in the form available from the Secretary of the Corporation upon
written request) that such person: (a)&nbsp;is not and will not become a party to (i)&nbsp;any agreement, arrangement or understanding with, and has not given any commitment or assurance to, any person or entity as to how such person, if elected as
a director of the Corporation, will act or vote on any issue or question (a &#147;<B><I>Voting Commitment</I></B>&#148;) that has not been disclosed to the Corporation or (ii)&nbsp;any Voting Commitment that could limit or interfere with such
person&#146;s ability to comply, if elected as a director of the Corporation, with such person&#146;s fiduciary duties under applicable law, (b)&nbsp;is not and will not become a party to any Compensation Arrangement (as defined below) that has not
been disclosed therein, (c)&nbsp;if elected as a director of the Corporation, will comply with all informational and similar requirements of applicable insurance policies and laws and regulations in connection with service or action as a director of
the Corporation, (d)&nbsp;if elected as a director of the Corporation, will comply with all corporate governance, conflict of interest, stock ownership requirements, confidentiality and trading policies and guidelines of the Corporation publicly
disclosed from time to time, (e)&nbsp;if elected as a director of the Corporation, will act in the best interests of the Corporation and its stockholders and not in the interests of individual constituencies, (f)&nbsp;consents to being named as a
nominee in any proxy materials relating to the Corporation&#146;s next meeting and agrees to serve if elected as a director, (g)&nbsp;intends to serve as a director for the full term for which such individual is to stand for election,
(h)&nbsp;represents and warrants that his or her candidacy or, if elected, Board membership, would not violate applicable state or federal law, the Certificate of Incorporation, these Bylaws, or the rules of any stock exchange on which shares of the
Corporation&#146;s common stock are traded, and (i)&nbsp;will provide facts, statements, and other information in all communications with the Corporation and its stockholders that are or will be true and correct in all material respects, and that do
not and will not omit to state a material fact necessary in order to make the statements made, in light of the circumstances under which they are made, not misleading. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.12.3 <U>Special Meetings of Stockholders</U>. Only such business shall be conducted at a special meeting of stockholders as shall have been brought before
the meeting pursuant to the Corporation&#146;s notice of such meeting. Nominations of persons for election to the Board may be made at a special meeting of stockholders at which directors are to be elected pursuant to the Corporation&#146;s notice
of such meeting (a)&nbsp;by or at the direction of the Board or (b)&nbsp;provided that the Board has determined that directors shall be elected at such meeting, by any stockholder of the Corporation who is a stockholder of record at the time of
giving of notice of the special meeting, who shall be entitled to vote at the meeting and who complies with the notice procedures set forth in this Section&nbsp;1.12. In the event the Corporation calls a special meeting of stockholders for the
purpose of electing one or more directors to the Board, any such stockholder may nominate a person or persons (as the case may be), for election to such position(s) as specified in the Corporation&#146;s notice of meeting, if (A)&nbsp;the
stockholder&#146;s notice required by Section&nbsp;1.12.1(b) shall be delivered to the Secretary of the Corporation at the principal executive offices of the Corporation (i)&nbsp;no earlier than the one hundred fifth (105th) day prior to such
special meeting and (ii)&nbsp;no later than the close of business on the later of the seventy fifth (75th) day prior to such special meeting or the tenth (10th) day following the day on which Public Announcement is first made of the date of the
special meeting and of the nominees proposed by the Board to be elected at such meeting, (B)&nbsp;the stockholder has complied in all respects with the requirements of Section&nbsp;14 of the Exchange Act, including, without limitation, if
applicable, the requirements of Rule <FONT STYLE="white-space:nowrap">14a-19</FONT> and (C)&nbsp;the Board or an executive officer designated thereby has determined that the stockholder has satisfied the requirements of Section&nbsp;1.12. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.12.4 <U>General</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;(i) Only such persons who are nominated in accordance with the procedures set forth in this Section&nbsp;1.12 shall be eligible to
serve as directors and only such business shall be conducted at a meeting of stockholders as shall have been brought before the meeting in accordance with the procedures set forth in this Section&nbsp;1.12. The number of nominees a stockholder may
nominate for election at a meeting of stockholders (or in the case of a Record Stockholder giving the notice on behalf of another Proposing Person, the number of nominees a stockholder may nominate for election at the meeting on behalf of such
Proposing Person) shall not exceed the number of directors to be elected at such meeting. Except as otherwise provided by law or these Bylaws, the chairperson of the meeting shall have the power and duty to determine whether a nomination or any
business proposed to be brought before the meeting was made or proposed, as the case may be, in accordance with the procedures set forth in this Section&nbsp;1.12 and, if any proposed nomination or business is not in compliance herewith, to declare
that such defective proposal or nomination shall be disregarded (and any such nominee shall be disqualified), including that if a stockholder provides notice pursuant to Rule <FONT STYLE="white-space:nowrap">14a-19(b)</FONT> promulgated under the
Exchange Act and subsequently fails to comply with the requirements of Rule <FONT STYLE="white-space:nowrap">14a-19(a)(2)</FONT> and Rule <FONT STYLE="white-space:nowrap">14a-19(a)(3)</FONT> promulgated under the Exchange Act, including the
provision to the Corporation of notices required thereunder in a timely manner, then the Corporation shall disregard any proxies or votes solicited for such stockholder&#146;s director nominees (and any such nominee shall be disqualified). If a
stockholder has given timely notice as required herein to make a nomination or bring a proposal of other business before any annual or special meeting of stockholders of the Corporation and intends to authorize a Qualified Representative (as defined
below) to act for such stockholder as a proxy to present the nomination or proposal at such meeting, the stockholder shall give notice of such authorization in writing to the Secretary not less than three (3)&nbsp;business days before the date of
such meeting, including the name and contact information for such person. Notwithstanding the foregoing provisions of Section&nbsp;1.12, unless otherwise required by law, no stockholder shall solicit proxies in support of director nominees other
than the Corporation&#146;s nominees unless such stockholder has complied with Rule <FONT STYLE="white-space:nowrap">14a-19</FONT> promulgated under the Exchange Act in connection with the solicitation of such proxies, including the provision to the
Corporation of notices required thereunder in a timely manner. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) The Board may request that any Proposing Person, and any proposed
nominee of such Proposing Person, furnish such additional information as may be reasonably required by the Board. Such Proposing Person and/or proposed nominee thereof shall provide such additional information within ten (10)&nbsp;days after it has
been requested by the Board. The Board may require any such proposed nominee to submit to interviews with the Board or any committee thereof, and such proposed nominee shall make themself available for any such interviews within no less than ten
(10)&nbsp;business days following the date of such request. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)For purposes of this Section&nbsp;1.12, the following definitions shall
apply: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(A) a person shall be deemed to be &#147;<B><I>Acting in Concert</I></B>&#148; with another person if such person knowingly acts (whether or not
pursuant to an express agreement, arrangement or understanding) in concert with, or toward a common goal relating to the management, governance or control of the Corporation in substantial parallel with, such other person where (1)&nbsp;each person
is conscious of the other person&#146;s conduct or intent and this awareness is an element in their decision-making processes and (2)&nbsp;at least one additional factor suggests that such persons intend to act in concert or in substantial parallel,
which such additional factors may include, without limitation, exchanging information (whether publicly or privately), attending meetings, conducting discussions or making or soliciting invitations to act in concert or in substantial parallel;
provided that a person shall not be deemed to be Acting in Concert with any other person solely as a result of the solicitation or receipt of revocable proxies or consents from such other person in response to a solicitation made pursuant to, and in
accordance with, Section&nbsp;14(a) (or any successor provision) of the Exchange Act by way of a proxy or consent solicitation statement filed on Schedule 14A. A person Acting in Concert with another person shall be deemed to be Acting in Concert
with any third party who is also Acting in Concert with such other person; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(B) &#147;<B><I>Associated Person</I></B>&#148; shall mean with respect to any
subject stockholder or other person (including any proposed nominee)&nbsp;(1) any person directly or indirectly controlling, controlled by or under common control with such stockholder or other person, (2)&nbsp;any beneficial owner of shares of
stock of the Corporation owned of record or beneficially by such stockholder or other person, (3)&nbsp;any associate of such stockholder or other person, and (4)&nbsp;any person directly or indirectly controlling, controlled by or under common
control or Acting in Concert with any such Associated Person; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(C) &#147;<B><I>Compensation Arrangement</I></B>&#148; shall mean any direct or indirect
compensatory payment or other financial agreement, arrangement or understanding with any person or entity other than the Corporation, including any agreement, arrangement or understanding with respect to any direct or indirect compensation,
reimbursement or indemnification in connection with candidacy, nomination, service or action as a nominee or as a director of the Corporation; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(D) &#147;<B><I>Proposing Person</I></B>&#148; shall mean (1)&nbsp;the Record Stockholder providing the notice of business proposed to be
brought before an annual meeting or nomination of persons for election to the Board at a stockholder meeting, (2)&nbsp;the beneficial owner or beneficial owners, if different, on whose behalf the notice of business proposed to be brought before the
annual meeting or nomination of persons for election to the Board at a stockholder meeting is made, and (3)&nbsp;any Associated Person on whose behalf the notice of business proposed to be brought before the annual meeting or nomination of persons
for election to the Board at a stockholder meeting is made; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(E) &#147;<B><I>Public Announcement</I></B>&#148; shall mean disclosure in a
press release reported by the Dow Jones News Service, Associated Press or comparable national news service or in a document publicly filed by the Corporation with the Securities and Exchange Commission pursuant to Section&nbsp;13, 14 or 15(d) of the
Exchange Act; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(F) To be considered a &#147;<B><I>Qualified Representative</I></B>&#148; of a stockholder, a person must be a duly
authorized officer, manager, trustee or partner of such stockholder or must be authorized by a writing executed by such stockholder or an electronic transmission delivered by such stockholder to act for such stockholder as a proxy at the meeting of
stockholders and such person must produce such writing or electronic transmission, or a reliable reproduction thereof, at the meeting. The Secretary of the Corporation, or any other person who shall be appointed to serve as secretary of the meeting,
may require, on behalf of the Corporation, reasonable and appropriate documentation to verify the status of a person purporting to be a &#147;Qualified Representative&#148; for purposes hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)Notwithstanding the foregoing provisions of this Section&nbsp;1.12, a stockholder shall also comply with all applicable requirements of the
Exchange Act and the rules and regulations thereunder with respect to the matters set forth herein, for the avoidance of doubt including, but not limited to, Rule <FONT STYLE="white-space:nowrap">14a-19</FONT> of the Exchange Act. Nothing in this
Section&nbsp;1.12 shall be deemed to affect any rights of stockholders to request inclusion of proposals in the Corporation&#146;s proxy statement pursuant to Rule <FONT STYLE="white-space:nowrap">14a-8</FONT> under the Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Section</U></B><B><U></U></B><B><U>&nbsp;1.13</U></B><B>: </B><B><U>Emergency Bylaws</U></B><B>.</B> This Section&nbsp;1.13 shall be operative during
any emergency condition as contemplated by Section&nbsp;110 of the DGCL (an &#147;<B><I>Emergency</I></B>&#148;), notwithstanding any different or conflicting provisions in these Bylaws, the Certificate of Incorporation or the DGCL. In the event of
any Emergency the director or directors in attendance at a meeting of the Board or a standing committee thereof shall constitute a quorum. Such director or directors in attendance may further take action to appoint one or more of themselves or other
directors to membership on any standing or temporary committees of the Board as they shall deem necessary and appropriate. In the event that no directors are able to attend a meeting of the Board or any committee thereof in an Emergency, then the
Designated Officers (as defined below) in attendance shall serve as directors, or committee members, as the case may be, for the meeting and will have full powers to act as directors, or committee members, as the case may be, of the Corporation.
Except as the Board may otherwise determine, during any Emergency, the Corporation and its directors and officers, may exercise any authority and take any action or measure contemplated by Section&nbsp;110 of the DGCL. For purposes of this
Section&nbsp;1.13, the term &#147;<B><I>Designated Officer</I></B>&#148; means an officer identified on a numbered list of officers of the Corporation who shall be deemed to be, in the order in which they appear on the list up until a quorum is
obtained, directors of the Corporation, or members of a committee of the Board, as the case may be, for purposes of obtaining a quorum during an Emergency, if a quorum of directors or committee members, as the case may be, cannot otherwise be
obtained during such Emergency, which list of Designated Officers shall be approved by the Board from time to time but in any event prior to such time or times as an Emergency may have occurred. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE II: BOARD OF DIRECTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Section</U></B><B><U></U></B><B><U>&nbsp;2.1</U></B><B>: </B><B><U>Number; Qualifications</U></B><B>.</B> The Board shall consist of one or more
members. The number of directors shall be fixed from time to time as set forth in the Certificate of Incorporation. No decrease in the authorized number of directors constituting the Board shall shorten the term of any incumbent director. Directors
need not be stockholders of the Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Section</U></B><B><U></U></B><B><U>&nbsp;2.2</U></B><B>: </B><B><U>Election; Resignation; Removal;
Vacancies</U></B><B>.</B> The directors shall be divided, with respect to the time for which they severally hold office, into classes as provided in the Certificate of Incorporation, and vacancies occurring in the Board and any newly created
directorships resulting from any increase in the authorized number of directors shall be filled, as provided in the Certificate of Incorporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Section</U></B><B><U></U></B><B><U>&nbsp;2.3</U></B><B>: </B><B><U>Regular Meetings</U></B><B>.</B> Regular meetings of the Board may be held at such
places, within or without the State of Delaware, and at such times as the Board may from time to time determine. Notice of regular meetings need not be given if the date, times and places thereof are fixed by resolution of the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Section</U></B><B><U></U></B><B><U>&nbsp;2.4</U></B><B>: </B><B><U>Special Meetings</U></B><B>.</B> Special meetings of the Board may be called by the
Chairperson of the Board, the Chief Executive Officer, the President or a majority of the members of the Board then in office and may be held at any time, date or place, within or without the State of Delaware, as the person or persons calling the
meeting shall fix. Notice of the time, date and place of such meeting shall be given, orally, in writing or by electronic transmission (including electronic mail), by the person or persons calling the meeting to all directors at least four
(4)&nbsp;days before the meeting if the notice is mailed, or at least twenty-four (24)&nbsp;hours before the meeting if such notice is given by telephone, hand delivery, or electronic transmission. Unless otherwise indicated in the notice, any and
all business may be transacted at a special meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Section</U></B><B><U></U></B><B><U>&nbsp;2.5</U></B><B>: </B><B><U>Remote Meetings
Permitted</U></B><B>.</B> Members of the Board, or any committee of the Board, may participate in a meeting of the Board or such committee by means of conference telephone or other communications equipment by means of which all persons participating
in the meeting can hear each other, and participation in a meeting pursuant to conference telephone or other communications equipment shall constitute presence in person at such meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Section</U></B><B><U></U></B><B><U>&nbsp;2.6</U></B><B>: </B><B><U>Quorum; Vote Required for Action</U></B><B>.</B> Subject to the Certificate of
Incorporation regarding the ability of members of the Board to fill a vacancy occurring in the Board, a majority of the Whole Board shall constitute a quorum for the transaction of business. If a quorum shall fail to attend any meeting, a majority
of those present may adjourn the meeting to another place, date or time without further notice thereof. Except as otherwise provided herein or in the Certificate of Incorporation, or required by law, the vote of a majority of the directors present
at a meeting at which a quorum is present shall be the act of the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Section</U></B><B><U></U></B><B><U>&nbsp;2.7</U></B><B>:
</B><B><U>Organization</U></B><B>.</B> Meetings of the Board shall be presided over by the Chairperson of the Board, or in such person&#146;s absence by the President, or in such person&#146;s absence by a chairperson chosen at the meeting. The
Secretary shall act as secretary of the meeting, but in such person&#146;s absence the chairperson of the meeting may appoint any person to act as secretary of the meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Section</U></B><B><U></U></B><B><U>&nbsp;2.8</U></B><B>: </B><B><U>Written Action by Directors</U></B><B>.</B> Any action required or permitted to be
taken at any meeting of the Board, or of any committee thereof, may be taken without a meeting if all members of the Board or such committee, as the case may be, consent thereto in writing or by electronic transmission. After an action is taken, the
writing or writings or electronic transmission or transmissions shall be filed with the minutes of proceedings of the Board or committee, respectively, in the minute books of the Corporation. Such filing shall be in paper form if the minutes are
maintained in paper form and shall be in electronic form if the minutes are maintained in electronic form. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Section</U></B><B><U></U></B><B><U>&nbsp;2.9</U></B><B>: </B><B><U>Powers</U></B><B>.</B> The Board may, except as otherwise required by law or the
Certificate of Incorporation, exercise all such powers and manage and direct all such acts and things as may be exercised or done by the Corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Section</U></B><B><U></U></B><B><U>&nbsp;2.10</U></B><B>: </B><B><U>Compensation of Directors</U></B><B>.</B> Members of the Board, as such, may
receive, pursuant to a resolution of the Board, fees and other compensation for their services as directors, including without limitation their services as members of committees of the Board. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE III: COMMITTEES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Section</U></B><B><U></U></B><B><U>&nbsp;3.1</U></B><B>: </B><B><U>Committees</U></B><B>.</B> The Board may designate one or more committees, each
committee to consist of one or more of the directors of the Corporation. The Board may designate one or more directors as alternate members of any committee, who may replace any absent or disqualified member at any meeting of the committee. In the
absence or disqualification of a member of the committee, the member or members thereof present at any meeting of such committee who are not disqualified from voting, whether or not such member or members constitute a quorum, may unanimously appoint
another member of the Board to act at the meeting in place of any such absent or disqualified member. Any such committee, to the extent provided in a resolution of the Board, shall have and may exercise all the powers and authority of the Board in
the management of the business and affairs of the Corporation and may authorize the seal of the Corporation to be affixed to all papers that may require it; but no such committee shall have the power or authority in reference to the following
matters: (a)&nbsp;approving, adopting, or recommending to the stockholders any action or matter (other than the election or removal of members of the Board) expressly required by the DGCL to be submitted to stockholders for approval or
(b)&nbsp;adopting, amending or repealing any bylaw of the Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Section</U></B><B><U></U></B><B><U>&nbsp;3.2</U></B><B>: </B><B><U>Committee
Rules</U></B><B>.</B> Unless the Board otherwise provides, each committee designated by the Board may make, alter and repeal rules for the conduct of its business. In the absence of such rules each committee shall conduct its business in the same
manner as the Board conducts its business pursuant to Article II of these Bylaws. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE IV: OFFICERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Section</U></B><B><U></U></B><B><U>&nbsp;4.1</U></B><B>: </B><B><U>Generally</U></B><B>.</B> The officers of the Corporation shall consist of a Chief
Executive Officer (who may not be the Chairperson of the Board, except pursuant to the last sentence of Section&nbsp;4.2 hereof, but who may be the President), a Secretary and a Treasurer and may consist of such other officers, including a Chief
Financial Officer and one or more Vice Presidents, as may from time to time be appointed by the Board. All officers shall be elected by the Board; <I><U>provided</U></I><I>, </I><I><U>however</U></I>, that the Board may empower the Chief Executive
Officer of the Corporation to appoint any officer other than the Chairperson of the Board, the Chief Executive Officer, the President, the Chief Financial Officer or the Treasurer. Each officer shall hold office until such person&#146;s successor is
appointed or until such person&#146;s earlier resignation, death or removal. Any number of offices may be held by the same person. Any officer may resign at any time upon written notice to the Corporation. Any vacancy occurring in any office of the
Corporation by death, resignation, removal or otherwise may be filled by the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Section</U></B><B><U></U></B><B><U>&nbsp;4.2</U></B><B>:
</B><B><U>Chief Executive Officer</U></B><B>.</B> Subject to the control of the Board and such supervisory powers, if any, as may be given by the Board, the powers and duties of the Chief Executive Officer of the Corporation are: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)To act as the general manager and, subject to the control of the Board, to have general supervision, direction and control of the business
and affairs of the Corporation; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)Subject to Article I, Section&nbsp;1.6, to preside at all meetings of the stockholders; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)Subject to Article I, Section&nbsp;1.2, to call special meetings of the stockholders to be held at such times and, subject to the
limitations prescribed by law or by these Bylaws, at such places as he or she shall deem proper; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)To affix the signature of the
Corporation to all deeds, conveyances, mortgages, guarantees, leases, obligations, bonds, certificates and other papers and instruments in writing which have been authorized by the Board or which, in the judgment of the Chief Executive Officer,
should be executed on behalf of the Corporation; to sign certificates for shares of stock of the Corporation; and, subject to the direction of the Board, to have general charge of the property of the Corporation and to supervise and control all
officers, agents and employees of the Corporation; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)To vote and otherwise act on, or to authorize any officer to vote or otherwise
act on, on behalf of the Corporation, in person or by proxy, at any meeting of stockholders of or with respect to any action of stockholders of any other corporation in which this Corporation may hold securities and otherwise to exercise, or
authorize any officer otherwise to exercise, any and all rights and powers which this Corporation may possess by reason of its ownership of securities in such other corporation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The President shall be the Chief Executive Officer of the Corporation unless the Board shall designate
another officer to be the Chief Executive Officer. If there is no President, and the Board has not designated any other officer to be the Chief Executive Officer, then the Chairperson of the Board shall be the Chief Executive Officer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Section</U></B><B><U></U></B><B><U>&nbsp;4.3</U></B><B>: </B><B><U>Chairperson of the Board</U></B><B>.</B> The Chairperson of the Board shall have the
power to preside at all meetings of the Board and shall have such other powers and duties as provided in these Bylaws and as the Board may from time to time prescribe. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Section</U></B><B><U></U></B><B><U>&nbsp;4.4</U></B><B>: </B><B><U>President</U></B><B>.</B> The Chief Executive Officer shall be the President of the
Corporation unless the Board shall have designated one individual as the President and a different individual as the Chief Executive Officer of the Corporation. Subject to the provisions of these Bylaws and to the direction of the Board, and subject
to the supervisory powers of the Chief Executive Officer (if the Chief Executive Officer is an officer other than the President), and subject to such supervisory powers and authority as may be given by the Board to the Chairperson of the Board,
and/or to any other officer, the President shall have the responsibility for the general management and control of the business and affairs of the Corporation and the general supervision and direction of all of the officers, employees and agents of
the Corporation (other than the Chief Executive Officer, if the Chief Executive Officer is an officer other than the President) and shall perform all duties and have all powers that are commonly incident to the office of President or that are
delegated to the President by the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Section</U></B><B><U></U></B><B><U>&nbsp;4.5</U></B><B>: </B><B><U>Vice President</U></B><B>.</B> Each
Vice President shall have all such powers and duties as are commonly incident to the office of Vice President, or that are delegated to him or her by the Board or the Chief Executive Officer. A Vice President may be designated by the Board to
perform the duties and exercise the powers of the Chief Executive Officer in the event of the Chief Executive Officer&#146;s absence or disability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Section</U></B><B><U></U></B><B><U>&nbsp;4.6</U></B><B>: </B><B><U>Chief Financial Officer</U></B><B>.</B> The Chief Financial Officer shall be the
Treasurer of the Corporation unless the Board shall have designated another officer as the Treasurer of the Corporation. Subject to the direction of the Board and the Chief Executive Officer, the Chief Financial Officer shall perform all duties and
have all powers that are commonly incident to the office of Chief Financial Officer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Section</U></B><B><U></U></B><B><U>&nbsp;4.7</U></B><B>:
</B><B><U>Treasurer</U></B><B>.</B> The Treasurer shall have custody of all moneys and securities of the Corporation. The Treasurer shall make such disbursements of the funds of the Corporation as are authorized and shall render from time to time an
account of all such transactions. The Treasurer shall also perform such other duties and have such other powers as are commonly incident to the office of Treasurer, or as the Board or the Chief Executive Officer may from time to time prescribe. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Section</U></B><B><U></U></B><B><U>&nbsp;4.8</U></B><B>: </B><B><U>Secretary</U></B><B>.</B> The Secretary shall issue or cause to be issued all
authorized notices for, and shall keep, or cause to be kept, minutes of all meetings of the stockholders and the Board. The Secretary shall have charge of the corporate minute books and similar records and shall perform such other duties and have
such other powers as are commonly incident to the office of Secretary, or as the Board or the Chief Executive Officer may from time to time prescribe. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Section</U></B><B><U></U></B><B><U>&nbsp;4.9</U></B><B>: </B><B><U>Delegation of Authority</U></B><B>.</B> The Board may from time to time delegate the
powers or duties of any officer to any other officers or agents, notwithstanding any provision hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Section</U></B><B><U></U></B><B><U>&nbsp;4.10</U></B><B>: </B><B><U>Removal</U></B><B>.</B> Any officer of the Corporation shall serve at the pleasure
of the Board and may be removed at any time, with or without cause, by the Board; provided that if the Board has empowered the Chief Executive Officer to appoint any Vice Presidents of the Corporation, then such Vice Presidents may be removed by the
Chief Executive Officer. Such removal shall be without prejudice to the contractual rights of such officer, if any, with the Corporation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE V: STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Section</U></B><B><U></U></B><B><U>&nbsp;5.1</U></B><B>: </B><B><U>Certificates</U></B><B>.</B> The shares of capital stock of the Corporation shall be
represented by certificates; provided, however, that the Board may provide by resolution or resolutions that some or all of any or all classes or series of its stock may be uncertificated shares. Notwithstanding the adoption of such resolution by
the Board, each holder of stock that is a certificated security shall be entitled to have a certificate signed by or in the name of the Corporation by the Chairperson or Vice-Chairperson of the Board, or the President or a Vice President, and by the
Treasurer or an Assistant Treasurer, or the Secretary or an Assistant Secretary, of the Corporation, certifying the number of shares owned by such stockholder in the Corporation. Any or all of the signatures on the certificate may be a facsimile. In
case any officer, transfer agent or registrar who has signed or whose facsimile signature has been placed upon a certificate shall have ceased to be such officer, transfer agent or registrar before such certificate is issued, it may be issued by the
Corporation with the same effect as if such person were an officer, transfer agent or registrar at the date of issue. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Section</U></B><B><U></U></B><B><U>&nbsp;5.2</U></B><B>: </B><B><U>Lost, Stolen or Destroyed Stock Certificates; Issuance of New Certificates or
Uncertificated Shares</U></B><B>.</B> The Corporation may issue a new certificate of stock, or uncertificated shares, in the place of any certificate previously issued by it, alleged to have been lost, stolen or destroyed, upon the making of an
affidavit of that fact by the person claiming the certificate of stock to be lost, stolen or destroyed, and the Corporation may require the owner of the lost, stolen or destroyed certificate, or such owner&#146;s legal representative, to agree to
indemnify the Corporation and/or to give the Corporation a bond sufficient to indemnify it, against any claim that may be made against it on account of the alleged loss, theft or destruction of any such certificate or the issuance of such new
certificate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Section</U></B><B><U></U></B><B><U>&nbsp;5.3</U></B><B>: </B><B><U>Other Regulations</U></B><B>.</B> The issue, transfer, conversion
and registration of stock certificates and uncertificated securities shall be governed by such other regulations as the Board may establish. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VI: INDEMNIFICATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Section</U></B><B><U></U></B><B><U>&nbsp;6.1</U></B><B>: </B><B><U>Indemnification of Officers and Directors</U></B><B>.</B> Each person who was or is
made a party to, or is threatened to be made a party to, or is involved in any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (a &#147;<B><I>Proceeding</I></B>&#148;), by reason
of the fact that such person (or a person of whom such person is the legal representative), is or was a member of the Board or officer of the Corporation or a Reincorporated Predecessor (as defined below) or is or was serving at the request of the
Corporation or a Reincorporated Predecessor as a member of the board of directors, officer or trustee of another corporation, or of a partnership, joint venture, trust or other enterprise, including service with respect to employee benefit plans
(for purposes of this Article VI, an &#147;<B><I>Indemnitee</I></B>&#148;), shall be indemnified and held harmless by the Corporation to the fullest extent permitted by applicable law as the same exists or may hereafter be amended (but, in the case
of any such amendment, only to the extent that such amendment permits the Corporation to provide broader indemnification rights than such law permitted the Corporation to provide prior to such amendment), against all expenses, liability and loss
(including attorneys&#146; fees, judgments, fines, ERISA excise taxes and penalties and amounts paid or to be paid in settlement) reasonably incurred or suffered by such Indemnitee in connection therewith, provided such Indemnitee acted in good
faith and in a manner that the Indemnitee reasonably believed to be in or not opposed to the best interests of the Corporation, and, with respect to any criminal action or Proceeding, had no reasonable cause to believe the Indemnitee&#146;s conduct
was unlawful. Such indemnification shall continue as to an Indemnitee who has ceased to be a director or officer and shall inure to the benefit of such Indemnitees&#146; heirs, executors and administrators. Notwithstanding the foregoing, the
Corporation shall indemnify any such Indemnitee seeking indemnity in connection with a Proceeding (or part thereof) initiated by such Indemnitee only if such Proceeding (or part thereof) was authorized by the Board or such indemnification is
authorized by an agreement approved by the Board. As used herein, the term the &#147;<B><I>Reincorporated Predecessor</I></B>&#148; means (a)&nbsp;a corporation that is merged with and into the Corporation in a statutory merger where (i)&nbsp;the
Corporation is the surviving corporation of such merger; (ii)&nbsp;the primary purpose of such merger is to change the corporate domicile of the Reincorporated Predecessor to Delaware or (b)&nbsp;a limited liability company that is converted into a
Delaware Corporation pursuant to DGCL &#167; 265. To the extent that a present or former director or officer of the corporation has been successful on the merits or otherwise in defense of any action, suit or proceeding described in this
Section&nbsp;6.1 or in defense of any claim, issue or matter therein, such person shall be indemnified against expenses (including attorneys&#146; fees) actually and reasonably incurred by such person in connection therewith. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Section</U></B><B><U></U></B><B><U>&nbsp;6.2</U></B><B>: </B><B><U>Advancement of
Expenses</U></B><B>.</B> Except as otherwise provided in a written indemnification agreement between the Corporation and an Indemnitee, the Corporation shall pay all reasonable expenses (including attorneys&#146; fees) incurred by such an Indemnitee
in defending any such Proceeding as they are incurred in advance of its final disposition; <I><U>provided</U></I><I>, </I><I><U>however</U></I>, that if the DGCL then so requires, the payment of such expenses incurred by such Indemnitee in advance
of the final disposition of such Proceeding shall be made only upon delivery to the Corporation of an undertaking, by or on behalf of such Indemnitee, to repay all amounts so advanced if it should be determined ultimately by final judicial decision
from which there is no appeal that such Indemnitee is not entitled to be indemnified under this Article VI or otherwise. Expenses (including attorneys&#146; fees) actually and reasonably incurred by an officer or director of the corporation in
defending any Proceeding shall be paid by the corporation in advance of the final disposition of such Proceeding upon receipt of a written request therefor (together with documentation reasonably evidencing such expenses) and an undertaking by or on
behalf of the person to repay such amounts if it shall ultimately be determined that the person is not entitled to be indemnified under this Article VI or the DGCL. Such expenses (including attorneys&#146; fees) incurred by former directors and
officers or other employees and agents of the corporation or by persons serving at the request of the corporation as directors, officers, employees or agents of another corporation, partnership, joint venture, trust or other enterprise may be so
paid upon such terms and conditions, if any, as the corporation deems appropriate. The right to advancement of expenses shall not apply to any claim for which indemnity is excluded pursuant to these bylaws, but shall apply to any Proceeding
referenced in Section&nbsp;6.1 prior to a determination that the person is not entitled to be indemnified by the corporation. Any advances of expenses or undertakings to repay pursuant to this Section&nbsp;6.2 shall be unsecured, interest free and
without regard to Indemnitee&#146;s ability to pay. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Section</U></B><B><U></U></B><B><U>&nbsp;6.3</U></B><B>: </B><B><U><FONT
STYLE="white-space:nowrap">Non-Exclusivity</FONT> of Rights</U></B><B>.</B> The rights conferred on any person in this Article VI shall not be exclusive of any other right that such person may have or hereafter acquire under any statute, provision
of the Certificate of Incorporation, Bylaw, agreement, vote or consent of stockholders or disinterested directors, or otherwise. Additionally, nothing in this Article VI shall limit the ability of the Corporation, in its discretion, to indemnify or
advance expenses to persons whom the Corporation is not obligated to indemnify or advance expenses pursuant to this Article VI. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Section</U></B><B><U></U></B><B><U>&nbsp;6.4</U></B><B>: </B><B><U>Indemnification Contracts</U></B><B>.</B> The Board is authorized to cause the
Corporation to enter into indemnification contracts with any director, officer, employee or agent of the Corporation, or any person serving at the request of the Corporation as a director, officer, employee or agent of another corporation,
partnership, joint venture, trust or other enterprise, including employee benefit plans, that provide indemnification or advancement rights to such person. Such rights may be greater than those provided in this Article VI. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Section</U></B><B><U></U></B><B><U>&nbsp;6.5</U></B><B>: </B><B><U>Right of Indemnitee to Bring Suit</U></B><B>. </B>The following shall apply to the
extent not in conflict with any indemnification contract provided for in Section&nbsp;6.4 above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6.5.1 <U>Right to Bring Suit</U>. If a claim under
Section&nbsp;6.1 or 6.2 of this Article VI is not paid in full by the Corporation within ninety (90)&nbsp;days after a written claim has been received by the Corporation, the Indemnitee may at any time thereafter bring suit against the Corporation
to recover the unpaid amount of the claim. If successful in whole or in part in any such suit, or in a suit brought by the Corporation to recover an advancement of expenses pursuant to the terms of an undertaking, the Indemnitee shall be entitled to
be paid also the expense of prosecuting or defending such suit. In (a)&nbsp;any suit brought by the Indemnitee to enforce a right to indemnification hereunder (but not in a suit brought by the Indemnitee to enforce a right to an advancement of
expenses) it shall be a defense that, and (b)&nbsp;in any suit brought by the Corporation to recover an advancement of expenses pursuant to the terms of an undertaking, the Corporation shall be entitled to recover such expenses upon a final
adjudication that, the Indemnitee has not met any applicable standard for indemnification set forth in applicable law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6.5.2 <U>Effect of
Determination</U>. Neither the failure of the Corporation (including its directors who are not parties to such action, a committee of such directors, independent legal counsel or its stockholders) to have made a determination prior to the
commencement of such suit that indemnification of the Indemnitee is proper in the circumstances because the Indemnitee has met the applicable standard of conduct set forth in applicable law, nor an actual determination by the Corporation (including
its directors who are not parties to such action, a committee of such directors, independent legal counsel or its stockholders) that the Indemnitee has not met such applicable standard of conduct, shall create a presumption that the Indemnitee has
not met the applicable standard of conduct or, in the case of such a suit brought by the Indemnitee, be a defense to such suit. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6.5.3 <U>Burden of Proof</U>. In any suit brought by the Indemnitee to enforce a right to indemnification or
to an advancement of expenses hereunder, or brought by the Corporation to recover an advancement of expenses pursuant to the terms of an undertaking, the burden of proving that the Indemnitee is not entitled to be indemnified, or to such advancement
of expenses, under this Article VI, or otherwise, shall be on the Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Section</U></B><B><U></U></B><B><U>&nbsp;6.6</U></B><B>:
</B><B><U>Nature of Rights</U></B><B>.</B> The rights conferred upon Indemnitees in this Article VI shall be contract rights and such rights shall continue as to an Indemnitee who has ceased to be a director, officer or trustee and shall inure to
the benefit of the Indemnitee&#146;s heirs, executors and administrators. Any amendment, repeal or modification of any provision of this Article VI that adversely affects any right of an Indemnitee or an Indemnitee&#146;s successors shall be
prospective only, and shall not adversely affect any right or protection conferred on a person pursuant to this Article VI and existing at the time of such amendment, repeal or modification. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Section</U></B><B><U></U></B><B><U>&nbsp;6.7</U></B><B>: </B><B><U>Insurance</U></B><B>.</B> The corporation may purchase and maintain insurance on
behalf of any person who is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust
or other enterprise against any liability asserted against such person and incurred by such person in any such capacity, or arising out of such person&#146;s status as such, whether or not the corporation would have the power to indemnify such
person against such liability under the provisions of the DGCL. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Section</U></B><B><U></U></B><B><U>&nbsp;6.8</U></B><B>: </B><B><U>Indemnification
for Successful Defense</U></B><B>. </B>To the extent that an Indemnitee has been successful on the merits or otherwise in defense of any Proceeding (or in defense of any claim, issue or matter therein), such Indemnitee shall be indemnified under
this Section&nbsp;6.8 against expenses (including attorneys&#146; fees) actually and reasonably incurred in connection with such defense. Indemnification under this Section&nbsp;6.8 shall not be subject to satisfaction of a standard of conduct, and
the Corporation may not assert the failure to satisfy a standard of conduct as a basis to deny indemnification or recover amounts advanced, including in a suit brought pursuant to Section&nbsp;6.5 (notwithstanding anything to the contrary therein);
<I><U>provided</U></I>, <I><U>however</U></I>, that, any Indemnitee who is not a current or former director or officer (as such term is defined in the final sentence of Section&nbsp;145(c)(1) of the DGCL) shall be entitled to indemnification under
Section&nbsp;6.1 and this Section&nbsp;6.8 only if such Indemnitee has satisfied the standard of conduct required for indemnification under Section&nbsp;145(a) or Section&nbsp;145(b) of the DGCL. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VII: NOTICES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Section</U><U></U><U>&nbsp;7.1</U>: <U>Notice</U>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7.1.1 <U>Form and Delivery</U>. Except as otherwise required by law, notice may be given in writing directed to a stockholder&#146;s mailing address as it
appears on the records of the Corporation and shall be given: (a)&nbsp;if mailed, when notice is deposited in the U.S. mail, postage prepaid; and (b)&nbsp;if delivered by courier service, the earlier of when the notice is received or left at such
stockholder&#146;s address. So long as the Corporation is subject to the Securities and Exchange Commission&#146;s proxy rules set forth in Regulation 14A under the Exchange Act, notice shall be given in the manner required by such rules. To the
extent permitted by such rules, or if the Corporation is not subject to Regulation 14A, notice may be given by electronic transmission directed to the stockholder&#146;s electronic mail address, and if so given, shall be given when directed to such
stockholder&#146;s electronic mail address unless the stockholder has notified the Corporation in writing or by electronic transmission of an objection to receiving notice by electronic mail or such notice is prohibited by Section&nbsp;232(e) of the
DGCL. If notice is given by electronic mail, such notice shall comply with the applicable provisions of Sections 232(a) and 232(d) of the DGCL. Notice may be given by other forms of electronic transmission with the consent of a stockholder in the
manner permitted by Section&nbsp;232(b) of the DGCL and shall be deemed given as provided therein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7.1.2 <U>Affidavit of Giving Notice</U>. An affidavit
of the Secretary or an Assistant Secretary or of the transfer agent or other agent of the Corporation that the notice has been given shall, in the absence of fraud, be prima facie evidence of the facts stated therein. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Section</U></B><B><U></U></B><B><U>&nbsp;7.2</U></B><B>: </B><B><U>Waiver of Notice</U></B><B>.</B>
Whenever notice is required to be given under any provision of the DGCL, the Certificate of Incorporation or these Bylaws, a written waiver of notice, signed by the person entitled to notice, or waiver by electronic transmission by such person,
whether before or after the time stated therein, shall be deemed equivalent to notice. Attendance of a person at a meeting shall constitute a waiver of notice of such meeting, except when the person attends a meeting for the express purpose of
objecting at the beginning of the meeting to the transaction of any business because the meeting is not lawfully called or convened. Neither the business to be transacted at, nor the purpose of, any regular or special meeting of the stockholders,
directors or members of a committee of directors need be specified in any waiver of notice. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VIII: INTERESTED DIRECTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Section</U></B><B><U></U></B><B><U>&nbsp;8.1</U></B><B>: </B><B><U>Interested Directors</U></B><B>.</B> No contract or transaction between the
Corporation and one or more of its members of the Board or officers, or between the Corporation and any other corporation, partnership, association or other organization in which one or more of its directors or officers are members of the board of
directors or officers, or have a financial interest, shall be void or voidable solely for this reason, or solely because the director or officer is present at or participates in the meeting of the Board or committee thereof that authorizes the
contract or transaction, or solely because his, her or their votes are counted for such purpose, if: (a)&nbsp;the material facts as to his, her or their relationship or interest and as to the contract or transaction are disclosed or are known to the
Board or the committee, and the Board or committee in good faith authorizes the contract or transaction by the affirmative votes of a majority of the disinterested directors, even though the disinterested directors be less than a quorum;
(b)&nbsp;the material facts as to his, her or their relationship or interest and as to the contract or transaction are disclosed or are known to the stockholders entitled to vote thereon, and the contract or transaction is specifically approved in
good faith by vote of the stockholders; or (c)&nbsp;the contract or transaction is fair as to the Corporation as of the time it is authorized, approved or ratified by the Board, a committee thereof, or the stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Section</U></B><B><U></U></B><B><U>&nbsp;8.2</U></B><B>: </B><B><U>Quorum</U></B><B>.</B> Interested directors may be counted in determining the
presence of a quorum at a meeting of the Board or of a committee which authorizes the contract or transaction. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE IX:
MISCELLANEOUS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Section</U></B><B><U></U></B><B><U>&nbsp;9.1</U></B><B>: </B><B><U>Fiscal Year</U></B><B>.</B> The fiscal year of the Corporation
shall be determined by resolution of the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Section</U></B><B><U></U></B><B><U>&nbsp;9.2</U></B><B>: </B><B><U>Seal</U></B><B>.</B> The Board
may provide for a corporate seal, which may have the name of the Corporation inscribed thereon and shall otherwise be in such form as may be approved from time to time by the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Section</U></B><B><U></U></B><B><U>&nbsp;9.3</U></B><B>: </B><B><U>Form of Records</U></B><B>.</B> Any records maintained by the Corporation in the
regular course of its business, including its stock ledger, books of account and minute books, may be kept on or by means of, or be in the form of, diskettes, CDs, or any other information storage device or method, provided that the records so kept
can be converted into clearly legible paper form within a reasonable time. The Corporation shall so convert any records so kept upon the request of any person entitled to inspect such records pursuant to any provision of the DGCL. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Section</U></B><B><U></U></B><B><U>&nbsp;9.4</U></B><B>: </B><B><U>Reliance upon Books and Records</U></B><B>.</B> A member of the Board, or a member of
any committee designated by the Board shall, in the performance of such person&#146;s duties, be fully protected in relying in good faith upon records of the Corporation and upon such information, opinions, reports or statements presented to the
Corporation by any of the Corporation&#146;s officers or employees, or committees of the Board, or by any other person as to matters the member reasonably believes are within such other person&#146;s professional or expert competence and who has
been selected with reasonable care by or on behalf of the Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Section</U></B><B><U></U></B><B><U>&nbsp;9.5</U></B><B>:
</B><B><U>Certificate of Incorporation Governs</U></B><B>.</B> In the event of any conflict between the provisions of the Certificate of Incorporation and Bylaws, the provisions of the Certificate of Incorporation shall govern. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Section</U></B><B><U></U></B><B><U>&nbsp;9.6</U></B><B>: </B><B><U>Severability</U></B><B>.</B> If any
provision of these Bylaws shall be held to be invalid, illegal, unenforceable or in conflict with the provisions of the Certificate of Incorporation, then such provision shall nonetheless be enforced to the maximum extent possible consistent with
such holding and the remaining provisions of these Bylaws (including without limitation, all portions of any section of these Bylaws containing any such provision held to be invalid, illegal, unenforceable or in conflict with the Certificate of
Incorporation, that are not themselves invalid, illegal, unenforceable or in conflict with the Certificate of Incorporation) shall remain in full force and effect. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE X: AMENDMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding any
other provision of these Bylaws, any amendment or repeal of these Bylaws, or adoption of Bylaws, shall require the approval of the Board or the stockholders of the Corporation as provided in the Certificate of Incorporation. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE XI: EXCLUSIVE FORUM </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless the
Corporation consents in writing to the selection of an alternative forum, to the fullest extent permitted by law, the federal district courts of the United States shall be the exclusive forum for the resolution of any complaint asserting a cause of
action arising under the Securities Act of 1933, as amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any person or entity purchasing or otherwise acquiring or holding any interest in any
security of the Corporation shall be deemed to have notice of and consented to the provisions of this Article XI. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED AND RESTATED
BYLAWS </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AEGLEA BIOTHERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(a Delaware corporation) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I, James Kastenmayer,
certify that I am the General Counsel and Secretary of Aeglea BioTherapeutics, Inc., a Delaware corporation (the &#147;<B><I>Corporation</I></B>&#148;), that I am duly authorized to make and deliver this certification, that the attached Bylaws are a
true and complete copy of the Amended and Restated Bylaws of the Corporation in effect as of the date of this certificate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: December&nbsp;15, 2022
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ James Kastenmayer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">James Kastenmayer</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General Counsel and Secretary</P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.3
<SEQUENCE>5
<FILENAME>d518298dex33.htm
<DESCRIPTION>EX-3.3
<TEXT>
<HTML><HEAD>
<TITLE>EX-3.3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 3.3 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AEGLEA BIOTHERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATE OF DESIGNATION OF PREFERENCES, </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RIGHTS AND LIMITATIONS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SERIES A <FONT
STYLE="white-space:nowrap">NON-VOTING</FONT> CONVERTIBLE PREFERRED STOCK </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Pursuant to Section&nbsp;151 of the </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">General Corporation Law of the State of Delaware </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">THE UNDERSIGNED DOES HEREBY CERTIFY, on behalf of Aeglea BioTherapeutics, Inc., a Delaware corporation (the &#147;<B><I>Corporation</I></B>&#148;), that the
following resolution was duly adopted by the Board of Directors of the Corporation (the &#147;<B><I>Board of Directors</I></B>&#148;), in accordance with the provisions of Section&nbsp;151 of the General Corporation Law of the State of Delaware (the
&#147;<B><I>DGCL</I></B>&#148;), at a meeting duly called and held on June&nbsp;21, 2023, which resolution provides for the creation of a series of the Corporation&#146;s Preferred Stock, par value $0.0001 per share, which is designated as
&#147;Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Convertible Preferred Stock,&#148; with the preferences, rights and limitations set forth therein relating to dividends, conversion, redemption, dissolution and distribution of assets
of the Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>: the Restated Certificate of Incorporation of the Corporation (the &#147;<B><I>Certificate of
Incorporation</I></B>&#148;), provides for a class of its authorized stock known as Preferred Stock, consisting of 10,000,000 shares, $0.0001 par value per share (the &#147;<B><I>Preferred Stock</I></B>&#148;), issuable from time to time in one or
more series. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>RESOLVED</B>: that, pursuant to authority conferred upon the Board of Directors by the Certificate of Incorporation,
(i)&nbsp;a series of Preferred Stock of the Corporation be, and hereby is authorized by the Board of Directors, (ii)&nbsp;the Board of Directors hereby authorizes the issuance of 1,086,341 shares of &#147;Series A
<FONT STYLE="white-space:nowrap">Non-Voting</FONT> Convertible Preferred Stock&#148; pursuant to the terms of (a)&nbsp;the Securities Purchase Agreement, dated as of the date hereof, by and among the Corporation and the initial Holders (as defined
below) (the &#147;<B><I>Purchase Agreement</I></B>&#148;) and (b)&nbsp;the Agreement and Plan of Merger, dated as of the date hereof, by and among the Corporation, Aspen Merger Sub I, Inc., a Delaware corporation and wholly owned subsidiary of
Parent, Sequoia Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of Parent and Spyre Therapeutics, Inc. (the &#147;<B><I>Merger Agreement</I></B>&#148;), and (iii)&nbsp;the Board of Directors hereby fixes the
designations, powers, preferences and relative, participating, optional or other special rights, and the qualifications, limitations or restrictions thereof, of such shares of Preferred Stock, in addition to any provisions set forth in the
Certificate of Incorporation that are applicable to the Preferred Stock of all classes and series, as follows: </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TERMS OF SERIES A <FONT
STYLE="white-space:nowrap">NON-VOTING</FONT> CONVERTIBLE PREFERRED STOCK </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1. <U>Definitions</U>. For the purposes hereof, the
following terms shall have the following meanings: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Business Day</I></B>&#148; means any day except any Saturday, any Sunday,
any day which is a federal legal holiday in the United States or any day on which banking institutions in the State of New York are authorized or required by law or other governmental action to&nbsp;close. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I><FONT STYLE="white-space:nowrap">Buy-In</FONT></I></B>&#148; shall have the meaning set forth in
<U>Section</U><U></U><U>&nbsp;6.5.4</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Closing Sale Price</I></B>&#148; means, for any security as of any date, the last
closing trade price for such security immediately prior to 4:00 p.m., New York City time, on the principal Trading Market where such security is listed or traded, as reported by Bloomberg, L.P. (or an equivalent, reliable reporting service), or if
the foregoing do not apply, the last trade price of such security in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market on the electronic bulletin board for such
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
security as reported by Bloomberg, L.P., or, if no last trade price is reported for such security by Bloomberg, L.P., the average of the bid prices of any market makers for such security as
reported on the OTC Pink Market by OTC Markets Group, Inc. If the Closing Sale Price cannot be calculated for a security on a particular date on any of the foregoing bases, the Closing Sale Price of such security on such date shall be the fair
market value as determined in good faith by the Board of Directors of the Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Commission</I></B>&#148; means the
United States Securities and Exchange Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Common Stock</I></B>&#148; means the Corporation&#146;s common stock, par
value $0.0001 per share, and stock of any other class of securities into which such securities may hereafter be reclassified or changed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Conversion Shares</I></B>&#148; means, collectively, the shares of Common Stock issuable upon conversion of the shares of Series A
<FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock in accordance with the terms hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Exchange
Act</I></B>&#148; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Holder</I></B>&#148; means a holder of shares of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Person</I></B>&#148; means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint
venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Trading Day</I></B>&#148; means a day on which the principal Trading Market is open for business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Trading Market</I></B>&#148; means any of the following markets or exchanges on which the Common Stock is listed or quoted for
trading on the date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, or the New York Stock Exchange (or any successors to any of the foregoing). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2. <U>Designation, Amount and Par Value</U>. The series of Preferred Stock shall be designated as the Corporation&#146;s Series A <FONT
STYLE="white-space:nowrap">Non-Voting</FONT> Convertible Preferred Stock (the &#147;<B><I>Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock</I></B>&#148;) and the number of shares so designated shall be 1,086,341. Each
share of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock shall have a par value of $0.0001 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.
<U>Dividends</U>. Holders shall be entitled to receive, and the Corporation shall pay, dividends on shares of the Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock (on an <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">as-if-converted-to-Common-Stock</FONT></FONT></FONT></FONT> basis, without regard to the Beneficial Ownership Limitation (as defined below)) equal to and in
the same form, and in the same manner, as dividends (other than dividends on shares of the Common Stock payable in the form of Common Stock) actually paid on shares of the Common Stock when, as and if such dividends (other than dividends payable in
the form of Common Stock) are paid on shares of the Common Stock; provided, however, in no event shall Holders of Series A Non-Voting Preferred Stock be entitled to receive the &#147;rights&#148; distributed pursuant to that certain Contingent Value
Rights Agreement dated as of June 22, 2023 by and between the Corporation and American Stock Transfer &amp; Trust Company, LLC, as may be amended from time to time (the &#147;CVR Agreement&#148;), or any amounts paid under the CVR Agreement. Other
than as set forth in the previous sentence, no other dividends shall be paid on shares of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock, and the Corporation shall pay no dividends (other than dividends payable in the
form of Common Stock) on shares of the Common Stock unless it simultaneously complies with the previous sentence. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4. <U>Voting
Rights</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.1 Except as otherwise provided herein or as otherwise required by the DGCL, the Series A
<FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock shall have no voting rights. However, as long as any shares of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock are outstanding, the Corporation shall not,
without the affirmative vote of the holders of a majority of the then outstanding shares of the Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock: (i)&nbsp;alter or change adversely
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the powers, preferences or rights given to the Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock or alter or amend this Certificate of Designation, amend or repeal any
provision of, or add any provision to, the Certificate of Incorporation or Amended and Restated Bylaws of the Corporation, or file any articles of amendment, certificate of designations, preferences, limitations and relative rights of any series of
Preferred Stock, if such action would adversely alter or change the preferences, rights, privileges or powers of, or restrictions provided for the benefit of the Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock, regardless
of whether any of the foregoing actions shall be by means of amendment to the Certificate of Incorporation or by merger, consolidation, recapitalization, reclassification, conversion or otherwise, (ii)&nbsp;issue further shares of Series A <FONT
STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock or increase or decrease (other than by conversion) the number of authorized shares of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock, (iii)&nbsp;prior to the
Stockholder Approval (as defined below) or at any time while at least 30% of the originally issued Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock remains issued and outstanding, consummate either: (A)&nbsp;any
Fundamental Transaction (as defined below) or (B)&nbsp;any merger or consolidation of the Corporation with or into another entity or any stock sale to, or other business combination in which the stockholders of the Corporation immediately before
such transaction do not hold at least a majority of the capital stock of the Corporation immediately after such transaction or (iv)&nbsp;enter into any agreement with respect to any of the foregoing. Holders of shares of Common Stock acquired upon
the conversion of shares of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock shall be entitled to the same voting rights as each other holder of Common Stock, except that such holders may not vote such shares upon the
proposal for Stockholder Approval in accordance with Rule 5635 of the listing rules of The Nasdaq Stock Market LLC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.2 Any vote
required or permitted under <U>Section</U><U></U><U>&nbsp;4.1</U> may be taken at a meeting of the Holders or through the execution of an action by written consent in lieu of such meeting, provided that the consent is executed by Holders
representing a majority of the outstanding shares of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.
<U>Rank; Liquidation</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">5.1 The Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock shall rank on parity with
the Common Stock as to distributions of assets upon liquidation, dissolution or winding up of the Corporation, whether voluntarily or involuntarily. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">5.2 Upon any liquidation, dissolution or <FONT STYLE="white-space:nowrap">winding-up</FONT> of the Corporation, whether voluntary or
involuntary (a &#147;<B><I>Liquidation</I></B>&#148;), each Holder shall be entitled to receive out of the assets, whether capital or surplus, of the Corporation the same amount that a holder of Common Stock would receive if the Series A <FONT
STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock were fully converted (disregarding for such purpose any Beneficial Ownership Limitations) to Common Stock which amounts shall be paid <I>pari</I><I> </I><I>passu</I> with all holders of
Common Stock, plus an additional amount equal to any dividends declared on but unpaid to such shares. If, upon any such Liquidation, the assets of the Corporation shall be insufficient to pay the Holders of shares of the Series A <FONT
STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock the amount required under the preceding sentence, then all remaining assets of the Corporation shall be distributed ratably to the Holders and the holders of Common Stock in accordance
with the respective amounts that would be payable on all such securities if all amounts payable thereon were paid in full. For the avoidance of any doubt, a Fundamental Transaction shall not be deemed a Liquidation unless the Corporation expressly
declares that such Fundamental Transaction shall be treated as if it were a Liquidation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6. <U>Conversion</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">6.1 <U>Automatic Conversion on Stockholder Approval</U>. Effective as of 5:00 p.m. Eastern time on the third Business Day after the date that
the Corporation&#146;s stockholders approve the conversion of the Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock into shares of Common Stock in accordance with the listing rules of the Nasdaq Stock Market, as set forth
in Section&nbsp;4.1 of the Merger Agreement (the &#147;<B><I>Stockholder Approval</I></B>&#148;), each share of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock then outstanding shall automatically convert into a number of
shares of Common Stock equal to the Conversion Ratio (as defined below), subject to the Beneficial Ownership Limitation (the &#147;<B><I>Automatic Conversion</I></B>&#148;). The Corporation shall inform each Holder of the occurrence of the
Stockholder </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Approval within one Business Day of such Stockholder Approval. In determining the application of the Beneficial Ownership Limitations solely with respect to the Automatic Conversion, the
Corporation shall calculate beneficial ownership for each Holder assuming beneficial ownership by such Holder of: (x)&nbsp;the number of shares of Common Stock issuable to such Holder in such Automatic Conversion, plus (y)&nbsp;any additional shares
of Common Stock for which a Holder has provided the Corporation with prior written notice of beneficial ownership within 30 days prior to the date of Stockholder Approval (a &#147;<B><I>Beneficial Ownership Statement</I></B>&#148;) and assuming the
conversion of all shares of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock held by all other Holders less the aggregate number of shares of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock held
by all other Holders that will not convert into shares of Common Stock on account of the application of any Beneficial Ownership Limitations applicable to any such other Holders. If a Holder fails to provide the Corporation with a Beneficial
Ownership Statement within 30 days prior to the date of Stockholder Approval, then the Corporation shall presume the Holder&#146;s beneficial ownership of Common Stock (excluding the Conversion Shares) to be zero. The shares of Series A <FONT
STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock that are converted in the Automatic Conversion are referred to as the &#147;<B><I>Converted Stock</I></B>&#148;. The Conversion Shares shall be issued as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">6.1.1 Converted Stock that is registered in book entry form shall be automatically cancelled upon the Automatic Conversion and converted into
the corresponding Conversion Shares, which shares shall be issued in book entry form and without any action on the part of the Holders and shall be delivered to the Holders within one Business Day of the effectiveness of the Automatic Conversion.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">6.1.2 Converted Stock that is issued in certificated form shall be deemed converted into the corresponding Conversion Shares on the date
of Automatic Conversion and the Holder&#146;s rights as a holder of such shares of Converted Stock shall cease and terminate on such date, excepting only the right to receive the Conversion Shares upon the Holder tendering to the Corporation (or its
designated agent) the stock certificate(s) (duly endorsed) representing such certificated Converted Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">6.1.3 Notwithstanding the
cancellation of the Converted Stock upon the Automatic Conversion, Holders of Converted Stock shall continue to have any remedies provided herein or otherwise available at law or in equity to such Holder because of a failure by the Corporation to
comply with the terms of this Certificate of Designation. In all cases, the Holder shall retain all of its rights and remedies for the Corporation&#146;s failure to convert the Converted Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">6.2 <U>Conversion at Option of Holder</U>. Subject to <U>Section</U><U></U><U>&nbsp;6.1</U>, <U>Section</U><U></U><U>&nbsp;6.4</U> and
<U>Section</U><U></U><U>&nbsp;6.5.3</U>, each share of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock then outstanding shall be convertible, at any time and from time to time following 5:00 p.m. Eastern time on the third
Business Day after the date that the Stockholder Approval is obtained by the Corporation, at the option of the Holder thereof, into a number of shares of Common Stock equal to the Conversion Ratio, subject to the Beneficial Ownership Limitation
(each, an &#147;<B><I>Optional Conversion</I></B>&#148;). Holders shall effect conversions by providing the Corporation with the form of conversion notice attached hereto as <B><U>Annex A</U></B> (a &#147;<B><I>Notice of Conversion</I></B>&#148;),
duly completed and executed. Provided the Corporation&#146;s transfer agent is participating in the Depository Trust Company (&#147;<B><I>DTC</I></B>&#148;) Fast Automated Securities Transfer program, the Notice of Conversion may specify, at the
Holder&#146;s election, whether the applicable Conversion Shares shall be credited to the account of the Holder&#146;s prime broker with DTC through its Deposit Withdrawal Agent Commission system (a &#147;<B><I>DWAC Delivery</I></B>&#148;). The date
on which an Optional Conversion shall be deemed effective (the &#147;<B><I>Conversion Date</I></B>&#148;) shall be the Trading Day that the Notice of Conversion, completed and executed, is sent via email to, and received during regular business
hours by, the Corporation; provided, that the original certificate(s) (if any) representing such shares of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock being converted, duly endorsed, and the accompanying Notice of
Conversion, are received by the Corporation within two (2)&nbsp;Trading Days thereafter. In all other cases, the Conversion Date shall be defined as the Trading Day on which the original certificate(s) (if any) representing such shares of Series A <FONT
STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock being converted, duly endorsed, and the accompanying Notice of Conversion, are received by the Corporation. The calculations set forth in the Notice of Conversion shall control in the
absence of manifest or mathematical error. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">6.3 <U>Conversion Ratio</U>. The &#147;<B><I>Conversion Ratio</I></B>&#148; for each share
of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock shall be 1,000 shares of Common Stock issuable upon the conversion (the &#147;<B><I>Conversion</I></B>&#148;) of each share of Series A
<FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock (corresponding to a ratio of 1,000:1), subject to adjustment as provided herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">6.4 <U>Beneficial Ownership Limitation</U>. Notwithstanding anything herein to the contrary, the Corporation shall not effect any conversion
of any share of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock, including pursuant to Section&nbsp;6.1, and a Holder shall not have the right to convert any portion of the Series A
<FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock pursuant to Section&nbsp;6.2, to the extent that, after giving effect to such attempted conversion set forth on an applicable Notice of Conversion (as defined in the Certificate of
Designation) with respect to the Series A Preferred Stock, such Holder (or any of such Holder&#146;s Affiliates or any other Person who would be a beneficial owner of Common Stock beneficially owned by the Holder for purposes of Section&nbsp;13(d)
or Section&nbsp;16 of the Exchange Act and the applicable rules and regulations of the Commission, including any &#147;group&#148; of which the Holder is a member (the foregoing, &#147;<B><I>Attribution Parties</I></B>&#148;)) would beneficially own
a number of shares of Common Stock in excess of the Beneficial Ownership Limitation. For purposes of the foregoing sentence, the aggregate number of shares of Common Stock beneficially owned by such Holder and its Attribution Parties shall include
the number of shares of Common Stock issuable upon conversion of the Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock subject to the Notice of Conversion or the Automatic Conversion, as applicable, with respect to which
such determination is being made, but shall exclude the number of shares of Common Stock which are issuable upon (A)&nbsp;conversion of the remaining, unconverted Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock
beneficially owned by such Holder or any of its Attribution Parties, and (B)&nbsp;exercise or conversion of the unexercised or unconverted portion of any other securities of the Corporation (including any warrants) beneficially owned by such Holder
or any of its Attribution Parties that are subject to and would exceed a limitation on conversion or exercise similar to the limitation contained herein. Except as set forth in the preceding sentence, for purposes of this
<U>Section</U><U></U><U>&nbsp;6.4</U>, beneficial ownership shall be calculated in accordance with Section&nbsp;13(d) of the Exchange Act and the applicable rules and regulations of the Commission, and the terms &#147;beneficial ownership&#148; and
&#147;beneficially own&#148; have the meanings ascribed to such terms therein. In addition, for purposes hereof, &#147;group&#148; has the meaning set forth in Section&nbsp;13(d) of the Exchange Act and the applicable rules and regulations of the
Commission. For purposes of this <U>Section</U><U></U><U>&nbsp;6.4</U>, in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as stated in the most recent of the
following: (A)&nbsp;the Corporation&#146;s most recent periodic or annual filing with the Commission, as the case may be, (B)&nbsp;a more recent public announcement by the Corporation that is filed with the Commission, or (C)&nbsp;a more recent
notice by the Corporation or the Corporation&#146;s transfer agent to the Holder setting forth the number of shares of Common Stock then outstanding. Upon the written request of a Holder (which may be by email), the Corporation shall, within two
(2)&nbsp;Trading Days thereof, confirm in writing to such Holder (which may be via email) the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to
any actual conversion or exercise of securities of the Corporation, including shares of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock, by such Holder or its Attribution Parties since the date as of which such number of
outstanding shares of Common Stock was last publicly reported or confirmed to the Holder. The &#147;<B><I>Beneficial Ownership Limitation</I></B>&#148; shall initially be set at the discretion of each Holder to a percentage designated by such Holder
on its signature page to the Purchase Agreement between 0% and 19.9% of the number of shares of the Common Stock outstanding or deemed to be outstanding as of the applicable measurement date, and such percentage shall be set at 19.9% for any Holder
that does not make such designation in the Purchase Agreement. The Corporation shall be entitled to rely on representations made to it by the Holder in any Notice of Conversion regarding its Beneficial Ownership Limitation. Notwithstanding the
foregoing, by written notice to the Corporation, (i)&nbsp;the Holder may reset the Beneficial Ownership Limitation percentage to a higher percentage, not to exceed 19.9%, which increase will not be effective until the sixty-first (61st) day after
such written notice is delivered to the Corporation, and (ii)&nbsp;the Holder may reset the Beneficial Ownership Limitation percentage to a lower percentage provided that such decrease shall not become effective until the later of (x) 5:00 p.m.
Eastern time on the third Business Day after the date of the Stockholder Approval and (y)&nbsp;if Stockholder Approval is not obtained within six months after the initial issuance of the Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT>
Preferred Stock, the date that is three Business Days after the date that is six months after the initial issuance of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock. Upon such a change by a Holder of the Beneficial Ownership Limitation, not to exceed 19.9%, the Beneficial Ownership
Limitation may not be further amended by such Holder without first providing the minimum notice required by this <U>Section</U><U></U><U>&nbsp;6.4</U>. Notwithstanding the foregoing, at any time following notice of a Fundamental Transaction, the
Holder may waive and/or change the Beneficial Ownership Limitation effective immediately upon written notice to the Corporation and may reinstitute a Beneficial Ownership Limitation at any time thereafter effective immediately upon written notice to
the Corporation. The provisions of this <U>Section</U><U></U><U>&nbsp;6.4 </U>shall be construed, corrected and implemented in a manner so as to effectuate the intended Beneficial Ownership Limitation herein contained and the shares of Common Stock
underlying the Securities in excess of the Beneficial Ownership Limitation shall not be deemed to be beneficially owned by the Purchaser for any purpose including for purposes of Section&nbsp;13(d) or Rule
<FONT STYLE="white-space:nowrap">16a-1(a)(1)</FONT> of the Exchange Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">6.5 <U>Mechanics of Conversion</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">6.5.1 <U>Delivery of Certificate or Electronic Issuance</U>. Upon Conversion not later than two (2)&nbsp;Trading Days after the applicable
Conversion Date, or if the Holder requests the issuance of physical certificate(s), two (2)&nbsp;Trading Days after receipt by the Corporation of the original certificate(s) representing such shares of Series A
<FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock being converted, duly endorsed, and the accompanying Notice of Conversion (the &#147;<B><I>Share Delivery Date</I></B>&#148;), the Corporation shall either: (a)&nbsp;deliver, or
cause to be delivered, to the converting Holder a physical certificate or certificates representing the number of Conversion Shares being acquired upon the conversion of shares of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred
Stock, or (b)&nbsp;in the case of a DWAC Delivery (if so requested by the Holder), electronically transfer such Conversion Shares by crediting the account of the Holder&#146;s prime broker with DTC through its DWAC system. If in the case of any
Notice of Conversion such certificate or certificates for the Conversion Shares are not delivered to or as directed by or, in the case of a DWAC Delivery, such shares are not electronically delivered to or as directed by, the applicable Holder by
the Share Delivery Date, the applicable Holder shall be entitled to elect to rescind such Notice of Conversion by written notice to the Corporation at any time on or before its receipt of such certificate or certificates for Conversion Shares or
electronic receipt of such shares, as applicable, in which event the Corporation shall promptly return to such Holder any original Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock certificate delivered to the Corporation
and such Holder shall promptly return to the Corporation any Common Stock certificates or otherwise direct the return of any shares of Common Stock delivered to the Holder through the DWAC system, representing the shares of Series A <FONT
STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock unsuccessfully tendered for conversion to the Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">6.5.2
<U>Obligation Absolute</U>. Subject to <U>Section</U><U></U><U>&nbsp;6.4</U> and subject to Holder&#146;s right to rescind a Notice of Conversion pursuant to <U>Section</U><U></U><U>&nbsp;6.5.1</U>, the Corporation&#146;s obligation to issue and
deliver the Conversion Shares upon conversion of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock in accordance with the terms hereof are absolute and unconditional, irrespective of any action or inaction by a Holder to
enforce the same, any waiver or consent with respect to any provision hereof, the recovery of any judgment against any Person or any action to enforce the same, or any setoff, counterclaim, recoupment, limitation or termination, or any breach or
alleged breach by such Holder or any other Person of any obligation to the Corporation or any violation or alleged violation of law by such Holder or any other Person, and irrespective of any other circumstance which might otherwise limit such
obligation of the Corporation to such Holder in connection with the issuance of such Conversion Shares. Subject to <U>Section</U><U></U><U>&nbsp;6.4</U> and subject to Holder&#146;s right to rescind a Notice of Conversion pursuant to
<U>Section</U><U></U><U>&nbsp;6.5.1</U>, in the event a Holder shall elect to convert any or all of its Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock, the Corporation may not refuse conversion based on any claim that
such Holder or anyone associated or affiliated with such Holder has been engaged in any violation of law, agreement or for any other reason, unless an injunction from a court, on notice to Holder, restraining and/or enjoining conversion of all or
part of the Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock of such Holder shall have been sought and obtained by the Corporation, and the Corporation posts a surety bond for the benefit of such Holder in the amount of
150% of the value of the Conversion Shares into which would be converted the Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock which is subject to such injunction, which bond shall remain in effect until the completion of
arbitration/litigation of the underlying dispute and the proceeds of which shall be payable to such Holder to the extent it obtains judgment. In the absence of such injunction, the Corporation shall, subject to <U>Section </U><U>6.4</U> and subject
to Holder&#146;s right to rescind a Notice of Conversion pursuant to <U>Section</U><U></U><U>&nbsp;6.5.1</U>, issue Conversion Shares upon a properly noticed conversion. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">6.5.3 <U>Cash Settlement</U>. If, at any time after the earlier of Stockholder Approval or
six months after the initial issuance of the Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock, the Corporation fails to deliver to a Holder such certificate or certificates, or electronically deliver (or cause its transfer
agent to electronically deliver) such shares in the case of a DWAC Delivery, pursuant to <U>Section</U><U></U><U>&nbsp;6.5.1</U> on or prior to the third (3rd) Trading Day after the Share Delivery Date applicable to such conversion (other than a
failure caused by (i)&nbsp;materially incorrect or incomplete information provided by Holder to the Corporation or (ii)&nbsp;the application of the Beneficial Ownership Limitation after Stockholder Approval (but, prior to the Stockholder Approval,
disregarding for such purpose any Beneficial Ownership Limitation), then, unless the Holder has rescinded the applicable Notice of Conversion pursuant to <U>Section</U><U></U><U>&nbsp;6.5.1</U>, the Corporation shall, at the request of the Holder,
pay an amount equal to the Fair Value (as defined below) of such undelivered shares, with such payment to be made within two Business Days from the date of request by the Holder, whereupon the Corporation&#146;s obligations to deliver such shares
underlying the Notice of Conversion shall be extinguished upon payment in full of the Fair Value of such undelivered shares; provided, however that such request shall be presumed to have been made by such Holder if Stockholder Approval shall not
have been obtained prior to the date on which the Notice of Conversion is delivered to the Corporation. For purposes of this <U>Section</U><U></U><U>&nbsp;6.5.3</U>, the &#147;Fair Value&#148; of shares shall be fixed with reference to the last
reported Closing Sale Price on the principal Trading Market on which the Common Stock is listed as of the Trading Day immediately prior to the date on which the Notice of Conversion is delivered to the Corporation. For the avoidance of doubt, the
cash settlement provisions set forth in this <U>Section</U><U></U><U>&nbsp;6.5.3</U> shall be available irrespective of the reason for the Corporation&#146;s failure to timely deliver Conversion Shares (other than a failure caused by
(i)&nbsp;materially incorrect or incomplete information provided by Holder to the Corporation or (ii)&nbsp;the application of the Beneficial Ownership Limitation after Stockholder Approval (but, prior to the Stockholder Approval, disregarding for
such purpose any Beneficial Ownership Limitation)), including due to limitations set forth in <U>Section</U><U></U><U>&nbsp;6.5.6</U>, the lack of obtaining Stockholder Approval, or due to applicable Trading Market rules. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">6.5.4 <U><FONT STYLE="white-space:nowrap">Buy-In</FONT> on Failure to Timely Deliver Certificates</U>. If the Corporation fails to deliver to
a Holder the applicable certificate or certificates or to effect a DWAC Delivery, as applicable, by the Share Delivery Date pursuant to <U>Section</U><U></U><U>&nbsp;6.5.1</U> (other than a failure caused by materially incorrect or incomplete
information provided by Holder to the Corporation or the application of the Beneficial Ownership Limitation), and if after such Share Delivery Date such Holder is required by its brokerage firm to purchase (in an open market transaction or
otherwise), or the Holder&#146;s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by such Holder of the Conversion Shares which such Holder was entitled to receive upon the conversion relating to such
Share Delivery Date (a &#147;<B><I><FONT STYLE="white-space:nowrap">Buy-In</FONT></I></B>&#148;), then the Corporation shall (A)&nbsp;pay in cash to such Holder (in addition to any other remedies available to or elected by such Holder) the amount by
which (x)&nbsp;such Holder&#146;s total purchase price (including any brokerage commissions) for the shares of Common Stock so purchased exceeds (y)&nbsp;the product of (1)&nbsp;the aggregate number of shares of Common Stock that such Holder was
entitled to receive from the conversion at issue multiplied by (2)&nbsp;the actual sale price at which the sell order giving rise to such purchase obligation was executed (including any brokerage commissions) and (B)&nbsp;at the option of such
Holder, either reissue (if surrendered) the shares of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock equal to the number of shares of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock submitted
for conversion or deliver to such Holder the number of shares of Common Stock that would have been issued if the Corporation had timely complied with its delivery requirements under <U>Section</U><U></U><U>&nbsp;6.5.1</U>. For example, if a Holder
purchases shares of Common Stock having a total purchase price of $11,000 to cover a <FONT STYLE="white-space:nowrap">Buy-In</FONT> with respect to an attempted conversion of shares of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT>
Preferred Stock with respect to which the actual sale price (including any brokerage commissions) giving rise to such purchase obligation was a total of $10,000 under clause (A)&nbsp;of the immediately preceding sentence, the Corporation shall be
required to pay such Holder $1,000. The Holder shall provide the Corporation written notice, within three (3)&nbsp;Trading Days after the occurrence of a <FONT STYLE="white-space:nowrap">Buy-In,</FONT> indicating the amounts payable to such Holder
in respect of such <FONT STYLE="white-space:nowrap">Buy-In</FONT> together with applicable confirmations and other evidence reasonably requested by the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Corporation. Nothing herein shall limit a Holder&#146;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific
performance and/or injunctive relief with respect to the Corporation&#146;s failure to timely deliver certificates representing shares of Common Stock upon conversion of the shares of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT>
Preferred Stock as required pursuant to the terms hereof or the cash settlement remedy set forth in <U>Section</U><U></U><U>&nbsp;6.5.3</U>; provided, however, that the Holder shall not be entitled to both (i)&nbsp;require the reissuance of the
shares of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock submitted for conversion for which such conversion was not timely honored and (ii)&nbsp;receive the number of shares of Common Stock that would have been issued if
the Corporation had timely complied with its delivery requirements under <U>Section</U><U></U><U>&nbsp;6.5.1</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">6.5.5 <U>Reservation
of Shares Issuable Upon Conversion</U>. The Corporation covenants that at all times it will reserve and keep available out of its authorized and unissued shares of Common Stock for the sole purpose of issuance upon conversion of the Series A <FONT
STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock, free from preemptive rights or any other actual contingent purchase rights of Persons other than the Holders of the Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred
Stock, not less than such aggregate number of shares of the Common Stock as shall be issuable (taking into account the adjustments of <U>Section</U><U></U><U>&nbsp;7</U>) upon the conversion of all outstanding shares of Series A <FONT
STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock. The Corporation covenants that all shares of Common Stock that shall be so issuable shall, upon issue, be duly authorized, validly issued, fully paid and
<FONT STYLE="white-space:nowrap">non-assessable.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">6.5.6 <U>Fractional Shares</U>. No fractional shares of Common Stock shall be
issued upon conversion of the Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock, no certificates or scrip for any such fractional shares shall be issued and no cash shall be paid for any such fractional shares. Any
fractional shares of Common Stock that a Holder of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock would otherwise be entitled to receive shall be aggregated with all fractional shares of Common Stock issuable to such
Holder and any remaining fractional shares shall be rounded up to the nearest whole share. Whether or not fractional shares would be issuable upon such conversion shall be determined on the basis of the total number of shares of Series A <FONT
STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock the Holder is at the time converting into Common Stock and the aggregate number of shares of Common Stock issuable upon such conversion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">6.5.7 <U>Transfer Taxes</U>. The issuance of certificates for shares of the Common Stock upon conversion of the Series A <FONT
STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock shall be made without charge to any Holder for any documentary stamp or similar taxes that may be payable in respect of the issue or delivery of such certificates, provided that the
Corporation shall not be required to pay any tax that may be payable in respect of any transfer involved in the issuance and delivery of any such certificate upon conversion in a name other than that of the registered Holder(s) of such shares of
Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock and the Corporation shall not be required to issue or deliver such certificates unless or until the Person or Persons requesting the issuance thereof shall have paid to the
Corporation the amount of such tax or shall have established to the satisfaction of the Corporation that such tax has been paid. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">6.6
<U>Status as Stockholder</U>. Upon each Conversion Date, (i)&nbsp;the shares of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock being converted shall be deemed converted into shares of Common Stock and (ii)&nbsp;the
Holder&#146;s rights as a holder of such converted shares of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock shall cease and terminate, excepting only the right to receive certificates for such shares of Common Stock and
to any remedies provided herein or otherwise available at law or in equity to such Holder because of a failure by the Corporation to comply with the terms of this Certificate of Designation. In all cases, the Holder shall retain all of its rights
and remedies for the Corporation&#146;s failure to convert Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock. In no event shall the Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock convert into
shares of Common Stock prior to the Stockholder Approval. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7. <U>Certain Adjustments</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">7.1 <U>Stock Dividends and Stock Splits</U>. If the Corporation, at any time while this Series A
<FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock is outstanding: (A)&nbsp;pays a stock dividend or otherwise makes a distribution or distributions payable in shares of Common Stock (which, for avoidance of doubt, shall not include
any shares of Common Stock issued by the Corporation upon conversion of this Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock) with respect to the then outstanding shares of Common Stock; (B)&nbsp;subdivides outstanding
shares of Common Stock into a larger number of shares; or (C)&nbsp;combines (including by way of a reverse stock split) outstanding shares of Common Stock into a smaller number of shares, then the Conversion Ratio shall be multiplied by a fraction
of which the numerator shall be the number of shares of Common Stock (excluding any treasury shares of the Corporation) outstanding immediately after such event and of which the denominator shall be the number of shares of Common Stock outstanding
immediately before such event (excluding any treasury shares of the Corporation). Any adjustment made pursuant to this <U>Section</U><U></U><U>&nbsp;7.1</U> shall become effective immediately after the record date for the determination of
stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision or combination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">7.2 <U>Fundamental Transaction</U>. If, at any time while this Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock is
outstanding, (A)&nbsp;the Corporation effects any merger or consolidation of the Corporation with or into another Person or any stock sale to, or other business combination (including, without limitation, a reorganization, recapitalization, <FONT
STYLE="white-space:nowrap">spin-off,</FONT> share exchange or scheme of arrangement) with or into another Person (other than such a transaction in which the Corporation is the surviving or continuing entity and its Common Stock is not exchanged for
or converted into other securities, cash or property), (B) the Corporation effects any sale, lease, transfer or exclusive license of all or substantially all of its assets in one transaction or a series of related transactions, (C)&nbsp;any tender
offer or exchange offer (whether by the Corporation or another Person) is completed pursuant to which more than 50% of the Common Stock not held by the Corporation or such Person is exchanged for or converted into other securities, cash or property,
or (D)&nbsp;the Corporation effects any reclassification of the Common Stock or any compulsory share exchange pursuant (other than as a result of a dividend, subdivision or combination covered by <U>Section</U><U></U><U>&nbsp;7.1</U>) to which the
Common Stock is effectively converted into or exchanged for other securities, cash or property (in any such case, a &#147;<B><I>Fundamental Transaction</I></B>&#148;), then, upon any subsequent conversion of this Series A <FONT
STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock the Holders shall have the right to receive, in lieu of the right to receive Conversion Shares, for each Conversion Share that would have been issuable upon such conversion immediately
prior to the occurrence of such Fundamental Transaction, the same kind and amount of securities, cash or property as it would have been entitled to receive upon the occurrence of such Fundamental Transaction if it had been, immediately prior to such
Fundamental Transaction, the holder of one share of Common Stock (the &#147;<B><I>Alternate Consideration</I></B>&#148;). For purposes of any such subsequent conversion, the determination of the Conversion Ratio shall be appropriately adjusted to
apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Corporation shall adjust the Conversion Ratio in a reasonable manner
reflecting the relative value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holders shall be
given the same choice as to the Alternate Consideration it receives upon any conversion of this Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock following such Fundamental Transaction. To the extent necessary to effectuate
the foregoing provisions, any successor to the Corporation or surviving entity in such Fundamental Transaction shall file a new certificate of designations with the same terms and conditions and issue to the Holders new preferred stock consistent
with the foregoing provisions and evidencing the Holders&#146; right to convert such preferred stock into Alternate Consideration. The terms of any agreement to which the Corporation is a party and pursuant to which a Fundamental Transaction is
effected shall include terms requiring any such successor or surviving entity to comply with the provisions of this <U>Section</U><U></U><U>&nbsp;7.2</U> and insuring that this Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred
Stock (or any such replacement security) will be similarly adjusted upon any subsequent transaction analogous to a Fundamental Transaction. The Corporation shall cause to be delivered to each Holder, at its last address as it shall appear upon the
stock books of the Corporation, written notice of any Fundamental Transaction at least 20 calendar days prior to the date on which such Fundamental Transaction is expected to become effective or close. Notwithstanding anything to the contrary
herein, the Corporation&#146;s disposition of certain assets pursuant to the CVR Agreement shall not constitute a Fundamental Transaction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">7.3 <U>Calculations</U>. All calculations under this <U>Section</U><U></U><U>&nbsp;7</U>
shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes of this <U>Section</U><U></U><U>&nbsp;7</U>, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be
the sum of the number of shares of Common Stock (excluding any treasury shares of the Corporation) issued and outstanding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.
<U>Redemption</U>. The shares of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock shall not be redeemable; provided, however, that the foregoing shall not limit the ability of the Corporation to purchase or otherwise deal
in such shares to the extent otherwise permitted hereby and by law, nor shall the foregoing limit the Holder&#146;s rights under <U>Section</U><U></U><U>&nbsp;6.5.3</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9. <U>Transfer</U>. A Holder may transfer any shares of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock together
with the accompanying rights set forth herein, held by such holder without the consent of the Corporation; provided that such transfer is in compliance with applicable securities laws. The Corporation shall in good faith (i)&nbsp;do and perform, or
cause to be done and performed, all such further acts and things, and (ii)&nbsp;execute and deliver all such other agreements, certificates, instruments and documents, in each case, as any holder of Series A
<FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock may reasonably request in order to carry out the intent and accomplish the purposes of this <U>Section</U><U></U><U>&nbsp;9</U>. The transferee of any shares of Series A <FONT
STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock shall be subject to the Beneficial Ownership Limitation applicable to the transferor as of the time of such transfer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">10. <U>Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock Register</U>. The Corporation shall maintain at its
principal executive offices (or such other office or agency of the Corporation as it may designate by notice to the Holders in accordance with <U>Section</U><U></U><U>&nbsp;11</U>), a register for the Series A
<FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock, in which the Corporation shall record (i)&nbsp;the name, address, and electronic mail address of each holder in whose name the shares of Series A
<FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock have been issued and (ii)&nbsp;the name, address, and electronic mail address of each transferee of any shares of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT>
Preferred Stock. The Corporation may deem and treat the registered Holder of shares of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock as the absolute owner thereof for the purpose of any conversion thereof and for all
other purposes. The Corporation shall keep the register open and available at all times during business hours for inspection by any holder of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock or his, her or its legal
representatives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">11. <U>Notices</U>. Any notice required or permitted by the provisions of this Certificate of Designation to be given to
a Holder of shares of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock shall be mailed, postage prepaid, to the post office address last shown on the records of the Corporation, or given by electronic communication in
compliance with the provisions of the Delaware General Corporation Law, and shall be deemed sent upon such mailing or electronic transmission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">12. <U>Book-Entry; Certificates</U>. The Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock will be issued in
book-entry form; provided that, if a Holder requests that such Holder&#146;s shares of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock be issued in certificated form, the Corporation will instead issue a stock certificate
to such Holder representing such Holder&#146;s shares of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock. To the extent that any shares of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock are
issued in book-entry form, references herein to &#147;certificates&#148; shall instead refer to the book-entry notation relating to such shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">13. <U>Waiver</U>. Any waiver by the Corporation or a Holder of a breach of any provision of this Certificate of Designation shall not operate
as or be construed to be a waiver of any other breach of such provision or of any breach of any other provision of this Certificate of Designation or a waiver by any other Holders. The failure of the Corporation or a Holder to insist upon strict
adherence to any term of this Certificate of Designation on one or more occasions shall not be considered a waiver or deprive that party (or any other Holder) of the right thereafter to insist upon strict adherence to that term or any other term of
this Certificate of Designation. Any waiver by the Corporation or a Holder must be in writing. Notwithstanding any provision in this Certificate of Designation to the contrary, any provision contained herein and any right of the Holders of Series A <FONT
STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
granted hereunder may be waived as to all shares of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock (and the Holders thereof) upon the written consent of the Holders
of not less than a majority of the shares of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock then outstanding, provided, however, that the Beneficial Ownership Limitation applicable to a Holder, and any provisions
contained herein that are related to such Beneficial Ownership Limitation, cannot be modified, waived or terminated without the consent of such Holder, provided further, that any proposed waiver that would, by its terms, have a disproportionate and
materially adverse effect on any Holder shall require the consent of such Holder(s). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">14. <U>Severability</U>. Whenever possible, each
provision hereof shall be interpreted in a manner as to be effective and valid under applicable law, but if any provision hereof is held to be prohibited by or invalid under applicable law, then such provision shall be ineffective only to the extent
of such prohibition or invalidity, without invalidating or otherwise adversely affecting the remaining provisions hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">15. <U>Status
of Converted Series </U><U>A</U><U> <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock</U>. If any shares of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock shall be converted or redeemed by the
Corporation, such shares shall, to the fullest extent permitted by applicable law, be retired and cancelled upon such acquisition, and shall not be reissued as a share of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock.
Any share of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock so acquired shall, upon its retirement and cancellation, and upon the taking of any action required by applicable law, resume the status of authorized but
unissued shares of preferred stock and shall no longer be designated as Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Remainder of Page Intentionally Left Blank</I>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, Aeglea BioTherapeutics, Inc. has caused this Certificate of
Designation of Preferences, Rights and Limitations of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Convertible Preferred Stock to be duly executed by its Chief Executive Officer on June&nbsp;22, 2023. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>AEGLEA BIOTHERAPEUTICS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Jonathan Alspaugh</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">Jonathan Alspaugh</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ANNEX A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">NOTICE OF CONVERSION </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(TO BE
EXECUTED BY THE REGISTERED HOLDER IN ORDER TO CONVERT SHARES OF SERIES A <FONT STYLE="white-space:nowrap">NON-VOTING</FONT> CONVERTIBLE PREFERRED STOCK) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned Holder hereby irrevocably elects to convert the number of shares of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred
Stock indicated below, represented in book-entry form, into shares of common stock, par value $0.0001 per share (the &#147;<B><I>Common Stock</I></B>&#148;), of Aeglea BioTherapeutics, Inc., a Delaware corporation (the
&#147;<B><I>Corporation</I></B>&#148;), as of the date written below. If securities are to be issued in the name of a Person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto. Capitalized terms
utilized but not defined herein shall have the meaning ascribed to such terms in that certain Certificate of Designation of Preferences, Rights and Limitations of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Convertible Preferred
Stock (the &#147;<B><I>Certificate of Designation</I></B>&#148;) filed by the Corporation with the Secretary of State of the State of Delaware on June&nbsp;22, 2023. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of the date hereof, the number of shares of Common Stock beneficially owned by the undersigned Holder (together with such Holder&#146;s Attribution
Parties), including the number of shares of Common Stock issuable upon conversion of the Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock subject to this Notice of Conversion, but excluding the number of shares of Common
Stock which are issuable upon (A)&nbsp;conversion of the remaining, unconverted Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock beneficially owned by such Holder or any of its Attribution Parties, and (B)&nbsp;exercise or
conversion of the unexercised or unconverted portion of any other securities of the Corporation (including any warrants) beneficially owned by such Holder or any of its Attribution Parties that are subject to a limitation on conversion or exercise
similar to the limitation contained in <U>Section</U><U></U><U>&nbsp;6.4</U> of the Certificate of Designation, is _____. For purposes hereof, beneficial ownership shall be calculated in accordance with Section&nbsp;13(d) of the Exchange Act and the
applicable regulations of the Commission. In addition, for purposes hereof, &#147;group&#148; has the meaning set forth in Section&nbsp;13(d) of the Exchange Act and the applicable regulations of the Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CONVERSION CALCULATIONS: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Date to Effect Conversion:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Number of shares of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock
owned prior to Conversion:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Number of shares of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock to
be Converted:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Number of shares of Common Stock to be Issued:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Address for delivery of physical certificates:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For DWAC Delivery, please provide the following: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Broker No.: ________________ </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Account No.: _______________ </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">[HOLDER]</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.4
<SEQUENCE>6
<FILENAME>d518298dex34.htm
<DESCRIPTION>EX-3.4
<TEXT>
<HTML><HEAD>
<TITLE>EX-3.4</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 3.4 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPYRE THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATE OF DESIGNATION OF PREFERENCES, </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RIGHTS AND LIMITATIONS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SERIES B <FONT
STYLE="white-space:nowrap">NON-VOTING</FONT> CONVERTIBLE PREFERRED STOCK </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Pursuant to Section&nbsp;151 of the </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">General Corporation Law of the State of Delaware </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">THE UNDERSIGNED DOES HEREBY CERTIFY, on behalf of Spyre Therapeutics, Inc., a Delaware corporation (the &#147;<B><I>Corporation</I></B>&#148;), that the
following resolution was duly adopted by the Board of Directors of the Corporation (the &#147;<B><I>Board of Directors</I></B>&#148;), in accordance with the provisions of Section&nbsp;151 of the General Corporation Law of the State of Delaware (the
&#147;<B><I>DGCL</I></B>&#148;), at a meeting duly called and held on November&nbsp;22, 2023, which resolution provides for the creation of a series of the Corporation&#146;s Preferred Stock, par value $0.0001 per share, which is designated as
&#147;Series B <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Convertible Preferred Stock,&#148; with the preferences, rights and limitations set forth therein relating to dividends, conversion, redemption, dissolution and distribution of assets
of the Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>: the Amended and Restated Certificate of Incorporation of the Corporation (the &#147;<B><I>Certificate
of Incorporation</I></B>&#148;), provides for a class of its authorized stock known as Preferred Stock, consisting of 10,000,000 shares, $0.0001 par value per share (the &#147;<B><I>Preferred Stock</I></B>&#148;), issuable from time to time in one
or more series. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>RESOLVED</B>: that, pursuant to authority conferred upon the Board of Directors by the Certificate of Incorporation,
(i)&nbsp;a series of Preferred Stock of the Corporation be, and hereby is authorized by the Board of Directors, (ii)&nbsp;the Board of Directors hereby authorizes the issuance of 150,000 shares of &#147;Series B
<FONT STYLE="white-space:nowrap">Non-Voting</FONT> Convertible Preferred Stock,&#148; and (iii)&nbsp;the Board of Directors hereby fixes the designations, powers, preferences and relative, participating, optional or other special rights, and the
qualifications, limitations or restrictions thereof, of such shares of Preferred Stock, in addition to any provisions set forth in the Certificate of Incorporation that are applicable to the Preferred Stock of all classes and series, as follows:
</P> <P STYLE="margin-top:24pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>TERMS OF SERIES B <FONT STYLE="white-space:nowrap">NON-VOTING</FONT> CONVERTIBLE PREFERRED STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1. <U>Definitions</U>. For the purposes hereof, the following terms shall have the following meanings: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Business Day</I></B>&#148; means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United
States or any day on which banking institutions in the State of New York are authorized or required by law or other governmental action to close. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I><FONT STYLE="white-space:nowrap">Buy-In</FONT></I></B>&#148; shall have the meaning set forth in
<U>Section</U><U></U><U>&nbsp;6.5.3</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Closing Sale Price</I></B>&#148; means, for any security as of any date, the last
closing trade price for such security immediately prior to 4:00 p.m., New York City time, on the principal Trading Market where such security is listed or traded, as reported by Bloomberg, L.P. (or an equivalent, reliable reporting service), or if
the foregoing do not apply, the last trade price of such security in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market on the electronic bulletin board for such security as reported by
Bloomberg, L.P., or, if no last trade price is reported for such security by Bloomberg, L.P., the average of the bid prices of any market makers for such security as reported on the OTC Pink Market by OTC Markets Group, Inc. If the Closing Sale
Price cannot be calculated for a security on a particular date on any of the foregoing bases, the Closing Sale Price of such security on such date shall be the fair market value as determined in good faith by the Board of Directors of the
Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Commission</I></B>&#148; means the United States Securities and Exchange Commission. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Common Stock</I></B>&#148; means the Corporation&#146;s common stock, par value
$0.0001 per share, and stock of any other class of securities into which such securities may hereafter be reclassified or changed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Conversion Shares</I></B>&#148; means, collectively, the shares of Common Stock issuable upon conversion of the shares of Series B
<FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock in accordance with the terms hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Exchange
Act</I></B>&#148; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Holder</I></B>&#148; means a holder of shares of Series B <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Person</I></B>&#148; means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint
venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Trading Day</I></B>&#148; means a day on which the principal Trading Market is open for business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Trading Market</I></B>&#148; means any of the following markets or exchanges on which the Common Stock is listed or quoted for
trading on the date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, or the New York Stock Exchange (or any successors to any of the foregoing). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2. <U>Designation, Amount and Par Value</U>. The series of Preferred Stock shall be designated as the Corporation&#146;s Series B <FONT
STYLE="white-space:nowrap">Non-Voting</FONT> Convertible Preferred Stock (the &#147;<B><I>Series B <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock</I></B>&#148;) and the number of shares so designated shall be 150,000. Each share
of Series B <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock shall have a par value of $0.0001 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.
<U>Dividends</U>. Holders shall be entitled to receive, and the Corporation shall pay, dividends on shares of the Series B <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock (on an <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">as-if-converted-to-Common-Stock</FONT></FONT></FONT></FONT> basis, without regard to the Beneficial Ownership Limitation (as defined below)) equal to and in
the same form, and in the same manner, as dividends (other than dividends on shares of the Common Stock payable in the form of Common Stock) actually paid on shares of the Common Stock when, as and if such dividends (other than dividends payable in
the form of Common Stock) are paid on shares of the Common Stock. Other than as set forth in the previous sentence, no other dividends shall be paid on shares of Series B <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock, and the
Corporation shall pay no dividends (other than dividends payable in the form of Common Stock) on shares of the Common Stock unless it simultaneously complies with the previous sentence. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4. <U>Voting Rights</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.1
Except as otherwise provided herein or as otherwise required by the DGCL, the Series B <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock shall have no voting rights. However, as long as any shares of Series B <FONT
STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock are outstanding, the Corporation shall not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series B
<FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock, alter or change adversely the powers, preferences or rights given to the Series B <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock or alter or amend this
Certificate of Designation, amend or repeal any provision of, or add any provision to, the Certificate of Incorporation or Amended and Restated Bylaws of the Corporation, or file any articles of amendment, certificate of designations, preferences,
limitations and relative rights of any series of Preferred Stock, if such action would adversely alter or change the preferences, rights, privileges or powers of, or restrictions provided for the benefit of the Series B <FONT
STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock, regardless of whether any of the foregoing actions shall be by means of amendment to the Certificate of Incorporation or by merger, consolidation, recapitalization, reclassification,
conversion or otherwise. Holders of shares of Common Stock acquired upon the conversion of shares of Series B <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock shall be entitled to the same voting rights as each other holder of
Common Stock, except that such holders may not vote such shares upon the proposal for Stockholder Approval (as defined below) in accordance with Rule 5635 of the listing rules of The Nasdaq Stock Market LLC. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.2 Any vote required or permitted under <U>Section</U><U></U><U>&nbsp;4.1</U> may be taken
at a meeting of the Holders or through the execution of an action by written consent in lieu of such meeting, provided that the consent is executed by Holders representing a majority of the outstanding shares of Series B <FONT
STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5. <U>Rank; Liquidation</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">5.1 The Series B <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock shall rank on parity with the Common Stock and the
Company&#146;s Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock as to distributions of assets upon liquidation, dissolution or winding up of the Corporation, whether voluntarily or involuntarily. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">5.2 Upon any liquidation, dissolution or <FONT STYLE="white-space:nowrap">winding-up</FONT> of the Corporation, whether voluntary or
involuntary (a &#147;<B><I>Liquidation</I></B>&#148;), each Holder shall be entitled to receive out of the assets, whether capital or surplus, of the Corporation the same amount that a holder of Common Stock would receive if the Series B <FONT
STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock were fully converted (disregarding for such purpose any Beneficial Ownership Limitations) to Common Stock which amounts shall be paid <I>pari</I><I></I><I>&nbsp;passu</I> with all holders
of Common Stock, plus an additional amount equal to any dividends declared on but unpaid to such shares. If, upon any such Liquidation, the assets of the Corporation shall be insufficient to pay the Holders of shares of the Series B <FONT
STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock the amount required under the preceding sentence, then all remaining assets of the Corporation shall be distributed ratably to the Holders and the holders of Common Stock in accordance
with the respective amounts that would be payable on all such securities if all amounts payable thereon were paid in full. For the avoidance of any doubt, a Fundamental Transaction shall not be deemed a Liquidation unless the Corporation expressly
declares that such Fundamental Transaction shall be treated as if it were a Liquidation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6. <U>Conversion</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">6.1 <U>Automatic Conversion on Stockholder Approval</U>. Effective as of 5:00 p.m. Eastern time on the third Business Day after the date that
the Corporation&#146;s stockholders approve the conversion of the Series B <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock into shares of Common Stock in accordance with the listing rules of the Nasdaq Stock Market (the
&#147;<B><I>Stockholder Approval</I></B>&#148;), each share of Series B <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock then outstanding shall automatically convert into a number of shares of Common Stock equal to the Conversion
Ratio (as defined below), subject to the Beneficial Ownership Limitation (the &#147;<B><I>Automatic Conversion</I></B>&#148;). The Corporation shall inform each Holder of the occurrence of the Stockholder Approval within one Business Day of such
Stockholder Approval. In determining the application of the Beneficial Ownership Limitations solely with respect to the Automatic Conversion, the Corporation shall calculate beneficial ownership for each Holder assuming beneficial ownership by such
Holder of: (x)&nbsp;the number of shares of Common Stock issuable to such Holder in such Automatic Conversion, plus (y)&nbsp;any additional shares of Common Stock for which a Holder has provided the Corporation with prior written notice of
beneficial ownership within 30 days prior to the date of Stockholder Approval (a &#147;<B><I>Beneficial Ownership Statement</I></B>&#148;) and assuming the conversion of all shares of Preferred Stock held by all other holders of Preferred Stock less
the aggregate number of shares of Preferred Stock held by all other holders of Preferred Stock that will not convert into shares of Common Stock on account of the application of any Beneficial Ownership Limitations applicable to any such other
holders. If a Holder fails to provide the Corporation with a Beneficial Ownership Statement within 30 days prior to the date of Stockholder Approval, then the Corporation shall presume the Holder&#146;s beneficial ownership of Common Stock
(excluding the Conversion Shares) to be zero. The shares of Series B <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock that are converted in the Automatic Conversion are referred to as the &#147;<B><I>Converted Stock</I></B>&#148;.
For the avoidance of doubt, any shares of Series B <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock that are not automatically converted pursuant to the Automatic Conversion as a result of a Beneficial Ownership Limitation shall
remain outstanding until such shares of Series B <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock are converted pursuant to <U>Section</U><U></U><U>&nbsp;6.2</U>. The Conversion Shares shall be issued as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">6.1.1 Converted Stock that is registered in book-entry form shall be automatically cancelled upon the Automatic Conversion and converted into
the corresponding Conversion Shares, which shares shall be issued in book-entry form and without any action on the part of the Holders and shall be delivered to the Holders within two Business Days of the effectiveness of the Automatic Conversion.
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">6.1.2 Converted Stock that is issued in certificated form shall be deemed converted into
the corresponding Conversion Shares on the date of Automatic Conversion and the Holder&#146;s rights as a holder of such shares of Converted Stock shall cease and terminate on such date, excepting only the right to receive the Conversion Shares upon
the Holder tendering to the Corporation (or its designated agent) the stock certificate(s) (duly endorsed) representing such certificated Converted Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">6.1.3 Notwithstanding the cancellation of the Converted Stock upon the Automatic Conversion, Holders of Converted Stock shall continue to
have any remedies provided herein or otherwise available at law or in equity to such Holder because of a failure by the Corporation to comply with the terms of this Certificate of Designation. In all cases, the Holder shall retain all of its rights
and remedies for the Corporation&#146;s failure to convert the Converted Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><U>6.2 Conversion at Option of Holder</U>. At any time
and from time to time following 5:00 p.m. Eastern Time on the third Business Day after the date that the Stockholder Approval is obtained by the Corporation, each share of Series B <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock
then outstanding, shall be convertible, at the option of the Holder thereof into a number of shares of Common Stock equal to the Conversion Ratio, subject to the Beneficial Ownership Limitation (each, an &#147;<B><I>Optional
Conversion</I></B>&#148;). Holders shall effect conversions by providing the Corporation with the form of conversion notice attached hereto as <B><U>Annex A</U></B> (a &#147;<B><I>Notice of Conversion</I></B>&#148;), duly completed and executed.
Provided the Corporation&#146;s transfer agent is participating in the Depository Trust Company (&#147;<B><I>DTC</I></B>&#148;) Fast Automated Securities Transfer program, the Notice of Conversion may specify, at the Holder&#146;s election, whether
the applicable Conversion Shares shall be credited to the account of the Holder&#146;s prime broker with DTC through its Deposit Withdrawal Agent Commission system (a &#147;<B><I>DWAC Delivery</I></B>&#148;). The date on which an Optional Conversion
shall be deemed effective (the &#147;<B><I>Conversion Date</I></B>&#148;) shall be the Trading Day that the Notice of Conversion, completed and executed, is sent via email to, and received during regular business hours by, the Corporation; provided,
that the original certificate(s) (if any) representing such shares of Series B <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock being converted, duly endorsed, and the accompanying Notice of Conversion, are received by the
Corporation within two (2)&nbsp;Trading Days thereafter. In all other cases, the Conversion Date shall be defined as the Trading Day on which the original certificate(s) (if any) representing such shares of Series B
<FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock being converted, duly endorsed, and the accompanying Notice of Conversion, are received by the Corporation. The calculations set forth in the Notice of Conversion shall control in
the absence of manifest or mathematical error. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">6.3 <U>Conversion Ratio</U>. The &#147;<B><I>Conversion Ratio</I></B>&#148; for each
share of Series B <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock shall be 40 shares of Common Stock issuable upon the conversion (the &#147;<B><I>Conversion</I></B>&#148;) of each share of Series B
<FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock (corresponding to a ratio of 40:1), subject to adjustment as provided herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">6.4 <U>Beneficial Ownership Limitation</U>. Notwithstanding anything herein to the contrary, the Corporation shall not effect any conversion
of any share of Series B <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock, including pursuant to <U>Section</U><U></U><U>&nbsp;6.1</U>, and a Holder shall not have the right to convert any portion of the Series B <FONT
STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock pursuant to <U>Section</U><U></U><U>&nbsp;6.2</U>, to the extent that, after giving effect to an attempted conversion set forth on an applicable Notice of Conversion with respect to the
Series B Preferred Stock, such Holder (or any of such Holder&#146;s Affiliates or any other Person who would be a beneficial owner of Common Stock beneficially owned by the Holder for purposes of Section&nbsp;13(d) or Section&nbsp;16 of the Exchange
Act and the applicable rules and regulations of the Commission, including any &#147;group&#148; of which the Holder is a member (the foregoing, &#147;<B><I>Attribution Parties</I></B>&#148;)), would beneficially own a number of shares of Common
Stock in excess of the Beneficial Ownership Limitation. For purposes of the foregoing sentence, the aggregate number of shares of Common Stock beneficially owned by such Holder and its Attribution Parties shall include the number of shares of Common
Stock issuable upon conversion of the Series B <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock subject to the Notice of Conversion or the Automatic Conversion, as applicable, with respect to which such determination is being made,
but shall exclude the number of shares of Common Stock which are issuable upon (A)&nbsp;conversion of the remaining, unconverted Series B <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock beneficially owned by such Holder or any of
its Attribution Parties, and (B)&nbsp;exercise or conversion of the unexercised or unconverted portion of any other securities of the Corporation (including any Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock or warrants)
beneficially owned by such Holder or any of its Attribution Parties that are subject to and would exceed a limitation on conversion or exercise similar to the limitation contained herein. Except as set forth in the preceding sentence, for purposes
of this <U>Section</U><U></U><U>&nbsp;6.4</U>, beneficial ownership shall be calculated in accordance with Section&nbsp;13(d) of the Exchange Act and the applicable rules and regulations of the Commission, and the terms &#147;beneficial
ownership&#148; and &#147;beneficially own&#148; have the meanings ascribed to such terms therein. In addition, for purposes hereof, &#147;group&#148; has the meaning set forth in Section&nbsp;13(d) of the Exchange Act and the
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
applicable rules and regulations of the Commission. For purposes of this <U>Section</U><U></U><U>&nbsp;6.4</U>, in determining the number of outstanding shares of Common Stock, a Holder may rely
on the number of outstanding shares of Common Stock as stated in the most recent of the following: (A)&nbsp;the Corporation&#146;s most recent periodic or annual filing with the Commission, as the case may be, (B)&nbsp;a more recent public
announcement by the Corporation that is filed with the Commission, or (C)&nbsp;a more recent notice by the Corporation or the Corporation&#146;s transfer agent to the Holder setting forth the number of shares of Common Stock then outstanding. Upon
the written request of a Holder (which may be by email), the Corporation shall, within two (2)&nbsp;Trading Days thereof, confirm in writing to such Holder (which may be via email) the number of shares of Common Stock then outstanding. In any case,
the number of outstanding shares of Common Stock shall be determined after giving effect to any actual conversion or exercise of securities of the Corporation, including shares of Series B <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred
Stock, by such Holder or its Attribution Parties since the date as of which such number of outstanding shares of Common Stock was last publicly reported or confirmed to the Holder. The &#147;<B><I>Beneficial Ownership Limitation</I></B>&#148; shall
initially be set at the discretion of each Holder between 0% and 19.9% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock pursuant to the Notice of Conversion or the
Automatic Conversion, as applicable (to the extent permitted pursuant to this <U>Section</U><U></U><U>&nbsp;6.4</U>). The Corporation shall be entitled to rely on representations made to it by the Holder in any Notice of Conversion regarding its
Beneficial Ownership Limitation. Notwithstanding the foregoing, by written notice to the Corporation, (i)&nbsp;the Holder may reset the Beneficial Ownership Limitation percentage to a higher percentage, not to exceed 19.9%, which increase will not
be effective until the sixty-first (61st) day after such written notice is delivered to the Corporation, and (ii)&nbsp;the Holder may reset the Beneficial Ownership Limitation percentage to a lower percentage effective immediately after the delivery
of such notice to the Corporation, provided that such decrease shall not become effective until after the later of (x) 5:00 p.m. Eastern time on the third Business Day after the date of the Stockholder Approval and (y)&nbsp;if Stockholder Approval
is not obtained within six months after the initial issuance of the Series B <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock, the date that is three Business Days after the date that is six months after the initial issuance of the
Series B <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock. Upon such an increase by a Holder of the Beneficial Ownership Limitation pursuant to clause (i), not to exceed 19.9%, the Beneficial Ownership Limitation may not be further
increased by such Holder without first providing the minimum notice required by this <U>Section</U><U></U><U>&nbsp;6.4</U>. Notwithstanding the foregoing, at any time following notice of a Fundamental Transaction, the Holder may waive and/or change
the Beneficial Ownership Limitation effective immediately upon written notice to the Corporation and may reinstitute a Beneficial Ownership Limitation at any time thereafter effective immediately upon written notice to the Corporation. The
provisions of this <U>Section</U><U></U><U>&nbsp;6.4</U> shall be construed, corrected and implemented in a manner so as to effectuate the intended Beneficial Ownership Limitation herein contained and the shares of Common Stock underlying the
Securities in excess of the Beneficial Ownership Limitation shall not be deemed to be beneficially owned by the Purchaser for any purpose including for purposes of Section&nbsp;13(d) or Rule <FONT STYLE="white-space:nowrap">16a-1(a)(1)</FONT> of the
Exchange Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">6.5 <U>Mechanics of Conversion</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">6.5.1 <U>Delivery of Certificate or Electronic Issuance</U>. Upon Conversion not later than two (2)&nbsp;Trading Days after the applicable
Conversion Date, or if the Holder requests the issuance of physical certificate(s), two (2)&nbsp;Trading Days after receipt by the Corporation of the original certificate(s) representing such shares of Series B
<FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock being converted, duly endorsed, and the accompanying Notice of Conversion (the &#147;<B><I>Share Delivery Date</I></B>&#148;), the Corporation shall either: (a)&nbsp;deliver, or
cause to be delivered, to the converting Holder a physical certificate or certificates representing the number of Conversion Shares being acquired upon the conversion of shares of Series B <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred
Stock, or (b)&nbsp;in the case of a DWAC Delivery (if so requested by the Holder), electronically transfer such Conversion Shares by crediting the account of the Holder&#146;s prime broker with DTC through its DWAC system. If in the case of any
Notice of Conversion such certificate or certificates for the Conversion Shares are not delivered to or as directed by or, in the case of a DWAC Delivery, such shares are not electronically delivered to or as directed by, the applicable Holder by
the Share Delivery Date, the applicable Holder shall be entitled to elect to rescind such Notice of Conversion by written notice to the Corporation at any time on or before its receipt of such certificate or certificates for Conversion Shares or
electronic receipt of such shares, as applicable, in which event the Corporation shall promptly return to such Holder any original Series B <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock certificate delivered to the Corporation
and such Holder shall promptly return to the Corporation any Common Stock certificates or otherwise direct the return of any shares of Common Stock delivered to the Holder through the DWAC system, representing the shares of Series B <FONT
STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock unsuccessfully tendered for conversion to the Corporation. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">6.5.2 <U>Obligation Absolute</U>. Subject to <U>Section</U><U></U><U>&nbsp;6.4</U> and
subject to Holder&#146;s right to rescind a Notice of Conversion pursuant to <U>Section</U><U></U><U>&nbsp;6.5.1</U>, the Corporation&#146;s obligation to issue and deliver the Conversion Shares upon conversion of Series B <FONT
STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock in accordance with the terms hereof are absolute and unconditional, irrespective of any action or inaction by a Holder to enforce the same, any waiver or consent with respect to any
provision hereof, the recovery of any judgment against any Person or any action to enforce the same, or any setoff, counterclaim, recoupment, limitation or termination, or any breach or alleged breach by such Holder or any other Person of any
obligation to the Corporation or any violation or alleged violation of law by such Holder or any other Person, and irrespective of any other circumstance which might otherwise limit such obligation of the Corporation to such Holder in connection
with the issuance of such Conversion Shares. Subject to <U>Section</U><U></U><U>&nbsp;6.4</U> and subject to Holder&#146;s right to rescind a Notice of Conversion pursuant to <U>Section</U><U></U><U>&nbsp;6.5.1</U>, in the event a Holder shall elect
to convert any or all of its Series B <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock, the Corporation may not refuse conversion based on any claim that such Holder or anyone associated or affiliated with such Holder has been
engaged in any violation of law, agreement or for any other reason, unless an injunction from a court, on notice to Holder, restraining and/or enjoining conversion of all or part of the Series B <FONT STYLE="white-space:nowrap">Non-Voting</FONT>
Preferred Stock of such Holder shall have been sought and obtained by the Corporation, and the Corporation posts a surety bond for the benefit of such Holder in the amount of 150% of the value of the Conversion Shares into which would be converted
the Series B <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock which is subject to such injunction, which bond shall remain in effect until the completion of arbitration/litigation of the underlying dispute and the proceeds of which
shall be payable to such Holder to the extent it obtains judgment. In the absence of such injunction, the Corporation shall, subject to <U>Section</U><U></U><U>&nbsp;6.4</U> and subject to Holder&#146;s right to rescind a Notice of Conversion
pursuant to <U>Section</U><U></U><U>&nbsp;6.5.1</U>, issue Conversion Shares upon a properly noticed conversion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">6.5.3 <U>Cash
Settlement</U>. If, at any time after the earlier of Stockholder Approval or six months after the initial issuance of the Series B <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock, the Corporation fails to deliver to a Holder such
certificate or certificates, or electronically deliver (or cause its transfer agent to electronically deliver) such shares in the case of a DWAC Delivery, pursuant to <U>Section</U><U></U><U>&nbsp;6.5.1</U> on or prior to the third (3rd) Trading Day
after the Share Delivery Date applicable to such conversion (other than a failure caused by (i)&nbsp;materially incorrect or incomplete information provided by Holder to the Corporation or (ii)&nbsp;the application of the Beneficial Ownership
Limitation after Stockholder Approval (but, prior to the Stockholder Approval, disregarding for such purpose any Beneficial Ownership Limitation)), then, unless the Holder has rescinded the applicable Notice of Conversion pursuant to
<U>Section</U><U></U><U>&nbsp;6.5.1</U>, the Corporation shall, at the request of the Holder, pay an amount equal to the Fair Value (as defined below) of such undelivered shares, with such payment to be made within two Business Days from the date of
request by the Holder, whereupon the Corporation&#146;s obligations to deliver such shares underlying the Notice of Conversion shall be extinguished upon payment in full of the Fair Value of such undelivered shares; provided, however that such
request shall be presumed to have been made by such Holder if Stockholder Approval shall not have been obtained prior to the date on which the Notice of Conversion is delivered to the Corporation. For purposes of this
<U>Section</U><U></U><U>&nbsp;6.5.3</U>, the &#147;Fair Value&#148; of shares shall be fixed with reference to the last reported Closing Sale Price on the principal Trading Market on which the Common Stock is listed as of the Trading Day immediately
prior to the date on which the Notice of Conversion is delivered to the Corporation. For the avoidance of doubt, the cash settlement provisions set forth in this <U>Section</U><U></U><U>&nbsp;6.5.3</U> shall be available irrespective of the reason
for the Corporation&#146;s failure to timely deliver Conversion Shares (other than a failure caused by (i)&nbsp;materially incorrect or incomplete information provided by Holder to the Corporation or (ii)&nbsp;the application of the Beneficial
Ownership Limitation after Stockholder Approval (but, prior to the Stockholder Approval, disregarding for such purpose any Beneficial Ownership Limitation)), including due to limitations set forth in <U>Section</U><U></U><U>&nbsp;6.5.6</U>, the lack
of obtaining Stockholder Approval, or due to applicable Trading Market rules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">6.5.4 <U>Buy-In on Failure to Timely Deliver
Certificates</U>. If the Corporation fails to deliver to a Holder the applicable certificate or certificates or to effect a DWAC Delivery, as applicable, by the Share Delivery Date pursuant to <U>Section</U><U></U><U>&nbsp;6.5.1</U> (other than a
failure caused by materially incorrect or incomplete information provided by Holder to the Corporation or the application of the Beneficial Ownership Limitation), and if after such Share Delivery Date such Holder is required by its brokerage firm to
purchase (in an open market transaction or otherwise), or the Holder&#146;s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by such Holder of the Conversion Shares which such Holder was entitled to
receive upon the conversion relating to such Share Delivery Date (a &#147;<B><I><FONT STYLE="white-space:nowrap">Buy-In</FONT></I></B>&#148;), then the Corporation shall (A)&nbsp;pay in cash to such Holder (in addition to any other remedies
available to or elected by such Holder) the amount by which (x)&nbsp;such Holder&#146;s total purchase price (including any brokerage commissions) for the shares of Common Stock so purchased </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
exceeds (y)&nbsp;the product of (1)&nbsp;the aggregate number of shares of Common Stock that such Holder was entitled to receive from the conversion at issue multiplied by (2)&nbsp;the actual
sale price at which the sell order giving rise to such purchase obligation was executed (including any brokerage commissions) and (B)&nbsp;at the option of such Holder, either reissue (if surrendered) the shares of Series B <FONT
STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock equal to the number of shares of Series B <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock submitted for conversion or deliver to such Holder the number of shares of
Common Stock that would have been issued if the Corporation had timely complied with its delivery requirements under <U>Section</U><U></U><U>&nbsp;6.5.1</U>. For example, if a Holder purchases shares of Common Stock having a total purchase price of
$11,000 to cover a <FONT STYLE="white-space:nowrap">Buy-In</FONT> with respect to an attempted conversion of shares of Series B <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock with respect to which the actual sale price (including
any brokerage commissions) giving rise to such purchase obligation was a total of $10,000 under clause (A)&nbsp;of the immediately preceding sentence, the Corporation shall be required to pay such Holder $1,000. The Holder shall provide the
Corporation written notice, within three (3)&nbsp;Trading Days after the occurrence of a <FONT STYLE="white-space:nowrap">Buy-In,</FONT> indicating the amounts payable to such Holder in respect of such <FONT STYLE="white-space:nowrap">Buy-In</FONT>
together with applicable confirmations and other evidence reasonably requested by the Corporation. Nothing herein shall limit a Holder&#146;s right to pursue any other remedies available to it hereunder, at law or in equity including, without
limitation, a decree of specific performance and/or injunctive relief with respect to the Corporation&#146;s failure to timely deliver certificates representing shares of Common Stock upon conversion of the shares of Series B <FONT
STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock as required pursuant to the terms hereof or the cash settlement remedy set forth in <U>Section</U><U></U><U>&nbsp;6.5.3</U>; provided, however, that the Holder shall not be entitled to
both (i)&nbsp;require the reissuance of the shares of Series B <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock submitted for conversion for which such conversion was not timely honored and (ii)&nbsp;receive the number of shares of
Common Stock that would have been issued if the Corporation had timely complied with its delivery requirements under <U>Section</U><U></U><U>&nbsp;6.5.1</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">6.5.5 <U>Reservation of Shares Issuable Upon Conversion</U>. The Corporation covenants that at all times it will reserve and keep available
out of its authorized and unissued shares of Common Stock for the sole purpose of issuance upon conversion of the Series B <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock, free from preemptive rights or any other actual contingent
purchase rights of Persons other than the Holders of the Series B <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock, not less than such aggregate number of shares of the Common Stock as shall be issuable (taking into account the
adjustments of <U>Section</U><U></U><U>&nbsp;7</U>) upon the conversion of all outstanding shares of Series B <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock. The Corporation covenants that all shares of Common Stock that shall be
so issuable shall, upon issue, be duly authorized, validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable.</FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">6.5.6 <U>Fractional Shares</U>. No fractional shares of Common Stock shall be issued upon conversion of the Series B <FONT
STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock, no certificates or scrip for any such fractional shares shall be issued and no cash shall be paid for any such fractional shares. Any fractional shares of Common Stock that a Holder of
Series B <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock would otherwise be entitled to receive shall be aggregated with all fractional shares of Common Stock issuable to such Holder and any remaining fractional shares shall be
rounded up to the nearest whole share. Whether or not fractional shares would be issuable upon such conversion shall be determined on the basis of the total number of shares of Series B <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred
Stock the Holder is at the time converting into Common Stock and the aggregate number of shares of Common Stock issuable upon such conversion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">6.5.7 <U>Transfer Taxes</U>. The issuance of certificates for shares of the Common Stock upon conversion of the Series B <FONT
STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock shall be made without charge to any Holder for any documentary stamp or similar taxes that may be payable in respect of the issue or delivery of such certificates, provided that the
Corporation shall not be required to pay any tax that may be payable in respect of any transfer involved in the issuance and delivery of any such certificate upon conversion in a name other than that of the registered Holder(s) of such shares of
Series B <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock and the Corporation shall not be required to issue or deliver such certificates unless or until the Person or Persons requesting the issuance thereof shall have paid to the
Corporation the amount of such tax or shall have established to the satisfaction of the Corporation that such tax has been paid. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">6.6
<U>Status as Stockholder</U>. Upon each Conversion Date, (i)&nbsp;the shares of Series B <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock being converted shall be deemed converted into shares of Common Stock and (ii)&nbsp;the
Holder&#146;s rights as a holder of such converted shares of Series B <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock shall cease and terminate, excepting only the right to receive certificates for such shares of Common Stock and
to any remedies provided herein or otherwise available at law or in equity to such Holder because of a failure by the Corporation to comply with the terms of this Certificate of Designation. In all cases, the Holder shall retain all of its rights
and remedies for the Corporation&#146;s failure to convert Series B <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock. In no event shall the Series B <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock convert into
shares of Common Stock prior to the Stockholder Approval. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7. <U>Certain Adjustments</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">7.1 <U>Stock Dividends and Stock Splits</U>. If the Corporation, at any time while this Series B
<FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock is outstanding: (A)&nbsp;pays a stock dividend or otherwise makes a distribution or distributions payable in shares of Common Stock (which, for avoidance of doubt, shall not include
any shares of Common Stock issued by the Corporation upon conversion of this Series B <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock) with respect to the then outstanding shares of Common Stock; (B)&nbsp;subdivides outstanding
shares of Common Stock into a larger number of shares; or (C)&nbsp;combines (including by way of a reverse stock split) outstanding shares of Common Stock into a smaller number of shares, then the Conversion Ratio shall be multiplied by a fraction
of which the numerator shall be the number of shares of Common Stock (excluding any treasury shares of the Corporation) outstanding immediately after such event and of which the denominator shall be the number of shares of Common Stock outstanding
immediately before such event (excluding any treasury shares of the Corporation). Any adjustment made pursuant to this <U>Section</U><U></U><U>&nbsp;7.1</U> shall become effective immediately after the record date for the determination of
stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision or combination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">7.2 <U>Fundamental Transaction</U>. If, at any time while this Series B <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock is
outstanding, (A)&nbsp;the Corporation effects any merger or consolidation of the Corporation with or into another Person or any stock sale to, or other business combination (including, without limitation, a reorganization, recapitalization, <FONT
STYLE="white-space:nowrap">spin-off,</FONT> share exchange or scheme of arrangement) with or into another Person (other than such a transaction in which the Corporation is the surviving or continuing entity and its Common Stock is not exchanged for
or converted into other securities, cash or property), (B) the Corporation effects any sale, lease, transfer or exclusive license of all or substantially all of its assets in one transaction or a series of related transactions, (C)&nbsp;any tender
offer or exchange offer (whether by the Corporation or another Person) is completed pursuant to which more than 50% of the Common Stock not held by the Corporation or such Person is exchanged for or converted into other securities, cash or property,
or (D)&nbsp;the Corporation effects any reclassification of the Common Stock or any compulsory share exchange pursuant (other than as a result of a dividend, subdivision or combination covered by <U>Section</U><U></U><U>&nbsp;7.1</U>) to which the
Common Stock is effectively converted into or exchanged for other securities, cash or property (in any such case, a &#147;<B><I>Fundamental Transaction</I></B>&#148;), then, upon any subsequent conversion of this Series B <FONT
STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock the Holders shall have the right to receive, in lieu of the right to receive Conversion Shares, for each Conversion Share that would have been issuable upon such conversion immediately
prior to the occurrence of such Fundamental Transaction, the same kind and amount of securities, cash or property as it would have been entitled to receive upon the occurrence of such Fundamental Transaction if it had been, immediately prior to such
Fundamental Transaction, the holder of one share of Common Stock (the &#147;<B><I>Alternate Consideration</I></B>&#148;). For purposes of any such subsequent conversion, the determination of the Conversion Ratio shall be appropriately adjusted to
apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Corporation shall adjust the Conversion Ratio in a reasonable manner
reflecting the relative value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holders shall be
given the same choice as to the Alternate Consideration it receives upon any conversion of this Series B <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock following such Fundamental Transaction. To the extent necessary to effectuate
the foregoing provisions, any successor to the Corporation or surviving entity in such Fundamental Transaction shall file a new certificate of designations with the same terms and conditions and issue to the Holders new preferred stock consistent
with the foregoing provisions and evidencing the Holders&#146; right to convert such preferred stock into Alternate Consideration. The terms of any agreement to which the Corporation is a party and pursuant to which a Fundamental Transaction is
effected shall include terms requiring any such successor or surviving entity to comply with the provisions of this <U>Section</U><U></U><U>&nbsp;7.2</U> and insuring that this Series B <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred
Stock (or any such replacement security) will be similarly adjusted upon any subsequent transaction analogous to a Fundamental Transaction. The Corporation shall cause to be delivered to each Holder, at its last address as it shall appear upon the
stock books of the Corporation, written notice of any Fundamental Transaction at least 20 calendar days prior to the date on which such Fundamental Transaction is expected to become effective or close. Notwithstanding anything to the contrary
herein, the Corporation&#146;s disposition of certain assets pursuant to that certain Contingent Value Rights Agreement dated as of July&nbsp;7, 2023 by and between the Corporation and American Stock Transfer&nbsp;&amp; Trust Company, LLC, as may be
amended from time to time, shall not constitute a Fundamental Transaction. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">7.3 <U>Calculations</U>. All calculations under this <U>Section</U><U></U><U>&nbsp;7</U>
shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes of this <U>Section</U><U></U><U>&nbsp;7</U>, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be
the sum of the number of shares of Common Stock (excluding any treasury shares of the Corporation) issued and outstanding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.
<U>Redemption</U>. The shares of Series B <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock shall not be redeemable; provided, however, that the foregoing shall not limit the ability of the Corporation to purchase or otherwise deal
in such shares to the extent otherwise permitted hereby and by law, nor shall the foregoing limit the Holder&#146;s rights under <U>Section</U><U></U><U>&nbsp;6.5.3</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9. <U>Transfer</U>. A Holder may transfer any shares of Series B <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock together
with the accompanying rights set forth herein, held by such holder without the consent of the Corporation; provided that such transfer is in compliance with applicable securities laws. The Corporation shall in good faith (i)&nbsp;do and perform, or
cause to be done and performed, all such further acts and things, and (ii)&nbsp;execute and deliver all such other agreements, certificates, instruments and documents, in each case, as any holder of Series B
<FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock may reasonably request in order to carry out the intent and accomplish the purposes of this <U>Section</U><U></U><U>&nbsp;9</U>. The transferee of any shares of Series B <FONT
STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock shall be subject to the Beneficial Ownership Limitation applicable to the transferor as of the time of such transfer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">10. <U>Series B <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock Register</U>. The Corporation shall maintain at its
principal executive offices (or such other office or agency of the Corporation as it may designate by notice to the Holders in accordance with <U>Section</U><U></U><U>&nbsp;11</U>), a register for the Series B
<FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock, in which the Corporation shall record (i)&nbsp;the name, address, and electronic mail address of each holder in whose name the shares of Series B
<FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock have been issued and (ii)&nbsp;the name, address, and electronic mail address of each transferee of any shares of Series B <FONT STYLE="white-space:nowrap">Non-Voting</FONT>
Preferred Stock. The Corporation may deem and treat the registered Holder of shares of Series B <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock as the absolute owner thereof for the purpose of any conversion thereof and for all
other purposes. The Corporation shall keep the register open and available at all times during business hours for inspection by any holder of Series B <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock or his, her or its legal
representatives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">11. <U>Notices</U>. Any notice required or permitted by the provisions of this Certificate of Designation to be given to
a Holder of shares of Series B <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock shall be mailed, postage prepaid, to the post office address last shown on the records of the Corporation, or given by electronic communication in
compliance with the provisions of the Delaware General Corporation Law, and shall be deemed sent upon such mailing or electronic transmission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">12. <U>Book-Entry; Certificates</U>. The Series B <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock will be issued in
book-entry form; provided that, if a Holder requests that such Holder&#146;s shares of Series B <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock be issued in certificated form, the Corporation will instead issue a stock certificate
to such Holder representing such Holder&#146;s shares of Series B <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock. To the extent that any shares of Series B <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock are
issued in book-entry form, references herein to &#147;certificates&#148; shall instead refer to the book-entry notation relating to such shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">13. <U>Lost or Mutilated Series B <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock Certificate</U>. If a Holder&#146;s
Series B <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock certificate shall be mutilated, lost, stolen or destroyed, the Corporation shall execute and deliver, in exchange and substitution for and upon cancellation of a mutilated
certificate, or in lieu of or in substitution for a lost, stolen or destroyed certificate, a new certificate for the shares of Series B <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock so mutilated, lost, stolen or destroyed, but
only upon receipt of evidence of such loss, theft or destruction of such certificate, and of the ownership hereof reasonably satisfactory to the Corporation. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">14. <U>Waiver</U>. Any waiver by the Corporation or a Holder of a breach of any provision of
this Certificate of Designation shall not operate as or be construed to be a waiver of any other breach of such provision or of any breach of any other provision of this Certificate of Designation. The failure of the Corporation or a Holder to
insist upon strict adherence to any term of this Certificate of Designation on one or more occasions shall not be considered a waiver or deprive that party (or any other Holder) of the right thereafter to insist upon strict adherence to that term or
any other term of this Certificate of Designation. Any waiver by the Corporation or a Holder must be in writing. Notwithstanding any provision in this Certificate of Designation to the contrary, any provision contained herein and any right of the
Holders of Series B <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock granted hereunder may be waived as to all shares of Series B <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock (and the Holders thereof) upon the
written consent of the Holders of not less than a majority of the shares of Series B <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock then outstanding; provided, however, that the Beneficial Ownership Limitation applicable to a
Holder, and any provisions contained herein that are related to such Beneficial Ownership Limitation, cannot be modified, waived or terminated without the consent of such Holder, provided further, that any proposed waiver that would, by its terms,
have a disproportionate and materially adverse effect on any Holder shall require the consent of such Holder(s). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">15. <U>Severability</U>.
Whenever possible, each provision hereof shall be interpreted in a manner as to be effective and valid under applicable law, but if any provision hereof is held to be prohibited by or invalid under applicable law, then such provision shall be
ineffective only to the extent of such prohibition or invalidity, without invalidating or otherwise adversely affecting the remaining provisions hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">16. <U>Status of Converted Series B <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock</U>. If any shares of Series B <FONT
STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock shall be converted or redeemed by the Corporation, such shares shall, to the fullest extent permitted by applicable law, be retired and cancelled upon such acquisition, and shall not be
reissued as a share of Series B <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock. Any share of Series B <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock so acquired shall, upon its retirement and cancellation, and
upon the taking of any action required by applicable law, resume the status of authorized but unissued shares of preferred stock and shall no longer be designated as Series B <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Remainder of Page Intentionally Left Blank</I>] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, Spyre Therapeutics, Inc. has caused this Certificate of
Designation of Preferences, Rights and Limitations of Series B <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Convertible Preferred Stock to be duly executed by its Chief Executive Officer on December&nbsp;8, 2023. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>SPYRE THERAPEUTICS, INC.</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">/s/ Cameron Turtle</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cameron Turtle</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Executive Officer</P></TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ANNEX A </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">NOTICE OF CONVERSION </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(TO BE
EXECUTED BY THE REGISTERED HOLDER IN ORDER TO CONVERT SHARES OF SERIES </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B <FONT STYLE="white-space:nowrap">NON-VOTING</FONT> CONVERTIBLE
PREFERRED STOCK) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned Holder hereby irrevocably elects to convert the number of shares of Series B
<FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock indicated below, represented in book-entry form, into shares of common stock, par value $0.0001 per share (the &#147;<B><I>Common Stock</I></B>&#148;), of Spyre Therapeutics, Inc., a
Delaware corporation (the &#147;<B><I>Corporation</I></B>&#148;), as of the date written below. If securities are to be issued in the name of a Person other than the undersigned, the undersigned will pay all transfer taxes payable with respect
thereto. Capitalized terms utilized but not defined herein shall have the meaning ascribed to such terms in that certain Certificate of Designation of Preferences, Rights and Limitations of Series B <FONT STYLE="white-space:nowrap">Non-Voting</FONT>
Convertible Preferred Stock (the &#147;<B><I>Certificate of Designation</I></B>&#148;) filed by the Corporation with the Secretary of State of the State of Delaware on December&nbsp;8, 2023. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of the date hereof, the number of shares of Common Stock beneficially owned by the undersigned Holder (together with such Holder&#146;s Attribution
Parties), including the number of shares of Common Stock issuable upon conversion of the Series B <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock subject to this Notice of Conversion, but excluding the number of shares of Common
Stock which are issuable upon (A)&nbsp;conversion of the remaining, unconverted Series B <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock beneficially owned by such Holder or any of its Attribution Parties, and (B)&nbsp;exercise or
conversion of the unexercised or unconverted portion of any other securities of the Corporation (including any Series A Preferred Stock or warrants) beneficially owned by such Holder or any of its Attribution Parties that are subject to a limitation
on conversion or exercise similar to the limitation contained in <U>Section</U><U></U><U>&nbsp;6.4</U> of the Certificate of Designation, is _____. For purposes hereof, beneficial ownership shall be calculated in accordance with Section&nbsp;13(d)
of the Exchange Act and the applicable regulations of the Commission. In addition, for purposes hereof, &#147;group&#148; has the meaning set forth in Section&nbsp;13(d) of the Exchange Act and the applicable regulations of the Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CONVERSION CALCULATIONS: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="97%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Date to Effect Conversion:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><U>&nbsp;&nbsp;&nbsp;&nbsp;</U></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Number of shares of Series B <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock
owned prior to Conversion:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><U>&nbsp;&nbsp;&nbsp;&nbsp;</U></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Number of shares of Series B <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock to
be Converted:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><U>&nbsp;&nbsp;&nbsp;&nbsp;</U></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Number of shares of Common Stock to be Issued:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><U>&nbsp;&nbsp;&nbsp;&nbsp;</U></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Address for delivery of physical certificates:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><U>&nbsp;&nbsp;&nbsp;&nbsp;</U></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For DWAC Delivery, please provide the following: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Broker No.: ________________ </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Account No.: _______________ </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[HOLDER]</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>7
<FILENAME>d518298dex41.htm
<DESCRIPTION>EX-4.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 4.1 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Execution Version </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REGISTRATION RIGHTS AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">This Registration Rights Agreement (this &#147;<I>Agreement</I>&#148;) is dated as of December 7, 2023, by and among Spyre Therapeutics, Inc.,
a Delaware corporation (the &#147;<I>Company</I>&#148;), and the several purchasers signatory hereto (each, including its successors and assigns, a &#147;<I>Purchaser</I>&#148; and collectively, the &#147;<I>Purchasers</I>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">This Agreement is made pursuant to the Securities Purchase Agreement, dated as of the date hereof, between the Company and each Purchaser (the
&#147;<I>Purchase Agreement</I>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for
other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Company and each of the Purchasers agree as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Definitions</U>. Capitalized terms used and not otherwise defined herein that are defined in the Purchase Agreement shall have the
meanings given such terms in the Purchase Agreement. As used in this Agreement, the following terms shall have the following meanings: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<I>Advice</I>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;6(d)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<I>Affiliate</I>&#148; means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or
is under common control with a Person, as such terms are used in and construed under Rule 405 of the Securities Act of 1933, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<I>Agreement</I>&#148; has the meaning set forth in the Preamble. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<I>Business Day</I>&#148; means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States
or any day on which banking institutions in the State of New York are authorized or required by law or other governmental action to close. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<I>Common Stock</I>&#148; means the Company&#146;s common stock, par value $0.0001 per share, and stock of any other class of securities
into which such securities may hereafter be reclassified or changed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<I>Company</I>&#148; has the meaning set forth in the
Preamble. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<I>Effective Date</I>&#148; means the date that the Registration Statement filed pursuant to
<U>Section</U><U></U><U>&nbsp;2(a)</U> is first declared effective by the Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<I>Effectiveness Deadline</I>&#148; means,
with respect to the Initial Registration Statement or the New Registration Statement, the ninetieth (90th) calendar day following the Closing Date (or, in the event the Commission reviews and has written comments to the Initial Registration
Statement or the New Registration Statement, the one hundred twentieth (120th) calendar day following the Closing Date); provided, however, that (i)&nbsp;if the Company is notified by the Commission that the Initial Registration Statement or the New
Registration Statement will not be reviewed or is no longer subject to further review and comments, the Effectiveness Deadline as to such Registration Statement shall be the fifth (5th) Trading Day following the date on which the Company is so
notified if such date precedes the dates otherwise required above; (ii)&nbsp;if the Effectiveness Deadline falls on a Saturday, Sunday or other day that the Commission is closed for business, the Effectiveness Deadline shall be extended to the next
Business Day on which the Commission is open for business and (iii)&nbsp;with respect to the Initial Registration Statement, if the Effectiveness Deadline is between <FONT STYLE="white-space:nowrap">forty-six</FONT> (46)&nbsp;and ninety
(90)&nbsp;days after the Company&#146;s 2023 fiscal year end and the Company does not on such date meet the conditions described under paragraph (c)&nbsp;of Regulation <FONT STYLE="white-space:nowrap">S-X,</FONT> Item
<FONT STYLE="white-space:nowrap">3-01</FONT> promulgated under the Securities Act and the Exchange Act, the Effectiveness Deadline shall be extended until ten (10)&nbsp;days after the earlier of the date the Company files its Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> for its fiscal year ending December&nbsp;31, 2023 and the due date for such Annual Report. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<I>Effectiveness Period</I>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;2(b)</U>. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<I>Exchange Act</I>&#148; means the Securities Exchange Act of 1934, as amended, and
the rules and regulations promulgated thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<I>Filing Deadline</I>&#148; means, with respect to the Initial Registration
Statement required to be filed pursuant to <U>Section</U><U></U><U>&nbsp;2(a)</U>, the thirtieth (30th) calendar day following the Closing Date, provided, however, that if the Filing Deadline falls on a Saturday, Sunday or other day that the
Commission is closed for business, the Filing Deadline shall be extended to the next Business Day on which the Commission is open for business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<I>FINRA</I>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;3(i)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<I>Holder</I>&#148; or &#147;<I>Holders</I>&#148; means the holder or holders, as the case may be, from time to time of Registrable
Securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<I>Indemnified Party</I>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;5(c)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<I>Indemnifying Party</I>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;5(c)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<I>Initial Registration Statement</I>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;2(a)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<I>Losses</I>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;5(a)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<I>New Registration Statement</I>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;2(a)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<I>Person</I>&#148; means an individual or a corporation, partnership, trust, incorporated or unincorporated association, joint venture,
limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<I>Principal Market</I>&#148; means the Trading Market on which the Common Stock are primarily listed on and quoted for trading, which,
as of the Closing Date, shall be the Nasdaq Capital Market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<I>Proceeding</I>&#148; means an action, claim, suit, investigation or
proceeding (including, without limitation, an investigation or partial proceeding, such as a deposition), whether commenced or threatened. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<I>Prospectus</I>&#148; means the prospectus included in a Registration Statement (including, without limitation, a prospectus that
includes any information previously omitted from a prospectus filed as part of an effective registration statement in reliance upon Rule 430B promulgated under the Securities Act), as amended or supplemented by any prospectus supplement, with
respect to the terms of the offering of any portion of the Registrable Securities covered by a Registration Statement, and all other amendments and supplements to the Prospectus, including post-effective amendments, and all material incorporated by
reference or deemed to be incorporated by reference in such Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<I>Purchase Agreement</I>&#148; has the meaning set forth
in the Recitals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<I>Purchaser</I>&#148; or &#147;<I>Purchasers</I>&#148; has the meaning set forth in the Preamble. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<I>Registrable Securities</I>&#148; means all of (i)&nbsp;the Shares, (ii)&nbsp;the Series B Preferred Stock issued pursuant to the
Purchase Agreement, and (iii)&nbsp;any securities issued or issuable upon any stock split, dividend or other distribution, recapitalization or similar event with respect to the foregoing, provided that the Holder has completed and delivered to the
Company a Selling Stockholder Questionnaire; and provided, further, that, with respect to a particular Holder, such Holder&#146;s Shares shall cease to be Registrable Securities upon the earlier to occur of the following: (A)&nbsp;a sale pursuant to
a Registration Statement or Rule 144 under the Securities Act (in which case, only such security sold by the Holder shall cease to be a Registrable Security); and (B)&nbsp;such Shares become eligible for resale by the Holder under Rule 144 without
the requirement for the Company to be in compliance with the current public information required thereunder and without volume or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">manner-of-sale</FONT></FONT> restrictions, pursuant
to a written opinion letter of counsel for the Company to such effect, addressed, delivered and reasonably acceptable to the Transfer Agent. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<I>Registration Statements</I>&#148; means any one or more registration statements of
the Company filed under the Securities Act that cover the resale of any of the Registrable Securities pursuant to the provisions of this Agreement (including without limitation the Initial Registration Statement, any New Registration Statement and
any Remainder Registration Statements), amendments and supplements to such Registration Statements, including post-effective amendments, all exhibits and all material incorporated by reference or deemed to be incorporated by reference in such
Registration Statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<I>Remainder Registration Statement</I>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;2(a)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<I>Rule 144</I>&#148; means Rule 144 promulgated by the Commission pursuant to the
Securities Act, as such Rule may be amended from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same effect as such Rule. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<I>Rule 172</I>&#148; means Rule 172 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended from time
to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same effect as such Rule. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<I>Rule 415</I>&#148; means Rule 415 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended from time
to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same effect as such Rule. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<I>Rule 424</I>&#148; means Rule 424 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended from time
to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same effect as such Rule. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<I>Rule 461</I>&#148; means Rule 461 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended from time
to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same effect as such Rule. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<I>SEC Guidance</I>&#148; means (i)&nbsp;any publicly-available written or oral guidance, comments, requirements or requests of the
Commission staff; provided, that any such oral guidance, comments, requirements or requests are reduced to writing by the Commission and (ii)&nbsp;the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<I>Securities Act</I>&#148; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<I>Selling Stockholder Questionnaire</I>&#148; means a questionnaire in the form attached as Annex B hereto, or such other form of
questionnaire or information provided to the Company in connection with the preparation of a Registration Statement hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<I>Series B Preferred Stock</I>&#148; means the Series B <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Convertible Preferred Stock,
par value $0.0001 per share, of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<I>Shares</I>&#148; means (i)&nbsp;the shares of Common Stock issued to the Purchasers
pursuant to the Purchase Agreement and (ii)&nbsp;the shares of Common Stock which may be issued upon conversion of the Series B Preferred Stock issued to the Purchasers pursuant to the Purchase Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<I>Trading Day</I>&#148; means a day on which the Principal Market is open for business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<I>Trading Market</I>&#148; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on
the date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, or the New York Stock Exchange (or any successors to any of the foregoing). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Registration</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) On or prior to the Filing Deadline, the Company shall prepare and file with the Commission a Registration Statement covering the resale
of all of the Registrable Securities not then registered on an existing and effective Registration Statement for an offering to be made on a continuous basis pursuant to Rule 415 or, if Rule 415 is not available for offers and sales of the
Registrable Securities, by such other means of distribution of Registrable Securities as the Holders may reasonably specify (the &#147;Initial Registration Statement&#148;). The Initial Registration Statement shall be on Form <FONT
STYLE="white-space:nowrap">S-1</FONT> subject to the provisions of <U>Section</U><U></U><U>&nbsp;2(c)</U> and shall contain (except if otherwise required pursuant to written comments received from the Commission upon a review of such Registration
Statement) the &#147;Plan of Distribution&#148; section substantially in the form attached hereto as <U>Annex A</U> (which may be modified to respond to comments, if any, provided by the Commission). Notwithstanding the registration obligations set
forth in this <U>Section</U><U></U><U>&nbsp;2</U>, in the event the Commission informs the Company that all of the Registrable Securities cannot, as a result of the application of Rule 415, be registered for resale as a secondary offering on a
single registration statement, the Company agrees to promptly (i)&nbsp;inform each of the Holders thereof and use its commercially reasonable efforts to file amendments to the Initial Registration Statement as required by the Commission and/or
(ii)&nbsp;withdraw the Initial Registration Statement and file a new registration statement (a &#147;<I>New Registration Statement</I>&#148;), in either case covering the maximum number of Registrable Securities permitted to be registered by the
Commission, on Form <FONT STYLE="white-space:nowrap">S-1;</FONT> <I>provided</I>, <I>however</I>, that prior to filing such amendment or New Registration Statement, the Company shall be obligated to use its commercially reasonable efforts to
advocate with the Commission for the registration of all of the Registrable Securities in accordance with the SEC Guidance, including without limitation, the Securities Act Rules Compliance and Disclosure Interpretations Question 612.09.
Notwithstanding any other provision of this Agreement, if the Commission or any SEC Guidance sets forth a limitation of the number of Registrable Securities permitted to be registered on a particular Registration Statement as a secondary offering
(and notwithstanding that the Company used diligent efforts to advocate with the Commission for the registration of all or a greater number of Registrable Securities), unless otherwise directed in writing by a Holder as to its Registrable
Securities, the number of Registrable Securities to be registered on such Registration Statement will first be reduced by Registrable Securities not acquired pursuant to the Purchase Agreement (whether pursuant to registration rights or otherwise),
and second by Registrable Securities represented by Shares applied to the Holders on a pro rata basis based on the total number of Shares held by such Holders, subject to a determination by the Commission that certain Holders must be reduced first
based on the number of Shares held by such Holders. In the event of a cutback hereunder, the Company shall give the Holder at least one (1)&nbsp;Trading Day prior notice along with the calculations as to such Holder&#146;s allotment. In the event
the Company amends the Initial Registration Statement or files a New Registration Statement, as the case may be, in accordance with the foregoing, the Company will use its commercially reasonable efforts to file with the Commission, as promptly as
allowed by Commission or SEC Guidance provided to the Company or to registrants of securities in general, one or more registration statements on Form <FONT STYLE="white-space:nowrap">S-1</FONT> or such other form available to register for resale
those Registrable Securities that were not registered for resale on the Initial Registration Statement, as amended, or the New Registration Statement (the &#147;<I>Remainder Registration Statements</I>&#148;). No Holder shall be named as an
&#147;underwriter&#148; in any Registration Statement without such Holder&#146;s prior written consent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) The Company shall use its
commercially reasonable efforts to cause each Registration Statement to be declared effective by the Commission as soon as practicable and, with respect to the Initial Registration Statement or the New Registration Statement, as applicable, no later
than the Effectiveness Deadline (including filing with the Commission a request for acceleration of effectiveness in accordance with Rule 461 promulgated under the Securities Act), and shall use its commercially reasonable efforts to keep each
Registration Statement continuously effective under the Securities Act until the earlier of (i)&nbsp;such time as all of the Registrable Securities covered by such Registration Statement have been publicly sold by the Holders; or (ii)&nbsp;the date
that all Registrable Securities covered by such Registration Statement may be sold by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> without volume or
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">manner-of-sale</FONT></FONT> restrictions pursuant to Rule 144, without the requirement for the Company to be in compliance with the current public information requirement under Rule
144 (the &#147;<I>Effectiveness Period</I>&#148;). The Company shall request effectiveness of a Registration Statement as of 4:00 P.M. New York City time on a Trading Day. The Company shall promptly notify the Holders via <FONT
STYLE="white-space:nowrap">e-mail</FONT> of the effectiveness of a Registration Statement or any post-effective amendment thereto on the same Trading Day that the Company telephonically confirms effectiveness with the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Commission, which date of confirmation shall initially be the date requested for effectiveness of such Registration Statement. The Company shall, by 9:30 A.M. New York City time on the first
Trading Day after the Effective Date, file a final Prospectus with the Commission, as required by Rule 424(b) and shall provide the Purchasers with copies of the final Prospectus to be used in connection with the sale or other disposition of the
securities covered thereby. The Company shall promptly inform each Holder in writing if, at any time during the Effectiveness Period, the Company does not satisfy the conditions specified in Rule 172 and, as a result thereof, the Holder is required
to deliver a Prospectus in connection with any disposition of Registrable Securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) Each Holder of Registrable Securities to be
sold agrees to furnish to the Company a completed Selling Stockholder Questionnaire not more than five (5)&nbsp;Trading Days following the date of this Agreement. At least 10 Trading Days prior to the first anticipated filing date of a Registration
Statement for any registration under this Agreement, the Company will notify each Holder of the information the Company requires from that Holder for inclusion in the Registration Statement other than the information contained in the Selling
Stockholder Questionnaire, if any, which shall be completed and delivered to the Company promptly upon request and, in any event, within three (3)&nbsp;Trading Days prior to the applicable anticipated filing date. Each Holder further agrees that it
shall not be entitled to be named as a selling securityholder in the Registration Statement or use the Prospectus for offers and resales of Registrable Securities at any time, unless such Holder has provided such information to the Company and
responded to any reasonable requests for further information as described in the previous sentence. Each Holder acknowledges and agrees that the information in the Selling Stockholder Questionnaire or request for further information as described in
this <U>Section</U><U></U><U>&nbsp;2(c)</U> will be used by the Company in the preparation of the Registration Statement and hereby consents to the inclusion of such information in the Registration Statement (subject to such Holder&#146;s right to
timely review the Registration Statement as set forth herein). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) The Company undertakes to register the Registrable Securities on Form
<FONT STYLE="white-space:nowrap">S-3</FONT> promptly after such form is available, <I>provided</I> that the Company shall maintain the effectiveness of the Registration Statement then in effect until such time as a Registration Statement on Form <FONT
STYLE="white-space:nowrap">S-3</FONT> covering the Registrable Securities has been declared effective by the Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;(i) If
a Registration Statement covering the Registrable Securities is not filed with the Commission on or prior to the Filing Deadline (a &#147;<I>Registration Failure</I>&#148;), then, in addition to any other rights the Purchasers may have hereunder or
under applicable law, the Company will make pro rata payments to each Purchaser of then outstanding Registrable Securities, as liquidated damages and not as a penalty (the &#147;<I>Registration Liquidated Damages</I>&#148;), in an amount equal to
one percent (1.0%) of the aggregate amount invested by such Purchaser for the Registrable Securities then held by such Purchaser for the initial day of a Registration Failure and for each thirty (30)&nbsp;day period (or pro rata portion thereof with
respect to a final period, if any) thereafter until the Registration Failure is cured. The Registration Liquidated Damages shall be paid monthly within ten (10)&nbsp;Business Days of the date of such Registration Failure and the end of each
subsequent thirty <FONT STYLE="white-space:nowrap">(30)-day</FONT> period (or portion thereof with respect to a final period, if any) thereafter until the Registration Failure is cured. Such payments shall be made in cash to each Purchaser then
holding Registrable Securities. Interest shall accrue at the rate of one percent (1%) per month on any such liquidated damages payments that shall not be paid by the applicable payment date until such amount is paid in full. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(ii) If (A)&nbsp;a Registration Statement covering the Registrable Securities is not declared effective by the Commission by the
Effectiveness Deadline or (B)&nbsp;after a Registration Statement has been declared effective by the Commission or otherwise becomes effective, sales cannot be made pursuant to such Registration Statement for any reason (including, without
limitation, by reason of a stop order or the Company&#146;s failure to update such Registration Statement) (each of (A)&nbsp;and (B), a &#147;<I>Maintenance Failure</I>&#148;), then the Company will make pro rata payments to each Purchaser then
holding Registrable Securities, as liquidated damages and not as a penalty (the &#147;<I>Effectiveness Liquidated Damages</I>&#148; and together with the Registration Liquidated Damages, the &#147;<I>Liquidated Damages</I>&#148;), in an amount equal
to one percent (1.0%) of the aggregate amount invested by such Investor for the Registrable Securities then held by such Investor for the initial day of a Maintenance Failure and for each thirty <FONT STYLE="white-space:nowrap">(30)-day</FONT>
period (pro rata for any portion thereof) thereafter until the Maintenance Failure is cured (each, a &#147;Blackout Period&#148;). The Effectiveness Liquidated Damages shall be paid monthly within ten (10)&nbsp;Business Days of the end of the date
of such Maintenance Failure and each subsequent thirty <FONT STYLE="white-space:nowrap">(30)-day</FONT> period (pro rata for any portion thereof). Such payments shall be made to each Investor then holding Registrable Securities in cash. Interest
shall accrue at the rate of one percent (1.0%) per month on any such liquidated damages payments that shall not be paid by the applicable payment date until such amount is paid in full. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(iii) Notwithstanding the foregoing, (A)&nbsp;no Liquidated Damages shall be payable with
respect to any period after the expiration of the Effectiveness Period (it being understood that this sentence shall not relieve the Company of any Liquidated Damages accruing prior to the expiration of the Effectiveness Period), (B) in no event
shall the aggregate amount of Liquidated Damages payable to a Purchaser exceed, in the aggregate, five percent (5.0%) of the aggregate purchase price paid by such Purchaser pursuant to the Purchase Agreement, (C)&nbsp;no Liquidated Damages shall
accrue or be payable with respect to any reduction in the number or Registrable Securities to be included in a Registration Statement due to the application of Rule 415 as set forth in Section&nbsp;2(a) and (D)&nbsp;no Liquidated Damages shall
accrue or be payable with respect to any allowed suspension pursuant to Section&nbsp;6(d) or a suspension as described in the last sentence of Section&nbsp;3(h). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Registration Procedures</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">In connection with the Company&#146;s registration obligations hereunder, the Company shall: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) Not less than five (5)&nbsp;Trading Days prior to the filing of each Registration Statement and not less than two (2)&nbsp;Trading Days
prior to the filing of any related Prospectus or any amendment or supplement thereto (except for Annual Reports on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> and Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> and
Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> and any similar or successor reports), (i) furnish to each Holder copies of such Registration Statement, Prospectus or amendment or supplement thereto, as proposed to be filed,
which documents will be subject to the review of such Holder (it being acknowledged and agreed that if a Holder does not object to or comment on the aforementioned documents within such five (5)&nbsp;Trading Day or two (2)&nbsp;Trading Day period,
as the case may be, then the Holder shall be deemed to have consented to and approved the use of such documents) and (ii)&nbsp;to the extent that a Holder is identified in the Registration Statement as an &#147;underwriter&#148; (as defined in the
Securities Act), use commercially reasonable efforts to cause its officers and directors, counsel and independent registered public accountants to respond to such inquiries as shall be necessary, in the reasonable opinion of respective counsel to
each Holder, to conduct a reasonable investigation within the meaning of the Securities Act. The Company shall not file any Registration Statement or amendment or supplement thereto in a form to which a Holder reasonably objects in good faith,
provided that, such Holder notifies the Company of such objection in writing within the five (5)&nbsp;Trading Day or two (2)&nbsp;Trading Day periods described above, as applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;(i) Prepare and file with the Commission such amendments (including post-effective amendments) and supplements, to each Registration
Statement and the Prospectus used in connection therewith as may be necessary to keep such Registration Statement continuously effective as to the applicable Registrable Securities for its Effectiveness Period and prepare and file with the
Commission such additional Registration Statements in order to register for resale under the Securities Act all of the Registrable Securities; (ii)&nbsp;cause the related Prospectus to be amended or supplemented by any required Prospectus supplement
(subject to the terms of this Agreement), and, as so supplemented or amended, to be filed pursuant to Rule 424; (iii) respond as promptly as reasonably practicable to any comments received from the Commission with respect to each Registration
Statement or any amendment thereto and, as promptly as reasonably possible, provide the Holders true and complete copies of all correspondence from and to the Commission relating to such Registration Statement that pertains to the Holders as
&#147;Selling Stockholders&#148; but not any comments that would result in the disclosure to the Holders of material and <FONT STYLE="white-space:nowrap">non-public</FONT> information concerning the Company (unless such Holder consents to receive
such material and <FONT STYLE="white-space:nowrap">non-public</FONT> information); and (iv)&nbsp;comply with the provisions of the Securities Act and the Exchange Act with respect to the disposition of all Registrable Securities covered by a
Registration Statement until such time as all of such Registrable Securities shall have been disposed of (subject to the terms of this Agreement) in accordance with the intended methods of disposition by the Holders thereof as set forth in such
Registration Statement as so amended or in such Prospectus as so supplemented; <I>provided, however</I>, that each Purchaser shall be responsible for the delivery of the Prospectus to the Persons to whom such Purchaser sells any of the Registrable
Securities (including in accordance with Rule 172 under the Securities Act) to the extent required under the Securities Act, and each Purchaser agrees to dispose of Registrable Securities in compliance with the &#147;Plan of Distribution&#148;
described in the Registration Statement and otherwise in compliance with applicable federal and state securities laws. In the case of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
amendments and supplements to a Registration Statement which are required to be filed pursuant to this Agreement (including pursuant to this Section&nbsp;3(b)) by reason of the Company filing a
report on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> Form <FONT STYLE="white-space:nowrap">10-Q</FONT> or Form <FONT STYLE="white-space:nowrap">8-K</FONT> or any analogous report under the Exchange Act, the Company shall have incorporated
such report by reference into such Registration Statement, if applicable, or shall file such amendments or supplements with the Commission on the same day on which the Exchange Act report which created the requirement for the Company to amend or
supplement such Registration Statement was filed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) Notify the Holders of Registrable Securities to be sold (which notice shall, if
given pursuant to clauses (iii)&nbsp;through (vi) hereof, be accompanied by an instruction to suspend the use of the Prospectus until the requisite changes have been made, provided that the Company shall omit any material, <FONT
STYLE="white-space:nowrap">non-public</FONT> information relating to the Company and/or any of its subsidiaries) as promptly as reasonably practicable (and, in the case of (i)(A) below, not less than one (1)&nbsp;Trading Day prior to such filing)
and (if requested by any such Person) confirm such notice in writing no later than one (1)&nbsp;Trading Day following the day: (i)(A) when a Prospectus or any Prospectus supplement or post-effective amendment to a Registration Statement is proposed
to be filed; (B)&nbsp;when the Commission notifies the Company whether there will be a &#147;review&#148; of such Registration Statement and whenever the Commission comments in writing on any Registration Statement (in which case the Company shall
provide to each of the Holders true and complete copies of all comments that pertain to the Holders as a &#147;Selling Stockholder&#148; or to the &#147;Plan of Distribution&#148; and all written responses thereto, but not information that the
Company believes would constitute material and <FONT STYLE="white-space:nowrap">non-public</FONT> information); and (C)&nbsp;with respect to each Registration Statement or any post-effective amendment, when the same has become effective;
(ii)&nbsp;of any request by the Commission or any other Federal or state governmental authority for amendments or supplements to a Registration Statement or Prospectus or for additional information that pertains to the Holders as &#147;Selling
Stockholders&#148; or the &#147;Plan of Distribution&#148;; (iii) of the issuance by the Commission or any other federal or state governmental authority of any stop order suspending the effectiveness of a Registration Statement covering any or all
of the Registrable Securities or the initiation of any Proceedings for that purpose; (iv)&nbsp;of the receipt by the Company of any notification with respect to the suspension of the qualification or exemption from qualification of any of the
Registrable Securities for sale in any jurisdiction, or the initiation or threatening of any Proceeding for such purpose; (v)&nbsp;of the occurrence of any event or passage of time that makes the financial statements included or incorporated by
reference in a Registration Statement ineligible for inclusion or incorporation by reference therein or any statement made in such Registration Statement or Prospectus or any document incorporated or deemed to be incorporated therein by reference
untrue in any material respect or that requires any revisions to such Registration Statement, Prospectus or other documents so that, in the case of such Registration Statement or the Prospectus, as the case may be, it will not contain any untrue
statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein (in the case of any Prospectus, form of prospectus or supplement thereto, in light of the circumstances under
which they were made), not misleading and (vi)&nbsp;of the occurrence or existence of any pending corporate development with respect to the Company that, upon the advice of legal counsel, the Company&#146;s board of directors reasonably believes may
be material and that, in the reasonable determination of the Company&#146;s board of directors, makes it not in the best interest of the Company to allow continued availability of a Registration Statement or Prospectus, <I>provided</I> that, any and
all such information shall remain confidential to each Holder until such information otherwise becomes public, unless disclosure by a Holder is required by law; and <I>provided</I>, <I>further</I>, that notwithstanding each Holder&#146;s agreement
to keep such information confidential, each such Holder makes no acknowledgement that any such information is material, <FONT STYLE="white-space:nowrap">non-public</FONT> information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) Use commercially reasonable efforts to avoid the issuance of, or, if issued, obtain the withdrawal of (i)&nbsp;any order stopping or
suspending the effectiveness of a Registration Statement, or (ii)&nbsp;any suspension of the qualification (or exemption from qualification) of any of the Registrable Securities for sale in any jurisdiction, as soon as practicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) If requested by a Holder, furnish to such Holder, without charge, at least one conformed copy of each Registration Statement and each
amendment thereto, including financial statements and schedules, all documents incorporated or deemed to be incorporated therein by reference to the extent requested by such Person, and all exhibits to the extent requested by such Person (including
those previously furnished or incorporated by reference) promptly after the filing of such documents with the Commission; <I>provided</I>, that the Company shall have no obligation to provide any document pursuant to this clause that is available on
the Commission&#146;s EDGAR system. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f) Prior to any resale of Registrable Securities by a Holder, use its commercially
reasonable efforts to register or qualify or cooperate with the selling Holders in connection with the registration or qualification (or exemption from the registration or qualification) of the resale of such Registrable Securities (or, in the case
of qualification, of such Registrable Securities for the resale) by the Holder under the securities or blue sky laws of such jurisdictions within the United States as any Holder reasonably requests in writing, to keep each registration or
qualification (or exemption therefrom) effective during the Effectiveness Period and to do any and all other acts or things reasonably necessary to enable the disposition in such jurisdictions of the Registrable Securities covered by each
Registration Statement; <I>provided</I>, that the Company shall not be required to qualify generally to do business in any jurisdiction where it is not then so qualified, subject the Company to any material tax in any such jurisdiction where it is
not then so subject or file a general consent to service of process in any such jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(g) Cooperate with such Holder to
facilitate the timely preparation and delivery of certificates or book entry statements, as applicable, representing Registrable Securities to be delivered to a transferee pursuant to the Registration Statement, which certificates or statements
shall be free, to the extent permitted by the Purchase Agreement and under law, of all restrictive legends, and to enable such Registrable Securities to be in such denominations and registered in such names as any such Holders may reasonably
request. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(h) Following the occurrence of any event contemplated by <U>Section</U><U></U><U>&nbsp;3(c)</U>, as promptly as reasonably
practicable (taking into account the Company&#146;s good faith assessment of any adverse consequences to the Company and its stockholders of the premature disclosure of such event), prepare a supplement or amendment, including a post-effective
amendment, to the affected Registration Statements or a supplement to the related Prospectus or any document incorporated or deemed to be incorporated therein by reference, and file any other required document so that, as thereafter delivered, no
Registration Statement nor any Prospectus will contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein (in the case of any Prospectus, form of
prospectus or supplement thereto, in light of the circumstances under which they were made), not misleading. If the Company notifies the Holders in accordance with clauses (iii)&nbsp;through (vi) of <U>Section</U><U></U><U>&nbsp;3(c)</U> above to
suspend the use of any Prospectus until the requisite changes to such Prospectus have been made, then the Holders shall suspend use of such Prospectus. The Company will use its commercially reasonable efforts to ensure that the use of the Prospectus
may be resumed as promptly as is practicable. The Company shall be entitled to exercise its right under this <U>Section</U><U></U><U>&nbsp;3(h)</U> to suspend the availability of a Registration Statement and Prospectus in accordance with the time
periods set forth in <U>Section</U><U></U><U>&nbsp;6(d)</U>, which may be extended only in accordance with Section&nbsp;6(f). For the avoidance of doubt, the Company&#146;s rights under this <U>Section</U><U></U><U>&nbsp;3(h)</U> shall include
suspensions of availability arising from the filing of a post-effective amendment to a Registration Statement to update the Prospectus therein to include the information contained in the Company&#146;s Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K,</FONT> which suspensions may extend for the amount of time reasonably required to respond to any comments of the staff of the Commission on such amendment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) The Company may require each selling Holder to furnish to the Company a certified statement as to (i)&nbsp;the number of shares of Common
Stock beneficially owned by such Holder and any Affiliate thereof, (ii)&nbsp;any Financial Industry Regulatory Authority (&#147;<I>FINRA</I>&#148;) affiliations, (iii)&nbsp;any natural persons who have the power to vote or dispose of the Common
Stock and (iv)&nbsp;any other information as may be requested by the Commission, FINRA or any state securities commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(j) The
Company shall cooperate with any registered broker through which a Holder proposes to resell its Registrable Securities in effecting a filing with FINRA pursuant to FINRA Rule 5110 as requested by any such Holder and the Company shall pay the filing
fee required for the first such filing within two (2)&nbsp;Business Days of the request therefor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(k) If at any time the Commission
takes the position that the offering of some or all of the Registrable Securities in a Registration Statement is not eligible to be made on a delayed or continuous basis under the provisions of Rule 415 under the Securities Act or requires any
Holder to be named as an &#147;underwriter,&#148; the Company shall use commercially reasonable efforts to persuade the Commission that the offering contemplated by such Registration Statement is a valid secondary offering and not an offering
&#147;by or on behalf of the issuer&#148; as defined in Rule 415 and that none of the Holders is an &#147;underwriter&#148;. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Registration Expenses</U>. All fees and expenses incident to the Company&#146;s
performance of or compliance with its obligations under this Agreement (excluding any underwriting discounts and selling commissions and all legal fees and expenses of legal counsel for any Holder) shall be borne by the Company whether or not any
Registrable Securities are sold pursuant to a Registration Statement. The fees and expenses referred to in the foregoing sentence shall include, without limitation, (i)&nbsp;all registration and filing fees (including, without limitation, fees and
expenses of the Company&#146;s counsel and independent registered public accountants (A)&nbsp;with respect to filings required to be made with any Trading Market on which the Common Stock are then listed for trading, (B)&nbsp;with respect to
compliance with applicable state securities or blue sky laws (including, without limitation, fees and disbursements of counsel for the Company in connection with blue sky qualifications or exemptions of the Registrable Securities and determination
of the eligibility of the Registrable Securities for investment under the laws of such jurisdictions as requested by the Holders) and (C)&nbsp;if not previously paid by the Company in connection with <U>Section</U><U></U><U>&nbsp;3(j)</U> above,
with respect to any filing that may be required to be made by any broker through which a Holder intends to make sales of Registrable Securities with FINRA pursuant to the FINRA Rule 5110, so long as the broker is receiving no more than a customary
brokerage commission in connection with such sale), (ii) printing expenses (including, without limitation, expenses of printing certificates for Registrable Securities and of printing prospectuses if the printing of prospectuses is reasonably
requested by the Holders of a majority of the Registrable Securities included in the Registration Statement), (iii) messenger, telephone and delivery expenses, (iv)&nbsp;fees, expenses and disbursements of counsel for the Company,
(v)&nbsp;Securities Act liability insurance, if the Company so desires such insurance, and (vi)&nbsp;fees and expenses of all other Persons retained by the Company in connection with the registrations and consummation of the transactions
contemplated by this Agreement. In addition, the Company shall be responsible for all of its internal expenses incurred in connection with the consummation of the transactions contemplated by this Agreement (including, without limitation, all
salaries and expenses of its officers and employees performing legal or accounting duties), the expense of any annual audit and the fees and expenses incurred in connection with the listing of the Registrable Securities on any securities exchange as
required hereunder. In no event shall the Company be responsible for any underwriting, broker or similar fees or commissions of any Holder or, except to the extent provided for in the Transaction Documents, any legal fees or other costs of the
Holders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Indemnification</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) <U>Indemnification by the Company</U>. The Company shall, notwithstanding any termination of this Agreement, indemnify, defend and hold
harmless each Holder and each of their respective officers, directors, agents, partners, members, managers, stockholders, Affiliates, investment advisers and employees of each of them, each Person who controls any such Holder (within the meaning of
Section&nbsp;15 of the Securities Act or Section&nbsp;20 of the Exchange Act) and the officers, directors, partners, members, managers, stockholders, agents, investment advisers and employees of each such controlling Person, to the fullest extent
permitted by applicable law, from and against any and all losses, claims, damages, liabilities, costs (including, without limitation, reasonable costs of preparation and investigation and reasonable attorneys&#146; fees), expenses and disbursements
(collectively, &#147;<I>Losses</I>&#148;), as incurred, that arise out of or are based upon (i)&nbsp;any untrue or alleged untrue statement of a material fact contained in any Registration Statement, any Prospectus or any form of prospectus or in
any amendment or supplement thereto or in any preliminary prospectus, or arising out of or relating to any omission or alleged omission to state a material fact required to be stated therein or necessary to make the statements therein (in the case
of any Prospectus or form of prospectus or supplement thereto, in light of the circumstances under which they were made) not misleading, or (ii)&nbsp;any violation or alleged violation by the Company or its agents of the Securities Act, the Exchange
Act or any state securities law or any rule or regulation thereunder, in connection with the performance of its obligations under this Agreement or any action or inaction required of the Company in connection with any registration, except to the
extent, but only to the extent, that (A)&nbsp;such untrue statements, alleged untrue statements, omissions or alleged omissions are based solely upon information regarding such Holder furnished in writing to the Company by such Holder expressly for
use therein, or to the extent that such information relates to such Holder or such Holder&#146;s proposed method of distribution of Registrable Securities and was reviewed and approved in writing by such Holder expressly for use in the Registration
Statement, such Prospectus or such form of Prospectus or in any amendment or supplement thereto (it being understood that each Holder has approved <U>Annex A</U> hereto for this purpose), (B) in the case of an occurrence of an event of the type
specified in <U>Section</U><U></U><U>&nbsp;3(c)(iii)-(vi)</U>, related to the use by a Holder of an outdated or defective Prospectus after the Company has notified such Holder in writing that the Prospectus is outdated or defective and prior to the
receipt by such Holder of the Advice contemplated and defined in <U>Section</U><U></U><U>&nbsp;6(d)</U> below, to the extent that following the receipt of the Advice the misstatement or omission giving rise to such Loss
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
would have been corrected or (C)&nbsp;to the extent that any such Losses arise out of the Purchaser&#146;s (or any other indemnified Person&#146;s) failure to send or give a copy of the
Prospectus or supplement (as then amended or supplemented), if required, pursuant to Rule 172 under the Securities Act (or any successor rule) to the Persons asserting an untrue statement or alleged untrue statement or alleged untrue statement or
omission or alleged omission at or prior to the written confirmation of the sale of Registrable Securities to such Person if such statement or omission was corrected in such Prospectus or supplement. The Company shall notify the Holders promptly of
the institution, threat or assertion of any Proceeding arising from or in connection with the transactions contemplated by this Agreement of which the Company is aware. Such indemnity shall remain in full force and effect regardless of any
investigation made by or on behalf of an Indemnified Party (as defined in <U>Section</U><U></U><U>&nbsp;5(c)</U>) and shall survive the transfer of the Registrable Securities by the Holders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) <U>Indemnification by Holders</U>. Each Holder shall, severally and not jointly, indemnify and hold harmless the Company, its directors,
officers, agents and employees, each Person who controls the Company (within the meaning of Section&nbsp;15 of the Securities Act and Section&nbsp;20 of the Exchange Act), and the directors, officers, agents or employees of such controlling Persons,
to the fullest extent permitted by applicable law, from and against all Losses, as incurred, arising out of or are based solely upon any untrue or alleged untrue statement of a material fact contained in any Registration Statement, any Prospectus,
or any form of prospectus, or in any amendment or supplement thereto or in any preliminary prospectus, or arising out of or relating to any omission or alleged omission of a material fact required to be stated therein or necessary to make the
statements therein (in the case of any Prospectus, or any form of prospectus or supplement thereto, in light of the circumstances under which they were made) not misleading (i)&nbsp;to the extent that such untrue statements or omissions are based
solely upon information regarding such Holder furnished in writing to the Company by such Holder expressly for use therein or (ii)&nbsp;to the extent that such information relates to such Holder or such Holder&#146;s proposed method of distribution
of Registrable Securities and was reviewed and approved in writing by such Holder expressly for use in a Registration Statement (it being understood that the Holder has approved <U>Annex A</U> hereto for this purpose), such Prospectus or such form
of Prospectus or in any amendment or supplement thereto or (iii)&nbsp;in the case of an occurrence of an event of the type specified in <U>Section</U><U></U><U>&nbsp;3(c)(iii)-(vi)</U>, to the extent related to the use by such Holder of an outdated
or defective Prospectus after the Company has notified such Holder in writing that the Prospectus is outdated or defective and prior to the receipt by such Holder of the Advice contemplated in <U>Section</U><U></U><U>&nbsp;6(d)</U>. In no event
shall the liability of any selling Holder hereunder be greater in amount than the dollar amount of the net proceeds received by such Holder upon the sale of the Registrable Securities giving rise to such indemnification obligation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) <U>Conduct of Indemnification Proceedings</U>. If any Proceeding shall be brought or asserted against any Person entitled to indemnity
hereunder (an &#147;<I>Indemnified Party</I>&#148;), such Indemnified Party shall promptly notify the Person from whom indemnity is sought (the &#147;<I>Indemnifying Party</I>&#148;) in writing, and the Indemnifying Party shall have the right to
assume the defense thereof, including the employment of counsel reasonably satisfactory to the Indemnified Party and the payment of all reasonable fees, expenses and disbursements incurred in connection with defense thereof; <I>provided</I>, that
the failure of any Indemnified Party to give such notice shall not relieve the Indemnifying Party of its obligations or liabilities pursuant to this Agreement, except (and only) to the extent that it shall be finally determined by a court of
competent jurisdiction (which determination is not subject to appeal or further review) that such failure shall have materially and adversely prejudiced the Indemnifying Party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">An Indemnified Party shall have the right to employ separate counsel in any such Proceeding and to participate in the defense thereof, but the
fees, expenses and disbursements of such counsel shall be at the expense of such Indemnified Party or Indemnified Parties unless: (1)&nbsp;the Indemnifying Party has agreed in writing to pay such fees, expenses and amounts; (2)&nbsp;the Indemnifying
Party shall have failed promptly to assume the defense of such Proceeding and to employ counsel reasonably satisfactory to such Indemnified Party in any such Proceeding; or (3)&nbsp;the named parties to any such Proceeding (including any impleaded
parties) include both such Indemnified Party and the Indemnifying Party, and such Indemnified Party shall have been advised by counsel that a conflict of interest exists if the same counsel were to represent such Indemnified Party and the
Indemnifying Party (in which case, if such Indemnified Party notifies the Indemnifying Party in writing that it elects to employ separate counsel at the expense of the Indemnifying Party, the Indemnifying Party shall not have the right to assume the
defense thereof and such counsel shall be at the expense of the Indemnifying Party); <I>provided</I>, that the Indemnifying Party shall not be liable for the fees, expenses and disbursements of more than one separate firm of attorneys at any time
for all Indemnified Parties. The Indemnifying Party shall not be liable for any settlement of any such Proceeding effected without its written consent, which consent shall not be unreasonably withheld, delayed or conditioned. No Indemnifying Party
shall, without the prior written consent of the Indemnified Party, effect any settlement of any pending Proceeding in respect of which any Indemnified Party is a party, unless such settlement includes an unconditional release of such Indemnified
Party from all liability on claims that are the subject matter of such Proceeding. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Subject to the terms of this Agreement, all fees, expenses and disbursements of the
Indemnified Party (including reasonable fees, expenses and disbursements to the extent incurred in connection with investigating or preparing to defend such Proceeding in a manner not inconsistent with this <U>Section</U><U></U><U>&nbsp;5</U>) shall
be paid to the Indemnified Party, as incurred, within 20 Trading Days of written notice thereof to the Indemnifying Party; <I>provided</I>, that the Indemnified Party shall promptly reimburse the Indemnifying Party for that portion of such fees,
expenses and disbursements applicable to such actions for which such Indemnified Party is finally judicially determined to not be entitled to indemnification hereunder. The failure to deliver written notice to the Indemnifying Party within a
reasonable time of the commencement of any such action shall not relieve such Indemnifying Party of any liability to the Indemnified Party under this <U>Section</U><U></U><U>&nbsp;5</U>, except to the extent that the Indemnifying Party is materially
and adversely prejudiced in its ability to defend such action. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) <U>Contribution</U>. If a claim for indemnification under
<U>Section</U><U></U><U>&nbsp;5(a)</U> or <U>5(b)</U> is unavailable to an Indemnified Party or insufficient to hold an Indemnified Party harmless for any Losses, then each Indemnifying Party, in lieu of indemnifying such Indemnified Party, shall
contribute to the amount paid or payable by such Indemnified Party as a result of such Losses, in such proportion as is appropriate to reflect the relative fault of the Indemnifying Party and Indemnified Party in connection with the actions,
statements or omissions that resulted in such Losses as well as any other relevant equitable considerations. The relative fault of such Indemnifying Party and Indemnified Party shall be determined by reference to, among other things, whether any
action in question, including any untrue or alleged untrue statement of a material fact or omission or alleged omission of a material fact, has been taken or made by, or relates to information supplied by, such Indemnifying Party or Indemnified
Party, and the parties&#146; relative intent, knowledge, access to information and opportunity to correct or prevent such action, statement or omission. The amount paid or payable by a party as a result of any Losses shall be deemed to include,
subject to the limitations set forth in this Agreement, any reasonable attorneys&#146; or other reasonable fees, expenses or disbursements incurred by such party in connection with any Proceeding to the extent such party would have been indemnified
for such fees, expenses or disbursements if the indemnification provided for in this <U>Section</U><U></U><U>&nbsp;5</U> was available to such party in accordance with its terms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The parties hereto agree that it would not be just and equitable if contribution pursuant to this <U>Section</U><U></U><U>&nbsp;5(d)</U> were
determined by pro rata allocation or by any other method of allocation that does not take into account the equitable considerations referred to in the immediately preceding paragraph. Notwithstanding the provisions of this
<U>Section</U><U></U><U>&nbsp;5(d)</U>, (A) no Holder shall be required to contribute, in the aggregate with any other amounts payable by it under this <U>Section</U><U></U><U>&nbsp;5</U>, any amount in excess of the net proceeds actually received
by such Holder from the sale of the Registrable Securities giving rise to such contribution obligation and (B)&nbsp;no contribution will be made under circumstances where the maker of such contribution would not have been required to indemnify the
Indemnified Party under the fault standards set forth in this <U>Section</U><U></U><U>&nbsp;5</U>. No person guilty of fraudulent misrepresentation (within the meaning of Section&nbsp;11(f) of the Securities Act) shall be entitled to contribution
from any Person who was not guilty of such fraudulent misrepresentation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indemnity and contribution agreements contained in this
<U>Section</U><U></U><U>&nbsp;5</U> are in addition to any liability that the Indemnifying Parties may have to the Indemnified Parties and are not in diminution or limitation of the indemnification provisions under the Purchase Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Miscellaneous</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a)
<U>Remedies</U>. In the event of a breach by the Company or by a Holder of any of their obligations under this Agreement, each Holder or the Company, as the case may be, in addition to being entitled to exercise all rights granted by law and under
this Agreement, including recovery of damages, will be entitled to seek specific performance of its rights under this Agreement, without the requirement of posting a bond. The Company and each Holder agree that monetary damages would not provide
adequate compensation for any losses incurred by reason of a breach by it of any of the provisions of this Agreement and hereby further agrees that, in the event of any action for specific performance in respect of such breach, it shall waive the
defense that a remedy at law would be adequate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) <U>No Piggyback on Registrations; Prohibition on Filing Other Registration
Statements</U>. Except and to the extent specified in the Purchase Agreement, neither the Company nor any of its security holders (other than the Holders in such capacity pursuant hereto) may include securities of the Company in a Registration
Statement other than the Registrable Securities and the Company shall not prior to the Effective Date enter into any agreement providing any such right to any of its security holders. For the avoidance of doubt, the provisions of this Agreement
shall not impact the terms of any <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement entered into by Purchaser for the benefit of the Company on or about the date hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) <U>Compliance</U>. Each Holder covenants and agrees that it will comply with the prospectus delivery requirements of the Securities Act
as applicable to it (unless an exemption therefrom is available) in connection with sales of Registrable Securities pursuant to the Registration Statement and shall sell the Registrable Securities only in accordance with a method of distribution
described in the Registration Statement, or pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) <U>Discontinued Disposition</U>. By its acquisition of Registrable Securities, each Holder agrees that, upon receipt of a notice from the
Company of the occurrence of any event of the kind described in <U>Section</U><U></U><U>&nbsp;3(c)</U>(<U>iii</U>)-(<U>vi</U>), such Holder will forthwith discontinue disposition of such Registrable Securities under a Registration Statement until it
is advised in writing (the &#147;<I>Advice</I>&#148;) by the Company that the use of the applicable Prospectus (as it may have been supplemented or amended) may be resumed. The Company will use its commercially reasonable efforts to ensure that the
use of the Prospectus may be resumed as promptly as is practicable. Notwithstanding anything herein to the contrary, no Holder shall be required to discontinue disposition of Registrable Securities under a Registration Statement by virtue of the
delivery by the Company of a notice of the occurrence of any event of the kind described in <U>Section</U><U></U><U>&nbsp;3(c)</U>(<U>vi</U>) on more than two occasions or for more than 90 total calendar days, in each case during any twelve-month
period, or for more than 45 calendar days during any <FONT STYLE="white-space:nowrap">90-day</FONT> period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) <U>No Inconsistent
Agreements</U>. Neither the Company nor any of its subsidiaries has entered, as of the date hereof, nor shall the Company or any of its subsidiaries, on or after the date hereof, enter into any agreement with respect to its securities, that would
have the effect of impairing the rights granted to the Holders in this Agreement or otherwise conflicts with the provisions hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f)
<U>Amendments and Waivers</U>. The provisions of this Agreement, including the provisions of this sentence, may not be amended, modified or supplemented, or waived unless the same shall be in writing and signed by the Company and Holders holding no
less than a majority of the then outstanding Registrable Securities, provided that (i)&nbsp;any party may give a waiver as to itself and (ii)&nbsp;any proposed amendment that would, by its terms, have a disproportionate and materially adverse effect
on any Holder shall require the consent of such Holder(s). Notwithstanding the foregoing, (1)&nbsp;a waiver or consent to depart from the provisions hereof with respect to a matter that relates exclusively to the rights of Holders and that does not
directly or indirectly affect the rights of other Holders may be given by Holders of all of the Registrable Securities to which such waiver or consent relates and (2)&nbsp;none of the definitions of Filing Deadline, Effectiveness Deadline or
Effectiveness Period, <U>Section</U><U></U><U>&nbsp;2(e)</U>, <U>Section</U><U></U><U>&nbsp;3(c)</U>, <U>Section</U><U></U><U>&nbsp;5</U>, <U>Section</U><U></U><U>&nbsp;6(d)</U>, or the provisions of this sentence, may be amended, modified, or
supplemented except with the consent of each Holder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(g) <U>Notices</U>. Any and all notices or other communications or deliveries
required or permitted to be provided hereunder shall be delivered as set forth in the Purchase Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(h) <U>Successors and
Assigns</U>. This Agreement shall inure to the benefit of and be binding upon the successors and permitted assigns of each of the parties and shall inure to the benefit of each Holder. Nothing in this Agreement, express or implied, is intended to
confer upon any party other than the parties hereto or their respective successors and assigns any rights, remedies, obligations, or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement. The Company may
not assign its rights (except by merger or in connection with another entity acquiring all or substantially all of the Company&#146;s assets) or obligations hereunder without the prior written consent of all the Holders of the then outstanding
Registrable Securities. Each Holder may assign its respective rights hereunder in the manner and to the Persons as permitted under the Purchase </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Agreement; provided in each case that (i)&nbsp;the Holder agrees in writing with the transferee or assignee to assign such rights and related obligations under this Agreement, and for the
transferee or assignee to assume such obligations, and a copy of such agreement is furnished to the Company within a reasonable time after such assignment, (ii)&nbsp;the Company is, within a reasonable time after such transfer or assignment,
furnished with written notice of the name and address of such transferee or assignee and the securities with respect to which such registration rights are being transferred or assigned, (iii)&nbsp;at or before the time the Company received the
written notice contemplated by clause (ii)&nbsp;of this sentence, the transferee or assignee agrees in writing with the Company to be bound by all of the provisions contained herein and (iv)&nbsp;the transferee is an &#147;accredited investor,&#148;
as that term is defined in Rule 501 of Regulation D. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) <U>Execution and Counterparts</U>. This Agreement may be executed in two or
more counterparts, each of which when so executed shall be deemed to be an original and, all of which taken together shall constitute one and the same Agreement and shall become effective when counterparts have been signed by each party and
delivered to the other party, it being understood that both parties need not sign the same counterpart. Counterparts may be delivered via facsimile, electronic mail (including any electronic signature covered by the U.S. federal ESIGN Act of 2000,
Uniform Electronic Transactions Act, the Electronic Signatures and Records Act or other applicable law, e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and
be valid and effective for all purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(j) <U>Governing Law</U>. All questions concerning the construction, validity, enforcement and
interpretation of this Agreement shall be determined in accordance with the provisions of the Purchase Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(k) <U>Cumulative
Remedies</U>. The remedies provided herein are cumulative and not exclusive of any other remedies provided by law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(l)
<U>Severability</U>. If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set
forth herein shall remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their good faith reasonable efforts to find and employ an alternative means to achieve the same or
substantially the same result as that contemplated by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would have executed the remaining terms, provisions, covenants and
restrictions without including any of such that may be hereafter declared invalid, illegal, void or unenforceable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(m) <U>Headings</U>.
The headings in this Agreement are for convenience only and shall not limit or otherwise affect the meaning hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(n) <U>Independent
Nature of Purchasers&#146; Obligations and Rights</U>. The obligations of each Purchaser under this Agreement are several and not joint with the obligations of any other Purchaser hereunder, and no Purchaser shall be responsible in any way for the
performance of the obligations of any other Purchaser hereunder. The decision of each Purchaser to purchase Securities pursuant to the Transaction Documents has been made by such Purchaser independently of any other Purchaser and independently of
any information, materials, statements or opinions as to the business, affairs, operations, assets, properties, liabilities, results of operations, condition (financial or otherwise) or prospects of the Company or any Subsidiary which may have been
made or given by any other Purchaser or by any agent or employee of any other Purchaser, and no Purchaser and any of its agents or employees shall have any liability to any other Purchaser (or any other Person) relating to or arising from any such
information, materials, statement or opinions. Nothing contained herein or in any Transaction Document, and no action taken by any Purchaser pursuant hereto or thereto, shall be deemed to constitute the Purchasers as a partnership, an association, a
joint venture or any other kind of entity, or create a presumption that the Purchasers are in any way acting in concert or as a group (including, without limitation, a &#147;group&#148; within the meaning of Section&nbsp;13(d)(3) of the Exchange
Act) with respect to such obligations or the transactions contemplated by the Transaction Documents. Each Purchaser acknowledges that no other Purchaser has acted as agent for such Purchaser in connection with making its investment hereunder and
that no Purchaser will be acting as agent of such Purchaser in connection with monitoring its investment in the securities or enforcing its rights under the Transaction Documents. Each Purchaser shall be entitled to independently protect and enforce
its rights, including, without limitation, the rights arising out of this Agreement or out of the other Transaction Documents, and it shall not be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
necessary for any other Purchaser to be joined as an additional party in any Proceeding for such purpose. The Company acknowledges that each of the Purchasers has been provided with the same
Registration Rights Agreement for the purpose of closing a transaction with multiple Purchasers and not because it was required or requested to do so by any Purchaser. It is expressly understood that each provision contained in this Agreement is
between the Company and a Purchaser, solely, and not between the Company and the Purchasers collectively and not between and among the Purchasers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(o) <U>Current Public Information</U>. With a view to making available to the Holders the benefits of Rule 144 (or its successor rule) and
any other rule or regulation of the Commission that may at any time permit the Holders to sell shares of Common Stock to the public without registration, for so long as the Shares remain outstanding, the Company covenants and agrees to use
commercially reasonable efforts to: (i)&nbsp;make and keep adequate current public information available, as those terms are understood and defined in Rule 144, until such date on which the Holders no longer hold any Registrable Securities; and
(ii)&nbsp;file with the SEC in a timely manner all reports and other documents required of the Company under the Exchange Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[REMAINDER
OF PAGE INTENTIONALLY LEFT BLANK] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Registration Rights Agreement as of the
date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">SPYRE THERAPEUTICS, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Cameron Turtle</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Registration Rights Agreement as of the
date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">[NAME OF INVESTING ENTITY]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><U>ANNEX A </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">PLAN OF DISTRIBUTION<SUP STYLE="font-size:75%; vertical-align:top">1</SUP> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are registering the shares of common stock of Spyre Therapeutics, Inc., par value of $0.0001 per share, or the Common Stock, which we refer
to herein as &#147;Shares,&#148; issued to the selling stockholders to permit the sale, transfer or other disposition of the Shares by the selling stockholders or their donees, pledgees, transferees or other <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">successors-in-interest</FONT></FONT> from time to time after the date of this prospectus. We will not receive any of the proceeds from the sale by the selling stockholders of the Shares. We will, or will procure to, bear
all fees and expenses incident to our obligation to register the Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selling stockholders may sell all or a portion of the Shares
beneficially owned by them and offered hereby from time to time directly or through one or more underwriters, broker-dealers or agents. If the Shares are sold through underwriters or broker-dealers, the selling stockholders will be responsible for
underwriting discounts (it being understood that the selling stockholders shall not be deemed to be underwriters solely as a result of their participation in this offering) or commissions or agent&#146;s commissions. The Shares may be sold on any
national securities exchange or quotation service on which the securities may be listed or quoted at the time of sale, in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market or in transactions
otherwise than on these exchanges or systems or in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market and in one or more transactions at fixed prices, at prevailing market prices at the time
of the sale, at varying prices determined at the time of sale, or at negotiated prices. These sales may be effected in transactions, which may involve crosses or block transactions. The selling stockholders may use any one or more of the following
methods when selling Shares: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">block trades in which the broker-dealer will attempt to sell the shares as agent but may position and resell a
portion of the block as principal to facilitate the transaction; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to or through underwriters or purchases by a broker-dealer as principal and resale by the broker-dealer for its
account; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an exchange distribution in accordance with the rules of the applicable exchange; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">privately negotiated transactions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">settlement of short sales entered into after the effective date of the registration statement of which this
prospectus is a part; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">broker-dealers may agree with the selling stockholders to sell a specified number of such Shares at a stipulated
price per Share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through the writing or settlement of options or other hedging transactions, whether such options are listed on an
options exchange or otherwise; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a combination of any such methods of sale; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other method permitted pursuant to applicable law. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selling stockholders also may resell all or a portion of the Shares in open market transactions in reliance upon Rule 144 under the
Securities Act, as amended, or the Securities Act, as permitted by that rule, or Section&nbsp;4(a)(1) under the Securities Act, if available, rather than under this prospectus, provided that they meet the criteria and conform to the requirements of
those provisions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Broker-dealers engaged by the selling stockholders may arrange for other broker-dealers to participate in sales. If the
selling stockholders effect such transactions by selling Shares to or through underwriters, broker-dealers or agents, such underwriters, broker-dealers or agents may receive commissions in the form of discounts, concessions or commissions from the
selling stockholders or commissions from purchasers of the Shares for whom they may act as agent or to whom they may sell as principal. Such commissions will be in amounts to be negotiated, but, except as set forth in a supplement to this
Prospectus, in the case of an agency transaction will not be in excess of a customary brokerage commission in compliance with FINRA Rule 2121; and in the case of a principal transaction a markup or markdown in compliance with FINRA <FONT
STYLE="white-space:nowrap">IM-2121.01.</FONT> </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Note to Draft</U>: Definitions to be conformed to resale <FONT STYLE="white-space:nowrap">S-1.</FONT>
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with sales of the Shares or otherwise, the selling stockholders may enter into
hedging transactions with broker-dealers or other financial institutions, which may in turn engage in short sales of the Shares in the course of hedging in positions they assume. The selling stockholders may also sell Shares short and if such short
sale takes place after the date that this Registration Statement is declared effective by the Commission, the selling stockholders may deliver Shares covered by this prospectus to close out short positions and to return borrowed Shares in connection
with such short sales. The selling stockholders may also loan or pledge Shares to broker-dealers that in turn may sell such Shares, to the extent permitted by applicable law. The selling stockholders may also enter into option or other transactions
with broker-dealers or other financial institutions or the creation of one or more derivative securities which require the delivery to such broker-dealer or other financial institution of shares offered by this prospectus, which shares such
broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction). Notwithstanding the foregoing, the selling stockholders have been advised that they may not use Shares the
resale of which has been registered on this registration statement to cover short sales of our Common Stock made prior to the date the registration statement, of which this prospectus forms a part, has been declared effective by the SEC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selling stockholders may, from time to time, pledge or grant a security interest in some or all of the Shares owned by them and, if they
default in the performance of their secured obligations, the pledgees or secured parties may offer and sell the Shares from time to time pursuant to this prospectus or any amendment to this prospectus under Rule 424(b)(3) or other applicable
provision of the Securities Act of 1933, amending, if necessary, the list of selling stockholders to include the pledgee, transferee or other successors in interest as selling stockholders under this prospectus. The selling stockholders also may
transfer and donate the Shares in other circumstances in which case the transferees, donees, pledgees or other successors in interest will be the selling beneficial owners for purposes of this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selling stockholders and any broker-dealer or agents participating in the distribution of the Shares may be deemed to be
&#147;underwriters&#148; within the meaning of Section&nbsp;2(11) of the Securities Act in connection with such sales. In such event, any commissions paid, or any discounts or concessions allowed to, any such broker-dealer or agent and any profit on
the resale of the shares purchased by them may be deemed to be underwriting commissions or discounts under the Securities Act. Selling Stockholders who are &#147;underwriters&#148; within the meaning of Section&nbsp;2(11) of the Securities Act will
be subject to the applicable prospectus delivery requirements of the Securities Act including Rule 172 thereunder and may be subject to certain statutory liabilities of, including but not limited to, Sections 11, 12 and 17 of the Securities Act and
Rule <FONT STYLE="white-space:nowrap">10b-5</FONT> under the Securities Exchange Act of 1934, as amended, or the Exchange Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each
selling stockholder has informed the Company that it is not a registered broker-dealer and does not have any written or oral agreement or understanding, directly or indirectly, with any person to distribute the Shares. Upon the Company being
notified in writing by a selling stockholder that any material arrangement has been entered into with a broker-dealer for the sale of Common Stock through a block trade, special offering, exchange distribution or secondary distribution or a purchase
by a broker or dealer, a supplement to this prospectus will be filed, if required, pursuant to Rule 424(b) under the Securities Act, disclosing (i)&nbsp;the name of each such selling stockholder and of the participating broker-dealer(s), (ii) the
number of Shares involved, (iii)&nbsp;the price at which such the Shares were sold, (iv)&nbsp;the commissions paid or discounts or concessions allowed to such broker-dealer(s), where applicable, (v)&nbsp;that such broker-dealer(s) did not conduct
any investigation to verify the information set out or incorporated by reference in this prospectus, and (vi)&nbsp;other facts material to the transaction. In no event shall any broker-dealer receive fees, commissions and markups, which, in the
aggregate, would exceed eight percent (8.0%). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the securities laws of some U.S. states, the Shares may be sold in such states only
through registered or licensed brokers or dealers. In addition, in some U.S. states the Shares may not be sold unless such shares have been registered or qualified for sale in such state or an exemption from registration or qualification is
available and is complied with. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There can be no assurance that any selling stockholder will sell any or all of the Shares registered
pursuant to the shelf registration statement, of which this prospectus forms a part. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each selling stockholder and any other person participating in such distribution will be
subject to applicable provisions of the Exchange Act and the rules and regulations thereunder, including, without limitation, to the extent applicable, Regulation M of the Exchange Act, which may limit the timing of purchases and sales of any of the
Shares by the selling stockholder and any other participating person. To the extent applicable, Regulation M may also restrict the ability of any person engaged in the distribution of the Shares to engage in market-making activities with respect to
the Shares. All of the foregoing may affect the marketability of the Shares and the ability of any person or entity to engage in market-making activities with respect to the Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will pay all expenses of the registration of the Shares pursuant to the registration rights agreement, including, without limitation,
Securities and Exchange Commission filing fees and expenses of compliance with state securities or &#147;blue sky&#148; laws; <I>provided</I>, <I>however</I>, that each selling stockholder will pay all underwriting discounts and selling commissions,
if any and any related legal expenses incurred by it. We will indemnify the selling stockholders against certain liabilities, including some liabilities under the Securities Act, in accordance with the registration rights agreement, or the selling
stockholders will be entitled to contribution. We may be indemnified by the selling stockholders against certain civil liabilities set forth in the registration rights agreement, including liabilities under the Securities Act, that may arise from
any written information furnished to us by the selling stockholders specifically for use in this prospectus, in accordance with the related registration rights agreements, or we may be entitled to contribution. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><U>ANNEX B </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SELLING STOCKHOLDER NOTICE AND QUESTIONNAIRE </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned holder of shares of the (i)&nbsp;common stock, par value $0.0001 per share, of Spyre Therapeutics, Inc. (the
&#147;<I>Company</I>&#148;) and/or (ii)&nbsp;Series B <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Convertible Preferred Shares, par value $0.0001 per share, of the Company issued pursuant to a certain Securities Purchase Agreement by and
among the Company and the Purchasers named therein, dated as of __________, 2023 (the &#147;<I>Agreement</I>&#148;), understands that the Company intends to file with the Securities and Exchange Commission a registration statement on Form <FONT
STYLE="white-space:nowrap">S-1</FONT> (the &#147;<I>Resale Registration Statement</I>&#148;) for the registration and the resale under Rule 415 of the Securities Act of 1933, as amended (the &#147;<I>Securities Act</I>&#148;), of the Registrable
Securities in accordance with the terms of the Agreement. All capitalized terms not otherwise defined herein shall have the meanings ascribed thereto in the Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to sell or otherwise dispose of any Registrable Securities pursuant to the Resale Registration Statement, a holder of Registrable
Securities generally will be required to be named as a selling stockholder in the related prospectus or a supplement thereto (as so supplemented, the &#147;<I>Prospectus</I>&#148;), deliver the Prospectus to purchasers of Registrable Securities
(including pursuant to Rule 172 under the Securities Act) and be bound by the provisions of the Agreement (including certain indemnification provisions, as described below). <B>Holders must complete and deliver this Notice and Questionnaire in order
to be named as selling stockholders in the Prospectus. Holders of Registrable Securities who do not complete, execute and return this Notice and Questionnaire within five (5)</B><B></B><B>&nbsp;Trading Days following the date of the Agreement
(1)</B><B></B><B>&nbsp;will not be named as selling stockholders in the Resale Registration Statement or the Prospectus and (2)</B><B></B><B>&nbsp;may not use the Prospectus for resales of Registrable Securities</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain legal consequences arise from being named as a selling stockholder in the Resale Registration Statement and the Prospectus. Holders of
Registrable Securities are advised to consult their own securities law counsel regarding the consequences of being named or not named as a selling stockholder in the Resale Registration Statement and the Prospectus. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTICE </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned
holder (the &#147;<I>Selling Stockholder</I>&#148;) of Registrable Securities hereby gives notice to the Company of its intention to sell or otherwise dispose of Registrable Securities owned by it and listed below in Item (3), unless otherwise
specified in Item (3), pursuant to the Resale Registration Statement. The undersigned, by signing and returning this Notice and Questionnaire, understands and agrees that it will be bound by the terms and conditions of this Notice and Questionnaire
and the Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned hereby provides the following information to the Company and represents and warrants that such
information is accurate and complete: </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>QUESTIONNAIRE </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Name. </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Full Legal Name of Selling Stockholder: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Full Legal Name of Registered Holder (if not the same as (a)&nbsp;above) through which Registrable Securities
Listed in Item 3 below are held: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Full Legal Name of Natural Control Person (which means a natural person who directly or indirectly alone or
with others has power to vote or dispose of the securities covered by the questionnaire): </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Address for Notices to Selling Stockholder: </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Telephone: </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Fax: </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Contact Person: </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail</FONT>
address of Contact Person:<U> </U> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Beneficial Ownership of Registrable Securities Issuable Pursuant to the Purchase Agreement:
</B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Type and Number of Registrable Securities beneficially owned and issued pursuant to the Agreement:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Number of Registrable Securities to be registered pursuant to this Notice for resale: </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Broker-Dealer Status: </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Are you a broker-dealer? </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If &#147;yes&#148; to Section&nbsp;4(a), did you receive your Registrable Securities as compensation for
investment banking services to the Company? </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Note: If no, the Commission&#146;s staff has indicated that you should be identified as an underwriter in the Registration Statement. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Are you an affiliate of a broker-dealer? </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Note: If yes, provide a narrative explanation below: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If you are an affiliate of a broker-dealer, do you certify that you bought the Registrable Securities in the
ordinary course of business, and at the time of the purchase of the Registrable Securities to be resold, you had no agreements or understandings, directly or indirectly, with any person to distribute the Registrable Securities?
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Note: If no, the Commission&#146;s staff has indicated that you should be identified as an underwriter in the Registration Statement. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Beneficial Ownership of Other Securities of the Company Owned by the Selling Stockholder.
</B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Except as set forth below in this Item 5, the undersigned is not the beneficial or registered owner of any securities of the
Company other than the Registrable Securities listed above in Item 3. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Type and amount of other securities beneficially owned: </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Relationships with the Company: </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Except as set forth below, neither the undersigned nor any of its affiliates, officers, directors or principal equity holders (owners of 5% of more of the
equity securities of the undersigned) has held any position or office or has had any other material relationship with the Company (or its predecessors or affiliates) during the past three years. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">State any exceptions here: </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Plan of Distribution: </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The undersigned has reviewed the form of Plan of Distribution attached as Annex A to the Registration Rights Agreement, and hereby confirms that, except as
set forth below, the information contained therein regarding the undersigned and its plan of distribution is correct and complete. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">State any
exceptions here: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">*********** </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned agrees to promptly notify the Company of any inaccuracies or changes in the information
provided herein that may occur subsequent to the date hereof and prior to the effective date of any applicable Resale Registration Statement. All notices hereunder and pursuant to the Agreement shall be made in writing, by hand delivery, confirmed
or facsimile transmission, first-class mail or air courier guaranteeing overnight delivery at the address set forth below. In the absence of any such notification, the Company shall be entitled to continue to rely on the accuracy of the information
in this Notice and Questionnaire. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By signing below, the undersigned consents to the disclosure of the information contained herein in its answers to
Items (1)&nbsp;through (7) above and the inclusion of such information in the Resale Registration Statement and the Prospectus. The undersigned understands that such information will be relied upon by the Company in connection with the preparation
or amendment of any such Registration Statement and the Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By signing below, the undersigned acknowledges that it understands its obligation to
comply, and agrees that it will comply, with the provisions of the Exchange Act and the rules and regulations thereunder, particularly Regulation M in connection with any offering of Registrable Securities pursuant to the Resale Registration
Statement. The undersigned also acknowledges that it understands that the answers to this Questionnaire are furnished for use in connection with Registration Statements filed pursuant to the Registration Rights Agreement and any amendments or
supplements thereto filed with the Commission pursuant to the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned hereby acknowledges and is advised of the following
Question 239.10 of the Securities Act Rules Compliance and Disclosure Interpretations regarding short selling: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<I>An Issuer filed a Form <FONT
STYLE="white-space:nowrap">S-3</FONT> registration statement for a secondary offering of common stock which is not yet effective. One of the selling stockholders wanted to do a short sale of common stock &#147;against the box&#148; and cover the
short sale with registered shares after the effective date. The issuer was advised that the short sale could not be made before the registration statement become effective, because the shares underlying the short sale are deemed to be sold at the
time such sale is made. There would, therefore, be a violation of Section</I><I></I><I>&nbsp;5 if the shares were effectively sold prior to the effective date</I>.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By returning this Questionnaire, the undersigned will be deemed to be aware of the foregoing interpretation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I confirm that, to the best of my knowledge and belief, the foregoing statements (including without limitation the answers to this Questionnaire) are correct.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF the undersigned, by authority duly given, has caused this Questionnaire to be executed and delivered either in person or by its duly
authorized agent. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dated:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Beneficial Owner:</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PLEASE EMAIL A COPY OF THE COMPLETED AND EXECUTED NOTICE AND QUESTIONNAIRE, AND RETURN THE ORIGINAL BY OVERNIGHT MAIL, TO:
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amanda Estep </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gibson, Dunn&nbsp;&amp; Crutcher LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">310 University Avenue, Palo Alto, CA 94301 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Telephone No.: (650) <FONT
STYLE="white-space:nowrap">849-5241</FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attention: Amanda Estep </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT> aestep@gibsondunn.com </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>8
<FILENAME>d518298dex42.htm
<DESCRIPTION>EX-4.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 4.2 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g518298dsp085.jpg" ALT="LOGO">
 </P> <P STYLE="font-family:Times New Roman; font-size:0.5pt"><FONT COLOR="#FFFFFF">Exhibit 4.2 The Corporation shall furnish without charge to each stockholder who so requests a statement of the powers, designations,
preferences and relative, participating, optional or other special rights of each class of stock of the Corporation or series thereof and the qualifications, limitations or restrictions of such preferences and/or rights. Such requests shall be made
to the Corporation&#146;s Secretary at the principal office of the Corporation. KEEP THIS CERTIFICATE IN A SAFE PLACE. IF IT IS LOST, STOLEN,OR DESTROYED THE CORPORATION WILL REQUIRE A BOND INDEMNITY AS A CONDITION TO THE ISSUANCE OF A REPLACEMENT
CERTIFICATE. The following abbreviations, when used in the inscription on the face of this certificate, shall be construed as though they were written out in full according to applicable laws or regulations: TEN COM &#150; as tenants in common UNIF
GIFT MIN ACT Custodian TEN ENT &#150; as tenants by the entireties (Cust) (Minor) JT TEN &#150; as joint tenants with right of under Uniform Gifts to Minors survivorship and not as tenants Act in common (State) COM PROP &#150; as community property
UNIF TRF MIN ACT. Custodian (until age ...) (Cust).. under Uniform Transfers (Minor) to Minors Act. (State) Additional abbreviations may also be used though not in the above list. FOR VALUE RECEIVED, hereby sell(s), assign(s) and transfer(s) unto
PLEASE INSERT SOCIAL SECURITY OR OTHER IDENTIFYING NUMBER OF ASSIGNEE (PLEASE PRINT OR TYPEWRITE NAME AND ADDRESS, INCLUDING ZIP CODE, OF ASSIGNEE) shares of the capital stock represented by within Certificate, and do hereby irrevocably constitute
and appoint <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> to transfer the said stock on the books of the within named Corporation with full power of the substitution in the premises. Dated
</FONT></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g518298dsp086.jpg" ALT="LOGO">
 </P> <P STYLE="font-family:Times New Roman; font-size:0.5pt"><FONT COLOR="#FFFFFF">X X Signature(s) Guaranteed: NOTICE: THE SIGNATURE TO THIS ASSIGNMENT MUST CORRESPOND WITH THE NAME AS WRITTEN UPON THE FACE OF THE
CERTIFICATE IN EVERY PARTICULAR, WITHOUT ALTERATION OR ENLARGEMENT OR ANY CHANGE WHATSOEVER. By THE SIGNATURE(S) SHOULD BE GUARANTEED BY AN ELIGIBLE GUARANTOR INSTITUTION, (BANKS, STOCKBROKERS, SAVINGS AND LOAN ASSOCIATIONS AND CREDIT UNIONS WITH
MEMBERSHIP IN AN APPROVED SIGNATURE GUARANTEE MEDALLION PROGRAM), PURSUANT TO S.E.C. RULE <FONT STYLE="white-space:nowrap">17Ad-15.</FONT> GUARANTEES BY A NOTARY PUBLIC ARE NOT ACCEPTABLE. SIGNATURE GUARANTEES MUST NOT BE DATED. </FONT></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.3
<SEQUENCE>9
<FILENAME>d518298dex43.htm
<DESCRIPTION>EX-4.3
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 4.3 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B></B><B><I>Execution Version</I></B><B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES PURCHASE AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This <B>S<SMALL>ECURITIES</SMALL> P<SMALL>URCHASE</SMALL> A<SMALL>GREEMENT</SMALL></B><SMALL></SMALL> (this
&#147;<B><I>Agreement</I></B>&#148;) is dated as of December&nbsp;7, 2023, by and among <B>S<SMALL>PYRE</SMALL> T<SMALL>HERAPEUTICS</SMALL>, I<SMALL>NC</SMALL>.</B>, a Delaware corporation (the &#147;<B><I>Company</I></B>&#148;), and each purchaser
identified on Annex A hereto (each, including its successors and assigns, a &#147;<B><I>Purchaser</I></B>&#148; and collectively, the &#147;<B><I>Purchasers</I></B>&#148;). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>A.</B> The
Company and each Purchaser is executing and delivering this Agreement in reliance upon the exemption from securities registration afforded by Section&nbsp;4(a)(2) of the Securities Act of 1933, as amended, and the rules and regulations thereunder
(the &#147;<B><I>Securities Act</I></B>&#148;), and Rule 506 of Regulation D (&#147;<B><I>Regulation D</I></B>&#148;) as promulgated by the United States Securities and Exchange Commission (the &#147;<B><I>Commission</I></B>&#148;) under the
Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>B.</B> Each Purchaser, severally and not jointly, wishes to purchase, and the Company wishes to issue and sell, upon
the terms and conditions stated in this Agreement, an aggregate of 6,000,000 shares (the &#147;<B><I>Common Shares</I></B>&#148;) of the Company&#146;s common stock, par value $0.0001 per share (&#147;<B><I>Common Stock</I></B>&#148;), and 150,000
shares (the &#147;<B><I>Preferred Shares</I></B>&#148; and together with the Common Shares, the &#147;<B><I>Securities</I></B>&#148;) of Series B <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Convertible Preferred Stock, par value $0.0001 per
share (and including any other class of securities into which the Series B Preferred Stock may hereafter be reclassified or changed into, the &#147;<B><I>Series B</I></B> <B><I>Preferred Stock</I></B>&#148;) of the Company, having the designation,
preferences, conversion or other rights, voting powers, restrictions, limitations as to dividends, qualifications and terms and conditions as specified in the Certificate of Designation, in the form attached hereto as <B>Exhibit A</B> (the
&#147;<B><I>Certificate of Designation</I></B>&#148;), which will be convertible into shares (the &#147;<B><I>Conversion Shares</I></B>&#148;) of Common Stock in accordance with the terms set forth in the Certificate of Designation, for an aggregate
purchase price of $180,000,000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>C.</B> Pursuant to the terms and conditions of the Certificate of Designation, the conversion of the
Series B Preferred Stock shall be subject to receipt of the Requisite Stockholder Approval (as defined herein). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>D.</B> The Company has
engaged Jefferies LLC; Cowen and Company, LLC; Stifel, Nicolaus&nbsp;&amp; Company, Incorporated; Guggenheim Securities, LLC and LifeSci Capital LLC as its exclusive placement agents (the &#147;<B><I>Placement Agents</I></B>&#148;) for the offering
of the Securities on a &#147;best efforts&#148; basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>E.</B> Prior to the Closing: (i)&nbsp;the parties hereto shall execute and
deliver a Registration Rights Agreement, substantially in the form attached hereto as <B>Exhibit B</B> (the &#147;<B><I>Registration Rights Agreement</I></B>&#148;), pursuant to which, among other things, the Company will agree to provide certain
registration rights with respect to the Common Shares and the Conversion Shares under the Securities Act and the rules and regulations promulgated thereunder and applicable state securities laws and (ii)&nbsp;the Company shall file with the Delaware
Secretary of State the Certificate of Designation, duly executed by an officer of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NOW, THEREFORE, </B>in consideration of
the mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Company and each Purchaser, severally and not jointly, hereby agree as follows: </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 1 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DEFINITIONS
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.1</B> <B>Definitions</B>. In addition to the terms defined elsewhere in this Agreement, for all purposes of this Agreement, the
following terms shall have the meanings indicated in this Section&nbsp;1.1: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Acquiring Person</I></B>&#148; has the meaning set
forth in Section&nbsp;4.5. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Action</I></B>&#148; means any action, suit, inquiry, notice of violation,
proceeding (including any partial proceeding such as a deposition) or investigation pending or, to the Company&#146;s Knowledge, threatened against the Company, its Subsidiaries or any of their respective properties, or any officer, director or
employee of the Company or any of its Subsidiaries acting in his or her capacity as an officer, director or employee, before or by any federal, state, county, local or foreign court, arbitrator, governmental or administrative agency, regulatory
authority, stock market, stock exchange or trading facility. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Affiliate</I></B>&#148; means, with respect to any Person, any
other Person that, directly or indirectly through one or more intermediaries, Controls, is controlled by or is under common control with such Person, as such terms are used in and construed under Rule 405 under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Agreement</I></B>&#148; has the meaning set forth in the Preamble. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Board of Directors</I></B>&#148; means the board of directors of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Business Day</I></B>&#148; means any day except Saturday, Sunday, any day which is a federal legal holiday in the United States or
any day on which banking institutions in the State of New York are authorized or required by law or other governmental action to close. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Certificate of Designation</I></B>&#148; has the meaning set forth in the Recitals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Closing</I></B>&#148; has the meaning set forth in Section&nbsp;2.2(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Code</I></B>&#148; means the Internal Revenue Code of 1986, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Commission</I></B>&#148; has the meaning set forth in the Recitals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Company</I></B>&#148; has the meaning set forth in the Preamble. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Company Counsel</I></B>&#148; means Gibson, Dunn&nbsp;&amp; Crutcher LLP, with offices at 555 Mission St., Suite 3000, San
Francisco, CA 94105. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Company Deliverables</I></B>&#148; has the meaning set forth in Section&nbsp;2.3(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Company&#146;s Knowledge</I></B>&#148; means with respect to any statement made to the Company&#146;s Knowledge, that the
statement is based upon the actual knowledge, or knowledge that would have been acquired after reasonable inquiry, of the executive officers or directors of the Company having responsibility for the matter or matters that are the subject of the
statement. With respect to any matters relating to Intellectual Property, such awareness or reasonable expectation to have knowledge does not require any such individual to conduct or have conducted or obtain or have obtained any freedom to operate
opinions of counsel or any Intellectual Property rights clearance searches. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Contract</I></B>&#148; means, with respect to any
Person, any written or oral agreement, contract, subcontract, lease (whether for real or personal property), mortgage, license, or other legally binding commitment or undertaking of any nature to which such Person is a party or by which such Person
or any of its assets are bound or affected under applicable Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Control</I></B>&#148; (including the terms
&#147;controlling&#148;, &#147;controlled by&#148; or &#147;under common control with&#148;) means the possession, direct or indirect, of the power to direct or cause the direction of the management and policies of a Person, whether through the
ownership of voting securities, by Contract or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Effect</I></B>&#148; means any effect, change, event, circumstance,
state of fact, occurrence or development. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Effective Date</I></B>&#148; means the date on which the initial Registration
Statement required by Section&nbsp;2(a) of the Registration Rights Agreement is first declared effective by the Commission. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Employee Plan</I></B>&#148; means any &#147;employee benefit plan&#148; as
defined in Section&nbsp;3(3) of ERISA and any other pension, retirement, deferred compensation, excess benefit, profit-sharing, bonus, incentive, equity or equity-based, phantom equity, employment, consulting, severance, <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">change-of-control,</FONT></FONT> retention, health, life, disability, group insurance, paid time off, holiday, welfare and fringe benefit plan, program, agreement, Contract, or arrangement
(whether written or unwritten, qualified or nonqualified, funded or unfunded, subject or not subject to ERISA and including any that have been frozen) that the Company or any of its Subsidiaries (i)&nbsp;sponsors, maintains, administers, or
contributes to, (ii)&nbsp;provides benefits under or through, (iii)&nbsp;has any obligation to contribute to or provide benefits under or through, (iv)&nbsp;with respect to which have any liability, or (v)&nbsp;utilizes to provide benefits to or
otherwise cover any current or former employee, officer, director or other service provider of the Company or any of its Subsidiaries (or their spouses, dependents, or beneficiaries). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Encumbrance</I></B>&#148; means any lien, pledge, hypothecation, charge, mortgage, security interest, lease, exclusive license,
option, easement, reservation, servitude, adverse title, claim, infringement, interference, option, right of first refusal, preemptive right, community property interest or restriction or encumbrance of any nature (including any restriction on the
voting of any security, any restriction on the transfer of any security or other asset, any restriction on the receipt of any income derived from any asset, any restriction on the use of any asset and any restriction on the possession, exercise or
transfer of any other attribute of ownership of any asset). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Environmental Laws</I></B>&#148; has the meaning set forth in
Section&nbsp;3.1(cc). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>ERISA</I></B>&#148; means the Employee Retirement Income Security Act of 1974, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Exchange Act</I></B>&#148; means the Securities Exchange Act of 1934, as amended, or any successor statute, and the rules and
regulations promulgated thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>GAAP</I></B>&#148; means generally accepted accounting principles and practices in effect
from time to time within the United States applied consistently throughout the period involved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Governmental
Authority</I></B>&#148; means any: (a)&nbsp;nation, state, commonwealth, province, territory, county, municipality, district or other jurisdiction of any nature, (b)&nbsp;federal, state, local, municipal, foreign, supra-national or other government,
(c)&nbsp;governmental or quasi-governmental authority of any nature (including any governmental division, department, agency, commission, bureau, instrumentality, official, ministry, fund, foundation, center, organization, unit, body or entity and
any court or other tribunal, and any taxing authority) or (d)&nbsp;self-regulatory organization (including Nasdaq). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Hazardous
Materials</I></B>&#148; means any pollutant, chemical, substance and any toxic, infectious, carcinogenic, reactive, corrosive, ignitable or flammable chemical, or chemical compound, or hazardous substance, material or waste, whether solid, liquid or
gas, that is subject to regulation, control or remediation under any Environmental Law, including without limitation, crude oil or any fraction thereof, and petroleum products or <FONT STYLE="white-space:nowrap">by-products.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Intellectual Property</I></B>&#148; has the meaning set forth in Section&nbsp;3.1(o). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Irrevocable Transfer Agent Instructions</I></B>&#148; means, with respect to the Company, the Irrevocable Transfer Agent
Instructions, in substantially the form of <B>Exhibit D</B>, executed by the Company and delivered to and acknowledged in writing by the Transfer Agent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Law</I></B>&#148; means any federal, state, national, supra-national, foreign, local or municipal or other law, statute,
constitution, principle of common law, resolution, ordinance, code, edict, decree, rule, regulation, ruling, order, judgment or requirement issued, enacted, adopted, promulgated, implemented or otherwise put into effect by or under the authority of
any Governmental Authority (including under the authority of Nasdaq or the Financial Industry Regulatory Authority, Inc.). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Material Adverse Effect</I></B>&#148; means any Effect, individually or together with any other Effect, that (a)&nbsp;has had,
has, or would reasonably be expected to have a material adverse effect on the business, condition (financial or otherwise), general affairs, management, assets, liabilities, results of operations, earnings, prospects or properties of
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Company or its Subsidiaries, taken as a whole; <I>provided</I>, <I>however</I>, that Effects arising or resulting from the following shall not be taken into account in determining whether
there has been a Material Adverse Effect: (1)&nbsp;the announcement or disclosure of the sale of the Securities or other transactions contemplated by this Agreement, (2)&nbsp;the taking of any action, or the failure to take any action, by the
Company that is required to comply with the terms of this Agreement, (3)&nbsp;any natural disaster or epidemics, pandemics or other force majeure events, or any act or threat of terrorism or war, any armed hostilities or terrorist activities
(including any escalation or general worsening of any of the foregoing) anywhere in the world or any governmental or other response or reaction to any of the foregoing, (4)&nbsp;any change in GAAP or applicable Law or the interpretation thereof,
(5)&nbsp;general economic or political conditions or conditions generally affecting the industries in which the Company and its Subsidiaries operate or (6)&nbsp;any change in the cash position of the Company and its Subsidiaries which results from
operations in the ordinary course of business; except in each case with respect to clauses (3), (4) and (5), (x) to the extent disproportionately affecting the Company and its Subsidiaries, taken as a whole, relative to other similarly situated
companies in the industries in which the Company and its Subsidiaries operate and (y)&nbsp;the underlying cause of such Effect may be considered except to the extent such underlying cause would otherwise be excluded in accordance with the foregoing;
or (b)&nbsp;prevents, materially adversely delays or materially adversely impedes, or could reasonably be expected to prevent, materially adversely delay or materially adversely impede the performance by the Company of its obligations under this
Agreement and the other Transaction Documents, including, without limitation, the issuance and sale of the Securities and the Conversion Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Material Contract</I></B>&#148; means any Contract to which the Company or any Subsidiary is a party or by which either is bound
that is material to the business of the Company, including those that have been filed as an exhibit to the SEC Reports pursuant to Item 601(b)(10) of Regulation <FONT STYLE="white-space:nowrap">S-K.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Nasdaq</I></B>&#148; means The Nasdaq Stock Market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>New York Courts</I></B>&#148; means the state and federal courts sitting in the City of New York, Borough of Manhattan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Outside Date</I></B>&#148; means the fifth (5th) Business Day following the date of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Per Share Purchase Price</I></B>&#148; means $15.00 per Common Share and $600.00 per Preferred Share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Permitted Encumbrances</I></B>&#148; means: (a)&nbsp;any Encumbrance for current taxes not yet due and payable or for taxes that
are being contested in good faith and, in each case, for which adequate reserves have been made on the Unaudited Interim Balance Sheet in accordance with GAAP; (b)&nbsp;minor liens that have arisen in the ordinary course of business and that do not
(individually or in the aggregate) materially detract from the value of the assets or properties subject thereto or materially impair the operations of the Company or any of its Subsidiaries; (c)&nbsp;statutory liens to secure obligations to
landlords, lessors or renters under leases or rental agreements; (d)&nbsp;deposits or pledges made in connection with, or to secure payment of, workers&#146; compensation, unemployment insurance or similar programs mandated by Law; <FONT
STYLE="white-space:nowrap">(e)&nbsp;non-exclusive</FONT> licenses of Intellectual Property rights granted by the Company or any of its Subsidiaries in the ordinary course of business and that do not (individually or in the aggregate) materially
detract from the value of the Intellectual Property rights subject thereto; and (f)&nbsp;statutory liens in favor of carriers, warehousemen, mechanics and materialmen, to secure claims for labor, materials or supplies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Person</I></B>&#148; means an individual or a corporation, partnership, trust, incorporated or unincorporated association, joint
venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Placement Agents</I></B>&#148; has the meaning set forth in the Recitals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Press Release</I></B>&#148; has the meaning set forth in Section&nbsp;4.4. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Principal Trading Market</I></B>&#148; means the Trading Market on which the Common Stock is primarily listed on and quoted for
trading, which, as of the date of this Agreement and the Closing Date, shall be the Nasdaq Capital Market. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Proceeding</I></B>&#148; means an action, claim, suit, investigation or
proceeding (including, without limitation, an investigation or partial proceeding, such as a deposition), whether commenced or threatened. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Purchaser</I></B>&#148; or &#147;<B><I>Purchasers</I></B>&#148; has the meaning set forth in the Preamble. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Purchaser Deliverables</I></B>&#148; has the meaning set forth in Section&nbsp;2.2(b). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Registrable Securities</I></B>&#148; has the meaning set forth in the Registration Rights Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Registration Rights Agreement</I></B>&#148; has the meaning set forth in the Recitals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Registration Statement</I></B>&#148; means a registration statement meeting the requirements set forth in the Registration Rights
Agreement and covering the resale by the Purchasers of the Registrable Securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Regulation D</I></B>&#148; has the meaning
set forth in the Recitals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Rule 144</I></B>&#148; means Rule 144 promulgated by the Commission pursuant to the Securities
Act, as such Rule may be amended from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same effect as such Rule. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>SEC Reports</I></B>&#148; has the meaning set forth in Section&nbsp;3.1(g). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Secretary&#146;s Certificate</I></B>&#148; has the meaning set forth in 2.3(a)(vi). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Securities</I></B>&#148; has the meaning set forth in the Recitals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Securities Act</I></B>&#148; has the meaning set forth in the Recitals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Series B Preferred Stock</I></B>&#148; has the meaning set forth in the Recitals, and also includes any other class of securities
into which the Series B Preferred Stock may hereafter be reclassified or changed into. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Short Sales</I></B>&#148; include,
without limitation, (i)&nbsp;all &#147;short sales&#148; as defined in Rule 200 promulgated under Regulation SHO under the Exchange Act, whether or not against the box, and all types of direct and indirect stock pledges, forward sale contracts,
options, puts, calls, short sales, swaps, &#147;put equivalent positions&#148; (as defined in Rule <FONT STYLE="white-space:nowrap">16a-1(h)</FONT> under the Exchange Act) and similar arrangements (including on a total return basis), and
(ii)&nbsp;sales and other transactions through <FONT STYLE="white-space:nowrap">non-U.S.</FONT> broker dealers or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulated brokers (but shall not be deemed to include the location and/or reservation
of borrowable shares of Common Stock). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Subscription Amount</I></B>&#148; means, with respect to each Purchaser, the aggregate
amount to be paid for the Securities purchased hereunder by such Purchaser set forth in the &#147;Aggregate Purchase Price&#148; column opposite such Purchaser&#146;s name in the table set forth on Annex A, in United States dollars and in
immediately available funds, which amount represents the number of Securities purchased by such Purchaser multiplied by the applicable Per Share Purchase Price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Subsidiary</I></B>&#148; means any material subsidiary of the Company, including Spyre Therapeutics, LLC, and shall include any
material subsidiary of the Company formed or acquired on or after the date hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Trading Day</I></B>&#148; means a day on
which the principal Trading Market is open for business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Trading Market</I></B>&#148; means any of the following markets or
exchanges on which the Common Stock is listed or quoted for trading on the date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, or the New York Stock Exchange (or any successors
to any of the foregoing). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Transaction Documents</I></B>&#148; means this Agreement, the schedules and
exhibits attached hereto, the Registration Rights Agreement, the Certificate of Designation, the Irrevocable Transfer Agent Instructions and any other documents or agreements explicitly contemplated hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Transfer Agent</I></B>&#148; means Equiniti Trust Company, LLC, the current transfer agent of the Company, or any successor
transfer agent for the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Unaudited Interim Balance Sheet</I></B>&#148; means the unaudited condensed consolidated
balance sheets of the Company and its Subsidiaries as of September&nbsp;30, 2023 included in the Company&#146;s Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> filed with the Commission on November&nbsp;9, 2023. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 2 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PURCHASE AND
SALE </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.1</B> <B>Purchase and Sale</B>. On the Closing Date, upon the terms and subject to the conditions set forth herein, the
Company will issue and sell to the Purchasers, and the Purchasers will purchase, severally and not jointly, the number of Securities set forth opposite the names of each such Purchaser under the headings &#147;Number of Common Shares Purchased&#148;
and &#147;Number of Preferred Shares Purchased,&#148; as applicable, on Annex A, for the aggregate purchase price set forth opposite the name of such Purchaser under the heading &#147;Aggregate Purchase Price&#148; on Annex A. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.2</B> <B>Closing</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Closing</B>. Upon the satisfaction or waiver of the conditions set forth in Section&nbsp;2.1, Section&nbsp;2.2 and Article 5,
the closing of the purchase and sale of the Securities (the &#147;<B><I>Closing</I></B>&#148;) shall take place remotely via exchange of executed documents and funds on the second (2nd) Business Day after the date hereof (the &#147;<B><I>Closing
Date</I></B>&#148;), or at such other time and place as mutually agreed by the Company and Purchasers, but in no event later than the second (2nd) Business Day following the date of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Payment</B>. On or prior to the Closing Date, each Purchaser shall deliver to the Company the Subscription Amount via wire
transfer of immediately available funds to an account designated in writing by the Company or by other means approved by the Company on or prior to the Closing Date. At the Closing, the Company shall deliver to such Purchaser against payment a
book-entry statement from the Transfer Agent evidencing the number of Securities set forth opposite such Purchaser&#146;s name on Annex A, registered in the name of such Purchaser (or its nominee in accordance with its delivery instructions), free
and clear of any liens or restrictions (other than those arising under state and federal securities laws) and bearing the legend set forth in Section&nbsp;4.1(b); provided that, notwithstanding anything in this Agreement to the contrary and as may
be agreed to among the Company and one or more Purchasers, a Purchaser shall not be required to wire its Subscription Amount as set forth on Annex A until it confirms receipt of a book-entry statement from the Transfer Agent evidencing the issuance
of the Securities to such Purchaser on and as of the Closing Date. If a Purchaser has delivered the Subscription Amount prior to the Closing Date, and the Closing does not occur for any reason on or prior to the fifth (5th) Business Day following
the expected Closing Date, the Company shall promptly (but not later than one (1)&nbsp;Business Day thereafter) return the Subscription Amount to such Purchasers by wire transfer of United States dollars in immediately available funds to the account
specified by such Purchaser, and any book entries for the Securities shall be deemed cancelled; provided that, unless this Agreement has been terminated pursuant to Section&nbsp;6.18, such return of funds shall not terminate this Agreement or
relieve the Purchasers of their respective obligations to purchase the Securities at the Closing. Notwithstanding anything in this Agreement to the contrary and as may be agreed to among the Company and one or more Purchasers, a Purchaser that is a
mutual fund and subject to regulations related to the timing of funding and the issuance of securities thereunder or a Purchaser that has internal policies and/or procedures relating to the timing of funding and issuance of securities thereafter
shall not be required to wire its respective portion of the Subscription Amount as set forth on Annex A until it confirms receipt of a book-entry statement from the Company&#146;s transfer agent evidencing the issuance of the Securities to such
Purchaser on and as of the Closing Date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.3</B> <B>Closing Deliverables</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> On or prior to the Closing, the Company shall issue, deliver or cause to be delivered to each Purchaser the following (the
&#147;<B><I>Company Deliverables</I></B>&#148;): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> evidence of the issuance of the Securities in the names of the Purchasers by
book-entry statement from the Transfer Agent (in the name of such Purchaser as set forth on the Stock Issuance Questionnaire included as <B>Exhibit C</B> hereto); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> a legal opinion of Company Counsel, dated as of the Closing Date and in form and substance reasonably satisfactory to the
Purchasers, executed by such counsel and addressed to the Purchasers and the Placement Agents; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> the Registration Rights
Agreement, duly executed by the Company; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> duly executed Irrevocable Transfer Agent Instructions acknowledged in writing by
the Transfer Agent instructing the Transfer Agent to deliver, on an expedited basis, of the issuance of the number of Securities set forth opposite the name of such Purchaser under the heading &#147;Number of Securities Purchased&#148; on Annex A
attached hereto, registered in the name of such Purchaser (or its nominee, as directed by the Purchaser); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(v)</B> the Company shall
have filed with Nasdaq a Notification Form: Listing of Additional Shares for the listing of the Common Shares and the Conversion Shares and shall have received confirmation from Nasdaq that it has completed its review of such form with no objections
to the transactions contemplated in the Transaction Documents; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(vi)</B> a certificate of the Secretary of the Company (the
&#147;<B><I>Secretary&#146;s Certificate</I></B>&#148;), dated as of the Closing Date, (A)&nbsp;certifying the resolutions adopted by the Board of Directors or a duly authorized committee thereof approving the transactions contemplated by this
Agreement, the other Transaction Documents and the issuance of the Securities and the Conversion Shares, (B)&nbsp;certifying the current versions of the certificate of incorporation, as amended, and bylaws of the Company and (C)&nbsp;certifying as
to the signatures and authority of persons signing the Transaction Documents and related documents on behalf of the Company, in substantially the form attached hereto as <B>Exhibit E</B>; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(vii)</B> the Compliance Certificate referred to in Section&nbsp;5.1(h); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(viii)</B> a certificate evidencing the formation and good standing of the Company issued by the Secretary of State of the State of
Delaware, as of a date within three (3)&nbsp;Business Days of the Closing Date; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ix)</B> a certificate evidencing the Company&#146;s
qualification as a foreign corporation and good standing issued by the Secretary of State (or comparable office) of each jurisdiction in which the Company is qualified to do business as a foreign corporation, as of a date within three
(3)&nbsp;Business Days of the Closing Date; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(x)</B> a certified copy of the Certificate of Designation, as filed with the
Secretary of State of the State of Delaware. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> On or prior to the Closing, each Purchaser shall deliver or cause to be delivered
to the Company the following (the &#147;<B><I>Purchaser Deliverables</I></B>&#148;): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> this Agreement, duly executed by such
Purchaser; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> its Subscription Amount, in United States dollars and in immediately available funds, in the amount set forth in
the &#147;Aggregate Purchase Price&#148; column opposite each Purchaser&#146;s name in the table set forth on Annex A by wire transfer to the Company; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> the Registration Rights Agreement, duly executed by such Purchaser; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> a fully completed and duly executed Stock Issuance Questionnaire in the form
attached hereto as <B>Exhibit C</B>. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 3 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REPRESENTATIONS AND WARRANTIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.1</B> <B>Representations and Warranties of the Company</B>. Except as previously disclosed in the SEC Reports, the Company hereby
represents and warrants the following as of the date hereof and the Closing Date (except for the representations and warranties that speak as of a specific date, which shall be made as of such date) to each of the Purchasers and to the Placement
Agents: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Due Organization; Subsidiaries</B>. Each of the Company and its Subsidiaries is a corporation or limited liability
company duly incorporated or formed, validly existing and in good standing under the Laws of the jurisdiction of its incorporation or organization and has all necessary corporate power and authority: (i)&nbsp;to conduct its business in the manner in
which its business is currently being conducted and as proposed to be conducted as described in the SEC Reports, (ii)&nbsp;to own or lease and use its property and assets in the manner in which its property and assets are currently owned or leased
and used and (iii)&nbsp;to perform its obligations under all Contracts by which it is bound. All of the Subsidiaries are wholly owned by the Company. Each of the Company and the Subsidiaries is licensed and qualified to do business, and is in good
standing (to the extent applicable in such jurisdiction), under the Laws of all jurisdictions where the nature of its business or the manner in which its business is currently being conducted requires such licensing or qualification other than in
jurisdictions where the failure to be so qualified individually or in the aggregate would not have or reasonably be expected to have a Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Authorization; Enforcement; Validity</B>. The Company has the requisite corporate power and authority to enter into the
Transaction Documents and to perform its obligations under and consummate the transactions contemplated hereby or thereby. All corporate action on the part of the Company, its directors and stockholders necessary for the authorization, execution,
sale, issuance and delivery of the Securities and, subject to the Requisite Stockholder Approval, the Conversion Shares contemplated herein has been taken. Each of the Transaction Documents have been (or upon delivery will have been) duly executed
and delivered by the Company and is, or when delivered in accordance with the terms hereof or thereof, will constitute the legal, valid and binding obligation of the Company enforceable against the Company in accordance with its respective terms,
except (i)&nbsp;as such enforceability may be limited by applicable bankruptcy, examinership, insolvency, reorganization, moratorium, liquidation or similar laws relating to, or affecting generally the enforcement of, creditors&#146; rights and
remedies or by other equitable principles of general application, (ii)&nbsp;as limited by Laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii)&nbsp;insofar as indemnification and
contribution provisions may be limited by applicable law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B>No Conflicts</B>. The execution, delivery and performance by the
Company of the Transaction Documents and the issuance, sale and delivery of the securities to be sold by the Company under the Transaction Documents (including the issuance of Securities and, subject to the Requisite Stockholder Approval, the
Conversion Shares upon the conversion of the Preferred Shares), the performance by the Company of its obligations under the Transaction Documents and the consummation of the transactions contemplated hereby or thereby (including without limitation,
the issuance of the Securities and the reservation for issuance of the Conversion Shares) do not and will not conflict with, result in the breach or violation of, or constitute (with or without the giving of notice or the passage of time or both) a
violation of, or default under, (i)&nbsp;any bond, debenture, note or other evidence of indebtedness, or under any lease, license, franchise, permit, indenture, mortgage, deed of trust, loan agreement, joint venture or other Contract, agreement or
instrument to which the Company or any of its Subsidiaries is a party or by which it or its properties may be bound or affected, (ii)&nbsp;the Company&#146;s amended and restated certificate of incorporation (the &#147;<B><I>Certificate of
Incorporation</I></B>&#148;), the Company&#146;s amended and restated bylaws (the &#147;<B><I>Bylaws</I></B>&#148;), or the equivalent document with respect to any of the Company&#146;s Subsidiaries, as amended and as in effect on the date hereof,
or (iii)&nbsp;subject to the Requisite Stockholder Approval, any statute or Law, judgment, decree, rule, regulation, ordinance or order of any court or governmental or regulatory body (including Nasdaq), governmental agency, arbitration panel or
authority applicable to the Company, any of its subsidiaries or their respective properties, except in the case of clauses (i)&nbsp;and (iii) for such conflicts, breaches, violations or defaults that would not reasonably be expected to have,
individually or in the aggregate, a Material Adverse Effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B>Filings, Consents and Approvals</B>. Except for any Current Report on Form <FONT
STYLE="white-space:nowrap">8-K</FONT> or Notice of Exempt Offering of Securities on Form D to be filed by the Company in connection with the transaction contemplated hereby, any required filing with Nasdaq (other than the Listing of Additional
Shares notification form for the listing of the Conversion Shares), the Requisite Stockholder Approval, the filing of the Certificate of Designation and the Registration Statement required to be filed by the Registration Rights Agreement, neither
the Company nor any of its Subsidiaries is required to give any notice to, or make any filings with, or obtain any authorization, consent, or approval of any government or governmental agency in order to consummate the transactions contemplated by
the Transaction Documents. Assuming the accuracy of the representations of the Purchasers in Section&nbsp;3.2, no consent, approval, authorization or other order of, or registration, qualification or filing with, any court, regulatory body,
administrative agency, self-regulatory organization, stock exchange or market (including Nasdaq), or other governmental body is required for the execution and delivery of the Transaction Documents, the valid issuance, sale and delivery of the
Securities to be sold pursuant to the Transaction Documents (including, subject to the Company obtaining the Requisite Stockholder Approval, the issuance of Conversion Shares upon conversion of the Preferred Shares) other than such as have been or
will be made or obtained, or for any securities filings required to be made under federal or state securities laws applicable to the offering of the Securities or the issuance of Conversion Shares upon conversion of the Preferred Shares (other than
the Requisite Stockholder Approval and filings that have been made, or will be made, pursuant to the rules and regulations of Nasdaq). The Company and its Subsidiaries are unaware of any facts or circumstances that might prevent the Company from
obtaining or effecting any of the registration, application or filings pursuant to this Section&nbsp;3.1(d). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> <B>Issuance of
the Securities and Conversion Shares</B>. The issuance of the Securities has been duly authorized, and the Securities, when issued and paid for in accordance with the terms of the Transaction Documents, will be duly and validly issued, fully paid
and nonassessable and free and clear of any Encumbrances, preemptive rights or restrictions (other than as provided in the Certificate of Designation or any restrictions on transfer generally imposed under applicable securities laws). The issuance
of the Conversion Shares has been duly authorized and the Conversion Shares, subject to the Requisite Stockholder Approval, when issued in accordance with the terms of the Certificate of Designation, will be duly authorized, validly issued, fully
paid and <FONT STYLE="white-space:nowrap">non-assessable,</FONT> and shall be free and clear of any Encumbrances, preemptive rights or restrictions (other than as provided in this Agreement or any restrictions on transfer generally imposed under
applicable securities laws). The Company has reserved such number of shares of Common Stock sufficient to enable full conversion of all of the Preferred Shares to the extent allowable prior to receipt of the Requisite Stockholder Approval and, upon
receipt of the Requisite Stockholder Approval, the Company shall have reserved such number of shares of Common Stock sufficient to enable the full conversion of all of the Preferred Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> <B>Capitalization</B>. The outstanding shares of capital stock of the Company have been duly authorized and validly issued and are
fully paid and <FONT STYLE="white-space:nowrap">non-assessable.</FONT> None of the outstanding shares of capital stock of the Company were issued in violation of the preemptive or other similar rights of any securityholder of the Company. As of
November&nbsp;30, 2023, there were (i) 30,021,007 shares of Common Stock issued and outstanding and (ii) 437,037 shares of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock of the Company, par value $0.0001 per share,
issued and outstanding. The Company has not issued any capital stock since its most recently filed periodic report under the Exchange Act, other than pursuant to incentive awards issued under the Company&#146;s incentive award plans, the issuance of
shares of Common Stock to employees pursuant to the Company&#146;s employee stock purchase plan, the issuance of shares pursuant to inducement awards issued outside of the Company&#146;s incentive award plans or the conversion of shares of the
Company&#146;s preferred stock into shares of Common Stock. There are no outstanding options, warrants, scrip rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities, rights or obligations convertible into
or exercisable or exchangeable for, or giving any Person any right to subscribe for or acquire, any shares of Common Stock or the capital stock of any Subsidiary, or contracts, commitments, understandings or arrangements by which the Company or any
Subsidiary is or may become bound to issue additional shares of Common Stock or capital stock of any Subsidiary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(g)</B> <B>SEC
Reports; Disclosure Materials</B>. The Company has filed or furnished, as applicable, on a timely basis all forms, statements, schedules, certifications, reports and other documents required to be filed or furnished by it with the Commission under
the Exchange Act or the Securities Act since January&nbsp;1, 2021 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(collectively, and in each case including all exhibits and schedules thereto and documents incorporated by reference therein, the &#147;<B><I>SEC Reports</I></B>&#148;). As of the time it was
filed with the Commission (or, if amended or superseded by a filing prior to the date of this Agreement, then on the date of such filing), each of the SEC Reports complied in all material respects with the applicable requirements of the Securities
Act or the Exchange Act (as the case may be) and as of the time they were filed, none of the SEC Reports contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to
make the statements therein, in the light of the circumstances under which they were made, not misleading. There are no material outstanding or unresolved comments in comment letters from the staff of the Division of Corporation Finance of the
Commission with respect to any of the SEC Reports. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(h)</B> <B>Financial Statements</B>. As of their respective filing dates, the
financial statements (including any related notes) contained or incorporated by reference in the SEC Reports (i)&nbsp;complied as to form in all material respects with the Securities Act and the Exchange Act, as applicable, and the published rules
and regulations of the Commission applicable thereto, (ii)&nbsp;were prepared in accordance with GAAP (except as may be indicated in the notes to such financial statements or, in the case of unaudited financial statements, as permitted by Form <FONT
STYLE="white-space:nowrap">10-Q</FONT> of the Commission, and except that the unaudited financial statements may not contain footnotes and are subject to normal and recurring <FONT STYLE="white-space:nowrap">year-end</FONT> adjustments that are not
reasonably expected to be material in amount) applied on a consistent basis unless otherwise noted therein throughout the periods indicated and (iii)&nbsp;fairly present, in all material respects, the consolidated financial position of the Company
as of the respective dates thereof and the results of operations and cash flows of the Company for the periods covered thereby. Other than as expressly disclosed in the SEC Reports filed at least one (1)&nbsp;Business Day prior to the date hereof,
there has been no material change in the Company&#146;s accounting methods or principles that would be required to be disclosed in the Company&#146;s financial statements in accordance with GAAP. Except as set forth in the consolidated financial
statements of the Company included in the SEC Reports filed at least one (1)&nbsp;Business Day prior to the date hereof, the Company has not incurred any liabilities, contingent or otherwise, except those incurred in the ordinary course of business,
consistent (as to amount and nature) with past practices since the date of such financial statements, none of which, individually or in the aggregate, have had or would reasonably be expected to have a Material Adverse Effect. The books of account
and other financial records of the Company and each of its Subsidiaries are true and complete in all material respects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i)</B>
<B>Independent Accountants</B>. PricewaterhouseCoopers LLP, who have certified certain financial statements of the Company and delivered their report with respect to the audited financial statements included in the SEC Reports, have at all times
since the date of enactment of the Sarbanes-Oxley Act been (i)&nbsp;a registered public accounting firm (as defined in Section&nbsp;2(a)(12) of the Sarbanes-Oxley Act), (ii) to the Company&#146;s Knowledge, &#147;independent&#148; with respect to
the Company within the meaning of Regulation <FONT STYLE="white-space:nowrap">S-X</FONT> under the Exchange Act and (iii)&nbsp;to the Company&#146;s Knowledge, in compliance with subsections (g)&nbsp;through (l) of Section&nbsp;10A of the Exchange
Act and the rules and regulations promulgated by the Commission and the Public Accounting Oversight Board thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(j)</B>
<B>Absence of Certain Changes</B>. Since the date of the Unaudited Interim Balance Sheet, there has been (i)&nbsp;no material adverse change to, and no material adverse development in, the assets, liabilities, business, properties, operations,
condition (financial or otherwise), results of operations or prospects of the Company or its Subsidiaries, (ii)&nbsp;no Material Adverse Effect, (iii)&nbsp;no satisfaction or discharge of any material lien, claim or encumbrance or payment of any
obligation by the Company, except in the ordinary course of business and with respect to payments under the Company&#146;s outstanding contingent value rights (&#147;<B><I>CVRs</I></B>&#148;) and (iv)&nbsp;no waiver, not in the ordinary course of
business, by the Company or any Subsidiary of a material right or of a material debt owed to it. Since the date of the Unaudited Interim Balance Sheet, neither the Company nor any of its Subsidiaries has (i)&nbsp;purchased any of its outstanding
Common Stock (other than from its employees or other service providers in connection with the termination of their service pursuant to the terms of its equity compensation plans or agreements) or declared or paid any dividends or distributions,
other than payments under the CVRs, (ii)&nbsp;sold any material assets, individually or in the aggregate, outside of the ordinary course of business, (iii)&nbsp;made any material change or material amendment to, or waiver of any material right, or
termination of, any Material Contract, (iv)&nbsp;entered into any material transaction or made any material capital expenditures, individually or in the aggregate, outside of the ordinary course of business or (v)&nbsp;experienced any loss of
services of any executive officer (as defined in Rule 405 under the Securities Act), other than as disclosed in the SEC Reports prior to the date hereof. Neither the Company nor any of its Subsidiaries has taken any steps to seek protection pursuant
to any bankruptcy law, nor does </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Company have any knowledge or reason to believe that its creditors (if any) intend to initiate involuntary bankruptcy proceedings or any actual knowledge of any fact that would reasonably
lead any such creditor to do so. The Company and its Subsidiaries, individually and on a consolidated basis, are not as of the date hereof, and after giving effect to the transactions contemplated hereby to occur at the Closing, will not be
Insolvent (as defined below). For purposes of this Section&nbsp;3.1(j), &#147;Insolvent&#148; means, with respect to any Person, (i)&nbsp;the present fair saleable value of such Person&#146;s assets is less than the amount required to pay such
Person&#146;s total indebtedness, (ii)&nbsp;such Person is unable to pay its debts and liabilities, subordinated, contingent or otherwise, as such debts and liabilities become absolute and matured, (iii)&nbsp;such Person intends to incur or believes
that it will incur debts that would be beyond its ability to pay as such debts mature or (iv)&nbsp;such Person has unreasonably small capital with which to conduct the business in which it is engaged as such business is now conducted and is proposed
to be conducted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(k)</B> <B>Litigation</B>. There is no action, suit, proceeding or investigation pending or, to the Company&#146;s
Knowledge, currently threatened against the Company, any of its Subsidiaries or any of their respective directors and officers that questions the validity of the Transaction Documents or the right of the Company to enter into the Transaction
Documents or to consummate the transactions contemplated hereby and thereby. There is no action, suit, proceeding or investigation pending or, to the Company&#146;s Knowledge, currently threatened against the Company or any Subsidiary or any of
their respective directors and officers which would, if there were an unfavorable decision, have or reasonably be expected to have, either individually or in the aggregate, a Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(l)</B> <B>Employment Matters</B>.<B> </B>No material labor dispute exists or, to the Company&#146;s Knowledge, is threatened with respect
to any of the employees of the Company or any of its Subsidiaries which would have or would reasonably be expected to result in a Material Adverse Effect. None of the Company&#146;s or any Subsidiary&#146;s employees is a member of a labor union
that relates to such employee&#146;s relationship with the Company, and neither the Company nor any of its Subsidiaries is a party to a collective bargaining agreement. To the Company&#146;s Knowledge, no executive officer or key employee of the
Company or any Subsidiary, is, or is now expected to be, in violation of any material term of any employment Contract, confidentiality, disclosure or proprietary information agreement or <FONT STYLE="white-space:nowrap">non-competition</FONT>
agreement, or any other Contract or agreement or any restrictive covenant in favor of any third party, and to the Company&#146;s Knowledge, the continued employment of each such executive officer or key employee does not subject the Company or any
Subsidiary to any liability with respect to any of the foregoing matters, except, in each case, matters that, individually or in the aggregate, would not reasonably be expected to result in a Material Adverse Effect. The Company is in compliance in
all material respects with all U.S. federal, state, local and foreign Laws and regulations relating to employment and employment practices, terms and conditions of employment and wages and hours. Any Employee Plans that are &#147;employee pension
benefit plans&#148; within the meaning of Section&nbsp;3(2) of ERISA and which are intended to meet the qualification requirements of Section&nbsp;401(a) of the Code have received determination or opinion letters from the Internal Revenue Service on
which they may currently rely to the effect that such plans are qualified under Section&nbsp;401(a) of the Code and the related trusts are exempt from federal income taxes under Section&nbsp;501(a) of the Code, respectively, and nothing has occurred
that would reasonably be expected to materially adversely affect the qualification of such Employee Plan or the tax exempt status of the related trust. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(m)</B> <B>Conduct of Business; Regulatory Permits</B>. Neither the Company nor any of its Subsidiaries is in violation of any term of or
in default under its Certificate of Incorporation, any Certificate of Designation of any outstanding series of preferred stock of the Company or the Bylaws or their organizational charter or bylaws, respectively. Neither the Company nor any of its
Subsidiaries (i)&nbsp;is in default of or in violation of, nor has the Company or any of its Subsidiaries received a claim that it is in default under or that it is in violation of, any Material Contract (whether or not such default or violation has
been waived), or (ii)&nbsp;is in violation of any judgment, decree or order or any statute, ordinance, rule or regulation applicable to the Company or its Subsidiaries, and neither the Company nor any of its Subsidiaries will conduct its business in
violation of any of the foregoing, except for possible violations which would not, individually or in the aggregate, have or reasonably be expected to have a Material Adverse Effect. Without limiting the generality of the foregoing, the Company is
not in violation of any of the rules, regulations or requirements of the Nasdaq and, to the Company&#146;s Knowledge, there exist no facts or circumstances that would reasonably lead to delisting or suspension of the Common Stock by Nasdaq in the
foreseeable future. The Company and its Subsidiaries possess all certificates, authorizations and permits issued by the appropriate regulatory authorities necessary to conduct their respective businesses as currently conducted and as
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
proposed to be conducted, except where the failure to possess such certificates, authorizations or permits would not reasonably be expected to have, individually or in the aggregate, a Material
Adverse Effect, and neither the Company nor any such Subsidiary has received any written notice of proceedings relating to the revocation or modification of any such certificate, authorization or permit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(n)</B> <B>Title to Properties and Assets</B>. None of the Company or its Subsidiaries owns, or has ever owned, any real property. The
Company&#146;s or is Subsidiary&#146;s possession, occupancy, lease, use and/or operation of each such leased property conforms to all applicable Laws in all material respects, and the Company or its Subsidiary, as applicable, has exclusive
possession of each such leased property and leasehold interest and has not granted any occupancy rights to tenants or licensees with respect to such leased property or leasehold interest. In addition, each such leased property and leasehold interest
is free and clear of all Encumbrances other than Permitted Encumbrances. The Company and each of its Subsidiaries owns, and has good and marketable title to, or, in the case of leased properties and assets, valid leasehold interests in, all tangible
properties or tangible assets and equipment used or held for use in their respective business or operations or purported to be owned by any of them, including: (a)&nbsp;all tangible assets reflected on the Unaudited Interim Balance Sheet and
(b)&nbsp;all other tangible assets reflected in the books and records of the Company as being owned by the Company or any of its Subsidiaries. All of such assets are owned or, in the case of leased assets, leased by the Company or any of its
Subsidiaries free and clear of any Encumbrances, other than Permitted Encumbrances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(o)</B> <B>Intellectual Property Rights</B>. The
Company and its Subsidiaries own, or have obtained valid and enforceable licenses for, the inventions, patent applications, patents, trademarks, trade names, service names, copyrights, trade secrets and other intellectual property described in the
SEC Reports as being owned or licensed by them or which are necessary for the conduct of their respective businesses as currently conducted or as currently proposed to be conducted (collectively, &#147;<B><I>Intellectual Property</I></B>&#148;) and
the conduct of their respective businesses does not and will not infringe, misappropriate or otherwise conflict in any material respect with any such rights of others. To the Company&#146;s Knowledge, the operation of the business of the Company and
its Subsidiaries, as now conducted or as proposed to be conducted in the SEC Reports, together with the Company&#146;s use of the Company&#146;s Intellectual Property, does not conflict with, infringe, misappropriate or otherwise violate the
Intellectual Property of any third party. No actions, suits, claims or proceedings have been asserted, or, to the Company&#146;s Knowledge, threatened against the Company or any of its Subsidiaries alleging any of the foregoing or seeking to
challenge, deny or restrict the operation of the business of the Company or its Subsidiaries, and the Company is unaware of any facts which would form a reasonable basis for any such claim. None of the Company or any of its Subsidiaries has received
any notice of a claim of infringement, misappropriation or conflict with Intellectual Property rights of others, except for such claims that would not, individually or the in aggregate, have or reasonably be expected to have a Material Adverse
Effect. The Intellectual Property rights owned by the Company and its Subsidiaries and, to the Company&#146;s Knowledge, any Intellectual Property rights licensed to the Company or its Subsidiaries, have not been adjudged invalid or unenforceable,
in whole or in part, and there is no pending or, to the Company&#146;s Knowledge, threatened action, suit, proceeding or claim by others challenging the validity or scope of any such Intellectual Property rights, and the Company is unaware of any
facts which would form a reasonable basis for any such challenge, except for such actions, suits, proceedings, or claims that would not, individually or the in aggregate, be reasonably expected to have a Material Adverse Effect. None of the Company
or any of its Subsidiaries is a party to or bound by any options, licenses or agreements with respect to the Intellectual Property rights of any other person or entity that are required to be set forth in the SEC Reports. None of the technology or
Intellectual Property used by the Company or its Subsidiaries in their respective businesses has been obtained or is being used by the Company in violation of any contractual obligation binding on the Company or any of its Subsidiaries or, to the
Company&#146;s Knowledge, any of their respective officers, directors or employees or otherwise in violation of the rights of any persons. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(p)</B> <B>Insurance</B>. Each of the Company and its Subsidiaries are insured by recognized, financially sound and reputable institutions
with policies in such amounts and with such deductibles and covering such risks as are generally deemed adequate and customary for their businesses including, but not limited to, policies covering real and personal property owned or leased by the
Company and its Subsidiaries against theft, damage, destruction, acts of vandalism and earthquakes and policies covering the Company and its Subsidiaries for product liability claims and clinical trial liability claims. The Company has no reason to
believe that it or any of its Subsidiaries will not be able to (i)&nbsp;renew its existing insurance coverage as and when such policies expire or (ii)&nbsp;obtain comparable coverage from similar institutions as may be necessary or appropriate to
conduct its business as now conducted and at a cost that could not reasonably be expected to result in a Material Adverse Effect. Neither the Company nor any of its Subsidiaries has been denied any insurance coverage which it has sought or for which
it has applied. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(q)</B> <B>Transactions with Affiliates and Employees</B>. Since the date of the
Company&#146;s Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> filed with the Commission on November&nbsp;15, 2023, no event has occurred that would be required to be reported by the Company pursuant to Item 404 of
Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> promulgated by the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(r)</B> <B>Company&#146;s Accounting System</B>. The
Company and each of its Subsidiaries makes and keeps accurate books and records and maintains a system of internal control over financial reporting (as defined in Rules <FONT STYLE="white-space:nowrap">13a-15</FONT> and <FONT
STYLE="white-space:nowrap">15d-15</FONT> under the Exchange Act) sufficient to provide reasonable assurance that: (i)&nbsp;transactions are executed in accordance with management&#146;s general or specific authorization; (ii)&nbsp;transactions are
recorded as necessary to permit preparation of financial statements in conformity with generally accepted accounting principles as applied in the United States and to maintain accountability for assets; (iii)&nbsp;access to assets is permitted only
in accordance with management&#146;s general or specific authorization; (iv)&nbsp;the recorded accountability for assets is compared with existing assets at reasonable intervals and appropriate action is taken with respect to any differences; and
(v)&nbsp;the interactive data in eXtensible Business Reporting Language included or incorporated by reference in the SEC Reports fairly presents the information called for in all material respects and is prepared in accordance with the
Commission&#146;s rules and guidelines applicable thereto, except as would not, individually or the in aggregate, be reasonably expected to have a Material Adverse Effect. Since January&nbsp;1, 2021, (i) neither the Company nor any Subsidiary nor,
to the Company&#146;s Knowledge, any director, officer, employee, auditor, accountant or representative of the Company or any Subsidiary has received or otherwise had or obtained knowledge of any material complaint, allegation, assertion or claim,
whether written or oral, regarding the accounting or auditing practices, procedures, methodologies or methods of the Company or any Subsidiary or their respective internal accounting controls, including any material complaint, allegation, assertion
or claim that the Company or any Subsidiary has engaged in questionable accounting or auditing practices. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(s)</B> <B>Sarbanes-Oxley;
Disclosure Controls</B>. The Company is in compliance in all material respects with the applicable provisions of the Sarbanes-Oxley Act of 2002 and the rules and regulations promulgated thereunder. The Company maintains a system of internal
accounting controls designed to ensure that (a)&nbsp;material information relating to the Company and its Subsidiaries, is made known to the Company&#146;s principal executive officer and its principal financial officer by others within those
entities and (b)&nbsp;that information required to be disclosed by the Company in reports that it file, furnishes or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the
Commission&#146;s rules and forms, including controls and procedures designed to ensure that such information is accumulated and communicated to the Company&#146;s management as appropriate to allow timely decisions regarding required disclosure.
The Company has established and maintains disclosure controls and procedures (as defined in Exchange Act Rules <FONT STYLE="white-space:nowrap">13a-15(e)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(e))</FONT> for the Company and designed such
disclosure controls and procedures to ensure that material information relating to the Company is made known to the certifying officers by others within those entities, particularly during the period in which the Company&#146;s most recently filed
periodic report under the Exchange Act, as the case may be, is being prepared. The Company has established internal control over financial reporting (as defined in Exchange Act Rules <FONT STYLE="white-space:nowrap">13a-15(f)</FONT> and <FONT
STYLE="white-space:nowrap">15d-15(f))</FONT> to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP. The Company&#146;s certifying
officers have evaluated the effectiveness of the Company&#146;s disclosure controls and procedures and the Company&#146;s internal control over financial reporting (collectively, &#147;<B><I>internal controls</I></B>&#148;) as of the end of the
period covered by the most recently filed periodic report under the Exchange Act (such date, the &#147;<B><I>Evaluation Date</I></B>&#148;). The Company presented in its most recently filed periodic report under the Exchange Act the conclusions of
the certifying officers about the effectiveness of such internal controls based on their evaluations as of the Evaluation Date. Since the Evaluation Date, there have been no significant changes in the Company&#146;s internal controls or, to the
Company&#146;s Knowledge, in other factors that could materially affect the Company&#146;s internal controls and there have been no material weaknesses in the Company&#146;s internal control over financial reporting (whether or not remediated). The
Company maintains and will continue to maintain a standard system of accounting established and administered in accordance with GAAP and the applicable requirements of the Exchange Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(t)</B> <B>[Reserved]</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(u)</B> <B>Certain Fees</B>. No person or entity will have, as a result of the transactions contemplated by this Agreement, any valid
right, interest or claim against or upon the Company or a Purchaser for any commission, fee or other compensation pursuant to any agreement, arrangement or understanding entered into by or on behalf of the Company, other than the Placement Agents
with respect to the offer and sale of the Securities (which placement agent fees are being paid by the Company). The Purchasers shall have no obligation with respect to any fees or with respect to any claims made by or on behalf of other Persons for
fees of a type contemplated in this Section&nbsp;3.1(u) that may be due in connection with the transactions contemplated by the Transaction Documents. The Company shall indemnify, pay, and hold each Purchaser harmless against, any liability, loss or
expense (including, without limitation, attorneys&#146; fees and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses) arising in connection with any such right, interest or claim. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(v)</B> <B>Private Placement</B>. Assuming the accuracy of the Purchasers&#146; representations and warranties set forth in
Section&nbsp;3.2 of this Agreement, no registration under the Securities Act is required for the offer and sale of the Securities by the Company to the Purchasers under the Transaction Documents (including, subject to the Company obtaining the
Requisite Stockholder Approval, the issuance of Conversion Shares upon the conversion of the Preferred Shares). The issuance and sale of the Securities hereunder (including, subject to the Company obtaining the Requisite Stockholder Approval, the
issuance of Conversion Shares upon the conversion of the Preferred Shares) does not contravene the rules and regulations of the Trading Market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(w)</B> <B>Company Not an &#147;</B><B><I>Investment Company</I></B><B>.&#148;</B> The Company is not, and will not be, immediately after
receipt of payment for the Securities, required to register as an &#147;investment company&#148; under the Investment Company Act of 1940, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(x)</B> <B>Registration Rights</B>. Other than each of the Purchasers, no Person has any right to cause the Company to effect the
registration under the Securities Act of the offer and sale of any securities of the Company other than those offers and sales which are currently registered on an effective registration statement on file with the Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(y)</B> <B>Listing and Maintenance Requirements</B>. The Company&#146;s Common Stock is registered pursuant to Section&nbsp;12(b) or
Section&nbsp;12(g) of the Exchange Act, and the Company has taken no action designed to terminate the registration of the Common Stock under the Exchange Act, nor has the Company received any notification that the Commission or the Principal Trading
Market is contemplating terminating such registration or listing. The Company is, and immediately following the Closing will be, in compliance with all applicable listing requirements of the Principal Trading Market. The Company has filed with
Nasdaq an additional shares listing application covering the Common Shares and the Conversion Shares and has not received any objections from Nasdaq with respect to such application with respect to the transactions contemplated hereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(z)</B> <B>Disclosure</B>. The Company confirms that it has not provided, and to the Company&#146;s Knowledge, none of its officers or
directors nor any other Person acting on its or their behalf (including, without limitation, the Placement Agents) has provided, and it has not authorized the Placement Agents to provide, any Purchaser or its respective agents or counsel with any
information that it believes constitutes material, <FONT STYLE="white-space:nowrap">non-public</FONT> information except insofar as the existence, provisions and terms of the Transaction Documents and the proposed transactions hereunder and
thereunder may constitute such information, all of which will be disclosed by the Company in the Press Release as contemplated by Section&nbsp;4.4 hereof. The Company understands and confirms that the Purchasers will rely on the foregoing
representations in effecting transactions in securities of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(aa)</B> <B>No Integrated Offering</B>. Assuming the accuracy
of the Purchasers&#146; representations and warranties set forth in Section&nbsp;3.2, none of the Company, its Subsidiaries nor, to the Company&#146;s Knowledge, any of its Affiliates or any Person acting on its behalf has, directly or indirectly,
at any time within the past six (6)&nbsp;months, made any offers or sales of any Company security or solicited any offers to buy any security under circumstances that would (i)&nbsp;eliminate the availability of the exemption from registration under
the Securities Act, including Regulation D, in connection with the offer and sale by the Company of the Securities as contemplated hereby or (ii)&nbsp;cause the offering of the Securities pursuant to the Transaction Documents to be integrated with
prior offerings by the Company for purposes of any applicable law, regulation or stockholder approval provisions, including, without limitation, under the rules and regulations of any Trading Market on which any of the securities of the Company are
listed or designated. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(bb)</B> <B>Tax Matters</B>. The Company and each of its Subsidiaries has timely filed
all income tax returns and all other material tax returns that were required to be filed by or with respect to it under applicable Law. All such tax returns were correct and complete in all material respects and have been prepared in material
compliance with all applicable Law. Subject to exceptions as would not be material, no claim has ever been made by a Governmental Authority in a jurisdiction where the Company or any of its Subsidiaries does not file tax returns that the Company or
any of its Subsidiaries is subject to taxation by that jurisdiction. All material amounts of taxes due and owing by the Company and each of its Subsidiaries (whether or not shown on any tax return) have been timely paid. The unpaid taxes of the
Company and each of its Subsidiaries for periods (or portions thereof) ending on or prior to the date of the Unaudited Interim Balance Sheet do not materially exceed the accruals for current taxes set forth on the Unaudited Interim Balance Sheet.
Since the date of the Unaudited Interim Balance Sheet, neither the Company nor any of its Subsidiaries has incurred any material liability for taxes outside the ordinary course of business or otherwise inconsistent with past custom and practice. The
Company is classified as a Subchapter C corporation for U.S. federal tax purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(cc)</B> <B>Compliance with Environmental Laws</B>.
Since January&nbsp;1, 2021, the Company and each of its Subsidiaries has complied with all applicable federal, state, local or foreign Law relating to pollution or protection of human health or the environment (including ambient air, surface water,
ground water, land surface or subsurface strata), including any law or regulation relating to emissions, discharges, releases or threatened releases of Hazardous Materials, or otherwise relating to the manufacture, processing, distribution, use,
treatment, storage, disposal, transport or handling of Hazardous Materials (&#147;<B><I>Environmental Laws</I></B>&#148;), which compliance includes the possession by the Company of all permits and other governmental authorizations required under
applicable Environmental Laws and compliance with the terms and conditions thereof, except for any failure to be in compliance that, individually or in the aggregate, would not result in or reasonably be expected to result in a Material Adverse
Effect. Neither the Company nor any of its Subsidiaries has received since January&nbsp;1, 2021, any written notice or other communication (in writing or otherwise), whether from a Governmental Authority, citizens group, employee or otherwise, that
alleges that the Company or any of its Subsidiaries is not in compliance with any Environmental Law, and, to the Company&#146;s Knowledge, there are no circumstances that may prevent or interfere with the Company&#146;s or any of its
Subsidiaries&#146; compliance with any Environmental Law in the future, except where such failure to comply would not reasonably be expected to have a Material Adverse Effect. To the Company&#146;s Knowledge: (i)&nbsp;no current or prior owner of
any property leased or controlled by the Company or any of its Subsidiaries has received, since January&nbsp;1, 2021, any written notice or other communication relating to property owned or leased at any time by the Company or any of its
Subsidiaries, whether from a Governmental Authority, citizens group, employee or otherwise, that alleges that such current or prior owner or the Company or any of its Subsidiaries is not in compliance with or violated any Environmental Law relating
to such property and (ii)&nbsp;neither the Company nor any of its Subsidiaries has any material liability under any Environmental Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(dd)</B> <B>No General Solicitation</B>. Neither the Company nor, to the Company&#146;s Knowledge, any person acting on behalf of the
Company has, directly or indirectly, offered or sold any of the Securities or Conversion Shares, or solicited any offers to buy any Securities or Conversion Shares, under any circumstances that would require registration under the Securities Act of
the Securities or the Conversion Shares, including by any form of general solicitation or general advertising. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ee)</B>
<B>Anti-Corruption and Anti-Bribery Laws</B>. Neither the Company nor any of its Subsidiaries nor any director, officer, or employee of the Company or any of its Subsidiaries, nor to the Company&#146;s Knowledge, any agent, Affiliate or other person
acting on behalf of the Company or any of its subsidiaries has, in the course of its actions for, or on behalf of, the Company or any of its subsidiaries (i)&nbsp;used any corporate funds for any unlawful contribution, gift, entertainment or other
unlawful expenses relating to political activity; (ii)&nbsp;made or taken any act in furtherance of an offer, promise, or authorization of any direct or indirect unlawful payment or benefit to any <FONT STYLE="white-space:nowrap">non-U.S.</FONT> or
domestic government official or employee, including of any government-owned or controlled entity or public international organization, or any political party, party official, or candidate for political office; (iii)&nbsp;violated or is in violation
of any provision of the U.S. Foreign Corrupt Practices Act of 1977, as amended (the &#147;<B><I>FCPA</I></B>&#148;), the UK Bribery Act 2010, or any other applicable anti-bribery or anti-corruption Law; or (iv)&nbsp;made, offered, authorized,
requested, or taken an act in furtherance of any unlawful bribe, rebate, payoff, influence payment, kickback or other unlawful payment or benefit. The Company and its Subsidiaries and, to the Company&#146;s Knowledge, the Company&#146;s Affiliates
have conducted their respective businesses in compliance with the FCPA and have instituted and maintain policies and procedures designed to ensure, and which are reasonably expected to continue to ensure, continued compliance therewith. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ff)</B> <B>Money Laundering Laws</B>. The operations of the Company and its Subsidiaries
are and have been conducted at all times in compliance with applicable financial recordkeeping and reporting requirements of the USA Patriot Act, the Bank Secrecy Act of 1970, as amended, the money laundering statutes of all jurisdictions, the rules
and regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered or enforced by any governmental agency (collectively, the &#147;<B><I>Money Laundering Laws</I></B>&#148;); and no action, suit or
proceeding by or before any court or governmental agency, authority or body or any arbitrator or <FONT STYLE="white-space:nowrap">non-governmental</FONT> authority involving the Company or its Subsidiaries with respect to the Money Laundering Laws
is pending or, to the Company&#146;s Knowledge, threatened. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(gg)</B> <B>OFAC</B>. Neither the Company nor its Subsidiaries nor any of
their respective Affiliates, directors, officers, nor to the Company&#146;s Knowledge, any agent or employee of the Company or its Subsidiaries is subject to any sanctions administered or enforced by the Office of Foreign Assets Control
(&#147;<B><I>OFAC</I></B>&#148;) of the United States Treasury Department, the U.S. Department of State, the United Nations Security Council, the European Union, His Majesty&#146;s Treasury or any other relevant sanctions authority; and the Company
will not directly or indirectly use the proceeds of the offering of the securities contemplated hereby, or lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other person or entity for the purpose
of financing the activities of any person that is the target of sanctions administered or enforced by such authorities or in connection with any country or territory that is the target of country- or territory-wide OFAC sanctions (currently, Iran,
Syria, Cuba, North Korea, the Crimea, <FONT STYLE="white-space:nowrap">so-called</FONT> Donetsk People&#146;s Republic, and <FONT STYLE="white-space:nowrap">so-called</FONT> Luhansk People&#146;s Republic regions of Ukraine). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(hh)</B> <B>Off Balance Sheet Arrangements</B>. There is no transaction, arrangement, or other relationship between the Company (or any
Subsidiary) and an unconsolidated or other off balance sheet entity that is required to be disclosed by the Company in SEC Reports and is not so disclosed and would have or reasonably be expected to result in a Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> <B>Acknowledgment Regarding Purchaser&#146;s Purchase of Securities</B>. The Company acknowledges and agrees that each Purchaser
is acting solely in the capacity of an arm&#146;s length purchaser with respect to this Agreement and the other Transaction Documents and the transactions contemplated hereby and thereby, and that the obligations of each Purchaser under this
Agreement and the other Transaction Documents are several and not joint. The Company further acknowledges that no Purchaser is acting as a financial advisor or fiduciary of the Company or any of its Subsidiaries (or in any similar capacity) with
respect to this Agreement and the other Transaction Documents and the transactions contemplated hereby and thereby, and any advice given by a Purchaser or any of its representatives or agents in connection with this Agreement and the other
Transaction Documents and the transactions contemplated hereby and thereby is merely incidental to such Purchaser&#146;s purchase of the Securities. The Company further represents to each Purchaser that the Company&#146;s decision to enter into the
Transaction Documents has been based solely on the independent evaluation by the Company and its representatives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(jj)</B> <B>No Price
Stabilization or Manipulation; Compliance with Regulation M</B>. Neither the Company nor any of its Subsidiaries has taken, directly or indirectly, any action designed to or that might cause or result in stabilization or manipulation of the price of
any security of the Company to facilitate the sale or resale of the Securities or Conversion Shares or otherwise, and has taken no action which would directly or indirectly violate Regulation M under the Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(kk)</B> <B>Clinical Data and Regulatory Compliance</B>. The preclinical tests, clinical trials and other studies (collectively,
&#147;<B><I>studies</I></B>&#148;) that are described in, or the results of which are referred to in, the SEC Reports were and, if still pending, are being conducted in all material respects in accordance with the protocols, procedures and controls
designed and approved for such studies and with standard medical and scientific research procedures. Each description of the results of such studies is accurate and complete in all material respects and fairly presents the data derived from such
studies, and the Company and its Subsidiaries have no knowledge of any other studies the results of which are inconsistent with, or otherwise call into question, the results described or referred to in the SEC Reports. The Company and its
Subsidiaries have made all such filings and obtained all such approvals as may be required by the Food and Drug Administration of the U.S. Department of Health and Human Services or any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
committee thereof or from any other U.S. or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> government or drug or medical device regulatory agency, or health care facility Institutional Review
Board (collectively, the &#147;<B><I>Regulatory Agencies</I></B>&#148;). Neither the Company nor any of its Subsidiaries has received any notice of, or correspondence from, any Regulatory Agency requiring the termination, suspension or modification
of any clinical trials that are described or referred to in the SEC Reports. The Company and its Subsidiaries have each operated and currently are in compliance in all material respects with all applicable rules, regulations and policies of the
Regulatory Agencies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ll)</B> <B>No Additional Agreements</B>. The Company does not have any agreement or understanding (including
side letters) with any Purchaser with respect to the transactions contemplated by the Transaction Documents other than as specified in the Transaction Documents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(mm)</B> <B>No Disqualification Events</B>. No &#147;bad actor&#148; disqualifying event described in Rule 506(d)(1)(i)-(viii) of the
Securities Act (a &#147;<B><I>Disqualification Event</I></B>&#148;) is applicable to the Company or, to the Company&#146;s Knowledge, any Company Covered Person (as defined below), except for a Disqualification Event as to which Rule
506(d)(2)(ii)-(iv) or (d)(3), is applicable. &#147;<B><I>Company Covered Person</I></B>&#148; means, with respect to the Company as an &#147;issuer&#148; for purposes of Rule 506 promulgated under the Securities Act, any person listed in the first
paragraph of Rule 506(d)(1). Other than the Placement Agents, the Company is not aware of any Person (other than any Company Covered Person) that has been or will be paid (directly or indirectly) remuneration for solicitation of purchasers in
connection with the sale of the Securities or the Conversion Shares pursuant to this Agreement. The Company has complied, to the extent applicable, with its disclosure obligations under Rule 506(e), and has furnished to the Placement Agents a copy
of any disclosures provided thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(nn)</B> <B>Security</B>. Except as would not reasonably be expected to have a Material
Adverse Effect, the Company and its Subsidiaries&#146; information technology assets and equipment, computers, systems, networks, hardware, software, websites, applications, and databases (collectively, &#147;<B><I>IT Systems</I></B>&#148;) are
adequate for, and operate and perform in all respects as required in connection with the operation of the business of the Company and its Subsidiaries as currently conducted, and are free and clear of all material Trojan horses, time bombs, malware
and other malicious code. The Company and its Subsidiaries have implemented and maintained commercially reasonable physical, technical and administrative controls designed to maintain and protect the confidentiality, integrity, availability, privacy
and security of all sensitive, confidential or regulated data (&#147;<B><I>Confidential Data</I></B>&#148;) used or maintained in connection with their businesses and Personal Data, and the integrity, availability continuous operation, redundancy
and security of all IT Systems. &#147;Personal Data&#148; means the following data used in connection with the Company&#146;s and its Subsidiaries&#146; businesses and in their possession or control: (i)&nbsp;a natural person&#146;s name, street
address, telephone number, <FONT STYLE="white-space:nowrap">e-mail</FONT> address, photograph, social security number or other tax identification number, driver&#146;s license number, passport number, credit card number, bank information, or
customer or account number; (ii)&nbsp;information that identifies, relates to, or may reasonably be used to identify an individual; (iii)&nbsp;any information regarding an individual&#146;s medical history, mental or physical condition, or medical
treatment or diagnosis by a health care professional; (iv)&nbsp;an individual&#146;s health insurance policy number or subscriber identification number, any unique identifier used by a health insurer to identify the individual, or any information in
an individual&#146;s application and claims history; (v)&nbsp;any information which would qualify as &#147;protected health information&#148; under the Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information
Technology for Economic and Clinical Health Act (collectively, &#147;<B><I>HIPAA</I></B>&#148;); (vi) any information which would qualify as &#147;personal data,&#148; &#147;personal information&#148; (or similar term) under the Privacy Laws; and
(vii)&nbsp;any other piece of information that alone, or combined with other information, allows the identification of such natural person, or his or her family, or permits the collection or analysis of any data related to an identified
person&#146;s health or sexual orientation. To the Company&#146;s Knowledge, there have been no breaches, outages or unauthorized uses of or accesses to the IT Systems, Confidential Data, and Personal Data. The Company and its Subsidiaries are
presently, and at all prior times were, in material compliance with all applicable laws or statutes and all judgments and orders binding on the Company, applicable binding rules and regulations of any court or arbitrator or governmental or
regulatory authority, and their internal policies and contractual obligations, each relating to the Processing, privacy and security of Personal Data and Confidential Data, the privacy and security of IT Systems and the protection of such IT
Systems, Confidential Data, and Personal Data from unauthorized use, access, misappropriation or modification. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(oo)</B> <B>Compliance with Data Privacy Laws</B>. The Company and its Subsidiaries are,
and at all prior times were, in material compliance with all applicable state and federal data privacy and security laws and regulations regarding the collection, use, storage, retention, disclosure, transfer, disposal, or any other processing
(collectively &#147;<B><I>Process</I></B>&#148; or &#147;<B><I>Processing</I></B>&#148;) of Personal Data, including HIPAA, the California Consumer Privacy Act, and the European Union General Data Protection Regulation (EU 2016/679) (collectively,
the &#147;<B><I>Privacy Laws</I></B>&#148;). To ensure compliance with the Privacy Laws, the Company and its subsidiaries have in place, comply with, and take all appropriate steps necessary to ensure compliance in all material respects with their
policies and procedures relating to data privacy and security, and the Processing of Personal Data and Confidential Data (the &#147;<B><I>Privacy Statements</I></B>&#148;). The Company and its Subsidiaries have, except as would not reasonably be
expected, individually or in the aggregate, to have a Material Adverse Effect, at all times since January&nbsp;1, 2021 provided accurate notice of its Privacy Statements then in effect to its clients, employees, third party vendors and
representatives. None of such disclosures made or contained in any Privacy Statements have been materially inaccurate, misleading, incomplete, or in material violation of any Privacy Laws. The Company further certifies that neither it nor any of its
Subsidiaries: (i)&nbsp;has received notice of any actual or potential claim, complaint, proceeding, regulatory proceeding or liability under or relating to, or actual or potential violation of, any of the Privacy Laws, contracts related to the
Processing of Personal Data or Confidential Data, or Privacy Statements, and has no knowledge of any event or condition that would reasonably be expected to result in any such notice; (ii)&nbsp;is currently conducting or paying for, in whole or in
part, any investigation, remediation, or other corrective action pursuant to any Privacy Law or contract; or (iii)&nbsp;is a party to any order, decree, or agreement that imposes any obligation or liability under any Privacy Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.2</B> <B>Representations and Warranties of the Purchasers</B>. Each Purchaser hereby, for itself and for no other Purchaser, represents
and warrants to the Company as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Organization; Authority</B>. Such Purchaser is an entity duly organized, validly
existing and in good standing under the Laws of the jurisdiction of its organization with the requisite corporate or, if such Purchaser is not a corporation, such partnership, limited liability company or other applicable power and authority to
enter into and to consummate the transactions contemplated by the applicable Transaction Documents and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of this Agreement by such Purchaser and performance by
such Purchaser of the transactions contemplated by this Agreement have been duly authorized by all necessary corporate or, if such Purchaser is not a corporation, such partnership, limited liability company or other applicable like action, on the
part of such Purchaser. Each Transaction Document to which it is a party has been duly executed by such Purchaser, and when delivered by such Purchaser in accordance with the terms hereof, will constitute the valid and legally binding obligation of
such Purchaser, enforceable against it in accordance with its terms, except as such enforceability may be limited by applicable bankruptcy, examinership, insolvency, reorganization, moratorium, liquidation or similar laws relating to, or affecting
generally the enforcement of, creditors&#146; rights and remedies or by other equitable principles of general application. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>
<B>No Conflicts</B>. The execution, delivery and performance by such Purchaser of this Agreement and the Registration Rights Agreement and the consummation by such Purchaser of the transactions contemplated hereby and thereby will not
(i)&nbsp;result in a violation of the organizational documents of such Purchaser, (ii)&nbsp;conflict with, or constitute a default (or an event which with notice or lapse of time or both would become a default) under, or give to others any rights of
termination, amendment, acceleration or cancellation of, any agreement, indenture or instrument to which such Purchaser is a party, or (iii)&nbsp;result in a violation of any Law, rule, regulation, order, judgment or decree (including U.S. federal
and state securities laws) applicable to such Purchaser, except in the case of clauses (ii)&nbsp;and (iii) above, for such conflicts, defaults, rights or violations which would not, individually or in the aggregate, reasonably be expected to have a
material adverse effect on the ability of such Purchaser to perform its obligations hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B>Investment Intent</B>. Such
Purchaser understands that the Securities are (and the Conversion Shares will be) &#147;restricted securities&#148; and the offer and sale thereof have not been registered under the Securities Act or any applicable U.S. state securities law and is
acquiring the Securities as principal for its own account and not with a view to, or for distributing or reselling such Securities (or the Conversion Shares) or any part thereof in violation of the Securities Act or any applicable U.S. state or
other securities laws, <I>provided</I>, <I>however</I>, that by making the representations herein, such Purchaser does not agree to hold any of the Securities or Conversion Shares for any minimum period of time and reserves the right, subject to the
provisions of this Agreement and the Registration Rights Agreement, at all times to sell or otherwise dispose of all or any part of such Securities or Conversion Shares pursuant to an effective registration statement under the Securities Act or
under an exemption from such registration and in compliance with applicable U.S. federal, state and other securities laws. Such Purchaser is acquiring the Securities hereunder in the ordinary course of its business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Such Purchaser does not presently have any agreement, plan or understanding, directly or
indirectly, with any Person to distribute or effect any distribution of any of the Securities (or any securities which are derivatives thereof) to or through any person or entity in violation of federal securities law; such Purchaser is not a
registered broker-dealer under Section&nbsp;15 of the Exchange Act or an entity engaged in a business that would require it to be so registered as a broker-dealer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B>Purchaser Status</B>. At the time such Purchaser was offered the Securities, it was, and at the date hereof it is, an
&#147;accredited investor&#148; as defined in Rule 501(a) under the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> <B>General Solicitation</B>. Such
Purchaser is not purchasing the Securities as a result of any advertisement, article, notice or other communication regarding the Securities published in any newspaper, magazine or similar media or broadcast over television or radio or presented at
any seminar or any other general advertisement. The purchase of the Securities by such Purchaser has not been solicited by or through anyone other than the Company or, on the Company&#146;s behalf, the Placement Agents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> <B>Experience of Such Purchaser</B>. Such Purchaser, either alone or together with its representatives, has such knowledge,
sophistication and experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment in the Securities, and has so evaluated the merits and risks of such investment. Such Purchaser is
able to bear the economic risk of an investment in the Securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(g)</B> <B>Access to Information</B>. Such Purchaser acknowledges
that it has had the opportunity to review the SEC Reports and has been afforded (i)&nbsp;the opportunity to ask such questions as it has deemed necessary of, and to receive answers from, representatives of the Company concerning the terms and
conditions of the offering of the Securities and the merits and risks of investing in the Securities; (ii)&nbsp;access to information about the Company and the Subsidiaries and their respective financial condition, results of operations, business,
properties, management and prospects sufficient to enable it to evaluate its investment; and (iii)&nbsp;the opportunity to obtain such additional information that the Company possesses or can acquire without unreasonable effort or expense that is
necessary to make an informed investment decision with respect to the investment. Neither such inquiries nor any other investigation conducted by or on behalf of such Purchaser or its representatives or counsel shall modify, amend or affect such
Purchaser&#146;s right to rely on the truth, accuracy and completeness of the SEC Reports and the Company&#146;s representations and warranties contained in the Transaction Documents. Such Purchaser has sought such accounting, legal and tax advice
as it has considered necessary to make an informed decision with respect to its acquisition of the Securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(h)</B> <B>Certain
Trading Activities</B>. Other than with respect to the transactions contemplated herein, since the time that such Purchaser was first contacted by the Company, the Placement Agents or any other Person regarding the transactions contemplated hereby,
the Purchaser has not, directly or indirectly, effected or agreed to effect any Short Sales. Notwithstanding the foregoing, (i)&nbsp;in the case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage
separate portions of such Purchaser&#146;s assets, the foregoing representation shall only apply with respect to the portion of assets managed by the portfolio manager that made the investment decision to purchase the Securities covered by this
Agreement and (ii)&nbsp;and in the case of a Purchaser whose investment adviser utilized an information barrier with respect to the information regarding the transactions contemplated hereunder after first being contacted by the Company or such
other Person representing the Company, the representation set forth above shall only apply after the point in time when the portfolio manager who manages such Purchaser&#146;s assets was informed of the information regarding the transactions
contemplated hereunder and, with respect to the Purchaser&#146;s investment adviser, the representation set forth above shall only apply with respect to any purchases or sales, including Short Sales, of the securities of the Company on behalf of
other funds or investment vehicles for which the Purchaser&#146;s investment adviser is also an investment adviser or <FONT STYLE="white-space:nowrap">sub-adviser</FONT> after the point in time when the portfolio manager who manages the assets of
such other funds or investment vehicles for which the Purchaser&#146;s investment adviser is also an investment adviser or <FONT STYLE="white-space:nowrap">sub-adviser</FONT> was informed of the information regarding the transactions contemplated
hereunder. Other than to other Persons party to this Agreement and to the Purchaser&#146;s representatives or agents, including, but not limited to, the Purchaser&#146;s legal, tax and investment advisors, such Purchaser has maintained the
confidentiality of all disclosures made to it in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
connection with this transaction (including the existence and terms of this transaction). Notwithstanding the foregoing, for avoidance of doubt, nothing contained herein shall constitute a
representation or warranty, or preclude any actions, with respect to the identification of the availability of, or securing of, available shares to borrow in order to effect Short Sales or similar transactions in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> <B>Brokers and Finders</B>. No Person will have, as a result of the transactions contemplated by this Agreement, any valid right,
interest or claim against or upon the Purchaser for any commission, fee or other compensation pursuant to any agreement, arrangement or understanding entered into by or on behalf of the Purchaser. No Purchaser shall have any obligation with respect
to any fees, or with respect to any claims made by or on behalf of other Persons for fees, in each case of the type contemplated by this Section&nbsp;3.2(i) that may be due in connection with the transactions contemplated by this Agreement or the
Transaction Documents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(j)</B> <B>Independent Investment Decision</B>. Such Purchaser has independently evaluated the merits of its
decision to purchase Securities pursuant to the Transaction Documents, and such Purchaser confirms that it has not relied on the advice of any other Purchaser&#146;s business and/or legal counsel in making such decision. Such Purchaser understands
that nothing in this Agreement or any other materials presented by or on behalf of the Company to the Purchaser in connection with the purchase of the Securities constitutes legal, tax or investment advice. Such Purchaser has consulted such legal,
tax and investment advisors as it, in its sole discretion, has deemed necessary or appropriate in connection with its purchase of the Securities. Such Purchaser understands that the Placement Agents have acted solely as the agent of the Company in
this placement of the Securities and such Purchaser has not relied on the business or legal advice of the Placement Agents or any of their agents, counsel or Affiliates in making its investment decision hereunder, and confirms that none of such
Persons has made any representations or warranties to such Purchaser in connection with the transactions contemplated by the Transaction Documents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(k)</B> <B>Reliance on Exemptions</B>. Such Purchaser understands that the Securities are being offered and sold to it in reliance on
specific exemptions from the registration requirements of United States federal and state securities laws and that the Company is relying in part upon the truth and accuracy of, and such Purchaser&#146;s compliance with, the representations,
warranties, agreements, acknowledgements and understandings of such Purchaser set forth herein in order to determine the availability of such exemptions and the eligibility of such Purchaser to acquire the Securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(l)</B> <B>No Governmental Review</B>. Such Purchaser understands that no United States federal or state agency or any other government or
governmental agency has passed on or made any recommendation or endorsement of the Securities or the fairness or suitability of the investment in the Securities nor have such authorities passed upon or endorsed the merits of the offering of the
Securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(m)</B> <B>Regulation M</B>. Such Purchaser is aware that the anti-manipulation rules of Regulation M under the Exchange
Act may apply to sales of Securities and other activities with respect to the Securities by the Purchasers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(n)</B> <B>Beneficial
Ownership</B>. The purchase by such Purchaser of the Securities issuable to it at the Closing will not result in such Purchaser (individually or together with any other Person with whom such Purchaser has identified, or will have identified, itself
as part of a &#147;group&#148; in a public filing made with the Commission involving the Company&#146;s securities) acquiring, or obtaining the right to acquire, beneficial ownership in excess of 19.9% of the outstanding shares of Common Stock or
the voting power of the Company on a post transaction basis that assumes that such Closing shall have occurred. Such Purchaser does not presently intend to, alone or together with others, make a public filing with the Commission to disclose that it
has (or that it together with such other Persons have) acquired, or obtained the right to acquire, as a result of such Closing when added to any other securities of the Company that it or they then own or have the right to acquire, beneficial
ownership in excess of 19.9% of the outstanding shares of Common Stock or the voting power of the Company on a post transaction basis that assumes that each Closing shall have occurred. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(o)</B> <B>Residency</B>. Such Purchaser&#146;s residence (if an individual) or offices in which its investment decision with respect to
the Securities was made (if an entity) are located at the address set forth under such Purchaser&#146;s name on Annex A hereto or as otherwise specified below its address on Annex A hereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company and each of the Purchasers acknowledge and agree that no party to this Agreement
has made or makes any representations or warranties with respect to the transactions contemplated hereby other than those specifically set forth in this Article 3 and the Transaction Documents. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 4 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OTHER
AGREEMENTS OF THE PARTIES </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.1</B> <B>Transfer Restrictions</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Compliance with Laws</B>. Notwithstanding any other provision of this Article 4, each Purchaser covenants that the Securities and
Conversion Shares may be disposed of only pursuant to an effective registration statement under, and in compliance with the requirements of, the Securities Act, or pursuant to an available exemption from, or in a transaction not subject to, the
registration requirements of the Securities Act, and in compliance with any applicable U.S. state and federal securities laws. In connection with any transfer of the Securities other than (i)&nbsp;pursuant to an effective registration statement,
(ii)&nbsp;to the Company, (iii)&nbsp;pursuant to Rule 144 (provided that the Purchaser provides the Company with reasonable assurances (in the form of seller and, if applicable, broker representation letters) that the securities may be sold pursuant
to such rule), or (iv)&nbsp;in connection with a bona fide pledge as contemplated in Section&nbsp;4.1(b), the Company may require the transferor thereof to provide to the Company an opinion of counsel selected by the transferor and reasonably
acceptable to the Company, the form and substance of which opinion shall be reasonably satisfactory to the Company, to the effect that such transfer does not require registration of such transferred Securities or Conversion Shares under the
Securities Act and, as a condition of transfer, any such transferee shall agree in writing to be bound by the terms of this Agreement and the Registration Rights Agreement and shall have the rights of a Purchaser under this Agreement and the
Registration Rights Agreement with respect to such transferred Securities or Conversion Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Legends</B>. Book-entry
statements evidencing the Securities and any Conversion Shares shall bear any legend as required by the &#147;blue sky&#148; Laws of any state and a restrictive legend in substantially the following form: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">THE OFFER AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE TO WHICH THIS CONFIRMATION RELATES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF
1933, AS AMENDED, OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE SECURITIES MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES
UNDER APPLICABLE SECURITIES LAWS, OR UNLESS OFFERED, SOLD, PLEDGED, HYPOTHECATED OR TRANSFERRED PURSUANT TO AN AVAILABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THOSE LAWS. THE COMPANY AND ITS TRANSFER AGENT SHALL BE ENTITLED TO REQUIRE AN
OPINION OF COUNSEL SATISFACTORY TO THE COMPANY AND THE TRANSFER AGENT THAT SUCH REGISTRATION IS NOT REQUIRED. NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING
ARRANGEMENT SECURED BY THE SECURITIES. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company acknowledges and agrees that a Purchaser may from time to time pledge, and/or grant a
security interest in, some or all of the legended Securities or Conversion Shares in connection with applicable securities laws, pursuant to a bona fide margin agreement in compliance with a bona fide margin loan. Such a pledge would not be subject
to approval or consent of the Company and no legal opinion of legal counsel to the pledgee, secured party or pledgor shall be required in connection with the pledge, but such legal opinion shall be required in connection with a subsequent transfer
or foreclosure following default by the Purchaser transferee of the pledge. No notice shall be required of such pledge, but Purchaser&#146;s transferee shall promptly notify the Company of any such subsequent transfer or foreclosure. Each Purchaser
acknowledges that the Company shall not be responsible for any pledges relating to, or the grant of any security interest in, any of the Securities or Conversion Shares or for any agreement, understanding or arrangement between any Purchaser and its
pledgee or secured party. At the appropriate Purchaser&#146;s expense, the Company will execute and deliver such reasonable documentation as a pledgee or secured party of Securities or Conversion Shares may reasonably request in connection with a
pledge or transfer of the Securities or Conversion Shares, as applicable, including the preparation and filing of any required prospectus </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
supplement under Rule 424(b)(3) of the Securities Act or other applicable provision of the Securities Act to appropriately amend the list of selling stockholders thereunder. Each Purchaser
acknowledges and agrees that, except as otherwise provided in Section&nbsp;4.1(c), any Securities or Conversion Shares subject to a pledge or security interest as contemplated by this Section&nbsp;4.1(b) shall continue to bear the legend set forth
in this Section&nbsp;4.1(b) and be subject to the restrictions on transfer set forth in Section&nbsp;4.1(b). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B>Removal of
Legends</B>. Once a Registration Statement covering the resale of the Common Shares and the Conversion Shares is declared effective, the Company shall remove all restrictive legends, including the legend set forth in Section&nbsp;4.1(b) above (or,
in the event that Conversion Shares are issued upon conversion after the Registration Statement is declared effective, the Conversion Shares shall be issued without restrictive legends), and the Company shall, upon request of the Purchaser or the
Company&#146;s transfer agent, provide a blanket opinion of counsel permitting such removal. Further, the Company shall remove all restrictive legends, including the legend set forth in Section&nbsp;4.1(b) above, (i)&nbsp;following any sale of such
Common Shares or Conversion Shares pursuant to Rule 144 or any other applicable exemption from the registration requirements of the Securities Act, or (ii)&nbsp;if such Common Shares or Conversion Shares are eligible for resale under Rule 144(b)(1)
or any successor provision (or, in the event that Conversion Shares are issued upon conversion after the conditions set forth in clauses (i)&nbsp;and (ii) above, the Conversion Shares shall be issued without restrictive legends). Without limiting
the foregoing, either (i)&nbsp;upon request of the Purchaser, upon receipt by the Company of an opinion of counsel reasonably satisfactory to the Company to the effect that such legend is no longer required under the Securities Act and applicable
state securities laws or (ii)&nbsp;as contemplated by the Irrevocable Transfer Agent Instructions, the Company shall promptly cause the legend to be removed from any book-entry statements for any Common Shares or Conversion Shares in accordance with
the terms of this Agreement and deliver, or cause to be delivered, to any Purchaser new book-entry statements representing the Common Shares or Conversion Shares that are free from all restrictive and other legends or, at the request of such
Purchaser, via DWAC transfer to such Purchaser&#146;s account. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B>Irrevocable Transfer Agent Instructions</B>. The Company
shall issue the Irrevocable Transfer Agent Instructions. The Company represents and warrants that no instruction other than the Irrevocable Transfer Agent Instructions referred to in this Section&nbsp;4.1(d) (or instructions that are consistent
therewith) will be given by the Company to its Transfer Agent in connection with this Agreement, and that the Securities and Conversion Shares shall otherwise be freely transferable on the books and records of the Company as and to the extent
provided in this Agreement and the other Transaction Documents and applicable law. The Company acknowledges that a breach by it of its obligations under this Section&nbsp;4.1(d) will cause irreparable harm to a Purchaser. Accordingly, the Company
acknowledges that the remedy at law for a breach of its obligations under this Section&nbsp;4.1(d) may be inadequate and agrees, in the event of a breach or threatened breach by the Company of the provisions of this Section&nbsp;4.1(d) that a
Purchaser shall be entitled, in addition to all other available remedies, to an order and/or injunction restraining any breach and requiring immediate issuance and transfer, without the necessity of showing irreparable harm or economic loss and
without any bond or other security being required. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> <B>Acknowledgement</B>. Each Purchaser hereunder acknowledges its primary
responsibilities under the Securities Act and accordingly will not sell or otherwise transfer the Securities or Conversion Shares or any interest therein without complying with the requirements of the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.2</B> <B>Furnishing of Information</B>. In order to enable the Purchasers to sell the Securities and Conversion Shares under Rule 144,
until such time as Purchaser may sell the Securities and Conversion Shares without limitation under Rule 144, the Company shall use its commercially reasonable efforts to timely file (or obtain extensions in respect thereof and file within the
applicable grace period) all reports required to be filed by the Company after the date hereof pursuant to the Exchange Act and, if during such period, the Company is not required to file reports pursuant to the Exchange Act, it will prepare and
furnish to the Purchasers and make publicly available in accordance with Rule 144(c) such information as is required for the Purchasers to sell the Securities and Conversion Shares under Rule 144. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.3</B> <B>Integration</B>. The Company shall not, and shall use its commercially reasonable efforts to ensure that no Affiliate of the
Company shall, sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined in Section&nbsp;2 of the Securities Act) that will be integrated with the offer or sale of the Securities in a manner that
would require the registration under the Securities Act of the sale of the Securities to the Purchasers, or that will be integrated with the offer or sale of the Securities for purposes of the rules and regulations of any Trading Market such that it
would require stockholder approval prior to the closing of such other transaction unless stockholder approval is obtained before the closing of such subsequent transaction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.4</B> <B>Securities Laws Disclosure; Publicity</B>. By no later than 9:00 A.M., New
York City time, on the Trading Day immediately following the date hereof (provided that, if this Agreement is executed between midnight and 9:00 A.M., New York City time on any Trading Day, no later than 9:01 A.M. on the date hereof), the Company
shall (a)&nbsp;issue a press release (the &#147;<B><I>Press Release</I></B>&#148;) reasonably acceptable to the Placement Agents disclosing all material terms of the transactions contemplated hereby and (b)&nbsp;file a Current Report on Form <FONT
STYLE="white-space:nowrap">8-K</FONT> with the Commission describing the terms of the Transaction Documents (and including as exhibits to such Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> the material Transaction Documents
(including, without limitation, this Agreement and the Registration Rights Agreement)); provided that the Press Release shall not publicly disclose the name of any Purchaser or investment adviser of any Purchaser, or include the name of any
Purchaser or an Affiliate of any Purchaser without the prior written consent of such Purchaser. In addition, notwithstanding the foregoing, the Company shall not publicly disclose the name of any Purchaser or investment adviser of any Purchaser, or
include the name of any Purchaser or an Affiliate of any Purchaser without the prior written consent of such Purchaser (i)&nbsp;in any press release or marketing materials or (ii)&nbsp;in any filing with the Commission or any regulatory agency or
Trading Market, except as required by U.S. federal securities law (A)&nbsp;in connection with any registration statement contemplated by the Registration Rights Agreement (which shall be subject to review and comment of the Purchasers pursuant to
the terms of the Registration Rights Agreement) or the filing of final Transaction Documents (including signature pages thereto) with the Commission and (B)&nbsp;to the extent such disclosure is required by law, request of the Commission&#146;s
staff or Trading Market regulations, in which case the Company shall provide the Purchasers with prior written notice of such disclosure permitted under this subclause (ii). From and after the issuance of the Press Release, no Purchaser shall be in
possession of any material, <FONT STYLE="white-space:nowrap">non-public</FONT> information received from the Company, any Subsidiary or any of their respective officers, directors, employees or agents, that is not disclosed in the Press Release.
Each Purchaser, severally and not jointly with the other Purchasers, covenants that until such time as the transactions contemplated by this Agreement are publicly disclosed by the Company pursuant to the Press Release, such Purchaser will maintain
the confidentiality of the existence and terms of this transaction and the information provided in connection therewith; provided, however, that any disclosure may be made by the Purchaser to the Purchaser&#146;s representatives or agents,
including, but not limited to, the Purchaser&#146;s legal, tax and investment advisors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.5</B> <B>Shareholder Rights Plan</B>. No
claim will be made or enforced by the Company or, with the consent of the Company, any other Person, that any Purchaser is an &#147;<B><I>Acquiring Person</I></B>&#148; under any control share acquisition, business combination, poison pill
(including any distribution under a rights agreement) or similar anti-takeover plan or arrangement or Law (including Section&nbsp;203 of the Delaware General Corporation Law) in effect or hereafter adopted by the Company, or that any Purchaser could
be deemed to trigger the provisions of any such plan or arrangement, in either case solely by virtue of receiving Securities or Conversion Shares under the Transaction Documents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.6</B> <B><FONT STYLE="white-space:nowrap">Non-Public</FONT> Information</B>. Except with respect to the material terms and conditions of
the transactions contemplated by the Transaction Documents, including this Agreement, or as expressly required by any applicable securities law, the Company covenants and agrees that neither it, nor any other Person acting on its behalf, will
provide any Purchaser or its agents or counsel with any information regarding the Company that the Company believes constitutes material <FONT STYLE="white-space:nowrap">non-public</FONT> information without the express written (email being
sufficient) consent of such Purchaser, (i)&nbsp;unless prior thereto such Purchaser shall have committed to customary obligations regarding the confidentiality and use of such information and (ii)&nbsp;except in the case of material, nonpublic
information provided to an observer of the Board of Directors or member of the Board of Directors who is affiliated with such Purchaser. The Company understands and confirms that each Purchaser shall be relying on the foregoing covenant in effecting
transactions in securities of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.7</B> <B>Use of Proceeds</B>. The Company shall use the net proceeds from the sale of the
Securities hereunder for working capital and general corporate purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.8</B> <B>Principal Trading Market Listing</B>. The Company
shall use its reasonable best efforts to take all steps necessary to cause the Common Shares and the Conversion Shares to be approved for listing on the Principal Trading Market as promptly as possible. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.9</B> <B>Form D; Blue Sky</B>. The Company agrees to timely file a Form D with respect
to the Securities as required under Regulation D and to provide a copy thereof, promptly upon the written request of any Purchaser. The Company, on or before the Closing Date, shall take such action as the Company shall reasonably determine is
necessary in order to obtain an exemption for or to qualify the Securities for sale to the Purchasers under applicable securities or &#147;blue sky&#148; Laws of the states of the United States (or to obtain an exemption from such qualification) and
shall provide evidence of such actions promptly upon the written request of any Purchaser. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.10</B> <B>Short Sales After the Date
Hereof</B>. Such Purchaser shall not engage, directly or indirectly, in any transactions in the Company&#146;s securities (including, without limitation, any Short Sales involving the Company&#146;s securities) during the period from the date hereof
until the earlier of such time as (i)&nbsp;the transactions contemplated by this Agreement are first publicly announced as required by and described in Section&nbsp;4.4 or (ii)&nbsp;this Agreement is terminated in full pursuant to Section&nbsp;6.18.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, no Purchaser makes any representation, warranty or covenant hereby that it will not engage in Short Sales
in the securities of the Company after the time that the transactions contemplated by this Agreement are first publicly announced as described in Section&nbsp;4.4; <I>provided</I>, <I>however</I>, each Purchaser agrees, severally and not jointly
with any Purchasers, that they will not enter into any Net Short Sales (as hereinafter defined) from the period commencing on the Closing Date and ending on the earliest of (x)&nbsp;the Effective Date, (y)&nbsp;the twenty-four (24)&nbsp;month
anniversary of the Closing Date or (z)&nbsp;the date that such Purchaser no longer holds any Securities. For purposes of this Section&nbsp;4.10, a &#147;<B><I>Net Short Sale</I></B>&#148; by any Purchaser shall mean a sale of Common Stock by such
Purchaser that is marked by such Purchaser as a short sale and that is made at a time when there is no equivalent offsetting long position in Common Stock held by such Purchaser. Notwithstanding the foregoing, in the event that a Purchaser is a
multi-managed investment vehicle whereby separate portfolio managers manage separate portions of such Purchaser&#146;s assets and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers managing
other portions of such Purchaser&#146;s assets, the representation set forth above shall apply only with respect to the portion of assets managed by the portfolio manager that have knowledge about the financing transaction contemplated by this
Agreement. Moreover, notwithstanding the foregoing, in the event that a Purchaser has sold Securities pursuant to Rule 144 prior to the Effective Date and the Company has failed to deliver shares without legends prior to the settlement date for such
sale (assuming that such shares meet the requirements set forth in Section&nbsp;4.1(c) for the removal of legends), the provisions of this Section&nbsp;4.10 shall not prohibit the Purchaser from entering into Net Short Sales for the purpose of
delivering shares of Common Stock in settlement of such sale. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.11</B> <B>Beneficial Ownership Limitation</B>. Notwithstanding
anything to the contrary set forth in the Certificate of Designation, the Company shall not effect any conversion of any share of Series B Preferred Stock, and a Purchaser shall not have the right to convert any portion of its Series B Preferred
Stock, to the extent that, after giving effect to such attempted conversion set forth on an applicable Notice of Conversion (as defined in the Certificate of Designation) with respect to the Series B Preferred Stock, such Purchaser (or any of such
Purchaser&#146;s Affiliates or any other Person who would be a beneficial owner of Common Stock beneficially owned by the Purchaser for purposes of Section&nbsp;13(d) or Section&nbsp;16 of the Exchange Act and the applicable rules and regulations of
the Commission, including any &#147;group&#148; of which the Purchaser is a member (the foregoing, &#147;<B><I>Attribution Parties</I></B>&#148;)) would beneficially own a number of shares of Common Stock in excess of the Beneficial Ownership
Limitation (as defined below). For purposes of the foregoing sentence, the aggregate number of shares of Common Stock beneficially owned by such Purchaser and its Attribution Parties shall include the number of shares of Common Stock issuable upon
conversion of the Series B Preferred Stock subject to the Notice of Conversion or the Automatic Conversion (as defined in the Certificate of Designation), as applicable, with respect to which such determination is being made, but shall exclude the
number of shares of Common Stock which are issuable upon (i)&nbsp;conversion of the remaining, unconverted Series B Preferred Stock beneficially owned by such Purchaser or any of its Attribution Parties, and (ii)&nbsp;exercise or conversion of the
unexercised or unconverted portion of any other securities of the Company beneficially owned by such Purchaser or any of its Attribution Parties that are subject to and would exceed a limitation on conversion or exercise similar to the limitation
contained herein. Except as set forth in the preceding sentence, for purposes of this Section&nbsp;4.11, beneficial ownership shall be calculated in accordance with Section&nbsp;13(d) of the Exchange Act and the applicable rules and regulations of
the Commission, and the terms &#147;beneficial ownership&#148; and &#147;beneficially own&#148; have the meanings ascribed to such terms therein. In addition, for purposes hereof, &#147;group&#148; has the meaning set forth in Section&nbsp;13(d) of
the Exchange Act and the applicable rules and regulations of the Commission. For purposes of this Section&nbsp;4.11, in determining the number of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
outstanding shares of Common Stock, a Purchaser may rely on the number of outstanding shares of Common Stock as stated in the most recent of the following: (i)&nbsp;the Company&#146;s most recent
periodic or annual filing with the Commission, as the case may be, (ii)&nbsp;a more recent public announcement by the Company that is filed with the Commission, or (iii)&nbsp;a more recent notice by the Company or the Company&#146;s transfer agent
to the Purchaser setting forth the number of shares of Common Stock then outstanding. For any reason at any time, upon the written request of a Purchaser (which may be by <FONT STYLE="white-space:nowrap">e-mail),</FONT> the Company shall, within two
(2)&nbsp;Trading Days of such request, confirm in writing to such Purchaser (which may be by <FONT STYLE="white-space:nowrap">e-mail)</FONT> the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of
Common Stock shall be determined after giving effect to any actual conversion or exercise of securities of the Company, including Series B Preferred Stock, by such Purchaser or its Attribution Parties since the date as of which such number of
outstanding shares of Common Stock was last publicly reported or confirmed to the Purchaser. The &#147;<B><I>Beneficial Ownership Limitation</I></B>&#148; shall initially be set at the discretion of each Purchaser to a percentage between 0% and
19.9% of the number of shares of the Common Stock outstanding or deemed to be outstanding as of the applicable measurement date, and such percentage shall be set at 9.9% for any Holder that does not make such designation on <U>Annex A</U> hereto.
The Company shall be entitled to rely on representations made to it by any Purchaser in any Notice of Conversion regarding its Beneficial Ownership Limitation. Notwithstanding the foregoing, by written notice to the Company, (i)&nbsp;any Purchaser
may reset the Beneficial Ownership Limitation percentage to a higher percentage, not to exceed 19.9%, which increase will not be effective until the sixty-first (61st) day after such written notice is delivered to the Company, and (ii)&nbsp;any
Purchaser may reset the Beneficial Ownership Limitation percentage to a lower percentage provided that such decrease shall not become effective until the later of (x) 5:00 p.m. Eastern time on the third Business Day after the date of the Requisite
Stockholder Approval and (y)&nbsp;if the Requisite Stockholder Approval is not obtained within six months after the initial issuance of the Series B Preferred Stock, the date that is three Business Days after the date that is six months after the
initial issuance of the Series B Preferred Stock. Upon such a change by a Purchaser of the Beneficial Ownership Limitation, not to exceed 19.9%, the Beneficial Ownership Limitation may not be further amended by such Purchaser without first providing
the minimum notice required by this Section&nbsp;4.11. Notwithstanding the foregoing, at any time following notice of a Fundamental Transaction (as defined in the Certificate of Designation), the Purchaser may waive and/or change the Beneficial
Ownership Limitation effective immediately upon written notice to the Company and may reinstitute a Beneficial Ownership Limitation at any time thereafter effective immediately upon written notice to the Company. The provisions of this
Section&nbsp;4.11 shall be construed, corrected and implemented in a manner so as to effectuate the intended Beneficial Ownership Limitation herein contained and the shares of Common Stock underlying the Securities in excess of the Beneficial
Ownership Limitation shall not be deemed to be beneficially owned by the Purchaser for any purpose including for purposes of Section&nbsp;13(d) or Rule <FONT STYLE="white-space:nowrap">16a-1(a)(1)</FONT> of the Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.12</B> <B>Requisite Stockholder Approval</B>. The Company shall use its best efforts to obtain stockholder approval of the conversion of
all issued and outstanding Series B Preferred Stock into shares of Common Stock in accordance with the Nasdaq Stock Market Rules (the &#147;<B><I>Requisite Stockholder Approval</I></B>&#148;) at its 2024 annual meeting of stockholders (the
&#147;<B><I>Annual Meeting</I></B>&#148;), which such Annual Meeting shall be held no later than May&nbsp;15, 2024. The Company shall use its best efforts to solicit its stockholders&#146; approval of such resolution and to cause the Board of
Directors to recommend to the stockholders that they approve such resolution. If the Requisite Stockholder Approval is not obtained at the Annual Meeting, the Company shall cause an additional Stockholder Meeting to be held within 90 days from the
date of the Annual Meeting (the &#147;<B><I>Extended Stockholder Approval Period</I></B>&#148;). If the Requisite Stockholder Approval is not obtained within the Extended Stockholder Approval Period, then the Company shall convene additional
stockholder meetings every 90 days thereafter until the Requisite Stockholder Approval is obtained. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.13</B> <B>Conversion and
Exercise Procedures</B>. The form of Notice of Conversion included in the Certificate of Designation sets forth the totality of the procedures required of the Purchasers in order to convert the Securities. Without limiting the preceding sentence, no
<FONT STYLE="white-space:nowrap">ink-original</FONT> Notice of Conversion shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Conversion form be required in order for the registered
holder thereof to convert the Securities. No additional legal opinion, other information or instructions shall be required of a Purchaser to convert its Securities. The Company shall honor conversions of the Securities and shall deliver Conversion
Shares in accordance with the terms, conditions and time periods set forth in the Transaction Documents. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.14</B> <B>Indemnification of Purchasers</B>. Subject to the provisions of this
Section&nbsp;4.13, the Company will indemnify and hold each Purchaser and its directors, officers, shareholders, members, partners, employees, investment advisers and agents (and any other Persons with a functionally equivalent role of a Person
holding such titles notwithstanding a lack of such title or any other title), each Person who controls such Purchaser (within the meaning of Section&nbsp;15 of the Securities Act and Section&nbsp;20 of the Exchange Act), and the directors, officers,
shareholders, agents, members, partners, investment advisers or employees (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding a lack of such title or any other title) of such controlling persons
(each, a &#147;<B><I>Purchaser Party</I></B>&#148;) harmless from any and all losses, liabilities, obligations, claims, contingencies, damages, costs and expenses, including all judgments, amounts paid in settlements, court costs and reasonable
attorneys&#146; fees and costs of investigation that any such Purchaser Party may suffer or incur as a result of or relating to (i)&nbsp;any breach of any of the representations, warranties, covenants or agreements made by the Company in this
Agreement or in the other Transaction Documents or (ii)&nbsp;any Action instituted against a Purchaser in any capacity, or any Purchaser Party, by any stockholder of the Company who is not an Affiliate of such Purchaser seeking indemnification, with
respect to any of the transactions contemplated by the Transaction Documents (unless such Action is based upon a breach of such Purchaser&#146;s representations, warranties or covenants under the Transaction Documents, or any agreements or
understandings such Purchaser may have with any such stockholder or any violations by the Purchaser of state or federal securities Laws or any conduct by such Purchaser which constitutes fraud, gross negligence, willful misconduct or malfeasance).
Promptly after receipt by any such Person (the &#147;<B><I>Indemnified Person</I></B>&#148;) of notice of any demand, claim or circumstances that would or may give rise to a claim or the commencement of any Proceeding or investigation in respect of
which indemnity may be sought pursuant to this Section&nbsp;4.13, such Indemnified Person shall promptly notify the Company in writing and the Company shall assume the defense thereof, including the employment of counsel reasonably satisfactory to
such Indemnified Person, and shall assume the payment of all fees and expenses relating to such Proceeding or investigation; provided, however, that the failure of any Indemnified Person so to notify the Company shall not relieve the Company of its
obligations hereunder except to the extent that the Company is actually and materially prejudiced by such failure to notify. In any such proceeding, any Indemnified Person shall have the right to retain its own counsel, but the fees and expenses of
such counsel shall be at the expense of such Indemnified Person unless: (i)&nbsp;the Company and the Indemnified Person shall have mutually agreed to the retention of such counsel; (ii)&nbsp;the Company shall have failed promptly to assume the
defense of such proceeding and to employ counsel reasonably satisfactory to such Indemnified Person in such proceeding; or (iii)&nbsp;in the reasonable judgment of counsel to such Indemnified Person, representation of both parties by the same
counsel would be inappropriate due to actual or potential differing interests between them. In the event of the circumstances described in the foregoing clause (iii), if the Indemnified Person notifies the Company in writing that such Indemnified
Person elects to employ separate counsel at the expense of the Company, then the Company shall not have the right to assume the defense of such claim on behalf of such Indemnified Person. The Company shall not be liable for any settlement of any
proceeding effected without its prior written consent, which consent shall not be unreasonably withheld, delayed or conditioned or to the extent fees or costs incurred pursuant to this Section&nbsp;4.13 are attributable to the Indemnified
Person&#146;s breach of any of the representations, warranties, covenants or agreements made by the Purchasers in this Agreement or the other Transaction Documents. Without the prior written consent of the Indemnified Person, which consent shall not
be unreasonably withheld, delayed or conditioned, the Company shall not effect any settlement of any pending or threatened proceeding in respect of which any Indemnified Person is or could have been a party and indemnity could have been sought
hereunder by such Indemnified Person, unless such settlement includes an unconditional release of such Indemnified Person from all liability arising out of such proceeding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.15</B> <B>Equal Treatment of Purchasers</B>. No consideration shall be offered or paid to any Purchaser to amend or consent to a waiver
or modification of any provision of this Agreement unless the same consideration is also offered to all of the Purchasers. For clarification purposes, this provision constitutes a separate right granted to each Purchaser by the Company and
negotiated separately by each Purchaser and shall not in any way be construed as the Purchasers acting in concert or as a group with respect to the purchase, disposition or voting of shares of Common Stock or otherwise. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 5 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONDITIONS PRECEDENT TO CLOSING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.1</B> <B>Conditions Precedent to the Obligations of the Purchasers to Purchase Securities</B>. The obligation of each Purchaser to
acquire Securities at the Closing is subject to the fulfillment to such Purchaser&#146;s satisfaction, on or prior to the Closing Date, of each of the following conditions, any of which may be waived by such Purchaser (as to itself only): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Representations and Warranties</B>. The representations and warranties of the Company contained herein shall be true and correct
in all respects as of the date when made and as of the Closing Date, as though made on and as of such date, except for such representations and warranties that speak as of a specific date, which shall be true and correct in all respects as of such
date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Performance</B>. The Company shall have performed, satisfied and complied in all material respects with all
covenants, agreements and conditions required by the Transaction Documents to be performed, satisfied or complied with by it at or prior to the Closing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B>No Injunction</B>. No statute, rule, regulation, order, executive order, decree, judgment, writ, order, ruling or injunction
shall have been enacted, entered, promulgated, issued or endorsed by any court of competent jurisdiction or any Governmental Authority that enjoins, prevents or prohibits the consummation of any of the transactions contemplated by the Transaction
Documents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B>Consents</B>. The Company shall have obtained in a timely fashion any and all consents, permits, approvals,
registrations and waivers necessary for consummation of the purchase and sale of the Securities (except for the Requisite Stockholder Approval), all of which shall be and remain so long as necessary in full force and effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> <B>Adverse Changes</B>. Since the date of execution of this Agreement, no event or series of events shall have occurred that has
had or would reasonably be expected to have a Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> <B>No Suspensions of Trading in Common Stock; No Stop
Orders; Listing</B>. The Common Stock shall not have been suspended by the Commission or the Principal Trading Market from trading on the Principal Trading Market nor shall suspension by the Commission or the Principal Trading Market have been
threatened, either (i)&nbsp;in writing by the Commission or the Principal Trading Market or (ii)&nbsp;by falling below the minimum listing maintenance requirements of the Principal Trading Market. No stop order shall have been imposed by Nasdaq, the
Commission or any other Governmental Authority or regulatory body with respect to public trading in the Common Stock. The Company shall have filed the Notification Form: Listing of Additional Shares for the listing of the Common Shares and
Conversion with Nasdaq, and Nasdaq shall have raised no objection to such notice and the transactions contemplated hereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(g)</B>
<B>Company Deliverables</B>. The Company shall have delivered the Company Deliverables in accordance with Section&nbsp;2.3(a). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(h)</B>
<B>Compliance Certificate</B>. The Company shall have delivered to each Purchaser a certificate, dated as of the Closing Date and signed by its Chief Executive Officer and its Chief Financial Officer, dated as of the Closing Date, certifying to the
fulfillment of the conditions specified in Sections 5.1(a), (b), (e) and (f)&nbsp;in the form attached hereto as <B>Exhibit F</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> <B>Termination</B>. This Agreement shall not have been terminated as to such Purchaser in accordance with Section&nbsp;6.18 herein.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.2</B> <B>Conditions Precedent to the Obligations of the Company to issue Securities</B>. The Company&#146;s obligation to issue the
Securities at the Closing to each Purchaser is subject to the fulfillment to the satisfaction of the Company on or prior to the Closing Date of the following conditions, any of which may be waived by the Company: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Representations and Warranties</B>. The representations and warranties made by each Purchaser in Section&nbsp;3.2 hereof shall be
true and correct in all material respects (except for those representations and warranties which are qualified as to materiality, in which case such representations and warranties shall be true and correct in all respects) as of the date when made,
and as of the Closing Date as though made on and as of such date, except for representations and warranties that speak as of a specific date, which shall be true and correct in all material respects (except for those representations and warranties
which are qualified as to materiality or Material Adverse Effect, which representations and warranties shall be true and correct in all respects) as of such date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Performance</B>. Such Purchaser shall have performed, satisfied and complied
in all material respects with all covenants, agreements and conditions required by the Transaction Documents to be performed, satisfied or complied with by such Purchaser at or prior to the Closing Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B>No Injunction</B>. No statute, rule, regulation, order, executive order, decree, judgment, writ, order, ruling or injunction
shall have been enacted, entered, promulgated, issued or endorsed by any court of competent jurisdiction or any Governmental Authority that enjoins, prevents or prohibits the consummation of any of the transactions contemplated by the Transaction
Documents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B>Purchasers Deliverables</B>. Such Purchaser shall have delivered its Purchaser Deliverables in accordance with
Section&nbsp;2.3(b). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> <B>Termination</B>. This Agreement shall not have been terminated as to such Purchaser in accordance with
Section&nbsp;6.18 herein. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 6 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MISCELLANEOUS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.1</B>
<B>Fees and Expenses</B>. The Company and the Purchasers shall each pay the fees and expenses of their respective advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party in connection with the
negotiation, preparation, execution, delivery and performance of this Agreement. The Company shall pay all Transfer Agent fees, stamp taxes and other taxes and duties levied in connection with the issuance and sale of the Securities to the
Purchasers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.2</B> <B>Entire Agreement</B>. The Transaction Documents, together with the exhibits and schedules thereto, contain the
entire understanding of the parties with respect to the subject matter hereof and thereof and supersede all prior agreements, understandings, discussions and representations, oral or written, with respect to such matters, which the parties
acknowledge have been merged into such documents, exhibits and schedules. Before or at the Closing, the Company and the Purchasers will execute and deliver to the other such further documents as may be reasonably requested in order to give practical
effect to the intention of the parties under the Transaction Documents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.3</B> <B>Notices</B>. Any and all notices or other
communications or deliveries required or permitted to be provided hereunder shall be in writing and shall be deemed given and effective on the earliest of (a)&nbsp;the date of transmission, if such notice or communication is delivered via electronic
mail at the <FONT STYLE="white-space:nowrap">e-mail</FONT> address specified in this Section&nbsp;6.3 prior to 5:00 P.M., New York City time, on a Trading Day, (b)&nbsp;the next Trading Day after the date of transmission, if such notice or
communication is delivered via electronic mail at the <FONT STYLE="white-space:nowrap">e-</FONT> mail address or facsimile number specified in this Section&nbsp;6.3 on a day that is not a Trading Day or later than 5:00 P.M., New York City time, on
any Trading Day, (c)&nbsp;the Trading Day following the date of mailing, if sent by U.S. nationally recognized overnight courier service with next day delivery specified, or (d)&nbsp;upon actual receipt by the party to whom such notice is required
to be given if delivered personally or if sent by U.S. certified or registered mail, return receipt requested; provided, in the case of clauses (a)&nbsp;and (b), that notice shall not be deemed given or effective if the sender receives an automatic
system-generated response that such electronic mail was undeliverable. The address for such notices and communications shall be as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="82%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If to the Company:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Spyre Therapeutics, Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">221 Crescent Street, Building 23, Suite 105, Waltham, Massachusetts 02453</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Telephone No.:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Attention: Heidy Abreu King-Jones, Chief Legal Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">E-mail:</FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="82%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">With a copy to:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Gibson, Dunn&nbsp;&amp; Crutcher LLP</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">555 Mission St., Suite 3000, San Francisco, CA 94105</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Telephone No.:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Attention: Ryan Murr, Branden Berns</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">E-mail:</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If to a Purchaser:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">To the address set forth under such Purchaser&#146;s name on Annex A hereto;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">or such other address as may be designated in writing hereafter, in the same manner, by such Person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.4</B> <B>Amendments; Waivers; No Additional Consideration</B>. No provision of this Agreement may be waived, modified, supplemented or
amended except in a written instrument signed, in the case of an amendment, by the Company and the Purchasers who collectively have subscribed to purchase at least a majority in interest of the Securities, which majority must include each Purchaser
that has a Subscription Amount (including the Subscription Amounts of such Purchaser&#146;s affiliate and related funds) that is no less than $20,000,000, provided that (i)&nbsp;no amendment to Section&nbsp;4.4, Section&nbsp;4.6, Section&nbsp;4.10,
Section&nbsp;4.11, Section&nbsp;4.12, Section&nbsp;4.14, Section&nbsp;4.15, this Section&nbsp;6.4 or Section&nbsp;6.18 may be made without the consent of each Purchaser, or, in the case of a waiver, by the party against whom enforcement of any such
waiver is sought and (ii)&nbsp;any proposed amendment that would, by its terms, have a disproportionate and materially adverse effect on any Purchaser shall require the consent of such Purchaser(s). No waiver of any default with respect to any
provision, condition or requirement of this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition or requirement hereof, nor shall any delay or omission
of either party to exercise any right hereunder in any manner impair the exercise of any such right. No consideration shall be offered or paid to any Purchaser to amend or consent to a waiver or modification of any provision of any Transaction
Document unless the same consideration is also offered to all Purchasers who then hold Securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.5</B> <B>Construction</B>. The
headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect any of the provisions hereof. The language used in this Agreement will be deemed to be the language chosen by the parties
to express their mutual intent, and no rules of strict construction will be applied against any party. This Agreement shall be construed as if drafted jointly by the parties, and no presumption or burden of proof shall arise favoring or disfavoring
any party by virtue of the authorship of any provisions of this Agreement or any of the Transaction Documents. As used in this Agreement, the words &#147;include&#148; and &#147;including,&#148; and variations thereof, shall not be deemed to be
terms of limitation, but rather shall be deemed to be followed by the words &#147;without limitation.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.6</B> <B>Successors and
Assigns</B>. The provisions of this Agreement shall inure to the benefit of and be binding upon the parties and their successors and permitted assigns. This Agreement, or any rights or obligations hereunder, may not be assigned by the Company
without the prior written consent of each Purchaser. Any Purchaser may assign its rights hereunder in whole or in part to any Person to whom such Purchaser assigns or transfers any Securities in compliance with the Transaction Documents and
applicable law, provided such transferee shall agree in writing to be bound, with respect to the transferred Securities, by the terms and conditions of this Agreement that apply to the Purchasers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.7</B> <B>No Third-Party Beneficiaries</B>. This Agreement is intended for the benefit of the parties hereto and their respective
successors and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other Person, except the Placement Agents are intended third-party beneficiaries of the representations and warranties in Article 3 and
Article 4, and of this Section&nbsp;6.7 and Section&nbsp;6.19. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.8</B> <B>Governing Law</B>. All questions concerning the construction, validity,
enforcement and interpretation of this Agreement shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of law thereof. Each party agrees that all
Proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this Agreement and any other Transaction Documents (whether brought against a party hereto or its respective Affiliates, employees or agents)
shall be commenced exclusively in the New York Courts. Each party hereto hereby irrevocably submits to the exclusive jurisdiction of the New York Courts for the adjudication of any dispute hereunder or in connection herewith or with any transaction
contemplated hereby or discussed herein (including with respect to the enforcement of any of the Transaction Documents), and hereby irrevocably waives, and agrees not to assert in any Proceeding, any claim that it is not personally subject to the
jurisdiction of any such New York Court, or that such Proceeding has been commenced in an improper or inconvenient forum. Each party hereto hereby irrevocably waives personal service of process and consents to process being served in any such
Proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good
and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. <B>EACH PARTY HERETO HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT
PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.9</B> <B>Survival</B>. Subject to applicable statute of limitations, the representations, warranties, agreements and covenants contained
herein shall survive the Closing and the delivery of the Securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.10</B> <B>Execution</B>. This Agreement may be executed in two
or more counterparts, all of which when taken together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party, it being understood that both parties
need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission, or by <FONT STYLE="white-space:nowrap">e-mail</FONT> delivery of a &#147;.pdf&#148; format data file, or by any electronic signature
complying with the U.S. ESIGN Act of 2000 or the New York Electronic Signatures and Records Act, such signature shall create a legally valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same
force and effect as if such facsimile or &#147;.pdf&#148; signature page were an original thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.11</B> <B>Severability</B>. If
any provision of this Agreement is held to be invalid or unenforceable in any respect, the validity and enforceability of the remaining terms and provisions of this Agreement shall not in any way be affected or impaired thereby and the parties will
attempt to agree upon a valid and enforceable provision that is a reasonable substitute therefor, and upon so agreeing, shall incorporate such substitute provision in this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.12</B> <B>Rescission and Withdrawal Right</B>. Notwithstanding anything to the contrary contained in (and without limiting any similar
provisions of) the Transaction Documents, whenever any Purchaser exercises a right, election, demand or option under a Transaction Document and the Company does not timely perform its related obligations within the periods therein provided, then
such Purchaser may rescind or withdraw, in its sole discretion from time to time upon written notice to the Company, any relevant notice, demand or election in whole or in part without prejudice to its future actions and rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.13</B> <B>Replacement of Securities</B>. If any certificate or instrument evidencing any Securities or Conversion Shares is mutilated,
lost, stolen or destroyed, the Company may issue or cause to be issued in exchange and substitution for and upon cancellation thereof, or in lieu of and substitution therefor, a new certificate or instrument, but only upon receipt of evidence
reasonably satisfactory to the Company and the Transfer Agent of such loss, theft or destruction and the execution by the holder thereof of a customary lost certificate affidavit of that fact and an agreement to indemnify and hold harmless the
Company and the Transfer Agent for any losses in connection therewith or, if required by the Transfer Agent, a bond in such form and amount as is required by the Transfer Agent. The applicants for a new certificate or instrument under such
circumstances shall also pay any reasonable third-party costs associated with the issuance of such replacement Securities or Conversion Shares. If a replacement certificate or instrument evidencing any Securities or Conversion Shares is requested
due to a mutilation thereof, the Company may require delivery of such mutilated certificate or instrument as a condition precedent to any issuance of a replacement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.14</B> <B>Remedies</B>. In addition to being entitled to exercise all rights provided
herein or granted by Law, including recovery of damages, each of the Purchasers and the Company will be entitled to specific performance under the Transaction Documents, without the requirement of posting a bond. The parties agree that monetary
damages may not be adequate compensation for any loss incurred by reason of any breach of obligations described in the foregoing sentence and hereby agree to waive in any action for specific performance of any such obligation (other than in
connection with any action for a temporary restraining order) the defense that a remedy at law would be adequate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.15</B> <B>Payment
Set Aside</B>. To the extent that the Company makes a payment or payments to any Purchaser pursuant to any Transaction Document or a Purchaser enforces or exercises its rights thereunder, and such payment or payments or the proceeds of such
enforcement or exercise or any part thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside, recovered from, disgorged by or are required to be refunded, repaid or otherwise restored to the Company, a trustee,
receiver or any other person under any Law (including, without limitation, any bankruptcy law, state or federal law, common law or equitable cause of action), then to the extent of any such restoration the obligation or part thereof originally
intended to be satisfied shall be revived and continued in full force and effect as if such payment had not been made or such enforcement or setoff had not occurred. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.16</B> <B>Adjustments in Share Numbers and Prices</B>. In the event of any stock split, subdivision, dividend or distribution payable in
shares of Common Stock (or other securities or rights convertible into, or entitling the holder thereof to receive directly or indirectly shares of Common Stock), combination or other similar recapitalization or event occurring after the date hereof
and prior to the Closing, each reference in any Transaction Document to a number of shares or a price per share shall be deemed to be amended to appropriately account for such event. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.17</B> <B>Independent Nature of Purchasers&#146; Obligations and Rights</B>. The obligations of each Purchaser under any Transaction
Document are several and not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the performance of the obligations of any other Purchaser under any Transaction Document. The decision of each
Purchaser to purchase Securities pursuant to the Transaction Documents has been made by such Purchaser independently of any other Purchaser and independently of any information, materials, statements or opinions as to the business, affairs,
operations, assets, properties, liabilities, results of operations, condition (financial or otherwise) or prospects of the Company or any Subsidiary which may have been made or given by any other Purchaser or by any agent or employee of any other
Purchaser, and no Purchaser and any of its agents or employees shall have any liability to any other Purchaser (or any other Person) relating to or arising from any such information, materials, statement or opinions. Nothing contained herein or in
any Transaction Document, and no action taken by any Purchaser pursuant thereto, shall be deemed to constitute the Purchasers as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Purchasers
are in any way acting in concert or as a group (including, without limitation, a &#147;group&#148; within the meaning of Section&nbsp;13(d)(3) of the Exchange Act) with respect to such obligations or the transactions contemplated by the Transaction
Documents. Each Purchaser acknowledges that no other Purchaser has acted as agent for such Purchaser in connection with making its investment hereunder and that no Purchaser will be acting as agent of such Purchaser in connection with monitoring its
investment in the Securities or enforcing its rights under the Transaction Documents. Each Purchaser shall be entitled to independently protect and enforce its rights, including without limitation the rights arising out of this Agreement or out of
the other Transaction Documents, and it shall not be necessary for any other Purchaser to be joined as an additional party in any proceeding for such purpose. Each Purchaser has been represented by its own separate legal counsel in its review and
negotiation of the Transaction Documents. For reasons of administrative convenience only, Purchasers and their respective counsels may choose to communicate with the Company through Covington&nbsp;&amp; Burling LLP, counsel to the Placement Agents.
Each Purchaser acknowledges that Covington&nbsp;&amp; Burling LLP has rendered legal advice to the Placement Agents and not to such Purchaser in connection with the transactions contemplated hereby, and that each such Purchaser has relied for such
matters on the advice of its own respective counsel. The Company has elected to provide all Purchasers with the same terms and Transaction Documents for the convenience of the Company and not because it was required or requested to do so by any
Purchaser. It is expressly understood that each provision contained in this Agreement is between the Company and a Purchaser, solely, and not between the Company and the Purchasers collectively and not between and among the Purchasers. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.18</B> <B>Termination</B>. This Agreement may be terminated and the sale and purchase
of the Securities abandoned at any time prior to the Closing (i)&nbsp;automatically if the Closing has not been consummated on or prior to 5:00 P.M., New York City time, on the Outside Date or (ii)&nbsp;by a Purchaser (with respect to itself) if any
of the conditions set forth in Section&nbsp;5.1 shall have become incapable of fulfillment, and shall not have been waived by such Purchaser; <I>provided</I>, <I>however</I>, that the right to terminate this Agreement under clause (ii)&nbsp;shall
not be available to any Person whose failure to comply with its obligations under this Agreement has been the cause of or resulted in the failure of the Closing to occur on or before such time. Nothing in this Section&nbsp;6.18 shall be deemed to
release any party from any liability for any breach by such party of the terms and provisions of this Agreement or the other Transaction Documents or to impair the right of any party to compel specific performance by any other party of its
obligations under this Agreement or the other Transaction Documents. In the event of a termination pursuant to this Section&nbsp;6.18, the Company shall promptly notify all <FONT STYLE="white-space:nowrap">non-terminating</FONT> Purchasers. Upon a
termination in accordance with this Section&nbsp;6.18, the Company and the terminating Purchaser(s) shall not have any further obligation or liability (including arising from such termination) to the other, and no Purchaser will have any liability
to any other Purchaser under the Transaction Documents as a result therefrom. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.19</B> <B>Exculpation of the Placement Agents</B>.
Each party hereto agrees for the express benefit of the Placement Agents, their Affiliates and their representatives that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> Each
Placement Agent is acting as placement agent for the Company solely in connection with the sale of the Securities and is not acting in any other capacity and is not and shall not be construed as a fiduciary for any Purchaser, or any other person or
entity in connection with the sale of Securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> None of the Placement Agents nor any of their Affiliates or any of their
respective representatives (i)&nbsp;shall be liable for any improper payment made in accordance with the information provided by the Company; (ii)&nbsp;has made or will make any representation or warranty, express or implied, of any kind or
character, and has not provided any recommendation in connection with the purchase or sale of the Securities; (iii)&nbsp;has any responsibilities as to the validity, accuracy, completeness, value or genuineness, as of any date, of any information,
certificates or documentation delivered by or on behalf of the Company pursuant to this Agreement, the other Transaction Documents, or in connection with any of the transactions contemplated by such agreements; (iv)&nbsp;shall be liable or have any
obligation (including, without limitation, for or with respect to any losses, claims, damages, obligations, penalties, judgments, awards, liabilities, costs, expenses or disbursements incurred by any Purchaser, the Company or any other Person or
entity), whether in contract, tort or otherwise to any Purchaser or to any person claiming through such Purchaser, (A)&nbsp;for any action taken, suffered or omitted by any of them in good faith and reasonably believed to be authorized or within the
discretion or rights or powers conferred upon it by this Agreement, any other Transaction Document, (B)&nbsp;for anything which any of them may do or refrain from doing in connection with this Agreement, any other Transaction Document, or
(C)&nbsp;for anything otherwise in connection with the purchase and sale of the Securities or the issuance of the Conversion Shares, except in each case for such party&#146;s own gross negligence or willful misconduct. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.20</B> <B>Waivers of Conflicts</B>. Each party to this Agreement acknowledges that Gibson, Dunn&nbsp;&amp; Crutcher LLP, counsel for the
Company, may have in the past performed and may continue to perform legal services to one or more Purchasers or their affiliates in matters unrelated to the transactions described in this Agreement, including the representation of one or more
Purchasers or their affiliates in matters of a similar nature to such transactions. Accordingly, except as otherwise agreed between the Company and a Purchaser, each party to this Agreement hereby (a)&nbsp;acknowledges that they have had an
opportunity to ask for information relevant to this disclosure; and (b)&nbsp;gives its informed consent to Gibson, Dunn&nbsp;&amp; Crutcher LLP&#146;s representation of (i)&nbsp;one or more Purchasers or their affiliates in such unrelated matters
and (ii)&nbsp;the Company in connection with this Agreement and the transactions contemplated hereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.21</B> <B>Arm&#146;s Length
Transaction</B>. The Company acknowledges and agrees that (i)&nbsp;the transactions described in this Agreement are an <FONT STYLE="white-space:nowrap">arm&#146;s-length</FONT> commercial transaction between the parties, (ii)&nbsp;the Purchasers
have not assumed nor will they assume an advisory or fiduciary responsibility in the Company&#146;s favor with respect to any of the transactions contemplated by this Agreement or the process leading thereto, and the Purchasers have no obligation to
the Company with respect to the transactions contemplated by this Agreement except those obligations expressly set forth in this Agreement or the other Transaction Documents to which they are a party, and (iii)&nbsp;the Company&#146;s decision to
enter into the Transaction Documents has been based solely on the independent evaluation by the Company and its representatives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL></B><SMALL></SMALL>, the
parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>S<SMALL>PYRE</SMALL> T<SMALL>HERAPEUTICS</SMALL>, I<SMALL>NC</SMALL>.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ &#147;Cameron Turtle&#148;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Cameron Turtle</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL></B><SMALL></SMALL>, the
parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>P<SMALL>URCHASER</SMALL>:</B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AI Biotechnology LLC</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By Access Industries Management, LLC</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Its Manager</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000">/s/ &#147;Alejandro Moreno&#148;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Alejandro Moreno</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Executive Vice President</TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="85%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">/s/ &#147;Suzette Del Giudice&#148;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Suzette Del Giudice</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Executive Vice President</P></TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL></B><SMALL></SMALL>, the
parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>P<SMALL>URCHASER</SMALL>:</B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Fidelity Select Portfolios: Pharmaceuticals Portfolio</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000">/s/ &#147;Chris Maher&#148;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chris Maher</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Authorized Signatory</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL></B><SMALL></SMALL>, the
parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>P<SMALL>URCHASER</SMALL>:</B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Fidelity Select Portfolios: Biotechnology Portfolio</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000">/s/ &#147;Chris Maher&#148;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chris Maher</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Authorized Signatory</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL>, the parties hereto have
caused this Securities Purchase Agreement to be duly executed by their respect</B>ive authorized signatories as of the date first indicated above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>P<SMALL>URCHASER</SMALL>:</B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Fidelity Advisor Series VII: Fidelity Advisor Biotechnology Fund</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000">/s/ &#147;Chris Maher&#148;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chris Maher</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Authorized Signatory</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL></B><SMALL></SMALL>, the
parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>P<SMALL>URCHASER</SMALL>:</B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Fidelity Mt. Vernon Street Trust: Fidelity Series Growth Company Fund</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000">/s/ &#147;Chris Maher&#148;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chris Maher</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Authorized Signatory</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL></B><SMALL></SMALL>, the
parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>P<SMALL>URCHASER</SMALL>:</B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Fidelity Mt. Vernon Street Trust: Fidelity Growth Company Fund</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000">/s/ &#147;Chris Maher&#148;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chris Maher</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Authorized Signatory</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL></B><SMALL></SMALL>, the
parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>P<SMALL>URCHASER</SMALL>:</B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Fidelity Growth Company Commingled Pool</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">By: Fidelity Management
Trust Company, as Trustee</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000">/s/ &#147;Chris Maher&#148;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chris Maher</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Authorized Signatory</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL></B><SMALL></SMALL>, the
parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>P<SMALL>URCHASER</SMALL>:</B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Fidelity Mt. Vernon Street Trust : Fidelity Growth Company K6 Fund</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000">/s/ &#147;Chris Maher&#148;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chris Maher</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Authorized Signatory</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL></B><SMALL></SMALL>, the
parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>P<SMALL>URCHASER</SMALL>:</B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">VENROCK HEALTHCARE CAPITAL PARTNERS EG, L.P.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">By: VHCP Management EG, LLC, its general partner</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000">/s/ &#147;Sherman Souther&#148;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Sherman Souther</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Authorized Signatory</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL></B><SMALL></SMALL>, the
parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>P<SMALL>URCHASER</SMALL>:</B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">VENROCK HEALTHCARE CAPITAL PARTNERS III, L.P.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By: VHCP Management III, LLC, its general partner</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">By: VR Adviser, LLC, its manager</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000">/s/ &#147;Sherman Souther&#148;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Sherman Souther</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Authorized Signatory</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL></B><SMALL></SMALL>, the
parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>P<SMALL>URCHASER</SMALL>:</B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">VHCP <FONT STYLE="white-space:nowrap">CO-INVESTMENT</FONT> HOLDINGS III, LLC</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By: VHCP Management III, LLC, its manager</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">By: VR Adviser, LLC,
its manager</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000">/s/ &#147;Sherman Souther&#148;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Sherman Souther</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Authorized Signatory</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL></B><SMALL></SMALL>, the
parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>P<SMALL>URCHASER</SMALL>:</B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">PERCEPTIVE LIFE SCIENCES MASTER FUND, LTD.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000">/s/ &#147;James H. Mannix&#148;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">James H. Mannix</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Operating Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL></B><SMALL></SMALL>, the
parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>P<SMALL>URCHASER</SMALL>:</B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BRAIDWELL PARTNERS MASTER FUND LP</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">By: its Investment Manager, Braidwell LP</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000">/s/ &#147;Colin Bettison&#148;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Colin Bettison</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Head of Finance&nbsp;&amp; Operations</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000">/s/ &#147;Manish K. Mital&#148;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Manish K. Mital</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Operating Officer&nbsp;&amp; General Counsel</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL></B><SMALL></SMALL>, the
parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>P<SMALL>URCHASER</SMALL>:</B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">RTW MASTER FUND, LTD.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000">/s/ &#147;Darshan Patel&#148;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Darshan Patel</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">RTW INNOVATION MASTER FUND, LTD.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ &#147;Darshan Patel&#148;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Darshan Patel</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">RTW BIOTECH OPPORTUNITIES LTD</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">By:
RTW Investments, LP, its Investment Manager</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ &#147;Roderick Wong, M.D.&#148;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Roderick Wong, M.D.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Managing Partner</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL></B><SMALL></SMALL>, the
parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>P<SMALL>URCHASER</SMALL>:</B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">FAIRMOUNT HEALTHCARE FUND II L.P.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000">/s/ &#147;Peter Harwin&#148;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Peter Harwin</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Managing Member</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL></B><SMALL></SMALL>, the
parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>P<SMALL>URCHASER</SMALL>:</B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">BOXER CAPITAL, LLC</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000">/s/ &#147;Aaron Davis&#148;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Aaron Davis</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL></B><SMALL></SMALL>, the
parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>P<SMALL>URCHASER</SMALL>:</B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cormorant Global Healthcare Master Fund, LP</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">By: Cormorant Global
Healthcare GP, LLC</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000">/s/ &#147;Bihua Chen&#148;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Bihua Chen</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Managing Member</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL></B><SMALL></SMALL>, the
parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>P<SMALL>URCHASER</SMALL>:</B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Deep Track Biotechnology Master Fund, Ltd.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000">/s/ &#147;Nir Messafi&#148;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Nir Messafi</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Authorized Person</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL></B><SMALL></SMALL>, the
parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>P<SMALL>URCHASER</SMALL>:</B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BLACKSTONE ANNEX MASTER FUND L.P.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By: Blackstone Alternative Asset</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Management Associates LLC, its
general partner</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000">/s/ &#147;Jack Pitts&#148;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Jack Pitts</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Authorized Person</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL></B><SMALL></SMALL>, the
parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>P<SMALL>URCHASER</SMALL>:</B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">CDK ASSOCIATES, L.L.C.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000">/s/ &#147;Karen Cross&#148;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Karen Cross</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Treasurer</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL></B><SMALL></SMALL>, the
parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>P<SMALL>URCHASER</SMALL>:</B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">THIRD STREET HOLDINGS LLC</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">By: Pelican Management LLC, its Managing Member</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000">/s/ &#147;Peter P. D&#146;Angelo&#148;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Peter P. D&#146;Angelo</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Manager</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL></B><SMALL></SMALL>, the
parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>P<SMALL>URCHASER</SMALL>:</B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">BIOMEDICAL VALUE FUND, L.P.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000">/s/ &#147;Tavi Yehudai&#148;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Tavi Yehudai</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Managing Director of Great Point Partners, LLC (the Investment Manager)</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL></B><SMALL></SMALL>, the
parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>P<SMALL>URCHASER</SMALL>:</B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">BIOMEDICAL OFFSHORE VALUE FUND, LTD.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000">/s/ &#147;TAVI YEHUDAI&#148;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Tavi Yehudai</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Managing Director of Great Point Partners, LLC (the Investment Manager)</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL></B><SMALL></SMALL>, the
parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>P<SMALL>URCHASER</SMALL>:</B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">CHEYNE SELECT MASTER FUND ICAV &#150; CHEYNE GLOBAL EQUITY FUND</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000">/s/ &#147;TAVI YEHUDAI&#148;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Tavi Yehudai</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Managing Director of Great Point Partners, LLC (the <FONT STYLE="white-space:nowrap">Sub-Advisor)</FONT></TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL></B><SMALL></SMALL>, the
parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>P<SMALL>URCHASER</SMALL>:</B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Polar Capital LLP for and on behalf of Polar Capital Funds PLC &#150; Biotechnology Fund</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000">/s/ &#147;Nicholas Farren&#148;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Nicholas Farren</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">COO</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL></B><SMALL></SMALL>, the
parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>P<SMALL>URCHASER</SMALL>:</B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Affinity Healthcare Fund, LP</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000">/s/ &#147;Michael Cho&#148;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Michael Cho</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Managing Partner</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL></B><SMALL></SMALL>, the
parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>P<SMALL>URCHASER</SMALL>:</B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Woodline Master Fund LP</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000">/s/ &#147;Erin Mullen&#148;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Erin Mullen</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">GC&nbsp;&amp; CCO</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL></B><SMALL></SMALL>, the
parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>P<SMALL>URCHASER</SMALL>:</B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">COMMODORE CAPITAL MASTER LP</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000">/s/ &#147;R. Egen Atkinson, MD&#148;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">R. Egen Atkinson, MD</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Authorized Signatory</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ANNEX A </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE OF PURCHASERS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Purchaser Name and Address</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Beneficial <BR>Ownership<BR>Limitation</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Common<BR>Shares<BR>Purchased</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Preferred <BR>Shares <BR>Purchased</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate<BR>Purchase</B><br><B>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">AI Biotechnology LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.99</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,000,000.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fidelity Select Portfolios: Pharmaceuticals Portfolio</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">136,582</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,048,730.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fidelity Select Portfolios: Biotechnology Portfolio</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,334</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">500,010.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fidelity Advisor Series VII: Fidelity Advisor Biotechnology Fund</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">455,168</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,827,520.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fidelity Mt. Vernon Street Trust: Fidelity Series Growth Company Fund</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">98,104</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,471,560.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fidelity Mt. Vernon Street Trust: Fidelity Growth Company Fund</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">366,184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,492,760.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fidelity Growth Company Commingled Pool</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By: Fidelity Management Trust Company, as Trustee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">460,763</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,911,445.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fidelity Mt. Vernon Street Trust : Fidelity Growth Company K6 Fund</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">116,531</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,747,965.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Venrock Healthcare Capital Partners EG, L.P.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.99</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">247,625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35,089</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24,767,775.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Venrock<B> </B>Healthcare Capital Partners III, L.P.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.99</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,127</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">299</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">211,305.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">VHCP <FONT STYLE="white-space:nowrap">Co-Investment</FONT> Holdings III, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.99</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">248</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,120.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Perceptive Life Sciences Master Fund, Ltd.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.99</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">710,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,083</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,499,800.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Braidwell Partners Master Fund LP</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.99</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">515,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,000,000.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RTW Master Fund, LTD.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.99</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">206,121</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,853</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,003,615.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RTW Innovation Master Fund, LTD.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.99</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">169,192</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,983</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,927,680.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RTW Biotech Opportunities LTD</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.99</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">139,687</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,289</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,068,705.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fairmount Healthcare Fund II L.P.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,000,200.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Boxer Capital, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.99</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,417</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,000,200.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cormorant Global Healthcare Master Fund, LP</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.99</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,417</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,000,200.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deep Track Biotechnology Master Fund, Ltd.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.99</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">235,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,792</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,000,200.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Blackstone Annex Master Fund L.P.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.90</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">70,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,583</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,999,800.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CDK Associates, L.L.C.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.90</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">98,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,232</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,819,700.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Third Street Holdings LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.90</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">143</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">180,300.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Biomedical Value Fund, L.P.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.99</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">71,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,538</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,987,800.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Biomedical Offshore Value Fund, Ltd.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.99</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">986</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,274,100.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cheyne Select Master Fund ICAV &#150; Cheyne Global Equity Fund</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.99</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">237,900.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Polar Capital Funds PLC &#150; Biotechnology Fund</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.99</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">125,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,708</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,499,800.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Affinity Healthcare Fund, LP</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.99</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">83,334</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,083</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,499,810.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Woodline Master Fund LP</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.99</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,500,000.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commodore Capital Master LP</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.99</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,500,000.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.4
<SEQUENCE>10
<FILENAME>d518298dex44.htm
<DESCRIPTION>EX-4.4
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.4</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 4.4 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Execution Version </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REGISTRATION RIGHTS AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">This Registration Rights Agreement (this &#147;<I>Agreement</I>&#148;) is dated as of June&nbsp;22, 2023, by and among Aeglea BioTherapeutics,
Inc., a Delaware corporation (the &#147;<I>Company</I>&#148;), and the several purchasers signatory hereto (each, including its successors and assigns, a &#147;<I>Purchaser</I>&#148; and collectively, the &#147;<I>Purchasers</I>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">This Agreement is made pursuant to the Securities Purchase Agreement, dated as of the date hereof, between the Company and each Purchaser (the
&#147;<I>Purchase Agreement</I>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for
other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Company and each of the Purchasers agree as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.&nbsp;&nbsp;&nbsp;&nbsp;<U>Definitions</U>. Capitalized terms used and not otherwise defined herein that are defined in the Purchase
Agreement shall have the meanings given such terms in the Purchase Agreement. As used in this Agreement, the following terms shall have the following meanings: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<I>Advice</I>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;6(d)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<I>Affiliate</I>&#148; means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or
is under common control with a Person, as such terms are used in and construed under Rule 405 of the Securities Act of 1933, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<I>Agreement</I>&#148; has the meaning set forth in the Preamble. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<I>Business Day</I>&#148; means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States
or any day on which banking institutions in the State of New York are authorized or required by law or other governmental action to close. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<I>Common Stock</I>&#148; means the Company&#146;s common stock, par value $0.0001 per share, and stock of any other class of securities
into which such securities may hereafter be reclassified or changed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<I>Company</I>&#148; has the meaning set forth in the
Preamble. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<I>Effective Date</I>&#148; means the date that the Registration Statement filed pursuant to
<U>Section</U><U></U><U>&nbsp;2(a)</U> is first declared effective by the Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<I>Effectiveness Deadline</I>&#148; means,
with respect to the Initial Registration Statement or the New Registration Statement, the thirtieth (30<SUP STYLE="font-size:75%; vertical-align:top">th</SUP>) calendar day following the Filing Deadline (or, in the event the Commission reviews and
has written comments to the Initial Registration Statement or the New Registration Statement, the sixtieth (60<SUP STYLE="font-size:75%; vertical-align:top">th</SUP>) calendar day following the Filing Deadline); provided, however, that if the
Company is notified by the Commission that the Initial Registration Statement or the New Registration Statement will not be reviewed or is no longer subject to further review and comments, the Effectiveness Deadline as to such Registration Statement
shall be the fifth (5<SUP STYLE="font-size:75%; vertical-align:top">th</SUP>) Trading Day following the date on which the Company is so notified if such date precedes the dates otherwise required above; provided, further, that if the Effectiveness
Deadline falls on a Saturday, Sunday or other day that the Commission is closed for business, the Effectiveness Deadline shall be extended to the next Business Day on which the Commission is open for business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<I>Effectiveness Period</I>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;2(b)</U>. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<I>Exchange Act</I>&#148; means the Securities Exchange Act of 1934, as amended, and
the rules and regulations promulgated thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<I>Filing Deadline</I>&#148; means, with respect to the Initial Registration
Statement required to be filed pursuant to <U>Section</U><U></U><U>&nbsp;2(a)</U>, the forty-fifth (45<SUP STYLE="font-size:75%; vertical-align:top">th</SUP>) calendar day following the Closing Date, provided, however, that if the Filing Deadline
falls on a Saturday, Sunday or other day that the Commission is closed for business, the Filing Deadline shall be extended to the next Business Day on which the Commission is open for business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<I>FINRA</I>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;3(i)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<I>Holder</I>&#148; or &#147;<I>Holders</I>&#148; means the holder or holders, as the case may be, from time to time of Registrable
Securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<I>Indemnified Party</I>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;5(c)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<I>Indemnifying Party</I>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;5(c)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<I>Initial Registration Statement</I>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;2(a)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<I>Losses</I>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;5(a)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<I>New Registration Statement</I>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;2(a)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<I>Person</I>&#148; means an individual or a corporation, partnership, trust, incorporated or unincorporated association, joint venture,
limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<I>Principal Market</I>&#148; means the Trading Market on which the Common Stock are primarily listed on and quoted for trading, which,
as of the Closing Date, shall be the Nasdaq Global Market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<I>Proceeding</I>&#148; means an action, claim, suit, investigation or
proceeding (including, without limitation, an investigation or partial proceeding, such as a deposition), whether commenced or threatened. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<I>Prospectus</I>&#148; means the prospectus included in a Registration Statement (including, without limitation, a prospectus that
includes any information previously omitted from a prospectus filed as part of an effective registration statement in reliance upon Rule 430B promulgated under the Securities Act), as amended or supplemented by any prospectus supplement, with
respect to the terms of the offering of any portion of the Registrable Securities covered by a Registration Statement, and all other amendments and supplements to the Prospectus, including post-effective amendments, and all material incorporated by
reference or deemed to be incorporated by reference in such Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<I>Purchase Agreement</I>&#148; has the meaning set forth
in the Recitals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<I>Purchaser</I>&#148; or &#147;<I>Purchasers</I>&#148; has the meaning set forth in the Preamble. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<I>Registrable Securities</I>&#148; means all of (i)&nbsp;the Shares, (ii)&nbsp;the Series A Preferred Stock issued pursuant to the
Purchase Agreement, (iii)&nbsp;any Common Stock issued on or around the date hereof pursuant to that certain Agreement and Plan of Merger, dated as of the date hereof, by and among the Company, Aspen Merger Sub I, Inc., a Delaware corporation and
wholly owned subsidiary of Parent, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Sequoia Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of Parent, and Spyre Therapeutics, Inc., and (iv)&nbsp;any securities issued or issuable upon any
stock split, dividend or other distribution, recapitalization or similar event with respect to the foregoing, provided that, with respect to a particular Holder, such Holder&#146;s Shares shall cease to be Registrable Securities upon the earlier to
occur of the following: (A)&nbsp;a sale pursuant to a Registration Statement or Rule 144 under the Securities Act (in which case, only such security sold by the Holder shall cease to be a Registrable Security); and (B)&nbsp;such Shares become
eligible for resale by the Holder under Rule 144 without the requirement for the Company to be in compliance with the current public information required thereunder and without volume or <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">manner-of-sale</FONT></FONT> restrictions, pursuant to a written opinion letter of counsel for the Company to such effect, addressed, delivered and reasonably acceptable to the Transfer Agent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<I>Registration Statements</I>&#148; means any one or more registration statements of the Company filed under the Securities Act that
cover the resale of any of the Registrable Securities pursuant to the provisions of this Agreement (including without limitation the Initial Registration Statement, any New Registration Statement and any Remainder Registration Statements),
amendments and supplements to such Registration Statements, including post-effective amendments, all exhibits and all material incorporated by reference or deemed to be incorporated by reference in such Registration Statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<I>Remainder Registration Statement</I>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;2(a)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<I>Rule 144</I>&#148; means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended from time
to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same effect as such Rule. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<I>Rule 172</I>&#148; means Rule 172 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended from time
to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same effect as such Rule. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<I>Rule 415</I>&#148; means Rule 415 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended from time
to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same effect as such Rule. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<I>Rule 424</I>&#148; means Rule 424 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended from time
to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same effect as such Rule. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<I>Rule 461</I>&#148; means Rule 461 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended from time
to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same effect as such Rule. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<I>SEC Guidance</I>&#148; means (i)&nbsp;any publicly-available written or oral guidance, comments, requirements or requests of the
Commission staff; provided, that any such oral guidance, comments, requirements or requests are reduced to writing by the Commission and (ii)&nbsp;the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<I>Securities Act</I>&#148; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<I>Selling Shareholder Questionnaire</I>&#148; means a questionnaire in the form attached as Annex B hereto, or such other form of
questionnaire or information provided to the Company in connection with the preparation of a Registration Statement hereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<I>Series A Preferred Stock</I>&#148; means the Series A <FONT
STYLE="white-space:nowrap">Non-Voting</FONT> Convertible Preferred Stock, par value $0.0001 per share, of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<I>Shares</I>&#148; means the shares of Common Stock which may be issued upon conversion of the Series A Preferred Stock held by
Purchasers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<I>Trading Day</I>&#148; means a day on which the Principal Market is open for business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<I>Trading Market</I>&#148; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on
the date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, or the New York Stock Exchange (or any successors to any of the foregoing). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.&nbsp;&nbsp;&nbsp;&nbsp;<U>Registration</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;On or prior to the Filing Deadline, the Company shall prepare and file with the Commission a Registration Statement
covering the resale of all of the Registrable Securities for an offering to be made on a continuous basis pursuant to Rule 415 (the &#147;<I>Initial Registration Statement</I>&#148;). The Initial Registration Statement shall be on Form <FONT
STYLE="white-space:nowrap">S-3</FONT> (except if the Company is then ineligible to register for resale the Registrable Securities on Form <FONT STYLE="white-space:nowrap">S-3,</FONT> in which case such registration shall be on such other form
available to register for resale the Registrable Securities as a secondary offering) subject to the provisions of <U>Section</U><U></U><U>&nbsp;2(c)</U> and shall contain (except if otherwise required pursuant to written comments received from the
Commission upon a review of such Registration Statement) the &#147;Plan of Distribution&#148; section substantially in the form attached hereto as <U>Annex A</U> (which may be modified to respond to comments, if any, provided by the Commission).
Notwithstanding the registration obligations set forth in this <U>Section</U><U></U><U>&nbsp;2</U>, in the event the Commission informs the Company that all of the Registrable Securities cannot, as a result of the application of Rule 415, be
registered for resale as a secondary offering on a single registration statement, the Company agrees to promptly (i)&nbsp;inform each of the Holders thereof and use its commercially reasonable efforts to file amendments to the Initial Registration
Statement as required by the Commission and/or (ii)&nbsp;withdraw the Initial Registration Statement and file a new registration statement (a &#147;<I>New Registration Statement</I>&#148;), in either case covering the maximum number of Registrable
Securities permitted to be registered by the Commission, on Form <FONT STYLE="white-space:nowrap">S-3</FONT> or, if the Company is ineligible to register the Registrable Securities on Form <FONT STYLE="white-space:nowrap">S-3,</FONT> such other form
available to register for resale the Registrable Securities as a secondary offering; <I>provided</I>, <I>however</I>, that prior to filing such amendment or New Registration Statement, the Company shall be obligated to use its commercially
reasonable efforts to advocate with the Commission for the registration of all of the Registrable Securities in accordance with the SEC Guidance, including without limitation, the Securities Act Rules Compliance and Disclosure Interpretations
Question 612.09. Notwithstanding any other provision of this Agreement, if the Commission or any SEC Guidance sets forth a limitation of the number of Registrable Securities permitted to be registered on a particular Registration Statement as a
secondary offering (and notwithstanding that the Company used diligent efforts to advocate with the Commission for the registration of all or a greater number of Registrable Securities), unless otherwise directed in writing by a Holder as to its
Registrable Securities, the number of Registrable Securities to be registered on such Registration Statement will first be reduced by Registrable Securities not acquired pursuant to the Purchase Agreement (whether pursuant to registration rights or
otherwise), and second by Registrable Securities represented by Shares applied to the Holders on a pro rata basis based on the total number of Shares held by such Holders, subject to a determination by the Commission that certain Holders must be
reduced first based on the number of Shares held by such Holders. In the event of a cutback hereunder, the Company shall give the Holder at least one (1)&nbsp;Trading Day prior notice along with the calculations as to such Holder&#146;s allotment.
In the event the Company amends the Initial Registration Statement or files a New Registration Statement, as the case may be, in accordance with the foregoing, the Company will use </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
its commercially reasonable efforts to file with the Commission, as promptly as allowed by Commission or SEC Guidance provided to the Company or to registrants of securities in general, one or
more registration statements on Form <FONT STYLE="white-space:nowrap">S-3</FONT> or such other form available to register for resale those Registrable Securities that were not registered for resale on the Initial Registration Statement, as amended,
or the New Registration Statement (the &#147;<I>Remainder Registration Statements</I>&#148;). No Holder shall be named as an &#147;underwriter&#148; in any Registration Statement without such Holder&#146;s prior written consent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;The Company shall use its commercially reasonable efforts to cause each Registration Statement to be declared
effective by the Commission as soon as practicable and, with respect to the Initial Registration Statement or the New Registration Statement, as applicable, no later than the Effectiveness Deadline (including filing with the Commission a request for
acceleration of effectiveness in accordance with Rule 461 promulgated under the Securities Act), and shall use its commercially reasonable efforts to keep each Registration Statement continuously effective under the Securities Act until the earlier
of (i)&nbsp;such time as all of the Registrable Securities covered by such Registration Statement have been publicly sold by the Holders; or (ii)&nbsp;the date that all Registrable Securities covered by such Registration Statement may be sold by <FONT
STYLE="white-space:nowrap">non-affiliates</FONT> without volume or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">manner-of-sale</FONT></FONT> restrictions pursuant to Rule 144, without the requirement for the Company to be in
compliance with the current public information requirement under Rule 144 (the &#147;<I>Effectiveness Period</I>&#148;). The Company shall request effectiveness of a Registration Statement as of 4:00 P.M. New York City time on a Trading Day. The
Company shall promptly notify the Holders via <FONT STYLE="white-space:nowrap">e-mail</FONT> of the effectiveness of a Registration Statement or any post-effective amendment thereto on the same Trading Day that the Company telephonically confirms
effectiveness with the Commission, which date of confirmation shall initially be the date requested for effectiveness of such Registration Statement. The Company shall, by 9:30 A.M. New York City time on the first Trading Day after the Effective
Date, file a final Prospectus with the Commission, as required by Rule 424(b) and shall provide the Purchasers with copies of the final Prospectus to be used in connection with the sale or other disposition of the securities covered thereby. The
Company shall promptly inform each Holder in writing if, at any time during the Effectiveness Period, the Company does not satisfy the conditions specified in Rule 172 and, as a result thereof, the Holder is required to deliver a Prospectus in
connection with any disposition of Registrable Securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;Each Holder of Registrable Securities to be sold
agrees to furnish to the Company a completed Selling Shareholder Questionnaire not more than five (5)&nbsp;Trading Days following the date of this Agreement. At least 10 Trading Days prior to the first anticipated filing date of a Registration
Statement for any registration under this Agreement, the Company will notify each Holder of the information the Company requires from that Holder for inclusion in the Registration Statement other than the information contained in the Selling
Shareholder Questionnaire, if any, which shall be completed and delivered to the Company promptly upon request and, in any event, within three (3)&nbsp;Trading Days prior to the applicable anticipated filing date. Each Holder further agrees that it
shall not be entitled to be named as a selling securityholder in the Registration Statement or use the Prospectus for offers and resales of Registrable Securities at any time, unless such Holder has provided such information to the Company and
responded to any reasonable requests for further information as described in the previous sentence. Each Holder acknowledges and agrees that the information in the Selling Shareholder Questionnaire or request for further information as described in
this <U>Section</U><U></U><U>&nbsp;2(c)</U> will be used by the Company in the preparation of the Registration Statement and hereby consents to the inclusion of such information in the Registration Statement (subject to such Holder&#146;s right to
timely review the Registration Statement as set forth herein). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;In the event that Form <FONT
STYLE="white-space:nowrap">S-3</FONT> is not available for the registration of the resale of Registrable Securities hereunder, the Company shall (i)&nbsp;register the resale of the Registrable Securities on another appropriate form reasonably
acceptable to the Holders and (ii)&nbsp;undertake to register the Registrable Securities on Form <FONT STYLE="white-space:nowrap">S-3</FONT> promptly after such form is available, <I>provided</I> that the Company shall maintain the effectiveness of
the Registration Statement then in effect until such time as a Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> covering the Registrable Securities has been declared effective by the Commission. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;If (i)&nbsp;a Registration Statement covering the Registrable
Securities is not filed with the Commission on or prior to the Filing Deadline, the Company will make pro rata payments to each Purchaser then holding Registrable Securities, or (ii)&nbsp;following receipt of the Requisite Stockholder Approval,
(A)&nbsp;a Registration Statement covering the Registrable Securities is not declared effective by the Commission prior to the Effectiveness Deadline or (B)&nbsp;after a Registration Statement has been declared effective by the Commission,
(1)&nbsp;such Registration Statement ceases for any reason (including, without limitation, by reason of a stop order, or the Company&#146;s failure to update the Registration Statement) to remain continuously effective as to sell all Registrable
Securities for which it is required to be effective, (2)&nbsp;the Purchasers are not permitted to utilize the Prospectus therein to resell such Registrable Securities (other than during permitted suspension under Section&nbsp;6(d)), or (3)&nbsp;a
permitted suspension of the Registration Statement under Section&nbsp;6(d) exceeds the length set forth therein, (each of the foregoing events in clauses (i)&nbsp;and (ii), a &#147;<I>Registration Failure</I>&#148;), then, in addition to any other
rights the Purchasers may have hereunder or under applicable law, the Company will make pro rata payments to each Purchaser of then outstanding Registrable Securities, as liquidated damages and not as a penalty (the &#147;<I>Liquidated
Damages</I>&#148;), in an amount equal to one percent (1.0%) of the aggregate amount invested by such Purchaser for the Registrable Securities then held by such Purchaser for the initial day of a Registration Failure and for each thirty
(30)&nbsp;day period (or pro rata portion thereof with respect to a final period, if any) thereafter until the Registration Failure is cured. The Liquidated Damages shall be paid monthly within ten (10)&nbsp;Business Days of the date of such
Registration Failure and the end of each subsequent thirty (30)&nbsp;day period (or portion thereof with respect to a final period, if any) thereafter until the Registration Failure is cured. Such payments shall be made in cash to each Purchaser
then holding Registrable Securities. Interest shall accrue at the rate of one percent (1%) per month on any such liquidated damages payments that shall not be paid by the applicable payment date until such amount is paid in full. Notwithstanding the
foregoing, (I)&nbsp;no Liquidated Damages shall be payable with respect to any period after the expiration of the Effectiveness Period (as defined below) (it being understood that this sentence shall not relieve the Company of any Liquidated Damages
accruing prior to the expiration of the Effectiveness Period), (II) in no event shall the aggregate amount of Liquidated Damages payable to a Purchaser exceed, in the aggregate, five percent (5.0%) of the aggregate purchase price paid by such
Purchaser pursuant to the Purchase Agreement and (III)&nbsp;no Liquidated Damages shall accrue or be payable with respect to any reduction in the number or Registrable Securities to be included in a Registration Statement due to the application of
Rule 415 as set forth in Section&nbsp;2(a). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.&nbsp;&nbsp;&nbsp;&nbsp;<U>Registration Procedures</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">In connection with the Company&#146;s registration obligations hereunder, the Company shall: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;Not less than five (5)&nbsp;Trading Days prior to the filing of each Registration Statement and not less than two
(2)&nbsp;Trading Days prior to the filing of any related Prospectus or any amendment or supplement thereto (except for Annual Reports on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> and Quarterly Reports on Form
<FONT STYLE="white-space:nowrap">10-Q</FONT> and Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> and any similar or successor reports), (i) furnish to each Holder copies of such Registration Statement, Prospectus or amendment or
supplement thereto, as proposed to be filed, which documents will be subject to the review of such Holder (it being acknowledged and agreed that if a Holder does not object to or comment on the aforementioned documents within such five
(5)&nbsp;Trading Day or two (2)&nbsp;Trading Day period, as the case may be, then the Holder shall be deemed to have consented to and approved the use of such documents) and (ii)&nbsp;to the extent that a Holder is identified in the Registration
Statement as an &#147;underwriter&#148; (as defined in the Securities Act), use commercially reasonable efforts to cause its officers and directors, counsel and independent registered public accountants to respond to such inquiries as shall be
necessary, in the reasonable opinion of respective </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
counsel to each Holder, to conduct a reasonable investigation within the meaning of the Securities Act. The Company shall not file any Registration Statement or amendment or supplement thereto in
a form to which a Holder reasonably objects in good faith, provided that, such Holder notifies the Company of such objection in writing within the five (5)&nbsp;Trading Day or two (2)&nbsp;Trading Day periods described above, as applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;(i) Prepare and file with the Commission such amendments (including post-effective amendments) and supplements, to
each Registration Statement and the Prospectus used in connection therewith as may be necessary to keep such Registration Statement continuously effective as to the applicable Registrable Securities for its Effectiveness Period and prepare and file
with the Commission such additional Registration Statements in order to register for resale under the Securities Act all of the Registrable Securities; (ii)&nbsp;cause the related Prospectus to be amended or supplemented by any required Prospectus
supplement (subject to the terms of this Agreement), and, as so supplemented or amended, to be filed pursuant to Rule 424; (iii) respond as promptly as reasonably practicable to any comments received from the Commission with respect to each
Registration Statement or any amendment thereto and, as promptly as reasonably possible, provide the Holders true and complete copies of all correspondence from and to the Commission relating to such Registration Statement that pertains to the
Holders as &#147;Selling Stockholders&#148; but not any comments that would result in the disclosure to the Holders of material and <FONT STYLE="white-space:nowrap">non-public</FONT> information concerning the Company (unless such Holder consents to
receive such material and <FONT STYLE="white-space:nowrap">non-public</FONT> information); and (iv)&nbsp;comply with the provisions of the Securities Act and the Exchange Act with respect to the disposition of all Registrable Securities covered by a
Registration Statement until such time as all of such Registrable Securities shall have been disposed of (subject to the terms of this Agreement) in accordance with the intended methods of disposition by the Holders thereof as set forth in such
Registration Statement as so amended or in such Prospectus as so supplemented; <I>provided, however</I>, that each Purchaser shall be responsible for the delivery of the Prospectus to the Persons to whom such Purchaser sells any of the Registrable
Securities (including in accordance with Rule 172 under the Securities Act) to the extent required under the Securities Act, and each Purchaser agrees to dispose of Registrable Securities in compliance with the &#147;Plan of Distribution&#148;
described in the Registration Statement and otherwise in compliance with applicable federal and state securities laws. In the case of amendments and supplements to a Registration Statement which are required to be filed pursuant to this Agreement
(including pursuant to this Section&nbsp;3(b)) by reason of the Company filing a report on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> Form <FONT STYLE="white-space:nowrap">10-Q</FONT> or Form <FONT STYLE="white-space:nowrap">8-K</FONT> or
any analogous report under the Exchange Act, the Company shall have incorporated such report by reference into such Registration Statement, if applicable, or shall file such amendments or supplements with the Commission on the same day on which the
Exchange Act report which created the requirement for the Company to amend or supplement such Registration Statement was filed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;Notify the Holders of Registrable Securities to be sold (which notice shall, if given pursuant to clauses
(iii)&nbsp;through (vi) hereof, be accompanied by an instruction to suspend the use of the Prospectus until the requisite changes have been made, provided that the Company shall omit any material, <FONT STYLE="white-space:nowrap">non-public</FONT>
information relating to the Company and/or any of its subsidiaries) as promptly as reasonably practicable (and, in the case of (i)(A) below, not less than one (1)&nbsp;Trading Day prior to such filing) and (if requested by any such Person) confirm
such notice in writing no later than one (1)&nbsp;Trading Day following the day: (i)(A) when a Prospectus or any Prospectus supplement or post-effective amendment to a Registration Statement is proposed to be filed; (B)&nbsp;when the Commission
notifies the Company whether there will be a &#147;review&#148; of such Registration Statement and whenever the Commission comments in writing on any Registration Statement (in which case the Company shall provide to each of the Holders true and
complete copies of all comments that pertain to the Holders as a &#147;Selling Stockholder&#148; or to the &#147;Plan of Distribution&#148; and all written responses thereto, but not information that the Company believes would constitute material
and <FONT STYLE="white-space:nowrap">non-public</FONT> information); and (C)&nbsp;with respect to each Registration Statement or any post-effective amendment, when the same has become effective; (ii)
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of any request by the Commission or any other Federal or state governmental authority for amendments or supplements to a Registration Statement or Prospectus or for additional information that
pertains to the Holders as &#147;Selling Stockholders&#148; or the &#147;Plan of Distribution&#148;; (iii) of the issuance by the Commission or any other federal or state governmental authority of any stop order suspending the effectiveness of a
Registration Statement covering any or all of the Registrable Securities or the initiation of any Proceedings for that purpose; (iv)&nbsp;of the receipt by the Company of any notification with respect to the suspension of the qualification or
exemption from qualification of any of the Registrable Securities for sale in any jurisdiction, or the initiation or threatening of any Proceeding for such purpose; (v)&nbsp;of the occurrence of any event or passage of time that makes the financial
statements included or incorporated by reference in a Registration Statement ineligible for inclusion or incorporation by reference therein or any statement made in such Registration Statement or Prospectus or any document incorporated or deemed to
be incorporated therein by reference untrue in any material respect or that requires any revisions to such Registration Statement, Prospectus or other documents so that, in the case of such Registration Statement or the Prospectus, as the case may
be, it will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein (in the case of any Prospectus, form of prospectus or supplement thereto, in
light of the circumstances under which they were made), not misleading and (vi)&nbsp;of the occurrence or existence of any pending corporate development with respect to the Company that , upon the advice of legal counsel, the Company&#146;s board of
directors reasonably believes may be material and that, in the reasonable determination of the Company&#146;s board of directors, makes it not in the best interest of the Company to allow continued availability of a Registration Statement or
Prospectus, <I>provided</I> that, any and all such information shall remain confidential to each Holder until such information otherwise becomes public, unless disclosure by a Holder is required by law; and <I>provided</I>, <I>further</I>, that
notwithstanding each Holder&#146;s agreement to keep such information confidential, each such Holder makes no acknowledgement that any such information is material, <FONT STYLE="white-space:nowrap">non-public</FONT> information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;Use commercially reasonable efforts to avoid the issuance of, or, if issued, obtain the withdrawal of (i)&nbsp;any
order stopping or suspending the effectiveness of a Registration Statement, or (ii)&nbsp;any suspension of the qualification (or exemption from qualification) of any of the Registrable Securities for sale in any jurisdiction, as soon as practicable.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;If requested by a Holder, furnish to such Holder, without charge, at least one conformed copy of each
Registration Statement and each amendment thereto, including financial statements and schedules, all documents incorporated or deemed to be incorporated therein by reference to the extent requested by such Person, and all exhibits to the extent
requested by such Person (including those previously furnished or incorporated by reference) promptly after the filing of such documents with the Commission; <I>provided</I>, that the Company shall have no obligation to provide any document pursuant
to this clause that is available on the Commission&#146;s EDGAR system. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;Prior to any resale of Registrable
Securities by a Holder, use its commercially reasonable efforts to register or qualify or cooperate with the selling Holders in connection with the registration or qualification (or exemption from the registration or qualification) of the resale of
such Registrable Securities (or, in the case of qualification, of such Registrable Securities for the resale) by the Holder under the securities or blue sky laws of such jurisdictions within the United States as any Holder reasonably requests in
writing, to keep each registration or qualification (or exemption therefrom) effective during the Effectiveness Period and to do any and all other acts or things reasonably necessary to enable the disposition in such jurisdictions of the Registrable
Securities covered by each Registration Statement; <I>provided</I>, that the Company shall not be required to qualify generally to do business in any jurisdiction where it is not then so qualified, subject the Company to any material tax in any such
jurisdiction where it is not then so subject or file a general consent to service of process in any such jurisdiction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(g)&nbsp;&nbsp;&nbsp;&nbsp;Cooperate with such Holder to facilitate the timely preparation
and delivery of certificates or book entry statements, as applicable, representing Registrable Securities to be delivered to a transferee pursuant to the Registration Statement, which certificates or statements shall be free, to the extent permitted
by the Purchase Agreement and under law, of all restrictive legends, and to enable such Registrable Securities to be in such denominations and registered in such names as any such Holders may reasonably request. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(h)&nbsp;&nbsp;&nbsp;&nbsp;Following the occurrence of any event contemplated by <U>Section</U><U></U><U>&nbsp;3(c)</U>, as promptly as
reasonably practicable (taking into account the Company&#146;s good faith assessment of any adverse consequences to the Company and its shareholders of the premature disclosure of such event), prepare a supplement or amendment, including a
post-effective amendment, to the affected Registration Statements or a supplement to the related Prospectus or any document incorporated or deemed to be incorporated therein by reference, and file any other required document so that, as thereafter
delivered, no Registration Statement nor any Prospectus will contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein (in the case of any Prospectus,
form of prospectus or supplement thereto, in light of the circumstances under which they were made), not misleading. If the Company notifies the Holders in accordance with clauses (iii)&nbsp;through (vi) of <U>Section</U><U></U><U>&nbsp;3(c)</U>
above to suspend the use of any Prospectus until the requisite changes to such Prospectus have been made, then the Holders shall suspend use of such Prospectus. The Company will use its commercially reasonable efforts to ensure that the use of the
Prospectus may be resumed as promptly as is practicable. The Company shall be entitled to exercise its right under this <U>Section</U><U></U><U>&nbsp;3(h)</U> to suspend the availability of a Registration Statement and Prospectus in accordance with
the time periods set forth in <U>Section</U><U></U><U>&nbsp;6(d)</U>, which may be extended only in accordance with Section&nbsp;6(f). For the avoidance of doubt, the Company&#146;s rights under this <U>Section</U><U></U><U>&nbsp;3(h)</U> shall
include suspensions of availability arising from the filing of a post-effective amendment to a Registration Statement to update the Prospectus therein to include the information contained in the Company&#146;s Annual Report on <FONT
STYLE="white-space:nowrap">Form&nbsp;10-K,</FONT> which suspensions may extend for the amount of time reasonably required to respond to any comments of the staff of the Commission on such amendment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;The Company may require each selling Holder to furnish to the Company a certified statement as to (i)&nbsp;the
number of shares of Common Stock beneficially owned by such Holder and any Affiliate thereof, (ii)&nbsp;any Financial Industry Regulatory Authority (&#147;<I>FINRA</I>&#148;) affiliations, (iii)&nbsp;any natural persons who have the power to vote or
dispose of the Common Stock and (iv)&nbsp;any other information as may be requested by the Commission, FINRA or any state securities commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(j)&nbsp;&nbsp;&nbsp;&nbsp;The Company shall cooperate with any registered broker through which a Holder proposes to resell its Registrable
Securities in effecting a filing with FINRA pursuant to FINRA Rule 5110 as requested by any such Holder and the Company shall pay the filing fee required for the first such filing within two (2)&nbsp;Business Days of the request therefor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(k)&nbsp;&nbsp;&nbsp;&nbsp;If at any time the Commission takes the position that the offering of some or all of the Registrable Securities in
a Registration Statement is not eligible to be made on a delayed or continuous basis under the provisions of Rule 415 under the Securities Act or requires any Holder to be named as an &#147;underwriter,&#148; the Company shall use commercially
reasonable efforts to persuade the Commission that the offering contemplated by such Registration Statement is a valid secondary offering and not an offering &#147;by or on behalf of the issuer&#148; as defined in Rule 415 and that none of the
Holders is an &#147;underwriter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.&nbsp;&nbsp;&nbsp;&nbsp;<U>Registration Expenses</U>. All fees and expenses incident to the
Company&#146;s performance of or compliance with its obligations under this Agreement (excluding any underwriting discounts and selling commissions and all legal fees and expenses of legal counsel for any Holder) shall be borne by the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Company whether or not any Registrable Securities are sold pursuant to a Registration Statement. The fees and expenses referred to in the foregoing sentence shall include, without limitation,
(i)&nbsp;all registration and filing fees (including, without limitation, fees and expenses of the Company&#146;s counsel and independent registered public accountants (A)&nbsp;with respect to filings required to be made with any Trading Market on
which the Common Stock are then listed for trading, (B)&nbsp;with respect to compliance with applicable state securities or blue sky laws (including, without limitation, fees and disbursements of counsel for the Company in connection with blue sky
qualifications or exemptions of the Registrable Securities and determination of the eligibility of the Registrable Securities for investment under the laws of such jurisdictions as requested by the Holders) and (C)&nbsp;if not previously paid by the
Company in connection with <U>Section</U><U></U><U>&nbsp;3(j)</U> above, with respect to any filing that may be required to be made by any broker through which a Holder intends to make sales of Registrable Securities with FINRA pursuant to the FINRA
Rule 5110, so long as the broker is receiving no more than a customary brokerage commission in connection with such sale), (ii) printing expenses (including, without limitation, expenses of printing certificates for Registrable Securities and of
printing prospectuses if the printing of prospectuses is reasonably requested by the Holders of a majority of the Registrable Securities included in the Registration Statement), (iii) messenger, telephone and delivery expenses, (iv)&nbsp;fees,
expenses and disbursements of counsel for the Company, (v)&nbsp;Securities Act liability insurance, if the Company so desires such insurance, and (vi)&nbsp;fees and expenses of all other Persons retained by the Company in connection with the
registrations and consummation of the transactions contemplated by this Agreement. In addition, the Company shall be responsible for all of its internal expenses incurred in connection with the consummation of the transactions contemplated by this
Agreement (including, without limitation, all salaries and expenses of its officers and employees performing legal or accounting duties), the expense of any annual audit and the fees and expenses incurred in connection with the listing of the
Registrable Securities on any securities exchange as required hereunder. In no event shall the Company be responsible for any underwriting, broker or similar fees or commissions of any Holder or, except to the extent provided for in the Transaction
Documents, any legal fees or other costs of the Holders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.&nbsp;&nbsp;&nbsp;&nbsp;<U>Indemnification</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Indemnification by the Company</U>. The Company shall, notwithstanding any termination of this Agreement,
indemnify, defend and hold harmless each Holder and each of their respective officers, directors, agents, partners, members, managers, stockholders, Affiliates, investment advisers and employees of each of them, each Person who controls any such
Holder (within the meaning of Section&nbsp;15 of the Securities Act or Section&nbsp;20 of the Exchange Act) and the officers, directors, partners, members, managers, stockholders, agents, investment advisers and employees of each such controlling
Person, to the fullest extent permitted by applicable law, from and against any and all losses, claims, damages, liabilities, costs (including, without limitation, reasonable costs of preparation and investigation and reasonable attorneys&#146;
fees), expenses and disbursements (collectively, &#147;<I>Losses</I>&#148;), as incurred, that arise out of or are based upon (i)&nbsp;any untrue or alleged untrue statement of a material fact contained in any Registration Statement, any Prospectus
or any form of prospectus or in any amendment or supplement thereto or in any preliminary prospectus, or arising out of or relating to any omission or alleged omission to state a material fact required to be stated therein or necessary to make the
statements therein (in the case of any Prospectus or form of prospectus or supplement thereto, in light of the circumstances under which they were made) not misleading, or (ii)&nbsp;any violation or alleged violation by the Company or its agents of
the Securities Act, the Exchange Act or any state securities law or any rule or regulation thereunder, in connection with the performance of its obligations under this Agreement or any action or inaction required of the Company in connection with
any registration, except to the extent, but only to the extent, that (A)&nbsp;such untrue statements, alleged untrue statements, omissions or alleged omissions are based solely upon information regarding such Holder furnished in writing to the
Company by such Holder expressly for use therein, or to the extent that such information relates to such Holder or such Holder&#146;s proposed method of distribution of Registrable Securities and was reviewed and approved in writing by
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
such Holder expressly for use in the Registration Statement, such Prospectus or such form of Prospectus or in any amendment or supplement thereto (it being understood that each Holder has
approved <U>Annex A</U> hereto for this purpose), (B) in the case of an occurrence of an event of the type specified in <U>Section</U><U></U><U>&nbsp;3(c)(iii)</U><U>-</U><U>(vi)</U>, related to the use by a Holder of an outdated or defective
Prospectus after the Company has notified such Holder in writing that the Prospectus is outdated or defective and prior to the receipt by such Holder of the Advice contemplated and defined in <U>Section</U><U></U><U>&nbsp;6(d)</U> below, to the
extent that following the receipt of the Advice the misstatement or omission giving rise to such Loss would have been corrected or (C)&nbsp;to the extent that any such Losses arise out of the Purchaser&#146;s (or any other indemnified Person&#146;s)
failure to send or give a copy of the Prospectus or supplement (as then amended or supplemented), if required, pursuant to Rule 172 under the Securities Act (or any successor rule) to the Persons asserting an untrue statement or alleged untrue
statement or alleged untrue statement or omission or alleged omission at or prior to the written confirmation of the sale of Registrable Securities to such Person if such statement or omission was corrected in such Prospectus or supplement. The
Company shall notify the Holders promptly of the institution, threat or assertion of any Proceeding arising from or in connection with the transactions contemplated by this Agreement of which the Company is aware. Such indemnity shall remain in full
force and effect regardless of any investigation made by or on behalf of an Indemnified Party (as defined in <U>Section</U><U></U><U>&nbsp;5(c)</U>) and shall survive the transfer of the Registrable Securities by the Holders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Indemnification by Holders</U>. Each Holder shall, severally and not jointly, indemnify and hold harmless the
Company, its directors, officers, agents and employees, each Person who controls the Company (within the meaning of Section&nbsp;15 of the Securities Act and Section&nbsp;20 of the Exchange Act), and the directors, officers, agents or employees of
such controlling Persons, to the fullest extent permitted by applicable law, from and against all Losses, as incurred, arising out of or are based solely upon any untrue or alleged untrue statement of a material fact contained in any Registration
Statement, any Prospectus, or any form of prospectus, or in any amendment or supplement thereto or in any preliminary prospectus, or arising out of or relating to any omission or alleged omission of a material fact required to be stated therein or
necessary to make the statements therein (in the case of any Prospectus, or any form of prospectus or supplement thereto, in light of the circumstances under which they were made) not misleading (i)&nbsp;to the extent that such untrue statements or
omissions are based solely upon information regarding such Holder furnished in writing to the Company by such Holder expressly for use therein or (ii)&nbsp;to the extent that such information relates to such Holder or such Holder&#146;s proposed
method of distribution of Registrable Securities and was reviewed and approved in writing by such Holder expressly for use in a Registration Statement (it being understood that the Holder has approved <U>Annex A</U> hereto for this purpose), such
Prospectus or such form of Prospectus or in any amendment or supplement thereto or (iii)&nbsp;in the case of an occurrence of an event of the type specified in <U>Section</U><U></U><U>&nbsp;3(c)(iii)</U><U>-</U><U>(vi)</U>, to the extent related to
the use by such Holder of an outdated or defective Prospectus after the Company has notified such Holder in writing that the Prospectus is outdated or defective and prior to the receipt by such Holder of the Advice contemplated in
<U>Section</U><U></U><U>&nbsp;6(d)</U>. In no event shall the liability of any selling Holder hereunder be greater in amount than the dollar amount of the net proceeds received by such Holder upon the sale of the Registrable Securities giving rise
to such indemnification obligation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Conduct of Indemnification Proceedings</U>. If any Proceeding shall be
brought or asserted against any Person entitled to indemnity hereunder (an &#147;<I>Indemnified Party</I>&#148;), such Indemnified Party shall promptly notify the Person from whom indemnity is sought (the &#147;<I>Indemnifying Party</I>&#148;) in
writing, and the Indemnifying Party shall have the right to assume the defense thereof, including the employment of counsel reasonably satisfactory to the Indemnified Party and the payment of all reasonable fees, expenses and disbursements incurred
in connection with defense thereof; <I>provided</I>, that the failure of any Indemnified Party to give such notice shall not relieve the Indemnifying Party of its obligations or liabilities pursuant to this Agreement, except (and only) to the extent
that it shall be finally determined by a court of competent jurisdiction (which determination is not subject to appeal or further review) that such failure shall have materially and adversely prejudiced the Indemnifying Party. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">An Indemnified Party shall have the right to employ separate counsel in any such Proceeding
and to participate in the defense thereof, but the fees, expenses and disbursements of such counsel shall be at the expense of such Indemnified Party or Indemnified Parties unless: (1)&nbsp;the Indemnifying Party has agreed in writing to pay such
fees, expenses and amounts; (2)&nbsp;the Indemnifying Party shall have failed promptly to assume the defense of such Proceeding and to employ counsel reasonably satisfactory to such Indemnified Party in any such Proceeding; or (3)&nbsp;the named
parties to any such Proceeding (including any impleaded parties) include both such Indemnified Party and the Indemnifying Party, and such Indemnified Party shall have been advised by counsel that a conflict of interest exists if the same counsel
were to represent such Indemnified Party and the Indemnifying Party (in which case, if such Indemnified Party notifies the Indemnifying Party in writing that it elects to employ separate counsel at the expense of the Indemnifying Party, the
Indemnifying Party shall not have the right to assume the defense thereof and such counsel shall be at the expense of the Indemnifying Party); <I>provided</I>, that the Indemnifying Party shall not be liable for the fees, expenses and disbursements
of more than one separate firm of attorneys at any time for all Indemnified Parties. The Indemnifying Party shall not be liable for any settlement of any such Proceeding effected without its written consent, which consent shall not be unreasonably
withheld, delayed or conditioned. No Indemnifying Party shall, without the prior written consent of the Indemnified Party, effect any settlement of any pending Proceeding in respect of which any Indemnified Party is a party, unless such settlement
includes an unconditional release of such Indemnified Party from all liability on claims that are the subject matter of such Proceeding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Subject to the terms of this Agreement, all fees, expenses and disbursements of the Indemnified Party (including reasonable fees, expenses and
disbursements to the extent incurred in connection with investigating or preparing to defend such Proceeding in a manner not inconsistent with this <U>Section</U><U></U><U>&nbsp;5</U>) shall be paid to the Indemnified Party, as incurred, within 20
Trading Days of written notice thereof to the Indemnifying Party; <I>provided</I>, that the Indemnified Party shall promptly reimburse the Indemnifying Party for that portion of such fees, expenses and disbursements applicable to such actions for
which such Indemnified Party is finally judicially determined to not be entitled to indemnification hereunder. The failure to deliver written notice to the Indemnifying Party within a reasonable time of the commencement of any such action shall not
relieve such Indemnifying Party of any liability to the Indemnified Party under this <U>Section</U><U></U><U>&nbsp;5</U>, except to the extent that the Indemnifying Party is materially and adversely prejudiced in its ability to defend such action.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<U>Contribution</U>. If a claim for indemnification under <U>Section</U><U></U><U>&nbsp;5(a)</U> or
<U>5(b)</U> is unavailable to an Indemnified Party or insufficient to hold an Indemnified Party harmless for any Losses, then each Indemnifying Party, in lieu of indemnifying such Indemnified Party, shall contribute to the amount paid or payable by
such Indemnified Party as a result of such Losses, in such proportion as is appropriate to reflect the relative fault of the Indemnifying Party and Indemnified Party in connection with the actions, statements or omissions that resulted in such
Losses as well as any other relevant equitable considerations. The relative fault of such Indemnifying Party and Indemnified Party shall be determined by reference to, among other things, whether any action in question, including any untrue or
alleged untrue statement of a material fact or omission or alleged omission of a material fact, has been taken or made by, or relates to information supplied by, such Indemnifying Party or Indemnified Party, and the parties&#146; relative intent,
knowledge, access to information and opportunity to correct or prevent such action, statement or omission. The amount paid or payable by a party as a result of any Losses shall be deemed to include, subject to the limitations set forth in this
Agreement, any reasonable attorneys&#146; or other reasonable fees, expenses or disbursements incurred by such party in connection with any Proceeding to the extent such party would have been indemnified for such fees, expenses or disbursements if
the indemnification provided for in this <U>Section</U><U></U><U>&nbsp;5</U> was available to such party in accordance with its terms. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The parties hereto agree that it would not be just and equitable if contribution pursuant to
this <U>Section</U><U></U><U>&nbsp;5(d)</U> were determined by pro rata allocation or by any other method of allocation that does not take into account the equitable considerations referred to in the immediately preceding paragraph. Notwithstanding
the provisions of this <U>Section</U><U></U><U>&nbsp;5(d)</U>, (A) no Holder shall be required to contribute, in the aggregate, any amount in excess of the amount by which the net proceeds actually received by such Holder from the sale of the
Registrable Securities subject to the Proceeding exceeds the amount of any damages that such Holder has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission and (B)&nbsp;no contribution
will be made under circumstances where the maker of such contribution would not have been required to indemnify the Indemnified Party under the fault standards set forth in this <U>Section</U><U></U><U>&nbsp;5</U>. No person guilty of fraudulent
misrepresentation (within the meaning of Section&nbsp;11(f) of the Securities Act) shall be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The indemnity and contribution agreements contained in this <U>Section</U><U></U><U>&nbsp;5</U> are in addition to any liability that the Indemnifying Parties
may have to the Indemnified Parties and are not in diminution or limitation of the indemnification provisions under the Purchase Agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.&nbsp;&nbsp;&nbsp;&nbsp;<U>Miscellaneous</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Remedies</U>. In the event of a breach by the Company or by a Holder of any of their obligations under this
Agreement, each Holder or the Company, as the case may be, in addition to being entitled to exercise all rights granted by law and under this Agreement, including recovery of damages, will be entitled to seek specific performance of its rights under
this Agreement, without the requirement of posting a bond. The Company and each Holder agree that monetary damages would not provide adequate compensation for any losses incurred by reason of a breach by it of any of the provisions of this Agreement
and hereby further agrees that, in the event of any action for specific performance in respect of such breach, it shall waive the defense that a remedy at law would be adequate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>No Piggyback on Registrations; Prohibition on Filing Other Registration Statements</U>. Except and to the
extent specified in the Purchase Agreement, neither the Company nor any of its security holders (other than the Holders in such capacity pursuant hereto) may include securities of the Company in a Registration Statement other than the Registrable
Securities and the Company shall not prior to the Effective Date enter into any agreement providing any such right to any of its security holders. For the avoidance of doubt, the provisions of this Agreement shall not impact the terms of any <FONT
STYLE="white-space:nowrap">lock-up</FONT> agreement entered into by Purchaser for the benefit of the Company on or about the date hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Compliance</U>. Each Holder covenants and agrees that it will comply with the prospectus delivery requirements
of the Securities Act as applicable to it (unless an exemption therefrom is available) in connection with sales of Registrable Securities pursuant to the Registration Statement and shall sell the Registrable Securities only in accordance with a
method of distribution described in the Registration Statement, or pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<U>Discontinued Disposition</U>. By its acquisition of Registrable Securities, each Holder agrees that, upon
receipt of a notice from the Company of the occurrence of any event of the kind described in <U>Section</U><U></U><U>&nbsp;3(c)</U>(<U>iii</U>)-(<U>vi</U>), such Holder will forthwith discontinue disposition of such Registrable Securities under a
Registration Statement until it is advised in writing (the &#147;<I>Advice</I>&#148;) by the Company that the use of the applicable Prospectus (as it may have been supplemented or amended) may be resumed. The
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Company will use its commercially reasonable efforts to ensure that the use of the Prospectus may be resumed as promptly as is practicable. Notwithstanding anything herein to the contrary, no
Holder shall be required to discontinue disposition of Registrable Securities under a Registration Statement by virtue of the delivery by the Company of a notice of the occurrence of any event of the kind described in
<U>Section</U><U></U><U>&nbsp;3(c)</U>(<U>vi</U>) on more than two occasions or for more than 90 total calendar days, in each case during any twelve-month period, or for more than 45 calendar days during any
<FONT STYLE="white-space:nowrap">90-day</FONT> period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;<U>No Inconsistent Agreements</U>. Neither the Company
nor any of its subsidiaries has entered, as of the date hereof, nor shall the Company or any of its subsidiaries, on or after the date hereof, enter into any agreement with respect to its securities, that would have the effect of impairing the
rights granted to the Holders in this Agreement or otherwise conflicts with the provisions hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;<U>Amendments and Waivers</U>. The provisions of this Agreement, including the provisions of this sentence, may
not be amended, modified or supplemented, or waived unless the same shall be in writing and signed by the Company and Holders holding no less than a majority of the then outstanding Registrable Securities, provided that (i)&nbsp;any party may give a
waiver as to itself and (ii)&nbsp;any proposed amendment that would, by its terms, have a disproportionate and materially adverse effect on any Holder shall require the consent of such Holder(s). Notwithstanding the foregoing, (1)&nbsp;a waiver or
consent to depart from the provisions hereof with respect to a matter that relates exclusively to the rights of Holders and that does not directly or indirectly affect the rights of other Holders may be given by Holders of all of the Registrable
Securities to which such waiver or consent relates and (2)&nbsp;none of the definitions of Filing Deadline, Effectiveness Deadline or Effectiveness Period, Section&nbsp;2(e), Section&nbsp;3(c), Section&nbsp;5, Section&nbsp;6(d), or the provisions of
this sentence, may be amended, modified, or supplemented except with the consent of each Holder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(g)&nbsp;&nbsp;&nbsp;&nbsp;<U>Notices</U>. Any and all notices or other communications or deliveries required or permitted to be provided
hereunder shall be delivered as set forth in the Purchase Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(h)&nbsp;&nbsp;&nbsp;&nbsp;<U>Successors and Assigns</U>. This
Agreement shall inure to the benefit of and be binding upon the successors and permitted assigns of each of the parties and shall inure to the benefit of each Holder. Nothing in this Agreement, express or implied, is intended to confer upon any
party other than the parties hereto or their respective successors and assigns any rights, remedies, obligations, or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement. The Company may not assign its
rights (except by merger or in connection with another entity acquiring all or substantially all of the Company&#146;s assets) or obligations hereunder without the prior written consent of all the Holders of the then outstanding Registrable
Securities. Each Holder may assign its respective rights hereunder in the manner and to the Persons as permitted under the Purchase Agreement; provided in each case that (i)&nbsp;the Holder agrees in writing with the transferee or assignee to assign
such rights and related obligations under this Agreement, and for the transferee or assignee to assume such obligations, and a copy of such agreement is furnished to the Company within a reasonable time after such assignment, (ii)&nbsp;the Company
is, within a reasonable time after such transfer or assignment, furnished with written notice of the name and address of such transferee or assignee and the securities with respect to which such registration rights are being transferred or assigned,
(iii)&nbsp;at or before the time the Company received the written notice contemplated by clause (ii)&nbsp;of this sentence, the transferee or assignee agrees in writing with the Company to be bound by all of the provisions contained herein and
(iv)&nbsp;the transferee is an &#147;accredited investor,&#148; as that term is defined in Rule 501 of Regulation D. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;<U>Execution and Counterparts</U>. This Agreement may be executed in two or more counterparts, each of which when
so executed shall be deemed to be an original and, all of which taken together shall constitute one and the same Agreement and shall become effective when counterparts have been signed by each party and delivered to the other party, it being
understood that both parties need not </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
sign the same counterpart. Counterparts may be delivered via facsimile, electronic mail (including any electronic signature covered by the U.S. federal ESIGN Act of 2000, Uniform Electronic
Transactions Act, the Electronic Signatures and Records Act or other applicable law, e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and
effective for all purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(j)&nbsp;&nbsp;&nbsp;&nbsp;<U>Governing Law</U>. All questions concerning the construction, validity,
enforcement and interpretation of this Agreement shall be determined in accordance with the provisions of the Purchase Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(k)&nbsp;&nbsp;&nbsp;&nbsp;<U>Cumulative Remedies</U>. The remedies provided herein are cumulative and not exclusive of any other remedies
provided by law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(l)&nbsp;&nbsp;&nbsp;&nbsp;<U>Severability</U>. If any term, provision, covenant or restriction of this Agreement is
held by a court of competent jurisdiction to be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full force and effect and shall in no way be affected,
impaired or invalidated, and the parties hereto shall use their good faith reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by such term, provision, covenant or
restriction. It is hereby stipulated and declared to be the intention of the parties that they would have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be hereafter declared invalid,
illegal, void or unenforceable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(m)&nbsp;&nbsp;&nbsp;&nbsp;<U>Headings</U>. The headings in this Agreement are for convenience only and
shall not limit or otherwise affect the meaning hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(n)&nbsp;&nbsp;&nbsp;&nbsp;<U>Independent Nature of
Purchasers</U><U>&#146;</U><U> Obligations and Rights</U>. The obligations of each Purchaser under this Agreement are several and not joint with the obligations of any other Purchaser hereunder, and no Purchaser shall be responsible in any way for
the performance of the obligations of any other Purchaser hereunder. The decision of each Purchaser to purchase Securities pursuant to the Transaction Documents has been made by such Purchaser independently of any other Purchaser and independently
of any information, materials, statements or opinions as to the business, affairs, operations, assets, properties, liabilities, results of operations, condition (financial or otherwise) or prospects of the Company or any Subsidiary which may have
been made or given by any other Purchaser or by any agent or employee of any other Purchaser, and no Purchaser and any of its agents or employees shall have any liability to any other Purchaser (or any other Person) relating to or arising from any
such information, materials, statement or opinions. Nothing contained herein or in any Transaction Document, and no action taken by any Purchaser pursuant hereto or thereto, shall be deemed to constitute the Purchasers as a partnership, an
association, a joint venture or any other kind of entity, or create a presumption that the Purchasers are in any way acting in concert or as a group (including, without limitation, a &#147;group&#148; within the meaning of Section&nbsp;13(d)(3) of
the Exchange Act) with respect to such obligations or the transactions contemplated by the Transaction Documents. Each Purchaser acknowledges that no other Purchaser has acted as agent for such Purchaser in connection with making its investment
hereunder and that no Purchaser will be acting as agent of such Purchaser in connection with monitoring its investment in the securities or enforcing its rights under the Transaction Documents. Each Purchaser shall be entitled to independently
protect and enforce its rights, including, without limitation, the rights arising out of this Agreement or out of the other Transaction Documents, and it shall not be necessary for any other Purchaser to be joined as an additional party in any
Proceeding for such purpose. The Company acknowledges that each of the Purchasers has been provided with the same Registration Rights Agreement for the purpose of closing a transaction with multiple Purchasers and not because it was required or
requested to do so by any Purchaser. It is expressly understood that each provision contained in this Agreement is between the Company and a Purchaser, solely, and not between the Company and the Purchasers collectively and not between and among the
Purchasers. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(o)&nbsp;&nbsp;&nbsp;&nbsp;<U>Current Public Information</U>. With a view to making
available to the Holders the benefits of Rule 144 (or its successor rule) and any other rule or regulation of the Commission that may at any time permit the Holders to sell shares of Common Stock to the public without registration, the Company
covenants and agrees to use commercially reasonable efforts to: (i)&nbsp;make and keep adequate current public information available, as those terms are understood and defined in Rule 144, until the earlier of (A)&nbsp;six months after such date as
all of the Registrable Securities may be sold without restriction by the holders thereof pursuant to Rule 144 or any other rule of similar effect or (B)&nbsp;such date as there are no longer Registrable Securities; and (ii)&nbsp;file with the SEC in
a timely manner all reports and other documents required of the Company under the Exchange Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[REMAINDER OF PAGE INTENTIONALLY LEFT
BLANK] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Registration Rights Agreement as of the
date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">AEGLEA BIOTHERAPEUTICS, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By:
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Registration Rights Agreement as of the
date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">[NAME OF INVESTING ENTITY]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><U>ANNEX A </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">PLAN OF DISTRIBUTION<SUP STYLE="font-size:75%; vertical-align:top">1</SUP> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are registering the shares of common stock of Aeglea BioTherapeutics, Inc., par value of $0.0001 per share, or the Common Stock, which we
refer to herein as &#147;Shares,&#148; issued to the selling stockholders to permit the sale, transfer or other disposition of the Shares by the selling stockholders or their donees, pledgees, transferees or other <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">successors-in-interest</FONT></FONT> from time to time after the date of this prospectus. We will not receive any of the proceeds from the sale by the selling stockholders of the Shares. We will, or will procure to, bear
all fees and expenses incident to our obligation to register the Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selling stockholders may sell all or a portion of the Shares
beneficially owned by them and offered hereby from time to time directly or through one or more underwriters, broker-dealers or agents. If the Shares are sold through underwriters or broker-dealers, the selling stockholders will be responsible for
underwriting discounts (it being understood that the selling stockholders shall not be deemed to be underwriters solely as a result of their participation in this offering) or commissions or agent&#146;s commissions. The Shares may be sold on any
national securities exchange or quotation service on which the securities may be listed or quoted at the time of sale, in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market or in transactions
otherwise than on these exchanges or systems or in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market and in one or more transactions at fixed prices, at prevailing market prices at the time
of the sale, at varying prices determined at the time of sale, or at negotiated prices. These sales may be effected in transactions, which may involve crosses or block transactions. The selling stockholders may use any one or more of the following
methods when selling Shares: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">block trades in which the broker-dealer will attempt to sell the shares as agent but may position and resell a
portion of the block as principal to facilitate the transaction; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to or through underwriters or purchases by a broker-dealer as principal and resale by the broker-dealer for its
account; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an exchange distribution in accordance with the rules of the applicable exchange; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">privately negotiated transactions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">settlement of short sales entered into after the effective date of the registration statement of which this
prospectus is a part; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">broker-dealers may agree with the selling stockholders to sell a specified number of such Shares at a stipulated
price per Share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through the writing or settlement of options or other hedging transactions, whether such options are listed on an
options exchange or otherwise; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a combination of any such methods of sale; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other method permitted pursuant to applicable law. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selling stockholders also may resell all or a portion of the Shares in open market transactions in reliance upon Rule 144 under the
Securities Act, as amended, or the Securities Act, as permitted by that rule, or Section&nbsp;4(a)(1) under the Securities Act, if available, rather than under this prospectus, provided that they meet the criteria and conform to the requirements of
those provisions. </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Note to Draft</U>: Definitions to be conformed to resale <FONT STYLE="white-space:nowrap">S-3.</FONT>
</P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Broker-dealers engaged by the selling stockholders may arrange for other broker-dealers to
participate in sales. If the selling stockholders effect such transactions by selling Shares to or through underwriters, broker-dealers or agents, such underwriters, broker-dealers or agents may receive commissions in the form of discounts,
concessions or commissions from the selling stockholders or commissions from purchasers of the Shares for whom they may act as agent or to whom they may sell as principal. Such commissions will be in amounts to be negotiated, but, except as set
forth in a supplement to this Prospectus, in the case of an agency transaction will not be in excess of a customary brokerage commission in compliance with FINRA Rule 2121; and in the case of a principal transaction a markup or markdown in
compliance with FINRA <FONT STYLE="white-space:nowrap">IM-2121.01.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with sales of the Shares or otherwise, the
selling stockholders may enter into hedging transactions with broker-dealers or other financial institutions, which may in turn engage in short sales of the Shares in the course of hedging in positions they assume. The selling stockholders may also
sell Shares short and if such short sale takes place after the date that this Registration Statement is declared effective by the Commission, the selling stockholders may deliver Shares covered by this prospectus to close out short positions and to
return borrowed Shares in connection with such short sales. The selling stockholders may also loan or pledge Shares to broker-dealers that in turn may sell such Shares, to the extent permitted by applicable law. The selling stockholders may also
enter into option or other transactions with broker-dealers or other financial institutions or the creation of one or more derivative securities which require the delivery to such broker-dealer or other financial institution of shares offered by
this prospectus, which shares such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction). Notwithstanding the foregoing, the selling stockholders have been
advised that they may not use Shares the resale of which has been registered on this registration statement to cover short sales of our Common Stock made prior to the date the registration statement, of which this prospectus forms a part, has been
declared effective by the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selling stockholders may, from time to time, pledge or grant a security interest in some or all of the
Shares owned by them and, if they default in the performance of their secured obligations, the pledgees or secured parties may offer and sell the Shares from time to time pursuant to this prospectus or any amendment to this prospectus under Rule
424(b)(3) or other applicable provision of the Securities Act of 1933, amending, if necessary, the list of selling stockholders to include the pledgee, transferee or other successors in interest as selling stockholders under this prospectus. The
selling stockholders also may transfer and donate the Shares in other circumstances in which case the transferees, donees, pledgees or other successors in interest will be the selling beneficial owners for purposes of this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selling stockholders and any broker-dealer or agents participating in the distribution of the Shares may be deemed to be
&#147;underwriters&#148; within the meaning of Section&nbsp;2(11) of the Securities Act in connection with such sales. In such event, any commissions paid, or any discounts or concessions allowed to, any such broker-dealer or agent and any profit on
the resale of the shares purchased by them may be deemed to be underwriting commissions or discounts under the Securities Act. Selling Stockholders who are &#147;underwriters&#148; within the meaning of Section&nbsp;2(11) of the Securities Act will
be subject to the applicable prospectus delivery requirements of the Securities Act including Rule 172 thereunder and may be subject to certain statutory liabilities of, including but not limited to, Sections 11, 12 and 17 of the Securities Act and
Rule <FONT STYLE="white-space:nowrap">10b-5</FONT> under the Securities Exchange Act of 1934, as amended, or the Exchange Act. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each selling stockholder has informed the Company that it is not a registered broker-dealer
and does not have any written or oral agreement or understanding, directly or indirectly, with any person to distribute the Shares. Upon the Company being notified in writing by a selling stockholder that any material arrangement has been entered
into with a broker-dealer for the sale of Common Stock through a block trade, special offering, exchange distribution or secondary distribution or a purchase by a broker or dealer, a supplement to this prospectus will be filed, if required, pursuant
to Rule 424(b) under the Securities Act, disclosing (i)&nbsp;the name of each such selling stockholder and of the participating broker-dealer(s), (ii) the number of Shares involved, (iii)&nbsp;the price at which such the Shares were sold,
(iv)&nbsp;the commissions paid or discounts or concessions allowed to such broker-dealer(s), where applicable, (v)&nbsp;that such broker-dealer(s) did not conduct any investigation to verify the information set out or incorporated by reference in
this prospectus, and (vi)&nbsp;other facts material to the transaction. In no event shall any broker-dealer receive fees, commissions and markups, which, in the aggregate, would exceed eight percent (8.0%). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the securities laws of some U.S. states, the Shares may be sold in such states only through registered or licensed brokers or dealers.
In addition, in some U.S. states the Shares may not be sold unless such shares have been registered or qualified for sale in such state or an exemption from registration or qualification is available and is complied with. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There can be no assurance that any selling stockholder will sell any or all of the Shares registered pursuant to the shelf registration
statement, of which this prospectus forms a part. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each selling stockholder and any other person participating in such distribution will
be subject to applicable provisions of the Exchange Act and the rules and regulations thereunder, including, without limitation, to the extent applicable, Regulation M of the Exchange Act, which may limit the timing of purchases and sales of any of
the Shares by the selling stockholder and any other participating person. To the extent applicable, Regulation M may also restrict the ability of any person engaged in the distribution of the Shares to engage in market-making activities with respect
to the Shares. All of the foregoing may affect the marketability of the Shares and the ability of any person or entity to engage in market-making activities with respect to the Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will pay all expenses of the registration of the Shares pursuant to the registration rights agreement, including, without limitation,
Securities and Exchange Commission filing fees and expenses of compliance with state securities or &#147;blue sky&#148; laws; <I>provided</I>, <I>however</I>, that each selling stockholder will pay all underwriting discounts and selling commissions,
if any and any related legal expenses incurred by it. We will indemnify the selling stockholders against certain liabilities, including some liabilities under the Securities Act, in accordance with the registration rights agreement, or the selling
stockholders will be entitled to contribution. We may be indemnified by the selling stockholders against certain civil liabilities set forth in the registration rights agreement, including liabilities under the Securities Act, that may arise from
any written information furnished to us by the selling stockholders specifically for use in this prospectus, in accordance with the related registration rights agreements, or we may be entitled to contribution. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><U>ANNEX B </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SELLING STOCKHOLDER NOTICE AND QUESTIONNAIRE </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned holder of shares of the (i)&nbsp;common stock, par value $0.0001 per share, of Aeglea BioTherapeutics, Inc. (the
&#147;<I>Company</I>&#148;) and/or (ii)&nbsp;Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Convertible Preferred Shares, par value $0.0001 per share, of the Company issued pursuant to a certain Securities Purchase Agreement by and
among the Company and the Purchasers named therein, dated as of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2023 (the
&#147;<I>Agreement</I>&#148;), understands that the Company intends to file with the Securities and Exchange Commission a registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> (the &#147;<I>Resale Registration
Statement</I>&#148;) for the registration and the resale under Rule 415 of the Securities Act of 1933, as amended (the &#147;<I>Securities Act</I>&#148;), of the Registrable Securities in accordance with the terms of the Agreement. All capitalized
terms not otherwise defined herein shall have the meanings ascribed thereto in the Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to sell or otherwise dispose of
any Registrable Securities pursuant to the Resale Registration Statement, a holder of Registrable Securities generally will be required to be named as a selling stockholder in the related prospectus or a supplement thereto (as so supplemented, the
&#147;<I>Prospectus</I>&#148;), deliver the Prospectus to purchasers of Registrable Securities (including pursuant to Rule 172 under the Securities Act) and be bound by the provisions of the Agreement (including certain indemnification provisions,
as described below). <B>Holders must complete and deliver this Notice and Questionnaire in order to be named as selling stockholders in the Prospectus. Holders of Registrable Securities who do not complete, execute and return this Notice and
Questionnaire within five (5)</B><B></B><B>&nbsp;Trading Days following the date of the Agreement (1)</B><B></B><B>&nbsp;will not be named as selling stockholders in the Resale Registration Statement or the Prospectus and (2)</B><B></B><B>&nbsp;may
not use the Prospectus for resales of Registrable Securities</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain legal consequences arise from being named as a selling
stockholder in the Resale Registration Statement and the Prospectus. Holders of Registrable Securities are advised to consult their own securities law counsel regarding the consequences of being named or not named as a selling stockholder in the
Resale Registration Statement and the Prospectus. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTICE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned holder (the &#147;<I>Selling Stockholder</I>&#148;) of Registrable Securities hereby gives notice to the Company of its
intention to sell or otherwise dispose of Registrable Securities owned by it and listed below in Item (3), unless otherwise specified in Item (3), pursuant to the Resale Registration Statement. The undersigned, by signing and returning this Notice
and Questionnaire, understands and agrees that it will be bound by the terms and conditions of this Notice and Questionnaire and the Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned hereby provides the following information to the Company and represents and warrants that such information is accurate and
complete: </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>QUESTIONNAIRE </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Name. </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Full Legal Name of Selling Stockholder: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Full Legal Name of Registered Holder (if not the same as (a)&nbsp;above) through which Registrable Securities
Listed in Item 3 below are held: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Full Legal Name of Natural Control Person (which means a natural person who directly or indirectly alone or
with others has power to vote or dispose of the securities covered by the questionnaire): </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Address for Notices to Selling Stockholder: </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Telephone:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Fax:&nbsp;&nbsp;&nbsp;&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;</U> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Contact
Person:&nbsp;&nbsp;&nbsp;&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail</FONT> address of Contact
Person:<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Beneficial Ownership of Registrable Securities Issuable Pursuant to the Purchase Agreement:
</B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Type and Number of Registrable Securities beneficially owned and issued pursuant to the Agreement:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U></U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Number of Registrable Securities to be registered pursuant to this Notice for resale: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U></U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Broker-Dealer Status: </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Are you a broker-dealer? </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes &nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9744; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If &#147;yes&#148; to Section&nbsp;4(a), did you receive your Registrable Securities as compensation for
investment banking services to the Company? </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Note: If no, the Commission&#146;s staff has indicated that you should be identified as an underwriter in the Registration Statement. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Are you an affiliate of a broker-dealer? </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Note:&nbsp;&nbsp;&nbsp;&nbsp;If yes, provide a narrative explanation below: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If you are an affiliate of a broker-dealer, do you certify that you bought the Registrable Securities in the
ordinary course of business, and at the time of the purchase of the Registrable Securities to be resold, you had no agreements or understandings, directly or indirectly, with any person to distribute the Registrable Securities?
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Note: If no, the Commission&#146;s staff has indicated that you should be identified as an underwriter in the Registration Statement. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Beneficial Ownership of Other Securities of the Company Owned by the Selling Stockholder.
</B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Except as set forth below in this Item 5, the undersigned is not the beneficial or registered owner of any
securities of the Company other than the Registrable Securities listed above in Item 3. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Type and amount of other securities
beneficially owned: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
</P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Relationships with the Company: </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Except as set forth below, neither the undersigned nor any of its affiliates, officers, directors or principal equity holders (owners of 5%
of more of the equity securities of the undersigned) has held any position or office or has had any other material relationship with the Company (or its predecessors or affiliates) during the past three years. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">State any exceptions here: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Plan of Distribution: </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>The undersigned has reviewed the form of Plan of Distribution attached as Annex A to the Registration Rights Agreement, and hereby confirms
that, except as set forth below, the information contained therein regarding the undersigned and its plan of distribution is correct and complete. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">State any exceptions here: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">*********** </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned agrees to
promptly notify the Company of any inaccuracies or changes in the information provided herein that may occur subsequent to the date hereof and prior to the effective date of any applicable Resale Registration Statement. All notices hereunder and
pursuant to the Agreement shall be made in writing, by hand delivery, confirmed or facsimile transmission, first-class mail or air courier guaranteeing overnight delivery at the address set forth below. In the absence of any such notification, the
Company shall be entitled to continue to rely on the accuracy of the information in this Notice and Questionnaire. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By signing below, the undersigned
consents to the disclosure of the information contained herein in its answers to Items (1)&nbsp;through (7) above and the inclusion of such information in the Resale Registration Statement and the Prospectus. The undersigned understands that such
information will be relied upon by the Company in connection with the preparation or amendment of any such Registration Statement and the Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By
signing below, the undersigned acknowledges that it understands its obligation to comply, and agrees that it will comply, with the provisions of the Exchange Act and the rules and regulations thereunder, particularly Regulation M in connection with
any offering of Registrable Securities pursuant to the Resale Registration Statement. The undersigned also acknowledges that it understands that the answers to this Questionnaire are furnished for use in connection with Registration Statements filed
pursuant to the Registration Rights Agreement and any amendments or supplements thereto filed with the Commission pursuant to the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
undersigned hereby acknowledges and is advised of the following Question 239.10 of the Securities Act Rules Compliance and Disclosure Interpretations regarding short selling: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<I>An Issuer filed a Form <FONT STYLE="white-space:nowrap">S-3</FONT> registration statement for a secondary offering of common stock which is not yet
effective. One of the selling stockholders wanted to do a short sale of common stock &#147;against the box&#148; and cover the short sale with registered shares after the effective date. The issuer was advised that the short sale could not be made
before the registration statement become effective, because the shares underlying the short sale are deemed to be sold at the time such sale is made. There would, therefore, be a violation of Section</I><I></I><I>&nbsp;5 if the shares were
effectively sold prior to the effective date</I>.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By returning this Questionnaire, the undersigned will be deemed to be aware of the foregoing
interpretation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I confirm that, to the best of my knowledge and belief, the foregoing statements (including without limitation the answers to this
Questionnaire) are correct. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF the undersigned, by authority duly given, has caused this Questionnaire to be executed
and delivered either in person or by its duly authorized agent. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Dated:<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Beneficial
Owner:<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="43%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PLEASE FAX A COPY OF THE COMPLETED AND EXECUTED NOTICE AND QUESTIONNAIRE, AND RETURN THE ORIGINAL BY OVERNIGHT MAIL, TO:
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Courtney Tygesson </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Cooley LLP </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">110 N. Upper Wacker
Dr., Suite 4200, Chicago, IL 60606 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Telephone No.: (312) <FONT STYLE="white-space:nowrap">881-6500</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: Courtney Tygesson </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">E-mail:</FONT> CTygesson@cooley.com </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.5
<SEQUENCE>11
<FILENAME>d518298dex45.htm
<DESCRIPTION>EX-4.5
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.5</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 4.5 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AEGLEA BIOTHERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WARRANT TO PURCHASE COMMON STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Number of Shares: [&nbsp;&nbsp;&nbsp;&nbsp;] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">(subject to adjustment) </P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrant No. [&nbsp;&nbsp;&nbsp;&nbsp;]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">Original Issue Date: [&nbsp;&nbsp;&nbsp;&nbsp;], 202[&nbsp;&nbsp;&nbsp;&nbsp;]</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aeglea BioTherapeutics, Inc., a Delaware corporation (the &#147;<B>Company</B>&#148;), hereby certifies that, for good and
valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [&nbsp;&nbsp;&nbsp;&nbsp;] or its registered assigns (the &#147;<B>Holder</B>&#148;), is entitled, subject to the terms set forth below, to purchase from the
Company up to a total of [&nbsp;&nbsp;&nbsp;&nbsp;] shares of common stock, $0.0001 par value per share (the &#147;<B>Common Stock</B>&#148;), of the Company (each such share, a &#147;<B>Warrant Share</B>&#148; and all such shares, the
&#147;<B>Warrant Shares</B>&#148;) at an exercise price per share equal to $0.0001 per share (as adjusted from time to time as provided in Section&nbsp;9 herein, the &#147;<B>Exercise Price</B>&#148;) upon surrender of this Warrant to Purchase
Common Stock (including any Warrants to Purchase Common Stock issued in exchange, transfer or replacement hereof, the &#147;<B>Warrant</B>&#148;) at any time and from time to time on or after the date hereof (the &#147;<B>Original Issue
Date</B>&#148;), subject to the following terms and conditions: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.<I> Definitions</I>. For purposes of this Warrant, the following terms shall have the
following meanings: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) &#147;<B>Affiliate</B>&#148; means any Person directly or indirectly controlled by, controlling or under common control with, a
Holder, as such terms are used in and construed under Rule 405 under the Securities Act, but only for so long as such control shall continue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b)
&#147;<B>Commission</B>&#148; means the United States Securities and Exchange Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(c) &#147;<B>Closing Sale Price</B>&#148; means, for any
security as of any date, the last trade price for such security on the Principal Trading Market for such security, as reported by Bloomberg L.P., or, if such Principal Trading Market begins to operate on an extended hours basis and does not
designate the last trade price, then the last trade price of such security prior to 4:00 P.M., New York City time, as reported by Bloomberg L.P., or if the security is not listed for trading on a national securities exchange or other trading market
on the relevant date, the last quoted bid price for the security in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market on the relevant date as reported by OTC Markets Group Inc. (or a similar
organization or agency succeeding to its functions of reporting prices). If the Closing Sale Price cannot be calculated for a security on a particular date on any of the foregoing bases, the Closing Sale Price of such security on such date shall be
the fair market value as mutually determined by the Company and the Holder. If the Company and the Holder are unable to agree upon the fair market value of such security, then the Board of Directors of the Company shall use its good faith judgment
to determine the fair market value. The Board of Directors&#146; determination shall be binding upon all parties absent demonstrable error. All such determinations shall be appropriately adjusted for any stock dividend, stock split, stock
combination or other similar transaction during the applicable calculation period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) &#147;<B>Principal Trading Market</B>&#148; means the national
securities exchange or other trading market on which the Common Stock is primarily listed on and quoted for trading, which, as of the Original Issue Date, shall be the Nasdaq Global Market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(e) &#147;<B>Registration Statement</B>&#148; means the Company&#146;s Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> (File <FONT
STYLE="white-space:nowrap">No.&nbsp;333-239706),</FONT> declared effective on July&nbsp;14, 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(f) &#147;<B>Securities Act</B>&#148; means the
Securities Act of 1933, as amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(g) &#147;<B>Trading Day</B>&#148; means any weekday on which the Principal Trading Market is open for trading. If
the Common Stock is not listed or admitted for trading, &#147;Trading Day&#148; means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or any day on which banking institutions in New York City
are authorized or required by law or other governmental action to close. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(h) &#147;<B>Transfer Agent</B>&#148; means American Stock Transfer and Trust
Company, LLC, the Company&#146;s transfer agent and registrar for the Common Stock, and any successor appointed in such capacity. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2.<I> Issuance of Securities; Registration of Warrants</I>. The Warrant, as initially issued by the Company,
is offered and sold pursuant to the Registration Statement. As of the Original Issue Date, the Warrant Shares are issuable under the Registration Statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accordingly, the Warrant and, assuming issuance pursuant to the Registration Statement or an exchange meeting the requirements of Section&nbsp;3(a)(9) of the
Exchange Act as in effect on the Original Issue Date, the Warrant Shares are not &#147;restricted securities&#148; under Rule 144 promulgated under the Securities Act. The Company shall register ownership of this Warrant, upon records to be
maintained by the Company for that purpose (the &#147;<B>Warrant Register</B>&#148;), in the name of the record Holder (which shall include the initial Holder or, as the case may be, any assignee to which this Warrant is assigned hereunder) from
time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the
contrary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3.<I> Registration of Transfers</I>. Subject to compliance with all applicable securities laws, the Company shall, or will cause its Transfer
Agent to, register the transfer of all or any portion of this Warrant in the Warrant Register, upon surrender of this Warrant, and payment for all applicable transfer taxes (if any). Upon any such registration or transfer, a new warrant to purchase
Common Stock in substantially the form of this Warrant (any such new warrant, a &#147;<B>New Warrant</B>&#148;) evidencing the portion of this Warrant so transferred shall be issued to the transferee, and a New Warrant evidencing the remaining
portion of this Warrant not so transferred, if any, shall be issued to the transferring Holder. The acceptance of the New Warrant by the transferee thereof shall be deemed the acceptance by such transferee of all of the rights and obligations in
respect of the New Warrant that the Holder has in respect of this Warrant. The Company shall, or will cause its Transfer Agent to, prepare, issue and deliver at the Company&#146;s own expense any New Warrant under this Section&nbsp;3. Until due
presentment for registration of transfer, the Company may treat the registered Holder hereof as the owner and holder for all purposes, and the Company shall not be affected by any notice to the contrary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4.<I> Exercise and Duration of Warrants</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) All or any
part of this Warrant shall be exercisable by the registered Holder in any manner permitted by this Warrant at any time and from time to time on or after the Original Issue Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b) The Holder may exercise this Warrant by delivering to the Company (i)&nbsp;an exercise notice, in the form attached as Schedule 1 hereto (the
&#147;<B>Exercise Notice</B>&#148;), completed and duly signed, and (ii)&nbsp;payment of the Exercise Price for the number of Warrant Shares as to which this Warrant is being exercised (which may take the form of a &#147;cashless exercise&#148; if
so indicated in the Exercise Notice pursuant to Section&nbsp;10 below). The date on which such exercise notice is delivered to the Company (as determined in accordance with the notice provisions hereof) is an<B> &#147;Exercise Date</B>.&#148; The
Holder shall not be required to deliver the original Warrant in order to effect an exercise hereunder. Execution and delivery of the Exercise Notice shall have the same effect as cancellation of the original Warrant and issuance of a New Warrant
evidencing the right to purchase the remaining number of Warrant Shares, if any.<B> The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a
portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5.<I> Delivery of Warrant Shares</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) Upon exercise of
this Warrant, the Company shall promptly (but in no event later than three (3)&nbsp;Trading Days after the Exercise Date), upon the request of the Holder, credit such aggregate number of shares of Common Stock to which the Holder is entitled
pursuant to such exercise to the Holder&#146;s or its designee&#146;s balance account with The Depository Trust Company (&#147;<B>DTC</B>&#148;) through its Deposit Withdrawal Agent Commission system, or if the Transfer Agent is not participating in
the Fast Automated Securities Transfer Program (the &#147;<B>FAST Program</B>&#148;) or if the certificates are required to bear a legend regarding restriction on transferability, issue and dispatch by overnight courier to the address as specified
in the Exercise Notice, a certificate, registered in the Company&#146;s share register in the name of the Holder or its designee, for the number of shares of Common Stock to which the Holder is entitled pursuant to such exercise. The Holder, or any
natural person or legal entity (each, a &#147;<B>Person</B>&#148;) so designated by the Holder to receive Warrant Shares, shall be deemed to have become the holder of record of such Warrant Shares as of the Exercise Date, irrespective of the date
such Warrant Shares are credited to the Holder&#146;s DTC account or the date of delivery of the certificates evidencing such Warrant Shares, as the case may be. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b) To the extent permitted by law, the Company&#146;s obligations to issue and deliver Warrant Shares in
accordance with and subject to the terms hereof (including the limitations set forth in Section&nbsp;11 below) are absolute and unconditional, irrespective of any action or inaction by the Holder to enforce the same, any waiver or consent with
respect to any provision hereof, the recovery of any judgment against any Person or any action to enforce the same, or any setoff, counterclaim, recoupment, limitation or termination, or any breach or alleged breach by the Holder or any other Person
of any obligation to the Company or any violation or alleged violation of law by the Holder or any other Person, and irrespective of any other circumstance that might otherwise limit such obligation of the Company to the Holder in connection with
the issuance of Warrant Shares. Nothing herein shall limit the Holder&#146;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief
with respect to the Company&#146;s failure to timely deliver certificates representing shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6.<I> Charges, Taxes and Expenses</I>. Issuance and delivery of certificates for shares of Common Stock upon exercise of this Warrant shall be made without
charge to the Holder for any issue or transfer tax, transfer agent fee or other incidental tax or expense (excluding any applicable stamp duties) in respect of the issuance of such certificates, all of which taxes and expenses shall be paid by the
Company;<I> provided</I>,<I> however</I>, that the Company shall not be required to pay any tax that may be payable in respect of any transfer involved in the registration of any certificates for Warrant Shares or the Warrants in a name other than
that of the Holder or an Affiliate thereof. The Holder shall be responsible for all other tax liability that may arise as a result of holding or transferring this Warrant or receiving Warrant Shares upon exercise hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7.<I> Replacement of Warrant</I>. If this Warrant is mutilated, lost, stolen or destroyed, the Company shall issue or cause to be issued in exchange and
substitution for and upon cancellation hereof, or in lieu of and substitution for this Warrant, a New Warrant, but only upon receipt of evidence reasonably satisfactory to the Company of such loss, theft or destruction (in such case) and, in each
case, a customary and reasonable indemnity and surety bond, if requested by the Company. Applicants for a New Warrant under such circumstances shall also comply with such other reasonable regulations and procedures and pay such other reasonable
third-party costs as the Company may prescribe. If a New Warrant is requested as a result of a mutilation of this Warrant, then the Holder shall deliver such mutilated Warrant to the Company as a condition precedent to the Company&#146;s obligation
to issue the New Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">8.<I> Reservation of Warrant Shares</I>. The Company covenants that it will, at all times while this Warrant is outstanding,
reserve and keep available out of the aggregate of its authorized but unissued and otherwise unreserved Common Stock, solely for the purpose of enabling it to issue Warrant Shares upon exercise of this Warrant as herein provided, the number of
Warrant Shares that are initially issuable and deliverable upon the exercise of this entire Warrant, free from preemptive rights or any other contingent purchase rights of persons other than the Holder (taking into account the adjustments and
restrictions of Section&nbsp;9). The Company covenants that all Warrant Shares so issuable and deliverable shall, upon issuance and the payment of the applicable Exercise Price in accordance with the terms hereof, be duly and validly authorized,
issued and fully paid and <FONT STYLE="white-space:nowrap">non-assessable.</FONT> The Company will take all such action as may be reasonably necessary to assure that such shares of Common Stock may be issued as provided herein without violation of
any applicable law or regulation, or of any requirements of any securities exchange or automated quotation system upon which the Common Stock may be listed. The Company further covenants that it will not, without the prior written consent of the
Holder, take any actions to increase the par value of the Common Stock at any time while this Warrant is outstanding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">9.<I> Certain Adjustments</I>. The
Exercise Price and number of Warrant Shares issuable upon exercise of this Warrant are subject to adjustment from time to time as set forth in this Section&nbsp;9. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a)<U> Stock Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding, (i)&nbsp;pays a stock dividend on its Common Stock or
otherwise makes a distribution on any class of capital stock issued and outstanding on the Original Issue Date and in accordance with the terms of such stock on the Original Issue Date or as amended, as described in the Registration Statement, that
is payable in shares of Common Stock, (ii)&nbsp;subdivides </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
its outstanding shares of Common Stock into a larger number of shares of Common Stock, (iii)&nbsp;combines its outstanding shares of Common Stock into a smaller number of shares of Common Stock
or (iv)&nbsp;issues by reclassification of shares of capital stock any additional shares of Common Stock of the Company, then in each such case the Exercise Price shall be multiplied by a fraction, the numerator of which shall be the number of
shares of Common Stock outstanding immediately before such event and the denominator of which shall be the number of shares of Common Stock outstanding immediately after such event. Any adjustment made pursuant to clause (i)&nbsp;of this paragraph
shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution, <I>provided</I>, <I>however</I>, that if such record date shall have been fixed and such dividend is
not fully paid on the date fixed therefor, the Exercise Price shall be recomputed accordingly as of the close of business on such record date and thereafter the Exercise Price shall be adjusted pursuant to this paragraph as of the time of actual
payment of such dividends. Any adjustment pursuant to clause (ii)&nbsp;or (iii) of this paragraph shall become effective immediately after the effective date of such subdivision or combination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b)<U> Pro Rata Distributions</U>. If the Company, at any time while this Warrant is outstanding, distributes to all holders of Common Stock for no
consideration (i)&nbsp;evidences of its indebtedness, (ii)&nbsp;any security (other than a distribution of Common Stock covered by the preceding paragraph) or (iii)&nbsp;rights or warrants to subscribe for or purchase any security, or (iv)&nbsp;cash
or any other asset (in each case, a &#147;<B>Distribution</B>&#148;), other than a reclassification as to which Section&nbsp;9(c) applies, then in each such case, the Holder shall be entitled to participate in such Distribution to the same extent
that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the
ownership limitation set forth in Section&nbsp;11(a) hereof) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of Common Stock are to be determined
for the participation in such Distribution; <I>provided</I>, <I>however</I>, to the extent that the Holder&#146;s right to participate in any such Distribution would result in the Holder exceeding the ownership limitation set forth in
Section&nbsp;11(a) hereof, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any Common Stock as a result of such Distribution to such extent) and the portion of such
Distribution shall be held in abeyance for the benefit of the Holder until the earlier of (i)&nbsp;such time, if ever, as the delivery to such Holder of such portion would not result in the Holder exceeding the ownership limitation set forth in
Section&nbsp;11(a) hereof and (ii)&nbsp;such time as the Holder has exercised this Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(c)<U> Fundamental Transactions</U>. If, at any time while
this Warrant is outstanding (i)&nbsp;the Company effects any merger or consolidation of the Company with or into another Person, in which the Company is not the surviving entity and in which the stockholders of the Company immediately prior to such
merger or consolidation do not own, directly or indirectly, at least 50% of the voting power of the surviving entity immediately after such merger or consolidation, (ii)&nbsp;the Company effects any sale to another Person of all or substantially all
of its assets in one transaction or a series of related transactions, (iii)&nbsp;pursuant to any tender offer or exchange offer (whether by the Company or another Person), holders of capital stock tender shares representing more than 50% of the
voting power of the capital stock of the Company and the Company or such other Person, as applicable, accepts such tender for payment, (iv)&nbsp;the Company consummates a stock purchase agreement or other business combination (including, without
limitation, a reorganization, recapitalization, <FONT STYLE="white-space:nowrap">spin-off</FONT> or scheme of arrangement) with another Person whereby such other Person acquires more than the 50% of the voting power of the capital stock of the
Company (except for any such transaction in which the stockholders of the Company immediately prior to such transaction maintain, in substantially the same proportions, the voting power of such Person immediately after the transaction) or
(v)&nbsp;the Company effects any reclassification of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property (other than as a result of a
subdivision or combination of shares of Common Stock covered by Section&nbsp;9(a) above) (in any such case, a &#147;<B>Fundamental Transaction</B>&#148;), then following such Fundamental Transaction the Holder shall have the right to receive, upon
exercise of this Warrant, the same amount and kind of securities, cash or property as it would have been entitled to receive upon the occurrence of such Fundamental Transaction if it had been, immediately prior to such Fundamental Transaction, the
holder of the number of Warrant Shares then issuable upon exercise in full of this Warrant without regard to any limitations on exercise contained herein (the &#147;<B>Alternate Consideration</B>&#148;). The Company shall not effect any Fundamental
Transaction in which the Company is not the surviving entity or the Alternate Consideration includes securities of another Person unless (i)&nbsp;the Alternate Consideration is solely cash and the Company provides for the simultaneous &#147;cashless
exercise&#148; of this Warrant pursuant to Section&nbsp;10 below or (ii)&nbsp;prior to or simultaneously with the consummation thereof, any successor to the Company, surviving entity or </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
other Person (including any purchaser of assets of the Company) shall assume the obligation to deliver to the Holder such Alternate Consideration as, in accordance with the foregoing provisions,
the Holder may be entitled to receive, and the other obligations under this Warrant. The provisions of this paragraph (c)&nbsp;shall similarly apply to subsequent transactions analogous of a Fundamental Transaction type. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d)<U> Number of Warrant Shares</U>. Simultaneously with any adjustment to the Exercise Price pursuant to Section&nbsp;9 (including any adjustment to the
Exercise Price that would have been effected but for the final sentence in this paragraph (d)), the number of Warrant Shares that may be purchased upon exercise of this Warrant shall be increased or decreased proportionately, so that after such
adjustment the aggregate Exercise Price payable hereunder for the increased or decreased number of Warrant Shares shall be the same as the aggregate Exercise Price in effect immediately prior to such adjustment. Notwithstanding the foregoing, in no
event may the Exercise Price be adjusted below the par value of the Common Stock then in effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(e)<U> Calculations</U>. All calculations under this
Section&nbsp;9 shall be made to the nearest <FONT STYLE="white-space:nowrap">one-hundredth</FONT> of one cent or the nearest share, as applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(f)<U>
Notice of Adjustments</U>. Upon the occurrence of each adjustment pursuant to this Section&nbsp;9, the Company at its expense will, at the written request of the Holder, promptly compute such adjustment, in good faith, in accordance with the terms
of this Warrant and prepare a certificate setting forth such adjustment, including a statement of the adjusted Exercise Price and adjusted number or type of Warrant Shares or other securities issuable upon exercise of this Warrant (as applicable),
describing the transactions giving rise to such adjustments and showing in detail the facts upon which such adjustment is based. Upon written request, the Company will promptly deliver a copy of each such certificate to the Holder and to the
Company&#146;s transfer agent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(g)<U> Notice of Corporate Events</U>. If, while this Warrant is outstanding, the Company (i)&nbsp;declares a dividend or
any other distribution of cash, securities or other property in respect of its Common Stock, including, without limitation, any granting of rights or warrants to subscribe for or purchase any capital stock of the Company or any subsidiary,
(ii)&nbsp;authorizes or approves, enters into any agreement contemplating or solicits stockholder approval for any Fundamental Transaction or (iii)&nbsp;authorizes the voluntary dissolution, liquidation or winding up of the affairs of the Company,
then, except if such notice and the contents thereof shall be deemed to constitute material <FONT STYLE="white-space:nowrap">non-public</FONT> information, the Company shall deliver to the Holder a notice of such transaction at least ten
(10)&nbsp;days prior to the applicable record or effective date on which a Person would need to hold Common Stock in order to participate in or vote with respect to such transaction; <I>provided</I>, <I>however</I>, that the failure to deliver such
notice or any defect therein shall not affect the validity of the corporate action required to be described in such notice. In addition, if while this Warrant is outstanding, the Company authorizes or approves, enters into any agreement
contemplating or solicits stockholder approval for any Fundamental Transaction contemplated by Section&nbsp;9(c), other than a Fundamental Transaction under clause (iii)&nbsp;of Section&nbsp;9(c), the Company shall deliver to the Holder a notice of
such Fundamental Transaction at least ten (10)&nbsp;days prior to the date such Fundamental Transaction is consummated. Holder agrees to maintain any information disclosed pursuant to this Section&nbsp;9(g) in confidence until such information is
publicly available, and shall comply with applicable law with respect to trading in the Company&#146;s securities following receipt of any such information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">10.<I> Payment of Cashless Exercise Price</I>. Notwithstanding anything contained herein to the contrary, the Holder may, in its sole discretion, satisfy its
obligation to pay the Exercise Price through a &#147;cashless exercise,&#148; in which event the Company shall issue to the Holder the number of Warrant Shares in an exchange of securities effected pursuant to Section&nbsp;3(a)(9) of the Securities
Act as determined as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">X = Y <FONT STYLE="white-space:nowrap">[(A-B)/A]</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">where: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;X&#148; equals the number of Warrant Shares to be
issued to the Holder; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Y&#148; equals the total number of Warrant Shares with respect to which this Warrant is then being exercised; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;A&#148; equals the Closing Sale Price per share of Common Stock as of the Trading Day on the date
immediately preceding the Exercise Date; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;B&#148; equals the Exercise Price per Warrant Share then in effect on the Exercise Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of Rule 144 promulgated under the Securities Act, it is intended, understood and acknowledged that the Warrant Shares issued in such a
&#147;cashless exercise&#148; transaction shall be deemed to have been acquired by the Holder, and the holding period for the Warrant Shares shall be deemed to have commenced, on the date this Warrant was originally issued (<I>provided</I> that the
Commission continues to take the position that such treatment is proper at the time of such exercise). In the event that the Registration Statement or another registration statement registering the issuance of Warrant shares is, for any reason, not
effective at the time of exercise of this Warrant, then the Warrant may only be exercised through a cashless exercise, as set forth in this Section&nbsp;10. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In no event will the exercise of this Warrant be settled in cash. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">11.<I> Limitations on Exercise</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) Notwithstanding
anything to the contrary contained herein, the Company shall not effect any exercise of this Warrant, and the Holder shall not be entitled to exercise this Warrant for a number of Warrant Shares in excess of that number of Warrant Shares which, upon
giving effect or immediately prior to such exercise, would cause (i)&nbsp;the aggregate number of shares of Common Stock beneficially owned by the Holder, its Affiliates and any other Persons whose beneficial ownership of Common Stock would be
aggregated with the Holder&#146;s for purposes of Section&nbsp;13(d) of the Exchange Act to exceed 4.99% (the &#147;<B>Maximum Percentage</B>&#148;) of the total number of issued and outstanding shares of Common Stock of the Company following such
exercise, or (ii)&nbsp;the combined voting power of the securities of the Company beneficially owned by the Holder and its Affiliates and any other Persons whose beneficial ownership of Common Stock would be aggregated with the Holder&#146;s for
purposes of Section&nbsp;13(d) of the Exchange Act to exceed 4.99% of the combined voting power of all of the securities of the Company then outstanding following such exercise. For purposes of this Warrant, in determining the number of outstanding
shares of Common Stock, the Holder may rely on the number of outstanding shares of Common Stock as reflected in (x)&nbsp;the Company&#146;s most recent Form <FONT STYLE="white-space:nowrap">10-Q</FONT> or Form
<FONT STYLE="white-space:nowrap">10-K,</FONT> as the case may be, filed with the Commission prior to the date hereof, (y)&nbsp;a more recent public announcement by the Company or (z)&nbsp;any other notice by the Company or its transfer agent setting
forth the number of shares of Common Stock outstanding. Upon the written request of the Holder, the Company shall within three (3)&nbsp;Trading Days confirm in writing or by electronic mail to the Holder the number of shares of Common Stock then
outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder since the date as of which such
number of outstanding shares of Common Stock was reported. By written notice to the Company, the Holder may from time to time increase or decrease the Maximum Percentage to any other percentage, not in excess of 19.99%, specified in such notice;
<I>provided</I> that any such increase will not be effective until the sixty-first (61st) day after such notice is delivered to the Company. For purposes of this Section&nbsp;11(a), the aggregate number of shares of Common Stock or voting securities
beneficially owned by the Holder and its Affiliates and any other Persons whose beneficial ownership of Common Stock would be aggregated with the Holder&#146;s for purposes of Section&nbsp;13(d) of the Exchange Act shall include the shares of Common
Stock issuable upon the exercise of this Warrant with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which would be issuable upon (x)&nbsp;exercise of the remaining unexercised and <FONT
STYLE="white-space:nowrap">non-cancelled</FONT> portion of this Warrant by the Holder and (y)&nbsp;exercise or conversion of the unexercised, <FONT STYLE="white-space:nowrap">non-converted</FONT> or
<FONT STYLE="white-space:nowrap">non-cancelled</FONT> portion of any other securities of the Company that do not have voting power (including without limitation any securities of the Company which would entitle the holder thereof to acquire at any
time Common Stock, including without limitation any debt, preferred stock, right, option, warrant or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive,
Common Stock), is subject to a limitation on conversion or exercise analogous to the limitation contained herein and is beneficially owned by the Holder or any of its Affiliates and other Persons whose beneficial ownership of Common Stock would be
aggregated with the Holder&#146;s for purposes of Section&nbsp;13(d) of the Exchange Act. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b) This Section&nbsp;11 shall not restrict the number of shares of Common Stock which a Holder may receive
or beneficially own in order to determine the amount of securities or other consideration that such Holder may receive in the event of a Fundamental Transaction as contemplated in Section&nbsp;9(c) of this Warrant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">12.<I> No Fractional Shares</I>. No fractional Warrant Shares will be issued in connection with any exercise of this Warrant. In lieu of any fractional shares
that would otherwise be issuable, the number of Warrant Shares to be issued shall be rounded down to the next whole number. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">13.<I> Notices</I>. Any and
all notices or other communications or deliveries hereunder (including, without limitation, any Exercise Notice) shall be in writing and shall be deemed given and effective on the earliest of (i)&nbsp;the date of transmission, if such notice or
communication is delivered via facsimile or confirmed <FONT STYLE="white-space:nowrap">e-mail</FONT> prior to 5:30 P.M., New York City time, on a Trading Day, (ii)&nbsp;the next Trading Day after the date of transmission, if such notice or
communication is delivered via facsimile or confirmed <FONT STYLE="white-space:nowrap">e-mail</FONT> on a day that is not a Trading Day or later than 5:30 P.M., New York City time, on any Trading Day, (iii)&nbsp;the Trading Day following the date of
mailing, if sent by nationally recognized overnight courier service specifying next business day delivery, or (iv)&nbsp;upon actual receipt by the Person to whom such notice is required to be given, if by hand delivery. The addresses, facsimile
numbers and <FONT STYLE="white-space:nowrap">e-mail</FONT> addresses for such communications shall be: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If to the Company: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aeglea BioTherapeutics, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attention: Chief Financial Officer
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">221 Crescent Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Building 23, Suite 105 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Waltham, MA 02453 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Telephone: (617) <FONT
STYLE="white-space:nowrap">651-5940</FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Email: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If to
the Holder, to its address, facsimile number or <FONT STYLE="white-space:nowrap">e-mail</FONT> address set forth herein or on the books and records of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Or, in each of the above instances, to such other address, facsimile number or <FONT STYLE="white-space:nowrap">e-mail</FONT> address as the recipient party
has specified by written notice given to each other party at least five (5)&nbsp;days prior to the effectiveness of such change. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">14.<I> Warrant
Agent</I>. The Company shall initially serve as warrant agent under this Warrant. Upon ten (10)&nbsp;days&#146; notice to the Holder, the Company may appoint a new warrant agent. Any corporation into which the Company or any new warrant agent may be
merged or any corporation resulting from any consolidation to which the Company or any new warrant agent shall be a party or any corporation to which the Company or any new warrant agent transfers substantially all of its corporate trust or
shareholders services business shall be a successor warrant agent under this Warrant without any further act. Any such successor warrant agent shall promptly cause notice of its succession as warrant agent to be mailed (by first class mail, postage
prepaid) to the Holder at the Holder&#146;s last address as shown on the Warrant Register. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">15.<I> Miscellaneous</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a)<U> No Rights as a Stockholder</U>. The Holder, solely in such Person&#146;s capacity as a holder of this Warrant, shall not be entitled to vote or receive
dividends or be deemed the holder of share capital of the Company for any purpose, nor shall anything contained in this Warrant be construed to confer upon the Holder, solely in such Person&#146;s capacity as the Holder of this Warrant, any of the
rights of a stockholder of the Company or any right to vote, give or withhold consent to any corporate action (whether any reorganization, issue of stock, reclassification of stock, consolidation, merger, amalgamation, conveyance or otherwise),
receive notice of meetings, receive dividends or subscription rights, or otherwise, prior to the issuance to the Holder of the Warrant Shares which such Person is then entitled to receive upon the due exercise of this Warrant. In addition, nothing
contained in this Warrant shall be construed as imposing any liabilities on the Holder to purchase any securities (upon exercise of this Warrant or otherwise) or as a stockholder of the Company, whether such liabilities are asserted by the Company
or by creditors of the Company. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b)<U> Authorized Shares</U>. Except and to the extent as waived or consented to by the Holder, the Company
shall not by any action, including, without limitation, amending its certificate or articles of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary
action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or
appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will (a)&nbsp;not increase the par value of any Warrant Shares above the amount payable
therefor upon such exercise immediately prior to such increase in par value, (b)&nbsp;take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and
<FONT STYLE="white-space:nowrap">non-assessable</FONT> Warrant Shares upon the exercise of this Warrant, and (c)&nbsp;use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body
having jurisdiction thereof as may be necessary to enable the Company to perform its obligations under this Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(c)<U> Successors and Assigns</U>.
Subject to compliance with applicable securities laws, this Warrant may be assigned by the Holder. This Warrant may not be assigned by the Company without the written consent of the Holder, except to a successor in the event of a Fundamental
Transaction. This Warrant shall be binding on and inure to the benefit of the Company and the Holder and their respective successors and assigns. Subject to the preceding sentence, nothing in this Warrant shall be construed to give to any Person
other than the Company and the Holder any legal or equitable right, remedy or cause of action under this Warrant. This Warrant may be amended only in writing signed by the Company and the Holder, or their successors and assigns. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d)<U> Amendment and Waiver</U>. Except as otherwise provided herein, the provisions of the Warrants may be amended and the Company may take any action herein
prohibited, or omit to perform any act herein required to be performed by it, only if the Company has obtained the written consent of the Holder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(e)<U>
Acceptance</U>. Receipt of this Warrant by the Holder shall constitute acceptance of and agreement to all of the terms and conditions contained herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(f)<U> Governing Law; Jurisdiction</U>. ALL QUESTIONS CONCERNING THE CONSTRUCTION, VALIDITY, ENFORCEMENT AND INTERPRETATION OF THIS WARRANT SHALL BE GOVERNED
BY AND CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK WITHOUT REGARD TO THE PRINCIPLES OF CONFLICTS OF LAW THEREOF. EACH OF THE COMPANY AND THE HOLDER HEREBY IRREVOCABLY SUBMITS TO THE EXCLUSIVE JURISDICTION OF THE STATE
AND FEDERAL COURTS SITTING IN THE CITY OF NEW YORK, BOROUGH OF MANHATTAN, FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION HEREWITH OR WITH ANY TRANSACTION CONTEMPLATED HEREBY OR DISCUSSED HEREIN (INCLUDING WITH RESPECT TO THE
ENFORCEMENT OF ANY OF THE TRANSACTION DOCUMENTS), AND HEREBY IRREVOCABLY WAIVES, AND AGREES NOT TO ASSERT IN ANY SUIT, ACTION OR PROCEEDING, ANY CLAIM THAT IT IS NOT PERSONALLY SUBJECT TO THE JURISDICTION OF ANY SUCH COURT. EACH OF THE COMPANY AND
THE HOLDER HEREBY IRREVOCABLY WAIVES PERSONAL SERVICE OF PROCESS AND CONSENTS TO PROCESS BEING SERVED IN ANY SUCH SUIT, ACTION OR PROCEEDING BY MAILING A COPY THEREOF VIA REGISTERED OR CERTIFIED MAIL OR OVERNIGHT DELIVERY (WITH EVIDENCE OF DELIVERY)
TO SUCH PERSON AT THE ADDRESS IN EFFECT FOR NOTICES TO IT AND AGREES THAT SUCH SERVICE SHALL CONSTITUTE GOOD AND SUFFICIENT SERVICE OF PROCESS AND NOTICE THEREOF. NOTHING CONTAINED HEREIN SHALL BE DEEMED TO LIMIT IN ANY WAY ANY RIGHT TO SERVE
PROCESS IN ANY MANNER PERMITTED BY LAW. EACH OF THE COMPANY AND THE HOLDER HEREBY WAIVES ALL RIGHTS TO A TRIAL BY JURY. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(g)<U> Headings</U>. The headings
herein are for convenience only, do not constitute a part of this Warrant and shall not be deemed to limit or affect any of the provisions hereof. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(h)<U> Severability</U>. In case any one or more of the provisions of this Warrant shall be invalid or
unenforceable in any respect, the validity and enforceability of the remaining terms and provisions of this Warrant shall not in any way be affected or impaired thereby, and the Company and the Holder will attempt in good faith to agree upon a valid
and enforceable provision which shall be a commercially reasonable substitute therefor, and upon so agreeing, shall incorporate such substitute provision in this Warrant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Company has caused this Warrant to be duly executed by its authorized officer as of
the date first indicated above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">AEGLEA BIOTHERAPEUTICS, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name: Scott Burrows</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title: Chief Financial Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 1 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF EXERCISE NOTICE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[To be executed by the Holder to purchase shares of Common Stock under the Warrant] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(1) The undersigned is the Holder of
Warrant No.<U> </U>(the &#147;Warrant&#148;) issued by Aeglea BioTherapeutics, Inc., a Delaware corporation (the &#147;Company&#148;). Capitalized terms used herein and not otherwise defined herein have the respective meanings set forth in the
Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(2) The undersigned hereby exercises its right to purchase ___________Warrant Shares pursuant to the Warrant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(3) The Holder intends that payment of the Exercise Price shall be made as (check one): </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Cash Exercise </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;Cashless Exercise&#148; under Section&nbsp;10 of the Warrant </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(4) If the Holder has elected a Cash Exercise, the Holder shall pay the sum of $____________ in immediately available funds to the Company in accordance with
the terms of the Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(5) Pursuant to this Exercise Notice, the Company shall deliver to the Holder Warrant Shares determined in accordance with the
terms of the Warrant. The Warrant Shares shall be delivered to the following DWAC Account Number:___________________________ </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(6) By its delivery of this
Exercise Notice, the undersigned represents and warrants to the Company that in giving effect to the exercise evidenced hereby the Holder will not beneficially own in excess of the number of shares of Common Stock (as determined in accordance with
Section&nbsp;13(d) of the Securities Exchange Act of 1934, as amended) permitted to be owned under Section&nbsp;11(a) of the Warrant to which this notice relates. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="82%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dated:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name&nbsp;of Holder:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Signature must conform in all respects to name of Holder as specified on the face of the Warrant) </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>12
<FILENAME>d518298dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 5.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="38%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="23%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g518298g1220183454377.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gibson, Dunn&nbsp;&amp; Crutcher LLP</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">One Embarcadero Center</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">San&nbsp;Francisco,&nbsp;CA&nbsp;94111-3715</FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tel 415.393.8200</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">gibsondunn.com</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Client: 06759-00003</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">December&nbsp;22, 2023 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Spyre
Therapeutics, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">221 Crescent Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Building 23, Suite
105 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Waltham, MA 02453 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">Re:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Spyre Therapeutics, Inc. </P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have acted as counsel to Spyre
Therapeutics, Inc., a Delaware corporation (the &#147;<U>Company</U>&#148;), in connection with the preparation and filing with the Securities and Exchange Commission (the &#147;<U>Commission</U>&#148;) of a Registration Statement on Form <FONT
STYLE="white-space:nowrap">S-1</FONT> (the &#147;<U>Registration Statement</U>&#148;) pursuant to the Securities Act of 1933, as amended (the &#147;<U>Securities Act</U>&#148;), relating to the resale from time to time by the selling stockholders
named therein of up to 12,000,000 shares of the Company&#146;s common stock, par value $0.0001 per share (the &#147;Shares&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In arriving at the
opinion expressed below, we have examined originals, or copies certified or otherwise identified to our satisfaction as being true and complete copies of the originals, of the specimen common stock certificates and such other documents, corporate
records, certificates of officers of the Company and of public officials and other instruments as we have deemed necessary or advisable to enable us to render these opinions. In our examination, we have assumed the genuineness of all signatures, the
legal capacity and competency of all natural persons, the authenticity of all documents submitted to us as originals and the conformity to original documents of all documents submitted to us as copies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on the foregoing, and subject to the assumptions, exceptions, qualifications and limitations set forth herein, we are of the opinion that the Shares,
when issued against payment therefor as set forth in the Registration Statement, will be validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the filing of this opinion as an exhibit to the Registration Statement, and we further consent to the use of our name under the caption
&#147;Legal Matters&#148; in the Registration Statement and the prospectus that forms a part thereof. In giving these consents, we do not thereby admit that we are within the category of persons whose consent is required under Section&nbsp;7 of the
Securities Act or the rules and regulations of the Commission. </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Abu Dhabi &#149; Beijing
&#149; Brussels &#149; Century City &#149; Dallas &#149; Denver &#149; Dubai &#149; Frankfurt &#149; Hong Kong &#149; Houston &#149; London &#149; Los Angeles </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Munich &#149; New York &#149; Orange County &#149; Palo Alto &#149; Paris &#149; Riyadh &#149; San Francisco &#149; Singapore &#149; Washington,
D.C. </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g518298g1220183455639.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Very truly yours, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Gibson, Dunn&nbsp;&amp; Crutcher LLP </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>13
<FILENAME>d518298dex101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I)&nbsp;IS
NOT MATERIAL AND (II)&nbsp;WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BIOLOGICS MASTER SERVICES AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Biologics Master Services Agreement (this &#147;<B>Agreement</B>&#148;) is dated as of June&nbsp;20, 2022 (the &#147;<B>Effective
Date</B>&#148;) and is between <B>Paragon Therapeutics, Inc., </B>a Delaware corporation, with an office at 34 Cypress Rd., Arlington, MA 02474 (&#147;<B>Client</B>&#148;) and <B>WuXi Biologics (Hong Kong) Limited, </B>with its registered address at
Flat/RM826, 8/F Ocean Centre Harbour City, 5 Canton Road TST, Hong Kong (&#147;<B>Provider</B>&#148;), each of Client and Provider being a &#147;<B>Party</B>,&#148; and collectively the <B>&#147;Parties.&#148;</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A.&nbsp;&nbsp;&nbsp;&nbsp;Client discovers and develops biologics. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">B.&nbsp;&nbsp;&nbsp;&nbsp;Provider coordinates the biologics development and manufacturing services, including those provided by certain affiliated operating
companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">C.&nbsp;&nbsp;&nbsp;&nbsp;The Parties desire that Provider or its Affiliates provide services to Client on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">project-by-project</FONT></FONT> basis. The services for each project (the &#147;<B>Services</B>&#148;) will be provided pursuant to a separate and distinct contract (a &#147;<B>Work Order</B>&#148;) that incorporates
certain terms of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Parties therefore agree as follows: </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>DEFINITIONS </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Affiliate</B>&#148;<B> </B>of a Person means any other Person that directly or indirectly Controls, is
controlled by, or is under common Control with, the Person. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Applicable Law</B>&#148;<B> </B>means all applicable laws, regulations and current Good Manufacturing
Practice (cGMP) and other official guidelines and directives of any Authority relevant to the Services performed under this Agreement, and the supply, use, marketing or sale of the Product. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Authority</B>&#148;<B> </B>means any government regulatory authority responsible for granting
approvals for the performance of Services under this Agreement or for issuing regulations pertaining to the Manufacture and/or use of Product in the intended country of use, including the FDA. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Cell Line</B>&#148;<B> </B>means the cell line that has been developed to produce a Product.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Certificate of Analysis</B>&#148;<B> </B>means a certificate of analysis for testing of Specifications
of a Product in a form agreed to by the Parties. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Certificate of Compliance</B>&#148;<B> </B>means a document issued by WuXi Biologics attesting that a
Product Batch has been manufactured in compliance with cGMP (as applicable) and that Manufacturing Batch records have been reviewed and approved by WuXi Biologics&#146; Quality Assurance. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Certificate of Testing</B>&#148;<B> </B>means a certificate for testing of selected Specifications of
a Product in a form agreed by both Parties, for the selected testing performed by WuXi Biologics. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Confidential Information</B>&#148; of a Party (the &#147;<B>Disclosing Party</B>&#148;) means all
information and materials disclosed by or on behalf of the Party to the other Party (the &#147;<B>Receiving Party</B>&#148;)<B> </B>or its Related Persons (as defined below) in connection with this Agreement that is reasonably considered to be
confidential and is not generally available to the public, and permits the Disclosing Party to obtain a business advantage over any third party(ies) that do not know or use such information. The Confidential Information of both Parties includes the
existence, terms and objectives of this Agreement, and the nature of any dispute and the outcome of any arbitration proceedings arising out of or in connection with this Agreement. All data and information developed by either party relating
specifically to the Products, including Cell Line validation data generated by Provider under Work Orders, constitutes Client&#146;s Confidential Information. Confidential Information excludes: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">information that at the time of disclosure to Receiving Party is in the public domain (through no act or
omission of Receiving Party); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">information that was known by Receiving Party prior to receipt from Disclosing Party (as proven by Receiving
Party&#146;s written records); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">information that is disclosed to Receiving Party by a third party without an obligation of confidentiality and
having the legal right to do so (as proven by Receiving Party&#146;s written records); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">information that is independently developed by Receiving Party without any benefit of, and not being derived or
arising from, Confidential Information. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Control</B>&#148;<B> </B>over a Person means (a)&nbsp;owning 50% or more of the voting securities or
other ownership interests of the Person or (b)&nbsp;having the power to direct the management or policies of the Person. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Facility</B>&#148;<B> </B>means the facility(ies) of Provider identified in the applicable Work Order.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.11</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>FDA</B>&#148;<B> </B>means the United States Food and Drug Administration, and any successor agency
having substantially the same functions. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.12</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Intellectual Property</B>&#148;<B> </B>means patents and patent applications, trademarks and
applications, trade names, service marks, domain names, copyrights and copyright applications and registrations, schematics, industrial models, inventions, <FONT STYLE="white-space:nowrap">know-how,</FONT> trade secrets, computer software programs
and other intangible proprietary information including Confidential Information. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.13</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Person</B>&#148;<B> </B>means an individual, a corporation, a partnership, an association, a trust or
other entity or organization, including a government or political subdivision or an agency thereof. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.14</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Product</B>&#148;<B> </B>means the drug substance, drug product, or a part or derivative of the drug
substance or drug product, that is manufactured through the Services or to be produced by a Cell Line. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.15</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Specifications</B>&#148;<B> </B>means the list of tests, references to any analytical procedures and
appropriate acceptance criteria which are numerical limits, ranges or other criteria for tests described in order to establish a set of criteria to which Product at any stage of Manufacture should conform to be considered acceptable for its intended
use that are provided by or approved by Client, as such specifications are amended or supplemented from time to time by Client in writing. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>SERVICES </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Work Orders. </B>Provider shall provide the Services to Client pursuant to each Work Order that is entered
into during the term of this Agreement. The preferred form of Work Order is provided in <B>Exhibit A. </B>Each Work Order will automatically incorporate the terms of this Agreement and be a separate and distinct agreement. If there is a
contradiction between a provision of this Agreement and a Work Order, then the provision in this Agreement will take precedence unless the Work Order specifically states that it takes precedence over such named provision, in which case such
precedence shall be limited in application to the Services under such Work Order. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Manufacturing. </B>Both Parties will comply with the manufacturing terms in <B>Exhibit B.</B>
</P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Affiliates</B> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Provider may delegate or subcontract the Services, or any part thereof, to an Affiliate of Provider listed on
Exhibit C for the provision of Services described. If the Services are provided by an Affiliate, then references to Provider in this Agreement will be deemed to be references to the Affiliate with the necessary modifications. Provider shall be
liable for the performance of the Affiliate to the same extent as if the performance was that of Provider. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">An Affiliate of a Party may enter into a Work Order instead of the Party. If a Work Order is entered into by an
Affiliate, then references to the Party in this Agreement will be deemed to be references to the Affiliate with the necessary modifications. The Party shall be liable for the performance of the Affiliate to the same extent as if the performance was
that of the Party. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>CONTRACT PRICE; PAYMENT </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Contract Price: </B>Client shall pay Provider the undisputed fees in the amount and manner provided in the
applicable Work Order (the &#147;<B>Contract Price</B>&#148;)<B>. </B>The Contract Price may be charged in accordance with a <FONT STYLE="white-space:nowrap">lump-sum</FONT> or other pricing structure as agreed by the Parties. The Contract Price
will include [***]. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Expenses. </B>Client shall reimburse Provider for reasonable and documented expenses that are
(a)&nbsp;authorized by Client, (b)&nbsp;described in the applicable Work Order, or (c)&nbsp;described in this Agreement, including Sections [***]. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Milestones. </B>If a Work Order includes a payment for completion of a project stage or other milestone,
then Provider shall notify Client [***] after the milestone is achieved. Client will be deemed to have agreed that the milestone was achieved unless it notifies Provider otherwise within [***] of receiving such notice. Each milestone payment is
designed to reflect the fair value of the corresponding Services, and is not dependent on any other milestone unless otherwise specified in the Work Order. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Payment. </B>Client shall pay undisputed amounts in each of Provider&#146;s invoices within [***] of receipt
by wire transfer to the account designated by Provider. All payments made under this Agreement and any Work Order will be made [***]. The Contract Price is exclusive of, and Client shall pay, any applicable taxes (other than taxes on Provider&#146;s
income) and other fees of any nature imposed by or under the authority of any government authority. Client may withhold any payment that the Client disputes [***] provided that Client informs Provider of such dispute within the original time for
payment, in which case the Parties will meet to resolve the dispute [***]. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>No Clawbacks. </B>Other than as agreed by the parties, under this Agreement or an applicable Work Order, the
Contract Price and other payments under this Agreement and any applicable Work Order are <FONT STYLE="white-space:nowrap">non-cancelable</FONT> and <FONT STYLE="white-space:nowrap">non-refundable,</FONT> provided that Provider shall refund any <FONT
STYLE="white-space:nowrap">pre-payments</FONT> made for Services not performed. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Payment Default. </B>In the event of an overdue undisputed amount (a &#147;<B>Payment Default</B>&#148;)<B>,
</B>interest of [***]% will accrue [***] on the overdue payment as of the date of the Payment Default. If the Payment Default is not rectified within [***] after Client&#146;s receipt of notice of such Payment Default, then it will be deemed an
incurable material breach of the applicable Work Order, and Provider may terminate the Work Order pursuant to Section&nbsp;11.3(b). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Annual Review. </B>At [***], each Party to a Work Order may propose a prospective adjustment of the Contract
Price to reflect documented changes in pricing factors including foreign exchange fluctuation, cost reductions and efficiency increases, inflation or deflation and changes in the price of raw materials. The Parties shall negotiate [***] with the aim
of identifying a mutually acceptable amendment of the Work Order. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>PROVISION OF SERVICES </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Specifications. </B>Provider shall provide all the Services at the Facility or other facilities agreed by
both parties and in accordance with the Specifications of the applicable Work Order. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Qualifications. </B>Provider shall ensure that the persons that provide the Services (the
&#147;<B>Personnel</B>&#148;)<B> </B>(a) have the appropriate skills, training and experience and (b)&nbsp;are bound by confidentiality obligations consistent with the terms of this Agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Compliance. </B>Provider shall provide the Services in compliance with Applicable Law and applicable Good
Practice (&#147;<B>GxP</B>&#148;)<B> </B>guidelines in all material respects. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><FONT STYLE="white-space:nowrap">On-Site</FONT> Monitoring. </B>Representatives of Client may, [***], visit
the facilities where the Services are provided and consult informally during such visits with appropriate Personnel in order to monitor the Services. The representatives will be bound by rules applicable to the facilities and may, [***], be
prohibited from entering or only given limited access to certain areas within the facilities. Provider may require that Client or the representatives execute an agreement that regulates the representatives&#146; conduct during its visit. Client
shall be responsible for all expenses incurred in connection with such visits [***], and all its personnel must be subject to the same level of confidentiality as in this Agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Regulatory Inspections. </B>Provider will permit visits and/or inspections by regulatory Authorities of any
country as required by Applicable Law, and will permit Client or its agents to be present and participate in any visit or inspection by such regulatory Authority of the Facility (to the extent it relates in any way to any Product) or the
manufacturing process. Provider will give as much advance notice as possible to Client of any such visit or inspection. Provider will provide Client with a redacted (only to protect confidential information of Provider&#146;s other customers and
remove the contents not related to the Client&#146;s project ) copy of any report or other written communication received from such Authority in connection with such visit or inspection, and any written communication received from any regulatory
Authority relating to the Product, the Facility (if it relates to or affects the development and/or manufacture of Product) or the manufacturing process, within [***] after receipt, and will consult with, and unless legally prohibited by regulatory
Authorities, seek approval from, Client before responding to each such communication if time permits. Provider will provide Client with a copy of its final responses within [***] after submission. [***] </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Facility. </B>Provider will not change the location of such Facility or use any additional facility for the
performance of manufacturing Services under this Agreement without at least [***] prior written notice to, and prior written consent from, Client, which consent will not be unreasonably withheld or delayed (it being understood and agreed that Client
may withhold consent pending satisfactory completion of a quality assurance audit and/or regulatory impact assessment of the new location or additional facility, as the case may </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
be). Provider will maintain, [***], the Facility and all Equipment required for the Manufacture of Product in a state of repair and operating efficiency consistent with the requirements of cGMP
(if applicable) and all Applicable Law. Provider will be responsible for performing all validation of the Facility, Equipment and cleaning and maintenance processes employed in the Manufacturing Process in accordance with cGMP (if applicable),
Provider&#146;s SOPs, the applicable Quality Agreement (if any), and Applicable Law. Provider will be responsible for obtaining, [***], any Facility or other licenses or permits, and any regulatory and government approvals necessary for the
performance of Services by Provider under this Agreement. [***] Provider will provide Client with copies of all such approvals, and Client will have the right to use any and all information contained in such approvals in connection with regulatory
approval and/or commercial development of Product. </TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>SOURCING OF MATERIAL </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Materials. </B>Provider shall, [***], purchase all materials necessary for the Services (the
&#147;<B>Materials</B>&#148;)<B>. </B>If a Material is not commercially available, then Client may elect to (a)&nbsp;supply, [***], the Material to Provider; or (b)&nbsp;amend the applicable Work Order to permit the use of a commercially available
substitute. Provider shall perform the market research and propose a list of vendors in compliance with Applicable Law and applicable GxP in all material respects, [***]. Provider shall take the inventory risk of the selected materials, such as the
damages to pass through materials caused by improper storage or pollutions, [***]. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Client Materials. </B>If a Material is to be supplied by Client (a &#147;<B>Client Material</B>&#148;)<B>,
</B>then Client shall provide the Client Material [***] and provide such information as may be required by Provider or Applicable Law concerning the stability, storage and safety requirements of the Client Material. Provider shall ensure that the
Client Material will be (a)&nbsp;used solely for the purpose of providing the Services, (b)&nbsp;only distributed to Personnel on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">need-to-know</FONT></FONT> basis for the provision
of the Services and (c)&nbsp;preserved and protected in a manner consistent with the specifications of the applicable Work Order and any relevant standard operating procedures or other instructions provided by Client. Client will at all times retain
title to and ownership of the Client Materials, Product, any intermediates and components of Client Materials or Product, and any work in process at each and every stage of the Manufacturing Process. Provider will provide within the Facility an area
or areas where the Client Materials, Product, any intermediates and components of Client Materials or Product, and any work in process are segregated and stored in accordance with the Specifications and cGMP (if applicable), and in such a way as to
be able at all times during the period of the Agreement or applicable Work Order to clearly distinguish such materials from products and materials belonging to Provider, or held by it for a third party&#146;s account. Provider will ensure that
Client Materials (which are under Provider&#146;s control), Product, any intermediates and components of Product, and any work in process are free and clear of any liens or encumbrances arising from disputes with any third party. Provider will at
all times during the period of the Agreement or applicable Work Order </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
take such measures as are required to protect the Client Materials, Product, any intermediates and components of any Client Materials or Product, and any work in process from loss, damage and
theft at all stages of the Manufacturing Process. Client agrees that it is responsible to insure such items against theft, damage or loss and under no circumstances shall Provider be liable for loss or damage to any such items. The foregoing
agreement does not limit the Provider&#146;s liability for Client Materials (for clarity, such Client Materials should be specified in the applicable Work Orders) loss or damage solely resulting from Provider&#146;s gross negligence or willful
misconduct while the Services are being performed or while such Client Materials are in the Provider&#146;s care. Provider will [***] notify Client if at any time it believes any Product or Client Materials, or any intermediates and components of
any Client Materials or Product, or any work in process have been damaged, lost or stolen. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Unused Client Materials and Other Materials. </B>Provider shall, [***], return, destroy or otherwise dispose
of unused Client Materials [***] after the earlier of (a)&nbsp;completion of the Services for which the Client Materials were provided, (b)&nbsp;termination of the applicable Work Order, or (c)&nbsp;receipt of written instructions from Client
pertaining to its disposition. Provider may dispose of other unused Materials at its sole discretion upon [***] prior written notice to Client, and Client may elect during the [***] period to have the Client Materials transferred to Client.
</P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>RECORDS </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Storage for Records. </B>All materials, data and documentation obtained or generated by Provider in the
course of providing the Services, including all computerized records and files (&#147;<B>Records</B>&#148;)<B>, </B>will be maintained in a secure area in accordance with industry standards and Applicable Law [***]. While it is the Parties&#146;
intent that Provider shall retain ownership of any Provider IP or Provider Confidential Information contained in the Records, the Records with exclusion of the Provider IP and Provider Confidential Information are the sole and exclusive property of
Client and Client shall be able to use the Records, unencumbered, for purposes related to the Product. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Retention of Records. </B>Upon termination of the applicable Work Order, Provider shall, at Client&#146;s
option, (a)&nbsp;destroy the Records, (b)&nbsp;deliver the Records to Client, or (c)&nbsp;retain the Records for [***] and then destroy the Records. If the Records are to be destroyed, then Provider shall give [***] notice to Client, and Client may
elect during the [***] period to have the Records transferred to Client. Notwithstanding the foregoing, the Records may be retained solely to the extent as required by Applicable Law or as otherwise necessary for regulatory or insurance purposes.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Storage for Product. </B>All the Products shall be stored in Provider&#146;s facilities for [***] after
Provider&#146;s issuance of a Certificate of Compliance with 1) a Certificate of Analysis (if full lot release testing is performed by Provider) or 2) a Certificate of Testing (if Client requests only selected lot release testing to be performed by
Provider), as applicable, and a monthly storage fee for Products shall be charged after the [***] period. Client agrees </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
that the commercial value and/or cost of replacement or remanufacture of any Products provided to Provider for storage is a matter that, as between Client and Provider, is within the sole and
exclusive knowledge of Client. Client agrees that it is responsible to insure such items against damage or loss and shall purchase appropriate insurance to cover its Products stored in Provider&#146;s facilities. [***] Transportation of Product by
Provider on behalf of Client shall be made at the sole risk and expense of Client, notwithstanding the use of any INCOTERMS delivery term on any waybill or other documentation relating to the transportation. Provider shall not be liable for the
actions or omission of any delivery services or carriers or freight forwarders. </TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>INTELLECTUAL PROPERTY </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Ownership</B> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Except as otherwise provided in this Agreement, (i)&nbsp;Provider has no ownership rights in any Intellectual
Property that is owned by Client, or licensed by any third party to Client, or any of its Affiliates, including Product, (&#147;<B>Client IP</B>&#148;)<B> </B>and (ii)&nbsp;Client has no ownership rights in any Intellectual Property that is owned by
Provider, or licensed by any third party to Provider, or any of its Affiliates (&#147;<B>Provider IP</B>&#148;)<B>.</B> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Provider shall ensure that each of the Personnel vests in Provider, or its applicable Affiliate, any and all
rights that such person(s) might otherwise have in the Intellectual Property created or developed in connection with the provision of the Services, and all Intellectual Property relating to such inventions (excluding moral rights) (&#147;<B>Project
IP</B>&#148;)<B>. </B>Improvements, modifications, and derivatives of Client IP constitute Project IP. Provider hereby assigns and shall assign (and require its Affiliates to assign) all right, title and interest in Project IP to Client. Client will
[***] , have sole control of filing and prosecuting applications for, and maintenance and enforcement of, patents for Project IP. Provider shall, [***], use [***] to assist Client to obtain, maintain and enforce the Project IP. Client shall use
[***] to [***] notify Provider of any patents granted for Project IP. Provider will be responsible for all payments to be made to Personnel of Provider and its Affiliates in accordance with any Applicable Law requiring remuneration for inventions.
For the avoidance of doubt, Provider has no right to file, prosecute, maintain, protect, defend, or enforce Intellectual Property claiming that covers any Product. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notwithstanding the foregoing, Intellectual Property created or developed in connection with the provision of
the Services (i)&nbsp;that relates solely to Provider IP, (ii)&nbsp;that relates to experimental methods independent of Client IP and Project IP, or (iii)&nbsp;that relates to manufacturing processes generally, in each case without reliance or
reference to Client IP or Project IP (collectively, &#147;<B>Manufacturing Improvements</B>&#148;)<B> </B>is Provider IP and not Project IP. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>General Licenses</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Provider acknowledges and agrees that it does not acquire a license or any other right to Client IP except for
the limited purpose of carrying out its duties and obligations under this Agreement and that such limited, <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> license will expire upon the completion of such duties and obligations or the
termination or expiration of this Agreement, whichever is the first to occur. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Provider hereby grants and shall ensure that each applicable Affiliate will grant and hereby does grant, to
Client and its applicable Affiliates a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> perpetual, irrevocable, royalty-free, <FONT STYLE="white-space:nowrap">non-transferable</FONT> (except in the case of Section&nbsp;14.2) and sublicensable
(through multiple tiers) license to Client and its Affiliates to use Provider IP solely to develop, Manufacture, have Manufactured, distribute, offer for sale, sell, and otherwise dispose of Product. Provider may, at its discretion, grant to Client
the right to use Manufacturing Improvements under mutually satisfactory terms to be negotiated. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Additional Licenses</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In the provision of Services under this Agreement, Provider may recommend to incorporate into the process or deliverables some specific
Provider IP that needs an additional license. Prior to incorporation of such IP into the process and deliverables, Provider shall submit to Client a written list of such IP, describing it in reasonable detail. Within [***] of Client&#146;s receipt
of the information noted in the preceding sentence, Client will notify Provider of its decision as to whether to incorporate such IP into the process or deliverables. Provider shall not incorporate such IP into the process or deliverables without
Client&#146;s express written consent. For any specific Provider IP included in the process or deliverables for which Provider has failed to notify Client and/or for which Client has not expressly consented to the inclusion thereof, Client&#146;s
rights to such IP shall be the same as Client&#146;s rights in the process or deliverables. If Client agrees that some specific Provider IP may be incorporated in the process or deliverables or may be necessary for Client&#146;s full utilization of
the deliverables, both parties shall discuss in good faith regarding such license required. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[***] <B>License. </B>If Client agrees to use Provider&#146;s [***] for the manufacture of Product, then Client
shall purchase from Provider a worldwide, fully <FONT STYLE="white-space:nowrap">paid-up,</FONT> sublicensable (through multiple tiers), <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license to research, develop, make, have made, and
commercialize the Product (the &#147;<B>License</B>&#148;)<B>. </B>The terms of the License to Provider&#146;s [***], including license fees and potential royalties, will be separately negotiated as a separate definitive agreement (&#147;<B>License
Agreement</B>&#148;)<B>.</B> </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>REPRESENTATIONS AND WARRANTIES </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">8.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Mutual. </B>Each Party represents and warrants that (a)&nbsp;it validly exists under the laws of the
jurisdiction in which it was organized, (b)&nbsp;it has the full power, right and authority to execute and deliver this Agreement and to perform its obligations under this Agreement, (c)&nbsp;this Agreement once executed will constitute a legal,
valid and binding agreement enforceable against it and (d)&nbsp;its performance of this Agreement will not conflict with any obligations it may have to any other person. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">8.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Infringement. </B>Client represents and warrants that, to the best of its knowledge, the use of Client
Intellectual Property and Client Materials in the performance of Services in accordance with this Agreement will not infringe the Intellectual Property rights of any third party. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">8.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Provider Representations and Warranties. </B>Provider represents and warrants to Client that
(i)&nbsp;neither it nor any of the Personnel involved in the Services has been debarred, or, to the best of its knowledge, is under consideration for debarment, by the United States Food and Drug Administration from working in or providing services
to any pharmaceutical or biotechnology company pursuant to the Generic Drug Enforcement Act of 1992 or any other governmental authority pursuant to analogous laws; (ii)&nbsp;to the best of its knowledge, the Provider IP will not violate the
intellectual property rights of any third party and it will [***] notify Client in writing should it become aware of any claims asserting such violation; and (iii)&nbsp;at the time of delivery to Client, the Product Manufactured under this Agreement
will have been Manufactured in accordance with cGMP (if applicable) and all other Applicable Law, the Manufacturing Process, the applicable Quality Agreement, and Specifications. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">8.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Compliance with Law. </B>Each Party represents and warrants that it shall, and shall ensure that each of its
Affiliate will, comply with all Applicable Law in connection with performance of this Agreement and any Work Orders. Each Party shall [***] notify the other Party upon becoming aware of a breach of this Section. Breach of this Section with respect
to the U.S. Foreign Corrupt Practices Act or any other applicable anti-bribery law will be deemed an incurable material breach for purposes of Section&nbsp;11.3(b). </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>INDEMNIFICATION; LIMITATION ON LIABILITY; INSURANCE </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">9.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Third Party Claims Against Client. </B>Provider shall defend, indemnify and hold Client and its Affiliates
and its directors, officers, employees, agents and consultants and legal, financial, accounting and other advisors (&#147;<B>Related Persons</B>&#148;)<B> </B>harmless from and against any and all liabilities and damages (including reasonable
attorneys&#146; fees) (&#147;<B>Losses</B>&#148;)<B> </B>resulting from any third party claims, demands, suits or proceedings (&#147;<B>Claims</B>&#148;)<B> </B>to the extent arising out of or relating to (a)&nbsp;its performance of the Services,
(b)&nbsp;a material breach of this Agreement by Provider, (c)&nbsp;a material violation of Applicable Law by Provider or any of its Related Persons, or (d)&nbsp;the gross negligence, recklessness or willful misconduct of Provider or any of its
Related Persons during the course of activities carried out in connection with this Agreement (except to the extent that such Losses are within the scope of the indemnification obligation of Client under Section&nbsp;9.2). The indemnification
obligations set forth in this Section&nbsp;9.1 do not apply to the extent that the Loss arises in whole or in part from the gross negligence, recklessness or willful misconduct of Client or any of its Related Persons or Client&#146;s material breach
of this Agreement. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">9.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Third Party Claims Against Provider. </B>Client shall defend, indemnify and hold Provider and its Related
Persons harmless from and against any and all Losses resulting from any Claims to the extent arising out of or relating to (a)&nbsp;Client&#146;s use of Project IP or deliverables produced in accordance with this Agreement and the written
instructions of Client that were provided or produced under a Work Order (including use of any license under Provider IP), or Provider&#146;s appropriate or proper use of Client Materials or Client IP provided by Client for use in the Services or
due to compliance to any written instructions provided by Client for use in the Services; (b)&nbsp;a material breach of this Agreement by Client, (c)&nbsp;a material violation of Applicable Law by Client or any of its Related Persons, (d)&nbsp;the
gross negligence, recklessness or willful misconduct of Client or any of its Related Persons during the course of activities carried out in connection with this Agreement, or (e)&nbsp;development or manufacture, use, handling, storage, or other
disposition of Products by or on behalf of Client or any of its Affiliates, sublicensees, agents or contractors (except by Provider), including Claims and threatened Claims based on product liability, bodily injury, risk of bodily injury, death or
property damage or the failure to comply with any Applicable Law; except to the extent that such Losses are within the scope of the indemnification obligation of Provider under Section&nbsp;9.1. The indemnification obligations set forth in this
Section&nbsp;9.2 do not apply to the extent that the Loss arises in whole or in part from the negligence, recklessness or willful misconduct of Provider or any of its Related Persons, or Provider&#146;s material breach of this Agreement.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">9.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Intellectual Property Claims. </B>Client shall defend, indemnify and hold Provider and its Related Persons
harmless from and against Losses resulting from Claims to the extent arising out of or related to infringement of any third party Intellectual Property rights in connection with the Services or the Product and where the infringement would not have
occurred but for Provider&#146;s reliance upon Client&#146;s written requirements, specifications and Client IP. To the extent Claims that are based on Provider IP independent of the Services or Product under this Agreement or Provider&#146;s breach
of this Agreement, Client shall not be required to defend, indemnify, and hold Provider and its Related Persons harmless from those Losses. Provider shall defend, indemnify and hold Client and its Related Persons harmless from and against Losses
resulting from Claims to the extent arising out of or related to infringement of any Intellectual Property rights related to the Services and that are based on Provider IP. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">9.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Defense. </B>Each Party shall notify the other Party within [***] upon learning of a Claim that is subject
to indemnification pursuant to Sections 9.1, 9.2, or 9.3 (but failure to notify shall not relieve the indemnifying Party of its indemnification obligations unless such failure materially prejudices its ability to defend the claim). The indemnifying
Party shall control, [***], the defense of the Claim [***] with counsel of its choice. The indemnified Party shall use [***] to cooperate in the defense at the indemnifying Party&#146;s request and expense, and may participate in the Claim [***]. No
compromise or settlement of any Claim may be made by the indemnifying Party without the indemnified Party&#146;s written consent; provided that, if a settlement contains an absolute waiver of liability for the indemnified party, and each party has
acted in compliance with the requirements of this Section&nbsp;9.4, then the indemnified party&#146;s consent will be deemed given. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">9.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Limitations on Liability</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">NEITHER PARTY WILL BE LIABLE UNDER ANY LEGAL THEORY (WHETHER TORT, CONTRACT OR OTHERWISE) FOR SPECIAL,
INDIRECT, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES ARISING OUT OF OR RELATED TO THIS AGREEMENT OR THE EXERCISE OF ITS RIGHTS HEREUNDER, INCLUDING LOST PROFITS ARISING FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT, HOWEVER CAUSED, EVEN IF THE
PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, EXCEPT AS A RESULT OF A BREACH OF THE CONFIDENTIALITY AND <FONT STYLE="white-space:nowrap">NON-USE</FONT> OBLIGATIONS, OR FOR GROSS NEGLIGENCE OR WILLFUL MISCONDUCT. NOTHING IN THIS SECTION
IS INTENDED TO LIMIT OR RESTRICT THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF EITHER PARTY. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[***]. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">9.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Insurance</B>. Each Party shall ensure that insurance coverage is carried and maintained with a financially
sound and reputable insurer against loss from such risks and in such amounts as is sufficient to support its obligations under this Agreement. Each Party shall provide a copy of the applicable insurance policy if requested by the other Party.
</P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>10.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>CONFIDENTIALITY AND PUBLICITY </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">10.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Confidentiality. </B>During the term of this Agreement and for [***] thereafter (other than with respect to
trade secrets, which shall remain confidential for so long as they are protected under Applicable Law), the Receiving Party shall, and shall ensure that it, its Affiliates, and its Related Persons will, (a)&nbsp;maintain the Confidential Information
of the Disclosing Party in confidence, (b)&nbsp;not use the Confidential Information of the Disclosing Party other than solely in connection with this Agreement and (c)&nbsp;not disclose the Confidential Information of the Disclosing Party to any
third party other than (i)&nbsp;those of its Related Persons that have a need to know the Confidential Information in connection with the Services and are obligated to maintain the Confidential Information in confidence on terms at least as strict
as those contained herein, and (ii)&nbsp;notify the Disclosing Party of any unauthorized disclosure of its Confidential Information [***] upon becoming aware of such disclosure. Notwithstanding the foregoing, Client may disclose the existence of
this Agreement and Confidential Information of Provider confidentially in connection with a potential financing or acquisition or collaboration, provided, however, Client shall be liable for the acts and consequences of such disclosure.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">10.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Return of Confidential Information. </B>Upon termination of this Agreement, and if requested in writing by
the Disclosing Party within [***] thereafter, the Receiving Party shall cause all Confidential Information of the Disclosing Party to be [***] destroyed or returned to the Disclosing Party; provided, however, that the Receiving Party may, subject
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
to its obligations of confidentiality hereunder, retain (a)&nbsp;a single secure copy of any Confidential Information for legal archival purposes, and (b)&nbsp;electronic <FONT
STYLE="white-space:nowrap">back-up</FONT> files that have been created by routine archiving and <FONT STYLE="white-space:nowrap">back-up</FONT> procedures need not be deleted. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">10.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Publicity. </B>Each Party shall not, and shall ensure that its Related Persons will not, use the name,
symbols or marks of the other Party or any of its Affiliates in any advertising or publicity material or make any form of representation or statement that would constitute an express or implied endorsement by the other Party or any of its Affiliates
of any commercial product or service, without the other Party&#146;s or Affiliate&#146;s prior written consent. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">10.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Audits. </B>Provider and its Affiliates may have in the past provided, and may currently or in the future
provide, services to other customers that are similar to the Services. Provider is absolutely committed to protecting Client&#146;s Confidential Information and Intellectual Property, and shall not use such Confidential Information or Intellectual
Property for the benefit of any person other than Client. In order to protect the Confidential Information of Client and the confidential information of other customers, Provider shall use [***] to ensure that other customers do not seek the
disclosure of Confidential Information of Client, and Client hereby agrees it shall not seek the disclosure of confidential information of other customers of Provider. Notwithstanding the foregoing, if Client wishes to conduct an audit that relates
to services provided to another customer for purposes of confirming that Client&#146;s Intellectual Property is adequately protected, then Provider shall use [***] to seek the other customer&#146;s approval to waive confidentiality obligations to
the extent necessary to allow Client to conduct the audit in a manner that does not involve disclosure of the other customer&#146;s confidential information to Client. If another customer wishes to conduct an audit that relates to the Services for
purposes of confirming that the other customer&#146;s Intellectual Property is adequately protected, then Client shall discuss whether to waive Provider&#146;s confidentiality obligations to Client to the extent necessary to allow the other customer
to conduct the audit in a manner that does not involve disclosure of Client&#146;s Confidential Information to the other customer. Such audits may involve an independent auditor designated by Provider and paid for by the person seeking the audit.
</P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>11.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>TERM AND TERMINATION </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">11.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Agreement. </B>The term of this Agreement commences on the Effective Date and, unless earlier terminated
pursuant to this Section&nbsp;11, will expire on the later of (a)&nbsp;five (5) years from the Effective Date; or (b)&nbsp;the completion of Services under all Work Orders executed by the parties prior to the fifth anniversary of the Effective Date.
The term of this Agreement may be extended by Client continuously for additional [***] periods upon written notice to Provider at least [***] prior to the expiration of the then-current term. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">11.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Client will have the right, in its sole discretion, to terminate this Agreement or Work Order (a)&nbsp;upon
thirty (30)&nbsp;days&#146; prior written notice to Provider; or (b)&nbsp;immediately upon written notice if Provider fails to obtain or maintain any material governmental licenses or
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
approvals required in connection with the Services. Client shall pay off Provider for the Services rendered and the <FONT STYLE="white-space:nowrap">non-cancellable</FONT> obligations occurred
prior to the termination date; provided that Provider will use good faith efforts to mitigate such <FONT STYLE="white-space:nowrap">non-cancellable</FONT> obligations if applicable. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">11.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Work Orders. </B>Work Orders are subject to the terms of this Agreement and are not affected by the
termination of this Agreement unless such Work Order is terminated together with the Agreement. The term of each Work Order commences on the date indicated in the Work Order and will, unless terminated earlier in accordance with this Agreement,
terminate upon completion of the Services. Notwithstanding the foregoing, either Party may terminate a Work Order: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">at any time with six (6)&nbsp;months&#146; advance notice to the other Party, provided, however, Provider shall
provide sufficient evidence to prove that there is reasonable cause to terminate the Work Order and discuss with Client in good faith prior to the termination; provided further, if Provider terminates a Work Order pursuant to this clause 11.3(a),
then no termination or cancellation fees shall be paid by Client, Provider shall continue to provide Services for the irrelative Work Orders; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">immediately upon notice to the other Party if </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a material breach of the Work Order by the other Party remains uncured thirty (30)&nbsp;days after notice of
the material breach was received by such other Party; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the other party files a petition in bankruptcy, or enters into an agreement with its creditors, or applies for
or consents to the appointment of a receiver or trustee, or makes an assignment for the benefit of creditors, or becomes subject to involuntary proceedings under any bankruptcy or insolvency law (which proceedings remain undismissed for sixty
(60)&nbsp;days); or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a Force Majeure Event occurs that will, or continues to, prevent performance (in whole or substantial part) of
this Agreement or any pending Work Order by the other party for a period of at least ninety (90)&nbsp;days. In the case of a Force Majeure Event relating solely to a pending Work Order, the right to terminate will be limited to such Work Order.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">11.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Survival</B>. Upon termination of this Agreement or a Work Order, all outstanding rights and obligations
between the Parties arising out of or in connection with this Agreement or the Work Order, as the case may be, will [***] terminate, other than any obligations that (a)&nbsp;matured prior to the effective date of the termination or (b)&nbsp;by its
nature are intended to survive, including Sections 2.1, 4.2, 4.3, 4.6, 6.1, 6.2, 11.4, 11.5 and Articles 1, <FONT STYLE="white-space:nowrap">7-10,</FONT> 12 and 14. Provider will, upon receipt of a termination notice from Client, [***] cease
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
performance of the applicable Services and will take all reasonable steps to mitigate the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses
incurred in connection therewith. Within [***] after the <FONT STYLE="white-space:nowrap">close-out</FONT> of a Work Order, Provider will provide to Client a written itemized statement of all work performed by it in connection with the terminated
Work Order, an itemized breakdown of the payments associated with that work, and a final invoice for that Work Order. If Client has <FONT STYLE="white-space:nowrap">pre-paid</FONT> to Provider more than the amount in a final invoice then Provider
agrees to [***] refund that money to Client, or to credit the excess payment toward another existing or future Work Order, at the election of Client. </TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">11.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Termination Fee.</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If a Work Order is terminated early by Client under Section&nbsp;11. 2 or 11.3, then Client shall pay Provider for the Services rendered in
accordance with the terms of this Agreement and all <FONT STYLE="white-space:nowrap">non-cancelable</FONT> obligations in connection with the Services to the extent specified in the applicable Work Order; provided that Provider will use good faith
efforts to mitigate such <FONT STYLE="white-space:nowrap">non-cancellable</FONT> obligations. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If <FONT STYLE="white-space:nowrap">non-manufacturing</FONT> Services, as specified in the applicable Work
Order, are terminated by Provider due to Client&#146;s material breach pursuant to Section&nbsp;11.3(b), then Provider may charge Client a termination fee equal to [***] of the remaining value of such
<FONT STYLE="white-space:nowrap">non-manufacturing</FONT> Services within the Work Order as liquidated damages in connection with the redeployment of reserved Personnel and administrative overhead and costs. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If manufacturing Services are terminated by Provider due to Client&#146;s material uncured breach or at
Client&#146;s request, Client may be charged cancellation fees as specified in Section&nbsp;12; If manufacturing Services (manufacturing run(s) including <FONT STYLE="white-space:nowrap">non-GMP</FONT> manufacturing, GMP manufacturing, and
engineering run) are terminated by Provider due to a Client request to cancel or due to a termination of the applicable Work Order by Provider because of Client&#146;s uncured material breach pursuant to Section&nbsp;11.3(b), Client shall be charged
cancellation fees as specified in Section&nbsp;12 below. If Client requests to 1) postpone or reschedule, or 2) materially change the production scale or batch size of, a manufacturing run originally scheduled under an executed Work Order or Change
Order and/or this Agreement, the same cancellation terms in Section&nbsp;12 will apply, provided that no cancellation fees will be charged in where such termination results from Provider&#146;s breach of this Agreement, or its negligence or willful
misconduct. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>12.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>CANCELLATION TERMS FOR MANUFACTURING SERVICES </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">12.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Cancellation of <FONT STYLE="white-space:nowrap">non-GMP</FONT> Drug Substance Manufacturing. </B>If a
notice to cancel a <FONT STYLE="white-space:nowrap">non-GMP</FONT> drug substance manufacturing batch in an executed Work Order and/or this Agreement is received, Provider will make [***] to find an alternative customer or project to fill the
manufacturing slot. In the case where no alternative customer or project can be identified to fill the slot(s), charges for cancelling the related work under this Agreement (&#147;<B>Cancellation Charge</B>(<B>s</B>)&#148;)<B> </B>will be applied
based on the following: </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[***] except the cost of raw materials purchased by Provider under the applicable Work Order for such <FONT
STYLE="white-space:nowrap">non-GMP</FONT> batch, if the cancellation notice is received [***] before the scheduled vial thaw; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[***] of a <FONT STYLE="white-space:nowrap">non-GMP</FONT> manufacturing batch fee plus the cost of raw
materials purchased by Provider under the applicable Work Order for such <FONT STYLE="white-space:nowrap">non-GMP</FONT> batch, if the cancellation notice is received [***] before the scheduled vial thaw; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[***] of a <FONT STYLE="white-space:nowrap">non-GMP</FONT> manufacturing batch fee plus the cost of raw
materials purchased by Provider under the applicable Work Order for such <FONT STYLE="white-space:nowrap">non-GMP</FONT> batch, if the cancellation notice is received [***] before the scheduled vial thaw; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[***] of a <FONT STYLE="white-space:nowrap">non-GMP</FONT> manufacturing batch fee plus the cost of raw
materials purchased by Provider under the applicable Work Order for such <FONT STYLE="white-space:nowrap">non-GMP</FONT> batch, if the cancellation notice is received [***] prior to the scheduled vial thaw. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[***] of a <FONT STYLE="white-space:nowrap">non-GMP</FONT> manufacturing batch fee plus the cost of raw
materials purchased by Provider under the applicable Work Order for such <FONT STYLE="white-space:nowrap">non-GMP</FONT> batch, if the cancellation notice is received [***]; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[***] a <FONT STYLE="white-space:nowrap">non-GMP</FONT> batch fee plus the cost of raw materials purchased by
Provider under the applicable Work Order for such <FONT STYLE="white-space:nowrap">non-GMP</FONT> batch, if the cancellation notice is received [***]. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">12.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Cancellations for Drug Substance cGMP Manufacturing Run or Engineering Run. </B>If a notice to cancel a drug
substance cGMP manufacturing run or an engineering run in an executed Work Order and/or this Agreement (as the case may be) is received, Provider will use [***] to find an alternative customer or project (but excluding any project under existing
contract with Provider) for the manufacturing slot. In the case where no alterative customer or project can be identified to fill the slot(s), Cancellation Charge(s) will be applied based on the following: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[***] except the cost of raw materials purchased by Provider under the applicable Work Order for purposes of
such cGMP manufacturing run or engineering run, if the cancellation notice is received [***] before the scheduled vial thaw; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[***] of the cGMP manufacturing run or engineering run batch fee plus the cost of raw materials purchased by
Provider under the applicable Work Order for purposes of such cGMP manufacturing run or engineering run, if the cancellation notice is received [***] before the scheduled vial thaw; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[***] of the cGMP manufacturing run or engineering run batch fee plus the cost of raw materials purchased by
Provider under the applicable Work Order for purposes of such cGMP manufacturing run or engineering run, if the cancellation notice is received [***] before the scheduled vial thaw or anytime thereafter. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">12.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Cancellation for Drug Product cGMP Manufacturing Run or Engineering Run. </B>If a notice to cancel a cGMP
drug product manufacturing run or an engineering run in an executed </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Work Order and/or this Agreement (as the case may be) is received, Provider will use [***] to find an alternative customer or project but excluding any project under existing contract with
Provider) to fill the manufacturing slot(s). In the case where no alternative customer or project can be identified to fill the slot(s), Cancellation Charge(s) will be applied based on the following: </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[***], except the cost of raw materials purchased by Provider under the applicable Work Order for purposes of
such cGMP manufacturing run or engineering run, if the cancellation notice is received [***] before the scheduled manufacturing run; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[***] of the cGMP manufacturing run or engineering run batch fee plus the cost of raw materials purchased by
Provider under the applicable Work Order for purposes of such cGMP manufacturing run or engineering run, if the cancellation notice is received between one [***] before the scheduled manufacturing run; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[***] of the cGMP manufacturing run or engineering run batch fee plus the cost of raw materials purchased by
Provider under the applicable Work Order for purposes of such cGMP manufacturing run or engineering run, if the cancellation notice is received [***] before the scheduled manufacturing run or anytime thereafter. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>13.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>SHIPPING </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">13.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All materials to be provided by Provider to Client will be delivered FCA (carrier named by Client) (Incoterms
2020), including Product and other deliverables produced under a Work Order, returned Client Materials, returned Records and returned Confidential Information. For the avoidance of doubt, FCA (carrier named by Client) means Provider is responsible
for handing over the materials, cleared for export, to a carrier named by Client. Client assumes risk at hand over and pays all costs as specified in Incoterms 2020. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">13.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All materials to be provided by Client to Provider will be delivered DDP (site designated by Provider)
(Incoterms 2020), including Client Materials. For the avoidance of doubt, DDP (site designated by Provider) means Client is responsible for delivery to and unloading at the site designated by Provider and pays all costs including import duties and
taxes. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>14.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>MISCELLANEOUS </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">14.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Force Majeure. </B>&#147;<B>Force Majeure</B>&#148;<B> </B>means and includes such circumstances or
occurrences which are beyond the reasonable control of the Party that materially prevent such Party from performing any of such Party&#146;s obligations under this Agreement (other than the payment of money), and that are not caused by the
Party&#146;s negligence, which may include, but not limited to, acts of God; pandemic(such as <FONT STYLE="white-space:nowrap">Covid-19),</FONT> strikes and labour problems affecting an entire industry or region; lightning, fire, flood, washout,
storm, or other actions of the elements; government actions, including embargos, sanctions, prohibitions; and war, civil disturbances or other imposition of sanctions by a governmental authority with jurisdiction over a Party. Neither Party shall be
liable for </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
<FONT STYLE="white-space:nowrap">non-fulfilment</FONT> of its obligations or in breach under this Agreement if such <FONT STYLE="white-space:nowrap">non-fulfilment</FONT> is due to Force Majeure
for the duration of such Force Majeure. Each Party shall use [***] to mitigate adverse consequences in the event of such Force Majeure. A Party that is prevented from performing any of its obligations due to Force Majeure will [***] give notice to
the other Party of the event and the obligations as to which performance is prevented or delayed. If a Force Majeure situation continues for more than [***], the unaffected Party may terminate any affected Work Order upon notice to the affected
Party, without penalty or liability (including without limitation penalties described in Section&nbsp;12). </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">14.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Assignment; Novation. </B>This Agreement may not be assigned by a Party without the prior written consent of
the other Party; provided, however, that (i)&nbsp;a Party may assign this Agreement to any of its Affiliates with net worth or insurance commensurate with such Party&#146;s obligations and sufficient capacity and personnel, without such consent, but
with notice to the other Party; and (ii)&nbsp;Client may, without Provider&#146;s consent, assign this Agreement (a)&nbsp;to a third party in connection with the transfer or sale of all or substantially all of its assets or the line of business or
Product to which this Agreement relates; (b)&nbsp;to a successor entity or acquirer in the event of a merger, consolidation or change of control. Any purported assignment in violation of this Section is void. This Agreement binds the Parties&#146;
successors and assigns. Notwithstanding anything to the contrary in this Agreement, upon written notice from Client that Client has executed an exclusive license as to all or substantially all of the Client&#146;s assets or Product to which one or
more Work Orders relates, Provider shall, and hereby does (and Client, by providing such notice, also shall, and hereby does): (i) novate this Agreement and the applicable Work Orders to the Client&#146;s exclusive licensee, on a form of novation
agreement provided by Client and reasonably accepted by Provider (which acceptance shall not be unreasonably withheld, conditioned, or delayed) at the time of such novation; and (ii)&nbsp;enter into a new agreement that is an exact copy of this
Agreement and includes only those Work Orders that are not subject to the novation in clause (i). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">14.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Notices. </B>All notices, requests, demands and other formal or legal communications required under this
Agreement must be in writing and will be deemed to have been given or made and sufficient in all respects when delivered by reputable international courier to the following addresses: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><B>To Client: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Paragon
Therapeutics, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">34 Cypress Rd., Arlington, MA 02474 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attn: [***] </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Tel.: [***] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Email: [***] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><B>To Provider: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">WuXi Biologics (Shanghai) Co., Ltd. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Area <FONT STYLE="white-space:nowrap">301-A,</FONT> Building No.2, 299 Fute Zhong Road </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">China (Shanghai) Pilot Free Trade Zone </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Shanghai, China 200131 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attn:
[***] </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Email: [***] </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">14.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Independent Contractor. </B>The Parties are independent contractors, and nothing contained in this Agreement
may be deemed or construed to create a partnership, joint venture, employment, franchise, agency, fiduciary or other relationship between the Parties. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">14.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><FONT STYLE="white-space:nowrap">Non-Solicitation.</FONT> </B>During the term of this Agreement and for
[***] thereafter, Client shall not directly or indirectly induce or solicit (or authorize or assist in the taking of any such actions by any third party) any employee or consultant of Provider or any of its Affiliates that have provided Services
under this Agreement to leave his or her employment or business association. Hiring advertisements and efforts not directed at a particular individual do not constitute a solicitation in violation of this Section&nbsp;14.5. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">14.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Governing Law. </B>The laws of the State of New York, USA, without regard to any choice of law principle
that would require the application of the law of another jurisdiction, govern all matters relating to this Agreement and the enforcement thereof. The parties expressly reject any application to this Agreement of (a)&nbsp;the United Nations
Convention on Contracts for the International Sale of Goods; and (b)&nbsp;the 1974 Convention on the Limitation Period in the International Sale of Goods, as amended by that certain Protocol, done at Vienna on April&nbsp;11, 1980.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">14.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Arbitration. </B>The Parties shall engage in [***] consultation to resolve any dispute arising out of or in
connection with this Agreement. Such consultation will begin [***] after one Party has delivered to the other Party a request for consultation. If the dispute cannot be resolved within [***] following the date on which the request for consultation
is delivered, then either Party may submit the dispute to the JAMS International Arbitration Rules (&#147;<B>Arbitration</B>&#148;)<B>. </B>The Arbitration tribunal will consist of three arbitrators. Within [***] after the commencement of the
Arbitration, each Party shall select one person to act as arbitrator, each of whom must be a practicing or retired attorney or judge having at least [***] of litigation experience within the biopharmaceutical industry. The two arbitrators so
selected shall select the chair within [***] of the commencement of the Arbitration, whom must a practicing or retired attorney or judge having at least [***] of litigation experience within the biopharmaceutical industry. If the arbitrators
selected by the Parties are unable or fail to agree upon the third arbitrator within the allotted time, the third arbitrator shall be appointed by JAMS in accordance with the JAMS International Arbitration Rules. All arbitrators shall serve as
neutral, independent and impartial arbitrators. The Arbitration shall be conducted in accordance with the expedited procedures set forth in the JAMS International Arbitration Rules. The place of arbitration
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
will be New York City. The official language of the arbitration will be English. The arbitration proceedings will be confidential, and the arbitrator may issue appropriate protective orders to
safeguard each Party&#146;s Confidential Information. During the course of arbitration, the Parties shall continue to implement the terms of this Agreement including all Work Orders then in effect. The arbitral award will be final and binding upon
the Parties, and the Party to the award may apply to a court of competent jurisdiction for enforcement of the award. Notwithstanding the foregoing, each Party has the right to institute an action in a court of proper jurisdiction for injunctive or
other equitable relief pending a final decision by the arbitrator. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">14.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Entire Agreement; <FONT STYLE="white-space:nowrap">Non-Reliance.</FONT> </B>This Agreement, together with
each Work Order, contains the entire agreement between the Parties with respect to the subject matter of this Agreement. Prior agreements are hereby superseded. For the avoidance of doubt, prior confidentiality obligations are superseded to the
extent that they cover Confidential Information. Each Party disclaims that it is relying on any representations or warranties other than those set forth in this Agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">14.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Amendment. </B>No modification or waiver of any term of this Agreement or any other form of amendment to
this Agreement will be binding unless made expressly in writing and signed by both Parties. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">14.10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>No Third Party Beneficiaries. </B>The provisions of this Agreement are for the sole benefit of the Parties.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">14.11</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Waiver. </B>The waiver by either Party of any breach of any term of this Agreement will not constitute a
waiver of any other breach of the same or any other term. Failure or delay on the part of either Party to fully exercise any right under this Agreement will not constitute a waiver or otherwise affect in any way the same or any other right.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">14.12</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Severability. </B>If any provision in this Agreement is held to be invalid, illegal or unenforceable in any
respect, then (a)&nbsp;the provision will be replaced by a valid and enforceable provision that achieves as far as possible the intention of the Parties and (b)&nbsp;all other provisions of this Agreement will remain in full force and effect as if
the original agreement had been executed without the invalidated, illegal or unenforceable provision. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">14.13</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Independent Counsel. </B>Each Party has had the opportunity to consult independent counsel, and as such,
this Agreement will not be construed to have been drafted by one Party or the other but will be construed as having been jointly drafted when interpreting its provisions. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">14.14</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Counterparts. </B>This Agreement may be executed in one or more counterparts, each of which will be deemed
an original, but all of which together constitute one and the same instrument. Executed counterparts may be exchanged by facsimile or <FONT STYLE="white-space:nowrap">e-mail</FONT> in PDF or similar electronic format. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature page follows] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Thus, this Agreement was executed on the date stated in the introductory clause. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="30%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="27%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="29%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"><B>WuXi Biologics (Hong Kong) Limited</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"><B>Paragon Therapeutics, Inc.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Zhislieng Chen</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Kenneth Evan Thompson</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Zhislieng Chen</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Kenneth Evan Thompson</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">CEO</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">COO</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit A&#151;Form of Work Order </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WORK ORDER (NUMBER [</B>&#9679;<B></B><B>]) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This work order is dated [&#9679;] and is between Paragon Therapeutics, Inc. (&#147;<B>Client</B>&#148;) and [WuXi Biologics (Hong Kong) Limited]
(&#147;<B>Provider</B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The terms of the Biologics Master Services Agreement between Paragon Therapeutics, Inc. and WuXi Biologics (Hong Kong)
Limited, dated [&#9679;] (the &#147;<B>Master Services Agreement</B>&#148;), are hereby incorporated by reference into this Work Order. Any modifications to the Master Services Agreement will be deemed to be references to this Work Order
automatically. Each capitalized term used but not defined in this Work Order has the meaning given in the Master Services Agreement. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>SERVICES INFORMATION </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Title</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>[Project title] </I></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Description</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>[Description of the Services including deliverables and specifications] </I></P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Tasks and Timeframe. </B>Provider shall complete the Services in accordance with the following schedule:
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Task</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Completion Date</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Client Materials</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>[Description of the Client Materials to be provided by Client to Provider that are necessary to perform the Services] </I></P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Reporting and Transfer of Data and Results</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>[Description of how data and results should be reported and transferred to Client, including electronic protocols for secure transmission of
data and instructions for physical handling and shipping of materials if chemicals are being synthesized or other materials are to be transferred to Client] </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Additional Requirements</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>[Any additional requirements such as additional obligations of the parties that do not appropriately fit into the task list and special
handling of materials] </I></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>FEES; PAYMENT SCHEDULE </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>General Terms. </B>Expenses, milestones, payment and default and other general terms are provided in
Section&nbsp;3 of the Master Services Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Contract Price and Upfront Payment. </B>The Contract Price will be USD [.1. On signing of this Work Order,
Client shall pay Provider [&#9679;] % of the Contract Price as a <FONT STYLE="white-space:nowrap">non-refundable</FONT> upfront payment. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Milestones. </B>The table below lists milestones and related information. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Milestone</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Deliverable</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Milestone Payment</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><I>[Description including work required, criteria for achievement and timeline]</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[&#9679;]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[&#9679;]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[&#9679;]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[&#9679;]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[&#9679;]</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Payment Instructions. </B>Unless an invoice provides otherwise, Client shall pay the invoice in USD by wire
transfer to the account listed below (as may be amended from time to time): </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="20%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="15%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="9">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="9">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="9">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="9">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>COMMUNICATIONS </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Technical Communications. </B>All technical communications required under this Work Order are to be sent via
reputable international courier or email and addressed as follows: </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><B>If to Client:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>If to Provider:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">[&#9679;]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[&#9679;]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">[&#9679;]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[&#9679;]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">[&#9679;]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[&#9679;]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Attn: [&#9679;]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Attn: [&#9679;]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Tel.: [&#9679;]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Tel.:[&#9679;]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Email: [&#9679;]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Email: [&#9679;]</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Thus, this Work Order is executed on the date stated in the introductory clause. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="30%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="27%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="29%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"><B>Paragon Therapeutics, Inc.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"><B>WuXi Biologics (Hong Kong) Limited</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>14
<FILENAME>d518298dex102.htm
<DESCRIPTION>EX-10.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT
MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CELL LINE LICENSE AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Cell Line License Agreement (&#147;Agreement&#148;), effective as of June&nbsp;20, 2022 (&#147;Effective Date&#148;), is entered and made by and between
<B>WuXi Biologics (Hong Kong) Limited</B>, having an address at Flat/RM826, 8/F Ocean Centre Harbour City, 5 Canton Road TST, Hong Kong (&#147;WuXi Biologics&#148;) and <B>Paragon Therapeutics, Inc., </B>a Delaware corporation, with an office at 34
Cypress Rd., Arlington, MA 02474 (&#147;Licensee&#148;). WuXi Biologics and Licensee may be referred to herein individually as a &#147;Party&#148; and collectively as the &#147;Parties.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Parties agree as follows: </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Definitions</U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;Affiliate&#148; </B>of a person means any other person that directly or indirectly Controls, is
Controlled by, or is under common Control with, the person. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;Client Product&#148; </B>means the [***] of interest to Licensee, which is designated by the Licensee
to be produced by the Licensed Cell Line. Each different Client Product covered under this Agreement shall be specified in Appendix I. An amendment to this Agreement is required for each new Client Product produced by the Licensed Cell Line.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Confidential Information</B>&#148; of a Party (the &#147;<B>Disclosing Party</B>&#148;) means all
nonpublic scientific, technical, financial regulatory or business information and materials disclosed by or on behalf of the Disclosing Party to the other Party (the &#147;<B>Receiving Party</B>&#148;) or its Related Persons (defined below) in
connection with this Agreement. Confidential information shall be identified as confidential in writing or, if disclosed verbally or by observation, summarized in writing and submitted to the Receiving Party within [***] of the oral or visual
disclosure thereof; provided, however, information need not be labeled or marked &#147;confidential&#148; to be deemed Confidential Information hereunder, if under the circumstances it is, or should be, understood to be confidential. The
Confidential Information of both Parties includes the existence, terms and objectives of this Agreement, and the nature of any dispute and the outcome of any arbitration proceedings arising out of or in connection with this Agreement.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 of 17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Construct</B>&#148; means a [***] developed by WuXi Biologics that is used for delivering genetic code
and for transfecting and/or transforming the Host Cell Line for purposes of creating the Licensed Cell Line. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;Control</B>&#148; over an entity means (a)&nbsp;owning 50% or more of the voting securities or other
ownership interests of such entity or (b)&nbsp;having the power to direct the management or policies of such entity. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;Drug Product&#148; </B>means the final dosage form which contains Client Product, in association with
other active or inactive ingredients. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;Drug Substance&#148; </B>means bulk Client Product, which has not yet been packaged into its final
dosage form. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;Host Cell Line&#148; </B>means the proprietary host cell line developed by WuXi Biologics, and
designated by WuXi Biologics as the [***], that is used to make the Licensed Cell Line. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;Licensed Cell Line&#148; </B>means a transformed or transfected (using WuXi Biologics&#146;
Construct(s)) version of the Host Cell Line that produces the Client Product. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;Licensed <FONT STYLE="white-space:nowrap">Know-How&#148;</FONT> </B>means any <FONT
STYLE="white-space:nowrap">know-how</FONT> and <FONT STYLE="white-space:nowrap">non-public</FONT> information owned or controlled by WuXi Biologics that is used or incorporated in the Process, and that is necessary or useful to operate the Process
as further described in the Technology Transfer Package. The word &#147;control&#148; when used in connection with Licensed <FONT STYLE="white-space:nowrap">Know-How</FONT> includes both exclusively and
<FONT STYLE="white-space:nowrap">non-exclusively</FONT> licensed <FONT STYLE="white-space:nowrap">know-how</FONT> and <FONT STYLE="white-space:nowrap">non-public</FONT> information, as well a right of WuXi Biologics to transfer such <FONT
STYLE="white-space:nowrap">know-how</FONT> and <FONT STYLE="white-space:nowrap">non-public</FONT> information to Licensee. As used in this definition <FONT STYLE="white-space:nowrap">&#147;know-how&#148;</FONT> means all confidential and proprietary
commercial, technical, scientific and other <FONT STYLE="white-space:nowrap">know-how</FONT> and information, trade secrets, knowledge, technology, methods, processes, practices, formulae, instructions,
</P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
skills, techniques, procedures, experiences, ideas, technical assistance, designs, drawings, assembly procedures, computer programs, specifications, data and results (including biological,
chemical, pharmacological, toxicological, pharmaceutical, physical and analytical, preclinical, clinical, safety, manufacturing and quality control data and <FONT STYLE="white-space:nowrap">know-how,</FONT> and including study designs and
protocols). </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.11</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Marketing Authorization Approval</B>&#148; means, with respect to a country or extra-national
territory, any and all approvals (including a New Drug Application or Biologics License Application approved by the FDA), licenses, registrations or authorizations of any Regulatory Authority necessary in order to commercially distribute, sell or
market a product in such country or some or all of such extranational territory, including any pricing or reimbursement approvals. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.12</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;Materials&#148; </B>means the biological materials, including the Licensed Cell Line, provided to
Licensee pursuant to the license granted under this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.13</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;Media and Feeds&#148; </B>means any proprietary media and feeds used in the Process.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.14</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Net Sales</B>&#148; means the amount earned and recognized as revenue by Licensee and its Affiliates
or sublicensees for bona fide sales of Client Product to a third-party ([***]), less: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">[***] </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">[***] </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">[***] </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">[***] </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">[***] </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">[***] </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">[***] </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Net Sales will not include [***]. Such amounts will be determined from the books and records of [***], maintained in accordance with GAAP
consistently applied. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.15</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;Process&#148; </B>means a process for manufacture of Client Product utilizing Licensed <FONT
STYLE="white-space:nowrap">Know-How,</FONT> Materials and Media and Feeds as described in the Technology Transfer Package. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.16</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Regulatory Authority</B>&#148; means any applicable supranational, national, regional, state or local
regulatory agency, department, bureau, commission, council, or other government entity involved in regulating development of and granting regulatory approval for a pharmaceutical product, including the FDA and EMA. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.17</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;Related Persons&#148; </B>means a Party&#146;s Affiliates and their respective directors, officers,
employees and agents. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.18</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Research Cell Bank</B>&#148; is a [***]. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.19</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;Technology Transfer Package&#148; </B>means all information and data describing the Process, together
with all Licensed <FONT STYLE="white-space:nowrap">Know-How,</FONT> Materials and Media and Feeds necessary or useful for the development and manufacture of Client Product using the Licensed Cell Line and/or the Process. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.20</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;Third Party&#148; </B>means any person other than the Parties to this Agreement.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.21</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;Third Party Manufacturer&#148; </B>means (i)&nbsp;a Third Party whose primary business is contract
manufacturing, or (ii)&nbsp;a Third Party who has a contractual arrangement with Licensee or with a sublicensee of Licensee that includes manufacturing of Client Product and/or Drug Product by such Third Party for Licensee or such sublicensee.
</P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>License</U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">WuXi Biologics hereby grants to Licensee and its Affiliates a
<FONT STYLE="white-space:nowrap">non-exclusive,</FONT> worldwide license, with the right to grant sublicenses as provided in Section&nbsp;2.3, to the Licensed <FONT STYLE="white-space:nowrap">Know-How</FONT> and the Licensed Cell Line, Materials,
and Media and Feeds, for the purpose of conducting the Process, including the following licensed activities: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">i.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to make, have made, import, sell and otherwise use Client Product; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">ii.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to make, have made, use, sell, have sold, offer for sale, import, keep and otherwise deal in and further
commercialize Drug Substance and Drug Product for any and all purposes. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Licensee or its Affiliates may contract with a Third Party Manufacturer for the limited purpose of
developing and manufacturing Client Product on behalf of the Licensee or its Affiliates, provided that, such Third Party Manufacturers are bound by the contract to comply with the confidentiality and use terms of this Agreement, and that the
Licensee or its Affiliates will remain liable for any Third Party Manufacturers&#146; breach of this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">2.2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For the benefit of doubt, a Third Party Manufacturer cannot manufacture Client Product, Drug Substance or Drug
Product utilizing the Licensed Cell Line and Licensed <FONT STYLE="white-space:nowrap">Know-How</FONT> without first being contracted with a Licensee, its Affiliates or sublicensee. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">2.2.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A Third Party Manufacturer that has been granted a sublicense cannot grant, issue or transfer a sublicense to
another Third Party. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to the terms and conditions of this Agreement, Licensee shall have the right to grant sublicenses to a
Third Party for the rights granted to Licensee under this Agreement. Each sublicense agreement shall be in writing and provided that the applicable sublicensee is bound by all applicable terms and conditions of this Agreement, and Licensee or its
Affiliates shall remain liable for any sublicensee&#146;s breach of this Agreement. Licensee shall inform WuXi Biologics in writing any and all such sublicenses. [***]. Licensee will notify WuXi Biologics in writing of any sublicense agreement with
a sublicensee within [***] of the execution of such agreement. Any sublicense granted by Licensee to any rights licensed to it hereunder will terminate [***] upon the termination of the license by WuXi Biologics under the terms of this Agreement;
provided, that such sublicensed rights will not terminate if, as of the effective date of such termination, a sublicensee is not in material default of its obligations under its sublicense agreement, and within [***] of such termination, the
sublicensee agrees in writing to be bound directly to WuXi Biologics under a license agreement substantially similar to this Agreement with respect to the rights sublicensed hereunder. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Except as expressly provided in this Agreement, nothing in this Agreement shall be deemed to have granted
Licensee (by implication, estoppel or otherwise) any right, title, license or other interest in or with respect to any intellectual property, <FONT STYLE="white-space:nowrap">Know-How</FONT> or information owned or controlled by WuXi Biologics.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Invoicing of License fees will commence from [***]. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Transfer of Materials and Licensed <FONT STYLE="white-space:nowrap">Know-How</FONT></U>
</B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">WuXi Biologics shall notify Licensee in writing within [***] following the date on which WuXi Biologics completes
transfection of the Host Cell Line to generate the Licensed Cell Line. Thereafter, [***] upon written request and the completion of due payment by Licensee (and in any event within [***] following designation of a Third Party Manufacturer), WuXi
Biologics shall disclose, make available, and conduct a full transfer, and shall cause its Affiliates to disclose, make available, and conduct a full transfer to Licensee, its Affiliates, or any one or more of its Third Party Manufacturers
designated by Licensee, all Materials and Licensed <FONT STYLE="white-space:nowrap">Know-How,</FONT> that is necessary or reasonably useful for Licensee and Third Party Manufacturers to solely develop and manufacture the Client Product. The Parties
shall agree to a schedule for such transfer of the Materials and Licensed <FONT STYLE="white-space:nowrap">Know-How.</FONT> WuXi Biologics will provide [***] assistance to enable such Third Party Manufacturer to manufacture Client Product<I>,
provided, however, </I>it is the Third Party Manufacturer&#146;s full responsibility to manufacture such Client Product after the transfer, WuXi Biologics will not be responsible for the Third Party Manufacturer&#146;s success or failure to
manufacture any Client Products. Initiation of such technology transfer will be determined by Licensee. WuXi Biologics will be reimbursed for such activities by Licensee on [***] rate. WuXi Biologics will provide [***] requested ongoing technical
support if requested by Licensee with such support reimbursed on a [***] rate basis. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>License Fee</U> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">As consideration for the license granted in Section&nbsp;2 of this Agreement, and the representation and warranty set forth in Section&nbsp;10
of this Agreement, Licensee agrees to pay WuXi Biologics a fixed <FONT STYLE="white-space:nowrap">non-creditable,</FONT> <FONT STYLE="white-space:nowrap">non-refundable</FONT> license fee of USD [***] for the Licensed Cell Line used in Client
Product. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Cell Line Royalties</U>. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If Licensee manufactures all of its commercial supplies of the applicable Drug Substance using manufacturing facilities other than WuXi
Biologics&#146; or its Affiliates&#146; manufacturing facilities, Licensee shall pay to WuXi Biologics a Royalty of [***] on the applicable Drug Product&#146;s global Net Sales sold by Licensee, its Affiliates, or sublicensees, paid to WuXi
Biologics [***]. If Licensee manufactures part of its commercial supplies of the applicable Drug Substance using WuXi Biologics&#146; or its Affiliates&#146; manufacturing facilities, the Royalty shall be reduced accordingly on [***] basis,
depending on [***]. If Licensee manufactures all of its commercial supplies of the applicable Drug Substance by WuXi Biologics or its Affiliates, no Royalty is applicable and no Royalty payment shall be due hereunder. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Payment Terms</U> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Licensee shall pay WuXi Biologics&#146; undisputed invoice(s) within [***] days of receipt by Licensee. Such payments will be made by wire
transfer to the account designated by WuXi Biologics. Invoices must be submitted, and payment must be made, [***]. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Bank Account Details</U> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Unless the Parties otherwise mutually agree in writing, and such mutual agreement is set forth in a particular invoice, Licensee shall pay each
invoice by wire transfer to the account designated by WuXi Biologics. With respect to Net Sales invoiced in U.S. dollars, the Net Sales and the amounts due hereunder will be expressed in U.S. dollars. With respect to Net Sales invoiced in a currency
other than U.S. dollars, payments will be calculated based on standard methodologies employed by Licensee or its Affiliates or sublicensees for consolidation purposes for the [***] for which remittance is made for Royalties. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Restriction</U> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Licensee agrees that no attempt will be made by or on behalf of Licensee to modify or reverse engineer the Licensed Cell Line or attempt to
reverse engineer, recreate or assemble the Construct(s). Licensee shall only use the Licensed Cell Line in the way as permitted by this Agreement and shall not use or have used the Licensed Cell Line for any purpose other than as provided hereunder,
including operating the Process, the manufacture of Client Product, Drug Substance and Drug Product, and for other purposes reasonably related to securing Marketing Authorization Approval for the Client Product and/or Drug Product. Licensee shall
not transfer the Licensed Cell Line to any Third Party except to a permitted sublicensee, as described in Section&nbsp;2.2 above, permitted Third Party Manufacturer, or an assignee. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Indemnity</U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Licensee agrees to indemnify, hold harmless and defend WuXi Biologics, its Affiliates, and their respective
directors, officers, employees and agents harmless (collectively, &#147;WuXi Indemnitees&#148;) from and against any and all liabilities and damages (including reasonable attorneys&#146; fees) resulting from any and all claims from any Third Party
(&#147;Claims&#148;) to the extent arising from the use of the Licensed Cell Line, Client Product, Drug Substance or Drug Product by Licensee; except to the extent WuXi Biologics is obligated to indemnify Licensee in accordance with Section&nbsp;9.2
of this Agreement, and provided further that Licensee shall have no obligation to indemnify any such Claims that arise from WuXi Biologics&#146; (i) negligence or intentional misconduct in connection with the Licensed Cell Line (ii)&nbsp;material
breach of this Agreement (including the representations and warranties set forth in Section&nbsp;10); or (iii)&nbsp;Host Cell Line components of the Licensed Cell Line or any Media and Feeds. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">WuXi Biologics will indemnify Licensee, its Affiliates, its sublicensees and their respective directors,
officers, employees and agents, and their respective successors, heirs and assigns (collectively, &#147;Licensee Indemnitees&#148;), and defend and hold each of them harmless, from and against any and all Losses in connection with any and all
Third-Party Claims against Licensee Indemnitees to the extent arising from or occurring as a result of: (i)&nbsp;the breach by WuXi Biologics of any provision of this Agreement; or (ii)&nbsp;any negligence or willful misconduct on the part of any
WuXi Indemnitee in connection with the Host Cell Line components of the Licensed Cell Line, except in each case to the extent Licensee is obligated to indemnify WuXi Biologics in accordance with Section&nbsp;9.1 of this Agreement.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each party must notify the other party within [***] of receipt of any claims made for which the other party
might be liable hereunder. The indemnifying party will have the sole right to defend, negotiate, and settle such claims. The indemnified party will be entitled to participate in the defense of such matter and to employ counsel at its expense to
assist in such defense. No compromise or settlement of any Claim may be made by the indemnifying Party without the indemnified Party&#146;s written consent; provided, however, that the indemnifying party will have final decision-making authority
regarding all aspects of the defense of any claim. The party seeking indemnification will provide the indemnifying party with such information and assistance as the indemnifying party may reasonably request, at the expense of the indemnifying party.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Limitation of Liability</U>. NEITHER PARTY WILL BE LIABLE UNDER ANY LEGAL THEORY (WHETHER TORT, CONTRACT OR
OTHERWISE) FOR SPECIAL, INDIRECT, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES ARISING OUT OF OR RELATED TO THIS AGREEMENT OR THE EXERCISE OF ITS RIGHTS HEREUNDER, INCLUDING LOST PROFITS ARISING FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT,
HOWEVER CAUSED, EVEN IF THE PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, EXCEPT AS A RESULT OF A BREACH OF THE CONFIDENTIALITY AND <FONT STYLE="white-space:nowrap">NON-USE</FONT> OBLIGATIONS IN SECTION 11. NOTHING IN THIS SECTION 9.4
IS INTENDED TO LIMIT OR RESTRICT THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF EITHER PARTY. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>10.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Representations and Warranties</U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">WuXi Biologics represents and warrants that: (i)&nbsp;it is a corporation duly organized validly existing and
in good standing under the laws of Hong Kong; (ii)&nbsp;the execution, delivery and performance of this Agreement have been duly authorized by all necessary corporate action on the part of WuXi Biologics; (iii)&nbsp;the performance of WuXi
Biologics&#146; obligations under this Agreement will not conflict with its charter documents or result in a material breach of any agreements, contracts or other arrangements to which it is a party; (iv)&nbsp;WuXi Biologics will not before the
termination of this Agreement enter into any agreements, contracts or other arrangements that would be materially inconsistent with its obligations under this Agreement; (v)&nbsp;WuXi Biologics has sufficient facilities, experienced personnel and
other capabilities reasonably suited to enable it to perform its obligations under this Agreement; (vi)&nbsp;WuXi Biologics has the right to grant the licenses or sublicenses, as the case may be, therefor granted under this Agreement;
(vii)&nbsp;WuXi Biologics is the sole and exclusive owner of the Licensed <FONT STYLE="white-space:nowrap">Know-how</FONT> and Licensed Cell Line, or otherwise has the right to license the Licensed <FONT STYLE="white-space:nowrap">Know-how</FONT>
and Licensed Cell Line and grant rights to Licensee as set forth in this Agreement and during the Term of the Agreement, (viii)&nbsp;to the best of its knowledge, WuXi Biologics is and will remain entitled to grant to Licensee the licenses and
rights specified or contemplated by this Agreement, and to the Licensed <FONT STYLE="white-space:nowrap">Know-How,</FONT> (ix)&nbsp;as of the Effective Date, neither WuXi Biologics nor any of its Affiliates has received any notice challenging WuXi
Biologics&#146; ownership or right to use the Licensed <FONT STYLE="white-space:nowrap">Know-How</FONT> in relation to the Licensed Cell Line and, Host Cell Line component of the Licensed Cell Line, (x)&nbsp;to the best of WuXi Biologics&#146;s
knowledge, there are no valid grounds for any claim against WuXi Biologics or any of its Affiliates except for any claims caused by Licensee&#146;s DNA sequence related to the Client Product incorporated into the Licensed Cell Line.
</P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Licensee represents and warrants that: (i)&nbsp;it is a corporation duly organized validly existing and in good
standing under the laws of the Commonwealth of Massachusetts; (ii)&nbsp;the execution, delivery and performance of this Agreement have been duly authorized by all necessary corporate action on the part of Licensee; (iii)&nbsp;the performance of
Licensee&#146;s obligations under this Agreement will not conflict with its charter documents or result in a material breach of any agreements, contracts or other arrangements to which it is a party; (iv)&nbsp;Licensee has sufficient facilities,
experienced personnel and other capabilities reasonably suited to enable it to perform its obligations under this Agreement; and (v)&nbsp;Licensee will not before the termination of this Agreement enter into any agreements, contracts or other
arrangements that would be materially inconsistent with its obligations under this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Disclaimer of Warranties. OTHER THAN AS PROVIDED IN THIS AGREEMENT, THE LICENSED
<FONT STYLE="white-space:nowrap">KNOW-HOW,</FONT> AND LICENSED CELL LINES ARE PROVIDED AND LICENSED TO LICENSEE &#147;AS IS&#148;, THE PARTIES MAKE NO REPRESENTATIONS AND EXTEND NO WARRANTIES OR CONDITIONS OF ANY KIND, EITHER EXPRESS OR IMPLIED,
WITH RESPECT THERETO OR TO THE PRODUCTS, INCLUDING, BUT NOT LIMITED TO, WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, VALIDITY OF THE RIGHTS LICENSED HEREUNDER, OR NONINFRINGEMENT OF THE INTELLECTUAL PROPERTY RIGHTS OF THIRD
PARTIES. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>11.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Confidentiality</U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">11.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to the exceptions listed below, during the term of this Agreement and for [***] thereafter, the
Receiving Party shall, and shall ensure that its Related Persons will, (a)&nbsp;maintain the Disclosing Party&#146;s Confidential Information in confidence, (b)&nbsp;not use such Confidential Information other than in connection with this Agreement,
and (c)&nbsp;not disclose such Confidential Information to any Third Party other than (i)&nbsp;those of its Related Persons that have a need to know such </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Confidential Information in connection with the Activities conducted pursuant to the Agreement and are obligated to maintain such Confidential Information in confidence and (ii)&nbsp;to the
extent required by applicable law or judicial order, or to the extent reasonably necessary to prosecute or defend litigation or arbitration in relation to this Agreement, and, in either case, only after the Receiving Party gives the Disclosing Party
[***] advance written notice of such requirement and [***] with the Disclosing Party&#146;s efforts to limit or avoid such disclosure, to seek a protective order or secure confidential treatment of the Confidential Information, and/or to seek any
other remedies available to the Disclosing Party at law or in equity. Notwithstanding the foregoing, the existence of this Agreement and its <FONT STYLE="white-space:nowrap">non-technical</FONT> terms may be disclosed confidentially in connection
with a potential financing, collaboration or acquisition or in discussion with a potential acquirer of Client Product. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">11.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Receiving Party&#146;s obligations set forth in Section&nbsp;11.1 do not apply to Confidential Information
if (a)&nbsp;the information is public knowledge or becomes public knowledge after disclosure through no act or omission of the Receiving Party or any of its Related Persons, (b)&nbsp;the information can be shown by the Receiving Party to have been
lawfully in its possession prior to disclosure, (c)&nbsp;the information was rightfully received on a <FONT STYLE="white-space:nowrap">non-confidential</FONT> basis from a Third Party that was not obligated to maintain the information in confidence,
or (d)&nbsp;the Receiving Party can show that equivalent information was developed independently by the Receiving Party without reference to the Disclosing Party&#146; Confidential Information. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">11.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Licensee may disclose the Confidential Information of WuXi Biologics to a Third Party for the purpose of
exercising Licensee&#146;s license rights hereunder (including disclosure to potential Third Party sublicensees), provided that Licensee shall, prior to such disclosure, ensure that each Third Party to which disclosure is to be made is made aware of
the obligations contained in this Agreement and agrees to be subject to obligations of confidentiality and <FONT STYLE="white-space:nowrap">non-use</FONT> no less onerous than those contained in this Agreement. Any breaches of the obligations of
confidentiality and <FONT STYLE="white-space:nowrap">non-use</FONT> contained in this Agreement by such Third Party shall be treated as a breach of such obligations by Licensee. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">11.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notwithstanding anything to the contrary in this Agreement, a Party may disclose this Agreement and its terms,
and material developments or material information generated under this Agreement, in securities filings with the U.S. Securities and Exchange Commission (or equivalent foreign agency) and any rules of stock exchanges where the Parties may be listed
to the extent required by applicable law after complying with the procedure set forth in this Section&nbsp;11.4. In such event, unless otherwise required to comply with applicable law, the Party seeking such disclosure will prepare a draft
confidential treatment request and proposed redacted version of this Agreement to request confidential treatment for this Agreement, and the other Party will [***] give its input in a [***] in order to allow the Party seeking disclosure to file its
request within the timelines proscribed by applicable laws and regulations. The Party seeking such disclosure shall exercise [***] to obtain confidential treatment of this Agreement from the U.S. Securities and Exchange Commission (or equivalent
foreign agency) as represented by the redacted version reviewed by the other Party. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">11.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The provisions of this Section&nbsp;11 shall survive termination or expiry of this Agreement.
</P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>12.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Termination</U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Voluntary Termination by Licensee</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Licensee shall have the right to terminate this Agreement upon at least six (6)&nbsp;months prior written notice to WuXi Biologics, and upon
payment of all undisputed amounts due to WuXi Biologics through such termination effective date. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Termination for Default</U> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Nonpayment</U>. In the event Licensee fails to pay any undisputed amounts due and payable to WuXi Biologics
hereunder, and fails to make such payments within thirty (30)&nbsp;days after receiving written notice of such failure, WuXi Biologics may terminate this Agreement [***] upon written notice to Licensee. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Material Breach.</U> In the event Licensee commits a material
breach of its obligation under this Agreement and fails to cure that breach within sixty (60)&nbsp;days after receiving written notice thereof, WuXi Biologics may terminate this Agreement [***] upon written notice to Licensee. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Termination Upon Bankruptcy</U>. If either Party makes an assignment for the benefit of creditors, appoints
or suffers appointment of a receiver or trustee over all or substantially all of its property, files a petition or commences a proceeding under any bankruptcy or insolvency act in any state or country or has any such petition or application filed
against it which is not discharged within [***] of the filing thereof, then the other Party may thereafter terminate this Agreement effective [***] upon written notice to such Party. All rights and licenses granted under or pursuant to this
Agreement by WuXi Biologics are, and will otherwise be deemed to be, for purposes of the relevant provisions of the Bankruptcy and Insolvency Act, R.S.C. 1985, c. <FONT STYLE="white-space:nowrap">B-3</FONT> (&#147;BIA&#148;), including Sections
65.11(7), 65.13(9), 72.1 and 246.1 of the BIA; and the relevant provisions of the Companies&#146; Creditors Arrangement Act, R.S.C. 1985, c. <FONT STYLE="white-space:nowrap">C-36</FONT> (&#147;CCAA&#148;), including Sections 32(6) and 36(8) of the
CCAA (the BIA and CCAA being referred to collectively as the &#147;Insolvency Legislation&#148;), a grant of a &#147;right to use&#148; &#147;intellectual property&#148; as used in the Insolvency Legislation. The Parties agree that Licensee and its
Affiliates and sublicensees, as licensees of such rights under this Agreement, will retain and may fully exercise all of their rights and elections under the Insolvency Legislation subject to the payment of amounts provided for herein. Without
limiting Licensee&#146;s rights under the Insolvency Legislation, if WuXi Biologics becomes insolvent or makes an assignment for the benefit of its creditors or there is filed by or against it any bankruptcy, receivership, reorganization or similar
proceeding pursuant to or under the Insolvency Legislation or otherwise, Licensee will be entitled to a copy of any and all information specified in the Technology Transfer Package unless WuXi Biologics, or its trustee or receiver, elects within
[***] to continue to perform all of its obligations under this Agreement. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Expiration or termination of this Agreement for any reason will not relieve either party of any obligation
accruing prior to such expiration or termination, including section 5 (Cell Line Royalties), shall survive termination or expiry of this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>13.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Miscellaneous</U>. </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Assignment</U>. This Agreement may not be assigned or otherwise transferred by either Party (subject to
Licensee&#146;s right to sublicense its rights hereunder) without the prior written consent of the other Party, which consent shall not be unreasonably withheld, conditioned or delayed; <I>provided, however</I>, that a Party may, without such
consent, assign this Agreement in its entirety (a)&nbsp;to an Affiliate, or (b)&nbsp;to a Third Party in connection with a merger, acquisition, consolidation or a sale involving all or substantially all of the assets or business of such Party. Any
attempted assignment or transfer in violation of this Section&nbsp;13.1 shall be void. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Regulatory Assistance</U>. WuXi Biologics will provide assistance to Licensee, and any sublicensee, in
respect of Licensee&#146;s or such sublicensee&#146;s regulatory filing activities for the Client Product and/or Drug Product, at Licensee&#146;s or such sublicensee&#146;s reasonable cost and expense on [***] rate. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Governing Law</U>. The laws of the State of New York, USA, without regard to any choice of law principle
that would require the application of the law of another jurisdiction, govern all matters relating to this Agreement and the enforcement thereof. The parties expressly reject any application to this Agreement of (a)&nbsp;the United Nations
Convention on Contracts for the International Sale of Goods; and (b)&nbsp;the 1974 Convention on the Limitation Period in the International Sale of Goods, as amended by that certain Protocol, done at Vienna on April&nbsp;11, 1980.
</P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Arbitration</U>. The parties shall engage in good faith consultation to resolve any dispute arising out of
or in connection with this agreement. Such consultation will begin [***] after one party has delivered to the other party a request for consultation. If the dispute cannot be resolved [***] following the date on which the request for consultation is
delivered, then either party may submit the dispute to JAMS International Arbitration Rules (&#147;Arbitration&#148;). The Arbitration tribunal will consist of three arbitrators. Within [***] after the commencement of the Arbitration, each Party
shall select one person to act as arbitrator, each of whom must be a practicing or retired attorney or judge have at least [***] of litigation experience within the biopharmaceutical industry. The two arbitrators so selected shall select the chair
within [***] of the commencement of the Arbitration, whom must a practicing or retired attorney or judge have at least [***] of litigation experience within the biopharmaceutical industry. If the arbitrators selected by the Parties are unable or
fail to agree upon the third arbitrator within the allotted time, the third arbitrator shall be appointed by JAMS in accordance with the JAMS International Arbitration Rules. All arbitrators shall serve as neutral, independent and impartial
arbitrators. (ii)&nbsp;The Arbitration shall be conducted in accordance with the expedited procedures set forth in the JAMS International Arbitration Rules. The place of arbitration will be Manhattan, New York. The official language of the
arbitration will be English. The arbitration proceedings will be confidential, and the arbitrator may issue appropriate protective orders to safeguard each party&#146;s Confidential Information. During the course of arbitration, the parties shall
continue to implement the terms of this agreement. The arbitral award will be final and binding upon the parties, and the party to the award may apply to a court of competent jurisdiction for enforcement of the award. Notwithstanding the foregoing,
each party has the right to institute an action in a court of proper jurisdiction for injunctive or other equitable relief pending a final decision by the arbitrator. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Counterparts</U>. This Agreement may be executed in two (2)&nbsp;or more counterparts, each of which shall
be deemed an original, but all of which together shall constitute one and the same instrument. This Agreement may be executed by facsimile, .pdf or other electronically transmitted signatures and such signatures shall be deemed to bind each Party
hereto as if they were the original signatures. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Parties hereto have caused this AGREEMENT to be duly executed as of the Effective
Date set forth above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="29%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="27%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"><B>WuXi Biologics (Hong Kong) Limited</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"><B>Paragon Therapeutics, Inc.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Zhisheng Chen</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Kenneth Evan Thompson</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3">Print&nbsp;Name:&nbsp;&nbsp;&nbsp;&nbsp;Zhisheng Chen</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Kenneth Evan Thompson</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3">Title:&nbsp;&nbsp;&nbsp;&nbsp;CEO</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">COO</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>15
<FILENAME>d518298dex103.htm
<DESCRIPTION>EX-10.3
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.3 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOVATION AGREEMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This
Novation Agreement (this &#147;<B>Novation Agreement</B>&#148;) dated as of July&nbsp;21, 2023 (the &#147;<B>Effective Date</B>&#148;), is entered into by and among (i)&nbsp;Paragon Therapeutics, Inc., a Delaware corporation with an office at 221
Crescent Street, Building 23, Suite 105, Waltham, MA 02453 (the &#147;<B>Transferor</B>&#148;), (ii) Aeglea Biotherapeutics, Inc., a Delaware corporation with an office at 221 Crescent Street Building 21, Suite 105, Waltham, MA 02453
(&#147;<B>Aeglea</B>&#148;), and (iii)&nbsp;WuXi Biologics (Hong Kong) Limited, a Hong Kong corporation with its registered address at Flat/RM826, 8/F Ocean Centre Harbour City, 5 Canton Road TST, Hong Kong (the &#147;<B>Counterparty</B>&#148;). All
capitalized but undefined terms herein shall have the meanings ascribed to them in the Original Contracts (as defined below). </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, Transferor and Counterparty entered into the Original Contracts; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the parties desire to novate the Original Contracts to replace the Transferor with Aeglea, and Counterparty wishes to consent to such
novation, in each case on the terms and conditions set forth in this Novation Agreement and each party hereby consents to such novation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the foregoing premises and the respective agreements, covenants and conditions herein contained, and other
good and valuable consideration, Transferor, Aeglea and Counterparty agree as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.&nbsp;&nbsp;&nbsp;&nbsp;<U>Contract Subject to
This Novation Agreement</U>. This Novation Agreement is entered into with reference to those certain contracts by and between Counterparty and the Transferor, referred to in <U>Exhibit A</U> (the &#147;<B>Original Contracts</B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.&nbsp;&nbsp;&nbsp;&nbsp;<U>Novation</U>. As of the Effective Date, Transferor hereby assigns to Aeglea all of Transferor&#146;s rights,
liabilities and obligations under the Original Contracts whether arising prior to, on or subsequent to the Effective Date, and Aeglea hereby accepts and assumes the assignment of all such Transferor&#146;s rights, liabilities and obligations under
the Original Contracts, and Aeglea shall be bound by all of the terms of the Original Contracts in every way as if Aeglea were a party to the Original Contracts. Aeglea shall be and hereby is substituted for the Transferor in the Original Contract
and shall acquire all the rights and liabilities and shall become obligated to perform all of the obligations of the Transferor, in each case, that are hereby assigned to Aeglea. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.&nbsp;&nbsp;&nbsp;&nbsp;<U>Release</U>. Transferor and Counterparty hereby mutually release each other from all obligations contained in the
Original Contracts and from all claims and demands whatsoever in respect of the Original Contracts whether arising prior to, on or subsequent to the Effective Date. In consideration of this novation, the Transferor shall be relieved of all
obligations to perform under the Original Contracts, and shall be, and hereby is, fully relieved of any and all liability arising out of the Original Contracts. Each of Aeglea and the Counterparty may enforce the Original Contracts and pursue any
claims and demands under or in connection with the Original Contracts against the other with respect to matters arising before, on or after the Effective Date as though Aeglea were the original party to the Original Contracts instead of the
Transferor. Aeglea agrees to perform any and all obligations, including payment obligations, of Transferor under the </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Original Contracts in the place of the Transferor. The obligations under the Original Contracts that Transferor has performed to the Counterparty in accordance with the Original Contracts need
not be performed by Aeglea to the Counterparty again. The obligations under the Original Contracts that Counterparty has performed to the Transferor in accordance with the Original Contracts need not be performed by the Counterparty to Aeglea again.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.&nbsp;&nbsp;&nbsp;&nbsp;<U>Governing Law</U>. This Novation Agreement shall be governed by, and construed in accordance with, the laws
of the State of New York, without giving effect to its conflicts of law principles. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.&nbsp;&nbsp;&nbsp;&nbsp;<U>Counterparts</U>. This
Novation Agreement may be executed and delivered in any number of counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Counterparts may be executed and delivered via
facsimile, electronic signature, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to
have been duly and validly delivered and be valid and effective for all purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.&nbsp;&nbsp;&nbsp;&nbsp;<U>Severability</U>. The
invalidity or unenforceability of any provision hereof shall in no way affect the validity or enforceability of any other provision. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">[SIGNATURE PAGE FOLLOWS] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties hereto have executed this Novation Agreement as of the Effective Date. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="26%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="73%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Transferor:</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>PARAGON THERAPEUTICS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Evan Thompson</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Print Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Evan Thompson</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>COO</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Aeglea:</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>AEGLEA BIOTHERAPEUTICS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Cameron Turtle</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Print Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Cameron Turtle</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>COO</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Counterparty<B>:</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>WuXi Biologics (Hong Kong) Limited</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Chris Chen</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Print Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Chris Chen</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT A </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Original Contracts </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Biologics Master Services Agreement effective June&nbsp;20, 2022, signed in April 2023 </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">B.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Cell Line License Agreement dated June&nbsp;20, 2022, signed in April 2023 </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">C.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Customer Order: WO.PARAG-20230601<B> </B>dated June&nbsp;9, 2023 </P></TD></TR></TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>16
<FILENAME>d518298dex104.htm
<DESCRIPTION>EX-10.4
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.4</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.4 </B></P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g518298dsp14a.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">November&nbsp;22, 2023 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cameron Turtle </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Re: Amended and Restated Employment Letter
Agreement </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Cameron: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On behalf of Aeglea
BioTherapeutics, Inc. (the &#147;<U>Company</U>&#148;), I am very pleased to offer you a position as Chief Executive Officer of the Company (the &#147;<U>Role</U>&#148;) pursuant to this letter agreement (the &#147;<U>Agreement</U>&#148;), provided
you accept such offer as indicated by your signature below, to be effective November&nbsp;22, 2023 (the &#147;<U>Effective Date</U>&#148;). This Agreement amends and restates that certain letter agreement date June&nbsp;22, 2023. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. Position</B>. While serving in the Role, you will report to the Board of Directors of the Company (the &#147;Board&#148;). You will have such duties,
authorities, and responsibilities as are customarily associated with the Role. This is a full-time employment position. It is understood and agreed that you will not engage in any other employment, consulting or other business activities (whether
full-time or part-time), except as expressly authorized in writing by the Company. Notwithstanding the foregoing, you may engage in religious, charitable and other community activities so long as such activities do not unreasonably interfere or
conflict with your obligations to the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Base Salary</B>. Upon and following the Effective Date, as cash compensation for your services, the
Company will pay you an initial base salary of $625,000 per year, payable in accordance with the Company&#146;s standard payroll schedule and subject to applicable deductions and withholdings. Your base salary will be subject to periodic review and
potential adjustment in the Company&#146;s discretion. Your base salary in effect at any given time is referred to herein as the &#147;<U>Base Salary</U>.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. Annual Bonus</B>. You will continue to be eligible to receive an annual performance bonus targeted at 55% of your Base Salary. The target annual bonus
in effect at any given time is referred to herein as &#147;<U>Target Bonus</U>.&#148; Your 2023 annual bonus will be prorated based on your period of employment with the Company. The actual bonus amount is discretionary and may be subject to
achievement of performance targets established by the Company for such year. To earn an annual bonus, you must be (except as otherwise provided herein) employed by the Company as of the payment date of such bonus. Any annual bonus will be paid no
later than March 15th of the calendar year following the calendar year to which such bonus relates. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g518298dsp14b.jpg" ALT="LOGO">
 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g518298dsp14a.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. Equity Grant</B>. Subject to approval by the Board or the Compensation Committee of the Board, as soon
as practicable following the Effective Date, the Company will grant you stock options to purchase 374,000 shares of the Company&#146;s common stock with an exercise price equal to the fair market value of the underlying shares on the date of grant
as determined by the Board or the Compensation Committee of the Board (the &#147;<U>Options</U>&#148;). The Options will vest over a four year period following your grant date, with 25% of the Options vesting on the first anniversary of the grant
date, and the remainder vesting in 36 equal monthly installments on each monthly anniversary thereafter, in each case, subject to your continued services with the Company through the applicable vesting dates. The Options will be governed by the
terms of the related award agreements, the Company&#146;s 2016 Equity Incentive Plan and the terms and conditions approved by the Board or the Compensation Committee of the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. Benefits/Paid Time Off. </B>You will continue to be eligible, subject to the terms of the applicable plans and programs, to participate in the employee
benefits and insurance programs generally made available to the Company&#146;s full-time employees. Details of such benefits programs, including applicable employee contributions and waiting periods, if applicable, will be made available to you when
such benefit(s) become available. You will be entitled to paid time off consistent with the terms of the Company&#146;s paid time off policy, as in effect from time to time. The Company reserves the right to modify, limit, amend or cancel any of its
benefits plans or programs at any time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. Expense Reimbursement. </B>The Company will reimburse you for all reasonable and necessary expenses
incurred by you in connection with performing your duties as an employee of the Company and that are <FONT STYLE="white-space:nowrap">pre-approved</FONT> by the Company, provided that you comply with any Company policy or practice on submitting,
accounting for and documenting such expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. Location</B>. Your primary work location will be remotely in Washington, provided that you may be
required to engage in reasonable travel for business, consistent with the Company&#146;s business needs. You may change your remote work location with prior written notice to and approval from the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8. <FONT STYLE="white-space:nowrap">At-Will</FONT> Employment; Date of Termination</B>. At all times, your employment with the Company is &#147;at
will,&#148; meaning you or the Company may terminate it at any time for any or no reason, subject to the terms of this Agreement. Although your job duties, title, reporting structure, compensation and benefits, as well as the Company&#146;s benefit
plans and personnel policies and procedures, may change from time to time (subject to the terms of this Agreement), the &#147;at will&#148; nature of your employment may only be changed in an express written agreement signed by you and an authorized
officer of the Company. Your last day of employment for any reason is referred to herein as the &#147;<U>Date of Termination</U>.&#148; In the event that you elect to end your employment other than for Good Reason, the Company requires you to
provide at least 30 days&#146; advance written notice to the Company; and in the event that the Company terminates you without &#147;Cause&#148;, you shall be given at least 30 days advance written notice by the Company. Notwithstanding the
foregoing, the Company may unilaterally accelerate the Date of Termination, and such acceleration shall not result in a termination without Cause by the Company for purposes of this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g518298dsp14b.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g518298dsp14a.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the extent applicable, you shall be deemed to have resigned from all officer and board member positions
that you hold with the Company or any of its respective subsidiaries and affiliates upon the termination of your employment for any reason. You shall execute any documents in reasonable form as may be requested to confirm or effectuate any such
resignations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. Accrued Obligations</B>. In the event of the ending of your employment for any reason, the Company shall pay you (i)&nbsp;your Base
Salary and, if applicable, any accrued but unused vacation, through the Date of Termination, and (ii)&nbsp;the amount of any documented expenses properly incurred by you on behalf of the Company prior to any such termination and not yet reimbursed
(the &#147;<U>Accrued Obligations</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10. Severance Pay and Benefits Outside of the Change in Control Period</B>. As explained below, under
certain circumstances you will be entitled to severance equal to the Severance Amount (as defined below), accelerated vesting of a portion of your unvested equity awards, plus continued employee benefits pursuant to COBRA (as defined below): </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event that the Company terminates your employment without Cause or you terminate your employment with Good Reason, in either case, outside of the
Change in Control Period (as such capitalized terms are defined in <U>Appendix A</U>), then, in addition to the Accrued Obligations, and subject to (i)&nbsp;your execution and <FONT STYLE="white-space:nowrap">non-revocation</FONT> of a separation
agreement and release in a form acceptable to the Company, which shall include a general release of claims against the Company and all related persons and entities and a reaffirmation of the Continuing Obligations (as defined below) and shall
provide that if you breach the Continuing Obligations, all payments of the Severance Amount (as defined below) shall immediately cease (the &#147;<U>Separation Agreement and Release</U>&#148;), and (ii)&nbsp;the Separation Agreement and Release
becoming irrevocable, all within 60 days after the Date of Termination (or such shorter period as set forth in the Separation Agreement and Release), which shall include a seven (7)&nbsp;day revocation period: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company shall pay you an amount equal to 12 months of your Base Salary plus any bonus earned but unpaid for
the year immediately prior to the year of termination (such salary and bonus together, the &#147;<U>Severance Amount</U>&#148;). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notwithstanding anything to the contrary in any applicable equity-based award agreement or plan, the unvested
portion of your then outstanding equity-based awards subject to time-based vesting (the &#147;<U>Time-Based Equity Awards</U>&#148;) that would have vested within the <FONT STYLE="white-space:nowrap">12-month</FONT> period following the Termination
Date shall immediately accelerate and become vested or nonforfeitable as of the later of (i)&nbsp;the Date of Termination or (ii)&nbsp;the effective date of the Separation Agreement and Release (such later date being the &#147;<U>Accelerated Vesting
Date</U>&#148;); </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g518298dsp14b.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g518298dsp14a.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
and provided further that any termination or forfeiture of the unvested portion of such Time-Based Equity Awards that would otherwise occur on the Date of Termination in the absence of this
Agreement will be delayed until the effective date of the Separation Agreement and Release and will only occur if the vesting pursuant to this subsection does not occur due to the absence of the Separation Agreement and Release becoming fully
effective within the time period set forth therein. Notwithstanding the foregoing, no additional vesting of the Time-Based Equity Awards shall occur during the period between the Date of Termination and the Accelerated Vesting Date.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to your copayment of premium amounts at the applicable active employees&#146; rate and your proper
election to receive benefits under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (&#147;<U>COBRA</U>&#148;), the Company shall pay to the group health plan provider(s), the COBRA provider or you a monthly payment equal to
the monthly employer contribution that the Company would have made to provide health insurance to you if you had remained employed by the Company until the earliest of (A)&nbsp;the <FONT STYLE="white-space:nowrap">12-month</FONT> anniversary of the
Date of Termination; (B)&nbsp;your eligibility for group health plan benefits under any other employer&#146;s group health plan; or (C)&nbsp;the cessation of your continuation rights under COBRA; provided, however, that if the Company reasonably
determines that it cannot pay such amounts to the group health plan provider(s) or the COBRA provider (if applicable) without potentially violating applicable law (including, without limitation, Section&nbsp;2716 of the Public Health Service Act),
then the Company shall convert such payments to payroll payments directly to you for the time period specified above. Such payments, if to you, shall be subject to <FONT STYLE="white-space:nowrap">tax-related</FONT> deductions and withholdings and
paid on the Company&#146;s regular payroll dates. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The amounts payable under <U>Section</U><U></U><U>&nbsp;10(a)</U> and <U>(c)</U>, to
the extent taxable, shall be paid out in substantially equal installments in accordance with the Company&#146;s payroll practice over 12 months commencing within 60 days after the Date of Termination; provided, however, that if the <FONT
STYLE="white-space:nowrap">60-day</FONT> period begins in one calendar year and ends in a second calendar year, the Severance Amount, to the extent it qualifies as <FONT STYLE="white-space:nowrap">&#147;non-qualified</FONT> deferred
compensation&#148; within the meaning of Section&nbsp;409A of the Internal Revenue Code of 1986, as amended (the &#147;<U>Code</U>&#148;), shall begin to be paid in the second calendar year by the last day of such
<FONT STYLE="white-space:nowrap">60-day</FONT> period; provided, further, that the initial payment shall include a <FONT STYLE="white-space:nowrap">catch-up</FONT> payment to cover amounts retroactive to the day immediately following the Date of
Termination. Each payment pursuant to this Agreement is intended to constitute a separate payment for purposes of Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-2(b)(2).</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g518298dsp14b.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g518298dsp14a.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding anything to the contrary in this Agreement, for the avoidance of doubt: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if your employment ends for as a result of a termination by the Company for Cause or a resignation by you
without Good Reason, you will be entitled to the Accrued Obligations and will not be entitled to any further compensation from the Company; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if your employment ends due to your death or Disability, you will receive (i)&nbsp;the Accrued Obligations and
(ii)&nbsp;all outstanding Time-Based Equity Awards shall immediately accelerate and become vested or nonforfeitable as of the Date of Termination, but will not be eligible for any other severance pay or benefits, whether pursuant to
<U>Section</U><U></U><U>&nbsp;10</U>, <U>Section</U><U></U><U>&nbsp;11</U> or otherwise. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11. Severance Pay and Benefits Within the
Change in Control Period</B>. In the event that the Company terminates your employment without Cause or you resign for Good Reason, in each case within the Change in Control Period, then, in addition to you being entitled to the Accrued Obligations,
and subject to your execution and <FONT STYLE="white-space:nowrap">non-revocation</FONT> of the Separation Agreement and Release and it becoming fully effective, all within 60 days after the Date of Termination (or such shorter period as set forth
in the Separation Agreement and Release), which shall include a <FONT STYLE="white-space:nowrap">seven-day</FONT> revocation period: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company shall pay you an amount equal (i)&nbsp;to 18 months of your Base Salary, plus (ii)&nbsp;any bonus
earned but unpaid for the year immediately prior to the year of termination, plus (iii)&nbsp;your Target Bonus for the year in which the termination occurs (in each case, calculated by reference to your Base Salary rate as in effect immediately
prior to your termination, but without giving effect to any prior reduction in Base Salary by the Company which would give rise to your right to resign for Good Reason) (such salary and bonuses together, the &#147;<U>CIC Severance Amount</U>&#148;).
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notwithstanding anything to the contrary in any applicable equity-based award agreement or plan, all of the
unvested Time-Based Equity Awards shall immediately accelerate and become vested or nonforfeitable as of the Accelerated Vesting Date. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All of your outstanding equity-based awards subject to performance-based vesting (the
&#147;<U>Performance-Based Equity Awards</U>&#148;) shall immediately accelerate and become vested or nonforfeitable as of the Accelerated Vesting Date with the performance criteria being deemed to have been met based on the greater of target or, if
determinable, actual performance; provided, however, that the applicable award agreement for any Performance-Based Equity Award may provide for alternative treatment upon a termination covered by this <U>Section</U><U></U><U>&nbsp;11</U>.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g518298dsp14b.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g518298dsp14a.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company shall pay to the group health plan provider(s), the COBRA provider or you a monthly payment equal
to the monthly COBRA continuation premiums until the earliest of (A)&nbsp;the <FONT STYLE="white-space:nowrap">18-month</FONT> anniversary of the Date of Termination; (B)&nbsp;your eligibility for group health plan benefits under any other
employer&#146;s group health plan; or (C)&nbsp;the cessation of your continuation rights under COBRA; provided, however, that if the Company reasonably determines that it cannot pay such amounts to the group health plan provider(s) or the COBRA
provider (if applicable) without potentially violating applicable law (including, without limitation, Section&nbsp;2716 of the Public Health Service Act), then the Company shall convert such payments to payroll payments directly to you for the time
period specified above. Such payments, if to you, shall be subject to <FONT STYLE="white-space:nowrap">tax-related</FONT> deductions and withholdings and paid on the Company&#146;s regular payroll dates. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The amounts payable under <U>Section</U><U></U><U>&nbsp;11(a)</U> and <U>(d)</U>, to the extent taxable, shall be paid out in substantially equal installments
in accordance with the Company&#146;s payroll practice over 18 months commencing within 60 days after the Date of Termination; provided, however, that if the <FONT STYLE="white-space:nowrap">60-day</FONT> period begins in one calendar year and ends
in a second calendar year, the Severance Amount, to the extent it qualifies as <FONT STYLE="white-space:nowrap">&#147;non-qualified</FONT> deferred compensation&#148; within the meaning of Section&nbsp;409A of the Code, shall begin to be paid in the
second calendar year by the last day of such <FONT STYLE="white-space:nowrap">60-day</FONT> period; provided, further, that the initial payment shall include a <FONT STYLE="white-space:nowrap">catch-up</FONT> payment to cover amounts retroactive to
the day immediately following the Date of Termination. Each payment pursuant to this Agreement is intended to constitute a separate payment for purposes of Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-2(b)(2).</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the avoidance of doubt, <U>Section</U><U></U><U>&nbsp;10</U> and <U>Section</U><U></U><U>&nbsp;11</U> of this Agreement are mutually exclusive and in no
event shall you be entitled to payments or benefits pursuant to both <U>Section</U><U></U><U>&nbsp;10</U> and <U>Section</U><U></U><U>&nbsp;11</U> of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12. Continuing Obligations</B>. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>EIACN Agreement</B>. You have previously entered into an Employee Invention Assignment, Confidentiality and <FONT
STYLE="white-space:nowrap">Non-Competition</FONT> Agreement (the &#147;<U>EIACN Agreement</U>&#148;). For purposes of this Agreement, the obligations in this <U>Section</U><U></U><U>&nbsp;12</U> and those that arise in the EIACN Agreement and any
other agreement relating to confidentiality, assignment of inventions, or other restrictive covenants shall collectively be referred to as the &#147;<U>Continuing Obligations</U>.&#148; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Third Party Agreements and Rights</B>. You hereby confirm that you are not bound by the terms of any
agreement with any previous employer or other party which would prevent you from performing your obligations hereunder. You represent to the Company that your execution of this Agreement, your employment with
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g518298dsp14b.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g518298dsp14a.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
the Company and the performance of your proposed duties for the Company will not violate any obligations you may have to any such previous employer or other party. In your work for the Company,
you will not disclose or make use of any information in violation of any agreements with or rights of any such previous employer or other party, and you will not bring to the premises of the Company any copies or other tangible embodiments of <FONT
STYLE="white-space:nowrap">non-public</FONT> information belonging to or obtained from any such previous employment or other party. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Litigation and Regulatory Cooperation</B>. You shall cooperate fully with the Company in (i)&nbsp;the
defense or prosecution of any claims or actions now in existence or which may be brought in the future against or on behalf of the Company which relate to events or occurrences that transpired while you were engaged or employed by the Company, and
(ii)&nbsp;the investigation, whether internal or external, of any matters about which the Company believes you may have knowledge or information. Your full cooperation in connection with such claims, actions or investigations shall include, but not
be limited to, being reasonably available to meet with counsel to answer questions or to prepare for discovery or trial and to act as a witness on behalf of the Company at mutually convenient times. During and after your engagement and employment,
you also shall cooperate fully with the Company in connection with any investigation or review of any federal, state or local regulatory authority as any such investigation or review relates to events or occurrences that transpired while you were
employed by the Company. The Company shall reimburse you for any reasonable <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred in connection with your performance of obligations pursuant
to this <U>Section</U><U></U><U>&nbsp;12</U><U>(c).</U> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Relief</B>. You agree that it would be difficult to measure any damages caused to the Company which might
result from your breach of any of the Continuing Obligations, and that in any event money damages would be an inadequate remedy for any such breach. Accordingly, you agree that if you breach, or propose to breach, any portion of the Continuing
Obligations, the Company shall be entitled, in addition to all other remedies that it may have, to seek an injunction or other appropriate equitable relief to restrain any such breach without showing or proving any actual damage to the Company.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13. Golden Parachute Taxes. </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Best <FONT STYLE="white-space:nowrap">After-Tax</FONT> Result</B>. In the event that any payment or benefit
received or to be received by you pursuant to this Agreement or otherwise (&#147;<U>Payments</U>&#148;) would (i)&nbsp;constitute a &#147;parachute payment&#148; within the meaning of Section&nbsp;280G of the Code and (ii)&nbsp;but for this
subsection (a), be subject to the excise tax imposed by </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g518298dsp14b.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g518298dsp14a.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Section&nbsp;4999 of the Code, any successor provisions, or any comparable federal, state, local or foreign excise tax (&#147;<U>Excise Tax</U>&#148;), then, subject to the provisions of
Section&nbsp;14, such Payments shall be either (A)&nbsp;provided in full pursuant to the terms of this Agreement or any other applicable agreement, or (B)&nbsp;provided as to such lesser extent which would result in the Payments being $1.00 less
than the amount at which any portion of the Payments would be subject to the Excise Tax, whichever of the foregoing amounts, taking into account the applicable federal, state, local and foreign income, employment and other taxes and the Excise Tax
(including, without limitation, any interest or penalties on such taxes), results in the receipt, on an <FONT STYLE="white-space:nowrap">after-tax</FONT> basis, of the greatest amount of payments and benefits provided for hereunder or otherwise,
notwithstanding that all or some portion of such Payments may be subject to the Excise Tax. Unless the Company and you otherwise agree in writing, any determination required under this Section shall be made by independent tax counsel designated by
the Company and reasonably acceptable to you (&#147;<U>Independent Tax Counsel</U>&#148;), whose determination shall be conclusive and binding upon you and the Company for all purposes. For purposes of making the calculations required under this
Section, Independent Tax Counsel may make reasonable assumptions and approximations concerning applicable taxes and may rely on reasonable, good faith interpretations concerning the application of Sections 280G and 4999 of the Code; provided that
Independent Tax Counsel shall assume that you pay all taxes at the highest marginal rate. The Company and you shall furnish to Independent Tax Counsel such information and documents as Independent Tax Counsel may reasonably request in order to make
a determination under this Section. The Company shall bear all costs that Independent Tax Counsel may reasonably incur in connection with any calculations contemplated by this Section. In the event that <U>Section</U><U></U><U>&nbsp;13(a)(ii)(B)</U>
above applies, then based on the information provided to you and the Company by Independent Tax Counsel, the cutback described hereunder will apply as to compensation not subject to Section&nbsp;409A of the Code prior to compensation subject to
Section&nbsp;409A of the Code and will otherwise apply on a reverse chronological basis from payments latest in time. If the Internal Revenue Service (the &#147;<U>IRS</U>&#148;) determines that any Payment is subject to the Excise Tax, then
<U>Section</U><U></U><U>&nbsp;13(b)</U> hereof shall apply, and the enforcement of <U>Section</U><U></U><U>&nbsp;13(b)</U> shall be the exclusive remedy to the Company. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Adjustments</B>. If, notwithstanding any reduction described in <U>Section</U><U></U><U>&nbsp;13(a)</U>
hereof (or in the absence of any such reduction), the IRS determines that you are liable for the Excise Tax as a result of the receipt of one or more Payments, then you shall be obligated to surrender or pay back to the Company within <FONT
STYLE="white-space:nowrap">one-hundred</FONT> 120 days after a final IRS determination, an amount of such payments or benefits equal to the &#147;<U>Repayment Amount</U>.&#148; The Repayment Amount with respect to such
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g518298dsp14b.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g518298dsp14a.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Payments shall be the smallest such amount, if any, as shall be required to be surrendered or paid to the Company so that your net proceeds with respect to such Payments (after taking into
account the payment of the Excise Tax imposed on such Payments) shall be maximized. Notwithstanding the foregoing, the Repayment Amount with respect to such Payments shall be zero if a Repayment Amount of more than zero would not eliminate the
Excise Tax imposed on such Payments or if a Repayment Amount of more than zero would not maximize the net amount received from the Payments. If the Excise Tax is not eliminated pursuant to this <U>Section</U><U></U><U>&nbsp;13(b)</U>, you shall pay
the Excise Tax. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14. Section</B><B></B><B>&nbsp;409A</B>. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Anything in this Agreement to the contrary notwithstanding, if at the time of your separation from service
within the meaning of Section&nbsp;409A of the Code, the Company determines that you are a &#147;specified employee&#148; within the meaning of Section&nbsp;409A(a)(2)(B)(i) of the Code, then to the extent any payment or benefit that you become
entitled to under this Agreement or otherwise on account of your separation from service would be considered deferred compensation otherwise subject to the additional tax imposed pursuant to Section&nbsp;409A(a) of the Code as a result of the
application of Section&nbsp;409A(a)(2)(B)(i) of the Code, such payment shall not be payable and such benefit shall not be provided until the date that is the earlier of (A)&nbsp;six months and one day after your separation from service, or
(B)&nbsp;your death. If any such delayed cash payment is otherwise payable on an installment basis, the first payment shall include a <FONT STYLE="white-space:nowrap">catch-up</FONT> payment covering amounts that would otherwise have been paid
during the <FONT STYLE="white-space:nowrap">six-month</FONT> period but for the application of this provision (without interest), and the balance of the installments shall be payable in accordance with their original schedule. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits provided and expenses eligible for reimbursement
under this Agreement shall be provided by the Company or incurred by you during the time periods set forth in this Agreement. All reimbursements shall be paid as soon as administratively practicable, but in no event shall any reimbursement be paid
after the last day of the taxable year following the taxable year in which the expense was incurred. The amount of <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits provided or reimbursable expenses incurred in one taxable year shall not
affect the <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits to be provided or the expenses eligible for reimbursement in any other taxable year (except for any lifetime or other aggregate limitation applicable to medical expenses). Such
right to reimbursement or <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits is not subject to liquidation or exchange for another benefit. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g518298dsp14b.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g518298dsp14a.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To the extent that any payment or benefit described in this Agreement constitutes <FONT
STYLE="white-space:nowrap">&#147;non-qualified</FONT> deferred compensation&#148; under Section&nbsp;409A of the Code, and to the extent that such payment or benefit is payable upon the termination of your employment, then such payments or benefits
shall be payable only upon your &#147;separation from service.&#148; The determination of whether and when a separation from service has occurred shall be made in accordance with the presumptions set forth in Treasury Regulation <FONT
STYLE="white-space:nowrap">Section&nbsp;1.409A-l(h).</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The parties intend that this Agreement will be administered in accordance with Section&nbsp;409A of the Code.
To the extent that any provision of this Agreement is ambiguous as to its compliance with Section&nbsp;409A of the Code, the provision shall be read in such a manner so that all payments hereunder comply with Section&nbsp;409A of the Code. Each
payment pursuant to this Agreement is intended to constitute a separate payment for purposes of Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-2(b)(2).</FONT> The parties agree that this Agreement may be amended, as
reasonably requested by either party, and as may be necessary to fully comply with Section&nbsp;409A of the Code and all related rules and regulations in order to preserve the payments and benefits provided hereunder without additional cost to
either party. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company makes no representation or warranty and shall have no liability to you or any other person if any
provisions of this Agreement are determined to constitute deferred compensation subject to Section&nbsp;409A of the Code but do not satisfy an exemption from, or the conditions of, such Section. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>15. Withholding; Tax Effect</B>. All forms of compensation referred to in this Agreement are subject to reduction to reflect applicable withholding and
payroll taxes and other deductions required by law. You hereby acknowledge that the Company does not have a duty to design its compensation policies in a manner that minimizes your tax liabilities, and you will not make any claim against the Company
or the Board related to tax liabilities arising from your compensation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>16. Recoupment</B>. Amounts paid or payable under this Agreement shall be
subject to the provisions of any applicable clawback or recoupment policies or procedures adopted by the Company, which clawback or recoupment policies may provide for forfeiture and/or recoupment of amounts paid or payable under this Agreement. No
forfeiture or recoupment under such policies or procedures will give rise to a right to resign for Good Reason or under any agreement between you and the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g518298dsp14b.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g518298dsp14a.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>17. Interpretation and Enforcement</B>. This Agreement, together with Appendix A and the EIACN Agreement,
constitute the complete agreement between you and the Company, contains all of the terms of your employment with the Company. The terms of this Agreement and the resolution of any disputes as to the meaning, effect, performance or validity of this
Agreement or arising out of, related to, or in any way connected with this Agreement, your employment with the Company or any other relationship between you and the Company (the &#147;<U>Disputes</U>&#148;) will be governed by federal law to the
extent applicable and otherwise by Washington law, excluding laws relating to conflicts or choice of law and excluding Disputes arising in connection with any equity incentive plan, which shall be governed by the terms of the applicable equity
incentive plan. You and the Company submit to the exclusive personal jurisdiction of the federal and state courts located in the State of Washington in connection with any Dispute or any claim related to any Dispute, except for Disputes arising
under any equity incentive plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>18. Assignment</B>. Neither you nor the Company may make any assignment of this Agreement or any interest in it, by
operation of law or otherwise, without the prior written consent of the other; provided, however, that the Company may assign its rights and obligations under this Agreement without your consent to any affiliate or to any person or entity with whom
the Company shall hereafter effect a reorganization, consolidate with, or merge into or to whom it transfers all or substantially all of its properties or assets; provided further, that if you remain employed or become employed by the Company, the
purchaser or any of their affiliates in connection with any such transaction, then you shall not be entitled to any payments, benefits or vesting pursuant to <U>Section</U><U></U><U>&nbsp;10</U> or pursuant to <U>Section</U><U></U><U>&nbsp;11</U> of
this Agreement solely as a result of such transaction. This Agreement shall inure to the benefit of and be binding upon you and the Company, and each of your and its respective successors, executors, administrators, heirs and permitted assigns. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>19. Waiver; Amendment</B>. No waiver of any provision hereof shall be effective unless made in writing and signed by the waiving party. The failure of any
party to require the performance of any term or obligation of this Agreement, or the waiver by any party of any breach of this Agreement, shall not prevent any subsequent enforcement of such term or obligation or be deemed a waiver of any subsequent
breach. This Agreement may be amended or modified only by a written instrument signed by you and by a duly authorized representative of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>20. Enforceability</B>. If any portion or provision of this Agreement (including, without limitation, any portion or provision of any section of this
Agreement) shall to any extent be declared illegal or unenforceable by a court of competent jurisdiction, then the remainder of this Agreement, or the application of such portion or provision in circumstances other than those as to which it is so
declared illegal or unenforceable, shall not be affected thereby, and each portion and provision of this Agreement shall be valid and enforceable to the fullest extent permitted by law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>21. Conditions</B>. You must submit satisfactory proof of your identity, successfully complete a criminal background check, which you hereby expressly
authorize by your execution of this Agreement, and provide documentation of your legal authorization to work in the United States on or prior to the Effective Date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g518298dsp14b.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g518298dsp14a.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>22. Employee Representations.</B> It is the policy of the Company not to solicit or accept proprietary
information and / or trade secrets of other companies or third parties. If you have or have had access to trade secrets or other confidential, proprietary information from your former employer or another third party, the use of such information in
performing your duties at the Company is prohibited. This may include, but is not limited to, confidential or proprietary information in the form of documents, magnetic media, software, customer lists, and business plans or strategies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In making this employment offer, the Company has relied on your representation that: (a)&nbsp;you are not currently a party to any agreement that would
restrict your ability to accept this offer or to perform services for the Company; (b)&nbsp;you are not subject to any noncompetition or <FONT STYLE="white-space:nowrap">non-solicitation</FONT> agreement or other restrictive covenants that might
restrict your employment by the Company as contemplated by this offer; (c)&nbsp;you have the full right, power and authority to execute and deliver the Agreement and to perform all of your obligations thereunder; and (d)&nbsp;you will not bring with
you to the Company or use in the performance of your responsibilities at the Company any materials, documents or work product of a former employer or other third party that are not generally available to the public, unless you have obtained written
authorization from such former employer or third party for their possession and use and have provided the Company with a copy of same. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>23. Other
Terms</B>. The provisions of this Agreement shall survive the termination of this Agreement and/or the termination of your employment to the extent necessary to effectuate the terms contained herein. The headings and other captions in this Agreement
are for convenience and reference only and shall not be used in interpreting, construing or enforcing any of the provisions of this Agreement. This Agreement may be executed in separate counterparts. When both counterparts are signed, they shall be
treated together as one and the same document. PDF copies of signed counterparts shall be equally effective as originals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I look forward to working with
you to make the Company a great success. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g518298dsp14b.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g518298dsp14a.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Sincerely,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Scott Burrows</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name: Scott Burrows</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title: Chief Financial Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Accepted and acknowledged:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Cameron Turtle</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Cameron Turtle</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: November&nbsp;22, 2023</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g518298dsp14b.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g518298dsp14a.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Appendix A </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1. &#147;<U>Cause</U>&#148; shall mean (i)&nbsp;your dishonest statements or acts with respect to the Company or any affiliate of the Company, or any current
or prospective customers, suppliers, vendors or other third parties with which such entity does business that results in or is reasonably anticipated to result in material harm to the Company; (ii)&nbsp;your conviction or plea of no contest to:
(A)&nbsp;a felony or (B)&nbsp;any misdemeanor involving moral turpitude, deceit, dishonesty or fraud; (iii)&nbsp;your failure to perform in all material respects your lawful assigned duties and responsibilities to the reasonable satisfaction of the
Board, which failure continues, in the reasonable judgment of the Board, for 30 days after written notice given to you describing such failure; (iv)&nbsp;your gross negligence, willful misconduct that results in or is reasonably anticipated to
result in material harm to the Company; or (v)&nbsp;your violation of any material provision of any agreement(s) between you and the Company or any written Company policies including, without limitation, agreements relating to <FONT
STYLE="white-space:nowrap">non-solicitation,</FONT> <FONT STYLE="white-space:nowrap">non-disclosure</FONT> and/or assignment of inventions or policies related to ethics or workplace conduct. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2. &#147;<U>Change in Control</U>&#148; shall have the meaning provided for the term &#147;Corporate Transaction&#148; under the Company&#146;s 2016 Equity
Incentive Plan (or the meaning provided to any word of similar import under any successor plan). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3. &#147;<U>Change in Control Period</U>&#148; shall
mean the period commencing three months prior to the first event constituting a Change in Control and ending 12 months following the first event constituting a Change in Control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4. &#147;<U>Disability</U>&#148; shall mean a permanent and total disability as defined in Section&nbsp;22(e)&nbsp;(3) of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5. &#147;<U>Good Reason</U>&#148; shall mean that you have complied with the Good Reason Process (hereinafter defined) following the occurrence, without your
written consent, of any of the following events: (i)&nbsp;a material diminution in your base salary or Target Bonus except for <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">across-the-board</FONT></FONT> salary and target bonus
reductions of no more than 10% based on the Company&#146;s financial performance similarly affecting all or substantially all senior management employees of the Company; (ii)&nbsp;a material change in the geographic location at which you are
required to provide services to the Company or a requirement that you change your remote location from your then-current residence; (iii)&nbsp;a material reduction in your duties, authority or responsibilities; (iv)&nbsp;the failure of the Company
to obtain the assumption of this Agreement by a successor; or (v)&nbsp;the material breach of this Agreement (or any other agreements with you) by the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6. &#147;<U>Good Reason Process</U>&#148; shall mean that (i)&nbsp;you reasonably determine in good faith that a &#147;Good Reason&#148; condition has
occurred; (ii)&nbsp;you notify the Company in writing of the first occurrence of the Good Reason condition within 60 days of the first occurrence of such condition; (iii)&nbsp;you cooperate in good faith with the Company&#146;s efforts, for a period
not less than 30 days following such notice (the &#147;<U>Cure Period</U>&#148;), to remedy the condition; (iv)&nbsp;notwithstanding such efforts, the Good Reason condition continues to exist; and (v)&nbsp;you terminate your employment within 30
days after the end of the Cure Period. If the Company cures the Good Reason condition during the Cure Period, Good Reason shall be deemed not to have occurred. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g518298dsp14b.jpg" ALT="LOGO">
 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>17
<FILENAME>d518298dex105.htm
<DESCRIPTION>EX-10.5
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.5</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.5 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I)&nbsp;IS
NOT MATERIAL AND (II)&nbsp;WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED AND RESTATED </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ANTIBODY DISCOVERY AND OPTION AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>T<SMALL>HIS</SMALL> A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL> A<SMALL>NTIBODY</SMALL> D<SMALL>ISCOVERY</SMALL>
<SMALL>AND</SMALL> O<SMALL>PTION</SMALL> A<SMALL>GREEMENT</SMALL></B><SMALL></SMALL> (&#147;<B>Agreement</B>&#148;) is entered into and effective as of September&nbsp;29, 2023 (the &#147;<B>New </B><B>Effective Date</B>&#148;), by and among Paragon
Therapeutics, Inc., a Delaware corporation (&#147;<B>Paragon</B>&#148;), Parapyre Holding LLC, a Delaware limited liability company (&#147;<B>Parapyre</B>&#148;) and Spyre Therapeutics, LLC (&#147;<B>Spyre</B>&#148;), a Delaware limited liability
company and wholly-owned subsidiary of Aeglea BioTherapeutics, Inc. (&#147;<B>Aeglea</B>&#148;). Paragon, Parapyre and Spyre are also referred to herein individually as a &#147;<B>Party</B>&#148;, or collectively as the &#147;<B>Parties</B>.&#148;
</P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>R<SMALL>ECITALS</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>W<SMALL>HEREAS</SMALL></B><SMALL></SMALL>, Paragon has developed a proprietary platform technology for the discovery and development of
antibodies against therapeutically relevant targets; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>W<SMALL>HEREAS</SMALL></B><SMALL></SMALL>, Spyre Therapeutics, Inc.
(&#147;<B>Predecessor</B>&#148;) engaged each of Paragon and Parapyre to identify, evaluate and develop one or more antibody candidates directed to certain mutually agreed therapeutic targets of interest to Predecessor pursuant to an Antibody
Discovery and Option Agreement (the &#147;<B>Original Agreement</B>&#148;) dated May&nbsp;25, 2023 (the &#147;<B>Effective Date</B>&#148;), among Predecessor, Paragon and Parapyre; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>W<SMALL>HEREAS</SMALL></B><SMALL></SMALL>, Paragon and Parapyre have been performing certain antibody discovery and development activities
pursuant to the Original Agreement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>W<SMALL>HEREAS</SMALL></B><SMALL></SMALL>, pursuant to the Original Agreement, Predecessor
received an exclusive option to enter into separate license agreements with Paragon and Parapyre, as applicable, to develop, manufacture and commercialize the resulting antibodies with respect to a given target, all on the terms and subject to the
conditions set forth in the Original Agreement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>W<SMALL>HEREAS</SMALL></B><SMALL></SMALL>, on June&nbsp;22, 2023, Spyre Therapeutics,
Inc. merged with and into Spyre (formerly known as Sequoia Merger Sub II, LLC), pursuant to which Spyre became the surviving entity (the &#147;<B>Merger</B>&#148;); and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>W<SMALL>HEREAS</SMALL></B><SMALL></SMALL>, the parties desire to amend and restate the Original Agreement to, among other matters, update
certain terms of the original arrangement and to amend the parties to the Original Agreement following the Merger. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>N<SMALL>OW</SMALL>
T<SMALL>HEREFORE</SMALL>, </B>in consideration of the foregoing premises and the mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be
legally bound, agree as follows: </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 1 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DEFINED TERMS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.1</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Actual Annual Costs</B>&#148;<B> </B>shall have the meaning set forth in Section&nbsp;5.2(b). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.2</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Aeglea</B>&#148; shall have the meaning provided in the first paragraph of this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1. </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.3</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Affiliate</B>&#148; shall mean any entity, other
than Spyre, Aeglea or Fairmount Funds Management LLC and its affiliated funds, controlled by, controlling, or under common control with a Party hereto. For the purpose of this definition, &#147;control&#148; (including, with correlative meaning, the
terms &#147;controlled by&#148; or &#147;under common control&#148;) means the direct or indirect ownership of more than fifty percent (50%) of the voting interest in, or more than fifty percent (50%) in the equity of, or the right to appoint more
than fifty percent (50%) of the directors or management of, such corporation or other business entity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.4</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Antibody</B>&#148; shall mean any molecule, including [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.5</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Applicable Law</B>&#148; means any national, supra-national, federal, state or local laws, rules,
guidances and regulations, in each case, as applicable to the subject matter and the party at issue. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.6</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Background IP</B>&#148; shall mean all Patents and <FONT STYLE="white-space:nowrap">Know-How</FONT>
Controlled by a Party (a)&nbsp;as of the Effective Date, or (b)&nbsp;that otherwise arise outside of and independently of this Agreement. Paragon&#146;s Background IP includes the Paragon Platform Technology. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.7</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Budget</B>&#148; means the agreed budget for the activities set forth in the applicable Research
Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.8</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Business </B><B>Day</B>&#148; shall mean any day other than Saturday, Sunday or other
national holidays in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.9</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Calendar Quarter</B>&#148; shall mean the respective
periods of three (3)&nbsp;consecutive calendar months ending on March&nbsp;31, June&nbsp;30, September&nbsp;30 and December 31. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.10</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Calendar Year</B>&#148; shall mean each successive period of twelve (12)&nbsp;months commencing on
January&nbsp;1 and ending on December 31. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.11</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Commercialize</B>&#148; or
&#147;<B>Commercializing</B>&#148; shall mean to market, promote, distribute, offer for sale, sell, have sold, import, have imported, export, have exported or otherwise commercialize an Antibody, including any Project Antibody or Derived Antibody,
or Product, as applicable. When used as a noun, &#147;Commercialization&#148; means any and all activities involved in Commercializing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.12</B>&nbsp;&nbsp;&nbsp;&nbsp;<B> </B>&#147;<B>Confidential Information</B>&#148; of a Party shall mean any and all <FONT
STYLE="white-space:nowrap">non-public</FONT> scientific, business, regulatory or technical information that is disclosed or made available by or on behalf of one Party (the &#147;<B>Disclosing Party</B>&#148;) to any other Party (a
&#147;<B>Receiving Party</B>&#148;) in connection with this Agreement, whether in writing, orally, visually or otherwise. Notwithstanding any provision of this Agreement to the contrary, all Project Antibody Inventions and Project Antibody
Technology shall be the Confidential Information of all Parties, and each Party shall be deemed as both the &#147;Disclosing Party&#148; and the &#147;Receiving Party&#148; with respect thereto; provided that if Spyre does not exercise its Option or
the Parties do not enter into a License Agreement in accordance with this Agreement, then the Project Antibody Inventions and Project Antibody Technology shall thereafter be the Confidential Information of Paragon. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.13</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Control</B>&#148; (including any variations such as<B> </B>&#147;<B>Controlled</B>&#148;<B>
</B>and &#147;<B>Controlling</B>&#148;) shall mean, with respect to any Technology or Intellectual Property Rights, possession by a Party and the ability (whether by ownership, license or otherwise) to grant a license or a sublicense of or under
such Technology or Intellectual Property Rights without violating the terms of any agreement or other arrangement with any Third Party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.14</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Cost Advance</B>&#148; shall have the meaning set forth in Section&nbsp;5.2(a). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.15</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Cover</B>&#148; or &#147;<B>Covering</B>&#148;
means, with respect to a Patent, that, in the absence of a license granted under, or ownership of, such Patent, the making, using, selling, importation, or exportation of such product would infringe a valid and unexpired claim of such Patent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.16</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Deliverables</B>&#148; has the meaning set forth in Section&nbsp;2.1(c). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.17</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>&#147;</B><B>Derived Antibody</B><B>&#148;</B><B> </B>shall mean any Antibody that (a)&nbsp;is derived
from or constitutes a modification of a Project Antibody, including [***], and (b) [***]. For avoidance of doubt, any Antibody that [***] will be deemed a Derived Antibody, irrespective of origin. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.18</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Derived Antibody Patent</B>&#148; means any Patent that Covers the composition of matter of, or
any method of specifically making or using, any Derived Antibody. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.19</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Develop</B>&#148;<B>
</B>or<B> </B>&#147;<B>Developing</B>&#148;<B> </B>shall<B> </B>mean to discover, evaluate, test, research or otherwise develop an Antibody, including a Project Antibody or Derived Antibody, or Product. When used as a noun,
&#147;<B>Development</B>&#148; means any and all activities involved in Developing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.20</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Development Costs</B>&#148; shall mean (a) [***] (such amounts, the &#147;<B>Third Party
Costs</B>&#148;), and (b) [***] (such development fees, the &#147;<B>Development Fees</B>&#148;, and the development fees to be paid in any given Calendar Year during the Research Program, the &#147;<B>Annual Development Fees</B>&#148;); in each
case ((a) and (b)) to the extent consistent with the applicable Research Plan (including [***]). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.21</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Directed </B><B>To</B>&#148; means, with regard to an Antibody or Product, that such Antibody or
Product is developed or designed to (a) [***], and (b) [***]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.22</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Dispute</B>&#148; shall have
the meaning provided in Section&nbsp;11.7. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.23</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Election Notice</B>&#148; shall have the meaning
provided in Section&nbsp;4.3. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.24</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Field</B>&#148; shall mean the prophylaxis, palliation,
treatment and diagnosis of human disease and disorders in all therapeutic areas, except with respect to <FONT STYLE="white-space:nowrap">IL-23,</FONT> where &#147;<B>Field</B>&#148; shall mean the prophylaxis, palliation, treatment and diagnosis of
human disease and disorders in the therapeutic area of inflammatory bowel disease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.25</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Indemnified Party</B>&#148;<B> </B>shall have the meaning provided in Section&nbsp;10.3. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.26</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Indemnifying Party</B>&#148; shall have the meaning provided in Section&nbsp;10.3. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.27</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Intellectual Property Rights</B>&#148; shall mean any and all proprietary rights provided under
(a)&nbsp;patent law, including any Patents; (b)&nbsp;copyright law; or (c)&nbsp;any other applicable statutory provision or common law principle, including trade secret law, that may provide a right in
<FONT STYLE="white-space:nowrap">Know-How,</FONT> or the expression or use thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.28</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>JDC</B><B>&#148;</B> shall have the meaning provided in Section&nbsp;3.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.29</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><FONT STYLE="white-space:nowrap">Know-How</FONT></B>&#148; shall mean all technical information
and <FONT STYLE="white-space:nowrap">know-how</FONT> in any tangible or intangible form, including (a)&nbsp;inventions, discoveries, trade secrets, data, specifications, instructions, processes, formulae, materials (including cell lines, vectors,
plasmids, nucleic acids and the like), methods, protocols, expertise and any other technology, including the applicability of any of the foregoing to formulations, compositions or products or to their manufacture, development, registration, use or
marketing or to methods of assaying or testing them or processes for their manufacture, formulations containing them or compositions incorporating or comprising them, and (b)&nbsp;all data, instructions, processes, formulae, strategies, and
expertise, whether biological, chemical, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
pharmacological, biochemical, toxicological, pharmaceutical, physical, analytical, or otherwise and whether related to safety, quality control, manufacturing or other disciplines. Notwithstanding
the foregoing, <FONT STYLE="white-space:nowrap">Know-How</FONT> excludes Patent claims. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.30</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>License Agreement</B>&#148; shall have the meaning set forth in Section&nbsp;4.4(b). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.31</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>License Template</B>&#148; shall have the meaning set forth in Sectdion 4.4(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.32</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Losses</B>&#148; shall have the meaning provided in Section&nbsp;10.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.33</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Manufacture</B>&#148; or &#147;<B>Manufacturing</B>&#148; shall mean to make, produce,
manufacture, process, fill, finish, package, label, perform quality assurance testing, release, ship or store an Antibody, including any a Project Antibody or Derived Antibody, or Product or any component thereof. When used as a noun,
&#147;Manufacture&#148; or &#147;Manufacturing&#148; means any and all activities involved in Manufacturing an Antibody, including any a Project Antibody or Derived Antibody, or Product or any component thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.34</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Option</B>&#148; shall have the meaning provided in Section&nbsp;4.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.35</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Option Period</B>&#148; shall have the meaning provided in Section&nbsp;4.3. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.36</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Paragon Indemnitee</B>&#148; shall have the meaning provided in Section&nbsp;10.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.37</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Paragon Platform <FONT STYLE="white-space:nowrap">Know-How</FONT></B>&#148; means <FONT
STYLE="white-space:nowrap">(a)&nbsp;Know-How</FONT> Controlled by Paragon or its Affiliates prior to or during the Term relating to antibody discovery and development, (b)&nbsp;all methods, materials and other
<FONT STYLE="white-space:nowrap">Know-How</FONT> used in the foregoing Controlled by Paragon or its Affiliates, and (c)&nbsp;platforms embodying, components, component steps and other portions of any of the foregoing in (a)&nbsp;or (b) Controlled by
Paragon or its Affiliates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.38</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Paragon Platform <FONT STYLE="white-space:nowrap">Know-How</FONT>
Improvement</B>&#148;<B> </B>means all <FONT STYLE="white-space:nowrap">Know-How</FONT> developed or discovered through or as a result of the activities performed by or on behalf of Paragon under a Research Program that constitutes an improvement,
enhancement, modification, substitution, or alteration to the Paragon Platform Technology; provided, however, to the extent any of the <FONT STYLE="white-space:nowrap">Know-How</FONT> developed or discovered during the Term that specifically relates
to a Project Antibody will be considered Project Antibody Technology and not Paragon Platform <FONT STYLE="white-space:nowrap">Know-How</FONT> Improvements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.39</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Paragon Platform Patents</B>&#148;<B> </B>means all Patents that Paragon or its Affiliates Control
prior to or during the Term that Cover Paragon Platform <FONT STYLE="white-space:nowrap">Know-How,</FONT> including Patents that Cover Paragon Platform <FONT STYLE="white-space:nowrap">Know-How</FONT> Improvements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.40</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Paragon Platform Technology</B>&#148; means Paragon Platform
<FONT STYLE="white-space:nowrap">Know-How,</FONT> Paragon Platform <FONT STYLE="white-space:nowrap">Know-How</FONT> Improvements and Paragon Platform Patents.<B> </B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.41</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Parapyre</B>&#148; shall have the meaning provided in the first paragraph of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.42</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Patents</B>&#148; shall mean (a)&nbsp;unexpired patents and patent applications, (b)&nbsp;any and
all divisionals, continuations, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">continuations-in-part,</FONT></FONT> reissues, renewals, substitutions, registrations, <FONT STYLE="white-space:nowrap">re-examinations,</FONT>
revalidations, extensions, supplementary protection certificates and the like of any such patents and patent applications, and (c)&nbsp;any and all foreign equivalents of the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.43</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Product</B>&#148; shall mean any product that comprises or contains (a)&nbsp;any Project Antibody
or (b)&nbsp;any Derived Antibody. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.44</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Project Antibody</B>&#148; any and all
Antibodies that are Directed To a particular Selected Target and that are discovered, generated, identified or characterized by Paragon in the course of performing the applicable Research Program. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.45</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Project Antibody Invention</B>&#148; shall mean (a)&nbsp;any invention or discovery, whether or
not patentable, that constitutes the composition of matter of, or any method of specifically making or using, any Project Antibody or a Derived Antibody; and (b)&nbsp;all Intellectual Property Rights therein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.46</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Project Antibody Patents</B>&#148; shall mean all Patents that Cover the composition of matter of,
or any method of specifically making or using, any Project Antibody. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.47</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Project Antibody
Samples</B>&#148; shall have the meaning provided in Section&nbsp;2.1(c). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.48</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Project Antibody
Selection Criteria</B>&#148; means those criteria agreed to by the Parties in the applicable Research Plan that establish that a Project Antibody is suitable for clinical testing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.49</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Project Antibody Technology</B>&#148; shall mean (a)&nbsp;the Project Antibody Inventions;
(b)&nbsp;the Project Antibody Patents, (c)&nbsp;the Sequence Information and Results; and (d)&nbsp;all Intellectual Property Rights therein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.50</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Representatives</B>&#148; of a Party shall mean such Party&#146;s officers, directors, employees,
contractors, subcontractors, agents and consultants and the officers, directors, employees, contractors, subcontractors, agents and consultants of such Party&#146;s ultimate parent entity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.51</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Research Plan</B>&#148; has the meaning set forth in Section&nbsp;2.1(b). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.52</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Research Program</B>&#148; means a research program agreed to by the Parties to identify Project
Antibodies with activity against one Selected Target and to perform such additional activities with respect to such Selected Target as set forth in the applicable Research Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.53</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Research Term</B>&#148; shall mean, on a Research <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Program-by-Research</FONT></FONT> Program basis, the period of time beginning on the Effective Date and continuing until completion of such Research Program or such other date mutually agreed upon by the Parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.54</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Results</B>&#148; means the data, results, analysis, conclusions, outcomes, information,
documentation and reports (in each case, excluding Project Antibody Technology) that are generated by or on behalf of Paragon in performance of a Research Program, excluding Project Antibodies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.55</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Selected Target</B>&#148; has the meaning set forth in Section&nbsp;2.1(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.56</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Sequence Information</B>&#148; means electronic files containing all Project Antibody sequences
generated under a given Research Program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.57</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Shares</B>&#148; means shares of common stock, par
value $0.0001, of Aeglea. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.58</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Spyre</B>&#148; shall have the meaning provided in the first
paragraph of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.59</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Spyre Indemnitee</B>&#148; shall have the meaning provided in
Section&nbsp;10.2. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.60</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Target</B>&#148; means a protein molecule that (a) [***], and (b) [***].
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.61</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Term</B>&#148; shall have the meaning provided in Section&nbsp;9.1. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.62</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Territory</B>&#148; shall mean worldwide. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.63</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Third Party</B>&#148; shall mean any person or entity other than Paragon, Parapyre, Aeglea or
Spyre or an Affiliate of any of Paragon, Parapyre, Aeglea or Spyre. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.64</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Third Party
Claim</B>&#148; shall have the meaning provided in Section&nbsp;10.1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.65</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Valid Claim</B>&#148;
means, with respect to a particular country, a claim (including a process, use, or composition of matter claim) of an issued and unexpired patent (or a supplementary protection certificate thereof) that has not (a)&nbsp;irretrievably lapsed or been
abandoned, permanently revoked, dedicated to the public or disclaimed, or (b)&nbsp;been held invalid, unenforceable or not patentable by a court, governmental agency, national or regional patent office or other appropriate body that has competent
jurisdiction, which holding, finding or decision is final and <FONT STYLE="white-space:nowrap">un-appealable</FONT> or <FONT STYLE="white-space:nowrap">un-appealed</FONT> within the time allowed for appeal. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 2 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONDUCT OF
RESEARCH PROGRAM </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.1&nbsp;&nbsp;&nbsp;&nbsp;Research Program. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Target Selection</B>. The Parties intend to initiate one or more Research Programs, each focused on a
particular Target (each, a &#147;<B>Selected Target</B>&#148;). No more than one (1)&nbsp;Selected Target will be included in any Research Program, unless the Parties otherwise agree in writing (e.g., in the case of a Research Program seeking to
develop a [***]). As of the Effective Date, the Parties have agreed to the Selected Targets listed on <U>Exhibit A</U>. Additional Targets may be added to the Selected Targets by mutual written agreement of the Parties, it being understood that each
Party may accept or reject a new Selected Target in its sole discretion and no Party shall be obligated under this Agreement to agree to any further Selected Targets. The Parties acknowledge that, prior to any agreement with respect to a Selected
Target and a Research Plan, it is intended that the Parties may initiate, from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">time-to-time,</FONT></FONT>
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;proof-of-concept&#148;</FONT></FONT> studies [***] at no <FONT STYLE="white-space:nowrap">up-front</FONT> Research Initiation Fee to Spyre; <U>provided</U>, that the costs of
any such <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;proof-of-concept&#148;</FONT></FONT> studies may be recaptured by Paragon within the specified Research Plan and associated fees, in each case, as agreed by the
Parties. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Research Plan. </B>No later than [***] days after the Effective Date (or in the case of any
Selected Target added after the Effective Date, no later than [***] days after the Parties&#146; written agreement on such additional Selected Target), the Parties will agree on a research plan, to the extent a research plan has not been previously
agreed upon, for the applicable Selected Target that will include design, modeling, synthesis, evaluation, and other mutually agreed activities (&#147;<B>Research Plan</B>&#148;). For clarity, if at the end of such [***] day period (or any extension
thereof mutually agreed in writing)&nbsp;(a) the Parties have not agreed on a Research Plan, or (b)&nbsp;Spyre has not paid Paragon the Research Initiation Fee, the target shall cease to be a Selected Target and Paragon shall have no obligations
with respect thereto. Once the Parties agree on a Research Plan and Spyre pays the Research Initiation Fee for the Research Program, Paragon and Parapyre shall conduct research under a Research Program directed to the applicable Selected Target in
an effort to produce Project Antibodies against such Selected Target for further Development, Manufacture and Commercialization by Spyre. The Parties may amend the Research Plan upon mutual written agreement. Paragon and Parapyre will use [***] to
conduct and complete the activities set forth in such Research Plan on the timelines set forth in such Research Plan and in compliance with the Budget. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(<SMALL>C</SMALL>)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Deliverables; Project Antibody Samples. </B>Following completion of a Research Program,
Paragon and Parapyre will deliver to Spyre a data package that includes Sequence Information for all Project Antibodies and all Results (the &#147;<B>Deliverables</B>&#148;). Additionally, upon request by Spyre, and at [***] cost and expense,
Paragon and Parapyre shall provide to Spyre samples of proteins corresponding to Project </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Antibodies that have been expressed in accordance with the Research Plan (&#147;<B>Project Antibody Samples</B>&#148;) to enable Spyre to evaluate the Option. During the Option Period, Spyre will
review the Deliverables and Project Antibody Samples to determine whether [***] Project Antibody meets the Project Antibody Selection Criteria. If Spyre determines that [***] Project Antibody meets the Project Antibody Selection Criteria, then Spyre
will so notify Paragon prior to the end of the Option Period. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Conduct of Research Program. </B>During
the Research Term,<B> </B>Paragon and Parapyre shall (a)&nbsp;perform the activities assigned to them under the applicable Research Plan in a professional, diligent and good scientific manner, in compliance with all Applicable Law, and in compliance
with the applicable Research Plans; (b)&nbsp;ensure that its Representatives and subcontractors diligently perform the applicable Research Program in a manner in accordance with generally accepted industry practices by appropriately trained
personnel who are experienced in the relevant fields and in compliance with Applicable Law; (c)&nbsp;keep Spyre fully informed regarding the progress and results of the Research Program; (d)&nbsp;promptly provide Spyre with any additional
information regarding the Research Program that Spyre reasonably requests; (e)&nbsp;participate in teleconference(s) at a time(s) agreed upon by the Parties to provide an update to Spyre on the performance of the Research Program; and (f)&nbsp;give
Spyre prompt written notice with respect to information known or believed by Paragon and Parapyre to be likely to materially impede or otherwise adversely affect the performance of the Research Program. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.2</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Subcontractors. </B>Paragon and Parapyre may perform some of the activities under a Research Program
through one or more subcontractors, provided that Paragon and Parapyre shall at all times be fully responsible for the compliance of such subcontractors with this Agreement and for the performance of their obligations under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.3</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Research Books and Records; Audit</B>.<B> </B>Paragon shall maintain complete and accurate records
related to the activities performed by Paragon and Parapyre under a Research Program. All such books and records shall be retained by Paragon until the later of: (a) [***] after the end of the applicable stage of research; and (b)&nbsp;such longer
period as may be required by Applicable Law. Upon Spyre&#146;s request and at [***] expense, Paragon shall provide copies of such records or such records shall be made available for Spyre&#146;s reasonable review, audit and inspection upon
reasonable notice and with reasonable frequency. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 3 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GOVERNANCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.1</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Joint Development Committee</B>. The Parties will establish a single Joint Development Committee (the
&#147;<B>JDC</B>&#148;) to oversee and coordinate the activities under all Research Programs in accordance with the remainder of this Article 3. The JDC shall be comprised of two (2)&nbsp;employees from Spyre or Aeglea and two (2)&nbsp;employees
from Paragon, with each Party designating one (1)&nbsp;such employee as its JDC <FONT STYLE="white-space:nowrap">co-chairperson.</FONT> Subject to the foregoing, each Party shall appoint its respective Representatives to the JDC from time to time,
and may change its Representatives, in its sole discretion, effective upon notice to the other Parties designating such change. Representatives from each Party shall have appropriate technical credentials, experience and knowledge pertaining to and
ongoing familiarity with the activities to be performed under the Research Programs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.2</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>JDC
Meetings</B>. The JDC shall meet in accordance with a schedule established by mutual written agreement of the Parties no less frequently than once every three (3)&nbsp;months until, on a Research <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Program-by-Research</FONT></FONT> Program basis, until the end of the period specified in Section&nbsp;3.5. The JDC may meet by means of teleconference, videoconference or other similar means, as jointly determined by the
Parties. As </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
appropriate, additional employees or consultants may from time to time attend the JDC meetings as nonvoting observers, provided that any such consultant shall agree in writing to comply with the
confidentiality obligations under this Agreement; and provided further that no Third Party personnel may attend unless otherwise agreed by all Parties. Each Party shall bear its own expenses related to the attendance of the JDC meetings by its
representatives. Each Party may also call for special meetings to resolve particular matters requested by such Party. Paragon shall be responsible for keeping minutes of each JDC meeting that record in writing all decisions made, action items
assigned or completed and other appropriate matters. Paragon shall send meeting minutes to all members of the JDC within [***] Business Days after a meeting for review. Each member shall have [***] Business Days from receipt in which to comment on
and to approve/provide comments to the minutes (such approval not to be unreasonably withheld, conditioned or delayed). If a member, within such time period, does not notify the drafting Party that s/he does not approve of the minutes, the minutes
shall be deemed to have been approved by such member. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.3</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>JDC Functions</B>. The JDC&#146;s
responsibilities are as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;Developing, reviewing, overseeing and coordinating the activities under
each Research Plan; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;Periodically reviewing the progress of activities under each Research Plan; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;Updating or modifying each Research Plan, provided that such update or modification does not obligate any
Party to perform any task or expend any resources outside of or beyond its obligations under the applicable Budget; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B>&nbsp;&nbsp;&nbsp;&nbsp;Reviewing performance against the Budget and timeline for each Research Program periodically (at least
[***]), and periodically meeting to review and (subject to mutual approval of the Parties), approving any discovery project Budget deviation where such deviation is greater than [***] percent ([***]%); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(e)</B>&nbsp;&nbsp;&nbsp;&nbsp;Reviewing the reconciliation of Actual Annual Costs against the Cost Advance at the end of each Calendar Year
for each Research Program; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(f)</B>&nbsp;&nbsp;&nbsp;&nbsp;Determining whether the Project Antibody Selection Criteria for a
Research Program are not achievable for any reason and therefore such Research Program no longer warrants further research. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.4</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>JDC Decision Making and Disputes</B>. The JDC will endeavor to make decisions by consensus, with each of
Spyre and Paragon having one vote. If consensus is not reached by the Parties&#146; Representatives pursuant to such vote, then disputes relating to: (a)&nbsp;the reconciliation of Actual Annual Costs against the Cost Advance, as set forth in
Section&nbsp;5.2(b), will be resolved in accordance with Section&nbsp;11.7; (b) technical or scientific decisions in the course of operationalizing each Research Program, including the nature of activities to be performed by Paragon thereunder,
shall be finally decided by [***]; and the Budget for any Research Program, and all other matters not covered by clauses (a)&nbsp;or (b) shall be finally decided by [***]. For clarity, and notwithstanding the creation of the JDC, each Party shall
retain the rights, powers and discretion granted to it hereunder, and the JDC shall not be delegated or vested with such rights, powers or discretion unless such delegation or vesting is expressly provided herein, or the Parties expressly so agree
in writing. The JDC shall not have the power to amend, waive or modify any term of this Agreement, and no decision of the JDC shall be in contravention of any terms and conditions of this Agreement. It is understood and agreed that issues to be
formally decided by the JDC are limited to those specific issues that are expressly provided in this Agreement to be decided by the JDC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.5</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Disbandment</B>. The JDC shall remain in effect from the date on which it is established in accordance
with Section&nbsp;3.1 until, on a Research <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Program-by-Research</FONT></FONT> Program basis, the earlier of (a)&nbsp;expiration of the Term and (b)&nbsp;Spyre&#146;s exercise of the
Option in accordance with Section&nbsp;4.3. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 4 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OPTION; LICENSE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.1</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Grant of Option.</B> Subject to the terms and conditions of this Agreement, on a Research <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Program-by-Research</FONT></FONT> Program basis, Paragon hereby grants to Spyre, during the Term and subject to delivery of the Election Notice in accordance with Section&nbsp;4.3, an
exclusive option (&#147;<B>Option</B>&#148;), to be granted an exclusive license to all of Paragon&#146;s right, title, and interest in and to the Project Antibody Technology under the applicable Research Program to Develop and Commercialize Project
Antibodies, Derived Antibodies and Products in the Field in the Territory. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.2</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Limited</B><B> License
Grant During Option Period.</B> Subject to the terms and conditions of this Agreement, on a Research <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Program-by-Research</FONT></FONT> Program basis, and effective only during the
Term, Paragon hereby grants to Spyre a limited, exclusive, royalty-free license, without the right to sublicense, under the Project Antibody Technology arising from such Research Program solely to evaluate the Option and for the purpose of allowing
Spyre to determine whether to exercise the Option with respect to such Research Program. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.3</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Option</B><B> Exercise.</B> On a Research
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Program-by-Research</FONT></FONT> Program basis, Spyre may, in its sole discretion, exercise the Option at any time during the period beginning on the initiation of activities under
such Research Program and ending [***] days following Spyre&#146;s receipt of the Deliverables for such Research Program, or such longer period as agreed upon by the Parties (&#147;<B>Option Period</B>&#148;) by delivering written notice of such
exercise to Paragon (&#147;<B>Election Notice</B>&#148;). If Spyre fails to exercise an Option in accordance with this Section&nbsp;4.3 prior to expiration of the applicable Option Period, then, upon such expiration, such Option shall terminate and
be of no further force or effect. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.4&nbsp;&nbsp;&nbsp;&nbsp;License Template; Execution After Option Exercise. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;Within [***] days of the Effective Date, the Parties shall negotiate [***] and use [***] to agree upon a form
of agreement template (&#147;<B>License Template</B>&#148;) to be used in connection with Spyre&#146;s exercise of its Option with respect to a given Research Program. The License Template will be consistent with the economic and other terms set
forth in <U>Exhibit B</U>, and upon mutual agreement by the Parties on the form of the License Template, will be attached to this Agreement and replace the terms on the existing <U>Exhibit B</U>. If the Parties are unable to reach agreement on the
definitive terms of the License Template within such [***] period, the matter will be resolved in accordance with Section&nbsp;11.7. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;Within [***] days of Spyre&#146;s exercise of its Option with respect to a Research Program as set forth in
Section&nbsp;4.3, the Parties shall use [***] to finalize and execute a definitive written agreement consistent with the License Template (the &#147;<B>License Agreement</B>&#148;) with respect to such Research Program. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 5 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PAYMENTS
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.1</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Research Initiation Fee</B>. Spyre shall pay to Paragon, on a Research <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Program-by-Research</FONT></FONT> Program basis, a <FONT STYLE="white-space:nowrap">one-time</FONT> nonrefundable fee of $750,000 (the &#147;<B>Research Initiation Fee</B>&#148;) no later
than [***] days following finalization of the Research Plan for such Research Program. For clarity, the Research Initiation Fee is nonrefundable and separate from any Development Costs (including <FONT STYLE="white-space:nowrap">Pre-Effective</FONT>
Date Development Costs) or Cost Advance paid or owing with respect to a particular Research Program. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.2&nbsp;&nbsp;&nbsp;&nbsp;Development Costs. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;On a quarterly basis for each Research Program, Spyre will advance to Paragon any Development Costs
contemplated in the Budget, including [***], and any [***] reasonably expected to be incurred by Paragon in the performance of the Research Program during the upcoming [***] (less any <FONT STYLE="white-space:nowrap">pre-payments</FONT> for Third
Party Costs from earlier [***] that Paragon reasonably anticipates will be carried over to such upcoming [***]) (the &#147;<B>Cost Advance</B>&#148;). Spyre will pay the Cost Advance within [***] days after receipt of Paragon&#146;s invoice for such
Development Costs. The Parties acknowledge that Paragon has incurred approximately $10,000,000 in Development Costs prior to the Effective Date, as a result of work performed by Paragon at risk on one or more Research Programs (the &#147;<B><FONT
STYLE="white-space:nowrap">Pre-Effective</FONT> Date Development Costs</B>&#148;), which amount includes for Research Initiation Fees of $3,000,000 for a total of four Research Programs. Spyre shall reimburse Paragon for the <FONT
STYLE="white-space:nowrap">Pre-Effective</FONT> Date Development Costs no later than [***] days after the later of (i)&nbsp;the Effective Date and (ii)&nbsp;Spyre&#146;s receipt of a written invoice that details the
<FONT STYLE="white-space:nowrap">Pre-Effective</FONT> Date Development Costs and includes reasonable documentation therefor. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;Within [***] after the end of each Calendar Year, Paragon will calculate and provide to Spyre a written
reconciliation of its actually-incurred Third Party Costs (incurred in a manner consistent with the Budget) for the prior Calendar Year (&#147;<B>Actual Annual Costs</B>&#148;) against that portion of the Cost Advance for such Third Party Costs for
that Calendar Year, including reasonable documentation of such Actual Annual Costs. The form of such reconciliation shall be subject to JDC review and approval. If the amounts paid for anticipated Third Party Costs in the Cost Advance exceeds the
Actual Annual Costs, then Paragon will credit such excess payment against Development Costs contemplated in the Budget and reasonably expected to be incurred by Paragon in the performance of the Research Program during any upcoming Calendar Year and
Spyre will deduct such amount from its next quarterly Cost Advance. If the Cost Advance is less than the Actual Annual Costs, then Paragon will invoice Spyre for the difference and Spyre will pay such amount together with its next quarterly Cost
Advance. If no further amounts will be owed to Paragon hereunder, Paragon will refund such amount. For clarity, the above reconciliation will not apply to Annual Development Fees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.3</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Financial Records</B><B>.</B> Paragon shall keep complete and accurate books of account and records in
sufficient detail to enable the Development Costs payable under this Agreement to be determined. Such books and records shall be kept at the principal place of business of Paragon, for at least [***] following the end of the [***] to which such
books and records pertain and Spyre shall be entitled to inspect such books and records at Paragon&#146;s offices upon Spyre&#146;s reasonable request. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.4</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Manner and Method of Payment</B>. All cash payment amounts hereunder are expressed in U.S. dollars (USD)
unless otherwise specified. Each payment shall be made by electronic funds transfer in immediately available funds to a bank and account designated in writing by Paragon, unless otherwise specified in writing by Paragon. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.5</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Tax</B>. Each Party shall be responsible for paying its own respective taxes in connection with any
activities that it performs and any payments that it receives under this Agreement. The Parties will commit [***] to provide each other with any tax forms that may be reasonably necessary in order for any Party to not pay or withhold tax or to pay
or withhold tax at a reduced rate under an applicable income tax treaty. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.6</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Late Payments</B>. In the
event that any cash payment due for any undisputed amount under this Agreement is not made when due, then the cash payment shall accrue interest from the date due at a per annum rate equal to two [***] above the then-current per annum prime rate
reported by the <I>Wall Street Journal</I> (U.S., Western Edition) or, if lower, the maximum legal annual interest rate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.7</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Equity Grants</B>. Upon completion of each of the
Calendar Years ending on December&nbsp;31, 2023 and December&nbsp;31, 2024, Spyre will grant Parapyre nonqualified stock options to purchase a number of Shares equal to 1.00% of the outstanding Shares as of the date of the grant, on a fully-diluted
basis (including, assuming the exercise or conversion of any convertible <FONT STYLE="white-space:nowrap">non-voting</FONT> preferred stock, stock options, <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants or similar instruments), with an
exercise price equal to the fair market value of the underlying Shares on the date of grant as determined by the board of directors of Aeglea (each grant, an &#147;<B>Equity Grant</B>&#148;). Such options will vest immediately upon grant, be
exercisable for a period of ten (10)&nbsp;years following the date of the grant. Each Equity Grant shall be effected on the last Business Day of each applicable Calendar Year. If the Term ends prior to the end of a Calendar Year, the Equity Grant
for such Calendar Year shall be <FONT STYLE="white-space:nowrap">pro-rated</FONT> for such Calendar Year and such Equity Grant shall be effected within five Business Days of the end of the Term. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 6 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INTELLECTUAL
PROPERTY RIGHTS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.1&nbsp;&nbsp;&nbsp;&nbsp;Ownership. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Background IP</B>. As between the Parties, each Party will retain all right, title and interest in and to
all of its Background IP. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Project Antibody Technology</B>. Subject to the rights and licenses granted
to Spyre in this Agreement, as between the Parties, Paragon or its Affiliates shall own all right, title and interest in and to all Project Antibody Technology, irrespective of inventorship. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.2&nbsp;&nbsp;&nbsp;&nbsp;Patent Prosecution, Maintenance and Enforcement &#150; Project Antibody Patents. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;Prior to execution of the License Agreement, Paragon shall have the sole right, but not the obligation, to
prepare, file, prosecute, maintain or enforce any Project Antibody Patents at Paragon&#146;s sole expense, and Spyre shall reasonably cooperate and assist Paragon in such preparation, filing, prosecution, maintenance and enforcement, at
Paragon&#146;s request. Following execution of the License Agreement, the Parties&#146; respective rights relating to the preparation, filing, prosecution, maintenance and enforcement of Project Antibody Patents shall be as set forth therein and
Spyre shall reimburse Paragon for any costs and expenses actually incurred by Paragon in the prosecution and maintenance of any Project Antibody Patents prior to the exercise of the Option by Spyre, in accordance with the terms of the License
Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;Spyre covenants and agrees that it will not file or prosecute any Patents Covering any
Project Antibody or Derived Antibody (including without limitation any Project Antibody Inventions) during the Term of this Agreement except as permitted under a License Agreement executed by all Parties with respect to a given Research Program.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.3</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Defense of Claims Brought by Third Parties.</B> If a Party becomes aware of any actual or potential
claim that the research, development, or manufacture of any Project Antibody, Derived Antibody or Product being Developed pursuant to this Agreement or that are contemplated for Development, Manufacture of Commercialization under a License
Agreement, infringes the Intellectual Property Rights of any Third Party, such Party will [***] notify the other Parties. In any such instance, the Parties will [***] thereafter meet (which may be through the JDC) to discuss [***] regarding the best
response to such notice. Certain additional rights and obligations of the Parties with respect to any such claim will be set forth in the applicable License Agreement (to the extent applicable). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.4</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>No Implied Licenses.</B> Except as expressly set forth
herein, no right or license under any Patents, <FONT STYLE="white-space:nowrap">Know-How</FONT> or Intellectual Property Right of any Party is granted or shall be granted by implication hereunder. All such rights or licenses are or shall be granted
only as expressly provided in this Agreement or the applicable License Agreement. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 7 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PROTECTION OF CONFIDENTIAL INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.1</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Confidentiality.</B> Except to the extent expressly authorized by this Agreement, the Receiving Party
agrees that, during the Term and for [***] years thereafter, it shall keep confidential and shall not publish or otherwise disclose to any Third Party, and shall not use for any purpose other than as expressly provided for in this Agreement, any
Confidential Information of the Disclosing Party. The Receiving Party may disclose Confidential Information of the Disclosing Party to those of the Receiving Party&#146;s Representatives who have a need for such information, provided that the
Receiving Party shall advise such Representatives of the confidential nature thereof, shall ensure that each such Representative is bound in writing by obligations of confidentiality and <FONT STYLE="white-space:nowrap">non-use</FONT> at least as
stringent as those contained in this Agreement, and shall be responsible for the compliance of its Representatives with the terms of this Agreement. The Receiving Party shall use at least the same standard of care as it uses to protect proprietary
or confidential information of its own (but in no event less than reasonable care) to ensure that its Representatives do not disclose or make any unauthorized use of the Confidential Information of the Disclosing Party. The Receiving Party shall
[***] notify the Disclosing Party upon discovery of any unauthorized use or disclosure of the Confidential Information of the Disclosing Party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.2</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Exceptions.</B> The Receiving Party&#146;s obligations under Section&nbsp;7.1 shall not apply to any
Confidential Information of the Disclosing Party that the Receiving Party can prove by competent evidence: (a)&nbsp;is now, or hereafter becomes, through no act or failure to act on the part of the Receiving Party in breach of this Agreement,
generally known or available; (b)&nbsp;is known by the Receiving Party at the time of receiving such information from the Disclosing Party; (c)&nbsp;is hereafter furnished to the Receiving Party by a Third Party, as a matter of right and without
restriction on disclosure; or (d)&nbsp;is independently discovered or developed by the Receiving Party, without the aid, use or application of any Confidential Information of the Disclosing Party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.3</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Authorized Disclosure.</B> Notwithstanding the provisions of this Article 7, the Receiving Party may
disclose Confidential Information, without violating its obligations under this Agreement, to the extent the disclosure is: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;required by a valid order of a court or other governmental body of competent jurisdiction or as otherwise
required by Applicable Law, rule, regulation (including securities laws and regulations), government requirement, or as may be required in connection with any filings made with, or by the disclosure policies of, a stock exchange, provided that the
Receiving Party shall give reasonable prior written notice to the Disclosing Party of such required disclosure and, at the [***] request and expense, shall cooperate with the Disclosing Party&#146;s efforts to contest such requirement, to obtain a
protective order requiring that the Confidential Information so disclosed be used only for the purposes for which the order was issued or the law, rule or regulation required, or to obtain other confidential treatment of such Confidential
Information; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;reasonably necessary to file or prosecute patent applications, prosecute or defend
litigation or otherwise establish rights or enforce obligations under this Agreement, in each case, in accordance with this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.4</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>No Requirement to Disclose Paragon Platform
Technology.</B> Notwithstanding anything to the contrary in this Agreement, Paragon will not be required to disclose any of the Paragon Platform Technology to Spyre other than as required to be included in the Deliverables. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.5</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Use of Names.</B> No Party shall use any other Party&#146;s name or trademarks in any advertising, sales,
or promotional material or in any publication without the prior written consent of such other Party or Parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.6</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Confidentiality of this Agreement.</B> This Agreement and its terms are considered Confidential
Information of all Parties, and each Party shall keep confidential and shall not publish or otherwise disclose the terms of this Agreement without the prior written consent of the applicable other Party, except as expressly permitted by
Section&nbsp;7.3 or Section&nbsp;7.7, and except that any Parties may disclose this Agreement and its terms to actual or potential investors, lenders, and strategic partners in connection with due diligence or similar investigations by such Third
Parties or in confidential financing documents, provided, in each case, that any such Third Party agrees to be bound by obligations of confidentiality and <FONT STYLE="white-space:nowrap">non-use</FONT> at least as restrictive as those set forth in
this Article 7 (provided that the confidentiality term applicable to such Third Party may be shorter so long as it is commercially reasonable). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.7</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Publicity.</B> Except to the extent required by Applicable Law or the rules of any stock exchange or
listing agency, no Party shall issue a press release announcing that they have entered into an Antibody discovery partnership, without the other Parties&#146; prior written consent, which shall not be unreasonably withheld. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 8 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REPRESENTATIONS, WARRANTIES AND COVENANTS; DISCLAIMER </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.1</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Mutual Representations and Warranties.</B> Each Party represents and warrants to each other Party that:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;it is duly organized and validly existing under the laws of its jurisdiction of incorporation or
formation, and has full corporate or other power and authority to enter into this Agreement and to carry out the provisions hereof; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;it is duly authorized to execute and deliver this Agreement and to perform its obligations hereunder; and
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;this Agreement is legally binding upon it, enforceable in accordance with its terms, and does not and
will not conflict with any agreement, instrument, or understanding, oral or written, to which it is or may become a party or by which it may be or become bound. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.2</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Paragon Representations, Warrants and Covenants</B>. Paragon hereby represents, warrants and covenants to
Spyre that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;it will perform its activities under a Research Program with due care and in accordance with
(i)&nbsp;Applicable Law, (ii)&nbsp;the terms and conditions contained herein and the applicable Research Plan, and (iii)&nbsp;generally prevailing industry standards; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;neither it nor any of its Affiliates have entered or will enter, directly or indirectly, into any contract or
any other transaction with any Third Party or Affiliate that conflicts or derogates from its undertakings under this Agreement; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;it has the unencumbered right to the Paragon Platform
Technology and the right, power and authority to use the Paragon Platform Technology in performance of the Research Plans and the performance of its obligations under this Agreement, in each case in accordance with the terms hereof; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B>&nbsp;&nbsp;&nbsp;&nbsp;each Representative employed or engaged by Paragon or its Affiliate to conduct the activities under a
Research Program has assigned and has executed an agreement assigning its entire right, title and interest in and to Project Antibody Technology to Paragon; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(e)</B>&nbsp;&nbsp;&nbsp;&nbsp;there are no claims, actions, or proceedings pending or threatened, nor are there any formal inquiries
initiated or written notices received that may lead to the institution of any such legal proceedings, in each case (or in aggregate) against Paragon or its properties, assets or business, which would, individually or in the aggregate, have a
material adverse effect on, or materially prevent, Paragon&#146;s ability to perform under this Agreement or to grant the Option or other rights granted to Spyre under this Agreement; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(f)</B>&nbsp;&nbsp;&nbsp;&nbsp;none of Paragon, its Representatives, or any other person used by Paragon in the performance of the
Agreement has been or is (i)&nbsp;debarred, convicted, or is subject to a pending debarment or conviction, pursuant to section 306 of the United States Food Drug and Cosmetic Act, 21 U.S.C. &#167; 335a, (ii)&nbsp;listed by any government or
regulatory agencies as ineligible to participate in any Federal healthcare programs (as that term is defined in 42 U.S.C. <FONT STYLE="white-space:nowrap">1320a-7b(f))</FONT> or government procurement or
<FONT STYLE="white-space:nowrap">non-procurement</FONT> programs, or excluded, debarred, suspended or otherwise made ineligible to participate in any such program, or (iii)&nbsp;convicted of a criminal offense related to the provision of healthcare
items or services, or is subject to any such pending action. Paragon agrees to inform Spyre in writing promptly if Paragon or any person who is performing activities on its behalf under the Agreement is subject to the foregoing, or if any action,
suit, claim, investigation, or proceeding relating to the foregoing is pending or threatened. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.3</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Disclaimer.</B> EXCEPT AS EXPRESSLY SET FORTH HEREIN, EACH PARTY EXPRESSLY DISCLAIMS ANY AND ALL
WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING THE WARRANTIES OF DESIGN, MERCHANTABILITY, DURABILITY, MERCHANTABLE QUALITY, FITNESS FOR A PARTICULAR PURPOSE, <FONT STYLE="white-space:nowrap">NON-INFRINGEMENT</FONT> OF THE INTELLECTUAL
PROPERTY RIGHTS OF THIRD PARTIES, OR ARISING FROM A COURSE OF DEALING, USAGE OR TRADE PRACTICES. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 9 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TERM AND TERMINATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.1</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Term.</B> The term of this Agreement (&#147;<B>Term</B>&#148;) shall commence on the Effective Date and,
subject to earlier termination of this Agreement in accordance with this Article 9, shall continue in force on a Research <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Program-by-Research</FONT></FONT> Program basis until the
earlier of: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(<SMALL>A</SMALL>)</B>&nbsp;&nbsp;&nbsp;&nbsp;the end of the Option Period for such Research Program, as applicable, if
such Option is not exercised by Spyre; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;the effective date of the License Agreement for such Research
Program if Spyre exercises its Option with respect to such Research Program, unless an extension is mutually agreed between the Parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the expiration of the Term for all then-existing Research Programs, this Agreement will automatically expire in its entirety. For
clarity, any executed License Agreements shall not be affected by such expiration. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.2</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Termination of Agreement for Material Breach.</B> Each
Party shall have the right to terminate this Agreement or a Research Program upon [***] days&#146; prior written notice to the other Parties upon or after the material breach of any provision of this Agreement by any other Party if the breaching
Party has not cured such breach by the end of such [***] day period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.3</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Termination for
Convenience.</B> Spyre shall have the right to terminate this Agreement or any Research Program for any reason or no reason upon [***] days&#146; prior written notice to Paragon; provided that Spyre will pay Paragon any unpaid fees due for
Development Costs accrued prior to such effective termination date, as well as any <FONT STYLE="white-space:nowrap">non-cancellable</FONT> obligations reasonably incurred by Paragon in connection with its activities under any terminated Research
Program, as evidenced by Paragon&#146;s records. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.4</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Termination for a Bankruptcy Event. </B>Each Party
will have the right to terminate this Agreement in the event of a Bankruptcy Event with respect to any other Party. &#147;<B>Bankruptcy Event&#148; </B>means the occurrence of any of the following: (a)&nbsp;the institution of any bankruptcy,
receivership, insolvency, reorganization or other similar proceedings by or against a Party under any bankruptcy, insolvency, or other similar law now or hereinafter in effect, including any section or chapter of the United States Bankruptcy Code,
as amended, or under any similar laws or statutes of the United States or any state thereof (the &#147;<B>Bankruptcy Code</B>&#148;),<B> </B>where in the case of involuntary proceedings, such proceedings have not been dismissed or discharged within
[***] days after they are instituted, (b)&nbsp;the insolvency or making of an assignment for the benefit of creditors or the admittance by a Party of any involuntary debts as they mature, (c)&nbsp;the institution of any reorganization, arrangement
or other readjustment of debt plan of a Party not involving the Bankruptcy Code, (d)&nbsp;the appointment of a receiver for all or substantially all of a Party&#146;s assets, or (e)&nbsp;any corporate action taken by the board of directors of a
Party in furtherance of any of the foregoing actions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.5</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Disposal of Confidential Information.</B> In
the event this Agreement expires or this Agreement or any Research Program is terminated and the Parties have not entered into a License Agreement with respect to an expired or terminated Research Program, each Party shall return to the applicable
other Party all Confidential Information of such other Party (including all copies thereof) in such Party&#146;s possession related to any expired or terminated Research Program; provided, however, that each Party may retain one copy of the such
other Party&#146;s Confidential Information in such Party&#146;s secure archives for the sole purpose of monitoring compliance with its obligations hereunder or applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.6</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Accrued Rights; Survival.</B> The expiration or termination of this Agreement for any reason shall not
release any Party from any liability or obligation that, at the time of such expiration or termination, has already accrued to any other Party or that is attributable to a period prior to such expiration or termination, nor will expiration or any
termination of this Agreement preclude any Party from pursuing all rights and remedies it may have under this Agreement, or at law or in equity, with respect to breach of this Agreement. In the event of expiration or any termination of this
Agreement, the following provisions of this Agreement shall survive such expiration or termination in accordance with their respective terms and conditions: Article 5, Article 7, Article 10 and Article 11, as well as Sections 2.3, 6.1, 6.2(a), 6.4,
9.3, 9.5 and 9.6. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 10 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INDEMNIFICATION; LIMITATION OF LIABILITY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.1</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>By </B><B>Spyre</B><B>.</B> Spyre hereby agrees to defend, indemnify, and hold harmless Paragon, its
Affiliates, including Parapyre, and its or their Representatives (each, an &#147;<B>Paragon Indemnitee</B>&#148;) from and against any and all losses, damages, liabilities, expenses, and costs, including reasonable legal expense and attorneys&#146;
fees (collectively, &#147;<B>Losses</B>&#148;), to which any Paragon Indemnitee may become subject as a result of any claim, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
demand, action, or other proceeding by any Third Party (&#147;<B>Third Party Claim</B>&#148;)<B> </B>to the extent such Losses result from: (a)&nbsp;the negligence or willful misconduct of any
Spyre Indemnitee in the performance of this Agreement; or (b)&nbsp;the material breach by any Spyre Indemnitee of this Agreement; except, in each case, to the extent such Losses result from the negligence or willful misconduct of any Paragon
Indemnitee or the material breach by Paragon of this Agreement, or where such Losses are subject to indemnification pursuant to Section&nbsp;10.2 below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.2</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>By Paragon.</B> Paragon hereby agrees to defend, indemnify, and hold harmless Spyre, Aeglea,
Spyre&#146;s and Aeglea&#146;s Affiliates, and their Representatives (each, a &#147;<B>Spyre</B><B> Indemnitee</B>&#148;) from and against any and all Losses to which any Spyre Indemnitee may become subject as a result of any Third Party Claim to
the extent such Losses result from: (a)&nbsp;the negligence or willful misconduct of any Paragon Indemnitee in the performance of this Agreement; or (b)&nbsp;the material breach by any Paragon Indemnitee of this Agreement; except, in each case, to
the extent such Losses result from the negligence or willful misconduct of any Spyre Indemnitee, the material breach by Spyre of this Agreement, or where such Losses are subject to indemnification pursuant to Section&nbsp;10.1 above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.3</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Indemnification Procedure. </B><B></B>In connection with any Third Party Claim for which a Party (the
&#147;<B>Indemnified Party</B>&#148;)<B> </B>seeks indemnification from another Party (the &#147;<B>Indemnifying Party</B>&#148;)<B> </B>pursuant to this Agreement, the Indemnified Party will: (a)&nbsp;give the Indemnifying Party [***] notice of the
Third Party Claim; <I>provided, however, </I>that failure to provide such notice will not relieve the Indemnifying Party from its liability or obligation hereunder, except to the extent of any material prejudice as a direct result of such failure;
(b)&nbsp;cooperate with the Indemnifying Party, at the Indemnifying Party&#146;s expense, in connection with the defense and settlement of the Third Party Claim; and (c)&nbsp;permit the Indemnifying Party to control the defense and settlement of the
Third Party Claim; <I>provided, however, </I>that the Indemnifying Party may not settle the Third Party Claim without the Indemnified Party&#146;s prior written consent, which will not be unreasonably withheld or delayed, in the event that such
settlement materially adversely impacts the Indemnified Party&#146;s rights or obligations. Further, the Indemnified Party will have the right to participate (but not control) and be represented in any suit or action by advisory counsel of its
selection and at its own expense.<B> </B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.4</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Limitation of Liability.</B> EXCEPT FOR LIABILITY FOR
BREACH OF ARTICLE 7 OR FOR INDEMNIFICATION CLAIMS UNDER ARTICLE 10, IN NO EVENT SHALL ANY PARTY BE ENTITLED TO RECOVER FROM ANY OTHER PARTY ANY SPECIAL, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES IN CONNECTION WITH THIS AGREEMENT, EVEN IF SUCH
OTHER PARTY HAD NOTICE OF THE POSSIBILITY OF SUCH DAMAGES. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 11 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MISCELLANEOUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.1</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Independent Contractor Relationship.</B> Each of Paragon&#146;s and Parapyre&#146;s relationship with
Spyre is that of an independent contractor, and nothing in this Agreement should be construed to create a partnership, joint venture or employer-employee relationship. No Party is an agent of any other Party or authorized to make any representation,
contract or commitment on behalf of any other Party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.2</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Force Majeure. </B>No Party will be charged
with any liability for delay or failure in performance of an obligation under this Agreement (other than any obligation to pay monies when due) to the extent such delay or failure is due to a cause beyond the reasonable control of the affected
Party, such as war, riots, labor disturbances, epidemic, pandemic, fire, explosion, and compliance in good faith with any Applicable Law. The Party affected will give prompt written notice to the other Parties of the nature of the cause of any
material delay or failure to perform, its anticipated duration and any action being taken to avoid or minimize the effect. The Party affected will use its diligent efforts to avoid or remove such causes of delay or failure to perform and to mitigate
the effect of such occurrence, and will continue performance in accordance with the terms of this </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Agreement whenever such causes are removed. The Party affected will give prompt written notice to the other Parties of such resumed performance. If any such failure or delay in a Party&#146;s
performance hereunder continues for more than [***] days, any of the other Parties may terminate this Agreement upon written notice to the affected Party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.3</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Entire Agreement; Amendment.</B> This Agreement, together with all Exhibits attached hereto, constitutes
the final, complete, and exclusive agreement of the Parties with respect to the subject matter hereof and supersedes all prior and contemporaneous understandings and agreements, relating to its subject matter. This Agreement (including its Exhibits)
may not be changed, modified, amended, or supplemented except by a written instrument signed by all Parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.4</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><FONT STYLE="white-space:nowrap">Non-Waiver.</FONT></B> The failure of a Party to insist upon strict
performance of any provision of this Agreement or to exercise any right arising out of this Agreement shall neither impair that provision or right nor constitute a waiver of that provision or right, in whole or in part, in that instance or in any
other instance. Any waiver by a Party of a particular provision or right shall be in writing, shall be as to a particular matter and, if applicable, for a particular period of time and shall be signed by such Party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.5</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Severability.</B> Should one or more of the provisions of this Agreement become void or unenforceable as
a matter of Applicable Law, then this Agreement shall be construed as if such provision were not contained herein and the remainder of this Agreement shall be in full force and effect, and the Parties will use their best efforts to substitute for
the invalid or unenforceable provision a valid and enforceable provision which conforms as nearly as possible with the original intent of the Parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.6</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Assignment.</B> Neither this Agreement nor any rights or obligations hereunder may be assigned by any
Party without the prior written consent of the other Parties (which consent shall not be unreasonably withheld); provided, however, that any Party may assign this Agreement and its rights and obligations hereunder without the other Parties&#146;
consent to its successor to all or substantially all of the business of such Party to which this Agreement relates, whether by merger, sale of stock, sale of assets or otherwise. The rights and obligations of the Parties under this Agreement shall
be binding upon and inure to the benefit of the successors and permitted assigns of the Parties, and the name of a Party appearing herein will be deemed to include the name of such Party&#146;s successors and permitted assigns to the extent
necessary to carry out the intent of this section. Any assignment not in accordance with this Agreement shall be void. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.7</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Dispute</B><B> Resolution.</B><B> </B>The Parties recognize that a <I>bona fide </I>dispute as to
certain matters may arise from time to time during the Term relating to any Party&#146;s rights or obligations hereunder or otherwise relating to the validity, enforceability or performance of this Agreement, including disputes relating to alleged
breach or termination of this Agreement but excluding any disputes relating to Article 7 (Confidentiality) hereof or disputes relating to the determination of the validity, scope, infringement, enforceability, inventorship or ownership of the
Parties&#146; respective Intellectual Property Rights (hereinafter, a &#147;<B>Dispute</B>&#148;).<B> </B><B></B>In the event of the occurrence of any Dispute, the Parties will follow the following procedures in an attempt to resolve the dispute or
disagreement: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;The Party claiming that such a Dispute exists will give notice in writing (a
&#147;<B>Notice of Dispute</B>&#148;)<B> </B>to the other Parties of the nature of the Dispute. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;The
Dispute will be referred to the then Chief Executive Officer of Paragon and the then Chief Executive Officer of Spyre who will meet no later than [***] following the initial receipt of the Notice of Dispute and use reasonable endeavors to resolve
the Dispute. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;If, within [***] days of initial receipt of the Notice of
Dispute, the Dispute has not been resolved, or if, for any reason, the meeting described in Section&nbsp;11.7(b) hereof has not been held within [***] days of initial receipt of the Notice of Dispute, then the Parties agree that such Dispute will be
finally resolved through binding arbitration to be administered by JAMS pursuant to its Comprehensive Arbitration Rules and Procedures and in accordance with the Expedited Procedures in those Rules, as specifically modified by the provisions of this
Section&nbsp;11.7(c). The arbitration will be conducted by a panel of three arbitrators. Within thirty (30)&nbsp;days after the initiation of the arbitration, each Party will nominate one person to act as arbitrator, and the two arbitrators so named
will then jointly appoint the third arbitrator within [***] days of their appointment, who will serve as chairman of the panel. All three arbitrators must be independent Third Parties having at least [***] years of dispute resolution experience
(which may include judicial experience) or legal or business experience in the biotech or pharmaceutical industry. If any Party fails to nominate its arbitrator, or if the arbitrators selected by the Parties cannot agree on a person to be named as
chairman within such [***]-day period, JAMS will make the necessary appointments for such arbitrator(s) or the chairman. Once appointed by a Party, such Party will have no <I>ex parte </I>communication with its appointed arbitrator. The place of
arbitration will be in Boston, Massachusetts or such other venue as the Parties may mutually agree. The arbitration proceedings and all communications with respect thereto will be in English. Any written evidence originally in another language will
be submitted in English translation accompanied by the original or a true copy thereof. The arbitrators have the power to decide all matters in Dispute, including any questions of whether or not such matters are subject to arbitration hereunder. The
arbitration will be governed by the Federal Arbitration Act, 9 U.S.C. &#167;&#167;1 <I>et seq., </I>and judgment upon the award rendered by the arbitrators may be entered in any court having competent jurisdiction thereof. The existence, content and
results of any arbitration proceedings pursuant to this Section&nbsp;11.7 will be deemed the Confidential Information of all Parties. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B>&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding any provision of this Agreement to the contrary, any Party may immediately initiate
litigation in any court of competent jurisdiction seeking any remedy at law or in equity, including the issuance of a preliminary, temporary or permanent injunction, to preserve or enforce its rights under this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(e)</B>&nbsp;&nbsp;&nbsp;&nbsp;The Parties agree that any disputes relating to Article 7 (Confidentiality) hereof or disputes relating to
the determination of the validity, scope, infringement, enforceability, inventorship or ownership of the Parties&#146; respective Intellectual Property Rights shall be subject to the exclusive jurisdiction of the state and federal courts in New
York, New York and each Party hereby submits to such jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.8</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Governing Law.</B> This
Agreement shall be governed by and construed in accordance with the laws of the Commonwealth of Massachusetts without reference to conflicts of laws principles. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.9</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Notices.</B> Any notice to be given under this Agreement must be in writing and delivered either in
person, by internationally recognized express courier, by email, or by facsimile, to the Party to be notified at its address(es) given below, or at any address such Party has previously designated by prior written notice to the other. Notice shall
be deemed sufficiently given for all purposes upon the earliest of: (a)&nbsp;the date of actual receipt; (b)&nbsp;if delivered by express courier, the next Business Day the express courier regularly makes deliveries; or (c)&nbsp;if delivered by
email, upon the date upon which the receipt of such email is confirmed by return email. Together with any notice provided by a Party to any other Party in accordance with this Section&nbsp;11.9, the Party shall send a copy of such notice by email to
such other Party. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="21%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="77%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If&nbsp;to&nbsp;Paragon&nbsp;or&nbsp;Parapyre:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Paragon Therapeutics, Inc.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">221
Crescent Street</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Building 23, Suite 105</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Waltham, MA 02453</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Attn: President</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="89%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If&nbsp;to&nbsp;Spyre:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Aeglea BioTherapeutics, Inc.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">221
Crescent Street,</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Building 23, Suite 105</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Waltham, MA 02453</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Attn: Corporate Secretary</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.10</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Interpretation.</B> Except where the context expressly requires
otherwise, (a)&nbsp;the use of any gender herein shall be deemed to encompass references to either or both genders, and the use of the singular shall be deemed to include the plural (and vice versa), (b)&nbsp;the words &#147;include&#148;,
&#147;includes&#148; and &#147;including&#148; shall be deemed to be followed by the phrase &#147;without limitation&#148;, (c)&nbsp;the word &#147;will&#148; shall be construed to have the same meaning and effect as the word &#147;shall&#148;,
(d)&nbsp;any definition of or reference to any agreement, instrument or other document herein shall be construed as referring to such agreement, instrument or other document as from time to time amended, supplemented or otherwise modified (subject
to any restrictions on such amendments, supplements or modifications set forth herein), (e) any reference herein to any person or entity shall be construed to include such person&#146;s or entity&#146;s successors and assigns, (f)&nbsp;the words
&#147;herein&#148;, &#147;hereof&#148; and &#147;hereunder&#148;, and words of similar import, shall be construed to refer to this Agreement in its entirety and not to any particular provision hereof, (g)&nbsp;all references herein to Sections or
Exhibits shall be construed to refer to Sections or Exhibits of this Agreement, and references to this Agreement include all Exhibits hereto, (h)&nbsp;the word &#147;notice&#148; means notice in writing (whether or not specifically stated) and shall
include notices, consents, approvals and other written communications contemplated under this Agreement, (i)&nbsp;provisions that require that a Party, the Parties or any committee hereunder &#147;agree,&#148; &#147;consent&#148; or
&#147;approve&#148; or the like shall require that such agreement, consent or approval be specific and in writing, whether by written agreement, letter, approved minutes or otherwise (but excluding <FONT STYLE="white-space:nowrap">e-mail</FONT> and
instant messaging), (j) references to any specific law, rule or regulation, or article, section or other division thereof, shall be deemed to include the then-current amendments thereto or any replacement or successor law, rule or regulation
thereof, and (k)&nbsp;the term &#147;or&#148; shall be interpreted in the inclusive sense commonly associated with the term &#147;or&#148;. The headings of clauses contained in this Agreement preceding the text of the sections, subsections and
paragraphs hereof are inserted solely for convenience and ease of reference only and shall not constitute any part of this Agreement or have any effect on its interpretation or construction. Ambiguities and uncertainties in this Agreement, if any,
shall not be interpreted against any Party, irrespective of which Party may be deemed to have caused the ambiguity or uncertainty to exist. This Agreement has been prepared in the English language, and the English language shall control its
interpretation. In addition, all notices required or permitted to be given hereunder, and all written, electronic, oral, or other communications between the Parties regarding this Agreement shall be in the English language. To the extent there is
any inconsistency or conflict between the terms and conditions of this Agreement and any Research Plan, the terms and conditions of this Agreement will prevail. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.11</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>No Third-Party Rights.</B> The provisions of this Agreement are for the exclusive benefit of the
Parties and their successors and permitted assigns, and no other person shall have any right or claim against any Party by reason of these provisions or be entitled to enforce any of these provisions against any Party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.12</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Counterparts.</B> This Agreement may be executed in counterparts, each of which shall be deemed an
original document, and all of which, together with this writing, shall be deemed one instrument. This Agreement may be executed by facsimile or PDF signatures, which signatures shall have the same force and effect as original signatures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.13</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Expenses</B>. Each Party shall pay its own costs, charges and expenses incurred in connection with the
negotiation, preparation and completion of this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.14</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Binding Effect</B>. This Agreement shall be binding
upon and inure to the benefit of the Parties and their respective legal representatives, successors and permitted assigns. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.15</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Construction</B>. The Parties hereto acknowledge and agree that: (a)&nbsp;each Party and its counsel
reviewed and negotiated the terms and provisions of this Agreement and have contributed to its revision; (b)&nbsp;the rule of construction to the effect that any ambiguities are resolved against the drafting Party shall not be employed in the
interpretation of this Agreement; and (c)&nbsp;the terms and provisions of this Agreement shall be construed fairly as to all Parties hereto and not in a favor of or against any Party, regardless of which Party was generally responsible for the
preparation of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.16</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Cumulative Remedies</B>. No remedy referred to in this Agreement is
intended to be exclusive unless explicitly stated to be so, but each shall be cumulative and in addition to any other remedy referred to in this Agreement or otherwise available under law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>[Remainder of page left intentionally blank; signature page follows.] </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL>,</B> the Parties hereto
have executed this Antibody Discovery and Option Agreement on the New Effective Date. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="70%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="35%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>P<SMALL>ARAGON</SMALL> T<SMALL>HERAPEUTICS</SMALL>, I<SMALL>NC</SMALL>.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>S<SMALL>PYRE</SMALL> T<SMALL>HERAPEUTICS</SMALL>, LLC</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><SMALL>BY</SMALL> <SMALL>ITS</SMALL> <SMALL>SOLE</SMALL> <SMALL>MEMBER</SMALL>, A<SMALL>EGLEA</SMALL></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">B<SMALL>IOTHERAPEUTICS</SMALL>, I<SMALL>NC</SMALL>.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ K. Evan Thompson</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Cameron Turtle</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">K. Evan Thompson</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Cameron Turtle</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>President</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Operating Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>P<SMALL>ARAPYRE</SMALL> H<SMALL>OLDING</SMALL> LLC</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ K. Evan Thompson</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">K. Evan Thompson</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>President</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">[***] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[***] </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.6
<SEQUENCE>18
<FILENAME>d518298dex106.htm
<DESCRIPTION>EX-10.6
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.6</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.6 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INDEMNITY AGREEMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This
Indemnity Agreement, dated as of [&#149;], 2018 is made by and between Aeglea BioTherapeutics, Inc., a Delaware corporation (the &#147;<B><I><U>Company</U></I></B>&#148;), and [&#149;], a director, officer or key employee of the Company or one of
the Company&#146;s subsidiaries or other service provider who satisfies the definition of Indemnifiable Person set forth below (&#147;<B><I><U>Indemnitee</U></I></B>&#148;). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A. The Company
is aware that competent and experienced persons are increasingly reluctant to serve as representatives of corporations unless they are protected by comprehensive liability insurance and indemnification, due to increased exposure to litigation costs
and risks resulting from their service to such corporations, and due to the fact that the exposure frequently bears no relationship to the compensation of such representatives; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">B. The members of the Board of Directors of the Company (the &#147;Board&#148;) have concluded that to retain and attract talented and
experienced individuals to serve as representatives of the Company and its Subsidiaries and Affiliates and to encourage such individuals to take the business risks necessary for the success of the Company and its Subsidiaries and Affiliates, it is
necessary for the Company to contractually indemnify certain of its representatives and the representatives of its Subsidiaries and Affiliates, and to assume for itself maximum liability for Expenses and Other Liabilities in connection with claims
against such representatives in connection with their service to the Company and its Subsidiaries and Affiliates; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">C. Section&nbsp;145 of
the Delaware General Corporation Law (&#147;Section&nbsp;145&#148;), empowers the Company to indemnify by agreement its officers, directors, employees and agents, and persons who serve, at the request of the Company, as directors, officers,
employees or agents of other corporations, partnerships, joint ventures, trusts or other enterprises, and expressly provides that the indemnification provided thereby is not exclusive; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">D. The Company desires and has requested Indemnitee to serve or continue to serve as a representative of the Company and/or the Subsidiaries
or Affiliates of the Company free from undue concern about inappropriate claims for damages arising out of or related to such services to the Company and/or the Subsidiaries or Affiliates of the Company. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AGREEMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, the parties
hereto, intending to be legally bound, hereby agree as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1. <U>Definitions.</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Affiliate</U>. For purposes of this Agreement, &#147;Affiliate&#148; of the Company means any corporation, partnership,
limited liability company, joint venture, trust or other enterprise in respect of which Indemnitee is or was or will be serving as a director, officer, trustee, manager, member, partner, employee, agent, attorney, consultant, member of the
entity&#146;s governing body (whether constituted as a board of directors, board of managers, general partner or otherwise), fiduciary, or in any other similar capacity at the request, election or direction of the Company, and including, but not
limited to, any employee benefit plan of the Company or a Subsidiary or Affiliate of the Company. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Change in Control</U>. For purposes of this Agreement,
&#147;<B><I>Change in Control</I></B>&#148; means (i)&nbsp;any &#147;<B><I>person</I></B>&#148; (as such term is used in Sections 13(d) and 14(d) of the Securities Exchange Act of 1934, as amended), other than a Subsidiary or a trustee or other
fiduciary holding securities under an employee benefit plan of the Company or Subsidiary, is or becomes the &#147;<B><I>Beneficial Owner</I></B>&#148; (as defined in Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> under said Act), directly or
indirectly, of securities of the Company representing 50% or more of the total voting power represented by the Company&#146;s then outstanding capital stock or (ii)&nbsp;during any period of two consecutive years, individuals who at the beginning of
such period constitute the Board and any new director whose election by the Board or nomination for election by the Company&#146;s stockholders was approved by a vote of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> (2/3) of the
directors then still in office who either were directors at the beginning of the period or whose election or nomination for election was previously so approved, cease for any reason to constitute a majority thereof, or (iii)&nbsp;the stockholders of
the Company approve a merger or consolidation of the Company with any other corporation, other than a merger or consolidation that would result in the outstanding capital stock of the Company outstanding immediately prior thereto continuing to
represent (either by remaining outstanding or by being converted into capital stock of the surviving entity) at least 80% of the total voting power represented by the capital stock of the Company or such surviving entity outstanding immediately
after such merger or consolidation, or the stockholders of the Company approve a plan of complete liquidation of the Company or an agreement for the sale or disposition by the Company (in one transaction or a series of transactions) of all or
substantially all of the Company&#146;s assets. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Expenses</U>. For purposes of this Agreement,
&#147;<B><I>Expenses</I></B>&#148; means all direct and indirect costs of any type or nature whatsoever (including, without limitation, all attorneys&#146; fees and related disbursements, and other <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs), paid or incurred by Indemnitee in connection with either the investigation, defense or appeal of, or being a witness in, a Proceeding (as defined below), or establishing or enforcing a
right to indemnification under this Agreement, Section&nbsp;145 or otherwise; provided, however, that Expenses shall not include any judgments, fines, ERISA excise taxes or penalties or amounts paid in settlement of a Proceeding. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Indemnifiable Event</U>. For purposes of this Agreement, &#147;<B><I>Indemnifiable Event</I></B>&#148; means any event
or occurrence related to Indemnitee&#146;s service for the Company or any Subsidiary or Affiliate as an Indemnifiable Person (as defined below), or by reason of anything done or not done, or any act or omission, by Indemnitee in any such capacity.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>Indemnifiable Person</U>. For the purposes of this Agreement, &#147;<B><I>Indemnifiable Person</I></B>&#148; means
any person who is or was a director, officer, trustee, manager, member, partner, employee, attorney, consultant, member of an entity&#146;s governing body (whether constituted as a board of directors, board of managers, general partner or otherwise)
or other agent or fiduciary of the Company or a Subsidiary or Affiliate of the Company. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) <U>Independent Counsel</U>. For purposes of this Agreement,
&#147;<B><I>Independent Counsel</I></B>&#148; means legal counsel that has not performed services for the Company or Indemnitee in the five years preceding the time in question and that would not, under applicable standards of professional conduct,
have a conflict of interest in representing either the Company or Indemnitee. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) <U>Independent Director</U>. For
purposes of this Agreement, &#147;<B><I>Independent Director</I></B>&#148; means a member of the Board who is not a party to the Proceeding for which a claim is made under this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) <U>Other Liabilities</U>. For purposes of this Agreement, &#147;<B><I>Other Liabilities</I></B>&#148; means any and all
liabilities of any type whatsoever (including, but not limited to, judgments, fines, penalties, ERISA (or other benefit plan related) excise taxes or penalties, and amounts paid in settlement and all interest, taxes, assessments and other charges
paid or payable in connection with or in respect of any such judgments, fines, ERISA (or other benefit plan related) excise taxes or penalties, or amounts paid in settlement). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) <U>Proceeding</U>. For the purposes of this Agreement, &#147;<B><I>Proceeding</I></B>&#148; means any threatened, pending,
or completed action, suit or other proceeding, whether civil, criminal, administrative, investigative, legislative or any other type whatsoever, preliminary, informal or formal, including any arbitration or other alternative dispute resolution and
including any appeal of any of the foregoing. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) <U>Subsidiary</U>. For purposes of this Agreement,
&#147;<B><I>Subsidiary</I></B>&#148; means any entity of which more than 50% of the outstanding voting securities is owned directly or indirectly by the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2. <U>Agreement to Serve</U>. The Indemnitee agrees to serve and/or continue to serve as an Indemnifiable Person in the capacity or capacities
in which Indemnitee currently serves the Company as an Indemnifiable Person, and any additional capacity in which Indemnitee may agree to serve, until such time as Indemnitee&#146;s service in a particular capacity shall end according to the terms
of an agreement, the Company&#146;s Certificate of Incorporation or Bylaws, governing law, or otherwise. Nothing contained in this Agreement is intended to create any right to continued employment or other form of service for the Company or a
Subsidiary or Affiliate of the Company by Indemnitee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3. <U>Mandatory Indemnification</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Agreement to Indemnify</U>. In the event Indemnitee is a person who was or is a party to or witness in or is threatened
to be made a party to or witness in any Proceeding by reason of an Indemnifiable Event, the Company shall indemnify Indemnitee from and against any and all Expenses and Other Liabilities incurred by Indemnitee in connection with (including in
preparation for) such Proceeding to the fullest extent not prohibited by the provisions of the Company&#146;s Bylaws and the Delaware General Corporation Law (&#147;<B><I><U>DGCL</U></I></B>&#148;), as the same may be amended from time to time (but
only to the extent that such amendment permits the Company to provide broader indemnification rights than the Bylaws or the DGCL permitted prior to the adoption of such amendment). </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Exception for Amounts Covered by Insurance and Other Sources</U>.
Notwithstanding the foregoing, the Company shall not be obligated to indemnify Indemnitee for Expenses or Other Liabilities of any type whatsoever (including, but not limited to judgments, fines, penalties, ERISA excise taxes or penalties and
amounts paid in settlement) to the extent such have been paid directly to Indemnitee (or paid directly to a third party on Indemnitee&#146;s behalf) by any directors and officers, or other type, of insurance maintained by the Company or pursuant to
other indemnity arrangements with third parties; <U>provided</U>, <U>however</U>, that payment made to Indemnitee pursuant to an insurance policy purchased and maintained by Indemnitee at his or her own expense of any amounts otherwise indemnifiable
or obligated to be made pursuant to this Agreement shall not reduce the Company&#146;s obligations to Indemnitee pursuant to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4. <U>Partial Indemnification</U>. If Indemnitee is entitled under any provision of this Agreement to indemnification by the Company for some
or a portion of any Expenses or Other Liabilities but not entitled, however, to indemnification for the total amount of such Expenses or Other Liabilities, the Company shall nevertheless indemnify Indemnitee for such total amount except as to the
portion thereof for which indemnification is prohibited by the provisions of the Company&#146;s Bylaws or the DGCL. In any review or Proceeding to determine the extent of indemnification, the Company shall bear the burden to establish, by clear and
convincing evidence, the lack of a successful resolution of a particular claim, issue or matter and which amounts sought in indemnity are allocable to claims, issues or matters which were not successfully resolved. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5. <U>Liability Insurance</U>. So long as Indemnitee shall continue to serve the Company or a Subsidiary or Affiliate of the Company as an
Indemnifiable Person and thereafter so long as Indemnitee shall be subject to any possible claim or threatened, pending or completed Proceeding as a result of an Indemnifiable Event, the Company shall use reasonable efforts to maintain in full force
and effect for the benefit of Indemnitee as an insured (i)&nbsp;liability insurance issued by one or more reputable insurers and having the policy amount and deductible deemed appropriate by the Board and providing in all respects coverage at least
comparable to and in the same amount as that provided to the Chairman of the Board or the Chief Executive Officer of the Company and (ii)&nbsp;any replacement or substitute policies issued by one or more reputable insurers providing in all respects
coverage at least comparable to and in the same amount as that being provided to the Chairman of the Board or the Chief Executive Officer of the Company. The purchase, establishment and maintenance of any such insurance or other arrangements shall
not in any way limit or affect the rights and obligations of the Company or of Indemnitee under this Agreement except as expressly provided herein, and the execution and delivery of this Agreement by the Company and Indemnitee shall not in any way
limit or affect the rights and obligations of the Company or the other party or parties thereto under any such insurance or other arrangement. In the event of a Change in Control subsequent to the date of this Agreement, or the Company&#146;s
becoming insolvent, including being placed into receivership or entering the federal bankruptcy process, the Company shall maintain in force any and all insurance policies then maintained by the Company in providing insurance&#151;directors&#146;
and officers&#146; liability, fiduciary, employment practices or <FONT STYLE="white-space:nowrap">otherwise--in</FONT> respect of the individual directors and officers of the Company, for a fixed period of six years thereafter. Such coverage shall
be <FONT STYLE="white-space:nowrap">non-cancelable</FONT> and shall be placed and serviced by the Company&#146;s incumbent insurance broker or a broker selected by a majority of the Independent Directors. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6. <U>Mandatory Advancement of Expenses</U>. If requested by Indemnitee, the Company shall
advance prior to the final disposition of the Proceeding all Expenses reasonably incurred by Indemnitee in connection with (including in preparation for) a Proceeding related to an Indemnifiable Event within (30)&nbsp;days after the receipt by the
Company of a statement or statements from Indemnitee requesting such advance or advances from time to time, whether prior to or after final disposition of such Proceeding. Such statement or statements shall reasonably evidence the Expenses incurred
by Indemnitee. The right to advances under this section shall in all events continue until final disposition of any Proceeding, including any appeal therein. Indemnitee hereby undertakes to repay such amounts advanced if, and only if and to the
extent that, it shall ultimately be determined that Indemnitee is not entitled to be indemnified by the Company under the provisions of this Agreement, the Company&#146;s Bylaws or the DGCL, and no additional form of undertaking with respect to such
obligation to repay shall be required. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indemnitee&#146;s undertaking to repay any Expenses advanced to Indemnitee hereunder shall be
unsecured and shall not be subject to the accrual or payment of any interest thereon. In the event that Indemnitee&#146;s request for the advancement of expenses shall be accompanied by an affidavit of counsel to Indemnitee to the effect that such
counsel has reviewed such Expenses and that such Expenses are reasonable in such counsel&#146;s view, then such expenses shall be deemed reasonable in the absence of clear and convincing evidence to the contrary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7. <U>Notice and Other Indemnification Procedures</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Notification</U>. Promptly after receipt by Indemnitee of notice of the commencement of or the threat of commencement of
any Proceeding, unless the Company is a named <FONT STYLE="white-space:nowrap">co-defendant</FONT> with Indemnitee, Indemnitee shall, if Indemnitee believes that indemnification or advancement of Expenses with respect thereto may be sought from the
Company under this Agreement, notify the Company of the commencement or threat of commencement thereof. However, a failure so to notify the Company promptly following Indemnitee&#146;s receipt of such notice shall not relieve the Company from any
liability that it may have to Indemnitee except to the extent that the Company is materially prejudiced in its defense of such Proceeding as a result of such failure. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Insurance and Other Matters</U>. If, at the time of the receipt of a notice of the commencement of a Proceeding pursuant
to Section<U></U>&nbsp;7(a) above, the Company has director and officer liability insurance in effect, the Company shall give prompt notice of the commencement of such Proceeding to the issuers in accordance with the procedures set forth in the
respective policies. The Company shall thereafter take all reasonable action to cause such insurers to pay, on behalf of Indemnitee, all amounts payable as a result of such Proceeding in accordance with the terms of such insurance policies. In
addition, the Company will instruct the insurers and the Company&#146;s insurance broker that they may communicate directly with Indemnitee regarding such claim. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Assumption of Defense</U>. In the event the Company shall be
obligated to advance the Expenses for any Proceeding against Indemnitee, the Company, if deemed appropriate by the Company, shall be entitled to assume the defense of such Proceeding as provided herein. Such defense by the Company may include the
representation of two or more parties by one attorney or law firm as permitted under the ethical rules and legal requirements related to joint representations. Following delivery of written notice to Indemnitee of the Company&#146;s election to
assume the defense of such Proceeding, the approval by Indemnitee (which approval shall not be unreasonably withheld) of counsel designated by the Company and the retention of such counsel by the Company, the Company will not be liable to Indemnitee
under this Agreement for any fees and expenses of counsel subsequently incurred by Indemnitee with respect to the same Proceeding. If (A)&nbsp;the employment of counsel by Indemnitee has been previously authorized by the Company, (B)&nbsp;Indemnitee
shall have notified the Board in writing that Indemnitee has reasonably concluded that there may be a conflict of interest between the Company and Indemnitee in the conduct of any such defense, (C)&nbsp;the Company fails to employ counsel to assume
the defense of such Proceeding, or (D)&nbsp;after a Change in Control, the employment of counsel by Indemnitee has been approved by the Independent Counsel, the Expenses related to work conducted by Indemnitee&#146;s counsel shall be subject to
indemnification and/or advancement pursuant to the terms of this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Nothing herein shall prevent Indemnitee from
employing counsel for any such Proceeding at Indemnitee&#146;s expense. Indemnitee agrees that any such separate counsel retained by Indemnitee will be a member of any approved list of panel counsel under the Company&#146;s applicable
directors&#146; and officers&#146; insurance policy, should the applicable policy provide for a panel of approved counsel. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Settlement</U>. The Company shall not be liable to indemnify Indemnitee under this Agreement or otherwise for any
amounts paid in settlement of any Proceeding effected without the Company&#146;s written consent; provided, however, that if a Change in Control has occurred subsequent to the date of this Agreement, the Company shall be liable for indemnification
of Indemnitee for amounts paid in settlement if the Independent Counsel has approved the settlement. Neither the Company nor any Subsidiary or Affiliate shall enter into a settlement of any Proceeding that might result in the imposition of any
Expense, Other Liability, penalty, limitation or detriment on Indemnitee, whether indemnifiable under this Agreement or otherwise, without Indemnitee&#146;s written consent. Neither the Company nor Indemnitee shall unreasonably withhold consent from
any settlement of any Proceeding. The Company shall promptly notify Indemnitee upon the Company&#146;s receipt of an offer to settle, or if the Company makes an offer to settle, any Proceeding, and provide Indemnitee with a reasonable amount of time
to consider such settlement, in the case of any such settlement for which the consent of Indemnitee would be required hereunder. The Company shall not, on its own behalf, settle any part of any Proceeding to which Indemnitee is a party with respect
to other parties (including the Company) without the written consent of Indemnitee if any portion of the settlement is to be funded from insurance proceeds unless approved by a majority of the Independent Directors, provided that this sentence shall
cease to be of any force and effect if it has been determined in accordance with this Agreement that Indemnitee is not entitled to indemnification hereunder with respect to such Proceeding or if the Company&#146;s obligations hereunder to Indemnitee
with respect to such Proceeding have been fully discharged. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8. <U>Determination of Right to Indemnification</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Success on the Merits or Otherwise</U>. To the extent that Indemnitee has been successful on the merits or otherwise in
defense of any Proceeding referred to in Section<U></U>&nbsp;3(a) above or in the defense of any claim, issue or matter described therein, the Company shall indemnify Indemnitee against Expenses actually and reasonably incurred in connection
therewith. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Indemnification in Other Situations</U>. In the event that Section&nbsp;8(a) is inapplicable, the
Company shall also indemnify Indemnitee if Indemnitee has not failed to meet the applicable standard of conduct for indemnification. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Forum</U>. Indemnitee shall be entitled to select the forum in which determination of whether or not Indemnitee has met
the applicable standard of conduct shall be decided, and such election will be made from among the following: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(1) Those members of the
Board who are Independent Directors even though less than a quorum; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(2) A committee of Independent Directors designated by a majority
vote of Independent Directors, even though less than a quorum; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(3) Independent Counsel selected by Indemnitee and approved by the
Board, which approval may not be unreasonably withheld, which counsel shall make such determination in a written opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Indemnitee
is an officer or a director of the Company at the time that Indemnitee is selecting the forum, then Indemnitee shall not select Independent Counsel as such forum unless there are no Independent Directors or unless the Independent Directors agree to
the selection of Independent Counsel as the forum. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selected forum shall be referred to herein as the &#147;<B><I>Reviewing
Party</I></B>&#148;. Notwithstanding the foregoing, following any Change in Control subsequent to the date of this Agreement, the Reviewing Party shall be Independent Counsel selected in the manner provided in c. above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Decision Timing and Expenses</U>. As soon as practicable, and in no event later than thirty (30)&nbsp;days after
receipt by the Company of written notice of Indemnitee&#146;s choice of forum pursuant to Section&nbsp;8(c) above, the Company and Indemnitee shall each submit to the Reviewing Party such information as they believe is appropriate for the Reviewing
Party to consider. The Reviewing Party shall arrive at its decision within a reasonable period of time following the receipt of all such information from the Company and Indemnitee, but in no event later than thirty (30)&nbsp;days following the
receipt of all such information, provided that the time by which the Reviewing Party must reach a decision may be extended by mutual agreement of the Company and Indemnitee. All Expenses associated with the process set forth in this
Section&nbsp;8(d), including but not limited to the Expenses of the Reviewing Party, shall be paid by the Company. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>Delaware Court of Chancery</U>. Notwithstanding a final determination
by any Reviewing Party that Indemnitee is not entitled to indemnification with respect to a specific Proceeding, Indemnitee shall have the right to apply to the Court of Chancery, for the purpose of enforcing Indemnitee&#146;s right to
indemnification pursuant to this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) <U>Expenses</U>. The Company shall indemnify Indemnitee against all
Expenses incurred by Indemnitee in connection with any hearing or Proceeding under this Section&nbsp;8 involving Indemnitee and against all Expenses and Other Liabilities incurred by Indemnitee in connection with any other Proceeding between the
Company and Indemnitee involving the interpretation or enforcement of the rights of Indemnitee under this Agreement unless a court of competent jurisdiction finds that each of the material claims of Indemnitee in any such Proceeding was frivolous or
made in bad faith. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) <U>Determination of &#147;Good Faith&#148;</U>. For purposes of any determination of whether
Indemnitee acted in &#147;<B><I>good faith</I></B>&#148;, Indemnitee shall be deemed to have acted in good faith if in taking or failing to take the action in question Indemnitee relied on the records or books of account of the Company or a
Subsidiary or Affiliate, including financial statements, or on information, opinions, reports or statements provided to Indemnitee by the officers or other employees of the Company or a Subsidiary or Affiliate in the course of their duties, or on
the advice of legal counsel for the Company or a Subsidiary or Affiliate, or on information or records given or reports made to the Company or a Subsidiary or Affiliate by an independent certified public accountant or by an appraiser or other expert
selected by the Company or a Subsidiary or Affiliate, or by any other person (including legal counsel, accountants and financial advisors) as to matters Indemnitee reasonably believes are within such other person&#146;s professional or expert
competence and who has been selected with reasonable care by or on behalf of the Company or a Subsidiary or Affiliate. In connection with any determination as to whether Indemnitee is entitled to be indemnified hereunder, or to advancement of
expenses, the Reviewing Party or court shall presume that Indemnitee has satisfied the applicable standard of conduct and is entitled to indemnification or advancement of Expenses, as the case may be, and the burden of proof shall be on the Company
to establish, by clear and convincing evidence, that Indemnitee is not so entitled. The provisions of this Section&nbsp;8(g) shall not be deemed to be exclusive or to limit in any way the other circumstances in which Indemnitee may be deemed to have
met the applicable standard of conduct set forth in this Agreement. In addition, the knowledge and/or actions, or failures to act, of any other person serving the Company or a Subsidiary or Affiliate as an Indemnifiable Person shall not be imputed
to Indemnitee for purposes of determining the right to indemnification hereunder. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9. <U>Exceptions</U>. Any other provision herein to the contrary notwithstanding, </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Claims Initiated by Indemnitee</U>. The Company shall not be obligated pursuant to the terms of this Agreement to
indemnify or advance Expenses to Indemnitee with respect to Proceedings or claims initiated or brought voluntarily by Indemnitee and not by way of defense, except (1)&nbsp;with respect to Proceedings brought to establish or enforce a right to
indemnification under this Agreement, any other statute or law, as permitted under Section&nbsp;145, or otherwise, (2)&nbsp;where the Board has consented to the initiation of such Proceeding, or (3)&nbsp;with respect to Proceedings brought to
discharge Indemnitee&#146;s fiduciary responsibilities, whether under ERISA or otherwise, but such indemnification or advancement of Expenses may be provided by the Company in specific cases if the Board finds it to be appropriate; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Actions Based on Federal Statutes Regarding Profit Recovery and Return of Bonus Payments</U>. The Company shall not be
obligated pursuant to the terms of this Agreement to indemnify Indemnitee on account of (i)&nbsp;any suit in which judgment is rendered against Indemnitee for an accounting of profits made from the purchase or sale by Indemnitee of securities of the
Company pursuant to the provisions of Section&nbsp;16(b) of the Securities Exchange Act of l934 and amendments thereto or similar provisions of any federal, state or local statutory law, or (ii)&nbsp;any reimbursement of the Company by the
Indemnitee of any bonus or other incentive-based or equity-based compensation or of any profits realized by the Indemnitee from the sale of securities of the Company, as required in each case under the Exchange Act (including any such reimbursements
that arise from an accounting restatement of the Company pursuant to Section&nbsp;304 of the Sarbanes-Oxley Act of 2002 (the &#147;<B><I>Sarbanes-Oxley Act</I></B>&#148;), or the payment to the Company of profits arising from the purchase and sale
by Indemnitee of securities in violation of Section&nbsp;306 of the Sarbanes-Oxley Act); or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Unlawful
Indemnification</U>. The Company shall not be obligated pursuant to the terms of this Agreement to indemnify Indemnitee for Other Liabilities if such indemnification is prohibited by law as determined by a court of competent jurisdiction in a final
adjudication not subject to further appeal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">10. <U><FONT STYLE="white-space:nowrap">Non-exclusivity</FONT></U>. The provisions for
indemnification and advancement of Expenses set forth in this Agreement shall not be deemed exclusive of any other rights which Indemnitee may have under any provision of law, the Company&#146;s Certificate of Incorporation or Bylaws, the vote of
the Company&#146;s stockholders or disinterested directors, other agreements, or otherwise, both as to acts or omissions in his or her official capacity and to acts or omissions in another capacity while serving the Company or a Subsidiary or
Affiliate as an Indemnifiable Person and Indemnitee&#146;s rights hereunder shall continue after Indemnitee has ceased serving the Company or a Subsidiary or Affiliate as an Indemnifiable Person and shall inure to the benefit of the heirs, executors
and administrators of Indemnitee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">11. <U>Severability</U>. If any provision or provisions of this Agreement shall be held to be invalid,
illegal or unenforceable for any reason whatsoever, (i)&nbsp;the validity, legality and enforceability of the remaining provisions of the Agreement (including, without limitation, all portions of any paragraphs of this Agreement containing any such
provision held to be invalid, illegal or unenforceable, that are not themselves invalid, illegal or unenforceable) shall not in any way be affected or impaired thereby, and (ii)&nbsp;to the fullest extent possible, the provisions of this Agreement
(including, without limitation, all portions of any paragraphs of this Agreement containing any such provision held to be invalid, illegal or unenforceable, that are not themselves invalid, illegal or unenforceable) shall be construed so as to give
effect to the intent manifested by the provision held invalid, illegal or unenforceable. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">12. <U>Supersession, Modification and Waiver</U>. This Agreement supersedes any prior
indemnification agreement between the Indemnitee and the Company, its Subsidiaries or its Affiliates. If the Company and Indemnitee have previously entered into an indemnification agreement providing for the indemnification of Indemnitee by the
Company, parties&#146; entry into this Agreement shall be deemed to amend and restate such prior agreement to read in its entirety as, and be superseded by, this Agreement. No supplement, modification or amendment of this Agreement shall be binding
unless executed in writing by both of the parties hereto. No waiver of any of the provisions of this Agreement shall be deemed or shall constitute a waiver of any other provision hereof (whether or not similar) and except as expressly provided
herein, no such waiver shall constitute a continuing waiver. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">13. <U>Successors and Assigns</U>. The terms of this Agreement shall bind,
and shall inure to the benefit of, and be enforceable by the parties hereto and their respective successors (including any direct or indirect successor by purchase, merger, consolidation or otherwise to all or substantially all of the business
and/or assets of the Company), assigns, spouses, heirs and personal and legal representatives. In addition, the Company shall require and cause any successor (whether direct or indirect by purchase, merger, consolidation or otherwise) to all,
substantially all, or a substantial part, of the business and/or assets of the Company, by written agreement in form and substance satisfactory to Indemnitee, expressly to assume and agree to perform this Agreement and indemnify Indemnitee to the
<U>fullest extent permitted by law.</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">14. <U>Notice</U>. All notices, requests, demands and other communications under this Agreement
shall be in writing and shall be deemed duly given (i)&nbsp;if delivered by hand and a receipt is provided by the party to whom such communication is delivered, (ii)&nbsp;if mailed by certified or registered mail with postage prepaid, return receipt
requested, on the signing by the recipient of an acknowledgement of receipt form accompanying delivery through the U.S. mail, (iii)&nbsp;personal service by a process server, or (iv)&nbsp;delivery to the recipient&#146;s address by overnight
delivery (e.g., FedEx, UPS or DHL) or other commercial delivery service. Addresses for notice to either party are as shown on the signature page of this Agreement, or as subsequently modified by written notice complying with the provisions of this
Section&nbsp;14. Delivery of communications to the Company with respect to this Agreement shall be sent to the attention of the Company&#146;s Vice President of Finance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">15. <U>No Presumptions</U>. For purposes of this Agreement, the termination of any Proceeding, by judgment, order, settlement (whether with or
without court approval) or conviction, or upon a plea of nolo contendere or its equivalent, shall not, of itself, create a presumption that Indemnitee did not meet any particular standard of conduct or have any particular belief or that a court has
determined that indemnification is not permitted by applicable law or otherwise. In addition, neither the failure of the Company or a Reviewing Party to have made a determination as to whether Indemnitee has met any particular standard of conduct or
had any particular belief, nor an actual determination by the Company, or a Reviewing Party that Indemnitee has not met such standard of conduct or did not have such belief, prior to the commencement of Proceedings by Indemnitee to secure a judicial
determination by exercising Indemnitee&#146;s rights under Section&nbsp;8(e) of this Agreement shall be a defense to Indemnitee&#146;s claim or create a presumption that Indemnitee has failed to meet any particular standard of conduct or did not
have any particular belief or is not entitled to indemnification under applicable law or otherwise. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">16. <U>Survival of Rights</U>. The rights conferred on Indemnitee by this Agreement shall
continue after Indemnitee has ceased to serve the Company or a Subsidiary or Affiliate of the Company as an Indemnifiable Person and shall inure to the benefit of Indemnitee&#146;s heirs, executors and administrators. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">17. <U>Subrogation and Contribution</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) In the event of payment under this Agreement, the Company shall be subrogated to the extent of such payment to all of the
rights of recovery of Indemnitee, who shall execute all documents required and shall do all acts that may be necessary to secure such rights and to enable the Company effectively to bring suit to enforce such rights. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) To the fullest extent permissible under applicable law, if the indemnification provided for in this Agreement is
unavailable to Indemnitee for any reason whatsoever, the Company, in lieu of indemnifying Indemnitee, shall contribute to the amount incurred by or on behalf of Indemnitee, whether for judgments, fines, penalties, excise taxes, amounts paid or to be
paid in settlement and/or for Expenses, in connection with any claim relating to an indemnifiable event under this Agreement, in such proportion as is deemed fair and reasonable in light of all of the circumstances of such Proceeding in order to
reflect (i)&nbsp;the relative benefits received by the Company and Indemnitee as a result of the event(s) and/or transaction(s) giving cause to such Proceeding; and/or (ii)&nbsp;the relative fault of the Company (and its directors, officers,
employees and agents) and Indemnitee in connection with such event(s) and/or transaction(s). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">18. <U>Specific Performance, Etc</U>. The
parties recognize that if any provision of this Agreement is violated by the Company, Indemnitee may be without an adequate remedy at law. Accordingly, in the event of any such violation, Indemnitee shall be entitled, if Indemnitee so elects, to
institute Proceedings, either in law or at equity, to obtain damages, to enforce specific performance, to enjoin such violation, or to obtain any relief or any combination of the foregoing as Indemnitee may elect to pursue. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">19. <U>Counterparts</U>. This Agreement may be executed in counterparts, each of which shall for all purposes be deemed to be an original but
all of which together shall constitute one and the same agreement. Only one such counterpart signed by the party against whom enforceability is sought needs to be produced to evidence the existence of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">20. <U>Headings</U>. The headings of the sections and paragraphs of this Agreement are inserted for convenience only and shall not be deemed
to constitute part of this Agreement or to affect the construction or interpretation thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">21. <U>Governing Law</U>. This Agreement
shall be governed exclusively by and construed according to the laws of the State of Delaware, as applied to contracts between Delaware residents entered into and to be performed entirely with Delaware. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">22. <U>Consent to Jurisdiction</U>. The Company and Indemnitee each hereby irrevocably
consent to the jurisdiction of the courts of the State of Delaware for all purposes in connection with any Proceeding which arises out of or relates to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page Follows</I>] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The parties hereto have entered into this Indemnity Agreement effective as of the date first above written.
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="80%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B><U>COMPANY:</U></B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>AEGLEA BIOTHERAPEUTICS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B><U>INDEMNITEE:</U></B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Signature:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Address:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>SIGNATURE PAGE TO AEGLEA BIOTHERAPEUTICS, INC. INDEMNITY AGREEMENT</I>] </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.7
<SEQUENCE>19
<FILENAME>d518298dex107.htm
<DESCRIPTION>EX-10.7
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.7</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.7 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AEGLEA BIOTHERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2015 EQUITY INCENTIVE PLAN </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>As Adopted on March&nbsp;10, 2015 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.
</B><B><U>PURPOSE</U></B><B>. </B>The purpose of this Plan is to provide incentives to attract, retain and motivate eligible persons whose present and potential contributions are important to the success of the Company, its Parent and Subsidiaries
by offering eligible persons an opportunity to participate in the Company&#146;s future performance through the grant of Awards covering Shares. Capitalized terms not defined in the text are defined in Section&nbsp;14 hereof. Although this Plan is
intended to be a written compensatory benefit plan within the meaning of Rule 701, grants may be made pursuant to this Plan that do not qualify for exemption under Rule 701 or Section&nbsp;25102(o). Any requirement of this Plan that is required in
law only because of Section&nbsp;25102(o) need not apply if the Committee so provides. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. <U>SHARES SUBJECT TO THE PLAN</U>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.1 </B><B><U>Number of Shares Available</U></B><B>.</B> Subject to Sections 2.2 and 11 hereof, the total number of Shares reserved and available for grant
and issuance pursuant to this Plan will be 12,901,499 Shares. Subject to Sections 2.2 and 11 hereof, Shares subject to Awards that are cancelled, forfeited, settled in cash, used to pay withholding obligations or pay the exercise price of an Option
or that expire by their terms at any time will again be available for grant and issuance in connection with other Awards. In the event that Shares previously issued under the Plan are reacquired by the Company pursuant to a forfeiture provision,
right of first refusal, or repurchase by the Company, such Shares shall be added to the number of Shares then available for issuance under the Plan. At all times the Company will reserve and keep available a sufficient number of Shares as will be
required to satisfy the requirements of all Awards granted and outstanding under this Plan. In no event shall the total number of Shares issued (counting each reissuance of a Share that was previously issued and then forfeited or repurchased by the
Company as a separate issuance) under the Plan upon exercise of ISOs exceed 25,802,998 Shares (adjusted in proportion to any adjustments under Section&nbsp;2.2 hereof) over the term of the Plan (the &#147;<B><I>ISO Limit</I></B>&#148;). Subject to
Sections 2.2 and 11 hereof, in the event that the number of Shares reserved for issuance under the Plan is increased, the ISO Limit shall be automatically increased by such number of Shares such that the ISO Limit equals (a)&nbsp;two (2) multiplied
by (b)&nbsp;the number of Shares reserved for issuance under the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.2 </B><B><U>Adjustment of Shares</U></B><B>. </B>In the event that the number
of outstanding shares of the Company&#146;s Common Stock is changed by a stock dividend, recapitalization, stock split, reverse stock split, subdivision, combination, reclassification or other change in the capital structure of the Company affecting
Shares without consideration, then in order to prevent diminution or enlargement of the benefits or potential benefits intended to be made available under the Plan (a)&nbsp;the number of Shares reserved for issuance under this Plan, (b)&nbsp;the
Exercise Prices of and number of Shares subject to outstanding Options and SARs, and (c)&nbsp;the Purchase Prices of and/or number of Shares subject to other outstanding Awards will (to the extent appropriate) be proportionately adjusted, subject to
any required action by the Board or the stockholders of the Company and compliance with applicable securities laws; <I><U>provided</U></I>, <I><U>however</U></I>, that fractions of a Share will not be issued but will either be paid in cash at the
Fair Market Value of such fraction of a Share or will be rounded down to the nearest whole Share, as determined by the Committee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. <U>PLAN FOR
BENEFIT OF SERVICE PROVIDERS</U>. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3.1 </B><B><U>Eligibility</U></B><B>. </B>The Committee will have the authority to select persons to receive
Awards. ISOs (as defined in Section&nbsp;4 hereof) may be granted only to employees (including officers and directors who are also employees) of the Company or of a Parent or Subsidiary of the Company. NQSOs (as defined in Section&nbsp;4 hereof) and
all other types of Awards may be granted to employees, officers, directors and consultants of the Company or any Parent or Subsidiary of the Company; <I><U>provided</U></I> such consultants render bona fide services not in connection with the offer
and sale of securities in a capital-raising transaction when Rule 701 is to apply to the Award granted for such services. A person may be granted more than one Award under this Plan. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3.2 </B><B><U>No Obligation to Employ</U></B><B>. </B>Nothing in this Plan or any Award granted under
this Plan will confer or be deemed to confer on any Participant any right to continue in the employ of, or to continue any other relationship with, the Company or any Parent or Subsidiary or limit in any way the right of the Company or any Parent or
Subsidiary to terminate Participant&#146;s employment or other relationship at any time, with or without Cause. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. </B><B><U>OPTIONS</U></B><B>.
</B>The Committee may grant Options to eligible persons described in Section&nbsp;3 hereof and will determine whether such Options will be Incentive Stock Options within the meaning of the Code (&#147;<B><I>ISOs</I></B>&#148;) or Nonqualified Stock
Options (&#147;<B><I>NQSOs</I></B>&#148;), the number of Shares subject to the Option, the Exercise Price of the Option, the period during which the Option may be exercised, and all other terms and conditions of the Option, subject to the following.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4.1 </B><B><U>Form of Option Grant</U></B><B>. </B>Each Option granted under this Plan will be evidenced by an Award Agreement which will expressly
identify the Option as an ISO or an NQSO (&#147;<B><I>Stock Option Agreement</I></B>&#148;), and will be in such form and contain such provisions (which need not be the same for each Participant) as the Committee may from time to time approve, and
which will comply with and be subject to the terms and conditions of this Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4.2 </B><B><U>Date of Grant</U></B><B>.</B> The date of grant of an
Option will be the date on which the Committee makes the determination to grant such Option, unless a later date is otherwise specified by the Committee. The Stock Option Agreement and a copy of this Plan will be delivered to the Participant within
a reasonable time after the granting of the Option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4.3 </B><B><U>Exercise Period</U></B><B>.</B> Options may be exercisable within the time or upon
the events determined by the Committee in the Award Agreement and may be awarded as immediately exercisable but subject to repurchase pursuant to Section&nbsp;10 hereof or may be exercisable within the times or upon the events determined by the
Committee as set forth in the Stock Option Agreement governing such Option; <I><U>provided</U></I>, <I><U>however</U></I>, that (a)&nbsp;no Option will be exercisable after the expiration of ten (10)&nbsp;years from the date the Option is granted;
and (b)&nbsp;no ISO granted to a person who directly or by attribution owns more than ten percent (10%) of the total combined voting power of all classes of stock of the Company or of any Parent or Subsidiary (&#147;<B><I>Ten Percent
Stockholder</I></B>&#148;) will be exercisable after the expiration of five (5)&nbsp;years from the date the ISO is granted. The Committee also may provide for Options to become exercisable at one time or from time to time, periodically or
otherwise, in such number of Shares or percentage of Shares as the Committee determines. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4.4 </B><B><U>Exercise Price</U></B><B>.</B> The Exercise
Price of an Option will be determined by the Committee when the Option is granted and shall not be less than the Fair Market Value per Share unless expressly determined in writing by the Committee on the Option&#146;s date of grant;
<I><U>provided</U></I> that the Exercise Price of an ISO granted to a Ten Percent Stockholder will not be less than one hundred ten percent (110%) of the Fair Market Value of the Shares on the date of grant. Payment for the Shares purchased must be
made in accordance with Section&nbsp;8 hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4.5 </B><B><U>Method of Exercise</U></B><B>.</B> Options may be exercised only by delivery to the
Company of a written stock option exercise agreement (the &#147;<B><I>Exercise Agreement</I></B>&#148;) in a form approved by the Committee (which need not be the same for each Participant). The Exercise Agreement will state (a)&nbsp;the number of
Shares being purchased, (b)&nbsp;the restrictions imposed on the Shares purchased under such Exercise Agreement, if any, and (c)&nbsp;such representations and agreements regarding Participant&#146;s investment intent and access to information and
other matters, if any, as may be required or desirable by the Company to comply with applicable securities laws. Each Participant&#146;s Exercise Agreement may be modified by (i)&nbsp;agreement of Participant and the Company or
(ii)&nbsp;substitution by the Company, upon becoming a public company, in order to add the payment terms set forth in Section&nbsp;8.1 that apply to a public company and such other terms as shall be necessary or advisable in order to exercise a
public company option. Upon exercise of an Option, Participant shall execute and deliver to the Company the Exercise Agreement then in effect, together with payment in full of the Exercise Price for the number of Shares being purchased and payment
of any applicable taxes. No adjustment will be made for a dividend or other right for which the record date is prior to the date the Shares are issued, except as provided in Section&nbsp;2.2 of the Plan. Exercising an Option in any manner will
decrease the number of Shares thereafter available, both for purposes of the Plan and for sale under the Option, by the number of Shares as to which the Option is exercised. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4.6 </B><B><U>Termination</U></B><B>.</B> Subject to earlier termination pursuant to Sections 11 and 13.3 hereof and notwithstanding the exercise periods
set forth in the Stock Option Agreement, exercise of an Option will always be subject to the following terms and conditions. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4.6.1 <U>Other than Death or Disability or for Cause</U>. If the Participant is Terminated for any reason
other than death, Disability or for Cause, then the Participant may exercise such Participant&#146;s Options only to the extent that such Options are exercisable as to Vested Shares upon the Termination Date or as otherwise determined by the
Committee. Such Options must be exercised by the Participant, if at all, as to all or some of the Vested Shares calculated as of the Termination Date or such other date determined by the Committee, within three (3)&nbsp;months after the Termination
Date (or within such shorter time period, not less than thirty (30)&nbsp;days, or within such longer time period after the Termination Date as may be determined by the Committee, with any exercise beyond three (3)&nbsp;months after the date
Participant ceases to be an employee deemed to be an NQSO) but in any event, no later than the expiration date of the Options. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4.6.2 <U>Death or
Disability</U>. If the Participant is Terminated because of Participant&#146;s death or Disability (or the Participant dies within three (3)&nbsp;months after a Termination other than for Cause), then Participant&#146;s Options may be exercised only
to the extent that such Options are exercisable as to Vested Shares by Participant on the Termination Date or as otherwise determined by the Committee. Such options must be exercised by Participant (or Participant&#146;s legal representative or
authorized assignee), if at all, as to all or some of the Vested Shares calculated as of the Termination Date or such other date determined by the Committee, within twelve (12)&nbsp;months after the Termination Date (or within such shorter time
period, not less than six (6)&nbsp;months, or within such longer time period, after the Termination Date as may be determined by the Committee, with any exercise beyond (a)&nbsp;three (3) months after the date Participant ceases to be an employee
when the Termination is for any reason other than the Participant&#146;s death or disability, within the meaning of Section&nbsp;22(e)(3) of the Code, or (b)&nbsp;twelve (12) months after the date Participant ceases to be an employee when the
Termination is for Participant&#146;s disability, within the meaning of Section&nbsp;22(e)(3) of the Code, deemed to be an NQSO) but in any event no later than the expiration date of the Options. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4.6.3 <U>For Cause</U>. If the Participant is terminated for Cause, the Participant may exercise such Participant&#146;s Options, but not to an extent greater
than such Options are exercisable as to Vested Shares upon the Termination Date and Participant&#146;s Options shall expire on such Participant&#146;s Termination Date, or at such later time and on such conditions as are determined by the Committee.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4.7 </B><B><U>Limitations on Exercise</U></B><B>.</B> The Committee may specify a reasonable minimum number of Shares that may be purchased on any
exercise of an Option, <I><U>provided</U></I> that such minimum number will not prevent Participant from exercising the Option for the full number of Shares for which it is then exercisable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4.8 </B><B><U>Limitations on ISOs</U></B><B>.</B> The aggregate Fair Market Value (determined as of the date of grant) of Shares with respect to which ISOs
are exercisable for the first time by a Participant during any calendar year (under this Plan or under any other incentive stock option plan of the Company or any Parent or Subsidiary of the Company) will not exceed One Hundred Thousand Dollars
($100,000). If the Fair Market Value of Shares on the date of grant with respect to which ISOs are exercisable for the first time by a Participant during any calendar year exceeds One Hundred Thousand Dollars ($100,000), then the Options for the
first One Hundred Thousand Dollars ($100,000) worth of Shares to become exercisable in such calendar year will be ISOs and the Options for the amount in excess of One Hundred Thousand Dollars ($100,000) that become exercisable in that calendar year
will be NQSOs. In the event that the Code or the regulations promulgated thereunder are amended after the Effective Date (as defined in Section&nbsp;13.1 hereof) to provide for a different limit on the Fair Market Value of Shares permitted to be
subject to ISOs, then such different limit will be automatically incorporated herein and will apply to any Options granted after the effective date of such amendment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4.9 </B><B><U>Modification, Extension or Renewal</U></B><B>.</B> The Committee may modify, extend or renew outstanding Options and authorize the grant of
new Options in substitution therefor, <I><U>provided</U></I> that any such action may not, without the written consent of a Participant, impair any of such Participant&#146;s rights under any Option previously granted. Any outstanding ISO that is
modified, extended, renewed or otherwise altered will be treated in accordance with Section&nbsp;424(h) of the Code. Subject to Section&nbsp;4.10 hereof, the Committee may reduce the Exercise Price of outstanding Options without the consent of
Participants by a written notice to them; <I><U>provided</U></I>, <I><U>however</U></I>, that the Exercise Price may not be reduced below the minimum Exercise Price that would be permitted under Section&nbsp;4.4 hereof for Options granted on the
date the action is taken to reduce the Exercise Price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4.10 </B><B><U>No Disqualification</U></B><B>.</B> Notwithstanding any other provision in this
Plan, no term of this Plan relating to ISOs will be interpreted, amended or altered, nor will any discretion or authority granted under this Plan be exercised, so as to disqualify this Plan under Section&nbsp;422 of the Code or, without the consent
of the Participant, to disqualify any Participant&#146;s ISO under Section&nbsp;422 of the Code. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. </B><B><U>RESTRICTED STOCK</U></B><B>. </B>A Restricted Stock Award is an offer by the Company to sell
to an eligible person Shares that are subject to certain specified restrictions. The Committee will determine to whom an offer will be made, the number of Shares the person may purchase, the Purchase Price, the restrictions to which the Shares will
be subject, and all other terms and conditions of the Restricted Stock Award, subject to the following terms and conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5.1 </B><B><U>Form of
Restricted Stock Award</U></B><B>.</B> All purchases under a Restricted Stock Award made pursuant to this Plan will be evidenced by an Award Agreement (&#147;<B><I>Restricted Stock Purchase Agreement</I></B>&#148;) that will be in such form (which
need not be the same for each Participant) as the Committee will from time to time approve, and will comply with and be subject to the terms and conditions of this Plan. The Restricted Stock Award will be accepted by the Participant&#146;s execution
and delivery of the Restricted Stock Purchase Agreement and full payment for the Shares to the Company within thirty (30)&nbsp;days from the date the Restricted Stock Purchase Agreement is delivered to the person. If such person does not execute and
deliver the Restricted Stock Purchase Agreement along with full payment for the Shares to the Company within such thirty (30)&nbsp;days, then the offer will terminate, unless otherwise determined by the Committee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5.2 </B><B><U>Purchase Price</U></B><B>.</B> The Purchase Price of Shares sold pursuant to a Restricted Stock Award will be determined by the Committee on
the date the Restricted Stock Award is granted or at the time the purchase is consummated. Payment of the Purchase Price must be made in accordance with Section&nbsp;8 hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5.3 </B><B><U>Dividends and Other Distributions</U></B><B>.</B> Participants holding Restricted Stock will be entitled to receive all dividends and other
distributions paid with respect to such Shares, unless the Committee provides otherwise at the time of award. If any such dividends or distributions are paid in Shares, the Shares will be subject to the same restrictions on transferability and
forfeitability as the Shares of Restricted Stock with respect to which they were paid. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5.4 </B><B><U>Restrictions</U></B><B>. </B>Restricted Stock
Awards may be subject to the restrictions set forth in Sections 9 and 10 hereof or, with respect to a Restricted Stock Award to which Section&nbsp;25102(o) is to apply, such other restrictions not inconsistent with Section 25102(o). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. <U>RESTRICTED STOCK UNITS</U>. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6.1
</B><B><U>Awards of Restricted Stock Units</U></B><B>.</B> A Restricted Stock Unit (&#147;<B><I>RSU</I></B>&#148;) is an Award covering a number of Shares that may be settled in cash, or by issuance of those Shares at a date in the future. No
Purchase Price shall apply to an RSU settled in Shares. All grants of Restricted Stock Units will be evidenced by an Award Agreement that will be in such form (which need not be the same for each Participant) as the Committee will from time to time
approve, and will comply with and be subject to the terms and conditions of this Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6.2 </B><B><U>Form and Timing of Settlement</U></B><B>.</B> To
the extent permissible under applicable law, the Committee may permit a Participant to defer payment under a RSU to a date or dates after the RSU is earned, <I><U>provided</U></I> that the terms of the RSU and any deferral satisfy the requirements
of Section&nbsp;409A of the Code (or any successor) and any regulations or rulings promulgated thereunder. Payment may be made in the form of cash or whole Shares or a combination thereof, all as the Committee determines. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. <U>STOCK APPRECIATION RIGHTS</U>. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7.1
</B><B><U>Awards of SARs</U></B><B>. </B>Stock Appreciation Rights (&#147;<B><I>SARs</I></B>&#148;) may be settled in cash, or Shares (which may consist of Restricted Stock or RSUs), having a value equal to the value determined by multiplying the
difference between the Fair Market Value on the date of exercise over the Exercise Price and the number of Shares with respect to which the SAR is being settled. All grants of SARs made pursuant to this Plan will be evidenced by an Award Agreement
that will be in such form (which need not be the same for each Participant) as the Committee will from time to time approve, and will comply with and be subject to the terms and conditions of this Plan. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7.2 </B><B><U>Exercise Period and Expiration Date</U></B><B>. </B>A SAR will be exercisable within the
times or upon the occurrence of events determined by the Committee and set forth in the Award Agreement governing such SAR. The Award Agreement shall set forth the Expiration Date; <I><U>provided</U></I> that no SAR will be exercisable after the
expiration of ten years from the date the SAR is granted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7.3 </B><B><U>Exercise Price</U></B><B>.</B> The Committee will determine the Exercise Price
of the SAR when the SAR is granted, and which may not be less than the Fair Market Value on the date of grant and may be settled in cash or in Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7.4 </B><B><U>Termination</U></B><B>. </B>Subject to earlier termination pursuant to Sections 11 and 13.1 hereof and notwithstanding the exercise periods
set forth in the Award Agreement, exercise of SARs will always be subject to the following terms and conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7.4.1 <U>Other than Death or Disability
or for Cause</U>. If the Participant is Terminated for any reason other than death, Disability or for Cause, then the Participant may exercise such Participant&#146;s SARs only to the extent that such SARs are exercisable as to Vested Shares upon
the Termination Date or as otherwise determined by the Committee. SARs must be exercised by the Participant, if at all, as to all or some of the Vested Shares calculated as of the Termination Date or such other date determined by the Committee,
within three (3)&nbsp;months after the Termination Date (or within such shorter time period, not less than thirty (30)&nbsp;days, or within such longer time period after the Termination Date as may be determined by the Committee) but in any event,
no later than the expiration date of the SARs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7.4.2 <U>Death or Disability</U>. If the Participant is Terminated because of Participant&#146;s death or
Disability (or the Participant dies within three (3)&nbsp;months after a Termination other than for Cause), then Participant&#146;s SARs may be exercised only to the extent that such SARs are exercisable as to Vested Shares by Participant on the
Termination Date or as otherwise determined by the Committee. Such SARs must be exercised by Participant (or Participant&#146;s legal representative or authorized assignee), if at all, as to all or some of the Vested Shares calculated as of the
Termination Date or such other date determined by the Committee, within twelve (12)&nbsp;months after the Termination Date (or within such shorter time period, not less than six (6)&nbsp;months, or within such longer time period after the
Termination Date as may be determined by the Committee) but in any event no later than the expiration date of the SARs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7.4.3 <U>For Cause</U>. If the
Participant is terminated for Cause, the Participant may exercise such Participant&#146;s SARs, but not to an extent greater than such SARs are exercisable as to Vested Shares upon the Termination Date and Participant&#146;s SARs shall expire on
such Participant&#146;s Termination Date, or at such later time and on such conditions as are determined by the Committee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8. <U>PAYMENT FOR PURCHASES
AND EXERCISES</U>. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8.1 </B><B><U>Payment in General</U></B><B>.</B> Payment for Shares acquired pursuant to this Plan may be made in cash (by
check) or, where expressly approved for the Participant by the Committee and where permitted by law: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) by cancellation of indebtedness of the Company
owed to the Participant; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b) by surrender of shares of the Company that are clear of all liens, claims, encumbrances or security interests and:
(i)&nbsp;for which the Company has received &#147;full payment of the purchase price&#148; within the meaning of SEC Rule 144 (and, if such shares were purchased from the Company by use of a promissory note, such note has been fully paid with
respect to such shares) or (ii)&nbsp;that were obtained by Participant in the public market; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(c) by tender of a full recourse promissory note having such
terms as may be approved by the Committee and bearing interest at a rate sufficient to avoid imputation of income under Sections 483 and 1274 of the Code; <I><U>provided</U></I>, <I><U>however</U></I>, that Participants who are not employees or
directors of the Company will not be entitled to purchase Shares with a promissory note unless the note is adequately secured by collateral other than the Shares; <I><U>provided</U></I>, <I><U>further</U></I>, that the portion of the Exercise Price
or Purchase Price, as the case may be, equal to the par value (if any) of the Shares must be paid in cash or other legal consideration permitted by the laws under which the Company is then incorporated or organized; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) by waiver of compensation due or accrued to the Participant from the Company for services rendered; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(e) by participating in a formal cashless exercise program implemented by the Committee in connection with the Plan; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(f) subject to compliance with applicable law, provided that a public market for the Company&#146;s Common Stock exists, by exercising through a &#147;same
day sale&#148; commitment from the Participant and a broker-dealer whereby the Participant irrevocably elects to exercise the Award and to sell a portion of the Shares so purchased sufficient to pay the total Exercise Price or Purchase Price, and
whereby the broker-dealer irrevocably commits upon receipt of such Shares to forward the total Exercise Price or Purchase Price directly to the Company; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(g) by any combination of the foregoing or any other method of payment approved by the Committee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8.2 <U>Withholding Taxes</U>. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">8.2.1 <U>Withholding
Generally</U>. Whenever Shares are to be issued in satisfaction of Awards granted under this Plan, the Company may require the Participant to remit to the Company an amount sufficient to satisfy applicable tax withholding requirements prior to the
delivery of any certificate or certificates for such Shares. Whenever, under this Plan, payments in satisfaction of Awards are to be made in cash by the Company, such payment will be net of an amount sufficient to satisfy applicable tax withholding
requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">8.2.2 <U>Stock Withholding</U>. When, under applicable tax laws, a Participant incurs tax liability in connection with the exercise or
vesting of any Award that is subject to tax withholding and the Participant is obligated to pay the Company the amount required to be withheld, the Committee may in its sole discretion allow the Participant to satisfy the minimum tax withholding
obligation by electing to have the Company withhold from the Shares to be issued up to the minimum number of Shares having a Fair Market Value on the date that the amount of tax to be withheld is to be determined that is not more than the minimum
amount to be withheld; or to arrange a mandatory &#147;sell to cover&#148; on Participant&#146;s behalf (without further authorization) but in no event will the Company withhold Shares or &#147;sell to cover&#148; if such withholding would result in
adverse accounting consequences to the Company. Any elections to have Shares withheld or sold for this purpose will be made in accordance with the requirements established by the Committee for such elections and be in writing in a form acceptable to
the Committee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. <U>RESTRICTIONS ON AWARDS</U>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9.1</B> <B><U>Transferability</U></B>. Except as permitted by the Committee, Awards granted under this Plan, and any interest therein, will not be
transferable or assignable by Participant, other than by will or by the laws of descent and distribution, and, with respect to NQSOs, by instrument to an inter vivos or testamentary trust in which the NQSOs are to be passed to beneficiaries upon the
death of the trustor (settlor), or by gift to &#147;family member&#148; as that term is defined in Rule 701, and may not be made subject to execution, attachment or similar process. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the avoidance of doubt, the prohibition against assignment and transfer applies to a stock option and, prior to exercise , the shares to be issued on
exercise of a stock option, and pursuant to the foregoing sentence shall be understood to include, without limitation, a prohibition against any pledge, hypothecation, or other transfer, including any short position, any &#147;put equivalent
position&#148; or any &#147;call equivalent position&#148; (in each case, as defined in Rule <FONT STYLE="white-space:nowrap">16a-1</FONT> promulgated under the Exchange Act). During the lifetime of the Participant an Award will be exercisable only
by the Participant or Participant&#146;s legal representative and any elections with respect to an Award may be made only by the Participant or Participant&#146;s legal representative. The terms of an Option shall be binding upon the executor,
administrator, successors and assigns of the Participant who is a party thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9.2 </B><B><U>Securities Law and Other Regulatory
Compliance</U></B><B>.</B> Although this Plan is intended to be a written compensatory benefit plan within the meaning of Rule 701 promulgated under the Securities Act, grants may be made pursuant to this Plan that do not qualify for exemption under
Rule 701 or Section&nbsp;25102(o). Any requirement </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of this Plan which is required in law only because of Section&nbsp;25102(o) need not apply with respect to a particular Award to which Section&nbsp;25102(o) will not apply. An Award will not be
effective unless such Award is in compliance with all applicable federal and state securities laws, rules and regulations of any governmental body, and the requirements of any stock exchange or automated quotation system upon which the Shares may
then be listed or quoted, as they are in effect on the date of grant of the Award and also on the date of exercise or other issuance. Notwithstanding any other provision in this Plan, the Company will have no obligation to issue or deliver
certificates for Shares under this Plan prior to (a)&nbsp;obtaining any approvals from governmental agencies that the Company determines are necessary or advisable, and/or (b)&nbsp;compliance with any exemption, completion of any registration or
other qualification of such Shares under any state or federal law or ruling of any governmental body that the Company determines to be necessary or advisable. The Company will be under no obligation to register the Shares with the SEC or to effect
compliance with the exemption, registration, qualification or listing requirements of any state securities laws, stock exchange or automated quotation system, and the Company will have no liability for any inability or failure so do. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9.3 </B><B><U>Exchange and Buyout of Awards</U></B><B>.</B> The Committee may, at any time or from time to time, authorize the Company, with the consent of
the respective Participants, to issue new Awards in exchange for the surrender and cancellation of any or all outstanding Awards. Without prior stockholder approval the Committee may reprice Options or SARs (and where such repricing is a reduction
in the Exercise Price of outstanding Options or SARs, the consent of the affected Participants is not required provided written notice is provided to them). The Committee may at any time buy from a Participant an Award previously granted with
payment in cash, Shares (including Restricted Stock) or other consideration, based on such terms and conditions as the Committee and the Participant may agree. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10. <U>RESTRICTIONS ON SHARES</U>. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10.1
</B><B><U>Privileges of Stock Ownership</U></B><B>.</B> No Participant will have any of the rights of a stockholder with respect to any Shares until such Shares are issued to the Participant. After Shares are issued to the Participant, the
Participant will be a stockholder and have all the rights of a stockholder with respect to such Shares, including the right to vote and receive all dividends or other distributions made or paid with respect to such Shares; <I><U>provided</U></I>,
that if such Shares are Restricted Stock, then any new, additional or different securities the Participant may become entitled to receive with respect to such Shares by virtue of a stock dividend, stock split or any other change in the corporate or
capital structure of the Company will be subject to the same restrictions as the Restricted Stock. The Participant will have no right to retain such stock dividends or stock distributions with respect to Unvested Shares that are repurchased as
described in this Section&nbsp;10. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10.2 </B><B><U>Rights of First Refusal and Repurchase</U></B><B>.</B> At the discretion of the Committee, the
Company may reserve to itself and/or its assignee(s) in the Award Agreement (a)&nbsp;a right of first refusal to purchase all Shares that a Participant (or a subsequent transferee) may propose to transfer to a third party, <I><U>provided</U></I>
that such right of first refusal terminates upon the Company&#146;s initial public offering of Common Stock pursuant to an effective registration statement filed under the Securities Act and (b)&nbsp;a right to repurchase Unvested Shares held by a
Participant for cash and/or cancellation of purchase money indebtedness owed to the Company by the Participant following such Participant&#146;s Termination at any time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10.3 </B><B><U>Escrow; Pledge of Shares</U></B><B>. </B>To enforce any restrictions on a Participant&#146;s Shares, the Committee may require the
Participant to deposit all certificates representing Shares, together with stock powers or other instruments of transfer approved by the Committee, appropriately endorsed in blank, with the Company or an agent designated by the Company to hold in
escrow until such restrictions have lapsed or terminated. The Committee may cause a legend or legends referencing such restrictions to be placed on the certificate. Any Participant who is permitted to execute a promissory note as partial or full
consideration for the purchase of Shares under this Plan will be required to pledge and deposit with the Company all or part of the Shares so purchased as collateral to secure the payment of Participant&#146;s obligation to the Company under the
promissory note; <I><U>provided</U></I>, <I><U>however</U></I>, that the Committee may require or accept other or additional forms of collateral to secure the payment of such obligation and, in any event, the Company will have full recourse against
the Participant under the promissory note notwithstanding any pledge of the Participant&#146;s Shares or other collateral. In connection with any pledge of the Shares, Participant will be required to execute and deliver a written pledge agreement in
such form as the Committee will from time to time approve. The Shares purchased with the promissory note may be released from the pledge on a pro rata basis as the promissory note is paid. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10.4 </B><B><U>Securities Law Restrictions</U></B><B>.</B> All certificates for Shares or other
securities delivered under this Plan will be subject to such stock transfer orders, legends and other restrictions as the Committee may deem necessary or advisable, including restrictions under any applicable federal, state or foreign securities
law, or any rules, regulations and other requirements of the SEC or any stock exchange or automated quotation system upon which the Shares may be listed or quoted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11. <U>CORPORATE TRANSACTIONS</U>. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11.1
</B><B><U>Acquisitions or Other Combinations</U></B><B>. </B>In the event that the Company is subject to an Acquisition or Other Combination, outstanding Awards acquired under the Plan shall be subject to the agreement evidencing the Acquisition or
Other Combination, which need not treat all outstanding Awards in an identical manner. Such agreement, without the Participant&#146;s consent, shall provide for one or more of the following with respect to all outstanding Awards as of the effective
date of such Acquisition or Other Combination: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) The continuation of such outstanding Awards by the Company (if the Company is the successor entity).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b) The assumption of outstanding Awards by the successor or acquiring entity (if any) in such Acquisition or Other Combination (or by any of its
Parents, if any), which assumption, will be binding on all Participants; provided that the exercise price and the number and nature of shares issuable upon exercise of any such option or stock appreciation right, or any award that is subject to
Section&nbsp;409A of the Code, will be adjusted appropriately pursuant to Section&nbsp;424(a) and Section&nbsp;409A of the Code. For the purposes of this Section&nbsp;11, an Award will be considered assumed if, following the Acquisition or Other
Combination, the Award confers the right to purchase or receive, for each Share subject to the Award immediately prior to the Acquisition or Other Combination, the consideration (whether stock, cash, or other securities or property) received in the
Acquisition or Other Combination by holders of Shares for each Share held on the effective date of the transaction (and if holders were offered a choice of consideration, the type of consideration chosen by the holders of a majority of the
outstanding Shares); provided, however, that if such consideration received in the Acquisition or Other Combination is not solely common stock of the successor corporation or its Parent, the Committee may, with the consent of the successor
corporation, provide for the consideration to be received upon the exercise of an Option or Stock Appreciation Right or upon the payout of a Restricted Stock Unit, for each Share subject to such Award, to be solely common stock of the successor
corporation or its Parent equal in fair market value to the per share consideration received by holders of Common Stock in the Acquisition or Other Combination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(c) The substitution by the successor or acquiring entity in such Acquisition or Other Combination (or by any of its Parents, if any) of equivalent awards
with substantially the same terms for such outstanding Awards (except that the exercise price and the number and nature of shares issuable upon exercise of any such option or stock appreciation right, or any award that is subject to
Section&nbsp;409A of the Code, will be adjusted appropriately pursuant to Section&nbsp;424(a) of the Code). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) The full or partial exercisability or
vesting and accelerated expiration of outstanding Awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(e) The settlement of the full value of such outstanding Award (whether or not then vested or
exercisable) in cash, cash equivalents, or securities of the successor entity (or its Parent, if any) with a Fair Market Value equal to the required amount, followed by the cancellation of such Awards; provided however, that such Award may be
cancelled without consideration if such Award has no value, as determined by the Committee, in its discretion. Subject to Section&nbsp;409A of the Code, such payment may be made in installments and may be deferred until the date or dates when the
Award would have become exercisable or vested. Such payment may be subject to vesting based on the Participant&#146;s continued service, provided that without the Participant&#146;s consent, the vesting schedule shall not be less favorable to the
Participant than the schedule under which the Award would have become vested or exercisable. For purposes of this Section&nbsp;11.1(e), the Fair Market Value of any security shall be determined without regard to any vesting conditions that may apply
to such security. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(f) The cancellation of outstanding Awards in exchange for no consideration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immediately following an Acquisition or Other Combination, outstanding Awards shall terminate and cease to be outstanding, except to the extent such Awards,
have been continued, assumed or substituted, as described in Sections 11.1(a), (b) and/or (c). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11.2 </B><B><U>Assumption of Awards by the
Company</U></B><B>. </B>The Company, from time to time, also may substitute or assume outstanding awards granted by another entity, whether in connection with an acquisition of such other entity or otherwise, by either (a)&nbsp;granting an Award
under this Plan in substitution of such other entity&#146;s award or (b)&nbsp;assuming and/or converting such award as if it had been granted under this Plan if the terms of such assumed award could be applied to an Award granted under this Plan.
Such substitution or assumption will be permissible if the holder of the substituted or assumed award would have been eligible to be granted an Award under this Plan if the other entity had applied the rules of this Plan to such grant. In the event
the Company assumes an award granted by another entity, the terms and conditions of such award will remain unchanged (except that the exercise price and the number and nature of shares issuable upon exercise of any such option or stock appreciation
right, or any award that is subject to Section&nbsp;409A of the Code, will be adjusted appropriately pursuant to Section&nbsp;424(a) of the Code). In the event the Company elects to grant a new Option or SAR rather than assuming an existing option
or stock appreciation right, such new Option or SAR may be granted with a similarly adjusted Exercise Price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12. <U>ADMINISTRATION</U>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12.1 </B><B><U>Committee Authority</U></B><B>.</B> This Plan will be administered by the Committee or the Board if no Committee is created by the Board.
Subject to the general purposes, terms and conditions of this Plan, and to the direction of the Board, the Committee will have full power to implement and carry out this Plan. Without limitation, the Committee will have the authority to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) construe and interpret this Plan, any Award Agreement and any other agreement or document executed pursuant to this Plan; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b) prescribe, amend, expand, modify and rescind or terminate rules and regulations relating to this Plan; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(c) approve persons to receive Awards; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) determine the form
and terms of Awards; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(e) determine the number of Shares or other consideration subject to Awards granted under this Plan; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(f) determine the Fair Market Value in good faith and interpret the applicable provisions of this Plan and the definition of Fair Market Value in connection
with circumstances that impact the Fair Market Value, if necessary; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(g) determine whether Awards will be granted singly, in combination with, in tandem
with, in replacement of, or as alternatives to, other Awards under this Plan or awards under any other incentive or compensation plan of the Company or any Parent or Subsidiary of the Company; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(h) grant waivers of any conditions of this Plan or any Award; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(i) determine the terms of vesting, exercisability and payment of Awards to be granted pursuant to this Plan; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(j) correct any defect, supply any omission, or reconcile any inconsistency in this Plan, any Award, any Award Agreement, any Exercise Agreement or any
Restricted Stock Purchase Agreement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(k) determine whether an Award has been earned; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(l) extend the vesting period beyond a Participant&#146;s Termination Date; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(m) adopt rules and/or procedures (including the adoption of any subplan under this Plan) relating to the
operation and administration of the Plan to accommodate requirements of local law and procedures outside of the United States; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(n) delegate any of the
foregoing to a subcommittee consisting of one or more executive officers pursuant to a specific delegation as may otherwise be permitted by applicable law; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(o) change the vesting schedule of Awards under the Plan prospectively in the event that the Participant&#146;s service status changes between full and part
time status in accordance with Company policies relating to work schedules and vesting of awards; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(p) make all other determinations necessary or
advisable in connection with the administration of this Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12.2 </B><B><U>Committee Composition and Discretion</U></B><B>. </B>The Board may
delegate full administrative authority over the Plan and Awards to a Committee consisting of at least one member of the Board (or such greater number as may then be required by applicable law). Unless in contravention of any express terms of this
Plan or Award, any determination made by the Committee with respect to any Award will be made in its sole discretion either (a)&nbsp;at the time of grant of the Award, or (b)&nbsp;subject to Section&nbsp;4.9 hereof, at any later time. Any such
determination will be final and binding on the Company and on all persons having an interest in any Award under this Plan. To the extent permitted by applicable law, the Committee may delegate to one or more officers of the Company the authority to
grant an Award under this Plan, <I><U>provided</U></I> that each such officer is a member of the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12.3 </B><B><U>Nonexclusivity of the
Plan</U></B><B>.</B> Neither the adoption of this Plan by the Board, the submission of this Plan to the stockholders of the Company for approval, nor any provision of this Plan will be construed as creating any limitations on the power of the Board
to adopt such additional compensation arrangements as it may deem desirable, including, without limitation, the granting of stock options and other equity awards otherwise than under this Plan, and such arrangements may be either generally
applicable or applicable only in specific cases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12.4 </B><B><U>Governing Law</U></B><B>.</B> This Plan and all agreements hereunder shall be governed
by and construed in accordance with the laws of the State of Texas, without giving effect to that body of laws pertaining to conflict of laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13.
<U>EFFECTIVENESS, AMENDMENT AND TERMINATION OF THE PLAN</U>. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13.1 </B><B><U>Adoption and Stockholder Approval</U></B><B>. </B>This Plan will
become effective on the date that it is adopted by the Board (the &#147;<B><I>Effective Date</I></B>&#148;). This Plan will be approved by the stockholders of the Company (excluding Shares issued pursuant to this Plan), consistent with applicable
laws, within twelve (12)&nbsp;months before or after the Effective Date. Upon the Effective Date, the Board may grant Awards pursuant to this Plan; <I><U>provided</U></I>, <I><U>however</U></I>, that: (a)&nbsp;no Option or SAR may be exercised prior
to initial stockholder approval of this Plan; (b)&nbsp;no Option or SAR granted pursuant to an increase in the number of Shares approved by the Board shall be exercised prior to the time such increase has been approved by the stockholders of the
Company; (c)&nbsp;in the event that initial stockholder approval is not obtained within the time period provided herein, all Awards for which only the exemption from California&#146;s securities qualification requirements provided by
Section&nbsp;25102(o) can apply shall be canceled, any Shares issued pursuant to any such Award shall be canceled and any purchase of such Shares issued hereunder shall be rescinded; and (d)&nbsp;Awards (to which only the exemption from
California&#146;s securities qualification requirements provided by Section&nbsp;25102(o) can apply) granted pursuant to an increase in the number of Shares approved by the Board which increase is not approved by stockholders within the time then
required under Section&nbsp;25102(o) shall be canceled, any Shares issued pursuant to any such Awards shall be canceled, and any purchase of Shares subject to any such Award shall be rescinded. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13.2 </B><B><U>Term of Plan</U></B><B>.</B> Unless earlier terminated as provided herein, this Plan will automatically terminate ten (10)&nbsp;years after
the later of (i)&nbsp;the Effective Date, or (ii)&nbsp;the most recent increase in the number of Shares reserved under Section&nbsp;2 that was approved by stockholders. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13.3 </B><B><U>Amendment or Termination of Plan</U></B><B>. </B>Subject to Section&nbsp;4.9 hereof, the
Board may at any time (a)&nbsp;terminate or amend this Plan in any respect, including without limitation amendment of any form of Award Agreement or instrument to be executed pursuant to this Plan and (b)&nbsp;terminate any and all outstanding
Options or SARs upon a dissolution or liquidation of the Company, followed by the payment of creditors and the distribution of any remaining funds to the Company&#146;s stockholders; <I><U>provided</U></I>, <I><U>however</U></I>, that the Board will
not, without the approval of the stockholders of the Company, amend this Plan in any manner that requires such stockholder approval pursuant to Section&nbsp;25102(o) or pursuant to the Code or the regulations promulgated under the Code as such
provisions apply to ISO plans. The termination of the Plan, or any amendment thereof, shall not affect any Share previously issued or any Award previously granted under the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14. </B><B><U>DEFINITIONS</U></B><B>. </B>For all purposes of this Plan, the following terms will have the following meanings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Acquisition</I></B>,&#148; for purposes of Section&nbsp;11, means: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) any consolidation or merger in which the Company is a constituent entity or is a party in which the voting stock and other voting securities of the Company
that are outstanding immediately prior to the consummation of such consolidation or merger represent, or are converted into, securities of the surviving entity of such consolidation or merger (or of any Parent of such surviving entity) that,
immediately after the consummation of such consolidation or merger, together possess less than fifty percent (50%) of the total voting power of all voting securities of such surviving entity (or of any of its Parents, if any) that are outstanding
immediately after the consummation of such consolidation or merger; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b) a sale or other transfer by the holders thereof of outstanding voting stock
and/or other voting securities of the Company possessing more than fifty percent (50%) of the total voting power of all outstanding voting securities of the Company, whether in one transaction or in a series of related transactions, pursuant to an
agreement or agreements to which the Company is a party and that has been approved by the Board, and pursuant to which such outstanding voting securities are sold or transferred to a single person or entity, to one or more persons or entities who
are Affiliates of each other, or to one or more persons or entities acting in concert; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(c) the sale, lease, transfer or other disposition, in a single
transaction or series of related transactions, by the Company and/or any Subsidiary or Subsidiaries of the Company, of all or substantially all the assets of the Company and its Subsidiaries taken as a whole, (or, if substantially all of the assets
of the Company and its Subsidiaries taken as a whole are held by one or more Subsidiaries, the sale or disposition (whether by consolidation, merger, conversion or otherwise) of such Subsidiaries of the Company), except where such sale, lease,
transfer or other disposition is made to the Company or one or more wholly owned Subsidiaries of the Company (an &#147;<B><I>Acquisition by Sale of Assets</I></B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>&#147;Affiliate&#148; </I></B>of a specified person means a person that directly, or indirectly through one or more intermediaries, controls or is
controlled by, or is under common control with, the person specified (where, for purposes of this definition, the term &#147;<B><I>control&#148;</I></B> (including the terms <B><I>controlling</I></B><I>,</I><B><I> controlled by</I></B> and
<B><I>under common control with</I></B>) means the possession, direct or indirect, of the power to direct or cause the direction of the management and policies of a person, whether through the ownership of voting securities, by contract, or
otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Award</I></B>&#148; means any award pursuant to the terms and conditions of this Plan, including any Option, Restricted Stock
Unit, Stock Appreciation Right or Restricted Stock Award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Award Agreement</I></B>&#148; means, with respect to each Award, the signed written
or electronic agreement between the Company and the Participant setting forth the terms and conditions of the Award as approved by the Committee. For purposes of the Plan, the Award Agreement may be executed via written or electronic means. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Board</I></B>&#148; means the Board of Directors of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Cause</I></B>&#148; means Termination because of (a)&nbsp;Participant&#146;s unauthorized misuse of the Company or a Parent or Subsidiary of the
Company&#146;s trade secrets or proprietary information, (b)&nbsp;Participant&#146;s conviction of or plea of nolo contendere to a felony or a crime involving moral turpitude, (c)&nbsp;Participant&#146;s committing an act of fraud against the
Company or a Parent or Subsidiary of the Company or (d)&nbsp;Participant&#146;s gross negligence or willful misconduct in the performance of his or her duties that has had or will have a material adverse effect on the Company or Parent or Subsidiary
of the Company&#146; reputation or business. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Code</I></B>&#148; means the Internal Revenue Code of 1986, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Committee</I></B>&#148; means the committee created and appointed by the Board to administer this Plan, or if no committee is created and
appointed, the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Company</I></B>&#148; means Aeglea BioTherapeutics, Inc., or any successor corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Disability</I></B>&#148; means that the Participant is unable to engage in any substantial gainful activity by reason of any medically
determinable physical or mental impairment that can be expected to result in death or can be expected to last for a continuous period of not less than 12 months. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Exchange Act</I></B>&#148; means the Securities Exchange Act of 1934, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Exercise Price</I></B>&#148; means the price per Share at which a holder of an Option may purchase Shares issuable upon exercise of the Option.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Fair Market Value</I></B>&#148; means, as of any date, the value of a share of the Company&#146;s Common Stock determined as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) if such Common Stock is then publicly traded on a national securities exchange, its closing price on the date of determination on the principal national
securities exchange on which the Common Stock is listed or admitted to trading as reported in <U>The Wall Street Journal</U>; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b) if such Common Stock is
publicly traded but is not listed or admitted to trading on a national securities exchange, the average of the closing bid and asked prices on the date of determination as reported by <U>The Wall Street Journal</U> (or, if not so reported, as
otherwise reported by any newspaper or other source as the Committee may determine); or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(c) if none of the foregoing is applicable to the valuation in
question, by the Committee in good faith. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Option</I></B>&#148; means an award of an option to purchase Shares pursuant to Section&nbsp;4 of
this Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Other Combination</I></B>&#148; for purposes of Section&nbsp;11 means any (a)&nbsp;consolidation or merger in which the Company is
a constituent entity and is not the surviving entity of such consolidation or merger or (b)&nbsp;any conversion of the Company into another form of entity; <I><U>provided</U></I> that such consolidation, merger or conversion does not constitute an
Acquisition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Parent</I></B>&#148; of a specified entity means, any entity that, either directly or indirectly, owns or controls such
specified entity, where for this purpose, &#147;<B><I>control</I></B>&#148; means the ownership of stock, securities or other interests that possess at least a majority of the voting power of such specified entity (including indirect ownership or
control of such stock, securities or other interests). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Participant</I></B>&#148; means a person who receives an Award under this Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Plan</I></B>&#148; means this 2015 Equity Incentive Plan, as amended from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Purchase Price</I></B>&#148; means the price at which a Participant may purchase Restricted Stock pursuant to this Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Restricted Stock</I></B>&#148; means Shares purchased pursuant to a Restricted Stock Award under this Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Restricted Stock Award</I></B>&#148; means an award of Shares pursuant to Section&nbsp;5 hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Restricted Stock Unit</I></B>&#148; or &#147;<B><I>RSU</I></B>&#148; means an award made pursuant to Section&nbsp;6 hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Rule 701</I></B>&#148; means Rule 701 <I>et seq. </I>promulgated by the Commission under the Securities Act. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>SEC</I></B>&#148; means the Securities and Exchange Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Section</I></B><B><I></I></B><B><I>&nbsp;25102(o)</I></B>&#148; means Section&nbsp;25102(o) of the California Corporations Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Securities Act</I></B>&#148; means the Securities Act of 1933, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Shares</I></B>&#148; means shares of the Company&#146;s Common Stock reserved for issuance under this Plan, as adjusted pursuant to Sections 2.2
and 11 hereof, and any successor security. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Stock Appreciation Right</I></B>&#148; or &#147;<B><I>SAR</I></B>&#148; means an award granted
pursuant to Section&nbsp;7 hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Subsidiary</I></B>&#148; means any entity (other than the Company) in an unbroken chain of entities
beginning with the Company if each of the entities other than the last entity in the unbroken chain owns stock or other equity securities representing fifty percent (50%) or more of the total combined voting power of all classes of stock or other
equity securities in one of the other entities in such chain. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Termination</I></B>&#148; or &#147;<B><I>Terminated</I></B>&#148; means, for
purposes of this Plan with respect to a Participant, that the Participant has for any reason ceased to provide services as an employee, officer, director or consultant to the Company or a Parent or Subsidiary of the Company. A Participant will not
be deemed to have ceased to provide services while the Participant is on a bona fide leave of absence, if such leave was approved by the Company in writing. In the case of an approved leave of absence, the Committee may make such provisions
respecting crediting of service, including suspension of vesting of the Award (including pursuant to a formal policy adopted from time to time by the Company) it may deem appropriate, except that in no event may an Option be exercised after the
expiration of the term set forth in the Stock Option Agreement. The Committee will have sole discretion to determine whether a Participant has ceased to provide services and the effective date on which the Participant ceased to provide services (the
&#147;<B><I>Termination Date</I></B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Unvested Shares</I></B>&#148; means &#147;<B><I>Unvested Shares</I></B>&#148; as defined in the
Award Agreement for an Award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Vested Shares</I></B>&#148; means &#147;<B><I>Vested Shares</I></B>&#148; as defined in the Award Agreement.
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B></B><B><I>OPTION GRANT NO</I></B><B>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>NOTICE OF STOCK OPTION GRANT </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AEGLEA BIOTHERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2015 EQUITY INCENTIVE PLAN </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Optionee
named below (&#147;<B><I>Optionee</I></B>&#148;) has been granted an option (this &#147;<B><I>Option</I></B>&#148;) to purchase shares of Common Stock, $0.001 par value per share (the &#147;<B><I>Common Stock</I></B>&#148;), of Aeglea
BioTherapeutics, Inc., a Delaware corporation (the &#147;<B><I>Company</I></B>&#148;), pursuant to the Company&#146;s 2015 Equity Incentive Plan, as amended from time to time (the &#147;<B><I>Plan</I></B>&#148;) on the terms, and subject to the
conditions, described below and in the Stock Option Agreement attached hereto as <B><U>Exhibit A</U></B>, including its annexes (the &#147;<B><I>Stock Option Agreement</I></B>&#148;). </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="71%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Optionee:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Maximum Number of Shares Subject to this Option (the &#147;Shares&#148;):</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Exercise Price Per Share:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$ per share</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Date of Grant:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Vesting Start Date:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Exercise Schedule:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">This Option will become exercisable during its term with respect to portions of the Shares in accordance with the Vesting Schedule set forth below.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Expiration Date:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The date ten (10)&nbsp;years after the Date of Grant set forth above, subject to earlier expiration in the event of Termination as provided in Section&nbsp;3 of the Stock Option Agreement.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Tax Status of Option:</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Check
<I><U>Only</U></I> One Box):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#9744; Incentive Stock Option (<I>To the fullest extent permitted by the Code</I>)</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#9744; Nonqualified Stock Option.</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(<I>If
</I><I><U>neither</U></I><I> box is checked, this Option is a Nonqualified Stock Option</I>).</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Vesting Schedule [EXAMPLE ONLY]:</B> For so long as Optionee continuously provides services to the Company (or any
Subsidiary or Parent of the Company) as an employee, officer, director, contractor or consultant, this Option will vest (that is, become exercisable) with respect to the Shares as follows: (a)&nbsp;prior to the first one (1)&nbsp;year anniversary of
the Vesting Start Date this Option will not be vested or exercisable as to any of the Shares; (b)&nbsp;this Option will become vested and exercisable with respect to [<B>1/4th]</B> of the Shares on the one (1)&nbsp;year anniversary of the Vesting
Start Date; and (c)&nbsp;thereafter, this Option will become vested and exercisable with respect to an additional [<B>1/48th</B>] of the Shares when Optionee completes each month of continuous service following the first one (1)&nbsp;year
anniversary of the Vesting Start Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General; Agreement: </B>By their signatures below, Optionee and the Company agree that this Option is granted
under and governed by this Notice of Stock Option Grant (this &#147;<B><I>Grant Notice</I></B>&#148;) and by the provisions of the Plan and the Stock Option Agreement. The Plan and the Stock Option Agreement are incorporated herein by reference.
Capitalized terms used but not defined herein shall have the meanings given to them in the Plan or in the Stock Option Agreement, as applicable. By signing below, Optionee acknowledges receipt of a copy of this Grant Notice, the Plan and the Stock
Option Agreement, represents that Optionee has carefully read and is familiar with their provisions, and hereby accepts the Option subject to all of their respective terms and conditions. Optionee acknowledges that there may be adverse tax
consequences upon exercise of the Option or disposition of the Shares and that Optionee should consult a tax adviser prior to such exercise or disposition. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Execution and Delivery:</B> This Grant Notice may be executed and delivered electronically whether via
the Company&#146;s intranet or the Internet site of a third party or via email or any other means of electronic delivery specified by the Company. By Optionee&#146;s acceptance hereof (whether written, electronic or otherwise), Optionee agrees, to
the fullest extent permitted by law, that in lieu of receiving documents in paper format, Optionee accepts the electronic delivery of any documents that the Company (or any third party the Company may designate), may deliver in connection with this
grant (including the Plan, this Grant Notice, the Stock Option Agreement, the information described in Rules 701(e)(2), (3), (4) and (5)&nbsp;under the Securities Act (the &#147;<B><I>701 Disclosures</I></B>&#148;), account statements, or other
communications or information) whether via the Company&#146;s intranet or the Internet site of such third party or via email or such other means of electronic delivery specified by the Company. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="34%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Aeglea BioTherapeutics, Inc.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="3" VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By/Signature:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Optionee&nbsp;Signature:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Typed Name:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Optionee&#146;s Name:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ATTACHMENT</B>: Exhibit A - Stock Option Agreement </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Exhibit A </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Stock Option Agreement </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>STOCK OPTION AGREEMENT </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>EGLEA</SMALL> B<SMALL>IO</SMALL>T<SMALL>HERAPEUTICS</SMALL>, I<SMALL>NC</SMALL>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2015 E<SMALL>QUITY</SMALL> I<SMALL>NCENTIVE</SMALL> P<SMALL>LAN</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Stock Option Agreement (this &#147;<B><I>Agreement</I></B>&#148;) is made and entered into as of the date of grant (the &#147;<B><I>Date of
Grant</I></B>&#148;) set forth on the Notice of Stock Option Grant attached as the facing page to this Agreement (the &#147;<B><I>Grant Notice</I></B>&#148;) by and between Aeglea BioTherapeutics, Inc., a Delaware corporation (the
&#147;<B><I>Company</I></B>&#148;), and the optionee named on the Grant Notice (&#147;<B><I>Optionee</I></B>&#148;). Capitalized terms not defined in this Agreement shall have the meaning ascribed to them in the Company&#146;s 2015 Equity Incentive
Plan, as amended from time to time (the &#147;<B><I>Plan</I></B>&#148;), or in the Grant Notice, as applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. GRANT OF OPTION. </B>The Company
hereby grants to Optionee an option (this &#147;<B><I>Option</I></B>&#148;) to purchase up to the total number of shares of Common Stock of the Company, $0.001 par value per share (the &#147;<B><I>Common Stock</I></B>&#148;), set forth in the Grant
Notice as the Shares (the &#147;<B><I>Shares</I></B>&#148;) at the Exercise Price Per Share set forth in the Grant Notice (the &#147;<B><I>Exercise Price</I></B>&#148;), subject to all of the terms and conditions of the Grant Notice, this Agreement
and the Plan. If designated as an Incentive Stock Option in the Grant Notice, this Option is intended to qualify as an incentive stock option (the &#147;<B><I>ISO</I></B>&#148;) within the meaning of Section&nbsp;422 of the Internal Revenue Code of
1986, as amended (the &#147;<B><I>Code</I></B>&#148;), except that if on the Date of Grant Optionee is not subject to U.S. income tax, then this Option shall be a NQSO. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. EXERCISE PERIOD. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.1 </B><B><U>Exercise Period of
Option</U></B><B>.</B> This Option is considered to be &#147;vested&#148; with respect to any particular Shares when this Option is exercisable with respect to such Shares. This Option will become vested during its term as to portions of the Shares
in accordance with the Vesting Schedule set forth in the Grant Notice. Notwithstanding any provision in the Plan or this Agreement to the contrary, on or after Optionee&#146;s Termination Date, this Option may not be exercised with respect to any
Shares that are Unvested Shares on Optionee&#146;s Termination Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.2 </B><B><U>Vesting of Option Shares</U></B><B>.</B> Shares with respect to
which this Option is vested and exercisable at a given time pursuant to the Vesting Schedule set forth in the Grant Notice are &#147;<B><I>Vested Shares</I></B>.<I>&#148;</I> Shares with respect to which this Option is not vested and exercisable at
a given time pursuant to the Vesting Schedule set forth in the Grant Notice are <I>&#147;</I><B><I>Unvested Shares</I></B>.<I>&#148;</I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.3
</B><B><U>Expiration</U></B><B>.</B> The Option shall expire on the Expiration Date set forth in the Grant Notice or earlier as provided in Section&nbsp;3 below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. TERMINATION. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3.1 </B><B><U>Termination for Any
Reason Except Death, Disability or Cause</U></B><B>.</B> Except as provided in subsection 3.2 in a case in which Optionee dies within three (3)&nbsp;months after Optionee is Terminated other than for Cause, if Optionee is Terminated for any reason
(other than Optionee&#146;s death or Disability or for Cause), then (a)&nbsp;on and after Optionee&#146;s Termination Date, this Option shall expire immediately with respect to any Shares that are Unvested Shares and may not be exercised with
respect to any Shares that are Unvested Shares on Optionee&#146;s Termination Date and (b)&nbsp;this Option to the extent (and only to the extent) that it is exercisable with respect to Vested Shares on Optionee&#146;s Termination Date, may be
exercised by Optionee no later than three (3)&nbsp;months after Optionee&#146;s Termination Date (but in no event may this Option be exercised after the Expiration Date). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3.2 </B><B><U>Termination Because of Death or Disability</U></B><B>.</B> If Optionee is Terminated because of Optionee&#146;s death or Disability (or if
Optionee dies within three (3)&nbsp;months of the date of Optionee&#146;s Termination for any reason other than for Cause), then (a)&nbsp;on and after Optionee&#146;s Termination Date, this Option shall expire immediately with respect to any Shares
that are Unvested Shares and may not be exercised with respect to any Shares that are Unvested Shares on Optionee&#146;s Termination Date and (b)&nbsp;this Option, to the extent (and only to the extent) that it is exercisable with respect to Vested
Shares on Optionee&#146;s Termination Date, may be exercised by Optionee (or </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Optionee&#146;s legal representative) no later than twelve (12)&nbsp;months after Optionee&#146;s Termination Date, but in no event later than the Expiration Date. Any exercise of this Option
beyond (i)&nbsp;three (3) months after the date Optionee ceases to be an employee when Optionee&#146;s Termination is for any reason other than Optionee&#146;s death or disability, within the meaning of Section&nbsp;22(e)(3) of the Code; or
(ii)&nbsp;twelve (12) months after the date Optionee ceases to be an employee when the termination is for Optionee&#146;s disability, within the meaning of Section&nbsp;22(e)(3) of the Code, is deemed to be an NQSO. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3.3 </B><B><U>Termination for Cause</U></B><B>.</B> If Optionee is Terminated for Cause, then Optionee may exercise this Option, but only with respect to
any Shares that are Vested Shares on Optionee&#146;s Termination Date, and this Option shall expire on Optionee&#146;s Termination Date, or at such later time and on such conditions as may be affirmatively determined by the Committee. On and after
Optionee&#146;s Termination Date, this Option shall expire immediately with respect to any Shares that are Unvested Shares and may not be exercised with respect to any Shares that are Unvested Shares on Optionee&#146;s Termination Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3.4 </B><B><U>No Obligation to Employ</U></B><B>.</B> Nothing in the Plan or this Agreement shall confer on Optionee any right to continue in the employ
of, or other relationship with, the Company or any Parent or Subsidiary of the Company, or limit in any way the right of the Company or any Parent or Subsidiary of the Company to terminate Optionee&#146;s employment or other relationship at any
time, with or without Cause. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. MANNER OF EXERCISE. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4.1 </B><B><U>Stock Option Exercise Notice and Agreement</U></B><B>.</B> To exercise this Option, Optionee (or in the case of exercise after
Optionee&#146;s death or incapacity, Optionee&#146;s executor, administrator, heir or legatee, as the case may be) must deliver to the Company an executed Stock Option Exercise Notice and Agreement in the form attached hereto as <B><U>Annex
A</U></B>, or in such other form as may be approved by the Committee from time to time (the &#147;<B><I>Exercise Agreement</I></B>&#148;) and payment for the shares being purchased in accordance with this Agreement. The Exercise Agreement shall set
forth, among other things, (i)&nbsp;Optionee&#146;s election to exercise this Option, (ii)&nbsp;the number of Shares being purchased, (iii)&nbsp;any representations, warranties and agreements regarding Optionee&#146;s investment intent and access to
information as may be required by the Company to comply with applicable securities laws in connection with any exercise of this Option and (iv)&nbsp;any other agreements required by the Company. If someone other than Optionee exercises this Option,
then such person must submit documentation reasonably acceptable to the Company verifying that such person has the legal right to exercise this Option and such person shall be subject to all of the restrictions contained herein as if such person
were Optionee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4.2 </B><B><U>Limitations on Exercise</U></B><B>.</B> This Option may not be exercised unless such exercise is in compliance with all
applicable federal and state securities laws, as they are in effect on the date of exercise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4.3 </B><B><U>Payment</U></B><B>.</B> The Exercise
Agreement shall be accompanied by full payment of the Exercise Price for the shares being purchased in cash (by check or wire transfer), or where permitted by law: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) by cancellation of indebtedness of the Company owed to Optionee; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b) by surrender of shares of the Company that are free and clear of all security interests, pledges, liens, claims or encumbrances and: (i)&nbsp;for which
the Company has received &#147;full payment of the purchase price&#148; within the meaning of SEC Rule 144 (and, if such shares were purchased from the Company by use of a promissory note, such note has been fully paid with respect to such shares)
or (ii)&nbsp;that were obtained by Optionee in the public market; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(c) by participating in a formal cashless exercise program implemented by the Committee
in connection with the Plan; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) provided that a public market for the Common Stock exists and subject to compliance with applicable law, by exercising
as set forth below, through a &#147;same day sale&#148; commitment from Optionee and a broker-dealer whereby Optionee irrevocably elects to exercise this Option and to sell a portion of the Shares so purchased sufficient to pay the total Exercise
Price, and whereby the broker-dealer irrevocably commits upon receipt of such Shares to forward the total Exercise Price directly to the Company; or </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(e) by any combination of the foregoing or any other method of payment approved by the Committee that
constitutes legal consideration for the issuance of Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4.4 </B><B><U>Tax Withholding</U></B><B>.</B> Prior to the issuance of the Shares upon
exercise of the Option, Optionee must pay or provide for any applicable federal, state and local withholding obligations of the Company. If the Committee permits, Optionee may provide for payment of withholding taxes upon exercise of the Option by
requesting that the Company retain the minimum number of Shares with a Fair Market Value equal to the minimum amount of taxes required to be withheld; or to arrange a mandatory &#147;sell to cover&#148; on Participant&#146;s behalf (without further
authorization); but in no event will the Company withhold Shares or &#147;sell to cover&#148; if such withholding would result in adverse accounting consequences to the Company. In case of stock withholding or a sell to cover, the Company shall
issue the net number of Shares to Optionee by deducting the Shares retained from the Shares issuable upon exercise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4.5 </B><B><U>Issuance of
Shares</U></B><B>.</B> Provided that the Exercise Agreement and payment are in form and substance satisfactory to counsel for the Company, the Company shall issue the Shares issuable upon a valid exercise of this Option registered in the name of
Optionee, Optionee&#146;s authorized assignee, or Optionee&#146;s legal representative, and shall deliver certificates representing the Shares with the appropriate legends affixed thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. COMPLIANCE WITH LAWS AND REGULATIONS.</B> The Plan and this Agreement are intended to comply with Section&nbsp;25102(o) and Rule 701. Any provision of
this Agreement that is inconsistent with Section&nbsp;25102(o) or Rule 701 shall, without further act or amendment by the Company or the Committee, be reformed to comply with the requirements of Section&nbsp;25102(o) and/or Rule 701. The exercise of
this Option and the issuance and transfer of Shares shall be subject to compliance by the Company and Optionee with all applicable requirements of federal and state securities laws and with all applicable requirements of any stock exchange on which
the Common Stock may be listed at the time of such issuance or transfer. Optionee understands that the Company is under no obligation to register or qualify the Shares with the SEC, any state securities commission or any stock exchange to effect
such compliance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. NONTRANSFERABILITY OF OPTION.</B> This Option may not be transferred in any manner other than by will or by the laws of descent
and distribution, and, with respect to NQSOs, by instrument to a testamentary trust in which the options are to be passed to beneficiaries upon the death of the trustor (settlor) or a revocable trust, or by gift to &#147;immediate family&#148; as
that term is defined in 17 C.F.R. <FONT STYLE="white-space:nowrap">240.16a-1(e),</FONT> and may be exercised during the lifetime of Optionee only by Optionee or in the event of Optionee&#146;s incapacity, by Optionee&#146;s legal representative. The
terms of this Option shall be binding upon the executors, administrators, successors and assigns of Optionee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. RESTRICTIONS ON TRANSFER. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7.1</B> <B><U>Disposition of Shares</U></B>. Optionee hereby agrees that Optionee shall make no disposition of any of the Shares (other than as permitted
by this Agreement) unless and until: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) Optionee shall have notified the Company of the proposed disposition and provided a written summary of the terms
and conditions of the proposed disposition; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b) Optionee shall have complied with all requirements of this Agreement applicable to the disposition of the
Shares; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(c) Optionee shall have provided the Company with written assurances, in form and substance satisfactory to counsel for the Company, that
(i)&nbsp;the proposed disposition does not require registration of the Shares under the Securities Act or under any applicable state securities laws or (ii)&nbsp;all appropriate actions necessary for compliance with the registration requirements of
the Securities Act or of any exemption from registration available under the Securities Act (including Rule 144) or applicable state securities laws have been taken; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Optionee shall have provided the Company with written assurances, in form and substance satisfactory to the Company, that the proposed disposition will
not result in the contravention of any transfer restrictions applicable to the Shares pursuant to the provisions of the regulations promulgated under Section&nbsp;25102(o), Rule 701 or under any other applicable securities laws or adversely affect
the Company&#146;s ability to rely on the exemption(s) from registration under the Securities Act or under any other applicable securities laws for the grant of the Option, the issuance of Shares thereunder or any other issuance of securities under
the Plan. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7.2 </B><B><U>Restriction on Transfer</U></B><B>.</B> Optionee shall not transfer, assign, grant a lien
or security interest in, pledge, hypothecate, encumber or otherwise dispose of any of the Shares which are subject to the Company&#146;s Right of First Refusal described below, except as permitted by this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7.3 </B><B><U>Transferee Obligations</U></B><B>.</B> Each person (other than the Company) to whom the Shares are transferred by means of one of the
permitted transfers specified in this Agreement must, as a condition precedent to the validity of such transfer, acknowledge in writing to the Company that such person is bound by the provisions of this Agreement and that the transferred Shares are
subject to (i)&nbsp;the Company&#146;s Right of First Refusal granted hereunder and (ii)&nbsp;the market <FONT STYLE="white-space:nowrap">stand-off</FONT> provisions of Section&nbsp;8 below, to the same extent such Shares would be so subject if
retained by Optionee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8. MARKET STANDOFF AGREEMENT.</B> Optionee agrees that, subject to any early release provisions that apply pro rata to
stockholders of the Company according to their holdings of Common Stock (determined on an <FONT STYLE="white-space:nowrap">as-converted</FONT> into Common Stock basis), Optionee will not, for a period of up to one hundred eighty (180)&nbsp;days
(plus up to an additional thirty five (35)&nbsp;days to the extent reasonably requested by the Company or such underwriter(s) to accommodate regulatory restrictions on the publication or other distribution of research reports or earnings releases by
the Company, including NASD and NYSE rules) following the effective date of the registration statement filed with the SEC relating to the initial underwritten sale of Common Stock of the Company to the public under the Securities Act (the
&#147;<B><I>IPO</I></B>&#148;), directly or indirectly sell, offer to sell, grant any option for the sale of, or otherwise dispose of any Common Stock or securities convertible into Common Stock, <U>except</U> <U>for</U>: (i)&nbsp;transfers of
Shares permitted under Section&nbsp;9.6 hereof so long as such transferee furnishes to the Company and the managing underwriter their written consent to be bound by this Section&nbsp;8 as a condition precedent to such transfer; and (ii)&nbsp;sales
of any securities to be included in the registration statement for the IPO. For the avoidance of doubt, the provisions of this Section shall only apply to the IPO. The restricted period shall in any event terminate two (2)&nbsp;years after the
closing date of the IPO. In order to enforce the foregoing covenant, the Company shall have the right to place restrictive legends on the certificates representing the Shares subject to this Section and to impose stop transfer instructions with
respect to the Shares until the end of such period. Optionee further agrees to enter into any agreement reasonably required by the underwriters to implement the foregoing restrictions on transfer. For the avoidance of doubt, the foregoing provisions
of this Section shall not apply to any registration of securities of the Company (a)&nbsp;under an employee benefit plan or (b)&nbsp;in a merger, consolidation, business combination or similar transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. COMPANY&#146;S RIGHT OF FIRST REFUSAL.</B> Before any Shares held by Optionee or any transferee of such Shares (either sometimes referred to herein as
the &#147;<B><I>Holder&#148;</I></B>) may be sold or otherwise transferred (including, without limitation, a transfer by gift or operation of law), the Company and/or its assignee(s) will have a right of first refusal to purchase the Shares to be
sold or transferred (the &#147;<B><I>Offered Shares&#148;</I></B>) on the terms and conditions set forth in this Section (the &#147;<B><I>Right of First Refusal&#148;</I></B>).<B> </B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9.1 </B><B><U>Notice of Proposed Transfer</U></B><B>.</B> The Holder of the Offered Shares will deliver to the Company a written notice (the
&#147;<B><I>Notice&#148;</I></B>) stating: (i)&nbsp;the Holder&#146;s bona fide intention to sell or otherwise transfer the Offered Shares; (ii)&nbsp;the name and address of each proposed purchaser or other transferee (the &#147;<B><I>Proposed
Transferee&#148;</I></B>); (iii) the number of Offered Shares to be transferred to each Proposed Transferee; (iv)&nbsp;the bona fide cash price or other consideration for which the Holder proposes to transfer the Offered Shares (the
&#147;<B><I>Offered Price&#148;</I></B>); and (v)&nbsp;that the Holder acknowledges this Notice is an offer to sell the Offered Shares to the Company and/or its assignee(s) pursuant to the Company&#146;s Right of First Refusal at the Offered Price
as provided for in this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9.2 </B><B><U>Exercise of Right of First Refusal</U></B><B>.</B> At any time within thirty (30)&nbsp;days after the
date of the Notice, the Company and/or its assignee(s) may, by giving written notice to the Holder, elect to purchase all (or, with the consent of the Holder, less than all) the Offered Shares proposed to be transferred to any one or more of the
Proposed Transferees named in the Notice, at the purchase price, determined as specified below. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9.3 </B><B><U>Purchase Price</U></B><B>.</B> The purchase price for the Offered Shares purchased under
this Section will be the Offered Price, <I><U>provided</U></I> that if the Offered Price consists of no legal consideration (as, for example, in the case of a transfer by gift) then the purchase price will be the fair market value of the Offered
Shares as determined in good faith by the Committee. If the Offered Price includes consideration other than cash, then the value of the <FONT STYLE="white-space:nowrap">non-cash</FONT> consideration, as determined in good faith by the Committee,
will conclusively be deemed to be the cash equivalent value of such <FONT STYLE="white-space:nowrap">non-cash</FONT> consideration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9.4
</B><B><U>Payment</U></B><B>.</B> Payment of the purchase price for the Offered Shares will be payable, at the option of the Company and/or its assignee(s) (as applicable), by check or by cancellation of all or a portion of any outstanding purchase
money indebtedness owed by the Holder to the Company (or to such assignee, in the case of a purchase of Offered Shares by such assignee) or by any combination thereof. The purchase price will be paid without interest within sixty (60)&nbsp;days
after the Company&#146;s receipt of the Notice, or, at the option of the Company and/or its assignee(s), in the manner and at the time(s) set forth in the Notice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9.5 </B><B><U>Holder&#146;s Right to Transfer</U></B><B>.</B> If all of the Offered Shares proposed in the Notice to be transferred to a given Proposed
Transferee are not purchased by the Company and/or its assignee(s) as provided in this Section, then the Holder may sell or otherwise transfer such Offered Shares to each Proposed Transferee at the Offered Price or at a higher price,
<I><U>provided</U></I> that (i)&nbsp;such sale or other transfer is consummated within ninety (90)&nbsp;days after the date of the Notice, (ii)&nbsp;any such sale or other transfer is effected in compliance with all applicable securities laws, and
(iii)&nbsp;each Proposed Transferee agrees in writing that the provisions of this Section will continue to apply to the Offered Shares in the hands of such Proposed Transferee. If the Offered Shares described in the Notice are not transferred to
each Proposed Transferee within such ninety (90)&nbsp;day period, then a new Notice must be given to the Company pursuant to which the Company will again be offered the Right of First Refusal before any Shares held by the Holder may be sold or
otherwise transferred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9.6 </B><B><U>Exempt Transfers</U></B><B>.</B> Notwithstanding anything to the contrary in this Section, the following
transfers of Shares will be exempt from the Right of First Refusal: (i)&nbsp;the transfer of any or all of the Shares during Optionee&#146;s lifetime by gift or on Optionee&#146;s death by will or intestacy to any member(s) of Optionee&#146;s
&#147;Immediate Family&#148; (as defined below) or to a trust for the benefit of Optionee and/or member(s) of Optionee&#146;s Immediate Family, <I><U>provided</U></I> that each transferee or other recipient agrees in a writing satisfactory to the
Company that the provisions of this Section will continue to apply to the transferred Shares in the hands of such transferee or other recipient; (ii)&nbsp;any transfer of Shares made pursuant to a statutory merger, statutory consolidation of the
Company with or into another corporation or corporations or a conversion of the Company into another form of legal entity (except that the Right of First Refusal will continue to apply thereafter to such Shares, in which case the surviving
corporation of such merger or consolidation or the resulting entity of such conversion shall succeed to the rights of the Company under this Section unless the agreement of merger or consolidation or conversion expressly otherwise provides); or
(iii)&nbsp;any transfer of Shares pursuant to the winding up and dissolution of the Company. As used herein, the term &#147;<B><I>Immediate Family</I></B>&#148; will mean Optionee&#146;s spouse, the lineal descendant or antecedent, father, mother,
brother or sister, child, adopted child, grandchild or adopted grandchild of Optionee or Optionee&#146;s spouse, or the spouse of any of the above or Spousal Equivalent, as defined herein. As used herein, a person is deemed to be a
&#147;<B><I>Spousal Equivalent</I></B>&#148; provided the following circumstances are true: (i)&nbsp;irrespective of whether or not Optionee and the Spousal Equivalent are the same sex, they are the sole spousal equivalent of the other for the last
twelve (12)&nbsp;months, (ii) they intend to remain so indefinitely, (iii)&nbsp;neither are married to anyone else, (iv)&nbsp;both are at least 18 years of age and mentally competent to consent to contract, (v)&nbsp;they are not related by blood to
a degree of closeness that which would prohibit legal marriage in the state in which they legally reside, (vi)&nbsp;they are jointly responsible for each other&#146;s common welfare and financial obligations, and (vii)&nbsp;they reside together in
the same residence for the last twelve (12)&nbsp;months and intend to do so indefinitely. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9.7 </B><B><U>Termination of Right of First
Refusal</U></B><B>.</B> The Right of First Refusal will terminate as to all Shares: (i)&nbsp;on the effective date of the first sale of Common Stock of the Company to the general public pursuant to a registration statement filed with and declared
effective by the SEC under the Securities Act (other than a registration statement relating solely to the issuance of Common Stock pursuant to a business combination or an employee incentive or benefit plan); (ii) on any transfer or conversion of
Shares made pursuant to a statutory merger or statutory consolidation of the Company with or into another corporation or corporations if the common stock of the surviving corporation or any direct or indirect parent corporation thereof is registered
under the Exchange Act; or (iii)&nbsp;on any transfer or conversion of Shares made pursuant to a statutory conversion of the Company into another form of legal entity if the common equity (or comparable equity security) of entity resulting from such
conversion is registered under the Exchange Act. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9.8 </B><B><U>Encumbrances on Shares</U></B><B>.</B> Optionee may grant a lien or security interest in,
or pledge, hypothecate or encumber Shares only if each party to whom such lien or security interest is granted, or to whom such pledge, hypothecation or other encumbrance is made, agrees in a writing satisfactory to the Company that: (i)&nbsp;such
lien, security interest, pledge, hypothecation or encumbrance will not adversely affect or impair the Right of First Refusal or the rights of the Company and/or its assignee(s) with respect thereto and will not apply to such Shares after they are
acquired by the Company and/or its assignees under this Section; and (ii)&nbsp;the provisions of this Agreement will continue to apply to such Shares in the hands of such party and any transferee of such party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10. RIGHTS AS A STOCKHOLDER.</B> Optionee shall not have any of the rights of a stockholder with respect to any Shares unless and until such Shares are
issued to Optionee. Subject to the terms and conditions of this Agreement, Optionee will have all of the rights of a stockholder of the Company with respect to the Shares from and after the date that Shares are issued to Optionee pursuant to, and in
accordance with, the terms of the Exercise Agreement until such time as Optionee disposes of the Shares or the Company and/or its assignee(s) exercise(s) the Right of First Refusal. Upon an exercise of the Right of First Refusal, Optionee will have
no further rights as a holder of the Shares so purchased upon such exercise, other than the right to receive payment for the Shares so purchased in accordance with the provisions of this Agreement, and Optionee will promptly surrender the stock
certificate(s) evidencing the Shares so purchased to the Company for transfer or cancellation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11. ESCROW.</B> As security for Optionee&#146;s
faithful performance of this Agreement, Optionee agrees, immediately upon receipt of the stock certificate(s) evidencing the Shares, to deliver such certificate(s) to the Secretary of the Company or other designee of the Company (the
&#147;<B><I>Escrow Holder</I></B>&#148;), who is hereby appointed to hold such certificate(s) in escrow and to take all such actions and to effectuate all such transfers and/or releases of such Shares as are in accordance with the terms of this
Agreement. Optionee and the Company agree that Escrow Holder will not be liable to any party to this Agreement (or to any other party) for any actions or omissions unless Escrow Holder is grossly negligent or intentionally fraudulent in carrying out
the duties of Escrow Holder under this Agreement. Escrow Holder may rely upon any letter, notice or other document executed with any signature purported to be genuine and may rely on the advice of counsel and obey any order of any court with respect
to the transactions contemplated by this Agreement and will not be liable for any act or omission taken by Escrow Holder in good faith reliance on such documents, the advice of counsel or a court order. The Shares will be released from escrow upon
termination of the Right of First Refusal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12. RESTRICTIVE LEGENDS AND STOP-TRANSFER ORDERS. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12.1 </B><B><U>Legends</U></B>. Optionee understands and agrees that the Company will place the legends set forth below or similar legends on any stock
certificate(s) evidencing the Shares, together with any other legends that may be required by state or U.S. Federal securities laws, the Company&#146;s Certificate of Incorporation or Bylaws, any other agreement between Optionee and the Company, or
any agreement between Optionee and any third party (and any other legend(s) that the Company may become obligated to place on the stock certificate(s) evidencing the Shares under the terms of any agreement to which the Company is or may become bound
or obligated): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &#147;SECURITIES
ACT&#148;), OR UNDER THE SECURITIES LAWS OF CERTAIN STATES. THESE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER THE SECURITIES ACT AND APPLICABLE STATE SECURITIES
LAWS, PURSUANT TO REGISTRATION OR EXEMPTION THEREFROM. INVESTORS SHOULD BE AWARE THAT THEY MAY BE REQUIRED TO BEAR THE FINANCIAL RISKS OF THIS INVESTMENT FOR AN INDEFINITE PERIOD OF TIME. THE ISSUER OF THESE SECURITIES MAY REQUIRE AN OPINION OF
COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER TO THE EFFECT THAT ANY PROPOSED TRANSFER OR RESALE IS IN COMPLIANCE WITH THE SECURITIES ACT AND ANY APPLICABLE STATE SECURITIES LAWS. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b) THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO CERTAIN RESTRICTIONS ON RESALE AND TRANSFER, INCLUDING THE RIGHT OF FIRST REFUSAL HELD BY THE
ISSUER AND/OR ITS ASSIGNEE(S) AS SET FORTH IN A STOCK OPTION AGREEMENT BETWEEN THE ISSUER </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
AND THE ORIGINAL HOLDER OF THESE SHARES, A COPY OF WHICH MAY BE OBTAINED AT THE PRINCIPAL OFFICE OF THE ISSUER. SUCH SALE AND TRANSFER RESTRICTIONS, INCLUDING THE RIGHT OF FIRST REFUSAL, ARE
BINDING ON TRANSFEREES OF THESE SHARES. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(c) THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO A MARKET STANDOFF RESTRICTION AS SET FORTH IN A
CERTAIN STOCK OPTION AGREEMENT BETWEEN THE ISSUER AND THE ORIGINAL HOLDER OF THESE SHARES, A COPY OF WHICH MAY BE OBTAINED AT THE PRINCIPAL OFFICE OF THE ISSUER. AS A RESULT OF SUCH AGREEMENT, THESE SHARES MAY NOT BE TRADED PRIOR TO 180 DAYS AFTER
THE EFFECTIVE DATE OF CERTAIN PUBLIC OFFERINGS OF THE COMMON STOCK OF THE ISSUER HEREOF. SUCH RESTRICTION IS BINDING ON TRANSFEREES OF THESE SHARES. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12.2 </B><B><U>Stop-Transfer Instructions</U></B><B>.</B> Optionee agrees that, to ensure compliance with the restrictions imposed by this Agreement, the
Company may issue appropriate &#147;stop-transfer&#148; instructions to its transfer agent, if any, and if the Company transfers its own securities, it may make appropriate notations to the same effect in its own records. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12.3 </B><B><U>Refusal to Transfer</U></B><B>.</B> The Company will not be required (i)&nbsp;to transfer on its books any Shares that have been sold or
otherwise transferred in violation of any of the provisions of this Agreement or (ii)&nbsp;to treat as owner of such Shares, or to accord the right to vote or pay dividends to any purchaser or other transferee to whom such Shares have been so
transferred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1<B>3. CERTAIN TAX CONSEQUENCES.</B> Set forth below is a brief summary as of the Effective Date of the Plan of some of the federal tax
consequences of exercise of the Option and disposition of the Shares. THIS SUMMARY IS NECESSARILY INCOMPLETE, AND THE TAX LAWS AND REGULATIONS ARE SUBJECT TO CHANGE. OPTIONEE SHOULD CONSULT A TAX ADVISER BEFORE EXERCISING THE OPTION OR DISPOSING OF
THE SHARES. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13.1 </B><B><U>Exercise of ISO</U></B><B>. </B>If the Option qualifies as an ISO, there will be no regular federal income tax liability
upon the exercise of the Option, although the excess, if any, of the Fair Market Value of the Shares on the date of exercise over the Exercise Price will be treated as a tax preference item for federal alternative minimum tax purposes and may
subject Optionee to the alternative minimum tax in the year of exercise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13.2 </B><B><U>Exercise of Nonqualified Stock Option</U></B><B>.</B> If the
Option does not qualify as an ISO, there may be a regular federal income tax liability upon the exercise of the Option. Optionee will be treated as having received compensation income (taxable at ordinary income tax rates) equal to the excess, if
any, of the Fair Market Value of the Shares on the date of exercise over the Exercise Price. If Optionee is a current or former employee of the Company, the Company may be required to withhold from Optionee&#146;s compensation or collect from
Optionee and pay to the applicable taxing authorities an amount equal to a percentage of this compensation income at the time of exercise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13.3
</B><B><U>Disposition of Shares</U></B><B>.</B> The following tax consequences may apply upon disposition of the Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) <U>Incentive Stock
Options</U>. If the Shares are held for more than twelve (12)&nbsp;months after the date of purchase of the Shares pursuant to the exercise of an ISO and are disposed of more than two (2)&nbsp;years after the Date of Grant, any gain realized on
disposition of the Shares will be treated as long term capital gain for federal income tax purposes. If Shares purchased under an ISO are disposed of within the applicable one (1)&nbsp;year or two (2)&nbsp;year period, any gain realized on such
disposition will be treated as compensation income (taxable at ordinary income rates in the year of the disposition) to the extent of the excess, if any, of the Fair Market Value of the Shares on the date of exercise over the Exercise Price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b) <U>Nonqualified Stock Options</U>. If the Shares are held for more than twelve (12)&nbsp;months after the date of purchase of the Shares pursuant to the
exercise of an NQSO, any gain realized on disposition of the Shares will be treated as long term capital gain. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14. GENERAL PROVISIONS. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14.1 </B><B><U>Interpretation</U></B><B>.</B> Any dispute regarding the interpretation of this Agreement shall be submitted by Optionee or the Company to
the Committee for review. The resolution of such a dispute by the Committee shall be final and binding on the Company and Optionee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14.2
</B><B><U>Entire Agreement</U></B><B>.</B> The Plan, the Grant Notice and the Exercise Agreement are each incorporated herein by reference. This Agreement, the Grant Notice, the Plan and the Exercise Agreement constitute the entire agreement of the
parties with respect to the subject matter hereof and supersede all prior undertakings and agreements with respect to such subject matter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>15.
NOTICES.</B> Any and all notices required or permitted to be given to a party pursuant to the provisions of this Agreement will be in writing and will be effective and deemed to provide such party sufficient notice under this Agreement on the
earliest of the following: (i)&nbsp;at the time of personal delivery, if delivery is in person; (ii)&nbsp;at the time an electronic confirmation of receipt is received, if delivery is by email; (iii)&nbsp;at the time of transmission by facsimile,
addressed to the other party at its facsimile number specified herein (or hereafter modified by subsequent notice to the parties hereto), with confirmation of receipt made by both telephone and printed confirmation sheet verifying successful
transmission of the facsimile; (iv)&nbsp;one (1) business day after deposit with an express overnight courier for United States deliveries, or two (2)&nbsp;business days after such deposit for deliveries outside of the United States, with proof of
delivery from the courier requested; or (v)&nbsp;three (3) business days after deposit in the United States mail by certified mail (return receipt requested) for United States deliveries. Any notice for delivery outside the United States will be
sent by email, facsimile or by express courier. Any notice not delivered personally or by email will be sent with postage and/or other charges prepaid and properly addressed to Optionee at the last known address or facsimile number on the books of
the Company, or at such other address or facsimile number as such other party may designate by one of the indicated means of notice herein to the other parties hereto or, in the case of the Company, to it at its principal place of business. Notices
to the Company will be marked &#147;Attention: Chief Financial Officer.&#148; Notices by facsimile shall be machine verified as received. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>16.
SUCCESSORS AND ASSIGNS. </B>The Company may assign any of its rights under this Agreement including its rights to purchase Shares under the Right of First Refusal. This Agreement shall be binding upon and inure to the benefit of the successors and
assigns of the Company. Subject to the restrictions on transfer set forth herein, this Agreement shall be binding upon Optionee and Optionee&#146;s heirs, executors, administrators, legal representatives, successors and assigns. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>17. GOVERNING LAW.</B> This Agreement shall be governed by and construed in accordance with the internal laws of the State of California as such laws are
applied to agreements between California residents entered into and to be performed entirely within California. If any provision of this Agreement is determined by a court of law to be illegal or unenforceable, then such provision will be enforced
to the maximum extent possible and the other provisions will remain fully effective and enforceable.<B> </B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>18. FURTHER ASSURANCES.</B> The parties
agree to execute such further documents and instruments and to take such further actions as may be reasonably necessary to carry out the purposes and intent of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>19. TITLES AND HEADINGS.</B> The titles, captions and headings of this Agreement are included for ease of reference only and will be disregarded in
interpreting or construing this Agreement. Unless otherwise specifically stated, all references herein to &#147;sections&#148; and &#147;exhibits&#148; will mean &#147;sections&#148; and &#147;exhibits&#148; to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>20. COUNTERPARTS.</B> This Agreement may be executed in any number of counterparts, each of which when so executed and delivered will be deemed an
original, and all of which together shall constitute one and the same agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>21. SEVERABILITY.</B> If any provision of this Agreement is
determined by any court or arbitrator of competent jurisdiction to be invalid, illegal or unenforceable in any respect, such provision will be enforced to the maximum extent possible given the intent of the parties hereto. If such clause or
provision cannot be so enforced, such provision shall be stricken from this Agreement and the remainder </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">of this Agreement shall be enforced as if such invalid, illegal or unenforceable clause or provision had (to
the extent not enforceable) never been contained in this Agreement. Notwithstanding the forgoing, if the value of this Agreement based upon the substantial benefit of the bargain for any party is materially impaired, which determination as made by
the presiding court or arbitrator of competent jurisdiction shall be binding, then both parties agree to substitute such provision(s) through good faith negotiations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">* * * * * </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Attachment:</B> <U>Annex A</U>:
Form of Stock Option Exercise Notice and Agreement </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>ANNEX A </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF STOCK OPTION EXERCISE NOTICE AND AGREEMENT </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>STOCK OPTION EXERCISE NOTICE AND AGREEMENT </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>EGLEA</SMALL> B<SMALL>IOTHERAPEUTICS</SMALL>, I<SMALL>NC</SMALL>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2015 E<SMALL>QUITY</SMALL> I<SMALL>NCENTIVE</SMALL> P<SMALL>LAN</SMALL> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B><I>*</I></B><U></U></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U><B>NOTE</B>:</U><B><I> You </I></B><B><I><U>must</U></I></B><B><I> sign this Notice on Page 3 before
submitting it to Aeglea BioTherapeutics, Inc. (the &#147;Company&#148;). </I></B> </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>O<SMALL>PTIONEE</SMALL>
I<SMALL>NFORMATION</SMALL></B><SMALL></SMALL>: <I>Please provide the following information about yourself (&#147;</I><B><I>Optionee</I></B><I>&#148;)</I>:<I> </I> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="18%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="34%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Social&nbsp;Security&nbsp;Number:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Address:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Employee Number:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>O<SMALL>PTION</SMALL> I<SMALL>NFORMATION</SMALL></B><SMALL></SMALL>: <I>Please provide this information on the option being
exercised </I>(<I>the</I> &#147;<B><I>Option</I></B>&#148;): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="21%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Grant No.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date of Grant:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Type of Stock Option:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Option Price per Share: $</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&#9744; Nonqualified (NQSO)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Total number of shares of Common Stock of the Company subject to the Option:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&#9744; Incentive (ISO)</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>E<SMALL>XERCISE</SMALL> I<SMALL>NFORMATION</SMALL>: </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Number of shares of Common Stock of the Company for which the Option is now being exercised [ ]. (These shares are referred to below as the
&#147;<B><I>Purchased Shares</I></B>.&#148;) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Total Exercise Price Being Paid for the Purchased Shares: $ </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Form of payment enclosed <B><I>[check all that apply]</I></B>: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Check for $ , payable to &#147;<B><I>Aeglea BioTherapeutics, Inc.</I></B>.&#148; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Certificate(s) for shares of Common Stock of the Company. These shares will be valued as of the date this
notice is received by the Company. <B><I>[Requires Company consent.]</I></B> </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>A<SMALL>GREEMENTS</SMALL>,
R<SMALL>EPRESENTATIONS</SMALL> <SMALL>AND</SMALL> A<SMALL>CKNOWLEDGMENTS</SMALL> <SMALL>OF</SMALL> O<SMALL>PTIONEE</SMALL>: </B>By signing this Stock Option Exercise Notice and Agreement, Optionee hereby agrees with, and represents to, the Company
as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Terms Governing. </B>I acknowledge and agree with the Company that I am acquiring the Purchased Shares by
exercise of this Option subject to all other terms and conditions of the Notice of Stock Option Grant and the Stock Option Agreement that govern the Option, including without limitation the terms of the Company&#146;s 2015 Equity Incentive Plan, as
it may be amended (the &#147;<B><I>Plan</I></B>&#148;). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Investment Intent; Securities Law Restrictions. </B>I represent and warrant to the Company that I am
acquiring and will hold the Purchased Shares for investment for my account only, and not with a view to, or for resale in connection with, any &#147;distribution&#148; of the Purchased Shares within the meaning of the Securities Act of 1933, as
amended (the &#147;<B><I>Securities Act</I></B>&#148;). I understand that the Purchased Shares have not been registered under the Securities Act by reason of a specific exemption from such registration requirement and that the Purchased Shares must
be held by me indefinitely, unless they are subsequently registered under the Securities Act or I obtain an opinion of counsel (in form and substance satisfactory to the Company and its counsel) that registration is not required. I acknowledge that
the Company is under no obligation to register the Purchased Shares under the Securities Act or under any other securities law. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Restrictions on Transfer: Rule 144.</B> I will not sell, transfer or otherwise dispose of the Purchased
Shares in violation of the Securities Act, the Securities Exchange Act of 1934, or the rules promulgated thereunder (including Rule 144 under the Securities Act described below &#147;Rule 144&#148;)) or of any other applicable securities laws. I am
aware of Rule 144, which permits limited public resales of securities acquired in a <FONT STYLE="white-space:nowrap">non-public</FONT> offering, subject to satisfaction of certain conditions, which include (without limitation) that: (a)&nbsp;certain
current public information about the Company is available; (b)&nbsp;the resale occurs only after the holding period required by Rule 144 has been met; (c)&nbsp;the sale occurs through an unsolicited &#147;broker&#146;s transaction&#148;; and
(d)&nbsp;the amount of securities being sold during any three-month period does not exceed specified limitations. I understand that the conditions for resale set forth in Rule 144 have not been satisfied and that the Company has no plans to satisfy
these conditions in the foreseeable future. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Access to Information; Understanding of Risk in Investment.</B> I acknowledge that I have received and had
access to such information as I consider necessary or appropriate for deciding whether to invest in the Purchased Shares and that I had an opportunity to ask questions and receive answers from the Company regarding the terms and conditions of the
issuance of the Purchased Shares. I am aware that my investment in the Company is a speculative investment that has limited liquidity and is subject to the risk of complete loss. I am able, without impairing my financial condition, to hold the
Purchased Shares for an indefinite period and to suffer a complete loss of my investment in the Purchased Shares. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Rights of First Refusal; Market <FONT STYLE="white-space:nowrap">Stand-off.</FONT></B> I acknowledge that
the Purchased Shares remain subject to the Company&#146;s Right of First Refusal and the market <FONT STYLE="white-space:nowrap">stand-off</FONT> covenants (sometimes referred to as the <FONT STYLE="white-space:nowrap">&#147;lock-up&#148;),</FONT>
all in accordance with the applicable Notice of Stock Option Grant and the Stock Option Agreement that govern the Option. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Form of Ownership.</B> I acknowledge that the Company has encouraged me to consult my own adviser to
determine the form of ownership of the Purchased Shares that is appropriate for me. In the event that I choose to transfer my Purchased Shares to a trust, I agree to sign a Stock Transfer Agreement. In the event that I choose to transfer my
Purchased Shares to a trust that is not an eligible revocable trust, I also acknowledge that the transfer will be treated as a &#147;disposition&#148; for tax purposes. As a result, the favorable ISO tax treatment will be unavailable and other
unfavorable tax consequences may occur. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Investigation of Tax Consequences.</B> I acknowledge that the Company has encouraged me to consult my own
adviser to determine the tax consequences of acquiring the Purchased Shares at this time. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Other Tax Matters.</B> I agree that the Company does not have a duty to design or administer the Plan or its
other compensation programs in a manner that minimizes my tax liabilities. I will not make any claim against the Company or its Board, officers or employees related to tax liabilities arising from my options or my other compensation. In particular,
I acknowledge that my options (including the Option) are exempt from section 409A of the Internal Revenue Code only if the exercise price per share is at least equal to the fair market value per share of the Common Stock at the time the option was
granted by the Board. Since shares of the Common Stock are not traded on an established securities market, the determination of their fair market value was made by the Board and/or by an independent valuation firm retained by the Company. I
acknowledge that there is no guarantee in either case that the Internal Revenue Service will agree with the valuation, and I will not make any claim against the Company or its Board, officers or employees in the event that the Internal Revenue
Service asserts that the valuation was too low. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Spouse Consent.</B> I agree to seek the consent of my spouse to the extent required by the Company to
enforce the foregoing. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>10.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Tax Withholding.</B> As a condition of exercising this Option, I agree to make adequate provision for
foreign, federal, state or other tax withholding obligations, if any, which arise upon the grant, vesting or exercise of this Option, or disposition of the Purchased Shares, whether by withholding, direct payment to the Company, or otherwise.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned hereby executes and delivers this Stock Option Exercise Notice and Agreement to agrees to be bound by its terms </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="51%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><B>S<SMALL>IGNATURE</SMALL>:</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>D<SMALL>ATE</SMALL>:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt"><B><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></B></FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Optionee&#146;s Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[Signature Page to Stock Option Exercise Notice and Agreement] </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B></B><B><I>OPTION GRANT NO</I></B><B>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>NOTICE OF STOCK OPTION GRANT </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>EGLEA</SMALL> B<SMALL>IO</SMALL>T<SMALL>HERAPEUTICS</SMALL>, I<SMALL>NC</SMALL>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2015 E<SMALL>QUITY</SMALL> I<SMALL>NCENTIVE</SMALL> P<SMALL>LAN</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Optionee named below (&#147;<B><I>Optionee</I></B>&#148;) has been granted an option (this &#147;<B><I>Option</I></B>&#148;) to purchase shares of Common
Stock, $0.001 par value per share (the &#147;<B><I>Common Stock</I></B>&#148;), of Aeglea BioTherapeutics, Inc., a Delaware corporation (the &#147;<B><I>Company</I></B>&#148;), pursuant to the Company&#146;s 2015 Equity Incentive Plan, as amended
from time to time (the &#147;<B><I>Plan</I></B>&#148;) on the terms, and subject to the conditions, described below and in the Stock Option Agreement attached hereto as <B><U>Exhibit A</U></B>, including its annexes (the &#147;<B><I>Stock Option
Agreement</I></B>&#148;). </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="71%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Optionee:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Maximum Number of Shares Subject to this Option (the
&#147;</B><B><I>Shares</I></B><B>&#148;):</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Exercise Price Per Share:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$ per share</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Date of Grant:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Vesting Start Date:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Exercise Schedule:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">This Option is immediately exercisable for all of the Shares, subject to the terms of the Stock Option Agreement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Expiration Date:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The date ten (10)&nbsp;years after the Date of Grant set forth above, subject to earlier expiration in the event of Termination as provided in Section&nbsp;3 of the Stock Option Agreement.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Tax Status of Option:</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Check
<I><U>Only</U></I> One Box):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#9744; Incentive Stock Option (<I>To the fullest extent permitted by the Code</I>)</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#9744; Nonqualified Stock Option.</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(<I>If
</I><I><U>neither</U></I><I> box is checked, this Option is a Nonqualified Stock Option</I>).</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Vesting Schedule [EXAMPLE ONLY]:</B> For so long as Optionee continuously provides services to the Company (or any
Subsidiary or Parent of the Company) as an employee, officer, director, contractor or consultant, the Shares subject to this Option will vest as follows: (a)&nbsp;prior to the first one (1)&nbsp;year anniversary of the Vesting Start Date, none of
the Shares will be vested; (b) [<B>1/4th]</B> of the Shares will be vested on the one (1)&nbsp;year anniversary of the Vesting Start Date; and (c)&nbsp;thereafter, this Option will become vested and exercisable with respect to an additional
[<B>1/48th</B>] of the Shares when Optionee completes each month of continuous service following the first one (1)&nbsp;year anniversary of the Vesting Start Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General; Agreement: </B>By their signatures below, Optionee and the Company agree that this Option is granted under and governed by this Notice of Stock
Option Grant (this &#147;<B><I>Grant Notice</I></B>&#148;) and by the provisions of the Plan and the Stock Option Agreement. The Plan and the Stock Option Agreement are incorporated herein by reference. Capitalized terms used but not defined herein
shall have the meanings given to them in the Plan or in the Stock Option Agreement, as applicable. By signing below, Optionee acknowledges receipt of a copy of this Grant Notice, the Plan and the Stock Option Agreement, represents that Optionee has
carefully read and is familiar with their provisions, and hereby accepts the Option subject to all of their respective terms and conditions. Optionee acknowledges that there may be adverse tax consequences upon exercise of the Option or disposition
of the Shares and that Optionee should consult a tax adviser prior to such exercise or disposition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Execution and Delivery:</B> This Grant Notice may
be executed and delivered electronically whether via the Company&#146;s intranet or the Internet site of a third party or via email or any other means of electronic delivery specified by the Company. By Optionee&#146;s acceptance hereof (whether
written, electronic or otherwise), Optionee agrees, to the fullest extent permitted by law, that in lieu of receiving documents in paper format, Optionee accepts </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the electronic delivery of any documents that the Company (or any third party the Company may designate), may deliver in connection with this grant (including the Plan, this Grant Notice, the
Stock Option Agreement, the information described in Rules 701(e)(2), (3), (4) and (5)&nbsp;under the Securities Act (the &#147;<B><I>701 Disclosures</I></B>&#148;), account statements, or other communications or information) whether via the
Company&#146;s intranet or the Internet site of such third party or via email or such other means of electronic delivery specified by the Company. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="34%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>AEGLEA BIOTHERAPEUTICS, INC.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="3" VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By/Signature:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Optionee&nbsp;Signature:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Typed Name:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Optionee&#146;s Name:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>A<SMALL>TTACHMENT</SMALL></B><SMALL></SMALL>: Exhibit A &#150; Stock Option Agreement </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Exhibit A </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Stock Option Agreement </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><U>EXHIBIT A </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>STOCK OPTION AGREEMENT </U></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>EGLEA</SMALL> B<SMALL>IOTHERAPEUTICS</SMALL>, I<SMALL>NC</SMALL>. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2015 E<SMALL>QUITY</SMALL> I<SMALL>NCENTIVE</SMALL> P<SMALL>LAN</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Stock Option Agreement (this &#147;<B><I>Agreement</I></B>&#148;) is made and entered into as of the date of grant (the &#147;<B><I>Date of
Grant</I></B>&#148;) set forth on the Notice of Stock Option Grant attached as the facing page to this Agreement (the &#147;<B><I>Grant Notice</I></B>&#148;) by and between Aeglea BioTherapeutics, Inc., a Delaware corporation (the
&#147;<B><I>Company</I></B>&#148;), and the optionee named on the Grant Notice (&#147;<B><I>Optionee</I></B>&#148;). Capitalized terms not defined in this Agreement shall have the meaning ascribed to them in the Company&#146;s 2015 Equity Incentive
Plan, as amended from time to time (the &#147;<B><I>Plan</I></B>&#148;), or in the Grant Notice, as applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. GRANT OF OPTION.</B> The Company
hereby grants to Optionee an option (this &#147;<B><I>Option</I></B>&#148;) to purchase up to the total number of shares of Common Stock of the Company, $0.001 par value per share (the &#147;<B><I>Common Stock</I></B>&#148;), set forth in the Grant
Notice as the Shares (the &#147;<B><I>Shares</I></B>&#148;) at the Exercise Price Per Share set forth in the Grant Notice (the &#147;<B><I>Exercise Price</I></B>&#148;), subject to all of the terms and conditions of the Grant Notice, this Agreement
and the Plan. If designated as an Incentive Stock Option in the Grant Notice, this Option is intended to qualify as an incentive stock option (the &#147;<B><I>ISO</I></B>&#148;) within the meaning of Section&nbsp;422 of the Internal Revenue Code of
1986, as amended (the &#147;<B><I>Code</I></B>&#148;), except that if on the Date of Grant Optionee is not subject to U.S. income tax, then this Option shall be a NQSO. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. EXERCISE PERIOD. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.1. </B><B><U>Exercise Period
of Option</U></B><B>.</B> Subject to the conditions set forth in this Agreement, all or part of this Option may be exercised at any time after the Date of Grant. Shares purchased by exercising this Option may be subject to the Repurchase Option as
set forth in Section&nbsp;7 below. This Option will become vested during its term as to portions of the Shares in accordance with the Vesting Schedule set forth in the Grant Notice. Notwithstanding any provision in the Plan or this Agreement to the
contrary, on or after Optionee&#146;s Termination Date, this Option may not be exercised with respect to any Shares that are Unvested Shares on Optionee&#146;s Termination Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.2. </B><B><U>Vesting of Option Shares</U></B><B>.</B> Shares with respect to which this Option is vested at a given time pursuant to the Vesting Schedule
set forth in the Grant Notice are &#147;<B><I>Vested Shares</I></B>.<I>&#148;</I> Shares with respect to which this Option is not vested at a given time pursuant to the Vesting Schedule set forth in the Grant Notice are <I>&#147;</I><B><I>Unvested
Shares</I></B>.<I>&#148;</I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.3. </B><B><U>Expiration</U></B><B>.</B> The Option shall expire on the Expiration Date set forth in the Grant Notice or
earlier as provided in Section&nbsp;3 below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. TERMINATION. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3.1. </B><B><U>Termination for Any Reason Except Death, Disability or Cause</U></B><B>.</B> Except as provided in subsection 3.2 in a case in which
Optionee dies within three (3)&nbsp;months after Optionee is Terminated other than for Cause, if Optionee is Terminated for any reason (other than Optionee&#146;s death or Disability or for Cause), then (a)&nbsp;on and after Optionee&#146;s
Termination Date, this Option shall expire immediately with respect to any Shares that are Unvested Shares and may not be exercised with respect to any Shares that are Unvested Shares on Optionee&#146;s Termination Date and (b)&nbsp;this Option to
the extent (and only to the extent) that it is exercisable with respect to Vested Shares on Optionee&#146;s Termination Date, may be exercised by Optionee no later than three (3)&nbsp;months after Optionee&#146;s Termination Date (but in no event
may this Option be exercised after the Expiration Date). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3.2. </B><B><U>Termination Because of Death or Disability</U></B><B>.</B> If Optionee is
Terminated because of Optionee&#146;s death or Disability (or if Optionee dies within three (3)&nbsp;months of the date of Optionee&#146;s Termination for any reason other than for Cause), then (a)&nbsp;on and after Optionee&#146;s Termination Date,
this Option shall expire immediately with respect to any Shares that are Unvested Shares and may not be exercised with respect to any Shares that are Unvested Shares on Optionee&#146;s Termination Date and (b)&nbsp;this Option, to the extent (and
only to the extent) that it is exercisable with respect to Vested Shares on Optionee&#146;s Termination Date, may be exercised by Optionee (or </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Optionee&#146;s legal representative) no later than twelve (12)&nbsp;months after Optionee&#146;s Termination Date, but in no event later than the Expiration Date. Any exercise of this Option
beyond (i)&nbsp;three (3) months after the date Optionee ceases to be an employee when Optionee&#146;s Termination is for any reason other than Optionee&#146;s death or disability, within the meaning of Section&nbsp;22(e)(3) of the Code; or
(ii)&nbsp;twelve (12) months after the date Optionee ceases to be an employee when the termination is for Optionee&#146;s disability, within the meaning of Section&nbsp;22(e)(3) of the Code, is deemed to be an NQSO. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3.3. </B><B><U>Termination for Cause</U></B><B>.</B> If Optionee is Terminated for Cause, then Optionee may exercise this Option, but only with respect to
any Shares that are Vested Shares on Optionee&#146;s Termination Date, and this Option shall expire on Optionee&#146;s Termination Date, or at such later time and on such conditions as may be affirmatively determined by the Committee. On and after
Optionee&#146;s Termination Date, this Option shall expire immediately with respect to any Shares that are Unvested Shares and may not be exercised with respect to any Shares that are Unvested Shares on Optionee&#146;s Termination Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3.4. </B><B><U>No Obligation to Employ</U></B><B>.</B> Nothing in the Plan or this Agreement shall confer on Optionee any right to continue in the employ
of, or other relationship with, the Company or any Parent or Subsidiary of the Company, or limit in any way the right of the Company or any Parent or Subsidiary of the Company to terminate Optionee&#146;s employment or other relationship at any
time, with or without Cause. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. MANNER OF EXERCISE. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4.1. </B><B><U>Stock Option Exercise Notice and Agreement</U></B><B>.</B> To exercise this Option, Optionee (or in the case of exercise after
Optionee&#146;s death or incapacity, Optionee&#146;s executor, administrator, heir or legatee, as the case may be) must deliver to the Company an executed Stock Option Exercise Notice and Agreement in the form attached hereto as <B><U>Annex
A</U></B>, or in such other form as may be approved by the Committee from time to time (the &#147;<B><I>Exercise Agreement</I></B>&#148;) and payment for the shares being purchased in accordance with this Agreement. The Exercise Agreement shall set
forth, among other things, (i)&nbsp;Optionee&#146;s election to exercise this Option, (ii)&nbsp;the number of Shares being purchased, (iii)&nbsp;any representations, warranties and agreements regarding Optionee&#146;s investment intent and access to
information as may be required by the Company to comply with applicable securities laws in connection with any exercise of this Option and (iv)&nbsp;any other agreements required by the Company to the Company. If someone other than Optionee
exercises this Option, then such person must submit documentation reasonably acceptable to the Company verifying that such person has the legal right to exercise this Option and such person shall be subject to all of the restrictions contained
herein as if such person were Optionee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4.2. </B><B><U>Limitations on Exercise</U></B><B>.</B> This Option may not be exercised unless such exercise
is in compliance with all applicable federal and state securities laws, as they are in effect on the date of exercise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4.3.
</B><B><U>Payment</U></B><B>.</B> The Exercise Agreement shall be accompanied by full payment of the Exercise Price for the shares being purchased in cash (by check or wire transfer), or where permitted by law: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) by cancellation of indebtedness of the Company owed to Optionee; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b) by surrender of shares of the Company that are free and clear of all security interests, pledges, liens, claims or encumbrances and: (i)&nbsp;for which
the Company has received &#147;full payment of the purchase price&#148; within the meaning of SEC Rule 144 (and, if such shares were purchased from the Company by use of a promissory note, such note has been fully paid with respect to such shares)
or (ii)&nbsp;that were obtained by Optionee in the public market; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(c) by participating in a formal cashless exercise program implemented by the Committee
in connection with the Plan; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) provided that a public market for the Common Stock exists, subject to compliance with applicable law, by exercising as
set forth below, through a &#147;same day sale&#148; commitment from Optionee and a broker-dealer whereby Optionee irrevocably elects to exercise this Option and to sell a portion of the Shares so purchased sufficient to pay the total Exercise
Price, and whereby the broker-dealer irrevocably commits upon receipt of such Shares to forward the total Exercise Price directly to the Company; or </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(e) by any combination of the foregoing or any other method of payment approved by the Committee that
constitutes legal consideration for the issuance of Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4.4. </B><B><U>Tax Withholding</U></B><B>.</B> Prior to the issuance of the Shares upon
exercise of the Option, Optionee must pay or provide for any applicable federal, state and local withholding obligations of the Company. If the Committee permits, Optionee may provide for payment of withholding taxes upon exercise of the Option by
requesting that the Company retain the minimum number of Shares with a Fair Market Value equal to the minimum amount of taxes required to be withheld; or to arrange a mandatory &#147;sell to cover&#148; on Participant&#146;s behalf (without further
authorization); but in no event will the Company withhold Shares or &#147;sell to cover&#148; if such withholding would result in adverse accounting consequences to the Company. In case of stock withholding or a sell to cover, the Company shall
issue the net number of Shares to Optionee by deducting the Shares retained from the Shares issuable upon exercise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4.5. </B><B><U>Issuance of
Shares</U></B><B>.</B> Provided that the Exercise Agreement and payment are in form and substance satisfactory to counsel for the Company, the Company shall issue the Shares issuable upon a valid exercise of this Option registered in the name of
Optionee, Optionee&#146;s authorized assignee, or Optionee&#146;s legal representative, and shall deliver certificates representing the Shares with the appropriate legends affixed thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. COMPLIANCE WITH LAWS AND REGULATIONS.</B> The Plan and this Agreement are intended to comply with Section&nbsp;25102(o) and Rule 701. Any provision of
this Agreement that is inconsistent with Section&nbsp;25102(o) or Rule 701 shall, without further act or amendment by the Company or the Committee, be reformed to comply with the requirements of Section&nbsp;25102(o) and/or Rule 701. The exercise of
this Option and the issuance and transfer of Shares shall be subject to compliance by the Company and Optionee with all applicable requirements of federal and state securities laws and with all applicable requirements of any stock exchange on which
the Common Stock may be listed at the time of such issuance or transfer. Optionee understands that the Company is under no obligation to register or qualify the Shares with the SEC, any state securities commission or any stock exchange to effect
such compliance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. NONTRANSFERABILITY OF OPTION.</B> This Option may not be transferred in any manner other than by will or by the laws of descent
and distribution, and, with respect to NQSOs, by instrument to a testamentary trust in which the options are to be passed to beneficiaries upon the death of the trustor (settlor) or a revocable trust, or by gift to &#147;immediate family&#148; as
that term is defined in 17 C.F.R. <FONT STYLE="white-space:nowrap">240.16a-1(e),</FONT> and may be exercised during the lifetime of Optionee only by Optionee or in the event of Optionee&#146;s incapacity, by Optionee&#146;s legal representative. The
terms of this Option shall be binding upon the executors, administrators, successors and assigns of Optionee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. COMPANY&#146;S REPURCHASE OPTION FOR
UNVESTED SHARES.</B> If Optionee is Terminated for any reason, or no reason, including without limitation, Optionee&#146;s death, Disability, voluntary resignation or termination by the Company with or without Cause and Optionee has acquired
Unvested Shares by exercising this Option, then the Company and/or its assignee(s) shall have the option to repurchase all or a portion of Optionee&#146;s Unvested Shares (as defined in Section&nbsp;2.2 of this Agreement) as of the Termination Date
on the terms and conditions set forth in this Section&nbsp;7 (the &#147;<B><I>Repurchase Option</I></B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7.1. </B><B><U>Termination and
Termination Date</U></B><B>.</B> In case of any dispute as to whether Optionee is Terminated, the Committee shall have discretion to determine whether Optionee has been Terminated and the effective date of such Termination (the
&#147;<B><I>Termination Date</I></B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7.2. </B><B><U>Exercise of Repurchase Option</U></B><B>.</B> Subject to the foregoing provisions of this
Section, at any time within ninety (90)&nbsp;days after Optionee&#146;s Termination Date, the Company and/or its assignee(s), may elect to repurchase any or all of Optionee&#146;s Unvested Shares by giving Optionee written notice of exercise of the
Repurchase Option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7.3. </B><B><U>Calculation of Repurchase Price for Unvested Shares</U></B><B>.</B> The Company or its assignee shall have the
option to repurchase from Optionee (or from Optionee&#146;s personal representative as the case may be) the Unvested Shares at Optionee&#146;s Exercise Price, as such may be proportionately adjusted for any stock split or similar change in the
capital structure of the Company as set forth in Section&nbsp;2.2 of the Plan (the &#147;<B><I>Repurchase Price</I></B>&#148;). </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7.4. </B><B><U>Payment of Repurchase Price</U></B><B>.</B> The Repurchase Price shall be payable, at the
option of the Company or its assignee, by check or by cancellation of all or a portion of any outstanding <U>indebtedness</U> owed by Optionee to the Company and/or such assignee, or by any combination thereof. The Repurchase Price shall be paid
without interest within the term of the Repurchase Option as described in Section&nbsp;7.2. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7.5. </B><B><U>Right of Termination
Unaffected</U></B><B>.</B> Nothing in this Agreement shall be construed to limit or <U>otherwise</U> affect in any manner whatsoever the right or power of the Company (or any Parent or Subsidiary of the Company) to terminate Optionee&#146;s
employment or other relationship with Company (or any Parent or Subsidiary of the Company) at any time, for any reason or no reason, with or without Cause. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8. RESTRICTIONS ON TRANSFER. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8.1.
</B><B><U>Disposition of Shares</U></B><B>.</B> Optionee hereby agrees that Optionee shall make no disposition of any of the Shares (other than as permitted by this Agreement) unless and until: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) Optionee shall have notified the Company of the proposed disposition and provided a written summary of the terms and conditions of the proposed
disposition; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b) Optionee shall have complied with all requirements of this Agreement applicable to the disposition of the Shares; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(c) Optionee shall have provided the Company with written assurances, in form and substance satisfactory to counsel for the Company, that (i)&nbsp;the
proposed disposition does not require registration of the Shares under the Securities Act or under any applicable state securities laws or (ii)&nbsp;all appropriate actions necessary for compliance with the registration requirements of the
Securities Act or of any exemption from registration available under the Securities Act (including Rule 144) or applicable state securities laws have been taken; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Optionee shall have provided the Company with written assurances, in form and substance satisfactory to the Company, that the proposed disposition will
not result in the contravention of any transfer restrictions applicable to the Shares pursuant to the provisions of the regulations promulgated under Section&nbsp;25102(o), Rule 701 or under any other applicable securities laws or adversely affect
the Company&#146;s ability to rely on the exemption(s) from registration under the Securities Act or under any other applicable securities laws for the grant of the Option, the issuance of Shares thereunder or any other issuance of securities under
the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8.2. </B><B><U>Restriction on Transfer</U></B><B>.</B> Optionee shall not transfer, assign, grant a lien or security interest in, pledge,
hypothecate, encumber or otherwise dispose of any of the Shares which are subject to the Company&#146;s Repurchase Option or the Right of First Refusal described below, except as permitted by this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8.3. </B><B><U>Transferee Obligations</U></B><B>.</B> Each person (other than the Company) to whom the Shares are transferred by means of one of the
permitted transfers specified in this Agreement must, as a condition precedent to the validity of such transfer, acknowledge in writing to the Company that such person is bound by the provisions of this Agreement and that the transferred Shares are
subject to (i)&nbsp;both the Company&#146;s Repurchase Option and the Company&#146;s Right of First Refusal granted hereunder and (ii)&nbsp;the market <FONT STYLE="white-space:nowrap">stand-off</FONT> provisions of Section&nbsp;9 below, to the same
extent such Shares would be so subject if retained by Optionee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. MARKET STANDOFF AGREEMENT.</B> Optionee agrees that, subject to any early release
provisions that apply pro rata to stockholders of the Company according to their holdings of Common Stock (determined on an <FONT STYLE="white-space:nowrap">as-converted</FONT> into Common Stock basis), Optionee will not, for a period of up to one
hundred eighty (180)&nbsp;days (plus up to an additional thirty five (35)&nbsp;days to the extent reasonably requested by the Company or such underwriter(s) to accommodate regulatory restrictions on the publication or other distribution of research
reports or earnings releases by the Company, including NASD and NYSE rules) following the effective date of the registration statement filed with the SEC relating to the initial underwritten sale of Common Stock of the Company to the public under
the Securities Act (the &#147;<B><I>IPO</I></B>&#148;), directly or indirectly sell, offer to sell, grant any option for the sale of, or otherwise dispose of any Common Stock or securities convertible into Common Stock, <U>except</U> <U>for</U>:
(i)&nbsp;transfers of Shares permitted under Section&nbsp;10.6 hereof so long as such transferee furnishes to the Company and the managing underwriter their written consent to be bound by this Section&nbsp;9 as a condition precedent to such
transfer; and (ii) </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
sales of any securities to be included in the registration statement for the IPO. For the avoidance of doubt, the provisions of this Section shall only apply to the IPO. The restricted period
shall in any event terminate two (2)&nbsp;years after the closing date of the IPO. In order to enforce the foregoing covenant, the Company shall have the right to place restrictive legends on the certificates representing the Shares subject to this
Section and to impose stop transfer instructions with respect to the Shares until the end of such period. Optionee further agrees to enter into any agreement reasonably required by the underwriters to implement the foregoing restrictions on
transfer. For the avoidance of doubt, the foregoing provisions of this Section shall not apply to any registration of securities of the Company (a)&nbsp;under an employee benefit plan or (b)&nbsp;in a merger, consolidation, business combination or
similar transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10. COMPANY&#146;S RIGHT OF FIRST REFUSAL</B>. Unvested Shares may not be sold or otherwise transferred, or pledged by Optionee
or made subject to a security interest, pledge or other lien without the Company&#146;s prior written consent, which may be withheld in the Company&#146;s sole and absolute discretion. Before any Vested Shares held by Optionee or any transferee of
such Vested Shares (either sometimes referred to herein as the &#147;<B><I>Holder&#148;</I></B>) may be sold or otherwise transferred (including, without limitation, a transfer by gift or operation of law), the Company and/or its assignee(s) will
have a right of first refusal to purchase the Vested Shares to be sold or transferred (the &#147;<B><I>Offered Shares&#148;</I></B>) on the terms and conditions set forth in this Section (the &#147;<B><I>Right of First Refusal&#148;</I></B>). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10.1. </B><B><U>Notice of Proposed Transfer</U></B><B>.</B> The Holder of the Offered Shares will deliver to the Company a written notice (the
&#147;<B><I>Notice&#148;</I></B>) stating: (i)&nbsp;the Holder&#146;s bona fide intention to sell or otherwise transfer the Offered Shares; (ii)&nbsp;the name and address of each proposed purchaser or other transferee (the &#147;<B><I>Proposed
Transferee&#148;</I></B>); (iii) the number of Offered Shares to be transferred to each Proposed Transferee; (iv)&nbsp;the bona fide cash price or other consideration for which the Holder proposes to transfer the Offered Shares (the
&#147;<B><I>Offered Price&#148;</I></B>); and (v)&nbsp;that the Holder acknowledges this Notice is an offer to sell the Offered Shares to the Company and/or its assignee(s) pursuant to the Company&#146;s Right of First Refusal at the Offered Price
as provided for in this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10.2. </B><B><U>Exercise of Right of First Refusal</U></B><B>.</B> At any time within thirty (30)&nbsp;days after
the date of the Notice, the Company and/or its assignee(s) may, by giving written notice to the Holder, elect to purchase all (or, with the consent of the Holder, less than all) the Offered Shares proposed to be transferred to any one or more of the
Proposed Transferees named in the Notice, at the purchase price, determined as specified below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10.3. </B><B><U>Purchase Price</U></B><B>.</B> The
purchase price for the Offered Shares purchased under this Section will be the Offered Price, <I><U>provided</U></I> that if the Offered Price consists of no legal consideration (as, for example, in the case of a transfer by gift) then the purchase
price will be the fair market value of the Offered Shares as determined in good faith by the Committee. If the Offered Price includes consideration other than cash, then the value of the <FONT STYLE="white-space:nowrap">non-cash</FONT>
consideration, as determined in good faith by the Committee, will conclusively be deemed to be the cash equivalent value of such <FONT STYLE="white-space:nowrap">non-cash</FONT> consideration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10.4. </B><B><U>Payment</U></B><B>.</B> Payment of the purchase price for the Offered Shares will be payable, at the option of the Company and/or its
assignee(s) (as applicable), by check or by cancellation of all or a portion of any outstanding purchase money indebtedness owed by the Holder to the Company (or to such assignee, in the case of a purchase of Offered Shares by such assignee) or by
any combination thereof. The purchase price will be paid without interest within sixty (60)&nbsp;days after the Company&#146;s receipt of the Notice, or, at the option of the Company and/or its assignee(s), in the manner and at the time(s) set forth
in the Notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10.5. </B><B><U>Holder&#146;s Right to Transfer</U></B><B>.</B> If all of the Offered Shares proposed in the Notice to be transferred
to a given Proposed Transferee are not purchased by the Company and/or its assignee(s) as provided in this Section, then the Holder may sell or otherwise transfer such Offered Shares to each Proposed Transferee at the Offered Price or at a higher
price, <I><U>provided</U></I> that (i)&nbsp;such sale or other transfer is consummated within ninety (90)&nbsp;days after the date of the Notice, (ii)&nbsp;any such sale or other transfer is effected in compliance with all applicable securities
laws, and (iii)&nbsp;each Proposed Transferee agrees in writing that the provisions of this Section will continue to apply to the Offered Shares in the hands of such Proposed Transferee. If the Offered Shares described in the Notice are not
transferred to each Proposed Transferee within such ninety (90)&nbsp;day period, then a new Notice must be given to the Company pursuant to which the Company will again be offered the Right of First Refusal before any Shares held by the Holder may
be sold or otherwise transferred. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10.6. </B><B><U>Exempt Transfers</U></B><B>.</B> Notwithstanding anything to the contrary in this
Section, the following transfers of Vested Shares will be exempt from the Right of First Refusal: (i)&nbsp;the transfer of any or all of the Vested Shares during Optionee&#146;s lifetime by gift or on Optionee&#146;s death by will or intestacy to
any member(s) of Optionee&#146;s &#147;Immediate Family&#148; (as defined below) or to a trust for the benefit of Optionee and/or member(s) of Optionee&#146;s Immediate Family, <I><U>provided</U></I> that each transferee or other recipient agrees in
a writing satisfactory to the Company that the provisions of this Section will continue to apply to the transferred Vested Shares in the hands of such transferee or other recipient; (ii)&nbsp;any transfer of Vested Shares made pursuant to a
statutory merger, statutory consolidation of the Company with or into another corporation or corporations or a conversion of the Company into another form of legal entity (except that the Right of First Refusal will continue to apply thereafter to
such Vested Shares, in which case the surviving corporation of such merger or consolidation or the resulting entity of such conversion shall succeed to the rights of the Company under this Section unless the agreement of merger or consolidation or
conversion expressly otherwise provides); or (iii)&nbsp;any transfer of Vested Shares pursuant to the winding up and dissolution of the Company. As used herein, the term &#147;<B><I>Immediate Family</I></B>&#148; will mean Optionee&#146;s spouse,
the lineal descendant or antecedent, father, mother, brother or sister, child, adopted child, grandchild or adopted grandchild of Optionee or Optionee&#146;s spouse, or the spouse of any of the above or Spousal Equivalent, as defined herein. As used
herein, a person is deemed to be a &#147;<B><I>Spousal Equivalent</I></B>&#148; provided the following circumstances are true: (i)&nbsp;irrespective of whether or not Optionee and the Spousal Equivalent are the same sex, they are the sole spousal
equivalent of the other for the last twelve (12)&nbsp;months, (ii) they intend to remain so indefinitely, (iii)&nbsp;neither are married to anyone else, (iv)&nbsp;both are at least 18 years of age and mentally competent to consent to contract,
(v)&nbsp;they are not related by blood to a degree of closeness that which would prohibit legal marriage in the state in which they legally reside, (vi)&nbsp;they are jointly responsible for each other&#146;s common welfare and financial
obligations, and (vii)&nbsp;they reside together in the same residence for the last twelve (12)&nbsp;months and intend to do so indefinitely. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10.7.
</B><B><U>Termination of Right of First Refusal</U></B><B>.</B> The Right of First Refusal will terminate as to all Shares: (i)&nbsp;on the effective date of the first sale of Common Stock of the Company to the general public pursuant to a
registration statement filed with and declared effective by the SEC under the Securities Act (other than a registration statement relating solely to the issuance of Common Stock pursuant to a business combination or an employee incentive or benefit
plan); (ii) on any transfer or conversion of Shares made pursuant to a statutory merger or statutory consolidation of the Company with or into another corporation or corporations if the common stock of the surviving corporation or any direct or
indirect parent corporation thereof is registered under the Exchange Act; or (iii)&nbsp;on any transfer or conversion of Shares made pursuant to a statutory conversion of the Company into another form of legal entity if the common equity (or
comparable equity security) of entity resulting from such conversion is registered under the Exchange Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10.8. </B><B><U>Encumbrances on Vested
Shares</U></B><B>.</B> Optionee may grant a lien or security interest in, or pledge, hypothecate or encumber Vested Shares only if each party to whom such lien or security interest is granted, or to whom such pledge, hypothecation or other
encumbrance is made, agrees in a writing satisfactory to the Company that: (i)&nbsp;such lien, security interest, pledge, hypothecation or encumbrance will not adversely affect or impair the Right of First Refusal or the rights of the Company and/or
its assignee(s) with respect thereto and will not apply to such Vested Shares after they are acquired by the Company and/or its assignees under this Section; and (ii)&nbsp;the provisions of this Agreement will continue to apply to such Vested Shares
in the hands of such party and any transferee of such party. Optionee may not grant a lien or security interest in, or pledge, hypothecate or encumber, any Unvested Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11. RIGHTS AS A STOCKHOLDER.</B> Optionee shall not have any of the rights of a stockholder with respect to any Shares unless and until such Shares are
issued to Optionee. Subject to the terms and conditions of this Agreement, Optionee will have all of the rights of a stockholder of the Company with respect to the Shares from and after the date that Shares are issued to Optionee pursuant to, and in
accordance with, the terms of the Exercise Agreement until such time as Optionee disposes of the Shares or the Company and/or its assignee(s) exercise(s) the Repurchase Option or the Right of First Refusal. Upon an exercise of the Repurchase Option
or the Right of First Refusal, Optionee will have no further rights as a holder of the Shares so purchased upon such exercise, other than the right to receive payment for the Shares so purchased in accordance with the provisions of this Agreement,
and Optionee will promptly surrender the stock certificate(s) evidencing the Shares so purchased to the Company for transfer or cancellation. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12. ESCROW.</B> As security for Optionee&#146;s faithful performance of this Agreement, Optionee agrees,
immediately upon receipt of the stock certificate(s) evidencing the Shares, to deliver such certificate(s) to the Secretary of the Company or other designee of the Company (the &#147;<B><I>Escrow Holder</I></B>&#148;), who is hereby appointed to
hold such certificate(s) and to take all such actions and to effectuate all such transfers and/or releases of such Shares as are in accordance with the terms of this Agreement. Optionee and the Company agree that Escrow Holder will not be liable to
any party to this Agreement (or to any other party) for any actions or omissions unless Escrow Holder is grossly negligent or intentionally fraudulent in carrying out the duties of Escrow Holder under this Agreement. Escrow Holder may rely upon any
letter, notice or other document executed with any signature purported to be genuine and may rely on the advice of counsel and obey any order of any court with respect to the transactions contemplated by this Agreement and will not be liable for any
act or omission taken by Escrow Holder in good faith reliance on such documents, the advice of counsel or a court order. The Shares will be released from escrow upon termination of both the Repurchase Option and the Right of First Refusal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13. RESTRICTIVE LEGENDS AND STOP-TRANSFER ORDERS. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13.1. </B><B><U>Legends</U></B><B>.</B> Optionee understands and agrees that the Company will place the legends set forth below or similar legends on any
stock certificate(s) evidencing the Shares, together with any other legends that may be required by state or U.S. Federal securities laws, the Company&#146;s Certificate of Incorporation or Bylaws, any other agreement between Optionee and the
Company, or any agreement between Optionee and any third party (and any other legend(s) that the Company may become obligated to place on the stock certificate(s) evidencing the Shares under the terms of any agreement to which the Company is or may
become bound or obligated): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE
&#147;SECURITIES ACT&#148;), OR UNDER THE SECURITIES LAWS OF CERTAIN STATES. THESE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER THE SECURITIES ACT AND APPLICABLE
STATE SECURITIES LAWS, PURSUANT TO REGISTRATION OR EXEMPTION THEREFROM. INVESTORS SHOULD BE AWARE THAT THEY MAY BE REQUIRED TO BEAR THE FINANCIAL RISKS OF THIS INVESTMENT FOR AN INDEFINITE PERIOD OF TIME. THE ISSUER OF THESE SECURITIES MAY REQUIRE
AN OPINION OF COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER TO THE EFFECT THAT ANY PROPOSED TRANSFER OR RESALE IS IN COMPLIANCE WITH THE SECURITIES ACT AND ANY APPLICABLE STATE SECURITIES LAWS. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b) THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO CERTAIN RESTRICTIONS ON RESALE AND TRANSFER, INCLUDING THE REPURCHASE OPTION AND RIGHT OF FIRST
REFUSAL HELD BY THE ISSUER AND/OR ITS ASSIGNEE(S) AS SET FORTH IN A STOCK OPTION AGREEMENT BETWEEN THE ISSUER AND THE ORIGINAL HOLDER OF THESE SHARES, A COPY OF WHICH MAY BE OBTAINED AT THE PRINCIPAL OFFICE OF THE ISSUER. SUCH SALE AND TRANSFER
RESTRICTIONS, INCLUDING THE REPURCHASE OPTION AND RIGHT OF FIRST REFUSAL, ARE BINDING ON TRANSFEREES OF THESE SHARES. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(c) THE SHARES REPRESENTED BY THIS
CERTIFICATE ARE SUBJECT TO A MARKET STANDOFF RESTRICTION AS SET FORTH IN A CERTAIN STOCK OPTION AGREEMENT BETWEEN THE ISSUER AND THE ORIGINAL HOLDER OF THESE SHARES, A COPY OF WHICH MAY BE OBTAINED AT THE PRINCIPAL OFFICE OF THE ISSUER. AS A RESULT
OF SUCH AGREEMENT, THESE SHARES MAY NOT BE TRADED PRIOR TO 180 DAYS AFTER THE EFFECTIVE DATE OF CERTAIN PUBLIC OFFERINGS OF THE COMMON STOCK OF THE ISSUER HEREOF. SUCH RESTRICTION IS BINDING ON TRANSFEREES OF THESE SHARES. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13.2. </B><B><U>Stop-Transfer Instructions</U></B><B>.</B> Optionee agrees that, to ensure compliance with the restrictions imposed by this Agreement, the
Company may issue appropriate &#147;stop-transfer&#148; instructions to its transfer agent, if any, and if the Company transfers its own securities, it may make appropriate notations to the same effect in its own records. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13.3. </B><B><U>Refusal to Transfer</U></B><B>.</B> The Company will not be required (i)&nbsp;to transfer on its books any Shares that have been sold or
otherwise transferred in violation of any of the provisions of this Agreement or (ii)&nbsp;to treat as owner of such Shares, or to accord the right to vote or pay dividends to any purchaser or other transferee to whom such Shares have been so
transferred. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14. CERTAIN TAX CONSEQUENCES.</B> Set forth below is a brief summary as of the Effective Date of the Plan
of some of the federal tax consequences of exercise of the Option and disposition of the Shares. THIS SUMMARY IS NECESSARILY INCOMPLETE, AND THE TAX LAWS AND REGULATIONS ARE SUBJECT TO CHANGE. OPTIONEE SHOULD CONSULT A TAX ADVISER BEFORE EXERCISING
THE OPTION OR DISPOSING OF THE SHARES.<B> </B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14.1. </B><B><U>Exercise of ISO</U></B><B>.</B> If the Option qualifies as an ISO, there will be no
regular federal income tax liability upon the exercise of the Option, although the excess, if any, of the Fair Market Value of the Shares on the date of exercise over the Exercise Price will be treated as a tax preference item for federal
alternative minimum tax purposes and may subject Optionee to the alternative minimum tax in the year of exercise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14.2. </B><B><U>Exercise of
Nonqualified Stock Option</U></B><B>.</B> If the Option does not qualify as an ISO, there may be a regular federal income tax liability upon the exercise of the Option. Optionee will be treated as having received compensation income (taxable at
ordinary income tax rates) equal to the excess, if any, of the Fair Market Value of the Shares on the date of exercise over the Exercise Price. If Optionee is a current or former employee of the Company, the Company may be required to withhold from
Optionee&#146;s compensation or collect from Optionee and pay to the applicable taxing authorities an amount equal to a percentage of this compensation income at the time of exercise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14.3. </B><B><U>Disposition of Shares</U></B><B>.</B> The following tax consequences may apply upon disposition of the Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) <U>Incentive Stock Options</U>. If the Shares are held for more than twelve (12)&nbsp;months after the date of purchase of the Shares pursuant to the
exercise of an ISO and are disposed of more than two (2)&nbsp;years after the Date of Grant, any gain realized on disposition of the Shares will be treated as long term capital gain for federal income tax purposes. If Vested Shares purchased under
an ISO are disposed of within the applicable one (1)&nbsp;year or two (2)&nbsp;year period, any gain realized on such disposition will be treated as compensation income (taxable at ordinary income rates in the year of the disposition) to the extent
of the excess, if any, of the Fair Market Value of the Shares on the date of exercise over the Exercise Price. To the extent the Shares were exercised prior to vesting coincident with the filing of an 83(b) Election, the amount taxed because of a
disqualifying disposition will be based upon the excess, if any, of the fair market value on the date of <U>vesting</U> over the exercise price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b)
<U>Nonqualified Stock Options</U>. If the Shares are held for more than twelve (12)&nbsp;months after the date of purchase of the Shares pursuant to the exercise of an NQSO, any gain realized on disposition of the Shares will be treated as long term
capital gain. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14.4. </B><B><U>Section</U></B><B><U></U></B><B><U>&nbsp;83(b) Election for Unvested Shares</U></B><B>.</B> With respect to Unvested
Shares, which are subject to the Repurchase Option, unless an election is filed by Optionee with the Internal Revenue Service (and, if necessary, the proper state taxing authorities), <U>within thirty (30)</U><U></U><U>&nbsp;days</U> of the purchase
of the Unvested Shares, electing pursuant to Section&nbsp;83(b) of the Code (and similar state tax provisions, if applicable) to be taxed currently on any difference between the Exercise Price of the Unvested Shares and their Fair Market Value on
the date of purchase, there may be a recognition of taxable income (including, where applicable, alternative minimum taxable income) to Optionee, measured by the excess, if any, of the Fair Market Value of the Unvested Shares at the time they cease
to be Unvested Shares, over the Exercise Price of the Unvested Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>15. GENERAL PROVISIONS. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>15.1. </B><B><U>Interpretation</U></B><B>.</B> Any dispute regarding the interpretation of this Agreement shall be submitted by Optionee or the Company to
the Committee for review. The resolution of such a dispute by the Committee shall be final and binding on the Company and Optionee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>15.2.
</B><B><U>Entire Agreement</U></B><B>.</B> The Plan, the Grant Notice and the Exercise Agreement are each incorporated herein by reference. This Agreement, the Grant Notice, the Plan and the Exercise Agreement constitute the entire agreement of the
parties with respect to the subject matter hereof and supersede all prior undertakings and agreements with respect to such subject matter. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>16. NOTICES.</B> Any and all notices required or permitted to be given to a party pursuant to the
provisions of this Agreement will be in writing and will be effective and deemed to provide such party sufficient notice under this Agreement on the earliest of the following: (i)&nbsp;at the time of personal delivery, if delivery is in person;
(ii)&nbsp;at the time an electronic confirmation of receipt is received, if delivery is by email; (iii)&nbsp;at the time of transmission by facsimile, addressed to the other party at its facsimile number specified herein (or hereafter modified by
subsequent notice to the parties hereto), with confirmation of receipt made by both telephone and printed confirmation sheet verifying successful transmission of the facsimile; (iv)&nbsp;one (1) business day after deposit with an express overnight
courier for United States deliveries, or two (2)&nbsp;business days after such deposit for deliveries outside of the United States, with proof of delivery from the courier requested; or (v)&nbsp;three (3) business days after deposit in the United
States mail by certified mail (return receipt requested) for United States deliveries. Any notice for delivery outside the United States will be sent by email, facsimile or by express courier. Any notice not delivered personally or by email will be
sent with postage and/or other charges prepaid and properly addressed to Optionee at the last known address or facsimile number on the books of the Company, or at such other address or facsimile number as such other party may designate by one of the
indicated means of notice herein to the other parties hereto or, in the case of the Company, to it at its principal place of business. Notices to the Company will be marked &#147;Attention: Chief Financial Officer.&#148; Notices by facsimile shall
be machine verified as received. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>17. SUCCESSORS AND ASSIGNS.</B> The Company may assign any of its rights under this Agreement including its rights to
purchase Shares under both the Right of First Refusal and Repurchase Option. This Agreement shall be binding upon and inure to the benefit of the successors and assigns of the Company. Subject to the restrictions on transfer set forth herein, this
Agreement shall be binding upon Optionee and Optionee&#146;s heirs, executors, administrators, legal representatives, successors and assigns. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>18.
GOVERNING LAW.</B> This Agreement shall be governed by and construed in accordance with the internal laws of the State of California as such laws are applied to agreements between California residents entered into and to be performed entirely within
California. If any provision of this Agreement is determined by a court of law to be illegal or unenforceable, then such provision will be enforced to the maximum extent possible and the other provisions will remain fully effective and enforceable.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>19. FURTHER ASSURANCES.</B> The parties agree to execute such further documents and instruments and to take such further actions as may be reasonably
necessary to carry out the purposes and intent of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>20. TITLES AND HEADINGS.</B> The titles, captions and headings of this Agreement are
included for ease of reference only and will be disregarded in interpreting or construing this Agreement. Unless otherwise specifically stated, all references herein to &#147;sections&#148; and &#147;exhibits&#148; will mean &#147;sections&#148; and
&#147;exhibits&#148; to this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>21.</B> <B>COUNTERPARTS.</B> This Agreement may be executed in any number of counterparts, each of which when
so executed and delivered will be deemed an original, and all of which together shall constitute one and the same agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>22. SEVERABILITY.</B> If
any provision of this Agreement is determined by any court or arbitrator of competent jurisdiction to be invalid, illegal or unenforceable in any respect, such provision will be enforced to the maximum extent possible given the intent of the parties
hereto. If such clause or provision cannot be so enforced, such provision shall be stricken from this Agreement and the remainder of this Agreement shall be enforced as if such invalid, illegal or unenforceable clause or provision had (to the extent
not enforceable) never been contained in this Agreement. Notwithstanding the forgoing, if the value of this Agreement based upon the substantial benefit of the bargain for any party is materially impaired, which determination as made by the
presiding court or arbitrator of competent jurisdiction shall be binding, then both parties agree to substitute such provision(s) through good faith negotiations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">* * * * * </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Attachments: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Annex A</U>: Form of Stock Option Exercise Notice and Agreement </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>ANNEX A </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF STOCK OPTION EXERCISE NOTICE AND AGREEMENT </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>STOCK OPTION EXERCISE NOTICE AND AGREEMENT </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>EGLEA</SMALL> B<SMALL>IO</SMALL>T<SMALL>HERAPEUTICS</SMALL>, I<SMALL>NC</SMALL>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2015 E<SMALL>QUITY</SMALL> I<SMALL>NCENTIVE</SMALL> P<SMALL>LAN</SMALL> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B></B><B><I>*</I></B><B><U></U></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>NOTE</U>:</B><I> </I><B></B><B><I>You </I></B><B></B><B><I><U>must</U></I></B><B></B><I>
</I><B></B><B><I>sign this Notice on Page 3 before submitting it to Aeglea BioTherapeutics, Inc. (the &#147;Company&#148;).</I></B><B> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>O<SMALL>PTIONEE</SMALL> I<SMALL>NFORMATION</SMALL>:</B> <I>Please provide the following information about yourself
(&#147;</I><B><I>Optionee</I></B><I>&#148;)</I>: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="18%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="35%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Social&nbsp;Security&nbsp;Number:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Employee&nbsp;Number:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>O<SMALL>PTION</SMALL> I<SMALL>NFORMATION</SMALL></B><SMALL></SMALL>: <I>Please provide this information on the option being
exercised </I>(<I>the &#147;</I><B><I>Option</I></B><I>&#148;</I>): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Grant No.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date of Grant:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Type of Stock Option:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Option Price per Share: $</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&#9744; Nonqualified (NQSO)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Total number of shares of</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Common Stock of the
Company subject to the Option:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&#9744; Incentive (ISO)</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>E<SMALL>XERCISE</SMALL> I<SMALL>NFORMATION</SMALL>: </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Number of shares of Common Stock of the Company for which the Option is now being exercised [ ]. (These shares are referred to below as the
&#147;<B><I>Purchased Shares</I></B>.&#148;) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Total Exercise Price Being Paid for the Purchased Shares: $ </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Form of payment enclosed <B><I>[check all that apply]</I></B>: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Check for $ , payable to &#147;<B><I>Aeglea BioTherapeutics, Inc.</I></B><I>.</I>&#148; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Certificate(s) for shares of Common Stock of the Company. These shares will be valued as of the date this
notice is received by the Company. <B><I>[Requires Company consent.]</I></B> </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>A<SMALL>GREEMENTS</SMALL>,
R<SMALL>EPRESENTATIONS</SMALL> <SMALL>AND</SMALL> A<SMALL>CKNOWLEDGMENTS</SMALL> <SMALL>OF</SMALL> O<SMALL>PTIONEE</SMALL></B><SMALL></SMALL>: By signing this Stock Option Exercise Notice and Agreement, Optionee hereby agrees with, and represents
to, the Company as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Terms Governing.</B> I acknowledge and agree with the Company that I am acquiring the Purchased Shares by
exercise of this Option subject to all other terms and conditions of the Notice of Stock Option Grant and the Stock Option Agreement that govern the Option, including without limitation the terms of the Company&#146;s 2015 Equity Incentive Plan, as
it may be amended (the &#147;<B><I>Plan</I></B>&#148;). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Investment Intent; Securities Law Restrictions.</B> I represent and warrant to the Company that I am
acquiring and will hold the Purchased Shares for investment for my account only, and not with a view to, or for resale in connection with, any &#147;distribution&#148; of the Purchased Shares within the meaning of the Securities Act of 1933, as
amended (the &#147;<B><I>Securities Act</I></B>&#148;). I understand that the Purchased Shares have not been registered under the Securities Act by reason of a specific exemption from such registration requirement and that the Purchased Shares must
be held by me indefinitely, unless they are subsequently registered under the Securities Act or I obtain an opinion of counsel (in form and substance satisfactory to the Company and its counsel) that registration is not required. I acknowledge that
the Company is under no obligation to register the Purchased Shares under the Securities Act or under any other securities law. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Restrictions on Transfer: Rule 144.</B> I will not sell, transfer or otherwise dispose of the Purchased
Shares in violation of the Securities Act, the Securities Exchange Act of 1934, or the rules promulgated thereunder (including Rule 144 under the Securities Act described below &#147;Rule 144&#148;)) or of any other applicable securities laws. I am
aware of Rule 144, which permits limited public resales of securities acquired in a <FONT STYLE="white-space:nowrap">non-public</FONT> offering, subject to satisfaction of certain conditions, which include (without limitation) that: (a)&nbsp;certain
current public information about the Company is available; (b)&nbsp;the resale occurs only after the holding period required by Rule 144 has been met; (c)&nbsp;the sale occurs through an unsolicited &#147;broker&#146;s transaction;&#148; and
(d)&nbsp;the amount of securities being sold during any three-month period does not exceed specified limitations. I understand that the conditions for resale set forth in Rule 144 have not been satisfied and that the Company has no plans to satisfy
these conditions in the foreseeable future. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Access to Information; Understanding of Risk in Investment.</B> I acknowledge that I have received and had
access to such information as I consider necessary or appropriate for deciding whether to invest in the Purchased Shares and that I had an opportunity to ask questions and receive answers from the Company regarding the terms and conditions of the
issuance of the Purchased Shares. I am aware that my investment in the Company is a speculative investment that has limited liquidity and is subject to the risk of complete loss. I am able, without impairing my financial condition, to hold the
Purchased Shares for an indefinite period and to suffer a complete loss of my investment in the Purchased Shares. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Rights of First Refusal; Repurchase Options; Market <FONT STYLE="white-space:nowrap">Stand-off.</FONT></B> I
acknowledge that the Purchased Shares remain subject to the Company&#146;s Right of First Refusal, the Company&#146;s Repurchase Option (with respect to unvested Purchased Shares) and the market <FONT STYLE="white-space:nowrap">stand-off</FONT>
covenants (sometimes referred to as the <FONT STYLE="white-space:nowrap">&#147;lock-up&#148;),</FONT> all in accordance with the applicable Notice of Stock Option Grant and the Stock Option Agreement that govern the Option </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Form of Ownership.</B> I acknowledge that the Company has encouraged me to consult my own adviser to
determine the form of ownership of the Purchased Shares that is appropriate for me. In the event that I choose to transfer my Purchased Shares to a trust, I agree to sign a Stock Transfer Agreement. In the event that I choose to transfer my
Purchased Shares to a trust that is not an eligible revocable trust, I also acknowledge that the transfer will be treated as a &#147;disposition&#148; for tax purposes. As a result, the favorable ISO tax treatment will be unavailable and other
unfavorable tax consequences may occur. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Investigation of Tax Consequences.</B> I acknowledge that the Company has encouraged me to consult my own
adviser to determine the tax consequences of acquiring the Purchased Shares at this time. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Other Tax Matters.</B> I agree that the Company does not have a duty to design or administer the Plan or its
other compensation programs in a manner that minimizes my tax liabilities. I will not make any claim against the Company or its Board, officers or employees related to tax liabilities arising from my options or my other compensation. In particular,
I acknowledge that my options (including the Option) are exempt from Section&nbsp;409A of the Internal Revenue Code only if the exercise price per share is at least equal to the fair market value per share of the Common Stock at the time the option
was granted by the Board. Since shares of the Common Stock are not traded on an established securities market, the determination of their fair market value was made by the Board and/or by an independent valuation firm retained by the Company. I
acknowledge that there is no guarantee in either case that the Internal Revenue Service will agree with the valuation, and I will not make any claim against the Company or its Board of Directors, officers or employees in the event that the Internal
Revenue Service asserts that the valuation was too low. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Spouse Consent.</B> I agree to seek the consent of my spouse to the extent required by the Company to
enforce the foregoing. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>10.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Tax Withholding.</B> As a condition of exercising this Option, I agree to make adequate provision for
foreign, federal, state or other tax withholding obligations, if any, which arise upon the grant, vesting or exercise of this Option, or disposition of the Purchased Shares, whether by withholding, direct payment to the Company, or otherwise.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>IMPORTANT NOTE</U></B><B>:</B> UNVESTED PURCHASED SHARES ARE SUBJECT TO REPURCHASE BY THE COMPANY. PLEASE CONSULT WITH YOUR TAX
ADVISER CONCERNING THE ADVISABILITY OF FILING AN 83(b) ELECTION WITH THE INTERNAL REVENUE SERVICE WHICH MUST BE FILED WITHIN THIRTY (30)&nbsp;DAYS AFTER THE PURCHASE OF SHARES TO BE EFFECTIVE. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>A form of Election under Section&nbsp;83(b) is attached hereto as <U>Exhibit 1</U> for reference. Unless
an 83(b) election is timely filed with the Internal Revenue Service (and, if necessary, the proper state taxing authorities), electing pursuant to Section&nbsp;83(b) of the Internal Revenue Code (and similar state tax provisions, if applicable) to
be taxed currently on any difference between the purchase price of the Unvested Purchased Shares and their fair market value on the date of purchase, there may be a recognition of taxable income (including, where applicable, alternative minimum
taxable income) to you, measured by the excess, if any, of the Fair Market Value of the Unvested Purchased Shares at the time they cease to be Unvested Purchased Shares, over the purchase price of the Unvested Purchased Shares. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned hereby executes and delivers this Stock Option Exercise Notice and Agreement and agrees to be bound by its terms </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>S<SMALL>IGNATURE</SMALL></B><SMALL></SMALL>:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>D<SMALL>ATE</SMALL>:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Optionee&#146;s Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Attachments: </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exhibit
1</B> &#150; Section&nbsp;83(b) Election Form </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[Signature Page to Stock Option Exercise Notice and Agreement] </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT 1 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>SECTION 83(b) ELECTION </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ELECTION UNDER SECTION 83(b) OF THE </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INTERNAL REVENUE CODE </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned
Taxpayer hereby elects, pursuant to Section&nbsp;83(b) of the Internal Revenue Code of 1986, as amended, to include the excess, if any, of the fair market value of the property described below at the time of transfer over the amount paid for such
property, as compensation for services in the calculation of: (1)&nbsp;regular gross income; (2)&nbsp;alternative minimum taxable income; or (3)&nbsp;disqualifying disposition gross income, as the case may be. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="76%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">1.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">TAXPAYER&#146;S NAME:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">TAXPAYER&#146;S ADDRESS:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">SOCIAL SECURITY NUMBER:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The property with respect to which the election is made is described as follows: shares of Common Stock, par
value $0.001 per share, of Aeglea BioTherapeutics, Inc., a Delaware corporation (the &#147;<B><I>Company</I></B>&#148;), which were transferred upon exercise of an option by the Company, which is Taxpayer&#146;s employer or the corporation for whom
the Taxpayer performs services. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The date on which the shares were transferred was pursuant to the exercise of the option was , and this
election is made for calendar year . </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares are subject to the following restrictions: The Company may repurchase all or a portion of the shares
at the Taxpayer&#146;s original purchase price under certain conditions at the time of Taxpayer&#146;s termination of employment or services. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The fair market value of the shares (without regard to restrictions other than restrictions which by their
terms will never lapse) was $ per share x shares = $ at the time of exercise of the option. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amount paid for such shares upon exercise of the option was $ per share x shares = $ .
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Taxpayer has submitted a copy of this statement to the Company. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amount to include in gross income is $ . [The result of the amount reported in Item 5 minus the amount
reported in Item 6.] </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>THIS ELECTION MUST BE FILED WITH THE INTERNAL REVENUE SERVICE (&#147;</I><B><I>IRS</I></B><I>&#148;), AT THE
OFFICE WHERE THE TAXPAYER FILES ANNUAL INCOME TAX RETURNS, <U>WITHIN 30 DAYS</U> AFTER THE DATE OF TRANSFER OF THE SHARES, AND MUST ALSO BE FILED WITH THE TAXPAYER&#146;S INCOME TAX RETURNS FOR THE CALENDAR YEAR. THE ELECTION CANNOT BE REVOKED
WITHOUT THE CONSENT OF THE IRS. </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Taxpayer&#146;s Signature</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AEGLEA BIOTHERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2015 EQUITY INCENTIVE PLAN </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>RESTRICTED STOCK PURCHASE AGREEMENT </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Restricted Stock Purchase Agreement (the &#147;<B><I>Agreement</I></B>&#148;) is made and entered into as of (the &#147;<B><I>Effective
Date</I></B>&#148;) by and between Aeglea BioTherapeutics, Inc., a Delaware corporation (the &#147;<B><I>Company</I></B>&#148;), and (&#147;<B><I>Purchaser</I></B>&#148;). Capitalized terms not defined herein shall have the meanings ascribed to them
in the Company&#146;s 2015 Equity Incentive Plan, as may be amended from time to time (the &#147;<B><I>Plan</I></B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. PURCHASE OF SHARES.
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.1 </B><B><U>Agreement to Purchase and Sell Shares</U></B><B>.</B> On the Effective Date and subject to the terms and conditions of this
Agreement and the Plan, Purchaser hereby purchases from the Company, and the Company hereby sells to Purchaser, <B>( )</B> shares of the Company&#146;s Common Stock (the &#147;<B><I>Shares</I></B>&#148;), at the price of (<B>$ )</B> per share (the
&#147;<B><I>Purchase Price Per Share</I></B>&#148;) for a Total Purchase Price of <B>($ )</B> (the &#147;<B><I>Purchase Price</I></B>&#148;). As used in this Agreement, the term &#147;<B><I>Shares</I></B>&#148; includes the Shares purchased under
this Agreement and all securities received (a)&nbsp;in replacement of the Shares, (b)&nbsp;as a result of stock dividends or stock splits with respect to the Shares, and (c)&nbsp;in replacement of the Shares in a merger, recapitalization,
reorganization or similar corporate transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.2 </B><B><U>Payment</U></B><B>.</B> Purchaser hereby delivers payment of the Purchase Price as
follows (check and complete as appropriate): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in cash (by check) in the amount of $ , receipt of which is acknowledged by the Company. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by cancellation of indebtedness of the Company owed to Purchaser in the amount of $ . </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by the waiver hereby of compensation due or accrued for services rendered in the amount of $ .
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by delivery of fully-paid, nonassessable and vested shares of the Common Stock of the Company owned by
Purchaser free and clear of all liens, claims, encumbrances or security interests, valued at the current Fair Market Value of $ per share (a)&nbsp;for which the Company has received &#147;full payment of the purchase price&#148; within the meaning
of SEC Rule 144, (if purchased by use of a promissory note, such note has been fully paid with respect to such vested shares), or (b)&nbsp;that were obtained by Purchaser in the open public market. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. DELIVERIES. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.1 </B><B><U>Deliveries by the
Purchaser</U></B><B>.</B> Purchaser hereby delivers to the Company at its principal executive offices: (a)&nbsp;this completed and signed Agreement, and (b)&nbsp;the Purchase Price, paid by delivery of the form of payment specified in
Section&nbsp;1.2. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.2 </B><B><U>Deliveries by the Company</U></B><B>.</B> Upon its receipt of the Purchase Price, payment or other provision for any
applicable tax obligations, if any, and all the documents to be executed and delivered by Purchaser to the Company as provided herein, the Company will issue a duly executed stock certificate evidencing the Shares in the name of Purchaser with the
appropriate legends affixed thereto, to be placed in escrow as provided in Section&nbsp;7.2 to secure performance of Purchaser&#146;s obligations under Sections 5 and 6 until expiration or termination of the Company&#146;s Repurchase Option and
Refusal Right (as such terms are defined in Sections 5 and 6, respectively). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. REPRESENTATIONS AND WARRANTIES OF PURCHASER.</B> Purchaser represents
and warrants to the Company as follows. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3.1 </B><B><U>Agrees to Terms of the Plan</U></B><B>.</B> Purchaser has received a copy of the Plan, has read
and understands the terms of the Plan and this Agreement, and agrees to be bound by their terms and conditions. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3.2 </B><B><U>Acknowledgment of Tax Risks</U></B><B>.</B> Purchaser acknowledges that there may be
adverse tax consequences upon the purchase and the disposition of the Shares, and that Purchaser has been advised by the Company to consult a tax adviser prior to such purchase or disposition. Purchaser further acknowledges that Purchaser is not
relying on the Company or its counsel for tax advice regarding Purchaser&#146;s purchaser or disposition of the Shares or the tax consequences to Purchaser of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3.3 </B><B><U>Shares Not Registered or Qualified</U></B><B>.</B> Purchaser understands and acknowledges that the Shares have not been registered with the
SEC under the Securities Act, or with any securities regulatory agency administering any state securities laws, and that, notwithstanding any other provision of this Agreement to the contrary, the purchase of any Shares is expressly conditioned upon
compliance with the Securities Act and all applicable state securities laws. Purchaser agrees to cooperate with the Company to ensure compliance with such laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3.4 </B><B><U>No Transfer Unless Registered or Exempt; Contractual Restrictions on Transfers</U></B><B>.</B> Purchaser understands that Purchaser may not
transfer any Shares unless such Shares are registered under the Securities Act or qualified under applicable state securities laws or unless, in the opinion of counsel to the Company, exemptions from such registration and qualification requirements
are available. Purchaser understands that only the Company may file a registration statement with the SEC and that the Company is under no obligation to do so with respect to the Shares. Purchaser has also been advised that exemptions from
registration and qualification may not be available or may not permit Purchaser to transfer all or any of the Shares in the amounts or at the times proposed by Purchaser. Purchaser further acknowledges that this Agreement imposes additional
restrictions on transfer of the Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3.5 </B><B><U>SEC Rule 701</U></B><B>.</B> Shares that are issued pursuant to SEC Rule 701 promulgated under
the Securities Act may become freely tradable by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> (under limited conditions regarding the method of sale) ninety (90)&nbsp;days after the first sale of Common Stock of the Company to the general
public pursuant to a registration statement filed with and declared effective by the SEC, subject to the lengthier market standoff agreement contained in Section&nbsp;4 of this Agreement or any other agreement entered into by Purchaser. Affiliates
must comply with the provisions (other than the holding period requirements) of Rule 144 which permits certain limited sales of unregistered securities. Rule 144 is not presently available with respect to the Shares and, in any event, requires that
the Shares be held for a minimum of six (6)&nbsp;months, and in certain cases one (1)&nbsp;year, after they have been purchased <U>and paid for</U> (within the meaning of Rule 144). Purchaser understands that use of a promissory note as payment for
the Shares may not be deemed to be &#147;full payment of the purchase price&#148; within the meaning of Rule 144 unless certain conditions are met and that, accordingly, the Rule 144 holding period of such Shares may not begin to run until such
Shares are fully paid for within the meaning of Rule 144. Purchaser understands that Rule 144 may indefinitely restrict transfer of the Shares so long as Purchaser remains an &#147;affiliate&#148; of the Company or if &#147;current public
information&#148; about the Company (as defined in Rule 144) is not publicly available. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3.6 </B><B><U>Access to Information</U></B><B>. </B>Purchaser
has had access to all information regarding the Company and its present and prospective business, assets, liabilities and financial condition that Purchaser reasonably considers important in making the decision to purchase the Shares, and Purchaser
has had ample opportunity to ask questions of the Company&#146;s representatives concerning such matters and this investment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3.7
</B><B><U>Understanding of Risks</U></B><B>. </B>Purchaser is fully aware of: (a)&nbsp;the highly speculative nature of the investment in the Shares; (b)&nbsp;the financial hazards involved; (c)&nbsp;the lack of liquidity of the Shares and the
restrictions on transferability of the Shares (<U>e.g.</U>, that Purchaser may not be able to sell or dispose of the Shares or use them as collateral for loans); (d) the qualifications and backgrounds of the management of the Company; and
(e)&nbsp;the tax consequences of investment in, and disposition of, the Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3.8 </B><B><U>Purchase for Own Account for Investment</U></B><B>.
</B>Purchaser is purchasing the Shares for Purchaser&#146;s own account for investment purposes only and not with a view to, or for sale in connection with, a distribution of the Shares within the meaning of the Securities Act. Purchaser has no
present intention of selling or otherwise disposing of all or any portion of the Shares and no one other than Purchaser has any beneficial ownership of any of the Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3.9 </B><B><U>No General Solicitation</U></B><B>.</B> At no time was Purchaser presented with or solicited by any publicly issued or circulated newspaper,
mail, radio, television or other form of general advertising or solicitation in connection with the offer, sale and purchase of the Shares. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3.10 </B><B><U>SEC Rule 144.</U></B> Purchaser has been advised that SEC Rule 144 promulgated under the
Securities Act, which permits certain limited sales of unregistered securities, is not presently available with respect to the Shares and, in any event, requires that the Shares be held for a minimum of six (6)&nbsp;months, and in certain cases one
(1)&nbsp;year, after they have been purchased <U>and paid for</U> (within the meaning of Rule 144), subject to the lengthier market standoff agreement contained in Section&nbsp;4 of this Agreement or any other agreement entered into by Purchaser.
Purchaser understands that Rule 144 may indefinitely restrict transfer of the Shares so long as Purchaser remains an &#147;affiliate&#148; of the Company or if &#147;current public information&#148; about the Company (as defined in Rule 144) is not
publicly available. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. MARKET STANDOFF AGREEMENT.</B> Subject to the provisions of this Section, Purchaser agrees in connection with any registration
of the Company&#146;s securities under the Securities Act or other registered public offering that, Purchaser will not sell or otherwise dispose of any Shares without the prior written consent of the Company or such managing underwriters, as the
case may be, for a period of time (not to exceed one hundred eighty (180)&nbsp;days) after the effective date of such registration requested by such managing underwriters and subject to all restrictions as the Company or the managing underwriters
may specify for employee-stockholders generally; <U>provided</U> <U>however</U>, that if during the last seventeen (17)&nbsp;days of the restricted period the Company issues an earnings release or material news, or a material event relating to the
Company occurs, or prior to the expiration of the restricted period the Company announces that it will release earnings results during the sixteen <FONT STYLE="white-space:nowrap">(16)-day</FONT> period beginning on the last day of the restricted
period, <U>then,</U> if required by the underwriters or the Company, for so long as, and to the extent that, Rule 2711 or any successor rule of the Financial Industry Regulatory Authority applies, the restrictions imposed by this Section&nbsp;4
shall continue to apply until the expiration of the <FONT STYLE="white-space:nowrap">18-day</FONT> period beginning on the issuance of the earnings release or the occurrence of the material news or material event. The restricted period shall in any
event terminate two (2)&nbsp;years after the closing date of the Company&#146;s initial public offering. For purposes of this Section&nbsp;4, the term &#147;Company&#148; shall include any wholly-owned subsidiary of the Company into which the
Company merges or consolidates. In order to enforce the foregoing covenant, the Company shall have the right to place restrictive legends on the certificates representing the shares subject to this Section and to impose stop transfer instructions
with respect to the Shares until the end of such period. Purchaser further agrees that the underwriters of any such registered public offering shall be third party beneficiaries of this Section&nbsp;4 and agrees to enter into any agreement
reasonably required by the underwriters to implement the foregoing. Notwithstanding anything in this Section to the contrary, for the avoidance of doubt, the foregoing provisions of this Section shall not apply to any registration of securities of
the Company (a)&nbsp;under an employee benefit plan or (b)&nbsp;in a merger, consolidation, business combination or similar transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5.
COMPANY&#146;S REPURCHASE OPTION FOR UNVESTED SHARES.</B> The Company, or (subject to Section&nbsp;5.6) its assignee, shall have the option to repurchase all or a portion of the Purchaser&#146;s Shares that are Unvested Shares (as defined below) on
the Termination Date on the terms and conditions set forth in this Section (the &#147;<B><I>Repurchase Option</I></B>&#148;) if Purchaser is Terminated (as defined in the Plan) for any reason, or no reason, including without limitation,
Purchaser&#146;s death, Disability (as defined in the Plan), voluntary resignation or termination by the Company with or without Cause. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5.1
</B><B><U>Termination and Termination Date</U></B><B>.</B> In case of any dispute as to whether Purchaser is Terminated, the Committee shall have discretion to determine in good faith whether Purchaser has been Terminated and the effective date of
such Termination (the &#147;<B><I>Termination Date</I></B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5.2 </B><B><U>Vested and Unvested Shares</U></B><B>.</B> Shares that are vested
pursuant to the schedule set forth in this Section&nbsp;5.2 are &#147;<B><I>Vested Shares</I></B>.&#148; Shares that are not vested pursuant to such schedule are <I>&#147;</I><B><I>Unvested Shares</I></B>.&#148; On the Effective Date, of the Shares
will be Unvested Shares (the &#147;<B><I>Initial Unvested Shares</I></B>&#148;). Provided Purchaser continues to provide services to the Company or any Subsidiary or Parent of the Company at all times from the Effective Date until (the
&#147;<B><I>First Vesting Date</I></B>&#148;), <U>then</U> on the First Vesting Date <FONT STYLE="white-space:nowrap">one-fourth</FONT> (1/4th) of the Initial Unvested Shares will become Vested Shares, and on the same day of each succeeding calendar
month thereafter (or if there is no such day in any month, then the last day of such calendar month), an additional one forty-eighth 1/48th of the Initial Unvested Shares shall vest until the earliest to occur of (a)&nbsp;the date all of the Shares
are Vested Shares, (b)&nbsp;the Termination Date or (c)&nbsp;the date vesting otherwise terminates pursuant to this Agreement or the Plan. No fractional Shares shall be issued. No Shares will become Vested Shares after the Termination Date. The
number of the Shares that are Vested Shares or Unvested Shares will be proportionally adjusted to reflect any stock split, reverse stock split or similar change in the capital structure of the Company as set forth in Section&nbsp;2.2 of the Plan
occurring after the Effective Date. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5.3 </B><B><U>Exercise of Repurchase Option</U></B><B>.</B> At any time within ninety (90)&nbsp;days
after the Purchaser&#146;s Termination Date, the Company, or its assignee, may, at its option, elect to repurchase any or all the Purchaser&#146;s Shares that are Unvested Shares on the Termination Date by giving Purchaser written notice of exercise
of the Repurchase Option, specifying the number of Unvested Shares to be repurchased. Such Unvested Shares shall be repurchased at the Purchase Price Per Share, proportionately adjusted for any stock split, reverse stock split or similar change in
the capital structure of the Company as set forth in Section&nbsp;2.2 of the Plan occurring after the Effective Date (the &#147;<B><I>Repurchase Price</I></B>&#148;). The Repurchase Price shall be payable, at the option of the Company or its
assignee, by check or by cancellation of all or a portion of any outstanding indebtedness owed by Purchaser to the Company and/or such assignee, or by any combination thereof. The Repurchase Price shall be paid without interest within the term of
the Repurchase Option as described in the first sentence of this Section&nbsp;5.3. The Company may, at its option, decline to exercise its Repurchase Option or may exercise its Repurchase Option only with respect to a portion of the Unvested Shares.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5.4 </B><B><U>Right of Termination Unaffected</U></B><B>.</B> Nothing in this Agreement shall be construed to limit or otherwise affect in any manner
whatsoever the right or power of the Company (or any Parent or Subsidiary of the Company) to terminate Purchaser&#146;s employment or other relationship with Company (or the Parent or Subsidiary of the Company) at any time, for any reason or no
reason, with or without Cause. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5.5 </B><B><U>Additional or Exchanged Securities and Property</U></B><B>.</B> Subject to the provisions of
Section&nbsp;5.2 above, in the event of a merger or consolidation of the Company with or into another entity, any other corporate reorganization, a stock split, the declaration of a stock dividend, the declaration of an extraordinary dividend
payable in a form other than stock, a <FONT STYLE="white-space:nowrap">spin-off,</FONT> a recapitalization or a similar transaction affecting the Company&#146;s outstanding securities, any securities or other property (including cash or cash
equivalents) that are by reason of such transaction exchanged for, or distributed or issued with respect to, any Unvested Shares shall immediately be subject to the Repurchase Option. Appropriate adjustments shall be made to the price per share to
be paid for Unvested Shares upon the exercise of the Repurchase Option (by allocating such price among the Unvested Shares and such other securities or property), <I><U>provided</U></I> that the aggregate purchase price payable for the Unvested
Shares and all such other securities and property shall remain the same price that was original payable under the Repurchase Option to repurchase such Unvested Shares. Subject to the provisions of Section&nbsp;5.2 above, in the event of a merger or
consolidation of the Company with or into another entity or any other corporate reorganization, the Repurchase Option may be exercised by the Company&#146;s successor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5.6 </B><B><U>Assignment of Repurchase Right</U></B><B>. </B>The Company may freely assign the Company&#146;s Repurchase Option, in whole or in part,
provided that any person who accepts an assignment of the Repurchase Option from the Company shall assume all of the Company&#146;s rights and obligations with respect to the Repurchase Option (to the extent so assigned) under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. COMPANY&#146;S REFUSAL RIGHT.</B> Unvested Shares shall be subject to the restrictions on transfer and the granting of encumbrances thereon as provided
in Section&nbsp;7 hereof. Before any Vested Shares (as defined in Section&nbsp;5 hereof) held by Purchaser or any transferee of such Vested Shares (either sometimes referred to herein as the &#147;<B><I>Holder</I></B>&#148;) may be sold or otherwise
transferred (including, without limitation, a transfer by gift or operation of law), the Company and/or its assignee(s) will have a right of first refusal to purchase the Vested Shares to be sold or transferred (the &#147;<B><I>Offered
Shares</I></B>&#148;) on the terms and conditions set forth in this Section (the &#147;<B><I>Refusal Right</I></B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6.1 </B><B><U>Notice of
Proposed Transfer</U></B><B>.</B> The Holder of the Offered Shares will deliver to the Company a written notice (the &#147;<B><I>Notice</I></B>&#148;) stating: (a)&nbsp;the Holder&#146;s bona fide intention to sell or otherwise transfer the Offered
Shares; (b)&nbsp;the name and address of each proposed purchaser or other transferee of Offered Shares (&#147;<B><I>Proposed Transferee</I></B>&#148;); (c) the number of Offered Shares to be transferred to each Proposed Transferee; (d)&nbsp;the bona
fide cash price or other consideration for which the Holder proposes to transfer the Offered Shares to each Proposed Transferee (the &#147;<B><I>Offered Price</I></B>&#148;); and (e)&nbsp;that the Holder acknowledges this Notice is an offer to sell
the Offered Shares to the Company and/or its assignee(s) pursuant to the Company&#146;s Refusal Right at the Offered Price as provided for in this Agreement. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6.2 </B><B><U>Exercise of Refusal Right</U></B><B>.</B> At any time within thirty (30)&nbsp;days after
the date the Notice is effective pursuant to Section&nbsp;9.2, the Company and/or its assignee(s) may, by giving written notice to the Holder, elect to purchase all (or, with the consent of the Holder, less than all) the Offered Shares proposed to
be transferred to any one or more of the Proposed Transferees named in the Notice, at the purchase price, determined as provided in Section&nbsp;6.3 below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6.3 </B><B><U>Purchase Price</U></B><B>.</B> The purchase price for the Offered Shares purchased under this Section will be the Offered Price,
<I><U>provided </U></I>that if the Offered Price consists of no legal consideration (as, for example, in the case of a transfer by gift), then the purchase price will be the fair market value of the Offered Shares as determined in good faith by the
Company&#146;s Board of Directors. If the Offered Price includes consideration other than cash, then the value of the <FONT STYLE="white-space:nowrap">non-cash</FONT> consideration, as determined in good faith by the Company&#146;s Board of
Directors, will conclusively be deemed to be the cash equivalent value of such <FONT STYLE="white-space:nowrap">non-cash</FONT> consideration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6.4
</B><B><U>Payment</U></B><B>.</B> The purchase price for the Offered Shares will be paid, at the option of the Company and/or its assignee(s) (as applicable), by check or by cancellation of all or a portion of any outstanding indebtedness owed by
the Holder to the Company (or to such assignee, in the case of a purchase of Offered Shares by such assignee) or by any combination thereof. The purchase price will be paid without interest within sixty (60)&nbsp;days after the Company&#146;s
receipt of the Notice, or, at the option of the Company and/or its assignee(s), in the manner and at the time(s) set forth in the Notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6.5
</B><B><U>Holder&#146;s Right to Transfer</U></B><B>.</B> If all of the Offered Shares proposed in the Notice to be transferred to a given Proposed Transferee are not purchased by the Company and/or its assignee(s) as provided in this Section, then
the Holder may sell or otherwise transfer such Offered Shares to such Proposed Transferee at the Offered Price or at a higher price, <I><U>provided</U></I> that (a)&nbsp;such sale or other transfer is consummated within one hundred twenty
(120)&nbsp;days after the date the Notice is effective pursuant to Section&nbsp;9.2, (b) any such sale or other transfer is effected in compliance with all applicable securities laws, and (c)&nbsp;such Proposed Transferee agrees in writing that the
provisions of this Section will continue to apply to the Offered Shares in the hands of such Proposed Transferee. If the Offered Shares described in the Notice are not transferred to such Proposed Transferee within such one hundred twenty
(120)&nbsp;day period, then a new Notice must be given to the Company pursuant to which the Company will again be offered the Refusal Right before any Shares held by the Holder may be sold or otherwise transferred. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6.6 </B><B><U>Exempt Transfers</U></B><B>.</B> Notwithstanding the foregoing, the following transfers of Vested Shares will be exempt from the Refusal
Right: (a)&nbsp;the transfer of any or all of the Vested Shares during Purchaser&#146;s lifetime by gift or on Purchaser&#146;s death by will or intestacy to Purchaser&#146;s &#147;Immediate Family&#148; (as defined below) or to a trust for the
benefit of Purchaser or Purchaser&#146;s Immediate Family, <I><U>provided</U></I> that each transferee agrees in a writing satisfactory to the Company that the provisions of this Section will continue to apply to the transferred Vested Shares in the
hands of such transferee; (b)&nbsp;any transfer of Vested Shares made pursuant to a statutory merger or statutory consolidation of the Company with or into another entity or entities (except that, subject to Section&nbsp;6.7, unless the agreement of
merger or consolidation expressly otherwise provides, the Refusal Right will continue to apply thereafter to such Vested Shares, in which case the surviving entity of such merger or consolidation shall succeed to the rights of the Company under this
Section); or (c)&nbsp;any transfer of Vested Shares pursuant to the winding up and dissolution of the Company. As used herein, the term &#147;<B><I>Immediate Family</I></B><I>&#148;</I> will mean Purchaser&#146;s spouse, the lineal descendant or
antecedent, father, mother, brother or sister, child, adopted child, grandchild or adopted grandchild of Purchaser or Purchaser&#146;s spouse, or the spouse of any of the above or Spousal Equivalent, as defined herein. As used herein, a person is
deemed to be a &#147;<B><I>Spousal Equivalent</I></B><I>&#148;</I> provided the following circumstances are true: (i)&nbsp;irrespective of whether or not the Purchaser and the Spousal Equivalent are the same sex, they are the sole spousal equivalent
of the other for the last twelve (12)&nbsp;months, (ii) they intend to remain so indefinitely, (iii)&nbsp;neither are married to anyone else, (iv)&nbsp;both are at least 18 years of age and mentally competent to consent to contract, (v)&nbsp;they
are not related by blood to a degree of closeness that which would prohibit legal marriage in the state in which they legally reside, (vi)&nbsp;they are jointly responsible for each other&#146;s common welfare and financial obligations, and
(vii)&nbsp;they reside together in the same residence for the last twelve (12)&nbsp;months and intend to do so indefinitely. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6.7 </B><B><U>Termination
of Refusal Right</U></B><B>.</B> The Refusal Right will terminate as to all Shares: (a)&nbsp;on the effective date of the first sale of Common Stock of the Company to the public pursuant to a registration statement filed with and declared effective
by the SEC under the Securities Act or, if expressly approved by the Board as terminating the Refusal Right, under the laws of any other country having substantially the same effect (other than a registration statement
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
relating solely to the issuance of Common Stock pursuant to a business combination or an employee incentive or benefit plan) or (b)&nbsp;on any transfer or conversion of Shares made pursuant to a
statutory merger or statutory consolidation of the Company with or into another entity or entities if the common stock of the surviving entity or any direct or indirect parent entity thereof is registered under the Securities Exchange Act of 1934,
as amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. ADDITIONAL RESTRICTIONS UPON SHARE OWNERSHIP OR TRANSFER. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7.1 </B><B><U>Rights as a Stockholder</U></B><B>.</B> Subject to the terms and conditions of this Agreement, Purchaser will have all of the rights of a
Stockholder of the Company with respect to the Shares from and after the date that Shares are issued to Purchaser until such time as Purchaser disposes of the Shares or the Company and/or its assignee(s) exercise(s) the Refusal Right or the
Repurchase Option. Upon an exercise of the Refusal Right or the Repurchase Option, Purchaser will have no further rights as a holder of the Shares so purchased upon such exercise, other than the right to receive payment for the Shares so purchased
in accordance with the provisions of this Agreement, and Purchaser will promptly surrender the stock certificate(s) evidencing the Shares so purchased to the Company for transfer or cancellation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7.2 </B><B><U>Escrow</U></B><B>.</B> As security for Purchaser&#146;s faithful performance of this Agreement, Purchaser agrees, immediately upon receipt of
the stock certificate(s) evidencing the Shares, to deliver such certificate(s) to the Secretary of the Company or other designee of the Company (the &#147;<B><I>Escrow Holder</I></B>&#148;), who is hereby appointed to hold such certificate(s) in
escrow and to take all such actions and to effectuate all such transfers and/or releases of such Shares as are in accordance with the terms of this Agreement. Purchaser and the Company agree that Escrow Holder will not be liable to any party to this
Agreement (or to any other person or entity) for any actions or omissions unless Escrow Holder is grossly negligent or intentionally fraudulent in carrying out the duties of Escrow Holder under this Agreement. Escrow Holder may rely upon any letter,
notice or other document executed with any signature purported to be genuine and may rely on the advice of counsel and obey any order of any court with respect to the transactions contemplated by this Agreement. The Shares will be released from
escrow upon termination of both the Refusal Right and the Repurchase Option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7.3 </B><B><U>Encumbrances on Shares</U></B><B>.</B> Without the
Company&#146;s prior written consent given with the approval of the Company&#146;s Board of Directors, Purchaser may not grant a lien or security interest in, or pledge, hypothecate or encumber, any Unvested Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7.4 </B><B><U>Restrictions on Transfers</U></B><B>.</B> Unvested Shares may not be sold or otherwise transferred by Purchaser without the Company&#146;s
prior written consent. Purchaser hereby agrees that Purchaser shall make no disposition of the Shares (other than as permitted by this Agreement) unless and until: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) Purchaser shall have notified the Company of the proposed disposition and provided a written summary of the terms and conditions of the proposed
disposition; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b) Purchaser shall have complied with all requirements of this Agreement applicable to the disposition of the Shares, including but not
limited to the Refusal Right, the Market Standoff and the Repurchase Option; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(c) Purchaser shall have provided the Company with written assurances,
in form and substance satisfactory to counsel for the Company, that (i)&nbsp;the proposed disposition does not require registration of the Shares under the Securities Act or under any state securities laws, and (ii)&nbsp;all appropriate actions
necessary for compliance with the registration and qualification requirements of the Securities Act and any state securities laws, or of any exemption from registration or qualification, available thereunder (including Rule 144) have been taken.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each person (other than the Company) to whom the Shares are transferred by means of one of the permitted transfers specified in this Agreement must, as a
condition precedent to the validity of such transfer, acknowledge in writing to the Company that such person is bound by the provisions of this Agreement and that the transferred Shares are subject to the Company&#146;s Refusal Right or the
Repurchase Option granted hereunder and the market <FONT STYLE="white-space:nowrap">stand-off</FONT> provisions of Section&nbsp;4 hereof, to the same extent such Shares would be so subject if retained by the Purchaser. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7.5 </B><B><U>Restrictive Legends and Stop-transfer Orders</U></B><B>.</B> Purchaser understands and
agrees that the Company will place the legends set forth below or similar legends on any stock certificate(s) evidencing the Shares, together with any other legends that may be required by applicable laws, the Company&#146;s Certificate of
Incorporation or Bylaws, any other agreement between Purchaser and the Company or any agreement between Purchaser and any third party: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>THE SECURITIES
REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &#147;SECURITIES ACT&#148;), OR UNDER THE SECURITIES LAWS OF CERTAIN STATES. THESE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND
MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER THE SECURITIES ACT AND APPLICABLE STATE SECURITIES LAWS, PURSUANT TO REGISTRATION OR EXEMPTION THEREFROM. INVESTORS SHOULD BE AWARE THAT THEY MAY BE REQUIRED TO BEAR THE FINANCIAL RISKS OF
THIS INVESTMENT FOR AN INDEFINITE PERIOD OF TIME. THE ISSUER OF THESE SECURITIES MAY REQUIRE AN OPINION OF COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER TO THE EFFECT THAT ANY PROPOSED TRANSFER OR RESALE IS IN COMPLIANCE WITH THE
SECURITIES ACT AND ANY APPLICABLE STATE SECURITIES LAWS. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO CERTAIN RESTRICTIONS ON PUBLIC
RESALE AND TRANSFER, INCLUDING THE RIGHT OF FIRST REFUSAL AND THE REPURCHASE OPTION HELD BY THE ISSUER AND/OR ITS ASSIGNEE(S), AND A MARKET STANDOFF AGREEMENT, AS SET FORTH IN A RESTRICTED STOCK PURCHASE AGREEMENT BETWEEN THE ISSUER AND THE ORIGINAL
HOLDER OF THESE SHARES, A COPY OF WHICH MAY BE OBTAINED AT THE PRINCIPAL OFFICE OF THE ISSUER. SUCH PUBLIC SALE AND TRANSFER RESTRICTIONS INCLUDING THE RIGHT OF FIRST REFUSAL, THE REPURCHASE OPTION AND THE MARKET STANDOFF ARE BINDING ON TRANSFEREES
OF THESE SHARES. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Purchaser also agrees that, to ensure compliance with the restrictions imposed by this Agreement, the Company may issue appropriate
&#147;stop-transfer&#148; instructions to its transfer agent, if any, and if the Company transfers its own securities, it may make appropriate notations to the same effect in its own records. The Company will not be required (a)&nbsp;to transfer on
its books any Shares that have been sold or otherwise transferred in violation of any of the provisions of this Agreement or (b)&nbsp;to treat as owner of such Shares, or to accord the right to vote or pay dividends to any purchaser or other
transferee to whom such Shares have been so transferred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8. TAX CONSEQUENCES.</B> <I>PURCHASER UNDERSTANDS THAT PURCHASER MAY SUFFER ADVERSE TAX
CONSEQUENCES AS A RESULT OF PURCHASER&#146;S PURCHASE OR DISPOSITION OF THE SHARES. PURCHASER REPRESENTS (a)</I><I></I><I>&nbsp;THAT PURCHASER HAS CONSULTED WITH ANY TAX ADVISER THAT PURCHASER DEEMS ADVISABLE IN CONNECTION WITH THE PURCHASE OR
DISPOSITION OF THE SHARES AND (b)</I><I></I><I>&nbsp;THAT PURCHASER IS NOT RELYING ON THE COMPANY FOR ANY TAX ADVICE.</I> Purchaser hereby acknowledges that Purchaser has been informed that, with respect to Unvested Shares, unless an election is
filed by Purchaser with the Internal Revenue Service (and, if necessary, the proper state taxing authorities) <B><U>within 30 days after the purchase</U></B> of the Shares electing, pursuant to Section&nbsp;83(b) of the Internal Revenue Code (and
similar state tax provisions, if applicable), to be taxed currently on any difference between the Purchase Price of the Unvested Shares and their Fair Market Value on the date of purchase, there will be a recognition of taxable income to Purchaser,
measured by the excess, if any, of the Fair Market Value of the Unvested Shares, at the time they cease to be Unvested Shares, over the Purchase Price for such Shares. Purchaser represents that Purchaser has consulted any tax advisers Purchaser
deems advisable in connection with Purchaser&#146;s purchase of the Shares and the filing of the election under Section&nbsp;83(b) and similar tax provisions. A form of Election under Section&nbsp;83(b) is attached hereto as <B><U>Exhibit 1
</U></B>for reference.<I> BY PROVIDING THE FORM OF ELECTION, NEITHER THE COMPANY NOR ITS LEGAL COUNSEL IS THEREBY UNDERTAKING TO FILE THE ELECTION FOR PURCHASER, WHICH OBLIGATION TO FILE SHALL REMAIN SOLELY WITH PURCHASER.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. GENERAL PROVISIONS. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9.1 </B><B><U>Successors and
Assigns</U></B><B>.</B> The Company may assign any of its rights under this Agreement, including its rights to purchase Shares under the Refusal Right or the Repurchase Option. Neither Purchaser, nor any of Purchaser&#146;s successors and assigns,
may assign, whether voluntarily or by operation of law, any of its rights and obligations under this Agreement, except with the prior written consent of the Company. This Agreement shall be binding upon and inure to the benefit of the successors and
assigns of the Company. Subject to the restrictions on transfer herein set forth, this Agreement will be binding upon Purchaser and Purchaser&#146;s heirs, executors, administrators, legal representatives, successors and assigns. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9.2 </B><B><U>Notices</U></B><B>.</B> Any and all notices required or permitted to be given to a party
pursuant to the provisions of this Agreement will be in writing and will be effective and deemed to provide such party sufficient notice under this Agreement on the earliest of the following: (i)&nbsp;at the time of personal delivery, if delivery is
in person; (ii)&nbsp;at the time an electronic confirmation of receipt is received, if delivery is by email; (iii)&nbsp;at the time of transmission by facsimile, addressed to the other party at its facsimile number specified herein (or hereafter
modified by subsequent notice to the parties hereto), with confirmation of receipt made by both telephone and printed confirmation sheet verifying successful transmission of the facsimile; (iv)&nbsp;one (1) business day after deposit with an express
overnight courier for United States deliveries, or two (2)&nbsp;business days after such deposit for deliveries outside of the United States, with proof of delivery from the courier requested; or (v)&nbsp;three (3) business days after deposit in the
United States mail by certified mail (return receipt requested) for United States deliveries. Any notice for delivery outside the United States will be sent by email, facsimile or by express courier. Any notice not delivered personally or by email
will be sent with postage and/or other charges prepaid and properly addressed to Purchaser at the last known address or facsimile number on the books of the Company, or at such other address or facsimile number as such other party may designate by
one of the indicated means of notice herein to the other parties hereto or, in the case of the Company, to it at its principal place of business. Notices to the Company will be marked &#147;Attention: Chief Financial Officer.&#148; Notices by
facsimile shall be machine verified as received. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9.3 </B><B><U>Further Assurances</U></B><B>.</B> The parties agree to execute such further documents
and instruments and to take such further actions as may be reasonably necessary to carry out the purposes and intent of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9.4
</B><B><U>Entire Agreement</U></B><B>.</B> The Plan is incorporated herein by reference. The Plan and this Agreement, together with all Exhibits hereto, constitute the entire agreement and understanding of the parties with respect to the subject
matter of this Agreement, and supersede all prior understandings and agreements, between the parties hereto with respect to the specific subject matter hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9.5 </B><B><U>Severability</U></B><B>.</B> If any provision of this Agreement is determined by any court or arbitrator of competent jurisdiction to be
invalid, illegal or unenforceable in any respect, such provision will be enforced to the maximum extent possible given the intent of the parties hereto. If such clause or provision cannot be so enforced, such provision shall be stricken from this
Agreement and the remainder of this Agreement shall be enforced as if such invalid, illegal or unenforceable clause or provision had (to the extent not enforceable) never been contained in this Agreement. Notwithstanding the forgoing, if the value
of this Agreement based upon the substantial benefit of the bargain for any party is materially impaired, which determination as made by the presiding court or arbitrator of competent jurisdiction shall be binding, then both parties agree to
substitute such provision(s) through good faith negotiations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9.6 </B><B><U>Execution</U></B><B>.</B> This Agreement may be entered into in two or
more counterparts, each of which shall be deemed an original and all of which shall constitute one and the same agreement. This Agreement may be executed and delivered by facsimile and, upon such delivery, the facsimile signature will be deemed to
have the same effect as if the original signature had been delivered to the other party. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[The remainder of this page has intentionally
been left blank] </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[Signature page follows] </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the Company has caused this Restricted Stock Purchase Agreement to be executed by
its duly authorized representative, and Purchaser has executed this Restricted Stock Purchase Agreement, as of the date first set forth above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>AEGLEA BIOTHERAPEUTICS, INC.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>PURCHASER</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="right">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Address:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Address:&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;</U></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fax&nbsp;No.:&nbsp;(&nbsp;)&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fax&nbsp;No.:&nbsp;(&nbsp;)&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><U>Exhibit</U></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exhibit 1:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Form of Election Pursuant to Section&nbsp;83(b)</P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT 1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>FORM OF SECTION 83(B) ELECTION </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ELECTION UNDER SECTION 83(b) OF THE </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INTERNAL REVENUE CODE </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned
Taxpayer hereby elects, pursuant to Section&nbsp;83(b) of the Internal Revenue Code of 1986, as amended, to include in gross income for the Taxpayer&#146;s current taxable year the excess, if any, of the fair market value of the property described
below at the time of transfer over the amount paid for such property, as compensation for services. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="64%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">1.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>TAXPAYER&#146;S NAME:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">TAXPAYER&#146;S ADDRESS:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">SOCIAL SECURITY NUMBER:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">TAXABLE YEAR:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Calendar Year</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2. The property with respect to which the election is made is described as follows: shares of Common Stock, par value $0.001
per share, of Aeglea BioTherapeutics, Inc., a Delaware corporation (the &#147;<B><I>Company</I></B>&#148;), which is Taxpayer&#146;s employer or the corporation for whom the Taxpayer performs services. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3. The date on which the shares were transferred was , . </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4.
The shares are subject to the following restrictions: The Company may repurchase all or a portion of the shares at the Taxpayer&#146;s original purchase price under certain conditions at the time of Taxpayer&#146;s termination of employment or
services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5. The fair market value of the shares at the time of transfer (without regard to restrictions other than a nonlapse restriction as defined in
&#167; <FONT STYLE="white-space:nowrap">1.83-3(h)</FONT> of the Income Tax Regulations) was $ per share x shares = $ . </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6. The amount paid for such shares
was $ per share x shares = $ . </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7. The amount to include in the Taxpayer&#146;s gross income for the Taxpayer&#146;s current taxable year is $ . </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>THIS ELECTION MUST BE FILED WITH THE INTERNAL REVENUE SERVICE (&#147;</I><B><I>IRS</I></B><I>&#148;), AT THE OFFICE WHERE THE TAXPAYER FILES ANNUAL INCOME
TAX RETURNS, <U>WITHIN 30 DAYS</U> AFTER THE DATE OF TRANSFER OF THE PROPERTY, AND MUST ALSO BE FILED WITH THE TAXPAYER&#146;S INCOME TAX RETURNS FOR THE CALENDAR YEAR. A COPY OF THE ELECTION HAS ALSO BEEN FURNISHED TO THE COMPANY. THE ELECTION
CANNOT BE REVOKED WITHOUT THE CONSENT OF THE IRS. </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dated:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Taxpayer&#146;s Signature</P></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.8
<SEQUENCE>20
<FILENAME>d518298dex108.htm
<DESCRIPTION>EX-10.8
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.8</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXHIBIT 10.8 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPYRE THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2016 EQUITY INCENTIVE PLAN </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AS AMENDED AND RESTATED EFFECTIVE NOVEMBER&nbsp;21, 2023 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.</B> <B><U>PURPOSE</U></B>. The purpose of this Plan is to provide incentives to attract, retain and motivate eligible persons whose present and
potential contributions are important to the success of the Company, and any Parents, Subsidiaries and Affiliates that exist now or in the future, by offering them an opportunity to participate in the Company&#146;s future performance through the
grant of Awards. The Plan was originally effective as of the Original Effective Date, was amended and restated as of October&nbsp;8, 2018 (the &#147;<B><I>2018 Amendment and Restatement</I></B>&#148;) and is hereby amended and restated effective as
of the Stockholder Approval Date. Capitalized terms not defined elsewhere in the text are defined in Section&nbsp;28. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. <U>SHARES SUBJECT TO THE
PLAN</U><U>.</U> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.1. </B><U>Number of Shares Available</U>. Subject to Sections 2.6 and 21 and any other applicable provisions
hereof, the total number of Shares reserved and available for grant and issuance pursuant to this Plan (the &#147;<B><I>Share Reserve</I></B>&#148;) is the sum of (a) 528,360 Shares, which is inclusive of Shares initially reserved under the Plan as
of the Original Effective Date and Shares added to the Share Reserve between the Original Effective Date and the Stockholder Approval Date as a result of (i)&nbsp;the 2018 Amendment and Restatement and (ii)&nbsp;the &#147;evergreen&#148; provision
in Section&nbsp;2.4 of the Plan, (b)&nbsp;an additional 4,481,152 Shares added to the Share Reserve as of the Stockholder Approval Date, and (c)&nbsp;the Prior Plan Returning Shares, less any Shares issued under the Plan on or prior to, or subject
to outstanding Awards as of, the Stockholder Approval Date, in each case, after giving effect to the Company&#146;s reverse stock split effected on September&nbsp;8, 2023. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.2. </B><U>Lapsed, Returned Awards</U>. Shares subject to Awards, and Shares issued under the Plan under any Award, will again be
available for grant and issuance in connection with subsequent Awards under this Plan to the extent such Shares: (a)&nbsp;are subject to issuance upon exercise of an Option or SAR granted under this Plan but which cease to be subject to the Option
or SAR for any reason other than exercise of the Option or SAR; (b)&nbsp;are subject to Awards granted under this Plan that are forfeited or are repurchased by the Company at the original issue price; (c)&nbsp;are subject to Awards granted under
this Plan that otherwise terminate without such Shares being issued; or (d)&nbsp;are surrendered pursuant to an Exchange Program. To the extent an Award under the Plan is paid out in cash or other property rather than Shares, such cash payment will
not result in reducing the number of Shares available for issuance under the Plan. Shares used to pay the exercise price of an Award or withheld to satisfy the tax withholding obligations related to an Award will become available for future grant or
sale under the Plan. For the avoidance of doubt, Shares that otherwise become available for grant and issuance because of the provisions of this Section&nbsp;2.2 shall not include Shares subject to Awards that initially became available because of
the substitution clause in Section&nbsp;21.2 hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.3. </B><U>Minimum Share Reserve</U>. At all times the Company shall reserve and
keep available a sufficient number of Shares as shall be required to satisfy the requirements of all outstanding Awards granted under this Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.4. </B><U>Automatic Share Reserve Increase</U>. The number of Shares available for grant and issuance under the Plan shall be increased
on January&nbsp;1, of each of 2024 through 2028, by the lesser of (a) 5% of the number of Outstanding Shares on each December&nbsp;31 immediately prior to the date of increase or (b)&nbsp;such number of Shares determined by the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.5. </B><U>Limitations</U>. No more than 5,009,512 Shares shall be issued pursuant to the exercise of ISOs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.6. </B><U>Adjustment of Shares</U>. If the number of outstanding shares of Common Stock of the Company is changed by a stock dividend,
recapitalization, stock split, reverse stock split, subdivision, combination, reclassification or similar change in the capital structure of the Company, without consideration, then (a)&nbsp;the number of Shares reserved for issuance and future
grant under the Plan set forth in Section&nbsp;2.1, including Shares reserved under <FONT STYLE="white-space:nowrap">sub-clauses</FONT> (a)-(c) of Section&nbsp;2.1, (b) the Exercise Prices of and number of Shares subject to outstanding Options and
SARs, (c)&nbsp;the number of Shares subject to other outstanding Awards, and (d)&nbsp;the maximum number of Shares that may be issued as ISOs set forth in Section&nbsp;2.5 shall be proportionately adjusted, subject to any required action by the
Board or the stockholders of the Company and in compliance with applicable securities laws; provided that fractions of a Share will not be issued. </P> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. </B><B><U>ELIGIBILITY</U></B>. ISOs may be granted only to Employees. All other Awards may be granted
to Employees, Consultants, Directors and <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors; <U>provided</U> such Consultants, Directors and <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors render bona fide services not in
connection with the offer and sale of securities in a capital-raising transaction. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. <U>ADMINISTRATION</U>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.1. </B><U>Committee Composition; Authority</U>. This Plan will be administered by the Committee or by the Board acting as the Committee.
Subject to the general purposes, terms and conditions of this Plan, and to the direction of the Board, the Committee will have full power to implement and carry out this Plan, except, however, the Board shall establish the terms for the grant of an
Award to <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors. The Committee will have the authority to: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) construe and
interpret this Plan, any Award Agreement and any other agreement or document executed pursuant to this Plan; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) prescribe, amend and
rescind rules and regulations relating to this Plan or any Award; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) select persons to receive Awards; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) determine the form and terms and conditions, not inconsistent with the terms of the Plan, of any Award granted hereunder. Such terms and
conditions include, but are not limited to, the exercise price, the time or times when Awards may vest and be exercised (which may be based on performance criteria) or settled, any vesting acceleration or waiver of forfeiture restrictions, the
method to satisfy tax withholding obligations or any other tax liability legally due and any restriction or limitation regarding any Award or the Shares relating thereto, based in each case on such factors as the Committee will determine; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) determine the number of Shares or other consideration subject to Awards; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) determine the Fair Market Value in good faith and interpret the applicable provisions of this Plan and the definition of Fair Market Value
in connection with circumstances that impact the Fair Market Value, if necessary; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) determine whether Awards will be granted singly, in
combination with, in tandem with, in replacement of, or as alternatives to, other Awards under this Plan or any other incentive or compensation plan of the Company or any Parent, Subsidiary or Affiliate; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) grant waivers of Plan or Award conditions; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) determine the vesting, exercisability and payment of Awards; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) correct any defect, supply any omission or reconcile any inconsistency in this Plan, any Award or any Award Agreement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k) determine whether an Award has been earned; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(l) determine the terms and conditions of any, and to institute any Exchange Program; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(m) reduce or waive any criteria with respect to Performance Factors; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(n) adjust performance goals or Performance Factors as the Committee deems necessary or appropriate; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(o) adopt rules and/or procedures (including the adoption of any subplan under this Plan) relating to the operation and administration of the
Plan to accommodate requirements of local law and procedures outside of the United States; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(p) make all other determinations necessary or advisable for the administration of this
Plan; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(q) delegate any of the foregoing to a subcommittee consisting of one or more executive officers pursuant to a specific delegation
as permitted by applicable law, including Sections 152 and 157 of the Delaware General Corporation Law, as provided in Section&nbsp;4.3; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(r) to exercise discretion with respect to Performance Awards, including, without limitation, increasing, reducing or eliminating the amount
to be paid to Participants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.2. </B><U>Committee Interpretation and Discretion</U>. Any determination made by the Committee with
respect to any Award shall be made in its sole discretion at the time of grant of the Award or, unless in contravention of any express term of the Plan or Award, at any later time, and such determination shall be final and binding on the Company and
all persons having an interest in any Award under the Plan. Any dispute regarding the interpretation of the Plan or any Award Agreement shall be submitted by the Participant or Company to the Committee for review. The resolution of such a dispute by
the Committee shall be final and binding on the Company and the Participant. The Committee may delegate to one or more executive officers the authority to review and resolve disputes with respect to Awards held by Participants who are not Insiders,
and such resolution shall be final and binding on the Company and the Participant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.3. </B><U>Delegation to Other Person or Body</U>.
The Board or any Committee may delegate to one or more persons or bodies the authority to do one or more of the following to the extent permitted by applicable law: (i)&nbsp;designate recipients, other than executive officers, of Awards, provided
that no person or body may be delegated authority to grant an Award to themselves; (ii)&nbsp;determine the number of Shares subject to such Awards; and (iii)&nbsp;determine the terms of such Awards; provided, however, that the Board or Committee
action regarding such delegation will fix the terms of such delegation in accordance with applicable law, including without limitation Sections 152 and 157 of the Delaware General Corporation Law. Unless provided otherwise in the Board or Committee
action regarding such delegation, each Award granted pursuant to this section will be granted on the applicable form of Award Agreement most recently approved for use by the Board or the Committee, with any modifications necessary to incorporate or
reflect the terms of such Award. Notwithstanding anything to the contrary herein, neither the Board nor any Committee may delegate to any person or body (who is not a <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director or that is not
comprised solely of <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors, respectively) the authority to determine the Fair Market Value of the Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.4. </B><U>Rule <FONT STYLE="white-space:nowrap">16b-3</FONT> Compliance</U>. The Committee administering the Plan in accordance with the
requirements of Rule <FONT STYLE="white-space:nowrap">16b-3</FONT> shall consist of at least two individuals, each of whom qualifies as a <FONT STYLE="white-space:nowrap">Non-</FONT> Employee Director under Rule
<FONT STYLE="white-space:nowrap">16b-3.</FONT> Awards granted to Participants who are subject to Section&nbsp;16 of the Exchange Act must be approved by two or more <FONT STYLE="white-space:nowrap">&#147;non-employee</FONT> directors&#148; (as
defined in the regulations promulgated under Section&nbsp;16 of the Exchange Act). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.5. </B><U>Documentation</U>. The Award Agreement
for a given Award, the Plan and any other documents may be delivered to, and accepted by, a Participant or any other person in any manner (including electronic distribution or posting) that meets applicable legal requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.6. </B><U>Foreign Award Recipients</U>. Notwithstanding any provision of the Plan to the contrary, in order to comply with the laws in
other countries in which the Company and its Subsidiaries and Affiliates operate or have employees or other individuals eligible for Awards, the Committee, in its sole discretion, shall have the power and authority to: (a)&nbsp;determine which
Subsidiaries and Affiliates shall be covered by the Plan; (b)&nbsp;determine which individuals outside the United States are eligible to participate in the Plan; (c)&nbsp;modify the terms and conditions of any Award granted to individuals outside
the United States to comply with applicable foreign laws; (d)&nbsp;establish subplans and modify exercise procedures and other terms and procedures, to the extent the Committee determines such actions to be necessary or advisable (and such subplans
and/or modifications shall be attached to this Plan as appendices); provided, however, that no such subplans and/or modifications shall increase the share limitations contained in Section&nbsp;2.1 hereof; and (e)&nbsp;take any action, before or
after an Award is made, that the Committee determines to be necessary or advisable to obtain approval or comply with any local governmental regulatory exemptions or approvals. Notwithstanding the foregoing, the Committee may not take any actions
hereunder, and no Awards shall be granted, that would violate the Exchange Act or any other applicable United States securities law, the Code, or any other applicable United States governing statute or law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. </B><B><U>OPTIONS</U></B>. An Option is the right but not the obligation to purchase a Share, subject
to certain conditions, if applicable. The Committee may grant Options to eligible Employees, Consultants and Directors and will determine whether such Options will be Incentive Stock Options within the meaning of the Code
(&#147;<B><I>ISOs</I></B>&#148;) or Nonqualified Stock Options (&#147;<B><I>NSOs</I></B>&#148;), the number of Shares subject to the Option, the Exercise Price of the Option, the period during which the Option may vest and be exercised, and all
other terms and conditions of the Option, subject to the following terms of this section. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.1. </B><U>Option Grant</U>. Each Option
granted under this Plan will identify the Option as an ISO or an NSO. An Option may be, but need not be, awarded upon satisfaction of such Performance Factors during any Performance Period as are set out in advance in the Participant&#146;s
individual Award Agreement. If the Option is being earned upon the satisfaction of Performance Factors, then the Committee will: (a)&nbsp;determine the nature, length and starting date of any Performance Period for each Option; and (b)&nbsp;select
from among the Performance Factors to be used to measure the performance, if any. Performance Periods may overlap and Participants may participate simultaneously with respect to Options that are subject to different performance goals and other
criteria. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.2. </B><U>Date of Grant</U>. The date of grant of an Option will be the date on which the Committee makes the
determination to grant such Option, or a specified future date. The Award Agreement will be delivered to the Participant within a reasonable time after the granting of the Option. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.3. </B><U>Exercise Period</U>. Options may be vested and exercisable within the times or upon the conditions as set forth in the Award
Agreement governing such Option; <U>provided</U>, <U>however</U>, that no Option will be exercisable after the expiration of 10 years from the date the Option is granted; and <U>provided further</U> that no ISO granted to a person who, at the time
the ISO is granted, directly or by attribution owns more than 10% of the total combined voting power of all classes of stock of the Company or of any Parent or Subsidiary (&#147;<B><I>Ten Percent Stockholder</I></B>&#148;) will be exercisable after
the expiration of five years from the date the ISO is granted. The Committee also may provide for Options to become exercisable at one time or from time to time, periodically or otherwise, in such number of Shares or percentage of Shares as the
Committee determines. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.4. </B><U>Exercise Price</U>. The Exercise Price of an Option will be determined by the Committee when the
Option is granted; provided that: (a)&nbsp;the Exercise Price of an Option will be not less than 100% of the Fair Market Value of the Shares on the date of grant and (b)&nbsp;the Exercise Price of any ISO granted to a Ten Percent Stockholder will
not be less than 110% of the Fair Market Value of the Shares on the date of grant. Payment for the Shares purchased may be made in accordance with Section&nbsp;11 and the Award Agreement and in accordance with any procedures established by the
Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.5. </B><U>Method of Exercise</U>. Any Option granted hereunder will be vested and exercisable according to the terms of the
Plan and at such times and under such conditions as determined by the Committee and set forth in the Award Agreement. An Option may not be exercised for a fraction of a Share. An Option will be deemed exercised when the Company receives:
(a)&nbsp;notice of exercise (in such form as the Committee may specify from time to time) from the person entitled to exercise the Option, and (b)&nbsp;full payment for the Shares with respect to which the Option is exercised (together with
applicable withholding taxes). Full payment may consist of any consideration and method of payment authorized by the Committee and permitted by the Award Agreement and the Plan. Shares issued upon exercise of an Option will be issued in the name of
the Participant. Until the Shares are issued (as evidenced by the appropriate entry on the books of the Company or of a duly authorized transfer agent of the Company), no right to vote or receive dividends or any other rights as a stockholder will
exist with respect to the Shares, notwithstanding the exercise of the Option. The Company will issue (or cause to be issued) such Shares promptly after the Option is exercised. No adjustment will be made for a dividend or other right for which the
record date is prior to the date the Shares are issued, except as provided in Section&nbsp;2.6 of the Plan. Exercising an Option in any manner will decrease the number of Shares thereafter available, both for purposes of the Plan and for sale under
the Option, by the number of Shares as to which the Option is exercised. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.6. </B><U>Termination of Service</U>. If the
Participant&#146;s Service terminates for any reason except for Cause or the Participant&#146;s death or Disability, then the Participant may exercise such Participant&#146;s Options only to the extent that such Options would have been exercisable
by the Participant on the date Participant&#146;s Service terminates no later than three months after the date Participant&#146;s Service terminates (or such shorter or longer time period as may be determined by the Committee, with any exercise
beyond three months after the date Participant&#146;s employment terminates deemed to be the exercise of an NSO), but in any event no later than the expiration date of the Options. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Death</U>. If the Participant&#146;s Service terminates because of the
Participant&#146;s death (or the Participant dies within three months after Participant&#146;s Service terminates other than for Cause or because of the Participant&#146;s Disability), then the Participant&#146;s Options may be exercised only to the
extent that such Options would have been exercisable by the Participant on the date Participant&#146;s Service terminates and must be exercised by the Participant&#146;s legal representative, or authorized assignee, no later than 12 months after the
date Participant&#146;s Service terminates (or such shorter or longer time period as may be determined by the Committee), but in any event no later than the expiration date of the Options. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Disability</U>. If the Participant&#146;s Service terminates because of the Participant&#146;s Disability, then the Participant&#146;s
Options may be exercised only to the extent that such Options would have been exercisable by the Participant on the date Participant&#146;s Service terminates and must be exercised by the Participant (or the Participant&#146;s legal representative
or authorized assignee) no later than 12 months (or such shorter or longer time period as may be determined by the Committee) after the date Participant&#146;s Service terminates (with any exercise beyond (a)&nbsp;three months after the date
Participant&#146;s employment terminates when the termination of Service is for a Disability that is not a &#147;permanent and total disability&#148; as defined in Section&nbsp;22(e)(3) of the Code, or (b) 12 months after the date Participant&#146;s
employment terminates when the termination of Service is for a Disability that is a &#147;permanent and total disability&#148; as defined in Section&nbsp;22(e)(3) of the Code, deemed to be exercise of an NSO), but in any event no later than the
expiration date of the Options. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Cause</U>. If the Participant is terminated for Cause, then Participant&#146;s Options shall
expire on such Participant&#146;s date of termination of Service, or at such later time and on such conditions as are determined by the Committee, but in any no event later than the expiration date of the Options. Unless otherwise provided in the
Award Agreement, Cause shall have the meaning set forth in the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.7. </B><U>Limitations on Exercise</U>. The Committee may
specify a minimum number of Shares that may be purchased on any exercise of an Option, provided that such minimum number will not prevent any Participant from exercising the Option for the full number of Shares for which it is then exercisable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.8. </B><U>Limitations on ISOs</U>. With respect to Awards granted as ISOs, to the extent that the aggregate Fair Market Value of the
Shares with respect to which such ISOs are exercisable for the first time by the Participant during any calendar year (under all plans of the Company and any Parent or Subsidiary) exceeds one hundred thousand dollars ($100,000), such Options will be
treated as NSOs. For purposes of this Section&nbsp;5.8, ISOs will be taken into account in the order in which they were granted. The Fair Market Value of the Shares will be determined as of the time the Option with respect to such Shares is granted.
In the event that the Code or the regulations promulgated thereunder are amended to provide for a different limit on the Fair Market Value of Shares permitted to be subject to ISOs, such different limit will be automatically incorporated herein and
will apply to any Options granted after the effective date of such amendment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.9. </B><U>Modification, Extension or Renewal</U>. The
Committee may modify, extend or renew outstanding Options and authorize the grant of new Options in substitution therefor, provided that any such action may not, without the written consent of a Participant, impair any of such Participant&#146;s
rights under any Option previously granted. Any outstanding ISO that is modified, extended, renewed or otherwise altered will be treated in accordance with Section&nbsp;424(h) of the Code. Subject to Section&nbsp;18 of this Plan, by written notice
to affected Participants, the Committee may reduce the Exercise Price of outstanding Options without the consent of such Participants; <U>provided</U>, <U>however</U>, that the Exercise Price may not be reduced below the Fair Market Value on the
date the action is taken to reduce the Exercise Price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.10. </B><U>No Disqualification</U>. Notwithstanding any other provision in
this Plan, no term of this Plan relating to ISOs will be interpreted, amended or altered, nor will any discretion or authority granted under this Plan be exercised, so as to disqualify this Plan under Section&nbsp;422 of the Code or, without the
consent of the Participant affected, to disqualify any ISO under Section&nbsp;422 of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. </B><B><U>RESTRICTED STOCK AWARDS</U></B>. A
Restricted Stock Award is an offer by the Company to grant or sell to an eligible Employee, Consultant, or Director a number of Shares that are subject to restrictions (&#147;<B><I>Restricted Stock</I></B>&#148;). The Committee will determine to
whom an offer will be made, the number of Shares the Participant may purchase, the Purchase Price (if any), the restrictions under which the Shares will be subject and all other terms and conditions of the Restricted Stock Award, subject to the
Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.1. </B><U>Restricted Stock Award Agreement</U>. All purchases under a Restricted Stock
Award will be evidenced by an Award Agreement. Except as may otherwise be provided in an Award Agreement, a Participant accepts a Restricted Stock Award by signing and delivering to the Company an Award Agreement with full payment of the Purchase
Price (if any), within 30 days from the date the Award Agreement was delivered to the Participant. If the Participant does not accept such Award within 30 days, then the offer of such Restricted Stock Award will terminate, unless the Committee
determines otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.2. </B><U>Purchase Price</U>. The Purchase Price for a Restricted Stock Award will be determined by the
Committee and the Committee may determine to grant Restricted Stock Awards with no Purchase Price. Payment of the Purchase Price must be made in accordance with Section&nbsp;11 of the Plan, and the Award Agreement and in accordance with any
procedures established by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.3. </B><U>Terms of Restricted Stock Awards</U>. Restricted Stock Awards will be subject to
such restrictions as the Committee may impose or are required by law. These restrictions may be based on completion of a specified number of years of service with the Company or upon completion of Performance Factors, if any, during any Performance
Period as set out in advance in the Participant&#146;s Award Agreement. Prior to the grant of a Restricted Stock Award, the Committee shall: (a)&nbsp;determine the nature, length and starting date of any Performance Period or other vesting criteria
for the Restricted Stock Award; (b)&nbsp;select from among the Performance Factors to be used to measure performance goals, if any; and (c)&nbsp;determine the number of Shares that may be awarded to the Participant. Performance Periods may overlap
and a Participant may participate simultaneously with respect to Restricted Stock Awards that are subject to different Performance Periods and having different performance goals and other criteria. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.4. </B><U>Termination of Service</U>. Except as may be set forth in the Participant&#146;s Award Agreement, vesting ceases on such date
Participant&#146;s Service terminates (unless determined otherwise by the Committee). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. </B><B><U>STOCK BONUS AWARDS</U></B>. A Stock Bonus Award is
an award to an eligible Employee, Consultant, or Director of Shares (or cash based on the Fair Market Value of Shares) for Services to be rendered or for past Services already rendered to the Company or any Parent, Subsidiary or Affiliate. All Stock
Bonus Awards shall be made pursuant to an Award Agreement. No payment from the Participant will be required for Shares awarded pursuant to a Stock Bonus Award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7.1. </B><U>Terms of Stock Bonus Awards.</U> The Committee will determine the number of Shares to be awarded to the Participant under a Stock Bonus Award
and any restrictions thereon. These restrictions may be based upon completion of a specified number of years of service with the Company or upon satisfaction of performance goals based on Performance Factors during any Performance Period as set out
in advance in the Participant&#146;s Award Agreement. Prior to the grant of any Stock Bonus Award the Committee shall: (a)&nbsp;determine the nature, length and starting date of any Performance Period or other vesting criteria for the Stock Bonus
Award; (b)&nbsp;select from among the Performance Factors to be used to measure performance goals; and (c)&nbsp;determine the number of Shares that may be awarded to the Participant. Performance Periods may overlap and a Participant may participate
simultaneously with respect to Stock Bonus Awards that are subject to different Performance Periods and different performance goals and other criteria. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7.2. </B><U>Form of Payment to Participant</U>. Payment may be made in the form of cash, whole Shares, or a combination thereof, based on the Fair Market
Value of the Shares earned under a Stock Bonus Award on the date of payment, as determined in the sole discretion of the Committee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7.3.
</B><U>Termination of Service</U>. Except as may be set forth in the Participant&#146;s Award Agreement, vesting ceases on such date Participant&#146;s Service terminates (unless determined otherwise by the Committee). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8. </B><B><U>STOCK APPRECIATION RIGHTS</U></B>. A Stock Appreciation Right (&#147;<B><I>SAR</I></B>&#148;) is an award to an eligible Employee, Consultant,
or Director that may be settled in cash or Shares (which may consist of Restricted Stock), having a value equal to (a)&nbsp;the difference between the Fair Market Value on the date of exercise over the Exercise Price multiplied by (b)&nbsp;the
number of Shares with respect to which the SAR is being settled (subject to any maximum number of Shares that may be issuable as specified in an Award Agreement). All SARs shall be made pursuant to an Award Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8.1. </B><U>Terms of SARs</U>. The Committee will determine the terms of each SAR including, without
limitation: (a)&nbsp;the number of Shares subject to the SAR; (b)&nbsp;the Exercise Price and the time or times during which the SAR may be settled; (c)&nbsp;the consideration to be distributed on settlement of the SAR; and (d)&nbsp;the effect of
the Participant&#146;s termination of Service on each SAR. The Exercise Price of the SAR will be determined by the Committee when the SAR is granted, and may not be less than the Fair Market Value of a Share on the date of grant. A SAR may be
awarded upon satisfaction of Performance Factors, if any, during any Performance Period as are set out in advance in the Participant&#146;s individual Award Agreement. If the SAR is being earned upon the satisfaction of Performance Factors, then the
Committee will determine the nature, length and starting date of any Performance Period for each SAR and the Performance Factors to be used to measure the performance, if any. Performance Periods may overlap and Participants may participate
simultaneously with respect to SARs that are subject to different Performance Factors and other criteria. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8.2. </B><U>Exercise Period and Expiration
Date</U>. A SAR will be exercisable within the times or upon the occurrence of events determined by the Committee and set forth in the Award Agreement governing such SAR. The Award Agreement shall set forth the expiration date; provided that no SAR
will be exercisable after the expiration of 10 years from the date the SAR is granted. The Committee may also provide for SARs to become exercisable at one time or from time to time, periodically or otherwise (including, without limitation, upon the
attainment during a Performance Period of performance goals based on Performance Factors), in such number of Shares or percentage of the Shares subject to the SAR as the Committee determines. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8.3. </B><U>Form of Settlement</U>. Upon exercise of a SAR, a Participant will be entitled to receive payment from the Company in an amount determined by
multiplying (a)&nbsp;the difference between the Fair Market Value of a Share on the date of exercise over the Exercise Price; times (b)&nbsp;the number of Shares with respect to which the SAR is exercised. At the discretion of the Committee, the
payment from the Company for the SAR exercise may be in cash, in Shares of equivalent value, or in some combination thereof. The portion of a SAR being settled may be paid currently or on a deferred basis with such interest or dividend equivalent,
if any, as the Committee determines, provided that the terms of the SAR and any deferral satisfy the requirements of Section&nbsp;409A of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8.4. </B><U>Termination of Service</U>. Except as may be set forth in the Participant&#146;s Award Agreement or Section&nbsp;5.6, vesting ceases on such
date Participant&#146;s Service terminates (unless determined otherwise by the Committee). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. </B><B><U>RESTRICTED STOCK UNITS</U></B>. A Restricted
Stock Unit (&#147;<B><I>RSU</I></B>&#148;) is an award to an eligible Employee, Consultant, or Director covering a number of Shares that may be settled in cash, or by issuance of those Shares (which may consist of Restricted Stock) based upon such
conditions as determined by the Committee. All RSUs shall be made pursuant to an Award Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9.1. </B><U>Terms of RSUs</U>. The Committee will
determine the terms of an RSU including, without limitation: (a)&nbsp;the number of Shares subject to the RSU; (b)&nbsp;the time or times during which the RSU may be settled; (c)&nbsp;the consideration to be distributed on settlement; and
(d)&nbsp;the effect of the Participant&#146;s termination of Service on each RSU; provided that no RSU shall have a term longer than 10 years. An RSU may be awarded upon satisfaction of such performance goals based on Performance Factors during any
Performance Period as are set out in advance in the Participant&#146;s Award Agreement. If the RSU is being earned upon satisfaction of Performance Factors, then the Committee will: (x)&nbsp;determine the nature, length and starting date of any
Performance Period for the RSU; (y)&nbsp;select the Performance Factors to be used to measure the performance, if any; and (z)&nbsp;determine the number of Shares deemed subject to the RSU and any Performance Factor. Performance Periods may overlap
and participants may participate simultaneously with respect to RSUs that are subject to different Performance Periods and different performance goals and other criteria. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.2. </B><U>Form and Timing of Settlement</U>. Payment of earned RSUs shall be made as soon as practicable after the date(s) determined by
the Committee and set forth in the Award Agreement. The Committee, in its sole discretion, may settle earned RSUs in cash, Shares, or a combination of both. The Committee may also permit a Participant to defer payment under a RSU to a date or dates
after the RSU is earned provided that the terms of the RSU and any deferral satisfy the requirements of Section&nbsp;409A of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.3. </B><U>Termination of Service</U>. Except as may be set forth in the Participant&#146;s Award Agreement, vesting ceases on such date
Participant&#146;s Service terminates (unless determined otherwise by the Committee). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10. </B><B><U>PERFORMANCE AWARDS</U></B>. A Performance Award is an award to an eligible Employee,
Consultant, or Director of the Company or any Parent, Subsidiary or Affiliate of a cash bonus, an award of Performance Shares, or an award of Performance Units. Grants of Performance Awards shall be made pursuant to an Award Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.1. </B><U>Types of Performance Awards</U>. Performance Awards shall include Performance Shares, Performance Units, and cash-based Awards
as set forth in Sections 10.1(a), 10.1(b), and 10.1(c) below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Performance Shares</U>. The Committee may grant Awards of
Performance Shares, designate the Participants to whom Performance Shares are to be awarded and determine the number of Performance Shares and the terms and conditions of each such Award. Performance Shares shall consist of a unit valued by
reference to a designated number of shares of Common Stock, the value of which may be paid to the Participant by delivery of shares of Common Stock or, if set forth in the instrument evidencing the Award, of such property as the Committee shall
determine, including, without limitation, cash, shares of Common Stock, other property, or any combination thereof, upon the attainment of performance goals, as established by the Committee, and other terms and conditions specified by the Committee.
The amount to be paid under an Award of Performance Shares may be adjusted on the basis of such further consideration as the Committee shall determine in its sole discretion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Performance Units</U>. The Committee may grant Awards of Performance Units, designate the Participants to whom Performance Units are to
be awarded and determine the number of Performance Units and the terms and conditions of each such Award. Performance Units shall consist of a unit valued by reference to a designated amount of property other than shares of Common Stock, which value
may be paid to the Participant by delivery of such property as the Committee shall determine, including, without limitation, cash, shares of Common Stock, other property, or any combination thereof, upon the attainment of performance goals, as
established by the Committee, and other terms and conditions specified by the Committee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Cash-Settled Performance Awards</U>. The
Committee may also grant cash-settled Performance Awards to Participants under the terms of this Plan. Such awards will be based on the attainment of any Performance Factors that are established by the Committee for the relevant Performance Period.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.2. </B><U>Terms of Performance Awards</U>. The Committee will determine, and each Award Agreement shall set forth, the terms of
each Performance Award including, without limitation: (a)&nbsp;the amount of any cash bonus, (b)&nbsp;the number of Shares deemed subject to an award of Performance Shares; (c)&nbsp;the Performance Factors and Performance Period that shall determine
the time and extent to which each award of Performance Award shall be settled; (d)&nbsp;the consideration to be distributed on settlement, and (e)&nbsp;the effect of the Participant&#146;s termination of Service on each Performance Award. In
establishing Performance Factors and the Performance Period the Committee will: (x)&nbsp;determine the nature, length and starting date of any Performance Period; (y)&nbsp;select the Performance Factors to be used; and (z)&nbsp;determine the number
of Shares deemed subject to the Performance Award, if any. Prior to settlement the Committee shall determine the extent to which Performance Awards have been earned. Performance Periods may overlap and Participants may participate simultaneously
with respect to Performance Awards that are subject to different Performance Periods and different performance goals and other criteria. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.3. </B><U>Termination of Service</U>. Except as may be set forth in the Participant&#146;s Award Agreement, vesting ceases on the date
Participant&#146;s Service terminates (unless determined otherwise by the Committee). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11. </B><B><U>PAYMENT FOR SHARE PURCHASES</U></B>. Payment from
a Participant for Shares purchased pursuant to this Plan may be made in cash or by check or, where approved for the Participant by the Committee and where permitted by law (and to the extent not otherwise set forth in the applicable Award
Agreement): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) by cancellation of indebtedness of the Company to the Participant; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) by surrender of shares of Common Stock by the Participant that have a Fair Market Value on the date of surrender equal to the aggregate
exercise price of the Shares as to which said Award will be exercised or settled; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) by waiver of compensation due or accrued to the
Participant for services rendered or to be rendered to the Company or a Parent or Subsidiary of the Company; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) by consideration received by the Company pursuant to a broker-assisted or other form of
cashless exercise program implemented by the Company in connection with the Plan; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) by any combination of the foregoing; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) by any other method of payment as is permitted by the Committee and applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12. </B><B><U>GRANTS TO <FONT STYLE="white-space:nowrap">NON-EMPLOYEE</FONT> DIRECTORS</U></B>. <FONT STYLE="white-space:nowrap">Non-Employee</FONT>
Directors are eligible to receive any type of Award offered under this Plan except ISOs. Awards pursuant to this Section&nbsp;12 may be automatically made pursuant to policy adopted by the Board, or made from time to time as determined in the
discretion of the Board. The aggregate value of all compensation granted or paid, as applicable, to any individual for service as a <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director with respect to any fiscal year, including Awards
granted and cash fees paid by the Company to such <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director for his or her service as a <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director, will not exceed (i) $750,000 in total value or
(ii)&nbsp;in the event such <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director is first appointed or elected to the Board during such fiscal year or in any fiscal year in which such <FONT STYLE="white-space:nowrap">Non-Employee</FONT>
Director serves as Chair of the Board, $1,000,000 in total value, in each case calculating the value of any equity awards based on the grant date fair value of such equity awards for financial reporting purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12.1. </B><U>Eligibility</U>. Awards pursuant to this Section&nbsp;12 shall be granted only to
<FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors. A <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director who is elected or <FONT STYLE="white-space:nowrap">re-elected</FONT> as a member of the Board will be eligible to receive
an Award under this Section&nbsp;12. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12.2. </B><U>Vesting, Exercisability and Settlement</U>. Except as set forth in Section&nbsp;21,
Awards shall vest, become exercisable and be settled as determined by the Board. With respect to Options and SARs, the exercise price granted to <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors shall not be less than the Fair Market
Value of the Shares at the time that such Option or SAR is granted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12.3. </B><U>Election to receive Awards in Lieu of Cash</U>. A <FONT
STYLE="white-space:nowrap">Non-Employee</FONT> Director may elect to receive his or her annual retainer payments and/or meeting fees from the Company in the form of cash or Awards or a combination thereof, as determined by the Committee. Such Awards
shall be issued under the Plan. An election under this Section&nbsp;12.3 shall be filed with the Company on the form prescribed by the Company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13.
<U>WITHHOLDING TAXES</U><U>.</U> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.1. </B><U>Withholding Generally</U>. Whenever Shares are to be issued in satisfaction of Awards
granted under this Plan or a tax event occurs, the Company may require the Participant to remit to the Company, or to the Parent, Subsidiary or applicable Affiliate employing the Participant, an amount sufficient to satisfy applicable U.S. federal,
state, local and international withholding tax requirements or any other tax or social insurance liability legally due from the Participant prior to the delivery of Shares pursuant to exercise or settlement of any Award. Whenever payments in
satisfaction of Awards granted under this Plan are to be made in cash, such payment will be net of an amount sufficient to satisfy applicable U.S. federal, state, local and international withholding tax or social insurance requirements or any other
tax liability legally due from the Participant. The Fair Market Value of the Shares will be determined as of the date that the taxes are required to be withheld and such Shares shall be valued based on the value of the actual trade or, if there is
none, the Fair Market Value of the Shares as of the previous trading day. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.2. </B><U>Stock Withholding</U>. The Committee, or its
delegate(s), as permitted by applicable law, in its sole discretion and pursuant to such procedures as it may specify from time to time and to limitations of local law, may require or permit a Participant to satisfy such tax withholding obligation
or any other tax liability legally due from the Participant, in whole or in part by (without limitation)&nbsp;(a) paying cash, (b)&nbsp;electing to have the Company withhold otherwise deliverable cash or Shares, (c)&nbsp;delivering to the Company
already-owned shares of Common Stock or (d)&nbsp;withholding from proceeds of the sale of otherwise deliverable Shares acquired pursuant to an Award either through a voluntary sale or through a mandatory sale arranged by the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14. <U>TRANSFERABILITY</U><U>.</U> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>14.1. </B><U>Transfer Generally</U>. Unless determined otherwise by the Committee or pursuant to Section&nbsp;14.2, an Award may not be
sold, pledged, assigned, hypothecated, transferred, or disposed of in any manner other than by will or by the laws of descent or distribution. If the Committee makes an Award transferable, including, without limitation, by instrument to an inter
vivos or testamentary trust in which the Awards are to be passed to beneficiaries upon the death of the trustor (settlor) or by gift or by domestic relations order to a Permitted Transferee, such Award will contain such additional terms and
conditions as the Committee deems appropriate. All Awards shall be exercisable: (a)&nbsp;during the Participant&#146;s lifetime only by (i)&nbsp;the Participant, or (ii)&nbsp;the Participant&#146;s guardian or legal representative; (b)&nbsp;after
the Participant&#146;s death, by the legal representative of the Participant&#146;s heirs or legatees; and (c)&nbsp;in the case of all awards except ISOs, by a Permitted Transferee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>14.2. </B><U>Award Transfer Program</U>. Notwithstanding any contrary provision of the Plan, the Committee shall have all discretion and
authority to determine and implement the terms and conditions of any Award Transfer Program instituted pursuant to this Section&nbsp;14.2 and shall have the authority to amend the terms of any Award participating, or otherwise eligible to
participate in, the Award Transfer Program, including (but not limited to) the authority to (a)&nbsp;amend (including to extend) the expiration date, post-termination exercise period and/or forfeiture conditions of any such Award, (b)&nbsp;amend or
remove any provisions of the Award relating to the Award holder&#146;s continued Service to the Company or its Parent, Subsidiary, or Affiliate, (c)&nbsp;amend the permissible payment methods with respect to the exercise or purchase of any such
Award, (d)&nbsp;amend the adjustments to be implemented in the event of changes in the capitalization and other similar events with respect to such Award, and (e)&nbsp;make such other changes to the terms of such Award as the Committee deems
necessary or appropriate in its sole discretion, to the extent permitted by applicable law. Notwithstanding anything to the contrary in the Plan, in no event will the Committee have the right to determine and implement the terms and conditions of
any Award Transfer Program without stockholder approval. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>15. <U>PRIVILEGES OF STOCK OWNERSHIP; RESTRICTIONS ON SHARES</U><U>.</U> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>15.1. </B><U>Voting and Dividends</U>. No Participant will have any of the rights of a stockholder with respect to any Shares until the
Shares are issued to the Participant, except for any dividend equivalent rights permitted by an applicable Award Agreement (&#147;<B><I>Dividend Equivalent Rights</I></B>&#148;). After Shares are issued to the Participant, the Participant will be a
stockholder and have all the rights of a stockholder with respect to such Shares, including the right to vote and receive all dividends or other distributions made or paid with respect to such Shares; <U>provided</U>, that if such Shares are
Restricted Stock, then any new, additional or different securities the Participant may become entitled to receive with respect to such Shares by virtue of a stock dividend, stock split or any other change in the corporate or capital structure of the
Company will be subject to the same restrictions as the Restricted Stock; <U>provided</U>, <U>further</U>, that the Participant will have no right to retain such stock dividends or stock distributions with respect to Shares that are repurchased at
the Participant&#146;s Purchase Price or Exercise Price, as the case may be, pursuant to Section&nbsp;15.2. However, the Committee, in its discretion, may provide in the Award Agreement evidencing any Award that the Participant shall be entitled to
Dividend Equivalent Rights with respect to the payment of cash dividends on Shares underlying an Award during the period beginning on the date the Award is granted and ending, with respect to each Share subject to the Award, on the earlier of the
date on which the Award is exercised or settled or the date on which it is forfeited. Such Dividend Equivalent Rights, if any, shall be credited to the Participant in the form of additional whole Shares (or cash as determined by the Committee) as of
the date of payment of such cash dividends on Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>15.2. </B><U>Restrictions on Shares</U>. At the discretion of the Committee, the
Company may reserve to itself and/or its assignee(s) a right to repurchase (a &#147;<B><I>Right of Repurchase</I></B>&#148;) a portion of any or all Unvested Shares held by a Participant following such Participant&#146;s termination of Service at
any time within 90 days (or such longer or shorter time determined by the Committee) after the later of the date Participant&#146;s Service terminates and the date the Participant purchases Shares under this Plan, for cash and/or cancellation of
purchase money indebtedness, at the Participant&#146;s Purchase Price or Exercise Price, as the case may be. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>16. </B><B><U>CERTIFICATES</U></B>. All
Shares or other securities whether or not certificated, delivered under this Plan will be subject to such stock transfer orders, legends and other restrictions as the Committee may deem necessary or advisable, including restrictions under any
applicable U.S. federal, state or foreign securities law, or any rules, regulations and other requirements of the SEC or any stock exchange or automated quotation system upon which the Shares may be listed or quoted and any <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> exchange controls or securities law restrictions to which the Shares are subject. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>17. </B><B><U>ESCROW; PLEDGE OF SHARES</U></B>. To enforce any restrictions on a Participant&#146;s
Shares, the Committee may require the Participant to deposit all certificates representing Shares, together with stock powers or other instruments of transfer approved by the Committee, appropriately endorsed in blank, with the Company or an agent
designated by the Company to hold in escrow until such restrictions have lapsed or terminated, and the Committee may cause a legend or legends referencing such restrictions to be placed on the certificates. Any Participant who is permitted to
execute a promissory note as partial or full consideration for the purchase of Shares under this Plan will be required to pledge and deposit with the Company all or part of the Shares so purchased as collateral to secure the payment of the
Participant&#146;s obligation to the Company under the promissory note; <U>provided</U>, <U>however</U>, that the Committee may require or accept other or additional forms of collateral to secure the payment of such obligation and, in any event, the
Company will have full recourse against the Participant under the promissory note notwithstanding any pledge of the Participant&#146;s Shares or other collateral. In connection with any pledge of the Shares, the Participant will be required to
execute and deliver a written pledge agreement in such form as the Committee will from time to time approve. The Shares purchased with the promissory note may be released from the pledge on a pro rata basis as the promissory note is paid. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>18. </B><B><U>REPRICING; EXCHANGE AND BUYOUT OF AWARDS</U></B><U>.</U> Without prior stockholder approval, the Committee may (a)&nbsp;reprice Options or
SARs (and where such repricing is a reduction in the Exercise Price of outstanding Options or SARs, the consent of the affected Participants is not required provided written notice is provided to them, notwithstanding any adverse tax consequences to
them arising from the repricing), and (b)&nbsp;with the consent of the respective Participants (unless not required pursuant to Section&nbsp;5.9 of the Plan), pay cash or issue new Awards in exchange for the surrender and cancellation of any, or
all, outstanding Awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>19. </B><B><U>SECURITIES LAW AND OTHER REGULATORY COMPLIANCE</U></B>. An Award will not be effective unless such Award is in
compliance with all applicable U.S. and foreign federal and state securities and exchange control laws, rules and regulations of any governmental body, and the requirements of any stock exchange or automated quotation system upon which the Shares
may then be listed or quoted, as they are in effect on the date of grant of the Award and also on the date of exercise or other issuance. Notwithstanding any other provision in this Plan, the Company will have no obligation to issue or deliver
certificates for Shares under this Plan prior to: (a)&nbsp;obtaining any approvals from governmental agencies that the Company determines are necessary or advisable; and/or (b)&nbsp;completion of any registration or other qualification of such
Shares under any state or federal or foreign law or ruling of any governmental body that the Company determines to be necessary or advisable. The Company will be under no obligation to register the Shares with the SEC or to effect compliance with
the registration, qualification or listing requirements of any foreign or state securities laws, exchange control laws, stock exchange or automated quotation system, and the Company will have no liability for any inability or failure to do so. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>20. <U>MISCELLANEOUS</U>. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>20.1.
</B><U>No Obligation to Employ</U>. Nothing in this Plan or any Award granted under this Plan will confer or be deemed to confer on any Participant any right to continue in the employ of, or to continue any other relationship with, the Company or
any Parent, Subsidiary or Affiliate or limit in any way the right of the Company or any Parent, Subsidiary or Affiliate to terminate Participant&#146;s employment or other relationship at any time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>20.2.</B> <U>Change in Time Commitment</U>. In the event that a Participant&#146;s regular level of time commitment in the performance of
his or her services for the Company or any Affiliate is reduced (for example, and without limitation, if the Participant is an Employee and has a change in status from a full-time Employee to a part-time Employee or takes an extended leave of
absence) after the date of grant of any Award to Participant, the Committee has the right in its sole discretion to (i)&nbsp;make a corresponding reduction in the number of Shares or cash amount subject to any portion of such Award that is scheduled
to vest or become payable after the date of such change in time commitment, and (ii)&nbsp;in lieu of or in combination with such a reduction, extend the vesting or payment schedule applicable to such Award. In the event of any such reduction, the
Participant will have no right with respect to any portion of the Award that is so reduced or extended. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>21. <U>CORPORATE TRANSACTIONS</U><U>.</U> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>21.1. </B><U>Assumption or Replacement of Awards by Successor</U>. In the event that the Company is subject to a Corporate Transaction,
outstanding Awards acquired under the Plan shall be subject to the agreement evidencing the Corporate Transaction and subject to such other determinations made by the Committee, each of which need not treat all outstanding Awards in an identical
manner. Such agreement or determination, without the Participant&#146;s consent, may provide for one or more of the following with respect to all outstanding Awards as of the effective date of such Corporate Transaction: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The continuation of an outstanding Award by the Company (if the Company is the successor entity). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The assumption of an outstanding Award by the successor or acquiring entity (if any) of such Corporate Transaction (or by its parents, if
any), which assumption, will be binding on all selected Participants; provided that the exercise price and the number and nature of shares issuable upon exercise of any such Option or SAR, or any award that is subject to Section&nbsp;409A of the
Code, will be adjusted appropriately pursuant to Section&nbsp;424(a) of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) The substitution by the successor or acquiring
entity in such Corporate Transaction (or by its parents, if any) of equivalent awards with substantially the same terms for such outstanding Awards (except that the exercise price and the number and nature of shares issuable upon exercise of any
such Option or SAR, or any award that is subject to Section&nbsp;409A of the Code, will be adjusted appropriately pursuant to Section&nbsp;424(a) of the Code). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The full or partial acceleration of exercisability or vesting and accelerated expiration of an outstanding Award and lapse of the
Company&#146;s right to repurchase or <FONT STYLE="white-space:nowrap">re-acquire</FONT> Shares acquired under an Award or lapse of forfeiture rights with respect to Shares acquired under an Award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) The settlement of the full value of such outstanding Award (whether or not then vested or exercisable) in cash, cash equivalents, or
securities of the successor entity (or its parent, if any) with a Fair Market Value equal to the required amount, followed by the cancellation of such Awards; provided however, that such Award may be cancelled if such Award has no value, as
determined by the Committee, in its discretion. Subject to Section&nbsp;409A of the Code, such payment may be made in installments and may be deferred until the date or dates the Award would have become exercisable or vested. Such payment may be
subject to vesting based on the Participant&#146;s continued service, provided that the vesting schedule shall not be less favorable to the Participant than the schedule under which the Award would have become vested or exercisable. For purposes of
this Section&nbsp;21.1(e), the Fair Market Value of any security shall be determined without regard to any vesting conditions that may apply to such security. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) The cancellation of outstanding Awards in exchange for no consideration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board shall have full power and authority to assign the Company&#146;s right to repurchase or <FONT STYLE="white-space:nowrap">re-</FONT>
acquire or forfeiture rights to such successor or acquiring corporation. In addition, in the event such successor or acquiring corporation refuses to assume, convert, replace or substitute Awards, as provided above, pursuant to a Corporate
Transaction, the Committee will notify the Participant in writing or electronically that such Award will be exercisable for a period of time determined by the Committee in its sole discretion, and such Award will terminate upon the expiration of
such period. Awards need not be treated similarly in a Corporate Transaction. In addition, following a Corporate Transaction, 100% of the total number of Shares subject to each Award held by an Employee shall become vested if the holder is subject
to an Involuntary Termination within 12 months after the Corporate Transaction; it being understood that the vesting acceleration set forth in the preceding clause is in addition to vesting of the Award or Shares that has occurred prior to the
Involuntary Termination, subject to the Participant executing a general release (in a form prescribed by the Company) of all known and unknown claims that he or she may then have against the Company or persons affiliated with the Company and such
release has become effective and agreeing not to prosecute any legal action or other proceeding based upon any of such claims except to the extent otherwise provided in an individual award agreement. The provisions of this Section&nbsp;21.1 shall
apply to Awards outstanding on the Original Effective Date under the Prior Plan; provided the vesting acceleration provisions set forth in any employment agreement or letter or similar agreement between the Company and an employee in effect on the
Original Effective Date, to the extent more favorable to such employee, will continue to apply to the equity awards held by the employee on the Original Effective Date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>21.2. </B><U>Assumption of Awards by the Company</U>. The Company, from time to time,
also may substitute or assume outstanding awards granted by another company, whether in connection with an acquisition of such other company or otherwise, by either; (a)&nbsp;granting an Award under this Plan in substitution of such other
company&#146;s award; or (b)&nbsp;assuming such award as if it had been granted under this Plan if the terms of such assumed award could be applied to an Award granted under this Plan. Such substitution or assumption will be permissible if the
holder of the substituted or assumed award would have been eligible to be granted an Award under this Plan if the other company had applied the rules of this Plan to such grant. In the event the Company assumes an award granted by another company,
the terms and conditions of such award will remain unchanged (except that the Purchase Price or the Exercise Price, as the case may be, and the number and nature of Shares issuable upon exercise or settlement of any such Award will be adjusted
appropriately pursuant to Section&nbsp;424(a) of the Code). In the event the Company elects to grant a new Option in substitution rather than assuming an existing option, such new Option may be granted with a similarly adjusted Exercise Price.
Substitute Awards shall not be credited toward the number of Shares authorized for grant under the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>21.3. </B><U><FONT
STYLE="white-space:nowrap">Non-Employee</FONT> Directors&#146; Awards</U>. Notwithstanding any provision to the contrary herein, in the event of a Corporate Transaction, the vesting of all Awards granted to
<FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors shall accelerate and such Awards shall become exercisable (as applicable) in full prior to the consummation of such event at such times and on such conditions as the Committee
determines. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>22. </B><B><U>ADOPTION AND STOCKHOLDER APPROVAL</U></B>. This Plan shall be submitted for the approval of the Company&#146;s stockholders,
consistent with applicable laws, within 12 months before or after the date this Plan is adopted by the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>23. </B><B><U>GOVERNING
LAW</U></B><U>.</U> This Plan and all Awards granted hereunder shall be governed by and construed in accordance with the laws of the State of Delaware (excluding its conflict of law rules). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>24. </B><B><U>AMENDMENT OR TERMINATION OF PLAN</U></B><U>.</U> The Board may at any time terminate or amend this Plan in any respect, including, without
limitation, amendment of any form of Award Agreement or instrument to be executed pursuant to this Plan; <U>provided</U>, <U>however</U>, that the Board will not, without the approval of the stockholders of the Company, amend this Plan in any manner
that requires such stockholder approval; <U>provided</U> <U>further</U>, that no amendment shall materially impair the rights of the holder of an Award without such holder&#146;s consent and a Participant&#146;s Award shall be governed by the
version of this Plan then in effect at the time such Award was granted. No Awards may be granted under the Plan while the Plan is suspended or after it is terminated. No ISOs may be granted after the tenth anniversary of the earlier of (i)&nbsp;the
Adoption Date or (ii)&nbsp;the Stockholder Approval Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>25. </B><B><U>NONEXCLUSIVITY OF THE PLAN</U></B>. Neither the adoption of this Plan by the
Board, the submission of this Plan to the stockholders of the Company for approval, nor any provision of this Plan will be construed as creating any limitations on the power of the Board to adopt such additional compensation arrangements as it may
deem desirable, including, without limitation, the granting of stock awards and bonuses otherwise than under this Plan, and such arrangements may be either generally applicable or applicable only in specific cases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>26. </B><B><U>INSIDER TRADING POLICY</U></B><U>.</U> Each Participant who receives an Award shall comply with any policy adopted by the Company from time
to time covering transactions in the Company&#146;s securities by Employees, officers and/or directors of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>27. </B><B><U>ALL AWARDS
SUBJECT TO COMPANY CLAWBACK OR RECOUPMENT POLICY</U></B><U>.</U> All Awards shall be subject to clawback or recoupment pursuant to any compensation clawback or recoupment policy adopted by the Board or required by law during or after the term of
Participant&#146;s employment or other service with the Company that is applicable to executive officers, employees, directors or other service providers of the Company. By accepting an Award, the Participant expressly agrees that, in addition to
any other remedies available under such policy and applicable law, the Company may require the cancelation of outstanding Awards and the recoupment of any gains realized with respect to Awards pursuant to such policy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>28. </B><B><U>DEFINITIONS</U></B><U>.</U> As used in this Plan, and except as elsewhere defined herein, the following terms will have the following
meanings: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.1.</B> &#147;<B><I>Adoption Date</I></B>&#148; means October&nbsp;25, 2023, which is
the date that this Plan, as amended and restated, was adopted by the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.2.</B> &#147;<B><I>Affiliate</I></B>&#148; means any
person or entity that directly or indirectly through one or more intermediaries controls, or is controlled by, or is under common control with, the Company, including any general partner, managing member, officer or director of the Company, in each
case as of the date on which, or at any time during the period for which, the determination of affiliation is being made. For purposes of this definition, the term &#147;control&#148; (including the correlative meanings of the terms &#147;controlled
by&#148; and &#147;under common control with&#148;), as used with respect to any person or entity, means the possession, directly or indirectly, of the power to direct or cause the direction of the management policies of such person or entity,
whether through the ownership of voting securities or by contract or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.3.</B> &#147;<B><I>Award</I></B>&#148; means any
award under the Plan, including any Option, Restricted Stock, Stock Bonus, SAR, RSU, or Performance Award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.4.</B> &#147;<B><I>Award
Agreement</I></B>&#148; means, with respect to each Award, the written or electronic agreement between the Company and the Participant setting forth the terms and conditions of the Award, and any country-specific appendix thereto for grants to <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> Participants, which shall be in substantially a form (which need not be the same for each Participant) that the Committee (or in the case of Award agreements that are not used for Insiders, the
Committee&#146;s delegate(s)) has from time to time approved, and will comply with and be subject to the terms and conditions of this Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.5.</B> &#147;<B><I>Award Transfer Program</I></B>&#148; means any program instituted by the Committee which would permit Participants
the opportunity to transfer any outstanding Awards to a financial institution or other person or entity approved by the Committee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.6.</B> &#147;<B><I>Board</I></B>&#148; means the Board of Directors of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.7.</B> &#147;<B><I>Cause</I></B>&#148;<B> </B>has the meaning set forth in the Award Agreement or the written employment, offer,
services or severance agreement or letter between the Participant and the Company or an Affiliate, or if there is no such agreement or no such term is defined in such agreement, means (i)&nbsp;an unauthorized use or disclosure by Participant of the
Company&#146;s confidential information or trade secrets, which use or disclosure causes material harm to the Company or is reasonably likely to cause material harm to the Company, (ii)&nbsp;a material breach of any agreement between Participant and
the Company, (iii)&nbsp;a material failure to comply with the Company&#146;s written policies or rules that has caused or is reasonably likely to cause material injury to the Company, its successor, or its affiliates, or any of their business,
(iv)&nbsp;conviction of, or plea of &#147;guilty&#148; or &#147;no contest&#148; to, a felony under the laws of the United States or any state thereof, (v)&nbsp;willful misconduct that has caused or is reasonably likely to cause material injury to
the Company, its successor, or its affiliates, or any of their business, (vi)&nbsp;embezzlement, (vii) failure to cooperate with the Company in any investigation or formal proceeding if the Company has requested Participant&#146;s reasonable
cooperation, (viii)&nbsp;violation of any applicable federal, state or foreign statutes or laws that govern or regulate employment, pharmaceutical drugs or securities, including but not limited to the laws enforced by the federal Equal Employment
Opportunity Commission, Department of Labor, Food and Drug Administration, Securities and Exchange Commission and Department of Justice or (ix)&nbsp;a continued failure to perform assigned duties after receiving written notification of such failure
from the Company&#146;s Chief Executive Officer (or with respect to the Company&#146;s Chief Executive Officer, the Board); <I>provided that </I>Participant must be provided with written notice of Participant&#146;s termination for &#147;Cause&#148;
and Participant must be provided with a 30 day period following Participant&#146;s receipt of such notice to cure the event(s) that trigger &#147;Cause,&#148; with the Company&#146;s Chief Executive Officer (or with respect to the Company&#146;s
Chief Executive Officer, the Board) making the final determination whether Participant has cured any Cause. The determination as to whether a Participant is being terminated for Cause shall be made in good faith by the Company and shall be final and
binding on the Participant. The foregoing definition does not in any way limit the Company&#146;s ability to terminate a Participant&#146;s employment or consulting relationship at any time as provided in Section&nbsp;20 above, and the term
&#147;Company&#148; will be interpreted to include any Parent, Subsidiary or Affiliate, as appropriate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.8.</B>
&#147;<B><I>Code</I></B>&#148; means the United States Internal Revenue Code of 1986, as amended, and the regulations promulgated thereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.9.</B> &#147;<B><I>Committee</I></B>&#148; means the Compensation Committee of the
Board or those persons to whom administration of the Plan, or part of the Plan, has been delegated as permitted by law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.10.</B>
&#147;<B><I>Common Stock</I></B>&#148; means the common stock of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.11.</B> &#147;<B><I>Company</I></B>&#148; means Spyre
Therapeutics, Inc., or any successor corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.12.</B> &#147;<B><I>Consultant</I></B>&#148; means any person, including an
advisor or independent contractor, engaged by the Company or a Parent, Subsidiary or Affiliate to render services to such entity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.13.</B> &#147;<B><I>Corporate Transaction</I></B>&#148; means the occurrence of any of the following events: (a)&nbsp;any
&#147;Person&#148; (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becomes the &#147;beneficial owner&#148; (as defined in Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> of the Exchange Act), directly or indirectly, of
securities of the Company representing more than 50% of the total voting power represented by the Company&#146;s then-outstanding voting securities; provided, however, that for purposes of this subclause (a)&nbsp;the acquisition of additional
securities by any one Person who is considered to own more than 50% of the total voting power of the securities of the Company will not be considered a Corporate Transaction; (b)&nbsp;the consummation of the sale or disposition by the Company of all
or substantially all of the Company&#146;s assets; (c)&nbsp;the consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company
outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least 50% of the total voting power represented by the voting
securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation; (d)&nbsp;any other transaction which qualifies as a &#147;corporate transaction&#148; under Section&nbsp;424 of the Code
(and the Treasury Regulations promulgated thereunder) wherein the stockholders of the Company give up all of their equity interest in the Company (except for the acquisition, sale or transfer of all or substantially all of the outstanding shares of
the Company) or (e)&nbsp;a change in the effective control of the Company that occurs on the date that a majority of members of the Board is replaced during any 12 month period by members of the Board whose appointment or election is not endorsed by
a majority of the members of the Board prior to the date of the appointment or election. For purpose of this subclause (e), if any Person is considered to be in effective control of the Company, the acquisition of additional control of the Company
by the same Person will not be considered a Corporate Transaction. For purposes of this definition, Persons will be considered to be acting as a group if they are owners of a corporation that enters into a merger, consolidation, purchase or
acquisition of stock, or similar business transaction with the Company. Notwithstanding the foregoing, to the extent that any amount constituting deferred compensation (as defined in Section&nbsp;409A of the Code) would become payable under this
Plan by reason of a Corporate Transaction, such amount shall become payable only if the event constituting a Corporate Transaction would also qualify as a change in ownership or effective control of the Company or a change in the ownership of a
substantial portion of the assets of the Company, each as defined within the meaning of Code Section&nbsp;409A, as it has been and may be amended from time to time, and any proposed or final Treasury Regulations and IRS guidance that has been
promulgated or may be promulgated thereunder from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.14.</B> &#147;<B><I>Director</I></B>&#148; means a member of the
Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.15.</B> &#147;<B><I>Disability</I></B>&#148; means in the case of ISOs, permanent and total disability as defined in
Section&nbsp;22(e)(3) of the Code and in the case of other Awards, that the Participant is unable to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment that can be expected to result in
death or can be expected to last for a continuous period of not less than 12 months. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.16.</B> &#147;<B><I>Employee</I></B>&#148;
means any person, including officers and Directors, employed by the Company or any Parent, Subsidiary or Affiliate. Neither service as a Director nor payment of a director&#146;s fee by the Company will be sufficient to constitute
&#147;employment&#148; by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.17.</B> &#147;<B><I>Exchange Act</I></B>&#148; means the United States Securities Exchange
Act of 1934, as amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.18.</B> &#147;<B><I>Exchange Program</I></B>&#148; means a program pursuant to which (a)&nbsp;outstanding
Awards are surrendered, cancelled or exchanged for cash, the same type of Award or a different Award (or combination thereof) or (b)&nbsp;the exercise price of an outstanding Award is increased or reduced. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.19.</B> &#147;<B><I>Exercise Price</I></B>&#148; means, with respect to an Option, the
price at which a holder may purchase the Shares issuable upon exercise of an Option and with respect to a SAR, the price at which the SAR is granted to the holder thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.20.</B> &#147;<B><I>Fair Market Value</I></B>&#148; means, as of any date, the value of a share of the Company&#146;s Common Stock
determined as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) if such Common Stock is publicly traded and is then listed on a national securities exchange,
its closing price on the date of determination on the principal national securities exchange on which the Common Stock is listed or admitted to trading as reported in <I>The Wall Street Journal</I> or such other source as the Committee deems
reliable; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) if such Common Stock is publicly traded but is neither listed nor admitted to trading on a national
securities exchange, the average of the closing bid and asked prices on the date of determination as reported in <I>The Wall Street Journal </I>or such other source as the Committee deems reliable; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) in the case of an Option or SAR grant made on the Original Effective Date, the price per share at which shares of the
Company&#146;s Common Stock were initially offered for sale to the public by the Company&#146;s underwriters in the initial public offering of the Company&#146;s Common Stock pursuant to a registration statement filed with the SEC under the
Securities Act; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) if none of the foregoing is applicable, by the Board or the Committee in good faith. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.21.</B> &#147;<B><I>Good Reason</I></B>&#148; has the meaning set forth in the Award Agreement or the written employment, offer,
services or severance agreement or letter between the Participant and the Company or an Affiliate, or if there is no such agreement or no such term is defined in such agreement, means, without the Participant&#146;s consent, (i)&nbsp;a material
reduction in the Participant&#146;s level of responsibility and/or scope of authority, (ii)&nbsp;a reduction by more than 10% in Participant&#146;s base salary (other than a reduction generally applicable to Participant officers of the Company and
in generally the same proportion as for the Participant), or (iii)&nbsp;relocation of the Participant&#146;s principal workplace by more than 35 miles from Participant&#146;s then current place of employment. For the purpose of clause (i), a change
in responsibility shall not be deemed to occur (A)&nbsp;solely because Participant is part of a larger organization or (B)&nbsp;solely because of a change in title. For the Participant to receive the benefits under this Agreement as a result of a
voluntary resignation for Good Reason, all of the following requirements must be satisfied: (1)&nbsp;the Participant must provide notice to the Company of his or her intent to assert Good Reason within 60 days of the initial existence of one or more
of the conditions set forth in subclauses (i)&nbsp;through (iii); (2) the Company will have 30 days (the &#147;<B><I>Company Cure Period</I></B>&#148;) from the date of such notice to remedy the condition and, if it does so, the Participant may
either withdraw his or her resignation or resign with no benefits; and (3)&nbsp;any termination of employment under this provision must occur within 10 days of the earlier of expiration of the Company Cure Period or written notice from the Company
that it will not undertake to cure the condition set forth in subclauses (i)&nbsp;through (iii). Should the Company remedy the condition as set forth above and then one or more of the conditions arise again, the Participant may assert Good Reason
again subject to all of the conditions set forth herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.22.</B> &#147;<B><I>Insider</I></B>&#148; means an officer or director of
the Company or any other person whose transactions in the Company&#146;s Common Stock are subject to Section&nbsp;16 of the Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.23.</B> &#147;<B><I>Involuntary Termination</I></B>&#148; means either (a)&nbsp;termination of Service without Cause or
(b)&nbsp;resignation from Service for Good Reason. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.24.</B> &#147;<B><I>IRS</I></B>&#148; means the United States Internal Revenue
Service. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.25.</B> <B></B>&#147;<B><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director</I></B>&#148; means a Director
who is not an Employee of the Company or any Parent, Subsidiary or Affiliate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.26.</B> &#147;<B><I>Option</I></B>&#148; means an
award of an option to purchase Shares pursuant to Section&nbsp;5. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.27.</B> &#147;<B><I>Original Effective Date</I></B>&#148; means
the day immediately prior to the date of the underwritten initial public offering of the Company&#146;s Common Stock pursuant to a registration statement that was declared effective by the SEC. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.28.</B> &#147;<B><I>Outstanding Shares</I></B>&#148; means, as of a specified date,
the sum of (a)&nbsp;the then-issued and outstanding Shares, (b)&nbsp;the number of Shares issuable pursuant to the exercise of any outstanding <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants to acquire Shares for a nominal exercise
price, and (c)&nbsp;the number of Shares issuable pursuant to the conversion of any outstanding shares of nonvoting convertible preferred stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.29.</B> &#147;<B><I>Parent</I></B>&#148; means any corporation (other than the Company) in an unbroken chain of corporations ending with
the Company if each of such corporations other than the Company owns stock possessing 50% or more of the total combined voting power of all classes of stock in one of the other corporations in such chain. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.30.</B> &#147;<B><I>Participant</I></B>&#148; means a person who holds an Award under this Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.31.</B> <I>&#147;</I><B><I>Performance Award</I></B><I>&#148; </I>means a cash or stock Award granted pursuant to Section&nbsp;10 of the
Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.32.</B> &#147;<B><I>Performance Factors</I></B>&#148;<B><I> </I></B>means any of the factors selected by the Committee and
specified in an Award Agreement, which, for the avoidance of doubt, may include any factors or measures that the Committee deems appropriate, either individually, alternatively or in any combination, applied to the Company as a whole or any business
unit or Subsidiary, either individually, alternatively, or in any combination, on a GAAP or <FONT STYLE="white-space:nowrap">non-GAAP</FONT> basis, and measured, to the extent applicable on an absolute basis or relative to a <FONT
STYLE="white-space:nowrap">pre-established</FONT> target, to determine whether the performance goals established by the Committee with respect to applicable Awards have been satisfied. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Committee may, in recognition of unusual or <FONT STYLE="white-space:nowrap">non-recurring</FONT> items such as acquisition-related
activities or changes in applicable accounting rules, provide for one or more equitable adjustments (based on objective standards) to the Performance Factors to preserve the Committee&#146;s original intent regarding the Performance Factors at the
time of the initial award grant. It is within the sole discretion of the Committee to make or not make any such equitable adjustments. The Committee is authorized to make adjustments as it deems appropriate in the method of calculating the
attainment of Performance Factors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.33.</B> &#147;<B><I>Performance Period</I></B>&#148; means one or more periods of time, which
may be of varying and overlapping durations, as the Committee may select, over which the attainment of one or more Performance Factors will be measured for the purpose of determining a Participant&#146;s right to, and the payment of, a Performance
Award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.34.</B> &#147;<B><I>Performance Share</I></B>&#148; means an Award granted pursuant to Section&nbsp;10 of the Plan, the
payment of which is contingent upon achieving certain performance goals established by the Committee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.35.</B>
&#147;<B><I>Performance Unit&#148; </I></B>means a right granted to a Participant pursuant to Section&nbsp;10 to receive Shares or cash, the payment of which is contingent upon achieving certain performance goals established by the Committee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.36.</B> &#147;<B><I>Permitted Transferee</I></B>&#148; means any child, stepchild, grandchild, parent, stepparent, grandparent, spouse,
former spouse, sibling, niece, nephew, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mother-in-law,</FONT></FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">father-in-law,</FONT></FONT> <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">son-in-law,</FONT></FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">daughter-in-law,</FONT></FONT>
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">brother-in-law,</FONT></FONT> or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">sister-in-law</FONT></FONT> (including adoptive relationships) of the Employee, any
person sharing the Employee&#146;s household (other than a tenant or employee), a trust in which these persons (or the Employee) have more than 50% of the beneficial interest, a foundation in which these persons (or the Employee) control the
management of assets, and any other entity in which these persons (or the Employee) own more than 50% of the voting interests. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.37.</B> &#147;<B><I>Plan</I></B>&#148; means this Spyre Therapeutics, Inc. 2016 Equity Incentive Plan, as amended from time to time.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.38.</B> &#147;<B><I>Prior Plan Returning Shares</I></B>&#148; means (a)&nbsp;shares that are subject to stock options or other
awards granted under the Company&#146;s 2015 Equity Incentive Plan (the &#147;<B><I>Prior Plan</I></B>&#148;) that cease to be subject to such stock options or other awards by forfeiture or otherwise after the Original Effective Date,
(b)&nbsp;shares issued under the Prior Plan before or after the Original Effective Date pursuant to the exercise of stock options that are, after the Original Effective Date, forfeited, (c)&nbsp;shares issued under the Prior Plan that are
repurchased by the Company at the original issue price and (d)&nbsp;shares that are subject to stock options or other awards under the Prior Plan that are used to pay the exercise price of an option or withheld to satisfy the tax withholding
obligations related to any award. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.39.</B> &#147;<B><I>Purchase Price</I></B>&#148; means the price to be paid for Shares
acquired under the Plan, other than Shares acquired upon exercise of an Option or SAR. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.40.</B> &#147;<B><I>Restricted Stock
Award</I></B>&#148; means an award of Shares pursuant to Section&nbsp;6 of the Plan, or issued pursuant to the early exercise of an Option. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.41.</B> &#147;<B><I>Restricted Stock Unit</I></B>&#148; means an Award granted pursuant to Section&nbsp;9 of the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.42.</B> &#147;<B><I>Rule <FONT STYLE="white-space:nowrap">16b-3</FONT></I></B>&#148; means Rule
<FONT STYLE="white-space:nowrap">16b-3</FONT> promulgated under the Exchange Act or any successor to Rule <FONT STYLE="white-space:nowrap">16b-3,</FONT> as in effect from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.43.</B> &#147;<B><I>SEC</I></B>&#148; means the United States Securities and Exchange Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.44.</B> &#147;<B><I>Securities Act</I></B>&#148; means the United States Securities Act of 1933, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.45.</B> &#147;<B><I>Service</I></B>&#148; shall mean service as an Employee, Consultant, Director or
<FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director, to the Company or a Parent, Subsidiary or Affiliate, subject to such further limitations as may be set forth in the Plan or the applicable Award Agreement. An Employee will not be deemed
to have ceased to provide Service in the case of (a)&nbsp;sick leave, (b)&nbsp;military leave, or (c)&nbsp;any other leave of absence approved by the Company; <U>provided</U>, that such leave is for a period of not more than 90 days (x)&nbsp;unless
reemployment upon the expiration of such leave is guaranteed by contract or statute, or (y)&nbsp;unless provided otherwise pursuant to formal policy adopted from time to time by the Company&#146;s Board and issued and promulgated to employees in
writing. In the case of any Employee on an approved leave of absence or a reduction in hours worked (for illustrative purposes only, a change in schedule from that of full-time to part-time), the Committee may make such provisions respecting
suspension of or modification to vesting of the Award while on leave from the employ of the Company or a Parent, Subsidiary or Affiliate or during such change in working hours as it may deem appropriate, except that in no event may an Award be
exercised after the expiration of the term set forth in the applicable Award Agreement. In the event of military leave, if required by applicable laws, vesting shall continue for the longest period that vesting continues under any other statutory or
Company approved leave of absence and, upon a Participant&#146;s returning from military leave (under conditions that would entitle him or her to protection upon such return under the Uniform Services Employment and Reemployment Rights Act), he or
she shall be given vesting credit with respect to Awards to the same extent as would have applied had the Participant continued to provide Service to the Company throughout the leave on the same terms as he or she was providing Service immediately
prior to such leave. An employee shall have terminated employment as of the date he or she ceases to provide Service (regardless of whether the termination is in breach of local employment laws or is later found to be invalid) and employment shall
not be extended by any notice period or garden leave mandated by local law, <I>provided however</I>, that a change in status from an employee to a consultant or advisor shall not terminate the service provider&#146;s Service, unless determined by
the Committee, in its discretion. The Committee will have sole discretion to determine whether a Participant has ceased to provide Service and the effective date on which the Participant ceased to provide Service. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.46.</B> &#147;<B><I>Shares</I></B>&#148; means shares of Common Stock and the common stock of any successor entity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.47.</B> &#147;<B><I>Stock Appreciation Right</I></B>&#148; means an Award granted pursuant to Section&nbsp;8 of the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.48.</B> &#147;<B><I>Stock Bonus</I></B>&#148; means an Award granted pursuant to Section&nbsp;7 of the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.49.</B> &#147;<B><I>Stockholder Approval Date</I></B>&#148; means , 2023, the date of the Company&#146;s special meeting of the
stockholders at which this amendment and restatement of the Plan was approved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.50.</B> &#147;<B><I>Subsidiary</I></B>&#148; means
any corporation (other than the Company) in an unbroken chain of corporations beginning with the Company if each of the corporations other than the last corporation in the unbroken chain owns stock possessing 50% or more of the total combined voting
power of all classes of stock in one of the other corporations in such chain. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.51.</B> &#147;<B><I>Treasury
Regulations</I></B>&#148; means regulations promulgated by the United States Treasury Department. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.52.</B> &#147;<B><I>Unvested
Shares</I></B>&#148; means Shares that have not yet vested or are subject to a right of repurchase in favor of the Company (or any successor thereto). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.9
<SEQUENCE>21
<FILENAME>d518298dex109.htm
<DESCRIPTION>EX-10.9
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.9</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.9 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AEGLEA BIOTHERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2016 EMPLOYEE STOCK PURCHASE PLAN </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.
PURPOSE. </B>Aeglea BioTherapeutics, Inc. has adopted this Plan effective as of the date of the IPO. The purpose of this Plan is to provide eligible employees of the Company and the Participating Corporations with a means of acquiring an equity
interest in the Company and to enhance such employees&#146; sense of participation in the Company&#146;s affairs. Capitalized terms not defined elsewhere in the text are defined in Section&nbsp;28. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. ESTABLISHMENT OF PLAN. </B>The Company proposes to grant rights to purchase shares of Common Stock to eligible employees of the Company and its
Participating Corporations pursuant to this Plan. The Company intends this Plan to qualify as an &#147;employee stock purchase plan&#148; under Section&nbsp;423 of the Code (including any amendments to or replacements of such Section), and this Plan
shall be so construed, although the Company makes no undertaking or representation to maintain such qualification. Any term not expressly defined in this Plan but defined in Section&nbsp;423 of the Code shall have the definition provided by
Section&nbsp;423 of the Code. In addition, with regard to offers of options to purchase shares of Common Stock under the Plan to employees working for a Subsidiary or an Affiliate outside the United States, this Plan authorizes the grant of options
under a <FONT STYLE="white-space:nowrap">Non-Section</FONT> 423 Component that is not intended to meet the requirements of Section&nbsp;423 of the Code provided that, to the extent necessary under Section&nbsp;423 of the Code, the other terms and
conditions of this Plan are met. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to Section&nbsp;14, a total of 165,000 shares of Common Stock is reserved for issuance under this Plan. In
addition, on each January&nbsp;1 for each of the calendar years beginning 2019 and ending 2026, the aggregate number of shares of Common Stock reserved for issuance under the Plan shall be increased automatically by the number of shares equal to one
percent (1%) of the total number of outstanding shares of Common Stock and Common Stock equivalents outstanding on the immediately preceding December&nbsp;31 (<U>rounded down to the nearest whole share</U>); <U>provided</U>, that the Board may in
its sole discretion reduce the amount of the increase in any particular year. Subject to Section&nbsp;14, no more than 2,900,000 shares of Common Stock may be issued over the term of this Plan. The number of shares initially reserved for issuance
under this Plan and the maximum number of shares that may be issued under this Plan shall be subject to adjustments effected in accordance with Section&nbsp;14. Any or all such shares may be granted under the Section&nbsp;423 Component. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. </B><B>ADMINISTRATION. </B>The Plan will be administered by the Committee. Subject to the provisions of this Plan and the limitations of
Section&nbsp;423 of the Code or any successor provision in the Code, all questions of interpretation or application of this Plan shall be determined by the Committee and its decisions shall be final and binding upon all eligible employees and
Participants. The Committee will have full and exclusive discretionary authority to construe, interpret and apply the terms of this Plan, to determine eligibility, to designate the Participating Corporations, to determine whether Participating
Corporations shall participate in the Section&nbsp;423 Component or <FONT STYLE="white-space:nowrap">Non-Section</FONT> 423 Component and to decide upon any and all claims filed under the Plan. Every finding, decision and determination made by the
Committee will, to the full extent permitted by law, be final and binding upon all parties. Notwithstanding any provision to the contrary in this Plan, the Committee may adopt rules, <FONT STYLE="white-space:nowrap">sub-plans,</FONT> and/or
procedures relating to the operation and administration of this Plan designed to comply with local laws, regulations or customs or to achieve tax, securities law or other objectives for eligible employees outside of the United States. The Committee
will have the authority to determine the Fair Market Value of the Common Stock (which determination shall be final, binding and conclusive for all purposes) in accordance with Section&nbsp;8 below and to interpret Section&nbsp;8 of this Plan in
connection with circumstances that impact the Fair Market Value. Members of the Committee shall receive no compensation for their services in connection with the administration of this Plan, other than standard fees as established from time to time
by the Board for services rendered by Board members serving on Board committees. All expenses incurred in connection with the administration of this Plan shall be paid by the Company. For purposes of this Plan, the Committee may designate separate
offerings under the Plan (the terms of which need not be identical) in which eligible employees of one or more Participating Corporations will participate, even if the dates of the applicable Offering Periods of each such offering are identical.
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. ELIGIBILITY. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) Any employee of the Company or the Participating Corporations is eligible to participate in an Offering Period under this Plan, except that one or more of
the following categories of employees may be excluded from eligibility under this Plan by the Committee (other than where such exclusion is prohibited by applicable law): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(i) employees who are customarily employed for twenty (20)&nbsp;hours or less per week; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(ii) employees who are customarily employed for five (5)&nbsp;months or less in a calendar year; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(iii) employees who do not meet any other eligibility requirements that the Committee may choose to impose (within the limits permitted by the Code). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, an individual shall not be eligible if his or her participation in this Plan is prohibited by the law of any country having
jurisdiction over him or her, if complying with the laws of the applicable country would cause the Plan to violate Section&nbsp;423 of the Code, or if he or she is subject to a collective bargaining agreement that does not provide for participation
in this Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b) No employee who, together with any other person whose stock would be attributed to such employee pursuant to Section&nbsp;424(d) of the
Code, owns stock or holds options to purchase stock possessing five percent (5%) or more of the total combined voting power or value of all classes of stock of the Company or its Parent or Subsidiary or who, as a result of being granted an option
under this Plan with respect to such Offering Period, would own stock or hold options to purchase stock possessing five percent (5%) or more of the total combined voting power or value of all classes of stock of the Company or its Parent or
Subsidiary shall be granted an option to purchase Common Stock under this Plan. Notwithstanding the foregoing, the rules of Section&nbsp;424(d) of the Code shall apply in determining share ownership and the extent to which shares held under
outstanding equity awards are to be treated as owned by the employee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. OFFERING DATES. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) Each Offering Period of this Plan may be of up to twenty-seven (27)&nbsp;months&#146; duration and shall commence and end at the times designated by the
Committee. Each Offering Period shall consist of one Purchase Period during which Contributions made by Participants are accumulated under this Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b)
The initial Offering Period shall commence on the Effective Date and shall end with the Purchase Date that occurs on August 15, 2016 or another date selected by the Committee which is approximately six (6)&nbsp;months after the commencement of the
initial Offering Period, but no more than twenty-seven (27)&nbsp;months after the commencement of the initial Offering period. The initial Offering Period shall consist of one Purchase Period. Thereafter, a
<FONT STYLE="white-space:nowrap">six-month</FONT> Offering Period shall commence on each February&nbsp;16 and August&nbsp;16, with each such Offering Period also consisting of one <FONT STYLE="white-space:nowrap">six-month</FONT> Purchase Period,
except as otherwise provided by an applicable <FONT STYLE="white-space:nowrap">sub-plan,</FONT> or on such other date determined by the Committee. The Committee may at any time establish a different duration for an Offering Period or Purchase Period
to be effective after the next scheduled Purchase Date, up to a maximum duration of twenty-seven (27)&nbsp;months. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(c) To the extent applicable, if the
Fair Market Value on the first day of the current Offering Period in which a Participant is enrolled is higher than the Fair Market Value on the first day of any subsequent Purchase Period, the current Offering Period shall end, and Participant
shall be automatically enrolled in the subsequent Offering Period, as specified under Section&nbsp;5(a) or Section&nbsp;5(b), as applicable. Any funds accumulated in a Participant&#146;s account prior to the first day of such subsequent Offering
Period will be applied to the purchase of shares on the Purchase Date immediately prior to the first day of such subsequent Offering Period, if any. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. PARTICIPATION IN THIS PLAN. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) Any employee who is an eligible employee determined in accordance with Section&nbsp;4 immediately prior to the initial Offering Period will be
automatically enrolled in the initial Offering Period under this Plan for the maximum number of shares of Common Stock purchasable. With respect to subsequent Offering Periods, any eligible employee determined in accordance with Section&nbsp;4 will
be eligible to participate in this Plan, subject to the requirement of Section&nbsp;6(b) hereof and the other terms and provisions of this Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b) With
respect to Offering Periods after the initial Offering Period, a Participant may elect to participate in this Plan by submitting an enrollment agreement prior to the commencement of the Offering Period (or such earlier date as the Committee may
determine) to which such agreement relates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(c) Once an employee becomes a Participant in an Offering Period, then such Participant will automatically
participate in<B> </B>each subsequent Offering Period commencing immediately following the last day of the prior Offering Period unless the Participant withdraws or is deemed to withdraw from this Plan or terminates further participation in an
Offering Period as set forth in<B> </B>Section&nbsp;11 below. A Participant who is continuing participation pursuant to the preceding sentence is not required to file any additional enrollment agreement in order to continue participation in this
Plan; a Participant who is not continuing participation pursuant to the preceding sentence is required to file an enrollment agreement prior to the commencement of the Offering Period (or such earlier date as the Committee may determine) to which
such agreement relates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. GRANT OF OPTION ON ENROLLMENT. </B>Becoming a Participant with respect to an Offering Period will constitute the grant (as
of the Offering Date) by the Company to such Participant of an option to purchase on the Purchase Date up to that number of shares of Common Stock of the Company determined by a fraction, the numerator of which is the amount accumulated in such
Participant&#146;s Contribution account during such Purchase Period and the denominator of which is the lower of (i)&nbsp;eighty-five percent (85%) of the Fair Market Value of a share of Common Stock on the Offering Date (but in no event less than
the par value of a share of the Common Stock), or (ii)&nbsp;eighty-five percent (85%) of the Fair Market Value of a share of the Common Stock on the Purchase Date;<U> provided, however</U>, that for the Purchase Period within the initial Offering
Period the numerator shall be fifteen percent (15%) of the Participant&#146;s compensation for such Purchase Period, or such lower percentage as determined by the Committee prior to the start of the Offering Period, and provided, further, that the
number of shares of Common Stock subject to any option granted pursuant to this Plan shall not exceed the lesser of (x)&nbsp;the maximum number of shares set by the Committee pursuant to Section l0(b) below with respect to the applicable Purchase
Date, or (y)&nbsp;the maximum number of shares which may be purchased pursuant to Section&nbsp;10(a) below with respect to the applicable Purchase Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8. PURCHASE PRICE. </B>The Purchase Price per share at which a share of Common Stock will be sold in any Offering Period shall be eighty-five percent (85%)
of the lesser of: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) The Fair Market Value on the Offering Date; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b) The Fair Market Value on the Purchase Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. PAYMENT
OF PURCHASE PRICE; CONTRIBUTION CHANGES; SHARE ISSUANCES. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) The Purchase Price shall be accumulated by regular payroll deductions made during each
Offering Period, unless the Committee determines with respect to categories of Participants outside the United States that Contributions may be made in another form due to local legal requirements. The Contributions are made as a percentage of the
Participant&#146;s Compensation in one percent (1%) increments not less than one percent (1%), nor greater than fifteen percent (15%) or such lower limit set by the Committee. <B><I>&#147;</I></B><B><I>Compensation</I></B><B><I>&#148; </I></B>shall
mean base salary (or in foreign jurisdictions, equivalent cash compensation); however, the Committee may at any time prior to the beginning of an Offering Period determine that for that and future Offering Periods, Compensation shall mean all cash
compensation reported on the employee&#146;s Form <FONT STYLE="white-space:nowrap">W-2</FONT> or corresponding local country tax return, including without limitation base salary or regular hourly wages , bonuses, incentive compensation, commissions,
overtime, shift premiums, and draws against commissions. For purposes of determining a Participant&#146;s Compensation, any election by such Participant to reduce his or her regular cash remuneration under Sections 125 or 40l(k) of the Code (or in
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
foreign jurisdictions, equivalent salary deductions) shall be treated as if the Participant did not make such election. Contributions shall commence on the first payday following the last
Purchase Date (with respect to the initial Offering Period, as soon as practicable following the effective date of filing with the U.S. Securities and Exchange Commission a securities registration statement for the Plan) and shall continue to the
end of the Offering Period unless sooner altered or terminated as provided in this Plan. Notwithstanding the foregoing, the terms of any <FONT STYLE="white-space:nowrap">sub-plan</FONT> may permit matching shares without the payment of any purchase
price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b) A Participant may decrease the rate of Contributions during an Offering Period by filing with the Company or a third party designated by the
Company a new authorization for Contributions, with the new rate to become effective no later than the second payroll period commencing after the Company&#146;s receipt of the authorization and continuing for the remainder of the Offering Period
unless changed as described below. A decrease in the rate of Contributions may be made once during an Offering Period, but up to twice during the initial Offering Period, or more frequently under rules determined by the Committee. A Participant may
increase or decrease the rate of Contributions for any subsequent Offering Period by filing with the Company or a third party designated by the Company a new authorization for Contributions prior to the beginning of such Offering Period, or such
other time period as specified by the Committee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(c) A Participant may reduce his or her Contribution percentage to zero during an Offering Period by
filing with the Company or a third party designated by the Company a request for cessation of Contributions. Such reduction shall be effective beginning no later than the second payroll period after the Company&#146;s receipt of the request and no
further Contributions will be made for the duration of the Offering Period. Contributions credited to the Participant&#146;s account prior to the effective date of the request shall be used to purchase shares of Common Stock in accordance with
Subsection (e)&nbsp;below. A reduction of the Contribution percentage to zero shall be treated as such Participant&#146;s withdrawal from such Offering Period and the Plan, effective as of the day after the next Purchase Date following the filing
date of such request with the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) All Contributions made for a Participant are credited to his or her book account under this Plan and are
deposited with the general funds of the Company, except to the extent local legal restrictions outside the United States require segregation of such Contributions. No interest accrues on the Contributions, except to the extent required due to local
legal requirements. All Contributions received or held by the Company may be used by the Company for any corporate purpose, and the Company shall not be obligated to segregate such Contributions, except to the extent necessary to comply with local
legal requirements outside the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(e) On each Purchase Date, so long as this Plan remains in effect and provided that the Participant has not
submitted a signed and completed withdrawal form before that date which notifies the Company that the Participant wishes to withdraw from that Offering Period under this Plan and have all Contributions accumulated in the account maintained on behalf
of the Participant as of that date returned to the Participant, the Company shall apply the funds then in the Participant&#146;s account to the purchase of whole shares of Common Stock reserved under the option granted to such Participant with
respect to the Offering Period to the extent that such option is exercisable on the Purchase Date. The Purchase Price per share for such automatic purchase shall be as specified in Section&nbsp;8 of this Plan. Any fractional share, as calculated
under this Subsection (e), shall be rounded down to the next lower whole share, unless the Committee determines with respect to all Participants that any fractional share shall be credited as a fractional share. Any amount remaining in a
Participant&#146;s account on a Purchase Date that is less than the amount necessary to purchase a full share of Common Stock shall be returned to the Participant, without interest (except to the extent necessary to comply with local legal
requirements outside the United States); however, the Committee may provide that such amounts may be carried forward into the next Purchase Period or Offering Period, as the case may be. In the event that this Plan has been oversubscribed, all funds
not used to purchase shares on the Purchase Date shall be returned to the Participant, without interest (except to the extent required due to local legal requirements outside the United States). No Common Stock shall be purchased on a Purchase Date
on behalf of any employee whose participation in this Plan has terminated prior to such Purchase Date, except to the extent required due to local legal requirements outside the United States. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(f) As promptly as practicable after the Purchase Date, the Company shall issue shares for the
Participant&#146;s benefit representing the shares purchased upon exercise of his or her option to purchase shares hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(g) During a
Participant&#146;s lifetime, his or her option to purchase shares hereunder is exercisable only by him or her. The Participant will have no interest or voting right in shares covered by his or her option until such option has beenexercised. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(h) To the extent required by applicable federal, state, local or foreign law, a Participant shall make arrangements satisfactory to the Company and the
Participating Corporation employing the Participant for the satisfaction of any withholding tax obligations that arise in connection with the Plan. The Company or any Subsidiary or Affiliate, as applicable, may withhold, by any method permissible
under the applicable law, the amount necessary for the Company or Subsidiary or Affiliate, as applicable, to meet applicable withholding obligations, including any withholding required to make available to the Company or Subsidiary or Affiliate, as
applicable, any tax deductions or benefits attributable to the sale or early disposition of shares of Common Stock by a Participant. The Company shall not be required to issue any shares of Common Stock under the Plan until such obligations are
satisfied. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10. LIMITATIONS ON SHARES TO BE PURCHASED. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) Any other provision of the Plan notwithstanding, no Participant shall purchase Common Stock with a Fair Market Value in excess of the following limit:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(i) In the case of Common Stock purchased during an Offering Period that commenced in the current calendar year, the limit shall be equal to (A) $25,000
minus (B)&nbsp;the Fair Market Value of the Common Stock that the Participant previously purchased in the current calendar year (under this Plan and all other employee stock purchase plans of the Company or any Parent or Subsidiary). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(ii) In the case of Common Stock purchased during an Offering Period that commenced in the immediately preceding calendar year, the limit shall be equal to
(A) $50,000 minus (B)&nbsp;the Fair Market Value of the Common Stock that the Participant previously purchased (under this Plan and all other employee stock purchase plans of the Company or any Parent or Subsidiary) in the current calendar year and
in the immediately preceding calendar year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of this Subsection (a), the Fair Market Value of Common Stock shall be determined in each case
as of the beginning of the Offering Period in which such Common Stock is purchased. Employee stock purchase plans not described in Section&nbsp;423 of the Code shall be disregarded. If a Participant is precluded by this Subsection (a)&nbsp;from
purchasing additional Common Stock under the Plan, then his or her Contributions shall automatically be discontinued and shall automatically resume at the beginning of the earliest Purchase Period that will end in the next calendar year (if he or
she then is an eligible employee), provided that when the Company automatically resumes such Contributions, the Company must apply the rate in effect immediately prior to such suspension. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b) In no event shall a Participant be permitted to purchase more than 2,000 shares on any one Purchase Date, or such lesser number as the Committee shall
determine. If a lower limit is set under this Subsection (b), then all Participants will be notified of such limit prior to the commencement of the next Offering Period for which it is to be effective. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(c) If the number of shares to be purchased on a Purchase Date by all Participants exceeds the number of shares then available for issuance under this Plan,
then the Company will make a pro rata allocation of the remaining shares in as uniform a manner as shall be reasonably practicable and as the Committee shall determine to be equitable. In such event, the Company will give notice of such reduction of
the number of shares to be purchased under a Participant&#146;s option to each Participant affected. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Any Contributions accumulated in a Participant&#146;s account that are not used to purchase stock due to
the limitations in this Section&nbsp;10, and not subject to the automatic purchase provision of Section&nbsp;9(e), shall be returned to the Participant as soon as practicable after the end of the applicable Purchase Period, without interest (except
to the extent required due to local legal requirements outside the United States). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11. WITHDRAW AL. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) Each Participant may withdraw from an Offering Period under this Plan pursuant to a method specified for such purpose by the Company. Such withdrawal may
be elected at any time prior to the end of an Offering Period, or such other time period as specified by the Committee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b) Upon withdrawal from this
Plan, the accumulated Contributions shall be returned to the withdrawn Participant, without interest (except to the extent required due to local legal requirements outside the United States), and his or her interest in this Plan shall terminate. In
the event a Participant voluntarily elects to withdraw from this Plan, he or she may not resume his or her participation in this Plan during the same Offering Period, but he or she may participate in any Offering Period under this Plan which
commences on a date subsequent to such withdrawal by filing a new authorization for Contributions in the same manner as set forth in Section&nbsp;6 above for initial participation in this Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12. TERMINATION OF EMPLOYMENT. </B>Termination of a Participant&#146;s employment for any reason, including retirement, death, disability, or the failure
of a Participant to remain an eligible employee of the Company or of a Participating Corporation, immediately terminates his or her participation in this Plan (except as required due to local legal requirements outside the United States). In such
event, accumulated Contributions credited to the Participant&#146;s account will be returned to him or her or, in the case of his or her death, to his or her legal representative, without interest (except to the extent required due to local legal
requirements outside the United States). For purposes of this Section&nbsp;12, an employee will not be deemed to have terminated employment or failed to remain in the continuous employ of the Company or of a Participating Corporation in the case of
sick leave, military leave, or any other leave of absence approved by the Company; <U>provided</U> that such leave is for a period of not more than ninety (90)&nbsp;days or reemployment upon the expiration of such leave is guaranteed by contract or
statute. The Company will have sole discretion to determine whether a Participant has terminated employment and the effective date on which the Participant terminated employment, regardless of any notice period or garden leave required under local
law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13. RETURN OF CONTRIBUTIONS. </B>In the event a Participant&#146;s interest in this Plan is terminated by withdrawal, termination of employment
or otherwise, or in the event this Plan is terminated by the Board, the Company shall deliver to the Participant all accumulated Contributions credited to such Participant&#146;s account. No interest shall accrue on the Contributions of a
Participant in this Plan (except to the extent required due to local legal requirements outside the United States). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14. CAPITAL CHANGES. </B>If the
number of outstanding shares is changed by a stock dividend, recapitalization, stock split, reverse stock split, subdivision, combination, reclassification or similar change in the capital structure of the Company, without consideration, then the
Committee shall adjust the number and class of Common Stock that may be delivered under the Plan, the Purchase Price per share and the number of shares of Common Stock covered by each option under the Plan which has not yet been exercised, and the
numerical limits of Sections 2 and 10 shall be proportionately adjusted, subject to any required action by the Board or the stockholders of the Company and in compliance with the applicable securities laws; provided that fractions of a share will
not be issued. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>15. NONASSIGNABILITY. </B>Neither Contributions credited to a Participant&#146;s account nor any rights with regard to the exercise of
an option or to receive shares under this Plan may be assigned, transferred, pledged or otherwise disposed of in any way (other than by will, the laws of descent and distribution or as provided in Section&nbsp;22 below) by the Participant. Any such
attempt at assignment, transfer, pledge or other disposition shall be void and without effect. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>16. USE OF PARTICIPANT FUNDS AND REPORTS. </B>The Company may use all Contributions received or held by
it under the Plan for any corporate purpose, and the Company will not be required to segregate Participant Contributions (except to the extent required due to local legal requirements outside the United States). Until shares are issued, Participants
will only have the rights of an unsecured creditor unless otherwise required under local law. Each Participant shall receive promptly after the end of each Purchase Period a report of his or her account setting forth the total Contributions
accumulated, the number of shares purchased, the per share price thereof and the remaining cash balance, if any, carried forward to the next Purchase Period or Offering Period, as the case may be. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>17. NOTICE OF DISPOSITION. </B>Each U.S. taxpayer Participant shall notify the Company in writing if the Participant disposes of any of the shares
purchased in any Offering Period pursuant to this Plan if such disposition occurs within two (2)&nbsp;years from the Offering Date or within one (1)&nbsp;year from the Purchase Date on which such shares were purchased (the <B><I>&#147;Notice
Period). </I></B>The Company may, at any time during the Notice Period, place a legend or legends on any certificate representing shares acquired pursuant to this Plan requesting the Company&#146;s transfer agent to notify the Company of any
transfer of the shares. The obligation of the Participant to provide such notice shall continue notwithstanding the placement of any such legend on the certificates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>18. NO RIGHTS TO CONTINUED EMPLOYMENT. </B>Neither this Plan nor the grant of any option hereunder shall confer any right on any employee to remain in the
employ of the Company or any Participating Corporation, or restrict the right of the Company or any Participating Corporation to terminate such employee&#146;s employment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>19. EQUAL RIGHTS AND PRIVILEGES. </B>All eligible employees granted an option under the Section&nbsp;423 Component of this Plan shall have equal rights and
privileges with respect to this Plan or within any separate offering under the Plan so that this Plan qualifies as an &#147;employee stock purchase plan&#148; within the meaning of Section&nbsp;423 or any successor provision of the Code and the
related regulations. Any provision of this Plan which is inconsistent with Section&nbsp;423 or any successor provision of the Code, without further act or amendment by the Company, the Committee or the Board, shall be reformed to comply with the
requirements of Section&nbsp;423. This Section&nbsp;19 shall take precedence over all other provisions in this Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>20. NOTICES. </B>All notices or
other communications by a Participant to the Company under or in connection with this Plan shall be deemed to have been duly given when received in the form specified by the Company at the location, or by the person, designated by the Company for
the receipt thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>21. TERM; STOCKHOLDER APPROVAL. </B>The amendment and restatement of the Plan shall be approved by the stockholders of the
Company, in any manner permitted by applicable corporate law, within twelve (12)&nbsp;months before or after the date this amendment and restatement of the Plan is adopted by the Board. The amendment and restatement of the Plan will become effective
upon approval by stockholders at the 2018 Annual Meeting of Stockholders. No purchase of shares that are subject to such stockholder approval before becoming available under this Plan shall occur prior to stockholder approval of such shares and the
Board or Committee may delay any Purchase Date and postpone the commencement of any Offering Period subsequent to such Purchase Date as deemed necessary or desirable to obtain such approval (provided that if a Purchase Date would occur more than
twenty-seven (27)&nbsp;months after commencement of the Offering Period to which it relates, then such Purchase Date shall not occur and instead such Offering Period shall terminate without the purchase of such shares and Participants in such
Offering Period shall be refunded their Contributions without interest). If the amendment and restatement of the Plan is not approved by the stockholders of the Company within twelve (12)&nbsp;months before or after the date this amendment and
restatement of the Plan is adopted by the Board, then it shall be null and void and the Plan shall continue in effect without the terms approved in the amendment and restatement. This Plan shall continue until the earlier to occur of
(a)&nbsp;termination of this Plan by the Board (which termination may be effected by the Board at any time pursuant to Section&nbsp;25 below), (b) issuance of all of the shares of Common Stock reserved for issuance under this Plan, or (c)&nbsp;the
tenth anniversary of the Effective Date under the Plan. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>22. DESIGNATION OF BENEFICIARY. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) Unless otherwise determined by the Committee, a Participant may file a written designation of a beneficiary who is to receive any cash from the
Participant&#146;s account under this Plan in the event of such Participant&#146;s death prior to a Purchase Date. Such form shall be valid only if it was filed with the Company at the prescribed location before the Participant&#146;s death. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b) If authorized by the Company, such designation of beneficiary may be changed by the Participant at any time by written notice filed with the Company at
the prescribed location before the Participant&#146;s death. In the event of the death of a Participant and in the absence of a beneficiary validly designated under this Plan who is living at the time of such Participant&#146;s death, the Company
shall deliver such cash to the executor or administrator of the estate of the Participant or to the legal heirs of the Participant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>23. CONDITIONS
UPON ISSUANCE OF SHARES; LIMITATION ON SALE OF SHARES. </B>Shares shall not be issued with respect to an option unless the exercise of such option and the issuance and delivery of such shares pursuant thereto shall comply with all applicable
provisions of law, domestic or foreign, including, without limitation, the U.S. Securities Act of 1933, as amended, the U.S. Securities Exchange Act of 1934, as amended, the rules and regulations promulgated thereunder, and the requirements of any
stock exchange or automated quotation system upon which the shares may then be listed, exchange control restrictions and/or securities law restrictions outside the United States, and shall be further subject to the approval of counsel for the
Company with respect to such compliance. Shares may be held in trust or subject to further restrictions as permitted by any subplan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>24. APPLICABLE
LAW. </B>The Plan shall be governed by the substantive laws (excluding the conflict of laws rules) of the State of Delaware. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>25. </B><B>AMENDMENT OR
TERMINATION. </B>The Committee, in its sole discretion, may amend, suspend, or terminate the Plan, or any part thereof, at any time and for any reason. Unless otherwise required by applicable law, if the Plan is terminated, the Committee, in its
discretion, may elect to terminate all outstanding Offering Periods either immediately or upon completion of the purchase of shares of Common Stock on the next Purchase Date (which may be sooner than originally scheduled, if determined by the
Committee in its discretion), or may elect to permit Offering Periods to expire in accordance with their terms (and subject to any adjustment pursuant to Section&nbsp;14). If an Offering Period is terminated prior to its previously-scheduled
expiration, all amounts then credited to Participants&#146; accounts for such Offering Period, which have not been used to purchase shares of Common Stock, shall be returned to those Participants (without interest thereon, except as otherwise
required under local laws) as soon as administratively practicable. Further, the Committee will be entitled to change the Purchase Periods and Offering Periods, limit the frequency and/or number of changes in the amount contributed during an
Offering Period, establish the exchange ratio applicable to amounts contributed in a currency other than U.S. dollars, permit payroll withholding in excess of the amount designated by a Participant in order to adjust for delays or mistakes in the
administration of the Plan, establish reasonable waiting and adjustment periods and/or accounting and crediting procedures to ensure that amounts applied toward the purchase of Common Stock for each Participant properly correspond with amounts
contributed from the Participant&#146;s base salary and other eligible compensation, and establish such other limitations or procedures as the Committee determines in its sole discretion advisable which are consistent with the Plan. Such actions
will not require stockholder approval or the consent of any Participants. However, no amendment shall be made without approval of the stockholders of the Company (obtained in accordance with Section&nbsp;21 above) within twelve (12)&nbsp;months of
the adoption of such amendment (or earlier if required by Section&nbsp;21) if such amendment would: (a)&nbsp;increase the number of shares that may be issued under this Plan; or (b)&nbsp;change the designation of the employees (or class of
employees) eligible for participation in this Plan. In addition, in the event the Board or Committee determines that the ongoing operation of the Plan may result in unfavorable financial accounting consequences, the Board or Committee may, in its
discretion and, to the extent necessary or desirable, modify, amend or terminate the Plan to reduce or eliminate such accounting consequences including, but not limited to: (i)&nbsp;amending the definition of compensation, including with respect to
an Offering Period underway at the time; (ii)&nbsp;altering the Purchase Price for any Offering Period including an Offering Period underway at the time of the </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
change in Purchase Price; (iii)&nbsp;shortening any Offering Period by setting a Purchase Date, including an Offering Period underway at the time of the Committee&#146;s action;
(iv)&nbsp;reducing the maximum percentage of Compensation a participant may elect to set aside as Contributions; and (v)&nbsp;reducing the maximum number of shares a Participant may purchase during any Offering Period. Such modifications or
amendments will not require approval of the stockholders of the Company or the consent of any Participants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>26. CORPORATE TRANSACTIONS. </B>In the
event of a Corporate Transaction, the Offering Period for each outstanding right to purchase Common Stock will be shortened by setting a new Purchase Date and will end on the new Purchase Date. The new Purchase Date shall occur on or prior to the
consummation of the Corporate Transaction, as determined by the Board or Committee, and the Plan shall terminate on the consummation of the Corporate Transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>27. CODE SECTION 409A; TAX QUALIFICATION. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) Options
granted under the Plan generally are exempt from the application of Section&nbsp;409A of the Code. However, options granted to U.S. taxpayers which are not intended to meet the Code Section&nbsp;423 requirements are intended to be exempt from the
application of Section&nbsp;409A of the Code under the short-term deferral exception and any ambiguities shall be construed and interpreted in accordance with such intent. Subject to Subsection (b), options granted to U.S. taxpayers outside of the
Code Section&nbsp;423 requirements shall be subject to such terms and conditions that will permit such options to satisfy the requirements of the short-term deferral exception available under Section&nbsp;409A of the Code, including the requirement
that the shares of Common Stock subject to an option be delivered within the short-term deferral period. Subject to Subsection (b), in the case of a Participant who would otherwise be subject to Section&nbsp;409A of the Code, to the extent the
Committee determines that an option or the exercise, payment, settlement or deferral thereof is subject to Section&nbsp;409A of the Code, the option shall be granted, exercised, paid, settled or deferred in a manner that will comply with
Section&nbsp;409A of the Code, including Treasury regulations and other interpretive guidance issued thereunder, including without limitation any such regulations or other guidance that may be issued after the Effective Date. Notwithstanding the
foregoing, the Company shall have no liability to a Participant or any other party if the option that is intended to be exempt from or compliant with Section&nbsp;409A of the Code is not so exempt or compliant or for any action taken by the
Committee with respect thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b) Although the Company may endeavor to (i)&nbsp;qualify an option for favorable tax treatment under the laws of the
United States or jurisdictions outside of the United States or (ii)&nbsp;avoid adverse tax treatment (e.g., under Section&nbsp;409A of the Code), the Company makes no representation to that effect and expressly disavows any covenant to maintain
favorable or avoid unfavorable tax treatment, notwithstanding anything to the contrary in this Plan, including Subsection (a). The Company shall be unconstrained in its corporate activities without regard to the potential negative tax impact on
Participants under the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>28. DEFINITIONS. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a)<B><I> &#147;Affiliate&#148; </I></B>means any entity, other than a Subsidiary or Parent, (i)&nbsp;that, directly or indirectly, is controlled by, controls
or is under common control with, the Company and (ii)&nbsp;in which the Company has a significant equity interest, in either case as determined by the Committee, whether now or hereafter existing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b)<B><I> &#147;Board&#146;&#146; </I></B>shall mean the Board of Directors of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(c)<B><I> &#147;Code&#148; </I></B>shall mean the U.S. Internal Revenue Code of 1986, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d)<B><I> &#147;Committee&#148; </I></B>shall mean the Compensation Committee of the Board that consists exclusively of one or more members of the Board
appointed by the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(e)<B><I> &#147;Common Stock&#148; </I></B>shall mean the common stock of the Company. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(f)<B><I> &#147;Company&#148; </I></B>shall mean Aeglea Biotherapeutics, Inc. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(g)<B><I>&#147;Contributions&#148; </I></B>means payroll deductions taken from a Participant&#146;s Compensation and used to purchase shares of Common Stock
under the Plan and, to the extent payroll deductions are not permitted by applicable laws (as determined by the Committee in its sole discretion) contributions by other means, provided, however, that allowing such other contributions does not
jeopardize the qualification of the Plan as an &#147;employee stock purchase plan&#148; under Section&nbsp;423 of the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(h)<B><I> &#147;Corporate
Transaction&#148; </I></B>means the occurrence of any of the following events: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(i)any &#147;person&#148; (as such term is used in Sections 13(d) and 14(d)
of the Exchange Act) becomes the &#147;beneficial owner&#148; (as defined in Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of
the total voting power represented by the Company&#146;s then outstanding voting securities; or (ii)&nbsp;the consummation of the sale or disposition by the Company of all or substantially all of the Company&#146;s assets; or (iii)&nbsp;the
consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent
(either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity
or its parent outstanding immediately after such merger or consolidation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(i)<B><I> &#147;Effective Date&#148; </I></B>shall mean the date on which the
Registration Statement covering the initial public offering of the shares of Common Stock is declared effective by the U.S. Securities and Exchange Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(j)<B><I> &#147;Fair Market Value&#148; </I></B>shall mean, as of any date, the value of a share of Common Stock determined as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(1) if such Common Stock is then quoted on the Nasdaq Global Select Market, the Nasdaq Global Market or the Nasdaq Capital Market (collectively, the
<B><I>&#147;Nasdaq Market&#148;), </I></B>its closing price on the Nasdaq Market on the date of determination, or if there are no sales for such date, then the last preceding business day on which there were sales, as reported in <I>The Wall Street
Journal </I>or such other source as the Board or the Committee deems reliable; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(2) if such Common Stock is publicly traded and is then listed on a
national securities exchange, its closing price on the date of determination on the principal national securities exchange on which the Common Stock is listed or admitted to trading as reported in <I>The Wall Street Journal </I>or such other source
as the Board or the Committee deems reliable; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(3) if such Common Stock is publicly traded but is neither quoted on the Nasdaq Market nor listed or
admitted to trading on a national securities exchange, the average of the closing bid and asked prices on the date of determination as reported in <I>The Wall Street Journal </I>or such other source as the Board or the Committee deems reliable; or
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(4) with respect to the initial Offering Period, Fair Market Value on the Offering Date shall be the price at which shares of Common Stock are offered to
the public pursuant to the Registration Statement covering the initial public offering of shares of Common Stock; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(5) if none of the foregoing is
applicable, by the Board or the Committee in good faith. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(k)<B><I></I></B><B><I> &#147;IPO</I></B><B><I>&#148; </I></B>shall mean the initial public
offering of Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(l)<B><I> <FONT STYLE="white-space:nowrap">&#147;Non-Section</FONT> 423 Component&#148;</I></B><I> </I>means the part of the
Plan which is not intended to meet the requirements set forth in Section&nbsp;423 of the Code. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(m)<B><I> &#147;Notice Period&#146;&#146;</I></B><I> </I>shall mean within two (2)&nbsp;years from the
Offering Date or within one (1)&nbsp;year from the Purchase Date on which such shares were purchased. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(n)<B><I> &#147;Offering Date&#148; </I></B>shall
mean the first business day of each Offering Period. However, for the initial Offering Period the Offering Date shall be the Effective Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(o)<B><I>
&#147;Offering Period&#146;&#146; </I></B>shall mean a period with respect to which the right to purchase Common Stock may be granted under the Plan, as determined by the Committee pursuant to Section&nbsp;5(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(p)<B><I> &#147;Parent&#148; </I></B>shall have the same meaning as &#147; parent corporation&#148; in Sections 424(e) and 424(&plusmn;) of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(q)<B><I>&#147;Participant&#148; </I></B>shall mean an eligible employee who meets the eligibility requirements set forth in Section&nbsp;4 and who is either
automatically enrolled in the initial Offering Period or who elects to participate in this Plan pursuant to Section&nbsp;6(b). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(r)<B><I>
&#147;Participating Corporation&#148; </I></B>shall mean any Parent, Subsidiary or Affiliate that the Committee designates from time to time as eligible to participate in this Plan. For purposes of the Section&nbsp;423 Component, only the Parent and
Subsidiaries may be Participating Corporations, provided, however, that at any given time a Parent or Subsidiary that is a Participating Corporation under the Section&nbsp;423 Component shall not be a Participating Corporation under the <FONT
STYLE="white-space:nowrap">Non-Section</FONT> 423 Component. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Committee may provide that any Participating Corporation shall only be eligible to
participate in the <FONT STYLE="white-space:nowrap">Non-Section</FONT> 423 Component. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(s)<B><I> &#147;Plan&#148; </I></B>shall mean this Aeglea
BioTherapeutics, Inc. 2016 Employee Stock Purchase Plan, as may be amended from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(t)<B><I> &#147;Purchase Date&#148; </I></B>shall mean the
last business day of each Purchase Period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(u)<B><I> &#147;Purchase Period&#146;&#146; </I></B>shall mean a period during which Contributions may be made
toward the purchase of Common Stock under the Plan, as determined by the Committee pursuant to Section S(b). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(v)<B><I> &#147;Purchase Price&#148;
</I></B>shall mean the price at which Participants may purchase shares of Common Stock under the Plan, as determined pursuant to Section&nbsp;8. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(w)<B><I> &#147;Section 423 Component&#148; </I></B>means the part of the Plan, which excludes the <FONT STYLE="white-space:nowrap">Non-</FONT>
Section&nbsp;423 Component, pursuant to which options to purchase shares of Common Stock under the Plan that satisfy the requirements for &#147;employee stock purchase plans&#148; set forth in Section&nbsp;423 of the Code may be granted to eligible
employees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(x)<B><I> &#147;Subsidiary&#148; </I></B>shall have the same meaning as &#147;subsidiary corporation&#148; in Sections 424(e) and 424(f) of
the Code. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.10
<SEQUENCE>22
<FILENAME>d518298dex1010.htm
<DESCRIPTION>EX-10.10
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.10</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXHIBIT 10.10 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AEGLEA BIOTHERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2018 EQUITY INDUCEMENT PLAN </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.
</B><B><U>PURPOSE</U></B>. The purpose of this Plan is to provide incentives to attract eligible persons whose potential contributions are important to the success of the Company, and any Parents, Subsidiaries and Affiliates that exist now or in the
future, by offering them an opportunity to participate in the Company&#146;s future performance through the grant of Awards. Each Award granted under the Plan is intended to qualify as an employment inducement award pursuant to Nasdaq Stock Market
Rule 5635(c)(4), and shall be interpreted and administered accordingly. Capitalized terms not defined elsewhere in the text are defined in Section&nbsp;21. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. </B><B><U>SHARES SUBJECT TO THE PLAN</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.1.</B><B> </B><U>Number of Shares Available</U>. Subject to Sections 2.4 and 15 and any other applicable provisions hereof, the total
number of Shares reserved and available for grant and issuance pursuant to this Plan as of the date of adoption of the Plan by the Board is 1,100,000. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.2. </B><U>Lapsed, Returned Awards</U>. Shares subject to Awards, and Shares issued under the Plan under any Award, will again be
available for grant and issuance in connection with subsequent Awards under this Plan to the extent such Shares: (a)&nbsp;are subject to issuance upon exercise of an Option granted under this Plan but which cease to be subject to the Option for any
reason other than exercise of the Option; (b)&nbsp;are subject to Awards granted under this Plan that are forfeited; or (c)&nbsp;are subject to Awards granted under this Plan that otherwise terminate without such Shares being issued. To the extent
an Award under the Plan is paid out in cash or other property rather than Shares, such cash payment will not result in reducing the number of Shares available for issuance under the Plan. Shares used to pay the exercise price of an Award or withheld
to satisfy the tax withholding obligations related to an Award will become available for future grant or sale under the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.3.
</B><U>Minimum Share Reserve</U>. At all times the Company shall reserve and keep available a sufficient number of Shares as shall be required to satisfy the requirements of all outstanding Awards granted under this Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.4. </B><U>Adjustment of Shares</U>. If the number of outstanding shares of Common Stock of the Company is changed by a stock dividend,
recapitalization, stock split, reverse stock split, subdivision, combination, reclassification or similar change in the capital structure of the Company, without consideration, then (a)&nbsp;the number of Shares reserved for issuance and future
grant under the Plan set forth in Section&nbsp;2.1, (b) the Exercise Prices of and number of Shares subject to outstanding Options, and (c)&nbsp;the number of Shares subject to other outstanding Awards shall be proportionately adjusted, subject to
any required action by the Board or the stockholders of the Company and in compliance with applicable securities laws; provided that fractions of a Share will not be issued. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. </B><B><U>ELIGIBILITY</U></B>. Awards may be granted only to a person who, at the time of grant (a)&nbsp;has not previously been an Employee or
Director, or (b)&nbsp;is commencing employment following a bona fide period of <FONT STYLE="white-space:nowrap">non-employment</FONT> by the Company or any Subsidiary; provided that in each case, the grant of the Award is made as a material
inducement to his or her commencement as an employee of the Company or a Subsidiary. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. </B><B><U>ADMINISTRATION</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.1. </B><U>Committee Composition; Authority</U>. This Plan will be administered by the Committee or by the Board acting as the Committee;
provided that any action taken by the Board in connection with the administration of the Plan shall not be deemed approved by the Board unless such actions are approved by a majority of the <FONT STYLE="white-space:nowrap">Non-Employee</FONT>
Directors. Subject to the general purposes, terms and conditions of this Plan, and to the direction of the Board, the Committee will have full power to implement and carry out this Plan. The Committee will have the authority to: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) construe and interpret this Plan, any Award Agreement and any other agreement or document executed pursuant to this Plan; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) prescribe, amend and rescind rules and regulations relating to this Plan or any Award; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) select persons to receive Awards; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) determine the form and terms and conditions, not inconsistent with the terms of the Plan, of any Award granted hereunder. Such terms and
conditions include, but are not limited to, the exercise price, the time or times when Awards may vest and be exercised (which may be based on performance criteria) or settled, any vesting acceleration or waiver of forfeiture restrictions, the
method to satisfy tax withholding obligations or any other tax liability legally due and any restriction or limitation regarding any Award or the Shares relating thereto, based in each case on such factors as the Committee will determine; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) determine the number of Shares or other consideration subject to Awards; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) determine the Fair Market Value in good faith and interpret the applicable provisions of this Plan and the definition of Fair Market Value
in connection with circumstances that impact the Fair Market Value, if necessary; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) determine whether Awards will be granted singly, in
combination with, in tandem with, or as alternatives to, other Awards under this Plan or any other incentive or compensation plan of the Company or any Parent, Subsidiary or Affiliate; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) grant waivers of Plan or Award conditions; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) determine the vesting, exercisability and payment of Awards; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) correct any defect, supply any omission or reconcile any inconsistency in this Plan, any Award or any Award Agreement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k) determine whether an Award has been earned; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(l) reduce or waive any criteria with respect to Performance Factors; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(m) adjust Performance Factors to take into account changes in law and accounting or tax rules as the Committee deems necessary or appropriate
to reflect the impact of extraordinary or unusual items, events or circumstances to avoid windfalls or hardships; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(n) adopt rules and/or
procedures (including the adoption of any subplan under this Plan) relating to the operation and administration of the Plan to accommodate requirements of local law and procedures outside of the United States; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(o) make all other determinations necessary or advisable for the administration of this Plan; and </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(p) to exercise negative discretion on Performance Awards, reducing or eliminating the
amount to be paid to Participants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.2. </B><U>Committee Interpretation and Discretion</U>. Any determination made by the Committee
with respect to any Award shall be made in its sole discretion at the time of grant of the Award or, unless in contravention of any express term of the Plan or Award, at any later time, and such determination shall be final and binding on the
Company and all persons having an interest in any Award under the Plan. Any dispute regarding the interpretation of the Plan or any Award Agreement shall be submitted by the Participant or Company to the Committee for review. The resolution of such
a dispute by the Committee shall be final and binding on the Company and the Participant. The Committee may delegate to one or more executive officers the authority to review and resolve disputes with respect to Awards held by Participants who are
not Insiders, and such resolution shall be final and binding on the Company and the Participant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.3.
</B><U>Section</U><U></U><U>&nbsp;16 of the Exchange Act</U>. Awards granted to Participants who are subject to Section&nbsp;16 of the Exchange Act must be approved by two or more <FONT STYLE="white-space:nowrap">&#147;non-employee</FONT>
directors&#148; (as defined in the regulations promulgated under Section&nbsp;16 of the Exchange Act). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.4. </B><U>Documentation</U>.
The Award Agreement for a given Award, the Plan and any other documents may be delivered to, and accepted by, a Participant or any other person in any manner (including electronic distribution or posting) that meets applicable legal requirements.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.5. </B><U>Foreign Award Recipients</U>. Notwithstanding any provision of the Plan to the contrary, in order to comply with the laws
in other countries in which the Company and its Subsidiaries and Affiliates operate or have Employees eligible for Awards, the Committee, in its sole discretion, shall have the power and authority to: (a)&nbsp;determine which Subsidiaries and
Affiliates shall be covered by the Plan; (b)&nbsp;determine which Employees outside the United States are eligible to participate in the Plan; (c)&nbsp;modify the terms and conditions of any Award granted to individuals outside the United States to
comply with applicable foreign laws; (d)&nbsp;establish subplans and modify exercise procedures and other terms and procedures, to the extent the Committee determines such actions to be necessary or advisable (and such subplans and/or modifications
shall be attached to this Plan as appendices); provided, however, that no such subplans and/or modifications shall increase the share limitations contained in the Plan; and (e)&nbsp;take any action, before or after<B> </B>an Award is made, that the
Committee determines to be necessary or advisable to obtain approval or comply with any local governmental regulatory exemptions or approvals. Notwithstanding the foregoing, the Committee may not take any actions hereunder, and no Awards shall be
granted, that would violate the Exchange Act or any other applicable United States securities law, the Code, or any other applicable United States governing statute or law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. </B><B><U>OPTIONS</U></B>. An Option is the right but not the obligation to purchase a Share, subject to certain conditions, if applicable. The
Committee may grant Options to eligible Employees and will determine the number of Shares subject to the Option, the Exercise Price of the Option, the period during which the Option may vest and be exercised, and all other terms and conditions of
the Option, subject to the following terms of this section. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.1. </B><U>Option Grant</U>. Each Option granted under this Plan will be
a nonqualified stock option. An Option may be, but need not be, awarded upon satisfaction of such Performance Factors during any Performance Period as are set out in advance in the Participant&#146;s individual Award Agreement. If the Option is
being earned upon the satisfaction of Performance Factors, then the Committee will: (a)&nbsp;determine the nature, length and starting date of any Performance Period for each Option; and (b)&nbsp;select from among the Performance Factors to be used
to measure the performance, if any. Performance Periods may overlap and Participants may participate simultaneously with respect to Options that are subject to different performance goals and other criteria. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.2. </B><U>Date of Grant</U>. The date of grant of an Option will be the date on which
the Committee makes the determination to grant such Option, or a specified future date. The Award Agreement will be delivered to the Participant within a reasonable time after the granting of the Option. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.3. </B><U>Exercise Period</U>. Options may be vested and exercisable within the times or upon the conditions as set forth in the Award
Agreement governing such Option; <U>provided</U>, <U>however</U>, that no Option will be exercisable after the expiration of ten (10)&nbsp;years from the date the Option is granted. The Committee also may provide for Options to become exercisable at
one time or from time to time, periodically or otherwise, in such number of Shares or percentage of Shares as the Committee determines. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.4. </B><U>Exercise Price</U>. The Exercise Price of an Option will be determined by the Committee when the Option is granted; provided
that the Exercise Price of an Option will be not less than one hundred percent (100%) of the Fair Market Value of the Shares on the date of grant. Payment for the Shares purchased may be made in accordance with Section&nbsp;7 and the Award Agreement
and in accordance with any procedures established by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.5. </B><U>Method of Exercise</U>. Any Option granted hereunder
will be vested and exercisable according to the terms of the Plan and at such times and under such conditions as determined by the Committee and set forth in the Award Agreement. An Option may not be exercised for a fraction of a Share. An Option
will be deemed exercised when the Company receives: (a)&nbsp;notice of exercise (in such form as the Committee may specify from time to time) from the person entitled to exercise the Option, and (b)&nbsp;full payment for the Shares with respect to
which the Option is exercised (together with applicable withholding taxes). Full payment may consist of any consideration and method of payment authorized by the Committee and permitted by the Award Agreement and the Plan. Shares issued upon
exercise of an Option will be issued in the name of the Participant. Until the Shares are issued (as evidenced by the appropriate entry on the books of the Company or of a duly authorized transfer agent of the Company), no right to vote or receive
dividends or any other rights as a stockholder will exist with respect to the Shares, notwithstanding the exercise of the Option. The Company will issue (or cause to be issued) such Shares promptly after the Option is exercised. No adjustment will
be made for a dividend or other right for which the record date is prior to the date the Shares are issued, except as provided in Section&nbsp;2.4 of the Plan. Exercising an Option in any manner will decrease the number of Shares thereafter
available, both for purposes of the Plan and for sale under the Option, by the number of Shares as to which the Option is exercised. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.6. </B><U>Termination of Service</U>. If the Participant&#146;s Service terminates for any reason except for Cause or the
Participant&#146;s death or Disability, then the Participant may exercise such Participant&#146;s Options only to the extent that such Options would have been exercisable by the Participant on the date Participant&#146;s Service terminates no later
than three (3)&nbsp;months after the date Participant&#146;s Service terminates (or such shorter or longer time period as may be determined by the Committee), but in any event no later than the expiration date of the Options. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Death</U>. If the Participant&#146;s Service terminates because of the Participant&#146;s death (or the Participant dies within three
(3)&nbsp;months after Participant&#146;s Service terminates other than for Cause or because of the Participant&#146;s Disability), then the Participant&#146;s Options may be exercised only to the extent that such Options would have been exercisable
by the Participant on the date Participant&#146;s Service terminates and must be exercised by the Participant&#146;s legal representative, or authorized assignee, no later than twelve (12)&nbsp;months after the date Participant&#146;s Service
terminates (or such shorter time period not less than six (6)&nbsp;months or longer time period as may be determined by the Committee), but in any event no later than the expiration date of the Options. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Disability</U>. If the Participant&#146;s Service terminates because of the
Participant&#146;s Disability, then the Participant&#146;s Options may be exercised only to the extent that such Options would have been exercisable by the Participant on the date Participant&#146;s Service terminates and must be exercised by the
Participant (or the Participant&#146;s legal representative or authorized assignee) no later than twelve (12)&nbsp;months after the date Participant&#146;s Service terminates, but in any event no later than the expiration date of the Options. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Cause</U>. If the Participant is terminated for Cause, then Participant&#146;s Options shall expire on such Participant&#146;s date of
termination of Service, or at such later time and on such conditions as are determined by the Committee, but in any no event later than the expiration date of the Options. Unless otherwise provided in the Award Agreement, Cause shall have the
meaning set forth in the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.7. </B><U>Limitations on Exercise</U>. The Committee may specify a minimum number of Shares that may
be purchased on any exercise of an Option, provided that such minimum number will not prevent any Participant from exercising the Option for the full number of Shares for which it is then exercisable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.8. </B><U>Modification, Extension or Renewal</U>. The Committee may modify, extend or renew outstanding Options and authorize the grant
of new Options in substitution therefor, provided that any such action may not, without the written consent of a Participant, impair any of such Participant&#146;s rights under any Option previously granted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. </B><B><U>RESTRICTED STOCK UNITS</U></B>. A Restricted Stock Unit (&#147;<B><I>RSU</I></B>&#148;) is an award to an eligible Employee covering a number
of Shares that may be settled in cash, or by issuance of those Shares. All RSUs shall be made pursuant to an Award Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.1.
</B><U>Terms of RSUs</U>. The Committee will determine the terms of an RSU including, without limitation: (a)&nbsp;the number of Shares subject to the RSU; (b)&nbsp;the time or times during which the RSU may be settled; (c)&nbsp;the consideration to
be distributed on settlement; and (d)&nbsp;the effect of the Participant&#146;s termination of Service on each RSU; provided that no RSU shall have a term longer than ten (10)&nbsp;years. An RSU may be awarded upon satisfaction of such performance
goals based on Performance Factors during any Performance Period as are set out in advance in the Participant&#146;s Award Agreement. If the RSU is being earned upon satisfaction of Performance Factors, then the Committee will: (x)&nbsp;determine
the nature, length and starting date of any Performance Period for the RSU; (y)&nbsp;select from among the Performance Factors to be used to measure the performance, if any; and (z)&nbsp;determine the number of Shares deemed subject to the RSU.
Performance Periods may overlap and participants may participate simultaneously with respect to RSUs that are subject to different Performance Periods and different performance goals and other criteria. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.2. </B><U>Form and Timing of Settlement</U>. Payment of earned RSUs shall be made as soon as practicable after the date(s) determined by
the Committee and set forth in the Award Agreement. The Committee, in its sole discretion, may settle earned RSUs in cash, Shares, or a combination of both. The Committee may also permit a Participant to defer payment under a RSU to a date or dates
after the RSU is earned provided that the terms of the RSU and any deferral satisfy the requirements of Section&nbsp;409A of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.3. </B><U>Termination of Service</U>. Except as may be set forth in the Participant&#146;s Award Agreement, vesting ceases on such date
Participant&#146;s Service terminates (unless determined otherwise by the Committee). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. </B><B><U>PAYMENT FOR SHARE PURCHASES</U></B>. Payment from a
Participant for Shares purchased pursuant to this Plan may be made in cash or by check or, where approved for the Participant by the Committee and where permitted by law (and to the extent not otherwise set forth in the applicable Award Agreement):
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) by cancellation of indebtedness of the Company to the Participant; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) by surrender of shares of the Company&#146;s common stock by the Participant that have a
Fair Market Value on the date of surrender equal to the aggregate exercise price of the Shares as to which said Award will be exercised or settled; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) by waiver of compensation due or accrued to the Participant for services rendered or to be rendered to the Company or a Parent or
Subsidiary of the Company; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) by consideration received by the Company pursuant to a broker-assisted or other form of cashless exercise
program implemented by the Company in connection with the Plan; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) by any combination of the foregoing; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) by any other method of payment as is permitted by applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8. </B><B><U>WITHHOLDING TAXES</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.1. </B><U>Withholding Generally</U>. Whenever Shares are to be issued in satisfaction of Awards granted under this Plan or a tax event
occurs, the Company may require the Participant to remit to the Company, or to the Parent, Subsidiary or applicable Affiliate employing the Participant, an amount sufficient to satisfy applicable U.S. federal, state, local and international
withholding tax requirements or any other tax or social insurance liability legally due from the Participant prior to the delivery of Shares pursuant to exercise or settlement of any Award. Whenever payments in satisfaction of Awards granted under
this Plan are to be made in cash, such payment will be net of an amount sufficient to satisfy applicable U.S. federal, state, local and international withholding tax or social insurance requirements or any other tax liability legally due from the
Participant. The Fair Market Value of the Shares will be determined as of the date that the taxes are required to be withheld and such Shares shall be valued based on the value of the actual trade or, if there is none, the Fair Market Value of the
Shares as of the previous trading day. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.2. </B><U>Stock Withholding</U>. The Committee, or its delegate(s), as permitted by
applicable law, in its sole discretion and pursuant to such procedures as it may specify from time to time and to limitations of local law, may require or permit a Participant to satisfy such tax withholding obligation or any other tax liability
legally due from the Participant, in whole or in part by (without limitation)&nbsp;(a) paying cash, (b)&nbsp;electing to have the Company withhold otherwise deliverable cash or Shares having a Fair Market Value equal to the minimum statutory amount
required to be withheld, (c)&nbsp;delivering to the Company already-owned shares of the Company&#146;s common stock having a Fair Market Value up to the maximum amount permitted to be withheld or (d)&nbsp;withholding from proceeds of the sale of
otherwise deliverable Shares acquired pursuant to an Award either through a voluntary sale or through a mandatory sale arranged by the Company for up to the maximum statutory amount permitted to be withheld. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. </B><B><U>TRANSFERABILITY</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.1. </B><U>Transfer Generally</U>. Unless determined otherwise by the Committee or pursuant to Section&nbsp;9.2, an Award may not be sold,
pledged, assigned, hypothecated, transferred, or disposed of in any manner other than by will or by the laws of descent or distribution. If the Committee makes an Award transferable, including, without limitation, by instrument to an inter vivos or
testamentary trust in which the Awards are to be passed to beneficiaries upon the death of the trustor (settlor) or by gift or by domestic relations order to a Permitted Transferee, such Award will contain such additional terms and conditions as the
Committee deems appropriate. All Awards shall be exercisable: (a)&nbsp;during the Participant&#146;s lifetime only by (i)&nbsp;the Participant, or (ii)&nbsp;the Participant&#146;s guardian or legal representative; (b)&nbsp;after the
Participant&#146;s death, by the legal representative of the Participant&#146;s heirs or legatees; and (c)&nbsp;by a Permitted Transferee. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.2. </B><U>Award Transfer Program</U>. Notwithstanding any contrary provision of the
Plan, the Committee shall have all discretion and authority to determine and implement the terms and conditions of any Award Transfer Program instituted pursuant to this Section&nbsp;9.2 and shall have the authority to amend the terms of any Award
participating, or otherwise eligible to participate in, the Award Transfer Program, including (but not limited to) the authority to (a)&nbsp;amend (including to extend) the expiration date, post-termination exercise period and/or forfeiture
conditions of any such Award, (b)&nbsp;amend or remove any provisions of the Award relating to the Award holder&#146;s continued Service to the Company or its Parent, Subsidiary, or Affiliate, (c)&nbsp;amend the permissible payment methods with
respect to the exercise or purchase of any such Award, (d)&nbsp;amend the adjustments to be implemented in the event of changes in the capitalization and other similar events with respect to such Award, and (e)&nbsp;make such other changes to the
terms of such Award as the Committee deems necessary or appropriate in its sole discretion. Notwithstanding anything to the contrary in the Plan, in no event will the Committee have the right to determine and implement the terms and conditions of
any Award Transfer Program without stockholder approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10. </B><B><U>PRIVILEGES OF STOCK OWNERSHIP; RESTRICTIONS ON SHARES</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.1. </B><U>Voting and Dividends</U>. No Participant will have any of the rights of a stockholder with respect to any Shares until the
Shares are issued to the Participant, except for any dividend equivalent rights permitted by an applicable Award Agreement (&#147;<B><I>Dividend Equivalent Rights</I></B>&#148;). After Shares are issued to the Participant, the Participant will be a
stockholder and have all the rights of a stockholder with respect to such Shares, including the right to vote and receive all dividends or other distributions made or paid with respect to such Shares; <U>provided</U>, that if such Shares are
Unvested Shares, then any new, additional or different securities the Participant may become entitled to receive with respect to such Shares by virtue of a stock dividend, stock split or any other change in the corporate or capital structure of the
Company will be subject to the same restrictions as the Unvested Shares; <U>provided</U>, <U>further</U>, that the Participant will have no right to retain such stock dividends or stock distributions with respect to Shares that are repurchased at
the Participant&#146;s Exercise Price pursuant to Section&nbsp;10.2. However, the Committee, in its discretion, may provide in the Award Agreement evidencing any Award that the Participant shall be entitled to Dividend Equivalent Rights with respect
to the payment of cash dividends on Shares underlying an Award during the period beginning on the date the Award is granted and ending, with respect to each Share subject to the Award, on the earlier of the date on which the Award is exercised or
settled or the date on which it is forfeited. Such Dividend Equivalent Rights, if any, shall be credited to the Participant in the form of additional whole Shares as of the date of payment of such cash dividends on Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.2. </B><U>Restrictions on Shares</U>. At the discretion of the Committee, the Company may reserve to itself and/or its assignee(s) a
right to repurchase (a &#147;<B><I>Right of Repurchase</I></B>&#148;) a portion of any or all Unvested Shares held by a Participant following such Participant&#146;s termination of Service at any time within ninety (90)&nbsp;days (or such longer or
shorter time determined by the Committee) after the later of the date Participant&#146;s Service terminates and the date the Participant purchases Shares under this Plan, for cash and/or cancellation of purchase money indebtedness, at the
Participant&#146;s Exercise Price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11. </B><B><U>CERTIFICATES</U></B>. All Shares or other securities whether or not certificated, delivered under
this Plan will be subject to such stock transfer orders, legends and other restrictions as the Committee may deem necessary or advisable, including restrictions under any applicable U.S. federal, state or foreign securities law, or any rules,
regulations and other requirements of the SEC or any stock exchange or automated quotation system upon which the Shares may be listed or quoted and any <FONT STYLE="white-space:nowrap">non-U.S.</FONT> exchange controls or securities law restrictions
to which the Shares are subject. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12. </B><B><U>ESCROW; PLEDGE OF SHARES</U></B>. To enforce any restrictions on a Participant&#146;s
Shares, the Committee may require the Participant to deposit all certificates representing Shares, together with stock powers or other instruments of transfer approved by the Committee, appropriately endorsed in blank, with the Company or an agent
designated by the Company to hold in escrow until such restrictions have lapsed or terminated, and the Committee may cause a legend or legends referencing such restrictions to be placed on the certificates. Any Participant who is permitted to
execute a promissory note as partial or full consideration for the purchase of Shares under this Plan will be required to pledge and deposit with the Company all or part of the Shares so purchased as collateral to secure the payment of the
Participant&#146;s obligation to the Company under the promissory note; <U>provided</U>, <U>however</U>, that the Committee may require or accept other or additional forms of collateral to secure the payment of such obligation and, in any event, the
Company will have full recourse against the Participant under the promissory note notwithstanding any pledge of the Participant&#146;s Shares or other collateral. In connection with any pledge of the Shares, the Participant will be required to
execute and deliver a written pledge agreement in such form as the Committee will from time to time approve. The Shares purchased with the promissory note may be released from the pledge on a pro rata basis as the promissory note is paid. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13. </B><B><U>SECURITIES LAW AND OTHER REGULATORY COMPLIANCE</U></B>. An Award will not be effective unless such Award is in compliance with all applicable
U.S. and foreign federal and state securities and exchange control laws, rules and regulations of any governmental body, and the requirements of any stock exchange or automated quotation system upon which the Shares may then be listed or quoted, as
they are in effect on the date of grant of the Award and also on the date of exercise or other issuance. Notwithstanding any other provision in this Plan, the Company will have no obligation to issue or deliver certificates for Shares under this
Plan prior to: (a)&nbsp;obtaining any approvals from governmental agencies that the Company determines are necessary or advisable; and/or (b)&nbsp;completion of any registration or other qualification of such Shares under any state or federal or
foreign law or ruling of any governmental body that the Company determines to be necessary or advisable. The Company will be under no obligation to register the Shares with the SEC or to effect compliance with the registration, qualification or
listing requirements of any foreign or state securities laws, exchange control laws, stock exchange or automated quotation system, and the Company will have no liability for any inability or failure to do so. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14. </B><B><U>NO OBLIGATION TO EMPLOY</U></B>. Nothing in this Plan or any Award granted under this Plan will confer or be deemed to confer on any
Participant any right to continue in the employ of, or to continue any other relationship with, the Company or any Parent, Subsidiary or Affiliate or limit in any way the right of the Company or any Parent, Subsidiary or Affiliate to terminate
Participant&#146;s employment or other relationship at any time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>15. </B><B><U>CORPORATE TRANSACTIONS</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>15.1.</B> <U>Assumption or Replacement of Awards by Successor</U>. In the event that the Company is subject to a Corporate Transaction,
outstanding Awards acquired under the Plan shall be subject to the agreement evidencing the Corporate Transaction, which need not treat all outstanding Awards in an identical manner. Such agreement, without the Participant&#146;s consent, shall
provide for one or more of the following with respect to all outstanding Awards as of the effective date of such Corporate Transaction: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The continuation of an outstanding Award by the Company (if the Company is the successor entity). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The assumption of an outstanding Award by the successor or acquiring entity (if any) of such Corporate Transaction (or by its parents, if
any), which assumption, will be binding on all selected Participants; provided that the exercise price and the number and nature of shares issuable upon exercise of any option or any award that is subject to Section&nbsp;409A of the Code will be
adjusted appropriately pursuant to Section&nbsp;424(a) of the Code. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) The substitution by the successor or acquiring entity in such Corporate Transaction (or
by its parents, if any) of equivalent awards with substantially the same terms for such outstanding Awards (except that the exercise price and the number and nature of shares issuable upon exercise of any option or any award that is subject to
Section&nbsp;409A of the Code will be adjusted appropriately pursuant to Section&nbsp;424(a) of the Code). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The full or partial
acceleration of exercisability or vesting and accelerated expiration of an outstanding Award and lapse of the Company&#146;s right to repurchase or <FONT STYLE="white-space:nowrap">re-acquire</FONT> shares acquired under an Award or lapse of
forfeiture rights with respect to shares acquired under an Award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) The settlement of the full value of such outstanding Award (whether
or not then vested or exercisable) in cash, cash equivalents, or securities of the successor entity (or its parent, if any) with a Fair Market Value equal to the required amount, followed by the cancellation of such Awards; provided however, that
such Award may be cancelled if such Award has no value, as determined by the Committee, in its discretion. Subject to Section&nbsp;409A of the Code, such payment may be made in installments and may be deferred until the date or dates the Award would
have become exercisable or vested. Such payment may be subject to vesting based on the Participant&#146;s continued service, provided that the vesting schedule shall not be less favorable to the Participant than the schedule under which the Award
would have become vested or exercisable. For purposes of this Section&nbsp;15.1(e), the Fair Market Value of any security shall be determined without regard to any vesting conditions that may apply to such security. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) The cancellation of outstanding Awards in exchange for no consideration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board shall have full power and authority to assign the Company&#146;s right to repurchase or <FONT STYLE="white-space:nowrap">re-acquire</FONT> or
forfeiture rights to such successor or acquiring corporation. In addition, in the event such successor or acquiring corporation refuses to assume, convert, replace or substitute Awards, as provided above, pursuant to a Corporate Transaction, the
Committee will notify the Participant in writing or electronically that such Award will be exercisable for a period of time determined by the Committee in its sole discretion, and such Award will terminate upon the expiration of such period. Awards
need not be treated similarly in a Corporate Transaction. In addition, following a Corporate Transaction, 100% of the total number of Shares subject to each Award held by an Employee shall become vested if the holder is subject to an Involuntary
Termination within 12 months after the Corporate Transaction; it being understood that the vesting acceleration set forth in the preceding clause is in addition to vesting of the Award or Shares that has occurred prior to the Involuntary
Termination, subject to the Participant executing a general release (in a form prescribed by the Company) of all known and unknown claims that he or she may then have against the Company or persons affiliated with the Company and such release has
become effective and agreeing not to prosecute any legal action or other proceeding based upon any of such claims except to the extent otherwise provided in an individual award agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>16. </B><B><U>TERM OF PLAN/GOVERNING LAW</U></B>. Unless earlier terminated as provided herein, this Plan will become effective on the Effective Date and
will terminate ten (10)&nbsp;years from the date this Plan is adopted by the Board. This Plan and all Awards granted hereunder shall be governed by and construed in accordance with the laws of the State of Delaware (excluding its conflict of law
rules). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>17. </B><B><U>AMENDMENT OR TERMINATION OF PLAN</U></B>. The Board may at any time terminate or amend this Plan in any respect, including,
without limitation, amendment of any form of Award Agreement or instrument to be executed pursuant to this Plan; <U>provided</U>, <U>however</U>, that the Board will not, without the approval of the stockholders of the Company, amend this Plan in
any manner that requires such stockholder approval; <U>provided further</U>, that a Participant&#146;s Award shall be governed by the version of this Plan then in effect at the time such Award was granted. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>18. </B><B><U>NONEXCLUSIVITY OF THE PLAN</U></B>. Neither the adoption of this Plan by the Board nor any
provision of this Plan will be construed as creating any limitations on the power of the Board to adopt such additional compensation arrangements as it may deem desirable, including, without limitation, the granting of stock awards and bonuses
otherwise than under this Plan, and such arrangements may be either generally applicable or applicable only in specific cases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>19. </B><B><U>INSIDER
TRADING POLICY</U></B>. Each Participant who receives an Award shall comply with any policy adopted by the Company from time to time covering transactions in the Company&#146;s securities by Employees, officers and/or directors of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>20. </B><B><U>ALL AWARDS SUBJECT TO COMPANY CLAWBACK OR RECOUPMENT POLICY</U></B>. All Awards shall be subject to clawback or recoupment pursuant to any
compensation clawback or recoupment policy adopted by the Board or required by law during the term of Participant&#146;s employment or other service with the Company that is applicable to executive officers, employees, directors or other service
providers of the Company, and in addition to any other remedies available under such policy and applicable law, may require the cancelation of outstanding Awards and the recoupment of any gains realized with respect to Awards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>21. </B><B><U>DEFINITIONS</U></B>. As used in this Plan, and except as elsewhere defined herein, the following terms will have the following meanings: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>21.1. </B>&#147;<B><I>Affiliate</I></B>&#148; means any person or entity that directly or indirectly through one or more intermediaries
controls, or is controlled by, or is under common control with, the Company, including any general partner, managing member, officer or director of the Company, in each case as of the date on which, or at any time during the period for which, the
determination of affiliation is being made. For purposes of this definition, the term &#147;control&#148; (including the correlative meanings of the terms &#147;controlled by&#148; and &#147;under common control with&#148;), as used with respect to
any person or entity, means the possession, directly or indirectly, of the power to direct or cause the direction of the management policies of such person or entity, whether through the ownership of voting securities or by contract or otherwise.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>21.2. </B>&#147;<B><I>Award</I></B>&#148; means any award under the Plan, including any Option or Restricted Stock Unit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>21.3. </B>&#147;<B><I>Award Agreement</I></B>&#148; means, with respect to each Award, the written or electronic agreement between the
Company and the Participant setting forth the terms and conditions of the Award, and country-specific appendix thereto for grants to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> Participants, which shall be in substantially a form (which need
not be the same for each Participant) that the Committee (or in the case of Award agreements that are not used for Insiders, the Committee&#146;s delegate(s)) has from time to time approved, and will comply with and be subject to the terms and
conditions of this Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>21.4. </B>&#147;<B><I>Award Transfer Program</I></B>&#148; means any program instituted by the Committee
which would permit Participants the opportunity to transfer any outstanding Awards to a financial institution or other person or entity approved by the Committee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>21.5.</B> &#147;<B><I>Board</I></B>&#148; means the Board of Directors of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>21.6. </B>&#147;<B><I>Cause</I></B>&#148; means (i)&nbsp;an unauthorized use or disclosure by Participant of the Company&#146;s
confidential information or trade secrets, which use or disclosure causes material harm to the Company or is reasonably likely to cause material harm to the Company, (ii)&nbsp;a material breach of any agreement between Participant and the Company,
(iii)&nbsp;a material failure to comply with the Company&#146;s written policies or rules that has caused or is reasonably likely to cause material injury to the Company, its successor, or its affiliates, or any of their business,
(iv)&nbsp;conviction of, or plea of &#147;guilty&#148; or &#147;no contest&#148; to, a felony under the laws of </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the United States or any state thereof, (v)&nbsp;willful misconduct that has caused or is reasonably likely to cause material injury to the Company, its successor, or its affiliates, or any of
their business, (vi)&nbsp;embezzlement, (vii) failure to cooperate with the Company in any investigation or formal proceeding if the Company has requested Participant&#146;s reasonable cooperation, (viii)&nbsp;violation of any applicable federal,
state or foreign statutes or laws that govern or regulate employment, pharmaceutical drugs or securities, including but not limited to the laws enforced by the federal Equal Employment Opportunity Commission, Department of Labor, Food and Drug
Administration, Securities and Exchange Commission and Department of Justice or (ix)&nbsp;a continued failure to perform assigned duties after receiving written notification of such failure from the Company&#146;s Chief Executive Officer;
<I>provided that</I> Participant must be provided with written notice of Participant&#146;s termination for &#147;Cause&#148; and Participant must be provided with a thirty (30)&nbsp;day period following Participant&#146;s receipt of such notice to
cure the event(s) that trigger &#147;Cause,&#148; with the Company&#146;s Chief Executive Officer making the final determination whether Participant has cured any Cause. The determination as to whether a Participant is being terminated for Cause
shall be made in good faith by the Company and shall be final and binding on the Participant. The foregoing definition does not in any way limit the Company&#146;s ability to terminate a Participant&#146;s employment or service at any time as
provided in Section&nbsp;14 above, and the term &#147;Company&#148; will be interpreted to include any Parent, Subsidiary or Affiliate, as appropriate.<B><I> </I></B>Notwithstanding the foregoing, the foregoing definition of &#147;Cause&#148; may,
in part or in whole, be modified or replaced in each individual employment agreement or Award Agreement with any Participant, provided that such document supersedes the definition provided in this Section&nbsp;21.6. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>21.7. </B>&#147;<B><I>Code</I></B>&#148; means the United States Internal Revenue Code of 1986, as amended, and the regulations promulgated
thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>21.8.</B> &#147;<B><I>Committee</I></B>&#148; means the Compensation Committee of the Board or the Board acting in such
capacity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>21.9. </B>&#147;<B><I>Common Stock</I></B>&#148; means the common stock of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>21.10. </B>&#147;<B><I>Company</I></B>&#148; means Aeglea BioTherapeutics, Inc., or any successor corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>21.11.</B> &#147;<B><I>Corporate Transaction</I></B>&#148; means the occurrence of any of the following events: (a)&nbsp;any
&#147;Person&#148; (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becomes the &#147;beneficial owner&#148; (as defined in Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> of the Exchange Act), directly or indirectly, of
securities of the Company representing more than fifty percent (50%) of the total voting power represented by the Company&#146;s then-outstanding voting securities; provided, however, that for purposes of this subclause (a)&nbsp;the acquisition of
additional securities by any one Person who is considered to own more than fifty percent (50%) of the total voting power of the securities of the Company will not be considered a Corporate Transaction; (b)&nbsp;the consummation of the sale or
disposition by the Company of all or substantially all of the Company&#146;s assets; (c)&nbsp;the consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the
voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the
total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation; (d)&nbsp;any other transaction which qualifies as a &#147;corporate
transaction&#148; under Section&nbsp;424(a) of the Code wherein the stockholders of the Company give up all of their equity interest in the Company (except for the acquisition, sale or transfer of all or substantially all of the outstanding shares
of the Company) or (e)&nbsp;a change in the effective control of the Company that occurs on the date that a majority of members of the Board is replaced during any twelve (12)&nbsp;month period by members of the Board whose appointment or election
is not endorsed by a majority of the members of the Board prior to the date of the appointment or election. For purpose of this subclause (e), if any Person is considered to be in effective control of the Company, the acquisition of additional
control of the Company </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
by the same Person will not be considered a Corporate Transaction. For purposes of this definition, Persons will be considered to be acting as a group if they are owners of a corporation that
enters into a merger, consolidation, purchase or acquisition of stock, or similar business transaction with the Company. Notwithstanding the foregoing, to the extent that any amount constituting deferred compensation (as defined in Section&nbsp;409A
of the Code) would become payable under this Plan by reason of a Corporate Transaction, such amount shall become payable only if the event constituting a Corporate Transaction would also qualify as a change in ownership or effective control of the
Company or a change in the ownership of a substantial portion of the assets of the Company, each as defined within the meaning of Code Section&nbsp;409A, as it has been and may be amended from time to time, and any proposed or final Treasury
Regulations and IRS guidance that has been promulgated or may be promulgated thereunder from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>21.12.
</B>&#147;<B><I>Director</I></B>&#148; means a member of the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>21.13. </B>&#147;<B><I>Disability</I></B>&#148; means that the
Participant is unable to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment that can be expected to result in death or can be expected to last for a continuous period of not less than 12
months. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>21.14. </B>&#147;<B><I>Effective Date</I></B>&#148; means February&nbsp;20, 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>21.15. </B>&#147;<B><I>Employee</I></B>&#148; means any person, including Officers, employed by the Company or any Parent, Subsidiary or
Affiliate. Neither service as a Director nor payment of a director&#146;s fee by the Company will be sufficient to constitute &#147;employment&#148; by the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>21.16. </B>&#147;<B><I>Exchange Act</I></B>&#148; means the United States Securities Exchange Act of 1934, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>21.17.</B> &#147;<B><I>Exercise Price</I></B>&#148; means, with respect to an Option, the price at which a holder may purchase the Shares
issuable upon exercise of an Option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>21.18. </B>&#147;<B><I>Fair Market Value</I></B>&#148; means, as of any date, the value of a
share of the Company&#146;s Common Stock determined as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) if such Common Stock is publicly traded and is then listed on a
national securities exchange, its closing price on the date of determination on the principal national securities exchange on which the Common Stock is listed or admitted to trading as reported in <I>The Wall Street </I>Journal or such other source
as the Committee deems reliable; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) if such Common Stock is publicly traded but is neither listed nor admitted to trading on a national
securities exchange, the average of the closing bid and asked prices on the date of determination as reported in <I>The Wall Street Journal</I> or such other source as the Committee deems reliable; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) if none of the foregoing is applicable, by the Board or the Committee in good faith. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>21.19. </B>&#147;<B>Good Reason</B>&#148; means, without the Participant&#146;s consent, (i)&nbsp;a material reduction in the
Participant&#146;s level of responsibility and/or scope of authority, (ii)&nbsp;a reduction by more than 10% in Participant&#146;s base salary (other than a reduction generally applicable to Participant officers of the Company and in generally the
same proportion as for the Participant), or (iii)&nbsp;relocation of the Participant&#146;s principal workplace by more than thirty-five (35)&nbsp;miles from Participant&#146;s then current place of employment. For the purpose of clause (i), a
change in responsibility shall not be deemed to occur (A)&nbsp;solely because Participant is part of a larger organization or (B)&nbsp;solely because of a change in title. For the Participant to receive the benefits under this Agreement as a result
of a voluntary resignation under this subsection (e), all of the </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
following requirements must be satisfied: (1)&nbsp;the Participant must provide notice to the Company of his or her intent to assert Good Reason within sixty (60)&nbsp;days of the initial
existence of one or more of the conditions set forth in subclauses (i)&nbsp;through (iii); (2) the Company will have thirty (30)&nbsp;days (the &#147;<B><I>Company Cure Period</I></B>&#148;) from the date of such notice to remedy the condition and,
if it does so, the Participant may withdraw his or her resignation or may resign with no benefits; and (3)&nbsp;any termination of employment under this provision must occur within ten (10)&nbsp;days of the earlier of expiration of the Company Cure
Period or written notice from the Company that it will not undertake to cure the condition set forth in subclauses (i)&nbsp;through (iii). Should the Company remedy the condition as set forth above and then one or more of the conditions arises again
within twelve months following the occurrence of a Change in Control, the Participant may assert Good Reason again subject to all of the conditions set forth herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>21.20.</B>&#147; <B><I>Insider</I></B>&#148; means an officer or director of the Company or any other person whose transactions in the
Company&#146;s Common Stock are subject to Section&nbsp;16 of the Exchange Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>21.21. </B>&#147;<B><I>Involuntary
Termination</I></B>&#148; means either (a)&nbsp;termination of Service without Cause or (b)&nbsp;resignation from Service for Good Reason. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>21.22. </B>&#147;<B><I>IRS</I></B>&#148; means the United States Internal Revenue Service. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>21.23. </B>&#147;<B><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director</I></B>&#148; means a Director of the Company who is
not an Employee of the Company or any Parent, Subsidiary or Affiliate, and who qualifies as &#147;independent&#148; within the meaning of Nasdaq Stock Market Rule 5605(a)(2), or any successor rule, if the Company&#146;s securities are traded on the
Nasdaq Stock Market, or if the requirements of any other established stock exchange on which the Company&#146;s securities are traded, as such rules or requirements may be amended from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>21.24. </B>&#147;<B><I>Option</I></B>&#148; means an award of an option to purchase Shares pursuant to Section&nbsp;5. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>21.25. </B>&#147;<B><I>Parent</I></B>&#148; means any corporation (other than the Company) in an unbroken chain of corporations ending with
the Company if each of such corporations other than the Company owns stock possessing fifty percent (50%) or more of the total combined voting power of all classes of stock in one of the other corporations in such chain. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>21.26. </B>&#147;<B><I>Participant</I></B>&#148; means a person who holds an Award under this Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>21.27.</B><I> </I><I>&#147;</I><B><I>Performance Factors</I></B><I>&#148;</I> means the factors selected by the Committee and specified in
an Award Agreement to determine whether the performance goals established by the Committee applicable to any Awards have been satisfied. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>21.28.</B> &#147;<B><I>Performance Period</I></B>&#148; means one or more periods of time, which may be of varying and overlapping
durations, as the Committee may select, over which the attainment of one or more Performance Factors will be measured for the purpose of determining a Participant&#146;s right to, and the payment of, a Performance Award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>21.29. </B>&#147;<B><I>Permitted Transferee</I></B>&#148; means any child, stepchild, grandchild, parent, stepparent, grandparent, spouse,
former spouse, sibling, niece, nephew, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mother-in-law,</FONT></FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">father-in-law,</FONT></FONT> <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">son-in-law,</FONT></FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">daughter-in-law,</FONT></FONT>
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">brother-in-law,</FONT></FONT> or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">sister-in-law</FONT></FONT> (including adoptive relationships) of the Employee, any
person sharing the Employee&#146;s household (other than a tenant or employee), a trust in which these persons (or the Employee) have more than 50% of the beneficial interest, a foundation in which these persons (or the Employee) control the
management of assets, and any other entity in which these persons (or the Employee) own more than 50% of the voting interests. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>21.30. </B>&#147;<B><I>Plan</I></B>&#148; means this Aeglea BioTherapeutics, Inc.<B>
</B>2018 Equity Inducement Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>21.31. </B>&#147;<B><I>Restricted Stock Unit</I></B>&#148; means an Award granted pursuant to
Section&nbsp;6 of the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>21.32. </B>&#147;<B><I>SEC</I></B>&#148; means the United States Securities and Exchange Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>21.33. </B>&#147;<B><I>Securities Act</I></B>&#148; means the United States Securities Act of 1933, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>21.34. </B>&#147;<B><I>Service</I></B>&#148; shall mean service as an Employee, Director or consultant to the Company or a Parent or
Subsidiary, subject to such further limitations as may be set forth in the Plan or the applicable Award Agreement. An employee will not be deemed to have ceased to provide Service in the case of leave of absence approved by the Company. In the case
of any employee on an approved leave of absence or a reduction in hours worked (for illustrative purposes only, a change in schedule from that of full-time to part-time), the Committee may make such provisions respecting suspension of, or
modification to, vesting of the Award while on leave from the employ of the Company or a Parent or Subsidiary or during such change in working hours as it may deem appropriate, except that in no event may an Award be exercised after the expiration
of the term set forth in the applicable Award Agreement. In the absence of such a determination, vesting of Awards shall be tolled during any unpaid leave of absence (unless otherwise required by applicable law). In the event of military leave, if
required by applicable laws, vesting shall continue for the longest period that vesting continues under any other statutory or Company approved leave of absence and, upon a Participant&#146;s returning from military leave (under conditions that
would entitle him or her to protection upon such return under the Uniform Services Employment and Reemployment Rights Act), he or she shall be given vesting credit with respect to Awards to the same extent as would have applied had the Participant
continued to provide Service throughout the leave on the same terms as he or she was providing Service immediately prior to such leave. Service shall not be considered interrupted or terminated in the case of a transfer between locations of the
Company or between the Company, its Parent, Subsidiaries or Affiliates, or their respective successors, or a change in status from an employee to a consultant or from a consultant to an employee. The Committee will have sole discretion to determine
whether a Participant has ceased to provide Service and the effective date on which the Participant ceased to provide Service. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>21.35.
</B>&#147;<B><I>Shares</I></B>&#148; means shares of Common Stock and the common stock of any successor entity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>21.36.</B>
&#147;<B><I>Subsidiary</I></B>&#148; means any corporation (other than the Company) in an unbroken chain of corporations beginning with the Company if each of the corporations other than the last corporation in the unbroken chain owns stock
possessing fifty percent (50%) or more of the total combined voting power of all classes of stock in one of the other corporations in such chain. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>21.37. </B>&#147;<B><I>Treasury Regulations</I></B>&#148; means regulations promulgated by the United States Treasury Department. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>21.38.</B> &#147;<B><I>Unvested Shares</I></B>&#148; means Shares that have not yet vested or are subject to a right of repurchase in favor
of the Company (or any successor thereto). </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FIRST AMENDMENT TO THE </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AEGLEA BIOTHERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2018 EQUITY INDUCEMENT PLAN </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>,<B> </B>Aeglea Biotherapeutics, Inc., a Delaware corporation (the &#147;<U>Company</U>&#148;) maintains the Aeglea
Biotherapeutics, Inc. 2018 Equity Inducement Plan (the &#147;<U>Plan</U>&#148;); and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, pursuant to Section&nbsp;17 of the
Plan, the Board of Directors (the &#147;<U>Board</U>&#148;) may amend the Plan at any time and for any purpose as permitted by law, including to increase the maximum number of Shares for which awards may be granted under the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NOW, THEREFORE</B>, pursuant to its authority under Section&nbsp;17 of the Plan, the Board hereby amends the Plan as follows, effective as
of June&nbsp;22, 2023 (the &#147;<U>Amendment Effective Date</U>&#148;): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Section&nbsp;2.1 of the Plan is hereby amended and restated in its entirety to read as follows:
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>2.1</B> <B><U>Number of Shares Available</U></B>. Subject to Sections 2.4 and 15 and any other
applicable provisions hereof, the total number of Shares reserved and available for grant and issuance pursuant to this Plan is 71,100,000.&#148; </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This First Amendment shall be governed by and construed in accordance with the laws of the State of Delaware
(excluding its conflict of law rules). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All capitalized terms used but not otherwise defined herein shall have the meaning assigned to them in the
Plan. Except as expressly amended hereby, the Plan shall remain in full force and effect in accordance with its terms. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page Follows] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the undersigned has executed this First Amendment to the Aeglea
Biotherapeutics, Inc. 2018 Equity Inducement Plan, effective as of the Amendment Effective Date. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>AEGLEA BIOTHERAPEUTICS, INC. </B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jonathan Alspaugh</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Jonathan Alspaugh</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">President and Chief Financial Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F<SMALL>IRST</SMALL> A<SMALL>MENDMENT</SMALL> <SMALL>TO</SMALL> <SMALL>THE</SMALL> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A<SMALL>EGLEA</SMALL> B<SMALL>IOTHERAPEUTICS</SMALL>, I<SMALL>NC</SMALL>. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2018 E<SMALL>QUITY</SMALL> I<SMALL>NDUCEMENT</SMALL> P<SMALL>LAN</SMALL> </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECOND AMENDMENT TO THE </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AEGLEA BIOTHERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2018 EQUITY INDUCEMENT PLAN </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>,<B> </B>Aeglea BioTherapeutics, Inc., a Delaware corporation (the &#147;<U>Company</U>&#148;) maintains the Aeglea
BioTherapeutics, Inc. 2018 Equity Inducement Plan, as amended on June&nbsp;22, 2023 (the &#147;<U>Plan</U>&#148;); and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>,
pursuant to Section&nbsp;17 of the Plan, the Board of Directors (the &#147;<U>Board</U>&#148;) may amend the Plan at any time and for any purpose as permitted by law, including to increase the maximum number of Shares for which awards may be granted
under the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NOW, THEREFORE</B>, pursuant to its authority under Section&nbsp;17 of the Plan, the Board hereby amends the Plan as
follows, effective as of August&nbsp;30, 2023 (the &#147;<U>Amendment Effective Date</U>&#148;): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Section&nbsp;2.1 of the Plan is hereby amended and restated in its entirety to read as follows:
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>2.1</B> <B><U>Number of Shares Available</U></B>. Subject to Sections 2.4 and 15 and any other
applicable provisions hereof, the total number of Shares reserved and available for grant and issuance pursuant to this Plan is 101,100,000.&#148; </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This Second Amendment shall be governed by and construed in accordance with the laws of the State of Delaware
(excluding its conflict of law rules). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All capitalized terms used but not otherwise defined herein shall have the meaning assigned to them in the
Plan. Except as expressly amended hereby, the Plan shall remain in full force and effect in accordance with its terms. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page Follows] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the undersigned has executed this Second Amendment to the Aeglea
BioTherapeutics, Inc. 2018 Equity Inducement Plan, effective as of the Amendment Effective Date. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>AEGLEA BIOTHERAPEUTICS, INC. </B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Cameron Turtle</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Cameron Turtle</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Operating Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S<SMALL>ECOND</SMALL> A<SMALL>MENDMENT</SMALL> <SMALL>TO</SMALL> <SMALL>THE</SMALL> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A<SMALL>EGLEA</SMALL> B<SMALL>IO</SMALL>T<SMALL>HERAPEUTICS</SMALL>, I<SMALL>NC</SMALL>. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2018 E<SMALL>QUITY</SMALL> I<SMALL>NDUCEMENT</SMALL> P<SMALL>LAN</SMALL> </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THIRD AMENDMENT TO THE </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AEGLEA BIOTHERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2018 EQUITY INDUCEMENT PLAN </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>,<B> </B>Aeglea BioTherapeutics, Inc., a Delaware corporation (the &#147;<U>Company</U>&#148;) maintains the
Aeglea BioTherapeutics, Inc. 2018 Equity Inducement Plan, as amended on June&nbsp;22, 2023 and August&nbsp;30, 2023 (the &#147;<U>Plan</U>&#148;); and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, pursuant to Section&nbsp;17 of the Plan, the Board of Directors (the &#147;<U>Board</U>&#148;) may amend the
Plan at any time and for any purpose as permitted by law, including to increase the maximum number of Shares for which awards may be granted under the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NOW, THEREFORE</B>, pursuant to its authority under Section&nbsp;17 of the Plan, the Board hereby amends the Plan as follows, effective as
of October&nbsp;30, 2023 (the &#147;<U>Amendment Effective</U> <U>Date</U>&#148;): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Section&nbsp;2.1 of the Plan is hereby amended and restated in its entirety to read as follows:
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>2.1 </B><B><U>Number of Shares Available</U></B>. Subject to Sections 2.4 and 15 and any other
applicable provisions hereof, the total number of Shares reserved and available for grant and issuance pursuant to this Plan is 6,044,000.&#148; </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This Third Amendment shall be governed by and construed in accordance with the laws of the State of Delaware
(excluding its conflict of law rules). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All capitalized terms used but not otherwise defined herein shall have the meaning assigned to them in the
Plan. Except as expressly amended hereby, the Plan shall remain in full force and effect in accordance with its terms. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page Follows] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the undersigned has executed this Third Amendment to the Aeglea
BioTherapeutics, Inc. 2018 Equity Inducement Plan, effective as of the Amendment Effective Date. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>AEGLEA BIOTHERAPEUTICS, INC. </B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Cameron Turtle</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Cameron Turtle</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Operating Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">T<SMALL>HIRD</SMALL> A<SMALL>MENDMENT</SMALL> <SMALL>TO</SMALL> <SMALL>THE</SMALL> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A<SMALL>EGLEA</SMALL> B<SMALL>IO</SMALL>T<SMALL>HERAPEUTICS</SMALL>, I<SMALL>NC</SMALL>. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2018 E<SMALL>QUITY</SMALL> I<SMALL>NDUCEMENT</SMALL> P<SMALL>LAN</SMALL> </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOURTH AMENDMENT TO THE </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AEGLEA BIOTHERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2018 EQUITY INDUCEMENT PLAN </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>,<B> </B>Spyre Therapeutics, Inc., a Delaware corporation (the &#147;<U>Company</U>&#148;) maintains the Aeglea BioTherapeutics,
Inc. 2018 Equity Inducement Plan, as amended on June&nbsp;22, 2023, August&nbsp;30, 2023 and October&nbsp;30, 2023 (the &#147;<U>Plan</U>&#148;); and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, pursuant to Section&nbsp;17 of the Plan, the Board of Directors (the &#147;<U>Board</U>&#148;) may amend the Plan at any time
and for any purpose as permitted by law; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, pursuant to an Amended and Restated Certificate of Incorporation, the
Company changed its name from &#147;Aeglea BioTherapeutics, Inc.&#148; to &#147;Spyre Therapeutics, Inc.&#148; effective November&nbsp;28, 2023; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, the Board has authorized an officer of the Company to amend the Plan to incorporate the Company&#146;s name change. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NOW, THEREFORE</B>, pursuant to its authority under Section&nbsp;17 of the Plan, the Board hereby amends the Plan as follows, effective as
of November&nbsp;28, 2023 (the &#147;<U>Amendment Effective Date</U>&#148;): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Plan shall hereby be referred to as the &#147;Spyre Therapeutics, Inc. 2018 Equity Inducement Plan.&#148;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Section&nbsp;21.10 of the Plan is hereby amended and restated in its entirety to read as follows:
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>21.10.</B> &#147;<B><I>Company</I></B>&#148; means Spyre Therapeutics, Inc., or any successor
corporation&#148; </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All references in the Plan and in any Award Agreements (as defined in the Plan) to &#147;Aeglea BioTherapeutics
Inc.&#148; shall instead refer to &#147;Spyre Therapeutics, Inc.&#148; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This Fourth Amendment shall be governed by and construed in accordance with the laws of the State of Delaware
(excluding its conflict of law rules). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All capitalized terms used but not otherwise defined herein shall have the meaning assigned to them in the
Plan. Except as expressly amended hereby, the Plan shall remain in full force and effect in accordance with its terms. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page Follows] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the undersigned has executed this Fourth Amendment to the Aeglea
BioTherapeutics, Inc. 2018 Equity Inducement Plan, effective as of the Amendment Effective Date. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>SPYRE THERAPEUTICS, INC. </B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Cameron Turtle</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Cameron Turtle</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Executive Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F<SMALL>OURTH</SMALL> A<SMALL>MENDMENT</SMALL> <SMALL>TO</SMALL> <SMALL>THE</SMALL> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A<SMALL>EGLEA</SMALL> B<SMALL>IO</SMALL>T<SMALL>HERAPEUTICS</SMALL>, I<SMALL>NC</SMALL>. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2018 E<SMALL>QUITY</SMALL> I<SMALL>NDUCEMENT</SMALL> P<SMALL>LAN</SMALL> </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.11
<SEQUENCE>23
<FILENAME>d518298dex1011.htm
<DESCRIPTION>EX-10.11
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.11</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.11 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTICE&nbsp;OF&nbsp;STOCK&nbsp;OPTION&nbsp;GRANT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AEGLEA BIOTHERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2018 EQUITY INDUCEMENT PLAN </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless
otherwise defined herein, the terms defined in the Aeglea BioTherapeutics, Inc. (the &#147;<B><I>Company</I></B>&#148;) 2018 Equity Inducement Plan (the &#147;<B><I>Plan</I></B>&#148;) shall have the same meanings in this Notice of Stock Option
Grant (the &#147;<B><I>Notice of Grant</I></B>&#148;) and the attached Stock Option Agreement (the &#147;<B><I>Option Agreement</I></B>&#148;). You have been granted an Option to purchase shares of Common Stock of the Company under the Plan subject
to the terms and conditions of the Plan, this Notice of Grant and the attached Option Agreement. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="20%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Name:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Address:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Date of Grant:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Vesting Commencement Date:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Exercise&nbsp;Price&nbsp;per&nbsp;Share:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Total Number of Shares:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Type of Option:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Expiration&nbsp;Date:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>; This Option expires earlier if your Service terminates earlier, as described in the Stock Option Agreement.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Vesting&nbsp;Schedule:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">For so long as Optionee continuously provides services to the Company (or any Subsidiary or Parent of the Company) as an employee, officer, director, contractor or consultant, this Option will vest and become exercisable
with respect to the Shares as follows:<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> .</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Additional&nbsp;Terms:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">&#9744;&nbsp;If this box is checked, the additional terms and conditions set forth on&nbsp;<U>Attachment</U> 1&nbsp;hereto (as executed by the Company) are applicable and are incorporated herein by reference. No document
need be attached as&nbsp;<U>Attachment 1</U>&nbsp;if the box is not checked.</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as specifically provided in your Offer Letter, the Option Agreement or the Plan, in the event that your employment or
engagement with the Company terminates, all unvested options will be forfeited immediately. Any offer will be in accordance with the terms of such plans or arrangements as they may be amended from time to time. As a condition to participation in any
such plans or arrangements, you agree that the opportunity to participate shall not form part of your entitlement to remuneration or benefits pursuant to your Offer Letter or any additional agreement entered into between you and the Company or any
Subsidiary and you agree that you shall not be entitled to seek any equitable relief or to receive any compensation or damage in consequence of any loss or potential loss which you may suffer in consequence of the loss or termination of your
employment for any reason whatsoever (including wrongful or unfair dismissal or their equivalents). By accepting this Option, you and the Company agree that this Option is granted under and governed by the terms and conditions of the Plan, the
Notice of Grant and the Option Agreement. By accepting this Option, you consent to electronic delivery as set forth in the Option Agreement. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Signature:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Print Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STOCK&nbsp;OPTION&nbsp;AGREEMENT </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AEGLEA BIOTHERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2018 EQUITY INDUCEMENT PLAN </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You have been granted an Option by Aeglea BioTherapeutics, Inc. (the &#147;<B><I>Company</I></B>&#148;) under the 2018 Equity Inducement Plan
(the &#147;<B><I>Plan</I></B>&#148;) to purchase Shares (the &#147;<B><I>Option</I></B>&#148;), subject to the terms, restrictions and conditions of the Plan, the Notice of Stock Option Grant (the &#147;<B><I>Notice of Grant</I></B>&#148;) and this
Stock Option Agreement (the &#147;<B><I>Agreement</I></B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1. </B><B><U>Grant of Option</U></B>. You have been granted an
Option for the number of Shares set forth in the Notice of Grant at the exercise price per Share set forth in the Notice of Grant (the &#147;<B><I>exercise price</I></B>&#148;). In the event of a conflict between the terms and conditions of the Plan
and the terms and conditions of this Agreement, the terms and conditions of the Plan shall prevail. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2. </B><B><U>Termination
Period</U></B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>General Rule</U>. If your Service terminates for any reason except death or Disability, and other than for Cause,
then this Option will expire at the close of business at Company headquarters on the date three months after your termination of Service (subject to the expiration detailed in Section&nbsp;6). If your Service is terminated for Cause, this Option
will expire upon the date of such termination. The Company determines when your Service terminates for all purposes under this Agreement. You acknowledge and agree that the Vesting Schedule may change prospectively in the event that your service
status changes between full and part-time status in accordance with Company policies relating to work schedules and vesting of awards. You acknowledge that the vesting of the Shares pursuant to this Notice is earned only by continuing Service. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Death; Disability</U>. If you die before your Service terminates (or you die within three months of your termination of Service other
than for Cause), then this Option will expire at the close of business at Company headquarters on the date 12 months after the date of death (subject to the expiration detailed in Section&nbsp;6). If your Service terminates because of your
Disability, then this Option will expire at the close of business at Company headquarters on the date 12 months after your termination date (subject to the expiration detailed in Section&nbsp;6). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>No Notice</U>. You are responsible for keeping track of these exercise periods following your termination of Service for any reason.
The Company will not provide further notice of such periods. In no event shall this Option be exercised later than the Expiration Date set forth in the Notice of Grant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3. </B><B><U>Exercise of Option</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Right to Exercise</U>. This Option is exercisable during its term in accordance with the Vesting Schedule set forth in the Notice of
Grant and the applicable provisions of the Plan and this Agreement. In the event of your death, Disability, or other cessation of Service, the exercisability of the Option is governed by the applicable provisions of the Plan, the Notice of Grant and
this Agreement. This Option may not be exercised for a fraction of a Share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Method of Exercise</U>. This Option is exercisable by
delivery of an exercise notice in a form specified by the Company (the &#147;<B><I>Exercise Notice</I></B>&#148;), which shall state the election to exercise the Option, the number of Shares in respect of which the Option is being exercised (the
&#147;<B><I>Exercised Shares</I></B>&#148;), and such other representations and agreements as may be required by the Company pursuant to the provisions of the Plan. The Exercise Notice shall be delivered in person, by mail, via electronic mail or
facsimile or by other authorized method to the Secretary of the Company or other person designated by the Company. The Exercise Notice shall be accompanied by payment of the aggregate exercise price as to all Exercised Shares. This Option shall be
deemed to be exercised upon receipt by the Company of a fully executed Exercise Notice accompanied by the aggregate exercise price and any applicable tax withholding due upon exercise of the Option in all and any relevant jurisdictions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Exercise by Another</U>. If another person wants to exercise this Option after it has been transferred to him or her in compliance with
this Agreement, that person must prove to the Company&#146;s satisfaction that he or she is entitled to exercise this Option. That person must also complete the proper Exercise Notice form (as described above) and pay the exercise price (as
described below) and any applicable tax withholding due upon exercise of the Option (as described below) in all and any relevant jurisdictions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4. </B><B><U>Method of Payment</U></B>. Payment of the aggregate exercise price shall be by any of the following, or a combination thereof,
at your election: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) your personal check, wire transfer, or a cashier&#146;s check; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) certificates for shares of Company stock that you own, along with any forms needed to effect a transfer of those shares to the Company;
the value of the shares, determined as of the effective date of the Option exercise, will be applied to the Option exercise price. Instead of surrendering shares of Company stock, you may attest to the ownership of those shares on a form provided by
the Company and have the same number of shares subtracted from the Option shares issued to you. However, you may not surrender, or attest to the ownership of, shares of Company stock in payment of the exercise price of your Option if your action
would cause the Company to recognize compensation expense (or additional compensation expense) with respect to this Option for financial reporting purposes; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) cashless exercise through irrevocable directions to a securities broker approved by the
Company to sell all or part of the Shares covered by this Option and to deliver to the Company from the sale proceeds an amount sufficient to pay the Option exercise price and any withholding taxes. The balance of the sale proceeds, if any, will be
delivered to you. The directions must be given by signing a special notice of exercise form provided by the Company; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) other method
authorized by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5. </B><B><U><FONT STYLE="white-space:nowrap">Non-Transferability</FONT> of Option</U></B>. In general,
except as provided below, only you may exercise this Option prior to your death. You may not transfer or assign this Option, except as provided below. For instance, you may not sell this Option or use it as security for a loan. If you attempt to do
any of these things, this Option will immediately become invalid. You may, however, dispose of this Option in your will or in a beneficiary designation. However, the Committee (as defined in the Plan) may, in its sole discretion, allow you to
transfer this Option as a gift to one or more family members. For purposes of this Agreement, &#147;family member&#148; means a child, stepchild, grandchild, parent, stepparent, grandparent, spouse, former spouse, sibling, niece, nephew, <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mother-in-</FONT></FONT> law, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">father-in-law,</FONT></FONT>
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">son-in-law,</FONT></FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">daughter-in-law,</FONT></FONT> <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">brother-in-law</FONT></FONT> or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">sister-in-law</FONT></FONT> (including adoptive relationships), any individual sharing your household (other than a tenant
or employee), a trust in which one or more of these individuals have more than 50% of the beneficial interest, a foundation in which you or one or more of these persons control the management of assets, and any entity in which you or one or more of
these persons own more than 50% of the voting interest. In addition, the Committee may, in its sole discretion, allow you to transfer this Option to your spouse or former spouse pursuant to a domestic relations order in settlement of marital
property rights. The Committee will allow you to transfer this Option only if both you and the transferee(s) execute the forms prescribed by the Committee, which include the consent of the transferee(s) to be bound by this Agreement. This Option may
not be transferred in any manner other than by will or by the laws of descent or distribution or court order and may be exercised during the lifetime of you only by you, your guardian, or legal representative, as permitted in the Plan. The terms of
the Plan and this Agreement shall be binding upon the executors, administrators, heirs, successors and assigns of you. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.
</B><B><U>Term of Option</U></B>. This Option shall in any event expire on the expiration date set forth in the Notice of Grant, which date is 10&nbsp;years after the grant date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7. </B><B><U>Tax Consequences</U></B>. You should consult a tax adviser for tax consequences relating to this Option in any jurisdiction in
which you are or have been subject to tax during the course of this agreement. YOU SHOULD CONSULT A TAX ADVISER BEFORE EXERCISING THIS OPTION OR DISPOSING OF THE SHARES. You will not be allowed to exercise this Option unless you make arrangements
acceptable to the Company to pay any withholding taxes that may be due as a result of the Option exercise in all or any relevant jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8. </B><B><U>Withholding Taxes and Stock Withholding</U></B>. Regardless of any action the Company or your actual employer (the
&#147;<B><I>Employer</I></B>&#148;) takes with respect to any or all income tax, social insurance, payroll tax, payment on account or other <FONT STYLE="white-space:nowrap">tax-related</FONT> withholding
(&#147;<B><I><FONT STYLE="white-space:nowrap">Tax-Related</FONT> Items</I></B>&#148;), you acknowledge that the ultimate liability for all <FONT STYLE="white-space:nowrap">Tax-Related</FONT> Items legally due by you is and remains your
responsibility and that the Company and/or the Employer (1)&nbsp;make no representations or undertakings regarding the treatment of any <FONT STYLE="white-space:nowrap">Tax-Related</FONT> Items in connection with any aspect of the Option grant,
including the grant, vesting or exercise of the Option, the subsequent sale of Shares acquired pursuant to such exercise and the receipt of any dividends; and (2)&nbsp;do not commit to structure the terms of the grant or any aspect of the Option to
reduce or eliminate your liability for <FONT STYLE="white-space:nowrap">Tax-Related</FONT> Items. You acknowledge that if you are subject to <FONT STYLE="white-space:nowrap">Tax-Related</FONT> Items in more than one jurisdiction, the Company and/or
the Employer may be required to withhold or account for <FONT STYLE="white-space:nowrap">Tax-Related</FONT> Items in more than one jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to
exercise of the Option, you shall pay or make adequate arrangements satisfactory to the Company and/or the Employer to satisfy all withholding and payment on account obligations of the Company and/or the Employer. In this regard, you authorize the
Company and/or the Employer to withhold all applicable <FONT STYLE="white-space:nowrap">Tax-Related</FONT> Items legally payable by you from your wages or other cash compensation paid to you by the Company and/or the Employer. With the
Company&#146;s consent, these arrangements may also include, if permissible under local law, (a)&nbsp;withholding Shares that otherwise would be issued to you when you exercise this Option by considering up to the maximum applicable statutory
withholding rates, (b)&nbsp;having the Company withhold taxes from the proceeds of the sale of the Shares, either through a voluntary sale or through a mandatory sale arranged by the Company (on your behalf and you hereby authorize such sales by
this authorization), (c)&nbsp;your payment of a cash amount, or (d)&nbsp;any other arrangement approved by the Company; all under such rules as may be established by the Committee and in compliance with the Company&#146;s Insider Trading Policy and <FONT
STYLE="white-space:nowrap">10b5-1</FONT> Trading Plan Policy, if applicable; provided however, that if you are a Section&nbsp;16 officer of the Company under the Exchange Act, then the Committee (as constituted in accordance with Rule <FONT
STYLE="white-space:nowrap">16b-3</FONT> under the Exchange Act) shall establish the method of withholding from alternatives (a)-(d)&nbsp;above prior to the <FONT STYLE="white-space:nowrap">Tax-Related</FONT> Items withholding event; and if no such
determination is made, then the method of withholding shall be in accordance with subsection (a)&nbsp;hereof. The Fair Market Value of these Shares, determined as of the effective date of the Option exercise, will be applied as a credit against the
withholding taxes. You shall pay to the Company or the Employer any amount of <FONT STYLE="white-space:nowrap">Tax-Related</FONT> Items that the Company or the Employer may be required </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to withhold as a result of your participation in the Plan or your purchase of Shares that cannot be satisfied by the means previously described. Finally, you acknowledge that the Company has no
obligation to deliver Shares to you until you have satisfied the obligations in connection with the <FONT STYLE="white-space:nowrap">Tax-Related</FONT> Items as described in this Section. For the avoidance of doubt the above clause will also apply
to any taxes or other liabilities due under the local statutes if you are or have been resident outside of the United States during the course of this agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9. </B><B><U>Insider Trading Restrictions/Market Abuse Laws</U></B><B>.</B> You acknowledge that, depending on your country, you may be
subject to insider trading restrictions and/or market abuse laws, which may affect your ability to acquire or sell the Shares or rights to Shares under the Plan during such times as you are considered to have &#147;inside information&#148; regarding
the Company (as defined by the laws in your country). Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company insider trading policy. You acknowledge
that it is your responsibility to comply with any applicable restrictions, and you are advised to speak to your personal advisor on this matter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10. </B><B><U>Acknowledgement</U></B>. The Company and you agree that the Option is granted under and governed by the Notice of Grant, this
Agreement and the provisions of the Plan (incorporated herein by reference). You: (i)&nbsp;acknowledge receipt of a copy of the Plan prospectus, (ii)&nbsp;represent that you have carefully read and are familiar with their provisions, and
(iii)&nbsp;hereby accept the Option subject to all of the terms and conditions set forth herein and those set forth in the Plan and the Notice of Grant. You hereby agree to accept as binding, conclusive and final all decisions or interpretations of
the Committee upon any questions relating to the Plan, the Notice of Grant and the Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11. </B><B><U>Consent to Electronic
Delivery of All Plan Documents and Disclosures</U></B>. By your acceptance of this Option, you consent to the electronic delivery of the Notice of Grant, this Agreement, account statements, Plan prospectuses required by the Securities and Exchange
Commission, U.S. financial reports of the Company, and all other documents that the Company is required to deliver to its security holders (including, without limitation, annual reports and proxy statements) or other communications or information
related to the Option. Electronic delivery may include the delivery of a link to a Company intranet or the internet site of a third party involved in administering the Plan, the delivery of the document via
<FONT STYLE="white-space:nowrap">e-mail</FONT> or such other delivery determined at the Company&#146;s discretion. You acknowledge that you may receive from the Company a paper copy of any documents delivered electronically at no cost if you contact
the Company by telephone, through a postal service or electronic mail at stockadmin@aegleabio.com. You further acknowledge that you will be provided with a paper copy of any documents delivered electronically if electronic delivery fails; similarly,
you understand that you must provide on request to the Company or any designated third party a paper copy of any documents delivered electronically if electronic delivery fails. Also, you understand that your consent may be revoked or changed,
including any change in the electronic mail address to which documents are delivered (if you have provided an electronic mail address), at any time by notifying the Company of such revised or revoked consent by telephone, postal service or
electronic mail at stockadmin@aegleabio.com. Finally, you understand that you are not required to consent to electronic delivery. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12.
</B><B><U>Compliance with Laws and Regulations</U></B>. The exercise of this Option will be subject to and conditioned upon compliance by the Company and you with all applicable state, federal and foreign laws and regulations and with all applicable
requirements of any stock exchange or automated quotation system on which the Company&#146;s Common Stock may be listed or quoted at the time of such issuance or transfer. The Shares issued pursuant to this Agreement shall be endorsed with
appropriate legends, if any, determined by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13. </B><B><U>Governing Law; Severability</U></B>. If one or more provisions
of this Agreement are held to be unenforceable under applicable law, the parties agree to renegotiate such provision in good faith. In the event that the parties cannot reach a mutually agreeable and enforceable replacement for such provision, then
(i)&nbsp;such provision shall be excluded from this Agreement, (ii)&nbsp;the balance of this Agreement shall be interpreted as if such provision were so excluded and (iii)&nbsp;the balance of this Agreement shall be enforceable in accordance with
its terms. This Agreement and all acts and transactions pursuant hereto and the rights and obligations of the parties hereto shall be governed, construed and interpreted in accordance with the laws of the State of Delaware, without giving effect to
principles of conflicts of law. For purposes of litigating any dispute that may arise directly or indirectly from the Plan, the Notice and this Agreement, the parties hereby submit and consent to litigation in the exclusive jurisdiction of the State
of California and agree that any such litigation shall be conducted only in the courts of California in San Francisco County or the federal courts of the United States for the Northern District of California and no other courts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>14. </B><B><U>No Rights as Employee</U></B>. Nothing in this Agreement shall affect in any manner whatsoever the right or power of the
Company, or a Parent, Subsidiary or Affiliate of the Company, to terminate your Service, for any reason, with or without Cause. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>15.
</B><B><U>Adjustment</U></B>. In the event of a stock split, a stock dividend or a similar change in Company stock, the number of Shares covered by this Option and the exercise price per Share may be adjusted pursuant to the Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>16. </B><B><U>Award Subject to Company Clawback or Recoupment</U></B>. To the extent
permitted by applicable law, the Option shall be subject to clawback or recoupment pursuant to any compensation clawback or recoupment policy adopted by the Board or required by law during the term of your employment or other Service that is
applicable to you. In addition to any other remedies available under such policy, applicable law may require the cancellation of your Option (whether vested or unvested) and the recoupment of any gains realized with respect to your Option. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>17. </B><B><U>Entire Agreement; Enforcement of Rights.</U></B> This Agreement, the Plan and the Notice constitute the entire agreement and
understanding of the parties relating to the subject matter herein and supersede all prior discussions between them. Any prior agreements, commitments or negotiations concerning this Option are superseded. No modification of or amendment to this
Agreement, nor any waiver of any rights under this Agreement, shall be effective unless in writing and signed by the parties to this Agreement. The failure by either party to enforce any rights under this Agreement shall not be construed as a waiver
of any rights of such party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BY ACCEPTING THIS OPTION, YOU AGREE TO ALL OF THE TERMS AND CONDITIONS DESCRIBED ABOVE AND IN THE PLAN. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.12
<SEQUENCE>24
<FILENAME>d518298dex1012.htm
<DESCRIPTION>EX-10.12
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.12</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.12 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPYRE THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>2023 EQUITY INCENTIVE PLAN </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED BY THE BOARD OF DIRECTORS: May&nbsp;19, 2023 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. <U>Purpose</U>. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The purpose of this
2023 Equity Incentive Plan (the &#147;<B>Plan</B>&#148;) of Spyre Therapeutics, Inc., a Delaware corporation (the &#147;<B>Company</B>&#148;), is to advance the interests of the Company&#146;s stockholders by enhancing the Company&#146;s ability to
attract, retain and motivate persons who are expected to make important contributions to the Company and by providing such persons with equity ownership opportunities and performance-based incentives that are intended to better align the interests
of such persons with those of the Company&#146;s stockholders. Except where the context otherwise requires, the term &#147;Company&#148; shall include any of the Company&#146;s present or future parent or subsidiary corporations as defined in
Sections&nbsp;424(e) or (f)&nbsp;of the Internal Revenue Code of 1986, as amended, and any regulations promulgated thereunder (the &#147;<B>Code</B>&#148;) and any other business venture (including, without limitation, joint venture or limited
liability company) in which the Company has a controlling interest, as determined by the Board of Directors of the Company (the &#147;<B>Board</B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. <U>Eligibility</U>. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All of the
Company&#146;s employees, officers, directors, consultants and advisors are eligible to be granted options, restricted stock, restricted stock units (&#147;<B>RSUs</B>&#148;) and other stock-based awards (each, an &#147;<B>Award</B>&#148;) under the
Plan. Each person who receives an Award under the Plan is deemed a &#147;<B>Participant</B>&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. <U>Administration and Delegation</U>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Administration by Board of Directors</U>. The Plan will be administered by the Board. The Board shall have authority to grant Awards
and to adopt, amend and repeal such administrative rules, guidelines and practices relating to the Plan as it shall deem advisable. The Board may construe and interpret the terms of the Plan and any Award agreements entered into under the Plan. The
Board may correct any defect, supply any omission or reconcile any inconsistency in the Plan or any Award in the manner and to the extent it shall deem expedient to carry the Plan into effect and it shall be the sole and final judge of such
expediency. All decisions by the Board shall be made in the Board&#146;s sole discretion and shall be final and binding on all persons having or claiming any interest in the Plan or in any Award. No director or person acting pursuant to the
authority delegated by the Board shall be liable for any action or determination relating to or under the Plan made in good faith. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)
<U>Appointment of Committees</U>. To the extent permitted by applicable law, the Board may delegate any or all of its powers under the Plan to one or more committees or subcommittees of the Board (a &#147;<B>Committee</B>&#148;). All references in
the Plan to the &#147;<B>Board</B>&#148; shall mean the Board or a Committee of the Board or the officers referred to in Section&nbsp;3(c) to the extent that the Board&#146;s powers or authority under the Plan have been delegated to such Committee
or officers. The Board may abolish any Committee at any time, and notwithstanding any delegation of authority, the Board will always retain full authority to take any action permitted under the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Delegation to Officers</U>. To the extent permitted by applicable law, the Board may delegate to one or more officers of the Company
the power to grant Awards (subject to any limitations under the Plan) to employees or officers of the Company and to exercise such other powers under the Plan as the Board may determine, <I>provided that</I> the Board shall fix the terms of the
Awards to be granted by such </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
officers (including the exercise price of such Awards, which may include a formula by which the exercise price will be determined) and the maximum number of shares subject to Awards that the
officers may grant; <I>provided further, however</I>, that no officer shall be authorized to grant Awards to any &#147;executive officer&#148; of the Company (as defined by Rule <FONT STYLE="white-space:nowrap">3b-7</FONT> under the Securities
Exchange Act of 1934, as amended (the &#147;<B>Exchange Act</B>&#148;)) or to any &#147;officer&#148; of the Company (as defined by Rule <FONT STYLE="white-space:nowrap">16a-1</FONT> under the Exchange Act). The Board may rescind any such delegation
at any time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. <U>Stock Available for Awards</U>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Number of Shares</U>. Subject to adjustment under Section&nbsp;8 hereof, Awards may be made under the Plan covering up to 2,049,133
shares of common stock of the Company (the &#147;<B>Common Stock</B>&#148;), all of which may be granted as Incentive Stock Options (as hereinafter defined). If any Award expires, lapses, or is terminated, surrendered or canceled without having been
fully exercised or is forfeited in whole or in part (including as the result of shares of Common Stock subject to such Award being repurchased by the Company at or below the original issuance price), in any case in a manner that results in any
shares of Common Stock covered by such Award not being issued or being so reacquired by the Company, the unused Common Stock covered by such Award shall again be available for the grant of Awards under the Plan. Further, shares of Common Stock
delivered (whether by actual delivery or attestation) or tendered to the Company by a Participant to satisfy the applicable exercise or purchase price of an Award and/or to satisfy any applicable tax withholding obligation (including shares retained
by the Company from the Award being exercised or purchased and/or creating the tax obligation) shall again be available for the grant of Awards under the Plan. However, in the case of Incentive Stock Options) the foregoing provisions shall be
subject to any limitations under the Code. Shares of Common Stock issued under the Plan may consist in whole or in part of authorized but unissued shares, shares purchased on the open market, or treasury shares. At no time while there is any Option
(as defined below) outstanding and held by a Participant who was a resident of the State of California on the date of grant of such Option, shall the total number of shares of Common Stock issuable upon exercise of all outstanding options and the
total number of shares provided for under any stock bonus or similar plan or agreement of the Company exceed the applicable percentage as calculated in accordance with the conditions and exclusions of Section&nbsp;260.140.45 of the California Code
of Regulations (the &#147;<B>California Regulations</B>&#148;), based on the shares of the Company which are outstanding at the time the calculation is made. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Substitute Awards</U>. In connection with a merger or consolidation of an entity with the Company or the acquisition by the Company of
property or stock of an entity, the Board may grant Awards in substitution for any options or other stock or stock-based awards granted prior to such merger or consolidation by such entity or an affiliate thereof. Substitute Awards may be granted on
such terms as the Board deems appropriate in the circumstances, notwithstanding any limitations on Awards contained in the Plan. Substitute Awards shall not count against the overall share limit set forth in Section&nbsp;4(a) hereof, except as may
be required by reason of Section&nbsp;422 and related provisions of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. <U>Stock Options</U>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>General</U>. The Board may grant options to purchase Common Stock (each, an &#147;<B>Option</B>&#148;) and determine the number of
shares of Common Stock to be covered by each Option, the exercise price of each Option and the conditions and limitations applicable to the exercise of each Option, including conditions relating to applicable federal or state securities laws, as it
considers necessary or advisable. An Option that is not intended to be an Incentive Stock Option shall be designated a &#147;<B>Nonstatutory Stock Option</B>&#148;.<SUP STYLE="font-size:75%; vertical-align:top"> </SUP> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Incentive Stock Options</U>. An Option that the Board intends to be an
&#147;incentive stock option&#148; as defined in Section&nbsp;422 of the Code (an &#147;<B>Incentive Stock Option</B>&#148;) shall only be granted to employees of the Company (including any of the Company&#146;s present or future parent or
subsidiary corporations as defined in Sections 424(e) or (f)&nbsp;of the Code but excluding any other business venture (including, without limitation, joint venture or limited liability company) in which the Company has a controlling interest). All
Options intended to qualify as Incentive Stock Options shall be subject to and shall be construed consistently with the requirements of Section&nbsp;422 of the Code, and without limiting generality of the foregoing, such Options shall be deemed to
include terms that comply with the eligibility standards described section 422(b) of the Code. Subject to the remaining provisions of this Section&nbsp;5(b), if an Option intended to qualify as an Incentive Stock Option does not so qualify, the
Board may, at its discretion, amend the Plan and Award with respect to such Option so that such Option qualifies as an Incentive Stock Option. To the extent that the aggregate Fair Market Value (determined at the time of grant) of Common Stock with
respect to which Incentive Stock Options are exercisable for the first time by any Participant during any calendar year (under all plans of the Company and any affiliates) exceeds $100,000 (or such other limit established in the Code) or otherwise
does not comply with the rules governing Incentive Stock Options, the Options or portions thereof that exceed such limit (according to the order in which they were granted) or otherwise do not comply with the rules will be treated as Nonstatutory
Stock Options, notwithstanding any contrary provision of the applicable Award. Neither the Company nor the Board shall have any liability to a Participant, or any other party, (i)&nbsp;if an Option (or any part thereof) which is intended to qualify
as an Incentive Stock Option fails to qualify as such or (ii)&nbsp;for any action or omission by the Company or Board that causes an Option not to qualify as an Incentive Stock Option, including without limitation the conversion of an Incentive
Stock Option to a Nonstatutory Stock Option or the grant of an Option intended as an Incentive Stock Option that fails to satisfy the requirements under the Code applicable to an Incentive Stock Option. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Exercise Price</U>. The Board shall establish the exercise price of each Option and specify the exercise price in the applicable option
agreement. The exercise price shall be not less than 100% of the Fair Market Value on the date the Option is granted. In the case of an Incentive Stock Option granted to an employee who, at the time of grant of the Option, owns (or is treated as
owning under Section&nbsp;424 of the Code) stock representing more than 10% of the voting power of all classes of stock of the Company (or a &#147;parent corporation&#148; or &#147;subsidiary corporation&#148; thereof within the meaning of Sections
424(e) or 424(f) of the Code, respectively) (such employee, a &#147;<B>10% Holder</B>&#148;), the per share exercise price shall be no less than 110% of the Fair Market Value on the date the Option is granted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Duration of Options</U>. Each Option shall be exercisable at such times and subject to such terms and conditions as the Board may
specify in the applicable option agreement, <I>provided that</I> the term of any Option shall not exceed 10 years. In the case of an Incentive Stock Option granted to a 10% Holder, the term of the Option shall not exceed five years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Exercise of Option; Notification of Disposition</U>. Options may be exercised by delivery to the Company of a written notice of
exercise signed by the proper person or by any other form of notice (including electronic notice) approved by the Board together with payment in full as specified in Section&nbsp;5(f) for the number of shares for which the Option is exercised.
Unless otherwise determined by the Board, an Option may not be exercised for a fraction of a share of Common Stock. Shares of Common Stock subject to the Option will be delivered by the Company as soon as practicable following exercise. If an Option
is designated as an Incentive Stock Option, the Participant shall give prompt notice to the Company of any disposition or other transfer of any shares of Common Stock acquired from the Option if such disposition or transfer is made (i)&nbsp;within
two years from the grant date with respect to such Option or (ii)&nbsp;within one year after the transfer of such shares to the Participant (other than any such disposition made in connection with a Reorganization Event). Such notice shall specify
the date of such disposition or other transfer and the amount realized, in cash, other property, assumption of indebtedness or other consideration, by the Participant in such disposition or other transfer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Payment Upon Exercise.</U> Common Stock purchased upon the exercise of an Option
granted under the Plan shall be paid for as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) in cash or by check, payable to the order of the Company; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) when the Common Stock is registered under the Exchange Act, except as may otherwise be provided in the applicable option agreement, by
(A)&nbsp;delivery of an irrevocable and unconditional undertaking by a creditworthy broker acceptable to the Company to deliver promptly to the Company sufficient funds to pay the exercise price and any required tax withholding or (B)&nbsp;delivery
by the Participant to the Company of a copy of irrevocable and unconditional instructions to a creditworthy broker acceptable to the Company to deliver promptly to the Company cash or a check sufficient to pay the exercise price and any required tax
withholding; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) when the Common Stock is registered under the Exchange Act and to the extent provided for in the applicable option
agreement or approved by the Board, in its sole discretion, by delivery (either by actual delivery or attestation) of shares of Common Stock owned by the Participant valued at their fair market value as determined by (or in a manner approved by) the
Board (&#147;<B>Fair Market Value</B>&#148;), <I>provided</I> (A)&nbsp;such method of payment is then permitted under applicable law, (B)&nbsp;such Common Stock, if acquired directly from the Company, was owned by the Participant for such minimum
period of time, if any, as may be established by the Board in its discretion and (C)&nbsp;such Common Stock is not subject to any repurchase, forfeiture, unfulfilled vesting or other similar requirements; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iv) to the extent permitted by applicable law and provided for in the applicable option agreement or approved by the Board, in its sole
discretion, by (A)&nbsp;delivery of a promissory note of the Participant to the Company on terms determined by the Board, or (B)&nbsp;payment of such other lawful consideration as the Board may determine; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(v) to the extent provided for in the applicable option agreement or approved by the Board, in its sole discretion, by having the Company
retain from the shares of Common Stock otherwise issuable upon the exercise of such Option a number of shares valued at their Fair Market Value; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(vi) by any combination of the above permitted forms of payment or any other lawful consideration as approved by the Board in its sole
discretion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <U>Early Exercise of Options</U>. The Board may provide in the terms of an option agreement that the Participant may
exercise an Option in whole or in part prior to the full vesting of the Option in exchange for unvested shares of Restricted Stock (as defined below) with respect to any unvested portion of the Option so exercised. Shares of Restricted Stock
acquired upon the exercise of any unvested portion of an Option shall be subject to such terms and conditions as the Board shall determine. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6.
<U>Restricted Stock; Restricted Stock Units</U>. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>General</U>. The Board may grant Awards entitling recipients to acquire
shares of Common Stock (&#147;<B>Restricted Stock</B>&#148;), subject to the right of the Company to repurchase all or part of such shares at their issue price or other stated or formula price (or to require forfeiture of such shares if issued at no
cost) from the recipient in the event that conditions specified by the Board in the applicable Award are not satisfied prior to the end of the applicable restriction period or periods established by the Board for such Award. Instead of granting
Awards for Restricted Stock, the Board may grant Awards entitling the recipient to receive shares of Common Stock or cash to be delivered at or following the time such Award vests (&#147;<B>Restricted Stock Units</B>&#148; or
&#147;<B>RSUs</B>&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Terms and Conditions</U>. The Board shall determine and set forth in the applicable
award agreement the terms and conditions of Restricted Stock or RSUs, including the conditions for vesting and repurchase (or forfeiture) and the issue price, if any. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Additional Provisions Relating to Restricted Stock</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) <U>Dividends</U>. Participants holding shares of Restricted Stock will be entitled to all ordinary cash dividends paid with respect to
such shares to the extent such dividends have a record date that is on or after the date on which the Participant to whom such Restricted Stock is granted becomes the record holder of such Restricted Stock, unless otherwise provided by the Board.
Unless otherwise provided by the Board, if any dividends or distributions are paid in shares, or consist of a dividend or distribution to holders of Common Stock other than an ordinary cash dividend, the shares or other property will be subject to
the same restrictions on transferability and forfeitability as the shares of Restricted Stock with respect to which they were paid. Each dividend payment will be made as provided in the applicable award agreement, but no later than the end of the
calendar year in which the dividends are paid to shareholders of that class of stock or, if later, the 15th day of the third month following the later of (A)&nbsp;the date the dividends are paid to shareholders of that class of stock and
(B)&nbsp;the date the dividends are no longer subject to forfeiture. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) <U>Stock Certificates</U>. The Company may require that any
stock certificates issued in respect of shares of Restricted Stock shall be deposited in escrow by the Participant, together with a stock power endorsed in blank, with the Company (or its designee). At the expiration of the applicable restriction
periods, the Company (or such designee) shall deliver the certificates no longer subject to such restrictions to the Participant or if the Participant has died, to the beneficiary designated, in a manner determined by the Board, by a Participant to
receive amounts due or exercise rights of the Participant in the event of the Participant&#146;s death (the &#147;<B>Designated Beneficiary</B>&#148;). In the absence of an effective designation by a Participant, &#147;Designated Beneficiary&#148;
shall mean the Participant&#146;s estate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Additional Provisions Relating to Restricted Stock Units</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) <U>Settlement</U>. Upon or following the vesting of a Restricted Stock Unit, the Participant shall be entitled to receive from the Company
one share of Common Stock or an amount of cash or other property equal to the Fair Market Value of one share of Common Stock on the settlement date, as the Board shall determine and as provided in the applicable award agreement. The Board may
provide that settlement of Restricted Stock Units shall occur upon or as soon as reasonably practicable after the vesting of the Restricted Stock Units or shall instead be deferred, on a mandatory basis or at the election of the Participant, in a
manner that complies with Section&nbsp;409A of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) <U>Voting Rights</U>. A Participant shall have no voting rights with
respect to any Restricted Stock Units unless and until shares are delivered in settlement thereof.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) <U>Dividend Equivalents</U>. To
the extent provided by the Board, a grant of Restricted Stock Units may provide a Participant with the right to receive Dividend Equivalents. Dividend Equivalents may be paid currently or credited to an account for the Participant, may be settled in
cash and/or shares of Common Stock and may be subject to the same restrictions on transfer and forfeitability as the Restricted Stock Units with respect to which the Dividend Equivalents are paid, as determined by the Board, subject, in each case,
to such terms and conditions as the Board shall establish and set forth in the applicable award agreement. &#147;<B>Dividend Equivalents</B>&#148; means a right granted to a Participant to receive the equivalent value (in cash or shares of Common
Stock) of dividends paid on shares of Common Stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. <U>Other Stock-Based Awards</U>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other Awards of shares of Common Stock, and other Awards that are valued in whole or in part by reference to, or are otherwise based on,
shares of Common Stock or other property, may be granted hereunder to Participants (&#147;<B>Other Stock-Based Awards</B>&#148;), including without limitation stock appreciation rights (&#147;<B>SARs</B>&#148;) (which shall be subject to the same
limitations applicable to awards of Nonstatutory Stock Options) and Awards entitling recipients to receive shares of Common Stock to be delivered in the future. Such Other Stock-Based Awards shall also be available as a form of payment in the
settlement of other Awards granted under the Plan or as payment in lieu of compensation to which a Participant is otherwise entitled. Other Stock-Based Awards may be paid in shares of Common Stock or cash, as the Board shall determine. Subject to
the provisions of the Plan, the Board shall determine the terms and conditions of each Other Stock-Based Award, including any purchase price, transfer restrictions, vesting conditions and other terms and conditions applicable thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8. <U>Adjustments for Changes in Common Stock and Certain Other Events</U>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) In the event of any stock split, reverse stock split, stock dividend, recapitalization, combination of shares, reclassification of shares,
<FONT STYLE="white-space:nowrap">spin-off</FONT> or other similar change in capitalization or event, or any dividend or distribution to holders of Common Stock other than an ordinary cash dividend, (i)&nbsp;the number and class of securities
available under this Plan, (ii)&nbsp;the number and class of securities and exercise price per share of each outstanding Option, (iii)&nbsp;the number of shares subject to and the repurchase price per share subject to each other outstanding Award,
and (iv)&nbsp;the terms of each other outstanding Award shall be equitably adjusted by the Company (or substituted Awards may be made, if applicable) in the manner determined by the Board; <I>provided that</I>, unless otherwise determined by the
Board, such changes to the Options shall comply with section <FONT STYLE="white-space:nowrap">1.424-1</FONT> of the Treasury Regulations. Without limiting the generality of the foregoing, in the event the Company effects a split of the Common Stock
by means of a stock dividend and the exercise price of and the number of shares subject to an outstanding Option are adjusted as of the date of the distribution of the dividend (rather than as of the record date for such dividend), then a
Participant who exercises an Option between the record date and the distribution date for such stock dividend shall be entitled to receive, on the distribution date, the stock dividend with respect to the shares of Common Stock acquired upon such
Option exercise, notwithstanding the fact that such shares were not outstanding as of the close of business on the record date for such stock dividend. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Reorganization Events</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) <U>Definition</U>. A &#147;<B>Reorganization Event</B>&#148; means the consummation of: (A)&nbsp;the dissolution or liquidation of the
Company, (B)&nbsp;the sale of all or substantially all of the assets of the Company on a consolidated basis to an unrelated person or entity, (C)&nbsp;a merger, reorganization or consolidation pursuant to which the holders of the Company&#146;s
outstanding voting power immediately prior to such transaction do not own a majority of the outstanding voting power of the surviving or resulting entity (or its ultimate parent, if applicable), (D) the acquisition of all or a majority of the
outstanding voting stock of the Company in a single transaction or a series of a related transactions by a person or group of persons, or (E)&nbsp;any other acquisition of the business of the Company, as determined by the Board; <I>provided,
however</I>, that the first firm commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended, covering the offer and sale by the Company of its equity securities, as a result
of or following which the Common Stock shall be public, any subsequent public offering or another capital raising event, or a merger effected solely to change the Company&#146;s domicile shall not constitute a &#147;Reorganization Event.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) <U>Consequences of a Reorganization Event on Awards</U>. In connection with a
Reorganization Event, the Board may take any one or more of the following actions as to all or any (or any portion of) outstanding Awards on such terms as the Board determines: (A)&nbsp;provide that Awards shall be assumed, or substantially
equivalent Awards shall be substituted, by the acquiring or succeeding corporation (or an affiliate thereof); <I>provided that</I>, unless otherwise determined by the Board, such assumption or substitution of the Options shall comply with section <FONT
STYLE="white-space:nowrap">1.424-1</FONT> of the Treasury Regulations, (B)&nbsp;upon written notice to a Participant, provide that the Participant&#146;s unexercised Awards will terminate immediately prior to the consummation of such Reorganization
Event unless exercised by the Participant within a specified period following the date of such notice, (C)&nbsp;provide that outstanding Awards shall become vested, exercisable, realizable, or deliverable, or restrictions applicable to an Award
shall lapse, in whole or in part prior to or upon such Reorganization Event, (D)&nbsp;in the event of a Reorganization Event under the terms of which holders of Common Stock will receive upon consummation thereof a cash payment for each share
surrendered in the Reorganization Event (the &#147;<B>Acquisition Price</B>&#148;), make or provide for a cash payment to a Participant equal to the excess, if any, of (I)&nbsp;the Acquisition Price times the number of shares of Common Stock subject
to the Participant&#146;s Awards (to the extent the exercise price does not exceed the Acquisition Price) over (II)&nbsp;the aggregate exercise price of all such outstanding Awards and any applicable tax withholdings, in exchange for the termination
of such Awards, (E)&nbsp;provide that, in connection with a liquidation or dissolution of the Company, Awards shall convert into the right to receive liquidation proceeds (if applicable, net of the exercise price thereof and any applicable tax
withholdings) and (F)&nbsp;any combination of the foregoing. In taking any of the actions permitted under this Section&nbsp;8(b), the Board shall not be obligated by the Plan to treat all Awards, all Awards held by a Participant, or all Awards of
the same type, identically. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">For purposes of clause (A)&nbsp;above, an Option shall be considered assumed if, following consummation of
the Reorganization Event, the Option confers the right to purchase, for each share of Common Stock subject to the Option immediately prior to the consummation of the Reorganization Event, the consideration (whether cash, securities or other
property) received as a result of the Reorganization Event by holders of Common Stock for each share of Common Stock held immediately prior to the consummation of the Reorganization Event (and if holders were offered a choice of consideration, the
type of consideration chosen by the holders of a majority of the outstanding shares of Common Stock); <I>provided, however</I>, that if the consideration received as a result of the Reorganization Event is not solely common stock of the acquiring or
succeeding corporation (or an affiliate thereof), the Company may, with the consent of the acquiring or succeeding corporation, provide for the consideration to be received upon the exercise of Options to consist solely of common stock of the
acquiring or succeeding corporation (or an affiliate thereof) equivalent in value (as determined by the Board) to the per share consideration received by holders of outstanding shares of Common Stock as a result of the Reorganization Event. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. <U>General Provisions Applicable to Awards</U>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Transferability of Awards</U>. Except as the Board may otherwise determine or provide in an Award, Awards shall not be sold, assigned,
transferred, pledged or otherwise encumbered by the person to whom they are granted, either voluntarily or by operation of law, except by will or the laws of descent and distribution or, other than in the case of an Incentive Stock Option, pursuant
to a qualified domestic relations order, and, during the life of the Participant, shall be exercisable only by the Participant. References to a Participant, to the extent relevant in the context, shall include references to authorized transferees.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Documentation</U>. Each Award shall be evidenced in such form (written, electronic or otherwise) as the Board shall determine.
Each Award may contain terms and conditions in addition to those set forth in the Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Board Discretion</U>. Except as otherwise provided by the Plan, each Award may be
made alone or in addition or in relation to any other Award. The terms of each Award need not be identical, and the Board need not treat Participants uniformly. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Termination of Status</U>. The Board shall determine the effect on an Award of the disability, death, retirement, termination or other
cessation of employment, authorized leave of absence or other change in the employment or other status of a Participant and the extent to which, and the period during which, the Participant, or the Participant&#146;s legal representative,
conservator, guardian or Designated Beneficiary, may exercise rights under the Award.<SUP STYLE="font-size:75%; vertical-align:top"> </SUP> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Withholding</U>. The Company shall not be obligated to deliver certificates, release from forfeiture, otherwise recognize a
Participant&#146;s unrestricted ownership in an Award or the cash or property proceeds therefrom, until the Company satisfies all applicable federal, state, and local or other income and employment tax withholding obligations. In its sole
discretion, the Company may satisfy such withholding obligations by any of the following means or by a combination of such means: (i)&nbsp;causing the Participant to tender to the Company cash payment; (ii)&nbsp;withholding cash from an Award
settled in cash; (iii)&nbsp;withholding from amounts otherwise payable by the Company to the Participant, including but not limited to additional withholding on the Participant&#146;s salary or wages, or from proceeds from the sale of Common Stock
issued pursuant to an Award; (iv)&nbsp;delivery of shares of Common Stock, including shares retained from the Award creating the tax obligation, valued at their Fair Market Value; <I>provided, however</I>, except as otherwise provided by the Board,
that the total tax withholding where stock is being used to satisfy such tax obligations cannot exceed the Company&#146;s minimum statutory withholding obligations (based on minimum statutory withholding rates for federal and state tax purposes,
including payroll taxes, that are applicable to such supplemental taxable income), and <I>provided, further</I>, shares surrendered to satisfy tax withholding requirements cannot be subject to any repurchase, forfeiture, unfulfilled vesting or other
similar requirements; or (v)&nbsp;by such other method as determined by the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Amendment of Award</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) The Board may amend, modify or terminate any outstanding Award, including but not limited to, substituting therefor another Award of the
same or a different type, changing the date of exercise or settlement, and converting an Incentive Stock Option to a Nonstatutory Stock Option. The Participant&#146;s consent to such action shall be required unless (A)&nbsp;the Board determines that
the action, taking into account any related action, would not materially and adversely affect the Participant&#146;s rights under the Plan, (B)&nbsp;the change is permitted under Section&nbsp;8 hereof, or (C)&nbsp;the change is to ensure that an
Option intended to qualify as an Incentive Stock Option qualifies as such. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) The Board may, without stockholder approval, amend any
outstanding Award granted under the Plan to provide an exercise price per share that is lower than the then-current exercise price per share of such outstanding Award. The Board may also, without stockholder approval, cancel any outstanding award
(whether or not granted under the Plan) and grant in substitution therefor new Awards under the Plan covering the same or a different number of shares of Common Stock and having an exercise price per share lower than the then-current exercise price
per share of the cancelled award.<SUP STYLE="font-size:75%; vertical-align:top"> </SUP> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <U>Conditions on Delivery of Stock</U>. The
Company will not be obligated to deliver any shares of Common Stock pursuant to the Plan or to remove restrictions from shares previously delivered under the Plan until (i)&nbsp;all conditions of the Award have been met or removed to the
satisfaction of the Company, (ii)&nbsp;in the opinion of the Company&#146;s counsel, all other legal matters in connection with the issuance and delivery of such shares have been satisfied, including any applicable securities laws and any applicable
stock exchange or stock market rules and regulations, and (iii)&nbsp;the Participant has executed and delivered to the Company such representations or agreements as the Company may consider appropriate to satisfy
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the requirements of any applicable laws, rules or regulations. The inability of the Company to obtain authority from any regulatory body having jurisdiction, which authority is determined by the
Board to be necessary to the lawful issuance and sale of any securities hereunder, shall relieve the Company of any liability in respect of the failure to issue or sell such shares at to which such requisite authority shall not have been obtained.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <U>Acceleration</U>. The Board may at any time provide that any Award shall become immediately exercisable in full or in part, free
of some or all restrictions or conditions, or otherwise realizable in full or in part, as the case may be. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10. <U>Miscellaneous</U>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>No Right To Employment or Other Status</U>. No person shall have any claim or right to be granted an Award, and the grant of an Award
shall not be construed as giving a Participant the right to continued employment or any other relationship with the Company. The Company expressly reserves the right at any time to dismiss or otherwise terminate its relationship with a Participant
free from any liability or claim under the Plan, except as expressly provided in the applicable Award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>No Rights As
Stockholder</U>. Subject to the provisions of the applicable Award, no Participant or Designated Beneficiary shall have any rights as a stockholder with respect to any shares of Common Stock to be distributed with respect to an Award until becoming
the record holder of such shares. Notwithstanding any other provision of the Plan, unless otherwise determined by the Board or required by any applicable laws, the Company shall not be required to deliver to any Participant certificates evidencing
shares of Common Stock issued in connection with any Award and instead such shares of Common Stock may be recorded in the books of the Company (or, as applicable, its transfer agent or stock plan administrator). The Company may place legends on any
stock certificates issued under the Plan deemed necessary or appropriate by the Board in order to comply with applicable laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)
<U>Effective Date and Term of Plan</U>. The Plan shall become effective on the date on which it is adopted by the Board. No Awards shall be granted under the Plan after the expiration of 10 years from the earlier of (i)&nbsp;the date on which the
Plan was adopted by the Board or (ii)&nbsp;the date the Plan was approved by the Company&#146;s stockholders, but Awards previously granted may extend beyond that date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Amendment of Plan</U>. The Board may amend, suspend or terminate the Plan or any portion thereof at any time; <I>provided that</I> if
at any time the approval of a Company stockholder is required as to any modification or amendment under Section&nbsp;422 of the Code or any successor provision with respect to Incentive Stock Options or pursuant to any other applicable law or
regulation, the Board may not effect such modification or amendment without stockholder approval. Unless otherwise specified in the amendment, any amendment to the Plan adopted in accordance with this Section&nbsp;10(d) shall apply to, and be
binding on the holders of, all Awards outstanding under the Plan at the time the amendment is adopted, <I>provided</I> the Board determines that such amendment does not materially and adversely affect the rights of Participants under the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Authorization of <FONT STYLE="white-space:nowrap">Sub-Plans</FONT></U>. The Board may from time to time establish one or more <FONT
STYLE="white-space:nowrap">sub-plans</FONT> under the Plan for purposes of satisfying applicable blue sky, securities or tax laws of various jurisdictions. The Board shall establish such <FONT STYLE="white-space:nowrap">sub-plans</FONT> by adopting
supplements to this Plan containing (i)&nbsp;such limitations on the Board&#146;s discretion under the Plan as the Board deems necessary or desirable or (ii)&nbsp;such additional terms and conditions not otherwise inconsistent with the Plan as the
Board shall deem necessary or desirable. All supplements adopted by the Board shall be deemed to be part of the Plan, but each supplement shall apply only to Participants within the affected jurisdiction and the Company shall not be required to
provide copies of any supplement to Participants in any jurisdiction which is not the subject of such supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Compliance with Code Section</U><U></U><U>&nbsp;409A</U>. Unless otherwise expressly
provided for in an Award, the Plan and Award will be interpreted to the greatest extent possible in a manner that makes the Plan and the Awards granted hereunder exempt from Section&nbsp;409A of the Code, and, to the extent not so exempt, in
compliance with Section&nbsp;409A of the Code. If the Board determines that any Award granted hereunder is not exempt from and is therefore subject to Section&nbsp;409A of the Code, the Award will incorporate the terms and conditions necessary to
avoid the consequences specified in Section&nbsp;409A(a)(1) of the Code, and to the extent an Award is silent on terms necessary for compliance, such terms as deemed necessary by the Board in its sole discretion are hereby incorporated by reference
into the Award. Without limiting the generality of the foregoing, if shares of Common Stock are publicly traded, and if a Participant holding an Award that constitutes &#147;deferred compensation&#148; under Section&nbsp;409A of the Code is a
&#147;specified employee&#148; for purposes of Section&nbsp;409A of the Code, no distribution or payment of any amount that is due because of a &#147;separation from service&#148; (as defined in Section&nbsp;409A of the Code without regard to
alternative definitions thereunder) will be issued or paid before the date that is six months following the date of such Participant&#146;s &#147;separation from service&#148; or, if earlier, the date of the Participant&#146;s death, unless such
distribution or payment can be made in a manner that complies with Section&nbsp;409A of the Code, and any amounts so deferred will be paid in a lump sum on the day after such six month period elapses, with the balance paid thereafter on the original
schedule. The Company shall have no liability to a Participant, or any other party, if an Award that is intended to be exempt from, or compliant with, Section&nbsp;409A of the Code is not so exempt or compliant or for any other action taken by the
Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <U>Governing Law</U>. The provisions of the Plan and all Awards made hereunder shall be governed by and interpreted in
accordance with the laws of the State of Delaware, excluding <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">choice-of-law</FONT></FONT> principles of the law of such state that would require the application of the laws of a
jurisdiction other than such state. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <U>Data Privacy</U>. As a condition of receipt of any Award, each Participant explicitly and
unambiguously consents to the collection, use and transfer, in electronic or other form, of personal data as described in this paragraph by and among, as applicable, the Company and its subsidiaries and affiliates for the exclusive purpose of
implementing, administering and managing the Participant&#146;s participation in the Plan. The Company and its subsidiaries and affiliates may hold certain personal information about a Participant, including but not limited to, the
Participant&#146;s name, home address and telephone number, date of birth, social security or insurance number or other identification number, salary, nationality, job title(s), any shares of stock held in the Company or any of its subsidiaries and
affiliates, details of all Awards, in each case, for the purpose of implementing, managing and administering the Plan and Awards (the &#147;<B>Data</B>&#148;). The Company and its subsidiaries and affiliates may transfer the Data amongst themselves
as necessary for the purpose of implementation, administration and management of a Participant&#146;s participation in the Plan, and the Company and its subsidiaries and affiliates may each further transfer the Data to any third parties assisting
the Company in the implementation, administration and management of the Plan. These recipients may be located in the Participant&#146;s country, or elsewhere, and the Participant&#146;s country may have different data privacy laws and protections
than the recipients&#146; country. Through acceptance of an Award, each Participant authorizes such recipients to receive, possess, use, retain and transfer the Data, in electronic or other form, for the purposes of implementing, administering and
managing the Participant&#146;s participation in the Plan, including any requisite transfer of such Data as may be required to a broker or other third party with whom the Company or the Participant may elect to deposit any shares of Common Stock.
The Data related to a Participant will be held only as long as is necessary to implement, administer, and manage the Participant&#146;s participation in the Plan. A Participant may, at any time, view the Data held by the Company with respect to such
Participant, request additional information about the storage and processing of the Data with respect to such Participant, recommend any necessary corrections to the Data with respect to the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Participant or refuse or withdraw the consents herein in writing, in any case without cost, by contacting his or her local human resources representative. The Company may cancel
Participant&#146;s ability to participate in the Plan and, in the Board&#146;s discretion, the Participant may forfeit any outstanding Awards if the Participant refuses or withdraws his or her consents as described herein. For more information on
the consequences of refusal to consent or withdrawal of consent, Participants may contact their local human resources representative. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)
<U>Restrictions on Shares; Clawback Provisions</U>. Shares of Common Stock acquired in respect of Awards shall be subject to such terms and conditions as the Board shall determine, including, without limitation, restrictions on the transferability
of shares of Common Stock, the right of the Company to repurchase shares of Common Stock, the right of the Company to require that shares of Common Stock be transferred in the event of certain transactions,
<FONT STYLE="white-space:nowrap">tag-along</FONT> rights, bring-along rights, redemption and <FONT STYLE="white-space:nowrap">co-sale</FONT> rights and voting requirements. Such terms and conditions may be additional to those contained in the Plan
and may, as determined by the Board, be contained in the applicable Award Agreement or in an exercise notice, stockholders&#146; agreement or in such other agreement as the Board shall determine, in each case in a form determined by the Board. The
issuance of such shares of Common Stock shall be conditioned on the Participant&#146;s consent to such terms and conditions and the Participant&#146;s entering into such agreement or agreements. All Awards (including any proceeds, gains or other
economic benefit actually or constructively received by Participant upon any receipt or exercise of any Award or upon the receipt or resale of any shares of Common Stock underlying the Award) shall be subject to the provisions of any clawback policy
implemented by the Company, including, without limitation, any clawback policy adopted to comply with the requirements of the Dodd-Frank Wall Street Reform and Consumer Protection Act and any rules or regulations promulgated thereunder, to the
extent set forth in such clawback policy and/or in the applicable Award Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPYRE THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>2023 EQUITY INCENTIVE PLAN </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CALIFORNIA SUPPLEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to Section&nbsp;10(e) of the Plan, the Board has adopted this supplement for purposes of satisfying the requirements of
Section&nbsp;25102(o) of the California Law: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any Awards granted under the Plan to a Participant who is a resident of the State of
California on the date of grant (a &#147;<B>California Participant</B>&#148;) shall be subject to the following additional limitations, terms and conditions: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. <U>Additional Limitations on Options</U>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Minimum Vesting Rate</U>. Except in the case of Options granted to California Participants who are officers, directors, managers,
consultants or advisors of the Company or its affiliates (which Options may become exercisable at whatever rate is determined by the Board), Options granted to California Participants shall become exercisable at a rate of not less than 20% per year
over five years from the date of grant; <I>provided,</I> <I>that</I>, such Options may be subject to such reasonable forfeiture conditions as the Board may choose to impose and which are not inconsistent with Section&nbsp;260.140.41 of the
California Regulations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Minimum Exercise Price</U>. The exercise price of Options granted to California Participants may not be
less than 85% of the Fair Market Value of the Common Stock on the date of grant in the case of a Nonstatutory Stock Option or less than 100% of the Fair Market Value of the Common Stock on the date of grant in the case of an Incentive Stock Option;
<I>provided, however</I>, that if the California Participant is a person who owns stock possessing more than 10% of the total combined voting power of all classes of stock of the Company or its parent or subsidiary corporations, the exercise price
shall be not less than 110% of the Fair Market Value of the Common Stock on the date of grant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Maximum Duration of Options</U>. No
Options granted to California Participants shall have a term in excess of 10 years measured from the Option grant date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Minimum
Exercise Period Following Termination</U>. Unless a California Participant&#146;s employment is terminated for cause (as defined by applicable law, the terms of any contract of employment between the Company and such Participant, or in the
instrument evidencing the grant of such Participant&#146;s Option), in the event of termination of employment of such Participant, such Participant shall have the right to exercise an Option, to the extent that he or she was otherwise entitled to
exercise such Option on the date employment terminated, as follows: (i)&nbsp;at least six months from the date of termination, if termination was caused by such Participant&#146;s death or &#147;permanent and total disability&#148; (within the
meaning of Section&nbsp;22(e)(3) of the Code) and (ii)&nbsp;at least 30 days from the date of termination, if termination was caused other than by such Participant&#146;s death or &#147;permanent and total disability&#148; (within the meaning of
Section&nbsp;22(e)(3) of the Code). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Limitation on Repurchase Rights</U>. If an Option granted to a California Participant gives
the Company the right to repurchase shares of Common Stock issued pursuant to the Plan upon termination of employment of such Participant, the terms of such repurchase right must comply with Section&nbsp;260.140.41(k) of the California Regulations.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. <U>Additional Limitations for Restricted Stock</U>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Minimum Purchase Price</U>. The purchase price for Restricted Stock granted to a California Participant shall be not less than 85% of
the Fair Market Value of the Common Stock at the time such Participant is granted the right to purchase shares under the Plan or at the time the purchase is consummated; <I>provided, however</I>, that if such Participant is a person who owns stock
possessing more than 10% of the total combined voting power or value of all classes of stock of the Company or its parent or subsidiary corporations, the purchase price shall be not less than 100% of the Fair Market Value of the Common Stock at the
time such Participant is granted the right to purchase shares under the Plan or at the time the purchase is consummated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)
<U>Limitation of Repurchase Rights</U>. If Restricted Stock granted to a California Participant gives the Company the right to repurchase shares of Common Stock issued pursuant to the Plan upon termination of employment of such Participant, the
terms of such repurchase right must comply with Section&nbsp;260.140.42(h) of the California Regulations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. <U>Additional Limitations for Other
Stock-Based Awards</U>. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The terms of all Awards granted to a California Participant under Section&nbsp;7 of the Plan shall comply, to
the extent applicable, with Section&nbsp;260.140.41 or Section&nbsp;260.140.42 of the California Regulations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. <U>Additional Requirement to Provide
Information to California Participants</U>. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company shall provide to each California Participant and to each California
Participant who acquires Common Stock pursuant to the Plan, not less frequently than annually, copies of annual financial statements (which need not be audited). The Company shall not be required to provide such statements to key employees whose
duties in connection with the Company assure their access to equivalent information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. <U>Additional Limitations on Timing of Awards</U>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No Award granted to a California Participant shall become exercisable, vested or realizable, as applicable to such Award, unless the Plan has
been approved by the holders of a majority of the Company&#146;s outstanding voting securities within 12 months before or after the date the Plan was adopted by the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. <U>Additional Limitations Relating to Definition of Fair Market Value</U>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of Section&nbsp;1(b) and 2(a) of this supplement, &#147;Fair Market Value&#148; shall be determined in a manner not inconsistent
with Section&nbsp;260.140.50 of the California Regulations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. <U>Additional Restriction Regarding Recapitalizations, Stock Splits, Etc</U>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of Section&nbsp;8 of the Plan, in the event of a stock split, reverse stock split, stock dividend, recapitalization, combination,
reclassification or other distribution of the Company&#146;s securities, the number of securities allocated to each California Participant must be adjusted proportionately and without the receipt by the Company of any consideration from any
California Participant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-2 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.13
<SEQUENCE>25
<FILENAME>d518298dex1013.htm
<DESCRIPTION>EX-10.13
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.13</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.13 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AEGLEA BIOTHERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STOCK RESTRICTION AGREEMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Stock
Restriction Agreement (this &#147;<B><I>Agreement</I></B>&#148;) is made and entered into as of March&nbsp;10, 2015 (the &#147;<B><I>Effective Date</I></B>&#148;) by and between Aeglea BioTherapeutics, Inc., a Delaware corporation (the
&#147;<B><I>Company</I></B>&#148;), and (&#147;<B><I>Stockholder</I></B>&#148;). </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>R E C I T A L S </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A. Stockholder was the owner of Common B Shares (the &#147;<B><I>Units</I></B>&#148;) of Aeglea BioTherapeutics Holdings, LLC, the predecessor in interest of
the Company (the &#147;<B><I>Predecessor LLC</I></B>&#148;), acquired pursuant to that certain Award Agreement dated as of by and between the Stockholder and the Predecessor LLC (the &#147;<B><I>Award Agreement</I></B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">B. Pursuant to that certain Plan of Conversion, dated as of the date hereof, the Units converted into shares (the &#147;<B><I>Shares</I></B>&#148;) of the
Company&#146;s Common Stock (such conversion of the Units into Shares, the &#147;<B><I>Conversion</I></B>&#148;), and as of such date % of the Units were vested and % of the Units were unvested in accordance with the terms of the Award
Agreement.<B><I> </I></B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">C. To induce certain investors to purchase shares of the Company&#146;s Series B Preferred Stock pursuant to that certain
Series B Preferred Stock Purchase Agreement by and among the Company and such investors dated of even date herewith, and as an incentive for Stockholder to remain with the Company or an Affiliate (as defined below) of the Company, the parties have
agreed upon a mechanism for the repurchase of certain of the Shares from Stockholder should Stockholder&#146;s relationship with the Company terminate, all as more fully set forth below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOW, THEREFORE,</B> in consideration of the mutual promises herein contained, the Company and Stockholder agree as follows. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. </B><B><U>MARKET STANDOFF AGREEMENT</U></B><B>.</B> Stockholder hereby agrees that during a period, not to exceed 180 days (or, if required by such
underwriter, such longer period of time as is necessary to enable such underwriter to issue a research report or make a public appearance that relates to an earnings release or announcement by the Company within 18 days prior to or after the date
that is one hundred eighty (180)&nbsp;days after the effective date of the registration statement relating to such offering, but in any event not to exceed two hundred ten (210)&nbsp;days following the effective date of the registration statement
relating to such offering), following the effective date of the initial, effective registration statement of the Company filed under the Securities Act (&#147;<B><I>IPO</I></B>&#148;), it shall not, to the extent requested by the Company and any
underwriter, sell, pledge, transfer, make any short sale of, loan, grant any option for the purchase of, or otherwise transfer or dispose of any Capital Stock of the Company held by it at any time during such period except Capital Stock included in
such registration. The underwriters in connection with the IPO are intended third-party beneficiaries of this Section&nbsp;1 and shall have the right, power and authority to enforce the provisions hereof as though they were a party hereto. Each
Holder further agrees to execute such agreements as may be reasonably requested by the underwriters in the IPO that are consistent with this Section&nbsp;1 or that are necessary to give further effect thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. </B><B><U>RESTRICTIONS ON TRANSFER</U></B>. Stockholder acknowledges and agrees that neither Unvested Shares (defined below) nor Vested Shares (defined
below) may be sold or otherwise transferred in any manner otherwise than by will or by the laws of descent or distribution, without the prior written consent of the Company. The terms of this Agreement shall be binding upon the executors,
administrators, heirs, successors and assigns of Stockholder. The restrictions on transfer set forth in this Section&nbsp;2 will expire on the earlier of an IPO or a Company Sale (as defined in the Company&#146;s restated certificate of
incorporation, as may be amended from time to time). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. </B><B><U>SUPPLEMENTAL RIGHT OF FIRST REFUSAL</U></B>. In addition to the restrictions on
transfer set forth in Section&nbsp;2 above, and any restrictions on transfer applicable under the that certain Right of First Refusal and <FONT STYLE="white-space:nowrap">Co-Sale</FONT> Agreement dated March&nbsp;9, 2015 between the Company and
certain investors and other stockholders, as may be </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
amended from time to time, Stockholder acknowledges and agrees that if the foregoing restrictions are not applicable for any reason, then the following restrictions on transfer shall instead
apply: (i)&nbsp;Unvested Shares (defined below) may not be sold or otherwise transferred by Stockholder without the Company&#146;s prior written consent, and (ii)&nbsp;that before any Vested Shares held by Stockholder or any transferee of such
Vested Shares (either sometimes referred to herein as the &#147;<B><I>Holder</I></B>&#148;) may be sold or otherwise transferred (including without limitation a transfer by gift or operation of law), the Company and/or its assignee(s) will have a
right of first refusal to purchase the Shares to be sold or transferred (the &#147;<B><I>Offered Shares</I></B>&#148;) on the terms and conditions set forth in this Section&nbsp;3 (the &#147;<B><I>Right of First Refusal</I></B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3.1. </B><B><U>Notice of Proposed Transfer</U></B><B>.</B> The Holder of the Offered Shares will deliver to the Company a written notice (the
&#147;<B><I>Notice</I></B>&#148;) stating: (a)&nbsp;the Holder&#146;s bona fide intention to sell or otherwise transfer the Offered Shares; (b)&nbsp;the name and address of each proposed purchaser or other transferee (the &#147;<B><I>Proposed
Transferee</I></B>&#148;); (c) the number of Offered Shares to be transferred to each Proposed Transferee; (d)&nbsp;the bona fide cash price or other consideration for which the Holder proposes to transfer the Offered Shares (the &#147;<B><I>Offered
Price</I></B>&#148;); and (e)&nbsp;that the Holder acknowledges this Notice is an offer to sell the Offered Shares to the Company and/or its assignee(s) pursuant to the Company&#146;s Right of First Refusal at the Offered Price as provided for in
this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3.2. </B><B><U>Exercise of Right of First Refusal</U></B>. At any time within thirty (30)&nbsp;days after the date the Notice was
effective in accordance with Section&nbsp;10.1 hereof, the Company and/or its assignee(s) may, by giving written notice to the Holder, elect to purchase all (or, with the consent of the Holder, less than all) the Offered Shares proposed to be
transferred to any one or more of the Proposed Transferees named in the Notice, at the purchase price determined in accordance with Section&nbsp;3.3 below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3.3. </B><B><U>Purchase Price</U></B>. The purchase price for the Offered Shares purchased under this Section will be the Offered Price, provided that if
the Offered Price consists of no legal consideration (as, for example, in the case of a transfer by gift), the purchase price will be the fair market value of the Offered Shares as determined in good faith by the Company&#146;s Board of Directors.
If the Offered Price includes consideration other than cash, then the value of the <FONT STYLE="white-space:nowrap">non-cash</FONT> consideration, as determined in good faith by the Company&#146;s Board of Directors, will conclusively be deemed to
be the cash equivalent value of such <FONT STYLE="white-space:nowrap">non-cash</FONT> consideration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3.4. </B><B><U>Payment</U></B>. Payment of the
purchase price for the Offered Shares will be payable, at the option of the Company and/or its assignee(s) (as applicable), by check or by cancellation of all or a portion of any outstanding indebtedness owed by the Holder to the Company (or to such
assignee, in the case of a purchase of Offered Shares by such assignee) or by any combination thereof. The purchase price will be paid without interest within sixty (60)&nbsp;days after the Company&#146;s receipt of the Notice, or, at the option of
the Company and/or its assignee(s), in the manner and at the time(s) set forth in the Notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3.5. </B><B><U>Exempt Transfers</U></B>. Notwithstanding
anything to the contrary in this Section, the following transfers of Vested Shares will be exempt from the Right of First Refusal: (a)&nbsp;the transfer of any or all of the Vested Shares during Stockholder&#146;s lifetime by gift or on
Stockholder&#146;s death by will or intestacy to Stockholder&#146;s &#147;<B><I>Immediate Family</I></B>&#148; (as defined below) or to a trust for the benefit of Stockholder or Stockholder&#146;s Immediate Family, provided that each transferee or
other recipient agrees in a writing satisfactory to the Company that the provisions of this Section will continue to apply to the transferred Vested Shares in the hands of such transferee or other recipient; (b)&nbsp;except as provided in
Section&nbsp;4.2.2 clause (b)&nbsp;below, any transfer or conversion of Vested Shares made pursuant to a statutory merger or statutory consolidation of the Company with or into another corporation or corporations; or (c)&nbsp;any transfer of Vested
Shares pursuant to the winding up and dissolution of the Company. As used herein, the term &#147;<B><I>Immediate Family</I></B>&#148; will mean Stockholder&#146;s spouse, the lineal descendant or antecedent, brother or sister, of Stockholder or
Stockholder&#146;s spouse, or the spouse of any lineal descendant or antecedent, brother or sister of Stockholder, or Stockholder&#146;s spouse, whether or not any of the above are adopted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3.6. </B><B><U>Termination of Right of First Refusal</U></B>. The Right of First Refusal will terminate as to all Shares (a)&nbsp;on the effective date of
the first sale of Common Stock of the Company to the general public pursuant to a registration statement filed with and declared effective by the SEC under the 1933 Act (other than a registration statement relating solely to the issuance of Common
Stock pursuant to a business combination or an employee incentive or benefit plan) or (b)&nbsp;on any transfer or conversion of Shares made pursuant to a statutory merger or statutory consolidation of the Company with or into another corporation or
corporations if the common stock of the surviving corporation or any direct or indirect parent corporation thereof is registered under the Securities Exchange Act of 1934, as amended. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. </B><B><U>COMPANY&#146;S REPURCHASE OPTIONS</U></B><B>.</B> The Company and its assignees shall have
the option, exercisable if Stockholder ceases to be employed by the Company (as defined herein) for any reason, or no reason, including without limitation Stockholder&#146;s death, disability, voluntary resignation or termination by the Company with
or without cause, to (i)&nbsp;repurchase all or a portion of the Unvested Shares then held by Stockholder on the terms and conditions set forth in Section&nbsp;4.4 (the &#147;<B><I>Unvested Share Repurchase Option</I></B>&#148;) and
(ii)&nbsp;repurchase all or a portion of the Vested Shares then held by Stockholder on the terms and conditions set forth in Section&nbsp;4.4 (the &#147;<B><I>Vested Share Repurchase Option</I></B>&#148;).<B><I> </I></B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4.1. </B><B><U>Definition of &#147;Employed by the Company&#148;; &#147;Termination Date&#148;</U></B><B>.</B> For purposes of this Agreement, Stockholder
will be considered to be &#147;<B><I>employed by the Company</I></B>&#148; if the Board of Directors of the Company (the &#147;<B><I>Board</I></B>&#148;) determines that Stockholder is rendering substantial services as an officer, employee,
consultant or independent contractor to the Company or to any Affiliate of the Company. In case of any dispute as to whether Stockholder is employed by the Company, the Board shall have sole discretion to determine whether Stockholder has ceased to
be employed by the Company or any Affiliate and the effective date on which Stockholder&#146;s employment terminated (the &#147;<B><I>Termination Date</I></B>&#148;). An &#147;<B><I>Affiliate</I></B>&#148; means any entity that owns, directly or
indirectly, shares representing more than 50% of the total combined voting power of all classes of capital stock of the Company or any entity in which the Company owns, directly or indirectly, equity interests representing more than 50% of the
voting power of such entity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4.2. </B><B><U>Unvested and Vested Shares</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4.2.1 </B><U>Vesting Schedule</U>. <B>[Example only]</B> Shares that are vested pursuant to the schedule set forth herein are &#147;<B><I>Vested
Shares</I></B>&#148;. Shares that are not vested pursuant to the schedule set forth herein are &#147;<B><I>Unvested Shares</I></B>&#148;. On the Effective Date [ ] of the Shares will be Unvested Shares and [ ] of the Shares will be Vested Shares. If
Stockholder has continuously been employed by the Company or any Affiliate, at all times from the Effective Date until [ ] (the &#147;<B><I>First Vesting Date</I></B>&#148;), then on the First Vesting Date, and additional [1/16th] of the Shares will
become Vested Shares; and thereafter, for so long (and only for so long) as Stockholder remains continuously employed by the Company or any Affiliate at all times after the First Vesting Date, on the last day of each succeeding three month period
elapsed after the First Vesting Date an additional [1/16th] of the Shares will become Vested Shares. No Unvested Shares will become Vested Shares after the Termination Date. If the application of the vesting percentage results in a fractional Share,
such fraction shall be rounded down to the nearest whole Share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4.3. </B><B><U>Adjustments</U></B><B>.</B> The number of Shares that are Vested Shares
or Unvested Shares will be proportionally adjusted to reflect any stock dividend, stock split, reverse stock split or recapitalization of the common stock of the Company occurring after the Effective Date.<B> </B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4.4. </B><B><U>Repurchase Option on Unvested Shares at $0.0001 Per Share</U></B>. At any time within ninety (90)&nbsp;days after the Termination Date, the
Company or its assignee shall have the right (but not the obligation), to repurchase any or all of the Unvested Shares (the &#147;<B><I>Unvested Share Repurchase Option</I></B>&#148;) by giving Stockholder written notice of exercise of the Unvested
Share Repurchase Option. The Company and/or its assignee(s) will then have the option to repurchase from Stockholder (or from Stockholder&#146;s personal representative as the case may be) any or all of the Unvested Shares at $0.0001 per Share, as
adjusted to reflect any stock dividend, stock split, reverse stock split or recapitalization of the common stock of the Company occurring after the Effective Date (the &#147;<B><I>Unvested Share Repurchase Price</I></B>&#148;). The Unvested Share
Repurchase Price will be payable, at the option of the Company and/or its assignee(s), as the case may be, by check or by cancellation of all or a portion of any outstanding indebtedness owed by Stockholder to the Company (or to such assignee) or by
any combination thereof. The Unvested Share Repurchase Price will be paid without interest within ninety (90)&nbsp;days after the Company gives the Stockholder written notice of the exercise of the Unvested Share Repurchase Option. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4.5. </B><B><U>Repurchase Option on Vested Shares at $0.0001 Per Share</U></B>. If Stockholder ceases to
be employed by the Company or an Affiliate due to termination by the Company or an Affiliate for Cause (as defined below), then at any time within ninety (90)&nbsp;days after the Termination Date, the Company or its assignee, shall have the right
(but not the obligation), to repurchase any or all of the Vested Shares (the &#147;<B><I>Vested Share Repurchase Option</I></B>&#148;) by giving Stockholder written notice of exercise of the Vested Share Repurchase Option. The Company and/or its
assignee(s) will then have the option to repurchase from Stockholder (or from Stockholder&#146;s personal representative as the case may be) any or all of the Vested Shares at $0.001 per Share, as adjusted to reflect any stock dividend, stock split,
reverse stock split or recapitalization of the common stock of the Company occurring after the Effective Date (the &#147;<B><I>Vested Share Repurchase Price</I></B>&#148;). The Vested Share Repurchase Price will be payable, at the option of the
Company and/or its assignee(s), as the case may be, by check or by cancellation of all or a portion of any outstanding indebtedness owed by Stockholder to the Company (or to such assignee) or by any combination thereof. The Vested Share Repurchase
Price will be paid without interest within ninety (90)&nbsp;days after the Company gives the Stockholder written notice of the exercise of the Vested Share Repurchase Option. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of this Section&nbsp;4.5, &#147;<B>Cause</B>&#148; shall mean the termination of Stockholder&#146;s status as an employee, a director or
consultant (as applicable) of the Company or an Affiliate for any of the following reasons, as determined by the Board of Directors of the Company; provided, that, with respect to a Stockholder that is party to an agreement with the Company where a
termination for cause is defined in such agreement, the definition in such agreement shall govern the determination under this Section&nbsp;4.5:(i) Stockholder commits a material breach of any consulting, employment, noncompetition, confidentiality
or similar agreement with the Company or an Affiliate, as determined under such agreement; (ii)&nbsp;Stockholder is convicted (including a trial, plea of guilty or plea of nolo contendere) for committing an act of fraud, embezzlement, theft, or
other act constituting a felony; or (iii)&nbsp;Stockholder willfully engages in gross misconduct or willfully violates the policies of the Company or an Affiliate in a manner that is materially and demonstrably injurious to the Company and/or the
Affiliate. However, no act, or failure to act, on the grantee&#146;s part shall be considered &#147;willful&#148; unless done, or omitted to be done, by the grantee not in good faith and without reasonable belief that the grantee&#146;s action or
omission was in the best interest of the Company or the Affiliate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4.6. </B><B><U>Right of Termination Unaffected</U></B>. Nothing in this Agreement
will be construed to limit or otherwise affect in any manner whatsoever the right or power of the Company (or any Affiliate) to terminate Stockholder&#146;s employment with the Company (or any Affiliate) at any time for any reason or no reason, with
or without cause. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. </B><B><U>RIGHTS AS OWNER OF SHARES</U></B><B>.</B> Subject to the terms and conditions of this Agreement, Stockholder will have
all of the rights to the Shares from and after the date that Stockholder acquired them in the Conversion until such time as Stockholder disposes of the Shares or the Company and/or its assignee(s) exercise(s) the Repurchase Option. Upon an exercise
of the Repurchase Option, Stockholder will have no further rights as a holder of the Shares so purchased upon such exercise, except the right to receive payment for the Shares so purchased in accordance with the provisions of this Agreement, and
Stockholder will promptly surrender the stock certificate(s) evidencing the Shares so purchased to the Company for transfer or cancellation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6.
</B><B><U>ESCROW</U></B>. As security for Stockholder&#146;s faithful performance of this Agreement, Stockholder agrees, immediately upon receipt of the stock certificate(s) evidencing the Shares, to deliver such certificate(s), together with the
Stock Powers attached in the form of <U>Exhibit 1</U> hereto executed by Stockholder and by Stockholder&#146;s spouse, if any (with the date, transferee, stock certificate number and number of Shares left blank), to the Secretary of the Company or
other designee of the Company (the &#147;<B><I>Escrow Holder</I></B>&#148;), who is hereby appointed to hold such certificate(s) and Stock Powers in escrow and to take all such actions and to effectuate all such transfers and/or releases of such
Shares as are in accordance with the terms of this Agreement. Escrow Holder will act solely for the Company as its agent and not as a fiduciary. Stockholder and the Company agree that Escrow Holder will not be liable to any party to this Agreement
(or to any other party) for any actions or omissions unless Escrow Holder is grossly negligent or intentionally fraudulent in carrying out the duties of Escrow Holder under this Agreement. Escrow Holder may rely upon any letter, notice or other
document executed with any signature purported to be genuine and may rely on the advice of counsel and obey any order of any court with respect to the transactions contemplated by this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. </B><B><U>TAX CONSEQUENCES</U></B>. STOCKHOLDER UNDERSTANDS THAT STOCKHOLDER MAY SUFFER ADVERSE TAX CONSEQUENCES AS A RESULT OF STOCKHOLDER&#146;S
PURCHASE OR DISPOSITION OF THE SHARES. STOCKHOLDER REPRESENTS (a)&nbsp;THAT STOCKHOLDER HAS CONSULTED WITH A TAX ADVISER THAT STOCKHOLDER DEEMS ADVISABLE IN CONNECTION WITH THE PURCHASE OR DISPOSITION OF THE SHARES AND (b)&nbsp;THAT STOCKHOLDER IS
NOT RELYING ON THE COMPANY </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
FOR ANY TAX ADVICE. Stockholder hereby acknowledges that Stockholder has been informed that, in addition to receiving taxable income upon the receipt of any Shares paid for by the cancellation of
compensation for services rendered, unless an election is filed by the Stockholder with the Internal Revenue Service (and, if necessary, the proper state taxing authorities) <U>within 30 days</U> after the acquisition of the Shares to be effective,
electing pursuant to Section&nbsp;83(b) of the Internal Revenue Code (and similar state tax provisions, if applicable) to be taxed currently on any difference between the purchase price of the Shares (&#147;<B><I>Purchase Price</I></B>&#148;) and
their fair market value on the date of purchase, there will be a recognition of taxable income to the Stockholder, measured by the excess, if any, of the fair market value of the Shares, at the time they cease to be Unvested Shares, over the
Purchase Price for such Shares. Stockholder represents that Stockholder has consulted any tax advisors Stockholder deems advisable in connection with Stockholder&#146;s acquisition of the Shares and the filing of the election under
Section&nbsp;83(b) and similar tax provisions. A form of Election under Section&nbsp;83(b) is attached hereto as <U>Exhibit 2</U> for reference. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">STOCKHOLDER HEREBY ASSUMES ALL RESPONSIBILITY FOR FILING SUCH ELECTION AND PAYING ANY TAXES RESULTING FROM SUCH ELECTION OR FROM FAILURE TO FILE THE ELECTION
AND PAYING TAXES RESULTING FROM THE LAPSE OF THE REPURCHASE RESTRICTIONS ON THE UNVESTED SHARES. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8. </B><B><U>RESTRICTIVE LEGENDS AND STOP-TRANSFER
ORDERS</U></B>. Stockholder understands and agrees that the Company will place the legends set forth below or similar legends on any stock certificate(s) evidencing the Shares, together with any other legends that may be required by state or federal
securities laws, the Company&#146;s Certificate of Incorporation or Bylaws, any other agreement between Stockholder and the Company or any third party: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &#147;</I><B><I>ACT</I></B><I>&#148;), OR UNDER
THE SECURITIES LAWS OF CERTAIN STATES. THESE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS, PURSUANT TO REGISTRATION
OR EXEMPTION THEREFROM. INVESTORS SHOULD BE AWARE THAT THEY MAY BE REQUIRED TO BEAR THE FINANCIAL RISKS OF THIS INVESTMENT FOR AN INDEFINITE PERIOD OF TIME. THE ISSUER OF THESE SECURITIES MAY REQUIRE AN OPINION OF COUNSEL IN FORM AND SUBSTANCE
SATISFACTORY TO THE ISSUER TO THE EFFECT THAT ANY PROPOSED TRANSFER OR RESALE IS IN COMPLIANCE WITH THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO CERTAIN RESTRICTIONS ON TRANSFER AS SET FORTH IN THE ISSUER&#146;S EQUITY INCENTIVE PLAN AND THE
STOCK RESTRICTION AGREEMENT RELATING TO THESE SHARES, COPIES OF WHICH MAY BE OBTAINED AT THE PRINCIPAL OFFICE OF THE ISSUER, SUCH TRANSFER RESTRICTIONS ARE BINDING ON TRANSFEREES OF THESE SHARES. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stockholder agrees that, to ensure compliance with the restrictions imposed by this Agreement, the Company may issue appropriate &#147;stop-transfer&#148;
instructions to its transfer agent, if any, and if the Company transfers its own securities, it may make appropriate notations to the same effect in its own records. The Company will not be required (a)&nbsp;to transfer on its books any Shares that
have been sold or otherwise transferred in violation of any of the provisions of this Agreement or (b)&nbsp;to treat as owner of such Shares, or to accord the right to vote or pay dividends, to any Stockholder or other transferee to whom such Shares
have been so transferred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. </B><B><U>COMPLIANCE WITH LAWS AND REGULATIONS</U></B>. The issuance and transfer of the Shares will be subject to and
conditioned upon compliance by the Company and Stockholder with all applicable state and federal laws and regulations and with all applicable requirements of any stock exchange or automated quotation system on which the Company&#146;s Common Stock
may be listed or quoted at the time of such issuance or transfer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10. </B><B><U>GENERAL PROVISIONS</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10.1. </B><B><U>Notices</U></B>. Any and all notices required or permitted to be given to a party pursuant to the provisions of this Agreement will be in
writing and will be effective and deemed to provide such party sufficient notice under this Agreement on the earliest of the following: (a)&nbsp;at the time of personal delivery, if delivery is in person; (b)&nbsp;one (1) business day after deposit
with an express overnight courier for United States deliveries, or two (2)&nbsp;business days after such deposit for deliveries outside of the United States; or (c)&nbsp;three (3) business days after deposit in the United States mail by certified
mail (return receipt requested) for United States deliveries. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All notices for delivery outside the United States will be sent by express courier. All notices not
delivered personally will be sent with postage and/or other charges prepaid and properly addressed to the party to be notified at the address set forth below the signature lines of this Agreement or at such other address as such other party may
designate by one of the indicated means of notice herein to the other party hereto. A &#147;<B><I>business day</I></B>&#148; shall be a day, other than Saturday or Sunday, when the banks in the city of San Francisco are open for business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10.2. </B><B><U>Further Assurances</U></B>. The parties agree to execute such further documents and instruments and to take such further actions as may be
reasonably necessary to carry out the purposes and intent of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10.3. </B><B><U>Titles and Headings</U></B>. The titles, captions and
headings of this Agreement are included for ease of reference only and will be disregarded in interpreting or construing this Agreement. Unless otherwise specifically stated, all references herein to &#147;sections&#148; and &#147;exhibits&#148;
will mean &#147;sections&#148; and &#147;exhibits&#148; to this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10.4. </B><B><U>Governing Law</U></B>. This Agreement will be governed by
and construed in accordance with the laws of the State of Delaware, without giving effect to that body of laws pertaining to conflict of laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10.5.
</B><B><U>Assignments; Successors and Assigns</U></B>. The Company may assign any of its rights and obligations under this Agreement, including but not limited to its rights to repurchase Shares under the Repurchase Option. Any assignment of rights
and obligations by any other party to this Agreement requires the Company&#146;s prior written consent. This Agreement, and the rights and obligations of the parties hereunder, will be binding upon and inure to the benefit of their respective
successors, assigns, heirs, executors, administrators and legal representatives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10.6. </B><B><U>Entire Agreement</U></B>. This Agreement and the
documents referred to herein constitute the entire agreement and understanding of the parties with respect to the subject matter of this Agreement, and supersede all prior understandings and agreements, whether oral or written, between or among the
parties hereto with respect to the specific subject matter hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10.7. </B><B><U>Amendment and Waivers</U></B>. This Agreement may be amended only
by a written agreement executed by each of the parties hereto. No amendment of or waiver of, or modification of any obligation under this Agreement will be enforceable unless set forth in a writing signed by the party against which enforcement is
sought. Any amendment effected in accordance with this section will be binding upon all parties hereto and each of their respective successors and assigns. No delay or failure to require performance of any provision of this Agreement shall
constitute a waiver of that provision as to that or any other instance. No waiver granted under this Agreement as to any one provision herein shall constitute a subsequent waiver of such provision or of any other provision herein, nor shall it
constitute the waiver of any performance other than the actual performance specifically waived. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10.8. </B><B><U>Severability</U></B>. If any provision
of this Agreement is determined by any court or arbitrator of competent jurisdiction to be invalid, illegal or unenforceable in any respect, such provision will be enforced to the maximum extent possible given the intent of the parties hereto. If
such clause or provision cannot be so enforced, such provision shall be stricken from this Agreement and the remainder of this Agreement shall be enforced as if such invalid, illegal or unenforceable clause or provision had (to the extent not
enforceable) never been contained in this Agreement. Notwithstanding the forgoing, if the value of this Agreement based upon the substantial benefit of the bargain for any party is materially impaired, which determination as made by the presiding
court or arbitrator of competent jurisdiction shall be binding, then both parties agree to substitute such provision(s) through good faith negotiations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10.9. </B><B><U>Counterparts; Facsimile Signatures</U></B>. This Agreement may be executed in any number of counterparts, each of which when so executed
and delivered will be deemed an original, and all of which together shall constitute one and the same agreement. This Agreement may be executed and delivered by facsimile or electronic transmission and upon such delivery the facsimile or electronic
signature will be deemed to have the same effect as if the original signature had been delivered to the other party. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature page follows] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the Company has caused this Stock Restriction Agreement to be executed by its
duly authorized representative and Stockholder has executed this Agreement, each as of the Effective Date.<B> </B> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="39%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"><B>COMPANY: AEGLEA BIOTHERAPEUTICS, INC.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>STOCKHOLDER:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><B>[Name]</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">David Lowe</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Address:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">CEO</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">901 S. MoPac Expressway</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Barton Oaks Plaza One,
Suite 250</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Austin, Texas 78746</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><U>LIST OF EXHIBITS </U></I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="90%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>Exhibit&nbsp;1:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Stock Power and Spouse Consent</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>Exhibit&nbsp;2:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Election Under Section&nbsp;83(b) of the Internal Revenue Code</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT 1 </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STOCK POWER AND ASSIGNMENT </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPARATE FROM CERTIFICATE </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">FOR VALUE
RECEIVED and pursuant to that certain Stock Restriction Agreement dated as of March , 2015 (the &#147;<B><I>Agreement</I></B>&#148;), the undersigned hereby sells, assigns and transfers unto , shares of the Common Stock, $0.0001 par value per share,
of Aeglea BioTherapeutics, Inc., a Delaware corporation (the &#147;<B><I>Company</I></B>&#148;), standing in the undersigned&#146;s name on the books of the Company represented by Certificate No(s). delivered herewith, and does hereby irrevocably
constitute and appoint the Secretary of the Company as the undersigned&#146;s <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact,</FONT></FONT> with full power of substitution, to transfer said stock on the books of
the Company. <I>THIS ASSIGNMENT MAY ONLY BE USED AS AUTHORIZED BY THE AGREEMENT AND ANY EXHIBITS THERETO</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">STOCKHOLDER</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(Signature)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(Please Print Name)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(Spouse&#146;s Signature, if any)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(Please Print Spouse&#146;s Name)</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Instructions to Stockholder</U></B><B>:</B> Please do <U>not</U> fill in any blanks other than the signature line.
The purpose of this Stock Power and Assignment is to enable the Company and/or its assignee(s) to acquire the shares upon exercise of its &#147;Repurchase Option&#148; and &#147;Right of First Refusal&#148; set forth in the Agreement without
requiring additional signatures on the part of the Stockholder or Stockholder&#146;s Spouse, if any. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPOUSE CONSENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned spouse of (&#147;<B><I>Stockholder</I></B>&#148;) has read, understands and hereby approves all the terms and conditions of the Stock
Restriction Agreement dated March , 2015 (the &#147;<B><I>Agreement</I></B>&#148;), by and between Stockholder and Aeglea BioTherapeutics, Inc., a Delaware corporation (the &#147;<B><I>Company</I></B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I hereby agree to be irrevocably bound by all the terms and conditions of the Agreement (including but not limited to the Company&#146;s Repurchase Option and
the Right of First Refusal contained therein) and further agree that any community property interest I may have in the shares of the Company&#146;s Common Stock that are held by Stockholder and are subject to the Agreement (the
&#147;<B><I>Shares</I></B>&#148;) will be similarly bound by the Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I hereby appoint Stockholder as my <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">attorney-in-fact,</FONT></FONT> to act in my name, place and stead with respect to any amendment of the Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Signature of Spouse [Sign Here]</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name of Spouse [Please Print]</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#9744;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Check this box if you do not have a spouse.</P></TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT 2 </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ELECTION UNDER SECTION 83(b) OF THE </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INTERNAL REVENUE CODE </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ELECTION UNDER SECTION 83(b) OF THE </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INTERNAL REVENUE CODE </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned
Taxpayer hereby elects, pursuant to Section&nbsp;83(b) of the Internal Revenue Code of 1986, as amended, to include the excess, if any, of the fair market value of the property described below at the time of transfer over the amount paid for such
property, as compensation for services in the calculation of: (1)&nbsp;regular gross income; (2)&nbsp;alternative minimum taxable income; or (3)&nbsp;disqualifying disposition gross income, as the case may be. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="28%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="15%"></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">1.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">TAXPAYER&#146;S NAME:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">TAXPAYER&#146;S ADDRESS:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SOCIAL&nbsp;SECURITY&nbsp;NUMBER:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The property with respect to which the election is made is described as follows: shares of Common Stock, par
value $0.0001 per share, of Aeglea BioTherapeutics, Inc., a Delaware corporation (the &#147;<B><I>Company</I></B>&#148;), which is Taxpayer&#146;s employer or the corporation for whom the Taxpayer performs services. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The date on which the shares were transferred was , and this election is made for the calendar year 2015.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares are subject to the following restrictions: The Company may repurchase all or a portion of the shares
at the Taxpayer&#146;s original purchase price per share, under certain conditions at the time of Taxpayer&#146;s termination of employment or services. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The fair market value of the shares (without regard to restrictions other than restrictions which by their
terms will never lapse) was $ per share x shares = $ . </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amount paid for such shares was $ per share x shares = . </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Taxpayer has submitted a copy of this statement to the Company. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amount to include in gross income is $ . </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>THIS ELECTION MUST BE FILED WITH THE INTERNAL REVENUE SERVICE (&#147;</I><B><I>IRS</I></B><I>&#148;), AT THE OFFICE WHERE THE TAXPAYER FILES ANNUAL INCOME
TAX RETURNS, <U>WITHIN 30 DAYS</U> AFTER THE DATE OF TRANSFER OF THE SHARES, AND MUST ALSO BE FILED WITH THE TAXPAYER&#146;S INCOME TAX RETURNS FOR THE CALENDAR YEAR. THE ELECTION CANNOT BE REVOKED WITHOUT THE CONSENT OF THE IRS. </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">[NAME]</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.14
<SEQUENCE>26
<FILENAME>d518298dex1014.htm
<DESCRIPTION>EX-10.14
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.14</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.14 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEVERANCE AGREEMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Severance
Agreement (the &#147;<B>Agreement</B>&#148;) is entered into as of April __, 2018 (the &#147;<B>Effective Date</B>&#148;) by and between __________________ (the &#147;<B>Executive</B>&#148;) and Aeglea BioTherapeutics, Inc., a Delaware corporation
(the &#147;<B>Company</B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. Term of Agreement</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Agreement shall terminate on the date the Executive&#146;s employment with the Company or its subsidiary, as applicable, terminates for a reason other
than a Qualifying Termination or CIC Qualifying Termination (the &#147;<B><I>Expiration Date</I></B>&#148;); provided however, if a definitive agreement relating to a Change in Control has been signed by the Company on or before the Expiration Date,
then this Agreement shall remain in effect through the earlier of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The date the Executive&#146;s employment with the Company terminates for a reason other than a Qualifying
Termination or CIC Qualifying Termination, or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The date the Company has met all of its obligations under this Agreement following a termination of the
Executive&#146;s employment with the Company due to a Qualifying Termination or CIC Qualifying Termination. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Qualifying
Termination</B>. If the Executive is subject to a Qualifying Termination, then, subject to Sections 4, 9, and 10 below, Executive will be entitled to the following benefits: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Severance Benefits</B>. The Company or its subsidiaries shall pay the Executive (i) 12 months of his monthly
base salary, <FONT STYLE="white-space:nowrap">(ii)&nbsp;one-hundred</FONT> percent (100%) of the Executive&#146;s annual target bonus (in each case, at the rate in effect immediately prior to the actions that resulted in the Qualifying Termination).
The severance benefits shall be paid through salary continuation in equal installments in accordance with the Company&#146;s or its subsidiary&#146;s, as applicable, standard payroll procedures, with the initial payment to occur on the first payroll
date following the sixtieth (60th) day following the Separation, with the first installment to include a catchup payment for amounts covering the period from the date of Separation through the first payment date, <I>provided that</I> the Release
Conditions have been satisfied. However, if the period comprising the sum of the sixty <FONT STYLE="white-space:nowrap">(60)-day</FONT> period described in the preceding sentence and the ten <FONT STYLE="white-space:nowrap">(10)-day</FONT> period
described in Section&nbsp;7(e)(3) below spans two calendar years, then the payments which constitute deferred compensation subject to Section&nbsp;409A will not in any case commence in the first calendar year. The period between the date of
Executive&#146;s Separation and final severance payment shall be referred to herein as the &#147;<B>Severance Period</B>.&#148; </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Continued Employee Benefits</B>. If Executive timely elects continued coverage under the Consolidated
Omnibus Budget Reconciliation Act (&#147;<B>COBRA</B>&#148;), the Company or its subsidiary shall pay the full amount of Executive&#146;s COBRA premiums on behalf of the Executive for the Executive&#146;s continued coverage under the Company&#146;s
or its subsidiary&#146;s, as applicable, health, dental and vision plans, including coverage for the Executive&#146;s eligible dependents, for the Severance Period. Notwithstanding the foregoing, if the Company, in its sole discretion, determines
that it cannot provide the foregoing subsidy of COBRA coverage without potentially violating or causing the Company or its subsidiary to incur additional expense as a result of noncompliance with applicable law (including, without limitation,
Section&nbsp;2716 of the Public Health Service Act), the Company or its subsidiary instead shall provide to Executive a taxable monthly payment in an amount equal to the monthly COBRA premium that Executive would be required to pay to continue the
group health coverage in effect on the date of the Separation (which amount shall be based on the premium for the first month of COBRA coverage), which payments shall be made regardless of whether Executive elects COBRA continuation coverage and
shall commence on the later of (i)&nbsp;the first day of the month following the month in which Executive experiences a Separation and (ii)&nbsp;the effective date of the Company&#146;s determination of violation of applicable law, and shall end on
the earlier of (x)&nbsp;the effective date on which Executive becomes covered by a health, dental or vision insurance plan of a subsequent employer, and (y)&nbsp;the last day of the Severance Period, <I>provided that</I>, any taxable payments under
this Section&nbsp;2(b) will not be paid before the first business day occurring after the sixtieth (60th) day following the Separation and, once they commence, will include any unpaid amounts accrued from the date of Executive&#146;s Separation (to
the extent not otherwise satisfied with continuation coverage). However, if the period comprising the sum of the sixty <FONT STYLE="white-space:nowrap">(60)-day</FONT> period described in the preceding sentence and the ten <FONT
STYLE="white-space:nowrap">(10)-day</FONT> period described in Section&nbsp;7(e)(3) below spans two calendar years, then the payments which constitute deferred compensation subject to Section&nbsp;409A will not in any case be paid in the first
calendar year. Executive shall have no right to an additional <FONT STYLE="white-space:nowrap">gross-up</FONT> payment to account for the fact that such COBRA premium amounts are paid on an <FONT STYLE="white-space:nowrap">after-tax</FONT> basis.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Equity</B>. Any outstanding Equity Awards, including awards that would otherwise vest only upon satisfaction
of performance criteria, shall accelerate and become vested and exercisable as if an additional twelve (12)&nbsp;months of vesting had occurred to the then-unvested shares subject to the Equity Award. Equity Awards subject to performance-based
vesting criteria as of the date of the Separation shall accelerate and become vested and exercisable as to the number of shares subject to such Equity Award that would have vested if Executive had completed an additional twelve (12)&nbsp;months of
service following the date of Separation, provided, however, that the vesting of such performance-based awards shall be as if all applicable performance criteria were achieved at target levels during such
<FONT STYLE="white-space:nowrap">12-month</FONT> period. Subject to Section&nbsp;4, the accelerated vesting described above shall be effective as of the Separation. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. CIC Qualifying Termination</B>. If the Executive is subject to a CIC Qualifying Termination, then, subject to Sections 4, 9, and 10 below, Executive
will be entitled to the following benefits: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Severance Benefits</B>. The Company or its subsidiary shall pay the Executive the severance benefits set
forth in Section&nbsp;2(a) above. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Continued Employee Benefits</B>. The Company or its subsidiary shall pay the Executive the continued
employee benefits set forth in Section&nbsp;2(b) above for the same period that the Executive is paid severance benefits pursuant to Section&nbsp;3(a) following the Executive&#146;s Separation or, if earlier, until Executive becomes covered by a
health, dental or vision insurance plan of a subsequent employer or until Executive is no longer eligible for COBRA benefits. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Equity</B>. Each of Executive&#146;s then outstanding Equity Awards, including awards that would otherwise
vest only upon satisfaction of performance criteria, shall accelerate and become vested and exercisable as to 100% of the then unvested shares underlying the Equity Award. For awards that would otherwise vest only upon satisfaction of performance
criteria, the foregoing acceleration shall be based on achievement of performance criteria at target, except to the extent otherwise provided in the award agreement evidencing such award. &#147;<B>Equity Awards</B>&#148; means all options to
purchase shares of Company common stock as well as any and all other stock-based awards granted to the Executive, including but not limited to stock bonus awards, restricted stock, restricted stock units or stock appreciation rights. Subject to
Section&nbsp;4, the accelerated vesting described above shall be effective as of the Separation. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. General Release</B>. Any other
provision of this Agreement notwithstanding, the benefits under Section&nbsp;2 and 3 shall not apply unless the Executive (i)&nbsp;has executed a general release (in a form prescribed by the Company) of all known and unknown claims that he or she
may then have against the Company or entities or persons affiliated with the Company and such release has become effective and (ii)&nbsp;has agreed not to prosecute any legal action or other proceeding based upon any of such claims. The release must
be in the form prescribed by the Company, without alterations (this document effecting the foregoing, the &#147;<B>Release</B>&#148;). The Company or its subsidiary will deliver the form of Release to the Executive within thirty (30)&nbsp;days after
the Executive&#146;s Separation. The Executive must execute and return the Release within the time period specified in the form. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. Accrued
Compensation and Benefits</B>. Notwithstanding anything to the contrary in Section&nbsp;2 and 3 above, in connection with any termination of employment upon or following a Change in Control (whether or not a Qualifying Termination or CIC Qualifying
Termination), the Company or its subsidiary shall pay Executive&#146;s earned but unpaid base salary and other vested but unpaid cash entitlements for the period through and including the termination of employment, including unused earned vacation
pay and unreimbursed documented business expenses incurred by Executive prior to the date of termination (collectively &#147;<B>Accrued Compensation and Expenses</B>&#148;), as required by law and the applicable Company or its subsidiary, as
applicable, plan or policy. In addition, Executive shall be entitled to any other vested benefits earned by Executive for the period through and including the termination date of Executive&#146;s employment under any other employee benefit plans and
arrangements maintained by the Company or its subsidiary, as applicable, in accordance with the terms of such plans and arrangements, except as modified herein (collectively &#147;<B>Accrued Benefits</B>&#148;). Any Accrued Compensation and Expenses
to which the Executive is entitled shall be paid to the Executive in </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
cash as soon as administratively practicable after the termination, and, in any event, no later than two and <FONT STYLE="white-space:nowrap">one-half</FONT>
<FONT STYLE="white-space:nowrap">(2-1/2)</FONT> months after the end of the taxable year of the Executive in which the termination occurs or at such earlier time as may be required by applicable law or Section&nbsp;10 below, and to such lesser
extent as may be mandated by Section&nbsp;9 below. Any Accrued Benefits to which the Executive is entitled shall be paid to the Executive as provided in the relevant plans and arrangements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. Covenants</B>. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><FONT STYLE="white-space:nowrap">Non-Competition</FONT></B>. The Executive agrees that the benefits provided
in this Agreement are granted in consideration for the ongoing promises and obligations of Executive under his employment agreement and any amendments thereto, including but not limited to Executive&#146;s obligations concerning <FONT
STYLE="white-space:nowrap">non-competition</FONT> and <FONT STYLE="white-space:nowrap">non-solicitation.</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Cooperation and <FONT STYLE="white-space:nowrap">Non-Disparagement</FONT></B>. The Executive agrees that,
during the Severance Period, he or she shall cooperate with the Company or its subsidiary in every reasonable respect and shall use his or her best efforts to assist the Company or its subsidiary with the transition of Executive&#146;s duties to his
or her successor. The Executive further agrees that following the date of Separation, he or she shall not in any way or by any means disparage the Company, its subsidiaries, or the members of their Board of Directors or their officers and employees.
</P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. Definitions</B>. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Cause</B>&#148; means (i)&nbsp;an unauthorized use or disclosure by Executive of the Company&#146;s or
its subsidiaries&#146; confidential information or trade secrets, which use or disclosure causes or is reasonably likely to cause material harm to the Company or its subsidiaries, (ii)&nbsp;a material breach of any agreement between Executive and
the Company or its subsidiaries, (iii)&nbsp;a material failure to comply with the Company&#146;s or its subsidiaries&#146; written policies or rules that has caused or is reasonably likely to cause material injury to the Company, its successor, or
its affiliates, or any of their business, (iv)&nbsp;conviction of, or plea of &#147;guilty&#148; or &#147;no contest&#148; to, a felony under the laws of the United States or any state thereof, (v)&nbsp;willful misconduct that has caused or is
reasonably likely to cause material injury to the Company, its successor, or its affiliates, or any of their business, (vi)&nbsp;embezzlement, (vii) failure to cooperate with the Company or its subsidiaries in any investigation or formal proceeding
if the Company or its subsidiary, as applicable, has requested Executive&#146;s reasonable cooperation, (viii)&nbsp;violation of any applicable federal, state or foreign statutes or laws that govern or regulate employment, pharmaceutical drugs or
securities, including but not limited to the laws enforced by the federal Equal Employment Opportunity Commission, Department of Labor, Food and Drug Administration, Securities and Exchange Commission and Department of Justice or (ix)&nbsp;a
continued failure to perform assigned duties after receiving written notification of such failure from the Company&#146;s or its subsidiarys&#146;, as applicable, Chief Executive Officer; <I>provided that</I> Executive must be provided with written
notice of Executive&#146;s termination for &#147;Cause&#148; and Executive must be provided with a thirty (30)&nbsp;day period following Executive&#146;s receipt of such notice to cure the event(s) that trigger &#147;Cause,&#148; with the
Company&#146;s or its subsidiarys&#146;, as applicable, Board of Directors making the final determination whether Executive has cured any Cause. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Code</B>&#148; means the Internal Revenue Code of 1986, as amended. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Change in Control</B>.&#148; For all purposes under this Agreement, a Change in Control shall mean a
&#147;Corporate Transaction,&#148; as such term is defined in the Company&#146;s 2015 Equity Incentive Plan, as may be amended from time to time, <I>provided that</I> the transaction (including any series of transactions) also qualifies as a change
in control under U.S. Treasury Regulation <FONT STYLE="white-space:nowrap">1.409A-3(i)(5)(v)</FONT> or <FONT STYLE="white-space:nowrap">1.409A-3(i)(5)(vii).</FONT> </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>CIC Qualifying Termination</B>&#148; means a Separation (A)&nbsp;within twelve (12)&nbsp;months
following a Change in Control or (B)&nbsp;within three (3)&nbsp;months preceding a Change in Control (but as to part (B), only if the Separation occurs after a Potential Change in Control) resulting, in either case (A)&nbsp;or (B), from (i)&nbsp;the
Company or its subsidiary, as applicable, terminating the Executive&#146;s employment for any reason other than Cause or (ii)&nbsp;the Executive voluntarily resigning his or her employment for Good Reason. A termination or resignation due to the
Executive&#146;s death or disability shall not constitute a CIC Qualifying Termination. A &#147;<B>Potential Change in Control</B>&#148; means the date of execution of a legally binding and definitive agreement for a corporate transaction which, if
consummated, would constitute the applicable Change in Control (which for the avoidance of doubt, would include a merger agreement, but not a term sheet for a merger agreement). In the case of a termination following a Potential Change in Control
and before a Change in Control, solely for purposes of benefits under this Agreement, the date of Separation will be deemed the date the Change in Control is consummated. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Good Reason</B>&#148; means, without the Executive&#146;s consent, (i)&nbsp;a material reduction in
the Executive&#146;s level of responsibility and/or scope of authority, (ii)&nbsp;a reduction by more than 10% in Executive&#146;s base salary (other than a reduction generally applicable to executive officers of the Company or its subsidiary, as
applicable, and in generally the same proportion as for the Executive), or (iii)&nbsp;relocation of the Executive&#146;s principal workplace by more than thirty-five (35)&nbsp;miles from Executive&#146;s then current place of employment. For the
purpose of clause (i), a change in responsibility shall not be deemed to occur (A)&nbsp;solely because Executive is part of a larger organization or (B)&nbsp;solely because of a change in title. For the Executive to receive the benefits under this
Agreement as a result of a voluntary resignation under this subsection (e), all of the following requirements must be satisfied: (1)&nbsp;the Executive must provide notice to the Company or its subsidiary, as applicable, of his or her intent to
assert Good Reason within sixty (60)&nbsp;days of the initial existence of one or more of the conditions set forth in subclauses (i)&nbsp;through (iii); (2) the Company or its subsidiary, as applicable, will have thirty (30)&nbsp;days (the
&#147;<B>Company Cure Period</B>&#148;) from the date of such notice to remedy the condition and, if it does so, the Executive may withdraw his or her resignation or may resign with no benefits; and (3)&nbsp;any termination of employment under this
provision must occur within ten (10)&nbsp;days of the earlier of expiration of the Company Cure Period or written notice from the Company or its subsidiary, as applicable, that it will not undertake to cure the condition set forth in subclauses
(i)&nbsp;through (iii). Should the Company or its subsidiary, as applicable, remedy the condition as set forth above and then one or more of the conditions arises again within twelve months following the occurrence of a Change in Control, the
Executive may assert Good Reason again subject to all of the conditions set forth herein. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Release Conditions</B>&#148; mean the following conditions: (i)&nbsp;Company has received the
Executive&#146;s executed Release and (ii)&nbsp;any rescission period applicable to the Executive&#146;s executed Release has expired. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Qualifying Termination</B>&#148; means a Separation that is not a CIC Qualifying Termination, but
which results from (i)&nbsp;the Company or its subsidiary, as applicable, terminating the Executive&#146;s employment for any reason other than Cause or (ii)&nbsp;the Executive voluntarily resigning his or her employment for Good Reason. A
termination or resignation due to the Executive&#146;s death or disability shall not constitute a Qualifying Termination. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Separation</B>&#148; means a &#147;separation from service,&#148; as defined in the regulations under
Section&nbsp;409A of the Code. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8. Successors</B>. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Company</B><B>&#146;</B><B>s Successors</B>. The Company shall require any successor (whether direct or
indirect and whether by purchase, lease, merger, consolidation, liquidation or otherwise) to all or substantially all of the Company&#146;s business and/or assets, by an agreement in substance and form satisfactory to the Executive, to assume this
Agreement and to agree expressly to perform this Agreement in the same manner and to the same extent as the Company would be required to perform it in the absence of a succession. For all purposes under this Agreement, the term &#147;Company&#148;
shall include any successor to the Company&#146;s business and/or assets or which becomes bound by this Agreement by operation of law. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Executive&#146;s Successors</B>. This Agreement and all rights of the Executive hereunder shall inure to the
benefit of, and be enforceable by, the Executive&#146;s personal or legal representatives, executors, administrators, successors, heirs, distributees, devisees and legatees. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. Golden Parachute Taxes</B>. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Best <FONT STYLE="white-space:nowrap">After-Tax</FONT> Result</B>. In the event that any payment or benefit
received or to be received by Executive pursuant to this Agreement or otherwise (&#147;<B>Payments</B>&#148;) would (i)&nbsp;constitute a &#147;parachute payment&#148; within the meaning of Section&nbsp;280G of the Code and (ii)&nbsp;but for this
subsection (a), be subject to the excise tax imposed by Section&nbsp;4999 of the Code, any successor provisions, or any comparable federal, state, local or foreign excise tax (&#147;<B>Excise Tax</B>&#148;), then, subject to the provisions of
Section&nbsp;10, such Payments shall be either (A)&nbsp;provided in full pursuant to the terms of this Agreement or any other applicable agreement, or (B)&nbsp;provided as to such lesser extent which would result in the Payments being $1.00 less
than the amount at which any portion of the Payments would be subject to the Excise Tax (&#147;<B>Reduced Amount</B>&#148;), whichever of the foregoing amounts, taking into account the applicable federal, state, local and foreign income, employment
and other taxes and the Excise Tax (including, without limitation, any interest or penalties on such taxes), results in the receipt by Executive, on an <FONT STYLE="white-space:nowrap">after-tax</FONT> basis, of the greatest amount of payments and
benefits provided for hereunder or otherwise, notwithstanding that all or some portion of such Payments may be subject to the Excise Tax. Unless the Company and Executive otherwise agree in writing, any determination required under this Section
shall be made by independent tax counsel designated by the Company and reasonably acceptable to Executive (&#147;<B>Independent Tax Counsel</B>&#148;), whose determination shall be conclusive and binding upon Executive and the Company for all
purposes. For purposes of making the calculations required under this Section, Independent Tax Counsel may make reasonable assumptions and approximations concerning applicable taxes and may rely on reasonable, good faith interpretations concerning
the application of Sections 280G and 4999 of the Code; <I>provided that</I> Independent Tax Counsel shall assume that Executive pays all taxes at the highest marginal rate. The Company and Executive shall furnish to Independent Tax Counsel such
information and documents as Independent Tax Counsel may reasonably request in order to make a determination under this Section. The Company shall bear all costs that Independent Tax Counsel may reasonably incur in connection with any calculations
contemplated by this Section. In the event that Section&nbsp;9(a)(ii)(B) above applies, then based on the information provided to Executive and the Company by Independent Tax Counsel, the cutback described hereunder will apply as to compensation not
subject to Section&nbsp;409A of the Code prior to compensation subject to Section&nbsp;409A of the Code and will otherwise apply on a reverse chronological basis from payments latest in time. If the Internal Revenue Service (the
&#147;<B>IRS</B>&#148;) determines that any Payment is subject to the Excise Tax, then Section&nbsp;9(b) hereof shall apply, and the enforcement of Section&nbsp;9(b) shall be the exclusive remedy to the Company. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Adjustments</B>. If, notwithstanding any reduction described in Section&nbsp;9(a) hereof (or in the absence
of any such reduction), the IRS determines that Executive is liable for the Excise Tax as a result of the receipt of one or more Payments, then Executive shall be obligated to surrender or pay back to the Company or its subsidiary, as applicable,
within <FONT STYLE="white-space:nowrap">one-hundred</FONT> twenty (120)&nbsp;days after a final IRS determination, an amount of such payments or benefits equal to the &#147;<B>Repayment Amount</B>.&#148; The Repayment Amount with respect to such
Payments shall be the smallest such amount, if any, as shall be required to be surrendered or paid to the Company or its subsidiary, as applicable, so that Executive&#146;s net proceeds with respect to such Payments (after taking into account the
payment of the Excise Tax imposed on such Payments) shall be maximized. Notwithstanding the foregoing, the Repayment Amount with respect to such Payments shall be zero (0)&nbsp;if a Repayment Amount of more than zero (0)&nbsp;would not eliminate the
Excise Tax imposed on such Payments or if a Repayment Amount of more than zero would not maximize the net amount received by Executive from the Payments. If the Excise Tax is not eliminated pursuant to this Section&nbsp;9(b), Executive shall pay the
Excise Tax. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10. Miscellaneous Provisions</B>. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(a)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Section</B><B></B><B>&nbsp;409A</B>. To the extent (i)&nbsp;any payments to which Executive becomes entitled
under this Agreement, or any agreement or plan referenced herein, in connection with Executive&#146;s termination of employment with the Company or its subsidiary, as applicable, constitute deferred compensation subject to Section&nbsp;409A of the
Code and (ii)&nbsp;Executive is deemed at the time of such termination of employment to be a &#147;specified&#148; employee under Section&nbsp;409A of the Code, then such payment or payments shall not be made or commence until the earlier of
(i)&nbsp;the expiration of the six (6)-month period measured from the Executive&#146;s Separation; or (ii)&nbsp;the date of Executive&#146;s death following such Separation; <I>provided, however</I>, that such deferral shall only be effected to the
extent required to avoid adverse tax treatment to Executive, including (without limitation) the additional twenty percent (20%) tax for which Executive would otherwise be liable under Section&nbsp;409A(a)(1)(B) of the Code in the absence of such
deferral.Upon the expiration of the applicable deferral period, any payments which would have otherwise been made during that period (whether in a single sum or in installments) in the absence of this paragraph shall be paid to Executive or
Executive&#146;s beneficiary in one lump sum (without interest). Except as otherwise expressly provided herein, to the extent any expense reimbursement or the provision of any <FONT STYLE="white-space:nowrap">in-kind</FONT> benefit under this
Agreement (or otherwise referenced herein) is determined to be subject to (and not exempt from) Section&nbsp;409A of the Code, the amount of any such expenses eligible for reimbursement, or the provision of any
<FONT STYLE="white-space:nowrap">in-kind</FONT> benefit, in one calendar year shall not affect the expenses eligible for reimbursement or in kind benefits to be provided in any other calendar year, in no event shall any expenses be reimbursed after
the last day of the calendar year following the calendar year in which Executive incurred such expenses, and in no event shall any right to reimbursement or the provision of any <FONT STYLE="white-space:nowrap">in-kind</FONT> benefit be subject to
liquidation or exchange for another benefit. To the extent that any provision of this Agreement is ambiguous as to its exemption or compliance with Section&nbsp;409A, the provision will be read in such a manner so that all payments hereunder are
exempt from Section&nbsp;409A to the maximum permissible extent, and for any payments where such construction is not tenable, that those payments comply with Section&nbsp;409A to the maximum permissible extent. To the extent any payment under this
Agreement may be classified as a &#147;short-term deferral&#148; within the meaning of Section&nbsp;409A, such payment shall be deemed a short-term deferral, even if it may also qualify for an exemption from Section&nbsp;409A under another provision
of Section&nbsp;409A. Payments pursuant to this Agreement (or referenced in this Agreement) are intended to constitute separate payments for purposes of <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-2(b)(2)</FONT> of the regulations under
Section&nbsp;409A. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(b)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Other Arrangements</B>. This Agreement supersedes Executive&#146;s prior Severance Agreement by and between
the Company and Executive, dated _________________. This Agreement also supersedes any and all cash severance arrangements and vesting acceleration arrangements on change in control under any agreement governing Equity Awards, severance and salary
continuation arrangements, programs and plans which were previously offered, or may be offered on the Effective Date or thereafter, by the Company or its subsidiary, as applicable, to the Executive, including change in control severance arrangements
and vesting acceleration arrangements pursuant to an agreement governing Equity Awards, employment agreement or offer letter, and Executive hereby waives Executive&#146;s rights to such other benefits. In no event shall any individual receive cash
severance benefits under both this Agreement and any other severance pay or salary continuation program, plan or other arrangement with the Company or its subsidiaries. For the avoidance of doubt, in no event shall Executive receive payment under
both Section&nbsp;2 and Section&nbsp;3 with respect to Executive&#146;s Separation. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Dispute Resolution</B>. To ensure rapid and economical resolution of any and all disputes that might arise
in connection with this Agreement, Executive and the Company agree that any and all disputes, claims, and causes of action, in law or equity, arising from or relating to this Agreement or its enforcement, performance, breach, or interpretation, will
be resolved solely and exclusively by final, binding, and confidential arbitration, by a single arbitrator, in San Francisco County, and conducted by Judicial Arbitration&nbsp;&amp; Mediation Services, Inc. (&#147;<B>JAMS</B>&#148;) under its
then-existing employment rules and procedures. Nothing in this section, however, is intended to prevent either party from obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any such arbitration. Each party to
an arbitration or litigation hereunder shall be responsible for the payment of its own attorneys&#146; fees. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Notice</B>. Notices and all other communications contemplated by this Agreement shall be in writing and
shall be deemed to have been duly given when personally delivered or when mailed by U.S. registered or certified mail, return receipt requested and postage prepaid or deposited with Federal Express Corporation, with shipping charges prepaid. In the
case of the Executive, mailed notices shall be addressed to him or her at the home address which he or she most recently communicated to the Company in writing. In the case of the Company, mailed notices shall be addressed to its corporate
headquarters, and all notices shall be directed to the attention of its Secretary. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Waiver</B>. No provision of this Agreement shall be modified, waived or discharged unless the modification,
waiver or discharge is agreed to in writing and signed by the Executive and by an authorized officer of the Company (other than the Executive). No waiver by either party of any breach of, or of compliance with, any condition or provision of this
Agreement by the other party shall be considered a waiver of any other condition or provision or of the same condition or provision at another time. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Withholding Taxes</B>. All payments made under this Agreement shall be subject to reduction to reflect taxes
or other charges required to be withheld by law. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Severability</B>. The invalidity or unenforceability of any provision or provisions of this Agreement shall
not affect the validity or enforceability of any other provision hereof, which shall remain in full force and effect. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>No Retention Rights</B>. Nothing in this Agreement shall confer upon the Executive any right to continue in
service for any period of specific duration or interfere with or otherwise restrict in any way the rights of the Company or any subsidiary of the Company or of the Executive, which rights are hereby expressly reserved by each, to terminate his or
her service at any time and for any reason, with or without Cause. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)<B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Choice of Law</B>. The validity, interpretation, construction and performance of this Agreement shall be
governed by the laws of the State of Texas (other than its <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">choice-of-law</FONT></FONT> provisions). </P></TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> F<SMALL>OLLOWS</SMALL>] </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, each of the parties has executed this Agreement, in the case of the Company by its duly
authorized officer, as of the day and year first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">AEGLEA BIOTHERAPEUTICS, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Anthony Quinn, M.B Ch.B, Ph.D.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: Interim Chief Executive Officer</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> S<SMALL>EVERANCE</SMALL> A<SMALL>GREEMENT</SMALL>] </B></P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.15
<SEQUENCE>27
<FILENAME>d518298dex1015.htm
<DESCRIPTION>EX-10.15
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.15</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.15 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>SEPARATION AND CONSULTING AGREEMENT </U></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>AND GENERAL RELEASE OF CLAIMS </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This SEPARATION AND CONSULTING AGREEMENT AND GENERAL RELEASE OF CLAIMS (this &#147;<U>Agreement</U>&#148;) is entered into by and between
Aeglea BioTherapeutics, Inc., a Delaware corporation (the &#147;<U>Company</U>&#148;), and Jonathan Alspaugh (&#147;<U>Executive</U>&#148;). Executive and the Company are each referred to herein as a &#147;<U>Party</U>&#148; and collectively as the
&#147;<U>Parties</U>.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, Executive&#146;s employment with the Company terminated effective as of September&nbsp;1,
2023 (the &#147;<U>Separation Date</U>&#148;); and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, as of the Separation Date, Executive holds the outstanding equity
awards set forth on <U>Exhibit A</U> hereto (collectively the &#147;<U>Options</U>&#148;), in each case, pursuant to those certain Notices of Stock Option Grants and Stock Option Agreements under the Aeglea BioTherapeutics, Inc. 2016 Equity
Incentive Plan (collectively, the &#147;<U>Award Agreements</U>&#148;) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, reference is made to that certain Employee
Invention Assignment, Confidentiality and <FONT STYLE="white-space:nowrap">Non-Competition</FONT> Agreement between Executive and the Company (the &#147;<U>EIACN Agreement</U>&#148;) and to that certain Severance Agreement between Executive and the
Company dated July&nbsp;6, 2021 (the &#147;<U>Severance Agreement</U>&#148;); and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, the Company wishes to provide Executive
with certain severance payments and benefits, which are conditioned upon Executive&#146;s execution, delivery, <FONT STYLE="white-space:nowrap">non-revocation</FONT> of and compliance with this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NOW, THEREFORE</B>, in consideration of the promises set forth herein, and for other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged by Executive and the Company, the Parties hereby agree as follows: </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.&nbsp;&nbsp;&nbsp;&nbsp;<U></U></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Separation from Employment</U>. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;The Company and Executive acknowledge and agree that Executive&#146;s employment with the Company will end as of the
Separation Date. As of the Separation Date, Executive will no longer be employed by the Company or any other Company Party (as defined below), and Executive will be deemed to have automatically resigned (i)&nbsp;as an officer of the Company and its
affiliates (as applicable) and (ii)&nbsp;from the board of managers, board of directors or similar governing body of each of the Company and its affiliates (as applicable) and any other corporation, limited liability company, trade organization, or
other entity in which the Company or any of its affiliates holds an equity interest or with respect to which board or similar governing body Executive serves as the designee or other representative of the Company or any of its affiliates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;Executive acknowledges and agrees that Executive has been paid in full all bonuses, been provided all benefits, and
otherwise received all wages, compensation and other sums that Executive has been owed by each Company Party. Executive further acknowledges and agrees that Executive has received all vacation and leaves (paid and unpaid), including payment of
accrued but unpaid paid time off, that Executive has been entitled to receive from each Company Party. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Separation Payments and Benefits</U></B>. Provided
that Executive: (x)&nbsp;executes this Agreement and returns a copy of this Agreement that has been executed by Executive to the Company so that it is received by Cameron Turtle, Chief Operating Officer, 221 Crescent Street, Built 17, Suite 102B,
Waltham, MA 02453 (email: ) no later than 5:00 pm CT on September&nbsp;22, 2023; (y) does not revoke this Agreement during the Release Revocation Period (as defined below); and (z)&nbsp;remains in compliance with the other terms and conditions set
forth in this Agreement (including under Section&nbsp;5), Executive shall receive the following separation payments and benefits: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;the Company shall pay to Executive aggregate severance payments of $623,000 (the &#147;<U>Severance
Amount</U>&#148;), which Severance Amount shall be paid through salary continuation in equal installments in accordance with the Company&#146;s standard payroll procedures, with the initial payment to occur on the first payroll date following the 60<SUP
STYLE="font-size:75%; vertical-align:top">th</SUP> day following the Separation Date, with the first installment to include a catchup payment for amounts covering the period from the date of Separation Date through the first payment date; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;if Executive timely elects continued coverage under the Consolidated Omnibus Budget Reconciliation Act
(&#147;<B><I>COBRA</I></B>&#148;), the Company shall pay the full amount of Executive&#146;s COBRA premiums on behalf of the Executive for the Executive&#146;s continued coverage under the Company&#146;s health, dental and vision plans, including
coverage for the Executive&#146;s eligible dependents, for the Severance Period (as defined in the Severance Agreement); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;the Company shall pay to Executive a lump sum payment of $168,246.58 (the &#147;<U>Retention Bonus</U>&#148;) in
accordance with the terms of that certain Incentive Agreement between Executive and the Company dated June&nbsp;21, 2023 (the &#147;<U>Incentive Agreement</U>&#148;), which Retention Bonus shall be paid following the expiration of the Release
Revocation Period but in no event later than December&nbsp;31, 2023; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;effective as of the last day of the
Consulting Period, all unvested Options scheduled to vest within the <FONT STYLE="white-space:nowrap">12-month</FONT> period following the last day of the Consulting Period shall immediately become fully vested and exercisable; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;all vested Options (after giving effect to Section&nbsp;2(d) and Section&nbsp;5(c)) will remain outstanding for six
months following the last day of the Consulting Period and may be exercised during such period in accordance with the terms of the Award Agreements; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;in the event that any sale, licensing, disposition, or monetization transaction or multiple transactions relating
to pegtarviliase or any of the Company&#146;s legacy development-stage assets is consummated prior to June&nbsp;23, 2024, then, and only then, the Company will pay to Executive a cash bonus equal to: (i) 1.0% of the value of the upfront
consideration received by the Company in such transactions, plus (ii) 0.5% of the risk-adjusted net present value of the contingent consideration payable to the Company in such transactions, in each case, to be paid within 30 days of the end of the
calendar quarter in which such transaction is consummated, in each case, in accordance the parameters established by the Compensation Committee of the Board of Directors of the Company on August&nbsp;1, 2023. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Executive acknowledges and agrees that the consideration referenced in this Section&nbsp;2 represents the
entirety of the amounts Executive is eligible to receive as severance pay and benefits from the Company or any other Company Party pursuant to the Severance Agreement and otherwise. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.&nbsp;&nbsp;&nbsp;&nbsp;<U></U></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Release of Liability for Claims</U>. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;For good and valuable consideration set forth in this Agreement, including the consideration set forth in
<U>Section</U><U></U><U>&nbsp;2</U>, Executive knowingly and voluntarily (for Executive, Executive&#146;s family, and Executive&#146;s heirs, executors, administrators and assigns) hereby releases and forever discharges the Company and its
affiliates, predecessors, successors, subsidiaries and benefit plans, and the foregoing entities&#146; respective equity-holders, officers, directors, managers, members, partners, employees, agents, representatives, and other affiliated persons, and
the Company&#146;s and its affiliates&#146; benefit plans (and the fiduciaries and trustees of such plans) (collectively, the &#147;<U>Company Parties</U>&#148;), from liability for, and Executive hereby waives, any and all claims, damages, or
causes of action of any kind related to Executive&#146;s ownership of any interest in any Company Party, Executive&#146;s employment with any Company Party, the termination of such employment, and any other acts or omissions related to any matter
occurring on or prior to the date that Executive executes this Agreement, including (i)&nbsp;any alleged violation through such time of: (A)&nbsp;any federal, state or local anti-discrimination or anti-retaliation law, regulation or ordinance,
including the Age Discrimination in Employment Act of 1967 (including as amended by the Older Workers Benefit Protection Act), Title VII of the Civil Rights Act of 1964, the Civil Rights Act of 1991, Sections 1981 through 1988 of Title 42 of the
United States Code and the Americans with Disabilities Act of 1990; (B) the Employee Retirement Income Security Act of 1974 (&#147;<U>ERISA</U>&#148;); (C) the Immigration Reform Control Act; (D)&nbsp;the National Labor Relations Act; (E)&nbsp;the
Occupational Safety and Health Act; (F)&nbsp;the Family and Medical Leave Act of 1993; (G) the Texas Labor Code (specifically including the Texas Payday Law, the Texas Anti-Retaliation Act, Chapter 21 of the Texas Labor Code, and the Texas
Whistleblower Act); (H) any federal, state or local wage and hour law; (I)&nbsp;any other local, state or federal law, regulation or ordinance; or (J)&nbsp;any public policy, contract, tort, or common law claim; (ii)&nbsp;any allegation for costs,
fees, or other expenses including attorneys&#146; fees incurred in or with respect to a Released Claim; (iii)&nbsp;any and all rights, benefits or claims Executive may have under any employment contract, incentive compensation plan or equity-based
plan with any Company Party or to any ownership interest in any Company Party (other than any rights under the Award Agreements), including any claims relating to an alleged change in control or potential change in control occurring prior to the
Separation Date ; and (iv)&nbsp;any claim for compensation or benefits of any kind not expressly set forth in this Agreement (collectively, the &#147;<U>Released Claims</U>&#148;). This Agreement is not intended to indicate that any such claims
exist or that, if they do exist, they are meritorious. Rather, Executive is simply agreeing that, in exchange for any consideration received by Executive pursuant to <U>Section</U><U></U><U>&nbsp;2</U>, any and all potential claims of this nature
that Executive may have against any of the Company Parties, regardless of whether they actually exist, are expressly settled, compromised and waived. <B>THIS RELEASE INCLUDES MATTERS ATTRIBUTABLE TO THE SOLE OR PARTIAL NEGLIGENCE (WHETHER GROSS OR
SIMPLE) OR OTHER FAULT, INCLUDING STRICT LIABILITY, OF ANY OF THE COMPANY PARTIES.</B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;In no event shall the
Released Claims include (i)&nbsp;any claim that arises after the date that Executive signs this Agreement; (ii)&nbsp;any claim to vested benefits under an employee benefit plan that is subject to ERISA, unemployment benefits, or worker&#146;s
compensation; and (iii)&nbsp;any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
claim for breach of, or otherwise arising out of, this Agreement. Further notwithstanding this release of liability, nothing in this Agreement prevents Executive from filing any <FONT
STYLE="white-space:nowrap">non-legally</FONT> waivable claim (including a challenge to the validity of this Agreement) with the Equal Employment Opportunity Commission (&#147;<U>EEOC</U>&#148;) or comparable state or local agency or participating in
any investigation or proceeding conducted by the EEOC or comparable state or local agency or cooperating in any such investigation or proceeding; however, Executive understands and agrees that Executive is waiving any and all rights to recover any
monetary or personal relief from a Company Party as a result of such EEOC or comparable state or local agency or proceeding or subsequent legal actions. Further, nothing in this Agreement prohibits or restricts Executive from filing a charge or
complaint with, or cooperating in any investigation with, the Securities and Exchange Commission, the Financial Industry Regulatory Authority, or any other governmental agency, entity or authority (each, a &#147;<U>Government Agency</U>&#148;). This
Agreement does not limit Executive&#146;s right to receive an award for information provided to a Government Agency. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4.</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Representations and Warranties Regarding Claims</U></B>. Executive represents and warrants that, as
of the time at which Executive signs this Agreement, Executive has not filed or joined any claims, complaints, charges, or lawsuits against any of the Company Parties with any governmental agency or with any state or federal court or arbitrator for,
or with respect to, a matter, claim, or incident that occurred or arose out of one or more occurrences that took place on or prior to the time at which Executive signs this Agreement. Executive further represents and warrants that Executive has not
made any assignment, sale, delivery, transfer or conveyance of any rights Executive has asserted or may have against any of the Company Parties with respect to any Released Claim. Executive represents and warrants that, as of the time at which
Executive signs this Agreement, Executive is not aware of any facts that may lead to a worker&#146;s compensation claim. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.&nbsp;&nbsp;&nbsp;&nbsp;<U></U></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Consulting Services</U>. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;Beginning on the Separation Date through February&nbsp;29, 2024 (such period, as may be extended or earlier
terminated as provided in <U>Section</U><U></U><U>&nbsp;5(e)</U>, the &#147;<U>Consulting Period</U>&#148;), the Company and Executive agree that Executive shall serve as a consultant to the Company providing the Services (as defined below) for no
more than 80 hours per month unless otherwise approved in writing. During the Consulting Period, Executive agrees to provide transition and advisory services, as may be requested from time to time by any officer or member of the Board of Directors
of the Company (the &#147;<U>Services</U>&#148;). Executive must submit to the Company a written statement detailing Executive&#146;s time incurred in performing the Services (each, a &#147;<U>Written Statement</U>&#148;) within 15 days following
the end of each calendar month. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;During the Consulting Period, Executive shall receive a consulting fee of $500
per hour, payable within 30 days following receipt by the Company of a Written Statement. As an independent contractor, no income or other taxes shall be withheld from the amounts paid to Executive pursuant to this
<U>Section</U><U></U><U>&nbsp;5(b)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;During the Consulting Period, Executive will continue to vest in the
Options in accordance with the terms of the Award Agreements. For the avoidance of doubt, all unvested Option (after giving effect to <U>Section</U><U></U><U>&nbsp;2(d)</U>) will be automatically forfeited upon termination of the Consulting Period.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;During the Consulting Period, Executive&#146;s relationship with
the Company shall be that of an independent contractor. Executive shall control and determine how the Services are to be accomplished; provided, however, that in all events Executive shall perform the Services in a quality, workmanlike manner and
within reasonable deadlines established by the Company and consistent with the professional talent of Executive that Executive applied during Executive&#146;s prior service with the Company. As an independent contractor, Executive shall not
participate as an active employee in any employee benefit plan of the Company or an affiliate (other than with respect to the Award Agreements). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding any other provision of this <U>Section</U><U></U><U>&nbsp;5</U> the Consulting Period may be
terminated (i)&nbsp;by Executive for any reason, (ii)&nbsp;by the Company for Cause (as defined in the Severance Agreement) or (iii)&nbsp;as a result of Executive&#146;s death or Disability (as defined in the Severance Agreement). The Consulting
Period may be extended by mutual agreement of the Parties. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.&nbsp;&nbsp;&nbsp;&nbsp;<U></U></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Restrictive Covenants</U>. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;Executive acknowledges and agrees that Executive has continuing obligations to the Company and its affiliates
pursuant to the EIACN Agreement, including obligations relating to intellectual property, confidentiality, <FONT STYLE="white-space:nowrap">non-competition</FONT> and <FONT STYLE="white-space:nowrap">non-solicitation</FONT> (collectively, the
&#147;<U>Covenants</U>&#148;). In entering into this Agreement, Executive acknowledges the continued effectiveness and enforceability of the Covenants, and Executive expressly reaffirms Executive&#146;s commitment to abide by, and agrees that
Executive will abide by, the terms of the Covenants. For the avoidance of doubt, the Post-Employment Period (as defined in the EIACN Agreement) shall commence on the Separation Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;Executive shall refrain from making (or causing or assisting any other person or entity to make) any oral or
written statements about the Company and any Company Party that (i)&nbsp;are slanderous, libelous, disparaging or defamatory or (ii)&nbsp;place the Company, any Company Party or any of their respective directors, officers, managers, members,
employees, consultants, agents or representatives in a false light before the public. Nothing in this Agreement or the EIACN Agreement prevents Executive from discussing or disclosing information about unlawful acts in the workplace, such as
harassment or discrimination or any other conduct that Executive has reason to believe is unlawful. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;Executive
agrees that this Agreement is confidential and agrees not to disclose any information regarding the terms of this Agreement, except to Executive&#146;s immediate family and any tax, legal or other counsel Executive has consulted regarding the
meaning or effect hereof or as required by law, and Executive will instruct each of the foregoing not to disclose the same to anyone. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7.</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Covenant to Cooperate in Legal Proceedings</U></B>. Executive agrees to reasonably cooperate with the
Company in any internal investigation, any administrative, regulatory, or judicial proceeding or any dispute with a third party. Executive understands and agrees that Executive&#146;s cooperation may include, but not be limited to, making Executive
available to the Company upon reasonable notice for interviews and factual investigations; appearing at the request of the Company to give testimony without requiring service of a subpoena or other legal process;
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
volunteering to the Company pertinent information received by Executive in Executive&#146;s capacity as an employee; and turning over to the Company all relevant documents which are or may come
into Executive&#146;s possession in Executive&#146;s capacity an employee or otherwise, all at times and on schedules that are reasonably consistent with Executive&#146;s other permitted activities and commitments. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8.</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Executive</U></B><B><U>&#146;</U></B><B><U>s Acknowledgements</U></B>. By executing and delivering
this Agreement, Executive expressly acknowledges that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;Executive has been given at least 21 days to review and
consider this Agreement. If Executive signs this Agreement before the expiration of 21 days after Executive&#146;s receipt of this Agreement, Executive has knowingly and voluntarily waived any longer consideration period than the one provided to
Executive and such waiver is not induced through fraud, misrepresentation, or threat to withdraw or alter the offer or by providing different terms if others sign the agreement prior to the expiration of 21 days. No changes (whether material or
immaterial) to this Agreement shall restart the running of this <FONT STYLE="white-space:nowrap">21-day</FONT> period; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;Executive is receiving, pursuant to this Agreement, consideration in addition to anything of value to which
Executive is already entitled; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;Executive has been advised, and hereby is advised in writing, to discuss this
Agreement with an attorney of Executive&#146;s choice and that Executive has had an adequate opportunity to do so prior to executing this Agreement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;Executive fully understands the final and binding effect of this Agreement; the only promises made to Executive to
sign this Agreement are those stated herein; and Executive is signing this Agreement knowingly, voluntarily and of Executive&#146;s own free will, and that Executive understands and agrees to each of the terms of this Agreement; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;No Company Party has provided any tax or legal advice regarding this Agreement, and Executive has had an adequate
opportunity to receive sufficient tax and legal advice from advisors of Executive&#146;s own choosing such that Executive enters into this Agreement with full understanding of the tax and legal implications thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9.</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Revocation Right</U></B>. Notwithstanding the initial effectiveness of this Agreement, Executive may
revoke the delivery (and therefore the effectiveness) of this Agreement within the <FONT STYLE="white-space:nowrap">seven-day</FONT> period beginning on the date Executive executes this Agreement (such
<FONT STYLE="white-space:nowrap">seven-day</FONT> period being referred to herein as the &#147;<U>Release Revocation Period</U>&#148;). To be effective, such revocation must be in writing signed by Executive and must be delivered personally or by
courier to the Company so that it is received by Cameron Turtle, Chief Operating Officer, 221 Crescent Street, Built 17, Suite 102B, Waltham, MA 02453 (email: ) no later than 11:59 pm CT on the last day of the Release Revocation Period. If an
effective revocation is delivered in the foregoing manner and timeframe, the release of claims set forth in <U>Section</U><U></U><U>&nbsp;3</U> will be of no force or effect, the Company&#146;s obligations in <U>Section</U><U></U><U>&nbsp;2</U>
shall have no further effect Executive, the Consulting Period under <U>Section</U><U></U><U>&nbsp;5</U> shall be terminated immediately, and the remainder of this Agreement will remain in full force and effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10.</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Return of Property</U></B>. Executive represents
and warrants that Executive has returned to the Company all property belonging to the Company or any other Company Party, including all computer files, electronically stored information, computers and other materials and items provided to Executive
by the Company or any other Company Party in the course of Executive&#146;s employment, and Executive further represents and warrants that Executive has not maintained a copy of any such materials or items in any form. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11.</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Governing Law</U></B><B><U>; Arbitration</U></B>. This Agreement and its performance will be
construed and interpreted in accordance with the laws of the State of Texas, without regard to principles of conflicts of law that would apply the substantive law of any other jurisdiction. For the avoidance of doubt, the arbitration and equitable
relief provisions of Section&nbsp;10(c) of the Severance Agreement shall apply to any dispute arising under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12.</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Counterparts</U></B>. This Agreement may be executed in several counterparts, including by .PDF or
..GIF attachment to email or by facsimile, each of which is deemed to be an original, and all of which taken together constitute one and the same agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13.</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Amendment; Entire Agreement</U></B>. This Agreement may not be changed orally but only by an
agreement in writing agreed to and signed by the Party to be charged. This Agreement, the EIACN Agreement and the Award Agreement constitute the entire agreement of the Parties with regard to the subject matter hereof and supersede all prior and
contemporaneous agreements and understandings, oral or written, between Executive and any Company Party with regard to the subject matter hereof. In executing this Agreement, neither Executive nor the Company have relied on any promise, agreement,
statement, or representation, not expressly contained in this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14.</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Third-Party
Beneficiaries</U></B>. Executive expressly acknowledges and agrees that each Company Party that is not a party to this Agreement shall be a third-party beneficiary of Sections <U>3</U>, <U>5</U>, <U>6</U>, <U>7</U> and <U>10</U> and entitled to
enforce such provisions as if it were a party hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>15.</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Further Assurances</U></B>. Executive
shall, and shall cause Executive&#146;s affiliates, representatives and agents to, from time to time at the request of the Company and without any additional consideration, furnish the Company with such further information or assurances, execute and
deliver such additional documents, instruments and conveyances, and take such other actions and do such other things, as may be reasonably necessary or desirable, as determined in the sole discretion of the Company, to carry out the provisions of
this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>16.</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Severability</U></B>. Any term or provision of this Agreement (or part thereof)
that renders such term or provision (or part thereof) or any other term or provision (or part thereof) hereof invalid or unenforceable in any respect shall be severable and shall be modified or severed to the extent necessary to avoid rendering such
term or provision (or part thereof) invalid or unenforceable, and such modification or severance shall be accomplished in the manner that most nearly preserves the benefit of the Parties&#146; bargain hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>17.</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Interpretation</U></B>. The Section headings have been inserted for purposes of convenience and
shall not be used for interpretive purposes. The words &#147;hereof,&#148; &#147;herein&#148; and &#147;hereunder&#148; and other compounds of the word &#147;here&#148; shall refer to the entire Agreement and not to any particular provision hereof.
The use herein of the word &#147;including&#148; following any general statement, term or matter shall not be construed to limit such statement, term or matter to the specific items or matters </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
set forth immediately following such word or to similar items or matters, whether or not <FONT STYLE="white-space:nowrap">non-limiting</FONT> language (such as &#147;without limitation&#148;,
&#147;but not limited to&#148;, or words of similar import) is used with reference thereto, but rather shall be deemed to refer to all other items or matters that could reasonably fall within the broadest possible scope of such general statement,
term or matter. The word &#147;or&#148; as used herein is not exclusive and is deemed to have the meaning &#147;and/or.&#148; Unless the context requires otherwise, all references herein to a law, agreement, instrument or other document shall be
deemed to refer to such law, agreement, instrument or other document as amended, supplemented, modified and restated from time to time to the extent permitted by the provisions thereof. Neither this Agreement nor any uncertainty or ambiguity herein
shall be construed against any Party, whether under any rule of construction or otherwise. This Agreement has been reviewed by each of the Parties and shall be construed and interpreted according to the ordinary meaning of the words used so as to
fairly accomplish the purposes and intentions of the Parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>18.</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>No Assignment</U></B>. No right
to receive payments and benefits under this Agreement shall be subject to set off, offset, anticipation, commutation, alienation, assignment, encumbrance, charge, pledge or hypothecation or to execution, attachment, levy, or similar process or
assignment by operation of law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>19.</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Withholdings; Deductions</U></B>. The Company may withhold and
deduct from any payments or benefits made or to be made pursuant to this Agreement (a)&nbsp;all federal, state, local and other taxes as may be required pursuant to any law or governmental regulation or ruling and (b)&nbsp;any deductions consented
to in writing by Executive. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>20.</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Section 409A</U></B>. This Agreement and the benefits provided
hereunder are intended be exempt from, or compliant with, the requirements of Section&nbsp;409A and shall be construed and administered in accordance with such intent. Each installment payment under this Agreement shall be deemed and treated as a
separate payment for purposes of Section&nbsp;409A. Notwithstanding the foregoing, the Company makes no representations that the benefits provided under this Agreement are exempt from the requirements of Section&nbsp;409A and in no event shall the
Company or any other Company Party be liable for all or any portion of any taxes, penalties, interest or other expenses that may be incurred by Executive on account of <FONT STYLE="white-space:nowrap">non-compliance</FONT> with Section&nbsp;409A.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the Parties have executed this Agreement as of the dates set
forth beneath their names below, effective for all purposes as provided above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"><B>EXECUTIVE</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jonathan Alspaugh</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3">Jonathan Alspaugh</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Date:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">September&nbsp;22, 2023</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"><B>AEGLEA BIOTHERAPEUTICS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Cameron Turtle</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Cameron Turtle</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Operating Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">September&nbsp;22, 2023</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S<SMALL>EPARATION</SMALL> <SMALL>AND</SMALL> C<SMALL>ONSULTING</SMALL> A<SMALL>GREEMENT</SMALL> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><SMALL>AND</SMALL> G<SMALL>ENERAL</SMALL> R<SMALL>ELEASE</SMALL> <SMALL>OF</SMALL> C<SMALL>LAIMS</SMALL> </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT A </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Options </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="57%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Grant
Date&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Total&nbsp;Options<BR>Granted</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Exercise<BR>Price</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Vested&nbsp;as&nbsp;of<BR>the&nbsp;Separation<BR>Date</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Unvested&nbsp;as&nbsp;of<BR>the&nbsp;Separation<BR>Date</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">June&nbsp;22, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,787,969</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">824,499</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,963,470</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">February&nbsp;23, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">400,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">350,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">August&nbsp;23, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">130,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">97,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">February&nbsp;17, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">170,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">63,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">106,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">June&nbsp;6, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">160,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.03</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">83,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">76,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">E<SMALL>XHIBIT</SMALL> A
</P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.16
<SEQUENCE>28
<FILENAME>d518298dex1016.htm
<DESCRIPTION>EX-10.16
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.16</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.16 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g518298dsp01.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">August&nbsp;10, 2023 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Scott
Burrows </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Re: Offer of Employment </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Scott: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On behalf of Aeglea BioTherapeutics, Inc. (the &#147;<U>Company</U>&#148;), I am very pleased to offer you a position as Chief Financial Officer (the
&#147;<U>Role</U>&#148;) pursuant to this letter agreement (the &#147;<U>Agreement</U>&#148;), provided you accept such offer as indicated by your signature below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Your employment with the Company in the Role will commence as of September&nbsp;1, 2023 (the &#147;<U>Effective Date</U>&#148;). Should you not commence
services by the Effective Date or if this Agreement is otherwise terminated on or prior to the Effective Date, you hereby agree that this Agreement shall be void <I>ab initio</I> and of no force or effect, other than as described herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.</B> <B>Position</B>. While serving in the Role, you will initially report to Cameron Turtle as the Company&#146;s Chief Operating Officer, and upon his
promotion to Chief Executive Officer, you shall report to the Company&#146;s Chief Executive Officer. You will have such duties, authorities, and responsibilities as are customarily associated with the Role. This is a full-time employment position.
It is understood and agreed that, commencing as of the Effective Date you will not engage in any other employment, consulting or other business activities (whether full-time or part-time), except as expressly authorized in writing by the Company.
Notwithstanding the foregoing, you may engage in religious, charitable and other community activities so long as such activities do not unreasonably interfere or conflict with your obligations to the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.</B> <B>Base Salary</B>. Upon and following the Effective Date, as cash compensation for your services, the Company will pay you an initial base salary
of $455,000 per year, payable in accordance with the Company&#146;s standard payroll schedule and subject to applicable deductions and withholdings. Your base salary will be subject to periodic review and potential adjustment in the Company&#146;s
discretion. Your base salary in effect at any given time is referred to herein as the &#147;<U>Base Salary</U>.&#148; </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Bonus Compensation. </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><FONT STYLE="white-space:nowrap">Sign-On</FONT> Bonus</B>. Within 30 days following the Effective Date, you
will receive a <FONT STYLE="white-space:nowrap">one-time</FONT> lump sum <FONT STYLE="white-space:nowrap">sign-on</FONT> bonus of $115,000 (the &#147;<U><FONT STYLE="white-space:nowrap">Sign-On</FONT> Bonus</U>&#148;). In the event of your
termination for Cause (as defined below) or resignation without Good Reason (as defined below), in either case, prior to the first anniversary of the Effective Date, you will be required to repay the full
<FONT STYLE="white-space:nowrap">Sign-On</FONT> Bonus within 30 days following the date of such termination of employment. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g518298dsp01.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Annual Bonus</B>. Commencing as of the Effective Date, you will be eligible to receive an annual performance
bonus targeted at 40% of your Base Salary. The target annual bonus in effect at any given time is referred to herein as &#147;<U>Target Bonus</U>.&#148; Your 2023 annual bonus will be prorated based on your period of employment following the
Effective Date. The actual bonus amount is discretionary and may be subject to achievement of performance targets established by the Company for such year. To earn an annual bonus, you must be (except as otherwise provided herein) employed by the
Company as of the payment date of such bonus. Any annual bonus will be paid no later than March 15th of the calendar year following the calendar year to which such bonus relates. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4.</B> <B>Inducement Grant</B>. Subject to approval by the Company&#146;s Board and as a material inducement to you agreeing to become employed by the
Company, as soon as practicable following the Effective Date, the Company will grant you (i)&nbsp;nonqualified stock options to purchase a number of shares of the Company&#146;s common stock equal to 0.75% of the total outstanding shares of the
Company&#146;s common stock as of the Effective Date with an exercise price equal to the fair market value of the underlying shares on the date of grant as determined by the Board (the &#147;<U>Inducement Options</U>&#148;) and (ii)&nbsp;a number of
restricted stock units (the &#147;<U>Inducement RSUs</U>&#148;) equal to 0.25% of the total outstanding shares of the Company&#146;s common stock as of the Effective Date. The Inducement Options will vest over a four year period following your grant
date, with 25% of the Inducement Options vesting on the first anniversary of your initial grant date, and the remainder vesting in 36 equal monthly installments on each monthly anniversary thereafter, in each case, subject to your continued services
with the Company through the applicable vesting dates. The Inducement RSUs will vest over a four-year period following your initial grant date, with 25% of the RSUs vesting on each anniversary of your grant date, in each case, subject to your
continued services with the Company through the applicable vesting dates. The Inducement Options and Inducement RSUs will be governed by the terms of the related award agreements, the Company&#146;s 2018 Equity Inducement Plan and the terms and
conditions approved by the Board. The Inducement Options and Inducement RSUs will be granted in compliance with NASDAQ Listing Rule 5635(c)(4) as a material inducement to you entering into employment with the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5.</B> <B>Benefits/Paid Time Off. </B>Commencing as of the Effective Date, you will be eligible, subject to the terms of the applicable plans and programs,
to participate in the employee benefits and insurance programs generally made available to the Company&#146;s full-time employees. Details of such benefits programs, including applicable employee contributions and waiting periods, if applicable,
will be made available to you when such benefit(s) become available. You will be entitled to paid time off consistent with the terms of the Company&#146;s paid time off policy, as in effect from time to time. The Company reserves the right to
modify, limit, amend or cancel any of its benefits plans or programs at any time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g518298dsp7.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g518298dsp01.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6.</B> <B>Expense Reimbursement. </B>The Company will reimburse you for all reasonable and necessary
expenses incurred by you in connection with performing your duties as an employee of the Company and that are <FONT STYLE="white-space:nowrap">pre-approved</FONT> by the Company, provided that you comply with any Company policy or practice on
submitting, accounting for and documenting such expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7.</B> <B>Location</B>. Your primary work location will be remotely in California, provided
that you may be required to engage in reasonable travel for business, consistent with the Company&#146;s business needs. You may change your remote work location with prior written notice to and approval from the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8.</B> <B><FONT STYLE="white-space:nowrap">At-Will</FONT> Employment; Date of Termination</B>. At all times, your employment with the Company is &#147;at
will,&#148; meaning you or the Company may terminate it at any time for any or no reason, subject to the terms of this Agreement. Although your job duties, title, reporting structure, compensation and benefits, as well as the Company&#146;s benefit
plans and personnel policies and procedures, may change from time to time (subject to the terms of this Agreement), the &#147;at will&#148; nature of your employment may only be changed in an express written agreement signed by you and an authorized
officer of the Company. Your last day of employment for any reason is referred to herein as the &#147;<U>Date of Termination</U>.&#148; In the event that you elect to end your employment other than for Good Reason, the Company requires you to
provide at least 30 days&#146; advance written notice to the Company; and in the event that the Company terminates you without &#147;Cause&#148;, you shall be given at least 30 days advance written notice by the Company. Notwithstanding the
foregoing, the Company may unilaterally accelerate the Date of Termination, and such acceleration shall not result in a termination without Cause by the Company for purposes of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the extent applicable, you shall be deemed to have resigned from all officer and board member positions that you hold with the Company or any of its
respective subsidiaries and affiliates upon the termination of your employment for any reason. You shall execute any documents in reasonable form as may be requested to confirm or effectuate any such resignations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9.</B> <B>Accrued Obligations</B>. In the event of the ending of your employment for any reason, the Company shall pay you (i)&nbsp;your Base Salary and,
if applicable, any accrued but unused vacation, through the Date of Termination, and (ii)&nbsp;the amount of any documented expenses properly incurred by you on behalf of the Company prior to any such termination and not yet reimbursed (the
&#147;<U>Accrued Obligations</U>&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g518298dsp7.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g518298dsp01.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10.</B> <B>Severance Pay and Benefits Outside of the Change in Control Period</B>. As explained below,
under certain circumstances you will be entitled to severance equal to the Severance Amount (as defined below), accelerated vesting of a portion of your unvested equity awards, plus continued employee benefits pursuant to COBRA (as defined below):
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event that the Company terminates your employment without Cause or you terminate your employment with Good Reason, in either case, outside of the
Change in Control Period (as such capitalized terms are defined in <U>Appendix A</U>), then, in addition to the Accrued Obligations, and subject to (i)&nbsp;your execution and <FONT STYLE="white-space:nowrap">non-revocation</FONT> of a separation
agreement and release in a form acceptable to the Company, which shall include a general release of claims against the Company and all related persons and entities and a reaffirmation of the Continuing Obligations (as defined below) and shall
provide that if you breach the Continuing Obligations, all payments of the Severance Amount (as defined below) shall immediately cease (the &#147;<U>Separation Agreement and Release</U>&#148;), and (ii)&nbsp;the Separation Agreement and Release
becoming irrevocable, all within 60 days after the Date of Termination (or such shorter period as set forth in the Separation Agreement and Release), which shall include a seven (7)&nbsp;day revocation period: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company shall pay you an amount equal to 12 months of your Base Salary plus any bonus earned but unpaid for
the year immediately prior to the year of termination (such salary and bonus together, the &#147;<U>Severance Amount</U>&#148;). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notwithstanding anything to the contrary in any applicable equity-based award agreement or plan, the unvested
portion of your then outstanding equity-based awards subject to time-based vesting (the &#147;<U>Time-Based Equity Awards</U>&#148;) that would have vested within the <FONT STYLE="white-space:nowrap">12-month</FONT> period following the Termination
Date shall immediately accelerate and become vested or nonforfeitable as of the later of (i)&nbsp;the Date of Termination or (ii)&nbsp;the effective date of the Separation Agreement and Release (such later date being the &#147;<U>Accelerated Vesting
Date</U>&#148;); and provided further that any termination or forfeiture of the unvested portion of such Time-Based Equity Awards that would otherwise occur on the Date of Termination in the absence of this Agreement will be delayed until the
effective date of the Separation Agreement and Release and will only occur if the vesting pursuant to this subsection does not occur due to the absence of the Separation Agreement and Release becoming fully effective within the time period set forth
therein. Notwithstanding the foregoing, no additional vesting of the Time-Based Equity Awards shall occur during the period between the Date of Termination and the Accelerated Vesting Date. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g518298dsp7.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g518298dsp01.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to your copayment of premium amounts at the applicable active employees&#146; rate and your proper
election to receive benefits under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (&#147;<U>COBRA</U>&#148;), the Company shall pay to the group health plan provider(s), the COBRA provider or you a monthly payment equal to
the monthly employer contribution that the Company would have made to provide health insurance to you if you had remained employed by the Company until the earliest of (A)&nbsp;the <FONT STYLE="white-space:nowrap">12-month</FONT> anniversary of the
Date of Termination; (B)&nbsp;your eligibility for group health plan benefits under any other employer&#146;s group health plan; or (C)&nbsp;the cessation of your continuation rights under COBRA; provided, however, that if the Company reasonably
determines that it cannot pay such amounts to the group health plan provider(s) or the COBRA provider (if applicable) without potentially violating applicable law (including, without limitation, Section&nbsp;2716 of the Public Health Service Act),
then the Company shall convert such payments to payroll payments directly to you for the time period specified above. Such payments, if to you, shall be subject to <FONT STYLE="white-space:nowrap">tax-related</FONT> deductions and withholdings and
paid on the Company&#146;s regular payroll dates. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The amounts payable under <U>Section</U><U></U><U>&nbsp;10(a)</U> and <U>(c)</U>, to
the extent taxable, shall be paid out in substantially equal installments in accordance with the Company&#146;s payroll practice over 12 months commencing within 60 days after the Date of Termination; provided, however, that if the <FONT
STYLE="white-space:nowrap">60-day</FONT> period begins in one calendar year and ends in a second calendar year, the Severance Amount, to the extent it qualifies as <FONT STYLE="white-space:nowrap">&#147;non-qualified</FONT> deferred
compensation&#148; within the meaning of Section&nbsp;409A of the Internal Revenue Code of 1986, as amended (the &#147;<U>Code</U>&#148;), shall begin to be paid in the second calendar year by the last day of such
<FONT STYLE="white-space:nowrap">60-day</FONT> period; provided, further, that the initial payment shall include a <FONT STYLE="white-space:nowrap">catch-up</FONT> payment to cover amounts retroactive to the day immediately following the Date of
Termination. Each payment pursuant to this Agreement is intended to constitute a separate payment for purposes of Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-2(b)(2).</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding anything to the contrary in this Agreement, for the avoidance of doubt: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if your employment ends for as a result of a termination by the Company for Cause or a resignation by you
without Good Reason, you will be entitled to the Accrued Obligations and will not be entitled to any further compensation from the Company; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if your employment ends due to your death or Disability, you will receive (i)&nbsp;the Accrued Obligations and
(ii)&nbsp;all outstanding Time-Based Equity Awards shall immediately accelerate and become vested or nonforfeitable as of the Date of Termination, but will not be eligible for any other severance pay or benefits, whether pursuant to
<U>Section</U><U></U><U>&nbsp;10</U>, <U>Section</U><U></U><U>&nbsp;11</U> or otherwise. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g518298dsp7.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g518298dsp01.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11.</B> <B>Severance Pay and Benefits Within the Change in Control Period</B>. In the event that the
Company terminates your employment without Cause or you resign for Good Reason, in each case within the Change in Control Period, then, in addition to you being entitled to the Accrued Obligations, and subject to your execution and <FONT
STYLE="white-space:nowrap">non-revocation</FONT> of the Separation Agreement and Release and it becoming fully effective, all within 60 days after the Date of Termination (or such shorter period as set forth in the Separation Agreement and Release),
which shall include a <FONT STYLE="white-space:nowrap">seven-day</FONT> revocation period: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company shall pay you an amount equal (i)&nbsp;to 18 months of your Base Salary, plus (ii)&nbsp;any bonus
earned but unpaid for the year immediately prior to the year of termination, plus (iii)&nbsp;your Target Bonus for the year in which the termination occurs (in each case, calculated by reference to your Base Salary rate as in effect immediately
prior to your termination, but without giving effect to any prior reduction in Base Salary by the Company which would give rise to your right to resign for Good Reason) (such salary and bonuses together, the &#147;<U>CIC Severance Amount</U>&#148;).
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notwithstanding anything to the contrary in any applicable equity-based award agreement or plan, all of the
unvested Time-Based Equity Awards shall immediately accelerate and become vested or nonforfeitable as of the Accelerated Vesting Date. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All of your outstanding equity-based awards subject to performance-based vesting (the
&#147;<U>Performance-Based Equity Awards</U>&#148;) shall immediately accelerate and become vested or nonforfeitable as of the Accelerated Vesting Date with the performance criteria being deemed to have been met based on the greater of target or, if
determinable, actual performance; provided, however, that the applicable award agreement for any Performance-Based Equity Award may provide for alternative treatment upon a termination covered by this <U>Section</U><U></U><U>&nbsp;11</U>.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company shall pay to the group health plan provider(s), the COBRA provider or you a monthly payment equal
to the monthly COBRA continuation premiums until the earliest of (A)&nbsp;the <FONT STYLE="white-space:nowrap">18-month</FONT> anniversary of the Date of Termination; (B)&nbsp;your eligibility for group health plan benefits under any other
employer&#146;s group health plan; or (C)&nbsp;the cessation of your continuation rights under COBRA; provided, however, that if the Company reasonably determines that it cannot pay such amounts to the group health plan provider(s) or the COBRA
provider (if </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g518298dsp7.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g518298dsp01.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
applicable) without potentially violating applicable law (including, without limitation, Section&nbsp;2716 of the Public Health Service Act), then the Company shall convert such payments to
payroll payments directly to you for the time period specified above. Such payments, if to you, shall be subject to <FONT STYLE="white-space:nowrap">tax-related</FONT> deductions and withholdings and paid on the Company&#146;s regular payroll dates.
</TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the avoidance of doubt, <U>Section</U><U></U><U>&nbsp;10</U> and <U>Section</U><U></U><U>&nbsp;11</U> of this Agreement are mutually
exclusive and in no event shall you be entitled to payments or benefits pursuant to both <U>Section</U><U></U><U>&nbsp;10</U> and <U>Section</U><U></U><U>&nbsp;11</U> of this Agreement. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>12.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Continuing Obligations. </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>EIACN Agreement</B>. As a condition of your employment, you are required to enter into an Employee Invention
Assignment, Confidentiality and <FONT STYLE="white-space:nowrap">Non-Competition</FONT> Agreement, which is enclosed with this Agreement (the &#147;<U>EIACN Agreement</U>&#148;), which must be signed prior to the Effective Date. For purposes of this
Agreement, the obligations in this <U>Section</U><U></U><U>&nbsp;12</U> and those that arise in the EIACN Agreement and any other agreement relating to confidentiality, assignment of inventions, or other restrictive covenants shall collectively be
referred to as the &#147;<U>Continuing Obligations</U>.&#148; You are advised to discuss the EIACN Agreement with an attorney of your choice, and you have had an adequate opportunity to do so prior to executing this Agreement or the EIACN Agreement.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Third Party Agreements and Rights</B>. You hereby confirm that you are not bound by the terms of any
agreement with any previous employer or other party which would prevent you from performing your obligations hereunder. You represent to the Company that your execution of this Agreement, your employment with the Company and the performance of your
proposed duties for the Company will not violate any obligations you may have to any such previous employer or other party. In your work for the Company, you will not disclose or make use of any information in violation of any agreements with or
rights of any such previous employer or other party, and you will not bring to the premises of the Company any copies or other tangible embodiments of <FONT STYLE="white-space:nowrap">non-public</FONT> information belonging to or obtained from any
such previous employment or other party. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Litigation and Regulatory Cooperation</B>. You shall cooperate fully with the Company in (i)&nbsp;the
defense or prosecution of any claims or actions now in existence or which may be brought in the future against or on behalf of the Company which relate to events or occurrences that transpired while you were engaged or employed by the Company, and
(ii)&nbsp;the investigation, whether </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g518298dsp7.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g518298dsp01.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
internal or external, of any matters about which the Company believes you may have knowledge or information. Your full cooperation in connection with such claims, actions or investigations shall
include, but not be limited to, being reasonably available to meet with counsel to answer questions or to prepare for discovery or trial and to act as a witness on behalf of the Company at mutually convenient times. During and after your engagement
and employment, you also shall cooperate fully with the Company in connection with any investigation or review of any federal, state or local regulatory authority as any such investigation or review relates to events or occurrences that transpired
while you were employed by the Company. The Company shall reimburse you for any reasonable <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred in connection with your performance of
obligations pursuant to this <U>Section</U><U></U><U>&nbsp;12(c).</U> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Relief</B>. You agree that it would be difficult to measure any damages caused to the Company which might
result from your breach of any of the Continuing Obligations, and that in any event money damages would be an inadequate remedy for any such breach. Accordingly, you agree that if you breach, or propose to breach, any portion of the Continuing
Obligations, the Company shall be entitled, in addition to all other remedies that it may have, to seek an injunction or other appropriate equitable relief to restrain any such breach without showing or proving any actual damage to the Company.
</P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>13.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Golden Parachute Taxes. </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Best <FONT STYLE="white-space:nowrap">After-Tax</FONT> Result</B>. In the event that any payment or benefit
received or to be received by you pursuant to this Agreement or otherwise (&#147;<U>Payments</U>&#148;) would (i)&nbsp;constitute a &#147;parachute payment&#148; within the meaning of Section&nbsp;280G of the Code and (ii)&nbsp;but for this
subsection (a), be subject to the excise tax imposed by Section&nbsp;4999 of the Code, any successor provisions, or any comparable federal, state, local or foreign excise tax (&#147;<U>Excise Tax</U>&#148;), then, subject to the provisions of
Section&nbsp;14, such Payments shall be either (A)&nbsp;provided in full pursuant to the terms of this Agreement or any other applicable agreement, or (B)&nbsp;provided as to such lesser extent which would result in the Payments being $1.00 less
than the amount at which any portion of the Payments would be subject to the Excise Tax, whichever of the foregoing amounts, taking into account the applicable federal, state, local and foreign income, employment and other taxes and the Excise Tax
(including, without limitation, any interest or penalties on such taxes), results in the receipt, on an <FONT STYLE="white-space:nowrap">after-tax</FONT> basis, of the greatest amount of payments and benefits provided for hereunder or otherwise,
notwithstanding that all or some portion of such Payments may be subject to the Excise Tax. Unless the Company </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g518298dsp7.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g518298dsp01.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
and you otherwise agree in writing, any determination required under this Section shall be made by independent tax counsel designated by the Company and reasonably acceptable to you
(&#147;<U>Independent Tax Counsel</U>&#148;), whose determination shall be conclusive and binding upon you and the Company for all purposes. For purposes of making the calculations required under this Section, Independent Tax Counsel may make
reasonable assumptions and approximations concerning applicable taxes and may rely on reasonable, good faith interpretations concerning the application of Sections 280G and 4999 of the Code; provided that Independent Tax Counsel shall assume that
you pay all taxes at the highest marginal rate. The Company and you shall furnish to Independent Tax Counsel such information and documents as Independent Tax Counsel may reasonably request in order to make a determination under this Section. The
Company shall bear all costs that Independent Tax Counsel may reasonably incur in connection with any calculations contemplated by this Section. In the event that <U>Section</U><U></U><U>&nbsp;13(a)(ii)(B)</U> above applies, then based on the
information provided to you and the Company by Independent Tax Counsel, the cutback described hereunder will apply as to compensation not subject to Section&nbsp;409A of the Code prior to compensation subject to Section&nbsp;409A of the Code and
will otherwise apply on a reverse chronological basis from payments latest in time. If the Internal Revenue Service (the &#147;<U>IRS</U>&#148;) determines that any Payment is subject to the Excise Tax, then <U>Section</U><U></U><U>&nbsp;13(b)</U>
hereof shall apply, and the enforcement of <U>Section</U><U></U><U>&nbsp;13(b)</U> shall be the exclusive remedy to the Company. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Adjustments</B>. If, notwithstanding any reduction described in <U>Section</U><U></U><U>&nbsp;13(a)</U>
hereof (or in the absence of any such reduction), the IRS determines that you are liable for the Excise Tax as a result of the receipt of one or more Payments, then you shall be obligated to surrender or pay back to the Company within <FONT
STYLE="white-space:nowrap">one-hundred</FONT> 120 days after a final IRS determination, an amount of such payments or benefits equal to the &#147;<U>Repayment Amount</U>.&#148; The Repayment Amount with respect to such Payments shall be the smallest
such amount, if any, as shall be required to be surrendered or paid to the Company so that your net proceeds with respect to such Payments (after taking into account the payment of the Excise Tax imposed on such Payments) shall be maximized.
Notwithstanding the foregoing, the Repayment Amount with respect to such Payments shall be zero if a Repayment Amount of more than zero would not eliminate the Excise Tax imposed on such Payments or if a Repayment Amount of more than zero would not
maximize the net amount received from the Payments. If the Excise Tax is not eliminated pursuant to this <U>Section</U><U></U><U>&nbsp;13(b)</U>, you shall pay the Excise Tax. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g518298dsp7.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g518298dsp01.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>14.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Section 409A. </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Anything in this Agreement to the contrary notwithstanding, if at the time of your separation from service
within the meaning of Section&nbsp;409A of the Code, the Company determines that you are a &#147;specified employee&#148; within the meaning of Section&nbsp;409A(a)(2)(B)(i) of the Code, then to the extent any payment or benefit that you become
entitled to under this Agreement or otherwise on account of your separation from service would be considered deferred compensation otherwise subject to the additional tax imposed pursuant to Section&nbsp;409A(a) of the Code as a result of the
application of Section&nbsp;409A(a)(2)(B)(i) of the Code, such payment shall not be payable and such benefit shall not be provided until the date that is the earlier of (A)&nbsp;six months and one day after your separation from service, or
(B)&nbsp;your death. If any such delayed cash payment is otherwise payable on an installment basis, the first payment shall include a <FONT STYLE="white-space:nowrap">catch-up</FONT> payment covering amounts that would otherwise have been paid
during the <FONT STYLE="white-space:nowrap">six-month</FONT> period but for the application of this provision (without interest), and the balance of the installments shall be payable in accordance with their original schedule. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits provided and expenses eligible for reimbursement
under this Agreement shall be provided by the Company or incurred by you during the time periods set forth in this Agreement. All reimbursements shall be paid as soon as administratively practicable, but in no event shall any reimbursement be paid
after the last day of the taxable year following the taxable year in which the expense was incurred. The amount of <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits provided or reimbursable expenses incurred in one taxable year shall not
affect the <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits to be provided or the expenses eligible for reimbursement in any other taxable year (except for any lifetime or other aggregate limitation applicable to medical expenses). Such
right to reimbursement or <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits is not subject to liquidation or exchange for another benefit. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To the extent that any payment or benefit described in this Agreement constitutes <FONT
STYLE="white-space:nowrap">&#147;non-qualified</FONT> deferred compensation&#148; under Section&nbsp;409A of the Code, and to the extent that such payment or benefit is payable upon the termination of your employment, then such payments or benefits
shall be payable only upon your &#147;separation from service.&#148; The determination of whether and when a separation from service has occurred shall be made in accordance with the presumptions set forth in Treasury Regulation <FONT
STYLE="white-space:nowrap">Section&nbsp;1.409A-l(h).</FONT> </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g518298dsp7.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g518298dsp01.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The parties intend that this Agreement will be administered in accordance with Section&nbsp;409A of the Code.
To the extent that any provision of this Agreement is ambiguous as to its compliance with Section&nbsp;409A of the Code, the provision shall be read in such a manner so that all payments hereunder comply with Section&nbsp;409A of the Code. Each
payment pursuant to this Agreement is intended to constitute a separate payment for purposes of Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-2(b)(2).</FONT> The parties agree that this Agreement may be amended, as
reasonably requested by either party, and as may be necessary to fully comply with Section&nbsp;409A of the Code and all related rules and regulations in order to preserve the payments and benefits provided hereunder without additional cost to
either party. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company makes no representation or warranty and shall have no liability to you or any other person if any
provisions of this Agreement are determined to constitute deferred compensation subject to Section&nbsp;409A of the Code but do not satisfy an exemption from, or the conditions of, such Section. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>15.</B> <B>Withholding; Tax Effect</B>. All forms of compensation referred to in this Agreement are subject to reduction to reflect applicable withholding
and payroll taxes and other deductions required by law. You hereby acknowledge that the Company does not have a duty to design its compensation policies in a manner that minimizes your tax liabilities, and you will not make any claim against the
Company or the Board related to tax liabilities arising from your compensation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>16.</B> <B>Recoupment</B>. Amounts paid or payable under this
Agreement shall be subject to the provisions of any applicable clawback or recoupment policies or procedures adopted by the Company, which clawback or recoupment policies may provide for forfeiture and/or recoupment of amounts paid or payable under
this Agreement. No forfeiture or recoupment under such policies or procedures will give rise to a right to resign for Good Reason or under any agreement between you and the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>17.</B> <B>Interpretation and Enforcement</B>. This Agreement, together with Appendix A and the EIACN Agreement, constitute the complete agreement between
you and the Company, contains all of the terms of your employment with the Company. The terms of this Agreement and the resolution of any disputes as to the meaning, effect, performance or validity of this Agreement or arising out of, related to, or
in any way connected with this Agreement, your employment with the Company or any other relationship between you and the Company (the &#147;<U>Disputes</U>&#148;) will be governed by federal law to the extent applicable and otherwise by California
law, excluding laws relating to conflicts or choice of law and excluding Disputes arising in connection with any equity incentive plan, which shall be governed by the terms of the applicable equity incentive plan. You and the Company submit to the
exclusive personal jurisdiction of the federal and state courts located in the Central District of California or in Los Angeles County, California in connection with any Dispute or any claim related to any Dispute, except for Disputes arising under
any equity incentive plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g518298dsp7.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g518298dsp01.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>18.</B> <B>Assignment</B>. Neither you nor the Company may make any assignment of this Agreement or any
interest in it, by operation of law or otherwise, without the prior written consent of the other; provided, however, that the Company may assign its rights and obligations under this Agreement without your consent to any affiliate or to any person
or entity with whom the Company shall hereafter effect a reorganization, consolidate with, or merge into or to whom it transfers all or substantially all of its properties or assets; provided further, that if you remain employed or become employed
by the Company, the purchaser or any of their affiliates in connection with any such transaction, then you shall not be entitled to any payments, benefits or vesting pursuant to <U>Section</U><U></U><U>&nbsp;10</U> or pursuant to
<U>Section</U><U></U><U>&nbsp;11</U> of this Agreement solely as a result of such transaction. This Agreement shall inure to the benefit of and be binding upon you and the Company, and each of your and its respective successors, executors,
administrators, heirs and permitted assigns. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>19.</B> <B>Waiver; Amendment</B>. No waiver of any provision hereof shall be effective unless made in
writing and signed by the waiving party. The failure of any party to require the performance of any term or obligation of this Agreement, or the waiver by any party of any breach of this Agreement, shall not prevent any subsequent enforcement of
such term or obligation or be deemed a waiver of any subsequent breach. This Agreement may be amended or modified only by a written instrument signed by you and by a duly authorized representative of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>20.</B> <B>Enforceability</B>. If any portion or provision of this Agreement (including, without limitation, any portion or provision of any section of
this Agreement) shall to any extent be declared illegal or unenforceable by a court of competent jurisdiction, then the remainder of this Agreement, or the application of such portion or provision in circumstances other than those as to which it is
so declared illegal or unenforceable, shall not be affected thereby, and each portion and provision of this Agreement shall be valid and enforceable to the fullest extent permitted by law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>21.</B> <B>Conditions</B>. You must submit satisfactory proof of your identity, successfully complete a criminal background check, which you hereby
expressly authorize by your execution of this Agreement, and provide documentation of your legal authorization to work in the United States on or prior to the Effective Date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g518298dsp7.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g518298dsp01.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>22.</B> <B>Employee Representations.</B> It is the policy of the Company not to solicit or accept
proprietary information and / or trade secrets of other companies or third parties. If you have or have had access to trade secrets or other confidential, proprietary information from your former employer or another third party, the use of such
information in performing your duties at the Company is prohibited. This may include, but is not limited to, confidential or proprietary information in the form of documents, magnetic media, software, customer lists, and business plans or
strategies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In making this employment offer, the Company has relied on your representation that: (a)&nbsp;you are not currently a party to any agreement
that would restrict your ability to accept this offer or to perform services for the Company; (b)&nbsp;you are not subject to any noncompetition or <FONT STYLE="white-space:nowrap">non-solicitation</FONT> agreement or other restrictive covenants
that might restrict your employment by the Company as contemplated by this offer; (c)&nbsp;you have the full right, power and authority to execute and deliver the Agreement and to perform all of your obligations thereunder; and (d)&nbsp;you will not
bring with you to the Company or use in the performance of your responsibilities at the Company any materials, documents or work product of a former employer or other third party that are not generally available to the public, unless you have
obtained written authorization from such former employer or third party for their possession and use and have provided the Company with a copy of same. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>23.</B> <B>Other Terms</B>. The provisions of this Agreement shall survive the termination of this Agreement and/or the termination of your employment to
the extent necessary to effectuate the terms contained herein. The headings and other captions in this Agreement are for convenience and reference only and shall not be used in interpreting, construing or enforcing any of the provisions of this
Agreement. This Agreement may be executed in separate counterparts. When both counterparts are signed, they shall be treated together as one and the same document. PDF copies of signed counterparts shall be equally effective as originals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I look forward to working with you to make the Company a great success. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g518298dsp7.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g518298dsp01.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="88%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Sincerely,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Cameron Turtle</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Cameron Turtle</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: Chief Operating Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Accepted and acknowledged:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Scott Burrows</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Scott Burrows</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">August&nbsp;10, 2023</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g518298dsp7.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g518298dsp01.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Appendix A </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1. &#147;<U>Cause</U>&#148; shall mean (i)&nbsp;your dishonest statements or acts with respect to the Company or any affiliate of the Company, or any current
or prospective customers, suppliers, vendors or other third parties with which such entity does business that results in or is reasonably anticipated to result in material harm to the Company; (ii)&nbsp;your conviction or plea of no contest to:
(A)&nbsp;a felony or (B)&nbsp;any misdemeanor involving moral turpitude, deceit, dishonesty or fraud; (iii)&nbsp;your failure to perform in all material respects your lawful assigned duties and responsibilities to the reasonable satisfaction of the
Board, which failure continues, in the reasonable judgment of the Board, for 30 days after written notice given to you describing such failure; (iv)&nbsp;your gross negligence, willful misconduct that results in or is reasonably anticipated to
result in material harm to the Company; or (v)&nbsp;your violation of any material provision of any agreement(s) between you and the Company or any written Company policies including, without limitation, agreements relating to <FONT
STYLE="white-space:nowrap">non-solicitation,</FONT> <FONT STYLE="white-space:nowrap">non-disclosure</FONT> and/or assignment of inventions or policies related to ethics or workplace conduct. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2. &#147;<U>Change in Control</U>&#148; shall have the meaning provided for the term &#147;Corporate Transaction&#148; under the Company&#146;s 2016 Equity
Incentive Plan (or the meaning provided to any word of similar import under any successor plan). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3. &#147;<U>Change in Control Period</U>&#148; shall
mean the period commencing three months prior to the first event constituting a Change in Control and ending 12 months following the first event constituting a Change in Control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4. &#147;<U>Disability</U>&#148; shall mean a permanent and total disability as defined in Section&nbsp;22(e)&nbsp;(3) of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5. &#147;<U>Good Reason</U>&#148; shall mean that you have complied with the Good Reason Process (hereinafter defined) following the occurrence, without your
written consent, of any of the following events: (i)&nbsp;a material diminution in your base salary or Target Bonus except for <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">across-the-board</FONT></FONT> salary and target bonus
reductions of no more than 10% based on the Company&#146;s financial performance similarly affecting all or substantially all senior management employees of the Company; (ii)&nbsp;a material change in the geographic location at which you are
required to provide services to the Company or a requirement that you change your remote location from your then-current residence; (iii)&nbsp;a material reduction in your duties, authority or responsibilities; (iv)&nbsp;the failure of the Company
to obtain the assumption of this Agreement by a successor; or (v)&nbsp;the material breach of this Agreement (or any other agreements with you) by the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g518298dsp7.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g518298dsp01.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6. &#147;<U>Good Reason Process</U>&#148; shall mean that (i)&nbsp;you reasonably determine in good faith
that a &#147;Good Reason&#148; condition has occurred; (ii)&nbsp;you notify the Company in writing of the first occurrence of the Good Reason condition within 60 days of the first occurrence of such condition; (iii)&nbsp;you cooperate in good faith
with the Company&#146;s efforts, for a period not less than 30 days following such notice (the &#147;<U>Cure Period</U>&#148;), to remedy the condition; (iv)&nbsp;notwithstanding such efforts, the Good Reason condition continues to exist; and
(v)&nbsp;you terminate your employment within 30 days after the end of the Cure Period. If the Company cures the Good Reason condition during the Cure Period, Good Reason shall be deemed not to have occurred. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g518298dsp7.jpg" ALT="LOGO">
 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.17
<SEQUENCE>29
<FILENAME>d518298dex1017.htm
<DESCRIPTION>EX-10.17
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.17</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.17 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Execution Version </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ASSET PURCHASE AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>dated as of </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>July&nbsp;27, 2023 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>by
and between </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AEGLEA BIOTHERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>and </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>IMMEDICA PHARMA AB
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" STYLE="border-bottom:1.00pt solid #000000">P<SMALL>AGE</SMALL></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3">ARTICLE I PURCHASE PRICE</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Section&nbsp;1.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Purchase Price</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Section&nbsp;1.2</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Milestone Payments</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3">ARTICLE II PURCHASE AND SALE</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Section&nbsp;2.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Acquired Assets</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Section&nbsp;2.2</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Excluded Assets</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Section&nbsp;2.3</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Assumption of Assumed Liabilities</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Section&nbsp;2.4</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Excluded Liabilities</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Section&nbsp;2.5</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Undisclosed Contracts</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Section&nbsp;2.6</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="white-space:nowrap">Non-Assignable</FONT> Assets</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Section&nbsp;2.7</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Designated Buyer</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Section&nbsp;2.8</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>ADA Assay License</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3">ARTICLE III CLOSING</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Section&nbsp;3.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Closing</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Section&nbsp;3.2</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Deliveries by Aeglea</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Section&nbsp;3.3</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Deliveries by Immedica at the Closing</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Section&nbsp;3.4</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Additional Closing Deliveries</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Section&nbsp;3.5</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Appointment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3">ARTICLE IV REPRESENTATIONS AND WARRANTIES OF AEGLEA</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Section&nbsp;4.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Organization and Good Standing</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Section&nbsp;4.2</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Authorization of Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Section&nbsp;4.3</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Subsidiaries</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Section&nbsp;4.4</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Conflicts; Consents of Third Parties</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Section&nbsp;4.5</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Acquired Assets</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Section&nbsp;4.6</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Transferred Product Registrations</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Section&nbsp;4.7</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Assigned Contracts</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Section&nbsp;4.8</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Sufficiency of the Assets; Title to Acquired Assets</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Section&nbsp;4.9</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Compliance with Laws; Litigation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Section&nbsp;4.10</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Regulatory Compliance</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Section&nbsp;4.11</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Intellectual Property; Data Privacy and Security</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Section&nbsp;4.12</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Taxes</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Section&nbsp;4.13</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Employee Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Section&nbsp;4.14</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Environmental Compliance</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Section&nbsp;4.15</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Finders Fees</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Section&nbsp;4.16</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>No Other Representations or Warranties</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3">ARTICLE V REPRESENTATIONS AND WARRANTIES OF IMMEDICA</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Section&nbsp;5.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Organization and Good Standing</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Section&nbsp;5.2</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Authorization of Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Section&nbsp;5.3</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Conflicts; Consents of Third Parties</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3">ARTICLE VI COVENANTS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Section&nbsp;6.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Cooperation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Section&nbsp;6.2</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Confidentiality</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Section&nbsp;6.3</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Publicity</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Section&nbsp;6.4</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Transfer of Acquired Assets; Transfer and Maintenance of Product Registrations; Cooperation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Section&nbsp;6.5</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Batch Disposition</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Section&nbsp;6.6</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Specified Patents</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Section&nbsp;6.7</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Misallocated Assets</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Section&nbsp;6.8</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Lien Releases</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Section&nbsp;6.9</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Certain Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Section&nbsp;6.10</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Reimbursement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Section&nbsp;6.11</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Delivery of Post-Closing Correspondence</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3">ARTICLE VII INDEMNIFICATION</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Section&nbsp;7.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Survival</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Section&nbsp;7.2</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Indemnification by Aeglea</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Section&nbsp;7.3</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Indemnification by Immedica</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Section&nbsp;7.4</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Indemnification Procedures</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Limitations on Indemnified Costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sources of Recovery</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exclusive Remedy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE VIII TAX MATTERS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax Matters; Cooperation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Allocation of Purchase Price; Treatment of Milestone Payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transfer Taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Apportioned Obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Withholding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE IX MISCELLANEOUS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Governing Law</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Specific Performance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jurisdiction</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">WAIVER OF JURY TRIAL</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entire Agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">License Agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.8</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amendments and Waivers</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.9</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Notices</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.10</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Severability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.11</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">No Third-Party Beneficiaries</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.12</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bulk Sales Laws</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.13</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assignment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.14</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Neutral Construction</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.15</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Counterparts; Effectiveness</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit&nbsp;10.17 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ASSET PURCHASE AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">This <B>ASSET PURCHASE AGREEMENT</B> is entered into as of July&nbsp;27, 2023 (this &#147;<U>Agreement</U>&#148;), by and between Aeglea
BioTherapeutics, Inc., a corporation organized and existing under the laws of Delaware (&#147;<U>Aeglea</U>&#148;), and Immedica Pharma AB, a limited company (<I>Aktiebolag</I>) organized and existing under the laws of Sweden
(&#147;<U>Immedica</U>&#148;). Each of Aeglea and Immedica are sometimes referred to herein individually as a &#147;<U>Party</U>&#148; and collectively as the &#147;<U>Parties</U>.&#148; Capitalized terms used herein and not otherwise defined shall
have the meanings set forth in <U>Exhibit A</U>.</P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>W I T N E S S E T H: </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, Aeglea has established a research, development and manufacturing program for pegzilarginase for the treatment of <FONT
STYLE="white-space:nowrap">Arginase-1</FONT> Deficiency as well as other therapeutic, prophylactic, palliative and diagnostic uses (the &#147;<U>Program</U>&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, Immedica and Aeglea are parties to that certain License and Supply Agreement dated as of March&nbsp;21, 2021, as amended by
that certain Memorandum of Understanding dated July&nbsp;1, 2021, that certain Memorandum of Understanding dated June&nbsp;22, 2022, and that certain Amendment No.&nbsp;2 to the Agreement dated March&nbsp;28, 2023 (the &#147;<U>License
Agreement</U>&#148;), pursuant to which Aeglea licenses to Immedica certain rights in and to the Product and Aeglea&#146;s Intellectual Property rights therein; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, Aeglea agrees to sell to Immedica, and Immedica agrees to purchase from Aeglea, assets owned by Aeglea and related to the
Product on the terms and subject to the conditions set forth herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>NOW, THEREFORE</B>, in consideration of the foregoing and the
mutual representations, warranties, covenants and agreements contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound hereby, the Parties hereby
agree as follows: </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE I </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PURCHASE PRICE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.1 <U>Purchase Price</U>. In consideration of the conveyance to Immedica of all right, title and interest in, under and to the
Acquired Assets and the other rights granted to Immedica hereunder, and subject to the terms and conditions hereof, Immedica shall pay to Aeglea:</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) An initial payment in cash of $15,000,000 in the aggregate (the &#147;<U>Initial Payment</U>&#148;)<I>, </I>by wire transfer of immediately
available funds in accordance with written instructions furnished to Immedica by Aeglea, payable at Closing; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Milestone Payments,
if any, subject to the terms and conditions of, and payable as set forth in, Section&nbsp;1.2; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) The Fuji Credit, subject to the
terms and conditions of, and payable as set forth in, Section&nbsp;6.10. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.2 <U>Milestone Payments</U>.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Subject to the remainder of this Section&nbsp;1.2, upon the first occurrence of the applicable milestone event described in the table set
forth below by Immedica (each such event, a &#147;<U>Milestone Event</U>&#148;), </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immedica shall pay an amount in cash equal to the applicable milestone
payment listed next to such Milestone Event in the table below (each such payment, a &#147;<U>Milestone Payment</U>&#148;), less any Milestone <FONT STYLE="white-space:nowrap">Set-Offs,</FONT> in accordance with Section&nbsp;1.2(b). The Milestone
Events and corresponding Milestone Payments are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="20%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center"><U>Milestone Event</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><U>Milestone Payment</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Pricing and Reimbursement Approval in France of the Product that is indicated for treatment of <FONT STYLE="white-space:nowrap">Arginase-1</FONT> Deficiency by the applicable Governmental Authority in France, where such Product has
previously received Regulatory Approval in France for the treatment of <FONT STYLE="white-space:nowrap">Arginase-1</FONT> Deficiency</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Reimbursement Earnout Amount for such Product in France</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Pricing and Reimbursement Approval in Germany of the Product that is indicated for treatment of <FONT STYLE="white-space:nowrap">Arginase-1</FONT> Deficiency by the applicable Governmental Authority in Germany, where such Product
has previously received Regulatory Approval in Germany for the treatment of <FONT STYLE="white-space:nowrap">Arginase-1</FONT> Deficiency</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Reimbursement Earnout Amount for such Product in Germany</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Pricing and Reimbursement Approval in the United Kingdom of the Product that is indicated for treatment of <FONT STYLE="white-space:nowrap">Arginase-1</FONT> Deficiency by the applicable Governmental Authority in the United Kingdom,
where such Product has previously received Regulatory Approval in the United Kingdom for the treatment of <FONT STYLE="white-space:nowrap">Arginase-1</FONT> Deficiency</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Reimbursement Earnout Amount for such Product in the United Kingdom</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Regulatory Approval of the BLA of the Product for the treatment of <FONT STYLE="white-space:nowrap">Arginase-1</FONT> Deficiency in the United States</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">$30,000,000</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Additional Milestone Event (as such term is defined in Schedule 1.2(a)).</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Additional Milestone Amount (as such term is defined in Schedule 1.2(a)).</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) No later than thirty (30)&nbsp;days after the achievement of a Milestone Event, Immedica shall provide
written notice to Aeglea of the achievement of such Milestone Event and shall pay to Aeglea the corresponding Milestone Payment, less any Milestone <FONT STYLE="white-space:nowrap">Set-Offs.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Each Milestone Payment to be paid by or on behalf of Immedica shall be paid in U.S. Dollars. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Notwithstanding anything to the contrary in this Agreement, (i)&nbsp;the maximum
aggregate amount of Milestone Payments Immedica shall be obligated to pay to Aeglea pursuant to the table set forth in this Section&nbsp;1.2 shall be $100,000,000, (ii) each unique row in the table set forth in this Section&nbsp;1.2 represents a
separate Milestone Event, and accordingly, there are five (5)&nbsp;distinct Milestone Events, (iii)&nbsp;each Milestone Event may be achieved no more than one time, (iv)&nbsp;each Milestone Payment shall be payable only once, if at all, upon the
first achievement of the applicable Milestone Event (regardless of (A)&nbsp;any subsequent or repeated achievement of a Milestone Event and (B)&nbsp;the number of subsequent Products achieving such Milestone Events). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Notwithstanding anything in this Agreement to the contrary, the Parties acknowledge and agree that, in addition to any other right or
remedy under this Agreement, Immedica shall have the right, but not the obligation, from time to time to set off against (x)&nbsp;any Milestone Payment that is owed and has not yet been paid and (y)&nbsp;if applicable, the Specified Patents Holdback
Amount if any portion of such amount continues to be held back in accordance with Section&nbsp;1.2(f) (clauses (x)&nbsp;and (y), the &#147;<U>Available Remedy Amounts</U>&#148;) (each of the following clauses (i), (ii) and (iii), a
&#147;<U>Milestone <FONT STYLE="white-space:nowrap">Set-Off</FONT></U>&#148;): (i) any Losses for which any Immedica Indemnified Party is entitled to indemnification pursuant to, and in accordance with, Article VII, (ii)&nbsp;any Losses in respect
of claims for intentional fraud or willful misconduct, and (iii)&nbsp;any Necessary IP Payments already paid or accrued or then payable by any Immedica Indemnified Party; <U>provided</U> that Immedica shall not be entitled to set off any Necessary
IP Payment to the extent that any Immedica Indemnified Party receives an indemnification payment for such Necessary IP Payment pursuant to Article VII. Notwithstanding anything in this Agreement to the contrary, to the extent that Immedica is unable
to set off any amount of any Necessary IP Payment (such amount, the &#147;<U>Necessary IP Payment Carryover</U>&#148;) against any Available Remedy Amount, such Necessary IP Payment Carryover may be set off against any subsequent Available Remedy
Amount. Immedica shall keep, and shall instruct any Immedica Indemnified Party to keep, reasonably complete and accurate records of any Milestone <FONT STYLE="white-space:nowrap">Set-Off.</FONT> Any Milestone
<FONT STYLE="white-space:nowrap">Set-Off</FONT> taken by Immedica will be accompanied by a written notice including an accounting of such Milestone <FONT STYLE="white-space:nowrap">Set-Off</FONT>
(&#147;<U><FONT STYLE="white-space:nowrap">Set-Off</FONT> Notice</U>&#148;); <U>provided</U> that any failure by Immedica to provide any such <FONT STYLE="white-space:nowrap">Set-Off</FONT> Notice to Aeglea shall not impact Immedica&#146;s rights
under this Section&nbsp;1.2(e). Upon reasonable written request by Aeglea, Immedica will provide reasonable documentation in support of any Milestone <FONT STYLE="white-space:nowrap">Set-Off,</FONT> such request to be made no more than six
(6)&nbsp;months after the date of the applicable <FONT STYLE="white-space:nowrap">Set-Off</FONT> Notice. The Parties shall negotiate in good faith to seek to resolve any dispute regarding any <FONT STYLE="white-space:nowrap">Set-Off</FONT> Notice
before making any claim to resolve such dispute. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) Aeglea and Immedica agree to be bound by and comply with the terms and conditions
set forth on Schedule 1.2(f) as though set forth in full herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) For purposes of this Section&nbsp;1.2: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) The definitions of Reimbursement Earnout Amount, Actual Reimbursement Percentage, Actual Reimbursement Price, Expected Reimbursement Price
and Pricing Reimbursement Approval are stated with respect to a 2 mg vial of the Product. In the event that any of the Milestone Events set forth in the first three rows of the table set forth in this Section&nbsp;1.2 occurs with respect to a vial
with a different amount of Product, the amounts in Euros and British Pounds Sterling will be proportionally adjusted, on a linear basis based on mg of Product, for purposes of calculating the Reimbursement Earnout Amount. By way of example, in the
event that any of the Milestone Events set forth in the first three rows of the table set forth in this Section&nbsp;1.2 occurs with respect to a 4 mg vial of Product, then the Expected Reimbursement Price of such 4 mg vial of Product (A)&nbsp;with
respect to France would be [*]/4 mg vial of such Product; (B)&nbsp;with respect to Germany would be [*]/4 mg vial of such Product; and (C)&nbsp;with respect to the United Kingdom would be [*]/4 mg vial of such Product, and the Reimbursement Earnout
Amount for such 4 mg vial of such Product would be determined using such amounts. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) &#147;<U>Actual Reimbursement Percentage</U>&#148; means, with respect to a 2 mg vial
of the Product in a given country, a number equal to the quotient of (A)&nbsp;the Actual Reimbursement Price for such 2 mg vial of the Product received by Immedica in such country, <I>divided by</I> (B)&nbsp;the Expected Reimbursement Price for such
2 mg vial of the Product in such country. By way of examples, if the Actual Reimbursement Price for a 2 mg vial of the Product received by Immedica in France is [*], then the Actual Reimbursement Percentage for such 2 mg vial of the Product in
France is [*] or 93%; and if the Actual Reimbursement Price for a 2 mg vial of the Product received by Immedica in Germany is [*], then the Actual Reimbursement Percentage for such 2 mg vial of the Product is [*] or 87%. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) &#147;<U>Actual Reimbursement Price</U>&#148; means, with respect to a given country, the price reimbursed by the applicable
Governmental Authority, net of any mandatory rebates, for a 2 mg vial of the&nbsp;Product in such country pursuant to the Pricing and Reimbursement Approval for such 2 mg vial of the Product in such country, where such reimbursed price may be the
listed price or a discounted price, net of any mandatory rebates, of such 2 mg vial of the Product that is agreed and approved between Immedica and such applicable Governmental Authority. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iv) &#147;<U>Expected Reimbursement Price</U>&#148; means, (A)&nbsp;with respect to France, [*]/2 mg vial of the Product; (B)&nbsp;with
respect to Germany, [*]/2 mg vial of the Product; and (C)&nbsp;with respect to the United Kingdom, [*]/2 mg vial of the Product. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(v)
[Reserved]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(vi) &#147;<U>Pricing and Reimbursement Approval</U>&#148; means, with respect to a 2 mg vial of the Product in a given
country, following Regulatory Approval of such 2 mg vial of the Product for the treatment of <FONT STYLE="white-space:nowrap">Arginase-1</FONT> Deficiency in such country by the applicable Regulatory Authority in such country, the later of
(A)&nbsp;the approval, agreement, determination or decision by (1)&nbsp;the Ministries of Health and Social Security in France as published in the Journal Officiel, (2)&nbsp;the National Institute for Health and Care Excellence in the United Kingdom
as set forth in the applicable commercial access agreement and (3)&nbsp;Spitzenverband der Gesetzlichen Krankenkassen <FONT STYLE="white-space:nowrap">(GKV-Spitzenverband)</FONT> in Germany as published in the Lauer Taxe establishing a price for
such 2 mg vial of the Product that can be legally charged to consumers, if required or desirable, in such country in connection with the broad commercialization of such 2 mg vial of the Product for the treatment of
<FONT STYLE="white-space:nowrap">Arginase-1</FONT> Deficiency in such country; and (B)&nbsp;the approval, agreement, determination or decision by the foregoing applicable Governmental Authority establishing the level of reimbursement for such 2 mg
vial of the Product that will be reimbursed by such Governmental Authority, if required or desirable, in such country in connection with the broad commercialization of such 2 mg vial of the Product for the treatment of
<FONT STYLE="white-space:nowrap">Arginase-1</FONT> Deficiency in such country. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(vii) [Reserved]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(viii) [Reserved]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ix)
[Reserved]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(x) &#147;<U>Reimbursement Earnout Amount</U>&#148; means, with respect to a 2 mg vial of the Product in a given country:
(A)&nbsp;if the Actual Reimbursement Percentage of such 2 mg vial of the Product in such country is equal to 100% or more, $10,000,000, (B) if the Actual Reimbursement Percentage of such 2 mg vial of the Product in such country is less than 80%,
zero, and (C)&nbsp;if the Actual Reimbursement Percentage </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of such 2 mg vial of the Product in such country is 80% or more but less than 100%, an amount equal to the sum of (i) $3,333,333 and (ii)&nbsp;the product of (A)(x) the Actual Reimbursement
Percentage for such 2 mg vial of the Product in such country <I>minus</I> 80% <I>divided by</I>&nbsp;(y) 20% <I>multiplied</I><I>&nbsp;by</I>&nbsp;(B) $6,666,666; or, in the case of the foregoing clause (C), the formula expressed as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="8%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="8%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ROWSPAN="2"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">$3,333,333</P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD ROWSPAN="2" NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD ROWSPAN="2" NOWRAP VALIGN="bottom" ALIGN="right">+</TD>
<TD ROWSPAN="2" NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Actual Reimbursement Percentage minus 80%</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD ROWSPAN="2" NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD ROWSPAN="2" NOWRAP VALIGN="bottom" ALIGN="right">x</TD>
<TD ROWSPAN="2" NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2" NOWRAP ALIGN="right">$6,666,666</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">20%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xi) [Reserved]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xii) [Reserved]. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE II
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PURCHASE AND SALE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.1 <U>Acquired Assets.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) On the terms and subject to the conditions set forth in this Agreement, at the Closing, Aeglea shall, and shall cause its Subsidiaries to,
sell, assign, transfer, convey and deliver to Immedica, and Immedica shall receive, acquire and accept, all right, title and interest of Aeglea and its Subsidiaries in, to and under the Acquired Assets (including the Assigned Intellectual Property),
free and clear of all Liens except for Permitted Liens. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) &#147;<U>Acquired Assets</U>&#148; means the following assets at the Closing:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) the assets listed on Schedule 2.1(b)(i)(D);</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) the Assigned Contracts; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) all Biological Materials;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iv) all Inventory; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(v) all
Product Registrations that are (A)&nbsp;used in or held for use in the Program or in connection with the Product or (B)&nbsp;listed on Schedule 2.1(b)(v) (collectively, the &#147;<U>Transferred Product Registrations</U>&#148;); <U>provided</U> that
Aeglea shall be entitled to retain copies of the Transferred Product Registrations solely to the extent necessary to comply with applicable Law and its internal document retention policies, subject to Aeglea&#146;s nonuse and confidentiality
obligations set forth in Section&nbsp;6.2;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(vi) all Documents primarily related to the Program or Product or that are otherwise related to
the Product or Program and reasonably necessary and useful to the Product or the Program (collectively, the &#147;<U>Transferred Documents</U>&#148;), including all attorney-client privilege and attorney work-product protection and all Documents
subject to the attorney-client privilege or work-product protection in each case that relate to the Product or the Program; <U>provided</U> that the Transferred Documents shall exclude all (w)&nbsp;personnel files for any current or former
directors, officers, employees, independent contractors or consultants (collectively, &#147;<U>Aeglea Service Providers</U>&#148;), (x) Documents relating to Spyre Therapeutics, Inc. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and its businesses or assets, as well as the transactions (the &#147;<U>Spyre Transactions</U>&#148;) contemplated by that certain Agreement and Plan of Merger, dated June&nbsp;22, 2023, by and
between Aeglea, Spyre Therapeutics, Inc., Aspen Merger Sub I, Inc. and Sequoia Merger Sub II, LLC (collectively, the &#147;<U>Spyre Documents</U>&#148;), (y) Documents subject to the attorney-client privilege or work-product protection relating
solely to the License Agreement (and not the Product or the Program), and (z)&nbsp;Documents relating to the determination by Aeglea or any of its Subsidiaries with respect to the wind-down or discontinuation of all or a portion of the Program or
any study related thereto; and <U>provided</U>, <U>further</U>, that Aeglea shall be entitled to (1)&nbsp;redact information from any Transferred Document that if in a separate document would fall within the foregoing exceptions or that relates
exclusively to something other than the Product or the Program, and (2)&nbsp;retain copies of the foregoing (A)&nbsp;to the extent necessary to comply with applicable Law and its internal document retention policies and (B)&nbsp;to the extent any
Transferred Document relates to Excluded Assets or Excluded Liabilities, in each case, subject to Aeglea&#146;s nonuse and confidentiality obligations set forth in Section&nbsp;6.2; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(vii) all claims, causes of action (including the right to sue for past infringement or misappropriation), defenses, rights of recovery and
rights of <FONT STYLE="white-space:nowrap">set-off</FONT> against third parties and all credits (including all guarantees, warranties, indemnities and similar rights) in favor of Aeglea or any of its Subsidiaries, in each case to the extent relating
to, arising out of or in connection with the Product, the Program, the Acquired Assets or the Assumed Liabilities; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(viii) all other
assets, properties and rights of a type not expressly covered in this Section&nbsp;2.1(b) that are exclusively related to, exclusively used in or exclusively held for use in Program or in connection with the Product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.2 <U>Excluded Assets</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Notwithstanding anything to the contrary in this Agreement, nothing herein contained shall be deemed to sell, transfer, assign or convey
to Immedica the Excluded Assets, and Aeglea and its Subsidiaries shall retain all right, title and interest to, in and under the Excluded Assets and Immedica shall not acquire any of the Excluded Assets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) &#147;<U>Excluded Assets</U>&#148; means each of the following assets at the Closing: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) all cash and cash equivalents, securities, negotiable instruments, accounts receivable, notes and other amounts receivable of Aeglea or its
Subsidiaries;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) any rights to Tax refunds, credits, deductions, allowances or other Tax benefits of Aeglea or its Subsidiaries; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) the company seal, minute books, charter documents, stock or equity record books and such other books and records as pertain to the
organization, existence or capitalization of Aeglea and its Subsidiaries, as well as any other records or materials relating to Aeglea or its Subsidiaries that are exclusively related to the Excluded Assets or are not related to the Acquired Assets,
the Program or the Product; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iv) the shares of capital stock, partnership interests, membership interests or other equity interests of
any Person (including Aeglea or any of its Subsidiaries); </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(v) other than the Assigned Intellectual Property and subject to the terms and conditions of
Section&nbsp;6.6 and the Specified Patent License Agreement, all right, title and interest in and to all Intellectual Property and all other intangible property of Aeglea; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(vi) all equipment and tangible personal property of Aeglea or any of its Subsidiaries; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(vii) all real property owned or leased by Aeglea or any of its Subsidiaries; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(viii) all Contracts listed on Schedule 2.2(b)(viii); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ix) all rights which accrue or will accrue to Aeglea or any of its Subsidiaries under this Agreement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(x)&nbsp;(A) all attorney-client privilege and attorney work-product protection of Aeglea or its Subsidiaries, (B)&nbsp;all Documents subject
to the attorney-client privilege or work-product protection, in the case of the foregoing clauses (A)&nbsp;and (B), solely to the extent not primarily related to the Program or Product or that are otherwise not related to the Product or Program and
not reasonably necessary and useful to the Product or the Program, (C)&nbsp;all Documents subject to the attorney-client privilege or work-product protection maintained by Aeglea or its Subsidiaries in connection with the Transaction, the License
Agreement or the Spyre Transaction and (D)&nbsp;all Documents (including those subject to attorney-client&nbsp;privilege or work-product protection) that (i)&nbsp;are personnel files for Aeglea Service Providers, (ii)&nbsp;are Spyre Documents or
(iii)&nbsp;relate to the determination by Aeglea or any of its Subsidiaries with respect to the wind-down or discontinuation of all or a portion of the Program or any study related thereto;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xi) Tax Returns of Aeglea and its Subsidiaries (other than Tax Returns or any portion thereof solely relating to any Acquired Asset); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xii) all current and prior insurance policies of Aeglea and its Subsidiaries and all rights of any nature with respect thereto, including all
insurance recoveries thereunder and rights to assert claims with respect to any such insurance recoveries;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xiii) all assets with respect
to any employee benefit plans, agreements or arrangements contributed to, sponsored, maintained or entered into by Aeglea or its Subsidiaries or otherwise relating to any Aeglea Service Providers;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xiv) the ADA Assays; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xv)
all other assets, properties, contractual rights, goodwill and other intangible assets, rights and claims of Aeglea and its Subsidiaries not included in the Acquired Assets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.3 <U>Assumption of Assumed Liabilities</U>.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) On the terms and subject to the conditions set forth in this Agreement, as of the Closing, Immedica shall assume and be responsible for,
and shall timely perform, satisfy and discharge in accordance with their terms, the Assumed Liabilities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) &#147;<U>Assumed Liabilities</U>&#148; means each of the following Liabilities of Aeglea
and its Subsidiaries at the Closing: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) all Liabilities of Aeglea arising under or in connection with the Assigned Contracts from and
after the Closing, excluding for clarity the Excluded Liabilities set forth in Sections 2.4(b)(iv) and 2.4(b)(v) below, but including the amounts as set forth in Schedule 2.3(b)(i); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) all Liabilities of Aeglea arising out of or relating to actions by Immedica or its Subsidiaries commenced after the Closing, irrespective
of the legal theory asserted, arising from the administration, manufacture, advertising, marketing, distribution, sale or use of the Product or conduct of the Program during the period of time on or after the Closing; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) without duplication of the other provisions of this Section&nbsp;2.3(b), all Liabilities arising out of or in connection with an event
first occurring at any time from and after the Closing to the extent relating to the Program or Product, or the use, ownership or operation of the Acquired Assets by Immedica or its Subsidiaries from and after the Closing, other than Liabilities of
Aeglea or any of its Subsidiaries arising out of a breach or termination of this Agreement by Aeglea or any of its Subsidiaries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.4 <U>Excluded Liabilities</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Notwithstanding any provision in this Agreement or any other writing to the contrary, Immedica is assuming only the Assumed Liabilities
and is not assuming any other Liability of or relating to Aeglea or any of its Subsidiaries (or any of their respective predecessors or any prior owner of all or part of its or their businesses and assets) of whatever nature, whether presently in
existence or arising hereafter. All such other Liabilities shall be retained by and remain Liabilities of Aeglea (or its applicable Affiliate) (all such Liabilities and obligations not being assumed, including those specifically enumerated in
Section&nbsp;2.4(b), being herein referred to as the &#147;<U>Excluded Liabilities</U>&#148;).</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) &#147;<U>Excluded Liabilities</U>&#148;
includes, without limitation, the following: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) all Liabilities to the extent not related to the Program, Product or the Acquired Assets;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) all Liabilities relating to or arising out of the Excluded Assets; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;(A) all Liabilities of Aeglea, its Affiliates or any consolidated, affiliated, combined or unitary group of which Aeglea or any of
its Affiliates is or has been a member, for Taxes and (B)&nbsp;all Liabilities for Taxes with respect to the Acquired Assets for taxable periods ending on or prior to the Closing Date; <U>provided</U> that any Transfer Taxes incurred in connection
with the Transaction and Apportioned Obligations shall be paid in the manner set forth in Article VIII; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iv) all Liabilities relating to
the Assigned Contracts to the extent such Liabilities (A)&nbsp;arise before the Closing, including, for the avoidance of doubt, any amounts owed under any Assigned Contract prior to the Closing pursuant to the terms thereof, regardless of whether
the work to be performed, services to be rendered or goods to be provided in exchange for such amounts owed are to be provided before or after payment therefor or before or after the Closing, and regardless of whether an invoice for any such payment
is rendered before or after the Closing; <U>provided</U> that the amounts listed on Schedule 2.3(b)(i) under the column &#147;Expense to be Assumed by Immedica&#148; shall be assumed by Immedica, (B)&nbsp;arise from or relate to any breach by Aeglea
or any of its Subsidiaries of any provision of any of such Assigned Contract or (C)&nbsp;arise from or relate to any action or inaction by Aeglea or any of its Subsidiaries in connection with any such Assigned Contract;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(v) all Liabilities under any Contract that is not an Assigned Contract and, subject to
Section&nbsp;2.6, all Liabilities under any Assigned Contract that is not validly and effectively assigned to Immedica pursuant to this Agreement or any other Instrument; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(vi) all Liabilities, whether arising prior to, upon or following the Closing, with respect to any Aeglea Service Providers, including,
without limitation, all Liabilities (A)&nbsp;under or relating to any employee benefit plan, contract, program, fund or arrangement and any trust, escrow or similar agreement related thereto, whether or not funded, in respect of any Aeglea Service
Provider or with respect to which Aeglea or any of its Affiliates has made or is required to make payments, transfers or contributions, or any management, employment, severance, change in control, noncompete, confidentiality, offer letter,
retention, incentive or similar Contract, and (B)&nbsp;the matters set forth on Schedule 2.4(b)(vi);</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(vii) all Liabilities of Aeglea or
any of its Affiliates in respect of Indebtedness; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(viii) all Liabilities in respect of any pending Legal Proceedings and any Legal
Proceedings initiated after the Closing arising out of or relating to the administration, development, manufacture, advertising, marketing, distribution, sale or use of the Product or conduct of the Program prior to the Closing; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ix) all Expenses of Aeglea or any of its Subsidiaries payable to Third Parties, including to any outside professionals (including any broker,
finder, agent, investment banker, legal, accounting or tax adviser), incurred by Aeglea or any of its Subsidiaries before, on or after the Closing, in connection with the authorization, preparation, negotiation, execution and performance of this
Agreement or the other&nbsp;Instruments, or the process of selling the Acquired Assets, including any investment banking or brokerage fees, finders&#146; fees or commissions; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(x) all other Liabilities arising out of or relating to the Product, the Program or the Acquired Assets, to the extent such Liabilities relate
to the period of time prior to Closing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.5 <U>Undisclosed Contracts</U>. If any Program Contract was not set forth on
Schedule 2.1(b)(i) or 2.2(b)(viii) and is identified following the Closing, Aeglea shall promptly notify Immedica in writing giving sufficient disclosure of such Program Contract and provide Immedica with a copy thereof, in which case Immedica shall
thereafter be entitled to deem such Program Contract an &#147;Assigned Contract&#148; and the provisions of this Agreement (including Section&nbsp;2.6) shall apply to such Program Contract as though it were an Assigned Contract, and Aeglea and
Immedica shall take such action reasonably requested by Immedica (and consistent with the other provisions of this Agreement (including Section&nbsp;2.6)) to assign such Program Contract to Immedica. Neither Aeglea nor any of its Subsidiaries shall
voluntarily terminate any such nondisclosed Program Contract prior to providing Immedica with written notice of the intent to terminate and giving Immedica a reasonable period of time to review such Program Contract and determine whether to exercise
its right to treat such Program Contract as an &#147;Assigned Contract.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.6
<U><FONT STYLE="white-space:nowrap">Non-Assignable</FONT> Assets</U>. Notwithstanding anything to the contrary in this Agreement, nothing in this Agreement or the consummation of the Transaction shall be construed as an attempt or agreement to
assign any Acquired Asset, including any Contract, Permit, certificate, approval, authorization or other right, which by its terms or by Law is <FONT STYLE="white-space:nowrap">non-assignable</FONT> without the consent of a Third Party or a
Governmental Authority or is terminable or cancelable by a Third Party or a Governmental Authority in the event of an assignment (any such Acquired Asset, a &#147;<U>Non</U><U><FONT STYLE="white-space:nowrap">-assignable</FONT> Asset</U>&#148;)
unless and until such consent shall have been obtained. Aeglea shall and shall cause its Subsidiaries to use all commercially reasonable efforts to obtain any such consents with respect to the Acquired Assets, including all <FONT
STYLE="white-space:nowrap">Non-assignable</FONT> Assets, and including all consents set forth on Schedule 4.4(a), as promptly as </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
practicable, and shall cooperate as reasonably requested by Immedica in any efforts made by Immedica or any of its Affiliates to obtain such consent. If any such consent or approval is not
obtained, Aeglea shall, and shall cause its Subsidiaries to, provide to Immedica the benefits of such <FONT STYLE="white-space:nowrap">Non-assignable</FONT> Asset in accordance with this Agreement and shall enforce, or cause its Subsidiaries to
enforce, at the request of and for the benefit of Immedica, any rights of Aeglea or its Subsidiaries arising thereunder, including the right to seek any available remedies or to terminate in accordance with the terms thereof, in each case at
Immedica&#146;s cost and expense. Aeglea shall and shall cause its Subsidiaries to promptly pay to Immedica when received all monies received by Aeglea or any of its Affiliates under any such <FONT STYLE="white-space:nowrap">Non-assignable</FONT>
Asset or any claim, right or benefit arising thereunder, except to the extent the same represents an Excluded Asset. As a condition to Aeglea providing Immedica with the benefits of any <FONT STYLE="white-space:nowrap">Non-assignable</FONT> Asset,
Immedica shall perform, in the name or on behalf of Aeglea or its applicable Subsidiary, all obligations of Aeglea or its applicable Subsidiary and shall indemnify Aeglea or its applicable Subsidiary for any Liabilities first arising thereunder
following the Closing, except to the extent such Liabilities relate to the gross negligence or willful misconduct of Aeglea or any Aeglea Indemnified Party or the failure of Aeglea or any Aeglea Indemnified Party to follow the reasonable written
(email being sufficient) instructions of Immedica or any of its Subsidiaries with respect to such <FONT STYLE="white-space:nowrap">Non-assignable</FONT> Asset. To the extent that, in connection with obtaining a Third Party&#146;s consent under any <FONT
STYLE="white-space:nowrap">Non-assignable</FONT> Asset, one or more of the Parties enter into an agreement with such Third Party that provides for an allocation of liability among the Parties with respect to such
<FONT STYLE="white-space:nowrap">Non-assignable</FONT> Asset that is inconsistent with the terms of this Agreement, the Parties agree that, as among themselves, the provisions of this Agreement shall control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.7 <U>Designated Buyer</U>. Notwithstanding anything to the contrary contained in this Agreement, Immedica may elect to have any
or all of the Acquired Assets sold, assigned, conveyed, transferred or delivered to, or any of the Assumed Liabilities assumed by, one or more of its Subsidiaries, in each case as set forth in the Instruments to be delivered at Closing;
<U>provided</U>, <U>however</U>, that no such sale, assignment, conveyance, transfer or delivery shall (a)&nbsp;relieve Immedica of any of its obligations to Aeglea hereunder with respect to the Assumed Liabilities or (b)&nbsp;otherwise increase or
expand the obligations of Aeglea hereunder.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.8 <U>ADA Assay License</U>. Aeglea and its Subsidiaries hereby grant to
Immedica and its Affiliates a royalty-free, fully <FONT STYLE="white-space:nowrap">paid-up,</FONT> worldwide, fully transferable, irrevocable, perpetual, <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> sublicensable (including the right to
sublicense through multiple tiers) license under their respective rights in and to the ADA Assays to use and otherwise Exploit the ADA Assays for any and all purposes. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE III </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CLOSING
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.1 <U>Closing</U>. The closing of the Transaction (the &#147;<U>Closing</U>&#148;) shall take place on the date hereof
(the &#147;<U>Closing Date</U>&#148;) remotely by exchange of documents and signatures (or their electronic counterparts), simultaneously with the execution and delivery of this Agreement.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.2 <U>Deliveries by Aeglea</U>.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) At the Closing, Aeglea shall pay an amount in cash equal to the Fuji Credit to Fujifilm by wire transfer of immediately available funds,
and, at or prior to the Closing, shall provide to Immedica proof of such payment that is reasonably satisfactory to Immedica. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) At the Closing, Aeglea shall deliver, or cause to be delivered, to Immedica, as
applicable, the following: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) an assignment and assumption agreement and bill of sale, in a form reasonably agreed among the Parties (the
&#147;<U>Assignment and Assumption and Bill of Sale</U>&#148;), executed by a duly authorized officer of Aeglea;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) the agreements
listed on Schedule 3.2(b); and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) the IP Assignment Agreement, executed by a duly authorized officer of Aeglea. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iv) [Reserved]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.3 <U>Deliveries by Immedica at the Closing</U>. At the Closing, Immedica shall deliver, or cause to be delivered, to Aeglea, as
applicable, the following: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) the Initial Payment by wire transfer of immediately available funds, in accordance with
Section&nbsp;1.1(a); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) the Assignment and Assumption and Bill of Sale, executed by a duly authorized officer of Immedica; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) the agreements listed on Schedule 3.3; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) the IP Assignment Agreement, executed by a duly authorized officer of Immedica. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) [Reserved]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.4 <U>Additional Closing Deliveries</U>. From time to time following the Closing, at the reasonable request of Aeglea or
Immedica, such other Party shall execute, acknowledge and deliver all such further&nbsp;conveyances, notices, assumptions, releases and acquittances and such other instruments, and shall take such further actions, as may be necessary to assure
(a)&nbsp;to Immedica and its successors and assigns, all of the properties, rights, titles, interests, estates, remedies, powers and privileges intended to be conveyed to Immedica under this Agreement and the other Instruments, and (b)&nbsp;to the
Parties and their respective Affiliates, and their respective successors and assigns, the assumption of the Liabilities intended to be assumed by Immedica under this Agreement and the other Instruments, and to otherwise make effective the
Transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.5 <U>Appointment</U>. Aeglea hereby constitutes and appoints, effective as of the Closing, Immedica and its
successors and assigns as the true and lawful attorney of Aeglea with full power of substitution in the name of Immedica, or in the name of Aeglea but for the benefit of Immedica, to collect for the account of Immedica any items of Acquired Assets.
Immedica shall be entitled to retain for its own account any amounts collected pursuant to the foregoing powers, including any amounts payable as interest in respect thereof and shall promptly remit to Aeglea without any <FONT
STYLE="white-space:nowrap">set-off</FONT> any amounts collected that are not Acquired Assets. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE IV </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REPRESENTATIONS AND WARRANTIES OF AEGLEA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Aeglea hereby represents and warrants to Immedica as of the Closing Date as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.1 <U>Organization and Good Standing</U>. Aeglea is an entity duly organized, validly existing and in good standing under the
applicable Laws of the state of its organization and has all requisite corporate or other similar organizational powers required to carry on its business as now conducted. Aeglea is duly qualified to do business as a foreign entity and, to the
extent legally applicable, in good standing as a foreign entity in each jurisdiction where such qualification is necessary, except for those jurisdictions where failure to be so qualified or in good standing would not, individually or in the
aggregate, reasonably be expected to be material to the Acquired Assets, the Product (which term &#147;Product,&#148; solely for purposes of this Article IV, shall refer to the Product in accordance with good manufacturing practices, as defined
under the applicable sections of the United States Code of Federal Regulations, and the specifications contained in the Transferred Product Registrations) or the Program (which term &#147;Program,&#148; solely for purposes of this Article IV, shall
refer to the research, development and manufacturing program for pegzilarginase solely with respect to the treatment of <FONT STYLE="white-space:nowrap">Arginase-1</FONT> Deficiency), or materially impede or materially delay the consummation by
Aeglea of the Transactions or the performance of its obligations under this Agreement or any Instrument to which it is a party.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.2 <U>Authorization of Agreement</U>. Aeglea and each of its applicable Subsidiaries has all requisite power and authority to
execute and deliver this Agreement and each other agreement, document or instrument contemplated by this Agreement to which it is a party (collectively, the &#147;<U>Instruments</U>&#148;), to perform its respective obligations hereunder and
thereunder and to consummate the Transaction and the other transactions contemplated hereby and thereby. The execution, delivery and performance by Aeglea and each of its applicable Subsidiaries of each of this Agreement and each other Instrument
and the consummation of the Transaction and the other transactions contemplated hereby and thereby have been duly authorized and approved by all requisite corporate or similar action on the part of Aeglea and each of its applicable Subsidiaries.
Each of the Instruments has been, or will be at or prior to the Closing, duly and validly executed and delivered by Aeglea and each of its Subsidiaries party thereto and (assuming the due authorization, execution and delivery by the other parties
thereto) each of the Instruments, when so executed and delivered, will constitute the legal, valid and binding obligations of Aeglea and each such Subsidiary, enforceable against it in accordance with its terms, subject to the effect of any
applicable Laws relating to bankruptcy, reorganization, insolvency, moratorium, fraudulent conveyance or preferential transfers, or similar Laws relating to or affecting creditors&#146; rights generally and subject, as to enforceability, to the
effect of general principles of equity (regardless of whether such enforceability is considered in a proceeding in equity or at Law). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.3 <U>Subsidiaries</U>. Each Subsidiary of Aeglea which has title to any Acquired Assets is duly organized, validly existing and
in good standing under the laws of its jurisdiction of organization and has all requisite corporate or similar power and authority to carry on its portion of the Program as currently conducted and is duly qualified to do business and is in good
standing as a foreign corporation or other entity in each jurisdiction where the ownership or operation of the Acquired Assets or the conduct of the Program requires such qualification, except for failures to be so duly organized, validly existing,
qualified or in good standing that would not, individually or in the aggregate, be material to the Acquired Assets, the Product or the Program or materially impede or materially delay the consummation by such Subsidiary of the Transactions or the
performance of its obligations under this Agreement or any Instrument to which it is a party. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.4 <U>Conflicts; Consents of Third Parties</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Assuming the receipt of the consents identified on Schedule 4.4(a), none of the execution and delivery of this Agreement or the
Instruments by Aeglea or any of its Subsidiaries, or the consummation of the Transaction or the other transactions contemplated hereby and thereby, will conflict with, or result in any violation of, or constitute a breach of, or conflict with or
constitute a default (with or without notice or lapse of time, or both) under any provision of, or require any consent or other action by any Person under, or give rise to any right of termination, cancellation or acceleration under: (i)&nbsp;the
certificate of incorporation and <FONT STYLE="white-space:nowrap">by-laws</FONT> or comparable organizational documents of Aeglea or any of its Subsidiaries party to any Instrument; (ii)&nbsp;any Contract to which Aeglea or any such Subsidiary is a
party or by which any of the properties or assets of Aeglea or any of its Subsidiaries used or held for use in the Program or in connection with the Product, or any Acquired Asset, is bound; (iii)&nbsp;any Order of any Governmental Authority
applicable to Aeglea or any of its Subsidiaries or by which any of the properties or assets of Aeglea used or held for use in the Program or in connection with the Product, or any Acquired Asset, is bound; or (iv)&nbsp;any applicable Law, except, in
the case of clauses (ii), (iii) and (iv)&nbsp;above, where such conflict, violation or default would not be material to the Acquired Assets, the Product or the Program or materially impede or materially delay the consummation by Aeglea or any such
Subsidiary of the Transactions or the performance of its obligations under this Agreement or any Instrument to which it is a party. None of the execution and delivery of this Agreement or the Instruments by Aeglea or any of its Subsidiaries, or the
consummation of the Transaction or the other transactions contemplated hereby and thereby, will result in the creation or imposition of any Lien on any Acquired Asset, except for Permitted Liens. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Assuming the receipt of the consents from a Governmental Authority identified on Schedule 4.4(a), and except for any such filings,
notices, Permits, authorizations, registrations, consents or approvals, the failure to make or obtain would not be material to the Acquired Assets, the Product or the Program and would not materially impede or materially delay the consummation by
Aeglea of the Transactions or the performance of its obligations under this Agreement or any Instrument to which it is a party, no consent, waiver, approval, Order, Permit or authorization of, or declaration or filing with, or notification to, any
Governmental Authority is required for Aeglea in connection with the execution and delivery of this Agreement or the Instruments, or the consummation of the Transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.5 <U>Acquired Assets</U>.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Except as set forth on Schedule 4.5(a), prior to the transfer of the Acquired Assets to Immedica at the Closing in accordance with this
Agreement, Aeglea owns and has good title to the Acquired Assets, free and clear of all Liens other than Permitted Liens. Other than any Permitted Liens, neither Aeglea nor any of its Subsidiaries has granted to any Third Party any interest, right
to use, license or entered into any covenants not to sue, releases for infringement, or waivers of claims for infringement, in, of or with respect to the Acquired Assets. Neither Aeglea nor any of its Subsidiaries has received any written notice
from any other Person challenging its ownership or rights to use any Acquired Assets and there are no pending Legal Proceedings against Aeglea or any of its Subsidiaries challenging such ownership or rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) There are no existing Contracts to which Aeglea or any of its Subsidiaries is a party, pursuant to which a Third Party is granted an
option to acquire any interest in any of the Acquired Assets. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Schedule 4.5(c) sets forth a true and complete list of all <FONT
STYLE="white-space:nowrap">Non-assignable</FONT> Assets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) All Inventory has been manufactured (i)&nbsp;in accordance with good
manufacturing practices, as defined under the applicable sections of the United States Code of Federal Regulations, (ii)&nbsp;in compliance with all applicable Law, (iii)&nbsp;in accordance with the Inventory Specifications and (iv)&nbsp;in
accordance with the specifications and standards contained in the Transferred Product Registrations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.6 <U>Transferred
Product Registrations.</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Transferred Product Registrations constitute all material registrations, applications, approvals,
licenses or permits granted by any Governmental Authority to develop and market the Product, other than any Product Registrations held by Immedica or its Subsidiaries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Except as set forth in Schedule 4.6(b), prior to the transfer of any Transferred Product Registration in accordance with this Agreement,
Aeglea is the sole and exclusive owner of such Transferred Product Registration other than any Product Registrations held by Immedica or its Subsidiaries, and has not granted any right of reference with respect thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.7 <U>Assigned Contracts.</U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Other than the Assigned Contracts and the Contracts listed on Schedule 2.2(b)(viii), neither Aeglea nor any of its Subsidiaries is party
to any Contract that is primarily related to, or otherwise material to, the Product or the Program. Each Assigned Contract is a valid, binding and enforceable agreement of Aeglea or its applicable Subsidiaries party thereto and, to the Knowledge of
Aeglea, of each other party to such Assigned Contract, and each such Assigned Contract is in full force and effect. In respect of each Assigned Contract, neither Aeglea nor any of its applicable Subsidiaries party thereto is, nor, to the Knowledge
of Aeglea, any other counterparty thereto is, in default or breach under the terms of any such Assigned Contract, and, to the Knowledge of Aeglea, no event has occurred that, with or without the lapse of time or the giving of notice or both, would
constitute a breach thereof or default thereunder by Aeglea or its applicable Subsidiaries party thereto or, to the Knowledge of Aeglea, any other party thereto, except for any such defaults or breaches that, individually or in the aggregate, would
not reasonably be expected to be material to the Acquired Assets, the Product or the Program. There are no disputes pending, or to Aeglea&#146;s Knowledge, threatened, with respect to any of the Assigned Contracts and neither Aeglea nor any of its
Subsidiaries has received any written notice of the intention of any other party to any Assigned Contract to terminate or not renew or reduce any commitment under any Assigned Contract, nor to the Knowledge of Aeglea is any such party intending to
do so, in each case, except where such dispute, or such termination or nonrenewal or commitment reduction would not be material to the Product or the Program. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) No Assigned Contract (i)&nbsp;contains a covenant not to compete or other covenants that purport to limit or restrict the business
activity of Aeglea or any of its Subsidiaries or limit the freedom of Aeglea or any of its Subsidiaries to use the Acquired Assets, or (ii)&nbsp;grants a Third Party a license, or a covenant not to be sued under, any Assigned Intellectual Property,
excluding nonexclusive licenses granted in the ordinary course of business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) There are no obligations to make any payments or any amounts owed under any Assigned
Contract, including under the Fuji Scope of Work, that have not been paid by Aeglea or any of its Subsidiaries at or prior to Closing, regardless of whether the work to be performed, services to be rendered or goods to be provided in exchange for
such payments are to be provided before or after payment therefor or before or after the Closing, and regardless of whether an invoice for any such payment is rendered before or after the Closing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.8 <U>Sufficiency of the Assets; Title to Acquired Assets</U>.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Acquired Assets, together with the license to the ADA Assays granted pursuant to Section&nbsp;2.8, comprise all of the property,
assets and rights, tangible and intangible, of any nature whatsoever, used or held for use in the Program or with the Product, except for any and all such assets or rights for the general operation of an entity, all personnel, all contracts in
support of clinical trials and the Excluded Assets (provided that for purposes of this Section&nbsp;4.8(a), the definition of &#147;Excluded Assets&#148; shall be deemed not to include clause (xv)&nbsp;thereof), and (subject to the foregoing
exceptions) are sufficient to conduct the Program, <I>provided</I> that this Section&nbsp;4.8(a) shall not be construed as a representation or warranty with respect to not infringing, misappropriating or otherwise violating Intellectual Property of
a Third Party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Aeglea hereby represents and warrants to Immedica as of the Closing Date as set forth on Schedule 4.8 as though set
forth in full herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.9 <U>Compliance with Laws; Litigation</U>.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Except as would not reasonably be expected to be material to the Program, the Acquired Assets or the Product, (i)&nbsp;neither Aeglea nor
any of its Subsidiaries is in violation of any applicable Law relating to the Program, the Product, the Acquired Assets or the Assumed Liabilities, (ii)&nbsp;except as set forth on Schedule 4.9, all governmental licenses, permits, approvals and
authorizations employed in, or necessary to the ongoing operation of the Program as currently conducted, are in full force and effect and (iii)&nbsp;neither Aeglea nor any of its Subsidiaries has received any communication from any Governmental
Authority relating to any violation of any applicable Law in connection with the Acquired Assets, Assumed Liabilities, the Product or the operation of the Program. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Program has been conducted and developed, and the Product been manufactured, processed, tested and stored, in accordance with all
applicable Laws, rules and regulations, in all material respects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) There is no Legal Proceeding pending against, or to the knowledge
of Aeglea or any of its Subsidiaries, threatened against or affecting, the Acquired Assets or relating to the Acquired Assets or the Program before any arbitrator or any Governmental Authority, and there are no outstanding Orders, injunctions or
decrees of any Governmental Authority that apply to or otherwise relate to the Acquired Assets or the Program (or that will apply to Immedica after Closing) that restrict the ownership, disposition or use of the Acquired Assets or the Product, or
the conduct of the Program. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.10 <U>Regulatory Compliance</U>.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Except as would not reasonably be expected to be material to the Program, the Acquired Assets or the Product, Aeglea and each of its
Subsidiaries is in compliance with all applicable legal requirements of the U.S. Centers for Medicare&nbsp;&amp; Medicaid Services, U.S. Centers for Disease Control and Prevention, U.S. Department of Health and Human Services, U.S. Drug Enforcement
Agency, U.S. Food and Drug Administration, U.S. Federal Trade Commission (the &#147;<U>FTC</U>&#148;), U.S. Department of Agriculture, U.S. Department of Commerce, and similar federal, state and local Governmental Authorities, and comparable <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> Governmental Authorities (collectively, the &#147;<U>Regulatory Bodies</U>&#148;), as well as all applicable healthcare-related legal requirements of the U.S. Department of Justice and healthcare-related
Presidential Executive Orders, including with respect to the maintenance, compilation and filing of reports and the sale, labeling, storing, testing, development, distribution, marketing, promotion and advertising of the Product, including all
anti-kickback laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Since January&nbsp;1, 2020, neither Aeglea nor any of its Subsidiaries (i)&nbsp;has received any written notice
or warning letter from any Regulatory Body or any other Governmental Authority alleging any violation of any requirements under applicable Law by Aeglea or any of its Subsidiaries, (ii)&nbsp;has received notice of nor is subject to any adverse
inspection, finding of deficiency, finding of noncompliance, compelled or voluntary recall, product seizure, investigation, penalty for corrective or remedial action or other compliance or enforcement action by any Governmental Authority, in each
case relating to the Product or to the facilities in which the Product is manufactured, produced, processed, packaged, labeled, collected, stored or handled. There is no corporate integrity agreement in effect with respect to Aeglea or otherwise
with respect to the Program or the Product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Neither Aeglea nor any of its Subsidiaries has received (i)&nbsp;any FDA Form 483
&#147;Inspectional Observations,&#148; or similar notice from any Governmental Authority, relating to the Product or the facilities in which the Product is manufactured; or (ii)&nbsp;any &#147;warning letters,&#148; or &#147;untitled letters,&#148;
or other similar Governmental Authority notice of inspectional observations or legal deficiencies or other written correspondence from the FDA or any other Governmental Authority asserting a violation of applicable Law concerning the Acquired
Assets, the Program or the Product. There has not been a recall or market withdrawal or replacement of any Product by, or on behalf of, Aeglea or any of its Subsidiaries, whether voluntary or involuntary. Aeglea and its Subsidiaries have complied at
all times with all adverse event reporting requirements applicable to the Product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Neither Aeglea nor any of its Subsidiaries has
made any false statements on, or omissions from, the applications, reports and other submissions or communications (written or oral) to the FDA or any other Governmental Authority with respect to the Program, the Product or its manufacture or any
other records, reports and documentation prepared or maintained to comply with the requirements of applicable Law, and all such applications, reports, submissions and communications were true, correct and complete in all material respects. Neither
Aeglea nor any of its Subsidiaries is the subject of any pending or, to Aeglea&#146;s Knowledge, threatened investigation by any Governmental Authority with respect to the Program, or the Product, including by (i)&nbsp;the FDA pursuant to its
&#147;Fraud, Untrue Statements of Material Facts, Bribery and Illegal Gratuities&#148; Final Policy set forth in 56 Fed. Reg. 46191 (September 10, 1991) and any amendments thereto; (ii)&nbsp;the FTC; or (iii)&nbsp;any other Governmental Authority
that has jurisdiction over the Program under any similar policy. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.11 <U>Intellectual Property; Data Privacy and Security</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Schedule 4.11(a<U>)</U> contains a true and complete list of each of the issuances, registrations and applications for issuance or
registration included in the Assigned Intellectual Property, specifying as to each such item, as applicable (i)&nbsp;the owner of such item, (ii)&nbsp;the title of such item, (iii)&nbsp;each jurisdiction in which such item is issued or registered or
in which any application for issuance or registration has been filed, (iv)&nbsp;the respective issuance, registration, or application number of such item and (v)&nbsp;the date of application and issuance or registration of such item (all such
Assigned Intellectual Property required to be listed on Schedule 4.11(a<U>)</U>, the &#147;<U>Registered IP</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Aeglea or one
of its Subsidiaries is the sole and exclusive owner of the Assigned Intellectual Property. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Except as set forth in Schedule 4.11(c),
there exist no restrictions on the disclosure, use, license or transfer of the Assigned Intellectual Property. The consummation of the transactions contemplated by this Agreement will not (i)&nbsp;alter, encumber, impair or extinguish any Assigned
Intellectual Property or Aeglea&#146;s or its applicable Subsidiary&#146;s rights under any Intellectual Property licensed to Aeglea or its Subsidiaries pursuant to an Assigned Contract (&#147;<U>Licensed Intellectual Property</U>&#148;); or
(ii)&nbsp;impair the right of Immedica or any of its Affiliates to develop, use, sell, license or otherwise dispose of, or to bring any action for the infringement, misappropriation or other violation of, any Assigned Intellectual Property. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The Assigned Intellectual Property (including the Specified Patents and CPRIT Technology), Licensed Intellectual Property and the ADA
Assays constitute all of the Intellectual Property (i)&nbsp;used or held for use by Aeglea and its Subsidiaries in, or (ii)&nbsp;owned or licensed by Aeglea or its Subsidiaries and otherwise necessary for, the conduct of the Program and the
Exploitation of the Product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)(i) None of the Assigned Intellectual Property has ever been found invalid or unenforceable, in whole or
in part, for any reason in any administrative, arbitration, judicial or other Legal Proceeding (other than in proceedings before a patent office in connection with the prosecution of any Assigned Patent) or been the subject of a final and
nonappealable finding of unpatentability, (ii)&nbsp;Aeglea has not received any written notice from any other Person that any issued Assigned Patent is not valid and enforceable, (iii)&nbsp;all Assigned Intellectual Property is, to Aeglea&#146;s
Knowledge, valid, enforceable, in full force and effect and subsisting, (iv)&nbsp;all registration, maintenance and renewal fees applicable to the Registered IP that are currently due have been paid and all documents and certificates related to such
items that are currently required to be filed have been filed with the relevant Governmental Authority or other authorities in the applicable jurisdictions for the purposes of maintaining such items, (v)&nbsp;effective written assignments
constituting an unbroken, complete <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">chain-of-title</FONT></FONT> from each original owner or inventor to Aeglea or its applicable Subsidiary have been obtained with respect to all the
Registered IP and have been duly recorded with the appropriate Governmental Authorities and (vi)&nbsp;to the Aeglea&#146;s Knowledge, there is no relevant prior art revealed, disclosed or discovered after the issuance of any Assigned Patent that was
not cited during the prosecution of such Assigned Patent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) There is no Legal Proceeding pending against, or, to Aeglea&#146;s
Knowledge, threatened against, Aeglea or any of its Subsidiaries or any of their respective present or, to Aeglea&#146;s Knowledge, former, officers, directors or employees (i)&nbsp;based upon, or challenging or seeking to deny or restrict, the
rights of Aeglea or any of its Subsidiaries in any of the Assigned Intellectual Property or, to Aeglea&#146;s Knowledge, Licensed Intellectual Property or (ii)&nbsp;alleging that any Assigned Intellectual Property or, to Aeglea&#146;s Knowledge,
Licensed Intellectual Property is invalid or unenforceable (including in any reexamination, reissue, opposition proceeding, or any similar proceeding). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) The Exploitation of the Product and the conduct of the Program has not infringed upon
(including inducing or contributing to the infringement of), misappropriated or otherwise violated, and, to Aeglea&#146;s Knowledge, will not infringe upon (including inducing or contributing to the infringement of), misappropriate or otherwise
violate, any Intellectual Property rights of any Third Party. There is no Legal Proceeding pending against, or, to Aeglea&#146;s Knowledge, threatened against, Aeglea or any of its Subsidiaries or any of their respective present or, to Aeglea&#146;s
Knowledge, former, officers, directors or employees alleging that the use of any of the Assigned Intellectual Property or Licensed Intellectual Property or the conduct of the Program conflicts with, misappropriates, infringes or otherwise violates
any Intellectual Property of any Person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) None of Aeglea nor its respective agents and advisors, has (i)&nbsp;put a Third Party on
notice of actual or potential infringement, misappropriation or other violation of any of the Assigned Intellectual Property or (ii)&nbsp;initiated any enforcement action with respect to any of the Assigned Intellectual Property, and, to
Aeglea&#146;s Knowledge, no Person has infringed, misappropriated or otherwise violated any Assigned Intellectual Property or Aeglea&#146;s or its applicable Subsidiary&#146;s rights under any Licensed Intellectual Property. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) Aeglea has taken reasonable steps in accordance with normal industry practice to maintain the confidentiality of all Assigned Intellectual
Property and Licensed Intellectual Property, the value of which to Aeglea is contingent upon maintaining the confidentiality thereof, and no such Intellectual Property has been disclosed other than pursuant to written confidentiality agreements or
enforceable confidentiality obligations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) Aeglea and its Subsidiaries have appropriate procedures in place designed to provide that
all Intellectual Property related to the Product or Program and conceived or developed by employees performing their duties for Aeglea and its Subsidiaries, and by Third Parties performing research and development for Aeglea or its Subsidiaries, has
been assigned to Aeglea or its Subsidiaries, as applicable, and to the extent that any such Intellectual Property has been developed or created by any Third Party (including any current or former employee), Aeglea or one of its Subsidiaries has a
written agreement with such Third Party with respect thereto, which provides that Aeglea or its applicable Subsidiary either (i)&nbsp;has obtained ownership of and is the sole and exclusive owner of or (ii)&nbsp;has obtained a valid and unrestricted
right to exploit, sufficient for the conduct of its business, as currently conducted or proposed to be conducted, such Intellectual Property. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k) Schedule 4.11(k) contains a true and complete list of any and all Assigned Intellectual Property that was created, developed or reduced to
practice, or is being created, developed or reduced to practice, (i)&nbsp;pursuant to, or in connection with, any contract with any Governmental Authority or Governmental Authority-affiliated entity, or university, college or other educational
institution, or (ii)&nbsp;using any funding or facilities of any Governmental Authority or Governmental Authority-affiliated entity, or university, college or other educational institution (collectively, &#147;<U>Government Funded IP</U>&#148;).
Except as set forth in Schedule 4.11(k), Aeglea and its Subsidiaries have taken any and all actions necessary to obtain, secure, maintain, enforce and protect Aeglea&#146;s or its applicable Subsidiary&#146;s right, title and interest in, to and
under all Government Funded IP, and Aeglea and its Subsidiaries have complied with any and all Intellectual Property disclosure and/or licensing obligations under any applicable contract referenced in clause (i)&nbsp;above. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(l) In connection with the conduct of the Program, Aeglea and each of its Subsidiaries have
complied in all material respects with (i)&nbsp;all applicable Laws, rules and regulations pertaining to data privacy, data security, security breach notification and the collection, storage and use of personally identifiable information and user
information gathered or accessed in the course of the conduct of the Program, (ii)&nbsp;all rules, policies and procedures established by any of Aeglea or its Subsidiaries with respect to the foregoing and (iii)&nbsp;all restrictions and
requirements with respect to the foregoing contained in any contractual obligations to which Aeglea or any of its Subsidiaries is bound. To Aeglea&#146;s Knowledge, there has been no (A)&nbsp;losses or thefts of, or security breaches relating to,
personally identifiable information in the possession, custody or control of Aeglea or any of its Subsidiaries and held in connection with the conduct of the Program; (B)&nbsp;unauthorized access or unauthorized use of any such personally
identifiable information; or (C)&nbsp;improper disclosure of any such personally identifiable information by Aeglea or any of its Subsidiaries or any Person acting on their behalf. No Legal Proceedings are pending or, to Aeglea&#146;s Knowledge,
threatened against Aeglea or any of its Subsidiaries by any Person alleging a violation of any Person&#146;s privacy, personal or confidentiality rights under any such applicable Laws, contractual obligations, or the rules, policies or procedures
established by any of Aeglea or its Subsidiaries relating to privacy, data protection and the collection and use of personal information gathered or accessed in the conduct of the Program. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.12 <U>Taxes</U>.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Aeglea has filed all material Tax Returns and paid all material Taxes (whether or not shown on any Tax Return), the failure of which could
result in a Lien on any Acquired Asset. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) There are no Liens on any Acquired Asset that arose in connection with any failure or alleged
failure to pay any Tax. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) No Taxing Authority has proposed or is threatening in writing to propose any adjustment to any item with
respect to material Taxes, the nonpayment of which could result in a Lien on any Acquired Asset. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) There is no Legal Proceeding now
pending or, to Aeglea&#146;s Knowledge, threatened against or with respect to Aeglea in respect of any material Tax, the nonpayment of which could result in a Lien on any Acquired Asset. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) None of the Acquired Assets being transferred to Immedica hereunder is a &#147;United States real property interest&#148; within the
meaning of Section&nbsp;897(c) of the Code. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.13 <U>Employee Matters</U>.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Neither Aeglea nor any of its Subsidiaries (nor any predecessor of the foregoing or any prior owner of all or part of the business or
assets of any of the foregoing) has had, at any time during the six (6)&nbsp;year period prior to the date of this Agreement, any direct or indirect Liability with respect to any plan subject to Title IV of the Employee Retirement Income Security
Act of 1974, as amended, including any &#147;multiemployer plan&#148; as defined in Section&nbsp;3(37) of such act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Aeglea and its
Subsidiaries are and have been in compliance with all applicable Laws relating to the Worker Adjustment and Retraining Notification Act and any comparable foreign, state or local Law, except for any failures to comply that would not result in any
direct or indirect Liability to Immedica or any of its Affiliates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.14 <U>Environmental Compliance</U>. Except as to
matters that would not reasonably be expected to be material to the Program, the Acquired Assets or the Product: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)(i) no written notice,
Order, request for information, complaint or penalty has been received by Aeglea or any of its Subsidiaries, and (ii)&nbsp;there are no Legal Proceedings pending or threatened, in the case of each of (i)&nbsp;and (ii), which allege a violation of
any Environmental Law and relate to the Acquired Assets; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Aeglea has obtained or caused to be obtained all environmental permits
necessary for the current operation and use of the Acquired Assets to comply with all applicable Environmental Laws and Aeglea and each of its Subsidiaries is in compliance with the terms of such permits and, with respect to the current operation
and use of the Acquired Assets, with all other applicable Environmental Laws; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) there is no written environmental audit that has
been conducted within the past five years by Aeglea or any of its Subsidiaries of any Acquired Asset. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.15 <U>Finders
Fees</U>. There is no investment banker, broker, finder or other intermediary which has been retained by or is authorized to act on behalf of Aeglea or any of its Affiliates who might be entitled to any fee or commission in connection with the
transactions contemplated by this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.16 <U>No Other Representations or Warranties</U>. <B>Except for the
representations and warranties contained in this Article IV and the representations and warranties contained in any other Instrument, Immedica acknowledges that neither Aeglea nor any other Person on behalf of Aeglea has made, and Immedica has not
relied upon, any representation or warranty, whether express or implied, with respect to the Program, Product, Acquired Assets, Aeglea or its Subsidiaries, or Aeglea&#146;s or its Subsidiaries&#146; businesses, affairs, assets, Liabilities,
financial condition, results of operations, future operating or financial results, estimates, projections, forecasts, plans or prospects (including the reasonableness of the assumptions underlying such estimates, projections, forecasts, plans or
prospects) or with respect to the accuracy or completeness of any other information provided or made available to Immedica by or on behalf of Aeglea in connection with the Transaction.</B> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE V </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REPRESENTATIONS AND WARRANTIES OF IMMEDICA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">Immedica hereby represents and warrants to Aeglea as of the Closing Date as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.1 <U>Organization and Good Standing</U>. Immedica is an entity duly organized, validly existing and, to the extent legally
applicable, in good standing under the applicable Laws of the country of its organization and has all requisite corporate or other similar organizational powers required to carry on its business as now conducted. Immedica is duly qualified to do
business as a foreign entity and, to the extent legally applicable, in good standing as a foreign entity in each jurisdiction where such qualification is necessary, except for those jurisdictions where the failure to be so qualified or in good
standing would not, individually or in the aggregate, reasonably be expected to materially impede or materially delay the consummation by Immedica of the Transactions or the performance of its obligations under this Agreement or any Instrument to
which it is a party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.2 <U>Authorization of Agreement</U>. Immedica has all requisite power and authority to execute and
deliver this Agreement and each Instrument to which it is a party, to perform its respective obligations hereunder and thereunder and to consummate the Transaction and the other transactions contemplated hereby and thereby. The execution, delivery
and performance by Immedica of each of this Agreement and each other Instrument to which it is a party and the consummation of the Transaction and the other transactions contemplated hereby and thereby have been duly authorized and approved by all
requisite corporate or similar action on the part of Immedica. Each of the Instruments to which Immedica is a party has been, or will be at or prior to the Closing, duly and validly executed and delivered by Immedica and (assuming the due
authorization, execution and delivery by the other parties thereto) each of such Instruments, when so executed and delivered, will constitute the legal, valid and binding obligations of Immedica, enforceable against it in accordance with its terms,
subject to the effect of any applicable Laws relating to bankruptcy, reorganization, insolvency, moratorium, fraudulent conveyance or preferential transfers, or similar Laws relating to or affecting creditors&#146; rights generally and subject, as
to enforceability, to the effect of general principles of equity (regardless of whether such enforceability is considered in a proceeding in equity or at Law). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.3 <U>Conflicts; Consents of Third Parties</U>. None of the execution and delivery of this Agreement or the Instruments to which
Immedica is a party by Immedica, or the consummation of the Transaction or the other transactions contemplated hereby and thereby, will conflict with, or result in any violation of, or constitute a breach of, or conflict with or constitute a default
(with or without notice or lapse of time, or both) under any provision of, or require any consent or other action by any Person under, or give rise to any right of termination, cancellation or acceleration under: (i)&nbsp;the certificate of
incorporation and <FONT STYLE="white-space:nowrap">by-laws</FONT> or comparable organizational documents of Immedica; (ii)&nbsp;any Order of any Governmental Authority applicable to Immedica; or (iii)&nbsp;any applicable Law, except, in the case of
clauses (ii)&nbsp;and (iii) above, where such conflict, violation or default would not reasonably be expected to materially impede or materially delay the consummation by Immedica of the Transactions or the performance of its obligations under this
Agreement or any Instrument to which it is a party. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VI </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">COVENANTS </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.1
<U>Cooperation</U>. Each of the Parties shall use commercially reasonable efforts to take, or cause to be taken, all actions and do, or cause to be done, all things necessary, proper or advisable to, in the most expeditious manner practicable, carry
out the intent of this Agreement.</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.2 <U>Confidentiality</U>. For a period of ten (10)&nbsp;years from and after
the Closing Date, each Party shall not, and shall cause its Affiliates and Representatives not to, directly or indirectly, disclose, reveal, divulge or communicate to any Person other than the other Party or any of their respective Affiliates or
Representatives, or, subject to the provisos set forth herein, use or otherwise exploit for the benefit of any Person other than the other Party or any of their respective Affiliates or Representatives, any Confidential Information of the other
Party without the prior written consent of such other Party; <U>provided</U>, that, with respect to any Confidential Information that constitutes a trade secret under applicable Law, the obligations under this Section&nbsp;6.2 shall remain in effect
until such Confidential Information is no longer maintained as a trade secret under applicable Law. Neither Party shall have any obligation to keep confidential any Confidential Information if and to the extent disclosure thereof is specifically
required by applicable Law; <U>provided</U>, that in the event disclosure is required by applicable Law, the disclosing Party shall, to the extent permissible under applicable Law, notify the other Party of such requirement prior to making any
disclosure so that the other Party may seek an appropriate protective order. For&nbsp;purposes of this Agreement, &#147;<U>Confidential Information</U>&#148; means all confidential and proprietary information of such Party; <U>provided</U>, that
Confidential Information of a Party shall not include, and there shall be no obligation hereunder with respect to, information that (i)&nbsp;is generally available to the public on the date of this Agreement, (ii)&nbsp;becomes generally available to
the public other than as a result of a disclosure by the receiving Party or any of its Affiliates or Representatives in breach of this Section&nbsp;6.2, (iii) is or becomes available to the receiving Party or any of its respective Affiliates from a
source that is not known, after reasonable inquiry, by such Person to be bound by an obligation of confidentiality (provided that the provisions of this clause (iii)&nbsp;shall only apply to Confidential Information relating to the Acquired Assets
and Assumed Liabilities to the extent that such information first becomes available after the Closing) or (iv)&nbsp;is independently developed by the receiving Party or any of its respective Affiliates after Closing without the use of, or reference
to, the disclosing Party&#146;s Confidential Information. For clarity, from and after Closing, Confidential Information relating to the Acquired Assets and Assumed Liabilities shall be the Confidential Information of Immedica, and Confidential
Information relating to the Excluded Assets and Excluded Liabilities shall remain the Confidential Information of Aeglea. Notwithstanding anything in the foregoing to the contrary, nothing shall prevent a Party from disclosing Confidential
Information that is reasonably required to be disclosed in connection with the enforcement of this Agreement or any other Instrument. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.3 <U>Publicity</U>. Neither Party nor their respective Affiliates shall issue any press release or public announcement
concerning this Agreement or the Transaction or make any other public disclosure containing the terms of this Agreement without obtaining the prior written approval of the other Party (not to be unreasonably withheld, conditioned or delayed) unless,
in the judgment of the disclosing Party, disclosure is otherwise required by applicable Law; <U>provided</U>,<I></I><U>&nbsp;however</U>, that if disclosure is required by applicable Law, the Parties shall, to the extent reasonably possible, provide
the other Party with prompt notice of such requirements prior to making any disclosure and confer with the other Party concerning the timing and content of such required public statement before the same is made; <U>provided</U>, <U>further</U>, that
Immedica may provide general information regarding this Agreement, the other Instruments and the transactions contemplated hereby and thereby to its existing or prospective investors on a confidential basis without consulting with or obtaining the
consent of Aeglea. Notwithstanding the foregoing, the Parties agree that (a)&nbsp;Immedica may issue a press release regarding the Transaction in the form mutually agreed by the Parties prior to the date hereof, and (b)&nbsp;Aeglea may file a Form <FONT
STYLE="white-space:nowrap">8-K</FONT> with the United States Securities and Exchange Commission regarding the Transaction, which <FONT STYLE="white-space:nowrap">8-K</FONT> may include a copy of this Agreement, <I>provided</I> that Immedica shall be
afforded a reasonable opportunity to review and comment on such <FONT STYLE="white-space:nowrap">8-K</FONT> prior to the filing thereof, which comments Aeglea shall consider in good faith.</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.4 <U>Transfer of Acquired Assets; Transfer and Maintenance of Product
Registrations; Cooperation</U>.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)On or as promptly as practicable after the Closing, Aeglea shall and shall cause its Subsidiaries to
(i)&nbsp;transfer or cause to be transferred (or implement arrangements for the transfer and delivery of physical possession of) all tangible assets included in the Acquired Assets that are in the possession of Aeglea or any of its Affiliates
(including, if applicable, all Inventory, Biological Materials and Transferred Documents, whether electronic or otherwise) to Immedica or its designated Representatives, and (ii)&nbsp;notify all of its agents and any other third parties that hold
files or other tangible assets included in the Acquired Assets that, effective as of the Closing, Immedica owns such Acquired Assets, with directions to transfer such Acquired Assets to Immedica in accordance with Immedica&#146;s reasonable
instructions; <U>provided</U><I></I>&nbsp;that Aeglea shall not, at Closing, be required to deliver to Immedica any information, data or files that is commingled with information, data or files pertaining to the Excluded Assets that is not
reasonably practicable to identify and extract prior to Closing, in which case, as promptly as practicable following Closing, Aeglea shall deliver to Immedica such information, data or files in accordance with this Section&nbsp;6.4(a), and until
such delivery, Aeglea shall provide Immedica and its Affiliates reasonable access to such materials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)On or as promptly as practicable
after the Closing, Aeglea shall and shall cause its Subsidiaries to transfer to Immedica or its designated Representatives the Transferred Product Registrations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)Without limiting Section&nbsp;6.4(b), Aeglea shall (or shall cause one of its Subsidiaries to) provide to Immedica a copy of the most
recent sequence submitted to the FDA with respect to the IND related to Product set forth on Schedule 6.4(c) (the &#147;<U>Product IND</U>&#148;) as promptly as possible following the Closing, and in any event within five (5)&nbsp;days of the
Closing. As soon as practicable following receipt by Immedica of such copy, on a date to be mutually agreed by Aeglea and Immedica that is no more than twenty (20)&nbsp;days following the Closing, (i)&nbsp;Aeglea shall (or shall cause one of its
Subsidiaries to) file with the FDA a letter authorizing the transfer of ownership from Aeglea (or its applicable Subsidiary) to Immedica of such Product IND and (ii)&nbsp;Immedica shall (or shall cause one of its Subsidiaries to) execute and submit
to the FDA a letter, accompanied by the transfer letter referred to in clause (i), acknowledging Immedica&#146;s commitment to assume ownership of the Product IND and commitment to the obligations and agreements therein. The parties shall use
commercially reasonable efforts to take such additional actions, and execute and deliver, and file with the FDA, such additional documents, as are reasonably necessary to effect the transfer and assignment to Immedica of the Product IND as
contemplated by this Section&nbsp;6.4(c). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)With respect to the Product, from and after the Closing Date, until the later of
(x)&nbsp;the date on which Immedica (or its applicable Affiliate) receives an assignment or transfer of the Transferred Product Registration for the Product or a replacement thereof naming Immedica (or its applicable Affiliate) as the Product
Registration holder for the Product, and (y)&nbsp;such other date on which regulatory responsibilities are assumed by Immedica in accordance with applicable Law, Aeglea shall, with respect to the Product, operate in compliance with the terms of the
relevant Transferred Product Registration, and with all applicable Law and all requirements of relevant Governmental Authorities. Until the completion of the transfer of the Transferred Product Registrations to Immedica: (i)&nbsp;Aeglea shall use
commercially reasonable efforts to maintain the Transferred Product Registration and (ii)&nbsp;if and to the extent reasonably requested by Immedica, Aeglea shall use commercially reasonable efforts to pursue, in such manner as may be reasonably
directed by Immedica, those ongoing variations, amendments and renewals which are pending at the Closing Date and shall not withdraw them. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)Immedica shall, and shall cause its Subsidiaries to, cooperate with Aeglea to deliver to
Aeglea any additional documentation and materials that may be reasonably requested by Aeglea to affect the transfer of the Transferred Product Registrations to Immedica. Each of Aeglea and Immedica shall bear 50% of the cost of all fees levied by
the relevant Governmental Authority in connection with the transfer of the Transferred Product Registrations pursuant to this Section&nbsp;6.4. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.5 <U>Batch Disposition</U>. Prior to the later of (i)&nbsp;thirty (30) days after Closing and (ii)&nbsp;ten (10) days following
the date on which Aeglea or its applicable Affiliate receives analysis results and batch documentation reasonably necessary to affect the following batch release, Aeglea shall, or shall cause one or more of its Subsidiaries to, perform batch
disposition and release of 2 mg vials of batch number B23020012 of the Inventory produced by Aeglea or one or more of its Subsidiaries to Immedica for secondary packaging. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.6 <U>Specified Patents</U>.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)Aeglea and Immedica agree to be bound by and comply with the terms and conditions set forth on Schedule 6.6 as though set forth in full
herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.7 <U>Misallocated Assets</U>. If, following the Closing, any right, property or asset not forming part of the
Acquired Assets is found to have been transferred to Immedica in error, either directly or indirectly, Immedica shall (a)&nbsp;transfer at no cost to Aeglea, such right, property or asset (and any related Liability) as soon as practicable to one or
more of Aeglea and its Subsidiaries designated by Aeglea and (b)&nbsp;prior to such transfer, ensure that Immedica shall, where permitted by the terms on which it has the right to such asset, hold the asset (or part&nbsp;thereof), and any monies,
goods or other benefits arising after the Closing by virtue of it, as agent of and trustee for Aeglea and its Subsidiaries and allow Aeglea and its Subsidiaries from and after the Closing to have full enjoyment and use of such asset and Aeglea and
its Subsidiaries shall bear all burdens relating to such asset. If, following the Closing, any right, property or asset forming part of the Acquired Assets is found to have been retained by Aeglea in error, either directly or indirectly, Aeglea
shall (i)&nbsp;transfer, at no cost to Immedica, such right, property or asset (and any related Liability) as soon as practicable to Immedica and (ii)&nbsp;prior to such transfer, ensure that Aeglea shall where permitted by the terms on which Aeglea
or its applicable Affiliate has the right to such asset, hold the asset (or part thereof), and any monies, goods or other benefits arising after the Closing by virtue of it, as agent of and trustee for Immedica and allow Immedica from and after the
Closing to have full enjoyment and use of such asset and Immedica shall bear all burdens relating to such asset. For the avoidance of doubt, the Parties understand and agree that (x)&nbsp;the Excluded Assets are not intended to, and shall not, be
transferred to Immedica and Aeglea shall retain such rights, properties and assets, and (y)&nbsp;the Acquired Assets are intended to, and shall, be transferred to Immedica and Immedica shall acquire such rights, properties and assets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.8 <U>Lien Releases</U>. Aeglea shall provide, and shall cause its Subsidiaries to provide, all assistance reasonably requested
by Immedica in connection with obtaining, effective at or as soon as possible following the Closing, appropriate termination statements under the Uniform Commercial Code (or equivalent documents pursuant to applicable Law), payoff letters and other
instruments, in connection with the release of security interests or other Liens against or relating to any of the Acquired Assets.</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.9 <U>Certain Matters</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)Aeglea and Immedica agree to be bound by and comply with the terms and conditions set forth on Schedule 6.9 as if set forth in full herein.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.10 <U>Reimbursement</U>. Following the Closing, promptly following the earlier of (a)&nbsp;receipt by Immedica of a
positive opinion from the European Medicines Agency&#146;s Committee for Medicinal Products for Human Use recommending the granting of a marketing authorization with respect to the Product and (b)&nbsp;the date of vial thaw by the applicable
manufacturer to Immedica of the first drug substance batch of the Product initiated by Immedica pursuant to the Fuji Scope of Work, Immedica shall, within thirty (30)&nbsp;days thereof, pay an amount equal to the Fuji Credit to Aeglea in cash by
wire transfer of immediately available funds in accordance with written instructions furnished to Immedica by Aeglea. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.11
<U>Delivery of Post-Closing Correspondence</U>. Following the Closing, Aeglea shall promptly forward to Immedica any mail (including electronic mail) and other correspondence that Aeglea or any of its Subsidiaries receives after the Closing Date
that is intended for the owner of the Acquired Assets, Assumed Liabilities, the Program or the Product. Following the Closing, Immedica shall promptly forward to Aeglea any mail (including electronic mail) and other correspondence that Immedica or
any of its Subsidiaries receives after the Closing Date that relates to the Excluded Assets, the Excluded Liabilities or is otherwise intended for the owner of the Excluded Assets. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VII </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">INDEMNIFICATION </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.1
<U>Survival</U>. The representations and warranties of the Parties contained in this Agreement or in any certificate or other writing delivered pursuant hereto shall survive until 5:00 p.m. Eastern Time on the twelve (12)-month anniversary of the
Closing Date; <U>provided</U>, that (a)&nbsp;the representations and warranties of Aeglea contained in Sections 4.1, 4.2, 4.3, 4.4(a)(i), 4.8(b) and 4.15 and the first two sentences of Section&nbsp;4.5(a) (collectively, the &#147;<U>Fundamental
Representations</U>&#148;) shall survive the Closing until 5:00 p.m. Eastern Time on May&nbsp;22, 2026 and (b)&nbsp;the representations and warranties of Aeglea contained in Section&nbsp;4.11 (the &#147;<U>IP Representations</U>&#148;)&nbsp;and the
representations and warranties of Aeglea contained in Section&nbsp;4.8(a) shall survive the Closing until 5:00 p.m. Eastern Time on May&nbsp;22, 2026 (as applicable, the &#147;<U>Survival Period</U>&#148;). The covenants and agreements of the
Parties contained in this Agreement or in any certificate or other writing delivered pursuant hereto shall survive indefinitely or for such shorter period explicitly specified therein. Upon termination and expiration of any representation and
warranty, covenant or agreement for the purposes of indemnification, all indemnification obligations with respect to such representation and warranty, covenant or agreement shall likewise terminate and expire, except to the extent that the Person to
be indemnified pursuant to this Article VII (the &#147;<U>Indemnified Party</U>&#148;) shall have (in good faith) given written notice a claim to the indemnifying party pursuant to this Article VII (the &#147;<U>Indemnifying Party</U>&#148;) before
termination of the applicable Survival Period, in which event the representation and warranty, covenant or agreement alleged in the claim to have been breached and any associated right to indemnification shall continue until such claim for
indemnification is resolved. For the avoidance of doubt, it is the intention of the Parties that the foregoing respective Survival Periods and termination dates supersede any applicable statutes of limitations that would otherwise apply to such
matters.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.2 <U>Indemnification by Aeglea</U>. From and after the Closing Date and subject to the provisions of this Article
VII, Aeglea shall reimburse, defend, indemnify and hold Immedica and its directors, officers, employees, Affiliates, agents, attorneys and Representatives, and each of their respective successors and permitted assigns (collectively, the
&#147;<U>Immedica Indemnified Parties</U>&#148;) harmless from and against any and all Losses incurred, resulting or arising from or relating to: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)the failure of any representation or warranty of Aeglea contained in this Agreement to be
true and correct as of the Closing Date (except for any such representation and warranty that addresses matters only as of a specific date, which representation and warranty shall be true and correct as of such specific date); <U>provided</U> that
for purposes of (i)&nbsp;determining whether any failure of a representation or warranty to be true and correct has occurred and (ii)&nbsp;calculating the amount of any Losses relating thereto, in each case, the representations and warranties shall
be considered and applied without regard to any reference to materiality, Material Adverse Effect or similar materiality qualification set forth therein; and <U>provided</U>, <U>further</U>, that if the absence of an asset has resulted in a failure
of a representation or warranty set forth in Section&nbsp;4.8(a) to be so true and correct, to the extent that such failure may be cured (in whole or in part) by the delivery of such asset to Immedica after the Closing (including by the grant of a
license if such absent asset was a license), Aeglea&#146;s indemnification obligations hereunder may (but without limiting any obligation set forth in this Agreement) be cured to such extent (and only such extent) by delivery of such asset, and the
remaining indemnification obligations with respect to such failure (if any) shall be satisfied in accordance with the other provisions of this Article VII; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)any breach of or failure to perform any covenant or obligation made or to be performed by Aeglea in this Agreement or in any certificate or
other writing delivered pursuant hereto; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)any Excluded Asset or Excluded Liability (including, for the avoidance of doubt, in respect
of any Person seeking to impose any Excluded Liability on any of the Immedica Indemnified Parties based upon any theory of successor liability or based upon any claim of fraudulent transfer or any other claim alleging that the consideration paid in
connection with the consummation of the transactions contemplated hereby is insufficient for any reason); and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)the matters set forth on
Schedule 7.2(d). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.3 <U>Indemnification by Immedica</U>. From and after the Closing Date and subject to the provisions of
this Article VII, Immedica shall reimburse, defend, indemnify and hold each of Aeglea and its respective directors, officers, employees, Affiliates, agents, attorneys, Representatives, successors and permitted&nbsp;assigns (the &#147;<U>Aeglea
Indemnified Parties</U>&#148;) harmless from and against any and all Losses incurred, resulting or arising from or relating to: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) the
failure of any representation or warranty of Immedica contained in this Agreement to be true and correct as of the Closing Date (except for any such representation and warranty that addresses matters only as of a specific date, which representation
and warranty shall be true and correct as of such specific date); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) any breach of or failure to perform any covenant or obligation made
by Immedica in this Agreement; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)the Assumed Liabilities, except (notwithstanding anything to the contrary herein) to the
extent due to the breach by Aeglea of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.4 <U>Indemnification Procedures</U>.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)A claim for indemnification for any matter not involving a Third-Party Claim may be asserted by prompt written notice to the Indemnifying
Party, including, to the extent known, the amount of the claim or an estimate thereof, to such Indemnifying Party; <U>provided</U> that the failure to so notify the Indemnifying Party shall not relieve the Indemnifying Party of any indemnification
obligation hereunder unless (and then solely to the extent that) the Indemnifying Party is materially prejudiced as a result of such failure. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)In the event that any Legal Proceedings shall be instituted, or that any claim or demand shall be asserted or threatened in writing, by any
Person not party to this Agreement in respect of which an Indemnification Claim may be made under this Agreement (a &#147;<U>Third-Party Claim</U>&#148;), the Indemnified Party shall promptly cause written notice of the assertion or written threat
of any Third-Party Claim of which it has knowledge that is or may be covered by this indemnity to be delivered to the Indemnifying Party; <U>provided</U> that the failure to so notify the Indemnifying Party shall not relieve the Indemnifying Party
of any indemnification obligation hereunder unless (and then solely to the extent that) the Indemnifying Party is materially prejudiced as a result of such failure. The Indemnifying Party shall have the right, at its sole option and expense, to be
represented by counsel of its choice, which must be reasonably satisfactory to the Indemnified Party, and to defend against, negotiate, settle or otherwise address any Third-Party Claim; <U>provided</U>, <U>however</U>, that prior to assuming
control of such defense, the Indemnifying Party must acknowledge that it would have an indemnity obligation for the Losses resulting from such Third-Party Claim as provided under this Article VII if the material facts alleged in such Third-Party
Claim at the time of its assumption of the defense are ultimately determined to be accurate; and <U>provided</U>, <U>further</U>, that the Indemnifying Party shall not be entitled to assume or maintain control of the defense of any Third-Party Claim
and shall pay the fees and expenses of counsel retained by the Indemnified Party if (1)&nbsp;the Indemnifying Party does not deliver the acknowledgment referred to in the preceding proviso within 30 days of receipt of notice of the Third-Party Claim
pursuant to this Section&nbsp;7.4, (2) the Third-Party Claim is made by a Governmental Authority or relates to or arises in connection with any criminal proceeding, action, indictment, allegation or investigation, (3)&nbsp;the Third-Party Claim
seeks an injunction or equitable relief against the Indemnified Party or any of its Affiliates, (4)&nbsp;the Indemnifying Party has failed or is failing to prosecute or defend vigorously the Third-Party Claim (after reasonable notice and opportunity
to cure) or (5)&nbsp;the Third-Party Claim relates to Taxes. If the Indemnifying Party is entitled to and elects to defend against, negotiate, settle or otherwise address any Third-Party Claim, it shall within twenty (20)&nbsp;Business Days (or
sooner, to the extent that the nature of the Third-Party Claim so requires) (&#147;<U>Dispute Period</U>&#148;) notify the Indemnified Party of its intent to do so. If the Indemnifying Party shall assume the defense of any Third-Party Claim, then
the Indemnified Party may participate, at his or its own expense, in the defense of such Third-Party Claim; <U>provided</U>, that such Indemnified Party shall be entitled to participate in any such defense with separate counsel at the expense of the
Indemnifying Party if (i)&nbsp;requested by the Indemnifying Party to participate, (ii)&nbsp;the named parties to any such Third-Party Claim (including any impleaded parties) include both the Indemnifying Party and the Indemnified Party or
(iii)&nbsp;representation of both the Indemnifying Party and the Indemnified Party by the same counsel would be inappropriate due to a conflict of interest between the Indemnified Party and the Indemnifying Party; <U>provided</U>, <U>further</U>,
that the Indemnifying Party shall not be required to pay for more than one such counsel for all Indemnified Parties in connection with any Third-Party Claim. If the Indemnifying Party does not elect (if so entitled) within the Dispute Period to
defend against, negotiate, settle or otherwise address any Third-Party Claim or fails </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to notify the Indemnified Party of its election during the Dispute Period, the Indemnified Party shall have the right, but not the obligation, to defend against such Third-Party Claim;
<U>provided</U> that the Indemnifying Party may nonetheless participate in the defense of such Third-Party Claim (but not control or make decisions related thereto) with its own counsel and at its own expense. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)If the Indemnifying Party elects to defend against, negotiate, settle or otherwise address any Third-Party Claim, the Indemnifying Party
shall (i)&nbsp;conduct the defense of such Third-Party Claim with reasonable diligence and keep the Indemnified Party reasonably informed of material developments in the Third-Party Claim at all stages thereof; (ii)&nbsp;promptly submit to the
Indemnified Party copies of all pleadings, responsive pleadings, motions and other similar legal documents and papers received or filed in connection therewith; (iii)&nbsp;permit the Indemnified Party and its counsel to confer on the conduct of the
defense thereof; and (iv)&nbsp;permit the Indemnified Party and its counsel an opportunity to review all legal papers to be submitted prior to their submission (to the extent practical). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)The Parties agree to provide reasonable access to each other Party to such documents and information as may reasonably be requested in
connection with the defense, negotiation or settlement of any such Third-Party Claim. The Indemnified Party shall have the right to negotiate, compromise and settle any Third-Party Claim for which the Indemnifying Party may have any Liability under
this Agreement but only with the prior written consent of the Indemnifying Party (which consent shall not be unreasonably withheld, conditioned or delayed). The Indemnifying Party may not enter into any compromise or settlement of, or cease to
defend against, a Third-Party Claim unless the Indemnifying Party (i)&nbsp;has assumed the defense of such claim pursuant to this Section&nbsp;7.4 and (ii)has received the prior written consent of the Indemnified Party (which consent shall not be
unreasonably withheld, conditioned or delayed). Notwithstanding the foregoing, the Indemnifying Party may enter into any compromise or settlement of any Third-Party Claim if (x)&nbsp;pursuant to or as a result of such compromise or settlement,
(A)&nbsp;injunctive or other equitable relief would not be imposed against the Indemnified Party, (B)&nbsp;each claimant or plaintiff in such Third-Party Claim has given to the Indemnified Party an unconditional release from all Liability with
respect to such Third-Party Claim, (C)&nbsp;a finding or admission of a violation of Law would not be made against the Indemnified Party, and (D)&nbsp;the Indemnified Party would not have a monetary Liability that will not be paid or reimbursed by
the Indemnifying Party in full; (y)&nbsp;such Third-Party Claim would not reasonably be expected to have a material impact on the ongoing business of the Indemnified Party; and (z)&nbsp;such Third-Party Claim is not brought by a Governmental
Authority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)After any final <FONT STYLE="white-space:nowrap">non-appealable</FONT> decision, judgment or award shall have been rendered
by a Governmental Authority of competent jurisdiction and the expiration of the time in which to appeal therefrom, or a settlement or arbitration shall have been consummated, or the Indemnified Party and the Indemnifying Party shall have arrived at
a mutually binding agreement with respect to an Indemnification Claim hereunder, the Indemnified Party shall forward to the Indemnifying Party notice of any sums due and owing by the Indemnifying Party pursuant to this Agreement with respect to such
matter and the Indemnifying Party shall make prompt payment thereof by wire transfer in immediately available funds within thirty (30)&nbsp;days after the date of such notice or, if applicable, pursuant to the terms of the agreement reached with
respect to the Indemnification Claim. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.5 <U>Limitations on Indemnified Costs</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)Notwithstanding anything to the contrary in this Agreement, with the exception of intentional fraud and willful misconduct, no Indemnifying
Party shall have any Liability for any Loss under Section&nbsp;7.2(a) (other than in respect of the Fundamental Representations or the IP Representations) or Section&nbsp;7.3(a) (other than in respect of the representations and warranties contained
in Section&nbsp;5.1, Section&nbsp;5.2 and Section&nbsp;5.3(i)), as applicable, (i)&nbsp;unless and until such Loss (or series of related Losses) equals or exceeds $15,000 (the &#147;<U>De Minimis Amount</U>&#148;), it being understood that if such
Loss (or series of related Losses) does not exceed the De Minimis Amount, such Loss (or series of related Losses) shall not be applied to or considered for purposes of calculating the aggregate amount of Losses incurred by any Indemnified Parties
pursuant to the immediately following clause (ii); and (ii)&nbsp;unless the aggregate amount of all Losses incurred by the Immedica Indemnified Parties under Section&nbsp;7.2(a) (other than in respect of the Fundamental Representations or the IP
Representations) or the Aeglea Indemnified Parties under Section&nbsp;7.3(a) (other than in respect of the representations and warranties contained in Section&nbsp;5.1, Section&nbsp;5.2 and Section&nbsp;5.3(i)), as applicable, exceeds $300,000 (the
&#147;<U>Basket</U>&#148;), it being understood that if such Losses exceed the Basket, the applicable Indemnifying Party shall be obligated for only the Losses of the applicable Indemnified Parties in excess of the Basket.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)Notwithstanding anything to the contrary in this Agreement, with the exception of intentional fraud and willful misconduct,
(i)&nbsp;Aeglea&#146;s maximum aggregate Liability to the Immedica Indemnified Parties for any Loss under Section&nbsp;7.2 (except for Sections 7.2(b) and 7.2(d), and except for Section&nbsp;7.2(a) with respect to Fundamental Representations, IP
Representations and the representations and warranties contained in Section&nbsp;4.8(a)) shall not exceed $1,800,000 <I>plus</I> 15% of the aggregate Milestone Payments received or that become payable to Aeglea (calculated prior to giving effect to
any Milestone <FONT STYLE="white-space:nowrap">Set-Off);</FONT> (ii) Aeglea&#146;s maximum aggregate Liability to the Immedica Indemnified Parties for any Loss under Section&nbsp;7.2(a) with respect to the representations and warranties contained in
Section&nbsp;4.8(a) shall not exceed $2,400,000 <I>plus </I>20% of the aggregate Milestone Payments that become payable to Aeglea (calculated prior to giving effect to any Milestone <FONT STYLE="white-space:nowrap">Set-Off);</FONT> (iii)
Aeglea&#146;s maximum aggregate Liability to the Immedica Indemnified Parties for any Loss under Section&nbsp;7.2(a) with respect to IP Representations shall not exceed $3,600,000 <I>plus </I>30% of the aggregate Milestone Payments that become
payable to Aeglea (calculated prior to giving effect to any Milestone <FONT STYLE="white-space:nowrap">Set-Off);</FONT> (iv) Aeglea&#146;s maximum aggregate Liability to the Immedica Indemnified Parties for all Losses under Section&nbsp;7.2(a) with
respect to Fundamental Representations, Section&nbsp;7.2(b) and Section&nbsp;7.2(d) shall not exceed the Initial Payment <I>plus </I>100% of the aggregate Milestone Payments that become payable to Aeglea (calculated prior to giving effect to any
Milestone <FONT STYLE="white-space:nowrap">Set-Off.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)Aeglea agrees that if a Third-Party Claim is made against an Immedica
Indemnified Party concerning an Excluded Asset or Excluded Liability, Aeglea shall, at its sole cost and expense, (i)&nbsp;communicate to the Person making such Third-Party Claim that Aeglea (rather than such Immedica Indemnified Party) is
responsible for or otherwise liable in respect of such Excluded Asset or Excluded Liability (and otherwise acknowledge that Aeglea rather than such Immedica Indemnified Party is the appropriate party in interest) and (ii)&nbsp;use commercially
reasonable efforts to cause such Immedica Indemnified Party to be released or otherwise dismissed from such Third-Party Claim and any related Legal Proceeding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)With respect to any Milestone <FONT STYLE="white-space:nowrap">Set-Off</FONT> pursuant to Section&nbsp;1.2(e) (and subject to the
limitations set forth in Sections 7.5(a) and 7.5(b) and the terms of Section&nbsp;1.2(e)), if at the time any Milestone Payment is due and payable (or any portion of the Specified Patents Holdback Amount continues to be held back in accordance with
Section&nbsp;1.2(f)), there shall be any outstanding Indemnification Claim delivered in accordance with Section&nbsp;7.4, the amount of Losses with respect to which shall not have been finally determined in accordance with this Article VII, then
Immedica shall be entitled, but shall not be required, to withhold from such Available Remedy Amount, the amount of Losses the applicable Immedica </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Indemnified Party reasonably estimates to be subject to such Indemnification Claim. If the final amount of Losses for such Indemnification Claim is determined in accordance with this Article VII
to be less than the amount withheld from such Available Remedy Amount, then Immedica shall promptly, and in any event within five (5)&nbsp;Business Days following the final determination of the amount of such Losses, deliver the difference to Aeglea
by wire transfer of immediately available funds to an account designated in writing by Aeglea (provided that no amount set off against the Specified Patents Holdback Amount shall be required to be so delivered to Aeglea unless, prior to such time,
the Specified Patents Holdback Amount was required to be released to Aeglea in accordance with the last sentence of Section&nbsp;1.2(f)). If the final amount of Losses for such Indemnification Claim is determined in accordance with this Article VII
to exceed the amount by which such Available Remedy Amount was reduced for such claim, then Immedica shall continue to be entitled to indemnification for the amount of such excess subject to the terms and conditions of this Article VII. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)<B>In no event shall any Indemnifying Party have Liability to any Indemnified Party for any consequential, special, incidental, indirect,
punitive or exemplary damages</B>, except, in each case of the foregoing damages, to the extent (i)&nbsp;any of the foregoing are payable to a Third Party pursuant to a Third-Party Claim, (ii)&nbsp;in the case of consequential or indirect damages,
to the extent such damages are the reasonably foreseeable result of the event that gave rise thereto or the matter for which indemnification is sought hereunder, (iii)&nbsp;arising under Section&nbsp;7.2(d) or (iv)&nbsp;any of the foregoing arise as
a result of intentional fraud or willful misconduct by the Indemnifying Party. No Indemnified Party shall be entitled to recover from an Indemnifying Party more than once in respect of Losses resulting from a single or series of related claims. Any
Liability for indemnification hereunder shall be determined without duplication of recovery by reason of state of facts giving rise to such Liability constituting a breach of more than one representation, warranty, covenant or agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f)The amount of any and all Losses under this Article VII shall be determined net of (i)&nbsp;any Tax benefit actually realized by the
applicable Indemnified Parties in the form of Tax refunds received or a reduction of Taxes otherwise owed in the taxable year of such Losses, and (ii)&nbsp;any insurance proceeds actually received by the applicable Indemnified Parties in connection
with the facts giving rise to the right of indemnification (net of any costs of recovery, deductibles or increased premiums as a result of paying such insurance claims), it being agreed that if third-party insurance or indemnification proceeds in
respect of such facts are recovered by the Indemnified Party subsequent to the Indemnifying Party&#146;s making of an indemnification payment in satisfaction of its applicable indemnification obligation, such proceeds shall be promptly remitted to
the Indemnifying Party to the extent of the indemnification payment made. The Parties shall make commercially reasonable efforts to mitigate any Losses subject to an Indemnification Claim in accordance with applicable Law; <U>provided</U>, that
(A)&nbsp;no Party is required to bring any suit, action or proceeding in connection with such mitigation and (B)&nbsp;any Liability of any Indemnifying Party under this Agreement for Losses suffered or incurred by the Indemnified Party shall include
the reasonable costs and expenses suffered or incurred by the Indemnified Party in performing its mitigation obligations hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.6 <U>Sources of Recovery</U>. The Milestone <FONT STYLE="white-space:nowrap">Set-off</FONT> shall be the sole and exclusive
recourse for any and all payments that may become owing to the Immedica Indemnified Parties pursuant to a claim for indemnification under this Article VII (other than (A)&nbsp;pursuant to Section&nbsp;7.2(d), (B) pursuant to Section&nbsp;7.2(b) with
respect to any breach of or failure to perform any covenant or obligation contained in this Agreement that by its terms contemplates performance thereof following the Closing and such breach remains uncured for a period greater than sixty
(60)&nbsp;days after Immedica provides written notice of such breach, and (C)&nbsp;with respect to willful misconduct or intentional fraud (collectively, the &#147;<U>Excluded Indemnity Matters</U>&#148;)); <U>provided</U> that (i)&nbsp;the Immedica
Indemnified Parties shall not be entitled to recover </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
any Loss (or series of related Losses) against Aeglea or any of its Subsidiaries (other than by means of a Milestone-Setoff) with respect to an Excluded Indemnity Matter referred to in the
foregoing clause (B)&nbsp;unless and until such Loss (or series of related Losses) equals or exceeds $100,000 and (ii)&nbsp;following May&nbsp;22, 2026, the Immedica Indemnified Parties shall not be entitled to recover any Loss against Aeglea or any
of its Subsidiaries (other than by means of a Milestone-Setoff) with respect to an Excluded Indemnity Matter referred to in the foregoing clause (A), except to the extent an Indemnification Claim in respect of such Loss was first made prior
May&nbsp;22, 2026 (it being understood, for the avoidance of doubt, that nothing in this proviso shall limit or otherwise affect an Immedica Indemnified Party&#146;s rights to recover Losses at any time with respect to an Excluded Indemnity Matter
by means of a Milestone-Setoff). No claim for indemnification under this Article VII by the Immedica Indemnified Parties shall be asserted against, and the Immedica Indemnified Parties shall not be entitled to indemnification from, Aeglea or any of
its Subsidiaries for a claim for indemnification under Article VII (other than in respect of the Excluded Indemnity Matters, but subject to the proviso in this Section&nbsp;7.6) except to the extent such recourse is limited to Milestone <FONT
STYLE="white-space:nowrap">Set-Offs.</FONT> For the avoidance of doubt, nothing in this Section&nbsp;7.6 shall limit or otherwise affect Immedica&#146;s right to specific performance as provided in Section&nbsp;9.3. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.7 <U>Exclusive Remedy</U>. Following the Closing Date, the sole and exclusive remedy of any Indemnified Parties for any Losses
(including any Losses from claims for breach of contract, warranty, tortious conduct (including negligence) or otherwise and whether predicated on common Law, statute, strict liability or otherwise) that each Party may at any time suffer or incur,
or become subject to, as a result of, or in connection with&nbsp;this Agreement, including any inaccuracy or breach of any representation and warranty contained in this Agreement by any Party, or any failure by any Party to perform or comply with
any covenant or agreement that, by its terms, was to have been performed, or complied with, under this Agreement, shall be indemnification in accordance with this Article VII and any Milestone <FONT STYLE="white-space:nowrap">Set-Off</FONT> pursuant
to Section&nbsp;1.2(e), except with respect to any claim based on intentional fraud or willful misconduct or claims for specific performance pursuant to Section&nbsp;9.3, injunction or other equitable relief. For the avoidance of doubt, the
limitations set forth in this Article VII shall not apply to claims for intentional fraud or willful misconduct. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VIII </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">TAX MATTERS&nbsp; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.1 <U>Tax Matters; Cooperation</U>. Each Party shall cooperate fully, as and to the extent reasonably requested by the other
Party, in connection with the filing of Tax Returns, making of elections and any audit or other Legal Proceeding with respect to Taxes attributable to the Acquired Assets. Such cooperation shall include the retention and (upon any other Party&#146;s
request) the provision of records and information that are reasonably relevant to any such audit or other Legal Proceeding for a period of at least six (6)&nbsp;years following the Closing Date. On or after the end of such period, each Party shall
provide the other with at least ten (10)&nbsp;days&#146; prior written notice before destroying any such books and records, during which period the Party receiving such notice can elect to take possession, at its own expense, of such books and
records. Each Party shall make employees available on a mutually convenient basis to provide additional information and explanation of any material provided hereunder. Each Party agrees, upon reasonable request, to use their commercially reasonable
efforts to obtain any certificate or other document from any Governmental Authority or any other Person as may be necessary to mitigate, reduce or eliminate any Tax that could be imposed (including with respect to the Transaction). The Parties shall
cooperate with each other in the conduct of any audit or other proceeding relating to Taxes involving the Acquired Assets. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.2 <U>Allocation of Purchase Price; Treatment of Milestone Payments</U>. The
Initial Payment, and any Milestone Payments, for the Acquired Assets shall be allocated as determined by the mutual agreement of the Parties. The Parties shall provide such information as any of them shall reasonably request. The Parties shall
(a)&nbsp;prepare each report relating to the federal, state and local and other tax consequences of the purchase and sale contemplated hereby in a manner consistent herewith and (b)&nbsp;not take any position in any tax filing, return, proceeding,
audit or otherwise which is inconsistent with the position of the other parties unless permitted to do so by Law. The Parties agree and acknowledge that any Milestone Payments shall be treated for all applicable Tax purposes as additional purchase
price for the Acquired Assets, except as otherwise required by applicable Law (including Section&nbsp;483 of the Code) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.3
<U>Transfer Taxes</U>. Aeglea and Immedica shall be each responsible for 50% of any Transfer Taxes in connection with the sale and purchase of the Acquired Assets, regardless of the Person liable for such Transfer Taxes under applicable Law, and the
Parties shall work together to timely file or caused to be filed all necessary documents (including all Tax Returns) with respect to such Transfer Taxes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.4 <U>Apportioned Obligations.</U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)All personal property Taxes and similar ad valorem obligations levied with respect to the Acquired Assets for a taxable period which
includes (but does not end on) the Closing Date (collectively, the &#147;<U>Apportioned Obligations</U>&#148;) shall be apportioned between Aeglea and Immedica based on the number of days of such taxable period up to and including the Closing Date
(any such portion of such taxable period, the &#147;<U><FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Tax Period</U>&#148;) and the number of days of such taxable period after the Closing Date (any such portion of such taxable period, the
&#147;<U>Post-Closing Tax Period</U>&#148;). Aeglea shall be liable for the proportionate amount of such Taxes that is attributable to the <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Tax Period, and Immedica shall be liable for the
proportionate amount of such Taxes that is attributable to the Post-Closing Tax Period.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)Apportioned Obligations shall be timely paid,
and all applicable filings, reports and returns shall be filed, as provided by applicable Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)The paying party of any Transfer Tax or
Apportioned Obligation shall be entitled to reimbursement from the <FONT STYLE="white-space:nowrap">non-paying</FONT> party in accordance with Section&nbsp;8.3 and Section&nbsp;8.4(a), respectively. Upon payment of any such Transfer Tax or
Apportioned Obligation, the paying party shall present a statement to the <FONT STYLE="white-space:nowrap">non-paying</FONT> party setting forth the amount of reimbursement to which the paying party is entitled under Section&nbsp;8.3 and
Section&nbsp;8.4(a), respectively, together with such supporting evidence as is reasonably necessary to calculate the amount to be reimbursed. The <FONT STYLE="white-space:nowrap">non-paying</FONT> party shall make such reimbursement promptly but in
no event later than ten (10)&nbsp;days after the presentation of such statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.5 <U>Withholding</U>. Immedica and its
Affiliates shall be entitled to deduct and withhold from any consideration payable hereunder, or other payment otherwise payable pursuant to this Agreement, the amounts required to be deducted and withheld under applicable Law. Immedica shall use
commercially reasonable efforts (a)&nbsp;to provide prompt notice to Aeglea if Immedica determines that any payment required to be made by Immedica or any of its Affiliates is subject to any such deduction or withholding, and (b)&nbsp;to cooperate
with Aeglea to reduce or eliminate such deduction or withholding. Any amounts so withheld shall be paid over to the appropriate Governmental Authority, and shall be treated for all purposes of this Agreement as having been paid to the applicable
Person in respect to which such deduction and withholding was made. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE IX </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">MISCELLANEOUS </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.1
<U>Expenses</U>. Except as specifically provided to the contrary in this Agreement, all costs and expenses incurred in connection with the negotiation and execution of this Agreement, and the other Instruments, and the consummation of the
Transaction shall be paid by the Party incurring such costs and expenses, whether or not the Transaction is consummated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.2
<U>Governing Law</U>. This Agreement and all Legal Proceedings relating to, arising out of or under or in connection with this Agreement and the Transaction, including the negotiation, execution and performance hereunder, shall be governed by, and
construed in accordance with, the Laws of the State of New York, regardless of the Laws that might otherwise govern under applicable principles of choice of Law or conflicts of Law rules or provisions thereof to the extent they would result in the
application of the Laws of another jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.3 <U>Specific Performance</U>. Each of Aeglea and Immedica acknowledges
and agrees that any breach of this Agreement may give rise to irreparable harm for which monetary damages would not be an adequate remedy. Each Party accordingly agrees that, in addition to any other remedies available under applicable Law or this
Agreement, each of Immedica and Aeglea shall be entitled to seek enforcement of the terms of this Agreement by decree of specific performance without the necessity of proving the inadequacy of monetary damages as a remedy and to obtain injunctive
relief against any breach or threatened breach of this Agreement. Any Party seeking an injunction or injunctions to prevent breaches of this Agreement and to enforce specifically the terms and provisions of this Agreement shall not be required to
provide any bond or other security in connection with such order or injunction. The rights and remedies provided for pursuant to this Section&nbsp;9.3 are cumulative to, and not exclusive of, any rights or remedies otherwise available hereunder.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.4 <U>Jurisdiction</U>. The Parties agree that any Legal Proceeding seeking to enforce any provision of, or based on any
matter arising out of or in connection with, this Agreement or the Transaction shall be brought exclusively in the United States District Court for the Southern District of New York or any New York State court sitting in New York City, Borough of
Manhattan, so long as one of such courts shall have subject matter jurisdiction over such Legal Proceeding, and that any cause of action arising out of this Agreement shall be deemed to have arisen from a transaction of business in the State of New
York, and each of the Parties hereby irrevocably consents to the jurisdiction of such courts (and of the appropriate appellate courts therefrom) in any such Legal Proceeding and irrevocably waives, to the fullest extent permitted by Law, any
objection that it may now or hereafter have to the laying of the venue of any such Legal Proceeding in any such court or that any such Legal Proceeding brought in any such court has been brought in an inconvenient forum. Process in any such Legal
Proceeding may be served on any Party anywhere in the world, whether within or without the jurisdiction of any such court. Without limiting the foregoing, each Party agrees that service of process on such party as provided in Section&nbsp;9.9 shall
be deemed effective service of process on such party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.5 <I><U>WAIVER OF JURY TRIAL</U></I>. EACH OF THE PARTIES HERETO
HEREBY IRREVOCABLY WAIVES ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATED TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.6 <U>Entire Agreement</U>. This Agreement (including all Exhibits and Schedules hereto) and other documents and instruments
delivered pursuant hereto constitute the entire agreement and supersede all prior representations, agreements, understandings and undertakings, both written and oral, between the Parties, with respect to the subject matter hereof, including the
License Agreement, and no Party is relying on any prior oral or written representations, agreements, understandings or undertakings with respect to the subject matter hereof and thereof.</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.7 <U>License Agreement</U>. The Parties hereby agree that, as of Closing,
(i)&nbsp;the License Agreement is hereby terminated in full, (ii)&nbsp;no rights or obligations (including any rights or obligations that purport to survive termination of the License Agreement) of either Party under the License Agreement shall
survive such termination, (<U>provided</U>, that Immedica shall remain responsible for the payment of the invoices set forth in Schedule 9.7), and (iii)&nbsp;the License Agreement shall have no further force or effect. For clarity, nothing in this
Section&nbsp;9.7 will be construed to limit or modify a Party&#146;s rights or obligations pursuant to this Agreement or any other Instrument.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Aeglea, on behalf of itself, its Affiliates and its and their current and former officers, employees, stockholders, agents,
representatives, attorneys, successors and assigns (collectively, the &#147;<U>Aeglea Releasing Parties</U>&#148;), hereby irrevocably and unconditionally releases and forever discharges Immedica and its Affiliates and their current and former
officers, directors, stockholders, employees, agents, representatives and attorneys (collectively, the &#147;<U>Immedica Releasees</U>&#148;), or any of them, from any and all Losses of any nature whatsoever, known or unknown, liquidated or
unliquidated, suspected or unsuspected, fixed or contingent, in law or in equity, arising under or in connection with the License Agreement that the Aeglea Releasing Parties now have, own or hold, or at any time heretofore ever had, owned or held or
could have had, owned or held against the Immedica Releasees, except for the payment of the invoices set forth in Schedule 9.7 and for any and all Losses arising from intentional fraud or willful misconduct of the Immedica Releasees.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Immedica, on behalf of itself, its Affiliates and its and their current and former officers, employees, stockholders, agents,
representatives, attorneys, successors and assigns (collectively, the &#147;<U>Immedica Releasing Parties</U>&#148;), hereby irrevocably and unconditionally releases and forever discharges Aeglea and its Affiliates and their current and former
officers, directors, stockholders, employees, agents, representatives and attorneys (collectively, the &#147;<U>Aeglea Releasees</U>&#148;), or any of them, from any and all Losses of any nature whatsoever, known or unknown, liquidated or
unliquidated, suspected or unsuspected, fixed or contingent, in law or in equity,&nbsp;arising under or in connection with the License Agreement that the Immedica Releasing Parties now have, own or hold, or at any time heretofore ever had, owned or
held or could have had, owned or held against the Aeglea Releasees, except for any and all Losses arising from intentional fraud or willful misconduct by the Aeglea Releasees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.8 <U>Amendments and Waivers</U>. This Agreement can be amended, supplemented or changed, and any provision hereof can be
waived, only by written instrument making specific reference to this Agreement signed by the Party against whom enforcement of any such amendment, supplement, modification or waiver is sought. The waiver by any Party of a breach of any provision of
this Agreement shall not operate or be construed as a further or continuing waiver of such breach or as a waiver of any other or subsequent breach. No failure on the part of any Party to exercise, and no delay in exercising, any right, power or
remedy hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of such right, power or remedy by such Party preclude any other or further exercise thereof or the exercise of any other right, power or remedy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.9 <U>Notices</U>. All notices or other communications which are required or permitted hereunder shall be in writing and
sufficient if delivered personally or sent by nationally recognized overnight courier or by registered or certified mail, postage prepaid, return receipt requested, or by email, as follows: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If to Aeglea, to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aeglea BioTherapeutics, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">221 Crescent Street </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Building 17, Suite 102B </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Waltham, MA 02453 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: Jonathan Alspaugh </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Email: [*] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">and by email to: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aeglea BioTherapeutics, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: General Counsel </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Email: bd@aeglea.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If to Immedica, to: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immedica Pharma AB </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Solnav&auml;gen 3H, 116 63 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stockholm, Sweden </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attention: Chief Executive Officer; General Counsel </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Email:
corporate@immedica.com; legal@immedica.com </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With a copy (which shall not constitute notice) to: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Davis Polk&nbsp;&amp; Wardwell LLP </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">450 Lexington Ave. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10017 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attention: William Chudd </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Email: william.chudd@davispolk.com </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">or to such other address as
the Party to whom notice is to be given may have furnished to the other Party in writing in accordance herewith. All such notices and other communications required or permitted by this Agreement shall&nbsp;be deemed to have been duly given
(a)&nbsp;if sent to a recipient at the proper address as determined pursuant to this Section&nbsp;9.9, by registered or certified mail, return receipt requested, five calendar days after being deposited in the United States mail, postage prepaid;
(b)&nbsp;if sent by Express Mail, Federal Express or similar reputable overnight delivery service that maintains records of receipt for next Business Day delivery, the next Business Day after being entrusted to such service, with delivery charges
prepaid or charged to the sender&#146;s account; (c)&nbsp;if sent by email, on the date of transmission with electronic confirmation of transmission; and (d)&nbsp;if delivered by hand, on the date of delivery. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.10 <U>Severability</U>. If any term or other provision of this Agreement is held by a court of competent jurisdiction or other
Governmental Authority to be invalid, illegal or incapable of being enforced under any applicable Law or public policy, all other terms or provisions of this Agreement shall nevertheless remain in full force and effect so long as the economic or
legal substance of the Transaction is not affected in any manner materially adverse to any Party. Upon such determination that any term or other provision is invalid, illegal or incapable of being enforced, the Parties shall negotiate in good faith
to modify this Agreement so as to affect the original intent of the Parties as closely as possible in an acceptable manner in order that the Transaction is consummated as originally contemplated to the greatest extent possible.</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.11 <U>No Third-Party Beneficiaries</U>. Nothing in this Agreement shall
create or be deemed to create any third-party beneficiary rights in any Person that is not a Party (or its permitted successors and assigns) except with respect to indemnification as contemplated by Section&nbsp;7.2 and Section&nbsp;7.3. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.12 <U>Bulk Sales Laws</U>. Immedica and Aeglea each hereby waive compliance by Aeglea with the provisions of the &#147;bulk
sales,&#148; &#147;bulk transfer&#148; or similar laws of any state. Aeglea agrees to indemnify and hold the Immedica Indemnified Parties harmless against any and all Losses (including any Taxes) incurred or suffered by any Immedica Indemnified
Party as a result of any failure to comply with any such &#147;bulk sales,&#148; &#147;bulk transfer&#148; or similar laws.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.13 <U>Assignment</U>. The provisions of this Agreement shall be binding upon and inure to the benefit of the Parties and their
respective successors and permitted assigns. No Party may assign or transfer this Agreement or any rights or obligations hereunder, directly or indirectly (by operation of Law or otherwise), without the prior written approval of the other Parties
and any attempted assignment without such required approval shall be null, void and of no effect; <U>provided</U>, that (a)&nbsp;Aeglea may assign its rights, interests, and obligations hereunder to an Affiliate of Aeglea or to any successor in
interest (whether by merger, acquisition, asset purchase or otherwise) to all or substantially all of its business, in each case without Immedica&#146;s prior written approval, and (b)&nbsp;Immedica may assign its rights, interests, and obligations
hereunder (in whole and not in part) to a wholly owned Affiliate of Immedica without Aeglea&#146; prior written approval; <U>provided</U> that any such assignment or designation pursuant to the foregoing clause (a)&nbsp;or (b) shall not relieve the
assigning Party of any of its obligations hereunder or otherwise adversely affect the other Party or any of its Affiliates. Upon any permitted assignment, the references in this Agreement to a Party shall also apply to any such assignee unless the
context otherwise requires. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.14 <U>Neutral Construction</U>. The Parties have participated jointly in the negotiation and
drafting of this Agreement and, in the event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as jointly drafted by the Parties and no presumption or burden of proof shall arise favoring or disfavoring
any Party by virtue of the authorship of any provision of this Agreement.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.15 <U>Counterparts; Effectiveness</U>. This
Agreement may be executed and delivered in one or more counterparts, and by the different Parties in separate counterparts, each of which when executed and delivered shall be deemed to be an original but all of which taken together shall constitute
one and the same agreement, with the same effect as if the signatures thereto were upon the same instrument. Counterparts may be delivered via electronic mail (including .pdf or any electronic signature complying with the U.S. federal ESIGN Act of
2000 (e.g., www.docusign.com)) or other transmission method and any counterpart so delivered shall be&nbsp;deemed to have been duly and validly delivered and be valid and effective as delivery of a manually executed counterpart of this Agreement.
Each of the Parties represents that it has undertaken commercially reasonable steps to verify the identity of each individual person executing any such counterparts via electronic signature on behalf of such Party and has and will maintain
sufficient records of the same. This Agreement shall become effective when each Party shall have received a counterpart hereof signed by all of the other Parties. Until and unless each Party has received a counterpart hereof signed by each other
Party, this Agreement shall have no effect and no Party shall have any right or obligation hereunder (whether by virtue of any other oral or written agreement or other communication). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Pages Follow] </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the Parties have caused this Agreement to be executed by their
respective officers thereunto duly authorized, as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"><B>IMMEDICA PHARMA AB</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"><B>AEGLEA BIOTHERAPEUTICS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to
Asset Purchase Agreement</I>] </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Exhibit A </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Definitions; Interpretations </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) For purposes of this Agreement, the following terms shall have the meanings specified in this <U>Exhibit A</U>, and the terms defined in
Schedule 1.2 shall have the meanings specified in such Schedule. Further, those additional capitalized terms not defined in this <U>Exhibit A</U> or Schedule 1.2 shall have the meaning as set forth in the Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>ADA Assays</U>&#148; means the assays used in connection with the Program for anti-drug antibody testing developed pursuant to that
certain Master Services Agreement by and between Aeglea and BioAgilytix Labs, LLC, dated as of October&nbsp;16, 2015. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Affiliate</U>&#148; means, with respect to a Person, any other Person that controls, is controlled by, or is under common control
with such Person. For purposes of this definition, &#147;control&#148; when used with respect to any Person means the power to direct the management and policies of such Person, directly or indirectly, whether through the ownership of voting
securities, by contract or otherwise, and the terms &#147;controlling&#148; and &#147;controlled&#148; have correlative meanings.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Assigned Contracts</U>&#148; means the Contracts set forth on Schedule 2.1(b)(ii), including all amendments and supplements thereto
and all Statements of Work and Purchase Orders thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Assigned Intellectual Property</U>&#148; means, any and all
Intellectual Property that is owned by Aeglea or any of its Subsidiaries and used or held for use in, or otherwise related to, the conduct of the Program or any Exploitation of the Product as of the Closing, including the Intellectual Property
listed on Schedule 2.1(b)(i)(A), but excluding the ADA Assays.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Assigned Patents</U>&#148; means any and all Patents included in
the Assigned Intellectual Property.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Biological Materials</U>&#148; means any biological substances and materials, including any
tissues, cells, cell lines, organisms, blood samples, genetic material, antibodies, and plasmids, in each case relating exclusively to the Product or held for exclusive use in the Program. For the sake of clarity, human tissue samples taken from a
human patient in the context of a Clinical Study with respect to a Product or a Program do not relate exclusively to such Product or such Program. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Bayh Dole Act&#148;</U> means the Bayh-Dole Act, 35 U.S.C. &#167; <FONT STYLE="white-space:nowrap">200-211</FONT> together with all
regulations implementing the same, including 37 CFR 401, as each may be amended from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>BLA</U>&#148; means a
Biologics License Application (as defined in 21 C.F.R. 600 et. seq.) filed with the FDA, and any amendments thereto.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Business
Day</U>&#148; means any day of the year on which national banking institutions in New York, U.S. and Stockholm, Sweden are open to the public for conducting business and are not required or authorized by applicable Law to close. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Clinical Study</U>&#148; means any investigation in human subjects intended to determine the clinical pharmacological,
pharmacokinetic, and/or other pharmacodynamic effects of an investigational agent, and/or to identify any adverse reactions to an investigational agent to assess the agent&#146;s safety and efficacy.</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Code</U>&#148; means the Internal Revenue Code of 1986, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Contract</U>&#148; means any written or oral agreement, contract, indenture, note, mortgage, loan, instrument, license, guarantee,
bond, lease, commitment, understanding or undertaking. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>CPRIT Technology</U>&#148; means (i)&nbsp;all Patents set forth on
Schedule 2.1(b)(i)(C) and (ii)&nbsp;any and all data generated pursuant to that certain Cancer Research Grant Contract between AERase, Inc. and Cancer Prevention and Research Institute of Texas dated as of June&nbsp;1, 2014. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Documents</U>&#148; means all files, documents (including all documents related to past or present preclinical and clinical trials,
nonclinical studies and stability studies, in each case in both raw data and processed data (i.e., JMP file) form), instruments, papers, books, reports (including clinical, preclinical and nonclinical reports, and all data sets associated with such
reports), records, budgets, forecasts, ledgers, journals, supplier lists, customer data, operating data and plans (including all launch preparation documentation), technical documentation, and other similar materials, and specifically including the
label components with respect to the Product, the safety database for the Product (including all source data, related correspondence with the FDA and any similar information), all information, reports, records, data or materials relating to quality
assurance matters with respect to the Product, in each case whether in hard copy or electronic format; <U>provided</U>, that &#147;Documents&#148; does not include Product Registrations or Permits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Environmental Law</U>&#148; means any applicable Law relating to the protection of the environment or the handling, treatment,
storage, disposal or release of hazardous substances, wastes or materials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Expenses</U>&#148; means any and all expenses, costs,
claims, demands, assessments, judgments, penalties and fees (including reasonable attorneys&#146; and other professionals&#146; fees and disbursements). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Exploit</U>&#148; means to research, have researched, develop, have developed, use, have used, make, have made, sell, have sold,
offer for sale, have offered for sale, commercialize, have commercialized, import, have imported, export, have exported, register, have registered, and otherwise exploit or have exploited. &#147;<U>Exploitation</U>&#148; has a correlative meaning.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>FD&amp;C Act</U>&#148; means the United States Federal Food, Drug, and Cosmetic Act, as amended, and the rules and regulations
promulgated thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>FDA</U>&#148; means the United States Food and Drug Administration or any successor agency thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Fuji Credit</U>&#148; means [*] to be paid by Aeglea to Fujifilm pursuant to the Fuji Scope of Work for services not yet rendered.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Fuji Scope of Work</U>&#148; means that certain Scope of Work 7 entitled &#147;Manufacturing
<FONT STYLE="white-space:nowrap">Pre-Production,</FONT> cGMP Production, Testing and Disposition for AEB1101,&#148; with Program Reference R2841.03, by and between Fujifilm and Aeglea dated as of November&nbsp;27, 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Fujifilm</U>&#148; means Fujifilm Diosynth Biotechnologies U.S.A., Inc. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Governmental Authority</U>&#148; means any nation or government or governmental or regulatory body thereof, or political subdivision
thereof, whether federal, state, local or foreign, or any agency, instrumentality or authority thereof, or any court or arbitrator (public or private) or any other entity exercising executive, judicial, legislative, regulatory or administrative
functions of or pertaining to regulation or to government. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>IND</U>&#148; means an Investigational New Drug Application submitted under
Section&nbsp;505(i) of the FD&amp;C Act, or an analogous application or submission with any analogous agency or Regulatory Authority outside of the United States for the purposes of obtaining permission to conduct clinical trials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Indebtedness</U>&#148; means any amount owed by Aeglea or any of its Subsidiaries (including (i)&nbsp;unpaid principal,
(ii)&nbsp;unpaid interest, (iii)&nbsp;premium thereon (including make-whole premiums) and (iv)&nbsp;prepayment penalties, breakage costs, fees, expenses or similar charges arising as a result of the discharge of such amount owed), without
duplication, in respect of: (a)&nbsp;obligations of Aeglea or any of its Subsidiaries for borrowed money (including the current portion thereof) and related accrued interest payable in respect of such borrowed money, (b)&nbsp;obligations of Aeglea
or any of its Subsidiaries evidenced by bonds, notes, debentures or other similar instruments (including a purchase money obligation), (c) all reimbursement obligations of Aeglea or any of its Subsidiaries relating to letters of credit,
bankers&#146; acceptances, surety, performance bonds or other bonds or similar instruments to the extent called, drawn or otherwise due, (d)&nbsp;capitalized lease obligations of Aeglea or any of its Subsidiaries (including the current portion
thereof) and related accrued interest payable in respect of such obligations, (e)&nbsp;all guarantees, including guarantees of any items set forth in clauses (a)&nbsp;through (d) and (f)&nbsp;obligations of Aeglea or any of its Subsidiaries that are
secured in whole or in part by the assets of Aeglea or any of its Subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Indemnification Claim</U>&#148; means any claim
in respect of which payment may be sought under Article VII of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Intellectual Property</U>&#148; means any and all
intellectual property rights or similar proprietary rights throughout the world, including all (i)&nbsp;Patents, (ii) Trademarks, (iii)&nbsp;copyrights and moral rights, including registrations or applications for registrations thereof and all
renewals, extensions, restorations and reversions of the foregoing (&#147;<U>Copyrights</U>&#148;), (iv) <FONT STYLE="white-space:nowrap">Know-How,</FONT> (v)&nbsp;database rights, industrial designs, industrial property rights, publicity rights and
privacy rights and (vi)&nbsp;rights to assert, claim or sue and collect damages for the past, present or future infringement, misappropriation or other violation of any of the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Inventory</U>&#148; means all inventory of the Product owned by Aeglea or its Subsidiaries as of the Closing Date, wherever located,
including all finished goods, work in process, raw materials, cell banks, vials and other reagents, starting materials, and intermediates from the synthesis of Product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Inventory Specifications</U>&#148; means the applicable specifications and standards set forth in the Marketing Authorization
Application (EMEA/H/C/005484) submitted by Immedica to the European Medicines Agency with respect to the Product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>IP Assignment
Agreement</U>&#148; means the Intellectual Property Assignment Agreement to be entered into between Aeglea (or an Affiliate thereof) and Immedica (or an Affiliate thereof) at the Closing in substantially the form attached hereto as <U>Exhibit B</U>.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U><FONT STYLE="white-space:nowrap">Know-How</FONT></U>&#148; means any and all <FONT STYLE="white-space:nowrap">know-how,</FONT>
trade secrets, data, results, technology, business or financial information or information of any type whatsoever, in any tangible or intangible form, including practices, techniques, methods, assays, techniques, processes, protocols, inventions,
discoveries, improvements, developments, specifications, formulations, formulae, algorithms, marketing reports, business plans, expertise, technology, software, test data (including pharmacological, biological, chemical, biochemical, medical,
toxicological, preclinical, and clinical test data and any other research or development data), standard operating procedures, manufacturing records, stability data and other study data and procedures. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Knowledge</U>&#148; means the actual knowledge of each of Jonathan Alspaugh,
Cortney Caudill and Jim Kastenmayer, after reasonable inquiry of each such individual&#146;s direct reports. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Law</U>&#148; means
any foreign, federal, state and local law (including common law), statute, code, ordinance, rule, regulation (including zoning and building code), permit, legislation, injunction, judgment, decree, ruling, Order or other requirement of any
Governmental Authority or any securities exchange upon which a Party is listed or becomes listed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Legal Proceeding</U>&#148;
means any judicial, administrative or arbitral actions, suits, mediations, audits, investigations, inquiries, hearings, proceedings (public or private), litigation, complaints, allegations, demands, charges, grievances, prosecutions or claims
(including counterclaims). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Liability</U>&#148; means any debt, liability or obligation (whether direct or indirect, absolute or
contingent, accrued or unaccrued, known or unknown, liquidated or unliquidated, or due or to become due) and including all costs and expenses relating thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Lien</U>&#148; means any lien, encumbrance, pledge, mortgage, deed of trust, security interest, charge, condition, restriction,
covenant, license, purchase option, lease, sublease or other third-party right, right of first refusal, easement, right of way, servitude, transfer restriction, encroachment, reservation or title defect of any kind or nature. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Losses</U>&#148; means all damages, losses, claims, Liabilities, charges, fines, penalties, diminution in value, lost profits,
judgments, amounts paid in settlement, costs and Expenses (including reasonable expenses of investigation and reasonable attorneys&#146; fees and expenses in connection with any Legal Proceeding, whether involving a Third-Party Claim or a claim
solely between the parties hereto to enforce the provisions hereof). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Material Adverse Effect</U>&#148; means any fact, event,
change, development, condition, circumstance or effect that, individually or in the aggregate, (A)&nbsp;has, or would reasonably be expected to have, a material adverse effect on the Program, the Product and the Acquired Assets taken as a whole, or
(B)&nbsp;prevents or materially impairs or delays, would be reasonably expected to prevent or materially impair or delay, the ability of Aeglea to perform its obligations hereunder, including the consummation of the Transaction; <U>provided</U>
that, in the case of <U>clause (A)</U>&nbsp;above, &#147;Material Adverse Effect&#148; shall not include any such fact, event, change, development, condition, circumstance or effect to the extent it results from (i)&nbsp;global or national political
conditions, including the outbreak or escalation of war or terrorist activities, (ii)&nbsp;global or national economic, monetary, or financial conditions, including changes in prevailing interest rates, credit markets, or financial market conditions
in or affecting the United States, (iii)&nbsp;changes in applicable Law (or the interpretations thereof) or GAAP (or the interpretations of), (iv) the taking of any action specifically required to be taken by this Agreement or taken by any Party or
any of its Affiliates or any of their respective Affiliates with the prior written consent or at the written request of the other Party, (v)&nbsp;earthquakes, hurricanes, tsunamis, typhoons, lightning, hailstorms, blizzards, tornadoes, droughts,
floods, cyclones, arctic frosts, mudslides, wildfires and other natural disasters and weather conditions, (vi)&nbsp;impacts on relationships with suppliers, employees, labor organizations, or Governmental Authorities, in each case attributable to
the execution, announcement or pendency of this Agreement or the Transaction, or (vii)&nbsp;changes generally in the life sciences and healthcare industries; except to the extent, in the case of <U>clauses (i)</U>, <U>(ii)</U>, <U>(iii)</U>,
<U>(v)</U> and (vii), such fact, event, change, development, condition, circumstance or effect disproportionately affects the Program, the Product or the Acquired Assets, relative to other participants in the industry or industries in which the
Program operates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Order</U>&#148; means any order, injunction, judgment, decree, determination,
ruling, writ, assessment or arbitration or other award of a Governmental Authority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Ordinary Course of Business</U>&#148; means,
with respect to any Person or business, the ordinary course of business of such Person and its Affiliates or such business, in each case, consistent with past practices. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Patents</U>&#148; means any and all patents (which shall include invention patents, utility models, design patents, industrial
designs, and priority rights), applications for patents, invention disclosures, provisional applications, substitutions, supplementary protection certificates, reissues, reexaminations, renewals, revisions, extensions, divisionals, continuations, <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">continuations-in-part,</FONT></FONT> inventors&#146; certificates, utility certificates, patents or certificates of addition, inventors&#146; certificates of addition, and utility
certificates of addition and other indices of invention ownership and the right to claim priority to any part of the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Permits</U>&#148; means any approvals, authorizations, consents, licenses, permits or certificates (including certificates of
occupancy) of a Governmental Authority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Permitted Liens</U>&#148; means (i)&nbsp;Liens for Taxes, assessments or other
governmental charges or levies not yet due or payable or that are being contested in good faith by appropriate Legal Proceedings and for which adequate reserves have been set aside in the relevant financial statements in accordance with generally
applicable accounting principles; (ii)&nbsp;statutory Liens of landlords and mechanics&#146;, carriers&#146;, warehousemen&#146;s, workers&#146;, repairers&#146; and similar Liens imposed by applicable Law or arising or incurred in the Ordinary
Course of Business with respect to amounts not yet due and payable or being contested in good faith by appropriate Legal Proceedings; (iii)&nbsp;Liens incurred or deposits made in the Ordinary Course of Business in connection with workers&#146;
compensation, unemployment insurance or other types of social security; (iv)&nbsp;rights under the Specified Patents licensed to the U.S. Federal Government on a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> basis pursuant to the Bayh Dole
Act; (v)&nbsp;rights under the CPRIT Technology licensed to the Cancer Prevention and Research Institute of Texas on a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> basis pursuant to that certain Cancer Research Grant Contract between
AERase, Inc. and Cancer Prevention and Research Institute of Texas dated as of June&nbsp;1, 2014; and <FONT STYLE="white-space:nowrap">(vi)&nbsp;non-exclusive</FONT> licenses that were entered into by Aeglea or any of its Subsidiaries in the
Ordinary Course of Business and where the grant of rights to use any Intellectual Property is solely for any performance of services under each such agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Person</U>&#148; means any individual, corporation, limited liability company, partnership, firm, joint venture, association,
joint-stock company, trust, unincorporated organization, Governmental Authority or other entity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Product</U>&#148; means any
pharmaceutical product containing, incorporating or comprising pegzilarginase (CAS Registry Number: <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1659310-95-8)</FONT></FONT> whether as the sole pharmaceutical ingredient, or in
combination with other active pharmaceutical ingredients, in any form, formulation, mode of administration, presentation or dosage form. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Product Registrations</U>&#148; means (i)&nbsp;any approvals, clearances, registrations, licenses, listings, permits, investigational
new drug exemptions, orphan drug designations, rare pediatric disease designations, clinical trial authorizations or marketing authorizations, together with any supplements or amendments thereto (collectively, &#147;<U>Approvals</U>&#148;), whether
existing, pending or issued or in draft form, to Aeglea or an Affiliate of Aeglea by the relevant Governmental Authority prior to the Closing Date related to the research, development, manufacture, importation, distribution, marketing and/or sale of
the Product, (ii)&nbsp;any rights that Aeglea or a Subsidiary of Aeglea has in any Approval referred to in clause (i)&nbsp;of this definition under any agreement pursuant to which any such Approval is held in the name of a third person,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(iii) any regulatory applications, submissions, dossiers, notifications, registrations, decisions, correspondence or other filings made to or with a Regulatory Authority with respect to the
Product or the Program, (iv)&nbsp;supporting documentation in Aeglea&#146;s or an Affiliate of Aeglea&#146;s files with respect to any of the foregoing clauses (i)-(iii), including annual reports and adverse event reports and (v)&nbsp;as applicable,
complete and accurate electronic copies of all items referred to in the foregoing clauses (i)-(iv). The Product Registrations shall include INDs, Regulatory Approvals and the pricing and reimbursement approval (if applicable or available) and all
national drug code numbers (if any) assigned to the Product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Program Contract</U>&#148; means any Contract that is primarily
related to, or otherwise material to, the Product or the Program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Regulatory Approvals</U>&#148; means, with respect to the
Product in any country or jurisdiction, any approval (including where required, pricing and reimbursement approvals), registration, license or authorization that is required by the applicable Governmental Authority to market and sell the Product in
such country or jurisdiction.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Regulatory Authority</U>&#148; means, with respect to a country, any national (e.g., the FDA),
supra-national (e.g., the European Commission, the Council of the European Union, or the European Medicines Agency), regional, state or local regulatory agency, department, bureau, commission, council or other Governmental Authority involved in the
granting of a Regulatory Approval or, to the extent required in such country, price approval, for biological or pharmaceutical Product in such country. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Representatives</U>&#148; means, with respect to any Person, such Person&#146;s directors, officers, employees, attorneys, counsel,
consultants, advisors, financing sources, accountants, auditors, authorized representatives, agents or Affiliates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Subsidiary</U>&#148; means, with respect to any Person, any entity of which securities or other ownership interests having ordinary
voting power to elect a majority of the board of directors or other persons performing similar functions are at the time directly or indirectly owned by such first Person.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Tax Return</U>&#148; means any return (including any information return), report, statement, schedule, notice, form or other document
or information filed with or submitted to, or required to be filed with or submitted to, any Taxing Authority in connection with the determination, assessment, collection or payment of any Tax or in connection with the administration, implementation
or enforcement of or compliance with any Law relating to any Tax. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Taxes</U>&#148; means (I)&nbsp;any and all federal, state,
local or foreign taxes, charges, fees, imposts, levies or other assessments, including all net income, gross receipts, capital, sales, use, ad valorem, value added, transfer, franchise, profits, inventory, capital stock, license, withholding,
payroll, employment, social security, unemployment, excise, severance, stamp, occupation, property and estimated taxes, customs duties, fees, assessments and charges of any kind whatsoever, together with any such Liabilities for any other Person,
whether arising by reason of consolidated, combined, or similar Tax Returns, as a transferee, by contract, by operation of Law, or otherwise; and (ii)&nbsp;all interest, penalties, fines, additions to tax or additional amounts imposed by any Taxing
Authority in connection with any item described in <U>clause (i)</U>&nbsp;above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Taxing Authority</U>&#148; means any
Governmental Authority responsible for the administration of any Tax. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Third Party</U>&#148; means any Person other than the
Parties or any of their respective Affiliates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Trademarks</U>&#148; means any and all trademarks, service marks, logos, slogans,
trade names, trade dress, internet domain names, social media handles, and any other indicator of the source of origin of goods or services, including all applications and registrations of, and all goodwill associated with, the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Transaction</U>&#148; means the purchase and sale of the Acquired Assets and the assumption of the Assumed Liabilities as
contemplated by this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Transfer Taxes</U>&#148; means any and all sale, use, stamp, documentary, filing, recording,
transfer, gross receipts, registration, duty or similar fees or Taxes or governmental charges (together with any interest or penalty, addition to tax or additional amount imposed) as levied by any Taxing Authority on the purchase and sale of the
Acquired Assets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>United States</U>&#148; or &#147;<U>U.S.</U>&#148; means the United States of America and its territories,
possessions and commonwealths. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Other Definitional and Interpretive Matters</U>. Unless otherwise expressly provided, for purposes
of this Agreement, the following rules of interpretation shall apply: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) <U>Calculation of Time Periods</U>. When calculating the period
of time before which, within which or following which any act is to be done or step taken pursuant to this Agreement, the date that is the reference date in calculating such period shall be excluded. If the last day of such period is a <FONT
STYLE="white-space:nowrap">non-Business</FONT> Day, the period in question shall end on the next succeeding Business Day. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii)
<U>Currency</U>. Unless otherwise specified in this Agreement, all references to &#147;$&#148; and dollars set forth herein shall mean United States (U.S.) dollars. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) <U>Exhibits/Schedules</U>. The Exhibits and Schedules to this Agreement are an integral part of this Agreement and are hereby
incorporated herein and made a part hereof as if set forth herein. Any capitalized terms used in any Exhibit or Schedule but not otherwise defined therein shall be defined as set forth in this Agreement. The representations and warranties contained
in Article IV are qualified by reference to the Schedules attached hereto and referred to in Article IV (collectively, the &#147;<U>Disclosure Schedule</U>&#148;). The Parties acknowledge and agree that (i)&nbsp;the Disclosure Schedule may include
items or information that Aeglea is not required to disclose under this Agreement, (ii)&nbsp;disclosure of such items or information shall not be deemed to expand the scope of the representations and warranties of Aeglea under this Agreement,
(iii)&nbsp;inclusion of information in the Disclosure Schedule shall not be construed as an admission that such information is necessarily material in any respect and (iv)&nbsp;reference in a particular Section of the Disclosure Schedule shall only
be deemed to be an exception to (or, as applicable, a disclosure for purposes of)&nbsp;(A) the representations and warranties (or covenants and agreements, as applicable) of Aeglea that are contained in the corresponding Section of this Agreement
and (B)&nbsp;any other representation and warranty (or covenant and agreement, as applicable) of Aeglea that is contained in this Agreement, but only if the relevance of that reference as an exception to (or a disclosure for purposes of) such
representation and warranty (or covenant and agreement, as applicable) would be reasonably apparent to a reasonable person without any independent knowledge regarding the matter(s) so disclosed.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iv) <U>Gender and Number</U>. Any reference in this Agreement to gender shall include all genders, and words imparting the singular number
only shall include the plural and vice versa. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(v) <U>Headings</U>. The provision of the Table of Contents, the division of this Agreement
into Articles, Sections and other subdivisions and the insertion of headings are for convenience of reference only and shall not affect or be utilized in construing or interpreting this Agreement. All references in this Agreement to any
&#147;Article,&#148; &#147;Section&#148; or other subdivision are to the corresponding Article, Section or other subdivision of this Agreement unless otherwise specified. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(vi) <U>Herein</U>. Words such as &#147;<U>herein</U>,&#148; &#147;<U>hereinafter</U>,&#148; &#147;<U>hereof</U>,&#148;
&#147;<U>hereunder</U>&#148; and &#147;<U>hereto</U>&#148; refer to this Agreement as a whole and not merely to a subdivision in which such words appear unless the context otherwise requires. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(vii) <U>Including</U>. The word &#147;<U>including</U>&#148; or any variation thereof means &#147;including without limitation,&#148; unless
otherwise specified and shall not be construed to limit any general statement that it follows to the specific or similar items or matters immediately following it. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(viii) <U>Other</U>. The word &#147;or&#148; shall be exclusive; references to &#147;written&#148; or &#147;in writing&#148; include in
electronic form (including email); any reference to &#147;days&#148; means calendar days unless Business Days are expressly specified; and references to any statute, rule, regulation, law or applicable Law shall be deemed to refer to all applicable
Laws as amended or supplemented from time to time and to any rules, regulations and interpretations promulgated thereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Exhibit B </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>IP Assignment Agreement </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Exhibit C </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Specified Patent Assignment Agreement </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Exhibit D </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Specified Patent License Agreement </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-1 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.18
<SEQUENCE>30
<FILENAME>d518298dex1018.htm
<DESCRIPTION>EX-10.18
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.18</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.18 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>LEASE TERMINATION AGREEMENT</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>THIS LEASE TERMINATION AGREEMENT</B> (this &#147;<B><U>Agreement</U></B>&#148;) is made as of the <U>7th</U> day of August, 2023
(&#147;<B><U>Effective Date</U></B>&#148;), by and between <B>LAS CIMAS OWNER LP</B>, a Delaware limited partnership (&#147;<B><U>Landlord</U></B>&#148;) and <B>AEGLEA BIOTHERAPEUTICS, INC.</B>, a Delaware corporation
(&#147;<B><U>Tenant</U></B>&#148;). </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>W&nbsp;I&nbsp;T&nbsp;N&nbsp;E&nbsp;S&nbsp;S&nbsp;E&nbsp;T&nbsp;H:</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Reference is hereby made to the following facts which constitute the background to this Agreement: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A.&nbsp;&nbsp;&nbsp;&nbsp;Landlord and Tenant entered into that certain Lease Agreement dated April&nbsp;30, 2019 (the &#147;<B><U>Original
Lease</U></B>&#148;) for Suites 100, 110, and 150 (collectively, the &#147;<B><U>Premises</U></B>&#148;), located in the building commonly known as 805 Las Cimas Parkway, Austin, Texas 78746 (as more particularly described in the Lease, the
&#147;<B><U>Building</U></B>&#148;). The Original Lease, as amended by that certain First Amendment to Lease Agreement dated October&nbsp;2, 2019, and by that certain Amended &amp; Restated Second Amendment to Lease Agreement dated January&nbsp;14,
2020 is referred to herein as the &#147;<B><U>Lease</U></B>&#148;. All capitalized words and phrases not otherwise defined herein shall have the meanings ascribed to them in the Original Lease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">B.&nbsp;&nbsp;&nbsp;&nbsp;Tenant desires to terminate the Lease and its obligations as tenant thereunder and to surrender the Premises to
Landlord, and Landlord desires to recover possession of the Premises and to terminate the Lease and its obligations thereunder, subject to and in accordance with the terms and conditions of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of One Dollar ($1.00) and other good and valuable consideration, the receipt, sufficiency and delivery of
which are hereby acknowledged, Landlord and Tenant hereby agree as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination of Lease</U>.
Effective as of 5:00 p.m. on the Effective Termination Date (defined below), the Lease shall terminate and expire with the same force and effect as if such Effective Termination Date had originally been specified in the Lease as the termination date
of the Term of the Lease. Prior to the Effective Termination Date, except as expressly set forth in this Agreement, both Landlord and Tenant shall perform all of their respective obligations thereunder (other than Tenant&#146;s obligations with
respect to the payment of Basic Rent and Additional Rent due under the Lease, which Landlord has agreed to abate following June&nbsp;30, 2023). As used herein, the &#147;<B><U>Effective Termination Date</U></B>&#148; means the date upon which the
Surrender Conditions (defined below) are fully satisfied to the reasonable satisfaction of Landlord. As used herein, the &#147;<B><U>Surrender Conditions</U></B>&#148; mean the completion by Tenant of all of the following: (a)&nbsp;payment of the
full Termination Fee (as defined in <U>Section&nbsp;3</U> below); (b) surrender of the Premises (including the Lab Area) to Landlord in strict accordance with the terms of <U>Section&nbsp;21</U> of the Original Lease, including, without limitation,
the Surrender Plan approved by Landlord and cleaning of all duct work and HVAC systems; (c)&nbsp;delivery of a photocopy of the original executed Bill of Sale (defined below); and (d)&nbsp;removal of Tenant&#146;s signage (including the repair of
all damage caused thereby and restoration of the Building to its condition before the installation of Tenant&#146;s signage), all at Tenant&#146;s sole cost and expense. Upon its belief that it has satisfied all
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Surrender Conditions, Tenant will provide written notice thereof to Landlord. In the event Landlord disputes the satisfaction of any Surrender Condition(s), Landlord shall provide written notice
identifying the Surrender Condition(s) that are not satisfied and basis therefor in reasonable detail within five (5)&nbsp;business days after Tenant has provided notice that it has satisfied the Surrender Conditions. Tenant will then have fifteen
(15)&nbsp;days to cure any remaining deficiencies (or if the same are not reasonably susceptible to cure within fifteen (15)&nbsp;days, or such additional time as reasonably necessary provided Tenant diligently commences and pursues such cure, not
to exceed thirty (30)&nbsp;total days) and, if Tenant fails to cure such deficiencies within such cure period, such failure shall be an Event of Default under the Lease. Upon the occurrence of an Event of Default, Landlord may (a)&nbsp;elect to
treat Tenant as a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">tenant-at-sufferance</FONT></FONT> and for each day between the date of such Event of Default and the day on which Tenant actually satisfies the Surrender
Conditions, Tenant shall pay a per diem holdover charge equal to 300% of the per diem Basic Rent and Additional Rent that otherwise would have been payable by Tenant for the month of June, 2023, and all other charges payable under the Lease; and/or
(b)&nbsp;to exercise all other rights and remedies available to Landlord under the Lease. Tenant acknowledges that Landlord has engaged a consultant to inspect the Premises to ensure the Premises has been surrendered in the condition required
hereunder, and it has agreed to reimburse Landlord for Landlord&#146;s actual, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred by Landlord in connection with such inspection upon
Landlord&#146;s written request therefor; Landlord presently anticipates that such expense will be in the amount of Five Thousand Dollars and No/100 ($5,000.00). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.&nbsp;&nbsp;&nbsp;&nbsp;<U>Obligations of Tenant under the Lease</U>. Upon the occurrence of the Effective Termination Date, Tenant shall be
released from any and all of its obligations and liabilities under the Lease which arise or accrue from and after the Effective Termination Date (&#147;<B><U>Release</U></B>&#148;). Nothing contained herein shall constitute a waiver or release of,
or derogate, limit or detract from, either (i)&nbsp;Tenant&#146;s liabilities and obligations under the Lease which arise or accrue prior to the Effective Termination Date (to avoid doubt, the obligation to pay Basic Rent and Additional Rent after
June&nbsp;30, 2023 is abated as provided above), or (ii)&nbsp;the obligations and liabilities of the Tenant under the Lease which expressly survive the expiration or termination of the Lease, all of which obligations shall be continuing and
expressly shall survive the termination of the Lease pursuant to this Agreement including, without limitation, indemnifications with respect to claims, liabilities, and obligations which accrue prior to the Effective Termination Date (whether or not
such claims, liabilities or obligations are asserted, known or unknown, or claimed prior to the Effective Termination Date). All such indemnifications shall survive the termination of the Lease and shall continue in full force and effect in
accordance with the terms of the Lease, including, without limitation, the indemnifications set forth in <U>Section&nbsp;9</U> of the Lease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.&nbsp;&nbsp;&nbsp;&nbsp; <U>Termination Fee</U>. As consideration for Landlord&#146;s agreement to release Tenant as provided herein, Tenant
shall pay to Landlord a termination fee in the amount of Two Million Dollars and No/100 ($2,000,000.00) (the &#147;<B><U>Termination Fee</U></B>&#148;). The Release provided in <U>Section&nbsp;6</U> of this Agreement shall be void ab initio and will
be of no force or effect if the Termination Fee or any part is ever invalidated, voided, avoided, rescinded, determined to be fraudulent or preferential, set aside, or required to be repaid or retransferred by operation of law, or by order of any
state or federal court of competent jurisdiction (including, without limitation, a United States Bankruptcy Court or a trustee in bankruptcy or other party in interest in any bankruptcy proceeding) in connection with an action or proceeding,
initiated or commenced in favor of, against, on behalf of, or in concert with, directly or indirectly, Tenant, or any person claiming by </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or through Tenant, or any of their respective agents, employees, representatives, officers, directors, shareholders, subsidiaries, affiliates, heirs, legal representatives, successors or assigns.
Without limitation, if the Termination Fee or any other payments made by Tenant to Landlord pursuant hereto or contemplated hereby, become invalidated, voided, avoided, rescinded, declared to be fraudulent or preferential, set aside, or required to
be repaid or retransferred to any person or entity, then the liability or indebtedness (or part thereof) which had been deemed paid, reduced, credited, discharged, waived, or satisfied by Landlord shall be reinstated as of the date such initial
payment, reduction, discharge, waiver, or satisfaction occurred; any partial invalidation, voidness, rescission, declaration, retransfer, or repayment shall result in partial reinstatement to the extent necessary to provide Landlord with the
benefits originally intended to be provided to it under this Agreement. Upon the Effective Termination Date, Landlord will return the Letter of Credit (currently in the amount of $1,000,000) to the Issuing Bank, together with instructions (in such
form as required by the Issuing Bank) to immediately terminate the Letter of Credit, and will confirm the same in writing to Tenant (which confirmation may be sent via <FONT STYLE="white-space:nowrap">e-mail</FONT> to Jonathan Alspaugh
jalspaugh@aeglea.com ). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.&nbsp;&nbsp;&nbsp;&nbsp;<U>Bill of Sale</U>. Contemporaneously with the execution hereof, Tenant shall transfer
to Landlord via a bill of sale in the form attached hereto as <U>Exhibit A</U> (the &#147;<B><U>Bill of Sale</U></B>&#148;), all of Tenant&#146;s right, title and interest in and to the personal property referenced therein (&#147;<B><U>Personal
Property</U></B>&#148;). Tenant hereby represents and warrants that, as of the date hereof, Tenant owns the Personal Property, the Personal Property is free and clear of all liens, financing interests, mortgages, charges and any other encumbrances
and Tenant has the full right, power and authority to sell the Personal Property to Landlord without notice to or consent by any third party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.&nbsp;&nbsp;&nbsp;&nbsp;<U>Release</U>. Upon the occurrence of the Effective Termination Date, Tenant, on behalf of itself and its partners,
limited partners, officers, directors, shareholders, agents, attorneys, employees, subsidiaries, parents, affiliates, successors and/or assigns (collectively, the &#147;<B><U>Tenant Related Parties</U></B>&#148;), hereby remises, releases and
forever discharges Landlord, and its respective general and limited partners, managers, members, officers, directors, shareholders, agents, attorneys, affiliates, parents, subsidiaries, trustees, beneficiaries, successors and/or assigns
(&#147;<B><U>Landlord Related Parties</U></B>&#148;) of and from any and all covenants, contracts, omissions, claims, causes of action, liabilities and damages of every nature whatsoever, whether known or unknown, disclosed or undisclosed, or in law
or in equity, that the Tenant Related Parties may have, or may hereafter have, or in the future may have based upon any action or inaction from the beginning of the world through and including the date of this Agreement against the Landlord Related
Parties arising out of, related to or concerning the Lease and/or Tenant&#146;s occupancy of the Premises and/or all matters arising out of or resulting therefrom; provided, however, nothing contained herein shall constitute a waiver or release of
Landlord&#146;s obligations under this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.&nbsp;&nbsp;&nbsp;&nbsp;<U>Agreement-Related Defaults</U>. If Tenant breaches any of
its obligations under this Agreement following the Effective Termination Date (an &#147;<B><U>Agreement-Related Default</U></B>&#148;) and fails to cure the same within fifteen (15)&nbsp;days following Landlord&#146;s notice (or such additional time
as reasonably necessary provided Tenant diligently commences and pursues such cure, not to exceed thirty (30)&nbsp;total days), Landlord may pursue any available remedies to it at law or in equity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.&nbsp;&nbsp;&nbsp;&nbsp;<U>Access to the Premises</U>. Notwithstanding anything to the contrary in the Lease, from and after the Effective
Date through the Effective Termination Date, Landlord and its </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
employees, agents, contractors, and representatives shall have the right to enter the Premises for any purpose, including, without limitation, to show the Premises to prospective tenants and to
permit inspection of the Premises by space planners, contractors and other parties in connection with improvements which may be constructed in the Premises. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.&nbsp;&nbsp;&nbsp;&nbsp;<U>Legal Fees and Expenses</U>. In the event of any action to enforce or interpret this Agreement, the <FONT
STYLE="white-space:nowrap">non-prevailing</FONT> party shall reimburse the prevailing party for all costs and expenses that the prevailing party may incur in connection with such action, including, but not necessarily limited to, the prevailing
party&#146;s reasonable attorneys&#146; fees and costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.&nbsp;&nbsp;&nbsp;&nbsp;<U>Complete Agreement; Disclaimer of Reliance</U>. This
Agreement contains the complete and entire agreement of the parties hereto and shall not be amended or modified in any way except by a written amendment signed by both Landlord and Tenant. Each party hereby acknowledges and confirms that it has not
relied upon any promises, warranties, or representations, which are not expressly set forth in this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.&nbsp;&nbsp;&nbsp;&nbsp;<U>Successors and Assignees</U>. This Agreement shall be binding upon, and inure to the benefit of, the respective
heirs, successors and assigns of Landlord and Tenant. Without limitation, in no event will this Agreement, or the rights and claims of Tenant hereunder, be assigned or transferred by Tenant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.&nbsp;&nbsp;&nbsp;&nbsp;<U>Severability</U>. In the event any provision of this Agreement shall be found to be invalid, that provision
shall be severed and the remaining provisions shall remain in full force and effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.&nbsp;&nbsp;&nbsp;&nbsp;<U>Time is of the
Essence</U>. Landlord and Tenant acknowledge and agree that time is of the essence with respect to all of the terms and conditions of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.&nbsp;&nbsp;&nbsp;&nbsp;<U>Governing Law</U>. This Agreement shall be governed in all respects by the laws of the State of Texas without
regard to choice of law principles. Any action to enforce the terms of this Agreement shall be brought exclusively in the state courts of the State of Texas. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.&nbsp;&nbsp;&nbsp;&nbsp;<U>Confidentiality</U>. Each party will keep the terms and conditions of this Agreement strictly confidential and
will not disclose any of said terms and conditions with any third-parties, without the prior consent of the party in each instance; provided, however, this provision shall not limit a party from making any disclosure that such party in good faith
determines it is legally obligated to make or from disclosing the terms and conditions of this Agreement to such party&#146;s directors, officers, shareholders, managers, members, attorneys&#146; accountants, or other professional advisors on a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;need-to-know&#148;</FONT></FONT> basis, provided the same are advised of the confidential nature of such terms and conditions. Tenant shall be liable for any disclosures made in
violation of this Section by Tenant or by any entity or individual to whom the terms of and conditions of this Agreement were disclosed or made available by Tenant; likewise, Landlord shall be liable for any disclosures made in violation of this
Section by Landlord or by any entity or individual to whom the terms of and conditions of this Agreement were disclosed or made available by Landlord. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15.&nbsp;&nbsp;&nbsp;&nbsp;<U>No Brokers</U>. Each of Landlord and Tenant represents and warrants to the other that it has not dealt with any
broker or agent in connection with this Agreement and that, to the best of its knowledge, no other broker negotiated this Agreement or is entitled to any fee or commission </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in connection herewith. Each of Landlord and Tenant shall indemnify, defend, protect and hold the other party harmless from and against any and all losses, liabilities, damages, claims,
judgments, fines, suits, demands, costs, interest and expenses of any kind or nature (including reasonable attorneys&#146; fees and disbursements)&nbsp;(a) arising out of or resulting from any breach of the covenants and obligations contained in
this <U>Section&nbsp;16</U>, or from any of the representations contained in this <U>Section&nbsp;16</U> being false, and/or (b)&nbsp;incurred in connection with any claim, proceeding or judgment and the defense thereof which the indemnified party
may incur by reason of any claim of or liability to any broker, finder or like agent arising out of any dealings which have occurred or are alleged or claimed to have occurred, between the indemnifying party and the claimant in connection with this
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16.&nbsp;&nbsp;&nbsp;&nbsp;<U>Authority</U>. Each party represents and warrants to the other that: (a)&nbsp;all necessary
respective corporate, trust and partnership actions on the part of each party to be taken in connection with the execution, delivery and performance of this Agreement have been duly and effectively taken; and (b)&nbsp;the execution, delivery and
performance by each party of this Agreement does not constitute a violation or breach of such party&#146;s respective charter documents, partnership documents, operating agreement or any other agreement or law by which such party is bound. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17.&nbsp;&nbsp;&nbsp;&nbsp;<U>Miscellaneous</U>. The submission of drafts of this document for examination and negotiation does not constitute
either an offer or the acceptance of an offer, and this Agreement shall not be binding upon the Landlord or the Tenant unless and until Landlord and Tenant shall both have executed and delivered this Agreement. This Agreement may be executed in any
number of counterparts, each of which shall be considered to be an original and all of which, when taken together, shall constitute one document. Each party acknowledges and represents that it has obtained, or has had the opportunity to obtain, the
advice of an attorney prior to signing this Agreement. Each party further represents that this Agreement is being executed voluntarily with full knowledge of its legal significance and with the express intention of the extinguishment of the rights
and claims of the parties under the Lease, in accordance with and subject to the terms and provisions hereof. Notwithstanding any provision contained in this Agreement to the contrary, the liability of the Landlord for its obligations under this
Agreement shall be limited to the interests of Landlord in the Building (and any proceeds therefrom). No partner, member, officer, trustee, manager, fiduciary, beneficiary, shareholder or director of Landlord or Tenant, nor any trust of which any
person holding Landlord&#146;s interest as trustee, nor any successor in interest to any of the foregoing shall ever be personally liable for any such judgment, or for the payment of any monetary obligation hereunder. Tenant and Landlord acknowledge
and agree that the benefits and rights received by each party under this Agreement are significant and granted by the other party in exchange for the various rights and benefits granted to the other party hereunder. Tenant and Landlord each
acknowledge that it has received full, fair and adequate consideration and reasonably equivalent value in return for its undertakings pursuant to this Agreement. The parties acknowledge and agree that this Agreement may be executed by electronic
signature, which shall be considered as an original signature for all purposes and shall have the same force and effect as an original signature. Without limitation, &#147;electronic signature&#148; shall include faxed versions of an original
signature or electronically scanned and transmitted versions (e.g., via pdf) of an original signature. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signatures on Following Page] </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties hereto have executed this Agreement as an instrument
under seal as of the day and year first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B><U>LANDLORD:</U></B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>LAS CIMAS OWNER LP</B>,</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">a
Delaware limited partnership</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Las Cimas Owner GP LLC, a Delaware limited liability company, its general partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="32"></TD>
<TD HEIGHT="32" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:<U> /s/ Joseph A. Goldman</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name: Joseph A. Goldman</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Its: Vice President</TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><U><B>TENANT</B>:</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>AEGLEA BIOTHERAPEUTICS, INC.,</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">a Delaware corporation</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="32"></TD>
<TD HEIGHT="32" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Jonathan Alspaugh</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name: Jonathan Alspaugh</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Its: President&nbsp;&amp; CFO</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT A</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>FORM OF BILL OF SALE</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>KNOW ALL MEN BY THESE PRESENTS</B>, that <B>AEGLEA BIOTHERAPEUTICS, </B><B>INC.</B>, a Delaware corporation (the
&#147;<B><U>Seller</U></B>&#148;), for and in consideration of the sum of Ten Dollars and other valuable consideration to it in hand paid by <B>LAS CIMAS OWNER LP</B>, a Delaware limited partnership (&#147;<B><U>Purchaser</U></B>&#148;), the receipt
and sufficiency of which are hereby acknowledged, hereby sells, assigns, transfers and conveys unto said Purchaser any and all of Seller&#146;s right, title and interest in and to all tangible personal property described on <U>Schedule 1</U>
attached hereto and hereby made a part hereof (the &#147;<B><U>Personal Property</U></B>&#148;), as is, where is, and without any warranty whatsoever, express or implied, including but not limited to warranty of title or use or warranty of
merchantability or fitness for a particular purpose.<B> </B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>TO HAVE AND TO HOLD</B> all of said personal property unto Purchaser, its
successors and assigns, to its own use forever. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[INTENTIONALLY LEFT BLANK &#150; SIGNATURE PAGE TO FOLLOW] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF, </B>Seller has executed this Bill of Sale as of the <U>7th</U> day of
<U>August</U>, 2023. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="98%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>SELLER</B>:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>AEGLEA&nbsp;BIOTHERAPEUTICS,&nbsp;INC.</B>,</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">a Delaware corporation</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="32"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:<U> /s/ Jonathan Alspaugh</U></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE &#147;1&#148; TO BILL OF SALE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PERSONAL PROPERTY </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Items</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Quantity</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Small&nbsp;Conference&nbsp;Table</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conference Table</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conference Chairs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Desks</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Small Desks</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Office Chairs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Guest Chairs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Monitors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Small Filing Cabinet</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cubicles</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Metal Shelves</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wine Chiller</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Refrigerator</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dining Chairs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Small Couch</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Padded Chair</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cabinets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reception Desk</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Walk-in</FONT> freezer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-3 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>31
<FILENAME>d518298dex211.htm
<DESCRIPTION>EX-21.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-21.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 21.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Subsidiaries of Aeglea BioTherapeutics, Inc. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Name of Subsidiary</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Jurisdiction</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Aeglea Development Company, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Delaware</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">AERase, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Delaware</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">AECase, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Delaware</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">AEMase, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Delaware</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">AE4ase, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Delaware</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">AE5ase, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Delaware</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">AE6ase, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Delaware</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Aeglea Biotherapeutics UK Limited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">England and Wales</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Aeglea Ireland Limited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ireland</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Aeglea BioTherapeutics US LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Delaware</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Spyre Therapeutics, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Delaware</P></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>32
<FILENAME>d518298dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We hereby consent to the use in this Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> of Spyre Therapeutics, Inc. of our report
dated March&nbsp;2, 2023, except for the effects of the reverse stock split discussed in Note 14 to the consolidated financial statements, as to which the date is November&nbsp;15, 2023, relating to the financial statements of Aeglea
BioTherapeutics, Inc., which appears in this Registration Statement. We also consent to the reference to us under the heading &#147;Experts&#148; in such Registration Statement. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">/s/ PricewaterhouseCoopers LLP</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Austin, Texas</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">December&nbsp;22, 2023</P></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>33
<FILENAME>d518298dex232.htm
<DESCRIPTION>EX-23.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We hereby consent to the use in this Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> of Spyre Therapeutics, Inc. of our report
dated October&nbsp;6, 2023 relating to the Statement of Assets Acquired and Liabilities Assumed from Spyre Therapeutics, Inc. by Aeglea BioTherapeutics, Inc., which appears in this Registration Statement. We also consent to the reference to us under
the heading &#147;Experts&#148; in such Registration Statement. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">/s/ PricewaterhouseCoopers LLP</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Austin, Texas</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">December&nbsp;22, 2023</P></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>34
<FILENAME>d518298dexfilingfees.htm
<DESCRIPTION>EX-FILING FEES
<TEXT>
<HTML><HEAD>
<TITLE>EX-FILING FEES</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 107 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Calculation of Filing Fee Tables </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT STYLE="white-space:nowrap">S-1</FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Form Type) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Spyre
Therapeutics, Inc. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Exact Name of Registrant as Specified in its Charter) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Table 1: Newly Registered and Carry Forward Securities </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="99%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="8%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="8%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="8%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"><B>Security<BR>Type</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"><B>Security<BR>Class<BR>Title</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"><B>Fee<BR>Calculation<BR>or Carry<BR>Forward<BR>Rule</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"><B>Amount<BR>Registered</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"><B>Proposed<BR>Maximum<BR>Offering<BR>Price Per<BR>Unit</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Maximum<BR>Aggregate<BR>Offering</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Price</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Fee</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Rate</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"><B>Amount of<BR>Registration<BR>Fee</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"><B>Carry<BR>Forward<BR>Form<BR>Type</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"><B>Carry<BR>Forward<BR>File<BR>Number</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"><B>Carry<BR>Forward<BR>Initial<BR>effective<BR>date</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; padding-right:2pt"><B>Filing Fee<BR>Previously<BR>PaidIn<BR>Connection<BR>with<BR>Unsold<BR>Securities<BR>to be<BR>Carried<BR>Forward</B></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="1" COLSPAN="25" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="25" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt; padding-right:2pt"><B>Newly Registered Securities</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-LEFT:1px solid #000000; padding-left:8pt">Fees to Be Paid</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">Equity</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">Common stock,<BR>par value<BR>$0.0001 per share<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">Rule 457(c)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">12,000,000 <SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">$15.14<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">$181,680,000<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">0.0001476</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">$26,815.97</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" COLSPAN="25" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="25" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt; padding-right:2pt"><B>Carry Forward Securities</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-LEFT:1px solid #000000; padding-left:8pt">Carry Forward Securities</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">N/A</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">N/A</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">N/A</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">N/A</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">N/A</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">N/A</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">N/A</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">N/A</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; padding-right:2pt">N/A</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" NOWRAP ALIGN="right" STYLE="padding-bottom:1pt ;"><B>Total Offering Amounts&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">$</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">$26,815.97</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" NOWRAP ALIGN="right" STYLE="padding-bottom:1pt ;"><B>Total Fees Previously Paid&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" NOWRAP ALIGN="right" STYLE="padding-bottom:1pt ;"><B>Total Fee Offsets&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" NOWRAP ALIGN="right" STYLE="padding-bottom:1pt ;BORDER-BOTTOM:1px solid #000000"><B>Net Fee Due&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-BOTTOM:1px solid #000000">$26,815.97</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Pursuant to Rule 416 under the Securities Act of 1933, as amended, this registration statement also covers such
an indeterminate amount of shares of common stock as may become issuable to prevent dilution resulting from stock splits, stock dividends and similar events. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amount registered consists of up to (i) 6,000,000 shares of Common Stock, and (ii) 6,000,000 shares of
Common Stock issuable upon the conversion of 150,000 shares of Series B Preferred Stock. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Estimated solely for the purpose of calculating the registration fee, based on the average of the high and low
prices of the shares of common stock on The Nasdaq Capital Market on December&nbsp;15, 2023 (such date being within five business days of the date that this registration statement was first filed with the Securities and Exchange Commission, in
accordance with Rule 457(c) under the Securities Act). </P></TD></TR></TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>35
<FILENAME>agle-20230930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 22-December-2023 [06:59:46] {PM}-->
<schema targetNamespace="http://www.spy.com/20230930" elementFormDefault="qualified" xmlns:agle="http://www.spy.com/20230930" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:srt="http://fasb.org/srt/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21">
<annotation>
<appinfo>
<link:roleType roleURI="http://www.spy.com/role/CoverPage" id="CoverPage">
<link:definition>1001 - Document -  Cover Page</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/CondensedConsolidatedBalanceSheets" id="CondensedConsolidatedBalanceSheets">
<link:definition>1002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/CondensedConsolidatedBalanceSheetsParenthetical" id="CondensedConsolidatedBalanceSheetsParenthetical">
<link:definition>1003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/CondensedConsolidatedStatementsOfOperations" id="CondensedConsolidatedStatementsOfOperations">
<link:definition>1004 - Statement - Condensed Consolidated Statements of Operations</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical" id="CondensedConsolidatedStatementsOfOperationsParenthetical">
<link:definition>1005 - Statement - Condensed Consolidated Statements of Operations (Parenthetical)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss" id="CondensedConsolidatedStatementsOfComprehensiveLoss">
<link:definition>1006 - Statement - Condensed Consolidated Statements of Comprehensive Loss</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/CondensedConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersDeficitEquity" id="CondensedConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersDeficitEquity">
<link:definition>1007 - Statement - Condensed Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders' (Deficit) Equity</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/CondensedConsolidatedStatementsOfCashFlows" id="CondensedConsolidatedStatementsOfCashFlows">
<link:definition>1008 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/StatementOfAssetsAcquiredAndLiabilitiesAssumed" id="StatementOfAssetsAcquiredAndLiabilitiesAssumed">
<link:definition>1009 - Statement - Statement of Assets Acquired and Liabilities Assumed</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/TheCompanyAndBasisOfPresentation" id="TheCompanyAndBasisOfPresentation">
<link:definition>1010 - Disclosure - The Company and Basis of Presentation</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
<link:definition>1011 - Disclosure - Summary of Significant Accounting Policies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/FairValueMeasurements" id="FairValueMeasurements">
<link:definition>1012 - Disclosure - Fair Value Measurements</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/CashEquivalentsAndMarketableSecurities" id="CashEquivalentsAndMarketableSecurities">
<link:definition>1013 - Disclosure - Cash Equivalents and Marketable Securities</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/PropertyAndEquipmentNet" id="PropertyAndEquipmentNet">
<link:definition>1014 - Disclosure - Property and Equipment, Net</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/AccruedAndOtherCurrentLiabilities" id="AccruedAndOtherCurrentLiabilities">
<link:definition>1015 - Disclosure - Accrued and Other Current Liabilities</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/Leases" id="Leases">
<link:definition>1016 - Disclosure - Leases</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/StockholdersEquity" id="StockholdersEquity">
<link:definition>1017 - Disclosure - Stockholders' Equity</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
<link:definition>1018 - Disclosure - Related Party Transactions</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/AssetAcquisition" id="AssetAcquisition">
<link:definition>1019 - Disclosure - Asset Acquisition</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/ParagonAgreement" id="ParagonAgreement">
<link:definition>1020 - Disclosure - Paragon Agreement</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/SeriesANonVotingConvertiblePreferredStock" id="SeriesANonVotingConvertiblePreferredStock">
<link:definition>1021 - Disclosure - Series A Non-Voting Convertible Preferred Stock</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquity" id="LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquity">
<link:definition>1022 - Disclosure - Liabilities, Convertible Preferred Stock and Stockholders' (Deficit) Equity</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/StrategicLicenseAgreements" id="StrategicLicenseAgreements">
<link:definition>1023 - Disclosure - Strategic License Agreements</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/SaleOfPegzilarginaseToImmedica" id="SaleOfPegzilarginaseToImmedica">
<link:definition>1024 - Disclosure - Sale of Pegzilarginase to Immedica</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/DefinedContributionPlan" id="DefinedContributionPlan">
<link:definition>1025 - Disclosure - Defined Contribution Plan</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/IncomeTaxes" id="IncomeTaxes">
<link:definition>1026 - Disclosure - Income Taxes</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/NetLossPerShare" id="NetLossPerShare">
<link:definition>1027 - Disclosure - Net Loss Per Share</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/RestructuringCharges" id="RestructuringCharges">
<link:definition>1028 - Disclosure - Restructuring Charges</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/NovationOfManufacturingAgreements" id="NovationOfManufacturingAgreements">
<link:definition>1029 - Disclosure - Novation of Manufacturing Agreements</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/ReverseStockSplit" id="ReverseStockSplit">
<link:definition>1030 - Disclosure - Reverse Stock Split</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPolicies" id="DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPolicies">
<link:definition>1031 - Disclosure - Description of the Business and Summary of Significant Accounting Policies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/AccruedLiabilities" id="AccruedLiabilities">
<link:definition>1032 - Disclosure - Accrued Liabilities</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/ParapyreOptionObligation" id="ParapyreOptionObligation">
<link:definition>1033 - Disclosure - Parapyre Option Obligation</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/SubsequentEvents" id="SubsequentEvents">
<link:definition>1034 - Disclosure - Subsequent Events</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesPolicies" id="DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesPolicies">
<link:definition>1035 - Disclosure - Description of the Business and Summary of Significant Accounting Policies (Policies)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesTables" id="DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesTables">
<link:definition>1036 - Disclosure - Description of the Business and Summary of Significant Accounting Policies (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
<link:definition>1037 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/AccruedLiabilitiesTables" id="AccruedLiabilitiesTables">
<link:definition>1038 - Disclosure - Accrued Liabilities (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/FairValueMeasurementTables" id="FairValueMeasurementTables">
<link:definition>1039 - Disclosure - Fair Value Measurement (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesTables" id="CashEquivalentsAndMarketableSecuritiesTables">
<link:definition>1040 - Disclosure - Cash Equivalents and Marketable Securities (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/PropertyAndEquipmentNetTables" id="PropertyAndEquipmentNetTables">
<link:definition>1041 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/AccruedAndOtherCurrentLiabilitiesTables" id="AccruedAndOtherCurrentLiabilitiesTables">
<link:definition>1042 - Disclosure - Accrued and Other Current Liabilities (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/LeasesTables" id="LeasesTables">
<link:definition>1043 - Disclosure - Leases (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/StockholdersEquityTables" id="StockholdersEquityTables">
<link:definition>1044 - Disclosure - Stockholders' Equity (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/RelatedPartyTransactionsTables" id="RelatedPartyTransactionsTables">
<link:definition>1045 - Disclosure - Related Party Transactions (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/AssetAcquisitionTables" id="AssetAcquisitionTables">
<link:definition>1046 - Disclosure - Asset Acquisition (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityTables" id="LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityTables">
<link:definition>1047 - Disclosure - Liabilities, Convertible Preferred Stock and Stockholders' (Deficit) Equity (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/StrategicLicenseAgreementsTables" id="StrategicLicenseAgreementsTables">
<link:definition>1048 - Disclosure - Strategic License Agreements (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
<link:definition>1049 - Disclosure - Income Taxes (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/NetLossPerShareTables" id="NetLossPerShareTables">
<link:definition>1050 - Disclosure - Net Loss Per Share (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/RestructuringChargesTables" id="RestructuringChargesTables">
<link:definition>1051 - Disclosure - Restructuring Charges (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/TheCompanyAndBasisOfPresentationNarrativeDetails" id="TheCompanyAndBasisOfPresentationNarrativeDetails">
<link:definition>1052 - Disclosure - The Company and Basis of Presentation - Narrative (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesSummaryOfAssetAcquisitionCostDetails" id="DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesSummaryOfAssetAcquisitionCostDetails">
<link:definition>1053 - Disclosure - Description of the Business and Summary of Significant Accounting Policies - Summary of Asset Acquisition Cost (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
<link:definition>1054 - Disclosure - Description of the Business and Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/AccruedLiabilitiesAccruedAndOtherCurrentLiabilitiesDetails" id="AccruedLiabilitiesAccruedAndOtherCurrentLiabilitiesDetails">
<link:definition>1055 - Disclosure - Accrued Liabilities - Accrued and Other Current Liabilities (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/AccruedLiabilitiesAdditionalInformationDetails" id="AccruedLiabilitiesAdditionalInformationDetails">
<link:definition>1056 - Disclosure - Accrued Liabilities - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/ParapyreOptionObligationAdditionalInformationDetails" id="ParapyreOptionObligationAdditionalInformationDetails">
<link:definition>1057 - Disclosure - Parapyre Option Obligation - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
<link:definition>1058 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfUsefulLivesOfPropertyAndEquipmentDetails" id="SummaryOfSignificantAccountingPoliciesSummaryOfUsefulLivesOfPropertyAndEquipmentDetails">
<link:definition>1059 - Disclosure - Summary of Significant Accounting Policies - Summary of Useful Lives of Property and Equipment (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" id="FairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails">
<link:definition>1060 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/FairValueMeasurementsNarrativeDetails" id="FairValueMeasurementsNarrativeDetails">
<link:definition>1061 - Disclosure - Fair Value Measurements - Narrative (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/FairValueMeasurementsChangesInDerivativeLiabilitiesDetails" id="FairValueMeasurementsChangesInDerivativeLiabilitiesDetails">
<link:definition>1062 - Disclosure - Fair Value Measurements - Changes in Derivative Liabilities (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/FairValueMeasurementsSignificantInputsUsedToEstimateTheFairValueOfDerivativeLiabilityDetails" id="FairValueMeasurementsSignificantInputsUsedToEstimateTheFairValueOfDerivativeLiabilityDetails">
<link:definition>1063 - Disclosure - Fair Value Measurements - Significant Inputs used to Estimate the Fair Value of Derivative Liability (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesEstimatedFairValueOfCashEquivalentsAndMarketableSecuritiesAndTheGrossUnrealizedGainsAndLossesDetails" id="CashEquivalentsAndMarketableSecuritiesEstimatedFairValueOfCashEquivalentsAndMarketableSecuritiesAndTheGrossUnrealizedGainsAndLossesDetails">
<link:definition>1064 - Disclosure - Cash Equivalents and Marketable Securities - Estimated Fair Value of Cash Equivalents and Marketable Securities and the Gross Unrealized Gains and Losses (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesAvailableForSaleSecuritiesInAnUnrealizedLossPositionDetails" id="CashEquivalentsAndMarketableSecuritiesAvailableForSaleSecuritiesInAnUnrealizedLossPositionDetails">
<link:definition>1065 - Disclosure - Cash Equivalents and Marketable Securities - Available-for-Sale Securities in an Unrealized Loss Position (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesNarrativeDetails" id="CashEquivalentsAndMarketableSecuritiesNarrativeDetails">
<link:definition>1066 - Disclosure - Cash Equivalents and Marketable Securities - Narrative (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesContractualMaturitiesOfMarketableSecuritiesAtEstimatedFairValueDetails" id="CashEquivalentsAndMarketableSecuritiesContractualMaturitiesOfMarketableSecuritiesAtEstimatedFairValueDetails">
<link:definition>1067 - Disclosure - Cash Equivalents and Marketable Securities - Contractual Maturities of Marketable Securities at Estimated Fair Value (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" id="PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails">
<link:definition>1068 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment Net (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/PropertyAndEquipmentNetAdditionalInformationDetails" id="PropertyAndEquipmentNetAdditionalInformationDetails">
<link:definition>1069 - Disclosure - Property and Equipment, Net - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/AccruedAndOtherCurrentLiabilitiesDetails" id="AccruedAndOtherCurrentLiabilitiesDetails">
<link:definition>1070 - Disclosure - Accrued and Other Current Liabilities (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/LeasesAdditionalInformationDetails" id="LeasesAdditionalInformationDetails">
<link:definition>1071 - Disclosure - Leases - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/LeasesScheduleOfOperatingAndFinancingLeasesPresentedInBalanceSheetDetails" id="LeasesScheduleOfOperatingAndFinancingLeasesPresentedInBalanceSheetDetails">
<link:definition>1072 - Disclosure - Leases - Schedule of Operating and Financing Leases Presented in Balance Sheet (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/LeasesSummaryOfWeightedAverageRemainingLeaseTermAndDiscountRatesForOperatingAndFinanceLeasesDetails" id="LeasesSummaryOfWeightedAverageRemainingLeaseTermAndDiscountRatesForOperatingAndFinanceLeasesDetails">
<link:definition>1073 - Disclosure - Leases - Summary of Weighted-Average Remaining Lease Term and Discount Rates for Operating and Finance Leases (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/LeasesSummaryOfLeaseCostDetails" id="LeasesSummaryOfLeaseCostDetails">
<link:definition>1074 - Disclosure - Leases - Summary of Lease Cost (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/LeasesScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails" id="LeasesScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails">
<link:definition>1075 - Disclosure - Leases - Schedule of Maturities of Operating and Finance Lease Liabilities (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/StockholdersEquityAdditionalInformationDetails" id="StockholdersEquityAdditionalInformationDetails">
<link:definition>1076 - Disclosure - Stockholders' Equity - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/StockholdersEquitySummaryOfPreFundedWarrantsForCommonStockIssuedAndOutstandingDetails" id="StockholdersEquitySummaryOfPreFundedWarrantsForCommonStockIssuedAndOutstandingDetails">
<link:definition>1077 - Disclosure - Stockholders' Equity - Summary of Pre-funded Warrants for Common Stock Issued and Outstanding (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/RelatedPartyTransactionsNarrativeDetails" id="RelatedPartyTransactionsNarrativeDetails">
<link:definition>1078 - Disclosure - Related Party Transactions - Narrative (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/RelatedPartyTransactionsExpensesRelatedToRelatedPartyWhichWereSettledInCashDetails" id="RelatedPartyTransactionsExpensesRelatedToRelatedPartyWhichWereSettledInCashDetails">
<link:definition>1079 - Disclosure - Related Party Transactions - Expenses related to Related Party which were Settled in Cash (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/RelatedPartyTransactionsRelatedPartyAccountsPayableDetails" id="RelatedPartyTransactionsRelatedPartyAccountsPayableDetails">
<link:definition>1080 - Disclosure - Related Party Transactions - Related Party Accounts Payable (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/AssetAcquisitionNarrativeDetails" id="AssetAcquisitionNarrativeDetails">
<link:definition>1081 - Disclosure - Asset Acquisition - Narrative (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/AssetAcquisitionAssetAcquisitionCostDetails" id="AssetAcquisitionAssetAcquisitionCostDetails">
<link:definition>1082 - Disclosure - Asset Acquisition - Asset Acquisition Cost (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/ParagonAgreementDetails" id="ParagonAgreementDetails">
<link:definition>1083 - Disclosure - Paragon Agreement (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/SeriesANonVotingConvertiblePreferredStockDetails" id="SeriesANonVotingConvertiblePreferredStockDetails">
<link:definition>1084 - Disclosure - Series A Non-Voting Convertible Preferred Stock (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityPreFundedWarrantsForCommonStockIssuedAndOutstandingDetails" id="LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityPreFundedWarrantsForCommonStockIssuedAndOutstandingDetails">
<link:definition>1085 - Disclosure - Liabilities, Convertible Preferred Stock and Stockholders' (Deficit) Equity - Pre-funded Warrants for Common Stock Issued and Outstanding (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityStockAwardsGrantedDetails" id="LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityStockAwardsGrantedDetails">
<link:definition>1086 - Disclosure - Liabilities, Convertible Preferred Stock and Stockholders' (Deficit) Equity - Stock Awards Granted (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails" id="LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails">
<link:definition>1087 - Disclosure - Liabilities, Convertible Preferred Stock and Stockholders' (Deficit) Equity - Narrative (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquitySummaryOfEmployeeAndNonEmployeeStockOptionActivityDetails" id="LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquitySummaryOfEmployeeAndNonEmployeeStockOptionActivityDetails">
<link:definition>1088 - Disclosure - Liabilities, Convertible Preferred Stock and Stockholders' (Deficit) Equity - Summary of Employee and Non-Employee Stock Option Activity (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquitySummaryOfEmployeeRestrictedStockActivityDetails" id="LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquitySummaryOfEmployeeRestrictedStockActivityDetails">
<link:definition>1089 - Disclosure - Liabilities, Convertible Preferred Stock and Stockholders' (Deficit) Equity - Summary of Employee Restricted Stock Activity (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityStockBasedCompensationExpenseDetails" id="LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityStockBasedCompensationExpenseDetails">
<link:definition>1090 - Disclosure - Liabilities, Convertible Preferred Stock and Stockholders' (Deficit) Equity - Stock-Based Compensation Expense (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityAssumptionsUsedToEstimateTheFairValueOfStockOptionsGrantedDetails" id="LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityAssumptionsUsedToEstimateTheFairValueOfStockOptionsGrantedDetails">
<link:definition>1091 - Disclosure - Liabilities, Convertible Preferred Stock and Stockholders' (Deficit) Equity - Assumptions used to Estimate the Fair Value of Stock Options Granted (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/StrategicLicenseAgreementsNarrativeDetails" id="StrategicLicenseAgreementsNarrativeDetails">
<link:definition>1092 - Disclosure - Strategic License Agreements - Narrative (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/StrategicLicenseAgreementsChangesInContractLiabilitiesDetails" id="StrategicLicenseAgreementsChangesInContractLiabilitiesDetails">
<link:definition>1093 - Disclosure - Strategic License Agreements - Changes in Contract Liabilities (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/SaleOfPegzilarginaseToImmedicaDetails" id="SaleOfPegzilarginaseToImmedicaDetails">
<link:definition>1094 - Disclosure - Sale of Pegzilarginase to Immedica (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/DefinedContributionPlanAdditionalInformationDetails" id="DefinedContributionPlanAdditionalInformationDetails">
<link:definition>1095 - Disclosure - Defined Contribution Plan - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/IncomeTaxesIncomeLossBeforeIncomeTaxExpenseByJurisdictionDetails" id="IncomeTaxesIncomeLossBeforeIncomeTaxExpenseByJurisdictionDetails">
<link:definition>1096 - Disclosure - Income Taxes - Income (Loss) Before Income Tax Expense by Jurisdiction (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/IncomeTaxesAdditionalInformationDetails" id="IncomeTaxesAdditionalInformationDetails">
<link:definition>1097 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/IncomeTaxesSummaryOfDifferenceBetweenProvisionForIncomeTaxesAndAmountsComputedByApplyingStatutoryFederalIncomeTaxRateToIncomeBeforeIncomeTaxesDetails" id="IncomeTaxesSummaryOfDifferenceBetweenProvisionForIncomeTaxesAndAmountsComputedByApplyingStatutoryFederalIncomeTaxRateToIncomeBeforeIncomeTaxesDetails">
<link:definition>1098 - Disclosure - Income Taxes - Summary of Difference Between Provision for Income Taxes and Amounts Computed by Applying Statutory Federal Income Tax Rate to Income Before Income Taxes (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" id="IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails">
<link:definition>1099 - Disclosure - Income Taxes - Components of Deferred Tax Assets and Liabilities (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/NetLossPerShareWeightedAverageEquityInstrumentsExcludedFromCalculationOfDilutedNetLossPerShareDetails" id="NetLossPerShareWeightedAverageEquityInstrumentsExcludedFromCalculationOfDilutedNetLossPerShareDetails">
<link:definition>1100 - Disclosure - Net Loss Per Share - Weighted-Average Equity Instruments Excluded from Calculation of Diluted Net Loss Per Share (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/NetLossPerShareScheduleOfReconciliationOfBasicAndDilutedNetLossPerShareDetails" id="NetLossPerShareScheduleOfReconciliationOfBasicAndDilutedNetLossPerShareDetails">
<link:definition>1101 - Disclosure - Net Loss Per Share - Schedule of Reconciliation of Basic and Diluted Net Loss Per Share (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/ReverseStockSplitAdditionalInformationDetails" id="ReverseStockSplitAdditionalInformationDetails">
<link:definition>1102 - Disclosure - Reverse Stock Split - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/RestructuringChargesNarrativeDetails" id="RestructuringChargesNarrativeDetails">
<link:definition>1103 - Disclosure - Restructuring Charges - Narrative (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/RestructuringChargesChangesInAccruedRestructuringBalanceDetails" id="RestructuringChargesChangesInAccruedRestructuringBalanceDetails">
<link:definition>1104 - Disclosure - Restructuring Charges - Changes in Accrued Restructuring Balance (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/RestructuringChargesChargesRelatedToTheRestructuringActivitiesDetails" id="RestructuringChargesChargesRelatedToTheRestructuringActivitiesDetails">
<link:definition>1105 - Disclosure - Restructuring Charges - Charges Related to the Restructuring Activities (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/SubsequentEventsAdditionalInformationDetails" id="SubsequentEventsAdditionalInformationDetails">
<link:definition>1106 - Disclosure - Subsequent Events - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/NovationOfManufacturingAgreementsDetails" id="NovationOfManufacturingAgreementsDetails">
<link:definition>1107 - Disclosure - Novation of Manufacturing Agreements (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/LeasesScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetailsAlternate1" id="LeasesScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetailsAlternate1">
<link:definition>1108 - Statement - Leases - Schedule of Maturities of Operating and Finance Lease Liabilities (Details) Alternate 1</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:linkbaseRef xlink:type="simple" xlink:href="agle-20230930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="agle-20230930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="agle-20230930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="agle-20230930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
</appinfo>
</annotation>
<import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
<import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
<import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
<import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
<import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
<import namespace="http://xbrl.sec.gov/currency/2023" schemaLocation="https://xbrl.sec.gov/currency/2023/currency-2023.xsd" />
<import namespace="http://xbrl.sec.gov/exch/2023" schemaLocation="https://xbrl.sec.gov/exch/2023/exch-2023.xsd" />
<import namespace="http://xbrl.sec.gov/naics/2023" schemaLocation="https://xbrl.sec.gov/naics/2023/naics-2023.xsd" />
<import namespace="http://xbrl.sec.gov/sic/2023" schemaLocation="https://xbrl.sec.gov/sic/2023/sic-2023.xsd" />
<import namespace="http://xbrl.sec.gov/stpr/2023" schemaLocation="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" />
<import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
<import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
<import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
<import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
<import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
<import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
<element name="SeriesANonVotingConvertiblePreferredStockMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="agle_SeriesANonVotingConvertiblePreferredStockMember" substitutionGroup="xbrli:item" />
<element name="AcquiredInProcessResearchAndDevelopment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="agle_AcquiredInProcessResearchAndDevelopment" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DevelopmentFeeMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="agle_DevelopmentFeeMember" substitutionGroup="xbrli:item" />
<element name="TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="agle_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" substitutionGroup="xbrli:item" />
<element name="TemporaryEquityFinancingCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="agle_TemporaryEquityFinancingCosts" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="agle_StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="StockIssuedDuringPeriodSharesOptionsExercisedAndEmployeeStockOwnershipPlan" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="agle_StockIssuedDuringPeriodSharesOptionsExercisedAndEmployeeStockOwnershipPlan" substitutionGroup="xbrli:item" />
<element name="StockIssuedDuringPeriodSharesCommonStockAndPreFundedWarrantsRegisteredDirectOffering" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="agle_StockIssuedDuringPeriodSharesCommonStockAndPreFundedWarrantsRegisteredDirectOffering" substitutionGroup="xbrli:item" />
<element name="StockIssuedDuringPeriodValueCommonStockAndPreFundedWarrantsRegisteredDirectOffering" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="agle_StockIssuedDuringPeriodValueCommonStockAndPreFundedWarrantsRegisteredDirectOffering" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ContingentValueRightDistributionToCommonStockholders" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="agle_ContingentValueRightDistributionToCommonStockholders" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="IssuanceOfCommonStockAndPreFundedWarrantsSharesInConnectionWithRegisteredDirectOfferingNetOfOfferingCosts" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="agle_IssuanceOfCommonStockAndPreFundedWarrantsSharesInConnectionWithRegisteredDirectOfferingNetOfOfferingCosts" substitutionGroup="xbrli:item" />
<element name="IssuanceOfCommonStockAndPreFundedWarrantsValueInConnectionWithRegisteredDirectOfferingNetOfOfferingCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="agle_IssuanceOfCommonStockAndPreFundedWarrantsValueInConnectionWithRegisteredDirectOfferingNetOfOfferingCosts" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="IssuanceOfCommonStockInConnectionWithExerciseOfPreFundedWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="agle_IssuanceOfCommonStockInConnectionWithExerciseOfPreFundedWarrants" substitutionGroup="xbrli:item" />
<element name="StockIssuedDuringPeriodSharesCommonStockAndPreFundedWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="agle_StockIssuedDuringPeriodSharesCommonStockAndPreFundedWarrants" substitutionGroup="xbrli:item" />
<element name="StockIssuedDuringPeriodValueCommonStockAndPreFundedWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="agle_StockIssuedDuringPeriodValueCommonStockAndPreFundedWarrants" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ContingentValueRightLiabilityMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="agle_ContingentValueRightLiabilityMember" substitutionGroup="xbrli:item" />
<element name="NonCashOperatingLeaseExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="agle_NonCashOperatingLeaseExpense" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PaymentForDiscountPremiumOnInvestmentsNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="agle_PaymentForDiscountPremiumOnInvestmentsNet" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="IncreaseDecreaseInOperatingLeaseLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="agle_IncreaseDecreaseInOperatingLeaseLiabilities" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfOfferingCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="agle_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfOfferingCosts" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="LeasedAssetsObtainedInExchangeForLeaseObligations" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="agle_LeasedAssetsObtainedInExchangeForLeaseObligations" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AccruedAndOtherCurrentLiabilitiesTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="agle_AccruedAndOtherCurrentLiabilitiesTextBlock" substitutionGroup="xbrli:item" />
<element name="LesseeOperatingAndFinanceLeasesDisclosureTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="agle_LesseeOperatingAndFinanceLeasesDisclosureTextBlock" substitutionGroup="xbrli:item" />
<element name="CollaborativeArrangementAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="agle_CollaborativeArrangementAbstract" substitutionGroup="xbrli:item" />
<element name="OptionAgreementTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="agle_OptionAgreementTextBlock" substitutionGroup="xbrli:item" />
<element name="LicenseAndCollaborationAgreementAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="agle_LicenseAndCollaborationAgreementAbstract" substitutionGroup="xbrli:item" />
<element name="StrategicLicenseAgreementTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="agle_StrategicLicenseAgreementTextBlock" substitutionGroup="xbrli:item" />
<element name="ReverseStockSplitTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="agle_ReverseStockSplitTextBlock" substitutionGroup="xbrli:item" />
<element name="DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="agle_DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAbstract" substitutionGroup="xbrli:item" />
<element name="AccruedLiabilitiesTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="agle_AccruedLiabilitiesTextBlock" substitutionGroup="xbrli:item" />
<element name="AccruedResearchAndDevelopmentExpensePolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="agle_AccruedResearchAndDevelopmentExpensePolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="AccruedLiabilitiesPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="agle_AccruedLiabilitiesPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="ConvertiblePreferredStockIssuedThroughPipePolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="agle_ConvertiblePreferredStockIssuedThroughPipePolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="agle_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" substitutionGroup="xbrli:item" />
<element name="ScheduleOfOperatingAndFinancingLeasesPresentedInBalanceSheetTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="agle_ScheduleOfOperatingAndFinancingLeasesPresentedInBalanceSheetTableTextBlock" substitutionGroup="xbrli:item" />
<element name="SummaryOfWeightedAverageRemainingLeaseTermAndDiscountRatesOfOperatingAndFinanceLeasesTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="agle_SummaryOfWeightedAverageRemainingLeaseTermAndDiscountRatesOfOperatingAndFinanceLeasesTableTextBlock" substitutionGroup="xbrli:item" />
<element name="ScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="agle_ScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesTableTextBlock" substitutionGroup="xbrli:item" />
<element name="ScheduleOfBalancesDueToAffiliatesTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="agle_ScheduleOfBalancesDueToAffiliatesTableTextBlock" substitutionGroup="xbrli:item" />
<element name="CompanyAndBasisOfPresentationTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="agle_CompanyAndBasisOfPresentationTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="Spyre2023EquityIncentivePlanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="agle_Spyre2023EquityIncentivePlanMember" substitutionGroup="xbrli:item" />
<element name="AssetAcquisitionMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="agle_AssetAcquisitionMember" substitutionGroup="xbrli:item" />
<element name="SpyreTherapeuticsIncMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="agle_SpyreTherapeuticsIncMember" substitutionGroup="xbrli:item" />
<element name="CompanyAndBasisOfPresentationLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="agle_CompanyAndBasisOfPresentationLineItems" substitutionGroup="xbrli:item" />
<element name="PlacementAgentAndOtherOfferingExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="agle_PlacementAgentAndOtherOfferingExpenses" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AssetAcquisitionStockholderPaymentPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="agle_AssetAcquisitionStockholderPaymentPeriod" substitutionGroup="xbrli:item" />
<element name="AssetAcquisitionCashPaymentThresholdPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="agle_AssetAcquisitionCashPaymentThresholdPeriod" substitutionGroup="xbrli:item" />
<element name="NumberOfEmployeesRetained" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="agle_NumberOfEmployeesRetained" substitutionGroup="xbrli:item" />
<element name="CashCashEquivalentsMarketableSecuritiesAndRestrictedCash" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="agle_CashCashEquivalentsMarketableSecuritiesAndRestrictedCash" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="WorkingCapital" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="agle_WorkingCapital" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="FixedExchangeRatio" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="agle_FixedExchangeRatio" substitutionGroup="xbrli:item" />
<element name="AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="agle_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares" substitutionGroup="xbrli:item" />
<element name="OutstandingAndUnexercisedStockOptions" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="agle_OutstandingAndUnexercisedStockOptions" substitutionGroup="xbrli:item" />
<element name="OrganizationConsolidationAndPresentationOfFinancialStatementsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="agle_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="agle_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" substitutionGroup="xbrli:item" />
<element name="AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableSharesOfCommonStockOnAnAsConvertedBasis" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="agle_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableSharesOfCommonStockOnAnAsConvertedBasis" substitutionGroup="xbrli:item" />
<element name="PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="agle_PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock" substitutionGroup="xbrli:item" />
<element name="AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="agle_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ParapyreOptionObligationMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="agle_ParapyreOptionObligationMember" substitutionGroup="xbrli:item" />
<element name="USBankingInstitutionMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="agle_USBankingInstitutionMember" substitutionGroup="xbrli:item" />
<element name="AccruedOptionCostPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="agle_AccruedOptionCostPayable" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AccruedLiabilitiesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="agle_AccruedLiabilitiesTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="AccruedLiabilitiesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="agle_AccruedLiabilitiesLineItems" substitutionGroup="xbrli:item" />
<element name="RelatedPartyExpensesIncurredPriorToAssetAcquisition" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="agle_RelatedPartyExpensesIncurredPriorToAssetAcquisition" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ResearchInitiationFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="agle_ResearchInitiationFees" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ReimbursableResearchCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="agle_ReimbursableResearchCosts" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="RelatedPartyExpensesUnpaidPriorToAssetAcquisition" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="agle_RelatedPartyExpensesUnpaidPriorToAssetAcquisition" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ParagonAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="agle_ParagonAgreementMember" substitutionGroup="xbrli:item" />
<element name="SummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="agle_SummaryOfSignificantAccountingPoliciesTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="SummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="agle_SummaryOfSignificantAccountingPoliciesLineItems" substitutionGroup="xbrli:item" />
<element name="MarketableSecuritiesMaturityPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="agle_MarketableSecuritiesMaturityPeriod" substitutionGroup="xbrli:item" />
<element name="NumberOfSubsidiaryCorporationsOwned" type="xbrli:integerItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="agle_NumberOfSubsidiaryCorporationsOwned" substitutionGroup="xbrli:item" />
<element name="LaboratoryEquipmentMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="agle_LaboratoryEquipmentMember" substitutionGroup="xbrli:item" />
<element name="PurchasedSoftwareMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="agle_PurchasedSoftwareMember" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodFairValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodFairValue" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="FairValueAssetsLevel1ToLevel2TransfersAmount1" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="agle_FairValueAssetsLevel1ToLevel2TransfersAmount1" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="MeasurementInputProabilityOfSuccessMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="agle_MeasurementInputProabilityOfSuccessMember" substitutionGroup="xbrli:item" />
<element name="CashEquivalentsUnrealizedGains" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="agle_CashEquivalentsUnrealizedGains" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="CashEquivalentsUnrealizedLosses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="agle_CashEquivalentsUnrealizedLosses" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="CashEquivalentsAndMarketableSecuritiesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="agle_CashEquivalentsAndMarketableSecuritiesTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="CashEquivalentsAndMarketableSecuritiesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="agle_CashEquivalentsAndMarketableSecuritiesLineItems" substitutionGroup="xbrli:item" />
<element name="ImpairmentOfMarketableSecurities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="agle_ImpairmentOfMarketableSecurities" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="NumberOfDomesticBankingInstitutions" type="xbrli:integerItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="agle_NumberOfDomesticBankingInstitutions" substitutionGroup="xbrli:item" />
<element name="DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="agle_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AccruedContractedResearchAndDevelopmentCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="agle_AccruedContractedResearchAndDevelopmentCosts" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ScheduleOfOperatingAndFinanceLeasedAssetsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="agle_ScheduleOfOperatingAndFinanceLeasedAssetsTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="ScheduleOfOperatingAndFinanceLeasedAssetsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="agle_ScheduleOfOperatingAndFinanceLeasedAssetsLineItems" substitutionGroup="xbrli:item" />
<element name="OperatingAndFinanceLeaseRightOfUseAsset" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="agle_OperatingAndFinanceLeaseRightOfUseAsset" substitutionGroup="xbrli:item" />
<element name="OperatingAndFinanceLeaseLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="agle_OperatingAndFinanceLeaseLiabilities" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="FollowOnPublicOfferingMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="agle_FollowOnPublicOfferingMember" substitutionGroup="xbrli:item" />
<element name="AtTheMarketSalesAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="agle_AtTheMarketSalesAgreementMember" substitutionGroup="xbrli:item" />
<element name="JonesTradingInstitutionalServicesLimitedLiabilityCompanyMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="agle_JonesTradingInstitutionalServicesLimitedLiabilityCompanyMember" substitutionGroup="xbrli:item" />
<element name="AggregateOfferingPriceOfCommonStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="agle_AggregateOfferingPriceOfCommonStock" substitutionGroup="xbrli:item" />
<element name="SharesAuthorized" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="agle_SharesAuthorized" substitutionGroup="xbrli:item" />
<element name="NumberOfCommonStockVotingRightsHeldPerShare" type="xbrli:integerItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="agle_NumberOfCommonStockVotingRightsHeldPerShare" substitutionGroup="xbrli:item" />
<element name="ClassOfWarrantOrRightOfferingPriceOfWarrantsOrRights" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="agle_ClassOfWarrantOrRightOfferingPriceOfWarrantsOrRights" substitutionGroup="xbrli:item" />
<element name="PlacementAgentFeesAndOfferingCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="agle_PlacementAgentFeesAndOfferingCosts" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="MaximumOwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercised" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="agle_MaximumOwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercised" substitutionGroup="xbrli:item" />
<element name="PeriodAfterNoticeReceivedByCompanyMaximumOwnershipPercentageToBeEffectiveDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="agle_PeriodAfterNoticeReceivedByCompanyMaximumOwnershipPercentageToBeEffectiveDescription" substitutionGroup="xbrli:item" />
<element name="OwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercisedToCertainHolders" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="agle_OwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercisedToCertainHolders" substitutionGroup="xbrli:item" />
<element name="ProceedsFromIssuanceOfCommonStockGross" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="agle_ProceedsFromIssuanceOfCommonStockGross" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="FebruaryTwoThousandNinteenMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="agle_FebruaryTwoThousandNinteenMember" substitutionGroup="xbrli:item" />
<element name="AprilTwoThousandTwentyMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="agle_AprilTwoThousandTwentyMember" substitutionGroup="xbrli:item" />
<element name="MayTwoThousandTwentyTwoMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="agle_MayTwoThousandTwentyTwoMember" substitutionGroup="xbrli:item" />
<element name="WarrantExpirationDate" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="agle_WarrantExpirationDate" substitutionGroup="xbrli:item" />
<element name="ParagonTherapeuticsIncMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="agle_ParagonTherapeuticsIncMember" substitutionGroup="xbrli:item" />
<element name="FairmountFundsManagementLlcMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="agle_FairmountFundsManagementLlcMember" substitutionGroup="xbrli:item" />
<element name="ParagonAndParapyreHoldingLlcMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="agle_ParagonAndParapyreHoldingLlcMember" substitutionGroup="xbrli:item" />
<element name="OwnershipInterestMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="agle_OwnershipInterestMember" substitutionGroup="xbrli:item" />
<element name="AppointOfBoardMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="agle_AppointOfBoardMember" substitutionGroup="xbrli:item" />
<element name="StockCompensationAndResearchAndDevelopmentExpenseMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="agle_StockCompensationAndResearchAndDevelopmentExpenseMember" substitutionGroup="xbrli:item" />
<element name="ReimbursableCostsUnderParagonAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="agle_ReimbursableCostsUnderParagonAgreementMember" substitutionGroup="xbrli:item" />
<element name="MilestonePaymentsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="agle_MilestonePaymentsMember" substitutionGroup="xbrli:item" />
<element name="Spy001LicenseAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="agle_Spy001LicenseAgreementMember" substitutionGroup="xbrli:item" />
<element name="RelatedPartyTransactionNumberOfBoardSeats" type="xbrli:integerItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="agle_RelatedPartyTransactionNumberOfBoardSeats" substitutionGroup="xbrli:item" />
<element name="MinorityInterestOwnershipPercentageByNoncontrollingOwnersHeldInThirdParty" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="agle_MinorityInterestOwnershipPercentageByNoncontrollingOwnersHeldInThirdParty" substitutionGroup="xbrli:item" />
<element name="RelatedPartyTransactionNumberOfProgramOptionsOutstanding" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="agle_RelatedPartyTransactionNumberOfProgramOptionsOutstanding" substitutionGroup="xbrli:item" />
<element name="AmountToBePaidUnderAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="agle_AmountToBePaidUnderAgreement" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="RelatedPartyTransactionReimbursableCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="agle_RelatedPartyTransactionReimbursableCosts" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AssumedLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="agle_AssumedLiabilities" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="LicenseAgreementMilestonePayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="agle_LicenseAgreementMilestonePayments" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="NonrefundableResearchInitiationFeeForOneProgramPaidInCash" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="agle_NonrefundableResearchInitiationFeeForOneProgramPaidInCash" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="NominationFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="agle_NominationFee" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PaymentOfMilestone" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="agle_PaymentOfMilestone" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PreferredStockRemainsIssuedAndOutstandingPercentage" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="agle_PreferredStockRemainsIssuedAndOutstandingPercentage" substitutionGroup="xbrli:item" />
<element name="BeneficiallyHoldersOwnedPercentage" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="agle_BeneficiallyHoldersOwnedPercentage" substitutionGroup="xbrli:item" />
<element name="FebruaryEightTwoThousandNinteenMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="agle_FebruaryEightTwoThousandNinteenMember" substitutionGroup="xbrli:item" />
<element name="AprilThirtyTwoThousandTwentyMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="agle_AprilThirtyTwoThousandTwentyMember" substitutionGroup="xbrli:item" />
<element name="MayTwentyTwoThousandTwentyTwoMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="agle_MayTwentyTwoThousandTwentyTwoMember" substitutionGroup="xbrli:item" />
<element name="NonQualifiedStockOptionsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="agle_NonQualifiedStockOptionsMember" substitutionGroup="xbrli:item" />
<element name="ServiceBasedAwardsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="agle_ServiceBasedAwardsMember" substitutionGroup="xbrli:item" />
<element name="EmployeesAndNonEmployeesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="agle_EmployeesAndNonEmployeesMember" substitutionGroup="xbrli:item" />
<element name="NewChiefExecutiveOfficerMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="agle_NewChiefExecutiveOfficerMember" substitutionGroup="xbrli:item" />
<element name="NonEmployeesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="agle_NonEmployeesMember" substitutionGroup="xbrli:item" />
<element name="GranteesWithMoreThanFiveYearsVestingTermPercent" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="agle_GranteesWithMoreThanFiveYearsVestingTermPercent" substitutionGroup="xbrli:item" />
<element name="MaximumVestingTermForMoreThanTenPercentGrantees" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="agle_MaximumVestingTermForMoreThanTenPercentGrantees" substitutionGroup="xbrli:item" />
<element name="IncreaseInCommonStockCapitalSharesReservedForFutureIssuance" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="agle_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance" substitutionGroup="xbrli:item" />
<element name="AnnualPercentageOfAdditionalSharesWhichEqualsToIssuedAndOutstandingShares" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="agle_AnnualPercentageOfAdditionalSharesWhichEqualsToIssuedAndOutstandingShares" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAnnualFairMarketValuePerEmployee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAnnualFairMarketValuePerEmployee" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalAnnualPercentageIncrease" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalAnnualPercentageIncrease" substitutionGroup="xbrli:item" />
<element name="OwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercised" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="agle_OwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercised" substitutionGroup="xbrli:item" />
<element name="ClassOfWarrantOrRightRevisedOwnershipPercentagePeriodToTakeEffectAfterNotice" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="agle_ClassOfWarrantOrRightRevisedOwnershipPercentagePeriodToTakeEffectAfterNotice" substitutionGroup="xbrli:item" />
<element name="StockOptionsGrantedToCertainMembersOfBoardOfDirectorsContingentOnStockholderApproval" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="agle_StockOptionsGrantedToCertainMembersOfBoardOfDirectorsContingentOnStockholderApproval" substitutionGroup="xbrli:item" />
<element name="StockBasedCompensationExpenseOnContingentAwards" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="agle_StockBasedCompensationExpenseOnContingentAwards" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodOfFirstTwentyFivePercent" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodOfFirstTwentyFivePercent" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodOfRemainingSeventyFivePercent" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodOfRemainingSeventyFivePercent" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsGrantedExercisablePeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="agle_ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsGrantedExercisablePeriod" substitutionGroup="xbrli:item" />
<element name="MaximumNumberOfSharesPurchasedUnderEmployeeStockPurchasePlan" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="agle_MaximumNumberOfSharesPurchasedUnderEmployeeStockPurchasePlan" substitutionGroup="xbrli:item" />
<element name="TwoThousandAndSixteenEquityIncentivePlanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="agle_TwoThousandAndSixteenEquityIncentivePlanMember" substitutionGroup="xbrli:item" />
<element name="TwoThousandAndEighteenEquityInducementPlanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="agle_TwoThousandAndEighteenEquityInducementPlanMember" substitutionGroup="xbrli:item" />
<element name="TwoThousandAndFifteenAndTwoThousandAndSixteenEquityIncentivePlanAndTwoThousandAndEighteenEquityInducementPlanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="agle_TwoThousandAndFifteenAndTwoThousandAndSixteenEquityIncentivePlanAndTwoThousandAndEighteenEquityInducementPlanMember" substitutionGroup="xbrli:item" />
<element name="TwoThousandAndSixteenEmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="agle_TwoThousandAndSixteenEmployeeStockPurchasePlanMember" substitutionGroup="xbrli:item" />
<element name="TwoThousandAndFifteenEquityIncentivePlanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="agle_TwoThousandAndFifteenEquityIncentivePlanMember" substitutionGroup="xbrli:item" />
<element name="EmployeesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="agle_EmployeesMember" substitutionGroup="xbrli:item" />
<element name="TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="agle_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember" substitutionGroup="xbrli:item" />
<element name="ImmedicaPharmaABMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="agle_ImmedicaPharmaABMember" substitutionGroup="xbrli:item" />
<element name="UniversityOfTexasAtAustinMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="agle_UniversityOfTexasAtAustinMember" substitutionGroup="xbrli:item" />
<element name="PeaceTrialAndBLAPackageMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="agle_PeaceTrialAndBLAPackageMember" substitutionGroup="xbrli:item" />
<element name="PIPTrialMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="agle_PIPTrialMember" substitutionGroup="xbrli:item" />
<element name="LicenseAgreementsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="agle_LicenseAgreementsMember" substitutionGroup="xbrli:item" />
<element name="PeacePhase3TrialAndDrugSupplyMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="agle_PeacePhase3TrialAndDrugSupplyMember" substitutionGroup="xbrli:item" />
<element name="NonRefundablePaymentReceived" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="agle_NonRefundablePaymentReceived" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PercentageOfPaymentForCostIncurredInPIPTrial" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="agle_PercentageOfPaymentForCostIncurredInPIPTrial" substitutionGroup="xbrli:item" />
<element name="CostsIncurredInPerformingTheTrial" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="agle_CostsIncurredInPerformingTheTrial" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="RateOfRevenueShare" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="agle_RateOfRevenueShare" substitutionGroup="xbrli:item" />
<element name="UpfrontPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="agle_UpfrontPayment" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ContractWithCustomerFullReimbursementOfCostsIncludedLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="agle_ContractWithCustomerFullReimbursementOfCostsIncludedLiability" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AllocatedAmountOfTransactionPrice" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="agle_AllocatedAmountOfTransactionPrice" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AllocationPriceTotal" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="agle_AllocationPriceTotal" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="LicenseAndSupplyAgreementDate" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="agle_LicenseAndSupplyAgreementDate" substitutionGroup="xbrli:item" />
<element name="MaximumFutureContingentLicensePayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="agle_MaximumFutureContingentLicensePayment" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="NumberOfLicenseAgreements" type="xbrli:integerItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="agle_NumberOfLicenseAgreements" substitutionGroup="xbrli:item" />
<element name="PaymentOfAnnualLicenseFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="agle_PaymentOfAnnualLicenseFees" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="MilestonePaymentsExchangeRate" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="agle_MilestonePaymentsExchangeRate" substitutionGroup="xbrli:item" />
<element name="ResearchAgreementDate" type="xbrli:gYearMonthItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="agle_ResearchAgreementDate" substitutionGroup="xbrli:item" />
<element name="AdditionalUpfrontPaymentAbilityToReceived" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="agle_AdditionalUpfrontPaymentAbilityToReceived" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AggregatePotentialMilestonePaymentsForFinalRegulatoryApprovalOfSecondIndication" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="agle_AggregatePotentialMilestonePaymentsForFinalRegulatoryApprovalOfSecondIndication" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AggregatePotentialMilestonePaymentsForReceiptOfRegulatoryApproval" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="agle_AggregatePotentialMilestonePaymentsForReceiptOfRegulatoryApproval" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ContractWithCustomerLiabilityAdditions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="agle_ContractWithCustomerLiabilityAdditions" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ContractWithCustomerLiabilityDeductionsThroughContractsAcquired" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="agle_ContractWithCustomerLiabilityDeductionsThroughContractsAcquired" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ContractWithCustomerLiabilityRevenueRecognizedIncludingAdditions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="agle_ContractWithCustomerLiabilityRevenueRecognizedIncludingAdditions" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="GlobalRightsToPegzilarginaseMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="agle_GlobalRightsToPegzilarginaseMember" substitutionGroup="xbrli:item" />
<element name="DisposalGroupIncludingDiscontinuedOperationContingentConsideration" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="agle_DisposalGroupIncludingDiscontinuedOperationContingentConsideration" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="IncomeTaxesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="agle_IncomeTaxesTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="IncomeTaxesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="agle_IncomeTaxesLineItems" substitutionGroup="xbrli:item" />
<element name="IncreaseInValuationPrimarilyDueToOperationLosses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="agle_IncreaseInValuationPrimarilyDueToOperationLosses" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="OperatingLossCarryforwardsExpirationYear" type="xbrli:gYearItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="agle_OperatingLossCarryforwardsExpirationYear" substitutionGroup="xbrli:item" />
<element name="TaxCreditCarryforwardExpirationYear" type="xbrli:gYearItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="agle_TaxCreditCarryforwardExpirationYear" substitutionGroup="xbrli:item" />
<element name="PercentageOfNetOperatingLossUtilizedToOffsetTaxableIncome" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="agle_PercentageOfNetOperatingLossUtilizedToOffsetTaxableIncome" substitutionGroup="xbrli:item" />
<element name="NetOperatingLossAndCreditCarryforwards" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="agle_NetOperatingLossAndCreditCarryforwards" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="IncomeTaxReconciliationTaxCostCredit" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="agle_IncomeTaxReconciliationTaxCostCredit" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="SeriesAConvertiblePreferredStockMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="agle_SeriesAConvertiblePreferredStockMember" substitutionGroup="xbrli:item" />
<element name="WeightedAverageNumberOfSharesPreFundedWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="agle_WeightedAverageNumberOfSharesPreFundedWarrants" substitutionGroup="xbrli:item" />
<element name="OperatingLeaseTerminationFeeAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="agle_OperatingLeaseTerminationFeeAmount" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="SeveranceLiabilityMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="agle_SeveranceLiabilityMember" substitutionGroup="xbrli:item" />
<element name="RestructuringActivitiesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="agle_RestructuringActivitiesMember" substitutionGroup="xbrli:item" />
<element name="OtherCommitmentRightToTerminateAgreementOrWorkOrderPriorWrittenNoticePeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="agle_OtherCommitmentRightToTerminateAgreementOrWorkOrderPriorWrittenNoticePeriod" substitutionGroup="xbrli:item" />
<element name="OtherCommitmentRightToTerminateWorkOrderReasonableCausePriorWrittenNoticePeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="agle_OtherCommitmentRightToTerminateWorkOrderReasonableCausePriorWrittenNoticePeriod" substitutionGroup="xbrli:item" />
<element name="OtherCommitmentRightToTerminateWorkOrderByCounterpartyReasonableCauseTerminationAmountPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="agle_OtherCommitmentRightToTerminateWorkOrderByCounterpartyReasonableCauseTerminationAmountPayable" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="OtherCommitmentRightToTerminateWorkOrderMaterialBreachUncuredPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="agle_OtherCommitmentRightToTerminateWorkOrderMaterialBreachUncuredPeriod" substitutionGroup="xbrli:item" />
<element name="OtherCommitmentRightToTerminateWorkOrderUnusualOrInfrequentCausePeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="agle_OtherCommitmentRightToTerminateWorkOrderUnusualOrInfrequentCausePeriod" substitutionGroup="xbrli:item" />
<element name="OtherCommitmentNonRefundableLicenseFeeAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="agle_OtherCommitmentNonRefundableLicenseFeeAmount" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="OtherCommitmentRoyaltyPercentage" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="agle_OtherCommitmentRoyaltyPercentage" substitutionGroup="xbrli:item" />
<element name="OtherCommitmentRightToTerminateAgreementPriorWrittenNoticePeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="agle_OtherCommitmentRightToTerminateAgreementPriorWrittenNoticePeriod" substitutionGroup="xbrli:item" />
<element name="OtherCommitmentRightToTerminateAgreementByCounterpartyMaterialBreachUncuredPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="agle_OtherCommitmentRightToTerminateAgreementByCounterpartyMaterialBreachUncuredPeriod" substitutionGroup="xbrli:item" />
<element name="OtherCommitmentRightToTerminateAgreementByCounterpartyPaymentsNotReceivedPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="agle_OtherCommitmentRightToTerminateAgreementByCounterpartyPaymentsNotReceivedPeriod" substitutionGroup="xbrli:item" />
<element name="DevelopmentFeeAndRoyaltyMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="agle_DevelopmentFeeAndRoyaltyMember" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>36
<FILENAME>agle-20230930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 22-December-2023 [06:59:46] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#CondensedConsolidatedBalanceSheets" roleURI="http://www.spy.com/role/CondensedConsolidatedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#CondensedConsolidatedStatementsOfOperations" roleURI="http://www.spy.com/role/CondensedConsolidatedStatementsOfOperations" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#CondensedConsolidatedStatementsOfComprehensiveLoss" roleURI="http://www.spy.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#CondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.spy.com/role/CondensedConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#StatementOfAssetsAcquiredAndLiabilitiesAssumed" roleURI="http://www.spy.com/role/StatementOfAssetsAcquiredAndLiabilitiesAssumed" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#AccruedLiabilitiesAccruedAndOtherCurrentLiabilitiesDetails" roleURI="http://www.spy.com/role/AccruedLiabilitiesAccruedAndOtherCurrentLiabilitiesDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#CashEquivalentsAndMarketableSecuritiesEstimatedFairValueOfCashEquivalentsAndMarketableSecuritiesAndTheGrossUnrealizedGainsAndLossesDetails" roleURI="http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesEstimatedFairValueOfCashEquivalentsAndMarketableSecuritiesAndTheGrossUnrealizedGainsAndLossesDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#CashEquivalentsAndMarketableSecuritiesAvailableForSaleSecuritiesInAnUnrealizedLossPositionDetails" roleURI="http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesAvailableForSaleSecuritiesInAnUnrealizedLossPositionDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#CashEquivalentsAndMarketableSecuritiesContractualMaturitiesOfMarketableSecuritiesAtEstimatedFairValueDetails" roleURI="http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesContractualMaturitiesOfMarketableSecuritiesAtEstimatedFairValueDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" roleURI="http://www.spy.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#AccruedAndOtherCurrentLiabilitiesDetails" roleURI="http://www.spy.com/role/AccruedAndOtherCurrentLiabilitiesDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#LeasesScheduleOfOperatingAndFinancingLeasesPresentedInBalanceSheetDetails" roleURI="http://www.spy.com/role/LeasesScheduleOfOperatingAndFinancingLeasesPresentedInBalanceSheetDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#LeasesSummaryOfLeaseCostDetails" roleURI="http://www.spy.com/role/LeasesSummaryOfLeaseCostDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#LeasesScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails" roleURI="http://www.spy.com/role/LeasesScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#IncomeTaxesIncomeLossBeforeIncomeTaxExpenseByJurisdictionDetails" roleURI="http://www.spy.com/role/IncomeTaxesIncomeLossBeforeIncomeTaxExpenseByJurisdictionDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#IncomeTaxesSummaryOfDifferenceBetweenProvisionForIncomeTaxesAndAmountsComputedByApplyingStatutoryFederalIncomeTaxRateToIncomeBeforeIncomeTaxesDetails" roleURI="http://www.spy.com/role/IncomeTaxesSummaryOfDifferenceBetweenProvisionForIncomeTaxesAndAmountsComputedByApplyingStatutoryFederalIncomeTaxRateToIncomeBeforeIncomeTaxesDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" roleURI="http://www.spy.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#RestructuringChargesChargesRelatedToTheRestructuringActivitiesDetails" roleURI="http://www.spy.com/role/RestructuringChargesChargesRelatedToTheRestructuringActivitiesDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#LeasesScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetailsAlternate1" roleURI="http://www.spy.com/role/LeasesScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetailsAlternate1" />
<calculationLink xlink:type="extended" xlink:role="http://www.spy.com/role/AccruedAndOtherCurrentLiabilitiesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="loc_us-gaap_AccruedSalariesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="loc_us-gaap_AccruedSalariesCurrent" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AccruedContractedResearchAndDevelopmentCosts" xlink:label="loc_AGLE_AccruedContractedResearchAndDevelopmentCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="loc_AGLE_AccruedContractedResearchAndDevelopmentCosts" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent" use="optional" order="4" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.spy.com/role/CondensedConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_AssetsCurrent" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NontradeReceivablesCurrent" xlink:label="loc_us-gaap_NontradeReceivablesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_NontradeReceivablesCurrent" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_RestrictedCashNoncurrent" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_OtherAssetsNoncurrent" use="optional" order="9" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.spy.com/role/CondensedConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_Liabilities" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_LiabilitiesCurrent" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableTradeCurrent" use="optional" order="12" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent" use="optional" order="13" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent" use="optional" order="14" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities" use="optional" order="15" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="loc_us-gaap_AccountsPayableOtherCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableOtherCurrent" use="optional" order="16" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_DeferredRevenueCurrent" use="optional" order="17" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent" use="optional" order="18" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" use="optional" order="19" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" use="optional" order="20" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent" use="optional" order="21" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_StockholdersEquity" use="optional" order="22" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_PreferredStockValue" use="optional" order="23" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_CommonStockValue" use="optional" order="24" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock" use="optional" order="25" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" use="optional" order="26" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit" use="optional" order="27" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" use="optional" order="28" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.spy.com/role/CondensedConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ProfitLoss" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ShareBasedCompensation" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AcquiredInProcessResearchAndDevelopment" xlink:label="loc_AGLE_AcquiredInProcessResearchAndDevelopment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_AGLE_AcquiredInProcessResearchAndDevelopment" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" use="optional" order="6" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" use="optional" order="7" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_AssetImpairmentCharges" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" use="optional" order="9" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" use="optional" order="11" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense" use="optional" order="12" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" use="optional" order="13" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade" use="optional" order="14" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" use="optional" order="15" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" use="optional" order="16" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" use="optional" order="17" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" use="optional" order="18" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayable" use="optional" order="19" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable" use="optional" order="20" weight="1" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_PaymentForDiscountPremiumOnInvestmentsNet" xlink:label="loc_AGLE_PaymentForDiscountPremiumOnInvestmentsNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_AGLE_PaymentForDiscountPremiumOnInvestmentsNet" use="optional" order="21" weight="-1" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_NonCashOperatingLeaseExpense" xlink:label="loc_AGLE_NonCashOperatingLeaseExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_AGLE_NonCashOperatingLeaseExpense" use="optional" order="22" weight="1" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:label="loc_AGLE_IncreaseDecreaseInOperatingLeaseLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_AGLE_IncreaseDecreaseInOperatingLeaseLiabilities" use="optional" order="23" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" use="optional" order="24" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_CashAcquiredFromAcquisition" use="optional" order="25" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:label="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets" use="optional" order="26" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" use="optional" order="27" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" use="optional" order="28" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" use="optional" order="29" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" use="optional" order="30" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" use="optional" order="31" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" use="optional" order="32" weight="1" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfOfferingCosts" xlink:label="loc_AGLE_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfOfferingCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_AGLE_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfOfferingCosts" use="optional" order="33" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" use="optional" order="34" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments" use="optional" order="35" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" use="optional" order="36" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.spy.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaap_NetIncomeLoss" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" use="optional" order="3" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.spy.com/role/CondensedConsolidatedStatementsOfOperations">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaap_OperatingIncomeLoss" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_OperatingExpenses" use="optional" order="3" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AcquiredInProcessResearchAndDevelopment" xlink:label="loc_AGLE_AcquiredInProcessResearchAndDevelopment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_AGLE_AcquiredInProcessResearchAndDevelopment" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" use="optional" order="7" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaap_NonoperatingIncomeExpense" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeNet" xlink:label="loc_us-gaap_InvestmentIncomeNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_InvestmentIncomeNet" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" use="optional" order="12" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense" use="optional" order="13" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit" use="optional" order="14" weight="-1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.spy.com/role/StatementOfAssetsAcquiredAndLiabilitiesAssumed">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" use="optional" order="4" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" use="optional" order="6" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.spy.com/role/AccruedLiabilitiesAccruedAndOtherCurrentLiabilitiesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AccruedOptionCostPayable" xlink:label="loc_AGLE_AccruedOptionCostPayable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="loc_AGLE_AccruedOptionCostPayable" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProgramRightsObligations" xlink:label="loc_us-gaap_ProgramRightsObligations" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="loc_us-gaap_ProgramRightsObligations" use="optional" order="3" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.spy.com/role/RestructuringChargesChargesRelatedToTheRestructuringActivitiesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCosts" xlink:label="loc_us-gaap_RestructuringCosts" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaap_SeveranceCosts1" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestructuringCosts" xlink:to="loc_us-gaap_SeveranceCosts1" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestructuringCosts" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestructuringCosts" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" use="optional" order="3" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestructuringCosts" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss" use="optional" order="4" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesEstimatedFairValueOfCashEquivalentsAndMarketableSecuritiesAndTheGrossUnrealizedGainsAndLossesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_CashEquivalentsUnrealizedGains" xlink:label="loc_AGLE_CashEquivalentsUnrealizedGains" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="loc_AGLE_CashEquivalentsUnrealizedGains" use="optional" order="1" weight="-1" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_CashEquivalentsUnrealizedLosses" xlink:label="loc_AGLE_CashEquivalentsUnrealizedLosses" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="loc_AGLE_CashEquivalentsUnrealizedLosses" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" use="optional" order="3" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.spy.com/role/IncomeTaxesIncomeLossBeforeIncomeTaxExpenseByJurisdictionDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" use="optional" order="2" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.spy.com/role/IncomeTaxesSummaryOfDifferenceBetweenProvisionForIncomeTaxesAndAmountsComputedByApplyingStatutoryFederalIncomeTaxRateToIncomeBeforeIncomeTaxesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_IncomeTaxReconciliationTaxCostCredit" xlink:label="loc_AGLE_IncomeTaxReconciliationTaxCostCredit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_AGLE_IncomeTaxReconciliationTaxCostCredit" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" use="optional" order="5" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.spy.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsOther" use="optional" order="7" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.spy.com/role/LeasesScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" use="optional" order="6" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.spy.com/role/LeasesScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiability" xlink:label="loc_us-gaap_FinanceLeaseLiability" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_FinanceLeaseLiability" use="optional" order="7" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.spy.com/role/LeasesScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetailsAlternate1">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_OperatingLeaseLiability" use="optional" order="9" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.spy.com/role/LeasesScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetailsAlternate1">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" use="optional" order="10" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.spy.com/role/LeasesSummaryOfLeaseCostDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaap_LeaseCost" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost" xlink:to="loc_us-gaap_OperatingLeaseCost" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaap_VariableLeaseCost" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost" xlink:to="loc_us-gaap_VariableLeaseCost" use="optional" order="2" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.spy.com/role/LeasesScheduleOfOperatingAndFinancingLeasesPresentedInBalanceSheetDetails">
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_OperatingAndFinanceLeaseRightOfUseAsset" xlink:label="loc_AGLE_OperatingAndFinanceLeaseRightOfUseAsset" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_AGLE_OperatingAndFinanceLeaseRightOfUseAsset" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_AGLE_OperatingAndFinanceLeaseRightOfUseAsset" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset" use="optional" order="2" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.spy.com/role/LeasesScheduleOfOperatingAndFinancingLeasesPresentedInBalanceSheetDetails">
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_OperatingAndFinanceLeaseLiabilities" xlink:label="loc_AGLE_OperatingAndFinanceLeaseLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_AGLE_OperatingAndFinanceLeaseLiabilities" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_AGLE_OperatingAndFinanceLeaseLiabilities" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_AGLE_OperatingAndFinanceLeaseLiabilities" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_AGLE_OperatingAndFinanceLeaseLiabilities" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent" use="optional" order="6" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.spy.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" use="optional" order="2" weight="-1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesContractualMaturitiesOfMarketableSecuritiesAtEstimatedFairValueDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne" xlink:label="loc_AGLE_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="loc_AGLE_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne" use="optional" order="2" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesAvailableForSaleSecuritiesInAnUnrealizedLossPositionDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" use="optional" order="2" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesAvailableForSaleSecuritiesInAnUnrealizedLossPositionDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" use="optional" order="4" weight="1" />
</calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>37
<FILENAME>agle-20230930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 22-December-2023 [06:59:46] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#CoverPage" roleURI="http://www.spy.com/role/CoverPage" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#CondensedConsolidatedBalanceSheets" roleURI="http://www.spy.com/role/CondensedConsolidatedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.spy.com/role/CondensedConsolidatedBalanceSheetsParenthetical" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#CondensedConsolidatedStatementsOfOperations" roleURI="http://www.spy.com/role/CondensedConsolidatedStatementsOfOperations" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#CondensedConsolidatedStatementsOfOperationsParenthetical" roleURI="http://www.spy.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#CondensedConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersDeficitEquity" roleURI="http://www.spy.com/role/CondensedConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersDeficitEquity" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#CondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.spy.com/role/CondensedConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#StatementOfAssetsAcquiredAndLiabilitiesAssumed" roleURI="http://www.spy.com/role/StatementOfAssetsAcquiredAndLiabilitiesAssumed" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#TheCompanyAndBasisOfPresentationNarrativeDetails" roleURI="http://www.spy.com/role/TheCompanyAndBasisOfPresentationNarrativeDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesSummaryOfAssetAcquisitionCostDetails" roleURI="http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesSummaryOfAssetAcquisitionCostDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" roleURI="http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#AccruedLiabilitiesAdditionalInformationDetails" roleURI="http://www.spy.com/role/AccruedLiabilitiesAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#ParapyreOptionObligationAdditionalInformationDetails" roleURI="http://www.spy.com/role/ParapyreOptionObligationAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" roleURI="http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfUsefulLivesOfPropertyAndEquipmentDetails" roleURI="http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfUsefulLivesOfPropertyAndEquipmentDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#FairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" roleURI="http://www.spy.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#FairValueMeasurementsNarrativeDetails" roleURI="http://www.spy.com/role/FairValueMeasurementsNarrativeDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#FairValueMeasurementsChangesInDerivativeLiabilitiesDetails" roleURI="http://www.spy.com/role/FairValueMeasurementsChangesInDerivativeLiabilitiesDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#FairValueMeasurementsSignificantInputsUsedToEstimateTheFairValueOfDerivativeLiabilityDetails" roleURI="http://www.spy.com/role/FairValueMeasurementsSignificantInputsUsedToEstimateTheFairValueOfDerivativeLiabilityDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#CashEquivalentsAndMarketableSecuritiesEstimatedFairValueOfCashEquivalentsAndMarketableSecuritiesAndTheGrossUnrealizedGainsAndLossesDetails" roleURI="http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesEstimatedFairValueOfCashEquivalentsAndMarketableSecuritiesAndTheGrossUnrealizedGainsAndLossesDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#CashEquivalentsAndMarketableSecuritiesAvailableForSaleSecuritiesInAnUnrealizedLossPositionDetails" roleURI="http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesAvailableForSaleSecuritiesInAnUnrealizedLossPositionDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#CashEquivalentsAndMarketableSecuritiesNarrativeDetails" roleURI="http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesNarrativeDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" roleURI="http://www.spy.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#PropertyAndEquipmentNetAdditionalInformationDetails" roleURI="http://www.spy.com/role/PropertyAndEquipmentNetAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#LeasesAdditionalInformationDetails" roleURI="http://www.spy.com/role/LeasesAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#StockholdersEquityAdditionalInformationDetails" roleURI="http://www.spy.com/role/StockholdersEquityAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#StockholdersEquitySummaryOfPreFundedWarrantsForCommonStockIssuedAndOutstandingDetails" roleURI="http://www.spy.com/role/StockholdersEquitySummaryOfPreFundedWarrantsForCommonStockIssuedAndOutstandingDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#RelatedPartyTransactionsNarrativeDetails" roleURI="http://www.spy.com/role/RelatedPartyTransactionsNarrativeDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#RelatedPartyTransactionsExpensesRelatedToRelatedPartyWhichWereSettledInCashDetails" roleURI="http://www.spy.com/role/RelatedPartyTransactionsExpensesRelatedToRelatedPartyWhichWereSettledInCashDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#RelatedPartyTransactionsRelatedPartyAccountsPayableDetails" roleURI="http://www.spy.com/role/RelatedPartyTransactionsRelatedPartyAccountsPayableDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#AssetAcquisitionNarrativeDetails" roleURI="http://www.spy.com/role/AssetAcquisitionNarrativeDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#AssetAcquisitionAssetAcquisitionCostDetails" roleURI="http://www.spy.com/role/AssetAcquisitionAssetAcquisitionCostDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#ParagonAgreementDetails" roleURI="http://www.spy.com/role/ParagonAgreementDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#SeriesANonVotingConvertiblePreferredStockDetails" roleURI="http://www.spy.com/role/SeriesANonVotingConvertiblePreferredStockDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityPreFundedWarrantsForCommonStockIssuedAndOutstandingDetails" roleURI="http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityPreFundedWarrantsForCommonStockIssuedAndOutstandingDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails" roleURI="http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquitySummaryOfEmployeeRestrictedStockActivityDetails" roleURI="http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquitySummaryOfEmployeeRestrictedStockActivityDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityStockBasedCompensationExpenseDetails" roleURI="http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityStockBasedCompensationExpenseDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityAssumptionsUsedToEstimateTheFairValueOfStockOptionsGrantedDetails" roleURI="http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityAssumptionsUsedToEstimateTheFairValueOfStockOptionsGrantedDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#StrategicLicenseAgreementsNarrativeDetails" roleURI="http://www.spy.com/role/StrategicLicenseAgreementsNarrativeDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#SaleOfPegzilarginaseToImmedicaDetails" roleURI="http://www.spy.com/role/SaleOfPegzilarginaseToImmedicaDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#IncomeTaxesAdditionalInformationDetails" roleURI="http://www.spy.com/role/IncomeTaxesAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#IncomeTaxesSummaryOfDifferenceBetweenProvisionForIncomeTaxesAndAmountsComputedByApplyingStatutoryFederalIncomeTaxRateToIncomeBeforeIncomeTaxesDetails" roleURI="http://www.spy.com/role/IncomeTaxesSummaryOfDifferenceBetweenProvisionForIncomeTaxesAndAmountsComputedByApplyingStatutoryFederalIncomeTaxRateToIncomeBeforeIncomeTaxesDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" roleURI="http://www.spy.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#NetLossPerShareWeightedAverageEquityInstrumentsExcludedFromCalculationOfDilutedNetLossPerShareDetails" roleURI="http://www.spy.com/role/NetLossPerShareWeightedAverageEquityInstrumentsExcludedFromCalculationOfDilutedNetLossPerShareDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#ReverseStockSplitAdditionalInformationDetails" roleURI="http://www.spy.com/role/ReverseStockSplitAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#RestructuringChargesNarrativeDetails" roleURI="http://www.spy.com/role/RestructuringChargesNarrativeDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#RestructuringChargesChangesInAccruedRestructuringBalanceDetails" roleURI="http://www.spy.com/role/RestructuringChargesChangesInAccruedRestructuringBalanceDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#RestructuringChargesChargesRelatedToTheRestructuringActivitiesDetails" roleURI="http://www.spy.com/role/RestructuringChargesChargesRelatedToTheRestructuringActivitiesDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#SubsequentEventsAdditionalInformationDetails" roleURI="http://www.spy.com/role/SubsequentEventsAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#LeasesScheduleOfOperatingAndFinancingLeasesPresentedInBalanceSheetDetails" roleURI="http://www.spy.com/role/LeasesScheduleOfOperatingAndFinancingLeasesPresentedInBalanceSheetDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityTables" roleURI="http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityTables" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#StockholdersEquityTables" roleURI="http://www.spy.com/role/StockholdersEquityTables" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#LeasesScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails" roleURI="http://www.spy.com/role/LeasesScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#PropertyAndEquipmentNetTables" roleURI="http://www.spy.com/role/PropertyAndEquipmentNetTables" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#StockholdersEquity" roleURI="http://www.spy.com/role/StockholdersEquity" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#SummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesTables" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#IncomeTaxesIncomeLossBeforeIncomeTaxExpenseByJurisdictionDetails" roleURI="http://www.spy.com/role/IncomeTaxesIncomeLossBeforeIncomeTaxExpenseByJurisdictionDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#NetLossPerShareScheduleOfReconciliationOfBasicAndDilutedNetLossPerShareDetails" roleURI="http://www.spy.com/role/NetLossPerShareScheduleOfReconciliationOfBasicAndDilutedNetLossPerShareDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#LeasesSummaryOfLeaseCostDetails" roleURI="http://www.spy.com/role/LeasesSummaryOfLeaseCostDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#DefinedContributionPlan" roleURI="http://www.spy.com/role/DefinedContributionPlan" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#IncomeTaxesTables" roleURI="http://www.spy.com/role/IncomeTaxesTables" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#DefinedContributionPlanAdditionalInformationDetails" roleURI="http://www.spy.com/role/DefinedContributionPlanAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#IncomeTaxes" roleURI="http://www.spy.com/role/IncomeTaxes" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#Leases" roleURI="http://www.spy.com/role/Leases" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#LeasesTables" roleURI="http://www.spy.com/role/LeasesTables" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#LeasesSummaryOfWeightedAverageRemainingLeaseTermAndDiscountRatesForOperatingAndFinanceLeasesDetails" roleURI="http://www.spy.com/role/LeasesSummaryOfWeightedAverageRemainingLeaseTermAndDiscountRatesForOperatingAndFinanceLeasesDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#PropertyAndEquipmentNet" roleURI="http://www.spy.com/role/PropertyAndEquipmentNet" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquitySummaryOfEmployeeAndNonEmployeeStockOptionActivityDetails" roleURI="http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquitySummaryOfEmployeeAndNonEmployeeStockOptionActivityDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#NovationOfManufacturingAgreementsDetails" roleURI="http://www.spy.com/role/NovationOfManufacturingAgreementsDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityStockAwardsGrantedDetails" roleURI="http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityStockAwardsGrantedDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#StrategicLicenseAgreementsChangesInContractLiabilitiesDetails" roleURI="http://www.spy.com/role/StrategicLicenseAgreementsChangesInContractLiabilitiesDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#CashEquivalentsAndMarketableSecuritiesContractualMaturitiesOfMarketableSecuritiesAtEstimatedFairValueDetails" roleURI="http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesContractualMaturitiesOfMarketableSecuritiesAtEstimatedFairValueDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#AccruedAndOtherCurrentLiabilitiesDetails" roleURI="http://www.spy.com/role/AccruedAndOtherCurrentLiabilitiesDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#TheCompanyAndBasisOfPresentation" roleURI="http://www.spy.com/role/TheCompanyAndBasisOfPresentation" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://www.spy.com/role/SummaryOfSignificantAccountingPolicies" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#FairValueMeasurements" roleURI="http://www.spy.com/role/FairValueMeasurements" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#CashEquivalentsAndMarketableSecurities" roleURI="http://www.spy.com/role/CashEquivalentsAndMarketableSecurities" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#AccruedAndOtherCurrentLiabilities" roleURI="http://www.spy.com/role/AccruedAndOtherCurrentLiabilities" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#RelatedPartyTransactions" roleURI="http://www.spy.com/role/RelatedPartyTransactions" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#AssetAcquisition" roleURI="http://www.spy.com/role/AssetAcquisition" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#ParagonAgreement" roleURI="http://www.spy.com/role/ParagonAgreement" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#SeriesANonVotingConvertiblePreferredStock" roleURI="http://www.spy.com/role/SeriesANonVotingConvertiblePreferredStock" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquity" roleURI="http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquity" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#StrategicLicenseAgreements" roleURI="http://www.spy.com/role/StrategicLicenseAgreements" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#SaleOfPegzilarginaseToImmedica" roleURI="http://www.spy.com/role/SaleOfPegzilarginaseToImmedica" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#NetLossPerShare" roleURI="http://www.spy.com/role/NetLossPerShare" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#RestructuringCharges" roleURI="http://www.spy.com/role/RestructuringCharges" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#NovationOfManufacturingAgreements" roleURI="http://www.spy.com/role/NovationOfManufacturingAgreements" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesPolicies" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#FairValueMeasurementTables" roleURI="http://www.spy.com/role/FairValueMeasurementTables" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#CashEquivalentsAndMarketableSecuritiesTables" roleURI="http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesTables" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#AccruedAndOtherCurrentLiabilitiesTables" roleURI="http://www.spy.com/role/AccruedAndOtherCurrentLiabilitiesTables" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#RelatedPartyTransactionsTables" roleURI="http://www.spy.com/role/RelatedPartyTransactionsTables" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#AssetAcquisitionTables" roleURI="http://www.spy.com/role/AssetAcquisitionTables" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#StrategicLicenseAgreementsTables" roleURI="http://www.spy.com/role/StrategicLicenseAgreementsTables" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#NetLossPerShareTables" roleURI="http://www.spy.com/role/NetLossPerShareTables" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#RestructuringChargesTables" roleURI="http://www.spy.com/role/RestructuringChargesTables" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#CondensedConsolidatedStatementsOfComprehensiveLoss" roleURI="http://www.spy.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPolicies" roleURI="http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPolicies" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesTables" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#ParapyreOptionObligation" roleURI="http://www.spy.com/role/ParapyreOptionObligation" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#SubsequentEvents" roleURI="http://www.spy.com/role/SubsequentEvents" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#ReverseStockSplit" roleURI="http://www.spy.com/role/ReverseStockSplit" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#AccruedLiabilities" roleURI="http://www.spy.com/role/AccruedLiabilities" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#AccruedLiabilitiesTables" roleURI="http://www.spy.com/role/AccruedLiabilitiesTables" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#AccruedLiabilitiesAccruedAndOtherCurrentLiabilitiesDetails" roleURI="http://www.spy.com/role/AccruedLiabilitiesAccruedAndOtherCurrentLiabilitiesDetails" />
<roleRef xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd#eedm" roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" />
<definitionLink xlink:type="extended" xlink:role="http://www.spy.com/role/CoverPage">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems_1923" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_102" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1923" xlink:to="loc_dei_DocumentType_102" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_107" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1923" xlink:to="loc_dei_EntityRegistrantName_107" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_108" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1923" xlink:to="loc_dei_EntityIncorporationStateCountryCode_108" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_109" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1923" xlink:to="loc_dei_EntityTaxIdentificationNumber_109" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_110" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1923" xlink:to="loc_dei_EntityAddressAddressLine1_110" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_dei_EntityAddressAddressLine2_111" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1923" xlink:to="loc_dei_EntityAddressAddressLine2_111" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_dei_EntityAddressAddressLine3_112" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1923" xlink:to="loc_dei_EntityAddressAddressLine3_112" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_113" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1923" xlink:to="loc_dei_EntityAddressCityOrTown_113" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_114" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1923" xlink:to="loc_dei_EntityAddressStateOrProvince_114" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_115" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1923" xlink:to="loc_dei_EntityAddressPostalZipCode_115" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_116" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1923" xlink:to="loc_dei_CityAreaCode_116" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_117" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1923" xlink:to="loc_dei_LocalPhoneNumber_117" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_123" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1923" xlink:to="loc_dei_EntityFilerCategory_123" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_124" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1923" xlink:to="loc_dei_EntitySmallBusiness_124" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_125" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1923" xlink:to="loc_dei_EntityEmergingGrowthCompany_125" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_128" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1923" xlink:to="loc_dei_EntityCentralIndexKey_128" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_130" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1923" xlink:to="loc_dei_AmendmentFlag_130" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable_1918" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_1923" xlink:to="loc_dei_DocumentInformationTable_1918" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_1919" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_1918" xlink:to="loc_dei_EntityAddressesAddressTypeAxis_1919" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain_1920" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_1919" xlink:to="loc_dei_AddressTypeDomain_1920" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain_1920_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_1919" xlink:to="loc_dei_AddressTypeDomain_1920_default" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_BusinessContactMember" xlink:label="loc_dei_BusinessContactMember_1921" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_AddressTypeDomain_1920" xlink:to="loc_dei_BusinessContactMember_1921" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ContactPersonnelName" xlink:label="loc_dei_ContactPersonnelName_1925" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1923" xlink:to="loc_dei_ContactPersonnelName_1925" use="optional" order="23" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.spy.com/role/CondensedConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1841" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_135" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1841" xlink:to="loc_us-gaap_StatementTable_135" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_136" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_135" xlink:to="loc_us-gaap_StatementClassOfStockAxis_136" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_137" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_136" xlink:to="loc_us-gaap_ClassOfStockDomain_137" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_137_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_136" xlink:to="loc_us-gaap_ClassOfStockDomain_137_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_SeriesANonVotingConvertiblePreferredStockMember" xlink:label="loc_agle_SeriesANonVotingConvertiblePreferredStockMember_138" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_137" xlink:to="loc_agle_SeriesANonVotingConvertiblePreferredStockMember_138" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_140" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1841" xlink:to="loc_us-gaap_AssetsAbstract_140" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_141" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_140" xlink:to="loc_us-gaap_AssetsCurrentAbstract_141" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_142" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_141" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_142" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_143" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_141" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_143" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NontradeReceivablesCurrent" xlink:label="loc_us-gaap_NontradeReceivablesCurrent_144" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_141" xlink:to="loc_us-gaap_NontradeReceivablesCurrent_144" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_145" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_141" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_145" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_146" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_141" xlink:to="loc_us-gaap_AssetsCurrent_146" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_147" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_140" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_147" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_148" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_140" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_148" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_149" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_140" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_149" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_150" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_140" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_150" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_151" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_140" xlink:to="loc_us-gaap_Assets_151" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_152" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1841" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_152" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_153" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_152" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_153" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent_154" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_153" xlink:to="loc_us-gaap_AccountsPayableTradeCurrent_154" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_155" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_153" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_155" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_156" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_153" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_156" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_158" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_153" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_158" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="loc_us-gaap_AccountsPayableOtherCurrent_159" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_153" xlink:to="loc_us-gaap_AccountsPayableOtherCurrent_159" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_160" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_153" xlink:to="loc_us-gaap_LiabilitiesCurrent_160" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_1520" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_153" xlink:to="loc_us-gaap_DeferredRevenueCurrent_1520" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_161" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_152" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_161" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_162" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_152" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_162" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_163" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_152" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_163" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_164" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_152" xlink:to="loc_us-gaap_Liabilities_164" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_165" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_152" xlink:to="loc_us-gaap_CommitmentsAndContingencies_165" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_166" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_152" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_166" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_167" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_152" xlink:to="loc_us-gaap_StockholdersEquityAbstract_167" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_168" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_167" xlink:to="loc_us-gaap_PreferredStockValue_168" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_169" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_167" xlink:to="loc_us-gaap_CommonStockValue_169" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_170" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_167" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_170" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_171" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_167" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_171" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_172" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_167" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_172" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_173" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_167" xlink:to="loc_us-gaap_StockholdersEquity_173" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_174" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_152" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_174" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_1553" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_152" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_1553" use="optional" order="41" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.spy.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_181" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_182" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_181" xlink:to="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_182" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_183" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_181" xlink:to="loc_us-gaap_TemporaryEquitySharesAuthorized_183" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_184" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_181" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_184" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_185" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_181" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_185" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_186" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_181" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_186" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_187" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_181" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_187" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_188" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_181" xlink:to="loc_us-gaap_PreferredStockSharesIssued_188" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_189" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_181" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_189" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_190" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_181" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_190" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_191" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_181" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_191" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_192" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_181" xlink:to="loc_us-gaap_CommonStockSharesIssued_192" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_193" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_181" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_193" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_177" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_181" xlink:to="loc_us-gaap_StatementTable_177" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_178" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_177" xlink:to="loc_us-gaap_StatementClassOfStockAxis_178" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_179" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_178" xlink:to="loc_us-gaap_ClassOfStockDomain_179" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_179_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_178" xlink:to="loc_us-gaap_ClassOfStockDomain_179_default" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_SeriesANonVotingConvertiblePreferredStockMember" xlink:label="loc_agle_SeriesANonVotingConvertiblePreferredStockMember_180" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_179" xlink:to="loc_agle_SeriesANonVotingConvertiblePreferredStockMember_180" use="optional" order="17" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.spy.com/role/CondensedConsolidatedStatementsOfOperations">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_200" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_196" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_200" xlink:to="loc_us-gaap_StatementTable_196" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_197" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_196" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_197" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_198" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_197" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_198" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_198_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_197" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_198_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForwardContractsMember" xlink:label="loc_us-gaap_ForwardContractsMember_199" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_198" xlink:to="loc_us-gaap_ForwardContractsMember_199" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_1150" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_196" xlink:to="loc_srt_ProductOrServiceAxis_1150" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_1151" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_1150" xlink:to="loc_srt_ProductsAndServicesDomain_1151" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_1151_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_1150" xlink:to="loc_srt_ProductsAndServicesDomain_1151_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_DevelopmentFeeMember" xlink:label="loc_agle_DevelopmentFeeMember_1424" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1151" xlink:to="loc_agle_DevelopmentFeeMember_1424" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaap_LicenseMember_1157" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1151" xlink:to="loc_us-gaap_LicenseMember_1157" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_201" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_200" xlink:to="loc_us-gaap_RevenuesAbstract_201" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_202" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_201" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_202" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_203" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_201" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_203" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_204" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_200" xlink:to="loc_us-gaap_OperatingExpensesAbstract_204" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_205" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_204" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_205" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_206" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_204" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_206" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AcquiredInProcessResearchAndDevelopment" xlink:label="loc_agle_AcquiredInProcessResearchAndDevelopment_207" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_204" xlink:to="loc_agle_AcquiredInProcessResearchAndDevelopment_207" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_208" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_204" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_208" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_209" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_204" xlink:to="loc_us-gaap_OperatingExpenses_209" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_1153" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_204" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_1153" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_210" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_200" xlink:to="loc_us-gaap_OperatingIncomeLoss_210" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_211" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_200" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_211" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeNet" xlink:label="loc_us-gaap_InvestmentIncomeNet_212" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_211" xlink:to="loc_us-gaap_InvestmentIncomeNet_212" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_213" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_211" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_213" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_214" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_211" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_214" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_215" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_211" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_215" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_216" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_200" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_216" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_217" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_200" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_217" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_218" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_200" xlink:to="loc_us-gaap_NetIncomeLoss_218" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_219" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_200" xlink:to="loc_us-gaap_EarningsPerShareBasic_219" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_220" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_200" xlink:to="loc_us-gaap_EarningsPerShareDiluted_220" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_221" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_200" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_221" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_222" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_200" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_222" use="optional" order="33" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.spy.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_229" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_225" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_229" xlink:to="loc_us-gaap_StatementTable_225" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_226" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_225" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_226" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_227" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_226" xlink:to="loc_us-gaap_RelatedPartyDomain_227" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_227_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_226" xlink:to="loc_us-gaap_RelatedPartyDomain_227_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaap_RelatedPartyMember_228" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_227" xlink:to="loc_us-gaap_RelatedPartyMember_228" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_230" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_229" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_230" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.spy.com/role/CondensedConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersDeficitEquity">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_250" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_240" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_250" xlink:to="loc_us-gaap_StatementTable_240" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_241" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_240" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_241" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_242" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_241" xlink:to="loc_us-gaap_EquityComponentDomain_242" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_242_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_241" xlink:to="loc_us-gaap_EquityComponentDomain_242_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_243" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_242" xlink:to="loc_us-gaap_CommonStockMember_243" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_244" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_242" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_244" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_245" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_242" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_245" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_246" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_242" xlink:to="loc_us-gaap_RetainedEarningsMember_246" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_247" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_240" xlink:to="loc_us-gaap_StatementClassOfStockAxis_247" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_248" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_247" xlink:to="loc_us-gaap_ClassOfStockDomain_248" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_248_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_247" xlink:to="loc_us-gaap_ClassOfStockDomain_248_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_SeriesANonVotingConvertiblePreferredStockMember" xlink:label="loc_agle_SeriesANonVotingConvertiblePreferredStockMember_249" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_248" xlink:to="loc_agle_SeriesANonVotingConvertiblePreferredStockMember_249" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_252" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_250" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_252" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_253" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_250" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_253" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_agle_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_254" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_250" xlink:to="loc_agle_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_254" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_255" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_250" xlink:to="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_255" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_TemporaryEquityFinancingCosts" xlink:label="loc_agle_TemporaryEquityFinancingCosts_256" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_250" xlink:to="loc_agle_TemporaryEquityFinancingCosts_256" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_260" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_250" xlink:to="loc_us-gaap_SharesOutstanding_260" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_261" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_250" xlink:to="loc_us-gaap_StockholdersEquity_261" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan" xlink:label="loc_agle_StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan_262" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_250" xlink:to="loc_agle_StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan_262" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_263" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_250" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_263" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_264" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_250" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_264" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_265" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_250" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_265" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_266" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_250" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_266" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_StockIssuedDuringPeriodSharesOptionsExercisedAndEmployeeStockOwnershipPlan" xlink:label="loc_agle_StockIssuedDuringPeriodSharesOptionsExercisedAndEmployeeStockOwnershipPlan_267" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_250" xlink:to="loc_agle_StockIssuedDuringPeriodSharesOptionsExercisedAndEmployeeStockOwnershipPlan_267" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_StockIssuedDuringPeriodSharesCommonStockAndPreFundedWarrantsRegisteredDirectOffering" xlink:label="loc_agle_StockIssuedDuringPeriodSharesCommonStockAndPreFundedWarrantsRegisteredDirectOffering_268" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_250" xlink:to="loc_agle_StockIssuedDuringPeriodSharesCommonStockAndPreFundedWarrantsRegisteredDirectOffering_268" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_269" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_250" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_269" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_270" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_250" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_270" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_271" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_250" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_271" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_StockIssuedDuringPeriodValueCommonStockAndPreFundedWarrantsRegisteredDirectOffering" xlink:label="loc_agle_StockIssuedDuringPeriodValueCommonStockAndPreFundedWarrantsRegisteredDirectOffering_272" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_250" xlink:to="loc_agle_StockIssuedDuringPeriodValueCommonStockAndPreFundedWarrantsRegisteredDirectOffering_272" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ContingentValueRightDistributionToCommonStockholders" xlink:label="loc_agle_ContingentValueRightDistributionToCommonStockholders_273" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_250" xlink:to="loc_agle_ContingentValueRightDistributionToCommonStockholders_273" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_274" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_250" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_274" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_275" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_250" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_275" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_276" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_250" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_276" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_277" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_250" xlink:to="loc_us-gaap_NetIncomeLoss_277" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_IssuanceOfCommonStockAndPreFundedWarrantsSharesInConnectionWithRegisteredDirectOfferingNetOfOfferingCosts" xlink:label="loc_agle_IssuanceOfCommonStockAndPreFundedWarrantsSharesInConnectionWithRegisteredDirectOfferingNetOfOfferingCosts_1690" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_250" xlink:to="loc_agle_IssuanceOfCommonStockAndPreFundedWarrantsSharesInConnectionWithRegisteredDirectOfferingNetOfOfferingCosts_1690" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_IssuanceOfCommonStockAndPreFundedWarrantsValueInConnectionWithRegisteredDirectOfferingNetOfOfferingCosts" xlink:label="loc_agle_IssuanceOfCommonStockAndPreFundedWarrantsValueInConnectionWithRegisteredDirectOfferingNetOfOfferingCosts_1660" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_250" xlink:to="loc_agle_IssuanceOfCommonStockAndPreFundedWarrantsValueInConnectionWithRegisteredDirectOfferingNetOfOfferingCosts_1660" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_IssuanceOfCommonStockInConnectionWithExerciseOfPreFundedWarrants" xlink:label="loc_agle_IssuanceOfCommonStockInConnectionWithExerciseOfPreFundedWarrants_1695" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_250" xlink:to="loc_agle_IssuanceOfCommonStockInConnectionWithExerciseOfPreFundedWarrants_1695" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_StockIssuedDuringPeriodSharesCommonStockAndPreFundedWarrants" xlink:label="loc_agle_StockIssuedDuringPeriodSharesCommonStockAndPreFundedWarrants_1585" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_250" xlink:to="loc_agle_StockIssuedDuringPeriodSharesCommonStockAndPreFundedWarrants_1585" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1654" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_250" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1654" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_StockIssuedDuringPeriodValueCommonStockAndPreFundedWarrants" xlink:label="loc_agle_StockIssuedDuringPeriodValueCommonStockAndPreFundedWarrants_1474" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_250" xlink:to="loc_agle_StockIssuedDuringPeriodValueCommonStockAndPreFundedWarrants_1474" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_1599" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_250" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_1599" use="optional" order="42" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.spy.com/role/CondensedConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_287" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_282" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_287" xlink:to="loc_us-gaap_StatementTable_282" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_283" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_282" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_283" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_284" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_283" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_284" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_284_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_283" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_284_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ContingentValueRightLiabilityMember" xlink:label="loc_agle_ContingentValueRightLiabilityMember_285" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_284" xlink:to="loc_agle_ContingentValueRightLiabilityMember_285" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForwardContractsMember" xlink:label="loc_us-gaap_ForwardContractsMember_286" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_284" xlink:to="loc_us-gaap_ForwardContractsMember_286" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_288" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_287" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_288" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_289" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_288" xlink:to="loc_us-gaap_ProfitLoss_289" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_290" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_288" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_290" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_291" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_290" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_291" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_292" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_290" xlink:to="loc_us-gaap_ShareBasedCompensation_292" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AcquiredInProcessResearchAndDevelopment" xlink:label="loc_agle_AcquiredInProcessResearchAndDevelopment_293" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_290" xlink:to="loc_agle_AcquiredInProcessResearchAndDevelopment_293" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_294" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_290" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_294" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_295" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_290" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_295" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_296" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_290" xlink:to="loc_us-gaap_AssetImpairmentCharges_296" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_297" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_290" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_297" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_298" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_290" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_298" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_299" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_290" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_299" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_300" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_290" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_300" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_NonCashOperatingLeaseExpense" xlink:label="loc_agle_NonCashOperatingLeaseExpense_1614" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_290" xlink:to="loc_agle_NonCashOperatingLeaseExpense_1614" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_PaymentForDiscountPremiumOnInvestmentsNet" xlink:label="loc_agle_PaymentForDiscountPremiumOnInvestmentsNet_1509" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_290" xlink:to="loc_agle_PaymentForDiscountPremiumOnInvestmentsNet_1509" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_301" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_288" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_301" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_302" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_301" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_302" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_303" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_301" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_303" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_304" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_301" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_304" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_305" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_301" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_305" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_306" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_301" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_306" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_307" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_301" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_307" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayable_308" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_301" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayable_308" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_1396" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_301" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_1396" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:label="loc_agle_IncreaseDecreaseInOperatingLeaseLiabilities_1615" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_301" xlink:to="loc_agle_IncreaseDecreaseInOperatingLeaseLiabilities_1615" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_309" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_288" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_309" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_310" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_288" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_310" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_315" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_310" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_315" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition_311" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_310" xlink:to="loc_us-gaap_CashAcquiredFromAcquisition_311" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:label="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_312" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_310" xlink:to="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_312" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_313" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_310" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_313" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_314" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_310" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_314" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_316" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_310" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_316" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_317" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_310" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_317" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_318" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_287" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_318" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_319" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_318" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_319" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfOfferingCosts" xlink:label="loc_agle_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfOfferingCosts_320" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_318" xlink:to="loc_agle_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfOfferingCosts_320" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_321" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_318" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_321" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_322" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_318" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_322" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_323" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_318" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_323" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_324" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_287" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_324" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_325" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_287" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_325" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract_326" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_287" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract_326" use="optional" order="49" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_327" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract_326" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_327" use="optional" order="50" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_1213" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract_326" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_1213" use="optional" order="51" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_329" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_287" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_329" use="optional" order="52" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssued1" xlink:label="loc_us-gaap_StockIssued1_330" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_329" xlink:to="loc_us-gaap_StockIssued1_330" use="optional" order="53" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_1397" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_329" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_1397" use="optional" order="54" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_LeasedAssetsObtainedInExchangeForLeaseObligations" xlink:label="loc_agle_LeasedAssetsObtainedInExchangeForLeaseObligations_1219" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_329" xlink:to="loc_agle_LeasedAssetsObtainedInExchangeForLeaseObligations_1219" use="optional" order="55" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.spy.com/role/StatementOfAssetsAcquiredAndLiabilitiesAssumed">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_1929" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1928" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1929" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1928" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_1930" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1929" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_1930" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_1931" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_1930" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_1931" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract_1932" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_1931" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract_1932" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_1933" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract_1932" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_1933" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_1934" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract_1932" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_1934" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_1935" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_1931" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_1935" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_1936" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_1930" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_1936" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract_1937" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_1936" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract_1937" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_1938" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract_1937" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_1938" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_1939" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract_1937" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_1939" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_1940" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_1936" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_1940" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_1941" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_1930" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_1941" use="optional" order="13" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.spy.com/role/TheCompanyAndBasisOfPresentationNarrativeDetails">
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_CompanyAndBasisOfPresentationLineItems" xlink:label="loc_agle_CompanyAndBasisOfPresentationLineItems_439" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_449" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agle_CompanyAndBasisOfPresentationLineItems_439" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_449" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_PlacementAgentAndOtherOfferingExpenses" xlink:label="loc_agle_PlacementAgentAndOtherOfferingExpenses_450" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agle_CompanyAndBasisOfPresentationLineItems_439" xlink:to="loc_agle_PlacementAgentAndOtherOfferingExpenses_450" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AssetAcquisitionStockholderPaymentPeriod" xlink:label="loc_agle_AssetAcquisitionStockholderPaymentPeriod_451" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agle_CompanyAndBasisOfPresentationLineItems_439" xlink:to="loc_agle_AssetAcquisitionStockholderPaymentPeriod_451" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AssetAcquisitionCashPaymentThresholdPeriod" xlink:label="loc_agle_AssetAcquisitionCashPaymentThresholdPeriod_452" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agle_CompanyAndBasisOfPresentationLineItems_439" xlink:to="loc_agle_AssetAcquisitionCashPaymentThresholdPeriod_452" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_453" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agle_CompanyAndBasisOfPresentationLineItems_439" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_453" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_454" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agle_CompanyAndBasisOfPresentationLineItems_439" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_454" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_NumberOfEmployeesRetained" xlink:label="loc_agle_NumberOfEmployeesRetained_455" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agle_CompanyAndBasisOfPresentationLineItems_439" xlink:to="loc_agle_NumberOfEmployeesRetained_455" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_CashCashEquivalentsMarketableSecuritiesAndRestrictedCash" xlink:label="loc_agle_CashCashEquivalentsMarketableSecuritiesAndRestrictedCash_1542" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agle_CompanyAndBasisOfPresentationLineItems_439" xlink:to="loc_agle_CashCashEquivalentsMarketableSecuritiesAndRestrictedCash_1542" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_WorkingCapital" xlink:label="loc_agle_WorkingCapital_1356" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agle_CompanyAndBasisOfPresentationLineItems_439" xlink:to="loc_agle_WorkingCapital_1356" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_CompanyAndBasisOfPresentationTable" xlink:label="loc_agle_CompanyAndBasisOfPresentationTable_422" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_agle_CompanyAndBasisOfPresentationLineItems_439" xlink:to="loc_agle_CompanyAndBasisOfPresentationTable_422" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_423" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_agle_CompanyAndBasisOfPresentationTable_422" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_423" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_424" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_423" xlink:to="loc_us-gaap_EquityComponentDomain_424" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_424_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_423" xlink:to="loc_us-gaap_EquityComponentDomain_424_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_425" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_424" xlink:to="loc_us-gaap_CommonStockMember_425" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_426" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_agle_CompanyAndBasisOfPresentationTable_422" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_426" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_427" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_426" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_427" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_427_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_426" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_427_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_428" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_427" xlink:to="loc_us-gaap_PrivatePlacementMember_428" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_429" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_agle_CompanyAndBasisOfPresentationTable_422" xlink:to="loc_us-gaap_StatementClassOfStockAxis_429" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_430" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_429" xlink:to="loc_us-gaap_ClassOfStockDomain_430" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_430_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_429" xlink:to="loc_us-gaap_ClassOfStockDomain_430_default" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_SeriesANonVotingConvertiblePreferredStockMember" xlink:label="loc_agle_SeriesANonVotingConvertiblePreferredStockMember_431" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_430" xlink:to="loc_agle_SeriesANonVotingConvertiblePreferredStockMember_431" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_432" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_agle_CompanyAndBasisOfPresentationTable_422" xlink:to="loc_us-gaap_PlanNameAxis_432" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_433" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_432" xlink:to="loc_us-gaap_PlanNameDomain_433" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_433_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_432" xlink:to="loc_us-gaap_PlanNameDomain_433_default" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_Spyre2023EquityIncentivePlanMember" xlink:label="loc_agle_Spyre2023EquityIncentivePlanMember_434" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_433" xlink:to="loc_agle_Spyre2023EquityIncentivePlanMember_434" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="loc_us-gaap_AssetAcquisitionAxis_435" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_agle_CompanyAndBasisOfPresentationTable_422" xlink:to="loc_us-gaap_AssetAcquisitionAxis_435" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaap_AssetAcquisitionDomain_436" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_435" xlink:to="loc_us-gaap_AssetAcquisitionDomain_436" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaap_AssetAcquisitionDomain_436_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_435" xlink:to="loc_us-gaap_AssetAcquisitionDomain_436_default" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AssetAcquisitionMember" xlink:label="loc_agle_AssetAcquisitionMember_437" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_436" xlink:to="loc_agle_AssetAcquisitionMember_437" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_SpyreTherapeuticsIncMember" xlink:label="loc_agle_SpyreTherapeuticsIncMember_438" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_436" xlink:to="loc_agle_SpyreTherapeuticsIncMember_438" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_440" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agle_CompanyAndBasisOfPresentationLineItems_439" xlink:to="loc_us-gaap_NumberOfOperatingSegments_440" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_441" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agle_CompanyAndBasisOfPresentationLineItems_439" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_441" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_FixedExchangeRatio" xlink:label="loc_agle_FixedExchangeRatio_443" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agle_CompanyAndBasisOfPresentationLineItems_439" xlink:to="loc_agle_FixedExchangeRatio_443" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares" xlink:label="loc_agle_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares_444" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agle_CompanyAndBasisOfPresentationLineItems_439" xlink:to="loc_agle_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares_444" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_445" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agle_CompanyAndBasisOfPresentationLineItems_439" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_445" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleConversionRatio" xlink:label="loc_us-gaap_PreferredStockConvertibleConversionRatio_446" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agle_CompanyAndBasisOfPresentationLineItems_439" xlink:to="loc_us-gaap_PreferredStockConvertibleConversionRatio_446" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_OutstandingAndUnexercisedStockOptions" xlink:label="loc_agle_OutstandingAndUnexercisedStockOptions_447" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agle_CompanyAndBasisOfPresentationLineItems_439" xlink:to="loc_agle_OutstandingAndUnexercisedStockOptions_447" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_448" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agle_CompanyAndBasisOfPresentationLineItems_439" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_448" use="optional" order="39" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesSummaryOfAssetAcquisitionCostDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="loc_us-gaap_AssetAcquisitionLineItems_1806" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionTable" xlink:label="loc_us-gaap_AssetAcquisitionTable_1802" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_1806" xlink:to="loc_us-gaap_AssetAcquisitionTable_1802" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="loc_us-gaap_AssetAcquisitionAxis_1803" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AssetAcquisitionTable_1802" xlink:to="loc_us-gaap_AssetAcquisitionAxis_1803" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaap_AssetAcquisitionDomain_1804" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_1803" xlink:to="loc_us-gaap_AssetAcquisitionDomain_1804" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaap_AssetAcquisitionDomain_1804_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_1803" xlink:to="loc_us-gaap_AssetAcquisitionDomain_1804_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_SpyreTherapeuticsIncMember" xlink:label="loc_agle_SpyreTherapeuticsIncMember_1805" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_1804" xlink:to="loc_agle_SpyreTherapeuticsIncMember_1805" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_1807" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_1806" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_1807" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_1808" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_1806" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_1808" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AcquiredInProcessResearchAndDevelopment" xlink:label="loc_agle_AcquiredInProcessResearchAndDevelopment_1809" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_1806" xlink:to="loc_agle_AcquiredInProcessResearchAndDevelopment_1809" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition_1810" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_1806" xlink:to="loc_us-gaap_CashAcquiredFromAcquisition_1810" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferred_1812" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_1806" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferred_1812" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_1813" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_1806" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_1813" use="optional" order="11" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:label="loc_agle_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_1820" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaap_StockholdersEquityReverseStockSplit_1816" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agle_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_1820" xlink:to="loc_us-gaap_StockholdersEquityReverseStockSplit_1816" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_FixedExchangeRatio" xlink:label="loc_agle_FixedExchangeRatio_1817" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agle_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_1820" xlink:to="loc_agle_FixedExchangeRatio_1817" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares" xlink:label="loc_agle_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares_1818" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agle_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_1820" xlink:to="loc_agle_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares_1818" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:label="loc_agle_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_1819" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_agle_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_1820" xlink:to="loc_agle_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_1819" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="loc_us-gaap_AssetAcquisitionAxis_1824" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_agle_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_1819" xlink:to="loc_us-gaap_AssetAcquisitionAxis_1824" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaap_AssetAcquisitionDomain_1825" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_1824" xlink:to="loc_us-gaap_AssetAcquisitionDomain_1825" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaap_AssetAcquisitionDomain_1825_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_1824" xlink:to="loc_us-gaap_AssetAcquisitionDomain_1825_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AssetAcquisitionMember" xlink:label="loc_agle_AssetAcquisitionMember_1826" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_1825" xlink:to="loc_agle_AssetAcquisitionMember_1826" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_SpyreTherapeuticsIncMember" xlink:label="loc_agle_SpyreTherapeuticsIncMember_1838" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_1825" xlink:to="loc_agle_SpyreTherapeuticsIncMember_1838" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1827" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_agle_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_1819" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1827" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1828" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1827" xlink:to="loc_us-gaap_ClassOfStockDomain_1828" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1828_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1827" xlink:to="loc_us-gaap_ClassOfStockDomain_1828_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_SeriesANonVotingConvertiblePreferredStockMember" xlink:label="loc_agle_SeriesANonVotingConvertiblePreferredStockMember_1829" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1828" xlink:to="loc_agle_SeriesANonVotingConvertiblePreferredStockMember_1829" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1830" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_agle_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_1819" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1830" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1831" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1830" xlink:to="loc_us-gaap_EquityComponentDomain_1831" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1831_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1830" xlink:to="loc_us-gaap_EquityComponentDomain_1831_default" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1832" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1831" xlink:to="loc_us-gaap_CommonStockMember_1832" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1855" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_1854" xlink:to="loc_us-gaap_CommonStockMember_1855" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1850" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_agle_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_1819" xlink:to="loc_us-gaap_PlanNameAxis_1850" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1851" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_1850" xlink:to="loc_us-gaap_PlanNameDomain_1851" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1851_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_1850" xlink:to="loc_us-gaap_PlanNameDomain_1851_default" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_Spyre2023EquityIncentivePlanMember" xlink:label="loc_agle_Spyre2023EquityIncentivePlanMember_1852" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1851" xlink:to="loc_agle_Spyre2023EquityIncentivePlanMember_1852" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ParapyreOptionObligationMember" xlink:label="loc_agle_ParapyreOptionObligationMember_1859" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1851" xlink:to="loc_agle_ParapyreOptionObligationMember_1859" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_1853" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_agle_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_1819" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_1853" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_1854" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_1853" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_1854" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_1854_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_1853" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_1854_default" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1860" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_agle_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_1819" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_1860" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1861" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1860" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1861" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1861_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1860" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1861_default" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_1862" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1861" xlink:to="loc_us-gaap_PrivatePlacementMember_1862" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_1863" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_agle_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_1819" xlink:to="loc_us-gaap_FinancialInstrumentAxis_1863" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1864" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1863" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1864" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1864_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1863" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1864_default" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_USBankingInstitutionMember" xlink:label="loc_agle_USBankingInstitutionMember_1865" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1864" xlink:to="loc_agle_USBankingInstitutionMember_1865" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_1821" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agle_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_1820" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_1821" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleConversionRatio" xlink:label="loc_us-gaap_PreferredStockConvertibleConversionRatio_1822" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agle_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_1820" xlink:to="loc_us-gaap_PreferredStockConvertibleConversionRatio_1822" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_OutstandingAndUnexercisedStockOptions" xlink:label="loc_agle_OutstandingAndUnexercisedStockOptions_1823" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agle_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_1820" xlink:to="loc_agle_OutstandingAndUnexercisedStockOptions_1823" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferred_1833" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agle_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_1820" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferred_1833" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableSharesOfCommonStockOnAnAsConvertedBasis" xlink:label="loc_agle_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableSharesOfCommonStockOnAnAsConvertedBasis_1835" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agle_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_1820" xlink:to="loc_agle_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableSharesOfCommonStockOnAnAsConvertedBasis_1835" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_1836" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agle_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_1820" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_1836" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock" xlink:label="loc_agle_PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock_1837" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agle_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_1820" xlink:to="loc_agle_PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock_1837" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AcquiredInProcessResearchAndDevelopment" xlink:label="loc_agle_AcquiredInProcessResearchAndDevelopment_1839" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agle_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_1820" xlink:to="loc_agle_AcquiredInProcessResearchAndDevelopment_1839" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_agle_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet_1842" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agle_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_1820" xlink:to="loc_agle_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet_1842" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_1843" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agle_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_1820" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_1843" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_NumberOfEmployeesRetained" xlink:label="loc_agle_NumberOfEmployeesRetained_1844" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agle_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_1820" xlink:to="loc_agle_NumberOfEmployeesRetained_1844" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_1845" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agle_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_1820" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_1845" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_1846" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agle_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_1820" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_1846" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_PlacementAgentAndOtherOfferingExpenses" xlink:label="loc_agle_PlacementAgentAndOtherOfferingExpenses_1847" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agle_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_1820" xlink:to="loc_agle_PlacementAgentAndOtherOfferingExpenses_1847" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1848" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agle_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_1820" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1848" use="optional" order="49" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_1849" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agle_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_1820" xlink:to="loc_us-gaap_Cash_1849" use="optional" order="50" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.spy.com/role/AccruedLiabilitiesAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AccruedLiabilitiesLineItems" xlink:label="loc_agle_AccruedLiabilitiesLineItems_1958" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AccruedLiabilitiesTable" xlink:label="loc_agle_AccruedLiabilitiesTable_1957" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_agle_AccruedLiabilitiesLineItems_1958" xlink:to="loc_agle_AccruedLiabilitiesTable_1957" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1963" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_agle_AccruedLiabilitiesTable_1957" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1963" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1964" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1963" xlink:to="loc_us-gaap_RelatedPartyDomain_1964" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1964_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1963" xlink:to="loc_us-gaap_RelatedPartyDomain_1964_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaap_RelatedPartyMember_1965" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_1964" xlink:to="loc_us-gaap_RelatedPartyMember_1965" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_1966" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_agle_AccruedLiabilitiesTable_1957" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_1966" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_1967" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_1966" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_1967" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_1967_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_1966" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_1967_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ParagonAgreementMember" xlink:label="loc_agle_ParagonAgreementMember_1968" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_1967" xlink:to="loc_agle_ParagonAgreementMember_1968" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_RelatedPartyExpensesIncurredPriorToAssetAcquisition" xlink:label="loc_agle_RelatedPartyExpensesIncurredPriorToAssetAcquisition_1959" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agle_AccruedLiabilitiesLineItems_1958" xlink:to="loc_agle_RelatedPartyExpensesIncurredPriorToAssetAcquisition_1959" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ResearchInitiationFees" xlink:label="loc_agle_ResearchInitiationFees_1960" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agle_AccruedLiabilitiesLineItems_1958" xlink:to="loc_agle_ResearchInitiationFees_1960" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ReimbursableResearchCosts" xlink:label="loc_agle_ReimbursableResearchCosts_1961" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agle_AccruedLiabilitiesLineItems_1958" xlink:to="loc_agle_ReimbursableResearchCosts_1961" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_RelatedPartyExpensesUnpaidPriorToAssetAcquisition" xlink:label="loc_agle_RelatedPartyExpensesUnpaidPriorToAssetAcquisition_1962" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agle_AccruedLiabilitiesLineItems_1958" xlink:to="loc_agle_RelatedPartyExpensesUnpaidPriorToAssetAcquisition_1962" use="optional" order="13" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.spy.com/role/ParapyreOptionObligationAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="loc_us-gaap_AssetAcquisitionLineItems_1872" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionTable" xlink:label="loc_us-gaap_AssetAcquisitionTable_1871" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_1872" xlink:to="loc_us-gaap_AssetAcquisitionTable_1871" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1874" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AssetAcquisitionTable_1871" xlink:to="loc_us-gaap_PlanNameAxis_1874" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1875" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_1874" xlink:to="loc_us-gaap_PlanNameDomain_1875" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1875_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_1874" xlink:to="loc_us-gaap_PlanNameDomain_1875_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ParapyreOptionObligationMember" xlink:label="loc_agle_ParapyreOptionObligationMember_1876" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1875" xlink:to="loc_agle_ParapyreOptionObligationMember_1876" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock" xlink:label="loc_agle_PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock_1873" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_1872" xlink:to="loc_agle_PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock_1873" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent" xlink:label="loc_us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent_1877" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_1872" xlink:to="loc_us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent_1877" use="optional" order="7" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_agle_SummaryOfSignificantAccountingPoliciesLineItems_1264" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_SummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_agle_SummaryOfSignificantAccountingPoliciesTable_1044" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_agle_SummaryOfSignificantAccountingPoliciesLineItems_1264" xlink:to="loc_agle_SummaryOfSignificantAccountingPoliciesTable_1044" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1043" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_agle_SummaryOfSignificantAccountingPoliciesTable_1044" xlink:to="loc_srt_RangeAxis_1043" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1041" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1043" xlink:to="loc_srt_RangeMember_1041" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1041_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1043" xlink:to="loc_srt_RangeMember_1041_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1042" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1041" xlink:to="loc_srt_MaximumMember_1042" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_MarketableSecuritiesMaturityPeriod" xlink:label="loc_agle_MarketableSecuritiesMaturityPeriod_1045" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agle_SummaryOfSignificantAccountingPoliciesLineItems_1264" xlink:to="loc_agle_MarketableSecuritiesMaturityPeriod_1045" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_1265" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agle_SummaryOfSignificantAccountingPoliciesLineItems_1264" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_1265" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_NumberOfSubsidiaryCorporationsOwned" xlink:label="loc_agle_NumberOfSubsidiaryCorporationsOwned_1276" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agle_SummaryOfSignificantAccountingPoliciesLineItems_1264" xlink:to="loc_agle_NumberOfSubsidiaryCorporationsOwned_1276" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_1337" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agle_SummaryOfSignificantAccountingPoliciesLineItems_1264" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_1337" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_1342" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agle_SummaryOfSignificantAccountingPoliciesLineItems_1264" xlink:to="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_1342" use="optional" order="10" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfUsefulLivesOfPropertyAndEquipmentDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1228" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1136" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1228" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1136" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1137" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1136" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1137" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1138" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1137" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1138" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1138_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1137" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1138_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_LaboratoryEquipmentMember" xlink:label="loc_agle_LaboratoryEquipmentMember_1139" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1138" xlink:to="loc_agle_LaboratoryEquipmentMember_1139" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_1229" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1138" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_1229" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_1299" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1138" xlink:to="loc_us-gaap_ComputerEquipmentMember_1299" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_PurchasedSoftwareMember" xlink:label="loc_agle_PurchasedSoftwareMember_1321" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1138" xlink:to="loc_agle_PurchasedSoftwareMember_1321" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_1354" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1138" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_1354" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentBasisOfValuation" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentBasisOfValuation_1227" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1228" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentBasisOfValuation_1227" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_2007" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1228" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_2007" use="optional" order="11" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.spy.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_481" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_458" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_481" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_458" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_459" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_458" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_459" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_460" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_459" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_460" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_460_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_459" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_460_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_461" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_460" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_461" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_462" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_458" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_462" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_463" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_462" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_463" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_463_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_462" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_463_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_464" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_463" xlink:to="loc_us-gaap_MoneyMarketFundsMember_464" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_465" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_463" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_465" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_466" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_458" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_466" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_467" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_466" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_467" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_467_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_466" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_467_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ParapyreOptionObligationMember" xlink:label="loc_agle_ParapyreOptionObligationMember_468" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_467" xlink:to="loc_agle_ParapyreOptionObligationMember_468" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ContingentValueRightLiabilityMember" xlink:label="loc_agle_ContingentValueRightLiabilityMember_469" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_467" xlink:to="loc_agle_ContingentValueRightLiabilityMember_469" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_470" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_458" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_470" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_471" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_470" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_471" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_471_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_470" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_471_default" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_472" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_471" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_472" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_473" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_471" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_473" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_474" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_471" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_474" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_475" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_458" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_475" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_476" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_475" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_476" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_476_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_475" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_476_default" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_477" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_476" xlink:to="loc_us-gaap_CommercialPaperMember_477" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_478" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_458" xlink:to="loc_us-gaap_InvestmentTypeAxis_478" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_479" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_478" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_479" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_479_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_478" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_479_default" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_480" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_479" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_480" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_482" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_481" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_482" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_483" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_482" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_483" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_484" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_481" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_484" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_485" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_484" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_485" use="optional" order="33" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.spy.com/role/FairValueMeasurementsNarrativeDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_509" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_488" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_509" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_488" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_489" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_488" xlink:to="loc_us-gaap_StatementClassOfStockAxis_489" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_490" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_489" xlink:to="loc_us-gaap_ClassOfStockDomain_490" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_490_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_489" xlink:to="loc_us-gaap_ClassOfStockDomain_490_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_SeriesANonVotingConvertiblePreferredStockMember" xlink:label="loc_agle_SeriesANonVotingConvertiblePreferredStockMember_491" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_490" xlink:to="loc_agle_SeriesANonVotingConvertiblePreferredStockMember_491" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_492" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_488" xlink:to="loc_us-gaap_PlanNameAxis_492" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_493" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_492" xlink:to="loc_us-gaap_PlanNameDomain_493" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_493_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_492" xlink:to="loc_us-gaap_PlanNameDomain_493_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ParapyreOptionObligationMember" xlink:label="loc_agle_ParapyreOptionObligationMember_494" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_493" xlink:to="loc_agle_ParapyreOptionObligationMember_494" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_495" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_488" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_495" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_496" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_495" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_496" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_496_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_495" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_496_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForwardContractsMember" xlink:label="loc_us-gaap_ForwardContractsMember_508" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_507" xlink:to="loc_us-gaap_ForwardContractsMember_508" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ContingentValueRightLiabilityMember" xlink:label="loc_agle_ContingentValueRightLiabilityMember_498" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_496" xlink:to="loc_agle_ContingentValueRightLiabilityMember_498" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="loc_us-gaap_AssetAcquisitionAxis_499" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_488" xlink:to="loc_us-gaap_AssetAcquisitionAxis_499" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaap_AssetAcquisitionDomain_500" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_499" xlink:to="loc_us-gaap_AssetAcquisitionDomain_500" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaap_AssetAcquisitionDomain_500_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_499" xlink:to="loc_us-gaap_AssetAcquisitionDomain_500_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AssetAcquisitionMember" xlink:label="loc_agle_AssetAcquisitionMember_501" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_500" xlink:to="loc_agle_AssetAcquisitionMember_501" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_SpyreTherapeuticsIncMember" xlink:label="loc_agle_SpyreTherapeuticsIncMember_502" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_500" xlink:to="loc_agle_SpyreTherapeuticsIncMember_502" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_503" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_488" xlink:to="loc_srt_StatementScenarioAxis_503" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_504" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_503" xlink:to="loc_srt_ScenarioUnspecifiedDomain_504" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_504_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_503" xlink:to="loc_srt_ScenarioUnspecifiedDomain_504_default" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember" xlink:label="loc_srt_ScenarioForecastMember_505" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_504" xlink:to="loc_srt_ScenarioForecastMember_505" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_506" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_488" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_506" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_507" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_506" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_507" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_507_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_506" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_507_default" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_510" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_509" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_510" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares" xlink:label="loc_agle_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares_511" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_509" xlink:to="loc_agle_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares_511" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_512" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_509" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_512" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_513" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_509" xlink:to="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_513" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_514" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_509" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_514" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock" xlink:label="loc_agle_PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock_515" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_509" xlink:to="loc_agle_PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock_515" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_516" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_509" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_516" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodFairValue" xlink:label="loc_agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodFairValue_517" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_509" xlink:to="loc_agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodFairValue_517" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_518" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_509" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_518" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_519" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_509" xlink:to="loc_us-gaap_ShareBasedCompensation_519" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AssetAcquisitionStockholderPaymentPeriod" xlink:label="loc_agle_AssetAcquisitionStockholderPaymentPeriod_520" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_509" xlink:to="loc_agle_AssetAcquisitionStockholderPaymentPeriod_520" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AssetAcquisitionCashPaymentThresholdPeriod" xlink:label="loc_agle_AssetAcquisitionCashPaymentThresholdPeriod_521" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_509" xlink:to="loc_agle_AssetAcquisitionCashPaymentThresholdPeriod_521" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_522" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_509" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_522" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_FairValueAssetsLevel1ToLevel2TransfersAmount1" xlink:label="loc_agle_FairValueAssetsLevel1ToLevel2TransfersAmount1_1163" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_509" xlink:to="loc_agle_FairValueAssetsLevel1ToLevel2TransfersAmount1_1163" use="optional" order="40" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.spy.com/role/FairValueMeasurementsChangesInDerivativeLiabilitiesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_530" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_525" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_530" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_525" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_526" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_525" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_526" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_527" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_526" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_527" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_527_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_526" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_527_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForwardContractsMember" xlink:label="loc_us-gaap_ForwardContractsMember_528" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_527" xlink:to="loc_us-gaap_ForwardContractsMember_528" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ContingentValueRightLiabilityMember" xlink:label="loc_agle_ContingentValueRightLiabilityMember_529" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_527" xlink:to="loc_agle_ContingentValueRightLiabilityMember_529" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_531" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_530" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_531" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_532" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_531" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_532" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_533" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_531" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_533" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_534" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_531" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_534" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_535" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_531" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_535" use="optional" order="11" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.spy.com/role/FairValueMeasurementsSignificantInputsUsedToEstimateTheFairValueOfDerivativeLiabilityDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_557" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_539" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_557" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_539" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_540" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_539" xlink:to="loc_srt_RangeAxis_540" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_541" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_540" xlink:to="loc_srt_RangeMember_541" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_541_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_540" xlink:to="loc_srt_RangeMember_541_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_542" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_541" xlink:to="loc_srt_MaximumMember_542" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_543" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_541" xlink:to="loc_srt_MinimumMember_543" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_544" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_539" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_544" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_545" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_544" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_545" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_545_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_544" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_545_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_546" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_545" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_546" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_547" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_539" xlink:to="loc_us-gaap_FinancialInstrumentAxis_547" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_548" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_547" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_548" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_548_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_547" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_548_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ContingentValueRightLiabilityMember" xlink:label="loc_agle_ContingentValueRightLiabilityMember_549" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_548" xlink:to="loc_agle_ContingentValueRightLiabilityMember_549" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_550" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_539" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_550" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_551" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_550" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_551" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_551_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_550" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_551_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_MeasurementInputProabilityOfSuccessMember" xlink:label="loc_agle_MeasurementInputProabilityOfSuccessMember_552" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_551" xlink:to="loc_agle_MeasurementInputProabilityOfSuccessMember_552" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_553" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_551" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_553" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_554" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_539" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_554" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_555" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_554" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_555" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_555_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_554" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_555_default" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="loc_us-gaap_DerivativeLiabilityMeasurementInput_558" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_557" xlink:to="loc_us-gaap_DerivativeLiabilityMeasurementInput_558" use="optional" order="23" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesEstimatedFairValueOfCashEquivalentsAndMarketableSecuritiesAndTheGrossUnrealizedGainsAndLossesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_568" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_561" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_568" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_561" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_562" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_561" xlink:to="loc_us-gaap_FinancialInstrumentAxis_562" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_563" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_562" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_563" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_563_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_562" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_563_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_564" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_563" xlink:to="loc_us-gaap_MoneyMarketFundsMember_564" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_565" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_563" xlink:to="loc_us-gaap_CommercialPaperMember_565" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_566" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_563" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_566" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_567" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_563" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_567" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_569" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_568" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_569" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_CashEquivalentsUnrealizedGains" xlink:label="loc_agle_CashEquivalentsUnrealizedGains_570" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_568" xlink:to="loc_agle_CashEquivalentsUnrealizedGains_570" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_CashEquivalentsUnrealizedLosses" xlink:label="loc_agle_CashEquivalentsUnrealizedLosses_571" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_568" xlink:to="loc_agle_CashEquivalentsUnrealizedLosses_571" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_572" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_568" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_572" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_573" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_568" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_573" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_574" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_568" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_574" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_575" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_568" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_575" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_576" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_568" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_576" use="optional" order="16" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesAvailableForSaleSecuritiesInAnUnrealizedLossPositionDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_585" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_579" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_585" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_579" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_580" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_579" xlink:to="loc_us-gaap_InvestmentTypeAxis_580" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_581" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_580" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_581" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_581_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_580" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_581_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_582" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_581" xlink:to="loc_us-gaap_CommercialPaperMember_582" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_583" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_581" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_583" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_584" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_581" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_584" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_586" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_585" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_586" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_587" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_586" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_587" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_588" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_586" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_588" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract" xlink:label="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_589" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_585" xlink:to="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_589" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_590" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_589" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_590" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_591" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_589" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_591" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_592" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_585" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_592" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_593" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_585" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_593" use="optional" order="15" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesNarrativeDetails">
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:label="loc_agle_CashEquivalentsAndMarketableSecuritiesLineItems_604" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_CashEquivalentsAndMarketableSecuritiesTable" xlink:label="loc_agle_CashEquivalentsAndMarketableSecuritiesTable_596" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_agle_CashEquivalentsAndMarketableSecuritiesLineItems_604" xlink:to="loc_agle_CashEquivalentsAndMarketableSecuritiesTable_596" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_597" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_agle_CashEquivalentsAndMarketableSecuritiesTable_596" xlink:to="loc_us-gaap_FinancialInstrumentAxis_597" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_598" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_597" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_598" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_598_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_597" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_598_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_599" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_598" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_599" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_USBankingInstitutionMember" xlink:label="loc_agle_USBankingInstitutionMember_600" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_598" xlink:to="loc_agle_USBankingInstitutionMember_600" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_601" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_agle_CashEquivalentsAndMarketableSecuritiesTable_596" xlink:to="loc_srt_RangeAxis_601" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_602" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_601" xlink:to="loc_srt_RangeMember_602" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_602_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_601" xlink:to="loc_srt_RangeMember_602_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_603" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_602" xlink:to="loc_srt_MaximumMember_603" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_605" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agle_CashEquivalentsAndMarketableSecuritiesLineItems_604" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_605" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ImpairmentOfMarketableSecurities" xlink:label="loc_agle_ImpairmentOfMarketableSecurities_606" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agle_CashEquivalentsAndMarketableSecuritiesLineItems_604" xlink:to="loc_agle_ImpairmentOfMarketableSecurities_606" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_NumberOfDomesticBankingInstitutions" xlink:label="loc_agle_NumberOfDomesticBankingInstitutions_607" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agle_CashEquivalentsAndMarketableSecuritiesLineItems_604" xlink:to="loc_agle_NumberOfDomesticBankingInstitutions_607" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaap_CashFDICInsuredAmount_608" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agle_CashEquivalentsAndMarketableSecuritiesLineItems_604" xlink:to="loc_us-gaap_CashFDICInsuredAmount_608" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_609" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agle_CashEquivalentsAndMarketableSecuritiesLineItems_604" xlink:to="loc_us-gaap_Cash_609" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments" xlink:label="loc_us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments_610" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agle_CashEquivalentsAndMarketableSecuritiesLineItems_604" xlink:to="loc_us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments_610" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestReceivable" xlink:label="loc_us-gaap_InterestReceivable_611" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agle_CashEquivalentsAndMarketableSecuritiesLineItems_604" xlink:to="loc_us-gaap_InterestReceivable_611" use="optional" order="17" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.spy.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1240" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_1142" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1240" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_1142" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1144" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1240" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1144" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1143" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1144" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1143" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1145" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1143" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1145" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1145_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1143" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1145_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_LaboratoryEquipmentMember" xlink:label="loc_agle_LaboratoryEquipmentMember_1146" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1145" xlink:to="loc_agle_LaboratoryEquipmentMember_1146" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_1241" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1145" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_1241" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_1290" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1145" xlink:to="loc_us-gaap_ComputerEquipmentMember_1290" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_PurchasedSoftwareMember" xlink:label="loc_agle_PurchasedSoftwareMember_1326" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1145" xlink:to="loc_agle_PurchasedSoftwareMember_1326" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_1348" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1145" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_1348" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1239" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1240" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1239" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1289" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1240" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_1289" use="optional" order="12" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.spy.com/role/PropertyAndEquipmentNetAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1218" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_1186" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1218" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_1186" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1190" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1218" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1190" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_1189" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1190" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_1189" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1188" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_1189" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1188" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1188_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_1189" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1188_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentMember" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentMember_1187" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1188" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentMember_1187" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.spy.com/role/LeasesAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ScheduleOfOperatingAndFinanceLeasedAssetsLineItems" xlink:label="loc_agle_ScheduleOfOperatingAndFinanceLeasedAssetsLineItems_1297" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ScheduleOfOperatingAndFinanceLeasedAssetsTable" xlink:label="loc_agle_ScheduleOfOperatingAndFinanceLeasedAssetsTable_1129" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_agle_ScheduleOfOperatingAndFinanceLeasedAssetsLineItems_1297" xlink:to="loc_agle_ScheduleOfOperatingAndFinanceLeasedAssetsTable_1129" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1131" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_agle_ScheduleOfOperatingAndFinanceLeasedAssetsTable_1129" xlink:to="loc_srt_RangeAxis_1131" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1126" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1131" xlink:to="loc_srt_RangeMember_1126" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1126_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1131" xlink:to="loc_srt_RangeMember_1126_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_1128" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1126" xlink:to="loc_srt_MinimumMember_1128" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1230" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1126" xlink:to="loc_srt_MaximumMember_1230" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_1231" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_agle_ScheduleOfOperatingAndFinanceLeasedAssetsTable_1129" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_1231" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_1127" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_1231" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_1127" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_1127_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_1231" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_1127_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LetterOfCreditMember" xlink:label="loc_us-gaap_LetterOfCreditMember_1130" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_1127" xlink:to="loc_us-gaap_LetterOfCreditMember_1130" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_1132" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agle_ScheduleOfOperatingAndFinanceLeasedAssetsLineItems_1297" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_1132" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeFinanceLeaseRenewalTerm1" xlink:label="loc_us-gaap_LesseeFinanceLeaseRenewalTerm1_1232" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agle_ScheduleOfOperatingAndFinanceLeasedAssetsLineItems_1297" xlink:to="loc_us-gaap_LesseeFinanceLeaseRenewalTerm1_1232" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AreaOfLand" xlink:label="loc_us-gaap_AreaOfLand_1298" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agle_ScheduleOfOperatingAndFinanceLeasedAssetsLineItems_1297" xlink:to="loc_us-gaap_AreaOfLand_1298" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseExpirationDate1" xlink:label="loc_us-gaap_LeaseExpirationDate1_1322" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agle_ScheduleOfOperatingAndFinanceLeasedAssetsLineItems_1297" xlink:to="loc_us-gaap_LeaseExpirationDate1_1322" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCredit" xlink:label="loc_us-gaap_LineOfCredit_1353" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agle_ScheduleOfOperatingAndFinanceLeasedAssetsLineItems_1297" xlink:to="loc_us-gaap_LineOfCredit_1353" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TenantImprovements" xlink:label="loc_us-gaap_TenantImprovements_1363" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agle_ScheduleOfOperatingAndFinanceLeasedAssetsLineItems_1297" xlink:to="loc_us-gaap_TenantImprovements_1363" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_1379" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agle_ScheduleOfOperatingAndFinanceLeasedAssetsLineItems_1297" xlink:to="loc_us-gaap_OperatingLeasePayments_1379" use="optional" order="17" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.spy.com/role/StockholdersEquityAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_1356" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_1165" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_1356" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_1165" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1168" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1165" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_1168" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1164" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1168" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1164" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1164_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1168" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1164_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_FollowOnPublicOfferingMember" xlink:label="loc_agle_FollowOnPublicOfferingMember_1161" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1164" xlink:to="loc_agle_FollowOnPublicOfferingMember_1161" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AtTheMarketSalesAgreementMember" xlink:label="loc_agle_AtTheMarketSalesAgreementMember_1220" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1164" xlink:to="loc_agle_AtTheMarketSalesAgreementMember_1220" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_1302" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1164" xlink:to="loc_us-gaap_OverAllotmentOptionMember_1302" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1222" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1165" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1222" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1166" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1222" xlink:to="loc_us-gaap_EquityComponentDomain_1166" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1166_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1222" xlink:to="loc_us-gaap_EquityComponentDomain_1166_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1169" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1166" xlink:to="loc_us-gaap_CommonStockMember_1169" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_1303" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1165" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_1303" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_1167" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_1303" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_1167" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_1167_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_1303" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_1167_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_JonesTradingInstitutionalServicesLimitedLiabilityCompanyMember" xlink:label="loc_agle_JonesTradingInstitutionalServicesLimitedLiabilityCompanyMember_1224" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_1167" xlink:to="loc_agle_JonesTradingInstitutionalServicesLimitedLiabilityCompanyMember_1224" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1318" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1165" xlink:to="loc_srt_RangeAxis_1318" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1162" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1318" xlink:to="loc_srt_RangeMember_1162" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1162_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1318" xlink:to="loc_srt_RangeMember_1162_default" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1163" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1162" xlink:to="loc_srt_MaximumMember_1163" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1170" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1356" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1170" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_1223" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1356" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_1223" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees" xlink:label="loc_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees_1319" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1356" xlink:to="loc_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees_1319" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_1357" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1356" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_1357" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AggregateOfferingPriceOfCommonStock" xlink:label="loc_agle_AggregateOfferingPriceOfCommonStock_1361" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1356" xlink:to="loc_agle_AggregateOfferingPriceOfCommonStock_1361" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_SharesAuthorized" xlink:label="loc_agle_SharesAuthorized_1384" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1356" xlink:to="loc_agle_SharesAuthorized_1384" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_1397" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1356" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_1397" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_1400" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1356" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_1400" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_1407" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1356" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_1407" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_1408" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1356" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_1408" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_NumberOfCommonStockVotingRightsHeldPerShare" xlink:label="loc_agle_NumberOfCommonStockVotingRightsHeldPerShare_1415" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1356" xlink:to="loc_agle_NumberOfCommonStockVotingRightsHeldPerShare_1415" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockVotingRights" xlink:label="loc_us-gaap_CommonStockVotingRights_1416" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1356" xlink:to="loc_us-gaap_CommonStockVotingRights_1416" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsCommonStock" xlink:label="loc_us-gaap_DividendsCommonStock_1422" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1356" xlink:to="loc_us-gaap_DividendsCommonStock_1422" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_1423" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1356" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_1423" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1427" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1356" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1427" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ClassOfWarrantOrRightOfferingPriceOfWarrantsOrRights" xlink:label="loc_agle_ClassOfWarrantOrRightOfferingPriceOfWarrantsOrRights_1430" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1356" xlink:to="loc_agle_ClassOfWarrantOrRightOfferingPriceOfWarrantsOrRights_1430" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1436" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1356" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1436" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_PlacementAgentFeesAndOfferingCosts" xlink:label="loc_agle_PlacementAgentFeesAndOfferingCosts_1439" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1356" xlink:to="loc_agle_PlacementAgentFeesAndOfferingCosts_1439" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_MaximumOwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercised" xlink:label="loc_agle_MaximumOwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercised_1443" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1356" xlink:to="loc_agle_MaximumOwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercised_1443" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_PeriodAfterNoticeReceivedByCompanyMaximumOwnershipPercentageToBeEffectiveDescription" xlink:label="loc_agle_PeriodAfterNoticeReceivedByCompanyMaximumOwnershipPercentageToBeEffectiveDescription_1444" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1356" xlink:to="loc_agle_PeriodAfterNoticeReceivedByCompanyMaximumOwnershipPercentageToBeEffectiveDescription_1444" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_OwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercisedToCertainHolders" xlink:label="loc_agle_OwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercisedToCertainHolders_1448" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1356" xlink:to="loc_agle_OwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercisedToCertainHolders_1448" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ProceedsFromIssuanceOfCommonStockGross" xlink:label="loc_agle_ProceedsFromIssuanceOfCommonStockGross_1450" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1356" xlink:to="loc_agle_ProceedsFromIssuanceOfCommonStockGross_1450" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1433" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1356" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1433" use="optional" order="42" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.spy.com/role/StockholdersEquitySummaryOfPreFundedWarrantsForCommonStockIssuedAndOutstandingDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1312" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1206" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1312" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1206" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1211" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1206" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1211" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1207" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1211" xlink:to="loc_us-gaap_EquityComponentDomain_1207" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1207_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1211" xlink:to="loc_us-gaap_EquityComponentDomain_1207_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_1208" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1207" xlink:to="loc_us-gaap_WarrantMember_1208" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaap_AwardDateAxis_1214" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1206" xlink:to="loc_us-gaap_AwardDateAxis_1214" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaap_AwardDateDomain_1209" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardDateAxis_1214" xlink:to="loc_us-gaap_AwardDateDomain_1209" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaap_AwardDateDomain_1209_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardDateAxis_1214" xlink:to="loc_us-gaap_AwardDateDomain_1209_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_FebruaryTwoThousandNinteenMember" xlink:label="loc_agle_FebruaryTwoThousandNinteenMember_1205" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AwardDateDomain_1209" xlink:to="loc_agle_FebruaryTwoThousandNinteenMember_1205" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AprilTwoThousandTwentyMember" xlink:label="loc_agle_AprilTwoThousandTwentyMember_1212" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AwardDateDomain_1209" xlink:to="loc_agle_AprilTwoThousandTwentyMember_1212" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_MayTwoThousandTwentyTwoMember" xlink:label="loc_agle_MayTwoThousandTwentyTwoMember_1310" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AwardDateDomain_1209" xlink:to="loc_agle_MayTwoThousandTwentyTwoMember_1310" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="loc_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_1210" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1312" xlink:to="loc_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_1210" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_WarrantExpirationDate" xlink:label="loc_agle_WarrantExpirationDate_1213" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1312" xlink:to="loc_agle_WarrantExpirationDate_1213" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_1314" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1312" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_1314" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1311" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1312" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1311" use="optional" order="15" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.spy.com/role/RelatedPartyTransactionsNarrativeDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_652" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_626" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_652" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_626" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis" xlink:label="loc_srt_OwnershipAxis_627" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_626" xlink:to="loc_srt_OwnershipAxis_627" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_628" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_627" xlink:to="loc_srt_OwnershipDomain_628" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_628_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_627" xlink:to="loc_srt_OwnershipDomain_628_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ParagonTherapeuticsIncMember" xlink:label="loc_agle_ParagonTherapeuticsIncMember_629" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_628" xlink:to="loc_agle_ParagonTherapeuticsIncMember_629" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_FairmountFundsManagementLlcMember" xlink:label="loc_agle_FairmountFundsManagementLlcMember_630" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_628" xlink:to="loc_agle_FairmountFundsManagementLlcMember_630" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ParagonAndParapyreHoldingLlcMember" xlink:label="loc_agle_ParagonAndParapyreHoldingLlcMember_2008" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_628" xlink:to="loc_agle_ParagonAndParapyreHoldingLlcMember_2008" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_631" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_626" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_631" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_632" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_631" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_632" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_632_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_631" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_632_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_OwnershipInterestMember" xlink:label="loc_agle_OwnershipInterestMember_633" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_632" xlink:to="loc_agle_OwnershipInterestMember_633" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AppointOfBoardMember" xlink:label="loc_agle_AppointOfBoardMember_634" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_632" xlink:to="loc_agle_AppointOfBoardMember_634" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ParagonAgreementMember" xlink:label="loc_agle_ParagonAgreementMember_635" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_632" xlink:to="loc_agle_ParagonAgreementMember_635" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_StockCompensationAndResearchAndDevelopmentExpenseMember" xlink:label="loc_agle_StockCompensationAndResearchAndDevelopmentExpenseMember_636" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_632" xlink:to="loc_agle_StockCompensationAndResearchAndDevelopmentExpenseMember_636" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ReimbursableCostsUnderParagonAgreementMember" xlink:label="loc_agle_ReimbursableCostsUnderParagonAgreementMember_637" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agle_StockCompensationAndResearchAndDevelopmentExpenseMember_636" xlink:to="loc_agle_ReimbursableCostsUnderParagonAgreementMember_637" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_MilestonePaymentsMember" xlink:label="loc_agle_MilestonePaymentsMember_638" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_632" xlink:to="loc_agle_MilestonePaymentsMember_638" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicensingAgreementsMember" xlink:label="loc_us-gaap_LicensingAgreementsMember_639" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_632" xlink:to="loc_us-gaap_LicensingAgreementsMember_639" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_Spy001LicenseAgreementMember" xlink:label="loc_agle_Spy001LicenseAgreementMember_640" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_632" xlink:to="loc_agle_Spy001LicenseAgreementMember_640" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_641" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_626" xlink:to="loc_srt_RangeAxis_641" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_642" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_641" xlink:to="loc_srt_RangeMember_642" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_642_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_641" xlink:to="loc_srt_RangeMember_642_default" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_643" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_642" xlink:to="loc_srt_MaximumMember_643" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_644" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_642" xlink:to="loc_srt_MinimumMember_644" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_645" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_626" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_645" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_646" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_645" xlink:to="loc_us-gaap_RelatedPartyDomain_646" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_646_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_645" xlink:to="loc_us-gaap_RelatedPartyDomain_646_default" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaap_RelatedPartyMember_647" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_646" xlink:to="loc_us-gaap_RelatedPartyMember_647" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_648" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_626" xlink:to="loc_srt_CounterpartyNameAxis_648" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_649" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_648" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_649" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_649_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_648" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_649_default" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_653" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_652" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_653" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_RelatedPartyTransactionNumberOfBoardSeats" xlink:label="loc_agle_RelatedPartyTransactionNumberOfBoardSeats_654" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_652" xlink:to="loc_agle_RelatedPartyTransactionNumberOfBoardSeats_654" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_MinorityInterestOwnershipPercentageByNoncontrollingOwnersHeldInThirdParty" xlink:label="loc_agle_MinorityInterestOwnershipPercentageByNoncontrollingOwnersHeldInThirdParty_655" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_652" xlink:to="loc_agle_MinorityInterestOwnershipPercentageByNoncontrollingOwnersHeldInThirdParty_655" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_RelatedPartyExpensesIncurredPriorToAssetAcquisition" xlink:label="loc_agle_RelatedPartyExpensesIncurredPriorToAssetAcquisition_656" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_652" xlink:to="loc_agle_RelatedPartyExpensesIncurredPriorToAssetAcquisition_656" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ResearchInitiationFees" xlink:label="loc_agle_ResearchInitiationFees_657" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_652" xlink:to="loc_agle_ResearchInitiationFees_657" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ReimbursableResearchCosts" xlink:label="loc_agle_ReimbursableResearchCosts_658" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_652" xlink:to="loc_agle_ReimbursableResearchCosts_658" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_RelatedPartyExpensesUnpaidPriorToAssetAcquisition" xlink:label="loc_agle_RelatedPartyExpensesUnpaidPriorToAssetAcquisition_659" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_652" xlink:to="loc_agle_RelatedPartyExpensesUnpaidPriorToAssetAcquisition_659" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_660" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_652" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_660" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_661" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_652" xlink:to="loc_us-gaap_AccountsPayableCurrent_661" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_RelatedPartyTransactionNumberOfProgramOptionsOutstanding" xlink:label="loc_agle_RelatedPartyTransactionNumberOfProgramOptionsOutstanding_662" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_652" xlink:to="loc_agle_RelatedPartyTransactionNumberOfProgramOptionsOutstanding_662" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AmountToBePaidUnderAgreement" xlink:label="loc_agle_AmountToBePaidUnderAgreement_663" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_652" xlink:to="loc_agle_AmountToBePaidUnderAgreement_663" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock" xlink:label="loc_agle_PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock_664" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_652" xlink:to="loc_agle_PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock_664" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_665" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_652" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_665" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_666" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_652" xlink:to="loc_us-gaap_ShareBasedCompensation_666" use="optional" order="44" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.spy.com/role/RelatedPartyTransactionsExpensesRelatedToRelatedPartyWhichWereSettledInCashDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_679" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_RelatedPartyTransactionReimbursableCosts" xlink:label="loc_agle_RelatedPartyTransactionReimbursableCosts_680" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_679" xlink:to="loc_agle_RelatedPartyTransactionReimbursableCosts_680" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_669" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_679" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_669" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_673" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_669" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_673" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_674" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_673" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_674" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_674_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_673" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_674_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ReimbursableCostsUnderParagonAgreementMember" xlink:label="loc_agle_ReimbursableCostsUnderParagonAgreementMember_675" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_674" xlink:to="loc_agle_ReimbursableCostsUnderParagonAgreementMember_675" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_676" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_669" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_676" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_677" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_676" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_677" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_677_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_676" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_677_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_678" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_677" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_678" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_670" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_669" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_670" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_671" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_670" xlink:to="loc_us-gaap_RelatedPartyDomain_671" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_671_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_670" xlink:to="loc_us-gaap_RelatedPartyDomain_671_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaap_RelatedPartyMember_672" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_671" xlink:to="loc_us-gaap_RelatedPartyMember_672" use="optional" order="14" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.spy.com/role/RelatedPartyTransactionsRelatedPartyAccountsPayableDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_691" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_683" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_691" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_683" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_684" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_683" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_684" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_685" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_684" xlink:to="loc_us-gaap_RelatedPartyDomain_685" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_685_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_684" xlink:to="loc_us-gaap_RelatedPartyDomain_685_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaap_RelatedPartyMember_686" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_685" xlink:to="loc_us-gaap_RelatedPartyMember_686" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_687" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_683" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_687" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_688" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_687" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_688" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_688_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_687" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_688_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ReimbursableCostsUnderParagonAgreementMember" xlink:label="loc_agle_ReimbursableCostsUnderParagonAgreementMember_689" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_688" xlink:to="loc_agle_ReimbursableCostsUnderParagonAgreementMember_689" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ParapyreOptionObligationMember" xlink:label="loc_agle_ParapyreOptionObligationMember_690" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_688" xlink:to="loc_agle_ParapyreOptionObligationMember_690" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_692" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_691" xlink:to="loc_us-gaap_AccountsPayableCurrent_692" use="optional" order="11" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.spy.com/role/AssetAcquisitionNarrativeDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="loc_us-gaap_AssetAcquisitionLineItems_708" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionTable" xlink:label="loc_us-gaap_AssetAcquisitionTable_695" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_708" xlink:to="loc_us-gaap_AssetAcquisitionTable_695" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_696" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AssetAcquisitionTable_695" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_696" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_697" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_696" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_697" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_697_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_696" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_697_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_698" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_697" xlink:to="loc_us-gaap_CommonStockMember_698" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_699" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AssetAcquisitionTable_695" xlink:to="loc_us-gaap_StatementClassOfStockAxis_699" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_700" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_699" xlink:to="loc_us-gaap_ClassOfStockDomain_700" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_700_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_699" xlink:to="loc_us-gaap_ClassOfStockDomain_700_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_SeriesANonVotingConvertiblePreferredStockMember" xlink:label="loc_agle_SeriesANonVotingConvertiblePreferredStockMember_701" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_700" xlink:to="loc_agle_SeriesANonVotingConvertiblePreferredStockMember_701" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_702" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AssetAcquisitionTable_695" xlink:to="loc_us-gaap_PlanNameAxis_702" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_703" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_702" xlink:to="loc_us-gaap_PlanNameDomain_703" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_703_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_702" xlink:to="loc_us-gaap_PlanNameDomain_703_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_Spyre2023EquityIncentivePlanMember" xlink:label="loc_agle_Spyre2023EquityIncentivePlanMember_704" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_703" xlink:to="loc_agle_Spyre2023EquityIncentivePlanMember_704" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="loc_us-gaap_AssetAcquisitionAxis_705" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AssetAcquisitionTable_695" xlink:to="loc_us-gaap_AssetAcquisitionAxis_705" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaap_AssetAcquisitionDomain_706" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_705" xlink:to="loc_us-gaap_AssetAcquisitionDomain_706" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaap_AssetAcquisitionDomain_706_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_705" xlink:to="loc_us-gaap_AssetAcquisitionDomain_706_default" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_SpyreTherapeuticsIncMember" xlink:label="loc_agle_SpyreTherapeuticsIncMember_707" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_706" xlink:to="loc_agle_SpyreTherapeuticsIncMember_707" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares" xlink:label="loc_agle_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares_709" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_708" xlink:to="loc_agle_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares_709" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_OutstandingAndUnexercisedStockOptions" xlink:label="loc_agle_OutstandingAndUnexercisedStockOptions_710" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_708" xlink:to="loc_agle_OutstandingAndUnexercisedStockOptions_710" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferred_711" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_708" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferred_711" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_712" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_708" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_712" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableSharesOfCommonStockOnAnAsConvertedBasis" xlink:label="loc_agle_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableSharesOfCommonStockOnAnAsConvertedBasis_713" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_708" xlink:to="loc_agle_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableSharesOfCommonStockOnAnAsConvertedBasis_713" use="optional" order="22" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.spy.com/role/AssetAcquisitionAssetAcquisitionCostDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="loc_us-gaap_AssetAcquisitionLineItems_720" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionTable" xlink:label="loc_us-gaap_AssetAcquisitionTable_716" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_720" xlink:to="loc_us-gaap_AssetAcquisitionTable_716" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="loc_us-gaap_AssetAcquisitionAxis_717" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AssetAcquisitionTable_716" xlink:to="loc_us-gaap_AssetAcquisitionAxis_717" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaap_AssetAcquisitionDomain_718" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_717" xlink:to="loc_us-gaap_AssetAcquisitionDomain_718" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaap_AssetAcquisitionDomain_718_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_717" xlink:to="loc_us-gaap_AssetAcquisitionDomain_718_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_SpyreTherapeuticsIncMember" xlink:label="loc_agle_SpyreTherapeuticsIncMember_719" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_718" xlink:to="loc_agle_SpyreTherapeuticsIncMember_719" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_721" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_720" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_721" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_722" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_720" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_722" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AcquiredInProcessResearchAndDevelopment" xlink:label="loc_agle_AcquiredInProcessResearchAndDevelopment_723" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_720" xlink:to="loc_agle_AcquiredInProcessResearchAndDevelopment_723" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition_724" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_720" xlink:to="loc_us-gaap_CashAcquiredFromAcquisition_724" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AssumedLiabilities" xlink:label="loc_agle_AssumedLiabilities_725" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_720" xlink:to="loc_agle_AssumedLiabilities_725" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferred_726" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_720" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferred_726" use="optional" order="11" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.spy.com/role/ParagonAgreementDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_748" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_LicenseAgreementMilestonePayments" xlink:label="loc_agle_LicenseAgreementMilestonePayments_759" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_748" xlink:to="loc_agle_LicenseAgreementMilestonePayments_759" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_729" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_748" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_729" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_730" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_729" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_730" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_731" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_730" xlink:to="loc_us-gaap_RelatedPartyDomain_731" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_731_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_730" xlink:to="loc_us-gaap_RelatedPartyDomain_731_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaap_RelatedPartyMember_732" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_731" xlink:to="loc_us-gaap_RelatedPartyMember_732" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_733" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_729" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_733" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_734" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_733" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_734" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_734_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_733" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_734_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ParagonAgreementMember" xlink:label="loc_agle_ParagonAgreementMember_735" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_734" xlink:to="loc_agle_ParagonAgreementMember_735" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_Spy001LicenseAgreementMember" xlink:label="loc_agle_Spy001LicenseAgreementMember_736" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_734" xlink:to="loc_agle_Spy001LicenseAgreementMember_736" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_StockCompensationAndResearchAndDevelopmentExpenseMember" xlink:label="loc_agle_StockCompensationAndResearchAndDevelopmentExpenseMember_738" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_734" xlink:to="loc_agle_StockCompensationAndResearchAndDevelopmentExpenseMember_738" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_739" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_729" xlink:to="loc_us-gaap_PlanNameAxis_739" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_740" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_739" xlink:to="loc_us-gaap_PlanNameDomain_740" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_740_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_739" xlink:to="loc_us-gaap_PlanNameDomain_740_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ParapyreOptionObligationMember" xlink:label="loc_agle_ParapyreOptionObligationMember_741" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_740" xlink:to="loc_agle_ParapyreOptionObligationMember_741" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_742" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_729" xlink:to="loc_srt_RangeAxis_742" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_743" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_742" xlink:to="loc_srt_RangeMember_743" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_743_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_742" xlink:to="loc_srt_RangeMember_743_default" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_744" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_743" xlink:to="loc_srt_MaximumMember_744" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_745" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_729" xlink:to="loc_srt_CounterpartyNameAxis_745" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_746" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_745" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_746" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_746_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_745" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_746_default" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ParagonTherapeuticsIncMember" xlink:label="loc_agle_ParagonTherapeuticsIncMember_747" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_746" xlink:to="loc_agle_ParagonTherapeuticsIncMember_747" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ResearchInitiationFees" xlink:label="loc_agle_ResearchInitiationFees_749" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_748" xlink:to="loc_agle_ResearchInitiationFees_749" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_RelatedPartyExpensesIncurredPriorToAssetAcquisition" xlink:label="loc_agle_RelatedPartyExpensesIncurredPriorToAssetAcquisition_750" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_748" xlink:to="loc_agle_RelatedPartyExpensesIncurredPriorToAssetAcquisition_750" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ReimbursableResearchCosts" xlink:label="loc_agle_ReimbursableResearchCosts_751" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_748" xlink:to="loc_agle_ReimbursableResearchCosts_751" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_RelatedPartyExpensesUnpaidPriorToAssetAcquisition" xlink:label="loc_agle_RelatedPartyExpensesUnpaidPriorToAssetAcquisition_752" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_748" xlink:to="loc_agle_RelatedPartyExpensesUnpaidPriorToAssetAcquisition_752" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock" xlink:label="loc_agle_PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock_753" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_748" xlink:to="loc_agle_PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock_753" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_NonrefundableResearchInitiationFeeForOneProgramPaidInCash" xlink:label="loc_agle_NonrefundableResearchInitiationFeeForOneProgramPaidInCash_754" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_748" xlink:to="loc_agle_NonrefundableResearchInitiationFeeForOneProgramPaidInCash_754" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_755" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_748" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_755" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AmountToBePaidUnderAgreement" xlink:label="loc_agle_AmountToBePaidUnderAgreement_756" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_748" xlink:to="loc_agle_AmountToBePaidUnderAgreement_756" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_NominationFee" xlink:label="loc_agle_NominationFee_757" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_748" xlink:to="loc_agle_NominationFee_757" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_PaymentOfMilestone" xlink:label="loc_agle_PaymentOfMilestone_758" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_748" xlink:to="loc_agle_PaymentOfMilestone_758" use="optional" order="34" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.spy.com/role/SeriesANonVotingConvertiblePreferredStockDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_776" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_762" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_762" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_763" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_762" xlink:to="loc_us-gaap_StatementClassOfStockAxis_763" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_764" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_763" xlink:to="loc_us-gaap_ClassOfStockDomain_764" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_764_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_763" xlink:to="loc_us-gaap_ClassOfStockDomain_764_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_SeriesANonVotingConvertiblePreferredStockMember" xlink:label="loc_agle_SeriesANonVotingConvertiblePreferredStockMember_765" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_764" xlink:to="loc_agle_SeriesANonVotingConvertiblePreferredStockMember_765" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_766" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_762" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_766" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_767" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_766" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_767" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_767_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_766" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_767_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_768" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_767" xlink:to="loc_us-gaap_PrivatePlacementMember_768" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_769" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_762" xlink:to="loc_srt_RangeAxis_769" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_770" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_769" xlink:to="loc_srt_RangeMember_770" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_770_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_769" xlink:to="loc_srt_RangeMember_770_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_771" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_770" xlink:to="loc_srt_MinimumMember_771" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_772" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_770" xlink:to="loc_srt_MaximumMember_772" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_773" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_762" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_773" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_774" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_773" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_774" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_774_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_773" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_774_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AssetAcquisitionMember" xlink:label="loc_agle_AssetAcquisitionMember_775" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_774" xlink:to="loc_agle_AssetAcquisitionMember_775" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_PreferredStockRemainsIssuedAndOutstandingPercentage" xlink:label="loc_agle_PreferredStockRemainsIssuedAndOutstandingPercentage_777" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_agle_PreferredStockRemainsIssuedAndOutstandingPercentage_777" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockRedemptionAmount" xlink:label="loc_us-gaap_PreferredStockRedemptionAmount_778" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_us-gaap_PreferredStockRedemptionAmount_778" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockRedemptionPricePerShare" xlink:label="loc_us-gaap_PreferredStockRedemptionPricePerShare_779" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_us-gaap_PreferredStockRedemptionPricePerShare_779" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleConversionRatio" xlink:label="loc_us-gaap_PreferredStockConvertibleConversionRatio_780" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_us-gaap_PreferredStockConvertibleConversionRatio_780" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_BeneficiallyHoldersOwnedPercentage" xlink:label="loc_agle_BeneficiallyHoldersOwnedPercentage_781" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_agle_BeneficiallyHoldersOwnedPercentage_781" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_agle_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_782" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_agle_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_782" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_783" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_783" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_784" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_784" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares" xlink:label="loc_agle_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares_785" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_agle_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares_785" use="optional" order="27" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityPreFundedWarrantsForCommonStockIssuedAndOutstandingDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_852" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_843" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_852" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_843" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_844" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_843" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_844" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_845" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_844" xlink:to="loc_us-gaap_EquityComponentDomain_845" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_845_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_844" xlink:to="loc_us-gaap_EquityComponentDomain_845_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_846" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_845" xlink:to="loc_us-gaap_WarrantMember_846" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaap_AwardDateAxis_847" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_843" xlink:to="loc_us-gaap_AwardDateAxis_847" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaap_AwardDateDomain_848" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardDateAxis_847" xlink:to="loc_us-gaap_AwardDateDomain_848" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaap_AwardDateDomain_848_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardDateAxis_847" xlink:to="loc_us-gaap_AwardDateDomain_848_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_FebruaryEightTwoThousandNinteenMember" xlink:label="loc_agle_FebruaryEightTwoThousandNinteenMember_849" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AwardDateDomain_848" xlink:to="loc_agle_FebruaryEightTwoThousandNinteenMember_849" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AprilThirtyTwoThousandTwentyMember" xlink:label="loc_agle_AprilThirtyTwoThousandTwentyMember_850" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AwardDateDomain_848" xlink:to="loc_agle_AprilThirtyTwoThousandTwentyMember_850" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_MayTwentyTwoThousandTwentyTwoMember" xlink:label="loc_agle_MayTwentyTwoThousandTwentyTwoMember_851" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AwardDateDomain_848" xlink:to="loc_agle_MayTwentyTwoThousandTwentyTwoMember_851" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_854" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_852" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_854" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_853" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_852" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_853" use="optional" order="13" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1245" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1245" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_GranteesWithMoreThanFiveYearsVestingTermPercent" xlink:label="loc_agle_GranteesWithMoreThanFiveYearsVestingTermPercent_1286" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_agle_GranteesWithMoreThanFiveYearsVestingTermPercent_1286" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_MaximumVestingTermForMoreThanTenPercentGrantees" xlink:label="loc_agle_MaximumVestingTermForMoreThanTenPercentGrantees_1329" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_agle_MaximumVestingTermForMoreThanTenPercentGrantees_1329" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_1349" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_1349" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_1365" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_1365" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1376" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1376" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_agle_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance_1387" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_agle_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance_1387" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_1394" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_1394" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AnnualPercentageOfAdditionalSharesWhichEqualsToIssuedAndOutstandingShares" xlink:label="loc_agle_AnnualPercentageOfAdditionalSharesWhichEqualsToIssuedAndOutstandingShares_1402" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_agle_AnnualPercentageOfAdditionalSharesWhichEqualsToIssuedAndOutstandingShares_1402" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant" xlink:label="loc_agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant_1405" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant_1405" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1410" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1410" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1413" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1413" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1418" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1418" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_1420" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_1420" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_1425" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_1425" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1431" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1431" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAnnualFairMarketValuePerEmployee" xlink:label="loc_agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAnnualFairMarketValuePerEmployee_1432" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAnnualFairMarketValuePerEmployee_1432" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalAnnualPercentageIncrease" xlink:label="loc_agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalAnnualPercentageIncrease_1438" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalAnnualPercentageIncrease_1438" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1441" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1441" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_1442" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_1442" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_1445" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_1445" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_1446" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_1446" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1449" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1449" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_1451" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_1451" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_1453" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_1453" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1972" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1972" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_1973" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_1973" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1974" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1974" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ClassOfWarrantOrRightOfferingPriceOfWarrantsOrRights" xlink:label="loc_agle_ClassOfWarrantOrRightOfferingPriceOfWarrantsOrRights_1975" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_agle_ClassOfWarrantOrRightOfferingPriceOfWarrantsOrRights_1975" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1977" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1977" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_PlacementAgentFeesAndOfferingCosts" xlink:label="loc_agle_PlacementAgentFeesAndOfferingCosts_1978" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_agle_PlacementAgentFeesAndOfferingCosts_1978" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_OwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercised" xlink:label="loc_agle_OwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercised_1986" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_agle_OwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercised_1986" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_OwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercisedToCertainHolders" xlink:label="loc_agle_OwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercisedToCertainHolders_1987" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_agle_OwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercisedToCertainHolders_1987" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ClassOfWarrantOrRightRevisedOwnershipPercentagePeriodToTakeEffectAfterNotice" xlink:label="loc_agle_ClassOfWarrantOrRightRevisedOwnershipPercentagePeriodToTakeEffectAfterNotice_1988" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_agle_ClassOfWarrantOrRightRevisedOwnershipPercentagePeriodToTakeEffectAfterNotice_1988" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1976" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1976" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1990" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1990" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_1991" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_1991" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_StockOptionsGrantedToCertainMembersOfBoardOfDirectorsContingentOnStockholderApproval" xlink:label="loc_agle_StockOptionsGrantedToCertainMembersOfBoardOfDirectorsContingentOnStockholderApproval_1993" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_agle_StockOptionsGrantedToCertainMembersOfBoardOfDirectorsContingentOnStockholderApproval_1993" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_StockBasedCompensationExpenseOnContingentAwards" xlink:label="loc_agle_StockBasedCompensationExpenseOnContingentAwards_1994" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_agle_StockBasedCompensationExpenseOnContingentAwards_1994" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_1996" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_1996" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_OutstandingAndUnexercisedStockOptions" xlink:label="loc_agle_OutstandingAndUnexercisedStockOptions_1997" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_agle_OutstandingAndUnexercisedStockOptions_1997" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_1999" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_1999" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_2000" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_2000" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_2001" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_us-gaap_ShareBasedCompensation_2001" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="loc_us-gaap_ProceedsFromStockPlans_2006" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_us-gaap_ProceedsFromStockPlans_2006" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1454" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1454" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1455" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1455" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1456" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1456" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1457" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1457" use="optional" order="49" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodOfFirstTwentyFivePercent" xlink:label="loc_agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodOfFirstTwentyFivePercent_1458" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodOfFirstTwentyFivePercent_1458" use="optional" order="50" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodOfRemainingSeventyFivePercent" xlink:label="loc_agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodOfRemainingSeventyFivePercent_1459" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodOfRemainingSeventyFivePercent_1459" use="optional" order="51" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsGrantedExercisablePeriod" xlink:label="loc_agle_ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsGrantedExercisablePeriod_1460" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_agle_ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsGrantedExercisablePeriod_1460" use="optional" order="52" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_MaximumNumberOfSharesPurchasedUnderEmployeeStockPurchasePlan" xlink:label="loc_agle_MaximumNumberOfSharesPurchasedUnderEmployeeStockPurchasePlan_1462" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_agle_MaximumNumberOfSharesPurchasedUnderEmployeeStockPurchasePlan_1462" use="optional" order="53" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1090" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1090" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="54" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1246" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1090" xlink:to="loc_srt_RangeAxis_1246" use="optional" order="55" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1091" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1246" xlink:to="loc_srt_RangeMember_1091" use="optional" order="56" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1091_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1246" xlink:to="loc_srt_RangeMember_1091_default" use="optional" order="57" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1243" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1091" xlink:to="loc_srt_MaximumMember_1243" use="optional" order="58" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_1093" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1091" xlink:to="loc_srt_MinimumMember_1093" use="optional" order="59" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1287" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1090" xlink:to="loc_us-gaap_AwardTypeAxis_1287" use="optional" order="60" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1097" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1287" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1097" use="optional" order="61" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1097_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1287" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1097_default" use="optional" order="62" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_NonQualifiedStockOptionsMember" xlink:label="loc_agle_NonQualifiedStockOptionsMember_1244" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1097" xlink:to="loc_agle_NonQualifiedStockOptionsMember_1244" use="optional" order="63" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_1285" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1097" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_1285" use="optional" order="64" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ServiceBasedAwardsMember" xlink:label="loc_agle_ServiceBasedAwardsMember_1328" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1097" xlink:to="loc_agle_ServiceBasedAwardsMember_1328" use="optional" order="65" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaap_StockOptionMember_1096" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1097" xlink:to="loc_us-gaap_StockOptionMember_1096" use="optional" order="66" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1330" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1090" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1330" use="optional" order="67" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1102" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1330" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1102" use="optional" order="68" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1102_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1330" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1102_default" use="optional" order="69" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_1088" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1102" xlink:to="loc_us-gaap_SubsequentEventMember_1088" use="optional" order="70" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_1350" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1090" xlink:to="loc_us-gaap_VestingAxis_1350" use="optional" order="71" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_1094" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_1350" xlink:to="loc_us-gaap_VestingDomain_1094" use="optional" order="72" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_1094_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_1350" xlink:to="loc_us-gaap_VestingDomain_1094_default" use="optional" order="73" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_1366" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1090" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_1366" use="optional" order="74" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_1092" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_1366" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_1092" use="optional" order="75" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_1092_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_1366" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_1092_default" use="optional" order="76" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1095" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_1092" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1095" use="optional" order="77" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_1377" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1090" xlink:to="loc_srt_TitleOfIndividualAxis_1377" use="optional" order="78" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1104" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_1377" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1104" use="optional" order="79" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1104_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_1377" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1104_default" use="optional" order="80" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_EmployeesAndNonEmployeesMember" xlink:label="loc_agle_EmployeesAndNonEmployeesMember_1247" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1104" xlink:to="loc_agle_EmployeesAndNonEmployeesMember_1247" use="optional" order="81" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_NewChiefExecutiveOfficerMember" xlink:label="loc_agle_NewChiefExecutiveOfficerMember_1288" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1104" xlink:to="loc_agle_NewChiefExecutiveOfficerMember_1288" use="optional" order="82" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_NonEmployeesMember" xlink:label="loc_agle_NonEmployeesMember_1101" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1104" xlink:to="loc_agle_NonEmployeesMember_1101" use="optional" order="83" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="loc_us-gaap_AssetAcquisitionAxis_1979" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1090" xlink:to="loc_us-gaap_AssetAcquisitionAxis_1979" use="optional" order="84" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaap_AssetAcquisitionDomain_1980" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_1979" xlink:to="loc_us-gaap_AssetAcquisitionDomain_1980" use="optional" order="85" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaap_AssetAcquisitionDomain_1980_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_1979" xlink:to="loc_us-gaap_AssetAcquisitionDomain_1980_default" use="optional" order="86" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AssetAcquisitionMember" xlink:label="loc_agle_AssetAcquisitionMember_1981" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_1980" xlink:to="loc_agle_AssetAcquisitionMember_1981" use="optional" order="87" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1982" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1090" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1982" use="optional" order="88" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1983" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1982" xlink:to="loc_us-gaap_EquityComponentDomain_1983" use="optional" order="89" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1983_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1982" xlink:to="loc_us-gaap_EquityComponentDomain_1983_default" use="optional" order="90" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1985" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1983" xlink:to="loc_us-gaap_CommonStockMember_1985" use="optional" order="91" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_2003" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1090" xlink:to="loc_srt_StatementScenarioAxis_2003" use="optional" order="92" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_2004" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_2003" xlink:to="loc_srt_ScenarioUnspecifiedDomain_2004" use="optional" order="93" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_2004_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_2003" xlink:to="loc_srt_ScenarioUnspecifiedDomain_2004_default" use="optional" order="94" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember" xlink:label="loc_srt_ScenarioForecastMember_2005" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_2004" xlink:to="loc_srt_ScenarioForecastMember_2005" use="optional" order="95" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1099" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1090" xlink:to="loc_us-gaap_PlanNameAxis_1099" use="optional" order="96" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1103" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_1099" xlink:to="loc_us-gaap_PlanNameDomain_1103" use="optional" order="97" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1103_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_1099" xlink:to="loc_us-gaap_PlanNameDomain_1103_default" use="optional" order="98" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_TwoThousandAndSixteenEquityIncentivePlanMember" xlink:label="loc_agle_TwoThousandAndSixteenEquityIncentivePlanMember_1242" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1103" xlink:to="loc_agle_TwoThousandAndSixteenEquityIncentivePlanMember_1242" use="optional" order="99" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_TwoThousandAndEighteenEquityInducementPlanMember" xlink:label="loc_agle_TwoThousandAndEighteenEquityInducementPlanMember_1284" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1103" xlink:to="loc_agle_TwoThousandAndEighteenEquityInducementPlanMember_1284" use="optional" order="100" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_TwoThousandAndFifteenAndTwoThousandAndSixteenEquityIncentivePlanAndTwoThousandAndEighteenEquityInducementPlanMember" xlink:label="loc_agle_TwoThousandAndFifteenAndTwoThousandAndSixteenEquityIncentivePlanAndTwoThousandAndEighteenEquityInducementPlanMember_1327" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1103" xlink:to="loc_agle_TwoThousandAndFifteenAndTwoThousandAndSixteenEquityIncentivePlanAndTwoThousandAndEighteenEquityInducementPlanMember_1327" use="optional" order="101" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_TwoThousandAndSixteenEmployeeStockPurchasePlanMember" xlink:label="loc_agle_TwoThousandAndSixteenEmployeeStockPurchasePlanMember_1347" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1103" xlink:to="loc_agle_TwoThousandAndSixteenEmployeeStockPurchasePlanMember_1347" use="optional" order="102" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_Spyre2023EquityIncentivePlanMember" xlink:label="loc_agle_Spyre2023EquityIncentivePlanMember_1998" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1103" xlink:to="loc_agle_Spyre2023EquityIncentivePlanMember_1998" use="optional" order="103" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ParapyreOptionObligationMember" xlink:label="loc_agle_ParapyreOptionObligationMember_2002" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1103" xlink:to="loc_agle_ParapyreOptionObligationMember_2002" use="optional" order="104" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_TwoThousandAndFifteenEquityIncentivePlanMember" xlink:label="loc_agle_TwoThousandAndFifteenEquityIncentivePlanMember_1089" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1103" xlink:to="loc_agle_TwoThousandAndFifteenEquityIncentivePlanMember_1089" use="optional" order="105" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_1098" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_1098" use="optional" order="106" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquitySummaryOfEmployeeRestrictedStockActivityDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1307" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1194" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1307" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1194" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1198" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1194" xlink:to="loc_us-gaap_AwardTypeAxis_1198" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1196" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1198" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1196" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1196_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1198" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1196_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_1195" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1196" xlink:to="loc_us-gaap_RestrictedStockMember_1195" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_1217" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1194" xlink:to="loc_srt_TitleOfIndividualAxis_1217" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1191" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_1217" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1191" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1191_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_1217" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1191_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_EmployeesMember" xlink:label="loc_agle_EmployeesMember_1199" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1191" xlink:to="loc_agle_EmployeesMember_1199" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1197" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1307" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1197" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1216" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1307" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1216" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1306" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1307" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1306" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1316" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1307" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1316" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1360" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1307" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1360" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1382" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1307" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1382" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1383" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1307" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1383" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_1398" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1307" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_1398" use="optional" order="17" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityStockBasedCompensationExpenseDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1338" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1029" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1338" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1029" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1028" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1029" xlink:to="loc_us-gaap_PlanNameAxis_1028" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1034" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_1028" xlink:to="loc_us-gaap_PlanNameDomain_1034" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1034_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_1028" xlink:to="loc_us-gaap_PlanNameDomain_1034_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember" xlink:label="loc_agle_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember_1027" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1034" xlink:to="loc_agle_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember_1027" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1266" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1029" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1266" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1030" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1266" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1030" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1030_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1266" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1030_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1032" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1030" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1032" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1267" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1030" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1267" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_1275" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1029" xlink:to="loc_srt_TitleOfIndividualAxis_1275" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1035" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_1275" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1035" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1035_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_1275" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1035_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_EmployeesMember" xlink:label="loc_agle_EmployeesMember_1033" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1035" xlink:to="loc_agle_EmployeesMember_1033" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_NonEmployeesMember" xlink:label="loc_agle_NonEmployeesMember_1268" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1035" xlink:to="loc_agle_NonEmployeesMember_1268" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_1031" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1338" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_1031" use="optional" order="16" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityAssumptionsUsedToEstimateTheFairValueOfStockOptionsGrantedDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1281" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1068" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1281" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1068" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1067" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1068" xlink:to="loc_us-gaap_PlanNameAxis_1067" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1072" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_1067" xlink:to="loc_us-gaap_PlanNameDomain_1072" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1072_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_1067" xlink:to="loc_us-gaap_PlanNameDomain_1072_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_TwoThousandAndSixteenEmployeeStockPurchasePlanMember" xlink:label="loc_agle_TwoThousandAndSixteenEmployeeStockPurchasePlanMember_1251" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1072" xlink:to="loc_agle_TwoThousandAndSixteenEmployeeStockPurchasePlanMember_1251" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_TwoThousandAndSixteenEquityIncentivePlanMember" xlink:label="loc_agle_TwoThousandAndSixteenEquityIncentivePlanMember_1948" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1072" xlink:to="loc_agle_TwoThousandAndSixteenEquityIncentivePlanMember_1948" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1252" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1068" xlink:to="loc_us-gaap_AwardTypeAxis_1252" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1070" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1252" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1070" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1070_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1252" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1070_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1069" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1070" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1069" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1071" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1281" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1071" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1253" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1281" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1253" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1282" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1281" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1282" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1332" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1281" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1332" use="optional" order="14" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.spy.com/role/StrategicLicenseAgreementsNarrativeDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_905" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_886" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_905" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_886" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_887" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_886" xlink:to="loc_us-gaap_TypeOfArrangementAxis_887" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_888" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_887" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_888" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_888_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_887" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_888_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ImmedicaPharmaABMember" xlink:label="loc_agle_ImmedicaPharmaABMember_1131" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_888" xlink:to="loc_agle_ImmedicaPharmaABMember_1131" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_UniversityOfTexasAtAustinMember" xlink:label="loc_agle_UniversityOfTexasAtAustinMember_1415" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_888" xlink:to="loc_agle_UniversityOfTexasAtAustinMember_1415" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_890" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_886" xlink:to="loc_srt_RangeAxis_890" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_891" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_890" xlink:to="loc_srt_RangeMember_891" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_891_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_890" xlink:to="loc_srt_RangeMember_891_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_892" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_891" xlink:to="loc_srt_MaximumMember_892" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_1426" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_891" xlink:to="loc_srt_MinimumMember_1426" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_893" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_886" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_893" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_894" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_893" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_894" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_894_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_893" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_894_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_PeaceTrialAndBLAPackageMember" xlink:label="loc_agle_PeaceTrialAndBLAPackageMember_895" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_894" xlink:to="loc_agle_PeaceTrialAndBLAPackageMember_895" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_PIPTrialMember" xlink:label="loc_agle_PIPTrialMember_896" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_894" xlink:to="loc_agle_PIPTrialMember_896" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_LicenseAgreementsMember" xlink:label="loc_agle_LicenseAgreementsMember_897" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_894" xlink:to="loc_agle_LicenseAgreementsMember_897" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_PeacePhase3TrialAndDrugSupplyMember" xlink:label="loc_agle_PeacePhase3TrialAndDrugSupplyMember_898" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_894" xlink:to="loc_agle_PeacePhase3TrialAndDrugSupplyMember_898" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_899" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_886" xlink:to="loc_srt_ProductOrServiceAxis_899" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_900" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_899" xlink:to="loc_srt_ProductsAndServicesDomain_900" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_900_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_899" xlink:to="loc_srt_ProductsAndServicesDomain_900_default" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaap_LicenseMember_901" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_900" xlink:to="loc_us-gaap_LicenseMember_901" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_NonRefundablePaymentReceived" xlink:label="loc_agle_NonRefundablePaymentReceived_906" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_905" xlink:to="loc_agle_NonRefundablePaymentReceived_906" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_PercentageOfPaymentForCostIncurredInPIPTrial" xlink:label="loc_agle_PercentageOfPaymentForCostIncurredInPIPTrial_907" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_905" xlink:to="loc_agle_PercentageOfPaymentForCostIncurredInPIPTrial_907" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_CostsIncurredInPerformingTheTrial" xlink:label="loc_agle_CostsIncurredInPerformingTheTrial_908" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_905" xlink:to="loc_agle_CostsIncurredInPerformingTheTrial_908" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_RateOfRevenueShare" xlink:label="loc_agle_RateOfRevenueShare_909" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_905" xlink:to="loc_agle_RateOfRevenueShare_909" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReimbursementFromLimitedPartnershipInvestment" xlink:label="loc_us-gaap_ReimbursementFromLimitedPartnershipInvestment_910" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_905" xlink:to="loc_us-gaap_ReimbursementFromLimitedPartnershipInvestment_910" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_UpfrontPayment" xlink:label="loc_agle_UpfrontPayment_911" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_905" xlink:to="loc_agle_UpfrontPayment_911" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ContractWithCustomerFullReimbursementOfCostsIncludedLiability" xlink:label="loc_agle_ContractWithCustomerFullReimbursementOfCostsIncludedLiability_912" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_905" xlink:to="loc_agle_ContractWithCustomerFullReimbursementOfCostsIncludedLiability_912" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_913" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_905" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_913" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_914" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_905" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_914" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AllocatedAmountOfTransactionPrice" xlink:label="loc_agle_AllocatedAmountOfTransactionPrice_915" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_905" xlink:to="loc_agle_AllocatedAmountOfTransactionPrice_915" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AllocationPriceTotal" xlink:label="loc_agle_AllocationPriceTotal_916" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_905" xlink:to="loc_agle_AllocationPriceTotal_916" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_917" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_905" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_917" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_918" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_905" xlink:to="loc_us-gaap_ContractWithCustomerLiability_918" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_919" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_905" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_919" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_920" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_905" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_920" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_LicenseAndSupplyAgreementDate" xlink:label="loc_agle_LicenseAndSupplyAgreementDate_1414" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_905" xlink:to="loc_agle_LicenseAndSupplyAgreementDate_1414" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_MaximumFutureContingentLicensePayment" xlink:label="loc_agle_MaximumFutureContingentLicensePayment_1776" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_905" xlink:to="loc_agle_MaximumFutureContingentLicensePayment_1776" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_NumberOfLicenseAgreements" xlink:label="loc_agle_NumberOfLicenseAgreements_1773" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_905" xlink:to="loc_agle_NumberOfLicenseAgreements_1773" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_PaymentOfAnnualLicenseFees" xlink:label="loc_agle_PaymentOfAnnualLicenseFees_1788" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_905" xlink:to="loc_agle_PaymentOfAnnualLicenseFees_1788" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_PaymentOfMilestone" xlink:label="loc_agle_PaymentOfMilestone_1785" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_905" xlink:to="loc_agle_PaymentOfMilestone_1785" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_MilestonePaymentsExchangeRate" xlink:label="loc_agle_MilestonePaymentsExchangeRate_1686" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_905" xlink:to="loc_agle_MilestonePaymentsExchangeRate_1686" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ResearchAgreementDate" xlink:label="loc_agle_ResearchAgreementDate_1130" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_905" xlink:to="loc_agle_ResearchAgreementDate_1130" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AdditionalUpfrontPaymentAbilityToReceived" xlink:label="loc_agle_AdditionalUpfrontPaymentAbilityToReceived_1648" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_905" xlink:to="loc_agle_AdditionalUpfrontPaymentAbilityToReceived_1648" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AggregatePotentialMilestonePaymentsForFinalRegulatoryApprovalOfSecondIndication" xlink:label="loc_agle_AggregatePotentialMilestonePaymentsForFinalRegulatoryApprovalOfSecondIndication_1782" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_905" xlink:to="loc_agle_AggregatePotentialMilestonePaymentsForFinalRegulatoryApprovalOfSecondIndication_1782" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AggregatePotentialMilestonePaymentsForReceiptOfRegulatoryApproval" xlink:label="loc_agle_AggregatePotentialMilestonePaymentsForReceiptOfRegulatoryApproval_1779" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_905" xlink:to="loc_agle_AggregatePotentialMilestonePaymentsForReceiptOfRegulatoryApproval_1779" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaap_DeferredRevenue_1751" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_905" xlink:to="loc_us-gaap_DeferredRevenue_1751" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_1755" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_905" xlink:to="loc_us-gaap_DeferredRevenueCurrent_1755" use="optional" order="49" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.spy.com/role/SaleOfPegzilarginaseToImmedicaDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_937" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_930" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_937" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_930" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_931" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_930" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_931" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_932" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_931" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_932" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_932_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_931" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_932_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_933" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_932" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_933" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_934" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_930" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_934" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_935" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_934" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_935" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_935_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_934" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_935_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_GlobalRightsToPegzilarginaseMember" xlink:label="loc_agle_GlobalRightsToPegzilarginaseMember_936" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_935" xlink:to="loc_agle_GlobalRightsToPegzilarginaseMember_936" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:label="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_938" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_937" xlink:to="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_938" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_DisposalGroupIncludingDiscontinuedOperationContingentConsideration" xlink:label="loc_agle_DisposalGroupIncludingDiscontinuedOperationContingentConsideration_939" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_937" xlink:to="loc_agle_DisposalGroupIncludingDiscontinuedOperationContingentConsideration_939" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_940" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_937" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_940" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_941" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_937" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_941" use="optional" order="13" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.spy.com/role/IncomeTaxesAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_IncomeTaxesLineItems" xlink:label="loc_agle_IncomeTaxesLineItems_1296" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1119" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agle_IncomeTaxesLineItems_1296" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_1119" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_IncomeTaxesTable" xlink:label="loc_agle_IncomeTaxesTable_1121" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_agle_IncomeTaxesLineItems_1296" xlink:to="loc_agle_IncomeTaxesTable_1121" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_1120" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_agle_IncomeTaxesTable_1121" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_1120" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_1123" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_1120" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_1123" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_1123_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_1120" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_1123_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_1294" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1123" xlink:to="loc_us-gaap_DomesticCountryMember_1294" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_1323" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1123" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_1323" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaap_ForeignCountryMember_1351" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1123" xlink:to="loc_us-gaap_ForeignCountryMember_1351" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodAxis" xlink:label="loc_us-gaap_TaxPeriodAxis_1235" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_agle_IncomeTaxesTable_1121" xlink:to="loc_us-gaap_TaxPeriodAxis_1235" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaap_TaxPeriodDomain_1118" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxPeriodAxis_1235" xlink:to="loc_us-gaap_TaxPeriodDomain_1118" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaap_TaxPeriodDomain_1118_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxPeriodAxis_1235" xlink:to="loc_us-gaap_TaxPeriodDomain_1118_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarliestTaxYearMember" xlink:label="loc_us-gaap_EarliestTaxYearMember_1122" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_1118" xlink:to="loc_us-gaap_EarliestTaxYearMember_1122" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_IncreaseInValuationPrimarilyDueToOperationLosses" xlink:label="loc_agle_IncreaseInValuationPrimarilyDueToOperationLosses_1234" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agle_IncomeTaxesLineItems_1296" xlink:to="loc_agle_IncreaseInValuationPrimarilyDueToOperationLosses_1234" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_1295" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agle_IncomeTaxesLineItems_1296" xlink:to="loc_us-gaap_OperatingLossCarryforwards_1295" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_1324" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agle_IncomeTaxesLineItems_1296" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_1324" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_OperatingLossCarryforwardsExpirationYear" xlink:label="loc_agle_OperatingLossCarryforwardsExpirationYear_1352" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agle_IncomeTaxesLineItems_1296" xlink:to="loc_agle_OperatingLossCarryforwardsExpirationYear_1352" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_TaxCreditCarryforwardExpirationYear" xlink:label="loc_agle_TaxCreditCarryforwardExpirationYear_1364" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agle_IncomeTaxesLineItems_1296" xlink:to="loc_agle_TaxCreditCarryforwardExpirationYear_1364" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_PercentageOfNetOperatingLossUtilizedToOffsetTaxableIncome" xlink:label="loc_agle_PercentageOfNetOperatingLossUtilizedToOffsetTaxableIncome_1378" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agle_IncomeTaxesLineItems_1296" xlink:to="loc_agle_PercentageOfNetOperatingLossUtilizedToOffsetTaxableIncome_1378" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_NetOperatingLossAndCreditCarryforwards" xlink:label="loc_agle_NetOperatingLossAndCreditCarryforwards_1386" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agle_IncomeTaxesLineItems_1296" xlink:to="loc_agle_NetOperatingLossAndCreditCarryforwards_1386" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_1395" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agle_IncomeTaxesLineItems_1296" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_1395" use="optional" order="20" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.spy.com/role/IncomeTaxesSummaryOfDifferenceBetweenProvisionForIncomeTaxesAndAmountsComputedByApplyingStatutoryFederalIncomeTaxRateToIncomeBeforeIncomeTaxesDetails">
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_IncomeTaxesLineItems" xlink:label="loc_agle_IncomeTaxesLineItems_1250" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_1082" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agle_IncomeTaxesLineItems_1250" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_1082" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_IncomeTaxesTable" xlink:label="loc_agle_IncomeTaxesTable_1084" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_agle_IncomeTaxesLineItems_1250" xlink:to="loc_agle_IncomeTaxesTable_1084" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_1083" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_agle_IncomeTaxesTable_1084" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_1083" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_1085" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_1083" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_1085" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_1085_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_1083" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_1085_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_1081" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1085" xlink:to="loc_us-gaap_DomesticCountryMember_1081" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_1248" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1085" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_1248" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_1249" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agle_IncomeTaxesLineItems_1250" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_1249" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_IncomeTaxReconciliationTaxCostCredit" xlink:label="loc_agle_IncomeTaxReconciliationTaxCostCredit_1283" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agle_IncomeTaxesLineItems_1250" xlink:to="loc_agle_IncomeTaxReconciliationTaxCostCredit_1283" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_1331" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agle_IncomeTaxesLineItems_1250" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_1331" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_1346" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agle_IncomeTaxesLineItems_1250" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_1346" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1367" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agle_IncomeTaxesLineItems_1250" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_1367" use="optional" order="12" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.spy.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails">
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_IncomeTaxesLineItems" xlink:label="loc_agle_IncomeTaxesLineItems_1261" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract_1050" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agle_IncomeTaxesLineItems_1261" xlink:to="loc_us-gaap_DeferredTaxAssetsNetAbstract_1050" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1054" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1050" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1054" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_1262" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1050" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_1262" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_1277" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1050" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_1277" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_1336" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1050" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_1336" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_1343" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1050" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_1343" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_1370" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1050" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_1370" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_1373" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1050" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_1373" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_1390" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1050" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_1390" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_IncomeTaxesTable" xlink:label="loc_agle_IncomeTaxesTable_1052" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_agle_IncomeTaxesLineItems_1261" xlink:to="loc_agle_IncomeTaxesTable_1052" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_1051" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_agle_IncomeTaxesTable_1052" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_1051" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_1053" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_1051" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_1053" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_1053_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_1051" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_1053_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_1049" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1053" xlink:to="loc_us-gaap_DomesticCountryMember_1049" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_1259" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1053" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_1259" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_1260" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agle_IncomeTaxesLineItems_1261" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_1260" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_1048" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_1260" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_1048" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_1258" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_1260" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_1258" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1309" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agle_IncomeTaxesLineItems_1261" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1309" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_1335" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agle_IncomeTaxesLineItems_1261" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_1335" use="optional" order="20" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.spy.com/role/NetLossPerShareWeightedAverageEquityInstrumentsExcludedFromCalculationOfDilutedNetLossPerShareDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1271" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1014" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1271" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1014" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1018" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1014" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1018" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1015" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1018" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1015" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1015_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1018" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1015_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_1017" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1015" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_1017" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1270" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1015" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1270" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_SeriesAConvertiblePreferredStockMember" xlink:label="loc_agle_SeriesAConvertiblePreferredStockMember_1789" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1015" xlink:to="loc_agle_SeriesAConvertiblePreferredStockMember_1789" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1016" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1271" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1016" use="optional" order="8" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.spy.com/role/ReverseStockSplitAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_1915" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_1914" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_1915" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_1914" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaap_StockholdersEquityReverseStockSplit_1916" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1915" xlink:to="loc_us-gaap_StockholdersEquityReverseStockSplit_1916" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_1917" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1915" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_1917" use="optional" order="3" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.spy.com/role/RestructuringChargesNarrativeDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_959" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_954" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_959" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_954" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_955" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_954" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_955" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_956" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_955" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_956" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_956_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_955" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_956_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_957" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_956" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_957" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_958" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_956" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_958" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_960" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_959" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_960" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaap_SeveranceCosts1_961" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_959" xlink:to="loc_us-gaap_SeveranceCosts1_961" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRestructuring" xlink:label="loc_us-gaap_PaymentsForRestructuring_962" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_959" xlink:to="loc_us-gaap_PaymentsForRestructuring_962" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_963" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_959" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_963" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_964" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_959" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_964" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_965" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_959" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_965" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_OperatingLeaseTerminationFeeAmount" xlink:label="loc_agle_OperatingLeaseTerminationFeeAmount_966" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_959" xlink:to="loc_agle_OperatingLeaseTerminationFeeAmount_966" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_967" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_959" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss_967" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLeasehold" xlink:label="loc_us-gaap_ImpairmentOfLeasehold_968" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_959" xlink:to="loc_us-gaap_ImpairmentOfLeasehold_968" use="optional" order="15" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.spy.com/role/RestructuringChargesChangesInAccruedRestructuringBalanceDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_975" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_971" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_975" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_971" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_972" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_971" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_972" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_973" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_972" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_973" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_973_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_972" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_973_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_SeveranceLiabilityMember" xlink:label="loc_agle_SeveranceLiabilityMember_974" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_973" xlink:to="loc_agle_SeveranceLiabilityMember_974" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserve" xlink:label="loc_us-gaap_RestructuringReserve_976" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_975" xlink:to="loc_us-gaap_RestructuringReserve_976" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_977" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_975" xlink:to="loc_us-gaap_RestructuringCharges_977" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRestructuring" xlink:label="loc_us-gaap_PaymentsForRestructuring_978" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_975" xlink:to="loc_us-gaap_PaymentsForRestructuring_978" use="optional" order="8" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.spy.com/role/RestructuringChargesChargesRelatedToTheRestructuringActivitiesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_990" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaap_SeveranceCosts1_991" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_990" xlink:to="loc_us-gaap_SeveranceCosts1_991" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_992" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_990" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_992" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_993" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_990" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_993" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_994" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_990" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss_994" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCosts" xlink:label="loc_us-gaap_RestructuringCosts_995" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_990" xlink:to="loc_us-gaap_RestructuringCosts_995" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_982" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_990" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_982" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_986" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_982" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_986" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_987" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_986" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_987" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_987_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_986" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_987_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_988" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_987" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_988" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_989" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_987" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_989" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_983" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_982" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_983" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_984" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_983" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_984" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_984_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_983" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_984_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_RestructuringActivitiesMember" xlink:label="loc_agle_RestructuringActivitiesMember_985" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_984" xlink:to="loc_agle_RestructuringActivitiesMember_985" use="optional" order="15" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.spy.com/role/SubsequentEventsAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_1884" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1883" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_1884" xlink:to="loc_us-gaap_SubsequentEventTable_1883" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1885" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1883" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1885" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1886" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1885" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1886" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1886_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1885" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1886_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_1887" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1886" xlink:to="loc_us-gaap_SubsequentEventMember_1887" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="loc_us-gaap_AssetAcquisitionAxis_1889" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1883" xlink:to="loc_us-gaap_AssetAcquisitionAxis_1889" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaap_AssetAcquisitionDomain_1890" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_1889" xlink:to="loc_us-gaap_AssetAcquisitionDomain_1890" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaap_AssetAcquisitionDomain_1890_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_1889" xlink:to="loc_us-gaap_AssetAcquisitionDomain_1890_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_SpyreTherapeuticsIncMember" xlink:label="loc_agle_SpyreTherapeuticsIncMember_1891" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_1890" xlink:to="loc_agle_SpyreTherapeuticsIncMember_1891" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1892" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1883" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1892" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1893" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1892" xlink:to="loc_us-gaap_ClassOfStockDomain_1893" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1893_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1892" xlink:to="loc_us-gaap_ClassOfStockDomain_1893_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_SeriesANonVotingConvertiblePreferredStockMember" xlink:label="loc_agle_SeriesANonVotingConvertiblePreferredStockMember_1894" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1893" xlink:to="loc_agle_SeriesANonVotingConvertiblePreferredStockMember_1894" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_1895" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1883" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_1895" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_1896" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_1895" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_1896" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_1896_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_1895" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_1896_default" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1897" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_1896" xlink:to="loc_us-gaap_CommonStockMember_1897" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1901" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1883" xlink:to="loc_srt_RangeAxis_1901" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1902" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1901" xlink:to="loc_srt_RangeMember_1902" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1902_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1901" xlink:to="loc_srt_RangeMember_1902_default" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1903" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1902" xlink:to="loc_srt_MaximumMember_1903" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_1904" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1902" xlink:to="loc_srt_MinimumMember_1904" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1906" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1883" xlink:to="loc_us-gaap_PlanNameAxis_1906" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1907" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_1906" xlink:to="loc_us-gaap_PlanNameDomain_1907" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1907_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_1906" xlink:to="loc_us-gaap_PlanNameDomain_1907_default" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ParapyreOptionObligationMember" xlink:label="loc_agle_ParapyreOptionObligationMember_1908" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1907" xlink:to="loc_agle_ParapyreOptionObligationMember_1908" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares" xlink:label="loc_agle_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares_1888" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1884" xlink:to="loc_agle_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares_1888" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_1898" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1884" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_1898" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaap_StockholdersEquityReverseStockSplit_1899" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1884" xlink:to="loc_us-gaap_StockholdersEquityReverseStockSplit_1899" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_1900" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1884" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_1900" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1905" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1884" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1905" use="optional" order="31" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_us-gaap_OtherAssetsNoncurrent" order="1.0" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="1.0" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_DevelopmentFeeAndRoyaltyMember" xlink:label="loc_AGLE_DevelopmentFeeAndRoyaltyMember" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="loc_AGLE_DevelopmentFeeAndRoyaltyMember" order="1.0" />
</definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>38
<FILENAME>agle-20230930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 22-December-2023 [06:59:46] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
<labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CoverAbstract" xml:lang="en-US">Cover [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentInformationTable" xml:lang="en-US">Document Information [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_dei_EntityAddressesAddressTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressesAddressTypeAxis" xml:lang="en-US">Entity Addresses, Address Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressesAddressTypeAxis" xlink:to="lab_dei_EntityAddressesAddressTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AddressTypeDomain" xml:lang="en-US">Address Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AddressTypeDomain" xlink:to="lab_dei_AddressTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_BusinessContactMember" xlink:label="loc_dei_BusinessContactMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_BusinessContactMember" xml:lang="en-US">Business Contact [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_BusinessContactMember" xlink:to="lab_dei_BusinessContactMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentInformationLineItems" xml:lang="en-US">Document Information [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="lab_dei_DocumentInformationLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentType" xml:lang="en-US">Document Type</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_DocumentType" xml:lang="en-US">Document Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityTaxIdentificationNumber" xml:lang="en-US">Entity Tax Identification Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityTaxIdentificationNumber" xml:lang="en-US">Entity Tax Identification Number</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressAddressLine1" xml:lang="en-US">Entity Address, Address Line One</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityAddressAddressLine1" xml:lang="en-US">Entity Address, Address Line One</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_dei_EntityAddressAddressLine2" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressAddressLine2" xml:lang="en-US">Entity Address, Address Line Two</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityAddressAddressLine2" xml:lang="en-US">Entity Address, Address Line Two</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_dei_EntityAddressAddressLine3" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressAddressLine3" xml:lang="en-US">Entity Address, Address Line Three</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityAddressAddressLine3" xml:lang="en-US">Entity Address, Address Line Three</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine3" xlink:to="lab_dei_EntityAddressAddressLine3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressCityOrTown" xml:lang="en-US">Entity Address, City or Town</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityAddressCityOrTown" xml:lang="en-US">Entity Address, City or Town</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressStateOrProvince" xml:lang="en-US">Entity Address, State or Province</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityAddressStateOrProvince" xml:lang="en-US">Entity Address, State or Province</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressPostalZipCode" xml:lang="en-US">Entity Address, Postal Zip Code</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityAddressPostalZipCode" xml:lang="en-US">Entity Address, Postal Zip Code</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CityAreaCode" xml:lang="en-US">City Area Code</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_CityAreaCode" xml:lang="en-US">City Area Code</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_LocalPhoneNumber" xml:lang="en-US">Local Phone Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_LocalPhoneNumber" xml:lang="en-US">Local Phone Number</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntitySmallBusiness" xml:lang="en-US">Entity Small Business</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntitySmallBusiness" xml:lang="en-US">Entity Small Business</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityEmergingGrowthCompany" xml:lang="en-US">Entity Emerging Growth Company</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityEmergingGrowthCompany" xml:lang="en-US">Entity Emerging Growth Company</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ContactPersonnelName" xlink:label="loc_dei_ContactPersonnelName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_ContactPersonnelName" xml:lang="en-US">Contact Personnel Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_ContactPersonnelName" xlink:to="lab_dei_ContactPersonnelName" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xml:lang="en-US">Class of Stock [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xml:lang="en-US">Class of Stock [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfStockDomain" xml:lang="en-US">Class of Stock [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfStockDomain" xml:lang="en-US">Class of Stock [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_SeriesANonVotingConvertiblePreferredStockMember" xlink:label="loc_agle_SeriesANonVotingConvertiblePreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_SeriesANonVotingConvertiblePreferredStockMember" xml:lang="en-US">Series A Non Voting Convertible Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_SeriesANonVotingConvertiblePreferredStockMember" xml:lang="en-US">Series A Non Voting Convertible Preferred Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_SeriesANonVotingConvertiblePreferredStockMember" xlink:to="lab_agle_SeriesANonVotingConvertiblePreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_SeriesANonVotingConvertiblePreferredStockMember" xml:lang="en-US">Series A non voting convertible preferred stock.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">Assets [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">ASSETS</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Assets, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">CURRENT ASSETS</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">cash and cash equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xml:lang="en-US">Debt Securities, Available-for-Sale, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xml:lang="en-US">Marketable securities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xml:lang="en-US">Marketable securities, estimated fair value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xml:lang="en-US">Total marketable securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NontradeReceivablesCurrent" xlink:label="loc_us-gaap_NontradeReceivablesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NontradeReceivablesCurrent" xml:lang="en-US">Nontrade Receivables, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NontradeReceivablesCurrent" xml:lang="en-US">Development receivables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NontradeReceivablesCurrent" xlink:to="lab_us-gaap_NontradeReceivablesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US">Prepaid expenses and other current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Total current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xml:lang="en-US">Restricted Cash, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xml:lang="en-US">Restricted cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent" xlink:to="lab_us-gaap_RestrictedCashNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property, Plant and Equipment, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property and equipment, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property and equipment, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xml:lang="en-US">Operating lease right-of-use assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xml:lang="en-US">Operating</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xml:lang="en-US">Other Assets, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xml:lang="en-US">Other non-current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">TOTAL ASSETS</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Liabilities, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">CURRENT LIABILITIES</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableTradeCurrent" xml:lang="en-US">Accounts Payable, Trade, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsPayableTradeCurrent" xml:lang="en-US">Accounts payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableTradeCurrent" xlink:to="lab_us-gaap_AccountsPayableTradeCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeLiabilitiesCurrent" xml:lang="en-US">Derivative Liability, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DerivativeLiabilitiesCurrent" xml:lang="en-US">CVR liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesCurrent" xlink:to="lab_us-gaap_DerivativeLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xml:lang="en-US">Operating Lease, Liability, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xml:lang="en-US">Operating lease liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xml:lang="en-US">Operating lease liabilities, current</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xml:lang="en-US">Accrued Liabilities and Other Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xml:lang="en-US">Accrued and other current liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xml:lang="en-US">Total accrued and other current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="loc_us-gaap_AccountsPayableOtherCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableOtherCurrent" xml:lang="en-US">Accounts Payable, Other, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsPayableOtherCurrent" xml:lang="en-US">Related party accounts payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableOtherCurrent" xlink:to="lab_us-gaap_AccountsPayableOtherCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Total current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredRevenueCurrent" xml:lang="en-US">Deferred Revenue, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredRevenueCurrent" xml:lang="en-US">Deferred revenue</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredRevenueCurrent" xml:lang="en-US">Current deferred revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueCurrent" xlink:to="lab_us-gaap_DeferredRevenueCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xml:lang="en-US">Derivative Liability, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xml:lang="en-US">Non-current CVR liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="lab_us-gaap_DerivativeLiabilitiesNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xml:lang="en-US">Non-current operating lease liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xml:lang="en-US">Operating lease liabilities, noncurrent</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xml:lang="en-US">Deferred revenue, net of current portion</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">TOTAL LIABILITIES</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and Contingencies</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and Contingencies (Note 11)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xml:lang="en-US">Temporary Equity, Carrying Amount, Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xml:lang="en-US">Series A non-voting convertible preferred stock, $0.0001 par value; 1,086,341 and no shares authorized as of September&#160;30, 2023 and December&#160;31, 2022, respectively; 1,086,339 and no shares issued and outstanding as of September&#160;30, 2023 and December&#160;31, 2022, respectively</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xml:lang="en-US">Beginning balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xml:lang="en-US">Ending balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">STOCKHOLDERS' (DEFICIT) EQUITY</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred Stock, Value, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock, Value, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xml:lang="en-US">Additional Paid in Capital, Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xml:lang="en-US">Additional paid-in capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US">Accumulated other comprehensive income (loss)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated deficit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">TOTAL STOCKHOLDERS' (DEFICIT) EQUITY</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Balances</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Balances</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Liabilities and Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">TOTAL LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' (DEFICIT) EQUITY</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xml:lang="en-US">Other Liabilities, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xml:lang="en-US">Other non-current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare" xml:lang="en-US">Temporary Equity, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare" xml:lang="en-US">Series A non-voting convertible preferred stock, par value (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquitySharesAuthorized" xml:lang="en-US">Temporary Equity, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TemporaryEquitySharesAuthorized" xml:lang="en-US">Series A non-voting convertible preferred stock, authorized (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesAuthorized" xlink:to="lab_us-gaap_TemporaryEquitySharesAuthorized" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquitySharesIssued" xml:lang="en-US">Temporary Equity, Shares Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TemporaryEquitySharesIssued" xml:lang="en-US">Series A non-voting convertible preferred stock, issued (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesIssued" xlink:to="lab_us-gaap_TemporaryEquitySharesIssued" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xml:lang="en-US">Temporary Equity, Shares Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xml:lang="en-US">Series A non-voting convertible preferred stock, outstanding (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xml:lang="en-US">Beginning balance (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xml:lang="en-US">Ending balance (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesOutstanding" xlink:to="lab_us-gaap_TemporaryEquitySharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred stock, par value (in dollars per share)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred stock, par value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred stock, authorized (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred stock, shares authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred Stock, Shares Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred stock, issued (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred stock, outstanding (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred stock, shares outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common stock, par value (in dollars per share)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common stock, par value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common stock, authorized (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common stock, shares authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common Stock, Shares, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common stock, issued (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common stock, outstanding (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementAbstract" xml:lang="en-US">Income Statement [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xml:lang="en-US">Derivative Instrument [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xml:lang="en-US">Derivative Instrument [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xml:lang="en-US">Derivative Contract [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xml:lang="en-US">Derivative Contract [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForwardContractsMember" xlink:label="loc_us-gaap_ForwardContractsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ForwardContractsMember" xml:lang="en-US">Forward Contracts [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ForwardContractsMember" xml:lang="en-US">Forward contract liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ForwardContractsMember" xml:lang="en-US">Forward Contracts</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForwardContractsMember" xlink:to="lab_us-gaap_ForwardContractsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenuesAbstract" xml:lang="en-US">Revenues [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RevenuesAbstract" xml:lang="en-US">Revenue:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xml:lang="en-US">Total revenue</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xml:lang="en-US">Revenue recognized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xml:lang="en-US">Revenue from Contract with Customer, Product and Service [Extensible Enumeration]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xml:lang="en-US">Revenue from Contract with Customer, Product and Service [Extensible Enumeration]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating Expenses [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating expenses (income):</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xml:lang="en-US">Research and development</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and Administrative Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and administrative</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AcquiredInProcessResearchAndDevelopment" xlink:label="loc_agle_AcquiredInProcessResearchAndDevelopment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_AcquiredInProcessResearchAndDevelopment" xml:lang="en-US">Acquired In Process Research And Development</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_AcquiredInProcessResearchAndDevelopment" xml:lang="en-US">Acquired in-process research and development</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_agle_AcquiredInProcessResearchAndDevelopment" xml:lang="en-US">Acquired in-process research and development</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_AcquiredInProcessResearchAndDevelopment" xlink:to="lab_agle_AcquiredInProcessResearchAndDevelopment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_AcquiredInProcessResearchAndDevelopment" xml:lang="en-US">Acquired in process research and development</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xml:lang="en-US">Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xml:lang="en-US">Gain recognized within operating expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xml:lang="en-US">Gain on sale of in-process research and development asset</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xml:lang="en-US">Gain recognized within operating expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:to="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Operating Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Total operating expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and Development Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and development</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Operating Income (Loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Loss from operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US">Other (expense) income:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeNet" xlink:label="loc_us-gaap_InvestmentIncomeNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentIncomeNet" xml:lang="en-US">Investment Income, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InvestmentIncomeNet" xml:lang="en-US">Interest income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNet" xlink:to="lab_us-gaap_InvestmentIncomeNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xml:lang="en-US">Gain (Loss) on Derivative Instruments, Net, Pretax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xml:lang="en-US">Change in fair value of forward contract liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xml:lang="en-US">Change in fair value of forward contract liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:to="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xml:lang="en-US">Other Nonoperating Income (Expense)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xml:lang="en-US">Other income, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Nonoperating Income (Expense)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Total other (expense) income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US">Loss before income tax expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income tax (expense) benefit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Provision or benefit from income taxes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income tax (benefit) expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasic" xml:lang="en-US">Earnings Per Share, Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasic" xml:lang="en-US">Net loss per share, basic (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xml:lang="en-US">Earnings Per Share, Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xml:lang="en-US">Net loss per share, diluted (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Weighted-average common shares outstanding, basic (in dollars per share)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Total basic weighed average shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Weighted-average common shares outstanding, diluted (in dollars per share)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Total diluted weighed average shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ProductOrServiceAxis" xml:lang="en-US">Product and Service [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_ProductOrServiceAxis" xml:lang="en-US">Product and Service</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ProductsAndServicesDomain" xml:lang="en-US">Product and Service [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_ProductsAndServicesDomain" xml:lang="en-US">Product and Service</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_DevelopmentFeeMember" xlink:label="loc_agle_DevelopmentFeeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_DevelopmentFeeMember" xml:lang="en-US">Development Fee [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_agle_DevelopmentFeeMember" xml:lang="en-US">Development Fee</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_DevelopmentFeeMember" xlink:to="lab_agle_DevelopmentFeeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_DevelopmentFeeMember" xml:lang="en-US">Development fee member.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaap_LicenseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LicenseMember" xml:lang="en-US">License [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LicenseMember" xml:lang="en-US">License</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember" xlink:to="lab_us-gaap_LicenseMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xml:lang="en-US">Related Party, Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xml:lang="en-US">Related Party, Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyDomain" xml:lang="en-US">Related Party, Type [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RelatedPartyDomain" xml:lang="en-US">Related Party, Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaap_RelatedPartyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyMember" xml:lang="en-US">Related Party [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RelatedPartyMember" xml:lang="en-US">Related Party</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyMember" xlink:to="lab_us-gaap_RelatedPartyMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xml:lang="en-US">Other comprehensive (loss) income:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xml:lang="en-US">Foreign currency translation adjustment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xml:lang="en-US">Unrealized (loss) gain on marketable securities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xml:lang="en-US">Unrealized gain (loss) on marketable securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xml:lang="en-US">Total comprehensive loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid-in Capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xml:lang="en-US">AOCI Attributable to Parent [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xml:lang="en-US">Accumulated Other Comprehensive (Loss) Income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsMember" xml:lang="en-US">Retained Earnings [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RetainedEarningsMember" xml:lang="en-US">Accumulated Deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_agle_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Shares, New Issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Issuance of Series A non-voting convertible preferred stock (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_agle_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Shares, New Issues</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Value, New Issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Issuance of Series A non-voting convertible preferred stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Issuance of Series A non-voting convertible preferred stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_TemporaryEquityFinancingCosts" xlink:label="loc_agle_TemporaryEquityFinancingCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_TemporaryEquityFinancingCosts" xml:lang="en-US">Temporary Equity, Financing Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_TemporaryEquityFinancingCosts" xml:lang="en-US">Settlement of financing costs in connection with private placement of Series A non-voting convertible preferred stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_TemporaryEquityFinancingCosts" xlink:to="lab_agle_TemporaryEquityFinancingCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_TemporaryEquityFinancingCosts" xml:lang="en-US">Temporary Equity, Financing Costs</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Shares, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Balances (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Balances (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan" xlink:label="loc_agle_StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan" xml:lang="en-US">Stock Issued During Period, Value, Options Exercised And Employee Stock Ownership Plan</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan" xml:lang="en-US">Issuance of common stock in connection with exercise of stock options and employee stock purchase plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan" xlink:to="lab_agle_StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan" xml:lang="en-US">Stock Issued During Period, Value, Options Exercised And Employee Stock Ownership Plan</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xml:lang="en-US">Stock Issued During Period, Value, Purchase of Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xml:lang="en-US">Issuance of common stock forward in connection with the asset acquisition of Spyre</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xml:lang="en-US">Stock Issued During Period, Shares, Acquisitions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xml:lang="en-US">Issuance of common stock in connection with the asset acquisition of Spyre and settlement of related forward contract (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xml:lang="en-US">Stock Issued During Period, Value, Acquisitions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xml:lang="en-US">Issuance of common stock in connection with the asset acquisition of Spyre and settlement of related forward contract</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xml:lang="en-US">Issuance of common stock in connection with exercise of pre-funded warrants (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_StockIssuedDuringPeriodSharesOptionsExercisedAndEmployeeStockOwnershipPlan" xlink:label="loc_agle_StockIssuedDuringPeriodSharesOptionsExercisedAndEmployeeStockOwnershipPlan" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_StockIssuedDuringPeriodSharesOptionsExercisedAndEmployeeStockOwnershipPlan" xml:lang="en-US">Stock Issued During Period, Shares, Options Exercised And Employee Stock Ownership Plan</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_StockIssuedDuringPeriodSharesOptionsExercisedAndEmployeeStockOwnershipPlan" xml:lang="en-US">Issuance of common stock in connection with exercise of stock options and employee stock purchase plan (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_StockIssuedDuringPeriodSharesOptionsExercisedAndEmployeeStockOwnershipPlan" xlink:to="lab_agle_StockIssuedDuringPeriodSharesOptionsExercisedAndEmployeeStockOwnershipPlan" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_StockIssuedDuringPeriodSharesOptionsExercisedAndEmployeeStockOwnershipPlan" xml:lang="en-US">Stock Issued During Period, Shares, Options Exercised And Employee Stock Ownership Plan</label>
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_StockIssuedDuringPeriodSharesCommonStockAndPreFundedWarrantsRegisteredDirectOffering" xlink:label="loc_agle_StockIssuedDuringPeriodSharesCommonStockAndPreFundedWarrantsRegisteredDirectOffering" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_StockIssuedDuringPeriodSharesCommonStockAndPreFundedWarrantsRegisteredDirectOffering" xml:lang="en-US">Stock Issued During Period Shares Common Stock And Pre Funded Warrants Registered Direct Offering</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_StockIssuedDuringPeriodSharesCommonStockAndPreFundedWarrantsRegisteredDirectOffering" xml:lang="en-US">Issuance of common stock and pre-funded warrants in connection with registered direct offering, net of offering costs (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_StockIssuedDuringPeriodSharesCommonStockAndPreFundedWarrantsRegisteredDirectOffering" xlink:to="lab_agle_StockIssuedDuringPeriodSharesCommonStockAndPreFundedWarrantsRegisteredDirectOffering" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_StockIssuedDuringPeriodSharesCommonStockAndPreFundedWarrantsRegisteredDirectOffering" xml:lang="en-US">Stock issued during period shares common stock and pre funded warrants registered direct offering.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xml:lang="en-US">Issuance of common stock in connection with exercise of pre-funded warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xml:lang="en-US">Issuance of common stock in connection with employee stock purchase plan (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xml:lang="en-US">Issuance of common stock in connection with employee stock purchase plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_StockIssuedDuringPeriodValueCommonStockAndPreFundedWarrantsRegisteredDirectOffering" xlink:label="loc_agle_StockIssuedDuringPeriodValueCommonStockAndPreFundedWarrantsRegisteredDirectOffering" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_StockIssuedDuringPeriodValueCommonStockAndPreFundedWarrantsRegisteredDirectOffering" xml:lang="en-US">Stock Issued During Period Value Common Stock And Pre Funded Warrants Registered Direct Offering</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_StockIssuedDuringPeriodValueCommonStockAndPreFundedWarrantsRegisteredDirectOffering" xml:lang="en-US">Issuance of common stock and pre-funded warrants in connection with registered direct offering, net of offering costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_StockIssuedDuringPeriodValueCommonStockAndPreFundedWarrantsRegisteredDirectOffering" xlink:to="lab_agle_StockIssuedDuringPeriodValueCommonStockAndPreFundedWarrantsRegisteredDirectOffering" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_StockIssuedDuringPeriodValueCommonStockAndPreFundedWarrantsRegisteredDirectOffering" xml:lang="en-US">Stock issued during period value common stock and pre funded warrants registered direct offering.</label>
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ContingentValueRightDistributionToCommonStockholders" xlink:label="loc_agle_ContingentValueRightDistributionToCommonStockholders" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_ContingentValueRightDistributionToCommonStockholders" xml:lang="en-US">Contingent Value Right Distribution To Common Stockholders</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_agle_ContingentValueRightDistributionToCommonStockholders" xml:lang="en-US">CVR distribution to common stockholders</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_ContingentValueRightDistributionToCommonStockholders" xlink:to="lab_agle_ContingentValueRightDistributionToCommonStockholders" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_ContingentValueRightDistributionToCommonStockholders" xml:lang="en-US">Contingent value right distribution to common stockholders.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xml:lang="en-US">Stock-based compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_IssuanceOfCommonStockAndPreFundedWarrantsSharesInConnectionWithRegisteredDirectOfferingNetOfOfferingCosts" xlink:label="loc_agle_IssuanceOfCommonStockAndPreFundedWarrantsSharesInConnectionWithRegisteredDirectOfferingNetOfOfferingCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_IssuanceOfCommonStockAndPreFundedWarrantsSharesInConnectionWithRegisteredDirectOfferingNetOfOfferingCosts" xml:lang="en-US">Issuance Of Common Stock And Pre-Funded Warrants Shares In Connection With Registered Direct Offering, Net Of Offering Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_agle_IssuanceOfCommonStockAndPreFundedWarrantsSharesInConnectionWithRegisteredDirectOfferingNetOfOfferingCosts" xml:lang="en-US">Issuance of common stock and pre-funded warrants in connection with registered direct offering, net of offering costs (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_IssuanceOfCommonStockAndPreFundedWarrantsSharesInConnectionWithRegisteredDirectOfferingNetOfOfferingCosts" xlink:to="lab_agle_IssuanceOfCommonStockAndPreFundedWarrantsSharesInConnectionWithRegisteredDirectOfferingNetOfOfferingCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_IssuanceOfCommonStockAndPreFundedWarrantsSharesInConnectionWithRegisteredDirectOfferingNetOfOfferingCosts" xml:lang="en-US">Issuance of common stock and pre-funded warrants shares in connection with registered direct offering, net of offering costs.</label>
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_IssuanceOfCommonStockAndPreFundedWarrantsValueInConnectionWithRegisteredDirectOfferingNetOfOfferingCosts" xlink:label="loc_agle_IssuanceOfCommonStockAndPreFundedWarrantsValueInConnectionWithRegisteredDirectOfferingNetOfOfferingCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_IssuanceOfCommonStockAndPreFundedWarrantsValueInConnectionWithRegisteredDirectOfferingNetOfOfferingCosts" xml:lang="en-US">Issuance Of Common Stock And Pre-Funded Warrants Value In Connection With Registered Direct Offering, Net Of Offering Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_agle_IssuanceOfCommonStockAndPreFundedWarrantsValueInConnectionWithRegisteredDirectOfferingNetOfOfferingCosts" xml:lang="en-US">Issuance of common stock and pre-funded warrants in connection with registered direct offering, net of offering costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_IssuanceOfCommonStockAndPreFundedWarrantsValueInConnectionWithRegisteredDirectOfferingNetOfOfferingCosts" xlink:to="lab_agle_IssuanceOfCommonStockAndPreFundedWarrantsValueInConnectionWithRegisteredDirectOfferingNetOfOfferingCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_IssuanceOfCommonStockAndPreFundedWarrantsValueInConnectionWithRegisteredDirectOfferingNetOfOfferingCosts" xml:lang="en-US">Issuance of common stock and pre-funded warrants value in connection with registered direct offering, net of offering costs.</label>
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_IssuanceOfCommonStockInConnectionWithExerciseOfPreFundedWarrants" xlink:label="loc_agle_IssuanceOfCommonStockInConnectionWithExerciseOfPreFundedWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_IssuanceOfCommonStockInConnectionWithExerciseOfPreFundedWarrants" xml:lang="en-US">Issuance Of Common Stock In Connection With Exercise Of Pre-Funded Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_agle_IssuanceOfCommonStockInConnectionWithExerciseOfPreFundedWarrants" xml:lang="en-US">Issuance of common stock in connection with exercise of pre-funded warrants (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_IssuanceOfCommonStockInConnectionWithExerciseOfPreFundedWarrants" xlink:to="lab_agle_IssuanceOfCommonStockInConnectionWithExerciseOfPreFundedWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_IssuanceOfCommonStockInConnectionWithExerciseOfPreFundedWarrants" xml:lang="en-US">Issuance of common stock in connection with exercise of pre-funded warrants.</label>
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_StockIssuedDuringPeriodSharesCommonStockAndPreFundedWarrants" xlink:label="loc_agle_StockIssuedDuringPeriodSharesCommonStockAndPreFundedWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_StockIssuedDuringPeriodSharesCommonStockAndPreFundedWarrants" xml:lang="en-US">Stock Issued During Period Shares Common Stock And Pre Funded Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_StockIssuedDuringPeriodSharesCommonStockAndPreFundedWarrants" xml:lang="en-US">Issuance of common stock and pre-funded warrants in connection with public and at-the-market offerings, net of offering costs (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_StockIssuedDuringPeriodSharesCommonStockAndPreFundedWarrants" xlink:to="lab_agle_StockIssuedDuringPeriodSharesCommonStockAndPreFundedWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_StockIssuedDuringPeriodSharesCommonStockAndPreFundedWarrants" xml:lang="en-US">Stock issued during period shares, common stock and pre-funded warrants.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Issuance of common stock in connection with exercise of stock options (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Shares Issuable Under Options, Exercised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_StockIssuedDuringPeriodValueCommonStockAndPreFundedWarrants" xlink:label="loc_agle_StockIssuedDuringPeriodValueCommonStockAndPreFundedWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_StockIssuedDuringPeriodValueCommonStockAndPreFundedWarrants" xml:lang="en-US">Stock Issued During Period Value Common Stock And Pre Funded Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_StockIssuedDuringPeriodValueCommonStockAndPreFundedWarrants" xml:lang="en-US">Issuance of common stock and pre-funded warrants in connection with public and at-the-market offerings, net of offering costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_StockIssuedDuringPeriodValueCommonStockAndPreFundedWarrants" xlink:to="lab_agle_StockIssuedDuringPeriodValueCommonStockAndPreFundedWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_StockIssuedDuringPeriodValueCommonStockAndPreFundedWarrants" xml:lang="en-US">Stock issued during period value, common stock and pre-funded warrants.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xml:lang="en-US">Issuance of common stock in connection with exercise of stock options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ContingentValueRightLiabilityMember" xlink:label="loc_agle_ContingentValueRightLiabilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_ContingentValueRightLiabilityMember" xml:lang="en-US">Contingent Value Right Liability [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_ContingentValueRightLiabilityMember" xml:lang="en-US">CVR liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_ContingentValueRightLiabilityMember" xlink:to="lab_agle_ContingentValueRightLiabilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_ContingentValueRightLiabilityMember" xml:lang="en-US">Contingent Value Right Liability</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProfitLoss" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProfitLoss" xml:lang="en-US">Net loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xml:lang="en-US">Depreciation, Depletion and Amortization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xml:lang="en-US">Depreciation and amortization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Stock-based compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Stock compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetImpairmentCharges" xml:lang="en-US">Asset Impairment Charges</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetImpairmentCharges" xml:lang="en-US">Lease ROU asset and leasehold improvement impairment loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xml:lang="en-US">Loss on disposal of long-lived assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xml:lang="en-US">Loss on Disposal of Long Lived Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Periodic Reduction</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xml:lang="en-US">Amortization of operating lease assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xml:lang="en-US">Net accretion of discount on marketable securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xml:lang="en-US">Other Noncash Income (Expense)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xml:lang="en-US">Other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_NonCashOperatingLeaseExpense" xlink:label="loc_agle_NonCashOperatingLeaseExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_NonCashOperatingLeaseExpense" xml:lang="en-US">Non Cash Operating Lease Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_NonCashOperatingLeaseExpense" xml:lang="en-US">Non-cash operating lease expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_NonCashOperatingLeaseExpense" xlink:to="lab_agle_NonCashOperatingLeaseExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_NonCashOperatingLeaseExpense" xml:lang="en-US">Non-cash operating lease expense.</label>
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_PaymentForDiscountPremiumOnInvestmentsNet" xlink:label="loc_agle_PaymentForDiscountPremiumOnInvestmentsNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_PaymentForDiscountPremiumOnInvestmentsNet" xml:lang="en-US">Payment For Discount Premium On Investments Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_agle_PaymentForDiscountPremiumOnInvestmentsNet" xml:lang="en-US">Purchase net (premium) discount on marketable securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_PaymentForDiscountPremiumOnInvestmentsNet" xlink:to="lab_agle_PaymentForDiscountPremiumOnInvestmentsNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_PaymentForDiscountPremiumOnInvestmentsNet" xml:lang="en-US">Payment for discount (premium) on investments net.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Changes in operating assets and liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US">Prepaid expenses and other assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xml:lang="en-US">Increase (Decrease) in Accounts Payable, Trade</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xml:lang="en-US">Accounts payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xml:lang="en-US">Deferred revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xml:lang="en-US">Development receivables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xml:lang="en-US">Operating lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xml:lang="en-US">Accrued and other liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayable" xml:lang="en-US">Increase (Decrease) in Other Accounts Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayable" xml:lang="en-US">Related party payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xml:lang="en-US">Increase (Decrease) in Accounts Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xml:lang="en-US">Accounts payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:label="loc_agle_IncreaseDecreaseInOperatingLeaseLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_IncreaseDecreaseInOperatingLeaseLiabilities" xml:lang="en-US">Increase Decrease In Operating Lease Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_IncreaseDecreaseInOperatingLeaseLiabilities" xml:lang="en-US">Operating lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:to="lab_agle_IncreaseDecreaseInOperatingLeaseLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_IncreaseDecreaseInOperatingLeaseLiabilities" xml:lang="en-US">Increase decrease in operating lease liabilities.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net cash used in operating activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-Sale</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xml:lang="en-US">Purchases of marketable securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAcquiredFromAcquisition" xml:lang="en-US">Cash Acquired from Acquisition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashAcquiredFromAcquisition" xml:lang="en-US">Cash assumed from asset acquisition of Spyre</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAcquiredFromAcquisition" xml:lang="en-US">Cash acquired</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAcquiredFromAcquisition" xlink:to="lab_us-gaap_CashAcquiredFromAcquisition" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:label="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets" xml:lang="en-US">Proceeds from Sale of Intangible Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets" xml:lang="en-US">Proceeds from sale of in-process research &amp; development asset</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets" xml:lang="en-US">Proceeds from sale of intangible assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:to="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Purchases of property and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xml:lang="en-US">Proceeds from sale of property and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xml:lang="en-US">Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xml:lang="en-US">Proceeds from maturities and sales of marketable securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net cash (used in) and provided by investing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xml:lang="en-US">Proceeds from Issuance of Convertible Preferred Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xml:lang="en-US">Proceeds from issuance of Series A non-voting convertible preferred stock in connection with private placement, net of placement and other offering costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfOfferingCosts" xlink:label="loc_agle_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfOfferingCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfOfferingCosts" xml:lang="en-US">Proceeds From Issuance Of Common Stock And Pre Funded Warrants In Public Offering Net Of Offering Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfOfferingCosts" xml:lang="en-US">Proceeds from issuance of common stock and pre-funded warrants in registered direct offering, net of offering costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfOfferingCosts" xlink:to="lab_agle_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfOfferingCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfOfferingCosts" xml:lang="en-US">Proceeds from issuance of common stock and pre-funded warrants in public offering net of offering costs.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xml:lang="en-US">Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xml:lang="en-US">Proceeds from employee stock plan purchases and stock option exercises</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xml:lang="en-US">Finance Lease, Principal Payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xml:lang="en-US">Principal payments on finance lease obligation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:to="lab_us-gaap_FinanceLeasePrincipalPayments" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net cash provided by financing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Effect of exchange rate on cash, cash equivalents, and restricted cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xml:lang="en-US">NET INCREASE IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract" xml:lang="en-US">CASH, CASH EQUIVALENTS, AND RESTRICTED CASH</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Beginning of period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">End of period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xml:lang="en-US">Beginning of period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xml:lang="en-US">End of period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xml:lang="en-US">Supplemental Disclosure of Non-Cash Investing and Financing Information:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssued1" xlink:label="loc_us-gaap_StockIssued1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssued1" xml:lang="en-US">Stock Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssued1" xml:lang="en-US">Settlement of forward contract liability and issuance of Series A non-voting convertible preferred stock in connection with the asset acquisition of Spyre</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssued1" xlink:to="lab_us-gaap_StockIssued1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xml:lang="en-US">Unpaid amounts related to purchase of property and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_LeasedAssetsObtainedInExchangeForLeaseObligations" xlink:label="loc_agle_LeasedAssetsObtainedInExchangeForLeaseObligations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_LeasedAssetsObtainedInExchangeForLeaseObligations" xml:lang="en-US">Leased Assets Obtained In Exchange For Lease Obligations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_LeasedAssetsObtainedInExchangeForLeaseObligations" xml:lang="en-US">Leased assets obtained in exchange for lease obligations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_LeasedAssetsObtainedInExchangeForLeaseObligations" xlink:to="lab_agle_LeasedAssetsObtainedInExchangeForLeaseObligations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_LeasedAssetsObtainedInExchangeForLeaseObligations" xml:lang="en-US">Leased assets obtained in exchange for lease obligations.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xml:lang="en-US">Business Combinations [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xml:lang="en-US">Business Acquisition [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xml:lang="en-US">ASSETS ACQUIRED</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract" xml:lang="en-US">Current assets:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xml:lang="en-US">Cash and cash equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xml:lang="en-US">Total current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xml:lang="en-US">Total assets acquired</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xml:lang="en-US">LIABILITIES ASSUMED</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract" xml:lang="en-US">Current liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xml:lang="en-US">Accrued liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xml:lang="en-US">Total current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xml:lang="en-US">Total liabilities assumed</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xml:lang="en-US">Net liabilities assumed</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xml:lang="en-US">The Company and Basis of Presentation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xml:lang="en-US">Accounting Policies [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US">Summary of Significant Accounting Policies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xml:lang="en-US">Fair Value Disclosures [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xml:lang="en-US">Fair Value Disclosures [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xml:lang="en-US">Fair Value Measurements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashAndCashEquivalentsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xml:lang="en-US">Cash, Cash Equivalents, and Marketable Securities [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xml:lang="en-US">Cash Equivalents and Marketable Securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:to="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xml:lang="en-US">Property, Plant and Equipment [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xml:lang="en-US">Property and Equipment, Net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xml:lang="en-US">Payables and Accruals [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AccruedAndOtherCurrentLiabilitiesTextBlock" xlink:label="loc_agle_AccruedAndOtherCurrentLiabilitiesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_AccruedAndOtherCurrentLiabilitiesTextBlock" xml:lang="en-US">Accrued And Other Current Liabilities [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_AccruedAndOtherCurrentLiabilitiesTextBlock" xml:lang="en-US">Accrued and Other Current Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_AccruedAndOtherCurrentLiabilitiesTextBlock" xlink:to="lab_agle_AccruedAndOtherCurrentLiabilitiesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_AccruedAndOtherCurrentLiabilitiesTextBlock" xml:lang="en-US">The entire disclosure for accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeasesAbstract" xml:lang="en-US">Leases [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_LesseeOperatingAndFinanceLeasesDisclosureTextBlock" xlink:label="loc_agle_LesseeOperatingAndFinanceLeasesDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_LesseeOperatingAndFinanceLeasesDisclosureTextBlock" xml:lang="en-US">Lessee Operating And Finance Leases Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_LesseeOperatingAndFinanceLeasesDisclosureTextBlock" xml:lang="en-US">Leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_LesseeOperatingAndFinanceLeasesDisclosureTextBlock" xlink:to="lab_agle_LesseeOperatingAndFinanceLeasesDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_LesseeOperatingAndFinanceLeasesDisclosureTextBlock" xml:lang="en-US">Lessee operating and finance leases disclosure.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityAbstract" xml:lang="en-US">Equity [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Stockholders' Equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xml:lang="en-US">Related Party Transactions [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xml:lang="en-US">Related Party Transactions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionTextBlock" xlink:label="loc_us-gaap_AssetAcquisitionTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetAcquisitionTextBlock" xml:lang="en-US">Asset Acquisition [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetAcquisitionTextBlock" xml:lang="en-US">Asset Acquisition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AssetAcquisitionTextBlock" xml:lang="en-US">Parapyre Option Obligation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionTextBlock" xlink:to="lab_us-gaap_AssetAcquisitionTextBlock" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_CollaborativeArrangementAbstract" xlink:label="loc_agle_CollaborativeArrangementAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_CollaborativeArrangementAbstract" xml:lang="en-US">Collaborative Arrangement [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_CollaborativeArrangementAbstract" xlink:to="lab_agle_CollaborativeArrangementAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_CollaborativeArrangementAbstract" xml:lang="en-US">Collaborative Arrangement [Abstract]</label>
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_OptionAgreementTextBlock" xlink:label="loc_agle_OptionAgreementTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_OptionAgreementTextBlock" xml:lang="en-US">Option Agreement [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_OptionAgreementTextBlock" xml:lang="en-US">Paragon Agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_OptionAgreementTextBlock" xlink:to="lab_agle_OptionAgreementTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_OptionAgreementTextBlock" xml:lang="en-US">Option agreement.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockTextBlock" xlink:label="loc_us-gaap_PreferredStockTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockTextBlock" xml:lang="en-US">Preferred Stock [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockTextBlock" xml:lang="en-US">Series A Non-Voting Convertible Preferred Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockTextBlock" xlink:to="lab_us-gaap_PreferredStockTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US">Liabilities, Convertible Preferred Stock and Stockholders' (Deficit) Equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_LicenseAndCollaborationAgreementAbstract" xlink:label="loc_agle_LicenseAndCollaborationAgreementAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_LicenseAndCollaborationAgreementAbstract" xml:lang="en-US">License And Collaboration Agreement [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_LicenseAndCollaborationAgreementAbstract" xlink:to="lab_agle_LicenseAndCollaborationAgreementAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_LicenseAndCollaborationAgreementAbstract" xml:lang="en-US">License and collaboration agreement.</label>
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_StrategicLicenseAgreementTextBlock" xlink:label="loc_agle_StrategicLicenseAgreementTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_StrategicLicenseAgreementTextBlock" xml:lang="en-US">Strategic License Agreement [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_StrategicLicenseAgreementTextBlock" xml:lang="en-US">Strategic License Agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_StrategicLicenseAgreementTextBlock" xlink:to="lab_agle_StrategicLicenseAgreementTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_StrategicLicenseAgreementTextBlock" xml:lang="en-US">Strategic license agreement.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xml:lang="en-US">Sale of Pegzilarginase to Immedica</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xml:lang="en-US">Retirement Benefits [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xml:lang="en-US">Compensation and Employee Benefit Plans [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xml:lang="en-US">Defined Contribution Plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">Income Taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xml:lang="en-US">Earnings Per Share [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xml:lang="en-US">Earnings Per Share [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xml:lang="en-US">Net Loss Per Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xml:lang="en-US">Restructuring and Related Activities [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xml:lang="en-US">Restructuring Charges</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsDisclosureTextBlock" xml:lang="en-US">Commitments Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommitmentsDisclosureTextBlock" xml:lang="en-US">Novation of Manufacturing Agreements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ReverseStockSplitTextBlock" xlink:label="loc_agle_ReverseStockSplitTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_ReverseStockSplitTextBlock" xml:lang="en-US">Reverse Stock Split [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_ReverseStockSplitTextBlock" xml:lang="en-US">Reverse Stock Split</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_ReverseStockSplitTextBlock" xlink:to="lab_agle_ReverseStockSplitTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_ReverseStockSplitTextBlock" xml:lang="en-US">Reverse stock split.</label>
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAbstract" xlink:label="loc_agle_DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAbstract" xml:lang="en-US">Description of the Business and Summary of Significant Accounting Policies [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAbstract" xlink:to="lab_agle_DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAbstract" xml:lang="en-US">Description of the business and summary of significant accounting policies.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xml:lang="en-US">Description of the Business and Summary of Significant Accounting Policies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AccruedLiabilitiesTextBlock" xlink:label="loc_agle_AccruedLiabilitiesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_AccruedLiabilitiesTextBlock" xml:lang="en-US">Accrued Liabilities [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_AccruedLiabilitiesTextBlock" xml:lang="en-US">Accrued Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_AccruedLiabilitiesTextBlock" xlink:to="lab_agle_AccruedLiabilitiesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_AccruedLiabilitiesTextBlock" xml:lang="en-US">Accrued liabilities.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAbstract" xlink:label="loc_us-gaap_AssetAcquisitionAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetAcquisitionAbstract" xml:lang="en-US">Asset Acquisition [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionAbstract" xlink:to="lab_us-gaap_AssetAcquisitionAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xml:lang="en-US">Subsequent Events [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent Events [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent Events</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AccruedResearchAndDevelopmentExpensePolicyTextBlock" xlink:label="loc_agle_AccruedResearchAndDevelopmentExpensePolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_AccruedResearchAndDevelopmentExpensePolicyTextBlock" xml:lang="en-US">Accrued Research And Development Expense Policy [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_AccruedResearchAndDevelopmentExpensePolicyTextBlock" xml:lang="en-US">Accrued Research And Development Costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_AccruedResearchAndDevelopmentExpensePolicyTextBlock" xlink:to="lab_agle_AccruedResearchAndDevelopmentExpensePolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_AccruedResearchAndDevelopmentExpensePolicyTextBlock" xml:lang="en-US">Accrued research and development expense policy.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xml:lang="en-US">Cash and Cash Equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xml:lang="en-US">Restricted Cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xml:lang="en-US">Comprehensive Loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xml:lang="en-US">Concentration of Credit Risk</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xml:lang="en-US">Fair Value of Financial Instruments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xml:lang="en-US">Impairment of Long-Lived Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xml:lang="en-US">Lessee, Leases [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xml:lang="en-US">Leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xml:lang="en-US">Marketable Securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesPolicy" xlink:to="lab_us-gaap_MarketableSecuritiesPolicy" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xml:lang="en-US">Property and Equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US">Research and Development Costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xml:lang="en-US">Revenue [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xml:lang="en-US">Revenue Recognition</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xml:lang="en-US">Stock-Based Compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xml:lang="en-US">Basis of Presentation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AccruedLiabilitiesPolicyTextBlock" xlink:label="loc_agle_AccruedLiabilitiesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_AccruedLiabilitiesPolicyTextBlock" xml:lang="en-US">Accrued Liabilities [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_AccruedLiabilitiesPolicyTextBlock" xml:lang="en-US">Accrued Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_AccruedLiabilitiesPolicyTextBlock" xlink:to="lab_agle_AccruedLiabilitiesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_AccruedLiabilitiesPolicyTextBlock" xml:lang="en-US">Accrued liabilities.</label>
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ConvertiblePreferredStockIssuedThroughPipePolicyTextBlock" xlink:label="loc_agle_ConvertiblePreferredStockIssuedThroughPipePolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_ConvertiblePreferredStockIssuedThroughPipePolicyTextBlock" xml:lang="en-US">Convertible Preferred Stock Issued Through Pipe [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_ConvertiblePreferredStockIssuedThroughPipePolicyTextBlock" xml:lang="en-US">Convertible Preferred Stock Issued through PIPE</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_ConvertiblePreferredStockIssuedThroughPipePolicyTextBlock" xlink:to="lab_agle_ConvertiblePreferredStockIssuedThroughPipePolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_ConvertiblePreferredStockIssuedThroughPipePolicyTextBlock" xml:lang="en-US">Convertible preferred stock issued through pipe.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="loc_us-gaap_BusinessCombinationsPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xml:lang="en-US">Acquisitions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_us-gaap_BusinessCombinationsPolicy" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xml:lang="en-US">Contingent Value Rights</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UseOfEstimates" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_UseOfEstimates" xml:lang="en-US">Use of Estimates</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">Recently Adopted Accounting Pronouncement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionTableTextBlock" xlink:label="loc_us-gaap_AssetAcquisitionTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetAcquisitionTableTextBlock" xml:lang="en-US">Asset Acquisition [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AssetAcquisitionTableTextBlock" xml:lang="en-US">Summary of Asset Acquisition Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetAcquisitionTableTextBlock" xml:lang="en-US">Asset Acquisition Cost</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionTableTextBlock" xlink:to="lab_us-gaap_AssetAcquisitionTableTextBlock" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" xlink:label="loc_agle_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" xml:lang="en-US">Schedule Of Estimated Useful Lives Of Property Plant And Equipment Table [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" xml:lang="en-US">Schedule Of Estimated Useful Lives Of Property Plant And Equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" xlink:to="lab_agle_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" xml:lang="en-US">Schedule of estimated useful lives of property plant and equipment.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xml:lang="en-US">Accrued and Other Current Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xml:lang="en-US">Accrued and Other Current Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xml:lang="en-US">Financial Assets and Liabilities Measured at Fair Value on Recurring Basis</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xml:lang="en-US">Significant Inputs used to Estimate the Fair Value of Derivative Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xml:lang="en-US">Changes in Derivative Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xml:lang="en-US">Cash, Cash Equivalents and Investments [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xml:lang="en-US">Estimated Fair Value of Cash Equivalents and Marketable Securities and the Gross Unrealized Gains and Losses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xml:lang="en-US">Available-for-Sale Securities in an Unrealized Loss Position</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xml:lang="en-US">Contractual Maturities of Marketable Securities at Estimated Fair Value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US">Schedule of Property and Equipment Net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ScheduleOfOperatingAndFinancingLeasesPresentedInBalanceSheetTableTextBlock" xlink:label="loc_agle_ScheduleOfOperatingAndFinancingLeasesPresentedInBalanceSheetTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_ScheduleOfOperatingAndFinancingLeasesPresentedInBalanceSheetTableTextBlock" xml:lang="en-US">Schedule Of Operating And Financing Leases Presented In Balance Sheet Table [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_ScheduleOfOperatingAndFinancingLeasesPresentedInBalanceSheetTableTextBlock" xml:lang="en-US">Summary of Operating and Finance Leases Presented in Balance Sheet</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_ScheduleOfOperatingAndFinancingLeasesPresentedInBalanceSheetTableTextBlock" xlink:to="lab_agle_ScheduleOfOperatingAndFinancingLeasesPresentedInBalanceSheetTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_ScheduleOfOperatingAndFinancingLeasesPresentedInBalanceSheetTableTextBlock" xml:lang="en-US">Schedule of operating and financing leases presented in balance sheet.</label>
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_SummaryOfWeightedAverageRemainingLeaseTermAndDiscountRatesOfOperatingAndFinanceLeasesTableTextBlock" xlink:label="loc_agle_SummaryOfWeightedAverageRemainingLeaseTermAndDiscountRatesOfOperatingAndFinanceLeasesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_SummaryOfWeightedAverageRemainingLeaseTermAndDiscountRatesOfOperatingAndFinanceLeasesTableTextBlock" xml:lang="en-US">Summary Of Weighted Average Remaining Lease Term And Discount Rates Of Operating And Finance Leases Table [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_SummaryOfWeightedAverageRemainingLeaseTermAndDiscountRatesOfOperatingAndFinanceLeasesTableTextBlock" xml:lang="en-US">Summary of Weighted Average Remaining Lease Term and Discount Rates For Company's Operating and Finance Leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_SummaryOfWeightedAverageRemainingLeaseTermAndDiscountRatesOfOperatingAndFinanceLeasesTableTextBlock" xlink:to="lab_agle_SummaryOfWeightedAverageRemainingLeaseTermAndDiscountRatesOfOperatingAndFinanceLeasesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_SummaryOfWeightedAverageRemainingLeaseTermAndDiscountRatesOfOperatingAndFinanceLeasesTableTextBlock" xml:lang="en-US">Summary of weighted average remaining lease term and discount rates of operating and finance leases.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xml:lang="en-US">Lease, Cost [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xml:lang="en-US">Summary of Lease Cost</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesTableTextBlock" xlink:label="loc_agle_ScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_ScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesTableTextBlock" xml:lang="en-US">Schedule Of Maturities Of Operating And Finance Lease Liabilities Table [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_ScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Maturities of Operating and Finance Lease Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_ScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesTableTextBlock" xlink:to="lab_agle_ScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_ScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of maturities of operating and finance lease liabilities.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xml:lang="en-US">Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xml:lang="en-US">Summary of Pre-funded Warrants for Common Stock Issued and Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xml:lang="en-US">Pre-funded Warrants for Common Stock Issued and Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xml:lang="en-US">Schedule of Related Party Transactions [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xml:lang="en-US">Expenses related to Related Party which were Settled in Cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ScheduleOfBalancesDueToAffiliatesTableTextBlock" xlink:label="loc_agle_ScheduleOfBalancesDueToAffiliatesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_ScheduleOfBalancesDueToAffiliatesTableTextBlock" xml:lang="en-US">Schedule Of Balances Due To Affiliates [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_ScheduleOfBalancesDueToAffiliatesTableTextBlock" xml:lang="en-US">Related Party Accounts Payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_ScheduleOfBalancesDueToAffiliatesTableTextBlock" xlink:to="lab_agle_ScheduleOfBalancesDueToAffiliatesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_ScheduleOfBalancesDueToAffiliatesTableTextBlock" xml:lang="en-US">Schedule of balances due to affiliates.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US">Summary of Employee and Non-Employee Stock Option Activity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:label="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xml:lang="en-US">Nonvested Restricted Stock Shares Activity [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xml:lang="en-US">Summary of Employee Restricted Stock Activity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:to="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xml:lang="en-US">Share-Based Payment Arrangement, Cost by Plan [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xml:lang="en-US">Stock-Based Compensation Expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xml:lang="en-US">Assumptions used to Estimate the Fair Value of Stock Options Granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock" xml:lang="en-US">Schedule of Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock" xml:lang="en-US">Stock Awards Granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xml:lang="en-US">Summary of Changes in Contract Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xml:lang="en-US">Schedule of Loss Income Before Income Tax Expense by Jurisdiction</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xml:lang="en-US">Summary of Difference Between Provision for Income Taxes and Amounts Computed by Applying Statutory Federal Income Tax Rate to Income Before Income Taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xml:lang="en-US">Components of Deferred Tax Assets and Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xml:lang="en-US">Weighted-Average Equity Instruments Excluded from Calculation of Diluted Net Loss Per Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xml:lang="en-US">Schedule of Weighted Average Number of Shares [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xml:lang="en-US">Schedule of Reconciliation of Basic and Diluted Net Loss Per Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xml:lang="en-US">Restructuring and Related Costs [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xml:lang="en-US">Charges Related to the Restructuring Activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xml:lang="en-US">Schedule of Restructuring Reserve by Type of Cost [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xml:lang="en-US">Changes in Accrued Restructuring Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_CompanyAndBasisOfPresentationTable" xlink:label="loc_agle_CompanyAndBasisOfPresentationTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_CompanyAndBasisOfPresentationTable" xml:lang="en-US">Company And Basis Of Presentation [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_CompanyAndBasisOfPresentationTable" xml:lang="en-US">Company and Basis of Presentation [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_CompanyAndBasisOfPresentationTable" xlink:to="lab_agle_CompanyAndBasisOfPresentationTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_CompanyAndBasisOfPresentationTable" xml:lang="en-US">Company and basis of presentation.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xml:lang="en-US">Sale of Stock [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xml:lang="en-US">Sale of Stock [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xml:lang="en-US">Sale of Stock [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xml:lang="en-US">Sale of Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrivatePlacementMember" xml:lang="en-US">Private Placement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PrivatePlacementMember" xml:lang="en-US">Private Placement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrivatePlacementMember" xlink:to="lab_us-gaap_PrivatePlacementMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameAxis" xml:lang="en-US">Plan Name [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameDomain" xml:lang="en-US">Plan Name [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PlanNameDomain" xml:lang="en-US">Plan Name [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PlanNameDomain" xml:lang="en-US">Plan Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_Spyre2023EquityIncentivePlanMember" xlink:label="loc_agle_Spyre2023EquityIncentivePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_Spyre2023EquityIncentivePlanMember" xml:lang="en-US">Spyre 2023 Equity Incentive Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_Spyre2023EquityIncentivePlanMember" xml:lang="en-US">Spyre 2023 Equity Incentive Plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_Spyre2023EquityIncentivePlanMember" xlink:to="lab_agle_Spyre2023EquityIncentivePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_Spyre2023EquityIncentivePlanMember" xml:lang="en-US">Spyre 2023 equity incentive plan.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="loc_us-gaap_AssetAcquisitionAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xml:lang="en-US">Asset Acquisition [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xml:lang="en-US">Asset Acquisition [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionAxis" xlink:to="lab_us-gaap_AssetAcquisitionAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaap_AssetAcquisitionDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xml:lang="en-US">Asset Acquisition [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xml:lang="en-US">Asset Acquisition [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionDomain" xlink:to="lab_us-gaap_AssetAcquisitionDomain" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AssetAcquisitionMember" xlink:label="loc_agle_AssetAcquisitionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_AssetAcquisitionMember" xml:lang="en-US">Asset Acquisition [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_AssetAcquisitionMember" xml:lang="en-US">Asset Acquisition</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_AssetAcquisitionMember" xlink:to="lab_agle_AssetAcquisitionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_AssetAcquisitionMember" xml:lang="en-US">Asset acquisition.</label>
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_SpyreTherapeuticsIncMember" xlink:label="loc_agle_SpyreTherapeuticsIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_SpyreTherapeuticsIncMember" xml:lang="en-US">Spyre Therapeutics, Inc. [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_SpyreTherapeuticsIncMember" xml:lang="en-US">Spyre Therapeutics, Inc.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_SpyreTherapeuticsIncMember" xlink:to="lab_agle_SpyreTherapeuticsIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_SpyreTherapeuticsIncMember" xml:lang="en-US">Spyre Therapeutics, Inc.</label>
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_CompanyAndBasisOfPresentationLineItems" xlink:label="loc_agle_CompanyAndBasisOfPresentationLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_CompanyAndBasisOfPresentationLineItems" xml:lang="en-US">Company And Basis Of Presentation [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_CompanyAndBasisOfPresentationLineItems" xml:lang="en-US">Company and Basis of Presentation [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_CompanyAndBasisOfPresentationLineItems" xlink:to="lab_agle_CompanyAndBasisOfPresentationLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_CompanyAndBasisOfPresentationLineItems" xml:lang="en-US">Company and basis of presentation.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xml:lang="en-US">Proceeds from Issuance of Private Placement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xml:lang="en-US">Gross proceeds received in private placement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_PlacementAgentAndOtherOfferingExpenses" xlink:label="loc_agle_PlacementAgentAndOtherOfferingExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_PlacementAgentAndOtherOfferingExpenses" xml:lang="en-US">Placement Agent And Other Offering Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_PlacementAgentAndOtherOfferingExpenses" xml:lang="en-US">Placement agent and other offering expenses in private placement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_PlacementAgentAndOtherOfferingExpenses" xlink:to="lab_agle_PlacementAgentAndOtherOfferingExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_PlacementAgentAndOtherOfferingExpenses" xml:lang="en-US">Placement agent and other offering expenses.</label>
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AssetAcquisitionStockholderPaymentPeriod" xlink:label="loc_agle_AssetAcquisitionStockholderPaymentPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_AssetAcquisitionStockholderPaymentPeriod" xml:lang="en-US">Asset Acquisition, Stockholder Payment Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_AssetAcquisitionStockholderPaymentPeriod" xml:lang="en-US">Asset acquisition, stockholder payment period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_AssetAcquisitionStockholderPaymentPeriod" xlink:to="lab_agle_AssetAcquisitionStockholderPaymentPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_AssetAcquisitionStockholderPaymentPeriod" xml:lang="en-US">Asset Acquisition, Stockholder Payment Period</label>
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AssetAcquisitionCashPaymentThresholdPeriod" xlink:label="loc_agle_AssetAcquisitionCashPaymentThresholdPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_AssetAcquisitionCashPaymentThresholdPeriod" xml:lang="en-US">Asset Acquisition, Cash Payment, Threshold Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_AssetAcquisitionCashPaymentThresholdPeriod" xml:lang="en-US">Asset acquisition, cash payment, threshold period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_AssetAcquisitionCashPaymentThresholdPeriod" xlink:to="lab_agle_AssetAcquisitionCashPaymentThresholdPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_AssetAcquisitionCashPaymentThresholdPeriod" xml:lang="en-US">Asset Acquisition, Cash Payment, Threshold Period</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xml:lang="en-US">Cash, Cash Equivalents, and Short-Term Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xml:lang="en-US">Cash, cash equivalents, and marketable securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_NumberOfEmployeesRetained" xlink:label="loc_agle_NumberOfEmployeesRetained" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_NumberOfEmployeesRetained" xml:lang="en-US">Number of Employees Retained</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_NumberOfEmployeesRetained" xml:lang="en-US">Number of employees retained</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_NumberOfEmployeesRetained" xlink:to="lab_agle_NumberOfEmployeesRetained" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_NumberOfEmployeesRetained" xml:lang="en-US">Number of employees retained.</label>
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_CashCashEquivalentsMarketableSecuritiesAndRestrictedCash" xlink:label="loc_agle_CashCashEquivalentsMarketableSecuritiesAndRestrictedCash" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_CashCashEquivalentsMarketableSecuritiesAndRestrictedCash" xml:lang="en-US">Cash Cash Equivalents Marketable Securities And Restricted Cash</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_CashCashEquivalentsMarketableSecuritiesAndRestrictedCash" xml:lang="en-US">Cash, cash equivalents, marketable securities, and restricted cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_CashCashEquivalentsMarketableSecuritiesAndRestrictedCash" xlink:to="lab_agle_CashCashEquivalentsMarketableSecuritiesAndRestrictedCash" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_CashCashEquivalentsMarketableSecuritiesAndRestrictedCash" xml:lang="en-US">Cash, cash equivalents, marketable securities and restricted cash.</label>
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_WorkingCapital" xlink:label="loc_agle_WorkingCapital" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_WorkingCapital" xml:lang="en-US">Working Capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_WorkingCapital" xml:lang="en-US">Working capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_WorkingCapital" xlink:to="lab_agle_WorkingCapital" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_WorkingCapital" xml:lang="en-US">Working capital.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xml:lang="en-US">Number of Operating Segments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xml:lang="en-US">Number of operating segments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xml:lang="en-US">Restructuring and Related Cost, Number of Positions Eliminated, Period Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xml:lang="en-US">Employee workforce, termination percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:to="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_FixedExchangeRatio" xlink:label="loc_agle_FixedExchangeRatio" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_FixedExchangeRatio" xml:lang="en-US">Fixed Exchange Ratio</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_FixedExchangeRatio" xml:lang="en-US">Fixed exchange ratio</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_FixedExchangeRatio" xlink:to="lab_agle_FixedExchangeRatio" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_FixedExchangeRatio" xml:lang="en-US">Fixed exchange ratio.</label>
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares" xlink:label="loc_agle_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares" xml:lang="en-US">Asset Acquisition Consideration Transferred Equity Interest Issued And Issuable, Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares" xml:lang="en-US">Number of shares transferred as equity interest in asset acquisition</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares" xlink:to="lab_agle_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares" xml:lang="en-US">Asset acquisition consideration transferred equity interest issued and issuable, shares.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleConversionRatio" xlink:label="loc_us-gaap_PreferredStockConvertibleConversionRatio" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockConvertibleConversionRatio" xml:lang="en-US">Preferred Stock, Convertible, Conversion Ratio</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockConvertibleConversionRatio" xml:lang="en-US">Conversion basis</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockConvertibleConversionRatio" xlink:to="lab_us-gaap_PreferredStockConvertibleConversionRatio" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_OutstandingAndUnexercisedStockOptions" xlink:label="loc_agle_OutstandingAndUnexercisedStockOptions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_OutstandingAndUnexercisedStockOptions" xml:lang="en-US">Outstanding and Unexercised Stock Options</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_OutstandingAndUnexercisedStockOptions" xml:lang="en-US">Number of outstanding and unexercised stock options to purchase (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_OutstandingAndUnexercisedStockOptions" xlink:to="lab_agle_OutstandingAndUnexercisedStockOptions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_OutstandingAndUnexercisedStockOptions" xml:lang="en-US">Outstanding and unexercised stock options.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xml:lang="en-US">Class of Warrant or Right, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xml:lang="en-US">Number of shares sold in private placement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/presentationGuidance" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xml:lang="en-US">Number of shares sold in private placement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xml:lang="en-US">Number of Warrants Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xml:lang="en-US">Number of Warrants Outstanding (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionTable" xlink:label="loc_us-gaap_AssetAcquisitionTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetAcquisitionTable" xml:lang="en-US">Asset Acquisition [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetAcquisitionTable" xml:lang="en-US">Asset Acquisition [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionTable" xlink:to="lab_us-gaap_AssetAcquisitionTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="loc_us-gaap_AssetAcquisitionLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetAcquisitionLineItems" xml:lang="en-US">Asset Acquisition [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetAcquisitionLineItems" xml:lang="en-US">Asset Acquisition [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionLineItems" xlink:to="lab_us-gaap_AssetAcquisitionLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xml:lang="en-US">Asset Acquisition, Consideration Transferred, Equity Interest Issued and Issuable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xml:lang="en-US">Consideration transferred in Series A Preferred Stock and common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xlink:to="lab_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xml:lang="en-US">Asset Acquisition, Consideration Transferred, Transaction Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xml:lang="en-US">Transaction costs incurred by Aeglea</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:to="lab_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferred" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferred" xml:lang="en-US">Asset Acquisition, Consideration Transferred</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferred" xml:lang="en-US">Cost to acquire asset</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferred" xml:lang="en-US">Cost to acquire asset</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionConsiderationTransferred" xlink:to="lab_us-gaap_AssetAcquisitionConsiderationTransferred" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Accrued Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Accrued liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:label="loc_agle_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xml:lang="en-US">Organization Consolidation And Presentation Of Financial Statements [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="lab_agle_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xml:lang="en-US">Organization consolidation and presentation of financial statements.</label>
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:label="loc_agle_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xml:lang="en-US">Organization Consolidation And Presentation Of Financial Statements [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="lab_agle_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xml:lang="en-US">Organization consolidation and presentation of financial statements.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaap_StockholdersEquityReverseStockSplit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityReverseStockSplit" xml:lang="en-US">Stockholders' Equity, Reverse Stock Split</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquityReverseStockSplit" xml:lang="en-US">Stockholders' equity, reverse stock split</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityReverseStockSplit" xlink:to="lab_us-gaap_StockholdersEquityReverseStockSplit" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableSharesOfCommonStockOnAnAsConvertedBasis" xlink:label="loc_agle_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableSharesOfCommonStockOnAnAsConvertedBasis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableSharesOfCommonStockOnAnAsConvertedBasis" xml:lang="en-US">Asset Acquisition Consideration Transferred Equity Interest Issued And Issuable Shares Of Common Stock On An As-converted Basis</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableSharesOfCommonStockOnAnAsConvertedBasis" xml:lang="en-US">Asset acquisition consideration transferred issuable shares of common stock on an as-converted basis</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableSharesOfCommonStockOnAnAsConvertedBasis" xlink:to="lab_agle_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableSharesOfCommonStockOnAnAsConvertedBasis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableSharesOfCommonStockOnAnAsConvertedBasis" xml:lang="en-US">Asset acquisition consideration transferred equity interest issued and issuable shares of common stock on an as-converted basis.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xml:lang="en-US">Shares Issued, Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xml:lang="en-US">Shares issued, price per share (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare" xlink:to="lab_us-gaap_SharesIssuedPricePerShare" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock" xlink:label="loc_agle_PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock" xml:lang="en-US">Percentage Of Annual Equity Grant Of Options To Purchase Outstanding Shares Of Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock" xml:lang="en-US">Percentage of annual equity grant of options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock" xlink:to="lab_agle_PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock" xml:lang="en-US">Percentage of annual equity grant of options to purchase outstanding shares of common stock.</label>
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_agle_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet" xml:lang="en-US">Asset Acquisition Assets Acquired and Liabilities Assumed Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet" xml:lang="en-US">Asset Acquisition, net liabilities assumed</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="lab_agle_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet" xml:lang="en-US">Asset acquisition assets acquired and liabilities assumed net.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Cash" xml:lang="en-US">Cash</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_Cash" xml:lang="en-US">Cash deposits in excess of FDIC limit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Cash" xlink:to="lab_us-gaap_Cash" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ParapyreOptionObligationMember" xlink:label="loc_agle_ParapyreOptionObligationMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_ParapyreOptionObligationMember" xml:lang="en-US">Parapyre Option Obligation [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_ParapyreOptionObligationMember" xml:lang="en-US">Parapyre Option Obligation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_ParapyreOptionObligationMember" xlink:to="lab_agle_ParapyreOptionObligationMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_ParapyreOptionObligationMember" xml:lang="en-US">Parapyre Option Obligation</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xml:lang="en-US">Equity Interest Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xml:lang="en-US">Equity Interest Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="lab_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xml:lang="en-US">Equity Interest Issued or Issuable, Type [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xml:lang="en-US">Equity Interest Issued or Issuable, Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:to="lab_us-gaap_EquityInterestIssuedOrIssuableTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xml:lang="en-US">Financial Instrument [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xml:lang="en-US">Financial Instruments [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xml:lang="en-US">Financial Instruments [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xml:lang="en-US">Financial Instruments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_USBankingInstitutionMember" xlink:label="loc_agle_USBankingInstitutionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_USBankingInstitutionMember" xml:lang="en-US">U.S. Banking Institution [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_USBankingInstitutionMember" xml:lang="en-US">U.S. Banking Institution</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_USBankingInstitutionMember" xlink:to="lab_agle_USBankingInstitutionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_USBankingInstitutionMember" xml:lang="en-US">U.S. Banking Institution [Member]</label>
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AccruedOptionCostPayable" xlink:label="loc_agle_AccruedOptionCostPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_AccruedOptionCostPayable" xml:lang="en-US">Accrued Option Cost Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_AccruedOptionCostPayable" xml:lang="en-US">Accrued option cost payable to Paragon</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_AccruedOptionCostPayable" xlink:to="lab_agle_AccruedOptionCostPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_AccruedOptionCostPayable" xml:lang="en-US">Accrued option cost payable.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xml:lang="en-US">Accrued Professional Fees, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xml:lang="en-US">Accrued professional and consulting fees</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProgramRightsObligations" xlink:label="loc_us-gaap_ProgramRightsObligations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProgramRightsObligations" xml:lang="en-US">Program Rights Obligations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProgramRightsObligations" xml:lang="en-US">Fair value of assumed Parapyre Option Obligation (Note&#160;3)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProgramRightsObligations" xlink:to="lab_us-gaap_ProgramRightsObligations" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xml:lang="en-US">Accrued Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xml:lang="en-US">Accrued liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AccruedLiabilitiesTable" xlink:label="loc_agle_AccruedLiabilitiesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_AccruedLiabilitiesTable" xml:lang="en-US">Accrued Liabilities [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_AccruedLiabilitiesTable" xlink:to="lab_agle_AccruedLiabilitiesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_AccruedLiabilitiesTable" xml:lang="en-US">Accrued liabilities.</label>
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AccruedLiabilitiesLineItems" xlink:label="loc_agle_AccruedLiabilitiesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_AccruedLiabilitiesLineItems" xml:lang="en-US">Accrued Liabilities [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_AccruedLiabilitiesLineItems" xlink:to="lab_agle_AccruedLiabilitiesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_AccruedLiabilitiesLineItems" xml:lang="en-US">Accrued liabilities.</label>
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_RelatedPartyExpensesIncurredPriorToAssetAcquisition" xlink:label="loc_agle_RelatedPartyExpensesIncurredPriorToAssetAcquisition" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_RelatedPartyExpensesIncurredPriorToAssetAcquisition" xml:lang="en-US">Related Party Expenses Incurred Prior To Asset Acquisition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_RelatedPartyExpensesIncurredPriorToAssetAcquisition" xml:lang="en-US">Related party expenses incurred prior to asset acquisition</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_RelatedPartyExpensesIncurredPriorToAssetAcquisition" xlink:to="lab_agle_RelatedPartyExpensesIncurredPriorToAssetAcquisition" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_RelatedPartyExpensesIncurredPriorToAssetAcquisition" xml:lang="en-US">Related party expenses incurred prior to asset acquisition.</label>
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ResearchInitiationFees" xlink:label="loc_agle_ResearchInitiationFees" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_ResearchInitiationFees" xml:lang="en-US">Research Initiation Fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_ResearchInitiationFees" xml:lang="en-US">Research initiation fees</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_ResearchInitiationFees" xlink:to="lab_agle_ResearchInitiationFees" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_ResearchInitiationFees" xml:lang="en-US">Research initiation fees.</label>
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ReimbursableResearchCosts" xlink:label="loc_agle_ReimbursableResearchCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_ReimbursableResearchCosts" xml:lang="en-US">Reimbursable Research Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_ReimbursableResearchCosts" xml:lang="en-US">Reimbursable research costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_ReimbursableResearchCosts" xlink:to="lab_agle_ReimbursableResearchCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_ReimbursableResearchCosts" xml:lang="en-US">Reimbursable research costs.</label>
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_RelatedPartyExpensesUnpaidPriorToAssetAcquisition" xlink:label="loc_agle_RelatedPartyExpensesUnpaidPriorToAssetAcquisition" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_RelatedPartyExpensesUnpaidPriorToAssetAcquisition" xml:lang="en-US">Related Party Expenses Unpaid Prior To Asset Acquisition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_RelatedPartyExpensesUnpaidPriorToAssetAcquisition" xml:lang="en-US">Related party expenses unpaid prior to asset acquisition</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_RelatedPartyExpensesUnpaidPriorToAssetAcquisition" xlink:to="lab_agle_RelatedPartyExpensesUnpaidPriorToAssetAcquisition" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_RelatedPartyExpensesUnpaidPriorToAssetAcquisition" xml:lang="en-US">Related party expenses unpaid prior to asset acquisition.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xml:lang="en-US">Related Party Transaction [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xml:lang="en-US">Related Party Transaction [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xml:lang="en-US">Related Party Transaction</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xml:lang="en-US">Related Party Transaction [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ParagonAgreementMember" xlink:label="loc_agle_ParagonAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_ParagonAgreementMember" xml:lang="en-US">Paragon Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_ParagonAgreementMember" xml:lang="en-US">Paragon Agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_ParagonAgreementMember" xlink:to="lab_agle_ParagonAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_ParagonAgreementMember" xml:lang="en-US">Paragon agreement.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent" xlink:label="loc_us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent" xml:lang="en-US">Asset Acquisition, Contingent Consideration, Liability, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent" xml:lang="en-US">Asset acquisition, contingent consideration, liability, current</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent" xlink:to="lab_us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_SummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_agle_SummaryOfSignificantAccountingPoliciesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_SummaryOfSignificantAccountingPoliciesTable" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_SummaryOfSignificantAccountingPoliciesTable" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_SummaryOfSignificantAccountingPoliciesTable" xlink:to="lab_agle_SummaryOfSignificantAccountingPoliciesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_SummaryOfSignificantAccountingPoliciesTable" xml:lang="en-US">Summary of significant accounting policies.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeAxis" xml:lang="en-US">Statistical Measurement [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_RangeAxis" xml:lang="en-US">Statistical Measurement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeMember" xml:lang="en-US">Statistical Measurement [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_RangeMember" xml:lang="en-US">Statistical Measurement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_RangeMember" xml:lang="en-US">Statistical Measurement [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MaximumMember" xml:lang="en-US">Maximum [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_MaximumMember" xml:lang="en-US">Maximum</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_srt_MaximumMember" xml:lang="en-US">Maximum</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_agle_SummaryOfSignificantAccountingPoliciesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_SummaryOfSignificantAccountingPoliciesLineItems" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_SummaryOfSignificantAccountingPoliciesLineItems" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="lab_agle_SummaryOfSignificantAccountingPoliciesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_SummaryOfSignificantAccountingPoliciesLineItems" xml:lang="en-US">Summary of significant accounting policies.</label>
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_MarketableSecuritiesMaturityPeriod" xlink:label="loc_agle_MarketableSecuritiesMaturityPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_MarketableSecuritiesMaturityPeriod" xml:lang="en-US">Marketable Securities Maturity Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_MarketableSecuritiesMaturityPeriod" xml:lang="en-US">Marketable securities stated maturity period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_MarketableSecuritiesMaturityPeriod" xlink:to="lab_agle_MarketableSecuritiesMaturityPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_MarketableSecuritiesMaturityPeriod" xml:lang="en-US">Marketable securities maturity period.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xml:lang="en-US">Impairment, Long-Lived Asset, Held-for-Use</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xml:lang="en-US">Impairments of long-lived assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_NumberOfSubsidiaryCorporationsOwned" xlink:label="loc_agle_NumberOfSubsidiaryCorporationsOwned" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_NumberOfSubsidiaryCorporationsOwned" xml:lang="en-US">Number Of Subsidiary Corporations Owned</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_NumberOfSubsidiaryCorporationsOwned" xml:lang="en-US">Number of subsidiary corporations owned</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_NumberOfSubsidiaryCorporationsOwned" xlink:to="lab_agle_NumberOfSubsidiaryCorporationsOwned" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_NumberOfSubsidiaryCorporationsOwned" xml:lang="en-US">Number of subsidiary corporations owned.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xml:lang="en-US">Unrecognized Tax Benefits</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xml:lang="en-US">Unrecognized Tax Benefits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xml:lang="en-US">Income Tax Examination, Penalties and Interest Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xml:lang="en-US">Interest or penalties incurred</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:to="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xml:lang="en-US">Schedule Of Property Plant And Equipment [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xml:lang="en-US">Long-Lived Tangible Asset</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xml:lang="en-US">Long-Lived Tangible Asset</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_LaboratoryEquipmentMember" xlink:label="loc_agle_LaboratoryEquipmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_LaboratoryEquipmentMember" xml:lang="en-US">Laboratory Equipment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_LaboratoryEquipmentMember" xml:lang="en-US">Laboratory Equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_LaboratoryEquipmentMember" xlink:to="lab_agle_LaboratoryEquipmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_LaboratoryEquipmentMember" xml:lang="en-US">Laboratory equipment.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xml:lang="en-US">Furniture and Fixtures [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xml:lang="en-US">Furniture and Office Equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComputerEquipmentMember" xml:lang="en-US">Computer Equipment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ComputerEquipmentMember" xml:lang="en-US">Computer Equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_PurchasedSoftwareMember" xlink:label="loc_agle_PurchasedSoftwareMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_PurchasedSoftwareMember" xml:lang="en-US">Purchased Software [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_PurchasedSoftwareMember" xml:lang="en-US">Software</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_PurchasedSoftwareMember" xlink:to="lab_agle_PurchasedSoftwareMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_PurchasedSoftwareMember" xml:lang="en-US">Purchased software.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xml:lang="en-US">Leasehold Improvements [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xml:lang="en-US">Leasehold Improvements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xml:lang="en-US">Property Plant And Equipment [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentBasisOfValuation" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentBasisOfValuation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentBasisOfValuation" xml:lang="en-US">Property, Plant and Equipment, Basis of Valuation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentBasisOfValuation" xml:lang="en-US">Useful lives of the property and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentBasisOfValuation" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentBasisOfValuation" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xml:lang="en-US">Useful lives of the property and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xml:lang="en-US">Measurement Frequency [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xml:lang="en-US">Measurement Frequency</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xml:lang="en-US">Measurement Frequency [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xml:lang="en-US">Measurement Frequency</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xml:lang="en-US">Fair Value, Recurring [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xml:lang="en-US">Fair Value, Measurements, Recurring</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xml:lang="en-US">Cash and Cash Equivalents [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xml:lang="en-US">Cash and Cash Equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xml:lang="en-US">Cash and Cash Equivalents [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xml:lang="en-US">Cash and Cash Equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xml:lang="en-US">Money Market Funds [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xml:lang="en-US">Money market funds</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xml:lang="en-US">US Government Corporations and Agencies Securities [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xml:lang="en-US">U.S. government securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xml:lang="en-US">Liability Class [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xml:lang="en-US">Liability Class [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xml:lang="en-US">Fair Value by Liability Class [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xml:lang="en-US">Fair Value by Liability Class [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xml:lang="en-US">Fair Value Hierarchy and NAV</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xml:lang="en-US">Level 1</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xml:lang="en-US">Level 2</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xml:lang="en-US">Level 3</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xml:lang="en-US">Asset Class [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xml:lang="en-US">Asset Class</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xml:lang="en-US">Asset Class [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xml:lang="en-US">Asset Class</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommercialPaperMember" xml:lang="en-US">Commercial Paper [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommercialPaperMember" xml:lang="en-US">Commercial paper</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentTypeAxis" xml:lang="en-US">Investment Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InvestmentTypeAxis" xml:lang="en-US">Investment Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xml:lang="en-US">Investments [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xml:lang="en-US">Investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xml:lang="en-US">Corporate Bond Securities [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xml:lang="en-US">Corporate bonds</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateBondSecuritiesMember" xlink:to="lab_us-gaap_CorporateBondSecuritiesMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xml:lang="en-US">Financial Assets:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xml:lang="en-US">Assets, Fair Value Disclosure</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xml:lang="en-US">Financial assets, fair value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xml:lang="en-US">Liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xml:lang="en-US">Liabilities, Fair Value Disclosure</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xml:lang="en-US">Liabilities, fair value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_StatementScenarioAxis" xml:lang="en-US">Scenario [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_StatementScenarioAxis" xml:lang="en-US">Scenario [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xml:lang="en-US">Scenario [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xml:lang="en-US">Scenario [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember" xlink:label="loc_srt_ScenarioForecastMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ScenarioForecastMember" xml:lang="en-US">Forecast [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_ScenarioForecastMember" xml:lang="en-US">Forecast</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xml:lang="en-US">Financial liabilities outstanding measured at fair value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xml:lang="en-US">Beginning balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xml:lang="en-US">Ending balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xml:lang="en-US">Share-based payment award, term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodFairValue" xlink:label="loc_agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodFairValue" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Granted In Period, Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodFairValue" xml:lang="en-US">Pro-rated estimated fair value of options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodFairValue" xlink:to="lab_agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodFairValue" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Granted In Period, Fair Value</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xml:lang="en-US">Asset Acquisition, Consideration Transferred, Contingent Consideration</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xml:lang="en-US">Fair value of contingent consideration assumed</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xlink:to="lab_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xml:lang="en-US">Change in fair value of liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xml:lang="en-US">Change in fair value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_FairValueAssetsLevel1ToLevel2TransfersAmount1" xlink:label="loc_agle_FairValueAssetsLevel1ToLevel2TransfersAmount1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_FairValueAssetsLevel1ToLevel2TransfersAmount1" xml:lang="en-US">Fair Value Assets Level1 To Level2 Transfers Amount1</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_FairValueAssetsLevel1ToLevel2TransfersAmount1" xml:lang="en-US">Fair value assets transferred from level 1 to level 2</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_FairValueAssetsLevel1ToLevel2TransfersAmount1" xlink:to="lab_agle_FairValueAssetsLevel1ToLevel2TransfersAmount1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_FairValueAssetsLevel1ToLevel2TransfersAmount1" xml:lang="en-US">Fair value assets level1 To level2 transfers amount1.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xml:lang="en-US">Issuance of Series A Preferred Stock on July 7, 2023</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xml:lang="en-US">Fair value at CVR issuance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MinimumMember" xml:lang="en-US">Minimum [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_MinimumMember" xml:lang="en-US">Minimum</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xml:lang="en-US">Measurement Input Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xml:lang="en-US">Measurement Input Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xml:lang="en-US">Measurement Input Type [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xml:lang="en-US">Measurement Input Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_MeasurementInputProabilityOfSuccessMember" xlink:label="loc_agle_MeasurementInputProabilityOfSuccessMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_MeasurementInputProabilityOfSuccessMember" xml:lang="en-US">Measurement Input, Proability Of Success [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_MeasurementInputProabilityOfSuccessMember" xml:lang="en-US">Estimated probability of success</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_MeasurementInputProabilityOfSuccessMember" xlink:to="lab_agle_MeasurementInputProabilityOfSuccessMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_MeasurementInputProabilityOfSuccessMember" xml:lang="en-US">Measurement Input, Proability Of Success</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xml:lang="en-US">Measurement Input, Discount Rate [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xml:lang="en-US">Risk-adjusted discount rates</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="loc_us-gaap_DerivativeLiabilityMeasurementInput" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeLiabilityMeasurementInput" xml:lang="en-US">Derivative Liability, Measurement Input</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DerivativeLiabilityMeasurementInput" xml:lang="en-US">Derivative liability, measurement input</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityMeasurementInput" xlink:to="lab_us-gaap_DerivativeLiabilityMeasurementInput" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xml:lang="en-US">Cash Equivalents, at Carrying Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xml:lang="en-US">Cash equivalents, amortized cost</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashEquivalentsAtCarryingValue" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_CashEquivalentsUnrealizedGains" xlink:label="loc_agle_CashEquivalentsUnrealizedGains" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_CashEquivalentsUnrealizedGains" xml:lang="en-US">Cash Equivalents Unrealized Gains</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_CashEquivalentsUnrealizedGains" xml:lang="en-US">Cash equivalents,Gross Unrealized Gains</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_CashEquivalentsUnrealizedGains" xlink:to="lab_agle_CashEquivalentsUnrealizedGains" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_CashEquivalentsUnrealizedGains" xml:lang="en-US">Cash equivalents unrealized gains.</label>
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_CashEquivalentsUnrealizedLosses" xlink:label="loc_agle_CashEquivalentsUnrealizedLosses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_CashEquivalentsUnrealizedLosses" xml:lang="en-US">Cash Equivalents Unrealized Losses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_agle_CashEquivalentsUnrealizedLosses" xml:lang="en-US">Cash equivalents, gross unrealized losses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_CashEquivalentsUnrealizedLosses" xlink:to="lab_agle_CashEquivalentsUnrealizedLosses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_CashEquivalentsUnrealizedLosses" xml:lang="en-US">Cash equivalents unrealized losses.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xml:lang="en-US">Cash equivalents, estimated fair value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xml:lang="en-US">Marketable securities, amortized cost</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xml:lang="en-US">Marketable securities, gross unrealized gains</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xml:lang="en-US">Marketable securities, gross unrealized losses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xml:lang="en-US">Fair Value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xml:lang="en-US">Less Than 12 Months</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xml:lang="en-US">12 Months or Longer</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract" xlink:label="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract" xml:lang="en-US">Unrealized Losses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract" xlink:to="lab_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xml:lang="en-US">Less Than 12 Months</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xml:lang="en-US">12 Months or Longer</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xml:lang="en-US">Total, Fair Value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xml:lang="en-US">Total, unrealized losses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_CashEquivalentsAndMarketableSecuritiesTable" xlink:label="loc_agle_CashEquivalentsAndMarketableSecuritiesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_CashEquivalentsAndMarketableSecuritiesTable" xml:lang="en-US">Cash Equivalents And Marketable Securities [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_CashEquivalentsAndMarketableSecuritiesTable" xml:lang="en-US">Cash Equivalents And Marketable Securities [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_CashEquivalentsAndMarketableSecuritiesTable" xlink:to="lab_agle_CashEquivalentsAndMarketableSecuritiesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_CashEquivalentsAndMarketableSecuritiesTable" xml:lang="en-US">Cash equivalents and marketable securities.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xml:lang="en-US">US Government Agencies Debt Securities [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xml:lang="en-US">US Government Agencies Debt Securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:label="loc_agle_CashEquivalentsAndMarketableSecuritiesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_CashEquivalentsAndMarketableSecuritiesLineItems" xml:lang="en-US">Cash Equivalents And Marketable Securities [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_CashEquivalentsAndMarketableSecuritiesLineItems" xml:lang="en-US">Cash Equivalents And Marketable Securities [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="lab_agle_CashEquivalentsAndMarketableSecuritiesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_CashEquivalentsAndMarketableSecuritiesLineItems" xml:lang="en-US">Cash equivalents and marketable securities.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xml:lang="en-US">Debt Securities, Available-for-Sale, Allowance for Credit Loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xml:lang="en-US">Debt securities, available-for-sale, allowance for credit loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ImpairmentOfMarketableSecurities" xlink:label="loc_agle_ImpairmentOfMarketableSecurities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_ImpairmentOfMarketableSecurities" xml:lang="en-US">Impairment Of Marketable Securities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_ImpairmentOfMarketableSecurities" xml:lang="en-US">Impairment of marketable securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_ImpairmentOfMarketableSecurities" xlink:to="lab_agle_ImpairmentOfMarketableSecurities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_ImpairmentOfMarketableSecurities" xml:lang="en-US">Impairment of marketable securities.</label>
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_NumberOfDomesticBankingInstitutions" xlink:label="loc_agle_NumberOfDomesticBankingInstitutions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_NumberOfDomesticBankingInstitutions" xml:lang="en-US">Number Of Domestic Banking Institutions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_NumberOfDomesticBankingInstitutions" xml:lang="en-US">Number of domestic banking institutions (in banks)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_NumberOfDomesticBankingInstitutions" xlink:to="lab_agle_NumberOfDomesticBankingInstitutions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_NumberOfDomesticBankingInstitutions" xml:lang="en-US">Number Of Domestic Banking Institutions</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaap_CashFDICInsuredAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashFDICInsuredAmount" xml:lang="en-US">Cash, FDIC Insured Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashFDICInsuredAmount" xml:lang="en-US">Cash, FDIC insured amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFDICInsuredAmount" xlink:to="lab_us-gaap_CashFDICInsuredAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments" xlink:label="loc_us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments" xml:lang="en-US">Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments" xml:lang="en-US">Realized gains or losses on marketable securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments" xlink:to="lab_us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestReceivable" xlink:label="loc_us-gaap_InterestReceivable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestReceivable" xml:lang="en-US">Interest Receivable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InterestReceivable" xml:lang="en-US">Accrued interest receivable on available-for-sale debt securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestReceivable" xlink:to="lab_us-gaap_InterestReceivable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xml:lang="en-US">Due in one year or less</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne" xlink:label="loc_agle_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne" xml:lang="en-US">Debt Securities, Available-For-Sale, Fair Value, Maturity, Allocated And Single Maturity Date, After Year One</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne" xml:lang="en-US">Due thereafter</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne" xlink:to="lab_agle_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne" xml:lang="en-US">Debt Securities, Available-For-Sale, Fair Value, Maturity, Allocated And Single Maturity Date, After Year One</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US">Property and equipment, gross</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Less: Accumulated depreciation and amortization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentMember" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentMember" xml:lang="en-US">Property, Plant and Equipment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentMember" xml:lang="en-US">Property, Plant and Equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentMember" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="loc_us-gaap_AccruedSalariesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedSalariesCurrent" xml:lang="en-US">Accrued Salaries, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccruedSalariesCurrent" xml:lang="en-US">Accrued compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedSalariesCurrent" xlink:to="lab_us-gaap_AccruedSalariesCurrent" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AccruedContractedResearchAndDevelopmentCosts" xlink:label="loc_agle_AccruedContractedResearchAndDevelopmentCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_AccruedContractedResearchAndDevelopmentCosts" xml:lang="en-US">Accrued Contracted Research And Development Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_AccruedContractedResearchAndDevelopmentCosts" xml:lang="en-US">Accrued contracted research and development costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_AccruedContractedResearchAndDevelopmentCosts" xlink:to="lab_agle_AccruedContractedResearchAndDevelopmentCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_AccruedContractedResearchAndDevelopmentCosts" xml:lang="en-US">Accrued contracted research and development costs.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xml:lang="en-US">Other Accrued Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xml:lang="en-US">Accrued other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ScheduleOfOperatingAndFinanceLeasedAssetsTable" xlink:label="loc_agle_ScheduleOfOperatingAndFinanceLeasedAssetsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_ScheduleOfOperatingAndFinanceLeasedAssetsTable" xml:lang="en-US">Schedule Of Operating And Finance Leased Assets [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_ScheduleOfOperatingAndFinanceLeasedAssetsTable" xml:lang="en-US">Schedule Of Operating And Finance Leased Assets [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_ScheduleOfOperatingAndFinanceLeasedAssetsTable" xlink:to="lab_agle_ScheduleOfOperatingAndFinanceLeasedAssetsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_ScheduleOfOperatingAndFinanceLeasedAssetsTable" xml:lang="en-US">Schedule of operating and finance leased assets.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xml:lang="en-US">Short-Term Debt, Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xml:lang="en-US">Short-term Debt, Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis" xlink:to="lab_us-gaap_ShortTermDebtTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xml:lang="en-US">Short-Term Debt, Type [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xml:lang="en-US">Short-term Debt, Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain" xlink:to="lab_us-gaap_ShortTermDebtTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LetterOfCreditMember" xlink:label="loc_us-gaap_LetterOfCreditMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LetterOfCreditMember" xml:lang="en-US">Letter of Credit [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LetterOfCreditMember" xml:lang="en-US">Letter of Credit Member</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LetterOfCreditMember" xlink:to="lab_us-gaap_LetterOfCreditMember" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ScheduleOfOperatingAndFinanceLeasedAssetsLineItems" xlink:label="loc_agle_ScheduleOfOperatingAndFinanceLeasedAssetsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_ScheduleOfOperatingAndFinanceLeasedAssetsLineItems" xml:lang="en-US">Schedule Of Operating And Finance Leased Assets [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_ScheduleOfOperatingAndFinanceLeasedAssetsLineItems" xml:lang="en-US">Schedule Of Operating And Finance Leased Assets Line Items</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_ScheduleOfOperatingAndFinanceLeasedAssetsLineItems" xlink:to="lab_agle_ScheduleOfOperatingAndFinanceLeasedAssetsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_ScheduleOfOperatingAndFinanceLeasedAssetsLineItems" xml:lang="en-US">Schedule of operating and finance leased assets.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xml:lang="en-US">Lessee, operating lease, renewal term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeFinanceLeaseRenewalTerm1" xlink:label="loc_us-gaap_LesseeFinanceLeaseRenewalTerm1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeFinanceLeaseRenewalTerm1" xml:lang="en-US">Lessee, Finance Lease, Renewal Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeFinanceLeaseRenewalTerm1" xml:lang="en-US">Lessee, finance lease, renewal term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeaseRenewalTerm1" xlink:to="lab_us-gaap_LesseeFinanceLeaseRenewalTerm1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AreaOfLand" xlink:label="loc_us-gaap_AreaOfLand" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AreaOfLand" xml:lang="en-US">Area of Land</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AreaOfLand" xml:lang="en-US">Area of land</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AreaOfLand" xlink:to="lab_us-gaap_AreaOfLand" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseExpirationDate1" xlink:label="loc_us-gaap_LeaseExpirationDate1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseExpirationDate1" xml:lang="en-US">Lease Expiration Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LeaseExpirationDate1" xml:lang="en-US">Lease expiration date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseExpirationDate1" xlink:to="lab_us-gaap_LeaseExpirationDate1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCredit" xlink:label="loc_us-gaap_LineOfCredit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCredit" xml:lang="en-US">Long-Term Line of Credit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LineOfCredit" xml:lang="en-US">Letter of credit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCredit" xlink:to="lab_us-gaap_LineOfCredit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TenantImprovements" xlink:label="loc_us-gaap_TenantImprovements" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TenantImprovements" xml:lang="en-US">Tenant Improvements</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TenantImprovements" xml:lang="en-US">Tenant improvement allowance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TenantImprovements" xlink:to="lab_us-gaap_TenantImprovements" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeasePayments" xml:lang="en-US">Operating Lease, Payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeasePayments" xml:lang="en-US">Operating lease, payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xml:lang="en-US">Finance Lease, Right-of-Use Asset, after Accumulated Amortization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xml:lang="en-US">Finance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAsset" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_OperatingAndFinanceLeaseRightOfUseAsset" xlink:label="loc_agle_OperatingAndFinanceLeaseRightOfUseAsset" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_OperatingAndFinanceLeaseRightOfUseAsset" xml:lang="en-US">Operating And Finance Lease Right Of Use Asset</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_agle_OperatingAndFinanceLeaseRightOfUseAsset" xml:lang="en-US">Total leased assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_OperatingAndFinanceLeaseRightOfUseAsset" xlink:to="lab_agle_OperatingAndFinanceLeaseRightOfUseAsset" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_OperatingAndFinanceLeaseRightOfUseAsset" xml:lang="en-US">Operating and financing lease right of use asset.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xml:lang="en-US">Finance Lease, Liability, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xml:lang="en-US">Finance lease liabilities, current</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xml:lang="en-US">Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xml:lang="en-US">Finance Lease, Liabilities, Current, Statement of Financial Position [Extensible List]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xml:lang="en-US">Finance Lease, Liability, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xml:lang="en-US">Finance lease liabilities, noncurrent</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xml:lang="en-US">Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xml:lang="en-US">Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_OperatingAndFinanceLeaseLiabilities" xlink:label="loc_agle_OperatingAndFinanceLeaseLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_OperatingAndFinanceLeaseLiabilities" xml:lang="en-US">Operating And Finance Lease Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_agle_OperatingAndFinanceLeaseLiabilities" xml:lang="en-US">Total lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_OperatingAndFinanceLeaseLiabilities" xlink:to="lab_agle_OperatingAndFinanceLeaseLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_OperatingAndFinanceLeaseLiabilities" xml:lang="en-US">Operating and Finance lease Liabilities.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xml:lang="en-US">Operating leases, Weighted-average remaining lease term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xml:lang="en-US">Finance Lease, Weighted Average Remaining Lease Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xml:lang="en-US">Finance leases, Weighted-average remaining lease term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xml:lang="en-US">Operating leases, Weighted-average discount rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xml:lang="en-US">Finance Lease, Weighted Average Discount Rate, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xml:lang="en-US">Finance leases, Weighted-average discount rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseCost" xml:lang="en-US">Operating Lease, Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseCost" xml:lang="en-US">Operating lease cost</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaap_VariableLeaseCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_VariableLeaseCost" xml:lang="en-US">Variable Lease, Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_VariableLeaseCost" xml:lang="en-US">Variable lease cost</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaap_LeaseCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseCost" xml:lang="en-US">Lease, Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LeaseCost" xml:lang="en-US">Total lease cost</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xml:lang="en-US">Operating Leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xml:lang="en-US">2023</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xml:lang="en-US">2024</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xml:lang="en-US">2025</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xml:lang="en-US">2026</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xml:lang="en-US">2027</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xml:lang="en-US">Thereafter</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xml:lang="en-US">Total lease payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xml:lang="en-US">Imputed interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiability" xml:lang="en-US">Operating Lease, Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiability" xml:lang="en-US">Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xml:lang="en-US">Finance Lease, Liability, to be Paid [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xml:lang="en-US">Finance Lease Liabilities, Payments, Due [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year One</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xml:lang="en-US">2023</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xml:lang="en-US">Finance Lease, Liability, to be Paid</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xml:lang="en-US">Total lease payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiability" xlink:label="loc_us-gaap_FinanceLeaseLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinanceLeaseLiability" xml:lang="en-US">Finance Lease, Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FinanceLeaseLiability" xml:lang="en-US">Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiability" xlink:to="lab_us-gaap_FinanceLeaseLiability" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xml:lang="en-US">Schedule of Stock by Class [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xml:lang="en-US">Schedule Of Stock By Class [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xml:lang="en-US">Schedule of Stock by Class [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_FollowOnPublicOfferingMember" xlink:label="loc_agle_FollowOnPublicOfferingMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_FollowOnPublicOfferingMember" xml:lang="en-US">Follow On Public Offering [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_FollowOnPublicOfferingMember" xml:lang="en-US">Follow-on Public Offering</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_FollowOnPublicOfferingMember" xlink:to="lab_agle_FollowOnPublicOfferingMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_FollowOnPublicOfferingMember" xml:lang="en-US">Follow on public offering.</label>
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AtTheMarketSalesAgreementMember" xlink:label="loc_agle_AtTheMarketSalesAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_AtTheMarketSalesAgreementMember" xml:lang="en-US">At The Market Sales Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_AtTheMarketSalesAgreementMember" xml:lang="en-US">At-the-Market (ATM) Sales Agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_AtTheMarketSalesAgreementMember" xlink:to="lab_agle_AtTheMarketSalesAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_AtTheMarketSalesAgreementMember" xml:lang="en-US">At the market sales agreement.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xml:lang="en-US">Over-Allotment Option [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xml:lang="en-US">Underwriters' Over-allotment Option</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember" xlink:to="lab_us-gaap_OverAllotmentOptionMember" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_JonesTradingInstitutionalServicesLimitedLiabilityCompanyMember" xlink:label="loc_agle_JonesTradingInstitutionalServicesLimitedLiabilityCompanyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_JonesTradingInstitutionalServicesLimitedLiabilityCompanyMember" xml:lang="en-US">Jones Trading Institutional Services Limited Liability Company [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_JonesTradingInstitutionalServicesLimitedLiabilityCompanyMember" xml:lang="en-US">JonesTrading Institutional Services LLC</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_JonesTradingInstitutionalServicesLimitedLiabilityCompanyMember" xlink:to="lab_agle_JonesTradingInstitutionalServicesLimitedLiabilityCompanyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_JonesTradingInstitutionalServicesLimitedLiabilityCompanyMember" xml:lang="en-US">Jones Trading Institutional Services Limited Liability Company.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfStockLineItems" xml:lang="en-US">Class of Stock [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfStockLineItems" xml:lang="en-US">Class Of Stock [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfStockLineItems" xml:lang="en-US">Class of Stock [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Number of shares issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xml:lang="en-US">Sale of Stock, Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xml:lang="en-US">Public offering price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xml:lang="en-US">Public offering price (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees" xlink:label="loc_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees" xml:lang="en-US">Expense Related to Distribution or Servicing and Underwriting Fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees" xml:lang="en-US">Underwriting discounts and commissions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees" xlink:to="lab_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xml:lang="en-US">Payments of Stock Issuance Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xml:lang="en-US">Offering costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AggregateOfferingPriceOfCommonStock" xlink:label="loc_agle_AggregateOfferingPriceOfCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_AggregateOfferingPriceOfCommonStock" xml:lang="en-US">Aggregate Offering Price Of Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_AggregateOfferingPriceOfCommonStock" xml:lang="en-US">Aggregate offering price of common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_AggregateOfferingPriceOfCommonStock" xlink:to="lab_agle_AggregateOfferingPriceOfCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_AggregateOfferingPriceOfCommonStock" xml:lang="en-US">Aggregate offering price of common stock.</label>
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_SharesAuthorized" xlink:label="loc_agle_SharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_SharesAuthorized" xml:lang="en-US">Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_SharesAuthorized" xml:lang="en-US">Shares authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_SharesAuthorized" xlink:to="lab_agle_SharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_SharesAuthorized" xml:lang="en-US">Shares authorized.</label>
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_NumberOfCommonStockVotingRightsHeldPerShare" xlink:label="loc_agle_NumberOfCommonStockVotingRightsHeldPerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_NumberOfCommonStockVotingRightsHeldPerShare" xml:lang="en-US">Number Of Common Stock Voting Rights Held Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_NumberOfCommonStockVotingRightsHeldPerShare" xml:lang="en-US">Number of common stock holders voting right</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_NumberOfCommonStockVotingRightsHeldPerShare" xlink:to="lab_agle_NumberOfCommonStockVotingRightsHeldPerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_NumberOfCommonStockVotingRightsHeldPerShare" xml:lang="en-US">Number of common stock voting rights held per share.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockVotingRights" xlink:label="loc_us-gaap_CommonStockVotingRights" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockVotingRights" xml:lang="en-US">Common Stock, Voting Rights</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockVotingRights" xml:lang="en-US">Common stock voting rights</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockVotingRights" xlink:to="lab_us-gaap_CommonStockVotingRights" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsCommonStock" xlink:label="loc_us-gaap_DividendsCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DividendsCommonStock" xml:lang="en-US">Dividends, Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DividendsCommonStock" xml:lang="en-US">Common stock dividends declared</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsCommonStock" xlink:to="lab_us-gaap_DividendsCommonStock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xml:lang="en-US">Warrants to purchase shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xml:lang="en-US">Warrants to purchase shares (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ClassOfWarrantOrRightOfferingPriceOfWarrantsOrRights" xlink:label="loc_agle_ClassOfWarrantOrRightOfferingPriceOfWarrantsOrRights" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_ClassOfWarrantOrRightOfferingPriceOfWarrantsOrRights" xml:lang="en-US">Class Of Warrant Or Right Offering Price Of Warrants Or Rights</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_agle_ClassOfWarrantOrRightOfferingPriceOfWarrantsOrRights" xml:lang="en-US">Offering price of warrant</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_ClassOfWarrantOrRightOfferingPriceOfWarrantsOrRights" xml:lang="en-US">Offering price of warrant (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_ClassOfWarrantOrRightOfferingPriceOfWarrantsOrRights" xlink:to="lab_agle_ClassOfWarrantOrRightOfferingPriceOfWarrantsOrRights" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_ClassOfWarrantOrRightOfferingPriceOfWarrantsOrRights" xml:lang="en-US">Class of warrant or right offering price of warrants or rights.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Net proceeds from sale of common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_PlacementAgentFeesAndOfferingCosts" xlink:label="loc_agle_PlacementAgentFeesAndOfferingCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_PlacementAgentFeesAndOfferingCosts" xml:lang="en-US">Placement Agent Fees And Offering Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_PlacementAgentFeesAndOfferingCosts" xml:lang="en-US">Placement agent fees and offering costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_PlacementAgentFeesAndOfferingCosts" xlink:to="lab_agle_PlacementAgentFeesAndOfferingCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_PlacementAgentFeesAndOfferingCosts" xml:lang="en-US">Placement agent fees and offering costs.</label>
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_MaximumOwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercised" xlink:label="loc_agle_MaximumOwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_MaximumOwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercised" xml:lang="en-US">Maximum Ownership Percentage For Outstanding Warrants To Purchase Shares Of Common Stock To Be Exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_MaximumOwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercised" xml:lang="en-US">Maximum ownership percentage of common stock shares for outstanding warrants to be exercised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_MaximumOwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercised" xlink:to="lab_agle_MaximumOwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_MaximumOwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercised" xml:lang="en-US">Maximum ownership percentage for outstanding warrants to purchase shares of common stock to be exercised.</label>
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_PeriodAfterNoticeReceivedByCompanyMaximumOwnershipPercentageToBeEffectiveDescription" xlink:label="loc_agle_PeriodAfterNoticeReceivedByCompanyMaximumOwnershipPercentageToBeEffectiveDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_PeriodAfterNoticeReceivedByCompanyMaximumOwnershipPercentageToBeEffectiveDescription" xml:lang="en-US">Period After Notice Received By Company Maximum Ownership Percentage To Be Effective Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_PeriodAfterNoticeReceivedByCompanyMaximumOwnershipPercentageToBeEffectiveDescription" xml:lang="en-US">Period after notice received by company maximum ownership percentage to be effective description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_PeriodAfterNoticeReceivedByCompanyMaximumOwnershipPercentageToBeEffectiveDescription" xlink:to="lab_agle_PeriodAfterNoticeReceivedByCompanyMaximumOwnershipPercentageToBeEffectiveDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_PeriodAfterNoticeReceivedByCompanyMaximumOwnershipPercentageToBeEffectiveDescription" xml:lang="en-US">Period after notice received by company maximum ownership percentage to be effective description.</label>
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_OwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercisedToCertainHolders" xlink:label="loc_agle_OwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercisedToCertainHolders" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_OwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercisedToCertainHolders" xml:lang="en-US">Ownership Percentage For Outstanding Warrants To Purchase Shares Of Common Stock To Be Exercised To Certain Holders</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_agle_OwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercisedToCertainHolders" xml:lang="en-US">Ownership percentage for outstanding warrants To purchase shares of common stock to be exercised to certain holders</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_agle_OwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercisedToCertainHolders" xml:lang="en-US">Ownership percentage for outstanding warrants to purchase shares of common stock to be exercised to certain holders</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_OwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercisedToCertainHolders" xlink:to="lab_agle_OwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercisedToCertainHolders" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_OwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercisedToCertainHolders" xml:lang="en-US">Ownership percentage for outstanding warrants To purchase shares of common stock to be exercised to certain holders.</label>
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ProceedsFromIssuanceOfCommonStockGross" xlink:label="loc_agle_ProceedsFromIssuanceOfCommonStockGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_ProceedsFromIssuanceOfCommonStockGross" xml:lang="en-US">Proceeds From Issuance Of Common Stock Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_ProceedsFromIssuanceOfCommonStockGross" xml:lang="en-US">Proceeds from issuance of common stock gross</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_ProceedsFromIssuanceOfCommonStockGross" xlink:to="lab_agle_ProceedsFromIssuanceOfCommonStockGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_ProceedsFromIssuanceOfCommonStockGross" xml:lang="en-US">Proceeds from issuance of common stock gross.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Exercise price per warrant</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Exercise Price (in dollars per share)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/presentationGuidance" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Exercise price per warrant (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xml:lang="en-US">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WarrantMember" xml:lang="en-US">Warrant [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WarrantMember" xml:lang="en-US">Pre-funded Warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaap_AwardDateAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AwardDateAxis" xml:lang="en-US">Award Date [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardDateAxis" xlink:to="lab_us-gaap_AwardDateAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaap_AwardDateDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AwardDateDomain" xml:lang="en-US">Award Date [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AwardDateDomain" xml:lang="en-US">Award Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AwardDateDomain" xml:lang="en-US">Award Date [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardDateDomain" xlink:to="lab_us-gaap_AwardDateDomain" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_FebruaryTwoThousandNinteenMember" xlink:label="loc_agle_FebruaryTwoThousandNinteenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_FebruaryTwoThousandNinteenMember" xml:lang="en-US">February Two Thousand Ninteen [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_FebruaryTwoThousandNinteenMember" xml:lang="en-US">February 2019</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_FebruaryTwoThousandNinteenMember" xlink:to="lab_agle_FebruaryTwoThousandNinteenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_FebruaryTwoThousandNinteenMember" xml:lang="en-US">February two thousand ninteen.</label>
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AprilTwoThousandTwentyMember" xlink:label="loc_agle_AprilTwoThousandTwentyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_AprilTwoThousandTwentyMember" xml:lang="en-US">April Two Thousand Twenty [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_AprilTwoThousandTwentyMember" xml:lang="en-US">April 2020</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_AprilTwoThousandTwentyMember" xlink:to="lab_agle_AprilTwoThousandTwentyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_AprilTwoThousandTwentyMember" xml:lang="en-US">April two thousand twenty Member.</label>
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_MayTwoThousandTwentyTwoMember" xlink:label="loc_agle_MayTwoThousandTwentyTwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_MayTwoThousandTwentyTwoMember" xml:lang="en-US">May Two Thousand Twenty Two [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_MayTwoThousandTwentyTwoMember" xml:lang="en-US">May 2022</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_MayTwoThousandTwentyTwoMember" xlink:to="lab_agle_MayTwoThousandTwentyTwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_MayTwoThousandTwentyTwoMember" xml:lang="en-US">May two thousand twenty two Member.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="loc_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xml:lang="en-US">Class of Warrant or Right, Date from which Warrants or Rights Exercisable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xml:lang="en-US">Issue Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:to="lab_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_WarrantExpirationDate" xlink:label="loc_agle_WarrantExpirationDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_WarrantExpirationDate" xml:lang="en-US">Warrant Expiration Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_WarrantExpirationDate" xml:lang="en-US">Expiration Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_WarrantExpirationDate" xlink:to="lab_agle_WarrantExpirationDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_WarrantExpirationDate" xml:lang="en-US">Warrant expiration date.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis" xlink:label="loc_srt_OwnershipAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_OwnershipAxis" xml:lang="en-US">Ownership [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_OwnershipAxis" xml:lang="en-US">Ownership [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_OwnershipDomain" xml:lang="en-US">Ownership [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_OwnershipDomain" xml:lang="en-US">Ownership [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ParagonTherapeuticsIncMember" xlink:label="loc_agle_ParagonTherapeuticsIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_ParagonTherapeuticsIncMember" xml:lang="en-US">Paragon Therapeutics Inc [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_ParagonTherapeuticsIncMember" xml:lang="en-US">Paragon Therapeutics Inc</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_ParagonTherapeuticsIncMember" xlink:to="lab_agle_ParagonTherapeuticsIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_ParagonTherapeuticsIncMember" xml:lang="en-US">Paragon therapeutics, Inc.</label>
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_FairmountFundsManagementLlcMember" xlink:label="loc_agle_FairmountFundsManagementLlcMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_FairmountFundsManagementLlcMember" xml:lang="en-US">Fairmount Funds Management LLC [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_FairmountFundsManagementLlcMember" xml:lang="en-US">Fairmount Funds Management LLC</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_FairmountFundsManagementLlcMember" xlink:to="lab_agle_FairmountFundsManagementLlcMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_FairmountFundsManagementLlcMember" xml:lang="en-US">Fairmount Funds Management LLC.</label>
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ParagonAndParapyreHoldingLlcMember" xlink:label="loc_agle_ParagonAndParapyreHoldingLlcMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_ParagonAndParapyreHoldingLlcMember" xml:lang="en-US">Paragon and Parapyre Holding LLC [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_agle_ParagonAndParapyreHoldingLlcMember" xml:lang="en-US">Paragon and Parapyre Holding LLC</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_ParagonAndParapyreHoldingLlcMember" xlink:to="lab_agle_ParagonAndParapyreHoldingLlcMember" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_OwnershipInterestMember" xlink:label="loc_agle_OwnershipInterestMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_OwnershipInterestMember" xml:lang="en-US">Ownership Interest [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_OwnershipInterestMember" xml:lang="en-US">Ownership Interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_OwnershipInterestMember" xlink:to="lab_agle_OwnershipInterestMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_OwnershipInterestMember" xml:lang="en-US">Ownership Interest</label>
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AppointOfBoardMember" xlink:label="loc_agle_AppointOfBoardMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_AppointOfBoardMember" xml:lang="en-US">Appoint Of Board [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_AppointOfBoardMember" xml:lang="en-US">Appoint Of Board</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_AppointOfBoardMember" xlink:to="lab_agle_AppointOfBoardMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_AppointOfBoardMember" xml:lang="en-US">Appoint Of Board.</label>
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_StockCompensationAndResearchAndDevelopmentExpenseMember" xlink:label="loc_agle_StockCompensationAndResearchAndDevelopmentExpenseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_StockCompensationAndResearchAndDevelopmentExpenseMember" xml:lang="en-US">Stock Compensation And Research And Development Expense [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_StockCompensationAndResearchAndDevelopmentExpenseMember" xml:lang="en-US">Stock Compensation And Research And Development Expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_StockCompensationAndResearchAndDevelopmentExpenseMember" xlink:to="lab_agle_StockCompensationAndResearchAndDevelopmentExpenseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_StockCompensationAndResearchAndDevelopmentExpenseMember" xml:lang="en-US">Stock Compensation And Research And Development Expense</label>
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ReimbursableCostsUnderParagonAgreementMember" xlink:label="loc_agle_ReimbursableCostsUnderParagonAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_ReimbursableCostsUnderParagonAgreementMember" xml:lang="en-US">Reimbursable Costs Under Paragon Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_ReimbursableCostsUnderParagonAgreementMember" xml:lang="en-US">Reimbursable Costs Under Paragon Agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_ReimbursableCostsUnderParagonAgreementMember" xlink:to="lab_agle_ReimbursableCostsUnderParagonAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_ReimbursableCostsUnderParagonAgreementMember" xml:lang="en-US">Reimbursable costs under paragon agreement.</label>
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_MilestonePaymentsMember" xlink:label="loc_agle_MilestonePaymentsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_MilestonePaymentsMember" xml:lang="en-US">Milestone Payments [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_MilestonePaymentsMember" xml:lang="en-US">Milestone Payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_MilestonePaymentsMember" xlink:to="lab_agle_MilestonePaymentsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_MilestonePaymentsMember" xml:lang="en-US">Milestone Payments</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicensingAgreementsMember" xlink:label="loc_us-gaap_LicensingAgreementsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LicensingAgreementsMember" xml:lang="en-US">Licensing Agreements [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LicensingAgreementsMember" xml:lang="en-US">Licensing Agreements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicensingAgreementsMember" xlink:to="lab_us-gaap_LicensingAgreementsMember" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_Spy001LicenseAgreementMember" xlink:label="loc_agle_Spy001LicenseAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_Spy001LicenseAgreementMember" xml:lang="en-US">SPY001 License Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_Spy001LicenseAgreementMember" xml:lang="en-US">SPY001 License Agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_Spy001LicenseAgreementMember" xlink:to="lab_agle_Spy001LicenseAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_Spy001LicenseAgreementMember" xml:lang="en-US">SPY001 License Agreement.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_CounterpartyNameAxis" xml:lang="en-US">Counterparty Name [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_CounterpartyNameAxis" xml:lang="en-US">Counterparty Name [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xml:lang="en-US">Counterparty Name [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xml:lang="en-US">Counterparty Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xml:lang="en-US">Related Party Transaction [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xml:lang="en-US">Related Party Transaction [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xml:lang="en-US">Subsidiary, Ownership Percentage, Noncontrolling Owner</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xml:lang="en-US">Percentage of ownership by noncontrolling owner</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_RelatedPartyTransactionNumberOfBoardSeats" xlink:label="loc_agle_RelatedPartyTransactionNumberOfBoardSeats" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_RelatedPartyTransactionNumberOfBoardSeats" xml:lang="en-US">Related Party Transaction, Number Of Board Seats</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_RelatedPartyTransactionNumberOfBoardSeats" xml:lang="en-US">Number of board seats held by related party</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_RelatedPartyTransactionNumberOfBoardSeats" xlink:to="lab_agle_RelatedPartyTransactionNumberOfBoardSeats" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_RelatedPartyTransactionNumberOfBoardSeats" xml:lang="en-US">Related Party Transaction, Number Of Board Seats</label>
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_MinorityInterestOwnershipPercentageByNoncontrollingOwnersHeldInThirdParty" xlink:label="loc_agle_MinorityInterestOwnershipPercentageByNoncontrollingOwnersHeldInThirdParty" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_MinorityInterestOwnershipPercentageByNoncontrollingOwnersHeldInThirdParty" xml:lang="en-US">Minority Interest Ownership Percentage By Noncontrolling Owners Held In Third Party</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_MinorityInterestOwnershipPercentageByNoncontrollingOwnersHeldInThirdParty" xml:lang="en-US">Percentage of ownership held in third party</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_MinorityInterestOwnershipPercentageByNoncontrollingOwnersHeldInThirdParty" xlink:to="lab_agle_MinorityInterestOwnershipPercentageByNoncontrollingOwnersHeldInThirdParty" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_MinorityInterestOwnershipPercentageByNoncontrollingOwnersHeldInThirdParty" xml:lang="en-US">Minority interest ownership percentage by noncontrolling owners held in third party.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xml:lang="en-US">Related Party Transaction, Amounts of Transaction</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xml:lang="en-US">Amount of related party transaction</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xml:lang="en-US">Transaction price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts Payable, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_RelatedPartyTransactionNumberOfProgramOptionsOutstanding" xlink:label="loc_agle_RelatedPartyTransactionNumberOfProgramOptionsOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_RelatedPartyTransactionNumberOfProgramOptionsOutstanding" xml:lang="en-US">Related Party Transaction, Number Of Program Options Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_RelatedPartyTransactionNumberOfProgramOptionsOutstanding" xml:lang="en-US">Number of program options outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_RelatedPartyTransactionNumberOfProgramOptionsOutstanding" xlink:to="lab_agle_RelatedPartyTransactionNumberOfProgramOptionsOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_RelatedPartyTransactionNumberOfProgramOptionsOutstanding" xml:lang="en-US">Related Party Transaction, Number Of Program Options Outstanding</label>
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AmountToBePaidUnderAgreement" xlink:label="loc_agle_AmountToBePaidUnderAgreement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_AmountToBePaidUnderAgreement" xml:lang="en-US">Amount To Be Paid Under Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_AmountToBePaidUnderAgreement" xml:lang="en-US">Contingent obligation based on milestones</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_AmountToBePaidUnderAgreement" xlink:to="lab_agle_AmountToBePaidUnderAgreement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_AmountToBePaidUnderAgreement" xml:lang="en-US">Amount to be paid under agreement.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xml:lang="en-US">Income Statement Location [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xml:lang="en-US">Income Statement Location [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xml:lang="en-US">Income Statement Location [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xml:lang="en-US">Income Statement Location</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xml:lang="en-US">Research and Development Expense [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xml:lang="en-US">Research and Development Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/presentationGuidance" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xml:lang="en-US">Research and Development</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_RelatedPartyTransactionReimbursableCosts" xlink:label="loc_agle_RelatedPartyTransactionReimbursableCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_RelatedPartyTransactionReimbursableCosts" xml:lang="en-US">Related Party Transaction Reimbursable Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_RelatedPartyTransactionReimbursableCosts" xml:lang="en-US">Reimbursable costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_RelatedPartyTransactionReimbursableCosts" xlink:to="lab_agle_RelatedPartyTransactionReimbursableCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_RelatedPartyTransactionReimbursableCosts" xml:lang="en-US">Related party transaction, reimbursable costs.</label>
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AssumedLiabilities" xlink:label="loc_agle_AssumedLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_AssumedLiabilities" xml:lang="en-US">Assumed Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_agle_AssumedLiabilities" xml:lang="en-US">Assumed liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_AssumedLiabilities" xlink:to="lab_agle_AssumedLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_AssumedLiabilities" xml:lang="en-US">Assumed liabilities.</label>
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_LicenseAgreementMilestonePayments" xlink:label="loc_agle_LicenseAgreementMilestonePayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_LicenseAgreementMilestonePayments" xml:lang="en-US">License Agreement, Milestone Payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_LicenseAgreementMilestonePayments" xml:lang="en-US">Milestone payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_LicenseAgreementMilestonePayments" xlink:to="lab_agle_LicenseAgreementMilestonePayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_LicenseAgreementMilestonePayments" xml:lang="en-US">License Agreement, Milestone Payments</label>
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_NonrefundableResearchInitiationFeeForOneProgramPaidInCash" xlink:label="loc_agle_NonrefundableResearchInitiationFeeForOneProgramPaidInCash" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_NonrefundableResearchInitiationFeeForOneProgramPaidInCash" xml:lang="en-US">Nonrefundable Research Initiation Fee For One Program Paid In Cash</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_NonrefundableResearchInitiationFeeForOneProgramPaidInCash" xml:lang="en-US">Nonrefundable research initiation fee for one program paid in cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_NonrefundableResearchInitiationFeeForOneProgramPaidInCash" xlink:to="lab_agle_NonrefundableResearchInitiationFeeForOneProgramPaidInCash" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_NonrefundableResearchInitiationFeeForOneProgramPaidInCash" xml:lang="en-US">Nonrefundable research initiation fee for one program paid in cash.</label>
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_NominationFee" xlink:label="loc_agle_NominationFee" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_NominationFee" xml:lang="en-US">Nomination Fee</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_NominationFee" xml:lang="en-US">Nomination fee</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_NominationFee" xlink:to="lab_agle_NominationFee" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_NominationFee" xml:lang="en-US">Nomination fee.</label>
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_PaymentOfMilestone" xlink:label="loc_agle_PaymentOfMilestone" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_PaymentOfMilestone" xml:lang="en-US">Payment Of Milestone</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_agle_PaymentOfMilestone" xml:lang="en-US">First milestone payment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_PaymentOfMilestone" xml:lang="en-US">Milestone payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_PaymentOfMilestone" xlink:to="lab_agle_PaymentOfMilestone" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_PaymentOfMilestone" xml:lang="en-US">Payment of milestone.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xml:lang="en-US">Business Acquisition [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xml:lang="en-US">Business Acquisition [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_PreferredStockRemainsIssuedAndOutstandingPercentage" xlink:label="loc_agle_PreferredStockRemainsIssuedAndOutstandingPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_PreferredStockRemainsIssuedAndOutstandingPercentage" xml:lang="en-US">Preferred Stock Remains Issued and Outstanding Percentage.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_PreferredStockRemainsIssuedAndOutstandingPercentage" xml:lang="en-US">Preferred stock issued and outstanding percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_PreferredStockRemainsIssuedAndOutstandingPercentage" xlink:to="lab_agle_PreferredStockRemainsIssuedAndOutstandingPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_PreferredStockRemainsIssuedAndOutstandingPercentage" xml:lang="en-US">Preferred stock remains issued and outstanding percentage.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockRedemptionAmount" xlink:label="loc_us-gaap_PreferredStockRedemptionAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockRedemptionAmount" xml:lang="en-US">Preferred Stock, Redemption Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockRedemptionAmount" xml:lang="en-US">Preferred stock, redemption value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockRedemptionAmount" xlink:to="lab_us-gaap_PreferredStockRedemptionAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockRedemptionPricePerShare" xlink:label="loc_us-gaap_PreferredStockRedemptionPricePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockRedemptionPricePerShare" xml:lang="en-US">Preferred Stock, Redemption Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockRedemptionPricePerShare" xml:lang="en-US">Preferred stock, redemption per share (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockRedemptionPricePerShare" xlink:to="lab_us-gaap_PreferredStockRedemptionPricePerShare" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_BeneficiallyHoldersOwnedPercentage" xlink:label="loc_agle_BeneficiallyHoldersOwnedPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_BeneficiallyHoldersOwnedPercentage" xml:lang="en-US">Beneficially Holders Owned Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_BeneficiallyHoldersOwnedPercentage" xml:lang="en-US">Beneficially holders owned percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_BeneficiallyHoldersOwnedPercentage" xlink:to="lab_agle_BeneficiallyHoldersOwnedPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_BeneficiallyHoldersOwnedPercentage" xml:lang="en-US">Beneficially holders owned percentage</label>
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_FebruaryEightTwoThousandNinteenMember" xlink:label="loc_agle_FebruaryEightTwoThousandNinteenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_FebruaryEightTwoThousandNinteenMember" xml:lang="en-US">February Eight Two Thousand Ninteen [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_FebruaryEightTwoThousandNinteenMember" xml:lang="en-US">February 8, 2019</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_FebruaryEightTwoThousandNinteenMember" xlink:to="lab_agle_FebruaryEightTwoThousandNinteenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_FebruaryEightTwoThousandNinteenMember" xml:lang="en-US">February eight two thousand ninteen.</label>
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AprilThirtyTwoThousandTwentyMember" xlink:label="loc_agle_AprilThirtyTwoThousandTwentyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_AprilThirtyTwoThousandTwentyMember" xml:lang="en-US">April Thirty Two Thousand Twenty [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_AprilThirtyTwoThousandTwentyMember" xml:lang="en-US">April 30, 2020</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_AprilThirtyTwoThousandTwentyMember" xlink:to="lab_agle_AprilThirtyTwoThousandTwentyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_AprilThirtyTwoThousandTwentyMember" xml:lang="en-US">April thirty two thousand twenty</label>
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_MayTwentyTwoThousandTwentyTwoMember" xlink:label="loc_agle_MayTwentyTwoThousandTwentyTwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_MayTwentyTwoThousandTwentyTwoMember" xml:lang="en-US">May Twenty Two Thousand Twenty Two [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_MayTwentyTwoThousandTwentyTwoMember" xml:lang="en-US">May 20, 2022</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_MayTwentyTwoThousandTwentyTwoMember" xlink:to="lab_agle_MayTwentyTwoThousandTwentyTwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_MayTwentyTwoThousandTwentyTwoMember" xml:lang="en-US">May twenty two thousand twenty two.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Grants (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Options granted (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Shares Issuable Under Options, Granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Grant Date Fair Value (in dollars per share)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AwardTypeAxis" xml:lang="en-US">Award Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AwardTypeAxis" xml:lang="en-US">Award Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xml:lang="en-US">Award Type [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xml:lang="en-US">Award Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_NonQualifiedStockOptionsMember" xlink:label="loc_agle_NonQualifiedStockOptionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_NonQualifiedStockOptionsMember" xml:lang="en-US">Non-Qualified Stock Options [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_agle_NonQualifiedStockOptionsMember" xml:lang="en-US">Non-Qualified Stock Options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_NonQualifiedStockOptionsMember" xlink:to="lab_agle_NonQualifiedStockOptionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_NonQualifiedStockOptionsMember" xml:lang="en-US">Non-Qualified Stock Options [Member]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xml:lang="en-US">Restricted Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xml:lang="en-US">Unvested restricted stock units</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ServiceBasedAwardsMember" xlink:label="loc_agle_ServiceBasedAwardsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_ServiceBasedAwardsMember" xml:lang="en-US">Service Based Awards [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_ServiceBasedAwardsMember" xml:lang="en-US">Service-based Awards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_ServiceBasedAwardsMember" xlink:to="lab_agle_ServiceBasedAwardsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_ServiceBasedAwardsMember" xml:lang="en-US">Service-based awards.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaap_StockOptionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockOptionMember" xml:lang="en-US">Equity Option [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockOptionMember" xml:lang="en-US">Stock option</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockOptionMember" xlink:to="lab_us-gaap_StockOptionMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xml:lang="en-US">Subsequent Event Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xml:lang="en-US">Subsequent Event Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventMember" xml:lang="en-US">Subsequent Event [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SubsequentEventMember" xml:lang="en-US">Subsequent Event</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_VestingAxis" xml:lang="en-US">Vesting [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_VestingAxis" xml:lang="en-US">Vesting</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_VestingDomain" xml:lang="en-US">Vesting [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_VestingDomain" xml:lang="en-US">Vesting</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityTypeAxis" xml:lang="en-US">Option Indexed to Issuer's Equity, Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityTypeAxis" xml:lang="en-US">Option Indexed to Issuer's Equity, Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="lab_us-gaap_OptionIndexedToIssuersEquityTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityTypeDomain" xml:lang="en-US">Option Indexed to Issuer's Equity, Type [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityTypeDomain" xml:lang="en-US">Option Indexed to Issuer's Equity, Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="lab_us-gaap_OptionIndexedToIssuersEquityTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Stock Options Granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Stock Options</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Options to purchase common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_TitleOfIndividualAxis" xml:lang="en-US">Title of Individual [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_TitleOfIndividualAxis" xml:lang="en-US">Title of Individual</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xml:lang="en-US">Title of Individual [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xml:lang="en-US">Title of Individual</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_EmployeesAndNonEmployeesMember" xlink:label="loc_agle_EmployeesAndNonEmployeesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_EmployeesAndNonEmployeesMember" xml:lang="en-US">Employees And Non Employees [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_EmployeesAndNonEmployeesMember" xml:lang="en-US">Employees and Non-Employees</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_EmployeesAndNonEmployeesMember" xlink:to="lab_agle_EmployeesAndNonEmployeesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_EmployeesAndNonEmployeesMember" xml:lang="en-US">Employees and non employees.</label>
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_NewChiefExecutiveOfficerMember" xlink:label="loc_agle_NewChiefExecutiveOfficerMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_NewChiefExecutiveOfficerMember" xml:lang="en-US">New Chief Executive Officer [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_agle_NewChiefExecutiveOfficerMember" xml:lang="en-US">New Chief Executive Officer</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_NewChiefExecutiveOfficerMember" xlink:to="lab_agle_NewChiefExecutiveOfficerMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_NewChiefExecutiveOfficerMember" xml:lang="en-US">New chief executive officer.</label>
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_NonEmployeesMember" xlink:label="loc_agle_NonEmployeesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_NonEmployeesMember" xml:lang="en-US">Non Employees [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_NonEmployeesMember" xml:lang="en-US">Non-Employees</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_NonEmployeesMember" xlink:to="lab_agle_NonEmployeesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_NonEmployeesMember" xml:lang="en-US">Non-employees.</label>
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_GranteesWithMoreThanFiveYearsVestingTermPercent" xlink:label="loc_agle_GranteesWithMoreThanFiveYearsVestingTermPercent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_GranteesWithMoreThanFiveYearsVestingTermPercent" xml:lang="en-US">Grantees With More Than Five Years Vesting Term Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_GranteesWithMoreThanFiveYearsVestingTermPercent" xml:lang="en-US">Grantees with more than five years vesting term, percent</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_GranteesWithMoreThanFiveYearsVestingTermPercent" xlink:to="lab_agle_GranteesWithMoreThanFiveYearsVestingTermPercent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_GranteesWithMoreThanFiveYearsVestingTermPercent" xml:lang="en-US">Grantees with more than five years vesting term, percent.</label>
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_MaximumVestingTermForMoreThanTenPercentGrantees" xlink:label="loc_agle_MaximumVestingTermForMoreThanTenPercentGrantees" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_MaximumVestingTermForMoreThanTenPercentGrantees" xml:lang="en-US">Maximum Vesting Term For More Than Ten Percent Grantees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_MaximumVestingTermForMoreThanTenPercentGrantees" xml:lang="en-US">Maximum vesting term for more than ten percent grantees</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_MaximumVestingTermForMoreThanTenPercentGrantees" xlink:to="lab_agle_MaximumVestingTermForMoreThanTenPercentGrantees" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_MaximumVestingTermForMoreThanTenPercentGrantees" xml:lang="en-US">Maximum vesting term for more than ten percent grantees.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Period Increase (Decrease)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xml:lang="en-US">Number of common stock to option outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xml:lang="en-US">Initial reserves of common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xml:lang="en-US">Number of common stock available for issuance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_agle_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance" xml:lang="en-US">Increase In Common Stock Capital Shares Reserved For Future Issuance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance" xml:lang="en-US">Increase in number of shares of common stock reserved for issuance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_agle_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance" xml:lang="en-US">Increase in common stock capital shares reserved for future issuance.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xml:lang="en-US">Share based compensation plan expiration date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AnnualPercentageOfAdditionalSharesWhichEqualsToIssuedAndOutstandingShares" xlink:label="loc_agle_AnnualPercentageOfAdditionalSharesWhichEqualsToIssuedAndOutstandingShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_AnnualPercentageOfAdditionalSharesWhichEqualsToIssuedAndOutstandingShares" xml:lang="en-US">Annual Percentage Of Additional Shares Which Equals To Issued And Outstanding Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_AnnualPercentageOfAdditionalSharesWhichEqualsToIssuedAndOutstandingShares" xml:lang="en-US">Annual percentage of additional shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_AnnualPercentageOfAdditionalSharesWhichEqualsToIssuedAndOutstandingShares" xlink:to="lab_agle_AnnualPercentageOfAdditionalSharesWhichEqualsToIssuedAndOutstandingShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_AnnualPercentageOfAdditionalSharesWhichEqualsToIssuedAndOutstandingShares" xml:lang="en-US">Annual percentage of additional shares which equals to the issued and outstanding shares.</label>
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant" xlink:label="loc_agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Additional Number Of Shares Available For Grant</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant" xml:lang="en-US">Additional number of shares available for issuance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant" xlink:to="lab_agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant" xml:lang="en-US">Share-based compensation arrangement by share-based payment award, additional number of shares available for grant.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xml:lang="en-US">Common stock available for future issuance (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Outstanding option awards</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Shares Issuable Under Options, Outstanding, Beginning balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Shares Issuable Under Options, Outstanding, Ending balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xml:lang="en-US">Awards granted, vesting period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xml:lang="en-US">Percentage of discount through payroll deductions to eligible employees to purchase common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Purchase Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xml:lang="en-US">Percentage of fair market value of common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAnnualFairMarketValuePerEmployee" xlink:label="loc_agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAnnualFairMarketValuePerEmployee" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAnnualFairMarketValuePerEmployee" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Maximum Annual Fair Market Value Per Employee</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAnnualFairMarketValuePerEmployee" xml:lang="en-US">Maximum purchase value per employee under employee stock purchase plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAnnualFairMarketValuePerEmployee" xlink:to="lab_agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAnnualFairMarketValuePerEmployee" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAnnualFairMarketValuePerEmployee" xml:lang="en-US">Share based compensation arrangement by share based payment award maximum annual fair market value per employee.</label>
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalAnnualPercentageIncrease" xlink:label="loc_agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalAnnualPercentageIncrease" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalAnnualPercentageIncrease" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Additional Annual Percentage Increase</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalAnnualPercentageIncrease" xml:lang="en-US">Additional annual percentage increase of common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalAnnualPercentageIncrease" xlink:to="lab_agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalAnnualPercentageIncrease" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalAnnualPercentageIncrease" xml:lang="en-US">Share based compensation arrangement by share based payment award additional annual percentage increase.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted-average grant date fair value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xml:lang="en-US">Intrinsic value of options exercised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xml:lang="en-US">Number of shares issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xml:lang="en-US">Stock option vested</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xml:lang="en-US">Equity instruments other than options, granted (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xml:lang="en-US">Shares, Granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xml:lang="en-US">Unrecognized stock-based compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xml:lang="en-US">Share-Based Payment Arrangement, Expense, Tax Benefit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xml:lang="en-US">Tax benefits recognized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_OwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercised" xlink:label="loc_agle_OwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_OwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercised" xml:lang="en-US">Ownership Percentage For Outstanding Warrants To Purchase Shares Of Common Stock To Be Exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_OwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercised" xml:lang="en-US">Maximum ownership percentage of common stock shares for outstanding warrants to be exercised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_OwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercised" xlink:to="lab_agle_OwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_OwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercised" xml:lang="en-US">Ownership Percentage For Outstanding Warrants To Purchase Shares Of Common Stock To Be Exercised</label>
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ClassOfWarrantOrRightRevisedOwnershipPercentagePeriodToTakeEffectAfterNotice" xlink:label="loc_agle_ClassOfWarrantOrRightRevisedOwnershipPercentagePeriodToTakeEffectAfterNotice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_ClassOfWarrantOrRightRevisedOwnershipPercentagePeriodToTakeEffectAfterNotice" xml:lang="en-US">Class Of Warrant Or Right, Revised Ownership Percentage, Period To Take Effect After Notice</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_ClassOfWarrantOrRightRevisedOwnershipPercentagePeriodToTakeEffectAfterNotice" xml:lang="en-US">Revised ownership percentage, period to take effect after notice</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_ClassOfWarrantOrRightRevisedOwnershipPercentagePeriodToTakeEffectAfterNotice" xlink:to="lab_agle_ClassOfWarrantOrRightRevisedOwnershipPercentagePeriodToTakeEffectAfterNotice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_ClassOfWarrantOrRightRevisedOwnershipPercentagePeriodToTakeEffectAfterNotice" xml:lang="en-US">Class Of Warrant Or Right, Revised Ownership Percentage, Period To Take Effect After Notice</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xml:lang="en-US">Equity instruments other than options, vested (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xml:lang="en-US">Shares, Vested</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Share-Based Payment Arrangement, Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/presentationGuidance" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Stock-based compensation expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Total stock-based compensation expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Stock-based compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_StockOptionsGrantedToCertainMembersOfBoardOfDirectorsContingentOnStockholderApproval" xlink:label="loc_agle_StockOptionsGrantedToCertainMembersOfBoardOfDirectorsContingentOnStockholderApproval" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_StockOptionsGrantedToCertainMembersOfBoardOfDirectorsContingentOnStockholderApproval" xml:lang="en-US">Stock Options Granted to Certain Members of Board of Directors, Contingent on Stockholder Approval</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_StockOptionsGrantedToCertainMembersOfBoardOfDirectorsContingentOnStockholderApproval" xml:lang="en-US">Stock options granted to certain members of board of directors, contingent on stockholder approval (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_StockOptionsGrantedToCertainMembersOfBoardOfDirectorsContingentOnStockholderApproval" xlink:to="lab_agle_StockOptionsGrantedToCertainMembersOfBoardOfDirectorsContingentOnStockholderApproval" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_StockOptionsGrantedToCertainMembersOfBoardOfDirectorsContingentOnStockholderApproval" xml:lang="en-US">Stock options granted to certain members of board of directors, contingent on stockholder approval.</label>
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_StockBasedCompensationExpenseOnContingentAwards" xlink:label="loc_agle_StockBasedCompensationExpenseOnContingentAwards" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_StockBasedCompensationExpenseOnContingentAwards" xml:lang="en-US">Stock Based Compensation Expense On Contingent Awards</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_StockBasedCompensationExpenseOnContingentAwards" xml:lang="en-US">Expense on contingent awards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_StockBasedCompensationExpenseOnContingentAwards" xlink:to="lab_agle_StockBasedCompensationExpenseOnContingentAwards" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_StockBasedCompensationExpenseOnContingentAwards" xml:lang="en-US">Stock based compensation expense on contingent awards.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xml:lang="en-US">Additional number of shares available for grant</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xml:lang="en-US">Pro-rated estimated fair value of options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="loc_us-gaap_ProceedsFromStockPlans" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xml:lang="en-US">Proceeds from Stock Plans</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xml:lang="en-US">Aggregate cash proceeds from sale of shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockPlans" xlink:to="lab_us-gaap_ProceedsFromStockPlans" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xml:lang="en-US">Unamortized expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xml:lang="en-US">Unrecognized stock-based compensation expense for options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xml:lang="en-US">Weighted average period over which unrecognized compensation is expected to be recognized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Expected dividend yield</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Dividend yield</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodOfFirstTwentyFivePercent" xlink:label="loc_agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodOfFirstTwentyFivePercent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodOfFirstTwentyFivePercent" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period Of First Twenty Five Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodOfFirstTwentyFivePercent" xml:lang="en-US">Vesting period of first 25% of options granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodOfFirstTwentyFivePercent" xlink:to="lab_agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodOfFirstTwentyFivePercent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodOfFirstTwentyFivePercent" xml:lang="en-US">Share based compensation arrangement by share based payment award award vesting period of first ywenty give percent.</label>
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodOfRemainingSeventyFivePercent" xlink:label="loc_agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodOfRemainingSeventyFivePercent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodOfRemainingSeventyFivePercent" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period Of Remaining Seventy Five Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodOfRemainingSeventyFivePercent" xml:lang="en-US">Vesting period of remaining 75% of options granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodOfRemainingSeventyFivePercent" xlink:to="lab_agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodOfRemainingSeventyFivePercent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodOfRemainingSeventyFivePercent" xml:lang="en-US">Share based compensation arrangement by share based payment award award vesting period of remaining seventy five percent.</label>
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsGrantedExercisablePeriod" xlink:label="loc_agle_ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsGrantedExercisablePeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsGrantedExercisablePeriod" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payments Award Options Granted Exercisable Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_agle_ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsGrantedExercisablePeriod" xml:lang="en-US">Options granted exercisable period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsGrantedExercisablePeriod" xlink:to="lab_agle_ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsGrantedExercisablePeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsGrantedExercisablePeriod" xml:lang="en-US">Share based compensation arrangement by share based payments award options granted exercisable period.</label>
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_MaximumNumberOfSharesPurchasedUnderEmployeeStockPurchasePlan" xlink:label="loc_agle_MaximumNumberOfSharesPurchasedUnderEmployeeStockPurchasePlan" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_MaximumNumberOfSharesPurchasedUnderEmployeeStockPurchasePlan" xml:lang="en-US">Maximum Number of Shares Purchased Under Employee Stock Purchase Plan</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_MaximumNumberOfSharesPurchasedUnderEmployeeStockPurchasePlan" xml:lang="en-US">Maximum number of shares purchased under employee stock purchase plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_MaximumNumberOfSharesPurchasedUnderEmployeeStockPurchasePlan" xlink:to="lab_agle_MaximumNumberOfSharesPurchasedUnderEmployeeStockPurchasePlan" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_MaximumNumberOfSharesPurchasedUnderEmployeeStockPurchasePlan" xml:lang="en-US">Maximum number of shares purchased under employee stock purchase plan.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xml:lang="en-US">Percentage of market value of common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_TwoThousandAndSixteenEquityIncentivePlanMember" xlink:label="loc_agle_TwoThousandAndSixteenEquityIncentivePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_TwoThousandAndSixteenEquityIncentivePlanMember" xml:lang="en-US">Two Thousand And Sixteen Equity Incentive Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_TwoThousandAndSixteenEquityIncentivePlanMember" xml:lang="en-US">2016 Equity Incentive Plan</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_agle_TwoThousandAndSixteenEquityIncentivePlanMember" xml:lang="en-US">2016 Plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_TwoThousandAndSixteenEquityIncentivePlanMember" xlink:to="lab_agle_TwoThousandAndSixteenEquityIncentivePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_TwoThousandAndSixteenEquityIncentivePlanMember" xml:lang="en-US">Two thousand and sixteen equity incentive plan.</label>
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_TwoThousandAndEighteenEquityInducementPlanMember" xlink:label="loc_agle_TwoThousandAndEighteenEquityInducementPlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_TwoThousandAndEighteenEquityInducementPlanMember" xml:lang="en-US">Two Thousand And Eighteen Equity Inducement Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_TwoThousandAndEighteenEquityInducementPlanMember" xml:lang="en-US">2018 Equity Inducement Plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_TwoThousandAndEighteenEquityInducementPlanMember" xlink:to="lab_agle_TwoThousandAndEighteenEquityInducementPlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_TwoThousandAndEighteenEquityInducementPlanMember" xml:lang="en-US">2018 equity inducement plan.</label>
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_TwoThousandAndFifteenAndTwoThousandAndSixteenEquityIncentivePlanAndTwoThousandAndEighteenEquityInducementPlanMember" xlink:label="loc_agle_TwoThousandAndFifteenAndTwoThousandAndSixteenEquityIncentivePlanAndTwoThousandAndEighteenEquityInducementPlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_TwoThousandAndFifteenAndTwoThousandAndSixteenEquityIncentivePlanAndTwoThousandAndEighteenEquityInducementPlanMember" xml:lang="en-US">Two Thousand And Fifteen And Two Thousand And Sixteen Equity Incentive Plan And Two Thousand And Eighteen Equity Inducement Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_TwoThousandAndFifteenAndTwoThousandAndSixteenEquityIncentivePlanAndTwoThousandAndEighteenEquityInducementPlanMember" xml:lang="en-US">2018 Plan, 2016 Plan and 2015 Plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_TwoThousandAndFifteenAndTwoThousandAndSixteenEquityIncentivePlanAndTwoThousandAndEighteenEquityInducementPlanMember" xlink:to="lab_agle_TwoThousandAndFifteenAndTwoThousandAndSixteenEquityIncentivePlanAndTwoThousandAndEighteenEquityInducementPlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_TwoThousandAndFifteenAndTwoThousandAndSixteenEquityIncentivePlanAndTwoThousandAndEighteenEquityInducementPlanMember" xml:lang="en-US">Two thousand and fifteen and two thousand and sixteen equity incentive plan and two thousand and eighteen equity inducement plan.</label>
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_TwoThousandAndSixteenEmployeeStockPurchasePlanMember" xlink:label="loc_agle_TwoThousandAndSixteenEmployeeStockPurchasePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_TwoThousandAndSixteenEmployeeStockPurchasePlanMember" xml:lang="en-US">Two Thousand And Sixteen Employee Stock Purchase Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_TwoThousandAndSixteenEmployeeStockPurchasePlanMember" xml:lang="en-US">2016 Employee Stock Purchase Plan</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_agle_TwoThousandAndSixteenEmployeeStockPurchasePlanMember" xml:lang="en-US">2016 ESPP</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_TwoThousandAndSixteenEmployeeStockPurchasePlanMember" xlink:to="lab_agle_TwoThousandAndSixteenEmployeeStockPurchasePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_TwoThousandAndSixteenEmployeeStockPurchasePlanMember" xml:lang="en-US">Two thousand and sixteen employee stock purchase plan.</label>
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_TwoThousandAndFifteenEquityIncentivePlanMember" xlink:label="loc_agle_TwoThousandAndFifteenEquityIncentivePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_TwoThousandAndFifteenEquityIncentivePlanMember" xml:lang="en-US">Two Thousand And Fifteen Equity Incentive Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_TwoThousandAndFifteenEquityIncentivePlanMember" xml:lang="en-US">2015 Equity Incentive Plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_TwoThousandAndFifteenEquityIncentivePlanMember" xlink:to="lab_agle_TwoThousandAndFifteenEquityIncentivePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_TwoThousandAndFifteenEquityIncentivePlanMember" xml:lang="en-US">Two thousand and fifteen equity incentive plan.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xml:lang="en-US">Shares Issuable Under Options, Forfeited</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xml:lang="en-US">Shares Issuable Under Options, Options vested and expected to vest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Shares Issuable Under Options, Options exercisable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Outstanding Beginning balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Outstanding Ending balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Exercised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Forfeited</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Options vested and expected to vest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Options exercisable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Weighted Average Remaining Contractual Term, Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Weighted Average Remaining Contractual Term, Options vested and expected to vest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Weighted Average Remaining Contractual Term, Options exercisable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xml:lang="en-US">Aggregate Intrinsic Value, Options vested and expected to vest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xml:lang="en-US">Aggregate Intrinsic Value, Options exercisable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedStockMember" xml:lang="en-US">Restricted Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestrictedStockMember" xml:lang="en-US">Restricted Common Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_EmployeesMember" xlink:label="loc_agle_EmployeesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_EmployeesMember" xml:lang="en-US">Employees [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_EmployeesMember" xml:lang="en-US">Employees</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_EmployeesMember" xlink:to="lab_agle_EmployeesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_EmployeesMember" xml:lang="en-US">Employees.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xml:lang="en-US">Shares, Unvested restricted common stock, Beginning balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xml:lang="en-US">Shares, Unvested restricted common stock, Ending balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xml:lang="en-US">Shares, Forfeited</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted Average Grant Date Fair Value, Unvested restricted common stock, Beginning balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted Average Grant Date Fair Value, Unvested restricted common stock, Ending balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted Average Grant Date Fair Value, Granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted Average Grant Date Fair Value, Vested</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted Average Grant Date Fair Value, Forfeited</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xml:lang="en-US">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember" xlink:label="loc_agle_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember" xml:lang="en-US">Two Thousand Eighteen Equity Inducement Plan And Two Thousand Sixteen Employee Stock Purchase Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember" xml:lang="en-US">2018 Equity Inducement Plan and 2016 Employee Stock Purchase Plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember" xlink:to="lab_agle_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember" xml:lang="en-US">Two thousand eighteen equity inducement plan and two thousand sixteen employee stock purchase plan.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xml:lang="en-US">General and Administrative Expense [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xml:lang="en-US">General and Administrative</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xml:lang="en-US">General and administrative</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xml:lang="en-US">Employee Service Share Based Compensation Allocation of Recognized Period Costs [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Expected term (in years)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Expected volatility</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Risk-free interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xml:lang="en-US">Schedule Of Research And Development Arrangement Contract To Perform For Others [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ImmedicaPharmaABMember" xlink:label="loc_agle_ImmedicaPharmaABMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_ImmedicaPharmaABMember" xml:lang="en-US">Immedica Pharma A B [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_ImmedicaPharmaABMember" xml:lang="en-US">Immedica Pharma AB</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_ImmedicaPharmaABMember" xlink:to="lab_agle_ImmedicaPharmaABMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_ImmedicaPharmaABMember" xml:lang="en-US">Immedica Pharma AB</label>
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_UniversityOfTexasAtAustinMember" xlink:label="loc_agle_UniversityOfTexasAtAustinMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_UniversityOfTexasAtAustinMember" xml:lang="en-US">University of Texas at Austin [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_UniversityOfTexasAtAustinMember" xml:lang="en-US">University of Texas at Austin</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_UniversityOfTexasAtAustinMember" xlink:to="lab_agle_UniversityOfTexasAtAustinMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_UniversityOfTexasAtAustinMember" xml:lang="en-US">University of Texas at Austin.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_PeaceTrialAndBLAPackageMember" xlink:label="loc_agle_PeaceTrialAndBLAPackageMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_PeaceTrialAndBLAPackageMember" xml:lang="en-US">Peace Trial And B L A Package [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_PeaceTrialAndBLAPackageMember" xml:lang="en-US">PEACE Trial and BLA Package</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_PeaceTrialAndBLAPackageMember" xlink:to="lab_agle_PeaceTrialAndBLAPackageMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_PeaceTrialAndBLAPackageMember" xml:lang="en-US">Peace Trial And BLA Package Member.</label>
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_PIPTrialMember" xlink:label="loc_agle_PIPTrialMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_PIPTrialMember" xml:lang="en-US">P I P Trial [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_PIPTrialMember" xml:lang="en-US">PIP Trial</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_PIPTrialMember" xlink:to="lab_agle_PIPTrialMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_PIPTrialMember" xml:lang="en-US">PIP trial.</label>
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_LicenseAgreementsMember" xlink:label="loc_agle_LicenseAgreementsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_LicenseAgreementsMember" xml:lang="en-US">License Agreements [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_LicenseAgreementsMember" xml:lang="en-US">License Agreements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_LicenseAgreementsMember" xlink:to="lab_agle_LicenseAgreementsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_LicenseAgreementsMember" xml:lang="en-US">License agreements.</label>
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_PeacePhase3TrialAndDrugSupplyMember" xlink:label="loc_agle_PeacePhase3TrialAndDrugSupplyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_PeacePhase3TrialAndDrugSupplyMember" xml:lang="en-US">Peace Phase 3 Trial And Drug Supply [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_PeacePhase3TrialAndDrugSupplyMember" xml:lang="en-US">Peace Phase 3 Trial and Drug Supply</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_PeacePhase3TrialAndDrugSupplyMember" xlink:to="lab_agle_PeacePhase3TrialAndDrugSupplyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_PeacePhase3TrialAndDrugSupplyMember" xml:lang="en-US">Peace phase 3 trial and drug supply.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xml:lang="en-US">Research And Development Arrangement Contract To Perform For Others [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_NonRefundablePaymentReceived" xlink:label="loc_agle_NonRefundablePaymentReceived" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_NonRefundablePaymentReceived" xml:lang="en-US">Non Refundable Payment Received</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_NonRefundablePaymentReceived" xml:lang="en-US">Non refundable payment received</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_NonRefundablePaymentReceived" xlink:to="lab_agle_NonRefundablePaymentReceived" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_NonRefundablePaymentReceived" xml:lang="en-US">Non refundable payment received.</label>
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_PercentageOfPaymentForCostIncurredInPIPTrial" xlink:label="loc_agle_PercentageOfPaymentForCostIncurredInPIPTrial" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_PercentageOfPaymentForCostIncurredInPIPTrial" xml:lang="en-US">Percentage Of Payment For Cost Incurred In P I P Trial</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_PercentageOfPaymentForCostIncurredInPIPTrial" xml:lang="en-US">Percentage of payment for cost incurred in PIP trial</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_PercentageOfPaymentForCostIncurredInPIPTrial" xlink:to="lab_agle_PercentageOfPaymentForCostIncurredInPIPTrial" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_PercentageOfPaymentForCostIncurredInPIPTrial" xml:lang="en-US">Percentage of payment for cost incurred in pip trial.</label>
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_CostsIncurredInPerformingTheTrial" xlink:label="loc_agle_CostsIncurredInPerformingTheTrial" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_CostsIncurredInPerformingTheTrial" xml:lang="en-US">Costs Incurred In Performing The Trial</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_CostsIncurredInPerformingTheTrial" xml:lang="en-US">Costs incurred in performing PIP Trial</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_CostsIncurredInPerformingTheTrial" xlink:to="lab_agle_CostsIncurredInPerformingTheTrial" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_CostsIncurredInPerformingTheTrial" xml:lang="en-US">Costs incurred in performing the pip trial.</label>
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_RateOfRevenueShare" xlink:label="loc_agle_RateOfRevenueShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_RateOfRevenueShare" xml:lang="en-US">Rate Of Revenue Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_RateOfRevenueShare" xml:lang="en-US">Rate of revenue share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_RateOfRevenueShare" xlink:to="lab_agle_RateOfRevenueShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_RateOfRevenueShare" xml:lang="en-US">Rate of revenue share.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReimbursementFromLimitedPartnershipInvestment" xlink:label="loc_us-gaap_ReimbursementFromLimitedPartnershipInvestment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ReimbursementFromLimitedPartnershipInvestment" xml:lang="en-US">Reimbursement from Limited Partnership Investment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ReimbursementFromLimitedPartnershipInvestment" xml:lang="en-US">Reimbursement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReimbursementFromLimitedPartnershipInvestment" xlink:to="lab_us-gaap_ReimbursementFromLimitedPartnershipInvestment" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_UpfrontPayment" xlink:label="loc_agle_UpfrontPayment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_UpfrontPayment" xml:lang="en-US">Upfront Payment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_UpfrontPayment" xml:lang="en-US">Upfront payment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_UpfrontPayment" xlink:to="lab_agle_UpfrontPayment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_UpfrontPayment" xml:lang="en-US">Upfront payment.</label>
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ContractWithCustomerFullReimbursementOfCostsIncludedLiability" xlink:label="loc_agle_ContractWithCustomerFullReimbursementOfCostsIncludedLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_ContractWithCustomerFullReimbursementOfCostsIncludedLiability" xml:lang="en-US">Contract With Customer, Full Reimbursement Of Costs Included Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_ContractWithCustomerFullReimbursementOfCostsIncludedLiability" xml:lang="en-US">Full reimbursement of costs included in upfront fixed payment received</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_ContractWithCustomerFullReimbursementOfCostsIncludedLiability" xlink:to="lab_agle_ContractWithCustomerFullReimbursementOfCostsIncludedLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_ContractWithCustomerFullReimbursementOfCostsIncludedLiability" xml:lang="en-US">Contract With Customer, Full Reimbursement Of Costs Included Liability</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xml:lang="en-US">Estimated amount incurred</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AllocatedAmountOfTransactionPrice" xlink:label="loc_agle_AllocatedAmountOfTransactionPrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_AllocatedAmountOfTransactionPrice" xml:lang="en-US">Allocated Amount Of Transaction Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_AllocatedAmountOfTransactionPrice" xml:lang="en-US">Allocated amount of transaction price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_AllocatedAmountOfTransactionPrice" xlink:to="lab_agle_AllocatedAmountOfTransactionPrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_AllocatedAmountOfTransactionPrice" xml:lang="en-US">Allocated amount of transaction price.</label>
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AllocationPriceTotal" xlink:label="loc_agle_AllocationPriceTotal" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_AllocationPriceTotal" xml:lang="en-US">Allocation Price Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_AllocationPriceTotal" xml:lang="en-US">Allocation price net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_AllocationPriceTotal" xlink:to="lab_agle_AllocationPriceTotal" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_AllocationPriceTotal" xml:lang="en-US">Allocation price total.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xml:lang="en-US">Contract with Customer, Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xml:lang="en-US">Deferred revenue</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xml:lang="en-US">Beginning balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xml:lang="en-US">Ending balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xml:lang="en-US">Contract with Customer, Liability, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xml:lang="en-US">Contract liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xml:lang="en-US">Beginning Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xml:lang="en-US">Ending Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xml:lang="en-US">Contract assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNet" xlink:to="lab_us-gaap_ContractWithCustomerAssetNet" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_LicenseAndSupplyAgreementDate" xlink:label="loc_agle_LicenseAndSupplyAgreementDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_LicenseAndSupplyAgreementDate" xml:lang="en-US">License and supply agreement date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_LicenseAndSupplyAgreementDate" xlink:to="lab_agle_LicenseAndSupplyAgreementDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_LicenseAndSupplyAgreementDate" xml:lang="en-US">License and supply agreement date.</label>
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_MaximumFutureContingentLicensePayment" xlink:label="loc_agle_MaximumFutureContingentLicensePayment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_MaximumFutureContingentLicensePayment" xml:lang="en-US">Maximum Future Contingent License Payment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_MaximumFutureContingentLicensePayment" xml:lang="en-US">Maximum future contingent license payment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_MaximumFutureContingentLicensePayment" xlink:to="lab_agle_MaximumFutureContingentLicensePayment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_MaximumFutureContingentLicensePayment" xml:lang="en-US">Maximum future contingent license payment.</label>
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_NumberOfLicenseAgreements" xlink:label="loc_agle_NumberOfLicenseAgreements" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_NumberOfLicenseAgreements" xml:lang="en-US">Number Of License Agreements</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_NumberOfLicenseAgreements" xml:lang="en-US">Number of license agreements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_NumberOfLicenseAgreements" xlink:to="lab_agle_NumberOfLicenseAgreements" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_NumberOfLicenseAgreements" xml:lang="en-US">Number of license agreements.</label>
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_PaymentOfAnnualLicenseFees" xlink:label="loc_agle_PaymentOfAnnualLicenseFees" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_PaymentOfAnnualLicenseFees" xml:lang="en-US">Payment Of Annual License Fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_PaymentOfAnnualLicenseFees" xml:lang="en-US">Annual license fees paid</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_PaymentOfAnnualLicenseFees" xlink:to="lab_agle_PaymentOfAnnualLicenseFees" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_PaymentOfAnnualLicenseFees" xml:lang="en-US">Payment of annual license fees.</label>
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_MilestonePaymentsExchangeRate" xlink:label="loc_agle_MilestonePaymentsExchangeRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_MilestonePaymentsExchangeRate" xml:lang="en-US">Milestone Payments Exchange Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_MilestonePaymentsExchangeRate" xml:lang="en-US">Milestone payments exchange rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_MilestonePaymentsExchangeRate" xlink:to="lab_agle_MilestonePaymentsExchangeRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_MilestonePaymentsExchangeRate" xml:lang="en-US">Milestone payments exchange rate.</label>
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ResearchAgreementDate" xlink:label="loc_agle_ResearchAgreementDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_ResearchAgreementDate" xml:lang="en-US">Research Agreement Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_ResearchAgreementDate" xml:lang="en-US">Research agreement date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_ResearchAgreementDate" xlink:to="lab_agle_ResearchAgreementDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_ResearchAgreementDate" xml:lang="en-US">Research agreement date.</label>
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AdditionalUpfrontPaymentAbilityToReceived" xlink:label="loc_agle_AdditionalUpfrontPaymentAbilityToReceived" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_AdditionalUpfrontPaymentAbilityToReceived" xml:lang="en-US">Additional Upfront Payment Ability To Received</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_AdditionalUpfrontPaymentAbilityToReceived" xml:lang="en-US">Additional upfront payment to be received</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_AdditionalUpfrontPaymentAbilityToReceived" xlink:to="lab_agle_AdditionalUpfrontPaymentAbilityToReceived" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_AdditionalUpfrontPaymentAbilityToReceived" xml:lang="en-US">Additional upfront payment ability to received.</label>
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AggregatePotentialMilestonePaymentsForFinalRegulatoryApprovalOfSecondIndication" xlink:label="loc_agle_AggregatePotentialMilestonePaymentsForFinalRegulatoryApprovalOfSecondIndication" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_AggregatePotentialMilestonePaymentsForFinalRegulatoryApprovalOfSecondIndication" xml:lang="en-US">Aggregate Potential Milestone Payments For Final Regulatory Approval Of Second Indication</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_AggregatePotentialMilestonePaymentsForFinalRegulatoryApprovalOfSecondIndication" xml:lang="en-US">Aggregate potential milestone payments for final regulatory approval of second indication</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_AggregatePotentialMilestonePaymentsForFinalRegulatoryApprovalOfSecondIndication" xlink:to="lab_agle_AggregatePotentialMilestonePaymentsForFinalRegulatoryApprovalOfSecondIndication" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_AggregatePotentialMilestonePaymentsForFinalRegulatoryApprovalOfSecondIndication" xml:lang="en-US">Aggregate potential milestone payments for final regulatory approval of second indication.</label>
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AggregatePotentialMilestonePaymentsForReceiptOfRegulatoryApproval" xlink:label="loc_agle_AggregatePotentialMilestonePaymentsForReceiptOfRegulatoryApproval" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_AggregatePotentialMilestonePaymentsForReceiptOfRegulatoryApproval" xml:lang="en-US">Aggregate Potential Milestone Payments For Receipt Of Regulatory Approval</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_AggregatePotentialMilestonePaymentsForReceiptOfRegulatoryApproval" xml:lang="en-US">Aggregate potential milestone payments for receipt of regulatory approval</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_AggregatePotentialMilestonePaymentsForReceiptOfRegulatoryApproval" xlink:to="lab_agle_AggregatePotentialMilestonePaymentsForReceiptOfRegulatoryApproval" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_AggregatePotentialMilestonePaymentsForReceiptOfRegulatoryApproval" xml:lang="en-US">Aggregate potential milestone payments for receipt of regulatory approval.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaap_DeferredRevenue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredRevenue" xml:lang="en-US">Deferred Revenue</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredRevenue" xml:lang="en-US">Total deferred revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenue" xlink:to="lab_us-gaap_DeferredRevenue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInContractWithCustomerLiabilityAbstract" xlink:label="loc_us-gaap_ChangeInContractWithCustomerLiabilityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ChangeInContractWithCustomerLiabilityAbstract" xml:lang="en-US">Change in Contract with Customer, Liability [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ChangeInContractWithCustomerLiabilityAbstract" xml:lang="en-US">Change in Contract with Customer, Liability [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInContractWithCustomerLiabilityAbstract" xlink:to="lab_us-gaap_ChangeInContractWithCustomerLiabilityAbstract" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ContractWithCustomerLiabilityAdditions" xlink:label="loc_agle_ContractWithCustomerLiabilityAdditions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_ContractWithCustomerLiabilityAdditions" xml:lang="en-US">Contract With Customer, Liability, Additions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_ContractWithCustomerLiabilityAdditions" xml:lang="en-US">Additions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_ContractWithCustomerLiabilityAdditions" xlink:to="lab_agle_ContractWithCustomerLiabilityAdditions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_ContractWithCustomerLiabilityAdditions" xml:lang="en-US">Contract With Customer, Liability, Additions</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination" xml:lang="en-US">Contract with Customer, Liability, Increase (Decrease) for Contract Acquired in Business Combination</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination" xml:lang="en-US">Deductions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ContractWithCustomerLiabilityDeductionsThroughContractsAcquired" xlink:label="loc_agle_ContractWithCustomerLiabilityDeductionsThroughContractsAcquired" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_ContractWithCustomerLiabilityDeductionsThroughContractsAcquired" xml:lang="en-US">Contract With Customer Liability Deductions Through Contracts Acquired</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_agle_ContractWithCustomerLiabilityDeductionsThroughContractsAcquired" xml:lang="en-US">Deductions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_ContractWithCustomerLiabilityDeductionsThroughContractsAcquired" xlink:to="lab_agle_ContractWithCustomerLiabilityDeductionsThroughContractsAcquired" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_ContractWithCustomerLiabilityDeductionsThroughContractsAcquired" xml:lang="en-US">Contract with customer liability deductions through contracts acquired.</label>
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ContractWithCustomerLiabilityRevenueRecognizedIncludingAdditions" xlink:label="loc_agle_ContractWithCustomerLiabilityRevenueRecognizedIncludingAdditions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_ContractWithCustomerLiabilityRevenueRecognizedIncludingAdditions" xml:lang="en-US">Contract With Customer Liability Revenue Recognized Including Additions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_ContractWithCustomerLiabilityRevenueRecognizedIncludingAdditions" xml:lang="en-US">Additions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_ContractWithCustomerLiabilityRevenueRecognizedIncludingAdditions" xlink:to="lab_agle_ContractWithCustomerLiabilityRevenueRecognizedIncludingAdditions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_ContractWithCustomerLiabilityRevenueRecognizedIncludingAdditions" xml:lang="en-US">Contract with customer liability revenue recognized including additions.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xml:lang="en-US">Disposal Group Classification [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xml:lang="en-US">Disposal Group Classification [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis" xlink:to="lab_us-gaap_DisposalGroupClassificationAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xml:lang="en-US">Disposal Group Classification [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xml:lang="en-US">Disposal Group Classification [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain" xlink:to="lab_us-gaap_DisposalGroupClassificationDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xml:lang="en-US">Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xml:lang="en-US">Disposal Group, Disposed of by Sale, Not Discontinued Operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:to="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xml:lang="en-US">Disposal Group Name [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xml:lang="en-US">Disposal Group Name [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xml:lang="en-US">Disposal Group Name [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xml:lang="en-US">Disposal Group Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_GlobalRightsToPegzilarginaseMember" xlink:label="loc_agle_GlobalRightsToPegzilarginaseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_GlobalRightsToPegzilarginaseMember" xml:lang="en-US">Global Rights To Pegzilarginase [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_GlobalRightsToPegzilarginaseMember" xml:lang="en-US">Global Rights To Pegzilarginase</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_GlobalRightsToPegzilarginaseMember" xlink:to="lab_agle_GlobalRightsToPegzilarginaseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_GlobalRightsToPegzilarginaseMember" xml:lang="en-US">Global Rights To Pegzilarginase</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_DisposalGroupIncludingDiscontinuedOperationContingentConsideration" xlink:label="loc_agle_DisposalGroupIncludingDiscontinuedOperationContingentConsideration" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_DisposalGroupIncludingDiscontinuedOperationContingentConsideration" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Contingent Consideration</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_DisposalGroupIncludingDiscontinuedOperationContingentConsideration" xml:lang="en-US">Contingent consideration</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_DisposalGroupIncludingDiscontinuedOperationContingentConsideration" xlink:to="lab_agle_DisposalGroupIncludingDiscontinuedOperationContingentConsideration" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_DisposalGroupIncludingDiscontinuedOperationContingentConsideration" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Contingent Consideration</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xml:lang="en-US">Carrying value of assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xml:lang="en-US">Defined Contribution Plan, Employer Discretionary Contribution Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xml:lang="en-US">Defined contribution plan, contribution amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xml:lang="en-US">Domestic</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xml:lang="en-US">Foreign</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xml:lang="en-US">Income (Loss) from Equity Method Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xml:lang="en-US">Loss before income tax expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_IncomeTaxesTable" xlink:label="loc_agle_IncomeTaxesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_IncomeTaxesTable" xml:lang="en-US">Income Taxes [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_IncomeTaxesTable" xml:lang="en-US">Income Taxes [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_IncomeTaxesTable" xlink:to="lab_agle_IncomeTaxesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_IncomeTaxesTable" xml:lang="en-US">Income taxes.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xml:lang="en-US">Income Tax Authority [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xml:lang="en-US">Income Tax Authority</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xml:lang="en-US">Income Tax Authority [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xml:lang="en-US">Income Tax Authority</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DomesticCountryMember" xml:lang="en-US">Domestic Tax Authority [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DomesticCountryMember" xml:lang="en-US">U.S</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DomesticCountryMember" xml:lang="en-US">Federal Tax Credits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xml:lang="en-US">State and Local Jurisdiction [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xml:lang="en-US">State</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xml:lang="en-US">State Tax Credits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaap_ForeignCountryMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ForeignCountryMember" xml:lang="en-US">Foreign Tax Authority [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ForeignCountryMember" xml:lang="en-US">Foreign subsidiaries</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember" xlink:to="lab_us-gaap_ForeignCountryMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodAxis" xlink:label="loc_us-gaap_TaxPeriodAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxPeriodAxis" xml:lang="en-US">Tax Period [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TaxPeriodAxis" xml:lang="en-US">Tax Period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodAxis" xlink:to="lab_us-gaap_TaxPeriodAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaap_TaxPeriodDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxPeriodDomain" xml:lang="en-US">Tax Period [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TaxPeriodDomain" xml:lang="en-US">Tax Period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodDomain" xlink:to="lab_us-gaap_TaxPeriodDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarliestTaxYearMember" xlink:label="loc_us-gaap_EarliestTaxYearMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarliestTaxYearMember" xml:lang="en-US">Earliest Tax Year [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarliestTaxYearMember" xml:lang="en-US">Earliest Tax Year</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarliestTaxYearMember" xlink:to="lab_us-gaap_EarliestTaxYearMember" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_IncomeTaxesLineItems" xlink:label="loc_agle_IncomeTaxesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_IncomeTaxesLineItems" xml:lang="en-US">Income Taxes [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_IncomeTaxesLineItems" xml:lang="en-US">Income Taxes [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_IncomeTaxesLineItems" xlink:to="lab_agle_IncomeTaxesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_IncomeTaxesLineItems" xml:lang="en-US">Income taxes line items.</label>
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_IncreaseInValuationPrimarilyDueToOperationLosses" xlink:label="loc_agle_IncreaseInValuationPrimarilyDueToOperationLosses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_IncreaseInValuationPrimarilyDueToOperationLosses" xml:lang="en-US">Increase In Valuation Primarily Due To Operation Losses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_IncreaseInValuationPrimarilyDueToOperationLosses" xml:lang="en-US">Increase in valuation primarily due to operation losses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_IncreaseInValuationPrimarilyDueToOperationLosses" xlink:to="lab_agle_IncreaseInValuationPrimarilyDueToOperationLosses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_IncreaseInValuationPrimarilyDueToOperationLosses" xml:lang="en-US">Increase in valuation primarily due to operation losses.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xml:lang="en-US">Operating Loss Carryforwards</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xml:lang="en-US">Net operating loss carryforwards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xml:lang="en-US">Tax Credit Carryforward, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xml:lang="en-US">Tax credit carryforwards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_OperatingLossCarryforwardsExpirationYear" xlink:label="loc_agle_OperatingLossCarryforwardsExpirationYear" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_OperatingLossCarryforwardsExpirationYear" xml:lang="en-US">Operating Loss Carryforwards Expiration Year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_OperatingLossCarryforwardsExpirationYear" xml:lang="en-US">Net operating loss carryforwards, expiration year</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_OperatingLossCarryforwardsExpirationYear" xlink:to="lab_agle_OperatingLossCarryforwardsExpirationYear" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_OperatingLossCarryforwardsExpirationYear" xml:lang="en-US">Operating loss carryforwards, expiration year.</label>
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_TaxCreditCarryforwardExpirationYear" xlink:label="loc_agle_TaxCreditCarryforwardExpirationYear" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_TaxCreditCarryforwardExpirationYear" xml:lang="en-US">Tax Credit Carryforward Expiration Year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_TaxCreditCarryforwardExpirationYear" xml:lang="en-US">Tax credit carryforwards, expiration year</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_TaxCreditCarryforwardExpirationYear" xlink:to="lab_agle_TaxCreditCarryforwardExpirationYear" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_TaxCreditCarryforwardExpirationYear" xml:lang="en-US">Tax credit carryforward, expiration year.</label>
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_PercentageOfNetOperatingLossUtilizedToOffsetTaxableIncome" xlink:label="loc_agle_PercentageOfNetOperatingLossUtilizedToOffsetTaxableIncome" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_PercentageOfNetOperatingLossUtilizedToOffsetTaxableIncome" xml:lang="en-US">Percentage of Net Operating Loss Utilized to Offset Taxable Income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_PercentageOfNetOperatingLossUtilizedToOffsetTaxableIncome" xml:lang="en-US">Percentage of net operating loss utilized to offset taxable income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_PercentageOfNetOperatingLossUtilizedToOffsetTaxableIncome" xlink:to="lab_agle_PercentageOfNetOperatingLossUtilizedToOffsetTaxableIncome" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_PercentageOfNetOperatingLossUtilizedToOffsetTaxableIncome" xml:lang="en-US">Percentage of net operating loss utilized to offset taxable income.</label>
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_NetOperatingLossAndCreditCarryforwards" xlink:label="loc_agle_NetOperatingLossAndCreditCarryforwards" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_NetOperatingLossAndCreditCarryforwards" xml:lang="en-US">Net Operating Loss And Credit Carryforwards</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_NetOperatingLossAndCreditCarryforwards" xml:lang="en-US">Net operating loss and tax credit carryforwards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_NetOperatingLossAndCreditCarryforwards" xlink:to="lab_agle_NetOperatingLossAndCreditCarryforwards" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_NetOperatingLossAndCreditCarryforwards" xml:lang="en-US">Net operating loss and credit carryforwards.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Tax provision derived by applying the federal statutory rate to income before income taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xml:lang="en-US">Permanent differences and other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_IncomeTaxReconciliationTaxCostCredit" xlink:label="loc_agle_IncomeTaxReconciliationTaxCostCredit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_IncomeTaxReconciliationTaxCostCredit" xml:lang="en-US">Income Tax Reconciliation Tax Cost Credit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_IncomeTaxReconciliationTaxCostCredit" xml:lang="en-US">Tax credits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_IncomeTaxReconciliationTaxCostCredit" xlink:to="lab_agle_IncomeTaxReconciliationTaxCostCredit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_IncomeTaxReconciliationTaxCostCredit" xml:lang="en-US">Income tax reconciliation tax cost (credit).</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xml:lang="en-US">Effect of tax rate on foreign jurisdiction</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xml:lang="en-US">Change in the valuation allowance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xml:lang="en-US">Deferred Tax Assets, Net [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xml:lang="en-US">Deferred tax assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsNetAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xml:lang="en-US">Net operating loss carryforward</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xml:lang="en-US">Deferred Tax Assets, Goodwill and Intangible Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xml:lang="en-US">Intangible assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xml:lang="en-US">Deferred Tax Assets, Deferred Income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xml:lang="en-US">Deferred revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="lab_us-gaap_DeferredTaxAssetsDeferredIncome" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xml:lang="en-US">Accrued expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xml:lang="en-US">Stock-based compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xml:lang="en-US">Tax credits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xml:lang="en-US">Deferred Tax Assets, Other</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xml:lang="en-US">Other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xml:lang="en-US">Deferred Tax Assets, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xml:lang="en-US">Total deferred tax assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xml:lang="en-US">Deferred Tax Liabilities, Net [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xml:lang="en-US">Deferred tax liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xml:lang="en-US">Depreciable assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xml:lang="en-US">Deferred Tax Liabilities, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xml:lang="en-US">Total deferred tax liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Less: Valuation allowance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xml:lang="en-US">Deferred Tax Assets, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xml:lang="en-US">Deferred tax assets, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xml:lang="en-US">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xml:lang="en-US">Antidilutive Securities [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xml:lang="en-US">Antidilutive Securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xml:lang="en-US">Antidilutive Securities, Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_SeriesAConvertiblePreferredStockMember" xlink:label="loc_agle_SeriesAConvertiblePreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_SeriesAConvertiblePreferredStockMember" xml:lang="en-US">Series A Convertible Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_SeriesAConvertiblePreferredStockMember" xml:lang="en-US">Series A Preferred Stock (on an as-converted basis)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_SeriesAConvertiblePreferredStockMember" xlink:to="lab_agle_SeriesAConvertiblePreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_SeriesAConvertiblePreferredStockMember" xml:lang="en-US">Series A Convertible Preferred Stock .</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xml:lang="en-US">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xml:lang="en-US">Weighted Average Number of Shares Issued, Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xml:lang="en-US">Weighted average common shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesIssuedBasic" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_WeightedAverageNumberOfSharesPreFundedWarrants" xlink:label="loc_agle_WeightedAverageNumberOfSharesPreFundedWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_WeightedAverageNumberOfSharesPreFundedWarrants" xml:lang="en-US">Weighted Average Number Of Shares Pre-funded Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_WeightedAverageNumberOfSharesPreFundedWarrants" xml:lang="en-US">Weighted average pre-funded warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_WeightedAverageNumberOfSharesPreFundedWarrants" xlink:to="lab_agle_WeightedAverageNumberOfSharesPreFundedWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_WeightedAverageNumberOfSharesPreFundedWarrants" xml:lang="en-US">Weighted average number of shares pre-funded warrants.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xml:lang="en-US">Stock Issued During Period, Shares, Reverse Stock Splits</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xml:lang="en-US">Stock Issued During Period, Shares, Reverse Stock Splits</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xml:lang="en-US">Reduction in the total number of authorized shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaap_SeveranceCosts1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SeveranceCosts1" xml:lang="en-US">Severance Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SeveranceCosts1" xml:lang="en-US">Cash severance payments and other employee-related costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SeveranceCosts1" xml:lang="en-US">Severance Related Expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeveranceCosts1" xlink:to="lab_us-gaap_SeveranceCosts1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRestructuring" xlink:label="loc_us-gaap_PaymentsForRestructuring" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsForRestructuring" xml:lang="en-US">Payments for Restructuring</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PaymentsForRestructuring" xml:lang="en-US">Cash payments for employee related restructuring charges</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsForRestructuring" xml:lang="en-US">Payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRestructuring" xlink:to="lab_us-gaap_PaymentsForRestructuring" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xml:lang="en-US">Share-Based Payment Arrangement, Accelerated Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xml:lang="en-US">Non-cash stock-based compensation expense related to accelerated vesting of stock-based awards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Consideration</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xml:lang="en-US">Total consideration from disposal of long lived assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_OperatingLeaseTerminationFeeAmount" xlink:label="loc_agle_OperatingLeaseTerminationFeeAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_OperatingLeaseTerminationFeeAmount" xml:lang="en-US">Operating Lease, Termination Fee Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_OperatingLeaseTerminationFeeAmount" xml:lang="en-US">Termination fee amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_OperatingLeaseTerminationFeeAmount" xlink:to="lab_agle_OperatingLeaseTerminationFeeAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_OperatingLeaseTerminationFeeAmount" xml:lang="en-US">Operating Lease, Termination Fee Amount</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseImpairmentLoss" xml:lang="en-US">Operating Lease, Impairment Loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseImpairmentLoss" xml:lang="en-US">Lease asset impairment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseImpairmentLoss" xml:lang="en-US">Lease Asset Impairment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseImpairmentLoss" xlink:to="lab_us-gaap_OperatingLeaseImpairmentLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLeasehold" xlink:label="loc_us-gaap_ImpairmentOfLeasehold" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ImpairmentOfLeasehold" xml:lang="en-US">Impairment of Leasehold</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ImpairmentOfLeasehold" xml:lang="en-US">Impairment on leasehold improvements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLeasehold" xlink:to="lab_us-gaap_ImpairmentOfLeasehold" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xml:lang="en-US">Restructuring Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xml:lang="en-US">Restructuring Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xml:lang="en-US">Type of Restructuring [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xml:lang="en-US">Type of Restructuring [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_SeveranceLiabilityMember" xlink:label="loc_agle_SeveranceLiabilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_SeveranceLiabilityMember" xml:lang="en-US">Severance Liability [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_SeveranceLiabilityMember" xml:lang="en-US">Severance Liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_SeveranceLiabilityMember" xlink:to="lab_agle_SeveranceLiabilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_SeveranceLiabilityMember" xml:lang="en-US">Severance liability.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserve" xlink:label="loc_us-gaap_RestructuringReserve" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestructuringReserve" xml:lang="en-US">Restructuring Reserve</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_RestructuringReserve" xml:lang="en-US">Beginning balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_RestructuringReserve" xml:lang="en-US">Ending balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve" xlink:to="lab_us-gaap_RestructuringReserve" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestructuringCharges" xml:lang="en-US">Restructuring Charges</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestructuringCharges" xml:lang="en-US">Charges</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCosts" xlink:label="loc_us-gaap_RestructuringCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestructuringCosts" xml:lang="en-US">Restructuring Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_RestructuringCosts" xml:lang="en-US">Total Restructuring Costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCosts" xlink:to="lab_us-gaap_RestructuringCosts" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_RestructuringActivitiesMember" xlink:label="loc_agle_RestructuringActivitiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_RestructuringActivitiesMember" xml:lang="en-US">Restructuring Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_RestructuringActivitiesMember" xml:lang="en-US">Restructuring Activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_RestructuringActivitiesMember" xlink:to="lab_agle_RestructuringActivitiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_RestructuringActivitiesMember" xml:lang="en-US">Restructuring activities.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTable" xml:lang="en-US">Subsequent Event [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventLineItems" xml:lang="en-US">Subsequent Event [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_OtherCommitmentRightToTerminateAgreementOrWorkOrderPriorWrittenNoticePeriod" xlink:label="loc_agle_OtherCommitmentRightToTerminateAgreementOrWorkOrderPriorWrittenNoticePeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_OtherCommitmentRightToTerminateAgreementOrWorkOrderPriorWrittenNoticePeriod" xml:lang="en-US">Other Commitment, Right To Terminate Agreement Or Work Order, Prior Written Notice Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_OtherCommitmentRightToTerminateAgreementOrWorkOrderPriorWrittenNoticePeriod" xml:lang="en-US">Right to terminate agreement or work order, prior written notice period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_OtherCommitmentRightToTerminateAgreementOrWorkOrderPriorWrittenNoticePeriod" xlink:to="lab_agle_OtherCommitmentRightToTerminateAgreementOrWorkOrderPriorWrittenNoticePeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_OtherCommitmentRightToTerminateAgreementOrWorkOrderPriorWrittenNoticePeriod" xml:lang="en-US">Other Commitment, Right To Terminate Agreement Or Work Order, Prior Written Notice Period</label>
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_OtherCommitmentRightToTerminateWorkOrderReasonableCausePriorWrittenNoticePeriod" xlink:label="loc_agle_OtherCommitmentRightToTerminateWorkOrderReasonableCausePriorWrittenNoticePeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_OtherCommitmentRightToTerminateWorkOrderReasonableCausePriorWrittenNoticePeriod" xml:lang="en-US">Other Commitment, Right To Terminate Work Order, Reasonable Cause, Prior Written Notice Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_OtherCommitmentRightToTerminateWorkOrderReasonableCausePriorWrittenNoticePeriod" xml:lang="en-US">Right to terminate work order, reasonable cause, prior written notice period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_OtherCommitmentRightToTerminateWorkOrderReasonableCausePriorWrittenNoticePeriod" xlink:to="lab_agle_OtherCommitmentRightToTerminateWorkOrderReasonableCausePriorWrittenNoticePeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_OtherCommitmentRightToTerminateWorkOrderReasonableCausePriorWrittenNoticePeriod" xml:lang="en-US">Other Commitment, Right To Terminate Work Order, Reasonable Cause, Prior Written Notice Period</label>
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_OtherCommitmentRightToTerminateWorkOrderByCounterpartyReasonableCauseTerminationAmountPayable" xlink:label="loc_agle_OtherCommitmentRightToTerminateWorkOrderByCounterpartyReasonableCauseTerminationAmountPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_OtherCommitmentRightToTerminateWorkOrderByCounterpartyReasonableCauseTerminationAmountPayable" xml:lang="en-US">Other Commitment, Right To Terminate Work Order By Counterparty, Reasonable Cause, Termination Amount Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_OtherCommitmentRightToTerminateWorkOrderByCounterpartyReasonableCauseTerminationAmountPayable" xml:lang="en-US">Right to terminate work order by counterparty, reasonable cause, termination amount payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_OtherCommitmentRightToTerminateWorkOrderByCounterpartyReasonableCauseTerminationAmountPayable" xlink:to="lab_agle_OtherCommitmentRightToTerminateWorkOrderByCounterpartyReasonableCauseTerminationAmountPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_OtherCommitmentRightToTerminateWorkOrderByCounterpartyReasonableCauseTerminationAmountPayable" xml:lang="en-US">Other Commitment, Right To Terminate Work Order By Counterparty, Reasonable Cause, Termination Amount Payable</label>
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_OtherCommitmentRightToTerminateWorkOrderMaterialBreachUncuredPeriod" xlink:label="loc_agle_OtherCommitmentRightToTerminateWorkOrderMaterialBreachUncuredPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_OtherCommitmentRightToTerminateWorkOrderMaterialBreachUncuredPeriod" xml:lang="en-US">Other Commitment, Right To Terminate Work Order, Material Breach, Uncured Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_OtherCommitmentRightToTerminateWorkOrderMaterialBreachUncuredPeriod" xml:lang="en-US">Right to terminate work order, material breach, uncured period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_OtherCommitmentRightToTerminateWorkOrderMaterialBreachUncuredPeriod" xlink:to="lab_agle_OtherCommitmentRightToTerminateWorkOrderMaterialBreachUncuredPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_OtherCommitmentRightToTerminateWorkOrderMaterialBreachUncuredPeriod" xml:lang="en-US">Other Commitment, Right To Terminate Work Order, Material Breach, Uncured Period</label>
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_OtherCommitmentRightToTerminateWorkOrderUnusualOrInfrequentCausePeriod" xlink:label="loc_agle_OtherCommitmentRightToTerminateWorkOrderUnusualOrInfrequentCausePeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_OtherCommitmentRightToTerminateWorkOrderUnusualOrInfrequentCausePeriod" xml:lang="en-US">Other Commitment, Right To Terminate Work Order, Unusual Or Infrequent Cause, Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_OtherCommitmentRightToTerminateWorkOrderUnusualOrInfrequentCausePeriod" xml:lang="en-US">Right to terminate work order, unusual or infrequent cause, period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_OtherCommitmentRightToTerminateWorkOrderUnusualOrInfrequentCausePeriod" xlink:to="lab_agle_OtherCommitmentRightToTerminateWorkOrderUnusualOrInfrequentCausePeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_OtherCommitmentRightToTerminateWorkOrderUnusualOrInfrequentCausePeriod" xml:lang="en-US">Other Commitment, Right To Terminate Work Order, Unusual Or Infrequent Cause, Period</label>
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_OtherCommitmentNonRefundableLicenseFeeAmount" xlink:label="loc_agle_OtherCommitmentNonRefundableLicenseFeeAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_OtherCommitmentNonRefundableLicenseFeeAmount" xml:lang="en-US">Other Commitment, Non-Refundable License Fee Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_OtherCommitmentNonRefundableLicenseFeeAmount" xml:lang="en-US">Non-refundable license fee amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_OtherCommitmentNonRefundableLicenseFeeAmount" xlink:to="lab_agle_OtherCommitmentNonRefundableLicenseFeeAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_OtherCommitmentNonRefundableLicenseFeeAmount" xml:lang="en-US">Other Commitment, Non-Refundable License Fee Amount</label>
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_OtherCommitmentRoyaltyPercentage" xlink:label="loc_agle_OtherCommitmentRoyaltyPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_OtherCommitmentRoyaltyPercentage" xml:lang="en-US">Other Commitment, Royalty Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_OtherCommitmentRoyaltyPercentage" xml:lang="en-US">Royalty percentage (less than)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_OtherCommitmentRoyaltyPercentage" xlink:to="lab_agle_OtherCommitmentRoyaltyPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_OtherCommitmentRoyaltyPercentage" xml:lang="en-US">Other Commitment, Royalty Percentage</label>
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_OtherCommitmentRightToTerminateAgreementPriorWrittenNoticePeriod" xlink:label="loc_agle_OtherCommitmentRightToTerminateAgreementPriorWrittenNoticePeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_OtherCommitmentRightToTerminateAgreementPriorWrittenNoticePeriod" xml:lang="en-US">Other Commitment, Right To Terminate Agreement, Prior Written Notice Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_OtherCommitmentRightToTerminateAgreementPriorWrittenNoticePeriod" xml:lang="en-US">Right to terminate agreement, prior written notice period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_OtherCommitmentRightToTerminateAgreementPriorWrittenNoticePeriod" xlink:to="lab_agle_OtherCommitmentRightToTerminateAgreementPriorWrittenNoticePeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_OtherCommitmentRightToTerminateAgreementPriorWrittenNoticePeriod" xml:lang="en-US">Other Commitment, Right To Terminate Agreement, Prior Written Notice Period</label>
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_OtherCommitmentRightToTerminateAgreementByCounterpartyMaterialBreachUncuredPeriod" xlink:label="loc_agle_OtherCommitmentRightToTerminateAgreementByCounterpartyMaterialBreachUncuredPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_OtherCommitmentRightToTerminateAgreementByCounterpartyMaterialBreachUncuredPeriod" xml:lang="en-US">Other Commitment, Right To Terminate Agreement By Counterparty, Material Breach, Uncured Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_OtherCommitmentRightToTerminateAgreementByCounterpartyMaterialBreachUncuredPeriod" xml:lang="en-US">Right to terminate agreement by counterparty, material breach, uncured period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_OtherCommitmentRightToTerminateAgreementByCounterpartyMaterialBreachUncuredPeriod" xlink:to="lab_agle_OtherCommitmentRightToTerminateAgreementByCounterpartyMaterialBreachUncuredPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_OtherCommitmentRightToTerminateAgreementByCounterpartyMaterialBreachUncuredPeriod" xml:lang="en-US">Other Commitment, Right To Terminate Agreement By Counterparty, Material Breach, Uncured Period</label>
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_OtherCommitmentRightToTerminateAgreementByCounterpartyPaymentsNotReceivedPeriod" xlink:label="loc_agle_OtherCommitmentRightToTerminateAgreementByCounterpartyPaymentsNotReceivedPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_OtherCommitmentRightToTerminateAgreementByCounterpartyPaymentsNotReceivedPeriod" xml:lang="en-US">Other Commitment, Right To Terminate Agreement By Counterparty, Payments Not Received, Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_agle_OtherCommitmentRightToTerminateAgreementByCounterpartyPaymentsNotReceivedPeriod" xml:lang="en-US">Right to terminate agreement by counterparty, payments not received, period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_OtherCommitmentRightToTerminateAgreementByCounterpartyPaymentsNotReceivedPeriod" xlink:to="lab_agle_OtherCommitmentRightToTerminateAgreementByCounterpartyPaymentsNotReceivedPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_agle_OtherCommitmentRightToTerminateAgreementByCounterpartyPaymentsNotReceivedPeriod" xml:lang="en-US">Other Commitment, Right To Terminate Agreement By Counterparty, Payments Not Received, Period</label>
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_DevelopmentFeeAndRoyaltyMember" xlink:label="loc_agle_DevelopmentFeeAndRoyaltyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_agle_DevelopmentFeeAndRoyaltyMember" xml:lang="en-US">Development Fee and Royalty [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agle_DevelopmentFeeAndRoyaltyMember" xlink:to="lab_agle_DevelopmentFeeAndRoyaltyMember" />
</labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>39
<FILENAME>agle-20230930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 22-December-2023 [06:59:46] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#CoverPage" roleURI="http://www.spy.com/role/CoverPage" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#CondensedConsolidatedBalanceSheets" roleURI="http://www.spy.com/role/CondensedConsolidatedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.spy.com/role/CondensedConsolidatedBalanceSheetsParenthetical" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#CondensedConsolidatedStatementsOfOperations" roleURI="http://www.spy.com/role/CondensedConsolidatedStatementsOfOperations" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#CondensedConsolidatedStatementsOfOperationsParenthetical" roleURI="http://www.spy.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#CondensedConsolidatedStatementsOfComprehensiveLoss" roleURI="http://www.spy.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#CondensedConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersDeficitEquity" roleURI="http://www.spy.com/role/CondensedConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersDeficitEquity" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#CondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.spy.com/role/CondensedConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#StatementOfAssetsAcquiredAndLiabilitiesAssumed" roleURI="http://www.spy.com/role/StatementOfAssetsAcquiredAndLiabilitiesAssumed" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#TheCompanyAndBasisOfPresentation" roleURI="http://www.spy.com/role/TheCompanyAndBasisOfPresentation" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://www.spy.com/role/SummaryOfSignificantAccountingPolicies" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#FairValueMeasurements" roleURI="http://www.spy.com/role/FairValueMeasurements" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#CashEquivalentsAndMarketableSecurities" roleURI="http://www.spy.com/role/CashEquivalentsAndMarketableSecurities" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#PropertyAndEquipmentNet" roleURI="http://www.spy.com/role/PropertyAndEquipmentNet" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#AccruedAndOtherCurrentLiabilities" roleURI="http://www.spy.com/role/AccruedAndOtherCurrentLiabilities" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#Leases" roleURI="http://www.spy.com/role/Leases" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#StockholdersEquity" roleURI="http://www.spy.com/role/StockholdersEquity" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#RelatedPartyTransactions" roleURI="http://www.spy.com/role/RelatedPartyTransactions" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#AssetAcquisition" roleURI="http://www.spy.com/role/AssetAcquisition" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#ParagonAgreement" roleURI="http://www.spy.com/role/ParagonAgreement" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#SeriesANonVotingConvertiblePreferredStock" roleURI="http://www.spy.com/role/SeriesANonVotingConvertiblePreferredStock" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquity" roleURI="http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquity" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#StrategicLicenseAgreements" roleURI="http://www.spy.com/role/StrategicLicenseAgreements" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#SaleOfPegzilarginaseToImmedica" roleURI="http://www.spy.com/role/SaleOfPegzilarginaseToImmedica" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#DefinedContributionPlan" roleURI="http://www.spy.com/role/DefinedContributionPlan" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#IncomeTaxes" roleURI="http://www.spy.com/role/IncomeTaxes" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#NetLossPerShare" roleURI="http://www.spy.com/role/NetLossPerShare" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#RestructuringCharges" roleURI="http://www.spy.com/role/RestructuringCharges" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#NovationOfManufacturingAgreements" roleURI="http://www.spy.com/role/NovationOfManufacturingAgreements" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#ReverseStockSplit" roleURI="http://www.spy.com/role/ReverseStockSplit" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPolicies" roleURI="http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPolicies" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#AccruedLiabilities" roleURI="http://www.spy.com/role/AccruedLiabilities" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#ParapyreOptionObligation" roleURI="http://www.spy.com/role/ParapyreOptionObligation" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#SubsequentEvents" roleURI="http://www.spy.com/role/SubsequentEvents" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesPolicies" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesTables" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#SummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesTables" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#AccruedLiabilitiesTables" roleURI="http://www.spy.com/role/AccruedLiabilitiesTables" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#FairValueMeasurementTables" roleURI="http://www.spy.com/role/FairValueMeasurementTables" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#CashEquivalentsAndMarketableSecuritiesTables" roleURI="http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesTables" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#PropertyAndEquipmentNetTables" roleURI="http://www.spy.com/role/PropertyAndEquipmentNetTables" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#AccruedAndOtherCurrentLiabilitiesTables" roleURI="http://www.spy.com/role/AccruedAndOtherCurrentLiabilitiesTables" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#LeasesTables" roleURI="http://www.spy.com/role/LeasesTables" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#StockholdersEquityTables" roleURI="http://www.spy.com/role/StockholdersEquityTables" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#RelatedPartyTransactionsTables" roleURI="http://www.spy.com/role/RelatedPartyTransactionsTables" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#AssetAcquisitionTables" roleURI="http://www.spy.com/role/AssetAcquisitionTables" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityTables" roleURI="http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityTables" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#StrategicLicenseAgreementsTables" roleURI="http://www.spy.com/role/StrategicLicenseAgreementsTables" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#IncomeTaxesTables" roleURI="http://www.spy.com/role/IncomeTaxesTables" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#NetLossPerShareTables" roleURI="http://www.spy.com/role/NetLossPerShareTables" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#RestructuringChargesTables" roleURI="http://www.spy.com/role/RestructuringChargesTables" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#TheCompanyAndBasisOfPresentationNarrativeDetails" roleURI="http://www.spy.com/role/TheCompanyAndBasisOfPresentationNarrativeDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesSummaryOfAssetAcquisitionCostDetails" roleURI="http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesSummaryOfAssetAcquisitionCostDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" roleURI="http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#AccruedLiabilitiesAccruedAndOtherCurrentLiabilitiesDetails" roleURI="http://www.spy.com/role/AccruedLiabilitiesAccruedAndOtherCurrentLiabilitiesDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#AccruedLiabilitiesAdditionalInformationDetails" roleURI="http://www.spy.com/role/AccruedLiabilitiesAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#ParapyreOptionObligationAdditionalInformationDetails" roleURI="http://www.spy.com/role/ParapyreOptionObligationAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" roleURI="http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfUsefulLivesOfPropertyAndEquipmentDetails" roleURI="http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfUsefulLivesOfPropertyAndEquipmentDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#FairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" roleURI="http://www.spy.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#FairValueMeasurementsNarrativeDetails" roleURI="http://www.spy.com/role/FairValueMeasurementsNarrativeDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#FairValueMeasurementsChangesInDerivativeLiabilitiesDetails" roleURI="http://www.spy.com/role/FairValueMeasurementsChangesInDerivativeLiabilitiesDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#FairValueMeasurementsSignificantInputsUsedToEstimateTheFairValueOfDerivativeLiabilityDetails" roleURI="http://www.spy.com/role/FairValueMeasurementsSignificantInputsUsedToEstimateTheFairValueOfDerivativeLiabilityDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#CashEquivalentsAndMarketableSecuritiesEstimatedFairValueOfCashEquivalentsAndMarketableSecuritiesAndTheGrossUnrealizedGainsAndLossesDetails" roleURI="http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesEstimatedFairValueOfCashEquivalentsAndMarketableSecuritiesAndTheGrossUnrealizedGainsAndLossesDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#CashEquivalentsAndMarketableSecuritiesAvailableForSaleSecuritiesInAnUnrealizedLossPositionDetails" roleURI="http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesAvailableForSaleSecuritiesInAnUnrealizedLossPositionDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#CashEquivalentsAndMarketableSecuritiesNarrativeDetails" roleURI="http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesNarrativeDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#CashEquivalentsAndMarketableSecuritiesContractualMaturitiesOfMarketableSecuritiesAtEstimatedFairValueDetails" roleURI="http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesContractualMaturitiesOfMarketableSecuritiesAtEstimatedFairValueDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" roleURI="http://www.spy.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#PropertyAndEquipmentNetAdditionalInformationDetails" roleURI="http://www.spy.com/role/PropertyAndEquipmentNetAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#AccruedAndOtherCurrentLiabilitiesDetails" roleURI="http://www.spy.com/role/AccruedAndOtherCurrentLiabilitiesDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#LeasesAdditionalInformationDetails" roleURI="http://www.spy.com/role/LeasesAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#LeasesScheduleOfOperatingAndFinancingLeasesPresentedInBalanceSheetDetails" roleURI="http://www.spy.com/role/LeasesScheduleOfOperatingAndFinancingLeasesPresentedInBalanceSheetDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#LeasesSummaryOfWeightedAverageRemainingLeaseTermAndDiscountRatesForOperatingAndFinanceLeasesDetails" roleURI="http://www.spy.com/role/LeasesSummaryOfWeightedAverageRemainingLeaseTermAndDiscountRatesForOperatingAndFinanceLeasesDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#LeasesSummaryOfLeaseCostDetails" roleURI="http://www.spy.com/role/LeasesSummaryOfLeaseCostDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#LeasesScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails" roleURI="http://www.spy.com/role/LeasesScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#StockholdersEquityAdditionalInformationDetails" roleURI="http://www.spy.com/role/StockholdersEquityAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#StockholdersEquitySummaryOfPreFundedWarrantsForCommonStockIssuedAndOutstandingDetails" roleURI="http://www.spy.com/role/StockholdersEquitySummaryOfPreFundedWarrantsForCommonStockIssuedAndOutstandingDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#RelatedPartyTransactionsNarrativeDetails" roleURI="http://www.spy.com/role/RelatedPartyTransactionsNarrativeDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#RelatedPartyTransactionsExpensesRelatedToRelatedPartyWhichWereSettledInCashDetails" roleURI="http://www.spy.com/role/RelatedPartyTransactionsExpensesRelatedToRelatedPartyWhichWereSettledInCashDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#RelatedPartyTransactionsRelatedPartyAccountsPayableDetails" roleURI="http://www.spy.com/role/RelatedPartyTransactionsRelatedPartyAccountsPayableDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#AssetAcquisitionNarrativeDetails" roleURI="http://www.spy.com/role/AssetAcquisitionNarrativeDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#AssetAcquisitionAssetAcquisitionCostDetails" roleURI="http://www.spy.com/role/AssetAcquisitionAssetAcquisitionCostDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#ParagonAgreementDetails" roleURI="http://www.spy.com/role/ParagonAgreementDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#SeriesANonVotingConvertiblePreferredStockDetails" roleURI="http://www.spy.com/role/SeriesANonVotingConvertiblePreferredStockDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityPreFundedWarrantsForCommonStockIssuedAndOutstandingDetails" roleURI="http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityPreFundedWarrantsForCommonStockIssuedAndOutstandingDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityStockAwardsGrantedDetails" roleURI="http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityStockAwardsGrantedDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails" roleURI="http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquitySummaryOfEmployeeAndNonEmployeeStockOptionActivityDetails" roleURI="http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquitySummaryOfEmployeeAndNonEmployeeStockOptionActivityDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquitySummaryOfEmployeeRestrictedStockActivityDetails" roleURI="http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquitySummaryOfEmployeeRestrictedStockActivityDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityStockBasedCompensationExpenseDetails" roleURI="http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityStockBasedCompensationExpenseDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityAssumptionsUsedToEstimateTheFairValueOfStockOptionsGrantedDetails" roleURI="http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityAssumptionsUsedToEstimateTheFairValueOfStockOptionsGrantedDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#StrategicLicenseAgreementsNarrativeDetails" roleURI="http://www.spy.com/role/StrategicLicenseAgreementsNarrativeDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#StrategicLicenseAgreementsChangesInContractLiabilitiesDetails" roleURI="http://www.spy.com/role/StrategicLicenseAgreementsChangesInContractLiabilitiesDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#SaleOfPegzilarginaseToImmedicaDetails" roleURI="http://www.spy.com/role/SaleOfPegzilarginaseToImmedicaDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#DefinedContributionPlanAdditionalInformationDetails" roleURI="http://www.spy.com/role/DefinedContributionPlanAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#IncomeTaxesIncomeLossBeforeIncomeTaxExpenseByJurisdictionDetails" roleURI="http://www.spy.com/role/IncomeTaxesIncomeLossBeforeIncomeTaxExpenseByJurisdictionDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#IncomeTaxesAdditionalInformationDetails" roleURI="http://www.spy.com/role/IncomeTaxesAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#IncomeTaxesSummaryOfDifferenceBetweenProvisionForIncomeTaxesAndAmountsComputedByApplyingStatutoryFederalIncomeTaxRateToIncomeBeforeIncomeTaxesDetails" roleURI="http://www.spy.com/role/IncomeTaxesSummaryOfDifferenceBetweenProvisionForIncomeTaxesAndAmountsComputedByApplyingStatutoryFederalIncomeTaxRateToIncomeBeforeIncomeTaxesDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" roleURI="http://www.spy.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#NetLossPerShareWeightedAverageEquityInstrumentsExcludedFromCalculationOfDilutedNetLossPerShareDetails" roleURI="http://www.spy.com/role/NetLossPerShareWeightedAverageEquityInstrumentsExcludedFromCalculationOfDilutedNetLossPerShareDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#NetLossPerShareScheduleOfReconciliationOfBasicAndDilutedNetLossPerShareDetails" roleURI="http://www.spy.com/role/NetLossPerShareScheduleOfReconciliationOfBasicAndDilutedNetLossPerShareDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#ReverseStockSplitAdditionalInformationDetails" roleURI="http://www.spy.com/role/ReverseStockSplitAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#RestructuringChargesNarrativeDetails" roleURI="http://www.spy.com/role/RestructuringChargesNarrativeDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#RestructuringChargesChangesInAccruedRestructuringBalanceDetails" roleURI="http://www.spy.com/role/RestructuringChargesChangesInAccruedRestructuringBalanceDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#RestructuringChargesChargesRelatedToTheRestructuringActivitiesDetails" roleURI="http://www.spy.com/role/RestructuringChargesChargesRelatedToTheRestructuringActivitiesDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#SubsequentEventsAdditionalInformationDetails" roleURI="http://www.spy.com/role/SubsequentEventsAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="agle-20230930.xsd#NovationOfManufacturingAgreementsDetails" roleURI="http://www.spy.com/role/NovationOfManufacturingAgreementsDetails" />
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/CoverPage">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_101" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable_1918" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_101" xlink:to="loc_dei_DocumentInformationTable_1918" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_1919" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_1918" xlink:to="loc_dei_EntityAddressesAddressTypeAxis_1919" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain_1920" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_1919" xlink:to="loc_dei_AddressTypeDomain_1920" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_BusinessContactMember" xlink:label="loc_dei_BusinessContactMember_1921" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_AddressTypeDomain_1920" xlink:to="loc_dei_BusinessContactMember_1921" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems_1923" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_1918" xlink:to="loc_dei_DocumentInformationLineItems_1923" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_102" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1923" xlink:to="loc_dei_DocumentType_102" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_107" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1923" xlink:to="loc_dei_EntityRegistrantName_107" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_108" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1923" xlink:to="loc_dei_EntityIncorporationStateCountryCode_108" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_109" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1923" xlink:to="loc_dei_EntityTaxIdentificationNumber_109" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_110" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1923" xlink:to="loc_dei_EntityAddressAddressLine1_110" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_dei_EntityAddressAddressLine2_111" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1923" xlink:to="loc_dei_EntityAddressAddressLine2_111" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_dei_EntityAddressAddressLine3_112" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1923" xlink:to="loc_dei_EntityAddressAddressLine3_112" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_113" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1923" xlink:to="loc_dei_EntityAddressCityOrTown_113" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_114" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1923" xlink:to="loc_dei_EntityAddressStateOrProvince_114" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_115" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1923" xlink:to="loc_dei_EntityAddressPostalZipCode_115" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_116" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1923" xlink:to="loc_dei_CityAreaCode_116" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_117" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1923" xlink:to="loc_dei_LocalPhoneNumber_117" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_123" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1923" xlink:to="loc_dei_EntityFilerCategory_123" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_124" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1923" xlink:to="loc_dei_EntitySmallBusiness_124" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_125" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1923" xlink:to="loc_dei_EntityEmergingGrowthCompany_125" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_128" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1923" xlink:to="loc_dei_EntityCentralIndexKey_128" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_130" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1923" xlink:to="loc_dei_AmendmentFlag_130" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ContactPersonnelName" xlink:label="loc_dei_ContactPersonnelName_1925" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1923" xlink:to="loc_dei_ContactPersonnelName_1925" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/CondensedConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_134" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_135" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_134" xlink:to="loc_us-gaap_StatementTable_135" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_136" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_135" xlink:to="loc_us-gaap_StatementClassOfStockAxis_136" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_137" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_136" xlink:to="loc_us-gaap_ClassOfStockDomain_137" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_SeriesANonVotingConvertiblePreferredStockMember" xlink:label="loc_agle_SeriesANonVotingConvertiblePreferredStockMember_138" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_137" xlink:to="loc_agle_SeriesANonVotingConvertiblePreferredStockMember_138" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1841" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_135" xlink:to="loc_us-gaap_StatementLineItems_1841" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_140" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1841" xlink:to="loc_us-gaap_AssetsAbstract_140" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_141" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_140" xlink:to="loc_us-gaap_AssetsCurrentAbstract_141" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_142" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_141" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_142" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_143" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_141" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_143" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NontradeReceivablesCurrent" xlink:label="loc_us-gaap_NontradeReceivablesCurrent_144" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_141" xlink:to="loc_us-gaap_NontradeReceivablesCurrent_144" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_145" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_141" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_145" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_146" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_141" xlink:to="loc_us-gaap_AssetsCurrent_146" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_147" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_140" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_147" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_148" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_140" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_148" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_149" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_140" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_149" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_150" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_140" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_150" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_151" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_140" xlink:to="loc_us-gaap_Assets_151" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_152" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1841" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_152" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_153" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_152" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_153" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent_154" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_153" xlink:to="loc_us-gaap_AccountsPayableTradeCurrent_154" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_155" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_153" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_155" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_156" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_153" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_156" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_1520" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_153" xlink:to="loc_us-gaap_DeferredRevenueCurrent_1520" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_158" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_153" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_158" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="loc_us-gaap_AccountsPayableOtherCurrent_159" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_153" xlink:to="loc_us-gaap_AccountsPayableOtherCurrent_159" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_160" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_153" xlink:to="loc_us-gaap_LiabilitiesCurrent_160" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_161" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_152" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_161" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_162" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_152" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_162" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_163" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_152" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_163" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_1553" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_152" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_1553" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_164" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_152" xlink:to="loc_us-gaap_Liabilities_164" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_165" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_152" xlink:to="loc_us-gaap_CommitmentsAndContingencies_165" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_166" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_152" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_166" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_167" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_152" xlink:to="loc_us-gaap_StockholdersEquityAbstract_167" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_168" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_167" xlink:to="loc_us-gaap_PreferredStockValue_168" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_169" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_167" xlink:to="loc_us-gaap_CommonStockValue_169" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_170" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_167" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_170" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_171" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_167" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_171" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_172" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_167" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_172" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_173" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_167" xlink:to="loc_us-gaap_StockholdersEquity_173" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_174" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_152" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_174" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_176" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_177" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_176" xlink:to="loc_us-gaap_StatementTable_177" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_178" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_177" xlink:to="loc_us-gaap_StatementClassOfStockAxis_178" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_179" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_178" xlink:to="loc_us-gaap_ClassOfStockDomain_179" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_SeriesANonVotingConvertiblePreferredStockMember" xlink:label="loc_agle_SeriesANonVotingConvertiblePreferredStockMember_180" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_179" xlink:to="loc_agle_SeriesANonVotingConvertiblePreferredStockMember_180" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_181" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_177" xlink:to="loc_us-gaap_StatementLineItems_181" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_182" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_181" xlink:to="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_182" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_183" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_181" xlink:to="loc_us-gaap_TemporaryEquitySharesAuthorized_183" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_184" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_181" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_184" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_185" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_181" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_185" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_186" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_181" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_186" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_187" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_181" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_187" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_188" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_181" xlink:to="loc_us-gaap_PreferredStockSharesIssued_188" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_189" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_181" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_189" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_190" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_181" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_190" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_191" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_181" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_191" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_192" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_181" xlink:to="loc_us-gaap_CommonStockSharesIssued_192" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_193" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_181" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_193" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/CondensedConsolidatedStatementsOfOperations">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_195" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_196" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_195" xlink:to="loc_us-gaap_StatementTable_196" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_197" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_196" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_197" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_198" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_197" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_198" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForwardContractsMember" xlink:label="loc_us-gaap_ForwardContractsMember_199" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_198" xlink:to="loc_us-gaap_ForwardContractsMember_199" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_1150" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_196" xlink:to="loc_srt_ProductOrServiceAxis_1150" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_1151" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_1150" xlink:to="loc_srt_ProductsAndServicesDomain_1151" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaap_LicenseMember_1157" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1151" xlink:to="loc_us-gaap_LicenseMember_1157" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_DevelopmentFeeMember" xlink:label="loc_agle_DevelopmentFeeMember_1424" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1151" xlink:to="loc_agle_DevelopmentFeeMember_1424" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_200" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_196" xlink:to="loc_us-gaap_StatementLineItems_200" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_201" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_200" xlink:to="loc_us-gaap_RevenuesAbstract_201" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_202" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_201" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_202" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_203" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_201" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_203" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_204" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_200" xlink:to="loc_us-gaap_OperatingExpensesAbstract_204" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_205" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_204" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_205" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_1153" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_204" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_1153" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_206" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_204" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_206" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AcquiredInProcessResearchAndDevelopment" xlink:label="loc_agle_AcquiredInProcessResearchAndDevelopment_207" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_204" xlink:to="loc_agle_AcquiredInProcessResearchAndDevelopment_207" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_208" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_204" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_208" use="optional" order="18" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_209" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_204" xlink:to="loc_us-gaap_OperatingExpenses_209" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_210" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_200" xlink:to="loc_us-gaap_OperatingIncomeLoss_210" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_211" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_200" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_211" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeNet" xlink:label="loc_us-gaap_InvestmentIncomeNet_212" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_211" xlink:to="loc_us-gaap_InvestmentIncomeNet_212" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_213" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_211" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_213" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_214" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_211" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_214" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_215" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_211" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_215" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_216" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_200" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_216" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_217" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_200" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_217" use="optional" order="27" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_218" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_200" xlink:to="loc_us-gaap_NetIncomeLoss_218" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_219" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_200" xlink:to="loc_us-gaap_EarningsPerShareBasic_219" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_220" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_200" xlink:to="loc_us-gaap_EarningsPerShareDiluted_220" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_221" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_200" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_221" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_222" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_200" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_222" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_224" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_225" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_224" xlink:to="loc_us-gaap_StatementTable_225" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_226" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_225" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_226" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_227" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_226" xlink:to="loc_us-gaap_RelatedPartyDomain_227" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaap_RelatedPartyMember_228" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_227" xlink:to="loc_us-gaap_RelatedPartyMember_228" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_229" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_225" xlink:to="loc_us-gaap_StatementLineItems_229" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_230" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_229" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_230" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_232" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_233" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_232" xlink:to="loc_us-gaap_NetIncomeLoss_233" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_234" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_232" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_234" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_235" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_234" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_235" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_236" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_234" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_236" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_237" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_234" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_237" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/CondensedConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersDeficitEquity">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_239" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_240" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_239" xlink:to="loc_us-gaap_StatementTable_240" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_241" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_240" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_241" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_242" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_241" xlink:to="loc_us-gaap_EquityComponentDomain_242" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_243" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_242" xlink:to="loc_us-gaap_CommonStockMember_243" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_244" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_242" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_244" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_245" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_242" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_245" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_246" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_242" xlink:to="loc_us-gaap_RetainedEarningsMember_246" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_247" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_240" xlink:to="loc_us-gaap_StatementClassOfStockAxis_247" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_248" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_247" xlink:to="loc_us-gaap_ClassOfStockDomain_248" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_SeriesANonVotingConvertiblePreferredStockMember" xlink:label="loc_agle_SeriesANonVotingConvertiblePreferredStockMember_249" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_248" xlink:to="loc_agle_SeriesANonVotingConvertiblePreferredStockMember_249" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_250" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_240" xlink:to="loc_us-gaap_StatementLineItems_250" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_260" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_250" xlink:to="loc_us-gaap_SharesOutstanding_260" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_261" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_250" xlink:to="loc_us-gaap_StockholdersEquity_261" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_252" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_250" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_252" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_253" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_250" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_253" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_StockIssuedDuringPeriodSharesCommonStockAndPreFundedWarrants" xlink:label="loc_agle_StockIssuedDuringPeriodSharesCommonStockAndPreFundedWarrants_1585" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_250" xlink:to="loc_agle_StockIssuedDuringPeriodSharesCommonStockAndPreFundedWarrants_1585" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_StockIssuedDuringPeriodValueCommonStockAndPreFundedWarrants" xlink:label="loc_agle_StockIssuedDuringPeriodValueCommonStockAndPreFundedWarrants_1474" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_250" xlink:to="loc_agle_StockIssuedDuringPeriodValueCommonStockAndPreFundedWarrants_1474" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1654" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_250" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1654" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_1599" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_250" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_1599" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_IssuanceOfCommonStockAndPreFundedWarrantsSharesInConnectionWithRegisteredDirectOfferingNetOfOfferingCosts" xlink:label="loc_agle_IssuanceOfCommonStockAndPreFundedWarrantsSharesInConnectionWithRegisteredDirectOfferingNetOfOfferingCosts_1690" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_250" xlink:to="loc_agle_IssuanceOfCommonStockAndPreFundedWarrantsSharesInConnectionWithRegisteredDirectOfferingNetOfOfferingCosts_1690" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_IssuanceOfCommonStockAndPreFundedWarrantsValueInConnectionWithRegisteredDirectOfferingNetOfOfferingCosts" xlink:label="loc_agle_IssuanceOfCommonStockAndPreFundedWarrantsValueInConnectionWithRegisteredDirectOfferingNetOfOfferingCosts_1660" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_250" xlink:to="loc_agle_IssuanceOfCommonStockAndPreFundedWarrantsValueInConnectionWithRegisteredDirectOfferingNetOfOfferingCosts_1660" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_agle_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_254" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_250" xlink:to="loc_agle_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_254" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_255" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_250" xlink:to="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_255" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_263" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_250" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_263" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_IssuanceOfCommonStockInConnectionWithExerciseOfPreFundedWarrants" xlink:label="loc_agle_IssuanceOfCommonStockInConnectionWithExerciseOfPreFundedWarrants_1695" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_250" xlink:to="loc_agle_IssuanceOfCommonStockInConnectionWithExerciseOfPreFundedWarrants_1695" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_270" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_250" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_270" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_271" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_250" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_271" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_StockIssuedDuringPeriodSharesOptionsExercisedAndEmployeeStockOwnershipPlan" xlink:label="loc_agle_StockIssuedDuringPeriodSharesOptionsExercisedAndEmployeeStockOwnershipPlan_267" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_250" xlink:to="loc_agle_StockIssuedDuringPeriodSharesOptionsExercisedAndEmployeeStockOwnershipPlan_267" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan" xlink:label="loc_agle_StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan_262" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_250" xlink:to="loc_agle_StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan_262" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_TemporaryEquityFinancingCosts" xlink:label="loc_agle_TemporaryEquityFinancingCosts_256" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_250" xlink:to="loc_agle_TemporaryEquityFinancingCosts_256" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_264" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_250" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_264" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_265" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_250" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_265" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_266" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_250" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_266" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_269" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_250" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_269" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_StockIssuedDuringPeriodSharesCommonStockAndPreFundedWarrantsRegisteredDirectOffering" xlink:label="loc_agle_StockIssuedDuringPeriodSharesCommonStockAndPreFundedWarrantsRegisteredDirectOffering_268" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_250" xlink:to="loc_agle_StockIssuedDuringPeriodSharesCommonStockAndPreFundedWarrantsRegisteredDirectOffering_268" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_StockIssuedDuringPeriodValueCommonStockAndPreFundedWarrantsRegisteredDirectOffering" xlink:label="loc_agle_StockIssuedDuringPeriodValueCommonStockAndPreFundedWarrantsRegisteredDirectOffering_272" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_250" xlink:to="loc_agle_StockIssuedDuringPeriodValueCommonStockAndPreFundedWarrantsRegisteredDirectOffering_272" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ContingentValueRightDistributionToCommonStockholders" xlink:label="loc_agle_ContingentValueRightDistributionToCommonStockholders_273" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_250" xlink:to="loc_agle_ContingentValueRightDistributionToCommonStockholders_273" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_274" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_250" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_274" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_275" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_250" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_275" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_276" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_250" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_276" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_277" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_250" xlink:to="loc_us-gaap_NetIncomeLoss_277" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_257" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_250" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_257" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_258" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_250" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_258" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_278" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_250" xlink:to="loc_us-gaap_SharesOutstanding_278" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_279" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_250" xlink:to="loc_us-gaap_StockholdersEquity_279" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/CondensedConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_281" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_282" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_281" xlink:to="loc_us-gaap_StatementTable_282" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_283" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_282" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_283" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_284" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_283" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_284" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ContingentValueRightLiabilityMember" xlink:label="loc_agle_ContingentValueRightLiabilityMember_285" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_284" xlink:to="loc_agle_ContingentValueRightLiabilityMember_285" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForwardContractsMember" xlink:label="loc_us-gaap_ForwardContractsMember_286" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_284" xlink:to="loc_us-gaap_ForwardContractsMember_286" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_287" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_282" xlink:to="loc_us-gaap_StatementLineItems_287" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_288" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_287" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_288" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_289" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_288" xlink:to="loc_us-gaap_ProfitLoss_289" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_290" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_288" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_290" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_291" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_290" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_291" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_292" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_290" xlink:to="loc_us-gaap_ShareBasedCompensation_292" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AcquiredInProcessResearchAndDevelopment" xlink:label="loc_agle_AcquiredInProcessResearchAndDevelopment_293" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_290" xlink:to="loc_agle_AcquiredInProcessResearchAndDevelopment_293" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_294" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_290" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_294" use="optional" order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_295" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_290" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_295" use="optional" order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_296" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_290" xlink:to="loc_us-gaap_AssetImpairmentCharges_296" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_297" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_290" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_297" use="optional" order="16" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_298" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_290" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_298" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_299" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_290" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_299" use="optional" order="18" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_300" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_290" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_300" use="optional" order="19" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_PaymentForDiscountPremiumOnInvestmentsNet" xlink:label="loc_agle_PaymentForDiscountPremiumOnInvestmentsNet_1509" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_290" xlink:to="loc_agle_PaymentForDiscountPremiumOnInvestmentsNet_1509" use="optional" order="20" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_NonCashOperatingLeaseExpense" xlink:label="loc_agle_NonCashOperatingLeaseExpense_1614" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_290" xlink:to="loc_agle_NonCashOperatingLeaseExpense_1614" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_301" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_288" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_301" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_302" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_301" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_302" use="optional" order="23" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_303" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_301" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_303" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_304" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_301" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_304" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_305" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_301" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_305" use="optional" order="26" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_306" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_301" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_306" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_307" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_301" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_307" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayable_308" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_301" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayable_308" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_1396" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_301" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_1396" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:label="loc_agle_IncreaseDecreaseInOperatingLeaseLiabilities_1615" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_301" xlink:to="loc_agle_IncreaseDecreaseInOperatingLeaseLiabilities_1615" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_309" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_288" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_309" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_310" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_288" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_310" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition_311" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_310" xlink:to="loc_us-gaap_CashAcquiredFromAcquisition_311" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:label="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_312" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_310" xlink:to="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_312" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_313" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_310" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_313" use="optional" order="36" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_314" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_310" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_314" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_315" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_310" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_315" use="optional" order="38" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_316" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_310" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_316" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_317" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_310" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_317" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_318" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_287" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_318" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_319" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_318" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_319" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfOfferingCosts" xlink:label="loc_agle_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfOfferingCosts_320" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_318" xlink:to="loc_agle_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfOfferingCosts_320" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_321" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_318" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_321" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_322" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_318" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_322" use="optional" order="45" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_323" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_318" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_323" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_324" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_287" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_324" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_325" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_287" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_325" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract_326" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_287" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract_326" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_327" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract_326" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_327" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_328" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract_326" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_328" use="optional" order="51" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_1213" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract_326" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_1213" use="optional" order="52" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_1391" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract_326" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_1391" use="optional" order="53" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_329" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_287" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_329" use="optional" order="54" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssued1" xlink:label="loc_us-gaap_StockIssued1_330" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_329" xlink:to="loc_us-gaap_StockIssued1_330" use="optional" order="55" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_LeasedAssetsObtainedInExchangeForLeaseObligations" xlink:label="loc_agle_LeasedAssetsObtainedInExchangeForLeaseObligations_1219" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_329" xlink:to="loc_agle_LeasedAssetsObtainedInExchangeForLeaseObligations_1219" use="optional" order="56" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_1397" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_329" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_1397" use="optional" order="57" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/StatementOfAssetsAcquiredAndLiabilitiesAssumed">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_1927" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1928" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_1927" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1928" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_1929" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1928" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_1929" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_1930" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1929" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_1930" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_1931" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_1930" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_1931" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract_1932" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_1931" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract_1932" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_1933" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract_1932" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_1933" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_1934" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract_1932" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_1934" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_1935" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_1931" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_1935" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_1936" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_1930" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_1936" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract_1937" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_1936" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract_1937" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_1938" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract_1937" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_1938" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_1939" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract_1937" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_1939" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_1940" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_1936" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_1940" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_1941" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_1930" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_1941" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/TheCompanyAndBasisOfPresentation">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_332" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_333" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_332" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_333" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/SummaryOfSignificantAccountingPolicies">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_335" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_336" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_335" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_336" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/FairValueMeasurements">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_338" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_339" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_338" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_339" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/CashEquivalentsAndMarketableSecurities">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_341" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_342" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_341" xlink:to="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_342" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/PropertyAndEquipmentNet">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_1154" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_1155" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_1154" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_1155" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/AccruedAndOtherCurrentLiabilities">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_344" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AccruedAndOtherCurrentLiabilitiesTextBlock" xlink:label="loc_agle_AccruedAndOtherCurrentLiabilitiesTextBlock_345" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_344" xlink:to="loc_agle_AccruedAndOtherCurrentLiabilitiesTextBlock_345" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/Leases">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_1179" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_LesseeOperatingAndFinanceLeasesDisclosureTextBlock" xlink:label="loc_agle_LesseeOperatingAndFinanceLeasesDisclosureTextBlock_1180" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1179" xlink:to="loc_agle_LesseeOperatingAndFinanceLeasesDisclosureTextBlock_1180" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/StockholdersEquity">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_1074" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1075" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_1074" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1075" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/RelatedPartyTransactions">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_347" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_348" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_347" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_348" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/AssetAcquisition">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_350" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionTextBlock" xlink:label="loc_us-gaap_AssetAcquisitionTextBlock_351" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_350" xlink:to="loc_us-gaap_AssetAcquisitionTextBlock_351" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/ParagonAgreement">
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_CollaborativeArrangementAbstract" xlink:label="loc_agle_CollaborativeArrangementAbstract_353" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_OptionAgreementTextBlock" xlink:label="loc_agle_OptionAgreementTextBlock_354" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_CollaborativeArrangementAbstract_353" xlink:to="loc_agle_OptionAgreementTextBlock_354" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/SeriesANonVotingConvertiblePreferredStock">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_356" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockTextBlock" xlink:label="loc_us-gaap_PreferredStockTextBlock_357" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_356" xlink:to="loc_us-gaap_PreferredStockTextBlock_357" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquity">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_359" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_360" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_359" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_360" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/StrategicLicenseAgreements">
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_LicenseAndCollaborationAgreementAbstract" xlink:label="loc_agle_LicenseAndCollaborationAgreementAbstract_362" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_StrategicLicenseAgreementTextBlock" xlink:label="loc_agle_StrategicLicenseAgreementTextBlock_363" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_LicenseAndCollaborationAgreementAbstract_362" xlink:to="loc_agle_StrategicLicenseAgreementTextBlock_363" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/SaleOfPegzilarginaseToImmedica">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_365" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_366" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_365" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_366" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/DefinedContributionPlan">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_1148" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_1149" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_1148" xlink:to="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_1149" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/IncomeTaxes">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1176" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_1177" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1176" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_1177" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/NetLossPerShare">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_368" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_369" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_368" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_369" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/RestructuringCharges">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_371" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_372" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_371" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_372" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/NovationOfManufacturingAgreements">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_374" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsDisclosureTextBlock_375" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_374" xlink:to="loc_us-gaap_CommitmentsDisclosureTextBlock_375" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/ReverseStockSplit">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_1910" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ReverseStockSplitTextBlock" xlink:label="loc_agle_ReverseStockSplitTextBlock_1911" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_1910" xlink:to="loc_agle_ReverseStockSplitTextBlock_1911" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPolicies">
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAbstract" xlink:label="loc_agle_DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAbstract_1792" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_1793" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAbstract_1792" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_1793" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/AccruedLiabilities">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_1943" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AccruedLiabilitiesTextBlock" xlink:label="loc_agle_AccruedLiabilitiesTextBlock_1944" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_1943" xlink:to="loc_agle_AccruedLiabilitiesTextBlock_1944" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/ParapyreOptionObligation">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAbstract" xlink:label="loc_us-gaap_AssetAcquisitionAbstract_1867" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionTextBlock" xlink:label="loc_us-gaap_AssetAcquisitionTextBlock_1868" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAbstract_1867" xlink:to="loc_us-gaap_AssetAcquisitionTextBlock_1868" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/SubsequentEvents">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_1879" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_1880" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_1879" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_1880" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesPolicies">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_377" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ConvertiblePreferredStockIssuedThroughPipePolicyTextBlock" xlink:label="loc_agle_ConvertiblePreferredStockIssuedThroughPipePolicyTextBlock_378" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_377" xlink:to="loc_agle_ConvertiblePreferredStockIssuedThroughPipePolicyTextBlock_378" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_379" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_377" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_379" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_380" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_377" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_380" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1794" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_377" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1794" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_381" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_377" xlink:to="loc_us-gaap_UseOfEstimates_381" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_382" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_377" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_382" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_1456" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_377" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_1456" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AccruedLiabilitiesPolicyTextBlock" xlink:label="loc_agle_AccruedLiabilitiesPolicyTextBlock_1796" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_377" xlink:to="loc_agle_AccruedLiabilitiesPolicyTextBlock_1796" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_1469" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_377" xlink:to="loc_us-gaap_MarketableSecuritiesPolicy_1469" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_1590" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_377" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_1590" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_1596" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_377" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_1596" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_1656" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_377" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_1656" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_1659" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_377" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_1659" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AccruedResearchAndDevelopmentExpensePolicyTextBlock" xlink:label="loc_agle_AccruedResearchAndDevelopmentExpensePolicyTextBlock_1691" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_377" xlink:to="loc_agle_AccruedResearchAndDevelopmentExpensePolicyTextBlock_1691" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_1694" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_377" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_1694" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_1711" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_377" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_1711" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_1714" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_377" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_1714" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_1726" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_377" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_1726" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_1729" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_377" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_1729" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_1740" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_377" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_1740" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_1742" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_377" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_1742" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_1798" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionTableTextBlock" xlink:label="loc_us-gaap_AssetAcquisitionTableTextBlock_1799" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_1798" xlink:to="loc_us-gaap_AssetAcquisitionTableTextBlock_1799" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1077" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" xlink:label="loc_agle_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock_1078" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1077" xlink:to="loc_agle_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock_1078" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/AccruedLiabilitiesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_1946" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_1947" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_1946" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_1947" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/FairValueMeasurementTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_385" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_386" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_385" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_386" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_387" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_385" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_387" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_388" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_385" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_388" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_390" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_391" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_390" xlink:to="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_391" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_392" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_390" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_392" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_393" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_390" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_393" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/PropertyAndEquipmentNetTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_1062" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_1063" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_1062" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_1063" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/AccruedAndOtherCurrentLiabilitiesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_395" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_396" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_395" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_396" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/LeasesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_1182" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ScheduleOfOperatingAndFinancingLeasesPresentedInBalanceSheetTableTextBlock" xlink:label="loc_agle_ScheduleOfOperatingAndFinancingLeasesPresentedInBalanceSheetTableTextBlock_1183" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1182" xlink:to="loc_agle_ScheduleOfOperatingAndFinancingLeasesPresentedInBalanceSheetTableTextBlock_1183" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_SummaryOfWeightedAverageRemainingLeaseTermAndDiscountRatesOfOperatingAndFinanceLeasesTableTextBlock" xlink:label="loc_agle_SummaryOfWeightedAverageRemainingLeaseTermAndDiscountRatesOfOperatingAndFinanceLeasesTableTextBlock_1219" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1182" xlink:to="loc_agle_SummaryOfWeightedAverageRemainingLeaseTermAndDiscountRatesOfOperatingAndFinanceLeasesTableTextBlock_1219" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_1305" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1182" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_1305" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesTableTextBlock" xlink:label="loc_agle_ScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesTableTextBlock_1317" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1182" xlink:to="loc_agle_ScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesTableTextBlock_1317" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/StockholdersEquityTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1037" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_1038" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1037" xlink:to="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_1038" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/RelatedPartyTransactionsTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_398" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_399" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_398" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_399" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ScheduleOfBalancesDueToAffiliatesTableTextBlock" xlink:label="loc_agle_ScheduleOfBalancesDueToAffiliatesTableTextBlock_400" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_398" xlink:to="loc_agle_ScheduleOfBalancesDueToAffiliatesTableTextBlock_400" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/AssetAcquisitionTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_402" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionTableTextBlock" xlink:label="loc_us-gaap_AssetAcquisitionTableTextBlock_403" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_402" xlink:to="loc_us-gaap_AssetAcquisitionTableTextBlock_403" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1023" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1024" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1023" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1024" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:label="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_1269" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1023" xlink:to="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_1269" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_1274" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1023" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_1274" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1339" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1023" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1339" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_1970" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1023" xlink:to="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_1970" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock_1971" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1023" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock_1971" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/StrategicLicenseAgreementsTables">
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_LicenseAndCollaborationAgreementAbstract" xlink:label="loc_agle_LicenseAndCollaborationAgreementAbstract_411" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_412" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_LicenseAndCollaborationAgreementAbstract_411" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_412" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/IncomeTaxesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1151" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_1152" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1151" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_1152" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_1226" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1151" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_1226" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_1300" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1151" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_1300" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/NetLossPerShareTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_414" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_415" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_414" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_415" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_1404" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_414" xlink:to="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_1404" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/RestructuringChargesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_417" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_418" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_417" xlink:to="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_418" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_419" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_417" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_419" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/TheCompanyAndBasisOfPresentationNarrativeDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_421" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_CompanyAndBasisOfPresentationTable" xlink:label="loc_agle_CompanyAndBasisOfPresentationTable_422" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_421" xlink:to="loc_agle_CompanyAndBasisOfPresentationTable_422" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_423" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_CompanyAndBasisOfPresentationTable_422" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_423" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_424" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_423" xlink:to="loc_us-gaap_EquityComponentDomain_424" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_425" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_424" xlink:to="loc_us-gaap_CommonStockMember_425" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_426" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_CompanyAndBasisOfPresentationTable_422" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_426" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_427" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_426" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_427" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_428" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_427" xlink:to="loc_us-gaap_PrivatePlacementMember_428" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_429" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_CompanyAndBasisOfPresentationTable_422" xlink:to="loc_us-gaap_StatementClassOfStockAxis_429" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_430" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_429" xlink:to="loc_us-gaap_ClassOfStockDomain_430" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_SeriesANonVotingConvertiblePreferredStockMember" xlink:label="loc_agle_SeriesANonVotingConvertiblePreferredStockMember_431" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_430" xlink:to="loc_agle_SeriesANonVotingConvertiblePreferredStockMember_431" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_432" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_CompanyAndBasisOfPresentationTable_422" xlink:to="loc_us-gaap_PlanNameAxis_432" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_433" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_432" xlink:to="loc_us-gaap_PlanNameDomain_433" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_Spyre2023EquityIncentivePlanMember" xlink:label="loc_agle_Spyre2023EquityIncentivePlanMember_434" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_433" xlink:to="loc_agle_Spyre2023EquityIncentivePlanMember_434" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="loc_us-gaap_AssetAcquisitionAxis_435" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_CompanyAndBasisOfPresentationTable_422" xlink:to="loc_us-gaap_AssetAcquisitionAxis_435" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaap_AssetAcquisitionDomain_436" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_435" xlink:to="loc_us-gaap_AssetAcquisitionDomain_436" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AssetAcquisitionMember" xlink:label="loc_agle_AssetAcquisitionMember_437" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_436" xlink:to="loc_agle_AssetAcquisitionMember_437" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_SpyreTherapeuticsIncMember" xlink:label="loc_agle_SpyreTherapeuticsIncMember_438" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_436" xlink:to="loc_agle_SpyreTherapeuticsIncMember_438" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_CompanyAndBasisOfPresentationLineItems" xlink:label="loc_agle_CompanyAndBasisOfPresentationLineItems_439" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_CompanyAndBasisOfPresentationTable_422" xlink:to="loc_agle_CompanyAndBasisOfPresentationLineItems_439" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_440" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_CompanyAndBasisOfPresentationLineItems_439" xlink:to="loc_us-gaap_NumberOfOperatingSegments_440" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_441" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_CompanyAndBasisOfPresentationLineItems_439" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_441" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_FixedExchangeRatio" xlink:label="loc_agle_FixedExchangeRatio_443" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_CompanyAndBasisOfPresentationLineItems_439" xlink:to="loc_agle_FixedExchangeRatio_443" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares" xlink:label="loc_agle_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares_444" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_CompanyAndBasisOfPresentationLineItems_439" xlink:to="loc_agle_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares_444" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_445" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_CompanyAndBasisOfPresentationLineItems_439" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_445" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleConversionRatio" xlink:label="loc_us-gaap_PreferredStockConvertibleConversionRatio_446" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_CompanyAndBasisOfPresentationLineItems_439" xlink:to="loc_us-gaap_PreferredStockConvertibleConversionRatio_446" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_OutstandingAndUnexercisedStockOptions" xlink:label="loc_agle_OutstandingAndUnexercisedStockOptions_447" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_CompanyAndBasisOfPresentationLineItems_439" xlink:to="loc_agle_OutstandingAndUnexercisedStockOptions_447" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_448" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_CompanyAndBasisOfPresentationLineItems_439" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_448" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_449" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_CompanyAndBasisOfPresentationLineItems_439" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_449" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_PlacementAgentAndOtherOfferingExpenses" xlink:label="loc_agle_PlacementAgentAndOtherOfferingExpenses_450" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_CompanyAndBasisOfPresentationLineItems_439" xlink:to="loc_agle_PlacementAgentAndOtherOfferingExpenses_450" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AssetAcquisitionStockholderPaymentPeriod" xlink:label="loc_agle_AssetAcquisitionStockholderPaymentPeriod_451" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_CompanyAndBasisOfPresentationLineItems_439" xlink:to="loc_agle_AssetAcquisitionStockholderPaymentPeriod_451" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AssetAcquisitionCashPaymentThresholdPeriod" xlink:label="loc_agle_AssetAcquisitionCashPaymentThresholdPeriod_452" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_CompanyAndBasisOfPresentationLineItems_439" xlink:to="loc_agle_AssetAcquisitionCashPaymentThresholdPeriod_452" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_453" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_CompanyAndBasisOfPresentationLineItems_439" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_453" use="optional" order="31" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_454" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_CompanyAndBasisOfPresentationLineItems_439" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_454" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_NumberOfEmployeesRetained" xlink:label="loc_agle_NumberOfEmployeesRetained_455" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_CompanyAndBasisOfPresentationLineItems_439" xlink:to="loc_agle_NumberOfEmployeesRetained_455" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_WorkingCapital" xlink:label="loc_agle_WorkingCapital_1356" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_CompanyAndBasisOfPresentationLineItems_439" xlink:to="loc_agle_WorkingCapital_1356" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_CashCashEquivalentsMarketableSecuritiesAndRestrictedCash" xlink:label="loc_agle_CashCashEquivalentsMarketableSecuritiesAndRestrictedCash_1542" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_CompanyAndBasisOfPresentationLineItems_439" xlink:to="loc_agle_CashCashEquivalentsMarketableSecuritiesAndRestrictedCash_1542" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesSummaryOfAssetAcquisitionCostDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_1801" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionTable" xlink:label="loc_us-gaap_AssetAcquisitionTable_1802" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_1801" xlink:to="loc_us-gaap_AssetAcquisitionTable_1802" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="loc_us-gaap_AssetAcquisitionAxis_1803" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionTable_1802" xlink:to="loc_us-gaap_AssetAcquisitionAxis_1803" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaap_AssetAcquisitionDomain_1804" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_1803" xlink:to="loc_us-gaap_AssetAcquisitionDomain_1804" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_SpyreTherapeuticsIncMember" xlink:label="loc_agle_SpyreTherapeuticsIncMember_1805" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_1804" xlink:to="loc_agle_SpyreTherapeuticsIncMember_1805" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="loc_us-gaap_AssetAcquisitionLineItems_1806" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionTable_1802" xlink:to="loc_us-gaap_AssetAcquisitionLineItems_1806" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_1807" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_1806" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_1807" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_1808" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_1806" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_1808" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AcquiredInProcessResearchAndDevelopment" xlink:label="loc_agle_AcquiredInProcessResearchAndDevelopment_1809" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_1806" xlink:to="loc_agle_AcquiredInProcessResearchAndDevelopment_1809" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition_1810" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_1806" xlink:to="loc_us-gaap_CashAcquiredFromAcquisition_1810" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_1813" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_1806" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_1813" use="optional" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferred_1812" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_1806" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferred_1812" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAbstract" xlink:label="loc_agle_DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAbstract_1815" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:label="loc_agle_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_1819" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAbstract_1815" xlink:to="loc_agle_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_1819" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="loc_us-gaap_AssetAcquisitionAxis_1824" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_1819" xlink:to="loc_us-gaap_AssetAcquisitionAxis_1824" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaap_AssetAcquisitionDomain_1825" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_1824" xlink:to="loc_us-gaap_AssetAcquisitionDomain_1825" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AssetAcquisitionMember" xlink:label="loc_agle_AssetAcquisitionMember_1826" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_1825" xlink:to="loc_agle_AssetAcquisitionMember_1826" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_SpyreTherapeuticsIncMember" xlink:label="loc_agle_SpyreTherapeuticsIncMember_1838" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_1825" xlink:to="loc_agle_SpyreTherapeuticsIncMember_1838" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1827" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_1819" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1827" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1828" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1827" xlink:to="loc_us-gaap_ClassOfStockDomain_1828" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_SeriesANonVotingConvertiblePreferredStockMember" xlink:label="loc_agle_SeriesANonVotingConvertiblePreferredStockMember_1829" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1828" xlink:to="loc_agle_SeriesANonVotingConvertiblePreferredStockMember_1829" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1830" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_1819" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1830" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1831" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1830" xlink:to="loc_us-gaap_EquityComponentDomain_1831" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1832" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1831" xlink:to="loc_us-gaap_CommonStockMember_1832" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1850" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_1819" xlink:to="loc_us-gaap_PlanNameAxis_1850" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1851" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_1850" xlink:to="loc_us-gaap_PlanNameDomain_1851" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_Spyre2023EquityIncentivePlanMember" xlink:label="loc_agle_Spyre2023EquityIncentivePlanMember_1852" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1851" xlink:to="loc_agle_Spyre2023EquityIncentivePlanMember_1852" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ParapyreOptionObligationMember" xlink:label="loc_agle_ParapyreOptionObligationMember_1859" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1851" xlink:to="loc_agle_ParapyreOptionObligationMember_1859" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_1853" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_1819" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_1853" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_1854" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_1853" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_1854" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1855" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_1854" xlink:to="loc_us-gaap_CommonStockMember_1855" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1860" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_1819" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_1860" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1861" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1860" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1861" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_1862" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1861" xlink:to="loc_us-gaap_PrivatePlacementMember_1862" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_1863" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_1819" xlink:to="loc_us-gaap_FinancialInstrumentAxis_1863" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1864" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1863" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1864" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_USBankingInstitutionMember" xlink:label="loc_agle_USBankingInstitutionMember_1865" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1864" xlink:to="loc_agle_USBankingInstitutionMember_1865" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:label="loc_agle_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_1820" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_1819" xlink:to="loc_agle_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_1820" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaap_StockholdersEquityReverseStockSplit_1816" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_1820" xlink:to="loc_us-gaap_StockholdersEquityReverseStockSplit_1816" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_FixedExchangeRatio" xlink:label="loc_agle_FixedExchangeRatio_1817" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_1820" xlink:to="loc_agle_FixedExchangeRatio_1817" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares" xlink:label="loc_agle_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares_1818" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_1820" xlink:to="loc_agle_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares_1818" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_1821" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_1820" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_1821" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleConversionRatio" xlink:label="loc_us-gaap_PreferredStockConvertibleConversionRatio_1822" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_1820" xlink:to="loc_us-gaap_PreferredStockConvertibleConversionRatio_1822" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_OutstandingAndUnexercisedStockOptions" xlink:label="loc_agle_OutstandingAndUnexercisedStockOptions_1823" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_1820" xlink:to="loc_agle_OutstandingAndUnexercisedStockOptions_1823" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferred_1833" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_1820" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferred_1833" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableSharesOfCommonStockOnAnAsConvertedBasis" xlink:label="loc_agle_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableSharesOfCommonStockOnAnAsConvertedBasis_1835" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_1820" xlink:to="loc_agle_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableSharesOfCommonStockOnAnAsConvertedBasis_1835" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_1836" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_1820" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_1836" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock" xlink:label="loc_agle_PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock_1837" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_1820" xlink:to="loc_agle_PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock_1837" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AcquiredInProcessResearchAndDevelopment" xlink:label="loc_agle_AcquiredInProcessResearchAndDevelopment_1839" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_1820" xlink:to="loc_agle_AcquiredInProcessResearchAndDevelopment_1839" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_agle_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet_1842" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_1820" xlink:to="loc_agle_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet_1842" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_1843" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_1820" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_1843" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_NumberOfEmployeesRetained" xlink:label="loc_agle_NumberOfEmployeesRetained_1844" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_1820" xlink:to="loc_agle_NumberOfEmployeesRetained_1844" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_1845" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_1820" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_1845" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/presentationGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_1846" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_1820" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_1846" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_PlacementAgentAndOtherOfferingExpenses" xlink:label="loc_agle_PlacementAgentAndOtherOfferingExpenses_1847" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_1820" xlink:to="loc_agle_PlacementAgentAndOtherOfferingExpenses_1847" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1848" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_1820" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1848" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_1849" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_1820" xlink:to="loc_us-gaap_Cash_1849" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/AccruedLiabilitiesAccruedAndOtherCurrentLiabilitiesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_1950" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AccruedOptionCostPayable" xlink:label="loc_agle_AccruedOptionCostPayable_1951" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_1950" xlink:to="loc_agle_AccruedOptionCostPayable_1951" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_1952" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_1950" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_1952" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProgramRightsObligations" xlink:label="loc_us-gaap_ProgramRightsObligations_1953" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_1950" xlink:to="loc_us-gaap_ProgramRightsObligations_1953" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_1954" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_1950" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_1954" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/AccruedLiabilitiesAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_1956" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AccruedLiabilitiesTable" xlink:label="loc_agle_AccruedLiabilitiesTable_1957" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_1956" xlink:to="loc_agle_AccruedLiabilitiesTable_1957" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1963" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_AccruedLiabilitiesTable_1957" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1963" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1964" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1963" xlink:to="loc_us-gaap_RelatedPartyDomain_1964" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaap_RelatedPartyMember_1965" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_1964" xlink:to="loc_us-gaap_RelatedPartyMember_1965" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_1966" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_AccruedLiabilitiesTable_1957" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_1966" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_1967" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_1966" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_1967" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ParagonAgreementMember" xlink:label="loc_agle_ParagonAgreementMember_1968" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_1967" xlink:to="loc_agle_ParagonAgreementMember_1968" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AccruedLiabilitiesLineItems" xlink:label="loc_agle_AccruedLiabilitiesLineItems_1958" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_AccruedLiabilitiesTable_1957" xlink:to="loc_agle_AccruedLiabilitiesLineItems_1958" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_RelatedPartyExpensesIncurredPriorToAssetAcquisition" xlink:label="loc_agle_RelatedPartyExpensesIncurredPriorToAssetAcquisition_1959" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_AccruedLiabilitiesLineItems_1958" xlink:to="loc_agle_RelatedPartyExpensesIncurredPriorToAssetAcquisition_1959" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ResearchInitiationFees" xlink:label="loc_agle_ResearchInitiationFees_1960" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_AccruedLiabilitiesLineItems_1958" xlink:to="loc_agle_ResearchInitiationFees_1960" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ReimbursableResearchCosts" xlink:label="loc_agle_ReimbursableResearchCosts_1961" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_AccruedLiabilitiesLineItems_1958" xlink:to="loc_agle_ReimbursableResearchCosts_1961" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_RelatedPartyExpensesUnpaidPriorToAssetAcquisition" xlink:label="loc_agle_RelatedPartyExpensesUnpaidPriorToAssetAcquisition_1962" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_AccruedLiabilitiesLineItems_1958" xlink:to="loc_agle_RelatedPartyExpensesUnpaidPriorToAssetAcquisition_1962" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/ParapyreOptionObligationAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAbstract" xlink:label="loc_us-gaap_AssetAcquisitionAbstract_1870" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionTable" xlink:label="loc_us-gaap_AssetAcquisitionTable_1871" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAbstract_1870" xlink:to="loc_us-gaap_AssetAcquisitionTable_1871" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1874" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionTable_1871" xlink:to="loc_us-gaap_PlanNameAxis_1874" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1875" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_1874" xlink:to="loc_us-gaap_PlanNameDomain_1875" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ParapyreOptionObligationMember" xlink:label="loc_agle_ParapyreOptionObligationMember_1876" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1875" xlink:to="loc_agle_ParapyreOptionObligationMember_1876" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="loc_us-gaap_AssetAcquisitionLineItems_1872" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionTable_1871" xlink:to="loc_us-gaap_AssetAcquisitionLineItems_1872" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock" xlink:label="loc_agle_PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock_1873" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_1872" xlink:to="loc_agle_PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock_1873" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent" xlink:label="loc_us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent_1877" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_1872" xlink:to="loc_us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent_1877" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1040" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_SummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_agle_SummaryOfSignificantAccountingPoliciesTable_1044" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1040" xlink:to="loc_agle_SummaryOfSignificantAccountingPoliciesTable_1044" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1043" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_SummaryOfSignificantAccountingPoliciesTable_1044" xlink:to="loc_srt_RangeAxis_1043" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1041" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1043" xlink:to="loc_srt_RangeMember_1041" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1042" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1041" xlink:to="loc_srt_MaximumMember_1042" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_agle_SummaryOfSignificantAccountingPoliciesLineItems_1264" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_SummaryOfSignificantAccountingPoliciesTable_1044" xlink:to="loc_agle_SummaryOfSignificantAccountingPoliciesLineItems_1264" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_MarketableSecuritiesMaturityPeriod" xlink:label="loc_agle_MarketableSecuritiesMaturityPeriod_1045" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_SummaryOfSignificantAccountingPoliciesLineItems_1264" xlink:to="loc_agle_MarketableSecuritiesMaturityPeriod_1045" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_1265" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_SummaryOfSignificantAccountingPoliciesLineItems_1264" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_1265" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_NumberOfSubsidiaryCorporationsOwned" xlink:label="loc_agle_NumberOfSubsidiaryCorporationsOwned_1276" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_SummaryOfSignificantAccountingPoliciesLineItems_1264" xlink:to="loc_agle_NumberOfSubsidiaryCorporationsOwned_1276" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_1337" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_SummaryOfSignificantAccountingPoliciesLineItems_1264" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_1337" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_1342" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_SummaryOfSignificantAccountingPoliciesLineItems_1264" xlink:to="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_1342" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfUsefulLivesOfPropertyAndEquipmentDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1134" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1136" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1134" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1136" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1137" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1136" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1137" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1138" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1137" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1138" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_LaboratoryEquipmentMember" xlink:label="loc_agle_LaboratoryEquipmentMember_1139" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1138" xlink:to="loc_agle_LaboratoryEquipmentMember_1139" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_1229" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1138" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_1229" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_1299" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1138" xlink:to="loc_us-gaap_ComputerEquipmentMember_1299" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_PurchasedSoftwareMember" xlink:label="loc_agle_PurchasedSoftwareMember_1321" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1138" xlink:to="loc_agle_PurchasedSoftwareMember_1321" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_1354" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1138" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_1354" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1228" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1136" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1228" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_2007" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1228" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_2007" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentBasisOfValuation" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentBasisOfValuation_1227" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1228" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentBasisOfValuation_1227" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_457" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_458" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_457" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_458" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_459" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_458" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_459" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_460" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_459" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_460" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_461" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_460" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_461" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_462" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_458" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_462" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_463" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_462" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_463" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_464" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_463" xlink:to="loc_us-gaap_MoneyMarketFundsMember_464" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_465" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_463" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_465" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_466" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_458" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_466" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_467" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_466" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_467" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ParapyreOptionObligationMember" xlink:label="loc_agle_ParapyreOptionObligationMember_468" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_467" xlink:to="loc_agle_ParapyreOptionObligationMember_468" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ContingentValueRightLiabilityMember" xlink:label="loc_agle_ContingentValueRightLiabilityMember_469" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_467" xlink:to="loc_agle_ContingentValueRightLiabilityMember_469" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_470" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_458" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_470" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_471" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_470" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_471" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_472" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_471" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_472" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_473" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_471" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_473" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_474" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_471" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_474" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_475" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_458" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_475" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_476" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_475" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_476" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_477" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_476" xlink:to="loc_us-gaap_CommercialPaperMember_477" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_478" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_458" xlink:to="loc_us-gaap_InvestmentTypeAxis_478" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_479" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_478" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_479" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_480" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_479" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_480" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_481" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_458" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_481" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_482" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_481" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_482" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_483" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_482" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_483" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_484" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_481" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_484" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_485" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_484" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_485" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/FairValueMeasurementsNarrativeDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_487" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_488" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_487" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_488" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_489" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_488" xlink:to="loc_us-gaap_StatementClassOfStockAxis_489" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_490" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_489" xlink:to="loc_us-gaap_ClassOfStockDomain_490" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_SeriesANonVotingConvertiblePreferredStockMember" xlink:label="loc_agle_SeriesANonVotingConvertiblePreferredStockMember_491" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_490" xlink:to="loc_agle_SeriesANonVotingConvertiblePreferredStockMember_491" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_492" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_488" xlink:to="loc_us-gaap_PlanNameAxis_492" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_493" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_492" xlink:to="loc_us-gaap_PlanNameDomain_493" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ParapyreOptionObligationMember" xlink:label="loc_agle_ParapyreOptionObligationMember_494" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_493" xlink:to="loc_agle_ParapyreOptionObligationMember_494" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_495" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_488" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_495" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_496" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_495" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_496" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ContingentValueRightLiabilityMember" xlink:label="loc_agle_ContingentValueRightLiabilityMember_498" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_496" xlink:to="loc_agle_ContingentValueRightLiabilityMember_498" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="loc_us-gaap_AssetAcquisitionAxis_499" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_488" xlink:to="loc_us-gaap_AssetAcquisitionAxis_499" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaap_AssetAcquisitionDomain_500" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_499" xlink:to="loc_us-gaap_AssetAcquisitionDomain_500" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AssetAcquisitionMember" xlink:label="loc_agle_AssetAcquisitionMember_501" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_500" xlink:to="loc_agle_AssetAcquisitionMember_501" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_SpyreTherapeuticsIncMember" xlink:label="loc_agle_SpyreTherapeuticsIncMember_502" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_500" xlink:to="loc_agle_SpyreTherapeuticsIncMember_502" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_503" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_488" xlink:to="loc_srt_StatementScenarioAxis_503" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_504" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_503" xlink:to="loc_srt_ScenarioUnspecifiedDomain_504" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember" xlink:label="loc_srt_ScenarioForecastMember_505" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_504" xlink:to="loc_srt_ScenarioForecastMember_505" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_506" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_488" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_506" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_507" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_506" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_507" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForwardContractsMember" xlink:label="loc_us-gaap_ForwardContractsMember_508" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_507" xlink:to="loc_us-gaap_ForwardContractsMember_508" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_509" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_488" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_509" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_510" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_509" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_510" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares" xlink:label="loc_agle_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares_511" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_509" xlink:to="loc_agle_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares_511" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_512" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_509" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_512" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_513" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_509" xlink:to="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_513" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_514" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_509" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_514" use="optional" order="26" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock" xlink:label="loc_agle_PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock_515" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_509" xlink:to="loc_agle_PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock_515" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_516" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_509" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_516" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodFairValue" xlink:label="loc_agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodFairValue_517" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_509" xlink:to="loc_agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodFairValue_517" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_518" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_509" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_518" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_519" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_509" xlink:to="loc_us-gaap_ShareBasedCompensation_519" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AssetAcquisitionStockholderPaymentPeriod" xlink:label="loc_agle_AssetAcquisitionStockholderPaymentPeriod_520" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_509" xlink:to="loc_agle_AssetAcquisitionStockholderPaymentPeriod_520" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AssetAcquisitionCashPaymentThresholdPeriod" xlink:label="loc_agle_AssetAcquisitionCashPaymentThresholdPeriod_521" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_509" xlink:to="loc_agle_AssetAcquisitionCashPaymentThresholdPeriod_521" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_522" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_509" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_522" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_FairValueAssetsLevel1ToLevel2TransfersAmount1" xlink:label="loc_agle_FairValueAssetsLevel1ToLevel2TransfersAmount1_1163" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_509" xlink:to="loc_agle_FairValueAssetsLevel1ToLevel2TransfersAmount1_1163" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/FairValueMeasurementsChangesInDerivativeLiabilitiesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract_524" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_525" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract_524" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_525" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_526" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_525" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_526" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_527" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_526" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_527" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForwardContractsMember" xlink:label="loc_us-gaap_ForwardContractsMember_528" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_527" xlink:to="loc_us-gaap_ForwardContractsMember_528" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ContingentValueRightLiabilityMember" xlink:label="loc_agle_ContingentValueRightLiabilityMember_529" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_527" xlink:to="loc_agle_ContingentValueRightLiabilityMember_529" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_530" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_525" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_530" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_531" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_530" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_531" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_532" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_531" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_532" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_533" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_531" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_533" use="optional" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_534" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_531" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_534" use="optional" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_535" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_531" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_535" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_536" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_531" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_536" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/FairValueMeasurementsSignificantInputsUsedToEstimateTheFairValueOfDerivativeLiabilityDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_538" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_539" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_538" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_539" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_540" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_539" xlink:to="loc_srt_RangeAxis_540" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_541" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_540" xlink:to="loc_srt_RangeMember_541" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_542" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_541" xlink:to="loc_srt_MaximumMember_542" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_543" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_541" xlink:to="loc_srt_MinimumMember_543" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_544" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_539" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_544" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_545" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_544" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_545" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_546" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_545" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_546" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_547" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_539" xlink:to="loc_us-gaap_FinancialInstrumentAxis_547" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_548" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_547" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_548" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ContingentValueRightLiabilityMember" xlink:label="loc_agle_ContingentValueRightLiabilityMember_549" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_548" xlink:to="loc_agle_ContingentValueRightLiabilityMember_549" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_550" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_539" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_550" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_551" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_550" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_551" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_MeasurementInputProabilityOfSuccessMember" xlink:label="loc_agle_MeasurementInputProabilityOfSuccessMember_552" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_551" xlink:to="loc_agle_MeasurementInputProabilityOfSuccessMember_552" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_553" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_551" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_553" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_554" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_539" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_554" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_555" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_554" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_555" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_557" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_539" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_557" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="loc_us-gaap_DerivativeLiabilityMeasurementInput_558" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_557" xlink:to="loc_us-gaap_DerivativeLiabilityMeasurementInput_558" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesEstimatedFairValueOfCashEquivalentsAndMarketableSecuritiesAndTheGrossUnrealizedGainsAndLossesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_560" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_561" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_560" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_561" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_562" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_561" xlink:to="loc_us-gaap_FinancialInstrumentAxis_562" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_563" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_562" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_563" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_564" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_563" xlink:to="loc_us-gaap_MoneyMarketFundsMember_564" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_565" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_563" xlink:to="loc_us-gaap_CommercialPaperMember_565" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_566" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_563" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_566" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_567" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_563" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_567" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_568" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_561" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_568" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_569" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_568" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_569" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_CashEquivalentsUnrealizedGains" xlink:label="loc_agle_CashEquivalentsUnrealizedGains_570" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_568" xlink:to="loc_agle_CashEquivalentsUnrealizedGains_570" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_CashEquivalentsUnrealizedLosses" xlink:label="loc_agle_CashEquivalentsUnrealizedLosses_571" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_568" xlink:to="loc_agle_CashEquivalentsUnrealizedLosses_571" use="optional" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_572" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_568" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_572" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_573" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_568" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_573" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_574" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_568" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_574" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_575" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_568" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_575" use="optional" order="15" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_576" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_568" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_576" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesAvailableForSaleSecuritiesInAnUnrealizedLossPositionDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_578" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_579" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_578" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_579" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_580" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_579" xlink:to="loc_us-gaap_InvestmentTypeAxis_580" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_581" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_580" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_581" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_582" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_581" xlink:to="loc_us-gaap_CommercialPaperMember_582" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_583" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_581" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_583" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_584" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_581" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_584" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_585" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_579" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_585" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_586" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_585" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_586" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_587" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_586" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_587" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_588" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_586" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_588" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract" xlink:label="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_589" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_585" xlink:to="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_589" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_590" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_589" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_590" use="optional" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_591" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_589" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_591" use="optional" order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_592" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_585" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_592" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_593" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_585" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_593" use="optional" order="15" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesNarrativeDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_595" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_CashEquivalentsAndMarketableSecuritiesTable" xlink:label="loc_agle_CashEquivalentsAndMarketableSecuritiesTable_596" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_595" xlink:to="loc_agle_CashEquivalentsAndMarketableSecuritiesTable_596" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_597" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_CashEquivalentsAndMarketableSecuritiesTable_596" xlink:to="loc_us-gaap_FinancialInstrumentAxis_597" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_598" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_597" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_598" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_599" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_598" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_599" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_USBankingInstitutionMember" xlink:label="loc_agle_USBankingInstitutionMember_600" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_598" xlink:to="loc_agle_USBankingInstitutionMember_600" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_601" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_CashEquivalentsAndMarketableSecuritiesTable_596" xlink:to="loc_srt_RangeAxis_601" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_602" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_601" xlink:to="loc_srt_RangeMember_602" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_603" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_602" xlink:to="loc_srt_MaximumMember_603" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:label="loc_agle_CashEquivalentsAndMarketableSecuritiesLineItems_604" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_CashEquivalentsAndMarketableSecuritiesTable_596" xlink:to="loc_agle_CashEquivalentsAndMarketableSecuritiesLineItems_604" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_605" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_CashEquivalentsAndMarketableSecuritiesLineItems_604" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_605" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ImpairmentOfMarketableSecurities" xlink:label="loc_agle_ImpairmentOfMarketableSecurities_606" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_CashEquivalentsAndMarketableSecuritiesLineItems_604" xlink:to="loc_agle_ImpairmentOfMarketableSecurities_606" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_NumberOfDomesticBankingInstitutions" xlink:label="loc_agle_NumberOfDomesticBankingInstitutions_607" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_CashEquivalentsAndMarketableSecuritiesLineItems_604" xlink:to="loc_agle_NumberOfDomesticBankingInstitutions_607" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaap_CashFDICInsuredAmount_608" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_CashEquivalentsAndMarketableSecuritiesLineItems_604" xlink:to="loc_us-gaap_CashFDICInsuredAmount_608" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_609" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_CashEquivalentsAndMarketableSecuritiesLineItems_604" xlink:to="loc_us-gaap_Cash_609" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments" xlink:label="loc_us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments_610" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_CashEquivalentsAndMarketableSecuritiesLineItems_604" xlink:to="loc_us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments_610" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestReceivable" xlink:label="loc_us-gaap_InterestReceivable_611" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_CashEquivalentsAndMarketableSecuritiesLineItems_604" xlink:to="loc_us-gaap_InterestReceivable_611" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesContractualMaturitiesOfMarketableSecuritiesAtEstimatedFairValueDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_613" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_614" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_613" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_614" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne" xlink:label="loc_agle_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne_615" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_613" xlink:to="loc_agle_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne_615" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_616" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_613" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_616" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_1141" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1144" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_1141" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1144" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1143" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1144" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1143" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1145" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1143" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1145" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_LaboratoryEquipmentMember" xlink:label="loc_agle_LaboratoryEquipmentMember_1146" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1145" xlink:to="loc_agle_LaboratoryEquipmentMember_1146" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_1241" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1145" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_1241" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_1290" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1145" xlink:to="loc_us-gaap_ComputerEquipmentMember_1290" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_PurchasedSoftwareMember" xlink:label="loc_agle_PurchasedSoftwareMember_1326" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1145" xlink:to="loc_agle_PurchasedSoftwareMember_1326" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_1348" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1145" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_1348" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1240" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1144" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1240" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_1142" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1240" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_1142" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1239" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1240" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1239" use="optional" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1289" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1240" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_1289" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/PropertyAndEquipmentNetAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_1185" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1190" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_1185" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1190" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_1189" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1190" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_1189" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1188" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_1189" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1188" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentMember" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentMember_1187" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1188" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentMember_1187" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1218" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1190" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1218" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_1186" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1218" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_1186" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/AccruedAndOtherCurrentLiabilitiesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_618" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="loc_us-gaap_AccruedSalariesCurrent_619" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_618" xlink:to="loc_us-gaap_AccruedSalariesCurrent_619" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AccruedContractedResearchAndDevelopmentCosts" xlink:label="loc_agle_AccruedContractedResearchAndDevelopmentCosts_620" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_618" xlink:to="loc_agle_AccruedContractedResearchAndDevelopmentCosts_620" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_621" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_618" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_621" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_622" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_618" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_622" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_623" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_618" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_623" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/LeasesAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_1125" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ScheduleOfOperatingAndFinanceLeasedAssetsTable" xlink:label="loc_agle_ScheduleOfOperatingAndFinanceLeasedAssetsTable_1129" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1125" xlink:to="loc_agle_ScheduleOfOperatingAndFinanceLeasedAssetsTable_1129" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1131" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_ScheduleOfOperatingAndFinanceLeasedAssetsTable_1129" xlink:to="loc_srt_RangeAxis_1131" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1126" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1131" xlink:to="loc_srt_RangeMember_1126" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_1128" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1126" xlink:to="loc_srt_MinimumMember_1128" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1230" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1126" xlink:to="loc_srt_MaximumMember_1230" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_1231" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_ScheduleOfOperatingAndFinanceLeasedAssetsTable_1129" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_1231" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_1127" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_1231" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_1127" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LetterOfCreditMember" xlink:label="loc_us-gaap_LetterOfCreditMember_1130" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_1127" xlink:to="loc_us-gaap_LetterOfCreditMember_1130" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ScheduleOfOperatingAndFinanceLeasedAssetsLineItems" xlink:label="loc_agle_ScheduleOfOperatingAndFinanceLeasedAssetsLineItems_1297" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_ScheduleOfOperatingAndFinanceLeasedAssetsTable_1129" xlink:to="loc_agle_ScheduleOfOperatingAndFinanceLeasedAssetsLineItems_1297" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_1132" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_ScheduleOfOperatingAndFinanceLeasedAssetsLineItems_1297" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_1132" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeFinanceLeaseRenewalTerm1" xlink:label="loc_us-gaap_LesseeFinanceLeaseRenewalTerm1_1232" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_ScheduleOfOperatingAndFinanceLeasedAssetsLineItems_1297" xlink:to="loc_us-gaap_LesseeFinanceLeaseRenewalTerm1_1232" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AreaOfLand" xlink:label="loc_us-gaap_AreaOfLand_1298" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_ScheduleOfOperatingAndFinanceLeasedAssetsLineItems_1297" xlink:to="loc_us-gaap_AreaOfLand_1298" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseExpirationDate1" xlink:label="loc_us-gaap_LeaseExpirationDate1_1322" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_ScheduleOfOperatingAndFinanceLeasedAssetsLineItems_1297" xlink:to="loc_us-gaap_LeaseExpirationDate1_1322" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCredit" xlink:label="loc_us-gaap_LineOfCredit_1353" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_ScheduleOfOperatingAndFinanceLeasedAssetsLineItems_1297" xlink:to="loc_us-gaap_LineOfCredit_1353" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TenantImprovements" xlink:label="loc_us-gaap_TenantImprovements_1363" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_ScheduleOfOperatingAndFinanceLeasedAssetsLineItems_1297" xlink:to="loc_us-gaap_TenantImprovements_1363" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_1379" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_ScheduleOfOperatingAndFinanceLeasedAssetsLineItems_1297" xlink:to="loc_us-gaap_OperatingLeasePayments_1379" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/LeasesScheduleOfOperatingAndFinancingLeasesPresentedInBalanceSheetDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_1010" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_1011" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1010" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_1011" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_1273" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1010" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_1273" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_1340" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1010" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_1340" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_OperatingAndFinanceLeaseRightOfUseAsset" xlink:label="loc_agle_OperatingAndFinanceLeaseRightOfUseAsset_1341" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1010" xlink:to="loc_agle_OperatingAndFinanceLeaseRightOfUseAsset_1341" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_1371" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1010" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_1371" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_1391" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1010" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_1391" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_1392" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1010" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_1392" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1403" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1010" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1403" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_1411" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1010" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_1411" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_1412" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1010" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_1412" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_OperatingAndFinanceLeaseLiabilities" xlink:label="loc_agle_OperatingAndFinanceLeaseLiabilities_1419" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1010" xlink:to="loc_agle_OperatingAndFinanceLeaseLiabilities_1419" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/LeasesSummaryOfWeightedAverageRemainingLeaseTermAndDiscountRatesForOperatingAndFinanceLeasesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_1201" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_1202" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1201" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_1202" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_1215" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1201" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_1215" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_1308" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1201" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_1308" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_1315" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1201" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_1315" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/LeasesSummaryOfLeaseCostDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_1112" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost_1113" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1112" xlink:to="loc_us-gaap_OperatingLeaseCost_1113" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaap_VariableLeaseCost_1236" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1112" xlink:to="loc_us-gaap_VariableLeaseCost_1236" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaap_LeaseCost_1293" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1112" xlink:to="loc_us-gaap_LeaseCost_1293" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/LeasesScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_1056" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_1058" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1056" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_1058" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1059" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_1058" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1059" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1256" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_1058" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1256" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_1280" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_1058" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_1280" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1334" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_1058" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1334" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_1345" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_1058" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_1345" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_1369" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_1058" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_1369" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1663" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_1058" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1663" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1255" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1056" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1255" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_1060" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1255" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_1060" use="optional" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_1257" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1255" xlink:to="loc_us-gaap_OperatingLeaseLiability_1257" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_1279" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1056" xlink:to="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_1279" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_1057" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_1279" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_1057" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_1374" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_1279" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_1374" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiability" xlink:label="loc_us-gaap_FinanceLeaseLiability_1393" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_1279" xlink:to="loc_us-gaap_FinanceLeaseLiability_1393" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/StockholdersEquityAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_1160" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_1165" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_1160" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_1165" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1168" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1165" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_1168" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1164" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1168" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1164" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_FollowOnPublicOfferingMember" xlink:label="loc_agle_FollowOnPublicOfferingMember_1161" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1164" xlink:to="loc_agle_FollowOnPublicOfferingMember_1161" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AtTheMarketSalesAgreementMember" xlink:label="loc_agle_AtTheMarketSalesAgreementMember_1220" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1164" xlink:to="loc_agle_AtTheMarketSalesAgreementMember_1220" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_1302" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1164" xlink:to="loc_us-gaap_OverAllotmentOptionMember_1302" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1222" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1165" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1222" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1166" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1222" xlink:to="loc_us-gaap_EquityComponentDomain_1166" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1169" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1166" xlink:to="loc_us-gaap_CommonStockMember_1169" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_1303" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1165" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_1303" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_1167" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_1303" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_1167" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_JonesTradingInstitutionalServicesLimitedLiabilityCompanyMember" xlink:label="loc_agle_JonesTradingInstitutionalServicesLimitedLiabilityCompanyMember_1224" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_1167" xlink:to="loc_agle_JonesTradingInstitutionalServicesLimitedLiabilityCompanyMember_1224" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1318" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1165" xlink:to="loc_srt_RangeAxis_1318" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1162" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1318" xlink:to="loc_srt_RangeMember_1162" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1163" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1162" xlink:to="loc_srt_MaximumMember_1163" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_1356" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1165" xlink:to="loc_us-gaap_ClassOfStockLineItems_1356" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1170" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1356" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1170" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_1223" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1356" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_1223" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees" xlink:label="loc_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees_1319" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1356" xlink:to="loc_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees_1319" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_1357" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1356" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_1357" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AggregateOfferingPriceOfCommonStock" xlink:label="loc_agle_AggregateOfferingPriceOfCommonStock_1361" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1356" xlink:to="loc_agle_AggregateOfferingPriceOfCommonStock_1361" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_SharesAuthorized" xlink:label="loc_agle_SharesAuthorized_1384" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1356" xlink:to="loc_agle_SharesAuthorized_1384" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_1397" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1356" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_1397" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_1400" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1356" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_1400" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_1407" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1356" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_1407" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_1408" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1356" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_1408" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_NumberOfCommonStockVotingRightsHeldPerShare" xlink:label="loc_agle_NumberOfCommonStockVotingRightsHeldPerShare_1415" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1356" xlink:to="loc_agle_NumberOfCommonStockVotingRightsHeldPerShare_1415" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockVotingRights" xlink:label="loc_us-gaap_CommonStockVotingRights_1416" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1356" xlink:to="loc_us-gaap_CommonStockVotingRights_1416" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsCommonStock" xlink:label="loc_us-gaap_DividendsCommonStock_1422" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1356" xlink:to="loc_us-gaap_DividendsCommonStock_1422" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_1423" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1356" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_1423" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1427" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1356" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1427" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ClassOfWarrantOrRightOfferingPriceOfWarrantsOrRights" xlink:label="loc_agle_ClassOfWarrantOrRightOfferingPriceOfWarrantsOrRights_1430" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1356" xlink:to="loc_agle_ClassOfWarrantOrRightOfferingPriceOfWarrantsOrRights_1430" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1433" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1356" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1433" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1436" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1356" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1436" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_PlacementAgentFeesAndOfferingCosts" xlink:label="loc_agle_PlacementAgentFeesAndOfferingCosts_1439" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1356" xlink:to="loc_agle_PlacementAgentFeesAndOfferingCosts_1439" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_MaximumOwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercised" xlink:label="loc_agle_MaximumOwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercised_1443" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1356" xlink:to="loc_agle_MaximumOwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercised_1443" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_PeriodAfterNoticeReceivedByCompanyMaximumOwnershipPercentageToBeEffectiveDescription" xlink:label="loc_agle_PeriodAfterNoticeReceivedByCompanyMaximumOwnershipPercentageToBeEffectiveDescription_1444" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1356" xlink:to="loc_agle_PeriodAfterNoticeReceivedByCompanyMaximumOwnershipPercentageToBeEffectiveDescription_1444" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_OwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercisedToCertainHolders" xlink:label="loc_agle_OwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercisedToCertainHolders_1448" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1356" xlink:to="loc_agle_OwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercisedToCertainHolders_1448" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ProceedsFromIssuanceOfCommonStockGross" xlink:label="loc_agle_ProceedsFromIssuanceOfCommonStockGross_1450" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1356" xlink:to="loc_agle_ProceedsFromIssuanceOfCommonStockGross_1450" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/StockholdersEquitySummaryOfPreFundedWarrantsForCommonStockIssuedAndOutstandingDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1204" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1206" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1204" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1206" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1211" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1206" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1211" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1207" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1211" xlink:to="loc_us-gaap_EquityComponentDomain_1207" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_1208" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1207" xlink:to="loc_us-gaap_WarrantMember_1208" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaap_AwardDateAxis_1214" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1206" xlink:to="loc_us-gaap_AwardDateAxis_1214" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaap_AwardDateDomain_1209" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardDateAxis_1214" xlink:to="loc_us-gaap_AwardDateDomain_1209" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_FebruaryTwoThousandNinteenMember" xlink:label="loc_agle_FebruaryTwoThousandNinteenMember_1205" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardDateDomain_1209" xlink:to="loc_agle_FebruaryTwoThousandNinteenMember_1205" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AprilTwoThousandTwentyMember" xlink:label="loc_agle_AprilTwoThousandTwentyMember_1212" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardDateDomain_1209" xlink:to="loc_agle_AprilTwoThousandTwentyMember_1212" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_MayTwoThousandTwentyTwoMember" xlink:label="loc_agle_MayTwoThousandTwentyTwoMember_1310" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardDateDomain_1209" xlink:to="loc_agle_MayTwoThousandTwentyTwoMember_1310" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1312" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1206" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1312" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="loc_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_1210" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1312" xlink:to="loc_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_1210" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_WarrantExpirationDate" xlink:label="loc_agle_WarrantExpirationDate_1213" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1312" xlink:to="loc_agle_WarrantExpirationDate_1213" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1311" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1312" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1311" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_1314" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1312" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_1314" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/RelatedPartyTransactionsNarrativeDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_625" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_626" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_625" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_626" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis" xlink:label="loc_srt_OwnershipAxis_627" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_626" xlink:to="loc_srt_OwnershipAxis_627" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_628" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_627" xlink:to="loc_srt_OwnershipDomain_628" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ParagonTherapeuticsIncMember" xlink:label="loc_agle_ParagonTherapeuticsIncMember_629" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_628" xlink:to="loc_agle_ParagonTherapeuticsIncMember_629" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_FairmountFundsManagementLlcMember" xlink:label="loc_agle_FairmountFundsManagementLlcMember_630" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_628" xlink:to="loc_agle_FairmountFundsManagementLlcMember_630" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ParagonAndParapyreHoldingLlcMember" xlink:label="loc_agle_ParagonAndParapyreHoldingLlcMember_2008" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_628" xlink:to="loc_agle_ParagonAndParapyreHoldingLlcMember_2008" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_631" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_626" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_631" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_632" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_631" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_632" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_OwnershipInterestMember" xlink:label="loc_agle_OwnershipInterestMember_633" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_632" xlink:to="loc_agle_OwnershipInterestMember_633" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AppointOfBoardMember" xlink:label="loc_agle_AppointOfBoardMember_634" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_632" xlink:to="loc_agle_AppointOfBoardMember_634" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ParagonAgreementMember" xlink:label="loc_agle_ParagonAgreementMember_635" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_632" xlink:to="loc_agle_ParagonAgreementMember_635" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_StockCompensationAndResearchAndDevelopmentExpenseMember" xlink:label="loc_agle_StockCompensationAndResearchAndDevelopmentExpenseMember_636" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_632" xlink:to="loc_agle_StockCompensationAndResearchAndDevelopmentExpenseMember_636" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ReimbursableCostsUnderParagonAgreementMember" xlink:label="loc_agle_ReimbursableCostsUnderParagonAgreementMember_637" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_StockCompensationAndResearchAndDevelopmentExpenseMember_636" xlink:to="loc_agle_ReimbursableCostsUnderParagonAgreementMember_637" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_MilestonePaymentsMember" xlink:label="loc_agle_MilestonePaymentsMember_638" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_632" xlink:to="loc_agle_MilestonePaymentsMember_638" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicensingAgreementsMember" xlink:label="loc_us-gaap_LicensingAgreementsMember_639" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_632" xlink:to="loc_us-gaap_LicensingAgreementsMember_639" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_Spy001LicenseAgreementMember" xlink:label="loc_agle_Spy001LicenseAgreementMember_640" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_632" xlink:to="loc_agle_Spy001LicenseAgreementMember_640" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_641" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_626" xlink:to="loc_srt_RangeAxis_641" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_642" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_641" xlink:to="loc_srt_RangeMember_642" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_643" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_642" xlink:to="loc_srt_MaximumMember_643" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_644" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_642" xlink:to="loc_srt_MinimumMember_644" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_645" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_626" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_645" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_646" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_645" xlink:to="loc_us-gaap_RelatedPartyDomain_646" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaap_RelatedPartyMember_647" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_646" xlink:to="loc_us-gaap_RelatedPartyMember_647" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_648" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_626" xlink:to="loc_srt_CounterpartyNameAxis_648" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_649" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_648" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_649" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_652" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_626" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_652" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_653" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_652" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_653" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_RelatedPartyTransactionNumberOfBoardSeats" xlink:label="loc_agle_RelatedPartyTransactionNumberOfBoardSeats_654" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_652" xlink:to="loc_agle_RelatedPartyTransactionNumberOfBoardSeats_654" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_MinorityInterestOwnershipPercentageByNoncontrollingOwnersHeldInThirdParty" xlink:label="loc_agle_MinorityInterestOwnershipPercentageByNoncontrollingOwnersHeldInThirdParty_655" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_652" xlink:to="loc_agle_MinorityInterestOwnershipPercentageByNoncontrollingOwnersHeldInThirdParty_655" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_RelatedPartyExpensesIncurredPriorToAssetAcquisition" xlink:label="loc_agle_RelatedPartyExpensesIncurredPriorToAssetAcquisition_656" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_652" xlink:to="loc_agle_RelatedPartyExpensesIncurredPriorToAssetAcquisition_656" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ResearchInitiationFees" xlink:label="loc_agle_ResearchInitiationFees_657" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_652" xlink:to="loc_agle_ResearchInitiationFees_657" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ReimbursableResearchCosts" xlink:label="loc_agle_ReimbursableResearchCosts_658" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_652" xlink:to="loc_agle_ReimbursableResearchCosts_658" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_RelatedPartyExpensesUnpaidPriorToAssetAcquisition" xlink:label="loc_agle_RelatedPartyExpensesUnpaidPriorToAssetAcquisition_659" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_652" xlink:to="loc_agle_RelatedPartyExpensesUnpaidPriorToAssetAcquisition_659" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_660" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_652" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_660" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_661" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_652" xlink:to="loc_us-gaap_AccountsPayableCurrent_661" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_RelatedPartyTransactionNumberOfProgramOptionsOutstanding" xlink:label="loc_agle_RelatedPartyTransactionNumberOfProgramOptionsOutstanding_662" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_652" xlink:to="loc_agle_RelatedPartyTransactionNumberOfProgramOptionsOutstanding_662" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AmountToBePaidUnderAgreement" xlink:label="loc_agle_AmountToBePaidUnderAgreement_663" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_652" xlink:to="loc_agle_AmountToBePaidUnderAgreement_663" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock" xlink:label="loc_agle_PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock_664" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_652" xlink:to="loc_agle_PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock_664" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_665" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_652" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_665" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_666" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_652" xlink:to="loc_us-gaap_ShareBasedCompensation_666" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/RelatedPartyTransactionsExpensesRelatedToRelatedPartyWhichWereSettledInCashDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_668" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_669" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_668" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_669" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_670" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_669" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_670" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_671" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_670" xlink:to="loc_us-gaap_RelatedPartyDomain_671" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaap_RelatedPartyMember_672" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_671" xlink:to="loc_us-gaap_RelatedPartyMember_672" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_673" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_669" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_673" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_674" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_673" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_674" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ReimbursableCostsUnderParagonAgreementMember" xlink:label="loc_agle_ReimbursableCostsUnderParagonAgreementMember_675" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_674" xlink:to="loc_agle_ReimbursableCostsUnderParagonAgreementMember_675" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_676" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_669" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_676" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_677" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_676" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_677" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_678" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_677" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_678" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_679" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_669" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_679" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_RelatedPartyTransactionReimbursableCosts" xlink:label="loc_agle_RelatedPartyTransactionReimbursableCosts_680" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_679" xlink:to="loc_agle_RelatedPartyTransactionReimbursableCosts_680" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/RelatedPartyTransactionsRelatedPartyAccountsPayableDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_682" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_683" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_682" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_683" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_684" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_683" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_684" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_685" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_684" xlink:to="loc_us-gaap_RelatedPartyDomain_685" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaap_RelatedPartyMember_686" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_685" xlink:to="loc_us-gaap_RelatedPartyMember_686" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_687" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_683" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_687" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_688" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_687" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_688" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ReimbursableCostsUnderParagonAgreementMember" xlink:label="loc_agle_ReimbursableCostsUnderParagonAgreementMember_689" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_688" xlink:to="loc_agle_ReimbursableCostsUnderParagonAgreementMember_689" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ParapyreOptionObligationMember" xlink:label="loc_agle_ParapyreOptionObligationMember_690" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_688" xlink:to="loc_agle_ParapyreOptionObligationMember_690" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_691" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_683" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_691" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_692" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_691" xlink:to="loc_us-gaap_AccountsPayableCurrent_692" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/AssetAcquisitionNarrativeDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_694" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionTable" xlink:label="loc_us-gaap_AssetAcquisitionTable_695" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_694" xlink:to="loc_us-gaap_AssetAcquisitionTable_695" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_696" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionTable_695" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_696" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_697" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_696" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_697" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_698" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_697" xlink:to="loc_us-gaap_CommonStockMember_698" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_699" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionTable_695" xlink:to="loc_us-gaap_StatementClassOfStockAxis_699" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_700" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_699" xlink:to="loc_us-gaap_ClassOfStockDomain_700" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_SeriesANonVotingConvertiblePreferredStockMember" xlink:label="loc_agle_SeriesANonVotingConvertiblePreferredStockMember_701" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_700" xlink:to="loc_agle_SeriesANonVotingConvertiblePreferredStockMember_701" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_702" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionTable_695" xlink:to="loc_us-gaap_PlanNameAxis_702" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_703" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_702" xlink:to="loc_us-gaap_PlanNameDomain_703" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_Spyre2023EquityIncentivePlanMember" xlink:label="loc_agle_Spyre2023EquityIncentivePlanMember_704" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_703" xlink:to="loc_agle_Spyre2023EquityIncentivePlanMember_704" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="loc_us-gaap_AssetAcquisitionAxis_705" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionTable_695" xlink:to="loc_us-gaap_AssetAcquisitionAxis_705" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaap_AssetAcquisitionDomain_706" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_705" xlink:to="loc_us-gaap_AssetAcquisitionDomain_706" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_SpyreTherapeuticsIncMember" xlink:label="loc_agle_SpyreTherapeuticsIncMember_707" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_706" xlink:to="loc_agle_SpyreTherapeuticsIncMember_707" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="loc_us-gaap_AssetAcquisitionLineItems_708" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionTable_695" xlink:to="loc_us-gaap_AssetAcquisitionLineItems_708" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares" xlink:label="loc_agle_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares_709" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_708" xlink:to="loc_agle_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares_709" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_OutstandingAndUnexercisedStockOptions" xlink:label="loc_agle_OutstandingAndUnexercisedStockOptions_710" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_708" xlink:to="loc_agle_OutstandingAndUnexercisedStockOptions_710" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferred_711" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_708" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferred_711" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_712" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_708" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_712" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableSharesOfCommonStockOnAnAsConvertedBasis" xlink:label="loc_agle_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableSharesOfCommonStockOnAnAsConvertedBasis_713" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_708" xlink:to="loc_agle_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableSharesOfCommonStockOnAnAsConvertedBasis_713" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/AssetAcquisitionAssetAcquisitionCostDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_715" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionTable" xlink:label="loc_us-gaap_AssetAcquisitionTable_716" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_715" xlink:to="loc_us-gaap_AssetAcquisitionTable_716" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="loc_us-gaap_AssetAcquisitionAxis_717" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionTable_716" xlink:to="loc_us-gaap_AssetAcquisitionAxis_717" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaap_AssetAcquisitionDomain_718" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_717" xlink:to="loc_us-gaap_AssetAcquisitionDomain_718" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_SpyreTherapeuticsIncMember" xlink:label="loc_agle_SpyreTherapeuticsIncMember_719" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_718" xlink:to="loc_agle_SpyreTherapeuticsIncMember_719" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="loc_us-gaap_AssetAcquisitionLineItems_720" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionTable_716" xlink:to="loc_us-gaap_AssetAcquisitionLineItems_720" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_721" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_720" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_721" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_722" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_720" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_722" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AcquiredInProcessResearchAndDevelopment" xlink:label="loc_agle_AcquiredInProcessResearchAndDevelopment_723" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_720" xlink:to="loc_agle_AcquiredInProcessResearchAndDevelopment_723" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition_724" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_720" xlink:to="loc_us-gaap_CashAcquiredFromAcquisition_724" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AssumedLiabilities" xlink:label="loc_agle_AssumedLiabilities_725" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_720" xlink:to="loc_agle_AssumedLiabilities_725" use="optional" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferred_726" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_720" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferred_726" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/ParagonAgreementDetails">
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_CollaborativeArrangementAbstract" xlink:label="loc_agle_CollaborativeArrangementAbstract_728" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_729" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_CollaborativeArrangementAbstract_728" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_729" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_730" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_729" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_730" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_731" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_730" xlink:to="loc_us-gaap_RelatedPartyDomain_731" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaap_RelatedPartyMember_732" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_731" xlink:to="loc_us-gaap_RelatedPartyMember_732" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_733" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_729" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_733" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_734" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_733" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_734" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ParagonAgreementMember" xlink:label="loc_agle_ParagonAgreementMember_735" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_734" xlink:to="loc_agle_ParagonAgreementMember_735" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_Spy001LicenseAgreementMember" xlink:label="loc_agle_Spy001LicenseAgreementMember_736" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_734" xlink:to="loc_agle_Spy001LicenseAgreementMember_736" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_StockCompensationAndResearchAndDevelopmentExpenseMember" xlink:label="loc_agle_StockCompensationAndResearchAndDevelopmentExpenseMember_738" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_734" xlink:to="loc_agle_StockCompensationAndResearchAndDevelopmentExpenseMember_738" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_739" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_729" xlink:to="loc_us-gaap_PlanNameAxis_739" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_740" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_739" xlink:to="loc_us-gaap_PlanNameDomain_740" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ParapyreOptionObligationMember" xlink:label="loc_agle_ParapyreOptionObligationMember_741" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_740" xlink:to="loc_agle_ParapyreOptionObligationMember_741" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_742" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_729" xlink:to="loc_srt_RangeAxis_742" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_743" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_742" xlink:to="loc_srt_RangeMember_743" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_744" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_743" xlink:to="loc_srt_MaximumMember_744" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_745" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_729" xlink:to="loc_srt_CounterpartyNameAxis_745" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_746" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_745" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_746" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ParagonTherapeuticsIncMember" xlink:label="loc_agle_ParagonTherapeuticsIncMember_747" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_746" xlink:to="loc_agle_ParagonTherapeuticsIncMember_747" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_748" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_729" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_748" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ResearchInitiationFees" xlink:label="loc_agle_ResearchInitiationFees_749" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_748" xlink:to="loc_agle_ResearchInitiationFees_749" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_RelatedPartyExpensesIncurredPriorToAssetAcquisition" xlink:label="loc_agle_RelatedPartyExpensesIncurredPriorToAssetAcquisition_750" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_748" xlink:to="loc_agle_RelatedPartyExpensesIncurredPriorToAssetAcquisition_750" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ReimbursableResearchCosts" xlink:label="loc_agle_ReimbursableResearchCosts_751" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_748" xlink:to="loc_agle_ReimbursableResearchCosts_751" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_RelatedPartyExpensesUnpaidPriorToAssetAcquisition" xlink:label="loc_agle_RelatedPartyExpensesUnpaidPriorToAssetAcquisition_752" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_748" xlink:to="loc_agle_RelatedPartyExpensesUnpaidPriorToAssetAcquisition_752" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock" xlink:label="loc_agle_PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock_753" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_748" xlink:to="loc_agle_PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock_753" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_NonrefundableResearchInitiationFeeForOneProgramPaidInCash" xlink:label="loc_agle_NonrefundableResearchInitiationFeeForOneProgramPaidInCash_754" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_748" xlink:to="loc_agle_NonrefundableResearchInitiationFeeForOneProgramPaidInCash_754" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_755" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_748" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_755" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AmountToBePaidUnderAgreement" xlink:label="loc_agle_AmountToBePaidUnderAgreement_756" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_748" xlink:to="loc_agle_AmountToBePaidUnderAgreement_756" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_NominationFee" xlink:label="loc_agle_NominationFee_757" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_748" xlink:to="loc_agle_NominationFee_757" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_PaymentOfMilestone" xlink:label="loc_agle_PaymentOfMilestone_758" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_748" xlink:to="loc_agle_PaymentOfMilestone_758" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_LicenseAgreementMilestonePayments" xlink:label="loc_agle_LicenseAgreementMilestonePayments_759" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_748" xlink:to="loc_agle_LicenseAgreementMilestonePayments_759" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/SeriesANonVotingConvertiblePreferredStockDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_761" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_762" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_761" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_762" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_763" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_762" xlink:to="loc_us-gaap_StatementClassOfStockAxis_763" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_764" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_763" xlink:to="loc_us-gaap_ClassOfStockDomain_764" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_SeriesANonVotingConvertiblePreferredStockMember" xlink:label="loc_agle_SeriesANonVotingConvertiblePreferredStockMember_765" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_764" xlink:to="loc_agle_SeriesANonVotingConvertiblePreferredStockMember_765" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_766" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_762" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_766" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_767" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_766" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_767" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_768" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_767" xlink:to="loc_us-gaap_PrivatePlacementMember_768" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_769" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_762" xlink:to="loc_srt_RangeAxis_769" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_770" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_769" xlink:to="loc_srt_RangeMember_770" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_771" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_770" xlink:to="loc_srt_MinimumMember_771" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_772" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_770" xlink:to="loc_srt_MaximumMember_772" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_773" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_762" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_773" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_774" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_773" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_774" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AssetAcquisitionMember" xlink:label="loc_agle_AssetAcquisitionMember_775" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_774" xlink:to="loc_agle_AssetAcquisitionMember_775" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_776" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_762" xlink:to="loc_us-gaap_ClassOfStockLineItems_776" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_PreferredStockRemainsIssuedAndOutstandingPercentage" xlink:label="loc_agle_PreferredStockRemainsIssuedAndOutstandingPercentage_777" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_agle_PreferredStockRemainsIssuedAndOutstandingPercentage_777" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockRedemptionAmount" xlink:label="loc_us-gaap_PreferredStockRedemptionAmount_778" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_us-gaap_PreferredStockRedemptionAmount_778" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockRedemptionPricePerShare" xlink:label="loc_us-gaap_PreferredStockRedemptionPricePerShare_779" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_us-gaap_PreferredStockRedemptionPricePerShare_779" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleConversionRatio" xlink:label="loc_us-gaap_PreferredStockConvertibleConversionRatio_780" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_us-gaap_PreferredStockConvertibleConversionRatio_780" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_BeneficiallyHoldersOwnedPercentage" xlink:label="loc_agle_BeneficiallyHoldersOwnedPercentage_781" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_agle_BeneficiallyHoldersOwnedPercentage_781" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_agle_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_782" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_agle_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_782" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_783" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_783" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_784" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_784" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares" xlink:label="loc_agle_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares_785" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_agle_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares_785" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityPreFundedWarrantsForCommonStockIssuedAndOutstandingDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_842" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_843" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_842" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_843" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_844" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_843" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_844" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_845" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_844" xlink:to="loc_us-gaap_EquityComponentDomain_845" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_846" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_845" xlink:to="loc_us-gaap_WarrantMember_846" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaap_AwardDateAxis_847" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_843" xlink:to="loc_us-gaap_AwardDateAxis_847" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaap_AwardDateDomain_848" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardDateAxis_847" xlink:to="loc_us-gaap_AwardDateDomain_848" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_FebruaryEightTwoThousandNinteenMember" xlink:label="loc_agle_FebruaryEightTwoThousandNinteenMember_849" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardDateDomain_848" xlink:to="loc_agle_FebruaryEightTwoThousandNinteenMember_849" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AprilThirtyTwoThousandTwentyMember" xlink:label="loc_agle_AprilThirtyTwoThousandTwentyMember_850" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardDateDomain_848" xlink:to="loc_agle_AprilThirtyTwoThousandTwentyMember_850" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_MayTwentyTwoThousandTwentyTwoMember" xlink:label="loc_agle_MayTwentyTwoThousandTwentyTwoMember_851" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardDateDomain_848" xlink:to="loc_agle_MayTwentyTwoThousandTwentyTwoMember_851" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_852" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_843" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_852" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_853" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_852" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_853" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_854" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_852" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_854" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityStockAwardsGrantedDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_856" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_857" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_856" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_857" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_858" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_856" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_858" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1087" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1090" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1087" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1090" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1099" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1090" xlink:to="loc_us-gaap_PlanNameAxis_1099" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1103" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_1099" xlink:to="loc_us-gaap_PlanNameDomain_1103" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_TwoThousandAndFifteenEquityIncentivePlanMember" xlink:label="loc_agle_TwoThousandAndFifteenEquityIncentivePlanMember_1089" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1103" xlink:to="loc_agle_TwoThousandAndFifteenEquityIncentivePlanMember_1089" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_TwoThousandAndSixteenEquityIncentivePlanMember" xlink:label="loc_agle_TwoThousandAndSixteenEquityIncentivePlanMember_1242" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1103" xlink:to="loc_agle_TwoThousandAndSixteenEquityIncentivePlanMember_1242" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_TwoThousandAndEighteenEquityInducementPlanMember" xlink:label="loc_agle_TwoThousandAndEighteenEquityInducementPlanMember_1284" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1103" xlink:to="loc_agle_TwoThousandAndEighteenEquityInducementPlanMember_1284" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_TwoThousandAndFifteenAndTwoThousandAndSixteenEquityIncentivePlanAndTwoThousandAndEighteenEquityInducementPlanMember" xlink:label="loc_agle_TwoThousandAndFifteenAndTwoThousandAndSixteenEquityIncentivePlanAndTwoThousandAndEighteenEquityInducementPlanMember_1327" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1103" xlink:to="loc_agle_TwoThousandAndFifteenAndTwoThousandAndSixteenEquityIncentivePlanAndTwoThousandAndEighteenEquityInducementPlanMember_1327" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_TwoThousandAndSixteenEmployeeStockPurchasePlanMember" xlink:label="loc_agle_TwoThousandAndSixteenEmployeeStockPurchasePlanMember_1347" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1103" xlink:to="loc_agle_TwoThousandAndSixteenEmployeeStockPurchasePlanMember_1347" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_Spyre2023EquityIncentivePlanMember" xlink:label="loc_agle_Spyre2023EquityIncentivePlanMember_1998" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1103" xlink:to="loc_agle_Spyre2023EquityIncentivePlanMember_1998" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ParapyreOptionObligationMember" xlink:label="loc_agle_ParapyreOptionObligationMember_2002" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1103" xlink:to="loc_agle_ParapyreOptionObligationMember_2002" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1982" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1090" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1982" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1983" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1982" xlink:to="loc_us-gaap_EquityComponentDomain_1983" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1985" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1983" xlink:to="loc_us-gaap_CommonStockMember_1985" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_2003" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1090" xlink:to="loc_srt_StatementScenarioAxis_2003" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_2004" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_2003" xlink:to="loc_srt_ScenarioUnspecifiedDomain_2004" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember" xlink:label="loc_srt_ScenarioForecastMember_2005" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_2004" xlink:to="loc_srt_ScenarioForecastMember_2005" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="loc_us-gaap_AssetAcquisitionAxis_1979" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1090" xlink:to="loc_us-gaap_AssetAcquisitionAxis_1979" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaap_AssetAcquisitionDomain_1980" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_1979" xlink:to="loc_us-gaap_AssetAcquisitionDomain_1980" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AssetAcquisitionMember" xlink:label="loc_agle_AssetAcquisitionMember_1981" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_1980" xlink:to="loc_agle_AssetAcquisitionMember_1981" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1246" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1090" xlink:to="loc_srt_RangeAxis_1246" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1091" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1246" xlink:to="loc_srt_RangeMember_1091" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_1093" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1091" xlink:to="loc_srt_MinimumMember_1093" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1243" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1091" xlink:to="loc_srt_MaximumMember_1243" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1287" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1090" xlink:to="loc_us-gaap_AwardTypeAxis_1287" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1097" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1287" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1097" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaap_StockOptionMember_1096" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1097" xlink:to="loc_us-gaap_StockOptionMember_1096" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_NonQualifiedStockOptionsMember" xlink:label="loc_agle_NonQualifiedStockOptionsMember_1244" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1097" xlink:to="loc_agle_NonQualifiedStockOptionsMember_1244" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_1285" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1097" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_1285" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ServiceBasedAwardsMember" xlink:label="loc_agle_ServiceBasedAwardsMember_1328" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1097" xlink:to="loc_agle_ServiceBasedAwardsMember_1328" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1330" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1090" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1330" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1102" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1330" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1102" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_1088" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1102" xlink:to="loc_us-gaap_SubsequentEventMember_1088" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_1350" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1090" xlink:to="loc_us-gaap_VestingAxis_1350" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_1094" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_1350" xlink:to="loc_us-gaap_VestingDomain_1094" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_1366" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1090" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_1366" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_1092" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_1366" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_1092" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1095" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_1092" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1095" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_1377" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1090" xlink:to="loc_srt_TitleOfIndividualAxis_1377" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1104" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_1377" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1104" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_NonEmployeesMember" xlink:label="loc_agle_NonEmployeesMember_1101" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1104" xlink:to="loc_agle_NonEmployeesMember_1101" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_EmployeesAndNonEmployeesMember" xlink:label="loc_agle_EmployeesAndNonEmployeesMember_1247" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1104" xlink:to="loc_agle_EmployeesAndNonEmployeesMember_1247" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_NewChiefExecutiveOfficerMember" xlink:label="loc_agle_NewChiefExecutiveOfficerMember_1288" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1104" xlink:to="loc_agle_NewChiefExecutiveOfficerMember_1288" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1090" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_1098" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_1098" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1245" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1245" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_GranteesWithMoreThanFiveYearsVestingTermPercent" xlink:label="loc_agle_GranteesWithMoreThanFiveYearsVestingTermPercent_1286" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_agle_GranteesWithMoreThanFiveYearsVestingTermPercent_1286" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_MaximumVestingTermForMoreThanTenPercentGrantees" xlink:label="loc_agle_MaximumVestingTermForMoreThanTenPercentGrantees_1329" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_agle_MaximumVestingTermForMoreThanTenPercentGrantees_1329" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_1349" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_1349" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_1365" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_1365" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1376" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1376" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_agle_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance_1387" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_agle_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance_1387" use="optional" order="51" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_1394" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_1394" use="optional" order="52" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AnnualPercentageOfAdditionalSharesWhichEqualsToIssuedAndOutstandingShares" xlink:label="loc_agle_AnnualPercentageOfAdditionalSharesWhichEqualsToIssuedAndOutstandingShares_1402" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_agle_AnnualPercentageOfAdditionalSharesWhichEqualsToIssuedAndOutstandingShares_1402" use="optional" order="53" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant" xlink:label="loc_agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant_1405" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant_1405" use="optional" order="54" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1410" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1410" use="optional" order="55" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1413" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1413" use="optional" order="56" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1418" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1418" use="optional" order="57" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_1420" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_1420" use="optional" order="58" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_1425" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_1425" use="optional" order="59" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1431" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1431" use="optional" order="60" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAnnualFairMarketValuePerEmployee" xlink:label="loc_agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAnnualFairMarketValuePerEmployee_1432" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAnnualFairMarketValuePerEmployee_1432" use="optional" order="61" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalAnnualPercentageIncrease" xlink:label="loc_agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalAnnualPercentageIncrease_1438" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalAnnualPercentageIncrease_1438" use="optional" order="62" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1441" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1441" use="optional" order="63" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_1442" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_1442" use="optional" order="64" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_1445" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_1445" use="optional" order="65" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_1446" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_1446" use="optional" order="66" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1449" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1449" use="optional" order="67" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_1451" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_1451" use="optional" order="68" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_1453" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_1453" use="optional" order="69" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1454" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1454" use="optional" order="70" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1455" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1455" use="optional" order="71" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1456" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1456" use="optional" order="72" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1457" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1457" use="optional" order="73" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodOfFirstTwentyFivePercent" xlink:label="loc_agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodOfFirstTwentyFivePercent_1458" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodOfFirstTwentyFivePercent_1458" use="optional" order="74" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodOfRemainingSeventyFivePercent" xlink:label="loc_agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodOfRemainingSeventyFivePercent_1459" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodOfRemainingSeventyFivePercent_1459" use="optional" order="75" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsGrantedExercisablePeriod" xlink:label="loc_agle_ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsGrantedExercisablePeriod_1460" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_agle_ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsGrantedExercisablePeriod_1460" use="optional" order="76" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_MaximumNumberOfSharesPurchasedUnderEmployeeStockPurchasePlan" xlink:label="loc_agle_MaximumNumberOfSharesPurchasedUnderEmployeeStockPurchasePlan_1462" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_agle_MaximumNumberOfSharesPurchasedUnderEmployeeStockPurchasePlan_1462" use="optional" order="77" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1972" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1972" use="optional" order="78" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_1973" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_1973" use="optional" order="79" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1974" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1974" use="optional" order="80" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ClassOfWarrantOrRightOfferingPriceOfWarrantsOrRights" xlink:label="loc_agle_ClassOfWarrantOrRightOfferingPriceOfWarrantsOrRights_1975" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_agle_ClassOfWarrantOrRightOfferingPriceOfWarrantsOrRights_1975" use="optional" order="81" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1976" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1976" use="optional" order="82" preferredLabel="http://www.xbrl.org/2003/role/presentationGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1977" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1977" use="optional" order="83" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_PlacementAgentFeesAndOfferingCosts" xlink:label="loc_agle_PlacementAgentFeesAndOfferingCosts_1978" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_agle_PlacementAgentFeesAndOfferingCosts_1978" use="optional" order="84" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_OwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercised" xlink:label="loc_agle_OwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercised_1986" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_agle_OwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercised_1986" use="optional" order="85" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_OwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercisedToCertainHolders" xlink:label="loc_agle_OwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercisedToCertainHolders_1987" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_agle_OwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercisedToCertainHolders_1987" use="optional" order="86" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ClassOfWarrantOrRightRevisedOwnershipPercentagePeriodToTakeEffectAfterNotice" xlink:label="loc_agle_ClassOfWarrantOrRightRevisedOwnershipPercentagePeriodToTakeEffectAfterNotice_1988" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_agle_ClassOfWarrantOrRightRevisedOwnershipPercentagePeriodToTakeEffectAfterNotice_1988" use="optional" order="87" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1990" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1990" use="optional" order="88" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_1991" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_1991" use="optional" order="89" preferredLabel="http://www.xbrl.org/2003/role/presentationGuidance" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_StockOptionsGrantedToCertainMembersOfBoardOfDirectorsContingentOnStockholderApproval" xlink:label="loc_agle_StockOptionsGrantedToCertainMembersOfBoardOfDirectorsContingentOnStockholderApproval_1993" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_agle_StockOptionsGrantedToCertainMembersOfBoardOfDirectorsContingentOnStockholderApproval_1993" use="optional" order="90" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_StockBasedCompensationExpenseOnContingentAwards" xlink:label="loc_agle_StockBasedCompensationExpenseOnContingentAwards_1994" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_agle_StockBasedCompensationExpenseOnContingentAwards_1994" use="optional" order="91" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_1996" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_1996" use="optional" order="92" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_OutstandingAndUnexercisedStockOptions" xlink:label="loc_agle_OutstandingAndUnexercisedStockOptions_1997" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_agle_OutstandingAndUnexercisedStockOptions_1997" use="optional" order="93" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_1999" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_1999" use="optional" order="94" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_2000" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_2000" use="optional" order="95" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_2001" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_us-gaap_ShareBasedCompensation_2001" use="optional" order="96" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="loc_us-gaap_ProceedsFromStockPlans_2006" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1388" xlink:to="loc_us-gaap_ProceedsFromStockPlans_2006" use="optional" order="97" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquitySummaryOfEmployeeAndNonEmployeeStockOptionActivityDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1157" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1158" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1157" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1158" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1225" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1157" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1225" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1301" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1157" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1301" use="optional" order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1320" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1157" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1320" use="optional" order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1355" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1157" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1355" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_1362" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1157" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_1362" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1380" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1157" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1380" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1385" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1157" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1385" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1396" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1157" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1396" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1401" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1157" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1401" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_1406" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1157" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_1406" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1409" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1157" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1409" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_1414" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1157" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_1414" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1417" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1157" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1417" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1421" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1157" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1421" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_1424" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1157" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_1424" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1428" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1157" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1428" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_1429" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1157" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_1429" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_1434" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1157" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_1434" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1435" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1157" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1435" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquitySummaryOfEmployeeRestrictedStockActivityDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1193" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1194" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1193" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1194" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1198" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1194" xlink:to="loc_us-gaap_AwardTypeAxis_1198" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1196" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1198" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1196" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_1195" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1196" xlink:to="loc_us-gaap_RestrictedStockMember_1195" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_1217" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1194" xlink:to="loc_srt_TitleOfIndividualAxis_1217" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1191" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_1217" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1191" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_EmployeesMember" xlink:label="loc_agle_EmployeesMember_1199" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1191" xlink:to="loc_agle_EmployeesMember_1199" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1307" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1194" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1307" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1197" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1307" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1197" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1216" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1307" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1216" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1306" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1307" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1306" use="optional" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1316" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1307" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1316" use="optional" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1358" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1307" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1358" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1360" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1307" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1360" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1382" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1307" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1382" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1383" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1307" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1383" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_1398" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1307" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_1398" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1399" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1307" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1399" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityStockBasedCompensationExpenseDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1026" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1029" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1026" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1029" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1028" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1029" xlink:to="loc_us-gaap_PlanNameAxis_1028" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1034" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_1028" xlink:to="loc_us-gaap_PlanNameDomain_1034" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember" xlink:label="loc_agle_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember_1027" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1034" xlink:to="loc_agle_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember_1027" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1266" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1029" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1266" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1030" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1266" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1030" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1032" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1030" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1032" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/presentationGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1267" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1030" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1267" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_1275" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1029" xlink:to="loc_srt_TitleOfIndividualAxis_1275" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1035" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_1275" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1035" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_EmployeesMember" xlink:label="loc_agle_EmployeesMember_1033" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1035" xlink:to="loc_agle_EmployeesMember_1033" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_NonEmployeesMember" xlink:label="loc_agle_NonEmployeesMember_1268" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1035" xlink:to="loc_agle_NonEmployeesMember_1268" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1338" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1029" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1338" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_1031" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1338" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_1031" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityAssumptionsUsedToEstimateTheFairValueOfStockOptionsGrantedDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1065" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1068" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1065" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1068" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1067" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1068" xlink:to="loc_us-gaap_PlanNameAxis_1067" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1072" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_1067" xlink:to="loc_us-gaap_PlanNameDomain_1072" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_TwoThousandAndSixteenEmployeeStockPurchasePlanMember" xlink:label="loc_agle_TwoThousandAndSixteenEmployeeStockPurchasePlanMember_1251" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1072" xlink:to="loc_agle_TwoThousandAndSixteenEmployeeStockPurchasePlanMember_1251" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_TwoThousandAndSixteenEquityIncentivePlanMember" xlink:label="loc_agle_TwoThousandAndSixteenEquityIncentivePlanMember_1948" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1072" xlink:to="loc_agle_TwoThousandAndSixteenEquityIncentivePlanMember_1948" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1252" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1068" xlink:to="loc_us-gaap_AwardTypeAxis_1252" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1070" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1252" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1070" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1069" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1070" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1069" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1281" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1068" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1281" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1071" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1281" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1071" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1253" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1281" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1253" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1282" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1281" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1282" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1332" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1281" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1332" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/StrategicLicenseAgreementsNarrativeDetails">
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_LicenseAndCollaborationAgreementAbstract" xlink:label="loc_agle_LicenseAndCollaborationAgreementAbstract_885" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_886" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_LicenseAndCollaborationAgreementAbstract_885" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_886" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_887" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_886" xlink:to="loc_us-gaap_TypeOfArrangementAxis_887" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_888" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_887" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_888" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ImmedicaPharmaABMember" xlink:label="loc_agle_ImmedicaPharmaABMember_1131" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_888" xlink:to="loc_agle_ImmedicaPharmaABMember_1131" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_UniversityOfTexasAtAustinMember" xlink:label="loc_agle_UniversityOfTexasAtAustinMember_1415" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_888" xlink:to="loc_agle_UniversityOfTexasAtAustinMember_1415" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_890" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_886" xlink:to="loc_srt_RangeAxis_890" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_891" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_890" xlink:to="loc_srt_RangeMember_891" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_892" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_891" xlink:to="loc_srt_MaximumMember_892" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_1426" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_891" xlink:to="loc_srt_MinimumMember_1426" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_893" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_886" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_893" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_894" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_893" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_894" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_PeaceTrialAndBLAPackageMember" xlink:label="loc_agle_PeaceTrialAndBLAPackageMember_895" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_894" xlink:to="loc_agle_PeaceTrialAndBLAPackageMember_895" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_PIPTrialMember" xlink:label="loc_agle_PIPTrialMember_896" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_894" xlink:to="loc_agle_PIPTrialMember_896" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_LicenseAgreementsMember" xlink:label="loc_agle_LicenseAgreementsMember_897" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_894" xlink:to="loc_agle_LicenseAgreementsMember_897" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_PeacePhase3TrialAndDrugSupplyMember" xlink:label="loc_agle_PeacePhase3TrialAndDrugSupplyMember_898" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_894" xlink:to="loc_agle_PeacePhase3TrialAndDrugSupplyMember_898" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_899" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_886" xlink:to="loc_srt_ProductOrServiceAxis_899" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_900" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_899" xlink:to="loc_srt_ProductsAndServicesDomain_900" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaap_LicenseMember_901" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_900" xlink:to="loc_us-gaap_LicenseMember_901" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_905" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_886" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_905" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_NonRefundablePaymentReceived" xlink:label="loc_agle_NonRefundablePaymentReceived_906" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_905" xlink:to="loc_agle_NonRefundablePaymentReceived_906" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_PercentageOfPaymentForCostIncurredInPIPTrial" xlink:label="loc_agle_PercentageOfPaymentForCostIncurredInPIPTrial_907" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_905" xlink:to="loc_agle_PercentageOfPaymentForCostIncurredInPIPTrial_907" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_CostsIncurredInPerformingTheTrial" xlink:label="loc_agle_CostsIncurredInPerformingTheTrial_908" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_905" xlink:to="loc_agle_CostsIncurredInPerformingTheTrial_908" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_RateOfRevenueShare" xlink:label="loc_agle_RateOfRevenueShare_909" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_905" xlink:to="loc_agle_RateOfRevenueShare_909" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReimbursementFromLimitedPartnershipInvestment" xlink:label="loc_us-gaap_ReimbursementFromLimitedPartnershipInvestment_910" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_905" xlink:to="loc_us-gaap_ReimbursementFromLimitedPartnershipInvestment_910" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_UpfrontPayment" xlink:label="loc_agle_UpfrontPayment_911" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_905" xlink:to="loc_agle_UpfrontPayment_911" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ContractWithCustomerFullReimbursementOfCostsIncludedLiability" xlink:label="loc_agle_ContractWithCustomerFullReimbursementOfCostsIncludedLiability_912" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_905" xlink:to="loc_agle_ContractWithCustomerFullReimbursementOfCostsIncludedLiability_912" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_913" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_905" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_913" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_914" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_905" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_914" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AllocatedAmountOfTransactionPrice" xlink:label="loc_agle_AllocatedAmountOfTransactionPrice_915" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_905" xlink:to="loc_agle_AllocatedAmountOfTransactionPrice_915" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AllocationPriceTotal" xlink:label="loc_agle_AllocationPriceTotal_916" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_905" xlink:to="loc_agle_AllocationPriceTotal_916" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_917" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_905" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_917" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_918" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_905" xlink:to="loc_us-gaap_ContractWithCustomerLiability_918" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_919" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_905" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_919" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_920" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_905" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_920" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ResearchAgreementDate" xlink:label="loc_agle_ResearchAgreementDate_1130" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_905" xlink:to="loc_agle_ResearchAgreementDate_1130" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_LicenseAndSupplyAgreementDate" xlink:label="loc_agle_LicenseAndSupplyAgreementDate_1414" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_905" xlink:to="loc_agle_LicenseAndSupplyAgreementDate_1414" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AdditionalUpfrontPaymentAbilityToReceived" xlink:label="loc_agle_AdditionalUpfrontPaymentAbilityToReceived_1648" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_905" xlink:to="loc_agle_AdditionalUpfrontPaymentAbilityToReceived_1648" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_MilestonePaymentsExchangeRate" xlink:label="loc_agle_MilestonePaymentsExchangeRate_1686" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_905" xlink:to="loc_agle_MilestonePaymentsExchangeRate_1686" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaap_DeferredRevenue_1751" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_905" xlink:to="loc_us-gaap_DeferredRevenue_1751" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_1755" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_905" xlink:to="loc_us-gaap_DeferredRevenueCurrent_1755" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_NumberOfLicenseAgreements" xlink:label="loc_agle_NumberOfLicenseAgreements_1773" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_905" xlink:to="loc_agle_NumberOfLicenseAgreements_1773" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_MaximumFutureContingentLicensePayment" xlink:label="loc_agle_MaximumFutureContingentLicensePayment_1776" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_905" xlink:to="loc_agle_MaximumFutureContingentLicensePayment_1776" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AggregatePotentialMilestonePaymentsForReceiptOfRegulatoryApproval" xlink:label="loc_agle_AggregatePotentialMilestonePaymentsForReceiptOfRegulatoryApproval_1779" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_905" xlink:to="loc_agle_AggregatePotentialMilestonePaymentsForReceiptOfRegulatoryApproval_1779" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AggregatePotentialMilestonePaymentsForFinalRegulatoryApprovalOfSecondIndication" xlink:label="loc_agle_AggregatePotentialMilestonePaymentsForFinalRegulatoryApprovalOfSecondIndication_1782" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_905" xlink:to="loc_agle_AggregatePotentialMilestonePaymentsForFinalRegulatoryApprovalOfSecondIndication_1782" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_PaymentOfMilestone" xlink:label="loc_agle_PaymentOfMilestone_1785" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_905" xlink:to="loc_agle_PaymentOfMilestone_1785" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_PaymentOfAnnualLicenseFees" xlink:label="loc_agle_PaymentOfAnnualLicenseFees_1788" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_905" xlink:to="loc_agle_PaymentOfAnnualLicenseFees_1788" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/StrategicLicenseAgreementsChangesInContractLiabilitiesDetails">
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_LicenseAndCollaborationAgreementAbstract" xlink:label="loc_agle_LicenseAndCollaborationAgreementAbstract_922" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInContractWithCustomerLiabilityAbstract" xlink:label="loc_us-gaap_ChangeInContractWithCustomerLiabilityAbstract_923" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_LicenseAndCollaborationAgreementAbstract_922" xlink:to="loc_us-gaap_ChangeInContractWithCustomerLiabilityAbstract_923" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_924" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInContractWithCustomerLiabilityAbstract_923" xlink:to="loc_us-gaap_ContractWithCustomerLiability_924" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ContractWithCustomerLiabilityAdditions" xlink:label="loc_agle_ContractWithCustomerLiabilityAdditions_925" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInContractWithCustomerLiabilityAbstract_923" xlink:to="loc_agle_ContractWithCustomerLiabilityAdditions_925" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination_926" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInContractWithCustomerLiabilityAbstract_923" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination_926" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_927" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInContractWithCustomerLiabilityAbstract_923" xlink:to="loc_us-gaap_ContractWithCustomerLiability_927" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_1442" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInContractWithCustomerLiabilityAbstract_923" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_1442" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ContractWithCustomerLiabilityRevenueRecognizedIncludingAdditions" xlink:label="loc_agle_ContractWithCustomerLiabilityRevenueRecognizedIncludingAdditions_1477" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInContractWithCustomerLiabilityAbstract_923" xlink:to="loc_agle_ContractWithCustomerLiabilityRevenueRecognizedIncludingAdditions_1477" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ContractWithCustomerLiabilityDeductionsThroughContractsAcquired" xlink:label="loc_agle_ContractWithCustomerLiabilityDeductionsThroughContractsAcquired_1583" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInContractWithCustomerLiabilityAbstract_923" xlink:to="loc_agle_ContractWithCustomerLiabilityDeductionsThroughContractsAcquired_1583" use="optional" order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_1600" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInContractWithCustomerLiabilityAbstract_923" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_1600" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/SaleOfPegzilarginaseToImmedicaDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_929" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_930" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_929" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_930" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_931" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_930" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_931" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_932" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_931" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_932" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_933" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_932" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_933" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_934" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_930" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_934" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_935" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_934" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_935" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_GlobalRightsToPegzilarginaseMember" xlink:label="loc_agle_GlobalRightsToPegzilarginaseMember_936" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_935" xlink:to="loc_agle_GlobalRightsToPegzilarginaseMember_936" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_937" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_930" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_937" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:label="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_938" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_937" xlink:to="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_938" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_DisposalGroupIncludingDiscontinuedOperationContingentConsideration" xlink:label="loc_agle_DisposalGroupIncludingDiscontinuedOperationContingentConsideration_939" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_937" xlink:to="loc_agle_DisposalGroupIncludingDiscontinuedOperationContingentConsideration_939" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_940" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_937" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_940" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_941" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_937" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_941" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/DefinedContributionPlanAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_1173" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_1174" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_1173" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_1174" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/IncomeTaxesIncomeLossBeforeIncomeTaxExpenseByJurisdictionDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1106" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_1107" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1106" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_1107" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_1238" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1106" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_1238" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_1291" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1106" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_1291" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/IncomeTaxesAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1116" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_IncomeTaxesTable" xlink:label="loc_agle_IncomeTaxesTable_1121" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1116" xlink:to="loc_agle_IncomeTaxesTable_1121" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_1120" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_IncomeTaxesTable_1121" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_1120" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_1123" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_1120" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_1123" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_1294" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1123" xlink:to="loc_us-gaap_DomesticCountryMember_1294" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_1323" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1123" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_1323" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaap_ForeignCountryMember_1351" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1123" xlink:to="loc_us-gaap_ForeignCountryMember_1351" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodAxis" xlink:label="loc_us-gaap_TaxPeriodAxis_1235" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_IncomeTaxesTable_1121" xlink:to="loc_us-gaap_TaxPeriodAxis_1235" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaap_TaxPeriodDomain_1118" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodAxis_1235" xlink:to="loc_us-gaap_TaxPeriodDomain_1118" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarliestTaxYearMember" xlink:label="loc_us-gaap_EarliestTaxYearMember_1122" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_1118" xlink:to="loc_us-gaap_EarliestTaxYearMember_1122" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_IncomeTaxesLineItems" xlink:label="loc_agle_IncomeTaxesLineItems_1296" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_IncomeTaxesTable_1121" xlink:to="loc_agle_IncomeTaxesLineItems_1296" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1119" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_IncomeTaxesLineItems_1296" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_1119" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_IncreaseInValuationPrimarilyDueToOperationLosses" xlink:label="loc_agle_IncreaseInValuationPrimarilyDueToOperationLosses_1234" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_IncomeTaxesLineItems_1296" xlink:to="loc_agle_IncreaseInValuationPrimarilyDueToOperationLosses_1234" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_1295" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_IncomeTaxesLineItems_1296" xlink:to="loc_us-gaap_OperatingLossCarryforwards_1295" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_1324" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_IncomeTaxesLineItems_1296" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_1324" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_OperatingLossCarryforwardsExpirationYear" xlink:label="loc_agle_OperatingLossCarryforwardsExpirationYear_1352" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_IncomeTaxesLineItems_1296" xlink:to="loc_agle_OperatingLossCarryforwardsExpirationYear_1352" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_TaxCreditCarryforwardExpirationYear" xlink:label="loc_agle_TaxCreditCarryforwardExpirationYear_1364" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_IncomeTaxesLineItems_1296" xlink:to="loc_agle_TaxCreditCarryforwardExpirationYear_1364" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_PercentageOfNetOperatingLossUtilizedToOffsetTaxableIncome" xlink:label="loc_agle_PercentageOfNetOperatingLossUtilizedToOffsetTaxableIncome_1378" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_IncomeTaxesLineItems_1296" xlink:to="loc_agle_PercentageOfNetOperatingLossUtilizedToOffsetTaxableIncome_1378" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_NetOperatingLossAndCreditCarryforwards" xlink:label="loc_agle_NetOperatingLossAndCreditCarryforwards_1386" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_IncomeTaxesLineItems_1296" xlink:to="loc_agle_NetOperatingLossAndCreditCarryforwards_1386" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_1395" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_IncomeTaxesLineItems_1296" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_1395" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/IncomeTaxesSummaryOfDifferenceBetweenProvisionForIncomeTaxesAndAmountsComputedByApplyingStatutoryFederalIncomeTaxRateToIncomeBeforeIncomeTaxesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1080" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_IncomeTaxesTable" xlink:label="loc_agle_IncomeTaxesTable_1084" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1080" xlink:to="loc_agle_IncomeTaxesTable_1084" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_1083" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_IncomeTaxesTable_1084" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_1083" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_1085" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_1083" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_1085" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_1081" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1085" xlink:to="loc_us-gaap_DomesticCountryMember_1081" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_1248" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1085" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_1248" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_IncomeTaxesLineItems" xlink:label="loc_agle_IncomeTaxesLineItems_1250" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_IncomeTaxesTable_1084" xlink:to="loc_agle_IncomeTaxesLineItems_1250" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_1082" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_IncomeTaxesLineItems_1250" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_1082" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_1249" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_IncomeTaxesLineItems_1250" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_1249" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_IncomeTaxReconciliationTaxCostCredit" xlink:label="loc_agle_IncomeTaxReconciliationTaxCostCredit_1283" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_IncomeTaxesLineItems_1250" xlink:to="loc_agle_IncomeTaxReconciliationTaxCostCredit_1283" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_1331" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_IncomeTaxesLineItems_1250" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_1331" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_1346" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_IncomeTaxesLineItems_1250" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_1346" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1367" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_IncomeTaxesLineItems_1250" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_1367" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1047" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_IncomeTaxesTable" xlink:label="loc_agle_IncomeTaxesTable_1052" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1047" xlink:to="loc_agle_IncomeTaxesTable_1052" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_1051" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_IncomeTaxesTable_1052" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_1051" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_1053" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_1051" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_1053" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_1049" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1053" xlink:to="loc_us-gaap_DomesticCountryMember_1049" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_1259" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1053" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_1259" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_IncomeTaxesLineItems" xlink:label="loc_agle_IncomeTaxesLineItems_1261" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_IncomeTaxesTable_1052" xlink:to="loc_agle_IncomeTaxesLineItems_1261" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract_1050" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_IncomeTaxesLineItems_1261" xlink:to="loc_us-gaap_DeferredTaxAssetsNetAbstract_1050" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1054" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1050" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1054" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_1262" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1050" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_1262" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_1277" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1050" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_1277" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_1336" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1050" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_1336" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_1343" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1050" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_1343" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_1370" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1050" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_1370" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_1373" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1050" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_1373" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_1390" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1050" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_1390" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_1260" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_IncomeTaxesLineItems_1261" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_1260" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_1048" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_1260" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_1048" use="optional" order="17" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_1258" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_1260" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_1258" use="optional" order="18" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1309" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_IncomeTaxesLineItems_1261" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1309" use="optional" order="19" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_1335" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agle_IncomeTaxesLineItems_1261" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_1335" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/NetLossPerShareWeightedAverageEquityInstrumentsExcludedFromCalculationOfDilutedNetLossPerShareDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_1013" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1014" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1013" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1014" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1018" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1014" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1018" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1015" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1018" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1015" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1270" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1015" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1270" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_1017" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1015" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_1017" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_SeriesAConvertiblePreferredStockMember" xlink:label="loc_agle_SeriesAConvertiblePreferredStockMember_1789" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1015" xlink:to="loc_agle_SeriesAConvertiblePreferredStockMember_1789" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1271" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1014" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1271" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1016" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1271" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1016" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/NetLossPerShareScheduleOfReconciliationOfBasicAndDilutedNetLossPerShareDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_1109" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_1110" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1109" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_1110" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_WeightedAverageNumberOfSharesPreFundedWarrants" xlink:label="loc_agle_WeightedAverageNumberOfSharesPreFundedWarrants_1237" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1109" xlink:to="loc_agle_WeightedAverageNumberOfSharesPreFundedWarrants_1237" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1292" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1109" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1292" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1325" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1109" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1325" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/ReverseStockSplitAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_1913" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_1914" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_1913" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_1914" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_1915" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1914" xlink:to="loc_us-gaap_ClassOfStockLineItems_1915" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaap_StockholdersEquityReverseStockSplit_1916" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1915" xlink:to="loc_us-gaap_StockholdersEquityReverseStockSplit_1916" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_1917" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1915" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_1917" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/RestructuringChargesNarrativeDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_953" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_954" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_953" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_954" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_955" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_954" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_955" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_956" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_955" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_956" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_957" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_956" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_957" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_958" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_956" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_958" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_959" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_954" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_959" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_960" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_959" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_960" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaap_SeveranceCosts1_961" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_959" xlink:to="loc_us-gaap_SeveranceCosts1_961" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRestructuring" xlink:label="loc_us-gaap_PaymentsForRestructuring_962" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_959" xlink:to="loc_us-gaap_PaymentsForRestructuring_962" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_963" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_959" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_963" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_964" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_959" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_964" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_965" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_959" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_965" use="optional" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_OperatingLeaseTerminationFeeAmount" xlink:label="loc_agle_OperatingLeaseTerminationFeeAmount_966" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_959" xlink:to="loc_agle_OperatingLeaseTerminationFeeAmount_966" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_967" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_959" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss_967" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLeasehold" xlink:label="loc_us-gaap_ImpairmentOfLeasehold_968" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_959" xlink:to="loc_us-gaap_ImpairmentOfLeasehold_968" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/RestructuringChargesChangesInAccruedRestructuringBalanceDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_970" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_971" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_970" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_971" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_972" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_971" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_972" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_973" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_972" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_973" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_SeveranceLiabilityMember" xlink:label="loc_agle_SeveranceLiabilityMember_974" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_973" xlink:to="loc_agle_SeveranceLiabilityMember_974" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_975" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_971" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_975" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserve" xlink:label="loc_us-gaap_RestructuringReserve_976" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_975" xlink:to="loc_us-gaap_RestructuringReserve_976" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_977" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_975" xlink:to="loc_us-gaap_RestructuringCharges_977" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRestructuring" xlink:label="loc_us-gaap_PaymentsForRestructuring_978" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_975" xlink:to="loc_us-gaap_PaymentsForRestructuring_978" use="optional" order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserve" xlink:label="loc_us-gaap_RestructuringReserve_979" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_975" xlink:to="loc_us-gaap_RestructuringReserve_979" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/RestructuringChargesChargesRelatedToTheRestructuringActivitiesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_981" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_982" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_981" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_982" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_983" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_982" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_983" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_984" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_983" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_984" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_RestructuringActivitiesMember" xlink:label="loc_agle_RestructuringActivitiesMember_985" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_984" xlink:to="loc_agle_RestructuringActivitiesMember_985" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_986" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_982" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_986" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_987" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_986" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_987" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_988" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_987" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_988" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_989" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_987" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_989" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_990" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_982" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_990" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaap_SeveranceCosts1_991" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_990" xlink:to="loc_us-gaap_SeveranceCosts1_991" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_992" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_990" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_992" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_993" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_990" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_993" use="optional" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_994" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_990" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss_994" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCosts" xlink:label="loc_us-gaap_RestructuringCosts_995" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_990" xlink:to="loc_us-gaap_RestructuringCosts_995" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/SubsequentEventsAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_1882" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1883" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_1882" xlink:to="loc_us-gaap_SubsequentEventTable_1883" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1885" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1883" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1885" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1886" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1885" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1886" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_1887" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1886" xlink:to="loc_us-gaap_SubsequentEventMember_1887" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="loc_us-gaap_AssetAcquisitionAxis_1889" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1883" xlink:to="loc_us-gaap_AssetAcquisitionAxis_1889" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaap_AssetAcquisitionDomain_1890" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_1889" xlink:to="loc_us-gaap_AssetAcquisitionDomain_1890" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_SpyreTherapeuticsIncMember" xlink:label="loc_agle_SpyreTherapeuticsIncMember_1891" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_1890" xlink:to="loc_agle_SpyreTherapeuticsIncMember_1891" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1892" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1883" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1892" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1893" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1892" xlink:to="loc_us-gaap_ClassOfStockDomain_1893" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_SeriesANonVotingConvertiblePreferredStockMember" xlink:label="loc_agle_SeriesANonVotingConvertiblePreferredStockMember_1894" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1893" xlink:to="loc_agle_SeriesANonVotingConvertiblePreferredStockMember_1894" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_1895" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1883" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_1895" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_1896" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_1895" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_1896" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1897" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_1896" xlink:to="loc_us-gaap_CommonStockMember_1897" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1901" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1883" xlink:to="loc_srt_RangeAxis_1901" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1902" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1901" xlink:to="loc_srt_RangeMember_1902" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1903" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1902" xlink:to="loc_srt_MaximumMember_1903" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_1904" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1902" xlink:to="loc_srt_MinimumMember_1904" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1906" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1883" xlink:to="loc_us-gaap_PlanNameAxis_1906" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1907" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_1906" xlink:to="loc_us-gaap_PlanNameDomain_1907" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_ParapyreOptionObligationMember" xlink:label="loc_agle_ParapyreOptionObligationMember_1908" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1907" xlink:to="loc_agle_ParapyreOptionObligationMember_1908" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_1884" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1883" xlink:to="loc_us-gaap_SubsequentEventLineItems_1884" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares" xlink:label="loc_agle_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares_1888" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1884" xlink:to="loc_agle_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares_1888" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_1898" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1884" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_1898" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaap_StockholdersEquityReverseStockSplit_1899" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1884" xlink:to="loc_us-gaap_StockholdersEquityReverseStockSplit_1899" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_1900" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1884" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_1900" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1905" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1884" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1905" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/NovationOfManufacturingAgreementsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_997" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_OtherCommitmentRightToTerminateAgreementOrWorkOrderPriorWrittenNoticePeriod" xlink:label="loc_agle_OtherCommitmentRightToTerminateAgreementOrWorkOrderPriorWrittenNoticePeriod_998" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_997" xlink:to="loc_agle_OtherCommitmentRightToTerminateAgreementOrWorkOrderPriorWrittenNoticePeriod_998" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_OtherCommitmentRightToTerminateWorkOrderReasonableCausePriorWrittenNoticePeriod" xlink:label="loc_agle_OtherCommitmentRightToTerminateWorkOrderReasonableCausePriorWrittenNoticePeriod_999" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_997" xlink:to="loc_agle_OtherCommitmentRightToTerminateWorkOrderReasonableCausePriorWrittenNoticePeriod_999" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_OtherCommitmentRightToTerminateWorkOrderByCounterpartyReasonableCauseTerminationAmountPayable" xlink:label="loc_agle_OtherCommitmentRightToTerminateWorkOrderByCounterpartyReasonableCauseTerminationAmountPayable_1000" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_997" xlink:to="loc_agle_OtherCommitmentRightToTerminateWorkOrderByCounterpartyReasonableCauseTerminationAmountPayable_1000" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_OtherCommitmentRightToTerminateWorkOrderMaterialBreachUncuredPeriod" xlink:label="loc_agle_OtherCommitmentRightToTerminateWorkOrderMaterialBreachUncuredPeriod_1001" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_997" xlink:to="loc_agle_OtherCommitmentRightToTerminateWorkOrderMaterialBreachUncuredPeriod_1001" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_OtherCommitmentRightToTerminateWorkOrderUnusualOrInfrequentCausePeriod" xlink:label="loc_agle_OtherCommitmentRightToTerminateWorkOrderUnusualOrInfrequentCausePeriod_1002" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_997" xlink:to="loc_agle_OtherCommitmentRightToTerminateWorkOrderUnusualOrInfrequentCausePeriod_1002" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_OtherCommitmentNonRefundableLicenseFeeAmount" xlink:label="loc_agle_OtherCommitmentNonRefundableLicenseFeeAmount_1003" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_997" xlink:to="loc_agle_OtherCommitmentNonRefundableLicenseFeeAmount_1003" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_OtherCommitmentRoyaltyPercentage" xlink:label="loc_agle_OtherCommitmentRoyaltyPercentage_1004" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_997" xlink:to="loc_agle_OtherCommitmentRoyaltyPercentage_1004" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_OtherCommitmentRightToTerminateAgreementPriorWrittenNoticePeriod" xlink:label="loc_agle_OtherCommitmentRightToTerminateAgreementPriorWrittenNoticePeriod_1005" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_997" xlink:to="loc_agle_OtherCommitmentRightToTerminateAgreementPriorWrittenNoticePeriod_1005" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_OtherCommitmentRightToTerminateAgreementByCounterpartyMaterialBreachUncuredPeriod" xlink:label="loc_agle_OtherCommitmentRightToTerminateAgreementByCounterpartyMaterialBreachUncuredPeriod_1006" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_997" xlink:to="loc_agle_OtherCommitmentRightToTerminateAgreementByCounterpartyMaterialBreachUncuredPeriod_1006" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="agle-20230930.xsd#agle_OtherCommitmentRightToTerminateAgreementByCounterpartyPaymentsNotReceivedPeriod" xlink:label="loc_agle_OtherCommitmentRightToTerminateAgreementByCounterpartyPaymentsNotReceivedPeriod_1007" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_997" xlink:to="loc_agle_OtherCommitmentRightToTerminateAgreementByCounterpartyPaymentsNotReceivedPeriod_1007" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>40
<FILENAME>g518298dsp01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g518298dsp01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1"617AI9@  34T *@    @ ! $[  (
M   ,   (2H=I  0    !   (5IR=  $    8   0=NH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $Q!3$E4($M5
M34%2   !ZAP !P  " P   AH     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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E<@4445)H%%%% !1110 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>41
<FILENAME>g518298dsp085.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g518298dsp085.jpg
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M'Q\?'Q\?'Q__P  1" -P FX# 1$  A$! Q$!_\0 O  !  (# 0$!
M      0% 0(#!@<( 0$! 0$! 0               0($ P40  (! P($ @8#
M#00'!04&!P$" P 1!!(%(3$3!D$B46$R%!4'<:$C@9'10E*2,Y/35-155K*4
M-1:Q8G)3<R25P8)#-!?PX<(E-O&BTK/#=+1UX@ACHV41 0 " @(! @0"" 8#
M       !$0(#(1($,4%1(C(387'P@9&AT4(4!;'!4B,S).'Q8O_:  P# 0 "
M$0,1 #\ _5- H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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M9A$B\D)UV]0!LH^XM2QZ##[!VB*S3EYV'@Q.G[W ?52U76-L>TXP'1QD4CQ
M%_JI8EI#$@ 1%4#D !4&]J!0*!0*!08,:-[2@_2*")/L^V3BTN-&P]!%!3YG
M86PS ].(P.?QHR1_HJV//9_RZW. F3;LGJ$<;-Y6_.732T>7W/9=SP]3;CMH
M?\J51YN'CU(]#?G TM6D&+"FV3XJ@+.F1%DX8F97'70ZC'<A0=2@CE51HV_3
MOE/C[G)EQQRVD9U0=168W8!6U7\/,G'T4%3GS;1#!DXV&SY.7E:+.R. EFU,
MQ)%WD;E8#Z:"QR<+%BV_'DSL5(LQI&;'B92?(XO:4#G]H?+>@Y8*[?FGIYF/
M"\+*09H457C8$@&RVL.?/GX4&,.*3#]]VPS231XK 1!UT(M[W*WYDWXT%QG8
M>]8FVG?H947"QY422$7$EP3YE(!\;6H+_:<H2)#*X0'(#,P96==: )J(!N2;
MM?1P%ZE"K[DW5\/!:: 7:8F-2=0.D'0%(\RZ;:>7FX<:1 C9N!O_ &[+M\^7
MD)DIGK940D%2=)*L;6((X$^-%>BQYA'CS:@!H173R$VU R )<W3SV;S\#4F$
M4.]9&=+FX>TX3*DN:Z@2$L!J;SZVN#Q )Y>6K )!NVT[[)LF=(F29$5M:!M&
MEQH'D%C=6/  _33U%^TP.'I8^9I&BU%?,03H:[J=/L  CVA4'GQ#N^_;^=JP
M)H\;HQM*7;4R  @$!2-7%A?CQO6AG9,K/,V3@Y1U3;>[WE6[6>.[:D/ "]^+
M'A02NZ,W'Q]N^W1M&0B1P11J%+,K+(5!)T@6!)?E;[@K(\_B;6W<*]))$QG1
M3[M&HD=7E9E!U3/87"+91I%6AQV1,MM[DP)(EBP=;01Q65"H7AJU<#J\2:HJ
MMVV/.@W*?&R=R2+$0E2 3UM*^ B Y_50>IWGJKL6S[7CQZ+0LXB/-);]2,L?
MRW3G]-!62&?%VN'KP*\;W:-66;6B,;E-49L4O<B_+E4F! @R</.F*XMX<KRA
M(->M943B5C<Z65["X1AQ\#?A5''.?3W%M&K5I?,/0#'S &)N?$4'WS9/TF9_
MMI_^6M95:4"@4"@4"@4"@4"@4"@A;U_@^;_P)/[)H/D7S$)_S5MZ@CS0R>0G
M@?(_'3K%_P P_2*6BEW#;7ES8H3">C!'"CQCA91")R/5J=R:U"JK:<+<\O*;
M.R<AX,>$A41"P5;\0D:"W(54>]GW;&S=MALKG<440.[ :64GV[C\8C@:@@Y>
MWB7<472LZC3I=CR4#DWJ%!VR8E:9,^9S/&I!CL-*EH^ 4CPC\#ZJ"#N![DW6
M>#)C!3'-T;&!U8RB.UPH(MHL?$7H)O:NU8F)O&9)C(7PXED65EXA!D+9(Q].
MG5]%O34D7SQ09L0D"%H"H$AL=4?C]GK))&E0&%CXU+%/B]J8$65&_G=T(ZD*
MJ]Q?@VG@0"I;APXB]+%VLT.#;WA(Q(]BB* 8QY;H08R+D/S/HX4$?<=JCS8'
MCT%H93:*8B[GV5M(+LW  E384L0MM[=P\:9IL<&<GD7#!0>8+F0$:2IN03SJ
MV+9,K$Q[8TP/5/"1D&EEX^?1I-A?2MAR^_457;GL,.5&HR4Z13S:T4E2NGVK
M*2P8LUF\U+0VS8X,.-ABH'))(GD46L!>P#CS/J2PL>5+%D<C$R <6%3J]E38
MW;D$62S6("DZJ"HW'MS&R<A9W7HS*19+'3K#%[!T\ND* 1Q(\*MBBS!#,9H7
MG.,QE,BR):]E(!7[M6 ??,K)PPFX8MLA(Q"V3&8M;A!8'B>#%>!/&@UQY<9L
M$O(FC)1@$A4HVE!P!=QQT?\ Q4$V6&60A1%DRLH!90"[J+7'"Q:U!+P>SY,Y
ME>>=HXF(86CDZS<?94.!YOJI8]]A=F;2N <>:'SN  ^J[H!R ?F3QX^NI:KG
M V[&P<:/'QU"K&H758!FL+78CF:@DT"@4"@4"@4"@4"@4"@4"@UDBCD4I(H=
M3S5@"/O&@HLCLK8Y,;+B2$+)DG4)39C&RFZZ >  /A2QX/<^PTAR'"R&.506
M?&D5G5O'7"]^*_ZO,<JL2BLPQGXQ)=,E!>R,^J/CP%@'LW,VX5H:YY*R2>2[
MCRJK:22Y%].IK^8$7#>BH.6#NDV''JBVQ6RB=8$CQ-$C\S9CY[7'*@CX\F0=
M>7N&3)+F3,>O&Q4H 2S72Q/"@NI=H?<#&9<FV&I#>[%[(;&Y;1PNPO?Z*ECT
M&$F/@B,/K@B4!8[,Z,ZG@TBGCIOI%@.!O4L1MRP8,V"3J#7%8M'(+E%D8%S'
MR1026L&YFK8J,7MI$R8WR,GWI(AHAC+]32;#2$!MI#%=/#D:6/1Q/! KPS$Q
M22 J82S@+^*H;5KU#0Y)OXU)D5>[[/%FJLC2=.8,.CDO<!T#&SJS6TA0O$ 6
MXT'#:NWQ#E-/([9V6X\I+F1S^*=3@JPT<#5L7@GQ^AT!,>LMGU%FL&'GMH(/
M'6=-_1QJ"BW/M]9,E9X9&P\JQ$GG,<E[!>#GS'7Q(X5;'?9]FAPHWT_:N2?>
M,E+E54FYDNA\Q96) (MPI8X=VXL>7C19* O%A&1LBSDWB?3"Y4'CJ70KV]1%
M2!71[+-FS1384PG@C0*((S8IH%R+7_&YW\:T.\A7<GCD>,)E1!8Y)N2-&.(!
M!_']?C0<\N!'R(\E8EG=0$2:0>92O :A>QM03A)AKNH?<9'FQDT3F5.+F6/F
M./I/"BO/]U39VYO+F8>5*K)=EQPQC*(#^*%X$**(\O"N5D+#N)'3RXVD2:0#
M2&,0#QR\+6/I]?&@N<S#,7<&VY1N1-F@V-V*]2%FT@WX6)J6/NVQ^WE_[:?_
M ):U%6M H% H% H% H% H% H(6^$#9LXGD()#_\ =-!\K[F?+W+<QF;7@SY+
MX^J"+) +1ZQY9-,9NETU6UOR\!XU814[)D;CA9A;*U9#!RTF.H,S.3S,DC6!
M)\3<U1:;GC;3(N(FWWB=F8SXA;649B.3#@;T$+WB3$S2C )$K:-)''Z:*Q!F
M0+FR('ZG3LK$<5*V'F]=Z(G2YZ(H;I]1<D\2W((#["@<!0>>WGN3<<C; R$P
M11Y)AG@0:5CC*W06'($W^DT'K^R9\.78)(D6SG( R&YZNJ;JWYG#[E25>JQ^
MPMNB1.ET4T@:=,-K<+?EU!V_R7!P^U2XM8](_B\OQ_"@XS?+[;)S>98)#>_F
M@OQ_/H.B=C8:>PT2>%UA(X W\']-!O\ Y+@_WJ>/_A'\;G^/XU*$=_EWM+R"
M1T@:0<G,%SQ_[]4=D[(Q4%DDC4<381$"Y%C^/Z*#)[*QV!5I(RIL+&(D<!8?
MCU!P7Y>;4CET2!7/-A!8_P!NJ.W^2,8+I65%4  !8B+!>(L-=N%!7-\K\1M5
M\^0LQNS:!^&EC4?*O!'$9KWMPNEQ][55L;1_*_&C-UW!Q>]_LQQ!Y@^:Q%+%
ME@=CX>,B=;(DR)(P%CDLJ%5'XO#C:EB\Q<#&QN,:DO:QD8EG/_>-Z@DT"@4"
M@4"@4"@4"@4"@4"@4"@4"@Y9&-!D1F.:-9$/XK"]!3Y'9^UOK>#5CY#FZS@A
MV4^K7JI8JI/EO#(VM]QD9O24'_8:6.;?+##9M1SI-5K7T_\ ]5+&&^5N"Z:9
M,V1O^X.7WZMB9!V&L(LFX2>JZ\O#@ P%0:9/R]@R01-G2L"2W.0<2;D\)!0;
MP]AK"H6/<)E500!=R!>U^<A]%!T'9;AF9=PD!<W8A2+W%N/GH(LWRWQ)I%DD
MS92Z^R;R"UN'A)ZJ"3'V2T?!=QEMPX-J;D"/%SZ: .R"(^F-PD"?D@,!P.K\
MOTT$8?+?$$W6&;-U?RM4G[2@D_Y);04.XRLIO<,&/,W\7H,2=C]1-#[A+IXV
M U"UP ;6<>BH/*=U0XG;V%/@+,TDD\;+CW)+&61KL/,6-E4ZCZJL(\9M+SX\
M<DL9959.C"!?4SW&G3;\FW.M"]CFFZL<63'J>1-64OY+7)!-N36YT'#<]TA$
M8FD5@H.F_$%C]'C?T^%%=)]S\@BQRK"W48%;F[<Q?T+0;XF' ^;BG)D]UBDL
M9'Y64\[#UT1)W2#;XL?W3;8NA'9@&D7J"0/P8EUNO$<*"G3;<R.;%.9B9$\.
M%()<=XO-("JD#B 1.H!]G@_H)Y4H?7.U,W'S8,C)QW$D,AC9'4W!!B4\.7IK
M*KV@4"@4"@4"@4"@4"@4$+>_\'SO^!)_9-!\R[ODRMNW&1]IR7Q,EXQ/)$CZ
M4DMY ^B_M+P#&W$<^56$4.'W]N>=@F;<-&4()%CS,=EX'7P62-EXJ>%CX518
MC*4*\,4*^7[1)E!#:2+C5]PT$3.FS)9\9$B6VM2[M?4NKAQ;T4&,>1,;),,D
M2J691J4@NI' L'MX^B@N(FR\E<G&Q!')!$#),T@UR!;VN HU'[E!7C=]FQG9
M]RVY9U*].3(D;W?6GY)3CU/5PO0;X.;L/OL)[:3*]]9T"8D@#120E_/JX JL
M8)9)&Y'AQO:I(^S17Z:WX<!45M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0* >5!\K[JQLO9]XRMTW7;TW+#R)
M 8,R0L5ACL!T65?T8U#5KY-X\A2$1TWV3)5?=<;&@D;RQH(Q&X!Y!9.-:&F;
MA[EMF*N1DR]-)VTG%DMU2;7U67C;UF@KMPRAJ;'B32KA?,223R)\QY T',C,
M@SP"$*%>)XMI+<2%OX^%Z"8,MXL=WG@$HOI4.2P'W:*YXG<,FWRRM&BQK +S
MR6U%M1LL:*UU%SXT1K'W?OFY3"/*RS!BR,(VCQB$)#\$C2W$,UFNW, &@^J=
MLXF/B1Y./CH(X8VC5$46  B4"LJNJ!0*!0*!0*!0*!0*!00M[_P?-_X$G]DT
M'S'O983O<-FODO"8E%_*BEK,66W%GN%3CZ3X58%)M8[7P,;*@0>]Y/"21VX1
MEUX"_P#J+>JBT@;J0(Q4J[_:H#8=8'\8$?BCPH.3O#D9\42R6EXBZ^Q<CB!0
M:9"3S1R9&/B]1,4K%+.H)L;6N:*J)M]RMDUY$,A3,DLMEYJA-R6MRO1$V9L'
M?MTQ(IU$&=ER8R]2VK2)A>1E4\ UAP^FI(^M]O=I[-L4)CP80KM^DF;S.Q]+
M,>)^[45<T"@4"@4"@4"@4"@4"@4"@4"DCPNP;?NN)W=O_<.9W/#F]NOJ1,(2
M73%9"#9[G1&8P".'._&N[;EC.O'",)C/X_%PZXF,\LYSB</\''/&Z]_[-O>S
M30S[!C13QC W-6UIE1 Z@PMHNC6!\K6XCC6L8Q\?+'+C.:YCX,=LO(QRQJ<(
MB>)^+UW;V)%MVTXNTC,.=-MT4<$TSL&E)5;7<7)!/KKCVY=LIRJK=NJ(QQC&
M[I97KS>A0+T"@7H% H%!\R^?/=7<';?;>!E[)EG#R)LP122*JM=.D[6\X;Q%
M?2_M>C#9G,91?#B\[;EAC$XS7+Z#LT\L^SX,\S:YI<>)Y&Y79D!)X>NN#9$1
ME,1\77A-Q"9>L-%Z!0+T"@4"@4"@4"@4"@4"@4"@4"@TEACFC,<BAD8$,IX@
M@T'QS><C#[?[LR,'$A"0F6 Q(1=8@ZDMI'@';C2$>7Q]]?+GR%W&4+D/(2'<
M\ ][%3?B!ZZT/3X>)ND&'\0>!6Q8[!'.DW-_Q1?C;QHKIE+CX\F,TCZVD7J>
M4< '))O1$F34OE>TDD@TI%';3*I'E-AR:@AX\NPYF)/'N"-'*2(CD0V*M8\-
M0_+3U<Z"O?:3C9F/C1-')$T\67&X!)/121=*D*QNRR:Q?T-QH/L6R_I,O_;3
M_P#*6LJM*!0*!0*!0*!0*!0*!00MZ_P?-_X$G]DT'R;YA8.:V\)D8K:V")JA
M3C*N@EED5!YG'/5IXK:_*K"*_8MNVF.";><@(,H:^GAPRDJTJ#4_4C(!1>-R
M/&J)^%/!NKS9N5)TXXD+%%%DX#@H/)$_T4$3"S#+GJKR)/BLX5^D+-$2?*P!
M ( -!<8LWPN?,P\I>I P.-,@.G4TANQ_[GA0>+WW:<##W"5M$\\=]4:2%1%Z
MM4@XD>J@]%\KNV=RW+>QO>79L6&1I!.!999"I55C'Y$8//TV Y5)'VP5%5N_
M[RVTX(R5Q9,R1I%B3'AMK9GY6U6%!X3(^>^QX\K1R[;DK8 AM<5FNVDV\WXI
MY^B@E[;\XL+<69<?:<CR@L2TD \HY-[5[&U$2)?FMA)&[C;Y7$=R^B6$V51=
MF]KD**JY/GQLD<K1R;9DHX8* 7BX@KJ#"S'@?"@L=N^;$&?$\L6T9")&!U"\
ML TD\;-9SQH-I_FMBPXXG;;)FC_&*RPG3<D+?S?C'E05(^?NQ$Z!M>5UCJM%
MJBU75M.GVN9Y_106V-\U\6?&]Y&V3)"20KM-  2/19C0<LWYOX&)&)'VR=U(
MX=.2%KL!J*#S<[<:"!!\^=CG=8X=LRI'(0LJO#P#\R?-^+^-0?3E-P#Z1>@S
M0*!0>.V'*[\A[MWG_,3XT/;3.$V5@T:LQ+>0#CJ)*^UJ\>5=>W'5.O'I??\
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M'&L6W1-:20SCH:SQ T1.5=AZV('HO5L0<C:LG9\B'*,\4R*VIVQW#F-1SZB
ML53TL"0/&U+'H]WV_*WCNQ=NP-48R L\\G^[C=09)+C\U/7]%2Q[S%["[2@2
M,?"\=FC  +1JUR/$W'$^LU%7D&/#!&L<*!$46"@6H.E!Y?YB8;Y>QPPI(T1]
MZB;6BM(1IN?90JQX^N@SVAA1Q]L;>DR0S3)&5DE*+YV#$%ONT1;^[8W^XAX_
MZB_@H,>Z8MQ]A#P_U%_!0>3G[%WGWK)R,;=QIG9VCQYH]21"4R7"%6!X"1=(
M\"M01\KY;[I)%*D>^2'J,"JR"PC&MV(4H0WX_CZ .54(OEON"='7NW&',;+9
MU5M4R,RL(I-3$*%"D#3Z:#VWNV->X@AX_P"HOX*#7W7%_P!Q"/H1?P4#W7%_
MW$/YB_@H/#_,C'PQD[>#CQWZ.0RLI5+:2E[I;S_]G.BOH\?Z-?H'^B@VH% H
M/(]S8?9?=>Y1]NYN:K[OMKKFIA1RE9%(' N!S%FXCG77HSVZ8[Q'RY<6X_(U
MZMT],I^:.73"7NJ/$/\ F*;;6AQUZ[[@H:RR1REN*-I4!8OQK\#5R^U,_P"W
MVN>*_5_%YQ&VO]R<*CF_RG^"QDW03RX,32IAR9@>7#'51FF:/B%"@-K1D.LZ
M3RKRC743/K7KQZ/6=O:<8^F_3GUK_*N7E\G;X.Z]L,F^C,P<SMO+,N7/C1MC
MIDOCC5JB#:F=+>SX^CG75&<Z<ODJ8SCB^:MS1A]_'_<N,M<\UQ=?#\%YV)WW
MM7>>U2[EML4T,<$S8[I.H!U* UP5+ @AA7-Y7BY:<NN3L\?R(VX]H?%^WFV3
MNOO+>U^8V\SXN5C2E,+;9<AL6  .P91Q4#0 MAX\^-?9V]M6O'[.-Q/K-7+Y
MVOKLSG[D_J1_FSLWRIVO9H\;MF<96_33)IC@R9,H+$+ERWF=1ZO&M^!L\C+*
M\XK'\J3RL-6.-8_4E_-;8\D=I=D;\^.\^W8F%CX^XHMP54B-Q<CV=0#+?P-8
M\';'W-F%\S,TUY6$],,O:(Y7VW[!_P#V[YV F='N"11LNIHYLV6.5#;V61GU
M7%>&6WS,9JOW/7'7XTQ=_O67R]VWY3[CN&[IV<F1[[#C28LF9)UVA9)QI)1G
M)4\?38_<KR\O/R,8Q^Y57=<-^/CIF9Z>KSGR/[HVKLZ?>NU>YYAM6X+DB1&R
M/)&Q5=#+J/ >R"I/ BNG^Y:<MT8[-?S13Q\+;&N9PRXE8_/3YB=J[AVL=BVS
M/BS\S)FC>3W=M:1QQG42SCRW)  %>?\ ;/$V8[.^45$-^=Y&$X=8FY>;[SBD
M;_\ M^[1<*2D>0-;#D-7647^DUT^//\ V\_R_@\=T?\ 7Q_3XO9]WY^S]Y?*
MM]I[?SH<_=<3$QLML&%@TVG'T=0%.=Q_IKB\?#+3O[9Q6,S,7^;IW91LU5C-
MS3R?R]V[Y*[ML&,F]S^Y;Y I3,CGRI8 S ^VEV5+$> Y5U^7GY.&<]><?;AS
MZ,=&6/S<9?FO,+:_D&>[-NVK;C-G;F\BO!+C2Y$\*21D,NMP2.8^CTVKPRS\
MO[<Y9<8_J>N./C]XB.95&?DX7<7S8WC:N_-VGV[:\)F7;,+K'&@8 C1=N \R
M>:_XWIKUQQG7X^.6K&)RGUGU>>4QGNF-DU$>A\R-@^3>S]L97P;*7(WR72N!
M%!EODG66%RRAF6VF_.KX>WR<\X[16/OQ1Y&O3CC\OU?F^E?)%'3Y9;,KJ48"
M:ZL"#^G?P-?,_N7_ #Y?I[.WPO\ BA[JN)U% H/"?-3"]\AVZ+B-)GEU*&8_
M9H#;2A#$'Q%!Z;%QL;W:&\$)/33FB\](]5$=#BXW^XA_,7\% ]UQ?]S#^:OX
M*#SF^=G9VX[O[YBYZX,!QS 8XUNP;CYUXZ >/.U!!F^7F\2ZT^/OT7B: ZHE
M+D--UNH6! UCV?9MIX4$<?+7=EPLG'&[*\\SPNF4XDUJ(DTE+!M.ECYK4'N(
ML2!(D1HH695 9M"BY L309]UQ?\ <0_F+^"@>ZXO+H0_F+^"@^?=TC"3YA[;
M",>,S%,62-D81F/3.02%MYPU^(H/J5%"*#FV/"P(*#B"";<>-!\BRNVX]@[X
M@:54CVS)<O#([!(U4'6\)8D!=-M:>JX\*1*(;]MR=Q;Q/N^3,L,.1(3&\I^T
MDB).EHXR5LEO9+'CSM5L39NV<W;4DBQ3%N&%D67H$*9%-N?3N5<?00P]=+56
M;7VOOLF\#(S5,&.A1DUCH*5B-TCC1N(&NQ8_Z2:6BZWG9,O,DP9;PEL7)6>9
MFE5G955E\@TR$M=N7#Z12Q]%V7])F>G6E_U:U%6E H% H% H% H% H% H(6]
M_P"#YO\ P)/[)H/#3QR)N.?D2O(Z=?1%"KD$$Q+;0&\O,4I&DVYXZ2'J31(R
MEC(BH2IN+^T&/,>0>@\:4&1&V3CR1HS)+TRRRQ,]GL@4!%7DPOQ%_2:#UVU;
M+MTNS88G@61V@CZC,22QT"Y-SQO1738NUMEV3JG;L<1&8C6Q)8V'LK<D^5;^
M5>0\*"WH% H/*?,Q=7;6DRF!3/'KF77=5XW(,9#7H.W9A0]I[98&W2\OT:CZ
M:B.7=?=VW]N# .2O4&9-H?SHG2@0 S3G5[2QZEN!QXU)FEB+5^)W_%/W;)L!
MQXAIRYL)67(#9&J&+JF1X"BVC8<+AR>7"G;E:>M\GK^K\%:9/+Z_J_!0/+Z_
MJ_!0+KZ_J_!0/+Z_J_!13R^OZOP4'SSYK;E[EE;..4<RY"R7OQ T'CI' >NH
MCZ='["_0/]%56U H%!11=D=M0]S3]S1X@7><F/IRY(9N14*2%OI#%0!<"O:?
M)SG#I?RP\8\?#OWKYGF\/LKL/9<S;]FR]RDESGR9LW#PLK(!:8RC2RM'P#I9
M>1''CSKKR\O=G$Y1'%1$S$.+'PM.$QC,W-S,1,^KOL,V[;EN,G<&]8TVP86Q
MB?'BV^4*89(@+^\7(!72HMY>'HK.[KCCTPF,YSJ;]_R73&6>7?..D87%>WYN
M_P N%V+*7=]ZV;>I]WQ=SRR[+,6M ZW)C56 (]OT<K5GS9SCKAEC&,XQ^UZ>
M%CC\V6.4Y1E/O[/78^+C8T?3QXDACN6T1J$6YXDV6W.N.9F?5VQ$1Z*;?.P^
MSM^G]XW?:,;,GM;K.@#D#TLMF/W:]M7D[=<5CE,///1AGZQ;?8^R.T=B<R;1
MM&+ARG_Q8XQK_/-V^NIL\G9G]64R8:<,?2*7$T,,T313(LD3@J\;@,K ^!!X
M&O&)F/1Z3#RTORG^7$LYG?M[#,A-R0FD7_V00OU5U1YV^(KM+PGQ=7^F'H]O
MVS;MMQEQ=OQHL3'7V8846-1]Q0*Y\\\LIN9N7MCC&,5#QWS1Q]N]TQ99>SF[
MLR97,>B)!KB11?4TEBP%^ %=?A3E<_/]N'/Y,17T]GR_?,'<\_8,K9=A^5T^
MSY&:45LXA6955PU@S*I%[?E5]35ECCG&6>Z,J]G#GC,X]<==6^P]D]IC;^P-
ML[=WJ"'):''"9<#@21EF8N5X@@Z2UKU\?R=_;=.>,UR^CIU5KC').V3LCM+8
M\M\S:-JQ\')D0QO+"NEBA()7Z+BL;/)V9Q664S#6&G#&;QBD?=OESV+N^2V5
MN.R8D^0YN\IC"LQ]+%=-_NUK7Y>W"*QRFDS\?7E-S$)VR=J=M[$A79]MQ\'5
MP9H8U5B/6WM'[]8V;\\_JF9:PU8X_3%.>_=G=K=P:3O.UX^<R"R22H"X'H#B
MS6^[35Y&S7],S!GIPS^J+1]F^7O9.RSC(VS9<3&R%]F98P7'T,UR/N5K9Y6W
M.*RRF6</'PQYB(>AKP>Q0*!0>!^;&/--C[<$G]WC4Y!G>SD]/I@$?9E6'TWH
M/6XQ7W6 7)^RCX^GRBB.GE]?U?@HIY?7]7X*!Y?7]7X*(>3U_5^"@>3U_50+
MKZ_J_!0/+Z_J_!12Z>OZOP41\X[RSLO'^8&T8ZK_ ,KER8::](/G25F(N!<<
M/N5!]4%52@4$7.VS SXQ%F8Z9$8(.B10PN#<<"".=!D;;@K[,0%N5K_AH/$;
MA#T>X-UE,DHQHY($2!9' &N$>P#=;ZN=$1I=Q@CE^TR%B92&9 "XL5%[D-;@
M!I;E9C>E#8QKEP"-2R,R I,DDEFLM]"JI/G!:QX\:4/3]F+(NW:)"6=5A5F)
M))(B4&Y/&BO04"@4"@4"@4"@4"@4"@A;W_@^;_P)/[)H/$[B[I/EN#IT-*4<
M.00Q6/RW'LD\/+;S4M'C\'%[:FPMWGWS)EBW./5[C'Q' *=.E0.)/H\.=:%O
MV[+D/MD?5(,VL%0]Q8&][!K"WI;VJR/INQ6^#8.GV?=XK?1H%%3Z!0*!0>3^
M9D(F[:$)=8^IDPH&=Q&@+$@:F/A0=^RA(.T=K#<6$-FX>(8WY7HCING:NR;M
ME-D;GB)F.<9L15G76B12'4^A2/*S<+L./ 5)A;0L#L/:L++BR5R,R=8)QEPX
MTTQ>$9 BZ0F*Z0Q;3Z6M?C:IU+>B\_H^JM(>?T?50//Z/JH'G]'U4#S^CZJ!
MY_1]5!\R^=7O,@VC%C "3&5I2=0LL90W!7C?U6-Z#ZPGL+] HK- H% H*#<^
MQ>V]S[DP.X\S&+[KMP QI0[!?*25U*#9M))(KWP\G/'"<(GY9>&?CX99QG,<
MPO)X(IX9()D$D,JE)(V%U96%B"/017A$U-P]IBXI V'MS9.W\'W#9L./"Q-9
MD,4=[%FYDDDDUZ;=N6R;RFY8UZ\<(K&*A95YO0H% H% H*7N'?9]KD@$<(F5
MU>26]^"QE >7+V^9KHT:(SNY<?E>3.J8J+_\4C#NC*='ECAB$<!1959SK8RR
M&->F /"WW>5;_I8CB_7^#S_K<IYB(J/\YKAA^Y\W'A9\C&61M&6RC'UM;W5P
MGFN. 8^/A2/&QF>)^'K^*3YF6,7,7]7I_P#+D_=F:N,^1T$5/>&@2XE;@@<E
MO("6_1^ X5J/%BZOVOV9GSLNMU_-7O\ C_!MD]YK"67HJ'7%$UB][3F,2]+R
MCB-!O<5,?#OW]_W>EKG_ '"O;^6_UU=?L9'=&Y"297PPH@@>=B1(-:KKTD!@
M"@;I_C"G]-CQSZS7^!_69W-X^D7[_C^ST]TJ3?,ULQ8<:.%HC/'CEV9B?M(>
MM<:>'#E6(TQ5S?I?[Z>L^3E.58Q%7$?MBW+$[AW'-@R)\;'B;W=/T!<B1Y"N
MH:>0"\?'GQJYZ,<9B)F>6</*SSB9QB./;W6VU9OON#'/J5F.I7TAE 96*LNE
M_,""+&]>&S#KE3JT[.^-I=8>I0*#P7S9$)P\02RB,.F3&NJ01(Q=%%F8^'J\
M:@];BAABP #E%'X?ZHJHZ>?T?50//Z/JH'G]'U4#S^CZJ!Y_1]5 \_H^J@>?
MT?50//Z/JJ#YWWMO65'WMLVS) .C/DX.3).;WLDCKI!N +<#XWH/J JJ4"@4
M \J#P>],Z[WN# A41M74UE2K>[I;S#V?#P\U$>+VW&[;R7W5^XIY(,A%)P%X
MK>X;S 6XL6/+QYU19=IS3R;<@D-Y-:&,27Y:QQ :PX@+=CQ]%4?0.S[>XO:U
MK1<N7Z)>5^-95?4"@4"@4"@4"@4"@4"@A;W_ (/F_P# D_LF@\1+FQ2;IF8B
ML(YX)KI,?Q/LU<\ "QU<+T1%R>W<>7(U28CL6;23'I(!"B_M&XXG7X<*MCKE
M2C;L(S2GIHD;&.%2RJI*7$H/F4L2+^J]17N>WWU['M[@W#XT+ _2@-!84"@4
M"@\S\P<:'(V.))M73&3$S:&"-PU6LS!@./I%!XF+OG+[?VW%VO"QX\^+$1E2
M5ER%)1+D7(!!<DVMX\Z(N8N^\R3',HCQ0RC4\;#(0VM?A?B3?PH-,'OW=,G6
M7QL2)4M<EICPOQ-K \!00LSYG[G#E+%#@PS1$J'FTY( UM8%18ZK#B;<J"?+
MW[FKC-/''BMIX,C==6U$\ !Q)'I- QN^]QFQ^O)!BPK<@B\S'@.'E''B:" /
MF?N9SAC^X1"$LR=<KDBQ50QNMN"F]E;QH)N7W]N$,2RPQ8DRN0%%YU;A[5UL
M=/H%^=!T7OG<!CK-+%BH'%U4&=R3>VFR\1]V@\KN?=N7OV4!DXD<$6/%(86$
M4[2,6<*!Y@.FWDXCQ%!]JC]A?H%%;4"@4"@4"@4"@4"@4"@4'*;%QIRIFB24
MH;H74-8^J]6,ICTEG+#'+UBV#A89D20P1F2/V'TK=>-^!MPXFKVGXI]O&[J&
MWN\!%C&MK,/9')^+#[OC4N5ZQ\&J8.$DAD2"-9&-RX502?3>WKJSG,^Z1KQB
M;B(9]SQ.GT^BG3O?1I%KVM>UO14[3ZVO3&JJ!\3%DE$TD*/*HLLC*"P'H!^[
M2,IB*LG#&9N8Y(L3%B0)%"B(IU*JJ  UK7%O&DY3/K)CAC'$0U; P6.IL>,F
MVFY1?9]'+EQJ]\OBDZL?A#I%#%$@CB18XUY(H  ^X*DS,\RUCC$14-ZBE H/
M%?,G 7.&V1.K-$&F8E +AP@*&Y#*#?E>@I\[O_>L**.*#;TS75/,5CR56T:7
M/FTVU$\ /&B)F-WKNL^-U1BPHZJ&>*1,E#:US;4.)OPM0:8?>^^9 D+X,$03
MC<]?B+VN 0.5!%S_ )B[WCS!(-L7(06,D@BRE #.%&D:26/B0.0H)[]Y[K[J
MT\6- VC@T;+D*U_Q=((N?6?"@TQ>]=YEA,LV'!"%-FX9#'D3<*!<W/#A00F^
M8V^>^K -K4P%^FV08\JP.@M?3;V?#5RO03LGO7>(L83Q8D$H:P":<A6O^-=;
M$@#T^- A[TW=L<32XD$=P;(%R&;5<64@#ASYT'G(]YW;>N[L.>; Z,+R0HI.
M/,3;'FNK L 8F-V]K@5H/L@HI0*!0#RH/ ;KEQOW+N6'<+*LD!C>X!0F%26X
M DW"V^BB(&3L$63,))L5Y&<JMXPI!)6[6U7(+ZM0Y5;$DHFW0*\A"1QKJ2$$
M@,UB.K<%EU<+CT4M7H^R)>MM2RWU=2.!]7.^J%3>HCT5%*!0*!0*!0*!0*!0
M*"%O?^#YW_ D_LF@\// D>Y9LR(CY$TY"J^G25$2 EN*D:>'C>@K,SN;"@R-
M,N1(TR797+E3Q%_9_P!K@W^K5B$3G,&=BF)W$D<B-TV-M9<*%TR$W:PXV8BH
M/>;$%&S8 4@J,>( CD0$%%3J!0*!0" >=!0=Q[EW#A2P_"< 9L6B23(%CJ\@
MN%0@@:CX \^59F9(5WQSN[IJWN!$I+%HO=I"%<&R0Z]?$../6MI6I<JXXV[_
M #'=SU-L@'35Y65@5#KI4HBMJ]HDD?<XTN3AEM][Z675'M@R,10RJ_1:*21V
M5]!Z;/J0:P%-SRX^-+DJ&PWCO<="23"""65$EB$#,T8$5Y/,C/<=3RAN5J7(
MDXN]]R_#1//@-),7* "!T:Y@UK>(LS!5G\A;E;C5N1$_S!WR"J2;4$E3P2)Y
M(YF)! #AOLO*QN6_&%2Y*AVV?=^\\C,P1EX2QX<JVS9#$Z,DA$A "L0; JHO
M:W&K$R.>5N_?6-BR%=NCRI!<B98V0CS2@#H@N6X(AOJ\>52Y.'J-MDGFV_'D
MR5M.Z*THTE+-;CY6XC[M:A$L50H% H% H% H% H% H% H% H% H% H% H% H
M% H,6%!6[COL.%E/CF&24PX[YF0Z:;1Q)>Q.H@DL5( %!'B[H@FSX<.'$F<S
M&95E.A4U0>TOF8$GCX>''TT$;&[VQ)LO;<5\2:&;<DZD:,T99%+,HU*KDGV+
MG3>WC02]X[FQMKRTQYH)9%*=226/3I0$L%N"P8W*GD*"/C]W)-[G_P#+YU.5
M,V-I+1%DD"ZP"H<DC1Q)7EXT"+O'';W0RX<L(RLM\$,6C8+*AMS5B&6]^*^@
MT%OA9\&8DSP D0R-$;VLS);BO'D;\*"IB[OQI'P4&)-JRSIEXQGH-UA !)9N
M/VC?BWX<:";N^]P[9D8,4T3NN=.N.DBE;*[D!;@D$\_"@L[4"@4"@4 \J#P.
MYP1IW+NF1H1I'E@0*VFS#H*&U7*D:0P//Z*"GSNY<''R52:=VD4Z@P=EX@<0
M!QY,MAZ5JTB=#-#FXZK(PDBE4!3PZFL*!9F-VT:GX&U@*@]1V:BIMVA3=46%
M0? @1**#T%%*!0*!0*!0*!0*!0*"%O?^#YO_  )/[)H/$[A'(^3DJ 6ZCRI$
M@2]WTQ\1?RG_ &B;BK"/);?G;;MN#N^)N&U^^9>9?W:< ,%N"%4L1==)\;>J
MJ+;MO$RX=KB1P59G4AUTDG1<'D0UQ^;61],V/_!\&_ ^[Q<#S]@45.H% H%
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MO[M'F8J3VT-98I&!XLALE@%X^4*?/?A4H>V[/(."Q%@"(K &XMTUY&HJ^H%
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MZ'!QHX Q;BLDI<^3R^<*0X_27!\>%6T>R[.;5@,W$ZA$;FWC$OHX5%7] H%
MH% H% H% H% H(6]_P"#YW_ D_LF@\%T9XM\W++,W2A,Q"O8V4B%?%031$F:
M7$:4.V&EE9B^IU#@<&((X7M82<>?*D0(^ZK-E;=+#C$PNL9+1#V5^S]NY(7S
M%K\/NT'N>W59=BVY6XLN-""3Z1&**L*!0*!0*"/N'_DIO]F@\^K7%C]PT1A@
M5/#E0.?A]R@P+J?5X45AE\1;UBH@I%K'E16.*_1Z*(VX'C5 ,1SJ*V(\0*J,
M@@\#08(L:#/M"WC0:WMP-[?Z* RWXB@P#?@:#4@J?5Z:BA (^Y1!6*FQY>!J
MC)!'F'WJBMA9A5& 2IM]=$;$ BXH"GF"/&U 9>-Z "#P/.@P05/_ &45@@$7
M%$8!/(U!@@CB.=%9!##P%!@>4U1L1?B.=!E6OPY&B'+Z*#:X;GSH,"ZFU!DJ
M"+B@T!L;<Q089;6(H'!AQ^]08\R>'/PH,LH/F7B:B@-QZZHG[*",I_04Y?=H
M+P4"@4"@4 \J#YWN$$Z]X[KE&7IPJ^. UC96$ L21<\_11'223$DD5CB*ZZQ
MK+N%=@R@F_(^<#7Q]%JM#GF:\G#:+&/2?0&>)1PL06,A/!..H'A]VH/0=BHT
M>T)&Y+.D< 8GF2(5HKTE H% H% H% H% H% H(6]_P"#YO\ P)/[)H/%9S6R
M\JR@LCR3:2FH,41+&P(+:1?S?BU81Y?!VS<-[Q-VW/XBF,-OU!8FXZ] /$L3
MR]!^Y5%GL.;-E;='D2 EPP2UKW#WNK,=6KD+*>'KK(^D['?X1A:KEO=XKD\[
MZ!14Z@4"@4"@C[@;84W^S04# $7'HXBB,!@18\;\J#!&D^J@<".5!@$J>)X5
M%891S%O2:H CD;41BQ7B.1\*@S8$7^]0%-C8T5L1XC[U5&58'@:#!!!\*#-P
MWTB@QQ!MX4 K<<A08'$$-Q/A16I!4\O+1&2 1?A:@PI*GCRJ*R1;B.7HJC;@
MP_TT1J"0>/W*#<@'B* K#D?3089?1]PT&0;\#SH-3=6]/I]= 9;BXH, ^'C4
M&"+&XH-A9AQ]%!J/*:*R1?B.!H-E;4/750(L;^%!L!<4&!=3X4!E!%Q0:@VX
M'D:@PRD6(^_5 6;PXU%8!*^L>(HC++>[+SH)^R$')?TZ/^VJJ\H% H% H!Y4
M'@]Z'_SO<%"@LTBO8IJ#=.!&6X!!>QOR]FB/)[=MNX=Q2;I.-P7#& ILK<==
M@3S)X*.'$<N543NVL_(RMO2647,;*@-KDAG"E6;S&QTV"<N-6A[SM&_N<FJ^
MK[.]^!OTUYVK*KZ@4"@4"@4"@4"@4"@4$+>_\'S?^!)_9-!XO*,4^7E0(#)-
M'/YH3J*N"BLP;BH' "W'Z:(\_F=KX$N2S-+T2Y 92"+V%CJ""QL[:/KK4"U@
M@Q\+#UK&(X8T:S$#49 M[-I*GI@W'+C61[W82#LN 1P!QXK#_N"BI] H% H%
M!'W#_P E-_LT'GE.GA1&S $%AQ](H /@?'QH-"-/T4&38\Z*Q<J;>%0&7Q%Z
M# :_ T&+%>7$&JC-@1<445K'C4&W#@0:J-E8'A>@P010.##C[7A08%U-O"@,
M.%_"@P#?RGZZ@U:ZGU&BL\#ZZ#"DJ;&B,D6\P^[16UPPJHP&93Q^Y0;'CQ'.
M@*W($\* 5Y4"]QI/.@U(()H#+<7%!@'P-%8(XW%09N&''G08!*FQH,GTCG0;
M*U^!Y^- /#C51L"&%KB]!@$CZ*#)%Q<4&@-N!\:@PRV-Q]RBGM?308!T^L>-
M5%CLP'O3$>*_]M%7= H*#M7<]VS7STW"2&0X\HCC,"D6X$D&_/PH+^@4%&^Z
MYH[E&"&7W4V4KH-KF)I.,GA)Y>"_D\:"@W=HY-\W/'6YF$L-H_,0^N% 0UB+
M+I7T\^=!YK/[;P9\EI&?W8L%#KQ%ORKZ.80L!6H1:[?@P8$"%4$<,/%WL->L
M<-(L5/3#*/#C6;5ZOLMP^VZP+!EA-ARXQ*>%!Z"@4"@4"@4"@4"@4"@4$+>O
M\'S?^!)_9-!X*;%BBW;<<QPS]2?1TU/F),*@:0P*^'T41UGWK1*.ID1H\;%^
MFJ%EXKX-<VNOE'*QH.>XPC<L1X) "QA-G!)#J$"A45;^8:N(N?$T'NM@CZ6R
M;?%RZ>-"MOH0"BI] H% H%!'W#_R4W^S0>?'F7CP/A1& 2K?]E!L1<7'$GG0
M8#7X'E08*V/JH',&@P+KPXD>%11E\11&%-^%48L5/JJ*R;,.!J@K$'C4&Q]7
MW:J,@W%C0""/HH!\P_UO7XT&MRI(\!]5!EA?C>@ W\I\/545IQ4CB2":#)&H
M?3085BO#P]-!L1QN/3QH,W##UU48!*GU^FH-B+\15!6\#>@,MO\ 30 ;C2U!
MJ00WT_70"H(N.=%8!\#SJ 00;B]Z#(LP]%4:W*FH-B+\1S%$9#7'K%4/9H-K
MAO&@QQ4T&2MQ<4&E[<#R-!AE(XC[AH%]0(\:@G[(+93^C3P^_55>"@4&J11H
M244 M;41S-N N?50;4'COFONV1M/:9S8)\C&D3(A'6P[=8 MQMK\ECR.NZV\
M*#7#G>3O+#D:,S=;"1_>7)4I>(G3=0L4C/Q/#EZA:@KMUQ84[IW?,DU'SXZ:
M0>/& *--P5Y_^^B,2[STI4#SQPF-E?IZ-8 "@+>QMP4:>%K-QH,9 ^(XXC>]
MS&"DP)*LH4G0H6YUC7R+<317I.R(1!M0@ MTDA2W^S"HH/14"@4"@4"@4"@4
M"@4"@A;W_@^;_P "3^R:#Q.X.ZY.6X.D1M*4<.0=6F/A<>S?\FW&K"/(8,/;
M<V'N\N^9,L.Y1ZA@1\5-M)*Z5 XD^(\.=46W;DN0VVQ&;C,&4@2$BP-]1 -A
M8^+>U61].V*WP;!MR]WBM;E[ HJ=0*!0*!0<,\VPY?\ 9H/.LI'F%Z(SP86/
M/P- !*G_ $B@R0#Q4?308# \#]PT&"-)X<J!SH-1=2+\O"H,LO"XJC /A08X
MK]%!GGRHK*DCG41DCQ%^%49!!%C]%!@BQH-O:''VJ#4$CG>W+Z* 1?E>@ ^#
M4&A!4CF109(N/I%084D&Q)M5&2".*\JBM@0PJC )4V^NB-K7%QP]-!D&UQ;U
M<:##+8^KU4 <19N?IH,6*GZ?"@PRZA<4& ? T4(-P0*B TL!Z:HP+K45DBXN
M.=4;*U^!YT0((Y7MXT&UP1XWH,>S09(!XB@U!(-K<*#5E\0>=06&RF^0_J7C
M]^JJ[H% H%!XSYM*G^47=HDF*3QE4E!,=S=?/I93R/#UVH..&&3NK:()K:TQ
M8V150, !CE3>0G7>^KF.5!KO18;UN)!TA6U:Q(5(;W=+<1['AX>:B/%[;#V[
MD2;JW<63)!D1J3@+Q4M<-Q MQ8GP\>=6!8]J2Y$FWIU#JEUH8U>X &L<0& 7
MD%NQ\WHJV/H'9]O<6Y<HN7$?HUY7K*KZ@4"@4"@4"@4"@4"@4$+>O\'S?^!)
M_9-!XB7,BEW3,Q PCG@GU)+^3]FKG@H9CJX7HB)D]N8TL^J7#=B6"DIIL"JB
M_M$D<6ZGAPJP.V4XV[":24])(XV*0@D*NI"1,/:4L2+^J]0>Y[??J;'M[CB&
MQH6OZ;H#15A0*!0*!01]P_\ )3?[-!YQ21P/+Z:(V92/,OC09X-P\?308%U/
M^D4&Q4$7'W108!OP/C08(TF_A0+7'*BM02IX\O T!EX7%!@$<C4 W4WY@T&2
M 1>@RI\#09(\0*J-@0>!H,$$&@S[0]!H-1P-B.%Z 5!Y"@P#<6:BM2I4\O+0
M9(!%Z#"M8\>7A1&2+>8?3:H-@0PXU1J#8\?N4&Y (N/O4 'P-J R^(Y>!H -
M[@CCZ:#!!5O3Z:@P5OQ%48!\#45@BW$51G@PX^BH,<0>-!DB_$<Z#96!X54+
M6Y<!0;#B +4&.*F@,H/&@UN1PYBH)^S #)8\[I_VU1=T4H% H/(?-+-.#VRN
M8K1(\.5"5><,R#5=#=8_M&)5B $XW-!QP55>[L-([K#'BQ 0J74*3 0"%8_H
M[+;S<C01=TS(F[FW/#N%F62!HY. *%H5);@"3<"UJ(K\G8(,B429&(\SL54F
M+38DKJ;@UV!?5J%[58D22B;?C*SD)$@U+$+A7-B!+P+*6X7'HJ#TG9$HEVI9
M0VKJ1POJO>]X5-[T5Z*@4"@4"@4"@4"@4"@4$+>O\'S?^!)_9-!XB?'2/<<V
M=%1YYIR%5].DJ(E4EN*D:3;QX^%*159G=.%CY&B2>1YE)*,793<B_L_[7!O]
M6K0GNT6?C&&1@\4B-TR;:BP4+:0F[6'&S6]50>[V$ ;+@!3=1CQ6/I&@45/H
M% H% H(^X&V%,?\ 5H//!;K<>-$974IXCAZ:@&,\UM;QJC(&L#E<<C0 K \N
M/B*#+(3YA]Z@!6Y$>'C0:,C*W^B@R5-N(H-+Z3;ZZBC+?BOJO50!\#45CBIX
M<JHVYCA41@-8VHK8CQ'.JC*L#P/W#0""#09X-]/A0:CRD"W 4 @'T"@P#<:3
MSH-6!4^JBLFS>-Z(PK:38_?J*R01Q'W:J-A9A16 2I_T41M8$7'WJ K6X$\*
M RVXCE0 ;^4\Z#!!!X?_ &T&& /$4& ?3SJ*P1;B*(S<,**QQ4V/IHC)%[$'
MC5&RMJ%CSH!X&]!L#J%!@$@T&2 PN/NT$S9O_,L#^3_VT5=B@4"@4'F?F'+D
M1=N-+!,D)25"\DD,>0 IN."2>75<\/7056WF:7O#;\R5KGW2*'0T.DJSXW4)
M! THS<;KZ!:@TW2!$[CW3("*\TDD"HC:=+ 0*&U$E2-.H'G]%$4V=W+A8V2(
MYY9&D0Z@0[+Q XA1QY,MAZ5JT)\,D6=CJKN'BE4!2;=0R!0-+%KMHN_ VL*E
M#U'9B*FW:%-U185!'(@1***]!0*!0*!0*!0*!0*!0*"%O?\ @^=_P)/[)H/%
M;A%*^3DJH+=1I4B0)>[E8[<_*?\ :)N*MH\EM^X;;MF#N^'N&U^]YF9J]VR
M P74"%4L1Y=)\?N<JHMNW,3*AVN*.2ZNS AAI).F]SP(;A^;61]+V._P?!OP
M_P"7BX'G[ HJ=0*!0*!01]P_\E-_LT'S7>-C[LE[@AW#:]P2# #8YFQF9E#K
M'KZH8*MVN&\HU?369B;6X5^?V9W>^^9FY;=O'NW5DD;$URO(J)*T!*-$1HTJ
ML3V7TD5.LEI2=N]\'8,'";>RFXP');(RPVK47B88P)T*75)"&(-N'#C5J:+A
MPA[9^8"8^F7>1/(8XQJ]X>,@+)JDBNL7%G7AUO:7T&I4EPXY79W?N5B1Q9&^
MB>0S1F4=5XDT1B J0$7CYHY;K^-J!)X6I4EPE[AVMWC\7W/*V[=>CBYV0TYQ
M#,Z>3[$*J.%?HFT;ZF4>/WK4EPK<CL/YALJ&+?H^LL[Y/6#2*%E97!?I!2KZ
MRXYFR6X WJ=9+A<[=V_WI%M>X0Y6\F7<9XH8\&4R%DBT &2Y"+YW-UZEB?&K
M$27#OVOVYO&UYF=F[KF>^9&:D$<9ZC2"-(=?DNP6]M8\UO-:YI$2DR]'P(/U
MUI&/9/J\*BC+XBJ-0WA1"Q7Z*BMN#<C1&%:WHJC8^HT&5(/#ZZ 18^J@SP8<
M?:H-02IL>5 8 B_H%%8!!\IM]V@U(*GG<$T1G@W*@PK%>!^_0;$<;K44N&'K
MJH E3QY^%%;$7X@_2*(*PY&@,MO]- !!&DT&+%6Y45@J"+B@P&\#SJ#!!YCG
M09N&%$8!*FQJJV(OQ'.H,JUQ8\#5"UC1&P(;AXT&/9-!/V@#WEB/R>/WZ"YH
MI0*#65 \;(>3 @_=%!\ES9NAV?N$N9DO%#B[B@][*%A&-+)JC4>UJU!3<<C?
MG0>IV[+D3NW P52%47;HBZ*$=DLAL%D?3*J\+ >:_,VH(^]HS;UN XE6?2J:
M-5W..EN?E;[O*B/';9F[?L[[O#NVV>^RY:M[NP <)8%=)/XO'F:HL.T\/*AV
MU4DNC/(BZAI8@A[VLI#< 1R\O#C2U>^[0O[D]^?V=[VO^C7T<*@OJ!0*!0*!
M0*!0*!0*!00M[_P?-_X$G]DT'@Y,L2[MN6',C&!)@Q8 7\L2LMF:X%BW.U$2
M)MNB]X&M\=W9M)ZERQ"J%\#^3<<.;U;$;=6.%@RS!6GEZ14N &!C:/V+$<+
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M+J$R=3<\9!'#[S(S%@HBTZR2Q%KZ3JT\[<;6J=H*2SO_ &4DR1-FXPDD7)=
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MQXC<\_8%%3J!0*!0*!PH,$J.9 H!*CF0*#/"@<*!PH'"@<*!PH% X4#A0.%
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MMV?M7O/I:ANFN9W9;=>9#% QC(6.0*3K70XU,/->Y]%*DLB[2[R:=#E[O[S
M,I)C&TLB@*DRR @*HOY%T:#Y?&E26QOO8^_;QDR^\;C_ ,GUWEBBZLP!#%M%
MU6P30C!+#@W,\:3C,D2U_P I=\*D,<>\B-8W4NZ22#4@6R@)I*((_0/;\:5)
M:VV+9>Y=OW'JY6?[[BO!''*LLLC,)1;6Z C2 3?AZ_#E5B)+>FK2% H% H%
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M"-FPQ"9#$(ET]86>UOQAQH)YH/+;H,)>\\ ,DCY4B!D==)52BN%U7&L AC<
M\?N4'B>X<,KV%N^)F8[/*V=&3'(>F>HQLSM)-Y'7@3YF MXCA0?4]ICZ>TX<
M8-]$$2W\O&R ?B$K]XVH/'[T/_G>X*%U,75[&/4#TH$9;BX+V-_]FB/)[;MF
M;W VZY)W!,08"FRL;A^!-[D\%'#B.7*M"?VUN&1E;='+,MS&ZJ+#B=3!2&;S
M&QTV"<JE#W?:-_<G)OJ/3O?@?T:\[5%7U H% H% H% H% H% H(6]?X/F_\
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MT'A-TQ8D[HW;-DU$=3'32";^: *--P5Y_P#OHCG+O*1R*KSI"T;*^@)K  4
M7L;>51I\+-QJT$H.XXXB?B3&-$H)*D!2= "ZO."_+5Q-0>D[)AZ&UB'ETDA2
MWHTPJ**]%0*!0*!0*!0*!0*!0*"%O?\ @^;_ ,"3^R:#Q.X22)D9;J=.AI2C
MARIUZ8^%P;K?AY0.-6$>0P,?MN?$W>;?)Y8MSBU>XQC4#;22ME XDVY?=JBV
M[<DR7VR,R_IPP(#W%KWU$ V%O2?:K(^G;%;X-@VY>[Q6^C0**G4"@4"@4"@4
M"@4"@4%#W9M:96-!FOD8\"[<9)6.;'UL;0\;(YD34GLJUP;_ .FLS"P\U#V/
M!G8?6VK?5Z$S.TC07$<DC2LQ!57LHLP0A?14ZEI6;V7!%L\>(NX1"3&S'W+(
MGR#( VN-HF+LLBO?CSU>%.I;&1V-N+3'*D[@DAC$TDY5&=4A!4>6,F0V$>DV
MO^4UZ=2W&;M":62':I-[@NZIEQX*]2[=%A9U5IF8I?S'_6IU+;8O:WO63''C
M]RMD';9TZD"2&Z  $J=+WU=0/:_@=/A2BTG=^P8MRRLDRY4 Q9\DY9)B_P"8
M,A"HT33!Q>*P]FWH'A2<2T.'Y=21X0Q\'>53'5=*:-?DT6#JFF0"TC K)<'[
M].I;TO;>PY>T=5),KWQ)@K--(7,@*(B*@U,PT *Q^[5B*25Y6@H% H%!X;N[
M(BR>ZL##G8>Z8$+YF0EUXV!X$<[<!S('TT'G^V=H.[9.?+-D:FSP<C)S(HS$
M90A,6.3&2P'F1G8<B5%!,?N/M+M7+S\*=)Y=QQ(H\G<,M8E.LS.H6Q9QINTE
M_!>?FO>@L9^].V9S[IF!W9\6',:"2,2 1Y,P@074NA?4X)"G@IO01MY[.P</
M;<^6)Y'5=3] D:$Q[#J1(+>K6"?QA?GQHBNDAR<?MO%S9)L5\_:,GJ"'$TVA
MCD:XC<%A9KW/-;7L**^I8TPFQXYEY2HK@>IA>@Z4"@4"@PRJZE6 96%F!Y$&
M@\4GR\RHHU$>Y:F0E-+HX1H$*KCQ/HD1CT8U]/%N-8ZK;KC=@3C:7V_,W2;)
MUYD.69S?7:$@\-18*SD<2*=2W)_EN8Y(1@[C-C8T+/H@#RV"%$5 "'4W&@^/
MXQIU+<&^6VY/#%')O!O'HT.$>\13BKQ><#7X:F!IU+=%^7&3[J(Y=S:60%"
M_59-*-KT6+^SK /W*=2UON/:9W+.&Y9,W2S1@MB)TBVA)'))DYC4!JX U9@M
M43_+O=&Z(@WJ2+00\C6D+&3@&<'J<-0%C4ZELYGR[SY$:/'W9XXN&@'JEE4.
M7,:GJ>Q)?SW!/#A3J6]AM^*^)@X^,\K3-!&D;2N268J -1))/'Z:W")% H%
MH%!5=T8&7N&RSX6*$,D^E#U/9TW\WU4'?8L.7"V?$Q)@%E@C".%-Q<>B@G4'
MG<_:MRD[OP=QA0'$BB,4[,VFU]1X!6!;_O CT>F@W[3V;,VH9T4ZC3-,)DFU
M*S.67S7TK&%TVL %H+\\J#P>],R[UN#!M(1KZPY4AO=X[<1[/AX>:B/&;;C]
MNY4FZOW%/+#D1J3@#BI((8W MQ8D\O'G5%CVG+DOMR=4WDUH8Q)< ><<0& 7
MD%\Q\WHJT/?]G_\ D6M:UHK6)(_1KZ>-95?T"@4"@4"@4"@4"@4"@A;W_@^;
M_P "3^R:#Q$F9'+NF;BJXCG@GNDWY/V:N1906.KA>B(N1VWC2SZI<-FNP6Z%
M+ JHOS-QQ;J<;<*6.N7)\/PC)*W3"QG1"I(4:D)$JD%E+$C5ZKT'K-@W_97V
M;!_Y^ M[M$6'46X\@O?C03_CVRVO[]!;AQZB^/+Q\:*YMW+V\OM;EBKQMQF0
M<>7B:#9>X-C9=2Y^.R\KB12/]-09._;*.>= .?.11RY^/A5&A[E[>!"G<\4,
M>0,R7X>J]!T^.[*0",Z @\B)%X_1QH,'?]D'//@'TR*.?$>-!H.Y>WBQ4;GB
MEAS7K1W%_5>@Z?'-FO;WV"_#_P 1?'EXT&I[AV("YW#' ]<J#EP]-!A.X]@D
M-H]QQGXV\LR'C]PT$3>\K8=VVC,VZ3<8HXLN)XGD21=2AN!(X^%2>2WF=Q[4
M[)DEDDAW>/#U2)-)><.255PQ=W?6Q;J:KEN! J=5MQ_R=VU+CR1+W#%)$Q8K
M&>E)&JN&N=)8W8:[JQ/ _>J=2S_(W:I@FBDWM9>M<*[LC,-;*2?,S79E72Q_
M&!IU.RP.W]O1]R[?OH[B@B?"QTQ/=P\(22,*1HN6\JL3JL.-QSMPJ]>2T*;M
M#MZ?);(;N%1%U^JD,;(B LS$W".!U+OP86^@GC4ZEL2]E]M212*^^1AST]$@
MZ:66(O?7I92[/U/.Q/%@#X6IU+:1]I=I19\$K=P0-# Q889:$!UZW697\UV!
M/.XIT+>D[8;:MHVL8TNYPSS.[RL_5# *3:- QM<1Q!4OZKUJ(I)E;-O^R+[6
M? /ID4>OTU1H.Y.WV;2NY8I8<P)HR>/W:#I\=V:]O?8.'/[1?'EXT&I[AV("
MYW#'%^(O*GX:#$?<6PR?H]QQG]&F5#R^@T'B.X7CS>YLU,21)_?-N=,?3:96
M=!Q41^16/"UM?WJ#KV&F5CH(LW'.+E2XL4K0,AC*Z))4<6))N"POQ/.]S04?
M>#?+^?N+-3=WW [E#&B%(1(8U)59%:'RLNIA&H/XM_"YH.4FV?+O,]XS'&XM
MFQ(KS;BI<9!B!CB1=2#0 K(C!-((M>U![6;*Q_\ *CY$<TF3 ^&QCFF.J5]:
M677P%W):Q]=1'E9M@R=GV+N#*R@JMN;0:1J7RE&*:;-Y0-(#7])-57O]KWK9
ML?:\.*7/QT=((PRF1!8A0/5_HH),?<>PR?H]QQG]&F5#_H-!M\>V6U_?H+>G
MJ+^&@U;N/8$OKW'&6W/5*@M]-S0;+W!L; E=PQR!S(E0CZC09^.[*.>=!Z/T
MB^B_IH.9[E[?! .Y8H)Y7FCXW^[0;C?ME(!&= 038$2*>/WZ =_V4<\Z #G<
MR+R/#TT&G^9>W]6D[EBAN=NM'?\ TT'0[[LO[]!Q%_TB\AX\Z#!W_9%]K/QQ
MX<9$'+[M!JO<G;[$JNY8I8&Q F0F_P!^@W^.;-^^P7!M;J+S]'.@T/<6Q#B=
MPQQPOQE0</3Q-!F/N'8I+=/<,9[\M,J-_H-!GX]LMK^_06YWZB^FWI]-!J_<
M6P1W,FY8R6YZID%OOF@R.X=B8$KN&.5',B5"!]XT&QWW9ASSH!X<9%^GTT'-
MNY.WU(!W+%!/*\R?AH-QOVRD!ESH""; B12"?OT [_LH%SG0 >DR+X\/30:?
MYE[>OI^)8NKGIZT=[<N5Z#?X]LO[]!RO^D7EZ>=!AM_V-?:S\<<;<9%'$?2:
M#QF5NN#F=P[E#CS)):6$PY,;!E0])=1!4,2>%B*(B9?;\65,))\1IG;2I,>G
MB2NIK!KL"]]0O;UTL2;+M^,KR$+&@U+$"0KFQ EN"RZN%QZ*6/1]D2B;:EF!
MU"1(7U<[WB4WH/144H% H% H% H% H% H(6]_P"#YO\ P)/[)H/#Y$"Q[CFS
M(J-/-,0JOITE1$JDMQ6UC;QN:"KS>YL''R-,L\C3)=D8N5/$7'E_VO:_U:L(
ML!)!FPK&SAXY%/28VU:P MI";MI'&S?<J2/1[;VMM,6'&80PUH&$JZ0;L/:4
MVX<Z#M_E?!UEQ+D!CS(E]%K>'A;AZ*#GE]G;)E"TT1(L  -( ]?L^/C0=4[8
MVV.,)$'BMR9&56M>]B0/30(NV,"/@'F9>;([AE;A8Z@1QOX^F@X3=E['--UY
M(F,FK4#Y>%_"VFH.\G;."T956EC6QNJ,%!Y<P!XVM5'CL'=,;*$J8]F,!*].
M>S"R@@V+V"L&;R^J@D?"MM@?WN-49S^C4B/42#Y=8(73JLWJX4$'<M[P<*1(
M<MB.( 2,F-%(-K);4.1\I_*K0EXF=BY\"N2KPR?I68*TBZBS (6N2I &H*.=
MZR-TVW$P;C'C@>:2]U(1D MQ)8:>*N+>DT@5F3W'ML.48VE=YEOTY&8@D-Q6
MZV_UO/\ <JR+/IX>>!&_3:)P3&[!0QXA29B06X!203SJ (<3 C,<018E'VLR
MJFI.!'V>D\=2L.5^!H*R#N;:GRQ&'=)&8=5E<FVGB;"WI'D]5Q5@63[=B9ZE
M9DA$L?$!1&L9%AIT\QJ9C:Q/"H-,G+QL*%I%TICIQB= %>0 WLVD^4 $Z;CG
M01-NWS RY#!C-?T+*=<98L!Y@0%MI7S7_&K0G#;-LGTYLH0,OZ2XC+ FY8JM
MO,JZEXCG>LB/N6[8V%$OO>F,,+/#'Y4%P"I8J64W*^8>BK ;?NF+GPGH,'1?
M+IFLQ"Z0MU+V >[&WC:DB1\+V_'D]ZA6-I'MTU(2YXW4.#ITW6[<>500MQWW
M;\-UAR7)-UL(V**K*=+*@\W+\0_35@2L?*Q<['1F*O#(!K)"F0,06LI:YZ9N
M.0L*DCHF#B;==8$@=C=G:R,@ L=0(*W(92+<_504^;ON,NX03X\C-F8+%RK,
M1U(>;<#Y00INU[?2M65>A?.S9(?B^3/AXX3)T;)('=>K!*H!@R=?LN[>CV;
MU$6<FX8^X8N1@QS';=TD0H8Y?+/$QY,HNNNW@5-J")M^W3;-(N5N>^ODXZ1N
MCIDE40LQ!#\^8"_709?-@W3<(,6XQ\9 <G%QY1HDRGC/E?I&S"%'-^/M'Z*#
MSF][[GF+!P=XGCBRL8Z]V?;WDCB:;4=,43&[\N?KYE?%$";BY&+FXJ%]+PR*
M 20ID#6+:06NQC)(Y"PXTD=4P,/ )7&2%F:Y8V0JH%CJ!!%V#*0/]%!5R]R;
M9'EF$R.TZW179R+AC925MXAO,/RK5H6AAP<^T<YC,3>9'(1;H6\S3<"VH*M^
M-KUD:NN/@Q-'&J1Q1K9I%5=:O:Q1=)Y'AJ-N5(%=B]R;7D9)BCD=7D)9CJ+\
M0I/$6X^8_FU9%FVV868-4Z0]:+@0HC6,D$!1';AQL>%^%J@XY>;C84!<D)C+
MPC:,!'D0$C4Q4G2=+>2X'&K C;;OF#F$Q8K Z>(64ZHB;DF^JR@:5N+_ (U)
M$P;7MD@&:X0/:QN$+ZK6/EM[(<A1;GSJ"-NF\8F'&/>K1AN)A0Z44\&%R-0:
MYOKK0Z86Z8F;!JB.M =++-I=PG!+H7_'YW Y\*R.Z[9@8K^\01Q-*Y!5"$-[
MF]GOIT^0ZO#T4%?G=P;;C3I'DR,74AEZ;% "!9@@X^R5\OJO6J$V%\;.QTU:
M)(I1P-EZFNWL$M=NGJ?@;6%25;IA8>!=<=8CS9W 1@J@@AU(():X-AZN51%9
M)W)MBY?2,CG('V6K61<%K>SZ"IXB_M58%HV-@[AY)^D8[:TD(1;H26+2\"=8
M%N?.I(U808,#)&J11QBS2*JZQ(5L4!4^S=>)M05V'W'MF1D&.&1P[DLVIBXU
M:>&H6X^9N/\ JUH64NVX.8>I,D(DC/%5Z83RD!1';@?*I//A:LCEE[ACX6.&
MDM'"."B&R/)&"5UL5)TMI8:1:@C[;O6%F#1C,K".QT2D-$;$NW!K*."^7T&K
M(F-M.V\,NR:P+"X3J:K6]FPX%_+?[M01=TWG#PUTY=D#@WAC.B-"?,O+4"#<
MZO7:K Z86YX>?%J1@T3'0XETO($)" HS_CV4ZK<321(CP</#/5QTC:28@A+I
MI(-[A_8M965O"HJOS>YL#&R F1-(TJ'6I5V3B!Q"CCR9;#TK6H1/@EASL=0[
M+)%*H"'AU-84#2Q-VT:GX&UA61ZCLQ%3;M"$%56%5(X@@1*.%!Z"BE H% H%
M H% H% H%!"WO_!\W_@2?V30>*SXY&R,E0&;J/*D2! ;OICX\?*?]HFXJPCR
M.WY^W[9@[OAY^U',R\S5[O. K*MP0JDD>72?&WU51;]M8N5%ML,<EU9G4JX*
MDG22#R(:X_-K(^DX=_<X.!!Z:<QQ]GQM0=?_ &Y?^ZH''_V'_NH''_V'_NH'
M'_V'_NH''_V'_NH,."48>KT?^Z@^2X;IF=TSY^)BG'QE870Z%):.W4>S66Y/
MI^Y6H'I621,*!G+O&)-3WC)4@E^ ))+?[+<.-Z@\S@Y.%LW<.5D[MMQS8I(S
M'%&JJ[1MP))7D-7U>%:&W;$$BPYDJQ=&*;5TT!4Z%<W5+#2WA^)QJ2/1[I#.
MZE+-(TD)6%711=@P\UO8(/Y=[U('D,//V_!V3<]LR]K]YW#+8F#+LK*-5M-V
M(\NGZ_&M"][:Q<J+!QHGNK:U;4FEB="D'Q#?G>6I(SW+B33XF7$H/5]N[+HT
MJ4 4F_L6)'E7API H<K-V[)V#;]GQ]J,&YXS@RYFE5!TDZB&YG5XCP\*H]=M
M,4PZ:7<,D6G0JK)[3@BX!TV'/\KQK,CSO=.+-+B8[K%U4B8=8'AU"A+,@9K,
MUU\6^Y6E:9^9A[SO>')M.V'!2"/IS!@JZV)-N'"X',7Y^-1'J56=L3*<%P"U
M[A05  6]W4G3Z/(+<+5('FMQ,6#W+B[EE8?O>WHQ)QPJ@LK7"OH'#@;\/'QK
M0;2R97<V5N>)B'$PI'U1Q70%;"S&S64&Y^GT5)'HV61,3',FLQB^J\=PVI6(
M5;DE[<M+FD#S&VYF%LF[Y\V[[8<Y<A-$04*W3(X,"/"_,GP\*HZ=K8F0F'D,
M8^FLQ.A1I-@Q#*E@5;EP\GW:S(]#NT,[K-'I9W>("%&10258W;\D @'SCB;T
M'DL#<,3;]@S-K?;FDW>:8/C;@@6P)*E&UF^G3X>GQJB;B;=GIBQ3>Y#,QE'6
M;$N"8WMI,D0!X7/#2PTGA<'S-4E7;&W**/9IL"+(@R98\8+A?%]1ME%R\DLA
M97\I1U8:6\.5!I[YN&-+E203[)@*NAL&=(Q/(I5D>42 !B1HU+Y;?Z* H=\B
M6?;XI\F=\B2:+<<R[''>06>/&8^>W#3Q/XI8#4O$..W9^+LV=FQ;MMQSHY(R
MD%@K:7'!B_K/I_%'!>'"JC?M7$R(MNEU(8Q*0% (-@S!E2RZ6X#\C[M21?[S
M#D.)D(9Y)(ATD=%!\K'4UAY!<#VUXF]:'D8,W @[:S-EGVLS;I/)>//LI7S$
M%3J(-K>'I\:#T7;V/E1X>+&X8,&+^32Y:R$'Q!N2/Q^'&U!P[KPLG(PIXD%Y
M5D;6[*%TZK:;D\1_L\JS I\_/V[/V[:=OP=J;$S<.WO&00JA@H 8:AQ;5]7*
MJ/7[9!D:3&I=66%8]"JK@$$\38Z;#GP\PI(\SW)CNWN61T.MCPLC31^R9-'%
MU#'S-S'F;C2!C*R\3=^Y(<G:MN.%CQQB.2-@B:VXD'3P' #A?A]VJ/4!9FPI
MGN^DRZV.FZ@:EO=@2?S?*;5F1YF9\?;>Z(=RSL$Y>" W_+A%U><$HW3Y<N%O
MOU0V(+-O.=N.-C^Z8<KL\,/D&A3=;V:PYF_#CZ*H])-'*N'C+)K9=!4 Q^T2
MGE"W)U6Y><W%9'EMKS,'9<K=!NVV>^ME(1"R@,([74J;\N/,^'A6I$GM3$R8
M<%E<&,RLH5A9K>;5ILI5N /XO#A4D7>\19#ID1E&>21%:)'10P"EM1/XJ\![
M2\32!Y*'-P8>UI]DDVPONTLMTS[*1<L"&UD'D/#[O.J/3[#CY,6-B1LK!E#R
M:8]+E@4MP%^)-K>?[E9D0>Z<+)GP9XD!,J2/K<@#3J;R\6X\;>SR%ZL"NW/(
MV[<-MVF/"VSW*3#UG*R& &H0HI=00+MJU#Q]7*J/38\Z1B=7G:,P(,=OL[KU
M$#7XC@./(J-7&LB@WO%:?<L!EB$R1S:)8F!02-CD"4:R.*@D7<\:T,9DV)N/
M="YVWX1P<:*!#+"4"FX4R L --^FOLW]'C4'HER%;"2;K,$GF+1JRFY4.M^(
MU'B6' >5OHJ"B$<.W=S2;OFXJYV!CB1'@C"LR@^S((@+6XA1;A5@-FQF._;E
M+'![I&7D,6/;BBG4/)J !]G6=/FM4D7;2++AP-J;HA3  \1%Y3#KLH:^L*HX
MLWLVH/,;9F[=M'Q%-RV[WZ3<8B^(P6^A;,!J+#RCUU53^U,/(AVY%DO&7D0:
MO*>(?5:RD-P!\/+PXU4>_P"T+^XO>][1\[7_ $:\[<*R+ZBE H% H% H% H%
M H%!"WO_  ?.OP^PDX_]TT'B<@;@VX9L3X,TV%)()(IHEC;4!&"NDLW"S>JB
M,/@Y#2ASA&2Y 9I(KM8*%')OR;WM^-QJ#7(BW&.(M%@Y&1.Z&/452V@KIT:7
M/#D+\>-46&V[_P!Q>[I'D;7+$P543[-#IMPU/:0WY<A0=UWSN+QQ@!:^KH&_
MHMIZGI^J@XYW<?<\0'NNU/,0?-]FMCQYC[1>8\*#M%W!OSP>? DBFYDF%64#
MAY;"2]SZ:#,>]]P7/4Q@0#P"P'S6N>9?RWX#C01<CN;NM<@+#L[M"38L40D?
M_P"P4$KX[OTD0"8;1/IL_4AN&:U[C3)P%^'&@JXL.80E9,*4HP!E@1 H8BX!
M)8E2;'B!SH(\<V^OD/'-M<_0==+2%(S<, K<-?B%M1767"R'52N%(=((19HP
M6"ERW-6TWO;E^+1&[09<*!XL2=Y(B3CJB*%1M0/!78WO<V-^ H(^.V[3(T69
MM61'&O% B1:O*"%TDN0O/APJ#M+@9$DQ9L(OJ8ZW:(ZK$!>'F_)'#_6JC&4N
MYPQEX,#(R)W73(Q6.S+8$+9FNMBH\>?&@QC'=)A%)D[?D0Y"&Z-H0@:F+-K.
MHL03S H$6!DQR*R8;)H"Z)1$=8((L3YN?$ZO2+4'/*^,8ZZ,/:\B52;O<1GS
M$%"U]2GBM!WZ&5.'>7!R(Y)5 F'3300"!8!6OJLHXWM:@Q'A98+GW1XRVH,(
M8].H'B5U%B%!;V>'"@XO/OT.5&F/M4YQT/D)2*RA2646UB]B:#L<.9X](PIE
M )812QJ5UZ--QH;@.)Y^-!LF',(F5L.4H;$P(@ )L5#'4Q!L+7 M<T'"/(WR
M7(DCR-KG$$EP[Z(SJ#D:N&NUSI]%!UDP\AU4C"D8J%"K/&&90"6XE6T\&/&W
MXM!L\.9"BO#AY$DD=Q#95"H-1X!78\[GC?EPH(^,V[SQ-'F;7DQ(/9Z:Q:KJ
MNA=+%R!84'63!R'E9VPBX<N7DZ1#7/H\U_ :;<J#:=]TA>-X-OGGF9@99BB6
ML%N/*66UF\#>@UEVYI4(]PD(%[)-$K7.G2;:3P4AFL#XT&B[1&@Z@VQNH![,
M42KYB/:.HF_LK<>F@UQY]]::2*?:YUQF\NK1$;JQ!:P#^-O10=),')<HPPY'
M("@+/&&8 $L 2K:38GS6YB@Z-#F0QJT.'/))'<0650$6Y\MG8\P3QORX4$?&
M.[3Q=/-VO)C"FZ:$BU JH1;$NP%A0=I,#(>9G;#+%RY=^D0USZ/-ZAI]%!KF
M?%859\; R,B=[&5],=F((9>#$%;-R%Z#./\ $ID1\C;\B&95LI"1E0+$G59B
MQN3X'G0(,#)BE#)B-%ITA)5B\_*W'S?D^U?QH..6=Y@"1X6U9#Q$^=2(VMJ7
M2_FU*3>W$T$@P9,^MI,&>-Y2IG#1IH8AK\ C7_%%^/*K$C$6%DJ&OAR*""'C
MB307 8-IU%B!YN7#EPI(X&??X\I$BVJ?W=>".4BX!-03@''(-PJ#NV#*T01<
M*;0NHI%+&IM=54VT-8</9OXT&?<\A8K>YRM8ZEBC0*@<K[5G8@\APX<>-!PA
MGWR6>5,K:L@0.>+:(C<%@[6\_BW'E0=9,+(?2WN4CL @ GC!*A;V!(:QXGS6
MYT&[Q9L,8:'#R)95&F,Z5 5/,-&ER3Q5O:ORH.&*VZSPA<W;,F(J;H52+4&L
M$!N7;@%'AX4'23 R&D9CALQ8NS/TB&U%B3;S>FVF@9C;MCJSXFWY$\['5+)I
MC\Y5@RD!B"MC>PO08A3/F19)]OR(9PF@$(FD+I;RM9BQN6X6-!S;9GDD&K$D
M15&A'1&!TM8-P#>(4:O701Y\3=(7MB[;ENDCEY+LC>>06=KZEN6]-!(7;)G4
M:L3)0EM<J2 -&SM)U2=*M?VE75?G097:)G33/C9!6S:HDNNL&X\S%BM_.UN'
ML\*")+B;JT\40VO*./"K+&_DX#D ;.+V%N!H)+;.2A6/$R>GTVB$4PO9/(-*
MZ&  L@T_70=5V_)CC!]WRI#'J9(H[JJR."6<:V-[LWJH(D,&[2S,,O;,M8T7
MIQ,-!*H5L>GY_*Q'#5:]!(&T2":.48<DC(L<8$R%K(BZ5#6;2;"^JWCRH.TL
M>;#%K@P<B:8+HCNJV"6*Z"KM^3S-^-!Z+LM9$V[IS1]*=%A66(VNC"%;J=)(
MX45Z&@4"@4"@4"@4"@4"@4&'174HX#*PLRGB"#X&@BC9]J'+#A_5K^"@?"-J
M_<X?U:_@H'PC:OW.'\Q?P4#X1M7[G#^K7\% ^$;5^Z0_F+^"@?"-J_<X?S%_
M!0/A&U?N</YB_@H'PC:OW.'\Q?P4H/A&U?N</YB_@H'PC:OW.'\Q?P4#X1M7
M[G#^8OX*!\(VK]SA_,7\% ^$;5^YP_F+^"@?"-J_<X?S%_!2@^$;5^YP_F+^
M"@?"-J_<X?S%_!0/A&U?N</YB_@H'PC:OW.'\Q?P4#X1M7[I#^8OX*4'PC:O
MW.'\Q?P4#X1M7[G#^8OX*!\(VK]SA_,7\% ^$;5^YP_F+^"@?"-J_=(?S%_!
M0/A&U?N</YB_@H'PC:OW.'\Q?P4#X1M7[G#^8OX*!\(VK]SA_,7\% ^#[5^Y
MP_JU_!0/A&U?N</YB_@H'PC:OW.'\Q?P4#X1M7[I#^8OX*!\(VK]SA_,7\%
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MM+)#%$\LK+'&@+.[$  #B22:#>P]%!I+)##&TLK+'&@+.[$  #B22:#>P]%
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M64+KTB%ETL+>:_AQ"N;M'OAL#0-[T9ABR(Y9!-/H=Y(]$4RCVHFU*'(4E1Q
M!X$!%?8.]=SFW(+EY&"3D3F!I,F>)=!3)6$!8QI-GFB:Z^72BBVJ]!(R.S>\
MIYLC)?<XQD,,GW31-D*(6GB**RGB19E4V^FU!MN'9W><[2/%OC*S&8@":>)2
MS#(,,A"#AHZT0*#R_9W\;4%]M.#O^$V9%FSC,Q<AYYXI0[&:'5IT0C@H8>W8
MBUN XGC0>6VGM+O:3:L;);=9H,Q\%3[KDY&2_3RRF.&ZG'B'Z4P;\@O=;VH)
MZ]F]QQY?6AS51)I<5LQ?>,@R21PXXB;[:VO4L@U#\L>U:@Y+V;WBL*1'>&:V
M/&K2>]Y0<9 EO*=7'6DD=N?LD<.!X!E>U.^UQ983NT<CA8Q [3Y(8QAUZD#L
M/2B768#6"2.(H+6'8>Y(<'=(!N(G?*:,X)F>6\2@_:*9%*MYE]GA<>)8<*"G
MQ^S^^HC&S[RLY"HF0DD^04F5$Q59;6^SUF"9BR\?/X\:"4W9_<D6S;3A86Y+
M!/M>U^YW62=(9,E#"$=HU(NI2*1"3Q77<<10<5[,[ICRNI!GQPQRSXTV2>MD
M/*RPQ012(SFW4U+%(MWX\0>'&@[[3V=W#BQ8D4VYD1XIQXVC26=E:!,1()T
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MW:*<]2*2(RAT"OJ/3/D=6%BWHH('^:>]G49#;-+(5*]'#6'(A+LLF8I8R$V
M=8H#I?@-=!W/=G>HS>D-H#8QX13=#)7J!EF*.;!^D T:!E()X^L4%Q'O^[9'
M;LV7!A,N]8J+)D;=)&X//4R)8V9FC!T6;G:_HH**;?>^H\S;\U]N<OTYL?,V
M^..4Q.PRL:(2*P+*I*F1T9OQ+W'C02-M[L[NR,[;UGVHQX>48_>+XV5')%U&
MD5E8R !3$474;6(-QP(-!O-W5W='G9,"[,\T<$V@,L,JZX_>)4U(['IN>BL3
M^T!Q/&_EH(<O<?>&>-N1MMR<+J9N,\IB@R RQIDPID02D@ !49V,GL.H\M!-
MR>XNZ,??9,:';6DP??!&\QBR7O"7PX]:-["C3/*W#R_9GUF@C;CO'>6-W2[0
MXTN3A12O N.L$PB>"5\$(XD4E-:]2<ZSP 5@1Z ECN'N2?M[%W!MM=,R3+56
MQ!%E1O''H)/42RN=$@TD^PPXCF*")#WEWF,?J3[#)*51FE$,$RL"(TDX1R$%
MK!F6RDEF6UA>@Y;QW?W;A863N#8*-CX19HV,&9"&5=O?(ZL@8CR=7[+2PX-_
MK4'2?N+OB/(+/M39*H;XT,,4\2RZ??0'+EB$ZG2@\DGLZ[^B@E87<_=LF]X^
M-/M=MNDE5#DB#(4M')UK2\;B+28T#*]SQ\+B@C[IW;WQ \WNNR:D1L@+JAGD
M-X1DF-?LSY^L(8BKC@.IIYT&_>&Z]VX^YQ/M4,KX\$<63%$F/-(DC]#,ZL4K
M1\_,D "\+,0:#O+O_<^7L/<4T>#)@YF)%*NVQ="9I3( ^AENH6;4-#+T^5[-
MQ%!PQNY>Y,?-.W)M>2^&DZP8^X3094EP6D_27+OI;IBTM]*ZAJX4$W$[C[DG
MV)<Z3;&ARI,I('@:&;7CQ-I$CO$VEY>F]QJC\K#S#A00\3<.[9,+=-SF@F@W
M%9<*.' ,<LD<<+QXSY(1 0)BC/,-:\>'JM05^U=P=[086/#+MTV5/ ).G--'
ME(7!B+()38ACJ&FY%KVY<Z"]W3N;N'&CQ#C;/--)/@G+:+I.UYE34V*S1EEA
MDX\-9LW%0;T%<>X^]IG5EPPF*K1:BN'EJ\B30SMRD*/'I>.-6\MUU<;4$2'?
M.ZL>;XB^WYN2/*HQ!'E6AB]QQI&(C)M,RS-*/-YF(TCC03,GNGO(Y:PX^UR/
M%'T'>88LZ"35HZB+U/9#=3VCQ2QU#@306^T]P[EF;+---BF/=ACODPX;P9,(
MMYA&CB1->K4NEK ^D"Q%!Y[%[G[SAS,V:3;,DQ905XL=\>:3H2K%C*0NABIC
M9GD/ \P3Z102>UL[N;,W])=PBS,;%R(\IY,>5)5BC9X-O9$!91[$AR G_>H-
M.V]^[XB3:-MW+;W=9$B27<Y(IRQ*QQ=:.8#5HD!9_M7LC$6'&@F;AW3W7'D9
MD6)L[OT)988P\,UCHCDDA82#R2)D%474OZ(GSB@X0]V=Z-D/$^S'29@@*PS
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M !N#<4'J=H&XKMN.NY%6S@EIV2Q!8>/ */JH)= H% H% H% H% H% H% H%
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M'D+(74@75V>+A>W#@ 102#_GH[7,;P+N#9EE 52J8M[7CNUF/XWGL;7'.U!
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M!0*!0*!0*!0*!0*!0*!0*!0*!0*"!O4V[PXT3;7 F1,9HUEC<V^Q)LY4D@7
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MD7D;&QY^@BQH.] H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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MU_E^V_WV?^$H'O'>O\OVW^^S_P )0/>.]?Y?MO\ ?9_X2@>\=Z_R_;?[[/\
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ML4JC%5IH\2&2)FCB$<LL@1I4+K*6C=&ZB6Z;+;2USQH/:0-(T,;2KHE*@NG
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M2,.5N'I!H.T6Z;;+*88LN&24,8S&LBEM:@$K8&]P#>U!)H% H% H% H% H%
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MJ)(C)%*0^E5M]ICHWDT_>H(2_+;MX'46R&D9(HYI"X)D7'Z)@U^6UXSBQV(
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3*!0*!0*!0*!0*!0*!0*!0*#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>42
<FILENAME>g518298dsp086.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g518298dsp086.jpg
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M'Q\?'Q\?'Q__P  1" -P FX# 1$  A$! Q$!_\0 ?0 !  ,! 0$! 0
M      ,$!0(!!@<( 0$                     $  " @$# P," P8&  4#
M!0   @$#!!$2!2$3!C$B%$$R42,'87'4%565@4)2,R06D:'!-!=B<D/1@E-C
M)1$!                     /_:  P# 0 "$0,1 #\ _JD
M
M
M
M
M
M
M
M
M
M                  ?+?J'Y%Y!XWQ5'.\;B)G\;@719S^)"LV3\#32R[&E6
MB-]/WRK1.Y8GTD"IXOYUD>6>394^/]B_PSCJHKNYC1FG+SK(A^UBM#0O;H2?
MS&F)U:=L>D@?:
M                                         #Y#]1KO*\G#Q?'?&J;*
MLOFW:C+YO;K3Q^)$?GW3,^MS+.VE?]76>D 8W@'C7*^ <_9X?A8U^7X-EUME
M\'F:S9.!='7(Q+WGKLL:>Y4T_694#](
M
M
M
M
M 'Q?ZL<'1F^+6<NF>G$<KXY,\IQ7+V3I71=0LS*V_P"JFU-:[%^L3Z:Z ?._
MHYR5WG65E?J%S.E/*U[N+PN"B6__ ,NI-K6PZO"3W\EM'9I7[-L1]0/U8
M
M                         ?-^7^%U>4W\73R&6T<'@Y$9>;Q*I$IFV5:-
M0MSS/^U6\;Y331ITU] /*_":<7SJSRSCLML-L[&C&YOCU2&JS&J_]O>TZQLM
MJC5=VDZKT ^E
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M2^V>G3]X&H
M
M
M
M          ^9\T\EY+A/A_"I2]LA<MFK9&=IG&Q7R%A85D^Z:]L_O M>-^5X
M?.PRT5.EM5:67]59%[J+95*M$ZLMJ/N2=(UCUTGH!N
M
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M_%@/@^8_UC"_M]G\6!H\=5R55$KR&35E7[IF+*:9H6%TC2-K67=?VZ@6@
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MU9*M5EY=F79\A6EJ+)O["1MNK:=NM6G7I^'J!]E&ND:])
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M5VK%4XTYB6653WGF(C)T99_+A)]R:*RMUC1>DP'VX
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MVVG9VYCKKM_^H#KDI\X;CK6Q9NCEOF65K2O:7&G'FYNRRO*.T1V87=/KKKK
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MNGK]>N@'U
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MV$UB%6N==5T_;J!].
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MO3I.DS].@%D
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MZ2!T
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M'E4O16F9A7VS]9C6)TF8 U0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
..               !_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>43
<FILENAME>g518298dsp14a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g518298dsp14a.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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;TBPH * "@ H * "@ H * "@ H * "@ H __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>44
<FILENAME>g518298dsp14b.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g518298dsp14b.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I
M*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1  (! @0$ P0'!00$  $"=P ! @,1
M! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H
M*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_  !$( !0!:P,!$0 "$0$#$0'_V@ ,
M P$  A$#$0 _ /W\H * "@ H * "@ H IV%_::E:0WUA,MQ:3JS0S('575':
M-B%=588=&'('2L,+B:&,H4\3A:BJT*J;A-)I-)N+T:3T::U70F$XSBIP?-%[
M/TT_0N5N4% !0 4 % !0 4 % !0!QJ_$/P0UAJFIIXGTAK#1;B&UU*Y2Z5DM
MY[F5K>TC4*"UQ]IN$>* PB03O&Z1%V0@5R25E9J^W]>1E[:E:3YU:.CUVZ+[
M]E;?H//C[P:LGA^)?$&GS/XJ0R^'EMGDNAJ<2S6]L\L#6T<@6)+BZ@B=Y"BH
M\@5B&! .66NEN7<?M::Y%SKW_AMUZ=/6QT46HV,U]=Z9%=1/J%A;V5U>6:MF
M:VM]0:[2QFE3^%)FL+P(>_V=_2IM9+MT^1::NXWUC9M=D[V_)_<7:!G,:MXT
M\*:%J=EHVK:]IUCJM_Y)M;":<&Y9+B;[-;RRQH&-M!+< Q1RS>6CNK(K%E(#
M47:Z6B(E5IPDH2DHR>R_!>G;4W;*\M=0M+>^LIEGM+F)9K>9 P62)AE64, 0
M"/4 TK6TVL4FFDUJGL6J!F3KFNZ1X:TR?6-<OH=-TRU:WCGNY]YC22[N8;*U
MC"QJSO)+=W$$2*JL6>50!DTTFW9+Y$RE&G'FD^6,;:_.R_'0DTC6-+U[3K;5
MM&OK?4=-NU9K:\M9!)#)Y<CPRKD<K)'-')&Z, R/&Z. RD :<7:UF@C*,HJ4
M'>+V:_KH3QW]G)>W.FQW$37]G;6EW=6BMF:"UOY+R*RGD3M'-)I]ZJGN;9_2
ME:WH--7<;ZQLVNR=[?D_N+= PH CEEBMXI)II(X(8(WEEEE=8XH8HU+R222.
M0L<:HI)8D  $G@4!MY)&/H'B70?$]I)?>']3MM4LX9O(>XM2YC$GEQS+M+HN
M^-H98I$D7*.LBLC$'--Q<=&K$PG":O"7,EV+T.IZ?//-:Q7<#7$%W)8R0%PD
M@NX;6&]E@1'P972TN(96V;@%<$G@X+-#4E>R>J=K>:5_R':A?V>E6-UJ5_,+
M>RL8)+FZG*22"&")2SN4B1G;:HSA58^@I)=$#:@FW[JCN<U<_$'P396FA7UU
MXFTBVL_$T4<^A7$UTL<>HVTOD!+J(OC9:[KFV5II-D:M<1*S!I%!KEEJK/W=
MR'6I14'SI*7PZ[KOZ:K4O6_B[PQ=Z]<^%K77-.G\064;27.DQW*-=Q+&D,DJ
M[!PTL4=Q;O)$I+QK/$SJHD4E<K2O:R[C52FYNFI+GCNNO]+\#<N;FWLK:XN[
MJ:.VM;2"6YN;B9A'%;V\$;2S32NV D:1JS,QX 4GM27E\BFU%-[*/Z$&EZGI
M^M:;8:OI-Y;ZAI>J6=O?Z=?6LBRVUY9742SVUS!(O#Q21.C*1V--IIVM9KH$
M9*45*+O&2336UNA:EFA@"F:6.%7DCA0RNL8>:5Q'#$I8C=(\C*JJ.6)  )-+
M]!W2\B&RO;74+2WOK&99[2ZB6:WG0,%EB<95U# '!'J!1:VFUA)II-:I[&%X
MF\9^&/!L-I/XFU>#1X;Z;[/:2W$=PR33AHHUA5H(9-LC23PHBM@NTJJN6.*<
M8M_"MB9U:=)+GERIZ+^D.L/&/AC4UTXV&M6-R=5O[S2]/B20BXN-0TZWFNK^
MT%LRB6.>WMH))9%D1=B[2V Z;CE:Z6Y?Z01J4WR\LD^9M+U6K5O);F:?B/X'
M2YUJS?Q'8PW7AZ/S=8@G%Q!)9Q_;AIB,5FA7S]^H,MM&(?,,DKJB;F8 ODEI
MIOL3[:DG)<Z3ANNVMOSTTZCU^(G@EKW1-.3Q%8/=>(T@?0T3SGCU+[0;E84M
M[A(C"9BUG=*8FD613;N&4%2*.25GI\.X>VI7C'G5Y?#Y_/;H_N-1_%?AN*#Q
M!=/K>FK;^%)GMO$<WVF,QZ+<1V5OJ+V]^P)$,ZV5W;2F,_-B=!C+ 4N5Z:;[
M?D5[2"4_>5J6DM?ALKZ]M&C>1E=5=<[64,N05.U@",JP!!P>A -+;Y%CJ /-
M/&'AGQ[J_B_P!J_ACQPOAOPUX?U"\N/&/ATZ;%='Q59S1PK;VHN7YM]FR9.P
M3[1YJY>)0;BXJ,DXW;V?8PJ0JRJ494ZO)"#?/&U^9=%?I_3)-+\.^,K3QWK6
MN7WB47/AB\MFCT_1M\[?9Y&$/DC[*Z"&W\@I*?-C=FE\WY@,G'R&!RG/\/Q-
MF&98K-_;Y+7@XT<)>?N/W.5>S:5.G[.TO?A)RJ<WO+5VPIT,5#&5:LZ_-AY*
MT:>NFUM-ERV>JU=]3C-,\!?&*T^&'B_PQJ'Q:2_\?:OJ.J7'AOQN-%A@70;&
MYN+:2TL39J,/MBBNE\P!C!]MQ%N%NF[['FI\\7R6C&UXEQHXF-"I3>(O5DWR
MSY;<JTLK??Z7TV/7_#5CJ^F>'M#T[7]6&NZW8:586FK:T+9+0:KJ-O;1Q7E^
M+6,[8/.G5Y-@Z;JS=KNRLNB[?\,=,%*,(QG+FE%).5K7:6KMTN3ZW%?3Z/JD
M&F"W.H36%W%9+=[A;&XD@=(EGV<^66(!Q7%F,,34P&,I8-4WBIT:D:2JW]G[
M1P:BIVUY;NS)JJ;I5(T[<[BU'FVO:ROY'B@\"^+%T^&W,)>P@U76)8M$>\TX
M/%;W]EI2V-Y'M4644MM=0:EA(PAB-V981N.#^=+AK/%A:=+V?-A:6)Q4HX1U
M:%XPKTL,J-6-DL/&5&I#$>['E=-U74HIRT?E?5,2H*-O<C.;5/FCHI1ARO\
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# /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>45
<FILENAME>g518298dsp7.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g518298dsp7.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MG[MOZV-7)J/-%<VETDTK_/8\EM/C2O\ 9>@ZAJWA#5]+G\9:5:7_ ((L$O\
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>46
<FILENAME>g518298g01q73.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g518298g01q73.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[2-^4&AO=&]S:&]P(#,N,  X0DE-! 0
M    (V*^D%@X0DE-! 0      !D< 5H  QLE1QP"   "   < E  !41E;'1A
M #A"24T$)0      $)_]]5M,FVC]2'%8$L(%V8@X0DE-!#H      .\    0
M     0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT
M965N=6T     26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP
M    "W!R:6YT97).86UE5$585     8 00!0 $0 +0 R       /<')I;G10
M<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *
M<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F
M"7!R;V]F0TU92P X0DE-!#L      BT    0     0      $G!R:6YT3W5T
M<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B;V]L      !2
M9W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O
M;       3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;
M0F-K9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M      !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@
M0G)D5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M    4G-L=%5N=$8C4'AL0%@            *=F5C=&]R1&%T86)O;VP!
M %!G4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M          !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F-
M60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1"
M;W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P
M4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE-
M ^T      !  E,S,  $  @"4S,P  0 ".$))300F       .
M #^    X0DE-! T       0   !:.$))3009       $    'CA"24T#\P
M    "0           0 X0DE-)Q        H  0         ".$))30/U
M  !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    !
M %H    &       ! #4    ! "T    &       !.$))30/X      !P  #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z     #_________
M____________________ ^@  #A"24T$"       $     $   )    "0
M   X0DE-!$0      !     "   "0    D      .$))300>       $
M #A"24T$&@     #00    8              6L   &J    !@!D ', <  Q
M #  -@    $                          0             !J@   6L
M                     0                         0     0
M &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0    0
M5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   6L
M    4F=H=&QO;F<   &J    !G-L:6-E<U9L3',    !3V)J8P    $
M  5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG
M          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N
M97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B
M;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
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M=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<      #A"24T$*
M    #     (_\        #A"24T$$0       0$ .$))3004       $
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MS;6[?=5NW_0]1)3=V,.I:/N\4MC 9#1/,QY;?^I4DDE,?3KYVCL.!VX3@ "
M("=))2DDDDE/_]+U3<"85?.HR;JZQC7>A8VQCW.@$.8#^EJ<WZ7Z1G[CZ_\
MT6_,^K4^KU4NU?\ ;K&DQ#ML-=6'.VASO:[V[EME)3AV=
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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ME:A3972(T]CQ_\0 ' $! 0 " P$!              $"!00&!P,(_\0 51$
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MH?NVV:]"E8R2A3KAS@EX75$4MXKAPV.3 6%3Z41A)H1K,G@P(^1S;7@@&<V
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M:5VVE-NQ%\$O9H1H;OAH7#?K$2JVL"Y*XUUX5J;G053(6GCQ?)O7)AWH81U
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M#IU :FSPVANFZ#%9KTB!*6(]E'U22A8C)452:8L"&D!;+J^F3SK>?JRO U#
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MKJW$W(73;="9L:6?4*.XHUMH3QMG;%;*5;RX=MDH0RHUHXEL92WA7%)?+O\
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M2MR;;3[JG&!3WXR9QWT]"4U!G2CGH,1QT\G"@%MQ,>).(^U@K]="ZH:B04Y
M&KU&COI!$.W=81QQ,ZGH&U<.&))XYE7%U%DFB)HB:(FB)HBZDM+0)2! EI6
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MZCM:3IBS"([4>+)CA<25CPDQ0M40>O,).%JI!@<(ZFX!U/#P6(9R9NQ-QX1
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M(SY8^X(]#[\_5I.@[SIR]79/J?;8_P"0ZWN.,?M2G./'[L8&.>?,8T2>'?\
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MW]DU3H;64B'$F7&Y(,*)?F(J4FO9Z"B+,S<""9J,D0#&44PH(@:[WK%ZL.H
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M3K2$J)2J)G5]H[![ZBH@L-X.334=T@4@D&K&PV@2!238,+G?^S?;-?8&TC:
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M*'U3K.Y)]DN-DX_Q]WU(\/.X/'8'(&2?'4  LA?7/UD\Y^!U':=9TY_8EQO
M_P /5].X_P#:!V/8]\C@@CC528\9^WT4?JG6=RDB4N."GL1?J^N?U_C!Y\#S
MV/;YE/BGZ_\ I^OT@-IMG0,>RW([@_P^7V/(S_Q@\\'L<CD\#OHK.OB.O\O=
MKJ$^J;9SM[)<8]^]^;Z'N<_R@^?]NV"3Z/'D;CZ<4^J=9W_@=QL^?QZOI_\
M$#'@/#P[^9LDE[QS'_+\U$;3K. #$G<8XSC-^KZGOX\W!.3Y9''./F2?3=]O
MD+G@AVG6=/'L=Q@.<XOU?0=P1X7 R>#VS@8&.PT2?1Y?Y?3\F?5/L[D$REQL
MC(_AZOI@@@#!_&",X & 1_VZ,-$G5NN6?\OA-RH?5.L]Q^Q;CCOVOW?3@'/
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M+DK9SKIRWJ:(J=<V/H2J<D9DHHSDC\T=^,@C/CV.3GPUK>TF_#XEY%,1)-=
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ML,D2P  .@8$40&8%W$$';P ,8//;/;CMR1VXQVX[<'79EY>0:7!)!DD@DF0
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M\U]I4C KQ: &%-6$ [.0<.G=,N[[S@29;)EMV[D X^0."?D>YY'G]_ZNQKS
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M8=7]IT8ST$4X8H:HD8I/N]E@4L7&9<@AJR U*]2]D33[C<WJJ<]ZK\H_>;2
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M=NDCIP*\E( _-]V4#  !([\]L=B<CCLOLOM5=6/32:G@QJ]&T0VZ,]9X2MB
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MX<RYJ90Z,YDWP?*:K3J!5#7*+2.D*$,!VK9-NEQ>M&%J5%*U^LZDJ"NG,;]
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M[E1 /J?,DY\1C[9^XYQG R,C/.<:XO\ \V5L]J><;0Y<=Y)S(7RV6:J"="1
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M*!''/F#S_1VUQA/9M0>?@<LU\?-L\FT9X7TV5A53(@UN+ _GSS)!<M<N13(
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M@_9R?#L=><>TF-35BT/ !(EP1^[P3D(DZRSEC?L?979]=8<5$[U) (:J!5C
MP:PS,Q-0B0'9QLN[C/8CL#CCC/&3XD8''A@#72<S?.]^OKIDMV6<M;+TZB/'
M/ZP>,>!/R&.V#Y@<#(?3EW<QK>0)3PCEZ<<GMS@GB$2.1SR.P/K,YSW.>1GO
MV..3CC-_U962?Z!&?]XEN]VM.6?TV0 F@TD;I-3,14 V]NR;, S"!8%@XJ.
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MRZC-=='LMV;_ $U#5L6J3F?XE[=!Q7S_ '%S9R2"85RQW[/*$2#X'EL\^''
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M4]%@7!TX^L=N- '&2X[> D^>1;[Q/ [?TYUL: S/+:\'NS_.+YJ$F;:6 O\
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>47
<FILENAME>g518298g1220183454377.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g518298g1220183454377.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  1 *P# 2(  A$! Q$!_\0
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M*/\ %J?,)?PH?(ZF_P#^0=<_]<F_D:AT7_D!:?\ ]>T?_H(HHKE_Y=_,Z?\
MEY\CG/$/_(4G_P!P?RIO@_\ X^Y/I117>_\ =WZ(XO\ E_\ ,[.O-/'O_(<A
M^@HHK++OX_R-,?\ P3O;?_D")_UP_I6!X;_Y"A_ZY'^8HHJ(?!,N?QP-C7_^
M/2U_Z_(/_1@K$\0_\A63_=6BBJPW3Y_H3B.OR_4Z]/N+]*R_#O\ R"/^V\W_
3 *-:BBN9?PWZK]3H?QKT?Z'_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>48
<FILENAME>g518298g1220183455639.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g518298g1220183455639.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  6 *X# 2(  A$! Q$!_\0
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0\ *  , <"BBIN]AVZG__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>49
<FILENAME>g518298g29e61.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g518298g29e61.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[1:"4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %F:^5S0X0DE-! 0      !D< 5H  QLE1QP"   "   < E  !41E;'1A
M #A"24T$)0      $)_]]5M,FVC]2'%8$L(%V8@X0DE-!#H      .\    0
M     0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT
M965N=6T     26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP
M    "W!R:6YT97).86UE5$585     8 00!0 $0 +0 R       /<')I;G10
M<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *
M<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F
M"7!R;V]F0TU92P X0DE-!#L      BT    0     0      $G!R:6YT3W5T
M<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B;V]L      !2
M9W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O
M;       3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;
M0F-K9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M      !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@
M0G)D5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M    4G-L=%5N=$8C4'AL0%@            *=F5C=&]R1&%T86)O;VP!
M %!G4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M          !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F-
M60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1"
M;W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P
M4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE-
M ^T      !  E,S,  $  0"4S,P  0 !.$))300F       .
M #^    X0DE- _(       H  /_______P  .$))300-       $    6CA"
M24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M   *  $          3A"24T#]0      2  O9F8  0!L9F8 !@       0 O
M9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M!@       3A"24T#^       <   _____________________________P/H
M     /____________________________\#Z     #_________________
M____________ ^@     _____________________________P/H   X0DE-
M! @      !     !   "0    D      .$))301$       0     @   D
M  )      #A"24T$'@      !      X0DE-!!H      T$    &
M      $*   "6P    8 9 !S '  ,  V #<    !
M      $              EL   $*                      $
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M     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N
M!V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX
M   '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO
M<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T
M<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/
M=71S971L;VYG       X0DE-!"@       P    "/_         X0DE-!!0
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M>]5CU>P"2W'C2?UAO?\ L-_-*5+A$ENTU.<R;F;'R?:'$Z=M40
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                _^+__TE#0U]04D]&24Q%  $)OLS^
M_AX "(!P041"10(0  !P<G1R0TU92TQA8B 'T  ' !H !0 I #5A8W-P05!0
M3     !!1$)%                     0  ]M8  0    #3+4%$0D4
M                                                          ID
M97-C    _    '1C<')T   !<    "MW='!T   !G    !1!,D(P   !L
MH@9!,D(R   !L   H@9!,D(Q  "CN   H@9",D$P  %%P  ".+1",D$Q  -^
M=  ".+1",D$R  6W*  ".+1G86UT  ?OW   D)%D97-C         !I5+E,N
M(%=E8B!#;V%T960@*%-73U I('8R
M
M             '1E>'0     0V]P>7)I9VAT(#(P,# @061O8F4@4WES=&5M
M<RP@26YC+@  6%E:(        +5:  "\9P  DC!M9G0R      0#"0   0
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MD^>9JJDWD9J'S*4PCX1U4*%HC;UB$IW\C%%-Z)KHBS@X09AJBJ(>RI?7B[,
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MPEZ6IJ;$O*N$UJ*VMW%R8I[VLOI?8YN&K[I+G)AUK1\V>Y7=I-8=IY4)E T
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MFFF,8K)AEZ9[>ZVFE31J!JDDDQA7[:3PD5U$X:$_D#4P/IY2D"H7/IXVCK@
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M>1B"'[_2>,MR%KI\>+EAH[5I>.I0<;"G>5,^"ZQS>>0IIJF6>FH/9JM9>PL
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MH&* 0KNUG3=P3;9 FG-?S[$)F"Q.KJPFEG$\E:?0E;(HPJ26E;P0*Z3CBNX
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M@&YUF\E^?V=F<,.,?JU6SKW6?D1&<;AT?BDTV;/,?E @]K#^?I\(9[#J?^<
M (H6@ "$2LZ%A\5U;\A\AD%F0\*%A/I6F;R]A"%&/[=+@YXTOK*1@X$A"Z^5
M@_@(YJ\H@_X  (HO@ "$1LU\CQ9U7\=LC1EF(,%RBV=6=KN;BAI&)+8HB4@T
MM;%FB/XA+*Y)B>0)7:V;AE4  (I%@ "$.<R8EH5U6,9XE =F'<!PD?!6:KJ7
MD$E&(;45CR0TQ+!5CM\A6JT@CWL)S*Q"AJ   (I8@ "$'<O4GB%U4,6DFQIF
M*+^.F)!6@[FOEIE&.+0OE4LTXZ]=E4HADJP8E$ *-*L;AN8  (IH@ "#_LLL
MI<]U2L3OHCEF-[[,GSM6H;CIG/U&7+-NF[DU#JZ:FZTAS:LREML*D:H?AR4
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MN7@(C*CFD70#URG/N'1YSPRX.G3VQS&@1764O\B'_W9<N/=O+W<XLNA51G@
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MK*";[)AOJ,&)Z)6WI/YW)9,ZH7YCNI#_GF9/;H\*F_$YPHUJFP(@58T6E=P
MR(FN@(>LD)KKMFJ;4)@-L>.)2)51K75VA9+.J59C()"3I<M.YHZGHTHY68T
MH5L@#(R0E:L O8D;@("L%)J<P)V:TY>^NV^(OI4 ME9U]Y)XL:)BGY YK<U.
M>HY,JUTX_(RNIF4?OHP^E78 M(BE@'JD":J1=#F3GZ;L=+R"L:-\=4]Q!:!%
M=?Q><YU*=L5*O)JH=Z(U5YB^>&L;0)EK>.P  (V>?Q&C,*F6?..3"Z7G?)N"
M)*)P?'-P=I\T?'!=VIPY?)=*(IF;?-XTOY>M?2T:T)@U?9@  (QL@ "B<ZB*
MA8B2/Z3DA(6!;*%F@Z1OLIXQ@OY='YL\@HA)>9BC@D0T+):R@BL:;9<9@L8
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MLC2.YJ&DKA!]])XCJA5L2)K:IGI9]9?@HY1&OI5,H@XR$9,NGW09)I,0D0$
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MC%.$[*W/BL)T^ZFDB6!D6:6QB#]2UJ(8AVA /9[RAM@KTIRZAL$2*YX&ALH
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MMVR"RJL7LQ%RU:;0KO%B*J*_JWQ0W)\)J7,^GIO4ILTJO)EDG.42!IGFC#
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MDF!XI;<6D&)IA+)!CJ99P*V>C3-)/ZE.C!PWCZ6LBY8CUZ-6C#X+2J.YAZ(
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M<OUMF<6V<S=?6,!_<YI0<[N"="= GK;?=,LO1;,A=60;!K'X=6L#;[!-=XD
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ME^1M5,":E9!>][L?DXY0 [75D?9 3[#ND.PO8:S2D0$<%:JFD L%Y*?A@_L
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M;PB8CIAS<$&'I98\<6EUL)0\<HQBM9)H<[=.DI#5=.<XU(_"=?0>HY"&=H0
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MG,:4#9,OFE&#"I$.E]YQ)(\:E89>=XU:DVA*RHO?D:XUF(K%D,<<(XKRCY$
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M=RZ*M*"D=X5ZPYW!=^EIY)L1>%Y7_)B;>.=$W9:">7HOZI4J>>T5II;4>=P
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MHH^'&)PHG\]W%9E$G0UF.9:*FG14G905F$%!_Y'\ELDMM)!MEH4489$XC<@
M (%+@ "5SIZQJY>&G9N]J$YVDIC2I/EEMI8.H==4'I.5GU%!AY&"GA M6(_I
MF^ 4.9"$C:P  (#@@ "5=9YBM/"&.YMKL2EV(IAXK49E096JJ:Y3M),JIPY!
M+Y$2I3HM#H]]GG84 I ,C8<  ("+@ ",G*\T;@!^5ZM[;Q=O7:@#<"]?>:3
M<4M.C*&[<F@\09\W<W<GS9WW="0-+Z"X<\4  ()_@ ",+*XY=D%^!JIZ=HYO
M *;M=O)?&J.5=VQ.*Z"#=_L[Z)WT>(PGA)R9>.0-.I[B>-$  ('%@ "+NJT-
M?EU]<ZE8??]N?*7"?;M>BZ)I?:)-IY]6?:@[>9S'?<8G,YM7?=X-/YTV?CL
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MIZ=[!:6*I+UKYZ'DH<Y;^)YBGR-+2ILYG3DYBIB9G*PE\Y;+F7(-2I<YB/P
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MA))Q!;)Q@[!BQJX]@O%3RJHX@F9#R::6@A0R<J.D@? >I*)B@A8&MJ%_@>0
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MK$=OT*\KJ59AA*K!IEU29*:"H^M"D**MHL,QE)^/G_,>=IW)E)D'H)O%A2@
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MB@ME7[P'B,A7P+=%A[9)=;*HAMHZ4:YSAE$IGJM'ADD5[:JOAI !D:15@0\
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MAEJ9I(8/A;>(D(4^A0!VBX2&A%-C>8/M@\-/7(-Y@TDYIH,X@N,?QH.8@K@
M ()O@ "HI87#C]N8F(3@CHJ'@X07C2)U8H-GB[9B;X+6BF1.:X)UB4HXX8(R
MB&X?,H)FB'L  ($N@ "GJX37F7Z7EH/ZEWZ&@8,PE5QT;X* DS-AC('QD3!-
MJH&&CW@X18%%CE(>M8%8C=T  ( @@ "FXH0<HS*6R(-%H(B%K8)VG:QSF8'"
MFLI@Q($WF"9- (#-E?(WQX!VE+H>48!LDE<  (  @ "F2H./K0B6(X*^J;J$
M^('GIB9RX8$FHHQ@$H"7GU9,4X YG-DW-W_?F[4=^'^GE$0  (  @ "EXX,M
MMQJ5I()@LS.$7H%\KNMR/("IJJ!??( 0IN]+UW^OI'HVS7]8H7D=GG\-E <
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MC2R, (WBC!![^(Q>BNEK"(KVB;]9+8FUB+)&'(B^A]PQ68@7AU 7L(C&AU@
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M:,R"UYQ,:HUSWYH";#1CQ)?O;<52AY8+;TD_[)2&<+$K2I/H<;,0;);><2\
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MDT=_%Y9XD<MP 90\D$!@"I(?CKI/,Y SC6 ])8Z?C&HI(HVVC%T/BX[ B9$
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M<&=UWJ36<4=GK:'G<BQ8@9\G<Q9(,)RK<_XV9YK#=,LB*YI'=1X(@)MT=3$
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MF(=R]Y^9ELYDN)RHE0)5G9G:DTU%II=1D?(T=Y4\D5LA%90>D.@(XI,.A@(
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M=NAI8*W8=QM< JI'=V!-H*;K=\,^**/L>"TM$*''>(08[J'I>%0"7IWY>E@
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MG0)GL:DMFSM:,J6&F59+V*(&EZ,\E)[LEK4KZYR3EG88NYO&D+D#B993@F0
M (  @ !T+JQ^I1=GM*B^HQE:+J3\H-!+N*%=GLD\>YXIG?,KZYN^FY,8T9KR
MD,@#K)6,@GP  (  @ !J,K\#9K1=SKM : Y0X[>6:7!#([0%:L8T*K#H:_0C
M'Z\^;*(.(;%(:^,  )\$<[   (  @ !I[;X];C)=S[HY;MA0];9";YQ#1;)W
M<&XT6Z\N<3$C<ZU*<9P.M:[H<.8  )W >"D  (  @ !IS;SG=61=G;C:=8!0
MU;3/=;A#)K#M=ADT4:V0=GPCD:N(=JX/'*S(=B8  )R)?"(  (  @ !IJ+MR
M?&M=8;=F?!Y0A[-=>^E"\J]W>]XT+:P4>_ CDZGR>_@/9ZKB>]@  )MH?Z$
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MH.M=([,3GTE04:ZUG7Q"EJJ;G"4SZ:<+FVXCL:24F"(05J2#BPP  )>R@
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MH"^9)707G;Z'ZG2CFQ9UP74UF&5BS'7:E>).VW: D[$YBG;KDB@@479SD,P
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M=M619H&(=XN!78$[>"MP$H$#>,!=P(#>>55*.(#7>>0U!8#S>D\;-X&:>BP
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MI?.,MGO<HU5\CGNGH&MK=WMYG7)9B7MQFLE&CWN#F,,R'WMME_D9('K$D/T
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M??N$"XBR?B1T\H?!?C5DZH;B?CM3J88N?D=!+H6I?E4LRX5V?E02N8:@?@8
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MJO> EX1EJ%=Q8X-BI45A/X)BHB%06(&7GY@^5H$*GF4JFX".FS41<8!%B\L
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MA%EW*I"QA =H^(\8@Z%9QHV:@S%)J(Q!@LDX!8M1@H<D.(K^@F<*[8KQ@>X
M (  @ "#NI%'C,AV<H^HB^]H/XX/BO19&(R)B>M)!HLNB/TWG(HEB%LCZXG
MB&L*V8EGAA0  (  @ "#)I!TE41U\8[=D_!GO(T[DF)8AHNHD,5(:XI-CV@W
M%(E"CI@CGHBRCL8*QH@=ATD  (  @ ""L8_6G<YU=HY"G 5G.HR7F>]8!(KV
ME\Q'ZHF3EAHVCXB,E6LC-(?IE!4*MH<0ASX  (  @ ""6H]DIH1U%HW.I%MF
MRXP7H<=7D8IGGR]'A(CWG5(V/(?EG' B[H<YEYX*E89&AR@  (  @ !ZD**E
M8G!N$Z F9)5@JYWN9J!2()OG:(I"6)H>:DXPXIC^:\,<@9G!;#\#WYBA;+X
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MB=]J^IESB3A=DY<PB'5/.I4)AZT_XI,BAP<O&9&YAK$;CY&=AQ8$J(YV@R8
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M:3]ANJD;:H]4_:9&:^%'0*.@;2HX-Z%@;E,G/Z Q;QL2<:(M;HH  )<M<VD
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MCGU?D:+2C:]2WY_GC+)%.IT>B[LVAIJ\BQLF.YDEBTH2I9FHB:$  )#;@
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M;NQ5=[*_;Y))7:]R<$4\0ZQ1<0<MUJG.<:<=%*D%<<D)7*FE<9T  )#A>X
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MDD94LJS+D7Y(F*E(D'8[A:7YCXDM2Z-!CV4=&*'LCKP*?*$?AQ<  (R<@
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M7L.6>G>O8;J&-'A<9'1TIWD49OMA\'G3:6=.!GJ;:[<XBWMF;;\>RWP[;M,
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MCU:0(&WOCCY_^&\3C/=NS7 LBYU<O7%%BE5)C7),B38TVW+RB&,;[W'+B$L
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M9YB)1GTY::1Z 7UD:X=ID7V<;4U7[7WC;OY$^WY!<(\P.7Z]<<D6-G^S<;L
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ME8F#VW4,E"-TMW5]DGQDD77ND,%3?79LCRE!07;BC>$M6G;\C5,4.79^BQ8
M (  @ "1:G.@GLR#-W0PG,IT"W2>FGACYW4(F!-2UW6&E?- H78 E&8LVG8'
MD_X3]75WC7X  (  @ "0_7+]J!R"NG./I8IS?7/THI-C5711GX]24W3&G/U
M,W4YFVHL;'4SF8P3BW2TC3<  (  @ "++(A^7?!^$8>M8,=OTX<=8VI@1X:X
M9=M/=(9Q:"<]*X9F:CLHO(;M:[D.!HC^:T<  (  >=.*488T9JU].H6D:+5N
M[(4M:II?<X3.;&).NH2*;@\\CX1\;X\H0(3?<(\-UX9);_4  (  ?5B)7H0'
M;U-\'8.D<*-M[8-"<=M>=X+S<OI-WX*[= L[V(*Q=/HGLX+W=8<-GH/G=.\
M (  @ "(3X(4=^AZ^H'%>)=LN(%X>2I=A($R>:A- ($->AX[(X$'>H$G+($R
M>JL-9H'1>ET  (  @ "'2H!6@(MY_8 ;@*-KPG_?@)9<BW^F@&Y,9W][@$DZ
MJ']]@"TFW'^.@! -4G_^?^@  (  @ "&:'\'B4]Y-G[8B--K GZ;B"-;PGY>
MAU9+C7XWAI<Y_7XLA@DF47XDA=D-#7YZA*,  (  @ "%L7WSDA%X>7W,D09J
M1WV-C[=;#7U.CE!*W'TIC0\Y9GT6C"PE]7SCC#H,ZGTRB)8  (  @ "%(GT=
MFM5WYWS[F41IL'RWEU]:>7QOE6)*27Q&D[(XTWPTDK$E@GOFDDH,RWPGB*8
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M=>EO1(KN=JIAWHGY=U13A8D3=_%#UXA=>'LRHX?V>.<>W8A&>.T&?(>2>;\
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MGTUL4H6^G<M>ZH2XF\90@H.EF:)!-H+"F"4PAH(FE[8=@8&OD_,&?8$4A&,
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M>Y!C%Y,,>^)6<9&"?!U(T) )?$,Z$H[/?&<I=8XQ?'P5G(\.?#H PXJJ?:8
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M6[!:$J0?7A5-\*(C8&5 JZ!;8HTQ\I\%9&@@YY\398H+^Z&[91H  (V4;=(
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M@%97<9P6@&%+=9GX@$@^?)?S@!HP599.?_H@)96B?_@,E98>@!$  (:T@
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M87U-NJWB8QM"(ZMJ9+DU?ZDN9CHG.J>]9V 5ZJC/9W #TJ:_:%$  (>@=K(
M (  @ !8"*Z2:&A-2JP+:9!!T*F):K0U.*<X:\XG&*6L;)H6"J9S;'P$.:/S
M;7@  (9G>MT  (  @ !7KJRG;SI,WZHF;_U!5Z>H<+DTYZ55<6TFWZ.\<>P6
M"J1.<:L$A*%<<OP  (5!?HH  (  @ !74JK]=AQ,BJB"=HI!!*7_=NHTBJ.F
M=S,FNJ'U=VT6":)==RD$PI\&>.$  (0^@    (  @ !6_ZFM?2-,4*<J?4I
MU:2=?4XT7J(W?3\FDJ!T?3,6&Z"7?18$_YSO?A8  (->@    (  @ !6NJB@
MA"U,*:82A!9 N:-U@\<T0:$"@VPF=)\T@T<6'9\M@X<%/ILA@GH  (*M@
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M=XB3U6)0>#"#EF24>,=R7V:X>5%?_FC->=Q,C&JJ>F,WJVOF>L\>^FJ=>N$
M_7Y4?&:AJ%U_@7V28& 9@5V"+6)\@29P_F2X@.)>Z&;A@*1+EVC4@'<VZ&H#
M@$L>:VAT@!T ZGYU?]2@8UN0BWN1*UY"BI:!"6"XB9)OZ6,)B(-=YF5 AX)*
MR6<UAJ,V0VA8A?@=[F:KA=H V7Z1@).?7UGYE720,ER\D\R &E\^D?MO!F&;
MD"1=$6/BCF]*$V7<C/,UOV;EB^$=CV4SBXP S'ZH@(J>G5B[GV&/<UN(G/=_
M65X-FEMN2F!LE[]<6F*XE6%):&2YDVDU-V6RDC<=.F0$D#8 P7ZZ@(*>'5?8
MJ3:.ZEJEI@Q^PUTCHJ=MLE][GTY;T&'$G%A(]6/"F@<TPV2BF.4<RV,-DW@
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M?PZ'9V>F?SQX,VE>?T9G^&KY?SE6QFR(?RQ$.6WM?R@P&FZ>?QX74FX&?O
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M6+&!)WE27 ERMWGA7RAB_GJ$8A-2 7LQ9-0_G7OO9UXK/'S%:5L0WGY0:6
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MA;9[1VWCA7IM#F[_A0Q=QW )A()-?W$'@_\[XW';@YDH6W'_@V4/6G.A@OH
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M8.)T:'[*8U]FU'[M9;58%W\>9^=("W]@:?(V<'_*:[DB9X"$;,D(WX'I;)H
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MBVIO9G40BMYB#'6)BA!3I77QB2A$-'98B%TS7':@A]D@2G8[B \(<GC8A54
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M9^=GK(4^:;-;"X3I:V9-(X2A;/D]^(1X;F0M!X2A;WT9 (69;Z "3H43<38
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MD"1CUWTOCW)717T CF=)JGRUC3PZ]7Q\C& JI'Q1C#P7D'NTBUL"GWUJ@<8
M (  @ !N_7Q3F$MC:GQ@ET)6TWPLE;]).WO6E"(ZEWN-DQ(J6WM)DO\747IU
MCX\"D'R@@;P  (  @ !I Y1_5PI=T)-(6?=1KI)57,5$49&57V(U>9$E8; D
M<I&B8U4/3Y2,8R<  (@):9H  (  ?M1H'9(C7JA='Y$48/U1"9 A8SA#S(]1
M94XU%X[,9Q\D/H\<:%L/:9%M9_H  (8B;F0  (  @ !G48^V9C=<0([,9_U0
M4(WG::U#'(T;:STTC8R1;)4CXHS";6X/7HZ";.D  (1><Z<  (  @ !F?HUQ
M;;Q;7HR>;O]/8HO)<"I"98L%<3PS[(J <B C;XJ8<IT/-XO/<@X  (*\>)H
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ME!E8K88ADWQ,RX5-DE,_X81/D08QXX-SD&XB H+MD"H.VX)=B@L  (  @
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M<H%/DI4$<UM$,).W=!PWQI)\=+<J I&K=2T9E)(<=2$',9 J==X  (  ?RX
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M5$U&8JB85M([3:<-63TN[*7D6VD@AJ797/<.EZBC70@  * (8'P  (  <2X
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M=F!#RI[3=O XY)TH=U4LZYN>=Y$?6)K7=YP.V)NI=UX <9/:>E0  (  @
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M9UF+GEU#:69\3U_U:UQKS&)^;3Q:/&3B;PE'=V;[<+PS*V@M<BX:NF>1<L\
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MF!J%>U%MED1VB%3%E$EFD5?;DE)5G5JWD)-#C%SZCRTP+%UXCGP8N5\YC.T
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M;VY_4V%H<-=P_F.K<B5AH67&<UA0_F?#='@_&VEC=8 K<6GK=D42DFQ'=@P
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MG9EZJE>]FY]L@EIGF59=7ES2EPA-15\#E18[^F"/D],I"5_ODV@1)&7OBY<
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M=H!S2&9S=V-EW&@^>")78&G=>,%'SVM:>50VI&QX>=,C;6PY>A4+"G&;>F4
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M4OYM!'IB5H]@#7L 6?91UWNP72E"1WQH8!\P_WU!8JX<XGYL9",$A(#I9.T
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M?)YG;VR/?1-:VFW/?5I-,F[B?7X^:F_.?9PN '!2?;T:X6^(?<($F'@\?H(
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M6DY@D'_!72%49H '7]!'$(!58E,X0X"Y9) G=(%K9D02UX+[9E\  ($):F(
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M@;-;RW.]@=M/]G1K@<5#"W3C@8PTZ74Y@6,D]W4O@601J77:@8D  (  @
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M8&-4+88Q8IA(UX879*\\+X8$9I8N!88D:"D=8H;U:/T)HX=1:.L  (  <V0
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MA<M0='OYA<Y%1GP;A7@Y!GOQA/TK;WNVA,,;C7M:A1L)4GQ<@]\  (  @
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M94!(!HW(9O$]*(U+:($Q+XSI:>$C5(T!:M 22HZ3:IT"'XKP;*0  (  >SP
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MB3-%6H5&B4 ZN83SB+TO$(0XB!0A[8.#B!H1Y(,=AR0"UX&T@>P  (  @
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M:.@[W9<,:BDQ7I98:T EJ)72; H7^Y9,;$L(=94/;*\  (?&="\  (  @
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M5YF#U5B[6OYU+5NV7DIE?UZ-8794HV$Q9'A"@&-J9THNN61=:;<63F9@:MH
M (  <K"/FE#D84F" E1M8]=SF5>Y9E!D EK/:*]35EVE:O)!8U_Q;1 MT6"=
M;MH5L6/@;XH  (  =V*-RDR3:NN 1U!S;*=Q]50!;E9BM%=2;_)2*5I9<7A
M:ERO<N<M$UT*=!@5.&&X=',  (  >W:,'$BN=(9^Q4S;=7MPDE"M=F-A8%0L
M=SQ1-%=<> T_E%F[>-0L<5FZ>7L4U5_G>:P  (  ?O.*L45(?AM]A$FX?DUO
M>DW$?G)@9E%V?HQ03E2_?JD^]%<=?M0K]5; ?PD4AUYD?U@  (  @ ")B$);
MAYY\?D<&APUNETM$AFU?GD\>A<U/E%)^A4,^6%34A-\KFU1,A,0455VBA/H
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M8$9WM%M;8M]J+5X<96-;7&"C9\5+:6+H:@,Z"V2A; TFN622;9D.$VN';<4
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MC:5QTDP*C,-DJD^VB[)6=U+XBIQ')U6JB;@VA%<*B2LD-U;"B6(-)6G(AS8
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M9]-KFE[::;Y>Y&%$:Y=1.V-R;5A"%V5+;NLQ;69E<$4>6&7><0$'#G03<<X
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MDIIG+5'MD:):L%3UD$M-+U>"CN(^F%EAC=(NBEF4C7D<0%N>C1D&G733A'D
M (  @ !PT7%S3>)E!G*34:18>'/-555*T74&6-X[S78M7" JYW=#7MD6G7@P
M8!8 IW[F8EH  (  >-IO#VSK5=QCNVYJ61-77V_<7"Y)Z7$V7R$[#7)J8= J
M4G-:9 ,60W0)9-< SGZD9R$  (  ?(1MEFBG7?=B4FIX8)%6-FPC8Q%(V&V=
M96DZ)F[=9X@IFF^?:3<5QW!]::T X'Z&;"H  (  ?[QL-62T9A=@^&;$:!)4
MXFB<:?='WFHV:[TY1FN$;4TH\&P1;H(576UN;JD \WYE<98  (  @ !JXV$C
M;D9?N&-F;Z13NV5D<.U&RF<7<A8XHVAN<R(H;6C#<^<5&VK)<]H!$WXN=QX
M (  @ !IQ5X#=H!>R&!V=U!2YV*6=_]%]&1<>) WS66C>1$GV66J>7@4KFB:
M>6<!$GXP>_0  (  @ !HW%M+?JM=[5WC?O12&V ??PQ%-F'R?PLW&V,K?Q,G
M1V+>?R\4<6:[?V8!)'X3?_H  (  @ !H)5D#AL!=1%N[AH]1>5X+AA=$H%_C
MA8DVB6$(A2DFM&!AA284!F54A40!,'W^@,X  (  @ !GGE<MCL9<Q5H CC-0
M]UQ>C39$(EXRC"(V(%\_BVHF9UYABXD3L&0XB?,!#WXU@+@  (  @ !DXWH,
M35I9W'JX4/A.!WN(5()! WQD5]TR='U,6MLAE'Z 70T,S("@77@  (  99T
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M<[)4!FD9=*1(OFJ<=70\:FO'=B(NSVQT=K ? VO;=OT+]'&9=Q\  (  ?=,
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M4WQ-A'_55HI">8!@67$V+(#Q7!LH$X&Q7DD6\8,S7T,$C80(8&X  (  ;?$
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M> I(<V_G>*D]Q'#V>1HQ]7&6>6LDH7&;>9\4HG(F>8 $D'A*>W,  (  @
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M6&=!'(9+6NDVO(:473PJUX;S7SL<W(?48(0+Y(B>8+\  (-49;H  (  =H@
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M>VP\ZW@#>] RO7B\>_@G77CM?  9^GB$>_L*;7IO?*T  (  ?W@  (  @
M (  @ !%TW3;@KP\AW9$@N R;W<@@I\G.G<Y@DL:)'9R@EL*SGBU@@8  (
M@    (  @    (  @ ! F9E%2*LWLIBM2^4MHYB43M0AJIE143L2>9PR4E,#
M4IF^5&   (2R7XH  (  < T  (  @  _-Y6\3P0V5)6.4=DL+)695&(@2Y9
M5F81;IBA5R\#"94563\  (&N9$   (  =0$  (  @  ^09(657@U.I(95^$K
M'I(^6@(?.I+76Z 0H)3#7!\"TI#/7BX  (  :2,  (  >70  (  @  ];XY]
M6_TT4(Z?7?8J&([57ZD>9X]D8.@/_Y#782H"JHT&8SH  (  ;E8  (  ?5@
M (  @  \FHL48IHS=(MI9"8I1(NM970=F8PB9DL/IXT09F<"F8G%:(<  (
M= 0  (  @    (  @  [RX?R:5TRIHB':H$HD(CE:VL=!HE":_$//XFD:]8"
MIH<#;C   (  >3L  (  @    (  @  [%84I<"DQ](7^<.\G^(9W<7D<C8:_
M<;0.YX:N<88"EH3%=%,  (  ?9@  (  @    (  @  Z?(*[=PHQ78//=WPG
M=H1E=ZX<+H27=Z@.HX1)=Y(";H,">BL  (  @    (  @    (  @  Z#8"J
M?B<PYX'V?D\G"X*L?C$;XX+,?@$.D8)<?BX"B8&(?O\  (  @    (  @
M (  @    /__  #__P  __\  &UF=#(     ! ,)   !
M     0                    $   $   (   (D!!T%V@=I"-D*-@N%#,<-
M_P\Q$%X1BQ*W$^(5"Q8R%U<8>1F8&K4;TASO'B4?62"'(;(BVB/_)2,F1"=F
M*(8IIRK'*^@M""XH+T@P:3&),J8SPC3>-?LW&#@U.5$Z;3N)/*4]PC[>/_A!
M$4(I0T)$7$5U1H]'J4C#2=U*]TP232Q.0T]94&]1AE*<4[)4R57?5O98#5DC
M6CI;45QF77A>BE^;8*UAOF+/8^!D\68"9Q)H(VDS:D)K4FQ>;6=N<6]Z<(-Q
MC'*4<YQTHW6J=K%WMWB]><-ZR'O-?,Y]S7[,?\N R8''@L6#PH2_A;N&MX>S
MB*Z)J8JDBYZ,F(V1CH:/>Y!PD6226)-,E$"5,Y8FEQF8#)C_F?*:Y)O6G,B=
MNYZMGY^@CJ%\HFJC5Z1%I3.F(*<.I_RHZJG7JL6KLZRAK8^N?:]KL%FQ1[(V
MLR2T$K4 M>VVVK?(N+6YH[J0NWZ\:[U9OD>_-< BP1#!_L+LP]K$Q\6UQJ/'
MD<A^R6S*6<M$S"[-&,X!SNO/U="^T:?2D--YU&'52=8QUQC8 -CFV<W:LMN8
MW'W=8MY'WRS@$.#TX=CBN^.>Y'OE5^8SYP[GZ.C!Z9KJ<>M([!WL\.W#[I;O
M=O!5\3/R#_+J\\/TG/5S]DGW'O?S^,;YE?IA^RG[Z_RG_5S^"_ZT_UK__P
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M:JIKJFRK;:MNJV^K<*EQJ'*E<Z-TH'6==IEWE7B1>8QZAWN"?'Q]=GYO?VF
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MF+RL6(*EE7ZFG'!SDFN@Y%YMCW";#$S7C%F4\SO'B4N.C"O/ABB'Z[>@GWG
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MM?AY8FG\K_]YPEMGJ>MZ:$SLHZ%[3S[KG0Y\8C&%E@5]TR5TCF]_J94\P2:
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M^CK8@F:*:"KV@:&%?++VB@*P2*)WB(BKI)%4AQFFN7_ A<RAIFX4A+&<D5R
M@\"79TM=@M*2"SJB@@B,7BKG@5*&8K*(B:ZY(:'ZB#BSGY#"AL*MLW\IA6RG
MCVV.A$ZA:EP6@V&;,$L)@H&4Q#IK@<2."RK:@1.''ZM:F<!ONYPCERMQ"HQ.
ME,=R47O2DH%SHFKKD$-U$5G?C@)VJ4D:B[9X9CB:B61Z<RD&AP-\[*J3F']X
M@9MQE@%XYXN/DZ=Y6'L:D65YWFHZCR]ZA%E!C/Y[2TB4BL)\+#A(B(1]0BD'
MAC5^F:G#ET.!+)I_E-B OHJRDH* 7GHZD$^ &FERCBE_\UB9C M_Y4@2B>-_
MXC?^A[I_^2D(A7^ )ZC5EBN)M)F D\6(AXFED7J'97E;CTB&3VBGC3:%65?W
MBRJ$:T>>B1:#?3>_AP."CBD)A-^!DZ?VE2N22YB;DM"078B]D(^.<7ATCF:,
MA&?OC$^*IE=@BEF(U4<UB%B&\C>(AEV$^2D*A%6"W*<JE'*:WY?EDAJ8,8@+
MC]>5<'>WC;"2J6<\BZ./Y%;0B:V-'4;/A[R*03=1A=2'."D*@^"#_J9_D^&C
M4Y<VD8^?XX=:CTF<27<.C2"8G6:GBQF4[E98B2F1,49^AS6-4C<HA5Z)/BD+
M@W^$]Z7WDW2KI9:JD26G;(;'CMNB\G9]C*N>5&8@BJ:9LE7EB,&4_$8OAM*0
M(#<%A/V+""D+@R^%RJ65DR.SWI8\D->NUH9)CH>I:G7\C$ZCRF6OBD2>)U6-
MB&*8<T7KAH&2F3;;A+F,BRD+@N^&=YW-HPMO6X^EG[5PHX#YG(MQ[G'"F7-S
M2F(TEE-TQU*1DR-V<$-*C]AX/C1HC'%Z7R:BB.%\Y)TVH?1WHX\GGJIX#H!P
MFWUXC7$\F&!Y)V&SE4)YYE(?DAQZRT+OCMU[S#1!BX9]!B;+B A^@)R9H,E_
MQ(YJG8Y_:7_'FF!_(G".ETQ_ &$9E#I^_U&BD21_&D*5C?9_1C0=BK)_DB;P
MATA_^YOBG[*'QHV=G'Z&MW[JF5N%N&_5EDF$U&!SDTB$#E$@D$.#6$(^C2:"
MI#/[B?6!^R</AJ&!5)LBGL^/M(SAFYZ-^7XLF(",2&\4E7.*HU_?DFN)!%"K
MCWB'>$'TC&F%WC/@B4R$.2<JAA&"B9J%G@B7L8Q"FN*51'V-E\:2SFY^E+>0
M5%]7D;*-W5!(CKB+:$&UB[J(YS/)B+6&2"= A9B#EYG\G7F?CXO,FE:<;GT6
MES*9*6W_E!R5U%[=D1Z2@T_ICBZ/*4%\BRR+N#.TB#F((R=3A3.$?IF,G1&G
M1(M:F>^C:7R?EL6?4&V+DZ:;&5YSD*B6Y$^.C<*2HD%!BL6.1S.BA]2)Q"=B
MA.&%0)DXG,2NVHK_F9^J/'PYEFZE0&TDDTB@&5X:D$::]4]*C6&5QD$0BG&0
M@C.+AXZ+(2=NA*"%WY#NK(YO!8.WJ'YP0G8>I(UQCF@;H)IR]%G:G(IT?TN8
MF%=V.3W*D_EX&C"#CV5Z3B2!BIE\VY"%JYMVVH-LIXEW0W7*HX=WRV?)GX5X
M>%F*FW%Y4$M7ET1Z4CV=DN][<C"(CFI\T"30B;%^:) ;JGE^>8+FIG)^*755
MHFM]]F=-GFQ]\UD?FF!^%4L%ED%^6CUMD?I^LC"+C8A_,R45B.9_TX^:J6"%
M\()0I5Z$^W2OH5^$'6;$G6&#9%BFF66"STJLE52"33T[D1V!U3"*C+^!<251
MB#:!&X\/J':-6('"I'F+PW0;H'^*/V8QG(.(S5@WF(.'<4I9E(.&)3T.D%F$
MU#"*C Z#AB6$AY^"/8Z.I\.4N8%'H\F2@W.DG\N02V6]F\V.&U?0E\V+\DH6
MD\*)S#SLCZ:'HS",BW*%;"6NAR&#.HXMIR2;^X#BHS"9'G,^GS&6*V5;FS*3
M,E=\ES60.DG=DRV-/#S7CP2*,S"/BN>''"72AKB$$8W7IKVC&8"MHL>?D7,&
MGKB;TF47FJ*7^U<WEJ"4+DF=DJR07SROCI6,AC"0BGR(F"7NAF.$Q8V3IG*J
M$H!JHG*EU7*^GEFA/V3.FCV<AU;ZEC>7WTEQDD23-SR6CCJ.BC",BC&)U"8%
MAA^%5X2[MD9NJGAAL8-OVFO&K,AQ)E[II^]REE'KHM]T,44$G9-U_SBGF QW
M]2STDCAZ/2*BC"=\TH2!M6YV%GA*L)EV>&NKJ[YW"%[-ILUWQU'0H;-XN$3U
MG&MYV3BLENM[&RTED2=\G2,5BS!^4X1,M$U].W?ZKWU\\6MHJII\SEZ%I:5\
MZ%&4H)!]+T30FU5]GCBFE>)^)BU.D#-^VR-XBEA_KX0#LRB$+G>;KER#36KY
MJ7Z"C5XMI(N!_%%*GX.!F$2BFE:!33B;E/2!$2UOCUN \B/-B9Z YX.MLC"+
M$7=#K6B)GFJ<J(V(1EW,HYJ'!E$(GI"%YT1VF72$WCB0E""#V"V,CIZ"X"06
MB/^!^X-9L761[';WK*N/YFI3I\J-Y5V&HM2+\U#+G<N*$T13F*F(0#B(DV2&
M;RVDC?B$H212B'J"Z(,/L.68GG:ZK!:6 &H:IRN34%U.HB^0HE"7G2J. T0V
MF V+:#B'DK^(S"VZC6F&+R2$B V#LH+>L&F?'G:,JYB;X6GKIJ>8?%T@H::5
M#5!NG*"1JD01EY".1CAZDD**YBW/C.^'AR2MA[2$68*NL!RE@G:%JSNAH&G@
MIC6=:5T#H1N9&5!8G F4ZT0,EOV0RCB#D<^,M2WBC)N(IB3-AVV$X7D:P#!N
M96U]NLMO@&'.M4IPQU8*KX!R/4I'J5QSYCZXHN%UR3/*G!=WU"FHE.UZ,2#Z
MC9%\R7D.OVEU;VV7N>1UP6'GM#-V458BKD=W'DI?J!1X)S[;H9MY9S0!FMAZ
MRRH&D\)\<2&-C(A^/GD0OCY\'FV!N+E[SV'6LO][M58,K0E[Z4I5IMA\4C[F
MH&I\[#0HF;5]HRI5DKE^BR(,BZ-_CGD#O0."D&U<MX&!N6&AL<F!#U7GJ]>
MHDH\I;& ;3[EGU* 6#1%F+" 62J8D<^ ?B)YBM^ N7CGN_6([6T_MG.'E6&
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M?+E]I-;O;AB#!<-;;[^"4:]$<52!KII[<MZ!-857=&^ UW 2=A2 BEKJ=]&
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M>8AWZ9(G>C!XG7XH>N)Y9&H&>ZEZ0E8.?(E[,D).?9=\22\Y?N=]D\CH=H*
MW;;E=TF @:0Y> > *I#'>,Q_ZGSV>9]_OVD#>HM_IE4Z>XU_D$&R?+Q_@R[C
M?BM_<\=D=0V+"[53=>&)O**K=K"(<(]P=XF','O%>'V&$&@$>8>$]E1T>JF#
MTT$F>_F"G2Z8?82!-<7Y<].5)[/P=+"2\J%+=8Z0MHX>=G>.?7JF=WN,3V<4
M>*2*,5.]>>&']T"I>TV%D"Y8?/*"TL3.<MR?.;+'<[^<)* F=*&8\8T$=925
MMGFG=J>2?F8Z=]V/0U,8>36+\$ Z>KJ(52XA?'6$1L/=<AJI,K'7<P"E.I\S
M<^&A"XP6=-B<QWC1=?B8A&6)=SZ4,%*.>**/KC_>>CZ*X"WT? N%C<,G<8FS
M!;$=<F^N*)YK<TNH^(M,=#^CGW@0=6:>1F3E=KV8VE(4>#&3,3^/>=B-*BW.
M>[2&IL*N<2J\I;"6<@RVV9W-<MRPG(JA<\:J)W=O=.VCKF1==DR=(5&B=\Z6
M4S\]>86/)"VQ>VZ'D+U@@GMK4JS=@AYM/YN)@=QO"XE>@:YPR':M@8QRE&/(
M@7AT?U$1@7)VBSZ'@8UXW2RS@=A[F[Q)@+9U&ZO)@(=V )IC@%]VVHA+@$9W
MMG6R@#MXHF+N@$1YIU!;@%UZP3X$@)I\!"QY@09]@+LF?Q=^V:J,?P9^QIE8
M?O%^L(<V?N]^HW2Y?OM^JV(<?R!^Q4^T?UI^YCV0?[Q_%"Q&@$E_2;G3?:V(
M=*DV?:6'A9?F?:2&BH7W?;2%D7.=?>&$KV$P?B6#U$[_?GN"]#T:?OJ"!"P9
M?Z* \KB2?'^1_*?V?'^0.9:K?(N.8(3,?*J,>W*B?.2*G&!>?46(R$YB?;6&
MWCRV?D^$S"OR?Q&"=K>&>Y.;@:;L>YJ8ZI6F>ZF6)X/2>]"33W'!?!:0<U^C
M?("-DDW8?0J*FSQ=?;R'8RO2?I6#T+:O>MBD[J82>N2A?Y3)>O*=S8+[>QN9
M]W$ >VZ6'5\&>^:2,4UE?'B.'CP5?4")PBNW?BV$_K8,>DNN.*5F>EJI[901
M>F2E1()#>HB@9G!3>N&;@EYP>VN6BDSV? J18#O6?-N+X"N@?=>& ;6A>>RW
M5Z3F>?RR*I-Z>?JL?8&D>A2FC&_">FN@E%WY>ON:B$R6>ZJ41CN3?(N-L2N/
M?9.&UZ]FBSMJLJ!.B?1LJ)!9B.!N?G^#A^YP1VXIAP=R(UR@ABET(TM7A5%V
M23I A)!XNRG[@^Q[G*Z*B9)SZI]JB']TZ8]=AX1UW'Z4AI]VU&U/A<AWX5OC
MA0!Y"4JYA$%Z2CG9@YU[NRGG@Q-];:V3B I\_YY(AQ-](XY;AB5]/GV1A59]
M8FQOA)1]F5LL@^9]Y4HM@T1^.SF"@K]^I"G6@E)_(*R"AJ6&"YTHA;J%8(TI
MA.&$H7R8A!Z#YVN6@W&#1%J$@MN"J4FQ@EB"#3DU@?:!:2G&@:B L:MCA7^.
M_IPLA)J-E(PO@\V,"WN,@Q:*<6JM@GJ(W%F_@@.'54DC@9:%O#CF@4J$!"FY
M@1:"'*IVA)V7\9LY@\"5P(L_@O637GJO@D.0W6GH@;&.6%DB@3Z+TTBS@.F)
M/3BD@+:&;RFN@)B#7ZFV@^J@QYIV@Q6=S8I[@DB:BGGN@9>7&6DY@0Z3HUB8
M@*>0(DA9@%2,@SAO@#B(HBFE@#"$=ZDE@V2I@)G;@I6EN(G4@<.ABGE(@0F=
M'&B?@(.8JE@,@"Z4*$?S?^F/ACA!?]**ERF>?]N%9:C$@P:R%YED@CRM?8E%
M@6"H57BS@)BBW&@>@ Z=8E>H?[Z7W4>H?XF2-#@2?X.,0RF8?Y:&*:'EE!1J
M3I/OD@)L/X4MD"UN&'6<CG9O[&67C,%QU55MBPESYD66B4QV'C8)AY=XIB=V
MA>E[FZ$UDIIS 9,^D+5T"(1ECNYU"W3@C3IV&63JBXUW/U3:B>9XA44?B#UY
MYC7'AI][?B>(A0A]6:!LD2E[C9))CV![Q8.&C:-[_G0!B_]\160HBF1\HU0\
MB-5]&$2JAT1]G#6,A<!^/">7A$!^]Y]ZC]N#[Y%(CAF#<H)TC&Z"[G,DBM*"
M:F-DB5"!^U.EA]B!ED1#AE^!-#59A/> U2>D@Y& <IZ5CK2,6)!<C/^+(X&+
MBU^)VW) B<^(A6*UB%"'-E,9AO&%\T/DA9&$I#4LA$.#0R>P@OJ!R)W-C=J4
MOX^HC"Z2TX#:BHZ0O7&%B0".CF(%AXN,7%*0AC"**D.%A.2'ZC3]@ZR%@B>Z
M@GJ"]9TIC2^= H[\BXJ:6X MB>B7<G#>B%F48F%PANR13%(:A9F.*T,\A$V*
M\C3;@RN'B2?"@A"#^)RIC*^E'(YUBQ"AMG^=B6B=]'!2A]&9^6#MAF:5]5&F
MA2*1XD+L@]^-MC2^@L&)4R?(@;F$TYQ/C%.M$XX,BK>H['\CB0>D06_5AV6?
M3&"!A?2:45%3A+2524*M@X"0)C28@G.*UB?-@7.%AY3CG21I_8?;FEUKY'HM
ME\AMOVO7E4-OGET@DK)QEDY5D!!SN#_QC5MV 3'YBIEXFR4KA\E[EY15F]UR
M,X=8F3!S/7F9EIQT3FM-E!)U<%RDD8-VKTWOCNUX$C^FC$9YDC'BB9=[3"5A
MAMM]19.WFH%Z.(:5E^MZ@GCNE5MZTVJ@DMQ[.UP0D%M[ODU\C=E\7#]:BT=]
M##',B*]]WR60A@I^T)+[F3J"%X7$EJZ!M7@-E"V!4VGKD;6 _UMPCTJ P$T#
MC-V D3\-BF& :#&UA^" 3"6YA52 .)(ZF"R)X(4)E::(VG=2DRV'RFDLD+V&
MMEKHCE"%IDR8B_F$IC[-B9&#GC&DARB"CR7;A+>!>9&:ETB1LX1GE-"0 W:Q
MDEF.-&B8C^F,4%ICC8&*:TQ!BR>(BCZ9B-2&HC&5AH:$HB7YA#."DY$5EJ&9
M8X/UE#"7"W8_D;*4=&@<CSJ1N5GIC-F._4OBBHN,/3YGB#B);S&&A?Z&@"81
M@\:#A)"KEB>@YH.&D[B=WW7*D32:?&>JCK*6Y%F C%*32DN$BA"/ISXIA\2+
M]C%YA9"((B8D@VR$3Y!=E<ZH/X,ODUZDAG5GD-&@2V=&CD6;RUDJB^"724M$
MB:&2P3W[AV..+3%CA4")@"8T@R6$](B IFQIIWQ1HOAK@6^CGZ5M76)VG$EO
M1U4%F,IQ4$>5E2ESA3JAD69UXBX[C7]XD",AB8![DX@2I5=Q;'O\H>AR<V]'
MGH)SC6(CFQ9TPU2\EY1V'$=?D_MWG3J$D$-Y/BY/C&]['"-YB(1],8>@I IX
M\GMKH*IY16[,G41YJV&HF=UZ,E17EF9ZV4<7DMY[HCI@CSA\@"Y<BWI]AR/&
MAZA^K(<6HL2 2GK-GVR  &X@G!)_OV$@F+)_EE/BE4U_B$;&D=A_CSHWCD=_
MHRYEBJ!_RR0(ANF  H:%H;.'D7H\GF.&KVV+FQ"%RV",E[.$ZU-YE%&$'D9W
MD/"#7CH0C7&"H"YLB>"!YB1 AD:!,H8%H.&.SGG"G9>-5&T5FD&+PV 8EN2*
M*%,2DX.(D$8]D!R&_CGWC*^%;2YSB3B#TB1OA;R".X6BH"V5YGE<G.N3SVRL
MF921B5^SEC:/*E*\DMF,R48%CWB*93GJC *'_2Y^B*6%B"26A4N#'(50G[:<
MUWDLG'2:*6QZF0Z7(%]TE9B3Y5)ZDC:0L$7#CNF-?SF_BX6*32Z!B#"'""2U
MA.^#V842GV&CG'CNG!6@2VPTF*.<=U\KE2288E(]D;Z45T68CG.04CFGBQ^,
M3RY^A]N(1B3.A*6$<GR^K^MI/W%+J]=K"V6+I\)LZ%E\HX)NWTU(GP1P_$$O
MFDQS236GE6-UORK.D$1XA"%7BPQ[C7QMKP-PG7$EJMAQG65HIIURP5EBHD)T
M"TTWG;MU@4$MF0IW)36[E"QXZRL+CQ]Z[B'.B@%]'WPEK;]WK'#(J9EX!64?
MI5AX?%D:H/QY)$T"G'UY\D$2E]QZZ#7 DP][^2L]CAI]-2(VB1E^BWO.K'%^
MA'!>J%%^362HI!E^*EC"G\1^+$RYFU5^4T#IEL9^DS6]D@U^Y2MFC3)_5"*/
MB%!_TGMPJU6%27  ISR$BF1'HPB#TUA=GK:#)TQZFDJ"F$# E<^"'S6WD2F!
MK"N'C&>!22+;AZ6 \WL9JGZ,!F^SIF6*OF/^HBR)9%@6G=B("4P[F6^&NT"A
ME/*%?36SD%Z$12NCB[:#$2,:AQ:![7K0J=>2EF]YI;N0PV/&H7J.P5?<G1^,
MK4P$F+N*HT"#E$6(HC6WCZR&I2N]BQV$IB-.AJ&"P7J?J4^8[V]+I2^6BF.3
MH.B3W5>IG(B1#$O5F"2.0D!7D[R+?#6HCR6(P"O7BIR&!2-XAD&#<7ITJ/F?
M)F]-I,F<.6./H&R8QU>.F_*5%TO#EX*1@D!6DQ^. #6SCJB*D2OIBD"'*2.:
MA?6$ '&!N:-HW&:KM01JDEO%L#%L;5#*JO]N<$70I6EPHCL-GX%S"S#RF5AU
MG">CDNEX>A_"C')[AW%$N.1OUV:KM!)PR%O4KP)Q\5#DJ:IS3D7QI ATXSL]
MGB5VK#$UF 9XF2@*D:YZQ"!7BU=]#7$HMZ)V<V: LLIVR5NZK;!W3%#,J$]X
M$T7KHK-Y"CM.G-YZ,3%CEM)[=BA?D)5\Z"#7BF)^;7$'MD-\SV9,L6]\HEMY
MK%M\F5"CIP-\PT72H71]'SM/F[)]FS&%E;Q^+RBFCYU^Y"%%B9!_IW#>M12#
M%&8FL$*"<%M1JR^!X%!TI=N!9T7!H%.!&#M0FJ: Z#&CE,: PRCCCL2 MR&C
MB-Z NG"XM"R)4F83KT^(-EM"JC6'$5!CI.&%]46PGV"$\#M5F;>$!3&^D^N#
M*BD7C@B"7B'PB$B!IW"7LWF/8&8+KHN-R%L^J6:,"5!;I!"*046IGI>(C#M:
MF/B&Z3'9DS"%52E&C6J#TB(PA\Z";W!^LO65-V8-K?"3(5M"J+R0P%!9HU^.
M146?G>F+W#M4F%R)A3'FDJ"'0REKC.>%$B)DAVJ#%7!MLI::V687K7*8/5M-
MJ"R5,5!<HL>1_$6CG5..W#M@E]"+U#'PDB>(Y2E]C(2&%R*-AQR#F\ZA;1AF
M^KOH;NQI/:BU<*UK<93J<EYMG("U=!)OSFQ6==IR%U@@=[]T?T0=>=]W)S#)
M?%EZ/LR^:K1QQ;IJ;,%RY*=@;JUT!I.^<(MU,'^D<FYV9VMB=&=WLU=)=GYY
M$D-T>,]ZFS!B>WA\8LKY:*=\?KBT:M)\@:7H;.1\C9)>;N9\MGYP</)\\VI<
M<Q=]059T=5M]ED+7=]I]^S '>JQ^;,D[9M>'#;;X:1N&"J0Y:T2%%I#K;6B$
M-7TI;YR#=FE.<>J"OU6E=%B" T)%=O^!/2^W>?> 5L>G95"1>[5Q9Z:/BZ*V
M:>6-GH]\;!Z+NWOU;F^)Z&A,<..(*%3B<W6&4T'!=D"$6B]R>5B"&\9?9!R;
MUK0R9GV9 Z%]:,:6&HY-:Q"3+WKA;7203&=D;_Z-:E0S<K**>$%+=9R'22\X
M>,^#M,5;8R:F$K,U98^B6Z!]9]R><HU1:BZ:>'G];*66AF:E;T22B%.?<@R.
M9$#J=1*)_B\(>%R%'<298G"P(+)V9-RK@9^R9R6FE(R :7>AA'DS:_B<>67X
M;JR78E,?<8F2$T"7=*",;R[@=_V&5<0:8?>YZ['T9&"T4I\99I^N5XO8:.BH
M+7B1:VNB!V5M;BF;T%*G<1657$ _=$".C"[ =["'6L""=/]F-*^/=?YHIIWE
M=O]J]8MX> %M,'B*>0YO<V5K>BYQT%)\>VET4#_$?-9W%"W3?I!Z2[\G<LAP
M>ZZ!<_]QU)SC=2-S'HJ$=D9T9W>C=W1UO62=>+YW*E'/>B5XKC]%>\1Z8BV.
M?:]\6+VO<-%ZGZSJ<B=Z\IMS<VI[0(DH=*][F79X=@5\ V.C=WE\?U$'>0I]
M!#ZZ>M-]G"U2?.1^2+PH;Q>$F:M9<(*#_IGI<=V#7H?;<SV"P750=+J".V*P
M=E.!O%!0> N!/#Y!>?N MBT=?#" &+J[;9^.>ZGX;QN-!)B-<(N+>H:-<@")
MZ'0_<Y.(7F',=5&&XD^F=RN%5#W4>3Z#J"SO>Y.!PKF2;'684ZC4;?R6 )=O
M;W63AH5[</J0^7-'<J".;&$!='&+W4\0=FN)/SUT>)V&:BS)>PV#0+BF:XBB
M"Z?H;1:>W):";I*;;(26<!^7W7)X<=B436!7<[R0KTZ3=<B,[STF>!6(\2RI
M>IV$C[?W:M>KF*<T;&>GB)7!;>&C'(/4;VV>@G&_<3"9Y5^Y<RJ5.4X@=4F0
M7SSB=Z6+-BR/>D"%K[>&:F&TZ*:S:^VO[94I;5RJ?(,R;N"DSW$I<*6?(%\\
M<JJ98$VV=-J3;#R5=TJ-*2QZ>?6&GK+5?2%EI*-U?41H+),Y?8%JB8(<?=!L
MSW!P?BYO'UZ2?IUQCDSP?R%T(CN-?\]W 2L(@+IZ5;'$>PQO2Z)J>VEPSY(;
M>\=R/H$3?#)SIV^$?*UU'5W*?4!VK$Q/?>IX5#LB?L)Z+2KF?]5\3+"<>2AX
MX:$J>:MY<I$->B1Y^8 ">JMZ?FZ5>T1[%%T%>_I[O$NZ?,M\<CK#?<U]/RK(
M?PE^):]&=WJ"2Y_0>!&"!X^A>*6!KG[/>42!46V%>@.! EPG>MV O$L5>]*
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M@2-XNW; @.EY;V:?@+]Z+U9:@*U[ T9H@*I[YC;;@,U\Y"AK@19^ :*;@!B
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MCBM\R3<[BU-];RQ/B'A^,"+5A:1^_WX$FG:!P7*QE^"!B&;OE3V!0EK<DHV
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M-*%L:K9^1I$H;*9^3(!&;IE^46[?<+!^95UE<NI^ADPZ=4U^K3MS=_1^WRO
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M@,%[WCUI@+A\IC"<@-1]@R4G@0Y^<HOZ@%" @7^[@!F E'+E?^* A665?[.
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MA1-_(FK*FM: 2V$]F$R 4E=8E9* .DU DK* %$,VC\1__#EHC--__# \B>N
M""?>AQ: &R#MA'" ,&IMF>F&I&#SEV:&+%<7E*J%=$T!D<F$GD+YCN6#TSE&
MC .#&3!'B2&";B?^AFN!OR$E@^F!%6HGF2J,OV"REJR+PU;6D_"*:4S&D0V(
MWT+'CBV'7CD5BUV%ZS WB(2$CB@>A=V#*R%2@WR!U&GOF**2LF"GEB*125;+
MDUF/.TRRD&",W$+%C76*F3DJBJV(<S!0A_2&9R@VA6^$6B%V@R6"<&*LJ\I>
M&EE]J'-@UU WI.-CO4;1H/%FT#UIG*5J&30XF!UMG2NUDW=Q32/ZCL=U11V5
MBE1Y56(5JI!DP5DOIR)FX5 $HV=I,$:]GUQKKSUQFPIN8C1?EHYQ2RO\D?MT
M6B1HC6AWHQXMB19Z^&&]J-YK)%C4I71LO$_%H<!N>$:+G;AP:CU=F7=RAS1M
ME1-TU2PQD)QW0"3%C"QYV1ZPB )\<V%PIQIQ5EA]H[QR<T]IH!5SJ493G"-U
M"3T[E_IVDC1MD[5X/2Q7CU]Z 241BQ5[YA\@AQ5]Q6$CI9)W>%@XHD%X(4\I
MGJ)XTT83FKEYE#TEEJ5Z?C1LDGU[ABQVCD=\G251BB-]RA]_ADM^[V#=I%U]
MDE@*H0Y]RD\&G7%][47TF8U^$#T-E81^2C1UD6E^I"R5C5%_#B6(B5)_@A_/
MA:-_\&"CHV:#>E?JH!6#04[PG'6"T47@F)2"3SS[E):!X31UD(N!B2RTC'Z!
M126YB**!!B 0A1B RF!VHJB)*E?8GT^(@$[EFZB'>$76E\2&2CSND\R%+S1H
MC]>$*BR\B]N#/B7@B!&"5R!$A*B!?V!9HAB.I%?3GJ^-AT[BFO^+X473EQ>*
M #SSDR&(-#1YCS>&@RS*BU"$[27UAY^#:2!NA$Z"$;=98K=:Z:;W95Y>6)8K
M9_9AN83.:HUE#7+^;3IH9V$ < UKVT]&<PUO>3W<=EMS:"UQ>@IWX[5R7VIE
M5*5^8F1GN93@94-J%X.L:!YL=7'[:Q%NVV ?;BUQ6TZ,<7AS^SU==1-VX"U&
M>0YZ++.I7(%OI*/.7[EQ 9-Q8M5R7()69>MSQ7#3:1MU/%\K;'IVR$W2< IX
M;#SG<^UZ0"TA>"M\5;'D6>EYQJ(9759Z*Y'-8*%ZE8#Y8^M[!V^B9UI[C5XV
M:O9\(TT>;L9\Q3QY<NE]@BT =V-^6[!!5ZN#Q*"76T6#1)!@7KR"P7^?8B^"
M0&Z49<R!R5U6::2!9$Q];:V _CP9<@B G2SD=K2 -Z[E5=.-J9];68^,2(\]
M72:*UGZ38+Z)76VA9(&'Z%R<:'^&>TOT;+V%"SO%<4F#ARS,=A^!XZW.5$^7
M9IY=6">5'XY36]22MWV[7X>00VS=8VV-TUO[9Y"+7TN&:_&(VCN$<*B&-"RY
M=:*#6ZS[4R&@YYV<5PN=LHV:6L::3WT-7HB6VVP\8H>3;5MM9LV/]DL>:U",
M8SM,<".(FRRI=3N$GJQS4DFJ#)T85CREV(T36?BA<WR(7;^= 6O%8<N8F%L-
M9B:4(DK*:L./ACL/;[6*K2R<=.B%K*K<:@Q:K)OZ:_U>-8QV;?%AGGP\;^YD
M\VN$<@1H4%JA=#]KRTH+=J1O=#G2>5-S=2JN?%IX *E:9O!DDYK=:31G'(MW
M:V1IDWM;;9EL FJ\;^AN>EGZ<F1Q#DF,=0]SQCF%> IVQRJ?>UIZ,*?,9"5N
M5IE!9J9OZXH-:0UQ=7H*:WIR_VF?;@9TEUD2<,)V1$C><ZYX##D?=NEZ!2J1
M>G9\/Z8W8:AW[9>Q9%EXH8B-9NYY27C2:8IY[6B.;%%ZGU@Z;TA[84A%<G%\
M,CC(=>E]'RJ%>:Q^*:2_7X&!:9938EJ!1X<_91F!#W>59]V RV>>:L^ CE=T
M;?Z 8$>[<5Z -3A]=0N #RIZ>/U_Z:.*7;R*T94Q8+.)V(8R8Y"(NW:<9G>'
MBV:_:8V&6U;/;.&%,D=&<'&$"#@\=$V"SBIR>&B!>J*47$F4#Y1(7UB2.X56
M8DF0-'7094J.$V8(:(*+\E8]:_F)S4;J;ZB'G3@*<ZV%3RIK=^N"V*'<6RB=
M$9.57D6:7X2D84*7:'4H9%*44&5K9Z.1.56T:SN.'$:+;PN*ZC?><RJ'C"IE
M=X6$!*%C6EFEO9,577RB*(0:8'J>.W2@8XZ:*63U9NR6'%58:IF2!T8Z;H.-
MUC>F<L")=2I@=S.$_IZE<9A:CI$B<LU>'X+;=!AABG/$=7=DWV0H=NYH/51D
M>(=KOT3Y>D9O<C7U?$ES@2@6?IEX&IUB;J5CVI &<"QF?H&_<:]I"G+)<T%K
MC&-2=.YN&E.X=L-PQT1[>,!SF36S>P5VM"@A?9-Z,9P::_5M%8ZY;;QNUX"W
M;W)PBG',<3-R-&* <Q)S[%,6=2%UO40/=UMWJ35_>>!YR"@K?*I\)YJP:8]V
M)HU6:X1W&G],;6=W^7"F;U-XSF%_<6UYK%),<[1ZG$."=BA[G34X>.1\NR@S
M>]U]]YEA9X!_'(P5:9E_2GX::Z)_5V^);;5_4&"M;_5_35&@<G%_6$,/=1A_
M:34!> 9_@2@Z>RQ_G9A,9<^( HL.: .'9GTF:B:&FVZF;%J%M%_C;KR$RE$1
M<5F#YD*N="V#!#31=TB"%2A >I6!%9=O9&R0O8HY9K2/57Q::.N-K&WJ:S:+
MWU\[;;B*#E".<'6(.T)B<V6&832O=J>$;2A%>AB"6Y;)8U69/(F39:R7!WNS
M9^Z4?&U-:D:1P5ZH;-^/!5 .;[V,1$(-<LJ)=32/=B2&@2A)>;&#<9998HJA
M;HD99.F>:WLN9RR:]VS):8F73%XY;"V3H$^Z;QZ/\$'#<D:,+#1==;V(12A-
M>5^$6)*N>6%:B(9->=Q>$'DB>G]A=VLJ>SMDS%RR? MH+TX:?/5KNC_H??UO
M=C(L?T!SDB6I@,)X+Y&7=I1C1(5-=V%E\W@C>#EHBVI)>2%K'EOW>A]MOTV)
M>SYP@3^&?']S:S(&??QVGR7/?[-Z,)!X= 9KXX05=1!MQW<>=A1OFVE6=RAQ
M:%LS>%9S0TSW>:MU-S\I>R-W23'E?-EYCR7P?L-\#X]%<;1T<H+><NUUE77O
M=!MVH6A[=55WJ%IY=K5XLTQR>#QYT3[<>>E[ S'+>]9\528,??%]QHX:;[U\
MYX';<1A]4W3P<FA]G6=T<\1]T%FS=4A^"$O.=P-^33YO>.!^FC&?>OE^\R8E
M?3U_5(TB;B&%2(#I;Y.$^G0-</R$>6:D<G6#V%C_=!>#-$M3=>Z"F#X@=_6!
M_S%_>CJ!7B8Y?*. LXQ:;,Z-?( I;E2,<G-6;\V+(67[<5J)IUAI<QF(*$KA
M=0Z&ISWE=RV%)#%K>9>#C29*?"2!Y(O!:\*5=G^0;5>3KW*];MJ1BF5M<'*/
M+U?E<D:,STIN=%F*;#V;=I*( C%7>1&%>R98>[R"YHM4:OJ=)G\=;)F:IG)!
M;A^7J&3T;[N49U>!<9>1(DHD<[R-VCU;=A"*AC$O>*R'&R9C>VF#NX;P@6U:
MA'N"@3A=_&]<@3)A7&)^@41DM54O@5YH($?.@8AKMCKA@<=O?BZ @C)SIB-L
M@L]X087Y?M!BN'JI?NAE:6Z'?PYH"V')?T%JKE2??X)M8T=F?]IP/3JF@$IS
M0"Y\@.IVCB.L@;5Z+H3^?&!JTGF7?+-LR&V@?0)NM&#S?5QPG5/S?<ARF4;I
M?E%TL3I>?O1VZ"YP?\5Y52/C@+U[]H/S>BYRRWB)>JAT%&R/>QYU36 N>YAV
M?E-+?#1WND9T?.QY"CH??;]Z;BYG?L%[]203?^1]EX+R>$1ZO7>0>.![66NF
M>75[V%]5>@]\15+(>L=\ND83>ZY].SGM?*U]R"YC?=U^9B0\?RI_#H(5=KR"
MGG;8=W&"D6L >!F"4UZI>,F!]5(F>9R!F$6I>IV!1CFJ>\. ^2Y0?1N JB1?
M?HV 6(%A=7J*3G8F=D&)E6I7=O:(E%X/=[B':E&<>*.&/$5">;Z%$CE\>OF#
MZBY(?'6"LR1[?@N!=(#5='F1P'6>=4^06VG1=@V.E5V4=M>,F%$L=]2*ED3?
M>0J(E#E >ER&DBY!>^V$?"22?:&"9(!L<[>8[W4T=)>6Y&EB=5F45%TK=B61
M?%#7=RF.H$2D>&Z+Q3D0>=J(YRXF>X:%_"2D?4R#*7MYB<%::7#DB.9=S66V
MB#1A*5GMAXYDB$W*AN!H 4&EAC5KJ38%A91O@BL'A1)SN2%DA+=X3WJ;AUQB
M'G NAL%DSF4*AB]G>EEBA9]J+TUBA1!L_4%CA(QO\S7NA!9S$BLC@\)V?"&]
M@Y%Z*7G$A0MIMV]&A*5KO&1,A#9MOUBT@\=OQTS>@UUQYD$,@P9T)37)@KUV
MA2LU@I9Y'"(*@H][W7CA@N]Q-&Y;@JQRF&-@@E]S\E@$@A%U3DQ,@=)VN4"J
M@:5X/#6:@8EYU2L]@8][E2)-@:Y]:G@'@2)XG6V.@/IY9&*;@,=Z%E=%@)-Z
MO4O9@&Q[;4!5@&Q\+S5R@'A\_BM&@*=]X2*&@.Y^S'=&?YM_]&S=?X^ 'F'[
M?W" (5:^?TV "DMM?SY_]$ S?U!_[S5I?X1_]2M5?]U__"*U@$V  W:G?FB'
M(FQA?G.&M&&-?EN& %90?CR%(DL ?D&$1S_<?F^#>35,?K6"LRM:?S.!X2+<
M?\>!#78I?7*.%VOH?8N-#V$8?7J+HE7I?6*)^DJE?72(5S^)?;J&O34=?A6%
M+"M??J>#BR+\?UJ!['7(?+:4RVN(?->3+V"X?,J1!%60?+2.C4I@?,N,&S];
M?1V)M#4 ?8Z'52M7?CN$[B,5?P."HW!UDEY:'F:LD-I=<%QMCW-@RE&SC@1D
M-D:YC'IGQ#O/BN-KAC%ZB4UO>"?9A\MSQ1^9AG%X6F^ID#1A8&84CN!D#5OD
MC8EFQE%,C"1IDD9TBJYL?3NQB3EOES&&A\ARV2@4AG!V92 )A3YZ(V[VC?YH
M@&55C-=JDEM,BYQLK%#$BE%NV$84B/UQ'SM\AZ]SC#&!AF=V&RA"A3MXXB!J
MA#%[QFX[B_!O@F23BN9Q %J)B<ER?U WB)UT"D6EAV]UJ3LZADIW9#%OA2UY
M.2ABA"M[-2"^@TA]0&V%BBQV<&/HB3UW7EGFB#9X04^?AQ]Y($5)A@UZ$CK]
MA0][&3%<A!A\,"A]@SU]7R$%@H%^D6SDB+I]36-9A^)]KUEHANE][T\MA>%^
M'D3LA.%^53KF@_%^HC%<@Q]^_"B7@FY_6B% @=I_MFQ:AX6#\F+4AL*#P%CL
MA=>#64Z]A-J"UD22@^R"6#JS@Q"!YC%N@D:!@RBR@;V!'"%Q@5& L&ONAIB*
M=6*:A>R)Q%B^A0&(JDZ4@_2'541U@P:&$SJ*@DF$YS%+@9Z#TBC#@2J"JR&9
M@."!@FN8A>&0OV))A3F/BEAMA%.-NDY-@TB+G$1!@EN)F#IM@::'K3%&@0^%
MURC1@+B#]B&X@(>"+67>FS%9H5SGF0A<Y5.9EN=@04GME)]COT 9DB)G:#9F
MCXEK3"U7C.=O7R4#BE=SQQX'A_QX8F4BF4=@?5QKES]C*5,NE1IE\4FEDLQH
MVC_UD%AKZ39JC=EO*RV$BU=RER5;B.YV2AZ,AKMZ'624ER=G+%O4E3]I3%*W
MDS-K@$D]D/EMUC^TCJ%P2C96C$1RZBV?B>EUK"6DAZQXIA\ A:-[L&0$E1IM
MMULXDTMO4%(6D5EP]TC-CSURM3]DC0ITCC8RBM5VARVJB*1XFB7<AI%ZV!]C
MA+)]&V-SDU=T,UJPD:)U25&:C\!V8$A8C;9W>C\DBZ!XL#8/B9%Z BVLAX=[
M9"8'A9Q\XA^W@^1^6V+PD>IZI5H]D$M[.E$WCG5[N$@%C'=\*S[BBG!\L#7_
MB')]5"VPAHM^!28HA,A^OQ_]@SA_<F*"D,& Z5GBCS6! %#IC6> WT>^BVV
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M?RQ_5VYF='B!?F3P=:"!E5L"=J*!<E"W=YV!+T94>+J ]3P<>@. S#*&>VB
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M=&I^O9DJ0NZ =HP92*^ 97YX3D" 5' \4]> 0F&H6:> -%+\7\F -$2W9C>
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MI#+AC=EA=BN[C"-FDR5!BGIKY!^4B/9Q;QL9A[1VYTW,D/I5N4=2C^U9?4"
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MT2&:@)Z &QX%@,2 5   __\  /__  #__P  ;69T,0     #!"$   $
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M:FUO<71V>7Q^@8.&B8N.D)*5EYF;G9^AHZ6GJ*JLK:^PLK.UMK>YNKN\O;_
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M@*22TX"DDM. I)+3@*22TX"DDM. I)+3@*22TX"DDM. I)+3@*22TX"DDM.
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M:'?L7&]PZ6)T:^=G=VCE;7EFY'![9>-S?6/B=GUBX7A^8N%Y?V'A>W]@X'V
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M6?>@4FCMH59XY*%:AMN>9)32FVZ@S)AXJL:5@;+$E8FVP9&.NK^,D+V]B)/
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MJUN*VZEEE-6F;IW/HW>ERI^ K,69AK2_DXR\N(V3P;*)F<6NAJ'(JH2IR:&
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MDE$W_Y=31?^95U/]F5M@]9AA;>V5:'GEDG*$WX]\CMJ,A9;5AXN<T8.0H<^
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MLKZ$D;*^A)&ROH21LKZ$D;*^A)&ROH21LKZ$D;*^_YLS%/^:02;_GT(S_Z9
M/?^M0$?_M$)/][M'5^W#35WDS%A@V<U@;,G%9GZ\O6N-L+5QFJ6O=J6<JGRM
MDZ:"M(RBB;F&H)"]@9Z9OWV>HL%[GJ_!?9FPP'^6LKY_EK*^?Y:ROG^6LKY_
MEK*^?Y:ROG^6LKY_EK*^?Y:ROG^6LKY_EK*^_YPS%/^:02;_H$$R_Z@_//^P
M/D7_MT%-],!%4^K)3E;BU5I7TM%>:\3)9'VVP6J,JKMOF9^U=*26L'JLC:R
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MN:G+;\&IPW'!J;QRP*JW<\"JMW/ JK=SP*JW<\"JMW/ JK=SP*JW<\"JMW/
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MM8*0N+6"D+BU@I"XM8*0N+6"D+BU_Y0L#O^4/1[_GC\H_Z8],?^M/CG_M$%
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M.1?_D$(C_YA'+?^<23C_GTQ"_Z!13/^@5U;[GEY@])ME:NV6;'/GD'9\X8J
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M2?]^4D?_A%-%_XM40_^154+^F%9!_9Y70/VF6$#\J5A _*E80/RI6$#\J5A
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M7T/'DVA/OXQP6;B'=V&R@G]HK7Z&;JEZCG.D=Y9XH'6>>YUSJ'Z:<K. EW'
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M?&.8XGQCF.)\8YCB?&.8XGQCF.)\_W@8 O^+%P'_G1T"_:L> NRX%P'>R!$
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M1>VA4$/MKE%"[KQ10>_,4D'OY5) [?%10.WQ44#M\5% [?%10.WQ44#M\5%
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MG3PV_Z<]-?^Q/C3_OCXS_\H_,__*/S/_RC\S_\H_,__*/S/_RC\S_\H_N+(
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MCNIP9X[J<&>.ZG!GCNIP_W,5 O^%$P'_E!0 _*,5 .JP$@#9O@P S<$; <+
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M8DVV]6)-MO5B3;;U8DVV]6)-MO5B_XD+ .&< P#0J@4 Q;4% +N_! "RRP@
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M)02$Z#,+>^@\%'/H1!MKZ$LB9.=2*%[G62U9YV R5>=H-5+G;SA/YW<[3.>
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MK(ME/Z6';$>@@W--FX![4Y9]@E>2>HI<CGB28(IVFV.'=:5FA'2Q9X)TP&B
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M:'1^\69T??)E=7SS9'5\\V1U?/-D=7SS9'5\\V1U?/-D_VD6 ?]X$P'_AQ0
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M8EZ3]6)>D_5B7I/U8EZ3]6)>D_5B_W4. /^&#0#KE@@ U:,' ,RM" #%M@<
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M' &<R"P&D\<Y#XK%1!F!PTTC>L%4+'._6S-MOF(Y9[QI/F*[<$->NG='6KF
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MF",R_J0D,?^Q)3#_OR8O_\\F+O_C)B[_XR8N_^,F+O_C)B[_XR8N_^,FK:T
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M6H-N^%F";_Q8@F_]5X)O_5>";_U7@F_]5X)O_5>";_U7_V 5 ?]N$0'_>Q,
M_X84 /:/%@#GEA@ VYP< ,^;+03%ESL-O)-'&+2.42.MBEDLIX9A-*&":3N<
M?W!!EWQW1I-Y?DN/=X9/BW6.4HASEU6$<J%8@G&L6G]QNEQ^<<Q<?7+G6WUR
M]EI\<OQ9?'+\5WQR_5=\<OU7?'+]5WQR_5=\<OU7_V(4 ?]Q$0'_?1$ _X@2
M /*2$@#CFA( U9\9 ,J>*P3!FSD,N)=%%["23R*ICE@KHHI?,YR&9SJ7@VY
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M6&U^_%AM?OQ8;7[\6&U^_%AM?OQ8_VD0 ?]X#@#_A0P XI(( -6;"0#.HPD
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MJ#5"SK@V0<_--4'.Z#5 S?4W/\O^.3[+_SD^R_\Y/LO_.3[+_SD^R_\YRI8
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M&BW[OAHL^\\;*_OG&RO[ZQLK^^L;*_OK&RO[ZQLK^^L;J*H  )JT  "-OP
M@,D  '33  !GW@  7O(( %G^$0!3_QH!3O\C DG_*P-%_S,$0?\Z!3[_008[
M_T<'./]."#7_5 DS_UH),?]A"B__:0LL_W(,*O]]#2C_B XF_Y4/)?^A$"3_
MKA$C_[H2(O_*$B+_T!(B_] 2(O_0$B+_T!(B_] 2G+(  (Z\  "!QP  <]$
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M2I9?^DF57_])DV#_2))@_T>28/]'DF#_1Y)@_T>28/]'_U@5 ?]C$0'_;A(
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M3'EO_TMY;_]+>6__2WEO_TMY;_]+_V / /]M#0#_>0P [H,+ -N+"0#4D0H
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MI4)-H[1#3*/(0TRCY$-+H?1#2Z#_1$N@_T1+H/]$2Z#_1$N@_T1+H/]$XWT
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M*S[)X2H^Q_(K/<;\+3S%_RX\Q?\N/,7_+CS%_RX\Q?\NQ),  +:?  "II@
MG:X  )*W  "&OP  >\<# '#/!P!GU@T 9-<: &#8*@%<V#8#6-A!!E382@I0
MV%(-3=A:$$K78A-'UVD61==R&$+7?!I V(<</=B3'CS8H1\ZV; @.=G#(#G9
MWR YU^\@.-7Y(C?4_R,WU/\C-]3_(S?4_R,WU/\CN9P  *ND  "?K   D[4
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M"1S_W0D<_]T)'/_="1S_W0D<_]T)F+   (JZ  !\Q   ;\T  &+8  !5W@
M2>0  $3[!0 __PX ._\5 #C_'  T_R0!,?\K 2W_,0$J_S8")_\\ B7_0@(C
M_T@"(/]. Q[_50,<_UT#&?]G!!?_<@05_W\$%/^,!1/_F@42_Z8%$?^R!1'_
MO 41_[P%$?^\!1'_O 41_[P%C+@  'W"  !OS   8M@  %3?  !'Y0  /O$
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M-:]/_3:M3_\VK$__-JM/_S:K3_\VJT__-JM/_S:K3_\V_TT7 ?]5$@'_7Q0
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M/HA@_SZ(8/\]B&#_/8A@_SV(8/\]_U</ /]B# #_; P ^'0, .EZ# #>?@P
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M.H)MCSU_:YD_?&NC0GEJL$-X:K]$=FK4179K[4-V:_M"=FO_079L_T!V;/]
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M06-^J$-A?;9$8'W)1%]]Y4-@??9"8'W_06%]_T!A??] 87W_0&%]_T!A??]
M_V<  .-T  #2?P  QX@! +Z/ @"VE0$ KI@& *::%0"?FB8"F)DS!I&7/PR+
ME4@4A9-0&G^16"!ZCU\E=HUE*G*+;"YNBG,R:HA[-F:'A#ECAHX\8(69/UV$
MID%;A+1"6H3'0UJ$XT):@_1!6X/_0%N#_T!;@_\_6X/_/UN#_S];@_\__VH
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M.$F>W3A)G? X29S\.$F;_SE)F_\Y29O_.4F;_SE)F_\YVWH  ,B'  "\D@
ML9H  *:@  "<I@  D:P  (>Q" "!LA8 ?+,F 7:R,P1QLCT):[%'#F:P3Q-B
MKU887JY='%JM9"!7K&LC5*QS)E"K?"E-JH8L2JJ2+TBIGS!&J:TR1:F_,D2J
MVC)$J.\R0Z?[,T.F_S-#I?\T0Z7_-$.E_S1#I?\TT($  ,&.  "UF   J9\
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M.<#Y(CB__R0XO_\D.+__)#B__R0XO_\DO9$  +";  "DH@  F*H  (RQ  "
MN0  =;\  &K&! !>S @ 6<\2 %?0(0!5T"X!4= Y D[00P1+T$P&2=!3"$;0
M6PM#T&,-0=!K#S[0=1$\T8 3.M&,%#C1FA8VT:D7-=&[%S32TA<UT.P6-,_W
M&#/._QHSSO\:,\[_&C/._QHSSO\:LYD  *:A  ":J0  CK$  (&Y  !UP
M:L<  %[- P!4U @ 3-T- $K=& !(WB8 1MXR 43?/ )"WT4#/]]-!#W@504[
MX%T&.>!F"#?@;PDUX7H*,^&&##'AE TPXJ,.+N*S#B[CQPXMX^,.+>#R#BS?
M^P\LW_T0+-_]$"S?_1 LW_T0J*   )RG  "/L   @[@  ';!  !JR0  7L\
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M @S_P@(,_\("A[8  'F_  !KR0  7M,  %#;  !#X   ..4  "_P   K_P
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M11H!_TL@ ?]-* '_3C("_TT\!/]*1P;Z2%,(]D9?"_)$:@[O0G01[$%^$^I
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M+IU/_RZ=4/\NG5#_+IU0_RZ=4/\N_TP0 /]4#0#_70X _V,/ /EG$0#K:14
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MISAI;[4Z:&_'.F=OXCIG;_0X:&__-VAO_S9H;_\V:&__-FAO_S9H;_\V_UX
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M4Q=UB5H;<8AA(&Z&:"-JA6\G9X1W*V.#?RY@@HDQ78&4,UN H399?Z\W5W_
M.%=_VC=7?_ W6'[]-EA^_S58?O\U6'[_-5A^_S58?O\UZ6@  -1T  #&?@
MNX<  +*-  "HD0  GI0  ):6#@"1EQP BY<K H66-P5_E$$*>9-)$'22415P
MD%@9;(]?'6B.9B%EC&TE88MT*%Z*?2Q;B8<O6(B2,56'GS-3AZTU4H>^-5&'
MUC51ANXU4H7[-%*%_S12A?\S4H7_,U*%_S-2A?\SXVP  ,YY  #!@P  MHL
M *R1  "BE0  EYD  (^;"P"*G1@ A)TG 7Z<- 1YFSX(<YI'#6^93Q)JF%87
M9I==&V.58QY?E&HB7)-R)5F2>RA5D84K4I&0+E"0G3!.D*LQ3)"\,DR0TS),
MC^TR3([Z,DR-_S%,C/\Q3(S_,4R,_S%,C/\QW'$  ,A^  "[B   L9$  *:6
M  "<F@  D)\  (>B!@"!HQ0 ?*0C 7>D, -RHSL&;:)$"VBA3 ]DH%038)]:
M%UV>81M9G6@>5IUP(5.<>210FX,G39J.*4J:FRQ(FJDM1YFZ+4::T"U&F.LM
M1I?Y+D:6_RY&EO\N1I;_+D:6_RY&EO\NT7<  ,&$  "VC@  JI4  *";  "5
MGP  BJ0  'VI  !WJQ  <ZL> &^L+ %JJS<$9:M!!V&J20M=J5$/6JE8$U>H
M7Q93IV894*=N'$VF=A]*I8$A2*6,)$6EF29#I*@G0J2X*$&DSB=!H^HG0*+X
M*$"A_RE H/\I0*#_*4"@_RE H/\IR7X  +J+  "OE   HYH  )B@  "-I0
M@JH  '6P  !LLPP :;08 &6T)P%AM#,"7K0]!%JT1@=6LTX*4[-5#5"S7!!-
MLF,32K)K%D>Q=!A%L7X:0K"*'4"PEQX^L*8@/+"W(#RPS" \K^@@.Z[W(3JM
M_R(ZK/\C.JS_(SJL_R,ZK/\CP(8  +.2  "GF0  G)\  )"F  "$K   >;$
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M"2;8_@DFV/X)I)T  )BE  "+K0  ?K0  '&\  !EPP  6<D  $W-  !#TP$
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M&[D\_QNX//\;N#S_&[@\_QNX//\;_SX4 /]$$ #_2A$ _T\4 /]1&P#[4B,
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MB5>A*896K2N%5KHL@U;,+()7YBR!5_<K@%C_*H!8_RJ 6/\I@%C_*8!8_RF
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MIRUV7K4N=5[&+W1>X2]T7_,N=%__+'1@_RMT8/\K=&#_*W1@_RMT8/\K_U,
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M,&-KV#!C:^\O9&O\+61K_RUE:_\L96O_+&5K_RQE:_\L]%L  -UF  #+;P
MP'8  +=[  "O?@  IGX! )]_$ "9@!\ DX M HU_.06(?4,)@WM+#7YZ4Q)Z
M>%H6=G=A&7-U9QQP=&X?;7-V(FIR?R9H<8DH97"4*V)PH"U@;ZTO7V^]+UYO
MU"]>;^TO7V_[+5]O_RQ@;_\L8&__+&!O_RQ@;_\LZUX  -AI  #'<@  O'D
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M*D^ _RI/@/\I3X#_*4^ _RE/@/\IVVH  ,=U  "Z?P  L(<  *:,  "<CP
MCY$  (:3!0" E!( >Y4A '>5+0%RE3@$;91"!VF32@MEDE$.8I%8$EZ07Q5;
MCV886(YM&U6.=AY2C8 A3XR+(TV+F"5+BZ4G28NU*$B+RBA(BN<G28GW*$F(
M_R=)A_\G28?_)TF'_R=)A_\GT6\  ,%[  "UA   JXP  *"0  "5E   B9<
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M&C:F_QHVIO\:NH0  *Z/  "BE@  EYL  (NA  !_I@  <ZL  &>O  !:M
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M>  8Y(@!%^6: 1;FK $5YL !%.?= 1/E[P$3X_H!$^/Z 1/C^@$3X_H!EJ(
M (FI  ![L0  ;KD  &'   !4Q@  2,H  #W/   STP  *MD  "+> @ >ZPH
M'.P0 !OM%P 9[1\ %^XF !7N+0 4[S4 $_ ] !'P1@ 0\5  #_);  [R:0 -
M\W@ #/2*  OUG  *]:X "?;"  GVV0 (]>T "/7M  CU[0 (]>T BZD  'VR
M  !ON@  8L(  %7)  !'S@  .](  #'8   GW0  '^$  !GH   6^ 8 %/H-
M !+[$@ 0_!< #OP=  W](P ,_2D "OXP  C_.  &_T$  _],  #_6   _V8
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MJA^(3K<@AT[((85.XB&$3_,@@T__((-/_Q^"4/\?@E#_'H)0_QZ"4/\>_T<
M /-1  #?6   T5T  ,E@ @##8 0 O5X- +5@&@"N82H J6 W J1>0P2?74T(
MFUM5"YA970Z56&01DE=K$X]6<A:-57D8BU2!&HA3B1R&4Y(>A%*<'X)2IR&
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M)7!:U25O6^TE;UO\(V];_R)O6_\B;UO_(6];_R%O6_\A^D\  .%:  #/8@
MQ&<  +MK  "S;   K&H$ *1K$@">;"$ F6PO 91K.@./:40&BFA-"89F50V#
M95P0@&1B$WUB:15Z8G 8>&%X&G5@@!US7XH?<%^4(6Y>H"-L7JTE:UZ\)FI>
MT29I7NPE:E_[)&I?_R-J7_\B:E__(FI?_R)J7_\B\%(  -U=  #+90  P&L
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M)%MJ_R-<:O\B7&K_(EQJ_R)<:O\BXUL  ,YF  # ;@  MG0  *QY  "C>P
MF'D  )!Z"P"*>Q8 A7PD (%\,0%\>SL$=WI$!G-Y3 IP>%,-;'=:$&EV81-G
M=6@69'1O&&%S>!M><H$=7'&,(%IQF")8<*8D5G"U)55PR"55<.4E57#V)%9O
M_R-6;_\B5V__(E=O_R)7;_\BWU\  ,II  "\<@  LG@  *E]  "??P  DGX
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M'D6"_QY%@O\>RFT  +IX  "O@0  I8<  )J+  "/C0  @8X  '21  !NDPH
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MAP<OL98(+K*F""VRN DLLM (++#L"2NO^0HKKO\+*JW_"RJM_PLJK?\+K8L
M *"2  "5F   B9T  'VC  !QJ   9*T  %FQ  !-M   0K@  #NZ"@ XNQ,
M-[P> #6\*0 TO3( ,[T[ #*]1  QODP +[Y5 2Z^7@$LOF@!*KYT BF^@@(G
MOY$#)K^B R2_M ,CO\L#([[H R.\]P0BN_\%(KO_!2*[_P4BN_\%I)(  )B8
M  ",G@  @*4  '.K  !GL   6[4  $^Y  !$O   .L   ##$!  JQPL *,@3
M "?)'0 FR2< )<DP "3*.0 CRD( (LM+ "'+50 @S%\ '\QL !W->@ <S8H
M&\V< !G.K@$8SL4 &,WD !C,] $8ROP!&,K_ AC*_P(8RO\"FYD  (^?  ""
MI@  =:T  &BS  !<N0  4+T  $3!   YQ   ,,@  "C, 0 @T 8 &=4+ !;7
M$  5V!D %=DB !39*P 3VC0 $]H] !+;2  1W%, $=U? !#=;0 0WGX #M^1
M  [@I  -X+@ #.#2  O?[0 ,WO< #-W[  S=^P ,W?L DI\  (6G  !WK@
M:K4  %V\  !0P0  1,4  #C)   NS0  )=$  ![5   6V@$ $=X& !#G#0 .
MYQ( #>@9  SH(0 +Z2D "NHQ  GJ.P 'ZT4 !>M1  3K7@ #ZVX  >N   #J
ME   ZJ<  .N\  #KT@  Z^D  .SO  #L[P  [.\ AZ<  'FO  !KMP  7KX
M %'%  !#R0  -\T  "W1   CU@  &]L  !/?   .XP  #.X"  KV"@ ']@X
M!?82  /V&   ]1X  /4E  #U+@  ]3<  /9"  #V3@  ]ET  /9N  #V@0
M]I4  />G  #WMP  ^,<  /C0  #XT   ^-  >Z\  &VX  !@P   4L@  $3-
M   WT0  *]<  "'<   8X   $>0   SG   '[P  !/H   '_ P  _P@  /\-
M  #^$   _A0  /\:  #_(0  _RD  /\S  #_/@  _TL  /];  #_;   _X
M /^2  #_H0  _ZT  /^S  #_LP  _[, _QPF /\<) #_&B4 _Q4G /\1+@#_
M$#H _PY' ?\-4P'_"U\!_PIK ?\*=0'_"G\!_PJ' ?\*C@'_"I4!_PJ; ?\)
MH '_":4 _PFK /\)L0#_";@ _PG! /X)S #\"=X ^0GK /4)]@#S"?\ \@K_
M /$*_P'Q"_\!\0O_ ?$+_P'Q"_\!_Q\C /\?(0#_'B$ _QDD /\7+ #_%3<
M_Q-$ /\14 '_$%P!_PYG ?\.<@'_#GL!_PZ$ ?\.BP'_#I(!_PZ8 ?\.G0'_
M#J,!_@ZH ?P.K@'[#K4 ^@Z^ /@.R0#U#ML \@[J .X.]0#L#O\!ZP__ >H/
M_P'J$/\!Z1#_ >D0_P'I$/\!_R(? /\B' #_(1P _Q\@ /\?*0#_'#0 _QI
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M!L8C_P;&(_\&_RP2 /\N#P#_,!  _S,4 /\S&P#_,B4 ^C P /(N/ #L+$D
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M7 B63F,*E$UJ#)%,<0Z/2W@/C4M_$8M*AQ*)2I 4ATF:%85)I1>#2;$8@DG
M&(%*UAE_2NT8?DO\&'Y+_Q=]2_\7?4O_%GU+_Q9]2_\6_T,  .9,  #64P
MR5@  ,!9  "Z6 $ M%8) *Q7%@"F6"4 H5@R 9U7/@*85D@$E551!I)46 B/
M4E\*C%)F#(I1;0Z(4'00A4][$H-/A!.!3HT5?TZ7%WU.H1A[3:X9>DZ]&GA.
MT1IW3NL:=T_Z&79/_QEV3_\8=D__%W9/_Q=V3_\7^$8  .)0  #05P  Q%P
M +M>  "T70  KEH& *9;$P"@7"( FUPO )=;.P*26D4#CUE-!HM850B(5UP*
MAE9C#(-5:@Z!5'$0?E1X$GQ3@!1Z4HD6>%*4&'92GQET4JL:<E*Z&W%2S1QP
M4N@;<%/Y&G!3_QIP4_\9<%/_&'!3_QAP4_\8[TD  -U3  #+6@  P%\  +=B
M  "O80  J%X" *%?$ ";8!X EF L )%@. &-7D(#B5U+!85<4@>"6UD*@%I@
M#'U99PY[6&X0>%AU$G97?11T5X<6<E:1&&]6G!IN5JD;;%:X'&M6RQUJ5N8<
M:E?W&VI7_QIJ5_\9:U?_&6M7_QEK5_\9ZTP  -A6  #(7@  O&(  +-E  "K
M90  HV(  )QB#@"68QP D60I (QC-0&(8C\#A&%(!8!@4 =]7U<)>EY="W==
M9 UU7&L0<UQR$G!;>Q1N6X07;%J/&&I:FAIH6J<<9EJV'65:R!UE6N0=95KV
M'&5:_QME6O\:95K_&65:_QEE6O\9Z$\  --9  #$80  N68  +!H  "G:0
MGF4  )=F#0"19QD C&@G (=G,@&#9CT"?V5&!'MD309X8U0)=6);"W)A80UP
M86D/;6!P$FM?>11I7X(69UZ-&65>F!IC7J4<85ZT'6!>QQU@7N,=8%[U'&!>
M_QM@7O\:85[_&F%>_QIA7O\:Y%(  ,]<  # 9   MFD  *QL  "C;   F6D
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M&5)J_QE2:O\9U%P  ,-F  "V;@  K'0  *)W  "6=@  B74  (%V 0!Z=P\
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MB0\^BI@1/(JG$CN*N!(ZBL\2.XCK$CN'^A,[AO\3.X;_$SN&_Q,[AO\3O'$
M *][  "E@P  F8<  (R(  !_B0  <XP  &60  !<DP  5Y4, %26%@!2EB(
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M!">LL 0FK,4$)JOD R6I]00EJ/\%):?_!26G_P4EI_\%IXD  )N/  "1E
MA)D  'B>  !KH@  7Z8  %.J  !(K0  /;   #2S P OM0X +;46 "RU(  K
MMBD *K8R "FW.@ HMT, )[=, ":X50 DN%\ ([AK "*X> $@N(@!'[B9 1VY
MJP$<N< !'+C? 1RV\@$;M?P"&[3_ ANT_P(;M/\"GX\  )25  "(FP  >Z$
M &ZF  !BJP  5K   $JS   _M@  -;D  "R\   DOP8 '\(- !W"%  <PAX
M&\,F !K#+P 9Q#@ &,1! !?$2@ 6Q54 %<5A !3&;P 3QG\ $L:1 !''I  0
MQ[D #\?4 !#&[@ 0Q/H $,/_ !##_P 0P_\ EY8  (N<  !^H@  <:D  &2O
M  !8M   2[@  $"[   UO@  *\$  "/%   ;R0$ %,P& !#0"P .T1$ #=$9
M  W1(0 ,T2H #-$T  O2/@ *TDD "=-5  G38@ (TW( !M2$  74F  $U*L
M ]7   '5W  !U>T  =7V  '5]@ !U?8 CIT  ("D  !SJP  9K$  %FX  !,
MO0  /\   #3#   JQP  (<H  !G.   2T@  #=8!  G;!0 &W T !-P1  /=
M&  !WB   -XH  #?,0  X#P  .%'  #B5   XV,  .-T  #DB   Y)L  .6N
M  #EP0  Y=4  .;G  #FYP  YN< @Z0  '6L  !HLP  6KL  $W!  ! Q
M,\@  "C,   ?T   %]0  !#9   +W0  !>$   #D    Y0<  .8-  #G$0
MZ!8  .D=  #J)0  ZRX  .TY  #O10  \%,  /%D  #Q=@  \HH  /.<  #S
MK0  ]+L  /3(  #TR   ],@ =ZT  &JU  !<O0  3\0  $#)   SS0  )]$
M !W6   4W   #N    CC   !Y@   .H   #N    [@   .\$  #P"@  \0X
M /,2  #T&   ]B   /@J  #Z-0  _4,  /Y2  #_8P  _W8  /^)  #_F@
M_Z8  /^P  #_L   _[  _Q8C /\5(0#_$2$ _PTD /\)*P#_!C< _P-$ /\
M40#_ %T _P!H /\ <@#_ 'L _P"# /\ B@#_ )$ _P"6 /\ G #_ *$ _0"F
M /L K #Y +, ]P"[ /4 Q0#S -$ \@#D /$ \0#O /H [@#_ .X _P#M /\
M[0#_ .T _P#M /\ _QD@ /\8'0#_%1T _Q ? /\.*0#_##0 _PI! /\'30#_
M!5D _P1D /\$;@#_ W< _P.  /\#AP#_ XT _0*3 /L"F0#Y IX ]P*D /4"
MJ@#S ;  \0&X .\!P@#M <\ ZP'C .H![P#H OL YP3_ .8%_P#F!O\ Y@;_
M .8&_P#F!O\ _QP; /\;&0#_%Q@ _Q4= /\3)0#_$3  _Q ] /\.20#_#%4
M_PM@ /\+:@#]"W, ^PM\ /D*@P#W"HH ]0J0 /0*E@#S"IL \0JA .\)IP#M
M":X ZPFV .@)P #F"<T Y GB .(*\ #?"_L W@S_ -P-_P#<#?\ VPW_ =L-
M_P';#?\!_Q\7 /\>$P#_&Q( _QP9 /\;(@#_&"P _Q4X /\31 #^$E  ^1%;
M /409@#S$&\ \!!W .X0?P#L$(8 ZA", .D0D@#H$)@ Y@^> .4/I0#C#ZP
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M /\J!0#_+@@ _R\, /\M$ #S*Q< Z"@B . F+P#9)CT TB=* ,TG50#**%\
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M"9DUW0F6-N\*E#;]"I,W_PJ2-_\*DC?_"I(W_PJ2-_\*_S,  /8Z  #D/P
MV$(  ,Y" 0#)/@8 Q#L/ +L^'0"U/RP L3\Z *T_10&I/T\!ICY8 J,]7P.A
M/6<$GSQM!9T\= :<.WL&FCN"!Y@[B@B6.Y,)E3J<"I,ZI@N1.K(+D#O #(X[
MU0R,/.P-BCS[#8D\_PV)//\,B#S_#(@\_PR(//\,_S<  .H_  #<10  SDD
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M$G%*_Q%Q2_\1<4O_$'%+_Q!Q2_\0[$,  -E,  #(4P  O5<  +18  "L5P
MI5(! )Y3#P"85!P DU0I (]4-0"+4T !B%-( H524 2"45<%?U!>!GU09 A[
M3VL)>4]R"W=.>PUU3H0.<TV.$'%-F1%O3:43;4VS%&Q-Q11K3N$4:T[T$VM.
M_Q)K3O\2:T[_$6M._Q%K3O\1Z$8  --0  #$5@  N5H  +!<  "F6@  GU8
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M$EQ9_Q)<6?\2W%   ,=9  "Z8   KV0  *1E  "99   D&   (AA!@""8A$
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MBA!*;9@126RG$DALN!-';,T31VSJ$TAK^A)(:_\22&K_$4AJ_Q%(:O\1QUX
M +AG  "L;@  H7(  )-R  "'<0  >G$  '%R  !K= < 9G41 &-V'0!@=R@
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M"S:$L0LVA,8+-H/D"S:"]@LV@?\,-H#_##: _PPV@/\,MF\  *IX  "??P
MD'X  (-_  !W@   :X(  %Z'  !5B@  3HP& $J.$ !(CQH 1X\E $60+P!$
MD#@ 0I!  $"01P$_D$\!/9!6 CN07P(YD&@#-X]S!#6/@ 4SCXX&,8^>!S".
MKP<OCL,'+X[A!R^,] @OB_\(+XK_""^*_PDOBO\)L'8  *5_  "8A   BH0
M 'V%  !PAP  98H  %J.  !/D@  1I4  $&8#  ^F!0 /9D? #N9*  ZFC$
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M !.QZP 3K_D $Z[_ 1.N_P$3KO\!FHT  )"2  "$EP  =9H  &B?  !;HP
M4*@  $6L   [L   ,;(  ">U   @N   &+H' !2\#@ 3O!4 $KP> !&])@ 1
MO2X $+TW !"^00 .ODP #KY7  V^90 ,OW0 "[^&  J^F0 (OJP ![["  >^
MWP (OO  "+WZ  B]_  (O?P DY0  (>9  !ZGP  ;*4  &"J  !3KP  1[,
M #RV   QN   )[L  !^^   7P0  $<0!  S("  (R0X !\D4  ;)'  %R20
M!,HL  /*-@ "RD   ,M,  #+60  RV@  ,MY  #,C   RY\  ,NS  #+R
MS.(  ,SO  #,\0  S/$ BIH  'RA  !OIP  8JT  %6S  !(N   .[L  #"^
M   FP0  '<0  !7(   /RP  "LX   32 @  TPH  -,/  #4%   U1H  -8B
M  #7*@  V30  -H_  #<2P  W%H  -UJ  #=?0  W9$  -VD  #>M@  WL@
M -[>  #>X@  WN( ?Z(  '&I  !DL   5K<  $F\   \P   +\0  "3'   ;
MRP  $\\   W2   'U@   -L   #>    WP,  . )  #A#@  XA(  .,7  #E
M'@  YB<  .@Q  #J/0  [$L  .Q:  #M;   [H   .Z4  #NI0  [K0  .["
M  #NQ@  [L8 =*H  &:R  !8N0  2\   #W%   OR0  ),T  !G1   1U@
M"]L   />    X0   .4   #H    Z0   .H   #K!@  [0L  .\/  #P$P
M\AH  /0C  #W+@  ^3L  /M*  #\6P  _6T  /V   #^DP  _J(  /ZM  #^
MKP  _J\ _Q ? /\.'0#_"AT _P$@ /\ * #_ #4 _P!! /\ 3@#_ %H _P!E
M /\ ;@#_ '< _P!_ /X A@#\ (P ^P"2 /D EP#X )P ]P"B /8 IP#U *T
M\P"U /( O0#Q ,D [P#< .X ZP#M /< [ #_ .L _P#J /\ Z@#_ .H _P#J
M /\ _Q,< /\1&0#_#1D _P8< /\#)0#_ #$ _P ^ /\ 2@#_ %8 _P!A /\
M:P#] ', ^@![ /< @P#U (D ] "/ /( E #Q )D \ "? .X I #M *L [ "R
M .H N@#H ,8 YP#6 .4 Z #D /4 XP#^ .( _P#A /\ X0#_ .$ _P#A /\
M_Q48 /\3% #_#Q0 _PT9 /\+(@#_""T _P0Y /\!1@#_ %$ _@!< /H 9@#V
M &\ \@!W .\ ?@#M (4 ZP"+ .H D0#H )8 YP"< .8 H0#D *@ XP"O .$
MN #? ,, W0#1 -L Y@#9 /, UP#] -4"_P#4 O\ U /_ -0#_P#4 _\ _Q@3
M /\5$ #_$@\ _Q(5 /\1'0#_#B@ _PPT /\*00#Y"$P ]097 /$&80#M!FH
MZ05R .8%>@#D!8$ X@6' . &C0#?!I( W0:8 -L&G@#9!J4 UP:M -0&M0#2
M!L  T ?/ ,X(Y0#,"?0 R@O_ ,@,_P#'#/\ QPS_ ,8,_P#&#/\ _QL. /\9
M# #_& T _Q@1 /\7& #_%"( ^Q$N /,0.@#M#D8 Z U2 .4-7 #A#64 W@UM
M -L-=0#8#7P U0V" -,-B0#1#8\ T V5 ,X-G #-#J, RPZK ,D.M #(#L
MQ@[/ ,,0Y@# $?4 O1+_ +P2_P"[$O\ NA+_ ;H2_P&Z$O\!_Q\* /\<! #_
M'P@ _Q\- /\=$@#X&AL [A8F .84,P#@$S\ VA-+ -035@#0$U\ SA1H ,L4
M;P#)%'< QQ5] ,85A #$%8H PQ61 ,$6F # %I\ OA:G +P7L "[%[P N1?+
M +<8X@"S&?(!L1K_ :\;_P&N&_\!KAO_ :T;_P&M&_\!_R($ /\B  #_)0(
M_"0' /<A# #L'1( X1H< -@:*@#0&S@ RQU% ,<=4 ##'EH P!YB +X>:@"\
M'W$ NA]X +D??@"W'X4 MA^, +0?DP"S'YH!L2"C ; @K &N(+<!K"'& :LA
MW0&G(N\"I2+] J,C_P*B(_\"HB/_ J$C_P*A(_\"_R4  /\H  #R*@  Y2L
M -\H!0#<(0L TB$4 ,DD) ##)3( OB8_ +HG2@"W)U0 M"== +(G9 "P)VP
MKB=R :TG>0&K)W\!JB>& :@GC@&G)Y8"I2>> J,HJ *B*+,"H"C! I\HU0*<
M*>P#FBKZ Y@J_P27*O\$ERK_!)8J_P26*O\$_R@  /4N  #E,P  VC4  - S
M 0#,+08 QBH0 +XM'@"X+BP LR\Z *\O10"L,$\ J2]8 *<O7P&E+V8!HR]M
M :$O<P*@+GH"GBZ! ITNB0*;+I$#F2Z: Y@NI 26+Z\$E2^]!),OSP21,.@%
MCS#X!8TQ_P6-,?\%C#'_!8PQ_P6,,?\%_RT  .HU  #<.@  SCT  ,8\  #
M-P( NS,- +,T&0"N-B< J3<T *4W0 "B-TH GS=3 9TV6@&;-F$!F39H I<U
M;P*5-74#E#5\ Y(UA 20-8T$CS66!8TUH 6+-:L&BC6Y!H@UR@>'-N4'A3;V
M!X0W_P>#-_\'@S?_!X(W_P>"-_\']#(  .,[  #200  QD0  +U#  "W/P
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M"V5*_PME2O\+X$0  ,M-  "]4@  LE8  *95  "<4@  E4X  (Y."0")3Q0
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MBPM469@-4UBF#E)9M@Y16<H/45GG#E%8^ U26/\-4EC_#%)8_PQ26/\,S5$
M +Q9  "P7P  HV$  )9@  "+7P  @5L  'E=  !S7@P ;UX5 &M?( !H7RL
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M"T-GL0Q"9\4,0F?B#$)F]0Q#9O\+0V7_"T-E_PM#9?\+OUP  +%D  "F:@
MEFD  (EI  !]:0  <6D  &=J  !B; $ 76T- %EN%@!7;R$ 57 K %-P-0!1
M<#T 4'!% 4YP3 %,<%,"2G!: TAP8@1&;VL%1&]U!D)O@@= ;H\)/VZ>"CUN
MKPH];L(*/&[@"CUM] H];/\*/6O_"CYK_PH^:_\*NF   *UI  "@;@  D6T
M (1M  !X;0  ;&X  &%P  !;<@  5G0* %)U$@!0=AT 3G<G $QW,0!+>#D
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M RF&[@,IA?P$*83_!"F$_P0IA/\$JG0  )Y[  ".>@  @'H  '1[  !H?@
M78$  %*%  !)B0  08P  #F0!0 UD0\ ,Y(7 #*2(0 QDBD ,),R "Z3.@ M
MDT$ +)-* "N44@ JE%P *)1G ">4<P$EE((!))23 2*3I $AD[<!()// 2&2
M[ $@D/H"((__ B"/_P(@C_\"I'P  )>   "'?P  >X   &Z"  !BA0  5XD
M $V.  !"D@  .I8  #*9   JG D *)T1 ":=&0 EG2( ))XJ ".>,@ BGCH
M(9Y" "">2P ?GU4 'I]@ !R?;0 ;GWP &I^- !B?GP 7G[( %I_) !:>Z  6
MG/< %IO_ 1>;_P$7F_\!G8,  (^&  ""A@  =(<  &>+  !;CP  4),  $:8
M   \G   ,Z   "NC   CI@  '*@+ !JI$0 8J1@ %ZDA !:J*0 5JC$ %*HY
M !.J0P 3JTT $JM8 !&K90 0JW0 #JN&  ZKF0 -JZP #*O!  RJWP ,J?(
M#:C\  VH_P -J/\ EHH  (F,  !ZC0  ;)$  &"5  !4F@  29\  #^C   U
MIP  *ZH  ".N   ;L   %+,!  ^U"@ -MA  #+86  NV'P *MB< ";8O  BV
M.0 'MT, !K=/  2W6P #MVH  K=[  "WC@  MZ$  +:T  "VRP  MN4  +7Q
M  "U]P  M?< CY$  (&4  !REP  99P  %BA  !,I@  0:L  #>O   LL@
M([4  !JX   3NP  #KT   G !0 #P0T  ,$1  #!%P  PAX  ,(F  #"+P
MPSD  ,1$  #$4   Q%X  ,5O  #%@0  Q94  ,6H  #%O   Q-$  ,3F  #$
M[@  Q.X AI@  'F>  !KHP  7:D  %"N  !$LP  -[8  "RY   BO   &;\
M !'"   ,Q0  !L@   #+    S <  ,P-  #-$0  S18  ,X=  #/)   T"T
M -(X  #41   U%(  -5A  #5<P  UH<  -:;  #6K0  U[\  -C.  #8W0
MV-T >Z   &ZF  !@K0  4[,  $6X   XO   *[\  "'"   7Q@  $,D   K,
M   "T    -0   #7    V    -H%  #;"P  W X  -X3  #?&0  X2$  .,J
M  #E-@  YT,  .=3  #H9   Z7<  .F,  #JGP  ZJX  .JZ  #JPP  ZL,
M<*@  &*O  !5M@  1[P  #G    LQ   (,@  !;,   .T   !]0   #9
MW0   .$   #C    Y    .8   #G 0  Z0<  .L,  #L$   [A4  / =  #S
M)P  ]C,  /=#  #X5   ^68  /EZ  #ZC@  ^IX  /NI  #[L   ^[  _PL;
M /\'&0#_ !D _P < /\ )0#_ #( _P _ /\ 2P#_ %< _P!B /\ :P#_ ',
M_0![ /L @@#Z (@ ^ "- /< D@#V )@ ]0"= /0 H@#S *D \0"P .\ N #N
M ,, [ #1 .L Y@#I /, Z #^ .@ _P#H /\ Z #_ .@ _P#H /\ _PX8 /\*
M%0#_ 10 _P 8 /\ (@#_ "X _P [ /\ 1P#_ %, _0!> /H 9P#W &\ ]0!W
M /, ?@#R (0 \ ") .\ CP#N )0 [ ": .L GP#I *4 Z "L .8 M #D +\
MXP#, .$ X@#? /  W@#[ -X _P#= /\ W0#_ -P _P#< /\ _Q 3 /\-$0#_
M!A  _P(5 /\ '@#_ "D _P V /\ 0@#Z $X ] !9 /$ 8@#N &L [ !R .H
M>0#H '\ YP"% .4 BP#D )  X@"6 .$ G #? *( W0"I -H L0#8 +L U0#(
M -( W0#1 .T T #Y ,\ _P#. /\ S0#_ ,T _P#- /\ _Q$/ /\.#0#_# T
M_PL2 /\'&0#_ B0 _P P /8 / #O $D Z@!3 .< 70#D &8 X0!M -\ = #=
M 'L VP"! -D A@#6 (P U "2 -( F #0 )X S@"F ,P K@#* +@ R #$ ,8
MUP#% .H PP#W ,( _P#! ?\ P +_ , "_P#  O\ _Q0+ /\0!@#_$ D _Q .
M /\.% #_"AX ]08I .L$-@#C T( WP-. -L$5P#6!&  TP1H - $;P#.!78
MS 5\ ,H%@@#)!8@ QP6. ,8%E #$!9L P@6C , &JP"^!K4 O0;" +L(U "Z
M">D MPOX +4,_P"T#/\ M S_ +0,_P"T#/\ _Q<$ /\4  #_%@, _Q0) /\1
M#@#R#A4 Z PA -X*+@#6"SL T Q' ,P,40#)#%H Q@UB ,0-:@#"#7$ P UW
M +\-?0"]#H, O Z* +H.D0"Y#I@ MPZ@ +8.J0"T#[0 L@_! +$0U "N$>L
MJQ+Z *D2_P"H$_\ IQ/_ *<3_P"G$_\ _QH  /\;  #Y&P  ZQD  .44!@#E
M$ X V0X7 ,\1)@#($C0 Q!-  +\42P"\%%0 N15= +<59 "U%6L M!5Q +(5
M> "Q%GX KQ:% *X6C "L%I0 JQ>< *D7I@"G&+  IAB] *08SP"B&N< GQKW
M )T;_P&<&_\!G!O_ 9L;_P&;&_\!_QT  /<A  #H)   W24  -0A 0#/&P@
MRA<1 ,(:( "\'"T MQTZ +,>10"P'D\ K1Y7 *L>7P"I'V8 J!]L *8?<P"E
M'WD HQ^  *(?AP"@((\ GR"8 )T@H@";(*P!FB&Y 9@AR@&6(N0!E"/U 9(C
M_P&1(_\!D"/_ 9 C_P&0(_\!_R(  .LI  #=+@  SR\  ,<M  #!)P, O2(-
M +8C&@"P)2@ K"8T *@F0 "E)TD HB=2 * G6@">)V$ G"=G )LG;0"9)W0
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M!'0W_P1T-_\$YS4  -(]  ##0@  N$0  *Q"  "D/@  GSD  )HX#@"4.AD
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MB@9>2)<'74BE"%M(M A;2,<)6DCD"%I)]@A:2?\'6DC_!EI(_P9:2/\&T44
M +],  "R4@  HU$  )=0  "-3@  ADH  (!* 0!Z2PX =DP7 '),(P!O3"T
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M"$Q4KPA,5,()2U3?"4Q4\PA,4_\'3%/_!TU3_P9-4_\&Q4X  +96  "G6@
MF%D  (M8  "!5P  =U0  '!5  !J5@8 9E<0 &)7&@!@6"0 75@N %M9-P!9
M63\ 5UE& %9930%4650!4UE; E%98P)/6&P#3EAV!$Q8@@5*6(\&25B>!TA8
MK@A'6, (1UC="$=8\@A'5_\'2%?_!TA7_P9(5_\&P5$  +)9  "C7   E%L
M (=;  !]6@  <E@  &M9  !E6@, 8%L. %U<%P!:7"$ 6%TK %9=- !47CP
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M!3=H[@4W9_P%.&;_!3AF_P4X9O\%M%X  *=E  "590  AF0  'IE  !O90
M9&8  %EH  !2:@  36P$ $EN#@!';A8 16\@ $1P*0!"<#( 07 Z $!Q0@ _
M<4D /7%1 #QQ60$Z<6(!.'%L C9P> (U<(8#,W"5 S)PI@0Q<+@$,'#0!#%O
M[ 0Q;OL$,6W_!#%L_P0Q;/\$KV0  *%I  "/:   @6@  '5I  !K:0  8&L
M %5N  !-<0  1G,  $)U"P _=A( /7<< #QW)0 Z>"T .7@U #AY/0 W>44
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M 1F(_P$9B/\!G7<  (QV  !]=@  <G<  &5Y  !:?   4(   $:$   \B0
M-(P  "V0   EDP( 'Y4, !V6$@ <EAH &Y<B !J7*@ 9ES( &)@Z !>80P 6
MF$T %9A8 !289  3F', $9B$ !"8E@ 0F*D #IB_  Z7W0 /EO( $)7\ !"4
M_P 0E/\ E7T  (5\  !X?   :WX  %^!  !4A@  2HH  $"/   VDP  +9<
M "::   >G0  %Z # !*B#  0HQ( $*,9  ^C(0 .I"D #J0Q  VD.@ ,I$4
M"Z10  JD7  )I&H !Z1[  :CC@ $HZ$  J.T  .BRP #HN8  Z'S  .A^P #
MH?L C8,  '^"  !QA   9(<  %B,  !-D0  0I8  #B:   OG@  )J(  !ZE
M   7J   $:L   RN!P 'KPT  Z\2  *O&0 !KR$  *\I  "P,@  L#P  +!'
M  "P4P  L&$  +!Q  "P@P  KY<  *^J  "OOP  KMD  *[K  "N]   KO0
MAXD  'B*  !JC@  79,  %&8  !%G0  .Z(  #"F   GJ@  'JX  !:Q   0
MM   "[8   6Y P  N@H  +H.  "Z$P  NQD  +LA  "\*   O#$  +T\  "^
M2   OE8  +YE  "^=P  OHP  +Z?  "]LP  OL<  +[>  "]ZP  O>L ?Y(
M '"5  !BF@  59\  $FE   ]JP  ,J\  "BT   >M@  %;D   Z\   )OP
M L(   #$    Q00  ,8*  #&#@  QQ(  ,@8  #)'P  RB<  ,PP  #./
MSDD  ,]9  #/:@  SWX  ,^3  #/I@  S[@  ,_(  #/VP  S]L =YP  &BA
M  !;IP  3JX  $&T   TMP  *+H  !V]   3P   #<0   ;'    R@   ,X
M  #0    T0   -("  #3"   U0P  -80  #9%0  VQP  -TD  #@+P  XCP
M .-+  #D7   Y&\  .6#  #EF   Y:D  .6V  #EPP  Y<, ;*4  %^L  !1
ML@  1+D  #6\   HP   ',0  !+(   ,RP   \\   #3    V    -P   #?
M    WP   .$   #C    Y ,  .8(  #H#0  Z1$  .P8  #N(@  \2X  /,\
M  #T30  ]5\  /9S  #WAP  ]YD  /BE  #XL   ^+  _P,7 /\ %0#_ !4
M_P 8 /\ (P#_ "\ _P \ /\ 2 #_ %0 _P!> /\ 9P#] &\ ^P!V /D ?0#X
M (, ]@"( /4 C@#T ), \@"8 /$ G@#P *0 [@"K .T LP#K +T Z@#+ .@
MX0#G /$ Y@#] .4 _P#D /\ Y #_ .0 _P#D /\ _P<3 /\ $0#_ !$ _P 5
M /\ 'P#_ "L _P W /\ 1 #^ $\ ^@!: /< 8P#T &L \@!R /  >0#O '\
M[0"$ .L B@#J (\ Z "4 .< F@#E *  Y "G .( KP#@ +D W@#& -P V@#:
M .P V #Y -8 _P#6 /\ UP#_ -@ _P#8 /\ _PH0 /\##@#_  T _P 2 /\
M&@#_ "8 _  R /< /P#T $H \0!5 .T 7@#J &8 Z !N .4 = #C 'H X@"
M .  A0#> (L W "0 -L E@#8 )P U0"C -, JP#1 +4 S@#! ,P T0#+ .<
MR0#U ,@ _P#( /\ R #_ ,@ _P#( /\ _PP, /\&" #_ @H _P / /\ %0#\
M "  \0 L .P .0#I $4 Y0!/ .$ 60#> &$ VP!H -< ;P#4 '4 T@![ -
M@ #. (8 S ", ,L D@#) )@ QP"@ ,4 J ## +$ P0"\ +\ RP"] ., O #R
M +L _0"[ /\ N@#_ +H _P"Z /\ _PX% /\)  #_"04 _P8+ /\!$ #P !D
MY@ E .$ ,@#< #\ U@!) -$ 4P#. %L RP!C ,@ :@#& '  Q0!V ,, >P#!
M ($ P "' +X C@"\ )0 NP"< +D I "W *X M0"Y +, R "Q -\ L 'O *\!
M^P"N O\ K0/_ *T#_P"M _\ _Q   /\.  #_#0  ]@L# /('"@#B 1$ VP(=
M -(#*P#, S< R 1# ,0$30#!!%8 O@5= +P%9 "Z!6L N 5Q +<%=@"U!7P
MLP:# +(&B0"P!I$ KP>9 *T'H0"K!ZL J0BW *@)Q@"F"MT I0OP *,,_0"B
M#?\ H0W_ *$-_P"@#?\ _Q$  /P2  #L$P  XA,  -L/ P#6"0L S@@4 ,8*
M(@# ##  O T\ +@-1@"U#4\ L@Y7 + .7P"N#F4 K0YK *L.<0"J#G@ J Y^
M *</A0"E#XT I ^6 *(0GP"@$*D GQ"U )T1Q0";$=X F1+Q )<3_P"6%/\
ME13_ )44_P"4%/\ _Q4  .T;  #@'P  TA\  ,D;  #$% 4 P1 . +H2&P"T
M$RD L!0U *P50 "I%4D IA52 *0660"B%F  H19F )\6; ">%G( G!9Y )L7
M@ "9%X@ F!>1 )88FP"4&*8 DQFR )$9P0"0&M@ C1ON (L<_0"*'/\ BAS_
M (D<_P")'/\ ]!T  .0E  #3*0  QRH  +PF  "V(   M!D+ *X:%0"H'",
MI!TO *$>.@">'D0 FQY, )D>5 "7'UL E1]A )0?9P"2'VT D1]T (\@? ".
M((0 C""- (H@EP")(:( AR&N (8BO0"%(M$!@B/K 8$D^P& )/\!?R3_ 7\D
M_P%_)/\!["4  -LM  #),0  O#$  +$N  "K*0  IR0% *,C$0">)!T FB4J
M )8F-0"3)C\ D29' (\F3P"-)E8 BR=< (DG8@"()VD AB=O (4G=P"#)W\
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MC )L-)@":C6E FDULP-H-<8#9S;B V8V]0-F-O\"9C;_ F8V_P)F-O\"V#<
M ,0^  "U0@  ID$  )L_  "3/   C3@  (@V!P"$-Q$ @#<< 'PX)P!Z.#$
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M!%9#K0150[\$5$/:!%1#\0140_X#5$/_ U1#_P-40_\#R$(  +A)  "G2P
MF$H  (U)  "#1P  ?4,  '9#  !Q1 H ;402 &I%'0!G12< 9$4P &)%. !@
M13\ 7T5' %U%30!;150 6D9; 5E&8P%71FP!5D9V E1&@0-31HX#4D><!%!'
MJP101[T$3T?6!4]'[P1/1_T$3T?_ T]'_P-01_\#Q$4  +5-  "C30  E4P
M (E+  !_2@  >$8  '%'  !L1P< :$@0 &1(&@!A220 7TDM %U)-0!;23T
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M!$%3[ 1!4OL#0E+_ T)2_P-"4?\#ND\  *I4  "85   B50  'U3  !S4P
M:5$  &)2  !<4P  6%0* %15$@!251L 3U8D $Y6+0!,5S4 2U<\ $I71 !(
M5TL 1UA2 $986@%$6&,!0UAM 4%8>0) 6(8"/EB5 SU8I0,\6+<$/%C-!#Q7
MZ@,\5_H#/5;_ SU6_P,]5O\#ME,  *57  "45P  A58  'E6  !O5@  954
M %Q6  !76   4ED' $Y:$ !,6A@ 2ELA $A<*@!'7#( 15PZ $1=00!#74@
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M BMG_P(K9_\"J6$  )5@  "$8   =V   &QA  !B80  6&,  $YF  !':
M0&L  #IN!0 V;PX -' 5 #-P'@ R<28 ,'$N "]Q-0 N<CT +7)% "QR30 K
M<E< *G)A "ER;0 G<GL )G*+ "1RG $C<JX!(W+# 2-QX@$C</0!(V__ 2-N
M_P$C;O\!H64  (YD  !_9   <F0  &AE  !>9@  5&D  $EL  !";P  .W(
M #1U   N> H *WD1 "IY&  I>B$ )WHH "9Z,  E>S@ )'M  "-[2  B>U(
M(7M< "![:  ??'8 '7R& !Q[F  ;>ZH &GN_ !I[W@ :>?( &WC^ !MW_P$;
M=_\!F6D  (AI  !Y:0  ;6D  &-J  !9;   3V\  $5S   ]=P  -7H  "Y]
M   G@0, (H,- ""$$@ ?A!H '80B !R%*@ ;A3$ &H4Y !F%0@ 8ADP %X96
M !:&8P 5AG$ %(:! !*&DP 1AJ8 $86[ !"%U@ 1@^\ $8+[ !*"_P 2@?\
MD6X  (%M  !T;@  :6X  %UP  !3<P  27<  $!\   W@   +X,  ">'   A
MB@  &HT& !6/#0 3D!, $I : !*0(@ 1D"H $)$R !"1.P /D40 #I%/  V1
M7  ,D6H "Y%Z  J1C0 (D)\ !Y"S  >/R0 'C^8 !X[T  B-_  (C?\ B7,
M 'MS  !O<P  8W4  %=X  !-?0  0X$  #F&   PB@  *(X  "&1   :E0
M$Y<   Z:"  +G X "9P3  B<&@ 'G"( !IPJ  2<,P #G#T  IU(  "=5
MG6(  )QR  "<A   G)<  )NJ  ";OP  FML  )KL  ":]0  F?@ @GD  '9Y
M  !H>@  7'X  %&"  !&AP  /(P  #*1   IE0  (9D  !F=   2H   #J,
M  FF!0 #IPP  *<0  "G%0  J!P  *@C  "H*P  J30  *D_  "I2P  J5D
M *EH  "I>@  J8X  *FA  "HM0  J,L  *?D  "G[P  I_, ?8   &^!  !A
MA   58D  $F.   ^E   -)D  "J>   AH@  &:8  !*I   -K   !Z\   "R
M    LP<  +,,  "S$   M!4  +0;  "U(@  MBL  +<U  "W0   N$X  +A=
M  "X;@  N((  +B7  "XJ@  M[X  +?2  "WY@  M^H =H@  &>+  !:D
M3I8  $*<   WH@  +*<  "*K   9KP  $;,   NV   $N0   +P   "^
MO@   +\&  # "P  P0\  ,(3  ##&0  Q"   ,4I  #'-   R$(  ,E1  #)
M8@  R74  ,F*  #)GP  RK$  ,K!  #)T0  R=D ;I,  &"8  !3G@  1J0
M #JK   OL   )+4  !FX   0O   "K\   '!    Q    ,@   #*    R@
M ,P   #- P  S@@  - -  #1$   TQ8  -8>  #:*   W30  -Y#  #?5
MWV<  .!\  #@D0  X*0  ."R  #@O@  X,, 9I\  %FF  !,K0  /[0  #*X
M   DO   &+\  !##   (QP   ,H   #-    T0   -4   #8    V0   -L
M  #=    WP   .$$  #C"@  Y0X  .<3  #J'   [2<  / U  #Q1@  \E@
M /-K  #S@   ])0  /2C  #TK@  ]+( _P 3 /\ $0#_ !$ _P 5 /\ 'P#_
M "P _P Y /\ 10#_ %  _P!: /X 8P#[ &L ^0!R /< > #U 'X ] "$ /(
MB0#Q (X \ "3 .X F0#M )\ [ "F .H K@#H +@ Y@#% .4 VP#C .T X@#[
M .( _P#A /\ X0#_ .$ _P#A /\ _P 0 /\ #@#_  T _P 2 /\ &P#_ "@
M_P T /X 00#[ $P ]P!6 /0 7P#Q &8 [P!M .P = #J 'H Z0!_ .< A0#F
M (H Y0"/ ., E0#A )L X "B -X J@#; +0 V0#  -8 T #3 .@ T@#W -$
M_P#1 /\ T #_ -  _P#0 /\ _P - /\ "0#_  H _P / /\ %@#[ "( ]P O
M /0 .P#P $< [0!1 .D 6@#E &( X@!I .  ;P#> '4 W !Z -H @ #8 (4
MU0"+ -, D0#1 )< SP"> ,T I@#+ *\ R0"Z ,< R0#% .( Q #R ,, _@#"
M /\ P0#_ ,( _P#" /\ _P,& /\  0#_  8 _P , /D $0#Q !T ZP I .<
M-@#C $$ WP!+ -L 5 #5 %P T@!C ,\ :@#- '  RP!U ,D >P#( (  Q@"&
M ,4 C ## ), P0": +\ H@"] *L NP"V +D Q "W -H M@#M +0 ^@"T /\
MM #_ +0 _P"T /\ _P0  /\   #_    _P & .P #0#E !8 W@ B -< +P#1
M #L S0!% ,H 3@#& %< Q !> ,$ 9 "_ &H O0!P +P =0"Z 'L N0"! +<
MAP"U (X LP"5 +( G@"P *< K@"R *P OP"J -$ J #H *@ ]P"G /\ IP#_
M *8 _P"F /\ _P8  /\%  #Q P  Z    .$ !P#5 !  S0 ; ,< )P## #,
MOP ^ +P 2 "Y %$ M@!8 +0 7P"R &4 L !J *\ < "M '8 K !\ *H @@"I
M (D IP"1 *4 F@"C *0 H0"N *  NP"> <T G0+F )P$] ";!/\ F@7_ )H%
M_P"9!?\ _PH  /$.  #D$   V0\  ,X+  #( PL P@ 3 +P"'P"W RP LP0W
M + %0@"M!DH J@92 *@'60"F!U\ I0=E *,':P"B"'$ H AW )\(?@"="(4
MFPF. )H)EP"8"J$ E@JL )4+N@"3"\P D@SE ) -]@"/#O\ C@[_ (X._P"-
M#O\ ]A$  .87  #6&P  QQD  +X5  "Y$   MPH- +$+%P"L#20 J XP *4.
M.P"B#D0 GP], )T/4P";#UH F@]@ )@09@"7$&P E1!R ),0>0"2$($ D!"*
M (\1E "-$9\ BQ&J (H2N "($LL AA/F (44]P"#%?\ @Q7_ ((5_P""%?\
M[1H  -PA  #*)0  NR(  +$?  "K&@  J10& *42$0"@%!X G!4J )D5-0"6
M%CX E!9' )(63@"0%E4 CA=; (P780"+%V< B1=M (@7= "&&'P A1B& (,9
MD "!&9L @!JG 'X:M0!]&\< ?!SB 'H=]0!Y'?\ >!W_ '@=_P!X'?\ Y2(
M - I  "_+   L"H  *<G  "@(P  G1\  )H:#@"5'!@ D1TD (X>+P",'CD
MB1Y! (<?20"%'U  @Q]6 ((?7 " 'V( ?Q]I 'T@< !\('@ >B"! 'DAC !W
M(9< =2*D '0BL@!S(\, <B/? ' D\P!O)/\ ;R3_ &XD_P!N)/\ W2D  ,@P
M  "W,@  J#   )XN  "7*@  DR<  ) C"@",(Q, B"0? (0E*@"")30 @"8]
M 'TF1 !\)DL >B92 '@F6 !W)EX =29E '0G; !R)W0 <2=] &\HB !N*)0
M;"BA &LIKP%J*< !:2K; 6<J\0%G*_\!9BO_ 68J_P%F*O\!U"\  ,(V  "O
M-@  H34  )8T  "0,   BBT  (<J!@"#*1  ?RH: 'PK)0!Y*R\ =RPX '4L
M0 !S+$< <2Q- ' L5 !N+%H ;2QA &LM: !J+7  :"UZ &<NA0!E+I$!9"Z>
M 6(OK %A+[T!83#5 6 P[P%?,/T!7S#_ 5\P_P%?,/\!S30  +P[  "I.@
MFSH  ) X  ")-0  @S(  '\P 0![+PX =S 6 '0P(0!Q,2L ;S$T &TQ/ !K
M,4, :C%* &@R4 !G,E< 93)= &0R90!B,FT 83-W %\S@@%>,XX!732< 5LT
MJ@%:-;L!6C72 5DU[0%9-?P!6#7_ 5@U_P%9-?\!R#@  +<^  "D/@  ECT
M (L\  "#.@  ?3<  '@T  !T- L <#43 &TU'0!J-2< :#8P &8V. !D-C\
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M DE"Z ))0OD"24'_ DE!_P%)0?\!O4,  *I%  "810  BD4  ']%  !V0P
M;T   &A   !C00$ 7T$- %Q!% !90AT 5T(F %5"+@!30C8 44(] $]"0P!/
M0TL 3D-2 $U$6@!,1&, 2D1M 4E%> %(184!1T64 45%HP)%1K0"1$;) D1&
MYP)$1?@"1$7_ D5%_P)%1?\!ND8  *9(  "42   AD@  'M'  !R1@  :D(
M &-#  !>1   6D4+ %9%$@!41AL 448C $]&*P!.1C, 3$<Z $M'00!*1TD
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M 390_P$W4/\!KD\  )E/  ")3P  >T\  '!/  !F3P  7$X  %1/  !/40
M2E(! $93# !#5!( 050; $!5(P ^52L /58R #Q6.@ [5D$ .E9) #E740 X
M5UH -E=C #57;P T5WP!,U>, 3%7G $P5ZT!,%?" 3!7X $P5O0!,5;_ 3%5
M_P$Q5?\!J%(  )52  "$4@  =U(  &Q2  !B4@  6%,  $]4  !)5@  1%<
M $!9"  ]6A  .UH7 #E;(  X6R< -UPO #9<-@ U7#X -%Q& #-=3@ Q75<
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M90 ?;'( 'FR" !ULE  <;*8 &VNZ !IKU  ;:NX '&G\ !QH_P <:/\ E5P
M (-<  !U7   :5T  %]=  !67@  3&$  $-D   \9P  -6H  "]M   H< 0
M(W(- "%R$@ @<QH 'W,A !YS*  ==#  ''0X !MT0  :=$H &714 !=U8  6
M=6X %75^ !1UD  3=*( $G2V !%TSP 2<^P $G+Z !-Q_P 3<?\ CF   'U@
M  !O80  96$  %MB  !19   2&<  #YK   W;@  ,'$  "EU   B>   ''L'
M !=]#@ 6?1, %7T; !1^(@ 3?BH $GXQ !%^.@ 1?D0 $'].  ]_6@ .?V@
M#7]X  Q_B@ +?IT "GZP  E]Q@ *?>0 "GST  M[_0 +>O\ AF4  '=E  !J
M90  868  %9H  !,:P  0F\  #ES   Q=P  *GH  "-^   <@0  %80  !"'
M"  -B0X #(D4  R)&P +B2, "HDK  F),P (B3T !HE(  6)5  $B6$  HEQ
M  &)@P  B98  (BI  "'O@  A]H  (;L  "&]0  AOH ?FH  '%J  !G:P
M6VP  %!P  !&=   /'@  #-]   J@0  (X4  !R(   5C   $(\   R2!@ &
MDPP  I,1  "4%@  E!T  )0D  "5+   E34  )5   "53   EED  )9I  "5
M>@  E8X  )2A  "4M0  D\P  )+F  "2\@  DO< >'   &UP  !@<@  5'4
M $EY   _?@  -8,  "R(   CC0  &Y$  !24   /EP  "IH   2= P  G@D
M )\.  "?$@  H!<  * =  "A)0  HBT  *(W  "C0P  HU   *-?  "C<0
MHX0  **9  "BK0  H<(  *'<  "AZP  H/( <W8  &9W  !9>P  38   $*%
M   XBP  +I   "25   ;F@  %)X   ZA   )I    J<   "J    JP0  *L*
M  "L#0  K1$  *T6  "N'   KR0  + M  "Q.0  L48  +)5  "R9@  LGD
M +*.  "QHP  LK<  +'*  "QX   L>D ;'X  %^"  !2AP  1HT  #N3   P
MF0  )IX  !RC   3IP  #:L   >N    L@   +4   "W    N    +D"  "Y
M"   N@P  +L0  "\%   O1L  +\C  #!+0  PCH  ,))  ##6@  PVP  ,2"
M  #$EP  Q*L  ,2\  #$RP  Q-H 98D  %B.  !+E0  /YL  #.B   HJ
M':T  !2Q   -M@  !KD   "\    OP   ,,   #$    Q0   ,8   #'
MR00  ,H)  #+#0  S1$  ,\8  #2(0  U2T  -8\  #830  V5\  -IS  #:
MB@  VYX  -NN  #;N@  W,, 7I8  %&<  !$HP  .*H  "RQ   @MP  %;L
M  V^   $P@   ,4   #)    S0   -    #2    T@   -4   #6    V0
M -L   #>!0  X H  .(/  #E%@  Z"   .PM  #M/@  [5$  .YE  #O>@
M[X\  /"?  #PJP  \+, _P 0 /\ #@#_  X _P 2 /\ '0#_ "D _P U /\
M00#_ $T _@!6 /L 7P#X &8 ]@!M /0 = #R 'D \0!_ /  A #N (D [0"/
M .L E0#J )L Z "B .8 J@#E +, XP#  .$ T@#@ .H WP#Y -T _P#= /\
MW0#_ -X _P#> /\ _P - /\ "@#_  D _P / /\ & #_ "0 _@ Q /L /0#X
M $@ ] !2 /  6@#M &( ZP!I .D ;P#G '4 Y0!Z ., ?P#B (4 X "* -X
MD #< )8 V@"= -@ I0#5 *\ T@"Z -  R@#. ., S0#T ,L _P#+ /\ RP#_
M ,L _P#+ /\ _P ( /\  P#_  4 _P , /P % #W !\ \@ K .\ -P#K $(
MYP!, .0 50#@ %T W0!D -H :@#8 '  U0!U -( >@#0 (  SP"% ,T BP#+
M )( R0"9 ,< H0#% *H PP"U ,$ PP"_ -H O@#N +T _ "\ /\ O #_ +P
M_P"\ /\ _P   /\   #_    ^0 ' /$ $ #J !H Y  E -\ ,0#; #P UP!'
M -( 4 #. %< RP!> ,D 90#& &H Q0!P ,, =0#! 'H P "  +X A@"\ (T
MN@"4 +D G "W *4 M0"P +, O0"Q ,\ KP#H *X ^ "N /\ K0#_ *T _P"M
M /\ _P   /\   #]    [@ ! ., # #: !0 T0 ? ,P *P#( #8 Q0!  ,(
M2@"_ %( O !9 +H 7P"X &4 M@!J +0 ;P"S '4 L0!Z +  @0"N (@ K0"/
M *L F "I *$ IP"K *4 N "C ,@ H@#B *$ \P"@ /X H #_ *  _P"@ /\
M_P   /8   #J    X    -, !@#)  \ P@ 8 +T ) "Y "\ M@ Z +0 0P"Q
M $P K@!3 *P 60"J %\ J0!D *< :@"F &\ I !U *, >P"A (( H "* )X
MDP"< )T F@"G )@ M "6 ,, E0#< )0 [P"3 /L DP#_ ), _P"2 /\ ^04
M .H+  #<#0  RPH  ,(%  "\  H M@ 1 +$ ' "N "@ J@ S *< /0"D $4
MH@!- *  4P"> %D G !? )L 9 ": &H F !P )< =@"5 'X DP"& )(!CP"0
M 9D C@*D (P"L0"+ \  B076 (@&[0"(!_H APC_ (8(_P"&"/\ [P\  -X4
M  #*%0  O!(  +,0  "N#   JP8- *<#%0"B!2  GP<L )P(-@"9"#\ EPE'
M )4)3@"3"50 D0I: ) *7P"."F4 C0IK (L*<@"*"WD B N" (<+C "%#)<
M@PRB ($-L " #<  ?PW8 'T.[P!\#_T >P__ 'L0_P![$/\ YA<  -$>  "]
M'0  KQP  *89  "A%0  GA $ )T-#P"8#AD E XE )$/+P"/$#D C!!! (H0
M2 "($$\ AQ!5 (406P"$$6$ @A%G ( 1;@!_$74 ?1%^ 'P2B !Z$I0 >!*@
M '<3K@!U$[X =!35 ',5[@!Q%OT <1;_ '$6_P!P%O\ W!\  ,8E  "S)0
MI2,  )PA  "6'@  DAD  )$4"P"-%!0 B14? (86*0"#%C, @1<\ ( 70P!^
M%TH ?!=0 'H75@!Y&%P =QAB '88:0!T&'$ <QEZ '$9A !O&I  ;AJ= &P;
MJP!K'+L :AS0 &D=[ !H'OL :![_ &<>_P!G'O\ T28  +TJ  "K*@  G2H
M ),H  "-)0  B"(  (8=!@"#&Q  ?QP: 'P=) !Z'2X =QXV '8>/@!T'D4
M<A]+ '$?40!O'U@ ;A]> &P?90!K(&T :2!V &@A@0!F(8T 92*: &,BJ !B
M([@ 82/- & DZ0!@)/H 7R3_ %\D_P!?)/\ RBP  +8O  "D+P  EB\  (PM
M  "%*@  @"@  'TD  !Z(@T =B,5 ',C( !Q)"D ;R0R &TD.@!K)4$ :B5'
M &@E30!F)50 925: &0F80!B)FD 829R %\G?0!>)XH 72B7 %LII0!:*;4
M6BK* %DJYP!8*O@ 6"K_ %@J_P!8*O\ Q3$  *\S  ">,P  D#,  (8R  !_
M+P  >2T  '4J  !R* H ;R@2 &LI&P!I*24 9RHM &4J-0!C*CT 8BI# & J
M2@!?*U  7BM7 %PK7@!;+&8 62QO %@M>@!7+8< 5BZ5 %0NHP!3+[, 4R_'
M %(OY0!2+_< 4B__ %(O_P!2+_\ P38  *HV  "9-@  BS8  ($U  !Y,P
M<S$  &\O  !K+@8 :"T0 &0N& !B+B$ 8"\J %XO,0!<+SD 6R]  %DO1@!8
M+TT 5S!3 %8P6P!4,6, 4S%L %(R=P!1,H0 3S.2 $XSH0!-,[$ 333% 4PT
MXP%,-/8 3#3_ $PT_P!,,_\ NSD  *8Y  "5.0  ASD  'PY  !T-P  ;C0
M &DS  !E,@( 83(- %XR% !<,QX 6C,F %@S+@!6,S4 530\ %,T0P!2-$H
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M 3X__P$^/_\!KD   )I   ")00  ?$$  '%!  !H0   83P  %L]  !6/@
M4CX% $X_#@!,/Q4 23\= $= )0!&0"P 1$ S $- .@!"04( 04%) $!!40 _
M0EH /D)C #U#;P \0WP .T.+ #I$FP Y1*L!.42^ 3A$VP$Y1/$!.4/^ 3E#
M_P$Y0_\!JD(  )9#  "&0P  >$,  &Y#  !E0P  74   %9   !10@  34("
M $E## !&0Q( 1$0: $)$(@!!1"H /T4Q #Y%.  ]13\ /$9' #M&3P Z1E<
M.4=A #A';  W1WH -DB) #5(F0 T2*H -$B] #-(V0 T2/  -$?] #1'_P U
M1O\ ID0  ))%  ""1@  =48  &I&  !A10  640  %%$  !,1@  2$<  $1'
M"@!!2!  /TD8 #U)(  \22< .DHN #E*-@ X2CT -TM$ #9+3  U2U4 -$Q?
M #-,:@ R3'< ,4R& #!,EP O3:@ +DV[ "Y-U0 N3.\ +TS] "]+_P P2_\
MH4<  (Y(  !^2   <4@  &9)  !=2   54@  $Q)  !'2@  0DL  #],!@ [
M30X .4X5 #=.'0 V3R0 -4\K #-/,P R4#H ,5!" #!02@ O45( +E%< "U1
M9P L474 *U&$ "I2E0 I4J8 *5*Y "A2T@ I4>X *5#\ "I0_P J3_\ G$H
M (E*  !Z2P  ;4L  &-,  !:3   44P  $A-  !#3P  /5   #E2 @ U4PP
M,U02 #%4&0 P52$ +E4H "U5+P L5C< *U8^ "I61@ I5D\ *%=9 "=79  F
M5W( )5>! "17D@ C5Z0 (E>W ")7SP B5^P (U;Z "-5_P D5?\ EDT  (1.
M  !U3@  :4X  %]/  !63P  35   $52   _4P  .58  #-8   O6@@ *UL/
M "I;%0 H7!T )UPD "9<*P E7#, )%TZ "-=0P B74P (5U6 "!>80 ?7FX
M'EY^ !U>CP <7J$ &UZT !I=S  ;7>D &USY !Q;_P <6_\ D%$  'Y1  !P
M40  9%(  %M2  !24P  2E0  $%7   [60  -5L  "Y>   H8 , )&(, ")C
M$0 A8Q@ 'V0@ !YD)P =9"X '&0V !ME/@ :94< &651 !AE70 796H %F5Z
M !5EBP 499X $V6Q !)ER  29.< $V/W !1B_P 48O\ B50  'A5  !K50
M8%8  %=6  !/5P  1ED  #U<   V7P  ,&(  "ED   C9P  '6H' !EL#@ 8
M;!, %FT: !5M(0 4;2D %&TP !-M.0 2;D( $6Y, !!N6  /;F4 #FYU  UN
MAP -;IH #&VM  MMP@ +;.  #&OS  UK_0 -:O\ @ED  ')9  !F60  7%H
M %1:  !*7   05\  #EC   Q9@  *FD  "1L   =;P  %W(  !)U"0 /=P\
M#G<4  YW&P -=R, #'<J  MW,P *=SP "7='  AW4@ '=U\ !7=O  1W@  #
M=Y0  7:G  !VNP !==4  73K  )T]@ "=/P >UT  &U=  !B7@  65X  $Y@
M  !%8P  /&<  #-K   K;@  )'(  !YU   7>0  $GP   U_!@ )@0P !8$1
M  .!%@ "@1T  8$D  "!+0  @C8  ()   ""3   @ED  ()H  "">0  @HT
M (&@  " M   @,L  '_G  !^\@  ?OD =&(  &AB  !>8@  4V0  $EG   _
M:P  -G   "UT   E>   'GP  !>    1@P  #88   B)!  "BPH  (L.  "+
M$P  C!@  (P?  "-)@  C2\  (XY  ".1   CE$  (Y@  ".<0  CH4  (Z9
M  "-K0  C,,  (S?  "+[@  B_8 ;F@  &1G  !8:0  36P  $)Q   X=@
M+WL  "9_   >A   %H@  !",   ,CP  !I(   "5    E@<  )<,  "7#P
MF!,  )D8  ":'P  FR8  )LP  "<.P  G$@  )Q7  "<:   G'L  )R0  ";
MI0  F[H  )K0  ":YP  FO$ :FT  %YO  !1<@  1G<  #M\   Q@@  )X<
M !Z,   6D0  $)4   J9   $G    *    "B    HP$  *,&  "D"P  I0X
M *82  "G%P  J!X  *HF  "K,0  JSX  *Q-  "L70  K'   *R%  "LFP
MJZ\  *O#  "KV0  JN@ 9'4  %=Y  !+?@  /X0  #2*   ID   'Y8  !:;
M   0GP  ":,   &G    J@   *X   "P    L    +$   "R P  M @  +4-
M  "V$   MQ4  +D=  "[)@  O#,  +U!  "]4@  O60  +YY  "^D   O:0
M +VW  "]Q@  O=< 7'\  %"%  !$BP  .)(  "R9   AGP  %Z0  !"I   )
MK@   +(   "V    N0   +T   "_    OP   ,    #!    PP   ,0%  #&
M"@  QPX  ,D3  #+'   SB8  - U  #110  TE<  -)K  #3@@  TY<  -.I
M  #2N   TL0 58P  $F3   ]F@  ,*(  "6H   :K@  $;0   FY    O0
M ,$   #$    R    ,L   #-    S0   ,\   #0    T@   -0   #8
MV@8  -T,  #@$0  XQH  .8G  #G.   Z$H  .E=  #J<@  ZX@  .N;  #L
MJ   [+( _P - /\ "P#_  L _P 0 /\ &@#_ "8 _P R /\ /0#_ $@ ^P!2
M /@ 6@#V &( \P!I /$ ;P#P '4 [@!Z .P ?P#K (0 Z0"* .@ D #F )8
MY "= .( I0#A *\ WP"[ -T RP#; .8 V0#W -@ _P#8 /\ UP#_ -< _P#4
M /\ _P ( /\ ! #_  0 _P - /\ %0#^ "$ ^@ L /< . #T $, \ !- .T
M50#J %T YP!D .0 :@#B '  X !U -X >@#= '\ VP"% -D BP#5 )$ TP"9
M -$ H #/ *H S0"U ,L Q #) -T R #Q ,< _P#& /\ Q@#_ ,8 _P#' /\
M_P   /\   #_    _P * /@ $0#Q !P [  G .D ,@#F #T X@!' -T 4 #9
M %@ U0!? -( 90#0 &H S@!P ,P =0#* 'H R0!_ ,< A0#% (P PP"4 ,$
MG "_ *4 O0"P +L O0"Z -  N #K +< ^P"V /\ M@#_ +8 _P"V /\ _P
M /\   #]    \P % .D #@#A !8 VP A -4 +0#1 #< S@!! ,H 2@#' %(
MQ !9 ,( 7P#  &4 O@!J +P ;P"[ '0 N0!Z +< @ "V (< M ". +( EP"P
M *  K@"J *T MP"K ,@ J0#C *@ ]0"G /\ IP#_ *< _P"F /\ _P   /X
M  #Q    Y0   -< "@#- !$ QP < ,( )@"_ #$ O  [ +H 1 "W $P M !3
M +( 60"Q %\ KP!D *T :0"L &\ J@!T *D >@"G ($ I@") *0 D0"B )L
MH "E )X L@"= ,$ FP#: )H [P"9 /T F #_ )@ _P"8 /\ _0   /    #A
M    T0   ,8 ! "]  T MP 5 +, ( "P "L K0 U *L /@"H $8 I@!- *0
M5 "C %D H0!? *  9 "> &D G0!N )L =0": 'L F "# )8 C "5 )8 DP"A
M )$ K0"/ +L C0#/ (P Z0"+ /@ C #_ (P _P", /\ \P(  .('  #,!P
MOP0  +<   "Q  @ JP 0 *< &0"D "0 H  N )X -P"< $  F@!' )@ 3@"6
M %0 E0!9 ), 7@"2 &0 D !I (\ ;P"- '8 BP!^ (H B "( )( A@"= (4
MJ0"# +@ @0#* (  Y0"  /4 ?P#_ '\ _P!_ /\ Z T  - 0  "^$   L0X
M *@-  "C"   H (, )P $P"8 !T E0 G )( ,0"0 #D C@%! (P!2 "* DX
MB0)4 (<"60"& E\ A -D (,#:P"! W( @ 1Z 'X$A !]!8X >P6: 'D&IP!X
M!K4 =@?( '4(XP!U"?0 = K_ ',*_P!S"O\ W14  ,07  "Q%P  I18  )P3
M  "6$0  E T$ ),(#0".!Q4 BPD@ (@)*@"%"C, @PL[ ($+0@" "TD ?@M/
M 'T,5 ![#%H >@Q@ '@,9P!W#&X =0UV '0-@ !R#8P < V9 &\.I@!M#K4
M; [) &L/Y@!J$/< :1#_ &D0_P!I$/\ T!T  +D>  "H'@  FQT  )(;  "+
M&0  B!4  (<1!P"%#A  @0\: 'X0) ![$"T >1 V '<1/0!V$40 =!%* ',1
M4 !Q$58 <!%< &X28@!M$FH :Q)S &D3?0!H$XD 9A.6 &44HP!C%;, 8A7&
M &(6XP!A%O8 8!?_ & 7_P!@%_\ QR(  + C  "?)   DB,  (DB  ""(
M?AT  'P9  !Z%0T =Q45 '06'P!Q%B@ ;Q<P &X7. !L%S\ :Q=% &D82P!H
M&%$ 9AA8 &487@!C&68 8AEO & 9>0!?&H4 71N2 %P;H0!;'+  6AS# %D=
MX !8'O0 6![_ %@>_P!8'O\ OR<  *DH  "9*   BR@  ((G  ![)0  =B,
M ',@  !Q' D ;AP1 &L<&@!I'2, 9QTL &4=,P!C'CH 8AY! & >1P!?'DT
M7AY4 %P?6P!;'V( 62!K %@@=@!6(8( 52&0 %0BG@!3(JX 4B/  %$CW0!1
M)/( 423_ %$D_P!1(_\ N2L  *,L  "3+   ABT  'PL  !T*@  ;R@  &LE
M  !I(@4 9B$. &,B%@!A(A\ 7R,G %TC+P!<(S8 6B,] %DD0P!7)$H 5B10
M %4D5P!3)5\ 4B5H %$F<P!/)G\ 3B>- $THG !,**P 2RF^ $LIV@!**?$
M2BG_ $LI_P!+*?\ LRX  )XO  ".,   @3   '<O  !O+@  :BL  &4J  !C
M)P$ 7R<, %PG$P!:)QL 6"@D %8H*P!5*#( 4R@Y %(I0 !0*48 3RE- $XI
M5 !-*EP 3"IE $HK< !)*WP 2"R+ $<MF@!&+:H 12Z\ $4NU@!%+N\ 12[^
M $4N_P!%+?\ KC$  )HR  "),P  ?#,  '(S  !K,0  92\  & M  !=+
M62P) %8L$ !4+!@ 4BP@ % L* !.+2\ 32TV $PM/ !*+4, 22U* $@N40!'
M+ED 1B]C $4P;0!#,'H 0C&) $$QF !!,J@ 0#*[ #\RTP _,NX 0#+] $ R
M_P! ,O\ JC,  )8U  "&-0  >38  &XU  !F-0  83(  %PP  !7,   5# &
M %$P#@!.,!4 3#$= $HQ)0!(,2P 1S$R $8Q.0!$,4  0S)' $(R3P!!,U<
M0#-@ #\T:P ^-7@ /36' #PVE@ [-J< .S:Y #HVT0 Z-NT .S;\ #LV_P [
M-O\ IC8  )(W  "".   =3@  &LX  !C-P  738  %<S  !3-   3S0# $LT
M# !)-!( 1C4: $4U(@!#-2D 034O $ U-@ _-CT /C9$ #TW3  \-U4 .SA>
M #HX:0 Y.78 .#F% #<ZE0 W.J4 -CJX #4ZSP V.NP -CK[ #8Y_P W.?\
MHC@  (XY  !^.@  <CL  &@[  !?.@  63D  %,V  !.-P  2C@  $8X"@!$
M.1  03D7 #\Y'P ^.28 /#DM #LZ-  Z.CL .3M" #@[2@ W.U, -CQ< #4\
M9P T/70 ,SV# #,^DP R/J0 ,3ZV #$^S0 Q/NH ,3[Z #(]_P R/?\ GCL
M (L\  ![/   ;CT  &0]  !</0  53P  $XZ  !).P  13P  $$]!P ^/0X
M/#T5 #H^'  Y/B, -SXJ #8_,0 U/S@ -#]  #- 2  R0%  ,4!: #!!90 O
M07( +D*! "U"D0 M0J( +$*U "M"RP L0ND +$+Y "U!_P M0?\ F3T  (<^
M  !W/P  :S\  &%   !9/P  4C\  $D^  !$/P  0$   #Q!!  Y0@T -T(2
M #5#&0 S0R$ ,D,H #%$+P P1#8 +T0] "Y%10 M14X +$58 "M&8P J1F\
M*49^ "A&CP G1Z$ )D>S "9'R0 F1N< )T;X "A%_P H1?\ E4   ()!  !S
M0@  9T(  %Y"  !50@  3D(  $5"   _1   .T4  #=&   T1PH ,4@0 "](
M%@ N21X +$DE "M)+  J23, *4HZ "A*0@ G2DL )DM5 "5+8  D2VT (TM\
M ")+C0 A3)\ (4RQ "!,QP @2^8 (4OW ")*_P B2O\ D$,  'Y$  !O1
M9$4  %I%  !210  2D8  $%'   \2   -TD  #)+   N30< *TX. "E.$P G
M3QH )D\A "5/*  D3S  (U W ")0/P A4$@ (%!2 !]170 >46H '5%Y !Q1
MB@ ;49P &E&O !E1Q0 94>0 &E#V !M/_P <3_\ BD8  'E'  !K1P  8$@
M %9(  !.2   1TD  #Y+   Y3   ,TX  "Y0   H4P( )%0+ ")5$  @518
M'U8> !Y6)  =5BP '%8S !M7.P :5T0 &5=. !A760 76&8 %5AU !18AP 4
M6)H $U>L !)7P@ 25^$ $U;T !15_P 45?\ A$D  '1*  !F2P  7$L  %-+
M  !+3   1$T  #Q/   U40  +U0  "E6   D60  'EL' !I=#0 871( %UT9
M !9>(  57B< %%XN !->-P 27D  $5]* !%?50 07V( #U]Q  Y?@P -7Y8
M#5^I  Q>O@ ,7MH #5WP  U<_  .7/\ ?DT  &Y.  !B3@  6$\  $]/  !(
M4   0%(  #A4   P5P  *EH  "1=   ?7P  &6(! !-E"0 19@\ $&84  ]F
M&P .9R( #6<I  UG,@ ,9SL "V=%  IG4  )9UT !V=L  9G?0 %9Y  !&:C
M  )FMP #9<\ !&7I  1D]0 $9/P =U$  &E2  !=4@  5%(  $Q3  !#50
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M  !Z<   >H,  'J8  !ZK   ><(  'C?  !X[P  =_< :EL  %];  !66P
M3%P  $)@   Y8P  ,&@  "AL   @<   &70  !-W   .>P  "7X   2! @
M@@@  (,-  "#$   A!0  (49  "&(   AB@  (<Q  "'/   ATD  (=7  "'
M:   AWL  (>0  "&I0  A;H  (73  "$Z@  A/0 96   %Q@  !180  1F0
M #QI   R;0  *7(  "%W   9>P  $H    V#   (AP   HH   "-    C@0
M (X)  "/#0  D!   )$4  "2&0  DR   )0I  "5,P  E4   )9.  "67P
ME7(  )6(  "5G0  E+(  )3(  "3X@  D^X 864  %9F  !*:@  /VX  #5T
M   K>0  (7\  !F$   1B0  #(T   :1    E    )@   ":    FP   )P"
M  "=!P  G@L  )\.  "A$@  HA@  *,@  "E*0  IC8  *9$  "F50  IF@
M *9]  "FE   I:D  *2]  "DT0  I.0 6VP  $]P  !#=0  .'L  "V!   C
MAP  &8T  !&2   +EP  !)P   "@    HP   *8   "H    J0   *H   "L
M    K00  *X)  "P#0  L1$  +,7  "U(   MBL  +<Z  "W2P  N%P  +AQ
M  "XB   N)T  +BQ  "WP@  M]  5'8  $A\   \@@  ,8D  ":0   ;EP
M$IT   RB   #IP   *L   "N    L@   +8   "X    N    +H   "[
MO0   +X   # !0  P0L  ,,0  #&%@  R2   ,HN  #+/@  S%   ,QD  #-
M>@  S9$  ,VD  #-M   S<  38,  $&*   UD0  *9D  !Z@   3I@  #*P
M  .Q    M@   +H   "^    P@   ,8   #(    R    ,H   #+    S0
M ,X   #0    T@$  -4(  #9#@  W14  .$A  #B,0  Y$,  .56  #F:P
MYH(  .>6  #GI0  YK  _P ) /\ !0#_  8 _P . /\ %@#_ "$ _P M /\
M. #] $, ^0!- /4 50#R %T \ !C .X :0#L &\ Z@!T .D >@#G '\ Y@"%
M .0 BP#C )$ X0"9 -\ H0#< *H V@"V -< Q@#5 .$ TP#T -( _P#1 /\
MT0#_ ,\ _P#* /\ _P ! /\   #_  $ _P , /\ $@#Z !T ]@ H /, ,P#P
M #X [ !( .@ 4 #E %@ X@!> -\ 9 #= &H VP!O -D = #6 'H U !_ -(
MA0#0 (P S@"3 ,P G #) *4 QP"P ,8 O@#$ -0 P@#N ,$ _@#  /\ P #_
M +\ _P"^ /\ _P   /\   #_    ^@ ' /$ #P#K !@ Y@ C .( +@#@ #@
MVP!" -4 2P#1 %( S@!9 ,L 7P#) &4 QP!J ,8 ;P#$ '0 P@!Z ,$ @ "_
M (8 O0". +L E@"Y *  MP"J +8 MP"T ,H L@#F +$ ^ "P /\ KP#_ *\
M_P"P /\ _P   /\   #W    Z@ " .$ # #7 !, T  = ,P * #) #( Q@ \
M ,( 10"_ $T O !3 +H 60"X %\ MP!D +4 :0"T &X L@!T +$ >@"O (
MK0"( *P D0"J )H J "E *8 L0"D ,$ HP#< *$ \@"A /\ H #_ *  _P"A
M /\ _P   /<   #H    V0   ,L " ## !  O0 8 +D (@"V "P M  V +(
M/P"O $< K !- *L 5 "I %D IP!> *8 8P"E &@ HP!N *( = "@ 'H G@""
M )P BP"; )4 F0"? )@ K "6 +H E #/ ), ZP"2 /L D@#_ )( _P"1 /\
M]P   .<   #3    Q@   +L  @"S  P K0 2 *H ' "G "8 I  P *, . "@
M $  G@!' )P 3@": %, F0!8 )< 70"6 &, E0!H ), ;@"2 '0 D !\ (\
MA0"- (\ BP": (H IP"( +4 A@#' (4 Y "$ /4 A #_ (, _P"# /\ [
M -,   #! 0  M    *P   "F  < H  . )T %@": "  EP I )4 ,@"3 #H
MD0!! (\ 2 "- $T C !3 (L 6 ") %T B !C (< :0"% &\ @P!W (( @ "
M (H ?@"6 'T HP![ +  >@#" 'D W0!X /$ =P#] '@ _P!X /\ W@H  ,0+
M  "R#   I@L  )T(  "9!   E0 * )$ $0". !D BP C (D + "' #0 A0 [
M (, 0@"" $@ @ !. '\ 4P!] %@ ? !> 'L 9 !Y &H > !R '8 >P!T (8
M<P"2 '$ GP!P *T ;@"^ &T!U@!M NT ; /Z &P#_P!L _\ SA   +<1  "F
M$@  FA$  )$0  "+#@  B0L# (<%# "$ 1, @0$< 'X")0!\ RX >@,V '@$
M/ !W!$, =05( '0%3@!S!50 <059 ' &7P!N!F8 ;09N &L'> !J!X, : B0
M &<)G0!E":P 9 F\ &,*U !C"^P 8@SZ &(,_P!B#/\ PQ8  *T7  "=&
MD!@  (<6  "!%   ?1$  'P.!@!\"@X > H6 '4+'P!R"R@ < PP &\,-P!M
M##X ; Q$ &L-2@!I#4\ : U5 &<-7 !E#6, 8PYK &(.=0!@#H$ 7PZ. %T/
MG !<$*L 6Q"] %H0U@!9$?  61'] %D1_P!9$?\ N1L  *4=  "4'@  B!X
M 'X=  !X&P  =!@  '$5  !Q$0D ;Q 1 &P0&0!I$"( 9Q$J &81,@!D$3D
M8Q$_ &(110!@$DL 7Q)1 %T26 !<$E\ 6A-H %D3<@!7%'T 5A2+ %05F0!3
M%:D 4A:Z %$6T@!1%^T 41?] %$7_P!1%_\ LB   )XB  ".(@  @2,  '<B
M  !P(0  ;!X  &D;  !G& 0 9A4. &,6%0!A%AX 7Q8F %T6+0!<%S0 6A<[
M %D700!8&$< 5AA- %485 !3&%P 4AED %$9;@!/&GH 3AN( $T;EP!+'*8
M2ARX $H=SP!)'>L 21W[ $D=_P!*'?\ K"0  )@E  "()@  >R<  '$F  !J
M)0  9B,  &(A  !@'@  7AP+ %L;$@!9'!H 5QPB %4<*0!4'#  4QTW %$=
M/0!0'4, 3QU* $T>40!,'E@ 2Q]A $D?:P!(('< 1R"% $8AE !$(J0 1"*V
M $,BS !#(^D 0R/Z $,C_P!#(O\ IB<  ),I  "#*@  =BH  &TJ  !E*0
M8"<  %PE  !9(P  5R$' %4A#P!2(18 4"$> $XA)0!-(BP 3"(S $HB.0!)
M(D  2")& $<C30!%(U4 1"1> $,D:0!")74 0":# #\FD@ ^)Z, /B>T #TG
MR@ ]*.@ /2CY #TG_P ^)_\ HBH  (XK  !_+0  <BT  &@M  !A+   7"L
M %@H  !4)@  428$ $XE#0!,)1, 2B8: $@F(@!')BD 128O $0F-@!#)SP
M02=# $ G2P _*%, /BE< #TI9@ \*G( .RJ! #HKD  Y*Z$ ."RR #<LR  W
M+.8 ."SX #@L_P X+/\ G2P  (HN  ![+P  ;S   &4P  !=+P  6"X  %,K
M  !0*@  3"H  $DJ"P!&*A$ 1"H7 $(J'P!!*B4 /RHL #XK,P ]*SD /"M
M #LL2  Z+%  .2U9 #@N9  W+G  -B]_ #4OCP T,)\ ,S"Q #(PQP R,.4
M,S#W #,P_P T+_\ F2\  (<Q  !W,@  :S(  &(R  !:,@  5#$  $\O  !+
M+0  1RX  $0N" !!+@X /RX4 #TN'  [+B( .2\I #@O+P W+S8 -C ^ #4P
M1@ U,4X -#%7 #,R8@ R,FX ,3-] # SC0 O-)X +C2P "TTQ0 M-., +C3V
M "\S_P O,_\ E3$  (,S  !T-   :#4  %XU  !7-   430  $LR  !&,0
M0C(  #\R!0 \,@T .3,2 #@S&0 V,R  -#,F #,S+0 R-#0 ,30[ # U0P P
M-4P +S95 "XV8  M-VP +#=[ "LWBP J.)P *3BN "@XPP H..( *3CU "HW
M_P J-_\ DC0  '\U  !Q-@  93<  %LW  !4-P  338  $<V  !"-0  /38
M #HV @ W-PL -#<0 #(W%@ Q.!T +S@D "XX*P M.3( +#DY "LY00 J.DD
M*CI3 "D[7@ H.VH )SMY "8\B0 E/)L )#RM ",\P@ C/.  )#ST "4[_P E
M._\ C38  'PX  !M.0  8CD  %@Z  !1.0  2CD  $0Y   ].0  .3H  #4[
M   R.P@ +SP. "T]%  L/1H *CTA "D]*  H/B\ )SXV "8^/@ E/T< )#]0
M "- 6P B0&@ (4!V "! AP ?09D 'T&K !Y!P  >0=X 'T#S !] _@ @/_\
MB3D  '@Z  !I.P  7CP  %4\  !-/   1SP  $ \   X/0  -#X  #!    M
M004 *D(, "="$0 F0Q@ )$,> "-#)0 B0RP (40S "!$.P ?1$0 'D5. !U%
M60 <164 &T5T !I%A0 91I< &4:I !A&O@ 71=P &$7Q !E$_0 :1/\ A#P
M ',]  !F/@  6S\  %(_  !*/P  1#\  #U    V00  ,4,  "Q$   G1@$
M)$<* "%(#P @210 'DD; !U)(@ <22D &THP !I*.  92D$ &$I+ !=+50 6
M2V( %4MQ !1+@@ 32Y0 $DNG !)+O  12]D $DKP !-*_  42?\ ?S\  &]
M  !A00  5T(  $Y"  !'0@  04(  #I#   R10  +4<  "A)   C2P  'DT&
M !M/#0 84!$ %U 7 !90'@ 54"4 %% L !-1-  243T $5%' !%14@ 045\
M#U)M  Y2?@ -49$ #5&D  Q1N  ,4=$ #5#L  U0^@ .3_\ >4,  &I$  !=
M1   4T4  $M%  !$10  /D8  #9(   O2@  *4P  "1/   ?40  &E,  !16
M"0 15PX $%@3 !!8&0 /6"  #E@H  U8,  -6#D #%A#  M83@ *6%H "%AH
M  =8>0 &6(P !5B?  18LP $5\H !5?F  57\P &5OP <T8  &1'  !92
M4$@  $A(  !!20  .DH  #)-   K4   )5(  "!5   :6   %5H  !!=!@ ,
M8 P "F 0  E@%0 (8!P !V C  5@*P $8#0  V ]  %@20  8%4  &!C  !@
M<P  8(8  %^:  !?K@  7\0  %[B  !>\   7O@ ;$H  %]+  !52P  3$P
M $5,   ]3@  -5   "Y3   G5@  (%D  !I<   57P  $&(   UE!  (9PL
M V<.  !H$P  :!@  &@?  !I)@  :2X  &DX  !I0P  :4\  &E=  !I;0
M:8   &F4  !HJ0  :+\  &?<  !F[@  9O< 9D\  %I/  !13P  2D\  $%1
M   X5   ,%<  "A;   A7@  &F(  !1E   0:   #&L   =N P !< D  ' -
M  !Q$   <10  '(:  !S(0  <R@  ',Q  !S/   =$@  '-6  !S9@  <WD
M '..  !SHP  <KD  ''2  !QZP  </0 85,  %93  !/4P  154  #M8   R
M7   *F   ")D   ;:   %&P   ]O   +<@  !G8   !Y    >@8  'H*  ![
M#@  ?!$  'T5  !^&P  ?R(  ( J  " -0  @$$  (!/  " 7P  @'$  ("&
M  " G0  ?[(  '[*  !^Y0  ??$ 7%@  %18  !)6@  /UT  #5A   L90
M(VH  !MO   4<P  #G<   E[   #?P   ((   "$    A@$  (8&  "("@
MB0T  (H0  "+%0  C!L  (XB  "/+   CS@  (]&  "/5@  CV@  (]^  "/
ME0  CJL  (W!  "-W   C.L 65T  $Y?  !#8@  .&8  "YL   D<0  ''<
M !1\   .@0  "(4   ")    C0   )    "2    DP   )0   "6 P  EP@
M )@,  ":#P  FQ,  )T:  "?(P  H"X  * \  "@3   H%X  *!T  "?C
MGZ(  )^W  ">RP  GN  4V0  $=H   \;0  ,7,  "=Y   =?P  %(4   V+
M   &D    )0   "8    G    )\   "A    H@   *0   "E    IP   *@$
M  "J"0  K T  *T2  "P&0  LB,  +(Q  "R0@  LE0  +)I  "R@   LI@
M +&L  "ROP  L<X 3&X  $!S   U>@  *H$  !^(   5C@  #I4   ::
MGP   *0   "H    K    *\   "Q    L0   +,   "U    M@   +@   "Z
M    O 8  +X,  # $0  PQD  ,4F  #%-P  QDD  ,9=  #'<@  QXH  ,B?
M  #(KP  R+P 1GH  #F!   NB0  (I   !>8   /GP  !Z4   "J    KP
M +,   "W    O    +\   #!    P@   ,0   #%    QP   ,D   #+
MS0   ,\#  #2"@  UA   -P:  #=*@  WCP  -]0  #@90  X7L  .&1  #B
MH@  XJT _P " /\   #_  , _P , /\ $P#_ !T _P H /X ,P#[ #X ]P!(
M /, 4 #P %< [0!> .L 9 #H &D YP!O .4 = #C 'D X@!_ .  A0#> (P
MW "3 -D G #6 *8 TP"Q -$ P #/ -H S@#Q ,P _P#+ /\ RP#_ ,8 _P#!
M /\ _P   /\   #_    _P ( /L $ #V !D \@ D .\ +@#M #D Z !" .,
M2P#@ %( W0!9 -D 7P#6 &0 TP!I -$ ;@#/ '0 S@!Y ,P ?P#* (8 R ".
M ,8 E@#$ *  P@"K ,  N0"^ ,T O #J +L _ "Z /\ N@#_ +H _P"V /\
M_P   /\   #^    ]  $ .L #0#D !0 WP ? -L *0#8 #, TP ] ,X 10#*
M $T QP!3 ,4 60## %\ P0!D +\ :0"] &X NP!S +H >0"X (  M@"( +0
MD "R )H L0"E *\ L@"M ,0 K #A *L ]@"J /\ J@#_ *H _P"J /\ _P
M /T   #N    X@   -4 "@#- !$ QP 9 ,0 (P#! "T OP W +L /P"W $<
MM0!. +( 4P"P %D KP!> *T 8P"L &@ JP!M *D <P"H 'H I@"! *0 B@"C
M )0 H0"? )\ K "> +L G #2 )L [@": /\ F@#_ )D _P"9 /\ _@   .X
M  #>    RP   ,$ !0"Y  T M  4 +$ '@"N "< JP P *H .0"G $$ I !(
M *( 30"A %, GP!8 )X 70"= &( FP!G )H ;0"8 ', EP![ )4 A "4 (X
MD@"9 )  I@". +0 C0#( (P Y@"+ /D B@#_ (H _P"+ /\ \    -L   #'
M    N@   +    "H  H I  0 *  & "= "$ FP J )H ,P"8 #L E@!! )0
M2 "2 $T D0!2 (\ 5P". %P C !A (L 9P"* &X B !U (< ?@"% (@ @P"4
M (( H "  *\ ?P#  'X W0!] /( ?0#_ 'T _P!] /\ X    ,8   "U
MJ@   *(   ";  4 E0 - )( $P"0 !P C0 D (L +0"* #0 B  [ (8 0@"%
M $< @P!- (( 4@"! %< ?P!< 'X 8@!] &@ >P!P 'H >0!X (, =@"/ '4
MG !T *H <@"Z '$ T0!P .P < #[ '  _P!P /\ S00  +<&  "G!P  FP8
M ),$  ".    B@ ( (8 #P"$ !8 @0 > '\ )P!] "X ?  V 'H / !Y $(
M=P!' '8 3 !U %( <P!7 '( 70!Q &, ;P!K &X = !L 'X :P"* &D F !H
M *8 9P"V &8 RP!E .< 90#W &4 _P!E /\ P P  *L-  ";#@  CPX  (8-
M  "!"P  ?@<! 'P!"P!Y !$ =P 8 '4 (0!S "D <0 P &\ -@!N #P ; !"
M &L 1P!J $T :0!2 &@ 6 !F %\ 90!G &, < !B 7H 8 &' %\"E0!> J,
M7 .S %P#QP!;!.0 6P7T %L&_@!;!O\ M1   *$2  "1$P  A1,  'P2  !V
M$0  <PX  '(,! !Q!PT ;@02 &P$&P!I!2, 9P4J &8&,0!D!C< 8P8] &('
M0P!A!TD 7P=. %X(50!="%P 6PEC %H);0!8"G@ 5PJ% %8+DP!4"Z( 4PNS
M %(,QP!2#.0 40WU %$-_P!1#?\ K14  )D7  ")&   ?1D  '08  !M%P
M:A0  &<1  !G#@< 9@P. &,,%0!A#!T 7PPE %T-+ !<#3, 6PTY %H-/P!8
M#44 5PU+ %8.40!5#ED 4PYA %(.:P!0#W8 3A"# $T0D@!,$*( 2Q"R $H1
MR !)$>4 21'W $D2_P!)$?\ I1D  )(<  "#'0  =AX  &T=  !F'   8AH
M %\7  !>% $ 7A$* %L0$0!9$1@ 5Q$@ %41)P!4$2X 4Q$T %$1.P!0$D$
M3Q)' $X23@!,$E4 2Q-> $D39P!(%', 1A2  $45CP!$%9\ 0Q:P $(6Q0!"
M%^, 0A?V $(7_P!"%_\ GQT  (P@  !](0  <2(  &@B  !A(0  7!\  %D<
M  !7&0  518& %05#@!1%10 3Q8< $X6(P!,%BH 2Q8P $H6-P!)%ST 1Q=#
M $872@!%&%( 0QA: $(99 !!&7  /QI] #X;C0 ]&YT /!RN #L<PP ['.$
M.QWU #L<_P \'/\ FB$  (<C  !X)   ;"4  &,E  !<)   5R,  %,@  !1
M'@  3QP" $T;# !+&A$ 2!L8 $<;( !%&R8 1!LM $,<,P!"'#D 0!Q  #\=
M1P ^'4\ /1Y8 #P>8@ Z'VT .1][ #@@BP W(9L -B&M #4AP0 U(=\ -2'S
M #8A_P V(?\ EB,  (,F  !T)P  :"@  %\H  !8)P  4R8  $\D  !,(@
M22   $<@"0!$'P\ 0A\5 $ @'  _(", /B I #P@+P [(38 .B$] #DA1  X
M(DP -R)5 #8C7P T(VL ,R1Y #(EB0 Q)9H ,"6K # FOP O)MP ,";R # F
M_P Q)?\ D28  '\H  !Q*@  92H  %PJ  !5*@  3RD  $LH  !()0  1"0
M $$D!0 _) T /202 #LD&0 Y)!\ -R0F #8D+  U)3, -"4Z #,F00 R)DH
M,2=3 # G70 O*&D +BEW "TIAP L*9@ *RJJ "HJO0 J*MH *RKQ "LJ_@ L
M*?\ C2@  'PJ  !M+   8BT  %DM  !1+0  3"P  $<K  !#*   /R@  #PH
M @ Y* L -R@0 #4H%@ S*!P ,B@C # H*0 O*3  +RHW "XJ/P M*T< +"M1
M "LL6P J+&< *2UU "@MA0 G+9< )BZH "4NO  E+M@ )B[P "8N_0 G+?\
MBBL  '@M  !J+@  7R\  %8O  !.+P  2"X  $,M   _+   .RP  #<L   T
M+ D ,BP. # M$P N+1H +2T@ "LM)P J+BT *BXU "DO/0 H+T4 )S!. "8P
M60 E,64 )#%S ",Q@P B,I4 (3*G "$RNP @,M0 (3+O "(Q_  B,?\ ABT
M '4O  !G,   7#$  %,Q  !+,0  13$  $ P   [,   -C   #,P   P,08
M+3$- "LQ$0 I,A< *#(> "<R)  E,RL )3,R "0S.@ C-$, (C1, "$U5P @
M-6, 'S5Q !XV@0 =-I, '#:E !LVN0 ;-M( '#;M !TV^P =-?\ @C   '$R
M  !C,P  630  % T  !)-   0C,  #TS   W,P  ,30  "XU   K-0( *#8+
M "4W$  D-Q4 (C<; "$X(@ @."@ 'S@P !XX-P =.4  '#E) !LZ5  :.F
M&3IN !@Z?P 7.Y$ %SND !8[MP 5.]  %CKL !<Z^@ 8.?\ ?3(  &TT  !@
M-0  538  $TV  !&-@  0#8  #HV   T-@  +C@  "HY   F.@  (SL( " \
M#@ >/1( '3T8 !P]'P ;/B4 &CXM !D^-  7/CT %C]' !4_40 4/UX %#]L
M !- ?  20(\ $4"B !% M@ 00,X $3_K !(_^0 2/O\ >34  &DW  !<.
M4CD  $HY  !#.0  /3D  #<Y   Q.@  *SP  "<]   B/P  'D$$ !I""P 8
M0Q  %T,5 !5$&P 41"( $T0I !-$,0 21#H $45# !!%3@ 015L #D5I  Y%
M>0 -18P #46?  Q%L@ +1<D #$7E  U$]@ -1/\ =#D  &4Z  !8.P  3SL
M $<\  ! /   .CP  #0\   N/@  *$   "-"   ?1   &D8  !5("  22@T
M$4H2 !!*&  /2QX #DLE  U++0 -2S8 #$M   M+2@ *2U8 "4MD  A+=  '
M2X< !4N:  1+K@ $2L0 !4K@  5*\  &2?H ;CP  & ]  !4/@  2SX  $0^
M   ]/@  -S\  #%    J0@  )$4  !]'   :20  %4P  !%.!0 .40L "U$0
M  I1%  )41L "%$B  =1*0 %43( !%([  -21@ !4E(  %)?  !2;P  4H$
M %&6  !1J0  4;\  %#<  !0[@  4/< :$   %M!  !000  2$$  $%!   [
M0@  -$,  "U%   F2   ($L  !M-   64   $5,   Y5!  *6 H !E@.  )8
M$@  61<  %D=  !9)0  62T  %DV  !900  64T  %I:  !::0  67P  %F0
M  !9I0  6+H  %C5  !7[   5_8 8T0  %9%  !-10  144  #]%   W1P
M+TD  "A,   B3P  &U(  !95   16   #5H   E= P $7PD  & -  !@$
M810  &$9  !B(   8B<  &(Q  !B.P  8D<  &)5  !C9   8G8  &*+  !B
MH   8;8  &'/  !@Z@  8/4 74@  %))  !*2   0T@  #I*   R30  *E
M "-3   <5P  %EH  !%=   -8   "&,   -F 0  9P8  &@+  !I#@  :A$
M &L5  !L&P  ;2(  &TJ  !M-   ;4   &U.  !M70  ;6\  &V$  !LF@
M;+   &O(  !KY@  :O, 6$T  $Y-  !(3   /DX  #51   L5   )%@  !U<
M   68   $&0   QG   ':P   6X   !P    <@,  '('  !S"P  =0X  '81
M  !W%@  >!P  'DC  !Z+0  >CD  'I'  !Z5@  >6@  'I\  !YE   >*H
M 'C!  !WWP  =^\ 5%$  $Q1  !"4@  .%4  "]9   F7@  'F(  !9G   0
M:P  "V\   5S    =P   'H   !\    ?@   '\"  " !@  @0H  (,-  "$
M$0  AA4  (@<  "))0  BC   (H^  ")30  B5\  (ES  "(BP  B*(  (>Y
M  "'T0  AN@ 4E8  $=7   \6@  ,E\  "AD   ?:0  %F\  !!T   *>0
M GT   "!    A0   (@   "*    C    (T   "/    D 0  )((  "3#
ME1   )<5  "9'0  FR<  )LT  ";1   FE8  )IJ  "9@@  FIH  )BP  "8
MQP  E]X 2UP  $!@   U90  *VH  "%Q   7=P  $'T   F#   !B    (P
M  "1    E0   )@   ":    FP   )T   "?    H    *(   "D!0  I@H
M *@.  "J%   K1T  *TJ  "M.0  K4L  *U?  "M=P  K)   *NG  "KN@
MJ\L 168  #EK   N<0  (W@  !E_   0A@  "8T   "3    F    )T   "A
M    I0   *@   "K    JP   *X   "O    L0   +,   "U    MP$  +D'
M  "\#0  OQ,  ,(?  #"+@  PD   ,)4  #!:P  P8,  ,";  #!K0  P;P
M/G(  #)X   G@   '(@  !*0   *EP   )T   "C    J    *T   "R
MM@   +D   "[    O    +X   #     P@   ,0   #&    R    ,L   #.
M!0  T0T  -84  #7(P  V#4  -E)  #:7@  VW4  -N,  #<GP  W*L _P
M /\   #_    _P ) /\ $ #_ !D _@ D /P +P#Y #D ] !# /  2P#M %(
MZ@!9 .< 7P#D &0 X@!I .  ;@#> ', W !Y -H ?P#7 (8 U ". -$ E@#/
M *$ S "L ,H NP#( -( Q@#N ,8 _P#% /\ Q0#_ +\ _P"Z /\ _P   /\
M  #_    _@ % /< #@#R !4 [@ ? .L *@#I #0 XP ] -X 10#9 $T U !3
M -$ 60#. %X S !C ,H : #) &T QP!S ,4 >0## (  P0"( +\ D "] )L
MNP"F +D M "W ,@ M@#F +4 ^P"T /\ M #_ +, _P"N /\ _P   /\   #X
M    [0   .4 "P#= !$ UP : -( ) #/ "X RP W ,< 0 ## $< P !. +X
M4P"\ %D N@!> +@ 8P"V &@ M0!M +, <P"Q 'D KP"! *T B@"K )0 J0"@
M *@ K0"F +X I0#; *0 ] "D /\ HP#_ *, _P"B /\ _P   /8   #F
MUP   ,L !@#$  X O@ 5 +L 'P"Y "@ MP Q +0 .@"P $$ K0!( *L 3@"I
M %, IP!8 *8 7 "D &$ HP!G *$ ; "@ ', G@!Z )T @P"; (X F0"9 )<
MI@"6 +8 E0#, )0 ZP"3 /T DP#_ ), _P"3 /\ ]P   .0   #0    P0
M +<  @"O  L JP 1 *< &0"E "( HP K *( ,P"? #L G !" )L 2 "9 $T
MEP!2 )8 5P"5 %L DP!A )( 9@"0 &T CP!T (T ?0", (< B@"3 (@ H "'
M *\ A0#" (4 X@"$ /< A #_ (0 _P"$ /\ Y0   ,T   "\    KP   *8
M  ">  < F@ . )8 % "4 !T D@ E )$ +0"0 #4 C0 \ (P 0@"* $< B !,
M (< 40"& %8 A !; (, 8 "! &< @ !N 'X =P!] ($ >P"- 'H F@!X *D
M=P"Z '8 TP!V .\ =@#^ '4 _P!U /\ T    +L   "K    GP   )<   "0
M  ( BP + (@ $ "& !< A  @ (( )P"! "\ ?P U 'T / !\ $$ >P!& 'D
M2P!X %  =P!5 '8 6P!T &$ <P!I '$ <0!P 'L ;@"' &T E0!K *, :@"T
M &H R0!I .@ :0#Y &D _P!I /\ P    *P   "< @  D (  (@   "#
M?P & 'L #0!Y !( =P : '8 (@!T "D <P P '$ -@!P #P ;P!! &T 1@!L
M $L :P!0 &H 5@!H %P 9P!D &4 ; !D '8 8P"" &$ D !@ )\ 7P"O %X
MPP!> .$ 7@#T %T _P!= /\ M <  * )  "0"P  A L  'P*  !W!P  = 0
M '$ "0!O  \ ;0 5 &L ' !I ", :  J &< ,0!E #8 9  \ &, 00!B $8
M8 !, %\ 4@!> %@ 70!? %L : !: '( 6 !^ %< C !6 )L 50"K %0 O@!4
M -H 4P#O %0 ^P!4 /\ J0T  )8.  "'$   >A   '(0  !L#@  :0P  &<)
M P!F! L 9  0 &( %P!@ !X 7@ E %T *P!< #$ 6@ W %D / !8 $( 5P%'
M %8!3@!5 E0 4P)< %(#90!1 V\ 3P1[ $X$B@!-!9D 3 6I $L%O !*!M0
M2@?M $H'^0!*!_\ H1   (X2  !^%   <Q0  &H4  !D$P  8!$  %X/  !=
M#04 70D- %H&$@!8!QD 5@<@ %4')P!3!RT 4@@S %$(. !0"#X 3PE$ $X)
M2@!,"5$ 2PI9 $H*8@!("VT 1PMZ $8,B !$#)@ 0PRI $(-O !"#=4 0@WN
M $(-^P!"#?\ FA0  (<6  !X&   ;!D  &,9  !=&   618  %83  !4$0
M5 X( %,-#@!1#10 3PT; $T-(@!,#2@ 2PTN $H-- !)#3H 1PY! $8.1P!%
M#D\ 1 Y7 $(/80!!$&P /Q!Y #X0B  ]$9@ .Q&I #L1O  Z$=8 .A'P #H2
M_0 [$?\ DQ@  ($:  !S'   9QT  %X=  !8'   4QL  % 8  !.%@  3!,#
M $P1"P!*$!  2!$7 $81'@!%$20 1!$J $(1, !!$3< 0!(] #\21  ]$DP
M/!-4 #L37@ Y%&D .!1V #<5A0 V%98 -!:G #06N@ S%M, ,Q;N #06_  T
M%O\ CAL  'P=  !N'P  8R   %H@  !3(   3AX  $H=  !(&@  1A@  $46
M!P!#%0X 0143 #\5&@ ^%2  /14G #L5+0 Z%C, .18Z #@600 W%TD -1=1
M #086P S&68 ,AES # :@P O&I0 +ANE "T;N  M&]  +1OL "X;^P N&_\
MBAX  '@@  !J(@  7R,  %8C  !/(@  2B$  $8@  !#'@  01L  #\: P ]
M&@P .QD1 #D9%@ W&AT -AHC #4:*0 T&C  ,QLV #$;/@ P'$8 +QQ/ "X=
M60 M'60 +!YQ "L?@0 J'Y( *1^D "@@MP G(,X )R#K "@@^@ I'_\ AB
M '0C  !G)   7"4  %,E  !,)0  1R0  $(C   _(0  /1\  #H>   W'@D
M-1X. #,>$P Q'AH ,!X@ "\>)@ N'RT +1\S "P@.P K($, *B%, "DA5@ H
M(F( )B)O "4C?P D(Y  (R.B "(DM0 B),P (B3I ",D^0 D(_\ @B,  '$E
M  !C)@  62<  % H  !))P  0R<  #\F   [)   ."(  #4B   R(@8 ,"(-
M "XB$0 L(A< *B(= "DB(P H(RH )R,Q "8D.  E)4$ )"5* ",F5  B)F
M(2=M " G?0 ?)X\ 'BBA !XHM  =*,H '2CH !XH^  ?)_\ ?B4  &XG  !@
M*0  5BD  $TJ  !&*@  02D  #PH   W)P  -"8  # F   M)@, *R<+ "@G
M$  G)Q0 )2<: "0G(0 C*"< (B@N "$I-@ @*3X 'RI( !XJ4@ =*UX '"MK
M !LK>P :+(T &2R? !@LL@ 8+,D &"SG !DK]P :*_\ >B<  &HJ  !=*P
M4RP  $HL  !#+   /BL  #DK   T*@  ,"H  "LJ   I*P  )BL( ",L#@ B
M+!( ("P8 !\L'@ >+24 '2TL !PM,P ;+CP &BY% !DO4  8+UP %R]I !8P
M>0 5,(L %#"> !0PL0 3,,< $S#E !0P]@ 5+_\ =BH  &<L  !:+0  4"X
M $@N  !!+@  .RX  #8M   Q+0  +"T  "<O   D+P  (3 % !\Q#  <,1
M&S(5 !HR'  9,B( &#(I !<S,0 6,SD %3-# !0T30 3-%D $C1G !$U=P 1
M-8D $#6< ! UL  .-<8 #S3D ! T]0 0-/\ <BP  &,N  !7,   33   $4P
M   ^,   .#   #,P   O,   *3$  "0R   A,P  '34" !HV"0 7-PX %3<3
M !0X&0 3.!\ $C@F !(X+@ 1.38 $#E  ! Y2P ..5< #CID  TZ=  ,.H8
M##J9  LYK  *.<$ "CG>  LY\0 ,./P ;B\  %\Q  !3,@  2C,  $(S   [
M,P  -C,  #$R   L,P  )S0  "$V   =.   &3D  !4[!@ 2/0P $#X0 ! ^
M%0 ./AP #CXC  T^*@ ,/C, ##X\  L_1P */U( "#]@  <_;P &/X$ !3^4
M  0_J  #/KP !#[7  4^[  %/O< :3,  %LT  !0-0  1S4  #\U   Y-0
M-#4  "XU   I-P  (S@  !X[   :/   %C\  !)!!  .0PH #$0.  I$$P )
M1!D "$0@  =$)P &1"\ !40X  -%0@ "14X  $5;  !%:@  17P  $60  !$
MI   1+D  $31  !$Z@  0_4 9#8  %<W  !,.   0S@  #PX   W.   ,3@
M "LY   E.P  (#T  !I    60@  $D0   Y'!  +20D !TH-  1+$0 !2Q8
M $L<  !+(P  2RL  $LT  !+/@  3$D  $Q7  !,9@  3'<  $N,  !+H0
M2[4  $K.  !*Z0  2O4 7SH  %([  !(.P  0#L  #H[   T.P  +CP  "<^
M   B00  '$,  !9&   220  #DL   M. P '4 @  E$,  !1$   4A,  %,8
M  !3'P  4R8  %,O  !3.0  4T4  %-2  !380  4W(  %.'  !2G   4K$
M %'*  !1YP  4?0 63X  $X^  !%/@  /CX  #@^   P0   *4(  "-$   =
M1P  %TH  !)-   .4   "U,   95 @  5P<  %@+  !9#@  6A$  %H5  !;
M&@  7"$  %PJ  !<-   7#\  %Q-  !<6P  7&P  %R!  !;EP  6ZT  %K%
M  !:Y   6?, 5$(  $I"  !"0@  /$(  #1#   L1@  )4D  !Y,   73P
M$E,   Y6   *60  !5L   !>    8 0  &$(  !B#   8PX  &01  !E%@
M9AP  &<C  !G+0  9SD  &=&  !G50  9V8  &=Z  !FD0  9:@  &7   !D
MW@  9/  3T8  $=&  ! 10  -T<  "]*   F30  'U$  !A5   260  #5P
M  A@   "8P   &8   !H    :@   &L$  !L"   ;0P  &\.  !P$@  <A<
M ',=  !T)@  =#(  '0_  !T3@  <U\  '1R  !SB@  <J$  '&X  !QU
M<.P 3$H  $5*   [2P  ,DX  "E2   @5@  &%L  !)?   -9   !V@   !K
M    ;P   '(   !U    =@   '<   !Y @  >@8  'P*  !^#@  @!$  ((6
M  "$'@  A"D  (0V  "$10  A%8  (-J  "#@0  @ID  (&Q  " R0  @.4
M2DX  #]0   U4P  *U<  ")<   98@  $F<   QL   %<0   '4   !Y
M?0   ($   "#    A0   (8   "(    B0   (L$  "-"   CPT  )(0  "4
M%@  EB   )8L  "6.P  EDP  )5@  "5=@  E)   ).G  "2O0  DM4 1%4
M #E9   O70  )&,  !II   2;P  #'4   1[    @    (4   ")    C0
M )$   "3    E    )8   "8    F@   )P   ">    H 8  *(+  "E$
MJ!<  *DC  "I,0  J4,  *E6  "H;0  IH<  *>>  "FLP  I<< /EX  #)C
M   G:@  '7   !-X   ,?P   X4   "+    D0   )8   ";    GP   *(
M  "D    I0   *<   "I    JP   *T   "P    L@   +4"  "W"0  NQ
M +X8  "^)@  OC@  +Y+  "]80  O'H  +N4  "ZJ0  NKD -VH  "MP   @
M>   %H    V(   %CP   )8   "<    H@   *<   "L    L    +,   "V
M    MP   +D   "[    O0   +\   #"    Q0   ,@   #*    S@@  -(0
M  #5&P  U2P  -1   #45P  TVX  -2&  #4FP  TZL _P   /\   #_
M_P % /\ #@#_ !4 _  @ /D *@#V #0 \0 ] .T 1@#I $T Y@!3 .0 60#A
M %X W@!C -P : #9 &X U0!S -, >0#0 (  S@"( ,L D0#) )P Q@"G ,0
MMP#" ,P P #L +\ _P"^ /\ O0#_ +< _P"R /\ _P   /\   #_    ^@ !
M /, "P#M !( Z  ; .4 )0#D "X WP X -@ 0 #2 $< S@!. ,L 5 #( %D
MQ@!> ,0 8P#" &< P !M +\ <P"] 'H NP"! +D BP"V )4 M "A +( KP"P
M ,( K@#C *X ^@"L /\ K0#_ *D _P"F /\ _P   /\   #R    Y@   -T
M!P#2  X S0 6 ,H ( #( "D Q0 R ,  .@"\ $( N0!( +< 3@"U %, LP!8
M +$ 70"P &( K@!G *P ; "J ', J0![ *< A "E (X HP": *$ J "? +D
MG@#2 )T \@"< /\ G0#_ )P _P"9 /\ _    .X   #=    S    ,$  @"Z
M  P M@ 2 +( &@"P ", KP L *T - "I #P I@!" *0 2 "B $T H !2 )X
M5P"= %L G !@ )H 9@"9 &P EP!T )4 ?0"3 (< D0"3 )  H0". +$ C0#&
M (P Z "+ /T C #_ (P _P", /\ [0   -@   #%    MP   *P   "F  @
MH0 . )\ %0"= !X FP F )H +@"7 #4 E0 \ ), 0@"1 $< D !, (X 40"-
M %4 BP!: (H 8 ") &8 AP!M (4 =@"$ (  @@", (  F@!_ *D ?0"\ 'P
MW !\ /4 ? #_ 'P _P!\ /\ V0   ,$   "Q    I    )P   "4  , D  ,
M (T $0"+ !@ B0 @ (D * "' "\ A0 V (, / "" $$ @ !& '\ 2P!] $\
M? !4 'L 6@!Y &  > !G '8 < !U 'H <P"& '$ DP!P *( ;P"T &X S !N
M .T ;@#^ &X _P!N /\ Q    *\   "@    E    (P   "&    @0 ( 'X
M#@!\ !0 >P ; 'D (@!X "D =P P '4 -@!T #L <@!  '$ 10!P $H ;P!/
M &T 5 !L %L :P!B &D :@!H '0 9@"  &4 C@!C )T 8@"M &$ P@!A .0
M80#X &$ _P!A /\ M    *    "1    A@   'X   !Y    =0 # '$ "P!O
M !  ;0 6 &P '0!K "0 :P J &D , !H #8 9@ [ &4 0 !D $4 8P!* &$
M3P!@ %8 7P!= %T 90!< &\ 6@!Z %D B !8 )@ 5P"H %8 NP!6 -@ 5@#Q
M %8 _P!6 /\ J $  )0%  "%!P  >@<  '(&  !L!   :0$  &< !P!D  T
M8P 1 &$ & !@ !\ 7P E %X *P!= #  6P V %H .P!9 $  6 !% %< 2P!6
M %$ 50!8 %, 80!2 &H 4 !V $\ A !. ), 30"D $P M@!, ,T 3 #K $P
M^@!, /\ G0D  (L+  !\#0  < T  &@-  !B#   7PH  %T& 0!< 0D 6@ .
M %@ $P!7 !D 5@ @ %4 )@!3 "L 4@ Q %$ -@!0 #L 3P!! $X 1P!- $T
M2P!5 $H 70!) &< 1P!S $8 @ !% )  1 "A $, L@!# ,@ 0P#F $, ]0!#
M /\ E0T  (,/  !T$   :1$  & 1  !:$   5@X  %0-  !3"@0 4P8+ %$#
M$ !/ 14 3@$; $P!(0!+ 2< 2@(L $D",@!( C< 1P,] $4#0P!$ TH 0P11
M $($6@! !60 /P5P #X&?@ ]!HX / >? #L'L0 Z!\8 .@?C #H'\P Z"/P
MCA   'P2  !N%   8A4  %H5  !4%   4!,  $T1  !+#@  2PT& $H*# !)
M"!$ 1P@6 $4('0!$"", 0@@H $$)+@! "3, /PDY #X*0  ]"D< / I/ #H+
M6  Y"V, . QO #8,?@ U#(X - V? #,-L0 R#<< ,@WC #(-]  R#?X B!,
M '<5  !I%P  7A@  %48  !/&   2A8  $<5  !%$P  0Q " $,." !"#0X
M0 T2 #\-&  ]#1\ / TD #L-*@ Y#3  . XW #<./0 V#D4 -0Y- #,/5P R
M#V( ,1!N "\0?0 N$(X +1&@ "P1L@ K$<@ *Q'F "L1]@ L$?\ @Q8  '(9
M  !D&@  61L  %$;  !+&P  1AH  $(8   _%P  /A0  #P2!  [$0H .A 0
M #@0%0 W$!L -1$A #01)P S$2T ,A$S # 1.@ O$D( +A)+ "T35  K$U\
M*A1L "D4>P H%(P )Q6> "85L  E%<8 )17D "45]@ F%?\ ?AD  &X;  !@
M'0  5AX  $T>  !''@  0AT  #X<   Z&@  .!@  #<6   U%0< -!0- #(4
M$@ P%!< +Q0= "T4(P L%2H *Q4P "H5-P I%C\ *!9( "<74@ F&%T )!AJ
M ",9>0 B&8H (1F< " 9KP ?&<0 'QGB " 9]  @&?\ >AL  &H>  !='P
M4R   $H@  !$(   /A\  #H>   W'0  -!P  #(9   P&00 +A@+ "P8$  J
M&!0 *1@: "<8(  F&28 )1DM "0:-0 C&CT (AM& "$;4  @'%L 'QUH !X=
M=P ='8@ '!Z; !L>K0 :'L, &A[@ !H=\P ;'?\ =QT  &<@  !:(0  4"(
M $@B  !!(@  .R(  #<A   S(   ,!\  "T=   K'0  *!T( "8=#@ E'1(
M(QT7 "$='0 A'20 (!XJ !\>,@ >'SH '1]# !P@30 ;(5D &B%F !DA=0 8
M(H< %R*9 !8BK  5(L$ %2+? !4A\@ 6(?X <R   &0B  !7(P  320  $4E
M   ^)   .20  #0C   P(@  +"(  "DA   F(0  )"$& "(A#  @(1  'B$5
M !TB&P ;(B$ &R(H !HC+P 9(S@ &"1! !<D2P 6)5< %25D !0F<P 3)H4
M$B:8 !$FJP 1)L  $";= !$E\0 2)?T <"(  &$D  !4)@  2B8  $(G   \
M)@  -B8  #$E   M)0  *20  "8D   B)0  'R4# !TF"@ ;)@X &2<2 !@G
M&  7)Q\ %B<E !4H+0 4*#4 $RD^ !(I20 1*54 $2IB ! J<0 /*H, #BJ6
M  XJJ0 -*KT #2K7  TJ[@ .*?L ;"0  %TF  !1*   2"@  $ I   Y*
M-"@  "\H   K)P  )R<  "(H   >*0  &RH  !@K!P 6*PT %"P1 !,L%@ 2
M+!P $2TC ! M*@ 0+3( #RX\  XN1@ -+E( #2Y?  PO;@ ++W\ "B^2  DO
MI0 )+KD ""[0  DNZ0 *+O< :"<  %HI  !.*@  12L  #TK   W*P  ,2H
M "TJ   I*@  )"H  " K   ;+0  &"X  !4O!  2,0H $#(.  \R$P .,AD
M#3(@  TR)P ,,B\ "S,X  HS0@ ),TX "#-;  8T:@ %-'L !#..  ,SH@ "
M,[8  C/-  ,SYP $,O, 9"H  %8L  !++0  0BT  #HM   T+0  +RP  "LL
M   F+   (BT  !TO   9,0  %3(  !(T P /-@D ##@-  HX$0 ).!8 "#@=
M  <X)  &."P !#@T  ,X/@ ".4H  #E7   Y90  .7<  #F+   XGP  .+,
M #C*   XY@  -_( 7RT  %(N  !(+P  /S   #@O   R+P  +2\  "DO   D
M,   'S$  !HS   5-0  $C<   \Y P ,.P@ "#T-  4^$  #/A0  #X:   ^
M(0  /B@  #XQ   _.P  /T8  #]3   _80  /W,  #^'   ^G   /K   #W'
M   ]Y   /?( 6C   $XR  !$,@  /#(  #4R   P,0  *S$  "8R   @-
M&S8  !8X   2.P  #ST   P_ P (00@ !$,,  !##@  1!(  $46  !%'0
M120  $4M  !&-@  1D(  $9.  !&70  1FX  $6"  !%F   1*T  $3$  !#
MXP  0_( 530  $HU  !!-0  .34  #,T   N-   *#4  "(W   =.@  %SP
M !(_   /00  #$0   A& 0 #2 8  $D*  !*#0  2Q   $P4  !-&0  3B
M $XH  !.,@  33T  $Y*  !.6   36D  $U]  !,E   3*H  $O!  !+X0
M2O( 4#@  $8X   ].   -S@  #$W   J.0  )#L  !X]   80   $T,   ]&
M   +20  !TL   ).    4 0  %$(  !2"P  4PX  %01  !5%0  5AL  %<C
M  !7+   5S@  %=$  !74@  5F,  %9W  !6C@  5:4  %2]  !3W0  4_
M2SP  $(\   [.P  -3L  "T\   F/P  'T(  !E%   32   #DL   M/   %
M40   %0   !7    6 $  %H%  !;"   7 P  %T.  !?$0  8!8  &(=  !B
M)@  8C$  &(^  !A3   85T  &%P  !@B   8*   %^W  !>U   7>X 1T
M #\_   Z/P  ,4   "E#   A1@  &DH  !-.   .40  "E4   18    6P
M %X   !A    8P   &0!  !E!   9P@  &@+  !J#@  ;!(  &X7  !O(
M;RH  &\V  !N10  ;E4  &YH  !M?P  ;9@  &RP  !KR@  :N@ 1$0  #Y#
M   U1   *T<  "-+   ;3P  $U0   Y8   (7    F    !D    9P   &L
M  !M    ;P   '    !R    = (  '4&  !W"@  >0X  'P2  !^&   ?R(
M '\N  !_/0  ?DT  'UA  !]=P  ?)   'NH  !ZP   >=\ 0T<  #E)   O
M3   )5   !Q5   46P  #F    =E    :@   &X   !R    =@   'D   !\
M    ?@   '\   "!    @P   (4   "' P  B@@  (P-  "/$0  DAD  )(E
M  "2,P  DD0  )%7  "0;0  CX8  (Z?  "-M0  C,T /4X  #)1   H5@
M'EP  !5B   .:   !VX   !T    >0   'X   ""    A@   (D   ",
MC@   )    "2    E    )8   "8    FP   )X&  "A#   I!$  *8;  "F
M*0  ICH  *5-  "E8@  I'L  *.4  "AJP  H;\ -E<  "Q<   A8@  %VD
M  ]P   '=P   'X   "$    B@   (\   "4    F    )L   ">    GP
M *(   "D    I@   *@   "K    K0   +    "S!   MPP  +L2  "['P
MNS   +M#  "Z6   N7   +>+  "WH0  M[, ,&(  "5I   :<   $'@   F
M    B    (\   "6    FP   *$   "F    J@   *X   "P    L0   +0
M  "V    N    +L   "]    P    ,,   #'    RP,  ,\,  #3%0  TB4
M -(X  #13@  T&4  ,]^  #-E@  S*D _P   /\   #_    _P # /\ "P#\
M !$ ^0 ; /< )0#S "\ [@ X .D 0 #F $@ X@!. -\ 5 #< %D V0!> -4
M8P#3 &@ T !M ,X <P#+ 'H R "" ,8 C ## )< P "C +X L@"\ ,@ N@#J
M +D _P"X /\ L0#_ *H _P"G /\ _P   /\   #[    ]@   .T !P#G  \
MX@ 6 -\ ( #> "D V0 S -$ .P#, $( R !( ,4 3@#" %, P !8 +X 70"\
M &( N@!G +D ;0"W '0 M0![ +( A0"P )  K@"< *P J@"I +T IP#> *8
M^0"E /\ HP#_ )T _P"; /\ _0   /8   #K    WP   -$  P#*  P Q0 2
M ,, &P#  "0 O@ L +D -0"V #P LP!# +  2 "N $X K !2 *L 5P"I %P
MIP!A *8 9P"D &T H@!T *  ?0"> (@ G "5 )H HP"8 +0 E@#- )4 \0"4
M /\ E0#_ )  _P". /\ \P   .8   #1    P@   +@   "Q  @ K0 / *H
M%@"H !X J  G *8 +P"B #8 GP \ )T 0@"; $< F0!, )< 40"6 %4 E !:
M ), 8 "1 &8 D !N (X =@", ($ B@"- (@ FP"& *P A0#! (0 Y@"# /T
MA #_ (, _P"! /\ Y    ,L   "Z    K    *(   "<  0 F  , )8 $0"4
M !D DP A )( * "/ #  C0 V (L / ") $$ B !& (8 2P"% $\ A !4 ((
M6@"! &  ?P!G 'X ;P!\ 'H >@"& '@ E !W *0 =0"W '0 U !S /0 = #_
M '0 _P!T /\ RP   +8   "F    F@   )(   "*    A@ ( (, #@"! !0
M@0 ; (  (P!_ "H ?0 P 'L -@!Z #L > !  '< 10!U $D = !. ', 5 !Q
M %H < !A &X :0!M ', :P!_ &D C0!H )T 9P"N &8 QP!E .H 9@#_ &8
M_P!G /\ N    *0   "5    B@   ($   !\    =@ $ '0 # !R !  <0 6
M '  '0!P "0 ;@ J &T , !K #4 :@ Z &D /P!H $0 9P!) &4 3@!D %0
M8P!; &$ 8P!@ &T 7@!Y %T AP!; )8 6@"H %D O0!9 -\ 60#X %H _P!:
M /\ J    )4   "'    >P   ',   !N    :@ ! &< " !E  X 9  2 &,
M& !C !\ 8@ E &$ *@!? #  7@ U %T .@!< #X 6P!$ %D 20!8 $\ 5P!6
M %8 7@!4 &@ 4P!S %$ @0!0 )$ 3P"B $X M0!. -  3@#P $X _P!/ /\
MG    (D   ![ P  < ,  &@#  !B 0  7P   %T ! !;  L 60 / %@ % !7
M !D 5P @ %8 )0!5 "H 4P P %( - !1 #D 4  _ $\ 1 !. $L 30!2 $L
M6@!* &, 20!O $< ? !& (P 10"= $4 L !$ ,< 1 #H $0 ^@!% /\ D@0
M ( '  !Q"@  9@H  %X*  !9"0  50<  %0$  !2  < 4  , $\ $ !. !4
M30 ; $P ( !+ "8 2@ K $D , !( #4 1P Z $8 0 !% $8 0P!. $( 5@!!
M %\ 0 !K #X >  ] (@ / "9 #P JP \ ,$ .P#@ #L ]  [ /\ B0H  '@,
M  !J#@  7PX  %<.  !1#@  30P  $L+  !*" ( 200) $@ #0!& !$ 10 6
M $0 ' !# "$ 0@ F $$ *P _ #$ /@ V #T /  \ $, .P!* #H 4@ Y %P
M. !H #8 =0 U (4 - "6 #0 J  S +P ,P#8 #, [P S /L @@T  '$/  !D
M$   61$  %$1  !+$0  1Q   $0.  !"#0  00L% $$'"P _!0X /@,2 #P"
M&  [ AT .@,B #D#*  X RT -P,R #8$.0 U!#\ - 5' #,%4  Q!EH , 9F
M "\'<P N!X, +0>5 "P'IP K![H *P?2 "L'ZP K!_< ?1   &P1  !?$P
M5!0  $P4  !&%   0A,  #X2   \$   .@X! #H-!@ Z"@P . D0 #8(%  U
M"!D - D? #())  Q"2D , DO "\*-@ N"CT +0I% "P+3@ K"UD *0QE "@,
M<P G#(, )@V5 "4-IP D#;L (PW2 ",-ZP C#?< >!(  &@4  !;%@  41<
M $@7  !"%@  /18  #D5   W$P  -1$  #,0 P S#@@ ,@T- # -$0 O#18
M+0T; "P-(0 K#2< *@TM "D.-  H#CL )PY$ "4.3@ D#UD (Q!E "$0<P @
M$(0 'Q"6 !X0J0 =$+T '!#8 !T0[@ =$/D <Q0  &06  !7&   31D  $49
M   _&0  .A@  #47   R%@  ,!4  "X3   M$00 +! * "L0#@ I$!( *! 8
M "80'@ E$"0 )! J ",1,0 B$3D (1%" " 22P >$E8 '1-C !P3<0 :$X(
M&125 !@4IP 7%+L %Q/4 !<3[@ 8$_H <!8  & 9  !4&@  2AL  $(<   \
M&P  -AL  #(:   O&0  +!@  "H6   H% $ )A,' "43#  C$Q  (A,5 " 3
M&@ ?$R$ 'A0G !T4+@ <%38 &Q4_ !H620 9%E0 &!=A !87<  5&($ %!B3
M !,8I@ 2&+H $A?2 !(7[  3%_H ;!D  %T;  !1'0  1QT  #\>   Y'0
M-!T  "\<   K&P  *!H  "89   D&   (A<$ " 7"@ >%PX '!<2 !H7%P 9
M&!X &1@D !@9+  7&30 %AH] !4:1P 4&U( $QM? !(<;@ 1''\ $!R2 ! <
MI0 /'+D #AS0  X;Z@ /&_@ :1L  %H=  !.'P  11\  #T@   V'P  ,1\
M "T>   I'0  )1T  ",<   @&P  '1L! !L;!P 9' T %QP0 !8<%0 5'!L
M%!TB !,=*0 2'C$ $1XZ !$?10 0'U  #R!=  X@;  -('P #2"/  P@H@ +
M(+4 "R#*  L@Y0 ,'_0 91T  %<?  !,(0  0B$  #HA   T(0  +R$  "H@
M   F'P  (Q\  " >   ='@  &2   !8@!  4( L $B$. !$A$P 1(AD $"(?
M  \B)@ .(R\ #B,W  TC00 ,)$T "R19  HD9P ))'@ ""2+  <DG@ ')+$
M!B3'  8CXP '(_$ 8A\  %0A  !)(P  0",  #@C   R(P  +",  "@B   D
M(0  (2$  !XA   :(0  %B,  !,D P 1)0@ #R8-  XG$0 -)Q8 #"<=  LG
M(P *)RL "2@T  @H/@ '*$D !BA5  4I9  $*70  RF'  (IFP !**\  "C%
M  $HX0 !)_  7B(  %$D  !&)0  /24  #4E   O)0  *B0  "8D   B(P
M'R,  !LD   8)0  %"8  !$H P /*0@ #"P,  HL$  (+!0 !RP:  8L(0 %
M+"@  RTP  (M.@ !+44  "U2   N8   +G$  "V$   MF0  +:T  "S"   L
MX   +/  6B0  $TF  !#)P  .B<  #,G   M)P  *"8  "0F   A)@  '28
M !DG   5*0  $2L   \L P -+@< "3 ,  8Q#@ #,1(  3(7   R'@  ,B4
M #(M   R-@  ,T(  #-.   S70  ,VT  #.!   RE@  ,JL  #'!   QWP
M,?  5B<  $HI   _*@  -RH  # J   K*0  )R@  ",H   >*0  &BH  !8L
M   2+@  #S    TQ @ *- < !34+  (V#@  -Q   #@4   X&@  ."(  #@J
M   Y,P  .3X  #E*   Y60  .6D  #E]   XDP  .*@  #>_   WW@  -O
M42L  $8L   \+   -"P  "XL   J*P  )2L  " L   ;+0  %R\  !,Q   0
M,P  #34   DW @ %.@8  3L*   \#0  /0\  #X2   _%P  0!X  $ E  !
M+P  0#H  $!&  ! 5   0&4  #]X   _CP  /J8  #Z]   ]W   /?  32X
M $(O   Y+P  ,B\  "TN   H+@  (B\  !TP   8,@  $S4  ! W   ,.@
M"3P   4^    000  $((  !#"P  1 T  $80  !'%   2!D  $@A  !(*@
M2#4  $A!  !(3P  2&   $=S  !'B@  1J(  $6Y  !%V0  1/  2#(  #XR
M   V,@  ,#$  "LQ   E,@  'S0  !DV   3.0  $#P   P_   (0@   T0
M  !&    2 (  $H%  !+"   3 L  $X.  !/$0  414  %(<  !2)0  4C
M %(\  !12@  45H  %%M  !0A   3YT  $ZU  !-T@  3>X 0S8  #LV   T
M-0  +S0  "<U   A.   &CL  !0^   000  #$0   ='   "2@   $T   !/
M    40   %,"  !4!0  50@  %<+  !9#@  6Q$  %T7  !='P  72H  %TV
M  !<1   7%0  %MG  !;?@  6I<  %FO  !8RP  5^H /SD  #@Y   S.
M*SD  ",\   </P  %4,  !!'   +2@  !4X   !1    5    %<   !:
M7    %T   !?    8 0  &('  !D"P  9@X  &@2  !K&0  :R,  &HN  !J
M/   :DT  &E?  !H=0  9X\  &:H  !EP@  9., /3T  #<\   N/0  )4
M !U$   620  $$T   I1   $50   %H   !=    8    &,   !F    :
M &H   !K    ;0   &\"  !Q!@  = H  '8.  !Y$P  >QL  'LG  !Z-0
M>44  'A9  !X;0  =X8  ':?  !UMP  =-( /$$  #)"   H10  ($H  !=.
M   05   "ED   )>    8P   &<   !K    ;P   '(   !U    =P   'D
M  ![    ?0   '\   ""    A ,  (<)  "*#@  CA,  (\>  ".*P  CCL
M (U.  "+8P  BGP  (J5  "(K0  A\4 -D<  "Q+   B3P  &54  !!;   *
M80   6<   !M    <@   '<   ![    ?P   (,   "&    B    (H   "-
M    CP   )$   "4    EP   )H!  "=!P  H0T  *44  "D(0  I#$  *-$
M  "B60  H'   )^+  "=H@  G;< ,%   "55   ;6P  $F(   MI   !<
M '<   !]    @P   (@   "-    D0   )4   "8    F@   )P   "?
MH0   *,   "F    J0   *P   "P    M <  +@.  "Z&   NB<  +DY  "X
M3@  MV4  +9^  "UE@  LZL *5L  !YB   4:0  #'$   )Y    @0   (D
M  "/    E@   )L   "@    I    *@   "K    K    *\   "R    M
M +8   "Y    O    ,    #$    R    ,T'  #2$   TAT  -$O  #01
MSUL  ,US  #+C0  RJ$ _P   /\   #[    ^@   /P " #X  \ ]0 7 /0
M( #Q "H ZP S .8 .P#B $, W@!) -H 3P#6 %0 TP!9 -  7@#. &, RP!H
M ,D ;@#& '4 PP!] ,$ A@"^ )( NP"> +D K@"V ,, M #H +, _P"O /\
MI0#_ )X _P"; /\ _0   /<   #R    \    .<  P#A  P W  2 -@ &P#6
M "0 T@ M ,P -@#& #T P@!# +\ 20"\ $X N@!3 +@ 6 "V %T M0!B +,
M9P"Q &X KP!V *P ?P"J (H J "7 *4 I@"C +D H0#9 *  ^0"> /\ F #_
M )( _P"/ /\ \P   .P   #C    TP   ,@   #!  D O0 / +L %@"Y !\
MMP G +, +P"O #< K  ] *H 0P"H $@ I@!- *0 4@"C %8 H0!; )\ 80">
M &< G !O )H > "7 (, E0"0 ), G@"1 +  D #( (X \ "- /\ B@#_ (4
M_P"" /\ YP   -T   #&    N    *X   "H  0 I0 , *$ $@"A !D H  B
M )\ *0"; #  F  W )8 /0"3 $( D@!' )  2P"/ %  C0!5 (P 6@"* &$
MB !H (< < "% 'L @P"( ($ E@!_ *< ?0"\ 'P XP!\ /T ? #_ '@ _P!V
M /\ U@   ,    "O    HP   )D   "3    CP ) (T #@"+ !0 B@ < (H
M(P"( "H A0 P (, -@"" #L @ !  '\ 10!^ $H ? !/ 'L 5 !Z %H > !A
M '8 :0!U ', <P"  '$ C@!O )\ ;@"R &T SP!L /0 ; #_ &L _P!I /\
MP    *L   ";    CP   (<   "     ?  $ 'H # !X !$ >  7 '@ '@!W
M "0 =0 J ', , !Q #4 <  Z &X /P!M $0 ; !) &L 3@!J %0 : !; &<
M8P!E &T 9 !X &( AP!@ )< 7P"J %X P@!> .D 7@#_ %X _P!= /\ K
M )D   "*    ?P   '<   !Q    ;0   &H " !I  X :  2 &< & !G !\
M9P E &4 *@!C "\ 8@ T &$ .0!@ #X 7P!# %X 2 != $X 6P!5 %H 70!8
M &< 5P!R %4 @0!4 )$ 4P"C %( N !1 -P 40#Y %( _P!2 /\ G0   (L
M  !\    <0   &D   !D    8    %X !0!<  L 6P / %L % !: !D 6@ ?
M %D )0!7 "H 5@ O %4 - !4 #@ 4P ] %( 0P!0 $D 3P!0 $X 6 !- &(
M2P!M $H >@!) (L 2 "= $< L0!' ,P 1@#P $< _P!' /\ D    'X   !P
M    9@   %X   !9    5@   %,  0!2  @ 4  - $\ $ !/ !4 3@ : $X
M( !- "4 3  J $H +@!) #, 2  X $< /@!& $0 10!+ $0 4P!# %T 00!H
M $  =0 _ (4 /@"7 #T JP ] ,, /0#F #T ^P ^ /\ AP   '4#  !H!@
M70<  %4&  !0!@  3 0  $H!  !)  0 1P * $8 #@!% !$ 10 6 $0 &P!#
M "  0@ E $$ *@!  "\ /P T #X .@ ] $  .P!' #H 3P Y %D . !D #<
M<0 V ($ -0"3 #0 I@ T +L - #= #0 ]0 U /\ ?@8  &T)  !@"P  5@P
M $X,  !("P  1 H  $((  ! !0$ /P$' #X "P ]  X /  2 #L %P [ !P
M.@ A #D )0 W "H -@ P #4 -0 T #P ,P!# #( 3  Q %4 , !@ "\ ;0 N
M 'T +0"/ "P H@ L +8 + #0 "P [@ L /P =PH  &<,  !:#@  4 X  $D.
M  !##@  /@T  #L,   Y"P  . D# #<%"  V @T -0$0 #0 $P S !@ ,@ =
M #$ (@ P "< +P L "X ,@ M #@ + !  "L 20 J %( *0!= "@ :P G 7H
M)@&, "4 GP E +( )0#* "4 Z  E /< <@T  &(.  !6$   3!$  $01   ^
M$0  .1   #8/   S#@  ,0T! # +!0 P" H +P8- "X%$0 L!!0 *P,9 "H#
M'@ I R, * 0I "<$+P F!34 )04] "0%1@ C!E  (@9< "$':0 @!WD 'P>+
M !X'G0 >![  '0;& !T&XP =!?, ;0X  %X1  !2$@  2!,  $ 3   Z$P
M-1(  #$1   N$   + \  "H. P J#0< *0L+ "@)#@ G"1$ )0@6 "0(&P C
M"2  (@DF "$)+  @"C, 'PH[ !X+1  ="T\ ' Q; !L,:0 :#'D & R+ !@,
MG@ 7#+  %@S% !8,X0 6"_  :1   %H2  !.%   114  #T5   W%0  ,10
M "T3   J$@  *!$  "80 0 D$ 0 (PX( ",-#  B# \ ( P3 !\,&  >#1T
M'0TC !P-*@ ;#3( &@XZ !@.1  7#E  %@]< !4/:@ 3$'L $A"- !$0H  1
M$+, $ _) ! /Y  1#_( 91(  %<4  !+%@  0A<  #H7   T%P  +Q8  "H5
M   G%   )!,  "(3   @$@, 'A$& !T0"0 <$ T &P\0 !D0%0 8$!L %Q A
M !80*  5$3  %!$Y !,10P 2$DX $1): ! 2:0 0$WD #A.,  X3G@ -$[$
M#1+%  P2X0 -$O$ 8A0  %06  !)&   /QD  #<9   Q&0  +!@  "@7   D
M%@  (18  !\5   <% ( &A,$ !D2!@ 7$@L %1(. !02$@ 3$Q@ $A,? !$3
M)@ 1%"T $!0V  \500 .%4P #A97  T690 ,%W4 "Q>'  H7F@ )%JT "!;!
M  @6W0 )%>X 7Q8  %$8  !&&@  /1H  #4;   O&@  *AH  "49   B&
M'Q@  !P7   9%@$ %Q8# !46!  3%@D $18- ! 7$0 /%Q8 #A<<  X8(P -
M&"H #!DS  P9/  +&D< "AI3  D:80 '&W$ !AN#  4;EP $&JH  QJ_  ,9
MV@ $&>P 7!@  $X:  !#'   .AP  #,<   L'   )QP  ",;   @&@  '1D
M !H9   7& $ %1@" !(9!  0&P< #AL,  T<$  ,'!, "QP9  H<'P )'2<
M"!TO  <>.0 &'D, !!Y0  ,?7@ "'VX  1^    ?E0  'JD  !Z]   =V
M'>P 6!H  $L<  !!'@  .!X  # >   J'@  )1T  "$<   >'   &QL  !@;
M   6&P$ $QL" !$<!  .'@< #!\+  H@#@ ((!( !B$7  4A'0 $(20  B(L
M  $B-0  (D   "--   C6@  (VL  "-^   CDP  (J<  "*\   AUP  (>T
M51T  $@?   ^(   -2   "X@   H(   (Q\  " >   ='0  &AT  !8=   3
M'@  $1\"  X@!  -(@< "B0+  8E#0 $)1   B84   F&@  )B$  "<I   G
M,@  )ST  "=)   H5P  *&<  "=[   GD   )Z4  ":[   FU@  )>T 42
M $4A   [(@  ,B(  "PB   F(0  (B$  !X@   ;'P  &"   !0@   1(@
M#R,   TE P *)@8 !B@*  ,I#0  *P\  "P2   L%P  +!X  "PF   M+P
M+3D  "U&   M5   +60  "UW   LC0  +*0  "NZ   KU@  *NX 32(  $$D
M   X)   ,"0  "DD   D(P  (2(  !TB   9(@  %2,  !(D   /)@  #2@
M  HJ @ &+ 4  BX)   O"P  , X  #(0   S%0  ,QL  #,B   S*P  ,S8
M #-"   S4   ,V   #-S   RB@  ,J$  #&X   PU@  ,.\ 224  #XF   T
M)P  +2<  "@F   C)0  'R0  !LE   6)@  $B@  ! J   -+   "BX   8P
M 0 ",@0  #0'   U"@  -PP  #@.   Z$@  .A<  #H?   Z)P  .C(  #H^
M   Z3   .EP  #IO   YA@  .)X  #BV   WU   -N\ 1"D  #HI   Q*0
M*RD  "8H   B)P  '2@  !@I   3*P  $"X   TP   ),@  !34   $W
M.0(  #L%   \"   /@L  #\-  !!$   0Q0  $,;  !#(P  0RX  $,Y  !#
M1P  0E<  $)J  !!@0  0)H  #^R   ^SP  /N\ /RP  #8L   O+   *BL
M "4J   ?*P  &2T  !0O   0,@  #34   @X   $.@   #P    _    00
M $,"  !%!0  1@@  $@+  !*#@  3!$  $T6  !-'@  32@  $TT  !,0@
M3%$  $MD  !+>P  2I0  $FM  !(R@  1^P .S   #,O   M+P  *"T  "(O
M   ;,0  %30  ! W   -.@  "#T   )     0P   $8   !(    2@   $P
M  !. 0  3P0  %$'  !3"P  50X  %@2  !9&0  6"(  %@N  !7/   5TL
M %9>  !6<P  58T  %2G  !2P@  4N8 .#,  #$R   L,0  )3(  !TU   6
M.   $3P   Q    '1    $<   !*    30   %    !3    50   %<   !9
M    6@   %P#  !>!P  80L  &0.  !F$P  9QP  &8G  !F-   940  &17
M  !D:P  8H4  &&?  !@N0  7MP -3<  # U   H-P  (#H  !@]   10@
M#$8   9*    3P   %,   !6    60   %P   !?    80   &0   !E
M9P   &D   !L 0  ;@8  '$+  !T#P  =Q4  '<@  !V+0  =CT  '5/  !T
M8P  <WL  '*5  !PKP  ;\D -3H  "L[   B/P  &D,  !)(   ,30  !5(
M  !7    7    &    !D    :    &L   !N    <0   ',   !U    =P
M 'H   !\    ?P   (($  "&"@  B@\  (P7  "+)   BC,  (E%  "'6P
MAG(  (6+  "#I0  @KP +T   "5$   <20  $TX   U4   $6@   &$   !F
M    :P   &\   !T    >0   'T   "     @P   (4   "'    B@   (P
M  "/    D@   )8   "9 @  G@D  *(0  "B&@  H2D  * [  "?4   G6<
M )J!  ":F0  F:\ *4D  !].   55   #EL   5B    :0   '    !W
M?0   ((   "&    BP   (\   "3    E0   )<   ":    G0   *    "C
M    I@   *H   "N    L@   +<*  "[$0  NA\  +DP  "W10  M5P  +1T
M  "QC@  KZ0 (E0  !A;   08@  !VH   !S    >P   ((   ")    D
M )4   ":    GP   *,   "F    J    *L   "N    L    +,   "V
MN@   +T   #"    QP   ,P!  #3"P  U!4  -,F  #1.@  T%$  ,UH  #+
M@0  RI8 _    /8   #R    \0   /, !0#T  P \@ 3 /  ' #M "4 Z  N
M .( -@#> #X V0!$ -0 2@#1 $\ S@!4 ,L 60#) %X Q@!C ,0 :0#! '
MO@!X +P @0"Y (T M@": +, JP"Q ,  KP#F *X _P"E /\ F@#_ )0 _P"/
M /\ ]    .P   #H    YP   -\   #9  D T@ 0 ,\ %P#/ "  S  H ,8
M, #  #< O  ^ +D 1 "W $D M0!. +, 4P"Q %< KP!= *T 8@"K &D J0!Q
M *< >@"E (4 H@"3 *  H@"= +8 FP#4 )D ^0"6 /\ C0#_ (@ _P"$ /\
MZ    -\   #9    R0   +\   "X  0 M0 - +, $@"Q !H L  B *T *@"I
M #$ I@ X *0 /0"B $, H !( )X 3 "< %$ FP!6 )D 7 "7 &( E0!I ),
M<@"1 'T CP"+ (T F@"+ *P B0#% (@ [@"& /\ ?P#_ 'H _P!X /\ V0
M ,T   "[    K@   *4   "?    G  ) )D #P"9 !4 F0 = )@ ) "4 "L
MD0 Q (X -P", #P BP!! (D 1@"( $L A@!0 (4 50"# %L @@!B (  :P!^
M '4 ? "" 'H D@!X *, =P"Y '8 X !U /\ <@#_ &X _P!L /\ QP   +4
M  "E    F0   (\   ")    A0 $ (0 # "" !$ @@ 7 (( '@"  "4 ?@ K
M 'P ,0!Z #8 >0 [ '< 0 !V $0 =0!) ', 3P!R %4 < !< &\ 9 !M &X
M; !Z &H B@!H )L 9P"O &8 S !E /4 9 #_ &$ _P!@ /\ M    *    "0
M    A0   'T   !W    <P   '  " !O  X ;P 2 &\ & !O !\ ;0 E &L
M*@!I #  :  T &< .0!F #X 90!# &, 2 !B $X 80!5 %\ 7@!> &< 7 !S
M %L @@!9 ), 6 "F %< OP!7 .H 5P#_ %8 _P!4 /\ H0   (X   !_
M=0   &P   !H    9    &$ ! !@  L 7P / %\ $P!? !D 7P ? %T )0!<
M "H 6P O %D ,P!8 #@ 5P ] %8 0P!5 $D 4P!0 %( 6 !1 &$ 4 !M $X
M>P!- (P 3 "? $L M0!* -P 2@#Z $H _P!* /\ D@   (    !R    9P
M %\   !:    5P   %4  0!3  < 4@ , %( $ !2 !0 4@ : %$ 'P!/ "0
M3@ I $T +@!, #, 2P X $H /0!) $, 2 !* $8 4@!% %P 1 !G $, =0!"
M (8 00"8 $  K@!  ,L /P#R $  _P!  /\ A0   '0   !G    70   %4
M  !/    3    $H   !(  0 1P * $< #0!& !$ 1@ 5 $8 &@!% !\ 1  D
M $, *0!" "T 00 S #\ .  ^ #X /0!% #P 3@ [ %< .@!B #D ;P X (
M-P"3 #8 IP V ,  -@#H #8 _@ V /\ ?    &L   !> @  5 ,  $T#  !'
M P  0P$  $$    _  $ /@ ' #T "P ]  X /  1 #P %@ \ !H .@ ? #D
M)  X "D -P N #8 ,P U #H - !! #, 20 R %, ,0!> #  :P O 'L +@".
M "T H@ M +@ +0#= "T ^  N /\ <P$  &0%  !7!P  30@  $8(  ! "
M.P<  #@%   W P  -@ $ #4 "  T  P -  / #0 $@ S !8 ,@ ; #$ (  P
M "0 +P I "X +P M #8 +  ] "L 10 J $\ *0!: "@ 9P G '< )@") "8
MG0 E +, )0#/ "4 \  F /\ ;08  %X)  !2"P  2 P  $ ,   Z"P  -@L
M #(*   P"   +@8" "X#!@ M  H +  - "P $  K !, *@ 7 "D '  H "
M)P E "8 *P E #( )  Y ", 0@ B $L (@!7 "$ 9  @ ', 'P"% !\ F0 >
M *X '@#' !X Z0 ? /H : D  %D,  !-#0  0PX  #P.   V#@  ,0T  "T-
M   J#   * L  "<)!  F!@@ )@0+ "4##@ D 1  ) $4 "(!&  A 1T (0 B
M "  *  ? "X '@$V !T!/P < 4D &P%4 !H!80 : 7  &0&" !@ E@ 8 *H
M& #! !@ X0 8 /0 8PP  %4.  !)#P  0!   #@0   R$   +0\  "D.   F
M#@  (PT  "(, P @"P8 ( D) !\'#  >!@X '@41 !P%%0 ;!1H &@4? !H%
M)0 9!2L & 4S !<&/  6!D8 %@92 !4'7P 4!VX $P>  !('E  2!J< $@6\
M !($V0 2 ^\ 7PX  %$/  !&$   /!$  #41   O$0  *A$  "80   B$
M( \  !T. @ <#04 &@T' !H+"@ 9"@T & D0 !<)$@ 6"1< %0D< !0)(@ 4
M"BD $PHQ !(*.@ 2"T4 $0M1 ! ,7P /#&X #@R   X,E  -"Z< #0NZ  T*
MT@ -"NH 7 \  $X1  !#$@  .A,  #(3   L$P  )Q(  ",1   ?$0  '!
M !H0 @ 8#P0 %@X' !4."0 4#0L $PP- !(,$  2#!0 $0P: !$-(  0#2@
M#PTP  X..P -#D8 #0Y1  P/7@ +#VT "@]_  D/DP )#Z8 " ZY  @.T  '
M#N@ 6!$  $L2  ! $P  -Q0  # 4   I%   )10  "$3   =$@  &A(  !<1
M @ 5$04 $Q ' !(0"0 1#PH $ X,  X.#@ .#Q( #1 8  T0'@ ,$"4 #! M
M  L1-@ *$4$ "1%-  @26@ '$FH !A)\  42D  $$J0  Q&X  ,1SP "$>@
M51(  $D4   ^%0  -18  "T6   G%@  (A4  !X4   ;%   &!,  !42 P 3
M$@4 $A$' ! 1"0 /$0H #1$+  P2#@ +$A$ "A(5  D3&P )$R( "!,J  <4
M,P %%#X !!5*  ,56  "%6<  15Z   5C@  %:,  !2W   4SP  $^D 4A0
M $86   [%P  ,A<  "L7   E%P  (18  !P6   9%0  %A0! !03!  2$P8
M$1((  \2"  .$PD #!0*  H5#0 (%A  !A83  46&0 $%Q\  Q<G  (8,  !
M&#L  !E'   950  &60  !EW   9C   &*(  !BW   7SP  %^H 3Q8  $,8
M   Y&0  ,!D  "D9   C&0  'Q@  !L7   8%@  %14" !,5!0 1% 8 $!0&
M  X5!P ,%@@ "A<*  <9#  $&@X  AL2  $;%@  &QT  !PD   <+0  '#@
M !U$   =4@  '6(  !UU   =B@  '*   !RV   ;T   &NL 3!@  $ :   V
M&P  +1L  "8;   A&@  '1D  !D9   7&   %!<# !(6!  0%P0 #A<$  P9
M!0 *&@< !QP)  ,="P  'PT  " 0   @%   (1H  "$B   A*@  (34  ")!
M   B3P  (E\  ")R   AB   (9\  ""V   ?T0  '^T 2!H  #T<   S'0
M*QT  "0=   @'   '!L  !@:   6&0$ $QD! !$9 0 .&@$ #!P"  H= P '
M'P4  R$(   B"@  ) P  "8.   F$@  )A@  "<?   G)P  )S(  "<^   G
M2P  )UP  "=N   FA0  )IT  "6T   DT0  (^X 1!T  #D?   P'P  *!\
M ",>   >'0  &QP  !@;   4'   $1P   X=   -'P  "B$   8B 0 #) 0
M "8&   H"   *@L  "L-   M$   +14  "T<   M)   +BX  "XZ   N2
M+5@  "UJ   M@0  +)H  "NR   JT   *>\ 0"   #8A   M(0  )B$  "$@
M   ='P  &AX  !8>   2'P  #R$   TB   *)   !B8   (H    *P(  "T$
M   O!@  , D  #(,   T#@  -1(  #48   U(   -2H  #4V   U0P  -5,
M #1F   T?   ,Y8  #*O   QS0  ,.\ /",  #(D   J)   )",  " B   <
M(0  %R$  !,C   0)0  #2<   DI   %*P   2X    P    ,@   #0!   V
M!   . 8  #H)   \#0  /A   #X4   ^'   /B8  #XQ   ^/P  /4X  #UA
M   \=P  .Y$  #JK   YR0  ..T -R<  "\G   H)@  (R4  !\D   9)0
M%"8  ! H   -*P  "2X   4P    ,P   #4    X    .@   #P    ^ 0
M0 ,  $('  !$"@  1@T  $D1  !)%P  2"$  $@L  !'.@  1TD  $9;  !%
M<0  1(L  $.E  !"PP  0>@ -"H  "PJ   G*   (B<  !PH   6*@  $2T
M  TP   ),P   S8    Y    /    #X   !!    0P   $8   !(    2@
M $P#  !.!@  4 H  %,.  !4$P  5!P  %,G  !3-   4T,  %)5  !1:@
M4(,  $^>  !-N0  3.  ,"T  "LL   F*P  'RP  !@N   2,@  #34   @Y
M   "/0   $    !#    1@   $D   !,    3@   %$   !3    50   %<
M  !9 0  7 8  %\*  !B#@  8Q4  &,?  !B+   83P  &!.  !?8@  7GL
M %R6  !;L   6<\ +S   "HO   B,   &C,  !,W   ..P  "#\   %$
M2    $P   !/    4@   %4   !8    6P   %T   !@    8@   &0   !F
M    :0   &T%  !P"P  =!   '08  !S)0  <C0  ')%  !P60  ;W$  &V+
M  !KI@  :L  +C,  "4U   =.   %#P   Y!   '1P   $P   !1    50
M %D   !=    80   &4   !H    :P   &T   !O    <@   '0   !W
M>@   'X   ""!   A@L  (H1  ")'   B"L  (8]  "$4@  @V<  (&!  !_
MFP  ?K( *3H  " ]   60@  #T@   A.    5    %H   !@    9    &D
M  !N    <@   '8   !Z    ?0   (    ""    A0   (@   "+    C@
M )(   "6    FP,  * ,  "B$P  H"$  )\S  "=1P  FEX  )AW  "7CP
ME:< (T,  !E(   13@  "54   !<    8P   &H   !Q    =@   'L   "
M    A@   (H   ".    D0   ),   "6    F0   )P   "@    HP   *<
M  "K    L    +8$  "\#0  NA<  +DH  "W/   M%(  +)J  "OA0  K9P
M'$X  !-4   +7    60   !L    =    'P   "#    B0   (\   "4
MF@   )\   "B    I    *<   "J    K@   +$   "T    N    +P   #!
M    QP   ,T   #4!0  V!   -4>  #3,0  T$@  ,U?  #+=@  R(X
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MA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VO?
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MD,]%F(['7:.-P6ZKC;UYL8RZ@;2)N(.WAK>%N82VAKJ#M8>[@K6(O(&TB;V
MM(J]?[2+OGZSC+Y^LXR^?K.,OGZSC+Y^LXR^?K.,OGZSC+Y^LXR^?K.,OGZS
MC+Y^LXR^?K.,OGZSC+Y^LXR^?K.,OL+1!Q:]U@@ZI_$.59OQ&VB1YBUXB=U
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MFW^YP)N(O;Z9B<"\E8K#NI&+QKB-C<BWBH_*MHB1S+6%D\VT@Y;/LX&9T+.
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MCJF$S(NIA<V(J(;.AJB'SH.HB<Z!IXS/@*>-SX"GC<^ IXW/@*>-SX"GC<^
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MA+&*P8*QB\&!L8S"@+&,PH"QC,* L8S"@+&,PH"QC,* L8S"@+&,PH"QC,*
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ME::#T(^EA-**I(;3AJ.(U(.CC-2!HY'4@*29TX"FH=& IJ'1@*:AT8"FH=&
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M?J7/J'ZGS*1_J<FA@*S&H8"LQJ& K,:A@*S&H8"LQJ& K,:A@*S&H8"LQJ&
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MFH.KQ_^M%P7_KB(6_ZLP+_^G/DOXH4MHYY]1@=F?5I?*G&*LQ9ULM,.?=;C
MH'Z\O:"'P;J=B,:WF(C+LY.)S[".C=2MB939J(:=VJ*%H=6>A:31FX6FSIF%
MJ<J7A:O'EX6KQY>%J\>7A:O'EX6KQY>%J\>7A:O'EX6KQY>%J\>7A:O'EX6K
MQ_^N%P3_KB(6_ZPP+_^G/DOXHDMHZ*%/@=F@4Y?*GE^LQI]IM,.A<KC HGR\
MO:*$P;F@A\>UG(?-LI>(TJZ3B]BJCI/?HHN<W)R)H-:9B*/2EXBFSI6(J<J4
MB*O'E(BKQY2(J\>4B*O'E(BKQY2(J\>4B*O'E(BKQY2(J\>4B*O'E(BKQ_^N
M%P3_KB$6_ZPO+_^H/4OXHDIHZ*)-@-FB4)?+H%RLQJ%EL\.D;K? I7B\O*6"
MPKBDA\BTH(?.L)V(U:N9BMVEEY/FFY&;W9:/H->4C:/3DHRFSY&+J,N0BJO(
MD(JKR)"*J\B0BJO(D(JKR)"*J\B0BJO(D(JKR)"*J\B0BJO(D(JKR/^N%@3_
MKR$6_ZTO+_^H/$OWHDEHZ*1*@-FD39;+HEBKQJ1AL\2G:K? J72\O*E^PKBH
MA\BSIH?/K**'UZ2=B=V:FHWAE9J;WI&5G]B/DZ+3CI"ET(Z/J,R-CJK)C8ZJ
MR8V.JLF-CJK)C8ZJR8V.JLF-CJK)C8ZJR8V.JLF-CJK)C8ZJR?^O%@3_KR$6
M_ZTN+_^I/$OWHTEIZ*9(?]JG2)7,I5.JQZA<LL2L9+;!KFZ[O:]XP+:LA,FN
MIX?0IJ.&U9V@AMF3G8G=C9V4W8V=G]B+F:'4BY:DT(J3I\V*D:G)BI&IR8J1
MJ<F*D:G)BI&IR8J1J<F*D:G)BI&IR8J1J<F*D:G)BI&IR?^O%03_L" 6_ZXN
M+_^I.TOWI$=IZ:A$?MNK0Y3-J4RIR*U4L,:S7+/"MV:YM[!WPK"KA,FIIX;/
MH:2$TY>BA-:.H(?9B)^/VH>AFMB'H*'4AYNDT8>8ILZ'E:G*AY6IRH>5J<J'
ME:G*AY6IRH>5J<J'E:G*AY6IRH>5J<J'E:G*AY6IRO^P%03_L" 5_ZXM+_^J
M.DOXID1HZJM ?=RO/)+/KT*FRK5)K<:\4K&YM6>[L+!XPZNLA,FDJ83-G*:#
MT).DA-.+HX;5A:*,UH*BE-:#I)W4@Z*DT8.>ILZ$FJC+A)JHRX2:J,N$FJC+
MA)JHRX2:J,N$FJC+A)JHRX2:J,N$FJC+A)JHR_^P% 3_L1\5_Z\L+O^K.4OX
MJ4!GZZ\[>]ZV,X_2NC2AS,(YJKNZ5;6PM&J]JK!YPZ>MA,>?JH3+F*B#S9"G
MA-")I8;2A*2*TX"DD--_I9?2?Z:@T'^EILZ H*C+@*"HRX"@J,N H*C+@*"H
MRX"@J,N H*C+@*"HRX"@J,N H*C+@*"HR_^Q$P3_LAX5_[ K+O^L-TSZK#ME
M[;4T>.*_*8G8S""8OK\]KK"X6;BILVR^I;!ZPJ*NA,6;K(/(E*J$RHZIA,R(
MJ(;.@Z>)SX"GC<]^IY//?*B:SGRIHLU\IZC+?*>HRWRGJ,M\IZC+?*>HRWRG
MJ,M\IZC+?*>HRWRGJ,M\IZC+?*>HR_^R$@3_LQT5_[$I+O^M-DS\L35B\;TJ
M<N;-'X#(S"&;L;Q%LJBW7KFCLV^^H+%[P9ZOA,.7KH3&D:R$QXRKA<F'JH?*
M@ZJ)RX"JC,Q]J9#,?*J5RWJJG,IYJZ3*>:NDRGFKI,IYJZ3*>:NDRGFKI,IY
MJZ3*>:NDRGFKI,IYJZ3*>:NDRO^S$03_M!L4_[,F+O^O,TS]N2M=Z\H?:=+?
M$7^YS"><I[U,L:"W8KF=M'&]F[)\OYJQA,&4L(3#CZ^%Q8JNAL:&K8?'@ZR)
MQX"LB\A^K([(?*R2R'NLE\AYK9['>:V>QWFMGL=YK9['>:V>QWFMGL=YK9['
M>:V>QWFMGL=YK9['>:V>Q_^U$ /_MAD4_[4D+?^T+$GRQ1]4UMT28L'?$X&L
MS2Z:G\!/JYJX9;>7M7*[EK1\O96R@[^1L87!C;&&PHFPA\.&KXC#@Z^)Q(&O
MB\1_KHW%?:Z0Q7NNE,5ZKYG$>J^9Q'JOF<1ZKYG$>J^9Q'JOF<1ZKYG$>J^9
MQ'JOF<1ZKYG$>J^9Q/^W#@/_N!83_[<@+?F_'T'<V1%$Q.L29K'?&(&@T#.5
ME\90HY/ 8ZV1NW&SD;A[N)"V@KN.M(6]B[.&OXBRA\"&LHG A+&*P8*QB\&
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M@5;?E8%6WY6!5M^5@5;?E8%6WY6!5M^5@5;?E8%6WY6!5M^5@=2]!0#$R <
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MGZ3.=:*FS72FJ,URJ:G,<:VJS'"RJ\MPMJO+;[RKR'# J\1QP*K$<<"JQ''
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M$0'_FR8*_YPZ'/^823'_F%%$_YI45/J;6&3PFEUTYYAC@MZ6;8_6DW>:T)&
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MN9&%M;F1A;6YD86UN9&%M;F1A;6YD86UN?^;$0'_GR8*_Y\W'/^;13+_H45
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M:L^6R&K/EO^%$@'_AR(&_X<U%/^%1B3_A%0U_XA<0_^(9%'^AVM>]X-R:?&
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M_[ X,O^X.COVP#]![,I'1>/65$76V5=8Q]!>:[C(9'ZJP6N.G+IRG(ZT>JB
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MFZAEPZRG8<*]JF.XOZMFL+^L::J_K&REOZMMHL"J;:+ JFVBP*IMHL"J;:+
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M6T+ZIUQ!^JQ<0?JL7$'ZK%Q!^JQ<0?JL7$'ZK%Q!^JQ<0?JL7,BV 0"UP0,
MI]$! )GK!0*/_Q()A?\@$GS_+!MS_S4C:O\]*F+_1#!<_TLT5_]2.%/_6#M/
M_UX]3/]C/TK_:$!'_VU"1?]R0T3_=T1"_WU%0/^#1C__BD@]_Y!)//^723O_
MGDH[_Z-+._^C2SO_HTL[_Z-+._^C2SO_HTL[_Z-+._^C2[:Z @"FR@  F-P
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M<DOCY').V.9S3M7G=$[5YW1.U>=T3M7G=$[5YW1.U>=T3M7G=/^6"@#>K (
MR[H% +W'!@"RV @!I_\2")S_(1:2_RXCB?\Y+X#_0CEW_TI";?]0267_5DY?
M_UY36OYE5E7\;5I2^G5<3_A^7TSWAV%*]9%B2/2<9$;SIF5%\K-F1/+!9T/R
MU&=%[N=G1NOH9T;KZ&=&Z^AG1NOH9T;KZ&=&Z^AG1NOH9^ZB  #-M ( O+X$
M *_-! "DW@<!FO\5"9#_)!6'_S @?O\[*G3_0C)K_T@Y8_]./UW_54-8_UU'
M4_]D2E#_:TU-_W)/2O]Y44?_@E-%_XM40_Z45D']GE= _:A8/_RS63[\OUH^
M^]%:/?O;6CW[VUH]^]M:/?O;6CW[VUH]^]M:/?O;6M*M  "]N ( KL4" *'5
M @"6]PL"C?\8"(3_)A%\_S$:<?\X(FC_/BE@_T4O6O],,U3_4S=0_UHZ3/]@
M/$G_9CY&_VU 1/]T0D'_>T,__X-%/?^,1CO_E4<Z_YY).?^G2CC_L4HW_[Y+
M-__"2S?_PDLW_\)+-__"2S?_PDLW_\)+-__"2[^S  "NO@  H,T  )+>  ")
M_PT!@?\:!7?_(PQM_RH39/\Q&5S_.!Y5_T B4/]()DS_3RE(_U4K1/];+4+_
M82\__V<Q/?]M,CO_<S,Y_WHU-_^"-C7_BS<S_Y0X,O^<.3'_I#HP_Z\[,/^R
M.S#_LCLP_[([,/^R.S#_LCLP_[([,/^R.["X  "@QP  D=@  (3O  !\_PT!
M;_\1 V;_&09>_R$*5O\I#U#_,A-+_SH61O]!&4+_2!L__TX=//]3'CG_62 W
M_UXA-?]D(C/_:2,Q_W D+_]W)2W_?B8L_X<G*O^/*"G_ERDH_Z J*/^C*BC_
MHRHH_Z,J*/^C*BC_HRHH_Z,J*/^C*J'"  "1T0  @N$  'C_  !L_P@!8/\-
M E?_$0-/_Q@%2/\@!D/_*0@__S$*._\X##C_/@XU_T0/,O])$##_3A$N_U,2
M+/]8$RK_710I_V,5)_]I%B7_;Q<D_W<7(O]^&"'_A1D?_X\:'_^1&A__D1H?
M_Y$:'_^1&A__D1H?_Y$:'_^1&O]H&0+_9",$_U\O!O]>0!#_8TL:_V=4)?]H
M72__9F<Y_V1R0?]B?4C_8(=._UV04O];F%;_6IY9_UBD6_]7JEW^5K!?_56U
M8/Q4O&'\5,1B^U/-8_E2W&/V4N9C\5/J8^Q4[6/F5N]BX%?P8^!7\&/@5_!C
MX%?P8^!7\&/@5_!CX%?P8_]I& +_92,$_V N!O]?0!#_9DD:_VI3)?]K7##_
M:64Z_V=P0O]D>TG_8H5/_U^.5/]=EEC_6YU;_UJC7?U8J5_\5Z]A^U:U8OI5
MO&3Z5<1E^53.9?=3W6;S4^9F[E7J9N=6[67A6.YEVUGO9MM9[V;;6>]FVUGO
M9MM9[V;;6>]FVUGO9O]J& +_9B($_V$N!_]@/Q#_:4@;_VU1)O]N6S#_;&0Z
M_VEN0_]G>4O_9(-1_V&,5O]?E5K_79Q=_5NB8/M:J6+Z6:]D^5BU9?E7O&?X
M5L5H]U7/:/54X&GP5>9IZ5?J:.)9[&C;6NUITUON:=-;[FG36^YITUON:=-;
M[FG36^YITUON:?]J& +_9R($_V(N!_]C/A#_;$8;_W%0)O]R63'_<&([_VQK
M1/]I=DS_9X%2_V2+6/]ADUS]7YM@^UVA8OI;J&7Y6JYG^%FU:/=8O&GV5\9J
M]5;1:_)5X6SL5^=LY%GI:]Q;ZVO47.QLS5WM;,U=[6S-7>ULS5WM;,U=[6S-
M7>ULS5WM;/]K%P+_:"$#_V,M!_]G/!#_<$4;_W1.)O]V5S'_=& [_W!I1?]M
M<TW_:GY4_V:(6OYCD5[[89EB^5^@9?A=IVCV7*UJ]5JT;/19O6WT6,=N\E?4
M;^Y7XF_F6>9OW5SI;M-=ZF_-7NMPQU_K<,=?ZW#'7^MPQU_K<,=?ZW#'7^MP
MQU_K</]L%P+_:2$#_V4M!_]K.A#_=$,;_WE,)O]Z53'_>5T\_W5F1?]P<$[_
M;7M6_VJ%7/QFCV'Z9)=E]V&?:/9?IFOT7:UM\URT;_):O7'Q6<ER[UC:<^A:
MXW/>7>9RTU[H<\M?Z'3&8.ATP6'H=,%AZ'3!8>ATP6'H=,%AZ'3!8>ATP6'H
M=/]M%@+_:B #_V8M!_]O.!#_>$$:_WU*)?]_4C'_?EL\_WMC1O]V;$__<7=7
M_FV"7OMJC&/X9I5H]62=;/-AI&_R7ZQQ\%VT<^]<OW7N6\MVZEO==^!=XW;3
M8.5WRF'E>,1BY7B^8^5XNF3E>+IDY7BZ9.5XNF3E>+IDY7BZ9.5XNF3E>/]N
M%@+_:R #_V@L!_]S-A#_?3\:_X)')?^$4##_A%@[_X%@1?]\:4__=G)7_G%]
M7_EMB&7V:I)J\V:;;_%CHW+O8:MU[5^U>.Q=P7GL7-!ZXUW?>]1AXGO*8N)\
MPF3A?;QEX7VW9N)\LV?B?+-GXGRS9^)\LV?B?+-GXGRS9^)\LV?B?/]P%0'_
M;!\#_VDL!_]W- __@3P9_X=%)/^*32__B54Z_X==1?^"94__?&Y8_79X8/AR
MA&?U;8YM\6F8<N]FH7;L8ZMYZV"V?.E>Q'[G7MA_V&'??LICWX#!9=Z!N6?>
M@;1HWH&P:=^ K&G??ZQIWW^L:=]_K&G??ZQIWW^L:=]_K&G??_]Q%0'_;1\#
M_VLK!_][,@__ACH8_XQ#(O^/2RW_CU,X_XU:0_^)8DW_@VE7_7QR8/AV?V?T
M<8IN\&R5=.UHGWGJ9*I]Z&&W@.9?R(+=8=N#S&3<A,!FW(6X:-N%L6K;A:UK
MW(2I;-V#IFS=@J9LW8*F;-V"IFS=@J9LW8*F;-V"IFS=@O]R% '_;QX#_V\I
M!_]_, [_BC@7_Y%!(?^42BS_E5$V_Y-80?^08$O[BV=5]81O7_!]>F?K=X5O
MYW*0=N-MFWS>:*:!VF6SA-5CQ(;/9-J'P6?9B+=IV(FO:]B)JFW9B*9NVH>C
M;MJ&H&_;A:!OVX6@;]N%H&_;A:!OVX6@;]N%H&_;A?]R% '_<!X#_W(H!_^"
M+@W_CC86_Y5 '_^92"G_F4\T_YA5/OJ67$GTDF13[8QK7>>%=F;A?X%OVWB,
M=]-REG[-;:&$R6JMB<5HNXO!:-",MFO5C:YMU8VG;]:,HW#6BY]QV(J=<=F)
MFW+:AYMRVH>;<MJ'FW+:AYMRVH>;<MJ'FW+:A_]S% '_<!T#_W4F!O^&+ W_
MD385_YE '?^<1B?_G4PQ_)U2._2<647MF6!/YI1H6=^.<V/5AGUNS7^'>,9X
MD8# <YN'NV^GC+9MM(^S;,B1K&[2D:5PTY"@<M2/G'/5C9ETUHR7=-B*EG79
MB99UV8F6==F)EG79B99UV8F6==F)EG79B?]T$P'_<1T#_W@D!O^)*PS_E343
M_YP^&_^@0R3_HDDN]Z-0-^^B5D'GH5U*WYUG5-25;V++C7ANPX6">;M_C(*U
M>9:)KW6ACJIRKY*F<<&4H7/0E)QTT9*8=M*1EG?3CY1WU8V2=]:,D7C8BI%X
MV(J1>-B*D7C8BI%XV(J1>-B*D7C8BO]U$P'_<AP#_WLC!O^,*0O_F#02_Y\\
M&?^C02+[ID8J\JA-,^JI5#SBJ5M$UZ-C4\R:;&+"DW5NNHM^>;*%AX.J?Y&*
MI'N<D)YXJI2:=KN6EW?/EI1YT)21>M&2CWK3D(YZU(^->M6-C'K7BXQZUXN,
M>M>+C'K7BXQZUXN,>M>+C'K7B_]U$P'_<QP#_WTA!?^.*0K_FS00_Z(Y%_^F
M/A_WJD0F[JY*+N6Q4C7<KUE!SZAA4L6@:6&[F')NL9%Z>:F+@X.AA8V+FH&8
MD91^I9:0?+:8C7W-EXQ^SY6*?M"3BG[2D8E^TX^)?=6-B'W6BXA]UHN(?=:+
MB'W6BXA]UHN(?=:+B'W6B_]V$@'_=!P#_X @!?^1* G_GC,/_Z0W%?ZJ.QOS
MKT$BZK1(*.*Y4"[4M%9 R:U?4;ZE9V"TGF]MJI=W>*&1@(*9C(J+D8>5D8N$
MHI:&@[*9@X3+F(2#SI:$@]"4A(+2DH2!TY"$@=2.A(#6C(2 UHR$@-:,A(#6
MC(2 UHR$@-:,A(#6C/]W$@'_=!L#_X(>!/^4)PC_H#(-_Z<T$_JN.!COM3T<
MYKQ&(=R_3"S.N50_P[%=4+>J95^MI&QLHYUT=YF8?(&1DX:*B8^2D8*,GY9]
MBJ^8>HO'F'R)SI9]B-"4?H;2DG^%TY!_A-2.@(/6C("#UHR @]:,@(/6C("#
MUHR @]:,@(/6C/]X$@'_=1L#_X4<!/^7)@?_HR\+_ZLP$/6S-!3KNSH7XL1$
M&-7$2"O(O5,]O+9;3K&P8UVFJFIJG*1Q=I*?>H")FH.)@9:.D'F3G)5TDJR7
M<9+#F'.1SY9VCM"4>(O2D7F*TY!ZB-6.>X?6C'N'UHQ[A]:,>X?6C'N'UHQ[
MA]:,>X?6C/]X$@'_=AL#_X@; _^:)0;_IBL)_J\L#/&Y+P[FPS8/W<T\%L[(
M1RG"PE$[MKQ93*JV85N?L&AHE:MO=(NF=WZ!HH"&>9^+C7&<F9)LFZF5:9N_
MEFN9T)1NE-&2<9'2D7./U(]UC=6-=HO6BW:+UHMVB]:+=HO6BW:+UHMVB]:+
M=HO6B_]Y$0'_>!H"_XP9 _^>(P3_JB8&^+0E".O * CAS3 'U-(W%,C-12>[
MR$\YK\)72J.]7UB8N&9EC;-M<8.O=7MZJWZ#<:B)BFJFEH]EI:>28J:]DF.C
MTI%GG=.0:IC4CVV5U8UNDM:,<)#8BG"0V(IPD-B*<)#8BG"0V(IPD-B*<)#8
MBO][$0'_?!<"_Y 7 O^B(0/_KB $\KL=!.7*'@/:VR0#S-DU$L#30R2TSDTV
MJ,E51YS$7561P&1BAKQK;7NX<W9RM7Q^:K.'A6.QE8I>L*6,6[&\C5NOU8U?
MI]6-8Z'6C&:<UXMHF=B*:I;9B&J6V8AJEMF(:I;9B&J6V8AJEMF(:I;9B/]\
M$ '_@10"_Y45 ?^G'0+\M18"Z\80 =K;#P#-X"4$P]\V#[C;02&LU4LSH-%3
M0Y3-6E&)R6)=?L9I9W3#<7!KP7MX9+^&?EV^E()8O:6%5KZ[AE6]VX98L]J'
M7*O:AU^FVH=AH=N&8YW;A6.=VX5CG=N%8YW;A6.=VX5CG=N%8YW;A?]^$ '_
MAQ$!_YH1 /^M% #:O@H T<T* ,OD$ '!Y"4'M^,U$ZWA0"&CWDDOE]M2/HO7
M64N U&!7=M%H86W/<&EES7IP7LR&=5C,E7E4S*9[4<V\?%#,XGQ3P>!_5;??
M@%BQWH%:J]Z!7*;?@5RFWX%<IM^!7*;?@5RFWX%<IM^!7*;?@?^ #P'_C@X!
M_Z(- -NU" #.P0@ QM ) +[I$@*TZ24*JN@S%Z#F/B66Y4<RB^-./X#A54EV
MX%U3;=YF6V7=;V%>W7IG6-R&:U/<E6]0W:9Q3=Z[<DW?X7%.T>=T4,;F=U*^
MY'A3N.1Y5;+C>E6RXWI5LN-Z5;+C>E6RXWI5LN-Z5;+C>O^##@'_E@L W:L$
M ,VX!@#"Q 8 NM0) +'O% .G[B4-GNXS&I3M/2>*[$8S@.M./G;K54=LZEM.
M9.IC55WJ;5I8ZG=>4^J#8D[JD65*ZZ%G1^RS:4;MT&E(YNAI2]GK:DS/[&U.
MQ^MO3\#J<$_ ZG!/P.IP3\#J<$_ ZG!/P.IP3\#J</^)"P#IH $ T+$$ ,&\
M!0"WR08 KMH) *3U%P6;]2<0DO4T'(CV/B=_]D<R=O9..VSV5$)D]EI(7?9B
M35?V:U%2]G553?> 6$CXC5I%^)M<0OBK7D'WOE] ]]]@0^[L8$?C\5](V_%A
M2=+R8TG2\F-)TO)C2=+R8TG2\F-)TO)C2=+R8_Z5  #4J0  PK4# +7! P"J
MSP4 H.<+ 9C]&@:/_BD0AO\U&W[_0"5T_T8M:_],-6/_4CI<_UD_5O]@0U#_
M:$=,_W%*1_][3$/_ATY _Y10/O^A4CW_L%0[_\-5._[A53SY\%5 \/150^?W
M5$/G]U1#Y_=40^?W5$/G]U1#Y_=40^?W5-NA  #%L   M;H" *C' @"=U@0
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M:5*O[VE2K^]I4J_O:5*O[VE2K^]I4J_O:?]_"@#ME@  TJ8! ,2R P"YO ,
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M!/]4, ;_6C8(_UY $/]@2AC_7E4@_UM@*/]8;2__5'DT_U&%.?].D3W_3)M
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M7_E<JU_Y7*M?^5RK7_E<JU_Y7/]9&P+_5B,#_V(@ _]L( /_=2@%_WTS"_^
M/1/_@4<;_W]0)/E[62WT=F(V[G%M/NIL>47F:(1+XF2.4=YAF%7;7J)9UERL
M6]-;N%[06L9?S5K?8,A:\F&^7/5BM5[T8JY@]6*J8?5AIF+V8:-C]U^C8_=?
MHV/W7Z-C]U^C8_=?HV/W7_]:&@+_62$"_V8= O]P'@/_>B8$_X(Q"?^&.Q#_
MB$09^89-(?*#5BOK?EXTY7EI/>!T=$7:;W],TVJ)4\]FDEC+8YQ=QV&F8,1?
ML6/!7K]DOE[29;I?[&:R8/)FJV+R9J5D\F6A9?-DGV7T8YQF]6*<9O5BG&;U
M8IQF]6*<9O5BG&;U8O];&@+_7!\"_VD; O]U' +_?B0#_X<N"/^,. [[CD(6
M\HY*'NN+4B?DAULPW8%F.M-Z<$7-=7I.R'"#5<-LC5N^:99@NF:@9+=DJV>T
M8[AIL6+*:JYCYFJH9.]JHF;O:9UG\&B::/%GF&GR9I9I\V26:?-DEFGS9)9I
M\V26:?-DEFGS9/];&0+_7QP"_VP8 O]Y&P+_@R$#_XPL!O^1-@OUE#\2[)5'
M&>233R+<CE@MTH=B.LJ!;$7#>W5.OG9_5KARB%VT;I%BKVN;9JMIIFJH9[-L
MI6?#;J)GX&Z>:>UMF6KN;)9K[VJ3;/!IDFSQ9Y!L\F:0;/)FD&SR9I!L\F:0
M;/)FD&SR9O]<&0'_8AH"_W 6 O]\&0+_AA\"_Y I!/J6,PGPFCP.YYM$%=^:
M2QW3E%4LRHU?.<*':46[@7%/M7Q[5Z]XA%ZJ=(UCI7&7:*%NHFR=;*YOFFR^
M<)ALV7&5;>MOD6[L;H]O[6R-;^]JC&_P:8MO\6>+;_%GBV_Q9XMO\6>+;_%G
MBV_Q9_]=&0'_9!D"_W(4 ?]_& '_BAT!_Y0F _:;, ;KGS@*XJ(_$-B?1QS-
MF5(KQ))=.;N,9D2TAVY.K8)W5Z=]@%ZB>8EDG7:3:9ASGFV4<:IQD'&Z<HYQ
MT7.,<NIQBG/K;XAS[6V'<^YKAW/O:H9R\&B&<O!HAG+P:(9R\&B&<O!HAG+P
M:/]>& '_9Q<!_W43 ?^#%@'_CAH!_I@C O&?+ 3GI3,'W:@Y#-&C11O'G5 J
MOI=:.+628T2MC&Q.IH=T5Z"#?%Z:?X9DE7R/:I!YFFZ+=Z9RB':V=(5VS'2$
M=^ER@W?J<()W[&Z"=NUL@G;O:H%V\&F!=O!I@7;P:8%V\&F!=O!I@7;P:?]>
M& '_:14!_W@2 ?^&% '_D1@!^IP? >VD)P+BJBP$UJPT"\NG0QK!HDXIN)Q8
M-J^784.GD6E-H(UQ5IF(>5Z3A8)DC8&,:HA_EV^#?:1R?WRS='U\R'5\?>AS
M?'SJ<7Q[[&]]>NUM?7GN:WUY\&E]>?!I?7GP:7UY\&E]>?!I?7GP:?]?& '_
M:Q,!_WL1 ?^)$P#_E14 ]: : >BI( '=L"0!T+ R"L:L01B\IDPGLZ%6-:J<
M7T&BEV=,FI)O59..=UV,BX!DAHB*:8&%E6Y\@Z%R=X*P='6"Q75T@^=S=8'J
M<79_ZV]W?NUM>'WN:WA\\&EX?/!I>'SP:7A\\&EX?/!I>'SP:?]@%P'_;A(!
M_WX0 /^,$0#_F1$ \:03 ..N%@#6MAP!R[0P",&P/Q>WJTLEK:94,Z2A74"<
MG65*E)AL4XR5=%N&D7UB?XZ':'F,DFUTBIYQ<(BM=&V(P71MB>1S;X?J<7"$
M[&]R@^UM<X'N:W2 \&ET@/!I=(#P:72 \&ET@/!I=(#P:?]A%P'_<1 !_X(.
M /^0#@#UG0T XZD, -FU# #/N1H Q;@N![NT/16QL$DCIZM2,9ZG6SZ6HV-(
MCI]J48:;<EE_F'I@>)6$9G*3CVQMD9QO:9"J<F:0OG-ED>%R:([K<&J*[&YL
MB.UL;8;O:VZ$\&ENA/!I;H3P:6Z$\&ENA/!I;H3P:?]C%0'_=0X!_X8- /B4
M"P#<H@@ U*T) ,^X"@#)O1< O[PK!K6Y.Q.KMD<AH;%0+YBM63N/JF%&AZ9H
M3W^C<%=XH'A><IZ!9&N;C&EFFIEM8IFH;U^9O'!>F=]O8);L;F.1[6UFCNYK
M9XOO:FF)\&AIB?!H:8GP:&F)\&AIB?!H:8GP:/]G$@'_>0P _XH* -^:! #3
MI@< S+$( ,>[" #!PA, N,(H!*Z_.!"EO$0>F[A.+)&U5SB(L5Y"@*YF2WBK
M;5-QJ79::Z=_8&6EBF1@HY=H6Z.F:UFCNFQ8H]QK6:#N:UR:[VI?EO!I89+Q
M:&./\69CC_%F8X_Q9F./\69CC_%F8X_Q9O]K$ '_?@D \9 $ -:> P#,J@8
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M4D>[_U)'N_]21[O_4N:*  #/FP  OZ<  +*P  "GNP  G,8# )/1!@"+Z@X
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M7&]]^EMP?/M:<'S[6G!\^UIP?/M:<'S[6O]?$0'_;PH _WX( .., P#6EP4
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M55B5_E58E?Y56)7^5?]O! #F@@  TI$  ,:=  "[I@$ LJX  *JW 0"BP@4
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M$2'_Q1(@_^D3'__\$Q[__Q,>__\3'O__$Q[__Q,>__\3'O__$Z:I  "8LP
MBK\  'O*  !NU0  8-\  %3G  !._P0 2?\. $/_%  __QT!.O\E C;_+ (R
M_S,#+_\Z RO_000H_T@$)?]/!2+_5P4@_V &'?]L!QK_>0<8_XH(%O^;"!7_
MK0D4_\,)$__C"1/_^ D3__\*$___"A/__PH3__\*$___"IJQ  "+O0  ?,@
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M3GMO_TU[;O]+>V[_2WMN_TM[;O]+>V[_2_]7$0#_8PH _W ' /!\!0#<A04
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M3&=^_TQG?O],9W[_3/]A"@#_;P  X'X  -")  #&DP$ OYL# +BA @"QI@L
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M/\G7+S_']3 ]Q/\S.\/_-3R^_S8]N/\W/;C_-SVX_S<]N/\W/;C_-]&&  #
ME0  LI\  *6G  ":KP  CK<  (._  !XQP, ;L\' &77#0!CV!T 8-@M EO8
M.@17V$8)4]A0#4_861%+UV(51]=L&$37=QM!UX0>/MB3(#S8HR$[V;<B.MK5
M(CK6\B,WU/\G-M+_*331_RLVRO\M-LK_+3;*_RTVRO\M-LK_+<60  "VG0
MJ*4  )RM  "/M@  @[X  '?'  !LSP( 8M8' %KD#@!8Y!P 5.0I 5#D-0-,
MY3\%2.5)!T7E4PI"YEP-/^9F#SSF<1(ZYWX4-^>,%C7GG!<SZ*X9,NG&&3+H
MZADQY?X9+^3_'"[D_QXMXO\@+>+_("WB_R MXO\@+>+_(+J:  "JHP  G:L
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M!0[_]@4.__\%#O__!0[__P4.__\%#O__!96O  "&N@  =\4  &C0  !:VP
M3.$  $#G   W\P  ,O\  "[_!P J_PX )O\3 "/_&@ ?_R  &_\F !C_*P$5
M_S(!$O\X 1#_0 $._T@!#/]2 0G_70(&_VL"!/]] @+_D (!_Z," /^V @#_
MS0, _^P# /_L P#_[ , _^P# /_L XBY  !XQ   :=   %O=  !+XP  /ND
M #+N   K_P  )O\  "'_   =_P@ &O\- !;_$0 3_Q8 $/\:  [_'P +_R0
M"?\J  ;_,  "_S<! /]  0#_2@$ _U8! /]D 0#_=0$ _X@! /^: 0#_J@$
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M,KI*_S.X2_\SLTS_,ZY-_S.J3O\RJ4[_,JE._S*I3O\RJ4[_,O]#&@'_3!,
M_U00 /]<$@#_81< _V4> ?MF)P'R9C$#ZF4]!N-C2@O<8%<2U5UB&=!:;1_,
M5W<CR%6 )\54B2O"4I(NP%&:,+Y0HS*[3ZTTN4^Y-;=/R#:T3^(VL4_T-ZY0
M_SBL4/\XIU'_-Z-2_S:@4_\UGU/_-9]3_S6?4_\UGU/_-?]&%P'_4!$ _U@-
M /]@$ #_9A, _VH9 /1L(0'J;2L"X6PW!-EJ10K09U(2RF->&L5@:"#!7G(F
MO5Q[*KI:A"ZW6(PQM%>5-+%5GC:O5*@XK52S.JI3PCNH4]H[I53P/*)5_SRA
M5?\[G5;_.II7_SF75_\XEU?_-Y=7_S>75_\WEU?_-_])% #_4PX _UP, /]E
M#0#_:P\ ^F\3 .QR&0#B=",!V',R \YQ0@G';4\2P6I:&KMG9"&W9&TGLV)V
M+*]??S"L7H<TJ5R0-Z=;F3JD6:,\H5FN/I]8O3^=6-% FEGL/YA9_C^76O\^
ME%O_/)%;_SN/6_\ZCUO_.H];_SJ/6_\ZCUO_.O],$@#_5@T _V ) /]H"@#Z
M;PP \W,. .5W$0#:>1L SWDN L=W/@F_=$L1N7!6&K-M8"&O:FDHJF=R+:=E
M>C*C8X,VH&&,.9U@E3R:7I\_EUVJ095=N$*37<M#D%WH0X]>_$&.7_] BU__
M/HI?_SV(7_\\B%__.XA?_SN(7_\[B%__._].$0#_6 H _V,' /IL!@#G<P8
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M/G)N_SYR;O\^<F[_/O]6"@#_8@  YF\  -=Y  #,@0$ Q8<# +^+! "YC@X
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M-D:FZ39%I/XW1:/_-T:@_S=(G/\W29K_-TF:_S=)FO\W29K_-^)T  #*@P
MO(\  +"8  "EG@  FZ0  )"K  "%L0  >K@$ ':Y% !RN24!;;DS!&BX/PAC
MN$D.7K=2$UJV6AA6MF(<4K5K($ZT=21+M( G2+..*D6SG2Q"LZXM0;/%+D&S
MZ2U L/XO/Z__,3ZM_S) J/\R0:;_,D&F_S)!IO\R0:;_,M5\  #"B@  M98
M *B=  "=HP  DJH  (>Q  !\MP  <+X# &C"#@!FPQT 8\,M 5[#.01:PT0(
M5L).#%+"5Q!/P5\42\%I%TC!<QI%P'X=0L",(#_ FR(]P*TC/,'$(SS Z2,Z
MOOXF.+S_*#>[_RDXN/\J.+;_*SBV_RLXMO\K.+;_*\F%  "YDP  K)P  *"B
M  "4J@  B+$  'RX  !QO@  9L4# %O+" !7S1, 5LXC %/.,@%0SCX#3<](
M!4G/4@A&SUL+0\]E#D#/;Q ^SWL3.\^)%3G/F1<WSZL8-M##&#;/Z!@TS?L;
M,LO_'3'*_Q\PR?\A+\C_(2_(_R$OR/\A+\C_(;Z/  "OF@  HJ$  ):I  "*
ML   ?;@  '&_  !FQ@  6\P" %#2!P!'V@P 1MP8 $7<)P!$W34!0=U  C_>
M2P,]WE4$.M]?!CC?:0<UWW8),^"$"S'@E POX:8-+N&\#BWBX XMWO@/*]W_
M$BK<_Q0IVO\6*-K_%BC:_Q8HVO\6*-K_%K.8  "EH   F:<  (NP  !^N
M<<   &7(  !9S@  3M,  $3;!  _Z0T />D7 #OJ(P YZBX -NLX 33K0@$Q
M[$L"+^U5 RWM7P,J[FL$*.YX!2;OB 8E[YH'(_"N!R+QR <B\.T'(>S_!R'K
M_P@@Z_\*'^K_"Q_J_PL?ZO\+'^K_"ZB?  ";I@  C:\  '^X  !QP0  9,H
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M 0#_\P$ __,! /_S 82W  !TP0  9<P  %;8  !'WP  .>4  "WJ   C[@
M'/T  !C_   5_P  $?\$  __"P -_PX "?\1  ;_%0 #_QH  /\@  #_)@
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M*Z-,_RJ?3?\JG4W_*9U-_RF=3?\IG4W_*?]#$0#_2PP _U,( /]:"P#_7@T
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M,'Y?_S!^7_\P?E__,/]-"0#_5@  [F$  -UI  #1;P  RG,# ,5U!@# =A
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M  #F9@  TG$  ,5Z  "[@0  LH<  *N*  "BC ( G(X4 )>/)@&1CC0%BXQ
M"X6*2A& B%,8>X9;'7:%8R)R@VHG;H)R*VJ >R]G?X8S8WZ1-F!]GCE=?*XZ
M6WS!.UM\XSI;?/HX7'O_-UU[_S5>>?\T7W?_,U]W_S-?=_\S7W?_,_Y<  #A
M:@  S74  ,!^  "VA@  KHL  *6.  ";D0  E9,1 )"4(@&+DS$#A9(]"7^1
M2 ]ZCU$6=8U9&W&,8"!LBF@E:(EP*62'>2UAAH,Q786/-%J$G#97@ZPX58._
M.56#X3A5@ODW5H+_-5:!_S18?_\S67W_,EE]_S)9??\R67W_,N]@  #;;@
MQWH  +N#  "RBP  J)   )^3  "4E@  C9D. (F:'@"$FBX"?IDZ!WF710UT
MEDX3;Y56&&J37AUFDF4A8I%M)EZ/=BI;CH$M5XV-,%2,FC-1C*HU3XR]-4^,
MWC5/B_<T3XK_,U")_S)1AO\Q4H3_,5*$_S%2A/\Q4H3_,>IE  #2<P  PG\
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M)3NG_R8[IO\F.Z3_)CND_R8[I/\F.Z3_)LQZ  "[B   KI(  **9  "7G@
MC*0  ("J  !UKP  :;0  %ZY!@!;NA0 6;LD %:[,0%3NST#4+M'!4V[4 =*
MNED*1[IB#42Z;!!!NG<3/KF$%3RYDQ<YN:,8.+FW&3>ZUADWN/0:-;;_'#2T
M_QXSL_\?,[+_(#.R_R SLO\@,[+_(,&#  "TD0  II@  )N>  "/I0  @JL
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M!1CC_P48X_\%&./_!:.=  "6I   B*P  'JU  !LO0  7\0  %/*  !'S@
M/-,  #+:   JWP  )>X) "/P$0 A\1D '_$B !WR*P ;\S0 &?0^ !?T2  5
M]5( $_9? !+V;@$1]X !$/B4 0_YJ@$.^<8!#OGM 0WV_P$-]/\!#?/_ 0WS
M_P$-\_\!#?/_ 9FC  "+K   ?+4  &V^  !?Q@  4LT  $72   YV   +]X
M ";B   ?Z@  '/L& !G_#@ 7_Q, %/\: !+_(0 0_R@ #O\P  W_.0 +_T,
M"?].  ;_7  $_VP  O^   '_E@  _ZT  /_*  #_\   __\  /__  #__P
M__\  /__ (VK  !]M0  ;K\  &#(  !2T   0]<  #?=   KX@  (N8  !GJ
M   5^0  $O\  !#_"  ._PX #/\1  G_%@ &_QP  _\B  #_*@  _S,  /\]
M  #_20  _U<  /]I  #_?@  _Y4  /^L  #_QP  _^@  /_Z  #_^@  __H
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M%,,T_Q7#,_\5P#3_%;\T_Q2_-/\4OS3_%/\V%0#_.Q  _SX- /]##P#_1A0
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M(9%-_R&13?\AD4W_(?]""@#_20  _U$  .97  #=6P$ U5P% -);"0#+7!0
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M,6-LV3!C;/0O8VS_+61L_RMD:_\I96K_*&5J_RAE:O\H96K_*/U3  #C7P
MSFD  ,%Q  "W=P  KWL  *=]  ">?0  F'X1 ). (@".@#$"B7\^!H1]2 Q_
M?%$1>WI9%G=Y8!IS=V@>;W9P(6QU>"5I=((H9G..*V-RFBY@<:@O7G&Z,%UQ
MU#!=<?(N7G'_+%YP_RM?</\I8&__*&!N_RA@;O\H8&[_*/%5  #>8@  RFT
M +UU  "S>P  JX   **"  "8@0  D8,/ (V%'P"(A2X"@X0[!7Z#10IZ@4X/
M=8!6%'%_7AAN?68<:GQM(&=[=B-C>H G8'F+*EUXF"Q:=Z8N6'>X+U=WT2]7
M=_$N6';_+%AV_RI9=?\I6G3_*%IT_R=:=/\G6G3_)^U9  #79@  Q7$  +EZ
M  "O@   IH0  )V&  "1AP  BHD, (:*&P""BRL!?8HX!'B)0@ATB$P-;X=4
M$FR%6Q9HA&,:9(-K'F&"="%=@7TD6H")*%=_EBI5?J0L4GZV+5%^SBU1?>\L
M4GW_*U)\_RE3>_\H5'K_)U1Z_R=4>O\G5'K_)^A>  #0:P  P'8  +1^  "K
MA0  H8D  )>+  ")C0  @X\( 'Z0%P![D2<!=I$T W*0/P9MCTD+:8Y1#V6-
M61-BC& 77HMH&UN*<1Y7B7LA5(B&)%&'E"=/AJ(I38:T*DN&S"I+A>XI3(3_
M*4R#_RA,@_\G38'_)DZ!_R9.@?\F3H'_)N%C  #)<   NWL  +"$  "FB@
MFXX  )&1  "$DP  >I4" '67$@!RF"( ;Y@P FJ7.P1FET4(8I9.#%^55@];
ME%T36)-E%U63;AI1DG@=3I&$($N0D2-)D*$D1Y"R)D60RB9%C^TE18W_)46,
M_R5&B_\D1HK_)$:*_R1&BO\D1HK_)-AI  ##=@  M8$  *N*  "?CP  E9,
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M%B^L_Q8OK/\6+ZS_%KN!  "NC@  H94  )::  ")H   ?:8  '&K  !EKP
M6;0  $ZW  !#O 4 0+T1 #^]'@ ^OBL /+XV #N_00 YOTL!-[]4 C7 7P(S
MP&H$,<!W!2_ A@8MP)<'*\"J""K!P@@JP.<'*;W]"BB\_PPGNO\-)[G_#B>Y
M_PXGN?\.)[G_#K*,  "EE   F9H  (VA  !_IP  <JT  &:S  !:N   3[L
M $2_   ZQ ( ,,D( "[*$0 MRAT +,LI "O+-0 KS$  *LU* "C-5@ GSF$
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M )6A  "&J0  >+(  &FZ  !;P@  3<@  $#,   TT0  *M8  "';   9X
M$N0   _P 0 -^0H "_H/  G[%0 '^QP !/PD  '\+   _#<  /Q"  #\4
M_&$  /UU  #\C   _*0  /S!  #\ZP  _/\  /W_  #]_P  _?\  /W_ (FI
M  !YL@  :KL  %S$  !.S   /]$  #+7   GW0  '>$  !7E   .Z   "O$
M  C]   %_P,  ?\)  #_#@  _Q(  /\7  #_'P  _R<  /\Q  #_/@  _TT
M /]?  #_=0  _XT  /^F  #_P@  _^<  /_\  #__P  __\  /__ 'RS  !L
MO   7<8  $[/   _U@  ,=T  "7B   :Y@  $>H   SN   %\@   /\   #_
M    _P   /\   #_!0  _PH  /\.  #_$@  _Q@  /\A  #_*P  _SD  /]*
M  #_70  _W,  /^,  #_I   _[D  /_4  #_W@  _]X  /_> /\8+ #_&2D
M_QDH /\5*P#_$#  _PLX ?\#1 '_ %$!_P!> ?\ ; '_ '@!_P"" ?\ C '_
M )0!_P"< /\ H@#_ *@ _P"O /\ M@#_ +X _P#( /\ UP#_ .< _P#S /\
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M NH3_P/I$_\#Z1/_ ^D3_P/I$_\#Z1/_ _\F'0#_*!@ _R@6 /\F%@#_)AT
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M#ZXT_P^N-/\/KC3_#_\U#@#_. < _SP" /] !@#_00L ^D$/ .T_%@#C/"(
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M)7%9TB5P6O C;UK_(F]:_R!P6O\><%K_'7!:_QQP6O\<<%K_'/](  #G4@
MTUL  ,5B  "[9@  LV@  *QH  "E9@4 GV<4 )II)0"5:30"D&A !(QG2@B(
M9E,,A&5;$(%D8A-^8VH6>V)R&7AA>AQV8(0><U^.(7!>FB-N7J@E;%VX)6I>
MSB9I7NXD:5[_(FI>_R!J7O\?:E[_'FI>_QUJ7O\=:E[_'?E*  #C50  SU\
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M(UEK_R%::_\?6VO_'EMJ_QY;:O\>6VK_'NM3  #38   PFD  +9Q  "L=@
MHWD  )EY  "-=P  AWD+ (-[& !_?"@ >WPU G=[0 5S>DD(;WE1#&QX60]H
M=V$3979H%F)U<!E?='H<7'2%'UISD2%7<J C57*P)%-RQ213<N<D4W'\(E1Q
M_R!4</\?57#_'E5O_QU5;_\=56__'>57  #-9   OFT  +)U  "H>P  GWX
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M&D*$_QI"A/\:0H3_&LUG  "\=   KWX  *6&  ":B@  CHP  (*-  !UD
M9Y0  &&5" !>EQ0 7)<C %J8+P!7F#H!5)A$ U*73 5/EU0'3)=<"4F690Q'
MEF\.1)5Z$4&5B!,_E)<5/92H%CN4O18[E-\6.I+X%SJ0_Q<ZC_\7.H[_%SJ.
M_Q<ZCO\7.H[_%\5N  "V>P  JH4  )Z+  "4CP  B)(  'N4  !NEP  8IL
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M!ZV*  "@D0  E9<  (B=  ![HP  ;J@  &&M  !5L0  2K0  #^W   TNP
M*[X# "3"#  BPA0 (L,? "'#*@ @Q#0 '\0_ ![%2@ =QE8 ',9C !O'<P :
MQX4 &<>9 !C(K@ 7R,L %\;Q 1?$_P$6P_\"%L'_ Q;!_P,6P?\#%L'_ Z.1
M  "8F   BYX  'VE  !PJP  8K$  %:V  !*N0  /KT  #3    JQ   (L@
M !G,!  3T H $=(1 !#2&@ 0TR4 #],P  [4/  .U$@ #=56  W590 ,UG@
M#-:-  O8I  *V+X "=GF  K6_@ +U/\ "]+_  O2_P$+TO\!"]+_ 9J8  ".
MGP  @*8  '*M  !DM   5[H  $F_   ]P@  ,L8  "C)   ?S0  %]$  !'6
M   ,VP4 "-X+  ;?$0 %WQH !. D  +A+@ !XCH  .-'  #D5@  Y&<  .5[
M  #FD@  YJH  .?(  #G\   Z/\  .C_  #H_P  Z/\  .C_ )&?  ""IP
M=*\  &6W  !7O@  2<,  #S'   PRP  )<\  !S4   4V0  #MT   GA   "
MY0   .D&  #I#0  Z1$  .H8  #K(0  [2L  .\W  #Q10  \E8  /-H  #S
M?@  ])<  /6P  #VT   ]_,  /?_  #W_P  ]_\  /?_ (6G  !VL   9K@
M %C!  !*R   .\P  "[1   CU@  &=P  !'@   ,XP  !.<   #J    ]0
M /0   #U!0  ]0L  /8/  #V%   ^!T  /HG  #\-   _T,  /]5  #_:0
M_X$  /^:  #_L@  _\\  /_M  #_^0  __D  /_Y 'BP  !HN@  6<,  $O+
M   [T0  +=@  "'=   6X@  #N8   CJ    [0   /    #X    _P   /\
M  #_    _P   /\&  #_#   _Q   /\8  #_(@  _S   /]   #_4P  _VD
M /^!  #_F0  _Z\  /_#  #_U0  _]4  /_5 /\3* #_$R4 _Q$E /\-)P#_
M!BT _P U /\ 00#_ $\ _P!< /\ :0#_ '0 _P!^ /\ B #_ )  _P"7 /\
MG0#_ *0 _P"J /\ L #_ +< _P#  /\ S #_ -\ _P#L /\ ^ #_ /\ _P#_
M /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\6)0#_%B( _Q0A /\0(P#_"B@
M_P P /\ /0#_ $L _P!8 /\ 9 #_ '  _P!Z /\ A #_ (P _P"3 /\ F@#_
M *  _P"F /\ K0#_ +0 _P"\ /X R #] -D ^P#I /H ]@#Y /\ ^ #_ /@
M_P#X /\ ^ #_ /D _P#Y /\ ^0#_ /\:(@#_&AX _Q@= /\3'@#_#B( _PHL
M /\'.0#_ T8 _P!3 /\ 8 #_ &L _P!V /\ ?P#_ (@ _P"/ /\ E@#_ )T
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M M(3_P+2$_\"TA/_ O\E$P#_)1  _R0- /\C#@#_(Q0 _R(> /\?*0#_'#4
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M%H1&T1:"1^X6@$?_%7]'_Q1_1_\2?T?_$7]'_Q%_1_\1?T?_$?\[  #N0P
MW$P  ,Q1  #!5   N50  +11  "N30L J$\9 *-1*0">4C<!FE)# I=13@24
M458&D5!>"8Y/9@N,3FT-B4YU#X=-?A&%38<3@DR1%8!,G!9^2ZD7?$NX&'M+
MS1AY3.L8>$S^%W=,_Q5W3/\4=TS_$W=,_Q)W3/\2=TS_$O\^  #H1P  U5
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M&F19_QAD6?\795G_%659_Q1E6?\495G_%.]&  #:4@  QEL  +IA  "P90
MIF8  )UC  "580  CV(. (MD' "'92L @V4W 7]E0@-\9$L&>&-3"'5C6PMS
M8F(.<&%J$&U@<A-K8'L5:%^&%V9>D1EC7I\;85VN'&!=P1Q?7>$<7UWX&E]=
M_QA?7?\78%W_%F!=_Q5@7?\58%W_%>M*  #45@  PUX  +9E  "L:0  HFD
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M%E!J_Q50:O\54&K_%=U5  #%80  MVH  *QQ  "B=0  E'0  (ET  !\<P
M=G4  '%W$ !O>!T ;'DK &EY-P%F>4 #8WE)!6!X40===U@)6W=@#%AV: Y5
M=7$14G5\$U!TB!9-=)<72W.F&$ESN1E(<]4927+S&$EQ_Q=*<?\62G#_%4MP
M_Q1+</\42W#_%-1:  # 9@  LV\  *AV  "=>0  CW@  (1X  !W>0  ;WP
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M#[YM  "P>0  I8(  )F'  ",B   ?X@  '**  !FC0  6I$  %"5  !)EPD
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M 1RRJ0$;LL$!&['G 1NO_@(:K?\"&JS_ QJK_P,:J_\#&JO_ ZB(  ";CP
MD90  (2:  !VGP  :*(  %NE  !/J0  1*T  #FP   OLP  )K8  !ZY!0 8
MNPX %[L6 !>\(  6O"H %;TU !2]0  3ODL $KY8 !*^9P 1OW@ $+^, !#
MH@ .P+H #L#A  ^]^P /O/\ $+K_ 1"Z_P$0NO\!$+K_ 9^/  "4E0  AYL
M 'FA  !KIP  7JP  %*Q  !%M   .K8  "^Y   EO   ';\  !7#   /Q@4
M"\H-  G*%  (RAT !\HG  ?*,@ &RSX !<M+  3,6@ #S&H  LQ^  ',E
MS*L  ,W(  #,[0  S/\  ,O_  '*_P !RO\  <K_ )>6  "*G   ?*,  &ZJ
M  !@L   4K8  $6Y   YO   +K\  "/#   ;Q@  $\H   W-   (T0   =0)
M  #4#@  U14  -8>  #8)P  V3$  -L^  #<2P  W5L  -YN  #>A   WYL
M -^T  #>V0  W_<  -__  #?_P  W_\  -__ (V=  !_I0  <*P  &&S  !3
MN@  1;\  #C"   LQ@  (<D  !C-   0T0  "]4   3:    W@   . !  #A
M"0  X@X  .03  #E&P  YR0  .DO  #K/   [4L  .Y=  #N<0  [XD  /"B
M  #PO   \.,  ._Y  #P_P  \/\  /#_ (&E  !RK0  8[4  %2]  !&Q
M-\@  "K,   ?T   %=4   [:   'W@   .(   #F    Z0   .H   #L
M[@4  .\,  #Q$   \Q<  /4@  #X*P  ^SD  /U*  #^7@  _W0  /^-  #_
MI@  _\   /_A  #_]0  __4  /_U '2N  !EMP  5L   $?(   XS0  *M(
M !W8   3W0  #.(   /F    Z0   .P   #P    \P   /0   #V    ^
M /H   #]!P  _PT  /\2  #_&P  _R@  /\W  #_2@  _UX  /]V  #_CP
M_Z8  /^Z  #_T0  _]$  /_1 /\/) #_#B( _PLA /\#) #_ "D _P R /\
M/@#_ $P _P!9 /\ 90#_ '  _P!Z /\ A #_ (P _P"2 /\ F0#_ )\ _P"E
M /\ JP#_ +( _P"Z /\ Q0#_ -, _P#G /\ ] #_ /\ _@#_ /\ _P#^ /\
M_@#_ /X _P#^ /\ _@#_ /\1(0#_$!X _PT= /\''P#_ ", _P M /\ .@#_
M $@ _P!5 /\ 80#_ &P _P!V /\ ?P#_ (< _P". /\ E0#_ )L _P"A /\
MIP#^ *X _0"V /P P #[ ,T ^0#B /@ \ #W /P ]@#_ /4 _P#U /\ ]0#_
M /4 _P#U /\ ]0#_ /\5'0#_$QH _Q 9 /\+&0#_ !T _P I /\ -@#_ $,
M_P!0 /\ 7 #_ &< _P!Q /\ >@#^ (, _ "* /H D0#Y )< ^ "= /< HP#U
M *H ] "R /( NP#Q ,@ [P#< .X [ #M /H ZP#_ .H _P#J /\ Z@#_ .H
M_P#J /\ Z@#_ /\8&0#_%A4 _Q,3 /\.$P#_"QH _P<D /\", #_ #X _P!+
M /\ 5P#_ &( _ !L /@ =0#U 'X \@"% /$ C #O ), [@"9 .P H #K *8
MZ0"N .< MP#F ,, Y #4 .( Z0#A /< WP#_ -T _P#= /\ W0#_ -T _P#=
M /\ W0#_ /\;$P#_&A  _Q8. /\2#@#_$A4 _P\? /\,*P#_"3@ _P9% /L#
M40#W EP \@)F .X"< #J G@ YP*  .8#AP#D XX X@.5 .$#G #?!*, W02K
M -L$M #8!<  U@70 -,&YP#0"/@ S@K_ ,P+_P#+#/\ RPS_ ,L+_P#+"_\
MRPO_ /\?$ #_'@L _QH' /\9"P#_&!$ _Q89 /\2) #Z$#  \PX^ .X-2@#I
M#%8 Y0QA .(,:@#>#7, VPU[ -D-@P#6#8H U V1 -(-F0#0#J  SPZI ,T.
MLP#+#K\ R@_0 ,81Z0#"$OD OQ/_ +T3_P&\$_\!O!/_ ;P3_P&[$_\!NQ/_
M ?\B# #_(00 _R   /\A!0#_'PP _QP1 /88' #L%2@ Y1,V -\20P#9$T\
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M60"R+&(!L"QJ :XM<@&L+7H"JBV! JDMB@*G+9(#I2V; Z0MI02B+;$$H"W
M!)\MV 2<+N\%F2[_!I<O_P:6+_\&E2[_!94N_P65+O\%E2[_!?\L  #_+@
MZC4  -TY  #1.0  RC8  ,<O!@#!+1$ NC A +0R,0"P-#X K#5* *DU5 &G
M-5T!I#5E J(U;0*@-70#GS5\!)TUA 2;-8T%FC27!I@TH0:6-*T'E#6["),U
MT B0->P(CC;^"(PV_PB+-O\(BS;_!XHU_P>*-?\'BC7_!_\O  #R-   XCP
M -)!  #'0@  P$   +LZ 0"V-@X L#D< *H[+ "F/#H HSU& )\]4 &=/5D"
MFCUA Y@]: 26/' %E#QW!I(\@ >1/(@'CSN2"(T[G0F+.ZD*B3NW"X@[R@N%
M/.@+@SS["X(\_PJ!//\*@3S_"8$\_PB!//\(@3S_"/\S  #L.@  VD,  ,I'
M  "_20  MT<  +%"  "M/@H ID 7 *)")P">0S4 FD1" 9=$3 &41%4"D4-=
M X]#9 6-0VL&BT)S!XE">PB'0H0*A4&."X-!F0R!0:4-?T&S#GY!Q@Y\0>0.
M>D+Y#7E"_PQX0O\+>$+_"WA"_PIX0?\*>$'_"O8V  #F0   T4@  ,--  "Y
M3@  L4T  *E)  "D108 GT83 )I((P"623( DDH^ 8]*2 *,2E$#BDE9!(=)
M8 6%26@'@TAO"(%(=PI_1X +?4>*#7I'E0YX1J(/=D:P$'5&PA!S1N 0<D?W
M#W%'_PYQ1_\-<4?_#'%'_PMQ1O\+<4;_"_,Y  #@1   S$P  +Y1  "T4P
MJE(  *).  "=2@$ ETL1 )--( "/3RX C$\Z 8A/10*%3TX#@T]6!(!.709^
M3F0'?$UL"7E-= MW3'T,=4R'#G-,D@]Q2Y\1;TNM$FU+OQ)L2]P2:TSU$6I,
M_P]J3/\.:DO_#6I+_PQJ2_\,:DO_#/ ]  #;2   QU   +I5  "P6   I58
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M#EI7_PU:5_\-6E?_#>-(  #+4P  NUL  +!A  "D8@  EV$  (Y?  "%7
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M#<M8  "Z8P  K6P  *%Q  "2<   A6\  'IO  !N<   97,  &!U!P!==A(
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M!S*'J@<PB, ',(?D!S"%^P@P@_\(,(+_"#"!_P@P@?\(,('_"+=K  "J=@
MH'\  )!^  ""?@  =G\  &J   !>@P  4X<  $J+  !!C@( /9 . #N0&  Z
MD2, .9$M #B2-P WDD  -I)) #234@ SDUP!,9-G 2^3= (MDH,#*Y*4 RJ2
MIP,HDKT$*)+A R>0^@0GCO\%)XW_!2>,_P4GC/\%)XS_!;%T  "E?@  F84
M (J$  !]A   ;X4  &.(  !8BP  38\  $.3   ZEP  ,IH' "Z;$  MFQH
M+)PD "N<+@ JG3@ *9U! "B=2P GGE4 )IYA "6>;@ CGGX!(IZ0 2">HP$?
MGKD!'I[= 1Z<^ (>FO\"'IG_ QZ7_P,>E_\#'I?_ ZI]  ">A0  DXL  (6*
M  !UBP  :(X  %N1  !0E0  1ID  #N=   RH   *J,  "*F"0 ?IQ$ 'J<:
M !VH)  <J"T &Z@W !JI00 9J4P &*E8 !>J9@ 6JG8 %:J) !2JG@ 3J[0
M$JO3 !*H]0 3I_\!$Z7_ 1.E_P$3I/\!$Z3_ :.&  "7C   C9$  'V2  !M
ME0  8)@  %2<  !(H   /J0  #2G   JJP  (:X  !FQ   2LP< #[40  ZU
M%P .M2$ #;4K  VU-@ ,MD$ "[9.  JV7  )MFP "+9_  >VE  &MJH !;;%
M  :VZ@ 'M?\ "+3_  BS_P )LO\ ";+_ )J-  "0DP  A)@  '2<  !EH
M5Z0  $NH  ! K   -;   "JS   AM0  &+@  !&[   ,O@( !L +  + $0 !
MP1D  ,$B  #"*P  PC8  ,-"  ##4   Q%\  ,1Q  #$AP  Q)T  ,2U  #$
MV@  Q/8  ,/_  ##_P  P_\  ,/_ ).4  "'F@  >*   &JF  !<K   3[$
M $&U   UMP  *;H  !^]   6P   $,,   K&   #R@   ,P%  #,#   S1$
M ,X8  #.(0  T"H  -$U  #30P  U%(  -1C  #5>   U8\  -6G  #6P@
MUND  -;]  #6_P  UO\  -;_ (J;  ![H@  ;*D  %ZP  !0M@  0KH  #2]
M   HP0  '<0  !3'   -RP  !LX   #2    UP   -D   #:!0  W L  -T0
M  #?%0  X1T  .,G  #E,P  YT(  .A4  #H9P  Z7X  .F7  #JKP  ZLX
M .OO  #K_@  Z_\  .O_ 'VC  !NJP  7[(  %&Z  !"P   -,,  "?'   ;
MRP  $L\   O3   "V    -T   #A    Y    .4   #G    Z0   .L'  #M
M#0  [Q$  /$9  #T)   ]S$  /E!  #Z50  ^FH  /N$  #[G0  _+8  /S2
M  #][0  _?0  /WT '&L  !AM0  4KT  $3$   TR0  )LT  !K2   0V
M"-T   #A    Y0   .@   #L    [P   /$   #S    ]0   /<   #Y 0
M^P@  /X.  #_%0  _R$  /\O  #_00  _U8  /]M  #_AP  _Z   /^V  #_
MR@  _]0  /_4 /\+( #_!QX _P = /\ ( #_ "4 _P N /\ .P#_ $D _P!6
M /\ 8@#_ &T _P!V /\ ?P#_ (< _P". /\ E #_ )H _P"@ /\ I@#_ *T
M_P"U /\ O@#_ ,L _P#A /\ \ #^ /T _0#_ /T _P#] /\ _0#_ /P _P#Y
M /\ ^0#_ /\-'0#_"QH _P09 /\ &@#_ !\ _P J /\ -P#_ $4 _P!1 /\
M7@#_ &@ _P!R /\ >@#_ (( _P") /\ D #_ )8 _P"< /X H@#\ *D ^P"P
M /D N0#X ,8 ]@#9 /4 ZP#T /D \P#_ /( _P#S /\ \P#_ /, _P#S /\
M\P#_ /\0&0#_#A4 _P@4 /\ % #_ !D _P E /\ ,@#_ $  _P!, /\ 60#_
M &, _@!M /P =0#Z 'T ^0"$ /< BP#V )$ ] "7 /, G@#R *0 \ "L .X
MM #M ,  ZP#/ .D Y@#H /4 Y@#_ .< _P#F /\ Y0#_ .4 _P#E /\ Y0#_
M /\2% #_$!  _PP/ /\#$ #_ !4 _P @ /\ + #_ #H _P!' /H 4P#W %X
M] !G /$ < #O '@ [0!_ .L A@#J (P Z "3 .< F0#E *  XP"G .$ L #?
M +H W0#) -L X #8 /  UP#^ -4 _P#4 /\ TP#_ -, _P#3 /\ TP#_ /\5
M$ #_$@P _PX) /\+# #_"1( _P,: /\ )@#] #, ] !  .\ 30#K %@ Z !A
M .4 :@#B '( X !Z -X @ #< (< V@". -@ E0#4 )P T@"C -  K #. +8
MS #$ ,H V0#( .T QP#[ ,4 _P#$ ?\ PP'_ ,0!_P#$ ?\ Q '_ /\8"P#_
M%04 _Q   /\0!@#_#PT _PP4 /P''P#Q RL YP Y .( 1@#> 5$ V@); -4"
M9 #2 VP SP-T ,T$>P#+!(( R@2) ,@%D #&!9@ Q 6@ ,(&J0#!!K0 OP;!
M +T(U0"[">P N O] +8,_P"U#?\ M W_ +0-_P"T#?\ M W_ /\;!0#_&
M_Q<  /\6  #[$P8 ^A . .X,%@#C"2( V@DP -,*/@#."TH R@Q5 ,<-7@#%
M#6< P@YO ,$.=@"_#GX O0^% +P/C0"Z$)4 N!"= +<0IP"U$;( LQ'  +(1
MU0"N$^X JQ3^ *D5_P"G%?\ IQ7_ *84_P&F%/\!IA3_ ?\?  #_'   ^AX
M .L>  #C'   WQ4% -X.#0#3#A@ RQ$H ,43-P# %$0 O!9/ +D760"W%V$
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M!(4O_P2$+_\#A"__ X,O_P.#+_\#@R__ _LI  #K,0  V3@  ,D\  "_/
MMCD  + R  "L+0L IR\7 *(Q)@">,S0 FC1  )@U2@"5-5, DS5; 9$U8@&/
M-6D"C35Q HPU>0.*-8(#B#6+!(8UE@2$-:(%@C6O!8$UP 9_-MP&?3;T!GLV
M_P5[-O\%>C;_!'HV_P1Z-?\$>C7_!/4M  #D-P  T#\  ,)#  "W1   K4
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M!V1&_P9D1?\&9$7_!N@[  #01@  OTT  +-1  "E40  FDX  ))+  "-1P
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M!]-*  # 5   LEP  *->  "570  B5P  '];  !V60  <%H  &M<#0!H71@
M9EXD &1?, !B7SH 8%]# 5Y?2P)<7U("6E]: UA?80557FH&4UYT!U%=?PE/
M78T*35V<"TM=K Q*7<$,25WC#$E<^@I)6_\)2EO_"$I:_PA*6O\'2EK_!\Y.
M  "\6   KF   )]A  "18   A5\  'M?  !P70  :E\  &5A"@!B8A0 8&,A
M %YD+0!<9#< 6F1  5AD2 %69% "5&17 U)D7P109&<%3F-Q!DQC?0A)8HL)
M1V*:"D9BJ@M$8K\+1&+A"T1A^0I$8/\)1&#_"$5?_P=%7_\'15__!\A2  "X
M7   JV0  )MD  ",8P  @&,  '9C  !J8@  8V0  %]F!@!;9Q$ 66@= %=I
M*0!6:C, 5&H\ %)J10%0:DP!3FI4 DQJ7 -*:F4$2&EO!49I>@=$:8@(0FB8
M"4!HJ0H_:+T*/FC>"3YG]PD^9O\(/V7_!S]E_P<_9/\'/V3_!\-7  "S80
MIVD  )9H  "'9P  >V<  '%G  !E:   7&H  %AL 0!4;@X 4F\8 %!O) !.
M<"X 37 X $MQ00!*<4D!2'%1 49Q60)$<&(#0G!L!$!P> 4^<(8&/&^5!SIO
MI@@X;[L(.&_;!SAN]@<X;?\'.&S_!CEK_P8Y:O\&.6K_!KU<  "O9@  HFT
M )%L  "":P  =VL  &QL  !A;@  5W   %!S  !,=0H 2783 $=W'P!&=RD
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M 2&*\0$@B/\"((;_ B"%_P(AA?\"(87_ JMR  "A?   CWL  (!Z  !S>@
M9GP  %M_  !0@@  1H8  #R*   TC0  +)$  ":3#  DE!, (Y0< "*5)@ A
ME2\ ()4X !^60@ >EDP '998 !R69  :EW0 &9>& !B7F0 7EZX %9?) !:5
M[@ 6D_\!%I+_ 1:1_P$6D/\!%I#_ :5[  "9@P  B8$  'N   !L@@  7X0
M %2(  !)BP  /Y   #64   MEP  )9H  !V> 0 6H P %*$2 !2A&P 3H24
M$J$N !&B.  1HD, $*)/  ^B7  .HVL #:-]  VCD@ ,HZ< "J+   NBY@ ,
MH/X #9__  V>_P -G?\ #9W_ )Z$  "2B0  @X@  '.(  !EBP  6(X  $R2
M  !!EP  -YL  "Z>   DH@  '*4  !6H   /JP0 "JX,  >M$@ &K1L !:TD
M  2N+@ "KCD  :Y%  "N4@  KF$  *YS  "NAP  KIT  *ZT  "NU0  K?0
M *W_  "L_P  J_\  *O_ ):+  ",D   >Y   &N2  !=E@  4)H  $2?   Y
MHP  +Z<  "6K   <K@  %+$   ZT   )MP   ;@)  "X#@  N10  +D<  "Z
M)0  NB\  +LZ  "\1P  O%8  +QG  "\>P  O)$  +RI  "\Q   O.L  +O^
M  "[_P  N_\  +O_ )"2  "#F   <YL  &.?  !5HP  1Z@  #NM   PL0
M);0  !NW   2N@  #+T   6_    PP   ,0"  #%"@  Q0X  ,84  #'&P
MR"0  ,HN  #,.@  S4D  ,U9  #-;   SH,  ,Z;  #-M0  SMH  ,[V  #-
M_P  S?\  ,W_ (:9  !WH   ::8  %JL  !,L@  /K8  #"Y   DO   &;\
M !'"   *Q0   LD   #,    T    -$   #2 0  TP@  -4-  #7$0  VA@
M -PA  #?+   X3H  .)*  #C70  Y'(  .2+  #EI0  Y<   .7F  #E^
MY?\  .7_ 'JA  !KJ0  7*\  $VV   _O   ,+\  "/#   7QP  #\H   ?.
M    T0   -8   #<    WP   .    #B    Y    .8#  #H"0  Z0X  .P5
M  #N'@  \2L  /0Z  #U30  ]F$  /=Y  #XDP  ^*T  /G&  #YY   ^?,
M /GS &VJ  !>L@  3[H  $#!   QQ0  (LD  !;.   -T@  !-@   #=
MX0   .0   #H    ZP   .T   #O    \0   /,   #V    ^ ,  /H+  #]
M$0  _QL  /\I  #_.P  _T\  /]F  #_?P  _YD  /^O  #_PP  _]8  /_6
M /\$' #_ !D _P 9 /\ ' #_ "( _P K /\ . #_ $8 _P!3 /\ 7@#_ &D
M_P!R /\ >@#_ (( _P") /\ CP#_ )4 _P"; /\ H0#_ *@ _P"O /\ N0#_
M ,4 _P#9 /X [ #] /L ^P#_ /L _P#[ /\ ^@#_ /0 _P#P /\ \ #_ /\'
M& #_ 14 _P 4 /\ %@#_ !L _P F /\ - #_ $( _P!. /\ 6@#_ &0 _P!M
M /\ =0#_ 'T _P"$ /\ B@#] )  _ "6 /H G0#Y *, ^ "K /< M #U +\
M] #. /, Y@#Q /8 \ #_ .\ _P#O /\ [@#_ .X _P#J /\ Z@#_ /\+% #_
M!A$ _P 0 /\ $ #_ !8 _P B /\ +@#_ #P _P!) /\ 5 #^ %\ ^P!H /D
M< #W '@ ]0!_ /, A0#R (L \ "2 .\ F #M )\ [ "F .H K@#H +D YP#'
M .4 W@#C /  X@#^ .  _P#@ /\ X0#_ .$ _P#A /\ X0#_ /\-$ #_"0T
M_P$, /\ # #_ !( _P < /\ * #\ #8 ^0!# /8 3@#R %D [P!B .P :P#J
M '( Z !Y .8 @ #D (8 X@", .$ DP#? )H W0"A -L J@#8 +0 U0#  -(
MTP#0 .H S@#Z ,T _P#- /\ S0#_ ,P _P#, /\ S #_ /\0# #_# < _P,"
M /\ " #_  X _P 6 /8 (@#P "\ [  \ .D 2 #E %, X0!< -X 90#; &P
MUP!S -0 >@#2 (  T "' ,X C@#, )4 R@"= ,@ I0#& *\ Q "[ ,( RP#
M .4 O@#U +T _P"\ /\ O #_ +P _P"\ /\ O #_ /\1!0#_#@  _PH  /\(
M 0#_! H ^  0 .D &@#C "@ W@ U -D 00#3 $P SP!6 ,L 7P#) &8 Q@!N
M ,0 = #" 'L P0"" +\ B0"] )  O "8 +H H0"X *L M@"W +0 QP"R .
ML0'R *\"_P"N _\ K03_ *T$_P"M!/\ K03_ /\4  #_$   _P\  /(-  #J
M"@  Z0,) -T $@#4 !\ S0$M ,@".@#$ T4 P -0 +T$60"[!6$ N05H +<&
M;P"U!G8 M =] +('A "Q"(P KPB5 *T)G@"K":@ J@JU *@*Q0"F"]\ I WT
M *(._P"@#O\ GP[_ )\._P"?#O\ GP[_ /\7  #_$P  [Q@  .09  #;%@
MTA " ,\)"P#("!8 P0HD +P,,@"W#3X M Y) +$.4P"O$%L K1!C *L0:@"I
M$7$ J!%X *81@ "E$8@ HQ*1 *$2FP"@$Z8 GA.S )P3PP";%-X EQ;T )46
M_P"4%_\ DQ?_ )(7_P"2%O\ DA;_ /\:  #T'0  Y2,  -4E  #*)   PAT
M +X6! "[$!  M!,= *\5*P"K%C@ IQA# *4930"B&58 H!I= )X;90"=&VP
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M G,O_P)S+_\"<R__ O J  #<-0  QSL  +H_  "L/   HC@  )PS  "8+P
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M ]H]  #$1P  M4X  *1.  "63   BTL  (-)  !]10  >$8" '1'$ !P2!L
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M!DM3IP=)4[H'2%/5!TA2\P9(4O\%2%'_!$E1_P1)4/\#25#_ \I(  "Y4@
MJE<  )A6  "*50  ?U0  '93  !L40  9U,  &)4" !?5A( 75<> %M7*0!9
M6#, 6%@\ %991 !564P!4UE3 5%96P)/6&0"35AM TM8> 1)6(8%1U>5!D57
MI09$5[@&0UC2!D-7\@9#5O\%0U7_!$15_P1$5/\#1%3_ \9,  "U5@  I5H
M )19  "&6   >U@  '%7  !F5@  85@  %U9! !96A  5UL; %5<)@!373
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M S%H[0,Q9_\#,6;_ S)E_P,R9/\#,F3_ [=;  "I9   EF0  (9C  !X8P
M;6,  &1D  !990  4&@  $EK  !#;00 0&X. #YO&  ];R( /' K #IP-  Y
M<3T .'%% #=Q3@ V<5< -'%A 3)Q;0$Q<7H!+W&* BUQG (K<:\"*G'( BIP
MZP(J;_\"*FW_ BIL_P(K;/\"*VS_ K%A  "D:0  D&@  (!G  !T9P  :6<
M %]H  !5:P  2VX  $-Q   \=   -W8* #1W$@ S>!P ,G@E #%Y+@ P>3<
M+WD_ "YY2  L>E( *WI< "IZ:  H>G8 )GJ' 25ZF0$C>JP!(GK% 2)YZ0$B
M=_\!(G;_ 2)U_P(B=/\"(W3_ JQH  "=;@  BFT  'ML  !O;   96P  %IN
M  !0<0  174  #UX   V?   +G\" "F!#0 G@A0 )H(> "6")P D@B\ (X,X
M "*#0@ A@TL ((16 !^$8@ >A'$ '(2" !N$E0 :A*D &(3! !B#Y@ 8@?T
M&8#_ 1E__P$9?O\!&7[_ :9P  "5<P  A'(  '9Q  !K<0  7G,  %1V  !)
M>0  /WT  #>!   OA   )X@  ""+!0 ;C0X &HT5 !F-'@ 8CB< %XXP !:.
M.0 5CD, %(]/ !./6P 2CVH $8][ !"/CP /CZ0 #H^[  V/X  .C?H #XO_
M !"*_P 0B?\ $(G_ *%Z  ".>0  ?G<  ')W  !D>   6'L  $U^  !"@@
M.88  "^*   GC@  ()$  !B5   2F 4 #IH.  V:%  ,FAT "YHF  N:,  *
MFCL "9I&  B:4P &FV$ !9IR  2:A@ "FIL  )JQ  &9SP "F?   IC_  27
M_P %EO\ !9;_ )F!  "'?P  >GX  &M^  !=@0  4(4  $6)   [C0  ,9(
M "B6   ?F0  &)T  !&@   ,HP( !J4*  &E$   I18  *8?  "F*   IC(
M *<]  "G2@  IU@  *=H  "G?   IY$  *:H  "FPP  I>D  *7\  "E_P
MI/\  *3_ )&'  ""A@  <H8  &.(  !5C   29$  #V6   RF@  *)X  !^B
M   7I@  $*D   NL   $KP   +$&  "Q#   LA$  +(7  "S'P  LR@  +0R
M  "U/P  M4T  +5=  "U<   M88  +6=  "UM@  M=P  +3W  "T_P  M/\
M +3_ (N/  !ZC@  :I$  %N5  !-F@  0)\  #6D   JJ   (*P  !:P   /
MM   ";<   &Y    O0   +X   "^!@  OPP  , 0  #!%@  PAT  ,,G  #%
M,@  QD   ,91  #'8P  QW@  ,>1  #'J0  Q\<  ,?L  #'_@  Q_\  ,?_
M (.7  !QF@  89X  %*C  !%J0  .*X  "RS   @MP  %KH   Z]   &P
M ,,   #'    R0   ,H   #,    S0,  ,X)  #0#@  TA,  -0;  #8)0
MVS(  -U"  #=5   WFD  -Z!  #>G   W[4  -_9  #?\P  W_\  -__ '>?
M  !HI@  6:T  $JS   [N   +;L  !^_   4P@  #,8   /)    S    -
M  #5    V0   -H   #<    W@   .    #B!0  Y L  .<0  #J&   [20
M / R  #Q1   \E@  /-O  #TB@  ]*0  /2_  #TWP  ]/,  /3T &JH  !;
MKP  3+<  #V]   MP0  '\8  !/*   +S@   -(   #7    W    .    #E
M    YP   .D   #K    [0   .\   #Q    \P   /8'  #Y#@  _!8  /\B
M  #_,P  _T<  /]=  #_=@  _Y$  /^I  #_O@  _]@  /_; /\ & #_ !8
M_P 5 /\ & #_ !X _P G /\ -@#_ $, _P!/ /\ 6@#_ &0 _P!M /\ =0#_
M 'T _P"$ /\ B@#_ )  _P"6 /\ G #_ *, _P"K /\ M #^ +\ _0#/ /L
MYP#Z /@ ^0#_ /D _P#Y /\ ]0#_ .X _P#I /\ YP#_ /\ % #_ !$ _P 1
M /\ $@#_ !< _P C /\ ,0#_ #X _P!* /\ 5@#_ &  _P!H /\ < #_ '@
M_0!^ /P A0#Z (L ^0"1 /@ F #W )X ]0"F /0 K@#R +D \0#' .\ X #N
M /( [ #_ .P _P#L /\ ZP#_ .4 _P#@ /\ W@#_ /\#$ #_  X _P - /\
M#0#_ !, _P > /\ *P#_ #@ _P!% /X 4 #[ %H ^ !C /4 :P#S '( \0!Y
M .\ ?P#N (8 [ ", .H D@#I )D YP"@ .8 J0#D +, X0#  .  TP#> .L
MW #[ -L _P#: /\ V@#_ -D _P#4 /\ T@#_ /\'#0#_  D _P & /\ "0#_
M  \ _P 8 /L )0#X #( ]0 _ /( 2@#M %0 Z@!= .< 90#D &P X@!S .
M>@#> (  W "& -H C0#7 )0 U "; -( I #/ *T S0"Y ,L R0#) .0 R #V
M ,8 _P#% /\ Q@#_ ,< _P#' /\ QP#_ /\*!@#_ 0  _P   /\ ! #_  L
M]  2 .\ 'P#J "P Y0 X .( 0P#= $X V0!7 -0 7P#1 &< S@!M ,P = #*
M 'H R "  ,8 AP#% (X PP"6 ,$ G@"_ *@ O0"S +H P@"Y -L MP#P +4
M_P"V /\ M0#_ +4 _P"U /\ M0#_ /\,  #_!   _P   /X   #V  , Z  -
M .  %P#9 "0 T0 Q ,T / #* $< Q@!1 ,, 60#  &  O@!G +P ;@"Z '0
MN0![ +< @@"U (D LP"1 +( F@"P *0 K@"O *P O0"J -  J #K *< ^P"F
M /\ I@#_ *4 _P"E /\ I0#_ /\-  #_!P  ] D  .H)  #B!   V@ ' ,\
M$0#( !P P@ I +X -0"[ $  MP!* +0 4P"R %L L !B *X : "L &\ JP!U
M *D ?0"H (0 I@"- *0 E@"C *  H0"K )\!N0"= \P G 3H )H&^0"9!_\
MF C_ )<(_P"7"/\ EPC_ /\0  #W$   Z!0  -P5  #.$0  Q@T  ,($"P"\
M !0 MP$A +(#+@"N!3H JP9$ *@(30"F"%4 I E< *(*8P"@"FH GPMQ )T+
M> "<"X  F@R) )D,DP"7#)X E0VJ )0-N "2#<P D [J (X0_ ",$/\ BQ#_
M (L0_P"+$/\ BA#_ /L3  #M&@  W2   ,PA  "_'0  MQ<  +,1  "R"PT
MJPT9 *<.)@"C#S, GQ ^ )T11P":$5  F!)7 )827@"5$V4 DQ-L )(3<P"0
M%'P CQ2% (T5CP"+%9H BA6G (@6M0"&%LD A!?G ((8^P" &?\ ?QG_ '\9
M_P!_&/\ ?QC_ /4:  #D(P  SRD  , J  "S)@  JB(  *4<  "D%0@ H!03
M )L6(0"7&"T E!DX )$:0@"/&TL C1Q2 (L<60")'6  B!UG (8>;P"%'G<
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M >(N  #*.   NCT  *@\  ":.@  D3<  (HS  "&,   @RX) '\O$P![,!\
M>#(K '8S-0!T,SX <C1& ' T3@!O-54 ;35< &PU9 !J-6P!:#5U 6<U@ %E
M-8P!8S6: F$VJ0)@-KL"7S;6 ETV\P)=-O\"7#;_ 5PU_P%<-?\!7#3_ =PS
M  #%/   M$$  *)   "5/@  BSP  (0Y  !_-@  >S0$ '<U$ !T-QP <3@G
M &\Y,@!M.3L :SI# &HZ2P!H.U( 9SM9 &4[80%C.VD!8CMR 6 [?0%>.XH"
M7#N7 EL[IP)9.[@#6#O2 U<[\0)6._\"5CO_ E8Z_P%6.O\!5CG_ =0W  #
M00  KT0  )U#  "00@  A4   'X^  !Y.P  =#H  '$Z#@!M/!@ :STD &D^
M+P!G/S@ 93]  &1 2 !B0$\ 84!7 %] 7@%=0&8!7$!O 5I >@)80(<"5D"5
M E1 I -30+8#4D#/ U% [P-00/_B__])0T-?4%)/1DE,10 &"?\"4#__ E _
M_P)1/O\!43[_ <\[  "]10  JD<  )E&  "+10  @40  'E"  !T/@  ;S\
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M L)'  "S3P  GD\  (U.  " 3@  =4T  &Q,  !C2@  7DP  %I- @!63@X
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M 31=F0(S7:L",5W" C%<Y0(Q6_P",5K_ C%9_P(R6?\!,EC_ ;94  "D60
MD%@  (!8  !S5P  :5<  &!8  !460  3EL  $A=  !#7P0 0& . #YA%P ]
M82  .V(I #IB,@ Y8CH .&-" #=C2P V8U0 -&-= #-C:  Q8W8!+V.% 2YC
ME@$L8ZD!*V._ 2ICXP$J8OL!*F#_ 2M?_P$K7_\!*U[_ ;%9  ">7   BUP
M 'M;  !O6P  95L  %Q<  !17@  26   $-B   \90  .&<* #5H$@ T:!L
M,VDD #)I+0 Q:34 +VH] "YJ1@ M:D\ +&I9 "MK90 I:W( *&N" "9KDP D
M:Z< (VN] ")JX  C:?D!(V?_ 2-F_P$C9O\!)&7_ :Q@  "88   A6   '9?
M  !J7P  86   %=@  !-8P  1&8  #UH   V:P  ,&X$ "QP#@ J<14 *7$>
M "AQ)@ G<B\ )G(W "5R0  D<DH (G)4 "%S8  @<VT 'G-] !USD  ;<Z,
M&G.Y !ESW  :<?< &G#_ !MO_P ;;O\!&VW_ :9F  "190  ?V0  '%D  !F
M9   760  %)F  !(:0  /VP  #=O   P<P  *78  ")Y"  ?>Q  'GL7 !Q[
M'P ;>R@ &GLP !E\.0 8?$, %WQ. !9\6@ 5?&< %'UX !)]BP 1?9\ $'VU
M  ]]U0 0>_4 $7G_ !%X_P 2=_\ $G?_ )YK  "*:@  >FD  &UI  !B:0
M5VH  $QM  !#<   .70  #%X   I>P  (G\  !N"   4A0D $880 !&&%P 0
MAQ\ $(<H  Z',0 .ASL #8=&  R'4P +AV$ "H=Q  F'A  'AY@ !H:N  6&
MR0 &A>P !X3_  B#_P )@O\ "8+_ )5Q  "#;P  =&X  &EN  !<;P  4'(
M $9U   \>0  ,GT  "J!   BA0  &XD  !2,   /CP, "I(+  :2$0 $DA@
M I(@  &2*0  DC,  ),^  "32P  DUD  )-I  "3>P  DI   )*F  "1OP
MD>4  )#Z  "/_P  C_\  (__ (UW  !]=0  <'0  &)U  !5>   27P  #^
M   TA   *XD  "*-   :D0  $Y0   Z7   )FP   9T(  "=#@  G1,  )X:
M  ">(@  GRL  )\U  "@0@  H%   *!?  "@<0  H(<  )^=  "?M0  GMH
M )WV  "=_P  G/\  )S_ (9]  !X?   :7P  %M_  !.@P  08@  #:,   L
MD0  (Y8  !J:   2G@  #:$   :D    IP   *D#  "I"@  J@X  *L3  "L
M&0  K2(  *XK  "O-P  KT4  *]4  "O9@  KWL  *Z4  "NJP  KLD  *[O
M  "M_P  K?\  *W_ (&$  !QA   88<  %.+  !&D   .98  "Z;   CH
M&J0  !*H   ,K   !*\   "R    M@   +<   "W @  N @  +D-  "Z$@
MNQ@  +TA  "^*P  P#@  ,!(  # 6@  P6X  ,&&  #!H   P;H  ,'C  #
M^0  P/\  ,#_ 'F-  !HD   690  $N:   ]H   ,:4  "6K   :KP  $;,
M  NX   "NP   +X   #!    Q    ,4   #&    QP   ,@%  #*"P  S \
M ,X5  #0'P  TRL  -4Z  #53   UF   -AW  #8D@  V*P  -G)  #9[
MV?L  -C_ '"9  !@G@  4:0  $.J   UL   *+8  !RZ   1O@  "<$   #%
M    R    ,L   #/    T@   -,   #6    V    -L   #=    WP<  .(-
M  #E$P  Z!T  .PJ  #M/   [5$  .YG  #O@0  [YP  /"W  #PTP  \.P
M /#T &>F  !8K0  2;0  #JZ   JO@  ',(  !#&   'R@   ,X   #2
MU@   -P   #@    XP   .0   #F    Z    .L   #M    [P   /("  #U
M"@  ^!$  /P<  #_+   _S\  /]5  #_;@  _XH  /^D  #_N@  _]$  /_A
M /\ % #_ !( _P 2 /\ % #_ !D _P E /\ ,@#_ #\ _P!+ /\ 5@#_ &
M_P!H /\ < #_ '@ _P!_ /\ A0#_ (L _P"1 /\ F #_ )X _@"F /T K@#\
M +D ^@#( /D X@#X /0 ]P#_ /8 _P#V /\ [P#_ .< _P#B /\ W@#_ /\
M$0#_  X _P . /\ #P#_ !0 _P @ /\ +0#_ #H _P!& /\ 40#_ %L _P!C
M /X :P#\ ', ^@!Y /D @ #W (8 ]@", /4 D@#S )D \@"@ /  J0#N +,
M[0#! .L U@#J .X Z0#^ .< _P#G /\ Y0#_ -T _P#5 /\ T0#_ /\ #0#_
M  H _P ( /\ "0#_ !  _P ; /\ * #_ #4 _P!  /H 2P#V %4 \P!> /$
M9@#N &T [ !T .L >@#I (  YP"& .8 C0#D ), X@"; .  HP#> *T W "Y
M -H R@#7 .8 U #X -( _P#2 /\ T@#_ ,X _P#) /\ Q@#_ /\ " #_  ,
M_P   /\  P#_  T _  6 /< (@#S "X [P Z .P 10#H $\ Y !8 .$ 8 #>
M &< VP!M -D = #5 'H TP"  -$ AP#/ (X S0"5 ,L G@#) *< QP"S ,4
MP@## -P P0#Q +\ _P"_ /\ O@#_ +X _P"] /\ NP#_ /\   #_    _P
M /\   #V  @ [@ 1 .< &P#A "< W0 S -D /@#3 $D SP!2 ,L 60#( &$
MQ@!G ,0 ;0#" ', P !Z +\ @ "] (@ NP"0 +D F "X *( M0"M +, NP"Q
M ,X L #J *\ _ "M /\ K0#_ *X _P"N /\ K@#_ /\"  #_    _0   /(
M  #H    W@ , -, %0#, "$ R  L ,0 . #! $( O0!+ +H 4P"X %H M@!A
M +0 9P"R &T L !T *\ >@"M (( K "* *H DP"H )T I@"H *0 M0"B ,8
MH0#C )\ ]@"> /\ G@#_ )X _P"> /\ G@#_ /\&  #[    [@4  .($  #5
M    RP & ,, #P"] !D N  E +0 ,0"Q #L K@!% *P 30"I %4 IP!; *4
M8@"D &@ H@!N *$ =0"? 'P G@"% )P C@": )@ F "D )8 L "5 ,$ DP#<
M )( \@"1 /\ D #_ )  _P"/ /\ CP#_ /T*  #P#@  X1$  ,X0  #"#0
MNP<  +< "@"Q !( K  > *@ *0"E #0 H@ ^ )\ 1P"= $\ FP!6 )D!7 "7
M 6, E@)I )0"< "3 W@ D0.  ) $B@".!)4 C 6A (H%K@")!KX APC8 (8)
M\ "$"O\ @PO_ (,+_P"#"_\ @PO_ /80  #F%P  TAP  , :  "S%@  K!(
M *@-  "F!PT H@46 )T'(@"9"2X E@HX )0+00"2#$H D Q1 (X-6 ",#5X
MBPUE (D-; "(#G0 A@Y] (4.AP"##I, @0^? ( 0K0!^$+X ?1#; 'H1] !X
M$O\ =Q+_ '<2_P!W$O\ =Q+_ .\7  #;(0  QB0  +0C  "H(   H!P  )L7
M  "9$00 F X0 ),0&P"/$2< C!(R (D3/ "'$T0 A11, (,44P"!%5H @!5@
M 'X6: !]%F\ >Q9X 'D7@P!X%X\ =AB< '08J@!S&;L <AG4 &\:\0!N&_\
M;1O_ &T:_P!M&O\ ;1K_ .<@  #0*0  O"L  *LJ  ">*   EB0  ) @  "-
M'   C!<, (@8%@"$&B( @1LM 'X<-P!\'4  >AU( 'D>3P!W'E4 =A]< '0?
M8P!S'VL <2!T ' @?P!N(8L ;"&8 &LAIP!I(K@ :"+/ &8B[@!E(_\ 9"/_
M &0B_P!D(O\ 9"'_ . F  #(+P  M#$  *,P  "6+@  C2L  (<H  "$)
M@B ( 'X@$@![(AX >",I '4D,P!S)3P <25# ' F2P!N)E( ;2=9 &LG8 !J
M)V@ :2AQ &<H>P!E*(@ 9"F5 &(II !@*;4 7RG+ %XJ[ !<*O\ 7"G_ %PI
M_P!<*?\ 7"C_ -@L  ##-0  K34  )TT  "0,P  AC$  ( M  !\*P  >2@#
M '8G$ !R*1H <"HE &TK+P!K+#@ :BQ  &@M1P!G+4X 92Y5 &0N70!C+F4
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M <<Z  "S0   GC\  (X_  "!/@  =ST  ' [  !J.   9C@  &(Y!P!?.A$
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M 3Y(EP$\2*D!.TB^ 3I(WP$Z1_@!.D;_ 3I%_P$[1?\!.T3_ ;M%  "F2
MDD<  ()'  !V1P  :T<  &-&  !;0P  5D4  %)'  !.2 H 3$D2 $I)' !(
M2B4 1THN $9+-@!%2SX 0TM& $),30!!3%8 0$Q? #Y,:@ \3'8 .TR% 3E,
ME0$W3*<!-DR\ 35,W0$U2_<!-4O_ 35*_P$V2?\!-DG_ ;A)  "B2P  CDH
M 'Y*  !R2@  :$H  %])  !52   4$H  $Q+  !)3 < 1DT0 $1.&0!"3R(
M04\K $!0,P _4#L /E!# #Q12@ [45, .E%< #A19P W47, -5&" #-1DP$R
M4:4!,%&Z 2]1V@$O4/8!+T__ 3!._P$P3O\!,$W_ ;1-  "=30  BDT  'I-
M  !N30  9$T  %M-  !130  2T\  $90  !"4@, /U,- #U4%0 \5!X .E4G
M #E5+P X53< -U8_ #961P U5E  ,U99 #)79  P5W$ +U>  "U7D0 K5Z,
M*E>X "E7U@ I5O4 *57_ "I4_P$J4_\!*E+_ :]1  "840  A5$  '90  !J
M4   8%   %A1  !.4@  1U,  $%5   [6   .%D* #5:$0 T6AH ,ULB #);
M*P Q6S, +UP[ "Y<0P M7$P +%Q6 "M=8  I76T *%U\ "9=C@ D7:$ (UVU
M ")=T@ B7/, (EO_ "-:_P C6?\ )%C_ *A5  "25   @%0  '%4  !F5
M7%0  %15  !*5@  0U@  #Q;   V70  ,& % "UA#@ K814 *F(= "EB)0 H
M8BX )V,V "9C/@ E8T< (V-1 ")D7  A9&D 'V1Y !YDB@ <9)X &V2S !ED
MS@ :8_$ &V'_ !M@_P <8/\ '%__ *%9  ",6   >U@  &U8  !B6   65@
M %!9  !'6P  /EX  #=@   Q8P  *F8  "1I"0 A:A  (&H7 !]J(  >:R@
M'6LP !QK.0 ;:T( &FQ, !EL6  7;&4 %FQT !1LA@ 3;)H $FRO !%LR@ 1
M:^\ $FG_ !-H_P 3:/\ $V?_ )E=  "%70  =5P  &A<  !>7   55P  $M>
M  !"80  .60  #)G   K:@  )&T  !YP 0 7<PL %701 !1T&  3="$ $G4I
M !%U,@ 1=3L $'5&  ]U4@ .=5\ #75N  QU@0 +=94 "G6J  ATPP )=.<
M"G/]  MQ_P ,<?\ #'#_ )%B  !_80  <&$  &1A  !:80  3V(  $5E   \
M:   ,VP  "MO   D<@  '78  !=Y   1? 0 #7\,  M_$@ *?QD "7\B  A_
M*@ &?S0 !7\_  1_2P "?U@  7]G  !_>0  ?XX  '^C  !^NP  ?>   'WW
M  !\_P  >_\  'O_ (EG  !X9P  :V8  &%F  !49P  26D  #]M   U<0
M+'4  "1Y   =?   %H   !"#   ,A@( !HD*  &)#P  B10  (H;  "*(P
MBRP  (LW  "+0P  BU   (M?  "+<0  BX8  (N<  "*LP  B=,  (CS  "(
M_P  A_\  (?_ ()M  !S;   :&P  %IM  !.;P  0G,  #AW   N>P  )8
M !V$   5B   $(P   N/   $D@   )0&  "5#   E1   )85  "7'   F"0
M )@N  "9.0  F4<  )E6  "9:   F7T  )F4  "8JP  E\@  );N  "6_P
ME?\  )7_ 'MT  !O<P  87,  %-V  !&>@  .W\  #"$   FB   '8T  !22
M   .E@  "9D   &<    H    *$   "B!@  H@P  *00  "E%   I1P  *<D
M  "H+P  J#T  *E,  "I7@  J7(  *B)  "HH@  J+P  *?E  "F^P  IO\
M *7_ '=[  !H>P  67X  $N"   ^AP  ,HT  ">2   =EP  %)P   Z@   '
MI    *@   "K    K@   *\   "P    L00  +,*  "T#@  M1,  +8;  "X
M)   NC$  +I   "Z4@  NV4  +M]  "ZEP  NK$  +K2  "Z\P  N?\  +G_
M &^#  !?A@  48L  $.0   VEP  *IT  !^B   5IP  #:P   6P    M
M +<   "[    O@   +\   #     P0   ,,!  #$!P  Q0T  ,<1  #*&0
MS20  ,XS  #/1   T%@  -!N  #1B   T*0  -#!  #1Y@  T?@  -'_ &>/
M  !7E   29H  #NA   NIP  (:T  !:S   .N   !KP   #     PP   ,8
M  #+    S0   ,X   #0    T0   -0   #6    V@(  -P)  #?#P  XQ<
M .8D  #G-@  Z$D  .E?  #J>   ZY0  .NO  #KS   [.@  .SV %^>  !0
MI   0JL  #2R   FN0  &;X   ["   $Q0   ,H   #-    T0   -@   #;
M    WP   .    #B    Y    .8   #I    ZP   .X   #Q!0  ]0T  /D6
M  #\)0  _3D  /Y/  #_9P  _X(  /^=  #_M0  _\L  /_D /\ $0#_  \
M_P / /\ $0#_ !8 _P B /\ +P#_ #L _P!' /\ 4@#_ %L _P!D /\ ; #_
M ', _P!Z /\ @ #_ (8 _P", /X DP#] )D ^P"A /H J0#X +0 ]P#" /8
MV@#U /$ ] #_ /, _P#S /\ Z0#_ .  _P#8 /\ TP#_ /\ #@#_  L _P *
M /\ "P#_ !$ _P = /\ *@#_ #8 _P!! /\ 3 #_ %8 _@!? /L 9@#Y &T
M]P!T /4 >@#T (  \@"& /  C0#O )0 [0"; .P I #J *X Z0"Z .< S0#E
M .D Y #[ ., _P#B /\ W@#_ -$ _P#, /\ R #_ /\ "0#_  0 _P ! /\
M! #_  X _P 8 /\ ) #] #  ^P [ /< 1@#S %  [P!9 .P 8 #J &< YP!N
M .8 = #D 'H X@"  .  AP#> (X W "5 -H G@#6 *@ U "S -$ PP#/ -\
MS@#T ,P _P#+ /\ RP#_ ,4 _P"_ /\ O #_ /\  @#_    _P   /\   #]
M  L ]P 3 /$ '@#M "H Z@ U .< 0 #B $H W0!2 -D 6@#5 &$ T@!G -
M;0#. ', S !Z ,H @ #( (< Q@"/ ,0 F #" *$ P "M +X NP"\ -  N@#M
M +D _@"X /\ N #_ +< _P"S /\ L #_ /\   #_    _P   /D   #N  4
MY0 . -X & #8 ", T@ N ,\ .0#+ $, QP!, ,0 5 #! %L OP!A +P 9P"[
M &T N0!S +< >@"U ($ M ") +( D@"P )L KP"G *P M "K ,8 J0#D *<
M^ "F /\ I@#_ *4 _P"E /\ I #_ /\   #_    ]0   .H   #>    T  *
M ,@ $@#" !T O@ H +L ,P"Y #T M0!& +( 30"P %4 K0!; *P 80"J &<
MJ !M *< <P"E 'H I "" *( C "@ )8 GP"A )T K@"; +X F0#8 )< \0"6
M /\ E@#_ )< _P"7 /\ EP#_ /\   #U    YP$  -0   #)    P  $ +@
M#@"S !8 KP A *L + "H #8 I@ _ *, 1P"A $\ GP!5 )T 6P"; &$ F@!G
M )@ ;@"7 '4 E0!] )0 A@"2 )$ D "< (X J0", +@ BP#- (D ZP"( /T
MB #_ (@ _P"( /\ B #_ /D&  #I#   U X  ,,,  "W"0  L (  *L "0"F
M !  H@ : )X )0"; #  F  Y )8 00"4 $D D@!0 )  5@". %P C0!B (L
M:0"* '  B !X (< @0"% (P A "8 (( I0"  +0 ?@#( 'T!YP!\ OD >P/_
M 'L$_P![!/\ >P3_ /$.  #>%0  Q14  +04  "I$0  H0X  )X*  "; PP
MEP 3 ), '@"0 2D C0(S (H#/ "(!$, A@5+ (4&40"#!E< @@=> ( '9 !_
M"&P ?0AT 'P(?@!Z"8D > F6 '<*HP!U"K, <PO' '(,Y@!P#?L < W_ &\-
M_P!O#?\ ;PW_ .@6  #0'@  N1T  *D<  "=&@  E18  ) 3  "/#@, C@H.
M (D+%P"&#", @PTM ( --@!^#CX ? Y& 'L.30!Y#U, >!!: '8080!U$&@
M<Q!Q '$1>P!P$8< ;A&4 &P1H@!K$K( :1+' &@3YP!F$_T 913_ &44_P!E
M$_\ 91/_ -\>  #&)   L"0  * C  "4(0  BQ\  (8;  "#%P  @A(( '\1
M$@!\$AT >10H '84,0!T%3H <A9! '$62 !O%T\ ;A=6 &P770!K&&0 :1AM
M &@9=P!F&8, 9!F0 &,:GP!A&J\ 8!K$ %X;Y !='/L 7!S_ %P;_P!<&_\
M7!O_ -4E  "]*@  J"D  )@I  ",*   @R4  'TB  !Y'P  >!L# '89#P!R
M&A@ ;QPC &T=+0!K'34 :1X] &@>1 !F'TL 91]2 &,@60!B(&$ 82!I %\A
M<P!=(7\ 7"&- %HBG !9(JP 5R+  %8CX0!5(_D 5"/_ %0B_P!4(O\ 5"+_
M ,TK  "V+@  HBX  )(N  "%+0  ?"L  '8H  !R)@  ;R,  &TA# !J(A4
M9R,? &4D*0!C)#$ 8B4Y & F00!?)D@ 729/ %PG5@!;)UT 62=F %@H< !6
M*'P 5"B* %,IF0!1*:H 4"F^ $\IW@!.*?< 32G_ $TI_P!-*/\ 3BC_ ,@P
M  "P,@  G#(  (PR  " ,0  =C   ' M  !K*P  :"D  &8H"0!C*!$ 8"D<
M %XJ)0!<*RX 6RLV %DL/0!8+$0 5RU, %4M4P!4+5L 4RUC %$N;@!0+GH
M3BZ( $POEP!++Z@ 22^[ $@OVP!(+_8 1R__ $<N_P!'+?\ 2"W_ ,0T  "K
M-0  ES4  (<U  ![-0  <C0  &LR  !F+P  8BX  %\M!0!<+A  6B\8 %@P
M(@!6,"L 53$S %,Q.@!2,D( 43)) % R4 !.,U@ 33-A $LS:P!*,W< 2#2%
M $<TE0!%-*8 0S2Y $(TU@!"-/0 0C3_ $(S_P!",O\ 0C+_ , X  "G.
MDS@  (,X  !W.   ;3<  &8V  !A,P  73(  %DR @!7,PT 5#05 %(U'P!1
M-2@ 3S8P $XV. !,-S\ 2S=& $HW3@!).%8 1SA? $8X:0!$.'4 0SB# $$Y
MDP! .:0 /CFX #TYTP \.?, /#C_ #TW_P ]-_\ /3;_ +L[  "B.P  CSL
M '\[  !S.P  :CH  &(Y  !=-P  6#8  %0W  !1. L 3SD3 $TY' !+.B4
M2CHM $@[-0!'.SP 1CQ$ $4\2P!$/%, 0CQ< $$]9P _/7, /CV! #P]D0 Z
M/:, .3VV #@]T0 W/?( -SS_ #@[_P X._\ .#K_ +8]  ">/@  BSX  'P^
M  !O/@  9CT  %X]  !8.P  4SH  $\[  !,/ @ 23T1 $<^&0!&/R( 1#\J
M $,_,@!"0#H 04!! $! 20 ^05$ /4%: #Q!9  Z07  .$%_ #=!CP U0J$
M-$*T #)"S@ R0?  ,D#_ #- _P S/_\ -#[_ +%   ":0   AT   'A!  !L
M00  8D   %M   !4/P  3C\  $I   !&004 1$(. $)#%@! 0Q\ /T0G #Y$
M+P \1#< .T4^ #I%1@ Y14X .$98 #9&8@ U1FX ,T9\ #%&C0 P1I\ +D:S
M "U&S  M1N\ +47_ "Y$_P N0_\ +D/_ *Q#  "60P  @T,  '1#  !H0P
M7T,  %=#  !00P  2$,  $1%  !!1@$ /D<, #Q($P Z2!P .4DD #A)+  V
M230 -4H[ #1*0P S2DP ,DI5 #!+7P O2VL +4MZ "Q+BP J2YT *$NQ "=+
MR@ G2^T )TK_ "A)_P H2/\ *4?_ *=&  "11@  ?T8  '!&  !E1@  6T8
M %1&  !,1P  1$@  #]*   [2P  -TP) #5-$  S3A@ ,DX@ #%/*  P3S
M+T\X "Y/0  L4$@ *U!2 "I07  H4&@ )U!W "50B  D4)L (E"O "%0R  @
M4.L (4__ ")._P B3?\ (TW_ *%)  ",20  >DD  &Q*  !A2@  6$H  %!*
M  !)2P  0$P  #M.   U4   ,5($ "U3#0 L5!0 *E0< "E5)  H52P )U4S
M "95/  E5D4 )%9. ")660 A5F4 'U9T !Y6A0 <5I@ &U:L !E6Q0 95ND
M&E7_ !M4_P ;4_\ '%+_ )M-  "&30  =4T  &A-  !=30  5$T  $U.  !%
M3P  /%$  #93   Q50  *U@  "9:"0 C6Q  (EL7 "%<'P @7"< 'UPN !U<
M-P <74  &UU* !I=50 876$ %UUP !5=@0 4794 $UVJ !%=P@ 17>< $EO^
M !-:_P 36O\ %%G_ )11  " 40  <%$  &11  !940  45$  $E2  !!4P
M.%8  #)9   K6P  )5X  !]A P :8PP &&01 !=D&0 69"$ %60I !1E,0 3
M93H $F5$ !%E4  095T #V5K  YE?0 -99$ #&6E  IDO  *9.  "V/Y  QB
M_P -8?\ #6'_ (U5  !Z50  :U4  %]5  !650  3E4  $17   \60  -%P
M "Q?   F8@  'V4  !EH   3:P4 $&T-  YN$@ -;AH #&XB  QN*P +;C0
M"FX^  AN2@ ';E< !FYE  1N=@ ";HH  &V?  !MM@  ;-8  &SS  %K_P "
M:O\  VK_ (5:  !T6@  9EH  %Q9  !360  2%H  #]=   V8   +F,  "9G
M   ?:@  &6T  !-Q   .= , "G<*  5W$  !=Q4  '<<  !W)   >"T  '@W
M  !X0P  >%   'A>  !X;P  >(0  'B9  !WL   =LT  '7P  !U_P  =/\
M '3_ 'Y?  !N7P  8EX  %E>  !-7P  0F(  #EE   P:   )VP  !]P   8
M=   $G<   U[   (?@   H (  "!#0  @1$  ((7  "#'@  @R8  (0P  "$
M.P  A$@  (17  "$:   A'P  (23  "#J@  @L4  ('K  "!_@  @/\  (#_
M '=E  !I9   7V,  %)D  !'9P  /&L  #%O   H<P  ('<  !A\   1?P
M#(,   :'    B@   (P#  ","0  C0X  (X1  "/%P  D!X  )$G  "2,@
MDC\  )).  "27P  DG,  )*+  "1H@  D;P  )#E  "/_   CO\  ([_ '%K
M  !F:@  6&L  $MM   _<0  -'8  "I[   @@   %X4  !")   +C0  !)$
M  "5    F    )D   ": P  FP@  )P-  ">$0  GQ8  * >  "B*   HC4
M *-$  "C50  HVD  **   "BF@  H;,  *#8  "@]@  G_\  )__ &YQ  !?
M<@  474  $1Y   W?@  +(0  "&*   7CP  $)0   J9   !G0   *    "D
M    IP   *@   "I    J@   *P&  "M"P  KQ   + 5  "R'@  M"D  +0Y
M  "T2@  M5T  +5S  "UC@  M:@  +3&  "S[0  LO\  ++_ &9Z  !7?0
M28(  #R'   OC@  (Y0  !B:   0GP  ":0   "I    K0   +    "T
MMP   +@   "Y    NP   +P   "^ @  P @  ,(.  #$%   QQX  ,@L  #)
M/0  RE   ,IF  #*?P  RIL  ,JX  #*W0  RO4  ,K_ %Z&  !/BP  09$
M #.8   GGP  &Z4  !&K   )L    +4   "Y    O0   ,$   #&    R
M ,D   #+    S    ,X   #0    T@   -0%  #9#   W1(  .$>  #B+@
MXT(  .17  #E;P  YHP  .:H  #EQ0  Y><  .;V %:4  !(FP  .J(  "RI
M   ?L   $[8   N\    P0   ,4   #)    S0   -(   #6    V@   -L
M  #>    X    .(   #D    YP   .D   #M    \ H  /01  #X'P  ^3(
M /I(  #[7P  _'H  /V7  #]KP  _<<  /WD /\ #@#_  T _P , /\ #@#_
M !, _P > /\ *@#_ #8 _P!" /\ 30#_ %< _P!? /\ 9P#_ &X _P!T /\
M>@#_ ($ _0"' /P C0#Z )0 ^0"< /< I0#U *\ ] "\ /, SP#Q .P \ #^
M .\ _P#O /\ XP#_ -< _P#. /\ R@#_ /\ "@#_  8 _P $ /\ " #_ !
M_P 9 /\ )0#_ #$ _P ] /\ 1P#^ %$ ^P!9 /D 80#V &@ ] !N /, = #Q
M 'H [P"! .X AP#L (X Z@"6 .@ GP#F *D XP"U .( Q@#@ ., WP#X -T
M_P#= /\ U #_ ,D _P#" /\ O@#_ /\  P#_    _P   /\  0#_  T _P 4
M /T ( #Z "L ]P V /, 00#O $L [ !4 .@ 6P#F &( XP!H .$ ;@#? '0
MW !Z -H @0#8 (@ U "0 -( F #/ *( S0"N ,L O #) -, QP#P ,8 _P#$
M /\ Q #_ +L _P"V /\ LP#_ /\   #_    _P   /\   #W  @ \  0 .L
M&@#G "4 Y  P .$ .P#< $4 U0!- -$ 50#. %L RP!B ,D 9P#' &T Q0!S
M ,, >@#! ($ OP") +T D@"[ )P N0"G +< M0"U ,@ LP#F +( ^P"Q /\
ML #_ *X _P"J /\ IP#_ /\   #_    _@   /$   #E  ( W  - -, % #-
M !\ R@ J ,< - #$ #X P !' +P 3@"Z %4 MP!; +4 80"S &< L@!M +
M<P"N 'H K "" *H BP"H )4 IP"@ *4 K0"C +X H0#; *  ] "? /\ G@#_
M )\ _P"= /\ FP#_ /\   #\    [@   .    #0    Q0 ( +X $ "Y !D
MM0 C +, +@"P #< K0!  *H 2 "H $\ I0!5 *, 6P"B &  H !F )\ ; "=
M ', FP![ )H A "8 (X E@": )4 IP"3 +< D0#, )  [ "/ /\ C@#_ (X
M_P". /\ CP#_ /P   #O    VP   ,D   "]    M0 " *X # "I !, I0 =
M *( )P"@ #$ G0 Z )H 0@"8 $D E@!/ )0 50"3 %L D0!@ )  9P". &T
MC0!U (L ?@") (D B "5 (8 H@"% +$ @P#$ ($ Y "  /D ?P#_ (  _P"
M /\ @ #_ /0"  #@"0  QP@  +<'  "L P  I@   *  !P";  \ F  7 )4
M(0"2 "H CP S (T / "+ $, B0!) (< 4 "& %4 A !; (, 80"! &@ @ !P
M 'X >0!\ (0 >P"0 'D G0!X *P =@"^ '4 W0!S /0 <P#_ ', _P!S /\
M<P#_ .D-  #/$   N1   *D0  ">#@  EPL  ),&  "0  L C  1 (D &@"&
M "0 @P N ($ -@!_ #X ?0!$ 'P 2P!Z %$ >0!7 '< 70!V &0 = !L ',!
M=0!Q 8  ;P*- &X"F@!L ZH :P.[ &D$U@!H!O$ : ?_ &<'_P!G!_\ 9P?_
M -\4  ##%P  KA<  )X6  "3%0  BQ(  (80  "$# ( @P8- ( #% !\!1X
M>0<H '<(, !U"#@ <PE  '()1@!P"DP ;PI3 &T+60!L"V$ :@MI &D,<@!G
M#'X 9@R+ &0-F0!B#:D 80V[ & -V !>#O, 70[_ %T._P!=#O\ 70[_ -0<
M  "Y'0  I!X  )4=  ")'   @1H  'L7  !X$P  >! & '<-#P!S#A@ < XB
M &X/*P!L$#, :A [ &D00@!G$4D 9A%/ &015@!C$ET 81)F & 2;P!>$GL
M7!.( %L3EP!9$Z< 5Q2Z %84U0!5%?, 5!7_ %05_P!4%?\ 5!3_ ,HB  "P
M(@  G2,  (TC  "!(@  >2$  ',>  !O&P  ;A<  &T3# !J%!0 9Q4> &46
M)P!C%B\ 81<W & 7/@!>&$4 71A+ %P94@!:&5H 61EB %<:; !6&G< 5!J%
M %(;E !1&Z0 3QNW $X;T !-'/$ 3!S_ $P<_P!-'/\ 31O_ ,,F  "J)P
MEB<  (<H  ![)P  <B8  &PD  !H(0  9AX  &0;" !B&Q$ 7QP: %T=(P!;
M'BL 6AXS %@?.@!7'T$ 5B!( %0@3P!3(%< 42%? % A:0!.(70 32&" $LB
MD0!)(J( 2"*T $<BS0!&(^\ 12/_ $4B_P!&(O\ 1B'_ +PJ  "D*P  D2L
M ((L  !V*P  ;2H  &8I  !B)@  7R0  %TB! !;(0X 6"(6 %8C'P!4)"@
M4R0P %(E-P!0)3X 3R9% $XF3 !,)E0 2R=< $DG9@!()W$ 1B=_ $4HCP!#
M**  02BR $ HRP _*.T /RC_ #\H_P! )_\ 0"?_ +<M  "?+@  C"\  'TO
M  !Q+P  :"X  &$M  !=*P  6B@  %<G  !4)PP 4B@3 % I' !.*24 32HL
M $LJ- !**SL 22M" $@L20!&+%$ 12Q: $0L9 !"+6\ 0"U] #\MC0 ]+9X
M/"VP #HMR  Z+>L .BW_ #HM_P Z+/\ .BS_ +(P  ";,0  B#(  'DR  !M
M,@  9#(  %TQ  !8+P  52P  %$L  !/+0D 3"T1 $HN&0!)+R( 1R\J $8P
M,0!%,#@ 0S _ $(Q1P!!,4\ 0#%7 #XQ80 ],FT .S)[ #DRBP X,IP -C*O
M #4RQP T,ND -#+_ #4Q_P U,?\ -3#_ *TS  "6-   A#4  '4U  !I-0
M8#4  %DT  !4,P  4#   $PQ  !),08 1S(/ $4S%@!#,Q\ 0C0G $ T+@ _
M-38 /C4] #TU1  \-DP .C95 #DV7P W-FL -C9X #0WB0 R-YH ,3>M "\W
MQ0 O-^@ +S;^ # U_P P-?\ ,#3_ *DV  "2-@  @#<  '(X  !F.   73<
M %8W  !0-@  2S0  $<U  !$-@, 03<- #\X%  ^.!P /#DD #LY+  Z.3,
M.3HZ #@Z0@ V.DH -3I3 #0[70 R.V@ ,#MV "\[AP M.YD +#NL "H[PP I
M.^8 *CK] "HZ_P K.?\ +#C_ *0X  "..0  ?#H  &XZ  !C.@  6CH  %,Z
M  !-.@  1C@  $(Z   _.P  /#P+ #H\$0 X/1D -STA #8^*0 T/C  ,SXW
M #(_/P Q/T< ,#]0 "X_6@ M0&8 *T!T "E A  H0)< )D"J "5 P0 D0.4
M)#_\ "4^_P F/?\ )CW_ )\[  "*/   >#T  &H]  !?/0  5CT  $\]  !)
M/0  0CT  #P^   Y/P  -D$( #1!#P R0A8 ,4(> "]#)0 N0RT +4,T "Q$
M/  K1$0 *D1- "A$6  G16, )45Q "-%@@ B194 ($6H !]%OP >1., 'T3[
M !]#_P @0O\ (4'_ )H^  "%/P  =$   &=   !<0   4T   $Q   !&0
M/D$  #A#   T10  ,$8# "U'#0 K2!( *D@: "E((@ H22D )TDQ "5).0 D
M24$ (TI* ")*50 @2F$ 'TIO !U*?P ;2I( &DJF !A*O0 72N  &$GZ !E(
M_P :1_\ &D?_ )5"  " 0@  <$,  &-#  !80P  4$,  $E#  !"1   .T4
M #5'   P20  *TL  "9-"0 D3A  (DX6 "%/'0 @3R4 'T\L !Y/-0 =3ST
M'%!' !I040 94%T %U!K !90?  44(\ $U"D !%0N@ 14-X $4_X !)._P 3
M3?\ %$W_ (]%  ![1@  :T8  %]'  !51P  34<  $9'   _1P  -TH  #%,
M   K3@  )E   "!3 P <50P &E81 !E6&  75B  %E8G !56,  45CD $U="
M !)730 15UD $%=H  ]7>0 .5XP #5>@  M7M@ +5M0 "U;T  Q5_P -5/\
M#E/_ (A)  !V2@  9TH  %M*  !12@  2DH  $-*   [3   ,TX  "Q1   F
M5   (58  !M9   57 < $5X- !!>$P 07AH #EXB  Y>*@ -7C, #%X]  M>
M2  *7E0 "%YB  =><P %7H8  UZ;  )>L0 "7<P  EWN  -<_P $6_\ !5O_
M (%.  !P3@  8DX  %=.  !.3@  1TX  #Y/   V40  +E0  "=7   A6@
M&UT  !5@   08P, #&8+  AG$  &9Q4 !6<<  1G)  "9RT  6<W  !G0@
M9TX  &=<  !G;0  9X   &:5  !FK   9<<  &7K  !D_   9/\  &/_ 'I2
M  !J4P  75(  %12  !+4@  0E,  #E5   P6   *%L  "%?   :8@  %&4
M !!H   ,:P$ !FX)  !O#@  ;Q(  &\8  !P'P  <"<  '$P  !Q.P  <4@
M '%6  !Q9@  <7D  '&/  !PIP  ;\$  &_G  !N_   ;?\  &W_ '-8  !E
M5P  6E<  %%6  !&5P  /%H  #)=   J80  (F0  !IH   4;   #F\   IR
M   $=@   '@%  !X"P  >0X  'H3  ![&0  ?"   'TI  !],P  ?4   'U.
M  !]7@  ?7(  'V(  !\H0  ?+H  'OB  !Z^@  >?\  'C_ &U=  !@7
M5UP  $M=  ! 7P  -6,  "MG   C:P  &F\  !-S   .=P  "'L   )^
M@@   (,!  "$!@  A0L  (8/  "($P  B1D  (HA  "+*P  BS<  (Q&  "+
M5@  BVD  (N   "+F0  BK,  (G8  "(]P  B/\  (?_ &AC  !>8@  46(
M $1E   X:0  +FX  "1S   :>   $WT   V!   &A0   (D   "-    D
M )(   "2    E 4  )4*  "7#@  F!(  )H8  ";(0  G"T  )T\  "=3
MG%\  )QV  ";D0  FZL  )K)  ":\   F?\  )C_ &5I  !7:0  26P  #UQ
M   P=@  )7P  !N!   2AP  #(P   21    E0   )D   "=    H    *$
M  "B    I    *4!  "G!P  J0P  *H1  "M&   KR(  *\P  "O00  KU0
M *]K  "NA0  KJ$  *Z^  "MY@  K/P  *S_ %YQ  !/=   0GD  #5_   H
MA0  '8P  !.2   ,F    YT   "B    I@   *H   "N    L    +$   "S
M    M    +8   "X    N@0  +P*  "^$   P1<  ,,D  ##-0  Q$D  ,1>
M  #%=P  Q9,  ,6O  #%T0  P_(  ,/_ %9\  !'@@  .H@  "R/   @E@
M%)T   VC   #J0   *X   "R    MP   +L   "_    P@   ,(   #%
MQ@   ,@   #*    S0   ,\   #2"   U0X  -L8  #=)P  WCH  -]0  #@
M:   X(0  .&A  #AO0  X>(  .#T $Z+  ! D@  ,ID  "6A   8J   #J\
M  6U    N@   +\   #$    R    ,X   #1    U    -4   #8    V@
M -T   #?    X@   .0   #G    ZP4  .\.  #T&0  ]2L  /9!  #W6
M^'(  /F0  #YJP  ^,0  /CA /\ "P#_  @ _P ) /\ # #_ !( _P : /\
M)@#_ #( _P ^ /\ 2 #_ %( _P!: /\ 8@#_ &D _P!O /\ =0#^ 'L _ "!
M /L B #Y (\ ]P"7 /4 H #S *H \@"W .\ R0#M .8 [ #[ .L _P#K /\
MW0#_ ,X _P#& /\ P@#_ /\ ! #_    _P   /\ !0#_  T _P 5 /\ (0#_
M "P _P X /\ 0P#] $P ^0!4 /< 7 #T &, \@!I /  ;P#N '4 [ ![ .H
M@@#H (D YP"1 .0 F@#B *0 X "P -T P #: -P V #T -4 _P#3 /\ RP#_
M ,$ _P"[ /\ MP#_ /\   #_    _P   /\   #_  H _0 1 /D &P#V "<
M]  R /  / #L $8 Z !. .0 5@#A %P W@!C -P : #9 &X U0!T -( >P#0
M (( S0"* ,L DP#( )T Q@"H ,0 MP#! ,P P #K +X _P"] /\ O0#_ +0
M_P"N /\ JP#_ /\   #_    _P   /H   #R  4 Z@ . .4 %@#@ "$ W0 K
M -L -@#3 #\ S@!( ,H 3P#' %8 Q !< ,( 80#  &< O@!M +P <P"Z 'H
MN "" +8 BP"T )8 L@"A +  KP"N ,$ K0#@ *L ]P"J /\ J0#_ *8 _P"A
M /\ GP#_ /\   #_    ]P   .@   #<    T  * ,H $0#% !L P@ E +\
M+P"\ #@ N !! +4 2 "R $\ L !5 *X 6P"L &$ J@!F *@ ; "G ', I0![
M *, A "A (X GP": )T IP"; +@ F@#0 )D [P"8 /\ EP#_ )8 _P"4 /\
MD@#_ /\   #V    Y    -(   #%    NP % +4 #@"P !4 K  ? *H *0"H
M #( I0 Z *( 0@"@ $D G@!/ )P 50": %H F !@ )8 9@"5 &P DP!T )(
M?0"0 (< C@"3 (P H0"+ +  B@#% (@ Y@"' /L A@#_ (< _P"' /\ A@#_
M /@   #E    S0   +T   "S    J@   *, "@"? !$ FP 9 )D (P"7 "P
ME0 T )( / "0 $, C@!) (P 3P"* %0 B0!: (< 8 "& &8 A !N (, =P"!
M ($ ?P"- 'X FP!\ *H >P"\ 'H VP!X /4 > #_ '@ _P!X /\ > #_ .T
M  #1 @  NP(  *P!  "B    FP   )8 !0"1  T C0 4 (L '0"( "8 A@ N
M (0 -@"" #T @ !# 'X 20!] $\ ? !5 'H 6P!Y &$ =P!I '4 <0!T 'P
M<@"( '$ E@!O *4 ;@"V &T S@!L .X :P#_ &L _P!K /\ :P#_ -\+  #"
M#   K@P  )X,  "3"P  C <  (@"  "%  D @0 0 '\ %P!\ "  >@ H '@
M, !V #@ =  ^ ', 1 !Q $H < !0 &X 5@!M %T ; !D &H ;0!H '< 9P"$
M &4 D@!D *$ 8P"R &$ R0!@ .D 8 #\ &  _P!@ /\ 8 #_ - 0  "V$0
MHA(  ),2  "($0  @ \  'P-  !Y"0$ > ,+ '4 $0!S !H <  C &X!*P!L
M 3, :@(Y &D#0 !G T8 9@1, &4$4@!C!5D 8@5A & %:@!?!G0 70:! %P'
MCP!:!Y\ 60>P %<'Q@!6">< 5@K[ %4*_P!5"O\ 5@K_ ,85  "M%P  F1@
M (H8  !_%P  =A8  '$3  !N$   ;0T% &T)#0!J"10 9PH= &4*)@!C"RX
M8@PU & ,/ !?#$( 7@U( %P-3P!;#58 60U> %@.: !6#G, 50Z  %,.CP!1
M#I\ 4 ZQ $X.R !-$.H 31#] $T0_P!-$/\ 31#_ +P;  "E'   DAT  (,>
M  !W'0  ;QP  &D:  !F%P  9!0  &00" !B#Q  7Q 8 %T0(0!;$2D 6A$Q
M %@2. !7$CX 5A)% %023 !3$U, 41-; % 390!.%'  3!1] $L4C !)%)P
M1Q6N $85Q0!%%>@ 11;^ $46_P!%%?\ 117_ +4?  ">(0  BR(  'PB  !Q
M(@  :"$  &(?  !?'0  7!H  %L7 @!:%0T 5Q84 %46'0!4%R4 4A@M %$8
M- !/&#L 3AE" $T92 !+&E  2AI8 $@:8@!'&FT 11MZ $,;B0!"&YH 0!NL
M #\;P@ ^'.4 /1S\ #X<_P ^&_\ /AO_ *\C  "8)   AB4  '<F  !L)@
M8R4  %TD  !9(@  5A\  %0=  !3' L 41P2 $X=&@!-'2( 2QXI $H>,0!)
M'S< 1Q\^ $8@10!%($T 0R!5 $(@7P! (6H /R%W #TAAP [(9@ .2&J #@B
MP  W(N, -R+[ #<B_P X(?\ ."'_ *HF  "4)P  @2D  ',I  !G*0  7RD
M %@H  !4)@  42,  $\B  !,(@< 2B(0 $@B%P!'(Q\ 120F $0D+@!")#0
M024[ $ E0P _)4H /293 #PF7  Z)F< .29U #<GA  U)Y8 -">H #(GO@ Q
M)^$ ,2?Y #(F_P R)O\ ,R7_ *4I  "/*@  ?2P  &\L  !D+0  6RP  %4K
M  !0*@  3"@  $HF  !')P0 1"<- $(H% !!*!P /RDC #XI*P ]*3( /"HY
M #LJ0  Y*D@ ."M0 #8K6@ U*V4 ,RMR #$K@@ P+)0 +BRG "PLO  K+-X
M+"SX "PK_P M*O\ +2K_ *$L  "++0  >2X  &LO  !@+P  6"\  %$N  !,
M+@  2"P  $4K  !!*P  /RP+ #TL$0 [+1D .BXA #DN*  W+B\ -B\V #4O
M/@ T+T4 ,R]. #$P6  P,&, +C!P "PP@  J,)( *3"E "<PN@ F,-P )C#W
M "<O_P H+_\ *"[_ )PN  "',   =C$  &@R  !=,@  53(  $XQ  !(,0
M1#   $ O   \,   .C$) #<Q$  V,A8 -3(> #,S)0 R,RP ,3,S # T.P O
M-$, +31, "PT5@ J-6$ *35N "<U?@ E-9  (S6C "(UN0 A-=D (33V "(T
M_P C,_\ (S+_ )@Q  "#,P  <C0  &4T  !:-0  434  $LT  !%-   0#0
M #HS   W-   -#4& #(V#@ P-Q, +S<; "XW(@ M."D *S@Q "HX.  I.4
M*#E) "8Y4P E.5\ (SEL "$Z?  @.HX 'CJB !PZMP ;.=4 '#GU !TX_P =
M./\ 'C?_ ),T  !_-@  ;C<  &$W  !7-P  3C<  $@W  !"-P  /#<  #4X
M   R.0  +SH" "P["P J/!$ *3P8 "@]'P F/28 )3TN "0]-0 C/CT (CY&
M " ^4  ?/EP '3]I !L_>0 :/XP &#^@ !8_M0 5/M( %C[S !<]_P 8//\
M&#S_ (XW  !Z.   :CD  %XZ  !3.@  2SH  $4Z   _.@  .3H  #(\   N
M/@  *4   "9!"  D0@X (D(4 "%"&P @0R, 'T,J !Y#,@ <0SH &T1# !I$
M30 81%D %T1G !5$=P 31(H $D2> !%$LP 01-  $$/R !%"_P 20O\ $T'_
M (D[  !V/   9CT  %H]  !0/0  2#T  $(]   \/0  -CX  "]    J0@
M)40  "%& P =2 P &TD1 !E)%P 821X %TDF !9)+@ 52C8 %$I  !-*2@ 1
M2E8 $$ID  ]*=  .2H< #4J;  Q*L  *2LH "TGL  Q(_P -1_\ #4?_ (,^
M  !Q/P  8D   %9   !-0   14   #]    Y00  ,D(  "M%   F1P  (4D
M !Q+   63@< $U . !)0$P 14!D $% A  ]0*0 .4#$ #5 [  U11@ +45$
M"E%?  E1;P '4($ !5"6  -0JP "4,4  T_H  -/^P %3O\ !DW_ 'U"  !K
M0P  740  %)$  !*1   0T,  #Q$   U10  +D<  "=*   A3   '$\  !=1
M   25 , #E<*  M8$  *6!4 "%@<  =8)  &6"P !5@V  -80  !6$P  %A:
M  !8:0  6'P  %B1  !7IP  5\   %;E  !6^0  5?\  %7_ '9'  !F1P
M64@  $]'  !'1P  0$<  #A(   P2@  *4T  ")0   <4P  %E4  !%8   -
M6P( "5X)  1?#@  7Q(  %\8  !@'P  8"<  & P  !@.P  8$<  &!4  !@
M8P  8'8  &"+  !?H@  7[L  %_B  !>^0  7?\  %W_ &]+  !A3   54P
M $Q+  !$2P  .TP  #).   K40  (U0  !Q7   66P  $5X   U@   (8P
M F8'  !G#   9P\  &@3  !I&0  :B$  &HI  !J-   :D   &I-  !J70
M:F\  &J%  !JG0  :;8  &C=  !H]P  9_\  &;_ &E1  !<4   4E   $I/
M   _4   -5,  "U6   D60  '5T  !9@   09   #&<   9J    ;@   &\#
M  !P"   <0T  '(0  !T%   =1L  '8C  !W+   =S@  '9&  !V5@  =F@
M '9^  !VEP  =;$  '33  !S]0  <_\  '+_ &-6  !850  4%0  $15   Y
M6   +UL  "9?   =8P  %6<  !!L   *<   !',   !V    >@   'P   !\
M P  ?@@  '\,  "!$   @A0  (0;  "%)   AB\  (8]  "&30  A5\  (5U
M  "%CP  A*D  (/)  ""\0  @?\  (#_ %];  !66@  25L  #U>   R80
M)V8  !YK   5<   #G4   EY   !?@   ($   "%    B    (H   "+
MC0$  (X&  "0"P  D0\  ),4  "5&P  ER8  )<T  "71   EU8  )9L  "5
MA@  E:(  )3!  "3Z@  DO\  )+_ %UA  !/80  0F0  #9I   J;@  'W0
M !5Y   .?P  !X0   ")    C@   )(   "6    F    )H   ";    G0
M )\   "A P  HP@  *4-  "G$P  J1P  *HH  "J.0  JDL  *IA  "I>@
MJ)D  *BU  "GW0  I_@  *;_ %9H  !(;   .G   "YV   B?0  %X0   Z*
M   'D    )8   ":    GP   *,   "G    J@   *L   "M    KP   +$
M  "S    M0   +@%  "Z#   O1(  , <  # +0  P$   +]5  "_;@  OHL
M +ZH  "^R0  O>\  +S^ $YT  ! >0  ,G\  "6'   9C@  $)4   ><
MH@   *<   "L    L    +4   "Y    O    +T   "_    P0   ,,   #&
M    R    ,H   #- @  T L  -42  #6(0  US0  -A)  #98   VGP  -J:
M  #;M0  V]D  -OR $:"   XB0  *Y   !V8   2H   "J<   "N    M
M +D   "^    P@   ,@   #+    S@   ,\   #2    U    -8   #:
MW0   -\   #B    Y@   .H*  #O$P  \"4  /(Z  #S40  ]&L  /2)  #U
MI0  ];\  /7= /\ !@#_  , _P % /\ "P#_ !  _P 7 /\ (@#_ "T _P Y
M /\ 1 #_ $T _P!5 /\ 70#_ &0 _P!J /\ < #] '8 ^P!\ /D @P#W (H
M]0"2 /, FP#P *8 [@"S .L Q #I .0 YP#Y .8 _P#E /\ TP#_ ,< _P"_
M /\ NP#_ /\   #_    _P   /\  @#_  L _P 2 /\ '0#_ "@ _P S /\
M/@#\ $< ^ !/ /0 5P#Q %T [@!C .P :0#J &\ Z !U .8 ? #D (, X@"+
M -\ E0#< )\ V0"K -4 NP#2 -0 SP#R ,T _P#, /\ Q0#_ +H _P"T /\
ML #_ /\   #_    _P   /\   #_  8 ^0 / /4 %P#S "( \0 M .T -P#G
M $  X@!) -\ 4 #; %< UP!= -0 8P#1 &@ SP!N ,P =0#* 'P R "$ ,4
MC0#" )@ P "D +T L@"[ ,8 N0#H +@ _0"W /\ M@#_ *T _P"G /\ HP#_
M /\   #_    _P   /4   #K  $ Y  , -X $P#9 !P TP F -$ , #, #H
MR !" ,0 2@#  %  O0!6 +L 7 "Y &$ MP!G +4 ;0"S '0 L0!\ *\ A0"M
M )  J@"< *@ J@"F +L I0#: *, ]0"C /\ H@#_ )X _P": /\ EP#_ /\
M  #^    [P   -\   #0    QP ' ,$ #P"\ !< N0 @ +< *@"U #, L  [
M *T 0P"K $D J !/ *8 50"D %H HP!@ *$ 9@"? &T G0!T )P ?0": (@
MF "4 )8 H@"4 +( D@#) )$ ZP"1 /\ D #_ )  _P", /\ B@#_ /P   #L
M    V0   ,<   "Z    L0 " *L # "G !( I  ; *$ ) "@ "P G@ U )L
M/ "8 $, E@!) )0 3P"2 %0 D !: (\ 7P"- &8 BP!M (D =@"( (  A@",
M (0 F@"" *H @0"^ (  X "  /D ?P#_ '\ _P!_ /\ ?@#_ /$   #8
MP@   +,   "H    H    )D !P"5  X D@ 5 )  '@". "8 C0 N (H -@"'
M #T A0!# (0 20"" $X @0!4 '\ 60!^ &  ? !G 'H ;P!Y 'H =P"& '4
ME !T *, <@"U '( SP!Q /$ < #_ '  _P!P /\ <0#_ .$   #$    L
M *(   "7    D0   (L  @"&  L @P 1 ($ & !_ "$ ?0 I 'P , !Y #<
M>  ] '8 0P!T $D <P!. '( 5 !P %H ;P!B &T :@!K '0 :@"  &@ C@!G
M )T 90"O &4 Q@!D .@ 9 #] &, _P!C /\ 9 #_ ,\%  "V!P  HP@  )0(
M  ")!P  @@,  'X   ![  8 =P . '4 $P!R !L <0 C &\ *P!M #( ;  X
M &H /@!I $0 9P!) &8 3P!E %8 8P!= &( 90!@ &\ 7P![ %T B0!< )D
M6P"J %D OP!9 .$ 6 #X %@ _P!8 /\ 60#_ ,(,  "J#0  EPX  (D.  !]
M#@  =@T  '$*  !O!@  ;0 * &L $ !I !8 9P > &4 )@!C "T 80 S &
M.0!? #\ 70!% %P 2P!; %( 6@!9 %@ 8@!7 &P 50!X %, A@!2 )8 40"G
M %  NP!/ =L 3@+T $X#_P!.!/\ 3@/_ +@0  "A$@  CA,  '\3  !T$P
M;!(  &<0  !E#@  8PL# &,&# !A!!$ 7@,9 %P$(0!;!2@ 608O %@&-0!6
M!SL 50=" %0'2 !3"$\ 40A6 % )7P!."6D 30EV $L*A !)"I0 2 JF $<*
MN@!&"M@ 10OS $4,_P!%#/\ 10S_ + 4  "9%@  AQ@  '@9  !M&   91<
M %\6  !<$P  6A$  %H.!@!:# T 5PP4 %4,' !3#20 4@TK % -,0!/#C@
M3@X^ $T.10!+#DT 2@Y5 $@/7@!'#V@ 10]U $,0A !!$)4 0!"F #X0NP ]
M$-P /1'V #T1_P ]$/\ /A#_ *D9  "2&P  @1P  '(=  !G'0  7QP  %D;
M  !5&0  4Q8  %(3  !2$0H 4! 0 $X1& !,$2  2A(G $D2+@!($S0 1Q,[
M $430@!$$TD 0Q12 $$46P _%&4 /A5R #P5@0 Z%9( .!6D #<5N0 U%=@
M-1;U #86_P V%O\ -Q7_ *,<  "-'@  >R   &TA  !B(0  6B$  %0?  !0
M'@  31L  $P9  !+%@8 218. $<7%0!%%QP 1!@D $(8*@!!&#$ 0!DX #\9
M/P ]&48 /!I/ #H:6  Y&F, -QMO #4;?@ S&Y  ,ANB # ;MP O&], +QSS
M "\;_P P&_\ ,!O_ )T?  "((@  =R,  &DD  !>)   5B0  % C  !+(@
M2"   $8=  !%' ( 0QP, $$<$@ _'1D /ATA #P>)P ['BX .A\U #D?/  W
M'T0 -A], #0@5@ S(&  ,2!M "\@?  M(8X +"&@ "HAM0 I(=  *2'R "DA
M_P J(/\ *R#_ )DB  "$)0  <R8  &4G  !;)P  4R<  $PF  !')0  1"0
M $(A   _(0  /2$) #LA$  Y(A8 ."(> #8C)0 U(RL -"0R #,D.0 R)$$
M,"1* "\E4P M)5X *R5K "HE>@ H)8P )B6? "0ELP C)<X (R7P "0E_P E
M)/\ )23_ )0E  " )P  ;RD  &(J  !7*@  3RH  $DI  !$*   0"<  #TF
M   Z)0  -R8& #4F#@ T)Q0 ,B<; #$H(@ P*"D +R@P "TI-P L*3\ *RE'
M "DI40 H*EP )BII "0J>  C*HH (2J= !\JL@ >*LP 'BKO !\I_P @*?\
M(2C_ ) H  !\*@  ;"L  %\L  !4+   3"P  $8L  !!*P  /"L  #@J   U
M*@  ,BL# # K#  N+!$ +2P8 "PL'P J+28 *2TM "@M-  G+CP )BY% "0N
M3P C+EH (2]G !\O=@ =+X@ '"^; !HOL  8+\H &"[M !DN_P ;+?\ &RW_
M (PK  !X+0  :"X  %LO  !1+P  22\  $,O   ^+@  .2X  #0N   P+@
M+2\  "LP"@ I,1  )S$5 "8Q'  E,B, )#(J ",R,0 A,SD (#-" !\S3  =
M,U< &S-D !HT=  8-(8 %C2: !0SK@ 3,\@ $S/L !0S_P 5,O\ %C'_ (<N
M  !T+P  93$  %@Q  !.,@  1C(  $ Q   [,0  -C$  #$Q   K,P  *#0
M "4U!@ C-@T (382 " W&0 ?-R  'C<G !TX+@ ;.#8 &C@_ !DX20 7.54
M%3EB !0Y<0 2.80 $3F8 ! YK0 ..,< #CCK ! X_P 0-_\ $3;_ (,Q  !P
M,@  830  %4T  !+-   1#0  #TT   X-   ,S0  "TU   H-P  )#D  " Z
M @ =.PL &SP0 !D]%0 8/1P %STC !8]*P 5/C, %#X\ !(^1@ 1/E( $#Y?
M  \^;P ./H$ ##Z5  L^J0 */L$ "CWD  L]^P ,//\ #3O_ 'TT  !K-@
M73<  %$W  !(-P  03<  #LW   U-P  ,#<  "HY   E.P  (#T  !P_   7
M008 %$,- !)#$@ 10Q@ $4,? !!$)P /1"\ #D0Y  U$0P ,1$X "T1;  E$
M:@ '1'P !D20  1#I0 "0[T  T/@  -#]@ $0O\ !D'_ '@X  !G.0  63H
M $XZ  !%.@  /CH  #@Z   S.@  +3L  "<]   A0   '$(  !=$   31@,
M#TD*  U*#P ,2A0 "TH;  E*(P (2BL !THT  5*/@ $2DD  DI6  !*90
M2G<  $J+  !*H0  2;D  $G=  !)]0  2/\  $C_ '(\  !B/0  53X  $H^
M  !"/0  /#T  #8]   O/@  *4   "-"   =10  %T<  !-*   /3 ( "T\)
M  =0#0 #41$  %$7  !1'@  428  %$O  !1.0  440  %)1  !28   47(
M %&'  !1G0  4;4  %#8  !0]0  3_\  $__ &Q   !=00  44$  $=!  !
M0   .4   #)!   J0P  )$8  !Y(   72P  $DX   Y1   +4P$ !E8'  !7
M#   6!   %@3  !9&0  6B$  %HI  !:,P  6C\  %I,  !:6@  6FP  %J!
M  !9F0  6;$  %C1  !8]   5_\  %?_ &5%  !810  344  $5$   ^1
M-44  "U'   E2@  'DT  !A0   24P  #E8   I9   $7    %X$  !?"0
M8 T  &$0  !B%0  8QL  &0C  !D+0  9#@  &1%  !D5   9&8  &1[  !C
MDP  8ZT  &+,  !A\@  8?\  &#_ %]*  !32@  2DD  $-(   Y20  +TP
M "=/   ?4@  &%4  !)9   -70  "&    )C    9@   &@!  !I!0  :@H
M &L-  !M$0  ;A8  ' =  !Q)@  <3$  ' ^  !P3@  <%\  '!S  !OC0
M;Z<  &[&  !M[P  ;/\  &S_ %I/  !03@  2$T  #U.   S40  *50  "!8
M   87   $6    QD   &:    &L   !O    <@   '0   !U    =P0  '@)
M  !Z#0  ?!   'T6  !_'@  @"@  ( U  " 10  ?U8  ']K  !_A   ?J
M 'V^  !\Z0  >_\  'K_ %94  !.4P  0E0  #=6   L6@  (E\  !AC   1
M:   "VT   -R    =@   'H   !]    @    (,   "$    A@   (<"  ")
M!P  BPP  (T0  "0%@  DA\  )(L  "2.P  DDT  )%B  "1>@  CY<  (^T
M  ".X0  C/L  (S_ %59  !(6@  .UT  "]A   D9@  &6P  !%R   *=P
M GT   ""    A@   (L   ".    D0   ),   "5    EP   )D   ";
MG00  )\*  "B#P  I!8  *8A  "F,0  ID,  *57  "D<   HXX  *.K  "A
MT   H/4  )__ $YA  ! 9   ,VD  "=N   ;=0  $7P   N#    B0   (X
M  "3    F    )T   "A    I    *4   "G    J0   *L   "M    L
M +(   "U"   N X  +P6  "\)0  O#<  +M,  "Z9   N8$  +>B  "WP
MM^H  +?\ $9K   Y<   *W<  !]_   3A@  "XX   &5    FP   *$   "F
M    JP   +    "S    MP   +<   "Z    O    +\   #!    Q    ,<
M  #*    S04  -$.  #4&0  U"L  -1   #36   TW0  -.2  #2L   TM,
M -+R #YY   Q@   (X@  !>1   -F0   Z    "G    K@   +,   "X
MO0   ,(   #&    R@   ,H   #-    SP   -(   #5    V0   -T   #?
M    XP   .<%  #K#P  [!\  .TS  #N2P  [V0  .^"  #PGP  \;D  /'8
M /\   #_    _P $ /\ "0#_  X _P 5 /\ '@#_ "D _P T /\ /P#_ $@
M_P!0 /\ 6 #_ %X _P!E /T :P#[ '$ ^0!W /@ ?@#V (4 \P"- /$ EP#N
M *( ZP"O .@ P #F .  XP#X .( _P#; /\ RP#_ ,$ _P"Y /\ M #_ /\
M  #_    _P   /\   #_  D _P 0 /\ &0#_ ", _P N /T .0#Y $( ]0!*
M /( 4@#N %@ ZP!> .D 9 #F &H Y !P .( =@#? 'T W0"& -D CP#5 )H
MT0"G ,X M@#+ ,X R0#P ,< _P#% /\ NP#_ +0 _P"M /\ J0#_ /\   #_
M    _P   /\   #[  ( ]@ - /$ $P#M !X [  H .D ,@#C #L W0!$ -@
M2P#3 %$ T !8 ,T 70#+ &, R0!H ,8 ;P#$ '8 P@!^ +\ AP"\ )( N@"?
M +< K0"U ,$ L@#D +$ _0"O /\ K #_ *4 _P"@ /\ G #_ /\   #_
M^P   .X   #D    W  ( -, $ #/ !@ RP B ,D *P#& #0 P0 ] +T 1 "Z
M $L MP!1 +4 5@"R %P L !A *X 9P"L &X J@!V *@ ?P"F (H HP"6 *$
MI0"? +8 G0#1 )P \P"; /\ G #_ )8 _P"3 /\ D #_ /\   #V    YP
M -,   #&    O0 # +@ #0"S !, L0 < *\ )0"N "X J0 V *8 /0"C $0
MH0!* )\ 3P"= %4 FP!: )H 8 "8 &8 E@!N )0 =P"2 ($ D ". (X G ",
M *T B@## (D Z "( /\ B0#_ (< _P"% /\ @@#_ /,   #C    S    +P
M  "P    IP   *$ " ">  \ FP 6 )D 'P"8 "< E@ O ), -P"1 #T C@!#
M (P 20"+ $X B0!4 (< 60"% &  A !G (( ;P"  'H ?@"& 'P E !Z *0
M>0"X '@ V !W /< > #_ '@ _P!W /\ =0#_ .8   #+    MP   *@   ">
M    E@   (\ ! "+  P B  2 (< &0"% "$ A  I (( , !_ #< ?0 ] 'P
M0P!Z $@ >0!- '< 4P!V %D = !A '( :0!Q ', ;P!_ &T C0!L )T :@"O
M &D R !H .T :0#_ &D _P!I /\ :0#_ -(   "X    I0   )<   "-
MA@   ($   !\  @ >0 . '< % !V !P =  C ', *P!Q #$ ;P W &X /0!L
M $, :P!( &H 3@!H %0 9P!; &4 8P!C &T 8@!X &  AP!? )8 70"H %T
MO@!< .0 7 #[ %P _P!< /\ 7 #_ ,(   "J 0  F ,  (D$  !_ @  >
M '0   !P  0 ;0 , &L $0!I !< :  > &8 )0!E "P 8P R &( . !@ #T
M7P!# %X 20!< $\ 6P!6 %H 7@!8 &@ 5P!S %4 @0!4 )$ 4@"C %$ MP!1
M -8 40#U %$ _P!1 /\ 4@#_ +8'  "?"0  C0L  'X,  !S"P  ; H  &@'
M  !E P  8P ' &$ #0!? !, 70 : %P (0!; "< 60 M %@ ,P!6 #D 50 _
M %0 10!3 $L 40!2 %  6@!/ &0 30!O $P ?0!* (T 20"? $@ L@!' ,P
M1P#O $8 _P!' /\ 1P#_ *P,  "5#@  @Q   '40  !K$   8P\  %X.  !;
M#   6@D" %D$"@!7  \ 50 5 %, ' !2 ", 40 I $\ +P!. #4 30$[ $P!
M00!* D@ 20)/ $@"5P!& V$ 10-M $,#>@!" XL 0 .< #\#KP ^ \@ /03J
M #T%_  ]!O\ /@;_ *00  ".$@  ?!,  &X4  !D%   7!,  %82  !3$0
M40X  % ,!0!0"0P 3P<1 $T'%P!+"!\ 20@E $@)*P!'"3$ 1@DX $0*/@!#
M"D4 0@I- $ +50 _"U\ /0MK #P+>0 Z#(H . R< #<,KP U#,< -0SI #4-
M_0 U#?\ -@S_ )T3  "'%0  =A<  &D8  !>&   5A@  % 7  !-%0  2A,
M $D1  !)#@< 2 T. $8-$P!$#1H 0PXA $(.* ! #BX /PXU #X//  ]#T,
M.Q!+ #H05  X$%X -A!K #00>0 R$(H ,1"< "\0L  M$,D +1'L "T1_P N
M$?\ +Q#_ )<6  ""&0  <1L  &0<  !9'   41P  $P;  !'&@  1!@  $,5
M  !"$P( 01(+ $ 1$  ^$A< /!(> #L3)0 Z$RL .!,R #<3.0 V%$  -!1(
M #,440 Q%%P ,!5H "X5=P L%8@ *A6: "@5K@ G%<< )A7J "<5_P H%?\
M*17_ )$:  !]'   ;1X  & ?  !6'P  3A\  $@>  !#'0  0!P  #X:   ]
M&   .Q<' #D6#@ X%Q0 -A<; #48(@ S&"@ ,A@O #$9-@ P&3T +AE& "T:
M3P K&ED *AIF "@:=  F&H8 )!J9 "(:K0 A&L4 (!KH "$:_@ B&O\ (QK_
M (T=  !Y'P  :2$  %PB  !2(@  2B(  $0A   _(0  /"   #D>   X&P
M-1P$ #0<#0 R'!( ,!T8 "\='P N'24 +1XL "L>,P J'CL *1]# "<?30 F
M'U< )!]D "(?<@ @'X0 'Q^7 !T?JP ;'\, &Q_G !L?_0 ='_\ 'A[_ (D@
M  !U(@  92,  %DD  !/)0  1R4  $$D   \(P  .",  #4B   S(   ," !
M "XA"@ L(1  *R$5 "HB'  H(B, )R(I "8C,  E(S@ (R-! "(D2@ A)%4
M'R1A !TD<  ;)(( &225 !<DJ@ 6),$ %23E !8D_  7(_\ &2/_ (4B  !Q
M)   8B8  %8G  !,)P  1"<  #XG   Y)@  -28  #$E   N)   *R4  "DE
M!P G)@X )283 "0G&0 C)R  (B<G "$H+@ @*#8 'B@^ !TH2  ;*5, &2E?
M !@I;@ 6*8  %"F4 !(IJ  1*<  $2CD !$H^P 3*/\ %"?_ ( E  !N)P
M7R@  %,I  !)*@  0BD  #LI   V*0  ,B@  "XH   J*   )BD  "0J!  B
M*PP ("L1 !\L%@ =+!T '"PD !LM*P :+3, &"T\ !<M10 6+E  %"Y= !(N
M;  1+GX $"Z2  XNIP -+;T #2W?  TM^0 .+/\ $"S_ 'PH  !J*@  6RL
M % L  !&+   /RP  #DL   T*P  +RL  "LK   F+   (BX  !\O   <, D
M&C$. !DQ$P 7,1H %C(A !4R*  4,C  $S(Y !(S0P 1,TX $#-;  XS:0 -
M,WH ##..  HSH@ (,KD "#+9  @R]  *,?\ "S'_ '<K  !F+0  6"X  $TO
M  !#+P  /"X  #8N   Q+@  +2X  "DN   C,   'S(  !LS   7-04 %#8,
M !(W$0 1-Q8 $3<= ! X)  /."P #C@U  TX/P ,.$H "SA7  DX90 '.'8
M!3B*  ,XGP !-[4  3?3  (W\0 #-O\ !3;_ ',N  !B,   5#$  $DQ  !!
M,0  .3$  #0Q   O,   *S   "4R   @,P  &S8  !<X   3.@( $#P)  T]
M#@ ,/1, "ST9  H](0 )/2D "#TQ  8^.P %/D8  SY2  $^80  /G(  #Z&
M   ]G   /;(  #W0   \\   //\  #S_ &TR  !=,P  4#0  $8T   ^-
M-S0  #(S   M,P  )S0  "(V   =.   &#H  !0]   0/P( #4$(  E##0 &
M1!$  T06  )$'0  1"0  $0M  !$-@  1$$  $1.  !$7   1&T  $2!  !$
MF   0Z\  $/-  !"\   0O\  $+_ &@V  !8-P  3#@  $,X   [-P  -38
M # V   I-P  (SD  !X[   8/0  $T   !!"   -10$ "$<'  -)#   20\
M $H3  !+&0  2R   $LH  !+,@  2ST  $Q)  !,5P  2V@  $M]  !+E
M2JP  $K*  !)[P  2?\  $G_ &(Z  !4.P  23L  $ [   Y.@  ,SD  "PZ
M   E/   'S\  !E!   31   $$<   Q)   (3    D\%  !0"@  4 T  %$0
M  !2%0  5!L  %0C  !4+   5#<  %1$  !44@  5&,  %1W  !4CP  4Z@
M %+&  !2[0  4?\  %'_ %P_  !//P  13\  #X^   W/0  +SX  "=    @
M0P  &48  !-)   /3   "T\   92    5    %<"  !8!P  60L  %H.  !;
M$0  718  %X=  !?)@  7S$  %X]  !>3   7ET  %YQ  !=B0  7:,  %S!
M  !;ZP  6O\  %K_ %9$  !+0P  0T(  #Q!   R0@  *44  "%(   :2P
M$TX   Y2   *50   UD   !;    7@   &    !B @  8P8  &4*  !F#@
M:!$  &H7  !K'P  :RD  &LV  !K10  :U8  &IJ  !J@@  :9T  &B[  !G
MYP  9O\  &7_ %%(  !(2   048  #='   L2@  (TT  !M1   350  #ED
M  A=   !80   &0   !G    :@   &P   !N    <    '(%  !S"0  =0T
M '<1  !Z&   >R$  'LN  !Z/0  >DX  'EB  !Y>0  >)8  '>S  !UX
M=/P  '/_ $Y-  !'3   .TT  #!/   F4P  '%@  !-<   -80  !F8   !J
M    ;P   '(   !V    >0   'P   !]    ?P   ($   "# @  A@<  (@,
M  "+$0  CA@  (XD  ".,P  C40  (Q8  "+;P  BHP  (FJ  "(SP  AO<
M (7_ $U1  !!4P  -%4  "E:   >7P  %&4   UJ   %<    '8   ![
M?P   (,   "'    B@   (T   ".    D0   ),   "5    F    )H%  "=
M#   H!$  *,:  "C*   HCH  *%.  "@90  H($  )Z@  "=P0  F^X  )K_
M $99   Y7   +6$  "%G   6;@  #G4   5[    @0   (<   "-    D@
M )8   ":    G0   )\   "A    I    *8   "H    JP   *X   "Q P
MM L  +@1  "Y'@  N2\  +A#  "W6@  M78  +27  "TM0  L>(  +#\ #]D
M   Q:0  )6\  !AW   /?P  !H<   ".    E    )H   "@    I0   *H
M  "N    L0   +(   "U    MP   +H   "\    OP   ,,   #&    R0
M ,X*  #2$P  TB,  -$W  #03P  SFH  ,V*  #*JP  R\L  ,OO #=Q   I
M>   '8   !&)   (D0   )H   "A    IP   *T   "S    N0   +X   #"
M    Q0   ,8   #)    S    ,X   #2    U0   -H   #>    X0   .4
M  #J"P  ZQ<  .HK  #J0P  ZEX  .IZ  #KF0  Z[4  .O5 /\   #_
M_P ! /\ !P#_  T _P 2 /\ &P#_ "4 _P O /\ .@#_ $, _P!+ /\ 4P#_
M %H _0!@ /L 9@#Z &L ^ !R /8 > #T (  \0") .\ D@#L )T Z0"J .8
MO #C -P WP#W -T _P#, /\ O@#_ +4 _P"P /\ K0#_ /\   #_    _P
M /\   #_  8 _P - /\ % #_ !\ _P I /L ,P#W #T \P!% .\ 30#L %,
MZ !9 .4 7P#C &4 X !J -T <0#: '@ U@"  -( B@#/ )4 S "B ,@ L@#%
M ,D P@#M ,  _P"[ /\ L #_ *@ _P"D /\ H0#_ /\   #_    _0   /H
M  #X    \  ) .P $0#H !D YP C .4 +0#> #8 U@ ^ -$ 1@#- $P R@!2
M ,@ 6 #% %T PP!C ,  :0"^ '  O !X +D @0"W (T M ": +$ J0"N +P
MK #A *H _ "H /\ H #_ )D _P"6 /\ E #_ /\   #Y    \@   .<   #;
M    T0 $ ,H #0#' !0 Q  = ,( )@"_ "\ NP W +< /P"T $4 L0!+ *X
M40"L %8 J@!< *@ 80"F &@ HP!P *$ >0"? (0 G0"1 )H H "8 +$ E@#,
M )4 \0"4 /\ D0#_ (L _P"( /\ A@#_ /<   #L    W@   ,D   "\
MM    *\ "@"K !  J0 7 *@ ( "G "@ H@ P )\ . "< #X F@!$ )@ 2@"6
M $\ E !5 ), 6@"1 &$ CP!H (T <0"+ 'L B0"( (< EP"% *@ @P"^ ($
MY "  /\ @ #_ 'P _P![ /\ >0#_ .D   #7    P0   +$   "F    G0
M )< !0"4  T D@ 2 )  &@"/ "( C@ J (L ,0") #@ AP ^ (4 0P"# $@
M@0!. '\ 5 !^ %H ? !A 'H :0!X ', =@!_ '4 C@!S )\ <0"S '  T !O
M /8 ;P#_ &\ _P!M /\ ; #_ -H   "_    K    )X   "3    C    (4
M  ""  D ?P / 'X %0!] !P ?  D 'H *P!W #$ =0 W '0 /0!R $( <0!(
M &\ 30!N %, ; !: &L 8@!I &P 9P!X &8 A@!D )< 8@"J &$ P@!@ .L
M80#_ &$ _P!A /\ 8 #_ ,4   "M    FP   (T   "#    ?    '<   !R
M  4 <  , &X $0!L !< ;  > &L )0!I "P 9P Q &8 -P!D #T 8P!" &(
M2 !@ $X 7P!5 %T 70!< &8 6@!R %D @ !7 )  5@"C %4 N0!4 -X 5 #[
M %0 _P!5 /\ 50#_ +8   "?    C0   '\   !U    ;@   &D   !F  $
M8P ) &$ #@!@ !, 7P 9 %X ( != "8 6P L %H ,@!8 #< 5P ] %8 0P!5
M $D 4P!0 %( 6 !1 &$ 3P!L $X >@!, (H 2P"< $H L0!) ,X 20#S $D
M_P!) /\ 2@#_ *H!  "4!0  @@<  '0(  !J"   8P8  %X$  !;    60 %
M %< # !6 !  5  5 %, &P!2 "( 40 H %  +0!. #, 30 X $P /@!+ $4
M2@!, $@ 5 !' %T 1@!H $0 =0!# (4 00"8 $  JP!  ,4 /P#J #\ _P!
M /\ 0 #_ * (  "*"P  >0T  &P-  !A#0  6@T  %4+  !2"0  4 8  $\"
M" !.  T 3  2 $L %P!* !X 20 C $< *0!& "\ 10 T $0 .@!" $$ 00!(
M $  4  ^ %H /0!D #P <@ Z (( .0"4 #@ IP W +X -@#C #8 ^0 V /\
M-P#_ )@-  "##@  <A   &41  !;$0  4Q   $X0  !*#@  2 T  $<* P!'
M!PH 100. $0"$P!" AH 00(@ $ #)0 ^ RL /00Q #P$-P [!#X .@5% #D%
M3@ W!5< -@5B #0&<  R!H  ,0:2 # &I0 O!;L +@7= "X&]0 M!_\ +@?_
M )$0  !]$0  ;!,  %\4  !5%   3A0  $@3  !$$@  01   $ .  ! #08
M0 H, #X)$  \"18 .PH< #D*(@ X"B@ -PLN #8+-0 U"SL ,PM# #(,3  P
M#%8 +PQA "T,;P K#'\ *@R2 "@,I0 G#+L )0S= "4-]0 F#?\ )PW_ (L2
M  !W%   9Q8  %L7  !1&   21<  $,7   _%0  /!0  #H2   Y$0$ .0\(
M #@.#0 W#A( -0X8 #0.'P R#B4 ,0\L # /,@ O$#H +1!" "P02P J$%4
M*!!A "80;P D$(  (Q"3 "$0IP ?$+T 'A#@ !X1]P ?$/\ (!#_ (84  !S
M%P  8QD  %<:  !-&P  11H  $ :   [&0  .!@  #46   T%   ,Q($ #(2
M"P Q$A  +Q(5 "T2'  L$R( *Q,I "H3,  H$S< )Q0_ "842  D%%, (A1?
M " 5;0 ?%7X '161 !L5I0 9%;L &!7> !@5^  9%/\ &A3_ ((7  !O&@
M7QP  %,=  !*'0  0AT  #P=   W'   -!L  #$:   O&0  +A8  "P7"  K
M%@X *1<3 "@7&0 G&"  )1@F "08+0 C&#0 (AD] " 91@ >&5$ '1E= !L:
M:P 9&GP %QJ/ !4:HP 4&;H $AG; !,9]@ 4&?\ %1C_ 'T:  !K'0  7!\
M % @  !'(   /R   #D?   T'P  ,1X  "T=   K'   *1L  "<;!0 E&PP
M)!P1 "(<%@ A'!T (!TC !\=*@ >'3( '!XZ !L>1  9'DX %QY; !8>:0 4
M'WH $AZ- !$>H@ 0'K@ #A[8  \>]0 0'?\ $1W_ 'H=  !G'P  62$  $TB
M  !$(@  /"(  #8B   R(0  +B$  "H@   G(   )!\  "(@ @ @( H 'B$/
M !TA%  <(1H &R(A !DB)P 8(B\ %R(X !4C00 4(TP $B-8 !$C9P 0(W@
M#B.+  TCGP ,([0 "R/0  LB\  ,(O\ #2'_ '8?  !D(@  5B,  $LD  !!
M)   .B0  #0D   O(P  *R,  "@C   D(P  (",  !TD   ;)0< &28- !<F
M$0 6)A< %2<> !0G)0 3)RP $B<U !$H/P 0*$H #BA6  TH9  ,*'0 "BB'
M  DHFP ')[$ !2?,  8G[  ')OX "";_ '$B  !@)   4R8  $@G   _)P
M-R8  #$F   M)@  *24  "4E   B)0  '2<  !DH   6*@0 %"L+ !(L$  1
M+!0 $"P; ! L(@ .+"D #BTR  TM.P ++48 "BU2  @M8  &+7  !"V#  (M
MF   +*X  "S)   LZP !*_P  BO_ &TE  !=)P  3R@  $4I   \*0  -2D
M "\H   K*   )R<  ",G   ?*   &RH  !<L   3+@( $# (  XQ#0 -,1(
M##$7  LQ'@ *,28 "#(N  <R-P %,D(  S).  $R7   ,FP  #)_   RE0
M,:P  #''   PZ@  ,/P  ##_ &@I  !8*@  3"L  $$L   Y+   ,BL  "TK
M   I*@  )2H  " K   <+   %RX  !,P   0,@( #C0'  HW#  '-Q  !3<4
M  ,W&P "-R(  #<J   X,P  .#X  #A*   X6   .&@  #A\   WD@  -ZD
M #;%   VZ@  -OT  #7_ &,L  !4+@  2"\  #XO   V+@  ,"X  "LM   G
M+0  (BT  !TO   8,0  %#,  ! U   .-P$ "CH'  8["P "/ X  #T2   ^
M%P  /AX  #XF   ^+P  /CH  #Y&   ^5   /F0  #YW   ^CP  /:<  #W#
M   \Z0  //T  #O_ %XP  !0,0  1#(  #LR   T,0  +C   "DO   D,
M'C(  !DT   4-@  $#D   T[   */0  !4 %  !!"@  0@T  $,0  !$%
M11H  $8B  !&*P  1C4  $9!  !&3P  1E\  $9S  !%B@  1:0  $3   !#
MZ   0_X  $+_ %@T  !+-0  034  #DU   R-   +3,  "8T   @-0  &C@
M !0Z   0/0  #4    E"   $10   $<#  !(!P  2@L  $L.  !,$0  3A4
M $\<  !/)0  3R\  $\\  !/2@  3UH  $YM  !.A0  3:   $R\  !+YP
M2_X  $K_ %,Y  !'.0  /CD  #<X   Q-P  *3<  "$Y   ;/   %3\  !!"
M   ,10  !T@   )*    30   $\   !1!   4@<  %0+  !5#@  5Q$  %D7
M  !:'P  62D  %DV  !91   650  %AG  !8?P  5YH  %:W  !5XP  5/T
M %3_ $X]  !#/0  /#P  #4[   L/   )#X  !Q!   51   $$@   M+   %
M3@   %$   !4    5P   %D   !;    70(  %X&  !@"P  8@X  &02  !G
M&   9R(  &8N  !F/   9DT  &5@  !E=P  9),  &.Q  !AW0  8/P  %__
M $E"  !!00  .C\  #!    F0P  'D8  !5*   03@  "E(   -6    6@
M %T   !@    8P   &4   !G    :0   &L!  !M!0  ;PH  '(.  !U$@
M=QL  '8F  !V-0  =48  '19  !T;P  <XL  '*I  !PS0  ;_<  &[_ $9&
M  ! 10  -48  "I(   @3   %U$  !!6   )6@   5\   !C    :    &L
M  !O    <@   '4   !W    >0   'L   !]    @ ,  (,(  "&#0  B1,
M (H=  "**P  B3P  (A/  "&9@  A8$  (2@  ""P@  @?   '__ $9+   Z
M3   +D\  "-3   86   $%X   ED    :0   &\   !T    >    'P   "!
M    A    (<   "(    BP   (X   "0    DP   )8   "9!P  G0T  *$4
M  "@(0  H#$  )Y$  "=6P  G'8  )F6  "9M0  EN4  )7^ #]2   R50
M)EH  !M@   19P  "6T   !T    >P   ($   "&    BP   )    "4
MEP   )D   "<    GP   *$   "D    IP   *H   "M    L08  +4-  "X
M%@  MR8  +8Y  "U4   M&H  +*)  "PJ@  KL\  *WU #=<   K80  'F@
M !-P   +>    (    "'    C@   )4   ":    GP   *0   "H    K
M *T   "P    LP   +4   "X    NP   +\   ##    QP   ,L%  #1#@
MT1L  - N  #/10  S5\  ,M^  #)G@  R+X  ,7I "]I   C<   %GD   V!
M   !BP   ),   ";    H@   *@   "N    M    +@   "]    P    ,(
M  #%    R    ,L   #.    T0   -8   #;    WP   .0   #H!@  ZQ$
M .HC  #J.@  Z50  .=R  #EDP  X[,  ./4 /\   #_    _P   /\ ! #_
M  L _P 0 /\ %P#_ "$ _P K /\ -0#_ #X _P!' /\ 3@#_ %4 _ !; /H
M80#X &8 ]@!M /0 <P#R 'L [P"$ .T C@#J )D Y@"G ., N0#? -4 VP#W
M -8 _P#  /\ L@#_ *H _P"E /\ H@#_ /\   #_    _@   /P   #\  ,
M_@ + /\ $0#_ !H _0 D /D +@#T #@ \ !  .P 2 #I $X Y@!4 .( 6@#?
M %\ W !E -@ :P#4 '( T ![ ,T A0#* )$ QP"> ,, K@#  ,4 O0#K +L
M_P"P /\ I #_ )P _P"8 /\ E0#_ /\   #Z    ]    /$   #R    Z@ %
M .< #@#B !4 X0 > .$ * #8 #$ T  Y ,L 0 #( $< Q0!- ,( 4P"_ %@
MO0!> +L 9 "Y &L M@!S +0 ? "Q (@ K@"5 *L I "H +@ I@#< *, ^P"?
M /\ E0#_ (\ _P"+ /\ B0#_ /D   #O    YP   -\   #/    R    ,$
M"@"_ !$ O  8 +L (0"Y "H M  R +$ .@"N $  JP!& *@ 3 "F %$ HP!6
M *$ 7 "? &, G0!J )L <P"9 'X E@", )0 FP"2 *T D #' (X \ "- /\
MA@#_ (  _P!] /\ ? #_ .T   #@    T0   +\   "S    J@   *8 !0"B
M  T H0 3 *  &P"? ", FP K )@ ,@"5 #D DP _ )$ 1 "/ $H C@!/ (P
M50"* %L B !C (8 :P"$ '8 @@"" (  D@!^ *, ? "Z 'H X0!Y /\ =P#_
M '( _P!P /\ ;P#_ -T   #+    M@   *<   "=    E    (X  0"+  H
MB0 0 (@ %0"' !T AP E (0 + "" #( ?P X 'T /0![ $, >0!( '@ 3@!V
M %0 =0!; ', 8P!Q &X ;P!Z &T B0!L )H :@"N &D S !H /8 9P#_ &4
M_P!D /\ 8P#_ ,H   "T    H0   ),   ")    @@   'L   !X  4 =@ ,
M '4 $0!T !@ <P ? '( )0!P "P ;@ R &P -P!J #P :0!" &@ 2 !F $X
M90!5 &, 70!B &8 8 !R %X @ != )( 6P"E %H O@!9 .D 60#_ %D _P!8
M /\ 6 #_ +D   "B    D    (,   !Y    <0   &T   !I  $ 9@ ) &4
M#@!D !, 8P 9 &, ( !A "8 8  L %X ,0!< #< 6P \ %H 0@!8 $@ 5P!/
M %8 5P!4 &  4P!L %$ >0!0 (H 3P"> $X M !- -H 30#[ $T _P!- /\
M30#_ *H   "4    @@   '4   !K    9    &    !=    6@ % %@ # !7
M !  5@ 5 %8 &P!5 "$ 4P G %( + !1 #$ 3P W $X /0!- $, 3 !* $H
M4@!) %L 2 !F $8 <P!% (0 1 "7 $, K !" ,D 0@#Q $( _P!# /\ 0P#_
M )X   ")    > ,  &H$  !A!   6@,  %4!  !2    4  " $X "0!-  T
M3  1 $L %P!* !P 20 B $@ )P!' "T 10 R $0 . !# #X 0@!% $$ 30 _
M %8 /@!A #T ;@ [ 'X .@"1 #D I@ X +\ . #H #@ _P Y /\ .0#_ )4#
M  " !P  ;PD  &(*  !8"P  40H  $P(  !)!@  1P,  $8 !@!$  L 0P /
M $( $P!! !@ 00 > #\ (P ^ "D /0 N #L -  Z #H .0!! #@ 20 W %(
M-@!= #0 :@ S 'H ,@", #$ H0 P +@ +P#> "\ ^0 O /\ , #_ (P)  !X
M#   : T  %P.  !2#@  2PX  $4-  !!#   /PH  #X( @ ]! @ / $- #L
M$  Z !4 .0 : #@ (  V "4 -0 K #0 ,  S #< ,@ ^ #$ 1@ O %  +@!:
M "T 9P K '< *@") "D G0 H +, )P#1 "< \@ G /\ )P#_ (8,  !R#@
M8Q   %81  !-$0  11$  $ 0   \#P  .0X  #<-   V"P0 -@@* #4&#@ T
M!1( ,@07 #$%'  P!2( +P4H "X&+@ M!C0 *P8\ "H&1  I!TX )P=9 "8'
M90 D!W4 (P>' "('FP @!K  ( ;+ !\%[0 ?!OX 'P?_ ( .  !M$0  7A(
M %(3  !($P  01,  #L3   W$@  -!$  #(0   P#P$ , T& # +"P O"A
M+0H4 "P+&0 J"Q\ *0LE "@,*P G##( )@PZ "0,0P C#$T (0U8 " -90 >
M#74 ' V( !H-G  9#;$ & S* !<,ZP 7#?P & S_ 'L1  !I$P  6A4  $X6
M  !%%@  /18  #@5   S%0  ,!0  "T3   K$@  *A # "H/"  I#@T * X1
M "8.%@ E#QT ) \C ",/*0 A$#$ (! Y !X00@ =$$P &Q!8 !D09@ 7$'8
M%1") !00G@ 2$+, $1#. !$0[@ 2$/X $A#_ '<3  !E%0  5Q<  $L8  !"
M&0  .AD  #08   P%P  +!<  "D6   G%0  )A0! "42!  C$@L (A(/ "$2
M%  @$AH 'A,@ !T3)P <$RX &A,V !D40  7%$H %A16 !049  2%'0 $12'
M ! 4G  .%+$ #13*  T4ZP .$_X #A/_ ',5  !A&   4QH  $@;   _&P
M-QL  #(:   M&@  *1D  "88   D&   (A<  " 6 0 >%@@ '18- !L7$@ :
M%Q< &1<= !@8)  6&"L %1@T !08/0 2&4@ $1E4 ! 98@ .&7( #1F$  P9
MF  *&:T "1C&  D8YP )&/H "A?_ &\8  !>&@  4!P  $4=   \'0  -1T
M "\=   J'   )AL  ",;   A&@  'AH  !P:   :&P4 &!L, !8<$  5'!4
M%!P; !,<(@ 2'2D $1TQ ! =.P .'44 #1Y1  P>7@ *'FT "1Z   <>E  %
M':H  QW"  ,=Y@ $'/@ !1S_ &L:  !;'0  31X  $(?   Z'P  ,A\  "T?
M   H'@  )!X  "$=   >'0  '!T  !@>   5'P( $R ) !(A#@ 0(1( $"$8
M  XA'P .(B8 #2(N  PB-P *(D$ "2)-  <B6@ %(FD  R)\  $BD0  (J@
M "'    AY0  (/@  "#_ &<=  !7'P  2B$  $ A   W(@  ,"$  "HA   F
M(   (B   !\?   <'P  &2   !8A   2(P( $"0'  XF#  ,)A  "R85  HF
M'  ))B( ""8J  8G,P $)ST  R=)  $G5@  )V8  "=Y   GCP  )J8  ":_
M   EY   )?D  "3_ &,@  !4(@  1R,  #TD   T)   +B,  "@C   D(@
M(2(  !XA   :(@  %R,  !,D   0)@( #B@'  LJ"P (*PX !BL3  0K&  "
M*Q\  2PG   L,   +#H  "Q%   L4P  +&,  "QV   LC   *Z0  "N^   J
MY   *OH  "G_ %\C  !0)0  1"8  #HF   R)@  *R8  "8E   C)   'R0
M !LD   7)0  %"<  !$I   .*P( "RT&  <O"P $, X  # 1   Q%0  ,1P
M #$C   R+   ,C8  #)"   R3P  ,E\  #)R   QB0  ,:(  #"\   PY
M+_L  "__ %HG  !,*   0"D  #<I   O*0  *2@  "4G   A)@  '"<  !@H
M   4*@  $2P   XN   +, $ !S(%  ,T"0  -0P  #8/   W$@  .!@  #@@
M   X*   .#(  #D]   Y2P  .5L  #AN   XA0  -Y\  #>Z   VY   -?P
M #7_ %4J  !(+   /2P  #0L   M*P  *"H  "0I   >*@  &2L  !0M   1
M+P  #3$   HT   '-@   C@$   Z!P  .PH  #T-   ^$   0!0  $ ;  !
M)   0"X  $ Y  ! 1P  0%8  $!I  ! @   /YL  #ZW   ]XP  //P  #S_
M % O  !#+P  .2\  #(O   L+0  )RP  " M   :+P  %3$  !$S   --@
M"3@   4[    /0   $ !  !!!   0P<  $4+  !&#@  2!$  $H6  !*'@
M2B@  $HT  !)0@  25$  $ED  !(>P  2)<  $>T  !&X   1?P  $3_ $HS
M   _,P  -C,  # Q   J,   (S$  !PS   6-0  $3@   T[   (/@   T$
M  !#    1@   $@   !*    3 0  $X'  !/"P  40X  %02  !5&0  52(
M %0N  !4/   5$L  %->  !3=   4I   %&N  !0UP  3_L  $[_ $4W   \
M-P  -38  "\T   F-0  'C<  !<Z   1/0  #$$   =$    2    $H   !-
M    4    %,   !5    5P   %@"  !;!@  70L  %\.  !B$P  8AL  &(G
M  !B-   844  &!7  !@;0  7XD  %VG  !<S   6O@  %G_ $$\   Z.P
M-#D  "HZ   A/   &$   !%#   ,1P  !DL   !/    4P   %8   !9
M7    %\   !A    8P   &4   !G 0  :@4  &T*  !P#@  <Q4  '(@  !R
M+0  <3T  '!/  !O90  ;H   &V?  !KP0  :?$  &C_ #]    Y/@  +C\
M "1"   :1@  $DH   Q/   $5    %@   !=    80   &4   !H    :P
M &X   !Q    <P   '4   !X    >P   'X#  "!"@  A0\  (<7  "&)
MA30  (1&  ""70  @78  '^6  !^M@  ?.<  'K_ #]$   S10  *$@  !U,
M   34@  #%<   -=    8P   &@   !M    <0   '8   !Z    ?@   ($
M  "#    A@   (D   "+    C@   )(   "5 0  F0D  )X0  ">&@  G2D
M )P\  ":4@  F&P  ):+  "4J@  DM0  )#Z #A+   L3@  (%,  !59   -
M8    V<   !N    =    'H   "     A    (H   ".    D@   )4   "7
M    F@   )T   "@    HP   *<   "K    KP   +0)  "X$   MQX  +4P
M  "S1@  L6   *]^  "LH   J\$  *GN #%5   D6P  &&$   YI   %<0
M 'D   "!    B    (\   "4    F@   )\   "D    J    *D   "L
MKP   +,   "U    N0   +T   #!    Q@   ,L   #1"@  TQ0  -$E  #0
M.P  S50  ,IQ  #(D@  Q;,  ,/> "EB   <:0  $7$   =[    A    (T
M  "5    G0   *,   "I    KP   +0   "Y    O    +X   #"    Q0
M ,@   #,    T    -0   #:    WP   .0   #J    [@P  .T:  #L+P
MZDD  .AE  #FA@  Y*4  .+& /\   #_    _P   /P  0#\  @ _@ . /\
M% #_ !T _P F /\ , #_ #H _P!" /\ 20#^ %  ^P!6 /D 7 #V &( ] !H
M /( ;P#P '8 [0!_ .H B0#G )4 Y "C .  M0#; -  U0#V ,H _P"V /\
MJ #_ )\ _P": /\ E@#_ /\   #[    ]@   /,   #S    ]@ ) /H #@#]
M !8 ^P @ /< *@#R #, [0 [ .D 0P#F $D X@!/ -X 50#; %L U@!@ -(
M9P#/ &X S !V ,D @ #& (P P@": +\ J@"[ ,$ N #I +8 _P"G /\ F@#_
M )( _P"- /\ B@#_ /H   #Q    Z@   .<   #G    Y  ! .  "P#; !$
MV@ : -L (P#1 "P R@ T ,8 .P#" $( OP!( +P 3@"Z %, N !9 +8 7P"S
M &8 L0!N *X =P"L (, J0"1 *8 H0"C +4 H #8 )X ^P"5 /\ BP#_ (4
M_P"  /\ ?@#_ .\   #C    V@   -,   #&    OP   +D !@"W  X M  4
M +0 '0"S "4 K@ M *L - "G #L I !! *$ 1@"? $P G0!1 )L 5P"9 %X
MEP!E )4 ;@"3 'D D "' (X EP", *D B0#$ (@ [P"% /\ ? #_ '8 _P!S
M /\ <@#_ .    #0    Q@   +8   "I    H0   )T  0"9  H F  0 )@
M%@"7 !X E  F )$ +0"/ #0 C  Z (H /P"( $4 AP!* (4 4 "# %8 @0!>
M (  9@!^ '$ ? !] 'D C0!W *  =0"V ', WP!R /\ ;@#_ &D _P!G /\
M90#_ ,P   "^    JP   )T   "3    B@   (4   ""  4 @  - '\ $0!_
M !@ @  @ 'T )@!Z "T =P S '4 . !T #X <@!# '  20!O $\ ;0!6 &P
M7@!J &@ : !U &< A !E )8 9 "K &( R0!A /8 8 #_ %P _P!; /\ 6@#_
M +T   "I    EP   (D   !^    >    ',   !O  $ ;0 ) &P #@!K !,
M:P 9 &H ( !H "8 9@ L &4 ,@!C #< 8@ \ &  0@!? $@ 70!/ %P 5P!:
M &$ 60!M %< >P!6 (X 50"B %, NP!2 .D 4@#_ %  _P!/ /\ 3P#_ *T
M  "8    A@   '@   !N    9P   &,   !@    70 % %P "P!; !  6P 5
M %L &P!: "$ 6  F %8 + !4 #$ 4P V %( / !1 $( 3P!) $X 40!- %L
M2P!F $H = !) (4 2 "9 $< L0!& -@ 1@#\ $4 _P!% /\ 10#_ )\   ")
M    >    &P   !B    6P   %8   !3    40 " $\ " !/  T 3@ 1 $X
M%@!- !P 3  A $H )@!) "P 2  Q $< -P!% #T 1 !$ $, 3 !" %4 0 !@
M #\ ;@ ^ 'X /0"2 #P J0 [ ,< .P#S #L _P [ /\ / #_ ),   !^
M;@   &$   !8    40   $P   !)    1P   $4 !0!$  L 0P . $, $@!#
M !< 0@ = $  (@ _ "< /@ L #T ,@ [ #@ .@ _ #D 1P X %  -P!; #4
M:  T '@ ,P", #( H@ Q +P ,0#G #$ _P R /\ ,P#_ (D   !V P  9@4
M %D'  !0!P  208  $,%  !  P  /@$  #P  P [  @ .@ - #H $  Y !0
M.0 9 #< '@ V ", -0 H #0 +@ S #0 ,@ [ #  0P O $P +@!7 "T 9  L
M ', *P"' "H G  I +4 *0#< "D ^P I /\ *@#_ ($$  !N"   7PH  %,+
M  !*"P  0@L  #T*   Y"0  -@@  #4%   T @8 ,P * #( #@ Q !$ ,0 5
M #  &@ O !\ +@ D "P *@ K #  *@ W "D /P H $D )P!4 "8 8  D &\
M(P"" "( EP A *X (0#, "$ \P A /\ (@#_ 'L)  !H#   6@T  $X.  !%
M#@  /0X  #@-   S#0  , P  "X+   M"0, +08( "P$#  K @\ *@$2 "D!
M%P H 1P )P A "8 )P E "T )  T ",!/0 B 48 (0%1 !\!70 > 6P ' %_
M !L E  : *H &@#% !H ZP 9 /\ &@#_ '4,  !D#@  50\  $H0  ! $
M.1   #,0   O#P  + X  "D.   G#0$ )PP% "<*"@ F" T )0<0 "0&%  B
M!AD (08? " ')  ?!RL '@<R !T'.@ <"$0 &@A/ !D(7  7"&L %@A] !4'
MD0 4!Z< $P:_ !(%Y  2!?H $@7_ '$.  !?$   41$  $82   ]$@  -A(
M # 2   K$0  *!$  "40   C$   (@X$ "$-!P A# L ( L. !\+$@ ="Q<
M' P< !L,(@ :#"D &0PQ !@,.0 6#4, %0U/ !,-7  2#6L $ U^  \-D@ .
M#:< #0R^  T,X  -#/4 #0S_ &T0  !<$0  3A,  $,4   Z%   ,A0  "T4
M   H$P  )1,  "(2   @$0  'A$# !P0!0 <#P@ &P\, !H.$  9#Q0 %P\:
M !8/(0 5$"@ %! P !(0.0 1$$0 $!!0  X070 -$&L #!!\  L0D  )$*4
M"!"\  <0WP '$/0 !P__ &D1  !8%   2Q4  $ 6   W%@  ,!8  "H6   F
M%0  (A4  !\4   =$P  &A," !D2!  7$@8 %A(* !42#@ 4$A( $A(8 !$3
M'@ 1$R4 $!,N  X3-P -%$  #!1+  L46  )%&< !Q1X  84C0 $%*,  Q.[
M  (3W0 !$O0  A+_ &43  !5%@  2!<  #T8   T&   +1@  "@8   C%P
M(!<  !T6   :%0  &!4" !85!  4%04 $A8( !$6#0 0%Q  #A<5  X7&P -
M%R( #!<I  L8,@ )&#P !QA'  485  $&&,  AAU  $8BP  %Z$  !>Y   7
MW0  %O4  !;_ &$6  !2&   11H  #L:   R&@  *QH  "4:   A&0  'A@
M !L8   8%P  %A<" !07 P 2& 4 $!D'  X;"P ,&P\ "QL3  H;&  ('!\
M!QPF  4<+P $'#@  AQ$   =40  '6   !UR   <B   '*   !NY   ;W@
M&O8  !K_ %X8  !/&@  0AP  #@<   O'0  *1P  ",<   ?&P  '!H  !D9
M   7&0$ %!D" !(: P 0&P0 #AT'  P>"P )'PX !B 1  4@%@ #(!P  2$C
M   A*P  (34  "%    A3@  (5T  "%O   AA@  ()X  ""X   ?W@  'O@
M ![_ %H;  !+'0  /QX  #4?   M'P  )QX  "(=   >'0  &QP  !@;   5
M&P  $AP  ! = @ .'P0 #"$&  DB"@ %(PT  B00   E$P  )1D  "8@   F
M*   )C(  "8]   F2@  )EH  "9L   F@P  )9P  "6W   DWP  (_D  "/_
M %4>  !'(   /"$  #(A   K(0  )2   " ?   ='@  &AT  !8>   3'@
M$"    XA   ,(P( ""4%  4G"0  * L  "H.   K$0  +!8  "P=   L)0
M+"X  "PZ   L1P  +%8  "QI   L@   *YH  "JU   IWP  *?L  "C_ %$B
M  !$(P  ."0  "\D   H(P  (R(  !\A   <(   %R   !,A   0(P  #B0
M  LF   (*   !"H$   L!P  +@D  # ,   Q#P  ,Q,  #,9   S(0  ,RH
M #,U   S0P  ,U(  #-E   R>P  ,I<  #&S   PW@  +_L  "[_ $PE   _
M)@  -2<  "TF   G)0  (B0  !XC   9(P  %"0  !$F   .*   "RH   <L
M   #+P   #$"   S!   -0<  #<*   Y#0  .A   #L5   ['0  .R8  #LQ
M   [/@  .TX  #M@   Z=P  .9(  #BP   WVP  -OP  #7_ $<I   [*@
M,BH  "LI   E)P  (28  !LG   5*   $2H   XL   *+P  !C$   $T
M-@   #@    [ 0  /00  #\'  !!"@  0PX  $41  !%&   12$  $4L  !$
M.0  1$@  $1;  !#<0  0HT  $&K  ! T@  /_H  #[_ $(M   X+@  +RT
M "DK   D*@  '2H  !<L   1+@  #3$   DT   $-P   #H    \    /P
M $$   !$    1@   $@#  !*!P  3 L  $X.  !0$P  4!P  % G  !/-
M3T,  $]5  !.:@  388  $RD  !*R@  2?@  $C_ #XR   U,0  +B\  "DN
M   @+@  &3$  !(S   .-P  "3H   (]    0    $0   !'    20   $P
M  !/    40   %,   !5 0  6 8  %H+  !=#@  7Q4  %X@  !>+   73P
M %Q.  !;8P  6GX  %B=  !7P   5?(  %3_ #HV   S-   +3(  "0S   ;
M-@  $SD   X]   (00   $4   !)    3    %    !3    5@   %D   !;
M    70   &    !B    90   &@%  !K"P  ;Q   &\8  !N)0  ;30  &U&
M  !K6P  :G4  &B4  !FM@  9.D  &+_ #@Y   R-P  *#D  !X[   5/P
M#D0   =)    30   %(   !6    6@   %X   !B    90   &@   !K
M;0   '    !S    =@   'D   !]!   @0L  (41  "$'0  @BP  ( ^  !^
M5   ?FL  'N*  !ZJ@  =]8  '7] #@]   L/@  (D$  !=&   /2P  !U$
M  !7    7    &(   !F    :P   &\   !T    >    'L   !^    @
M (,   "&    B@   (T   "1    E@,  )L,  "=$P  FR$  )HS  "720
ME&(  )-_  "0H   CL4  (SS #%$   E2   &DT  !!3   (6@   &$   !H
M    ;@   '0   !Y    ?P   (0   ")    C0   )$   "3    E@   )D
M  "=    H    *0   "H    K    +(#  "W#0  MQ<  +4H  "R/@  L%8
M *QS  "JE   J;0  *7E "I/   >5   $EL   IB    :@   ',   ![
M@@   (D   ".    E    )H   "?    I    *8   "I    K0   +    "S
M    MP   +L   #     Q0   ,L   #1!   U0X  -,=  #0,@  S4L  ,IF
M  #&AP  PJD  ,'+ ");   68@  #&L   %T    ?0   (<   "0    EP
M )X   "D    JP   +$   "V    N@   +P   #     Q    ,@   #+
MSP   -0   #:    X    .8   #K    \08  / 3  #N)P  [#\  .I;  #G
M>@  Y)L  ."[ /\   #[    ]@   /,   #T  4 ]@ , /H $0#_ !D _P B
M /\ + #_ #4 _P ] /\ 10#\ $P ^@!2 /< 6 #U %X \P!D /$ :@#N '(
M[ !Z .D A0#E )$ X0"@ -T L@#8 ,X T@#V ,$ _P"M /\ G@#_ )8 _P"0
M /\ C #_ /H   #R    [    .D   #I    [  % /( # #X !( ]P ; /4
M)0#P "X ZP W .8 /@#B $4 W0!+ -@ 4 #3 %8 T !< ,T 8@#* &H R !R
M ,4 ? #" (@ O@"6 +H J "W +\ M #H *X _P"= /\ D #_ (@ _P"# /\
M@ #_ /    #E    W@   -H   #;    W    -@ !P#1  X T0 5 -( '@#+
M "< Q0 O ,  -P"] #T N@!$ +< 20"U $\ L@!5 +  6P"N &$ K !I *D
M<P"G '\ I "- *$ G@"> +( FP#5 )D _ ", /\ @@#_ 'L _P!V /\ = #_
M .(   #3    R@   ,<   "\    M@   +   0"O  L K  1 *T & "M "
MJ  H *0 +P"@ #8 G0 \ )L 0@"9 $< EP!- )4 4P"3 %D D0!A (\ :@",
M '4 B@"# (@ E "& *< @P#" (( \ !\ /\ <P#_ &T _P!J /\ : #_ ,\
M  #!    N0   *T   "@    F    )0   "1  8 D  - )  $@"/ !D C@ A
M (L * "( "\ A@ U (0 .@"" $  @ !% 'X 2P!\ %( >@!9 '@ 8@!V &P
M= !Y '( B0!Q )T ;P"T &T WP!L /\ 90#_ &  _P!> /\ 7 #_ +X   "Q
M    H    )(   ")    @@   'P   !Z  $ >  ) '< #@!X !0 =P : '0
M(0!R "< <  M &X ,P!L #@ :P ^ &D 1 !H $H 9@!1 &0 6@!C &0 80!P
M %\ ?P!> ), 70"I %P R !; /< 5P#_ %0 _P!2 /\ 40#_ +    "?
MC0   '\   !T    ;@   &H   !F    90 $ &, "P!C !  8P 5 &, &P!A
M "$ 7P G %T + !< #( 6@ W %D /0!7 $, 5@!+ %4 4P!3 %P 4@!H %
M=P!/ (D 3@"? $T N@!, .D 2P#_ $D _P!' /\ 1P#_ *(   "-    ?
M &X   !E    7@   %D   !7    50 ! %0 !P!3  T 4P 1 %0 %@!2 !L
M40 A $\ )@!. "L 3  Q $L -P!* #T 20!$ $< 3 !& %8 1 !A $, < !"
M ($ 00"7 $  KP _ -< /P#_ #X _P ] /\ /@#_ )0   !_    ;P   &,
M  !9    40   $T   !*    2    $< ! !'  H 1@ . $8 $0!' !8 10 <
M $0 (0!" "8 00 K $  ,0 ^ #< /0 ^ #P 1P Z %  .0!; #@ :0 W 'H
M-@"/ #4 IP U ,8 - #U #0 _P T /\ -0#_ (@   !T    90   %@   !/
M    2    $,    _    /0   #P  @ \  < .P , #L #P [ !( .@ 7 #D
M'  W "$ -@ F #4 +  T #( ,P Y #$ 00 P $L +P!6 "X 8P M ', + "(
M "P H  K +L *P#J "L _P K /\ + #_ '\   !L    70$  %$"  !( P
M0 ,  #L"   W    -    #,    R  4 ,@ ) #( #0 Q !  ,0 3 #  &  O
M !T +0 B "P *  K "X *@ U "D /0 H $8 )P!1 "8 7@ E &X ) "" ",
MF0 C +, (@#> "( _P C /\ ) #_ '<   !E!   5@8  $L'  !""   .@@
M #4'   P!@  +04  "P#   K  , *@ ' "D "P I  X *0 1 "@ %0 G !D
M)@ > "4 )  D "H (P Q "( .0 A $, ( !. !\ 6@ > &D '0!\ !P DP ;
M *P &P#- !L ]@ ; /\ ' #_ ' %  !?"   40H  $8+   ]"P  -0L  # +
M   K"@  * D  "4(   D!P( (P0& ",""0 B 0P (@ / "$ $@ @ !8 'P ;
M !X (  = "8 '  N !L -@ : #\ &0!* !@ 5P 7 &8 %@!X !4 CP 5 *8
M% ## !0 [@ 4 /\ %0#_ &L(  !;"P  30P  $(-   Y#0  ,0T  "P-   G
M#0  (PP  "$,   ?"P$ '@H% !T("  =!@L ' 4- !P$$  ;!!0 &008 !D$
M'@ 8!", %P0K !8$,P 5!#P % 1' !,#5  2 V, $0-U ! "B@ 0 :( #P"\
M  \ Y0 / /X $ #_ &<+  !7#0  20X  #X/   U#P  +@\  "@/   D#@
M( X  !T.   ;#0$ &0T$ !@,!P 8"PD %PD, !<)#@ 6"1( %0D6 !0)&P 3
M"2$ $@DH !(),  1"3H $ E%  \)4@ ."6$ #0ES  P(B  +")\ "@>W  H&
MVP *!?8 "@3_ &,-  !3#@  1A   #L1   R$0  *Q$  "40   A$   '1
M !H/   8#P$ %@X$ !4.!P 4#0D $PT+ !,,#0 2#!  $0P4 ! ,&0 0#!\
M#PPG  X-+P -#3D # U%  L-40 )#6  " UQ  8-A@ %#9T ! RT  ,,T@ "
M#/$  @O_ %\.  !0$   0Q$  #@2   O$@  *!(  ",2   >$0  &Q$  !@1
M   5$ ( %! % !(0!P 1#PD $ \* ! .#  .#@X #@\2  T/%P ,$!T #! D
M  H0+  )$#8 "!!!  803@ %$%T  Q!O  $0A   $)P   ^T   .U   #O,
M  [_ %P0  !-$@  0!,  #84   M%   )A0  "$3   <$P  &1(  !82   4
M$0, $A$& !$1"  0$ H #A +  T1"P ,$0T "Q(1  H2%0 )$AH "!(A  83
M*0 %$S,  Q,^  (32P  $UH  !-L   3@@  $IL  !*T   1UP  $?4  !'_
M %@2  !)%   /14  #,6   K%@  )!4  !\5   :%   %Q0  !03 0 3$@0
M$1(' ! 2"0 .$@D #1()  L3"@ )% T !Q4/  86$P $%A@  Q8?  (6)P
M%S   !<[   72   %U@  !=J   6@   %ID  !6T   5V0  %/<  !/_ %44
M  !&%@  .A<  # 8   H&   (A<  !T6   9%@  %A4  !,4 P 2$P8 $!,'
M  \3!P -% < "Q4(  D6"0 && P  QH.  $:$0  &A8  !L<   ;)   &RT
M !LX   ;1@  '%4  !MG   ;?0  &Y<  !JS   9VP  &/D  !?_ %$6  !#
M&   -QD  "X:   F&@  (!D  !L8   8%P  %18! !,5!0 1%00 #Q4$  T6
M!  +%P4 "1D&  8:"  "' H  !X-   @$   (!,  " 9   @(0  (2H  "$U
M   A0@  (5(  "!D   @>@  'Y4  !^Q   >VP  '?H  !S_ $T9   _&P
M-!P  "L<   D'   'AL  !H:   7&   %!<" !(7 @ 0& $ #1D!  L: @ (
M' , !1T$  (?!@  (0@  ",+   E#@  )A$  "86   F'@  )R<  "<R   G
M/P  )DX  "9@   F=P  )9(  "2O   CV@  (OL  "'_ $@=   \'@  ,1\
M "@>   B'@  '1P  !D;   6&@  $AH  ! ;   -'   "QT   @?   $(0
M 2,"   E!   )P8  "D)   L#   +@\  "X3   N&@  +B,  "XN   N.P
M+DH  "U<   M<@  +(X  "NL   JU   *?L  "C_ $0@   X(0  +B$  "8A
M   @(   '!X  !@=   4'0  $!X   X?   +(0  !R,   ,E    )P   "D
M   L 0  +@,  # &   S"@  -0T  #81   V%P  -A\  #8I   V-@  -D4
M #57   U;0  -(D  #*H   QSP  ,/H  "__ #\D   T)   *R0  "0C   ?
M(0  &R   !8@   1(0  #B,   HE   &*    BH    M    +P   #(    T
M    -P   #D#   [!@  /@H  $ .  !!$@  01H  $ E  ! ,0  0$   #]2
M   ^9P  /8(  #RB   ZQP  .?@  #C_ #HH   P*   *2<  ",E   ?(P
M&"0  !(E   .*   "BH   4M    ,    #,    V    .    #L    ^
M0    $(   !% @  1P8  $H*  !-#@  314  $P?  !,*P  2SH  $I,  !)
M80  2'P  $>;  !%OP  0_,  $+_ #8L   M*P  )RD  ",G   ;*   %"H
M  XM   *,   !#,    W    .@   #T   !     0P   $8   !(    2P
M $T   !0    4P$  %8&  !9"P  6Q   %L9  !:)0  630  %A&  !76@
M570  %23  !2M0  4.H  $__ #,P   L+@  )RP  !XM   6+P  $#(   HV
M   #.@   #\   !"    1@   $D   !,    3P   %(   !5    6    %H
M  !=    8    &,   !G!@  :PP  &P2  !K'@  :RP  &D]  !G4@  9FH
M &2)  !AJP  7]P  %W_ #$S   L,0  (C(  !DU   1.0  "CT   )"
M1P   $P   !0    5    %@   !;    7P   &(   !E    :    &L   !N
M    <0   '4   !Y    ?08  ((-  ""%@  @"0  'XU  !\20  >V$  'A_
M  !VGP  <\8  '#W #$V   F.   '#L  !)    +10   DL   !1    5@
M %L   !@    90   &D   !N    <@   '8   !Y    ?    'X   ""
MA0   (D   ".    DP   )@&  "<#@  FQH  )@K  "60   DED  )%S  "-
ME0  B[4  (CH "L^   @00  %4<   U-   "5    %L   !A    :    &X
M  !S    >0   'X   "#    B    (P   "/    D@   )4   "9    G0
M *$   "E    J@   +    "W!P  N!$  +4A  "R-0  KTT  *II  "HB
MIJ@  *+1 "-(   83@  #E0   1<    9    &T   !U    ?    (,   ")
M    CP   )4   ";    H    *,   "F    J0   *T   "Q    M0   +D
M  "^    Q    ,H   #2    V@H  -86  #2*0  SD$  ,I<  #%?   PIT
M ,&] !Q5   17   !V4   !N    =P   '\   "(    D    )@   "?
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M__________________________________________\
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M_ZUE5_BI;VCMHWAYXYM_A]N2A934BXR>SX61ILN E:S'?)FQQ7F>M<)VH[G
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MS(R)K,6,B;# C(FPP(R)L,",B;# C(FPP(R)L,",B;# C(FPP(R)L,",B;#
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M0NO-657?R6!JS\)F?<*Y;(VVL7*;JZMXIJ*E?JZ9H(2UDIV+NHR:D[Z'F)O
MA)>EPH"6K\)_DK.\@)&XM8"1N+6 D;BU@)&XM8"1N+6 D;BU@)&XM8"1N+6
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M;47_BWA/_X:$6?R"CF'W?99H]'B=;O%THW/N<:EW[&ZN>NILLWWI:KE_YVC
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MDS00_YL\%_^A12#_ITTM_Z98._^D8DK\H6Q9]YQV:.^6@'7GCXF!X(>0C-J
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ML4HK_;53._:U7$ONLV1=Y:YL;]NE<X'.G7J/Q96!F;Z.B**WB)"IL827KJR
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MC!@#_XHC!O^:)P?_IR\*_[,W#_R]/QCSQD8CZM!,,N#54D7/SUE:P<A@;+3
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MF=B);9G8B6V9V(EMF=B);9G8B6V9V(G_?1@"_X<: _^8'@/_IB,#_[,I!//
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M%K/D1"6HX4LUG-U21)'965*&U6!=?--F9G31;6YLSW1T9LY\>6'-A7U<S(Z
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M-D;_LS=$_[\X1/_%.$3_Q3A$_\4X1/_%.$3_Q3A$_\4X1/_%.$3_Q3C!LP
MLKX" *7, 0"9W0, D/\2 H;_'P5[_R<*<?\N#FC_-A-A_SX76O]&&E7_31U1
M_U4?3O]=($O_9"))_VLC1_]Q)$;_>"5$_W\F0_^&)T'_CBA _Y8H/_^>*3W_
MIRD\_[ J//^T*CS_M"H\_[0J//^T*CS_M"H\_[0J//^T*CS_M"JSN $ I<8
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M7$SKTEU+ZNE=2N/S7$KC\UQ*X_-<2N/S7$KC\UQ*X_-<2N/S7$KC\USYF0,
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M(S7_N2,U_[DC-?^Y(S7_N2,U_[DC-?^Y(S7_N2.MM@  G\0  )+2  "$X0
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M_Y,+ .&E!0#2LP< R;X' ,++" "\W0X M-TC ZK:,PV?UD <E--**HK04C>
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M0T3R^D)$\OI"1/+Z0D3R^D)$\OI"1/+Z0D3R^D+1H@  P*X  +*X 0"GQ (
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M64^\_E50NOY54+K^55"Z_E50NOY54+K^55"Z_E7_A0( W9@  ,VF @#!L0,
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M6V":_E9AF/]289C_4F&8_U)AF/]289C_4F&8_U+_<@L _X,% -^3 0#1GP0
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M0DC'_T)(Q_]"2,?_0DC'_T+>C0  RYP  +VG  "QL   IKH  )S$ P"3SP<
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M8?\XL&'_.+!A_SC_4AL!_UX6 ?]H% '_<AD!_WD? O]^)P/Y@# %\($Y"N>
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M4G&$_TURA/](<H3_1W*$_T=RA/]'<H3_1W*$_T?_9@T _W4' /:#!0#<CP,
MTI@& ,RA!P#(J @ OZD: +6H+06LI#P0I*!'&YR=4264F5DOCI9@-HB39SV"
MD&Y#?8YV2'F,?4QTBH50<(B/5&R'F5=IAJ599H:S6V6&Q5MEAN-9:(CV4FN*
M_TULBO](;(G_1VR)_T=LB?]';(G_1VR)_T?_:0L _W@$ .6'  #6D@, S9P%
M ,:D!@#!JP8 N:T7 +"L*P2GJ3H.GZ9%&9:B3R./GU<MB)Q?-8*99CM]EVQ!
M>)5S1G.3>TMND8-/:H^-4F:.EU5CC:-88(VQ65^-PUI>C>!88H_U4F20_TUF
MD/](9H__1V:/_T=FC_]'9H__1V:/_T?_; @ _GP  -Z*  #0E@( R)\$ ,"G
M! "YK@, LK(4 *JQ* .AKS<,F:Q#%Y&H32&)I54J@J-<,GR@8SEWGFH^<IQQ
M1&V:>4AHF8%,9)>+4&"6E5-=EJ)56I6P5UF5P5=8E=Y66Y;S4%V7_TQ?E_]'
M8);_1F"6_T9@EO]&8);_1F"6_T;_< , ZX$  -:/  #*F@$ P:,# +FJ @"Q
ML@$ JK<1 *.W) *;M30*D[) %(JO2AZ#K5,G?*M:+G:H835PIV@[:Z5O0&>C
M=T1BHG](7J&)3%J@E$]7GZ!15)^N4U.?P%-2G]U259_S3E>@_TI9H/]&69__
M15F?_T59G_]%69__15F?_T7_=0  X(8  ,^3  #$GP$ NJ<! +&N  "IM@
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M$"G_I! H_[01)__'$2?_X1$F__(1)O_V$2;_]A$F__81)O_V$2;_]A&GJ0
MF;,  (N^  !^R0  <-,  &3>  !8YP  4O\) $W_$0!'_QD!0_\B 3[_*@(Z
M_S(#-_\Y S/_/P0P_T8%+?]-!2O_5 8H_UL')O]C!R/_;0@A_WD)'_^'"1[_
ME0H=_Z,*'/^Q"AO_P L:_]8+&O_?"QK_WPL:_]\+&O_?"QK_WPN;L0  C;P
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M1GYS_T%_=/\]@'7_.H!U_SJ =?\Z@'7_.H!U_SK_70X _VH& /]V!@#D@ ,
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M/&J&_SQJAO\\:H;_/&J&_SS_9P0 ]G8  -R"  #.C0  Q94" +Z< P"WH0(
MKZ01 *BD) *@HC0(F)] $9&<2AJ*F5,BA)=;*7Z58C!YDFDU=9!P.G"/=SYL
MC7]":(R)1F6*DTEAB9]+7HFL35V)O4Y<B=9-7HKP2&"+_D-BB_\_8XS_/&.,
M_SQCC/\\8XS_/&.,_SS_:@  YGH  -6&  #)D0  P)D! +B? 0"PI0  J*D.
M **I(0&:J#$&DZ4^#XNC2!B$H%$@?IY9)WB<8"USFF<R;YAN-VJ6=3QFE7T_
M8I2'0U^2D49;DIU)69&K2E>1NTM6D=-+5Y+O1UJ2_4)<D_\^79/_.UV3_SM=
MD_\[79/_.UV3_SO_;@  X'X  ,Z+  #$E0  NIT  +&C  "IJ0  H:X+ )NO
M'0&4KBX$C*P[#(6J1A5^J$X<>*96(W*D72IMHF0O::%K-&2?<SA@GGL\7)V%
M/UF<CT)5FYQ%4YNJ1U&;ND=0F]%'49ON1%.;_$!5F_\\5IO_.E:;_SI6F_\Z
M5IO_.E:;_SKQ=   V8,  ,B0  "^F@  LZ$  *JG  "AK@  E[4& )*V& ",
MM2H#A;0W"7ZR0A%WL$P8<:Y4'VRM6R5GJV(J8JII+UZI<3-:J'HW5J>#.E.F
MCCU0IIM 3:6I04NEND)+IM%"2Z7M/TVE_#Q.I/\Y3Z3_-T^D_S=/I/\W3Z3_
M-T^D_S?D>@  SXD  ,*5  "VGP  K*4  **L  "8LP  CKL" (B]$@"#O24!
M?+PS!G:[/PUONDD4:KA1&F6W61]@MF D7+5G*5BT;RQ4LW@P4;.",TVRC39*
MLIHX2+&H.D:RN3I%LM$Z1K'M.4>P_#9'L/\T2*__,TBO_S-(K_\S2*__,TBO
M_S/;@@  QY   +N<  "NHP  I*H  )FQ  "/N0  A, # 'O&#0!XQAX <\8N
M VW%.@AGQ$4.8L-.$UW#5AA9PEX=5<%F(5'!;B1.P'<H2\"!*TB_C"U%OYHO
M0[^H,4&_NC%!P-(Q0;[N,$&]_2]!O/\N0;S_+4&\_RU!O/\M0;S_+4&\_RW.
MB@  OY@  +&@  "FJ   F[   )"X  "%OP  >L<$ &_/"0!KT14 9]$F 6/1
M- 1>T$ (6=!*#%7/4Q!1SUL43L]C&$O.:QM(SG4>1<Y_($+.C") SIDD/LZH
M)CS.NB8\S]0F/,WO)3O,^R4[R_\E.\K_)3O*_R4[RO\E.\K_)3O*_R7#DP
MM9X  *BF  "=K@  D;8  (6_  !YQP  ;\X$ &36"0!>WA$ 6]X@ %?>+0)3
MWSH$4-]$!DS?3@E)WU<,1M]?#T/?:!%!WW$3/M]\%3S?B1<ZX)89.."E&C?@
MMQHVX<T:-M_L&C7>^1HTW?\;--S_&S3<_QLTW/\;--S_&S3<_QNYG   JJ0
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M!A3_P 84_]8&$__I!A/_Z083_^D&$__I!A/_Z0:7KP  B+H  'K%  !LSP
M7MH  %#@  !$Y@  //4  #?_!  S_PT +_\3 "O_&@ H_R$ )?\G 2'_+0$>
M_S(!&_\X 1G_/P$6_T8"%/]- A'_5@(0_V "#O]L @S_>P,+_XL#"O^: PK_
MJ ,)_[4#"/_" PC_P@,(_\(#"/_" PC_P@.*N   >\,  &S.  !>VP  3^(
M $+G   V[   ,?\  "S_   G_P< (_\. "#_$@ <_Q@ &/\= !7_(0 2_R8
M$/\L 0[_,0$-_S<!"O\^ 0C_1@$%_T\! ?]9 0#_9@$ _W0! /^" @#_D (
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M.(UB_S..9/\PCF3_+(YE_RR.9?\LCF7_+(YE_RS_50X _U\& /]I!@#T<@8
MXG@& -M\"0#9?PP S8$= ,1_, .[?#\*M'A+$JUU51JH<5XAHVYF)I]L;BN;
M:G4OF&A],Y5GA#:298PYCV25/(QCGSZ)8JI AV&W0H5AR4*$8N1!A63W.X9F
M_S6'9_\QAVC_+H=I_RV':?\MAVG_+8=I_RW_5PP _V$$ /YL P#D=0$ VWL%
M -. " #0@PH QX4: +Z$+0.V@3P)KWU($JAY4AFB=EL@G7-C)IEP:RN5;G(O
MD6UY,XYK@3:+:8DZB&B2/(5GG#^"9J=!@&:T0WYFQ41\9N%#?FCU/']J_S>
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M,79T_S%V=/\Q=G3_,79T_S'_708 _VD  .)T  #4?0  RX4" ,2*! "_C04
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M-DFAM#9(H<@W2*#G-4F@^3)*G_\P2Y__+DN?_RU+G_\M2Y__+4N?_RW=>0
MR88  +R2  "QF@  IJ   )RF  "1K   AK(  'VV#0!YMAT =;8L F^U.09J
MM$,+9;-,$6"R5!9<L5L:6+!C'E6O:R%1KW,E3JY]*$NMB"I(K94M1:VC+D2M
MLR]#K<@O0JSG+T.K^2U$J_\K1*K_*42J_RE$JO\I1*K_*42J_RG1@   P8T
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M$3#8]A(PUO\3+]3_$R_4_Q,OU/\3+]3_$R_4_Q.SF@  IJ$  )JI  "-L0
M@+H  '3!  !HR0  7,\  %+5 P!(W @ 1>42 $/E'@!!YBH /N8U 3OG/@$Y
MYT<"-^=0 S3H600RZ&(%,.AM!B[I>0<LZ8<(*^J6"2GJIPHHZKH*)^O6"B?I
M\ HGY_T))N;_"B;F_PHFYO\*)N;_"B;F_PJHH   G*<  (^P  ""N0  =,(
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M 0#_R@$ _\H! /_* 0#_R@&&MP  =\$  &C,  !:UP  2]X  #[D   RZ0
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M)J10_R.C4?\@HU+_'J)2_QVB4O\=HE+_':)2_QW_2@\ _U(* /]:"0#_8 L
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M)H)D_R6"9/\E@F3_)8)D_R7_4P8 _UT  .=G  #;;P  T'0" ,IX!0#&>0<
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M-EB LC=6@,4W5H#C-EB!]S%9@?\M6X+_*EN"_RE;@O\I6X+_*5N"_RGL9@
MV',  ,=^  "\AP  LXX  *F2  "@E0  EI@! )"9$P"*F20!A9@R!'^6/@EY
ME$@.=)-0%&^15QEKD%X=:(YE(62-;25@C'4H78M^*UJ*B"Y7B90Q5(FA,U*(
ML#11B,,U4(CB-%*(]C!3B/\L5(C_*56(_RA5B/\H58C_*%6(_RCF:P  T'@
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M)3^F]"- I?\B0*7_(4"D_R! I/\@0*3_($"D_R#*?@  NXL  *^5  "DFP
MF:$  (ZF  ""K   =[$  &JV  !CN X 8;@= %ZX+ %:N#@"5[A"!5.X2PA0
MMU,+3;=;#DJV8Q!'MFL31+5U%D*U@1@_M8X:/;6<'#NUK!PZM< =.;7?'#FS
M]!PYLO\<.;'_&SFP_QLYL/\;.;#_&SFP_QO!A@  M),  *>:  "<H   D:<
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M!1_@_P4?X/\%'^#_!1_@_P6DG@  F*4  (NN  !]M@  <+X  &/&  !6RP
M2]   $#5   VW   +^4' "WM$  K[A@ *>XB "?O*P E[S0 (_ \ "'P10 ?
M\4X '?)8 1OR9 $9\W$!&/.! 1?TD@(5]*4"%/6Z A/UU@(3].\"$O+\ A+P
M_P(2\/\"$O#_ A+P_P*:I   C:T  '^V  !QOP  8\<  %;.  !)TP  /=H
M #/?   JXP  )O0% "3[#0 A_!, 'OT; !S](@ 9_BD %_XQ !7_.0 3_T$
M$?]* !#_50 ._V$ #/]O 0S_@ $*_Y,!"?^F 0C_N@$'_]0!!__K 0;_]@$&
M__8!!O_V 0;_]@&/K   @+8  '*_  !CR0  5M$  $C8   [W0  ,.(  ";F
M   ?\   '/\  !G_"0 6_PX %/\3 !'_&0 /_QX #?\D  O_*P )_S( !O\[
M  /_1   _T\  /]<  #_:P  _WT  /^0  #_HP  _[0  /_&  #_U@  _]8
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M$<(Z_Q#!.O\/P#K_#K\Z_PZ_.O\.OSK_#K\Z_P[_/1, _T(/ /]&#0#_2Q
M_TX6 /]/'P#]3BD!]$PT >Q(00+F1TX$X$5;!MM$9@G60G ,TD%Y#L] @A#-
M0(H1RC^1$\D_F13'/J 5Q3ZH%L,^L1?!/KP7P#[+&+T^XABZ/O(7MS__%K5
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M&I11_QB44?\8E%'_&)11_QC_20@ _U   /M8  #E7@  W6(# -9C!P#480H
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M+F5KLB]D:\0P8FOA+V1L]BIF;?\F9FW_(V=N_R!G;O\@9V[_(&=N_R#V60
MX&4  ,YO  #"=@  N7P  +%_  "I@   H( ' )F!%P"4@2@!CH U XA^00B#
M?$H-?GI2$7IX615V=V 9<W9G''!T;A]M<W8C:G)_)F=QB2ED<94K8G"A+6!P
ML"]><,(O77#?+U]Q]2I@<?\F87+_(V)R_R!B<O\@8G+_(&)R_R#O7   W&D
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M*DV#\2=/@_\D4(/_(E"#_Q]0@_\?4(/_'U"#_Q_>:0  R74  +R   "RB
MJ(T  )V1  "3DP  A98  'Z7"P!YEQD =9<H 7&7-0-LEC\&:)5("F244 UA
MDU<179)>%5J19AA7D&X;5(]W'E&.@2!.CHTC2XV:)4F-J29(C;LG1XW4)T>,
M\"1(C/\B28O_($J+_QY*B_\>2HO_'DJ+_Q[5;@  PWL  +>%  "LC0  HI(
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M%#2K_Q0TJ_\4-*O_%#2K_Q2[A0  KY   *.7  "8G0  C*,  ("H  !TK0
M:+(  %RV  !0N@$ 2;P- $B\&0!&O2< 1;TS $.]/0%!O4<!/[U0 CV]6 ,Z
MO6$%.+UK!C:]=P@TO80),KV3"C"]I LOO;<,+K[0"RZ\[@PMNOX-++G_#2RX
M_PXLN/\.++C_#BRX_PZSCP  II<  )N=  "/HP  @ZH  ':P  !JM0  7KH
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M  SK_P"7HP  B:L  'NT  !MO   7\0  %+*  !%S@  .=,  "_8   EW0
M'>$  !CL @ 6]PL %/<1 !'X%P 0^!X #ODE  WY+0 +^C4 "?L_  ?[2@ $
M_%<  _UF  +^=P  _8L  /V?  #\M0  _-$  /SM  #\_   _/T  /S]  #\
M_0"+JP  ?;0  &Z]  !@Q@  4LT  $32   WV   +-T  "+A   9Y0  $^H
M !#Z   ._P8 #?\,  K_$  '_Q0 !/\:  '_(   _R<  /\P  #_.@  _T4
M /]3  #_8@  _W4  /^*  #_GP  _[,  /_'  #_Y0  _^4  /_E  #_Y0!_
MM   <+T  &''  !3T   0]8  #;=   JX@  '^8  !;J   0[0  #/H   G_
M   &_P   O\$  #_"0  _PT  /\0  #_%   _QH  /\A  #_*0  _S0  /]
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M N@;_P/G'/\#YAS_ ^4<_P/E&_\#Y1O_ ^4;_P/_+1L _S 7 /\Q%0#_,!8
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M#*TZ_PNM.O\+K3K_"ZTZ_PO_/ T _T & /]%! #_20D _TL- /E*$0#M21H
MXT8F -I&-@#11D4!RT51 \9$7 7"0F8(OT)O"KQ!=PNZ0'\-N#^&#K8_CA"T
M/I41LCZ=$K ^IA.O/K 4K3Z]%*L^S16I/N85IC_W$Z1 _Q*C0/\0HD#_#Z)
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M(W):LB1Q6L0E;UKA)7!;]B!Q7/\<<5W_&G%=_QAQ7?\7<5W_%W%=_Q?]3P
MY5D  --B  #':   O6P  +9M  "O;   IVL+ *!L&0";;"H!E6LW I!I0P6+
M:$P)AV94#(-E6Q" 8V(3?6)I%7IA<!AX87@:=6"!'7-?BQ]P7I8B;EZB)&Q>
ML"5K7L$F:5[>)FI?]"%K8/\=:V'_&VQA_QEL8?\8;&'_&&QA_QCU40  XEP
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M)EIL[R-;;/\?7&W_'%UM_QI=;?\976W_&5UM_QGH6@  TF8  ,-O  "X=@
MKWL  *9^  "=?@  D7P  (I\#P"%?1X @7TM 7Q\.0-W>D,&<WE+"7!X4PQL
M=UH0:79A$V9U:!9C=&\887-X&UYR@AY;<HT@67&:(E=QJ"15<;DE5''0)51Q
M[B)6<?X>5W'_'%=Q_QI8<?\96''_&5AQ_QGC7@  S6D  +]S  "T>@  JW\
M **"  "8@P  BX$  (2!#0!_@AH >X(I 7:!-@)R@4 %;G])"&I^4 MG?5<.
M9'Q>$6%[9A1>>FT76WIV&5EY@!Q6>(L?4WB8(5%WIB)0=[<C3W?.(T]W["%0
M=_T>47?_&U)W_QE2=_\94G?_&5)W_QG>8@  R&X  +MW  "P?P  IX0  )V'
M  "2AP  A(<  'V'"0!XB!8 =(@F '"(,@)LAST$:(9&!F6%3@EAA54,7H1<
M#UN#8Q)9@FL55H%T%U. ?AI0@(D<3G^6'DQ_I2!*?[8A27_,(4E^ZQ]*?OP<
M2W[_&DM^_QE,?O\83'[_&$Q^_QC59P  PW,  +9\  "LA   HHD  )B+  "-
MC0  ?(T  '6.! !OCQ( ;9 A &F0+@%ECSD"8HY"!%Z.2P=;C5(*6(Q9#%:+
M80]3BV@24(IQ%$V)>Q=*B8<92(B5&T:(HQU$B+0=0XC*'4.'ZAQ$AOL:1(;_
M&$6&_Q=%A?\7187_%T6%_Q?-;0  O7@  +&"  "GB@  G(X  )*0  "&DP
M>94  &R7  !FEPX 8Y@; &&8*0!>F#4!6I<^ U>71P55ED\'4I96"4^57@Q,
ME&8.2I1O$$>3>1-$DX450I*3%T"2HA@^DK,9/9+)&3V1Z1@]D/H7/H__%CZ/
M_Q4^C_\5/H__%3Z/_Q7%<P  MW\  *R)  "ACP  EI,  (N6  !_F0  <YP
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M"":R_PBOC0  HI0  )>:  "+H   ?J8  '&K  !EL   6;0  $VW  !"NP
M.+X! "_""0 MPQ( +,,> "O#*0 JQ#, *<0] "C%1P GQ5$ )L5< "7&:  C
MQG8!(L:& 2#&F $?QJL!'L?! 1[&Y $=Q/@"',+_ QS!_P,<P?\$','_!!S!
M_P2EE   FIH  (ZA  "!IP  <ZX  &>T  !:N0  3KT  $+    XPP  +\<
M ";+!  >T H &]$1 !K2&@ 9TB4 &-,O !C3.@ 7U$0 %M10 !7570 4U6L
M$]9\ !+7CP 1V*0 $-F[ !#9W@ 0U?, $-/_ !#2_P$0T?\!$-'_ 1#1_P&<
MF@  D:$  (.H  !UL   :+<  %N]  !.P0  0L4  #?(   MS   )-   !S5
M   5V@4 $.(+ !#C$0 .Y!H #N0C  WE+0 ,Y3< "^9"  KF3P )YUT ".=M
M  ;F@  %YI4 !.:K  +FQ  !YN8  .?Y  #G_P  YO\  .;_  #F_P"3H0
MA:D  '>Q  !IN0  6\   $[&  !!R@  -<X  "K2   AU@  &=L  !+?   -
MXP  "_$(  GS#@ '\Q, !/(:  +R(@  \BH  /(T  #R/P  \DP  /)<  #R
M;0  \H(  /*8  #SK0  \\8  /3E  #T]@  ]/L  /3[  #T^P"'J0  >;(
M &JZ  !<P@  3LD  $#.   STP  *-@  ![=   5X0  #^0   KH   %\P
M _T!  #\"   ^PT  /L1  #[%@  _!X  /PF  #\,   _3P  /Y)  #^6@
M_FT  /^"  #_F   _ZP  /_   #_V   _^0  /_D  #_Y ![L@  ;+L  %W$
M  !/S0  0-(  #+9   FW@  &^(  !+F   ,Z@  !>T   #T    _P   /\
M  #_    _P0  /\)  #_#@  _Q(  /\8  #_(0  _RL  /\W  #_1@  _U@
M /]K  #_@   _Y4  /^F  #_LP  _[L  /^[  #_NP#_&R8 _QPD /\:) #_
M%2< _Q M /\*-@#_!4, _P%0 ?\ 7@'_ &L!_P!V ?\ @0#_ (H _P"2 /\
MF@#_ *  _P"F /\ K #_ +( _P"Y /\ P@#_ ,T _P#? /\ [ #_ /@ _P#_
M /T _P#] /\ _0#_ /T _P#] /\ _0#_ /T _P#_'R, _Q\A /\>(0#_&2,
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M M ;_P+0&_\"T!O_ M ;_P+_+1( _RX/ /\N#0#_+Q  _R\7 /\N(0#_+"T
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M"9PZ_PG_.P( _SX  /=$  #F1P  WT@! -I&!@#90 L S4(9 ,5$*P"^1#L
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M%H5(M1>#2,<8@4CD&(%*]Q6 2O\2@$O_$(!+_P^ 2_\.@$O_#H!+_P[_0P
M[$L  -U3  #.6   Q%H  +U:  "X5P$ L50. *I6'@"E5BX GU8[ 9M51@.7
M5% %DU-8")!27PJ-468,BU!M#HA/=!"&3WP2A$Z%$X).CA6 39D7?DVD&'Q-
MLAEZ3<,:>4W?&GA.]!=X3_\4>$__$GA0_Q!X4/\/>%#_#WA0_P_]1@  YT\
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M:U;5'6M6\!IK5_\7:UC_%&Q8_Q)L6/\1;%C_$6Q8_Q'Q2P  WU8  ,Q>  #
M9   MV<  *YH  "G9@  GV(& )AC% "29"0 C6,R 8EB/0*$84<$@6!/!WU?
M5@EZ7ET+=UUD#75<:Q!S7',2<%M[%&Y;A1=L6I 9:EJ<&VA9JAQF6KH=95K1
M'65:[AME6_X79EO_%69<_Q-G7/\29US_$F=<_Q+M3@  VED  ,AA  "\9P
MLVH  *ML  "B:@  F6<" ))G$0"-9R$ B&<O 81F.P)_940$>V1-!GAC5 EU
M8EL+<F%A#7!A:0]M8' 2:U]Y%&E?@Q=F7HX99%Z:&V)>J!QA7K@=7U[.'5]>
M[!M@7_T885__%6%?_Q-B7_\28E__$F)?_Q+J40  U%P  ,1D  "Y:@  L&X
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M%5)L_Q12;/\34FS_$U)L_Q/<7   QV<  +EO  "O=@  I7L  )Q\  "1?
M@G@  'IY!P!U>10 <GHC &YZ+P%K>3H":'E# V1X2P5A=U((7W=9"EQV8 Q9
M=6@/5W1P$51T>A-2<X863W.3&$URH1E,<K$:2G+&&DIRY1I+<OD73'+_%4QR
M_Q--<O\237+_$DUR_Q+48   PFL  +5T  "K>P  HG\  )>!  ",@0  >GX
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M#CF)_PZ_<@  LGT  *>&  "<B@  D8X  (:1  !ZDP  ;94  %^7  !4F0$
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M 22QE (CL:8"(K*[ B&RVP(AK_,#(*[_ R"M_P0?K/\$'ZS_!!^L_P2JBP
MG9$  ).7  "'G   >J(  &VG  !@JP  5:\  $FQ   ^M   ,[<  "JZ P D
MO T (KT5 "&](  AO2H (+TS !^^/0 >OD< ';Y2 !R_7@ :OVP &;]\ !B_
MC@ 7P*$ %L"V !3 TP 5OO$ %;S_ 16[_P$4NO\"%+K_ A2Z_P*AD@  EI@
M (J>  !]I   ;ZH  &*O  !6M   2K<  #ZZ   SO0  *L   "'$   9QP4
M$\L+ !',$@ 1S!L $,PE  _-+P .S3H #LU&  W-4@ -SF  #,YP  O.@P *
MSI< "<ZL  C.Q@ (SN@ ",W[  G+_P )R_\ "<O_  G+_P"8F   C9X  '^E
M  !QK   9+,  %>Y  !*O0  /L   #+#   HQ@  '\H  !?-   1T0  #-8%
M  C9#  &V1( !=H;  3:)  #VRX  =LY  #<10  W5(  -YB  #><P  WH@
M -^=  #?LP  W\X  .#N  #?^@  W_\  -__  #?_P"/GP  @:8  '.N  !E
MM0  6+T  $K"   ]Q0  ,<D  ";,   =T   %-0   [9   )W0   ^$   #C
M!P  XPT  .02  #E&0  YB(  .<K  #I-@  ZT,  .Q2  #L8@  [78  .Z,
M  #NH0  [[<  ._1  #OZP  \/8  /#V  #P]@"$IP  =:\  &>W  !9OP
M2\8  #S*   OS@  )-(  !K8   2W   #.    7C    YP   .L   #K
M[04  .X+  #P$   \14  /,>  #T)P  ]S,  /E   #Z40  ^V,  /QW  #]
MC0  _:,  /ZV  #^R0  _]\  /_?  #_WP!WL   :+D  %K!  !,R@  /,\
M "[4   BV@  %]X  !#B   )Y@   .D   #L    \    /8   #V    ]P
M /@   #Z!P  ^PT  /T1  #_&0  _R,  /\O  #_/@  _T\  /]B  #_=P
M_XT  /^?  #_K@  _[H  /^Z  #_N@#_%B, _Q4A /\2(0#_#B0 _P8J /\
M,P#_ $$ _P!. /\ 7 #_ &@ _P!T /\ ?@#_ (< _P"/ /\ E@#_ )P _P"B
M /\ J #_ *X _P"U /\ O0#_ ,< _P#6 /\ YP#^ /, _@#^ /T _P#\ /\
M^P#_ /L _P#[ /\ ^P#_ /L _P#_&B  _QD> /\6'@#_$"  _PHE /\$, #_
M #T _P!+ /\ 6 #_ &0 _P!P /\ >@#_ (, _P"+ /\ D@#_ )@ _P"> /\
MI #_ *H _P"Q /T N0#[ ,, ^@#0 /@ XP#W /$ ]@#\ /0 _P#T /\ \P#_
M /, _P#S /\ \P#_ /, _P#_'1P _QP9 /\9&0#_%!L _PXA /\,+ #_"3D
M_P5& /\"4P#_ %\ _P!K /\ =0#_ 'X _P"& /\ C@#_ )0 _@"; /P H0#Z
M *< ^ "N /4 M0#S +\ \0#+ /  WP#N .X [ #Y .L _P#J /\ Z@'_ .D!
M_P#I ?\ Z0'_ .D!_P#_(!< _Q\4 /\<$P#_%Q4 _Q8= /\3* #_$#0 _PU!
M /\,3@#_"5H _PAF /\(< #^!WD _ >! /H'B0#X!Y  ]@:6 /,&G0#Q!J,
M[P:J .T&L@#_XO__24-#7U!23T9)3$4 " GJ!KL Z ;( .8&W #D!NP X@CZ
M . *_P#>"_\ W0O_ -T,_P#<#/\ W S_ -P,_P#_(Q( _R,0 /\A#@#_'A
M_QX8 /\<(P#_&"\ _Q0[ /\220#\$%4 ^ ]@ /0/:@#Q#W0 [PY\ .T.A #K
M#HL Z0Z2 .<.F0#F#J  Y ZG .(.KP#@#K@ W@[% -P.V@#6$.P TA'Z ,\2
M_P#-$O\!S!+_ <L3_P'*$_\!RA+_ <H2_P'_)P\ _R<, /\E"0#_)@T _R43
M /\C' #_("@ ^QPU /4:0@#O&$\ ZA=: .8690#C%FX X!9W -X6?P#<%H<
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M!*(M_P2B+/\$HBS_!*(L_P3_,@  _S,  /DX  #I.0  XCD  -XU!P#>+@T
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M"7I&_PGU/@  YD@  --/  #'5   O54  +94  "P4   J4P+ *)-& "=3B@
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M$FE1IA1G4;859E'+%652Z11E4OL19E/_#V93_PUF4_\,9E/_#&93_PSJ20
MU5,  ,5:  "Z7P  L&(  *AB  "?7P  EEH  (]:$ "*6QX A5LL (%;. %]
M6T$">EI* W=9401T6%@&<5A?!V]79@EM5VT+:U9V#6E6?P]G58H19567$V-5
MI!1A5;058%7(%E]5YQ5@5OH28%;_#V%7_PYA5_\-85?_#&%7_PSG3   T58
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M%5!BX1518O8246+_$%)B_PY28O\-4F+_#5)B_PW95@  Q&   +=H  "L;@
MHW$  )IS  "/<0  ?VL  'AK!0!R:Q( ;FP? &ML+ !H;#<!9FQ  F-K2 -@
M:T\$7FI6!EQJ70=9:64)5VEM"U5I=PU3:((/4&B/$4YGG1--9ZP42VC %$MH
MWA1+9_423&?_#TQG_PY-9_\-36?_#4UG_PW26@  P&0  +-L  "I<@  H'8
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M##I[_PLZ>O\+.GK_"SIZ_PO :0  LG0  *=\  "=@0  DH0  (>&  ![AP
M;H<  &"'  !5AP$ 4(@. $Z(&@!-B28 2XDP $F).@!(B4(!1HE* 42)4@)"
MB5H#0(AC!#V(;04[B'@&.8>&"#>'E0DUAZ8*-(>Y"C.'TPHSAO ),X7_"3.$
M_PDS@_\),X/_"3.#_PFY<   K7H  **"  "7AP  C8H  (&,  !UC@  :(\
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M ABF_P*EB0  F8\  (^4  "#F0  =9X  &BB  !<I@  4*D  $2L   YK@
M+[   ":S   >M08 &;</ !BW%P 7MR$ %K<J !6W-  4N#X $[A) !*X5  2
MN6( $;EQ !"Y@P /N9< #KFL  VYQ  -N.< #K;[  ZU_P .M/\ #K3_  ZT
M_P"<D   DI4  (:;  !YH   :Z8  %ZK  !2KP  1K(  #JU   OMP  );H
M !V]   5P   $,,&  O&#@ *Q14 "<4>  C%*  'Q3( !L8]  7&20 %QE<
M \9F  +&=P !QHL  ,:@  #%M@  QM(  ,7O  #%_   Q?\  ,7_  #%_P"5
ME@  B9P  'NC  !MJ0  8*\  %.T  !&N   .KL  "Z^   DP0  &\0  !/'
M   .R@  ",X!  '0"@  T!   - 6  #1'@  TB<  -,Q  #4/   U4D  -98
M  #6:0  UGP  -:2  #6IP  UK\  -;@  #6\P  UOX  -;_  #6_P",G0
M?J0  &^K  !AL@  5+D  $:]   YP0  +<0  "+'   9RP  $<X   S2   %
MU0   -L   #< P  W0H  -X/  #?%   X1P  .(D  #D+@  YCH  .=)  #H
M60  Z&L  .F!  #IF   Z:T  .G%  #IX@  Z?(  .GU  #I]0" I0  <:T
M &.U  !5O   1\(  #G&   LR@  (,X  !;2   /U@  "-L   #?    XP
M .4   #G    Z $  .H'  #K#0  [1$  .\8  #Q(0  \RL  /8X  #W2
M^%H  /EM  #ZA   ^IL  /JO  #ZP@  ^MH  /K?  #ZWP!TK@  9;8  %:^
M  !(Q@  .<L  "O0   ?U   %-H   W?   %XP   .8   #I    [0   .\
M  #Q    \P   /4   #V @  ^ D  /H.  #]$P  _QP  /\H  #_-@  _T<
M /]:  #_;@  _X4  /^:  #_JP  _[D  /^\  #_O #_$2  _Q > /\,'@#_
M!"$ _P G /\ , #_ #X _P!, /\ 60#_ &4 _P!P /\ >@#_ (, _P"+ /\
MD@#_ )@ _P"> /\ I #_ *H _P"P /\ N #_ ,( _P#. /\ X@#^ /  _0#[
M /L _P#[ /\ ^P#_ /H _P#Z /\ ^@#_ /H _P#_%!P _Q(: /\.&@#_"!P
M_P A /\ +0#_ #H _P!( /\ 50#_ &$ _P!L /\ =@#_ '\ _P"' /\ C@#_
M )0 _P": /X H #] *8 _ "L /L M #Y +T ^ #) /< W #U .P \P#X /,
M_P#R /\ \0#_ /  _P#P /\ \ #_ /  _P#_%Q@ _Q46 /\1%0#_#!< _P4=
M /\ * #_ #8 _P!# /\ 4 #_ %P _P!G /\ <0#_ 'H _ "" /H B0#X )
M]P"6 /4 G #T *( \P"H /$ L #P +@ [@## .P TP#J .< Z0#U .< _P#F
M /\ Y0#_ .4 _P#E /\ Y0#_ .4 _P#_&A, _Q@1 /\4$ #_#Q$ _PT9 /\*
M) #_!3  _P$^ /\ 2P#_ %< _@!B /H ; #U '4 \@!] /  A #N (L [ "1
M .L EP#I )X YP"D .8 K #D +0 X@"_ .  S0#> ., W #R -H _0#8 /\
MU@#_ -4!_P#5 ?\ U0+_ -4"_P#_'A  _QP- /\7"P#_%0X _Q05 /\1'P#_
M#BH _PLX /T(10#X!E$ ] 1< .X$9@#J!&\ Y@-W .0$?P#B!(8 X 2, -X$
MDP#=!9H VP6@ -@%J #5!;$ T@6[ - &R0#.!^  S CQ ,D*_P#'"_\ Q@S_
M ,4,_P#%#/\ Q0S_ ,4,_P#_(0P _R & /\< P#_'0H _QL0 /\8& #_%",
M]A$P .\./@#J#DH Y0U6 .$-8 #=#6D V0UQ -4->0#3#8$ T0V( ,\-CP#-
M#I8 RPZ= ,H.I0#(#JX Q@^Y ,00R #"$-\ OA'R +L2_P"Y$_\ MQ/_ ;83
M_P&V$_\!MA/_ ;83_P'_)08 _R,  /\C  #_) , _R$* /T=$0#Q&AL Z!8G
M .$4-0#:$T, TQ1/ ,X560#+%6, R!9K ,46<P##%WL P1>" , 8B0"^&)
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M Y M_P/_,   \C,  .0Z  #6/0  S#P  ,<Y  ##,04 O2X1 +4P(0"P,C
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M"7H^J0EX/K@*=S_-"G4_Z@IT0/P(=$#_!W1 _P9S0/\&<T#_!G- _P;Q.P
MWT4  ,Q,  "_3P  ME   *Y/  "G2@  H$0' )I%% "51B( D$8P (Q'/ ")
M1D4!AD9. 8-&50*!15P#?D5C!'Q$:@1Z1'$%>41Y!G=$@@AU0XT)<T.9"G%#
MI@MP0[4,;D3)#&U$YPQM1?H*;$7_"&Q%_P=L1?\';$7_!VQ%_P?L/P  V$D
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M3 )M4E,":U)9 VE28 1G46@&95%P!V-1>0AA480*8%"1#%Y0G@U<4*T.6U'
M#EI1W@]:4?4,6E+_"EM2_PE;4?\(6U'_"%M1_PC?2@  R5,  +M:  "P7P
MIF$  )UA  "47@  B%<  (!6"@!Z5Q4 =E<B '-8+@!P5SD ;5=! 6I720)H
M5E "9E97 V167@1B564%8%5M!UY5=PA<58(*6E6.#%E5G U75:L.5E6^#U55
MVP]55?,-557_"U95_PE65?\)5E7_"%95_PC;30  Q5<  +A>  "M8@  HV4
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M"D=B_PE'8O\)1V+_"$=B_PC*6   NF(  *YI  "C;@  FG$  )!R  "$<0
M=&L  &EI  !C:0L 7VD5 %QJ(0!::BT 6&LV %9K/P%5:T<!4VI. E%J50-/
M:ET$36IE!4II;@9(:7D'1FF&"41IE0I#:*4+06FW#$!ISPQ :.X+06C_"D%G
M_PE!9_\(0F?_"$)G_PC%70  MF8  *IM  "@<P  EG8  (MW  " =@  <'(
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M!2U]_P6S;@  J'@  )U_  "2@P  B(8  'V'  !PB   8XD  %6*  !+B@
M08H" #N+#@ YBQ< .(PB #>,+  VC#4 -(P] #.,1@ RC4\ ,8U8 "^-8@$M
MC&X!*XQ[ 2J,BP(HC)P")HRO B6,Q@(EB^@")8K[ R6(_P,EB/\#)8?_ R6'
M_P.M=@  HX   )>%  "-B0  @HP  ':.  !ID   7)(  %"3  !$E   .I4
M #&6"  MEQ$ +)<: "N7)  JERT *9<V "B8/P GF$@ )IA2 "687  CF&@
M(IAW ""8AP ?F)D!'9BL 1R8PP$<E^4!')7Z 1N4_P$;D_\"&Y/_ AN3_P*G
M?P  G(8  )&+  "'CP  >I(  &V5  !AF   59L  $F=   ]G@  ,Y\  "JA
M   AHPH 'Z,1 !ZC&@ =I"0 '*0M !ND-@ :I#\ &:1* !BD50 6I6$ %:5P
M !2E@0 3I90 $J6H !&EOP 0I.( $:+X !&A_P 1H/\!$:#_ 1&@_P&@A@
ME8P  (R1  !_E0  <9H  &2>  !8H0  3*0  $"F   UIP  *JD  "*L   9
MK@  $K ) !"Q$  0L1@ #K$B  ZQ*P -L34 #;%   RQ2P +L5@ "K%G  BQ
M>  'L8L !;&@  2PM0 $L-  !+#O  6O_@ &KO\ !J[_  :N_P"8C@  CY,
M (*8  !UG0  9Z(  %JG  !.JP  0:T  #6O   KL0  (;0  !BV   1N0
M#;P#  >^#  #O1(  ;T9  "^(@  OBL  +XV  "^00  OTX  +]<  "_;0
MOX   +Z5  "^J@  OL(  +WD  "]]@  O?\  +W_  "]_P"2E   A9H  'B@
M  !JI@  7*L  $^P  !"LP  -;8  "JX   @NP  %[X  !#!   +Q   !,<
M  #)!P  R0T  ,D2  #*&0  RR(  ,LK  #--0  SD$  ,Y0  #/8   SW(
M ,^'  #/G0  S[,  ,_.  #/ZP  SO@  ,[^  #._@"(FP  >J(  &RH  !>
MKP  4+4  $*Y   UO   *;\  !["   5Q@  #LD   C,    T    -,   #5
M    U@8  -@,  #9$0  VQ8  -P?  #>*   X#0  .)!  #B40  XV,  .-W
M  #DC@  Y*0  .2Z  #EU   Y>H  .7S  #E\P!\HP  ;JH  &"R  !1N0
M0[X  #7"   HQ@  ',D  !/-   ,T0  !-4   #:    W@   .$   #B
MY    .4#  #G"0  Z0X  .L2  #M&@  [R0  /(Q  #T00  ]%,  /5F  #U
M?   ]I,  /:I  #WO   ]\X  /??  #WWP!PK   8;0  %.[  !%PP  -L<
M "?,   ;T   $=4   K;    WP   .(   #E    Z0   .P   #M    \
M /$   #S    ]00  /<*  #Z$   _!8  /\A  #_+@  _T   /]3  #_:
M_X   /^6  #_J   _[8  /^_  #_OP#_#1P _PH; /\"&P#_ !X _P D /\
M+@#_ #P _P!* /\ 5@#_ &, _P!M /\ =P#_ '\ _P"' /\ C@#_ )0 _P":
M /\ H #_ *8 _P"L /\ M #_ +T _P#) /X W0#] .T _ #Z /L _P#Z /\
M^0#_ /H _P#Z /\ ^@#_ /H _P#_$!D _PT7 /\&%@#_ !@ _P > /\ *@#_
M #< _P!% /\ 4@#_ %X _P!I /\ <@#_ 'L _P"" /\ B0#_ )  _@"6 /T
MG #\ *$ ^P"H /D KP#X +@ ]@## /0 T@#S .< \@#V /  _P#O /\ \ #_
M .\ _P#O /\ [@#_ .X _P#_$A0 _P\2 /\+$@#_ !( _P : /\ )0#_ #,
M_P!  /\ 30#_ %D _P!D /T ;0#[ '8 ^0!] /< A #U (L ] "1 /, EP#Q
M )T \ "C .X J@#L +, Z@"] .@ RP#G .$ Y0#Q ., _0#C /\ X@#_ .$
M_P#A /\ X #_ .  _P#_%!  _Q$. /\-#0#_!P\ _P(5 /\ ( #_ "T _P Z
M /\ 1P#Y %, ]0!> /( : #P '  [0!X .L ?P#I (4 Z ", .8 D@#E )@
MXP"? .$ I@#? *X W "X -H Q0#6 -D U #L -( ^0#1 /\ SP#_ ,X _P#.
M /\ S@#_ ,X _P#_%PP _Q0( /\/!0#_#@L _PP1 /\'&@#_ 28 _  T /0
M00#M $T Z0!8 .8 8@#C &H X !R -X >0#; (  V0"& -8 C0#3 ), T0":
M ,\ H0#- *H RP"S ,D OP#& -  Q0#H ,, ]@#! /\ P +_ +\#_P"_ _\
MOP/_ +\#_P#_&P8 _Q<  /\4  #_$P4 _Q$- /\.% #Y"A\ \ 8L .8#.0#@
M T8 W -1 -8$6P#2!&0 SP5L ,P%<P#*!7H R 6! ,8%AP#%!HX PP:6 ,$&
MG0"_!J8 O0:P +L'O "Y",T N KE +4+]P"S#?\ L0W_ + -_P"P#O\ KP[_
M *\._P#_'@  _QL  /\;  #Z&@  ]18% /81#0#K#A4 X@LB -@+,0#0##X
MRPU* ,<-50#$#EX P0YF +\.;0"]#G0 NP][ +D/@@"W$(H MA"1 +00F@"R
M$*, L!&M *\1N@"M$<H JA+E *<4]P"E%?\ HQ7_ *(5_P"B%?\ HA7_ *(5
M_P#_(@  _R   / C  #F)   X"$  -P9!0#;$ P T!$9 ,@3*0#"%3< O19$
M +D73@"U%U< LQA@ + 89P"N&&X K!EU *L9? "I&80 J!J, *8:E "D&IX
MHQNH *$;M "?',4 GAS? )H=\P&8'O\!EQ[_ 98?_P&5'_\!E1__ 94?_P'_
M)@  ]"<  .8M  #:+P  SRT  ,HG  #''P@ P1P3 +H>(@"T'S$ KR ] *LA
M2 "H(E( IB): *,C8@"A(VD H"-O )XC=P"<(WX FR.& )DDCP&7))D!EB2C
M 90DL &2);\!D276 8XF[P&,)_\"BR?_ HHG_P*))_\"B2?_ 8DG_P'Z*0
M[#   -TV  #-.   Q#<  +XR  "Z*P( M24. *XG'0"H*2L I"HX * J0P"=
M*TP FBM5 )@K7 "6*V, E"MJ 9(K<0&0+'@!CRR! 8TLB@&++)0"BBR? H@L
MJP*&++H"A2W. X,NZ@.!+OP#@"[_ G\N_P)_+O\"?B[_ GXN_P+T+@  Y#<
M -(]  #%/P  NS\  +0\  "O-0  J2\+ *,O%P">,28 F3(S )8R/@"2,T@
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M3P%Z/U8!>#]= 78^9 )T/FL"<CYS W ^? -O/H<$;3Z3!6L^H 9J/JX&:3_
M!V<_W@=G/_4&9D#_!69 _P1F0/\$9C__!&8__P3E/0  ST8  +],  "T3P
MJE   *)/  "92@  D40  (I!#0"$0AD @$,F 'U$,@!Z1#P =T1$ '5$3 %R
M1%,!<$-9 6]#8 )M0V<":T-O VE#>01H0X,%9D./!F1#G0=C0ZL'84.]"&!$
MV0A@1/,'8$3_!E]$_P5?1/\$8$3_!&!$_P3@00  RDH  +M0  "P4P  IU4
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M!U!0_P904/\%4%#_!5!0_P702P  OU0  +):  "G7@  G6   )1@  ")70
M?%<  ')4  !L4PX :%09 &54) !B5"\ 8%0X %Y40 !<5$@!6E1/ 5E45@%7
M5%T"551E U14;@125'D%4%2&!DY4E =-5*0(2U2U"$M4S E*5.L(2U3^!TM4
M_P9+5/\%2U3_!4M4_P7,3@  NU<  *Y>  "D8@  FF0  )%D  "&8@  =UL
M &U8  !F6 P 8E@6 %]8(@!=62P 6UDV %E9/@!7648 5EE- 5195 %265L"
M45EC T]9; --67<$2UB$!4E8D@=(6*('1UFS"$99R@A%6>H(1EG]!D98_P9&
M6/\%1UC_!4=8_P7'4@  N%L  *MA  "A9@  F&@  (YI  "#9P  <F   &A>
M  !A70D 7%T3 %I='@!772D 5EXS %1>.P!27D, 45Y* 4]>4@%.7ED"3%YA
M DI>:@-(7G4$1EZ"!41=D 9#7J '05ZQ!T!>R = 7N@'0%W\!D%=_P5!7?\%
M05S_!4%<_P7#5@  M%\  *AF  ">:@  E6T  (IM  !_;   ;V<  &1D  !;
M8@4 5F(0 %1B&P!28R4 4&,O $YD. !-9$  2V1( $ID3P%(9%<!1F1? D5D
M: )#9',#06-_!#]CC@4]8YX&/&.P!CMDQ@8[9.8&.V/Z!3MB_P4[8O\%/&'_
M!#QA_P2^6P  L&,  *5J  ";;P  D7(  (9R  ![<0  ;&T  &!K  !5:0
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M 2M[AP$J>Y@"*'NJ B=[OP(F>^$")GKW B9X_P(F>/\")W?_ B=W_P*N;
MHW8  )E\  ".?P  A((  'B#  !LA   7X0  %&$  !'A   /(0  #.$"0 P
MA!$ +X0: "V$)  LA2T *X4U "J%/@ IA4< *(90 ">&6@ FAF8 )(9S ".&
M@P AAI4 ((:G 1Z&O $>AMX 'H3U 1Z"_P$>@O\!'H'_ 1Z!_P&H=   GGT
M )."  ")A0  ?H@  '&*  !EBP  6(P  $R-  ! C@  -HX  "R/   ED P
M(Y 3 "*0'  AD"4 ()$N !^1-@ >D4  '9%) !R15  :D6  &9%N !B1?@ 6
MDI  %9*D !21N0 3D=@ $X_T !2._P 4C?\ %(S_ 12,_P&C?0  F(,  (Z(
M  "$C   =X\  &F1  !=DP  4)4  $67   YF   +ID  "6:   =FP( %IT,
M !6=$P 4G1L $YTD !*=+0 1GC< $9Y! !">3  /GE@ #IYG  V>=P ,GHH
M"YV>  J=L@ )G<P "9SL  J;_@ +FO\ "YG_  N9_P"<A   D8H  (B.  ![
MD@  ;98  &"9  !4G   2)\  #R@   PH0  )J,  !VE   5IP  $*D%  NK
M#0 (JA, !ZH;  :J)  %JBX !*HX  *J1  !JE   *I>  "J;@  JH$  *J5
M  "IJ@  J<$  *CD  "H]@  I_\  *?_  "G_P"5BP  C)   '^5  !QF@
M8YX  %:B  !*I@  /:@  #&J   FJP  ':T  !2P   .L@  ";4!  *V"@
MM@\  +85  "W'0  MR4  +<O  "X.0  N$8  +A4  "X9   N'8  +B+  "W
MH   M[8  +?3  "V[P  MOP  +;_  "V_P"/D@  @I<  '2=  !FH@  6*<
M $NL   ^KP  ,;$  ":S   <M@  $[@   V[   &O@   ,$   #"!   P@L
M ,,0  #$%0  Q!P  ,4D  #&+@  R#H  ,E'  #)5P  R6D  ,E]  #)E
MR*H  ,C#  #(Y   R/0  ,C]  #(_0"%F0  =Y\  &BF  !:JP  3;$  #^U
M   QN   );H  !J]   1P   "\,   /'    R@   ,T   #.    SP,  - )
M  #1#@  TQ(  -49  #7(@  VBT  -TY  #>20  WEH  -]N  #?A0  WYP
M -^R  #>RP  WN8  -_T  #?] !YH0  :Z@  %RO  !.M0  0+L  #&^   D
MP0  &<4  !#(   )S    ,\   #3    V0   -P   #=    WP   .$   #B
M!0  Y L  .80  #H%@  ZB   .TK  #P.@  \4L  /%>  #R<P  \XL  /.B
M  #SM@  \\D  //A  #SX0!MJ@  7K$  %"Y  !!OP  ,L0  "3(   7S
M#M    ;5    V@   -X   #B    Y@   .D   #J    [    .X   #P
M\@   /0&  #V#   ^1(  /P<  #_*0  _SH  /]-  #_8@  _W@  /^0  #_
MHP  _[,  /_!  #_P0#_!QD _P$7 /\ %P#_ !H _P A /\ *P#_ #D _P!'
M /\ 5 #_ %\ _P!J /\ <P#_ 'L _P"# /\ B@#_ )  _P"6 /\ FP#_ *$
M_P"H /\ KP#_ +@ _P#$ /X U0#\ .H ^P#X /H _P#Y /\ ^ #_ /@ _P#V
M /\ \P#_ /$ _P#_"Q4 _P43 /\ $P#_ !0 _P : /\ )P#_ #0 _P!" /\
M3P#_ %L _P!E /\ ;@#_ '8 _P!^ /\ A0#^ (L _0"1 /L EP#Z )T ^ "C
M /< JP#V +, ] "^ /, S #Q ., [P#S .X _P#M /\ [ #_ .L _P#L /\
M[ #_ .L _P#_#1$ _PD0 /\ #P#_ !  _P 6 /\ (@#_ "\ _P ] /\ 2@#_
M %4 _0!@ /H :0#X '$ ]@!Y /0 ?P#S (8 \0", .\ D@#N )@ [ "? .L
MI@#I *X YP"X .4 Q0#C -H X0#M -\ ^P#> /\ W0#_ -T _P#= /\ W0#_
M -T _P#_#PT _PP+ /\#"0#_  P _P 2 /\ '0#_ "D ^P W /@ 1 #U %
M\@!: .X 8P#L &L Z0!S .< >@#E (  XP"& .$ C #? ), W0"9 -L H0#9
M *D U0"R -( O@#0 ,X S@#F ,P ]@#* /\ R@#_ ,D _P#( /\ R #_ ,@
M_P#_$0@ _PT" /\'  #_!0@ _P . /\ %@#W "( [P P .L /0#H $D Y !4
M .  70#= &4 V0!M -4 <P#2 'H T "  ,X AP#, (T R@"4 ,@ FP#& *0
MQ "M ,( N #  ,< O0#? +P \0"[ /X N0#_ +@ _P"X /\ N #_ +@ _P#_
M%   _P\  /\-  #_#   _P<) /@!$ #H !H XP H -T -@#8 $( T@!- ,X
M5P#* %\ QP!F ,4 ;0## '0 P0!Z +\ @0"] (@ NP"/ +D EP"W )\ M0"H
M +, LP"Q ,( KP#8 *X"[0"L _L JP7_ *H&_P"I!O\ J0;_ *D&_P#_%@
M_Q(  /<2  #L$0  Y@X  .4&" #= Q( U ,@ ,T$+0#(!#H PP5& +\%4 "\
M!E@ N09@ +<'9P"U!VX LP=U +$(>P"O"(( K@F* *P)D@"J"9L J JE *8*
ML "E"[\ HPS4 *$-[0"?#OX G0[_ )P/_P";#_\ FP__ )L/_P#_&@  ]QD
M .H>  #?'@  U1H  - 3 @#.# L QPL6 , -)0"Z#C( M@X_ +(/20"O$%(
MK!!: *H080"H$6@ IA%O *01=@"B$7T H1&% )\2C@"=$I< G!*B )H3K0"8
M$[P EQ30 )05[ "2%OT D!?_ (\7_P".%_\ CA?_ (X7_P#Z'0  [B,  -\H
M  #0*@  QR<  ,$A  "]&04 N1(0 +(5'@"M%BP J!<X *080P"A&4P GQE4
M )P:7 ":&F( F1II )<;< "5&W< E!M_ )(<B "0')( CQR= (T=J0"+';<
MBA[* (@?YP"&(/H A"#_ 8,@_P&#(/\!@B#_ 8(@_P'U)   Y2P  -,Q  #&
M,P  O#$  +8M  "P)0  K!T, *8>& "A("8 G"$R )DB/0"5(D< DR-/ )$C
M5@"/(UT C21D (LD:P"))'( B"1Z (8D@P"$)8T @R68 8$EI & )K(!?B;%
M 7TGX@%[)_<!>2C_ 7@H_P%X*/\!>"C_ 7@H_P'O*P  W3,  ,HY  "^.P
MM#H  *TV  "F+P  H2@' )LG$P"6*"  D2DM (XJ. "+*T( B"M* (8K4@"$
M*U@ @BQ? ( L9@!_+&T ?2QU 'LL?@%Z+(@!>"R4 78MH %U+:X"="W  G(N
MW0)Q+O0"<"__ F\O_P)O+_\!;B__ 6XO_P'H,0  TSH  ,,_  "W00  KD$
M *8^  ">.   ES$! )$N$ ",+QP B# H (0Q,P"!,CT ?S)& 'TR30![,E0
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M UD__P-9/_\"63__ ED^_P+6/P  PT<  +5,  "J4   H%   )=/  ".2P
MA$4  'I !@!U/Q$ <4 < &U * !K03( :4$[ &=!0@!E04D 8T%0 &%!5P!@
M05X!7D%F 5U";P);0GH"6D*& UA"E -70J,$54.S!%1#R0140^D$4T/] U-#
M_P-40_\#5$/_ E1#_P+00@  OTH  +)0  "G4P  G50  )13  "*4   ?TH
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M T5._P/$3   M54  *E;  "?7@  E6   (M@  " 7@  <E<  &=3  !>40<
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M CE>AP(W7I<"-EZI S5>O0,T7]T#-%[U S5=_P(U7?\"-5S_ C5<_P*X60
MJF$  *!G  "6;   C&X  (%N  !V;   9VD  %QF  !19   2&() $1B$0!"
M8AL 06,D #]C+0 ^8S4 /60] #QD10 [9$T .615 #AD7P V9&D!-61V 3-D
MA0$Q994",&6G B]ENP(N9=H"+F3T BYC_P(O8_\"+V+_ B]B_P*S7@  IV8
M )QM  "3<0  B',  'US  !R<@  9'   %AN  !-;   0FH# #QI#@ Z:A8
M.6H@ #AJ*  V:S$ -6LY #1K00 S;$D ,FQ2 #%L7  O;&8 +FQS "QL@@$J
M;),!*6RE 2ALN0$G;=8!)VOR 2=J_P$G:O\!*&G_ BAI_P*N9   HVP  )ES
M  ".=@  A'@  'EY  !M>   8'<  %-V  !(=0  /G,  #1R"@ Q<Q$ ,',:
M "]S(P N<RL +70T "QT/  K=$0 *71- "AU5P G=6, )75O "1U?P B=9
M(76B "!UMP ?==( 'W3Q !]S_P$?<O\!(''_ 2!Q_P&I:P  GG,  )1Y  "*
M?   @'X  '1_  !G?P  6G\  $U^  !#?@  .'T  "]] @ H?0T )GT4 "1]
M'  C?B4 (GXM "%^-@ A?C\ 'W]( !Y_4@ =?UX '']K !I_>@ 9?XP %W^?
M !9_LP 5?\X %7[O !9\_P 6>_\ %GO_ !=[_P"D<@  FGH  (]_  "%@@
M>X0  &V&  !@AP  5(<  $B(   \B   ,H@  "B(   @B 4 &HD. !F)%0 8
MB1T %XHF !:*+@ 5BC< %(I! !.*3  2BU@ $8ME !"+=0 /BX< #HJ;  V*
MKP ,BL@ #(GJ  V'_  .A_\ #H;_  Z&_P"?>P  E($  (J%  " B   <XL
M &6-  !9CP  3)   $&2   TD@  *I(  "&3   9E   $I8&  Z7#@ -EQ4
M#)<=  R7)@ +ER\ "I<Y  F71  (EU  !I=>  67;@ #EH   9:4  "5J
ME;X  )3@  "4]   D_\  9+_  &2_P"8@@  CH@  (6,  !WCP  :I(  %V5
M  !0F   1)H  #B;   LG   (IT  !F>   2H   #:("  >C"P !HQ   *,7
M  "C'P  HR<  *,Q  "D/   I$@  *16  "D90  HW<  *.+  "CH   HK8
M *'2  "A\   H/L  *#_  "@_P"1B@  B8X  'N2  !MEP  8)L  %.>  !&
MH0  .:,  "VD   CI@  &:@  !&J   ,K   !:X   "O!P  KPT  *\1  "P
M&   L"   +$H  "Q,@  LCX  +),  "R6P  LFP  +*!  "QEP  L:P  +#&
M  "PZ   K_<  *__  "O_P",D   ?Y4  '&:  !CGP  5:0  $>H   ZJ@
M+:P  "*N   8L   $+,   JU   "N    +L   "[    O <  +P-  "]$0
MOA8  +\>  # )P  P3(  ,)   ##3P  PV   ,-T  ##BP  PZ$  ,.X  #"
MUP  PN\  ,+Z  #!_@"!EP  <YT  &6C  !7J   2:T  #NQ   MLP  (;8
M !:Y   .NP  ![X   #!    Q0   ,<   #(    R0   ,H%  #+"P  S0\
M ,X4  #0'   TR8  -8R  #800  V%,  -EF  #9?   V90  -FK  #9PP
MV>$  -GP  #9] !VGP  9Z8  %FL  !+L@  /+<  "ZZ   AO0  %<    W$
M   %QP   ,H   #.    T@   -4   #6    V0   -L   #=    WP<  .$,
M  #C$0  YAD  .DD  #L,@  [4,  .Y6  #O:P  [X0  .^<  #OL@  [\8
M ._=  #OY !JJ   6Z\  $RV   ^O   +\   "#$   4R   #,P   +0
MU    -D   #>    X@   .4   #F    Z    .D   #L    [@   / "  #R
M"0  ]0\  /@7  #\(P  _S,  /]&  #_6@  _W$  /^)  #_GP  _[$  /_
M  #_Q@#_ !4 _P 4 /\ % #_ !< _P = /\ * #_ #< _P!$ /\ 40#_ %P
M_P!F /\ ;P#_ '< _P!^ /\ A0#_ (L _P"1 /\ EP#_ )T _P"D /\ JP#_
M +0 _@"_ /T S@#[ .8 ^0#V /@ _P#W /\ ]P#_ /< _P#P /\ [ #_ .D
M_P#_ Q( _P 0 /\ $ #_ !$ _P 7 /\ ) #_ #( _P _ /\ 3 #_ %< _P!A
M /\ :@#_ '( _P!Y /T @ #\ (8 ^@", /D D@#X )@ ]@"? /4 I@#T *X
M\@"Y /  Q@#N -X [0#P .L _@#J /\ Z0#_ .D _P#G /\ XP#_ .  _P#_
M!PX _P - /\ "P#_  P _P 3 /\ 'P#_ "P _P Z /\ 1@#^ %( ^P!< /@
M90#U &P \P!T /$ >@#O ($ [@"' .P C0#J ), Z0": .< H0#F *D XP"S
M .$ OP#? -  W0#I -H ^0#9 /\ UP#_ -4 _P#5 /\ U0#_ -0 _P#_"0H
M_P$% /\  P#_  D _P 0 /\ &0#[ "8 ]P T /0 0 #R $P [@!6 .H 7P#G
M &< Y !N .( = #@ 'L W@"! -P AP#: (T U@"4 -0 FP#1 *, SP"M ,P
MN #* ,< R #@ ,8 \P#% /\ PP#_ ,, _P## /\ PP#_ ,, _P#_"P$ _P,
M /\   #_  , _P + /, $@#N !\ Z@ M .8 .@#B $4 W@!/ -D 6 #4 &
MT0!H ,X ;@#, '0 R@![ ,@ @0#& (< Q ". ,( E@#  )X O@"G +L L@"Y
M ,  MP#4 +4 [ "S /L LP#_ +( _P"R /\ L0#_ +$ _P#_#0  _P8  /\#
M  #W    ]  # .< #0#@ !@ V@ E -, ,@#. #X R@!) ,8 4@## %H P !A
M +X : "\ &X N@!T +@ >P"V ($ M "( +( D "P )D K@"B *P K0"J +H
MJ #+ *8 Y@"E /< I #_ *, _P"B /\ H@#_ *( _P#_$   ^PP  .\.  #F
M#0  WPD  -H !@#0 !$ R0 = ,0 *@"_ #< NP!" +< 2P"T %0 L@!; *\
M8@"M &@ JP!N *D =0"H 'L I@"# *0 BP"B )0 H "> )X!J "< K4 FP/&
M )D%X@"8!O0 E@C_ )4)_P"4"?\ E G_ )0)_P#\$0  \14  .,9  #6&0
MS!4  ,<0  #$!PH O0,4 +<$(0"R!BX K@@Z *H)1 "G"4T I I5 *(*7 "@
M"F( G@MI )P+;P";"W8 F0Q^ )<,A@"6#)  E R: )(-I@"1#;, CPW% (T.
MX@"+$/8 B1#_ (@1_P"'$?\ AQ'_ (<1_P#V&0  YR   -8D  #()0  OR(
M +D<  "T% $ L0T. *H.&0"E#R< H1 S )T1/@":$4< F!)/ )425@"3$EP
MD1)C ) 3:0".$W  C!-X (L3@0")%(L AQ26 (85H@"$%;  @Q;! ($7W0!_
M&/0 ?1G_ 'P9_P!\&?\ >QG_ 'L9_P#O(0  W2D  ,HM  "^+P  M2P  *XG
M  "H(   HQ<( )X6$P"9%R$ E!DM )$:. ".&D$ BQM) (D;4 "'&U< A1Q>
M (0<9 ""'&L @!QS '\=? !]'88 ?!Z1 'H>G@!X'ZL =Q^\ '8@U !T(?
M<B'_ '$B_P!Q(?\ <2'_ '$A_P#H*   TC   ,(U  "W-P  K34  *4Q  ">
M*P  F"," )(>$ "-(!L B2$G (8B,@"#(SP @2-$ 'XC2P!\)%( >R19 'DD
M7P!W)&8 =B5N '0E=P!S)8$ <2:- &\FF0!N)J< ;2>X &PGS@%J*.T!:2G_
M 6@I_P%H*?\!:"C_ 6@H_P'A+@  RS8  +P[  "Q/0  IST  )\Y  "7,P
MCRT  (@G# "#)Q8 ?R@B 'PI+0!Y*C< =RH_ '4J1P!S*TX <2M4 ' K6P!N
M*V( ;"MJ &LL<@!I+'T :"R) &8ME@%E+:0!9"ZT 6,NR@%A+^D!8"_] 6 O
M_P%@+_\!8"__ 6 N_P':-   Q3P  +=!  "L0P  HD,  )E   "0.@  B#0
M ( N" !Z+1( =RX> ',O*0!Q,#, ;S [ &TP0P!K,4H :3%1 &<Q5P!F,5X
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M 4T]_P')0   N$@  *Q-  "A4   EU$  (Y/  "$2P  >44  &Y   !F/0L
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M 4))A@%!298!0$JG C]*NP(^2]@"/DKS CY*_P(^2?\!/TG_ 3])_P&]2@
MKU(  *-8  "96P  D%T  (9<  ![60  ;5,  &)/  !73 $ 44H- $Y*%0!,
M2Q\ 2DLH $E+, !'2S@ 1DP_ $5,1@!$3$X 0TU6 $)-7P! 36H /TUV 3U.
MA $\3I0!.TZE 3E/N0(Y3]0".4_R 3E._P$Y3O\!.4W_ 3I-_P&Z3@  K%8
M *%;  "77P  C6$  (-A  !X7@  :5@  %]6  !44@  3$\+ $E/$@!'4!P
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M "A?LP$G7\P )U_M 2=>_P$G7?\!*%W_ 2A<_P&M7   HF0  )AJ  ".;@
M@V\  'EO  !N;@  8&L  %1I  !)9P  /V4  #5C"0 R8Q$ ,&,9 "]D(0 N
M9"D +60Q "QD.0 K94( *F5* "AE5  G95\ )F9K "1F>@ C9HL (F:= "!F
ML0 ?9LD 'V;K "!E_@ @9/\ (&/_ 2%C_P&I8@  GFH  )5P  "*<P  @'4
M '5U  !I=   7'(  $]Q  !$;P  .FX  #!M P I; T )VP4 "9L'  E;20
M)&TL "-M-  B;3T (6Y& "!N4  >;EL '6YG !QN=@ :;H< &6^: !AOK@ 6
M;\8 %F[I !=M_  8;/\ &&O_ !AK_P"D:0  FG$  )!V  "&>0  ?'L  '%[
M  !D>P  5WH  $IY   _>   -7@  "MW   B=@< '78/ !QW%@ ;=QX &G<F
M !EW+@ 8=S< %WA  !5X2@ 4>%8 $WAC !)X<@ 1>(, $'B7  ]XJP .>,,
M#G?F  YV^@ /=?\ $'7_ !!T_P"?<0  E7@  (M\  ""?P  =X$  &J"  !=
M@@  4((  $2"   X@@  +H(  "2"   <@@  %(() !&#$  0@Q8 $(,>  Z#
M)P .@S  #8,Y  V#1  ,@U  "X-=  F#;  (@WX !H.1  6"I0 #@KL !(';
M  2!\@ %@/\ !G__  9__P":>0  D'X  (:#  !]A0  ;X<  &*)  !5B@
M28L  #V,   QC   )HP  !V-   5C@  #X\#  J0#  &D!$ !(\8  ./(  !
MCRD  (\R  "0/0  D$D  (]6  "/90  CW8  (^*  ".GP  CK0  (W/  ",
M[@  C/L  (O_  "+_P"4@   BX4  (*)  !TC   9H\  %F1  !,DP  0)4
M #26   HE@  'I<  !68   /F@  "IL   *<"0  G X  )P3  "<&@  G"(
M )TK  "=-0  G4   )U.  "=7   G6X  )R!  "<EP  G*P  )O&  ":Z
MF?D  )G_  "8_P".B   AHP  'B0  !JE   7)<  $^:  !"G0  -IX  "F?
M   ?H0  %:(   ZD   (I@   *@   "I!   J0H  *D.  "I$P  JAH  *HB
M  "K*P  K#8  *Q$  "L4P  K&,  *QW  "KC@  JZ0  *N\  "JW@  J?0
M *G]  "I_P")C@  >Y,  &V7  !?G   4:   $2D   VI@  *J@  !ZI   4
MJP  #:X   :P    L@   +4   "U    M0,  +8)  "W#@  N!(  +@9  "Z
M(0  NRL  +PX  "]1P  O5@  +UK  "]@0  O9D  +VP  "]S   O.H  +SW
M  "[_@!^E0  <)L  &*@  !3I0  1JH  #BM   JKP  'K$  !.T   ,MP
M [D   "\    OP   ,(   #"    PP   ,0   #&!@  QPP  ,@0  #*%@
MS"   ,\K  #0.@  T4L  -%>  #2<P  THL  -*D  #3NP  T]@  -/M  #3
M]@!SG0  9*,  %:I  !'KP  .;,  "JV   =N0  $KP   J_    PP   ,8
M  #)    S0   ,\   #0    T@   -0   #6    V0(  -L(  #>#@  X1,
M .0=  #H*@  Z#P  .E/  #I9   ZGP  .N5  #KK   Z\(  .S5  #LY0!F
MI@  6*P  $FS   [N0  *[P  !W    1Q   "<@   #,    SP   -,   #9
M    W0   .    #A    XP   .4   #G    Z@   .P   #N!   \0L  /42
M  #X'   ^RL  /T^  #^4P  _FH  /^#  #_FP  _ZX  /^^  #_R@#_ !(
M_P 0 /\ $0#_ !, _P 9 /\ )@#_ #0 _P!! /\ 30#_ %@ _P!B /\ :P#_
M ', _P!Z /\ @0#_ (< _P"- /\ DP#_ )D _P"@ /\ IP#^ *\ _ "Z /H
MR0#Y .$ ^ #S /< _P#V /\ ]0#_ /$ _P#I /\ Y #_ .$ _P#_  \ _P -
M /\ #0#_  X _P 4 /\ (0#_ "X _P \ /\ 2 #_ %, _P!= /\ 9@#^ &T
M_ !U /L >P#Y (( ^ "( /< C@#V )0 ] "; /, H@#Q *H [P"T .T P0#K
M -4 Z@#L .@ _ #G /\ Y0#_ .8 _P#@ /\ V0#_ -0 _P#_  L _P ( /\
M!@#_  D _P 0 /\ ' #_ "D _P V /\ 0@#[ $X ]P!7 /0 8 #R &@ [P!O
M .T =@#L 'P Z@"" .@ B #G (X Y0"5 ., G #A *0 WP"N -T N0#: ,H
MUP#D -0 ]@#1 /\ T #_ -  _P#/ /\ RP#_ ,< _P#_  , _P   /\   #_
M  0 _P - /H %@#V ", \P P /  / #M $< Z0!1 .4 6@#B &( WP!I -T
M;P#: '8 V !\ -0 @@#2 (@ T "/ ,T E@#+ )X R0"H ,< LP#% ,$ P@#8
M ,  [P"_ /X O@#_ +T _P"\ /\ O #_ +P _P#_ @  _P   /\   #_
M]  ' .T $0#H !P XP I -\ -0#; $$ U@!+ -$ 5 #- %P R@!C ,@ :0#&
M &\ PP!U ,$ >P"_ (( O@"( +P D "Z )@ N "B +4 K "S +D L0#+ *\
MYP"N /@ K #_ *L _P"L /\ K #_ *L _P#_!   _P   /8   #N    YP
M -\ # #6 !4 SP B ,H +@#' #H PP!$ ,  30"\ %4 N0!< +< 8P"U &D
MLP!O +$ =0"O 'L K0"" *L B@"I )( IP"< *4 I@"C +, H0## )\ W@">
M /( G0#_ )P _P"< /\ FP#_ )L _P#_!P  ]@D  .D+  #?"@  U00  ,X
M!0#& !  P  : +L )P"W #( LP ] +  1@"M $\ J@!6 *@ 7 "F &, I !H
M *( ;P"A '4 GP!\ )T A "; (T F0"7 )< H@"5 *X DP"] )$ TP"0 .T
MCP#\ (X _P"- ?\ C0'_ (T!_P#Y#@  ZA(  -P5  #-%0  Q!$  +X,  "Z
M @H M  2 *X '@"J "H I@ U *( /P"@ $@ G0%0 )L"5@"9 EP EP-C )4#
M:0"3 V\ D01V ) $?P".!8@ C 62 (H&G@"(!JH A@>Z (4(SP"$"NL @@O\
M ($,_P" #/\ @ S_ ( ,_P#Q%0  X!T  ,T@  #!(0  N!T  +$7  "L$
MJ D- *('%@"="2, F0HN )4+. "3#$$ D Q) (X-4 ",#5< B@U= (@-8P"'
M#6H A0YQ (,.>@""#H0 @ Z/ 'X/FP!\#Z@ >Q"X 'H0S@!X$>P =A+_ '42
M_P!T$_\ =!/_ '03_P#H'@  TR8  ,,J  "X*@  KB@  *<C  "@'   FQ,#
M )8/$ "0$!L C!$G (D2,@"&$SL A!-# ((42P" %%$ ?A17 'P47@![%64
M>15L '<5= !V%GX =!:* '(7E@!Q%Z0 ;QBT &X8R0!M&>@ :QK\ &H;_P!J
M&_\ :AO_ &H;_P#@)@  RBT  +PQ  "P,P  IS$  )\L  "7)@  D!\  (H7
M# "%&!8 @1DB 'X:+ ![&S8 >1L^ '<<10!U'$P <QQ3 '$=60!P'6  ;AUG
M &T>< !K'GH :AZ% &@?D@!G'Z  92"P &0AQ0!C(>0 8B+Z &$B_P!A(O\
M82+_ &$B_P#7+   PS0  +8X  "J.0  H3@  )@U  "0+P  B"@  ( A" ![
M(!( =R$= '0B)P!Q(C$ ;R,Y &TC00!K(T@ :2-. &@D50!F)%L 921C &,E
M:P!B)74 826! %\FC@!>)IT 72>M %LHP0!;*.  6BGW %DI_P!9*?\ 62G_
M %DH_P#/,@  OCD  +$]  "F/P  G#\  ),\  "*-@  @3   'DJ P!R)@\
M;B<9 &LH(P!I*"P 9BDU &4I/ !C*4, 82I* & J40!>*E< 72I? %PK: !:
M*W( 62Q] %@LBP!6+9H 52VJ %0NO0!3+MP 4B_U %(O_P!2+O\ 4B[_ %(N
M_P#*-@  NCT  *U"  "B1   F$0  (]!  "%/   >S<  '(Q  !K+ P 9RT5
M &0M'P!A+B@ 7RXQ %TN.0!<+T  6B]& %@O30!7+U0 5C!< %4P9 !3,6X
M4C%Z %$QB !0,I< 3C*H $TSNP!---@ 3#3S $PT_P!,-/\ 3#/_ $PS_P#&
M.@  MD(  *E&  ">20  E4D  (M'  "!0@  =ST  &TW  !D,@D 8#(2 %TR
M' !:,B4 6#,M %8S-0!5,SP 4S1# %(T2@!1-%$ 4#19 $\U80!--6P 3#9W
M $LVA0!*-Y4 2#>F $<XN %'.-,!1CCQ 48X_P%&./\ 1CC_ $8W_P#!/@
MLD4  *9*  "<30  DDT  (A+  !^1P  <T(  &D]  !?-P8 6C80 %<W& !4
M-R( 4C<J % W,@!/.#D 33A  $PX1P!+.$X 2CE6 $DY7P!(.FD 1SIU $4[
M@P!$.Y, 0SRD 4(\M@%!/= !03WP 4$]_P%!//\!03S_ 4$\_P"^0@  KTD
M *-.  "94   CU$  (50  ![3   ;T8  &5"  !:/0( 5#L. %$[%0!/.Q\
M33LG $L[+P!)/#8 1SP] $<\1 !&/4L 13U4 $0^7 !#/F< 0C]S $ _@0 _
M/Y$ /D"B #U M0$\0<X!/$'N 3Q!_P$\0/\!/$#_ 3T__P&Z10  K$P  *%1
M  "75   C54  (-4  !X40  ;$L  &%'  !60@  3T , $P_$P!)0!P 1T D
M $9 + !$0#, 0T Z $)!0@!!04D 0$)1 #]"6@ ^0V4 /4-Q #M#?P Z1(\
M.42@ #A%LP$W1<L!-T7L 3=%_P$W1/\!.$3_ 3A#_P"W20  J5   )Y5  "4
M6   BUD  (!8  !V5@  :%   %U,  !32   2D4) $9$$0!$1!D 0D0B $%%
M*0 _13$ /D4X #U%/P \1D< .T9/ #I'6  Y1V( .$AN #9(?  U2(T -$F>
M #-)L0 R2<D ,4GK #))_@ R2/\ ,DC_ #-(_P"T3   IU0  )Q9  "27
MB%T  'Y=  !S6@  954  %M2  !03@  1DH% $!)#@ ^218 /4D> #M*)@ Z
M2BX .4HU #A+/0 W2T0 -DM- #1,5@ S3&  ,DQL #%->@ P38L +DV< "U.
MKP L3L< +$[I "Q-_0 M3?\ +4S_ "U,_P"P4   I%@  )E=  "/80  AF(
M 'MA  !P7P  8EL  %A8  !.50  0U$! #M/#  X3Q, -D\; #5/(P T4"L
M,U R #)0.@ Q4$( ,%%* "Y14P M4ET +%)I "M2>  I4H@ *%.: "=3K0 F
M4\4 )E/G "93_  G4O\ )U'_ "=1_P"L50  H%P  )9B  "-9@  @V<  'AF
M  !M90  8&$  %5>  !*6P  /U@  #56"  Q51  ,%87 "Y6'P M5B< +%8O
M "M7-@ J5SX *5=' "A74  F6%H )5AG "18=0 C688 (5F8 "!9JP ?6<(
M'UGE !]8^@ @6/\ (%?_ "%7_P"H6@  G6(  )-G  "*:P  ?VP  '5L  !J
M:P  76@  %%E  !&8P  .V   #%> P J70T *%T3 "9=&P E7B, )%XJ "->
M,@ B7CH (5Y# "!?3  ?7U< 'E]C !Q@<0 ;8(( &6"5 !A@J0 78,  %F#B
M !=?^0 87O\ &5[_ !E=_P"D8   F6@  )!N  "&<   ?'(  ')R  !F<0
M6&X  $QL  !!:P  -FD  "UG   C9@@ 'V8/ !UF%0 <9AT &V8E !IF+0 9
M9S4 &&<^ !=G2  69U, %6A? !-H;@ 2:'\ $6B2 !!HI@ /:+T #FC@ !!G
M]P 09O\ $67_ !%E_P"?9P  EF\  (QS  ""=@  >'@  &UX  !@=P  4W8
M $9T   [<P  ,7(  "=Q   ><0  %G * !-P$  3<!< $G ? !%Q)P 0<2\
M$'$X  YQ0@ .<4X #7%;  QQ:0 +<7H "G&-  AQH0 &<;8 !G#2  =P[P (
M;_\ "6[_  EN_P";;P  D74  (=Y  !^?   ='X  &9^  !9?@  37X  $!]
M   U?0  *GP  "%\   8?   $7P$  Q\#  *?!$ "7P9  A\(0 '?"D !GPR
M  1\/0 #?$@  7Q5  !\8P  ?'0  'R'  ![G   >[$  'K+  !YZP  >?H
M 'G_  !X_P"6=P  C'P  (.   !Y@P  ;(0  %Z%  !1A@  18<  #F'   M
MAP  (X<  !J'   2AP  #8@!  :)"@ !B0\  (D4  "(&P  B",  (DL  ")
M-@  B4(  (A.  "(70  B&T  (B!  "'E0  AZL  (;$  "%Y@  A/@  (3_
M  "$_P"0?@  AX,  'Z'  !QB0  8XL  %:-  !)CP  /)$  #"1   DD0
M&I(  !*3   -E   !I4   "6!@  E@P  )40  "6%0  EAT  )8D  "6+@
MECD  )9&  "650  EF4  )9X  "5C@  E:0  )2\  "3WP  D_4  )+_  "2
M_P"+A@  @XH  '6-  !GD   690  $R7   _F0  ,IH  ":;   ;G   $IT
M  R?   $H    *(   "C 0  HP<  *,,  "C$   I!4  *0<  "E)0  IB\
M *8\  "F2P  IEL  *9N  "EA   I9L  *2S  "CT   H^\  *+\  "B_P"&
MC0  >)$  &J5  !<F0  3IT  $&@   SH@  )J,  !NE   1IP  "JD   &K
M    K0   *\   "P    L    + %  "Q"P  L@\  +,4  "T&P  M20  +<P
M  "W/P  MU   +=B  "W>   MY   +:I  "VP@  MN0  +;U  "U_@![DP
M;9@  %^=  !0H@  0J8  #2I   FJP  &JT  !"O   )L@   +0   "W
MN@   +P   "]    O@   +X   #  @  P0@  ,(-  #$$@  QAD  ,DD  #*
M,@  RT,  ,M5  #,:@  S(,  ,R<  #+M0  S,X  ,SI  #,]@!PFP  8:$
M %*F  !$JP  -K   ">R   :M0  $+@   >[    O@   ,$   #$    R
M ,L   #+    S0   ,X   #0    T@   -4#  #8"@  VQ   -X8  #B)
MXS4  .1(  #E7   YG,  .:-  #FI0  YKP  .;3  #GYP!CI   5:H  $:P
M   XM0  *+D  !J\   /P   !<0   #'    RP   ,\   #4    V    -P
M  #=    WP   .$   #C    Y0   .@   #J    [08  /$.  #U%@  ^"4
M /DX  #Y30  ^F,  /M\  #\E0  _*H  /R[  #]RP#_  \ _P . /\ #@#_
M !  _P 6 /\ (P#_ #  _P ] /\ 20#_ %0 _P!> /\ 9@#_ &X _P!V /\
M? #_ (( _P") /\ CP#_ )4 _@"; /T HP#[ *L ^@"U /D PP#W -L ]@#P
M /0 _P#S /\ \@#_ .P _P#B /\ W #_ -8 _P#_  P _P ) /\ " #_  H
M_P 2 /\ '@#_ "L _P X /\ 1 #_ $\ _P!9 /X 80#\ &D ^@!P /@ =P#W
M 'T ]@"# /0 B0#R (\ \0"6 .\ G0#M *4 [ "O .H O #H ,T Y@#H .0
M^@#C /\ X@#_ .  _P#5 /\ S@#_ ,L _P#_  8 _P ! /\   #_  0 _P .
M /\ &0#_ "4 _0 R /L /@#W $D \P!3 /  7 #N &, [ !J .H <0#H '<
MY@!] .0 @P#B (D X "0 -X EP#< )\ V0"I -8 M #3 ,0 T #> ,X \P#,
M /\ RP#_ ,H _P#( /\ P@#_ +X _P#_    _P   /\   #_    ^P + /8
M$P#Q "  [0 L .H . #G $, XP!- .  5@#< %T V0!D -4 :P#2 '$ T !V
M ,X ? #, (, R@") ,@ D0#& )D Q "C ,$ K0"_ +L O0#/ +L ZP"Y /P
MMP#_ +< _P"V /\ M #_ +$ _P#_    _P   /\   #V    [@ % .< #P#A
M !D VP E -4 ,0#2 #P S@!& ,H 3P#' %< Q !> ,$ 9 "_ &H O0!P +L
M=@"Y 'P N "# +8 B@"S ), L0"< *\ IP"M +, JP#% *D X0"G /4 I@#_
M *4 _P"D /\ I #_ *0 _P#_    _    /$   #H    X    -0 "P#, !,
MQP ? ,( *@"_ #4 O  _ +@ 2 "U %  LP!7 +  7@"N &0 K !I *L ;P"I
M '4 IP!\ *4 A "C (P H0"6 )\ H0"= *T F@"\ )@ T@"7 .X E0#^ )0
M_P"5 /\ E0#_ )4 _P#\ 0  \ 4  .,'  #5!0  S    ,4 ! "^  X N  7
M +, (P"O "X JP X *D 00"F $H HP!1 *$ 5P"? %T G0!C )L :0": &\
MF !V )8 ?0"4 (8 D@"0 )  FP". *< C "V (H R0"( .< AP#Y (< _P"&
M /\ A@#_ (8 _P#T#   Y!   -$2  #%$0  O0X  +8(  "Q  @ JP 1 *8
M&P"A "8 G@ Q )H .@"8 $, E0!* ), 40"1 %< CP!= (X 8P", &D B@!P
M (@ =P"& (  A "+ (( E@"  *, ?@"Q 'T Q ![ N$ >@/U 'H%_P!Y!?\
M> ;_ '@&_P#J$P  UAH  ,8=  "Z'   L1D  *H3  "D#0  GP4, )D % "5
M !\ D0(I (T#,P"+!#P B 5$ (8&2P"$!E$ @@=7 ($'70!_!V, ?0AJ 'L(
M<@!Z"'P > F& '8)D@!T"J  <PJO '$+P0!P#-\ ;PWV &X._P!M#O\ ;0[_
M &T._P#A'   RR,  +PF  "Q)@  J"0  * >  "9&   DQ " (X+#@"("Q<
MA PB ($-+ !^#34 ? X] 'H.10!X#DL =PY1 '4/6 !S#UX <1!E ' 0;@!N
M$'< ;!"" &L0CP!I$9T :!&M &82P !E$M\ 9!/V &,4_P!C%/\ 8A3_ &(4
M_P#6)   PRH  +4N  "J+P  H"T  )@H  "0(@  B1L  ((3" !]$1( >1(<
M '83)P!S%#  <10X &\5/P!M%48 ;!5, &H64P!H%ED 9Q9A &46:0!D%W(
M8A=^ &$8BP!?&)D 7AFI %P9O !<&M@ 6AOS %H<_P!9'/\ 61S_ %D<_P#-
M*@  O3$  *\U  "D-@  FS0  )(Q  ")*P  @24  'D= P!S& X ;QD8 &P:
M(@!I&RL 9QLS &4<.P!D'$$ 8AU( & =3@!?'54 71U< %P>9 !;'FX 61]Y
M %@?AP!6()8 52"F %0AN !3(=( 4B+Q %(C_P!2(_\ 4B+_ %(B_P#(+P
MN#8  *LZ  "@/   ECL  (TX  "#,@  >BT  '(F  !J( P 9B 3 &,A'0!A
M(28 7R(O %TB-@!;(CT 6B-$ %@C2@!7(U$ 52-8 %0D80!3)&H 425V % E
M@P!/)I, 3B>C $PGM0!,*,X 2RCN $LI_P!+*/\ 2RC_ $LH_P##-   LSL
M *<_  "<00  DD   (D^  !_.0  =3,  &PM  !C)P@ 7B81 %PF&0!9)R(
M5R<K %4H,@!4*#D 4BA  %$H1@!0*4T 3BE5 $TI70!,*F< 2RIS $DK@ !(
M*Y  1RRA $8MLP!%+<L 12[L $0N_P!$+O\ 12W_ $4M_P"^.   L#\  *1#
M  "910  CT4  (5#  ![/@  <3D  &<T  !>+@0 6"L. %4K%@!2+!\ 4"PG
M $\L+P!-+38 3"T\ $HM0P!)+4H 2"Y2 $<N6@!&+V0 12]P $,P?@!",(T
M03&> $ RL0 _,L@ /S/J #\S_@ _,O\ /S+_ #\R_P"[/   K4,  *%'  "6
M20  C$D  (-(  !X1   ;3X  &,Y  !:-   4C , $\P$P!,,!P 2C D $DQ
M*P!',3( 1C$Y $0Q0 !#,D< 0C)/ $$S6 ! ,V( /S1M #XT>P ]-8L /#:<
M #LVKP Z-\8 .3?H #DW_  Z-_\ .C;_ #HV_P"W0   JD8  )Y+  "430
MBDX  (!,  !U2   :D,  & ^  !6.0  334) $DT$0!'-1D 134A $,U* !!
M-2\ 0#4V #\V/0 ^-D4 /3=- #PW50 [.&  .CAK #DY>0 X.8D -SJ; #4Z
MK0 U.\0 -#OF #0[^P U._\ -3K_ #4Z_P"T0P  ITH  )Q.  "240  B%(
M 'Y0  !S30  9T@  %Q$  !2/P  2#H& $0Y#P!!.18 /SD> #XY)@ \.2T
M.SHT #HZ.P Y.T( .#M* #<\4P V/%T -3UI #0]=P S/H< ,3Z9 # _JP O
M/\( +S_D "\_^@ P/_\ ,#[_ # ^_P"Q1P  I$T  )E2  "/50  AE8  'Q5
M  !Q4@  9$P  %E)  !/10  14 # #\^#0 \/A, .CX; #D^(P W/BH -C\Q
M #4_.  T/T  ,T!( #) 40 Q05L ,$%G "Y"=0 M0H4 +$.7 "M#J@ J0\
M*43B "I#^0 J0_\ *T+_ "M"_P"N2@  H5$  )=6  "-60  @UH  'E:  !N
M5P  85(  %=.  !-2P  0T<  #I#"@ V0Q$ -$,8 #-#(  R1"< ,40O #!$
M-@ O13T +45& "Q%3P K1ED *D9D "E'<@ H1X, )D>5 "5(J  D2+X (TC@
M "1(]P E1_\ )4?_ "9'_P"J3P  GU4  )1:  "+7@  @5\  '=>  !K7
M7U@  %55  !+40  0$T  #5*!P P20X +DD5 "U)'0 L220 *THK "I*,P H
M2CL )TM# "9+3  E2U8 )$QB "-,<  A3(  ($V3 !]-I@ >3;L '4[= !Y-
M]@ >3/\ 'TS_ "!+_P"G4P  G%H  ))?  "(8P  ?F0  '1C  !I80  7%X
M %);  !'6   /%4  #)2 @ J4 P )T\2 "90&0 E4"  )% H "-0+P B43<
M(5%  "!120 >4E, '5)? !Q2;0 :4WT &5.0 !A3I  64[D %5/9 !93]  7
M4O\ &%'_ !E1_P"C60  F&   (]E  "%:   >VD  '%I  !F9P  660  $UA
M  !"7P  .%P  "Y:   E6 @ (%<. !Y7%  =5QP '%@C !M8*P :6#, &5@\
M !A810 665  %5E; !19:0 36GH $EJ- !%:H0 06K< #EK5 !!9\P 06?\
M$5C_ !%8_P"?7P  E68  (QK  "";0  >&X  &YO  !B;0  56H  $AH   ^
M9@  ,V4  "EC   @80$ && + !5@$  48!< $V > !)@)@ 28"X $6$W !!A
M0  /84L #F%8  UA9@ ,8G8 "V*)  IAG0 )8;( "&'+  AAZP )8/T "E__
M  M?_P";9@  DFT  (AQ  !^<P  =74  &IT  !<<P  3W(  $-P   X;P
M+6X  "1L   ;:P  $VL$  YJ#  -:A( #&H9  MJ(0 *:BD "6HR  AJ/  '
M:T< !6M3  1K80 ":W$  &J$  !JF   :JT  &G&  !IYP  :?@  &C_  !H
M_P"7;0  C7,  (1W  ![>@  <'L  &-[  !6>@  27H  #UY   Q>   )W<
M !UV   5=@  #W8"  EV"@ $=@\  '85  !V'   =B0  '4L  !U-@  =4$
M '5.  !U7   =6P  '5^  !TDP  =*@  '/   !SXP  <O<  '+_  !Q_P"2
M=0  B7H  (!^  !V@   :8$  %N"  !.@@  08(  #6#   I@@  'X$  !:!
M   0@@  "H(   *#!P  @@T  ((1  ""%P  @AX  ((F  ""+P  @CL  ()'
M  ""50  @64  (%X  "!C0  @*(  '^Z  !_W0  ?O0  'W_  !]_P"-?
MA($  'N$  !NA@  8(@  %**  !%BP  .8P  "R,   AC   %XP  !"-   )
MC@   H\   "0 P  CPD  (\.  "/$@  D!@  ) ?  "0*   D#(  ) _  "0
M30  D%T  (]P  "/A0  CIP  (ZS  "-T   C/   (O^  "+_P"(A   @(@
M '*+  !DC0  5I   $B3   [E0  +I8  "*6   7EP  #Y@   B9    FP
M )T   "=    G0,  )T)  "=#0  GA$  )X7  "?'P  GRD  * U  "@0P
MH%0  *!F  "?>P  GI,  )ZK  "=Q@  G>D  )SY  "<_P"#BP  =8X  &>2
M  !9E@  2YD  #V<   PG@  (Y\  !>@   .H@  !Z0   "F    J    *H
M  "J    J@   *L!  "K!P  K P  *T0  "N%@  KQX  +$I  "Q.   L4@
M +%:  "Q;P  L8@  +&@  "PN@  K]T  *_R  "O_0!XD0  :I8  %R:  !-
MGP  /Z,  #&F   CIP  %ZD   ZK   %K@   +    "R    M0   +<   "W
M    N    +D   "Z    O ,  +T)  "^#@  P!0  ,,>  #%*P  Q3P  ,9.
M  #&8@  QGH  ,:4  #&K0  QL@  ,7E  #%\P!LF0  7IX  $^D  !!J
M,JP  "2O   6L0  #;0   .W    N@   +T   #     Q    ,8   #&
MR    ,D   #+    S    ,X   #0!@  TPT  -@3  #<'@  WBT  -]   #@
M5   X6L  .&%  #AGP  X;<  .'/  #AY@!@H0  4J<  $.M   TL@  );4
M !>Y   -O    ;\   ##    QP   ,H   #/    TP   -8   #7    V@
M -P   #?    X0   .,   #F    Z0$  .P+  #P$@  \Q\  /0Q  #V1@
M]UP  /AT  #XCP  ^:8  /FX  #XR0#_  T _P + /\ "P#_  X _P 3 /\
M'P#_ "P _P Y /\ 10#_ %  _P!9 /\ 8@#_ &H _P!Q /\ =P#_ 'X _P"$
M /X B@#] )  _ "7 /H G@#Y *< ]P"Q /8 O@#U -( \P#L /$ _@#P /\
M\ #_ .8 _P#< /\ T@#_ ,T _P#_  < _P $ /\  @#_  8 _P 0 /\ &P#_
M "< _P S /\ /P#_ $H _@!4 /L 70#Y &0 ]P!K /4 <@#S '@ \@!^ /
MA #O (H [0"1 .P F0#J *$ Z "K .8 M@#D ,< X@#C .  ]P#> /\ W0#_
M -D _P#, /\ Q0#_ ,$ _P#_    _P   /\   #_  $ _P - /\ %@#\ "(
M^0 N /8 .0#S $4 [P!. .P 5P#I %X Y@!E .0 ; #B '( X !W -\ ?@#=
M (0 VP"+ -@ D@#5 )L T@"D ,\ KP#- +X RP#5 ,D [P#' /\ Q0#_ ,0
M_P"^ /\ N #_ +4 _P#_    _P   /\   #^    ]P ) /$ $0#K !P YP H
M .0 ,P#A #X W0!( -@ 40#3 %@ T !? ,X 90#, &L R@!Q ,@ =P#& 'T
MQ "$ ,( C #  )0 O@"> +L J "Y +8 MP#( +4 Y@"S /H L0#_ +  _P"P
M /\ K #_ *D _P#_    _P   /H   #Q    Z  # .  #0#8 !8 T0 B ,T
M+0#* #< Q@!! ,( 2@"_ %( O0!9 +H 7P"X &4 MP!J +4 < "S '8 L0!]
M *\ A0"M (T JP"7 *D H0"G *X I0"^ *( V "@ /( GP#_ )X _P"> /\
MG@#_ )P _P#_    ]P   .L   #A    U@   ,L "0#% !$ OP ; +L )@"W
M #$ M  Z +$ 0P"N $L JP!2 *D 6 "G %X I@!D *0 :0"B '  H !V )X
M?@"< (8 F@"0 )@ FP"6 *< E "V )( R@"0 .D CP#\ (X _P"- /\ C #_
M (T _P#X    Z0(  -L#  #, 0  Q    +T  @"V  T L  5 *L ( "G "H
MI  T *$ / "> $0 G !+ )H 4@"8 %@ E@!= )4 8P"3 &D D0!P (\ =P"-
M (  BP"* (D E0"' *$ A0"O (, P0"! .  @ #U '\ _P!_ /\ ?P#_ '\
M_P#N"@  W X  ,H0  "^#@  M0L  *\#  "I  < HP 0 )X & "9 ", E@ L
M ), -0"0 #X C@!% (P 2P"* %$ B !7 (8 70"% &, @P!J ($ <0!_ 'H
M?0"$ 'L CP!Y )P =P"J '4 NP!T -0 <@#P '( _P!R /\ <0#_ '$ _P#C
M$0  S1<  +\9  "S&0  JA4  *,0  "="@  EP$* )$ $@"- !L B0 E (4
M+P"# #< @  ^ 'X 10!] $L >P!1 'D 5P!X %T =@!D '0!:P!R 70 < )_
M &X"BP!L Y@ :P.F &D$MP!H!<X 9P?L &8(_0!F"?\ 90G_ &4)_P#6&@
MQ"   +8C  "K(P  H2   )D;  "2%   C X! (8'#0" !!0 ? 8> 'D'* !V
M"#  = @X '()/P!P"44 ;PI, &T*4@!L"E@ :@M? &@+9P!G"W  90QZ &,,
MAP!B#)4 8 VD %\-M@!>#<X 7 [M %P/_P!;$/\ 6Q#_ %L0_P#-(0  O"@
M *\K  "D*P  FBD  )(D  ")'P  @A@  'L1!0!U#0\ <0T7 &X.(0!K#BH
M:0\R &<0.0!E$$  9!!& &,030!A$%, 7Q%: %X18@!<$6L 6Q%V %D2@P!8
M$I( 5A.B %43M !4$\L 4Q3L %(5_P!2%O\ 4A7_ %(5_P#&*   MBX  *DR
M  "?,@  E3$  (PM  "#)P  >B$  '(:  !K$PL 9Q,3 &04' !A%"4 7Q4M
M %T5- !<%3L 6Q9" %D62 !8%D\ 5A=6 %477@!3%V< 4AAR % 8?P!/&8X
M3AJ? $P:L !+&\< 2QOI $H<_0!*'/\ 2AS_ $H<_P#!+0  L30  *4W  ":
M.   D#<  (<T  !]+P  ="D  &PC  !D' < 7AD0 %L:& !9&R$ 5QLI %4;
M, !4'#< 4AP] %$<1 !/'4L 3AU2 $T=6@!+'F, 2AYN $D?? !''XL 1B"<
M $4AK@!$(<0 0R+F $,B_ !#(O\ 0R+_ $,B_P"\,@  K3@  *$\  "7/@
MC3T  (,Z  !Y-0  ;S   &8J  !>) ( 5R - %0@% !1(!T 3R$E $XA+ !,
M(3, 2R(Z $DB0 !((D< 1R). $8C5P!$(V  0R1K $(D>0!!)8@ /R:9 #XF
MJP ])\$ /2?C #TH^@ ]*/\ /2?_ #TG_P"X-@  JCT  )Y   "40@  BD(
M ( _  !V.P  ;#8  &(P  !9*@  424+ $TE$0!+)1D 224A $<F* !%)B\
M1"8V $,F/0!")T0 02=+ #\H5  ^*%T /2EI #PI=@ [*H8 .2N7 #@KJ0 W
M++\ -RS@ #<L^  W+/\ -RS_ #@L_P"U.@  IT   )Q$  "11@  AT8  'U$
M  !S0   :#L  %\V  !5,0  3"L' $<I#P!%*A8 0RH> $$J)0 _*BP /BLS
M #TK.0 \*T$ .RQ( #HL40 Y+5L ."YF #8N<P U+X, -"^5 #,PIP R,+T
M,3'> #$Q]P R,?\ ,C#_ #,P_P"Q/@  I$0  )E(  "/2@  A4H  'M)  !P
M10  94   %L[  !2-@  2#$$ $(N#0 _+A, /2X; #LN(@ Y+RD ."\O #<O
M-@ V,#X -3!& #0Q3P S,5D ,C)D #$R<0 P,X$ +S23 "XTI@ L-;L +#7;
M "PU]0 M-?\ +33_ "XT_P"N00  HD@  )=,  "-3@  @TX  'E-  !N2@
M8D4  %A   !./   13<  #TS"P Y,Q$ -S,8 #8S'P T,R8 ,S,M #(T-  Q
M-#P ,#5$ "\U3  N-E8 +39B "PW;P K-W\ *CB1 "@XI  G.;D )CG8 "<Y
M]  H.?\ *#C_ "DX_P"K10  GTL  )1/  "+4@  @5,  '=2  !L3P  7TD
M %9&  !,0@  0CT  #@X"  T. \ ,C@5 #$X'0 O."0 +C@K "TY,@ L.3D
M*SI! "HZ2@ I.U0 *#M? "<\;0 E/'T )#V/ ",]H@ B/;< (3[4 "$^\P B
M/?\ (SW_ ",\_P"H20  G4\  ))3  ")5@  ?U<  '56  !J4P  74\  %-,
M  !*2   0$0  #9 !0 O/0T +3T3 "L]&@ J/B$ *3XH "@^+P G/C< )C\_
M "0_2  C0%( (D!= "%!:@ @07H 'D&- !U"H  <0K4 &T+1 !M"\0 <0O\
M'4'_ !Y!_P"E30  FE,  )!8  "&6P  ?5P  ');  !G6   6U0  %%2  !(
M3@  /4H  #-'   J0PL )D,0 "5#%@ D0QX (T0E ")$+  A1#0 ($4\ !Y%
M10 =14\ '$9: !M&:  91G@ &$>* !='G@ 61[, %$C. !5'[P 61_\ %T;_
M !=&_P"B4@  EU@  (U=  "$8   >F$  '!@  !E7@  65H  $]8  !$5
M.5$  "].   F2P8 ($H. !Y*$P =2AH '$HA !M+*  :2S  &4LX !=+0@ 6
M3$P %4Q7 !1,90 3374 $DV( !%-G  03;$ #D[,  ]-[@ 03?\ $4S_ !%,
M_P">5P  E%T  (MB  "!90  =V8  &UF  !C9   5F$  $I>   _6P  -5@
M "M6   B5 $ &E(* !92$  54A8 %%(= !-2)  24BP $5(T !%2/@ 04T@
M#U-4  Y38@ -5'( #%2$  M4F  )5*T "%3%  E4YP *4_L "U+_  M2_P";
M70  D60  (AH  !^:P  =&P  &ML  !?:@  4F<  $5D   Z8@  ,&   "9>
M   =70  %5L% !!:#  .6A$ #EH8  U;(  ,6R< "ULP  I;.@ )6T4 !UM1
M  9;7@ $6VT  UN   %;E   6Z@  %O   !:X@  6O8  5K_  )9_P"79
MCFL  (1N  ![<   <G(  &=Q  !9<   3&X  $!L   U:P  *FD  "%G   8
M9@  $68!  QE"@ '90\ !&44  -D&P "9",  &0L  !D-0  9$   &1,  !D
M6@  9&D  &1[  !DCP  8Z0  &.[  !BW0  8O0  &+_  !A_P"3;   B7$
M (!U  !X=P  ;7@  &!W  !2=@  1G4  #ET   N=   (W(  !IQ   2<0
M#7$   9Q"   < T  ' 2  !P%P  ;Q\  &\F  !O,   ;SL  &]'  !O5
M;V0  &]U  !NB@  ;:   &VV  !LU@  :_(  &O_  !K_P".<P  A7@  'U[
M  !S?0  97X  %A^  !+?@  /GX  #)^   F?0  ''P  !-\   -?   !GT
M  !]!0  ? L  'P/  !\$P  ?!D  'PA  !\*0  ?#0  'M   ![3@  >UX
M 'MO  !ZA   >IH  'FQ  !XS@  =^\  ';^  !V_P")>@  @7\  'B"  !K
M@P  784  $^&  !"AP  -8@  "F'   =AP  %(<   V(   &B0   (H   "*
M    B08  (D,  ")#P  B1,  (D:  "*(@  BBP  (HX  "*1@  B58  (EH
M  ")?   B)0  (>K  "&Q@  A>H  (7[  "$_P"%@@  ?88  &^(  !ABP
M4XT  $6/   XD0  *Y$  !^2   4D@  #9,   24    E@   )<   "8
MEP   )<%  "7"P  F X  )@3  "9&@  F2(  )HN  ":/0  F4T  )E>  "9
M<P  F(L  )BC  "7O   EN(  );W  "5_P" B0  <HP  &2/  !6DP  2)8
M #J9   LF@  'YL  !2<   ,G@   Y\   "A    HP   *4   "E    I0
M *4   "F @  IP@  *<-  "H$0  J1D  *LC  "K,0  JT$  *Q3  "L9P
MJX   *J:  "JLP  JM   *GO  "I^P!UCP  9Y0  %F8  !*G   /)\  "VB
M   @HP  $Z4   NG   !J0   *L   "N    L0   +(   "R    LP   +0
M  "U    M@   +@$  "Y"P  NQ   +T8  "_)   OS4  ,!'  # 6P  P'(
M ,"-  #!I@  P,$  +_C  "^\P!JEP  6YP  $VA   ^I0  +ZD  "&K   3
MK0  "[    "S    M0   +@   "\    OP   ,$   #!    PP   ,0   #&
M    QP   ,D   #+    S@@  -$/  #5&   V"<  -DY  #:30  VV0  -M^
M  #<F0  W+   -S)  #<XP!=GP  3Z4  $"J   RKP  (K(  !2U   *N
M +L   "_    PP   ,8   #+    S@   -$   #1    U    -8   #9
MVP   -X   #@    Y    .<&  #K#@  [QD  / J  #R/P  \U4  /1M  #T
MB   ]*$  /2V  #TQP#_  D _P & /\ !P#_  P _P 1 /\ ' #_ "@ _P T
M /\ 00#_ $P _P!5 /\ 70#_ &4 _P!L /\ <@#^ '@ _ !^ /L A #Z (L
M^0"2 /< F0#V *( ] "L /, N0#Q ,L \ #H .X ^P#M /\ [ #_ .$ _P#2
M /\ R0#_ ,0 _P#_  $ _P   /\   #_  0 _P . /\ %P#_ ", _P O /\
M.P#] $8 ^@!0 /< 6 #T %\ \@!F /  ; #O '( [0!X .P ?@#J (4 Z0",
M .< DP#E )P XP"F .$ L0#? ,$ W0#= -L ] #9 /\ U@#_ ,\ _P#$ /\
MO0#_ +D _P#_    _P   /\   #_    _P + /P $P#W !X ]  J /( -0#N
M $  Z0!* .8 4@#C %D X !@ -X 9@#< &P V@!R -< > #4 'X T@"% -
MC0#. )4 S "? ,D J@#' +@ Q0#- ,, ZP#  /X OP#_ +X _P"V /\ L #_
M *T _P#_    _P   /\   #Y    \@ & .L #P#F !D X0 D -X +P#: #D
MTP!# ,\ 3 #, %, R0!: ,< 8 #% &8 PP!K ,$ <0"_ '< O0!^ +L A@"Y
M (X MP"8 +4 HP"S +  L0#" *X X "L /< JP#_ *H _P"H /\ HP#_ *
M_P#_    _P   /4   #K    X0   -8 # #/ !, R@ > ,8 *0#" #, OP ]
M +L 10"X $T M@!4 +, 6@"Q %\ L !E *X :@"L '  JP!W *D ?P"G (<
MI0"1 *, G "@ *D G@"X )P S@": .X F0#_ )< _P"6 /\ E@#_ ), _P#]
M    \0   .4   #9    S0   ,0 !@"]  \ MP 8 +, (@"P "P K0 V *D
M/@"G $8 I !- *( 4P"@ %D GP!> )T 9 "; &H F@!P )@ =P"6 (  E "*
M )$ E0"/ *( C0"P (L PP") ., B #Y (8 _P"& /\ A@#_ (8 _P#S
MXP   -$   #%    O0   +8   "N  L J  2 *0 ' "@ "8 G  O )H -P"7
M #\ E0!& )( 3 "1 %( CP!8 (T 70"+ &, B@!J (@ <0"& 'D A "# ((
MCP!_ )L ?@"I 'P NP!Z -4 > #R '@ _P!W /\ =P#_ '< _P#G!P  T0P
M ,,-  "X#   K@@  *@   "B  4 FP . )8 %0"2 !\ C@ H (L ,0"( #D
MA@!  (0 1@"" $P @ !2 '\ 5P!] %T >P!C 'H :P!X ', =@!] '0 B !Q
M )4 < "D &X M !L ,H :P#J &H _ !J /\ :@#_ &H _P#:$   QA0  +@6
M  "M%0  I!(  )P.  "6!P  D  ) (H $ "% !@ @0 A 'X *@![ #( >0 Y
M '< 0 !U $8 <P!, '( 40!P %< ;@!> &T 90!K &X :0!W &< @P!E )$
M8P"? &( KP!@ ,0 7P#D %\!^ !> O\ 7@+_ %X"_P#.&   O1T  + @  "E
M'P  FQP  ),7  "+$0  A P  'X$"P!Y !( =0 ; '( (P!O "L ;0$S &L!
M.@!I D  9P-& &8#3 !D!%( 8P19 &$$8 !?!6D 7@5S %P&?P!:!HT 60><
M %<(K0!6",$ 50GA %0+]@!4"_\ 5 O_ %0+_P#&'P  MB4  *DH  ">*
ME"4  (LA  "#&P  >Q0  '0. P!N"0T :0@4 &8)'0!D"B4 8@HM & +- !>
M"SH 70M  %L,1P!:#$T 6 Q4 %<-7 !5#60 5 UO %(->P!0#HH 3PZ: $X.
MK !,#\( 3!#C $L0^0!+$/\ 2Q'_ $L0_P"_)@  L"L  *0O  "9+P  CRT
M (8I  !])   =!X  &P7  !E$0< 7PX0 %P/%P!:$!\ 6! G %80+@!4$#4
M4Q [ %(10@!0$4@ 3Q%0 $X15P!,$F  2Q)K $D2> !($X< 1A.7 $44J0!$
M%+X 0Q7? $,6^ !#%O\ 0Q;_ $,6_P"Z*P  JS$  * T  "5-0  BS0  ($Q
M  !X*P  ;R8  &8@  !>&0$ 5Q0- %04$P!1%!L 3Q4C $X5*@!,%3$ 2Q8W
M $D6/@!(%D0 1Q=, $475 !$%UT 0QAG $$8= ! &8, /QJ4 #T:I@ \&[L
M.QO; #L<]@ \'/\ /!S_ #P<_P"U,   J#8  )PY  "1.P  ASH  'XW  !S
M,@  :BT  &$G  !9(0  41L) $P9$ !*&A< 2!H? $8:)@!%&RT 0QLS $(;
M.@!!'$$ 0!Q( #X<4  ]'5D /!YD #L><0 Y'X  .!^2 #<@I  V(+@ -2'6
M #4A]  U(O\ -2'_ #8A_P"R-   I#H  )D^  "//P  A3\  'L\  !P.
M9S(  %TM  !4*   3"(% $8?#@!#'Q0 01\; #\?(@ ^("D /2 P #L@-@ Z
M(3T .2%% #@B30 W(E< -B-B #0C;@ S)'X ,B2/ #$EH@ O);8 +R;2 "\F
M\@ O)O\ ,";_ # F_P"O.   HCX  )9"  ",0P  @D,  'A!  !N/0  8S@
M %HS  !1+@  2"@! $ D#  ](Q$ .R08 #DD'P X)"8 -B0L #4E,P T)3H
M,R9" #(F2@ Q)U0 ,"=? "\H;  N*'L +"F- "LJH  J*K0 *2K/ "DK\  J
M*_\ *BK_ "LJ_P"L/   GT(  )1&  "*1P  @$<  '9%  !L0@  83T  %<X
M  !.,P  1"X  #PI"0 W*!  -2@5 #,H'  R*", ,"@I "\I,  O*C< +BH_
M "TK2  L*U( *RQ= "HL:@ H+7D )RV+ "8NG@ E+K, )"_- "0O[@ E+_\
M)2__ "8N_P"I/P  G44  )))  "(2P  ?DP  '1*  !J1P  7D(  %0]  !+
M.0  030  #@O!@ R+0T ,"T3 "XM&0 M+2  *RTG "HN+@ I+C4 *2\] "@O
M1@ G,$\ )3!; "0Q:  C,7< (C*) "$RG0 ?,[$ 'C/+ !XS[0 ?,_\ (#/_
M "$R_P"F0P  FDD  )!-  "&3P  ?%   '-/  !H3   7$8  %)#  !)/P
M/SL  #8V @ N,@P *S(1 "DR%P H,AX )C(D "4S*P D,S( (S0Z "(T0P A
M-4T (#58 !\V90 >-G4 '#>' !LWFP :-Z\ &3C( !DXZP :./\ &S?_ !LW
M_P"C1P  F$T  (Y1  "$4P  >U0  '%3  !F4   6DP  %!)  !'10  /4$
M #,]   J.0D )3<. ",W%  B.!L (3@B " X*  ?.#  'CDX !TY00 <.DL
M&CI6 !D[8P 8.W( %CN% !4\F0 4/*T $SW& !,]Z0 4//T %3S_ !8[_P"@
M2P  E5$  (M5  ""6   >5D  &Y8  !D5@  6%$  $Y/  !%2P  .D<  #!#
M   G0 4 (#X- !T^$0 </A< &SX> !H^)0 9/BT &#\U !8_/@ 5/T@ %$!3
M !- 8  207  $4&" !!!EP /0:P #D+$  Y"YP /0?P $$'_ !! _P"=4
MDU8  (E:  " 70  =EX  &Q=  !B6P  5E<  $Q5  !!40  -DX  "Q+   C
M2   &T4) !=$#P 51!0 %$4; !-%(@ 212D $44Q !%%.P 01D4 #T90  Y'
M7@ -1VT #$=_  M'DP )1Z< "$>^  A'X  )1_8 "D;_  M&_P":50  D%L
M (=@  !]8@  <V,  &IB  !@80  4UX  $=:   \5P  ,E4  "A2   ?4
M%TX$ !%,#  /3!$ #DP7  Y,'@ -324 #$TN  M--P *34( "4U-  =.6@ &
M3FD !$Y[  ).CP !3J0  $VZ  !-VP !3?(  4W_  ),_P"66P  C6(  (1F
M  !Z:   <6D  &AI  !<9P  3V0  $)A   W7P  +5P  "-:   :6   $E<!
M  U6"0 )50X !U43  95&@ $52(  U4J  )5-   53X  %5*  !65P  5F4
M %5W  !5BP  5:   %6V  !4U   5/$  %/]  !3_P"38@  BF@  (!L  !W
M;@  ;V\  &-N  !6;   26H  #UH   R9@  )V4  !UC   58@  #F$   E@
M"  #8 T  %\1  !?%P  7QX  %\F  !?+P  7SH  %]%  !?4P  7V$  %YR
M  !>AP  79P  %VR  !<SP  7.\  %O]  !;_P"0:@  AF\  'UR  !U=
M:G4  %UT  !/<P  0G(  #9P   K;P  (&X  !=M   0;   "FP   )K!@
M:PL  &H/  !J%   :AH  &HA  !I*@  :30  &E   !I3@  :5P  &EM  !H
M@@  :)@  &>N  !FR@  9>T  &7\  !D_P"+<0  @G8  'IY  !P>P  8GL
M %5[  !(>@  .WH  "]Z   C>0  &7@  !%W   *=P   W<   !W @  =P@
M '8-  !V$   =A4  '8;  !V(P  =BX  '4Z  !U1P  =58  '5H  !T?
M=)(  '.J  !RQ   <>D  '#[  !P_P"&>0  ?WT  '9_  !H@0  6H(  $R"
M   _@P  ,H0  "6#   :@P  $8,   J#   "@P   (0   "%    A ,  (,(
M  "##0  @Q   (,5  "$'   A"8  (0R  "$/P  @T\  (-@  ""=0  @HP
M (&D  " O0  ?^,  '[Y  !^_P""@   >H0  &R&  !>B   4(H  $*+   U
MC0  )XT  !N-   1C@  "HX   "/    D0   )(   "2    D@   )(!  "2
M!P  D@P  )(0  "3%0  DQT  )0H  "4-@  E$4  )-7  "3:P  DX(  )*<
M  "1M@  D-@  (_S  "/_P!^AP  <(H  &&-  !3D   19,  #>5   IE@
M')<  !&8   )F0   )L   "<    G@   *    "@    H    *    "A
MH00  *()  "C#@  I!0  *4=  "F*@  ICH  *9,  "E8   I7@  *62  "D
MK   I,D  */K  "B^@!SC@  9)$  %:5  !'F0  .9P  "J>   =H   $:$
M  BC    I0   *<   "I    K    *X   "N    K@   *\   "P    L0
M +(   "S!@  M0T  +<3  "Y'@  N2X  +I   "Z5   NVH  +J%  "YH0
MN;L  +K>  "Y\@!GE0  6)D  $J>   [H@  +*8  !VH   1J@  !ZP   "O
M    L0   +0   "X    NP   +P   "\    O@   +\   #     P@   ,0
M  #&    R ,  ,L+  #/$@  T2   -$R  #21@  TUT  -1V  #4D@  U:L
M -7$  #4X@!;G0  3*(  #VG   OK   'Z\  !&Q   'M0   +@   "[
MO@   ,(   #'    R@   ,P   #,    S@   -    #2    U0   -@   #;
M    WP   .(   #F"P  ZQ,  .PD  #M.   [DX  .]G  #P@@  \)P  /"R
M  #QQ0#_  , _P ! /\ ! #_  D _P / /\ & #_ "0 _P P /\ / #_ $<
M_P!1 /\ 60#_ &  _0!G /P ;0#Z ', ^0!Y /@ ?P#V (4 ]0", /, E #R
M )T \ "G .X LP#L ,0 ZP#A .H ^ #I /\ YP#_ -D _P#+ /\ P@#_ +T
M_P#_    _P   /\   #_    _P , /\ % #_ "  _P K /X -P#Z $( ]@!+
M /( 4P#P %L [@!A .P 9P#J &T Z !S .< >0#E '\ XP"& .$ C@#? )8
MW0"@ -L K #8 +L U #1 -, \ #0 /\ S@#_ ,@ _P"] /\ M@#_ +( _P#_
M    _P   /\   #_    _0 ( /< $ #S !H [P F .T ,0#H #L XP!% .
M30#< %4 V0!; -8 80#3 &< T0!L ,\ <@#- '@ RP!_ ,D AP#' )  Q0":
M ,, I0#  +( O@#% +P Y0"Z /L N #_ +< _P"P /\ J0#_ *4 _P#_
M_P   /X   #U    [  # .4 #0#? !4 V@ @ -0 *@#0 #4 RP ^ ,@ 1P#%
M $X P@!5 ,  6P"^ &$ O !F +H ; "X '( M@!X +4 @ "S (@ L0"2 *X
MG@"L *H J0"[ *@ U0"F /, I #_ *, _P"A /\ FP#_ )@ _P#_    ^P
M /    #E    V    ,X "0#' !$ P@ : +X ) "[ "X MP X +0 0 "Q $@
MK@!. *P 5 "J %H J0!? *< 90"E &L I !Q *( > "@ ($ G@"+ )P E@"9
M *, EP"R )8 QP"3 .@ D@#^ )$ _P"0 /\ C0#_ (L _P#Y    ZP   -T
M  #/    Q@   +P ! "U  T L  5 *P '@"H "@ I0 Q *( .0"? $$ G0!(
M )L 3@"9 %, EP!9 )8 7@"4 &0 D@!J )  <0". 'H C "# (H CP"( )P
MA@"J (0 O "" -P @0#V (  _P!_ /\ ?P#_ 'X _P#L    V@   ,D   "^
M    M@   *X   "G  D H0 0 )P & "8 "( E0 J )( ,@"0 #H C0!! (L
M1P") $T AP!2 (8 6 "$ %T @@!D ($ :P!_ ', ?0!] 'L B !X )4 =@"C
M '4 M !S ,P <0#M '  _P!P /\ < #_ '  _P#?!0  R@H  +P+  "Q"0
MJ 0  *$   ";  , E  , (\ $P"* !L AP D (0 + "! #, ?P Z 'T 00![
M $< >0!, '< 4@!V %< = != '( 9 !P &T ;P!V &P @@!J (\ :0"= &<
MK@!E ,, 9 #D &, ^@!C /\ 8@#_ &, _P#0#@  OQ(  +(3  "G$@  G1
M )4+  "/ P  B0 ' (( #@!^ !4 >@ > '8 )0!T "T <0 T &\ .@!N $
M; !& &H 3 !I %( 9P!8 &8 7P!D &< 8@!Q &  ? !> (D 7 "8 %L J0!9
M +P 6 #< %@ ] !8 /\ 5P#_ %< _P#&%@  MAH  *H=  "?'   E1D  (T4
M  "%#P  ?@D  '<!"@!R !  ;@ 7 &H 'P!H "< 90 N &0 - !B #L 8 !
M %\ 1@!= $P 7 !3 %H 6@!8 &( 5P!L %4 =P!3 (4 4@"4 % !I0!/ ;@
M3@+2 $T$\ !-!?\ 307_ $T%_P"_'0  L"(  *,E  "9)0  CR(  (4=  !]
M&   =1(  &X- @!G!@P 8P,1 %\"&0!= R$ 6P0H %D$+P!7!34 5@4[ %0&
M00!3!D< 409. % '50!.!UX 30AG $L(<P!)"8$ 2 F2 $<*HP!%"K8 1 O0
M $0,[P!##?\ 0PW_ $0-_P"Y)   JBD  )XL  "4+   BBH  ( F  !W(0
M;AL  &84  !?#P4 60L- %4*$P!3"QL 40LB $\,*0!-#"\ 3 PV $L-/ !)
M#4( 2 U) $8-40!%#EH 1 YD $(.< ! #G\ /P^0 #X0H@ \$+8 .Q#1 #L1
M\0 [$?\ .Q'_ #P1_P"T*0  IB\  )HR  "0,@  AC$  'PM  !R*   :2,
M &$=  !9%@  41$( $P/$ !*$!8 2! = $80) !%$"L 0Q$Q $(1-P!!$3X
M0!%% #X230 ]$E8 /!)A #H3;0 Y$WP -Q2- #84GP U%;, -!7- #,6[@ T
M%O\ -!;_ #06_P"O+@  HC0  )<W  ",.   @C8  '@T  !N+@  92H  %PD
M  !4'@  3!@$ $84#0!"%!( 0!09 #\4(  ]%2< /!4M #L5-  Y%CH .!9"
M #<62@ V%U, -1=> #,8:@ R&7D ,!F* "\:G0 N&K$ +1O* "T;[  M'/\
M+AO_ "X;_P"L,@  GS@  )0[  "*/   @#P  '8Y  !K-   8B\  %DJ  !0
M)0  1Q\  $ :"@ \&1  .AD6 #@9'0 V&B, -1HI #0:,  S&C< ,AL^ #$;
M1P O'%  +AU; "T=9P L'G8 *AZ( "D?FP H'ZX )R#' "8@Z@ G(/X *"#_
M "@@_P"I-@  G3P  )(_  "'00  ?4   '0^  !I.@  7S4  %8P  !-*P
M1"4  #L@!P V'@X ,QX3 #(>&0 P'B  +QXF "X?+0 M'S0 +" [ "L@1  J
M(4X *2%8 "<B90 F(G0 )2.% ",CF0 B)*T (23% "$EZ  B)?T (B3_ ",D
M_P"F.@  FC\  (]#  "%10  >T0  ')#  !G/P  73H  %,V  !*,0  02P
M #@F P Q(PP +B(1 "PB%@ J(AT *2(C "@C*@ G(S$ )B0Y "4E00 D)4L
M(R96 "(F8P A)W( 'R># !XHEP =**L &RG# !LIY@ <*?L '2G_ !XH_P"C
M/@  F$,  (U'  "#20  >DD  '!'  !F1   6C\  %$[  !'-P  /C(  #4M
M   L* D *"</ "<G%  E)QH )"<A ",H)P B*"X (2DV " I/P ?*DD 'BI4
M !TK8  ;*V\ &BR! !DLE0 7+:D %BW! !8MY  7+?H &"W_ !DM_P"A00
ME4<  (M+  ""30  >$T  &Y,  !D20  6$0  $]   !&/0  /3@  #,T   J
M+P8 )"P- "$L$@ @+!@ 'RT> !XM)0 =+2P '"XT !LN/  :+T8 &"]1 !<P
M7@ 6,&T %3%_ !,QDP 2,:@ $3*_ !$RX@ 2,OD $S'_ !,Q_P">10  DTL
M (E/  " 40  =E(  &U0  !B3@  5DD  $U&  !$0P  .S\  #$Z   G-@,
M'S(+ !PR$  ;,A4 &3(; !@R(@ 7,RD %C,Q !4T.@ 4-$0 $S1/ !(U7  1
M-6L $#9]  \VD0 .-J8 #3>\  TWW0 --O8 #C;_  \V_P";20  D4\  (=3
M  !^5@  =58  &I5  !@4P  54\  $Q,  !"20  .$4  "Y!   D/0  '#H(
M !8X#@ 5.!( %#@8 !,Y'P 2.28 $3DN ! Y-P /.D$ #CI,  T[60 -.V@
M"SMZ  H[C0 )/*( !SRX  <\U0 (//  "3O_  H[_P"83@  CE0  (58  !\
M6P  <EL  &A:  !>6   4U4  $E2   ^3@  -$L  "I'   A1   &$(# !)
M"P 0/Q  #C\5  X_'  -0", #$ K  M -  *0#X "4%*  =!5@ &064 !$%V
M  -!B@ !09\  $&T  !!T  !0>X  4'\  ) _P"55   C%D  (->  !Y8
M<&   &9@  !=7@  45L  $57   Z5   +U$  "5/   <3   %$H   Y("  +
M1PX "$<2  ='&0 &1R  !4@H  -(,0 "2#L  $A'  !(4P  2&(  $AS  !(
MA@  2)L  $BQ  !'S   1^T  $?[  !'_P"26@  B6   (!C  !W90  ;F8
M &5F  !99   3&   $!=   U6P  *ED  "!7   750  $%,   M2!P %40T
M 5 1  !0%@  4!T  % E  !0+@  4#@  %!#  !04   4%X  %!O  !0@P
M3Y@  $^N  !.R0  3NL  $W[  !-_P"/80  AF8  'UI  !T;   ;&T  &%K
M  !3:0  1F<  #ID   O8P  )&$  !I?   27@  #%P   9<!@  6PL  %H/
M  !:$P  6AD  %DA  !9*0  63,  %D_  !93   65H  %EK  !8?@  6)0
M %>K  !7Q0  5ND  %7[  !5_P",:   @FT  'IP  !R<@  9W(  %IQ  !,
M<   /VX  #-M   H:P  '6H  !1H   -9P  !V<   !F P  9@D  &4-  !E
M$0  9!4  &0<  !D)   9"X  &0Z  !C1P  8U4  &-F  !C>@  8I   &&G
M  !@P0  7^8  %_Z  !>_P"';P  ?W0  'AW  !N>   8'@  %)W  !%=P
M.'8  "MV   @=   %G,   YS   '<@   '(   !R    <04  '$*  !Q#@
M<!$  ' 7  !P'@  <"<  ' S  !O0   ;U   &]@  !N=   ;HL  &VB  !L
MO   :^(  &KX  !I_P"#=P  ?'L  '-]  !E?@  5W\  $E_   \?P  +X
M ")_   7?@  #WX   =^    ?P   '\   !_    ?@   'X%  !^"@  ?@T
M 'X1  !^%P  ?B   'XK  !].0  ?4@  'U9  !\;0  ?(0  'N<  !ZM@
M>=H  'CU  !W_P" ?P  =X(  &F#  !;A0  388  #^(   RB0  )(D  !B)
M   /B0  !XH   "+    C    (T   "-    C    (P   ", P  C @  (T-
M  "-$0  C1<  (XB  ".+P  CC\  (U0  "-9   C'L  (R5  "+K@  BLT
M (GO  ")_P![A0  ;8@  %Z*  !0C0  0H\  #21   FD@  &9,   Z4   &
ME0   )8   "8    F@   )L   ";    FP   )L   ";    G    )T%  "=
M"P  GA   )\7  "@)   H#0  *!&  "@60  GW   )^*  ">I0  GL(  )WH
M  "<^0!PC   88\  %.2  !$E@  -ID  ">;   9G   #YT   6?    H0
M *,   "E    J    *D   "I    J0   *H   "K    K    *T   "N 0
ML D  +(/  "S&   M"<  +0Y  "U30  M&0  +1^  "SF@  L[0  +/5  "S
M\ !DDP  59<  $>;   XGP  *:(  !JD   .I@  !*@   "K    K0   +
M  "T    M@   +@   "X    N0   +H   "\    O0   +\   #     PP
M ,4'  #)#P  RAH  ,LL  #,0   S58  ,YO  #-BP  S*@  ,S"  #,X@!8
MFP  2:   #JE   LJ0  '*L   ^N   $L0   +0   "W    N@   +X   ##
M    Q@   ,@   #(    R@   ,L   #-    SP   -(   #5    V0   -T
M  #A!0  Y@\  .<>  #H,@  Z4@  .I@  #K>P  ZY<  .RN  #LP@#_
M_P   /\   #_  8 _P - /\ %0#_ "$ _P L /\ . #_ $, _P!, /X 5 #[
M %L ^@!B /@ : #V &X ]0!T /0 >@#R (  \0"' .\ CP#M )< ZP"A .D
MK0#G +T Y0#8 .0 \P#B /\ X #_ -  _P#$ /\ O #_ +8 _P#_    _P
M /\   #_    _P ) /\ $0#_ !P _0 G /D ,@#U #T \0!& .T 3P#K %8
MZ !< .8 8@#D &@ XP!N .$ <P#? 'D W0"  -H B #8 )$ U "; -( I@#/
M +0 S #) ,D Z0#( /\ QP#_ ,$ _P"W /\ KP#_ *L _P#_    _P   /\
M  #_    ^  % /( #@#N !< Z@ B .8 + #A #< W0!  -@ 20#3 %  T !6
M ,X 7 #, &( R@!G ,@ ;0#& ', Q !Y ,( @0#  (H O@"4 +P GP"Y *P
MM@"^ +0 W0"S /< L0#_ +  _P"H /\ H@#_ )X _P#_    _P   /D   #O
M    Y@   -\ "P#6 !( T  < ,P )@#( #  Q  Z ,  0@"] $H NP!0 +@
M5@"V %L M0!A +, 9@"Q &P L !R *X >@"L (( J0", *< F "E *4 HP"T
M *  RP"? .X G0#_ )P _P"9 /\ E #_ )$ _P#_    ]@   .H   #=
MSP   ,< !@#   \ NP 7 +< ( "S "H L  S *T .P"J $, IP!) *4 3P"C
M %4 H@!: *  7P"> &4 G0!K )L <@"9 'L EP"% )0 D "2 )T D "L (X
MOP", .( BP#Z (D _P") /\ A@#_ (, _P#T    Y    -0   #(    OP
M +4  0"N  L J0 2 *4 &P"A ", G@ L )L - "8 #P E@!# )0 20"2 $X
MD !3 (X 60"- %X BP!D (D :P"' ', A0!] (, B "! )4 ?P"D 'T M0![
M ,\ >0#Q '@ _P!W /\ =P#_ '4 _P#E    T0   ,,   "X    KP   *@
M  "@  8 F@ . )4 %0"1 !X C@ F (L +0"( #4 A@ \ (0 0@"" $< @ !-
M '\ 4@!] %@ >P!> 'D 90!X &T =@!V ', @0!Q (X ;P"= &T K@!L ,0
M:@#G &D _0!H /\ : #_ &D _P#5 P  PP<  +8(  "K!@  H@   )L   "4
M    C0 * (@ $ "# !@ ?P @ 'P )P!Z "X =P U '4 .P!T $$ <@!' '
M3 !O %( ;0!8 &L 7P!I &8 9P!P &4 >P!C (@ 8@"7 &  IP!> +L 70#<
M %P ]@!< /\ 6P#_ %L _P#)#0  N1   *P1  "A$   EPT  (\(  "(
M@@ % 'L #0!W !( <P : &\ (0!L "@ :@ O &@ -0!G #L 90!! &, 1@!B
M $P 8 !2 %\ 60!= &$ 6P!J %D =0!7 (( 50"1 %0 H@!3 +4 40#/ %
M[P!0 /\ 4 #_ %  _P"_%   L!@  *0:  "9&0  CQ8  (<1  !_#0  =P8
M '$ " !K  X 9P 4 &0 &P!A "( 7@ I %T +P!; #4 60 [ %@ 00!6 $8
M50!- %, 5 !2 %P 4 !E $X < !, 'T 2P"- $D G@!( +  1P#' $8 Z0!&
M /L 1@#_ $4 _P"X&P  JB   )XB  "3(@  B1\  ( :  !W%0  ;Q   &@+
M  !A! H 70 0 %D %@!6 !T 5  C %( *@!0 #  3P U $X .P!, $$ 2P!(
M $D 3P!' 5< 1@%A $0"; !# GD 00.) $ #F@ ^!*T /03$ #P%Y0 \!_@
M/ ?_ #P'_P"R(@  I2<  )DI  ".*0  A"<  'LC  !Q'@  :1@  &$2  !:
M#0, 4P@, $\%$0!,!1< 2@8> $@&) !'!BH 10<P $0'-@!#"#T 00A# $ (
M2P ^"5, /0E= #L*:  Z"G8 . N' #<+F0 U"ZP - S" #,,Y  S#?D ,PW_
M #0-_P"M)P  H"P  )4O  "++P  @"X  '<J  !M)0  9"   %P:  !4%
M3 \& $8,#0!##!( 00P8 #\,'P ^#"4 / TK #L-,@ Z#3@ . T_ #<.1P V
M#E  - Y: #,.9@ Q#W0 , ^% "X0F  M$*L +!## "L1Y0 L$?H +!'_ "T1
M_P"J+   G3$  )(T  "'-0  ?30  '0Q  !J*P  8"<  %@A  !/&P  1Q8
M $ 1"0 [$ \ .1 4 #<0&P V$"$ -! G #,1+0 R$30 ,1$[ # 10P N$DT
M+1)7 "P28P J$W$ *1." "<4E0 F%*D )17  "05XP E%OH )A;_ "85_P"F
M,0  FC8  (\Y  "%.@  >SD  '$V  !G,0  72T  %0H  !,(@  0QT  #L7
M!0 U% T ,A,1 #$4%P O%!T +A0D "P4*@ K%3$ *A4X "D60  H%DH )Q=4
M "878  D&&\ (QB  "$9DP @&:< 'QF^ !X:X  ?&O@ (!K_ " :_P"C-
MF#H  (T]  "#/@  >3T  &\[  !E-P  6S(  %(M  !)*   0",  #@> 0 P
M&0H +!@/ "H8%  I&!H )Q@@ "89)P E&2T )!HU ",:/@ B&T< (1M2 " <
M7@ ?'6P '1U^ !P=D0 :'J4 &1Z\ !@?W0 9'_8 &A__ !L>_P"A.   E3T
M (M!  "!0@  =T(  &U   !C/   63<  $\S  !&+@  /2D  #4D   M( <
M)QT- "4=$@ C'1< (1T= "$=)  @'BL 'QXR !X?.P ='T4 '"!/ !HA7  9
M(6H &")[ !8BCP 5(J, %".Z !,CV@ 4(_4 %2/_ !8C_P">/   DT$  (E$
M  !_1@  =48  &Q$  !B00  5SP  $TX  !$-   /#   #,K   J)@, (R(+
M " A$  >(14 '"(; !LB(0 :(B@ &B,P !DC.  8)$( %B5- !4E60 4)F@
M$R9Y !(FC0 1)Z( $">X  XGU@ 0*/0 $2?_ !$G_P"<0   D44  (=(  !]
M2@  =$H  &I)  !@1@  54$  $P^  !#.@  .C8  #$R   H+0  ("D) !LG
M#@ 9)Q( &"<8 !8G'P 5*"4 %"@M !,H-@ 2*4  $BE+ !$J5P 0*F8 #BMW
M  XKBP -+)\ #"RU  LLSP ,+.\ #2S_  TK_P"91   CTD  (5,  !\3@
M<T\  &E.  !>2P  4T<  $I$  !"0   .3T  "\X   E-   '3 % !8M#  4
M+!  $RT5 !(M'  1+2, $"TJ  \N,P .+CT #2](  TO50 ,,&, "C!T  DP
MB  (,9P !C&Q  8QRP &,>L !S#\  @P_P"72   C4T  (-1  !Z4P  <50
M &=2  !=4   4DP  $E*  ! 1@  -4(  "L^   B.@  &C<! !(T"0 /,PX
M#C,3  TS&0 -,R  ##0H  LT,0 *-3L "#5&  <U4@ %-F  !#9Q  (VA
M-ID  #:O   VR   -N@  #;Y  $U_P"430  BE(  (%6  !X6   ;UD  &58
M  !;50  45(  $=/   \3   ,4@  "=$   >00  %C\  ! \!P +.@T "3H1
M  @[%P &.QX !3LF  0[+@ ".S@  3Q#   \3P  /%X  #QN   \@0  /)<
M #RL   [Q0  .^<  #OX   [_P"14@  B%@  ']<  !V70  ;5X  &-=  !:
M7   3E@  $)4   W40  +4X  "-+   :20  $D8   U$!@ '0PP  T,0  !#
M%0  0QL  $,C  !#*P  0S4  $-   !#30  0UL  $-K  !#?@  0Y0  $*J
M  !"PP  0>8  $'Y  !!_P".6   AEX  'UA  !S8P  :V0  &)C  !780
M25T  #U:   R6   )U4  !Y3   540  #D\   E-!0 "30L  $P.  !,$P
M2Q@  $L?  !+*   2S(  $L]  !+20  2U<  $MG  !*>P  2I   $FG  !)
MP   2.0  $CX  !'_P"+7P  @V0  'IG  !Q:0  :6H  %YI  !09@  0V0
M #=A   L7P  (5T  !A;   060  "E@   -7 P  5PD  %8-  !5$   514
M %0;  !4(P  5"T  %0Y  !410  5%,  %1D  !3=P  4XT  %*D  !1O0
M4.(  %#X  !/_P"(9P  ?VL  '=N  !O<   97   %=N  !*;   /6L  #!I
M   E:   &F8  !%D   +8P  !&(   !B 0  808  & +  !@#@  7Q(  %\7
M  !?'@  7B@  %XS  !>0   7D\  %Y?  !=<@  78@  %R@  !;N0  6M\
M %GW  !8_P"$;@  ?'(  '5U  !K=@  774  $]T  !"<P  -7,  "AR   =
M<   $V\   QN   $;@   &X   !N    ; (  &P'  !K"P  :PX  &L2  !J
M&0  :B(  &HM  !J.@  :4D  &E:  !I;   :(,  &>;  !FM0  9=@  &3U
M  !D_P" =0  >GD  '![  !B>P  5'P  $9\   Y?   +'P  !][   4>@
M#7H   1Z    >@   'H   !Z    >0   'D!  !X!@  > L  '@.  !X$P
M>!H  '@E  !X,@  =T$  '=2  !W90  =GP  '65  !TKP  <\X  '+Q  !Q
M_P!^?0  =8   &>!  !8@@  2H,  #R$   NA0  (84  !6%   -A0   X4
M  "&    AP   (@   "(    AP   (<   "'    AP0  (<)  "'#@  B!,
M (@<  "(*0  B#@  (=*  "'70  AG,  (:-  "%IP  A,4  (/L  ""_@!X
MA   :H8  %R(  !-B@  /XP  #&.   CCP  %H\   V0   "D0   )(   "3
M    E0   )8   "6    E@   )8   "6    EP   )<   "7!P  F T  )D3
M  ":'P  FBT  )H_  ":4@  FF@  )F#  "9GP  F+H  )?B  "6^ !MB@
M7XT  %"0  !!DP  ,Y8  "27   6F   #9D   &;    G0   )\   "A
MI    *4   "D    I0   *4   "F    IP   *@   "I    J@0  *P,  "N
M$P  KB$  *XS  "N1P  KET  *YV  "NDP  KJX  *W-  "L[P!AD0  4Y4
M $28   UG   )I\  !>A   -HP   *4   "G    J@   *P   "P    L@
M +0   "S    M    +4   "W    N    +D   "[    O0   +\!  ##"P
MQ14  ,4E  #&.0  QT\  ,=H  #&A0  QJ(  ,:\  #&W@!5F0  1YT  #BB
M   II@  &:@   VK    K0   +$   "T    MP   +H   "_    P0   ,0
M  ##    Q0   ,8   #(    R@   ,T   #/    T@   -8   #;    X P
M .$8  #C*P  Y$$  .5:  #F=   YI$  .6L  #EQ #_    _P   /\   #_
M  $ _P * /\ $@#_ !T _P H /\ - #_ #X _0!( /H 4 #W %< ]0!= /0
M8P#R &D \ !O .\ = #M 'L ZP"! .D B0#H )( Y@"< .0 J #B +< WP#-
M -P [@#9 /\ V0#_ ,H _P"^ /\ M0#_ +  _P#_    _P   /\   #_
M_P & /\ #P#\ !@ ^  C /0 +@#P #@ ZP!" .@ 2@#E %$ X@!8 .  70#>
M &, W !H -D ;@#6 '0 U ![ -$ @@#/ (L S0"5 ,H H0#( *\ Q0#! ,(
MXP#  /L P #_ +L _P"P /\ J #_ *0 _P#_    _P   /\   #[    \P !
M .T # #H !, XP > .  * #: #( TP \ ,\ 1 #, $L R0!1 ,8 5P#$ %T
MP@!B ,$ 9P"_ &T O0!T +L >P"Y (0 MP". +0 F0"R *< KP"W *T T "K
M /( J@#_ *D _P"A /\ FP#_ )< _P#_    _P   /0   #I    X    -4
M" #. !  R0 8 ,4 (@#! "L O  U +D /0"V $4 LP!+ +$ 40"O %8 K@!;
M *P 80"J &8 J0!M *8 = "D 'P H@"& *  D@"> )\ G "N )D PP"7 .<
ME@#_ )4 _P"2 /\ C0#_ (H _P#\    \    .,   #4    R    +\  P"Y
M  T LP 3 *\ ' "L "4 J0 N *4 -@"C #X H !$ )X 2@"= %  FP!5 )D
M6@"7 %\ E@!F )0 ; "2 '4 D !^ (X B@"+ )< B0"F (< N "% -8 A #V
M (( _P"! /\ ?@#_ 'P _P#M    W0   ,P   #!    N    *X   "G  D
MH@ 0 )X %P": !\ EP G )0 +P"1 #< CP ] (T 0P"+ $D B0!. (@ 4P"&
M %D A !? (( 90"  &T ?@!W 'P @@!Z (\ > "> '4 KP!S ,< <@#L '$
M_P!P /\ < #_ &X _P#=    R0   +P   "Q    J0   *$   "9  , DP ,
M (X $@"* !D AP A (0 *0"! #  ?P W 'T /0![ $( >0!( '@ 30!V %(
M= !8 '( 7P!Q &< ;P!P &P >P!J (@ : "7 &8 J !E +P 8P#A &( ^@!A
M /\ 80#_ &$ _P#- 0  O 4  *\%  "E @  G    )0   "-    A@ ( ($
M#@!\ !0 >  ; '4 (P!R "D <  P &X -@!M #P :P!! &D 1P!H $P 9@!2
M &0 60!C &  80!I %\ = != ($ 6P"0 %D H0!7 +0 5@#0 %4 \@!5 /\
M5 #_ %4 _P#!#   L@X  *8/  ";#@  D@L  (D%  ""    >P " '4 "P!P
M !  ;  6 &@ '0!F ", 8P J &$ , !@ #8 7@ [ %T 00!; $8 6@!, %@
M4P!6 %L 5 !D %( ;@!1 'L 3P"* $T FP!, *X 2P#& $H Z@!) /X 20#_
M $D _P"Y$@  JA8  )X7  "4%@  BA,  ($0  !Y"P  <0,  &L !@!E  T
M80 1 %T & !: !X 6  D %8 *@!4 #  4P V %$ .P!0 $$ 3@!' $T 3@!+
M %8 20!? $< :0!& '8 1 "% $, EP!! *D 0 "_ #\ X@ _ /@ /@#_ #\
M_P"R&0  I!X  )@?  ".'P  A!P  'H8  !R$@  :@X  &((  !< 0@ 5P .
M %, $P!0 !D 3@ ? $P )0!* "L 2  P $< -@!& #P 1 !" $, 20!! %$
M/P!: #X 90 \ '( .@"! #D DP X *4 -@"Z #8 VP U /0 -0#_ #4 _P"L
M(   GR0  )0F  "))@  ?R0  '4@  !L&P  9!4  %P0  !4# $ 3@8* $H"
M#P!' !0 1  : $( ( !  "4 /P K #X!,0 \ 3< .P(^ #D"10 X TT -@-6
M #4$80 S!&X ,05^ # %D  O!:, +0:X "P&U  L!_  + C_ "P(_P"H)0
MFRH  ) L  "&+0  >RL  '(G  !H(@  7QT  %<7  !/$@  2 X$ $$*"P ^
M!Q  .P85 #D'&P X!R$ -@@F #4(+  S"#( ,@DY #$)00 O"4D +@I3 "P*
M7@ K"VP *0M\ "@,CP F#*( )0RW "0,TP C#?  ) W_ "4-_P"D*@  F"\
M (TR  "#,@  >3$  &\N  !E*0  7"0  %,?  !+&0  0Q,  #P0!@ U#0P
M,PP1 #$,%@ O#!P +@TB "T-*  K#2X *@TU "D-/0 G#D8 )@Y0 "0.7  C
M#VH (@][ " 0C@ ?$*( '1"W !P0U  =$?( '1'_ !X1_P"A+P  E3,  (HV
M  " -P  =C8  &TS  !C+P  62H  % E  !((   /QH  #@5   P$0@ +! .
M "H0$@ H$!@ )Q > "40)  D$"H (Q$R "(1.@ A$4, (!). !X26@ =$V@
M&Q-X !H3BP 8%*  %Q2U !84T0 6%?$ %Q7_ !@4_P">,P  DS<  (@Z  !^
M.P  =#L  &LX  !A-   5R\  $XK  !%)@  /2$  #0<   M%P4 )A,, ",3
M$  B$Q4 (!,: !\3(0 >%"< '10O !P5-P ;%4$ &A9+ !D65P 7%V4 %A=V
M !08B0 3&)X $ABS !$9S@ 1&>\ $AG_ !,9_P"<-@  D3L  (8^  !\/P
M<S\  &D]  !?.0  534  $PP  !#+   .B<  #(B   J'@$ (AD) !X7#@ <
M%Q( &A<7 !D8'@ 9&"0 &!DL !<9-  6&CX %1I) !,;50 2&V, $1QT ! <
MAP /'9P #AVQ  T=RP -'>P #AW_  \=_P"9.@  CS\  (1"  ![1   <4,
M &A"  !>/@  4SH  $HV  !!,@  .2T  #$I   H)0  (" & !H=#  7'!
M%1P5 !0=&P 4'2( $QTI !(>,@ 1'SP $!]& ! @4P .(&$ #2%Q  PAA0 +
M(ID "B*N  DBQP )(N< "B+[  LA_P"7/@  C$,  (-&  !Y2   <$@  &=&
M  !<1   4C\  $D[  ! .   .#0  "\P   G+   'B<# !8C"@ 2(0X $2$3
M ! B&0 0(B  #R(G  XC+P -)#D #"1$  LE4  *)5X "29O  <F@@ &)I8
M!":L  ,FQ  $)N4 !";W  8F_P"50@  BD<  (%*  !X3   ;TP  &5+  !;
M2   4$0  $=!   _/@  -SL  "TV   D,0  &RT  !,J!P /* T #2<1  TH
M%@ ,*!T "R@E  HI+0 )*3< !RI"  8J3@ $*UP  RML  $K?P  *Y0  "NI
M   KP0  *^,  "OV   J_P"21@  B$L  ']/  !V40  ;5$  &-0  !:30
M3TH  $='   ^1   ,T   "D\   @.   %S0  !$Q!0 ,+PP "2X0  <N%0 &
M+QL !2\C  ,O*P ",#4  # _   P3   ,5D  #%I   Q?   ,9$  #&G   P
MOP  ,.$  ##U   O_P"02P  AE   'U4  !U5@  :U8  &)5  !84P  3E
M $5-   Z20  +T4  "5"   </@  %#L   XY!0 )-PL !#8/  $V$P  -AD
M #8@   V*0  -C(  #<]   W20  -U<  #=G   W>0  -X\  #:E   VO0
M-N   #7U   U_P"-4   A%8  'Q:  !R6P  :5L  &!;  !760  3%8  $!2
M   U3@  *DL  "!(   71@  $$,   M!!  $0 H  #\.   ^$0  /A8  #X=
M   ^)@  /B\  #XZ   ^1@  /E0  #YD   ^=@  /8P  #VC   \NP  /-X
M #OU   [_P"*5P  @EP  'E?  !P80  :&$  %]A  !47@  1UL  #I7   O
M50  )5(  !M0   230  #$L   9* P  20D  $@-  !'$   1Q0  $8:  !&
M(@  1BP  $8W  !&0P  1E$  $9@  !%<P  18D  $2@  !$N   0]P  $+U
M  !"_P"(70  ?V(  '=E  !N9P  9V@  %MF  !.8P  06$  #1>   I7
M'UH  !57   .5@  !U0   !3 0  4@8  %$+  !1#@  4!$  $\6  !/'@
M3R<  $\R  !//P  3TT  $Y=  !.;P  3H4  $V=  !,M0  2]@  $KU  !*
M_P"%90  ?&D  '1L  !M;@  8FT  %1K  !':0  .F<  "UE   B9   &&(
M !!@   )7P   %X   !>    70,  %P(  !;#   6@\  %H3  !9&0  62(
M %DM  !9.@  64@  %A8  !8:P  5X$  %>9  !6L@  5=(  %3T  !3_P"!
M;   >7   '-S  !H<P  6G(  $QQ   _<   ,F\  "5N   :;   $6L   EJ
M    :@   &D   !I    :    &<#  !F"   9@P  &8/  !E%   91P  &4G
M  !D-   9$,  &13  !D90  8WL  &*4  !AK0  8,T  %_Q  !>_P!]=
M=W<  &YY  !?>0  47D  $-Y   V>   *7@  !QW   1=@  "G4   !U
M=0   '8   !U    =    '0   !S @  <P<  ',,  !R$   <A4  '(@  !R
M+   <CL  '%,  !Q7P  <70  '".  !OJ   ;L8  &SM  !K_P![>P  <GX
M &1^  !5?P  1X   #F!   K@@  'H$  !*!   *@0   ($   ""    @P
M (,   "#    @@   ((   ""    @@   ((%  """@  @@\  ((7  ""(P
M@C(  ()#  "!5@  @6P  ("&  !_H0  ?KT  'WF  !\_ !V@@  :(,  %F%
M  !+AP  /(D  "Z*   @BP  $XL   J+    C    (T   "/    D0   )(
M  "1    D0   )$   "1    D0   )(   "2 @  DPD  )0/  "4&0  E"<
M )0X  "43   DV(  )-\  "3F   DK,  )'8  "0]@!JB   7(H  $V-   _
MD   ,)(  "&4   4E0  "I8   "7    F0   )L   "=    GP   *    "@
M    H    *    "A    H@   *,   "D    I0   *8'  "H$   J!P  *@M
M  "I0   J58  *EO  "IBP  J*@  *?'  "F[ !?CP  4)(  $&6   SF0
M(YP  !2=   *GP   *$   "C    I@   *@   "L    K@   *\   "O
ML    +    "R    LP   +0   "V    MP   +H   "]!P  OQ   +\?  #
M,P  P$D  ,!B  # ?@  P)L  ,"W  "_V !3EP  1)L  #6?   FHP  %J4
M  NG    J@   *T   "P    LP   +8   "[    O0   ,    "_    P0
M ,(   #$    Q@   ,@   #*    S    ,\   #3    V@<  -L3  #=)0
MWCL  -]3  #@;@  WXP  -VI  #=P@#_    _P   /\   #_    _P ' /\
M$ #_ !D _P D /\ +P#\ #H ^0!# /4 2P#S %( \0!9 .\ 7@#M &0 ZP!I
M .D ;P#G '4 Y@!\ .0 A #B (T X "7 -T H@#: +$ U0#% -( Z #0 /\
MSP#_ ,0 _P"X /\ KP#_ *D _P#_    _P   /\   #_    _P " /L #0#W
M !4 \P ? .\ *0#J #0 Y@ ] .( 10#> $P VP!3 -@ 6 #4 %X T@!C -
M:0#. &X S !U ,H ?0#( (4 Q@"0 ,( FP#  *D O@"Z +L V0"Y /< N #_
M +0 _P"I /\ H@#_ )T _P#_    _P   /\   #V    [@   .< "@#A !$
MW  : -< (P#0 "X RP W ,< /P#$ $8 P0!- +\ 4@"] %@ NP!= +D 8@"X
M &@ M@!N +0 =0"Q 'X KP"( *T DP"J *$ J "Q *8 R "D .T H@#_ *(
M_P"; /\ E0#_ )$ _P#_    _    .X   #C    V    ,T !0#&  X P0 5
M +T '@"Y "< M0 P +( . "O $  K !& *H 3 "H %$ IP!6 *4 6P"C &$
MH0!G )\ ;@"> '8 FP"  )D C "7 )D E "H )( O "0 -\ C@#[ (X _P"+
M /\ A@#_ (, _P#X    Z0   -P   #,    P0   +@   "R  H K  1 *@
M& "E "$ H@ I )X ,@"< #D F0 _ )< 10"5 $H E !0 )( 50"0 %H CP!@
M (T 9P"+ &\ B0!X (8 A "$ )$ @@"@ (  L@!] ,P ? #Q 'L _P!Z /\
M=P#_ '4 _P#F    TP   ,8   "[    L0   *<   "A  4 FP - )< $P"3
M !L D  C (P *P"* #( B  X (8 /@"$ $0 @@!) ($ 3@!_ %, ?0!9 'L
M8 !Y &@ =P!Q '4 ? !S (D < "8 &\ J0!M +\ :P#F &H _P!I /\ :0#_
M &< _P#3    PP   +4   "K    HP   )L   "2    C  * (< $ "# !8
M?P = 'T ) !Z "L >  R '8 . !T #T <@!" '$ 2 !O $T ;0!3 &P 60!J
M &$ : !J &8 = !D ($ 80"1 %\ H@!> +8 7 #5 %L ]P!; /\ 6@#_ %H
M_P#%    M@(  *D"  "?    E@   (X   "'    @  % 'H # !U !$ <0 8
M &X '@!K "4 :0 K &< ,0!F #< 9  \ &, 00!A $< 7P!- %X 4P!< %L
M6@!D %@ ;@!6 'L 5 "* %( FP!1 *X 4 #( $\ [@!. /\ 3@#_ $T _P"[
M"@  K T  * -  "5#   C @  (,"  !\    =0   &X " !I  X 90 3 &(
M&0!? !\ 70 E %L *P!9 #$ 6  V %8 .P!5 $$ 4P!' %$ 3@!0 %4 3@!>
M $P : !* '4 2 "$ $< E0!% *@ 1 "_ $, Y !" /P 0@#_ $( _P"R$0
MI10  )D5  ".$P  A!$  'L-  !S"   ;    &4  P!?  L 6P / %< % !4
M !H 40 ? $\ )0!. "L 3  P $L -@!) #P 2 !" $8 2 !% %  0P!9 $$
M8P _ &\ /@!^ #P D  [ *, .@"X #D V0 X /4 . #_ #@ _P"L%P  GQL
M ),=  ")'   ?QD  '45  !L$   9 P  %T&  !6  8 40 , $T $ !* !4
M1P : $4 ( !$ "8 0@ K $$ ,0 _ #8 /@ ] #P 1  [ $L .0!4 #< 7P V
M &L - !Z #( C  Q )X , "S "\ S@ O .\ +@#_ "X _P"G'@  FB(  (\D
M  "$)   >B$  '$=  !G&   7Q,  %<.  !0"@  20,( $4 #0!! !$ /@ 6
M #P &P Z "$ .0 F #< +  V #( -  X #, /P Q $< , !0 "X 6P M &<
M*P!V "H B  H )P )P"P "8 R0 E .H )0'[ "4!_P"B(P  EB@  (LJ  "!
M*@  =R@  &TE  !D(   6QL  %(5  !+$   0PP" #T'"0 Y PX -@$2 #,!
M%P Q 1P , $B "\")P M BT + ,T "H#.P I!$, * 1- "8%6  E!64 (P9T
M "(&A@ @!IH 'P>N !X'Q@ =!^< '0CX !T)_P"?*   DRT  (@O  !^+P
M="X  &HK  !A)@  6"$  $\<  !'%P  /Q(  #@.!  Q"PH +@@. "L'$@ I
M!Q< * @= "<((P E""D ) DP ",)-P A"D  ( I* !\+50 ="V( &PQR !H,
MA0 8#)D %PRM !8,Q@ 5#>8 %0WY !8-_P"<+0  D#$  (8T  !\-   <C,
M &@Q  !?+   52<  $PC  !$'0  /!@  #03   M$ 8 )@T+ "0,#P B#!,
M(0P9 !\,'P >#24 '0TL !L--  :#CT &0Y' !<.4P 6#F$ % ]Q !,0A  2
M$)@ $1"N ! 0Q@ 0$.@ $!#[ !$0_P"9,0  CC4  (0X  !Z.0  <#@  &<V
M  !=,@  4RT  $HH  !")   .1\  #$:   J%0$ (Q$' !T0#0 ;#Q  &0\5
M !@0&P 7$"$ %A I !40,0 4$3H $Q%% !(240 1$E\ $!)O  X3@@ .$Y8
M#1.K  L3P@ +%., #!3Z  T3_P"7-0  C#D  ((\  !X/0  ;ST  &4Z  !;
M-P  4C(  $DN  ! *@  -R4  "\A   H'   (!@# !D4"@ 5$@X %!(2 !,3
M&  2$Q\ $10F !$4+@ 0%#@ #Q5"  X63P -%EP #!=L  L7?P )&), "!BH
M  88OP '&.  !QCU  D8_P"5.   BCT  (!   !W00  ;4$  &0_  !:/
M4#@  $<S   ^,   -BL  "XG   G(P  'Q\  !<:"  2%PT $!<1  \7%@ .
M&!P #A@C  T9+  ,&C4 "QI   H;3  )&UH !QQI  4<?  $'9$  AVF  $=
MO  "'-T  ASR  ,<_P"3/   B$$  ']$  !U10  ;$4  &-$  !900  3ST
M $8Y   ^-@  -3(  "XN   E*@  '24  !0A!  /'0L #1T0  P=%  +'1H
M"AXB  @>*@ ''S, !B ^  0@2@ #(5<  2%G   A>0  (8X  "&D   AN@
M(=L  "'R   @_@"00   AD4  'U(  !T2@  :TH  &))  !81@  3D(  $4_
M   ]/   -3D  "LT   B+P  &2L  !(H!  -) H "2,.  8C$@ %(QD !"0@
M  (D*  !)3$  "4\   E2   )E4  "9E   F=P  )HP  ":B   FN0  )MD
M "7R   E_@".10  A$D  'M-  !S3P  :D\  &!.  !72P  34@  $1%   \
M0@  ,3T  "<Y   >-0  %3(   \N P *+ H !2L.  $J$0  *A8  "H>   J
M)@  *R\  "LY   K10  +%,  "QB   L=0  +(H  "N@   KMP  *]8  "KR
M   J_P",20  @DX  'I2  !Q5   :%0  %]3  !640  3$X  $-+   W1P
M+4,  ",_   :/   $C@   PV P &,PD  #(-   R$   ,10  #$;   Q(P
M,2P  #(W   R0P  ,E   #)@   R<@  ,H<  #&>   QM0  ,-0  ##R   O
M_P")3P  @%0  'A7  !O60  9ED  %Y9  !55P  25,  #Y/   R3   *$@
M !Y%   50@  #D    @] @ !/ @  #L,   Z#P  .1(  #D8   Y(   .2D
M #DT   Y0   .4X  #E=   Y;P  .(4  #B<   WLP  -](  #;R   U_P"'
M50  ?UH  '9=  !M7P  95\  %U?  !27   1%@  #A5   M4@  (D\  !A,
M   02@  "D@   -& 0  108  $0*  !##0  0A   $$5  !!'0  028  $$Q
M  !!/0  04H  $%:  !!;   0($  #^9   _L0  /M   #WR   \_P"$7
M?&   '-C  !L90  9&8  %ED  !+80  /EX  #);   F60  '%8  !)4   ,
M4@  !%$   !/    3@,  $T(  !,#   2PX  $L2  !*&0  2B(  $HL  !*
M.0  2D<  $I6  !):   27X  $B6  !'KP  1LT  $7Q  !$_P"!8P  >6<
M ')J  !K;   8&L  %)I  !$9@  -V0  "IB   ?8   %5X   U=   &6P
M %H   !9    6    %<$  !6"   5@P  %40  !4%   5!T  %0G  !4-
M5$(  %-2  !39   4GD  %*2  !1JP  4,H  $_O  !._P!^:@  =VX  '!Q
M  !F<0  6'   $IO   \;0  +VP  ")J   7:0  #F<   9F    90   &4
M  !E    8P   &(   !B!   80@  &$-  !@$   8!<  & A  !?+@  7SP
M %]-  !>7@  7G0  %V-  !<IP  6\4  %KM  !9_P![<@  =78  &MW  !=
M=@  3W8  $%U   S=0  )G0  !ES   0<@  !W$   !Q    <0   '$   !Q
M    ;P   &\   !N    ;@(  &X(  !M#   ;1$  &T:  !M)@  ;#4  &Q&
M  !K6   :VT  &J&  !IH0  :+X  &?H  !F_@!Y>@  <'P  &%\  !3?0
M1'T  #9^   H?@  &WT  !!]   '?0   'T   !]    ?@   '\   !^
M?0   'T   !\    ?    'P   !\!@  ? P  'P2  !\'0  ?"P  'P\  !\
M3P  >V4  'M^  !ZF@  >;8  'C?  !W^@!S@   98$  %:#  !(A   .88
M "N'   =AP  $8<   >(    B    (D   "*    C    (T   "-    C
M (P   ",    C    (P   "-    C00  (X,  ".$P  CR$  (XR  ".1@
MCEL  (UT  "-D   C*T  (O.  "*\P!HA@  6H@  $N+   \C0  +8\  !Z0
M   1D0  !Y(   "3    E0   )<   "9    FP   )P   ";    FP   )P
M  "<    G0   )X   ">    GP   *$#  "B#   HA8  *,F  "C.@  HT\
M *-H  "BA@  HJ(  *+   "AZ !<C0  39   #^3   PE@  (9D  !*:   '
MFP   )T   "@    H@   *0   "H    J@   *L   "J    JP   *P   "M
M    K@   *\   "Q    L@   +0   "W 0  N0T  +D:  "Z+0  ND,  +I;
M  "Z=P  NY0  +NQ  "YT@!0E0  09@  #*<   CH   $Z(   BD    IP
M *H   "L    KP   +(   "W    N0   +L   "Z    O    +T   "_
MP    ,(   #$    Q@   ,D   #-    T@$  -0/  #5'P  US4  -A-  #8
M:0  UX8  ->C  #6O0#_    _P   /\   #_    _P # /\ #0#_ !4 _P @
M /P *P#X #4 ]  _ /  1P#N $X ZP!4 .D 6@#G %\ Y0!D ., :@#A '
MWP!V -T ?@#; (< V "1 -, G0#/ *L S0"] ,L X #) /L QP#_ +T _P"Q
M /\ J0#_ *, _P#_    _P   /\   #_    _    /8 "P#Q !$ [0 ; .D
M)0#D #  WP Y -H 00#5 $@ T0!. ,\ 5 #- %D RP!> ,D 8P#' &D Q0!O
M ,, =P#  '\ O@"* +L E0"X *, M@"T +0 S0"R /( L #_ *P _P"C /\
MG #_ )< _P#_    _P   /H   #Q    Z    .  !@#9  X T@ 6 ,X 'P#(
M "D Q  R ,  .@"] $$ N@!( +@ 30"V %, M !8 +( 70"P &( K@!I *P
M;P"J '@ J "" *8 C@"D )L H0"K )\ P "= .8 FP#_ )H _P"4 /\ C@#_
M (H _P#_    ]@   .@   #<    S@   ,8  0"_  L N@ 1 +8 &@"R "(
MK@ K *H - "H #L I0!! *, 1P"A $P GP!1 )X 5@"< %P F@!B )D : "7
M '  E0!Z )( A@"0 ), C0"B (L M0") -, AP#W (8 _P"$ /\ ?P#_ 'P
M_P#R    XP   -(   #%    N@   +$   "K  < I0 . *$ % "> !P F@ E
M )< +0"4 #0 D@ Z )  0 ". $4 C0!* (L 4 ") %4 B !; (8 80"$ &D
M@@!R '\ ?0!] (L >P": '@ JP!V ,0 = #K ', _P!S /\ < #_ &X _P#?
M    S    +\   "T    JP   *$   ":  ( E  + )  $ ", !< B  > (4
M)@"# "T @0 S '\ .0!] #\ >P!$ 'D 20!X $X =@!4 '0 6@!S &( < !K
M &X =0!L (, :@"2 &@ HP!F +@ 9 #> &, ^P!B /\ 8@#_ &  _P#,
MO    *\   "E    G0   )0   ",    A@ ' ($ #0!\ !( >  9 '4 'P!S
M "8 <0 M &\ ,@!M #@ :P ] &H 0@!H $@ 9P!. &4 5 !C %L 80!D %\
M;@!= 'L 6P"* %D FP!7 *\ 5@#+ %4 \@!4 /\ 5 #_ %0 _P"^    L
M *0   "9    D    (@   "!    >0 " ', "@!O  \ :P 4 &< &@!E "
M8P F &$ + !? #( 7@ W %P / !; $( 60!' %< 3@!6 %4 5 !> %( : !0
M '0 3@"# $P E0!* *@ 20#  $@ Z !' /\ 1P#_ $< _P"T"0  I@L  )L,
M  "0"@  A@4  'X   !V    ;P   &@ !0!C  P 7P 0 %L %0!8 !H 5@ A
M %0 )@!3 "P 40 Q %  -@!. #P 30!" $L 2 !) %  2 !8 $8 8@!$ &X
M0@!] $  C@ _ *( /0"X #T W0 \ /@ / #_ #P _P"L$   GQ(  )02  ")
M$0  ?P\  '8,  !N!0  9@   &   0!9  @ 50 - %$ $0!. !8 2P ; $D
M(0!( "8 1@ K $4 ,0!# #8 0@ \ $  0P ^ $L /0!3 #L 70 Y &D -P!X
M #8 B0 T )P ,P"Q #( S@ R /$ ,0#_ #$ _P"F%@  FAD  (X:  "$&@
M>A8  ' 2  !H#@  7PH  %@#  !1  0 3  * $@ #@!$ !( 00 6 #\ &P ]
M "$ /  F #H +  Y #$ -P W #8 /@ T $8 ,P!/ #$ 60 O &4 +@!S "P
MA0 K )@ *@"M "D Q@ H .H * #^ "@ _P"A'   E2   (HA  !_(0  =1\
M &P:  !C%@  6A$  %(-  !+!P  1  & $  "P \  \ .  2 #8 %P T !P
M,P A #$ )P P "P +@ S "T .@ K $( *@!+ "@ 50 F &$ )0!P "0 @0 B
M )4 (0"I "  P0 @ .0 'P#Y !\ _P"=(@  D28  (8H  !\)P  <B4  &DB
M  !?'0  5Q@  $X3  !&#@  /PL  #@%!P T  P ,0 0 "X $P L !@ *@ =
M "D (@ G "@ )@ N "0 -@ C #X (@!' "  4@ ? %X '0!M !P ?@ : )(
M&0"G !@ O0 7 -\ %P'U !<"_P":)P  CBL  (0M  !Y+0  <"L  &8H  !=
M)   5!\  $L:  !#%   .Q   #0- @ M"0D *04- "8#$  D 1, (@(9 "$"
M'@ @ B0 '@,J !T#,@ ;!#H &@5$ !D%3P 7!EP %@9J !0'?  3!Y  $@>E
M !$'NP 0!]L $ CR ! )_P"7*P  C"\  ($Q  !W,@  ;C$  &0N  !;*@
M424  $D@  ! &P  .!8  #$2   I#@0 (PP) !\)#0 =!Q  &P<5 !D(&@ 8
M""  %PDG !8)+@ 5"C< $PI! !(+30 1"UH $ MI  X,>P .#)  #0RE  P-
MNP +#=D "PWQ  P-_P"5+P  BC,  '\V  !V-@  ;#4  &,S  !9+P  4"L
M $<F   ^(0  -AT  "X8   G$P  (! % !D."@ 5# X % P1 !,,%@ 2#!P
M$0TC ! -*P /#30 #@X_  T.2@ ,#U@ "P]G  H0>0 ($(T !Q"B  80N  %
M$-0 !1#O  80_P"2,P  B#<  'XZ  !T.P  :SH  &$X  !8-0  3C   $4L
M   ])P  -2,  "T?   F&@  'A8! !<3!@ 1$ L #@X.  X/$P -$!D #1 @
M  P0*  +$3( "A$\  @22  '$E4 !A-E  03=@ #$XL  12@   3M@  $]$
M !/N   3^P"0-@  ACL  'P^  !S/P  :C\  & ]  !7.0  338  $0Q   \
M+@  -"H  "PF   E(@  'AX  !8: @ 0%0D #!,.  H3$@ )%!< "!0?  <5
M)@ &%2\ !!8Z  ,61@ !%U,  !=B   8=   &(D  !B?   8M0  %]   !?M
M   7^P"..@  A#\  'M"  !R0P  :$,  %]"  !6/P  3#L  $,W   [-
M,S   "PL   D*0  &R0  !,? @ -&PD "1D-  89$0 $&18  AD=  $:)
M&BT  !LX   ;1   '%$  !Q@   =<@  '8<  !R=   <LP  ',X  !OM   ;
M_ ",/@  @D,  'E&  !P2   :$@  %Y&  !51   2T   $,]   [.@  ,S<
M "HR   @+0  %RD  ! E @ +(@D !2 -  $?$   'Q0  !\;   @(@  ("L
M "$V   A00  (4\  "%>   B<   (H4  "&;   AL@  (<T  "#M   ?_ "*
M0P  @$@  'A+  !O3   9DT  %U+  !420  2D8  $)#   Z0   +SL  "4W
M   <,P  $R\   TL @ '*0@  2<,   F#@  )1(  "89   F(0  )BD  "8S
M   G/P  )TT  "=<   G;0  )X(  ">9   FL   )<P  "7N   D_0"(2
M?TP  '90  !N40  95(  %Q1  !33P  2DP  $%)   U1   *T   "$\   7
M.0  $#8   HR 0 #, <  "\+   N#@  +1$  "T6   M'@  +2<  "TQ   M
M/0  +4H  "U9   M:P  +8   "R7   LKP  *\L  "KN   J_@"%30  ?5(
M '55  !L5P  8U<  %M6  !350  1U$  #M-   P20  )48  !Q#   3/P
M#3T   8Z    . 4  #<)   V#0  -0\  #04   T&P  -"0  #0N   T.@
M-$<  #17   T:   -'T  #.5   RK0  ,<H  #'N   P_P"#4P  >U@  '-;
M  !J70  8ET  %M=  !/6@  0E8  #92   J3P  ($P  !9)   .1P  "$0
M  !"    00,  #\'   ^"P  /0X  #T1   \&   /"$  #PK   \-P  /$0
M #Q3   \90  .WH  #J2   ZJP  .<@  #CM   W_P"!6@  >5X  '%A  !I
M8P  8F0  %=B  !)7@  /%L  "]8   D50  &5,  !!1   *3P   4T   !,
M    2@   $D$  !("   1PP  $8/  !&%   11P  $4G  !%,P  14   $50
M  !$80  1'8  $./  !"J   0<8  $#L   __P!^80  =F4  &]H  !H:@
M76D  $]F  !"9   -&$  "A?   =70  $EL   M9   "6    %8   !6
M5    %,   !2!   40D  % -  !0$   3Q@  $\B  !/+@  3SP  $]+  !.
M70  3G(  $V+  !,I0  2\(  $GJ  !(_P![:0  =&P  &YO  !D;P  56T
M $=L   Y:@  +&D  "!G   490  #60   -B    8@   &$   !@    7P
M %X   !=    7 0  %P)  !;#0  6Q(  %L<  !:*   6C8  %I&  !96
M66T  %B%  !7H   5KT  %7H  !3_@!Y<   <W0  &EU  !;=   3',  #YS
M   P<@  (W$  !9O   -;@  !&T   !M    ;0   &T   !L    :P   &H
M  !I    :0   &D#  !H"0  : X  &@5  !G(0  9R\  &<_  !F4@  9F8
M &5_  !DF@  8[<  &+A  !A_ !W>   ;7H  %]Z  !0>@  0GH  #-[   E
M>P  &'H   YY   $>0   'D   !Y    >@   'H   !Z    >    '@   !W
M    =P   '<   !W 0  =P@  '<.  !W&   =R8  '8V  !V20  =5\  '5W
M  !TDP  <Z\  '+3  !Q]P!Q?@  8W\  %2   !%@@  -H,  "B$   :A
M#H,   2$    A    (4   "&    B    (D   "(    AP   (<   "'
MAP   (<   "(    B    (@'  ")$   B1P  (DL  "(/P  B%4  (AM  "'
MB0  AJ<  (7'  "$[P!FA   5X8  $B(   YB@  *HP  !N-   /C0  !(X
M  "0    D0   ),   "5    EP   )@   "6    EP   )<   "7    F
M )@   "9    F@   )L   "=!P  G1$  )TA  "=,P  G4D  )QB  "<?P
MG)P  )RY  ";X@!:BP  2XX  #R1   MDP  'I4  !"6   $F    )H   "<
M    G@   *$   "D    I@   *<   "F    IP   *<   "H    J0   *H
M  "L    K0   *\   "Q    LPD  +,5  "T)P  M#T  +55  "U<   M(X
M +2L  "TS !-D@  /Y8  "^:   @G0  $9\   6A    HP   *8   "I
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M________________________________________________
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MV=K;W-W>W^#AXN/DY>;GZ.GJZ^SM[N_P\?+S]/7V]_CY^OO\_?[_;69T,0
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M____________J#4          %S3____________________________?0T
M         %36___________________________N?44          $34____
M_______________________\JF0O @  !"(W25C.____________________
M________Z:1K02@_8W^5I[K:_______________________________5LJRR
MS.3Z________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________________ENY=W8LC_____________
M____________________VYYG-@H  HS_____________________________
M___(?S\%     %[/_____________________________]F!.0       #RJ
M_____________________________YY,         ".0________________
M____________W&\:         !!]^?__________________________KT@
M          !O[O__________________________A!,           !DYO__
M_______________________L40            !7WO__________________
M______^X%0            !(UO________________________]T%
M       XS_________________________FB6A,            CQ?______
M___________________?FUPL           -NO______________________
M____[[%]53DB$0<! A$BLO______________________________W[^EF9B:
MH*R]VO______________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________X[Z=@'S[________________________________\K>$5S . !VL
M_______________________________2BDP5      !R\_______________
M_____________]9_-@        !+R?__________________________^I$^
M           OJ___________________________P%H            :E?__
M________________________C20            (A/__________________
M_______G7@              =_________________________^T)0
M        :O________________________]]                6_3_____
M__________________TK                3.O_____________________
M_Z4                 /.'______________________S ,
M    +=G_____________________F8IA)P              )]?_________
M_____________^V^B54G            )=S_________________________
M_LJ==EU*/#(M+# Y1][_______________________________WFW=;2T-/9
MY/__________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________________OU+O6________________
M_________________^>XCVI++Q5O_______________________________D
MH6<T!P     \R?___________________________]:".P         2E___
M________________________[84Q            ;___________________
M________ID(             4.'________________________L:0
M        -\G_______________________^S+P              (K;_____
M__________________]Y                $*?_____________________
M__(T                 )G______________________ZD
M     (S______________________T8                  '__________
M____________WP                   '3_____________________EP
M                 &K_____________________S@
M &/______________________RDB 0               &'_____________
M_________[FC@%<W%P           &C___________________________K3
MKI2&?'5Q<')W@93_____________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________________V[J=@FEIT___
M____________________________R)-E/1D    =GO__________________
M_________]N.3!,         ;O__________________________VWPL
M        1=?_________________________BRH             (K3_____
M___________________"1                Y?_____________________
M__]] 0               '_______________________^<V
M     &K______________________YT                  %C_________
M_____________T8                  $?X____________________Z0
M                 #7I____________________E@
M "7;____________________O                    !C.____________
M________ZP                    _"_____________________P
M              JY_____________________R<                   JU
M_____________________W                    VY________________
M_____^"<C'!50C,F&Q0/#0X2&B:_____________________________^>38
MTL[,R\S/UN#\________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________Z].\X________________________________]*I
MA65(+!(!A?____________________________&K<3P/        3^#_____
M____________________U7\U            '[+_____________________
M___C=1T              (G_______________________^0(P
M     &?______________________]5#                 $CV________
M_____________XH                  "[=_____________________S@
M                 !?(____________________O@
M  2V____________________G                     "E____________
M________N@                    "3____________________W
M              ""_____________________P                    !T
M_____________________Q,                   !H________________
M_____T(                   !@_____________________WH
M          !=_____________________]$                   !A____
M__________________\D                  !F____________________
M___)K)F)?79Q;&EG9F=K<'J,____________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________XL6JD7EA=_______________________
M_______=IG=0+ P     ,<3_________________________X)).$P
M     (_________________________2<!T              &#_________
M_____________^YO#P               #?B_____________________Y8<
M                 !3 _____________________T
M  "C____________________K@                    ")____________
M________G@                    !R____________________O
M              !?____________________V@                    !-
M____________________^@                     [________________
M_____PX                    J^?___________________S,
M           ;Z?___________________UX                    /V___
M_________________X\                    &T/__________________
M_]                      RO____________________\K
M        R/____________________^                     R_______
M_______________W%@$%!0,!       !!@T8R_______________________
M_.OAV,_,S<_0TM37W.+J________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__':QO______________________________\<:CA&A-,A@ %:O_________
M_________________[E\1A@          ''________________________7
M?"\              #OC_____________________]]D"0
M  RU_____________________W0#                  "-____________
M________Q14                   !J____________________F0
M              !+____________________M@                     P
M_?__________________UP                     9Y_______________
M____]@                     %T____________________PX
M            P?___________________R\                     K___
M_________________U(                     GO__________________
M_WD                     CO___________________Z4
M        @/___________________]@                     =/______
M______________\V                    ;?____________________]\
M                    :?_____________________7#0
M    :/______________________<                   8?__________
M_____________U \1DY465UA9&AL<'9^B?__________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________[]6[HXMS6I7___________________________B_CF1!(04
M %+\_______________________WG588             !?!____________
M_________^5L%@                "-_____________________V,
M              !>____________________G0                     U
M_/__________________H0                     1V?______________
M____R@                      N___________________[@
M            H?___________________PP                     BO__
M_________________RT                     =O__________________
M_TT                     9/___________________V\
M        4O___________________Y0                     0/______
M_____________[P                     ,/___________________^H.
M                    (O____________________]$
M    %?____________________^!                    "_7_________
M___________("P                   NS_____________________7@
M                 .7_____________________R1P
M -K______________________YT!              <.%\7_____________
M___________5N;S!Q\[5V^'F[?3[________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________________XW\______________
M________________[,:EB&U4.R$' #+>________________________UY)9
M*0            "@______________________^)-@                !G
M_____________________V8                    R]O______________
M____E0                     #R/__________________IP
M            H/__________________UP                      ?/__
M_________________P                      7O__________________
M_R4                     0____________________T@
M        +/___________________VH                     &/______
M_____________XL                     !?/__________________Z\
M                     .'__________________]4
M     ,____________________\D                     +[_________
M__________]4                     *[___________________^+
M                 )_____________________+#@
M )+_____________________5P                   (;_____________
M________J@H                  'G______________________VT
M             &;_______________________=5                 $7_
M________________________:B,K-3]*56!J=7Z'D9S_________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________________________________________^C/MIV#:4ZY
M_________________________^RR@UPZ'0(       ![________________
M_______%;2D               ! _____________________X,;
M           'R___________________D@                      F/__
M________________I                       :O__________________
MW0                      0?___________________PX
M        '?___________________SD                      .C_____
M_____________V                       ,[__________________X4
M                     +?__________________Z@
M     */__________________\L                      )#_________
M_________^\6                     'W___________________\^
M                 &S___________________]I
M %K___________________^9                     $G_____________
M_______2%@                   #G_____________________6
M             "G_____________________H@                   !G_
M____________________]58                   3_________________
M_____[LO                  #X______________________^K*0
M          #/________________________R4<     !Q,@+CY2:(3M____
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________]-7)____________________________^M*P
MDG==0B@,  !*________________________Q7U%%P             1V/__
M_________________\10                    G___________________
MH@P                     :/__________________E
M        -O__________________V@                      !^S_____
M_____________Q4                      ,3__________________T@
M                     *+__________________W4
M     (/__________________YT                      &G_________
M_________\,                      %+__________________^</
M                 #[___________________\S
M "O___________________]8                     !C_____________
M______^!                      7___________________^L
M              #____________________>(@                    #R
M____________________7                     #?________________
M____GP                    #,____________________Z$H
M          "W_____________________Z 6                  "<____
M__________________]Z @                !W____________________
M____>@L               5,_________________________Z)7:'2 C9RK
MO-#G________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________________^WC____________________
M_______2HWI8.BDC'!8.!@  G_____________________^L4@X
M        :?__________________Y$,                     -/______
M____________>0                       ./_________________S0
M                     ++__________________Q,
M     (7__________________T\                      %W_________
M_________X,                      #K__________________[(
M                 !S__________________]L#
M  +___________________\J                      #[____________
M______]/                      #G__________________]T
M              #4__________________^;                      #
M___________________$!P                    "M________________
M___P,P                    ":____________________9P
M          "&____________________HP                    !R____
M________________XT0                   !<____________________
M_Y$&                  !!_____________________^M?
M       =_______________________*2P                  ________
M________________RU<   P8)#$_3F!TBZ?'________________________
M___7Y_+_____________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________KU,W'PKZZM[.PK:FHI?___________________]U^
M4S\P(QD1"0(          -O_________________=@
M     *?_________________N@                       '7_________
M_________P<                      $;__________________TX
M                 !K__________________XP
M  #]_________________\$                       #;____________
M______$9                      "^__________________]$
M              "D__________________]K                      "-
M__________________^1                      !Y________________
M__^W                      !F___________________>(0
M          !3____________________2@                     _____
M________________=P                     K____________________
MK H                    6____________________YT4
M        _____________________XH                     ________
M_____________]9-                    _?____________________^G
M+@                  U?______________________F"H           88
M+45@X/_______________________ZAC=(&/G*N[S>+Z________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________GR[>IG96.B82 ?'AT<&QH99#_________________O&I(+1D*
M                 #'__________________P
M  /__________________T(                       #<____________
M_____XX                       "R_________________\X
M              "-__________________\I                      !K
M__________________]:                      !.________________
M__^&                       T__________________^N
M           >___________________4%P                     *____
M_______________Z/0                      ____________________
M90                      ____________________C@
M        ____________________O!D                     [_______
M____________\4X                     V/___________________XL
M                    O____________________\Q#
M    H?____________________^1&0                  >O__________
M___________R= H                17_______________________Z'03
M'RPX15-B<H6;M-+U___________________________7Z/3_____________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________________OW\_'N[.OK[/'_____________
M_____]FRF8=Y;61=5E%+1D$\.#(M*"/$_________________TLE"P
M              "2_________________X@                       !F
M_________________]<                        ]________________
M__\S                       8__________________]L
M            __________________^=                        ____
M_______________)#                       ]O_________________Q
M-0                      W___________________6P
M        R___________________@@                      M_______
M____________J08                     H___________________TR\
M                    C?___________________UX
M    =____________________Y,'                    7O__________
M_________\U#                    0/____________________^'$
M                '/_____________________87@
M /______________________OTX       X<+#Y2:H:ER/______________
M_________\)\C)JGML76Z/W_____________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________^[AU\_)P[ZZMK&MJ:>FIJ>N________________
M_[Z&;5M,0#<O*"(<%A +!      4_________________]<%
M            __________________\T                        ]O__
M______________]V                        TO________________^P
M                        LO_________________A)
M        EO__________________40                      ?/______
M____________>0                      9O__________________H
M                    4?__________________QR,
M    //__________________[DL                     )___________
M_________W0                     $/___________________Z,6
M                 /___________________]A,
M /____________________^(#P                   /______________
M_______+4P                   /______________________I3@
M      D=-$YKC/_______________________YDY0U%?;GV.H+7+Y?______
M_______________________K^?__________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________KS+FLH9F1BX:!?'AT<&MH9F9H\?________________]A
M13(C& X&                GO________________]^
M        =?_________________#                        4O______
M___________[-P                      ,O__________________:@
M                    %O__________________E@
M     /__________________OQL                      /__________
M________YD(                      /___________________VD
M                 /___________________Y "
M /___________________[DL                     /3_____________
M_____^A<                     -G___________________^1&
M             +S____________________*4P                   )W_
M____________________F"X             $"E&9L3_________________
M____[G\=#!HH-T97:7Z5K\SN_________________________^>@JKG(V.G\
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________________________?7PZ^;BW]O8U-+1T-+7X/______
M___________.GHI\<6EA6U913$A#/CHV,B\N,?_________________2)1$#
M                     /__________________0@
M     /__________________?0                       /__________
M________L L                      /;_________________W3D
M                 -S__________________V(
M ,7__________________XD                      *______________
M_____Z\B                     )G__________________]9(
M             (+___________________]R                     &G_
M__________________^A*                    $[_________________
M___37                    #/_____________________EBX
M     !4R4G?_____________________X'(3   !#Q\O0EAPBZC([/______
M_________________\IO;GZ.GK##V.______________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________^>#2R,"ZM;"LJ*6BGYV;FYR@I___________
M________@F162T,\-C K)R(=&!,."00  -3_________________D@
M                 *W_________________S!X
M (O_________________^U(                      &W_____________
M_____X                       %'__________________ZD;
M             #K__________________]!"                     "/_
M__________________5H                      S_________________
M__^/%                     #___________________^X/@
M          #____________________E;0,                   #_____
M________________GS<              ! O4'3_____________________
MW7(4      87*D%:=92VVO_______________________[Q81%1D=8::K\CC
M_______________________________2S>'Q________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________________________\^_K[_?__
M____________________[KFHG9:/BH:"?WMX=G1R<W5X?Y#_____________
M____ZT\Z,"@A&Q40"P<"         "/__________________VD
M              #__________________YL*                      #_
M_________________\@Y                      #_________________
M__!C                      #___________________^*#@
M          #___________________^P-                     #_____
M_______________56P                    #_____________________
MA1H                   /L____________________L4D
M !@Y78'_____________________Y7L>       ,(3A2;X^SV?__________
M_____________[M8*3E)6FR E[#-[?____________________________^S
MGK3%U^O_____________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________Z[^?AW-G6U-+0T-#1T]G@Z_?_
M_________________[B*?G=Q;&AD85Y;65A75UE>97'_________________
M_[\Q'Q80"@4               #__________________^U6
M          #H__________________^"!                     #,____
M______________^K+P                    "S___________________2
M5P                    ";___________________W?!
M      "%____________________HC<                 !2N4________
M____________RV$"            #"Q0=I[1____________________]8TP
M       -(SM7=IF^Y?_______________________\-C&"H[3%]TC:?&Y___
M__________________________^H?Y:HN]#G________________________
M_____________?______________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________=SL6_O+FVM+.QLK*UN<#)U>/_____
M______________^7;&1>65513TQ*2$=&2$M066:A__________________^G
M)@X' @                !6___________________.4
M       Z___________________T>0L                    A________
M____________GS(                    .____________________Q%@
M               (,5J$____________________Z7\?           &)TMQ
MFL+I_____________________Z=)      (7+TIHBJ[5_/______________
M_________]-U'B8X2EYUCZO+[_____________________________^N<H68
MK,+;]O__________________________________W^__________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________O[*JIJ.AH)^?H:.FK+3 S=WL________
M____________BEI33TM(1D1#0D%"0T=.66E]____________________GBX&
M                    ____________________PU8
M !5!____________________YWL:              DT8(NT____________
M_________Y\_          0E2G&9PNO______________________\9F#P
M !,J1&*#I\WU_________________________^N.-2L^46B!G;S>________
M______________________^^=G^4J<'<^?__________________________
M________TMCS________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________________V\O#O[^_Q\_C]____
M________________________^+"?FI>6EI:8FY^DK+;"T>'N____________
M_________HY02D=%1$1$149'2U%::(.I_____________________Z9! 0
M        !S9CC[KA_____________________\9E"@      !"=,<YS$[/__
M_____________________^6(+P  $RI$8H*FS/3_____________________
M______^K4#9*87N6M-;Z_______________________________2AWR8L<OI
M____________________________________U,[M____________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________________MY>/CY.;H[?'Y________
M______________________VQE)*2E9F=HZFRO-#M____________________
M______^=4T=)35%68'.*K];\__________________________^R5@ :-5!M
MBZ[2]______________________________-;SY?>YFWU_G_____________
M___________________NGX.FPN'_________________________________
M____X\[K____________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M
M
M                                                  #_________
M____________________________________________________________
M____________________________________________________________
M_________________________________________P    #_X4"P:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@
M:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM
M;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R
M92 Y+C$M8S P,2 W.2XQ-#8R.#DY+" R,#(S+S V+S(U+3(P.C Q.C4U(" @
M(" @(" B/@H@(" \<F1F.E)$1B!X;6QN<SIR9&8](FAT=' Z+R]W=W<N=S,N
M;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/@H@(" @(" \<F1F.D1E
M<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIP9&8]
M(FAT=' Z+R]N<RYA9&]B92YC;VTO<&1F+S$N,R\B"B @(" @(" @(" @('AM
M;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+R(*(" @(" @
M(" @(" @>&UL;G,Z>&UP34T](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N
M,"]M;2\B"B @(" @(" @(" @('AM;&YS.G-T179T/2)H='1P.B\O;G,N861O
M8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V5%=F5N=",B"B @(" @(" @
M(" @('AM;&YS.G-T4F5F/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O
M<U1Y<&4O4F5S;W5R8V52968C(@H@(" @(" @(" @("!X;6QN<SID8STB:'1T
M<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B"B @(" @(" @(" @('AM
M;&YS.G!H;W1O<VAO<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]P:&]T;W-H;W O
M,2XP+R(*(" @(" @(" @(" @>&UL;G,Z=&EF9CTB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]T:69F+S$N,"\B"B @(" @(" @(" @('AM;&YS.F5X:68](FAT=' Z
M+R]N<RYA9&]B92YC;VTO97AI9B\Q+C O(CX*(" @(" @(" @/'!D9CI0<F]D
M=6-E<CY-:6-R;W-O9G3"KB!7;W)D(#(P,3D\+W!D9CI0<F]D=6-E<CX*(" @
M(" @(" @/'AM<#I#<F5A=&]R5&]O;#Y-:6-R;W-O9G3"KB!7;W)D(#(P,3D\
M+WAM<#I#<F5A=&]R5&]O;#X*(" @(" @(" @/'AM<#I#<F5A=&5$871E/C(P
M,C,M,3(M,C!4,34Z,#(Z,3 K,#4Z,S \+WAM<#I#<F5A=&5$871E/@H@(" @
M(" @(" \>&UP.DUO9&EF>41A=&4^,C R,RTQ,BTR,%0Q-3HS,SHU."LP-3HS
M,#PO>&UP.DUO9&EF>41A=&4^"B @(" @(" @(#QX;7 Z365T861A=&%$871E
M/C(P,C,M,3(M,C!4,34Z,S,Z-3@K,#4Z,S \+WAM<#I-971A9&%T841A=&4^
M"B @(" @(" @(#QX;7!-33I$;V-U;65N=$E$/F%D;V)E.F1O8VED.G!H;W1O
M<VAO<#HY,S=D,C<T,RUD,&,P+3<P-#DM.&4V9"TT8S)C-C0X,#=C8S0\+WAM
M<$U-.D1O8W5M96YT240^"B @(" @(" @(#QX;7!-33I);G-T86YC94E$/GAM
M<"YI:60Z-C$T,65F8F$M9C<W,RUA-#0T+3AD9F4M8V%E8V,W9#%A-65D/"]X
M;7!-33I);G-T86YC94E$/@H@(" @(" @(" \>&UP34TZ3W)I9VEN86Q$;V-U
M;65N=$E$/G5U:60Z1C(U0T0Y-S8M,CDP-2TT,S1&+3A"130M,T5$-$0W,S4W
M,# T/"]X;7!-33I/<FEG:6YA;$1O8W5M96YT240^"B @(" @(" @(#QX;7!-
M33I(:7-T;W)Y/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @
M(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*
M(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#IC
M-6$W-CDW9BUB,3EF+3$Y-&8M834Y-BTX9#=A-V$U,F8X8CD\+W-T179T.FEN
M<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,C,M
M,3(M,C!4,34Z,34Z,#DK,#4Z,S \+W-T179T.G=H96X^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O<VAO<" R
M-2XP("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @
M(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @
M(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@
M<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z8S(Y,V9C-&4M,C,U
M-RUD9#1E+3@V9C0M-C$S9#8P-S4U9&8V/"]S=$5V=#II;G-T86YC94E$/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#(S+3$R+3(P5#$U.C,S
M.C4X*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @,C4N," H5VEN9&]W
M<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @
M(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO
M;CYC;VYV97)T960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @
M/'-T179T.G!A<F%M971E<G,^9G)O;2!A<'!L:6-A=&EO;B]V;F0N861O8F4N
M<&AO=&]S:&]P('1O(&EM86=E+V5P<V8\+W-T179T.G!A<F%M971E<G,^"B @
M(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI
M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @
M/'-T179T.F%C=&EO;CYD97)I=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IP87)A;65T97)S/F-O;G9E<G1E9"!F<F]M(&%P
M<&QI8V%T:6]N+W9N9"YA9&]B92YP:&]T;W-H;W @=&\@:6UA9V4O97!S9CPO
M<W1%=G0Z<&%R86UE=&5R<SX*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V
M=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$
M/GAM<"YI:60Z-C$T,65F8F$M9C<W,RUA-#0T+3AD9F4M8V%E8V,W9#%A-65D
M/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z
M=VAE;CXR,#(S+3$R+3(P5#$U.C,S.C4X*S U.C,P/"]S=$5V=#IW:&5N/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!0
M:&]T;W-H;W @,C4N," H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H
M86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \
M+W)D9CI397$^"B @(" @(" @(#PO>&UP34TZ2&ES=&]R>3X*(" @(" @(" @
M/'AM<$U-.D1E<FEV961&<F]M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*
M(" @(" @(" @(" @/'-T4F5F.FEN<W1A;F-E240^>&UP+FEI9#IC,CDS9F,T
M92TR,S4W+61D-&4M.#9F-"TV,3-D-C W-35D9C8\+W-T4F5F.FEN<W1A;F-E
M240^"B @(" @(" @(" @(#QS=%)E9CID;V-U;65N=$E$/G5U:60Z1C(U0T0Y
M-S8M,CDP-2TT,S1&+3A"130M,T5$-$0W,S4W,# T/"]S=%)E9CID;V-U;65N
M=$E$/@H@(" @(" @(" @(" \<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/G5U
M:60Z1C(U0T0Y-S8M,CDP-2TT,S1&+3A"130M,T5$-$0W,S4W,# T/"]S=%)E
M9CIO<FEG:6YA;$1O8W5M96YT240^"B @(" @(" @(#PO>&UP34TZ1&5R:79E
M9$9R;VT^"B @(" @(" @(#QD8SIC<F5A=&]R/@H@(" @(" @(" @(" \<F1F
M.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:3Y$96QT83PO<F1F.FQI/@H@
M(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @(#PO9&,Z8W)E871O<CX*
M(" @(" @(" @/&1C.F9O<FUA=#YI;6%G92]E<'-F/"]D8SIF;W)M870^"B @
M(" @(" @(#QP:&]T;W-H;W Z0V]L;W)-;V1E/C0\+W!H;W1O<VAO<#I#;VQO
M<DUO9&4^"B @(" @(" @(#QP:&]T;W-H;W Z24-#4')O9FEL93Y5+E,N(%=E
M8B!#;V%T960@*%-73U I('8R/"]P:&]T;W-H;W Z24-#4')O9FEL93X*(" @
M(" @(" @/'1I9F8Z3W)I96YT871I;VX^,3PO=&EF9CI/<FEE;G1A=&EO;CX*
M(" @(" @(" @/'1I9F8Z6%)E<V]L=71I;VX^.38P,# P+S$P,# P/"]T:69F
M.EA297-O;'5T:6]N/@H@(" @(" @(" \=&EF9CI94F5S;VQU=&EO;CXY-C P
M,# O,3 P,# \+W1I9F8Z65)E<V]L=71I;VX^"B @(" @(" @(#QT:69F.E)E
M<V]L=71I;VY5;FET/C(\+W1I9F8Z4F5S;VQU=&EO;E5N:70^"B @(" @(" @
M(#QE>&EF.D-O;&]R4W!A8V4^-C4U,S4\+V5X:68Z0V]L;W)3<&%C93X*(" @
M(" @(" @/&5X:68Z4&EX96Q81&EM96YS:6]N/C8P,SPO97AI9CI0:7AE;%A$
M:6UE;G-I;VX^"B @(" @(" @(#QE>&EF.E!I>&5L641I;65N<VEO;CXR-C8\
M+V5X:68Z4&EX96Q91&EM96YS:6]N/@H@(" @(" \+W)D9CI$97-C<FEP=&EO
M;CX*(" @/"]R9&8Z4D1&/@H\+W@Z>&UP;65T83X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,  0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$(
M 0H"6P,!$0 "$0$#$0'_Q  >  $  00# 0$              0(#!@<$!0@)
M"O_$ &X0  $# P," @4%" H+"@H%#0$" P0%!A$ !R$2,0A!$Q06(E$)%3)A
M<1<9(R4F5H&1)S4V0D9255>6H20S-$549I6QU-;P-T-B97:&D\'1TAA$1U-C
M9W*VQ/%UDJ;5X71W@H.$AY27HJ6RL\;_Q  < 0$! 0 " P$
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M?7#N?A2?1_*GK>^7\@[4?TMN\^9_Q*'EC].=6D^C^56S,WV':W]I5#/;VOO
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MM?>'(SW/Y$\9'8#J.<YP.YN(Y,=?E\^%.[X>O+F!3US??'[GMI<Y('Y87AC
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M\?Z4M!.9YNX8>;>&M9N. !SV'<DG]))))^)))/F=2K4Z4II2FE*:4J  .
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M-W'15%0ZI<?JR5*@HKZ[#;IMD2+BC)$N9:E*A6]ZRNBQ&834T@6:W%V&@Y>
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MUQL+>];%GW#<#S%88ITI3].F52+2JE(;5)IYDLUN#6US!/FSVS@L]'U+WM+
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M@@-I2@ C'0D)^B -*4]"UE9]$WEQ16L]"<K66TLE:SC*E%E*6BHY/HTI1GI
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M$]*D.)2E+B2"E82D*! &E[S2UHJ^$I3GI &25'  RHG))QW)/)/<GOI2I
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ML=LC'?@Y((Y-Q'H.WQ\.3M\:'R^=0%$I6I*U*Z\J2 HDA)&1TCRZ>_'/PS@
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MRWYUOI$Q-NURX7H2:C4TOTMQ*9*;4I E,LI;=3>#,I)4W15A(%R8< <= +L
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M$N$@"3NA+ , *\EL_3'3;)W<3:5G$4I0=>TD HP@E.$5$I)6Z2LK*R>R6;#
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MIH"S&8;]&EQ*&2U^$,=Q*%X,ZO/>)8$EB8[1 @A-S 8EAD&:HK9]JW5*&!B
M "586($@$A+J4 6#]D&.UK6MH.\NV]5CUFK0;[I4VFT&^8]CUI^)5F)+-*NV
M5,I-J)MB3&AN-S(DU%P55F*Y'F)<$>8I;CJT+#:XFS@XB2 0J05)>73VLVD0
M^MLGKNGH3I,#!)V?'2K'PSC(0<': 588PW)3]ENE@ IDXCIWTE3 E0V:W5(Q
M4PVN6VAV0I?JK;DZ$A^1)!494=J.9*_2B)R.A+CX;Z2 XM*4KUCJW<A2F222
MH;Q 2HC=*G2P!,)<&,G+'J*V?:$.3@K4$I2I1W,0 .">U 9)2 L.J0;P6[UH
MY;;)*E90@]2PD+.4CE82 D*/=02 D'. !C49HNT/KX5PWR;@8(X$&?&J]*4T
MI6CMZ]LU[FT^TS3:^NV;GL&]J3N#:E91 15&6*G0$.MR8=0ITC+$EB9!J+X0
MVK#G4&76E)2A176)M?++@]FOF;GOK+@&;7U,2<QW!^\.*\S3O E:%=M./1[E
MO>_:E>C5WFYD[C6_7+SL13\>1O#.WCGTR58EKUV+9ZBBHJ?BQJPJ$N>[+8MV
M47$2(%.Z8W#-I>#F[P SM9Y%4%];/;S ,F8(#L&,S60[3^&V[*3>4J];IN9=
M,C6[O)O]=]G6Y3*%2?G/V7W*NFY9<*#)N=P.5-='J0JB;BFT%XJCSJMT2Z@V
MY-R^@UY_&?S\.4FH^0&6A!FPR$<P;M9J]-[1[;4[:7;.S=NHLU=7:M&B4Z#*
MJTIAIN36:E&:0N?7YK2.H&I5>IA^LSY"E./2*E)D3'77)#BW#7^##A+_ #\:
MOQN6>8:WIVK9VI5II2FE*:4II2FE*:4II2M=;F674K^M2?;M(NRK69/ER8TF
M-7Z2TW+7'<@N!1B2H,EQ#$RG3.E3<V&YB/*;*VWNI*@ER^H]3GISK/G,.\$.
M.Z1?\J\ITOP3V;(G0IVX4FV[NCHW-IV[-<L]K;ZVJ-M[(JU/L*^]OW9$>U(D
M TEN=<<2\':K=4IR,9=;E4]CYQ,CU=IPP!^!/',<QG ^#&:I(^&1L[$GN<M^
M%;QO'8JS[ALJT[%I=(H%K4"S=S-KMQZ;1:%2(%,H3"MNKTMZ[I,-B%%CQHC3
M,N53IRWG$-)6N1+6MY)6ZZ5(BP:WGYY5!F+DW8\@9BS6O6$[@>'"%>%Z5NMN
M71(IMG77>^U%Y7Y:8I<62]<5S[7/L3;;?AU*0VXJ*B=4:58$::T0I+].HLN
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M$9'IL*Y'2S*' \QD<#!QV!&.0!P7NF##;4#F/VC#&G!3P(F,K"GUCT:!&VH
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M@GL2,ZF\,'=S )D<"[\6KL[$I*,7>463O(EC(1BX*B&!DLA4) M >:^1=O\
M@+WAI5DP* *]:%$:IL+;&'4[8HLZX*K;FX(VZI5TBH3;JC2[5>BPZM<M5KE.
M34VH*)\5*:#3XZ);S-.IIUY7"VY"$X0*5*W$!!4H)[/W1NI (=+)=S(9Y)-?
M1L#VBZ$1@[/AJV;?Q482$XN(</8TCK$I3ADMBXN&LI)'6;VX5;J@_;W@G*ZW
MX'KYJ<JN047C0':/6MEJKMU.A7--J]PLS*P[9=N4* _)K52M=NL,Q4U6ER)K
MDMJXIKO5)<F)MQ,A4EEGD'2"0D%E??)_A$'$*@" HDD(+*"A)S<[U=9?M3T,
ME)(V=+[T;V'L@+%:@6",8E.Z@ L4C>:"ISB':UU>&O<&YK:L6##W BPU6U'F
M0V;5CO49FR;3<>VCN?;FH4_;^90-N*/=509BU2I-N/-W4&RRW#2XAF/+9;8'
M6ZT;ZU=6KM*!+).\)+%04H@?>!2$J(,EV %>,^N^B%8V(LX* ,4XA2K]G*]T
MXN(LI4E6.4@)ZUDC#Q%@@$)2@)&&.3M]X5+ML:AW5;=&W&JMFPJHBT75TRRW
M:/68-4J=.M6-3+CD5IB]+$J-8A0+@KC;U5E+MRI1ILAQ]Z4%,23(&LJQ74A1
M0LL5$*6&[+@=DA1!(9NT<AV@2U87TUT6K%PCAX.$2@+*DK&SH4@'[K;N*I!Q
M"@*(&*UPR\/?._JBD>#S=>';M+AP)VU]"JE)8OOTTBES=Q:BNXZK=.WE'M^=
M=$ABYI;U-C5FLU*$_5*L^FF1^N1*<=7EU4DI[*=M0F%]:6"1]U/9W%DI=25)
M40"3"MX$ ,945=C8.G>AMGQU8B\-TJ4E0 P]D4$@XB5*8)Q$D[H;?;? PTI_
MB*CB<&E^";=NGILY9OBVX,VV[SNFK%"WZG'HB;9J]Q6]4HEMT^VIEI3D1WXM
M.IU0IZ)5 F4V$@2Y9AK3'F+1K1Z1P^UV%$%@DA(202[D,MY9+6(9XWC7L.-[
M7>SV%NI.RI.\G#"$]3L+J[.(%J*SM@2$D;OV:PC$0YW@=XIP]S;2^':]]KCN
M^]4+LIU1H-_4Y2*7169S;]2^>YE;NB9/E2Y]:H5KU!Q,QJXJ;$6JJ5RH37F8
M49J7493K#;KG4Q=J0I2"4ET8@4 2P8&00%%*B63D0!8S7KN/T]T)B;3@K3@H
M0!M)QE HP A.$HNL;N'BK0M1<!"2%L=X I2H$^<+-\)V[UD3;4N.VK;1%N*D
M+V]D%V94HLJ _/I6TUP6??TZ2U&O5R*]'JMXU>@5Q:&UK]9E4R3-69#WHY"Z
M-M2H$$DI4%@L$.Y4"&(6#">R2&NS*+&O9-FZ9]G%)'6IP1AE*RLIV?!&(V*I
M*L$)W "DC"2O>4@I6E03NE1(4.A1X/MX*-:M?H4*FOW-"O.C[<U6\(MT-T*@
MP)%>LNZFK@J+[E8HUWHJE1E368#[3M7J)D5&06K6E3YBW(;9:T=L2H@J2IT[
MV[8!S%RH@F9+.'$@$OY=7MG[-[B,+&V?9T*V0JV?!ZM.SX@Q,,(3AC%Q I2!
MAK(4"4A*^I(Q$)QMU6,FLMH?ABWKHUQ;65^/&F4:1;%T2:[)0U5K6J%NT.VE
MW[4*VJR[1H]=C56M,Q*;;<Z';L2I4&H0D2:1#@M-DQD,(,5MR2DI4EBI.[+
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MW &1RKRSY#M_3C_VK:G:YQML@]PRO$<9I^FOM(Q;I?I418;9MEY<QBC, <G
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M-H-6?:B6T)-L6^5=" HFBTS*B$@'JQ&P3QSY?#7"@*&&@+)4K<2%E1*BI02
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M5A$Q]ZG&F/>GANTJL4&W*S3I005)$RF56X&&9C2U%#3C;O2X2VWUW5\GUO\
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M?;D ,_\ :<$JE,AV)#J<&Q2S!H-4]*/XRB>."1]1[CMD=SG(YU??\!K(\$W
MLV_,=[,SBJW1USMV&3=_><#M.I5[@"02"R7=W;<%02DY'4KD8^D.>X!XQSG(
M*CWY SDA4.W;.?X4N7?=2D,Y($=8QT8LQ=R1:-T<"/VW#8$G^TX!D & $ D,
M7@Y$N2P+".W6L 'GWD^6.^ ./=\QW!SSJG;]G)?=3#W"3#N ?M((?M680"UH
M$]'@?VS!.\Z7]YP7$'M -O$%Q9S#!R:CH1YK7S_P@<=LYQGN.?,D=N<#3W_
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M3Q]'G.076LCZ6/WYR20!P< GOP=2KO#AGF/"XGRXU)>2,GW>!D?A&^3QQ]+
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M\9[$9 4"9]:;=;WE?#M-+$Q&H?T]!](OM2[_ %OTA=_[1CDY,"^(S,[P7!X
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M-(UUR]2?1IO<K:AC^+#5M8U!]' )2"?_ $C6/_\ /)_0,9XSCG4[W]6J@O\
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MOP#W^O0C4#*X&5LJD&Q?O]?E4^P-E9YMVEY[?VHYY)&/I_'(Q\?K&C</+O\
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M1 9S>K^B?LN6(V?9>74]'L69V_9G.9-N! 85(9;'&#GX@9[]N"@<=^_/? .
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M6N6+M&!_' \QSCJQU DG ./KX)[<G&=C&4 _6K<PV^3HRG"@38EQK$S4]QV
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M4%' ).==<1?$5# @XCN6!SUDC4DQ77V_#Z.V5!?;<)*@"Q&T8"788D_P,VX
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M93ST@=N,8"0!TI[)QTX(  QC/ R ,J5O',GC=Y?,W\:XDIW0;#Y99"WA5_\
MJUFM4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E4E"".DH24]75TE((ZN
MKKZL8QU=?OY[]7O9SSHYUHPTJK SG R 0#Y@'&1GX' S\<#X:4J$I2D82D)'
M PD #   ''P  'P  ' TI4!M"0$A" D!0"0D  *.5  #&%'E0[$\G2C"S1I0
MH0<90DX)(RD'!(4DD9'!(6L$^86H=E'*HPT'I_F?$U5I5II2K9::( +39 *B
M 4)(!4%I40",94EQP*/F'%@Y"E9.=:C#057@9S@9&<''(SR?UGD_'STJU.E*
M:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2NCK=&36X8B/3ZQ!
MZ7P[Z:AU671Y91UG#:I$1]APH]'A*@5X*AD 9.GKUZ_"H7XG@#Q[K-^'&L?%
M@4T#FX;[..Y-]W1GC(Y_&8'<<C !(Y'<%2-?,Y=_CYU/L#3<_N@OD<X_=W=/
M?' P:H?U=S^^SHQTX]VM(&>@DY_,\*>P--!'Y07R#VQ[=W1R<#XU//UX\L_9
M@QTI#WF<_P ,V%0; IO?VAOH=_X>73@>9_OIY?$Y('GR=*,&N>;GY^NZ@L&F
M#GVAOD@_&^[HQC('\J?'C(^/QU6.GKU/=2-;\7X0[^7RJ38%-Y/M!?0''/MW
M=..W_P!)XY[_ .; XU+Y>%&;,ZR?Z1'QJ/8&FDD>T%]'(X ORZ>,CN,5,*[8
M())^/VVUQX\*08!.4O/H^!I[ TT']T-]'/.#?=T=L_54P<9SV/U>0Q,K=_X4
M86<YF^N?RRJ38%-!.;@OH#/;V\ND <9QGYTZN<9^EQSC THP N<Y)]"/*]/8
M&F\#VAOG/;]W=T9)!/\ QGWX((QC@\9R=&.GKT1XTC7SX-^![W-6E;?4M62+
MDOU.22.F_P"Z< Y!P,U0\#.,<C!^PZK'0^% 1$@Y7O\ G5P6#3,#%PWR>.#[
M>70<\]\FJ'/8C/G@_7J,=/7HCQI#W\S\'X'P-2+ IHY-P7T0,Y)ONZ<'(['%
M4 &,Y&,'Z\:483)\;>+M4&P::3Q<-]#.< 7W<_V>=3/GQ\<^><ZO=W^O&G!\
MOR>*GV IHX]H;Z!Y/[N[HSC'_P!)]A@GX]^<<:G=Z]&G!],_DUVRB.=/8"G8
M(]H+ZY P?;NZ"0/(@_.?)5YYS\!QI1N?B?G3V!IH(_*"^1D8 ]N[I]X_'FJ<
MGD=N.W'."I;,R<SQ=O4MG5/L#3/SBOKOC]WET#GX<5,<\]M5CH;/W:\J1KPO
MGIS]9"I]@:9G/M#?..3CV[NC&,$D?MIG&.>^0!D$<ZE&XE^?X6\JD6#31[OM
M!?.23WONZ"KR) S4\\? =@?LPI&O"_#Q=OGK3V!IOYP7S_3NZ>W Q^VF/,<X
MZLGOSI1IN9%GTTS\Z@6#3/*X;Z/3R3[>70>#VS^-,8QG![^>3@8K'3AZY4C6
MS9_'F->?&GL#3!P;AOGG@$WW=&?/M^,^><^1[8[9&I3O]9>L_"M,4JRZ+$WC
MW#+U=O)HNV;M: MV]JVA2L7#N20H==1"E=1"5$G/6A:B0HK*ALX0 "T@=L20
MD.2&?^$9P22;.&+"NWL!QBG: C9$%)7C@8BMG6K>; PB5!8=U@.QC=##[I:M
MBILRF!W"KDN[U9MK\"O[H%?ZRVV>EL!1J:6@HMDJ+8PGO@%/&LJPL):-U2ED
MWW88%C&ZQ).3FV<AJZ"=EVWWY6,K"VA0*RIEC%5A3C!4H*2&DAK]62 "2YY8
MLNCE.1=5XCJZ5 JW$KX/20".I*:E@G''"@/+D#GC& @-]]@-UF$9,.RV9 $V
M .3=I>#M!6L]0I]XGLX>($@%3EDE,!@;LPM:GL52,G-TW>21R?NAUX\>0(-2
MS@^0![C/4![NM=2BWVG<!HW\LD',@#@X%9&#M,_8+Y%&(6O+-GHYR9A CV(H
MX42;HO# [9W$KP&!V _&AZ<$#   '!'(&!P4,7.)%B6\#V0"_%[R<J# VIQ]
MAB:$##7,7L1%X#OP9GL72?=S=-X 9P0-QJ]@9P<\U/[2!R<8)&0,P82!/;?6
M.!+PUA,!V=P\/=]J<?8XEPXZM?)ON9F/"7$\]G;NB]*7$5R\^I82LK1?-R'J
M)]XD+14L*R3DJ3WX((XUHI'\K@!I&5I^&EZXMP))! 2MSO!F5O3O BX+ER(+
MU>7MY2' $N5V]EISU!*[XN50SD@'"JD>1D@'N/CG4W$FZ$D<4O+7Y@>0JD P
M>;'Y'(G7NR:L;?4L8":[?">,83?-T#Z/&?VSR"G@8& #@8\B8:".%LQ\Z,-<
MWALFB,LO*I-@TQ7]_P"^,'CB^[I()YSC-4/)&00/+)X/(U(RD3Q%&!S<3I,6
M@#CZ%3[ TP 8K]\ >7Y=W2!CDX'XT[8[8[ #'GEKY\)]7HUI/"1F,OB&MRBJ
M38--_.&^1V/[N[H&!DCSJ?8DX).3D#GODQT-(&=AF>4GYU/L%3 1FX+YSR0#
M?=T#( ^ J@R .>/M.<#$H1<N1WV;G'/QO4>P--*OW17UG)PD7Y=&.1R,?.>3
MY$9R1Y8R<F.E(L\\YMPX3'.GL#33VN&^NV.+[NCSSSQ4^_!Y[\'1B+BD'/P/
MRJ?8.F#^$%\8SG/MW='.23CFI]L''!S@#!!R36.AI %^\MGZY=S-'L#3.QN&
M^01P?R\NC)/.,YJ?!/)P,#CL<'4HPU-]3X/?QUY4-@TWO[0WT!YGV[NC'(P/
M[YXYSGRYQCZKP:=)]1^%($N;NY,<M&]:4-@4W/[H;Z'4>![=W1WYX3FIGX'C
MGM]1U*-S\2/@WRJ18%-R#[0WT>>WMW=&#QR#^,_@,\<]SYG2C<3PGT[<7UN]
M/8&F\GV@OG'_ "[NG"<GCO5/T#JR#YYTHP&9[S\_P;PI[ TTY(N"^>.^+[NC
M ([Y_&9 ^L< ? :4C6Q>_?/#@<JCV IOE<-]_']WET'R'_&? Q@\8^/GR[J=
M_GZUY6:I-@4[SN"^OZ=W1Y ?\9^6,_I.<\84;B<L]/GG3V!IN<^T%]8^ECV[
MNG &0?Y4SCC')Q@GSY"C<3X^O"W"[Q[ TT_PBOH=^U]W/Y=_[Y^7<CR^SO6.
MC^.=O'*D:MWZ%SX9\*DV#33D^T%\@?5?=T8&.#R:F?TY/?4IWVS=K:LU/8&F
MXS[07UC&2?;NZ,8!SG/SGP,<$@CC]!TI?OT/PH;"IF3FX+Y&>,>W=TC& .V:
MIG..3DGODCMJL=/3^A2!GXG0>B?.]4FP:9G]T5\YSR/;RYQ\1C'SG_5QSHQT
M/-CXU(>\Z/W6?\WJ?8&F9Q[17UGMCV\N?//U?.??X:,;LXUGQJEGNQT?\/Q$
M\:DV#33_  AOD<#@7W=';OGFID\@$YSVSSC1CH:1KEJT7R897TH+!IN,BX;Z
MQ@G/MW=!!^LYJ9X';C \\9YU&-FG2D7>+WC3P_&H%A4S(_*&^21P0;\NCG!Q
MR!5!R"<'MS@'/;1CIZ%Z1K(87\'!B>(J?8"FC ]H+Z'PS?=T9/8>=3R?+CXG
M5UCXQZXO1K2?&]A/IB3-1[ 4TG]T-]$CX7W='G\0*G]N/_P&)2/1.;\>/IA5
M;=APF5,N(KM[.*9?+O2_?%SN-NI*RHMNI545)6UC 2CI   &2,]2/7];"6],
M(/HL!Y3WO6;H2$(0@=1"$I2"M:W%82 !U..%3CBN.5K4I:CE2B5$G2K56E*:
M4II2FE*:4II2FE*:4II2FE*:4II2FE*:4I@9S@9^/G^O2E8I7[AHELQ55*Y+
M@I]"A3*E&I--FU2:*=#14:F&J="@N./.ML+>EU!"S$+G=;A#:DJY506;.SP+
M7:W-];6K)SR@YVR<SX1#$WKD1JY2Y=3J]$@U>)(J]#DPV:K"#OI)%*-:8%3@
M":R7 4JE1?VO!Z1Z-2$I"@>DH.5AEFVD'*3WTD9W+!^,ZSH+5WK4AIYIMU*@
M$N-H< 60E20M(4 M.?=4,@$'L<C4JN-1753:W2Z<]"9EU2#%<JM2^:8*9$A(
M]:J[C'K,6FL!2R/6'H;+KOH$ +7TE:!UKPN^O7J1I1SPSR)S#?GH:QM-Z6O(
MK]=M6/=E'-R4*DQK@K5NHN&E)N&B4&J(,:)5ZI2WBIVFT=*H[LI%0=.06R3Z
M1UXQY" V?=&?)S9G;C%\AS:W$S(!&1\7>=:Q6J[V;746DT2Z:SNQMS3+3NI,
MCV:K$^[J%3H-?9C.H:E.V_7GZ\*5550Y3R(KS;<=B4CE#ZFW&SUKS'P&3Z:V
M$Z0STNS2\6,LYM\RSB\VS>3>]LP$6V*C<-&CKN^?$H]K.&H1EIK]0EP1.2S3
MA'D.LR7'&D.+9]5?D-E/0I#Q0ZA2WKS[_-O@]!=QW..0?E/%_!ZS+4JTTI32
ME-*4TI6,7!<-*MJF2ZO<M<IUMT: 779U?J<ZFTBDP6@L>KM2Y=8<4TA;K:FT
MEQ" VMPJZ"A10V;Z'CZOEW5'OYG2,@7?X2+S6KG_ !";+0*"FZZGO)MK"MIZ
ML(H#=S2;WMR%;"K@0XJIHMMNH3*L'':VY29#3KC;3*4/1D"4AEAI34-L"+$:
M^<1RXQ,,9J$&[GE>Q>8SM'*8%9-1MRK"N1UA-L[A6S</51Y=R0W*+==%J2ZG
M1*:\Y#G3EHCH=IZ:-3WJG#]-58[JW'%"*7UN%M)=9N6:YT [I#.-)AV>DLP>
M(XGQ@O)-XEGMP?NO[?/56W:'$W#L656[LB2ZM;-&C7I1HU4NN)%J,B+3DVK"
MGK<^?XU0=BO0Y4V#(99>] J53R\PMPM2_H#/3U%JH^4.3R(,=^N?'N+:W LN
M\%7!#MF_;9N1RE*FIJR:#<,"LF@(:+U/]7J,NF>B-!FQ94&8F9!J2WZA#E-2
M$.O=;9Z+SF<F XV'KDPI+0;B'\O4^+DY90Z[2;HI4&MT&K0*O2)P4]$J5*EM
M38,QM+AZ'(DQ@J9E17 DJ;>:/1(8+;K:E-.96B6?O'<>7 \N=)S83D>\>5QH
M<K5W25=24J(*2I(44GN,@'!R <CMR!]@U*M5:4II2FE*:4K\OWRH6[V[5@^-
M"K4^R]QKWL^ER-G]O9+M/MB[;@H$.0^B\=Q&VY3\6E5&(R[(#0Z?3*;4Z4D@
M*"<#7LO16RHVC!P]Y"520=Y(+LLZH420Y3_X;.U?J?Z&O9KH/I;H[".V;/L^
M)BX@Q=_K,+9%E2E8FQ(5O==@XIE*V[0(8G4BOGM_X2WB+<R5;Z;MX4D* ^Z7
M>1'23Y#YZP D'@'. .0#KW'9>A=G7A@G PB&']SAL(3_ .Z,R;F0SU]I'T<>
MS0Z0<[)L>ZX+'!Z/M[P[$>XAE0Q,P)O-/_A+>(H'I3OWNV.<=!W&O(](()Q^
MW!SY#)"@<GGD8YST!LKOU&#N@WZO#";AA^X:V3PQ!ER>+'^C[V:&-C#W;8VZ
MW$(3U.P%FQ"! V*S%@2V=@ :#Q+^(KL=^]W.K/EN->?()]W/XX[8//O'MQC/
M&3T#LI!/483.Q'5X=K./L#%W#GORXOU?^S4E.S;)#Q[OL-DA\MAAPYL)8)))
MH?$OXB3WW\W<&"2?V1;QP,$@DYK.._4E0'UY)[F_46RC_#X(WH?JL,R'SZ@O
M_I()?LVEJ?H^]F_\C8R0W]QL+EW#SL+]J>#$%@#%'_A+>(W+7[.^[I/IL'.Y
MEYI2H=9.%)%;& 0" G. ,I]W Q!T!LYML^$>(P42Q _R2##%S#7<E+P^P'LV
M/\-LA_A?J>CY!+!_V(PUKWTBOV!>$FL5>O>&382LUVIU"LUBJ;46I.J=4J<V
M34:C4)KU)A+=E2YLMU^3*D.*4HJ>?=<<43[RCDC7R_;\,86W[;A !(PMLVG#
M LD!&.M  8!DL(8",A:OPS[7[/A;'[6>T^R8  P=E]H.F]GP4H2E*1A8'26T
M86&$I2 A("$ )2E(2!   :O1NNI7K]-*4TI32E-*4TI32E-*4TI32E-*4TI3
M2E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*
M4TI32E-*4TI32E-*4TI32E-*4TI32E>/O%UM(]O;9UFV*Y;DVZ*%,WIV<J5S
M1XK[41^GVY1;QE/URO1GG$E;"K7:$2IN*:2"^AI+:0XJ2OKNC\\LV[^^VF=3
M,S)_ _A9@V;W%>,+:VI\3-"W"OF9N1;FX%QV2-P=M(%PW1M7<7L[>N]UE6=M
M/=-J67<3<R%N'0JG1W85?E6M5;R@F1!<J-3B>E>2'(X6WW4]3U:1]F<0(DK#
M]H,5;X>2"#NDR!O;@*0*  R&'(-?XW&L .'!-;$H&W_C&#5GVO-N2ZXC5?L*
M+?-9K=3N*5,J%MW]M\F]8-&LBH5%NIS4.Q;S?JFSU8NB U.E4^NLV7?L:>Y/
M1=-25)UOX+E13ALD[H 2EE @'>B8D#=( DELINC(#R>XL^3.9<Z,';'-I-K]
M_C5=L:E?J-QZU[,WKMA<UTTB^2\F@0;KMVU]V(]XW51[BN[<W<*ZZS(J%1K%
M%><:MJ@6Q1)#5,I#4&@TNGQX-.A1\([PW<.4* *0DD$[H!W0R005!B5.)8DJ
M4VF G>$7&@)-K!B[ 0S#2.PW4V5WI/B6W3W+L"U*A+@[K4.P-BZ[<<:;\S.1
M+"NZWX[-SW<S&;=8DB;8]1C^NT]]S+]*EU&2MKT3LA]2B%;/N#?2D*91 @N$
MK)#JNJP #D*9F:*C6YCNF]BSN9#E_$<[9#:V[-@G8<^L[.UJ^[3=VJ^YU0X]
M IUM2ZW9ZJ1N'N14)= DV]4[E:@(MO<.V:_:CM8DQ(45V<S3*3\[L-.4R*(6
M5]4OLC<000"-U(<9L0 72SC=+.&6"%'=2&L;SGDSY:E@[6R#ZFD^&OQ.7#;5
MM6Q2Z79U#?V+M)VX-MTWE)N2L3:#NK<FYTK=&W[;M6NT*LJI ?V^L2VMO]GW
MJW4!-A_,-9NN@)J$FCUR<Q+WO8#A6ZB7(["  &W9WC"01O. 5$R'#@U0',&&
MSAW%VD'66@I:/L5:=2J59M6V:O6*/,MZKU6WZ-4JK;]07'<GT.I3J=&E3J/.
M<B 15S*9*==A25Q@(ZGF%J9'HRG716V\K=^[O'=Y.6S.7$\Z5D&LTII2FE*:
M4KS[XD;9FW?M56Z#3+8K5W5"94(,IJC6[<-(MFY%MTZ0AUZH6\]<@>HDV?3&
MFT/-4JJ(33:HI*PZDH>0':?P'=.?/O8%KB)/F1+S! 9I@MI8FU>'*!MKOK<M
M?M!^DTNJVS$HV]].JL3<'<C;/:-K<"52'-H;EHU:=ORQMNJI;]LU0TZK5.D1
M8M;<A,S&UT^GOQ8\-$>*AB<H8$6L#;(",B1,%]9GJ]YN01D^39&P(R%;)W"\
M)D^AV?;)LJX;J<W F[VQY=W779S1M>7)L3?:_P"WZ?OO3Z=2XKSZ:!;=-M27
M*N6F/,U"H2:7<T!ZX%+76W9,V0TTSX]]Q:QXFJ6+O?*'GON ]PV3YUC]_P"S
M-UTVZZU9%B[9/0:5=FX?A?J]G7O3%415J;:V1MG6:#)O*RI9EW1 J!IMOV_9
MUW7<Q38L*+&N*;?,.D^J.O/.EPS08?1^+D0'?(N,W:@-SD.1SARY:&>\FL/M
M38W?6I6[9=I6U;,#;.=:NRE"VCW!N:\Y3=,.Y,AFOVM'KM0H$RT:C?$RH/0:
M=;]39M^\K@@L57T&X+L]:V9T)U"C&6#7OS.3BS.3F<@:@(N2]FDG09V-H+D3
M)FO8G@WM*[[#\.]BVQ?5L1;/K=!C3H[5OQ9*I(IU,9?<138[SBH=/<<=C0TH
MBI<?I\)];++2U0HG4&$!H.[O+SWGA#58DN[.;P,LOD3>O5&E6FE*:4II2FE*
M_)I\KX1_X<,GOT_<4V[XP,=7MEN&/H^?O85GG)/8'7O7LI@E13B+[:"HLA;E
M((Q,)+I"@0\*M_,9$@?K;Z!@@;-A%>( _7#=4JWVW1A# V#.2'#&<WKYF!.2
M">H' 'NJ[=N"!Y#DC]Z0 2%'D_0]H4G"P",,)PBQ#H 2?N&6 $. ,B(8@-7Z
M,7LZ<;:^SM#=MP48H26ZVP8$N4G>FQ@15S&"4Y)P ,]78 <G''/ R3P><<D:
MZV'BD(2HXG\"264Y,!W=3B2+[Q@DPU<R]GV<+4A6(A2DJ4DE2\,ETF224NIP
MY463*FN[0"1QU$=O//!QW[I[?I&<>\>!OK@&[9WFCMP!+2^68#.\&)QU&S">
MMP^)WT.T!W L'NQOVB'+0%CWCU# X ZOJR<]7F?>Z<'/ETC).F-O8>&E?6*(
MW-YM\@,05$RV0BV6L=;!Q=DP,3&7C%"D)7B%*<7JU)"-YV 60E@$$,#F6U'H
M[PS>&#</Q0[@QK2LQAZDT:FR(4ZYKSETY4NC6Y3'E!<V,\E2%M52HUA'6FG(
M5UJI"G4^B+/HB1ZYMO3R=B2I165*3O!*-YRLC> 8=:)) )40Q$@%BFOFWMW]
M('1?0^'BG!5AX:T@@)V<X"%%7[6D) PMJ0HDK2EG"0C=!#  U^RK:JP*5M;M
MK8VW=#7+=I-EVM0;7IZYS[DB7ZG1J;$IJ#(?>)<<D+3&#DIU9]*_*4Z\Z5/+
M43\QVC&5M&T8VT+ "L?&Q<93"-_%6K$5?+>4>[4N_P"&^EML7TCTKTGTCB3B
M;?TAMFV+92E#>VK:<3&4RU*4I4K)WBHJ5<DDO6Q-<-="FE*:4II2FE*:4II2
MFE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:
M4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2K;C+3R5)=:;=2MMQ
ME:7$)6E33H =:4% A3;@2D.((*5@ *!P-*5!994"%--*!2XD@MH(*7E!;J2"
M.4NK 4X#PM0"E9(SJN=3EY6\,M*4]"QE1]"UU..I?6?1HRMYM#;:'E'&5.H;
M::0EPY6E#;:00E"0#G4V;N-QRI52FVU=74A!ZQTKZDI/6G"D]*LCWATJ4,'(
MPI0Q@G,<ZVD<]?(>%*>C;ZNOH1UC)Z^E/4,@)4>K&>P"3SV !X&CG6E24H)"
MBE)4E1*5$ E*BDI)![A11E)(YZ<@\<:.9F]^/.E4!EE*_2!II*P GK"$!0 2
M$@=0 4!TX2!G 2  ,:KEF<MHY;PI5W4I32E-*4TI32E4%IL^DRV@^E'2[E"3
MZ1/3T]+F1[XZ24X5D=)QVTHPTO?C0MMJ!2IM"DJ2I!24)(*% )4@@C!2I*4A
M23P0 ", :48:<.[2H0TTCZ#;:.7%>XA*?>><+KRN .7727'#W6X2M65$G2E2
MEIM*$-I;0E#02&D)0D(;"!TH"$@80$#A(2!TC@8&E*I=88?06WF6GFSU@H=;
M0X@AU"VG 4K!2?2-NN-KX]]#BT*RE:@5*K*4DY*4D]*DY(!/2L@K3DCZ*BE)
M4.RBD9S@:4JK2E-*4TI32E-*5\@_$]\GU:OBL\3-W7O4[ZKUO3*/M]M=2A$I
M4*+,0AE%P[C/O+4)33S02ZMMPJ1T@%0RLY!&O8=AZ77T;@8*4886IE*/:*0
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M!D]G);*GZJ_9D./<]F': !*-B%WEO<1IQUM17RA/C%_GJK_<CB#;0(S@C/\
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MKYC@MQJ7Z%@1T(0 OXFP]>?A5.5X@.2;//AD3D+$UZG004(*<])2DIZB2K!
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M7#P2??5@$8_X6/B>>"/UZNZ+[YEC]ZS&,M?EP$^KL6!UZR)!/6*-YD'#+N'
M<L((#N:>D=Q_;%C))/OJ&,G)(R?/!/&,#.<Y.84IS40.)8]F[OD& 8@,W$5?
MJ[&#_M"Y"G^U5=32.P<I%B^;$U02H<DDY!R2223GG)YR0>>Y/&3C6@I5ABK9
MFA9&ZSQS8'DUA:H.C<6"<8F2XZQ7:!F1N-H^NIL*LN#'OK P!PH\?# &!@9
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M%1C$GH]3 ,4J2H%R%[JFQ%)N$*251V4/O@EC)8;'LGL&YAA:B%H[2EI.&!B
M*.]O)5@*2=XH"MS>6,/>5AH)0X.7T?QIWU':FRJY8U%?M"DMU"#.O2%=LR;<
M%<N6W-BK:WCJ#SU!IM@FB.46M4RMMV[ JM&ENH=7$<<B-J;<B(U@[ 0HI2HA
M22AQ) 2O$4@$$7*5)),@;S A-JXE>RG1_6+PT8BBL;BBGL'#1AXV)B(0H%D+
M6I"<,J658Q$%0P@5IPAK&[?'7N?5*=4*E;[%FT:#2;8\1"9K$:LR:W*JU=VS
ML^V[@M1ZDR:G2(CK4:X'ZG)5&0N-%=4SZ)Q;270&T=E'1R$,5)Q%*'5*(-AU
MBE(;L@ [I!4I]X;H=V+5E7LIAI6K=05C?!04B"DJ9)9. $K"6&\T$$?>46K;
M50\=%TTZ?>L=BR:'56+5INYBHE/CW?<*;N5.VOHT"KRZA7:8Y9+M+A4.Z%3V
MJ919,61+2N>V\F([*)](CC^K$]D[ZF5U:@K=;#4,512$)[6\%)9R5*,%)93M
M7 ?9/>401N@;BR2A"<-2%J6!AI*<%*TK0R2M0400I(93A".GK_C@W LZ2I5Q
M[<4!Q5'O.X+7NIVEWU4G8L=%+I%@U*F2:5'>I<=V:V]+W!GPY*UPH[K@H*''
M6TK]&U'TKHQ!3O(6O<.%A8B20 W6'$<$[@*G&$Z0X9XW@JN3:/9K9L+!*TE0
M2<##4"$81(WDK4M25*P'4XPP0"&0"LN^)V?J1#FID4YB8A;3J7V674K9<+C*
MDNL(="V7.ZVU)4%MJ[K20K )X\*04D@@@I)!! !<7!!L8L]XKYYM*!@XF(AB
M-U2DLI@0RE)8M#AI;,%C78MJZFVU?QD)5SWY2#S^O4KB$@<A5>E6FE*:4II2
MJ"VV5=10@J*>DJ*4E73U=73DC/3U>]CMU<]]*5;4AL%7NM\E)6.E/O !*!U#
M )PDX&3CIPCL2-4$C-H/=_7\ZA .0+D/:<IU8?*U=!2:#2+;9G,46"S2T52N
M5>XI_H&&D-/5>MSY%0JU06VT$MF1/ER'I$I\I#C[KJWGUK=4LG0+L[,   ;E
MF@D$%HS@>-<9&Z[%0)45.0"$R782+&;$@R<J[]+,=:&"&F5(:Z'6/P2.EM0;
M+:'&AC\&H-*+:2G!2VHH!"21K#O-WF[^>?.N0,P9F8$,&'#\&JH,,)0VVEEH
M-M!L-(#: AH,_P!J#:0.E :_WL) Z/WN-*K#2I2TT@DI;;22A+9*4)!*$%90
M@X RA)<<*4GA)6L@ J5E1A9HTJ/0L]:U^A:ZW"T7%^C1UN%DY9*U8RHM'EHJ
M)+9Y3@Z4HU'880EIAAEEM( 2VTVAM"0E16 E"$A( 6I2@ !A1*AR2=*5<2E*
M$I0A(2E("4I2 E*4I& E(&        !@:4J=*4TI32E6BPRK'4RT>E16G+:#
MTK+J7RH9'"B^A#Q4.2ZA+F>M((4JH--A*TAM 2X5%Q(0GI<*AA16,845  **
MLY P<C2C#2]Z@M-*6EQ3;9<0VXTA90DK2TZ6U.MI41U);<4TT7$ A*RTV5 E
M"<*55TIZBOI3U$ %6!U$)ZND%6,X3UKP,X'6K'TCE2J?0M9*O1-]2G \I70G
M)=2A+272<9+B6TI;"S[P0E* >D !2JDI2A*4(2E"$)"4(2 E*4I "4I2  E*
M0       !C2E5  # & . !V ^&E*:4II2FE*:4KXB^,KY/NX_%?XHKDO6B[B
MTJU&Z!M=MU2UQ)-KU"H.O.+NS<E_"WF926WP&V%I"DISU=.&P"0//]&]+CH_
M#2D)4HI4Y U44KE6^C,-8@:EG/U;Z/\ Z0OT:PU81&*V&O%0 @M.]LB]YE;7
MLXW7P2 0TP[6\\#Y%2_0$D[Z6RE>"0T;.J*7#CZ(2CUL$CNV!W"ATCX:\MM'
MM8O$00</$0 ()^ZX2<^O $2PRWM8^@X7T['#VT*4G%W-X$,=XD''!:>F 78"
M+.+C*VKY%#<%1*ONY6X,J!]ZS:H,=1*L8]:QYGD< @Y!P0,8?M21AH'5XA(0
M X<A3 =H'K3!@B2SYQ7>7]/8*UJW<=BLJ;>8W/9('2[)S!$BQ9KU?>4[_P"/
MV<+>P,XQ9E5/(P,D>L=P, 9R!@C/&!R?I66'V&(>XWR_OA;)W%VBT_7T#_#B
MZ?O (_\ WL)B[DAP654?>3]PL$_=RMT9.<^QU3 &?+"96,8\@1P, COI^E2G
M;JL1B'8$Z%X&*!!;/,7M4_7T'/9QR(;MD:M_[6<:D0_B*J^\GW\<#[N5 QG&
M/8VJ =0^&)7;G&1YG Y.-0>U2A'4K8$Q)+ 7?KF9W;O8FGZ^A?=VAWAE .'T
M^N&>7$.(AF(H^\H;@=64[YV[\0/8ZIC(&,]1]9./B1W//([BCVJ+-U.(/]QO
M_P#-O^#68U1]/:7)W,=V2[K=V?\ _%H.I (.DFJA\BIN!_/?;AP,'\BZF<D
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M+YEWZ^0 >SC2Q#X@U#NW2YEG ,@, S.:D_(I;@#(^[A;Q&,G\C*H!C@?O9)
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M4=TCAQ_:K&7AJ3@H4G$7"5%9&Y=E!ED%37!# M?/P/3?TQ[1MN$OW;K!B*!
M*\8("02L[P(Z0Q@=W?!W"AB0S@"ONK;M"I%OT2CT>D4^+3(%*I%/I$")&C-1
MVH4"!"CQ(D-EM#:/1,1F&&F6FND):0V$=">G ]17B*Q,1:UJ*\12U+627*EE
M14HJER2HDDZDZU\&VW:\?;-HVG&Q\?$QE8^T8^.M:UE>_B8V(M:\0DD@J45D
ME0=WN:[UMM*!@ <XSP/( 8  & #Y=@>>Y.LDD_U)^.==-*0D,/( 6T L.%7-
M2K32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*5&!\!\>P[_'48
M:"E4K;;<!2MM"P3DA:$J!/3TY((()Z?=SWZ>.W&JYUX=VGF?&JE2DETDI)N4
MD@EF(D,;@> T%8_['VCZ)UGV6MST+\AN6\U\R4ST3TIE)0U)=;]5Z')#2"4-
MO+!<0DE*5 <:Y.MQ7!ZS$< I!WU.$FZ07< YBQKMCI'I!.ZVW;8-Q'5H;:L<
M;J'!W$LOLH=*3NA@Z06@5?7;%M.EPN6]0W"ZIU;I728"RXM^&W3GUN%4<E:G
MJ>TU =4K)<AM-Q5DL(2@3K,2!UBV 8#?5 "BL 3 "R5-_,2JY>LC;MM3]W;-
MJ3]VVT8P^XM6(BR_X<12L1/\JU*6&42:H%J6L'U21;5 $E:5(5(%&IWIU(4B
M.VI"G?5O2*2IN)$0I)40418Z2"EEL)=9B-N]8MHC?4T;S0[1O*;3>5J:W]8]
M( !(V_;0 7 ]ZQV!<EP.L8%U*,9J)S-!:EK!2U"VJ %+D"6M0H]."ERQ!;I8
MDK/JV52!3&FJ<'B2X(+3<3J]70EL.LQ+=8MFW6WE?=WM[=O;>[36WIO6??\
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M#-W4^;=S/SJL;^@MR? _^LOXX^SGOWTHWISZ&?EW/FW<WSNJQO/M8ER=R?\
M\Y8SV'PQR!@$Z/Z8<_7A:C?G)T\_+6]/FW<W&/:JQOK/L)<G;ZOV2R1Y^?P_
M0I.?D3\6'XT^;MS./RJL;S_@)<8[X')&Y1R?@3C'<=CI1CZ4<^/P\8I\V[F_
MG58W]!;D''_\RR,_]?.C^F%0#UO*/QJGU+<8$@WE98(SE(LBJ@ C.0 N_EK
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M ,A;YCWE;NSL&V021-K%VSJM/RM/BX.%"1MSU8!(%N7%@#S']W#."//R"<#
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MI]2T7=\\I<P\YRPE[\:.Y W1P.A R&CM,2S5H"]-\MP*=XEYFZ;=-W"7X?\
M;^_*3X?+LK$2MT2F[7?-E9Q1+LN)%+1<\>KRKNM/=RY;#I46YC1FI$>T[=OF
M/#=C1GY;6EBV5LP7XB=',WC2K<#QU\&;6,R,C-?5U@E3#*E*0I2FFR5-)"&U
M$H!*FTAUX)03RA(>="4D .N =9518>OA5W2E-*4TI7FGQ7U*33]C;X>8O!=B
M.=%,:%T*758L&B(<JD5M:ZW4[;=]H*11ZDWUQI%7HY;GTYN0'4+0H%!&WA9\
M\\N7 E[5FYD\0#PM8R]YR!SKYV1ZS6;ECV?8=N4^Y+]HD?Q(TE=5IFW_ (DM
MP[ZVRKL.%LCN;+ETVR-_(DR#?C"7KKMVWZK=6W-\5"H42AU624(3*E-&6KO8
M8PRA#C#2=Q0*RE,$6)262H@N=XC>@R07&F G,_%V8WW0P#FQTBMP7);7B)V7
MLFS;MIMX^I7#5-SY>VQLN[[NNG="V:!8&]%^T6G6E5G*[69$JHW)=>SLV;%J
M[=4J+!%2M'YSM9EQ%-:$55WL)9W0E)  +I'5DJ<@I+[H 5O!I&[NLZ72H0@#
M(.S2 7AB;@DVLY*CW5NJXK7NC;_<CPPQ(NY^XC]I0(M^6A<%/N"KO2*179%.
MVRN.MQ[OORK51V?<-8KKE4AJ<AJJD^HVQ%>C-K@4B&&HJ7NFHNI1@ J46%A)
M8" &#Y ,##&H<X MS #'*<CG<:6\>TC<"S[C:K-:VQW[N69LO)OC:6PKUK%>
MWL%:OB[:>WO0B1N-N%&#UT0!M];;C<MZV*A<]GM4&35;/KUP/,M0F;!LZ%"Q
M\Q![\X;+\J=W(M( (B''%,#BYKWQX4JS4J]M[7Y":Y4+CMF#NGN'1=NJQ4JK
M5:V[,L2C7'4H-M34UVH2Y$NOT*51FHSM!J+TB0B=#7$DI=6AQEU(,=0'SNT?
MUEL^ JL1FY;N!GQ%IGR)/J=!"D)4"2%)202,$@@$$C"<$CDCI&#Q@=M*M5:4
MII2FE*:4K\G/RO33(\<$O\$V?2[);<ETE"#UDWGN'T]>0.O&2 #DIP#R<X]S
M]G,+%6C#(6H(WE )"U!+]:D$$ $!Y8P>($U^L/H(VI P,+#QMDPL<(.($*Q,
M 8I'V_1Q24J6I@05G=(8#>+#,_,I1Q@ $   XP$D XP1W ^ P!Q[OP/T#M8>
M"G[10*4I((60H]F"2 !+2[FX@V_1^T8N)M.TX>'@X+(< 824*2D#K"EMU*UI
M9BE+I @,P9J@H&22A)4.^!R2GGWA\3SU<COGXYT%K8$XV*3%L0WG-R)FY+"S
M/6^KW.RK8\)12-U_=_O*3"E*.<CM/P-GITI.?=1W\D]N1V[9'&/(8ZL GLWU
M2^+BY767US,N;L [YWK6Y?\ 8\&[QLY8Z2TAAI+AKR"!CA#9R.>"2._F/LSG
MX9&>^KOF?M<22TXA.<R^9S)?(,[$RFC9,,!BS;.7<%FRR C0ER[U/(PD8X!!
MZ4YYSY@_'/;'Q&!CAOJ8CKL;,$]86#/ DW;)R<Y>H07(]TPB6!C9G/?)AXY@
M@D9R"KI]W([$\G@<=L$=R1G P  1[P  *4S];B,6))6;%Q!)8.8B8#9&J0HG
M^R818$D=027+B)&=R [18EJO2+X'6?,?2/T<YX\NQ'Z"?B='5/VF)Q.^9S>(
MTEGD2]A*C'NF$2(#X$@ L1+P04L^1$O!>D=\EJ&.Q"E8'(Y5DG!.,<  ' 'U
M9WBQ^VQ,G[8BXYI '(3#U25@_P!EPG=_W!+A1<D,Y!B?F!5/O$JR,G)*LG)[
MC)_>CR'![ ]AV(*,_:XI_P#F'-FL0 [_ (9@5&4 ?V3"+2W4$& 0S!A<.P/W
M2YB:>]\!C(!R!C)))X)^P\X(XX&>+OJ_S<3@.L9R6)L7>4N QM=Q4[1#^Z80
M)8.=G86.1(#"7!(=W<93E8*L'&.H=C@# )([<X&#WPGC&,#3?42YQL602.W#
M-)<$@V)GPU$&?V7#(9O[.18PT0S-DSATAYHZE9!!4 /AR._D<^9R>, 'MW.A
M4LLV+BR!99+OIJ9@BYU8E/64I94H' %SV1A*($N0 ]F%B&DE@U1GN<'.1Y>>
M,Y).21D]L\9)'.=0+6S];B9$=LWLY .1L&!8N 3(F\2"?=TG1\,EG$R7!<Y$
M<<S7)2V\.AI+4N2\\[&8APX;*Y,J5(F8#;3;2$E6.HD)';CI!&1GAVW:,%.S
MMV O<[2CNN5!*TEU%1.\[*42SER;&KMO3"N@=B5M&V[9B]3U)Q,/ Q,<=5AX
M:L%6($)1C8N$$H0G"*4H"MQ"3NADN1^G[Y*7P\[A;,;275<E_P 4T2=N75:9
M<-)I<A#C<JF6[$H\1J M3!!]1ESTJ;>J3:>AQ4I3KSP6]DCY3TUM*<;:% +*
MAA'$![1*4.M9(DLX2SE-CF"&K\3_ $N^U.R>TG2R!LA"C@':DK&&4A(Q,3'Q
M]TOAX^.E2NV% .% P94"?K?%SZM'ZEE:O0,]2U A2SZ-.5J!P05'D@C.3SKP
MP+@&[@'2_*/"OC:00E())(2 27<D"278N3=YJ_JUJFE*:4II2FE*:4II2FE*
M:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II
M2FE*:4II2FE*:4KCKB17&7(SD:.N.ZIQ;L=;+:F7%NNJ?=4XT4EM:G7E*><4
MI)*W5*<42LDE2J&H$%EA$9F%$9C-.)>;CM1F6V&WD.>F0ZAI" VAQ+P#J5I2
M%)<'6"%<ZKG4V:^6G+A2L-M:P;9L]JIL46EEINMW3=UT5)V04NNKJ=X5J;7*
MTE!QU)ILRI37GDPQB.$!"G&U*)4=%1B186\7)/\ $#F.X@"GCXZ?)SWN>-9T
MEM(2A)0C\&$](2D!*% 8R@'/0!R$XY XSK),F3.MS.?J]3(.S^3\*J*4JQU)
M!P01D X([$9[$>1'(U*M<)VF4U]$QMZGP7FZBXEZH-NQ([B)SJ68T=+LQ"VR
MF2XF/"AL)6^%J#,2,T"$,-)0I5#-(I,>,(3%+IS$-,IN<F(S"C-QA-:EMSVI
M@80TEH2FYS34QN0$>F1+;;D)6'D)6%*O?-\#U94+U*)ZFL.!<3U9GU90=6MQ
MT*8Z/1*#CCCBW 4'K6XM2LJ6HE1AI7+TI32E-*4TI5MQEEU#C;K33C;J%M.M
MN-I6AQMS(<;<0H%*T. GK0H%*LGJ!R=*5Q&:92XX:3'IT!@,2!*8#,2.V&90
MB&GB2T$-I]'($%2H0>1TN>J*,;J]"2C5<ZFS7R%ARX4JZ["A/'\-$BNGTD=[
M\*PRL^FB2%3(COO(/X2++4J5'<^DS(4I]LI=)7HYU.E\K-X12JW8L9]<5QZ.
MP\Y">5)A..LMN+B2%1I$-3\52TE4=Y4.7*BJ=:*%F-)D,%7HGG$*E*ZEJUK8
M8]*6;<H+)D0FJ:^6J13V_34YAQ3S%/=Z(X])"9>4IUJ*OJ8;<4I:&PHDZ4KN
MD-MM-H::;0VTVE*&VT)2AMM" $H0A"0$I2A*0E*4@!(    &E*KTI32E-*4T
MI32E?G_\>_@8WF\2/BTN.\MNGK5<IU/VAVVICJ*_4ZA%Z)/M?N(XI+1@!2VE
M!L+*_=1[Z"E*BHY/LW1'2N%L."E.(2&4IB$DL2L+_A4""0 0XG_PN1]W^C/V
M]Z&]F]E0C;#NXN$<5!*<)&*LK*]EQ/[O'3C !.$KM;H9@ =XAO*:?DA?%,#U
M&5MLC Z_1&O7<X0GO@?D?(4I*,] 69$@*'!D.'#BO+;1[3X:\,!"L1V"8"@-
MUE0/M@)>QF[B8^L;+].WL[@[:"7.%':7@80+'&0IR#TCO!D@QNAG8@$34?DA
M_%><J3+VL*3D@*K=U!73@X"@JR220G!()/<J//?"/:3#"$ J4X2 1NK.@+?:
MD7#$6+,[6[.-]/\ [/'%Q2D%2#B+(;9\$05*((/UFEANE["&B#5)^2(\58)R
M_MDE6.PK]TXSQP,60 1V*<\8&><X-_23#/\ &O0$#$B1IB,P9F;Y5Q_K^Z 8
M]EB0'!P=G<__ -4N8$F &LU#\D1XJ_\ "=LD@@*RJNW4 3C!/%DDD<G![8[$
M#&K^DJ,EK@W"<2"'_P#>V:&:QM0?3[[/AG#"['!P(%X_XH6D7&N8@!\D3XK!
MTA4C;3!&,_/]U #'?GV)4>"#_P#5YSVT/M,@VQ%V @8@(#BWVL.2!%P X@4_
M7[T 7=+";X."Q )NW2AG/A/&GWHCQ6GGTVVF,^==ND9YXP?8C!ZN,8[DX\P"
M_29#GMJ=R?NKCE]I#?UJ_K\]GX<*9A;!PI<B"?K0V<S,68V?>B?%81@R-L^^
M,&N74 >>X_(HYQSR,X(X/)('VF0?XUP-%Y__ #&F[EN=J@^GWH 0$JDEOL<
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M9)QGR^TC.=9?'9MX/K]IE9I#=[N1+5>W_*AV%TJ[]7S/"+O58F;@@8]G+..
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MNN]P/A[%<9^O[.3W:_,'^O=3M?Z? ^O'^L^N;A\_B&S./\:Z[_G]B>?T=O\
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M.'4M"B&#%*P"/W2_X64[_>8GC]3]B_80>T8V9;+(Q')W!!*UX6"ROV3&!;K
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M(/ ;P!OU!=MX:O =R*GZAL)OO[4!:^;N0_U2'4 W#E>@^6PW1( &SEH C/\
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MTJ.Z22[OG(/W7-86=O!4"K:"4J4"0K'<$*(41O%PY9X$7TJ"MS.2XO/VD#!
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8I32E-*4TI32E-*4TI32E-*4TI32E?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>50
<FILENAME>g518298g81i79.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g518298g81i79.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[14^4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %2*^5! X0DE-!"4      !                      .$))300Z
M  #O    $     $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!
M     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y"
M:71B;V]L      MP<FEN=&5R3F%M951%6%0    & $$ 4 !$ "T ,@
M#W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '4
M<       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT:6Y0
M<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $      !)P
M<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R8F]O
M;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
M3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O
M;VP      $)C:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B
M0&_@            1W)N(&1O=6) ;^            !";" @9&]U8D!OX
M         $)R9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
M             %)S;'15;G1&(U!X;$!RP           "G9E8W1O<D1A=&%B
M;V]L 0    !09U!S96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C
M4FQT                5&]P(%5N=$8C4FQT                4V-L(%5N
M=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R
M;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M   -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P
M    .$))30/M       0 )3,S  !  ( E,S,  $  CA"24T$)@      #@
M           _@   .$))300-       $    'CA"24T$&0      !    !XX
M0DE- _,       D           $ .$))32<0       *  $          CA"
M24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@
M 0 R     0!:    !@       0 U     0 M    !@       3A"24T#^
M    <   _____________________________P/H     /______________
M______________\#Z     #_____________________________ ^@
M_____________________________P/H   X0DE-! @      !     !   "
M0    D      .$))301$       0     @   D    )      #A"24T$'@
M    !      X0DE-!!H      T$    &              ".   "1P    8
M9 !S '  ,  P #,    !                          $
M D<   ".                      $                         $
M  $       !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$
M   $     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO
M;F<   ".     %)G:'1L;VYG   "1P    9S;&EC97-6;$QS     4]B:F,
M   !       %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U
M<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -
M875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM
M9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG    C@    !29VAT
M;&]N9P   D<    #=7)L5$585     $       !N=6QL5$585     $
M  !-<V=E5$585     $       9A;'1486=415A4     0      #F-E;&Q4
M97AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO<GI!
M;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R
M=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB
M9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90
M  ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P         ,
M8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG       X
M0DE-!"@       P    "/_         X0DE-!!$       $! #A"24T$%
M    !     4X0DE-! P     "N\    !    C    "(   &D   WR   "M,
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M=H:6IK;&UN;V)P
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M,6%Q=H&6L<'P)2@R-#8W.$%%676'D9>FM=;_Q  < 0  !P$!
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M%Q!3KCS#1.7PW%+S@@9Y/@G$BGJJBE,QIY6B-13RTLVT*>I3S@++$=P/JN
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JSU$Q!DE>VYMJJBBP 4*B*J(J@*J*JJ H P:J% "BP'8#'?\ J/@\?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>51
<FILENAME>g518298g94u77.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g518298g94u77.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[2,&4&AO=&]S:&]P(#,N,  X0DE-! 0
M    (NJ^B3@X0DE-! 0      !D< 5H  QLE1QP"   "   < E  !41E;'1A
M #A"24T$)0      $)_]]5M,FVC]2'%8$L(%V8@X0DE-!#H      .\    0
M     0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT
M965N=6T     26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP
M    "W!R:6YT97).86UE5$585     8 00!0 $0 +0 R       /<')I;G10
M<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *
M<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F
M"7!R;V]F0TU92P X0DE-!#L      BT    0     0      $G!R:6YT3W5T
M<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B;V]L      !2
M9W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O
M;       3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;
M0F-K9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M      !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@
M0G)D5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M    4G-L=%5N=$8C4'AL0%@            *=F5C=&]R1&%T86)O;VP!
M %!G4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M          !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F-
M60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1"
M;W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P
M4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE-
M ^T      !  E,S,  $  @"4S,P  0 ".$))300F       .
M #^    X0DE-! T       0   !:.$))3009       $    'CA"24T#\P
M    "0           0 X0DE-)Q        H  0         ".$))30/U
M  !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    !
M %H    &       ! #4    ! "T    &       !.$))30/X      !P  #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z     #_________
M____________________ ^@  #A"24T$"       $     $   )    "0
M   X0DE-!$0      !     "   "0    D      .$))300>       $
M #A"24T$&@     #00    8              6H   &I    !@!D ', <  Q
M #  -P    $                          0             !J0   6H
M                     0                         0     0
M &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0    0
M5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   6H
M    4F=H=&QO;F<   &I    !G-L:6-E<U9L3',    !3V)J8P    $
M  5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG
M          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N
M97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B
M;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
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M=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<      #A"24T$*
M    #     (_\        #A"24T$$0       0$ .$))3004       $
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M%8+,FQM-9(;O>8$GZ/N4:,_"R7FNB]EKVB2UI!,>WW?U?>Q%"[:<>^EKG4M
M> _:YHD</&Z/SE/[/C_Z)G,_1'/BB))*8"FD&16T$<$ *)Q<8Z&IA$S]$<_<
MBI)*1MHI:20QH)@S'AH/RIAC8X! J8 8!&T<#Z*>^^G'J==>\5U5B7O/ '[S
MD&OJ?3[;6TU9%=ECS#6M<#)BQT-V_P G'O\ ^V;?]&DI.ZJIWTF-/Q *1II)
MDUM)^ [@-_ZEJFDDIAZ56GL;I
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M<N+;9-QUVZ@H@JC1XDM,9%=J R_G!N($R+VRC/!,C4B12@+$Q!I:0L!GGO\
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MEQXSL:;YD8,.--RR!*%4R(D>$J$8XZC/HT%P!I:AS!>A-RH[:N'#$G,]-1F
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M9:C,G(J>5;L';3F8*C6K[$:7/S#PC2[^52IA]K<4ZX>AK+4@UQVW_.X%RN<
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M)';B^?"0STY"^JLV6V%5>4GZ;&F+W3=2I])O.;[(I$5E08"4/CXOG?NS @B
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M!5WW<3N&O^>]@[$',DDDCZ"2UV!^/-_CGM[O-7\H#D8X!QXY.2.^>X']KOM
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M &/IIQ4;P6MDU3%*JS@2)NX;8^U0FZI")IP("IA0,& GU,6/&P8,$()2N*J
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M+$B2+MCIE8,U-*@P5R.+/0',QKYO!JDR\4N&IRI-:319<;B&%<E^;+7"VX%
M<=9N>]ZLP77-M"+/_2U<::W7>]J.Z)0)>+%(085N9)44)BH_8S":$4^L7#(!
MM 3F;/Z#Z-53+,!K<)($NSO7-J*)[EV2O79ES4U&W22O*](#WN_#OO=5Q&OV
MV13ZFX'-??;W#>K?F&W'-M4H0NR#9=\M+0H, H1 A3$V)V/=BH_61),\NQ3I
M34ZHXSFC 10=:UBLN2HEN:T]VCO8EPK?.!FWB>M.K<Y?F(Q44YQMPU27K*=Y
M#V<UJ8%S8Y>4O*K9<+;'+VJ-MD(5$G(,-3T$ZF7NO%IT.&GN=&M8<!J72.7J
M^39OU60^Z1K7^F+N4)_6+H;T<,:1L'<AM3*J*]8U.;TA58UU-OKFC2T)M^]L
MO)+?3RL]+W:DK8O9*ILTQ]2L!=03 3-P(@&Q=WC,1>11N8LQ(31F8O\ 8S8A
M[<Y5^Q&Q<ZN[?MU36==.=3SI3V7=FA66:;D@RU4=T9AO.V<"#+M-V+FC[1%,
M1]SSQ@2 >T:- 1;N*RY2-%5,!<OI1W?(0_Z2]A]65&XMY"#P: (BF/LQ:+=1
M9M-:8UH(4\ZK4L&58$.QU4BN):[J4:T3LOI:F)?S;@M+DF(V7$Q[)LAV(M"_
MYJ>DT1H;T8M.CQX<_;==PHB;Z<<@\D94 Z,PM1Q),6-7:A=Z_(U\EWM/>8F>
MK,U1:U>V=I- H%^7)::0D7$N!58L\N^]F?AX:MS4S$2(EX!315=/U:'[%F +
M;E4&\$6).(CJ"]].,:OPX'1(NQ:KV@R>P%D!?>W]\'G<+:C&GYV3G(#"W>5Y
MZPZ];!N(EJPQK?G:MN6M0ER.2"\OK"D8\7WNN8UTK5!1UH@.9:5J1"@Q &;_
M $J+0S7YQ%)PL[U=P1&>?W@&%+=[;JMMSO>Z*%;"F7K@V/8&T+9-9]BH;LG;
M*OQKK5&T%SMX3K=UM'<'?+P%0%^Z-TFFF.GUENX +P6(4W%Z8:89^<A_OD)G
M]%3ZN)-=!42!&M1)7.8V_P!XX^V]Y;9$TJK)NC7=WKCO+2KPE,,4"$U7)O&&
MX]KW6ANU)"TO*WC(C2S B,@J5<@W)9T (AHM'&1=:(H<C;ZOZ9U2K9$-SR:I
MI,!I=3WN:L=7;M7/M4ZK?1*JRKIVA95VZ[:2[TK1UU>CLY]NQRVHETMMT0%K
ME(KG85QFFT73*W/9R?62RI2#"GDQ(=RD6SGY=<PUXI+T[O=&C,4F:9]U4 T=
M@7Y7<:TK\=#.N5;:=I^R]^-)YKM;%MB^?H*Z3NN6RW/$MU!BO-DQ@[BF7:\>
M)#C0DPX$3K]0I4,1ES(5S@ QQI+ 5T+L[) =L[PYJ*<A];\GO8>]53L7OWLG
M":577<#=*^+A.&T[Q158D:B46+=6U[69[4=#I=<)40M"<V[QFM @H@(A(4I#
M.9GU3KF(GLD. S8<'YWB1%*O2CN=&>/K+&7R;BLH+#P;V4^\5[Z=<8UQQM"9
MG8,RRWG7.JC5?U$)W/!$)L1VQ+P5,1<-#4BMGZ.># ,M-U*WDFSX=U$"ZT*H
M1D4/EE-AD\7O'6\)$/0OJ_"8XT JT+-O462:(FB)HB:(FB)HB:(FB)HB:(FB
M)HB:(FB)HB:(FB)HB9_T\?U=]$7'K'_&_P#X5?\ 5HC]L4Z4^7]NL=W#EYGZ
MHN7^GZ_]/T:R1-$31$T16=[H-6 [)AX0&W0H3LFY"%39US"AHAUN-2H8/[46
MX$PTQ?5('(A&-RE*89'V4%-[J.%*]Y*:?(^M,^?";QU%4T1-$5N^[K>^G?>O
MZ&D/>7Z.^B_IP24/Z8^C"L1/9S%]3Z_U?K1^1@DI'2/L9A H_P!6NV;?+YPK
MBT531$T1-$31$T1-$31%X=2H5)KL&7@5>G254@RLZF=APZC))BH1%2(G2M$.
M*GH*TE>"2DH4D86A78EBV1NYUO\ 33T7N:+)-$31$T1-$31$T1-$31$T1-$3
M1$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1>'*PU!0';@''CC
M$3!)^R>.4Y R!DY!QKZFG  F+=!-@& 9WJN-L\)!I7[F:4>HF(EE"VX"@7G<
MMJ'51["NJ@L^[D_"4AHNYPI2*)2)GZ:AJ2N:$1H/Q,6&J608!@"F15=2D1E"
M7APEA/SX"=<B'KRR9IR"[3PNVP[,^^'PR=TR#&)R0<0!!PG$ ^'%&*"YPOIA
MOA8'TPU0M:^)%UWYM[<ANSE(BBI-)G-EIAY.-/3#3ZEL*A68B=$1688APNE6
M1]I/2A)5K2_:_LWQ)V6,#;8<8? -S",1QXB/RYP[V$ ##O8MY\0)!H2 O??P
MM[<_9/X;QVPQ[7P7B/#X\.SVH'B=I_>HV&QWL.V)V>U_*\3M<>]M"<&'9G#L
MMJ'G>PX<1)Q!VF;7_28-:X3@F;<Q:Y92MQ6=ZN;=EXI&7K5'K5'2XFO']UH'
MM;1?L-46'!A1X@$-?K4PDQ(F.A"UIZ;V=[.\5OGW_P CW1O8L>$G"<()?!BP
MX!M,1%']TX88M Q;C^)?Q'^R;;>&P/L,7M%MJ-S8>''M?9[39[7=_BX,?B]I
MX/982!A.%\.U&U!Q/AP@;QP[G-H=LO2#LZX\Y6-T-[[;W&MPMM5V3IM#9DC
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M<?*S2S>O)WR*V5-:FS%#H-(HDU.)GYFCTND4Z)/B0^C$S @I3!RF'E2<E,,
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M0J\\&BIC/>-N#VQP[G."8;I'K$MIK/1B/NU[O@M"*@@QF._XUQ))<P8D2"8
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M"7]Y;)B!CPDEF!.(.V\?>?9X=V@N6</F,?S,)8#'A9R!<029F-YCNN9B"\Y
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M+E]0#OY_=4;DN3C^_+(_D^8'U'8"OZ_^-I&M//KY^2D^>9ITKIYJGP_N\_\
M"IW)#MR)RR/]GU'8SGY<@#/<C0@:^E\G[I17NKI]0#PX/Q4;DLC'^[;(X_3^
M(WGP[CG)S\T:]\_+E=2>S]N\H5?J =_CNIW)>?\ ?=D/GQ@6. P. #WYSW .
MBO=>^XHH;NQ;!QM5J3U7K5[;NOZ45/I(;SQ5;M5'6#SB(AK6[DXH2@$A.4DG
MJ.4I/.M5_$&W.SV4'%)#3A8$?DN7;$0V]0X0'T9);"Y@P0!5B7@8O>(:C7J9
M6-'3@]0!R>H@$_E<@9!' /220..H8YYSKSG^\\>'$SY-\-1AI_#H=8"RNX-)
M.*15ZC,%@1_FD!B_/(&"1G/)(/;Y\@#(/!\B21PK6']Y[0DSE;"SAB?^K:9@
M-),U!ZG?Q48OQ#WBF4&*6H@4>Q3]E)..<GQ)4K'G@YP<GA/"0-4>U-H^>5(+
MN2?W8+&00[L0Y)#J[V+*T7<L&#B#$@!LAKD_;>U+F<31H]>I]]+U,Z5G806E
MOM"/;>%1Z4.I8(0EUV[G%*0D)!)("B2.E!P#KTGV+M\6,;V]BW23O  ,&&T)
M<^[A9ZF7SEEVC%I!)?(7D'$8DQ1R[-#-+'U /''&ZG<:3V!*[&=L]B/J/ Q^
MC[OGM.+W@Q<7<>[+AS #P!4P9NITO84:!#4+G@6#,Z?#^[_\JG<GX_[LLC\\
M?XCS_FQ\\:(GU /#_*HW)$# R9VR.>"><?4;@GMW/.2#P!I&OWZT[93ZY]]$
M^']W_P"53N2X!_W99'O\_P 1W/<C)S@ <>17NO?=E3X?W?S^ZIW)YY_W;9$?
M/PL=QSQP.!^K2->SQGL(GP_O#! W4[DN<_[MLAGY?XC3CC'/GGOW)AKKT%)^
MF=2IV)XU[/DGP_N_/^%1N2__ *VR7Z./J.P<^.<D>9TC,T'=?.INDZ=?LJC;
M^[_'=3N2[_\ ?MD3Q_ZCAV\OUG2+/S_4JI]0#O/?=3N2\>TY9#L1_P"(X?+C
M''<'/=WW/G]43X?WA_E4[DCGOF=LAQQX?B-\\#/!QD]^"14^']W_ .53N3Q_
M^NV1SXX_Q'?=GG/F3CE&O?/C/#DGL_;AV)J=O[O\-U.Y+G.?V[9'SR",V-//
MR&!X<C2)D]\XY54GL_:>Y06 =_CNHW)#C']^61/Z>;'#G_3MQI%GY_J54^']
MW@<;J=R7Z9RR/S\?J./CC]'W8+O/Y]T15^']W\?NJ=R??_ORR';! /\  =R>
MV0>,^)P,D5/J =XQ^ZIW)<><Y9 \\^=CCD<^/RXX&"=U[[XI]0#O_P JC<EQ
MV_;ED>3WY_$=Y_?P.!@D:=]SW1,_KVW95/A_=_/[JG<F?+,[9'YG^8WCP'&>
M._S1KK]I\H2?I/VCS51M_> _X5.Y(G&!F=LCYG_F-QVQS@GC'?*BC7OGGW82
M=.OV4LL6AU!OT"6HU:<;H=\]()4%UUV*;L2MQR2"KK4V)>4A=7(Y,$Q2,)]8
M1TIU>&?;V:O4NX48$EY:8MYN_!@>K]"YER&C:&WC_ND_*JBA,>US9<;Z>U:]
ME*H=*;+5H41TN&;4 3U8DY>+,*2E15%/5#"NL=:'<QH,I]3K"::V!BA-'@ZL
MP>H 6([YWTVR8UBG#N(JEN;UUBWC-G:[!<,)ELJ&\URM#EDS,1QW#B+:;JG&
M>ZV-+@JC&=EY^-,PU"9CP99"EDID9EN#$]:><V,JSUYL_JUH :I#3?M*WE68
MK-^QMZI-4JJWV7.XF+[?$I<?Z%7<1HVS9UY7-;3VM0"O?"4LZZVZ^3+=)0)6
M.HE>8*I>*O!%?N8R9SH)9+2_+*&'$P'JY@K,7158G;NX]4@;;;IIH-WJ_8FM
M33<%.IEV&])2]9<334NM" F8;4LXXB($PZHD KA0T3*8RA%2E:48@PHT,>XL
MT=>ZNIISS%:/H>%EJ:]'\=FEN=UCRMM:1^T^\=_^B$UKS;EG[1'/<)_75<\)
MMK=T>VDMN'>-Z;AF(\9?U<.<N.Q[=IAV[7[GPUQ:?*3D,2YD9:@LW&^9/%LJ
MI8MP:HFCAJ9Y="OH6U55HRWXUA^73NA2K6+L'Z2ZHVBMS$K"G;/[5Y#;+0&W
M>Y+IA,YTM=<"Z3PO=;R_3.9[$BAXM"8]Q)BWLQ$FIB+!BU28EH,HJ'&F\<V<
M\;VT#0H^H^M&^7D5LBVY4UR0[:4IQ5NINR!0WW2&,_&$P'S.S+@?MHVXX+>M
M$(MB]G<ZGJ]YAYO&"[_>*-,NQ4TN%$C3$>G>OB0Y9$[.4<6?R>MYR >L LP0
MCA4VK70\7;B*K*O15-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-
M$6.^XW MU.Y3_OE2.#WXBHX .!Y#G!R-:[^(O]VS]\.<_>V=GUU'JOEM/@PM
M!WA<P-W$XUZOYD:^^"<$GN<'(SGDG)Y3WP#@]_M X//D>T^,\  ?^4-81T\U
MQ<3OP8D",G83/)\P+5)S_&_XJ0G.3SWZ<XYR<8.,C !U3[U<XJQ/TH[%A9W4
M7%.>,=_+&?/G!&,# )[D\DYP<2(,L]_,R#-'89LXH6P_;_@6O;&!SFN G@$_
MA!.$YX!_C<C[P><'7JWL+X0)G?R;XL=(D, ,F<EP%V((&!P+,SAV? *Q,NUC
M!4^*[']']HULY=H+4GFHN6JB:(H8N%>:VUJ($C.7#=M(;B*PA<*FKB1XRHU2
MBPYB4A1H<.B(1'BE<.*X&W#BCF(J.XY7K]2CHC&O]M#$V;SR*Q:+O0F )>H)
M:ID5G.%:$#=)82H7IE=OM-N=0)N\%0H(<DNS))8J<T:$INI=$&O*4E/,&8;/
M3&AQ1&*8J(J (:\@JCVXW[#/D+H \O6HJ/.[08K40R\9][P]LEMK=T.\#VNV
MV:%;IQU\-MM/"8B5@49UUXHF>B6;BX$.(EU1.N@1X:(DBF90E$M$Z9D>L*)B
M\;"._/\ 5)T=YZ7ESE,T-ED_39N5J4A*U"5 ]GGH<.<AD]SZT!84<'@Y[^>"
M".2-1^,@<Q;Y*@ ]7O4&6YKT-%4T1-$31$T1-$31$T1-$31$T1-$31%C9=2R
ML=_5LNVDOAUT^LTMB.IITRWD\X(JK'.NLNAONB4,6Z]LD0_97A#_  D$>-"B
MQ1$]3#A*"%>IR;=\GLXR&7F-9HL7@#A+L7J16"U ,V=J:T&;Z,UX-VP=\-JZ
M)JV*=O>X![W=<GU/56=N;6Z#MB@N^(F);([>'$(L")%A6^>LB'VAFPY:V<JN
M+%A&0B6\*HL$S/3TSR_49LJ].%@SZ9W>:,7+ J7+8>C?DV'NG;E\C<2?K3>:
M%ZGWN%IDE72J([:T_P!Z[465M/<T=QS:X<%,U)Q(3<<SW3,"&$&>>2H Y0I0
M34SUDU-8O/*38X;)IM !B+4/V(6V;151=<UH3MP+?.QERJ)-45P4Q5+2AQ&(
M*08:CU*];[OK3-)0"E/4GJ2HE* $=(Y'KU\^[<U!=K<P&M!^X<<%KDVZ6HW%
M6_G+?6Z;NSW;/MKM):RH.">I;S9VZ2YMY8\93IBS<1T5]MVKF+&VWF'8]WGF
M;7-/6XMQ?:)2(ZYB-$AW$Z(\&*Y$9/H;2=9.4RR.!#N?L. #TXF%MLT57S[>
MDWV=LYS/5HWDM7L>VYWXN-<N6<<W>.X5UMNMR]P=>F9AF-QGPFO,1(%I'NPY
MN57!94H[8D&6C3T68N46LR+/VVE_;G^/5LJZOZ5M&E@IWWS<<EMOVI4Y5/VO
M[<*3/MI+1G*=8*TDC4F@AM51G%IS$"W+1EYEL%J*RIF*I2T)D(C%B$1)14&'
M!.8LM%*PTR>)%+6'"H#FQ0^;M((:?M1P_,+)K15-$31%KF<6^BCM[>7*;/)]
MN2-$<,VR:)<BF5U\.^:8\9X-Q5:0EWIM; #+G&B^XUO@N--7&A0KD2L>#*M5
MURPD#$EDJBQQKW32M9I;,QF7XWKPY"-3,0BU?2G6MN&UV ZK>24E79V[>XBV
M=DK1,RH/*)1'E$HUU8CXB-"Y-T6JEG(BL5C/YE6L=K]MLI$M<556DE2D*I3#
M!)JR;=U\R[&A)#U?YM%R1<J-3)C+"H9M'I$,UX M&TWI@[:WFJ]D(K<MVX))
MOW+G-G#7<$W4W'!A3[.?V]>AWDG6FUTH1 *'3%92K70X-0C( ,6$Z8$>7@0%
M2V4VI%/2>19NF;/* ,#)JXN6:\.3E7)XG=KJ*KSJA4I*D24>HU*<EY*1DD%<
M[.31]5#A(2$_:*N ,E0QW&5 )!)QIWU4RZ$M);3J<A6BL0WEM)D_C3MOV'9\
MML]R "1[><'Y'](QR*W1]/1Z:OS"CGRU_P#+493P5?KDM+C/UIVVQX?ATV<8
M)X)/M^01VQV_[KG&A[[<UZ9*A\AI/V#=.*I]<EI<D?6G;?.#P'RVC@Y('^[_
M .L\8YZ3P2Z=M!8T\WC@EXRX3.A]>6;ZY+2YP;IVVY&,A]-DXXSG^_L#(\2<
M8!(!(.GRK^CA^75)Z@\CQ;UY JB;R6E/^-2VYSQR^FR#X#(_;J>>Y'&,_+\E
M KY3Z&\OR9G4D^>DVKA[U5?KEM'W^M2W'8\%\-K \ <^W9SG&? 9/?&-&X<7
M#\Y("/QX,8X>ZY_4I]<MI,Y^M2V^. 1[\MG@GR'M^2.,YZ@/'&,::1Q[+?/F
MK-?++.S_ "X!/KDM+_.G;;GS?39& !P?[^'Y1'.>.V.X&G0</*_W%Z)/RZ7H
M*SI1JI]<MI/YU+;C. /PY;7GA6<S_!3G(SWX)P-&X=1]?3U1_M5^A$=FB"\M
MI,C\:=N,'_EPV_O/'MV>.P)(R ">=.G73BW'7D$GOB/\KWZ!\R*F\EI!C\:E
MM^Q/[^FS@_I%0//ECOY'G2)\O/6-:MZB_E-?H?EPRXB\MI#_ (U+<?+\.6UY
M\=69X=/]>,_<=&X=1EQX<^#&$G7SS_TF-<NJA.^;_8KD9$[3*"_&G6:J9R$$
MR%,<;<JZBH'E"H9B+ Q]DXZ4D9(.1G6N?B-OR&O8%@!.Q>"#4:F7>0P^6,@C
M#.(MB<D!P 1B#NPN0 !$D&&6%G (/(&!U>'.!E/V<D<9!R>YY)(R?)-J'QX@
M7KPL/+Y+C%W/D3/ SR(C70  >">PX'<\=@ ,#[6/,YR,$DC-+T:UX%@] YM
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M6=&"+26ZS_T):WW8/[0P<COW!!Y\=1.1Z^5=>&M$^I:SO'XH[<_T(:W&?/\
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M$)=S501=)$E[#,59W%_UR,3(:6D"7XDNT'JU86]W556LO<CZ.:PVXZ[C7O\
MO20FGL^&+,T&>;3*NS7G7=2QZIQM..!.1(D&TCG=Z;>T!XS9BS;2C3\I!@=4
M-?4J7,03*H0V-*\S&<"M 0"X9F*@-9-*FP+_ *3-7=PL\+=4J?I3"9E,JU#:
M[<JTDVJ+3Z@W6;!*&51YB!0I>'%H37"Y>&I#7DXB#"D (92$P@A(4#Q=?0Z\
M(X0VMWZ2#E345DGH3$B:BJ:(FB+4#?7<M>VSV_>US,=M2K\CM5NO%;C$9+IM
M=2VJ]C2[Q^\C+];;+<"V74"]FA#?_O1[';9^6[6(9B.MD0(D*)+'K4H?EPTJ
M<KVA3TST+M,E^F;V6'C:W5;ZVJ\*%;"_2[JM>Y-XMU.VIHU%/TG9&Y=K&=8*
M[PW&NWWAV]W.M!8VV*%0HZ+4!A^JN7]95R\HE8R$1>J%&A'O+,T4S%.',YE(
M!.8<EXHUR7-32@A1=MC])?N^NPX-KM=>4&)*I=U3]&0T'*W9)OT.ETA_T;=J
MV-WWUL7.DS%7,1I6!#%KVP_(<M+*A0I>&T8DO+2J8,9:-*_J>![SR5H[\2[=
MLWDSKZDM$5NN2OP6U0ZG7(TA6*I#ITDN<73Z%3UU6L14 *4M,K*PU%,9>$E2
M4J6F&!"60I20$B^>CU;IGI?52O%NCZ@'+7G"@KXDJ2>UH]R/Z;%W X_7+_K
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MC+!OA<4L ?2]5QL3N7FC7L");._.[*@P.#G/B.$_9 _0>H@X/Z<A1UDUGJ6
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M7+F&+<F:9H;YQ3/)/CD#L?+D'.2<X[$]^Q &N)MP'$YUR@?>'ODQY>)]S&U
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M&,8J_F;P($NSBJ]F]G>/\=XG98-KCQX][%A&,^]L<6#>;&Y;#AP@D8<( .Y
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MZ3V!P1CN0<'IQQC.>1CFV:<PYFC &(=P*@&UG^2IV_XO!22#WQGOR0>0.00
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M"@$4SN%EX $D DL6 =L+_P 2E<088H>CXMTO)^A[;8 +#6H)&/P&H6,Y)ZL
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M_"#L<,$Y)NW;O &#W'O,,=N>3X\ <BQW^G'[W.<CY?\ FM=/BDVU@X.X.Q_
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MCQXK:SS(Z .3)$,Y:U0-R2SEF)>A@N0=3;W1 /P\5#(P0G^*#GCQ''AG/R)
M (.1D'K_ &B?_9&,,Y]ULBWBMF23 $ /#M*Y&TGVA@)(8'%('_R& 8M<M$.
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M-4%TMZ+[GK=\-4LMIMX3/14(L),2$4PX,%$V_8$T:^1&7(2-"]:US@X6+"1
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M \!!&%1(:CTISE/)4.R\I*1K\8>*)Q>T-N<1WC^9C&]BJV$'!A#N !A#!@#
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MOMM9\?A!P[SDT +_ +H'# (?"['%O/J\+^A30#AJ43C_ 'II9[@<=$('I)!
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MCGSSE\\8_3G/AHXUH]#W\](1CI5JCOY:RJC<54O';GN1'/YD-?MYG\.0.W.
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M-N&;Q(#!_:&#_AL"U@Y=RMK/.#C'EQP>/ECOX8';([^'H_?>=_K1?FKOO/\
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MU:FME%751-$7\D&_X/UYWP!\+Q7 !'_@NA( &?#('?.1GOG7OWLL2(&?#^+
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M2@!D))2C=,2>KP )42#GD8.H>)_&OC/$8\6T.'"^+=<[VQ&\0P%?"X02P,
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EN7G]X_\ MD?V<?=J@!J7Q>I'I"+GJHFB)HB:(FB)HB:(FB+_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140168001424368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">S-1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Spyre Therapeutics, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">46-4312787<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">221 Crescent Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Building 23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine3', window );">Entity Address, Address Line Three</a></td>
<td class="text">Suite 105<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Waltham<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02453<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">651-5940<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001636282<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember', window );">Business Contact [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">221 Crescent Street<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Building 23<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine3', window );">Entity Address, Address Line Three</a></td>
<td class="text">Suite 105<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Waltham<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02453<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">651-5940<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_ContactPersonnelName', window );">Contact Personnel Name</a></td>
<td class="text">Heidy King-Jones<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of contact personnel</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 3 such as an Office Park</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140168002165088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 90,592<span></span>
</td>
<td class="nump">$ 34,863<span></span>
</td>
<td class="nump">$ 15,142<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">113,007<span></span>
</td>
<td class="nump">20,848<span></span>
</td>
<td class="nump">77,986<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NontradeReceivablesCurrent', window );">Development receivables</a></td>
<td class="nump">163<span></span>
</td>
<td class="nump">375<span></span>
</td>
<td class="nump">815<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">2,187<span></span>
</td>
<td class="nump">6,172<span></span>
</td>
<td class="nump">4,948<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">205,949<span></span>
</td>
<td class="nump">62,258<span></span>
</td>
<td class="nump">98,891<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">1,307<span></span>
</td>
<td class="nump">1,553<span></span>
</td>
<td class="nump">1,838<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,220<span></span>
</td>
<td class="nump">4,549<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,430<span></span>
</td>
<td class="nump">3,806<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">683<span></span>
</td>
<td class="nump">842<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">207,265<span></span>
</td>
<td class="nump">71,144<span></span>
</td>
<td class="nump">109,926<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Accounts payable</a></td>
<td class="nump">1,678<span></span>
</td>
<td class="nump">677<span></span>
</td>
<td class="nump">3,319<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">CVR liability</a></td>
<td class="nump">7,510<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">625<span></span>
</td>
<td class="nump">436<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">517<span></span>
</td>
<td class="nump">2,359<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued and other current liabilities</a></td>
<td class="nump">15,861<span></span>
</td>
<td class="nump">12,837<span></span>
</td>
<td class="nump">14,030<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Related party accounts payable</a></td>
<td class="nump">19,823<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">44,872<span></span>
</td>
<td class="nump">14,656<span></span>
</td>
<td class="nump">20,144<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Non-current CVR liability</a></td>
<td class="nump">20,690<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current operating lease liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,004<span></span>
</td>
<td class="nump">4,608<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,179<span></span>
</td>
<td class="nump">1,217<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">TOTAL LIABILITIES</a></td>
<td class="nump">65,562<span></span>
</td>
<td class="nump">20,839<span></span>
</td>
<td class="nump">25,985<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies (Note 11)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS' (DEFICIT) EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">455,957<span></span>
</td>
<td class="nump">475,971<span></span>
</td>
<td class="nump">425,765<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="num">(132)<span></span>
</td>
<td class="num">(48)<span></span>
</td>
<td class="num">(20)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(701,234)<span></span>
</td>
<td class="num">(425,624)<span></span>
</td>
<td class="num">(341,809)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">TOTAL STOCKHOLDERS' (DEFICIT) EQUITY</a></td>
<td class="num">(245,402)<span></span>
</td>
<td class="nump">50,305<span></span>
</td>
<td class="nump">83,941<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' (DEFICIT) EQUITY</a></td>
<td class="nump">207,265<span></span>
</td>
<td class="nump">71,144<span></span>
</td>
<td class="nump">109,926<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=agle_SeriesANonVotingConvertiblePreferredStockMember', window );">Series A Non Voting Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Series A non-voting convertible preferred stock, $0.0001 par value; 1,086,341 and no shares authorized as of September&#160;30, 2023 and December&#160;31, 2022, respectively; 1,086,339 and no shares issued and outstanding as of September&#160;30, 2023 and December&#160;31, 2022, respectively</a></td>
<td class="nump">$ 387,105<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NontradeReceivablesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of amounts currently receivable other than from customers. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NontradeReceivablesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480632/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.E.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=agle_SeriesANonVotingConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=agle_SeriesANonVotingConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140168002478768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized (in shares)</a></td>
<td class="nump">8,913,659<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized (in shares)</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued (in shares)</a></td>
<td class="nump">4,048,687<span></span>
</td>
<td class="nump">2,614,014<span></span>
</td>
<td class="nump">1,974,205<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding (in shares)</a></td>
<td class="nump">4,048,687<span></span>
</td>
<td class="nump">2,614,014<span></span>
</td>
<td class="nump">1,974,205<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=agle_SeriesANonVotingConvertiblePreferredStockMember', window );">Series A Non Voting Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Series A non-voting convertible preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Series A non-voting convertible preferred stock, authorized (in shares)</a></td>
<td class="nump">1,086,341<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Series A non-voting convertible preferred stock, issued (in shares)</a></td>
<td class="nump">1,086,339<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Series A non-voting convertible preferred stock, outstanding (in shares)</a></td>
<td class="nump">1,086,339<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480244/480-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=agle_SeriesANonVotingConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=agle_SeriesANonVotingConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140168002282928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 174<span></span>
</td>
<td class="nump">$ 886<span></span>
</td>
<td class="nump">$ 2,161<span></span>
</td>
<td class="nump">$ 2,329<span></span>
</td>
<td class="nump">$ 18,739<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList', window );">Revenue from Contract with Customer, Product and Service [Extensible Enumeration]</a></td>
<td class="text">Development Fee and Royalty [Member]<span></span>
</td>
<td class="text">Development Fee and Royalty [Member]<span></span>
</td>
<td class="text">Development Fee and Royalty [Member]<span></span>
</td>
<td class="text">Development Fee and Royalty [Member]<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses (income):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">$ 24,660<span></span>
</td>
<td class="nump">$ 11,977<span></span>
</td>
<td class="nump">$ 55,822<span></span>
</td>
<td class="nump">$ 44,328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,579<span></span>
</td>
<td class="nump">57,069<span></span>
</td>
<td class="nump">59,638<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">8,584<span></span>
</td>
<td class="nump">6,952<span></span>
</td>
<td class="nump">25,874<span></span>
</td>
<td class="nump">23,452<span></span>
</td>
<td class="nump">28,531<span></span>
</td>
<td class="nump">27,319<span></span>
</td>
<td class="nump">21,843<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_AcquiredInProcessResearchAndDevelopment', window );">Acquired in-process research and development</a></td>
<td class="num">(298)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">130,188<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal', window );">Gain recognized within operating expenses</a></td>
<td class="num">(14,609)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(14,609)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">18,337<span></span>
</td>
<td class="nump">18,929<span></span>
</td>
<td class="nump">197,275<span></span>
</td>
<td class="nump">67,780<span></span>
</td>
<td class="nump">87,110<span></span>
</td>
<td class="nump">84,388<span></span>
</td>
<td class="nump">81,481<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(18,337)<span></span>
</td>
<td class="num">(18,755)<span></span>
</td>
<td class="num">(196,389)<span></span>
</td>
<td class="num">(65,619)<span></span>
</td>
<td class="num">(84,781)<span></span>
</td>
<td class="num">(65,649)<span></span>
</td>
<td class="num">(81,481)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other (expense) income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Interest income</a></td>
<td class="nump">1,251<span></span>
</td>
<td class="nump">288<span></span>
</td>
<td class="nump">2,021<span></span>
</td>
<td class="nump">427<span></span>
</td>
<td class="nump">837<span></span>
</td>
<td class="nump">111<span></span>
</td>
<td class="nump">593<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">2,342<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="nump">2,262<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="num">(122)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other (expense) income</a></td>
<td class="num">(21,767)<span></span>
</td>
<td class="nump">312<span></span>
</td>
<td class="num">(79,247)<span></span>
</td>
<td class="nump">452<span></span>
</td>
<td class="nump">830<span></span>
</td>
<td class="num">(11)<span></span>
</td>
<td class="nump">588<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income tax expense</a></td>
<td class="num">(40,104)<span></span>
</td>
<td class="num">(18,443)<span></span>
</td>
<td class="num">(275,636)<span></span>
</td>
<td class="num">(65,167)<span></span>
</td>
<td class="num">(83,951)<span></span>
</td>
<td class="num">(65,660)<span></span>
</td>
<td class="num">(80,893)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (expense) benefit</a></td>
<td class="num">(3)<span></span>
</td>
<td class="nump">209<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="nump">174<span></span>
</td>
<td class="nump">136<span></span>
</td>
<td class="num">(141)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (40,107)<span></span>
</td>
<td class="num">$ (18,234)<span></span>
</td>
<td class="num">$ (275,610)<span></span>
</td>
<td class="num">$ (64,993)<span></span>
</td>
<td class="num">$ (83,815)<span></span>
</td>
<td class="num">$ (65,801)<span></span>
</td>
<td class="num">$ (80,893)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic (in dollars per share)</a></td>
<td class="num">$ (9.34)<span></span>
</td>
<td class="num">$ (4.84)<span></span>
</td>
<td class="num">$ (69.57)<span></span>
</td>
<td class="num">$ (20.17)<span></span>
</td>
<td class="num">$ (24.86)<span></span>
</td>
<td class="num">$ (25.02)<span></span>
</td>
<td class="num">$ (37.89)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted (in dollars per share)</a></td>
<td class="num">$ (9.34)<span></span>
</td>
<td class="num">$ (4.84)<span></span>
</td>
<td class="num">$ (69.57)<span></span>
</td>
<td class="num">$ (20.17)<span></span>
</td>
<td class="num">$ (24.86)<span></span>
</td>
<td class="num">$ (25.02)<span></span>
</td>
<td class="num">$ (37.89)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding, basic (in dollars per share)</a></td>
<td class="nump">4,293,812<span></span>
</td>
<td class="nump">3,767,918<span></span>
</td>
<td class="nump">3,961,546<span></span>
</td>
<td class="nump">3,222,987<span></span>
</td>
<td class="nump">3,371,231<span></span>
</td>
<td class="nump">2,629,784<span></span>
</td>
<td class="nump">2,134,869<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding, diluted (in dollars per share)</a></td>
<td class="nump">4,293,812<span></span>
</td>
<td class="nump">3,767,918<span></span>
</td>
<td class="nump">3,961,546<span></span>
</td>
<td class="nump">3,222,987<span></span>
</td>
<td class="nump">3,371,231<span></span>
</td>
<td class="nump">2,629,784<span></span>
</td>
<td class="nump">2,134,869<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 12,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=agle_DevelopmentFeeMember', window );">Development Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,329<span></span>
</td>
<td class="nump">$ 6,739<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForwardContractsMember', window );">Forward contract liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other (expense) income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Change in fair value of forward contract liability</a></td>
<td class="num">$ (25,360)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (83,530)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_AcquiredInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Acquired in process research and development</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_AcquiredInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDerivativeInstrumentsNetPretax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates product and service for revenue from satisfaction of performance obligation by transferring promised product and service to customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=agle_DevelopmentFeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=agle_DevelopmentFeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForwardContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForwardContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140168002619008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">$ 24,660,000<span></span>
</td>
<td class="nump">$ 11,977,000<span></span>
</td>
<td class="nump">$ 55,822,000<span></span>
</td>
<td class="nump">$ 44,328,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">$ 19,400,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 20,800,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140168001344912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (40,107)<span></span>
</td>
<td class="num">$ (18,234)<span></span>
</td>
<td class="num">$ (275,610)<span></span>
</td>
<td class="num">$ (64,993)<span></span>
</td>
<td class="num">$ (83,815)<span></span>
</td>
<td class="num">$ (65,801)<span></span>
</td>
<td class="num">$ (80,893)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive (loss) income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="num">(29)<span></span>
</td>
<td class="num">(38)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(87)<span></span>
</td>
<td class="num">(35)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized (loss) gain on marketable securities</a></td>
<td class="num">(114)<span></span>
</td>
<td class="nump">74<span></span>
</td>
<td class="num">(83)<span></span>
</td>
<td class="num">(77)<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="num">(30)<span></span>
</td>
<td class="num">(59)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive loss</a></td>
<td class="num">$ (40,250)<span></span>
</td>
<td class="num">$ (18,198)<span></span>
</td>
<td class="num">$ (275,694)<span></span>
</td>
<td class="num">$ (65,157)<span></span>
</td>
<td class="num">$ (83,843)<span></span>
</td>
<td class="num">$ (65,832)<span></span>
</td>
<td class="num">$ (80,933)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a-c)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481839/830-10-45-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482014/830-20-35-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140167995042256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders' (Deficit) Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Series A Non Voting Convertible Preferred Stock</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive (Loss) Income</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balances (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,163,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Dec. 31, 2019</a></td>
<td class="nump">$ 60,081<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 255,142<span></span>
</td>
<td class="nump">$ 51<span></span>
</td>
<td class="num">$ (195,115)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_StockIssuedDuringPeriodSharesCommonStockAndPreFundedWarrants', window );">Issuance of common stock and pre-funded warrants in connection with public and at-the-market offerings, net of offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">747,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_StockIssuedDuringPeriodValueCommonStockAndPreFundedWarrants', window );">Issuance of common stock and pre-funded warrants in connection with public and at-the-market offerings, net of offering costs</a></td>
<td class="nump">153,572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">153,570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock in connection with exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock in connection with exercise of stock options</a></td>
<td class="nump">490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock in connection with employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock in connection with employee stock purchase plan</a></td>
<td class="nump">366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">6,256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="num">(59)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(59)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(80,893)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(80,893)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balances (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,918,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Dec. 31, 2020</a></td>
<td class="nump">139,832<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">415,824<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="num">(276,008)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock in connection with exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock in connection with exercise of stock options</a></td>
<td class="nump">1,449<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,449<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_IssuanceOfCommonStockInConnectionWithExerciseOfPreFundedWarrants', window );">Issuance of common stock in connection with exercise of pre-funded warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock in connection with employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock in connection with employee stock purchase plan</a></td>
<td class="nump">454<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">454<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">8,038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="num">(30)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(30)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(65,801)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(65,801)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending balance at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balances (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,974,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Dec. 31, 2021</a></td>
<td class="nump">83,941<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">425,765<span></span>
</td>
<td class="num">(20)<span></span>
</td>
<td class="num">(341,809)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock in connection with employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock in connection with employee stock purchase plan</a></td>
<td class="nump">184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">2,101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="num">(13)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="num">(120)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(120)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(24,436)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24,436)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balances (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,977,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Mar. 31, 2022</a></td>
<td class="nump">61,657<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">428,050<span></span>
</td>
<td class="num">(153)<span></span>
</td>
<td class="num">(366,245)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balances (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,974,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Dec. 31, 2021</a></td>
<td class="nump">83,941<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">425,765<span></span>
</td>
<td class="num">(20)<span></span>
</td>
<td class="num">(341,809)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="num">(87)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="num">(77)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(64,993)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending balance at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balances (in shares) at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,460,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Sep. 30, 2022</a></td>
<td class="nump">67,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">474,535<span></span>
</td>
<td class="num">(184)<span></span>
</td>
<td class="num">(406,802)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balances (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,974,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Dec. 31, 2021</a></td>
<td class="nump">$ 83,941<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">425,765<span></span>
</td>
<td class="num">(20)<span></span>
</td>
<td class="num">(341,809)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock in connection with exercise of stock options (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_IssuanceOfCommonStockAndPreFundedWarrantsSharesInConnectionWithRegisteredDirectOfferingNetOfOfferingCosts', window );">Issuance of common stock and pre-funded warrants in connection with registered direct offering, net of offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">430,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_IssuanceOfCommonStockAndPreFundedWarrantsValueInConnectionWithRegisteredDirectOfferingNetOfOfferingCosts', window );">Issuance of common stock and pre-funded warrants in connection with registered direct offering, net of offering costs</a></td>
<td class="nump">$ 42,874<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">42,873<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_IssuanceOfCommonStockInConnectionWithExerciseOfPreFundedWarrants', window );">Issuance of common stock in connection with exercise of pre-funded warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">204,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock in connection with employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock in connection with employee stock purchase plan</a></td>
<td class="nump">222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">7,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="num">(35)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(35)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(83,815)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(83,815)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending balance at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balances (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,614,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Dec. 31, 2022</a></td>
<td class="nump">50,305<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">475,971<span></span>
</td>
<td class="num">(48)<span></span>
</td>
<td class="num">(425,624)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balances (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,977,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Mar. 31, 2022</a></td>
<td class="nump">61,657<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">428,050<span></span>
</td>
<td class="num">(153)<span></span>
</td>
<td class="num">(366,245)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Beginning balance at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common stock in connection with exercise of pre-funded warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_StockIssuedDuringPeriodSharesCommonStockAndPreFundedWarrantsRegisteredDirectOffering', window );">Issuance of common stock and pre-funded warrants in connection with registered direct offering, net of offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">430,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_StockIssuedDuringPeriodValueCommonStockAndPreFundedWarrantsRegisteredDirectOffering', window );">Issuance of common stock and pre-funded warrants in connection with registered direct offering, net of offering costs</a></td>
<td class="nump">42,873<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">42,872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">2,017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="num">(36)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(36)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="num">(31)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(31)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(22,323)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22,323)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending balance at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balances (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,447,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Jun. 30, 2022</a></td>
<td class="nump">84,157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">472,939<span></span>
</td>
<td class="num">(220)<span></span>
</td>
<td class="num">(388,568)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock in connection with employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock in connection with employee stock purchase plan</a></td>
<td class="nump">38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of common stock in connection with exercise of pre-funded warrants</a></td>
<td class="num">(8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_StockIssuedDuringPeriodSharesCommonStockAndPreFundedWarrantsRegisteredDirectOffering', window );">Issuance of common stock and pre-funded warrants in connection with registered direct offering, net of offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">1,566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="num">(38)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(38)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="nump">74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(18,234)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18,234)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending balance at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balances (in shares) at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,460,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Sep. 30, 2022</a></td>
<td class="nump">67,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">474,535<span></span>
</td>
<td class="num">(184)<span></span>
</td>
<td class="num">(406,802)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balances (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,614,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Dec. 31, 2022</a></td>
<td class="nump">50,305<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">475,971<span></span>
</td>
<td class="num">(48)<span></span>
</td>
<td class="num">(425,624)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock in connection with employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock in connection with employee stock purchase plan</a></td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">1,709<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,709<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="nump">32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(18,422)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18,422)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending balance at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balances (in shares) at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,616,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Mar. 31, 2023</a></td>
<td class="nump">33,652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">477,698<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="num">(444,046)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balances (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,614,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Dec. 31, 2022</a></td>
<td class="nump">50,305<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">475,971<span></span>
</td>
<td class="num">(48)<span></span>
</td>
<td class="num">(425,624)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="num">(83)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(275,610)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,086,339<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending balance at Sep. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 387,105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balances (in shares) at Sep. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,049<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Sep. 30, 2023</a></td>
<td class="num">(245,402)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">455,957<span></span>
</td>
<td class="num">(132)<span></span>
</td>
<td class="num">(701,234)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balances (in shares) at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,616,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Mar. 31, 2023</a></td>
<td class="nump">$ 33,652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">477,698<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="num">(444,046)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Beginning balance at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Series A non-voting convertible preferred stock (in shares)</a></td>
<td class="nump">721,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of Series A non-voting convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 197,323<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets', window );">Issuance of common stock forward in connection with the asset acquisition of Spyre</a></td>
<td class="nump">$ 3,768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common stock in connection with exercise of pre-funded warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">624,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_ContingentValueRightDistributionToCommonStockholders', window );">CVR distribution to common stockholders</a></td>
<td class="num">(29,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(29,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">1,775<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,775<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(217,081)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(217,081)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">721,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending balance at Jun. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 197,323<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balances (in shares) at Jun. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,240,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Jun. 30, 2023</a></td>
<td class="num">$ (207,369)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">453,741<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="num">(661,127)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Series A non-voting convertible preferred stock (in shares)</a></td>
<td class="nump">365,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of Series A non-voting convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">189,741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_StockIssuedDuringPeriodSharesOptionsExercisedAndEmployeeStockOwnershipPlan', window );">Issuance of common stock in connection with exercise of stock options and employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan', window );">Issuance of common stock in connection with exercise of stock options and employee stock purchase plan</a></td>
<td class="nump">$ 105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_TemporaryEquityFinancingCosts', window );">Settlement of financing costs in connection with private placement of Series A non-voting convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issuance of common stock in connection with the asset acquisition of Spyre and settlement of related forward contract (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">518,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Issuance of common stock in connection with the asset acquisition of Spyre and settlement of related forward contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common stock in connection with exercise of pre-funded warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">281,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">2,112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="num">(29)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(29)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="num">(114)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(114)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(40,107)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(40,107)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,086,339<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending balance at Sep. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 387,105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balances (in shares) at Sep. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,049<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Sep. 30, 2023</a></td>
<td class="num">$ (245,402)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 455,957<span></span>
</td>
<td class="num">$ (132)<span></span>
</td>
<td class="num">$ (701,234)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_ContingentValueRightDistributionToCommonStockholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent value right distribution to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_ContingentValueRightDistributionToCommonStockholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_IssuanceOfCommonStockAndPreFundedWarrantsSharesInConnectionWithRegisteredDirectOfferingNetOfOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock and pre-funded warrants shares in connection with registered direct offering, net of offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_IssuanceOfCommonStockAndPreFundedWarrantsSharesInConnectionWithRegisteredDirectOfferingNetOfOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_IssuanceOfCommonStockAndPreFundedWarrantsValueInConnectionWithRegisteredDirectOfferingNetOfOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock and pre-funded warrants value in connection with registered direct offering, net of offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_IssuanceOfCommonStockAndPreFundedWarrantsValueInConnectionWithRegisteredDirectOfferingNetOfOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_IssuanceOfCommonStockInConnectionWithExerciseOfPreFundedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock in connection with exercise of pre-funded warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_IssuanceOfCommonStockInConnectionWithExerciseOfPreFundedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_StockIssuedDuringPeriodSharesCommonStockAndPreFundedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares, common stock and pre-funded warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_StockIssuedDuringPeriodSharesCommonStockAndPreFundedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_StockIssuedDuringPeriodSharesCommonStockAndPreFundedWarrantsRegisteredDirectOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares common stock and pre funded warrants registered direct offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_StockIssuedDuringPeriodSharesCommonStockAndPreFundedWarrantsRegisteredDirectOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_StockIssuedDuringPeriodSharesOptionsExercisedAndEmployeeStockOwnershipPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Options Exercised And Employee Stock Ownership Plan</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_StockIssuedDuringPeriodSharesOptionsExercisedAndEmployeeStockOwnershipPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_StockIssuedDuringPeriodValueCommonStockAndPreFundedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value, common stock and pre-funded warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_StockIssuedDuringPeriodValueCommonStockAndPreFundedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_StockIssuedDuringPeriodValueCommonStockAndPreFundedWarrantsRegisteredDirectOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value common stock and pre funded warrants registered direct offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_StockIssuedDuringPeriodValueCommonStockAndPreFundedWarrantsRegisteredDirectOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Options Exercised And Employee Stock Ownership Plan</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_TemporaryEquityFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Financing Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_TemporaryEquityFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Stock Issued During Period, Shares, New Issues</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a-c)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481839/830-10-45-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482014/830-20-35-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.E.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140167998352160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (275,610)<span></span>
</td>
<td class="num">$ (64,993)<span></span>
</td>
<td class="num">$ (83,815)<span></span>
</td>
<td class="num">$ (65,801)<span></span>
</td>
<td class="num">$ (80,893)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">744<span></span>
</td>
<td class="nump">1,182<span></span>
</td>
<td class="nump">1,567<span></span>
</td>
<td class="nump">1,576<span></span>
</td>
<td class="nump">996<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">8,405<span></span>
</td>
<td class="nump">5,684<span></span>
</td>
<td class="nump">7,111<span></span>
</td>
<td class="nump">8,038<span></span>
</td>
<td class="nump">6,256<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_AcquiredInProcessResearchAndDevelopment', window );">Acquired in-process research and development</a></td>
<td class="nump">130,188<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal', window );">Gain on sale of in-process research and development asset</a></td>
<td class="num">(14,609)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Lease ROU asset and leasehold improvement impairment loss</a></td>
<td class="nump">2,580<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of long-lived assets</a></td>
<td class="nump">915<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of operating lease assets</a></td>
<td class="nump">220<span></span>
</td>
<td class="nump">292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Net accretion of discount on marketable securities</a></td>
<td class="num">(612)<span></span>
</td>
<td class="num">(175)<span></span>
</td>
<td class="num">(327)<span></span>
</td>
<td class="nump">548<span></span>
</td>
<td class="nump">73<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">351<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_PaymentForDiscountPremiumOnInvestmentsNet', window );">Purchase net (premium) discount on marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">428<span></span>
</td>
<td class="num">(344)<span></span>
</td>
<td class="num">(286)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_NonCashOperatingLeaseExpense', window );">Non-cash operating lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">397<span></span>
</td>
<td class="nump">425<span></span>
</td>
<td class="nump">628<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">3,310<span></span>
</td>
<td class="num">(2,863)<span></span>
</td>
<td class="num">(1,144)<span></span>
</td>
<td class="num">(1,216)<span></span>
</td>
<td class="num">(1,101)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">Accounts payable</a></td>
<td class="nump">1,001<span></span>
</td>
<td class="nump">859<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">575<span></span>
</td>
<td class="num">(897)<span></span>
</td>
<td class="num">(880)<span></span>
</td>
<td class="nump">3,576<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Development receivables</a></td>
<td class="nump">212<span></span>
</td>
<td class="nump">146<span></span>
</td>
<td class="nump">440<span></span>
</td>
<td class="num">(815)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(2,326)<span></span>
</td>
<td class="num">(297)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued and other liabilities</a></td>
<td class="num">(4,000)<span></span>
</td>
<td class="num">(1,293)<span></span>
</td>
<td class="num">(843)<span></span>
</td>
<td class="num">(373)<span></span>
</td>
<td class="num">(1,146)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayable', window );">Related party payable</a></td>
<td class="num">(2,115)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,641)<span></span>
</td>
<td class="nump">1,065<span></span>
</td>
<td class="num">(544)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_IncreaseDecreaseInOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(435)<span></span>
</td>
<td class="num">(404)<span></span>
</td>
<td class="nump">251<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(68,874)<span></span>
</td>
<td class="num">(62,004)<span></span>
</td>
<td class="num">(80,144)<span></span>
</td>
<td class="num">(53,716)<span></span>
</td>
<td class="num">(75,775)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAcquiredFromAcquisition', window );">Cash assumed from asset acquisition of Spyre</a></td>
<td class="nump">3,035<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfIntangibleAssets', window );">Proceeds from sale of in-process research &amp; development asset</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(38)<span></span>
</td>
<td class="num">(38)<span></span>
</td>
<td class="num">(573)<span></span>
</td>
<td class="num">(4,280)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of property and equipment</a></td>
<td class="nump">475<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of marketable securities</a></td>
<td class="num">(112,631)<span></span>
</td>
<td class="num">(35,000)<span></span>
</td>
<td class="num">(39,500)<span></span>
</td>
<td class="num">(133,079)<span></span>
</td>
<td class="num">(129,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from maturities and sales of marketable securities</a></td>
<td class="nump">21,000<span></span>
</td>
<td class="nump">78,046<span></span>
</td>
<td class="nump">96,546<span></span>
</td>
<td class="nump">111,033<span></span>
</td>
<td class="nump">125,676<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) and provided by investing activities</a></td>
<td class="num">(73,121)<span></span>
</td>
<td class="nump">43,008<span></span>
</td>
<td class="nump">57,008<span></span>
</td>
<td class="num">(22,619)<span></span>
</td>
<td class="num">(7,604)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from issuance of Series A non-voting convertible preferred stock in connection with private placement, net of placement and other offering costs</a></td>
<td class="nump">197,364<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfOfferingCosts', window );">Proceeds from issuance of common stock and pre-funded warrants in registered direct offering, net of offering costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">42,874<span></span>
</td>
<td class="nump">42,874<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">153,716<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from employee stock plan purchases and stock option exercises</a></td>
<td class="nump">123<span></span>
</td>
<td class="nump">222<span></span>
</td>
<td class="nump">222<span></span>
</td>
<td class="nump">1,903<span></span>
</td>
<td class="nump">816<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Principal payments on finance lease obligation</a></td>
<td class="num">(16)<span></span>
</td>
<td class="num">(410)<span></span>
</td>
<td class="num">(418)<span></span>
</td>
<td class="num">(510)<span></span>
</td>
<td class="num">(20)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">197,471<span></span>
</td>
<td class="nump">42,686<span></span>
</td>
<td class="nump">42,678<span></span>
</td>
<td class="nump">1,393<span></span>
</td>
<td class="nump">154,512<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate on cash, cash equivalents, and restricted cash</a></td>
<td class="nump">7<span></span>
</td>
<td class="num">(152)<span></span>
</td>
<td class="num">(106)<span></span>
</td>
<td class="num">(15)<span></span>
</td>
<td class="nump">51<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">NET INCREASE IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH</a></td>
<td class="nump">55,483<span></span>
</td>
<td class="nump">23,538<span></span>
</td>
<td class="nump">19,436<span></span>
</td>
<td class="num">(74,957)<span></span>
</td>
<td class="nump">71,184<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract', window );"><strong>CASH, CASH EQUIVALENTS, AND RESTRICTED CASH</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Beginning of period</a></td>
<td class="nump">36,416<span></span>
</td>
<td class="nump">16,980<span></span>
</td>
<td class="nump">16,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">End of period</a></td>
<td class="nump">91,899<span></span>
</td>
<td class="nump">40,518<span></span>
</td>
<td class="nump">36,416<span></span>
</td>
<td class="nump">16,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Beginning of period</a></td>
<td class="nump">36,416<span></span>
</td>
<td class="nump">16,980<span></span>
</td>
<td class="nump">16,980<span></span>
</td>
<td class="nump">91,937<span></span>
</td>
<td class="nump">20,753<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">End of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,416<span></span>
</td>
<td class="nump">16,980<span></span>
</td>
<td class="nump">91,937<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental Disclosure of Non-Cash Investing and Financing Information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Settlement of forward contract liability and issuance of Series A non-voting convertible preferred stock in connection with the asset acquisition of Spyre</a></td>
<td class="nump">189,741<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_LeasedAssetsObtainedInExchangeForLeaseObligations', window );">Leased assets obtained in exchange for lease obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="nump">872<span></span>
</td>
<td class="nump">172<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Unpaid amounts related to purchase of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 224<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=agle_ContingentValueRightLiabilityMember', window );">CVR liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Change in fair value of forward contract liability</a></td>
<td class="num">(1,300)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForwardContractsMember', window );">Forward contract liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Change in fair value of forward contract liability</a></td>
<td class="nump">$ 83,530<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_AcquiredInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Acquired in process research and development</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_AcquiredInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_IncreaseDecreaseInOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_IncreaseDecreaseInOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_LeasedAssetsObtainedInExchangeForLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Leased assets obtained in exchange for lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_LeasedAssetsObtainedInExchangeForLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_NonCashOperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-cash operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_NonCashOperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_PaymentForDiscountPremiumOnInvestmentsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment for discount (premium) on investments net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_PaymentForDiscountPremiumOnInvestmentsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of common stock and pre-funded warrants in public offering net of offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAcquiredFromAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAcquiredFromAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDerivativeInstrumentsNetPretax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482312/912-310-45-11<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligations classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=agle_ContingentValueRightLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=agle_ContingentValueRightLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForwardContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForwardContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140168004070928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statement of Assets Acquired and Liabilities Assumed<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 22, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 3,035<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets', window );">Total current assets</a></td>
<td class="nump">3,035<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Total assets acquired</a></td>
<td class="nump">3,035<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Accrued liabilities</a></td>
<td class="nump">20,047<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities', window );">Total current liabilities</a></td>
<td class="nump">20,047<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Total liabilities assumed</a></td>
<td class="nump">20,047<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Net liabilities assumed</a></td>
<td class="num">$ (17,012)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479303/805-10-55-37<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140168003169456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The Company and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">The Company and Basis of Presentation</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1. The Company and Basis of Presentation </div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Aeglea BioTherapeutics, Inc. (&#8220;Aeglea&#8221; or the &#8220;Company&#8221;) is a preclinical stage biotechnology company focused on developing next generation therapeutics for patients living with inflammatory bowel disease. The Company was formed as a Limited Liability Company (&#8220;LLC&#8221;) in Delaware on December&#160;16, 2013 under the name Aeglea BioTherapeutics Holdings, LLC and was converted from a Delaware LLC to a Delaware corporation on March&#160;10, 2015. The Company operates in one segment and has its principal offices in Waltham, Massachusetts. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&#160;12, 2023, based on the review of the inconclusive interim results from the Company&#8217;s Phase 1/2 clinical trial of pegtarviliase for the treatment of classical homocystinuria and other business considerations, the Company announced that it had initiated a process to explore strategic alternatives to maximize stockholder value and engaged an independent exclusive financial advisor to support this process. In April 2023, the Company implemented a restructuring plan resulting in an approximate 83% reduction of the Company&#8217;s existing headcount. On September&#160;8, 2023, Aeglea effected a reverse stock split of its common stock at a ratio of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">1-for-25</div></div> (the &#8220;Reverse Split&#8221;). All share numbers related to the Company&#8217;s common stock disclosed in these financial statements have been adjusted on a post-Reverse Split basis. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;22, 2023, the Company acquired, in accordance with the terms of the Agreement and Plan of Merger (the &#8220;Acquisition Agreement&#8221;), the assets from Spyre Therapeutics, Inc. (&#8220;Spyre&#8221;), as disclosed in Notes 7 and 8, a privately held biotechnology company advancing a pipeline of antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease through a research and development option agreement (&#8220;Paragon Agreement&#8221;) with Paragon Therapeutics (&#8220;Paragon&#8221;). The transaction was structured as a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">stock-for-stock</div></div> transaction pursuant to which all of Spyre&#8217;s outstanding equity interests were exchanged based on a fixed exchange ratio of 0.5494488 to 1 for consideration from Aeglea of 517,809 shares of common stock and 364,887 shares of Series A <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-voting</div> convertible preferred stock, par value of $0.0001 per share (&#8220;Series A Preferred Stock&#8221;) (convertible on a 40 to 1 basis) in addition to the assumption of outstanding and unexercised stock options to purchase 2,734 shares of common stock from the Amended and Restated Spyre 2023 Equity Incentive Plan (the &#8220;Asset Acquisition&#8221;). The Aeglea common stock and Aeglea Series A Preferred Stock related to the Asset Acquisition were issued to the Spyre stockholders on July&#160;7, 2023. For additional information, see Notes 7 and 8. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Asset Acquisition, on June&#160;26, 2023, the Company completed a private placement of shares of Series A Preferred Stock (the &#8220;PIPE&#8221;) to a group of investors (the &#8220;Investors&#8221;). The Company sold an aggregate of 721,452 shares of Series A Preferred Stock for an aggregate purchase price of approximately $210.0&#160;million before deducting approximately $12.7&#160;million in placement agent and other offering expenses (together with the Asset Acquisition, the &#8220;Transactions&#8221;). For additional information, see Note 9. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Asset Acquisition and pursuant to a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-transferable</div> contingent value right (&#8220;CVR&#8221;) agreement (the &#8220;CVR Agreement&#8221;) a CVR was distributed to each Aeglea stockholder of record as of the close of business on July&#160;3, 2023 (the &#8220;Legacy Stockholders&#8221;), but was not distributed to the holders of shares of common stock or Series A Preferred Stock issued to the former stockholders of Spyre or Investors in the Transactions. Holders of the CVRs will be entitled to receive cash payments from proceeds received by Aeglea for a three-year period, if any, related to the disposition or monetization of its legacy assets for a period of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-year</div> following the closing of the Asset Acquisition. For additional information see Note 3. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Liquidity </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of September&#160;30, 2023, the Company had an accumulated deficit of $701.2&#160;million, and cash, cash equivalents, and marketable securities of $203.6&#160;million. The Company has not generated any product revenues </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">and has not achieved profitable operations. There can be no assurance that profitable operations will ever be achieved, and, if achieved, whether it can be sustained on a continuing basis. In addition, development activities, clinical and nonclinical testing, and commercialization of the Company&#8217;s product candidates will require significant additional financing before a commercial drug can be produced and marketed. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is subject to a number of risks similar to other life science companies, including, but not limited to, risks related to the successful discovery, development, and commercialization of product candidates, raising additional capital, development of competing drugs and therapies, protection of proprietary technology and market acceptance of the Company&#8217;s product candidates. As a result of these and other factors and uncertainties, there can be no assurance of the Company&#8217;s future success. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2023, the Board of Directors (the &#8220;Board&#8221;) approved a restructuring of the Company&#8217;s workforce pursuant to which the Company&#8217;s workforce was reduced by approximately 83% and the Company retained approximately 10 employees. Following a review of the interim results from its ongoing Phase 1/2 clinical trial of pegtarviliase for the treatment of classical homocystinuria and other business considerations, the Company explored strategic alternatives with the goal of maximizing stockholder value, including possible business combinations and/or a divestiture of the Company&#8217;s clinical programs. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;22, 2023, the Company acquired, in accordance with the terms of the Acquisition Agreement, the net assets of Spyre, as disclosed in Notes 7 and 8. Additionally, the Company completed the PIPE. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with Accounting Standards Codification (&#8220;ASC&#8221;) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">205-40,</div> Going Concern, the Company has evaluated and determined that there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date the accompanying condensed consolidated financial statements included in this Quarterly Report are issued. The Company&#8217;s Series A Preferred Stock agreement requires it to seek stockholder approval for the conversion of the Series A Preferred Stock to common stock. The Company has agreed to hold a stockholders&#8217; meeting to submit this matter to its stockholders for their consideration. In connection with this, the Company filed with the Securities and Exchange Commission (&#8220;SEC&#8221;) a definitive proxy statement and other relevant materials. The special meeting of stockholders is scheduled for November&#160;21, 2023. If the Company&#8217;s stockholders do not timely approve the conversion of its Series A Preferred Stock into common stock, then the holders of its Series A Preferred Stock are entitled to require the Company to settle their shares of Series A Preferred Stock for cash at a price per share equal to the fair value of the Series A Preferred Stock, as described in the Certificate of Designation relating to the Series A Preferred Stock (see Note 9). The cash redemption is not in the Company&#8217;s control and raises substantial doubt about the Company&#8217;s ability to continue as a going concern. The accompanying condensed consolidated financial statements assume the Company will continue as a going concern through the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Unaudited Interim Financial Information </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The interim condensed consolidated financial statements included in this Quarterly Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q</div> are unaudited. The unaudited interim financial statements have been prepared on the same basis as the annual financial statements and reflect, in the opinion of management, all adjustments of a normal and recurring nature that are necessary for a fair statement of the Company&#8217;s financial position as of September&#160;30, 2023, and its results of operations for the three and nine months ended September&#160;30, 2023 and 2022, changes in convertible preferred stock and stockholders&#8217; (deficit) equity for the three and nine months ended September&#160;30, 2023 and 2022, and cash flows for the nine months ended September&#160;30, 2023 and 2022. The results of operations for the three and nine months ended September&#160;30, 2023, are not necessarily indicative of the results to be expected for the year ending December&#160;31, 2023 or for any other future annual or interim period. The December&#160;31, 2022 balance sheet was derived from audited financial statements, but does not include all disclosures required by accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;). These financial statements should </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">be read in conjunction with the audited financial statements included in the Company&#8217;s Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> for the year ended December&#160;31, 2022 (the &#8220;Annual Report&#8221;) as filed with <div style="display:inline;">the </div>SEC. </div><span></span>
</td>
<td class="text"><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">1. The Company and Basis of Presentation </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Aeglea BioTherapeutics, Inc. (&#8220;Aeglea&#8221; or the &#8220;Company&#8221;) is a clinical-stage biotechnology company developing human enzyme therapeutics to benefit people with rare metabolic diseases. The Company was formed as a Limited Liability Company (LLC) in Delaware on December&#160;16, 2013 under the name Aeglea BioTherapeutics Holdings, LLC and was converted from a Delaware LLC to a Delaware corporation on March&#160;10, 2015. The Company operates in one segment and has its principal offices in Austin, Texas. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Liquidity </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2022, the Company had working capital of $47.6&#160;million, an accumulated deficit of $425.6&#160;million, and cash, cash equivalents, marketable securities, and restricted cash of $57.3&#160;million. The Company has not generated any product revenues and has not achieved profitable operations. There is no assurance that profitable operations will ever be achieved, and, if achieved, could be sustained on a continuing basis. In addition, development activities, clinical and nonclinical testing, and commercialization of the Company&#8217;s products will require significant additional financing. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is subject to a number of risks similar to other life science companies, including, but not limited to, risks related to the successful discovery, development, and commercialization of product candidates, raising additional capital, development of competing drugs and therapies, protection of proprietary technology and market acceptance of the Company&#8217;s products. As a result of these and other factors and the related uncertainties, there can be no assurance of the Company&#8217;s future success. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">205-40,</div> Going Concern, the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date the financial statements included in this Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> are issued. Based upon the Company&#8217;s current operating plans, the Company believes that it has sufficient resources to fund operations into the fourth quarter of 2023 with its existing cash, cash equivalents, and marketable securities. Accordingly, based on its recurring losses from operations incurred since inception, the expectation of continued operating losses, and the need to raise additional capital to finance its future operations, the Company determined that there is substantial doubt about the Company&#8217;s ability to continue as a going concern within twelve months of the issuance date of these financial statements. The accompanying consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty and assumes the Company will continue as a going concern through the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business. The Company plans to address this condition through the sale of common stock in public offerings and/or private placements, debt financings, or through other capital sources, including collaborations with other companies or other strategic transactions. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although the Company has been successful in raising capital in the past, there is no assurance that it will be successful in obtaining such additional financing on terms acceptable to the Company, if at all, nor is it considered probable under the accounting standards. If the Company is unable to obtain sufficient funding on acceptable terms, it could be forced to delay, reduce or eliminate some or all of its research and development programs or commercialization activities, which could materially adversely affect its business prospects or its ability to continue operations. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Basis of Presentation </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States (&#8220;U.S. GAAP&#8221;) as defined by the Financial Accounting Standards Board (&#8220;FASB&#8221;) and include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140168003224400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2. Summary of Significant Accounting Policies </div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other than policies noted below, there have been no significant changes from the significant accounting policies and estimates disclosed in Note 2 of the &#8220;Notes to Consolidated Financial Statements&#8221; included in our Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> for the year ended December&#160;31, 2022. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These interim condensed consolidated financial statements have been prepared in accordance with U.S. GAAP and SEC instructions for interim financial information, and should be read in conjunction with the Company&#8217;s Annual Report. Significant accounting policies and other disclosures normally provided have been omitted since such items are disclosed in the Company&#8217;s Annual Report. The Company uses the same accounting policies in preparing quarterly and annual financial statements. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Convertible Preferred Stock Issued through PIPE </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company records shares of convertible preferred stock at their respective fair values on the dates of issuance, net of issuance costs. The Company has applied the guidance in ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">480-10-S99-3A</div></div></div> as well as SEC Staff Announcement, Classification and Measurement of Redeemable Securities, and has therefore classified the Series A Preferred Stock outside of stockholders&#8217; (deficit) equity because, if conversion to common stock is not approved by the stockholders, the Series A Preferred Stock will be redeemable at the option of the holders for cash equal to the closing price of the common stock on the last trading day prior to the holder&#8217;s redemption request. The Company has determined that the conversion and redemption are outside of the Company&#8217;s control. Additionally, the Company has determined the conversion and redemption features do not require bifurcation as derivatives. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Acquisitions </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company evaluates acquisitions of assets and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first applying a screen test to determine whether substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If so, the transaction is accounted for as an asset acquisition. If not, further determination is required as to whether or not the Company has acquired inputs and processes that have the ability to create outputs, which would meet the definition of a business. Significant judgment is required in the application of the test to determine whether an acquisition is a business combination or an acquisition of assets. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Acquisitions meeting the definition of business combinations are accounted for using the acquisition method of accounting, which requires that the purchase price be allocated to the net assets acquired at their respective fair values. In a business combination, any excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company measures and recognizes asset acquisitions that are not deemed to be business combinations based on the cost to acquire the assets, which includes <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-acquisition</div> direct costs recorded in accrued professional and consulting fees. Goodwill is not recognized in asset acquisitions. When a transaction accounted for as an asset acquisition includes an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development (&#8220;IPR&amp;D&#8221;) asset, the IPR&amp;D asset is only capitalized if it has an alternative future use other than in a particular research and development project. Otherwise, the cost allocated to acquire an IPR&amp;D asset with no alternative future use is charged to expense at the acquisition date. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Contingent Value Rights </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company evaluates its contracts to determine if those contracts qualify as derivatives under ASC 815, Derivatives and Hedging (&#8220;ASC 815&#8221;). For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-valued</div> at each reporting date. Any changes in fair value are recorded as other income or expense for each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> based on whether or not <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">net-cash</div> settlement of the derivative instrument is probable within the next 12 months from the balance sheet date. The Company determined that certain contingent payments under the CVR Agreement qualified as derivatives under ASC 815, and as such, were recorded as a liability on the balance sheet. This value is then remeasured for future expected payout as well as the increase in fair value due to the time value of money. These gains or losses, if any, are recognized in the consolidated statements of operations and comprehensive loss within Other (expense) income, net. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company applies a scenario-based method and weighs them based on the possible achievement of certain milestones. The milestone payments are contingent on formal reimbursement decisions by national authorities in key European markets and pegzilarginase approval by the U.S. Food and Drug Administration (&#8220;FDA&#8221;), among other events. This fair value measurement is based on significant inputs not observable in the market and thus represents a Level&#160;3 measurement as defined in ASC 820, Fair Value Measurement. The key assumptions used include the discount rate, probability of regulatory success, and reimbursement rates from certain government agencies. The estimated value of the CVR consideration is based upon available information and certain assumptions which the Company&#8217;s management believes are reasonable under the circumstances. The ultimate payout under the CVRs may differ materially from the assumptions used in determining the fair value of the CVR consideration. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets, liabilities, and equity and the amount of revenues and expenses. Actual results could differ significantly from those estimates. The most significant estimates and assumptions that management considers in the preparation of the Company&#8217;s financial statements relate to the valuation of consideration transferred in acquiring IPR&amp;D; the discount rate, probabilities of success, and timing of estimated cash flows in the valuation of the CVR liability; inputs used in the Black-Scholes model for stock-based compensation expense; estimated future cash flows used in calculating the impairment of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> lease assets; and estimated cost to complete performance obligations related to revenue recognition. The consideration transferred in acquiring IPR&amp;D in connection with the acquisition of Spyre was comprised of shares of the Company&#8217;s common stock and shares of Series A Preferred Stock. To determine the fair value of the equity transferred, the Company considered the per share value of the PIPE, which was an over-subscribed financing event involving a group of accredited investors. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Recently Adopted Accounting Pronouncement </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company early adopted the Financial Accounting Standards Board&#8217;s Accounting Standards Update <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06,</div> Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity (&#8220;ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06&#8221;),</div> effective as of January&#160;1, 2023 using the modified retrospective method. Among other amendments, ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06</div> eliminates the cash conversion and beneficial conversion feature models in ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">470-20</div> that required an issuer of certain convertible debt and preferred stock to separately account for embedded conversion features as a component of equity, as well as changes the accounting for diluted <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">earnings-per-share</div></div> for convertible instruments and contracts that may be settled in cash or stock. Additionally, ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06</div> requires the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">if-converted</div> method, </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">which is more dilutive than the treasury stock method, be used for all convertible instruments. The Company applied ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06</div> to all Series A Preferred Stock during fiscal year 2023, and, accordingly, the Company did not apply the cash conversion or beneficial conversion feature models in its analysis of the Series A <div style="display:inline;"><div style="display:inline;">Preferred </div></div>Stock. </div><span></span>
</td>
<td class="text"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">2. Summary of Significant Accounting Policies </div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Use of Estimates </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances, the results of which form the basis for making judgements about the carrying value of assets, liabilities, and equity and the amount of revenues and expenses. Estimates are used in accounting for, among other items, accrued research and development costs and revenue recognition. Actual results could differ materially from those estimates. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Cash and Cash Equivalents </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company considers all highly liquid investments with original maturities of three months or less from the date of purchase to be cash equivalents. Cash equivalents consist of money market funds and debt securities and are stated at fair value. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Marketable Securities </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All investments have been classified as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> and are carried at estimated fair value as determined based upon quoted market prices or pricing models for similar securities. Management determines the appropriate classification of its investments in debt securities at the time of purchase. The Company may hold securities with stated maturities greater than one year until maturity. All <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> securities are considered available to support current operations and are classified as current assets. The Company presents credit losses as an allowance rather than as a reduction in the amortized cost of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> securities. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> debt securities in an unrealized loss position, the Company first assesses whether it intends to sell, or it is more likely than not that it will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security&#8217;s amortized cost basis is written down to fair value and recognized in other income (expense) in the results of operations. For <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> debt securities that do not meet the aforementioned criteria, the Company evaluates whether the decline in fair value has resulted from credit losses or other factors. In making this assessment, management considers the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and adverse conditions specifically related to the security, among other factors. If this assessment indicates that a credit loss exists, an allowance is recorded for the difference between the present value of cash flows expected to be collected and the amortized cost basis of the security. Impairment losses attributable to credit loss factors are charged against the allowance when management believes an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> security is uncollectible or when either of the criteria regarding intent or requirement to sell is met. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any unrealized losses from declines in fair value below the amortized cost basis as a result of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-credit</div> loss factors is recognized as a component of accumulated other comprehensive (loss) income, along with unrealized gains. Realized gains and losses and declines in fair value, if any, on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> securities are included in other income (expense) in the results of operations. The cost of securities sold is based on the specific-identification method. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Restricted Cash </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Restricted cash consists of money market accounts held by financial institutions as collateral for the Company&#8217;s obligations under a credit agreement and a facility lease for the Company&#8217;s corporate headquarters in Austin, Texas. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Concentration of Credit Risk </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash, cash equivalents, marketable securities, and restricted cash. The Company&#8217;s investment policy limits investments to high credit quality securities issued by the U.S. government, U.S. government-sponsored agencies, highly rated banks, and corporate issuers, subject to certain concentration limits and restrictions on maturities. The Company&#8217;s cash, cash equivalents, marketable securities, and restricted cash are held by financial institutions that management believes are of high credit quality. Amounts on deposit may at times exceed federally insured limits. The Company has not experienced any losses on its deposits of cash, cash equivalents, and restricted cash and its accounts are monitored by management to mitigate risk. The Company is exposed to credit risk in the event of default by the financial institutions holding its cash, cash equivalents, and restricted cash, and bond issuers. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Property and Equipment </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Property and equipment are stated at cost, net of accumulated depreciation and amortization. Depreciation and amortization are computed using the straight-line method over the estimated useful lives of the assets. Repairs and maintenance that do not extend the life or improve an asset are expensed as incurred. Upon retirement or sale, the cost of disposed assets and their related accumulated depreciation and amortization are removed from the balance sheet. Any gain or loss is credited or charged to operations. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The useful lives of the property and equipment are as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:39%"></td>
<td style="vertical-align:bottom;width:2%"></td>
<td style="width:59%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Laboratory equipment</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">5 years</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Furniture and office equipment</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">5 years</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Computer equipment</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">3 years</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Software</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">3 years</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Leasehold improvements</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Shorter of remaining lease term or estimated useful life</td></tr></table><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Impairment of Long-Lived Assets </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Long-lived assets are reviewed for indications of possible impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amounts to the future undiscounted cash flows attributable to these assets. An impairment loss is recognized to the extent an asset group is not recoverable, and the carrying amount exceeds the fair value. There were no impairments of long-lived assets for the years ended December&#160;31, 2022, 2021, and 2020. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Accrued Research and Development Costs </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company records the costs associated with research nonclinical studies, clinical trials, and manufacturing development as incurred. These costs are a significant component of the Company&#8217;s research and development expenses, with a substantial portion of the Company&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">on-going</div> research and development activities conducted by third-party service providers, including contract research and manufacturing organizations. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company accrues for expenses resulting from obligations under agreements with contract research organizations (&#8220;CROs&#8221;), contract manufacturing organizations (&#8220;CMOs&#8221;), and other outside service providers for which payment flows do not match the periods over which materials or services are provided to the Company. Accruals are recorded based on estimates of services received and efforts expended pursuant to agreements established with CROs, CMOs, and other outside service providers. These estimates are typically based on contracted amounts applied to the proportion of work performed and determined through analysis with internal personnel and external service providers as to the progress or stage of completion of the services. The Company </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">makes significant judgments and estimates in determining the accrual balance in each reporting period. In the event advance payments are made to a CRO, CMO, or outside service provider, the payments will be recorded as a prepaid asset which will be amortized as the contracted services are performed. As actual costs become known, the Company adjusts its accruals. Inputs, such as the services performed, the number of patients enrolled, or the study duration, may vary from the Company&#8217;s estimates, resulting in adjustments to research and development expense in future periods. Changes in these estimates that result in material changes to the Company&#8217;s accruals could materially affect the Company&#8217;s results of operations. Historically, the Company has not <div style="display:inline;">experienced </div>any material deviations between accrued and actual research and development expenses. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Leases </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company determines if an arrangement is a lease at inception. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Right-of-use</div></div> (&#8220;ROU&#8221;) assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. The classification of the Company&#8217;s leases as operating or finance leases along with the initial measurement and recognition of the associated ROU assets and lease liabilities is performed at the lease commencement date. The measurement of lease liabilities is based on the present value of future lease payments over the lease term. As the Company&#8217;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of future lease payments. To determine the incremental borrowing rate, the Company uses the lease-term appropriate current treasury bond rates adjusted for collateral and inflation risks combined with quoted bank financing rates. The ROU asset is based on the measurement of the lease liability and also includes any lease payments made prior to or on lease commencement and excludes lease incentives and initial direct costs incurred, as applicable. The lease terms may include options to extend or terminate the lease when it is reasonably certain the Company will exercise any such options. Rent expense for the Company&#8217;s operating leases is recognized on a straight-line basis over the lease term. Amortization expense for the ROU asset associated with its finance leases is recognized on a straight-line basis over the term of the lease and interest expense associated with its finance leases is recognized on the balance of the lease liability using the effective interest method based on the estimated incremental borrowing rate. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has lease agreements with lease and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components. As allowed under Topic 842, the Company has elected to not separate lease and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components for any leases involving real estate and office equipment classes of assets and, as a result, accounts for the lease and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components as a single lease component. The Company has also elected to not apply the recognition requirement of Topic 842 to leases with a term of 12 months or less for all classes of assets. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Fair Value of Financial Instruments </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company uses fair value measurements to record fair value adjustments to certain financial and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-financial</div> assets and liabilities and to determine fair value disclosures. The accounting standards define fair value, establish a framework for measuring fair value, and require disclosures about fair value measurements. Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required to be recorded at fair value, the principal or most advantageous market in which the Company would transact are considered along with assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accounting standard for fair value establishes a fair value hierarchy based on three levels of inputs, the first two of which are considered observable and the last unobservable, that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. A financial instrument&#8217;s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The three levels of inputs that may be used to measure fair value are as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:9%"></td>
<td style="vertical-align:bottom;width:2%"></td>
<td style="width:90%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Level&#160;1:</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Observable inputs, such as quoted prices in active markets for identical assets or liabilities.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td colspan="2" style="height:6pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Level&#160;2:</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Observable inputs other than Level&#160;1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td colspan="2" style="height:6pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Level&#160;3:</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Valuations based on unobservable inputs to the valuation methodology and including data about assumptions that market participants would use in pricing the asset or liability based on the best information available under the circumstances.</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Financial instruments carried at fair value include cash, cash equivalents, marketable securities, and restricted cash. The carrying amounts of accounts payable and accrued liabilities approximate fair value due to their relatively short maturities. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Revenue Recognition </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under ASC Topic 606, &#8220;Revenue from Contracts with Customers&#8221; (&#8220;Topic 606&#8221;), an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of Topic 606, the entity performs the following five steps: (i)&#160;identify the contract(s) with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price, including variable consideration, if any; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the entity satisfies a performance obligation. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company assesses its license arrangements within the scope of Topic 606 in accordance with this framework as follows: </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">License revenue </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company assesses whether the goods or services promised within each contract are distinct to identify those that are performance obligations. This assessment involves subjective determinations and requires management to make judgments about the individual promised goods or services and whether such are separable from the other aspects of the contractual relationship. In assessing whether a promised good or service is distinct, and therefore a performance obligation, the Company considers factors such as the research, stage of development of the licensed product, manufacturing and commercialization capabilities of the customer and the availability of the associated expertise in the general marketplace. The Company also considers the intended benefit of the contract in assessing whether a promised good or service is separately identifiable from other promises in the contract. If a promised good or service is not distinct, the Company is required to combine that good or service with other promised goods or services until it identifies a bundle of goods or services that is distinct. Arrangements that include rights to additional goods or services that are exercisable at a customer&#8217;s discretion are generally considered options. The Company assesses if these options provide a material right to the customer and if so, they are considered performance obligations. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transaction price is determined and allocated to the identified performance obligations in proportion to their stand-alone selling prices (&#8220;SSP&#8221;) on a relative SSP basis. SSP is based on observable prices of the performance obligations or, when such prices are not observable, are estimated. The estimation of SSP may include factors such as forecasted revenues or costs, development timelines, discount rates, probabilities of technical and regulatory success, and considerations such as market conditions and entity-specific factors. In certain circumstances, the Company may apply the residual method to determine the SSP of a good or service if the SSP is considered highly variable or uncertain. The Company validates the SSP for performance obligations </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">by evaluating whether changes in the key assumptions used to determine the SSP will have a significant effect on the allocation of arrangement consideration between multiple performance obligations. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the consideration promised in a contract includes a variable amount, the Company estimates the amount of consideration to which it will be entitled in exchange for transferring the promised goods or services to a customer. The Company determines the amount of variable consideration by using the expected value method or the most likely amount method. The Company includes the amount of estimated variable consideration in the transaction price to the extent that it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-evaluates</div> the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">catch-up</div> basis in the period of adjustment. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an arrangement includes development, regulatory or commercial milestone payments, the Company evaluates whether the milestones are considered likely of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant cumulative revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company&#8217;s control or the licensee&#8217;s control, such as regulatory approvals, are generally not considered likely of being achieved until those approvals are received. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In determining the transaction price, the Company adjusts consideration for the effects of the time value of money if the timing of payments provides the Company with a significant benefit of financing. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the licensee and the transfer of the promised goods or services to the licensees will be one year or less. For arrangements with licenses of intellectual property that include sales-based royalties, including milestone payments based on the level of sales, and if the license is deemed to be the predominant item to which the royalties relate, the Company recognizes royalty revenue and sales-based milestones at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which the royalty has been allocated has been satisfied. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied at a point in time or over time, and if over time, recognition is based on the use of an output or input method. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#8217;s contracts may be modified for changes in the customer&#8217;s requirements. If contract modifications are for additional goods and services that are distinct from the existing contract, the modification will be accounted for as either a separate contract or a termination of the existing contract, depending on whether the additional goods or services reflects the SSP. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the additional goods or services in a contract modification are not distinct from the existing contract, they are accounted for as if they were part of the original contract. The effect of the contract modification on the transaction price and the measure of progress for the performance obligation to which it relates is recognized as an adjustment to revenue on a cumulative <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">catch-up</div> basis. The cumulative <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">catch-up</div> adjustment is calculated using an updated measure of progress applied to the sum of (1)&#160;the remaining consideration allocated to the partially satisfied performance obligation and (2)&#160;the revenue already recognized on that performance obligation. The revenue recognized for fully satisfied goods or services and distinct from the remaining performance obligations is not altered by the modification. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Collaborative arrangements </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company analyzes its license arrangements to assess whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">and rewards dependent on the commercial success of such activities and therefore within the scope of ASC Topic 808, Collaborative Arrangements (&#8220;Topic 808&#8221;). This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. For arrangements within the scope of Topic 808 that contain multiple elements, the Company first determines which elements of the collaboration are deemed to be within the scope of Topic 808 and which elements of the collaboration are more reflective of a vendor-customer relationship and therefore within the scope of Topic 606. For elements of collaboration arrangements that are accounted for pursuant to Topic 808, an appropriate recognition method is determined and applied consistently, either by analogy to authoritative accounting literature or by applying a reasonable and rational policy election. For those elements of the arrangement that are accounted for pursuant to Topic 606, the Company applies the five-step model described <div style="display:inline;">above</div>. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Research and Development Costs </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development costs are expensed as incurred. Research and development costs include, but are not limited to, salaries, benefits, travel, stock-based compensation, consulting costs, contract research service costs, laboratory supplies and facilities, contract manufacturing costs, and costs paid to other third parties that conduct research and development activities on the Company&#8217;s behalf. Amounts incurred in connection with license agreements are also included in research and development expense. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Advance payments for goods or services to be rendered in the future for use in research and development activities are recorded as a prepaid asset and expensed as the related goods are delivered or the services are performed. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Stock-Based Compensation </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognizes the cost of stock-based awards granted to employees and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employees</div> based on the estimated grant-date fair values of the awards. The fair values of stock options are estimated on the date of grant using the Black-Scholes option pricing model. The fair values of restricted stock units (&#8220;RSUs&#8221;) are based on the fair value of the Company&#8217;s common stock on the date of the grant. The value of the award is recognized as compensation expense on a straight-line basis over the requisite service period. Forfeitures are recognized when they occur, which may result in the reversal of compensation costs in subsequent periods as the forfeitures arise. Compensation expense for employee and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> share-based payment awards with performance conditions is recognized when the performance condition is deemed probable. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Income Taxes </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company and its ten wholly owned subsidiary corporations use the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial statements and the tax bases of assets and liabilities. Additionally, any changes in income tax laws are immediately recognized in the year of enactment. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A valuation allowance is established against the deferred tax assets to reduce their carrying value to an amount that is more likely than not to be realized. The deferred tax assets and liabilities are classified as noncurrent along with the related valuation allowance. Due to a lack of earnings history, the net deferred tax assets have been fully offset by a valuation allowance. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognizes benefits of uncertain tax positions if it is more likely than not that such positions will be sustained upon examination based solely on the technical merits, as the largest amount of benefits that is more likely than not to be realized upon the ultimate settlement. The Company&#8217;s policy is to recognize interest and penalties related to the unrecognized tax benefits as a component of income tax expense, if applicable. As of December&#160;31, 2022 and 2021, the Company had no unrecognized tax benefits and there were no interest or penalties incurred by the Company in the years ended December&#160;31, 2022, 2021, or 2020. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Comprehensive Loss </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Comprehensive loss is the change in stockholders&#8217; equity from transactions and other events and circumstances other than those resulting from investments by stockholders and distributions to stockholders. The Company&#8217;s other comprehensive income (loss) is currently comprised of changes in unrealized losses and gains on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> securities and foreign currency translation adjustments reflecting the cumulative effect of changes in exchange rates between the foreign entity&#8217;s functional currency and the reporting currency. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140168001421312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3. Fair Value Measurements </div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company measures and reports certain financial instruments as assets and liabilities at fair value on a recurring basis. The following tables set forth the fair value of the Company&#8217;s financial assets and liabilities at fair value on a recurring basis based on the three-tier fair value hierarchy (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:56%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">September&#160;30, 2023</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Level&#160;1</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Level&#160;2</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Level&#160;3</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Total</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Financial Assets:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Money market funds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">55,451</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">55,451</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial paper</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">107,093</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">107,093</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate bonds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">22,828</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">22,828</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total financial assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">55,451</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">129,921</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">185,372</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Liabilities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Parapyre Option Obligation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,952</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,952</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">CVR liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">28,200</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">28,200</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,952</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">28,200</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">31,152</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td colspan="16" style="height:12pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">December&#160;31, 2022</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Level&#160;1</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Level&#160;2</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Level&#160;3</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Total</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Financial Assets:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Money market funds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,250</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,250</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial paper</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">23,641</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">23,641</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">U.S. government securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,230</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,230</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate bonds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,732</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,732</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total financial assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,250</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">31,603</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">46,853</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company measures the fair value of money market funds on quoted prices in active markets for identical assets or liabilities. The Level&#160;2 assets include commercial paper, U.S. government securities and corporate bonds and are valued based on quoted prices for similar assets in active markets and inputs other than quoted prices that are derived from observable market data. The Company evaluates transfers between levels at the end of each reporting period. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Parapyre Option Obligation (as defined in Note 6) is considered a Level&#160;2 liability based on observable market data for substantially the full term of the liability. The Parapyre Option Obligation is measured each period using a Black-Scholes model to estimate the fair value of the option grant. Changes in the fair value of the Parapyre Option Obligation are recorded as stock-based compensation within Research and development expenses for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employees</div> who provided <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> testing services. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The CVR liability value is based on significant inputs not observable in the market such as estimated cash flows, estimated probabilities of success, and risk-adjusted discount rates, which represent a Level&#160;3 liability. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2022, the Company had no financial liabilities outstanding measured at fair value. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Forward Contract Liability </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Asset Acquisition, the Company entered into a contract for the issuance of 364,887 shares of Series A Preferred Stock as part of the consideration transferred. This forward contract was classified as </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">a liability because the underlying preferred shares were contingently redeemable. Further, the forward contract liability was considered a Level&#160;2 liability based on observable market data for substantially the full term of the liability and was initially measured at its estimated fair value on the transaction date based on the underlying price per share on an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">as-converted</div> basis of the Series A Preferred Stock issued in the PIPE. Subsequent remeasurement of the fair value of the forward contract liability through its settlement date was based on the market price of the Company&#8217;s common stock, which represents the redemption value of the Series A Preferred Stock. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fair value of the forward contract at the transaction date, June&#160;22, 2023, was $106.2&#160;million. The liability was settled with the issuance of the Series A Preferred Stock on July&#160;7, 2023 for $189.7&#160;million. For the three and nine months ended September&#160;30, 2023, $25.4&#160;million and $83.5&#160;million, respectively, was recorded as Other (expense) income in the consolidated statements of operations in connection with the change in fair value of the forward contract liability. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents changes in the forward contract liability for the periods presented (in millions): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:86%"></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Forward<br/> Contract<br/> Liability</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Beginning balance as of June&#160;22, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">106.2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">58.1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Ending balance as of June&#160;30, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">164.3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">25.4</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of Series A Preferred Stock on July&#160;7, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(189.7</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Ending balance as of September&#160;30, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Parapyre Option Obligation </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;22, 2023, in connection with the Asset Acquisition, the Company assumed the Parapyre Option Obligation which provided for an annual equity grant of options for Parapyre Holding LLC (&#8220;Parapyre&#8221;) to purchase 1% of the then outstanding shares of Spyre&#8217;s common stock, on a fully diluted basis, on the last business day of each calendar year during the term of the Paragon Agreement, at the fair market value determined by the board of directors of Spyre. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&#160;29, 2023, the Company amended the Paragon Agreement to amend and restate certain terms of the option grant pertaining to the Parapyre Option Obligation, including but not limited to (i)&#160;defining that the annual equity grant of options is based on the outstanding shares of Aeglea&#8217;s common stock, (ii)&#160;establishing the grant date as the last business day of each applicable calendar year, and (iii)&#160;defining the term of the options granted as ten years. The liability related to the Parapyre Option Obligation will be recorded pursuant to the amended Paragon Agreement. As of September&#160;30, 2023, the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pro-rated</div> estimated fair value of the options to be granted on December&#160;31, 2023, was approximately $3.0&#160;million, of which $0.1&#160;million was recognized as part of the liabilities assumed with the Asset Acquisition on June&#160;22, 2023. For the three and nine months ended September&#160;30, 2023, $2.7&#160;million and $2.9&#160;million, respectively, was recognized as stock compensation expense related to the Parapyre Option Obligation. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">CVR Liability </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Asset Acquisition, a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-transferable</div> contingent value right (a &#8220;CVR&#8221;) was distributed to Aeglea stockholders of record as of the close of business on July&#160;3, 2023, but was not distributed to holders of shares of Common Stock or Series A Preferred Stock issued to the Investors or former stockholders of Spyre in connection with the Transactions. Holders of the CVR will be entitled to receive certain cash payments from proceeds received by the Company for a three-year period, if any, related to the disposition or monetization of Aeglea&#8217;s legacy assets for a period of one year following the closing of the Asset Acquisition. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of the CVR liability was determined using the probability weighted discounted cash flow method to estimate future cash flows associated with the sale of the legacy assets. Analogous to a dividend being declared/approved in one period and paid out in another, the liability was recorded at the date of approval, June&#160;22, 2023, as a common stock dividend, returning capital to the Legacy Stockholders. Changes in fair value of the liability will be recognized as a component of Other income (expense) in the condensed consolidated statement of operations and comprehensive loss in each reporting period. The liability value is based on significant inputs not observable in the market such as estimated cash flows, estimated probabilities of success, and risk-adjusted discount rates, which represent a Level&#160;3 measurement within the fair value hierarchy. The significant inputs used to estimate the fair value of the CVR liability were as follows: </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 67%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td style="width: 29%;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">September&#160;30, 2023</div></div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Estimated cash flow dates</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="display:inline;">11/28/23 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">-</div> 06/22/26</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Estimated probability of success</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="display:inline;">27% - 100%</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-adjusted discount rates</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="display:inline;">7.14% - 7.57%</div></td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The change in fair value between June&#160;30, 2023 and September&#160;30, 2023 was a $1.3&#160;million decrease, and was primarily driven by changes in the likelihood of a successful disposition of pegtarviliase, changes in the expected timing of achievement of certain milestones, updates to expenses and deductions, partially offset by changes in the likelihood of certain milestones related to the favorable Committee for Medicinal Products Human Use (&#8220;CHMP&#8221;) opinion received by Immedica Pharma AB (&#8220;Immedica&#8221;). </div></div></div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents changes in the CVR liability for the periods presented (in thousands): </div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:85%"></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">CVR<br/> Liability</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Beginning balance as of December&#160;31, 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Fair value at CVR issuance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">29,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Changes in the fair value of the CVR liability since issuance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,300</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Ending Balance as of September&#160;30, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">28,200</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">3. Fair Value Measurements </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company measures and reports certain financial instruments as assets and liabilities at fair value on a recurring basis. The following tables sets forth the fair value of the Company&#8217;s financial assets and liabilities at fair value on a recurring basis based on the three-tier fair value hierarchy (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:63%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Financial Assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Money market funds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,250</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,250</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial paper</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">23,641</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">23,641</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">U.S. government securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,230</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,230</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate bonds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,732</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,732</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total financial assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,250</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">31,603</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">46,853</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:64%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Financial Assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Money market funds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,888</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,888</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial paper</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">65,412</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">65,412</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate bonds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12,574</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12,574</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total financial assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,888</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">77,986</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">86,874</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company measures the fair value of money market funds on quoted prices in active markets for identical asset or liabilities. The Level&#160;2 assets include U.S. government agency securities, commercial paper and corporate bonds, and are valued based on quoted prices for similar assets in active markets and inputs other than quoted prices that are derived from observable market data. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company evaluates transfers between levels at the end of each reporting period. There were no transfers between Level&#160;1 and Level&#160;2 during the periods presented. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140168003269024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash Equivalents and Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock', window );">Cash Equivalents and Marketable Securities</a></td>
<td class="text"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4. Cash Equivalents and Marketable Securities </div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following tables summarize the estimated fair value of the Company&#8217;s cash equivalents and marketable securities and the gross unrealized gains and losses (in thousands): </div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:57%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">September&#160;30, 2023</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Amortized<br/> Cost</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Gross<br/> Unrealized<br/> Gains</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Gross<br/> Unrealized<br/> Losses</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Estimated<br/> Fair Value</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash equivalents:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Money market funds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">55,451</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">55,451</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial paper</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16,911</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16,914</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total cash equivalents</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">72,362</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">72,365</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Marketable securities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial paper</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">90,272</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(93</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">90,179</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate bonds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">22,849</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(22</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">22,828</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">U.S. government securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">113,121</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(115</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">113,007</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="16" style="height:12pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">December&#160;31, 2022</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Amortized<br/> Cost</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Gross<br/> Unrealized<br/> Gains</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Gross<br/> Unrealized<br/> Losses</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Estimated<br/> Fair&#160;Value</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash equivalents:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Money market funds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,250</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,250</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial paper</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,021</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,020</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">U.S. government securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,736</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,735</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total cash equivalents</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">26,007</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">26,005</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Marketable securities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial paper</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16,644</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(25</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16,621</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate bonds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,738</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(6</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,732</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">U.S. government securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">495</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">495</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">20,877</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(31</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">20,848</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div></div><div><div style="line-height:normal;background-color:white;display: inline;"></div></div><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> securities in an unrealized loss position for which an allowance for credit losses has not been recorded as of September&#160;30, 2023 and December&#160;31, 2022, aggregated by major security type and length of time in a continuous unrealized loss position: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:56%"></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="22" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">September&#160;30, 2023</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Less Than 12 Months</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">12 Months or<br/> Longer</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Total</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Fair<br/> Value</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Unrealized<br/> Losses</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Fair<br/> Value</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Unrealized<br/> Losses</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Fair<br/> Value</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Unrealized<br/> Losses</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial paper</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">78,820</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(93</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">78,820</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(93</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">U.S. government securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate bonds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18,373</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(22</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18,373</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(22</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">97,193</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(115</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">97,193</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(115</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td colspan="24" style="height:12pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="22" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">December&#160;31, 2022</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Less Than 12 Months</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">12 Months or<br/> Longer</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Total</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Fair<br/> Value</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Unrealized<br/> Losses</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Fair<br/> Value</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Unrealized<br/> Losses</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Fair<br/> Value</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Unrealized<br/> Losses</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial paper</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17,699</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(27</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17,699</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(27</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">U.S. government securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,735</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,735</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate bonds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,732</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(6</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,732</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(6</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">25,166</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(34</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">25,166</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(34</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company evaluated its securities for credit losses and considered the decline in market value to be primarily attributable to current economic and market conditions and not to a credit loss or other factors. Additionally, the Company does not intend to sell the securities in an unrealized loss position and does not expect it will be required to sell the securities before recovery of the unamortized cost basis. As of September&#160;30, 2023 and December&#160;31, 2022, an allowance for credit losses had not been recognized. Given the Company&#8217;s intent and ability to hold such securities until recovery, and the lack of significant change in credit risk of these investments, the Company does not consider these marketable securities to be impaired as of September&#160;30, 2023 and December&#160;31, 2022. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The financial instruments that potentially subject the Company to a concentration of credit risk consist principally of cash deposits. Accounts at each of our three U.S. banking institutions are insured by the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) up to $250,000 per depositor. At September&#160;30, 2023 and December&#160;31, 2022, the Company had $16.9&#160;million and $23.5&#160;million, respectively, of U.S. cash deposits in excess of the FDIC insured limit. Uninsured foreign cash deposits were immaterial for both periods. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There were no realized gains or losses on marketable securities for the three and nine months ended September&#160;30, 2023 and 2022. Interest on marketable securities is included in interest income. Accrued interest receivable on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> debt securities at September&#160;30, 2023 and December&#160;31, 2022 was $0.4&#160;million and $0.1&#160;million, respectively. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the contractual maturities of the Company&#8217;s marketable securities at estimated fair value (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:67%"></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">September&#160;30,<br/> 2023</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">December&#160;31,<br/> 2022</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Due in one year or less</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">102,518</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">20,848</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Due thereafter</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10,489</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">113,007</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">20,848</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company may sell investments at any time for use in current operations even if they have not yet reached maturity. As a result, the Company classifies marketable securities, including securities with maturities beyond twelve months as current <div style="display:inline;">assets</div>. </div><span></span>
</td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">4. Cash Equivalents and Marketable Securities </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following tables summarize the estimated fair value of the Company&#8217;s cash equivalents and marketable securities and the gross unrealized gains and losses (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:57%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amortized<br/> Cost</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross<br/> Unrealized<br/> Gains</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross<br/> Unrealized<br/> Losses</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Estimated<br/> Fair<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash equivalents:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Money market funds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,250</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,250</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial paper</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,021</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,020</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">U.S. government securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,736</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,735</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total cash equivalents</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">26,007</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">26,005</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:56%"></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amortized<br/> Cost</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross<br/> Unrealized<br/> Gains</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross<br/> Unrealized<br/> Losses</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Estimated<br/> Fair&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Marketable securities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial paper</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16,644</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(25</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16,621</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate bonds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,738</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(6</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,732</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">U.S. government securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">495</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">495</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">20,877</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(31</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">20,848</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:57%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amortized<br/> Cost</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross<br/> Unrealized<br/> Gains</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross<br/> Unrealized<br/> Losses</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Estimated<br/> Fair&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash equivalents:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Money market funds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,888</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,888</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total cash equivalents</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,888</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,888</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Marketable securities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial paper</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">65,443</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(34</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">65,412</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate bonds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12,581</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12,574</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">78,024</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(41</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">77,986</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> securities in an unrealized loss position for which an allowance for credit losses has not been recorded as of December&#160;31, 2022 and 2021, aggregated by major security type and length of time in a continuous unrealized loss position: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:46%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="22" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Less Than 12 Months</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">12&#160;Months&#160;or&#160;Longer</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Losses</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Losses</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Losses</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial paper</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17,699</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(27</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17,699</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(27</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">U.S. government securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,735</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,735</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate bonds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,732</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(6</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,732</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(6</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">25,166</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(34</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">25,166</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(34</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:46%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="22" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Less Than 12 Months</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">12&#160;Months&#160;or&#160;Longer</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Losses</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Losses</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Losses</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial paper</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">47,425</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(34</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">47,425</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(34</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate bonds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12,573</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12,573</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">59,998</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(41</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">59,998</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(41</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company evaluated its securities for credit losses and considered the decline in market value to be primarily attributable to current economic and market conditions and not to a credit loss or other factors. Additionally, the Company does not intend to sell the securities in an unrealized loss position and does not expect they will be required to sell the securities before recovery of the unamortized cost basis. As of December&#160;31, 2022 and 2021, an allowance for credit losses had not been recognized. Given the Company&#8217;s intent and ability to hold such securities until recovery, and the lack of significant change in credit risk of these investments, the Company does not consider these marketable securities to be impaired as of December&#160;31, 2022 and 2021. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div></div><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There were no realized gains or losses on marketable securities for the years ended December&#160;31, 2022 and 2021. Interest on marketable securities is included in interest income. Accrued interest receivable on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> debt securities totaled $0.1&#160;million and $0.1&#160;million as of December&#160;31, 2022 and 2021, respectively, and is excluded from the estimate of credit losses. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the contractual maturities of the Company&#8217;s marketable securities at estimated fair value (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:74%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Due in one year or less</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">20,848</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">77,986</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Due in 1 &#8211; 2 years</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">20,848</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">77,986</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company may sell investments at any time for use in current operations even if they have not yet reached maturity. As a result, the <div style="letter-spacing: 0px; top: 0px;;display:inline;">Company </div>classifies marketable securities, including securities with maturities beyond twelve months as current assets. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//320/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140168003388128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">5. Property and Equipment, Net </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Property and equipment, net consist of the following (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:76%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Laboratory equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,257</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,245</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Furniture and office equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">520</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">520</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Computer equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">73</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">54</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Software</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">121</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">139</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Leasehold improvements</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,393</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,393</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Property and equipment, gross</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,364</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,351</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: Accumulated depreciation and amortization</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(4,144</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,802</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Property and equipment, net</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,220</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,549</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depreciation and amortization expense for the years ended December&#160;31, 2022, 2021, and 2020 was $1.4&#160;million, $1.4&#160;million, and $1.0&#160;million, respectively. All of the Company&#8217;s long-lived assets are located in the United States. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140168004078304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_AccruedAndOtherCurrentLiabilitiesTextBlock', window );">Accrued and Other Current Liabilities</a></td>
<td class="text"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5. Accrued and Other Current Liabilities </div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accrued and other current liabilities consist of the following (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:66%"></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">September&#160;30,<br/> 2023</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">December&#160;31,<br/> 2022</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued compensation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,368</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,589</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued contracted research and development costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,669</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,972</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued professional and consulting fees</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,484</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">946</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued other</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">340</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">330</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total accrued and other current liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,861</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12,837</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">6. Accrued and Other Current Liabilities </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accrued and other current liabilities consist of the following (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:74%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued compensation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,589</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,988</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued contracted research and development costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,972</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,995</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued professional and consulting fees</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">946</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,264</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">330</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">783</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total accrued and other current liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12,837</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14,030</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_AccruedAndOtherCurrentLiabilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_AccruedAndOtherCurrentLiabilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140168003321376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_LesseeOperatingAndFinanceLeasesDisclosureTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">7. Leases </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company leases certain office space, laboratory facilities, and equipment. These leases require monthly lease payments that may be subject to annual increases throughout the lease term. Certain of these leases also include renewal options at the election of the Company to renew or extend the lease for an additional <span style="-sec-ix-hidden:hidden95765451"><span style="-sec-ix-hidden:hidden95765453">thre</span>e</span> to five years. These optional periods have not been considered in the determination of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets or lease liabilities associated with these leases as the Company did not consider it reasonably certain it would exercise the options. The Company performed evaluations of its contracts and determined it has both operating and finance leases. Variable lease expense for these leases primarily consists of common area maintenance and other operating costs. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2019, the Company entered into a lease agreement (the &#8220;Las Cimas Lease&#8221;) for its corporate headquarters and laboratory space located in Austin, Texas. The Las Cimas Lease includes approximately 30,000 square feet and commenced on April&#160;30, 2019, with an expiration on April 30, 2028. The Company posted a customary letter of credit in the amount of $1.5&#160;million as security, which is subject to automatic reductions per the terms of the Las Cimas Lease. A tenant allowance of up to $1.0&#160;million was provided by the lessor and fully reimbursed to the Company. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the Company&#8217;s recognition of its operating and finance leases (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:31%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td style="width:50%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Classification</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Assets</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,430</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,806</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><span style="-sec-ix-hidden:hidden95765537">Finan</span><span style="-sec-ix-hidden:hidden95765538">ce</span></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> assets</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">597</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">798</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td colspan="3" style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total leased assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,027</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,604</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Leases</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Current</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Operating lease liabilities</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">625</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">436</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><span style="-sec-ix-hidden:hidden95765544">Fin</span><span style="-sec-ix-hidden:hidden95765545">ance</span></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Accrued and other current liabilities</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">418</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div> operating lease liabilities</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,004</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,608</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><span style="-sec-ix-hidden:hidden95765401"><span style="-sec-ix-hidden:hidden95765511">Finan</span>ce</span></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> liabilities</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td colspan="3" style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,645</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,478</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the weighted-average remaining lease term and discount rates for the Company&#8217;s operating and finance leases: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:83%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Lease term (years)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating leases</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5.3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Finance leases</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Discount rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating leases</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10.6</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10.7</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Finance leases</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10.2</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.7</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the lease costs pertaining to the Company&#8217;s operating leases (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:70%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease cost</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">910</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">991</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,258</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Variable lease cost</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">472</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">519</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">665</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total lease cost</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,382</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,510</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,923</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cash paid for amounts included in the measurement of operating lease liabilities during the years ended December&#160;31, 2022 and 2021 was $0.9&#160;million and $1.1&#160;million, respectively, and was included within net cash used in operating activities in the cash flows. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The maturities of the Company&#8217;s operating and finance lease liabilities as of December&#160;31, 2022 were as follows (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:76%"></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Operating</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Leases</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Finance</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Leases</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,078</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2024</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,103</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2025</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,129</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2026</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,163</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2027</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,198</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Thereafter</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">403</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total lease payments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,074</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Imputed interest</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,445</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,629</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_LesseeOperatingAndFinanceLeasesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee operating and finance leases disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_LesseeOperatingAndFinanceLeasesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140168003386464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">8. Stockholders&#8217; Equity </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is authorized to issue 30,000,000 shares of capital stock of which 20,000,000 shares are designated as common stock and 10,000,000 shares are designated as preferred stock, all with a par value of $0.0001 per share. Each holder of common stock is entitled to one vote for each share of common stock held. The Company&#8217;s common stock is not entitled to preemptive rights, and is not subject to conversion, redemption or sinking fund provisions. Subject to preferences that may apply to any shares of preferred stock outstanding at the time, the holders of common stock are entitled to receive dividends out of funds legally available if the board of directors, in its discretion, determines to issue dividends and then only at the times and in the amounts that the board of directors may determine. As of December&#160;31, 2022 and 2021, no common stock dividends had been declared by the board of directors and there were no shares of preferred stock outstanding. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Registered Direct Offering </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May 2022, the Company issued and sold 430,107 shares of common stock at an offering price of $40.00 per share and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants to purchase up to 694,892 shares of common stock at an offering price of $39.9975 per warrant (representing the price per share of common stock sold in the offering minus the $0.0025 exercise price per warrant) in a registered direct offering pursuant to a shelf registration statement on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-3.</div> The net proceeds to the Company from this offering were approximately $42.9&#160;million, after deducting placement agent fees and offering costs of $2.1&#160;million. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Follow-on</div> Public Offerings </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2019, the Company issued and sold 185,000 shares of common stock at a public offering price of $200.00 per share and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants to purchase up to 160,000 shares of common stock at a public offering price of $199.9975 per warrant in an underwritten public offering pursuant to a shelf registration statement on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-3.</div> This includes the full exercise by the underwriters of their option to purchase up to 45,000 additional shares of common stock. The net proceeds to the Company from this public offering were $64.5&#160;million, after deducting underwriting discounts and commissions of $4.1&#160;million and offering costs of $0.4&#160;million. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2020, the Company issued and sold 617,692 shares of common stock at a public offering price of $118.75 per share and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants to purchase up to 544,413 shares of common stock at a public offering price of $118.7475 per warrant in an underwritten public offering pursuant to a shelf registration statement on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-3.</div> This includes the full exercise by the underwriters of their option to purchase up to 151,578 additional shares of common stock. The net proceeds to the Company from this public offering were $129.0&#160;million, after deducting underwriting discounts and commissions of $8.2&#160;million and offering costs of $0.8&#160;million. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Funded</div> Warrants </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2019, April 2020 and May 2022, the Company issued <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants to purchase the Company&#8217;s common stock in underwritten public offerings at the offering price of the common stock, less the $0.0025 per share exercise price of each warrant. The warrants were recorded as a component of stockholders&#8217; equity within additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital and have no expiration date. Per the terms of the warrant agreements, the outstanding warrants to purchase shares of common stock may not be exercised if the holder&#8217;s ownership of the Company&#8217;s common stock would exceed 4.99% (&#8220;Maximum Ownership Percentage&#8221;) or 9.99% for certain holders. By written notice to the Company, each holder may increase or decrease the Maximum Ownership Percentage to any other percentage (not in excess of 19.99% for the majority of such warrants). The revised Maximum Ownership Percentage would be effective 61 days after the notice is received by the Company. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2022, the following <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants to purchase common stock were issued and outstanding: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:46%"></td>
<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Issue Date</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Expiration&#160;Date</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Exercise&#160;Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of&#160;Warrants</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Outstanding</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><span style="-sec-ix-hidden:hidden95765421">February 2019</span></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">None</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.0025</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">150,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><span style="-sec-ix-hidden:hidden95765422">April 2020</span></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">None</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.0025</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">474,413</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><span style="-sec-ix-hidden:hidden95765423">May 2022</span></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">None</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.0025</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">531,250</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,155,663</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">At-The-Market</div></div> Offering </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2020, the Company entered into a new sales agreement with JonesTrading Institutional Services LLC, as sales agent, to issue and sell shares of its common stock for an aggregate offering price of $60.0&#160;million under an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">at-the-market</div></div> (&#8220;2020 ATM&#8221;) offering program. In the fourth quarter of 2020, the Company issued and sold 129,803 shares of common stock under the 2020 ATM for gross proceeds of $25.3&#160;million, resulting in net proceeds of $24.6&#160;million, after deducting underwriting discounts, commissions, and offering costs. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140168003216864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 22, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">4. Related Party Transactions </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Paragon and Parapyre Holding LLC each beneficially owns less than 5% of the Company&#8217;s capital stock through their respective holdings of Common Stock and Series A Preferred Stock of the Company. Fairmount Funds Management LLC (&#8220;Fairmount&#8221;) beneficially owns more than 5% of our capital stock, has two seats on the Company&#8217;s board of directors and beneficially owns more than 5% of Paragon, which is a joint venture between Fairmount and Fair Journey Biologics. Fairmount has appointed Paragon&#8217;s board of directors and has the contractual right to approve the appointment of any executive officers. Parapyre is an entity formed by Paragon as a vehicle to hold equity in Spyre in order to share profits with certain employees of Paragon. </div><span></span>
</td>
<td class="text"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6. Related Party Transactions </div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Paragon and Parapyre Holding LLC each beneficially owns less than 5% of the Company&#8217;s capital stock through their respective holdings of the Company&#8217;s common stock and Series A Preferred Stock. Fairmount Funds Management LLC (&#8220;Fairmount&#8221;) beneficially owns more than 5% of the Company&#8217;s capital stock, has two seats on the Board and beneficially owns more than 5% of Paragon, which is a joint venture between Fairmount and Fair Journey Biologics. Fairmount appointed Paragon&#8217;s board of directors and has the contractual right to approve the appointment of any executive officers. Parapyre is an entity formed by Paragon as a vehicle to hold equity in Spyre in order to share profits with certain employees of Paragon. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Asset Acquisition, the Company assumed the rights and obligations of Spyre under the Paragon Agreement. Under the Paragon Agreement, Spyre is obligated to compensate Paragon for its services performed under each research program based on the actual costs incurred with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mark-up</div> costs pursuant to the terms of the Paragon Agreement. As of the date of the Asset Acquisition, Spyre had incurred total expenses of $19.0&#160;million under the Paragon Agreement since inception, inclusive of a $3.0&#160;million research initiation fee that was due upon signing of the Paragon Agreement and $16.0&#160;million of reimbursable expenses under the Paragon Agreement for historical costs owed to Paragon. As of the acquisition date, $19.0&#160;million was unpaid and was assumed by the Company through the Asset Acquisition. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the three and nine months ended September&#160;30, 2023, the Company recognized expenses related to services provided by Paragon subsequent to the Asset Acquisition totaling $19.4&#160;million and $20.8&#160;million, respectively, which were recorded as Research and development expenses in the consolidated statements of operations. As of September&#160;30, 2023, $16.8&#160;million was unpaid and was included in Related party payable on the Company&#8217;s consolidated balance sheets. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the three and nine months ended September&#160;30, 2023, the Company made payments totaling $20.0&#160;million to Paragon. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July 2023, the Company exercised its option for the SPY001 program with the remaining three options for the SPY002, SPY003, SPY004 programs remaining outstanding. Following the execution of the license agreement with respect to the SPY001 program (the &#8220;SPY001 License Agreement&#8221;), the Company will be obligated to pay Paragon up to $22.0&#160;million upon the achievement of specific development and clinical milestones for the first product under the SPY001 License Agreement that achieves such specified milestones. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is the summary of expenses related to the Paragon Agreement, which were ultimately settled in cash (in millions): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:52%"></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Three Months<br/> Ended<br/> September&#160;30,</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Nine Months<br/> Ended<br/> September&#160;30,</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">2023</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">2022</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">2023</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">2022</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Financial&#160;Statement&#160;Line&#160;Item</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Reimbursable costs under the Paragon Agreement</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16.7</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17.9</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Research&#160;and&#160;development</td></tr></table><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Parapyre Option Obligation </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Paragon Agreement provided for an annual equity grant of options to purchase 1% of the then outstanding shares of Spyre&#8217;s common stock, on a fully diluted basis, on the last business day of each calendar year, at the fair market value determined by the board of directors of Spyre (the &#8220;Parapyre Option Obligation&#8221;). </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Asset Acquisition, the Company assumed the rights and obligations of Spyre under the Paragon Agreement, including the Parapyre Option Obligation. As a result, the Parapyre Option Obligation shall continue and Parapyre shall be entitled to receive the equivalent shares of the Company with the same terms. On September&#160;29, 2023, the Company amended the Paragon Agreement to amend and restate certain terms of the option grant pertaining to the Parapyre Option Obligation, including but not limited to (i)&#160;defining that the annual equity grant of options is based on the outstanding shares of Aeglea&#8217;s common stock, (ii)&#160;establishing the grant date as the last business day of each applicable calendar year, and (iii)&#160;defining the term of the options granted as ten years. See Notes 3 and 10 for disclosures related to the Parapyre Option Obligation. For the three and nine months ended September&#160;30, 2023, $2.7&#160;million and $2.9&#160;million, respectively, was recognized as stock compensation expense related to the Parapyre Option Obligation. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is the summary of Related party accounts payable (in millions): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:67%"></td>
<td style="vertical-align:bottom;width:12%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:12%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">September&#160;30,<br/> 2023</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">December&#160;31,<br/> 2022</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Reimbursable costs under the Paragon Agreement</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16.8</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Parapyre Option Obligation liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total related party accounts payable</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">19.8</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140168004078304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Asset Acquisition<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 22, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionTextBlock', window );">Asset Acquisition</a></td>
<td class="text"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">3. Parapyre Option Obligation </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;22, 2023, in connection with the Asset Acquisition, the Company assumed the Parapyre Option Obligation which provided for an annual equity grant of options for Parapyre to purchase 1% of the then outstanding shares of Spyre&#8217;s common stock, on a fully diluted basis, on the last business day of each calendar year during the term of the Paragon Agreement, at the fair market value determined by the board of directors of Spyre. As a result of the Asset Acquisition the Parapyre Option Obligation shall continue and Parapyre shall be entitled to receive the equivalent shares of the Company with the same terms. The Parapyre Option Obligation is considered a Level&#160;2 liability based on observable market data for substantially the full term of the liabilities. The Parapyre Option Obligation is measured each period using a Black-Scholes model to estimate the fair value of the option grant. Changes in the fair value of the Parapyre Option Obligation are recorded as stock-based compensation within Research and development expenses for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employees</div> who provided <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> testing services within Research and development expenses. As of June&#160;22, 2023, the estimated liability of the Parapyre Option Obligation was $0.1&#160;million and was included in accrued liabilities. </div><span></span>
</td>
<td class="text"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7. Asset Acquisition </div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;22, 2023, the Company acquired Spyre pursuant to the Acquisition Agreement, by and among the Company, Aspen Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (&#8220;First Merger Sub&#8221;), Sequoia Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of the Company (&#8220;Second Merger Sub&#8221;), and Spyre. Pursuant to the Acquisition Agreement, First Merger Sub merged with and into Spyre, pursuant to which Spyre was the surviving corporation and became a wholly owned subsidiary of the Company (the &#8220;First Merger&#8221;). Immediately following the First Merger, Spyre merged with and into Second Merger Sub, pursuant to which Second Merger Sub became the surviving entity. Spyre was a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> stage biotechnology company that was incorporated on April&#160;28, 2023 under the direction of Peter Harwin, a Managing Member of Fairmount, for the purpose of holding rights to certain intellectual property being developed by Paragon. Fairmount is a founder of Paragon. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company completed the Asset Acquisition of Spyre, in accordance with the terms of the Acquisition Agreement. Under the terms of the Acquisition Agreement, the Company issued 517,809 shares of common stock and 364,887 shares of Series A Preferred Stock to former Spyre security holders. In addition, outstanding and unexercised stock options to purchase 2,734 shares of common stock were assumed from the Amended and Restated Spyre 2023 Equity Incentive Plan. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the acquisition date, the Company recorded forward contracts to represent the obligation to issue shares of the Company&#8217;s common stock and shares of Series A Preferred Stock, respectively. The forward contract related to the common stock was recorded as Additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital as the instrument is indexed to the Company&#8217;s common stock. The forward contract related to the Series A Preferred Stock was recorded as a liability, as the underlying stock has a cash redemption feature. On July&#160;7, 2023, both the shares of common stock and Series A Preferred Stock were issued and the forward contract liability associated with the Series A Preferred Stock was settled accordingly. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company concluded that the arrangement meets the definition of an asset acquisition rather than a business combination, as substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset, Spyre&#8217;s option (the &#8220;Option&#8221;) to exclusively license IPR&amp;D. The Company determined that the Option to license IPR&amp;D was a single asset as the Company&#8217;s strategy relies on developing the entire portfolio of individual treatments to create combination treatments that simultaneously address different mechanisms of irritable bowel disease with a single treatment. The Company also determined that the pipeline candidates within the portfolio are similar in nature and risk profile. In addition, the Company did not obtain any substantive processes, assembled workforce, or employees capable of producing outputs in connection with the Asset Acquisition. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company determined that the cost to acquire the asset was $113.2&#160;million which was recorded as acquired IPR&amp;D. The fair value of the consideration issued consisted of the 364,887 shares of Series A Preferred Stock (14,595,480 shares of common stock on an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">as-converted</div> basis) and 517,809 shares of common stock, valued at $291.08 per share and $7.277 per share, respectively. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Asset Acquisition Costs are shown on the following table (in millions): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:87%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">June&#160;22,<br/> 2023</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Consideration transferred in Series A Preferred Stock and common stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">110.0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Transaction costs incurred by Aeglea</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total cost to acquire asset</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">113.2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The allocation of the purchase price to net assets acquired is as a follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:87%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">June&#160;22,<br/> 2023</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Acquired <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">130.2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash acquired</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Assumed liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(20.0</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total cost to acquire asset</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">113.2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480123/805-50-15-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140168003396224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Paragon Agreement<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_CollaborativeArrangementAbstract', window );"><strong>Collaborative Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_OptionAgreementTextBlock', window );">Paragon Agreement</a></td>
<td class="text"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">8. Paragon Agreement </div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May 2023, Spyre entered into the Paragon Agreement with Paragon and Parapyre. In consideration for the Option granted under the Paragon Agreement, Spyre was obligated to pay Paragon an upfront cash amount of $3.0&#160;million in research initiation fees. In addition, Spyre was obligated to compensate Paragon on a quarterly basis for its services performed under each research program based on the actual costs incurred with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mark-up</div> costs pursuant to the terms of the Paragon Agreement. As of the date of the Asset Acquisition, Spyre had incurred total expenses of $19.0&#160;million under the Paragon Agreement since inception, which included the $3.0&#160;million research initiation fee and $16.0&#160;million of historical reimbursable expenses owed to Paragon. As of June&#160;22, 2023, $19.0&#160;million was unpaid and was assumed by the Company through the Asset Acquisition. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Furthermore, the Paragon Agreement provided for an annual equity grant of options to purchase 1% of the then outstanding shares of Spyre&#8217;s common stock, on a fully diluted basis, on the last business day of each calendar year, during the term of the Paragon Agreement, at the fair market value determined by the board of directors of Spyre. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result of the Asset Acquisition, the Company assumed the rights and obligations of Spyre under the Paragon Agreement, including the Parapyre Option Obligation. Pursuant to the Paragon Agreement, on a research <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">program-by-research</div></div> program basis following the finalization of the research plan for each respective research program, the Company is required to pay Paragon a nonrefundable fee in cash of $0.8&#160;million. For the three and nine months ended September&#160;30, 2023, the Company incurred $19.4&#160;million and $20.8&#160;million, respectively, in costs reimbursable to Paragon, which were recorded as Research and development expenses in the consolidated statements of operations. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the three and nine months ended September&#160;30, 2023, the Company made payments totaling $20.0&#160;million to Paragon. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&#160;12, 2023, the Company exercised its Option available under the Paragon Agreement with respect to the SPY001 research program and expects to enter into a SPY001 license agreement (the &#8220;SPY001 License Agreement&#8221;). The Company&#8217;s Option available under the Paragon Agreement with respect to the SPY002, SPY003 and SPY004 programs remains unexercised. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the execution of the SPY001 License Agreement, the Company will be obligated to pay Paragon up to $22.0&#160;million upon the achievement of specific development and clinical milestones for the first product under the SPY001 License Agreement that achieves such specified milestones. Upon execution of the SPY001 License Agreement, the Company expects to pay Paragon a $1.5&#160;million fee for nomination of a development candidate, and the Company expects to be obligated to make a further milestone payment of $2.5&#160;million upon the first dosing of a human patient in a Phase 1 trial. Subject to the execution of the Option with respect to the SPY002, SPY003 or SPY004 research programs, the Company expects to be obligated to make similar payments upon and following the execution of license agreements with respect to the these research programs, respectively. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_CollaborativeArrangementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_CollaborativeArrangementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_OptionAgreementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Option agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_OptionAgreementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140168003346464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Series A Non-Voting Convertible Preferred Stock<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockTextBlock', window );">Series A Non-Voting Convertible Preferred Stock</a></td>
<td class="text"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">9. Series A <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Voting</div> Convertible Preferred Stock </div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;22, 2023, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of the Series A Preferred Stock with the Secretary of State of the State of Delaware (the &#8220;Certificate of Designation&#8221;) in connection with the Asset Acquisition and the PIPE. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Certificate of Designation, holders of Series A Preferred Stock are entitled to receive dividends on shares of Series A Preferred Stock equal to, on an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">as-if-converted-to-common-stock</div></div></div></div> basis, and in the same form as, dividends actually paid on shares of the Company&#8217;s common stock. Except as provided in the Certificate of Designation or as otherwise required by law, the Series A Preferred Stock does not have voting rights. However, as long as any shares of Series A Preferred Stock are outstanding, the Company will not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series A Preferred Stock: (a)&#160;alter or change adversely the powers, preferences or rights given to the Series A Preferred Stock, or alter or amend the Certificate of Designation, amend or repeal any provision of, or add any provision to, the Company&#8217;s Certificate of Incorporation or its Bylaws, or file any articles of amendment, certificate of designations, preferences, limitations and relative rights of any series of Preferred Stock, if such action would adversely alter or change the preferences, rights, privileges or powers of, or restrictions provided for the benefit of the Series A Preferred Stock, regardless of whether any of the foregoing actions will be by means of amendment to the Certificate of Incorporation or by merger, consolidation, recapitalization, reclassification, conversion or otherwise, (b)&#160;issue further shares of Series A Preferred Stock or increase or decrease (other than by conversion) the number of authorized shares of Series A Preferred Stock, (c)&#160;prior to the stockholder approval of the conversion of the Series A Preferred Stock into shares of Common Stock in accordance with Nasdaq Stock </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Market Rules (the &#8220;Conversion Proposal&#8221;) or at any time while at least 30% of the originally issued Series A Preferred Stock remains issued and outstanding, consummate (x)&#160;any Fundamental Transaction (as defined in the Certificate of Designation) or (y)&#160;any merger or consolidation of the Company with or into another entity or any stock sale to, or other business combination in which our stockholders immediately before such transaction do not hold at least a majority of our capital stock immediately after such transaction or (d)&#160;enter into any agreement with respect to any of the foregoing. The Series A Preferred Stock does not have a preference upon any liquidation, dissolution or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">winding-up</div> of the Company. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has agreed to hold a stockholders&#8217; meeting to submit the following matters to its stockholders for their consideration: (i)&#160;the approval of the Conversion Proposal, and (ii)&#160;if deemed necessary or appropriate by the Company or as otherwise required by law or contract, the approval of an amendment to the Certificate of Incorporation to authorize sufficient shares of common stock for the conversion of the Series A Preferred Stock issued pursuant to the Acquisition Agreement. In connection with these matters, the Company filed with the SEC a definitive proxy statement and other relevant materials. The stockholder meeting has not occurred as of September&#160;30, 2023. The Series A Preferred Stock is recorded outside of stockholders&#8217; (deficit) equity because, if conversion to common stock is not approved by the stockholders, the Series A Preferred Stock will be redeemable at the option of the holders for cash equal to the closing price of the common stock per share of common stock underlying the Series A Preferred Stock, on the last trading day prior to the holder&#8217;s redemption request. As of September&#160;30, 2023, the redemption value of the Company&#8217;s outstanding Series A Preferred Stock was $532.3&#160;million based on the closing stock price of the Company&#8217;s common stock on September&#160;30, 2023 of $12.25 per share. The Company has determined that the conversion and redemption features of the Series A Preferred Stock do not require bifurcation as derivatives. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following stockholder approval of the Conversion Proposal, each share of Series A Preferred Stock will automatically convert into 40 shares of common stock, subject to certain limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series A Preferred Stock into shares of common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (established by the holder between 0% and 19.99%) of the total number of shares of common stock issued and outstanding immediately after giving effect to such conversion. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;26, 2023, the Company completed a private placement of 721,452 shares of Series A Preferred Stock in exchange for gross proceeds of $210.0&#160;million, or net proceeds of $197.3&#160;million, after deducting placement agent and other offering costs. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&#160;7, 2023, the Company issued 364,887 shares of Series A Preferred Stock as part of its consideration transferred in connection with the Asset Acquisition that closed on June&#160;22, 2023 which settled the related forward contract liability. For additional information, see Note 3. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&#160;27, 2023, the Company filed a definitive proxy statement with the SEC to solicit approval of the Conversion Proposal, among other matters, at a special meeting of stockholders to be held on November&#160;21, 2023. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140168006419392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liabilities, Convertible Preferred Stock and Stockholders' (Deficit) Equity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Liabilities, Convertible Preferred Stock and Stockholders' (Deficit) Equity</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">10. Liabilities, Convertible Preferred Stock and Stockholders&#8217; (Deficit) Equity </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Registered Direct Offering </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May 2022, the Company issued and sold 430,107 shares of common stock at an offering price of $40.00 per share and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants to purchase up to 694,892 shares of common stock at an offering price of $39.9975 per warrant (representing the price per share of common stock sold in the offering minus the $0.0025 exercise price per warrant) in a registered direct offering pursuant to a shelf registration statement on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-3.</div> The net proceeds to the Company from this offering were approximately $42.9&#160;million, after deducting placement agent fees and offering costs of $2.1&#160;million. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Funded</div> Warrants </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2019, April 2020 and May 2022, the Company issued <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants to purchase the Company&#8217;s common stock in underwritten public offerings at the offering price of the common stock, less the $0.0025 per share exercise price of each warrant. The warrants were recorded as a component of stockholders&#8217; (deficit) equity within additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital and have no expiration date. Per the terms of the warrant agreements, the outstanding warrants to purchase shares of common stock may not be exercised if the holder&#8217;s ownership of the Company&#8217;s common stock would exceed 4.99% (&#8220;Maximum Ownership Percentage&#8221;), or 9.99% for certain holders. By written notice to the Company, each holder may increase or decrease the Maximum Ownership Percentage to any other percentage (not in excess of 19.99% for the majority of such warrants). The revised Maximum Ownership Percentage would be effective 61 days after the notice is received by the Company. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of September&#160;30, 2023, the following <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants for common stock were issued and outstanding: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:48%"></td>
<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">Issue Date</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Expiration&#160;Date</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Exercise&#160;Price</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Number&#160;of&#160;Warrants<br/> Outstanding</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">February&#160;8, 2019</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">None</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.0025</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">April&#160;30, 2020</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">None</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.0025</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">May&#160;20, 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">None</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.0025</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">250,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">250,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stock-Based Compensation </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2016 Equity Incentive Plan </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2016 Equity Incentive Plan (&#8220;2016 Plan&#8221;) provides for an automatic increase in the number of shares reserved for issuance thereunder on January&#160;<div style="display:inline;">1</div> of each year for the remaining term of the plan (through 2028) equal to (a) 4.0% of the number of issued and outstanding shares of common stock on December&#160;31 of the immediately preceding year, or (b)&#160;a lesser amount as approved by the Board each year. As a result of this provision, on January&#160;1, 2023 and January&#160;1, 2022, an additional 104,560 and 78,968 shares, respectively, became available for issuance under the 2016 Plan. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July 2020, the Company granted <div style="display:inline;">9,128</div> restricted stock units (&#8220;RSUs&#8221;) to certain employees, with vesting terms subject to regulatory, commercial, and clinical milestones, in addition to a service condition. As of September&#160;30, 2023, <div style="display:inline;">none</div> of these RSUs had vested and all RSUs were forfeited since the performance milestones were not met within the required time frame. <div style="display:inline;">No</div> stock-based compensation expense was recognized on these awards. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;22, 2023, concurrent with the closing of the Asset Acquisition, the Board approved an amendment of the 2016 Plan to eliminate the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">per-participant</div> annual award limits originally intended to comply with the qualified performance-based compensation exception set forth in Section&#160;162(m) of the Internal Revenue Code, in light of the repeal of such exception pursuant to the Tax Cuts and Jobs Act of 2017. In addition, the Company approved <div style="display:inline;">2,720,033</div> options contingent on stockholder approval to certain members of the Board, legacy Aeglea employees and consultants under the 2016 Plan. These awards are in excess of the shares available for issuance under the 2016 Plan and require stockholder approval before being granted. Accordingly, <div style="display:inline;">no</div> expense has been recognized on these contingent awards since they are contingent on stockholder approval. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of September&#160;30, 2023, the 2016 Plan had <div style="display:inline;">293,497</div> shares available for future issuance. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2018 Equity Inducement Plan </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the nine months ended September&#160;30, 2023, the Board approved an increase of <div style="display:inline;">2,800,000</div> in the number of shares reserved for issuance to the 2018 Equity Inducement Plan and granted <div style="display:inline;">3,583,880</div> inducement awards to new hires. The grant-date fair value of these inducement awards will be recognized as expense on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pro-rata</div> basis over the vesting period. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The awards have an exercise price equal to the grant date closing price of the Company&#8217;s common stock, vest ratably over <div style="display:inline;">four years</div>, and have a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="display:inline;">ten-year</div></div> exercise period from the grant date. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Spyre 2023 Equity Incentive Plan </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;22, 2023, in connection with the Asset Acquisition, the Company assumed the Amended and Restated Spyre 2023 Equity Incentive Plan (the &#8220;Spyre Equity Plan&#8221;) and its outstanding and unexercised stock options, which were converted to options to purchase <div style="display:inline;">2,734</div> shares of Aeglea common stock. The acquisition-date fair value of these grants will be recognized as an expense on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pro-rata</div> basis over the vesting period. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Parapyre Option Obligation </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;22, 2023, in connection with the Asset Acquisition, the Company assumed the Parapyre Option Obligation which provided for an annual equity grant of options to purchase 1% of the then outstanding shares of Spyre&#8217;s common stock, on a fully diluted basis, on the last business day of each calendar year during the term of the Paragon Agreement, at the fair market value determined by the board of directors of Spyre. As a result of the Asset Acquisition the Parapyre Option Obligation shall continue and Parapyre shall be entitled to receive the equivalent shares of the Company with the same terms. As of September&#160;30, 2023, the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pro-rated</div> estimated fair value of the options to be granted on December&#160;31, 2023, was approximately $3.0&#160;million, of which $0.1&#160;million was recognized as part of the liabilities assumed with the Asset Acquisition. For the three and nine months ended September&#160;30, 2023, $2.7&#160;million and $2.9&#160;million, respectively, was recognized as stock compensation expense related to the Parapyre Option Obligation. As of September&#160;30, 2023, the unamortized expense related to the Parapyre Option Obligation was $2.1&#160;million. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the Company&#8217;s stock awards granted under all plans for each of the periods indicated: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:34%"></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Three Months Ended September&#160;30,</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Nine Months Ended September&#160;30,</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">2023</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">2022</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">2023</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">2022</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Grants</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Weighted<br/> Average<br/> Grant<br/> Date Fair<br/> Value</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Grants</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Weighted<br/> Average<br/> Grant<br/> Date Fair<br/> Value</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Grants</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Weighted<br/> Average<br/> Grant<br/> Date Fair<br/> Value</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Grants</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Weighted<br/> Average<br/> Grant<br/> Date Fair<br/> Value</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock options</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,044,667</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14.50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">50,806</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16.75</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,867,366</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9.65</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">153,686</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">52.50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2016 Employee Stock Purchase Plan </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Company&#8217;s 2016 Employee Stock Purchase Plan (&#8220;2016 ESPP&#8221;), the Company issued and sold 2,496 shares for aggregate cash proceeds of less than $0.1&#160;million during the nine months ended September&#160;30, 2023. There were 6,073 shares issued and sold under the 2016 ESPP for aggregate cash proceeds of $0.2&#160;million during the nine months ended September&#160;30, 2022. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div></div><div><div style="line-height:normal;background-color:white;display: inline;"></div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stock-based Compensation Expense </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Total stock-based compensation expense related to all plans was as follows (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:64%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Three&#160;Months&#160;Ended<br/> September&#160;30,</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Nine Months Ended<br/> September&#160;30,</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">2023</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">2022</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">2023</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">2022</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development <div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">(1)</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,965</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">639</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,136</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,031</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">General and administrative</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,820</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">926</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,269</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,653</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total stock-based compensation expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,785</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,565</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,405</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,684</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">(1)</div>&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">For the three and nine months ended September&#160;30, 2023, $2.7&#160;million and $2.9&#160;million, respectively, was recognized as stock compensation expense related to the Parapyre Option Obligation. There were no such expenses for the three and nine months ended September&#160;30, 2022. </div></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the weighted-average Black-Scholes option pricing model assumptions used to estimate the fair value of stock options granted under the Company&#8217;s 2016 Plan, and the shares purchasable under the 2016 ESPP during the periods presented: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:67%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Three&#160;Months&#160;Ended<br/> September&#160;30,</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Nine&#160;Months&#160;Ended<br/> September&#160;30,</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">2023</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">2022</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">2023</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">2022</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2016 Plan</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected term (in years)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.08</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.02</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.04</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5.96</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected volatility</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">101</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">85</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">111</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">83</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Risk-free interest</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.28</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.16</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.07</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.43</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Dividend yield</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2016 ESPP</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected term (in years)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.49</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.49</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected volatility</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">222</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">95</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">181</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">84</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Risk-free interest</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5.29</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.26</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.99</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.95</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Dividend yield</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><span></span>
</td>
<td class="text"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">10. Stock-Based Compensation </div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">2015 Equity Incentive Plan </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2015, the Company adopted the 2015 Equity Incentive Plan (&#8220;2015 Plan&#8221;), administered by the board of directors, and provides for the Company to sell or issue common stock or restricted common stock, or to grant incentive stock options or nonqualified stock options for the purchase of common stock, to employees, members of the board of directors and consultants of the Company. Under the terms of the 2015 Plan, the exercise prices, vesting and other restrictions may be determined at the discretion of the board of directors, or their committee if so delegated, except that the exercise price per share of stock options may not be less than 100% of the fair market value of the share of common stock on the date of grant, the term of stock options may not be greater than ten years for all grants, and for grantees holding more than 10% of the total combined voting power of all classes of stock, the term may not be greater than five years. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company granted options under the 2015 Plan until April 2016 when it was terminated as to future awards, although it continues to govern the terms of options that remain outstanding under the 2015 Plan. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2022, a total of 3,785 shares of common stock are subject to options outstanding under the 2015 Plan and will become available under the 2016 Equity Incentive Plan (&#8220;2016 Plan&#8221;) to the extent the options are forfeited or lapse unexercised. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">2016 Equity Incentive Plan </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2016 Plan became effective in April 2016 and serves as the successor to the 2015 Plan. Under the 2016 Plan, the Company may grant stock options, stock appreciation rights, restricted stock awards, restricted stock units, performance awards, and stock bonuses. The 2016 Plan provides for an initial reserve of 44,000 shares of common stock, plus 20,394 shares of common stock remaining under the 2015 Plan, and any share awards that subsequently are forfeited or lapse unexercised under the 2015 Plan. The shares reserved exclude shares of common stock reserved for issuance under the 2015 Plan. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2018, the 2016 plan was amended to increase the number of shares of common stock reserved for issuance thereunder by 70,384 shares, extend the term of the 2016 Plan through August 7, 2028, and provide for an automatic increase in the number of shares reserved for issuance thereunder on January&#160;1 of each year for the remaining term of the plan equal to (a) 4.0% of the number of issued and outstanding shares of common stock on December&#160;31 of the immediately preceding year, or (b)&#160;a lesser amount as approved by the board each year. As a result of the operation of each of these provisions, on January&#160;1, 2022, 2021, and 2020, an additional 78,968, 76,734, and 46,535 shares, respectively, became available for issuance under the 2016 Plan. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2022, the total number of shares reserved for issuance under the 2016 Plan was 432,725, of which 319,122 shares were subject to outstanding option awards and restricted unit awards. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">2018 Equity Inducement Plan </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2018, the board of directors approved and adopted the 2018 Equity Inducement Plan (&#8220;2018 Plan&#8221;), which became effective on the same date. The board of directors approved an initial reserve of 44,000 shares of common stock to be used exclusively for individuals who were not previously employees or directors, or following a bona fide period of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employment,</div> as an inducement material to the individual entering into employment with the Company. Nonqualified stock options or restricted stock units may be granted under the 2018 Plan at the discretion of the Compensation Committee or the board of directors. The Company did not seek stockholder approval of the 2018 Plan pursuant to Nasdaq Rule 5635(c)(4). </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2022, the total number of shares reserved for issuance under the 2018 Plan was 44,000, of which 12,440 shares were subject to outstanding option awards. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the 2016 Plan and 2018 Plan, the Company may grant stock-based awards with service conditions (&#8220;service-based&#8221; awards), performance conditions (&#8220;performance-based&#8221; awards), and market conditions (&#8220;market-based&#8221; awards). Service-based awards granted under the 2018 Plan, 2016 Plan, and 2015 Plan generally vest over four years and expire after ten years, although awards have been granted with vesting terms less than four years. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">CEO Inducement Grant </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November 2022, the Company granted 75,393 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-qualified</div> stock options to the new Chief Executive Officer in a stand alone inducement grant. The first 25% of these options vest on the one year anniversary of the grant, and the remaining 75% vest in equal amounts over 48 months following the one year anniversary date and are exercisable for a term of ten years. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes employee and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> stock option activity for the year ended December&#160;31, 2022: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:55%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Issuable</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Under</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Options</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Average</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Exercise<br/> Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Average</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Remaining</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Contractual</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Term</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Aggregate</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Intrinsic</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(in years)</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(in&#160;thousands)</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Outstanding as of December&#160;31, 2021</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">264,303</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">189.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7.90</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">328</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Granted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">235,199</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">45.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercised</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Forfeited</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(94,421</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">153.50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Outstanding as of December&#160;31, 2022</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">405,081</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">113.75</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.72</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Options vested and expected to vest as of December&#160;31, 2022</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">397,772</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">112.50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.78</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Options exercisable as of December&#160;31, 2022</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">163,450</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">171.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.93</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aggregate intrinsic value of options outstanding, exercisable, vested and expected to vest were calculated as the difference between the exercise price of the options and the fair value of the Company&#8217;s common stock as of the reporting date. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the years ended December&#160;31, 2022, 2021, and 2020, the weighted-average grant date fair value of options granted was $45.00, $124.00, and $117.00, respectively. No options were exercised in the year ended December&#160;31, 2022. The total intrinsic value of options exercised during the years ended December&#160;31, 2021, and 2020 was $0.7&#160;million and $0.4&#160;million, respectively. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There were no stock options issued to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employees</div> during the years ended December&#160;31, 2022, 2021, and 2020. For the year ended December&#160;31, 2020, 66 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> stock options vested in the period. For the years ended December&#160;31, 2022 and 2021, no <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> stock options vested in the period. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">2016 Employee Stock Purchase Plan </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2016 Employee Stock Purchase Plan (&#8220;2016 ESPP&#8221;) became effective in April 2016. A total of 6,600 shares of common stock were reserved for issuance under the 2016 ESPP. Eligible employees may purchase shares of common stock under the 2016 ESPP at 85% of the lower of the fair market value of the Company&#8217;s common stock as of the first or the last day of each offering period. Employees are limited to contributing 15% of the employee&#8217;s eligible compensation and may not purchase more than $25,000 of stock during any calendar year. The 2016 ESPP will terminate ten years from the first purchase date under the plan, unless terminated earlier by the board of directors. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2018, the 2016 ESPP was amended to provide for an automatic annual increase in the number of shares reserved for issuance thereunder on January&#160;1 of each year for the remaining term of the year equal to (a) 1.0% of the number of issued and outstanding shares of common stock on December&#160;31 of the immediately preceding year, or (b)&#160;a lesser amount as approved by the board of directors each year. As a result of the operation of this provision, on January&#160;1, 2022, 2021 and 2020, an additional 19,742, 19,183, and 11,633 shares, respectively, became available for issuance under the 2016 ESPP. As of December&#160;31, 2022, the reserve remaining and available for future issuance under the 2016 ESPP was 48,665 shares. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2023, the 2016 ESPP was amended to increase the maximum shares purchased during any one period from 80 shares to 400 shares or a lesser amount determined by the board of directors. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Restricted Common Stock Units </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company granted 9,128 restricted stock units (&#8220;RSUs&#8221;) during the year ended December&#160;31, 2020 to certain employees with regulatory, commercial, and clinical milestones in addition to a service condition. There were no RSUs granted for the years ended December&#160;31, 2022 and 2021. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2022, the performance conditions of the granted RSUs were not probable of being achieved. If and when the performance milestones are deemed probable of being achieved within the required time frame, the Company may recognize up to $1.2&#160;million of stock-based compensation for the remaining unvested RSUs as of December&#160;31, 2022. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes employee restricted stock activity for the year ended December&#160;31, 2022: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:71%"></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average&#160;Grant<br/> Date&#160;Fair&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Unvested restricted stock units as of December&#160;31, 2021</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,600</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">203.25</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Granted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Vested</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Forfeited</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,940</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">203.25</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Unvested restricted stock units as of December&#160;31, 2022</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,660</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">203.25</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There were no RSUs granted to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employees</div> during the years ended December&#160;31, 2022, 2021, and 2020. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Stock-Based Compensation Expense </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Total stock-based compensation expense recognized from the Company&#8217;s equity incentive plans, 2018 Plan, and the 2016 ESPP for the years ended December&#160;31, 2022, 2021, and 2020 was as follows (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:47%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="22" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Employees</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Non-</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Employees</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Employees</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Non-</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Employees</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Employees</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Non-</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Employees</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,591</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,723</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,168</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">36</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">General and administrative</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,520</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,315</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,052</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total stock-based compensation expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,111</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,038</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,220</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">36</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No related tax benefits were recognized for the years ended December&#160;31, 2022, 2021, and 2020 (see Note 11). </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The employee and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> awards contain both performance and service-based vesting conditions. No expense was recognized for the unvested employee and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> awards with only a performance condition for the years ended December&#160;31, 2022, 2021, and 2020. The performance-based vesting conditions represent specific performance targets. Compensation expense for employee and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> share-based payment awards with performance conditions is recognized when the performance condition is deemed probable of achievement. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2022, the Company had an aggregate of $11.6&#160;million of unrecognized stock-based compensation expense for options outstanding, which is expected to be recognized over a weighted average period of 1.6 years. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In determining the fair value of the stock-based awards, the Company uses the Black-Scholes option-pricing model and assumptions discussed below. Each of these inputs is subjective and generally requires significant judgment to determine. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Expected Term </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#8217;s expected term represents the period that the Company&#8217;s stock-based awards are expected to be outstanding and is determined using the simplified method (based on the midpoint between the vesting date and the end of the contractual term). The Company utilizes this method due to lack of historical exercise data and the plain-vanilla nature of the Company&#8217;s stock-based awards. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Expected Volatility </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since the Company was privately held through April 2016, it alone does not have the relevant company-specific historical data to support its expected volatility. As such, the Company has used an average of expected volatilities based on the volatilities of a representative group of publicly traded biopharmaceutical companies over a period equal to the expected term of the stock option grants. Subsequent to the Company&#8217;s initial public offering, it began to consider the Company&#8217;s own historic volatility. However, due to its limited history as a public company, the Company still uses peer company data to assist in this analysis. For purposes of identifying comparable companies, the Company selected companies with comparable characteristics to it, including enterprise value, risk profiles, position within the industry, and with historical share price information sufficient to meet the expected life of the stock-based awards. The historical volatility data was computed using the daily closing prices for the selected companies&#8217; shares during the equivalent period of the calculated expected term of the stock-based awards. The Company intends to consistently apply this process using the same or similar comparable entities until a sufficient amount of historical information regarding the volatility of the Company&#8217;s own share price becomes available. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Risk-Free Interest Rate </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of option. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Expected Dividend </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has never paid dividends on its common stock and has no plans to pay dividends on its common stock. Therefore, the Company used an expected dividend yield of zero. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Valuation of Stock Options and 2016 ESPP </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fair value of the stock options granted under the 2018 Plan, 2016 Plan, 2015 Plan and the CEO inducement grant, as well as the shares available for purchase under the 2016 ESPP were determined using the Black-Scholes option-pricing model. The following table summarizes the weighted-average assumptions used in calculating the fair value of the awards: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:78%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Stock Options Granted</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected term (in years)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5.99</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.10</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected volatility</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">84</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">83</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">76</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Risk-free interest</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.93</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.88</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.06</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Dividend yield</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">2016 ESPP</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected term (in years)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.49</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected volatility</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">84</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">86</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">76</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Risk-free interest</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.95</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.08</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.75</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Dividend yield</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140168006537232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Strategic License Agreements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_LicenseAndCollaborationAgreementAbstract', window );"><strong>License And Collaboration Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_StrategicLicenseAgreementTextBlock', window );">Strategic License Agreement</a></td>
<td class="text"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">11. Strategic License Agreements </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&#160;21, 2021, the Company entered into an exclusive license and supply agreement with Immedica (the &#8220;Immedica Agreement&#8221;). By entering into this agreement, the Company agreed to provide Immedica the following goods and services: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">i.</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Deliver an exclusive, sublicensable, license and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> (the &#8220;License&#8221;) to develop and commercialize pegzilarginase (the &#8220;Product&#8221;) in the territory comprising the members states of the European Economic Area (&#8220;EEA&#8221;), United Kingdom (&#8220;UK&#8221;), Switzerland, Andorra, Monaco, San Marino, Vatican City, Turkey, Saudi Arabia, United Arab Emirates, Qatar, Kuwait, Bahrain, and Oman (the &#8220;Territory&#8221;); </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">ii.</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Complete the global pivotal PEACE (Pegzilarginase Effect on Arginase 1 Deficiency Clinical Endpoints) Phase 3 trial (&#8220;PEACE Trial&#8221;) and related Biologics License Application (&#8220;BLA&#8221;) package to file with the FDA, which will be leveraged by Immedica in obtaining the necessary regulatory approvals in the Territory; and </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">iii.</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Perform a Pediatric Investigation Plan trial (&#8220;PIP Trial&#8221;) in order for Immedica to be able to receive certain regulatory approvals within the Territory. </div></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the Company and Immedica formed a Joint Steering Committee (&#8220;JSC&#8221;) to provide oversight to the activities performed under the agreement; however, the substance of the Company&#8217;s participation in the JSC </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">did not represent an additional promised service, but rather, a right of the Company to protect its own interests in the arrangement. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, the Company agreed to supply to Immedica, and Immedica agreed to purchase from the Company, substantially all commercial requirements of the Product. The terms of the agreement did not provide for either (i)&#160;an option to Immedica to purchase the Product from the Company at a discount from the standalone selling price or (ii)&#160;minimum purchase quantities. Immedica was expected to bear (i)&#160;all costs and expenses for any development or commercialization of the Product in the Territory subject to the License exclusive of the Company&#8217;s promised goods and services summarized above and (ii)&#160;all costs and fees associated with applying for regulatory approval of the Product in the Territory. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company received a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-refundable</div> payment of $21.5&#160;million and Immedica agreed to provide payment of 50% of the Company&#8217;s costs incurred in performing the PIP Trial up to a maximum of $1.8&#160;million. In addition, the Company had the ability to receive regulatory and commercial milestone payments. The Company was also entitled to receive royalties in the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mid-20%</div> range on net sales of the Product in the Territory. In July 2021, the Company modified the agreement with Immedica to provide certain additional services in relation to the PEACE Trial and BLA package performance obligation in exchange for the reimbursement of up to $3.0&#160;million of the actual costs incurred in relation to such incremental services. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company concluded that Immedica met the definition to be accounted for as a customer because the Company was delivering intellectual property and other services within the Company&#8217;s normal course of business, in which the parties are not jointly sharing the risks and rewards. Therefore, the Company concluded that the promises summarized above represent transactions with a customer within the scope of ASC 606. The Company determined that the following promises represent distinct promised services, and therefore, performance obligations: (i)&#160;the License, (ii)&#160;the PEACE Trial and BLA package, and (iii)&#160;the PIP Trial. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Specifically, in making these determinations, the Company considered the following factors: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">As of inception of the agreement, the Company had completed the Phase 1/2 clinical trial related to the Product and was conducting the PEACE Trial. Accordingly, the Company was not promising, nor expecting, to perform additional research and development activities pursuant to the agreement that would either significantly modify, customize or be considered highly interdependent or interrelated with pegzilarginase. </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">The License represented functional intellectual property given the functionality of the License was not expected to change substantially as a result of the company&#8217;s ongoing activities. </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">The services necessary to complete the PEACE Trial, BLA package and PIP Trial could have been performed by other parties. </div></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Given that Immedica was not obligated to purchase any minimum amount or quantities of Product, the supply of Product for commercial use to Immedica was determined to be an option for Immedica, rather than a performance obligation of the Company at contract inception and will be accounted for if and when exercised. The Company also determined that Immedica&#8217;s option to purchase the Product did not create a material right as the expected pricing is not at a discount. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company determined that the upfront fixed payment amount of $21.5&#160;million should be included in the transaction price. Additionally, the Company determined at inception of the arrangement that 50% of the probable estimated costs to be incurred in relation to the PIP Trial exceeded $1.8&#160;million and included the full reimbursement amount of $1.8&#160;million in the transaction price. Upon subsequent <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-evaluation</div> due to changing facts and circumstances, the Company determined the probable estimated costs were less than the maximum allowable reimbursement and a portion of the variable consideration was constrained, which did not materially impact the revenue recognized as of September&#160;30, 2023. Additionally, upon the modification of the agreement </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">in July 2021, the Company determined that the probable estimated costs to perform the additional services related to the PEACE Trial and BLA package exceeded the maximum allowable reimbursement of $3.0&#160;million. Therefore, the Company included an estimated total of $3.6&#160;million that was due in relation to the PIP Trial, PEACE Trial, and BLA package in the transaction price and concluded that it is probable that a significant reversal will not occur in the future. In total, the modified transaction price was determined to be $25.1&#160;million. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company allocated $9.6&#160;million and $3.5&#160;million of the modified transaction price to the PEACE Trial and BLA package and PIP Trial performance obligations, respectively, based on the stand-alone selling prices (&#8220;SSP&#8221;), which were based on the estimated costs that a third-party would charge in performing such services on a stand-alone basis. The SSP for the License was established at inception of the arrangement using a residual value approach due to the uniqueness of and lack of observable data related to the License, and without a specific analog from which to make reliable estimates, resulting in an allocation of $12.0&#160;million. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The potential regulatory milestone payments that the Company was eligible to receive were excluded from the transaction price, as the milestone amounts were fully constrained based on the probability of achievement, since the milestones related to successful achievement of certain regulatory approvals, which might not have been achieved. The Company determined that the royalties and commercial milestone payments related predominantly to the license of intellectual property and therefore should be excluded from the transaction price under the sales- or usage-based royalty exception under ASC 606. The Company intends to reevaluate the transaction price, including all constrained amounts, at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur, the Company intends to adjust its estimate of the transaction price as necessary. The Company recognized the royalties and commercial milestone payments as revenue when the associated sales occurred, and relevant sales-based thresholds were met. The Company also assessed the arrangement with Immedica and concluded that a significant financing component does not exist. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognized revenue allocated to the License performance obligation at a point in time and upon transfer of the License. The Company completed the transfer of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> necessary for Immedica to benefit from the License in September 2021 and recognized $12.0&#160;million of revenue at that time. The development fee allocated to the PEACE Trial, BLA package and PIP Trial performance obligations is recognized over time using an input method of costs incurred related to the performance obligations. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognized revenue of $0.9&#160;million under the Immedica Agreement for the nine months ended September&#160;30, 2023. There was no such revenue for the three months ended September&#160;30, 2023. The total revenue generated in the nine months ended September&#160;30, 2023 was attributable to the PEACE Phase 3 and PIP trials, drug supply, and royalties from an early access program in France. For the three and nine months ended September&#160;30, 2022, the Company recognized revenue of $0.2&#160;million and $2.2&#160;million, respectively, related to the PEACE Trial and BLA package performance obligation. As of December&#160;31, 2022, the Company recorded deferred revenue of $3.6&#160;million associated with the Immedica Agreement, of which $2.4&#160;million was classified as current. There was no such revenue associated with the Immedica Agreement as of September&#160;30, 2023. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&#160;27, 2023, the Company announced that it had entered into an agreement to sell the global rights to pegzilarginase to Immedica and concurrently terminated the Immedica Agreement. Remaining deferred revenue was recognized as part of the gain on disposal of the assets. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Contract Balances from Customer Contract </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The timing of revenue recognition, billings and cash collections results in contract assets and contract liabilities on the Company&#8217;s balance sheets. The Company recognizes license and development receivables based on billed services, which are derecognized upon reimbursement. When consideration is received, or such consideration is unconditionally due, from a customer prior to transferring goods or services to the customer under the terms of a contract, a contract liability is recorded. Contract liabilities are recognized as revenue after control of the goods or services is transferred to the customer and all revenue recognition criteria have been met. </div><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents changes in the Company&#8217;s contract liabilities for the periods presented (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:52%"></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">Nine Months Ended September&#160;30, 2023</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">December&#160;31,<br/> 2022</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Additions</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Deductions</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">September&#160;30,<br/> 2023</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Contract liabilities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred revenue</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,696</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">575</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3,271</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company had no contract assets during the nine months ended September&#160;30, 2023 and 2022. </div><span></span>
</td>
<td class="text"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">9. Strategic License Agreements </div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Immedica Pharma AB License and Development Agreement </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March 21, 2021, the Company entered into an exclusive license and supply agreement with Immedica Pharma AB (&#8220;Immedica&#8221;). By entering into this agreement, the Company agreed to provide Immedica the following goods and services: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">i.</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Deliver an exclusive, sublicensable, license and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> (the &#8220;License&#8221;) to develop and commercialize pegzilarginase (the &#8220;Product&#8221;) in the territory comprising the members states of the European Economic Area, United Kingdom, Switzerland, Andorra, Monaco, San Marino, Vatican City, Turkey, Saudi Arabia, United Arab Emirates, Qatar, Kuwait, Bahrain, and Oman (the &#8220;Territory&#8221;); </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">ii.</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Complete the global pivotal PEACE (Pegzilarginase Effect on Arginase 1 Deficiency Clinical Endpoints) Phase 3 trial (&#8220;PEACE Trial&#8221;) and related Biologics License Application (&#8220;BLA&#8221;) package to file with the United States Food and Drug Administration (&#8220;FDA&#8221;), which will be leveraged by Immedica in obtaining the necessary regulatory approvals in the Territory; and </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">iii.</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Perform a Pediatric Investigation Plan trial (&#8220;PIP Trial&#8221;) in order for Immedica to be able to receive certain regulatory approvals within the Territory. </div></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the Company and Immedica formed a Joint Steering Committee (&#8220;JSC&#8221;) to provide oversight to the activities performed under the agreement; however, the substance of the Company&#8217;s participation in the JSC does not represent an additional promised service, but rather, a right of the Company to protect its own interests in the arrangement. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, the Company agreed to supply to Immedica, and Immedica agreed to purchase from the Company, substantially all commercial requirements of the Product. The terms of the agreement do not provide for either (i)&#160;an option to Immedica to purchase the Product from the Company at a discount from the standalone selling price or (ii)&#160;minimum purchase quantities. Finally, Immedica will bear (i)&#160;all costs and expenses for any development or commercialization of the Product in the Territory subject to the License exclusive of the Company&#8217;s promised goods and services summarized above and (ii)&#160;all costs and fees associated with applying for regulatory approval of the Product in the Territory. In July 2021, the Company modified the agreement with Immedica to provide certain additional services in relation to the PEACE Phase 3 Trial and BLA package performance obligation in exchange for the reimbursement of up to $3.0&#160;million of the actual costs incurred in relation to such incremental services. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company received a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-refundable</div> payment of $21.5&#160;million and Immedica agreed to provide payment of 50% of the Company&#8217;s costs incurred in performing the PIP Trial up to a maximum of $1.8&#160;million. In addition, the Company has the ability to receive additional payments under the agreement of up to approximately $120.8&#160;million in regulatory and commercial milestone payments, assuming an exchange rate of $1.07 to &#8364;1.00. The Company is also entitled to receive royalties in the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="display:inline;"><span style="-sec-ix-hidden:hidden95765599">mid-20</span></div>&#160;percent</div> range on net sales of the Product in the Territory. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company concluded that Immedica meets the definition to be accounted for as a customer because the Company is delivering intellectual property and other services within the Company&#8217;s normal course of business, in which the parties are not jointly sharing the risks and rewards. Therefore, the Company concluded that the promises summarized above represent transactions with a customer within the scope of ASC 606. The Company determined that the following promises represent distinct promised services, and therefore, performance obligations: (i)&#160;the License, (ii)&#160;the PEACE Trial and BLA package, and (iii)&#160;the PIP Trial. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Specifically, in making these determinations, the Company considered the following factors: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">As of inception of the agreement, the Company had completed the Phase 1/2 clinical trial related to the Product and were conducting the ongoing PEACE Trial. Accordingly, the Company is not promising, </div></td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; line-height: normal;">nor expecting, to perform additional research and development activities pursuant to the agreement that would either significantly modify, customize or be considered highly interdependent or interrelated with pegzilarginase. </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">The License represents functional intellectual property given the functionality of the License is not expected to change substantially as a result of the company&#8217;s ongoing activities. </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">The services necessary to complete the PEACE Trial, BLA package and PIP Trial could be performed by other parties. </div></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Given that Immedica is not obligated to purchase any minimum amount or quantities of the Product, the supply of the Product for commercial use to Immedica was determined to be an option for Immedica, rather than a performance obligation of the Company at contract inception and will be accounted for if and when exercised. The Company also determined that Immedica&#8217;s option to purchase the Product does not create a material right as the expected pricing is not at a discount. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company determined that the upfront fixed payment amount of $21.5&#160;million must be included in the transaction price. Additionally, the Company determined at inception of the arrangement that 50% of the estimated costs to be incurred in relation to the PIP Trial exceeded $1.8&#160;million and included the full reimbursement amount of $1.8&#160;million in the transaction price. Upon subsequent <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-evaluation</div> due to changing facts and circumstances, the Company determined the estimated costs are now less than the maximum allowable reimbursement and a portion of the variable consideration was constrained, which did not materially impact the revenue recognized to date. Additionally, upon the modification of the agreement in July 2021, the Company determined that the estimated costs to perform the additional services related to the PEACE Trial and BLA package exceeds the maximum allowable reimbursement of $3.0&#160;million. Therefore, the Company included an estimated total of $3.6&#160;million that will be due in relation to the PIP Trial, PEACE Trial, and BLA package in the transaction price and it is probable that a significant reversal will not occur in the future. In total, the modified transaction price was determined to be $25.1&#160;million. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has allocated $9.6&#160;million and $3.5&#160;million of the modified transaction price to the PEACE Trial and BLA package and PIP Trial performance obligations, respectively, based on the stand-alone selling prices (&#8220;SSP&#8221;), which was based on the estimated costs that a third-party would charge in performing such services on a stand-alone basis. The SSP for the License was established at inception of the arrangement using a residual value approach due to the uniqueness of and lack of observable data related to the License, and without a specific analog from which to make reliable estimates, resulting in an allocation of $12.0&#160;million. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The potential regulatory milestone payments that the Company is eligible to receive were excluded from the transaction price, as the milestone amounts were fully constrained based on the probability of achievement, since the milestones relate to successful achievement of certain regulatory approvals, which might not be achieved. The Company determined that the royalties and commercial milestone payments relate predominantly to the license of intellectual property and are therefore excluded from the transaction price under the sales- or usage-based royalty exception of ASC 606. The Company will reevaluate the transaction price, including all constrained amounts, at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur, the Company will adjust its estimate of the transaction price as necessary. The Company will recognize the royalties and commercial milestone payments as revenue when the associated sales occur, and relevant sales-based thresholds are met. The Company assessed the arrangement with Immedica and concluded that a significant financing component does not exist. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognized revenue allocated to the License performance obligation at a point in time and upon transfer of the License. The Company completed the transfer of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> necessary for Immedica to benefit from the License in June 2021 and recognized $12.0&#160;million of revenue at that time. The development fee allocated to the PEACE Trial, BLA package and PIP Trial performance obligations will be recognized over time using an input method of costs incurred related to the performance obligations. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December&#160;31, 2022, the Company recognized revenue of $2.3&#160;million related to the PEACE Trial and BLA package performance obligation using a cost to cost model. The Company recognized revenue of $6.7&#160;million related to the PEACE Trial and BLA package performance obligation using a cost to cost model and $12.0&#160;million related to the transfer of the License for the year ended December&#160;31, 2021 and no revenue for the year ended December&#160;31, 2020. As of December&#160;31, 2022, the Company has recorded deferred revenue of $2.7&#160;million associated with the license and supply agreement with Immedica, of which $0.5&#160;million is classified as current. As of December&#160;31, 2021, the Company had recorded deferred revenue of $3.6&#160;million associated with the license and supply agreement with Immedica, of which $2.4&#160;million was classified as current. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Contract Balances from Customer Contract </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The timing of revenue recognition, billings and cash collections results in contract assets and contract liabilities on the balance sheets. The Company recognizes license and development receivables based on billed services, which are derecognized upon reimbursement. When consideration is received, or such consideration is unconditionally due, from a customer prior to transferring goods or services to the customer under the terms of a contract, a contract liability is recorded. Contract liabilities are recognized as revenue after control of the goods or services is transferred to the customer and all revenue recognition criteria have been met. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents changes in the Company&#8217;s contract liabilities for the periods presented (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:51%"></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Additions</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Deductions</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Contract liabilities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred revenue</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,576</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,449</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,329</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,696</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company had no contract assets during the years ended December&#160;31, 2022, 2021 and 2020 and no contract liabilities during the year ended December&#160;31, 2020. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">University of Texas at Austin License Agreement </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2013, two of the Company&#8217;s wholly owned subsidiaries AECase, Inc. and AEMase, Inc. each entered into an exclusive, worldwide license agreement, including the right to grant sublicenses, with the University of Texas at Austin (the &#8220;University&#8221;) for certain intellectual property owned by the University related to cystinase and methioninase. In January 2017, the Company and the University entered into an Amended and Restated Patent License Agreement (the &#8220;Restated License&#8221;), which <span style="-sec-ix-hidden:hidden95765449">consolidated</span> the two license agreements, revised certain obligations, and licensed additional patent applications and invention disclosures to us. The Restated License was amended in August 2017, December 2017, and December 2018 to revise diligence milestones and license additional patent applications, including our program candidates under the pegtarviliase and Cystinuria Programs. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the Restated License, the Company may be required to pay the University up to $6.4&#160;million in milestone payments based on the achievement of certain development milestones, including clinical trials and regulatory approvals, the majority of which are due upon the achievement of later development milestones, including a $5.0&#160;million payment due on regulatory approval of a product and a $0.5&#160;million payment payable on final regulatory approval of a product for a second indication. In addition, the Company is required to pay the University a low single-digit royalty on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">worldwide-net</div> sales of products covered under the Restated License, together with a revenue share on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-royalty</div> consideration received from sublicensees. The rate of the revenue share ranges from 6.5% to 25% depending on the date the sublicense agreement is signed. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the year ended December&#160;31, 2022, the Company paid $0.1&#160;million in milestone payments pursuant to the Restated License. For the years ended December&#160;31, 2021 and 2020, the Company paid $0.1&#160;million in license fees annually. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_LicenseAndCollaborationAgreementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License and collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_LicenseAndCollaborationAgreementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_StrategicLicenseAgreementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Strategic license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_StrategicLicenseAgreementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140168003275872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Sale of Pegzilarginase to Immedica<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">Sale of Pegzilarginase to Immedica</a></td>
<td class="text"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">12. Sale of Pegzilarginase to Immedica </div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&#160;27, 2023, the Company announced that it had entered into an agreement to sell the global rights to pegzilarginase, an investigational treatment for the rare metabolic disease Arginase 1 Deficiency, to Immedica for $15.0&#160;million in upfront cash proceeds and up to $100.0&#160;million in contingent milestone payments. The sale of pegzilarginase to Immedica superseded and terminated the previous license agreement between the Company and Immedica. On July&#160;27, 2023, the carrying value of the asset was zero as it was internally developed. Accordingly the Company recognized a $14.6&#160;million gain within operating expenses, which is the full $15.0&#160;million in upfront cash proceeds, net of transaction costs and the derecognition of pegzilarginase related nonfinancial assets and liabilities. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The milestone payments are contingent on formal reimbursement decisions by national authorities in key European markets and pegzilarginase approval by the FDA, among other events. The upfront payment and contingent milestone payments if paid, net of expenses and adjustments, will be distributed to holders of Aeglea&#8217;s CVR pursuant to the CVR Agreement resulting from the Asset Acquisition. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205-20/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//360/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140168004228384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Defined Contribution Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">Defined Contribution Plan</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">11. Defined Contribution Plan </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company sponsors a 401(k) retirement plan in which substantially all of its full-time employees are eligible to participate. Participants may contribute a percentage of their annual compensation to this plan, subject to statutory limitations. During the years ended December&#160;31, 2022, 2021, 2020, the Company provided $0.6&#160;million, $0.6&#160;million, and $0.5&#160;million, respectively, in contributions to the plan. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 710<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//710/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 712<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//712/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//715/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140168006538832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">12. Income Taxes </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the (loss) income before income tax expense by jurisdiction for the periods indicated: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:64%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Domestic</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(84,113</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(65,940</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(80,893</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Foreign</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">162</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">280</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Loss before income tax expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(83,951</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(65,660</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(80,893</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December&#160;31, 2022, the Company recognized an income tax expense of $0.1&#160;million, related to foreign subsidiaries refund from research client and foreign subsidiaries income tax expense. For the year ended December&#160;31, 2021, the Company recognized an income tax expense of $0.1&#160;million, related to foreign subsidiaries income tax expense and the Texas margins tax. For the year ended December&#160;31, 2020, the Company recognized no provision or benefit from income taxes. The difference between the Company&#8217;s provision for income taxes and the amounts computed by applying the statutory federal income tax rate to income before income taxes is as follows (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:64%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Tax provision derived by applying the federal statutory rate to income before income taxes</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(17,630</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(13,789</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(16,988</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Permanent differences and other</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,042</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,002</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">482</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Federal tax credits</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3,559</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3,815</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3,905</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">State tax credits</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(640</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(152</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(251</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Effect of tax rate on foreign jurisdiction</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">42</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(5</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in the valuation allowance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">20,609</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16,900</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">20,662</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Income tax (benefit) expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(136</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">141</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The components of the deferred tax assets and liabilities consist of the following (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:70%"></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred tax assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net operating loss carryforward</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">68,917</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">64,531</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Intangible assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11,149</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">57</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred revenue</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">566</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">668</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">846</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock-based compensation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,293</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,767</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Federal tax credits</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21,914</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18,579</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">State tax credits</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,631</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">991</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">190</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">220</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total deferred tax assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">108,328</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">87,991</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred tax liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Depreciable assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(676</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(948</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total deferred tax liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(676</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(948</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: Valuation allowance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(107,652</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(87,043</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred tax assets, net</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has established a full federal and state valuation allowance equal to the net deferred tax assets due to uncertainties regarding the realization of the deferred tax asset based on the Company&#8217;s lack of earnings history. The valuation allowance increased by $20.6&#160;million, $16.9&#160;million, and $20.7&#160;million during the years ended December&#160;31, 2022, 2021, and 2020, respectively, primarily due to continuing loss from operations. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2022 and 2021, the Company had U.S. net operating loss carryforwards (&#8220;NOL&#8221;) of $328.2&#160;million and $307.3&#160;million, respectively. As of December&#160;31, 2022 and 2021, the Company had U.S. tax credit carryforwards of $21.9&#160;million and $18.6&#160;million, respectively, and state tax credit carryforwards of $1.6&#160;million and $1.0&#160;million, respectively. Of the net operating loss and tax credit carryforwards, $58.4&#160;million and $21.9&#160;million, respectively, will expire in 2033, if not utilized. Any remaining net operating loss will carry forward indefinitely and can be utilized to offset up to 80% of the taxable income in any tax year. The net </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div><div></div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">operating loss and credit carryforwards are subject to Internal Revenue Service adjustments until the statute closes on the year the net operating loss or tax credits are utilized. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has not completed a study to assess whether an ownership change has occurred or whether there have been multiple ownership changes since the Company&#8217;s formation due to the complexity and cost associated with such a study, and the fact that there may be additional such ownership changes in the future. If the Company has experienced an ownership change at any time since its formation, utilization of the NOL or research and development credit carryforwards would be subject to an annual limitation under Section&#160;<div style="display:inline;">382</div> or 383 of the Internal Revenue Code, which is determined by first multiplying the value of the Company&#8217;s stock at the time of the ownership change by the applicable long-term, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">tax-exempt</div> rate, and then could be subject to additional adjustments, as required. Additionally, the separate return limitation year (&#8220;SRLY&#8221;) rules may apply to losses of the Company&#8217;s eight wholly owned U.S. subsidiary corporations. The SRLY rules limit the consolidated group&#8217;s use of a subsidiary corporation&#8217;s net operating losses to the amount of income generated by the subsidiary corporation after it becomes a member of the group. Any limitation may result in expiration of a portion of the NOL or research and development credit carryforwards before utilization. Further, until a study is completed and any limitation known, no amounts are being considered as an uncertain tax position or disclosed as an unrecognized tax benefit. Additionally, the Company does not expect any unrecognized tax benefits to change significantly over the next twelve months. Due to the existence of the valuation allowance, future changes in the Company&#8217;s unrecognized tax benefits will not impact its effective tax rate. Any carryforwards that will expire prior to utilization as a result of such limitations will be removed from deferred tax assets with a corresponding reduction of the valuation allowance. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is subject to examination by taxing authorities in its significant jurisdictions for the 2018 and subsequent years. However, due to NOL and tax attribute carryovers, the taxing authorities have the ability to adjust the NOLs and other tax attributes related to closed years. As of December&#160;31, 2022 and 2021, there were no amounts recorded for uncertain tax positions. As of December&#160;31, 2022, undistributed earnings of the Company&#8217;s newly incorporated foreign subsidiaries are immaterial. Under the Global Intangible <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Low-Taxed</div> Income (&#8220;GILTI&#8221;) provisions of the 2017 Tax Cuts and Jobs Act, U.S. income taxes have been incurred on the undistributed earnings of the foreign subsidiaries and therefore, the tax impact upon distribution is limited to state income and withholding taxes and is not material. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140168003204912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">13. Net Loss Per Share </div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company computes net loss attributable per common stockholder using the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-class</div> method required for participating securities. The Company considers convertible. preferred stock to be participating securities. In the event that the Company paid out distributions, holders of convertible preferred stock would participate in the distribution. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-class</div> method is an earnings (loss) allocation method under which earnings (loss) per share is calculated for common stock and participating security considering a participating security&#8217;s rights to undistributed earnings (loss) as if all such earnings (loss) had been distributed during the period. The holders of Series A Preferred Stock do not have an obligation to fund losses and therefore the Series A Preferred Stock was excluded from the calculation of basic net loss per share. The Company included in the calculation of basic net loss per share, contingently issuable common shares related to the Asset Acquisition because they will be issued for no consideration due to the consideration already having been satisfied as of September&#160;30, 2023. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per share is computed by dividing the net loss by the weighted-average number of common stock and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants outstanding during the period, without consideration of potential dilutive securities. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants are included in the computation of basic net loss per share as the exercise price is negligible and they are fully vested and exercisable. For periods in which the Company generated a net loss, the Company does not include the potential impact of dilutive securities in diluted net loss per share, as the impact of these items is anti-dilutive. The Company has generated a net loss for all periods presented, therefore diluted net loss per share is the same as basic net loss per share since the inclusion of potentially dilutive securities would be anti-dilutive. </div><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following weighted-average equity instruments were excluded from the calculation of diluted net loss per share because their effect would have been anti-dilutive for the periods presented: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:54%"></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Three Months Ended<br/> September&#160;30,</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Nine Months Ended<br/> September&#160;30,</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">2023</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">2022</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">2023</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">2022</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Options to purchase common stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,135,672</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">351,533</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,426,224</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">335,395</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unvested restricted stock units</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">252</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,315</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Series A Preferred Stock (on an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">as-converted</div> basis)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">42,501,681</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14,851,447</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><span></span>
</td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">13. Net Loss Per Share </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per share is computed by dividing net loss by the weighted-average number of common stock and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants outstanding during the period. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants are included in the computation of basic net loss per share as the exercise price is negligible and they are fully vested and exercisable. For periods in which the Company generated a net loss, the Company does not include the potential impact of dilutive securities in diluted net loss per share, as the impact of these items is anti-dilutive. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following weighted-average equity instruments were excluded from the calculation of diluted net loss per share because their effect would have been anti-dilutive for the periods presented: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:84%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:67%"></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Options to purchase common stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">346,331</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">264,858</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">201,977</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unvested restricted stock units</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,982</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,975</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,239</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a reconciliation of the shares used as the denominator for the calculation of basic and diluted net loss per share: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:61%"></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average common shares</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,307,668</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,956,933</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,608,952</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,063,563</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">672,851</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">525,917</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total basic and diluted weighted average shares</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,371,231</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,629,784</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,134,869</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140168006779632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring Charges<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Restructuring Charges</a></td>
<td class="text"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">14. Restructuring Charges </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Severance and Stock Compensation </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&#160;12, 2023, based on the review of the inconclusive interim results from the Company&#8217;s Phase 1/2 clinical trial of pegtarviliase for the treatment of classical homocystinuria and other business considerations, the Company announced that it had initiated a process to explore strategic alternatives to maximize stockholder value and engaged an independent exclusive financial advisor to support this process. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result, the Company implemented a restructuring plan resulting in an approximate 83% reduction of the Company&#8217;s existing headcount by June&#160;30, 2023. The Company recognized restructuring expenses consisting of cash severance payments and other employee-related costs of nil and $6.4&#160;million during the three and nine months ended September&#160;30, 2023, respectively. Cash payments for employee related restructuring charges of $4.5&#160;million were paid as of September&#160;30, 2023. In addition, the Company recognized $1.0&#160;million in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> stock-based compensation expense related to the accelerated vesting of stock-based awards for certain employees. The Company recorded these restructuring charges based on each employee&#8217;s role to the respective research and development and general and administrative operating expense categories on its condensed consolidated statements of operations and comprehensive loss. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the changes in the Company&#8217;s accrued restructuring balance (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:45%"></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Beginning&#160;Balance<br/> December&#160;31,&#160;2022</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Charges</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Payments</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Ending&#160;Balance<br/> September&#160;30,&#160;2023</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Severance liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,448</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(4,527</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,921</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Sale of Assets </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the second quarter of 2023, the Company sold various lab equipment, consumables, and furniture and fixtures for total consideration of $0.5&#160;million. After recording the disposal of all property and equipment net of proceeds, the Company recorded a $0.7&#160;million and $0.2&#160;million loss on disposal of long lived assets which is included in Research and development and General and administrative expenses, respectively. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Right-of-use</div></div> Asset and Leasehold Improvement Impairment </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Effective June&#160;30, 2023, the Company abandoned its leased office space in Austin, Texas. As a result, the Company recognized an impairment loss of $0.9&#160;million related to the operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> asset and $1.7&#160;million related to leasehold improvements. On August&#160;7, 2023, the Company terminated its building lease in Austin, Texas. The negotiated termination agreement obligated the Company to pay the lessor a $2.0&#160;million termination fee in exchange for releasing the Company of all further obligations under the lease. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All charges related to the restructuring activities were recognized during the second quarter of 2023. No further restructuring charges will be incurred under the restructuring plan. A summary of the charges related to the restructuring activities is as follows (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:33%"></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Severance&#160;Related<br/> Expenses</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Stock&#160;Compensation<br/> Expenses</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Loss&#160;on&#160;Disposal&#160;of<br/> Long Lived Assets</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Lease&#160;Asset<br/> Impairment</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Total&#160;Restructuring&#160;Costs</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,182</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">123</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">749</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,405</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,459</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">General and administrative</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,266</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">870</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">182</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,175</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,493</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,448</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">993</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">931</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,580</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10,952</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//420/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140168003199200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Novation of Manufacturing Agreements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsDisclosureTextBlock', window );">Novation of Manufacturing Agreements</a></td>
<td class="text"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">15. Novation of Manufacturing Agreements </div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to a Novation Agreement dated September&#160;19, 2023 (the &#8220;Novation Agreement&#8221;), by and between the Company, Paragon and WuXi Biologics (Hong Kong) Limited (&#8220;WuXi Biologics&#8221;), the Company novated (i)&#160;a Biologics Master Services Agreement (the &#8220;WuXi Biologics MSA&#8221;) and (ii)&#160;a Cell Line License Agreement (the &#8220;Cell Line License Agreement&#8221;). </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Biologics Master Services Agreement </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2023, Paragon and WuXi Biologics entered into the WuXi Biologics MSA, which was subsequently novated to the Company by Paragon on September&#160;19, 2023 pursuant to the Novation Agreement. The WuXi Biologics MSA governs certain development activities and GMP manufacturing and testing for the SPY001 program, as well as potential future programs, on a work order basis. Under the WuXi Biologics MSA, the Company is obligated to pay WuXi Biologics a service fee and all <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cancellable</div> obligations in the amount specified in each work order associated with the agreement for the provision of services. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The WuXi Biologics MSA terminates on the later of (i)&#160;June&#160;20, 2027 or (ii)&#160;the completion of services under all work orders executed by the parties prior to June&#160;20, 2027, unless terminated earlier. The term of each work order terminates upon completion of the services under such work order, unless terminated earlier. The Company can terminate the WuXi Biologics MSA or any work order at any time upon 30 days&#8217; prior written notice and immediately upon written notice if WuXi Biologics fails to obtain or maintain required material governmental licenses or approvals. Either party may terminate a work order (i)&#160;at any time upon six months&#8217; prior notice with reasonable cause, provided however that if WuXi Biologics terminates a work order in such manner, no termination or cancellation fees shall be paid by the Company and (ii)&#160;immediately for cause upon (a)&#160;the other party&#8217;s material breach that remains uncured for 30 days after notice of such breach, (b)&#160;the other party&#8217;s bankruptcy or (c)&#160;a force majeure event that prevents performance for a period of at least 90 days. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cell Line License Agreement </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2023, Paragon and WuXi Biologics entered into the Cell Line License Agreement, which was subsequently novated to the Company by Paragon pursuant to the Novation Agreement. Under the Cell Line License Agreement, the Company received a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-exclusive,</div> worldwide, sublicensable license to certain of WuXi Biologics&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how,</div> cell line, biological materials (the &#8220;WuXi Biologics Licensed Technology&#8221;) and media and feeds to make, have made, use, sell and import certain therapeutic products produced through the use of the cell line licensed by WuXi Biologics under the Cell Line License Agreement (the &#8220;WuXi Biologics Licensed Products&#8221;). Specifically, the WuXi Biologics Licensed Technology is used in certain manufacturing activities in support of the SPY001 program. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In consideration for the license, the Company agreed to pay WuXi Biologics a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-refundable</div> license fee of $0.2&#160;million. Additionally, if the Company manufactures all of its commercial supplies of bulk drug product with a manufacturer other than WuXi Biologics or its affiliates, the Company is required to make royalty payments to WuXi Biologics of less than one percent of global net sales of WuXi Biologics Licensed Products manufactured </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">by a third-party manufacturer (the &#8220;Royalty&#8221;). If the Company manufactures part of its commercial supplies of the WuXi Biologics Licensed Products with WuXi Biologics or its affiliates, then the Royalty will be reduced accordingly on a pro rata basis. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Cell Line License Agreement will continue indefinitely unless terminated (i)&#160;by the Company upon six months&#8217; prior written notice and our payment of all undisputed <div style="display:inline;">amounts </div>due to WuXi Biologics through the effective date of termination, (ii)&#160;by WuXi Biologics for a material breach by the Company that remains uncured for 60 days after written notice, (iii)&#160;by WuXi Biologics if the Company fails to make a payment and such failure continues for 30 days after receiving notice of such failure, or (iv)&#160;by either party upon the other party&#8217;s bankruptcy. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140168003325856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reverse Stock Split<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_ReverseStockSplitTextBlock', window );">Reverse Stock Split</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">14. Reverse Stock Split </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&#160;8, 2023, the Company effected a reverse stock split of its common stock at a ratio of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">1-for-25</div></div> (the &#8220;Reverse Split&#8221;). Upon the effectiveness of the Reverse Split, (i)&#160;every 25 shares of outstanding common stock were reclassified and combined into one share of common stock, (ii)&#160;the number of shares of common stock for which each outstanding option and warrant to purchase common stock is exercisable was proportionally decreased and the exercise price of each outstanding option and warrant to purchase common stock proportionally increased, and (iii)&#160;the total number of authorized shares of common stock was proportionally decreased. No fractional shares were issued as a result of the Reverse Split. Accordingly, all share and per share amounts for all periods presented in these financial statements and notes thereto have been adjusted retroactively, where applicable, to reflect the Reverse Split and adjustment of the exercise price of each outstanding option and warrant as if the transaction had occurred as of the beginning of the earliest period presented. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_ReverseStockSplitTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reverse stock split.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_ReverseStockSplitTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140168006507712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Description of the Business and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th"><div>Jun. 22, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAbstract', window );"><strong>Description of the Business and Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Description of the Business and Summary of Significant Accounting Policies</a></td>
<td class="text"><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">1. Description of the Business and Summary of Significant Accounting Policies </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;22, 2023, Aeglea BioTherapeutics, Inc. (&#8220;Aeglea&#8221;, the &#8220;Company&#8221;, and &#8220;our&#8221;) acquired, in accordance with the terms of the Agreement and Plan of Merger (the &#8220;Acquisition Agreement&#8221;), the assets from Spyre Therapeutics, Inc (&#8220;Spyre&#8221;), a privately held biotechnology company advancing a pipeline of antibody therapeutics through a research and development option agreement (&#8220;Paragon Agreement&#8221;) with Paragon Therapeutics (&#8220;Paragon&#8221;). Spyre was incorporated on April&#160;28, 2023, for the purpose of holding rights to certain intellectual property being developed by Paragon. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&#160;8, 2023, Aeglea effected a reverse stock split of its Common Stock at a ratio of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">1-for-25</div></div> (the &#8220;Reverse Split&#8221;). Except as indicated otherwise, all share numbers related to our Common Stock disclosed in this statement have been adjusted on a post-Reverse Split basis. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transaction (the &#8220;Asset Acquisition&#8221;) was structured as a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">stock-for-stock</div></div> transaction pursuant to which all of Spyre&#8217;s outstanding equity interests were exchanged based on a fixed exchange ratio of 0.5494488 to 1 for consideration from Aeglea of 517,809 shares of common stock and 364,887 shares of Series A <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-voting</div> convertible preferred stock, par value of $0.0001 per share (&#8220;Series A Preferred Stock&#8221;) (convertible on a 40 to 1 basis) in addition to the assumption of outstanding and unexercised stock options to purchase 2,734 shares of common stock from the Amended and Restated Spyre 2023 Equity Incentive Plan. The Aeglea common stock and the Aeglea Series A Preferred Stock related to the Asset Acquisition were issued to the Spyre stockholders on July&#160;7, 2023. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company concluded that the arrangement meets the definition of an asset acquisition rather than a business combination, as substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset, Spyre&#8217;s option (the &#8220;Option&#8221;) to exclusively license certain <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development (&#8220;IPR&amp;D&#8221;). The Company determined that the Option to license IPR&amp;D was a single asset as the Company&#8217;s strategy relies on developing a portfolio of combination treatments that simultaneously address different mechanisms of irritable bowel disease. The Company also determined that the pipeline candidates within the portfolio are similar in nature and risk profile. In addition, the Company did not obtain any substantive processes, assembled workforce, or employees capable of producing outputs in connection with the Asset Acquisition. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company determined that the cost to acquire the asset was $113.2&#160;million, which was recorded as acquired IPR&amp;D. The fair value of the consideration issued consisted of the 364,887 shares of Series A Preferred Stock (14,595,480 shares of common stock on an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">as-converted</div> basis) and 517,809 shares of common stock, valued at $291.08 per share and $7.277 per share, respectively. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Paragon Agreement provided for an annual equity grant of options to purchase 1% of the then outstanding shares of Spyre&#8217;s common stock, on a fully diluted basis, on the last business day of each calendar year during the term of the Option, at the fair market value determined by the board of directors of Spyre (the &#8220;Parapyre Option Obligation&#8221;). In connection with the Asset Acquisition, the Company assumed the rights and obligations of Spyre under the Paragon Agreement, including the Parapyre Option Obligation. As a result, the Parapyre Option Obligation shall continue and Parapyre shall be entitled to receive the equivalent shares of common stock of the Company on the same terms. For additional information, see Note&#160;3. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Asset Acquisition costs are shown on the following table (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:80%"></td>
<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;of&#160;June&#160;22,<br/>2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Consideration transferred in Series A Preferred Stock and common stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">109,979</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Transaction costs incurred by Aeglea</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,197</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total cost to acquire asset</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">113,176</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#8217;s allocation of the purchase price to net assets acquired is as follows (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:80%"></td>
<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;of&#160;June&#160;22,<br/>2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Acquired <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">130,188</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash acquired</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,035</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(20,047</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total cost to acquire asset</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">113,176</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">730-10-25-2(c),</div></div></div> intangible assets used in research and developmental activities acquired in an asset acquisition should be expensed at the acquisition date if there is no alternative future use in other R&amp;D projects or otherwise (i.e., if they have no economic value). The Company determined that product candidates pertaining to Spyre had no alternative future use at the time of acquisition and recorded $130.2&#160;million to Acquired <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">In-process</div> Research and Development Expenses as of the date of acquisition. The difference between this amount and the $113.2&#160;million cost to acquire Spyre represents the net liabilities assumed of $17.0&#160;million. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Basis of Presentation</div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result of acquiring Spyre, and based on the criteria in Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-05</div> of the Securities and Exchange Commission&#8217;s (the &#8220;SEC&#8221;) Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-X,</div> the Company would ordinarily be required to file certain historical audited financial statements for Spyre and corresponding pro forma financial information pursuant to Article 11 of Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-X.</div> Further, the historical financial statements could require the inclusion of predecessor entity information, if warranted. However, because the Company believes that Spyre&#8217;s full financial statements are not material to the Company&#8217;s shareholders and would be of limited value to investors, the Company requested relief from the SEC from the requirements under Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-05</div> and Article 11 of Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-X</div> to file audited financial statements and pro forma financial information in connection with the acquisition of Spyre. In response to the waiver request, the SEC provided the Company with a waiver that it could file an audited Statement of Assets Acquired and Liabilities Assumed from Spyre Therapeutics, Inc. on the basis of the allocation of the Company&#8217;s purchase price as of the acquisition date of June&#160;22, 2023. Stand-alone full financial statements related to the assets acquired have not been prepared previously. This financial statement is not intended to be a complete presentation of the financial position, results of operations, or cash flows of Spyre. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company determined that it was the acquirer of Spyre under ASC 805 due to the relative voting rights in the combined entity, the composition of the governing body of the combined entity, and the composition of the senior management of the combined entity remaining relatively the same before and after the consummation of the transaction. The Company determined that the future conversion of the Series A Preferred Stock, if approved by the Company&#8217;s voting shareholders, was an independent event based on it being outside of the control of the Company and therefore substantive. The Company did not succeed to substantially all of Paragon&#8217;s business nor acquire from Paragon any separately identifiable line of business, the Company concluded that Paragon did not meet the definition of predecessor. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company evaluates acquisitions of assets and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first applying a screen test to determine whether substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If so, the transaction is accounted for as an asset acquisition. If not, further determination is required as to whether or not the Company has acquired inputs and processes that have the ability to create outputs, which would meet the definition of a business. Significant judgment is required in the application of the screen test to determine whether an acquisition is a business combination or an acquisition of assets. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company concluded that the arrangement meets the definition of an asset acquisition rather than a business combination, as substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset, Spyre&#8217;s option to exclusively license IPR&amp;D. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company measures and recognizes asset acquisitions that are not deemed to be business combinations based on the cost to acquire the assets, which includes <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-acquisition</div> direct costs recorded in accrued professional and consulting fees. Goodwill is not recognized in asset acquisitions. When a transaction accounted for as an asset acquisition includes an IPR&amp;D asset, the IPR&amp;D asset is only capitalized if it has an alternative future use other than in a particular research and development project. Otherwise, the cost allocated to acquire an IPR&amp;D asset with no alternative future use is charged to expense at the acquisition date. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has not generated any product revenues and has not achieved profitable operations. There is no assurance that profitable operations will ever be achieved, and, if achieved, could be sustained on a continuing basis. In addition, development activities, clinical and nonclinical testing, and commercialization of the Company&#8217;s product candidates will require significant additional financing before a commercial drug can be produced and marketed. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is subject to a number of risks similar to other life science companies, including, but not limited to, risks related to the successful discovery, development, and commercialization of product candidates, raising additional capital, development of competing drugs and therapies, protection of proprietary technology and market acceptance of the Company&#8217;s product candidates. As a result of these and other factors and the related uncertainties, there can be no assurance of the Company&#8217;s future success. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2023, the Board of Directors approved a restructuring of the Company&#8217;s workforce pursuant to which the Company&#8217;s workforce was reduced by approximately 83%, retaining approximately 10 employees. Additionally, the Company announced interim results from its ongoing Phase 1/2 clinical trial of pegtarviliase for the treatment of classical homocystinuria. Following a review of the interim results and other business considerations, the Company explored strategic alternatives with the goal of maximizing stockholder value, including possible business combinations and/or a divestiture of the Company&#8217;s clinical programs. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;22, 2023, the Company acquired the net liabilities from Spyre. Additionally, on June&#160;26, 2023, the Company completed a private placement of shares of Series A Preferred Stock and sold an aggregate of 721,452 shares of Series A Preferred Stock for an aggregate purchase price of approximately $210.0&#160;million before deducting approximately $12.7&#160;million placement agent and other offering expenses. In accordance with ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">205-40,</div> Going Concern, in connection with the preparation of the statement of assets acquired and liabilities assumed of Spyre, the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date the financial statement is available to be issued. Our Series A Preferred Stock agreement requires us to seek stockholder approval for the conversion of the Series A Preferred Stock to Common Stock. The Company has agreed to hold a stockholders&#8217; meeting to submit this matter to its stockholders for their consideration. In connection with this, the Company filed with the SEC a preliminary proxy statement and other relevant materials. The stockholder meeting has not occurred as of October&#160;6, 2023. If our stockholders do not timely approve the conversion of our Series A Preferred Stock, then the holders of our Series A Preferred Stock </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">are entitled to require us to settle their shares of Series A Preferred Stock for cash at a price per share equal to the fair value of the Series A Preferred Stock, as described in our Certificate of Designation relating to the Series&#160;A Preferred Stock. The cash redemption is not in our control and raises substantial doubt about our ability to continue as a going concern. The accompanying financial statement assumes the Company will continue as a going concern through the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Use of Estimates</div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and certain financial statement disclosures. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets, liabilities, and equity and the amount of revenues and expenses. Actual results could differ significantly from those estimates. Key estimates that management considers in the preparation of the Company&#8217;s financial statements relate to accrued option costs payable to Paragon and the valuation of consideration transferred. The consideration transferred in acquiring IPR&amp;D in connection with the acquisition of Spyre was comprised of the Company&#8217;s common stock and shares of Series A preferred stock. To determine the fair value of the equity transferred, the Company considered the per share value of its concurrent private financing transaction, which was an over-subscribed financing event involving a group of investors. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Cash and Cash Equivalents</div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June&#160;22, 2023, Spyre held $3.0&#160;million in cash and cash equivalents, which consisted of a single deposit account denominated in U.S. dollars. At June&#160;22, 2023, U.S. cash deposits in excess of the Federal Deposit Insurance Corporation&#8217;s insured limit were $2.8&#160;million. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Accrued Liabilities</div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accrued liabilities primarily consist of research initiation fees, reimbursable expenses under the Paragon Agreement for historical costs incurred by Paragon, professional and consulting fees, and the fair of assumed Parapyre Option Obligation. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the business and summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140168003211296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Liabilities<br></strong></div></th>
<th class="th"><div>Jun. 22, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_AccruedLiabilitiesTextBlock', window );">Accrued Liabilities</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">2. Accrued liabilities </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Asset Acquisition, the Company assumed the rights and obligations of Spyre under the Paragon Agreement. Under the Paragon Agreement, Spyre is obligated to compensate Paragon on a quarterly basis for its services performed under each research program based on the actual costs incurred with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mark-up</div> costs pursuant to the terms of the Paragon Agreement. As of the date of the Asset Acquisition, Spyre had incurred total expenses of $19.0&#160;million under the Paragon Agreement since inception, inclusive of a $3.0&#160;million research initiation fee that was due upon signing of the Paragon Agreement and $16.0&#160;million of historical reimbursable expenses owed to Paragon. As of June&#160;22, 2023, $19.0&#160;million was unpaid and was assumed by the Company through the Asset Acquisition. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accrued liabilities consist of the following (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:80%"></td>
<td style="vertical-align:bottom;width:11%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;of&#160;June&#160;22,<br/>2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued option cost payable to Paragon</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18,987</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued professional and consulting fees</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">917</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Fair value of assumed Parapyre Option Obligation (Note&#160;3)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">143</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">20,047</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_AccruedLiabilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_AccruedLiabilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140168008202064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Parapyre Option Obligation<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 22, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAbstract', window );"><strong>Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionTextBlock', window );">Parapyre Option Obligation</a></td>
<td class="text"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">3. Parapyre Option Obligation </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;22, 2023, in connection with the Asset Acquisition, the Company assumed the Parapyre Option Obligation which provided for an annual equity grant of options for Parapyre to purchase 1% of the then outstanding shares of Spyre&#8217;s common stock, on a fully diluted basis, on the last business day of each calendar year during the term of the Paragon Agreement, at the fair market value determined by the board of directors of Spyre. As a result of the Asset Acquisition the Parapyre Option Obligation shall continue and Parapyre shall be entitled to receive the equivalent shares of the Company with the same terms. The Parapyre Option Obligation is considered a Level&#160;2 liability based on observable market data for substantially the full term of the liabilities. The Parapyre Option Obligation is measured each period using a Black-Scholes model to estimate the fair value of the option grant. Changes in the fair value of the Parapyre Option Obligation are recorded as stock-based compensation within Research and development expenses for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employees</div> who provided <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> testing services within Research and development expenses. As of June&#160;22, 2023, the estimated liability of the Parapyre Option Obligation was $0.1&#160;million and was included in accrued liabilities. </div><span></span>
</td>
<td class="text"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7. Asset Acquisition </div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;22, 2023, the Company acquired Spyre pursuant to the Acquisition Agreement, by and among the Company, Aspen Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (&#8220;First Merger Sub&#8221;), Sequoia Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of the Company (&#8220;Second Merger Sub&#8221;), and Spyre. Pursuant to the Acquisition Agreement, First Merger Sub merged with and into Spyre, pursuant to which Spyre was the surviving corporation and became a wholly owned subsidiary of the Company (the &#8220;First Merger&#8221;). Immediately following the First Merger, Spyre merged with and into Second Merger Sub, pursuant to which Second Merger Sub became the surviving entity. Spyre was a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> stage biotechnology company that was incorporated on April&#160;28, 2023 under the direction of Peter Harwin, a Managing Member of Fairmount, for the purpose of holding rights to certain intellectual property being developed by Paragon. Fairmount is a founder of Paragon. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company completed the Asset Acquisition of Spyre, in accordance with the terms of the Acquisition Agreement. Under the terms of the Acquisition Agreement, the Company issued 517,809 shares of common stock and 364,887 shares of Series A Preferred Stock to former Spyre security holders. In addition, outstanding and unexercised stock options to purchase 2,734 shares of common stock were assumed from the Amended and Restated Spyre 2023 Equity Incentive Plan. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the acquisition date, the Company recorded forward contracts to represent the obligation to issue shares of the Company&#8217;s common stock and shares of Series A Preferred Stock, respectively. The forward contract related to the common stock was recorded as Additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital as the instrument is indexed to the Company&#8217;s common stock. The forward contract related to the Series A Preferred Stock was recorded as a liability, as the underlying stock has a cash redemption feature. On July&#160;7, 2023, both the shares of common stock and Series A Preferred Stock were issued and the forward contract liability associated with the Series A Preferred Stock was settled accordingly. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company concluded that the arrangement meets the definition of an asset acquisition rather than a business combination, as substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset, Spyre&#8217;s option (the &#8220;Option&#8221;) to exclusively license IPR&amp;D. The Company determined that the Option to license IPR&amp;D was a single asset as the Company&#8217;s strategy relies on developing the entire portfolio of individual treatments to create combination treatments that simultaneously address different mechanisms of irritable bowel disease with a single treatment. The Company also determined that the pipeline candidates within the portfolio are similar in nature and risk profile. In addition, the Company did not obtain any substantive processes, assembled workforce, or employees capable of producing outputs in connection with the Asset Acquisition. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company determined that the cost to acquire the asset was $113.2&#160;million which was recorded as acquired IPR&amp;D. The fair value of the consideration issued consisted of the 364,887 shares of Series A Preferred Stock (14,595,480 shares of common stock on an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">as-converted</div> basis) and 517,809 shares of common stock, valued at $291.08 per share and $7.277 per share, respectively. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Asset Acquisition Costs are shown on the following table (in millions): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:87%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">June&#160;22,<br/> 2023</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Consideration transferred in Series A Preferred Stock and common stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">110.0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Transaction costs incurred by Aeglea</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total cost to acquire asset</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">113.2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The allocation of the purchase price to net assets acquired is as a follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:87%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">June&#160;22,<br/> 2023</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Acquired <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">130.2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash acquired</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Assumed liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(20.0</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total cost to acquire asset</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">113.2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480123/805-50-15-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140168003321376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th"><div>Jun. 22, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">5. Subsequent Events </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#8217;s management has evaluated subsequent events up to October&#160;6, 2023, the date the Statement of Assets Acquired and Liabilities Assumed from Spyre, Inc. was available to be issued. There have been no subsequent events that require recognition or disclosure in this financial statement except for the following described below. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&#160;7, 2023, the Company issued 517,809 shares of common stock and 364,887 shares of Series&#160;A Preferred Stock as part of its consideration transferred in connection with the Asset Acquisition. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August&#160;8, 2023, the Company filed a preliminary proxy statement with the SEC to solicit approval of the conversion of the Series A Preferred Stock into shares of Common Stock in connection with the Asset acquisition, among other matters, at a special meeting of stockholders. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&#160;8, 2023, the Company&#8217;s Board of Directors approved a reverse stock split of the Company&#8217;s common stock, par value $0.0001 per share, at a ratio of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">1-for-25</div></div> and a reduction in the total number of authorized shares of Common Stock from 500,000,000 shares to 20,000,000 shares. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&#160;29, 2023, the Company amended the Paragon Agreement to amend and restate certain terms of the option grant pertaining to the Parapyre Option Obligation, including but not limited to (i)&#160;defining that the annual equity grant of options is based on the outstanding shares of Aeglea&#8217;s common stock, (ii)&#160;establishing the grant date as the last business day of each applicable calendar year, and (iii)&#160;defining the term of the options granted is ten years. The liability related to the Parapyre Option Obligation will be recorded pursuant to the amended Paragon Agreement on a go forward basis. The Company determined that these amendments would not have materially impacted the liability as of June&#160;22, 2023. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140168003896448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of the Business and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 22, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_ConvertiblePreferredStockIssuedThroughPipePolicyTextBlock', window );">Convertible Preferred Stock Issued through PIPE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Convertible Preferred Stock Issued through PIPE </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company records shares of convertible preferred stock at their respective fair values on the dates of issuance, net of issuance costs. The Company has applied the guidance in ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">480-10-S99-3A</div></div></div> as well as SEC Staff Announcement, Classification and Measurement of Redeemable Securities, and has therefore classified the Series A Preferred Stock outside of stockholders&#8217; (deficit) equity because, if conversion to common stock is not approved by the stockholders, the Series A Preferred Stock will be redeemable at the option of the holders for cash equal to the closing price of the common stock on the last trading day prior to the holder&#8217;s redemption request. The Company has determined that the conversion and redemption are outside of the Company&#8217;s control. Additionally, the Company has determined the conversion and redemption features do not require bifurcation as derivatives. </div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Acquisitions </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company evaluates acquisitions of assets and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first applying a screen test to determine whether substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If so, the transaction is accounted for as an asset acquisition. If not, further determination is required as to whether or not the Company has acquired inputs and processes that have the ability to create outputs, which would meet the definition of a business. Significant judgment is required in the application of the test to determine whether an acquisition is a business combination or an acquisition of assets. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Acquisitions meeting the definition of business combinations are accounted for using the acquisition method of accounting, which requires that the purchase price be allocated to the net assets acquired at their respective fair values. In a business combination, any excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company measures and recognizes asset acquisitions that are not deemed to be business combinations based on the cost to acquire the assets, which includes <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-acquisition</div> direct costs recorded in accrued professional and consulting fees. Goodwill is not recognized in asset acquisitions. When a transaction accounted for as an asset acquisition includes an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development (&#8220;IPR&amp;D&#8221;) asset, the IPR&amp;D asset is only capitalized if it has an alternative future use other than in a particular research and development project. Otherwise, the cost allocated to acquire an IPR&amp;D asset with no alternative future use is charged to expense at the acquisition date. </div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Contingent Value Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Contingent Value Rights </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company evaluates its contracts to determine if those contracts qualify as derivatives under ASC 815, Derivatives and Hedging (&#8220;ASC 815&#8221;). For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-valued</div> at each reporting date. Any changes in fair value are recorded as other income or expense for each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> based on whether or not <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">net-cash</div> settlement of the derivative instrument is probable within the next 12 months from the balance sheet date. The Company determined that certain contingent payments under the CVR Agreement qualified as derivatives under ASC 815, and as such, were recorded as a liability on the balance sheet. This value is then remeasured for future expected payout as well as the increase in fair value due to the time value of money. These gains or losses, if any, are recognized in the consolidated statements of operations and comprehensive loss within Other (expense) income, net. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company applies a scenario-based method and weighs them based on the possible achievement of certain milestones. The milestone payments are contingent on formal reimbursement decisions by national authorities in key European markets and pegzilarginase approval by the U.S. Food and Drug Administration (&#8220;FDA&#8221;), among other events. This fair value measurement is based on significant inputs not observable in the market and thus represents a Level&#160;3 measurement as defined in ASC 820, Fair Value Measurement. The key assumptions used include the discount rate, probability of regulatory success, and reimbursement rates from certain government agencies. The estimated value of the CVR consideration is based upon available information and certain assumptions which the Company&#8217;s management believes are reasonable under the circumstances. The ultimate payout under the CVRs may differ materially from the assumptions used in determining the fair value of the CVR consideration. </div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Basis of Presentation</div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result of acquiring Spyre, and based on the criteria in Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-05</div> of the Securities and Exchange Commission&#8217;s (the &#8220;SEC&#8221;) Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-X,</div> the Company would ordinarily be required to file certain historical audited financial statements for Spyre and corresponding pro forma financial information pursuant to Article 11 of Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-X.</div> Further, the historical financial statements could require the inclusion of predecessor entity information, if warranted. However, because the Company believes that Spyre&#8217;s full financial statements are not material to the Company&#8217;s shareholders and would be of limited value to investors, the Company requested relief from the SEC from the requirements under Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-05</div> and Article 11 of Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-X</div> to file audited financial statements and pro forma financial information in connection with the acquisition of Spyre. In response to the waiver request, the SEC provided the Company with a waiver that it could file an audited Statement of Assets Acquired and Liabilities Assumed from Spyre Therapeutics, Inc. on the basis of the allocation of the Company&#8217;s purchase price as of the acquisition date of June&#160;22, 2023. Stand-alone full financial statements related to the assets acquired have not been prepared previously. This financial statement is not intended to be a complete presentation of the financial position, results of operations, or cash flows of Spyre. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company determined that it was the acquirer of Spyre under ASC 805 due to the relative voting rights in the combined entity, the composition of the governing body of the combined entity, and the composition of the senior management of the combined entity remaining relatively the same before and after the consummation of the transaction. The Company determined that the future conversion of the Series A Preferred Stock, if approved by the Company&#8217;s voting shareholders, was an independent event based on it being outside of the control of the Company and therefore substantive. The Company did not succeed to substantially all of Paragon&#8217;s business nor acquire from Paragon any separately identifiable line of business, the Company concluded that Paragon did not meet the definition of predecessor. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company evaluates acquisitions of assets and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first applying a screen test to determine whether substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If so, the transaction is accounted for as an asset acquisition. If not, further determination is required as to whether or not the Company has acquired inputs and processes that have the ability to create outputs, which would meet the definition of a business. Significant judgment is required in the application of the screen test to determine whether an acquisition is a business combination or an acquisition of assets. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company concluded that the arrangement meets the definition of an asset acquisition rather than a business combination, as substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset, Spyre&#8217;s option to exclusively license IPR&amp;D. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company measures and recognizes asset acquisitions that are not deemed to be business combinations based on the cost to acquire the assets, which includes <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-acquisition</div> direct costs recorded in accrued professional and consulting fees. Goodwill is not recognized in asset acquisitions. When a transaction accounted for as an asset acquisition includes an IPR&amp;D asset, the IPR&amp;D asset is only capitalized if it has an alternative future use other than in a particular research and development project. Otherwise, the cost allocated to acquire an IPR&amp;D asset with no alternative future use is charged to expense at the acquisition date. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has not generated any product revenues and has not achieved profitable operations. There is no assurance that profitable operations will ever be achieved, and, if achieved, could be sustained on a continuing basis. In addition, development activities, clinical and nonclinical testing, and commercialization of the Company&#8217;s product candidates will require significant additional financing before a commercial drug can be produced and marketed. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is subject to a number of risks similar to other life science companies, including, but not limited to, risks related to the successful discovery, development, and commercialization of product candidates, raising additional capital, development of competing drugs and therapies, protection of proprietary technology and market acceptance of the Company&#8217;s product candidates. As a result of these and other factors and the related uncertainties, there can be no assurance of the Company&#8217;s future success. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2023, the Board of Directors approved a restructuring of the Company&#8217;s workforce pursuant to which the Company&#8217;s workforce was reduced by approximately 83%, retaining approximately 10 employees. Additionally, the Company announced interim results from its ongoing Phase 1/2 clinical trial of pegtarviliase for the treatment of classical homocystinuria. Following a review of the interim results and other business considerations, the Company explored strategic alternatives with the goal of maximizing stockholder value, including possible business combinations and/or a divestiture of the Company&#8217;s clinical programs. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;22, 2023, the Company acquired the net liabilities from Spyre. Additionally, on June&#160;26, 2023, the Company completed a private placement of shares of Series A Preferred Stock and sold an aggregate of 721,452 shares of Series A Preferred Stock for an aggregate purchase price of approximately $210.0&#160;million before deducting approximately $12.7&#160;million placement agent and other offering expenses. In accordance with ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">205-40,</div> Going Concern, in connection with the preparation of the statement of assets acquired and liabilities assumed of Spyre, the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date the financial statement is available to be issued. Our Series A Preferred Stock agreement requires us to seek stockholder approval for the conversion of the Series A Preferred Stock to Common Stock. The Company has agreed to hold a stockholders&#8217; meeting to submit this matter to its stockholders for their consideration. In connection with this, the Company filed with the SEC a preliminary proxy statement and other relevant materials. The stockholder meeting has not occurred as of October&#160;6, 2023. If our stockholders do not timely approve the conversion of our Series A Preferred Stock, then the holders of our Series A Preferred Stock </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">are entitled to require us to settle their shares of Series A Preferred Stock for cash at a price per share equal to the fair value of the Series A Preferred Stock, as described in our Certificate of Designation relating to the Series&#160;A Preferred Stock. The cash redemption is not in our control and raises substantial doubt about our ability to continue as a going concern. The accompanying financial statement assumes the Company will continue as a going concern through the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business. </div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Use of Estimates</div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and certain financial statement disclosures. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets, liabilities, and equity and the amount of revenues and expenses. Actual results could differ significantly from those estimates. Key estimates that management considers in the preparation of the Company&#8217;s financial statements relate to accrued option costs payable to Paragon and the valuation of consideration transferred. The consideration transferred in acquiring IPR&amp;D in connection with the acquisition of Spyre was comprised of the Company&#8217;s common stock and shares of Series A preferred stock. To determine the fair value of the equity transferred, the Company considered the per share value of its concurrent private financing transaction, which was an over-subscribed financing event involving a group of investors. </div><span></span>
</td>
<td class="text"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets, liabilities, and equity and the amount of revenues and expenses. Actual results could differ significantly from those estimates. The most significant estimates and assumptions that management considers in the preparation of the Company&#8217;s financial statements relate to the valuation of consideration transferred in acquiring IPR&amp;D; the discount rate, probabilities of success, and timing of estimated cash flows in the valuation of the CVR liability; inputs used in the Black-Scholes model for stock-based compensation expense; estimated future cash flows used in calculating the impairment of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> lease assets; and estimated cost to complete performance obligations related to revenue recognition. The consideration transferred in acquiring IPR&amp;D in connection with the acquisition of Spyre was comprised of shares of the Company&#8217;s common stock and shares of Series A Preferred Stock. To determine the fair value of the equity transferred, the Company considered the per share value of the PIPE, which was an over-subscribed financing event involving a group of accredited investors. </div><span></span>
</td>
<td class="text"><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Use of Estimates </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances, the results of which form the basis for making judgements about the carrying value of assets, liabilities, and equity and the amount of revenues and expenses. Estimates are used in accounting for, among other items, accrued research and development costs and revenue recognition. Actual results could differ materially from those estimates. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Recently Adopted Accounting Pronouncement </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company early adopted the Financial Accounting Standards Board&#8217;s Accounting Standards Update <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06,</div> Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity (&#8220;ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06&#8221;),</div> effective as of January&#160;1, 2023 using the modified retrospective method. Among other amendments, ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06</div> eliminates the cash conversion and beneficial conversion feature models in ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">470-20</div> that required an issuer of certain convertible debt and preferred stock to separately account for embedded conversion features as a component of equity, as well as changes the accounting for diluted <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">earnings-per-share</div></div> for convertible instruments and contracts that may be settled in cash or stock. Additionally, ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06</div> requires the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">if-converted</div> method, </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">which is more dilutive than the treasury stock method, be used for all convertible instruments. The Company applied ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06</div> to all Series A Preferred Stock during fiscal year 2023, and, accordingly, the Company did not apply the cash conversion or beneficial conversion feature models in its analysis of the Series A <div style="display:inline;"><div style="display:inline;">Preferred </div></div>Stock. </div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Cash and Cash Equivalents</div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June&#160;22, 2023, Spyre held $3.0&#160;million in cash and cash equivalents, which consisted of a single deposit account denominated in U.S. dollars. At June&#160;22, 2023, U.S. cash deposits in excess of the Federal Deposit Insurance Corporation&#8217;s insured limit were $2.8&#160;million. </div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Cash and Cash Equivalents </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company considers all highly liquid investments with original maturities of three months or less from the date of purchase to be cash equivalents. Cash equivalents consist of money market funds and debt securities and are stated at fair value. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_AccruedLiabilitiesPolicyTextBlock', window );">Accrued Liabilities</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Accrued Liabilities</div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accrued liabilities primarily consist of research initiation fees, reimbursable expenses under the Paragon Agreement for historical costs incurred by Paragon, professional and consulting fees, and the fair of assumed Parapyre Option Obligation. </div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Marketable Securities </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All investments have been classified as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> and are carried at estimated fair value as determined based upon quoted market prices or pricing models for similar securities. Management determines the appropriate classification of its investments in debt securities at the time of purchase. The Company may hold securities with stated maturities greater than one year until maturity. All <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> securities are considered available to support current operations and are classified as current assets. The Company presents credit losses as an allowance rather than as a reduction in the amortized cost of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> securities. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> debt securities in an unrealized loss position, the Company first assesses whether it intends to sell, or it is more likely than not that it will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security&#8217;s amortized cost basis is written down to fair value and recognized in other income (expense) in the results of operations. For <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> debt securities that do not meet the aforementioned criteria, the Company evaluates whether the decline in fair value has resulted from credit losses or other factors. In making this assessment, management considers the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and adverse conditions specifically related to the security, among other factors. If this assessment indicates that a credit loss exists, an allowance is recorded for the difference between the present value of cash flows expected to be collected and the amortized cost basis of the security. Impairment losses attributable to credit loss factors are charged against the allowance when management believes an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> security is uncollectible or when either of the criteria regarding intent or requirement to sell is met. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any unrealized losses from declines in fair value below the amortized cost basis as a result of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-credit</div> loss factors is recognized as a component of accumulated other comprehensive (loss) income, along with unrealized gains. Realized gains and losses and declines in fair value, if any, on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> securities are included in other income (expense) in the results of operations. The cost of securities sold is based on the specific-identification method. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Restricted Cash </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Restricted cash consists of money market accounts held by financial institutions as collateral for the Company&#8217;s obligations under a credit agreement and a facility lease for the Company&#8217;s corporate headquarters in Austin, Texas. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Concentration of Credit Risk </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash, cash equivalents, marketable securities, and restricted cash. The Company&#8217;s investment policy limits investments to high credit quality securities issued by the U.S. government, U.S. government-sponsored agencies, highly rated banks, and corporate issuers, subject to certain concentration limits and restrictions on maturities. The Company&#8217;s cash, cash equivalents, marketable securities, and restricted cash are held by financial institutions that management believes are of high credit quality. Amounts on deposit may at times exceed federally insured limits. The Company has not experienced any losses on its deposits of cash, cash equivalents, and restricted cash and its accounts are monitored by management to mitigate risk. The Company is exposed to credit risk in the event of default by the financial institutions holding its cash, cash equivalents, and restricted cash, and bond issuers. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Property and Equipment </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Property and equipment are stated at cost, net of accumulated depreciation and amortization. Depreciation and amortization are computed using the straight-line method over the estimated useful lives of the assets. Repairs and maintenance that do not extend the life or improve an asset are expensed as incurred. Upon retirement or sale, the cost of disposed assets and their related accumulated depreciation and amortization are removed from the balance sheet. Any gain or loss is credited or charged to operations. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The useful lives of the property and equipment are as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:39%"></td>
<td style="vertical-align:bottom;width:2%"></td>
<td style="width:59%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Laboratory equipment</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">5 years</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Furniture and office equipment</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">5 years</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Computer equipment</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">3 years</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Software</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">3 years</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Leasehold improvements</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Shorter of remaining lease term or estimated useful life</td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Impairment of Long-Lived Assets </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Long-lived assets are reviewed for indications of possible impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amounts to the future undiscounted cash flows attributable to these assets. An impairment loss is recognized to the extent an asset group is not recoverable, and the carrying amount exceeds the fair value. There were no impairments of long-lived assets for the years ended December&#160;31, 2022, 2021, and 2020. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_AccruedResearchAndDevelopmentExpensePolicyTextBlock', window );">Accrued Research And Development Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Accrued Research and Development Costs </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company records the costs associated with research nonclinical studies, clinical trials, and manufacturing development as incurred. These costs are a significant component of the Company&#8217;s research and development expenses, with a substantial portion of the Company&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">on-going</div> research and development activities conducted by third-party service providers, including contract research and manufacturing organizations. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company accrues for expenses resulting from obligations under agreements with contract research organizations (&#8220;CROs&#8221;), contract manufacturing organizations (&#8220;CMOs&#8221;), and other outside service providers for which payment flows do not match the periods over which materials or services are provided to the Company. Accruals are recorded based on estimates of services received and efforts expended pursuant to agreements established with CROs, CMOs, and other outside service providers. These estimates are typically based on contracted amounts applied to the proportion of work performed and determined through analysis with internal personnel and external service providers as to the progress or stage of completion of the services. The Company </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">makes significant judgments and estimates in determining the accrual balance in each reporting period. In the event advance payments are made to a CRO, CMO, or outside service provider, the payments will be recorded as a prepaid asset which will be amortized as the contracted services are performed. As actual costs become known, the Company adjusts its accruals. Inputs, such as the services performed, the number of patients enrolled, or the study duration, may vary from the Company&#8217;s estimates, resulting in adjustments to research and development expense in future periods. Changes in these estimates that result in material changes to the Company&#8217;s accruals could materially affect the Company&#8217;s results of operations. Historically, the Company has not <div style="display:inline;">experienced </div>any material deviations between accrued and actual research and development expenses. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Leases </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company determines if an arrangement is a lease at inception. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Right-of-use</div></div> (&#8220;ROU&#8221;) assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. The classification of the Company&#8217;s leases as operating or finance leases along with the initial measurement and recognition of the associated ROU assets and lease liabilities is performed at the lease commencement date. The measurement of lease liabilities is based on the present value of future lease payments over the lease term. As the Company&#8217;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of future lease payments. To determine the incremental borrowing rate, the Company uses the lease-term appropriate current treasury bond rates adjusted for collateral and inflation risks combined with quoted bank financing rates. The ROU asset is based on the measurement of the lease liability and also includes any lease payments made prior to or on lease commencement and excludes lease incentives and initial direct costs incurred, as applicable. The lease terms may include options to extend or terminate the lease when it is reasonably certain the Company will exercise any such options. Rent expense for the Company&#8217;s operating leases is recognized on a straight-line basis over the lease term. Amortization expense for the ROU asset associated with its finance leases is recognized on a straight-line basis over the term of the lease and interest expense associated with its finance leases is recognized on the balance of the lease liability using the effective interest method based on the estimated incremental borrowing rate. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has lease agreements with lease and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components. As allowed under Topic 842, the Company has elected to not separate lease and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components for any leases involving real estate and office equipment classes of assets and, as a result, accounts for the lease and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components as a single lease component. The Company has also elected to not apply the recognition requirement of Topic 842 to leases with a term of 12 months or less for all classes of assets. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Fair Value of Financial Instruments </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company uses fair value measurements to record fair value adjustments to certain financial and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-financial</div> assets and liabilities and to determine fair value disclosures. The accounting standards define fair value, establish a framework for measuring fair value, and require disclosures about fair value measurements. Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required to be recorded at fair value, the principal or most advantageous market in which the Company would transact are considered along with assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accounting standard for fair value establishes a fair value hierarchy based on three levels of inputs, the first two of which are considered observable and the last unobservable, that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. A financial instrument&#8217;s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The three levels of inputs that may be used to measure fair value are as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:9%"></td>
<td style="vertical-align:bottom;width:2%"></td>
<td style="width:90%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Level&#160;1:</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Observable inputs, such as quoted prices in active markets for identical assets or liabilities.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td colspan="2" style="height:6pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Level&#160;2:</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Observable inputs other than Level&#160;1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td colspan="2" style="height:6pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Level&#160;3:</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Valuations based on unobservable inputs to the valuation methodology and including data about assumptions that market participants would use in pricing the asset or liability based on the best information available under the circumstances.</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Financial instruments carried at fair value include cash, cash equivalents, marketable securities, and restricted cash. The carrying amounts of accounts payable and accrued liabilities approximate fair value due to their relatively short maturities. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Revenue Recognition </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under ASC Topic 606, &#8220;Revenue from Contracts with Customers&#8221; (&#8220;Topic 606&#8221;), an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of Topic 606, the entity performs the following five steps: (i)&#160;identify the contract(s) with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price, including variable consideration, if any; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the entity satisfies a performance obligation. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company assesses its license arrangements within the scope of Topic 606 in accordance with this framework as follows: </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">License revenue </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company assesses whether the goods or services promised within each contract are distinct to identify those that are performance obligations. This assessment involves subjective determinations and requires management to make judgments about the individual promised goods or services and whether such are separable from the other aspects of the contractual relationship. In assessing whether a promised good or service is distinct, and therefore a performance obligation, the Company considers factors such as the research, stage of development of the licensed product, manufacturing and commercialization capabilities of the customer and the availability of the associated expertise in the general marketplace. The Company also considers the intended benefit of the contract in assessing whether a promised good or service is separately identifiable from other promises in the contract. If a promised good or service is not distinct, the Company is required to combine that good or service with other promised goods or services until it identifies a bundle of goods or services that is distinct. Arrangements that include rights to additional goods or services that are exercisable at a customer&#8217;s discretion are generally considered options. The Company assesses if these options provide a material right to the customer and if so, they are considered performance obligations. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transaction price is determined and allocated to the identified performance obligations in proportion to their stand-alone selling prices (&#8220;SSP&#8221;) on a relative SSP basis. SSP is based on observable prices of the performance obligations or, when such prices are not observable, are estimated. The estimation of SSP may include factors such as forecasted revenues or costs, development timelines, discount rates, probabilities of technical and regulatory success, and considerations such as market conditions and entity-specific factors. In certain circumstances, the Company may apply the residual method to determine the SSP of a good or service if the SSP is considered highly variable or uncertain. The Company validates the SSP for performance obligations </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">by evaluating whether changes in the key assumptions used to determine the SSP will have a significant effect on the allocation of arrangement consideration between multiple performance obligations. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the consideration promised in a contract includes a variable amount, the Company estimates the amount of consideration to which it will be entitled in exchange for transferring the promised goods or services to a customer. The Company determines the amount of variable consideration by using the expected value method or the most likely amount method. The Company includes the amount of estimated variable consideration in the transaction price to the extent that it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-evaluates</div> the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">catch-up</div> basis in the period of adjustment. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an arrangement includes development, regulatory or commercial milestone payments, the Company evaluates whether the milestones are considered likely of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant cumulative revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company&#8217;s control or the licensee&#8217;s control, such as regulatory approvals, are generally not considered likely of being achieved until those approvals are received. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In determining the transaction price, the Company adjusts consideration for the effects of the time value of money if the timing of payments provides the Company with a significant benefit of financing. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the licensee and the transfer of the promised goods or services to the licensees will be one year or less. For arrangements with licenses of intellectual property that include sales-based royalties, including milestone payments based on the level of sales, and if the license is deemed to be the predominant item to which the royalties relate, the Company recognizes royalty revenue and sales-based milestones at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which the royalty has been allocated has been satisfied. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied at a point in time or over time, and if over time, recognition is based on the use of an output or input method. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#8217;s contracts may be modified for changes in the customer&#8217;s requirements. If contract modifications are for additional goods and services that are distinct from the existing contract, the modification will be accounted for as either a separate contract or a termination of the existing contract, depending on whether the additional goods or services reflects the SSP. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the additional goods or services in a contract modification are not distinct from the existing contract, they are accounted for as if they were part of the original contract. The effect of the contract modification on the transaction price and the measure of progress for the performance obligation to which it relates is recognized as an adjustment to revenue on a cumulative <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">catch-up</div> basis. The cumulative <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">catch-up</div> adjustment is calculated using an updated measure of progress applied to the sum of (1)&#160;the remaining consideration allocated to the partially satisfied performance obligation and (2)&#160;the revenue already recognized on that performance obligation. The revenue recognized for fully satisfied goods or services and distinct from the remaining performance obligations is not altered by the modification. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Collaborative arrangements </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company analyzes its license arrangements to assess whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">and rewards dependent on the commercial success of such activities and therefore within the scope of ASC Topic 808, Collaborative Arrangements (&#8220;Topic 808&#8221;). This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. For arrangements within the scope of Topic 808 that contain multiple elements, the Company first determines which elements of the collaboration are deemed to be within the scope of Topic 808 and which elements of the collaboration are more reflective of a vendor-customer relationship and therefore within the scope of Topic 606. For elements of collaboration arrangements that are accounted for pursuant to Topic 808, an appropriate recognition method is determined and applied consistently, either by analogy to authoritative accounting literature or by applying a reasonable and rational policy election. For those elements of the arrangement that are accounted for pursuant to Topic 606, the Company applies the five-step model described <div style="display:inline;">above</div>. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Research and Development Costs </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development costs are expensed as incurred. Research and development costs include, but are not limited to, salaries, benefits, travel, stock-based compensation, consulting costs, contract research service costs, laboratory supplies and facilities, contract manufacturing costs, and costs paid to other third parties that conduct research and development activities on the Company&#8217;s behalf. Amounts incurred in connection with license agreements are also included in research and development expense. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Advance payments for goods or services to be rendered in the future for use in research and development activities are recorded as a prepaid asset and expensed as the related goods are delivered or the services are performed. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Stock-Based Compensation </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognizes the cost of stock-based awards granted to employees and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employees</div> based on the estimated grant-date fair values of the awards. The fair values of stock options are estimated on the date of grant using the Black-Scholes option pricing model. The fair values of restricted stock units (&#8220;RSUs&#8221;) are based on the fair value of the Company&#8217;s common stock on the date of the grant. The value of the award is recognized as compensation expense on a straight-line basis over the requisite service period. Forfeitures are recognized when they occur, which may result in the reversal of compensation costs in subsequent periods as the forfeitures arise. Compensation expense for employee and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> share-based payment awards with performance conditions is recognized when the performance condition is deemed probable. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Income Taxes </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company and its ten wholly owned subsidiary corporations use the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial statements and the tax bases of assets and liabilities. Additionally, any changes in income tax laws are immediately recognized in the year of enactment. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A valuation allowance is established against the deferred tax assets to reduce their carrying value to an amount that is more likely than not to be realized. The deferred tax assets and liabilities are classified as noncurrent along with the related valuation allowance. Due to a lack of earnings history, the net deferred tax assets have been fully offset by a valuation allowance. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognizes benefits of uncertain tax positions if it is more likely than not that such positions will be sustained upon examination based solely on the technical merits, as the largest amount of benefits that is more likely than not to be realized upon the ultimate settlement. The Company&#8217;s policy is to recognize interest and penalties related to the unrecognized tax benefits as a component of income tax expense, if applicable. As of December&#160;31, 2022 and 2021, the Company had no unrecognized tax benefits and there were no interest or penalties incurred by the Company in the years ended December&#160;31, 2022, 2021, or 2020. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Comprehensive Loss </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Comprehensive loss is the change in stockholders&#8217; equity from transactions and other events and circumstances other than those resulting from investments by stockholders and distributions to stockholders. The Company&#8217;s other comprehensive income (loss) is currently comprised of changes in unrealized losses and gains on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> securities and foreign currency translation adjustments reflecting the cumulative effect of changes in exchange rates between the foreign entity&#8217;s functional currency and the reporting currency. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_AccruedLiabilitiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_AccruedLiabilitiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_AccruedResearchAndDevelopmentExpensePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development expense policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_AccruedResearchAndDevelopmentExpensePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_ConvertiblePreferredStockIssuedThroughPipePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible preferred stock issued through pipe.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_ConvertiblePreferredStockIssuedThroughPipePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479515/805-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480981/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 60<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482053/820-10-60-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480832/942-320-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140168004099488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of the Business and Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 22, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionTableTextBlock', window );">Summary of Asset Acquisition Cost</a></td>
<td class="text"><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Asset Acquisition costs are shown on the following table (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:80%"></td>
<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;of&#160;June&#160;22,<br/>2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Consideration transferred in Series A Preferred Stock and common stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">109,979</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Transaction costs incurred by Aeglea</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,197</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total cost to acquire asset</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">113,176</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#8217;s allocation of the purchase price to net assets acquired is as follows (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:80%"></td>
<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;of&#160;June&#160;22,<br/>2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Acquired <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">130,188</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash acquired</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,035</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(20,047</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total cost to acquire asset</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">113,176</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Asset Acquisition Costs are shown on the following table (in millions): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:87%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">June&#160;22,<br/> 2023</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Consideration transferred in Series A Preferred Stock and common stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">110.0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Transaction costs incurred by Aeglea</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total cost to acquire asset</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">113.2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The allocation of the purchase price to net assets acquired is as a follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:87%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">June&#160;22,<br/> 2023</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Acquired <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">130.2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash acquired</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Assumed liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(20.0</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total cost to acquire asset</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">113.2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480123/805-50-15-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140168003385648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock', window );">Schedule Of Estimated Useful Lives Of Property Plant And Equipment</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The useful lives of the property and equipment are as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:39%"></td>
<td style="vertical-align:bottom;width:2%"></td>
<td style="width:59%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Laboratory equipment</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">5 years</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Furniture and office equipment</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">5 years</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Computer equipment</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">3 years</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Software</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">3 years</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Leasehold improvements</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Shorter of remaining lease term or estimated useful life</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of estimated useful lives of property plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140168001372960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 22, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Accrued and Other Current Liabilities</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accrued liabilities consist of the following (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:80%"></td>
<td style="vertical-align:bottom;width:11%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;of&#160;June&#160;22,<br/>2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued option cost payable to Paragon</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18,987</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued professional and consulting fees</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">917</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Fair value of assumed Parapyre Option Obligation (Note&#160;3)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">143</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">20,047</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
<td class="text"><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accrued and other current liabilities consist of the following (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:66%"></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">September&#160;30,<br/> 2023</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">December&#160;31,<br/> 2022</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued compensation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,368</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,589</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued contracted research and development costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,669</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,972</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued professional and consulting fees</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,484</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">946</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued other</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">340</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">330</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total accrued and other current liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,861</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12,837</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
<td class="text"><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accrued and other current liabilities consist of the following (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:74%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued compensation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,589</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,988</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued contracted research and development costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,972</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,995</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued professional and consulting fees</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">946</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,264</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">330</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">783</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total accrued and other current liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12,837</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14,030</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140168001255792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Financial Assets and Liabilities Measured at Fair Value on Recurring Basis</a></td>
<td class="text">The following tables set forth the fair value of the Company&#8217;s financial assets and liabilities at fair value on a recurring basis based on the three-tier fair value hierarchy (in thousands): <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:56%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">September&#160;30, 2023</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Level&#160;1</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Level&#160;2</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Level&#160;3</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Total</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Financial Assets:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Money market funds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">55,451</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">55,451</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial paper</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">107,093</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">107,093</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate bonds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">22,828</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">22,828</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total financial assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">55,451</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">129,921</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">185,372</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Liabilities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Parapyre Option Obligation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,952</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,952</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">CVR liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">28,200</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">28,200</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,952</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">28,200</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">31,152</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td colspan="16" style="height:12pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">December&#160;31, 2022</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Level&#160;1</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Level&#160;2</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Level&#160;3</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Total</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Financial Assets:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Money market funds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,250</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,250</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial paper</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">23,641</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">23,641</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">U.S. government securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,230</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,230</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate bonds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,732</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,732</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total financial assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,250</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">31,603</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">46,853</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
<td class="text">The following tables sets forth the fair value of the Company&#8217;s financial assets and liabilities at fair value on a recurring basis based on the three-tier fair value hierarchy (in thousands): <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:63%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Financial Assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Money market funds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,250</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,250</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial paper</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">23,641</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">23,641</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">U.S. government securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,230</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,230</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate bonds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,732</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,732</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total financial assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,250</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">31,603</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">46,853</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:64%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Financial Assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Money market funds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,888</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,888</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial paper</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">65,412</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">65,412</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate bonds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12,574</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12,574</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total financial assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,888</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">77,986</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">86,874</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Significant Inputs used to Estimate the Fair Value of Derivative Liabilities</a></td>
<td class="text">The significant inputs used to estimate the fair value of the CVR liability were as follows: <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 67%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td style="width: 29%;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">September&#160;30, 2023</div></div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Estimated cash flow dates</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="display:inline;">11/28/23 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">-</div> 06/22/26</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Estimated probability of success</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="display:inline;">27% - 100%</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-adjusted discount rates</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="display:inline;">7.14% - 7.57%</div></td></tr></table><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Changes in Derivative Liabilities</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents changes in the forward contract liability for the periods presented (in millions): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:86%"></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Forward<br/> Contract<br/> Liability</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Beginning balance as of June&#160;22, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">106.2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">58.1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Ending balance as of June&#160;30, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">164.3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">25.4</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of Series A Preferred Stock on July&#160;7, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(189.7</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Ending balance as of September&#160;30, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents changes in the CVR liability for the periods presented (in thousands): </div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:85%"></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">CVR<br/> Liability</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Beginning balance as of December&#160;31, 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Fair value at CVR issuance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">29,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Changes in the fair value of the CVR liability since issuance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,300</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Ending Balance as of September&#160;30, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">28,200</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140168008240240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash Equivalents and Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">Estimated Fair Value of Cash Equivalents and Marketable Securities and the Gross Unrealized Gains and Losses</a></td>
<td class="text"><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following tables summarize the estimated fair value of the Company&#8217;s cash equivalents and marketable securities and the gross unrealized gains and losses (in thousands): </div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:57%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">September&#160;30, 2023</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Amortized<br/> Cost</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Gross<br/> Unrealized<br/> Gains</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Gross<br/> Unrealized<br/> Losses</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Estimated<br/> Fair Value</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash equivalents:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Money market funds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">55,451</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">55,451</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial paper</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16,911</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16,914</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total cash equivalents</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">72,362</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">72,365</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Marketable securities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial paper</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">90,272</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(93</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">90,179</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate bonds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">22,849</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(22</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">22,828</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">U.S. government securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">113,121</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(115</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">113,007</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="16" style="height:12pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">December&#160;31, 2022</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Amortized<br/> Cost</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Gross<br/> Unrealized<br/> Gains</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Gross<br/> Unrealized<br/> Losses</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Estimated<br/> Fair&#160;Value</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash equivalents:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Money market funds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,250</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,250</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial paper</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,021</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,020</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">U.S. government securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,736</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,735</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total cash equivalents</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">26,007</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">26,005</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Marketable securities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial paper</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16,644</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(25</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16,621</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate bonds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,738</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(6</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,732</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">U.S. government securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">495</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">495</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">20,877</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(31</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">20,848</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
<td class="text"><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following tables summarize the estimated fair value of the Company&#8217;s cash equivalents and marketable securities and the gross unrealized gains and losses (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:57%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amortized<br/> Cost</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross<br/> Unrealized<br/> Gains</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross<br/> Unrealized<br/> Losses</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Estimated<br/> Fair<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash equivalents:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Money market funds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,250</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,250</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial paper</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,021</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,020</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">U.S. government securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,736</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,735</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total cash equivalents</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">26,007</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">26,005</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:56%"></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amortized<br/> Cost</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross<br/> Unrealized<br/> Gains</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross<br/> Unrealized<br/> Losses</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Estimated<br/> Fair&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Marketable securities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial paper</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16,644</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(25</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16,621</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate bonds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,738</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(6</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,732</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">U.S. government securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">495</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">495</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">20,877</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(31</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">20,848</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:57%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amortized<br/> Cost</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross<br/> Unrealized<br/> Gains</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross<br/> Unrealized<br/> Losses</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Estimated<br/> Fair&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash equivalents:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Money market funds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,888</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,888</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total cash equivalents</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,888</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,888</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Marketable securities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial paper</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">65,443</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(34</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">65,412</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate bonds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12,581</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12,574</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">78,024</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(41</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">77,986</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock', window );">Available-for-Sale Securities in an Unrealized Loss Position</a></td>
<td class="text"><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> securities in an unrealized loss position for which an allowance for credit losses has not been recorded as of September&#160;30, 2023 and December&#160;31, 2022, aggregated by major security type and length of time in a continuous unrealized loss position: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:56%"></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="22" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">September&#160;30, 2023</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Less Than 12 Months</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">12 Months or<br/> Longer</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Total</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Fair<br/> Value</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Unrealized<br/> Losses</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Fair<br/> Value</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Unrealized<br/> Losses</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Fair<br/> Value</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Unrealized<br/> Losses</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial paper</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">78,820</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(93</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">78,820</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(93</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">U.S. government securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate bonds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18,373</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(22</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18,373</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(22</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">97,193</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(115</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">97,193</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(115</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td colspan="24" style="height:12pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="22" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">December&#160;31, 2022</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Less Than 12 Months</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">12 Months or<br/> Longer</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Total</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Fair<br/> Value</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Unrealized<br/> Losses</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Fair<br/> Value</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Unrealized<br/> Losses</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Fair<br/> Value</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Unrealized<br/> Losses</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial paper</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17,699</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(27</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17,699</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(27</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">U.S. government securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,735</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,735</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate bonds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,732</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(6</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,732</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(6</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">25,166</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(34</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">25,166</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(34</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> securities in an unrealized loss position for which an allowance for credit losses has not been recorded as of December&#160;31, 2022 and 2021, aggregated by major security type and length of time in a continuous unrealized loss position: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:46%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="22" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Less Than 12 Months</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">12&#160;Months&#160;or&#160;Longer</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Losses</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Losses</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Losses</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial paper</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17,699</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(27</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17,699</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(27</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">U.S. government securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,735</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,735</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate bonds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,732</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(6</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,732</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(6</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">25,166</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(34</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">25,166</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(34</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:46%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="22" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Less Than 12 Months</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">12&#160;Months&#160;or&#160;Longer</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Losses</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Losses</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Losses</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial paper</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">47,425</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(34</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">47,425</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(34</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate bonds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12,573</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12,573</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">59,998</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(41</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">59,998</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(41</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Contractual Maturities of Marketable Securities at Estimated Fair Value</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the contractual maturities of the Company&#8217;s marketable securities at estimated fair value (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:67%"></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">September&#160;30,<br/> 2023</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">December&#160;31,<br/> 2022</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Due in one year or less</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">102,518</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">20,848</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Due thereafter</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10,489</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">113,007</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">20,848</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the contractual maturities of the Company&#8217;s marketable securities at estimated fair value (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:74%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Due in one year or less</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">20,848</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">77,986</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Due in 1 &#8211; 2 years</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">20,848</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">77,986</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-6<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash, cash equivalents, and investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140168006544896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment Net</a></td>
<td class="text"><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Property and equipment, net consist of the following (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:76%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Laboratory equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,257</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,245</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Furniture and office equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">520</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">520</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Computer equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">73</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">54</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Software</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">121</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">139</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Leasehold improvements</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,393</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,393</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Property and equipment, gross</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,364</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,351</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: Accumulated depreciation and amortization</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(4,144</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,802</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Property and equipment, net</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,220</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,549</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140168003290320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued and Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 22, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Accrued and Other Current Liabilities</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accrued liabilities consist of the following (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:80%"></td>
<td style="vertical-align:bottom;width:11%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;of&#160;June&#160;22,<br/>2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued option cost payable to Paragon</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18,987</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued professional and consulting fees</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">917</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Fair value of assumed Parapyre Option Obligation (Note&#160;3)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">143</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">20,047</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
<td class="text"><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accrued and other current liabilities consist of the following (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:66%"></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">September&#160;30,<br/> 2023</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">December&#160;31,<br/> 2022</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued compensation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,368</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,589</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued contracted research and development costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,669</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,972</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued professional and consulting fees</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,484</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">946</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued other</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">340</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">330</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total accrued and other current liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,861</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12,837</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
<td class="text"><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accrued and other current liabilities consist of the following (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:74%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued compensation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,589</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,988</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued contracted research and development costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,972</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,995</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued professional and consulting fees</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">946</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,264</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">330</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">783</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total accrued and other current liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12,837</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14,030</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140168006465280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_ScheduleOfOperatingAndFinancingLeasesPresentedInBalanceSheetTableTextBlock', window );">Summary of Operating and Finance Leases Presented in Balance Sheet</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the Company&#8217;s recognition of its operating and finance leases (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:31%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td style="width:50%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Classification</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Assets</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,430</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,806</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><span style="-sec-ix-hidden:hidden95765537">Finan</span><span style="-sec-ix-hidden:hidden95765538">ce</span></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> assets</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">597</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">798</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td colspan="3" style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total leased assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,027</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,604</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Leases</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Current</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Operating lease liabilities</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">625</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">436</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><span style="-sec-ix-hidden:hidden95765544">Fin</span><span style="-sec-ix-hidden:hidden95765545">ance</span></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Accrued and other current liabilities</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">418</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div> operating lease liabilities</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,004</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,608</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><span style="-sec-ix-hidden:hidden95765401"><span style="-sec-ix-hidden:hidden95765511">Finan</span>ce</span></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> liabilities</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td colspan="3" style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,645</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,478</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_SummaryOfWeightedAverageRemainingLeaseTermAndDiscountRatesOfOperatingAndFinanceLeasesTableTextBlock', window );">Summary of Weighted Average Remaining Lease Term and Discount Rates For Company's Operating and Finance Leases</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the weighted-average remaining lease term and discount rates for the Company&#8217;s operating and finance leases: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:83%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Lease term (years)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating leases</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5.3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Finance leases</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Discount rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating leases</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10.6</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10.7</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Finance leases</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10.2</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.7</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Summary of Lease Cost</a></td>
<td class="text"><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the lease costs pertaining to the Company&#8217;s operating leases (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:70%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease cost</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">910</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">991</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,258</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Variable lease cost</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">472</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">519</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">665</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total lease cost</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,382</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,510</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,923</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_ScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesTableTextBlock', window );">Schedule of Maturities of Operating and Finance Lease Liabilities</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The maturities of the Company&#8217;s operating and finance lease liabilities as of December&#160;31, 2022 were as follows (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:76%"></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Operating</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Leases</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Finance</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Leases</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,078</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2024</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,103</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2025</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,129</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2026</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,163</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2027</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,198</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Thereafter</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">403</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total lease payments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,074</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Imputed interest</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,445</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,629</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_ScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of maturities of operating and finance lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_ScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_ScheduleOfOperatingAndFinancingLeasesPresentedInBalanceSheetTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of operating and financing leases presented in balance sheet.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_ScheduleOfOperatingAndFinancingLeasesPresentedInBalanceSheetTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_SummaryOfWeightedAverageRemainingLeaseTermAndDiscountRatesOfOperatingAndFinanceLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of weighted average remaining lease term and discount rates of operating and finance leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_SummaryOfWeightedAverageRemainingLeaseTermAndDiscountRatesOfOperatingAndFinanceLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140168008130112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock', window );">Summary of Pre-funded Warrants for Common Stock Issued and Outstanding</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of September&#160;30, 2023, the following <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants for common stock were issued and outstanding: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:48%"></td>
<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">Issue Date</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Expiration&#160;Date</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Exercise&#160;Price</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Number&#160;of&#160;Warrants<br/> Outstanding</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">February&#160;8, 2019</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">None</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.0025</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">April&#160;30, 2020</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">None</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.0025</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">May&#160;20, 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">None</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.0025</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">250,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">250,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2022, the following <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants to purchase common stock were issued and outstanding: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:46%"></td>
<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Issue Date</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Expiration&#160;Date</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Exercise&#160;Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of&#160;Warrants</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Outstanding</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><span style="-sec-ix-hidden:hidden95765421">February 2019</span></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">None</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.0025</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">150,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><span style="-sec-ix-hidden:hidden95765422">April 2020</span></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">None</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.0025</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">474,413</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><span style="-sec-ix-hidden:hidden95765423">May 2022</span></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">None</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.0025</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">531,250</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,155,663</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the notional amounts of outstanding derivative positions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140168007934288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Expenses related to Related Party which were Settled in Cash</a></td>
<td class="text"><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is the summary of expenses related to the Paragon Agreement, which were ultimately settled in cash (in millions): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:52%"></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Three Months<br/> Ended<br/> September&#160;30,</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Nine Months<br/> Ended<br/> September&#160;30,</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">2023</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">2022</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">2023</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">2022</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Financial&#160;Statement&#160;Line&#160;Item</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Reimbursable costs under the Paragon Agreement</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16.7</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17.9</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Research&#160;and&#160;development</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_ScheduleOfBalancesDueToAffiliatesTableTextBlock', window );">Related Party Accounts Payable</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is the summary of Related party accounts payable (in millions): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:67%"></td>
<td style="vertical-align:bottom;width:12%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:12%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">September&#160;30,<br/> 2023</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">December&#160;31,<br/> 2022</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Reimbursable costs under the Paragon Agreement</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16.8</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Parapyre Option Obligation liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total related party accounts payable</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">19.8</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_ScheduleOfBalancesDueToAffiliatesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of balances due to affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_ScheduleOfBalancesDueToAffiliatesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140168001834208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Asset Acquisition (Tables)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 22, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionTableTextBlock', window );">Asset Acquisition Cost</a></td>
<td class="text"><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Asset Acquisition costs are shown on the following table (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:80%"></td>
<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;of&#160;June&#160;22,<br/>2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Consideration transferred in Series A Preferred Stock and common stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">109,979</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Transaction costs incurred by Aeglea</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,197</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total cost to acquire asset</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">113,176</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#8217;s allocation of the purchase price to net assets acquired is as follows (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:80%"></td>
<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;of&#160;June&#160;22,<br/>2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Acquired <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">130,188</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash acquired</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,035</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(20,047</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total cost to acquire asset</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">113,176</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Asset Acquisition Costs are shown on the following table (in millions): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:87%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">June&#160;22,<br/> 2023</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Consideration transferred in Series A Preferred Stock and common stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">110.0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Transaction costs incurred by Aeglea</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total cost to acquire asset</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">113.2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The allocation of the purchase price to net assets acquired is as a follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:87%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">June&#160;22,<br/> 2023</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Acquired <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">130.2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash acquired</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Assumed liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(20.0</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total cost to acquire asset</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">113.2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480123/805-50-15-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140168001347376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liabilities, Convertible Preferred Stock and Stockholders' (Deficit) Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Employee and Non-Employee Stock Option Activity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes employee and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> stock option activity for the year ended December&#160;31, 2022: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:55%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Issuable</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Under</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Options</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Average</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Exercise<br/> Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Average</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Remaining</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Contractual</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Term</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Aggregate</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Intrinsic</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(in years)</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(in&#160;thousands)</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Outstanding as of December&#160;31, 2021</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">264,303</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">189.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7.90</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">328</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Granted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">235,199</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">45.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercised</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Forfeited</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(94,421</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">153.50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Outstanding as of December&#160;31, 2022</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">405,081</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">113.75</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.72</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Options vested and expected to vest as of December&#160;31, 2022</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">397,772</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">112.50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.78</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Options exercisable as of December&#160;31, 2022</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">163,450</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">171.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.93</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock', window );">Summary of Employee Restricted Stock Activity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes employee restricted stock activity for the year ended December&#160;31, 2022: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:71%"></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average&#160;Grant<br/> Date&#160;Fair&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Unvested restricted stock units as of December&#160;31, 2021</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,600</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">203.25</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Granted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Vested</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Forfeited</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,940</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">203.25</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Unvested restricted stock units as of December&#160;31, 2022</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,660</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">203.25</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Stock-Based Compensation Expense</a></td>
<td class="text"><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Total stock-based compensation expense related to all plans was as follows (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:64%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Three&#160;Months&#160;Ended<br/> September&#160;30,</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Nine Months Ended<br/> September&#160;30,</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">2023</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">2022</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">2023</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">2022</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development <div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">(1)</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,965</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">639</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,136</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,031</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">General and administrative</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,820</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">926</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,269</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,653</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total stock-based compensation expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,785</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,565</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,405</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,684</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">(1)</div>&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">For the three and nine months ended September&#160;30, 2023, $2.7&#160;million and $2.9&#160;million, respectively, was recognized as stock compensation expense related to the Parapyre Option Obligation. There were no such expenses for the three and nine months ended September&#160;30, 2022. </div></td></tr></table><span></span>
</td>
<td class="text"><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Total stock-based compensation expense recognized from the Company&#8217;s equity incentive plans, 2018 Plan, and the 2016 ESPP for the years ended December&#160;31, 2022, 2021, and 2020 was as follows (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:47%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="22" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Employees</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Non-</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Employees</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Employees</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Non-</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Employees</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Employees</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Non-</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Employees</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,591</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,723</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,168</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">36</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">General and administrative</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,520</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,315</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,052</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total stock-based compensation expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,111</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,038</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,220</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">36</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Assumptions used to Estimate the Fair Value of Stock Options Granted</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the weighted-average Black-Scholes option pricing model assumptions used to estimate the fair value of stock options granted under the Company&#8217;s 2016 Plan, and the shares purchasable under the 2016 ESPP during the periods presented: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:67%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Three&#160;Months&#160;Ended<br/> September&#160;30,</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Nine&#160;Months&#160;Ended<br/> September&#160;30,</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">2023</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">2022</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">2023</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">2022</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2016 Plan</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected term (in years)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.08</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.02</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.04</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5.96</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected volatility</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">101</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">85</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">111</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">83</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Risk-free interest</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.28</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.16</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.07</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.43</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Dividend yield</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2016 ESPP</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected term (in years)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.49</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.49</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected volatility</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">222</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">95</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">181</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">84</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Risk-free interest</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5.29</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.26</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.99</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.95</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Dividend yield</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><span></span>
</td>
<td class="text">The following table summarizes the weighted-average assumptions used in calculating the fair value of the awards: <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:78%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Stock Options Granted</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected term (in years)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5.99</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.10</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected volatility</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">84</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">83</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">76</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Risk-free interest</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.93</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.88</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.06</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Dividend yield</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">2016 ESPP</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected term (in years)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.49</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected volatility</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">84</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">86</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">76</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Risk-free interest</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.95</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.08</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.75</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Dividend yield</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock', window );">Pre-funded Warrants for Common Stock Issued and Outstanding</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of September&#160;30, 2023, the following <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants for common stock were issued and outstanding: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:48%"></td>
<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">Issue Date</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Expiration&#160;Date</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Exercise&#160;Price</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Number&#160;of&#160;Warrants<br/> Outstanding</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">February&#160;8, 2019</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">None</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.0025</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">April&#160;30, 2020</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">None</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.0025</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">May&#160;20, 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">None</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.0025</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">250,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">250,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2022, the following <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants to purchase common stock were issued and outstanding: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:46%"></td>
<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Issue Date</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Expiration&#160;Date</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Exercise&#160;Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of&#160;Warrants</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Outstanding</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><span style="-sec-ix-hidden:hidden95765421">February 2019</span></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">None</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.0025</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">150,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><span style="-sec-ix-hidden:hidden95765422">April 2020</span></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">None</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.0025</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">474,413</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><span style="-sec-ix-hidden:hidden95765423">May 2022</span></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">None</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.0025</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">531,250</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,155,663</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock', window );">Stock Awards Granted</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the Company&#8217;s stock awards granted under all plans for each of the periods indicated: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:34%"></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Three Months Ended September&#160;30,</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Nine Months Ended September&#160;30,</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">2023</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">2022</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">2023</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">2022</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Grants</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Weighted<br/> Average<br/> Grant<br/> Date Fair<br/> Value</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Grants</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Weighted<br/> Average<br/> Grant<br/> Date Fair<br/> Value</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Grants</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Weighted<br/> Average<br/> Grant<br/> Date Fair<br/> Value</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Grants</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Weighted<br/> Average<br/> Grant<br/> Date Fair<br/> Value</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock options</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,044,667</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14.50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">50,806</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16.75</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,867,366</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9.65</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">153,686</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">52.50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Subparagraph (c)<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the notional amounts of outstanding derivative positions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the total intrinsic value of options exercised (or share units converted), share-based liabilities paid, and the total fair value of shares vested during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (d)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140168007895376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Strategic License Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_LicenseAndCollaborationAgreementAbstract', window );"><strong>License And Collaboration Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Summary of Changes in Contract Liabilities</a></td>
<td class="text"><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents changes in the Company&#8217;s contract liabilities for the periods presented (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:52%"></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">Nine Months Ended September&#160;30, 2023</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">December&#160;31,<br/> 2022</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Additions</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Deductions</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">September&#160;30,<br/> 2023</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Contract liabilities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred revenue</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,696</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">575</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3,271</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><span></span>
</td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents changes in the Company&#8217;s contract liabilities for the periods presented (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:51%"></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Additions</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Deductions</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Contract liabilities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred revenue</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,576</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,449</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,329</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,696</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_LicenseAndCollaborationAgreementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License and collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_LicenseAndCollaborationAgreementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140168005462368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Loss Income Before Income Tax Expense by Jurisdiction</a></td>
<td class="text"><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the (loss) income before income tax expense by jurisdiction for the periods indicated: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:64%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Domestic</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(84,113</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(65,940</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(80,893</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Foreign</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">162</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">280</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Loss before income tax expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(83,951</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(65,660</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(80,893</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Summary of Difference Between Provision for Income Taxes and Amounts Computed by Applying Statutory Federal Income Tax Rate to Income Before Income Taxes</a></td>
<td class="text">The difference between the Company&#8217;s provision for income taxes and the amounts computed by applying the statutory federal income tax rate to income before income taxes is as follows (in thousands): <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:64%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Tax provision derived by applying the federal statutory rate to income before income taxes</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(17,630</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(13,789</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(16,988</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Permanent differences and other</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,042</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,002</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">482</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Federal tax credits</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3,559</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3,815</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3,905</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">State tax credits</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(640</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(152</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(251</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Effect of tax rate on foreign jurisdiction</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">42</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(5</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in the valuation allowance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">20,609</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16,900</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">20,662</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Income tax (benefit) expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(136</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">141</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Components of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The components of the deferred tax assets and liabilities consist of the following (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:70%"></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred tax assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net operating loss carryforward</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">68,917</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">64,531</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Intangible assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11,149</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">57</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred revenue</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">566</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">668</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">846</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock-based compensation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,293</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,767</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Federal tax credits</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21,914</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18,579</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">State tax credits</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,631</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">991</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">190</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">220</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total deferred tax assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">108,328</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">87,991</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred tax liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Depreciable assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(676</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(948</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total deferred tax liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(676</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(948</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: Valuation allowance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(107,652</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(87,043</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred tax assets, net</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 12<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140168001422944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Weighted-Average Equity Instruments Excluded from Calculation of Diluted Net Loss Per Share</a></td>
<td class="text"><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following weighted-average equity instruments were excluded from the calculation of diluted net loss per share because their effect would have been anti-dilutive for the periods presented: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:54%"></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Three Months Ended<br/> September&#160;30,</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Nine Months Ended<br/> September&#160;30,</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">2023</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">2022</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">2023</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">2022</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Options to purchase common stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,135,672</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">351,533</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,426,224</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">335,395</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unvested restricted stock units</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">252</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,315</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Series A Preferred Stock (on an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">as-converted</div> basis)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">42,501,681</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14,851,447</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><span></span>
</td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following weighted-average equity instruments were excluded from the calculation of diluted net loss per share because their effect would have been anti-dilutive for the periods presented: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:84%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:67%"></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Options to purchase common stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">346,331</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">264,858</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">201,977</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unvested restricted stock units</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,982</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,975</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,239</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock', window );">Schedule of Reconciliation of Basic and Diluted Net Loss Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a reconciliation of the shares used as the denominator for the calculation of basic and diluted net loss per share: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:61%"></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average common shares</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,307,668</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,956,933</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,608,952</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,063,563</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">672,851</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">525,917</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total basic and diluted weighted average shares</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,371,231</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,629,784</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,134,869</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140168007888032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring Charges (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock', window );">Changes in Accrued Restructuring Balance</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the changes in the Company&#8217;s accrued restructuring balance (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:45%"></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Beginning&#160;Balance<br/> December&#160;31,&#160;2022</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Charges</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Payments</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Ending&#160;Balance<br/> September&#160;30,&#160;2023</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Severance liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,448</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(4,527</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,921</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock', window );">Charges Related to the Restructuring Activities</a></td>
<td class="text">A summary of the charges related to the restructuring activities is as follows (in thousands): <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:33%"></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Severance&#160;Related<br/> Expenses</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Stock&#160;Compensation<br/> Expenses</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Loss&#160;on&#160;Disposal&#160;of<br/> Long Lived Assets</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Lease&#160;Asset<br/> Impairment</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Total&#160;Restructuring&#160;Costs</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,182</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">123</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">749</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,405</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,459</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">General and administrative</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,266</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">870</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">182</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,175</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,493</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,448</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">993</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">931</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,580</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10,952</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140168003687024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The Company and Basis of Presentation - Narrative (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 26, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 22, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 30, 2023 </div>
<div>employee</div>
</th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($) </div>
<div>SEGMENT </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>SEGMENT </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_CompanyAndBasisOfPresentationLineItems', window );"><strong>Company and Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | SEGMENT</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent', window );">Employee workforce, termination percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83.00%<span></span>
</td>
<td class="nump">83.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 701,234<span></span>
</td>
<td class="nump">$ 425,624<span></span>
</td>
<td class="nump">$ 341,809<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents, and marketable securities | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 203,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_NumberOfEmployeesRetained', window );">Number of employees retained | employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_WorkingCapital', window );">Working capital | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_CashCashEquivalentsMarketableSecuritiesAndRestrictedCash', window );">Cash, cash equivalents, marketable securities, and restricted cash | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 57,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=agle_AssetAcquisitionMember', window );">Asset Acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_CompanyAndBasisOfPresentationLineItems', window );"><strong>Company and Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_FixedExchangeRatio', window );">Fixed exchange ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.54945%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=agle_SpyreTherapeuticsIncMember', window );">Spyre Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_CompanyAndBasisOfPresentationLineItems', window );"><strong>Company and Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_AssetAcquisitionStockholderPaymentPeriod', window );">Asset acquisition, stockholder payment period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_AssetAcquisitionCashPaymentThresholdPeriod', window );">Asset acquisition, cash payment, threshold period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=agle_Spyre2023EquityIncentivePlanMember', window );">Spyre 2023 Equity Incentive Plan | Asset Acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_CompanyAndBasisOfPresentationLineItems', window );"><strong>Company and Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_OutstandingAndUnexercisedStockOptions', window );">Number of outstanding and unexercised stock options to purchase (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,734<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=agle_Spyre2023EquityIncentivePlanMember', window );">Spyre 2023 Equity Incentive Plan | Spyre Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_CompanyAndBasisOfPresentationLineItems', window );"><strong>Company and Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_OutstandingAndUnexercisedStockOptions', window );">Number of outstanding and unexercised stock options to purchase (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,734<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=agle_SeriesANonVotingConvertiblePreferredStockMember', window );">Series A Non Voting Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_CompanyAndBasisOfPresentationLineItems', window );"><strong>Company and Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Conversion basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=agle_SeriesANonVotingConvertiblePreferredStockMember', window );">Series A Non Voting Convertible Preferred Stock | Asset Acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_CompanyAndBasisOfPresentationLineItems', window );"><strong>Company and Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares', window );">Number of shares transferred as equity interest in asset acquisition | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">364,887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Conversion basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=agle_SeriesANonVotingConvertiblePreferredStockMember', window );">Series A Non Voting Convertible Preferred Stock | Spyre Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_CompanyAndBasisOfPresentationLineItems', window );"><strong>Company and Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares', window );">Number of shares transferred as equity interest in asset acquisition | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">364,887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement | Series A Non Voting Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_CompanyAndBasisOfPresentationLineItems', window );"><strong>Company and Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of shares sold in private placement | shares</a></td>
<td class="nump">721,452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Gross proceeds received in private placement | $</a></td>
<td class="nump">$ 210,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_PlacementAgentAndOtherOfferingExpenses', window );">Placement agent and other offering expenses in private placement | $</a></td>
<td class="nump">$ 12,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Asset Acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_CompanyAndBasisOfPresentationLineItems', window );"><strong>Company and Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares', window );">Number of shares transferred as equity interest in asset acquisition | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">517,809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_AssetAcquisitionCashPaymentThresholdPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Cash Payment, Threshold Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_AssetAcquisitionCashPaymentThresholdPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset acquisition consideration transferred equity interest issued and issuable, shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_AssetAcquisitionStockholderPaymentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Stockholder Payment Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_AssetAcquisitionStockholderPaymentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_CashCashEquivalentsMarketableSecuritiesAndRestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash, cash equivalents, marketable securities and restricted cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_CashCashEquivalentsMarketableSecuritiesAndRestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_CompanyAndBasisOfPresentationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Company and basis of presentation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_CompanyAndBasisOfPresentationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_FixedExchangeRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fixed exchange ratio.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_FixedExchangeRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_NumberOfEmployeesRetained">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of employees retained.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_NumberOfEmployeesRetained</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_OutstandingAndUnexercisedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Outstanding and unexercised stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_OutstandingAndUnexercisedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_PlacementAgentAndOtherOfferingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Placement agent and other offering expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_PlacementAgentAndOtherOfferingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_WorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Working capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_WorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common shares issuable upon conversion for each share of preferred stock to be converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=agle_AssetAcquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=agle_AssetAcquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=agle_SpyreTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=agle_SpyreTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=agle_Spyre2023EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=agle_Spyre2023EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=agle_SeriesANonVotingConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=agle_SeriesANonVotingConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140168001429680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of the Business and Summary of Significant Accounting Policies - Summary of Asset Acquisition Cost (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 22, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_AcquiredInProcessResearchAndDevelopment', window );">Acquired in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (298)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 130,188<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAcquiredFromAcquisition', window );">Cash acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,035<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Cost to acquire asset</a></td>
<td class="nump">$ 113,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=agle_SpyreTherapeuticsIncMember', window );">Spyre Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable', window );">Consideration transferred in Series A Preferred Stock and common stock</a></td>
<td class="nump">109,979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost', window );">Transaction costs incurred by Aeglea</a></td>
<td class="nump">3,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_AcquiredInProcessResearchAndDevelopment', window );">Acquired in-process research and development</a></td>
<td class="nump">130,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAcquiredFromAcquisition', window );">Cash acquired</a></td>
<td class="nump">3,035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="num">(20,047)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Cost to acquire asset</a></td>
<td class="nump">$ 113,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_AcquiredInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Acquired in process research and development</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_AcquiredInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479908/805-50-55-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480060/805-50-25-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of acquirer's equity interest issued and issuable as part of consideration transferred in asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480060/805-50-25-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction cost incurred as part of consideration transferred in asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479908/805-50-55-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480060/805-50-25-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480123/805-50-15-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAcquiredFromAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAcquiredFromAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=agle_SpyreTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=agle_SpyreTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140167991117552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of the Business and Summary of Significant Accounting Policies - Additional Information (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 08, 2023</div></th>
<th class="th">
<div>Jun. 26, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 22, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 30, 2023 </div>
<div>employee</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>May 31, 2023</div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Stockholders' equity, reverse stock split</a></td>
<td class="text">1-for-25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Cost to acquire asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 113,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_AcquiredInProcessResearchAndDevelopment', window );">Acquired in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (298)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 130,188<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent', window );">Employee workforce, termination percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_NumberOfEmployeesRetained', window );">Number of employees retained | employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,592<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,592<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,863<span></span>
</td>
<td class="nump">$ 15,142<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=agle_USBankingInstitutionMember', window );">U.S. Banking Institution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=agle_ParapyreOptionObligationMember', window );">Parapyre Option Obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock', window );">Percentage of annual equity grant of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=agle_SeriesANonVotingConvertiblePreferredStockMember', window );">Series A Non Voting Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Conversion basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=agle_SeriesANonVotingConvertiblePreferredStockMember', window );">Series A Non Voting Convertible Preferred Stock | Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of shares sold in private placement | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">721,452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Gross proceeds received in private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 210,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_PlacementAgentAndOtherOfferingExpenses', window );">Placement agent and other offering expenses in private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=agle_AssetAcquisitionMember', window );">Asset Acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_FixedExchangeRatio', window );">Fixed exchange ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.54945%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=agle_AssetAcquisitionMember', window );">Asset Acquisition | Spyre 2023 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_OutstandingAndUnexercisedStockOptions', window );">Number of outstanding and unexercised stock options to purchase (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,734<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=agle_AssetAcquisitionMember', window );">Asset Acquisition | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares', window );">Number of shares transferred as equity interest in asset acquisition | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">517,809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=agle_AssetAcquisitionMember', window );">Asset Acquisition | Series A Non Voting Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares', window );">Number of shares transferred as equity interest in asset acquisition | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">364,887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Conversion basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=agle_SpyreTherapeuticsIncMember', window );">Spyre Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Cost to acquire asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 113,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableSharesOfCommonStockOnAnAsConvertedBasis', window );">Asset acquisition consideration transferred issuable shares of common stock on an as-converted basis | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,595,480<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_AcquiredInProcessResearchAndDevelopment', window );">Acquired in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 130,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet', window );">Asset Acquisition, net liabilities assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=agle_SpyreTherapeuticsIncMember', window );">Spyre Therapeutics, Inc. | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares', window );">Number of shares transferred as equity interest in asset acquisition | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">517,809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=agle_SpyreTherapeuticsIncMember', window );">Spyre Therapeutics, Inc. | Spyre 2023 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_OutstandingAndUnexercisedStockOptions', window );">Number of outstanding and unexercised stock options to purchase (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,734<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=agle_SpyreTherapeuticsIncMember', window );">Spyre Therapeutics, Inc. | Series A Non Voting Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares', window );">Number of shares transferred as equity interest in asset acquisition | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">364,887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 291.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_AcquiredInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Acquired in process research and development</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_AcquiredInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset acquisition assets acquired and liabilities assumed net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset acquisition consideration transferred equity interest issued and issuable, shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableSharesOfCommonStockOnAnAsConvertedBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset acquisition consideration transferred equity interest issued and issuable shares of common stock on an as-converted basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableSharesOfCommonStockOnAnAsConvertedBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_FixedExchangeRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fixed exchange ratio.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_FixedExchangeRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_NumberOfEmployeesRetained">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of employees retained.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_NumberOfEmployeesRetained</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Organization consolidation and presentation of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_OutstandingAndUnexercisedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Outstanding and unexercised stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_OutstandingAndUnexercisedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of annual equity grant of options to purchase outstanding shares of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_PlacementAgentAndOtherOfferingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Placement agent and other offering expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_PlacementAgentAndOtherOfferingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479908/805-50-55-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480060/805-50-25-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480555/946-210-45-21<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480555/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common shares issuable upon conversion for each share of preferred stock to be converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=agle_USBankingInstitutionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=agle_USBankingInstitutionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=agle_ParapyreOptionObligationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=agle_ParapyreOptionObligationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=agle_SeriesANonVotingConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=agle_SeriesANonVotingConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=agle_AssetAcquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=agle_AssetAcquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=agle_Spyre2023EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=agle_Spyre2023EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=agle_SpyreTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=agle_SpyreTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140168002169648">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Liabilities - Accrued and Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jun. 22, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_AccruedOptionCostPayable', window );">Accrued option cost payable to Paragon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,987<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional and consulting fees</a></td>
<td class="nump">$ 3,484<span></span>
</td>
<td class="nump">917<span></span>
</td>
<td class="nump">$ 946<span></span>
</td>
<td class="nump">$ 2,264<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProgramRightsObligations', window );">Fair value of assumed Parapyre Option Obligation (Note&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent', window );">Accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_AccruedOptionCostPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued option cost payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_AccruedOptionCostPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProgramRightsObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total amount of obligations related to rights to programming, including, but not limited to, feature films and episodic series, acquired under license agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProgramRightsObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140168002279984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Liabilities - Additional Information (Details) - Related Party - Paragon Agreement<br> $ in Millions</strong></div></th>
<th class="th">
<div>Jun. 22, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_AccruedLiabilitiesLineItems', window );"><strong>Accrued Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_RelatedPartyExpensesIncurredPriorToAssetAcquisition', window );">Related party expenses incurred prior to asset acquisition</a></td>
<td class="nump">$ 19.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_ResearchInitiationFees', window );">Research initiation fees</a></td>
<td class="nump">3.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_ReimbursableResearchCosts', window );">Reimbursable research costs</a></td>
<td class="nump">16.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_RelatedPartyExpensesUnpaidPriorToAssetAcquisition', window );">Related party expenses unpaid prior to asset acquisition</a></td>
<td class="nump">$ 19.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_AccruedLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_AccruedLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_ReimbursableResearchCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reimbursable research costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_ReimbursableResearchCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_RelatedPartyExpensesIncurredPriorToAssetAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related party expenses incurred prior to asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_RelatedPartyExpensesIncurredPriorToAssetAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_RelatedPartyExpensesUnpaidPriorToAssetAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related party expenses unpaid prior to asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_RelatedPartyExpensesUnpaidPriorToAssetAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_ResearchInitiationFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research initiation fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_ResearchInitiationFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=agle_ParagonAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=agle_ParagonAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140168002305696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Parapyre Option Obligation - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 22, 2023</div></th>
<th class="th"><div>May 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent', window );">Asset acquisition, contingent consideration, liability, current</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=agle_ParapyreOptionObligationMember', window );">Parapyre Option Obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock', window );">Percentage of annual equity grant of options</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of annual equity grant of options to purchase outstanding shares of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized from contingent consideration in asset acquisition, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480123/805-50-15-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480123/805-50-15-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=agle_ParapyreOptionObligationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=agle_ParapyreOptionObligationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140168002310880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>SUBSIDARY</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairments of long-lived assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_NumberOfSubsidiaryCorporationsOwned', window );">Number of subsidiary corporations owned | SUBSIDARY</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized Tax Benefits</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense', window );">Interest or penalties incurred</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_MarketableSecuritiesMaturityPeriod', window );">Marketable securities stated maturity period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_MarketableSecuritiesMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Marketable securities maturity period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_MarketableSecuritiesMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_NumberOfSubsidiaryCorporationsOwned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of subsidiary corporations owned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_NumberOfSubsidiaryCorporationsOwned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140167994879824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Summary of Useful Lives of Property and Equipment (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=agle_LaboratoryEquipmentMember', window );">Laboratory Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful lives of the property and equipment</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Office Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful lives of the property and equipment</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful lives of the property and equipment</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=agle_PurchasedSoftwareMember', window );">Software</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful lives of the property and equipment</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentBasisOfValuation', window );">Useful lives of the property and equipment</a></td>
<td class="text">Shorter of remaining lease term or estimated useful life<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentBasisOfValuation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Describes the basis at which an entity records its property, plant and equipment (for example at cost, fair value).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentBasisOfValuation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=agle_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=agle_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=agle_PurchasedSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=agle_PurchasedSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140167993917136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - Fair Value, Measurements, Recurring - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets, fair value</a></td>
<td class="nump">$ 185,372<span></span>
</td>
<td class="nump">$ 46,853<span></span>
</td>
<td class="nump">$ 86,874<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">31,152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets, fair value</a></td>
<td class="nump">22,828<span></span>
</td>
<td class="nump">3,732<span></span>
</td>
<td class="nump">12,574<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets, fair value</a></td>
<td class="nump">107,093<span></span>
</td>
<td class="nump">23,641<span></span>
</td>
<td class="nump">65,412<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets, fair value</a></td>
<td class="nump">55,451<span></span>
</td>
<td class="nump">15,250<span></span>
</td>
<td class="nump">8,888<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets, fair value</a></td>
<td class="nump">129,921<span></span>
</td>
<td class="nump">31,603<span></span>
</td>
<td class="nump">77,986<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">2,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets, fair value</a></td>
<td class="nump">22,828<span></span>
</td>
<td class="nump">3,732<span></span>
</td>
<td class="nump">12,574<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets, fair value</a></td>
<td class="nump">107,093<span></span>
</td>
<td class="nump">23,641<span></span>
</td>
<td class="nump">65,412<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">28,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Parapyre Option Obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">2,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Parapyre Option Obligation | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Parapyre Option Obligation | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">2,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Parapyre Option Obligation | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">CVR liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">28,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">CVR liability | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">CVR liability | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">CVR liability | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">28,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets, fair value</a></td>
<td class="nump">55,451<span></span>
</td>
<td class="nump">15,250<span></span>
</td>
<td class="nump">8,888<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money market funds | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets, fair value</a></td>
<td class="nump">55,451<span></span>
</td>
<td class="nump">15,250<span></span>
</td>
<td class="nump">$ 8,888<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money market funds | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money market funds | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets, fair value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. government securities | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. government securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. government securities | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=agle_ParapyreOptionObligationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=agle_ParapyreOptionObligationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=agle_ContingentValueRightLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=agle_ContingentValueRightLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140167990751984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Sep. 29, 2023</div></th>
<th class="th"><div>Jul. 07, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 26, 2023</div></th>
<th class="th"><div>Jun. 22, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>May 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Financial liabilities outstanding measured at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,405,000<span></span>
</td>
<td class="nump">$ 5,684,000<span></span>
</td>
<td class="nump">7,111,000<span></span>
</td>
<td class="nump">$ 8,038,000<span></span>
</td>
<td class="nump">$ 6,256,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_FairValueAssetsLevel1ToLevel2TransfersAmount1', window );">Fair value assets transferred from level 1 to level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForwardContractsMember', window );">Forward contract liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Financial liabilities outstanding measured at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 164,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 106,200,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 164,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 106,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Change in fair value of forward contract liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,360,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">83,530,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value of liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (58,100,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25,400,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=agle_SpyreTherapeuticsIncMember', window );">Spyre Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_AssetAcquisitionStockholderPaymentPeriod', window );">Asset acquisition, stockholder payment period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_AssetAcquisitionCashPaymentThresholdPeriod', window );">Asset acquisition, cash payment, threshold period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=agle_ContingentValueRightLiabilityMember', window );">CVR liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value of liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=agle_ParapyreOptionObligationMember', window );">Parapyre Option Obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock', window );">Percentage of annual equity grant of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-based payment award, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration', window );">Fair value of contingent consideration assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,900,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=agle_ParapyreOptionObligationMember', window );">Parapyre Option Obligation | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodFairValue', window );">Pro-rated estimated fair value of options</a></td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=agle_SeriesANonVotingConvertiblePreferredStockMember', window );">Series A Non Voting Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of Series A non-voting convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 189,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 197,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 189,741,000<span></span>
</td>
<td class="nump">$ 197,323,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=agle_SeriesANonVotingConvertiblePreferredStockMember', window );">Series A Non Voting Convertible Preferred Stock | Asset Acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares', window );">Number of shares transferred as equity interest in asset acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">364,887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=agle_SeriesANonVotingConvertiblePreferredStockMember', window );">Series A Non Voting Convertible Preferred Stock | Spyre Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares', window );">Number of shares transferred as equity interest in asset acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">364,887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_AssetAcquisitionCashPaymentThresholdPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Cash Payment, Threshold Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_AssetAcquisitionCashPaymentThresholdPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset acquisition consideration transferred equity interest issued and issuable, shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_AssetAcquisitionStockholderPaymentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Stockholder Payment Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_AssetAcquisitionStockholderPaymentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_FairValueAssetsLevel1ToLevel2TransfersAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value assets level1 To level2 transfers amount1.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_FairValueAssetsLevel1ToLevel2TransfersAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of annual equity grant of options to purchase outstanding shares of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Granted In Period, Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contingent consideration recognized as part of consideration transferred in asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480060/805-50-25-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDerivativeInstrumentsNetPretax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForwardContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForwardContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=agle_SpyreTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=agle_SpyreTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=agle_ContingentValueRightLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=agle_ContingentValueRightLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=agle_ParapyreOptionObligationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=agle_ParapyreOptionObligationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=agle_SeriesANonVotingConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=agle_SeriesANonVotingConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=agle_AssetAcquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=agle_AssetAcquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140168002300176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Changes in Derivative Liabilities (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForwardContractsMember', window );">Forward Contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">$ 106,200,000<span></span>
</td>
<td class="nump">$ 164,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value</a></td>
<td class="nump">58,100,000<span></span>
</td>
<td class="nump">25,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Issuance of Series A Preferred Stock on July 7, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(189,700,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">$ 164,300,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=agle_ContingentValueRightLiabilityMember', window );">CVR liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,300,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Fair value at CVR issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,200,000<span></span>
</td>
<td class="nump">$ 28,200,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForwardContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForwardContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=agle_ContingentValueRightLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=agle_ContingentValueRightLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140167994879984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Significant Inputs used to Estimate the Fair Value of Derivative Liability (Details) - Level 3 - CVR liability<br></strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Estimated probability of success</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Risk-adjusted discount rates</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="nump">0.0757<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Estimated probability of success</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="nump">0.27<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Risk-adjusted discount rates</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="nump">0.0714<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure derivative liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=agle_ContingentValueRightLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=agle_ContingentValueRightLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=agle_MeasurementInputProabilityOfSuccessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=agle_MeasurementInputProabilityOfSuccessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140167990739552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash Equivalents and Marketable Securities - Estimated Fair Value of Cash Equivalents and Marketable Securities and the Gross Unrealized Gains and Losses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents, amortized cost</a></td>
<td class="nump">$ 72,362<span></span>
</td>
<td class="nump">$ 26,007<span></span>
</td>
<td class="nump">$ 8,888<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_CashEquivalentsUnrealizedGains', window );">Cash equivalents,Gross Unrealized Gains</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_CashEquivalentsUnrealizedLosses', window );">Cash equivalents, gross unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents, estimated fair value</a></td>
<td class="nump">72,365<span></span>
</td>
<td class="nump">26,005<span></span>
</td>
<td class="nump">8,888<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Marketable securities, amortized cost</a></td>
<td class="nump">113,121<span></span>
</td>
<td class="nump">20,877<span></span>
</td>
<td class="nump">78,024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Marketable securities, gross unrealized gains</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Marketable securities, gross unrealized losses</a></td>
<td class="num">(115)<span></span>
</td>
<td class="num">(31)<span></span>
</td>
<td class="num">(41)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities, estimated fair value</a></td>
<td class="nump">113,007<span></span>
</td>
<td class="nump">20,848<span></span>
</td>
<td class="nump">77,986<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents, amortized cost</a></td>
<td class="nump">55,451<span></span>
</td>
<td class="nump">15,250<span></span>
</td>
<td class="nump">8,888<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_CashEquivalentsUnrealizedGains', window );">Cash equivalents,Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_CashEquivalentsUnrealizedLosses', window );">Cash equivalents, gross unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents, estimated fair value</a></td>
<td class="nump">55,451<span></span>
</td>
<td class="nump">15,250<span></span>
</td>
<td class="nump">8,888<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents, amortized cost</a></td>
<td class="nump">16,911<span></span>
</td>
<td class="nump">7,021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_CashEquivalentsUnrealizedGains', window );">Cash equivalents,Gross Unrealized Gains</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_CashEquivalentsUnrealizedLosses', window );">Cash equivalents, gross unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents, estimated fair value</a></td>
<td class="nump">16,914<span></span>
</td>
<td class="nump">7,020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Marketable securities, amortized cost</a></td>
<td class="nump">90,272<span></span>
</td>
<td class="nump">16,644<span></span>
</td>
<td class="nump">65,443<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Marketable securities, gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Marketable securities, gross unrealized losses</a></td>
<td class="num">(93)<span></span>
</td>
<td class="num">(25)<span></span>
</td>
<td class="num">(34)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities, estimated fair value</a></td>
<td class="nump">90,179<span></span>
</td>
<td class="nump">16,621<span></span>
</td>
<td class="nump">65,412<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Marketable securities, amortized cost</a></td>
<td class="nump">22,849<span></span>
</td>
<td class="nump">3,738<span></span>
</td>
<td class="nump">12,581<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Marketable securities, gross unrealized gains</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Marketable securities, gross unrealized losses</a></td>
<td class="num">(22)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities, estimated fair value</a></td>
<td class="nump">22,828<span></span>
</td>
<td class="nump">3,732<span></span>
</td>
<td class="nump">$ 12,574<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember', window );">U.S. government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents, amortized cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,736<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_CashEquivalentsUnrealizedGains', window );">Cash equivalents,Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_CashEquivalentsUnrealizedLosses', window );">Cash equivalents, gross unrealized losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents, estimated fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,735<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Marketable securities, amortized cost</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Marketable securities, gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Marketable securities, gross unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities, estimated fair value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_CashEquivalentsUnrealizedGains">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash equivalents unrealized gains.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_CashEquivalentsUnrealizedGains</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_CashEquivalentsUnrealizedLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash equivalents unrealized losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_CashEquivalentsUnrealizedLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140167990774848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash Equivalents and Marketable Securities - Available-for-Sale Securities in an Unrealized Loss Position (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less Than 12 Months</a></td>
<td class="nump">$ 97,193<span></span>
</td>
<td class="nump">$ 25,166<span></span>
</td>
<td class="nump">$ 59,998<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 Months or Longer</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract', window );"><strong>Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less Than 12 Months</a></td>
<td class="num">(115)<span></span>
</td>
<td class="num">(34)<span></span>
</td>
<td class="num">(41)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 Months or Longer</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total, Fair Value</a></td>
<td class="nump">97,193<span></span>
</td>
<td class="nump">25,166<span></span>
</td>
<td class="nump">59,998<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total, unrealized losses</a></td>
<td class="num">(115)<span></span>
</td>
<td class="num">(34)<span></span>
</td>
<td class="num">(41)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less Than 12 Months</a></td>
<td class="nump">78,820<span></span>
</td>
<td class="nump">17,699<span></span>
</td>
<td class="nump">47,425<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 Months or Longer</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract', window );"><strong>Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less Than 12 Months</a></td>
<td class="num">(93)<span></span>
</td>
<td class="num">(27)<span></span>
</td>
<td class="num">(34)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 Months or Longer</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total, Fair Value</a></td>
<td class="nump">78,820<span></span>
</td>
<td class="nump">17,699<span></span>
</td>
<td class="nump">47,425<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total, unrealized losses</a></td>
<td class="num">(93)<span></span>
</td>
<td class="num">(27)<span></span>
</td>
<td class="num">(34)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember', window );">U.S. government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less Than 12 Months</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,735<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 Months or Longer</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract', window );"><strong>Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less Than 12 Months</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 Months or Longer</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total, Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,735<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total, unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less Than 12 Months</a></td>
<td class="nump">18,373<span></span>
</td>
<td class="nump">3,732<span></span>
</td>
<td class="nump">12,573<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 Months or Longer</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract', window );"><strong>Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less Than 12 Months</a></td>
<td class="num">(22)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 Months or Longer</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total, Fair Value</a></td>
<td class="nump">18,373<span></span>
</td>
<td class="nump">3,732<span></span>
</td>
<td class="nump">12,573<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total, unrealized losses</a></td>
<td class="num">$ (22)<span></span>
</td>
<td class="num">$ (6)<span></span>
</td>
<td class="num">$ (7)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140167990687424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash Equivalents and Marketable Securities - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($) </div>
<div>bank</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($) </div>
<div>bank</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 22, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_CashEquivalentsAndMarketableSecuritiesLineItems', window );"><strong>Cash Equivalents And Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_NumberOfDomesticBankingInstitutions', window );">Number of domestic banking institutions (in banks) | bank</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">US Government Agencies Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_CashEquivalentsAndMarketableSecuritiesLineItems', window );"><strong>Cash Equivalents And Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Debt securities, available-for-sale, allowance for credit loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_ImpairmentOfMarketableSecurities', window );">Impairment of marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments', window );">Realized gains or losses on marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestReceivable', window );">Accrued interest receivable on available-for-sale debt securities</a></td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=agle_USBankingInstitutionMember', window );">U.S. Banking Institution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_CashEquivalentsAndMarketableSecuritiesLineItems', window );"><strong>Cash Equivalents And Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash deposits in excess of FDIC limit</a></td>
<td class="nump">16,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=agle_USBankingInstitutionMember', window );">U.S. Banking Institution | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_CashEquivalentsAndMarketableSecuritiesLineItems', window );"><strong>Cash Equivalents And Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">Cash, FDIC insured amount</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_CashEquivalentsAndMarketableSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash equivalents and marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_CashEquivalentsAndMarketableSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_ImpairmentOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Impairment of marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_ImpairmentOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_NumberOfDomesticBankingInstitutions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Domestic Banking Institutions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_NumberOfDomesticBankingInstitutions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480555/946-210-45-21<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480555/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFDICInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFDICInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480833/946-310-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=agle_USBankingInstitutionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=agle_USBankingInstitutionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140168001258240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash Equivalents and Marketable Securities - Contractual Maturities of Marketable Securities at Estimated Fair Value (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Due in one year or less</a></td>
<td class="nump">$ 102,518<span></span>
</td>
<td class="nump">$ 20,848<span></span>
</td>
<td class="nump">$ 77,986<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne', window );">Due thereafter</a></td>
<td class="nump">10,489<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Total marketable securities</a></td>
<td class="nump">$ 113,007<span></span>
</td>
<td class="nump">$ 20,848<span></span>
</td>
<td class="nump">$ 77,986<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-For-Sale, Fair Value, Maturity, Allocated And Single Maturity Date, After Year One</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480832/942-320-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140168003947712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment, Net - Schedule of Property and Equipment Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,364<span></span>
</td>
<td class="nump">$ 7,351<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,144)<span></span>
</td>
<td class="num">(2,802)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">3,220<span></span>
</td>
<td class="nump">4,549<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=agle_LaboratoryEquipmentMember', window );">Laboratory Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,257<span></span>
</td>
<td class="nump">2,245<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Office Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">520<span></span>
</td>
<td class="nump">520<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73<span></span>
</td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=agle_PurchasedSoftwareMember', window );">Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">121<span></span>
</td>
<td class="nump">139<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,393<span></span>
</td>
<td class="nump">$ 4,393<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=agle_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=agle_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=agle_PurchasedSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=agle_PurchasedSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140168002327696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">$ 744<span></span>
</td>
<td class="nump">$ 1,182<span></span>
</td>
<td class="nump">$ 1,567<span></span>
</td>
<td class="nump">$ 1,576<span></span>
</td>
<td class="nump">$ 996<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_PropertyPlantAndEquipmentMember', window );">Property, Plant and Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_PropertyPlantAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_PropertyPlantAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140168005692928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued and Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jun. 22, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Accrued compensation</a></td>
<td class="nump">$ 5,368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,589<span></span>
</td>
<td class="nump">$ 4,988<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_AccruedContractedResearchAndDevelopmentCosts', window );">Accrued contracted research and development costs</a></td>
<td class="nump">6,669<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,972<span></span>
</td>
<td class="nump">5,995<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional and consulting fees</a></td>
<td class="nump">3,484<span></span>
</td>
<td class="nump">$ 917<span></span>
</td>
<td class="nump">946<span></span>
</td>
<td class="nump">2,264<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued other</a></td>
<td class="nump">340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">330<span></span>
</td>
<td class="nump">783<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Total accrued and other current liabilities</a></td>
<td class="nump">$ 15,861<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,837<span></span>
</td>
<td class="nump">$ 14,030<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_AccruedContractedResearchAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued contracted research and development costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_AccruedContractedResearchAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140168003628560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Apr. 30, 2019 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_ScheduleOfOperatingAndFinanceLeasedAssetsLineItems', window );"><strong>Schedule Of Operating And Finance Leased Assets Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Area of land | ft&#178;</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiration date</a></td>
<td class="text">Apr. 30,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating lease, payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_LetterOfCreditMember', window );">Letter of Credit Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_ScheduleOfOperatingAndFinanceLeasedAssetsLineItems', window );"><strong>Schedule Of Operating And Finance Leased Assets Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Letter of credit</a></td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_ScheduleOfOperatingAndFinanceLeasedAssetsLineItems', window );"><strong>Schedule Of Operating And Finance Leased Assets Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lessee, operating lease, renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseRenewalTerm1', window );">Lessee, finance lease, renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_ScheduleOfOperatingAndFinanceLeasedAssetsLineItems', window );"><strong>Schedule Of Operating And Finance Leased Assets Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lessee, operating lease, renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseRenewalTerm1', window );">Lessee, finance lease, renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TenantImprovements', window );">Tenant improvement allowance</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_ScheduleOfOperatingAndFinanceLeasedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of operating and finance leased assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_ScheduleOfOperatingAndFinanceLeasedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfLand">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of land held.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfLand</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseRenewalTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's finance lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseRenewalTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TenantImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of improvements having a life longer than one year that were made for the benefit of one or more tenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TenantImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140167990744128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Operating and Financing Leases Presented in Balance Sheet (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 3,430<span></span>
</td>
<td class="nump">$ 3,806<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 597<span></span>
</td>
<td class="nump">$ 798<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Other non-current assets<span></span>
</td>
<td class="text">Other non-current assets<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_OperatingAndFinanceLeaseRightOfUseAsset', window );">Total leased assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,027<span></span>
</td>
<td class="nump">$ 4,604<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">625<span></span>
</td>
<td class="nump">436<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease liabilities, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">$ 418<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Liabilities, Current, Statement of Financial Position [Extensible List]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Accrued and other current liabilities<span></span>
</td>
<td class="text">Accrued and other current liabilities<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, noncurrent</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 4,004<span></span>
</td>
<td class="nump">$ 4,608<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease liabilities, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Other non-current liabilities<span></span>
</td>
<td class="text">Other non-current liabilities<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_OperatingAndFinanceLeaseLiabilities', window );">Total lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,645<span></span>
</td>
<td class="nump">$ 5,478<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_OperatingAndFinanceLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating and Finance lease Liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_OperatingAndFinanceLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_OperatingAndFinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating and financing lease right of use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_OperatingAndFinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140168008126784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Summary of Weighted-Average Remaining Lease Term and Discount Rates for Operating and Finance Leases (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating leases, Weighted-average remaining lease term</a></td>
<td class="text">5 years 3 months 18 days<span></span>
</td>
<td class="text">6 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Finance leases, Weighted-average remaining lease term</a></td>
<td class="text">7 months 6 days<span></span>
</td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating leases, Weighted-average discount rate</a></td>
<td class="nump">10.60%<span></span>
</td>
<td class="nump">10.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Finance leases, Weighted-average discount rate</a></td>
<td class="nump">10.20%<span></span>
</td>
<td class="nump">6.70%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140168001823456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Summary of Lease Cost (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 910<span></span>
</td>
<td class="nump">$ 991<span></span>
</td>
<td class="nump">$ 1,258<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">472<span></span>
</td>
<td class="nump">519<span></span>
</td>
<td class="nump">665<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">$ 1,382<span></span>
</td>
<td class="nump">$ 1,510<span></span>
</td>
<td class="nump">$ 1,923<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140167995009648">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Maturities of Operating and Finance Lease Liabilities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 1,078<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">1,103<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">1,129<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">1,163<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2027</a></td>
<td class="nump">1,198<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">403<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">6,074<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Imputed interest</a></td>
<td class="num">(1,445)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total</a></td>
<td class="nump">4,629<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">6,074<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Finance Lease Liabilities, Payments, Due [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Total</a></td>
<td class="nump">$ 16<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140167994547632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1">40 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 30, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 28, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>VOTE </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees', window );">Underwriting discounts and commissions | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,200,000<span></span>
</td>
<td class="nump">$ 4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Offering costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_SharesAuthorized', window );">Shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,913,659<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_NumberOfCommonStockVotingRightsHeldPerShare', window );">Number of common stock holders voting right | VOTE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockVotingRights', window );">Common stock voting rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Each holder of common stock is entitled to one vote for each share of common stock held<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStock', window );">Common stock dividends declared | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares</a></td>
<td class="nump">694,892<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">694,892<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_ClassOfWarrantOrRightOfferingPriceOfWarrantsOrRights', window );">Offering price of warrant | $ / shares</a></td>
<td class="nump">$ 39.9975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39.9975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant | $ / shares</a></td>
<td class="nump">$ 0.0025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from sale of common stock | $</a></td>
<td class="nump">$ 42,900,000<span></span>
</td>
<td class="nump">$ 129,000,000<span></span>
</td>
<td class="nump">$ 64,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_PlacementAgentFeesAndOfferingCosts', window );">Placement agent fees and offering costs | $</a></td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_MaximumOwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercised', window );">Maximum ownership percentage of common stock shares for outstanding warrants to be exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_PeriodAfterNoticeReceivedByCompanyMaximumOwnershipPercentageToBeEffectiveDescription', window );">Period after notice received by company maximum ownership percentage to be effective description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The revised Maximum Ownership Percentage would be effective 61 days after the notice is received by the Company.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_OwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercisedToCertainHolders', window );">Ownership percentage for outstanding warrants To purchase shares of common stock to be exercised to certain holders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares</a></td>
<td class="nump">694,892<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">694,892<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_MaximumOwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercised', window );">Maximum ownership percentage of common stock shares for outstanding warrants to be exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="nump">430,107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Public offering price | $ / shares</a></td>
<td class="nump">$ 40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=agle_FollowOnPublicOfferingMember', window );">Follow-on Public Offering | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">617,692<span></span>
</td>
<td class="nump">185,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Public offering price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 118.75<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 118.7475<span></span>
</td>
<td class="nump">$ 199.9975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=agle_FollowOnPublicOfferingMember', window );">Follow-on Public Offering | Common Stock | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">544,413<span></span>
</td>
<td class="nump">160,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=agle_AtTheMarketSalesAgreementMember', window );">At-the-Market (ATM) Sales Agreement | JonesTrading Institutional Services LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">129,803<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_AggregateOfferingPriceOfCommonStock', window );">Aggregate offering price of common stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from sale of common stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_ProceedsFromIssuanceOfCommonStockGross', window );">Proceeds from issuance of common stock gross | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Underwriters' Over-allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">151,578<span></span>
</td>
<td class="nump">45,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_AggregateOfferingPriceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate offering price of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_AggregateOfferingPriceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_ClassOfWarrantOrRightOfferingPriceOfWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right offering price of warrants or rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_ClassOfWarrantOrRightOfferingPriceOfWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_MaximumOwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum ownership percentage for outstanding warrants to purchase shares of common stock to be exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_MaximumOwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_NumberOfCommonStockVotingRightsHeldPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common stock voting rights held per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_NumberOfCommonStockVotingRightsHeldPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_OwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercisedToCertainHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ownership percentage for outstanding warrants To purchase shares of common stock to be exercised to certain holders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_OwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercisedToCertainHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_PeriodAfterNoticeReceivedByCompanyMaximumOwnershipPercentageToBeEffectiveDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period after notice received by company maximum ownership percentage to be effective description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_PeriodAfterNoticeReceivedByCompanyMaximumOwnershipPercentageToBeEffectiveDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_PlacementAgentFeesAndOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Placement agent fees and offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_PlacementAgentFeesAndOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_ProceedsFromIssuanceOfCommonStockGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of common stock gross.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_ProceedsFromIssuanceOfCommonStockGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_SharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_SharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -SubTopic 405<br> -Topic 942<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481071/942-405-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expense related to distribution, servicing and underwriting fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.14)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=agle_FollowOnPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=agle_FollowOnPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=agle_AtTheMarketSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=agle_AtTheMarketSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=agle_JonesTradingInstitutionalServicesLimitedLiabilityCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=agle_JonesTradingInstitutionalServicesLimitedLiabilityCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140167994549600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Summary of Pre-funded Warrants for Common Stock Issued and Outstanding (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>May 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="nump">$ 0.0025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0025<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Pre-funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants Outstanding</a></td>
<td class="nump">1,155,663<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Pre-funded Warrants | February 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Issue Date</a></td>
<td class="text">Feb. 28,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_WarrantExpirationDate', window );">Expiration Date</a></td>
<td class="text">None<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="nump">$ 0.0025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants Outstanding</a></td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Pre-funded Warrants | April 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Issue Date</a></td>
<td class="text">Apr. 30,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_WarrantExpirationDate', window );">Expiration Date</a></td>
<td class="text">None<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="nump">$ 0.0025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants Outstanding</a></td>
<td class="nump">474,413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Pre-funded Warrants | May 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Issue Date</a></td>
<td class="text">May 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_WarrantExpirationDate', window );">Expiration Date</a></td>
<td class="text">None<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="nump">$ 0.0025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants Outstanding</a></td>
<td class="nump">531,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_WarrantExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant expiration date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_WarrantExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date the warrants or rights are exercisable, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=agle_FebruaryTwoThousandNinteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=agle_FebruaryTwoThousandNinteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=agle_AprilTwoThousandTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=agle_AprilTwoThousandTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=agle_MayTwoThousandTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=agle_MayTwoThousandTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>129
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140168003571328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 29, 2023</div></th>
<th class="th">
<div>Jun. 22, 2023 </div>
<div>USD ($) </div>
<div>BOARDSEAT</div>
</th>
<th class="th">
<div>Jul. 31, 2023 </div>
<div>USD ($) </div>
<div>PROGRAMOPTION</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($) </div>
<div>BOARDSEAT</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($) </div>
<div>BOARDSEAT</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 12, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_RelatedPartyTransactionNumberOfBoardSeats', window );">Number of board seats held by related party | BOARDSEAT</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,405<span></span>
</td>
<td class="nump">$ 5,684<span></span>
</td>
<td class="nump">$ 7,111<span></span>
</td>
<td class="nump">$ 8,038<span></span>
</td>
<td class="nump">$ 6,256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,800<span></span>
</td>
<td class="nump">$ 19,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=agle_AppointOfBoardMember', window );">Appoint Of Board | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_RelatedPartyTransactionNumberOfBoardSeats', window );">Number of board seats held by related party | BOARDSEAT</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=agle_ParagonAgreementMember', window );">Paragon Agreement | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_RelatedPartyExpensesIncurredPriorToAssetAcquisition', window );">Related party expenses incurred prior to asset acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_ResearchInitiationFees', window );">Research initiation fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_ReimbursableResearchCosts', window );">Reimbursable research costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_RelatedPartyExpensesUnpaidPriorToAssetAcquisition', window );">Related party expenses unpaid prior to asset acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock', window );">Percentage of annual equity grant of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-based payment award, term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,700<span></span>
</td>
<td class="nump">$ 2,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=agle_StockCompensationAndResearchAndDevelopmentExpenseMember', window );">Stock Compensation And Research And Development Expense | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Amount of related party transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,400<span></span>
</td>
<td class="nump">20,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=agle_ReimbursableCostsUnderParagonAgreementMember', window );">Reimbursable Costs Under Paragon Agreement | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,800<span></span>
</td>
<td class="nump">16,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=agle_MilestonePaymentsMember', window );">Milestone Payments | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Amount of related party transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=us-gaap_LicensingAgreementsMember', window );">Licensing Agreements | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_RelatedPartyTransactionNumberOfProgramOptionsOutstanding', window );">Number of program options outstanding | PROGRAMOPTION</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=agle_Spy001LicenseAgreementMember', window );">SPY001 License Agreement | Maximum | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_AmountToBePaidUnderAgreement', window );">Contingent obligation based on milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=agle_ParagonTherapeuticsIncMember', window );">Paragon Therapeutics Inc | Ownership Interest | Maximum | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Percentage of ownership by noncontrolling owner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=agle_ParagonTherapeuticsIncMember', window );">Paragon Therapeutics Inc | SPY001 License Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_AmountToBePaidUnderAgreement', window );">Contingent obligation based on milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=agle_FairmountFundsManagementLlcMember', window );">Fairmount Funds Management LLC | Ownership Interest | Minimum | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Percentage of ownership by noncontrolling owner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_MinorityInterestOwnershipPercentageByNoncontrollingOwnersHeldInThirdParty', window );">Percentage of ownership held in third party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=agle_ParagonAndParapyreHoldingLlcMember', window );">Paragon and Parapyre Holding LLC | Ownership Interest | Maximum | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Percentage of ownership by noncontrolling owner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_AmountToBePaidUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount to be paid under agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_AmountToBePaidUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_MinorityInterestOwnershipPercentageByNoncontrollingOwnersHeldInThirdParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minority interest ownership percentage by noncontrolling owners held in third party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_MinorityInterestOwnershipPercentageByNoncontrollingOwnersHeldInThirdParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of annual equity grant of options to purchase outstanding shares of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_ReimbursableResearchCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reimbursable research costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_ReimbursableResearchCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_RelatedPartyExpensesIncurredPriorToAssetAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related party expenses incurred prior to asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_RelatedPartyExpensesIncurredPriorToAssetAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_RelatedPartyExpensesUnpaidPriorToAssetAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related party expenses unpaid prior to asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_RelatedPartyExpensesUnpaidPriorToAssetAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_RelatedPartyTransactionNumberOfBoardSeats">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related Party Transaction, Number Of Board Seats</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_RelatedPartyTransactionNumberOfBoardSeats</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_RelatedPartyTransactionNumberOfProgramOptionsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related Party Transaction, Number Of Program Options Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_RelatedPartyTransactionNumberOfProgramOptionsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_ResearchInitiationFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research initiation fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_ResearchInitiationFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=agle_AppointOfBoardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=agle_AppointOfBoardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=agle_ParagonAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=agle_ParagonAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=agle_StockCompensationAndResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=agle_StockCompensationAndResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=agle_ReimbursableCostsUnderParagonAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=agle_ReimbursableCostsUnderParagonAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=agle_MilestonePaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=agle_MilestonePaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=agle_Spy001LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=agle_Spy001LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=agle_ParagonTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=agle_ParagonTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=agle_OwnershipInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=agle_OwnershipInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=agle_FairmountFundsManagementLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=agle_FairmountFundsManagementLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=agle_ParagonAndParapyreHoldingLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=agle_ParagonAndParapyreHoldingLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>130
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140168003619248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Expenses related to Related Party which were Settled in Cash (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | Reimbursable Costs Under Paragon Agreement | Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_RelatedPartyTransactionReimbursableCosts', window );">Reimbursable costs</a></td>
<td class="nump">$ 16.7<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 17.9<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_RelatedPartyTransactionReimbursableCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related party transaction, reimbursable costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_RelatedPartyTransactionReimbursableCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=agle_ReimbursableCostsUnderParagonAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=agle_ReimbursableCostsUnderParagonAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>131
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140168007738624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Related Party Transactions - Related Party Accounts Payable (Details) - Related Party - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">$ 19.8<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Reimbursable Costs Under Paragon Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">16.8<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Parapyre Option Obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">$ 3.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=agle_ReimbursableCostsUnderParagonAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=agle_ReimbursableCostsUnderParagonAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=agle_ParapyreOptionObligationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=agle_ParapyreOptionObligationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>132
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140168003927120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Asset Acquisition - Narrative (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 22, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Cost to acquire asset | $</a></td>
<td class="nump">$ 113,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=agle_SpyreTherapeuticsIncMember', window );">Spyre Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Cost to acquire asset | $</a></td>
<td class="nump">$ 113,176<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableSharesOfCommonStockOnAnAsConvertedBasis', window );">Asset acquisition consideration transferred issuable shares of common stock on an as-converted basis</a></td>
<td class="nump">14,595,480<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=agle_Spyre2023EquityIncentivePlanMember', window );">Spyre 2023 Equity Incentive Plan | Spyre Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_OutstandingAndUnexercisedStockOptions', window );">Number of outstanding and unexercised stock options to purchase (in shares)</a></td>
<td class="nump">2,734<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=agle_SeriesANonVotingConvertiblePreferredStockMember', window );">Series A Non Voting Convertible Preferred Stock | Spyre Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares', window );">Number of shares transferred as equity interest in asset acquisition</a></td>
<td class="nump">364,887<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 291.08<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_CommonStockMember', window );">Common Stock | Spyre Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares', window );">Number of shares transferred as equity interest in asset acquisition</a></td>
<td class="nump">517,809<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 7.277<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset acquisition consideration transferred equity interest issued and issuable, shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableSharesOfCommonStockOnAnAsConvertedBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset acquisition consideration transferred equity interest issued and issuable shares of common stock on an as-converted basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableSharesOfCommonStockOnAnAsConvertedBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_OutstandingAndUnexercisedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Outstanding and unexercised stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_OutstandingAndUnexercisedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479908/805-50-55-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480060/805-50-25-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480123/805-50-15-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=agle_SpyreTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=agle_SpyreTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=agle_Spyre2023EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=agle_Spyre2023EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=agle_SeriesANonVotingConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=agle_SeriesANonVotingConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>133
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140168002343312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Asset Acquisition - Asset Acquisition Cost (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 22, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_AcquiredInProcessResearchAndDevelopment', window );">Acquired in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (298)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 130,188<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAcquiredFromAcquisition', window );">Cash acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,035<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Cost to acquire asset</a></td>
<td class="nump">$ 113,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=agle_SpyreTherapeuticsIncMember', window );">Spyre Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable', window );">Consideration transferred in Series A Preferred Stock and common stock</a></td>
<td class="nump">109,979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost', window );">Transaction costs incurred by Aeglea</a></td>
<td class="nump">3,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_AcquiredInProcessResearchAndDevelopment', window );">Acquired in-process research and development</a></td>
<td class="nump">130,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAcquiredFromAcquisition', window );">Cash acquired</a></td>
<td class="nump">3,035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_AssumedLiabilities', window );">Assumed liabilities</a></td>
<td class="num">(20,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Cost to acquire asset</a></td>
<td class="nump">$ 113,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_AcquiredInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Acquired in process research and development</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_AcquiredInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_AssumedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Assumed liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_AssumedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479908/805-50-55-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480060/805-50-25-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of acquirer's equity interest issued and issuable as part of consideration transferred in asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480060/805-50-25-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction cost incurred as part of consideration transferred in asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479908/805-50-55-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480060/805-50-25-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480123/805-50-15-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAcquiredFromAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAcquiredFromAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=agle_SpyreTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=agle_SpyreTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>134
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140167993876080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Paragon Agreement (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 12, 2023</div></th>
<th class="th"><div>Jun. 22, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>May 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=agle_ParagonTherapeuticsIncMember', window );">Paragon Therapeutics Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_LicenseAgreementMilestonePayments', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.0<span></span>
</td>
<td class="nump">$ 20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=agle_ParapyreOptionObligationMember', window );">Parapyre Option Obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock', window );">Percentage of annual equity grant of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_NonrefundableResearchInitiationFeeForOneProgramPaidInCash', window );">Nonrefundable research initiation fee for one program paid in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | Paragon Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_ResearchInitiationFees', window );">Research initiation fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_RelatedPartyExpensesIncurredPriorToAssetAcquisition', window );">Related party expenses incurred prior to asset acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_ReimbursableResearchCosts', window );">Reimbursable research costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_RelatedPartyExpensesUnpaidPriorToAssetAcquisition', window );">Related party expenses unpaid prior to asset acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock', window );">Percentage of annual equity grant of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | SPY001 License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_NominationFee', window );">Nomination fee</a></td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_PaymentOfMilestone', window );">First milestone payment</a></td>
<td class="nump">2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | SPY001 License Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_AmountToBePaidUnderAgreement', window );">Contingent obligation based on milestones</a></td>
<td class="nump">$ 22.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | Stock Compensation And Research And Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Amount of related party transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19.4<span></span>
</td>
<td class="nump">$ 20.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_AmountToBePaidUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount to be paid under agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_AmountToBePaidUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_LicenseAgreementMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_LicenseAgreementMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_NominationFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nomination fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_NominationFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_NonrefundableResearchInitiationFeeForOneProgramPaidInCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nonrefundable research initiation fee for one program paid in cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_NonrefundableResearchInitiationFeeForOneProgramPaidInCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_PaymentOfMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment of milestone.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_PaymentOfMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of annual equity grant of options to purchase outstanding shares of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_ReimbursableResearchCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reimbursable research costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_ReimbursableResearchCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_RelatedPartyExpensesIncurredPriorToAssetAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related party expenses incurred prior to asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_RelatedPartyExpensesIncurredPriorToAssetAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_RelatedPartyExpensesUnpaidPriorToAssetAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related party expenses unpaid prior to asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_RelatedPartyExpensesUnpaidPriorToAssetAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_ResearchInitiationFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research initiation fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_ResearchInitiationFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=agle_ParagonTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=agle_ParagonTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=agle_ParapyreOptionObligationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=agle_ParapyreOptionObligationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=agle_ParagonAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=agle_ParagonAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=agle_Spy001LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=agle_Spy001LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=agle_StockCompensationAndResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=agle_StockCompensationAndResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>135
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140167994989056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Series A Non-Voting Convertible Preferred Stock (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 07, 2023</div></th>
<th class="th"><div>Jun. 26, 2023</div></th>
<th class="th"><div>Jun. 22, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Series A non-voting convertible preferred stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">365,000<span></span>
</td>
<td class="nump">721,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=agle_SeriesANonVotingConvertiblePreferredStockMember', window );">Series A Non Voting Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_PreferredStockRemainsIssuedAndOutstandingPercentage', window );">Preferred stock issued and outstanding percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockRedemptionAmount', window );">Preferred stock, redemption value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 532,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockRedemptionPricePerShare', window );">Preferred stock, redemption per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Conversion basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Series A non-voting convertible preferred stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">721,452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of Series A non-voting convertible preferred stock</a></td>
<td class="nump">$ 189,700<span></span>
</td>
<td class="nump">$ 197,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 189,741<span></span>
</td>
<td class="nump">$ 197,323<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=agle_SeriesANonVotingConvertiblePreferredStockMember', window );">Series A Non Voting Convertible Preferred Stock | Asset Acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares', window );">Number of shares transferred as equity interest in asset acquisition</a></td>
<td class="nump">364,887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=agle_SeriesANonVotingConvertiblePreferredStockMember', window );">Series A Non Voting Convertible Preferred Stock | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_BeneficiallyHoldersOwnedPercentage', window );">Beneficially holders owned percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=agle_SeriesANonVotingConvertiblePreferredStockMember', window );">Series A Non Voting Convertible Preferred Stock | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_BeneficiallyHoldersOwnedPercentage', window );">Beneficially holders owned percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=agle_SeriesANonVotingConvertiblePreferredStockMember', window );">Series A Non Voting Convertible Preferred Stock | Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Gross proceeds received in private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 210,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset acquisition consideration transferred equity interest issued and issuable, shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_BeneficiallyHoldersOwnedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Beneficially holders owned percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_BeneficiallyHoldersOwnedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_PreferredStockRemainsIssuedAndOutstandingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Preferred stock remains issued and outstanding percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_PreferredStockRemainsIssuedAndOutstandingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Stock Issued During Period, Shares, New Issues</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common shares issuable upon conversion for each share of preferred stock to be converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockRedemptionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The redemption (or callable) amount of currently redeemable preferred stock. Includes amounts representing dividends not currently declared or paid but which will be payable under the redemption features or for which ultimate payment is solely within the control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-11<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.27(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockRedemptionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockRedemptionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share at which the preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity is redeemed or may be called at. The redemption features of this preferred stock are solely within the control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-5<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockRedemptionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=agle_SeriesANonVotingConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=agle_SeriesANonVotingConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=agle_AssetAcquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=agle_AssetAcquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>136
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140168003929120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Liabilities, Convertible Preferred Stock and Stockholders' (Deficit) Equity - Pre-funded Warrants for Common Stock Issued and Outstanding (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>May 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0025<span></span>
</td>
<td class="nump">$ 0.0025<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Pre-funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants Outstanding (in shares)</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="nump">1,155,663<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Pre-funded Warrants | February 8, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 0.0025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants Outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Pre-funded Warrants | April 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 0.0025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants Outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Pre-funded Warrants | May 20, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 0.0025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants Outstanding (in shares)</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=agle_FebruaryEightTwoThousandNinteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=agle_FebruaryEightTwoThousandNinteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=agle_AprilThirtyTwoThousandTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=agle_AprilThirtyTwoThousandTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=agle_MayTwentyTwoThousandTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=agle_MayTwentyTwoThousandTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>137
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140168002394128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liabilities, Convertible Preferred Stock and Stockholders' (Deficit) Equity - Stock Awards Granted (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Grants (in shares)</a></td>
<td class="nump">1,044,667<span></span>
</td>
<td class="nump">50,806<span></span>
</td>
<td class="nump">3,867,366<span></span>
</td>
<td class="nump">153,686<span></span>
</td>
<td class="nump">235,199<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Grant Date Fair Value (in dollars per share)</a></td>
<td class="nump">$ 14.5<span></span>
</td>
<td class="nump">$ 16.75<span></span>
</td>
<td class="nump">$ 9.65<span></span>
</td>
<td class="nump">$ 52.5<span></span>
</td>
<td class="nump">$ 45<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>138
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140167982355984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liabilities, Convertible Preferred Stock and Stockholders' (Deficit) Equity - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="11">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1">39 Months Ended</th>
<th class="th" colspan="1">40 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Sep. 29, 2023</div></th>
<th class="th"><div>Jun. 22, 2023</div></th>
<th class="th"><div>Feb. 28, 2023</div></th>
<th class="th"><div>Nov. 30, 2022</div></th>
<th class="th"><div>May 31, 2022</div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th"><div>Feb. 28, 2019</div></th>
<th class="th"><div>Oct. 31, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Feb. 28, 2018</div></th>
<th class="th"><div>Apr. 30, 2016</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>May 31, 2022</div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Jan. 01, 2022</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Jan. 01, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding option awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">405,081<span></span>
</td>
<td class="nump">264,303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,044,667<span></span>
</td>
<td class="nump">50,806<span></span>
</td>
<td class="nump">3,867,366<span></span>
</td>
<td class="nump">153,686<span></span>
</td>
<td class="nump">235,199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Tax benefits recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">694,892<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">694,892<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_ClassOfWarrantOrRightOfferingPriceOfWarrantsOrRights', window );">Offering price of warrant (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39.9975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39.9975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from sale of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 129,000,000<span></span>
</td>
<td class="nump">$ 64,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_PlacementAgentFeesAndOfferingCosts', window );">Placement agent fees and offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_OwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercised', window );">Maximum ownership percentage of common stock shares for outstanding warrants to be exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_OwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercisedToCertainHolders', window );">Ownership percentage for outstanding warrants to purchase shares of common stock to be exercised to certain holders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_ClassOfWarrantOrRightRevisedOwnershipPercentagePeriodToTakeEffectAfterNotice', window );">Revised ownership percentage, period to take effect after notice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">61 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,785,000<span></span>
</td>
<td class="nump">$ 1,565,000<span></span>
</td>
<td class="nump">$ 8,405,000<span></span>
</td>
<td class="nump">$ 5,684,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,405,000<span></span>
</td>
<td class="nump">$ 5,684,000<span></span>
</td>
<td class="nump">$ 7,111,000<span></span>
</td>
<td class="nump">$ 8,038,000<span></span>
</td>
<td class="nump">$ 6,256,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=agle_EmployeesAndNonEmployeesMember', window );">Employees and Non-Employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unamortized expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45<span></span>
</td>
<td class="nump">$ 124<span></span>
</td>
<td class="nump">$ 117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized stock-based compensation expense for options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period over which unrecognized compensation is expected to be recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options | Non-Employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Stock option vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=agle_NonQualifiedStockOptionsMember', window );">Non-Qualified Stock Options | New Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,393,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodOfFirstTwentyFivePercent', window );">Vesting period of first 25% of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodOfRemainingSeventyFivePercent', window );">Vesting period of remaining 75% of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">48 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsGrantedExercisablePeriod', window );">Options granted exercisable period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Equity instruments other than options, granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Common Stock | Non-Employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Equity instruments other than options, granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">694,892<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">694,892<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_OwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercised', window );">Maximum ownership percentage of common stock shares for outstanding warrants to be exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">430,107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Public offering price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=agle_TwoThousandAndFifteenEquityIncentivePlanMember', window );">2015 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_GranteesWithMoreThanFiveYearsVestingTermPercent', window );">Grantees with more than five years vesting term, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_MaximumVestingTermForMoreThanTenPercentGrantees', window );">Maximum vesting term for more than ten percent grantees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease', window );">Number of common stock to option outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,785<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of common stock available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,394<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=agle_TwoThousandAndFifteenEquityIncentivePlanMember', window );">2015 Equity Incentive Plan | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Percentage of market value of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=agle_TwoThousandAndFifteenEquityIncentivePlanMember', window );">2015 Equity Incentive Plan | Maximum | Stock option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-based payment award, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=agle_TwoThousandAndSixteenEquityIncentivePlanMember', window );">2016 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Initial reserves of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance', window );">Increase in number of shares of common stock reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Share based compensation plan expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aug.  07,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_AnnualPercentageOfAdditionalSharesWhichEqualsToIssuedAndOutstandingShares', window );">Annual percentage of additional shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant', window );">Additional number of shares available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104,560<span></span>
</td>
<td class="nump">78,968<span></span>
</td>
<td class="nump">76,734<span></span>
</td>
<td class="nump">46,535<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock available for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">293,497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">293,497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">432,725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">293,497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding option awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">319,122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_StockOptionsGrantedToCertainMembersOfBoardOfDirectorsContingentOnStockholderApproval', window );">Stock options granted to certain members of board of directors, contingent on stockholder approval (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,720,033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_StockBasedCompensationExpenseOnContingentAwards', window );">Expense on contingent awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=agle_TwoThousandAndSixteenEquityIncentivePlanMember', window );">2016 Equity Incentive Plan | Restricted Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Equity instruments other than options, granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Equity instruments other than options, vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=agle_TwoThousandAndEighteenEquityInducementPlanMember', window );">2018 Equity Inducement Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-based payment award, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Initial reserves of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock available for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding option awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Awards granted, vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,583,880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional number of shares available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=agle_TwoThousandAndFifteenAndTwoThousandAndSixteenEquityIncentivePlanAndTwoThousandAndEighteenEquityInducementPlanMember', window );">2018 Plan, 2016 Plan and 2015 Plan | Service-based Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-based payment award, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Awards granted, vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=agle_TwoThousandAndFifteenAndTwoThousandAndSixteenEquityIncentivePlanAndTwoThousandAndEighteenEquityInducementPlanMember', window );">2018 Plan, 2016 Plan and 2015 Plan | Maximum | Service-based Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Awards granted, vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=agle_TwoThousandAndSixteenEmployeeStockPurchasePlanMember', window );">2016 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant', window );">Additional number of shares available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,742<span></span>
</td>
<td class="nump">19,183<span></span>
</td>
<td class="nump">11,633<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock available for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,665<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate', window );">Percentage of discount through payroll deductions to eligible employees to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate', window );">Percentage of fair market value of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalAnnualPercentageIncrease', window );">Additional annual percentage increase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,496<span></span>
</td>
<td class="nump">6,073<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Aggregate cash proceeds from sale of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=agle_TwoThousandAndSixteenEmployeeStockPurchasePlanMember', window );">2016 Employee Stock Purchase Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAnnualFairMarketValuePerEmployee', window );">Maximum purchase value per employee under employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_MaximumNumberOfSharesPurchasedUnderEmployeeStockPurchasePlan', window );">Maximum number of shares purchased under employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=agle_TwoThousandAndSixteenEmployeeStockPurchasePlanMember', window );">2016 Employee Stock Purchase Plan | Maximum | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_MaximumNumberOfSharesPurchasedUnderEmployeeStockPurchasePlan', window );">Maximum number of shares purchased under employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=agle_Spyre2023EquityIncentivePlanMember', window );">Spyre 2023 Equity Incentive Plan | Asset Acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_OutstandingAndUnexercisedStockOptions', window );">Number of outstanding and unexercised stock options to purchase (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,734<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=agle_ParapyreOptionObligationMember', window );">Parapyre Option Obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-based payment award, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_AnnualPercentageOfAdditionalSharesWhichEqualsToIssuedAndOutstandingShares', window );">Annual percentage of additional shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unamortized expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration', window );">Fair value of contingent consideration assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,700,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,900,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=agle_ParapyreOptionObligationMember', window );">Parapyre Option Obligation | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-based payment award, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=agle_ParapyreOptionObligationMember', window );">Parapyre Option Obligation | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Pro-rated estimated fair value of options</a></td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_AnnualPercentageOfAdditionalSharesWhichEqualsToIssuedAndOutstandingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual percentage of additional shares which equals to the issued and outstanding shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_AnnualPercentageOfAdditionalSharesWhichEqualsToIssuedAndOutstandingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_ClassOfWarrantOrRightOfferingPriceOfWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right offering price of warrants or rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_ClassOfWarrantOrRightOfferingPriceOfWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_ClassOfWarrantOrRightRevisedOwnershipPercentagePeriodToTakeEffectAfterNotice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Revised Ownership Percentage, Period To Take Effect After Notice</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_ClassOfWarrantOrRightRevisedOwnershipPercentagePeriodToTakeEffectAfterNotice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_GranteesWithMoreThanFiveYearsVestingTermPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Grantees with more than five years vesting term, percent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_GranteesWithMoreThanFiveYearsVestingTermPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase in common stock capital shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_MaximumNumberOfSharesPurchasedUnderEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares purchased under employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_MaximumNumberOfSharesPurchasedUnderEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_MaximumVestingTermForMoreThanTenPercentGrantees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum vesting term for more than ten percent grantees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_MaximumVestingTermForMoreThanTenPercentGrantees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_OutstandingAndUnexercisedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Outstanding and unexercised stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_OutstandingAndUnexercisedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_OwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ownership Percentage For Outstanding Warrants To Purchase Shares Of Common Stock To Be Exercised</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_OwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_OwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercisedToCertainHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ownership percentage for outstanding warrants To purchase shares of common stock to be exercised to certain holders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_OwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercisedToCertainHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_PlacementAgentFeesAndOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Placement agent fees and offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_PlacementAgentFeesAndOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalAnnualPercentageIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award additional annual percentage increase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalAnnualPercentageIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award, additional number of shares available for grant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodOfFirstTwentyFivePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award award vesting period of first ywenty give percent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodOfFirstTwentyFivePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodOfRemainingSeventyFivePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award award vesting period of remaining seventy five percent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodOfRemainingSeventyFivePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAnnualFairMarketValuePerEmployee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award maximum annual fair market value per employee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAnnualFairMarketValuePerEmployee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsGrantedExercisablePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payments award options granted exercisable period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsGrantedExercisablePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_StockBasedCompensationExpenseOnContingentAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock based compensation expense on contingent awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_StockBasedCompensationExpenseOnContingentAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_StockOptionsGrantedToCertainMembersOfBoardOfDirectorsContingentOnStockholderApproval">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock options granted to certain members of board of directors, contingent on stockholder approval.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_StockOptionsGrantedToCertainMembersOfBoardOfDirectorsContingentOnStockholderApproval</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contingent consideration recognized as part of consideration transferred in asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480060/805-50-25-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit for recognition of expense of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate from fair value on purchase date that participants pay for shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date the equity-based award expires, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase or decrease in number of shares reserved for issuance under stock option agreements awarded under the plan that validly exist and are outstanding, including vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=agle_EmployeesAndNonEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=agle_EmployeesAndNonEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=agle_NonEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=agle_NonEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=agle_NonQualifiedStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=agle_NonQualifiedStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=agle_NewChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=agle_NewChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=agle_TwoThousandAndFifteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=agle_TwoThousandAndFifteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=agle_TwoThousandAndSixteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=agle_TwoThousandAndSixteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=agle_TwoThousandAndEighteenEquityInducementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=agle_TwoThousandAndEighteenEquityInducementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=agle_TwoThousandAndFifteenAndTwoThousandAndSixteenEquityIncentivePlanAndTwoThousandAndEighteenEquityInducementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=agle_TwoThousandAndFifteenAndTwoThousandAndSixteenEquityIncentivePlanAndTwoThousandAndEighteenEquityInducementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=agle_ServiceBasedAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=agle_ServiceBasedAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=agle_TwoThousandAndSixteenEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=agle_TwoThousandAndSixteenEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=agle_Spyre2023EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=agle_Spyre2023EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=agle_AssetAcquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=agle_AssetAcquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=agle_ParapyreOptionObligationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=agle_ParapyreOptionObligationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>139
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140168003411744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liabilities, Convertible Preferred Stock and Stockholders' (Deficit) Equity - Summary of Employee and Non-Employee Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares Issuable Under Options, Outstanding, Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">405,081<span></span>
</td>
<td class="nump">264,303<span></span>
</td>
<td class="nump">264,303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Shares Issuable Under Options, Granted</a></td>
<td class="nump">1,044,667<span></span>
</td>
<td class="nump">50,806<span></span>
</td>
<td class="nump">3,867,366<span></span>
</td>
<td class="nump">153,686<span></span>
</td>
<td class="nump">235,199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares Issuable Under Options, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Shares Issuable Under Options, Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(94,421)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares Issuable Under Options, Outstanding, Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">405,081<span></span>
</td>
<td class="nump">264,303<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Shares Issuable Under Options, Options vested and expected to vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">397,772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Shares Issuable Under Options, Options exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">163,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 113.75<span></span>
</td>
<td class="nump">$ 189<span></span>
</td>
<td class="nump">$ 189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="nump">$ 14.5<span></span>
</td>
<td class="nump">$ 16.75<span></span>
</td>
<td class="nump">$ 9.65<span></span>
</td>
<td class="nump">$ 52.5<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">153.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">113.75<span></span>
</td>
<td class="nump">$ 189<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options vested and expected to vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term, Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 8 months 19 days<span></span>
</td>
<td class="text">7 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term, Options vested and expected to vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 9 months 10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term, Options exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 11 months 4 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 328<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Options vested and expected to vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Options exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>140
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140167992051920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liabilities, Convertible Preferred Stock and Stockholders' (Deficit) Equity - Summary of Employee Restricted Stock Activity (Details) - Restricted Common Stock - Employees<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Shares, Unvested restricted common stock, Beginning balance | shares</a></td>
<td class="nump">7,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Shares, Granted | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Shares, Vested | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Shares, Forfeited | shares</a></td>
<td class="num">(1,940)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Shares, Unvested restricted common stock, Ending balance | shares</a></td>
<td class="nump">5,660<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Unvested restricted common stock, Beginning balance | $ / shares</a></td>
<td class="nump">$ 203.25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Granted | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Vested | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Forfeited | $ / shares</a></td>
<td class="nump">203.25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Unvested restricted common stock, Ending balance | $ / shares</a></td>
<td class="nump">$ 203.25<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=agle_EmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=agle_EmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>141
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140167993854240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liabilities, Convertible Preferred Stock and Stockholders' (Deficit) Equity - Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 4,785<span></span>
</td>
<td class="nump">$ 1,565<span></span>
</td>
<td class="nump">$ 8,405<span></span>
</td>
<td class="nump">$ 5,684<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">2,965<span></span>
</td>
<td class="nump">639<span></span>
</td>
<td class="nump">4,136<span></span>
</td>
<td class="nump">2,031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 1,820<span></span>
</td>
<td class="nump">$ 926<span></span>
</td>
<td class="nump">$ 4,269<span></span>
</td>
<td class="nump">$ 3,653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=agle_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember', window );">2018 Equity Inducement Plan and 2016 Employee Stock Purchase Plan | Employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,111<span></span>
</td>
<td class="nump">$ 8,038<span></span>
</td>
<td class="nump">$ 6,220<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=agle_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember', window );">2018 Equity Inducement Plan and 2016 Employee Stock Purchase Plan | Non-Employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=agle_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember', window );">2018 Equity Inducement Plan and 2016 Employee Stock Purchase Plan | Research and Development | Employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,591<span></span>
</td>
<td class="nump">2,723<span></span>
</td>
<td class="nump">2,168<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=agle_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember', window );">2018 Equity Inducement Plan and 2016 Employee Stock Purchase Plan | Research and Development | Non-Employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=agle_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember', window );">2018 Equity Inducement Plan and 2016 Employee Stock Purchase Plan | General and Administrative | Employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,520<span></span>
</td>
<td class="nump">5,315<span></span>
</td>
<td class="nump">4,052<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=agle_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember', window );">2018 Equity Inducement Plan and 2016 Employee Stock Purchase Plan | General and Administrative | Non-Employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=agle_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=agle_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=agle_EmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=agle_EmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=agle_NonEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=agle_NonEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>142
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140167991890640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liabilities, Convertible Preferred Stock and Stockholders' (Deficit) Equity - Assumptions used to Estimate the Fair Value of Stock Options Granted (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">5 years 11 months 26 days<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84.00%<span></span>
</td>
<td class="nump">83.00%<span></span>
</td>
<td class="nump">76.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.93%<span></span>
</td>
<td class="nump">0.88%<span></span>
</td>
<td class="nump">1.06%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=agle_TwoThousandAndSixteenEmployeeStockPurchasePlanMember', window );">2016 ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">5 months 26 days<span></span>
</td>
<td class="text">5 months 26 days<span></span>
</td>
<td class="text">5 months 26 days<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">222.00%<span></span>
</td>
<td class="nump">95.00%<span></span>
</td>
<td class="nump">181.00%<span></span>
</td>
<td class="nump">84.00%<span></span>
</td>
<td class="nump">84.00%<span></span>
</td>
<td class="nump">86.00%<span></span>
</td>
<td class="nump">76.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest</a></td>
<td class="nump">5.29%<span></span>
</td>
<td class="nump">3.26%<span></span>
</td>
<td class="nump">4.99%<span></span>
</td>
<td class="nump">1.95%<span></span>
</td>
<td class="nump">1.95%<span></span>
</td>
<td class="nump">0.08%<span></span>
</td>
<td class="nump">0.75%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=agle_TwoThousandAndSixteenEquityIncentivePlanMember', window );">2016 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 29 days<span></span>
</td>
<td class="text">6 years 7 days<span></span>
</td>
<td class="text">6 years 14 days<span></span>
</td>
<td class="text">5 years 11 months 15 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="nump">111.00%<span></span>
</td>
<td class="nump">83.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest</a></td>
<td class="nump">4.28%<span></span>
</td>
<td class="nump">3.16%<span></span>
</td>
<td class="nump">4.07%<span></span>
</td>
<td class="nump">2.43%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=agle_TwoThousandAndSixteenEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=agle_TwoThousandAndSixteenEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=agle_TwoThousandAndSixteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=agle_TwoThousandAndSixteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>143
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140167993534272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Strategic License Agreements - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 21, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2017 </div>
<div>USD ($) </div>
<div>LICENSEAGREEMENT</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / LICENSEAGREEMENT </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / LICENSEAGREEMENT </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 174,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 886,000<span></span>
</td>
<td class="nump">$ 2,161,000<span></span>
</td>
<td class="nump">$ 2,329,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,739,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,696,000<span></span>
</td>
<td class="nump">$ 2,696,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,696,000<span></span>
</td>
<td class="nump">2,696,000<span></span>
</td>
<td class="nump">3,576,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Current deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">517,000<span></span>
</td>
<td class="nump">517,000<span></span>
</td>
<td class="nump">2,359,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_NumberOfLicenseAgreements', window );">Number of license agreements | LICENSEAGREEMENT</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=agle_ImmedicaPharmaABMember', window );">Immedica Pharma AB</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_NonRefundablePaymentReceived', window );">Non refundable payment received</a></td>
<td class="nump">$ 21,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_PercentageOfPaymentForCostIncurredInPIPTrial', window );">Percentage of payment for cost incurred in PIP trial</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_RateOfRevenueShare', window );">Rate of revenue share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReimbursementFromLimitedPartnershipInvestment', window );">Reimbursement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_UpfrontPayment', window );">Upfront payment</a></td>
<td class="nump">$ 21,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross', window );">Estimated amount incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_AllocationPriceTotal', window );">Allocation price net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,600,000<span></span>
</td>
<td class="nump">3,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400,000<span></span>
</td>
<td class="nump">2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_LicenseAndSupplyAgreementDate', window );">License and supply agreement date</a></td>
<td class="text">Mar. 21,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_AdditionalUpfrontPaymentAbilityToReceived', window );">Additional upfront payment to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Total deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,700,000<span></span>
</td>
<td class="nump">2,700,000<span></span>
</td>
<td class="nump">3,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Current deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=agle_ImmedicaPharmaABMember', window );">Immedica Pharma AB | License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_ContractWithCustomerFullReimbursementOfCostsIncludedLiability', window );">Full reimbursement of costs included in upfront fixed payment received</a></td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=agle_ImmedicaPharmaABMember', window );">Immedica Pharma AB | PEACE Trial and BLA Package</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_AllocatedAmountOfTransactionPrice', window );">Allocated amount of transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=agle_ImmedicaPharmaABMember', window );">Immedica Pharma AB | PIP Trial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_AllocatedAmountOfTransactionPrice', window );">Allocated amount of transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=agle_ImmedicaPharmaABMember', window );">Immedica Pharma AB | License Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=agle_ImmedicaPharmaABMember', window );">Immedica Pharma AB | Peace Phase 3 Trial and Drug Supply</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=agle_ImmedicaPharmaABMember', window );">Immedica Pharma AB | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_PercentageOfPaymentForCostIncurredInPIPTrial', window );">Percentage of payment for cost incurred in PIP trial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_CostsIncurredInPerformingTheTrial', window );">Costs incurred in performing PIP Trial</a></td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_MilestonePaymentsExchangeRate', window );">Milestone payments exchange rate | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=agle_ImmedicaPharmaABMember', window );">Immedica Pharma AB | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_MilestonePaymentsExchangeRate', window );">Milestone payments exchange rate | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=agle_UniversityOfTexasAtAustinMember', window );">University of Texas at Austin | License Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_ResearchAgreementDate', window );">Research agreement date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2013-12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_NumberOfLicenseAgreements', window );">Number of license agreements | $ / LICENSEAGREEMENT</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_MaximumFutureContingentLicensePayment', window );">Maximum future contingent license payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_AggregatePotentialMilestonePaymentsForReceiptOfRegulatoryApproval', window );">Aggregate potential milestone payments for receipt of regulatory approval</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_AggregatePotentialMilestonePaymentsForFinalRegulatoryApprovalOfSecondIndication', window );">Aggregate potential milestone payments for final regulatory approval of second indication</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_PaymentOfMilestone', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_PaymentOfAnnualLicenseFees', window );">Annual license fees paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=agle_UniversityOfTexasAtAustinMember', window );">University of Texas at Austin | Maximum | License Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_RateOfRevenueShare', window );">Rate of revenue share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=agle_UniversityOfTexasAtAustinMember', window );">University of Texas at Austin | Minimum | License Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_RateOfRevenueShare', window );">Rate of revenue share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_AdditionalUpfrontPaymentAbilityToReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional upfront payment ability to received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_AdditionalUpfrontPaymentAbilityToReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_AggregatePotentialMilestonePaymentsForFinalRegulatoryApprovalOfSecondIndication">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate potential milestone payments for final regulatory approval of second indication.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_AggregatePotentialMilestonePaymentsForFinalRegulatoryApprovalOfSecondIndication</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_AggregatePotentialMilestonePaymentsForReceiptOfRegulatoryApproval">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate potential milestone payments for receipt of regulatory approval.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_AggregatePotentialMilestonePaymentsForReceiptOfRegulatoryApproval</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_AllocatedAmountOfTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Allocated amount of transaction price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_AllocatedAmountOfTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_AllocationPriceTotal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Allocation price total.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_AllocationPriceTotal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_ContractWithCustomerFullReimbursementOfCostsIncludedLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Full Reimbursement Of Costs Included Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_ContractWithCustomerFullReimbursementOfCostsIncludedLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_CostsIncurredInPerformingTheTrial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Costs incurred in performing the pip trial.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_CostsIncurredInPerformingTheTrial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_LicenseAndSupplyAgreementDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License and supply agreement date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_LicenseAndSupplyAgreementDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_MaximumFutureContingentLicensePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum future contingent license payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_MaximumFutureContingentLicensePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_MilestonePaymentsExchangeRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payments exchange rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_MilestonePaymentsExchangeRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_NonRefundablePaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non refundable payment received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_NonRefundablePaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_NumberOfLicenseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of license agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_NumberOfLicenseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_PaymentOfAnnualLicenseFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment of annual license fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_PaymentOfAnnualLicenseFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_PaymentOfMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment of milestone.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_PaymentOfMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_PercentageOfPaymentForCostIncurredInPIPTrial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of payment for cost incurred in pip trial.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_PercentageOfPaymentForCostIncurredInPIPTrial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_RateOfRevenueShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rate of revenue share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_RateOfRevenueShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_ResearchAgreementDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research agreement date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_ResearchAgreementDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_UpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_UpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReimbursementFromLimitedPartnershipInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A payment from an investee, in which the investment basis has previously been reduced to zero. This amount reduces net cash used in operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReimbursementFromLimitedPartnershipInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of costs incurred under a research and development arrangement accounted for as a contract to perform research and development for others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483041/730-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483041/730-20-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483041/730-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=agle_ImmedicaPharmaABMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=agle_ImmedicaPharmaABMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=agle_PeaceTrialAndBLAPackageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=agle_PeaceTrialAndBLAPackageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=agle_PIPTrialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=agle_PIPTrialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=agle_LicenseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=agle_LicenseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=agle_PeacePhase3TrialAndDrugSupplyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=agle_PeacePhase3TrialAndDrugSupplyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=agle_UniversityOfTexasAtAustinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=agle_UniversityOfTexasAtAustinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>144
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140168006893776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Strategic License Agreements - Changes in Contract Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInContractWithCustomerLiabilityAbstract', window );"><strong>Change in Contract with Customer, Liability [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Beginning balance</a></td>
<td class="nump">$ 2,696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_ContractWithCustomerLiabilityAdditions', window );">Additions</a></td>
<td class="nump">575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination', window );">Deductions</a></td>
<td class="num">(3,271)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Ending balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 2,696<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Beginning Balance</a></td>
<td class="nump">$ 2,696<span></span>
</td>
<td class="nump">3,576<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_ContractWithCustomerLiabilityRevenueRecognizedIncludingAdditions', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,449<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_ContractWithCustomerLiabilityDeductionsThroughContractsAcquired', window );">Deductions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,329)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Ending Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,696<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_ContractWithCustomerLiabilityAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Liability, Additions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_ContractWithCustomerLiabilityAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_ContractWithCustomerLiabilityDeductionsThroughContractsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract with customer liability deductions through contracts acquired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_ContractWithCustomerLiabilityDeductionsThroughContractsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_ContractWithCustomerLiabilityRevenueRecognizedIncludingAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract with customer liability revenue recognized including additions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_ContractWithCustomerLiabilityRevenueRecognizedIncludingAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInContractWithCustomerLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInContractWithCustomerLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration from customer has been received or is due, from business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>145
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140168003971600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Sale of Pegzilarginase to Immedica (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 27, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfIntangibleAssets', window );">Proceeds from sale of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal', window );">Gain recognized within operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,609<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 14,609<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember', window );">Disposal Group, Disposed of by Sale, Not Discontinued Operations | Global Rights To Pegzilarginase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfIntangibleAssets', window );">Proceeds from sale of intangible assets</a></td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_DisposalGroupIncludingDiscontinuedOperationContingentConsideration', window );">Contingent consideration</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation', window );">Carrying value of assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal', window );">Gain recognized within operating expenses</a></td>
<td class="nump">$ 14,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_DisposalGroupIncludingDiscontinuedOperationContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Contingent Consideration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_DisposalGroupIncludingDiscontinuedOperationContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=agle_GlobalRightsToPegzilarginaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=agle_GlobalRightsToPegzilarginaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>146
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140168007900352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Defined Contribution Plan - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Defined contribution plan, contribution amount</a></td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>147
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140168004080784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Income (Loss) Before Income Tax Expense by Jurisdiction (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic</a></td>
<td class="num">$ (84,113)<span></span>
</td>
<td class="num">$ (65,940)<span></span>
</td>
<td class="num">$ (80,893)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="nump">162<span></span>
</td>
<td class="nump">280<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss before income tax expense</a></td>
<td class="num">$ (83,951)<span></span>
</td>
<td class="num">$ (65,660)<span></span>
</td>
<td class="num">$ (80,893)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481664/323-10-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>148
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140167994550896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision or benefit from income taxes</a></td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="num">$ (209,000)<span></span>
</td>
<td class="num">$ (26,000)<span></span>
</td>
<td class="num">$ (174,000)<span></span>
</td>
<td class="num">$ (136,000)<span></span>
</td>
<td class="nump">$ 141,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_IncreaseInValuationPrimarilyDueToOperationLosses', window );">Increase in valuation primarily due to operation losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,600,000<span></span>
</td>
<td class="nump">16,900,000<span></span>
</td>
<td class="nump">$ 20,700,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 328,200,000<span></span>
</td>
<td class="nump">307,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_PercentageOfNetOperatingLossUtilizedToOffsetTaxableIncome', window );">Percentage of net operating loss utilized to offset taxable income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_NetOperatingLossAndCreditCarryforwards', window );">Net operating loss and tax credit carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 58,400,000<span></span>
</td>
<td class="nump">21,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized Tax Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=us-gaap_EarliestTaxYearMember', window );">Earliest Tax Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_OperatingLossCarryforwardsExpirationYear', window );">Net operating loss carryforwards, expiration year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_TaxCreditCarryforwardExpirationYear', window );">Tax credit carryforwards, expiration year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">U.S</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,900,000<span></span>
</td>
<td class="nump">18,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign subsidiaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision or benefit from income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_IncomeTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income taxes line items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_IncomeTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_IncreaseInValuationPrimarilyDueToOperationLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase in valuation primarily due to operation losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_IncreaseInValuationPrimarilyDueToOperationLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_NetOperatingLossAndCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net operating loss and credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_NetOperatingLossAndCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_OperatingLossCarryforwardsExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards, expiration year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_OperatingLossCarryforwardsExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_PercentageOfNetOperatingLossUtilizedToOffsetTaxableIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of net operating loss utilized to offset taxable income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_PercentageOfNetOperatingLossUtilizedToOffsetTaxableIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_TaxCreditCarryforwardExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax credit carryforward, expiration year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_TaxCreditCarryforwardExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=us-gaap_EarliestTaxYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=us-gaap_EarliestTaxYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>149
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140167990765072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summary of Difference Between Provision for Income Taxes and Amounts Computed by Applying Statutory Federal Income Tax Rate to Income Before Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Tax provision derived by applying the federal statutory rate to income before income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (17,630)<span></span>
</td>
<td class="num">$ (13,789)<span></span>
</td>
<td class="num">$ (16,988)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate', window );">Permanent differences and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,042<span></span>
</td>
<td class="nump">1,002<span></span>
</td>
<td class="nump">482<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Effect of tax rate on foreign jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in the valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,609<span></span>
</td>
<td class="nump">16,900<span></span>
</td>
<td class="nump">20,662<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (benefit) expense</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="num">$ (209)<span></span>
</td>
<td class="num">$ (26)<span></span>
</td>
<td class="num">$ (174)<span></span>
</td>
<td class="num">(136)<span></span>
</td>
<td class="nump">141<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal Tax Credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_IncomeTaxReconciliationTaxCostCredit', window );">Tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,559)<span></span>
</td>
<td class="num">(3,815)<span></span>
</td>
<td class="num">(3,905)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State Tax Credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_IncomeTaxReconciliationTaxCostCredit', window );">Tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (640)<span></span>
</td>
<td class="num">$ (152)<span></span>
</td>
<td class="num">$ (251)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_IncomeTaxReconciliationTaxCostCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation tax cost (credit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_IncomeTaxReconciliationTaxCostCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_IncomeTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income taxes line items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_IncomeTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>150
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140167993522064">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Components of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforward</a></td>
<td class="nump">$ 68,917<span></span>
</td>
<td class="nump">$ 64,531<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangible assets</a></td>
<td class="nump">11,149<span></span>
</td>
<td class="nump">57<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">566<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accrued expense</a></td>
<td class="nump">668<span></span>
</td>
<td class="nump">846<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">3,293<span></span>
</td>
<td class="nump">2,767<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">190<span></span>
</td>
<td class="nump">220<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">108,328<span></span>
</td>
<td class="nump">87,991<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred tax liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Depreciable assets</a></td>
<td class="num">(676)<span></span>
</td>
<td class="num">(948)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(676)<span></span>
</td>
<td class="num">(948)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: Valuation allowance</a></td>
<td class="num">(107,652)<span></span>
</td>
<td class="num">(87,043)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Deferred tax assets, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal Tax Credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credits</a></td>
<td class="nump">21,914<span></span>
</td>
<td class="nump">18,579<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State Tax Credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credits</a></td>
<td class="nump">$ 1,631<span></span>
</td>
<td class="nump">$ 991<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>151
<FILENAME>R100.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140167997935088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Weighted-Average Equity Instruments Excluded from Calculation of Diluted Net Loss Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share</a></td>
<td class="nump">3,135,672<span></span>
</td>
<td class="nump">351,533<span></span>
</td>
<td class="nump">1,426,224<span></span>
</td>
<td class="nump">335,395<span></span>
</td>
<td class="nump">346,331<span></span>
</td>
<td class="nump">264,858<span></span>
</td>
<td class="nump">201,977<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="nump">252<span></span>
</td>
<td class="nump">7,315<span></span>
</td>
<td class="nump">6,982<span></span>
</td>
<td class="nump">7,975<span></span>
</td>
<td class="nump">4,239<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=agle_SeriesAConvertiblePreferredStockMember', window );">Series A Preferred Stock (on an as-converted basis)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share</a></td>
<td class="nump">42,501,681<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">14,851,447<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=agle_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=agle_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>152
<FILENAME>R101.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140168005545376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Schedule of Reconciliation of Basic and Diluted Net Loss Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesIssuedBasic', window );">Weighted average common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,307,668<span></span>
</td>
<td class="nump">1,956,933<span></span>
</td>
<td class="nump">1,608,952<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_WeightedAverageNumberOfSharesPreFundedWarrants', window );">Weighted average pre-funded warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,063,563<span></span>
</td>
<td class="nump">672,851<span></span>
</td>
<td class="nump">525,917<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Total basic weighed average shares</a></td>
<td class="nump">4,293,812<span></span>
</td>
<td class="nump">3,767,918<span></span>
</td>
<td class="nump">3,961,546<span></span>
</td>
<td class="nump">3,222,987<span></span>
</td>
<td class="nump">3,371,231<span></span>
</td>
<td class="nump">2,629,784<span></span>
</td>
<td class="nump">2,134,869<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Total diluted weighed average shares</a></td>
<td class="nump">4,293,812<span></span>
</td>
<td class="nump">3,767,918<span></span>
</td>
<td class="nump">3,961,546<span></span>
</td>
<td class="nump">3,222,987<span></span>
</td>
<td class="nump">3,371,231<span></span>
</td>
<td class="nump">2,629,784<span></span>
</td>
<td class="nump">2,134,869<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_WeightedAverageNumberOfSharesPreFundedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average number of shares pre-funded warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_WeightedAverageNumberOfSharesPreFundedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesIssuedBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesIssuedBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>153
<FILENAME>R102.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140168008248352">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Reverse Stock Split - Additional Information (Details)<br></strong></div></th>
<th class="th">
<div>Sep. 08, 2023 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Stockholders' equity, reverse stock split</a></td>
<td class="text">1-for-25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits', window );">Stock Issued During Period, Shares, Reverse Stock Splits</a></td>
<td class="nump">25<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reduction in the number of shares during the period as a result of a reverse stock split.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>154
<FILENAME>R103.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140167992001648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring Charges - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Aug. 07, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent', window );">Employee workforce, termination percentage</a></td>
<td class="nump">83.00%<span></span>
</td>
<td class="nump">83.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Cash severance payments and other employee-related costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Cash payments for employee related restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost', window );">Non-cash stock-based compensation expense related to accelerated vesting of stock-based awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration', window );">Total consideration from disposal of long lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 915<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_OperatingLeaseTerminationFeeAmount', window );">Termination fee amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseImpairmentLoss', window );">Lease asset impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLeasehold', window );">Impairment on leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_OperatingLeaseTerminationFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Termination Fee Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_OperatingLeaseTerminationFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLeasehold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The adjustment to reduce the value of existing agreements that specify the lessee's rights to use the leased property. This expense is charged when the estimates of future profits generated by the leased property are reduced.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLeasehold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from impairment of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479365/842-20-25-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of additional cost recognized for award under share-based payment arrangement from occurrence of event accelerating recognition of cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>155
<FILENAME>R104.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140168002319712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring Charges - Changes in Accrued Restructuring Balance (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payments</a></td>
<td class="num">$ (4,500)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=agle_SeveranceLiabilityMember', window );">Severance Liability</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning balance</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Charges</a></td>
<td class="nump">6,448<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payments</a></td>
<td class="num">(4,527)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending balance</a></td>
<td class="nump">$ 1,921<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482047/420-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=agle_SeveranceLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=agle_SeveranceLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>156
<FILENAME>R105.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140167993389168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring Charges - Charges Related to the Restructuring Activities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance Related Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 4,785<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,565<span></span>
</td>
<td class="nump">8,405<span></span>
</td>
<td class="nump">$ 5,684<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on Disposal of Long Lived Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">915<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseImpairmentLoss', window );">Lease Asset Impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">2,965<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">639<span></span>
</td>
<td class="nump">4,136<span></span>
</td>
<td class="nump">2,031<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on Disposal of Long Lived Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 1,820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 926<span></span>
</td>
<td class="nump">$ 4,269<span></span>
</td>
<td class="nump">$ 3,653<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on Disposal of Long Lived Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=agle_RestructuringActivitiesMember', window );">Restructuring Activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance Related Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,448<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on Disposal of Long Lived Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseImpairmentLoss', window );">Lease Asset Impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCosts', window );">Total Restructuring Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=agle_RestructuringActivitiesMember', window );">Restructuring Activities | Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance Related Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on Disposal of Long Lived Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">749<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseImpairmentLoss', window );">Lease Asset Impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,405<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCosts', window );">Total Restructuring Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=agle_RestructuringActivitiesMember', window );">Restructuring Activities | General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance Related Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">870<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on Disposal of Long Lived Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseImpairmentLoss', window );">Lease Asset Impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCosts', window );">Total Restructuring Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,493<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from impairment of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479365/842-20-25-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=agle_RestructuringActivitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=agle_RestructuringActivitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>157
<FILENAME>R106.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140167998472720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events - Additional Information (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 29, 2023</div></th>
<th class="th"><div>Sep. 08, 2023</div></th>
<th class="th"><div>Jul. 07, 2023</div></th>
<th class="th"><div>Jun. 22, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Stockholders' equity, reverse stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1-for-25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits', window );">Reduction in the total number of authorized shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=agle_ParapyreOptionObligationMember', window );">Parapyre Option Obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-based payment award, term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=agle_SpyreTherapeuticsIncMember', window );">Spyre Therapeutics, Inc. | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares', window );">Number of shares transferred as equity interest in asset acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">517,809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=agle_SpyreTherapeuticsIncMember', window );">Spyre Therapeutics, Inc. | Series A Non Voting Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares', window );">Number of shares transferred as equity interest in asset acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">364,887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Stockholders' equity, reverse stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1-for-25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Parapyre Option Obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-based payment award, term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits', window );">Reduction in the total number of authorized shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits', window );">Reduction in the total number of authorized shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Spyre Therapeutics, Inc. | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares', window );">Number of shares transferred as equity interest in asset acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">517,809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Spyre Therapeutics, Inc. | Series A Non Voting Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares', window );">Number of shares transferred as equity interest in asset acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">364,887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset acquisition consideration transferred equity interest issued and issuable, shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reduction in the number of shares during the period as a result of a reverse stock split.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=agle_ParapyreOptionObligationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=agle_ParapyreOptionObligationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=agle_SpyreTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=agle_SpyreTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=agle_SeriesANonVotingConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=agle_SeriesANonVotingConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>158
<FILENAME>R107.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140168004095472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Novation of Manufacturing Agreements (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Apr. 30, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_OtherCommitmentRightToTerminateAgreementOrWorkOrderPriorWrittenNoticePeriod', window );">Right to terminate agreement or work order, prior written notice period</a></td>
<td class="text">30 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_OtherCommitmentRightToTerminateWorkOrderReasonableCausePriorWrittenNoticePeriod', window );">Right to terminate work order, reasonable cause, prior written notice period</a></td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_OtherCommitmentRightToTerminateWorkOrderByCounterpartyReasonableCauseTerminationAmountPayable', window );">Right to terminate work order by counterparty, reasonable cause, termination amount payable</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_OtherCommitmentRightToTerminateWorkOrderMaterialBreachUncuredPeriod', window );">Right to terminate work order, material breach, uncured period</a></td>
<td class="text">30 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_OtherCommitmentRightToTerminateWorkOrderUnusualOrInfrequentCausePeriod', window );">Right to terminate work order, unusual or infrequent cause, period</a></td>
<td class="text">90 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_OtherCommitmentNonRefundableLicenseFeeAmount', window );">Non-refundable license fee amount</a></td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_OtherCommitmentRoyaltyPercentage', window );">Royalty percentage (less than)</a></td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_OtherCommitmentRightToTerminateAgreementPriorWrittenNoticePeriod', window );">Right to terminate agreement, prior written notice period</a></td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_OtherCommitmentRightToTerminateAgreementByCounterpartyMaterialBreachUncuredPeriod', window );">Right to terminate agreement by counterparty, material breach, uncured period</a></td>
<td class="text">60 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agle_OtherCommitmentRightToTerminateAgreementByCounterpartyPaymentsNotReceivedPeriod', window );">Right to terminate agreement by counterparty, payments not received, period</a></td>
<td class="text">30 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_OtherCommitmentNonRefundableLicenseFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Commitment, Non-Refundable License Fee Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_OtherCommitmentNonRefundableLicenseFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_OtherCommitmentRightToTerminateAgreementByCounterpartyMaterialBreachUncuredPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Commitment, Right To Terminate Agreement By Counterparty, Material Breach, Uncured Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_OtherCommitmentRightToTerminateAgreementByCounterpartyMaterialBreachUncuredPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_OtherCommitmentRightToTerminateAgreementByCounterpartyPaymentsNotReceivedPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Commitment, Right To Terminate Agreement By Counterparty, Payments Not Received, Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_OtherCommitmentRightToTerminateAgreementByCounterpartyPaymentsNotReceivedPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_OtherCommitmentRightToTerminateAgreementOrWorkOrderPriorWrittenNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Commitment, Right To Terminate Agreement Or Work Order, Prior Written Notice Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_OtherCommitmentRightToTerminateAgreementOrWorkOrderPriorWrittenNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_OtherCommitmentRightToTerminateAgreementPriorWrittenNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Commitment, Right To Terminate Agreement, Prior Written Notice Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_OtherCommitmentRightToTerminateAgreementPriorWrittenNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_OtherCommitmentRightToTerminateWorkOrderByCounterpartyReasonableCauseTerminationAmountPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Commitment, Right To Terminate Work Order By Counterparty, Reasonable Cause, Termination Amount Payable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_OtherCommitmentRightToTerminateWorkOrderByCounterpartyReasonableCauseTerminationAmountPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_OtherCommitmentRightToTerminateWorkOrderMaterialBreachUncuredPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Commitment, Right To Terminate Work Order, Material Breach, Uncured Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_OtherCommitmentRightToTerminateWorkOrderMaterialBreachUncuredPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_OtherCommitmentRightToTerminateWorkOrderReasonableCausePriorWrittenNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Commitment, Right To Terminate Work Order, Reasonable Cause, Prior Written Notice Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_OtherCommitmentRightToTerminateWorkOrderReasonableCausePriorWrittenNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_OtherCommitmentRightToTerminateWorkOrderUnusualOrInfrequentCausePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Commitment, Right To Terminate Work Order, Unusual Or Infrequent Cause, Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_OtherCommitmentRightToTerminateWorkOrderUnusualOrInfrequentCausePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agle_OtherCommitmentRoyaltyPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Commitment, Royalty Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agle_OtherCommitmentRoyaltyPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agle_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>159
<FILENAME>d518298ds1_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:agle="http://www.spy.com/20230930"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="agle-20230930.xsd" xlink:type="simple"/>
    <context id="PAsOn12_31_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P07_01_2023To09_30_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2022To09_30_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2023To09_30_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P04_01_2023To04_30_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-04-30</endDate>
        </period>
    </context>
    <context id="P04_01_2023To06_30_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="PAsOn09_30_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="P06_22_2023To06_22_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
        </entity>
        <period>
            <startDate>2023-06-22</startDate>
            <endDate>2023-06-22</endDate>
        </period>
    </context>
    <context id="PAsOn06_22_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
        </entity>
        <period>
            <instant>2023-06-22</instant>
        </period>
    </context>
    <context id="PAsOn04_30_2019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
        </entity>
        <period>
            <instant>2019-04-30</instant>
        </period>
    </context>
    <context id="P04_01_2020To04_30_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="P02_01_2019To02_28_2019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-28</endDate>
        </period>
    </context>
    <context id="P04_01_2019To04_30_2019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="PAsOn04_30_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
        </entity>
        <period>
            <instant>2023-04-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="PAsOn08_07_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
        </entity>
        <period>
            <instant>2023-08-07</instant>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="PAsOn12_31_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn05_31_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="P04_01_2022To06_30_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P05_01_2022To05_31_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="PAsOn01_31_2017">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
        </entity>
        <period>
            <instant>2017-01-31</instant>
        </period>
    </context>
    <context id="P09_08_2023To09_08_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
        </entity>
        <period>
            <startDate>2023-09-08</startDate>
            <endDate>2023-09-08</endDate>
        </period>
    </context>
    <context id="P02_01_2019To05_31_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="PAsOn12_31_2019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_PurchasedSoftwareMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">agle:PurchasedSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_LaboratoryEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">agle:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_USGovernmentAgenciesDebtSecuritiesMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_ReimbursableCostsUnderParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">agle:ReimbursableCostsUnderParagonAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_ParapyreOptionObligationMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">agle:ParapyreOptionObligationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CommercialPaperMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CommercialPaperMemberusgaapFairValueByAssetClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapCashAndCashEquivalentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapCashAndCashEquivalentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapCashAndCashEquivalentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapCashAndCashEquivalentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CommercialPaperMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CommercialPaperMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CorporateBondSecuritiesMemberusgaapInvestmentTypeAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CorporateBondSecuritiesMemberusgaapInvestmentTypeAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CorporateBondSecuritiesMemberusgaapInvestmentTypeAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CorporateBondSecuritiesMemberusgaapInvestmentTypeAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CommercialPaperMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_MoneyMarketFundsMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CorporateBondSecuritiesMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CommercialPaperMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">agle:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FebruaryTwoThousandNinteenMemberusgaapAwardDateAxis_WarrantMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">agle:FebruaryTwoThousandNinteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AprilTwoThousandTwentyMemberusgaapAwardDateAxis_WarrantMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">agle:AprilTwoThousandTwentyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_MayTwoThousandTwentyTwoMemberusgaapAwardDateAxis_WarrantMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">agle:MayTwoThousandTwentyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_WarrantMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_USBankingInstitutionMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">agle:USBankingInstitutionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agle:TwoThousandAndSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agle:TwoThousandAndSixteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_TwoThousandAndEighteenEquityInducementPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agle:TwoThousandAndEighteenEquityInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agle:ImmedicaPharmaABMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_EmployeesAndNonEmployeesMembersrtTitleOfIndividualAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">agle:EmployeesAndNonEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_LicenseAgreementsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_UniversityOfTexasAtAustinMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">agle:LicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agle:UniversityOfTexasAtAustinMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2023_FebruaryEightTwoThousandNinteenMemberusgaapAwardDateAxis_WarrantMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">agle:FebruaryEightTwoThousandNinteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2023_AprilThirtyTwoThousandTwentyMemberusgaapAwardDateAxis_WarrantMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">agle:AprilThirtyTwoThousandTwentyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2023_MayTwentyTwoThousandTwentyTwoMemberusgaapAwardDateAxis_WarrantMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">agle:MayTwentyTwoThousandTwentyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2023_USGovernmentAgenciesDebtSecuritiesMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2023_MaximumMembersrtRangeAxis_OwnershipInterestMemberusgaapRelatedPartyTransactionAxis_ParagonTherapeuticsIncMembersrtOwnershipAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">agle:ParagonTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">agle:OwnershipInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2023_FairmountFundsManagementLlcMembersrtOwnershipAxis_MinimumMembersrtRangeAxis_OwnershipInterestMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">agle:FairmountFundsManagementLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">agle:OwnershipInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2023_ReimbursableCostsUnderParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">agle:ReimbursableCostsUnderParagonAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2023_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2023_ParapyreOptionObligationMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">agle:ParapyreOptionObligationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2023_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2023_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2023_CommercialPaperMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2023_CommercialPaperMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2023_CorporateBondSecuritiesMemberusgaapInvestmentTypeAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2023_CorporateBondSecuritiesMemberusgaapInvestmentTypeAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2023_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2023_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2023_CorporateBondSecuritiesMemberusgaapInvestmentTypeAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2023_CorporateBondSecuritiesMemberusgaapInvestmentTypeAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2023_CommercialPaperMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2023_CommercialPaperMemberusgaapFairValueByAssetClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_ParapyreOptionObligationMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">agle:ParapyreOptionObligationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2023_ContingentValueRightLiabilityMemberusgaapFairValueByLiabilityClassAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">agle:ContingentValueRightLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2023_ContingentValueRightLiabilityMemberusgaapFairValueByLiabilityClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">agle:ContingentValueRightLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2023_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_ParapyreOptionObligationMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">agle:ParapyreOptionObligationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_ParapyreOptionObligationMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">agle:ParapyreOptionObligationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2023_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_ParapyreOptionObligationMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">agle:ParapyreOptionObligationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2023_ContingentValueRightLiabilityMemberusgaapFairValueByLiabilityClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">agle:ContingentValueRightLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2023_ContingentValueRightLiabilityMemberusgaapFairValueByLiabilityClassAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">agle:ContingentValueRightLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2023_ContingentValueRightLiabilityMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputProabilityOfSuccessMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">agle:ContingentValueRightLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">agle:MeasurementInputProabilityOfSuccessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2023_ContingentValueRightLiabilityMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MaximumMembersrtRangeAxis_MeasurementInputProabilityOfSuccessMemberusgaapMeasurementInputTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">agle:ContingentValueRightLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">agle:MeasurementInputProabilityOfSuccessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2023_ContingentValueRightLiabilityMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">agle:ContingentValueRightLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2023_ContingentValueRightLiabilityMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MaximumMembersrtRangeAxis_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">agle:ContingentValueRightLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2023_MoneyMarketFundsMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2023_CommercialPaperMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2023_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2023_CorporateBondSecuritiesMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2023_CommercialPaperMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">agle:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2023_AppointOfBoardMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">agle:AppointOfBoardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2023_WarrantMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2023_MaximumMembersrtRangeAxis_USBankingInstitutionMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">agle:USBankingInstitutionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2023_USBankingInstitutionMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">agle:USBankingInstitutionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2023_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2023_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2023_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agle:TwoThousandAndSixteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2023_ParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">agle:ParagonAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2023_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agle:ImmedicaPharmaABMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2023_ParapyreOptionObligationMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agle:ParapyreOptionObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_SeriesAConvertiblePreferredStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">agle:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agle:TwoThousandAndSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agle:TwoThousandAndSixteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_ReimbursableCostsUnderParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">agle:ReimbursableCostsUnderParagonAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_ForwardContractsMemberusgaapDerivativeInstrumentRiskAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_ContingentValueRightLiabilityMemberusgaapDerivativeInstrumentRiskAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">agle:ContingentValueRightLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_USGovernmentAgenciesDebtSecuritiesMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_PeaceTrialAndBLAPackageMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">agle:PeaceTrialAndBLAPackageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agle:ImmedicaPharmaABMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_ParapyreOptionObligationMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agle:ParapyreOptionObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2022To09_30_2022_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2022To09_30_2022_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2022To09_30_2022_SeriesAConvertiblePreferredStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">agle:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2022To09_30_2022_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2022To09_30_2022_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2022To09_30_2022_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agle:TwoThousandAndSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2022To09_30_2022_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agle:TwoThousandAndSixteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2022To09_30_2022_ReimbursableCostsUnderParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">agle:ReimbursableCostsUnderParagonAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2022To09_30_2022_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2022To09_30_2022_ForwardContractsMemberusgaapDerivativeInstrumentRiskAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2022To09_30_2022_USGovernmentAgenciesDebtSecuritiesMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2022To09_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2022To09_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2022To09_30_2022_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_PeaceTrialAndBLAPackageMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">agle:PeaceTrialAndBLAPackageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agle:ImmedicaPharmaABMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2022To09_30_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2022To09_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2022To09_30_2022_ParapyreOptionObligationMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agle:ParapyreOptionObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2023To09_30_2023_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2023To09_30_2023_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2023To09_30_2023_SeriesAConvertiblePreferredStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">agle:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2023To09_30_2023_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2023To09_30_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2023To09_30_2023_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agle:TwoThousandAndSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2023To09_30_2023_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agle:TwoThousandAndSixteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2023To09_30_2023_TwoThousandAndEighteenEquityInducementPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agle:TwoThousandAndEighteenEquityInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2023To09_30_2023_ReimbursableCostsUnderParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">agle:ReimbursableCostsUnderParagonAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2023To09_30_2023_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2023To09_30_2023_ForwardContractsMemberusgaapDerivativeInstrumentRiskAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2023To09_30_2023_ContingentValueRightLiabilityMemberusgaapDerivativeInstrumentRiskAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">agle:ContingentValueRightLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2023To09_30_2023_USGovernmentAgenciesDebtSecuritiesMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2023To09_30_2023_SeveranceLiabilityMemberusgaapRestructuringCostAndReserveAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">agle:SeveranceLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2023To09_30_2023_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_StockCompensationAndResearchAndDevelopmentExpenseMemberusgaapRelatedPartyTransactionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">agle:StockCompensationAndResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2023To09_30_2023_MilestonePaymentsMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">agle:MilestonePaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2023To09_30_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2023To09_30_2023_ParapyreOptionObligationMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agle:ParapyreOptionObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2023To09_30_2023_ParagonTherapeuticsIncMembersrtCounterpartyNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">agle:ParagonTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2023To09_30_2023_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_PeacePhase3TrialAndDrugSupplyMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">agle:PeacePhase3TrialAndDrugSupplyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agle:ImmedicaPharmaABMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2023To09_30_2023_ParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">agle:ParagonAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2023To09_30_2023_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agle:TwoThousandAndSixteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2023To09_30_2023_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2023To09_30_2023_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2023To09_30_2023_SeriesAConvertiblePreferredStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">agle:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2023To09_30_2023_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2023To09_30_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2023To09_30_2023_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agle:TwoThousandAndSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2023To09_30_2023_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agle:TwoThousandAndSixteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2023To09_30_2023_ReimbursableCostsUnderParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">agle:ReimbursableCostsUnderParagonAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2023To09_30_2023_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2023To09_30_2023_ForwardContractsMemberusgaapDerivativeInstrumentRiskAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2023To09_30_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">agle:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2023To09_30_2023_USGovernmentAgenciesDebtSecuritiesMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2023To09_30_2023_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_StockCompensationAndResearchAndDevelopmentExpenseMemberusgaapRelatedPartyTransactionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">agle:StockCompensationAndResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2023To09_30_2023_MilestonePaymentsMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">agle:MilestonePaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2023To09_30_2023_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2023To09_30_2023_ParapyreOptionObligationMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agle:ParapyreOptionObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2023To09_30_2023_ParagonTherapeuticsIncMembersrtCounterpartyNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">agle:ParagonTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2023To09_30_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2023To09_30_2023_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_PeacePhase3TrialAndDrugSupplyMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">agle:PeacePhase3TrialAndDrugSupplyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agle:ImmedicaPharmaABMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2023To09_30_2023_ContingentValueRightLiabilityMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">agle:ContingentValueRightLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2023To09_30_2023_ParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">agle:ParagonAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2023To09_30_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2023To09_30_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2023To06_30_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_RestructuringActivitiesMemberusgaapRestructuringCostAndReserveAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">agle:RestructuringActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2023To06_30_2023_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_RestructuringActivitiesMemberusgaapRestructuringCostAndReserveAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">agle:RestructuringActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2023To06_30_2023_RestructuringActivitiesMemberusgaapRestructuringCostAndReserveAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">agle:RestructuringActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2023To06_30_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">agle:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2023To06_30_2023_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2023To06_30_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2023To06_30_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2023To06_30_2023_ContingentValueRightLiabilityMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">agle:ContingentValueRightLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2023To06_30_2023_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2023To06_30_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2023To06_30_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="PAsOn12_31_2021_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_PurchasedSoftwareMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">agle:PurchasedSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_LaboratoryEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">agle:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_USGovernmentAgenciesDebtSecuritiesMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CommercialPaperMemberusgaapFairValueByAssetClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CorporateBondSecuritiesMemberusgaapInvestmentTypeAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CorporateBondSecuritiesMemberusgaapInvestmentTypeAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CommercialPaperMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_MoneyMarketFundsMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CommercialPaperMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CorporateBondSecuritiesMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CommercialPaperMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_EmployeesAndNonEmployeesMembersrtTitleOfIndividualAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">agle:EmployeesAndNonEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agle:ImmedicaPharmaABMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2022To06_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2022To06_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2022To06_30_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2022To06_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P06_22_2023To06_22_2023_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">agle:SpyreTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-22</startDate>
            <endDate>2023-06-22</endDate>
        </period>
    </context>
    <context id="P06_22_2023To06_22_2023_CommonStockMemberusgaapEquityInterestIssuedOrIssuableByTypeAxis_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">agle:SpyreTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-22</startDate>
            <endDate>2023-06-22</endDate>
        </period>
    </context>
    <context id="P06_22_2023To06_22_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">agle:SpyreTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">agle:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-22</startDate>
            <endDate>2023-06-22</endDate>
        </period>
    </context>
    <context id="P06_22_2023To06_22_2023_ParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">agle:ParagonAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-22</startDate>
            <endDate>2023-06-22</endDate>
        </period>
    </context>
    <context id="P06_22_2023To06_22_2023_AssetAcquisitionMemberusgaapAssetAcquisitionAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">agle:AssetAcquisitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">agle:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-22</startDate>
            <endDate>2023-06-22</endDate>
        </period>
    </context>
    <context id="P06_22_2023To06_22_2023_Spyre2023EquityIncentivePlanMemberusgaapPlanNameAxis_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">agle:SpyreTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agle:Spyre2023EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-22</startDate>
            <endDate>2023-06-22</endDate>
        </period>
    </context>
    <context id="P06_22_2023To06_22_2023_MinimumMembersrtRangeAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">agle:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-22</startDate>
            <endDate>2023-06-22</endDate>
        </period>
    </context>
    <context id="P06_22_2023To06_22_2023_MaximumMembersrtRangeAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">agle:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-22</startDate>
            <endDate>2023-06-22</endDate>
        </period>
    </context>
    <context id="P06_22_2023To06_22_2023_AssetAcquisitionMemberusgaapAssetAcquisitionAxis_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">agle:AssetAcquisitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-22</startDate>
            <endDate>2023-06-22</endDate>
        </period>
    </context>
    <context id="P06_22_2023To06_22_2023_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-22</startDate>
            <endDate>2023-06-22</endDate>
        </period>
    </context>
    <context id="P06_22_2023To06_22_2023_AssetAcquisitionMemberusgaapAssetAcquisitionAxis_Spyre2023EquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">agle:AssetAcquisitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agle:Spyre2023EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-22</startDate>
            <endDate>2023-06-22</endDate>
        </period>
    </context>
    <context id="P06_22_2023To06_22_2023_ParapyreOptionObligationMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agle:ParapyreOptionObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-22</startDate>
            <endDate>2023-06-22</endDate>
        </period>
    </context>
    <context id="P06_22_2023To06_22_2023_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agle:TwoThousandAndSixteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-22</startDate>
            <endDate>2023-06-22</endDate>
        </period>
    </context>
    <context id="PAsOn06_22_2023_MaximumMembersrtRangeAxis_OwnershipInterestMemberusgaapRelatedPartyTransactionAxis_ParagonAndParapyreHoldingLlcMembersrtOwnershipAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">agle:ParagonAndParapyreHoldingLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">agle:OwnershipInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-22</instant>
        </period>
    </context>
    <context id="PAsOn06_22_2023_FairmountFundsManagementLlcMembersrtOwnershipAxis_MinimumMembersrtRangeAxis_OwnershipInterestMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">agle:FairmountFundsManagementLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">agle:OwnershipInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-22</instant>
        </period>
    </context>
    <context id="PAsOn06_22_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">agle:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-22</instant>
        </period>
    </context>
    <context id="PAsOn06_22_2023_ForwardContractsMemberusgaapDerivativeInstrumentRiskAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-22</instant>
        </period>
    </context>
    <context id="PAsOn06_22_2023_AssetAcquisitionMemberusgaapAssetAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">agle:AssetAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-22</instant>
        </period>
    </context>
    <context id="PAsOn06_22_2023_ParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">agle:ParagonAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-22</instant>
        </period>
    </context>
    <context id="PAsOn06_22_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">agle:SpyreTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">agle:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-22</instant>
        </period>
    </context>
    <context id="PAsOn06_22_2023_CommonStockMemberusgaapEquityInterestIssuedOrIssuableByTypeAxis_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">agle:SpyreTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-22</instant>
        </period>
    </context>
    <context id="PAsOn06_22_2023_AssetAcquisitionMemberusgaapAssetAcquisitionAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">agle:AssetAcquisitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">agle:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-22</instant>
        </period>
    </context>
    <context id="PAsOn06_22_2023_ParapyreOptionObligationMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agle:ParapyreOptionObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-22</instant>
        </period>
    </context>
    <context id="PAsOn06_22_2023_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">agle:SpyreTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-22</instant>
        </period>
    </context>
    <context id="PAsOn06_22_2023_USBankingInstitutionMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">agle:USBankingInstitutionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-22</instant>
        </period>
    </context>
    <context id="PAsOn06_22_2023_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agle:TwoThousandAndSixteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-22</instant>
        </period>
    </context>
    <context id="P06_26_2023To06_26_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">agle:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-26</startDate>
            <endDate>2023-06-26</endDate>
        </period>
    </context>
    <context id="P06_26_2023To06_26_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">agle:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-26</startDate>
            <endDate>2023-06-26</endDate>
        </period>
    </context>
    <context id="PAsOn06_26_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">agle:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-26</instant>
        </period>
    </context>
    <context id="P07_07_2023To07_07_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">agle:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-07</startDate>
            <endDate>2023-07-07</endDate>
        </period>
    </context>
    <context id="P07_07_2023To07_07_2023_AssetAcquisitionMemberusgaapBusinessAcquisitionAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">agle:AssetAcquisitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">agle:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-07</startDate>
            <endDate>2023-07-07</endDate>
        </period>
    </context>
    <context id="P07_07_2023To07_07_2023_CommonStockMemberusgaapEquityInterestIssuedOrIssuableByTypeAxis_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">agle:SpyreTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-07</startDate>
            <endDate>2023-07-07</endDate>
        </period>
    </context>
    <context id="P07_07_2023To07_07_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">agle:SpyreTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">agle:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-07</startDate>
            <endDate>2023-07-07</endDate>
        </period>
    </context>
    <context id="P06_23_2023To06_30_2023_ForwardContractsMemberusgaapDerivativeInstrumentRiskAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-23</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="P12_31_2023To12_31_2023_ParapyreOptionObligationMemberusgaapPlanNameAxis_ScenarioForecastMembersrtStatementScenarioAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agle:ParapyreOptionObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-31</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="PAsOn07_31_2023_MaximumMembersrtRangeAxis_ParagonTherapeuticsIncMembersrtOwnershipAxis_Spy001LicenseAgreementMemberusgaapRelatedPartyTransactionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">agle:ParagonTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">agle:Spy001LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-31</instant>
        </period>
    </context>
    <context id="PAsOn05_31_2023_ParapyreOptionObligationMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agle:ParapyreOptionObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="P07_12_2023To07_12_2023_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_Spy001LicenseAgreementMemberusgaapRelatedPartyTransactionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">agle:Spy001LicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-12</startDate>
            <endDate>2023-07-12</endDate>
        </period>
    </context>
    <context id="PAsOn07_12_2023_MaximumMembersrtRangeAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_Spy001LicenseAgreementMemberusgaapRelatedPartyTransactionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">agle:Spy001LicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-12</instant>
        </period>
    </context>
    <context id="P05_01_2022To05_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="PAsOn05_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="PAsOn05_31_2022_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="P02_01_2019To05_31_2022_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="P01_01_2016To12_31_2016_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agle:TwoThousandAndSixteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="P07_01_2020To07_31_2020_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agle:TwoThousandAndSixteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="P07_01_2020To09_30_2023_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agle:TwoThousandAndSixteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="PAsOn01_01_2022_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agle:TwoThousandAndSixteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="PAsOn01_01_2022_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agle:TwoThousandAndSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="PAsOn01_01_2023_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agle:TwoThousandAndSixteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="P03_21_2021To03_21_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agle:ImmedicaPharmaABMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-21</startDate>
            <endDate>2021-03-21</endDate>
        </period>
    </context>
    <context id="P03_21_2021To03_21_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agle:ImmedicaPharmaABMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-21</startDate>
            <endDate>2021-03-21</endDate>
        </period>
    </context>
    <context id="PAsOn03_21_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_LicenseMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agle:ImmedicaPharmaABMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-21</instant>
        </period>
    </context>
    <context id="P07_01_2021To07_31_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agle:ImmedicaPharmaABMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="P07_01_2021To07_31_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_PIPTrialMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">agle:PIPTrialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agle:ImmedicaPharmaABMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="P07_01_2021To07_31_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_PeaceTrialAndBLAPackageMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">agle:PeaceTrialAndBLAPackageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agle:ImmedicaPharmaABMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="P07_27_2023To07_27_2023_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberusgaapDisposalGroupClassificationAxis_GlobalRightsToPegzilarginaseMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">agle:GlobalRightsToPegzilarginaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-27</startDate>
            <endDate>2023-07-27</endDate>
        </period>
    </context>
    <context id="PAsOn07_27_2023_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberusgaapDisposalGroupClassificationAxis_GlobalRightsToPegzilarginaseMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">agle:GlobalRightsToPegzilarginaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-27</instant>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_EmployeesMembersrtTitleOfIndividualAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">agle:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agle:TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_NonEmployeesMembersrtTitleOfIndividualAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">agle:NonEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agle:TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_EmployeesMembersrtTitleOfIndividualAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">agle:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agle:TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_NonEmployeesMembersrtTitleOfIndividualAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">agle:NonEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agle:TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_EmployeesMembersrtTitleOfIndividualAxis_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">agle:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agle:TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_NonEmployeesMembersrtTitleOfIndividualAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">agle:NonEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agle:TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agle:TwoThousandAndSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_PropertyPlantAndEquipmentMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_LicenseMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_DevelopmentFeeMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agle:DevelopmentFeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_LicenseAgreementsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">agle:LicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agle:ImmedicaPharmaABMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis_NonEmployeesMembersrtTitleOfIndividualAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">agle:NonEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_NonEmployeesMembersrtTitleOfIndividualAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">agle:NonEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_LicenseAgreementsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_UniversityOfTexasAtAustinMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">agle:LicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agle:UniversityOfTexasAtAustinMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_EmployeesMembersrtTitleOfIndividualAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">agle:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agle:TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_NonEmployeesMembersrtTitleOfIndividualAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">agle:NonEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agle:TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_EmployeesMembersrtTitleOfIndividualAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">agle:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agle:TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_NonEmployeesMembersrtTitleOfIndividualAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">agle:NonEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agle:TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_EmployeesMembersrtTitleOfIndividualAxis_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">agle:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agle:TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_NonEmployeesMembersrtTitleOfIndividualAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">agle:NonEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agle:TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agle:TwoThousandAndSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_ForeignCountryMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_PropertyPlantAndEquipmentMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_LicenseMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_DevelopmentFeeMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agle:DevelopmentFeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_USGovernmentAgenciesDebtSecuritiesMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_LicenseAgreementsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">agle:LicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agle:ImmedicaPharmaABMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_PeaceTrialAndBLAPackageMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">agle:PeaceTrialAndBLAPackageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agle:ImmedicaPharmaABMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis_NonEmployeesMembersrtTitleOfIndividualAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">agle:NonEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_NonEmployeesMembersrtTitleOfIndividualAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">agle:NonEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_LicenseAgreementsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_UniversityOfTexasAtAustinMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">agle:LicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agle:UniversityOfTexasAtAustinMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_EmployeesMembersrtTitleOfIndividualAxis_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">agle:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agle:TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_NonEmployeesMembersrtTitleOfIndividualAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">agle:NonEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agle:TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_EmployeesMembersrtTitleOfIndividualAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">agle:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agle:TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_NonEmployeesMembersrtTitleOfIndividualAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">agle:NonEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agle:TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_EmployeesMembersrtTitleOfIndividualAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">agle:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agle:TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_NonEmployeesMembersrtTitleOfIndividualAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">agle:NonEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agle:TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agle:TwoThousandAndSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ForeignCountryMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_PropertyPlantAndEquipmentMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_FebruaryTwoThousandNinteenMemberusgaapAwardDateAxis_WarrantMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">agle:FebruaryTwoThousandNinteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_AprilTwoThousandTwentyMemberusgaapAwardDateAxis_WarrantMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">agle:AprilTwoThousandTwentyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_MayTwoThousandTwentyTwoMemberusgaapAwardDateAxis_WarrantMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">agle:MayTwoThousandTwentyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_EmployeesMembersrtTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">agle:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_LicenseMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_DevelopmentFeeMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agle:DevelopmentFeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_USGovernmentAgenciesDebtSecuritiesMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_TwoThousandAndFifteenEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agle:TwoThousandAndFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_EarliestTaxYearMemberusgaapTaxPeriodAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:EarliestTaxYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agle:TwoThousandAndSixteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_PeaceTrialAndBLAPackageMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">agle:PeaceTrialAndBLAPackageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agle:ImmedicaPharmaABMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis_NonEmployeesMembersrtTitleOfIndividualAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">agle:NonEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_NonEmployeesMembersrtTitleOfIndividualAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">agle:NonEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_LicenseAgreementsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_UniversityOfTexasAtAustinMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">agle:LicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agle:UniversityOfTexasAtAustinMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agle:ImmedicaPharmaABMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agle:ImmedicaPharmaABMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="PAsOn12_31_2020_EmployeesAndNonEmployeesMembersrtTitleOfIndividualAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">agle:EmployeesAndNonEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn04_30_2019_LetterOfCreditMemberusgaapShortTermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-30</instant>
        </period>
    </context>
    <context id="PAsOn04_30_2019_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-30</instant>
        </period>
    </context>
    <context id="P02_01_2019To02_28_2019_CommonStockMemberusgaapStatementEquityComponentsAxis_FollowOnPublicOfferingMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">agle:FollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-28</endDate>
        </period>
    </context>
    <context id="P02_01_2019To02_28_2019_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-28</endDate>
        </period>
    </context>
    <context id="PAsOn02_28_2019_CommonStockMemberusgaapStatementEquityComponentsAxis_FollowOnPublicOfferingMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">agle:FollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-28</instant>
        </period>
    </context>
    <context id="PAsOn02_28_2019_CommonStockMemberusgaapStatementEquityComponentsAxis_FollowOnPublicOfferingMemberusgaapSubsidiarySaleOfStockAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">agle:FollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-28</instant>
        </period>
    </context>
    <context id="P04_01_2020To04_30_2020_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="P04_01_2020To04_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_FollowOnPublicOfferingMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">agle:FollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="P04_01_2020To04_30_2020_AtTheMarketSalesAgreementMemberusgaapSubsidiarySaleOfStockAxis_JonesTradingInstitutionalServicesLimitedLiabilityCompanyMemberusgaapRelatedPartyTransactionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">agle:JonesTradingInstitutionalServicesLimitedLiabilityCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">agle:AtTheMarketSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="PAsOn04_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_FollowOnPublicOfferingMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">agle:FollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="PAsOn04_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_FollowOnPublicOfferingMemberusgaapSubsidiarySaleOfStockAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">agle:FollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="P10_01_2020To12_31_2020_AtTheMarketSalesAgreementMemberusgaapSubsidiarySaleOfStockAxis_JonesTradingInstitutionalServicesLimitedLiabilityCompanyMemberusgaapRelatedPartyTransactionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">agle:JonesTradingInstitutionalServicesLimitedLiabilityCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">agle:AtTheMarketSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To03_31_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agle:ImmedicaPharmaABMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To03_31_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agle:ImmedicaPharmaABMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To03_31_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_PeaceTrialAndBLAPackageMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">agle:PeaceTrialAndBLAPackageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agle:ImmedicaPharmaABMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To03_31_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_PIPTrialMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">agle:PIPTrialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agle:ImmedicaPharmaABMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P06_01_2021To06_30_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_LicenseAgreementsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">agle:LicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agle:ImmedicaPharmaABMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2017To01_31_2017_LicenseAgreementsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_MinimumMembersrtRangeAxis_UniversityOfTexasAtAustinMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">agle:LicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agle:UniversityOfTexasAtAustinMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-01-31</endDate>
        </period>
    </context>
    <context id="P01_01_2017To01_31_2017_LicenseAgreementsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_MaximumMembersrtRangeAxis_UniversityOfTexasAtAustinMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">agle:LicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agle:UniversityOfTexasAtAustinMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-01-31</endDate>
        </period>
    </context>
    <context id="P01_01_2017To01_31_2017_LicenseAgreementsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_UniversityOfTexasAtAustinMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">agle:LicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agle:UniversityOfTexasAtAustinMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-01-31</endDate>
        </period>
    </context>
    <context id="P03_01_2015To03_31_2015_MinimumMembersrtRangeAxis_TwoThousandAndFifteenEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agle:TwoThousandAndFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-03-01</startDate>
            <endDate>2015-03-31</endDate>
        </period>
    </context>
    <context id="P03_01_2015To03_31_2015_MaximumMembersrtRangeAxis_StockOptionMemberusgaapAwardTypeAxis_TwoThousandAndFifteenEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agle:TwoThousandAndFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-03-01</startDate>
            <endDate>2015-03-31</endDate>
        </period>
    </context>
    <context id="P03_01_2015To03_31_2015_TwoThousandAndFifteenEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agle:TwoThousandAndFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-03-01</startDate>
            <endDate>2015-03-31</endDate>
        </period>
    </context>
    <context id="PAsOn04_30_2016_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agle:TwoThousandAndSixteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-04-30</instant>
        </period>
    </context>
    <context id="PAsOn04_30_2016_TwoThousandAndFifteenEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agle:TwoThousandAndFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-04-30</instant>
        </period>
    </context>
    <context id="PAsOn04_30_2016_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agle:TwoThousandAndSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-04-30</instant>
        </period>
    </context>
    <context id="P10_01_2018To10_31_2018_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agle:TwoThousandAndSixteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-31</endDate>
        </period>
    </context>
    <context id="PAsOn01_01_2020_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agle:TwoThousandAndSixteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-01</instant>
        </period>
    </context>
    <context id="PAsOn01_01_2020_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agle:TwoThousandAndSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-01</instant>
        </period>
    </context>
    <context id="PAsOn01_01_2021_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agle:TwoThousandAndSixteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="PAsOn01_01_2021_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agle:TwoThousandAndSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="PAsOn02_28_2018_TwoThousandAndEighteenEquityInducementPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agle:TwoThousandAndEighteenEquityInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-02-28</instant>
        </period>
    </context>
    <context id="P11_01_2022To11_30_2022_NewChiefExecutiveOfficerMembersrtTitleOfIndividualAxis_NonQualifiedStockOptionsMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">agle:NewChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agle:NonQualifiedStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="P04_01_2016To04_30_2016_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agle:TwoThousandAndSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-04-01</startDate>
            <endDate>2016-04-30</endDate>
        </period>
    </context>
    <context id="P04_01_2016To04_30_2016_MaximumMembersrtRangeAxis_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agle:TwoThousandAndSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-04-01</startDate>
            <endDate>2016-04-30</endDate>
        </period>
    </context>
    <context id="P06_01_2018To06_30_2018_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agle:TwoThousandAndSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="P02_01_2023To02_28_2023_MaximumMembersrtRangeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agle:TwoThousandAndSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2023-02-28</endDate>
        </period>
    </context>
    <context id="P09_08_2023To09_08_2023_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-08</startDate>
            <endDate>2023-09-08</endDate>
        </period>
    </context>
    <context id="P09_08_2023To09_08_2023_MaximumMembersrtRangeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-08</startDate>
            <endDate>2023-09-08</endDate>
        </period>
    </context>
    <context id="P09_08_2023To09_08_2023_MinimumMembersrtRangeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-08</startDate>
            <endDate>2023-09-08</endDate>
        </period>
    </context>
    <context id="PAsOn09_08_2023_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-08</instant>
        </period>
    </context>
    <context id="P09_29_2023To09_29_2023_ParapyreOptionObligationMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agle:ParapyreOptionObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-29</startDate>
            <endDate>2023-09-29</endDate>
        </period>
    </context>
    <context id="P09_29_2023To09_29_2023_ParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">agle:ParagonAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-29</startDate>
            <endDate>2023-09-29</endDate>
        </period>
    </context>
    <context id="P09_29_2023To09_29_2023_ParapyreOptionObligationMemberusgaapPlanNameAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agle:ParapyreOptionObligationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-29</startDate>
            <endDate>2023-09-29</endDate>
        </period>
    </context>
    <context id="P02_01_2018To02_28_2018_ServiceBasedAwardsMemberusgaapAwardTypeAxis_TwoThousandAndFifteenAndTwoThousandAndSixteenEquityIncentivePlanAndTwoThousandAndEighteenEquityInducementPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agle:ServiceBasedAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agle:TwoThousandAndFifteenAndTwoThousandAndSixteenEquityIncentivePlanAndTwoThousandAndEighteenEquityInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-01</startDate>
            <endDate>2018-02-28</endDate>
        </period>
    </context>
    <context id="P02_01_2018To02_28_2018_MaximumMembersrtRangeAxis_ServiceBasedAwardsMemberusgaapAwardTypeAxis_TwoThousandAndFifteenAndTwoThousandAndSixteenEquityIncentivePlanAndTwoThousandAndEighteenEquityInducementPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agle:ServiceBasedAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agle:TwoThousandAndFifteenAndTwoThousandAndSixteenEquityIncentivePlanAndTwoThousandAndEighteenEquityInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-01</startDate>
            <endDate>2018-02-28</endDate>
        </period>
    </context>
    <context id="P07_01_2023To07_31_2023_LicensingAgreementsMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-07-31</endDate>
        </period>
    </context>
    <context id="P09_01_2021To09_30_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_LicenseAgreementsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">agle:LicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agle:ImmedicaPharmaABMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="PAsOn12_31_2022_SeveranceLiabilityMemberusgaapRestructuringCostAndReserveAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">agle:SeveranceLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_ContingentValueRightLiabilityMemberusgaapDerivativeInstrumentRiskAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">agle:ContingentValueRightLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_EmployeesMembersrtTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">agle:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2023_SeveranceLiabilityMemberusgaapRestructuringCostAndReserveAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">agle:SeveranceLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2023_ContingentValueRightLiabilityMemberusgaapDerivativeInstrumentRiskAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">agle:ContingentValueRightLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2023_ForwardContractsMemberusgaapDerivativeInstrumentRiskAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">agle:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2023_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">agle:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">agle:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2023_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2023_ForwardContractsMemberusgaapDerivativeInstrumentRiskAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_EmployeesMembersrtTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">agle:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">agle:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">agle:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">agle:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <unit id="Unit_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_shares">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Year">
        <measure>utr:Year</measure>
    </unit>
    <unit id="Unit_pure">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Day">
        <measure>utr:Day</measure>
    </unit>
    <unit id="Unit_Month">
        <measure>utr:Month</measure>
    </unit>
    <unit id="Unit_sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="Unit_USD_per_Share">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_SEGMENT">
        <measure>agle:SEGMENT</measure>
    </unit>
    <unit id="Unit_BOARDSEAT">
        <measure>agle:BOARDSEAT</measure>
    </unit>
    <unit id="Unit_SUBSIDARY">
        <measure>agle:SUBSIDARY</measure>
    </unit>
    <unit id="Unit_bank">
        <measure>agle:bank</measure>
    </unit>
    <unit id="Unit_PROGRAMOPTION">
        <measure>agle:PROGRAMOPTION</measure>
    </unit>
    <unit id="Unit_VOTE">
        <measure>agle:VOTE</measure>
    </unit>
    <unit id="Unit_employee">
        <measure>agle:employee</measure>
    </unit>
    <unit id="Unit_EUR_per_Share">
        <divide>
            <unitNumerator>
                <measure>iso4217:EUR</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_LICENSEAGREEMENT">
        <measure>agle:LICENSEAGREEMENT</measure>
    </unit>
    <unit id="Unit_USD_LICENSEAGREEMENT">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>agle:LICENSEAGREEMENT</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityAddressStateOrProvince contextRef="P01_01_2023To09_30_2023" id="hidden95764034">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressStateOrProvince
      contextRef="P01_01_2023To09_30_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"
      id="hidden95764035">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityCentralIndexKey contextRef="P01_01_2023To09_30_2023">0001636282</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="P01_01_2023To09_30_2023">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="P01_01_2023To09_30_2023">S-1</dei:DocumentType>
    <dei:EntityRegistrantName contextRef="P01_01_2023To09_30_2023">Spyre Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="P01_01_2023To09_30_2023">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="P01_01_2023To09_30_2023">46-4312787</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="P01_01_2023To09_30_2023">221 Crescent Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="P01_01_2023To09_30_2023">Building 23</dei:EntityAddressAddressLine2>
    <dei:EntityAddressAddressLine3 contextRef="P01_01_2023To09_30_2023">Suite 105</dei:EntityAddressAddressLine3>
    <dei:EntityAddressCityOrTown contextRef="P01_01_2023To09_30_2023">Waltham</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="P01_01_2023To09_30_2023">02453</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="P01_01_2023To09_30_2023">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="P01_01_2023To09_30_2023">651-5940</dei:LocalPhoneNumber>
    <dei:ContactPersonnelName contextRef="P01_01_2023To09_30_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">Heidy King-Jones</dei:ContactPersonnelName>
    <dei:EntityAddressAddressLine1 contextRef="P01_01_2023To09_30_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">221 Crescent Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="P01_01_2023To09_30_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">Building 23</dei:EntityAddressAddressLine2>
    <dei:EntityAddressAddressLine3 contextRef="P01_01_2023To09_30_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">Suite 105</dei:EntityAddressAddressLine3>
    <dei:EntityAddressCityOrTown contextRef="P01_01_2023To09_30_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">Waltham</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="P01_01_2023To09_30_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">02453</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="P01_01_2023To09_30_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="P01_01_2023To09_30_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">651-5940</dei:LocalPhoneNumber>
    <dei:EntityFilerCategory contextRef="P01_01_2023To09_30_2023">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="P01_01_2023To09_30_2023">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="P01_01_2023To09_30_2023">false</dei:EntityEmergingGrowthCompany>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="PAsOn12_31_2022_MinimumMembersrtRangeAxis"
      id="hidden95765451">P3Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
      contextRef="P01_01_2022To12_31_2022_FebruaryTwoThousandNinteenMemberusgaapAwardDateAxis_WarrantMemberusgaapStatementEquityComponentsAxis"
      id="hidden95765421">2019-02-28</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
      contextRef="P01_01_2022To12_31_2022_AprilTwoThousandTwentyMemberusgaapAwardDateAxis_WarrantMemberusgaapStatementEquityComponentsAxis"
      id="hidden95765422">2020-04-30</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
      contextRef="P01_01_2022To12_31_2022_MayTwoThousandTwentyTwoMemberusgaapAwardDateAxis_WarrantMemberusgaapStatementEquityComponentsAxis"
      id="hidden95765423">2022-05-31</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <us-gaap:LesseeFinanceLeaseRenewalTerm1
      contextRef="PAsOn12_31_2022_MinimumMembersrtRangeAxis"
      id="hidden95765453">P3Y</us-gaap:LesseeFinanceLeaseRenewalTerm1>
    <us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList contextRef="P07_01_2023To09_30_2023" id="hidden95764124">http://www.spy.com/20230930#DevelopmentFeeAndRoyaltyMember</us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList>
    <us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList contextRef="P07_01_2022To09_30_2022" id="hidden95764125">http://www.spy.com/20230930#DevelopmentFeeAndRoyaltyMember</us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList>
    <us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList contextRef="P01_01_2023To09_30_2023" id="hidden95764126">http://www.spy.com/20230930#DevelopmentFeeAndRoyaltyMember</us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList>
    <us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList contextRef="P01_01_2022To09_30_2022" id="hidden95764127">http://www.spy.com/20230930#DevelopmentFeeAndRoyaltyMember</us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList>
    <us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList contextRef="PAsOn12_31_2022" id="hidden95765537">http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent</us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList contextRef="PAsOn12_31_2021" id="hidden95765538">http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent</us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <agle:RateOfRevenueShare
      contextRef="P01_01_2021To03_31_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis"
      decimals="4"
      id="hidden95765599"
      unitRef="Unit_pure">0.2500</agle:RateOfRevenueShare>
    <us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList contextRef="PAsOn12_31_2022" id="hidden95765544">http://fasb.org/us-gaap/2023#AccruedLiabilitiesAndOtherLiabilities</us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList contextRef="PAsOn12_31_2021" id="hidden95765545">http://fasb.org/us-gaap/2023#AccruedLiabilitiesAndOtherLiabilities</us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      id="hidden95764152"
      unitRef="Unit_shares">2614014</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      id="hidden95764153"
      unitRef="Unit_shares">2614014</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList contextRef="PAsOn12_31_2021" id="hidden95765511">http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent</us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList contextRef="PAsOn12_31_2022" id="hidden95765401">http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent</us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <agle:NumberOfLicenseAgreements
      contextRef="PAsOn01_31_2017"
      decimals="0"
      id="hidden95765449"
      unitRef="Unit_LICENSEAGREEMENT">1</agle:NumberOfLicenseAgreements>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">34863000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">15142000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">20848000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">77986000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:NontradeReceivablesCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">375000</us-gaap:NontradeReceivablesCurrent>
    <us-gaap:NontradeReceivablesCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">815000</us-gaap:NontradeReceivablesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">6172000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">4948000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">62258000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">98891000</us-gaap:AssetsCurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">1553000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1838000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">3220000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">4549000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">3430000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">3806000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">683000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">842000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">71144000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">109926000</us-gaap:Assets>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">677000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">3319000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">625000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">436000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">517000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2359000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">12837000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">14030000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">14656000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">20144000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">4004000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">4608000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">2179000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1217000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">16000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">20839000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">25985000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="PAsOn12_31_2022"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="PAsOn12_31_2021"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2021"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2021"
      decimals="INF"
      unitRef="Unit_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      unitRef="Unit_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn12_31_2021"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2021"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2021"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2021"
      decimals="INF"
      unitRef="Unit_shares">20000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      unitRef="Unit_shares">20000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2021"
      decimals="INF"
      unitRef="Unit_shares">1974205</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2021"
      decimals="INF"
      unitRef="Unit_shares">1974205</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">6000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">5000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">475971000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">425765000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-48000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-20000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-425624000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-341809000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">50305000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">83941000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">71144000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">109926000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To12_31_2022_LicenseMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To12_31_2021_LicenseMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">12000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2020To12_31_2020_LicenseMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To12_31_2022_DevelopmentFeeMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">2329000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To12_31_2021_DevelopmentFeeMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">6739000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2020To12_31_2020_DevelopmentFeeMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">2329000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">18739000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">58579000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">57069000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">59638000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">28531000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">27319000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">21843000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">87110000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">84388000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">81481000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-84781000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-65649000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-81481000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeNet
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">837000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">111000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">593000</us-gaap:InvestmentIncomeNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-7000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-122000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-5000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">830000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-11000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">588000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-83951000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-65660000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-80893000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-136000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">141000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-83815000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-65801000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-80893000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2022To12_31_2022"
      decimals="2"
      unitRef="Unit_USD_per_Share">-24.86</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2022To12_31_2022"
      decimals="2"
      unitRef="Unit_USD_per_Share">-24.86</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2021To12_31_2021"
      decimals="2"
      unitRef="Unit_USD_per_Share">-25.02</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2021To12_31_2021"
      decimals="2"
      unitRef="Unit_USD_per_Share">-25.02</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2020To12_31_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">-37.89</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2020To12_31_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">-37.89</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      unitRef="Unit_shares">3371231</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      unitRef="Unit_shares">3371231</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_shares">2629784</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_shares">2629784</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_shares">2134869</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_shares">2134869</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-83815000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-65801000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-80893000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-35000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-1000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">19000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">7000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-30000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-59000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-83843000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-65832000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-80933000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">1163000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">255142000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2019_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">51000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-195115000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">60081000</us-gaap:StockholdersEquity>
    <agle:StockIssuedDuringPeriodSharesCommonStockAndPreFundedWarrants
      contextRef="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">747000</agle:StockIssuedDuringPeriodSharesCommonStockAndPreFundedWarrants>
    <agle:StockIssuedDuringPeriodValueCommonStockAndPreFundedWarrants
      contextRef="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">2000</agle:StockIssuedDuringPeriodValueCommonStockAndPreFundedWarrants>
    <agle:StockIssuedDuringPeriodValueCommonStockAndPreFundedWarrants
      contextRef="P01_01_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">153570000</agle:StockIssuedDuringPeriodValueCommonStockAndPreFundedWarrants>
    <agle:StockIssuedDuringPeriodValueCommonStockAndPreFundedWarrants
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">153572000</agle:StockIssuedDuringPeriodValueCommonStockAndPreFundedWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">5000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P01_01_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">490000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">490000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">3000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="P01_01_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">366000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">366000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="P01_01_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">6256000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">6256000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="P01_01_2020To12_31_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">19000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">19000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="P01_01_2020To12_31_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-59000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-59000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2020To12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-80893000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-80893000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">1918000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">415824000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">11000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-276008000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">139832000</us-gaap:StockholdersEquity>
    <agle:IssuanceOfCommonStockInConnectionWithExerciseOfPreFundedWarrants
      contextRef="P01_01_2021To12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">40</agle:IssuanceOfCommonStockInConnectionWithExerciseOfPreFundedWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="P01_01_2021To12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">13000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P01_01_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">1449000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1449000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="P01_01_2021To12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">3000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="P01_01_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">454000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">454000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="P01_01_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">8038000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">8038000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="P01_01_2021To12_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-1000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-1000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="P01_01_2021To12_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-30000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-30000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-65801000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-65801000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">1974000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">425765000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-20000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-341809000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">83941000</us-gaap:StockholdersEquity>
    <agle:IssuanceOfCommonStockAndPreFundedWarrantsSharesInConnectionWithRegisteredDirectOfferingNetOfOfferingCosts
      contextRef="P01_01_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">430000</agle:IssuanceOfCommonStockAndPreFundedWarrantsSharesInConnectionWithRegisteredDirectOfferingNetOfOfferingCosts>
    <agle:IssuanceOfCommonStockAndPreFundedWarrantsValueInConnectionWithRegisteredDirectOfferingNetOfOfferingCosts
      contextRef="P01_01_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">1000</agle:IssuanceOfCommonStockAndPreFundedWarrantsValueInConnectionWithRegisteredDirectOfferingNetOfOfferingCosts>
    <agle:IssuanceOfCommonStockAndPreFundedWarrantsValueInConnectionWithRegisteredDirectOfferingNetOfOfferingCosts
      contextRef="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">42873000</agle:IssuanceOfCommonStockAndPreFundedWarrantsValueInConnectionWithRegisteredDirectOfferingNetOfOfferingCosts>
    <agle:IssuanceOfCommonStockAndPreFundedWarrantsValueInConnectionWithRegisteredDirectOfferingNetOfOfferingCosts
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">42874000</agle:IssuanceOfCommonStockAndPreFundedWarrantsValueInConnectionWithRegisteredDirectOfferingNetOfOfferingCosts>
    <agle:IssuanceOfCommonStockInConnectionWithExerciseOfPreFundedWarrants
      contextRef="P01_01_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">204000</agle:IssuanceOfCommonStockInConnectionWithExerciseOfPreFundedWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="P01_01_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">6000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">222000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">222000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">7111000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">7111000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="P01_01_2022To12_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-35000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-35000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="P01_01_2022To12_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">7000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">7000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-83815000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-83815000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">2614000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">6000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">475971000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-48000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-425624000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">50305000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-83815000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-65801000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-80893000</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">7111000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">8038000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">6256000</us-gaap:ShareBasedCompensation>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">1567000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1576000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">996000</us-gaap:DepreciationDepletionAndAmortization>
    <agle:PaymentForDiscountPremiumOnInvestmentsNet
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-428000</agle:PaymentForDiscountPremiumOnInvestmentsNet>
    <agle:PaymentForDiscountPremiumOnInvestmentsNet
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">344000</agle:PaymentForDiscountPremiumOnInvestmentsNet>
    <agle:PaymentForDiscountPremiumOnInvestmentsNet
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">286000</agle:PaymentForDiscountPremiumOnInvestmentsNet>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">327000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-548000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-73000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <agle:NonCashOperatingLeaseExpense
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">397000</agle:NonCashOperatingLeaseExpense>
    <agle:NonCashOperatingLeaseExpense
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">425000</agle:NonCashOperatingLeaseExpense>
    <agle:NonCashOperatingLeaseExpense
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">628000</agle:NonCashOperatingLeaseExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">2000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-9000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">9000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-440000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">815000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-2641000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1065000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-544000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">1144000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1216000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1101000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-880000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">3576000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <agle:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-435000</agle:IncreaseDecreaseInOperatingLeaseLiabilities>
    <agle:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-404000</agle:IncreaseDecreaseInOperatingLeaseLiabilities>
    <agle:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">251000</agle:IncreaseDecreaseInOperatingLeaseLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-843000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-373000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-1146000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-80144000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-53716000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-75775000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">38000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">573000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">4280000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">39500000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">133079000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">129000000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">96546000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">111033000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">125676000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">57008000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-22619000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-7604000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <agle:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfOfferingCosts
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">42874000</agle:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfOfferingCosts>
    <agle:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfOfferingCosts
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</agle:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfOfferingCosts>
    <agle:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfOfferingCosts
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">153716000</agle:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfOfferingCosts>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">222000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1903000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">816000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">418000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">510000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">20000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">42678000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1393000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">154512000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-106000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-15000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">51000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">19436000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-74957000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">71184000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">16980000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">91937000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">20753000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">36416000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">16980000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">91937000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <agle:LeasedAssetsObtainedInExchangeForLeaseObligations
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">21000</agle:LeasedAssetsObtainedInExchangeForLeaseObligations>
    <agle:LeasedAssetsObtainedInExchangeForLeaseObligations
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">872000</agle:LeasedAssetsObtainedInExchangeForLeaseObligations>
    <agle:LeasedAssetsObtainedInExchangeForLeaseObligations
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">172000</agle:LeasedAssetsObtainedInExchangeForLeaseObligations>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">224000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1. The Company and Basis of Presentation &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Aeglea BioTherapeutics, Inc. (&#x201c;Aeglea&#x201d; or the &#x201c;Company&#x201d;) is a clinical-stage biotechnology company developing human enzyme therapeutics to benefit people with rare metabolic diseases. The Company was formed as a Limited Liability Company (LLC) in Delaware on December&#160;16, 2013 under the name Aeglea BioTherapeutics Holdings, LLC and was converted from a Delaware LLC to a Delaware corporation on March&#160;10, 2015. The Company operates in one segment and has its principal offices in Austin, Texas. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liquidity &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;As of December&#160;31, 2022, the Company had working capital of $47.6&#160;million, an accumulated deficit of $425.6&#160;million, and cash, cash equivalents, marketable securities, and restricted cash of $57.3&#160;million. The Company has not generated any product revenues and has not achieved profitable operations. There is no assurance that profitable operations will ever be achieved, and, if achieved, could be sustained on a continuing basis. In addition, development activities, clinical and nonclinical testing, and commercialization of the Company&#x2019;s products will require significant additional financing. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company is subject to a number of risks similar to other life science companies, including, but not limited to, risks related to the successful discovery, development, and commercialization of product candidates, raising additional capital, development of competing drugs and therapies, protection of proprietary technology and market acceptance of the Company&#x2019;s products. As a result of these and other factors and the related uncertainties, there can be no assurance of the Company&#x2019;s future success. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In accordance with ASC &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;205-40,&lt;/div&gt; Going Concern, the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company&#x2019;s ability to continue as a going concern within one year after the date the financial statements included in this Annual Report on Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10-K&lt;/div&gt; are issued. Based upon the Company&#x2019;s current operating plans, the Company believes that it has sufficient resources to fund operations into the fourth quarter of 2023 with its existing cash, cash equivalents, and marketable securities. Accordingly, based on its recurring losses from operations incurred since inception, the expectation of continued operating losses, and the need to raise additional capital to finance its future operations, the Company determined that there is substantial doubt about the Company&#x2019;s ability to continue as a going concern within twelve months of the issuance date of these financial statements. The accompanying consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty and assumes the Company will continue as a going concern through the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business. The Company plans to address this condition through the sale of common stock in public offerings and/or private placements, debt financings, or through other capital sources, including collaborations with other companies or other strategic transactions. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Although the Company has been successful in raising capital in the past, there is no assurance that it will be successful in obtaining such additional financing on terms acceptable to the Company, if at all, nor is it considered probable under the accounting standards. If the Company is unable to obtain sufficient funding on acceptable terms, it could be forced to delay, reduce or eliminate some or all of its research and development programs or commercialization activities, which could materially adversely affect its business prospects or its ability to continue operations. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basis of Presentation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States (&#x201c;U.S. GAAP&#x201d;) as defined by the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) and include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. &lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      unitRef="Unit_SEGMENT">1</us-gaap:NumberOfOperatingSegments>
    <agle:WorkingCapital
      contextRef="PAsOn12_31_2022"
      decimals="-5"
      unitRef="Unit_USD">47600000</agle:WorkingCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn12_31_2022"
      decimals="-5"
      unitRef="Unit_USD">-425600000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <agle:CashCashEquivalentsMarketableSecuritiesAndRestrictedCash
      contextRef="PAsOn12_31_2022"
      decimals="-5"
      unitRef="Unit_USD">57300000</agle:CashCashEquivalentsMarketableSecuritiesAndRestrictedCash>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2. Summary of Significant Accounting Policies &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Use of Estimates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances, the results of which form the basis for making judgements about the carrying value of assets, liabilities, and equity and the amount of revenues and expenses. Estimates are used in accounting for, among other items, accrued research and development costs and revenue recognition. Actual results could differ materially from those estimates. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and Cash Equivalents &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company considers all highly liquid investments with original maturities of three months or less from the date of purchase to be cash equivalents. Cash equivalents consist of money market funds and debt securities and are stated at fair value. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Marketable Securities &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;All investments have been classified as &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; and are carried at estimated fair value as determined based upon quoted market prices or pricing models for similar securities. Management determines the appropriate classification of its investments in debt securities at the time of purchase. The Company may hold securities with stated maturities greater than one year until maturity. All &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; securities are considered available to support current operations and are classified as current assets. The Company presents credit losses as an allowance rather than as a reduction in the amortized cost of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; securities. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;For &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; debt securities in an unrealized loss position, the Company first assesses whether it intends to sell, or it is more likely than not that it will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security&#x2019;s amortized cost basis is written down to fair value and recognized in other income (expense) in the results of operations. For &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; debt securities that do not meet the aforementioned criteria, the Company evaluates whether the decline in fair value has resulted from credit losses or other factors. In making this assessment, management considers the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and adverse conditions specifically related to the security, among other factors. If this assessment indicates that a credit loss exists, an allowance is recorded for the difference between the present value of cash flows expected to be collected and the amortized cost basis of the security. Impairment losses attributable to credit loss factors are charged against the allowance when management believes an &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; security is uncollectible or when either of the criteria regarding intent or requirement to sell is met. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Any unrealized losses from declines in fair value below the amortized cost basis as a result of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-credit&lt;/div&gt; loss factors is recognized as a component of accumulated other comprehensive (loss) income, along with unrealized gains. Realized gains and losses and declines in fair value, if any, on &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; securities are included in other income (expense) in the results of operations. The cost of securities sold is based on the specific-identification method. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Restricted Cash &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Restricted cash consists of money market accounts held by financial institutions as collateral for the Company&#x2019;s obligations under a credit agreement and a facility lease for the Company&#x2019;s corporate headquarters in Austin, Texas. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Concentration of Credit Risk &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash, cash equivalents, marketable securities, and restricted cash. The Company&#x2019;s investment policy limits investments to high credit quality securities issued by the U.S. government, U.S. government-sponsored agencies, highly rated banks, and corporate issuers, subject to certain concentration limits and restrictions on maturities. The Company&#x2019;s cash, cash equivalents, marketable securities, and restricted cash are held by financial institutions that management believes are of high credit quality. Amounts on deposit may at times exceed federally insured limits. The Company has not experienced any losses on its deposits of cash, cash equivalents, and restricted cash and its accounts are monitored by management to mitigate risk. The Company is exposed to credit risk in the event of default by the financial institutions holding its cash, cash equivalents, and restricted cash, and bond issuers. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and Equipment &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Property and equipment are stated at cost, net of accumulated depreciation and amortization. Depreciation and amortization are computed using the straight-line method over the estimated useful lives of the assets. Repairs and maintenance that do not extend the life or improve an asset are expensed as incurred. Upon retirement or sale, the cost of disposed assets and their related accumulated depreciation and amortization are removed from the balance sheet. Any gain or loss is credited or charged to operations. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The useful lives of the property and equipment are as follows: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:39%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td style="width:59%"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Laboratory equipment&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;5 years&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Furniture and office equipment&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;5 years&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Computer equipment&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;3 years&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Software&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;3 years&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Leasehold improvements&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;Shorter of remaining lease term or estimated useful life&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Impairment of Long-Lived Assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Long-lived assets are reviewed for indications of possible impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amounts to the future undiscounted cash flows attributable to these assets. An impairment loss is recognized to the extent an asset group is not recoverable, and the carrying amount exceeds the fair value. There were no impairments of long-lived assets for the years ended December&#160;31, 2022, 2021, and 2020. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued Research and Development Costs &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company records the costs associated with research nonclinical studies, clinical trials, and manufacturing development as incurred. These costs are a significant component of the Company&#x2019;s research and development expenses, with a substantial portion of the Company&#x2019;s &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;on-going&lt;/div&gt; research and development activities conducted by third-party service providers, including contract research and manufacturing organizations. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company accrues for expenses resulting from obligations under agreements with contract research organizations (&#x201c;CROs&#x201d;), contract manufacturing organizations (&#x201c;CMOs&#x201d;), and other outside service providers for which payment flows do not match the periods over which materials or services are provided to the Company. Accruals are recorded based on estimates of services received and efforts expended pursuant to agreements established with CROs, CMOs, and other outside service providers. These estimates are typically based on contracted amounts applied to the proportion of work performed and determined through analysis with internal personnel and external service providers as to the progress or stage of completion of the services. The Company &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;makes significant judgments and estimates in determining the accrual balance in each reporting period. In the event advance payments are made to a CRO, CMO, or outside service provider, the payments will be recorded as a prepaid asset which will be amortized as the contracted services are performed. As actual costs become known, the Company adjusts its accruals. Inputs, such as the services performed, the number of patients enrolled, or the study duration, may vary from the Company&#x2019;s estimates, resulting in adjustments to research and development expense in future periods. Changes in these estimates that result in material changes to the Company&#x2019;s accruals could materially affect the Company&#x2019;s results of operations. Historically, the Company has not &lt;div style="display:inline;"&gt;experienced &lt;/div&gt;any material deviations between accrued and actual research and development expenses. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Leases &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company determines if an arrangement is a lease at inception. &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Right-of-use&lt;/div&gt;&lt;/div&gt; (&#x201c;ROU&#x201d;) assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. The classification of the Company&#x2019;s leases as operating or finance leases along with the initial measurement and recognition of the associated ROU assets and lease liabilities is performed at the lease commencement date. The measurement of lease liabilities is based on the present value of future lease payments over the lease term. As the Company&#x2019;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of future lease payments. To determine the incremental borrowing rate, the Company uses the lease-term appropriate current treasury bond rates adjusted for collateral and inflation risks combined with quoted bank financing rates. The ROU asset is based on the measurement of the lease liability and also includes any lease payments made prior to or on lease commencement and excludes lease incentives and initial direct costs incurred, as applicable. The lease terms may include options to extend or terminate the lease when it is reasonably certain the Company will exercise any such options. Rent expense for the Company&#x2019;s operating leases is recognized on a straight-line basis over the lease term. Amortization expense for the ROU asset associated with its finance leases is recognized on a straight-line basis over the term of the lease and interest expense associated with its finance leases is recognized on the balance of the lease liability using the effective interest method based on the estimated incremental borrowing rate. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company has lease agreements with lease and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-lease&lt;/div&gt; components. As allowed under Topic 842, the Company has elected to not separate lease and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-lease&lt;/div&gt; components for any leases involving real estate and office equipment classes of assets and, as a result, accounts for the lease and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-lease&lt;/div&gt; components as a single lease component. The Company has also elected to not apply the recognition requirement of Topic 842 to leases with a term of 12 months or less for all classes of assets. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair Value of Financial Instruments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company uses fair value measurements to record fair value adjustments to certain financial and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-financial&lt;/div&gt; assets and liabilities and to determine fair value disclosures. The accounting standards define fair value, establish a framework for measuring fair value, and require disclosures about fair value measurements. Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required to be recorded at fair value, the principal or most advantageous market in which the Company would transact are considered along with assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The accounting standard for fair value establishes a fair value hierarchy based on three levels of inputs, the first two of which are considered observable and the last unobservable, that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. A financial instrument&#x2019;s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The three levels of inputs that may be used to measure fair value are as follows: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:9%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td style="width:90%"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Level&#160;1:&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;Observable inputs, such as quoted prices in active markets for identical assets or liabilities.&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&lt;/td&gt;
&lt;td colspan="2" style="height:6pt"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Level&#160;2:&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;Observable inputs other than Level&#160;1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&lt;/td&gt;
&lt;td colspan="2" style="height:6pt"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Level&#160;3:&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;Valuations based on unobservable inputs to the valuation methodology and including data about assumptions that market participants would use in pricing the asset or liability based on the best information available under the circumstances.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Financial instruments carried at fair value include cash, cash equivalents, marketable securities, and restricted cash. The carrying amounts of accounts payable and accrued liabilities approximate fair value due to their relatively short maturities. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenue Recognition &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Under ASC Topic 606, &#x201c;Revenue from Contracts with Customers&#x201d; (&#x201c;Topic 606&#x201d;), an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of Topic 606, the entity performs the following five steps: (i)&#160;identify the contract(s) with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price, including variable consideration, if any; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the entity satisfies a performance obligation. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company assesses its license arrangements within the scope of Topic 606 in accordance with this framework as follows: &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;License revenue &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company assesses whether the goods or services promised within each contract are distinct to identify those that are performance obligations. This assessment involves subjective determinations and requires management to make judgments about the individual promised goods or services and whether such are separable from the other aspects of the contractual relationship. In assessing whether a promised good or service is distinct, and therefore a performance obligation, the Company considers factors such as the research, stage of development of the licensed product, manufacturing and commercialization capabilities of the customer and the availability of the associated expertise in the general marketplace. The Company also considers the intended benefit of the contract in assessing whether a promised good or service is separately identifiable from other promises in the contract. If a promised good or service is not distinct, the Company is required to combine that good or service with other promised goods or services until it identifies a bundle of goods or services that is distinct. Arrangements that include rights to additional goods or services that are exercisable at a customer&#x2019;s discretion are generally considered options. The Company assesses if these options provide a material right to the customer and if so, they are considered performance obligations. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The transaction price is determined and allocated to the identified performance obligations in proportion to their stand-alone selling prices (&#x201c;SSP&#x201d;) on a relative SSP basis. SSP is based on observable prices of the performance obligations or, when such prices are not observable, are estimated. The estimation of SSP may include factors such as forecasted revenues or costs, development timelines, discount rates, probabilities of technical and regulatory success, and considerations such as market conditions and entity-specific factors. In certain circumstances, the Company may apply the residual method to determine the SSP of a good or service if the SSP is considered highly variable or uncertain. The Company validates the SSP for performance obligations &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;by evaluating whether changes in the key assumptions used to determine the SSP will have a significant effect on the allocation of arrangement consideration between multiple performance obligations. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;If the consideration promised in a contract includes a variable amount, the Company estimates the amount of consideration to which it will be entitled in exchange for transferring the promised goods or services to a customer. The Company determines the amount of variable consideration by using the expected value method or the most likely amount method. The Company includes the amount of estimated variable consideration in the transaction price to the extent that it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-evaluates&lt;/div&gt; the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;catch-up&lt;/div&gt; basis in the period of adjustment. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;If an arrangement includes development, regulatory or commercial milestone payments, the Company evaluates whether the milestones are considered likely of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant cumulative revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company&#x2019;s control or the licensee&#x2019;s control, such as regulatory approvals, are generally not considered likely of being achieved until those approvals are received. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In determining the transaction price, the Company adjusts consideration for the effects of the time value of money if the timing of payments provides the Company with a significant benefit of financing. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the licensee and the transfer of the promised goods or services to the licensees will be one year or less. For arrangements with licenses of intellectual property that include sales-based royalties, including milestone payments based on the level of sales, and if the license is deemed to be the predominant item to which the royalties relate, the Company recognizes royalty revenue and sales-based milestones at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which the royalty has been allocated has been satisfied. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied at a point in time or over time, and if over time, recognition is based on the use of an output or input method. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company&#x2019;s contracts may be modified for changes in the customer&#x2019;s requirements. If contract modifications are for additional goods and services that are distinct from the existing contract, the modification will be accounted for as either a separate contract or a termination of the existing contract, depending on whether the additional goods or services reflects the SSP. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;If the additional goods or services in a contract modification are not distinct from the existing contract, they are accounted for as if they were part of the original contract. The effect of the contract modification on the transaction price and the measure of progress for the performance obligation to which it relates is recognized as an adjustment to revenue on a cumulative &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;catch-up&lt;/div&gt; basis. The cumulative &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;catch-up&lt;/div&gt; adjustment is calculated using an updated measure of progress applied to the sum of (1)&#160;the remaining consideration allocated to the partially satisfied performance obligation and (2)&#160;the revenue already recognized on that performance obligation. The revenue recognized for fully satisfied goods or services and distinct from the remaining performance obligations is not altered by the modification. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Collaborative arrangements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company analyzes its license arrangements to assess whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;and rewards dependent on the commercial success of such activities and therefore within the scope of ASC Topic 808, Collaborative Arrangements (&#x201c;Topic 808&#x201d;). This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. For arrangements within the scope of Topic 808 that contain multiple elements, the Company first determines which elements of the collaboration are deemed to be within the scope of Topic 808 and which elements of the collaboration are more reflective of a vendor-customer relationship and therefore within the scope of Topic 606. For elements of collaboration arrangements that are accounted for pursuant to Topic 808, an appropriate recognition method is determined and applied consistently, either by analogy to authoritative accounting literature or by applying a reasonable and rational policy election. For those elements of the arrangement that are accounted for pursuant to Topic 606, the Company applies the five-step model described &lt;div style="display:inline;"&gt;above&lt;/div&gt;. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and Development Costs &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Research and development costs are expensed as incurred. Research and development costs include, but are not limited to, salaries, benefits, travel, stock-based compensation, consulting costs, contract research service costs, laboratory supplies and facilities, contract manufacturing costs, and costs paid to other third parties that conduct research and development activities on the Company&#x2019;s behalf. Amounts incurred in connection with license agreements are also included in research and development expense. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Advance payments for goods or services to be rendered in the future for use in research and development activities are recorded as a prepaid asset and expensed as the related goods are delivered or the services are performed. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock-Based Compensation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company recognizes the cost of stock-based awards granted to employees and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employees&lt;/div&gt; based on the estimated grant-date fair values of the awards. The fair values of stock options are estimated on the date of grant using the Black-Scholes option pricing model. The fair values of restricted stock units (&#x201c;RSUs&#x201d;) are based on the fair value of the Company&#x2019;s common stock on the date of the grant. The value of the award is recognized as compensation expense on a straight-line basis over the requisite service period. Forfeitures are recognized when they occur, which may result in the reversal of compensation costs in subsequent periods as the forfeitures arise. Compensation expense for employee and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employee&lt;/div&gt; share-based payment awards with performance conditions is recognized when the performance condition is deemed probable. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income Taxes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company and its ten wholly owned subsidiary corporations use the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial statements and the tax bases of assets and liabilities. Additionally, any changes in income tax laws are immediately recognized in the year of enactment. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;A valuation allowance is established against the deferred tax assets to reduce their carrying value to an amount that is more likely than not to be realized. The deferred tax assets and liabilities are classified as noncurrent along with the related valuation allowance. Due to a lack of earnings history, the net deferred tax assets have been fully offset by a valuation allowance. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company recognizes benefits of uncertain tax positions if it is more likely than not that such positions will be sustained upon examination based solely on the technical merits, as the largest amount of benefits that is more likely than not to be realized upon the ultimate settlement. The Company&#x2019;s policy is to recognize interest and penalties related to the unrecognized tax benefits as a component of income tax expense, if applicable. As of December&#160;31, 2022 and 2021, the Company had no unrecognized tax benefits and there were no interest or penalties incurred by the Company in the years ended December&#160;31, 2022, 2021, or 2020. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Comprehensive Loss &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Comprehensive loss is the change in stockholders&#x2019; equity from transactions and other events and circumstances other than those resulting from investments by stockholders and distributions to stockholders. The Company&#x2019;s other comprehensive income (loss) is currently comprised of changes in unrealized losses and gains on &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; securities and foreign currency translation adjustments reflecting the cumulative effect of changes in exchange rates between the foreign entity&#x2019;s functional currency and the reporting currency. &lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Use of Estimates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances, the results of which form the basis for making judgements about the carrying value of assets, liabilities, and equity and the amount of revenues and expenses. Estimates are used in accounting for, among other items, accrued research and development costs and revenue recognition. Actual results could differ materially from those estimates. &lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and Cash Equivalents &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company considers all highly liquid investments with original maturities of three months or less from the date of purchase to be cash equivalents. Cash equivalents consist of money market funds and debt securities and are stated at fair value. &lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:MarketableSecuritiesPolicy contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Marketable Securities &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;All investments have been classified as &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; and are carried at estimated fair value as determined based upon quoted market prices or pricing models for similar securities. Management determines the appropriate classification of its investments in debt securities at the time of purchase. The Company may hold securities with stated maturities greater than one year until maturity. All &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; securities are considered available to support current operations and are classified as current assets. The Company presents credit losses as an allowance rather than as a reduction in the amortized cost of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; securities. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;For &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; debt securities in an unrealized loss position, the Company first assesses whether it intends to sell, or it is more likely than not that it will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security&#x2019;s amortized cost basis is written down to fair value and recognized in other income (expense) in the results of operations. For &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; debt securities that do not meet the aforementioned criteria, the Company evaluates whether the decline in fair value has resulted from credit losses or other factors. In making this assessment, management considers the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and adverse conditions specifically related to the security, among other factors. If this assessment indicates that a credit loss exists, an allowance is recorded for the difference between the present value of cash flows expected to be collected and the amortized cost basis of the security. Impairment losses attributable to credit loss factors are charged against the allowance when management believes an &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; security is uncollectible or when either of the criteria regarding intent or requirement to sell is met. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Any unrealized losses from declines in fair value below the amortized cost basis as a result of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-credit&lt;/div&gt; loss factors is recognized as a component of accumulated other comprehensive (loss) income, along with unrealized gains. Realized gains and losses and declines in fair value, if any, on &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; securities are included in other income (expense) in the results of operations. The cost of securities sold is based on the specific-identification method. &lt;/div&gt;</us-gaap:MarketableSecuritiesPolicy>
    <agle:MarketableSecuritiesMaturityPeriod contextRef="P01_01_2022To12_31_2022_MaximumMembersrtRangeAxis">P1Y</agle:MarketableSecuritiesMaturityPeriod>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Restricted Cash &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Restricted cash consists of money market accounts held by financial institutions as collateral for the Company&#x2019;s obligations under a credit agreement and a facility lease for the Company&#x2019;s corporate headquarters in Austin, Texas. &lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Concentration of Credit Risk &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash, cash equivalents, marketable securities, and restricted cash. The Company&#x2019;s investment policy limits investments to high credit quality securities issued by the U.S. government, U.S. government-sponsored agencies, highly rated banks, and corporate issuers, subject to certain concentration limits and restrictions on maturities. The Company&#x2019;s cash, cash equivalents, marketable securities, and restricted cash are held by financial institutions that management believes are of high credit quality. Amounts on deposit may at times exceed federally insured limits. The Company has not experienced any losses on its deposits of cash, cash equivalents, and restricted cash and its accounts are monitored by management to mitigate risk. The Company is exposed to credit risk in the event of default by the financial institutions holding its cash, cash equivalents, and restricted cash, and bond issuers. &lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and Equipment &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Property and equipment are stated at cost, net of accumulated depreciation and amortization. Depreciation and amortization are computed using the straight-line method over the estimated useful lives of the assets. Repairs and maintenance that do not extend the life or improve an asset are expensed as incurred. Upon retirement or sale, the cost of disposed assets and their related accumulated depreciation and amortization are removed from the balance sheet. Any gain or loss is credited or charged to operations. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The useful lives of the property and equipment are as follows: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:39%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td style="width:59%"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Laboratory equipment&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;5 years&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Furniture and office equipment&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;5 years&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Computer equipment&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;3 years&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Software&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;3 years&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Leasehold improvements&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;Shorter of remaining lease term or estimated useful life&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <agle:ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The useful lives of the property and equipment are as follows: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:39%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td style="width:59%"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Laboratory equipment&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;5 years&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Furniture and office equipment&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;5 years&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Computer equipment&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;3 years&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Software&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;3 years&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Leasehold improvements&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;Shorter of remaining lease term or estimated useful life&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</agle:ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="PAsOn12_31_2022_LaboratoryEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="PAsOn12_31_2022_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="PAsOn12_31_2022_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="PAsOn12_31_2022_PurchasedSoftwareMemberusgaapPropertyPlantAndEquipmentByTypeAxis">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentBasisOfValuation contextRef="P01_01_2022To12_31_2022_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">Shorter of remaining lease term or estimated useful life</us-gaap:PropertyPlantAndEquipmentBasisOfValuation>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Impairment of Long-Lived Assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Long-lived assets are reviewed for indications of possible impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amounts to the future undiscounted cash flows attributable to these assets. An impairment loss is recognized to the extent an asset group is not recoverable, and the carrying amount exceeds the fair value. There were no impairments of long-lived assets for the years ended December&#160;31, 2022, 2021, and 2020. &lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <agle:AccruedResearchAndDevelopmentExpensePolicyTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued Research and Development Costs &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company records the costs associated with research nonclinical studies, clinical trials, and manufacturing development as incurred. These costs are a significant component of the Company&#x2019;s research and development expenses, with a substantial portion of the Company&#x2019;s &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;on-going&lt;/div&gt; research and development activities conducted by third-party service providers, including contract research and manufacturing organizations. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company accrues for expenses resulting from obligations under agreements with contract research organizations (&#x201c;CROs&#x201d;), contract manufacturing organizations (&#x201c;CMOs&#x201d;), and other outside service providers for which payment flows do not match the periods over which materials or services are provided to the Company. Accruals are recorded based on estimates of services received and efforts expended pursuant to agreements established with CROs, CMOs, and other outside service providers. These estimates are typically based on contracted amounts applied to the proportion of work performed and determined through analysis with internal personnel and external service providers as to the progress or stage of completion of the services. The Company &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;makes significant judgments and estimates in determining the accrual balance in each reporting period. In the event advance payments are made to a CRO, CMO, or outside service provider, the payments will be recorded as a prepaid asset which will be amortized as the contracted services are performed. As actual costs become known, the Company adjusts its accruals. Inputs, such as the services performed, the number of patients enrolled, or the study duration, may vary from the Company&#x2019;s estimates, resulting in adjustments to research and development expense in future periods. Changes in these estimates that result in material changes to the Company&#x2019;s accruals could materially affect the Company&#x2019;s results of operations. Historically, the Company has not &lt;div style="display:inline;"&gt;experienced &lt;/div&gt;any material deviations between accrued and actual research and development expenses. &lt;/div&gt;</agle:AccruedResearchAndDevelopmentExpensePolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Leases &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company determines if an arrangement is a lease at inception. &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Right-of-use&lt;/div&gt;&lt;/div&gt; (&#x201c;ROU&#x201d;) assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. The classification of the Company&#x2019;s leases as operating or finance leases along with the initial measurement and recognition of the associated ROU assets and lease liabilities is performed at the lease commencement date. The measurement of lease liabilities is based on the present value of future lease payments over the lease term. As the Company&#x2019;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of future lease payments. To determine the incremental borrowing rate, the Company uses the lease-term appropriate current treasury bond rates adjusted for collateral and inflation risks combined with quoted bank financing rates. The ROU asset is based on the measurement of the lease liability and also includes any lease payments made prior to or on lease commencement and excludes lease incentives and initial direct costs incurred, as applicable. The lease terms may include options to extend or terminate the lease when it is reasonably certain the Company will exercise any such options. Rent expense for the Company&#x2019;s operating leases is recognized on a straight-line basis over the lease term. Amortization expense for the ROU asset associated with its finance leases is recognized on a straight-line basis over the term of the lease and interest expense associated with its finance leases is recognized on the balance of the lease liability using the effective interest method based on the estimated incremental borrowing rate. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company has lease agreements with lease and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-lease&lt;/div&gt; components. As allowed under Topic 842, the Company has elected to not separate lease and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-lease&lt;/div&gt; components for any leases involving real estate and office equipment classes of assets and, as a result, accounts for the lease and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-lease&lt;/div&gt; components as a single lease component. The Company has also elected to not apply the recognition requirement of Topic 842 to leases with a term of 12 months or less for all classes of assets. &lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair Value of Financial Instruments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company uses fair value measurements to record fair value adjustments to certain financial and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-financial&lt;/div&gt; assets and liabilities and to determine fair value disclosures. The accounting standards define fair value, establish a framework for measuring fair value, and require disclosures about fair value measurements. Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required to be recorded at fair value, the principal or most advantageous market in which the Company would transact are considered along with assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The accounting standard for fair value establishes a fair value hierarchy based on three levels of inputs, the first two of which are considered observable and the last unobservable, that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. A financial instrument&#x2019;s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The three levels of inputs that may be used to measure fair value are as follows: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:9%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td style="width:90%"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Level&#160;1:&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;Observable inputs, such as quoted prices in active markets for identical assets or liabilities.&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&lt;/td&gt;
&lt;td colspan="2" style="height:6pt"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Level&#160;2:&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;Observable inputs other than Level&#160;1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&lt;/td&gt;
&lt;td colspan="2" style="height:6pt"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Level&#160;3:&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;Valuations based on unobservable inputs to the valuation methodology and including data about assumptions that market participants would use in pricing the asset or liability based on the best information available under the circumstances.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Financial instruments carried at fair value include cash, cash equivalents, marketable securities, and restricted cash. The carrying amounts of accounts payable and accrued liabilities approximate fair value due to their relatively short maturities. &lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenue Recognition &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Under ASC Topic 606, &#x201c;Revenue from Contracts with Customers&#x201d; (&#x201c;Topic 606&#x201d;), an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of Topic 606, the entity performs the following five steps: (i)&#160;identify the contract(s) with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price, including variable consideration, if any; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the entity satisfies a performance obligation. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company assesses its license arrangements within the scope of Topic 606 in accordance with this framework as follows: &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;License revenue &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company assesses whether the goods or services promised within each contract are distinct to identify those that are performance obligations. This assessment involves subjective determinations and requires management to make judgments about the individual promised goods or services and whether such are separable from the other aspects of the contractual relationship. In assessing whether a promised good or service is distinct, and therefore a performance obligation, the Company considers factors such as the research, stage of development of the licensed product, manufacturing and commercialization capabilities of the customer and the availability of the associated expertise in the general marketplace. The Company also considers the intended benefit of the contract in assessing whether a promised good or service is separately identifiable from other promises in the contract. If a promised good or service is not distinct, the Company is required to combine that good or service with other promised goods or services until it identifies a bundle of goods or services that is distinct. Arrangements that include rights to additional goods or services that are exercisable at a customer&#x2019;s discretion are generally considered options. The Company assesses if these options provide a material right to the customer and if so, they are considered performance obligations. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The transaction price is determined and allocated to the identified performance obligations in proportion to their stand-alone selling prices (&#x201c;SSP&#x201d;) on a relative SSP basis. SSP is based on observable prices of the performance obligations or, when such prices are not observable, are estimated. The estimation of SSP may include factors such as forecasted revenues or costs, development timelines, discount rates, probabilities of technical and regulatory success, and considerations such as market conditions and entity-specific factors. In certain circumstances, the Company may apply the residual method to determine the SSP of a good or service if the SSP is considered highly variable or uncertain. The Company validates the SSP for performance obligations &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;by evaluating whether changes in the key assumptions used to determine the SSP will have a significant effect on the allocation of arrangement consideration between multiple performance obligations. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;If the consideration promised in a contract includes a variable amount, the Company estimates the amount of consideration to which it will be entitled in exchange for transferring the promised goods or services to a customer. The Company determines the amount of variable consideration by using the expected value method or the most likely amount method. The Company includes the amount of estimated variable consideration in the transaction price to the extent that it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-evaluates&lt;/div&gt; the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;catch-up&lt;/div&gt; basis in the period of adjustment. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;If an arrangement includes development, regulatory or commercial milestone payments, the Company evaluates whether the milestones are considered likely of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant cumulative revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company&#x2019;s control or the licensee&#x2019;s control, such as regulatory approvals, are generally not considered likely of being achieved until those approvals are received. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In determining the transaction price, the Company adjusts consideration for the effects of the time value of money if the timing of payments provides the Company with a significant benefit of financing. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the licensee and the transfer of the promised goods or services to the licensees will be one year or less. For arrangements with licenses of intellectual property that include sales-based royalties, including milestone payments based on the level of sales, and if the license is deemed to be the predominant item to which the royalties relate, the Company recognizes royalty revenue and sales-based milestones at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which the royalty has been allocated has been satisfied. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied at a point in time or over time, and if over time, recognition is based on the use of an output or input method. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company&#x2019;s contracts may be modified for changes in the customer&#x2019;s requirements. If contract modifications are for additional goods and services that are distinct from the existing contract, the modification will be accounted for as either a separate contract or a termination of the existing contract, depending on whether the additional goods or services reflects the SSP. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;If the additional goods or services in a contract modification are not distinct from the existing contract, they are accounted for as if they were part of the original contract. The effect of the contract modification on the transaction price and the measure of progress for the performance obligation to which it relates is recognized as an adjustment to revenue on a cumulative &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;catch-up&lt;/div&gt; basis. The cumulative &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;catch-up&lt;/div&gt; adjustment is calculated using an updated measure of progress applied to the sum of (1)&#160;the remaining consideration allocated to the partially satisfied performance obligation and (2)&#160;the revenue already recognized on that performance obligation. The revenue recognized for fully satisfied goods or services and distinct from the remaining performance obligations is not altered by the modification. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Collaborative arrangements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company analyzes its license arrangements to assess whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;and rewards dependent on the commercial success of such activities and therefore within the scope of ASC Topic 808, Collaborative Arrangements (&#x201c;Topic 808&#x201d;). This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. For arrangements within the scope of Topic 808 that contain multiple elements, the Company first determines which elements of the collaboration are deemed to be within the scope of Topic 808 and which elements of the collaboration are more reflective of a vendor-customer relationship and therefore within the scope of Topic 606. For elements of collaboration arrangements that are accounted for pursuant to Topic 808, an appropriate recognition method is determined and applied consistently, either by analogy to authoritative accounting literature or by applying a reasonable and rational policy election. For those elements of the arrangement that are accounted for pursuant to Topic 606, the Company applies the five-step model described &lt;div style="display:inline;"&gt;above&lt;/div&gt;. &lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and Development Costs &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Research and development costs are expensed as incurred. Research and development costs include, but are not limited to, salaries, benefits, travel, stock-based compensation, consulting costs, contract research service costs, laboratory supplies and facilities, contract manufacturing costs, and costs paid to other third parties that conduct research and development activities on the Company&#x2019;s behalf. Amounts incurred in connection with license agreements are also included in research and development expense. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Advance payments for goods or services to be rendered in the future for use in research and development activities are recorded as a prepaid asset and expensed as the related goods are delivered or the services are performed. &lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock-Based Compensation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company recognizes the cost of stock-based awards granted to employees and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employees&lt;/div&gt; based on the estimated grant-date fair values of the awards. The fair values of stock options are estimated on the date of grant using the Black-Scholes option pricing model. The fair values of restricted stock units (&#x201c;RSUs&#x201d;) are based on the fair value of the Company&#x2019;s common stock on the date of the grant. The value of the award is recognized as compensation expense on a straight-line basis over the requisite service period. Forfeitures are recognized when they occur, which may result in the reversal of compensation costs in subsequent periods as the forfeitures arise. Compensation expense for employee and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employee&lt;/div&gt; share-based payment awards with performance conditions is recognized when the performance condition is deemed probable. &lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income Taxes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company and its ten wholly owned subsidiary corporations use the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial statements and the tax bases of assets and liabilities. Additionally, any changes in income tax laws are immediately recognized in the year of enactment. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;A valuation allowance is established against the deferred tax assets to reduce their carrying value to an amount that is more likely than not to be realized. The deferred tax assets and liabilities are classified as noncurrent along with the related valuation allowance. Due to a lack of earnings history, the net deferred tax assets have been fully offset by a valuation allowance. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company recognizes benefits of uncertain tax positions if it is more likely than not that such positions will be sustained upon examination based solely on the technical merits, as the largest amount of benefits that is more likely than not to be realized upon the ultimate settlement. The Company&#x2019;s policy is to recognize interest and penalties related to the unrecognized tax benefits as a component of income tax expense, if applicable. As of December&#160;31, 2022 and 2021, the Company had no unrecognized tax benefits and there were no interest or penalties incurred by the Company in the years ended December&#160;31, 2022, 2021, or 2020. &lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <agle:NumberOfSubsidiaryCorporationsOwned
      contextRef="PAsOn12_31_2022"
      decimals="0"
      unitRef="Unit_SUBSIDARY">10</agle:NumberOfSubsidiaryCorporationsOwned>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="PAsOn12_31_2022"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="PAsOn12_31_2021"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Comprehensive Loss &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Comprehensive loss is the change in stockholders&#x2019; equity from transactions and other events and circumstances other than those resulting from investments by stockholders and distributions to stockholders. The Company&#x2019;s other comprehensive income (loss) is currently comprised of changes in unrealized losses and gains on &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; securities and foreign currency translation adjustments reflecting the cumulative effect of changes in exchange rates between the foreign entity&#x2019;s functional currency and the reporting currency. &lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3. Fair Value Measurements &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company measures and reports certain financial instruments as assets and liabilities at fair value on a recurring basis. The following tables sets forth the fair value of the Company&#x2019;s financial assets and liabilities at fair value on a recurring basis based on the three-tier fair value hierarchy (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:63%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Financial Assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Money market funds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15,250&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15,250&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Commercial paper&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;23,641&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;23,641&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;U.S. government securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,230&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,230&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Corporate bonds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,732&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,732&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total financial assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15,250&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;31,603&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;46,853&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:64%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Financial Assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Money market funds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8,888&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8,888&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Commercial paper&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;65,412&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;65,412&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Corporate bonds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;12,574&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;12,574&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total financial assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8,888&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;77,986&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;86,874&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company measures the fair value of money market funds on quoted prices in active markets for identical asset or liabilities. The Level&#160;2 assets include U.S. government agency securities, commercial paper and corporate bonds, and are valued based on quoted prices for similar assets in active markets and inputs other than quoted prices that are derived from observable market data. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company evaluates transfers between levels at the end of each reporting period. There were no transfers between Level&#160;1 and Level&#160;2 during the periods presented. &lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="P01_01_2022To12_31_2022">The following tables sets forth the fair value of the Company&#x2019;s financial assets and liabilities at fair value on a recurring basis based on the three-tier fair value hierarchy (in thousands): &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:63%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Financial Assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Money market funds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15,250&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15,250&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Commercial paper&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;23,641&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;23,641&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;U.S. government securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,230&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,230&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Corporate bonds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,732&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,732&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total financial assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15,250&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;31,603&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;46,853&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:64%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Financial Assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Money market funds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8,888&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8,888&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Commercial paper&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;65,412&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;65,412&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Corporate bonds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;12,574&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;12,574&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total financial assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8,888&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;77,986&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;86,874&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis"
      decimals="-3"
      unitRef="Unit_USD">15250000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis"
      decimals="-3"
      unitRef="Unit_USD">15250000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">23641000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapFairValueByAssetClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">23641000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapCashAndCashEquivalentsAxis"
      decimals="-3"
      unitRef="Unit_USD">4230000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapCashAndCashEquivalentsAxis"
      decimals="-3"
      unitRef="Unit_USD">4230000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2022_CorporateBondSecuritiesMemberusgaapInvestmentTypeAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">3732000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2022_CorporateBondSecuritiesMemberusgaapInvestmentTypeAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">3732000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">15250000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">31603000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">46853000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis"
      decimals="-3"
      unitRef="Unit_USD">8888000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis"
      decimals="-3"
      unitRef="Unit_USD">8888000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2021_CommercialPaperMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">65412000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2021_CommercialPaperMemberusgaapFairValueByAssetClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">65412000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2021_CorporateBondSecuritiesMemberusgaapInvestmentTypeAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">12574000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2021_CorporateBondSecuritiesMemberusgaapInvestmentTypeAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">12574000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">8888000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">77986000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">86874000</us-gaap:AssetsFairValueDisclosure>
    <agle:FairValueAssetsLevel1ToLevel2TransfersAmount1
      contextRef="PAsOn12_31_2021"
      decimals="0"
      unitRef="Unit_USD">0</agle:FairValueAssetsLevel1ToLevel2TransfersAmount1>
    <agle:FairValueAssetsLevel1ToLevel2TransfersAmount1
      contextRef="PAsOn12_31_2022"
      decimals="0"
      unitRef="Unit_USD">0</agle:FairValueAssetsLevel1ToLevel2TransfersAmount1>
    <us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4. Cash Equivalents and Marketable Securities &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following tables summarize the estimated fair value of the Company&#x2019;s cash equivalents and marketable securities and the gross unrealized gains and losses (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:57%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amortized&lt;br/&gt; Cost&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Gross&lt;br/&gt; Unrealized&lt;br/&gt; Gains&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Gross&lt;br/&gt; Unrealized&lt;br/&gt; Losses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Estimated&lt;br/&gt; Fair&lt;br/&gt; Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Cash equivalents:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Money market funds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15,250&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15,250&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Commercial paper&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7,021&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7,020&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;U.S. government securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,736&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,735&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total cash equivalents&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;26,007&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;26,005&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:56%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amortized&lt;br/&gt; Cost&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Gross&lt;br/&gt; Unrealized&lt;br/&gt; Gains&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Gross&lt;br/&gt; Unrealized&lt;br/&gt; Losses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Estimated&lt;br/&gt; Fair&#160;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Marketable securities:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Commercial paper&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16,644&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(25&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16,621&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Corporate bonds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,738&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,732&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;U.S. government securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;495&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;495&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total marketable securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;20,877&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(31&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;20,848&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:57%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amortized&lt;br/&gt; Cost&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Gross&lt;br/&gt; Unrealized&lt;br/&gt; Gains&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Gross&lt;br/&gt; Unrealized&lt;br/&gt; Losses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Estimated&lt;br/&gt; Fair&#160;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Cash equivalents:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Money market funds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8,888&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8,888&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total cash equivalents&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8,888&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8,888&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Marketable securities:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Commercial paper&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;65,443&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(34&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;65,412&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Corporate bonds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;12,581&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(7&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;12,574&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total marketable securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;78,024&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(41&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;77,986&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following table summarizes the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; securities in an unrealized loss position for which an allowance for credit losses has not been recorded as of December&#160;31, 2022 and 2021, aggregated by major security type and length of time in a continuous unrealized loss position: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:46%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="22" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Less Than 12 Months&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;12&#160;Months&#160;or&#160;Longer&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&#160;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unrealized&lt;br/&gt; Losses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&#160;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unrealized&lt;br/&gt; Losses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&#160;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unrealized&lt;br/&gt; Losses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Commercial paper&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;17,699&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(27&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;17,699&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(27&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;U.S. government securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,735&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,735&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Corporate bonds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,732&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,732&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total marketable securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;25,166&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(34&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;25,166&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(34&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:46%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="22" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Less Than 12 Months&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;12&#160;Months&#160;or&#160;Longer&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&#160;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unrealized&lt;br/&gt; Losses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&#160;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unrealized&lt;br/&gt; Losses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&#160;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unrealized&lt;br/&gt; Losses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Commercial paper&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;47,425&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(34&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;47,425&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(34&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Corporate bonds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;12,573&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(7&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;12,573&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(7&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total marketable securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;59,998&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(41&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;59,998&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(41&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company evaluated its securities for credit losses and considered the decline in market value to be primarily attributable to current economic and market conditions and not to a credit loss or other factors. Additionally, the Company does not intend to sell the securities in an unrealized loss position and does not expect they will be required to sell the securities before recovery of the unamortized cost basis. As of December&#160;31, 2022 and 2021, an allowance for credit losses had not been recognized. Given the Company&#x2019;s intent and ability to hold such securities until recovery, and the lack of significant change in credit risk of these investments, the Company does not consider these marketable securities to be impaired as of December&#160;31, 2022 and 2021. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;There were no realized gains or losses on marketable securities for the years ended December&#160;31, 2022 and 2021. Interest on marketable securities is included in interest income. Accrued interest receivable on &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; debt securities totaled $0.1&#160;million and $0.1&#160;million as of December&#160;31, 2022 and 2021, respectively, and is excluded from the estimate of credit losses. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following table summarizes the contractual maturities of the Company&#x2019;s marketable securities at estimated fair value (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:74%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Due in one year or less&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;20,848&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;77,986&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Due in 1 &#x2013; 2 years&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total marketable securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;20,848&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;77,986&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company may sell investments at any time for use in current operations even if they have not yet reached maturity. As a result, the &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Company &lt;/div&gt;classifies marketable securities, including securities with maturities beyond twelve months as current assets. &lt;/div&gt;</us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock>
    <us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following tables summarize the estimated fair value of the Company&#x2019;s cash equivalents and marketable securities and the gross unrealized gains and losses (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:57%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amortized&lt;br/&gt; Cost&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Gross&lt;br/&gt; Unrealized&lt;br/&gt; Gains&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Gross&lt;br/&gt; Unrealized&lt;br/&gt; Losses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Estimated&lt;br/&gt; Fair&lt;br/&gt; Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Cash equivalents:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Money market funds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15,250&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15,250&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Commercial paper&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7,021&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7,020&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;U.S. government securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,736&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,735&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total cash equivalents&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;26,007&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;26,005&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:56%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amortized&lt;br/&gt; Cost&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Gross&lt;br/&gt; Unrealized&lt;br/&gt; Gains&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Gross&lt;br/&gt; Unrealized&lt;br/&gt; Losses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Estimated&lt;br/&gt; Fair&#160;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Marketable securities:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Commercial paper&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16,644&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(25&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16,621&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Corporate bonds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,738&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,732&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;U.S. government securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;495&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;495&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total marketable securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;20,877&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(31&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;20,848&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:57%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amortized&lt;br/&gt; Cost&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Gross&lt;br/&gt; Unrealized&lt;br/&gt; Gains&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Gross&lt;br/&gt; Unrealized&lt;br/&gt; Losses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Estimated&lt;br/&gt; Fair&#160;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Cash equivalents:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Money market funds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8,888&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8,888&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total cash equivalents&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8,888&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8,888&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Marketable securities:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Commercial paper&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;65,443&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(34&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;65,412&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Corporate bonds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;12,581&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(7&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;12,574&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total marketable securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;78,024&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(41&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;77,986&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2022_MoneyMarketFundsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">15250000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn12_31_2022_MoneyMarketFundsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">15250000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">7021000</us-gaap:CashEquivalentsAtCarryingValue>
    <agle:CashEquivalentsUnrealizedGains
      contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">1000</agle:CashEquivalentsUnrealizedGains>
    <agle:CashEquivalentsUnrealizedLosses
      contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">2000</agle:CashEquivalentsUnrealizedLosses>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">7020000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2022_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">3736000</us-gaap:CashEquivalentsAtCarryingValue>
    <agle:CashEquivalentsUnrealizedLosses
      contextRef="PAsOn12_31_2022_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">1000</agle:CashEquivalentsUnrealizedLosses>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn12_31_2022_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">3735000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">26007000</us-gaap:CashEquivalentsAtCarryingValue>
    <agle:CashEquivalentsUnrealizedGains
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">1000</agle:CashEquivalentsUnrealizedGains>
    <agle:CashEquivalentsUnrealizedLosses
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">3000</agle:CashEquivalentsUnrealizedLosses>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">26005000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">16644000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">25000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">16621000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="PAsOn12_31_2022_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">3738000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="PAsOn12_31_2022_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">6000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="PAsOn12_31_2022_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">3732000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="PAsOn12_31_2022_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">495000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="PAsOn12_31_2022_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">495000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">20877000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">31000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">20848000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2021_MoneyMarketFundsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">8888000</us-gaap:CashEquivalentsAtCarryingValue>
    <agle:CashEquivalentsUnrealizedLosses
      contextRef="PAsOn12_31_2021_MoneyMarketFundsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">0</agle:CashEquivalentsUnrealizedLosses>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn12_31_2021_MoneyMarketFundsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">8888000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">8888000</us-gaap:CashEquivalentsAtCarryingValue>
    <agle:CashEquivalentsUnrealizedLosses
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</agle:CashEquivalentsUnrealizedLosses>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">8888000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="PAsOn12_31_2021_CommercialPaperMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">65443000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="PAsOn12_31_2021_CommercialPaperMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="PAsOn12_31_2021_CommercialPaperMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">34000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="PAsOn12_31_2021_CommercialPaperMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">65412000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="PAsOn12_31_2021_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">12581000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="PAsOn12_31_2021_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">7000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="PAsOn12_31_2021_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">12574000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">78024000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">41000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">77986000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following table summarizes the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; securities in an unrealized loss position for which an allowance for credit losses has not been recorded as of December&#160;31, 2022 and 2021, aggregated by major security type and length of time in a continuous unrealized loss position: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:46%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="22" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Less Than 12 Months&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;12&#160;Months&#160;or&#160;Longer&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&#160;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unrealized&lt;br/&gt; Losses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&#160;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unrealized&lt;br/&gt; Losses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&#160;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unrealized&lt;br/&gt; Losses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Commercial paper&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;17,699&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(27&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;17,699&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(27&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;U.S. government securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,735&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,735&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Corporate bonds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,732&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,732&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total marketable securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;25,166&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(34&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;25,166&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(34&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:46%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="22" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Less Than 12 Months&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;12&#160;Months&#160;or&#160;Longer&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&#160;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unrealized&lt;br/&gt; Losses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&#160;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unrealized&lt;br/&gt; Losses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&#160;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unrealized&lt;br/&gt; Losses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Commercial paper&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;47,425&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(34&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;47,425&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(34&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Corporate bonds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;12,573&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(7&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;12,573&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(7&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total marketable securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;59,998&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(41&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;59,998&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(41&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="PAsOn12_31_2021_USGovernmentAgenciesDebtSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="PAsOn12_31_2022_USGovernmentAgenciesDebtSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">17699000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">27000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">17699000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">27000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="PAsOn12_31_2022_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">3735000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="PAsOn12_31_2022_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">1000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="PAsOn12_31_2022_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">3735000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="PAsOn12_31_2022_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">1000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="PAsOn12_31_2022_CorporateBondSecuritiesMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">3732000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="PAsOn12_31_2022_CorporateBondSecuritiesMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">6000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="PAsOn12_31_2022_CorporateBondSecuritiesMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">3732000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="PAsOn12_31_2022_CorporateBondSecuritiesMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">6000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">25166000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">34000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">25166000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">34000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="PAsOn12_31_2021_CommercialPaperMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">47425000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="PAsOn12_31_2021_CommercialPaperMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">34000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="PAsOn12_31_2021_CommercialPaperMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">47425000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="PAsOn12_31_2021_CommercialPaperMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">34000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="PAsOn12_31_2021_CorporateBondSecuritiesMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">12573000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="PAsOn12_31_2021_CorporateBondSecuritiesMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">7000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="PAsOn12_31_2021_CorporateBondSecuritiesMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">12573000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="PAsOn12_31_2021_CorporateBondSecuritiesMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">7000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">59998000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">41000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">59998000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">41000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <agle:ImpairmentOfMarketableSecurities
      contextRef="P01_01_2022To12_31_2022_USGovernmentAgenciesDebtSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="0"
      unitRef="Unit_USD">0</agle:ImpairmentOfMarketableSecurities>
    <agle:ImpairmentOfMarketableSecurities
      contextRef="P01_01_2021To12_31_2021_USGovernmentAgenciesDebtSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="0"
      unitRef="Unit_USD">0</agle:ImpairmentOfMarketableSecurities>
    <agle:ImpairmentOfMarketableSecurities
      contextRef="P01_01_2022To12_31_2022_USGovernmentAgenciesDebtSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="0"
      unitRef="Unit_USD">0</agle:ImpairmentOfMarketableSecurities>
    <agle:ImpairmentOfMarketableSecurities
      contextRef="P01_01_2021To12_31_2021_USGovernmentAgenciesDebtSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="0"
      unitRef="Unit_USD">0</agle:ImpairmentOfMarketableSecurities>
    <us-gaap:MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments
      contextRef="P01_01_2022To12_31_2022_USGovernmentAgenciesDebtSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments>
    <us-gaap:MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments
      contextRef="P01_01_2021To12_31_2021_USGovernmentAgenciesDebtSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments>
    <us-gaap:InterestReceivable
      contextRef="PAsOn12_31_2022_USGovernmentAgenciesDebtSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">100000</us-gaap:InterestReceivable>
    <us-gaap:InterestReceivable
      contextRef="PAsOn12_31_2021_USGovernmentAgenciesDebtSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">100000</us-gaap:InterestReceivable>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following table summarizes the contractual maturities of the Company&#x2019;s marketable securities at estimated fair value (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:74%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Due in one year or less&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;20,848&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;77,986&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Due in 1 &#x2013; 2 years&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total marketable securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;20,848&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;77,986&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">20848000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">77986000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">20848000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">77986000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5. Property and Equipment, Net &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Property and equipment, net consist of the following (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:76%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Laboratory equipment&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,257&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,245&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Furniture and office equipment&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;520&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;520&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Computer equipment&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;73&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;54&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Software&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;121&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;139&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Leasehold improvements&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,393&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,393&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Property and equipment, gross&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7,364&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7,351&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less: Accumulated depreciation and amortization&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(4,144&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,802&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Property and equipment, net&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,220&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,549&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Depreciation and amortization expense for the years ended December&#160;31, 2022, 2021, and 2020 was $1.4&#160;million, $1.4&#160;million, and $1.0&#160;million, respectively. All of the Company&#x2019;s long-lived assets are located in the United States. &lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Property and equipment, net consist of the following (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:76%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Laboratory equipment&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,257&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,245&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Furniture and office equipment&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;520&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;520&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Computer equipment&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;73&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;54&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Software&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;121&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;139&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Leasehold improvements&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,393&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,393&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Property and equipment, gross&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7,364&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7,351&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less: Accumulated depreciation and amortization&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(4,144&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,802&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Property and equipment, net&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,220&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,549&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2022_LaboratoryEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">2257000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2021_LaboratoryEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">2245000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2022_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">520000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2021_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">520000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2022_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">73000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2021_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">54000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2022_PurchasedSoftwareMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">121000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2021_PurchasedSoftwareMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">139000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2022_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">4393000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2021_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">4393000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">7364000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">7351000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">4144000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2802000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">3220000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">4549000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="P01_01_2022To12_31_2022_PropertyPlantAndEquipmentMemberusgaapFairValueByAssetClassAxis"
      decimals="-5"
      unitRef="Unit_USD">1400000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="P01_01_2021To12_31_2021_PropertyPlantAndEquipmentMemberusgaapFairValueByAssetClassAxis"
      decimals="-5"
      unitRef="Unit_USD">1400000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="P01_01_2020To12_31_2020_PropertyPlantAndEquipmentMemberusgaapFairValueByAssetClassAxis"
      decimals="-5"
      unitRef="Unit_USD">1000000</us-gaap:DepreciationDepletionAndAmortization>
    <agle:AccruedAndOtherCurrentLiabilitiesTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;6. Accrued and Other Current Liabilities &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Accrued and other current liabilities consist of the following (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:74%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued compensation&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,589&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,988&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued contracted research and development costs&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,972&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,995&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued professional and consulting fees&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;946&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,264&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;330&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;783&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total accrued and other current liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;12,837&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;14,030&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</agle:AccruedAndOtherCurrentLiabilitiesTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Accrued and other current liabilities consist of the following (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:74%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued compensation&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,589&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,988&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued contracted research and development costs&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,972&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,995&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued professional and consulting fees&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;946&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,264&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;330&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;783&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total accrued and other current liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;12,837&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;14,030&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedSalariesCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">4589000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedSalariesCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">4988000</us-gaap:AccruedSalariesCurrent>
    <agle:AccruedContractedResearchAndDevelopmentCosts
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">6972000</agle:AccruedContractedResearchAndDevelopmentCosts>
    <agle:AccruedContractedResearchAndDevelopmentCosts
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">5995000</agle:AccruedContractedResearchAndDevelopmentCosts>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">946000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2264000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">330000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">783000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">12837000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">14030000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <agle:LesseeOperatingAndFinanceLeasesDisclosureTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;7. Leases &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company leases certain office space, laboratory facilities, and equipment. These leases require monthly lease payments that may be subject to annual increases throughout the lease term. Certain of these leases also include renewal options at the election of the Company to renew or extend the lease for an additional &lt;span style="-sec-ix-hidden:hidden95765451"&gt;&lt;span style="-sec-ix-hidden:hidden95765453"&gt;thre&lt;/span&gt;e&lt;/span&gt; to five years. These optional periods have not been considered in the determination of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; assets or lease liabilities associated with these leases as the Company did not consider it reasonably certain it would exercise the options. The Company performed evaluations of its contracts and determined it has both operating and finance leases. Variable lease expense for these leases primarily consists of common area maintenance and other operating costs. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In April 2019, the Company entered into a lease agreement (the &#x201c;Las Cimas Lease&#x201d;) for its corporate headquarters and laboratory space located in Austin, Texas. The Las Cimas Lease includes approximately 30,000 square feet and commenced on April&#160;30, 2019, with an expiration on April 30, 2028. The Company posted a customary letter of credit in the amount of $1.5&#160;million as security, which is subject to automatic reductions per the terms of the Las Cimas Lease. A tenant allowance of up to $1.0&#160;million was provided by the lessor and fully reimbursed to the Company. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following table summarizes the Company&#x2019;s recognition of its operating and finance leases (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:31%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td style="width:50%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Classification&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Operating&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;Operating lease &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; assets&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,430&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,806&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;span style="-sec-ix-hidden:hidden95765537"&gt;Finan&lt;/span&gt;&lt;span style="-sec-ix-hidden:hidden95765538"&gt;ce&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;Other &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; assets&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;597&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;798&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td colspan="3" style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total leased assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,027&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,604&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Leases&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Current&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Operating&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;Operating lease liabilities&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;625&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;436&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;span style="-sec-ix-hidden:hidden95765544"&gt;Fin&lt;/span&gt;&lt;span style="-sec-ix-hidden:hidden95765545"&gt;ance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;Accrued and other current liabilities&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;418&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-current&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Operating&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-current&lt;/div&gt; operating lease liabilities&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,004&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,608&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;span style="-sec-ix-hidden:hidden95765401"&gt;&lt;span style="-sec-ix-hidden:hidden95765511"&gt;Finan&lt;/span&gt;ce&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;Other &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; liabilities&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td colspan="3" style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total lease liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,645&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,478&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following table summarizes the weighted-average remaining lease term and discount rates for the Company&#x2019;s operating and finance leases: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:83%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Lease term (years)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Operating leases&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5.3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Finance leases&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Discount rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Operating leases&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10.6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10.7&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Finance leases&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10.2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.7&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following table summarizes the lease costs pertaining to the Company&#x2019;s operating leases (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:70%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Operating lease cost&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;910&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;991&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,258&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Variable lease cost&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;472&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;519&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;665&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total lease cost&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,382&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,510&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,923&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Cash paid for amounts included in the measurement of operating lease liabilities during the years ended December&#160;31, 2022 and 2021 was $0.9&#160;million and $1.1&#160;million, respectively, and was included within net cash used in operating activities in the cash flows. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The maturities of the Company&#x2019;s operating and finance lease liabilities as of December&#160;31, 2022 were as follows (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:76%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:8%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:8%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Operating&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Leases&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Finance&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Leases&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,078&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2024&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,103&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2025&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,129&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2026&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,163&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2027&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,198&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Thereafter&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;403&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total lease payments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,074&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Imputed interest&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,445&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,629&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</agle:LesseeOperatingAndFinanceLeasesDisclosureTextBlock>
    <us-gaap:LesseeFinanceLeaseRenewalTerm1 contextRef="PAsOn12_31_2022_MaximumMembersrtRangeAxis">P5Y</us-gaap:LesseeFinanceLeaseRenewalTerm1>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="PAsOn12_31_2022_MaximumMembersrtRangeAxis">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:AreaOfLand
      contextRef="PAsOn04_30_2019"
      decimals="INF"
      unitRef="Unit_sqft">30000</us-gaap:AreaOfLand>
    <us-gaap:LeaseExpirationDate1 contextRef="P04_01_2019To04_30_2019">2028-04-30</us-gaap:LeaseExpirationDate1>
    <us-gaap:LineOfCredit
      contextRef="PAsOn04_30_2019_LetterOfCreditMemberusgaapShortTermDebtTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">1500000</us-gaap:LineOfCredit>
    <us-gaap:TenantImprovements
      contextRef="PAsOn04_30_2019_MaximumMembersrtRangeAxis"
      decimals="INF"
      unitRef="Unit_USD">1000000</us-gaap:TenantImprovements>
    <agle:ScheduleOfOperatingAndFinancingLeasesPresentedInBalanceSheetTableTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following table summarizes the Company&#x2019;s recognition of its operating and finance leases (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:31%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td style="width:50%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Classification&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Operating&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;Operating lease &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; assets&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,430&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,806&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;span style="-sec-ix-hidden:hidden95765537"&gt;Finan&lt;/span&gt;&lt;span style="-sec-ix-hidden:hidden95765538"&gt;ce&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;Other &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; assets&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;597&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;798&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td colspan="3" style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total leased assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,027&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,604&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Leases&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Current&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Operating&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;Operating lease liabilities&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;625&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;436&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;span style="-sec-ix-hidden:hidden95765544"&gt;Fin&lt;/span&gt;&lt;span style="-sec-ix-hidden:hidden95765545"&gt;ance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;Accrued and other current liabilities&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;418&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-current&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Operating&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-current&lt;/div&gt; operating lease liabilities&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,004&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,608&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;span style="-sec-ix-hidden:hidden95765401"&gt;&lt;span style="-sec-ix-hidden:hidden95765511"&gt;Finan&lt;/span&gt;ce&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;Other &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; liabilities&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td colspan="3" style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total lease liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,645&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,478&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</agle:ScheduleOfOperatingAndFinancingLeasesPresentedInBalanceSheetTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">3430000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">3806000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">597000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">798000</us-gaap:FinanceLeaseRightOfUseAsset>
    <agle:OperatingAndFinanceLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">4027000</agle:OperatingAndFinanceLeaseRightOfUseAsset>
    <agle:OperatingAndFinanceLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">4604000</agle:OperatingAndFinanceLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">625000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">436000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">16000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">418000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">4004000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">4608000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">16000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <agle:OperatingAndFinanceLeaseLiabilities
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">4645000</agle:OperatingAndFinanceLeaseLiabilities>
    <agle:OperatingAndFinanceLeaseLiabilities
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">5478000</agle:OperatingAndFinanceLeaseLiabilities>
    <agle:SummaryOfWeightedAverageRemainingLeaseTermAndDiscountRatesOfOperatingAndFinanceLeasesTableTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following table summarizes the weighted-average remaining lease term and discount rates for the Company&#x2019;s operating and finance leases: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:83%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Lease term (years)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Operating leases&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5.3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Finance leases&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Discount rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Operating leases&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10.6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10.7&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Finance leases&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10.2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.7&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</agle:SummaryOfWeightedAverageRemainingLeaseTermAndDiscountRatesOfOperatingAndFinanceLeasesTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="PAsOn12_31_2022">P5Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="PAsOn12_31_2021">P6Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1 contextRef="PAsOn12_31_2022">P0Y7M6D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1 contextRef="PAsOn12_31_2021">P0Y6M</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="PAsOn12_31_2022"
      decimals="3"
      unitRef="Unit_pure">0.106</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="PAsOn12_31_2021"
      decimals="3"
      unitRef="Unit_pure">0.107</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="PAsOn12_31_2022"
      decimals="3"
      unitRef="Unit_pure">0.102</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="PAsOn12_31_2021"
      decimals="3"
      unitRef="Unit_pure">0.067</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LeaseCostTableTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following table summarizes the lease costs pertaining to the Company&#x2019;s operating leases (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:70%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Operating lease cost&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;910&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;991&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,258&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Variable lease cost&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;472&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;519&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;665&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total lease cost&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,382&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,510&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,923&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">910000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">991000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1258000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">472000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">519000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">665000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">1382000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1510000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1923000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="P01_01_2022To12_31_2022"
      decimals="-5"
      unitRef="Unit_USD">900000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="P01_01_2021To12_31_2021"
      decimals="-5"
      unitRef="Unit_USD">1100000</us-gaap:OperatingLeasePayments>
    <agle:ScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesTableTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The maturities of the Company&#x2019;s operating and finance lease liabilities as of December&#160;31, 2022 were as follows (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:76%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:8%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:8%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Operating&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Leases&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Finance&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Leases&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,078&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2024&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,103&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2025&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,129&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2026&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,163&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2027&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,198&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Thereafter&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;403&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total lease payments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,074&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Imputed interest&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,445&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,629&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</agle:ScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">1078000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">16000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">1103000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">1129000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">1163000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">1198000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">403000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">6074000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">16000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">1445000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">4629000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">16000</us-gaap:FinanceLeaseLiability>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;8. Stockholders&#x2019; Equity &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company is authorized to issue 30,000,000 shares of capital stock of which 20,000,000 shares are designated as common stock and 10,000,000 shares are designated as preferred stock, all with a par value of $0.0001 per share. Each holder of common stock is entitled to one vote for each share of common stock held. The Company&#x2019;s common stock is not entitled to preemptive rights, and is not subject to conversion, redemption or sinking fund provisions. Subject to preferences that may apply to any shares of preferred stock outstanding at the time, the holders of common stock are entitled to receive dividends out of funds legally available if the board of directors, in its discretion, determines to issue dividends and then only at the times and in the amounts that the board of directors may determine. As of December&#160;31, 2022 and 2021, no common stock dividends had been declared by the board of directors and there were no shares of preferred stock outstanding. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Registered Direct Offering &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In May 2022, the Company issued and sold 430,107 shares of common stock at an offering price of $40.00 per share and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-funded&lt;/div&gt; warrants to purchase up to 694,892 shares of common stock at an offering price of $39.9975 per warrant (representing the price per share of common stock sold in the offering minus the $0.0025 exercise price per warrant) in a registered direct offering pursuant to a shelf registration statement on Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;S-3.&lt;/div&gt; The net proceeds to the Company from this offering were approximately $42.9&#160;million, after deducting placement agent fees and offering costs of $2.1&#160;million. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Follow-on&lt;/div&gt; Public Offerings &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In February 2019, the Company issued and sold 185,000 shares of common stock at a public offering price of $200.00 per share and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-funded&lt;/div&gt; warrants to purchase up to 160,000 shares of common stock at a public offering price of $199.9975 per warrant in an underwritten public offering pursuant to a shelf registration statement on Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;S-3.&lt;/div&gt; This includes the full exercise by the underwriters of their option to purchase up to 45,000 additional shares of common stock. The net proceeds to the Company from this public offering were $64.5&#160;million, after deducting underwriting discounts and commissions of $4.1&#160;million and offering costs of $0.4&#160;million. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In April 2020, the Company issued and sold 617,692 shares of common stock at a public offering price of $118.75 per share and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-funded&lt;/div&gt; warrants to purchase up to 544,413 shares of common stock at a public offering price of $118.7475 per warrant in an underwritten public offering pursuant to a shelf registration statement on Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;S-3.&lt;/div&gt; This includes the full exercise by the underwriters of their option to purchase up to 151,578 additional shares of common stock. The net proceeds to the Company from this public offering were $129.0&#160;million, after deducting underwriting discounts and commissions of $8.2&#160;million and offering costs of $0.8&#160;million. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pre-Funded&lt;/div&gt; Warrants &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In February 2019, April 2020 and May 2022, the Company issued &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-funded&lt;/div&gt; warrants to purchase the Company&#x2019;s common stock in underwritten public offerings at the offering price of the common stock, less the $0.0025 per share exercise price of each warrant. The warrants were recorded as a component of stockholders&#x2019; equity within additional &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;paid-in&lt;/div&gt; capital and have no expiration date. Per the terms of the warrant agreements, the outstanding warrants to purchase shares of common stock may not be exercised if the holder&#x2019;s ownership of the Company&#x2019;s common stock would exceed 4.99% (&#x201c;Maximum Ownership Percentage&#x201d;) or 9.99% for certain holders. By written notice to the Company, each holder may increase or decrease the Maximum Ownership Percentage to any other percentage (not in excess of 19.99% for the majority of such warrants). The revised Maximum Ownership Percentage would be effective 61 days after the notice is received by the Company. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;As of December&#160;31, 2022, the following &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-funded&lt;/div&gt; warrants to purchase common stock were issued and outstanding: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:46%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:10%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:10%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:10%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Issue Date&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Expiration&#160;Date&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Exercise&#160;Price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&#160;of&#160;Warrants&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Outstanding&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;span style="-sec-ix-hidden:hidden95765421"&gt;February 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;None&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.0025&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;150,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;span style="-sec-ix-hidden:hidden95765422"&gt;April 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;None&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.0025&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;474,413&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;span style="-sec-ix-hidden:hidden95765423"&gt;May 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;None&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.0025&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;531,250&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-funded&lt;/div&gt; warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,155,663&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;At-The-Market&lt;/div&gt;&lt;/div&gt; Offering &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In April 2020, the Company entered into a new sales agreement with JonesTrading Institutional Services LLC, as sales agent, to issue and sell shares of its common stock for an aggregate offering price of $60.0&#160;million under an &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;at-the-market&lt;/div&gt;&lt;/div&gt; (&#x201c;2020 ATM&#x201d;) offering program. In the fourth quarter of 2020, the Company issued and sold 129,803 shares of common stock under the 2020 ATM for gross proceeds of $25.3&#160;million, resulting in net proceeds of $24.6&#160;million, after deducting underwriting discounts, commissions, and offering costs. &lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <agle:SharesAuthorized
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      unitRef="Unit_shares">30000000</agle:SharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      unitRef="Unit_shares">20000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      unitRef="Unit_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2022"
      decimals="4"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CommonStockVotingRights contextRef="P01_01_2022To12_31_2022">Each holder of common stock is entitled to one vote for each share of common stock held</us-gaap:CommonStockVotingRights>
    <agle:NumberOfCommonStockVotingRightsHeldPerShare
      contextRef="PAsOn12_31_2022"
      decimals="0"
      unitRef="Unit_VOTE">1</agle:NumberOfCommonStockVotingRightsHeldPerShare>
    <us-gaap:DividendsCommonStock
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:DividendsCommonStock>
    <us-gaap:DividendsCommonStock
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:DividendsCommonStock>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2021"
      decimals="0"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2022"
      decimals="0"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P05_01_2022To05_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">430107</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="PAsOn05_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">40</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn05_31_2022_MaximumMembersrtRangeAxis"
      decimals="INF"
      unitRef="Unit_shares">694892</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <agle:ClassOfWarrantOrRightOfferingPriceOfWarrantsOrRights
      contextRef="PAsOn05_31_2022"
      decimals="INF"
      unitRef="Unit_USD_per_Share">39.9975</agle:ClassOfWarrantOrRightOfferingPriceOfWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn05_31_2022"
      decimals="4"
      unitRef="Unit_USD_per_Share">0.0025</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="P05_01_2022To05_31_2022"
      decimals="-5"
      unitRef="Unit_USD">42900000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <agle:PlacementAgentFeesAndOfferingCosts
      contextRef="P05_01_2022To05_31_2022"
      decimals="-5"
      unitRef="Unit_USD">2100000</agle:PlacementAgentFeesAndOfferingCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P02_01_2019To02_28_2019_CommonStockMemberusgaapStatementEquityComponentsAxis_FollowOnPublicOfferingMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">185000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="PAsOn02_28_2019_CommonStockMemberusgaapStatementEquityComponentsAxis_FollowOnPublicOfferingMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">200</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn02_28_2019_CommonStockMemberusgaapStatementEquityComponentsAxis_FollowOnPublicOfferingMemberusgaapSubsidiarySaleOfStockAxis_MaximumMembersrtRangeAxis"
      decimals="INF"
      unitRef="Unit_shares">160000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn02_28_2019_CommonStockMemberusgaapStatementEquityComponentsAxis_FollowOnPublicOfferingMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">199.9975</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P02_01_2019To02_28_2019_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">45000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="P02_01_2019To02_28_2019"
      decimals="-5"
      unitRef="Unit_USD">64500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ExpenseRelatedToDistributionOrServicingAndUnderwritingFees
      contextRef="P02_01_2019To02_28_2019"
      decimals="-5"
      unitRef="Unit_USD">4100000</us-gaap:ExpenseRelatedToDistributionOrServicingAndUnderwritingFees>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="P02_01_2019To02_28_2019"
      decimals="-5"
      unitRef="Unit_USD">400000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P04_01_2020To04_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_FollowOnPublicOfferingMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">617692</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="PAsOn04_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_FollowOnPublicOfferingMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">118.75</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn04_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_FollowOnPublicOfferingMemberusgaapSubsidiarySaleOfStockAxis_MaximumMembersrtRangeAxis"
      decimals="INF"
      unitRef="Unit_shares">544413</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn04_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_FollowOnPublicOfferingMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">118.7475</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P04_01_2020To04_30_2020_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">151578</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="P04_01_2020To04_30_2020"
      decimals="-5"
      unitRef="Unit_USD">129000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ExpenseRelatedToDistributionOrServicingAndUnderwritingFees
      contextRef="P04_01_2020To04_30_2020"
      decimals="-5"
      unitRef="Unit_USD">8200000</us-gaap:ExpenseRelatedToDistributionOrServicingAndUnderwritingFees>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="P04_01_2020To04_30_2020"
      decimals="-5"
      unitRef="Unit_USD">800000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn12_31_2022"
      decimals="4"
      unitRef="Unit_USD_per_Share">0.0025</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <agle:MaximumOwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercised
      contextRef="P01_01_2022To12_31_2022"
      decimals="INF"
      unitRef="Unit_pure">0.0499</agle:MaximumOwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercised>
    <agle:OwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercisedToCertainHolders
      contextRef="P01_01_2022To12_31_2022"
      decimals="INF"
      unitRef="Unit_pure">0.0999</agle:OwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercisedToCertainHolders>
    <agle:MaximumOwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercised
      contextRef="P01_01_2022To12_31_2022_MaximumMembersrtRangeAxis"
      decimals="4"
      unitRef="Unit_pure">0.1999</agle:MaximumOwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercised>
    <agle:PeriodAfterNoticeReceivedByCompanyMaximumOwnershipPercentageToBeEffectiveDescription contextRef="P01_01_2022To12_31_2022">The revised Maximum Ownership Percentage would be effective 61 days after the notice is received by the Company.</agle:PeriodAfterNoticeReceivedByCompanyMaximumOwnershipPercentageToBeEffectiveDescription>
    <us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;As of December&#160;31, 2022, the following &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-funded&lt;/div&gt; warrants to purchase common stock were issued and outstanding: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:46%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:10%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:10%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:10%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Issue Date&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Expiration&#160;Date&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Exercise&#160;Price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&#160;of&#160;Warrants&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Outstanding&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;span style="-sec-ix-hidden:hidden95765421"&gt;February 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;None&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.0025&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;150,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;span style="-sec-ix-hidden:hidden95765422"&gt;April 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;None&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.0025&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;474,413&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;span style="-sec-ix-hidden:hidden95765423"&gt;May 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;None&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.0025&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;531,250&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-funded&lt;/div&gt; warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,155,663&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock>
    <agle:WarrantExpirationDate contextRef="P01_01_2022To12_31_2022_FebruaryTwoThousandNinteenMemberusgaapAwardDateAxis_WarrantMemberusgaapStatementEquityComponentsAxis">None</agle:WarrantExpirationDate>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn12_31_2022_FebruaryTwoThousandNinteenMemberusgaapAwardDateAxis_WarrantMemberusgaapStatementEquityComponentsAxis"
      decimals="4"
      unitRef="Unit_USD_per_Share">0.0025</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn12_31_2022_FebruaryTwoThousandNinteenMemberusgaapAwardDateAxis_WarrantMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">150000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <agle:WarrantExpirationDate contextRef="P01_01_2022To12_31_2022_AprilTwoThousandTwentyMemberusgaapAwardDateAxis_WarrantMemberusgaapStatementEquityComponentsAxis">None</agle:WarrantExpirationDate>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn12_31_2022_AprilTwoThousandTwentyMemberusgaapAwardDateAxis_WarrantMemberusgaapStatementEquityComponentsAxis"
      decimals="4"
      unitRef="Unit_USD_per_Share">0.0025</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn12_31_2022_AprilTwoThousandTwentyMemberusgaapAwardDateAxis_WarrantMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">474413</us-gaap:ClassOfWarrantOrRightOutstanding>
    <agle:WarrantExpirationDate contextRef="P01_01_2022To12_31_2022_MayTwoThousandTwentyTwoMemberusgaapAwardDateAxis_WarrantMemberusgaapStatementEquityComponentsAxis">None</agle:WarrantExpirationDate>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn12_31_2022_MayTwoThousandTwentyTwoMemberusgaapAwardDateAxis_WarrantMemberusgaapStatementEquityComponentsAxis"
      decimals="4"
      unitRef="Unit_USD_per_Share">0.0025</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn12_31_2022_MayTwoThousandTwentyTwoMemberusgaapAwardDateAxis_WarrantMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">531250</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn12_31_2022_WarrantMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">1155663</us-gaap:ClassOfWarrantOrRightOutstanding>
    <agle:AggregateOfferingPriceOfCommonStock
      contextRef="P04_01_2020To04_30_2020_AtTheMarketSalesAgreementMemberusgaapSubsidiarySaleOfStockAxis_JonesTradingInstitutionalServicesLimitedLiabilityCompanyMemberusgaapRelatedPartyTransactionAxis"
      decimals="-5"
      unitRef="Unit_USD">60000000</agle:AggregateOfferingPriceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P10_01_2020To12_31_2020_AtTheMarketSalesAgreementMemberusgaapSubsidiarySaleOfStockAxis_JonesTradingInstitutionalServicesLimitedLiabilityCompanyMemberusgaapRelatedPartyTransactionAxis"
      decimals="INF"
      unitRef="Unit_shares">129803</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <agle:ProceedsFromIssuanceOfCommonStockGross
      contextRef="P10_01_2020To12_31_2020_AtTheMarketSalesAgreementMemberusgaapSubsidiarySaleOfStockAxis_JonesTradingInstitutionalServicesLimitedLiabilityCompanyMemberusgaapRelatedPartyTransactionAxis"
      decimals="-5"
      unitRef="Unit_USD">25300000</agle:ProceedsFromIssuanceOfCommonStockGross>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="P10_01_2020To12_31_2020_AtTheMarketSalesAgreementMemberusgaapSubsidiarySaleOfStockAxis_JonesTradingInstitutionalServicesLimitedLiabilityCompanyMemberusgaapRelatedPartyTransactionAxis"
      decimals="-5"
      unitRef="Unit_USD">24600000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <agle:StrategicLicenseAgreementTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;9. Strategic License Agreements &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Immedica Pharma AB License and Development Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On March 21, 2021, the Company entered into an exclusive license and supply agreement with Immedica Pharma AB (&#x201c;Immedica&#x201d;). By entering into this agreement, the Company agreed to provide Immedica the following goods and services: &lt;/div&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;i.&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;Deliver an exclusive, sublicensable, license and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;know-how&lt;/div&gt; (the &#x201c;License&#x201d;) to develop and commercialize pegzilarginase (the &#x201c;Product&#x201d;) in the territory comprising the members states of the European Economic Area, United Kingdom, Switzerland, Andorra, Monaco, San Marino, Vatican City, Turkey, Saudi Arabia, United Arab Emirates, Qatar, Kuwait, Bahrain, and Oman (the &#x201c;Territory&#x201d;); &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;ii.&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;Complete the global pivotal PEACE (Pegzilarginase Effect on Arginase 1 Deficiency Clinical Endpoints) Phase 3 trial (&#x201c;PEACE Trial&#x201d;) and related Biologics License Application (&#x201c;BLA&#x201d;) package to file with the United States Food and Drug Administration (&#x201c;FDA&#x201d;), which will be leveraged by Immedica in obtaining the necessary regulatory approvals in the Territory; and &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;iii.&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;Perform a Pediatric Investigation Plan trial (&#x201c;PIP Trial&#x201d;) in order for Immedica to be able to receive certain regulatory approvals within the Territory. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In addition, the Company and Immedica formed a Joint Steering Committee (&#x201c;JSC&#x201d;) to provide oversight to the activities performed under the agreement; however, the substance of the Company&#x2019;s participation in the JSC does not represent an additional promised service, but rather, a right of the Company to protect its own interests in the arrangement. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Further, the Company agreed to supply to Immedica, and Immedica agreed to purchase from the Company, substantially all commercial requirements of the Product. The terms of the agreement do not provide for either (i)&#160;an option to Immedica to purchase the Product from the Company at a discount from the standalone selling price or (ii)&#160;minimum purchase quantities. Finally, Immedica will bear (i)&#160;all costs and expenses for any development or commercialization of the Product in the Territory subject to the License exclusive of the Company&#x2019;s promised goods and services summarized above and (ii)&#160;all costs and fees associated with applying for regulatory approval of the Product in the Territory. In July 2021, the Company modified the agreement with Immedica to provide certain additional services in relation to the PEACE Phase 3 Trial and BLA package performance obligation in exchange for the reimbursement of up to $3.0&#160;million of the actual costs incurred in relation to such incremental services. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company received a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-refundable&lt;/div&gt; payment of $21.5&#160;million and Immedica agreed to provide payment of 50% of the Company&#x2019;s costs incurred in performing the PIP Trial up to a maximum of $1.8&#160;million. In addition, the Company has the ability to receive additional payments under the agreement of up to approximately $120.8&#160;million in regulatory and commercial milestone payments, assuming an exchange rate of $1.07 to &#x20ac;1.00. The Company is also entitled to receive royalties in the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="display:inline;"&gt;&lt;span style="-sec-ix-hidden:hidden95765599"&gt;mid-20&lt;/span&gt;&lt;/div&gt;&#160;percent&lt;/div&gt; range on net sales of the Product in the Territory. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company concluded that Immedica meets the definition to be accounted for as a customer because the Company is delivering intellectual property and other services within the Company&#x2019;s normal course of business, in which the parties are not jointly sharing the risks and rewards. Therefore, the Company concluded that the promises summarized above represent transactions with a customer within the scope of ASC 606. The Company determined that the following promises represent distinct promised services, and therefore, performance obligations: (i)&#160;the License, (ii)&#160;the PEACE Trial and BLA package, and (iii)&#160;the PIP Trial. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Specifically, in making these determinations, the Company considered the following factors: &lt;/div&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:5%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:3%;vertical-align:top;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: left; line-height: normal;"&gt;As of inception of the agreement, the Company had completed the Phase 1/2 clinical trial related to the Product and were conducting the ongoing PEACE Trial. Accordingly, the Company is not promising, &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:9%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; line-height: normal;"&gt;nor expecting, to perform additional research and development activities pursuant to the agreement that would either significantly modify, customize or be considered highly interdependent or interrelated with pegzilarginase. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:5%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:3%;vertical-align:top;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: left; line-height: normal;"&gt;The License represents functional intellectual property given the functionality of the License is not expected to change substantially as a result of the company&#x2019;s ongoing activities. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:5%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:3%;vertical-align:top;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: left; line-height: normal;"&gt;The services necessary to complete the PEACE Trial, BLA package and PIP Trial could be performed by other parties. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Given that Immedica is not obligated to purchase any minimum amount or quantities of the Product, the supply of the Product for commercial use to Immedica was determined to be an option for Immedica, rather than a performance obligation of the Company at contract inception and will be accounted for if and when exercised. The Company also determined that Immedica&#x2019;s option to purchase the Product does not create a material right as the expected pricing is not at a discount. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company determined that the upfront fixed payment amount of $21.5&#160;million must be included in the transaction price. Additionally, the Company determined at inception of the arrangement that 50% of the estimated costs to be incurred in relation to the PIP Trial exceeded $1.8&#160;million and included the full reimbursement amount of $1.8&#160;million in the transaction price. Upon subsequent &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-evaluation&lt;/div&gt; due to changing facts and circumstances, the Company determined the estimated costs are now less than the maximum allowable reimbursement and a portion of the variable consideration was constrained, which did not materially impact the revenue recognized to date. Additionally, upon the modification of the agreement in July 2021, the Company determined that the estimated costs to perform the additional services related to the PEACE Trial and BLA package exceeds the maximum allowable reimbursement of $3.0&#160;million. Therefore, the Company included an estimated total of $3.6&#160;million that will be due in relation to the PIP Trial, PEACE Trial, and BLA package in the transaction price and it is probable that a significant reversal will not occur in the future. In total, the modified transaction price was determined to be $25.1&#160;million. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company has allocated $9.6&#160;million and $3.5&#160;million of the modified transaction price to the PEACE Trial and BLA package and PIP Trial performance obligations, respectively, based on the stand-alone selling prices (&#x201c;SSP&#x201d;), which was based on the estimated costs that a third-party would charge in performing such services on a stand-alone basis. The SSP for the License was established at inception of the arrangement using a residual value approach due to the uniqueness of and lack of observable data related to the License, and without a specific analog from which to make reliable estimates, resulting in an allocation of $12.0&#160;million. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The potential regulatory milestone payments that the Company is eligible to receive were excluded from the transaction price, as the milestone amounts were fully constrained based on the probability of achievement, since the milestones relate to successful achievement of certain regulatory approvals, which might not be achieved. The Company determined that the royalties and commercial milestone payments relate predominantly to the license of intellectual property and are therefore excluded from the transaction price under the sales- or usage-based royalty exception of ASC 606. The Company will reevaluate the transaction price, including all constrained amounts, at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur, the Company will adjust its estimate of the transaction price as necessary. The Company will recognize the royalties and commercial milestone payments as revenue when the associated sales occur, and relevant sales-based thresholds are met. The Company assessed the arrangement with Immedica and concluded that a significant financing component does not exist. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company recognized revenue allocated to the License performance obligation at a point in time and upon transfer of the License. The Company completed the transfer of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;know-how&lt;/div&gt; necessary for Immedica to benefit from the License in June 2021 and recognized $12.0&#160;million of revenue at that time. The development fee allocated to the PEACE Trial, BLA package and PIP Trial performance obligations will be recognized over time using an input method of costs incurred related to the performance obligations. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;For the year ended December&#160;31, 2022, the Company recognized revenue of $2.3&#160;million related to the PEACE Trial and BLA package performance obligation using a cost to cost model. The Company recognized revenue of $6.7&#160;million related to the PEACE Trial and BLA package performance obligation using a cost to cost model and $12.0&#160;million related to the transfer of the License for the year ended December&#160;31, 2021 and no revenue for the year ended December&#160;31, 2020. As of December&#160;31, 2022, the Company has recorded deferred revenue of $2.7&#160;million associated with the license and supply agreement with Immedica, of which $0.5&#160;million is classified as current. As of December&#160;31, 2021, the Company had recorded deferred revenue of $3.6&#160;million associated with the license and supply agreement with Immedica, of which $2.4&#160;million was classified as current. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Contract Balances from Customer Contract &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The timing of revenue recognition, billings and cash collections results in contract assets and contract liabilities on the balance sheets. The Company recognizes license and development receivables based on billed services, which are derecognized upon reimbursement. When consideration is received, or such consideration is unconditionally due, from a customer prior to transferring goods or services to the customer under the terms of a contract, a contract liability is recorded. Contract liabilities are recognized as revenue after control of the goods or services is transferred to the customer and all revenue recognition criteria have been met. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following table presents changes in the Company&#x2019;s contract liabilities for the periods presented (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:51%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Additions&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Deductions&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Contract liabilities:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Deferred revenue&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,576&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,449&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,329&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,696&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company had no contract assets during the years ended December&#160;31, 2022, 2021 and 2020 and no contract liabilities during the year ended December&#160;31, 2020. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;University of Texas at Austin License Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In December 2013, two of the Company&#x2019;s wholly owned subsidiaries AECase, Inc. and AEMase, Inc. each entered into an exclusive, worldwide license agreement, including the right to grant sublicenses, with the University of Texas at Austin (the &#x201c;University&#x201d;) for certain intellectual property owned by the University related to cystinase and methioninase. In January 2017, the Company and the University entered into an Amended and Restated Patent License Agreement (the &#x201c;Restated License&#x201d;), which &lt;span style="-sec-ix-hidden:hidden95765449"&gt;consolidated&lt;/span&gt; the two license agreements, revised certain obligations, and licensed additional patent applications and invention disclosures to us. The Restated License was amended in August 2017, December 2017, and December 2018 to revise diligence milestones and license additional patent applications, including our program candidates under the pegtarviliase and Cystinuria Programs. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Pursuant to the terms of the Restated License, the Company may be required to pay the University up to $6.4&#160;million in milestone payments based on the achievement of certain development milestones, including clinical trials and regulatory approvals, the majority of which are due upon the achievement of later development milestones, including a $5.0&#160;million payment due on regulatory approval of a product and a $0.5&#160;million payment payable on final regulatory approval of a product for a second indication. In addition, the Company is required to pay the University a low single-digit royalty on &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;worldwide-net&lt;/div&gt; sales of products covered under the Restated License, together with a revenue share on &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-royalty&lt;/div&gt; consideration received from sublicensees. The rate of the revenue share ranges from 6.5% to 25% depending on the date the sublicense agreement is signed. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In the year ended December&#160;31, 2022, the Company paid $0.1&#160;million in milestone payments pursuant to the Restated License. For the years ended December&#160;31, 2021 and 2020, the Company paid $0.1&#160;million in license fees annually. &lt;/div&gt;</agle:StrategicLicenseAgreementTextBlock>
    <agle:LicenseAndSupplyAgreementDate contextRef="P03_21_2021To03_21_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis">2021-03-21</agle:LicenseAndSupplyAgreementDate>
    <us-gaap:ReimbursementFromLimitedPartnershipInvestment
      contextRef="P07_01_2021To07_31_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      unitRef="Unit_USD">3000000</us-gaap:ReimbursementFromLimitedPartnershipInvestment>
    <agle:NonRefundablePaymentReceived
      contextRef="P01_01_2021To03_31_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      unitRef="Unit_USD">21500000</agle:NonRefundablePaymentReceived>
    <agle:PercentageOfPaymentForCostIncurredInPIPTrial
      contextRef="P01_01_2021To03_31_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_MaximumMembersrtRangeAxis"
      decimals="2"
      unitRef="Unit_pure">0.50</agle:PercentageOfPaymentForCostIncurredInPIPTrial>
    <agle:CostsIncurredInPerformingTheTrial
      contextRef="P01_01_2021To03_31_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_MaximumMembersrtRangeAxis"
      decimals="-5"
      unitRef="Unit_USD">1800000</agle:CostsIncurredInPerformingTheTrial>
    <agle:AdditionalUpfrontPaymentAbilityToReceived
      contextRef="P01_01_2021To03_31_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      unitRef="Unit_USD">120800000</agle:AdditionalUpfrontPaymentAbilityToReceived>
    <agle:MilestonePaymentsExchangeRate
      contextRef="P01_01_2022To12_31_2022_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_MinimumMembersrtRangeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">1.07</agle:MilestonePaymentsExchangeRate>
    <agle:MilestonePaymentsExchangeRate
      contextRef="P01_01_2022To12_31_2022_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_MaximumMembersrtRangeAxis"
      decimals="2"
      unitRef="Unit_EUR_per_Share">1</agle:MilestonePaymentsExchangeRate>
    <agle:UpfrontPayment
      contextRef="P01_01_2021To03_31_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      unitRef="Unit_USD">21500000</agle:UpfrontPayment>
    <agle:PercentageOfPaymentForCostIncurredInPIPTrial
      contextRef="P01_01_2021To03_31_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_MaximumMembersrtRangeAxis"
      decimals="2"
      unitRef="Unit_pure">0.50</agle:PercentageOfPaymentForCostIncurredInPIPTrial>
    <agle:CostsIncurredInPerformingTheTrial
      contextRef="P01_01_2021To03_31_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_MaximumMembersrtRangeAxis"
      decimals="-5"
      unitRef="Unit_USD">1800000</agle:CostsIncurredInPerformingTheTrial>
    <agle:CostsIncurredInPerformingTheTrial
      contextRef="P01_01_2021To03_31_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_MaximumMembersrtRangeAxis"
      decimals="-5"
      unitRef="Unit_USD">1800000</agle:CostsIncurredInPerformingTheTrial>
    <us-gaap:ReimbursementFromLimitedPartnershipInvestment
      contextRef="P07_01_2021To07_31_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      unitRef="Unit_USD">3000000</us-gaap:ReimbursementFromLimitedPartnershipInvestment>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross
      contextRef="P07_01_2021To07_31_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      unitRef="Unit_USD">3600000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="P07_01_2021To07_31_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      unitRef="Unit_USD">25100000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <agle:AllocatedAmountOfTransactionPrice
      contextRef="P01_01_2021To03_31_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_PeaceTrialAndBLAPackageMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">9600000</agle:AllocatedAmountOfTransactionPrice>
    <agle:AllocatedAmountOfTransactionPrice
      contextRef="P01_01_2021To03_31_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_PIPTrialMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">3500000</agle:AllocatedAmountOfTransactionPrice>
    <agle:AllocationPriceTotal
      contextRef="P01_01_2021To03_31_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      unitRef="Unit_USD">12000000</agle:AllocationPriceTotal>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P06_01_2021To06_30_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_LicenseAgreementsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">12000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To12_31_2022_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_PeaceTrialAndBLAPackageMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">2300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To12_31_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_PeaceTrialAndBLAPackageMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">6700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To12_31_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_LicenseAgreementsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">12000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2020To12_31_2020_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_LicenseAgreementsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:DeferredRevenue
      contextRef="PAsOn12_31_2022_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      unitRef="Unit_USD">2700000</us-gaap:DeferredRevenue>
    <us-gaap:DeferredRevenueCurrent
      contextRef="PAsOn12_31_2022_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      unitRef="Unit_USD">500000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenue
      contextRef="PAsOn12_31_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      unitRef="Unit_USD">3600000</us-gaap:DeferredRevenue>
    <us-gaap:DeferredRevenueCurrent
      contextRef="PAsOn12_31_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      unitRef="Unit_USD">2400000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following table presents changes in the Company&#x2019;s contract liabilities for the periods presented (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:51%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Additions&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Deductions&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Contract liabilities:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Deferred revenue&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,576&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,449&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,329&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,696&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">3576000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <agle:ContractWithCustomerLiabilityRevenueRecognizedIncludingAdditions
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">1449000</agle:ContractWithCustomerLiabilityRevenueRecognizedIncludingAdditions>
    <agle:ContractWithCustomerLiabilityDeductionsThroughContractsAcquired
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">2329000</agle:ContractWithCustomerLiabilityDeductionsThroughContractsAcquired>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">2696000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <agle:ResearchAgreementDate contextRef="P01_01_2022To12_31_2022_LicenseAgreementsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_UniversityOfTexasAtAustinMemberusgaapTypeOfArrangementAxis">2013-12</agle:ResearchAgreementDate>
    <agle:NumberOfLicenseAgreements
      contextRef="PAsOn12_31_2022_LicenseAgreementsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_UniversityOfTexasAtAustinMemberusgaapTypeOfArrangementAxis"
      decimals="0"
      unitRef="Unit_USD_LICENSEAGREEMENT">2</agle:NumberOfLicenseAgreements>
    <agle:MaximumFutureContingentLicensePayment
      contextRef="P01_01_2017To01_31_2017_LicenseAgreementsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_UniversityOfTexasAtAustinMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      unitRef="Unit_USD">6400000</agle:MaximumFutureContingentLicensePayment>
    <agle:AggregatePotentialMilestonePaymentsForReceiptOfRegulatoryApproval
      contextRef="P01_01_2017To01_31_2017_LicenseAgreementsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_UniversityOfTexasAtAustinMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      unitRef="Unit_USD">5000000</agle:AggregatePotentialMilestonePaymentsForReceiptOfRegulatoryApproval>
    <agle:AggregatePotentialMilestonePaymentsForFinalRegulatoryApprovalOfSecondIndication
      contextRef="P01_01_2017To01_31_2017_LicenseAgreementsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_UniversityOfTexasAtAustinMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      unitRef="Unit_USD">500000</agle:AggregatePotentialMilestonePaymentsForFinalRegulatoryApprovalOfSecondIndication>
    <agle:RateOfRevenueShare
      contextRef="P01_01_2017To01_31_2017_LicenseAgreementsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_MinimumMembersrtRangeAxis_UniversityOfTexasAtAustinMemberusgaapTypeOfArrangementAxis"
      decimals="INF"
      unitRef="Unit_pure">0.065</agle:RateOfRevenueShare>
    <agle:RateOfRevenueShare
      contextRef="P01_01_2017To01_31_2017_LicenseAgreementsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_MaximumMembersrtRangeAxis_UniversityOfTexasAtAustinMemberusgaapTypeOfArrangementAxis"
      decimals="INF"
      unitRef="Unit_pure">0.25</agle:RateOfRevenueShare>
    <agle:PaymentOfMilestone
      contextRef="P01_01_2022To12_31_2022_LicenseAgreementsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_UniversityOfTexasAtAustinMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      unitRef="Unit_USD">100000</agle:PaymentOfMilestone>
    <agle:PaymentOfAnnualLicenseFees
      contextRef="P01_01_2021To12_31_2021_LicenseAgreementsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_UniversityOfTexasAtAustinMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      unitRef="Unit_USD">100000</agle:PaymentOfAnnualLicenseFees>
    <agle:PaymentOfAnnualLicenseFees
      contextRef="P01_01_2020To12_31_2020_LicenseAgreementsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_UniversityOfTexasAtAustinMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      unitRef="Unit_USD">100000</agle:PaymentOfAnnualLicenseFees>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;10. Stock-Based Compensation &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2015 Equity Incentive Plan &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In March 2015, the Company adopted the 2015 Equity Incentive Plan (&#x201c;2015 Plan&#x201d;), administered by the board of directors, and provides for the Company to sell or issue common stock or restricted common stock, or to grant incentive stock options or nonqualified stock options for the purchase of common stock, to employees, members of the board of directors and consultants of the Company. Under the terms of the 2015 Plan, the exercise prices, vesting and other restrictions may be determined at the discretion of the board of directors, or their committee if so delegated, except that the exercise price per share of stock options may not be less than 100% of the fair market value of the share of common stock on the date of grant, the term of stock options may not be greater than ten years for all grants, and for grantees holding more than 10% of the total combined voting power of all classes of stock, the term may not be greater than five years. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company granted options under the 2015 Plan until April 2016 when it was terminated as to future awards, although it continues to govern the terms of options that remain outstanding under the 2015 Plan. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;As of December&#160;31, 2022, a total of 3,785 shares of common stock are subject to options outstanding under the 2015 Plan and will become available under the 2016 Equity Incentive Plan (&#x201c;2016 Plan&#x201d;) to the extent the options are forfeited or lapse unexercised. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2016 Equity Incentive Plan &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The 2016 Plan became effective in April 2016 and serves as the successor to the 2015 Plan. Under the 2016 Plan, the Company may grant stock options, stock appreciation rights, restricted stock awards, restricted stock units, performance awards, and stock bonuses. The 2016 Plan provides for an initial reserve of 44,000 shares of common stock, plus 20,394 shares of common stock remaining under the 2015 Plan, and any share awards that subsequently are forfeited or lapse unexercised under the 2015 Plan. The shares reserved exclude shares of common stock reserved for issuance under the 2015 Plan. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In October 2018, the 2016 plan was amended to increase the number of shares of common stock reserved for issuance thereunder by 70,384 shares, extend the term of the 2016 Plan through August 7, 2028, and provide for an automatic increase in the number of shares reserved for issuance thereunder on January&#160;1 of each year for the remaining term of the plan equal to (a) 4.0% of the number of issued and outstanding shares of common stock on December&#160;31 of the immediately preceding year, or (b)&#160;a lesser amount as approved by the board each year. As a result of the operation of each of these provisions, on January&#160;1, 2022, 2021, and 2020, an additional 78,968, 76,734, and 46,535 shares, respectively, became available for issuance under the 2016 Plan. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;As of December&#160;31, 2022, the total number of shares reserved for issuance under the 2016 Plan was 432,725, of which 319,122 shares were subject to outstanding option awards and restricted unit awards. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2018 Equity Inducement Plan &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In February 2018, the board of directors approved and adopted the 2018 Equity Inducement Plan (&#x201c;2018 Plan&#x201d;), which became effective on the same date. The board of directors approved an initial reserve of 44,000 shares of common stock to be used exclusively for individuals who were not previously employees or directors, or following a bona fide period of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employment,&lt;/div&gt; as an inducement material to the individual entering into employment with the Company. Nonqualified stock options or restricted stock units may be granted under the 2018 Plan at the discretion of the Compensation Committee or the board of directors. The Company did not seek stockholder approval of the 2018 Plan pursuant to Nasdaq Rule 5635(c)(4). &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;As of December&#160;31, 2022, the total number of shares reserved for issuance under the 2018 Plan was 44,000, of which 12,440 shares were subject to outstanding option awards. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Under the 2016 Plan and 2018 Plan, the Company may grant stock-based awards with service conditions (&#x201c;service-based&#x201d; awards), performance conditions (&#x201c;performance-based&#x201d; awards), and market conditions (&#x201c;market-based&#x201d; awards). Service-based awards granted under the 2018 Plan, 2016 Plan, and 2015 Plan generally vest over four years and expire after ten years, although awards have been granted with vesting terms less than four years. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;CEO Inducement Grant &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In November 2022, the Company granted 75,393 &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-qualified&lt;/div&gt; stock options to the new Chief Executive Officer in a stand alone inducement grant. The first 25% of these options vest on the one year anniversary of the grant, and the remaining 75% vest in equal amounts over 48 months following the one year anniversary date and are exercisable for a term of ten years. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following table summarizes employee and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employee&lt;/div&gt; stock option activity for the year ended December&#160;31, 2022: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:55%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Shares&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Issuable&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Under&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Options&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Average&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Exercise&lt;br/&gt; Price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Average&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Remaining&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Contractual&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Term&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Aggregate&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Intrinsic&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(in years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(in&#160;thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Outstanding as of December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;264,303&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;189.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7.90&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;328&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Granted&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;235,199&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;45.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Exercised&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Forfeited&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(94,421&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;153.50&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Outstanding as of December&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;405,081&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;113.75&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.72&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Options vested and expected to vest as of December&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;397,772&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;112.50&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.78&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Options exercisable as of December&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;163,450&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;171.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4.93&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The aggregate intrinsic value of options outstanding, exercisable, vested and expected to vest were calculated as the difference between the exercise price of the options and the fair value of the Company&#x2019;s common stock as of the reporting date. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;For the years ended December&#160;31, 2022, 2021, and 2020, the weighted-average grant date fair value of options granted was $45.00, $124.00, and $117.00, respectively. No options were exercised in the year ended December&#160;31, 2022. The total intrinsic value of options exercised during the years ended December&#160;31, 2021, and 2020 was $0.7&#160;million and $0.4&#160;million, respectively. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;There were no stock options issued to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employees&lt;/div&gt; during the years ended December&#160;31, 2022, 2021, and 2020. For the year ended December&#160;31, 2020, 66 &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employee&lt;/div&gt; stock options vested in the period. For the years ended December&#160;31, 2022 and 2021, no &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employee&lt;/div&gt; stock options vested in the period. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2016 Employee Stock Purchase Plan &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The 2016 Employee Stock Purchase Plan (&#x201c;2016 ESPP&#x201d;) became effective in April 2016. A total of 6,600 shares of common stock were reserved for issuance under the 2016 ESPP. Eligible employees may purchase shares of common stock under the 2016 ESPP at 85% of the lower of the fair market value of the Company&#x2019;s common stock as of the first or the last day of each offering period. Employees are limited to contributing 15% of the employee&#x2019;s eligible compensation and may not purchase more than $25,000 of stock during any calendar year. The 2016 ESPP will terminate ten years from the first purchase date under the plan, unless terminated earlier by the board of directors. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In June 2018, the 2016 ESPP was amended to provide for an automatic annual increase in the number of shares reserved for issuance thereunder on January&#160;1 of each year for the remaining term of the year equal to (a) 1.0% of the number of issued and outstanding shares of common stock on December&#160;31 of the immediately preceding year, or (b)&#160;a lesser amount as approved by the board of directors each year. As a result of the operation of this provision, on January&#160;1, 2022, 2021 and 2020, an additional 19,742, 19,183, and 11,633 shares, respectively, became available for issuance under the 2016 ESPP. As of December&#160;31, 2022, the reserve remaining and available for future issuance under the 2016 ESPP was 48,665 shares. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In February 2023, the 2016 ESPP was amended to increase the maximum shares purchased during any one period from 80 shares to 400 shares or a lesser amount determined by the board of directors. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Restricted Common Stock Units &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company granted 9,128 restricted stock units (&#x201c;RSUs&#x201d;) during the year ended December&#160;31, 2020 to certain employees with regulatory, commercial, and clinical milestones in addition to a service condition. There were no RSUs granted for the years ended December&#160;31, 2022 and 2021. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;As of December&#160;31, 2022, the performance conditions of the granted RSUs were not probable of being achieved. If and when the performance milestones are deemed probable of being achieved within the required time frame, the Company may recognize up to $1.2&#160;million of stock-based compensation for the remaining unvested RSUs as of December&#160;31, 2022. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following table summarizes employee restricted stock activity for the year ended December&#160;31, 2022: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:71%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt; Average&#160;Grant&lt;br/&gt; Date&#160;Fair&#160;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unvested restricted stock units as of December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7,600&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;203.25&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Granted&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Vested&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Forfeited&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,940&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;203.25&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unvested restricted stock units as of December&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,660&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;203.25&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;There were no RSUs granted to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employees&lt;/div&gt; during the years ended December&#160;31, 2022, 2021, and 2020. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock-Based Compensation Expense &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Total stock-based compensation expense recognized from the Company&#x2019;s equity incentive plans, 2018 Plan, and the 2016 ESPP for the years ended December&#160;31, 2022, 2021, and 2020 was as follows (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:47%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="22" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Employees&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Non-&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Employees&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Employees&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Non-&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Employees&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Employees&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Non-&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Employees&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Research and development&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,591&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,723&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,168&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;36&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;General and administrative&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,520&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,315&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,052&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total stock-based compensation expense&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7,111&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8,038&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,220&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;36&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;No related tax benefits were recognized for the years ended December&#160;31, 2022, 2021, and 2020 (see Note 11). &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The employee and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employee&lt;/div&gt; awards contain both performance and service-based vesting conditions. No expense was recognized for the unvested employee and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employee&lt;/div&gt; awards with only a performance condition for the years ended December&#160;31, 2022, 2021, and 2020. The performance-based vesting conditions represent specific performance targets. Compensation expense for employee and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employee&lt;/div&gt; share-based payment awards with performance conditions is recognized when the performance condition is deemed probable of achievement. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;As of December&#160;31, 2022, the Company had an aggregate of $11.6&#160;million of unrecognized stock-based compensation expense for options outstanding, which is expected to be recognized over a weighted average period of 1.6 years. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In determining the fair value of the stock-based awards, the Company uses the Black-Scholes option-pricing model and assumptions discussed below. Each of these inputs is subjective and generally requires significant judgment to determine. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected Term &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company&#x2019;s expected term represents the period that the Company&#x2019;s stock-based awards are expected to be outstanding and is determined using the simplified method (based on the midpoint between the vesting date and the end of the contractual term). The Company utilizes this method due to lack of historical exercise data and the plain-vanilla nature of the Company&#x2019;s stock-based awards. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected Volatility &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Since the Company was privately held through April 2016, it alone does not have the relevant company-specific historical data to support its expected volatility. As such, the Company has used an average of expected volatilities based on the volatilities of a representative group of publicly traded biopharmaceutical companies over a period equal to the expected term of the stock option grants. Subsequent to the Company&#x2019;s initial public offering, it began to consider the Company&#x2019;s own historic volatility. However, due to its limited history as a public company, the Company still uses peer company data to assist in this analysis. For purposes of identifying comparable companies, the Company selected companies with comparable characteristics to it, including enterprise value, risk profiles, position within the industry, and with historical share price information sufficient to meet the expected life of the stock-based awards. The historical volatility data was computed using the daily closing prices for the selected companies&#x2019; shares during the equivalent period of the calculated expected term of the stock-based awards. The Company intends to consistently apply this process using the same or similar comparable entities until a sufficient amount of historical information regarding the volatility of the Company&#x2019;s own share price becomes available. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Risk-Free Interest Rate &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of option. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected Dividend &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company has never paid dividends on its common stock and has no plans to pay dividends on its common stock. Therefore, the Company used an expected dividend yield of zero. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Valuation of Stock Options and 2016 ESPP &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The fair value of the stock options granted under the 2018 Plan, 2016 Plan, 2015 Plan and the CEO inducement grant, as well as the shares available for purchase under the 2016 ESPP were determined using the Black-Scholes option-pricing model. The following table summarizes the weighted-average assumptions used in calculating the fair value of the awards: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:78%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year&#160;Ended&#160;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Stock Options Granted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected term (in years)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5.99&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.10&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected volatility&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;84&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;83&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;76&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Risk-free interest&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.93&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.88&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.06&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Dividend yield&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2016 ESPP&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected term (in years)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.49&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.50&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.50&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected volatility&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;84&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;86&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;76&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Risk-free interest&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.95&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.08&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.75&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Dividend yield&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="P03_01_2015To03_31_2015_MinimumMembersrtRangeAxis_TwoThousandAndFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_pure">1</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="P03_01_2015To03_31_2015_MaximumMembersrtRangeAxis_StockOptionMemberusgaapAwardTypeAxis_TwoThousandAndFifteenEquityIncentivePlanMemberusgaapPlanNameAxis">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <agle:GranteesWithMoreThanFiveYearsVestingTermPercent
      contextRef="P03_01_2015To03_31_2015_TwoThousandAndFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_pure">0.10</agle:GranteesWithMoreThanFiveYearsVestingTermPercent>
    <agle:MaximumVestingTermForMoreThanTenPercentGrantees contextRef="P03_01_2015To03_31_2015_TwoThousandAndFifteenEquityIncentivePlanMemberusgaapPlanNameAxis">P5Y</agle:MaximumVestingTermForMoreThanTenPercentGrantees>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease
      contextRef="P01_01_2022To12_31_2022_TwoThousandAndFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">3785</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="PAsOn04_30_2016_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">44000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="PAsOn04_30_2016_TwoThousandAndFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">20394</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <agle:IncreaseInCommonStockCapitalSharesReservedForFutureIssuance
      contextRef="P10_01_2018To10_31_2018_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">70384</agle:IncreaseInCommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="P10_01_2018To10_31_2018_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis">2028-08-07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <agle:AnnualPercentageOfAdditionalSharesWhichEqualsToIssuedAndOutstandingShares
      contextRef="P01_01_2022To12_31_2022_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="3"
      unitRef="Unit_pure">0.04</agle:AnnualPercentageOfAdditionalSharesWhichEqualsToIssuedAndOutstandingShares>
    <agle:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant
      contextRef="PAsOn01_01_2022_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">78968</agle:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant>
    <agle:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant
      contextRef="PAsOn01_01_2021_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">76734</agle:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant>
    <agle:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant
      contextRef="PAsOn01_01_2020_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">46535</agle:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn12_31_2022_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">432725</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn12_31_2022_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">319122</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="PAsOn02_28_2018_TwoThousandAndEighteenEquityInducementPlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">44000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn12_31_2022_TwoThousandAndEighteenEquityInducementPlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">44000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn12_31_2022_TwoThousandAndEighteenEquityInducementPlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">12440</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="P02_01_2018To02_28_2018_ServiceBasedAwardsMemberusgaapAwardTypeAxis_TwoThousandAndFifteenAndTwoThousandAndSixteenEquityIncentivePlanAndTwoThousandAndEighteenEquityInducementPlanMemberusgaapPlanNameAxis">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="P02_01_2018To02_28_2018_ServiceBasedAwardsMemberusgaapAwardTypeAxis_TwoThousandAndFifteenAndTwoThousandAndSixteenEquityIncentivePlanAndTwoThousandAndEighteenEquityInducementPlanMemberusgaapPlanNameAxis">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="P02_01_2018To02_28_2018_MaximumMembersrtRangeAxis_ServiceBasedAwardsMemberusgaapAwardTypeAxis_TwoThousandAndFifteenAndTwoThousandAndSixteenEquityIncentivePlanAndTwoThousandAndEighteenEquityInducementPlanMemberusgaapPlanNameAxis">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="P11_01_2022To11_30_2022_NewChiefExecutiveOfficerMembersrtTitleOfIndividualAxis_NonQualifiedStockOptionsMemberusgaapAwardTypeAxis"
      decimals="-6"
      unitRef="Unit_shares">75393000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <agle:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodOfFirstTwentyFivePercent contextRef="P11_01_2022To11_30_2022_NewChiefExecutiveOfficerMembersrtTitleOfIndividualAxis_NonQualifiedStockOptionsMemberusgaapAwardTypeAxis">P1Y</agle:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodOfFirstTwentyFivePercent>
    <agle:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodOfRemainingSeventyFivePercent contextRef="P11_01_2022To11_30_2022_NewChiefExecutiveOfficerMembersrtTitleOfIndividualAxis_NonQualifiedStockOptionsMemberusgaapAwardTypeAxis">P48M</agle:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodOfRemainingSeventyFivePercent>
    <agle:ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsGrantedExercisablePeriod contextRef="P11_01_2022To11_30_2022_NewChiefExecutiveOfficerMembersrtTitleOfIndividualAxis_NonQualifiedStockOptionsMemberusgaapAwardTypeAxis">P10Y</agle:ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsGrantedExercisablePeriod>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following table summarizes employee and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employee&lt;/div&gt; stock option activity for the year ended December&#160;31, 2022: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:55%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Shares&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Issuable&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Under&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Options&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Average&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Exercise&lt;br/&gt; Price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Average&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Remaining&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Contractual&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Term&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Aggregate&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Intrinsic&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(in years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(in&#160;thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Outstanding as of December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;264,303&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;189.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7.90&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;328&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Granted&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;235,199&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;45.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Exercised&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Forfeited&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(94,421&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;153.50&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Outstanding as of December&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;405,081&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;113.75&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.72&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Options vested and expected to vest as of December&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;397,772&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;112.50&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.78&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Options exercisable as of December&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;163,450&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;171.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4.93&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn12_31_2021"
      decimals="0"
      unitRef="Unit_shares">264303</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2021"
      decimals="2"
      unitRef="Unit_USD_per_Share">189</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="P01_01_2021To12_31_2021">P7Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">328000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      unitRef="Unit_shares">235199</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2022To12_31_2022"
      decimals="2"
      unitRef="Unit_USD_per_Share">45</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      unitRef="Unit_shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      unitRef="Unit_USD_per_Share">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      unitRef="Unit_shares">94421</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2022To12_31_2022"
      decimals="2"
      unitRef="Unit_USD_per_Share">153.5</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn12_31_2022"
      decimals="0"
      unitRef="Unit_shares">405081</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2022"
      decimals="2"
      unitRef="Unit_USD_per_Share">113.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="P01_01_2022To12_31_2022">P6Y8M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">2000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="PAsOn12_31_2022"
      decimals="0"
      unitRef="Unit_shares">397772</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2022"
      decimals="2"
      unitRef="Unit_USD_per_Share">112.5</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="P01_01_2022To12_31_2022">P6Y9M10D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">2000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="PAsOn12_31_2022"
      decimals="0"
      unitRef="Unit_shares">163450</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2022"
      decimals="2"
      unitRef="Unit_USD_per_Share">171</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="P01_01_2022To12_31_2022">P4Y11M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="P01_01_2022To12_31_2022_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">124</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">117</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="P01_01_2022To12_31_2022_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis_NonEmployeesMembersrtTitleOfIndividualAxis"
      decimals="0"
      unitRef="Unit_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis_NonEmployeesMembersrtTitleOfIndividualAxis"
      decimals="0"
      unitRef="Unit_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="P01_01_2022To12_31_2022_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis_NonEmployeesMembersrtTitleOfIndividualAxis"
      decimals="0"
      unitRef="Unit_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis_NonEmployeesMembersrtTitleOfIndividualAxis"
      decimals="INF"
      unitRef="Unit_shares">66</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis_NonEmployeesMembersrtTitleOfIndividualAxis"
      decimals="0"
      unitRef="Unit_shares">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="P01_01_2022To12_31_2022_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis_NonEmployeesMembersrtTitleOfIndividualAxis"
      decimals="0"
      unitRef="Unit_shares">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn04_30_2016_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">6600</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate
      contextRef="P04_01_2016To04_30_2016_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_pure">0.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate
      contextRef="PAsOn04_30_2016_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_pure">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
    <agle:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAnnualFairMarketValuePerEmployee
      contextRef="P04_01_2016To04_30_2016_MaximumMembersrtRangeAxis_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_USD">25000</agle:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAnnualFairMarketValuePerEmployee>
    <agle:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalAnnualPercentageIncrease
      contextRef="P06_01_2018To06_30_2018_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="3"
      unitRef="Unit_pure">0.01</agle:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalAnnualPercentageIncrease>
    <agle:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant
      contextRef="PAsOn01_01_2022_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">19742</agle:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant>
    <agle:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant
      contextRef="PAsOn01_01_2021_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">19183</agle:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant>
    <agle:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant
      contextRef="PAsOn01_01_2020_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">11633</agle:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn12_31_2022_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">48665</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <agle:MaximumNumberOfSharesPurchasedUnderEmployeeStockPurchasePlan
      contextRef="P04_01_2016To04_30_2016_MaximumMembersrtRangeAxis_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">80</agle:MaximumNumberOfSharesPurchasedUnderEmployeeStockPurchasePlan>
    <agle:MaximumNumberOfSharesPurchasedUnderEmployeeStockPurchasePlan
      contextRef="P02_01_2023To02_28_2023_MaximumMembersrtRangeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">400</agle:MaximumNumberOfSharesPurchasedUnderEmployeeStockPurchasePlan>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="P01_01_2020To12_31_2020_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="INF"
      unitRef="Unit_shares">9128</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="P01_01_2022To12_31_2022_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="P01_01_2021To12_31_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="PAsOn12_31_2022_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">1200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following table summarizes employee restricted stock activity for the year ended December&#160;31, 2022: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:71%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt; Average&#160;Grant&lt;br/&gt; Date&#160;Fair&#160;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unvested restricted stock units as of December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7,600&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;203.25&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Granted&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Vested&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Forfeited&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,940&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;203.25&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unvested restricted stock units as of December&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,660&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;203.25&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="PAsOn12_31_2021_EmployeesMembersrtTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="INF"
      unitRef="Unit_shares">7600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="PAsOn12_31_2021_EmployeesMembersrtTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">203.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="P01_01_2022To12_31_2022_EmployeesMembersrtTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="P01_01_2022To12_31_2022_EmployeesMembersrtTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_USD_per_Share">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="P01_01_2022To12_31_2022_EmployeesMembersrtTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="P01_01_2022To12_31_2022_EmployeesMembersrtTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_USD_per_Share">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="P01_01_2022To12_31_2022_EmployeesMembersrtTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="INF"
      unitRef="Unit_shares">1940</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="P01_01_2022To12_31_2022_EmployeesMembersrtTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">203.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="PAsOn12_31_2022_EmployeesMembersrtTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="INF"
      unitRef="Unit_shares">5660</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="PAsOn12_31_2022_EmployeesMembersrtTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">203.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="P01_01_2021To12_31_2021_NonEmployeesMembersrtTitleOfIndividualAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="P01_01_2020To12_31_2020_NonEmployeesMembersrtTitleOfIndividualAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="P01_01_2022To12_31_2022_NonEmployeesMembersrtTitleOfIndividualAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Total stock-based compensation expense recognized from the Company&#x2019;s equity incentive plans, 2018 Plan, and the 2016 ESPP for the years ended December&#160;31, 2022, 2021, and 2020 was as follows (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:47%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="22" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Employees&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Non-&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Employees&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Employees&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Non-&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Employees&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Employees&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Non-&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Employees&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Research and development&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,591&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,723&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,168&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;36&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;General and administrative&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,520&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,315&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,052&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total stock-based compensation expense&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7,111&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8,038&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,220&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;36&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2022To12_31_2022_EmployeesMembersrtTitleOfIndividualAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="-3"
      unitRef="Unit_USD">2591000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2022To12_31_2022_NonEmployeesMembersrtTitleOfIndividualAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2021To12_31_2021_EmployeesMembersrtTitleOfIndividualAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="-3"
      unitRef="Unit_USD">2723000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2021To12_31_2021_NonEmployeesMembersrtTitleOfIndividualAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2020To12_31_2020_EmployeesMembersrtTitleOfIndividualAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="-3"
      unitRef="Unit_USD">2168000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2020To12_31_2020_NonEmployeesMembersrtTitleOfIndividualAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="-3"
      unitRef="Unit_USD">36000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2022To12_31_2022_EmployeesMembersrtTitleOfIndividualAxis_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="-3"
      unitRef="Unit_USD">4520000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2022To12_31_2022_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_NonEmployeesMembersrtTitleOfIndividualAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2021To12_31_2021_EmployeesMembersrtTitleOfIndividualAxis_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="-3"
      unitRef="Unit_USD">5315000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2021To12_31_2021_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_NonEmployeesMembersrtTitleOfIndividualAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2020To12_31_2020_EmployeesMembersrtTitleOfIndividualAxis_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="-3"
      unitRef="Unit_USD">4052000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2020To12_31_2020_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_NonEmployeesMembersrtTitleOfIndividualAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2022To12_31_2022_EmployeesMembersrtTitleOfIndividualAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="-3"
      unitRef="Unit_USD">7111000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2022To12_31_2022_NonEmployeesMembersrtTitleOfIndividualAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2021To12_31_2021_EmployeesMembersrtTitleOfIndividualAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="-3"
      unitRef="Unit_USD">8038000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2021To12_31_2021_NonEmployeesMembersrtTitleOfIndividualAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2020To12_31_2020_EmployeesMembersrtTitleOfIndividualAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="-3"
      unitRef="Unit_USD">6220000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2020To12_31_2020_NonEmployeesMembersrtTitleOfIndividualAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="-3"
      unitRef="Unit_USD">36000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="PAsOn12_31_2021_EmployeesAndNonEmployeesMembersrtTitleOfIndividualAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="PAsOn12_31_2020_EmployeesAndNonEmployeesMembersrtTitleOfIndividualAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="PAsOn12_31_2022_EmployeesAndNonEmployeesMembersrtTitleOfIndividualAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="PAsOn12_31_2022_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">11600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="P01_01_2022To12_31_2022_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis">P1Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="P01_01_2022To12_31_2022">The following table summarizes the weighted-average assumptions used in calculating the fair value of the awards: &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:78%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year&#160;Ended&#160;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Stock Options Granted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected term (in years)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5.99&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.10&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected volatility&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;84&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;83&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;76&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Risk-free interest&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.93&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.88&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.06&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Dividend yield&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2016 ESPP&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected term (in years)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.49&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.50&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.50&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected volatility&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;84&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;86&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;76&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Risk-free interest&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.95&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.08&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.75&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Dividend yield&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P01_01_2022To12_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis">P5Y11M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P01_01_2022To12_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_pure">0.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_pure">0.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_pure">0.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2022To12_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="4"
      unitRef="Unit_pure">0.0293</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="4"
      unitRef="Unit_pure">0.0088</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="4"
      unitRef="Unit_pure">0.0106</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P01_01_2022To12_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="INF"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="INF"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="INF"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P01_01_2022To12_31_2022_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis">P0Y5M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P01_01_2021To12_31_2021_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P01_01_2020To12_31_2020_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P01_01_2022To12_31_2022_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_pure">0.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P01_01_2021To12_31_2021_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_pure">0.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P01_01_2020To12_31_2020_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_pure">0.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2022To12_31_2022_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="4"
      unitRef="Unit_pure">0.0195</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2021To12_31_2021_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="4"
      unitRef="Unit_pure">0.0008</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2020To12_31_2020_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="4"
      unitRef="Unit_pure">0.0075</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P01_01_2022To12_31_2022_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P01_01_2021To12_31_2021_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P01_01_2020To12_31_2020_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;11. Defined Contribution Plan &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company sponsors a 401(k) retirement plan in which substantially all of its full-time employees are eligible to participate. Participants may contribute a percentage of their annual compensation to this plan, subject to statutory limitations. During the years ended December&#160;31, 2022, 2021, 2020, the Company provided $0.6&#160;million, $0.6&#160;million, and $0.5&#160;million, respectively, in contributions to the plan. &lt;/div&gt;</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="P01_01_2022To12_31_2022"
      decimals="-5"
      unitRef="Unit_USD">600000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="P01_01_2021To12_31_2021"
      decimals="-5"
      unitRef="Unit_USD">600000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="P01_01_2020To12_31_2020"
      decimals="-5"
      unitRef="Unit_USD">500000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;12. Income Taxes &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following table summarizes the (loss) income before income tax expense by jurisdiction for the periods indicated: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:64%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Domestic&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(84,113&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(65,940&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(80,893&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Foreign&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;162&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;280&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Loss before income tax expense&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(83,951&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(65,660&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(80,893&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;For the year ended December&#160;31, 2022, the Company recognized an income tax expense of $0.1&#160;million, related to foreign subsidiaries refund from research client and foreign subsidiaries income tax expense. For the year ended December&#160;31, 2021, the Company recognized an income tax expense of $0.1&#160;million, related to foreign subsidiaries income tax expense and the Texas margins tax. For the year ended December&#160;31, 2020, the Company recognized no provision or benefit from income taxes. The difference between the Company&#x2019;s provision for income taxes and the amounts computed by applying the statutory federal income tax rate to income before income taxes is as follows (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:64%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Tax provision derived by applying the federal statutory rate to income before income taxes&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(17,630&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(13,789&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(16,988&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Permanent differences and other&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,042&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,002&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;482&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Federal tax credits&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,559&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,815&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,905&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;State tax credits&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(640&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(152&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(251&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Effect of tax rate on foreign jurisdiction&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;42&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Change in the valuation allowance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;20,609&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16,900&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;20,662&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Income tax (benefit) expense&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(136&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;141&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The components of the deferred tax assets and liabilities consist of the following (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:70%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Deferred tax assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net operating loss carryforward&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;68,917&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;64,531&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Intangible assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;11,149&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;57&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Deferred revenue&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;566&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued expense&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;668&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;846&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Stock-based compensation&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,293&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,767&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Federal tax credits&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;21,914&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18,579&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;State tax credits&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,631&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;991&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;190&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;220&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total deferred tax assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;108,328&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;87,991&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Deferred tax liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Depreciable assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(676&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(948&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total deferred tax liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(676&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(948&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less: Valuation allowance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(107,652&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(87,043&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Deferred tax assets, net&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company has established a full federal and state valuation allowance equal to the net deferred tax assets due to uncertainties regarding the realization of the deferred tax asset based on the Company&#x2019;s lack of earnings history. The valuation allowance increased by $20.6&#160;million, $16.9&#160;million, and $20.7&#160;million during the years ended December&#160;31, 2022, 2021, and 2020, respectively, primarily due to continuing loss from operations. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;As of December&#160;31, 2022 and 2021, the Company had U.S. net operating loss carryforwards (&#x201c;NOL&#x201d;) of $328.2&#160;million and $307.3&#160;million, respectively. As of December&#160;31, 2022 and 2021, the Company had U.S. tax credit carryforwards of $21.9&#160;million and $18.6&#160;million, respectively, and state tax credit carryforwards of $1.6&#160;million and $1.0&#160;million, respectively. Of the net operating loss and tax credit carryforwards, $58.4&#160;million and $21.9&#160;million, respectively, will expire in 2033, if not utilized. Any remaining net operating loss will carry forward indefinitely and can be utilized to offset up to 80% of the taxable income in any tax year. The net &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;operating loss and credit carryforwards are subject to Internal Revenue Service adjustments until the statute closes on the year the net operating loss or tax credits are utilized. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company has not completed a study to assess whether an ownership change has occurred or whether there have been multiple ownership changes since the Company&#x2019;s formation due to the complexity and cost associated with such a study, and the fact that there may be additional such ownership changes in the future. If the Company has experienced an ownership change at any time since its formation, utilization of the NOL or research and development credit carryforwards would be subject to an annual limitation under Section&#160;&lt;div style="display:inline;"&gt;382&lt;/div&gt; or 383 of the Internal Revenue Code, which is determined by first multiplying the value of the Company&#x2019;s stock at the time of the ownership change by the applicable long-term, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;tax-exempt&lt;/div&gt; rate, and then could be subject to additional adjustments, as required. Additionally, the separate return limitation year (&#x201c;SRLY&#x201d;) rules may apply to losses of the Company&#x2019;s eight wholly owned U.S. subsidiary corporations. The SRLY rules limit the consolidated group&#x2019;s use of a subsidiary corporation&#x2019;s net operating losses to the amount of income generated by the subsidiary corporation after it becomes a member of the group. Any limitation may result in expiration of a portion of the NOL or research and development credit carryforwards before utilization. Further, until a study is completed and any limitation known, no amounts are being considered as an uncertain tax position or disclosed as an unrecognized tax benefit. Additionally, the Company does not expect any unrecognized tax benefits to change significantly over the next twelve months. Due to the existence of the valuation allowance, future changes in the Company&#x2019;s unrecognized tax benefits will not impact its effective tax rate. Any carryforwards that will expire prior to utilization as a result of such limitations will be removed from deferred tax assets with a corresponding reduction of the valuation allowance. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company is subject to examination by taxing authorities in its significant jurisdictions for the 2018 and subsequent years. However, due to NOL and tax attribute carryovers, the taxing authorities have the ability to adjust the NOLs and other tax attributes related to closed years. As of December&#160;31, 2022 and 2021, there were no amounts recorded for uncertain tax positions. As of December&#160;31, 2022, undistributed earnings of the Company&#x2019;s newly incorporated foreign subsidiaries are immaterial. Under the Global Intangible &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Low-Taxed&lt;/div&gt; Income (&#x201c;GILTI&#x201d;) provisions of the 2017 Tax Cuts and Jobs Act, U.S. income taxes have been incurred on the undistributed earnings of the foreign subsidiaries and therefore, the tax impact upon distribution is limited to state income and withholding taxes and is not material. &lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following table summarizes the (loss) income before income tax expense by jurisdiction for the periods indicated: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:64%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Domestic&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(84,113&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(65,940&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(80,893&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Foreign&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;162&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;280&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Loss before income tax expense&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(83,951&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(65,660&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(80,893&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-84113000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-65940000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-80893000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">162000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">280000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-83951000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-65660000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-80893000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2022To12_31_2022_ForeignCountryMemberusgaapIncomeTaxAuthorityAxis"
      decimals="-5"
      unitRef="Unit_USD">100000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2021To12_31_2021_ForeignCountryMemberusgaapIncomeTaxAuthorityAxis"
      decimals="-5"
      unitRef="Unit_USD">100000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="P01_01_2022To12_31_2022">The difference between the Company&#x2019;s provision for income taxes and the amounts computed by applying the statutory federal income tax rate to income before income taxes is as follows (in thousands): &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:64%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Tax provision derived by applying the federal statutory rate to income before income taxes&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(17,630&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(13,789&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(16,988&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Permanent differences and other&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,042&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,002&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;482&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Federal tax credits&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,559&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,815&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,905&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;State tax credits&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(640&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(152&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(251&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Effect of tax rate on foreign jurisdiction&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;42&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Change in the valuation allowance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;20,609&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16,900&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;20,662&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Income tax (benefit) expense&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(136&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;141&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-17630000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-13789000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-16988000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">1042000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1002000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">482000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <agle:IncomeTaxReconciliationTaxCostCredit
      contextRef="P01_01_2022To12_31_2022_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis"
      decimals="-3"
      unitRef="Unit_USD">-3559000</agle:IncomeTaxReconciliationTaxCostCredit>
    <agle:IncomeTaxReconciliationTaxCostCredit
      contextRef="P01_01_2021To12_31_2021_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis"
      decimals="-3"
      unitRef="Unit_USD">-3815000</agle:IncomeTaxReconciliationTaxCostCredit>
    <agle:IncomeTaxReconciliationTaxCostCredit
      contextRef="P01_01_2020To12_31_2020_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis"
      decimals="-3"
      unitRef="Unit_USD">-3905000</agle:IncomeTaxReconciliationTaxCostCredit>
    <agle:IncomeTaxReconciliationTaxCostCredit
      contextRef="P01_01_2022To12_31_2022_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis"
      decimals="-3"
      unitRef="Unit_USD">-640000</agle:IncomeTaxReconciliationTaxCostCredit>
    <agle:IncomeTaxReconciliationTaxCostCredit
      contextRef="P01_01_2021To12_31_2021_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis"
      decimals="-3"
      unitRef="Unit_USD">-152000</agle:IncomeTaxReconciliationTaxCostCredit>
    <agle:IncomeTaxReconciliationTaxCostCredit
      contextRef="P01_01_2020To12_31_2020_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis"
      decimals="-3"
      unitRef="Unit_USD">-251000</agle:IncomeTaxReconciliationTaxCostCredit>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">42000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-5000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">20609000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">16900000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">20662000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-136000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">141000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The components of the deferred tax assets and liabilities consist of the following (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:70%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Deferred tax assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net operating loss carryforward&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;68,917&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;64,531&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Intangible assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;11,149&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;57&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Deferred revenue&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;566&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued expense&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;668&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;846&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Stock-based compensation&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,293&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,767&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Federal tax credits&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;21,914&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18,579&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;State tax credits&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,631&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;991&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;190&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;220&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total deferred tax assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;108,328&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;87,991&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Deferred tax liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Depreciable assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(676&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(948&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total deferred tax liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(676&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(948&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less: Valuation allowance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(107,652&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(87,043&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Deferred tax assets, net&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">68917000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">64531000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">11149000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">57000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">566000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">668000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">846000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">3293000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2767000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="PAsOn12_31_2022_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis"
      decimals="-3"
      unitRef="Unit_USD">21914000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="PAsOn12_31_2021_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis"
      decimals="-3"
      unitRef="Unit_USD">18579000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="PAsOn12_31_2022_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis"
      decimals="-3"
      unitRef="Unit_USD">1631000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="PAsOn12_31_2021_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis"
      decimals="-3"
      unitRef="Unit_USD">991000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">190000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">220000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">108328000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">87991000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">676000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">948000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">676000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">948000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">107652000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">87043000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <agle:IncreaseInValuationPrimarilyDueToOperationLosses
      contextRef="P01_01_2022To12_31_2022"
      decimals="-5"
      unitRef="Unit_USD">20600000</agle:IncreaseInValuationPrimarilyDueToOperationLosses>
    <agle:IncreaseInValuationPrimarilyDueToOperationLosses
      contextRef="P01_01_2021To12_31_2021"
      decimals="-5"
      unitRef="Unit_USD">16900000</agle:IncreaseInValuationPrimarilyDueToOperationLosses>
    <agle:IncreaseInValuationPrimarilyDueToOperationLosses
      contextRef="P01_01_2020To12_31_2020"
      decimals="-5"
      unitRef="Unit_USD">20700000</agle:IncreaseInValuationPrimarilyDueToOperationLosses>
    <us-gaap:OperatingLossCarryforwards
      contextRef="PAsOn12_31_2022"
      decimals="-5"
      unitRef="Unit_USD">328200000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="PAsOn12_31_2021"
      decimals="-5"
      unitRef="Unit_USD">307300000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="PAsOn12_31_2022_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis"
      decimals="-5"
      unitRef="Unit_USD">21900000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="PAsOn12_31_2021_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis"
      decimals="-5"
      unitRef="Unit_USD">18600000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="PAsOn12_31_2022_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis"
      decimals="-5"
      unitRef="Unit_USD">1600000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="PAsOn12_31_2021_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis"
      decimals="-5"
      unitRef="Unit_USD">1000000</us-gaap:TaxCreditCarryforwardAmount>
    <agle:NetOperatingLossAndCreditCarryforwards
      contextRef="PAsOn12_31_2022"
      decimals="-5"
      unitRef="Unit_USD">58400000</agle:NetOperatingLossAndCreditCarryforwards>
    <agle:NetOperatingLossAndCreditCarryforwards
      contextRef="PAsOn12_31_2021"
      decimals="-5"
      unitRef="Unit_USD">21900000</agle:NetOperatingLossAndCreditCarryforwards>
    <agle:TaxCreditCarryforwardExpirationYear contextRef="P01_01_2022To12_31_2022_EarliestTaxYearMemberusgaapTaxPeriodAxis">2033</agle:TaxCreditCarryforwardExpirationYear>
    <agle:OperatingLossCarryforwardsExpirationYear contextRef="P01_01_2022To12_31_2022_EarliestTaxYearMemberusgaapTaxPeriodAxis">2033</agle:OperatingLossCarryforwardsExpirationYear>
    <agle:PercentageOfNetOperatingLossUtilizedToOffsetTaxableIncome
      contextRef="P01_01_2022To12_31_2022"
      decimals="2"
      unitRef="Unit_pure">0.80</agle:PercentageOfNetOperatingLossUtilizedToOffsetTaxableIncome>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="PAsOn12_31_2022"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="PAsOn12_31_2021"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:EarningsPerShareTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;13. Net Loss Per Share &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Basic and diluted net loss per share is computed by dividing net loss by the weighted-average number of common stock and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-funded&lt;/div&gt; warrants outstanding during the period. The &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-funded&lt;/div&gt; warrants are included in the computation of basic net loss per share as the exercise price is negligible and they are fully vested and exercisable. For periods in which the Company generated a net loss, the Company does not include the potential impact of dilutive securities in diluted net loss per share, as the impact of these items is anti-dilutive. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following weighted-average equity instruments were excluded from the calculation of diluted net loss per share because their effect would have been anti-dilutive for the periods presented: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:67%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Options to purchase common stock&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;346,331&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;264,858&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;201,977&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Unvested restricted stock units&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,982&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7,975&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,239&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following is a reconciliation of the shares used as the denominator for the calculation of basic and diluted net loss per share: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:61%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Weighted average common shares&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,307,668&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,956,933&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,608,952&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Weighted average &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-funded&lt;/div&gt; warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,063,563&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;672,851&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;525,917&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total basic and diluted weighted average shares&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,371,231&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,629,784&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,134,869&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following weighted-average equity instruments were excluded from the calculation of diluted net loss per share because their effect would have been anti-dilutive for the periods presented: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:67%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Options to purchase common stock&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;346,331&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;264,858&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;201,977&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Unvested restricted stock units&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,982&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7,975&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,239&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2022To12_31_2022_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="INF"
      unitRef="Unit_shares">346331</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="INF"
      unitRef="Unit_shares">264858</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="INF"
      unitRef="Unit_shares">201977</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2022To12_31_2022_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="INF"
      unitRef="Unit_shares">6982</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2021To12_31_2021_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="INF"
      unitRef="Unit_shares">7975</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2020To12_31_2020_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="INF"
      unitRef="Unit_shares">4239</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following is a reconciliation of the shares used as the denominator for the calculation of basic and diluted net loss per share: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:61%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Weighted average common shares&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,307,668&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,956,933&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,608,952&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Weighted average &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-funded&lt;/div&gt; warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,063,563&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;672,851&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;525,917&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total basic and diluted weighted average shares&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,371,231&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,629,784&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,134,869&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      unitRef="Unit_shares">2307668</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_shares">1956933</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_shares">1608952</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <agle:WeightedAverageNumberOfSharesPreFundedWarrants
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      unitRef="Unit_shares">1063563</agle:WeightedAverageNumberOfSharesPreFundedWarrants>
    <agle:WeightedAverageNumberOfSharesPreFundedWarrants
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_shares">672851</agle:WeightedAverageNumberOfSharesPreFundedWarrants>
    <agle:WeightedAverageNumberOfSharesPreFundedWarrants
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_shares">525917</agle:WeightedAverageNumberOfSharesPreFundedWarrants>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      unitRef="Unit_shares">3371231</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      unitRef="Unit_shares">3371231</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_shares">2629784</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_shares">2629784</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_shares">2134869</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_shares">2134869</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <agle:ReverseStockSplitTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;14. Reverse Stock Split &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On September&#160;8, 2023, the Company effected a reverse stock split of its common stock at a ratio of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1-for-25&lt;/div&gt;&lt;/div&gt; (the &#x201c;Reverse Split&#x201d;). Upon the effectiveness of the Reverse Split, (i)&#160;every 25 shares of outstanding common stock were reclassified and combined into one share of common stock, (ii)&#160;the number of shares of common stock for which each outstanding option and warrant to purchase common stock is exercisable was proportionally decreased and the exercise price of each outstanding option and warrant to purchase common stock proportionally increased, and (iii)&#160;the total number of authorized shares of common stock was proportionally decreased. No fractional shares were issued as a result of the Reverse Split. Accordingly, all share and per share amounts for all periods presented in these financial statements and notes thereto have been adjusted retroactively, where applicable, to reflect the Reverse Split and adjustment of the exercise price of each outstanding option and warrant as if the transaction had occurred as of the beginning of the earliest period presented. &lt;/div&gt;</agle:ReverseStockSplitTextBlock>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="P09_08_2023To09_08_2023">1-for-25</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits
      contextRef="P09_08_2023To09_08_2023"
      decimals="0"
      unitRef="Unit_shares">25</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="PAsOn06_22_2023"
      decimals="-3"
      unitRef="Unit_USD">3035000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets
      contextRef="PAsOn06_22_2023"
      decimals="-3"
      unitRef="Unit_USD">3035000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
      contextRef="PAsOn06_22_2023"
      decimals="-3"
      unitRef="Unit_USD">3035000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable
      contextRef="PAsOn06_22_2023"
      decimals="-3"
      unitRef="Unit_USD">20047000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities
      contextRef="PAsOn06_22_2023"
      decimals="-3"
      unitRef="Unit_USD">20047000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
      contextRef="PAsOn06_22_2023"
      decimals="-3"
      unitRef="Unit_USD">20047000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="PAsOn06_22_2023"
      decimals="-3"
      unitRef="Unit_USD">-17012000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef="P06_22_2023To06_22_2023">&lt;div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1. Description of the Business and Summary of Significant Accounting Policies &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On June&#160;22, 2023, Aeglea BioTherapeutics, Inc. (&#x201c;Aeglea&#x201d;, the &#x201c;Company&#x201d;, and &#x201c;our&#x201d;) acquired, in accordance with the terms of the Agreement and Plan of Merger (the &#x201c;Acquisition Agreement&#x201d;), the assets from Spyre Therapeutics, Inc (&#x201c;Spyre&#x201d;), a privately held biotechnology company advancing a pipeline of antibody therapeutics through a research and development option agreement (&#x201c;Paragon Agreement&#x201d;) with Paragon Therapeutics (&#x201c;Paragon&#x201d;). Spyre was incorporated on April&#160;28, 2023, for the purpose of holding rights to certain intellectual property being developed by Paragon. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On September&#160;8, 2023, Aeglea effected a reverse stock split of its Common Stock at a ratio of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1-for-25&lt;/div&gt;&lt;/div&gt; (the &#x201c;Reverse Split&#x201d;). Except as indicated otherwise, all share numbers related to our Common Stock disclosed in this statement have been adjusted on a post-Reverse Split basis. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The transaction (the &#x201c;Asset Acquisition&#x201d;) was structured as a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;stock-for-stock&lt;/div&gt;&lt;/div&gt; transaction pursuant to which all of Spyre&#x2019;s outstanding equity interests were exchanged based on a fixed exchange ratio of 0.5494488 to 1 for consideration from Aeglea of 517,809 shares of common stock and 364,887 shares of Series A &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-voting&lt;/div&gt; convertible preferred stock, par value of $0.0001 per share (&#x201c;Series A Preferred Stock&#x201d;) (convertible on a 40 to 1 basis) in addition to the assumption of outstanding and unexercised stock options to purchase 2,734 shares of common stock from the Amended and Restated Spyre 2023 Equity Incentive Plan. The Aeglea common stock and the Aeglea Series A Preferred Stock related to the Asset Acquisition were issued to the Spyre stockholders on July&#160;7, 2023. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company concluded that the arrangement meets the definition of an asset acquisition rather than a business combination, as substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset, Spyre&#x2019;s option (the &#x201c;Option&#x201d;) to exclusively license certain &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-process&lt;/div&gt; research and development (&#x201c;IPR&amp;amp;D&#x201d;). The Company determined that the Option to license IPR&amp;amp;D was a single asset as the Company&#x2019;s strategy relies on developing a portfolio of combination treatments that simultaneously address different mechanisms of irritable bowel disease. The Company also determined that the pipeline candidates within the portfolio are similar in nature and risk profile. In addition, the Company did not obtain any substantive processes, assembled workforce, or employees capable of producing outputs in connection with the Asset Acquisition. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company determined that the cost to acquire the asset was $113.2&#160;million, which was recorded as acquired IPR&amp;amp;D. The fair value of the consideration issued consisted of the 364,887 shares of Series A Preferred Stock (14,595,480 shares of common stock on an &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;as-converted&lt;/div&gt; basis) and 517,809 shares of common stock, valued at $291.08 per share and $7.277 per share, respectively. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Paragon Agreement provided for an annual equity grant of options to purchase 1% of the then outstanding shares of Spyre&#x2019;s common stock, on a fully diluted basis, on the last business day of each calendar year during the term of the Option, at the fair market value determined by the board of directors of Spyre (the &#x201c;Parapyre Option Obligation&#x201d;). In connection with the Asset Acquisition, the Company assumed the rights and obligations of Spyre under the Paragon Agreement, including the Parapyre Option Obligation. As a result, the Parapyre Option Obligation shall continue and Parapyre shall be entitled to receive the equivalent shares of common stock of the Company on the same terms. For additional information, see Note&#160;3. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Asset Acquisition costs are shown on the following table (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:80%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:10%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As&#160;of&#160;June&#160;22,&lt;br/&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Consideration transferred in Series A Preferred Stock and common stock&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;109,979&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Transaction costs incurred by Aeglea&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,197&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total cost to acquire asset&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;113,176&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company&#x2019;s allocation of the purchase price to net assets acquired is as follows (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:80%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:10%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As&#160;of&#160;June&#160;22,&lt;br/&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Acquired &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-process&lt;/div&gt; research and development&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;130,188&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Cash acquired&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,035&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(20,047&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total cost to acquire asset&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;113,176&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In accordance with ASC &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;730-10-25-2(c),&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; intangible assets used in research and developmental activities acquired in an asset acquisition should be expensed at the acquisition date if there is no alternative future use in other R&amp;amp;D projects or otherwise (i.e., if they have no economic value). The Company determined that product candidates pertaining to Spyre had no alternative future use at the time of acquisition and recorded $130.2&#160;million to Acquired &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In-process&lt;/div&gt; Research and Development Expenses as of the date of acquisition. The difference between this amount and the $113.2&#160;million cost to acquire Spyre represents the net liabilities assumed of $17.0&#160;million. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basis of Presentation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;As a result of acquiring Spyre, and based on the criteria in Rule &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3-05&lt;/div&gt; of the Securities and Exchange Commission&#x2019;s (the &#x201c;SEC&#x201d;) Regulation &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;S-X,&lt;/div&gt; the Company would ordinarily be required to file certain historical audited financial statements for Spyre and corresponding pro forma financial information pursuant to Article 11 of Regulation &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;S-X.&lt;/div&gt; Further, the historical financial statements could require the inclusion of predecessor entity information, if warranted. However, because the Company believes that Spyre&#x2019;s full financial statements are not material to the Company&#x2019;s shareholders and would be of limited value to investors, the Company requested relief from the SEC from the requirements under Rule &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3-05&lt;/div&gt; and Article 11 of Regulation &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;S-X&lt;/div&gt; to file audited financial statements and pro forma financial information in connection with the acquisition of Spyre. In response to the waiver request, the SEC provided the Company with a waiver that it could file an audited Statement of Assets Acquired and Liabilities Assumed from Spyre Therapeutics, Inc. on the basis of the allocation of the Company&#x2019;s purchase price as of the acquisition date of June&#160;22, 2023. Stand-alone full financial statements related to the assets acquired have not been prepared previously. This financial statement is not intended to be a complete presentation of the financial position, results of operations, or cash flows of Spyre. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company determined that it was the acquirer of Spyre under ASC 805 due to the relative voting rights in the combined entity, the composition of the governing body of the combined entity, and the composition of the senior management of the combined entity remaining relatively the same before and after the consummation of the transaction. The Company determined that the future conversion of the Series A Preferred Stock, if approved by the Company&#x2019;s voting shareholders, was an independent event based on it being outside of the control of the Company and therefore substantive. The Company did not succeed to substantially all of Paragon&#x2019;s business nor acquire from Paragon any separately identifiable line of business, the Company concluded that Paragon did not meet the definition of predecessor. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company evaluates acquisitions of assets and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first applying a screen test to determine whether substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If so, the transaction is accounted for as an asset acquisition. If not, further determination is required as to whether or not the Company has acquired inputs and processes that have the ability to create outputs, which would meet the definition of a business. Significant judgment is required in the application of the screen test to determine whether an acquisition is a business combination or an acquisition of assets. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company concluded that the arrangement meets the definition of an asset acquisition rather than a business combination, as substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset, Spyre&#x2019;s option to exclusively license IPR&amp;amp;D. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company measures and recognizes asset acquisitions that are not deemed to be business combinations based on the cost to acquire the assets, which includes &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-acquisition&lt;/div&gt; direct costs recorded in accrued professional and consulting fees. Goodwill is not recognized in asset acquisitions. When a transaction accounted for as an asset acquisition includes an IPR&amp;amp;D asset, the IPR&amp;amp;D asset is only capitalized if it has an alternative future use other than in a particular research and development project. Otherwise, the cost allocated to acquire an IPR&amp;amp;D asset with no alternative future use is charged to expense at the acquisition date. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company has not generated any product revenues and has not achieved profitable operations. There is no assurance that profitable operations will ever be achieved, and, if achieved, could be sustained on a continuing basis. In addition, development activities, clinical and nonclinical testing, and commercialization of the Company&#x2019;s product candidates will require significant additional financing before a commercial drug can be produced and marketed. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company is subject to a number of risks similar to other life science companies, including, but not limited to, risks related to the successful discovery, development, and commercialization of product candidates, raising additional capital, development of competing drugs and therapies, protection of proprietary technology and market acceptance of the Company&#x2019;s product candidates. As a result of these and other factors and the related uncertainties, there can be no assurance of the Company&#x2019;s future success. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In April 2023, the Board of Directors approved a restructuring of the Company&#x2019;s workforce pursuant to which the Company&#x2019;s workforce was reduced by approximately 83%, retaining approximately 10 employees. Additionally, the Company announced interim results from its ongoing Phase 1/2 clinical trial of pegtarviliase for the treatment of classical homocystinuria. Following a review of the interim results and other business considerations, the Company explored strategic alternatives with the goal of maximizing stockholder value, including possible business combinations and/or a divestiture of the Company&#x2019;s clinical programs. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On June&#160;22, 2023, the Company acquired the net liabilities from Spyre. Additionally, on June&#160;26, 2023, the Company completed a private placement of shares of Series A Preferred Stock and sold an aggregate of 721,452 shares of Series A Preferred Stock for an aggregate purchase price of approximately $210.0&#160;million before deducting approximately $12.7&#160;million placement agent and other offering expenses. In accordance with ASC &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;205-40,&lt;/div&gt; Going Concern, in connection with the preparation of the statement of assets acquired and liabilities assumed of Spyre, the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company&#x2019;s ability to continue as a going concern within one year after the date the financial statement is available to be issued. Our Series A Preferred Stock agreement requires us to seek stockholder approval for the conversion of the Series A Preferred Stock to Common Stock. The Company has agreed to hold a stockholders&#x2019; meeting to submit this matter to its stockholders for their consideration. In connection with this, the Company filed with the SEC a preliminary proxy statement and other relevant materials. The stockholder meeting has not occurred as of October&#160;6, 2023. If our stockholders do not timely approve the conversion of our Series A Preferred Stock, then the holders of our Series A Preferred Stock &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;are entitled to require us to settle their shares of Series A Preferred Stock for cash at a price per share equal to the fair value of the Series A Preferred Stock, as described in our Certificate of Designation relating to the Series&#160;A Preferred Stock. The cash redemption is not in our control and raises substantial doubt about our ability to continue as a going concern. The accompanying financial statement assumes the Company will continue as a going concern through the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Use of Estimates&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and certain financial statement disclosures. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets, liabilities, and equity and the amount of revenues and expenses. Actual results could differ significantly from those estimates. Key estimates that management considers in the preparation of the Company&#x2019;s financial statements relate to accrued option costs payable to Paragon and the valuation of consideration transferred. The consideration transferred in acquiring IPR&amp;amp;D in connection with the acquisition of Spyre was comprised of the Company&#x2019;s common stock and shares of Series A preferred stock. To determine the fair value of the equity transferred, the Company considered the per share value of its concurrent private financing transaction, which was an over-subscribed financing event involving a group of investors. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and Cash Equivalents&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;As of June&#160;22, 2023, Spyre held $3.0&#160;million in cash and cash equivalents, which consisted of a single deposit account denominated in U.S. dollars. At June&#160;22, 2023, U.S. cash deposits in excess of the Federal Deposit Insurance Corporation&#x2019;s insured limit were $2.8&#160;million. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued Liabilities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Accrued liabilities primarily consist of research initiation fees, reimbursable expenses under the Paragon Agreement for historical costs incurred by Paragon, professional and consulting fees, and the fair of assumed Parapyre Option Obligation. &lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="P09_08_2023To09_08_2023">1-for-25</us-gaap:StockholdersEquityReverseStockSplit>
    <agle:FixedExchangeRatio
      contextRef="PAsOn06_22_2023_AssetAcquisitionMemberusgaapAssetAcquisitionAxis"
      decimals="9"
      unitRef="Unit_pure">0.005494488</agle:FixedExchangeRatio>
    <agle:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares
      contextRef="P06_22_2023To06_22_2023_AssetAcquisitionMemberusgaapAssetAcquisitionAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">517809</agle:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares>
    <agle:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares
      contextRef="P06_22_2023To06_22_2023_AssetAcquisitionMemberusgaapAssetAcquisitionAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">364887</agle:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn06_22_2023_AssetAcquisitionMemberusgaapAssetAcquisitionAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="4"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockConvertibleConversionRatio
      contextRef="PAsOn06_22_2023_AssetAcquisitionMemberusgaapAssetAcquisitionAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_pure">40</us-gaap:PreferredStockConvertibleConversionRatio>
    <agle:OutstandingAndUnexercisedStockOptions
      contextRef="P06_22_2023To06_22_2023_AssetAcquisitionMemberusgaapAssetAcquisitionAxis_Spyre2023EquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">2734</agle:OutstandingAndUnexercisedStockOptions>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="P06_22_2023To06_22_2023"
      decimals="-5"
      unitRef="Unit_USD">113200000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <agle:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares
      contextRef="P06_22_2023To06_22_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis"
      decimals="INF"
      unitRef="Unit_shares">364887</agle:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares>
    <agle:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableSharesOfCommonStockOnAnAsConvertedBasis
      contextRef="P06_22_2023To06_22_2023_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis"
      decimals="INF"
      unitRef="Unit_shares">14595480</agle:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableSharesOfCommonStockOnAnAsConvertedBasis>
    <agle:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares
      contextRef="P06_22_2023To06_22_2023_CommonStockMemberusgaapEquityInterestIssuedOrIssuableByTypeAxis_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis"
      decimals="INF"
      unitRef="Unit_shares">517809</agle:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="PAsOn06_22_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">291.08</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="PAsOn06_22_2023_CommonStockMemberusgaapEquityInterestIssuedOrIssuableByTypeAxis_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis"
      decimals="3"
      unitRef="Unit_USD_per_Share">7.277</us-gaap:SharesIssuedPricePerShare>
    <agle:PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock
      contextRef="PAsOn06_22_2023_ParapyreOptionObligationMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_pure">0.01</agle:PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock>
    <us-gaap:AssetAcquisitionTableTextBlock contextRef="P06_22_2023To06_22_2023">&lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Asset Acquisition costs are shown on the following table (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:80%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:10%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As&#160;of&#160;June&#160;22,&lt;br/&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Consideration transferred in Series A Preferred Stock and common stock&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;109,979&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Transaction costs incurred by Aeglea&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,197&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total cost to acquire asset&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;113,176&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company&#x2019;s allocation of the purchase price to net assets acquired is as follows (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:80%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:10%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As&#160;of&#160;June&#160;22,&lt;br/&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Acquired &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-process&lt;/div&gt; research and development&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;130,188&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Cash acquired&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,035&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(20,047&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total cost to acquire asset&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;113,176&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:AssetAcquisitionTableTextBlock>
    <us-gaap:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable
      contextRef="P06_22_2023To06_22_2023_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis"
      decimals="-3"
      unitRef="Unit_USD">109979000</us-gaap:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable>
    <us-gaap:AssetAcquisitionConsiderationTransferredTransactionCost
      contextRef="P06_22_2023To06_22_2023_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis"
      decimals="-3"
      unitRef="Unit_USD">3197000</us-gaap:AssetAcquisitionConsiderationTransferredTransactionCost>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="P06_22_2023To06_22_2023_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis"
      decimals="-3"
      unitRef="Unit_USD">113176000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <agle:AcquiredInProcessResearchAndDevelopment
      contextRef="P06_22_2023To06_22_2023_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis"
      decimals="-3"
      unitRef="Unit_USD">130188000</agle:AcquiredInProcessResearchAndDevelopment>
    <us-gaap:CashAcquiredFromAcquisition
      contextRef="P06_22_2023To06_22_2023_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis"
      decimals="-3"
      unitRef="Unit_USD">3035000</us-gaap:CashAcquiredFromAcquisition>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="PAsOn06_22_2023_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis"
      decimals="-3"
      unitRef="Unit_USD">20047000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="P06_22_2023To06_22_2023_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis"
      decimals="-3"
      unitRef="Unit_USD">113176000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <agle:AcquiredInProcessResearchAndDevelopment
      contextRef="P06_22_2023To06_22_2023_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">130200000</agle:AcquiredInProcessResearchAndDevelopment>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="P06_22_2023To06_22_2023_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">113200000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <agle:AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="P06_22_2023To06_22_2023_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">17000000</agle:AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="P06_22_2023To06_22_2023">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basis of Presentation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;As a result of acquiring Spyre, and based on the criteria in Rule &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3-05&lt;/div&gt; of the Securities and Exchange Commission&#x2019;s (the &#x201c;SEC&#x201d;) Regulation &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;S-X,&lt;/div&gt; the Company would ordinarily be required to file certain historical audited financial statements for Spyre and corresponding pro forma financial information pursuant to Article 11 of Regulation &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;S-X.&lt;/div&gt; Further, the historical financial statements could require the inclusion of predecessor entity information, if warranted. However, because the Company believes that Spyre&#x2019;s full financial statements are not material to the Company&#x2019;s shareholders and would be of limited value to investors, the Company requested relief from the SEC from the requirements under Rule &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3-05&lt;/div&gt; and Article 11 of Regulation &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;S-X&lt;/div&gt; to file audited financial statements and pro forma financial information in connection with the acquisition of Spyre. In response to the waiver request, the SEC provided the Company with a waiver that it could file an audited Statement of Assets Acquired and Liabilities Assumed from Spyre Therapeutics, Inc. on the basis of the allocation of the Company&#x2019;s purchase price as of the acquisition date of June&#160;22, 2023. Stand-alone full financial statements related to the assets acquired have not been prepared previously. This financial statement is not intended to be a complete presentation of the financial position, results of operations, or cash flows of Spyre. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company determined that it was the acquirer of Spyre under ASC 805 due to the relative voting rights in the combined entity, the composition of the governing body of the combined entity, and the composition of the senior management of the combined entity remaining relatively the same before and after the consummation of the transaction. The Company determined that the future conversion of the Series A Preferred Stock, if approved by the Company&#x2019;s voting shareholders, was an independent event based on it being outside of the control of the Company and therefore substantive. The Company did not succeed to substantially all of Paragon&#x2019;s business nor acquire from Paragon any separately identifiable line of business, the Company concluded that Paragon did not meet the definition of predecessor. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company evaluates acquisitions of assets and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first applying a screen test to determine whether substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If so, the transaction is accounted for as an asset acquisition. If not, further determination is required as to whether or not the Company has acquired inputs and processes that have the ability to create outputs, which would meet the definition of a business. Significant judgment is required in the application of the screen test to determine whether an acquisition is a business combination or an acquisition of assets. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company concluded that the arrangement meets the definition of an asset acquisition rather than a business combination, as substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset, Spyre&#x2019;s option to exclusively license IPR&amp;amp;D. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company measures and recognizes asset acquisitions that are not deemed to be business combinations based on the cost to acquire the assets, which includes &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-acquisition&lt;/div&gt; direct costs recorded in accrued professional and consulting fees. Goodwill is not recognized in asset acquisitions. When a transaction accounted for as an asset acquisition includes an IPR&amp;amp;D asset, the IPR&amp;amp;D asset is only capitalized if it has an alternative future use other than in a particular research and development project. Otherwise, the cost allocated to acquire an IPR&amp;amp;D asset with no alternative future use is charged to expense at the acquisition date. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company has not generated any product revenues and has not achieved profitable operations. There is no assurance that profitable operations will ever be achieved, and, if achieved, could be sustained on a continuing basis. In addition, development activities, clinical and nonclinical testing, and commercialization of the Company&#x2019;s product candidates will require significant additional financing before a commercial drug can be produced and marketed. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company is subject to a number of risks similar to other life science companies, including, but not limited to, risks related to the successful discovery, development, and commercialization of product candidates, raising additional capital, development of competing drugs and therapies, protection of proprietary technology and market acceptance of the Company&#x2019;s product candidates. As a result of these and other factors and the related uncertainties, there can be no assurance of the Company&#x2019;s future success. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In April 2023, the Board of Directors approved a restructuring of the Company&#x2019;s workforce pursuant to which the Company&#x2019;s workforce was reduced by approximately 83%, retaining approximately 10 employees. Additionally, the Company announced interim results from its ongoing Phase 1/2 clinical trial of pegtarviliase for the treatment of classical homocystinuria. Following a review of the interim results and other business considerations, the Company explored strategic alternatives with the goal of maximizing stockholder value, including possible business combinations and/or a divestiture of the Company&#x2019;s clinical programs. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On June&#160;22, 2023, the Company acquired the net liabilities from Spyre. Additionally, on June&#160;26, 2023, the Company completed a private placement of shares of Series A Preferred Stock and sold an aggregate of 721,452 shares of Series A Preferred Stock for an aggregate purchase price of approximately $210.0&#160;million before deducting approximately $12.7&#160;million placement agent and other offering expenses. In accordance with ASC &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;205-40,&lt;/div&gt; Going Concern, in connection with the preparation of the statement of assets acquired and liabilities assumed of Spyre, the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company&#x2019;s ability to continue as a going concern within one year after the date the financial statement is available to be issued. Our Series A Preferred Stock agreement requires us to seek stockholder approval for the conversion of the Series A Preferred Stock to Common Stock. The Company has agreed to hold a stockholders&#x2019; meeting to submit this matter to its stockholders for their consideration. In connection with this, the Company filed with the SEC a preliminary proxy statement and other relevant materials. The stockholder meeting has not occurred as of October&#160;6, 2023. If our stockholders do not timely approve the conversion of our Series A Preferred Stock, then the holders of our Series A Preferred Stock &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;are entitled to require us to settle their shares of Series A Preferred Stock for cash at a price per share equal to the fair value of the Series A Preferred Stock, as described in our Certificate of Designation relating to the Series&#160;A Preferred Stock. The cash redemption is not in our control and raises substantial doubt about our ability to continue as a going concern. The accompanying financial statement assumes the Company will continue as a going concern through the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business. &lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
      contextRef="P04_01_2023To04_30_2023"
      decimals="2"
      unitRef="Unit_pure">0.83</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent>
    <agle:NumberOfEmployeesRetained
      contextRef="P04_01_2023To04_30_2023"
      decimals="0"
      unitRef="Unit_employee">10</agle:NumberOfEmployeesRetained>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn06_26_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">721452</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="P06_26_2023To06_26_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-5"
      unitRef="Unit_USD">210000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <agle:PlacementAgentAndOtherOfferingExpenses
      contextRef="P06_26_2023To06_26_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-5"
      unitRef="Unit_USD">12700000</agle:PlacementAgentAndOtherOfferingExpenses>
    <us-gaap:UseOfEstimates contextRef="P06_22_2023To06_22_2023">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Use of Estimates&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and certain financial statement disclosures. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets, liabilities, and equity and the amount of revenues and expenses. Actual results could differ significantly from those estimates. Key estimates that management considers in the preparation of the Company&#x2019;s financial statements relate to accrued option costs payable to Paragon and the valuation of consideration transferred. The consideration transferred in acquiring IPR&amp;amp;D in connection with the acquisition of Spyre was comprised of the Company&#x2019;s common stock and shares of Series A preferred stock. To determine the fair value of the equity transferred, the Company considered the per share value of its concurrent private financing transaction, which was an over-subscribed financing event involving a group of investors. &lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="P06_22_2023To06_22_2023">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and Cash Equivalents&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;As of June&#160;22, 2023, Spyre held $3.0&#160;million in cash and cash equivalents, which consisted of a single deposit account denominated in U.S. dollars. At June&#160;22, 2023, U.S. cash deposits in excess of the Federal Deposit Insurance Corporation&#x2019;s insured limit were $2.8&#160;million. &lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn06_22_2023"
      decimals="-5"
      unitRef="Unit_USD">3000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:Cash
      contextRef="PAsOn06_22_2023_USBankingInstitutionMemberusgaapFinancialInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">2800000</us-gaap:Cash>
    <agle:AccruedLiabilitiesPolicyTextBlock contextRef="P06_22_2023To06_22_2023">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued Liabilities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Accrued liabilities primarily consist of research initiation fees, reimbursable expenses under the Paragon Agreement for historical costs incurred by Paragon, professional and consulting fees, and the fair of assumed Parapyre Option Obligation. &lt;/div&gt;</agle:AccruedLiabilitiesPolicyTextBlock>
    <agle:AccruedLiabilitiesTextBlock contextRef="P06_22_2023To06_22_2023">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2. Accrued liabilities &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In connection with the Asset Acquisition, the Company assumed the rights and obligations of Spyre under the Paragon Agreement. Under the Paragon Agreement, Spyre is obligated to compensate Paragon on a quarterly basis for its services performed under each research program based on the actual costs incurred with &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;mark-up&lt;/div&gt; costs pursuant to the terms of the Paragon Agreement. As of the date of the Asset Acquisition, Spyre had incurred total expenses of $19.0&#160;million under the Paragon Agreement since inception, inclusive of a $3.0&#160;million research initiation fee that was due upon signing of the Paragon Agreement and $16.0&#160;million of historical reimbursable expenses owed to Paragon. As of June&#160;22, 2023, $19.0&#160;million was unpaid and was assumed by the Company through the Asset Acquisition. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Accrued liabilities consist of the following (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:80%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:11%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As&#160;of&#160;June&#160;22,&lt;br/&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued option cost payable to Paragon&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18,987&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued professional and consulting fees&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;917&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Fair value of assumed Parapyre Option Obligation (Note&#160;3)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;143&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;20,047&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</agle:AccruedLiabilitiesTextBlock>
    <agle:RelatedPartyExpensesIncurredPriorToAssetAcquisition
      contextRef="P06_22_2023To06_22_2023_ParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">19000000</agle:RelatedPartyExpensesIncurredPriorToAssetAcquisition>
    <agle:ResearchInitiationFees
      contextRef="P06_22_2023To06_22_2023_ParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">3000000</agle:ResearchInitiationFees>
    <agle:ReimbursableResearchCosts
      contextRef="P06_22_2023To06_22_2023_ParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">16000000</agle:ReimbursableResearchCosts>
    <agle:RelatedPartyExpensesUnpaidPriorToAssetAcquisition
      contextRef="PAsOn06_22_2023_ParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">19000000</agle:RelatedPartyExpensesUnpaidPriorToAssetAcquisition>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="P06_22_2023To06_22_2023">&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Accrued liabilities consist of the following (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:80%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:11%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As&#160;of&#160;June&#160;22,&lt;br/&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued option cost payable to Paragon&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18,987&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued professional and consulting fees&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;917&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Fair value of assumed Parapyre Option Obligation (Note&#160;3)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;143&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;20,047&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <agle:AccruedOptionCostPayable
      contextRef="PAsOn06_22_2023"
      decimals="-3"
      unitRef="Unit_USD">18987000</agle:AccruedOptionCostPayable>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="PAsOn06_22_2023"
      decimals="-3"
      unitRef="Unit_USD">917000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:ProgramRightsObligations
      contextRef="PAsOn06_22_2023"
      decimals="-3"
      unitRef="Unit_USD">143000</us-gaap:ProgramRightsObligations>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent
      contextRef="PAsOn06_22_2023"
      decimals="-3"
      unitRef="Unit_USD">20047000</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AssetAcquisitionTextBlock contextRef="P06_22_2023To06_22_2023">&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3. Parapyre Option Obligation &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On June&#160;22, 2023, in connection with the Asset Acquisition, the Company assumed the Parapyre Option Obligation which provided for an annual equity grant of options for Parapyre to purchase 1% of the then outstanding shares of Spyre&#x2019;s common stock, on a fully diluted basis, on the last business day of each calendar year during the term of the Paragon Agreement, at the fair market value determined by the board of directors of Spyre. As a result of the Asset Acquisition the Parapyre Option Obligation shall continue and Parapyre shall be entitled to receive the equivalent shares of the Company with the same terms. The Parapyre Option Obligation is considered a Level&#160;2 liability based on observable market data for substantially the full term of the liabilities. The Parapyre Option Obligation is measured each period using a Black-Scholes model to estimate the fair value of the option grant. Changes in the fair value of the Parapyre Option Obligation are recorded as stock-based compensation within Research and development expenses for &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employees&lt;/div&gt; who provided &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-clinical&lt;/div&gt; testing services within Research and development expenses. As of June&#160;22, 2023, the estimated liability of the Parapyre Option Obligation was $0.1&#160;million and was included in accrued liabilities. &lt;/div&gt;</us-gaap:AssetAcquisitionTextBlock>
    <agle:PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock
      contextRef="PAsOn06_22_2023_ParapyreOptionObligationMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_pure">0.01</agle:PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock>
    <us-gaap:AssetAcquisitionContingentConsiderationLiabilityCurrent
      contextRef="PAsOn06_22_2023"
      decimals="-5"
      unitRef="Unit_USD">100000</us-gaap:AssetAcquisitionContingentConsiderationLiabilityCurrent>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="P06_22_2023To06_22_2023">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4. Related Party Transactions &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Paragon and Parapyre Holding LLC each beneficially owns less than 5% of the Company&#x2019;s capital stock through their respective holdings of Common Stock and Series A Preferred Stock of the Company. Fairmount Funds Management LLC (&#x201c;Fairmount&#x201d;) beneficially owns more than 5% of our capital stock, has two seats on the Company&#x2019;s board of directors and beneficially owns more than 5% of Paragon, which is a joint venture between Fairmount and Fair Journey Biologics. Fairmount has appointed Paragon&#x2019;s board of directors and has the contractual right to approve the appointment of any executive officers. Parapyre is an entity formed by Paragon as a vehicle to hold equity in Spyre in order to share profits with certain employees of Paragon. &lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="PAsOn06_22_2023_MaximumMembersrtRangeAxis_OwnershipInterestMemberusgaapRelatedPartyTransactionAxis_ParagonAndParapyreHoldingLlcMembersrtOwnershipAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="2"
      unitRef="Unit_pure">0.05</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="PAsOn06_22_2023_FairmountFundsManagementLlcMembersrtOwnershipAxis_MinimumMembersrtRangeAxis_OwnershipInterestMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="2"
      unitRef="Unit_pure">0.05</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <agle:RelatedPartyTransactionNumberOfBoardSeats
      contextRef="PAsOn06_22_2023"
      decimals="0"
      unitRef="Unit_BOARDSEAT">2</agle:RelatedPartyTransactionNumberOfBoardSeats>
    <agle:MinorityInterestOwnershipPercentageByNoncontrollingOwnersHeldInThirdParty
      contextRef="PAsOn06_22_2023_FairmountFundsManagementLlcMembersrtOwnershipAxis_MinimumMembersrtRangeAxis_OwnershipInterestMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="2"
      unitRef="Unit_pure">0.05</agle:MinorityInterestOwnershipPercentageByNoncontrollingOwnersHeldInThirdParty>
    <us-gaap:SubsequentEventsTextBlock contextRef="P06_22_2023To06_22_2023">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5. Subsequent Events &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company&#x2019;s management has evaluated subsequent events up to October&#160;6, 2023, the date the Statement of Assets Acquired and Liabilities Assumed from Spyre, Inc. was available to be issued. There have been no subsequent events that require recognition or disclosure in this financial statement except for the following described below. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On July&#160;7, 2023, the Company issued 517,809 shares of common stock and 364,887 shares of Series&#160;A Preferred Stock as part of its consideration transferred in connection with the Asset Acquisition. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On August&#160;8, 2023, the Company filed a preliminary proxy statement with the SEC to solicit approval of the conversion of the Series A Preferred Stock into shares of Common Stock in connection with the Asset acquisition, among other matters, at a special meeting of stockholders. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On September&#160;8, 2023, the Company&#x2019;s Board of Directors approved a reverse stock split of the Company&#x2019;s common stock, par value $0.0001 per share, at a ratio of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1-for-25&lt;/div&gt;&lt;/div&gt; and a reduction in the total number of authorized shares of Common Stock from 500,000,000 shares to 20,000,000 shares. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On September&#160;29, 2023, the Company amended the Paragon Agreement to amend and restate certain terms of the option grant pertaining to the Parapyre Option Obligation, including but not limited to (i)&#160;defining that the annual equity grant of options is based on the outstanding shares of Aeglea&#x2019;s common stock, (ii)&#160;establishing the grant date as the last business day of each applicable calendar year, and (iii)&#160;defining the term of the options granted is ten years. The liability related to the Parapyre Option Obligation will be recorded pursuant to the amended Paragon Agreement on a go forward basis. The Company determined that these amendments would not have materially impacted the liability as of June&#160;22, 2023. &lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <agle:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares
      contextRef="P07_07_2023To07_07_2023_CommonStockMemberusgaapEquityInterestIssuedOrIssuableByTypeAxis_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="0"
      unitRef="Unit_shares">517809</agle:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares>
    <agle:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares
      contextRef="P07_07_2023To07_07_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="0"
      unitRef="Unit_shares">364887</agle:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn09_08_2023_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="4"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="P09_08_2023To09_08_2023_SubsequentEventMemberusgaapSubsequentEventTypeAxis">1-for-25</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits
      contextRef="P09_08_2023To09_08_2023_MaximumMembersrtRangeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="INF"
      unitRef="Unit_shares">500000000</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
    <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits
      contextRef="P09_08_2023To09_08_2023_MinimumMembersrtRangeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="INF"
      unitRef="Unit_shares">20000000</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="P09_29_2023To09_29_2023_ParapyreOptionObligationMemberusgaapPlanNameAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">90592000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">34863000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="PAsOn09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">113007000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">20848000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:NontradeReceivablesCurrent
      contextRef="PAsOn09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">163000</us-gaap:NontradeReceivablesCurrent>
    <us-gaap:NontradeReceivablesCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">375000</us-gaap:NontradeReceivablesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="PAsOn09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">2187000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">6172000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">205949000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">62258000</us-gaap:AssetsCurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="PAsOn09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">1307000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">1553000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">3220000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">3430000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="PAsOn09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">9000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">683000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="PAsOn09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">207265000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">71144000</us-gaap:Assets>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="PAsOn09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">1678000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">677000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="PAsOn09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">7510000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">625000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="PAsOn09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">517000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="PAsOn09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">15861000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">12837000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccountsPayableOtherCurrent
      contextRef="PAsOn09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">19823000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:AccountsPayableOtherCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">44872000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">14656000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="PAsOn09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">20690000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">4004000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="PAsOn09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">2179000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="PAsOn09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">65562000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">20839000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="PAsOn09_30_2023"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="PAsOn12_31_2022"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="PAsOn12_31_2022_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="PAsOn09_30_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="PAsOn09_30_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">1086341</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="PAsOn12_31_2022_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="PAsOn09_30_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">1086339</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="PAsOn09_30_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">1086339</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="PAsOn12_31_2022_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="PAsOn12_31_2022_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="PAsOn09_30_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">387105000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="PAsOn12_31_2022_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn09_30_2023"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn09_30_2023"
      decimals="INF"
      unitRef="Unit_shares">8913659</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      unitRef="Unit_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn09_30_2023"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn09_30_2023"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="PAsOn09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn09_30_2023"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      unitRef="Unit_shares">20000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn09_30_2023"
      decimals="INF"
      unitRef="Unit_shares">20000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn09_30_2023"
      decimals="INF"
      unitRef="Unit_shares">4048687</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn09_30_2023"
      decimals="INF"
      unitRef="Unit_shares">4048687</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      unitRef="Unit_shares">2614014</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      unitRef="Unit_shares">2614014</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="PAsOn09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">7000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">6000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="PAsOn09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">455957000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">475971000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">-132000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-48000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">-701234000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-425624000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">-245402000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">50305000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">207265000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">71144000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P07_01_2023To09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P07_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">174000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">886000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">2161000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P07_01_2023To09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P07_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">174000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">886000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">2161000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="P07_01_2023To09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">24660000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="P07_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">11977000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">55822000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">44328000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P07_01_2023To09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">8584000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P07_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">6952000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">25874000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">23452000</us-gaap:GeneralAndAdministrativeExpense>
    <agle:AcquiredInProcessResearchAndDevelopment
      contextRef="P07_01_2023To09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">-298000</agle:AcquiredInProcessResearchAndDevelopment>
    <agle:AcquiredInProcessResearchAndDevelopment
      contextRef="P07_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">0</agle:AcquiredInProcessResearchAndDevelopment>
    <agle:AcquiredInProcessResearchAndDevelopment
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">130188000</agle:AcquiredInProcessResearchAndDevelopment>
    <agle:AcquiredInProcessResearchAndDevelopment
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">0</agle:AcquiredInProcessResearchAndDevelopment>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
      contextRef="P07_01_2023To09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">14609000</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
      contextRef="P07_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">14609000</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <us-gaap:OperatingExpenses
      contextRef="P07_01_2023To09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">18337000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="P07_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">18929000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">197275000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">67780000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="P07_01_2023To09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">-18337000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P07_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-18755000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">-196389000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-65619000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeNet
      contextRef="P07_01_2023To09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">1251000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="P07_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">288000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">2021000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">427000</us-gaap:InvestmentIncomeNet>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="P07_01_2023To09_30_2023_ForwardContractsMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="-3"
      unitRef="Unit_USD">-25360000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="P07_01_2022To09_30_2022_ForwardContractsMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="P01_01_2023To09_30_2023_ForwardContractsMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="-3"
      unitRef="Unit_USD">-83530000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="P01_01_2022To09_30_2022_ForwardContractsMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="P07_01_2023To09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">2342000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="P07_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">24000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">2262000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">25000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="P07_01_2023To09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">-21767000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="P07_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">312000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">-79247000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">452000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P07_01_2023To09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">-40104000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P07_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-18443000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">-275636000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-65167000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P07_01_2023To09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">3000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P07_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-209000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">-26000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-174000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="P07_01_2023To09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">-40107000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P07_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-18234000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">-275610000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-64993000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P07_01_2023To09_30_2023"
      decimals="2"
      unitRef="Unit_USD_per_Share">-9.34</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P07_01_2023To09_30_2023"
      decimals="2"
      unitRef="Unit_USD_per_Share">-9.34</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P07_01_2022To09_30_2022"
      decimals="2"
      unitRef="Unit_USD_per_Share">-4.84</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P07_01_2022To09_30_2022"
      decimals="2"
      unitRef="Unit_USD_per_Share">-4.84</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2023To09_30_2023"
      decimals="2"
      unitRef="Unit_USD_per_Share">-69.57</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2023To09_30_2023"
      decimals="2"
      unitRef="Unit_USD_per_Share">-69.57</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2022To09_30_2022"
      decimals="2"
      unitRef="Unit_USD_per_Share">-20.17</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2022To09_30_2022"
      decimals="2"
      unitRef="Unit_USD_per_Share">-20.17</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P07_01_2023To09_30_2023"
      decimals="0"
      unitRef="Unit_shares">4293812</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P07_01_2023To09_30_2023"
      decimals="0"
      unitRef="Unit_shares">4293812</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P07_01_2022To09_30_2022"
      decimals="0"
      unitRef="Unit_shares">3767918</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P07_01_2022To09_30_2022"
      decimals="0"
      unitRef="Unit_shares">3767918</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2023To09_30_2023"
      decimals="0"
      unitRef="Unit_shares">3961546</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2023To09_30_2023"
      decimals="0"
      unitRef="Unit_shares">3961546</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2022To09_30_2022"
      decimals="0"
      unitRef="Unit_shares">3222987</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2022To09_30_2022"
      decimals="0"
      unitRef="Unit_shares">3222987</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="P07_01_2023To09_30_2023_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">19400000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="P01_01_2023To09_30_2023_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">20800000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="P01_01_2022To09_30_2022_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="P07_01_2022To09_30_2022_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:NetIncomeLoss
      contextRef="P07_01_2023To09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">-40107000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P07_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-18234000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">-275610000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-64993000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="P07_01_2023To09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">-29000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="P07_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-38000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">-1000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-87000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="P07_01_2023To09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">-114000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="P07_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">74000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">-83000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-77000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="P07_01_2023To09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">-40250000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="P07_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-18198000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">-275694000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-65157000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="PAsOn12_31_2022_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="PAsOn12_31_2022_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">2614000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">6000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">475971000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-48000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-425624000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">50305000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="P01_01_2023To03_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">2000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="P01_01_2023To03_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">18000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">18000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="P01_01_2023To03_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">1709000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">1709000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="P01_01_2023To03_31_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">10000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">10000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="P01_01_2023To03_31_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">32000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">32000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2023To03_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-18422000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">-18422000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="PAsOn03_31_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="PAsOn03_31_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn03_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">2616000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">6000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">477698000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-6000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-444046000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">33652000</us-gaap:StockholdersEquity>
    <agle:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="P04_01_2023To06_30_2023"
      decimals="-3"
      unitRef="Unit_shares">721000</agle:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="P04_01_2023To06_30_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">197323000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets
      contextRef="P04_01_2023To06_30_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">3768000</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
    <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets
      contextRef="P04_01_2023To06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">3768000</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="P04_01_2023To06_30_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">624000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <agle:ContingentValueRightDistributionToCommonStockholders
      contextRef="P04_01_2023To06_30_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-29500000</agle:ContingentValueRightDistributionToCommonStockholders>
    <agle:ContingentValueRightDistributionToCommonStockholders
      contextRef="P04_01_2023To06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">-29500000</agle:ContingentValueRightDistributionToCommonStockholders>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="P04_01_2023To06_30_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">1775000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="P04_01_2023To06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">1775000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="P04_01_2023To06_30_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">18000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="P04_01_2023To06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">18000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="P04_01_2023To06_30_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-1000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="P04_01_2023To06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">-1000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="P04_01_2023To06_30_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-217081000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P04_01_2023To06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">-217081000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="PAsOn06_30_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_shares">721000</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="PAsOn06_30_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">197323000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn06_30_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">3240000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn06_30_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">6000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn06_30_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">453741000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn06_30_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">11000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn06_30_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-661127000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">-207369000</us-gaap:StockholdersEquity>
    <agle:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="P07_01_2023To09_30_2023"
      decimals="-3"
      unitRef="Unit_shares">365000</agle:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="P07_01_2023To09_30_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">189741000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <agle:TemporaryEquityFinancingCosts
      contextRef="P07_01_2023To09_30_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">41000</agle:TemporaryEquityFinancingCosts>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="P07_01_2023To09_30_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">518000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="P07_01_2023To09_30_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">1000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="P07_01_2023To09_30_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-1000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="P07_01_2023To09_30_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">281000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <agle:StockIssuedDuringPeriodSharesOptionsExercisedAndEmployeeStockOwnershipPlan
      contextRef="P07_01_2023To09_30_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">10000</agle:StockIssuedDuringPeriodSharesOptionsExercisedAndEmployeeStockOwnershipPlan>
    <agle:StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan
      contextRef="P07_01_2023To09_30_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">105000</agle:StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan>
    <agle:StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan
      contextRef="P07_01_2023To09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">105000</agle:StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="P07_01_2023To09_30_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">2112000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="P07_01_2023To09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">2112000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="P07_01_2023To09_30_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-29000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="P07_01_2023To09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">-29000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="P07_01_2023To09_30_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-114000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="P07_01_2023To09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">-114000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="P07_01_2023To09_30_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-40107000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P07_01_2023To09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">-40107000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="PAsOn09_30_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_shares">1086000</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="PAsOn09_30_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">387105000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn09_30_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">4049</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn09_30_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">7000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn09_30_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">455957000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn09_30_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-132000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn09_30_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-701234000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">-245402000</us-gaap:StockholdersEquity>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="PAsOn12_31_2021_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="PAsOn12_31_2021_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">1974000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">425765000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-20000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-341809000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">83941000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="P01_01_2022To03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">3000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="P01_01_2022To03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">184000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">184000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="P01_01_2022To03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">2101000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">2101000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="P01_01_2022To03_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-13000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-13000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="P01_01_2022To03_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-120000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-120000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2022To03_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-24436000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-24436000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="PAsOn03_31_2022_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="PAsOn03_31_2022_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">1977000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">428050000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-153000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-366245000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">61657000</us-gaap:StockholdersEquity>
    <agle:StockIssuedDuringPeriodSharesCommonStockAndPreFundedWarrantsRegisteredDirectOffering
      contextRef="P04_01_2022To06_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">430000</agle:StockIssuedDuringPeriodSharesCommonStockAndPreFundedWarrantsRegisteredDirectOffering>
    <agle:StockIssuedDuringPeriodValueCommonStockAndPreFundedWarrantsRegisteredDirectOffering
      contextRef="P04_01_2022To06_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">1000</agle:StockIssuedDuringPeriodValueCommonStockAndPreFundedWarrantsRegisteredDirectOffering>
    <agle:StockIssuedDuringPeriodValueCommonStockAndPreFundedWarrantsRegisteredDirectOffering
      contextRef="P04_01_2022To06_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">42872000</agle:StockIssuedDuringPeriodValueCommonStockAndPreFundedWarrantsRegisteredDirectOffering>
    <agle:StockIssuedDuringPeriodValueCommonStockAndPreFundedWarrantsRegisteredDirectOffering
      contextRef="P04_01_2022To06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">42873000</agle:StockIssuedDuringPeriodValueCommonStockAndPreFundedWarrantsRegisteredDirectOffering>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="P04_01_2022To06_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">40000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="P04_01_2022To06_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">2017000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="P04_01_2022To06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">2017000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="P04_01_2022To06_30_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-36000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="P04_01_2022To06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-36000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="P04_01_2022To06_30_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-31000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="P04_01_2022To06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-31000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="P04_01_2022To06_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-22323000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P04_01_2022To06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-22323000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="PAsOn06_30_2022_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="PAsOn06_30_2022_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn06_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">2447000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn06_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">6000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn06_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">472939000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn06_30_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-220000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn06_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-388568000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">84157000</us-gaap:StockholdersEquity>
    <agle:StockIssuedDuringPeriodSharesCommonStockAndPreFundedWarrantsRegisteredDirectOffering
      contextRef="P07_01_2022To09_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">10000</agle:StockIssuedDuringPeriodSharesCommonStockAndPreFundedWarrantsRegisteredDirectOffering>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="P07_01_2022To09_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-8000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="P07_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-8000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="P07_01_2022To09_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">3000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="P07_01_2022To09_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">38000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="P07_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">38000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="P07_01_2022To09_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">1566000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="P07_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">1566000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="P07_01_2022To09_30_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-38000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="P07_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-38000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="P07_01_2022To09_30_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">74000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="P07_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">74000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="P07_01_2022To09_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-18234000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P07_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-18234000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="PAsOn09_30_2022_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="PAsOn09_30_2022_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn09_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">2460000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn09_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">6000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn09_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">474535000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn09_30_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-184000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn09_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-406802000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">67555000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">-275610000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-64993000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">744000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">1182000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">8405000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">5684000</us-gaap:ShareBasedCompensation>
    <agle:AcquiredInProcessResearchAndDevelopment
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">130188000</agle:AcquiredInProcessResearchAndDevelopment>
    <agle:AcquiredInProcessResearchAndDevelopment
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">0</agle:AcquiredInProcessResearchAndDevelopment>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="P01_01_2023To09_30_2023_ContingentValueRightLiabilityMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="-3"
      unitRef="Unit_USD">1300000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="P01_01_2022To09_30_2022_ContingentValueRightLiabilityMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="P01_01_2023To09_30_2023_ForwardContractsMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="-3"
      unitRef="Unit_USD">-83530000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="P01_01_2022To09_30_2022_ForwardContractsMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">14609000</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <us-gaap:AssetImpairmentCharges
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">2580000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">-915000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">220000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">292000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">612000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">175000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">-18000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-351000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">-3310000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">2863000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">1001000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">859000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">575000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-897000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">-212000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-146000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">-2326000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-297000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">-4000000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-1293000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayable
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">-2115000</us-gaap:IncreaseDecreaseInOtherAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayable
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:IncreaseDecreaseInOtherAccountsPayable>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">-68874000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-62004000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:CashAcquiredFromAcquisition
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">3035000</us-gaap:CashAcquiredFromAcquisition>
    <us-gaap:CashAcquiredFromAcquisition
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:CashAcquiredFromAcquisition>
    <us-gaap:ProceedsFromSaleOfIntangibleAssets
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">15000000</us-gaap:ProceedsFromSaleOfIntangibleAssets>
    <us-gaap:ProceedsFromSaleOfIntangibleAssets
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:ProceedsFromSaleOfIntangibleAssets>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">38000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">475000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">112631000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">35000000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">21000000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">78046000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">-73121000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">43008000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">197364000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <agle:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfOfferingCosts
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">0</agle:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfOfferingCosts>
    <agle:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfOfferingCosts
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">42874000</agle:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfOfferingCosts>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">123000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">222000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">16000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">410000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">197471000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">42686000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">7000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-152000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">55483000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">23538000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">36416000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">16980000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">91899000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">40518000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:StockIssued1
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">189741000</us-gaap:StockIssued1>
    <us-gaap:StockIssued1
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:StockIssued1>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="P01_01_2023To09_30_2023">&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;1. The Company and Basis of Presentation &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Aeglea BioTherapeutics, Inc. (&#x201c;Aeglea&#x201d; or the &#x201c;Company&#x201d;) is a preclinical stage biotechnology company focused on developing next generation therapeutics for patients living with inflammatory bowel disease. The Company was formed as a Limited Liability Company (&#x201c;LLC&#x201d;) in Delaware on December&#160;16, 2013 under the name Aeglea BioTherapeutics Holdings, LLC and was converted from a Delaware LLC to a Delaware corporation on March&#160;10, 2015. The Company operates in one segment and has its principal offices in Waltham, Massachusetts. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On April&#160;12, 2023, based on the review of the inconclusive interim results from the Company&#x2019;s Phase 1/2 clinical trial of pegtarviliase for the treatment of classical homocystinuria and other business considerations, the Company announced that it had initiated a process to explore strategic alternatives to maximize stockholder value and engaged an independent exclusive financial advisor to support this process. In April 2023, the Company implemented a restructuring plan resulting in an approximate 83% reduction of the Company&#x2019;s existing headcount. On September&#160;8, 2023, Aeglea effected a reverse stock split of its common stock at a ratio of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1-for-25&lt;/div&gt;&lt;/div&gt; (the &#x201c;Reverse Split&#x201d;). All share numbers related to the Company&#x2019;s common stock disclosed in these financial statements have been adjusted on a post-Reverse Split basis. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On June&#160;22, 2023, the Company acquired, in accordance with the terms of the Agreement and Plan of Merger (the &#x201c;Acquisition Agreement&#x201d;), the assets from Spyre Therapeutics, Inc. (&#x201c;Spyre&#x201d;), as disclosed in Notes 7 and 8, a privately held biotechnology company advancing a pipeline of antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease through a research and development option agreement (&#x201c;Paragon Agreement&#x201d;) with Paragon Therapeutics (&#x201c;Paragon&#x201d;). The transaction was structured as a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;stock-for-stock&lt;/div&gt;&lt;/div&gt; transaction pursuant to which all of Spyre&#x2019;s outstanding equity interests were exchanged based on a fixed exchange ratio of 0.5494488 to 1 for consideration from Aeglea of 517,809 shares of common stock and 364,887 shares of Series A &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-voting&lt;/div&gt; convertible preferred stock, par value of $0.0001 per share (&#x201c;Series A Preferred Stock&#x201d;) (convertible on a 40 to 1 basis) in addition to the assumption of outstanding and unexercised stock options to purchase 2,734 shares of common stock from the Amended and Restated Spyre 2023 Equity Incentive Plan (the &#x201c;Asset Acquisition&#x201d;). The Aeglea common stock and Aeglea Series A Preferred Stock related to the Asset Acquisition were issued to the Spyre stockholders on July&#160;7, 2023. For additional information, see Notes 7 and 8. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In connection with the Asset Acquisition, on June&#160;26, 2023, the Company completed a private placement of shares of Series A Preferred Stock (the &#x201c;PIPE&#x201d;) to a group of investors (the &#x201c;Investors&#x201d;). The Company sold an aggregate of 721,452 shares of Series A Preferred Stock for an aggregate purchase price of approximately $210.0&#160;million before deducting approximately $12.7&#160;million in placement agent and other offering expenses (together with the Asset Acquisition, the &#x201c;Transactions&#x201d;). For additional information, see Note 9. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In connection with the Asset Acquisition and pursuant to a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-transferable&lt;/div&gt; contingent value right (&#x201c;CVR&#x201d;) agreement (the &#x201c;CVR Agreement&#x201d;) a CVR was distributed to each Aeglea stockholder of record as of the close of business on July&#160;3, 2023 (the &#x201c;Legacy Stockholders&#x201d;), but was not distributed to the holders of shares of common stock or Series A Preferred Stock issued to the former stockholders of Spyre or Investors in the Transactions. Holders of the CVRs will be entitled to receive cash payments from proceeds received by Aeglea for a three-year period, if any, related to the disposition or monetization of its legacy assets for a period of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;one-year&lt;/div&gt; following the closing of the Asset Acquisition. For additional information see Note 3. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Liquidity &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;As of September&#160;30, 2023, the Company had an accumulated deficit of $701.2&#160;million, and cash, cash equivalents, and marketable securities of $203.6&#160;million. The Company has not generated any product revenues &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;and has not achieved profitable operations. There can be no assurance that profitable operations will ever be achieved, and, if achieved, whether it can be sustained on a continuing basis. In addition, development activities, clinical and nonclinical testing, and commercialization of the Company&#x2019;s product candidates will require significant additional financing before a commercial drug can be produced and marketed. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company is subject to a number of risks similar to other life science companies, including, but not limited to, risks related to the successful discovery, development, and commercialization of product candidates, raising additional capital, development of competing drugs and therapies, protection of proprietary technology and market acceptance of the Company&#x2019;s product candidates. As a result of these and other factors and uncertainties, there can be no assurance of the Company&#x2019;s future success. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In April 2023, the Board of Directors (the &#x201c;Board&#x201d;) approved a restructuring of the Company&#x2019;s workforce pursuant to which the Company&#x2019;s workforce was reduced by approximately 83% and the Company retained approximately 10 employees. Following a review of the interim results from its ongoing Phase 1/2 clinical trial of pegtarviliase for the treatment of classical homocystinuria and other business considerations, the Company explored strategic alternatives with the goal of maximizing stockholder value, including possible business combinations and/or a divestiture of the Company&#x2019;s clinical programs. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On June&#160;22, 2023, the Company acquired, in accordance with the terms of the Acquisition Agreement, the net assets of Spyre, as disclosed in Notes 7 and 8. Additionally, the Company completed the PIPE. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In accordance with Accounting Standards Codification (&#x201c;ASC&#x201d;) &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;205-40,&lt;/div&gt; Going Concern, the Company has evaluated and determined that there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company&#x2019;s ability to continue as a going concern within one year after the date the accompanying condensed consolidated financial statements included in this Quarterly Report are issued. The Company&#x2019;s Series A Preferred Stock agreement requires it to seek stockholder approval for the conversion of the Series A Preferred Stock to common stock. The Company has agreed to hold a stockholders&#x2019; meeting to submit this matter to its stockholders for their consideration. In connection with this, the Company filed with the Securities and Exchange Commission (&#x201c;SEC&#x201d;) a definitive proxy statement and other relevant materials. The special meeting of stockholders is scheduled for November&#160;21, 2023. If the Company&#x2019;s stockholders do not timely approve the conversion of its Series A Preferred Stock into common stock, then the holders of its Series A Preferred Stock are entitled to require the Company to settle their shares of Series A Preferred Stock for cash at a price per share equal to the fair value of the Series A Preferred Stock, as described in the Certificate of Designation relating to the Series A Preferred Stock (see Note 9). The cash redemption is not in the Company&#x2019;s control and raises substantial doubt about the Company&#x2019;s ability to continue as a going concern. The accompanying condensed consolidated financial statements assume the Company will continue as a going concern through the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Unaudited Interim Financial Information &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The interim condensed consolidated financial statements included in this Quarterly Report on Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10-Q&lt;/div&gt; are unaudited. The unaudited interim financial statements have been prepared on the same basis as the annual financial statements and reflect, in the opinion of management, all adjustments of a normal and recurring nature that are necessary for a fair statement of the Company&#x2019;s financial position as of September&#160;30, 2023, and its results of operations for the three and nine months ended September&#160;30, 2023 and 2022, changes in convertible preferred stock and stockholders&#x2019; (deficit) equity for the three and nine months ended September&#160;30, 2023 and 2022, and cash flows for the nine months ended September&#160;30, 2023 and 2022. The results of operations for the three and nine months ended September&#160;30, 2023, are not necessarily indicative of the results to be expected for the year ending December&#160;31, 2023 or for any other future annual or interim period. The December&#160;31, 2022 balance sheet was derived from audited financial statements, but does not include all disclosures required by accounting principles generally accepted in the United States (&#x201c;U.S. GAAP&#x201d;). These financial statements should &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;be read in conjunction with the audited financial statements included in the Company&#x2019;s Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10-K&lt;/div&gt; for the year ended December&#160;31, 2022 (the &#x201c;Annual Report&#x201d;) as filed with &lt;div style="display:inline;"&gt;the &lt;/div&gt;SEC. &lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="P01_01_2023To09_30_2023"
      decimals="0"
      unitRef="Unit_SEGMENT">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
      contextRef="P04_01_2023To04_30_2023"
      decimals="2"
      unitRef="Unit_pure">0.83</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent>
    <agle:FixedExchangeRatio
      contextRef="PAsOn06_22_2023_AssetAcquisitionMemberusgaapAssetAcquisitionAxis"
      decimals="9"
      unitRef="Unit_pure">0.005494488</agle:FixedExchangeRatio>
    <agle:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares
      contextRef="P06_22_2023To06_22_2023_AssetAcquisitionMemberusgaapAssetAcquisitionAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">517809</agle:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares>
    <agle:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares
      contextRef="P06_22_2023To06_22_2023_AssetAcquisitionMemberusgaapAssetAcquisitionAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">364887</agle:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn06_22_2023_AssetAcquisitionMemberusgaapAssetAcquisitionAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="4"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockConvertibleConversionRatio
      contextRef="PAsOn06_22_2023_AssetAcquisitionMemberusgaapAssetAcquisitionAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_pure">40</us-gaap:PreferredStockConvertibleConversionRatio>
    <agle:OutstandingAndUnexercisedStockOptions
      contextRef="P06_22_2023To06_22_2023_AssetAcquisitionMemberusgaapAssetAcquisitionAxis_Spyre2023EquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">2734</agle:OutstandingAndUnexercisedStockOptions>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn06_26_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">721452</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="P06_26_2023To06_26_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-5"
      unitRef="Unit_USD">210000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <agle:PlacementAgentAndOtherOfferingExpenses
      contextRef="P06_26_2023To06_26_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-5"
      unitRef="Unit_USD">12700000</agle:PlacementAgentAndOtherOfferingExpenses>
    <agle:AssetAcquisitionStockholderPaymentPeriod contextRef="P06_22_2023To06_22_2023_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis">P3Y</agle:AssetAcquisitionStockholderPaymentPeriod>
    <agle:AssetAcquisitionCashPaymentThresholdPeriod contextRef="P06_22_2023To06_22_2023_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis">P1Y</agle:AssetAcquisitionCashPaymentThresholdPeriod>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn09_30_2023"
      decimals="-5"
      unitRef="Unit_USD">-701200000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="PAsOn09_30_2023"
      decimals="-5"
      unitRef="Unit_USD">203600000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
      contextRef="P04_01_2023To04_30_2023"
      decimals="2"
      unitRef="Unit_pure">0.83</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent>
    <agle:NumberOfEmployeesRetained
      contextRef="P04_01_2023To04_30_2023"
      decimals="0"
      unitRef="Unit_employee">10</agle:NumberOfEmployeesRetained>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="P01_01_2023To09_30_2023">&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;2. Summary of Significant Accounting Policies &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Other than policies noted below, there have been no significant changes from the significant accounting policies and estimates disclosed in Note 2 of the &#x201c;Notes to Consolidated Financial Statements&#x201d; included in our Annual Report on Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10-K&lt;/div&gt; for the year ended December&#160;31, 2022. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;These interim condensed consolidated financial statements have been prepared in accordance with U.S. GAAP and SEC instructions for interim financial information, and should be read in conjunction with the Company&#x2019;s Annual Report. Significant accounting policies and other disclosures normally provided have been omitted since such items are disclosed in the Company&#x2019;s Annual Report. The Company uses the same accounting policies in preparing quarterly and annual financial statements. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Convertible Preferred Stock Issued through PIPE &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company records shares of convertible preferred stock at their respective fair values on the dates of issuance, net of issuance costs. The Company has applied the guidance in ASC &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;480-10-S99-3A&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; as well as SEC Staff Announcement, Classification and Measurement of Redeemable Securities, and has therefore classified the Series A Preferred Stock outside of stockholders&#x2019; (deficit) equity because, if conversion to common stock is not approved by the stockholders, the Series A Preferred Stock will be redeemable at the option of the holders for cash equal to the closing price of the common stock on the last trading day prior to the holder&#x2019;s redemption request. The Company has determined that the conversion and redemption are outside of the Company&#x2019;s control. Additionally, the Company has determined the conversion and redemption features do not require bifurcation as derivatives. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Acquisitions &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company evaluates acquisitions of assets and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first applying a screen test to determine whether substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If so, the transaction is accounted for as an asset acquisition. If not, further determination is required as to whether or not the Company has acquired inputs and processes that have the ability to create outputs, which would meet the definition of a business. Significant judgment is required in the application of the test to determine whether an acquisition is a business combination or an acquisition of assets. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Acquisitions meeting the definition of business combinations are accounted for using the acquisition method of accounting, which requires that the purchase price be allocated to the net assets acquired at their respective fair values. In a business combination, any excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company measures and recognizes asset acquisitions that are not deemed to be business combinations based on the cost to acquire the assets, which includes &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-acquisition&lt;/div&gt; direct costs recorded in accrued professional and consulting fees. Goodwill is not recognized in asset acquisitions. When a transaction accounted for as an asset acquisition includes an &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-process&lt;/div&gt; research and development (&#x201c;IPR&amp;amp;D&#x201d;) asset, the IPR&amp;amp;D asset is only capitalized if it has an alternative future use other than in a particular research and development project. Otherwise, the cost allocated to acquire an IPR&amp;amp;D asset with no alternative future use is charged to expense at the acquisition date. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Contingent Value Rights &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company evaluates its contracts to determine if those contracts qualify as derivatives under ASC 815, Derivatives and Hedging (&#x201c;ASC 815&#x201d;). For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-valued&lt;/div&gt; at each reporting date. Any changes in fair value are recorded as other income or expense for each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; based on whether or not &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;net-cash&lt;/div&gt; settlement of the derivative instrument is probable within the next 12 months from the balance sheet date. The Company determined that certain contingent payments under the CVR Agreement qualified as derivatives under ASC 815, and as such, were recorded as a liability on the balance sheet. This value is then remeasured for future expected payout as well as the increase in fair value due to the time value of money. These gains or losses, if any, are recognized in the consolidated statements of operations and comprehensive loss within Other (expense) income, net. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company applies a scenario-based method and weighs them based on the possible achievement of certain milestones. The milestone payments are contingent on formal reimbursement decisions by national authorities in key European markets and pegzilarginase approval by the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;), among other events. This fair value measurement is based on significant inputs not observable in the market and thus represents a Level&#160;3 measurement as defined in ASC 820, Fair Value Measurement. The key assumptions used include the discount rate, probability of regulatory success, and reimbursement rates from certain government agencies. The estimated value of the CVR consideration is based upon available information and certain assumptions which the Company&#x2019;s management believes are reasonable under the circumstances. The ultimate payout under the CVRs may differ materially from the assumptions used in determining the fair value of the CVR consideration. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Use of Estimates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets, liabilities, and equity and the amount of revenues and expenses. Actual results could differ significantly from those estimates. The most significant estimates and assumptions that management considers in the preparation of the Company&#x2019;s financial statements relate to the valuation of consideration transferred in acquiring IPR&amp;amp;D; the discount rate, probabilities of success, and timing of estimated cash flows in the valuation of the CVR liability; inputs used in the Black-Scholes model for stock-based compensation expense; estimated future cash flows used in calculating the impairment of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; lease assets; and estimated cost to complete performance obligations related to revenue recognition. The consideration transferred in acquiring IPR&amp;amp;D in connection with the acquisition of Spyre was comprised of shares of the Company&#x2019;s common stock and shares of Series A Preferred Stock. To determine the fair value of the equity transferred, the Company considered the per share value of the PIPE, which was an over-subscribed financing event involving a group of accredited investors. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Recently Adopted Accounting Pronouncement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company early adopted the Financial Accounting Standards Board&#x2019;s Accounting Standards Update &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020-06,&lt;/div&gt; Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity (&#x201c;ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020-06&#x201d;),&lt;/div&gt; effective as of January&#160;1, 2023 using the modified retrospective method. Among other amendments, ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020-06&lt;/div&gt; eliminates the cash conversion and beneficial conversion feature models in ASC &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;470-20&lt;/div&gt; that required an issuer of certain convertible debt and preferred stock to separately account for embedded conversion features as a component of equity, as well as changes the accounting for diluted &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;earnings-per-share&lt;/div&gt;&lt;/div&gt; for convertible instruments and contracts that may be settled in cash or stock. Additionally, ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020-06&lt;/div&gt; requires the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;if-converted&lt;/div&gt; method, &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;which is more dilutive than the treasury stock method, be used for all convertible instruments. The Company applied ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020-06&lt;/div&gt; to all Series A Preferred Stock during fiscal year 2023, and, accordingly, the Company did not apply the cash conversion or beneficial conversion feature models in its analysis of the Series A &lt;div style="display:inline;"&gt;&lt;div style="display:inline;"&gt;Preferred &lt;/div&gt;&lt;/div&gt;Stock. &lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <agle:ConvertiblePreferredStockIssuedThroughPipePolicyTextBlock contextRef="P01_01_2023To09_30_2023">&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Convertible Preferred Stock Issued through PIPE &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company records shares of convertible preferred stock at their respective fair values on the dates of issuance, net of issuance costs. The Company has applied the guidance in ASC &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;480-10-S99-3A&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; as well as SEC Staff Announcement, Classification and Measurement of Redeemable Securities, and has therefore classified the Series A Preferred Stock outside of stockholders&#x2019; (deficit) equity because, if conversion to common stock is not approved by the stockholders, the Series A Preferred Stock will be redeemable at the option of the holders for cash equal to the closing price of the common stock on the last trading day prior to the holder&#x2019;s redemption request. The Company has determined that the conversion and redemption are outside of the Company&#x2019;s control. Additionally, the Company has determined the conversion and redemption features do not require bifurcation as derivatives. &lt;/div&gt;</agle:ConvertiblePreferredStockIssuedThroughPipePolicyTextBlock>
    <us-gaap:BusinessCombinationsPolicy contextRef="P01_01_2023To09_30_2023">&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Acquisitions &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company evaluates acquisitions of assets and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first applying a screen test to determine whether substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If so, the transaction is accounted for as an asset acquisition. If not, further determination is required as to whether or not the Company has acquired inputs and processes that have the ability to create outputs, which would meet the definition of a business. Significant judgment is required in the application of the test to determine whether an acquisition is a business combination or an acquisition of assets. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Acquisitions meeting the definition of business combinations are accounted for using the acquisition method of accounting, which requires that the purchase price be allocated to the net assets acquired at their respective fair values. In a business combination, any excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company measures and recognizes asset acquisitions that are not deemed to be business combinations based on the cost to acquire the assets, which includes &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-acquisition&lt;/div&gt; direct costs recorded in accrued professional and consulting fees. Goodwill is not recognized in asset acquisitions. When a transaction accounted for as an asset acquisition includes an &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-process&lt;/div&gt; research and development (&#x201c;IPR&amp;amp;D&#x201d;) asset, the IPR&amp;amp;D asset is only capitalized if it has an alternative future use other than in a particular research and development project. Otherwise, the cost allocated to acquire an IPR&amp;amp;D asset with no alternative future use is charged to expense at the acquisition date. &lt;/div&gt;</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:DerivativesPolicyTextBlock contextRef="P01_01_2023To09_30_2023">&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Contingent Value Rights &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company evaluates its contracts to determine if those contracts qualify as derivatives under ASC 815, Derivatives and Hedging (&#x201c;ASC 815&#x201d;). For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-valued&lt;/div&gt; at each reporting date. Any changes in fair value are recorded as other income or expense for each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; based on whether or not &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;net-cash&lt;/div&gt; settlement of the derivative instrument is probable within the next 12 months from the balance sheet date. The Company determined that certain contingent payments under the CVR Agreement qualified as derivatives under ASC 815, and as such, were recorded as a liability on the balance sheet. This value is then remeasured for future expected payout as well as the increase in fair value due to the time value of money. These gains or losses, if any, are recognized in the consolidated statements of operations and comprehensive loss within Other (expense) income, net. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company applies a scenario-based method and weighs them based on the possible achievement of certain milestones. The milestone payments are contingent on formal reimbursement decisions by national authorities in key European markets and pegzilarginase approval by the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;), among other events. This fair value measurement is based on significant inputs not observable in the market and thus represents a Level&#160;3 measurement as defined in ASC 820, Fair Value Measurement. The key assumptions used include the discount rate, probability of regulatory success, and reimbursement rates from certain government agencies. The estimated value of the CVR consideration is based upon available information and certain assumptions which the Company&#x2019;s management believes are reasonable under the circumstances. The ultimate payout under the CVRs may differ materially from the assumptions used in determining the fair value of the CVR consideration. &lt;/div&gt;</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="P01_01_2023To09_30_2023">&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Use of Estimates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets, liabilities, and equity and the amount of revenues and expenses. Actual results could differ significantly from those estimates. The most significant estimates and assumptions that management considers in the preparation of the Company&#x2019;s financial statements relate to the valuation of consideration transferred in acquiring IPR&amp;amp;D; the discount rate, probabilities of success, and timing of estimated cash flows in the valuation of the CVR liability; inputs used in the Black-Scholes model for stock-based compensation expense; estimated future cash flows used in calculating the impairment of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; lease assets; and estimated cost to complete performance obligations related to revenue recognition. The consideration transferred in acquiring IPR&amp;amp;D in connection with the acquisition of Spyre was comprised of shares of the Company&#x2019;s common stock and shares of Series A Preferred Stock. To determine the fair value of the equity transferred, the Company considered the per share value of the PIPE, which was an over-subscribed financing event involving a group of accredited investors. &lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="P01_01_2023To09_30_2023">&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Recently Adopted Accounting Pronouncement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company early adopted the Financial Accounting Standards Board&#x2019;s Accounting Standards Update &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020-06,&lt;/div&gt; Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity (&#x201c;ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020-06&#x201d;),&lt;/div&gt; effective as of January&#160;1, 2023 using the modified retrospective method. Among other amendments, ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020-06&lt;/div&gt; eliminates the cash conversion and beneficial conversion feature models in ASC &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;470-20&lt;/div&gt; that required an issuer of certain convertible debt and preferred stock to separately account for embedded conversion features as a component of equity, as well as changes the accounting for diluted &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;earnings-per-share&lt;/div&gt;&lt;/div&gt; for convertible instruments and contracts that may be settled in cash or stock. Additionally, ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020-06&lt;/div&gt; requires the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;if-converted&lt;/div&gt; method, &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;which is more dilutive than the treasury stock method, be used for all convertible instruments. The Company applied ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020-06&lt;/div&gt; to all Series A Preferred Stock during fiscal year 2023, and, accordingly, the Company did not apply the cash conversion or beneficial conversion feature models in its analysis of the Series A &lt;div style="display:inline;"&gt;&lt;div style="display:inline;"&gt;Preferred &lt;/div&gt;&lt;/div&gt;Stock. &lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="P01_01_2023To09_30_2023">&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;3. Fair Value Measurements &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company measures and reports certain financial instruments as assets and liabilities at fair value on a recurring basis. The following tables set forth the fair value of the Company&#x2019;s financial assets and liabilities at fair value on a recurring basis based on the three-tier fair value hierarchy (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:56%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;September&#160;30, 2023&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Level&#160;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Level&#160;2&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Level&#160;3&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Total&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Financial Assets:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Money market funds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;55,451&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;55,451&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Commercial paper&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;107,093&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;107,093&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Corporate bonds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;22,828&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;22,828&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total financial assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;55,451&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;129,921&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;185,372&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Liabilities:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Parapyre Option Obligation&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,952&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,952&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;CVR liability&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;28,200&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;28,200&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,952&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;28,200&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;31,152&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:12pt"&gt;&lt;/td&gt;
&lt;td colspan="16" style="height:12pt"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;December&#160;31, 2022&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Level&#160;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Level&#160;2&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Level&#160;3&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Total&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Financial Assets:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Money market funds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15,250&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15,250&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Commercial paper&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;23,641&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;23,641&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;U.S. government securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,230&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,230&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Corporate bonds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,732&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,732&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total financial assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15,250&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;31,603&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;46,853&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company measures the fair value of money market funds on quoted prices in active markets for identical assets or liabilities. The Level&#160;2 assets include commercial paper, U.S. government securities and corporate bonds and are valued based on quoted prices for similar assets in active markets and inputs other than quoted prices that are derived from observable market data. The Company evaluates transfers between levels at the end of each reporting period. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Parapyre Option Obligation (as defined in Note 6) is considered a Level&#160;2 liability based on observable market data for substantially the full term of the liability. The Parapyre Option Obligation is measured each period using a Black-Scholes model to estimate the fair value of the option grant. Changes in the fair value of the Parapyre Option Obligation are recorded as stock-based compensation within Research and development expenses for &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employees&lt;/div&gt; who provided &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-clinical&lt;/div&gt; testing services. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The CVR liability value is based on significant inputs not observable in the market such as estimated cash flows, estimated probabilities of success, and risk-adjusted discount rates, which represent a Level&#160;3 liability. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;As of December&#160;31, 2022, the Company had no financial liabilities outstanding measured at fair value. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Forward Contract Liability &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In connection with the Asset Acquisition, the Company entered into a contract for the issuance of 364,887 shares of Series A Preferred Stock as part of the consideration transferred. This forward contract was classified as &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;a liability because the underlying preferred shares were contingently redeemable. Further, the forward contract liability was considered a Level&#160;2 liability based on observable market data for substantially the full term of the liability and was initially measured at its estimated fair value on the transaction date based on the underlying price per share on an &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;as-converted&lt;/div&gt; basis of the Series A Preferred Stock issued in the PIPE. Subsequent remeasurement of the fair value of the forward contract liability through its settlement date was based on the market price of the Company&#x2019;s common stock, which represents the redemption value of the Series A Preferred Stock. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The fair value of the forward contract at the transaction date, June&#160;22, 2023, was $106.2&#160;million. The liability was settled with the issuance of the Series A Preferred Stock on July&#160;7, 2023 for $189.7&#160;million. For the three and nine months ended September&#160;30, 2023, $25.4&#160;million and $83.5&#160;million, respectively, was recorded as Other (expense) income in the consolidated statements of operations in connection with the change in fair value of the forward contract liability. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following table presents changes in the forward contract liability for the periods presented (in millions): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:86%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Forward&lt;br/&gt; Contract&lt;br/&gt; Liability&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Beginning balance as of June&#160;22, 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;106.2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Change in fair value&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;58.1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Ending balance as of June&#160;30, 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;164.3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Change in fair value&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;25.4&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Issuance of Series A Preferred Stock on July&#160;7, 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(189.7&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Ending balance as of September&#160;30, 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Parapyre Option Obligation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On June&#160;22, 2023, in connection with the Asset Acquisition, the Company assumed the Parapyre Option Obligation which provided for an annual equity grant of options for Parapyre Holding LLC (&#x201c;Parapyre&#x201d;) to purchase 1% of the then outstanding shares of Spyre&#x2019;s common stock, on a fully diluted basis, on the last business day of each calendar year during the term of the Paragon Agreement, at the fair market value determined by the board of directors of Spyre. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On September&#160;29, 2023, the Company amended the Paragon Agreement to amend and restate certain terms of the option grant pertaining to the Parapyre Option Obligation, including but not limited to (i)&#160;defining that the annual equity grant of options is based on the outstanding shares of Aeglea&#x2019;s common stock, (ii)&#160;establishing the grant date as the last business day of each applicable calendar year, and (iii)&#160;defining the term of the options granted as ten years. The liability related to the Parapyre Option Obligation will be recorded pursuant to the amended Paragon Agreement. As of September&#160;30, 2023, the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pro-rated&lt;/div&gt; estimated fair value of the options to be granted on December&#160;31, 2023, was approximately $3.0&#160;million, of which $0.1&#160;million was recognized as part of the liabilities assumed with the Asset Acquisition on June&#160;22, 2023. For the three and nine months ended September&#160;30, 2023, $2.7&#160;million and $2.9&#160;million, respectively, was recognized as stock compensation expense related to the Parapyre Option Obligation. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;CVR Liability &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In connection with the Asset Acquisition, a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-transferable&lt;/div&gt; contingent value right (a &#x201c;CVR&#x201d;) was distributed to Aeglea stockholders of record as of the close of business on July&#160;3, 2023, but was not distributed to holders of shares of Common Stock or Series A Preferred Stock issued to the Investors or former stockholders of Spyre in connection with the Transactions. Holders of the CVR will be entitled to receive certain cash payments from proceeds received by the Company for a three-year period, if any, related to the disposition or monetization of Aeglea&#x2019;s legacy assets for a period of one year following the closing of the Asset Acquisition. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The fair value of the CVR liability was determined using the probability weighted discounted cash flow method to estimate future cash flows associated with the sale of the legacy assets. Analogous to a dividend being declared/approved in one period and paid out in another, the liability was recorded at the date of approval, June&#160;22, 2023, as a common stock dividend, returning capital to the Legacy Stockholders. Changes in fair value of the liability will be recognized as a component of Other income (expense) in the condensed consolidated statement of operations and comprehensive loss in each reporting period. The liability value is based on significant inputs not observable in the market such as estimated cash flows, estimated probabilities of success, and risk-adjusted discount rates, which represent a Level&#160;3 measurement within the fair value hierarchy. The significant inputs used to estimate the fair value of the CVR liability were as follows: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 67%;"&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td style="width: 29%;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;September&#160;30, 2023&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Estimated cash flow dates&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;&lt;div style="display:inline;"&gt;11/28/23 &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;-&lt;/div&gt; 06/22/26&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Estimated probability of success&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;&lt;div style="display:inline;"&gt;27% - 100%&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Risk-adjusted discount rates&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;&lt;div style="display:inline;"&gt;7.14% - 7.57%&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The change in fair value between June&#160;30, 2023 and September&#160;30, 2023 was a $1.3&#160;million decrease, and was primarily driven by changes in the likelihood of a successful disposition of pegtarviliase, changes in the expected timing of achievement of certain milestones, updates to expenses and deductions, partially offset by changes in the likelihood of certain milestones related to the favorable Committee for Medicinal Products Human Use (&#x201c;CHMP&#x201d;) opinion received by Immedica Pharma AB (&#x201c;Immedica&#x201d;). &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following table presents changes in the CVR liability for the periods presented (in thousands): &lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:85%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;CVR&lt;br/&gt; Liability&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Beginning balance as of December&#160;31, 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Fair value at CVR issuance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;29,500&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Changes in the fair value of the CVR liability since issuance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,300&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Ending Balance as of September&#160;30, 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;28,200&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="P01_01_2023To09_30_2023">The following tables set forth the fair value of the Company&#x2019;s financial assets and liabilities at fair value on a recurring basis based on the three-tier fair value hierarchy (in thousands): &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:56%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;September&#160;30, 2023&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Level&#160;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Level&#160;2&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Level&#160;3&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Total&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Financial Assets:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Money market funds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;55,451&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;55,451&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Commercial paper&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;107,093&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;107,093&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Corporate bonds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;22,828&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;22,828&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total financial assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;55,451&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;129,921&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;185,372&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Liabilities:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Parapyre Option Obligation&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,952&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,952&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;CVR liability&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;28,200&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;28,200&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,952&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;28,200&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;31,152&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:12pt"&gt;&lt;/td&gt;
&lt;td colspan="16" style="height:12pt"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;December&#160;31, 2022&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Level&#160;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Level&#160;2&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Level&#160;3&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Total&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Financial Assets:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Money market funds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15,250&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15,250&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Commercial paper&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;23,641&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;23,641&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;U.S. government securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,230&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,230&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Corporate bonds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,732&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,732&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total financial assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15,250&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;31,603&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;46,853&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn09_30_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis"
      decimals="-3"
      unitRef="Unit_USD">55451000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn09_30_2023_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn09_30_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn09_30_2023_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis"
      decimals="-3"
      unitRef="Unit_USD">55451000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn09_30_2023_CommercialPaperMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn09_30_2023_CommercialPaperMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">107093000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn09_30_2023_CommercialPaperMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn09_30_2023_CommercialPaperMemberusgaapFairValueByAssetClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">107093000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn09_30_2023_CorporateBondSecuritiesMemberusgaapInvestmentTypeAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn09_30_2023_CorporateBondSecuritiesMemberusgaapInvestmentTypeAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">22828000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn09_30_2023_CorporateBondSecuritiesMemberusgaapInvestmentTypeAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn09_30_2023_CorporateBondSecuritiesMemberusgaapInvestmentTypeAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">22828000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn09_30_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">55451000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn09_30_2023_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">129921000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn09_30_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn09_30_2023_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">185372000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn09_30_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_ParapyreOptionObligationMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn09_30_2023_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_ParapyreOptionObligationMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      unitRef="Unit_USD">2952000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn09_30_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_ParapyreOptionObligationMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn09_30_2023_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_ParapyreOptionObligationMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      unitRef="Unit_USD">2952000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn09_30_2023_ContingentValueRightLiabilityMemberusgaapFairValueByLiabilityClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn09_30_2023_ContingentValueRightLiabilityMemberusgaapFairValueByLiabilityClassAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn09_30_2023_ContingentValueRightLiabilityMemberusgaapFairValueByLiabilityClassAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">28200000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn09_30_2023_ContingentValueRightLiabilityMemberusgaapFairValueByLiabilityClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">28200000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn09_30_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn09_30_2023_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">2952000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn09_30_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">28200000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn09_30_2023_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">31152000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis"
      decimals="-3"
      unitRef="Unit_USD">15250000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis"
      decimals="-3"
      unitRef="Unit_USD">15250000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">23641000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapFairValueByAssetClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">23641000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapCashAndCashEquivalentsAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapCashAndCashEquivalentsAxis"
      decimals="-3"
      unitRef="Unit_USD">4230000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapCashAndCashEquivalentsAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapCashAndCashEquivalentsAxis"
      decimals="-3"
      unitRef="Unit_USD">4230000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2022_CorporateBondSecuritiesMemberusgaapInvestmentTypeAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2022_CorporateBondSecuritiesMemberusgaapInvestmentTypeAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">3732000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2022_CorporateBondSecuritiesMemberusgaapInvestmentTypeAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2022_CorporateBondSecuritiesMemberusgaapInvestmentTypeAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">3732000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">15250000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">31603000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">46853000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn12_31_2022"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <agle:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares
      contextRef="P06_22_2023To06_22_2023_AssetAcquisitionMemberusgaapAssetAcquisitionAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">364887</agle:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn06_22_2023_ForwardContractsMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="-5"
      unitRef="Unit_USD">106200000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="P07_07_2023To07_07_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-5"
      unitRef="Unit_USD">189700000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="P07_01_2023To09_30_2023_ForwardContractsMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="-5"
      unitRef="Unit_USD">-25400000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="P01_01_2023To09_30_2023_ForwardContractsMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="-5"
      unitRef="Unit_USD">-83500000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="P01_01_2023To09_30_2023">&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following table presents changes in the forward contract liability for the periods presented (in millions): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:86%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Forward&lt;br/&gt; Contract&lt;br/&gt; Liability&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Beginning balance as of June&#160;22, 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;106.2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Change in fair value&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;58.1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Ending balance as of June&#160;30, 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;164.3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Change in fair value&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;25.4&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Issuance of Series A Preferred Stock on July&#160;7, 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(189.7&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Ending balance as of September&#160;30, 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following table presents changes in the CVR liability for the periods presented (in thousands): &lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:85%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;CVR&lt;br/&gt; Liability&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Beginning balance as of December&#160;31, 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Fair value at CVR issuance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;29,500&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Changes in the fair value of the CVR liability since issuance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,300&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Ending Balance as of September&#160;30, 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;28,200&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn06_22_2023_ForwardContractsMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="-5"
      unitRef="Unit_USD">106200000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="P06_23_2023To06_30_2023_ForwardContractsMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="-5"
      unitRef="Unit_USD">-58100000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn06_30_2023_ForwardContractsMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="-5"
      unitRef="Unit_USD">164300000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="P07_01_2023To09_30_2023_ForwardContractsMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="-5"
      unitRef="Unit_USD">-25400000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="P07_01_2023To09_30_2023_ForwardContractsMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="-5"
      unitRef="Unit_USD">189700000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn09_30_2023_ForwardContractsMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="-6"
      unitRef="Unit_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <agle:PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock
      contextRef="PAsOn06_22_2023_ParapyreOptionObligationMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_pure">0.01</agle:PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="P09_29_2023To09_29_2023_ParapyreOptionObligationMemberusgaapPlanNameAxis">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <agle:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodFairValue
      contextRef="P12_31_2023To12_31_2023_ParapyreOptionObligationMemberusgaapPlanNameAxis_ScenarioForecastMembersrtStatementScenarioAxis"
      decimals="-5"
      unitRef="Unit_USD">3000000</agle:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodFairValue>
    <us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration
      contextRef="P06_22_2023To06_22_2023_ParapyreOptionObligationMemberusgaapPlanNameAxis"
      decimals="-5"
      unitRef="Unit_USD">100000</us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration>
    <us-gaap:ShareBasedCompensation
      contextRef="P07_01_2023To09_30_2023_ParapyreOptionObligationMemberusgaapPlanNameAxis"
      decimals="-5"
      unitRef="Unit_USD">2700000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2023To09_30_2023_ParapyreOptionObligationMemberusgaapPlanNameAxis"
      decimals="-5"
      unitRef="Unit_USD">2900000</us-gaap:ShareBasedCompensation>
    <agle:AssetAcquisitionStockholderPaymentPeriod contextRef="P06_22_2023To06_22_2023_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis">P3Y</agle:AssetAcquisitionStockholderPaymentPeriod>
    <agle:AssetAcquisitionCashPaymentThresholdPeriod contextRef="P06_22_2023To06_22_2023_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis">P1Y</agle:AssetAcquisitionCashPaymentThresholdPeriod>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="P01_01_2023To09_30_2023">The significant inputs used to estimate the fair value of the CVR liability were as follows: &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 67%;"&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td style="width: 29%;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;September&#160;30, 2023&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Estimated cash flow dates&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;&lt;div style="display:inline;"&gt;11/28/23 &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;-&lt;/div&gt; 06/22/26&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Estimated probability of success&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;&lt;div style="display:inline;"&gt;27% - 100%&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Risk-adjusted discount rates&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;&lt;div style="display:inline;"&gt;7.14% - 7.57%&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="PAsOn09_30_2023_ContingentValueRightLiabilityMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputProabilityOfSuccessMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis"
      decimals="INF"
      unitRef="Unit_pure">0.27</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="PAsOn09_30_2023_ContingentValueRightLiabilityMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MaximumMembersrtRangeAxis_MeasurementInputProabilityOfSuccessMemberusgaapMeasurementInputTypeAxis"
      decimals="INF"
      unitRef="Unit_pure">1</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="PAsOn09_30_2023_ContingentValueRightLiabilityMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis"
      decimals="INF"
      unitRef="Unit_pure">0.0714</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="PAsOn09_30_2023_ContingentValueRightLiabilityMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MaximumMembersrtRangeAxis_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis"
      decimals="INF"
      unitRef="Unit_pure">0.0757</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="P04_01_2023To06_30_2023_ContingentValueRightLiabilityMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-5"
      unitRef="Unit_USD">1300000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="P07_01_2023To09_30_2023_ContingentValueRightLiabilityMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-5"
      unitRef="Unit_USD">1300000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn12_31_2022_ContingentValueRightLiabilityMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="P01_01_2023To09_30_2023_ContingentValueRightLiabilityMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="-3"
      unitRef="Unit_USD">29500000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="P01_01_2023To09_30_2023_ContingentValueRightLiabilityMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="-3"
      unitRef="Unit_USD">1300000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn09_30_2023_ContingentValueRightLiabilityMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="-3"
      unitRef="Unit_USD">28200000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock contextRef="P01_01_2023To09_30_2023">&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;4. Cash Equivalents and Marketable Securities &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following tables summarize the estimated fair value of the Company&#x2019;s cash equivalents and marketable securities and the gross unrealized gains and losses (in thousands): &lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:57%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;September&#160;30, 2023&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Amortized&lt;br/&gt; Cost&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Gross&lt;br/&gt; Unrealized&lt;br/&gt; Gains&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Gross&lt;br/&gt; Unrealized&lt;br/&gt; Losses&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Estimated&lt;br/&gt; Fair Value&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Cash equivalents:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Money market funds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;55,451&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;55,451&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Commercial paper&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16,911&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16,914&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total cash equivalents&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;72,362&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;72,365&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Marketable securities:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Commercial paper&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;90,272&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(93&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;90,179&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Corporate bonds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;22,849&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(22&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;22,828&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;U.S. government securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total marketable securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;113,121&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(115&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;113,007&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="16" style="height:12pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;December&#160;31, 2022&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Amortized&lt;br/&gt; Cost&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Gross&lt;br/&gt; Unrealized&lt;br/&gt; Gains&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Gross&lt;br/&gt; Unrealized&lt;br/&gt; Losses&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Estimated&lt;br/&gt; Fair&#160;Value&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Cash equivalents:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Money market funds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15,250&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15,250&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Commercial paper&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7,021&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7,020&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;U.S. government securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,736&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,735&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total cash equivalents&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;26,007&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;26,005&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Marketable securities:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Commercial paper&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16,644&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(25&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16,621&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Corporate bonds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,738&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,732&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;U.S. government securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;495&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;495&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total marketable securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;20,877&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(31&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;20,848&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;div style="line-height:normal;background-color:white;display: inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following table summarizes the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; securities in an unrealized loss position for which an allowance for credit losses has not been recorded as of September&#160;30, 2023 and December&#160;31, 2022, aggregated by major security type and length of time in a continuous unrealized loss position: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:56%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="22" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;September&#160;30, 2023&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Less Than 12 Months&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;12 Months or&lt;br/&gt; Longer&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Total&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Fair&lt;br/&gt; Value&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Unrealized&lt;br/&gt; Losses&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Fair&lt;br/&gt; Value&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Unrealized&lt;br/&gt; Losses&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Fair&lt;br/&gt; Value&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Unrealized&lt;br/&gt; Losses&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Commercial paper&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;78,820&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(93&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;78,820&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(93&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;U.S. government securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Corporate bonds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18,373&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(22&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18,373&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(22&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total marketable securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;97,193&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(115&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;97,193&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(115&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:12pt"&gt;&lt;/td&gt;
&lt;td colspan="24" style="height:12pt"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="22" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;December&#160;31, 2022&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Less Than 12 Months&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;12 Months or&lt;br/&gt; Longer&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Total&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Fair&lt;br/&gt; Value&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Unrealized&lt;br/&gt; Losses&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Fair&lt;br/&gt; Value&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Unrealized&lt;br/&gt; Losses&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Fair&lt;br/&gt; Value&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Unrealized&lt;br/&gt; Losses&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Commercial paper&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;17,699&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(27&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;17,699&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(27&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;U.S. government securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,735&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,735&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Corporate bonds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,732&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,732&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total marketable securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;25,166&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(34&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;25,166&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(34&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company evaluated its securities for credit losses and considered the decline in market value to be primarily attributable to current economic and market conditions and not to a credit loss or other factors. Additionally, the Company does not intend to sell the securities in an unrealized loss position and does not expect it will be required to sell the securities before recovery of the unamortized cost basis. As of September&#160;30, 2023 and December&#160;31, 2022, an allowance for credit losses had not been recognized. Given the Company&#x2019;s intent and ability to hold such securities until recovery, and the lack of significant change in credit risk of these investments, the Company does not consider these marketable securities to be impaired as of September&#160;30, 2023 and December&#160;31, 2022. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The financial instruments that potentially subject the Company to a concentration of credit risk consist principally of cash deposits. Accounts at each of our three U.S. banking institutions are insured by the Federal Deposit Insurance Corporation (&#x201c;FDIC&#x201d;) up to $250,000 per depositor. At September&#160;30, 2023 and December&#160;31, 2022, the Company had $16.9&#160;million and $23.5&#160;million, respectively, of U.S. cash deposits in excess of the FDIC insured limit. Uninsured foreign cash deposits were immaterial for both periods. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;There were no realized gains or losses on marketable securities for the three and nine months ended September&#160;30, 2023 and 2022. Interest on marketable securities is included in interest income. Accrued interest receivable on &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; debt securities at September&#160;30, 2023 and December&#160;31, 2022 was $0.4&#160;million and $0.1&#160;million, respectively. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following table summarizes the contractual maturities of the Company&#x2019;s marketable securities at estimated fair value (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:67%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:8%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:8%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;September&#160;30,&lt;br/&gt; 2023&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Due in one year or less&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;102,518&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;20,848&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Due thereafter&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10,489&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total marketable securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;113,007&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;20,848&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company may sell investments at any time for use in current operations even if they have not yet reached maturity. As a result, the Company classifies marketable securities, including securities with maturities beyond twelve months as current &lt;div style="display:inline;"&gt;assets&lt;/div&gt;. &lt;/div&gt;</us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock>
    <us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock contextRef="P01_01_2023To09_30_2023">&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following tables summarize the estimated fair value of the Company&#x2019;s cash equivalents and marketable securities and the gross unrealized gains and losses (in thousands): &lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:57%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;September&#160;30, 2023&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Amortized&lt;br/&gt; Cost&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Gross&lt;br/&gt; Unrealized&lt;br/&gt; Gains&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Gross&lt;br/&gt; Unrealized&lt;br/&gt; Losses&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Estimated&lt;br/&gt; Fair Value&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Cash equivalents:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Money market funds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;55,451&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;55,451&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Commercial paper&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16,911&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16,914&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total cash equivalents&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;72,362&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;72,365&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Marketable securities:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Commercial paper&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;90,272&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(93&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;90,179&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Corporate bonds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;22,849&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(22&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;22,828&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;U.S. government securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total marketable securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;113,121&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(115&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;113,007&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="16" style="height:12pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;December&#160;31, 2022&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Amortized&lt;br/&gt; Cost&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Gross&lt;br/&gt; Unrealized&lt;br/&gt; Gains&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Gross&lt;br/&gt; Unrealized&lt;br/&gt; Losses&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Estimated&lt;br/&gt; Fair&#160;Value&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Cash equivalents:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Money market funds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15,250&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15,250&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Commercial paper&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7,021&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7,020&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;U.S. government securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,736&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,735&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total cash equivalents&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;26,007&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;26,005&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Marketable securities:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Commercial paper&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16,644&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(25&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16,621&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Corporate bonds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,738&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,732&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;U.S. government securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;495&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;495&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total marketable securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;20,877&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(31&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;20,848&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="PAsOn09_30_2023_MoneyMarketFundsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">55451000</us-gaap:CashEquivalentsAtCarryingValue>
    <agle:CashEquivalentsUnrealizedGains
      contextRef="PAsOn09_30_2023_MoneyMarketFundsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">0</agle:CashEquivalentsUnrealizedGains>
    <agle:CashEquivalentsUnrealizedLosses
      contextRef="PAsOn09_30_2023_MoneyMarketFundsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">0</agle:CashEquivalentsUnrealizedLosses>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn09_30_2023_MoneyMarketFundsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">55451000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="PAsOn09_30_2023_CommercialPaperMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">16911000</us-gaap:CashEquivalentsAtCarryingValue>
    <agle:CashEquivalentsUnrealizedGains
      contextRef="PAsOn09_30_2023_CommercialPaperMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">3000</agle:CashEquivalentsUnrealizedGains>
    <agle:CashEquivalentsUnrealizedLosses
      contextRef="PAsOn09_30_2023_CommercialPaperMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">0</agle:CashEquivalentsUnrealizedLosses>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn09_30_2023_CommercialPaperMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">16914000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="PAsOn09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">72362000</us-gaap:CashEquivalentsAtCarryingValue>
    <agle:CashEquivalentsUnrealizedGains
      contextRef="PAsOn09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">3000</agle:CashEquivalentsUnrealizedGains>
    <agle:CashEquivalentsUnrealizedLosses
      contextRef="PAsOn09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">0</agle:CashEquivalentsUnrealizedLosses>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">72365000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="PAsOn09_30_2023_CommercialPaperMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">90272000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="PAsOn09_30_2023_CommercialPaperMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="PAsOn09_30_2023_CommercialPaperMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">93000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="PAsOn09_30_2023_CommercialPaperMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">90179000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="PAsOn09_30_2023_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">22849000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="PAsOn09_30_2023_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="PAsOn09_30_2023_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">22000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="PAsOn09_30_2023_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">22828000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="PAsOn09_30_2023_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="PAsOn09_30_2023_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="PAsOn09_30_2023_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="PAsOn09_30_2023_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="PAsOn09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">113121000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="PAsOn09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="PAsOn09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">115000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="PAsOn09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">113007000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2022_MoneyMarketFundsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">15250000</us-gaap:CashEquivalentsAtCarryingValue>
    <agle:CashEquivalentsUnrealizedGains
      contextRef="PAsOn12_31_2022_MoneyMarketFundsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">0</agle:CashEquivalentsUnrealizedGains>
    <agle:CashEquivalentsUnrealizedLosses
      contextRef="PAsOn12_31_2022_MoneyMarketFundsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">0</agle:CashEquivalentsUnrealizedLosses>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn12_31_2022_MoneyMarketFundsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">15250000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">7021000</us-gaap:CashEquivalentsAtCarryingValue>
    <agle:CashEquivalentsUnrealizedGains
      contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">1000</agle:CashEquivalentsUnrealizedGains>
    <agle:CashEquivalentsUnrealizedLosses
      contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">2000</agle:CashEquivalentsUnrealizedLosses>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">7020000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2022_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">3736000</us-gaap:CashEquivalentsAtCarryingValue>
    <agle:CashEquivalentsUnrealizedGains
      contextRef="PAsOn12_31_2022_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">0</agle:CashEquivalentsUnrealizedGains>
    <agle:CashEquivalentsUnrealizedLosses
      contextRef="PAsOn12_31_2022_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">1000</agle:CashEquivalentsUnrealizedLosses>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn12_31_2022_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">3735000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">26007000</us-gaap:CashEquivalentsAtCarryingValue>
    <agle:CashEquivalentsUnrealizedGains
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">1000</agle:CashEquivalentsUnrealizedGains>
    <agle:CashEquivalentsUnrealizedLosses
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">3000</agle:CashEquivalentsUnrealizedLosses>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">26005000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">16644000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">25000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">16621000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="PAsOn12_31_2022_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">3738000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="PAsOn12_31_2022_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="PAsOn12_31_2022_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">6000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="PAsOn12_31_2022_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">3732000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="PAsOn12_31_2022_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">495000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="PAsOn12_31_2022_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="PAsOn12_31_2022_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="PAsOn12_31_2022_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">495000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">20877000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">31000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">20848000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock contextRef="P01_01_2023To09_30_2023">&lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following table summarizes the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; securities in an unrealized loss position for which an allowance for credit losses has not been recorded as of September&#160;30, 2023 and December&#160;31, 2022, aggregated by major security type and length of time in a continuous unrealized loss position: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:56%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="22" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;September&#160;30, 2023&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Less Than 12 Months&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;12 Months or&lt;br/&gt; Longer&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Total&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Fair&lt;br/&gt; Value&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Unrealized&lt;br/&gt; Losses&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Fair&lt;br/&gt; Value&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Unrealized&lt;br/&gt; Losses&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Fair&lt;br/&gt; Value&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Unrealized&lt;br/&gt; Losses&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Commercial paper&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;78,820&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(93&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;78,820&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(93&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;U.S. government securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Corporate bonds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18,373&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(22&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18,373&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(22&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total marketable securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;97,193&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(115&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;97,193&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(115&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:12pt"&gt;&lt;/td&gt;
&lt;td colspan="24" style="height:12pt"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="22" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;December&#160;31, 2022&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Less Than 12 Months&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;12 Months or&lt;br/&gt; Longer&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Total&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Fair&lt;br/&gt; Value&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Unrealized&lt;br/&gt; Losses&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Fair&lt;br/&gt; Value&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Unrealized&lt;br/&gt; Losses&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Fair&lt;br/&gt; Value&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Unrealized&lt;br/&gt; Losses&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Commercial paper&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;17,699&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(27&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;17,699&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(27&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;U.S. government securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,735&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,735&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Corporate bonds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,732&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,732&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total marketable securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;25,166&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(34&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;25,166&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(34&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="PAsOn09_30_2023_CommercialPaperMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">78820000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="PAsOn09_30_2023_CommercialPaperMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">93000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="PAsOn09_30_2023_CommercialPaperMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="PAsOn09_30_2023_CommercialPaperMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="PAsOn09_30_2023_CommercialPaperMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">78820000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="PAsOn09_30_2023_CommercialPaperMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">93000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="PAsOn09_30_2023_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="PAsOn09_30_2023_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="PAsOn09_30_2023_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="PAsOn09_30_2023_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="PAsOn09_30_2023_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="PAsOn09_30_2023_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="PAsOn09_30_2023_CorporateBondSecuritiesMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">18373000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="PAsOn09_30_2023_CorporateBondSecuritiesMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">22000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="PAsOn09_30_2023_CorporateBondSecuritiesMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="PAsOn09_30_2023_CorporateBondSecuritiesMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="PAsOn09_30_2023_CorporateBondSecuritiesMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">18373000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="PAsOn09_30_2023_CorporateBondSecuritiesMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">22000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="PAsOn09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">97193000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="PAsOn09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">115000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="PAsOn09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="PAsOn09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="PAsOn09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">97193000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="PAsOn09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">115000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">17699000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">27000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">17699000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">27000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="PAsOn12_31_2022_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">3735000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="PAsOn12_31_2022_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">1000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="PAsOn12_31_2022_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="PAsOn12_31_2022_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="PAsOn12_31_2022_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">3735000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="PAsOn12_31_2022_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">1000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="PAsOn12_31_2022_CorporateBondSecuritiesMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">3732000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="PAsOn12_31_2022_CorporateBondSecuritiesMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">6000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="PAsOn12_31_2022_CorporateBondSecuritiesMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="PAsOn12_31_2022_CorporateBondSecuritiesMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="PAsOn12_31_2022_CorporateBondSecuritiesMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">3732000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="PAsOn12_31_2022_CorporateBondSecuritiesMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">6000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">25166000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">34000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">25166000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">34000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="PAsOn09_30_2023_USGovernmentAgenciesDebtSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="PAsOn12_31_2022_USGovernmentAgenciesDebtSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <agle:ImpairmentOfMarketableSecurities
      contextRef="P01_01_2023To09_30_2023_USGovernmentAgenciesDebtSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="0"
      unitRef="Unit_USD">0</agle:ImpairmentOfMarketableSecurities>
    <agle:ImpairmentOfMarketableSecurities
      contextRef="P01_01_2022To12_31_2022_USGovernmentAgenciesDebtSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="0"
      unitRef="Unit_USD">0</agle:ImpairmentOfMarketableSecurities>
    <agle:NumberOfDomesticBankingInstitutions
      contextRef="PAsOn09_30_2023"
      decimals="0"
      unitRef="Unit_bank">3</agle:NumberOfDomesticBankingInstitutions>
    <us-gaap:CashFDICInsuredAmount
      contextRef="PAsOn09_30_2023_MaximumMembersrtRangeAxis_USBankingInstitutionMemberusgaapFinancialInstrumentAxis"
      decimals="0"
      unitRef="Unit_USD">250000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:Cash
      contextRef="PAsOn09_30_2023_USBankingInstitutionMemberusgaapFinancialInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">16900000</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="PAsOn12_31_2022_USBankingInstitutionMemberusgaapFinancialInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">23500000</us-gaap:Cash>
    <us-gaap:MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments
      contextRef="P01_01_2023To09_30_2023_USGovernmentAgenciesDebtSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments>
    <us-gaap:MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments
      contextRef="P07_01_2022To09_30_2022_USGovernmentAgenciesDebtSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments>
    <us-gaap:MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments
      contextRef="P01_01_2022To09_30_2022_USGovernmentAgenciesDebtSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments>
    <us-gaap:MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments
      contextRef="P07_01_2023To09_30_2023_USGovernmentAgenciesDebtSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments>
    <us-gaap:InterestReceivable
      contextRef="PAsOn09_30_2023_USGovernmentAgenciesDebtSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">400000</us-gaap:InterestReceivable>
    <us-gaap:InterestReceivable
      contextRef="PAsOn12_31_2022_USGovernmentAgenciesDebtSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">100000</us-gaap:InterestReceivable>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock contextRef="P01_01_2023To09_30_2023">&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following table summarizes the contractual maturities of the Company&#x2019;s marketable securities at estimated fair value (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:67%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:8%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:8%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;September&#160;30,&lt;br/&gt; 2023&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Due in one year or less&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;102,518&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;20,848&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Due thereafter&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10,489&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total marketable securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;113,007&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;20,848&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="PAsOn09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">102518000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">20848000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <agle:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne
      contextRef="PAsOn09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">10489000</agle:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne>
    <agle:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">0</agle:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="PAsOn09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">113007000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">20848000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <agle:AccruedAndOtherCurrentLiabilitiesTextBlock contextRef="P01_01_2023To09_30_2023">&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;5. Accrued and Other Current Liabilities &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Accrued and other current liabilities consist of the following (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:66%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:9%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:9%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;September&#160;30,&lt;br/&gt; 2023&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued compensation&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,368&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,589&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued contracted research and development costs&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,669&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,972&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued professional and consulting fees&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,484&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;946&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued other&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;340&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;330&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total accrued and other current liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15,861&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;12,837&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</agle:AccruedAndOtherCurrentLiabilitiesTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="P01_01_2023To09_30_2023">&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Accrued and other current liabilities consist of the following (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:66%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:9%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:9%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;September&#160;30,&lt;br/&gt; 2023&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued compensation&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,368&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,589&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued contracted research and development costs&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,669&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,972&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued professional and consulting fees&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,484&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;946&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued other&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;340&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;330&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total accrued and other current liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15,861&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;12,837&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedSalariesCurrent
      contextRef="PAsOn09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">5368000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedSalariesCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">4589000</us-gaap:AccruedSalariesCurrent>
    <agle:AccruedContractedResearchAndDevelopmentCosts
      contextRef="PAsOn09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">6669000</agle:AccruedContractedResearchAndDevelopmentCosts>
    <agle:AccruedContractedResearchAndDevelopmentCosts
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">6972000</agle:AccruedContractedResearchAndDevelopmentCosts>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="PAsOn09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">3484000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">946000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="PAsOn09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">340000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">330000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="PAsOn09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">15861000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">12837000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="P01_01_2023To09_30_2023">&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;6. Related Party Transactions &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Paragon and Parapyre Holding LLC each beneficially owns less than 5% of the Company&#x2019;s capital stock through their respective holdings of the Company&#x2019;s common stock and Series A Preferred Stock. Fairmount Funds Management LLC (&#x201c;Fairmount&#x201d;) beneficially owns more than 5% of the Company&#x2019;s capital stock, has two seats on the Board and beneficially owns more than 5% of Paragon, which is a joint venture between Fairmount and Fair Journey Biologics. Fairmount appointed Paragon&#x2019;s board of directors and has the contractual right to approve the appointment of any executive officers. Parapyre is an entity formed by Paragon as a vehicle to hold equity in Spyre in order to share profits with certain employees of Paragon. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In connection with the Asset Acquisition, the Company assumed the rights and obligations of Spyre under the Paragon Agreement. Under the Paragon Agreement, Spyre is obligated to compensate Paragon for its services performed under each research program based on the actual costs incurred with &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;mark-up&lt;/div&gt; costs pursuant to the terms of the Paragon Agreement. As of the date of the Asset Acquisition, Spyre had incurred total expenses of $19.0&#160;million under the Paragon Agreement since inception, inclusive of a $3.0&#160;million research initiation fee that was due upon signing of the Paragon Agreement and $16.0&#160;million of reimbursable expenses under the Paragon Agreement for historical costs owed to Paragon. As of the acquisition date, $19.0&#160;million was unpaid and was assumed by the Company through the Asset Acquisition. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;For the three and nine months ended September&#160;30, 2023, the Company recognized expenses related to services provided by Paragon subsequent to the Asset Acquisition totaling $19.4&#160;million and $20.8&#160;million, respectively, which were recorded as Research and development expenses in the consolidated statements of operations. As of September&#160;30, 2023, $16.8&#160;million was unpaid and was included in Related party payable on the Company&#x2019;s consolidated balance sheets. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;For the three and nine months ended September&#160;30, 2023, the Company made payments totaling $20.0&#160;million to Paragon. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In July 2023, the Company exercised its option for the SPY001 program with the remaining three options for the SPY002, SPY003, SPY004 programs remaining outstanding. Following the execution of the license agreement with respect to the SPY001 program (the &#x201c;SPY001 License Agreement&#x201d;), the Company will be obligated to pay Paragon up to $22.0&#160;million upon the achievement of specific development and clinical milestones for the first product under the SPY001 License Agreement that achieves such specified milestones. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following is the summary of expenses related to the Paragon Agreement, which were ultimately settled in cash (in millions): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:52%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Three Months&lt;br/&gt; Ended&lt;br/&gt; September&#160;30,&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Nine Months&lt;br/&gt; Ended&lt;br/&gt; September&#160;30,&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;2023&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;2022&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;2023&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;2022&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Financial&#160;Statement&#160;Line&#160;Item&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Reimbursable costs under the Paragon Agreement&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16.7&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;17.9&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;Research&#160;and&#160;development&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Parapyre Option Obligation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Paragon Agreement provided for an annual equity grant of options to purchase 1% of the then outstanding shares of Spyre&#x2019;s common stock, on a fully diluted basis, on the last business day of each calendar year, at the fair market value determined by the board of directors of Spyre (the &#x201c;Parapyre Option Obligation&#x201d;). &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In connection with the Asset Acquisition, the Company assumed the rights and obligations of Spyre under the Paragon Agreement, including the Parapyre Option Obligation. As a result, the Parapyre Option Obligation shall continue and Parapyre shall be entitled to receive the equivalent shares of the Company with the same terms. On September&#160;29, 2023, the Company amended the Paragon Agreement to amend and restate certain terms of the option grant pertaining to the Parapyre Option Obligation, including but not limited to (i)&#160;defining that the annual equity grant of options is based on the outstanding shares of Aeglea&#x2019;s common stock, (ii)&#160;establishing the grant date as the last business day of each applicable calendar year, and (iii)&#160;defining the term of the options granted as ten years. See Notes 3 and 10 for disclosures related to the Parapyre Option Obligation. For the three and nine months ended September&#160;30, 2023, $2.7&#160;million and $2.9&#160;million, respectively, was recognized as stock compensation expense related to the Parapyre Option Obligation. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following is the summary of Related party accounts payable (in millions): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:67%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:12%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:12%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;September&#160;30,&lt;br/&gt; 2023&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Reimbursable costs under the Paragon Agreement&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16.8&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Parapyre Option Obligation liability&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total related party accounts payable&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;19.8&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="PAsOn09_30_2023_MaximumMembersrtRangeAxis_OwnershipInterestMemberusgaapRelatedPartyTransactionAxis_ParagonTherapeuticsIncMembersrtOwnershipAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="2"
      unitRef="Unit_pure">0.05</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="PAsOn09_30_2023_FairmountFundsManagementLlcMembersrtOwnershipAxis_MinimumMembersrtRangeAxis_OwnershipInterestMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="2"
      unitRef="Unit_pure">0.05</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <agle:RelatedPartyTransactionNumberOfBoardSeats
      contextRef="PAsOn09_30_2023_AppointOfBoardMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      unitRef="Unit_BOARDSEAT">2</agle:RelatedPartyTransactionNumberOfBoardSeats>
    <agle:MinorityInterestOwnershipPercentageByNoncontrollingOwnersHeldInThirdParty
      contextRef="PAsOn09_30_2023_FairmountFundsManagementLlcMembersrtOwnershipAxis_MinimumMembersrtRangeAxis_OwnershipInterestMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="2"
      unitRef="Unit_pure">0.05</agle:MinorityInterestOwnershipPercentageByNoncontrollingOwnersHeldInThirdParty>
    <agle:RelatedPartyExpensesIncurredPriorToAssetAcquisition
      contextRef="P06_22_2023To06_22_2023_ParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">19000000</agle:RelatedPartyExpensesIncurredPriorToAssetAcquisition>
    <agle:ResearchInitiationFees
      contextRef="P06_22_2023To06_22_2023_ParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">3000000</agle:ResearchInitiationFees>
    <agle:ReimbursableResearchCosts
      contextRef="P06_22_2023To06_22_2023_ParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">16000000</agle:ReimbursableResearchCosts>
    <agle:RelatedPartyExpensesUnpaidPriorToAssetAcquisition
      contextRef="PAsOn06_22_2023_ParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">19000000</agle:RelatedPartyExpensesUnpaidPriorToAssetAcquisition>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="P07_01_2023To09_30_2023_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_StockCompensationAndResearchAndDevelopmentExpenseMemberusgaapRelatedPartyTransactionAxis"
      decimals="-5"
      unitRef="Unit_USD">19400000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="P01_01_2023To09_30_2023_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_StockCompensationAndResearchAndDevelopmentExpenseMemberusgaapRelatedPartyTransactionAxis"
      decimals="-5"
      unitRef="Unit_USD">20800000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:AccountsPayableCurrent
      contextRef="PAsOn09_30_2023_ReimbursableCostsUnderParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">16800000</us-gaap:AccountsPayableCurrent>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="P07_01_2023To09_30_2023_MilestonePaymentsMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">20000000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="P01_01_2023To09_30_2023_MilestonePaymentsMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">20000000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <agle:RelatedPartyTransactionNumberOfProgramOptionsOutstanding
      contextRef="P07_01_2023To07_31_2023_LicensingAgreementsMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      unitRef="Unit_PROGRAMOPTION">3</agle:RelatedPartyTransactionNumberOfProgramOptionsOutstanding>
    <agle:AmountToBePaidUnderAgreement
      contextRef="PAsOn07_31_2023_MaximumMembersrtRangeAxis_ParagonTherapeuticsIncMembersrtOwnershipAxis_Spy001LicenseAgreementMemberusgaapRelatedPartyTransactionAxis"
      decimals="-5"
      unitRef="Unit_USD">22000000</agle:AmountToBePaidUnderAgreement>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock contextRef="P01_01_2023To09_30_2023">&lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following is the summary of expenses related to the Paragon Agreement, which were ultimately settled in cash (in millions): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:52%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Three Months&lt;br/&gt; Ended&lt;br/&gt; September&#160;30,&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Nine Months&lt;br/&gt; Ended&lt;br/&gt; September&#160;30,&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;2023&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;2022&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;2023&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;2022&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Financial&#160;Statement&#160;Line&#160;Item&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Reimbursable costs under the Paragon Agreement&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16.7&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;17.9&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;Research&#160;and&#160;development&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <agle:RelatedPartyTransactionReimbursableCosts
      contextRef="P07_01_2023To09_30_2023_ReimbursableCostsUnderParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-5"
      unitRef="Unit_USD">16700000</agle:RelatedPartyTransactionReimbursableCosts>
    <agle:RelatedPartyTransactionReimbursableCosts
      contextRef="P07_01_2022To09_30_2022_ReimbursableCostsUnderParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-6"
      unitRef="Unit_USD">0</agle:RelatedPartyTransactionReimbursableCosts>
    <agle:RelatedPartyTransactionReimbursableCosts
      contextRef="P01_01_2023To09_30_2023_ReimbursableCostsUnderParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-5"
      unitRef="Unit_USD">17900000</agle:RelatedPartyTransactionReimbursableCosts>
    <agle:RelatedPartyTransactionReimbursableCosts
      contextRef="P01_01_2022To09_30_2022_ReimbursableCostsUnderParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-6"
      unitRef="Unit_USD">0</agle:RelatedPartyTransactionReimbursableCosts>
    <agle:PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock
      contextRef="PAsOn09_30_2023_ParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="2"
      unitRef="Unit_pure">0.01</agle:PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="P09_29_2023To09_29_2023_ParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensation
      contextRef="P07_01_2023To09_30_2023_ParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">2700000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2023To09_30_2023_ParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">2900000</us-gaap:ShareBasedCompensation>
    <agle:ScheduleOfBalancesDueToAffiliatesTableTextBlock contextRef="P01_01_2023To09_30_2023">&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following is the summary of Related party accounts payable (in millions): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:67%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:12%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:12%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;September&#160;30,&lt;br/&gt; 2023&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Reimbursable costs under the Paragon Agreement&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16.8&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Parapyre Option Obligation liability&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total related party accounts payable&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;19.8&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</agle:ScheduleOfBalancesDueToAffiliatesTableTextBlock>
    <us-gaap:AccountsPayableCurrent
      contextRef="PAsOn09_30_2023_ReimbursableCostsUnderParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">16800000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="PAsOn12_31_2022_ReimbursableCostsUnderParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-6"
      unitRef="Unit_USD">0</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="PAsOn09_30_2023_ParapyreOptionObligationMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">3000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="PAsOn12_31_2022_ParapyreOptionObligationMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-6"
      unitRef="Unit_USD">0</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="PAsOn09_30_2023_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">19800000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="PAsOn12_31_2022_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-6"
      unitRef="Unit_USD">0</us-gaap:AccountsPayableCurrent>
    <us-gaap:AssetAcquisitionTextBlock contextRef="P01_01_2023To09_30_2023">&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;7. Asset Acquisition &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On June&#160;22, 2023, the Company acquired Spyre pursuant to the Acquisition Agreement, by and among the Company, Aspen Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (&#x201c;First Merger Sub&#x201d;), Sequoia Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of the Company (&#x201c;Second Merger Sub&#x201d;), and Spyre. Pursuant to the Acquisition Agreement, First Merger Sub merged with and into Spyre, pursuant to which Spyre was the surviving corporation and became a wholly owned subsidiary of the Company (the &#x201c;First Merger&#x201d;). Immediately following the First Merger, Spyre merged with and into Second Merger Sub, pursuant to which Second Merger Sub became the surviving entity. Spyre was a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-clinical&lt;/div&gt; stage biotechnology company that was incorporated on April&#160;28, 2023 under the direction of Peter Harwin, a Managing Member of Fairmount, for the purpose of holding rights to certain intellectual property being developed by Paragon. Fairmount is a founder of Paragon. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company completed the Asset Acquisition of Spyre, in accordance with the terms of the Acquisition Agreement. Under the terms of the Acquisition Agreement, the Company issued 517,809 shares of common stock and 364,887 shares of Series A Preferred Stock to former Spyre security holders. In addition, outstanding and unexercised stock options to purchase 2,734 shares of common stock were assumed from the Amended and Restated Spyre 2023 Equity Incentive Plan. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;At the acquisition date, the Company recorded forward contracts to represent the obligation to issue shares of the Company&#x2019;s common stock and shares of Series A Preferred Stock, respectively. The forward contract related to the common stock was recorded as Additional &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;paid-in&lt;/div&gt; capital as the instrument is indexed to the Company&#x2019;s common stock. The forward contract related to the Series A Preferred Stock was recorded as a liability, as the underlying stock has a cash redemption feature. On July&#160;7, 2023, both the shares of common stock and Series A Preferred Stock were issued and the forward contract liability associated with the Series A Preferred Stock was settled accordingly. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company concluded that the arrangement meets the definition of an asset acquisition rather than a business combination, as substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset, Spyre&#x2019;s option (the &#x201c;Option&#x201d;) to exclusively license IPR&amp;amp;D. The Company determined that the Option to license IPR&amp;amp;D was a single asset as the Company&#x2019;s strategy relies on developing the entire portfolio of individual treatments to create combination treatments that simultaneously address different mechanisms of irritable bowel disease with a single treatment. The Company also determined that the pipeline candidates within the portfolio are similar in nature and risk profile. In addition, the Company did not obtain any substantive processes, assembled workforce, or employees capable of producing outputs in connection with the Asset Acquisition. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company determined that the cost to acquire the asset was $113.2&#160;million which was recorded as acquired IPR&amp;amp;D. The fair value of the consideration issued consisted of the 364,887 shares of Series A Preferred Stock (14,595,480 shares of common stock on an &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;as-converted&lt;/div&gt; basis) and 517,809 shares of common stock, valued at $291.08 per share and $7.277 per share, respectively. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Asset Acquisition Costs are shown on the following table (in millions): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:87%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;June&#160;22,&lt;br/&gt; 2023&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Consideration transferred in Series A Preferred Stock and common stock&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;110.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Transaction costs incurred by Aeglea&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total cost to acquire asset&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;113.2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The allocation of the purchase price to net assets acquired is as a follows: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:87%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;June&#160;22,&lt;br/&gt; 2023&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Acquired &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-process&lt;/div&gt; research and development&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;130.2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Cash acquired&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Assumed liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(20.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total cost to acquire asset&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;113.2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:AssetAcquisitionTextBlock>
    <agle:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares
      contextRef="P06_22_2023To06_22_2023_CommonStockMemberusgaapEquityInterestIssuedOrIssuableByTypeAxis_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis"
      decimals="INF"
      unitRef="Unit_shares">517809</agle:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares>
    <agle:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares
      contextRef="P06_22_2023To06_22_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis"
      decimals="INF"
      unitRef="Unit_shares">364887</agle:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares>
    <agle:OutstandingAndUnexercisedStockOptions
      contextRef="P06_22_2023To06_22_2023_Spyre2023EquityIncentivePlanMemberusgaapPlanNameAxis_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis"
      decimals="INF"
      unitRef="Unit_shares">2734</agle:OutstandingAndUnexercisedStockOptions>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="P06_22_2023To06_22_2023"
      decimals="-5"
      unitRef="Unit_USD">113200000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <agle:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares
      contextRef="P06_22_2023To06_22_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis"
      decimals="INF"
      unitRef="Unit_shares">364887</agle:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares>
    <agle:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableSharesOfCommonStockOnAnAsConvertedBasis
      contextRef="P06_22_2023To06_22_2023_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis"
      decimals="INF"
      unitRef="Unit_shares">14595480</agle:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableSharesOfCommonStockOnAnAsConvertedBasis>
    <agle:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares
      contextRef="P06_22_2023To06_22_2023_CommonStockMemberusgaapEquityInterestIssuedOrIssuableByTypeAxis_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis"
      decimals="INF"
      unitRef="Unit_shares">517809</agle:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="PAsOn06_22_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">291.08</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="PAsOn06_22_2023_CommonStockMemberusgaapEquityInterestIssuedOrIssuableByTypeAxis_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis"
      decimals="3"
      unitRef="Unit_USD_per_Share">7.277</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:AssetAcquisitionTableTextBlock contextRef="P01_01_2023To09_30_2023">&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Asset Acquisition Costs are shown on the following table (in millions): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:87%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;June&#160;22,&lt;br/&gt; 2023&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Consideration transferred in Series A Preferred Stock and common stock&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;110.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Transaction costs incurred by Aeglea&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total cost to acquire asset&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;113.2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The allocation of the purchase price to net assets acquired is as a follows: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:87%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;June&#160;22,&lt;br/&gt; 2023&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Acquired &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-process&lt;/div&gt; research and development&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;130.2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Cash acquired&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Assumed liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(20.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total cost to acquire asset&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;113.2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:AssetAcquisitionTableTextBlock>
    <us-gaap:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable
      contextRef="P06_22_2023To06_22_2023_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">110000000</us-gaap:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable>
    <us-gaap:AssetAcquisitionConsiderationTransferredTransactionCost
      contextRef="P06_22_2023To06_22_2023_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">3200000</us-gaap:AssetAcquisitionConsiderationTransferredTransactionCost>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="P06_22_2023To06_22_2023_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">113200000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <agle:AcquiredInProcessResearchAndDevelopment
      contextRef="P06_22_2023To06_22_2023_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">130200000</agle:AcquiredInProcessResearchAndDevelopment>
    <us-gaap:CashAcquiredFromAcquisition
      contextRef="P06_22_2023To06_22_2023_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">3000000</us-gaap:CashAcquiredFromAcquisition>
    <agle:AssumedLiabilities
      contextRef="P06_22_2023To06_22_2023_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">20000000</agle:AssumedLiabilities>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="P06_22_2023To06_22_2023_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">113200000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <agle:OptionAgreementTextBlock contextRef="P01_01_2023To09_30_2023">&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;8. Paragon Agreement &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In May 2023, Spyre entered into the Paragon Agreement with Paragon and Parapyre. In consideration for the Option granted under the Paragon Agreement, Spyre was obligated to pay Paragon an upfront cash amount of $3.0&#160;million in research initiation fees. In addition, Spyre was obligated to compensate Paragon on a quarterly basis for its services performed under each research program based on the actual costs incurred with &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;mark-up&lt;/div&gt; costs pursuant to the terms of the Paragon Agreement. As of the date of the Asset Acquisition, Spyre had incurred total expenses of $19.0&#160;million under the Paragon Agreement since inception, which included the $3.0&#160;million research initiation fee and $16.0&#160;million of historical reimbursable expenses owed to Paragon. As of June&#160;22, 2023, $19.0&#160;million was unpaid and was assumed by the Company through the Asset Acquisition. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Furthermore, the Paragon Agreement provided for an annual equity grant of options to purchase 1% of the then outstanding shares of Spyre&#x2019;s common stock, on a fully diluted basis, on the last business day of each calendar year, during the term of the Paragon Agreement, at the fair market value determined by the board of directors of Spyre. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;As a result of the Asset Acquisition, the Company assumed the rights and obligations of Spyre under the Paragon Agreement, including the Parapyre Option Obligation. Pursuant to the Paragon Agreement, on a research &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;program-by-research&lt;/div&gt;&lt;/div&gt; program basis following the finalization of the research plan for each respective research program, the Company is required to pay Paragon a nonrefundable fee in cash of $0.8&#160;million. For the three and nine months ended September&#160;30, 2023, the Company incurred $19.4&#160;million and $20.8&#160;million, respectively, in costs reimbursable to Paragon, which were recorded as Research and development expenses in the consolidated statements of operations. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;For the three and nine months ended September&#160;30, 2023, the Company made payments totaling $20.0&#160;million to Paragon. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On July&#160;12, 2023, the Company exercised its Option available under the Paragon Agreement with respect to the SPY001 research program and expects to enter into a SPY001 license agreement (the &#x201c;SPY001 License Agreement&#x201d;). The Company&#x2019;s Option available under the Paragon Agreement with respect to the SPY002, SPY003 and SPY004 programs remains unexercised. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Following the execution of the SPY001 License Agreement, the Company will be obligated to pay Paragon up to $22.0&#160;million upon the achievement of specific development and clinical milestones for the first product under the SPY001 License Agreement that achieves such specified milestones. Upon execution of the SPY001 License Agreement, the Company expects to pay Paragon a $1.5&#160;million fee for nomination of a development candidate, and the Company expects to be obligated to make a further milestone payment of $2.5&#160;million upon the first dosing of a human patient in a Phase 1 trial. Subject to the execution of the Option with respect to the SPY002, SPY003 or SPY004 research programs, the Company expects to be obligated to make similar payments upon and following the execution of license agreements with respect to the these research programs, respectively. &lt;/div&gt;</agle:OptionAgreementTextBlock>
    <agle:ResearchInitiationFees
      contextRef="P06_22_2023To06_22_2023_ParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">3000000</agle:ResearchInitiationFees>
    <agle:RelatedPartyExpensesIncurredPriorToAssetAcquisition
      contextRef="P06_22_2023To06_22_2023_ParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">19000000</agle:RelatedPartyExpensesIncurredPriorToAssetAcquisition>
    <agle:ResearchInitiationFees
      contextRef="P06_22_2023To06_22_2023_ParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">3000000</agle:ResearchInitiationFees>
    <agle:ReimbursableResearchCosts
      contextRef="P06_22_2023To06_22_2023_ParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">16000000</agle:ReimbursableResearchCosts>
    <agle:RelatedPartyExpensesUnpaidPriorToAssetAcquisition
      contextRef="PAsOn06_22_2023_ParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">19000000</agle:RelatedPartyExpensesUnpaidPriorToAssetAcquisition>
    <agle:PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock
      contextRef="PAsOn05_31_2023_ParapyreOptionObligationMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_pure">0.01</agle:PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock>
    <agle:NonrefundableResearchInitiationFeeForOneProgramPaidInCash
      contextRef="P06_22_2023To06_22_2023_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">800000</agle:NonrefundableResearchInitiationFeeForOneProgramPaidInCash>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="P07_01_2023To09_30_2023_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_StockCompensationAndResearchAndDevelopmentExpenseMemberusgaapRelatedPartyTransactionAxis"
      decimals="-5"
      unitRef="Unit_USD">19400000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="P01_01_2023To09_30_2023_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_StockCompensationAndResearchAndDevelopmentExpenseMemberusgaapRelatedPartyTransactionAxis"
      decimals="-5"
      unitRef="Unit_USD">20800000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <agle:LicenseAgreementMilestonePayments
      contextRef="P07_01_2023To09_30_2023_ParagonTherapeuticsIncMembersrtCounterpartyNameAxis"
      decimals="-5"
      unitRef="Unit_USD">20000000</agle:LicenseAgreementMilestonePayments>
    <agle:LicenseAgreementMilestonePayments
      contextRef="P01_01_2023To09_30_2023_ParagonTherapeuticsIncMembersrtCounterpartyNameAxis"
      decimals="-5"
      unitRef="Unit_USD">20000000</agle:LicenseAgreementMilestonePayments>
    <agle:AmountToBePaidUnderAgreement
      contextRef="PAsOn07_12_2023_MaximumMembersrtRangeAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_Spy001LicenseAgreementMemberusgaapRelatedPartyTransactionAxis"
      decimals="-5"
      unitRef="Unit_USD">22000000</agle:AmountToBePaidUnderAgreement>
    <agle:NominationFee
      contextRef="P07_12_2023To07_12_2023_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_Spy001LicenseAgreementMemberusgaapRelatedPartyTransactionAxis"
      decimals="-5"
      unitRef="Unit_USD">1500000</agle:NominationFee>
    <agle:PaymentOfMilestone
      contextRef="P07_12_2023To07_12_2023_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_Spy001LicenseAgreementMemberusgaapRelatedPartyTransactionAxis"
      decimals="-5"
      unitRef="Unit_USD">2500000</agle:PaymentOfMilestone>
    <us-gaap:PreferredStockTextBlock contextRef="P01_01_2023To09_30_2023">&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;9. Series A &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-Voting&lt;/div&gt; Convertible Preferred Stock &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On June&#160;22, 2023, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of the Series A Preferred Stock with the Secretary of State of the State of Delaware (the &#x201c;Certificate of Designation&#x201d;) in connection with the Asset Acquisition and the PIPE. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Pursuant to the Certificate of Designation, holders of Series A Preferred Stock are entitled to receive dividends on shares of Series A Preferred Stock equal to, on an &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;as-if-converted-to-common-stock&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; basis, and in the same form as, dividends actually paid on shares of the Company&#x2019;s common stock. Except as provided in the Certificate of Designation or as otherwise required by law, the Series A Preferred Stock does not have voting rights. However, as long as any shares of Series A Preferred Stock are outstanding, the Company will not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series A Preferred Stock: (a)&#160;alter or change adversely the powers, preferences or rights given to the Series A Preferred Stock, or alter or amend the Certificate of Designation, amend or repeal any provision of, or add any provision to, the Company&#x2019;s Certificate of Incorporation or its Bylaws, or file any articles of amendment, certificate of designations, preferences, limitations and relative rights of any series of Preferred Stock, if such action would adversely alter or change the preferences, rights, privileges or powers of, or restrictions provided for the benefit of the Series A Preferred Stock, regardless of whether any of the foregoing actions will be by means of amendment to the Certificate of Incorporation or by merger, consolidation, recapitalization, reclassification, conversion or otherwise, (b)&#160;issue further shares of Series A Preferred Stock or increase or decrease (other than by conversion) the number of authorized shares of Series A Preferred Stock, (c)&#160;prior to the stockholder approval of the conversion of the Series A Preferred Stock into shares of Common Stock in accordance with Nasdaq Stock &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Market Rules (the &#x201c;Conversion Proposal&#x201d;) or at any time while at least 30% of the originally issued Series A Preferred Stock remains issued and outstanding, consummate (x)&#160;any Fundamental Transaction (as defined in the Certificate of Designation) or (y)&#160;any merger or consolidation of the Company with or into another entity or any stock sale to, or other business combination in which our stockholders immediately before such transaction do not hold at least a majority of our capital stock immediately after such transaction or (d)&#160;enter into any agreement with respect to any of the foregoing. The Series A Preferred Stock does not have a preference upon any liquidation, dissolution or &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;winding-up&lt;/div&gt; of the Company. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company has agreed to hold a stockholders&#x2019; meeting to submit the following matters to its stockholders for their consideration: (i)&#160;the approval of the Conversion Proposal, and (ii)&#160;if deemed necessary or appropriate by the Company or as otherwise required by law or contract, the approval of an amendment to the Certificate of Incorporation to authorize sufficient shares of common stock for the conversion of the Series A Preferred Stock issued pursuant to the Acquisition Agreement. In connection with these matters, the Company filed with the SEC a definitive proxy statement and other relevant materials. The stockholder meeting has not occurred as of September&#160;30, 2023. The Series A Preferred Stock is recorded outside of stockholders&#x2019; (deficit) equity because, if conversion to common stock is not approved by the stockholders, the Series A Preferred Stock will be redeemable at the option of the holders for cash equal to the closing price of the common stock per share of common stock underlying the Series A Preferred Stock, on the last trading day prior to the holder&#x2019;s redemption request. As of September&#160;30, 2023, the redemption value of the Company&#x2019;s outstanding Series A Preferred Stock was $532.3&#160;million based on the closing stock price of the Company&#x2019;s common stock on September&#160;30, 2023 of $12.25 per share. The Company has determined that the conversion and redemption features of the Series A Preferred Stock do not require bifurcation as derivatives. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Following stockholder approval of the Conversion Proposal, each share of Series A Preferred Stock will automatically convert into 40 shares of common stock, subject to certain limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series A Preferred Stock into shares of common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (established by the holder between 0% and 19.99%) of the total number of shares of common stock issued and outstanding immediately after giving effect to such conversion. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On June&#160;26, 2023, the Company completed a private placement of 721,452 shares of Series A Preferred Stock in exchange for gross proceeds of $210.0&#160;million, or net proceeds of $197.3&#160;million, after deducting placement agent and other offering costs. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On July&#160;7, 2023, the Company issued 364,887 shares of Series A Preferred Stock as part of its consideration transferred in connection with the Asset Acquisition that closed on June&#160;22, 2023 which settled the related forward contract liability. For additional information, see Note 3. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On October&#160;27, 2023, the Company filed a definitive proxy statement with the SEC to solicit approval of the Conversion Proposal, among other matters, at a special meeting of stockholders to be held on November&#160;21, 2023. &lt;/div&gt;</us-gaap:PreferredStockTextBlock>
    <agle:PreferredStockRemainsIssuedAndOutstandingPercentage
      contextRef="PAsOn06_22_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      unitRef="Unit_pure">0.30</agle:PreferredStockRemainsIssuedAndOutstandingPercentage>
    <us-gaap:PreferredStockRedemptionAmount
      contextRef="PAsOn09_30_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-5"
      unitRef="Unit_USD">532300000</us-gaap:PreferredStockRedemptionAmount>
    <us-gaap:PreferredStockRedemptionPricePerShare
      contextRef="PAsOn09_30_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">12.25</us-gaap:PreferredStockRedemptionPricePerShare>
    <us-gaap:PreferredStockConvertibleConversionRatio
      contextRef="PAsOn06_22_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_pure">40</us-gaap:PreferredStockConvertibleConversionRatio>
    <agle:BeneficiallyHoldersOwnedPercentage
      contextRef="P06_22_2023To06_22_2023_MinimumMembersrtRangeAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      unitRef="Unit_pure">0</agle:BeneficiallyHoldersOwnedPercentage>
    <agle:BeneficiallyHoldersOwnedPercentage
      contextRef="P06_22_2023To06_22_2023_MaximumMembersrtRangeAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="4"
      unitRef="Unit_pure">0.1999</agle:BeneficiallyHoldersOwnedPercentage>
    <agle:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="P06_26_2023To06_26_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">721452</agle:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="P06_26_2023To06_26_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-5"
      unitRef="Unit_USD">210000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="P06_26_2023To06_26_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-5"
      unitRef="Unit_USD">197300000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <agle:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares
      contextRef="P07_07_2023To07_07_2023_AssetAcquisitionMemberusgaapBusinessAcquisitionAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">364887</agle:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="P01_01_2023To09_30_2023">&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;10. Liabilities, Convertible Preferred Stock and Stockholders&#x2019; (Deficit) Equity &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Registered Direct Offering &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In May 2022, the Company issued and sold 430,107 shares of common stock at an offering price of $40.00 per share and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-funded&lt;/div&gt; warrants to purchase up to 694,892 shares of common stock at an offering price of $39.9975 per warrant (representing the price per share of common stock sold in the offering minus the $0.0025 exercise price per warrant) in a registered direct offering pursuant to a shelf registration statement on Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;S-3.&lt;/div&gt; The net proceeds to the Company from this offering were approximately $42.9&#160;million, after deducting placement agent fees and offering costs of $2.1&#160;million. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pre-Funded&lt;/div&gt; Warrants &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In February 2019, April 2020 and May 2022, the Company issued &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-funded&lt;/div&gt; warrants to purchase the Company&#x2019;s common stock in underwritten public offerings at the offering price of the common stock, less the $0.0025 per share exercise price of each warrant. The warrants were recorded as a component of stockholders&#x2019; (deficit) equity within additional &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;paid-in&lt;/div&gt; capital and have no expiration date. Per the terms of the warrant agreements, the outstanding warrants to purchase shares of common stock may not be exercised if the holder&#x2019;s ownership of the Company&#x2019;s common stock would exceed 4.99% (&#x201c;Maximum Ownership Percentage&#x201d;), or 9.99% for certain holders. By written notice to the Company, each holder may increase or decrease the Maximum Ownership Percentage to any other percentage (not in excess of 19.99% for the majority of such warrants). The revised Maximum Ownership Percentage would be effective 61 days after the notice is received by the Company. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;As of September&#160;30, 2023, the following &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-funded&lt;/div&gt; warrants for common stock were issued and outstanding: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:48%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:10%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:10%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:10%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;Issue Date&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Expiration&#160;Date&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Exercise&#160;Price&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Number&#160;of&#160;Warrants&lt;br/&gt; Outstanding&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;February&#160;8, 2019&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;None&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.0025&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;April&#160;30, 2020&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;None&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.0025&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;May&#160;20, 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;None&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.0025&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;250,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-funded&lt;/div&gt; warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;250,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Stock-Based Compensation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;2016 Equity Incentive Plan &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The 2016 Equity Incentive Plan (&#x201c;2016 Plan&#x201d;) provides for an automatic increase in the number of shares reserved for issuance thereunder on January&#160;&lt;div style="display:inline;"&gt;1&lt;/div&gt; of each year for the remaining term of the plan (through 2028) equal to (a) 4.0% of the number of issued and outstanding shares of common stock on December&#160;31 of the immediately preceding year, or (b)&#160;a lesser amount as approved by the Board each year. As a result of this provision, on January&#160;1, 2023 and January&#160;1, 2022, an additional 104,560 and 78,968 shares, respectively, became available for issuance under the 2016 Plan. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In July 2020, the Company granted &lt;div style="display:inline;"&gt;9,128&lt;/div&gt; restricted stock units (&#x201c;RSUs&#x201d;) to certain employees, with vesting terms subject to regulatory, commercial, and clinical milestones, in addition to a service condition. As of September&#160;30, 2023, &lt;div style="display:inline;"&gt;none&lt;/div&gt; of these RSUs had vested and all RSUs were forfeited since the performance milestones were not met within the required time frame. &lt;div style="display:inline;"&gt;No&lt;/div&gt; stock-based compensation expense was recognized on these awards. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On June&#160;22, 2023, concurrent with the closing of the Asset Acquisition, the Board approved an amendment of the 2016 Plan to eliminate the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;per-participant&lt;/div&gt; annual award limits originally intended to comply with the qualified performance-based compensation exception set forth in Section&#160;162(m) of the Internal Revenue Code, in light of the repeal of such exception pursuant to the Tax Cuts and Jobs Act of 2017. In addition, the Company approved &lt;div style="display:inline;"&gt;2,720,033&lt;/div&gt; options contingent on stockholder approval to certain members of the Board, legacy Aeglea employees and consultants under the 2016 Plan. These awards are in excess of the shares available for issuance under the 2016 Plan and require stockholder approval before being granted. Accordingly, &lt;div style="display:inline;"&gt;no&lt;/div&gt; expense has been recognized on these contingent awards since they are contingent on stockholder approval. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;As of September&#160;30, 2023, the 2016 Plan had &lt;div style="display:inline;"&gt;293,497&lt;/div&gt; shares available for future issuance. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;2018 Equity Inducement Plan &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;During the nine months ended September&#160;30, 2023, the Board approved an increase of &lt;div style="display:inline;"&gt;2,800,000&lt;/div&gt; in the number of shares reserved for issuance to the 2018 Equity Inducement Plan and granted &lt;div style="display:inline;"&gt;3,583,880&lt;/div&gt; inducement awards to new hires. The grant-date fair value of these inducement awards will be recognized as expense on a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pro-rata&lt;/div&gt; basis over the vesting period. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The awards have an exercise price equal to the grant date closing price of the Company&#x2019;s common stock, vest ratably over &lt;div style="display:inline;"&gt;four years&lt;/div&gt;, and have a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="display:inline;"&gt;ten-year&lt;/div&gt;&lt;/div&gt; exercise period from the grant date. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Spyre 2023 Equity Incentive Plan &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On June&#160;22, 2023, in connection with the Asset Acquisition, the Company assumed the Amended and Restated Spyre 2023 Equity Incentive Plan (the &#x201c;Spyre Equity Plan&#x201d;) and its outstanding and unexercised stock options, which were converted to options to purchase &lt;div style="display:inline;"&gt;2,734&lt;/div&gt; shares of Aeglea common stock. The acquisition-date fair value of these grants will be recognized as an expense on a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pro-rata&lt;/div&gt; basis over the vesting period. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Parapyre Option Obligation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On June&#160;22, 2023, in connection with the Asset Acquisition, the Company assumed the Parapyre Option Obligation which provided for an annual equity grant of options to purchase 1% of the then outstanding shares of Spyre&#x2019;s common stock, on a fully diluted basis, on the last business day of each calendar year during the term of the Paragon Agreement, at the fair market value determined by the board of directors of Spyre. As a result of the Asset Acquisition the Parapyre Option Obligation shall continue and Parapyre shall be entitled to receive the equivalent shares of the Company with the same terms. As of September&#160;30, 2023, the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pro-rated&lt;/div&gt; estimated fair value of the options to be granted on December&#160;31, 2023, was approximately $3.0&#160;million, of which $0.1&#160;million was recognized as part of the liabilities assumed with the Asset Acquisition. For the three and nine months ended September&#160;30, 2023, $2.7&#160;million and $2.9&#160;million, respectively, was recognized as stock compensation expense related to the Parapyre Option Obligation. As of September&#160;30, 2023, the unamortized expense related to the Parapyre Option Obligation was $2.1&#160;million. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following table summarizes the Company&#x2019;s stock awards granted under all plans for each of the periods indicated: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:34%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Three Months Ended September&#160;30,&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Nine Months Ended September&#160;30,&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;2023&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;2022&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;2023&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;2022&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Grants&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Grant&lt;br/&gt; Date Fair&lt;br/&gt; Value&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Grants&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Grant&lt;br/&gt; Date Fair&lt;br/&gt; Value&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Grants&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Grant&lt;br/&gt; Date Fair&lt;br/&gt; Value&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Grants&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Grant&lt;br/&gt; Date Fair&lt;br/&gt; Value&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Stock options&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,044,667&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;14.50&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;50,806&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16.75&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,867,366&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9.65&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;153,686&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;52.50&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;2016 Employee Stock Purchase Plan &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Under the Company&#x2019;s 2016 Employee Stock Purchase Plan (&#x201c;2016 ESPP&#x201d;), the Company issued and sold 2,496 shares for aggregate cash proceeds of less than $0.1&#160;million during the nine months ended September&#160;30, 2023. There were 6,073 shares issued and sold under the 2016 ESPP for aggregate cash proceeds of $0.2&#160;million during the nine months ended September&#160;30, 2022. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;div style="line-height:normal;background-color:white;display: inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Stock-based Compensation Expense &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Total stock-based compensation expense related to all plans was as follows (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:64%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Three&#160;Months&#160;Ended&lt;br/&gt; September&#160;30,&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Nine Months Ended&lt;br/&gt; September&#160;30,&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;2023&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;2022&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;2023&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;2022&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Research and development &lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,965&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;639&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,136&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,031&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;General and administrative&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,820&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;926&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,269&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,653&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total stock-based compensation expense&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,785&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,565&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8,405&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,684&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px"&gt;(1)&lt;/div&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;For the three and nine months ended September&#160;30, 2023, $2.7&#160;million and $2.9&#160;million, respectively, was recognized as stock compensation expense related to the Parapyre Option Obligation. There were no such expenses for the three and nine months ended September&#160;30, 2022. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following table summarizes the weighted-average Black-Scholes option pricing model assumptions used to estimate the fair value of stock options granted under the Company&#x2019;s 2016 Plan, and the shares purchasable under the 2016 ESPP during the periods presented: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:67%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Three&#160;Months&#160;Ended&lt;br/&gt; September&#160;30,&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Nine&#160;Months&#160;Ended&lt;br/&gt; September&#160;30,&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;2023&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;2022&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;2023&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;2022&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2016 Plan&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected term (in years)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.08&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.02&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.04&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5.96&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected volatility&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;101&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;85&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;111&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;83&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Risk-free interest&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4.28&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.16&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4.07&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.43&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Dividend yield&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2016 ESPP&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected term (in years)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.50&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.50&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.49&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.49&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected volatility&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;222&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;95&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;181&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;84&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Risk-free interest&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5.29&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.26&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4.99&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.95&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Dividend yield&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P05_01_2022To05_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">430107</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="PAsOn05_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">40</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn05_31_2022"
      decimals="0"
      unitRef="Unit_shares">694892</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <agle:ClassOfWarrantOrRightOfferingPriceOfWarrantsOrRights
      contextRef="PAsOn05_31_2022"
      decimals="4"
      unitRef="Unit_USD_per_Share">39.9975</agle:ClassOfWarrantOrRightOfferingPriceOfWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn05_31_2022"
      decimals="4"
      unitRef="Unit_USD_per_Share">0.0025</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="P05_01_2022To05_31_2022"
      decimals="-5"
      unitRef="Unit_USD">42900000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <agle:PlacementAgentFeesAndOfferingCosts
      contextRef="P05_01_2022To05_31_2022"
      decimals="-5"
      unitRef="Unit_USD">2100000</agle:PlacementAgentFeesAndOfferingCosts>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn05_31_2022"
      decimals="4"
      unitRef="Unit_USD_per_Share">0.0025</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <agle:OwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercised
      contextRef="P02_01_2019To05_31_2022"
      decimals="4"
      unitRef="Unit_pure">0.0499</agle:OwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercised>
    <agle:OwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercisedToCertainHolders
      contextRef="P02_01_2019To05_31_2022"
      decimals="4"
      unitRef="Unit_pure">0.0999</agle:OwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercisedToCertainHolders>
    <agle:OwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercised
      contextRef="P02_01_2019To05_31_2022_MaximumMembersrtRangeAxis"
      decimals="4"
      unitRef="Unit_pure">0.1999</agle:OwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercised>
    <agle:ClassOfWarrantOrRightRevisedOwnershipPercentagePeriodToTakeEffectAfterNotice contextRef="P02_01_2019To05_31_2022">P61D</agle:ClassOfWarrantOrRightRevisedOwnershipPercentagePeriodToTakeEffectAfterNotice>
    <us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock contextRef="P01_01_2023To09_30_2023">&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;As of September&#160;30, 2023, the following &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-funded&lt;/div&gt; warrants for common stock were issued and outstanding: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:48%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:10%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:10%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:10%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;Issue Date&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Expiration&#160;Date&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Exercise&#160;Price&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Number&#160;of&#160;Warrants&lt;br/&gt; Outstanding&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;February&#160;8, 2019&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;None&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.0025&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;April&#160;30, 2020&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;None&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.0025&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;May&#160;20, 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;None&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.0025&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;250,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-funded&lt;/div&gt; warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;250,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn09_30_2023_FebruaryEightTwoThousandNinteenMemberusgaapAwardDateAxis_WarrantMemberusgaapStatementEquityComponentsAxis"
      decimals="4"
      unitRef="Unit_USD_per_Share">0.0025</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn09_30_2023_FebruaryEightTwoThousandNinteenMemberusgaapAwardDateAxis_WarrantMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn09_30_2023_AprilThirtyTwoThousandTwentyMemberusgaapAwardDateAxis_WarrantMemberusgaapStatementEquityComponentsAxis"
      decimals="4"
      unitRef="Unit_USD_per_Share">0.0025</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn09_30_2023_AprilThirtyTwoThousandTwentyMemberusgaapAwardDateAxis_WarrantMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn09_30_2023_MayTwentyTwoThousandTwentyTwoMemberusgaapAwardDateAxis_WarrantMemberusgaapStatementEquityComponentsAxis"
      decimals="4"
      unitRef="Unit_USD_per_Share">0.0025</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn09_30_2023_MayTwentyTwoThousandTwentyTwoMemberusgaapAwardDateAxis_WarrantMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">250000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn09_30_2023_WarrantMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">250000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <agle:AnnualPercentageOfAdditionalSharesWhichEqualsToIssuedAndOutstandingShares
      contextRef="P01_01_2016To12_31_2016_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="3"
      unitRef="Unit_pure">0.04</agle:AnnualPercentageOfAdditionalSharesWhichEqualsToIssuedAndOutstandingShares>
    <agle:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant
      contextRef="PAsOn01_01_2023_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">104560</agle:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant>
    <agle:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant
      contextRef="PAsOn01_01_2022_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">78968</agle:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="P07_01_2020To07_31_2020_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">9128</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="P07_01_2020To09_30_2023_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2023To09_30_2023_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <agle:StockOptionsGrantedToCertainMembersOfBoardOfDirectorsContingentOnStockholderApproval
      contextRef="P06_22_2023To06_22_2023_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">2720033</agle:StockOptionsGrantedToCertainMembersOfBoardOfDirectorsContingentOnStockholderApproval>
    <agle:StockBasedCompensationExpenseOnContingentAwards
      contextRef="PAsOn06_22_2023_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_USD">0</agle:StockBasedCompensationExpenseOnContingentAwards>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn09_30_2023_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">293497</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="P01_01_2023To09_30_2023_TwoThousandAndEighteenEquityInducementPlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">2800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="P01_01_2023To09_30_2023_TwoThousandAndEighteenEquityInducementPlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">3583880</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="P01_01_2023To09_30_2023_TwoThousandAndEighteenEquityInducementPlanMemberusgaapPlanNameAxis">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="P01_01_2023To09_30_2023_TwoThousandAndEighteenEquityInducementPlanMemberusgaapPlanNameAxis">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <agle:OutstandingAndUnexercisedStockOptions
      contextRef="P06_22_2023To06_22_2023_AssetAcquisitionMemberusgaapAssetAcquisitionAxis_Spyre2023EquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">2734</agle:OutstandingAndUnexercisedStockOptions>
    <agle:AnnualPercentageOfAdditionalSharesWhichEqualsToIssuedAndOutstandingShares
      contextRef="P06_22_2023To06_22_2023_ParapyreOptionObligationMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_pure">0.01</agle:AnnualPercentageOfAdditionalSharesWhichEqualsToIssuedAndOutstandingShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="P12_31_2023To12_31_2023_ParapyreOptionObligationMemberusgaapPlanNameAxis_ScenarioForecastMembersrtStatementScenarioAxis"
      decimals="-5"
      unitRef="Unit_USD">3000000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration
      contextRef="P06_22_2023To06_22_2023_ParapyreOptionObligationMemberusgaapPlanNameAxis"
      decimals="-5"
      unitRef="Unit_USD">100000</us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration>
    <us-gaap:ShareBasedCompensation
      contextRef="P07_01_2023To09_30_2023_ParapyreOptionObligationMemberusgaapPlanNameAxis"
      decimals="-5"
      unitRef="Unit_USD">2700000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2023To09_30_2023_ParapyreOptionObligationMemberusgaapPlanNameAxis"
      decimals="-5"
      unitRef="Unit_USD">2900000</us-gaap:ShareBasedCompensation>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="PAsOn09_30_2023_ParapyreOptionObligationMemberusgaapPlanNameAxis"
      decimals="-5"
      unitRef="Unit_USD">2100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock contextRef="P01_01_2023To09_30_2023">&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following table summarizes the Company&#x2019;s stock awards granted under all plans for each of the periods indicated: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:34%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Three Months Ended September&#160;30,&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Nine Months Ended September&#160;30,&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;2023&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;2022&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;2023&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;2022&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Grants&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Grant&lt;br/&gt; Date Fair&lt;br/&gt; Value&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Grants&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Grant&lt;br/&gt; Date Fair&lt;br/&gt; Value&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Grants&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Grant&lt;br/&gt; Date Fair&lt;br/&gt; Value&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Grants&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Grant&lt;br/&gt; Date Fair&lt;br/&gt; Value&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Stock options&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,044,667&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;14.50&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;50,806&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16.75&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,867,366&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9.65&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;153,686&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;52.50&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="P07_01_2023To09_30_2023"
      decimals="INF"
      unitRef="Unit_shares">1044667</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="P07_01_2023To09_30_2023"
      decimals="2"
      unitRef="Unit_USD_per_Share">14.5</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="P07_01_2022To09_30_2022"
      decimals="INF"
      unitRef="Unit_shares">50806</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="P07_01_2022To09_30_2022"
      decimals="2"
      unitRef="Unit_USD_per_Share">16.75</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="P01_01_2023To09_30_2023"
      decimals="INF"
      unitRef="Unit_shares">3867366</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2023To09_30_2023"
      decimals="2"
      unitRef="Unit_USD_per_Share">9.65</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="P01_01_2022To09_30_2022"
      decimals="INF"
      unitRef="Unit_shares">153686</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2022To09_30_2022"
      decimals="2"
      unitRef="Unit_USD_per_Share">52.5</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="P01_01_2023To09_30_2023_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">2496</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ProceedsFromStockPlans
      contextRef="P01_01_2023To09_30_2023_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="-5"
      unitRef="Unit_USD">100000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="P01_01_2022To09_30_2022_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">6073</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ProceedsFromStockPlans
      contextRef="P01_01_2022To09_30_2022_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="-5"
      unitRef="Unit_USD">200000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock contextRef="P01_01_2023To09_30_2023">&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Total stock-based compensation expense related to all plans was as follows (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:64%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Three&#160;Months&#160;Ended&lt;br/&gt; September&#160;30,&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Nine Months Ended&lt;br/&gt; September&#160;30,&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;2023&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;2022&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;2023&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;2022&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Research and development &lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,965&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;639&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,136&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,031&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;General and administrative&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,820&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;926&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,269&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,653&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total stock-based compensation expense&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,785&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,565&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8,405&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,684&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px"&gt;(1)&lt;/div&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;For the three and nine months ended September&#160;30, 2023, $2.7&#160;million and $2.9&#160;million, respectively, was recognized as stock compensation expense related to the Parapyre Option Obligation. There were no such expenses for the three and nine months ended September&#160;30, 2022. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P07_01_2023To09_30_2023_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">2965000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P07_01_2022To09_30_2022_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">639000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2023To09_30_2023_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">4136000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2022To09_30_2022_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">2031000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P07_01_2023To09_30_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">1820000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P07_01_2022To09_30_2022_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">926000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2023To09_30_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">4269000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2022To09_30_2022_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">3653000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P07_01_2023To09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">4785000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P07_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">1565000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">8405000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">5684000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensation
      contextRef="P07_01_2023To09_30_2023_ParapyreOptionObligationMemberusgaapPlanNameAxis"
      decimals="-5"
      unitRef="Unit_USD">2700000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2023To09_30_2023_ParapyreOptionObligationMemberusgaapPlanNameAxis"
      decimals="-5"
      unitRef="Unit_USD">2900000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2022To09_30_2022_ParapyreOptionObligationMemberusgaapPlanNameAxis"
      decimals="-6"
      unitRef="Unit_USD">0</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="P07_01_2022To09_30_2022_ParapyreOptionObligationMemberusgaapPlanNameAxis"
      decimals="-6"
      unitRef="Unit_USD">0</us-gaap:ShareBasedCompensation>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="P01_01_2023To09_30_2023">&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following table summarizes the weighted-average Black-Scholes option pricing model assumptions used to estimate the fair value of stock options granted under the Company&#x2019;s 2016 Plan, and the shares purchasable under the 2016 ESPP during the periods presented: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:67%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Three&#160;Months&#160;Ended&lt;br/&gt; September&#160;30,&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Nine&#160;Months&#160;Ended&lt;br/&gt; September&#160;30,&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;2023&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;2022&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;2023&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;2022&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2016 Plan&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected term (in years)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.08&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.02&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.04&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5.96&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected volatility&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;101&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;85&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;111&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;83&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Risk-free interest&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4.28&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.16&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4.07&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.43&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Dividend yield&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2016 ESPP&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected term (in years)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.50&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.50&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.49&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.49&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected volatility&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;222&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;95&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;181&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;84&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Risk-free interest&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5.29&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.26&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4.99&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.95&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Dividend yield&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P07_01_2023To09_30_2023_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P07_01_2022To09_30_2022_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis">P6Y7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P01_01_2023To09_30_2023_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis">P6Y14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P01_01_2022To09_30_2022_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis">P5Y11M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P07_01_2023To09_30_2023_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_pure">1.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P07_01_2022To09_30_2022_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_pure">0.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P01_01_2023To09_30_2023_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_pure">1.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P01_01_2022To09_30_2022_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_pure">0.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P07_01_2023To09_30_2023_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="4"
      unitRef="Unit_pure">0.0428</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P07_01_2022To09_30_2022_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="4"
      unitRef="Unit_pure">0.0316</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2023To09_30_2023_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="4"
      unitRef="Unit_pure">0.0407</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2022To09_30_2022_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="4"
      unitRef="Unit_pure">0.0243</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P07_01_2023To09_30_2023_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P07_01_2022To09_30_2022_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P01_01_2023To09_30_2023_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P01_01_2022To09_30_2022_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P07_01_2023To09_30_2023_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P07_01_2022To09_30_2022_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P01_01_2023To09_30_2023_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis">P0Y5M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P01_01_2022To09_30_2022_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis">P0Y5M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P07_01_2023To09_30_2023_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_pure">2.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P07_01_2022To09_30_2022_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_pure">0.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P01_01_2023To09_30_2023_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_pure">1.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P01_01_2022To09_30_2022_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_pure">0.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P07_01_2023To09_30_2023_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="4"
      unitRef="Unit_pure">0.0529</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P07_01_2022To09_30_2022_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="4"
      unitRef="Unit_pure">0.0326</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2023To09_30_2023_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="4"
      unitRef="Unit_pure">0.0499</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2022To09_30_2022_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="4"
      unitRef="Unit_pure">0.0195</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P07_01_2023To09_30_2023_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P07_01_2022To09_30_2022_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P01_01_2023To09_30_2023_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P01_01_2022To09_30_2022_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <agle:StrategicLicenseAgreementTextBlock contextRef="P01_01_2023To09_30_2023">&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;11. Strategic License Agreements &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On March&#160;21, 2021, the Company entered into an exclusive license and supply agreement with Immedica (the &#x201c;Immedica Agreement&#x201d;). By entering into this agreement, the Company agreed to provide Immedica the following goods and services: &lt;/div&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;i.&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;Deliver an exclusive, sublicensable, license and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;know-how&lt;/div&gt; (the &#x201c;License&#x201d;) to develop and commercialize pegzilarginase (the &#x201c;Product&#x201d;) in the territory comprising the members states of the European Economic Area (&#x201c;EEA&#x201d;), United Kingdom (&#x201c;UK&#x201d;), Switzerland, Andorra, Monaco, San Marino, Vatican City, Turkey, Saudi Arabia, United Arab Emirates, Qatar, Kuwait, Bahrain, and Oman (the &#x201c;Territory&#x201d;); &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;ii.&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;Complete the global pivotal PEACE (Pegzilarginase Effect on Arginase 1 Deficiency Clinical Endpoints) Phase 3 trial (&#x201c;PEACE Trial&#x201d;) and related Biologics License Application (&#x201c;BLA&#x201d;) package to file with the FDA, which will be leveraged by Immedica in obtaining the necessary regulatory approvals in the Territory; and &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;iii.&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;Perform a Pediatric Investigation Plan trial (&#x201c;PIP Trial&#x201d;) in order for Immedica to be able to receive certain regulatory approvals within the Territory. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In addition, the Company and Immedica formed a Joint Steering Committee (&#x201c;JSC&#x201d;) to provide oversight to the activities performed under the agreement; however, the substance of the Company&#x2019;s participation in the JSC &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;did not represent an additional promised service, but rather, a right of the Company to protect its own interests in the arrangement. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Further, the Company agreed to supply to Immedica, and Immedica agreed to purchase from the Company, substantially all commercial requirements of the Product. The terms of the agreement did not provide for either (i)&#160;an option to Immedica to purchase the Product from the Company at a discount from the standalone selling price or (ii)&#160;minimum purchase quantities. Immedica was expected to bear (i)&#160;all costs and expenses for any development or commercialization of the Product in the Territory subject to the License exclusive of the Company&#x2019;s promised goods and services summarized above and (ii)&#160;all costs and fees associated with applying for regulatory approval of the Product in the Territory. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company received a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-refundable&lt;/div&gt; payment of $21.5&#160;million and Immedica agreed to provide payment of 50% of the Company&#x2019;s costs incurred in performing the PIP Trial up to a maximum of $1.8&#160;million. In addition, the Company had the ability to receive regulatory and commercial milestone payments. The Company was also entitled to receive royalties in the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;mid-20%&lt;/div&gt; range on net sales of the Product in the Territory. In July 2021, the Company modified the agreement with Immedica to provide certain additional services in relation to the PEACE Trial and BLA package performance obligation in exchange for the reimbursement of up to $3.0&#160;million of the actual costs incurred in relation to such incremental services. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company concluded that Immedica met the definition to be accounted for as a customer because the Company was delivering intellectual property and other services within the Company&#x2019;s normal course of business, in which the parties are not jointly sharing the risks and rewards. Therefore, the Company concluded that the promises summarized above represent transactions with a customer within the scope of ASC 606. The Company determined that the following promises represent distinct promised services, and therefore, performance obligations: (i)&#160;the License, (ii)&#160;the PEACE Trial and BLA package, and (iii)&#160;the PIP Trial. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Specifically, in making these determinations, the Company considered the following factors: &lt;/div&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:5%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:3%;vertical-align:top;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: left; line-height: normal;"&gt;As of inception of the agreement, the Company had completed the Phase 1/2 clinical trial related to the Product and was conducting the PEACE Trial. Accordingly, the Company was not promising, nor expecting, to perform additional research and development activities pursuant to the agreement that would either significantly modify, customize or be considered highly interdependent or interrelated with pegzilarginase. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:5%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:3%;vertical-align:top;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: left; line-height: normal;"&gt;The License represented functional intellectual property given the functionality of the License was not expected to change substantially as a result of the company&#x2019;s ongoing activities. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:5%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:3%;vertical-align:top;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: left; line-height: normal;"&gt;The services necessary to complete the PEACE Trial, BLA package and PIP Trial could have been performed by other parties. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Given that Immedica was not obligated to purchase any minimum amount or quantities of Product, the supply of Product for commercial use to Immedica was determined to be an option for Immedica, rather than a performance obligation of the Company at contract inception and will be accounted for if and when exercised. The Company also determined that Immedica&#x2019;s option to purchase the Product did not create a material right as the expected pricing is not at a discount. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company determined that the upfront fixed payment amount of $21.5&#160;million should be included in the transaction price. Additionally, the Company determined at inception of the arrangement that 50% of the probable estimated costs to be incurred in relation to the PIP Trial exceeded $1.8&#160;million and included the full reimbursement amount of $1.8&#160;million in the transaction price. Upon subsequent &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-evaluation&lt;/div&gt; due to changing facts and circumstances, the Company determined the probable estimated costs were less than the maximum allowable reimbursement and a portion of the variable consideration was constrained, which did not materially impact the revenue recognized as of September&#160;30, 2023. Additionally, upon the modification of the agreement &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;in July 2021, the Company determined that the probable estimated costs to perform the additional services related to the PEACE Trial and BLA package exceeded the maximum allowable reimbursement of $3.0&#160;million. Therefore, the Company included an estimated total of $3.6&#160;million that was due in relation to the PIP Trial, PEACE Trial, and BLA package in the transaction price and concluded that it is probable that a significant reversal will not occur in the future. In total, the modified transaction price was determined to be $25.1&#160;million. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company allocated $9.6&#160;million and $3.5&#160;million of the modified transaction price to the PEACE Trial and BLA package and PIP Trial performance obligations, respectively, based on the stand-alone selling prices (&#x201c;SSP&#x201d;), which were based on the estimated costs that a third-party would charge in performing such services on a stand-alone basis. The SSP for the License was established at inception of the arrangement using a residual value approach due to the uniqueness of and lack of observable data related to the License, and without a specific analog from which to make reliable estimates, resulting in an allocation of $12.0&#160;million. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The potential regulatory milestone payments that the Company was eligible to receive were excluded from the transaction price, as the milestone amounts were fully constrained based on the probability of achievement, since the milestones related to successful achievement of certain regulatory approvals, which might not have been achieved. The Company determined that the royalties and commercial milestone payments related predominantly to the license of intellectual property and therefore should be excluded from the transaction price under the sales- or usage-based royalty exception under ASC 606. The Company intends to reevaluate the transaction price, including all constrained amounts, at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur, the Company intends to adjust its estimate of the transaction price as necessary. The Company recognized the royalties and commercial milestone payments as revenue when the associated sales occurred, and relevant sales-based thresholds were met. The Company also assessed the arrangement with Immedica and concluded that a significant financing component does not exist. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company recognized revenue allocated to the License performance obligation at a point in time and upon transfer of the License. The Company completed the transfer of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;know-how&lt;/div&gt; necessary for Immedica to benefit from the License in September 2021 and recognized $12.0&#160;million of revenue at that time. The development fee allocated to the PEACE Trial, BLA package and PIP Trial performance obligations is recognized over time using an input method of costs incurred related to the performance obligations. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company recognized revenue of $0.9&#160;million under the Immedica Agreement for the nine months ended September&#160;30, 2023. There was no such revenue for the three months ended September&#160;30, 2023. The total revenue generated in the nine months ended September&#160;30, 2023 was attributable to the PEACE Phase 3 and PIP trials, drug supply, and royalties from an early access program in France. For the three and nine months ended September&#160;30, 2022, the Company recognized revenue of $0.2&#160;million and $2.2&#160;million, respectively, related to the PEACE Trial and BLA package performance obligation. As of December&#160;31, 2022, the Company recorded deferred revenue of $3.6&#160;million associated with the Immedica Agreement, of which $2.4&#160;million was classified as current. There was no such revenue associated with the Immedica Agreement as of September&#160;30, 2023. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On July&#160;27, 2023, the Company announced that it had entered into an agreement to sell the global rights to pegzilarginase to Immedica and concurrently terminated the Immedica Agreement. Remaining deferred revenue was recognized as part of the gain on disposal of the assets. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Contract Balances from Customer Contract &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The timing of revenue recognition, billings and cash collections results in contract assets and contract liabilities on the Company&#x2019;s balance sheets. The Company recognizes license and development receivables based on billed services, which are derecognized upon reimbursement. When consideration is received, or such consideration is unconditionally due, from a customer prior to transferring goods or services to the customer under the terms of a contract, a contract liability is recorded. Contract liabilities are recognized as revenue after control of the goods or services is transferred to the customer and all revenue recognition criteria have been met. &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following table presents changes in the Company&#x2019;s contract liabilities for the periods presented (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:52%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:8%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:8%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:8%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:8%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;Nine Months Ended September&#160;30, 2023&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Additions&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Deductions&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;September&#160;30,&lt;br/&gt; 2023&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Contract liabilities:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Deferred revenue&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,696&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;575&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,271&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company had no contract assets during the nine months ended September&#160;30, 2023 and 2022. &lt;/div&gt;</agle:StrategicLicenseAgreementTextBlock>
    <agle:NonRefundablePaymentReceived
      contextRef="P03_21_2021To03_21_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      unitRef="Unit_USD">21500000</agle:NonRefundablePaymentReceived>
    <agle:PercentageOfPaymentForCostIncurredInPIPTrial
      contextRef="P03_21_2021To03_21_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis"
      decimals="2"
      unitRef="Unit_pure">0.50</agle:PercentageOfPaymentForCostIncurredInPIPTrial>
    <agle:CostsIncurredInPerformingTheTrial
      contextRef="P03_21_2021To03_21_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_MaximumMembersrtRangeAxis"
      decimals="-5"
      unitRef="Unit_USD">1800000</agle:CostsIncurredInPerformingTheTrial>
    <us-gaap:ReimbursementFromLimitedPartnershipInvestment
      contextRef="P07_01_2021To07_31_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      unitRef="Unit_USD">3000000</us-gaap:ReimbursementFromLimitedPartnershipInvestment>
    <agle:UpfrontPayment
      contextRef="P03_21_2021To03_21_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      unitRef="Unit_USD">21500000</agle:UpfrontPayment>
    <agle:PercentageOfPaymentForCostIncurredInPIPTrial
      contextRef="P03_21_2021To03_21_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis"
      decimals="2"
      unitRef="Unit_pure">0.50</agle:PercentageOfPaymentForCostIncurredInPIPTrial>
    <agle:CostsIncurredInPerformingTheTrial
      contextRef="P03_21_2021To03_21_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_MaximumMembersrtRangeAxis"
      decimals="-5"
      unitRef="Unit_USD">1800000</agle:CostsIncurredInPerformingTheTrial>
    <agle:ContractWithCustomerFullReimbursementOfCostsIncludedLiability
      contextRef="PAsOn03_21_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_LicenseMembersrtProductOrServiceAxis"
      decimals="-5"
      unitRef="Unit_USD">1800000</agle:ContractWithCustomerFullReimbursementOfCostsIncludedLiability>
    <us-gaap:ReimbursementFromLimitedPartnershipInvestment
      contextRef="P07_01_2021To07_31_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      unitRef="Unit_USD">3000000</us-gaap:ReimbursementFromLimitedPartnershipInvestment>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross
      contextRef="P07_01_2021To07_31_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      unitRef="Unit_USD">3600000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="P07_01_2021To07_31_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      unitRef="Unit_USD">25100000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <agle:AllocatedAmountOfTransactionPrice
      contextRef="P07_01_2021To07_31_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_PeaceTrialAndBLAPackageMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">9600000</agle:AllocatedAmountOfTransactionPrice>
    <agle:AllocatedAmountOfTransactionPrice
      contextRef="P07_01_2021To07_31_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_PIPTrialMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">3500000</agle:AllocatedAmountOfTransactionPrice>
    <agle:AllocationPriceTotal
      contextRef="P07_01_2021To07_31_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      unitRef="Unit_USD">12000000</agle:AllocationPriceTotal>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P09_01_2021To09_30_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_LicenseAgreementsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">12000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2023To09_30_2023_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_PeacePhase3TrialAndDrugSupplyMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P07_01_2023To09_30_2023_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_PeacePhase3TrialAndDrugSupplyMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P07_01_2022To09_30_2022_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_PeaceTrialAndBLAPackageMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To09_30_2022_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_PeaceTrialAndBLAPackageMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">2200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiability
      contextRef="PAsOn12_31_2022_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      unitRef="Unit_USD">3600000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="PAsOn12_31_2022_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      unitRef="Unit_USD">2400000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="PAsOn09_30_2023_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock contextRef="P01_01_2023To09_30_2023">&lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following table presents changes in the Company&#x2019;s contract liabilities for the periods presented (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:52%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:8%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:8%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:8%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:8%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;Nine Months Ended September&#160;30, 2023&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Additions&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Deductions&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;September&#160;30,&lt;br/&gt; 2023&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Contract liabilities:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Deferred revenue&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,696&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;575&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,271&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerLiability
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">2696000</us-gaap:ContractWithCustomerLiability>
    <agle:ContractWithCustomerLiabilityAdditions
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">575000</agle:ContractWithCustomerLiabilityAdditions>
    <us-gaap:ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">-3271000</us-gaap:ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination>
    <us-gaap:ContractWithCustomerLiability
      contextRef="PAsOn09_30_2023"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="PAsOn09_30_2023"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="PAsOn09_30_2022"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock contextRef="P01_01_2023To09_30_2023">&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;12. Sale of Pegzilarginase to Immedica &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On July&#160;27, 2023, the Company announced that it had entered into an agreement to sell the global rights to pegzilarginase, an investigational treatment for the rare metabolic disease Arginase 1 Deficiency, to Immedica for $15.0&#160;million in upfront cash proceeds and up to $100.0&#160;million in contingent milestone payments. The sale of pegzilarginase to Immedica superseded and terminated the previous license agreement between the Company and Immedica. On July&#160;27, 2023, the carrying value of the asset was zero as it was internally developed. Accordingly the Company recognized a $14.6&#160;million gain within operating expenses, which is the full $15.0&#160;million in upfront cash proceeds, net of transaction costs and the derecognition of pegzilarginase related nonfinancial assets and liabilities. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The milestone payments are contingent on formal reimbursement decisions by national authorities in key European markets and pegzilarginase approval by the FDA, among other events. The upfront payment and contingent milestone payments if paid, net of expenses and adjustments, will be distributed to holders of Aeglea&#x2019;s CVR pursuant to the CVR Agreement resulting from the Asset Acquisition. &lt;/div&gt;</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
    <us-gaap:ProceedsFromSaleOfIntangibleAssets
      contextRef="P07_27_2023To07_27_2023_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberusgaapDisposalGroupClassificationAxis_GlobalRightsToPegzilarginaseMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"
      decimals="-5"
      unitRef="Unit_USD">15000000</us-gaap:ProceedsFromSaleOfIntangibleAssets>
    <agle:DisposalGroupIncludingDiscontinuedOperationContingentConsideration
      contextRef="PAsOn07_27_2023_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberusgaapDisposalGroupClassificationAxis_GlobalRightsToPegzilarginaseMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"
      decimals="-5"
      unitRef="Unit_USD">100000000</agle:DisposalGroupIncludingDiscontinuedOperationContingentConsideration>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation
      contextRef="PAsOn07_27_2023_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberusgaapDisposalGroupClassificationAxis_GlobalRightsToPegzilarginaseMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"
      decimals="-6"
      unitRef="Unit_USD">0</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
      contextRef="P07_27_2023To07_27_2023_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberusgaapDisposalGroupClassificationAxis_GlobalRightsToPegzilarginaseMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"
      decimals="-5"
      unitRef="Unit_USD">14600000</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <us-gaap:ProceedsFromSaleOfIntangibleAssets
      contextRef="P07_27_2023To07_27_2023_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberusgaapDisposalGroupClassificationAxis_GlobalRightsToPegzilarginaseMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"
      decimals="-5"
      unitRef="Unit_USD">15000000</us-gaap:ProceedsFromSaleOfIntangibleAssets>
    <us-gaap:EarningsPerShareTextBlock contextRef="P01_01_2023To09_30_2023">&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;13. Net Loss Per Share &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company computes net loss attributable per common stockholder using the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;two-class&lt;/div&gt; method required for participating securities. The Company considers convertible. preferred stock to be participating securities. In the event that the Company paid out distributions, holders of convertible preferred stock would participate in the distribution. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;two-class&lt;/div&gt; method is an earnings (loss) allocation method under which earnings (loss) per share is calculated for common stock and participating security considering a participating security&#x2019;s rights to undistributed earnings (loss) as if all such earnings (loss) had been distributed during the period. The holders of Series A Preferred Stock do not have an obligation to fund losses and therefore the Series A Preferred Stock was excluded from the calculation of basic net loss per share. The Company included in the calculation of basic net loss per share, contingently issuable common shares related to the Asset Acquisition because they will be issued for no consideration due to the consideration already having been satisfied as of September&#160;30, 2023. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Basic and diluted net loss per share is computed by dividing the net loss by the weighted-average number of common stock and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-funded&lt;/div&gt; warrants outstanding during the period, without consideration of potential dilutive securities. The &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-funded&lt;/div&gt; warrants are included in the computation of basic net loss per share as the exercise price is negligible and they are fully vested and exercisable. For periods in which the Company generated a net loss, the Company does not include the potential impact of dilutive securities in diluted net loss per share, as the impact of these items is anti-dilutive. The Company has generated a net loss for all periods presented, therefore diluted net loss per share is the same as basic net loss per share since the inclusion of potentially dilutive securities would be anti-dilutive. &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following weighted-average equity instruments were excluded from the calculation of diluted net loss per share because their effect would have been anti-dilutive for the periods presented: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:54%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Three Months Ended&lt;br/&gt; September&#160;30,&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Nine Months Ended&lt;br/&gt; September&#160;30,&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;2023&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;2022&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;2023&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;2022&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Options to purchase common stock&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,135,672&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;351,533&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,426,224&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;335,395&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Unvested restricted stock units&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;252&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7,315&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Series A Preferred Stock (on an &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;as-converted&lt;/div&gt; basis)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;42,501,681&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;14,851,447&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="P01_01_2023To09_30_2023">&lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following weighted-average equity instruments were excluded from the calculation of diluted net loss per share because their effect would have been anti-dilutive for the periods presented: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:54%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Three Months Ended&lt;br/&gt; September&#160;30,&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Nine Months Ended&lt;br/&gt; September&#160;30,&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;2023&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;2022&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;2023&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;2022&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Options to purchase common stock&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,135,672&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;351,533&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,426,224&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;335,395&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Unvested restricted stock units&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;252&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7,315&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Series A Preferred Stock (on an &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;as-converted&lt;/div&gt; basis)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;42,501,681&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;14,851,447&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P07_01_2023To09_30_2023_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      unitRef="Unit_shares">3135672</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P07_01_2022To09_30_2022_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      unitRef="Unit_shares">351533</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2023To09_30_2023_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      unitRef="Unit_shares">1426224</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2022To09_30_2022_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      unitRef="Unit_shares">335395</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P07_01_2023To09_30_2023_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      unitRef="Unit_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P07_01_2022To09_30_2022_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      unitRef="Unit_shares">6000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2023To09_30_2023_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      unitRef="Unit_shares">252</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2022To09_30_2022_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      unitRef="Unit_shares">7315</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P07_01_2023To09_30_2023_SeriesAConvertiblePreferredStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      unitRef="Unit_shares">42501681</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P07_01_2022To09_30_2022_SeriesAConvertiblePreferredStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      unitRef="Unit_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2023To09_30_2023_SeriesAConvertiblePreferredStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      unitRef="Unit_shares">14851447</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2022To09_30_2022_SeriesAConvertiblePreferredStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      unitRef="Unit_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock contextRef="P01_01_2023To09_30_2023">&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;14. Restructuring Charges &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Severance and Stock Compensation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On April&#160;12, 2023, based on the review of the inconclusive interim results from the Company&#x2019;s Phase 1/2 clinical trial of pegtarviliase for the treatment of classical homocystinuria and other business considerations, the Company announced that it had initiated a process to explore strategic alternatives to maximize stockholder value and engaged an independent exclusive financial advisor to support this process. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;As a result, the Company implemented a restructuring plan resulting in an approximate 83% reduction of the Company&#x2019;s existing headcount by June&#160;30, 2023. The Company recognized restructuring expenses consisting of cash severance payments and other employee-related costs of nil and $6.4&#160;million during the three and nine months ended September&#160;30, 2023, respectively. Cash payments for employee related restructuring charges of $4.5&#160;million were paid as of September&#160;30, 2023. In addition, the Company recognized $1.0&#160;million in &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-cash&lt;/div&gt; stock-based compensation expense related to the accelerated vesting of stock-based awards for certain employees. The Company recorded these restructuring charges based on each employee&#x2019;s role to the respective research and development and general and administrative operating expense categories on its condensed consolidated statements of operations and comprehensive loss. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following table summarizes the changes in the Company&#x2019;s accrued restructuring balance (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:45%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:9%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:9%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:9%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:9%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Beginning&#160;Balance&lt;br/&gt; December&#160;31,&#160;2022&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Charges&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Payments&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Ending&#160;Balance&lt;br/&gt; September&#160;30,&#160;2023&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Severance liability&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,448&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(4,527&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,921&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Sale of Assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;During the second quarter of 2023, the Company sold various lab equipment, consumables, and furniture and fixtures for total consideration of $0.5&#160;million. After recording the disposal of all property and equipment net of proceeds, the Company recorded a $0.7&#160;million and $0.2&#160;million loss on disposal of long lived assets which is included in Research and development and General and administrative expenses, respectively. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Lease &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Right-of-use&lt;/div&gt;&lt;/div&gt; Asset and Leasehold Improvement Impairment &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Effective June&#160;30, 2023, the Company abandoned its leased office space in Austin, Texas. As a result, the Company recognized an impairment loss of $0.9&#160;million related to the operating lease &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; asset and $1.7&#160;million related to leasehold improvements. On August&#160;7, 2023, the Company terminated its building lease in Austin, Texas. The negotiated termination agreement obligated the Company to pay the lessor a $2.0&#160;million termination fee in exchange for releasing the Company of all further obligations under the lease. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;All charges related to the restructuring activities were recognized during the second quarter of 2023. No further restructuring charges will be incurred under the restructuring plan. A summary of the charges related to the restructuring activities is as follows (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:33%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:9%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:9%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:9%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:9%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:9%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Severance&#160;Related&lt;br/&gt; Expenses&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Stock&#160;Compensation&lt;br/&gt; Expenses&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Loss&#160;on&#160;Disposal&#160;of&lt;br/&gt; Long Lived Assets&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Lease&#160;Asset&lt;br/&gt; Impairment&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Total&#160;Restructuring&#160;Costs&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Research and development&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,182&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;123&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;749&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,405&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,459&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;General and administrative&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,266&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;870&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;182&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,175&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,493&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,448&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;993&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;931&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,580&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10,952&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
      contextRef="P04_01_2023To06_30_2023"
      decimals="2"
      unitRef="Unit_pure">0.83</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
      contextRef="P04_01_2023To04_30_2023"
      decimals="2"
      unitRef="Unit_pure">0.83</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent>
    <us-gaap:SeveranceCosts1
      contextRef="P01_01_2023To09_30_2023"
      decimals="-5"
      unitRef="Unit_USD">6400000</us-gaap:SeveranceCosts1>
    <us-gaap:PaymentsForRestructuring
      contextRef="P01_01_2023To09_30_2023"
      decimals="-5"
      unitRef="Unit_USD">4500000</us-gaap:PaymentsForRestructuring>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost
      contextRef="P01_01_2023To09_30_2023"
      decimals="-5"
      unitRef="Unit_USD">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost>
    <us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock contextRef="P01_01_2023To09_30_2023">&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following table summarizes the changes in the Company&#x2019;s accrued restructuring balance (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:45%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:9%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:9%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:9%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:9%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Beginning&#160;Balance&lt;br/&gt; December&#160;31,&#160;2022&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Charges&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Payments&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Ending&#160;Balance&lt;br/&gt; September&#160;30,&#160;2023&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Severance liability&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,448&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(4,527&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,921&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock>
    <us-gaap:RestructuringReserve
      contextRef="PAsOn12_31_2022_SeveranceLiabilityMemberusgaapRestructuringCostAndReserveAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringCharges
      contextRef="P01_01_2023To09_30_2023_SeveranceLiabilityMemberusgaapRestructuringCostAndReserveAxis"
      decimals="-3"
      unitRef="Unit_USD">6448000</us-gaap:RestructuringCharges>
    <us-gaap:PaymentsForRestructuring
      contextRef="P01_01_2023To09_30_2023_SeveranceLiabilityMemberusgaapRestructuringCostAndReserveAxis"
      decimals="-3"
      unitRef="Unit_USD">4527000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserve
      contextRef="PAsOn09_30_2023_SeveranceLiabilityMemberusgaapRestructuringCostAndReserveAxis"
      decimals="-3"
      unitRef="Unit_USD">1921000</us-gaap:RestructuringReserve>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration
      contextRef="PAsOn06_30_2023"
      decimals="-5"
      unitRef="Unit_USD">500000</us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="P04_01_2023To06_30_2023_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-5"
      unitRef="Unit_USD">-700000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="P04_01_2023To06_30_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-5"
      unitRef="Unit_USD">-200000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="P04_01_2023To06_30_2023"
      decimals="-5"
      unitRef="Unit_USD">900000</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:ImpairmentOfLeasehold
      contextRef="P04_01_2023To06_30_2023"
      decimals="-5"
      unitRef="Unit_USD">1700000</us-gaap:ImpairmentOfLeasehold>
    <agle:OperatingLeaseTerminationFeeAmount
      contextRef="PAsOn08_07_2023"
      decimals="-5"
      unitRef="Unit_USD">2000000</agle:OperatingLeaseTerminationFeeAmount>
    <us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock contextRef="P01_01_2023To09_30_2023">A summary of the charges related to the restructuring activities is as follows (in thousands): &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:33%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:9%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:9%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:9%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:9%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:9%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Severance&#160;Related&lt;br/&gt; Expenses&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Stock&#160;Compensation&lt;br/&gt; Expenses&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Loss&#160;on&#160;Disposal&#160;of&lt;br/&gt; Long Lived Assets&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Lease&#160;Asset&lt;br/&gt; Impairment&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Total&#160;Restructuring&#160;Costs&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Research and development&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,182&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;123&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;749&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,405&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,459&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;General and administrative&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,266&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;870&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;182&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,175&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,493&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,448&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;993&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;931&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,580&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10,952&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock>
    <us-gaap:SeveranceCosts1
      contextRef="P04_01_2023To06_30_2023_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_RestructuringActivitiesMemberusgaapRestructuringCostAndReserveAxis"
      decimals="-3"
      unitRef="Unit_USD">3182000</us-gaap:SeveranceCosts1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P04_01_2023To06_30_2023_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_RestructuringActivitiesMemberusgaapRestructuringCostAndReserveAxis"
      decimals="-3"
      unitRef="Unit_USD">123000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="P04_01_2023To06_30_2023_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_RestructuringActivitiesMemberusgaapRestructuringCostAndReserveAxis"
      decimals="-3"
      unitRef="Unit_USD">-749000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="P04_01_2023To06_30_2023_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_RestructuringActivitiesMemberusgaapRestructuringCostAndReserveAxis"
      decimals="-3"
      unitRef="Unit_USD">1405000</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:RestructuringCosts
      contextRef="P04_01_2023To06_30_2023_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_RestructuringActivitiesMemberusgaapRestructuringCostAndReserveAxis"
      decimals="-3"
      unitRef="Unit_USD">5459000</us-gaap:RestructuringCosts>
    <us-gaap:SeveranceCosts1
      contextRef="P04_01_2023To06_30_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_RestructuringActivitiesMemberusgaapRestructuringCostAndReserveAxis"
      decimals="-3"
      unitRef="Unit_USD">3266000</us-gaap:SeveranceCosts1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P04_01_2023To06_30_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_RestructuringActivitiesMemberusgaapRestructuringCostAndReserveAxis"
      decimals="-3"
      unitRef="Unit_USD">870000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="P04_01_2023To06_30_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_RestructuringActivitiesMemberusgaapRestructuringCostAndReserveAxis"
      decimals="-3"
      unitRef="Unit_USD">-182000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="P04_01_2023To06_30_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_RestructuringActivitiesMemberusgaapRestructuringCostAndReserveAxis"
      decimals="-3"
      unitRef="Unit_USD">1175000</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:RestructuringCosts
      contextRef="P04_01_2023To06_30_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_RestructuringActivitiesMemberusgaapRestructuringCostAndReserveAxis"
      decimals="-3"
      unitRef="Unit_USD">5493000</us-gaap:RestructuringCosts>
    <us-gaap:SeveranceCosts1
      contextRef="P04_01_2023To06_30_2023_RestructuringActivitiesMemberusgaapRestructuringCostAndReserveAxis"
      decimals="-3"
      unitRef="Unit_USD">6448000</us-gaap:SeveranceCosts1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P04_01_2023To06_30_2023_RestructuringActivitiesMemberusgaapRestructuringCostAndReserveAxis"
      decimals="-3"
      unitRef="Unit_USD">993000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="P04_01_2023To06_30_2023_RestructuringActivitiesMemberusgaapRestructuringCostAndReserveAxis"
      decimals="-3"
      unitRef="Unit_USD">-931000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="P04_01_2023To06_30_2023_RestructuringActivitiesMemberusgaapRestructuringCostAndReserveAxis"
      decimals="-3"
      unitRef="Unit_USD">2580000</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:RestructuringCosts
      contextRef="P04_01_2023To06_30_2023_RestructuringActivitiesMemberusgaapRestructuringCostAndReserveAxis"
      decimals="-3"
      unitRef="Unit_USD">10952000</us-gaap:RestructuringCosts>
    <us-gaap:CommitmentsDisclosureTextBlock contextRef="P01_01_2023To09_30_2023">&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;15. Novation of Manufacturing Agreements &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Pursuant to a Novation Agreement dated September&#160;19, 2023 (the &#x201c;Novation Agreement&#x201d;), by and between the Company, Paragon and WuXi Biologics (Hong Kong) Limited (&#x201c;WuXi Biologics&#x201d;), the Company novated (i)&#160;a Biologics Master Services Agreement (the &#x201c;WuXi Biologics MSA&#x201d;) and (ii)&#160;a Cell Line License Agreement (the &#x201c;Cell Line License Agreement&#x201d;). &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Biologics Master Services Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In April 2023, Paragon and WuXi Biologics entered into the WuXi Biologics MSA, which was subsequently novated to the Company by Paragon on September&#160;19, 2023 pursuant to the Novation Agreement. The WuXi Biologics MSA governs certain development activities and GMP manufacturing and testing for the SPY001 program, as well as potential future programs, on a work order basis. Under the WuXi Biologics MSA, the Company is obligated to pay WuXi Biologics a service fee and all &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-cancellable&lt;/div&gt; obligations in the amount specified in each work order associated with the agreement for the provision of services. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The WuXi Biologics MSA terminates on the later of (i)&#160;June&#160;20, 2027 or (ii)&#160;the completion of services under all work orders executed by the parties prior to June&#160;20, 2027, unless terminated earlier. The term of each work order terminates upon completion of the services under such work order, unless terminated earlier. The Company can terminate the WuXi Biologics MSA or any work order at any time upon 30 days&#x2019; prior written notice and immediately upon written notice if WuXi Biologics fails to obtain or maintain required material governmental licenses or approvals. Either party may terminate a work order (i)&#160;at any time upon six months&#x2019; prior notice with reasonable cause, provided however that if WuXi Biologics terminates a work order in such manner, no termination or cancellation fees shall be paid by the Company and (ii)&#160;immediately for cause upon (a)&#160;the other party&#x2019;s material breach that remains uncured for 30 days after notice of such breach, (b)&#160;the other party&#x2019;s bankruptcy or (c)&#160;a force majeure event that prevents performance for a period of at least 90 days. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Cell Line License Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In April 2023, Paragon and WuXi Biologics entered into the Cell Line License Agreement, which was subsequently novated to the Company by Paragon pursuant to the Novation Agreement. Under the Cell Line License Agreement, the Company received a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-exclusive,&lt;/div&gt; worldwide, sublicensable license to certain of WuXi Biologics&#x2019;s &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;know-how,&lt;/div&gt; cell line, biological materials (the &#x201c;WuXi Biologics Licensed Technology&#x201d;) and media and feeds to make, have made, use, sell and import certain therapeutic products produced through the use of the cell line licensed by WuXi Biologics under the Cell Line License Agreement (the &#x201c;WuXi Biologics Licensed Products&#x201d;). Specifically, the WuXi Biologics Licensed Technology is used in certain manufacturing activities in support of the SPY001 program. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In consideration for the license, the Company agreed to pay WuXi Biologics a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-refundable&lt;/div&gt; license fee of $0.2&#160;million. Additionally, if the Company manufactures all of its commercial supplies of bulk drug product with a manufacturer other than WuXi Biologics or its affiliates, the Company is required to make royalty payments to WuXi Biologics of less than one percent of global net sales of WuXi Biologics Licensed Products manufactured &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;by a third-party manufacturer (the &#x201c;Royalty&#x201d;). If the Company manufactures part of its commercial supplies of the WuXi Biologics Licensed Products with WuXi Biologics or its affiliates, then the Royalty will be reduced accordingly on a pro rata basis. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Cell Line License Agreement will continue indefinitely unless terminated (i)&#160;by the Company upon six months&#x2019; prior written notice and our payment of all undisputed &lt;div style="display:inline;"&gt;amounts &lt;/div&gt;due to WuXi Biologics through the effective date of termination, (ii)&#160;by WuXi Biologics for a material breach by the Company that remains uncured for 60 days after written notice, (iii)&#160;by WuXi Biologics if the Company fails to make a payment and such failure continues for 30 days after receiving notice of such failure, or (iv)&#160;by either party upon the other party&#x2019;s bankruptcy. &lt;/div&gt;</us-gaap:CommitmentsDisclosureTextBlock>
    <agle:OtherCommitmentRightToTerminateAgreementOrWorkOrderPriorWrittenNoticePeriod contextRef="P04_01_2023To04_30_2023">P30D</agle:OtherCommitmentRightToTerminateAgreementOrWorkOrderPriorWrittenNoticePeriod>
    <agle:OtherCommitmentRightToTerminateWorkOrderReasonableCausePriorWrittenNoticePeriod contextRef="P04_01_2023To04_30_2023">P6M</agle:OtherCommitmentRightToTerminateWorkOrderReasonableCausePriorWrittenNoticePeriod>
    <agle:OtherCommitmentRightToTerminateWorkOrderByCounterpartyReasonableCauseTerminationAmountPayable
      contextRef="PAsOn04_30_2023"
      decimals="0"
      unitRef="Unit_USD">0</agle:OtherCommitmentRightToTerminateWorkOrderByCounterpartyReasonableCauseTerminationAmountPayable>
    <agle:OtherCommitmentRightToTerminateWorkOrderMaterialBreachUncuredPeriod contextRef="P04_01_2023To04_30_2023">P30D</agle:OtherCommitmentRightToTerminateWorkOrderMaterialBreachUncuredPeriod>
    <agle:OtherCommitmentRightToTerminateWorkOrderUnusualOrInfrequentCausePeriod contextRef="P04_01_2023To04_30_2023">P90D</agle:OtherCommitmentRightToTerminateWorkOrderUnusualOrInfrequentCausePeriod>
    <agle:OtherCommitmentNonRefundableLicenseFeeAmount
      contextRef="PAsOn04_30_2023"
      decimals="-5"
      unitRef="Unit_USD">200000</agle:OtherCommitmentNonRefundableLicenseFeeAmount>
    <agle:OtherCommitmentRoyaltyPercentage
      contextRef="PAsOn04_30_2023"
      decimals="INF"
      unitRef="Unit_pure">0.01</agle:OtherCommitmentRoyaltyPercentage>
    <agle:OtherCommitmentRightToTerminateAgreementPriorWrittenNoticePeriod contextRef="P04_01_2023To04_30_2023">P6M</agle:OtherCommitmentRightToTerminateAgreementPriorWrittenNoticePeriod>
    <agle:OtherCommitmentRightToTerminateAgreementByCounterpartyMaterialBreachUncuredPeriod contextRef="P04_01_2023To04_30_2023">P60D</agle:OtherCommitmentRightToTerminateAgreementByCounterpartyMaterialBreachUncuredPeriod>
    <agle:OtherCommitmentRightToTerminateAgreementByCounterpartyPaymentsNotReceivedPeriod contextRef="P04_01_2023To04_30_2023">P30D</agle:OtherCommitmentRightToTerminateAgreementByCounterpartyPaymentsNotReceivedPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>160
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M$IR#;_,0?/SP"7P 2086:[HMHVQ97@P9OP<1:1COKW==7P_U7&].\L\ 6V<
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MPW:QP:BQ[IJ1CBTBE*B2M-WMUX^4%-FR%'VDR45,4N\YY//*9 ZS/'/Q)&,
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M>F4UREE%.1M!.7R/S1IVNZU[9S-4& P0U@CG%>%\!.&P'39OK,5SO+D_G]W
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M@@FH)PW!M5PAOYS+(-NSA$GKRR!BN6*J&@ H:HI<(8!R+2IDJPL Y5 L*AE
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M#B92OQD \FS7<T2WBB @IJ9KC]FJK]N)^H622VSU#9/+/-=:,G#$6@ 0MA8
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M,!#^*U8V3:VT-2$O0%F(5%ZF[4,U!.KVV4T.$M6),]M ^^]W=D)&FY15&WS
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M&B"T NZO.5>'A3;0?+I$OP%02P,$%     @ \(.65_#E-143!   I1$  !@
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M/T]VY_)NL_EU]\L/-Z\OIKLNU:MZT>XTYMW_/M37]6JUD^HZ\MM!]>(YZ.[
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M::B:0:G9QNCI9A8T#]C+#%#VF-']-X@9H&6(4#4-53,H-=L,@ZU^9>SH4]K
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M>^?Z9G873^>Q^.#(<O--^]>)__WI^O/TC_CF?O[&F=Y$SET\O[^[GMW'40L
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MAL:!<;[=;%;MM(+0 %%>9ZNRWE:M=)7[Y-M5R^M^]D\X)#F4N]=%]XH=H0S
MC=O4YMK@S"I;9)4MMLJ6V&(;ODJAUX3,K GGO&FZD)!1(%S\G%;R@?&BJ83
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MK9+5]F$UQZN5 TY@>YKF]H9M>+$NZ?M]V8R8+EBI60QH+4N[@W$614LN3?*
M=G$ /05E6Q*2]_O&,KRFV(Q6N([P<GUW4[QX>;DD!K_[RU^6SZ])[G\=K;/"
M<^DR!K P &4ZA#8OG3-#RA/.[FQ3DJ;HR]:5RK\DE1CH7/&P-3R,&)JT!\.4
MC$PX6(D)L:*Q.$:Q&HF!L$C5[59$-9[!/Q(,*63%ZD!D[=W 9S^ ]&7AJAZ\
M2(<8 $]MB!/(?3 !)#>2G2&FM\S&](]7,)$:_LFF[P@,?W9LS'(-R BY+9UH
M4#D'SV^(ZB01M/+:EF ! 9@@IW7&/1;U6#L>1@1]2[]WBR-<63>#I/88&[P
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M_NJ)=%;X+T.WYS\V0!$\!4W\$:^0,#T&T._KKAO\%VP0_ES%=_\-4$L#!!0
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MIB> R^[++']A5>X^;EHH:U7J?JX%AX%I ]:7"AXH+^B ^O.XJW\#4$L#!!0
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MC8>C(@#=#_*>L*KUPW.I+(UBOUW3VX?:"=!YK93=$\[ X36=_0)02P,$%
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M3".<\4[SQJT'WE2A[9P9CR8V?.;XKX$L;\#ZW.#I;0?L8/-_R/0_4$L#!!0
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M0CW[YB*=O+ITK$\)\^A6V?VPD689-&3)E0ZL891GV+FHI?-B$1P2UCF1(Z!
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M?&#<V!I,&'DX>J"I/W.$!-9G.7'=\",,(_6&U:OYY-$,P3NA@<^IDJ#]BD%
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MTCN/:0X#FF\RF+"$R*\MUGU<.VW$.Q*,@+.L07T#12O1HS<V\A]B?F^-:;I
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MF-VV(M>E,+,:$9,D3F^6"H*V"(H@:]& ,(./<DVZDH6EY^FI=ZJJ--UZ0AQ
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M]EW[,&@'P=:I&2]L0&M/GR7>4NSB!JPOK0V[03R@>YW-_@%02P,$%     @
M\(.65XBYB7'D @  ;@8  !D   !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL
ME57;;MLP#/T5PAN&#<ABQTF[HDL"-.V&[:% T.[R,.Q!<9A8JRZ>1#?UWX^2
M$S<;D@![D46*/#RD1'J\L>[!EX@$3UH9/TE*HNHR37U1HA:^;RLT?+*R3@MB
MT:U37SD4R^BD59IGV7FJA33)=!QU<S<=VYJ4-#AWX&NMA6MFJ.QFD@R2G>).
MKDL*BG0ZKL0:[Y&^5G/'4MJA+*5&XZ4UX' U2:X&E[-1L(\&WR1N_-X>0B8+
M:Q^"\'DY2;) "!46%! $?Q[Q&I4*0$SC]Q8SZ4(&Q_W]#OUCS)US60B/UU9]
METLJ)\E% DM<B5K1G=U\PFT^9P&OL,K'%3:M[9 C%K4GJ[?.+&MIVJ]XVM9A
MS^$B.^*0;QWRR+L-%%G>"!+3L;,;<,&:T<(FIAJ]F9PTX5+NR?&I9#^:WN"*
M-4NXMH:<7-2Q5',ES#@EA@]&:;&%FK50^1&H00ZWC%)Z^&"6N/P;(&5>';E\
M1VZ6GT2\P:(/PT$/\BS/3^ -NV2'$6]X!.\.23KD)T4P0\.9DX<?5PM/CA_'
MST,9MWBCPWBA82Y])0J<)-P1'MTC)M-7+P;GV?L3;$<=V]$I]/^[FI-0AXD.
M!GTX&@.^E,A:70G3@*^L\=9Y$##*!J\?WG [=I6L@K4TL"EE47)S<SF%(2F4
M:H 7L"L(=5[52KTE[F= 72G;(#*<8TG)M5PH!+)0"4>RD)4@[,-\)QCVUJ*!
M8L<1F4>%KN#H/#=" "I1.A#&U$*QG>:1Y47,A5&IE#ZR[ 5VOW@<!"VSI)JL
M:T!)+2E:>RY([:19!T!H4'#*&-XRUZE O4#7O<:XMONL%\UWQ:J<?93!YV76
M/^>658J1>_](PL3SLV<-7TN%<42IIA?J6>Q=B6_SP)A&'PX]KG1O!FATZSCI
M/*/4AMIQT&F[87K5SI!G\W82WPJWEAQ3X8I=L_Z[LP1<.]U:@6P5)\K"$L^G
MN"WYAX N&/#YREK:"2% ]XN9_@%02P,$%     @ \(.65\,@XR2+"    A8
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M"<64 AO13SAY"Q7&RHP]8R?I(HBB.3NEZV09K!>AOT[#(%WC^00YB RK691
M1!JR'W](XRA^.7D/ZY^PFD3,@_4RZD4GR8AHY\F!S!8/S'94#-R*-ZK:\?J
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MXK,XG"7'-O<L2F;KXRVA0"M6W2,XI3OCJ7F9QX<'WW5)@N]F:/$[X0XDY2%
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M=V]R:W-H965T<R]S:&5E=#(W+GAM;.U7WV_;-A!^]U]!J$"Q!R:22$FV4]M
MDG;H@+4+ZG3%,.R!ELX6$4E422I._OL=:5NU$\<+L#T.""S^N._CW?'N>)FL
ME;XS)8 E#W75F&E06MM>A*')2ZB%.5<M-+BS5+H6%J=Z%9I6@R@\J*Y"%D59
M6 O9!+.)7[O1LXGJ;"4;N-'$='4M].,55&H]#>)@M_!%KDKK%L+9I!4KF(/]
MVMYHG(4]2R%K:(Q4#=&PG :7\<5UXN2]P.\2UF9O3)PE"Z7NW.278AI$3B&H
M(+>.0>#G'JZAJAP1JO%]RQGT1SK@_GC'_K.W'6U9" /7JOHF"UM.@U% "EB*
MKK)?U/HC;.U)'5^N*N-_R7HCRZ. Y)VQJMZ"48-:-INO>-CZ80\P>@G M@#V
M6@#? K@W=*.9-^N]L&(VT6I-M)-&-C?POO%HM$8V[A;G5N.N1)R=?<9 ^549
M0VY DWDI-$Q"B[QN-\RW'%<;#O8"QYA\4HTM#?G0%% <P5^?QL?L!$&(!O56
ML9U55^PDXQS:<\(C2EC$^#&%3L/?0X[PV,/9"75X[V3N^?@+?!^$;F2SVG,R
M^?-R8:S&(/[KF+\W=,EQ.I?8%Z85.4P#S%P#^AZ"V=LW<1:].V;K?T1V8'G2
M6YZ<8G]E>)WD.*YAS,_)<W)R6P*Y5G4KFD>2X[>S8$B#<I63$]9JN>BL6%1
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M03L!W%\J97<3=T#_7\#L;U!+ P04    " #P@Y97X8$H81\&   I#@  &0
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MND:SC2@2V3K$WR,5479JB14?5L5 ?'H4BIC9!3GCA2(7L)<PI1?8/F4D'=>
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MG#+CY1S'>G(L@-\SBU>;YH8=K/]1</$O4$L#!!0    ( /"#EE?F+IYY/0(
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M2"[BSR<$SD:!LU/T__T/IR'); )'0/!=P1I;0KE! Y?A4J=G0#7"2LN6JU?
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MA-+T IXO#;KD^(%^;=C_5O3-?P!02P,$%     @ \(.65U; .#@$ P  8P8
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MR?C\-.HZ9W?QI@EK9&T\+:5PK.@K@)852%X88M-?>#,-WY7%'U!+ P04
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M?A:*X<ZFTV3)408'B_[Q(YQXD NXK"%6G1YK)+EU[ 48M@!9TG/6LN&R47"
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MJU2<07#HZ64P@O@J+W_K<D#'[.&YZ#"A8)9]5)_S:9/H/-2-G]]9BBT)<.)
MN.3)?]#VTR ;';5,_*BC73UDM*GU1\;20<'4SK3*I1[ZG*H(85%^5=$?7#@#
M\Z-B+8X,.QL S-L@3 /<<:4K";LGYDV$89W(A?E6NM@SFK6)+(:9(@!T<Z-2
MM'8?XRO-)?EQ+5(HC)GU+\SM#GT^E%TK-3,S!S$YAW"9UY^LR_9RS$XOP;3V
M*$/-Q0!3.LH:8BIP=G8=(=1A@OSO"4U \P[),>I#RCE'9H#<8-.XZ&GM;2$L
MP\&0J<;(/MHR:.:R$8/9\;&!,M"9 #,3@EN,,S=%M5%I@ VFT@0+#I( "_E:
M&R0IK@MDK&Z-(,6>*Q'(29DNR/<'&8DP1V,YHR0^'N(_Y$ 03%!ZYC@N'"$]
M9C,A"J6@U/V7)(4VABH4B0^GQ6MHLG ^W=K@/=;Z->*>0VML-^9@FA[HBP7K
M,4>[>M BL^2R\I=32PU1DV^V 0S5;3O.>RRQC+#0H4).D)88"U=3/TO-YG;7
M40:EKVO''#ERRU,QB:ML/RP/[ZS"--6*,NC$>^"2WC\H]/);R0?%[+TZ9#"7
M1HX=7&4#B#)H0=/K+2541@GOC3?+"/HZ0^LD^V5'B4FMEGI)#%@ [[J**E89
MI;9\;*)4BU9*Z)F ]R:F5 YN*=_3&_#+O*)U40NG$\+(:Y3%:.EC,CTFS]-Q
M14=.DX&1WZSY%/>RO0>IN1OGC1R]XY@M:5_\R]M\B=H!"S?#34^S/=B\]E]^
MZIJ:\P[)Y;]:80K9X6V7S =-]--C^>G:K-I;?*>[\!:1&<H0MU^L(J\W&-/@
M1&E?4\8H#J/KN/X!YEE-8OM0(7\^72+_)@DKO37U>OY6XU9=T,X/RI*CULH?
M=;2KAXQV!PGX2D57W'$@EL8\6W$-Z[J4(AGB09_=&@7M;C>JICH#+I46KJ[7
M;/TE01XWG K5+CYB$P(P_JRC(D>YL.2("+P#H0;*$OF#[0+T?7-]""E1"HF!
M+@P1S]X[K$^0Y!@EV!\2=DT#J'D+NF[9M2X31E+/71>1.B:".]N^-L7G[Y-0
M:\.B."%#4B"C946UFSV2,(2QO4P45Q)"+M;:1).AG:H.]M893G1D,ZQ\+$$=
M%(IJ&5QO,OKO.<\%/?S3^CP4")]/5P@[Q]P'YW>[P'K\* 9VB5ZSP3-YS!S'
MRZ..=O60T0XHD0]18K!UE]-C5/9D4"UA^ ==S=Z=&=?;V+8KTXH<RLD7) =0
ML\/L5"Y/2(IY8J7ZD7A>WDIE-''*!549UU$I<=]P&(UY.L_JC!>0)RF_& J?
M2,4P]9P3<I/0%-&5N=R[;=F71.Y5U,\#3@?G:Q"?O6LM$B9NFG5>B\:WOEW$
MY8>?;8C<^:=2HHX\^BY^-$HLEUICY!-*Z@8]RK$&7!+'@*2YAL@G04V@/J5:
M!(T6 XQ"T(R?< %B$LLR-.^DC._EE!#RA)WH^ 0K ^E+XLODHE2"51@1[E,L
M;!"8K&#*K>5]P(?CXI:(Y# 42#X-4$GX&,DZRY!"]Z*,8T^5A.;;_0ZY'4P]
M/V>W05&VK6] 9SRP"ER'939(3<P^D#4E1>N<_PW&6K5'OR7-G0I2T+$/SUG,
M8:PD@4 N'^YK;J.W U4L;U(+)J"KOJI46L'/U.[51N:?,&5^H.Q54A@\=0;Z
M3>2\V1ZV8O0OIQ951 XL:"&FHBJ'8%CFY0W=GG1[V>8E9Y3B/M(VSG!!8]O'
MP-R/0&GWRXCCR!M,:3I:=)C+@I0[@P\Y=\+1;W/*ZFXGN9J,\RE8IBWA;5N5
M?:K-;=TKIBE_[2B2PQ8['0FD A<EVPZ%FDVV);R'1PIE@CN0 <SQ=0,8'6\0
M98Q">I^572/UN0AY;K $P!L4?>GGMW,6B3?,1*'Y>M_479*7//.,?T1LG&27
M ;:UO8-%>$U<\[KV8L4CO52(^,DZPDG62I2N$N5 #2@-EP04VT1_\3&V?J7:
MD-MF"K:$JH3SZ;17LFN&8<D#\M F8,DQ1[NZUZ*&.W)8*@VNDQITJG)GJPU[
MH-18Q$F^A ]1JMZ!&TT>Z.E7N<J5P7/^:^!?4YL7TI;.I_.6HL9(P$G!)_TF
M^*0'=_:H*4M''>WJ(:/=@PS)YG44Q!ML="6"!>5STJ LE3R'%2ANO\,55YPE
M65)6LJ0(ZD0C!X!@*1#D?]AHD L@W?9Q^3[F550HZ;@EK4AJ]GIBDX_VUH3$
M0FE/YI+TH_Y<S@RK<HL=GL(O,R<%)?$3SHETS*&\3ZH/Y7J!CC-.DZ9?O@4&
M:M_^G?%KW+UH5POU"<%&EM_%8$^ZR%W?JC6(2O%3X<D3M_ @"=->6[1T<XL]
M,(B8GI:\>IU"C<-2PVV_"=GPQCAO_]YGHB$1^=F$N?JN+9K3^8OLYS[!@E+^
MK3,M=5+0['.0;O2^<QPY-JA1!?4I8/,8'70A;>1$7K08>)' 4LJPD^G(N\:F
M0,G3TB1@\'4,E#AK-"(/!3["ZZGTDRK8X0@VAGQ\[/.(;I)P;9FW.;\W:??!
M;H^J$@=<[*,=H<#C%R0]^MTRACCV( ^>7<6A$4 HDZ;I<=[N0!HQK6"7 [HK
M- @E/ R$'SK&+4A5#V!=CQR?TIYV]%@B(R==XWPON=%6;\/Q2W3+Z'Z>E.^F
M=ZQ8Y(&ORJQ"P,B594GN]T&N4U32',\Q-"-S?FYNNF+1/YL$_Z8:[8>LR\5T
MUN4'R6+^$+*8AQ3M]"A?JFB/.MK5EZ\P^\7W?_MHP #-OL4D7['YW?T$ZB]]
M^U*V>>FC$& /BE/ .PK\,+&W(/1H\SUP7-(XZ0L*X,F((!50$=NX;QGPQY;J
MY; I;^(4F)&@K)W3453="C_HX:VKN*+%.7!E0HB]"X\0%/<Z1=<E&0CB?,3D
M](,7]^KM!G+@.4DY0%(G'3TU(OR*(C-2>+8 $P(7'FU*-&NQV,2WZIM-K'#Z
MME4[^R+[6G_CNAKM$ROS:_N-<UXYBL/FZ?[M\@KN-1(YH$*A!XU&C\*S:>%A
MW,>+=$G<:@)+-4@<)#O#W7WJ/0YX\XWO(ST\G'= W'>2*'F^AF$]_Z7L]S6U
M%_LF)C'7P7,GVN'7]'+,J0&<U*VXME#)YD]NKRO*B+LQM-2[M<FWBAP[$9S(
MWLH+W"H&9^+:?^$;#]@W'"F9%_E/O$LPIZ1\3$#BW(R(-_ T>#4_L@/2>):G
ML@W%G<JW)$)631JUN12/\?*DH6H_C,S<Z++C=B,C,H*;!OL^> *CN?4@,J)W
M6C"4R2W+A+A]8NZJ62J>[$;ON(,&K1#9VC=;2R<2S0-!J*.I#YLTKL_3,"6'
MRW.M[Q\4.W2<[V06G'&]SD@<HBXX"BU=BV8]]^]P5Z8BWR45?408)[!],1)C
M%-^(5X".\_F3GP-.E>\ES'W&*@$;U+RD=Z@J:Z)%\X:W[)Q=PL,KW?9W*=-?
MOBEC32C9^TX#R.,'HH6Z#TZ/3@W=_+;'VQFW]Z.^(-30E ]7?R#.S8_G,L3H
M:)A6V C4K4-QK[^ZK(@?#I]PUI&;(5AI!QK+@45I 8N^TM"%:V1(3GA )N*<
M=.K[XCC&FWP8P6R43TL0AJB20G2N\.^7]'AQZWIKR6W.3PMO\]X^FK?3&0G7
M:M][<M\WK2<DVY!&0A(&7SLAW?ZG$/R>C [.5H)WZ7OP2XZ&>5YAIW*KJHH<
MW&RC.=AU??W> 2[N@^?[]\(OKA,>_C/N^AW90C*<2]@8F1_6"I+&)+DCS[BN
MA;'+@;;?)4DD3;1=,P28"IK1CK?Z @VE(I@7K?+EA1RB1_=WVO$-$^8H:WN6
MUB';@4)DZO#FV_R--0I/.W#Y*8F!AP7Z.F@LQ@NAUE060MK!9S0>EHR&, C7
MI^V="&=E)ME*;;^E Y*-"JD.!,W*_ZYMS,>2B^E1%W[ZPS692\\46%W2JM"-
MA !VC!66OF]N+&B+Q!<_W,E]<%$4':%"@316J]CA+F:QG"G7MBAR]Z8P?ZG:
M6ZPWV&*@85=-X)0W7GU$CWL)JUU'25$MTD0S#^1DNZ/7I2V*/\0ENCU3Q'7,
MPX(SB0WYAEL'1HBKQ'<.A DEP,G((N9&>ECWIS8,RG&30SX=VTJJ]!XS3JAC
M@$E]#2K]"96H#,LW]#) '0G3U\<-]@<GHEU5Z(@E(.DJKM^YMG+V*X=5$Z9"
MB=)8[I G:7,H*7LVW.\$CF%C2+@51==0+2(;"53/2)@9/56@Q16-FX8?4[9H
MU#QTFBXP_#WO=H0?>I$+1Z.D6V8DK$@.^JZ@AQ^QZ'&C?V=L$(1/8?05GVPB
M=O%2W$T=5NE"Y$.<S;5^VG4$'MVJP$D3S/)F=8_]&]PSV5)VN?DMF_51:""7
M>,+LW5,_R=X=?BDDZ=@;&7>'%1[BQFAB_*WZOP<G;+33[LL@=M;#1_C.B3WS
M;7D9$++1Y@=S*1*4^D"*JA]?'S#@AX+,Z1EUF5HLLCV60/T<&AMP<8[V/TDK
M$$]5@6_]WG:<;!.Q0 3_?1^AGJPS2GH4I[W9(X%.[;Z384-/HI D))-E\2?>
MV#;1"LHW"*0]#-_'(BG@M9'+@Y&D=L<)WGYR0CY*FYV0\?$0(0\!6113Y5R-
M+G\6Z, 1X9Z4T ;8/N@Q$S.:<W43Z(\IR59ZJ#1FGU=MVAEXZ%,ZB4/;!V5H
MI)E#W]$B&$)'C:^9!*JDRG#<AU9MTSZS?B:2!MV7M\'92#?NO;3@3H=A2;$T
M;"6,)BG Z$@CR,OXC#.LZ5DG8("^Y#_S=PV#C:&I<]"92B.#N> O.1]43X<F
MC<3]DE*%.J(LQ=@[,$VB#[&-3#[QDY'>&[D1#X&;MW3[-)JT&DL"C!A1#C[\
MX=D@NA([4'6/B23LB+W$J,T^I=I3D&\ :Z0"ECS7$K?;FI+-L)4Y0*P')JI8
MZ-)6XLTJ2INC85R:,<I4<OCV36/BM0/;V#O7O/-)?:9+:_^"F>C*\):00]3_
M,H+2(MN<+R-,D_KVQE]$<+W@#M_'GQ8AD5PG:&'2WD_<[8#E/:B>?"J%ULDJ
M?1O\>])H/_Q!,Q8O>TXUQK"<6[EO<1"\.!^]WCIP*"53,V/@QLEP%POFH 6G
MQSG%>)=<P&(H$C#]G&SY](5/6.!P!9][;GH? )$'EOX?EUC72E%7_#U1!8E+
M!?,"?Y_R8!]^YT2<J=$]XN?-?J5#+XE0A$A<K_TH0Q$4(85+XX.Q-*CK11;%
ML53W 8PPD'0Z<O5D"<*GGO1LY-]2(YOPV1S_T00/H<7ZEU9EF_X[@IMVR(<?
M8F?/SY[/>M1.G&EIB SN#M_N.W"7QV22S$WG\^8B(SEBD=T0\D93D8;"'8%:
M[ C!1B".](ZP8:@1T# <O8!U\.[AB:&O[#FC6U5JP![AK);($F7F=S>'\^?I
M*"(A 0?3\V&'__V&I09$(L-PR\B] F>K-,W<.PMCQ_\]>,+'=9B2\23Z$S@(
M#QZ(LC@-.6(TE @[_GP!55M&>E-,\P&?I*0/NZX\V&-JYI3'DF4 9CW@29=O
M&8K4"%E/%7Z2+.<.\(TT\7=?(8H:IG%?;!'_4H^L*B4?UOK)!U;[&Q1S]+T)
MX@.D_<](XC4,B\XQ+"H] 4/'<-B'FZFLO47H&+.8[A@S71<QF$=PS%XGET<=
M[>HAH]U1&?)A++$W%&D,UT?>\: 8*/QE$@<<XJ^3 %3/&S)6Q&1$<=3D,,YL
MM#/D+&YQ(R[GPQH+YWJ5&ZI0O6@[]Q73NG2-(+BF9;CD0D9@WS,W,M9E^"X+
MR)>F3#4E.J&[>#)]ZD0JS S[)99JDU>K4(KN>_\,=#/V<" DQM*QQ/A<[#VY
M*WT;O^'02\'' SUHWU)2?<W^#9<'R)G?_/EJ-?G"6(4WT^GY4</$,L12V= 3
M"$_:!\O2&N4]GF.Y^E/R)#0/6DPWUJ'/$,Q_(,Z\C#AS4)(<M7_044>[>N R
MQ^Q=UN!<$QT?WIPQWAI4AUBU_ELQ/HTW7(G_FMJMT)!G,=V0YTU-Y1@?\\_#
M:??3CW_Q#AVU&\]#1HO7V[,AN%<$( O 7P8]E>86P0<ZR76I^2L1OOT>!82<
M@U9.8DB('/H6O53WTNM;?/V)9+!1LHSK$EFZWHYPR^C7"9K$T>^=ER[((;(&
M1T!E0!Y^%R$%YH$5-.ZSN?R#\_(QY!AI?4O&(PS)/6Y'OYW0_]8-)7\$5!\(
M %KGEM>BP9HI-6<Q1.L2R<DNP56F:A",#/$OHHQ7= C=<B556M^68Q< ZS]>
M>$!5,D3Q<TX2J>YULD4<F>;FN8Z?XK&F;&3Z"J-KN$M=N=@@O^\VIEW%ZM"=
M'B/FZ]"/WPGU@76?9%<RW0R[2'-PASN92I<\*=[!WA5#\PH]SC!/&5WQ*^1H
MA,?#[QN1< ZD<'J]"R#CB]R'<<FQH2<HB63F^+Q_POF-PK?R*&E>?<Z]5X@%
MJ345!1+$S>'#Y6 #$7(2]8C?+L<,Y>!P]//^@ET.F?O^"]7\7:&0A7_PJ34V
M)+2OZ>!L/JIBI G5F%Q1)UYA[^7$KF^ASAU/H9LTH8*D+#@Z8H(-W*=[\?.;
M5,_/O5(/:M%=$?IYO]H+U=#4')Q5&6KCW:HH#.\6%?=HC%\0G?0[Z^1AP#O+
MY!>AJ]CBKJYB6] -&R 2FHIOC1U6@D?M)7;4T:Z^>(%9>LGU42!\PE%[7<=?
M7+/"P:Y_-WLTXX\(A\)A:4A!UD#2AB(JX&#;N5<H'O?Y6NZ3US,^UI9;0VCY
M:G%\Q_!YXU<6R6+E:'R-B_Z&LDU8W%;[],,FD<(Z[+>(\R'=DL7%#9-]$D^I
M.<U5WN:O7X$\6JM+57&-9@V[AJ:ZOXK^'"RU>W&Q>'0*3X;;7[_:Y6OU#N07
MOKM2*WCT[.39TT><)>;^:,T.AT1O9&NV]$_LSZ<:O %^7QG3NC_P!9BA2]-[
M_3]02P,$%     @ \(.65_!DA;6' P  A@D  !D   !X;"]W;W)K<VAE971S
M+W-H965T,S8N>&ULM59=;]LV%'WWKR#4H6@ SY(E)XY3VX#B;E@+%##J;'L8
M]D!3UQ81BE1YJ;KY][ND;-59G-38QXLM4O<<WG/O$<GISMA[+ $<^UHIC;.H
M=*Z^B6,4)50<!Z8&36\VQE;<T=!N8ZPM\"* *A6G27(55USJ:#X-<TL[GYK&
M*:EA:1DV5<7MPRTHLYM%P^@P\4EN2^<GXOFTYEM8@?NU7EH:Q1U+(2O0*(UF
M%C:S*!_>+$8^/@3\)F&'1\_,*UD;<^\'[XM9E/B$0(%PGH'3WQ=8@%*>B-+X
MO.>,NB4]\/CYP/YST$Y:UAQA8=3OLG#E++J.6 $;WBCWR>Q^@;V>2\\GC,+P
MRW;[V"1BHD%GJCV8,JBD;O_YUWT=S@&D>T!Z+B#; [(@M,TLR'K''9]/K=DQ
MZZ.)S3^$V@0TJ9':=W'E++V5A'/S=X#"RCJ4U&R8*X'=-DA!B(SK@JW:[OIW
M*[G5<B,%UX[E0IA&.ZFW;&F4%!*0O;GC:P5X,8T=)>;I8[%/8M$FD3Z3Q(1]
M--J5R'[2!12/\3$)ZE2E!U6WZ8N$'QH]8&G:9VF29J?R>1F^@GK LN04_%$Z
M65?D+/!ES_!U%5V8:BTU;PU,U<T1P1?S<R-1AMD_\C4Z2^;^\T3:M^TRH]/+
M^ _^!FLN8!;1%XU@OT T?_UJ>)6\/56#_XCL445&745&+['/CVSUM 8+@^Z4
M^I<I[\BZ3[D$<9&3+3 LS8X\KH/'-T;1_N7MZ[QIV1OIYTV#U!6\N.GEZ%,C
M&X&W46]A:-LJP+:=H_YHW("U4##"K<!Z^^=L23M0.[MR1MR'#@M3503!,/$#
M&R:3_F0\Z=UY"BZ.4I1:- &[?F Y;!5PEO6'DW'OSCBN0A!SAK8]TD9J>%!*
MA$.*&E_UO'IR5\WUP^M7U^EP_)94DT;!CS_MNK&BI$V/U58*\'R:6 (7'JA)
M$SWCOD3XO=+D'4K_6%LCO,TI+?IZAM?7O07'\AMQUD^R2T((V]!(2;Z6BMKD
M]XXTZ2>C,;LX3^XI._\3=RS.=T<EE2*(K\#_8(MA,DC.-,4@_7Z-? SI^'<&
MX <+'"E^MMNTXM]Z38*HX$WUM-.#Y)P^#])3^TQ\=-158+?A!H LG$;MJ=?-
M=I>,/)RM\;?P]H;RD=NMU,@4; B:#,:7$;/MJ=\.G*G#P;DVCH[A\%C210FL
M#Z#W&V/<8> 7Z*Y>\[\ 4$L#!!0    ( /"#EE=_[?5OL (  . %   9
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M'-H[/CN)P+3SI-TXJD,/+\GQ1 C+DD<P&N_ YP61VVX\03?4TW]02P,$%
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MB#1D]!(/O3)3.$J J5SP$BR 1EPA),2)_01AU",$Z%27Q)U/IW>G:,8?6%G
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MPHM9)O05-LU:RX2X$I+ES69DD*=%?2<_&C\<L\%I-CB:=VU(L[PFDDS'G&V
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M#EN! D&=;1^&?:"ELT6$(E4>53?_?D?*5IU628V]?)'(TST/[[D[D9SOM7G
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MS+0G=CNQNO:'WD9;.D+]L*1+#ACG0-^W6MOCQ"W079N6?P-02P,$%     @
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M[+$@Z\ NMF#L!; Q?)2-*31<-SGF!^POC]M'[ A 0)[U[K&=>Q?L*.(<UZ?
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M:;#$NV&%?RHH:X#[:RG-?F(#]+_T[&]02P,$%     @ \(.65\7H?UXS"@
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M:1Z4YD-I 9060FD1BJ;+KYFSMT>G3K;067HHS8/2?"@M@-)"*"U"T711-O:
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MRBKH1D#&_^EHWW7%&W3SU$1]Q0L<P=R2,S$']@C6XM=?W)'S6Y=2)F%KD[#
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MTGE>_ZM\;5X[.%$FJ[Q(%TWC<@T6<;+^/_K6_"(V&JC#/0VTIH&VU4"[VM-
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M40H?.VI)S" Q<XU=;'YR;'TF6&1_-HDY).:2F$=B/HD%)!9"6&=LJX/V$OQ
M.KHG4;[>RZV_J$X7/T7SZII1WWB66\<.:%0S&FUS%.J#G0-:M$^KI\^KP>A*
MV]J113MU4,T];!,\M%,?U8)&V]PEUX?CBZV=F+#G9>I('6K]YX+4C1"+*AU!
M?YS=GRD?H^1+%4AQD[R(BU6U1]L[@*34T0.(U Q4,U'-0C4;U1Q4<U'-0S4?
MU0)4"RFM6P2TM@AH;Q[2:%:!*AZD9J":B6H6JMFHYJ":BVH>JOFH%J!:2&G=
MXM$&O%1I(.3FKMSU[AWP:"P+U8Q&V]R;TL:[N]MHXJJG3_7B:KM3&^W4037W
ML$WPT$Y]5 OZWGE]M+T)(=5I=TRU*2A5GE7Z%&71\GLFE-_6^?+?/L_CQVCO
M?CF9!+E#-0/53%2S4,U&-0?57%3S4,U'M0#50DKKEH$V%Z6.WGZ_'(U0H9J!
M:B:J6:AFHYJ#:BZJ>:CFHUJ :B&E=8M'&_-2Y3FO3R^7I*NK7U&2K,K"L$Y4
M*X]9=2M:N3BM]R_Z3Y>C^2]4,QJM>^%W.S]GHGU:J&:CFH-J+JIYJ.8?],X'
M:)\AI74'<IOP4N41KWN153>)WBJ_EA_S_TCK6T?+G8$GD17QY[E0VOAT??=$
M[UA&8UZH9J":B6H6JMFHYJ":BVH>JOFH%J!:2&G=VM#&TM3QVQ\AH/$U5#-0
MS40U"]5L5'-0S44U#]5\5 M0+:2T;O%HHW&J/!NWWHFH)Y+Y'.5Q_U$ FH)#
M-4/=C:X-=\[ADSU:J&:CFH-J+JIYJ.:C6H!J(:5UIS]I W&:/!!WY+&"\F>Y
M)'XJ=P643_-RK?;=)2+O]=@J@&H&JIFH9J&:C6H.JKFHYJ&:CVH!JH64UJT7
M;?Q/4]_\^$%#8X.H9J":B6H6JMFHYJ":BVH>JOFH%J!:2&G=XM'&!C5ILFCC
MWIKG"<W2>74CJK)L]BF6S_L4Y7[&_CD<Y+T<71^TG8."2TT=CK8RX0;:JXEJ
M%JK9J.:@FHMJ'JKYJ!:@6DAIW9'?9OXT>>;/SM(\5^K[S<6TNJ%N(N(GT3_V
M>X<\F@W4>C)=ZF#G]AD#[=5$-0O5;%1S4,U%-0_5?%0+4"VDM.Z0;R.)FC3K
M=/-R?D")'NM_R\.#M)C5G_\/(JM.-(AO2Y'DZQEJ#RL#9%CKKM$ZZ53M<K<*
MD)V:J&:AFHUJ#JJYJ.:AFH]J :J%E-:M FTB49-/U79;31:EU)/.Y/&^/++<
M.'I8HY%"5#-1S4(U&]4<5'-1S4,U']4"5 LIK3OZVTBA=O'V9PO1V"&J&:AF
MHIJ%:C:J.:CFHIJ':CZJ!:@64EJW>+0Q1DT>8[3B;V):'B-,9E'R*)2L*A.]
M!0#-*J*:T6C59 S%YIR<H^'5<+25/$![ME#-1C4'U5Q4\U#-1[4 U4)*ZP[O
M-HFHR6?(VSDR4/Y4[NM[&.NG<)CK&P_<I+HG(7ZJ\P;]!P]HVA#5#%0S4<U"
M-1O5'%1S4<U#-1_5 E0+*:U;(-JTH7;U]@</:%H1U0Q4,U'-0C4;U1Q4<U'-
M0S4?U0)4"RFM^Q"I-M>HRW.-;=0@715Y$273ZH)#=0UBE8AO(IO$^?/C(Y[O
M::SFN%^NLO)P(Q?*SW'2)!!^D681Y*MQ; %!-4/?G>Q.N]2'6X<=:)\6JMFH
MYJ":BVH>JOFH%J!:2&G=PM &&'7Y_(5]AQUWZ6)1?K'W;D@Y>?0@1P.)J&:B
MFH5J-JHYJ.:BFH=J/JH%J!926K<8M(%$_>WG,=31M"*J&:AFHIJ%:C:J.:CF
MHIJ':CZJ!:@64EJW>&P\J%:>:=Q),Q=9E.3-W5)1_CQU2IP4HOQI486<ZD=G
MK1^D];+S(3FV8)]3RSZH5M\YMABIE^/!U?;1!?L06O8IM.QC:-GGT+(/HF6?
M1,L^BI9]%NV/"#WJ;>A1E\:I^B]J_/O3L<A[/;H2D)J!:B:J6:AFHYJ#:BZJ
M>:CFHUJ :B&E=>M%&X_4WW["1AU-5Z*:@6HFJEFH9J.:@VHNJGFHYJ-:@&HA
MI76+1YNNU.43-O[X Q T6HEJ1J-U'H!T,1R/+[</0-#0)*K9J.:@FHMJ'JKY
MJ!:@6DAIW9K0AB9U>6BR/9BHKVV>*LLH4YZB^4J4(_TGY5PVVM$<):H9C?;:
M$]!-M%<+U6Q4<U#-134/U7Q4"U MI+3N:&\SE+H\0WG(A&QRXNAAC>8C&TTZ
M(1O:HX5J-JHYJ.:BFH=J/JH%J!926G=(MZE'73['XCH"_?>9R**E6!7Q)#^M
M0M!GO4,;32^BFH%J)JI9J&:CFH-J+JIYJ.:C6H!J(:5UBL"P32\.!V]^6G"(
M)A=1S4 U$]4L5+-1S4$U%]4\5/-1+4"UD-*ZQ:--. [E"<>[-"^J+'-]EJ_<
MEZC/^?56 #36B&I&HW7F9E%U]?)BZ^@ [=5"-1O5'%1S4<U#-1_5 E0+*:T[
MMMO XE ^@^+MSOG[2;EW$$]%MMX9V+P"$.?Y*JH"!LW5@?2A?'$==&YN>TB4
MJ+HB\&ZR#B.43>J3"-)+ O+U.[IFH&G&X>Y,CNIP=#4:CK?/*:#]6JAFHYJ#
M:BZJ>:CFHUJ :B&E=:M&FU0<RI.*M^L]@6JZQ7?U'(QY-05C+J)L,JOOB9J*
M)S%/E_NF79/S1P]Z-(@X['G$L#Y0Q^/M(8\&$5'-1C4'U5Q4\U#-1[4 U4)*
MZP[Y-H@XE :7=H.(ITI2+IC'T>=X7BXH]P?*XX+50DQ[!SR9L;I#-:/1.@/^
M<F?N5A/MU$(U&]4<5'-1S4,U']4"5 LIK3O>VR#A4#[/XK[+!@?<W2B7CQ[L
M:#X0U4Q4LU#-1C4'U5Q4\U#-1[4 U4)*Z]:$-A\X?/O9%X=H1!#5#%0S4<U"
M-1O5'%1S4<U#-1_5 E0+*:U;/-H@X5 >)/SAX6)Y_T=7#C1NV&BOWMV(]FJA
MFHUJ#JJYJ.:AFH]J :J%E-:M"6W<<"B/&]ZO*T%U84%,3ZM'-DR$LBRK1#W*
MZSF3INE\'F5YN_275W/'\DZ/+@1H0+'15'6C$ER>:9?;=QF@O5JH9J.:@VHN
MJGFHYJ-:@&HAI74+01M2'/YK(<5_<0I7>6]'5P TQXAJ)JI9J&:CFH-J+JIY
MJ.:C6H!J(:5UZL2HS3&.WC['.$)SC*AFH)J):A:JV:CFH)J+:AZJ^:@6H%I(
M:=WBT>881_(<XW]J"E?Y:AQ=0- 89*.],H4KVJ>%:C:J.:CFHIJ':CZJ!:@6
M4EJW,+0AR)$\!"D[^OCWYUJ2=WYT.4 3CJAFHIJ%:C:J.:CFHIJ':CZJ!:@6
M4EJW;+0IR)'^]@<C:%(2U0Q4,U'-0C4;U1Q4<U'-0S4?U0)4"RFM6SS:/.5(
MFM_Z\9=#Y?T?73E(S6BT5^=:0GNU4,U&-0?57%3S4,U'M0#50DKKUH0V<SEZ
M)7/Y0RZ'RCL]NA"@<<Q&&V^>CKA2SP;;-UN@O5JH9J.:@VHNJGFHYJ-:@&HA
MI:T+P7D^$Z(PHB*ZN5Z([%'<B?D\5R;I*BFJPXN-I4HF'LI"H;Z_U4[.=Y9;
MZGM'[5GNJN^]>OEYR]]<+Z-'$4;98YSDREP\E%T-SB[+#<OBQ]G+-T6Z_'"B
MGBB?TZ)(%_67,Q%-15:]H/SY0YH6S]]4'7Q-LR_UYMS\/U!+ P04    " #P
M@Y97V7B8Z1L#  !D"P  &0   'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6RM
M5FUOVC 0_BM65DVMM)%74MI!I!:HMFE;45FW#],^F' !JTZ<V0ZT_WZVDZ90
M J)2OB2V<\]SON<N]O77C#^()8!$CRG-Q,!:2IE?VK:(EY!BT6$Y9.I+PGB*
MI9KRA2UR#GAN0"FU/<<)[123S(KZ9FW"HSXK)"493#@219IB_G0-E*T'EFL]
M+]R1Q5+J!3OJYW@!4Y#W^82KF5VSS$D*F2 L0QR2@77E7HY#;6\,?A%8BXTQ
MTI',&'O0DR_S@>7H#0&%6&H&K%XK& *EFDAMXU_%:=4N-7!S_,Q^8V)7L<RP
M@"&CO\E<+@=6ST)S2'!!Y1U;?X8JGJ[FBQD5YHG6E:UCH;@0DJ456.T@)5GY
MQH^5#AL -]@#\"J =RS KP#^L8"@ @3' KH5P(1NE[$;X498XJC/V1IQ;:W8
M],"H;]!*+Y+I.IE*KKX2A9/151SS N;H&\$S0HDD(-!']+R*LSFZE4O@:%AP
M#IG<LCL=@<2$BC.%N)^.T.G)&3I!)$,_EZP0"BOZME1[U)[LN-K/=;D?;\]^
MII!WD.]\0)[C^0WPX6'XUR+K(,_;"Q\=AH\@5MY= _<:X./CX>XVW%9YJ9/C
MU<GQ#)^_AV^"G_",*J5U'DQ.,!7HS]5,2*[^L+]-\I:,03.C/G4N18YC&%CJ
M6!' 5V!%[]^YH?.I2>PVR49MDHU;(MM*BU^GQ3_$7O\S+#=G7<R$1'F9*B09
MFF".%RQK2LY!WK<FIR3K&C)]':PBMW?1.^_;JTW5VW0Y;HEL2_6@5CTX2O6<
MLP2$OJ<P-3]&S#*AK@62+5 "T'CF!#M2^4$OV%9J6!J%&T87[FLU=XDN@G#;
M9KQKXWGAB[.MX+MU\-V#P=]@PM$*TP(02Q 6ZEI74NA*RY\XH-NR$F]GE"RP
M&9[^8!)*[?VS)DD.^GMK*79WI',#_Y5T;3H<MT2VE8NPSD5X5"'2EZNP2>"#
M)&\5.-RM*<<)7E=GFR['+9&5$ML;'8KN/[]COB"90!021>]TSE5HO.SIRHED
MN6E:9DRJ%L@,EZH-!JX-U/>$J?JN)KH/JAOKZ#]02P,$%     @ \(.65RQY
M6%%^ @  &08  !D   !X;"]W;W)K<VAE971S+W-H965T-38N>&ULG55M3]LP
M$/XK5H8FD#:2IFVVL312 4TP@52!V#Y,^^ FU\;"L8-]:>'?[^RD4:<%$/M2
MO]WS<KZ>DVZUN;<E ++'2BH["TK$^B0,;5Y"Q>VQKD'1R4J;BB,MS3JTM0%>
M>% EPSB*DK#B0@59ZO<6)DMU@U(H6!AFFZKBYND4I-[.@E&PV[@1ZQ+=1IBE
M-5_#+>!=O3"T"GN60E2@K-"*&5C-@OGHY#1Q\3[@AX"MW9LSE\E2ZWNWN"QF
M0>0,@80<'0.G80-G(*4C(AL/'6?02SK@_GS'_LWG3KDLN84S+7^* LM9\#E@
M!:QX(_%&;R^@RV?J^'(MK?]EVRXV"EC>6-15!R8'E5#MR!^[>]@#Q/$S@+@#
MQ-YW*^1=GG/D66KTEAD736QNXE/U:#(GE"O*+1HZ%83#;)[GIH&"70F^%%*@
M ,L^LGE1"'=I7+)+U5;>7>'A.2 7TAY1R U(C@1<<(-/M*:1KREFOC8 5#5D
M!TPH=BVD)*A-0R2W3C/,.V>GK;/X&6??&W7,XO@#BZ-XS.YNS]GAP='?-"$E
MVV<<]QG'GG?\AHQ_75$0NT2H[.\AIRWC9)C1]<V)K7D.LX :PX+90)"]?S=*
MHJ\O^!WW?L<OL6>[BZ[]1<,CM:,ERT+EC3%NWPAM&&K&K:4FYOE#(ZROWE F
MK=;4:[F&W62C+VFX&? WZ?U-7O%G@9N\)$>DVOY15@"#%6^9DCWU\;#XM!>?
MOB(NJF5C+%]*8&;G)-<6!_6G_^B/DF$#26\@^9_J-*KFXJVU25ZO3;C7Z>[1
MO.9F+91E$E8$BHX_$=JT#U&[0%W[YE]JI*?$3TMZN\&X #I?:8V[A7M/^J]!
M]@=02P,$%     @ \(.65_GTHO&D @  &P@  !D   !X;"]W;W)K<VAE971S
M+W-H965T-3<N>&ULK591;]HP$/XK5E9-K=21D #;NA")4DWKM*JH5;>':0\F
M.8)5QTYM!\J_W]E),Z@"TR9>R-F^[_-]Y[./>"W5HUX"&/)<<*''WM*8\L+W
M=;J$@NJ>+$'@RD*J@AH<JMS7I0*:.5#!_3 (1GY!F?"2V,W-5!++RG F8*:(
MKHJ"JLTE<+D>>WWO9>*.Y4MC)_PD+FD.]V >RIG"D=^R9*P H9D41,%B[$WZ
M%].1]7<.WQFL]99-K)*YE(]V<)V-O< &!!Q28QDH?E8P!<XM$8;QU'!Z[986
MN&V_L']VVE'+G&J82OZ#968Y]CYX)(,%K;BYD^LOT.@96KY4<NU^R;KQ#3R2
M5MK(H@%C! 43]9<^-WG8 O0'>P!A PA? Z(]@*@!1$YH'9F3=44-36(EUT19
M;V2SALN-0Z,:)NPIWAN%JPQQ)IE11<N- G);NK3>SCG+J3/?D4F6,6M23JY%
M73%VX?0*#&5<GZ'+P_T5.3TY(R>$"7+#.$<''?L&0[,;^&D3QF4=1K@GC*^5
MZ)$P/"=A$$8=\.EA^ W=D*C?A?8Q'VU2PC8IH:.+]M!-M,;[,TF?*J9= LC/
M;^A"K@T4^E>7NIIOT,UG;^*%+FD*8P^OF@:U B]Y^Z8_"CYU:3T2V8[TJ)4>
M'6)OI-,_TL])*H5A(@=AK*E9!HK6*YS1.>/,;-"I4@H]NG)3;]BOS\Z^*JLD
MZ/5C?[6M^6!4_ZEYT&H>'-2\_PYTR3G(]:]'?22R'=G#5O;PR%4^/*;T(Y'M
M2!^UTD>'3QQ4BM6*;8K(!:%"5/C$ 2;";$BN*%8Z3DM7#9V/6<W^<:>B@]<E
M_1>G.G!_Z^FV;?.&JIP)33@L$!;TWF.:5-V*ZH&1I7O-Y])@;W#F$KLW*.N
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M!Y%5&Y2_?TS38OE#-<!+FGV?/\R;/P!02P,$%     @ \(.65Z$K8A,>!
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MC.;'5Y:.)X)MBY=X'ID0+"D.-Y2L*,\!\OX38^+Y)'\OJ'IQ;/X_4$L#!!0
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MSU7P>;DEJSR1;%UL\'ED4K*T.%P1'!.N.ZCK"\;DRXEV4&^,F_X'4$L#!!0
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M-S N>&ULK59M;]HP$/XK5E9-K;0U[PET@-0"TS9M&NK+]F':!Q,.8M6),]M
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M+BZ58KP\_2YO),N+\^![)B7+BLLUD!BX;J"^7S(F]S>Z@_HWB.!_4$L#!!0
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MJ6NCL@'T?BFEV4UL8VC_!R1_ 5!+ P04    " #P@Y97HWKS6K("   &"
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MQ]9?H?$3:KV4%<+\HG6-C2(+I4LA6=F0508EH?43/S=UV"*XAPA>0_"ZA.
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MS!'T&;D4.0EA:JE#((!OP H^?\*^\Z4COWZ37[\K>J#*[9MRJE2#4J6/V2;
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M^JD(GB'ZLR+0IWT@_40@C=Q'8;I*B!W.^;PAOZW.;YS+3\_$U\\!7#7 '"@
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M7"B-H6BRGDOCRU!OC.NX4D9-ZZSG^EWMAJ9I:D:U\]!PS[U1PT8Y:.DHE.9
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MYXN!,7B]XSZ<S?/RCN'E^5+,Y(/,?U_>I<6MX4:9A@L99V$2DU0^70RNC+/
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MY0+%]Y^2)'^]4:[@.4F_5@_G\D]02P,$%     @ \(.65XUG'2_P @  V@D
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M\ 72".#]0@B]V1@%S3@7_@)02P,$%     @ \(.65UN#*H7, @  ;@H  !D
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MQ@VS7*N!$+@.4.<KQN331L\<Y8@9_@502P,$%     @ \(.65SKX9 7M P
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M(6BJ+C<$P]I85H#G*TK%_D8ZJ(^=)O\"4$L#!!0    ( /"#EE<0O#UA0P8
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MF;0%S/F%$/IEQU;0K(Z:_0=02P,$%     @ \(.65PM BE7Q!0  ;BX  !D
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M$GG.6^0ZKM=@/F\W]R%0YC@W=QO,_7;SSV1_PMI6=Z:Z/6YU>]P<YYUR1HN
M9FIAAUI$%>V"Y/%RH]5=@XI B69[=-QO0?;YZ9L=X2'Z^Y-"HEL)L?BG2<QB
M_%[S^#KK7(N4!#"Q5%H1P+=@37_Y"0^<WYJD-0GS#<%JNGN5[EX;??K^ 7A
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MNH.ZOF),/A[H=_C51Y[I?U!+ P04    " #P@Y97+8!]*T<#  !T"@  &0
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M075V_Z=79_?9ZFR4DUA.9CF%Y526TUA.9SF#Y4R6LUC.9CF'Y5R6\UC.9[F
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M\UDN8+F0Y2*6BUDN8;F4Y3*6RUFN8#FQ+1#\0"2".Y<I[R@2'70N#WYZY_*
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ME*NUS%)4^E?X[0&7/.'F SQ^WW)S@&N8N]B"7,)COLGD 1&>4!O%$U-IFMA
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M41S.N3_C:1X@7[]+$O'T)&]@?<N>R?]02P,$%     @ \(.65_;/6NU?!@
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M79O%^E'[LIE&39H4:.D:U4Q4LU#-1C4'U5Q4\U#-1[4 U4)4BU M1K6$TL0
MZTK7H[<O78_0TC6JF:AFH9J-:@ZJN:CFH9J/:@&JA:@6H5J,:@FEB<'6E:Y'
MRL)EW[,SL@-ZBVHFJEFH9J.:TVK/SRY?SEJ-#NBAFB_9_"O)"4B CAJB6H1J
M,:HEE"8F25>M'JFKU=)SO"C]F<_7<VFFH"5K5#-1S4(U&]4<5'-1S4,U']4"
M5 M1+4*U&-422A-#JFM^CR9O?QZ'=L51S40U"]5L5'-0S44U#]5\5 M0+42U
M"-5B5$LH30RVKBL^4D^K7>?4M,ZN]#%KRI2["97JZ-I,OK3_DNAF[J7F1I?J
MM1M=U,.<'%YH'QS5+%2S4<U!-1?5O%:[>GX6^F[\HH*)#AF@6HAJ$:K%J)90
MFIA)7<U[=&3J[MVT;_OH66V/IO+%H_IVN]%AU5<^V9MZ"TX.&'2.;E2S4<U!
M-1?5O+YOOH\.&Z!:B&H1JL6HEE":&#)=SWND[GE'^2PKJV5]1M8>])1:]G/Z
MU)S,:45:9=J_M=]^N1Q.1K]KYUKYE!;R[V54CW+R<0_:^48U"]5L5'-0S44U
M#]5\5 M0+42UJ-6$.'_QW0+H@ FE"8$T[HK<8V6?\I7KX/GBM>O@:N[4Y$$U
M$]4L5+-1S4$U%]4\5/-1+4"U$-4B5(M1+:$T,:2Z4O98?_/KX&.TTHUJ)JI9
MJ&:CFH-J+JIYJ.:C6H!J(:I%J!:C6D)I8K 97;"IF^8]3@=_59X(JOV34PNM
MEZ.:A6HVJCFHYJ*:AVH^J@6H%K;:Y?-3MW>#BQ=SR*%CQJB64)J81EUM?*QL
M;U[_L<B_UX=*>?57\ZG<U^QG6FII?9"U+JM\T7L^ O4@)T<26@Q'-0O5;%1S
M4,U%-0_5?%0+4"U$M0C58E1+*$V,KJX87O_XYF>((S382,U$-0O5;%1S4,U%
M-0_5?%0+4"U$M0C58E1+*$T,MJZG/CXV!7@;;.GNH$N[KT\,I?F$5M11S40U
M"]5L5'-0S44U#]5\5 M0+3RR5QD#??A/W9!F$5I'1[6$TL0LZNKH8_5$Y/%Z
M_BTKFG/#67LFN ^ELKU2%7JW5OS%NG$^6U9DQ5^E.84VSE'-1#4+U6Q4<U#-
M134/U7Q4"U M;+7GTY<8+R]8'5TD1K<IH30Q9;IN^%C=#6]OPM,>UM6ZR+1I
M?=*6UV=P]8'/+G7::^72;$$+X:AFHIJ%:G:K/:^]3$:2%J.##NNBFH=J/JH%
MJ!:B6H1J,:HEE":&45<*'Q^9^_NQ/L)Y;#Z)6RVK.G.:69_FAQ_:-7>N;+X.
M?+69';Q>93U+JV7QEY:N5L7RN[PWKA[[Y+!"R^6H9J&:W6K/_T4<RR8'<]!A
M753S4,U'M0#50E2+4"U&M832Q+#JRN5C=;G\A+!ZR!?U7TIRJHFO,JL/NIH[
M8)IB:/,5!]+P0BOHJ&:BFH5J]OBP8"S[6@ ''=5%-0_5?%0+4"U$M0C58E1+
M*$W(KDG70Y^H>^B'32A9Z*B14T,'U4Q4LU#-1C4'U5Q4\U#-1[4 U<)6$^Y4
MD7UI)CIJC&H)I8FAT_7*)^K)OF\6BW5]R+.[KO20964=/[ET4CDU=7+TH/UP
M5+-0S48U!]5<5/-0S4>U -5"5(M0+9Y()K6731Q^?#DQ5(PN5-2=[F,MRMWU
M[;Y]2O5P)P</6O%&-0O5;%1S4,U%-0_5?%0+4"U$M0C58E1+*$T,L:X*/GG[
M&<0G:%$<U4Q4LU#-1C4'U5Q4\U#-1[4 U4)4BU M1K6$TL1@ZXKB$V5?\_IS
M<WE\\Q'==B;QS:UUTG12.B>G$ZF9J&:AFMUJXH1KQHL9UQQT3!?5/%3S42U
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M3NZ'?9+NI'K2%8 ASS47>A)4QC378:B+"FJJ![(!@3LKJ6IJT%3K4#<*:.E
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M>. Z0+V?,B;7$[U!_Y\A_0=02P,$%     @ \(.65Q[OL0X9!@  AS4  !D
M  !X;"]W;W)K<VAE971S+W-H965T.3<N>&ULM9O];Z,V&,?_%2N;ICOIKL'D
MO6LC70N$2KNINEXW3=-^H,%)T '.C-.T^^MG7AI"<=QD]]TO;8#G^3S&_F*;
MQ_ABR\6W;,68)$])G&:7G964Z_-N-YNO6!)D9WS-4G5EP4422'4HEMUL+5@0
M%DY)W+4M:]A-@BCM3"^*<[=B>L$W,HY2=BM(MDF20#Q?L9AO+SNT\W+B2[1<
MR?Q$=WJQ#I;LCLG[]:U01]T=)8P2EF813XE@B\O.)WKNVW;N4%C\%K%MMO>;
MY+?RP/FW_. FO.Q8>8E8S.8R1P3JWR.[9G&<DU0Y_JZ@G5W,W''_]PO=*VY>
MW<Q#D+%K'O\>A7)UV1EW2,@6P2:67_C69]4-#7+>G,=9\9=L2]OAJ$/FFTSR
MI')6)4BBM/P?/%45L>>@.'H'NW*P7SOT#SCT*H?>L1'ZE4/_V B#RF'PVF%X
MP&%8.0R/C3"J'$;'.HPKAW'1NF5S%&WI!#*87@B^)2*W5K3\1R&(PELU893F
MVKV30EV-E)^<WJ1SGC#R-7AB&?E(/H5AE&LJB,E-6CX9N<+>.4P&49R]5R;W
M=PYY]^/[BZY4X7-(=UZ%NBI#V0="]<AGGLI51MPT9*'&WS'[3][R]\S^U#8
MNJK>=I5GOU3>E6TDWK'U&>E9'XAMV3U-@:Z/=[=U]?%]T=WOB^Z9W1TV5^[T
MH/OL>'>J<?>/=[<,+=G;/0:]@M<[YC'X\Q=UE=Q(EF1_Z61>HOIZ5#[8G&?K
M8,XN.VHTR9AX9)WI3S_0H?6S3B)(F(.$N4B8AX3-D# ?!&O(KK^37=]$G]X*
M_A@5TP"NAF"6LD4DR4+PA$2E(&4N2)T&2^Z@X.;SD\=IS[+4D_"XKZVVT4?;
MFK3L')W=L&7F:LSHJ-^R\W1VO39OUK:C?=HR\]MFM46CU@>[6A\8:UT][&J:
MES%5R>0QB#?E&+<6D9J]1?$S"3>JXCE1\T-17HIYENF;P1CHU*X "7.0,!<)
M\TK8<*\];2M71TL?;4,ZG&@,_4%+(;8U:AHVA#+<"65H%,JOZMVA4D&Z+%1
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MV>F\?VH(NBN/S"LJY &\O-P"D:51!<CG:TK%:T.=PNNO+K/_ 5!+ P04
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M66: 2@NQ:&V-NVR.:\T>Z'0.HR)*S"NC#V^2&2^-U*!:D/8J1$WBH-)\5%J
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MH2^ \TO.U?..+J#YXF7Q/U!+ P04    " #P@Y97Y=!SMKP"   $"   &@
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M%@[QY_UQ+6A."DIC4#1=N,[#(78/YXN0ZJ0SAS[#YQRHA=/0]K7#SL(G??%
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M>D;/]8+*%]7\D+>Y4GE:O9R+:"9DN8+^_"[/U=>%<LK)S;RJD_\ 4$L#!!0
M   ( /"#EE=-P8Q?<@,  &H+   :    >&PO=V]R:W-H965T<R]S:&5E=#$P
M-RYX;6RE5MMNVS@0_96!MEBD0!I=G#AQUA;@)%NT#RF"!NT^+/:!ED8648I4
M2<J._[Y#RE9<5)8WJ1\LD>+,G#.<VW2M]#=3(EIXJH0TLZ"TMKX.0Y.56#%S
MIFJ4]*50NF*6EGH9FEHCR[U0)<(DBL9AQ;@,TJG?>]#I5#56<(D/&DQ354QO
M;E"H]2R(@]W&9[XLK=L(TVG-EOB(]DO]H&D5=EIR7J$T7$G06,R">7Q]$X^<
M@#_QE>/:[+V#H[)0ZIM;?,QG0>00H<#,.A6,'BN\12&<)L+Q?:LTZ&PZP?WW
MG?;WGCR163"#MTK\PW-;SH*K '(L6"/L9[7^@%M"%TY?IH3Q_[#>GHT"R!IC
M5;45)@05E^V3/6T=L2>0) <$DJU XG&WACS*.V99.M5J#=J=)FWNQ5/UT@2.
M2W<KCU;35TYR-OVD5LR[1Q5PSV13D)L:S>42YDN-2/ZW!D[NT#(NS-MI:,FF
MDPRSK?Z;5G]R0'\,]TK:TL#?,L?\9_F0L': DQW@FV10X;S69S"*3B&)DA%\
M>;R#DS=O!_2..D>,O-[1 ;VWJJJX;?DRF<,MP28WH,PX&KCC)A/*-!KAW_G"
M6$UN^J_/&ZV1\WXC+L6N3<TRG 640P;U"H/TSS_B<?37 (7SCL+YD/;4IQ18
M!18UA0JS"&QWB:"TSP]ZYJA/H=;<[6AN+4J0RO(,H4;:S?MH#1L>19"SC1F@
M<-%1N'@IA7W45'>,DFPA$#+6&'PQCV'K8ZA\L X0&7=$QJ\G HL-9*J1]*UF
MVF[ZB.WD?.FJW&&HV<:=Z./5@KGP8%PA7J71-%SUX+_L\%_^SD50.20?,P$+
M0IZ5I]#(C)(C'W#]L+WC(735(;_Z'>2-;$Q#P"EJN"PT?F]<=NRBZ2#Z89N3
MH^@G'?K)H*9/2KZCOM3(W >#H'"6!J% W$9!'[C)+[=/39E^_2$01\^](1IV
MI=HP83?.+03#4I>&$X'&@"V9[&\&K<+)?B">1?$!('M-*GYU97MQ#3ABZW\4
M@3AY!IZ\OB3_4@5>D55'[(^/!F;\W"#CP>;U0BY4K-IF2O=!Y2U#&K[RH0P[
M8GV@0(1[XT^%>NF'/-/B:2>A;K<;).?M^/1\O)U"[YE><FE 8$&BT=DE)95N
M![MV857MAZF%LC2:^=>2AF'4[@!]+Y2RNX4ST(W7Z0]02P,$%     @ \(.6
M5W$I4WAJ P  FQ<   T   !X;"]S='EL97,N>&ULW5AM;]HP$/XK4;I.K30U
MA*R!K("T(56:M$V5V@_[5AGB@"7'R1S3P7[]?'8(@?H0[8<5%@2Q[_P\]_A\
MS@N#2JTXO9]3JKQESD4U].=*E9^"H)K.:4ZJJZ*D0GNR0N9$Z:Z<!54I*4DK
M .4\Z'8Z<9 3)OS10"SRVUQ5WK18"#7TPTYC\^SI:ZJM\4??LWSC(J5#__'B
M_:]%H6[>>?9\]N'LK/-X>;-KOS".2S]PDEX?0'K5T0?*;+P8?7P8_3YRC+JW
M36V&GVLB"SS'8'T'S$RA!:[[&$5R8,[VI@PA[W4.(M]#C1&'V,2WIXW!NV[X
M5M*PC/4B)[@%-<"@W@BC05:(S7Z(?&O0S"2GWA/A0W],.)M(!JB,Y(ROK+D+
MAFG!"^DIO1%UJ! LU1_K#FT/]FC-DS-12!/;1K"_DWKXCF/= X&,\T9@U[>&
MT: D2E$I;G7'##;&9RZO;C^L2JUP)LDJ[%[[&X YZ2"30J94;JX+_MHT&G":
M@1S)9G,XJZ(,P*E4D>M&RLBL$,1H6"/JAJ:=4L[OX0+V,]OB7F:M-3-E*)JF
M%E0W+8WM '^;S7*W:7NOXO5*]E2H+PL]'6'Z4.#T3M*,+4U_F34",/809R=E
MR5>?.9N)G-K)'QQP-"!KG#<O)/NCHT&I3+6!2M][HE*Q:=OR6Y+R@2[5NIR6
M&:ZY>X*:_VV>9U1027A;M*[]8\[RJQ77-_RWT&PN*[N*G2*CWO%KK!]RCEUD
M? HB3V*Y^Z<@,CD!D;TWNVJ^1&1X_"*CDUCM[BF(C(Y29% _^+:>KK>>K1NK
M!^\P0_\'O WQ35!OLF!<,5'WYBQ-J7CVB*WI%9EPNLVOQZ<T(PNN'AKGT-^T
MO].4+?*D&74'B:A';=K?8'IAW+Q Z5A,I'1)TW'=E;.):7JZH:/6!P!V/;?F
M<'LPC/6Y/>##XF *,(Q%87'^I_GTT?E8'Z:M[_3T44P?Q5B4RS,V'RR.&Y/H
MPSW3)(FB.,8R.AX[%8RQO,4Q?-ULF#9 8'$@TLMRC:\V7B'[ZP!;TWT5@LT4
MKT1LIGBNP>/.&R"2Q+W:6!Q 8*N U0[$=\>!FG)CH@A6%=.&[6#<DR28!VK1
M7:-QC&0GAH][?;!=$D5)XO: SZT@BC /[$;<@RD #9@GBLQ]<.=^%*SO4\'F
M[_C17U!+ P04    " #P@Y97EXJ[',     3 @  "P   %]R96QS+RYR96QS
MG9*Y;L,P#$!_Q=">, ?0(8@S9?$6!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2
MW!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N
M&6:WO606IW.D5XA<UYVE/=LO3T%O@*\Z3'%":4A+,P[PS=)_,O?S##5%Y4HC
ME5L:>-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,E
MC'%BM/XU@LD/['X 4$L#!!0    ( /"#EE<!DK+!B <  '%&   /    >&PO
M=V]R:V)O;VLN>&ULQ9Q!;]LX$$;_"N'+MD"SD65+EHNF0-JTNP':)*B#[G'!
M2+1-5)9<4DJ;_OHEZ;H9ILJ'O4Q\BBW;\C,E\@V'P[SZUIHO-VW[17S?U(T]
M&:V[;OOR^-B6:[61]L]VJQKWRK(U&]FYIV9U;+=&R<JNE>HV]7&:)/GQ1NIF
M]/K5_EQ7YI@^:3M5=KIMW$%_X+-6W^S]Z_ZIN-56W^A:=W<GH_"X5B.QT8W>
MZ!^J.ADE(V'7[;>_6Z-_M$TGZT5IVKH^&8UW+WQ6IM/E;X<7'O):WMAPI),W
MGZ0#.1GEB3OA4AO;A7>$\TO'>*O<FW?/^JY]K^M.F3/9J;],VV]UL_*G<;_B
MF/R,T [[O[M&?&G^3S.VRZ4NU5E;]AO5=+MV-*KV@(U=ZZT=B49NU,GH;7NK
MC+B2*^5_E/N6\VKW SM'1IK+O-3N!7->!49.GJ92C565<(]L6^O*<53BC:QE
M4RI!(%, F1X0\M^40$X Y.0@D N/XSY*(*< <GI R*@E,P"9'1)R0B!S )D?
M$G)*(&< <G9(R(Q %@"RX(7<]Y!.M$MQ:JT;@<5I^;77QJ%*VG'F '+."WF]
M5JX--UO9W#DF/_98;3WPE5$VZMWC!(WF"7-;]IN--'<>;*%7C78?DZYA3\NR
M[9M.4TPH'6;KO)?:B,^R[I7XJ*3M3;C^EN(AW8RY?2/M6KQS=^"MK#U7N.(?
MI?FB7-111^9&PADS&\<%8UL7*NUN2(^[]1]X(2Y41Q&1;L;,OG$WGNE#-Z[$
M9;=VH<_;WAC?US]H>1/=CT@X8V;C?' WH8IN/V26,;-:%EU;?EFW=:6,_2-<
MV.Z.LB&AC)F-\LD?=!?T2OH;[]K(QLHP'XA:#]EDS*R38)"=0*SVKU(P9) Q
MLT)<D\E5VXC3E5%AO*/!-9)&RBT-9;1RSA47;7/TN>W<W,C'"[=^&A8/=RF2
M1LHLC3!BN%FE8WU!^;R"E\I03#A789;'HC/NFU>Z=$-<Z8.O^PM.^TB*S)$R
MFV/AO!:"%[7ZH6MI5KIQ Z#H6G&^V:B*8B)[I,SV.%-+W>R"U\[HF]Z_05S5
M44R8(F^DS-XX;\IVH\2U_![9(T7V2)GMX>PO/K36NHMKQ&(M3=2!D3M2=G?8
MSO1EUYLPPCBT5=QL2!LILS8NVMMPT'>+C[+IEW(/&KHOQ40229DE\DFY8<]U
MU1 CB,76C8<T_8$T,F'6R)FRI=';?2.Z:$^\Z:WKP#8$T!03:63"K)%]2$IT
M0M&0.B;,ZO 1PO;.*'&Y:\7+FUJOY(,89@)S7-SBZ&^L^MK[ /[=[0.C39 J
M)NRJ #=?G")$PI@P"P-CTM36!#EDPCT#06F$N#614";,0AGHRN+9M9^BV^>4
M$7EEPNR5X53'(";RRH39*S#E$5WQ*7+,E-DQ(.7AFY1B(L=,G\@Q@VF/N#61
M;Z;,OMFE/8;NQ2F2S)1;,@/YCT%(N)#"+)S'$R$!E6(BX4R9A?-;-F2P(9%K
MILRN@=/ZN*\@UTR978.F]:Y-*2;2S919-W1&.GBID62FS)+Y?6HZA)@AP63,
M@AF<HPY2(K]DS'Z!JU'Q,B[R2\;L%QSMTC72#/DF8_8-QJ2KI!DR3O9$:RDT
MVCT2OT(-B@D7[[F-,XQ954$_$2;23L:LG<?GVH&68B+M9-S:@3,Q.F',D'8R
M[C5\B!GU="2@C%E CZP[NRO^7C=16CE'$LJ9)?0XYH4TAG:A'%DH/\PJOL-T
MWFQ6%!-9*&>VT..8X5:EF,A".7?]&)R!1U5/R$(Y=P49Q*0]/4<6RKEKR" F
M=7H.B\BXJ\@@9DXQD85R9@NAM(OK1A0362AGMA#&/*68R$(YLX5P=HCV]!FR
MT(S90C^S0R1VJ\5YLSM5O"0Q0Q::<9<%[#$7[F15OUO8OG3W@0R%#!0366CV
M-+DVAWD?*OVC]&K=J>KH])9B(@O-F"TTA!F.N?FF[:+61!::,5MH\*)_E'[:
M_F!!;X8L-&.VT& F\[Y#44QDH=D!"L[(+4 Q83'SP6K/0F1,,9&%9LP6@ICO
MOE-,9*$9>R4!P/Q$"QX*9*&"V4*_)[!_SH+\!A_QC&(B"Q7<*SX#F.08Q406
M*IZ@PB"J013/SERHJ>LHMUD@ Q7<JS^H&C'*;1;(0 6W@>"R!0WB"F2@@KNR
M&6+2Z5J!#%0<=!$HVJB"#%0P&PACTNE: 3?4,!L(8\XH)C)0P6P@C%D0S#DR
MT)Q['@0QYQ03&6C.;""X0'E$@[@Y,M#\@.71(AK>Y\A"\T-62,>8R$+S0U5(
M[V89%!-9:/Z$==*.[.?39WXM^+EX0V/-.;+0G-E"#S ?YCTH)K+0G-E"#S#)
M3/U,+Y=1:R(+S9^R%.$HK%>W3>CFGC3"A!L[G[XHX8AD9@CF.,%;.YD]- AZ
MG_^(0.'FSH391 ,UZH^L (\3N,TS87;1<+''K_EE! HW>B;,-GH,-*RSQ1L7
M$[C=,V&OBGL4U#P$A1L^$^[,W,-"]GB\CT#A7M"$>SL/VI<2!2+C!&X,38*5
MCL/;[>M7U2YRN'!?8MWQ4M;EE1'^3SA7.LW\9LEE7]=OW;'+YD,KJ_U_3-G_
MMY?7_P%02P,$%     @ \(.65YC0E^X% P  VCX  !H   !X;"]?<F5L<R]W
M;W)K8F]O:RYX;6PN<F5L<\W;.V[;0!A%X:T(7( Y[T=@NTKC-O &!)F2#.L%
MD4'LW4>P"^D.4J0Q>"IA*'!TJ@\".?_]KV&WG%Z/AW'[>AH7[_O=87SHMM-T
M^M'WXVH[[)?CW?$T'"[?K(_G_7*Z+,^;_K1<O2TW0^^,2?WY=H_N\?YVS\7S
MQVGXGQV/Z_7K:OAY7/W>#X?I'QOW?X[GMW$[#%.W>%Z>-\/TT/7ON^OEL?_\
ML'>7G;O%T\M#=WYZL5T_=Y"3(#=_D)<@/W]0D* P?U"4H#A_4)*@-']0EJ \
M?U"1H#)_4)6@.G^0-2JC 20U6 .TMLJU!7AM%6P+$-LJV19@ME6T+4!MJVQ;
M@-M6X;8 N:W2;0%V6\7; O1VJK<#Z.U4;P?0VS5_M@%Z.]7; ?1VJK<#Z.U4
M;P?0VZG>#J"W4[T=0&^G>CN WD[U=@"]O>KM 7I[U=L#]/:JMP?H[9N')0"]
MO>KM 7I[U=L#]/:JMP?H[55O#]#;J]X>H+=7O3U [Z!Z!X#>0?4. +V#ZAT
M>@?5.P#T#LW#;H#>0?4. +V#ZAT >@?5.P#T#JIW .@=5.\ T#NJWA&@=U2]
M(T#OJ'I'@-Y1]8X O:/J'0%ZQ^9E)4#OJ'I'@-Y1]8X O:/J'0%Z1]4[ O1.
MJG<"Z)U4[P30.ZG>":!W4KT30.^D>B> WDGU3@"]4W/8!*!W4KT30.^D>B>
MWDGU3@"]L^J= 7IGU3L#],ZJ=P;HG57O#- [J]X9H'=6O3- [ZQZ9X#>N3DL
M"- [J]X9H'=6O3- [Z)Z%X#>1?4N +V+ZET >A?5NP#T+JIW >A=5.\"T+NH
MW@6@=U&]"T#OTASV!NA=5.\"T+NJWA6@=U6]*T#OJGI7@-Y5]:X O:OJ70%Z
M5]6[ O2NJG<%Z%U5[PK0NZK>%:!W;89U 'I;TX[K /RVIAG8,0#!K6E&=@S
M<&N:H1T#4-R:9FS' !RWIAG<,0#)K6E&=PS <FN:X1WSG9J/T\=N&*]%7^LF
MX#OMGB[W#M??_UQ^76P1^N2ZO\T8'_\"4$L#!!0    ( /"#EE?R?@/O<0(
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M_RGL]W'<_^/XY1GW53N\YHOE'\@W/P%02P$"% ,4    " #O@Y97!T%-8H$
M  "Q    $               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4
M Q0    ( .^#EE<38S93[0   "L"   1              "  :\   !D;V-0
M<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( .^#EE>97)PC$ 8  )PG   3
M          "  <L!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @
M[X.65]S<M=B?!   %14  !@              ("!# @  'AL+W=O<FMS:&5E
M=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( /"#EE?P/BPNX <  *0E   8
M          " @>$,  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4
M    " #P@Y97'0 JSZ0#  "C$   &               @('W%   >&PO=V]R
M:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ \(.65P2R(+Y?"0  !D(
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M965T."YX;6Q02P$"% ,4    " #P@Y97()Y-@YD"  #*!P  &
M    @(%T4   >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @
M\(.65\>=@XV2"P  WR,  !D              ("!0U,  'AL+W=O<FMS:&5E
M=',O<VAE970Q,"YX;6Q02P$"% ,4    " #P@Y97<^1JVI,>  "Z8@  &0
M            @($,7P  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4
M Q0    ( /"#EE<G U?AO0L  "HG   9              " @=9]  !X;"]W
M;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ \(.65UIK4Y>4"
M%2,  !D              ("!RHD  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX
M;6Q02P$"% ,4    " #P@Y97)1&Q#TL#  !9!P  &0              @(&5
MD@  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( /"#EE<2
M<[B &0,  -0(   9              " @1>6  !X;"]W;W)K<VAE971S+W-H
M965T,34N>&UL4$L! A0#%     @ \(.65_#OIGY!!@  RPX  !D
M     ("!9YD  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( /"#EE? J5M!!@@  /(4   9              "
M@;V[  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @ \(.6
M5]KBNH<6%@  ,4@  !D              ("!^L,  'AL+W=O<FMS:&5E=',O
M<VAE970R,BYX;6Q02P$"% ,4    " #P@Y97V2_[C?01  !<40  &0
M        @(%'V@  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0
M   ( /"#EE?Z[-(73 0  *D)   9              " @7+L  !X;"]W;W)K
M<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ \(.65XBYB7'D @  ;@8
M !D              ("!]?   'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q0
M2P$"% ,4    " #P@Y97PR#C)(L(   "%@  &0              @($0]
M>&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( /"#EE>T'Z .
M7P0  !$,   9              " @=+\  !X;"]W;W)K<VAE971S+W-H965T
M,C<N>&UL4$L! A0#%     @ \(.65^&!*&$?!@  *0X  !D
M ("!: $! 'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4    " #P
M@Y97F$'<^R,&   T$   &0              @(&^!P$ >&PO=V]R:W-H965T
M<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( /"#EE?F+IYY/0(   D%   9
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M970S-"YX;6Q02P$"% ,4    " #P@Y97<KX>M%LF   MDP  &0
M    @(&0, $ >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    (
M /"#EE?P9(6UAP,  (8)   9              " @2)7 0!X;"]W;W)K<VAE
M971S+W-H965T,S8N>&UL4$L! A0#%     @ \(.65W_M]6^P @  X 4  !D
M             ("!X%H! 'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"
M% ,4    " #P@Y97;@/WB),#  !K"@  &0              @(''70$ >&PO
M=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( /"#EE<3PAFAD04
M ($2   9              " @9%A 0!X;"]W;W)K<VAE971S+W-H965T,SDN
M>&UL4$L! A0#%     @ \(.65]DE>^/6!0  &AD  !D              ("!
M66<! 'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4    " #P@Y97
M,>0N<.P"  !-!@  &0              @(%F;0$ >&PO=V]R:W-H965T<R]S
M:&5E=#0Q+GAM;%!+ 0(4 Q0    ( /"#EE=MA/X&D@,  'T*   9
M      " @8EP 0!X;"]W;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#%
M  @ \(.65[E+*]BC!   H P  !D              ("!4G0! 'AL+W=O<FMS
M:&5E=',O<VAE970T,RYX;6Q02P$"% ,4    " #P@Y97IHE-\PX#  #[!P
M&0              @($L>0$ >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+
M 0(4 Q0    ( /"#EE<W7%F0'@,  *@'   9              " @7%\ 0!X
M;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @ \(.65\E:_\EE
M P  0@D  !D              ("!QG\! 'AL+W=O<FMS:&5E=',O<VAE970T
M-BYX;6Q02P$"% ,4    " #P@Y97VFE_ZW((  #V&@  &0
M@(%B@P$ >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    ( /"#
MEE<U@B#7# ,  %H(   9              " @0N, 0!X;"]W;W)K<VAE971S
M+W-H965T-#@N>&UL4$L! A0#%     @ \(.65Q<ZE),?!0  J@P  !D
M         ("!3H\! 'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q02P$"% ,4
M    " #P@Y974QZKFSP$  #("P  &0              @(&DE $ >&PO=V]R
M:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    ( /"#EE=\$9Q66 ,  +$'
M   9              " @1>9 0!X;"]W;W)K<VAE971S+W-H965T-3$N>&UL
M4$L! A0#%     @ \(.65\7H?UXS"@  ?FT  !D              ("!IIP!
M 'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6Q02P$"% ,4    " #P@Y97QT]I
M'9P$  #&&@  &0              @($0IP$ >&PO=V]R:W-H965T<R]S:&5E
M=#4S+GAM;%!+ 0(4 Q0    ( /"#EE<,L@A^X0\  *+>   9
M  " @>.K 0!X;"]W;W)K<VAE971S+W-H965T-30N>&UL4$L! A0#%     @
M\(.65]EXF.D; P  9 L  !D              ("!^[L! 'AL+W=O<FMS:&5E
M=',O<VAE970U-2YX;6Q02P$"% ,4    " #P@Y97+'E847X"   9!@  &0
M            @(%-OP$ >&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+ 0(4
M Q0    ( /"#EE?Y]*+QI (  !L(   9              " @0+" 0!X;"]W
M;W)K<VAE971S+W-H965T-3<N>&UL4$L! A0#%     @ \(.65SB^URE_ P
MFPT  !D              ("!W<0! 'AL+W=O<FMS:&5E=',O<VAE970U."YX
M;6Q02P$"% ,4    " #P@Y97T_<$USH#   )#@  &0              @(&3
MR $ >&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+ 0(4 Q0    ( /"#EE>?
M/#?!" H  (AN   9              " @03, 0!X;"]W;W)K<VAE971S+W-H
M965T-C N>&UL4$L! A0#%     @ \(.65TI;+^A\#   9;4  !D
M     ("!0]8! 'AL+W=O<FMS:&5E=',O<VAE970V,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( /"#EE<I/=PH:04  "0G   9              "
M@3WW 0!X;"]W;W)K<VAE971S+W-H965T-C8N>&UL4$L! A0#%     @ \(.6
M5P.UF1J\ @  !@@  !D              ("!W?P! 'AL+W=O<FMS:&5E=',O
M<VAE970V-RYX;6Q02P$"% ,4    " #P@Y97U1L%;BH$  #Y&0  &0
M        @('0_P$ >&PO=V]R:W-H965T<R]S:&5E=#8X+GAM;%!+ 0(4 Q0
M   ( /"#EE?YMRZ*, ,   P.   9              " @3$$ @!X;"]W;W)K
M<VAE971S+W-H965T-CDN>&UL4$L! A0#%     @ \(.65V3JV3=$ P  8@L
M !D              ("!F <" 'AL+W=O<FMS:&5E=',O<VAE970W,"YX;6Q0
M2P$"% ,4    " #P@Y97%S\]YC4$  "/&   &0              @($3"P(
M>&PO=V]R:W-H965T<R]S:&5E=#<Q+GAM;%!+ 0(4 Q0    ( /"#EE<)YZ9%
MXP,  "D1   9              " @7\/ @!X;"]W;W)K<VAE971S+W-H965T
M-S(N>&UL4$L! A0#%     @ \(.65ZUCR/>C @  $P@  !D
M ("!F1," 'AL+W=O<FMS:&5E=',O<VAE970W,RYX;6Q02P$"% ,4    " #P
M@Y97HWKS6K("   &"   &0              @(%S%@( >&PO=V]R:W-H965T
M<R]S:&5E=#<T+GAM;%!+ 0(4 Q0    ( /"#EE?W8P(5#P,  %L*   9
M          " @5P9 @!X;"]W;W)K<VAE971S+W-H965T-S4N>&UL4$L! A0#
M%     @ \(.65P\: HC0"P  KH   !D              ("!HAP" 'AL+W=O
M<FMS:&5E=',O<VAE970W-BYX;6Q02P$"% ,4    " #P@Y97S8JXN/,$  "%
M(0  &0              @(&I* ( >&PO=V]R:W-H965T<R]S:&5E=#<W+GAM
M;%!+ 0(4 Q0    ( /"#EE?Z,<Z%&0P  *"B   9              " @=,M
M @!X;"]W;W)K<VAE971S+W-H965T-S@N>&UL4$L! A0#%     @ \(.65XUG
M'2_P @  V@D  !D              ("!(SH" 'AL+W=O<FMS:&5E=',O<VAE
M970W.2YX;6Q02P$"% ,4    " #P@Y976X,JA<P"  !N"@  &0
M    @(%*/0( >&PO=V]R:W-H965T<R]S:&5E=#@P+GAM;%!+ 0(4 Q0    (
M /"#EE<Z^&0%[0,  .4.   9              " @4U  @!X;"]W;W)K<VAE
M971S+W-H965T.#$N>&UL4$L! A0#%     @ \(.65^/-5CMP!   @AH  !D
M             ("!<40" 'AL+W=O<FMS:&5E=',O<VAE970X,BYX;6Q02P$"
M% ,4    " #P@Y97$+P]84,&   I-0  &0              @($820( >&PO
M=V]R:W-H965T<R]S:&5E=#@S+GAM;%!+ 0(4 Q0    ( /"#EE<+0(I5\04
M &XN   9              " @9)/ @!X;"]W;W)K<VAE971S+W-H965T.#0N
M>&UL4$L! A0#%     @ \(.65UHO._XL!   \!D  !D              ("!
MNE4" 'AL+W=O<FMS:&5E=',O<VAE970X-2YX;6Q02P$"% ,4    " #P@Y97
M+8!]*T<#  !T"@  &0              @($=6@( >&PO=V]R:W-H965T<R]S
M:&5E=#@V+GAM;%!+ 0(4 Q0    ( /"#EE?*'12QW#<  (]V!  9
M      " @9M= @!X;"]W;W)K<VAE971S+W-H965T.#<N>&UL4$L! A0#%
M  @ \(.65_RO'Z#%!@  ,#(  !D              ("!KI4" 'AL+W=O<FMS
M:&5E=',O<VAE970X."YX;6Q02P$"% ,4    " #P@Y97XC%39G$#  !."P
M&0              @(&JG ( >&PO=V]R:W-H965T<R]S:&5E=#@Y+GAM;%!+
M 0(4 Q0    ( /"#EE>F87V9\P8  +Y'   9              " @5*@ @!X
M;"]W;W)K<VAE971S+W-H965T.3 N>&UL4$L! A0#%     @ \(.65_;/6NU?
M!@  \#$  !D              ("!?*<" 'AL+W=O<FMS:&5E=',O<VAE970Y
M,2YX;6Q02P$"% ,4    " #P@Y97"QF2#@D3  #]+@$ &0
M@($2K@( >&PO=V]R:W-H965T<R]S:&5E=#DR+GAM;%!+ 0(4 Q0    ( /"#
MEE<PXY4Q'P,  #$+   9              " @5+! @!X;"]W;W)K<VAE971S
M+W-H965T.3,N>&UL4$L! A0#%     @ \(.65[=]/U4R!   2!8  !D
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M=#DX+GAM;%!+ 0(4 Q0    ( /"#EE?^]&AC&@0  ($1   9
M  " @9C: @!X;"]W;W)K<VAE971S+W-H965T.3DN>&UL4$L! A0#%     @
M\(.65WK\_H*I!   %QP  !H              ("!Z=X" 'AL+W=O<FMS:&5E
M=',O<VAE970Q,# N>&UL4$L! A0#%     @ \(.65X6U;V/$ P  L1   !H
M             ("!RN," 'AL+W=O<FMS:&5E=',O<VAE970Q,#$N>&UL4$L!
M A0#%     @ \(.65ZDD2(([ @  Z00  !H              ("!QN<" 'AL
M+W=O<FMS:&5E=',O<VAE970Q,#(N>&UL4$L! A0#%     @ \(.65R)(AT]#
M!0  _2(  !H              ("!.>H" 'AL+W=O<FMS:&5E=',O<VAE970Q
M,#,N>&UL4$L! A0#%     @ \(.65^70<[:\ @  ! @  !H
M ("!M.\" 'AL+W=O<FMS:&5E=',O<VAE970Q,#0N>&UL4$L! A0#%     @
M\(.65T'+*NL$!P  X$$  !H              ("!J/(" 'AL+W=O<FMS:&5E
M=',O<VAE970Q,#4N>&UL4$L! A0#%     @ \(.65YALTV)#!P  8U4  !H
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M+G)E;'-02P$"% ,4    " #P@Y97 9*RP8@'  !Q1@  #P
M@ &'"0, >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ \(.65YC0E^X% P
MVCX  !H              ( !/!$# 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR
M96QS4$L! A0#%     @ \(.65_)^ ^]Q @  B3P  !,              ( !
M>10# %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     ', <P"D'P  &Q<#

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>161
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>162
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>163
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>516</ContextCount>
  <ElementCount>525</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>110</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>18</UnitCount>
  <MyReports>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>1001 - Document -  Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1004 - Statement - Condensed Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/CondensedConsolidatedStatementsOfOperations</Role>
      <ShortName>Condensed Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1005 - Statement - Condensed Consolidated Statements of Operations (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical</Role>
      <ShortName>Condensed Consolidated Statements of Operations (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1006 - Statement - Condensed Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1007 - Statement - Condensed Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders' (Deficit) Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/CondensedConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersDeficitEquity</Role>
      <ShortName>Condensed Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders' (Deficit) Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1008 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/CondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>1009 - Statement - Statement of Assets Acquired and Liabilities Assumed</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/StatementOfAssetsAcquiredAndLiabilitiesAssumed</Role>
      <ShortName>Statement of Assets Acquired and Liabilities Assumed</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>1010 - Disclosure - The Company and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/TheCompanyAndBasisOfPresentation</Role>
      <ShortName>The Company and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>1011 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>1012 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>1013 - Disclosure - Cash Equivalents and Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/CashEquivalentsAndMarketableSecurities</Role>
      <ShortName>Cash Equivalents and Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>1014 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/PropertyAndEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>1015 - Disclosure - Accrued and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/AccruedAndOtherCurrentLiabilities</Role>
      <ShortName>Accrued and Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>1016 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>1017 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>1018 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>1019 - Disclosure - Asset Acquisition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/AssetAcquisition</Role>
      <ShortName>Asset Acquisition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>1020 - Disclosure - Paragon Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/ParagonAgreement</Role>
      <ShortName>Paragon Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>1021 - Disclosure - Series A Non-Voting Convertible Preferred Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/SeriesANonVotingConvertiblePreferredStock</Role>
      <ShortName>Series A Non-Voting Convertible Preferred Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>1022 - Disclosure - Liabilities, Convertible Preferred Stock and Stockholders' (Deficit) Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquity</Role>
      <ShortName>Liabilities, Convertible Preferred Stock and Stockholders' (Deficit) Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>1023 - Disclosure - Strategic License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/StrategicLicenseAgreements</Role>
      <ShortName>Strategic License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>1024 - Disclosure - Sale of Pegzilarginase to Immedica</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/SaleOfPegzilarginaseToImmedica</Role>
      <ShortName>Sale of Pegzilarginase to Immedica</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>1025 - Disclosure - Defined Contribution Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/DefinedContributionPlan</Role>
      <ShortName>Defined Contribution Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>1026 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>1027 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>1028 - Disclosure - Restructuring Charges</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/RestructuringCharges</Role>
      <ShortName>Restructuring Charges</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>1029 - Disclosure - Novation of Manufacturing Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/NovationOfManufacturingAgreements</Role>
      <ShortName>Novation of Manufacturing Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>1030 - Disclosure - Reverse Stock Split</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/ReverseStockSplit</Role>
      <ShortName>Reverse Stock Split</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>1031 - Disclosure - Description of the Business and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Description of the Business and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>1032 - Disclosure - Accrued Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/AccruedLiabilities</Role>
      <ShortName>Accrued Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>1033 - Disclosure - Parapyre Option Obligation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/ParapyreOptionObligation</Role>
      <ShortName>Parapyre Option Obligation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>1034 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>1035 - Disclosure - Description of the Business and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Description of the Business and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.spy.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>1036 - Disclosure - Description of the Business and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Description of the Business and Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>1037 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.spy.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>1038 - Disclosure - Accrued Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/AccruedLiabilitiesTables</Role>
      <ShortName>Accrued Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.spy.com/role/AccruedLiabilities</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>1039 - Disclosure - Fair Value Measurement (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/FairValueMeasurementTables</Role>
      <ShortName>Fair Value Measurement (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.spy.com/role/FairValueMeasurements</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>1040 - Disclosure - Cash Equivalents and Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesTables</Role>
      <ShortName>Cash Equivalents and Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.spy.com/role/CashEquivalentsAndMarketableSecurities</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>1041 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/PropertyAndEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.spy.com/role/PropertyAndEquipmentNet</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>1042 - Disclosure - Accrued and Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/AccruedAndOtherCurrentLiabilitiesTables</Role>
      <ShortName>Accrued and Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.spy.com/role/AccruedAndOtherCurrentLiabilities</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>1043 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.spy.com/role/Leases</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>1044 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.spy.com/role/StockholdersEquity</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>1045 - Disclosure - Related Party Transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/RelatedPartyTransactionsTables</Role>
      <ShortName>Related Party Transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.spy.com/role/RelatedPartyTransactions</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>1046 - Disclosure - Asset Acquisition (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/AssetAcquisitionTables</Role>
      <ShortName>Asset Acquisition (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.spy.com/role/AssetAcquisition</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>1047 - Disclosure - Liabilities, Convertible Preferred Stock and Stockholders' (Deficit) Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityTables</Role>
      <ShortName>Liabilities, Convertible Preferred Stock and Stockholders' (Deficit) Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquity</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>1048 - Disclosure - Strategic License Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/StrategicLicenseAgreementsTables</Role>
      <ShortName>Strategic License Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.spy.com/role/StrategicLicenseAgreements</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>1049 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.spy.com/role/IncomeTaxes</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>1050 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.spy.com/role/NetLossPerShare</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>1051 - Disclosure - Restructuring Charges (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/RestructuringChargesTables</Role>
      <ShortName>Restructuring Charges (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.spy.com/role/RestructuringCharges</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>1052 - Disclosure - The Company and Basis of Presentation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/TheCompanyAndBasisOfPresentationNarrativeDetails</Role>
      <ShortName>The Company and Basis of Presentation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>1053 - Disclosure - Description of the Business and Summary of Significant Accounting Policies - Summary of Asset Acquisition Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesSummaryOfAssetAcquisitionCostDetails</Role>
      <ShortName>Description of the Business and Summary of Significant Accounting Policies - Summary of Asset Acquisition Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>1054 - Disclosure - Description of the Business and Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Description of the Business and Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>1055 - Disclosure - Accrued Liabilities - Accrued and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/AccruedLiabilitiesAccruedAndOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Accrued Liabilities - Accrued and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>1056 - Disclosure - Accrued Liabilities - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/AccruedLiabilitiesAdditionalInformationDetails</Role>
      <ShortName>Accrued Liabilities - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>1057 - Disclosure - Parapyre Option Obligation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/ParapyreOptionObligationAdditionalInformationDetails</Role>
      <ShortName>Parapyre Option Obligation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>1058 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>1059 - Disclosure - Summary of Significant Accounting Policies - Summary of Useful Lives of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfUsefulLivesOfPropertyAndEquipmentDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Summary of Useful Lives of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>1060 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>1061 - Disclosure - Fair Value Measurements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/FairValueMeasurementsNarrativeDetails</Role>
      <ShortName>Fair Value Measurements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>1062 - Disclosure - Fair Value Measurements - Changes in Derivative Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/FairValueMeasurementsChangesInDerivativeLiabilitiesDetails</Role>
      <ShortName>Fair Value Measurements - Changes in Derivative Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>1063 - Disclosure - Fair Value Measurements - Significant Inputs used to Estimate the Fair Value of Derivative Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/FairValueMeasurementsSignificantInputsUsedToEstimateTheFairValueOfDerivativeLiabilityDetails</Role>
      <ShortName>Fair Value Measurements - Significant Inputs used to Estimate the Fair Value of Derivative Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>1064 - Disclosure - Cash Equivalents and Marketable Securities - Estimated Fair Value of Cash Equivalents and Marketable Securities and the Gross Unrealized Gains and Losses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesEstimatedFairValueOfCashEquivalentsAndMarketableSecuritiesAndTheGrossUnrealizedGainsAndLossesDetails</Role>
      <ShortName>Cash Equivalents and Marketable Securities - Estimated Fair Value of Cash Equivalents and Marketable Securities and the Gross Unrealized Gains and Losses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>1065 - Disclosure - Cash Equivalents and Marketable Securities - Available-for-Sale Securities in an Unrealized Loss Position (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesAvailableForSaleSecuritiesInAnUnrealizedLossPositionDetails</Role>
      <ShortName>Cash Equivalents and Marketable Securities - Available-for-Sale Securities in an Unrealized Loss Position (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>1066 - Disclosure - Cash Equivalents and Marketable Securities - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesNarrativeDetails</Role>
      <ShortName>Cash Equivalents and Marketable Securities - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>1067 - Disclosure - Cash Equivalents and Marketable Securities - Contractual Maturities of Marketable Securities at Estimated Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesContractualMaturitiesOfMarketableSecuritiesAtEstimatedFairValueDetails</Role>
      <ShortName>Cash Equivalents and Marketable Securities - Contractual Maturities of Marketable Securities at Estimated Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>1068 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails</Role>
      <ShortName>Property and Equipment, Net - Schedule of Property and Equipment Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>1069 - Disclosure - Property and Equipment, Net - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/PropertyAndEquipmentNetAdditionalInformationDetails</Role>
      <ShortName>Property and Equipment, Net - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>1070 - Disclosure - Accrued and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/AccruedAndOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Accrued and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.spy.com/role/AccruedAndOtherCurrentLiabilitiesTables</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>1071 - Disclosure - Leases - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/LeasesAdditionalInformationDetails</Role>
      <ShortName>Leases - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>1072 - Disclosure - Leases - Schedule of Operating and Financing Leases Presented in Balance Sheet (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/LeasesScheduleOfOperatingAndFinancingLeasesPresentedInBalanceSheetDetails</Role>
      <ShortName>Leases - Schedule of Operating and Financing Leases Presented in Balance Sheet (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>1073 - Disclosure - Leases - Summary of Weighted-Average Remaining Lease Term and Discount Rates for Operating and Finance Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/LeasesSummaryOfWeightedAverageRemainingLeaseTermAndDiscountRatesForOperatingAndFinanceLeasesDetails</Role>
      <ShortName>Leases - Summary of Weighted-Average Remaining Lease Term and Discount Rates for Operating and Finance Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>1074 - Disclosure - Leases - Summary of Lease Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/LeasesSummaryOfLeaseCostDetails</Role>
      <ShortName>Leases - Summary of Lease Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>1075 - Disclosure - Leases - Schedule of Maturities of Operating and Finance Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/LeasesScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails</Role>
      <ShortName>Leases - Schedule of Maturities of Operating and Finance Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>1076 - Disclosure - Stockholders' Equity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/StockholdersEquityAdditionalInformationDetails</Role>
      <ShortName>Stockholders' Equity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>1077 - Disclosure - Stockholders' Equity - Summary of Pre-funded Warrants for Common Stock Issued and Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/StockholdersEquitySummaryOfPreFundedWarrantsForCommonStockIssuedAndOutstandingDetails</Role>
      <ShortName>Stockholders' Equity - Summary of Pre-funded Warrants for Common Stock Issued and Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>1078 - Disclosure - Related Party Transactions - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/RelatedPartyTransactionsNarrativeDetails</Role>
      <ShortName>Related Party Transactions - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>1079 - Disclosure - Related Party Transactions - Expenses related to Related Party which were Settled in Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/RelatedPartyTransactionsExpensesRelatedToRelatedPartyWhichWereSettledInCashDetails</Role>
      <ShortName>Related Party Transactions - Expenses related to Related Party which were Settled in Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>1080 - Disclosure - Related Party Transactions - Related Party Accounts Payable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/RelatedPartyTransactionsRelatedPartyAccountsPayableDetails</Role>
      <ShortName>Related Party Transactions - Related Party Accounts Payable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>1081 - Disclosure - Asset Acquisition - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/AssetAcquisitionNarrativeDetails</Role>
      <ShortName>Asset Acquisition - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>1082 - Disclosure - Asset Acquisition - Asset Acquisition Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/AssetAcquisitionAssetAcquisitionCostDetails</Role>
      <ShortName>Asset Acquisition - Asset Acquisition Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>1083 - Disclosure - Paragon Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/ParagonAgreementDetails</Role>
      <ShortName>Paragon Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.spy.com/role/ParagonAgreement</ParentRole>
      <Position>83</Position>
    </Report>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>1084 - Disclosure - Series A Non-Voting Convertible Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/SeriesANonVotingConvertiblePreferredStockDetails</Role>
      <ShortName>Series A Non-Voting Convertible Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.spy.com/role/SeriesANonVotingConvertiblePreferredStock</ParentRole>
      <Position>84</Position>
    </Report>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>1085 - Disclosure - Liabilities, Convertible Preferred Stock and Stockholders' (Deficit) Equity - Pre-funded Warrants for Common Stock Issued and Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityPreFundedWarrantsForCommonStockIssuedAndOutstandingDetails</Role>
      <ShortName>Liabilities, Convertible Preferred Stock and Stockholders' (Deficit) Equity - Pre-funded Warrants for Common Stock Issued and Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityTables</ParentRole>
      <Position>85</Position>
    </Report>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>1086 - Disclosure - Liabilities, Convertible Preferred Stock and Stockholders' (Deficit) Equity - Stock Awards Granted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityStockAwardsGrantedDetails</Role>
      <ShortName>Liabilities, Convertible Preferred Stock and Stockholders' (Deficit) Equity - Stock Awards Granted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityTables</ParentRole>
      <Position>86</Position>
    </Report>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>1087 - Disclosure - Liabilities, Convertible Preferred Stock and Stockholders' (Deficit) Equity - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails</Role>
      <ShortName>Liabilities, Convertible Preferred Stock and Stockholders' (Deficit) Equity - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityTables</ParentRole>
      <Position>87</Position>
    </Report>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>1088 - Disclosure - Liabilities, Convertible Preferred Stock and Stockholders' (Deficit) Equity - Summary of Employee and Non-Employee Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquitySummaryOfEmployeeAndNonEmployeeStockOptionActivityDetails</Role>
      <ShortName>Liabilities, Convertible Preferred Stock and Stockholders' (Deficit) Equity - Summary of Employee and Non-Employee Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityTables</ParentRole>
      <Position>88</Position>
    </Report>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>1089 - Disclosure - Liabilities, Convertible Preferred Stock and Stockholders' (Deficit) Equity - Summary of Employee Restricted Stock Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquitySummaryOfEmployeeRestrictedStockActivityDetails</Role>
      <ShortName>Liabilities, Convertible Preferred Stock and Stockholders' (Deficit) Equity - Summary of Employee Restricted Stock Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityTables</ParentRole>
      <Position>89</Position>
    </Report>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>1090 - Disclosure - Liabilities, Convertible Preferred Stock and Stockholders' (Deficit) Equity - Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityStockBasedCompensationExpenseDetails</Role>
      <ShortName>Liabilities, Convertible Preferred Stock and Stockholders' (Deficit) Equity - Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityTables</ParentRole>
      <Position>90</Position>
    </Report>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>1091 - Disclosure - Liabilities, Convertible Preferred Stock and Stockholders' (Deficit) Equity - Assumptions used to Estimate the Fair Value of Stock Options Granted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityAssumptionsUsedToEstimateTheFairValueOfStockOptionsGrantedDetails</Role>
      <ShortName>Liabilities, Convertible Preferred Stock and Stockholders' (Deficit) Equity - Assumptions used to Estimate the Fair Value of Stock Options Granted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityTables</ParentRole>
      <Position>91</Position>
    </Report>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>1092 - Disclosure - Strategic License Agreements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/StrategicLicenseAgreementsNarrativeDetails</Role>
      <ShortName>Strategic License Agreements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>92</Position>
    </Report>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>1093 - Disclosure - Strategic License Agreements - Changes in Contract Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/StrategicLicenseAgreementsChangesInContractLiabilitiesDetails</Role>
      <ShortName>Strategic License Agreements - Changes in Contract Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>93</Position>
    </Report>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>1094 - Disclosure - Sale of Pegzilarginase to Immedica (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/SaleOfPegzilarginaseToImmedicaDetails</Role>
      <ShortName>Sale of Pegzilarginase to Immedica (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.spy.com/role/SaleOfPegzilarginaseToImmedica</ParentRole>
      <Position>94</Position>
    </Report>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>1095 - Disclosure - Defined Contribution Plan - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/DefinedContributionPlanAdditionalInformationDetails</Role>
      <ShortName>Defined Contribution Plan - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>95</Position>
    </Report>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>1096 - Disclosure - Income Taxes - Income (Loss) Before Income Tax Expense by Jurisdiction (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/IncomeTaxesIncomeLossBeforeIncomeTaxExpenseByJurisdictionDetails</Role>
      <ShortName>Income Taxes - Income (Loss) Before Income Tax Expense by Jurisdiction (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>96</Position>
    </Report>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>1097 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/IncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>97</Position>
    </Report>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>1098 - Disclosure - Income Taxes - Summary of Difference Between Provision for Income Taxes and Amounts Computed by Applying Statutory Federal Income Tax Rate to Income Before Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/IncomeTaxesSummaryOfDifferenceBetweenProvisionForIncomeTaxesAndAmountsComputedByApplyingStatutoryFederalIncomeTaxRateToIncomeBeforeIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Summary of Difference Between Provision for Income Taxes and Amounts Computed by Applying Statutory Federal Income Tax Rate to Income Before Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>98</Position>
    </Report>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>1099 - Disclosure - Income Taxes - Components of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Components of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>99</Position>
    </Report>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R100.htm</HtmlFileName>
      <LongName>1100 - Disclosure - Net Loss Per Share - Weighted-Average Equity Instruments Excluded from Calculation of Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/NetLossPerShareWeightedAverageEquityInstrumentsExcludedFromCalculationOfDilutedNetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share - Weighted-Average Equity Instruments Excluded from Calculation of Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>100</Position>
    </Report>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R101.htm</HtmlFileName>
      <LongName>1101 - Disclosure - Net Loss Per Share - Schedule of Reconciliation of Basic and Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/NetLossPerShareScheduleOfReconciliationOfBasicAndDilutedNetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share - Schedule of Reconciliation of Basic and Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>101</Position>
    </Report>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R102.htm</HtmlFileName>
      <LongName>1102 - Disclosure - Reverse Stock Split - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/ReverseStockSplitAdditionalInformationDetails</Role>
      <ShortName>Reverse Stock Split - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>102</Position>
    </Report>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R103.htm</HtmlFileName>
      <LongName>1103 - Disclosure - Restructuring Charges - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/RestructuringChargesNarrativeDetails</Role>
      <ShortName>Restructuring Charges - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>103</Position>
    </Report>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R104.htm</HtmlFileName>
      <LongName>1104 - Disclosure - Restructuring Charges - Changes in Accrued Restructuring Balance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/RestructuringChargesChangesInAccruedRestructuringBalanceDetails</Role>
      <ShortName>Restructuring Charges - Changes in Accrued Restructuring Balance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>104</Position>
    </Report>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R105.htm</HtmlFileName>
      <LongName>1105 - Disclosure - Restructuring Charges - Charges Related to the Restructuring Activities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/RestructuringChargesChargesRelatedToTheRestructuringActivitiesDetails</Role>
      <ShortName>Restructuring Charges - Charges Related to the Restructuring Activities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>105</Position>
    </Report>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R106.htm</HtmlFileName>
      <LongName>1106 - Disclosure - Subsequent Events - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/SubsequentEventsAdditionalInformationDetails</Role>
      <ShortName>Subsequent Events - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>106</Position>
    </Report>
    <Report instance="d518298ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R107.htm</HtmlFileName>
      <LongName>1107 - Disclosure - Novation of Manufacturing Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/NovationOfManufacturingAgreementsDetails</Role>
      <ShortName>Novation of Manufacturing Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.spy.com/role/NovationOfManufacturingAgreements</ParentRole>
      <Position>107</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>agle-20230930.xsd</File>
    <File>agle-20230930_cal.xml</File>
    <File>agle-20230930_def.xml</File>
    <File>agle-20230930_lab.xml</File>
    <File>agle-20230930_pre.xml</File>
    <File doctype="S-1" isDefinitelyFs="true" isUsgaap="true" original="d518298ds1.htm">d518298ds1.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>g518298g01q73.jpg</File>
    <File>g518298g29e61.jpg</File>
    <File>g518298g81i79.jpg</File>
    <File>g518298g94u77.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1603">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="26">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>166
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d518298ds1.htm": {
   "nsprefix": "agle",
   "nsuri": "http://www.spy.com/20230930",
   "dts": {
    "schema": {
     "local": [
      "agle-20230930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/currency/2023/currency-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/exch/2023/exch-2023.xsd",
      "https://xbrl.sec.gov/naics/2023/naics-2023.xsd",
      "https://xbrl.sec.gov/sic/2023/sic-2023.xsd",
      "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "agle-20230930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "agle-20230930_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "agle-20230930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "agle-20230930_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "d518298ds1.htm"
     ]
    }
   },
   "keyStandard": 388,
   "keyCustom": 137,
   "axisStandard": 40,
   "axisCustom": 0,
   "memberStandard": 42,
   "memberCustom": 52,
   "hidden": {
    "total": 23,
    "http://fasb.org/us-gaap/2023": 17,
    "http://xbrl.sec.gov/dei/2023": 4,
    "http://www.spy.com/20230930": 2
   },
   "contextCount": 516,
   "entityCount": 1,
   "segmentCount": 110,
   "elementCount": 810,
   "unitCount": 18,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 1603,
    "http://xbrl.sec.gov/dei/2023": 26
   },
   "report": {
    "R1": {
     "role": "http://www.spy.com/role/CoverPage",
     "longName": "1001 - Document -  Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "P01_01_2023To09_30_2023",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To09_30_2023",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.spy.com/role/CondensedConsolidatedBalanceSheets",
     "longName": "1002 - Statement - Condensed Consolidated Balance Sheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "PAsOn09_30_2023",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn09_30_2023",
      "name": "us-gaap:NontradeReceivablesCurrent",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.spy.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "longName": "1003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "PAsOn09_30_2023",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn09_30_2023",
      "name": "us-gaap:PreferredStockSharesIssued",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:PreferredStockSharesOutstanding",
       "us-gaap:PreferredStockSharesOutstanding",
       "us-gaap:PreferredStockSharesIssued",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.spy.com/role/CondensedConsolidatedStatementsOfOperations",
     "longName": "1004 - Statement - Condensed Consolidated Statements of Operations",
     "shortName": "Condensed Consolidated Statements of Operations",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "P07_01_2023To09_30_2023",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2022To12_31_2022",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.spy.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical",
     "longName": "1005 - Statement - Condensed Consolidated Statements of Operations (Parenthetical)",
     "shortName": "Condensed Consolidated Statements of Operations (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "P07_01_2023To09_30_2023",
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P07_01_2023To09_30_2023_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis",
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.spy.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss",
     "longName": "1006 - Statement - Condensed Consolidated Statements of Comprehensive Loss",
     "shortName": "Condensed Consolidated Statements of Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "P07_01_2023To09_30_2023",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P07_01_2023To09_30_2023",
      "name": "us-gaap:ComprehensiveIncomeNetOfTax",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.spy.com/role/CondensedConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersDeficitEquity",
     "longName": "1007 - Statement - Condensed Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders' (Deficit) Equity",
     "shortName": "Condensed Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders' (Deficit) Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis",
      "name": "us-gaap:SharesOutstanding",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis",
      "name": "us-gaap:SharesOutstanding",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.spy.com/role/CondensedConsolidatedStatementsOfCashFlows",
     "longName": "1008 - Statement - Condensed Consolidated Statements of Cash Flows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "8",
     "firstAnchor": {
      "contextRef": "P01_01_2023To09_30_2023",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To09_30_2023",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.spy.com/role/StatementOfAssetsAcquiredAndLiabilitiesAssumed",
     "longName": "1009 - Statement - Statement of Assets Acquired and Liabilities Assumed",
     "shortName": "Statement of Assets Acquired and Liabilities Assumed",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "9",
     "firstAnchor": {
      "contextRef": "PAsOn06_22_2023",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn06_22_2023",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.spy.com/role/TheCompanyAndBasisOfPresentation",
     "longName": "1010 - Disclosure - The Company and Basis of Presentation",
     "shortName": "The Company and Basis of Presentation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "P01_01_2023To09_30_2023",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To09_30_2023",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.spy.com/role/SummaryOfSignificantAccountingPolicies",
     "longName": "1011 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "P01_01_2023To09_30_2023",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To09_30_2023",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.spy.com/role/FairValueMeasurements",
     "longName": "1012 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "P01_01_2023To09_30_2023",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To09_30_2023",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.spy.com/role/CashEquivalentsAndMarketableSecurities",
     "longName": "1013 - Disclosure - Cash Equivalents and Marketable Securities",
     "shortName": "Cash Equivalents and Marketable Securities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "P01_01_2023To09_30_2023",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To09_30_2023",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.spy.com/role/PropertyAndEquipmentNet",
     "longName": "1014 - Disclosure - Property and Equipment, Net",
     "shortName": "Property and Equipment, Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "P01_01_2022To12_31_2022",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2022To12_31_2022",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.spy.com/role/AccruedAndOtherCurrentLiabilities",
     "longName": "1015 - Disclosure - Accrued and Other Current Liabilities",
     "shortName": "Accrued and Other Current Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "P01_01_2023To09_30_2023",
      "name": "agle:AccruedAndOtherCurrentLiabilitiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To09_30_2023",
      "name": "agle:AccruedAndOtherCurrentLiabilitiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.spy.com/role/Leases",
     "longName": "1016 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "P01_01_2022To12_31_2022",
      "name": "agle:LesseeOperatingAndFinanceLeasesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2022To12_31_2022",
      "name": "agle:LesseeOperatingAndFinanceLeasesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.spy.com/role/StockholdersEquity",
     "longName": "1017 - Disclosure - Stockholders' Equity",
     "shortName": "Stockholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "P01_01_2022To12_31_2022",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2022To12_31_2022",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.spy.com/role/RelatedPartyTransactions",
     "longName": "1018 - Disclosure - Related Party Transactions",
     "shortName": "Related Party Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "P06_22_2023To06_22_2023",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P06_22_2023To06_22_2023",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.spy.com/role/AssetAcquisition",
     "longName": "1019 - Disclosure - Asset Acquisition",
     "shortName": "Asset Acquisition",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "P06_22_2023To06_22_2023",
      "name": "us-gaap:AssetAcquisitionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R20": {
     "role": "http://www.spy.com/role/ParagonAgreement",
     "longName": "1020 - Disclosure - Paragon Agreement",
     "shortName": "Paragon Agreement",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "P01_01_2023To09_30_2023",
      "name": "agle:OptionAgreementTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To09_30_2023",
      "name": "agle:OptionAgreementTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.spy.com/role/SeriesANonVotingConvertiblePreferredStock",
     "longName": "1021 - Disclosure - Series A Non-Voting Convertible Preferred Stock",
     "shortName": "Series A Non-Voting Convertible Preferred Stock",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "P01_01_2023To09_30_2023",
      "name": "us-gaap:PreferredStockTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To09_30_2023",
      "name": "us-gaap:PreferredStockTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquity",
     "longName": "1022 - Disclosure - Liabilities, Convertible Preferred Stock and Stockholders' (Deficit) Equity",
     "shortName": "Liabilities, Convertible Preferred Stock and Stockholders' (Deficit) Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "P01_01_2023To09_30_2023",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To09_30_2023",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.spy.com/role/StrategicLicenseAgreements",
     "longName": "1023 - Disclosure - Strategic License Agreements",
     "shortName": "Strategic License Agreements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "P01_01_2023To09_30_2023",
      "name": "agle:StrategicLicenseAgreementTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To09_30_2023",
      "name": "agle:StrategicLicenseAgreementTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.spy.com/role/SaleOfPegzilarginaseToImmedica",
     "longName": "1024 - Disclosure - Sale of Pegzilarginase to Immedica",
     "shortName": "Sale of Pegzilarginase to Immedica",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "P01_01_2023To09_30_2023",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To09_30_2023",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.spy.com/role/DefinedContributionPlan",
     "longName": "1025 - Disclosure - Defined Contribution Plan",
     "shortName": "Defined Contribution Plan",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "P01_01_2022To12_31_2022",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2022To12_31_2022",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.spy.com/role/IncomeTaxes",
     "longName": "1026 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "P01_01_2022To12_31_2022",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2022To12_31_2022",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.spy.com/role/NetLossPerShare",
     "longName": "1027 - Disclosure - Net Loss Per Share",
     "shortName": "Net Loss Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "P01_01_2023To09_30_2023",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To09_30_2023",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.spy.com/role/RestructuringCharges",
     "longName": "1028 - Disclosure - Restructuring Charges",
     "shortName": "Restructuring Charges",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "28",
     "firstAnchor": {
      "contextRef": "P01_01_2023To09_30_2023",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To09_30_2023",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.spy.com/role/NovationOfManufacturingAgreements",
     "longName": "1029 - Disclosure - Novation of Manufacturing Agreements",
     "shortName": "Novation of Manufacturing Agreements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "29",
     "firstAnchor": {
      "contextRef": "P01_01_2023To09_30_2023",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To09_30_2023",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.spy.com/role/ReverseStockSplit",
     "longName": "1030 - Disclosure - Reverse Stock Split",
     "shortName": "Reverse Stock Split",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "30",
     "firstAnchor": {
      "contextRef": "P01_01_2022To12_31_2022",
      "name": "agle:ReverseStockSplitTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2022To12_31_2022",
      "name": "agle:ReverseStockSplitTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPolicies",
     "longName": "1031 - Disclosure - Description of the Business and Summary of Significant Accounting Policies",
     "shortName": "Description of the Business and Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "31",
     "firstAnchor": {
      "contextRef": "P06_22_2023To06_22_2023",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P06_22_2023To06_22_2023",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.spy.com/role/AccruedLiabilities",
     "longName": "1032 - Disclosure - Accrued Liabilities",
     "shortName": "Accrued Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "32",
     "firstAnchor": {
      "contextRef": "P06_22_2023To06_22_2023",
      "name": "agle:AccruedLiabilitiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P06_22_2023To06_22_2023",
      "name": "agle:AccruedLiabilitiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.spy.com/role/ParapyreOptionObligation",
     "longName": "1033 - Disclosure - Parapyre Option Obligation",
     "shortName": "Parapyre Option Obligation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "33",
     "firstAnchor": {
      "contextRef": "P06_22_2023To06_22_2023",
      "name": "us-gaap:AssetAcquisitionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R34": {
     "role": "http://www.spy.com/role/SubsequentEvents",
     "longName": "1034 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "34",
     "firstAnchor": {
      "contextRef": "P06_22_2023To06_22_2023",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P06_22_2023To06_22_2023",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "1035 - Disclosure - Description of the Business and Summary of Significant Accounting Policies (Policies)",
     "shortName": "Description of the Business and Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "35",
     "firstAnchor": {
      "contextRef": "P01_01_2023To09_30_2023",
      "name": "agle:ConvertiblePreferredStockIssuedThroughPipePolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To09_30_2023",
      "name": "agle:ConvertiblePreferredStockIssuedThroughPipePolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesTables",
     "longName": "1036 - Disclosure - Description of the Business and Summary of Significant Accounting Policies (Tables)",
     "shortName": "Description of the Business and Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "P06_22_2023To06_22_2023",
      "name": "us-gaap:AssetAcquisitionTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R37": {
     "role": "http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesTables",
     "longName": "1037 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "P01_01_2022To12_31_2022",
      "name": "agle:ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2022To12_31_2022",
      "name": "agle:ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.spy.com/role/AccruedLiabilitiesTables",
     "longName": "1038 - Disclosure - Accrued Liabilities (Tables)",
     "shortName": "Accrued Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "P06_22_2023To06_22_2023",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "agle:AccruedLiabilitiesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R39": {
     "role": "http://www.spy.com/role/FairValueMeasurementTables",
     "longName": "1039 - Disclosure - Fair Value Measurement (Tables)",
     "shortName": "Fair Value Measurement (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "P01_01_2023To09_30_2023",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To09_30_2023",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesTables",
     "longName": "1040 - Disclosure - Cash Equivalents and Marketable Securities (Tables)",
     "shortName": "Cash Equivalents and Marketable Securities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "40",
     "firstAnchor": {
      "contextRef": "P01_01_2023To09_30_2023",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To09_30_2023",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.spy.com/role/PropertyAndEquipmentNetTables",
     "longName": "1041 - Disclosure - Property and Equipment, Net (Tables)",
     "shortName": "Property and Equipment, Net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "41",
     "firstAnchor": {
      "contextRef": "P01_01_2022To12_31_2022",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2022To12_31_2022",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.spy.com/role/AccruedAndOtherCurrentLiabilitiesTables",
     "longName": "1042 - Disclosure - Accrued and Other Current Liabilities (Tables)",
     "shortName": "Accrued and Other Current Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "42",
     "firstAnchor": {
      "contextRef": "P06_22_2023To06_22_2023",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "agle:AccruedLiabilitiesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R43": {
     "role": "http://www.spy.com/role/LeasesTables",
     "longName": "1043 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "43",
     "firstAnchor": {
      "contextRef": "P01_01_2022To12_31_2022",
      "name": "agle:ScheduleOfOperatingAndFinancingLeasesPresentedInBalanceSheetTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "agle:LesseeOperatingAndFinanceLeasesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2022To12_31_2022",
      "name": "agle:ScheduleOfOperatingAndFinancingLeasesPresentedInBalanceSheetTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "agle:LesseeOperatingAndFinanceLeasesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.spy.com/role/StockholdersEquityTables",
     "longName": "1044 - Disclosure - Stockholders' Equity (Tables)",
     "shortName": "Stockholders' Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "44",
     "firstAnchor": {
      "contextRef": "P01_01_2023To09_30_2023",
      "name": "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R45": {
     "role": "http://www.spy.com/role/RelatedPartyTransactionsTables",
     "longName": "1045 - Disclosure - Related Party Transactions (Tables)",
     "shortName": "Related Party Transactions (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "45",
     "firstAnchor": {
      "contextRef": "P01_01_2023To09_30_2023",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To09_30_2023",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.spy.com/role/AssetAcquisitionTables",
     "longName": "1046 - Disclosure - Asset Acquisition (Tables)",
     "shortName": "Asset Acquisition (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "46",
     "firstAnchor": {
      "contextRef": "P06_22_2023To06_22_2023",
      "name": "us-gaap:AssetAcquisitionTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R47": {
     "role": "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityTables",
     "longName": "1047 - Disclosure - Liabilities, Convertible Preferred Stock and Stockholders' (Deficit) Equity (Tables)",
     "shortName": "Liabilities, Convertible Preferred Stock and Stockholders' (Deficit) Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "47",
     "firstAnchor": {
      "contextRef": "P01_01_2022To12_31_2022",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2022To12_31_2022",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.spy.com/role/StrategicLicenseAgreementsTables",
     "longName": "1048 - Disclosure - Strategic License Agreements (Tables)",
     "shortName": "Strategic License Agreements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "48",
     "firstAnchor": {
      "contextRef": "P01_01_2023To09_30_2023",
      "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To09_30_2023",
      "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.spy.com/role/IncomeTaxesTables",
     "longName": "1049 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "49",
     "firstAnchor": {
      "contextRef": "P01_01_2022To12_31_2022",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2022To12_31_2022",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.spy.com/role/NetLossPerShareTables",
     "longName": "1050 - Disclosure - Net Loss Per Share (Tables)",
     "shortName": "Net Loss Per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "50",
     "firstAnchor": {
      "contextRef": "P01_01_2023To09_30_2023",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To09_30_2023",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.spy.com/role/RestructuringChargesTables",
     "longName": "1051 - Disclosure - Restructuring Charges (Tables)",
     "shortName": "Restructuring Charges (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "51",
     "firstAnchor": {
      "contextRef": "P01_01_2023To09_30_2023",
      "name": "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To09_30_2023",
      "name": "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.spy.com/role/TheCompanyAndBasisOfPresentationNarrativeDetails",
     "longName": "1052 - Disclosure - The Company and Basis of Presentation - Narrative (Details)",
     "shortName": "The Company and Basis of Presentation - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "P01_01_2023To09_30_2023",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "Unit_SEGMENT",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To09_30_2023",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "Unit_SEGMENT",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesSummaryOfAssetAcquisitionCostDetails",
     "longName": "1053 - Disclosure - Description of the Business and Summary of Significant Accounting Policies - Summary of Asset Acquisition Cost (Details)",
     "shortName": "Description of the Business and Summary of Significant Accounting Policies - Summary of Asset Acquisition Cost (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "P07_01_2023To09_30_2023",
      "name": "agle:AcquiredInProcessResearchAndDevelopment",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn06_22_2023_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis",
      "name": "us-gaap:AccruedLiabilitiesCurrent",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:AssetAcquisitionTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
     "longName": "1054 - Disclosure - Description of the Business and Summary of Significant Accounting Policies - Additional Information (Details)",
     "shortName": "Description of the Business and Summary of Significant Accounting Policies - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "P09_08_2023To09_08_2023",
      "name": "us-gaap:StockholdersEquityReverseStockSplit",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "agle:ReverseStockSplitTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn06_22_2023",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.spy.com/role/AccruedLiabilitiesAccruedAndOtherCurrentLiabilitiesDetails",
     "longName": "1055 - Disclosure - Accrued Liabilities - Accrued and Other Current Liabilities (Details)",
     "shortName": "Accrued Liabilities - Accrued and Other Current Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "PAsOn06_22_2023",
      "name": "agle:AccruedOptionCostPayable",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "agle:AccruedLiabilitiesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn06_22_2023",
      "name": "agle:AccruedOptionCostPayable",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "agle:AccruedLiabilitiesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.spy.com/role/AccruedLiabilitiesAdditionalInformationDetails",
     "longName": "1056 - Disclosure - Accrued Liabilities - Additional Information (Details)",
     "shortName": "Accrued Liabilities - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "P06_22_2023To06_22_2023_ParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis",
      "name": "agle:RelatedPartyExpensesIncurredPriorToAssetAcquisition",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "agle:AccruedLiabilitiesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R57": {
     "role": "http://www.spy.com/role/ParapyreOptionObligationAdditionalInformationDetails",
     "longName": "1057 - Disclosure - Parapyre Option Obligation - Additional Information (Details)",
     "shortName": "Parapyre Option Obligation - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "PAsOn06_22_2023",
      "name": "us-gaap:AssetAcquisitionContingentConsiderationLiabilityCurrent",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "us-gaap:AssetAcquisitionTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn06_22_2023",
      "name": "us-gaap:AssetAcquisitionContingentConsiderationLiabilityCurrent",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "us-gaap:AssetAcquisitionTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
     "longName": "1058 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "P01_01_2022To12_31_2022",
      "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
       "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
       "div",
       "us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2022To12_31_2022",
      "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
       "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
       "div",
       "us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfUsefulLivesOfPropertyAndEquipmentDetails",
     "longName": "1059 - Disclosure - Summary of Significant Accounting Policies - Summary of Useful Lives of Property and Equipment (Details)",
     "shortName": "Summary of Significant Accounting Policies - Summary of Useful Lives of Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2022_LaboratoryEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "agle:ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2022_LaboratoryEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "agle:ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.spy.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
     "longName": "1060 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "shortName": "Fair Value Measurements - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "PAsOn09_30_2023_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn09_30_2023_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.spy.com/role/FairValueMeasurementsNarrativeDetails",
     "longName": "1061 - Disclosure - Fair Value Measurements - Narrative (Details)",
     "shortName": "Fair Value Measurements - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2022",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2022",
      "name": "agle:FairValueAssetsLevel1ToLevel2TransfersAmount1",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "agle:FairValueAssetsLevel1ToLevel2TransfersAmount1",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.spy.com/role/FairValueMeasurementsChangesInDerivativeLiabilitiesDetails",
     "longName": "1062 - Disclosure - Fair Value Measurements - Changes in Derivative Liabilities (Details)",
     "shortName": "Fair Value Measurements - Changes in Derivative Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2022",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P07_01_2023To09_30_2023_ForwardContractsMemberusgaapDerivativeInstrumentRiskAxis",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.spy.com/role/FairValueMeasurementsSignificantInputsUsedToEstimateTheFairValueOfDerivativeLiabilityDetails",
     "longName": "1063 - Disclosure - Fair Value Measurements - Significant Inputs used to Estimate the Fair Value of Derivative Liability (Details)",
     "shortName": "Fair Value Measurements - Significant Inputs used to Estimate the Fair Value of Derivative Liability (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "PAsOn09_30_2023_ContingentValueRightLiabilityMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MaximumMembersrtRangeAxis_MeasurementInputProabilityOfSuccessMemberusgaapMeasurementInputTypeAxis",
      "name": "us-gaap:DerivativeLiabilityMeasurementInput",
      "unitRef": "Unit_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn09_30_2023_ContingentValueRightLiabilityMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MaximumMembersrtRangeAxis_MeasurementInputProabilityOfSuccessMemberusgaapMeasurementInputTypeAxis",
      "name": "us-gaap:DerivativeLiabilityMeasurementInput",
      "unitRef": "Unit_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesEstimatedFairValueOfCashEquivalentsAndMarketableSecuritiesAndTheGrossUnrealizedGainsAndLossesDetails",
     "longName": "1064 - Disclosure - Cash Equivalents and Marketable Securities - Estimated Fair Value of Cash Equivalents and Marketable Securities and the Gross Unrealized Gains and Losses (Details)",
     "shortName": "Cash Equivalents and Marketable Securities - Estimated Fair Value of Cash Equivalents and Marketable Securities and the Gross Unrealized Gains and Losses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "PAsOn09_30_2023",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn09_30_2023",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesAvailableForSaleSecuritiesInAnUnrealizedLossPositionDetails",
     "longName": "1065 - Disclosure - Cash Equivalents and Marketable Securities - Available-for-Sale Securities in an Unrealized Loss Position (Details)",
     "shortName": "Cash Equivalents and Marketable Securities - Available-for-Sale Securities in an Unrealized Loss Position (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "PAsOn09_30_2023",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn09_30_2023",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesNarrativeDetails",
     "longName": "1066 - Disclosure - Cash Equivalents and Marketable Securities - Narrative (Details)",
     "shortName": "Cash Equivalents and Marketable Securities - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "PAsOn09_30_2023",
      "name": "agle:NumberOfDomesticBankingInstitutions",
      "unitRef": "Unit_bank",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2022_USGovernmentAgenciesDebtSecuritiesMemberusgaapFinancialInstrumentAxis",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesContractualMaturitiesOfMarketableSecuritiesAtEstimatedFairValueDetails",
     "longName": "1067 - Disclosure - Cash Equivalents and Marketable Securities - Contractual Maturities of Marketable Securities at Estimated Fair Value (Details)",
     "shortName": "Cash Equivalents and Marketable Securities - Contractual Maturities of Marketable Securities at Estimated Fair Value (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "PAsOn09_30_2023",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn09_30_2023",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.spy.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
     "longName": "1068 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment Net (Details)",
     "shortName": "Property and Equipment, Net - Schedule of Property and Equipment Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2022",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2022",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R69": {
     "role": "http://www.spy.com/role/PropertyAndEquipmentNetAdditionalInformationDetails",
     "longName": "1069 - Disclosure - Property and Equipment, Net - Additional Information (Details)",
     "shortName": "Property and Equipment, Net - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "P01_01_2023To09_30_2023",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2022To12_31_2022_PropertyPlantAndEquipmentMemberusgaapFairValueByAssetClassAxis",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "unique": true
     }
    },
    "R70": {
     "role": "http://www.spy.com/role/AccruedAndOtherCurrentLiabilitiesDetails",
     "longName": "1070 - Disclosure - Accrued and Other Current Liabilities (Details)",
     "shortName": "Accrued and Other Current Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "PAsOn09_30_2023",
      "name": "us-gaap:AccruedSalariesCurrent",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "agle:AccruedAndOtherCurrentLiabilitiesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn09_30_2023",
      "name": "us-gaap:AccruedSalariesCurrent",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "agle:AccruedAndOtherCurrentLiabilitiesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R71": {
     "role": "http://www.spy.com/role/LeasesAdditionalInformationDetails",
     "longName": "1071 - Disclosure - Leases - Additional Information (Details)",
     "shortName": "Leases - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "PAsOn04_30_2019",
      "name": "us-gaap:AreaOfLand",
      "unitRef": "Unit_sqft",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "div",
       "agle:LesseeOperatingAndFinanceLeasesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn04_30_2019",
      "name": "us-gaap:AreaOfLand",
      "unitRef": "Unit_sqft",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "div",
       "agle:LesseeOperatingAndFinanceLeasesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R72": {
     "role": "http://www.spy.com/role/LeasesScheduleOfOperatingAndFinancingLeasesPresentedInBalanceSheetDetails",
     "longName": "1072 - Disclosure - Leases - Schedule of Operating and Financing Leases Presented in Balance Sheet (Details)",
     "shortName": "Leases - Schedule of Operating and Financing Leases Presented in Balance Sheet (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "PAsOn09_30_2023",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2022",
      "name": "us-gaap:FinanceLeaseRightOfUseAsset",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "agle:ScheduleOfOperatingAndFinancingLeasesPresentedInBalanceSheetTableTextBlock",
       "agle:LesseeOperatingAndFinanceLeasesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "unique": true
     }
    },
    "R73": {
     "role": "http://www.spy.com/role/LeasesSummaryOfWeightedAverageRemainingLeaseTermAndDiscountRatesForOperatingAndFinanceLeasesDetails",
     "longName": "1073 - Disclosure - Leases - Summary of Weighted-Average Remaining Lease Term and Discount Rates for Operating and Finance Leases (Details)",
     "shortName": "Leases - Summary of Weighted-Average Remaining Lease Term and Discount Rates for Operating and Finance Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2022",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "agle:SummaryOfWeightedAverageRemainingLeaseTermAndDiscountRatesOfOperatingAndFinanceLeasesTableTextBlock",
       "agle:LesseeOperatingAndFinanceLeasesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2022",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "agle:SummaryOfWeightedAverageRemainingLeaseTermAndDiscountRatesOfOperatingAndFinanceLeasesTableTextBlock",
       "agle:LesseeOperatingAndFinanceLeasesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R74": {
     "role": "http://www.spy.com/role/LeasesSummaryOfLeaseCostDetails",
     "longName": "1074 - Disclosure - Leases - Summary of Lease Cost (Details)",
     "shortName": "Leases - Summary of Lease Cost (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "P01_01_2022To12_31_2022",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2022To12_31_2022",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R75": {
     "role": "http://www.spy.com/role/LeasesScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails",
     "longName": "1075 - Disclosure - Leases - Schedule of Maturities of Operating and Finance Lease Liabilities (Details)",
     "shortName": "Leases - Schedule of Maturities of Operating and Finance Lease Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2022",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "agle:ScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2022",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "agle:ScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R76": {
     "role": "http://www.spy.com/role/StockholdersEquityAdditionalInformationDetails",
     "longName": "1076 - Disclosure - Stockholders' Equity - Additional Information (Details)",
     "shortName": "Stockholders' Equity - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "P04_01_2020To04_30_2020",
      "name": "us-gaap:ExpenseRelatedToDistributionOrServicingAndUnderwritingFees",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P04_01_2020To04_30_2020",
      "name": "us-gaap:ExpenseRelatedToDistributionOrServicingAndUnderwritingFees",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R77": {
     "role": "http://www.spy.com/role/StockholdersEquitySummaryOfPreFundedWarrantsForCommonStockIssuedAndOutstandingDetails",
     "longName": "1077 - Disclosure - Stockholders' Equity - Summary of Pre-funded Warrants for Common Stock Issued and Outstanding (Details)",
     "shortName": "Stockholders' Equity - Summary of Pre-funded Warrants for Common Stock Issued and Outstanding (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2022",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2022To12_31_2022_FebruaryTwoThousandNinteenMemberusgaapAwardDateAxis_WarrantMemberusgaapStatementEquityComponentsAxis",
      "name": "agle:WarrantExpirationDate",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "unique": true
     }
    },
    "R78": {
     "role": "http://www.spy.com/role/RelatedPartyTransactionsNarrativeDetails",
     "longName": "1078 - Disclosure - Related Party Transactions - Narrative (Details)",
     "shortName": "Related Party Transactions - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "PAsOn06_22_2023",
      "name": "agle:RelatedPartyTransactionNumberOfBoardSeats",
      "unitRef": "Unit_BOARDSEAT",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn06_22_2023",
      "name": "agle:RelatedPartyTransactionNumberOfBoardSeats",
      "unitRef": "Unit_BOARDSEAT",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R79": {
     "role": "http://www.spy.com/role/RelatedPartyTransactionsExpensesRelatedToRelatedPartyWhichWereSettledInCashDetails",
     "longName": "1079 - Disclosure - Related Party Transactions - Expenses related to Related Party which were Settled in Cash (Details)",
     "shortName": "Related Party Transactions - Expenses related to Related Party which were Settled in Cash (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "P07_01_2023To09_30_2023_ReimbursableCostsUnderParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis",
      "name": "agle:RelatedPartyTransactionReimbursableCosts",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P07_01_2023To09_30_2023_ReimbursableCostsUnderParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis",
      "name": "agle:RelatedPartyTransactionReimbursableCosts",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R80": {
     "role": "http://www.spy.com/role/RelatedPartyTransactionsRelatedPartyAccountsPayableDetails",
     "longName": "1080 - Disclosure - Related Party Transactions - Related Party Accounts Payable (Details)",
     "shortName": "Related Party Transactions - Related Party Accounts Payable (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "PAsOn09_30_2023_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis",
      "name": "us-gaap:AccountsPayableCurrent",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "td",
       "tr",
       "table",
       "agle:ScheduleOfBalancesDueToAffiliatesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn09_30_2023_ParapyreOptionObligationMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis",
      "name": "us-gaap:AccountsPayableCurrent",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "td",
       "tr",
       "table",
       "agle:ScheduleOfBalancesDueToAffiliatesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "unique": true
     }
    },
    "R81": {
     "role": "http://www.spy.com/role/AssetAcquisitionNarrativeDetails",
     "longName": "1081 - Disclosure - Asset Acquisition - Narrative (Details)",
     "shortName": "Asset Acquisition - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "P06_22_2023To06_22_2023",
      "name": "us-gaap:AssetAcquisitionConsiderationTransferred",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R82": {
     "role": "http://www.spy.com/role/AssetAcquisitionAssetAcquisitionCostDetails",
     "longName": "1082 - Disclosure - Asset Acquisition - Asset Acquisition Cost (Details)",
     "shortName": "Asset Acquisition - Asset Acquisition Cost (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "82",
     "firstAnchor": {
      "contextRef": "P07_01_2023To09_30_2023",
      "name": "agle:AcquiredInProcessResearchAndDevelopment",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P06_22_2023To06_22_2023_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis",
      "name": "agle:AssumedLiabilities",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:AssetAcquisitionTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "unique": true
     }
    },
    "R83": {
     "role": "http://www.spy.com/role/ParagonAgreementDetails",
     "longName": "1083 - Disclosure - Paragon Agreement (Details)",
     "shortName": "Paragon Agreement (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "83",
     "firstAnchor": {
      "contextRef": "P07_01_2023To09_30_2023_ParagonTherapeuticsIncMembersrtCounterpartyNameAxis",
      "name": "agle:LicenseAgreementMilestonePayments",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P07_01_2023To09_30_2023_ParagonTherapeuticsIncMembersrtCounterpartyNameAxis",
      "name": "agle:LicenseAgreementMilestonePayments",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R84": {
     "role": "http://www.spy.com/role/SeriesANonVotingConvertiblePreferredStockDetails",
     "longName": "1084 - Disclosure - Series A Non-Voting Convertible Preferred Stock (Details)",
     "shortName": "Series A Non-Voting Convertible Preferred Stock (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "84",
     "firstAnchor": {
      "contextRef": "P07_01_2023To09_30_2023",
      "name": "agle:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn06_22_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis",
      "name": "agle:PreferredStockRemainsIssuedAndOutstandingPercentage",
      "unitRef": "Unit_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "unique": true
     }
    },
    "R85": {
     "role": "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityPreFundedWarrantsForCommonStockIssuedAndOutstandingDetails",
     "longName": "1085 - Disclosure - Liabilities, Convertible Preferred Stock and Stockholders' (Deficit) Equity - Pre-funded Warrants for Common Stock Issued and Outstanding (Details)",
     "shortName": "Liabilities, Convertible Preferred Stock and Stockholders' (Deficit) Equity - Pre-funded Warrants for Common Stock Issued and Outstanding (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "85",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2022",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn09_30_2023_FebruaryEightTwoThousandNinteenMemberusgaapAwardDateAxis_WarrantMemberusgaapStatementEquityComponentsAxis",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "unique": true
     }
    },
    "R86": {
     "role": "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityStockAwardsGrantedDetails",
     "longName": "1086 - Disclosure - Liabilities, Convertible Preferred Stock and Stockholders' (Deficit) Equity - Stock Awards Granted (Details)",
     "shortName": "Liabilities, Convertible Preferred Stock and Stockholders' (Deficit) Equity - Stock Awards Granted (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "86",
     "firstAnchor": {
      "contextRef": "P07_01_2023To09_30_2023",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R87": {
     "role": "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails",
     "longName": "1087 - Disclosure - Liabilities, Convertible Preferred Stock and Stockholders' (Deficit) Equity - Narrative (Details)",
     "shortName": "Liabilities, Convertible Preferred Stock and Stockholders' (Deficit) Equity - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "87",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2022",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2022To12_31_2022",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
       "us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "unique": true
     }
    },
    "R88": {
     "role": "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquitySummaryOfEmployeeAndNonEmployeeStockOptionActivityDetails",
     "longName": "1088 - Disclosure - Liabilities, Convertible Preferred Stock and Stockholders' (Deficit) Equity - Summary of Employee and Non-Employee Stock Option Activity (Details)",
     "shortName": "Liabilities, Convertible Preferred Stock and Stockholders' (Deficit) Equity - Summary of Employee and Non-Employee Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "88",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2022",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2022To12_31_2022",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "unique": true
     }
    },
    "R89": {
     "role": "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquitySummaryOfEmployeeRestrictedStockActivityDetails",
     "longName": "1089 - Disclosure - Liabilities, Convertible Preferred Stock and Stockholders' (Deficit) Equity - Summary of Employee Restricted Stock Activity (Details)",
     "shortName": "Liabilities, Convertible Preferred Stock and Stockholders' (Deficit) Equity - Summary of Employee Restricted Stock Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "89",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2021_EmployeesMembersrtTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2021_EmployeesMembersrtTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R90": {
     "role": "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityStockBasedCompensationExpenseDetails",
     "longName": "1090 - Disclosure - Liabilities, Convertible Preferred Stock and Stockholders' (Deficit) Equity - Stock-Based Compensation Expense (Details)",
     "shortName": "Liabilities, Convertible Preferred Stock and Stockholders' (Deficit) Equity - Stock-Based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "90",
     "firstAnchor": {
      "contextRef": "P07_01_2023To09_30_2023",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2022To12_31_2022_EmployeesMembersrtTitleOfIndividualAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "unique": true
     }
    },
    "R91": {
     "role": "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityAssumptionsUsedToEstimateTheFairValueOfStockOptionsGrantedDetails",
     "longName": "1091 - Disclosure - Liabilities, Convertible Preferred Stock and Stockholders' (Deficit) Equity - Assumptions used to Estimate the Fair Value of Stock Options Granted (Details)",
     "shortName": "Liabilities, Convertible Preferred Stock and Stockholders' (Deficit) Equity - Assumptions used to Estimate the Fair Value of Stock Options Granted (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "91",
     "firstAnchor": {
      "contextRef": "P01_01_2022To12_31_2022",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "unitRef": "Unit_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
       "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2022To12_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "unique": true
     }
    },
    "R92": {
     "role": "http://www.spy.com/role/StrategicLicenseAgreementsNarrativeDetails",
     "longName": "1092 - Disclosure - Strategic License Agreements - Narrative (Details)",
     "shortName": "Strategic License Agreements - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "92",
     "firstAnchor": {
      "contextRef": "P07_01_2023To09_30_2023",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2020",
      "name": "us-gaap:ContractWithCustomerLiabilityCurrent",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "unique": true
     }
    },
    "R93": {
     "role": "http://www.spy.com/role/StrategicLicenseAgreementsChangesInContractLiabilitiesDetails",
     "longName": "1093 - Disclosure - Strategic License Agreements - Changes in Contract Liabilities (Details)",
     "shortName": "Strategic License Agreements - Changes in Contract Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "93",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2022",
      "name": "us-gaap:ContractWithCustomerLiability",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To09_30_2023",
      "name": "agle:ContractWithCustomerLiabilityAdditions",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "unique": true
     }
    },
    "R94": {
     "role": "http://www.spy.com/role/SaleOfPegzilarginaseToImmedicaDetails",
     "longName": "1094 - Disclosure - Sale of Pegzilarginase to Immedica (Details)",
     "shortName": "Sale of Pegzilarginase to Immedica (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "94",
     "firstAnchor": {
      "contextRef": "P01_01_2023To09_30_2023",
      "name": "us-gaap:ProceedsFromSaleOfIntangibleAssets",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P07_27_2023To07_27_2023_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberusgaapDisposalGroupClassificationAxis_GlobalRightsToPegzilarginaseMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
      "name": "us-gaap:ProceedsFromSaleOfIntangibleAssets",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "unique": true
     }
    },
    "R95": {
     "role": "http://www.spy.com/role/DefinedContributionPlanAdditionalInformationDetails",
     "longName": "1095 - Disclosure - Defined Contribution Plan - Additional Information (Details)",
     "shortName": "Defined Contribution Plan - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "95",
     "firstAnchor": {
      "contextRef": "P01_01_2022To12_31_2022",
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2022To12_31_2022",
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R96": {
     "role": "http://www.spy.com/role/IncomeTaxesIncomeLossBeforeIncomeTaxExpenseByJurisdictionDetails",
     "longName": "1096 - Disclosure - Income Taxes - Income (Loss) Before Income Tax Expense by Jurisdiction (Details)",
     "shortName": "Income Taxes - Income (Loss) Before Income Tax Expense by Jurisdiction (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "96",
     "firstAnchor": {
      "contextRef": "P01_01_2022To12_31_2022",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2022To12_31_2022",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R97": {
     "role": "http://www.spy.com/role/IncomeTaxesAdditionalInformationDetails",
     "longName": "1097 - Disclosure - Income Taxes - Additional Information (Details)",
     "shortName": "Income Taxes - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "97",
     "firstAnchor": {
      "contextRef": "P07_01_2023To09_30_2023",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2022To12_31_2022",
      "name": "agle:IncreaseInValuationPrimarilyDueToOperationLosses",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "unique": true
     }
    },
    "R98": {
     "role": "http://www.spy.com/role/IncomeTaxesSummaryOfDifferenceBetweenProvisionForIncomeTaxesAndAmountsComputedByApplyingStatutoryFederalIncomeTaxRateToIncomeBeforeIncomeTaxesDetails",
     "longName": "1098 - Disclosure - Income Taxes - Summary of Difference Between Provision for Income Taxes and Amounts Computed by Applying Statutory Federal Income Tax Rate to Income Before Income Taxes (Details)",
     "shortName": "Income Taxes - Summary of Difference Between Provision for Income Taxes and Amounts Computed by Applying Statutory Federal Income Tax Rate to Income Before Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "98",
     "firstAnchor": {
      "contextRef": "P01_01_2022To12_31_2022",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2022To12_31_2022",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R99": {
     "role": "http://www.spy.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails",
     "longName": "1099 - Disclosure - Income Taxes - Components of Deferred Tax Assets and Liabilities (Details)",
     "shortName": "Income Taxes - Components of Deferred Tax Assets and Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "99",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2022",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2022",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R100": {
     "role": "http://www.spy.com/role/NetLossPerShareWeightedAverageEquityInstrumentsExcludedFromCalculationOfDilutedNetLossPerShareDetails",
     "longName": "1100 - Disclosure - Net Loss Per Share - Weighted-Average Equity Instruments Excluded from Calculation of Diluted Net Loss Per Share (Details)",
     "shortName": "Net Loss Per Share - Weighted-Average Equity Instruments Excluded from Calculation of Diluted Net Loss Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "100",
     "firstAnchor": {
      "contextRef": "P07_01_2023To09_30_2023_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P07_01_2023To09_30_2023_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R101": {
     "role": "http://www.spy.com/role/NetLossPerShareScheduleOfReconciliationOfBasicAndDilutedNetLossPerShareDetails",
     "longName": "1101 - Disclosure - Net Loss Per Share - Schedule of Reconciliation of Basic and Diluted Net Loss Per Share (Details)",
     "shortName": "Net Loss Per Share - Schedule of Reconciliation of Basic and Diluted Net Loss Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "101",
     "firstAnchor": {
      "contextRef": "P01_01_2022To12_31_2022",
      "name": "us-gaap:WeightedAverageNumberOfSharesIssuedBasic",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2022To12_31_2022",
      "name": "us-gaap:WeightedAverageNumberOfSharesIssuedBasic",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R102": {
     "role": "http://www.spy.com/role/ReverseStockSplitAdditionalInformationDetails",
     "longName": "1102 - Disclosure - Reverse Stock Split - Additional Information (Details)",
     "shortName": "Reverse Stock Split - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "102",
     "firstAnchor": {
      "contextRef": "P09_08_2023To09_08_2023",
      "name": "us-gaap:StockholdersEquityReverseStockSplit",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "agle:ReverseStockSplitTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R103": {
     "role": "http://www.spy.com/role/RestructuringChargesNarrativeDetails",
     "longName": "1103 - Disclosure - Restructuring Charges - Narrative (Details)",
     "shortName": "Restructuring Charges - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "103",
     "firstAnchor": {
      "contextRef": "P04_01_2023To04_30_2023",
      "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
      "unitRef": "Unit_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To09_30_2023",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "unique": true
     }
    },
    "R104": {
     "role": "http://www.spy.com/role/RestructuringChargesChangesInAccruedRestructuringBalanceDetails",
     "longName": "1104 - Disclosure - Restructuring Charges - Changes in Accrued Restructuring Balance (Details)",
     "shortName": "Restructuring Charges - Changes in Accrued Restructuring Balance (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "104",
     "firstAnchor": {
      "contextRef": "P01_01_2023To09_30_2023",
      "name": "us-gaap:PaymentsForRestructuring",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2022_SeveranceLiabilityMemberusgaapRestructuringCostAndReserveAxis",
      "name": "us-gaap:RestructuringReserve",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "unique": true
     }
    },
    "R105": {
     "role": "http://www.spy.com/role/RestructuringChargesChargesRelatedToTheRestructuringActivitiesDetails",
     "longName": "1105 - Disclosure - Restructuring Charges - Charges Related to the Restructuring Activities (Details)",
     "shortName": "Restructuring Charges - Charges Related to the Restructuring Activities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "105",
     "firstAnchor": {
      "contextRef": "P01_01_2023To09_30_2023",
      "name": "us-gaap:SeveranceCosts1",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P04_01_2023To06_30_2023_RestructuringActivitiesMemberusgaapRestructuringCostAndReserveAxis",
      "name": "us-gaap:SeveranceCosts1",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "unique": true
     }
    },
    "R106": {
     "role": "http://www.spy.com/role/SubsequentEventsAdditionalInformationDetails",
     "longName": "1106 - Disclosure - Subsequent Events - Additional Information (Details)",
     "shortName": "Subsequent Events - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "106",
     "firstAnchor": {
      "contextRef": "PAsOn09_30_2023",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn09_08_2023_SubsequentEventMemberusgaapSubsequentEventTypeAxis",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "div",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "unique": true
     }
    },
    "R107": {
     "role": "http://www.spy.com/role/NovationOfManufacturingAgreementsDetails",
     "longName": "1107 - Disclosure - Novation of Manufacturing Agreements (Details)",
     "shortName": "Novation of Manufacturing Agreements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "107",
     "firstAnchor": {
      "contextRef": "P04_01_2023To04_30_2023",
      "name": "agle:OtherCommitmentRightToTerminateAgreementOrWorkOrderPriorWrittenNoticePeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P04_01_2023To04_30_2023",
      "name": "agle:OtherCommitmentRightToTerminateAgreementOrWorkOrderPriorWrittenNoticePeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298ds1.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedLabel": "Net accretion of discount on marketable securities",
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r147"
     ]
    },
    "us-gaap_TemporaryEquityParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityParOrStatedValuePerShare",
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Par or Stated Value Per Share",
        "terseLabel": "Series A non-voting convertible preferred stock, par value (in dollars per share)",
        "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r68"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesEstimatedFairValueOfCashEquivalentsAndMarketableSecuritiesAndTheGrossUnrealizedGainsAndLossesDetails",
      "http://www.spy.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r864"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract",
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations [Abstract]",
        "terseLabel": "CASH, CASH EQUIVALENTS, AND RESTRICTED CASH"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r203",
      "r246",
      "r247",
      "r248",
      "r250",
      "r256",
      "r258",
      "r328",
      "r329",
      "r449",
      "r450",
      "r451",
      "r479",
      "r480",
      "r496",
      "r498",
      "r499",
      "r501",
      "r504",
      "r631",
      "r633",
      "r651",
      "r927"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r449",
      "r450",
      "r451",
      "r651",
      "r838",
      "r839",
      "r840",
      "r904",
      "r927"
     ]
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.spy.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure",
        "terseLabel": "Liabilities, fair value",
        "documentation": "Fair value of financial and nonfinancial obligations."
       }
      }
     },
     "auth_ref": [
      "r101"
     ]
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Financial assets, fair value",
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r101"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Acquisitions",
        "terseLabel": "Issuance of common stock in connection with the asset acquisition of Spyre and settlement of related forward contract (in shares)",
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r127",
      "r162"
     ]
    },
    "us-gaap_TenantImprovements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TenantImprovements",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tenant Improvements",
        "terseLabel": "Tenant improvement allowance",
        "documentation": "Carrying amount as of the balance sheet date of improvements having a life longer than one year that were made for the benefit of one or more tenants."
       }
      }
     },
     "auth_ref": [
      "r922"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Issuance of common stock in connection with employee stock purchase plan (in shares)",
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r126",
      "r127",
      "r162"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersDeficitEquity",
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquitySummaryOfEmployeeAndNonEmployeeStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "terseLabel": "Issuance of common stock in connection with exercise of stock options (in shares)",
        "negatedLabel": "Shares Issuable Under Options, Exercised",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r126",
      "r127",
      "r162",
      "r424"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Issuance of common stock in connection with exercise of pre-funded warrants (in shares)",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r40",
      "r73",
      "r162",
      "r374"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesReverseStockSplits",
     "presentation": [
      "http://www.spy.com/role/ReverseStockSplitAdditionalInformationDetails",
      "http://www.spy.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Reverse Stock Splits",
        "verboseLabel": "Stock Issued During Period, Shares, Reverse Stock Splits",
        "terseLabel": "Reduction in the total number of authorized shares",
        "documentation": "Reduction in the number of shares during the period as a result of a reverse stock split."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersDeficitEquity",
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails",
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityPreFundedWarrantsForCommonStockIssuedAndOutstandingDetails",
      "http://www.spy.com/role/StockholdersEquityAdditionalInformationDetails",
      "http://www.spy.com/role/StockholdersEquitySummaryOfPreFundedWarrantsForCommonStockIssuedAndOutstandingDetails",
      "http://www.spy.com/role/TheCompanyAndBasisOfPresentationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r203",
      "r226",
      "r227",
      "r228",
      "r246",
      "r247",
      "r248",
      "r250",
      "r256",
      "r258",
      "r273",
      "r328",
      "r329",
      "r394",
      "r449",
      "r450",
      "r451",
      "r479",
      "r480",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r504",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r541",
      "r631",
      "r632",
      "r633",
      "r651",
      "r724"
     ]
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://www.spy.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.spy.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails",
      "http://www.spy.com/role/IncomeTaxesSummaryOfDifferenceBetweenProvisionForIncomeTaxesAndAmountsComputedByApplyingStatutoryFederalIncomeTaxRateToIncomeBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State and Local Jurisdiction [Member]",
        "verboseLabel": "State",
        "terseLabel": "State Tax Credits",
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AOCI Attributable to Parent [Member]",
        "verboseLabel": "Accumulated Other Comprehensive (Loss) Income",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r15",
      "r43",
      "r497",
      "r500",
      "r541",
      "r631",
      "r632",
      "r828",
      "r829",
      "r830",
      "r838",
      "r839",
      "r840"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails",
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityStockAwardsGrantedDetails",
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquitySummaryOfEmployeeAndNonEmployeeStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "verboseLabel": "Grants (in shares)",
        "terseLabel": "Options granted (in shares)",
        "definitionGuidance": "Shares Issuable Under Options, Granted",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r423"
     ]
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "TOTAL ASSETS",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r212",
      "r238",
      "r276",
      "r284",
      "r288",
      "r327",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r490",
      "r494",
      "r516",
      "r604",
      "r693",
      "r793",
      "r806",
      "r858",
      "r859",
      "r912"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentBasisOfValuation": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentBasisOfValuation",
     "presentation": [
      "http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Basis of Valuation",
        "terseLabel": "Useful lives of the property and equipment",
        "documentation": "Describes the basis at which an entity records its property, plant and equipment (for example at cost, fair value)."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating lease, payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r532",
      "r537"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r209",
      "r615"
     ]
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Supplemental Disclosure of Non-Cash Investing and Financing Information:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income, net",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r142"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 7.0
      },
      "http://www.spy.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.spy.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r602",
      "r615",
      "r793"
     ]
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Unpaid amounts related to purchase of property and equipment",
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r51",
      "r52"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.spy.com/role/ReverseStockSplitAdditionalInformationDetails",
      "http://www.spy.com/role/SeriesANonVotingConvertiblePreferredStockDetails",
      "http://www.spy.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]",
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r70",
      "r71",
      "r73",
      "r74",
      "r75",
      "r77",
      "r160",
      "r161",
      "r162",
      "r213",
      "r214",
      "r215",
      "r274",
      "r377",
      "r378",
      "r380",
      "r382",
      "r385",
      "r390",
      "r392",
      "r641",
      "r642",
      "r643",
      "r644",
      "r777",
      "r810",
      "r835"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.spy.com/role/ReverseStockSplitAdditionalInformationDetails",
      "http://www.spy.com/role/SeriesANonVotingConvertiblePreferredStockDetails",
      "http://www.spy.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r213",
      "r214",
      "r215",
      "r274",
      "r377",
      "r378",
      "r380",
      "r382",
      "r385",
      "r390",
      "r392",
      "r641",
      "r642",
      "r643",
      "r644",
      "r777",
      "r810",
      "r835"
     ]
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeasePrincipalPayments",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 35.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Principal Payments",
        "negatedLabel": "Principal payments on finance lease obligation",
        "documentation": "Amount of cash outflow for principal payment on finance lease."
       }
      }
     },
     "auth_ref": [
      "r531",
      "r537"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Total deferred tax liabilities",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r124",
      "r179",
      "r473"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: Accumulated depreciation and amortization",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r210",
      "r614"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityAssumptionsUsedToEstimateTheFairValueOfStockOptionsGrantedDetails",
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails",
      "http://www.spy.com/role/NetLossPerShareWeightedAverageEquityInstrumentsExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Options Granted",
        "terseLabel": "Stock Options",
        "verboseLabel": "Options to purchase common stock",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r411",
      "r418",
      "r437",
      "r438",
      "r439",
      "r440",
      "r443",
      "r452",
      "r453",
      "r454",
      "r455"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 26.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income (loss)",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r43",
      "r133",
      "r216",
      "r610",
      "r635",
      "r636"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r196",
      "r199",
      "r613"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments of Stock Issuance Costs",
        "terseLabel": "Offering costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.spy.com/role/AccruedLiabilitiesAdditionalInformationDetails",
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical",
      "http://www.spy.com/role/ParagonAgreementDetails",
      "http://www.spy.com/role/RelatedPartyTransactionsExpensesRelatedToRelatedPartyWhichWereSettledInCashDetails",
      "http://www.spy.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://www.spy.com/role/RelatedPartyTransactionsRelatedPartyAccountsPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party, Type [Axis]",
        "terseLabel": "Related Party, Type [Axis]",
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r408",
      "r545",
      "r546",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r698",
      "r700",
      "r731",
      "r911"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted Accounting Pronouncement",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "agle_NonEmployeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "NonEmployeesMember",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails",
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non Employees [Member]",
        "terseLabel": "Non-Employees",
        "documentation": "Non-employees."
       }
      }
     },
     "auth_ref": []
    },
    "agle_MaximumVestingTermForMoreThanTenPercentGrantees": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "MaximumVestingTermForMoreThanTenPercentGrantees",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum Vesting Term For More Than Ten Percent Grantees",
        "terseLabel": "Maximum vesting term for more than ten percent grantees",
        "documentation": "Maximum vesting term for more than ten percent grantees."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentMember",
     "presentation": [
      "http://www.spy.com/role/PropertyAndEquipmentNetAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Member]",
        "terseLabel": "Property, Plant and Equipment",
        "documentation": "Physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": []
    },
    "agle_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "IncreaseInCommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase In Common Stock Capital Shares Reserved For Future Issuance",
        "terseLabel": "Increase in number of shares of common stock reserved for issuance",
        "documentation": "Increase in common stock capital shares reserved for future issuance."
       }
      }
     },
     "auth_ref": []
    },
    "agle_AnnualPercentageOfAdditionalSharesWhichEqualsToIssuedAndOutstandingShares": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "AnnualPercentageOfAdditionalSharesWhichEqualsToIssuedAndOutstandingShares",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Percentage Of Additional Shares Which Equals To Issued And Outstanding Shares",
        "terseLabel": "Annual percentage of additional shares",
        "documentation": "Annual percentage of additional shares which equals to the issued and outstanding shares."
       }
      }
     },
     "auth_ref": []
    },
    "agle_GranteesWithMoreThanFiveYearsVestingTermPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "GranteesWithMoreThanFiveYearsVestingTermPercent",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grantees With More Than Five Years Vesting Term Percent",
        "terseLabel": "Grantees with more than five years vesting term, percent",
        "documentation": "Grantees with more than five years vesting term, percent."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "terseLabel": "Description of the Business and Summary of Significant Accounting Policies",
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r148",
      "r149",
      "r174"
     ]
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "presentation": [
      "http://www.spy.com/role/SaleOfPegzilarginaseToImmedicaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group Name [Domain]",
        "terseLabel": "Disposal Group Name [Domain]",
        "documentation": "Name of disposal group."
       }
      }
     },
     "auth_ref": [
      "r783",
      "r784"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income tax expense",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r134",
      "r183",
      "r276",
      "r283",
      "r287",
      "r289",
      "r600",
      "r617",
      "r772"
     ]
    },
    "agle_Spy001LicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "Spy001LicenseAgreementMember",
     "presentation": [
      "http://www.spy.com/role/ParagonAgreementDetails",
      "http://www.spy.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SPY001 License Agreement [Member]",
        "terseLabel": "SPY001 License Agreement",
        "documentation": "SPY001 License Agreement."
       }
      }
     },
     "auth_ref": []
    },
    "agle_LicenseAgreementMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "LicenseAgreementMilestonePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/ParagonAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License Agreement, Milestone Payments",
        "terseLabel": "Milestone payments",
        "documentation": "License Agreement, Milestone Payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r827"
     ]
    },
    "agle_RelatedPartyTransactionNumberOfBoardSeats": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "RelatedPartyTransactionNumberOfBoardSeats",
     "presentation": [
      "http://www.spy.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction, Number Of Board Seats",
        "terseLabel": "Number of board seats held by related party",
        "documentation": "Related Party Transaction, Number Of Board Seats"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/StrategicLicenseAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross",
        "terseLabel": "Estimated amount incurred",
        "documentation": "The amount of costs incurred under a research and development arrangement accounted for as a contract to perform research and development for others."
       }
      }
     },
     "auth_ref": [
      "r461"
     ]
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "presentation": [
      "http://www.spy.com/role/SaleOfPegzilarginaseToImmedicaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group Name [Axis]",
        "terseLabel": "Disposal Group Name [Axis]",
        "documentation": "Information by name of disposal group."
       }
      }
     },
     "auth_ref": [
      "r783",
      "r784"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.spy.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.spy.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r508",
      "r509",
      "r514"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Costs",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r458"
     ]
    },
    "agle_EmployeesAndNonEmployeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "EmployeesAndNonEmployeesMember",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employees And Non Employees [Member]",
        "terseLabel": "Employees and Non-Employees",
        "documentation": "Employees and non employees."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "terseLabel": "Research and development",
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept."
       }
      }
     },
     "auth_ref": [
      "r892"
     ]
    },
    "agle_RelatedPartyTransactionNumberOfProgramOptionsOutstanding": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "RelatedPartyTransactionNumberOfProgramOptionsOutstanding",
     "presentation": [
      "http://www.spy.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction, Number Of Program Options Outstanding",
        "terseLabel": "Number of program options outstanding",
        "documentation": "Related Party Transaction, Number Of Program Options Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "agle_MinorityInterestOwnershipPercentageByNoncontrollingOwnersHeldInThirdParty": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwnersHeldInThirdParty",
     "presentation": [
      "http://www.spy.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minority Interest Ownership Percentage By Noncontrolling Owners Held In Third Party",
        "terseLabel": "Percentage of ownership held in third party",
        "documentation": "Minority interest ownership percentage by noncontrolling owners held in third party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.spy.com/role/LeasesScheduleOfOperatingAndFinancingLeasesPresentedInBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Finance Lease, Liabilities, Current, Statement of Financial Position [Extensible List]",
        "documentation": "Indicates line item in statement of financial position that includes current finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r530"
     ]
    },
    "us-gaap_EquityInterestIssuedOrIssuableTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityInterestIssuedOrIssuableTypeDomain",
     "presentation": [
      "http://www.spy.com/role/AssetAcquisitionNarrativeDetails",
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.spy.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Interest Issued or Issuable, Type [Domain]",
        "terseLabel": "Equity Interest Issued or Issuable, Type [Domain]",
        "documentation": "Name of equity interest issued or issuable to acquire an entity in a business combination."
       }
      }
     },
     "auth_ref": [
      "r173"
     ]
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "presentation": [
      "http://www.spy.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "agle_RelatedPartyTransactionReimbursableCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "RelatedPartyTransactionReimbursableCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/RelatedPartyTransactionsExpensesRelatedToRelatedPartyWhichWereSettledInCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction Reimbursable Costs",
        "terseLabel": "Reimbursable costs",
        "documentation": "Related party transaction, reimbursable costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.spy.com/role/LeasesScheduleOfOperatingAndFinancingLeasesPresentedInBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]",
        "documentation": "Indicates line item in statement of financial position that includes noncurrent finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r530"
     ]
    },
    "agle_AmountToBePaidUnderAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "AmountToBePaidUnderAgreement",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/ParagonAgreementDetails",
      "http://www.spy.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount To Be Paid Under Agreement",
        "terseLabel": "Contingent obligation based on milestones",
        "documentation": "Amount to be paid under agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.spy.com/role/LeasesScheduleOfOperatingAndFinancingLeasesPresentedInBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]",
        "documentation": "Indicates line item in statement of financial position that includes finance lease right-of-use asset."
       }
      }
     },
     "auth_ref": [
      "r530"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityStockBasedCompensationExpenseDetails",
      "http://www.spy.com/role/RelatedPartyTransactionsExpensesRelatedToRelatedPartyWhichWereSettledInCashDetails",
      "http://www.spy.com/role/RestructuringChargesChargesRelatedToTheRestructuringActivitiesDetails",
      "http://www.spy.com/role/RestructuringChargesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development Expense",
        "presentationGuidance": "Research and Development",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
     "presentation": [
      "http://www.spy.com/role/SaleOfPegzilarginaseToImmedicaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringCostAndReserveLineItems",
     "presentation": [
      "http://www.spy.com/role/RestructuringChargesChangesInAccruedRestructuringBalanceDetails",
      "http://www.spy.com/role/RestructuringChargesChargesRelatedToTheRestructuringActivitiesDetails",
      "http://www.spy.com/role/RestructuringChargesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Cost and Reserve [Line Items]",
        "terseLabel": "Restructuring Cost and Reserve [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r348",
      "r349",
      "r350",
      "r351",
      "r355",
      "r356",
      "r357"
     ]
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringCostAndReserveAxis",
     "presentation": [
      "http://www.spy.com/role/RestructuringChargesChangesInAccruedRestructuringBalanceDetails",
      "http://www.spy.com/role/RestructuringChargesChargesRelatedToTheRestructuringActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Type [Axis]",
        "terseLabel": "Restructuring Type [Axis]",
        "documentation": "Information by type of restructuring cost."
       }
      }
     },
     "auth_ref": [
      "r348",
      "r349",
      "r355",
      "r356"
     ]
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable",
     "presentation": [
      "http://www.spy.com/role/SaleOfPegzilarginaseToImmedicaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Groups, Including Discontinued Operations [Table]",
        "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]",
        "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r23",
      "r28",
      "r113",
      "r114",
      "r115",
      "r116",
      "r117",
      "r118",
      "r120",
      "r121",
      "r122",
      "r155"
     ]
    },
    "agle_AssumedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "AssumedLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/AssetAcquisitionAssetAcquisitionCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assumed Liabilities",
        "negatedLabel": "Assumed liabilities",
        "documentation": "Assumed liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByLiabilityClassAxis",
     "presentation": [
      "http://www.spy.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.spy.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.spy.com/role/FairValueMeasurementsSignificantInputsUsedToEstimateTheFairValueOfDerivativeLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liability Class [Axis]",
        "terseLabel": "Liability Class [Axis]",
        "documentation": "Information by class of liability."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r176"
     ]
    },
    "agle_NominationFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "NominationFee",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/ParagonAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nomination Fee",
        "terseLabel": "Nomination fee",
        "documentation": "Nomination fee."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://www.spy.com/role/SeriesANonVotingConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r86",
      "r487",
      "r783",
      "r784"
     ]
    },
    "agle_NonrefundableResearchInitiationFeeForOneProgramPaidInCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "NonrefundableResearchInitiationFeeForOneProgramPaidInCash",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/ParagonAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonrefundable Research Initiation Fee For One Program Paid In Cash",
        "terseLabel": "Nonrefundable research initiation fee for one program paid in cash",
        "documentation": "Nonrefundable research initiation fee for one program paid in cash."
       }
      }
     },
     "auth_ref": []
    },
    "agle_PreferredStockRemainsIssuedAndOutstandingPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "PreferredStockRemainsIssuedAndOutstandingPercentage",
     "presentation": [
      "http://www.spy.com/role/SeriesANonVotingConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock Remains Issued and Outstanding Percentage.",
        "terseLabel": "Preferred stock issued and outstanding percentage",
        "documentation": "Preferred stock remains issued and outstanding percentage."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://www.spy.com/role/SeriesANonVotingConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]",
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "auth_ref": [
      "r487",
      "r783",
      "r784"
     ]
    },
    "agle_PaymentOfMilestone": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "PaymentOfMilestone",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/ParagonAgreementDetails",
      "http://www.spy.com/role/StrategicLicenseAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment Of Milestone",
        "verboseLabel": "First milestone payment",
        "terseLabel": "Milestone payments",
        "documentation": "Payment of milestone."
       }
      }
     },
     "auth_ref": []
    },
    "agle_FebruaryEightTwoThousandNinteenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "FebruaryEightTwoThousandNinteenMember",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityPreFundedWarrantsForCommonStockIssuedAndOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "February Eight Two Thousand Ninteen [Member]",
        "terseLabel": "February 8, 2019",
        "documentation": "February eight two thousand ninteen."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "presentation": [
      "http://www.spy.com/role/StatementOfAssetsAcquiredAndLiabilitiesAssumed"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r86",
      "r487"
     ]
    },
    "agle_BeneficiallyHoldersOwnedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "BeneficiallyHoldersOwnedPercentage",
     "presentation": [
      "http://www.spy.com/role/SeriesANonVotingConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Beneficially Holders Owned Percentage",
        "terseLabel": "Beneficially holders owned percentage",
        "documentation": "Beneficially holders owned percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionLineItems",
     "presentation": [
      "http://www.spy.com/role/StatementOfAssetsAcquiredAndLiabilitiesAssumed"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r487"
     ]
    },
    "agle_ServiceBasedAwardsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "ServiceBasedAwardsMember",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Service Based Awards [Member]",
        "terseLabel": "Service-based Awards",
        "documentation": "Service-based awards."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByAssetClassAxis",
     "presentation": [
      "http://www.spy.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.spy.com/role/PropertyAndEquipmentNetAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class",
        "documentation": "Information by class of asset."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r103"
     ]
    },
    "agle_AprilThirtyTwoThousandTwentyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "AprilThirtyTwoThousandTwentyMember",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityPreFundedWarrantsForCommonStockIssuedAndOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "April Thirty Two Thousand Twenty [Member]",
        "terseLabel": "April 30, 2020",
        "documentation": "April thirty two thousand twenty"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.spy.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.spy.com/role/FairValueMeasurementsSignificantInputsUsedToEstimateTheFairValueOfDerivativeLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r373",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r509",
      "r556",
      "r557",
      "r558",
      "r775",
      "r776",
      "r780",
      "r781",
      "r782"
     ]
    },
    "agle_MayTwentyTwoThousandTwentyTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "MayTwentyTwoThousandTwentyTwoMember",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityPreFundedWarrantsForCommonStockIssuedAndOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "May Twenty Two Thousand Twenty Two [Member]",
        "terseLabel": "May 20, 2022",
        "documentation": "May twenty two thousand twenty two."
       }
      }
     },
     "auth_ref": []
    },
    "agle_NonQualifiedStockOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "NonQualifiedStockOptionsMember",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Qualified Stock Options [Member]",
        "verboseLabel": "Non-Qualified Stock Options",
        "documentation": "Non-Qualified Stock Options [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquitySummaryOfEmployeeAndNonEmployeeStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Options vested and expected to vest",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r435"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/StrategicLicenseAgreementsChangesInContractLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Liability, Increase (Decrease) for Contract Acquired in Business Combination",
        "verboseLabel": "Deductions",
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration from customer has been received or is due, from business combination."
       }
      }
     },
     "auth_ref": [
      "r778"
     ]
    },
    "agle_NewChiefExecutiveOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "NewChiefExecutiveOfficerMember",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Chief Executive Officer [Member]",
        "verboseLabel": "New Chief Executive Officer",
        "documentation": "New chief executive officer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationsPolicy",
     "presentation": [
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations Policy [Policy Text Block]",
        "terseLabel": "Acquisitions",
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy."
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Percentage of market value of common stock",
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.spy.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r508",
      "r509",
      "r511",
      "r512",
      "r515"
     ]
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/TheCompanyAndBasisOfPresentationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, and Short-Term Investments",
        "terseLabel": "Cash, cash equivalents, and marketable securities",
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable."
       }
      }
     },
     "auth_ref": [
      "r827"
     ]
    },
    "us-gaap_SeveranceCosts1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeveranceCosts1",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/RestructuringChargesChargesRelatedToTheRestructuringActivitiesDetails": {
       "parentTag": "us-gaap_RestructuringCosts",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/RestructuringChargesChargesRelatedToTheRestructuringActivitiesDetails",
      "http://www.spy.com/role/RestructuringChargesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Severance Costs",
        "terseLabel": "Cash severance payments and other employee-related costs",
        "verboseLabel": "Severance Related Expenses",
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesEstimatedFairValueOfCashEquivalentsAndMarketableSecuritiesAndTheGrossUnrealizedGainsAndLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Equivalents, at Carrying Value",
        "totalLabel": "Cash equivalents, amortized cost",
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r822",
      "r924"
     ]
    },
    "us-gaap_RelatedPartyTransactionAmountsOfTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionAmountsOfTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/ParagonAgreementDetails",
      "http://www.spy.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://www.spy.com/role/StrategicLicenseAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction, Amounts of Transaction",
        "terseLabel": "Amount of related party transaction",
        "verboseLabel": "Transaction price",
        "documentation": "Amount of transactions with related party during the financial reporting period."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r545"
     ]
    },
    "srt_ScenarioForecastMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScenarioForecastMember",
     "presentation": [
      "http://www.spy.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "auth_ref": [
      "r410",
      "r841"
     ]
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "presentation": [
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Restricted Cash",
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r177"
     ]
    },
    "us-gaap_CorporateBondSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CorporateBondSecuritiesMember",
     "presentation": [
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesAvailableForSaleSecuritiesInAnUnrealizedLossPositionDetails",
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesEstimatedFairValueOfCashEquivalentsAndMarketableSecuritiesAndTheGrossUnrealizedGainsAndLossesDetails",
      "http://www.spy.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Corporate Bond Securities [Member]",
        "terseLabel": "Corporate bonds",
        "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesSummaryOfAssetAcquisitionCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities, Current",
        "negatedLabel": "Accrued liabilities",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://www.spy.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "auth_ref": [
      "r259",
      "r410",
      "r811",
      "r812",
      "r841"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://www.spy.com/role/ParagonAgreementDetails",
      "http://www.spy.com/role/RelatedPartyTransactionsExpensesRelatedToRelatedPartyWhichWereSettledInCashDetails",
      "http://www.spy.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://www.spy.com/role/RelatedPartyTransactionsRelatedPartyAccountsPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]",
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r105",
      "r705",
      "r706",
      "r709"
     ]
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesEstimatedFairValueOfCashEquivalentsAndMarketableSecuritiesAndTheGrossUnrealizedGainsAndLossesDetails",
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesNarrativeDetails",
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.spy.com/role/FairValueMeasurementsSignificantInputsUsedToEstimateTheFairValueOfDerivativeLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r375",
      "r390",
      "r502",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r620",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r847",
      "r848",
      "r849",
      "r850"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://www.spy.com/role/RelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Transactions",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r542",
      "r543",
      "r544",
      "r546",
      "r549",
      "r647",
      "r648",
      "r649",
      "r707",
      "r708",
      "r709",
      "r728",
      "r730"
     ]
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://www.spy.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "auth_ref": [
      "r259",
      "r410",
      "r811",
      "r841"
     ]
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/AccruedLiabilitiesAccruedAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.spy.com/role/AccruedAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/AccruedAndOtherCurrentLiabilitiesDetails",
      "http://www.spy.com/role/AccruedLiabilitiesAccruedAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued professional and consulting fees",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsDeferredIncome",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Deferred Income",
        "verboseLabel": "Deferred revenue",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r898"
     ]
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://www.spy.com/role/ParagonAgreementDetails",
      "http://www.spy.com/role/RelatedPartyTransactionsExpensesRelatedToRelatedPartyWhichWereSettledInCashDetails",
      "http://www.spy.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://www.spy.com/role/RelatedPartyTransactionsRelatedPartyAccountsPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r705",
      "r706",
      "r709"
     ]
    },
    "us-gaap_AccruedSalariesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedSalariesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/AccruedAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/AccruedAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Salaries, Current",
        "terseLabel": "Accrued compensation",
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r764"
     ]
    },
    "us-gaap_CommitmentsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsDisclosureTextBlock",
     "presentation": [
      "http://www.spy.com/role/NovationOfManufacturingAgreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments Disclosure [Text Block]",
        "terseLabel": "Novation of Manufacturing Agreements",
        "documentation": "The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights."
       }
      }
     },
     "auth_ref": [
      "r157"
     ]
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.spy.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r474"
     ]
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "presentation": [
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "US Government Agencies Debt Securities",
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB)."
       }
      }
     },
     "auth_ref": [
      "r769",
      "r780",
      "r921"
     ]
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.spy.com/role/AssetAcquisitionNarrativeDetails",
      "http://www.spy.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.spy.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersDeficitEquity",
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.spy.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.spy.com/role/SeriesANonVotingConvertiblePreferredStockDetails",
      "http://www.spy.com/role/SubsequentEventsAdditionalInformationDetails",
      "http://www.spy.com/role/TheCompanyAndBasisOfPresentationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r202",
      "r213",
      "r214",
      "r215",
      "r238",
      "r263",
      "r264",
      "r266",
      "r268",
      "r274",
      "r275",
      "r327",
      "r363",
      "r365",
      "r366",
      "r367",
      "r370",
      "r371",
      "r377",
      "r378",
      "r382",
      "r385",
      "r392",
      "r516",
      "r641",
      "r642",
      "r643",
      "r644",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r663",
      "r680",
      "r702",
      "r724",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r810",
      "r835",
      "r842"
     ]
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Deferred tax assets, net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r897"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "presentation": [
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesAvailableForSaleSecuritiesInAnUnrealizedLossPositionDetails",
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesEstimatedFairValueOfCashEquivalentsAndMarketableSecuritiesAndTheGrossUnrealizedGainsAndLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Table]",
        "terseLabel": "Debt Securities, Available-for-Sale [Table]",
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforward",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r898"
     ]
    },
    "us-gaap_PaymentsForRestructuring": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForRestructuring",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/RestructuringChargesChangesInAccruedRestructuringBalanceDetails",
      "http://www.spy.com/role/RestructuringChargesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments for Restructuring",
        "terseLabel": "Cash payments for employee related restructuring charges",
        "negatedLabel": "Payments",
        "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r349",
      "r831"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/RestructuringChargesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Consideration",
        "terseLabel": "Total consideration from disposal of long lived assets",
        "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r898"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesEstimatedFairValueOfCashEquivalentsAndMarketableSecuritiesAndTheGrossUnrealizedGainsAndLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Marketable securities, gross unrealized losses",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r300"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r25"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesEstimatedFairValueOfCashEquivalentsAndMarketableSecuritiesAndTheGrossUnrealizedGainsAndLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Marketable securities, gross unrealized gains",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r299"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.spy.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCredit",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Line of Credit",
        "terseLabel": "Letter of credit",
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r180",
      "r923"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.spy.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersDeficitEquity",
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r246",
      "r247",
      "r248",
      "r273",
      "r585",
      "r639",
      "r663",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r680",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r689",
      "r690",
      "r691",
      "r692",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r700",
      "r703",
      "r704",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r724",
      "r799"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://www.spy.com/role/FairValueMeasurementsSignificantInputsUsedToEstimateTheFairValueOfDerivativeLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]",
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails",
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityStockBasedCompensationExpenseDetails",
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquitySummaryOfEmployeeRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "auth_ref": [
      "r844",
      "r910"
     ]
    },
    "us-gaap_PreferredStockRedemptionAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockRedemptionAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/SeriesANonVotingConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Redemption Amount",
        "terseLabel": "Preferred stock, redemption value",
        "documentation": "The redemption (or callable) amount of currently redeemable preferred stock. Includes amounts representing dividends not currently declared or paid but which will be payable under the redemption features or for which ultimate payment is solely within the control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r72"
     ]
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.spy.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://www.spy.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "terseLabel": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract",
     "presentation": [
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesAvailableForSaleSecuritiesInAnUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss [Abstract]",
        "terseLabel": "Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeLiabilityMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeLiabilityMeasurementInput",
     "presentation": [
      "http://www.spy.com/role/FairValueMeasurementsSignificantInputsUsedToEstimateTheFairValueOfDerivativeLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Liability, Measurement Input",
        "terseLabel": "Derivative liability, measurement input",
        "documentation": "Value of input used to measure derivative liability."
       }
      }
     },
     "auth_ref": [
      "r512"
     ]
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.spy.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails",
      "http://www.spy.com/role/NetLossPerShareWeightedAverageEquityInstrumentsExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Common Stock",
        "verboseLabel": "Unvested restricted stock units",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 21.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other non-current liabilities",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.spy.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.spy.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.spy.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r508",
      "r509",
      "r514"
     ]
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsFairValueDisclosureAbstract",
     "presentation": [
      "http://www.spy.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Financial Assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExaminationPenaltiesAndInterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Examination, Penalties and Interest Expense",
        "terseLabel": "Interest or penalties incurred",
        "documentation": "The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations."
       }
      }
     },
     "auth_ref": [
      "r895"
     ]
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.spy.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "presentation": [
      "http://www.spy.com/role/FairValueMeasurementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "terseLabel": "Significant Inputs used to Estimate the Fair Value of Derivative Liabilities",
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.spy.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
      "http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and Office Equipment",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromSaleOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleOfIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 26.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://www.spy.com/role/SaleOfPegzilarginaseToImmedicaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Sale of Intangible Assets",
        "verboseLabel": "Proceeds from sale of in-process research &amp; development asset",
        "terseLabel": "Proceeds from sale of intangible assets",
        "documentation": "The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill."
       }
      }
     },
     "auth_ref": [
      "r143"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.spy.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 28.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "terseLabel": "Proceeds from sale of property and equipment",
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r143"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.spy.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OverAllotmentOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OverAllotmentOptionMember",
     "presentation": [
      "http://www.spy.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Underwriters' Over-allotment Option",
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecuritiesPolicy",
     "presentation": [
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "terseLabel": "Marketable Securities",
        "documentation": "Disclosure of accounting policy for investment classified as marketable security."
       }
      }
     },
     "auth_ref": [
      "r108"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.spy.com/role/PropertyAndEquipmentNetAdditionalInformationDetails",
      "http://www.spy.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
      "http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Schedule Of Property Plant And Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.spy.com/role/PropertyAndEquipmentNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment, Net",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r196",
      "r199",
      "r200"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.spy.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
      "http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r152"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeFinanceLeaseRenewalTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeFinanceLeaseRenewalTerm1",
     "presentation": [
      "http://www.spy.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Finance Lease, Renewal Term",
        "terseLabel": "Lessee, finance lease, renewal term",
        "documentation": "Term of lessee's finance lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r908"
     ]
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.spy.com/role/LeasesSummaryOfWeightedAverageRemainingLeaseTermAndDiscountRatesForOperatingAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Finance leases, Weighted-average remaining lease term",
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r538",
      "r792"
     ]
    },
    "us-gaap_LeaseExpirationDate1": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseExpirationDate1",
     "presentation": [
      "http://www.spy.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Expiration Date",
        "terseLabel": "Lease expiration date",
        "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share, diluted (in dollars per share)",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r230",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r263",
      "r266",
      "r267",
      "r268",
      "r272",
      "r505",
      "r506",
      "r599",
      "r622",
      "r770"
     ]
    },
    "us-gaap_ProgramRightsObligations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProgramRightsObligations",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/AccruedLiabilitiesAccruedAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/AccruedLiabilitiesAccruedAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Program Rights Obligations",
        "terseLabel": "Fair value of assumed Parapyre Option Obligation (Note\u00a03)",
        "documentation": "Total amount of obligations related to rights to programming, including, but not limited to, feature films and episodic series, acquired under license agreements."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LicenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LicenseMember",
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://www.spy.com/role/StrategicLicenseAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License [Member]",
        "verboseLabel": "License",
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark."
       }
      }
     },
     "auth_ref": [
      "r863"
     ]
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
     "presentation": [
      "http://www.spy.com/role/SaleOfPegzilarginaseToImmedica"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]",
        "terseLabel": "Sale of Pegzilarginase to Immedica",
        "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r151"
     ]
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.spy.com/role/SeriesANonVotingConvertiblePreferredStockDetails",
      "http://www.spy.com/role/StockholdersEquityAdditionalInformationDetails",
      "http://www.spy.com/role/TheCompanyAndBasisOfPresentationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails",
      "http://www.spy.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Price Per Share",
        "definitionGuidance": "Public offering price",
        "terseLabel": "Public offering price (in dollars per share)",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://www.spy.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r527",
      "r551"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.spy.com/role/StockholdersEquityAdditionalInformationDetails",
      "http://www.spy.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share",
        "verboseLabel": "Common stock, par value (in dollars per share)",
        "terseLabel": "Common stock, par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r127"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://www.spy.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued."
       }
      }
     },
     "auth_ref": [
      "r527",
      "r551"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails",
      "http://www.spy.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r527",
      "r551"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.spy.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Measurements, Recurring",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r507",
      "r515"
     ]
    },
    "us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ExpenseRelatedToDistributionOrServicingAndUnderwritingFees",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expense Related to Distribution or Servicing and Underwriting Fees",
        "terseLabel": "Underwriting discounts and commissions",
        "documentation": "Expense related to distribution, servicing and underwriting fees."
       }
      }
     },
     "auth_ref": [
      "r185"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://www.spy.com/role/RelatedPartyTransactionsRelatedPartyAccountsPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r793"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 22.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "TOTAL STOCKHOLDERS' (DEFICIT) EQUITY",
        "periodStartLabel": "Balances",
        "periodEndLabel": "Balances",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r130",
      "r131",
      "r150",
      "r682",
      "r699",
      "r725",
      "r726",
      "r793",
      "r806",
      "r836",
      "r851",
      "r906",
      "r927"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r459",
      "r920"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails",
      "http://www.spy.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r527",
      "r551"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersDeficitEquity",
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax",
        "terseLabel": "Foreign currency translation adjustment",
        "documentation": "Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r133",
      "r517",
      "r518",
      "r520"
     ]
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/DefinedContributionPlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "terseLabel": "Defined contribution plan, contribution amount",
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableOtherCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableOtherCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Other, Current",
        "terseLabel": "Related party accounts payable",
        "documentation": "Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Awards granted, vesting period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted average period over which unrecognized compensation is expected to be recognized",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r447"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://www.spy.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Lessee, operating lease, renewal term",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r908"
     ]
    },
    "us-gaap_AccountsPayableTradeCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableTradeCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Trade, Current",
        "terseLabel": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r31"
     ]
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNetAbstract",
     "presentation": [
      "http://www.spy.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net [Abstract]",
        "terseLabel": "Deferred tax assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.spy.com/role/SeriesANonVotingConvertiblePreferredStockDetails",
      "http://www.spy.com/role/StockholdersEquityAdditionalInformationDetails",
      "http://www.spy.com/role/TheCompanyAndBasisOfPresentationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Cash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Cash",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesNarrativeDetails",
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash",
        "terseLabel": "Cash deposits in excess of FDIC limit",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r191",
      "r606",
      "r662",
      "r688",
      "r793",
      "r806",
      "r822"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.spy.com/role/LeasesSummaryOfWeightedAverageRemainingLeaseTermAndDiscountRatesForOperatingAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Operating leases, Weighted-average remaining lease term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r538",
      "r792"
     ]
    },
    "us-gaap_ReimbursementFromLimitedPartnershipInvestment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReimbursementFromLimitedPartnershipInvestment",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/StrategicLicenseAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reimbursement from Limited Partnership Investment",
        "terseLabel": "Reimbursement",
        "documentation": "A payment from an investee, in which the investment basis has previously been reduced to zero. This amount reduces net cash used in operating activities."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "agle_PaymentOfAnnualLicenseFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "PaymentOfAnnualLicenseFees",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/StrategicLicenseAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment Of Annual License Fees",
        "terseLabel": "Annual license fees paid",
        "documentation": "Payment of annual license fees."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://www.spy.com/role/FairValueMeasurementsSignificantInputsUsedToEstimateTheFairValueOfDerivativeLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r510"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 27.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r144"
     ]
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://www.spy.com/role/AssetAcquisitionNarrativeDetails",
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Shares issued, price per share (in dollars per share)",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "agle_SeriesAConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "SeriesAConvertiblePreferredStockMember",
     "presentation": [
      "http://www.spy.com/role/NetLossPerShareWeightedAverageEquityInstrumentsExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A Convertible Preferred Stock [Member]",
        "terseLabel": "Series A Preferred Stock (on an as-converted basis)",
        "documentation": "Series A Convertible Preferred Stock ."
       }
      }
     },
     "auth_ref": []
    },
    "agle_OperatingLeaseTerminationFeeAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "OperatingLeaseTerminationFeeAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/RestructuringChargesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Termination Fee Amount",
        "terseLabel": "Termination fee amount",
        "documentation": "Operating Lease, Termination Fee Amount"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://www.spy.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantMember",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityPreFundedWarrantsForCommonStockIssuedAndOutstandingDetails",
      "http://www.spy.com/role/StockholdersEquitySummaryOfPreFundedWarrantsForCommonStockIssuedAndOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "terseLabel": "Pre-funded Warrants",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r796",
      "r797",
      "r800",
      "r801",
      "r802",
      "r803"
     ]
    },
    "agle_SeveranceLiabilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "SeveranceLiabilityMember",
     "presentation": [
      "http://www.spy.com/role/RestructuringChargesChangesInAccruedRestructuringBalanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Severance Liability [Member]",
        "terseLabel": "Severance Liability",
        "documentation": "Severance liability."
       }
      }
     },
     "auth_ref": []
    },
    "agle_WeightedAverageNumberOfSharesPreFundedWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "WeightedAverageNumberOfSharesPreFundedWarrants",
     "presentation": [
      "http://www.spy.com/role/NetLossPerShareScheduleOfReconciliationOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number Of Shares Pre-funded Warrants",
        "terseLabel": "Weighted average pre-funded warrants",
        "documentation": "Weighted average number of shares pre-funded warrants."
       }
      }
     },
     "auth_ref": []
    },
    "agle_IncomeTaxReconciliationTaxCostCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "IncomeTaxReconciliationTaxCostCredit",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/IncomeTaxesSummaryOfDifferenceBetweenProvisionForIncomeTaxesAndAmountsComputedByApplyingStatutoryFederalIncomeTaxRateToIncomeBeforeIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/IncomeTaxesSummaryOfDifferenceBetweenProvisionForIncomeTaxesAndAmountsComputedByApplyingStatutoryFederalIncomeTaxRateToIncomeBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Reconciliation Tax Cost Credit",
        "terseLabel": "Tax credits",
        "documentation": "Income tax reconciliation tax cost (credit)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeContractTypeDomain",
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://www.spy.com/role/FairValueMeasurementsChangesInDerivativeLiabilitiesDetails",
      "http://www.spy.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract [Domain]",
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset."
       }
      }
     },
     "auth_ref": [
      "r668",
      "r671",
      "r685",
      "r686",
      "r687",
      "r689",
      "r690",
      "r691",
      "r692",
      "r694",
      "r695",
      "r696",
      "r697",
      "r712",
      "r713",
      "r714",
      "r715",
      "r718",
      "r719",
      "r720",
      "r721",
      "r741",
      "r742",
      "r743",
      "r744",
      "r796",
      "r798"
     ]
    },
    "agle_PercentageOfNetOperatingLossUtilizedToOffsetTaxableIncome": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "PercentageOfNetOperatingLossUtilizedToOffsetTaxableIncome",
     "presentation": [
      "http://www.spy.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of Net Operating Loss Utilized to Offset Taxable Income",
        "terseLabel": "Percentage of net operating loss utilized to offset taxable income",
        "documentation": "Percentage of net operating loss utilized to offset taxable income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashFDICInsuredAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashFDICInsuredAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, FDIC Insured Amount",
        "terseLabel": "Cash, FDIC insured amount",
        "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNoncashIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Other",
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other."
       }
      }
     },
     "auth_ref": [
      "r147"
     ]
    },
    "agle_AdditionalUpfrontPaymentAbilityToReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "AdditionalUpfrontPaymentAbilityToReceived",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/StrategicLicenseAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Upfront Payment Ability To Received",
        "terseLabel": "Additional upfront payment to be received",
        "documentation": "Additional upfront payment ability to received."
       }
      }
     },
     "auth_ref": []
    },
    "agle_LicenseAndSupplyAgreementDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "LicenseAndSupplyAgreementDate",
     "presentation": [
      "http://www.spy.com/role/StrategicLicenseAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License and supply agreement date",
        "documentation": "License and supply agreement date."
       }
      }
     },
     "auth_ref": []
    },
    "agle_MaximumFutureContingentLicensePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "MaximumFutureContingentLicensePayment",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/StrategicLicenseAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum Future Contingent License Payment",
        "terseLabel": "Maximum future contingent license payment",
        "documentation": "Maximum future contingent license payment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AreaOfLand": {
     "xbrltype": "areaItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AreaOfLand",
     "presentation": [
      "http://www.spy.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Area of Land",
        "terseLabel": "Area of land",
        "documentation": "Area of land held."
       }
      }
     },
     "auth_ref": []
    },
    "agle_MilestonePaymentsExchangeRate": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "MilestonePaymentsExchangeRate",
     "presentation": [
      "http://www.spy.com/role/StrategicLicenseAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Milestone Payments Exchange Rate",
        "terseLabel": "Milestone payments exchange rate",
        "documentation": "Milestone payments exchange rate."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestReceivable",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Receivable",
        "terseLabel": "Accrued interest receivable on available-for-sale debt securities",
        "documentation": "Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable."
       }
      }
     },
     "auth_ref": [
      "r826",
      "r929"
     ]
    },
    "agle_NumberOfLicenseAgreements": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "NumberOfLicenseAgreements",
     "presentation": [
      "http://www.spy.com/role/StrategicLicenseAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number Of License Agreements",
        "terseLabel": "Number of license agreements",
        "documentation": "Number of license agreements."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCountryMember",
     "presentation": [
      "http://www.spy.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Tax Authority [Member]",
        "terseLabel": "Foreign subsidiaries",
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Stock-based compensation expense",
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r126",
      "r127",
      "r162"
     ]
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
     "presentation": [
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.spy.com/role/RestructuringChargesNarrativeDetails",
      "http://www.spy.com/role/TheCompanyAndBasisOfPresentationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Cost, Number of Positions Eliminated, Period Percent",
        "terseLabel": "Employee workforce, termination percentage",
        "documentation": "The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s)."
       }
      }
     },
     "auth_ref": []
    },
    "agle_NetOperatingLossAndCreditCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "NetOperatingLossAndCreditCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Operating Loss And Credit Carryforwards",
        "terseLabel": "Net operating loss and tax credit carryforwards",
        "documentation": "Net operating loss and credit carryforwards."
       }
      }
     },
     "auth_ref": []
    },
    "agle_ResearchAgreementDate": {
     "xbrltype": "gYearMonthItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "ResearchAgreementDate",
     "presentation": [
      "http://www.spy.com/role/StrategicLicenseAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research Agreement Date",
        "terseLabel": "Research agreement date",
        "documentation": "Research agreement date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Other Accounts Payable",
        "terseLabel": "Related party payable",
        "documentation": "Amount of increase (decrease) in obligations classified as other, payable within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issuance of common stock in connection with employee stock purchase plan",
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r126",
      "r127",
      "r162"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Development receivables",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "agle_IncomeTaxesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "IncomeTaxesLineItems",
     "presentation": [
      "http://www.spy.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.spy.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails",
      "http://www.spy.com/role/IncomeTaxesSummaryOfDifferenceBetweenProvisionForIncomeTaxesAndAmountsComputedByApplyingStatutoryFederalIncomeTaxRateToIncomeBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes [Line Items]",
        "terseLabel": "Income Taxes [Line Items]",
        "documentation": "Income taxes line items."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueAcquisitions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueAcquisitions",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Acquisitions",
        "terseLabel": "Issuance of common stock in connection with the asset acquisition of Spyre and settlement of related forward contract",
        "documentation": "Value of stock issued pursuant to acquisitions during the period."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r41",
      "r162"
     ]
    },
    "agle_AggregatePotentialMilestonePaymentsForReceiptOfRegulatoryApproval": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "AggregatePotentialMilestonePaymentsForReceiptOfRegulatoryApproval",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/StrategicLicenseAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Potential Milestone Payments For Receipt Of Regulatory Approval",
        "terseLabel": "Aggregate potential milestone payments for receipt of regulatory approval",
        "documentation": "Aggregate potential milestone payments for receipt of regulatory approval."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Issuance of common stock in connection with exercise of stock options",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r41",
      "r162"
     ]
    },
    "agle_AggregatePotentialMilestonePaymentsForFinalRegulatoryApprovalOfSecondIndication": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "AggregatePotentialMilestonePaymentsForFinalRegulatoryApprovalOfSecondIndication",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/StrategicLicenseAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Potential Milestone Payments For Final Regulatory Approval Of Second Indication",
        "terseLabel": "Aggregate potential milestone payments for final regulatory approval of second indication",
        "documentation": "Aggregate potential milestone payments for final regulatory approval of second indication."
       }
      }
     },
     "auth_ref": []
    },
    "agle_IncreaseInValuationPrimarilyDueToOperationLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "IncreaseInValuationPrimarilyDueToOperationLosses",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase In Valuation Primarily Due To Operation Losses",
        "terseLabel": "Increase in valuation primarily due to operation losses",
        "documentation": "Increase in valuation primarily due to operation losses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Issuance of common stock in connection with exercise of pre-funded warrants",
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r41",
      "r162"
     ]
    },
    "agle_ContractWithCustomerLiabilityAdditions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "ContractWithCustomerLiabilityAdditions",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/StrategicLicenseAgreementsChangesInContractLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract With Customer, Liability, Additions",
        "terseLabel": "Additions",
        "documentation": "Contract With Customer, Liability, Additions"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAcquiredFromAcquisition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAcquiredFromAcquisition",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 25.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/AssetAcquisitionAssetAcquisitionCostDetails",
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesSummaryOfAssetAcquisitionCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Acquired from Acquisition",
        "verboseLabel": "Cash assumed from asset acquisition of Spyre",
        "terseLabel": "Cash acquired",
        "documentation": "The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business)."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputDiscountRateMember",
     "presentation": [
      "http://www.spy.com/role/FairValueMeasurementsSignificantInputsUsedToEstimateTheFairValueOfDerivativeLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Risk-adjusted discount rates",
        "documentation": "Measurement input using interest rate to determine present value of future cash flows."
       }
      }
     },
     "auth_ref": [
      "r905"
     ]
    },
    "agle_ContractWithCustomerLiabilityDeductionsThroughContractsAcquired": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "ContractWithCustomerLiabilityDeductionsThroughContractsAcquired",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/StrategicLicenseAgreementsChangesInContractLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract With Customer Liability Deductions Through Contracts Acquired",
        "negatedLabel": "Deductions",
        "documentation": "Contract with customer liability deductions through contracts acquired."
       }
      }
     },
     "auth_ref": []
    },
    "agle_ContractWithCustomerLiabilityRevenueRecognizedIncludingAdditions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "ContractWithCustomerLiabilityRevenueRecognizedIncludingAdditions",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/StrategicLicenseAgreementsChangesInContractLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract With Customer Liability Revenue Recognized Including Additions",
        "terseLabel": "Additions",
        "documentation": "Contract with customer liability revenue recognized including additions."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails",
      "http://www.spy.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, New Issues",
        "verboseLabel": "Number of shares issued",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r126",
      "r127",
      "r162",
      "r641",
      "r724",
      "r754"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r208",
      "r763"
     ]
    },
    "agle_GlobalRightsToPegzilarginaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "GlobalRightsToPegzilarginaseMember",
     "presentation": [
      "http://www.spy.com/role/SaleOfPegzilarginaseToImmedicaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Global Rights To Pegzilarginase [Member]",
        "terseLabel": "Global Rights To Pegzilarginase",
        "documentation": "Global Rights To Pegzilarginase"
       }
      }
     },
     "auth_ref": []
    },
    "agle_DisposalGroupIncludingDiscontinuedOperationContingentConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "DisposalGroupIncludingDiscontinuedOperationContingentConsideration",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/SaleOfPegzilarginaseToImmedicaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Contingent Consideration",
        "terseLabel": "Contingent consideration",
        "documentation": "Disposal Group, Including Discontinued Operation, Contingent Consideration"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "agle_IncomeTaxesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "IncomeTaxesTable",
     "presentation": [
      "http://www.spy.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.spy.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails",
      "http://www.spy.com/role/IncomeTaxesSummaryOfDifferenceBetweenProvisionForIncomeTaxesAndAmountsComputedByApplyingStatutoryFederalIncomeTaxRateToIncomeBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes [Table]",
        "terseLabel": "Income Taxes [Table]",
        "documentation": "Income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForwardContractsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForwardContractsMember",
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://www.spy.com/role/FairValueMeasurementsChangesInDerivativeLiabilitiesDetails",
      "http://www.spy.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forward Contracts [Member]",
        "terseLabel": "Forward contract liability",
        "verboseLabel": "Forward Contracts",
        "documentation": "Contracts negotiated between two parties to purchase and sell a specific quantity of a financial instrument, foreign currency, or commodity at a price specified at origination of the contract, with delivery and settlement at a specified future date."
       }
      }
     },
     "auth_ref": [
      "r903"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersDeficitEquity",
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails",
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityPreFundedWarrantsForCommonStockIssuedAndOutstandingDetails",
      "http://www.spy.com/role/StockholdersEquityAdditionalInformationDetails",
      "http://www.spy.com/role/StockholdersEquitySummaryOfPreFundedWarrantsForCommonStockIssuedAndOutstandingDetails",
      "http://www.spy.com/role/TheCompanyAndBasisOfPresentationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r41",
      "r203",
      "r226",
      "r227",
      "r228",
      "r246",
      "r247",
      "r248",
      "r250",
      "r256",
      "r258",
      "r273",
      "r328",
      "r329",
      "r394",
      "r449",
      "r450",
      "r451",
      "r479",
      "r480",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r504",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r541",
      "r631",
      "r632",
      "r633",
      "r651",
      "r724"
     ]
    },
    "agle_TaxCreditCarryforwardExpirationYear": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "TaxCreditCarryforwardExpirationYear",
     "presentation": [
      "http://www.spy.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward Expiration Year",
        "terseLabel": "Tax credit carryforwards, expiration year",
        "documentation": "Tax credit carryforward, expiration year."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://www.spy.com/role/NetLossPerShareScheduleOfReconciliationOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average common shares outstanding, diluted (in dollars per share)",
        "verboseLabel": "Total diluted weighed average shares",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r262",
      "r268"
     ]
    },
    "agle_OperatingLossCarryforwardsExpirationYear": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "OperatingLossCarryforwardsExpirationYear",
     "presentation": [
      "http://www.spy.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards Expiration Year",
        "terseLabel": "Net operating loss carryforwards, expiration year",
        "documentation": "Operating loss carryforwards, expiration year."
       }
      }
     },
     "auth_ref": []
    },
    "agle_CashEquivalentsUnrealizedLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "CashEquivalentsUnrealizedLosses",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesEstimatedFairValueOfCashEquivalentsAndMarketableSecuritiesAndTheGrossUnrealizedGainsAndLossesDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesEstimatedFairValueOfCashEquivalentsAndMarketableSecuritiesAndTheGrossUnrealizedGainsAndLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Equivalents Unrealized Losses",
        "negatedLabel": "Cash equivalents, gross unrealized losses",
        "documentation": "Cash equivalents unrealized losses."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.spy.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r807"
     ]
    },
    "us-gaap_EquityInterestIssuedOrIssuableByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityInterestIssuedOrIssuableByTypeAxis",
     "presentation": [
      "http://www.spy.com/role/AssetAcquisitionNarrativeDetails",
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.spy.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Interest Type [Axis]",
        "terseLabel": "Equity Interest Type [Axis]",
        "documentation": "Information by type of equity interests that are issued or issuable in a business combination."
       }
      }
     },
     "auth_ref": []
    },
    "agle_LicenseAndCollaborationAgreementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "LicenseAndCollaborationAgreementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "License And Collaboration Agreement [Abstract]",
        "documentation": "License and collaboration agreement."
       }
      }
     },
     "auth_ref": []
    },
    "agle_OperatingAndFinanceLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "OperatingAndFinanceLeaseLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/LeasesScheduleOfOperatingAndFinancingLeasesPresentedInBalanceSheetDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.spy.com/role/LeasesScheduleOfOperatingAndFinancingLeasesPresentedInBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating And Finance Lease Liabilities",
        "totalLabel": "Total lease liabilities",
        "documentation": "Operating and Finance lease Liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "agle_FixedExchangeRatio": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "FixedExchangeRatio",
     "presentation": [
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.spy.com/role/TheCompanyAndBasisOfPresentationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fixed Exchange Ratio",
        "terseLabel": "Fixed exchange ratio",
        "documentation": "Fixed exchange ratio."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativesPolicyTextBlock",
     "presentation": [
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivatives, Policy [Policy Text Block]",
        "terseLabel": "Contingent Value Rights",
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r90",
      "r91",
      "r93",
      "r98",
      "r245"
     ]
    },
    "agle_AtTheMarketSalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "AtTheMarketSalesAgreementMember",
     "presentation": [
      "http://www.spy.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "At The Market Sales Agreement [Member]",
        "terseLabel": "At-the-Market (ATM) Sales Agreement",
        "documentation": "At the market sales agreement."
       }
      }
     },
     "auth_ref": []
    },
    "agle_OutstandingAndUnexercisedStockOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "OutstandingAndUnexercisedStockOptions",
     "presentation": [
      "http://www.spy.com/role/AssetAcquisitionNarrativeDetails",
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails",
      "http://www.spy.com/role/TheCompanyAndBasisOfPresentationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding and Unexercised Stock Options",
        "terseLabel": "Number of outstanding and unexercised stock options to purchase (in shares)",
        "documentation": "Outstanding and unexercised stock options."
       }
      }
     },
     "auth_ref": []
    },
    "agle_JonesTradingInstitutionalServicesLimitedLiabilityCompanyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "JonesTradingInstitutionalServicesLimitedLiabilityCompanyMember",
     "presentation": [
      "http://www.spy.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Jones Trading Institutional Services Limited Liability Company [Member]",
        "terseLabel": "JonesTrading Institutional Services LLC",
        "documentation": "Jones Trading Institutional Services Limited Liability Company."
       }
      }
     },
     "auth_ref": []
    },
    "agle_NumberOfCommonStockVotingRightsHeldPerShare": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "NumberOfCommonStockVotingRightsHeldPerShare",
     "presentation": [
      "http://www.spy.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number Of Common Stock Voting Rights Held Per Share",
        "terseLabel": "Number of common stock holders voting right",
        "documentation": "Number of common stock voting rights held per share."
       }
      }
     },
     "auth_ref": []
    },
    "agle_OrganizationConsolidationAndPresentationOfFinancialStatementsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsTable",
     "presentation": [
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization Consolidation And Presentation Of Financial Statements [Table]",
        "documentation": "Organization consolidation and presentation of financial statements."
       }
      }
     },
     "auth_ref": []
    },
    "agle_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableSharesOfCommonStockOnAnAsConvertedBasis": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableSharesOfCommonStockOnAnAsConvertedBasis",
     "presentation": [
      "http://www.spy.com/role/AssetAcquisitionNarrativeDetails",
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition Consideration Transferred Equity Interest Issued And Issuable Shares Of Common Stock On An As-converted Basis",
        "terseLabel": "Asset acquisition consideration transferred issuable shares of common stock on an as-converted basis",
        "documentation": "Asset acquisition consideration transferred equity interest issued and issuable shares of common stock on an as-converted basis."
       }
      }
     },
     "auth_ref": []
    },
    "agle_PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock",
     "presentation": [
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.spy.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.spy.com/role/ParagonAgreementDetails",
      "http://www.spy.com/role/ParapyreOptionObligationAdditionalInformationDetails",
      "http://www.spy.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage Of Annual Equity Grant Of Options To Purchase Outstanding Shares Of Common Stock",
        "terseLabel": "Percentage of annual equity grant of options",
        "documentation": "Percentage of annual equity grant of options to purchase outstanding shares of common stock."
       }
      }
     },
     "auth_ref": []
    },
    "agle_AppointOfBoardMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "AppointOfBoardMember",
     "presentation": [
      "http://www.spy.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Appoint Of Board [Member]",
        "terseLabel": "Appoint Of Board",
        "documentation": "Appoint Of Board."
       }
      }
     },
     "auth_ref": []
    },
    "agle_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems",
     "presentation": [
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization Consolidation And Presentation Of Financial Statements [Line Items]",
        "documentation": "Organization consolidation and presentation of financial statements."
       }
      }
     },
     "auth_ref": []
    },
    "agle_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares",
     "presentation": [
      "http://www.spy.com/role/AssetAcquisitionNarrativeDetails",
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.spy.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.spy.com/role/SeriesANonVotingConvertiblePreferredStockDetails",
      "http://www.spy.com/role/SubsequentEventsAdditionalInformationDetails",
      "http://www.spy.com/role/TheCompanyAndBasisOfPresentationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition Consideration Transferred Equity Interest Issued And Issuable, Shares",
        "terseLabel": "Number of shares transferred as equity interest in asset acquisition",
        "documentation": "Asset acquisition consideration transferred equity interest issued and issuable, shares."
       }
      }
     },
     "auth_ref": []
    },
    "agle_ReimbursableCostsUnderParagonAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "ReimbursableCostsUnderParagonAgreementMember",
     "presentation": [
      "http://www.spy.com/role/RelatedPartyTransactionsExpensesRelatedToRelatedPartyWhichWereSettledInCashDetails",
      "http://www.spy.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://www.spy.com/role/RelatedPartyTransactionsRelatedPartyAccountsPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reimbursable Costs Under Paragon Agreement [Member]",
        "terseLabel": "Reimbursable Costs Under Paragon Agreement",
        "documentation": "Reimbursable costs under paragon agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.spy.com/role/StrategicLicenseAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r488"
     ]
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeInstrumentRiskAxis",
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://www.spy.com/role/FairValueMeasurementsChangesInDerivativeLiabilitiesDetails",
      "http://www.spy.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]",
        "documentation": "Information by type of derivative contract."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r95",
      "r96",
      "r97",
      "r668",
      "r671",
      "r685",
      "r686",
      "r687",
      "r689",
      "r690",
      "r691",
      "r692",
      "r694",
      "r695",
      "r696",
      "r697",
      "r712",
      "r713",
      "r714",
      "r715",
      "r718",
      "r719",
      "r720",
      "r721",
      "r741",
      "r742",
      "r743",
      "r744",
      "r767",
      "r796",
      "r798"
     ]
    },
    "agle_DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of the Business and Summary of Significant Accounting Policies [Abstract]",
        "documentation": "Description of the business and summary of significant accounting policies."
       }
      }
     },
     "auth_ref": []
    },
    "agle_StockCompensationAndResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "StockCompensationAndResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.spy.com/role/ParagonAgreementDetails",
      "http://www.spy.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Compensation And Research And Development Expense [Member]",
        "terseLabel": "Stock Compensation And Research And Development Expense",
        "documentation": "Stock Compensation And Research And Development Expense"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.spy.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "agle_ReverseStockSplitTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "ReverseStockSplitTextBlock",
     "presentation": [
      "http://www.spy.com/role/ReverseStockSplit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reverse Stock Split [Text Block]",
        "terseLabel": "Reverse Stock Split",
        "documentation": "Reverse stock split."
       }
      }
     },
     "auth_ref": []
    },
    "agle_StrategicLicenseAgreementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "StrategicLicenseAgreementTextBlock",
     "presentation": [
      "http://www.spy.com/role/StrategicLicenseAgreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Strategic License Agreement [Text Block]",
        "terseLabel": "Strategic License Agreement",
        "documentation": "Strategic license agreement."
       }
      }
     },
     "auth_ref": []
    },
    "agle_MilestonePaymentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "MilestonePaymentsMember",
     "presentation": [
      "http://www.spy.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Milestone Payments [Member]",
        "terseLabel": "Milestone Payments",
        "documentation": "Milestone Payments"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.spy.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r807"
     ]
    },
    "agle_SpyreTherapeuticsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "SpyreTherapeuticsIncMember",
     "presentation": [
      "http://www.spy.com/role/AssetAcquisitionAssetAcquisitionCostDetails",
      "http://www.spy.com/role/AssetAcquisitionNarrativeDetails",
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesSummaryOfAssetAcquisitionCostDetails",
      "http://www.spy.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.spy.com/role/SubsequentEventsAdditionalInformationDetails",
      "http://www.spy.com/role/TheCompanyAndBasisOfPresentationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Spyre Therapeutics, Inc. [Member]",
        "terseLabel": "Spyre Therapeutics, Inc.",
        "documentation": "Spyre Therapeutics, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "agle_FollowOnPublicOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "FollowOnPublicOfferingMember",
     "presentation": [
      "http://www.spy.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Follow On Public Offering [Member]",
        "terseLabel": "Follow-on Public Offering",
        "documentation": "Follow on public offering."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.spy.com/role/StrategicLicenseAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r488"
     ]
    },
    "agle_AccruedLiabilitiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "AccruedLiabilitiesTextBlock",
     "presentation": [
      "http://www.spy.com/role/AccruedLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities [Text Block]",
        "terseLabel": "Accrued Liabilities",
        "documentation": "Accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails",
      "http://www.spy.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Net proceeds from sale of common stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "agle_AccruedResearchAndDevelopmentExpensePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "AccruedResearchAndDevelopmentExpensePolicyTextBlock",
     "presentation": [
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Research And Development Expense Policy [Text Block]",
        "terseLabel": "Accrued Research And Development Costs",
        "documentation": "Accrued research and development expense policy."
       }
      }
     },
     "auth_ref": []
    },
    "agle_SharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "SharesAuthorized",
     "presentation": [
      "http://www.spy.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Authorized",
        "terseLabel": "Shares authorized",
        "documentation": "Shares authorized."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]",
        "verboseLabel": "Stock-Based Compensation Expense",
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Useful lives of the property and equipment",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "agle_AggregateOfferingPriceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "AggregateOfferingPriceOfCommonStock",
     "presentation": [
      "http://www.spy.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Offering Price Of Common Stock",
        "terseLabel": "Aggregate offering price of common stock",
        "documentation": "Aggregate offering price of common stock."
       }
      }
     },
     "auth_ref": []
    },
    "agle_ConvertiblePreferredStockIssuedThroughPipePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "ConvertiblePreferredStockIssuedThroughPipePolicyTextBlock",
     "presentation": [
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Preferred Stock Issued Through Pipe [Policy Text Block]",
        "terseLabel": "Convertible Preferred Stock Issued through PIPE",
        "documentation": "Convertible preferred stock issued through pipe."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 32.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Convertible Preferred Stock",
        "terseLabel": "Proceeds from issuance of Series A non-voting convertible preferred stock in connection with private placement, net of placement and other offering costs",
        "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "agle_ParagonTherapeuticsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "ParagonTherapeuticsIncMember",
     "presentation": [
      "http://www.spy.com/role/ParagonAgreementDetails",
      "http://www.spy.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Paragon Therapeutics Inc [Member]",
        "terseLabel": "Paragon Therapeutics Inc",
        "documentation": "Paragon therapeutics, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "agle_AccruedLiabilitiesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "AccruedLiabilitiesPolicyTextBlock",
     "presentation": [
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities [Policy Text Block]",
        "terseLabel": "Accrued Liabilities",
        "documentation": "Accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquitySummaryOfEmployeeRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Common Stock",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "agle_CompanyAndBasisOfPresentationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "CompanyAndBasisOfPresentationLineItems",
     "presentation": [
      "http://www.spy.com/role/TheCompanyAndBasisOfPresentationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company And Basis Of Presentation [Line Items]",
        "terseLabel": "Company and Basis of Presentation [Line Items]",
        "documentation": "Company and basis of presentation."
       }
      }
     },
     "auth_ref": []
    },
    "agle_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock",
     "presentation": [
      "http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Estimated Useful Lives Of Property Plant And Equipment Table [Text Block]",
        "terseLabel": "Schedule Of Estimated Useful Lives Of Property Plant And Equipment",
        "documentation": "Schedule of estimated useful lives of property plant and equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value [Table Text Block]",
        "terseLabel": "Stock Awards Granted",
        "documentation": "Tabular disclosure of the total intrinsic value of options exercised (or share units converted), share-based liabilities paid, and the total fair value of shares vested during the year."
       }
      }
     },
     "auth_ref": [
      "r168"
     ]
    },
    "agle_MayTwoThousandTwentyTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "MayTwoThousandTwentyTwoMember",
     "presentation": [
      "http://www.spy.com/role/StockholdersEquitySummaryOfPreFundedWarrantsForCommonStockIssuedAndOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "May Two Thousand Twenty Two [Member]",
        "terseLabel": "May 2022",
        "documentation": "May two thousand twenty two Member."
       }
      }
     },
     "auth_ref": []
    },
    "agle_PlacementAgentFeesAndOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "PlacementAgentFeesAndOfferingCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails",
      "http://www.spy.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Placement Agent Fees And Offering Costs",
        "terseLabel": "Placement agent fees and offering costs",
        "documentation": "Placement agent fees and offering costs."
       }
      }
     },
     "auth_ref": []
    },
    "agle_ScheduleOfOperatingAndFinancingLeasesPresentedInBalanceSheetTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "ScheduleOfOperatingAndFinancingLeasesPresentedInBalanceSheetTableTextBlock",
     "presentation": [
      "http://www.spy.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Operating And Financing Leases Presented In Balance Sheet Table [Text Block]",
        "terseLabel": "Summary of Operating and Finance Leases Presented in Balance Sheet",
        "documentation": "Schedule of operating and financing leases presented in balance sheet."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract",
     "presentation": [
      "http://www.spy.com/role/StatementOfAssetsAcquiredAndLiabilitiesAssumed"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "agle_ClassOfWarrantOrRightOfferingPriceOfWarrantsOrRights": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "ClassOfWarrantOrRightOfferingPriceOfWarrantsOrRights",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails",
      "http://www.spy.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class Of Warrant Or Right Offering Price Of Warrants Or Rights",
        "verboseLabel": "Offering price of warrant",
        "terseLabel": "Offering price of warrant (in dollars per share)",
        "documentation": "Class of warrant or right offering price of warrants or rights."
       }
      }
     },
     "auth_ref": []
    },
    "agle_SummaryOfWeightedAverageRemainingLeaseTermAndDiscountRatesOfOperatingAndFinanceLeasesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "SummaryOfWeightedAverageRemainingLeaseTermAndDiscountRatesOfOperatingAndFinanceLeasesTableTextBlock",
     "presentation": [
      "http://www.spy.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary Of Weighted Average Remaining Lease Term And Discount Rates Of Operating And Finance Leases Table [Text Block]",
        "terseLabel": "Summary of Weighted Average Remaining Lease Term and Discount Rates For Company's Operating and Finance Leases",
        "documentation": "Summary of weighted average remaining lease term and discount rates of operating and finance leases."
       }
      }
     },
     "auth_ref": []
    },
    "agle_ScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "ScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.spy.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Maturities Of Operating And Finance Lease Liabilities Table [Text Block]",
        "terseLabel": "Schedule of Maturities of Operating and Finance Lease Liabilities",
        "documentation": "Schedule of maturities of operating and finance lease liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "agle_WarrantExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "WarrantExpirationDate",
     "presentation": [
      "http://www.spy.com/role/StockholdersEquitySummaryOfPreFundedWarrantsForCommonStockIssuedAndOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Expiration Date",
        "terseLabel": "Expiration Date",
        "documentation": "Warrant expiration date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Employee and Non-Employee Stock Option Activity",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r21",
      "r79"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "verboseLabel": "Assumptions used to Estimate the Fair Value of Stock Options Granted",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r170"
     ]
    },
    "agle_MaximumOwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercised": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "MaximumOwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercised",
     "presentation": [
      "http://www.spy.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum Ownership Percentage For Outstanding Warrants To Purchase Shares Of Common Stock To Be Exercised",
        "terseLabel": "Maximum ownership percentage of common stock shares for outstanding warrants to be exercised",
        "documentation": "Maximum ownership percentage for outstanding warrants to purchase shares of common stock to be exercised."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.spy.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r807"
     ]
    },
    "agle_ScheduleOfBalancesDueToAffiliatesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "ScheduleOfBalancesDueToAffiliatesTableTextBlock",
     "presentation": [
      "http://www.spy.com/role/RelatedPartyTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Balances Due To Affiliates [Table Text Block]",
        "terseLabel": "Related Party Accounts Payable",
        "documentation": "Schedule of balances due to affiliates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r192",
      "r823",
      "r834"
     ]
    },
    "agle_PeriodAfterNoticeReceivedByCompanyMaximumOwnershipPercentageToBeEffectiveDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "PeriodAfterNoticeReceivedByCompanyMaximumOwnershipPercentageToBeEffectiveDescription",
     "presentation": [
      "http://www.spy.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Period After Notice Received By Company Maximum Ownership Percentage To Be Effective Description",
        "terseLabel": "Period after notice received by company maximum ownership percentage to be effective description",
        "documentation": "Period after notice received by company maximum ownership percentage to be effective description."
       }
      }
     },
     "auth_ref": []
    },
    "agle_CompanyAndBasisOfPresentationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "CompanyAndBasisOfPresentationTable",
     "presentation": [
      "http://www.spy.com/role/TheCompanyAndBasisOfPresentationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company And Basis Of Presentation [Table]",
        "terseLabel": "Company and Basis of Presentation [Table]",
        "documentation": "Company and basis of presentation."
       }
      }
     },
     "auth_ref": []
    },
    "agle_OwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercisedToCertainHolders": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "OwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercisedToCertainHolders",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails",
      "http://www.spy.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership Percentage For Outstanding Warrants To Purchase Shares Of Common Stock To Be Exercised To Certain Holders",
        "verboseLabel": "Ownership percentage for outstanding warrants To purchase shares of common stock to be exercised to certain holders",
        "definitionGuidance": "Ownership percentage for outstanding warrants to purchase shares of common stock to be exercised to certain holders",
        "documentation": "Ownership percentage for outstanding warrants To purchase shares of common stock to be exercised to certain holders."
       }
      }
     },
     "auth_ref": []
    },
    "agle_Spyre2023EquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "Spyre2023EquityIncentivePlanMember",
     "presentation": [
      "http://www.spy.com/role/AssetAcquisitionNarrativeDetails",
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails",
      "http://www.spy.com/role/TheCompanyAndBasisOfPresentationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Spyre 2023 Equity Incentive Plan [Member]",
        "terseLabel": "Spyre 2023 Equity Incentive Plan",
        "documentation": "Spyre 2023 equity incentive plan."
       }
      }
     },
     "auth_ref": []
    },
    "agle_ProceedsFromIssuanceOfCommonStockGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "ProceedsFromIssuanceOfCommonStockGross",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds From Issuance Of Common Stock Gross",
        "terseLabel": "Proceeds from issuance of common stock gross",
        "documentation": "Proceeds from issuance of common stock gross."
       }
      }
     },
     "auth_ref": []
    },
    "agle_AssetAcquisitionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "AssetAcquisitionMember",
     "presentation": [
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.spy.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails",
      "http://www.spy.com/role/SeriesANonVotingConvertiblePreferredStockDetails",
      "http://www.spy.com/role/TheCompanyAndBasisOfPresentationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Member]",
        "terseLabel": "Asset Acquisition",
        "documentation": "Asset acquisition."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.spy.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.spy.com/role/SeriesANonVotingConvertiblePreferredStockDetails",
      "http://www.spy.com/role/TheCompanyAndBasisOfPresentationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Private Placement",
        "terseLabel": "Gross proceeds received in private placement",
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "agle_FebruaryTwoThousandNinteenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "FebruaryTwoThousandNinteenMember",
     "presentation": [
      "http://www.spy.com/role/StockholdersEquitySummaryOfPreFundedWarrantsForCommonStockIssuedAndOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "February Two Thousand Ninteen [Member]",
        "terseLabel": "February 2019",
        "documentation": "February two thousand ninteen."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.spy.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.spy.com/role/FairValueMeasurementsSignificantInputsUsedToEstimateTheFairValueOfDerivativeLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r373",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r556",
      "r557",
      "r558",
      "r775",
      "r776",
      "r780",
      "r781",
      "r782"
     ]
    },
    "agle_AprilTwoThousandTwentyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "AprilTwoThousandTwentyMember",
     "presentation": [
      "http://www.spy.com/role/StockholdersEquitySummaryOfPreFundedWarrantsForCommonStockIssuedAndOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "April Two Thousand Twenty [Member]",
        "terseLabel": "April 2020",
        "documentation": "April two thousand twenty Member."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.spy.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.spy.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.spy.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails",
      "http://www.spy.com/role/IncomeTaxesSummaryOfDifferenceBetweenProvisionForIncomeTaxesAndAmountsComputedByApplyingStatutoryFederalIncomeTaxRateToIncomeBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority",
        "documentation": "Information by tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "agle_CashCashEquivalentsMarketableSecuritiesAndRestrictedCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "CashCashEquivalentsMarketableSecuritiesAndRestrictedCash",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/TheCompanyAndBasisOfPresentationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Cash Equivalents Marketable Securities And Restricted Cash",
        "terseLabel": "Cash, cash equivalents, marketable securities, and restricted cash",
        "documentation": "Cash, cash equivalents, marketable securities and restricted cash."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/StatementOfAssetsAcquiredAndLiabilitiesAssumed": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.spy.com/role/StatementOfAssetsAcquiredAndLiabilitiesAssumed"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net",
        "totalLabel": "Net liabilities assumed",
        "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r88"
     ]
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://www.spy.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Summary of Lease Cost",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r909"
     ]
    },
    "agle_AssetAcquisitionStockholderPaymentPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "AssetAcquisitionStockholderPaymentPeriod",
     "presentation": [
      "http://www.spy.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.spy.com/role/TheCompanyAndBasisOfPresentationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition, Stockholder Payment Period",
        "terseLabel": "Asset acquisition, stockholder payment period",
        "documentation": "Asset Acquisition, Stockholder Payment Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityTables",
      "http://www.spy.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]",
        "verboseLabel": "Summary of Pre-funded Warrants for Common Stock Issued and Outstanding",
        "terseLabel": "Pre-funded Warrants for Common Stock Issued and Outstanding",
        "documentation": "Tabular disclosure of the notional amounts of outstanding derivative positions."
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "agle_PlacementAgentAndOtherOfferingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "PlacementAgentAndOtherOfferingExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.spy.com/role/TheCompanyAndBasisOfPresentationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Placement Agent And Other Offering Expenses",
        "terseLabel": "Placement agent and other offering expenses in private placement",
        "documentation": "Placement agent and other offering expenses."
       }
      }
     },
     "auth_ref": []
    },
    "agle_AssetAcquisitionCashPaymentThresholdPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "AssetAcquisitionCashPaymentThresholdPeriod",
     "presentation": [
      "http://www.spy.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.spy.com/role/TheCompanyAndBasisOfPresentationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition, Cash Payment, Threshold Period",
        "terseLabel": "Asset acquisition, cash payment, threshold period",
        "documentation": "Asset Acquisition, Cash Payment, Threshold Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 36.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "terseLabel": "Effect of exchange rate on cash, cash equivalents, and restricted cash",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r519"
     ]
    },
    "agle_FairmountFundsManagementLlcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "FairmountFundsManagementLlcMember",
     "presentation": [
      "http://www.spy.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fairmount Funds Management LLC [Member]",
        "terseLabel": "Fairmount Funds Management LLC",
        "documentation": "Fairmount Funds Management LLC."
       }
      }
     },
     "auth_ref": []
    },
    "agle_NumberOfEmployeesRetained": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "NumberOfEmployeesRetained",
     "presentation": [
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.spy.com/role/TheCompanyAndBasisOfPresentationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Employees Retained",
        "terseLabel": "Number of employees retained",
        "documentation": "Number of employees retained."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodStartLabel": "Beginning of period",
        "periodEndLabel": "End of period",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r145",
      "r235"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityAssumptionsUsedToEstimateTheFairValueOfStockOptionsGrantedDetails",
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "us-gaap_AssetImpairmentCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetImpairmentCharges",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Impairment Charges",
        "terseLabel": "Lease ROU asset and leasehold improvement impairment loss",
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r60"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "periodStartLabel": "Beginning of period",
        "periodEndLabel": "End of period",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r145",
      "r235"
     ]
    },
    "agle_OwnershipInterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "OwnershipInterestMember",
     "presentation": [
      "http://www.spy.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership Interest [Member]",
        "terseLabel": "Ownership Interest",
        "documentation": "Ownership Interest"
       }
      }
     },
     "auth_ref": []
    },
    "agle_WorkingCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "WorkingCapital",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/TheCompanyAndBasisOfPresentationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Working Capital",
        "terseLabel": "Working capital",
        "documentation": "Working capital."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "NET INCREASE IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r145"
     ]
    },
    "us-gaap_AwardDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardDateAxis",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityPreFundedWarrantsForCommonStockIssuedAndOutstandingDetails",
      "http://www.spy.com/role/StockholdersEquitySummaryOfPreFundedWarrantsForCommonStockIssuedAndOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Date [Axis]",
        "documentation": "Information by date or year award under share-based payment arrangement is granted."
       }
      }
     },
     "auth_ref": [
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890"
     ]
    },
    "agle_ParagonAndParapyreHoldingLlcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "ParagonAndParapyreHoldingLlcMember",
     "presentation": [
      "http://www.spy.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Paragon and Parapyre Holding LLC [Member]",
        "verboseLabel": "Paragon and Parapyre Holding LLC"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/LeasesScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetailsAlternate1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/LeasesScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Imputed interest",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r540"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/LeasesScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetailsAlternate1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/LeasesScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability",
        "terseLabel": "Total",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r529"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.spy.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
      "http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold Improvements",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r152"
     ]
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "presentation": [
      "http://www.spy.com/role/StrategicLicenseAgreementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "terseLabel": "Summary of Changes in Contract Liabilities",
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability."
       }
      }
     },
     "auth_ref": [
      "r861"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/LeasesScheduleOfOperatingAndFinancingLeasesPresentedInBalanceSheetDetails": {
       "parentTag": "agle_OperatingAndFinanceLeaseLiabilities",
       "weight": 1.0,
       "order": 6.0
      },
      "http://www.spy.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.spy.com/role/LeasesScheduleOfOperatingAndFinancingLeasesPresentedInBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities",
        "verboseLabel": "Operating lease liabilities, current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r529"
     ]
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share, basic (in dollars per share)",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r230",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r261",
      "r263",
      "r266",
      "r267",
      "r268",
      "r272",
      "r505",
      "r506",
      "r599",
      "r622",
      "r770"
     ]
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.spy.com/role/FairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r507"
     ]
    },
    "us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss",
        "terseLabel": "Realized gains or losses on marketable securities",
        "documentation": "Amount of realized gain (loss) on investment in marketable security."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Issued",
        "verboseLabel": "Common stock, issued (in shares)",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r127"
     ]
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquitySharesIssued",
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Shares Issued",
        "terseLabel": "Series A non-voting convertible preferred stock, issued (in shares)",
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.spy.com/role/ParagonAgreementDetails",
      "http://www.spy.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r243",
      "r244",
      "r372",
      "r380",
      "r548",
      "r766",
      "r767"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails",
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityStockBasedCompensationExpenseDetails",
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquitySummaryOfEmployeeRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners",
     "presentation": [
      "http://www.spy.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary, Ownership Percentage, Noncontrolling Owner",
        "terseLabel": "Percentage of ownership by noncontrolling owner",
        "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 24.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r608",
      "r793"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/LeasesScheduleOfOperatingAndFinancingLeasesPresentedInBalanceSheetDetails": {
       "parentTag": "agle_OperatingAndFinanceLeaseLiabilities",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.spy.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.spy.com/role/LeasesScheduleOfOperatingAndFinancingLeasesPresentedInBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Non-current operating lease liabilities",
        "verboseLabel": "Operating lease liabilities, noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r529"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.spy.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized",
        "verboseLabel": "Common stock, authorized (in shares)",
        "terseLabel": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r680"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Outstanding",
        "verboseLabel": "Common stock, outstanding (in shares)",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r127",
      "r680",
      "r699",
      "r927",
      "r928"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/AccruedAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/AccruedAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Accrued other",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "us-gaap_TemporaryEquitySharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquitySharesAuthorized",
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Shares Authorized",
        "terseLabel": "Series A non-voting convertible preferred stock, authorized (in shares)",
        "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquitySharesOutstanding",
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Shares Outstanding",
        "terseLabel": "Series A non-voting convertible preferred stock, outstanding (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "us-gaap_LetterOfCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LetterOfCreditMember",
     "presentation": [
      "http://www.spy.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Letter of Credit [Member]",
        "terseLabel": "Letter of Credit Member",
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/LeasesSummaryOfLeaseCostDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.spy.com/role/LeasesSummaryOfLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost",
        "totalLabel": "Total lease cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r534",
      "r792"
     ]
    },
    "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract",
     "presentation": [
      "http://www.spy.com/role/LeasesScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, to be Paid [Abstract]",
        "terseLabel": "Finance Lease Liabilities, Payments, Due [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/LeasesSummaryOfLeaseCostDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/LeasesSummaryOfLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r535",
      "r792"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.spy.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.spy.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails",
      "http://www.spy.com/role/IncomeTaxesSummaryOfDifferenceBetweenProvisionForIncomeTaxesAndAmountsComputedByApplyingStatutoryFederalIncomeTaxRateToIncomeBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority",
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VariableLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/LeasesSummaryOfLeaseCostDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/LeasesSummaryOfLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease cost",
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases."
       }
      }
     },
     "auth_ref": [
      "r536",
      "r792"
     ]
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/RestructuringChargesChargesRelatedToTheRestructuringActivitiesDetails": {
       "parentTag": "us-gaap_RestructuringCosts",
       "weight": -1.0,
       "order": 3.0
      },
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://www.spy.com/role/RestructuringChargesChargesRelatedToTheRestructuringActivitiesDetails",
      "http://www.spy.com/role/RestructuringChargesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedLabel": "Loss on disposal of long-lived assets",
        "negatedTerseLabel": "Loss on Disposal of Long Lived Assets",
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://www.spy.com/role/AccruedLiabilitiesAdditionalInformationDetails",
      "http://www.spy.com/role/ParagonAgreementDetails",
      "http://www.spy.com/role/RelatedPartyTransactionsExpensesRelatedToRelatedPartyWhichWereSettledInCashDetails",
      "http://www.spy.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://www.spy.com/role/RelatedPartyTransactionsRelatedPartyAccountsPayableDetails",
      "http://www.spy.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction [Domain]",
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupNotDiscontinuedOperationGainLossOnDisposal",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      },
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://www.spy.com/role/SaleOfPegzilarginaseToImmedicaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal",
        "negatedTerseLabel": "Gain recognized within operating expenses",
        "negatedLabel": "Gain on sale of in-process research and development asset",
        "terseLabel": "Gain recognized within operating expenses",
        "documentation": "Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations."
       }
      }
     },
     "auth_ref": [
      "r344",
      "r833",
      "r853"
     ]
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.spy.com/role/NetLossPerShareWeightedAverageEquityInstrumentsExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract",
     "presentation": [
      "http://www.spy.com/role/StatementOfAssetsAcquiredAndLiabilitiesAssumed"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate",
        "terseLabel": "Percentage of discount through payroll deductions to eligible employees to purchase common stock",
        "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesEstimatedFairValueOfCashEquivalentsAndMarketableSecuritiesAndTheGrossUnrealizedGainsAndLossesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesEstimatedFairValueOfCashEquivalentsAndMarketableSecuritiesAndTheGrossUnrealizedGainsAndLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Marketable securities, amortized cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r296",
      "r335",
      "r603"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period",
        "terseLabel": "Number of shares issued",
        "documentation": "Number of shares issued under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses (income):"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Liabilities, Convertible Preferred Stock and Stockholders' (Deficit) Equity",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r411",
      "r414",
      "r445",
      "r446",
      "r448",
      "r786"
     ]
    },
    "us-gaap_VestingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VestingAxis",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting",
        "documentation": "Information by vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract",
     "presentation": [
      "http://www.spy.com/role/StatementOfAssetsAcquiredAndLiabilitiesAssumed"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r156"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r704"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.spy.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersDeficitEquity",
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r246",
      "r247",
      "r248",
      "r273",
      "r585",
      "r639",
      "r663",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r680",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r689",
      "r690",
      "r691",
      "r692",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r700",
      "r703",
      "r704",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r724",
      "r799"
     ]
    },
    "us-gaap_VestingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VestingDomain",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting",
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract",
     "presentation": [
      "http://www.spy.com/role/StatementOfAssetsAcquiredAndLiabilitiesAssumed"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract]",
        "terseLabel": "ASSETS ACQUIRED"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract",
     "presentation": [
      "http://www.spy.com/role/StatementOfAssetsAcquiredAndLiabilitiesAssumed"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities [Abstract]",
        "terseLabel": "LIABILITIES ASSUMED"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.spy.com/role/NetLossPerShareWeightedAverageEquityInstrumentsExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock",
     "presentation": [
      "http://www.spy.com/role/RelatedPartyTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Related Party Transactions [Table Text Block]",
        "terseLabel": "Expenses related to Related Party which were Settled in Cash",
        "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.spy.com/role/NetLossPerShareWeightedAverageEquityInstrumentsExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquitySummaryOfEmployeeAndNonEmployeeStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term, Outstanding",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r169"
     ]
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://www.spy.com/role/AccruedLiabilitiesAdditionalInformationDetails",
      "http://www.spy.com/role/ParagonAgreementDetails",
      "http://www.spy.com/role/RelatedPartyTransactionsExpensesRelatedToRelatedPartyWhichWereSettledInCashDetails",
      "http://www.spy.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://www.spy.com/role/RelatedPartyTransactionsRelatedPartyAccountsPayableDetails",
      "http://www.spy.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Axis]",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r545",
      "r546",
      "r911"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquitySummaryOfEmployeeAndNonEmployeeStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term, Options exercisable",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.spy.com/role/NetLossPerShareWeightedAverageEquityInstrumentsExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r269"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquitySummaryOfEmployeeAndNonEmployeeStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term, Options vested and expected to vest",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r435"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityAssumptionsUsedToEstimateTheFairValueOfStockOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r439"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/FairValueMeasurementsChangesInDerivativeLiabilitiesDetails",
      "http://www.spy.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "terseLabel": "Financial liabilities outstanding measured at fair value",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityStockBasedCompensationExpenseDetails",
      "http://www.spy.com/role/RestructuringChargesChargesRelatedToTheRestructuringActivitiesDetails",
      "http://www.spy.com/role/RestructuringChargesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "verboseLabel": "General and Administrative",
        "terseLabel": "General and administrative",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableTrade": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayableTrade",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Payable, Trade",
        "terseLabel": "Accounts payable",
        "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.spy.com/role/NetLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r260",
      "r269",
      "r270",
      "r271"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.spy.com/role/NetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Weighted-Average Equity Instruments Excluded from Calculation of Diluted Net Loss Per Share",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesCurrentAndNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/AccruedLiabilitiesAccruedAndOtherCurrentLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.spy.com/role/AccruedLiabilitiesAccruedAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities",
        "totalLabel": "Accrued liabilities",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities."
       }
      }
     },
     "auth_ref": [
      "r106"
     ]
    },
    "us-gaap_EarliestTaxYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarliestTaxYearMember",
     "presentation": [
      "http://www.spy.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earliest Tax Year [Member]",
        "terseLabel": "Earliest Tax Year",
        "documentation": "Earliest identified tax year."
       }
      }
     },
     "auth_ref": [
      "r896"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.spy.com/role/NetLossPerShareWeightedAverageEquityInstrumentsExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]",
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 27.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.spy.com/role/TheCompanyAndBasisOfPresentationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit",
        "negatedLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r162",
      "r611",
      "r634",
      "r636",
      "r645",
      "r681",
      "r793"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesEstimatedFairValueOfCashEquivalentsAndMarketableSecuritiesAndTheGrossUnrealizedGainsAndLossesDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesEstimatedFairValueOfCashEquivalentsAndMarketableSecuritiesAndTheGrossUnrealizedGainsAndLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash equivalents, estimated fair value",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "agle_CashEquivalentsAndMarketableSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "CashEquivalentsAndMarketableSecuritiesLineItems",
     "presentation": [
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Equivalents And Marketable Securities [Line Items]",
        "terseLabel": "Cash Equivalents And Marketable Securities [Line Items]",
        "documentation": "Cash equivalents and marketable securities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/StatementOfAssetsAcquiredAndLiabilitiesAssumed": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/StatementOfAssetsAcquiredAndLiabilitiesAssumed"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets",
        "totalLabel": "Total assets acquired",
        "documentation": "Amount of assets acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r533"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r205",
      "r221",
      "r223",
      "r233",
      "r238",
      "r249",
      "r257",
      "r258",
      "r276",
      "r283",
      "r287",
      "r289",
      "r327",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r489",
      "r492",
      "r493",
      "r506",
      "r516",
      "r600",
      "r618",
      "r650",
      "r701",
      "r722",
      "r723",
      "r772",
      "r790",
      "r791",
      "r805",
      "r830",
      "r858"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits",
        "terseLabel": "Unrecognized Tax Benefits",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r463",
      "r470"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Date",
        "terseLabel": "Share based compensation plan expiration date",
        "documentation": "Date the equity-based award expires, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r866"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "agle_ImpairmentOfMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "ImpairmentOfMarketableSecurities",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment Of Marketable Securities",
        "terseLabel": "Impairment of marketable securities",
        "documentation": "Impairment of marketable securities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersDeficitEquity",
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss",
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net loss",
        "terseLabel": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r147",
      "r184",
      "r205",
      "r221",
      "r223",
      "r228",
      "r238",
      "r249",
      "r251",
      "r252",
      "r253",
      "r254",
      "r257",
      "r258",
      "r265",
      "r276",
      "r283",
      "r287",
      "r289",
      "r327",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r506",
      "r516",
      "r619",
      "r701",
      "r722",
      "r723",
      "r772",
      "r804",
      "r858"
     ]
    },
    "us-gaap_AwardDateDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardDateDomain",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityPreFundedWarrantsForCommonStockIssuedAndOutstandingDetails",
      "http://www.spy.com/role/StockholdersEquitySummaryOfPreFundedWarrantsForCommonStockIssuedAndOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Date [Domain]",
        "terseLabel": "Award Date [Domain]",
        "documentation": "Date or year award under share-based payment arrangement is granted."
       }
      }
     },
     "auth_ref": [
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890"
     ]
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.spy.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r550",
      "r552"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/StatementOfAssetsAcquiredAndLiabilitiesAssumed": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/StatementOfAssetsAcquiredAndLiabilitiesAssumed"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "terseLabel": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "agle_NumberOfDomesticBankingInstitutions": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "NumberOfDomesticBankingInstitutions",
     "presentation": [
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number Of Domestic Banking Institutions",
        "terseLabel": "Number of domestic banking institutions (in banks)",
        "documentation": "Number Of Domestic Banking Institutions"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/StatementOfAssetsAcquiredAndLiabilitiesAssumed": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/StatementOfAssetsAcquiredAndLiabilitiesAssumed"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities",
        "totalLabel": "Total liabilities assumed",
        "documentation": "Amount of liabilities assumed at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesIssuedBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesIssuedBasic",
     "presentation": [
      "http://www.spy.com/role/NetLossPerShareScheduleOfReconciliationOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Issued, Basic",
        "terseLabel": "Weighted average common shares",
        "documentation": "This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic)."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r54"
     ]
    },
    "agle_SeriesANonVotingConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "SeriesANonVotingConvertiblePreferredStockMember",
     "presentation": [
      "http://www.spy.com/role/AssetAcquisitionNarrativeDetails",
      "http://www.spy.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.spy.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersDeficitEquity",
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.spy.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.spy.com/role/SeriesANonVotingConvertiblePreferredStockDetails",
      "http://www.spy.com/role/SubsequentEventsAdditionalInformationDetails",
      "http://www.spy.com/role/TheCompanyAndBasisOfPresentationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A Non Voting Convertible Preferred Stock [Member]",
        "terseLabel": "Series A Non Voting Convertible Preferred Stock",
        "documentation": "Series A non voting convertible preferred stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "agle_AcquiredInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "AcquiredInProcessResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      },
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/AssetAcquisitionAssetAcquisitionCostDetails",
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesSummaryOfAssetAcquisitionCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquired In Process Research And Development",
        "terseLabel": "Acquired in-process research and development",
        "verboseLabel": "Acquired in-process research and development",
        "documentation": "Acquired in process research and development"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and Contingencies (Note 11)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r107",
      "r605",
      "r679"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/StatementOfAssetsAcquiredAndLiabilitiesAssumed": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/StatementOfAssetsAcquiredAndLiabilitiesAssumed"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets",
        "totalLabel": "Total current assets",
        "documentation": "Amount of assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "agle_DevelopmentFeeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "DevelopmentFeeMember",
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Development Fee [Member]",
        "verboseLabel": "Development Fee",
        "documentation": "Development fee member."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]",
        "terseLabel": "Summary of Employee Restricted Stock Activity",
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.spy.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails",
      "http://www.spy.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://www.spy.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Share-based payment award, term",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "agle_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersDeficitEquity",
      "http://www.spy.com/role/SeriesANonVotingConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of Series A non-voting convertible preferred stock (in shares)",
        "documentation": "Temporary Equity, Stock Issued During Period, Shares, New Issues"
       }
      }
     },
     "auth_ref": []
    },
    "agle_PaymentForDiscountPremiumOnInvestmentsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "PaymentForDiscountPremiumOnInvestmentsNet",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 21.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment For Discount Premium On Investments Net",
        "negatedLabel": "Purchase net (premium) discount on marketable securities",
        "documentation": "Payment for discount (premium) on investments net."
       }
      }
     },
     "auth_ref": []
    },
    "agle_LeasedAssetsObtainedInExchangeForLeaseObligations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "LeasedAssetsObtainedInExchangeForLeaseObligations",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leased Assets Obtained In Exchange For Lease Obligations",
        "terseLabel": "Leased assets obtained in exchange for lease obligations",
        "documentation": "Leased assets obtained in exchange for lease obligations."
       }
      }
     },
     "auth_ref": []
    },
    "agle_LesseeOperatingAndFinanceLeasesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "LesseeOperatingAndFinanceLeasesDisclosureTextBlock",
     "presentation": [
      "http://www.spy.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee Operating And Finance Leases Disclosure [Text Block]",
        "terseLabel": "Leases",
        "documentation": "Lessee operating and finance leases disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r58",
      "r59",
      "r193",
      "r194",
      "r197",
      "r198"
     ]
    },
    "agle_OptionAgreementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "OptionAgreementTextBlock",
     "presentation": [
      "http://www.spy.com/role/ParagonAgreement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Agreement [Text Block]",
        "terseLabel": "Paragon Agreement",
        "documentation": "Option agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/StatementOfAssetsAcquiredAndLiabilitiesAssumed": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/StatementOfAssetsAcquiredAndLiabilitiesAssumed"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable",
        "terseLabel": "Accrued liabilities",
        "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/StatementOfAssetsAcquiredAndLiabilitiesAssumed": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/StatementOfAssetsAcquiredAndLiabilitiesAssumed"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities",
        "totalLabel": "Total current liabilities",
        "documentation": "Amount of liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "agle_CollaborativeArrangementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "CollaborativeArrangementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement [Abstract]",
        "documentation": "Collaborative Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "agle_AccruedAndOtherCurrentLiabilitiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "AccruedAndOtherCurrentLiabilitiesTextBlock",
     "presentation": [
      "http://www.spy.com/role/AccruedAndOtherCurrentLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued And Other Current Liabilities [Text Block]",
        "terseLabel": "Accrued and Other Current Liabilities",
        "documentation": "The entire disclosure for accrued expenses, and other liabilities that are classified as current at the end of the reporting period."
       }
      }
     },
     "auth_ref": []
    },
    "agle_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfOfferingCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 33.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds From Issuance Of Common Stock And Pre Funded Warrants In Public Offering Net Of Offering Costs",
        "terseLabel": "Proceeds from issuance of common stock and pre-funded warrants in registered direct offering, net of offering costs",
        "documentation": "Proceeds from issuance of common stock and pre-funded warrants in public offering net of offering costs."
       }
      }
     },
     "auth_ref": []
    },
    "agle_IncreaseDecreaseInOperatingLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "IncreaseDecreaseInOperatingLeaseLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 23.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase Decrease In Operating Lease Liabilities",
        "terseLabel": "Operating lease liabilities",
        "documentation": "Increase decrease in operating lease liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromStockPlans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromStockPlans",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Stock Plans",
        "terseLabel": "Aggregate cash proceeds from sale of shares",
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.spy.com/role/TheCompanyAndBasisOfPresentationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r843"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares",
        "terseLabel": "Stock option vested",
        "documentation": "Number of options vested."
       }
      }
     },
     "auth_ref": []
    },
    "agle_TemporaryEquityFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "TemporaryEquityFinancingCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Financing Costs",
        "terseLabel": "Settlement of financing costs in connection with private placement of Series A non-voting convertible preferred stock",
        "documentation": "Temporary Equity, Financing Costs"
       }
      }
     },
     "auth_ref": []
    },
    "agle_StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Options Exercised And Employee Stock Ownership Plan",
        "terseLabel": "Issuance of common stock in connection with exercise of stock options and employee stock purchase plan",
        "documentation": "Stock Issued During Period, Value, Options Exercised And Employee Stock Ownership Plan"
       }
      }
     },
     "auth_ref": []
    },
    "agle_StockIssuedDuringPeriodSharesCommonStockAndPreFundedWarrantsRegisteredDirectOffering": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "StockIssuedDuringPeriodSharesCommonStockAndPreFundedWarrantsRegisteredDirectOffering",
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period Shares Common Stock And Pre Funded Warrants Registered Direct Offering",
        "terseLabel": "Issuance of common stock and pre-funded warrants in connection with registered direct offering, net of offering costs (in shares)",
        "documentation": "Stock issued during period shares common stock and pre funded warrants registered direct offering."
       }
      }
     },
     "auth_ref": []
    },
    "agle_StockIssuedDuringPeriodSharesOptionsExercisedAndEmployeeStockOwnershipPlan": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "StockIssuedDuringPeriodSharesOptionsExercisedAndEmployeeStockOwnershipPlan",
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Options Exercised And Employee Stock Ownership Plan",
        "terseLabel": "Issuance of common stock in connection with exercise of stock options and employee stock purchase plan (in shares)",
        "documentation": "Stock Issued During Period, Shares, Options Exercised And Employee Stock Ownership Plan"
       }
      }
     },
     "auth_ref": []
    },
    "agle_StockIssuedDuringPeriodValueCommonStockAndPreFundedWarrantsRegisteredDirectOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "StockIssuedDuringPeriodValueCommonStockAndPreFundedWarrantsRegisteredDirectOffering",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period Value Common Stock And Pre Funded Warrants Registered Direct Offering",
        "terseLabel": "Issuance of common stock and pre-funded warrants in connection with registered direct offering, net of offering costs",
        "documentation": "Stock issued during period value common stock and pre funded warrants registered direct offering."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable",
     "presentation": [
      "http://www.spy.com/role/StrategicLicenseAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]",
        "terseLabel": "Schedule Of Research And Development Arrangement Contract To Perform For Others [Table]",
        "documentation": "A schedule reflecting the terms of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements."
       }
      }
     },
     "auth_ref": [
      "r460",
      "r893"
     ]
    },
    "agle_ContingentValueRightDistributionToCommonStockholders": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "ContingentValueRightDistributionToCommonStockholders",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent Value Right Distribution To Common Stockholders",
        "verboseLabel": "CVR distribution to common stockholders",
        "documentation": "Contingent value right distribution to common stockholders."
       }
      }
     },
     "auth_ref": []
    },
    "agle_IssuanceOfCommonStockAndPreFundedWarrantsSharesInConnectionWithRegisteredDirectOfferingNetOfOfferingCosts": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "IssuanceOfCommonStockAndPreFundedWarrantsSharesInConnectionWithRegisteredDirectOfferingNetOfOfferingCosts",
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance Of Common Stock And Pre-Funded Warrants Shares In Connection With Registered Direct Offering, Net Of Offering Costs",
        "verboseLabel": "Issuance of common stock and pre-funded warrants in connection with registered direct offering, net of offering costs (in shares)",
        "documentation": "Issuance of common stock and pre-funded warrants shares in connection with registered direct offering, net of offering costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "presentation": [
      "http://www.spy.com/role/StrategicLicenseAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type",
        "documentation": "Information by form of arrangement related to research and development."
       }
      }
     },
     "auth_ref": [
      "r460",
      "r893"
     ]
    },
    "agle_IssuanceOfCommonStockAndPreFundedWarrantsValueInConnectionWithRegisteredDirectOfferingNetOfOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "IssuanceOfCommonStockAndPreFundedWarrantsValueInConnectionWithRegisteredDirectOfferingNetOfOfferingCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance Of Common Stock And Pre-Funded Warrants Value In Connection With Registered Direct Offering, Net Of Offering Costs",
        "verboseLabel": "Issuance of common stock and pre-funded warrants in connection with registered direct offering, net of offering costs",
        "documentation": "Issuance of common stock and pre-funded warrants value in connection with registered direct offering, net of offering costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue",
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r584",
      "r832"
     ]
    },
    "agle_IssuanceOfCommonStockInConnectionWithExerciseOfPreFundedWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "IssuanceOfCommonStockInConnectionWithExerciseOfPreFundedWarrants",
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance Of Common Stock In Connection With Exercise Of Pre-Funded Warrants",
        "verboseLabel": "Issuance of common stock in connection with exercise of pre-funded warrants (in shares)",
        "documentation": "Issuance of common stock in connection with exercise of pre-funded warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentTypeAxis",
     "presentation": [
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesAvailableForSaleSecuritiesInAnUnrealizedLossPositionDetails",
      "http://www.spy.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type",
        "documentation": "Information by type of investments."
       }
      }
     },
     "auth_ref": [
      "r664",
      "r665",
      "r666",
      "r667",
      "r669",
      "r732",
      "r734",
      "r736",
      "r739",
      "r740",
      "r745",
      "r746",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r798"
     ]
    },
    "us-gaap_StockIssued1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssued1",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued",
        "terseLabel": "Settlement of forward contract liability and issuance of Series A non-voting convertible preferred stock in connection with the asset acquisition of Spyre",
        "documentation": "The fair value of stock issued in noncash financing activities."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r51",
      "r52"
     ]
    },
    "agle_StockIssuedDuringPeriodSharesCommonStockAndPreFundedWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "StockIssuedDuringPeriodSharesCommonStockAndPreFundedWarrants",
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period Shares Common Stock And Pre Funded Warrants",
        "terseLabel": "Issuance of common stock and pre-funded warrants in connection with public and at-the-market offerings, net of offering costs (in shares)",
        "documentation": "Stock issued during period shares, common stock and pre-funded warrants."
       }
      }
     },
     "auth_ref": []
    },
    "agle_StockIssuedDuringPeriodValueCommonStockAndPreFundedWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "StockIssuedDuringPeriodValueCommonStockAndPreFundedWarrants",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period Value Common Stock And Pre Funded Warrants",
        "terseLabel": "Issuance of common stock and pre-funded warrants in connection with public and at-the-market offerings, net of offering costs",
        "documentation": "Stock issued during period value, common stock and pre-funded warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "presentation": [
      "http://www.spy.com/role/StrategicLicenseAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type",
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others."
       }
      }
     },
     "auth_ref": [
      "r460",
      "r893"
     ]
    },
    "agle_ContingentValueRightLiabilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "ContingentValueRightLiabilityMember",
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://www.spy.com/role/FairValueMeasurementsChangesInDerivativeLiabilitiesDetails",
      "http://www.spy.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.spy.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.spy.com/role/FairValueMeasurementsSignificantInputsUsedToEstimateTheFairValueOfDerivativeLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent Value Right Liability [Member]",
        "terseLabel": "CVR liability",
        "documentation": "Contingent Value Right Liability"
       }
      }
     },
     "auth_ref": []
    },
    "agle_NonCashOperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "NonCashOperatingLeaseExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 22.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non Cash Operating Lease Expense",
        "terseLabel": "Non-cash operating lease expense",
        "documentation": "Non-cash operating lease expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems",
     "presentation": [
      "http://www.spy.com/role/StrategicLicenseAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Arrangement, Contract to Perform for Others [Line Items]",
        "terseLabel": "Research And Development Arrangement Contract To Perform For Others [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r460",
      "r893"
     ]
    },
    "us-gaap_AssetAcquisitionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionTextBlock",
     "presentation": [
      "http://www.spy.com/role/AssetAcquisition",
      "http://www.spy.com/role/ParapyreOptionObligation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Text Block]",
        "terseLabel": "Asset Acquisition",
        "verboseLabel": "Parapyre Option Obligation",
        "documentation": "The entire disclosure for asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r899"
     ]
    },
    "us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionContingentConsiderationLiabilityCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/ParapyreOptionObligationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition, Contingent Consideration, Liability, Current",
        "terseLabel": "Asset acquisition, contingent consideration, liability, current",
        "documentation": "Amount of liability recognized from contingent consideration in asset acquisition, classified as current."
       }
      }
     },
     "auth_ref": [
      "r899"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerProductAndServiceExtensibleList",
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer, Product and Service [Extensible Enumeration]",
        "terseLabel": "Revenue from Contract with Customer, Product and Service [Extensible Enumeration]",
        "documentation": "Indicates product and service for revenue from satisfaction of performance obligation by transferring promised product and service to customer."
       }
      }
     },
     "auth_ref": [
      "r779"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAxis",
     "presentation": [
      "http://www.spy.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents",
        "documentation": "Information by type of cash and cash equivalent balance."
       }
      }
     },
     "auth_ref": [
      "r208"
     ]
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityStockBasedCompensationExpenseDetails",
      "http://www.spy.com/role/RelatedPartyTransactionsExpensesRelatedToRelatedPartyWhichWereSettledInCashDetails",
      "http://www.spy.com/role/RestructuringChargesChargesRelatedToTheRestructuringActivitiesDetails",
      "http://www.spy.com/role/RestructuringChargesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r345",
      "r350",
      "r709"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carryforwards",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityStockBasedCompensationExpenseDetails",
      "http://www.spy.com/role/RelatedPartyTransactionsExpensesRelatedToRelatedPartyWhichWereSettledInCashDetails",
      "http://www.spy.com/role/RestructuringChargesChargesRelatedToTheRestructuringActivitiesDetails",
      "http://www.spy.com/role/RestructuringChargesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location",
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r350",
      "r709"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails",
      "http://www.spy.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "verboseLabel": "Subsequent Event",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r527",
      "r551"
     ]
    },
    "us-gaap_TaxPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxPeriodAxis",
     "presentation": [
      "http://www.spy.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Period [Axis]",
        "terseLabel": "Tax Period",
        "documentation": "Information about the period subject to enacted tax laws."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 28.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "terseLabel": "Series A non-voting convertible preferred stock, $0.0001 par value; 1,086,341 and no shares authorized as of September\u00a030, 2023 and December\u00a031, 2022, respectively; 1,086,339 and no shares issued and outstanding as of September\u00a030, 2023 and December\u00a031, 2022, respectively",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r363",
      "r365",
      "r366",
      "r367",
      "r370",
      "r371",
      "r456",
      "r609"
     ]
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock",
     "presentation": [
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecurities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, and Marketable Securities [Text Block]",
        "terseLabel": "Cash Equivalents and Marketable Securities",
        "documentation": "The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r845"
     ]
    },
    "us-gaap_TaxPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxPeriodDomain",
     "presentation": [
      "http://www.spy.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Period [Domain]",
        "terseLabel": "Tax Period",
        "documentation": "Identified tax period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails",
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityPreFundedWarrantsForCommonStockIssuedAndOutstandingDetails",
      "http://www.spy.com/role/StockholdersEquityAdditionalInformationDetails",
      "http://www.spy.com/role/StockholdersEquitySummaryOfPreFundedWarrantsForCommonStockIssuedAndOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "definitionGuidance": "Exercise price per warrant",
        "verboseLabel": "Exercise Price (in dollars per share)",
        "presentationGuidance": "Exercise price per warrant (in dollars per share)",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r393"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersDeficitEquity",
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "verboseLabel": "Unrealized (loss) gain on marketable securities",
        "terseLabel": "Unrealized gain (loss) on marketable securities",
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r219",
      "r220",
      "r325"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/RestructuringChargesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Accelerated Cost",
        "terseLabel": "Non-cash stock-based compensation expense related to accelerated vesting of stock-based awards",
        "documentation": "Amount of additional cost recognized for award under share-based payment arrangement from occurrence of event accelerating recognition of cost."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquitySummaryOfEmployeeAndNonEmployeeStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Forfeited",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r425"
     ]
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://www.spy.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Additional number of shares available for grant",
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupClassificationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupClassificationAxis",
     "presentation": [
      "http://www.spy.com/role/SaleOfPegzilarginaseToImmedicaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group Classification [Axis]",
        "terseLabel": "Disposal Group Classification [Axis]",
        "documentation": "Information by disposal group classification."
       }
      }
     },
     "auth_ref": [
      "r204"
     ]
    },
    "us-gaap_PreferredStockTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockTextBlock",
     "presentation": [
      "http://www.spy.com/role/SeriesANonVotingConvertiblePreferredStock"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock [Text Block]",
        "terseLabel": "Series A Non-Voting Convertible Preferred Stock",
        "documentation": "The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock."
       }
      }
     },
     "auth_ref": [
      "r159"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquitySummaryOfEmployeeAndNonEmployeeStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Exercised",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r424"
     ]
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares, Outstanding",
        "periodStartLabel": "Balances (in shares)",
        "periodEndLabel": "Balances (in shares)",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Pro-rated estimated fair value of options",
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock."
       }
      }
     },
     "auth_ref": [
      "r434"
     ]
    },
    "us-gaap_DisposalGroupClassificationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupClassificationDomain",
     "presentation": [
      "http://www.spy.com/role/SaleOfPegzilarginaseToImmedicaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group Classification [Domain]",
        "terseLabel": "Disposal Group Classification [Domain]",
        "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityStockAwardsGrantedDetails",
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquitySummaryOfEmployeeAndNonEmployeeStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Grant Date Fair Value (in dollars per share)",
        "verboseLabel": "Weighted Average Exercise Price, Granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r423"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesContractualMaturitiesOfMarketableSecuritiesAtEstimatedFairValueDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesContractualMaturitiesOfMarketableSecuritiesAtEstimatedFairValueDetails",
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesEstimatedFairValueOfCashEquivalentsAndMarketableSecuritiesAndTheGrossUnrealizedGainsAndLossesDetails",
      "http://www.spy.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Current",
        "terseLabel": "Marketable securities",
        "verboseLabel": "Marketable securities, estimated fair value",
        "totalLabel": "Total marketable securities",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current."
       }
      }
     },
     "auth_ref": [
      "r294",
      "r335"
     ]
    },
    "agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Additional Number Of Shares Available For Grant",
        "terseLabel": "Additional number of shares available for issuance",
        "documentation": "Share-based compensation arrangement by share-based payment award, additional number of shares available for grant."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/FairValueMeasurementsChangesInDerivativeLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances",
        "terseLabel": "Fair value at CVR issuance",
        "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "us-gaap_ContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/StrategicLicenseAgreementsChangesInContractLiabilitiesDetails",
      "http://www.spy.com/role/StrategicLicenseAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Liability",
        "terseLabel": "Deferred revenue",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r395",
      "r396",
      "r400"
     ]
    },
    "agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAnnualFairMarketValuePerEmployee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAnnualFairMarketValuePerEmployee",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Maximum Annual Fair Market Value Per Employee",
        "terseLabel": "Maximum purchase value per employee under employee stock purchase plan",
        "documentation": "Share based compensation arrangement by share based payment award maximum annual fair market value per employee."
       }
      }
     },
     "auth_ref": []
    },
    "agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalAnnualPercentageIncrease": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalAnnualPercentageIncrease",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Additional Annual Percentage Increase",
        "terseLabel": "Additional annual percentage increase of common stock",
        "documentation": "Share based compensation arrangement by share based payment award additional annual percentage increase."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/FairValueMeasurementsChangesInDerivativeLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements",
        "negatedTerseLabel": "Issuance of Series A Preferred Stock on July 7, 2023",
        "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "agle_ImmedicaPharmaABMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "ImmedicaPharmaABMember",
     "presentation": [
      "http://www.spy.com/role/StrategicLicenseAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Immedica Pharma A B [Member]",
        "terseLabel": "Immedica Pharma AB",
        "documentation": "Immedica Pharma AB"
       }
      }
     },
     "auth_ref": []
    },
    "agle_UniversityOfTexasAtAustinMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "UniversityOfTexasAtAustinMember",
     "presentation": [
      "http://www.spy.com/role/StrategicLicenseAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "University of Texas at Austin [Member]",
        "terseLabel": "University of Texas at Austin",
        "documentation": "University of Texas at Austin."
       }
      }
     },
     "auth_ref": []
    },
    "agle_PercentageOfPaymentForCostIncurredInPIPTrial": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "PercentageOfPaymentForCostIncurredInPIPTrial",
     "presentation": [
      "http://www.spy.com/role/StrategicLicenseAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage Of Payment For Cost Incurred In P I P Trial",
        "terseLabel": "Percentage of payment for cost incurred in PIP trial",
        "documentation": "Percentage of payment for cost incurred in pip trial."
       }
      }
     },
     "auth_ref": []
    },
    "agle_ContractWithCustomerFullReimbursementOfCostsIncludedLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "ContractWithCustomerFullReimbursementOfCostsIncludedLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/StrategicLicenseAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract With Customer, Full Reimbursement Of Costs Included Liability",
        "terseLabel": "Full reimbursement of costs included in upfront fixed payment received",
        "documentation": "Contract With Customer, Full Reimbursement Of Costs Included Liability"
       }
      }
     },
     "auth_ref": []
    },
    "agle_AllocatedAmountOfTransactionPrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "AllocatedAmountOfTransactionPrice",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/StrategicLicenseAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Allocated Amount Of Transaction Price",
        "terseLabel": "Allocated amount of transaction price",
        "documentation": "Allocated amount of transaction price."
       }
      }
     },
     "auth_ref": []
    },
    "agle_AllocationPriceTotal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "AllocationPriceTotal",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/StrategicLicenseAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Allocation Price Total",
        "terseLabel": "Allocation price net",
        "documentation": "Allocation price total."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable",
     "presentation": [
      "http://www.spy.com/role/StockholdersEquitySummaryOfPreFundedWarrantsForCommonStockIssuedAndOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Date from which Warrants or Rights Exercisable",
        "terseLabel": "Issue Date",
        "documentation": "Date the warrants or rights are exercisable, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r393"
     ]
    },
    "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
     "presentation": [
      "http://www.spy.com/role/RestructuringChargesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]",
        "terseLabel": "Changes in Accrued Restructuring Balance",
        "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r66"
     ]
    },
    "agle_UpfrontPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "UpfrontPayment",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/StrategicLicenseAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Upfront Payment",
        "terseLabel": "Upfront payment",
        "documentation": "Upfront payment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Liability, Noncurrent",
        "terseLabel": "Non-current CVR liability",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r218"
     ]
    },
    "agle_OwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercised": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "OwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercised",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership Percentage For Outstanding Warrants To Purchase Shares Of Common Stock To Be Exercised",
        "terseLabel": "Maximum ownership percentage of common stock shares for outstanding warrants to be exercised",
        "documentation": "Ownership Percentage For Outstanding Warrants To Purchase Shares Of Common Stock To Be Exercised"
       }
      }
     },
     "auth_ref": []
    },
    "agle_ClassOfWarrantOrRightRevisedOwnershipPercentagePeriodToTakeEffectAfterNotice": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "ClassOfWarrantOrRightRevisedOwnershipPercentagePeriodToTakeEffectAfterNotice",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class Of Warrant Or Right, Revised Ownership Percentage, Period To Take Effect After Notice",
        "terseLabel": "Revised ownership percentage, period to take effect after notice",
        "documentation": "Class Of Warrant Or Right, Revised Ownership Percentage, Period To Take Effect After Notice"
       }
      }
     },
     "auth_ref": []
    },
    "dei_BusinessContactMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "BusinessContactMember",
     "presentation": [
      "http://www.spy.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Contact [Member]",
        "documentation": "Business contact for the entity"
       }
      }
     },
     "auth_ref": [
      "r808",
      "r809"
     ]
    },
    "agle_StockOptionsGrantedToCertainMembersOfBoardOfDirectorsContingentOnStockholderApproval": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "StockOptionsGrantedToCertainMembersOfBoardOfDirectorsContingentOnStockholderApproval",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Options Granted to Certain Members of Board of Directors, Contingent on Stockholder Approval",
        "terseLabel": "Stock options granted to certain members of board of directors, contingent on stockholder approval (in shares)",
        "documentation": "Stock options granted to certain members of board of directors, contingent on stockholder approval."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "agle_StockBasedCompensationExpenseOnContingentAwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "StockBasedCompensationExpenseOnContingentAwards",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Based Compensation Expense On Contingent Awards",
        "terseLabel": "Expense on contingent awards",
        "documentation": "Stock based compensation expense on contingent awards."
       }
      }
     },
     "auth_ref": []
    },
    "agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodOfFirstTwentyFivePercent": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodOfFirstTwentyFivePercent",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period Of First Twenty Five Percent",
        "verboseLabel": "Vesting period of first 25% of options granted",
        "documentation": "Share based compensation arrangement by share based payment award award vesting period of first ywenty give percent."
       }
      }
     },
     "auth_ref": []
    },
    "agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodOfRemainingSeventyFivePercent": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodOfRemainingSeventyFivePercent",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period Of Remaining Seventy Five Percent",
        "verboseLabel": "Vesting period of remaining 75% of options granted",
        "documentation": "Share based compensation arrangement by share based payment award award vesting period of remaining seventy five percent."
       }
      }
     },
     "auth_ref": []
    },
    "agle_ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsGrantedExercisablePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsGrantedExercisablePeriod",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payments Award Options Granted Exercisable Period",
        "verboseLabel": "Options granted exercisable period",
        "documentation": "Share based compensation arrangement by share based payments award options granted exercisable period."
       }
      }
     },
     "auth_ref": []
    },
    "agle_MaximumNumberOfSharesPurchasedUnderEmployeeStockPurchasePlan": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "MaximumNumberOfSharesPurchasedUnderEmployeeStockPurchasePlan",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum Number of Shares Purchased Under Employee Stock Purchase Plan",
        "terseLabel": "Maximum number of shares purchased under employee stock purchase plan",
        "documentation": "Maximum number of shares purchased under employee stock purchase plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.spy.com/role/AccruedLiabilitiesAdditionalInformationDetails",
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical",
      "http://www.spy.com/role/ParagonAgreementDetails",
      "http://www.spy.com/role/RelatedPartyTransactionsExpensesRelatedToRelatedPartyWhichWereSettledInCashDetails",
      "http://www.spy.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://www.spy.com/role/RelatedPartyTransactionsRelatedPartyAccountsPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party, Type [Domain]",
        "terseLabel": "Related Party, Type [Domain]",
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r408",
      "r545",
      "r546",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r698",
      "r700",
      "r731"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "presentation": [
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesAvailableForSaleSecuritiesInAnUnrealizedLossPositionDetails",
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesEstimatedFairValueOfCashEquivalentsAndMarketableSecuritiesAndTheGrossUnrealizedGainsAndLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-Sale [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306"
     ]
    },
    "agle_TwoThousandAndSixteenEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "TwoThousandAndSixteenEquityIncentivePlanMember",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityAssumptionsUsedToEstimateTheFairValueOfStockOptionsGrantedDetails",
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Thousand And Sixteen Equity Incentive Plan [Member]",
        "terseLabel": "2016 Equity Incentive Plan",
        "verboseLabel": "2016 Plan",
        "documentation": "Two thousand and sixteen equity incentive plan."
       }
      }
     },
     "auth_ref": []
    },
    "agle_TwoThousandAndEighteenEquityInducementPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "TwoThousandAndEighteenEquityInducementPlanMember",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Thousand And Eighteen Equity Inducement Plan [Member]",
        "terseLabel": "2018 Equity Inducement Plan",
        "documentation": "2018 equity inducement plan."
       }
      }
     },
     "auth_ref": []
    },
    "agle_TwoThousandAndFifteenAndTwoThousandAndSixteenEquityIncentivePlanAndTwoThousandAndEighteenEquityInducementPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "TwoThousandAndFifteenAndTwoThousandAndSixteenEquityIncentivePlanAndTwoThousandAndEighteenEquityInducementPlanMember",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Thousand And Fifteen And Two Thousand And Sixteen Equity Incentive Plan And Two Thousand And Eighteen Equity Inducement Plan [Member]",
        "terseLabel": "2018 Plan, 2016 Plan and 2015 Plan",
        "documentation": "Two thousand and fifteen and two thousand and sixteen equity incentive plan and two thousand and eighteen equity inducement plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/LeasesScheduleOfOperatingAndFinancingLeasesPresentedInBalanceSheetDetails": {
       "parentTag": "agle_OperatingAndFinanceLeaseRightOfUseAsset",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.spy.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.spy.com/role/LeasesScheduleOfOperatingAndFinancingLeasesPresentedInBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets",
        "verboseLabel": "Operating",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r528"
     ]
    },
    "agle_TwoThousandAndSixteenEmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "TwoThousandAndSixteenEmployeeStockPurchasePlanMember",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityAssumptionsUsedToEstimateTheFairValueOfStockOptionsGrantedDetails",
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Thousand And Sixteen Employee Stock Purchase Plan [Member]",
        "terseLabel": "2016 Employee Stock Purchase Plan",
        "verboseLabel": "2016 ESPP",
        "documentation": "Two thousand and sixteen employee stock purchase plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DividendsCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DividendsCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends, Common Stock",
        "terseLabel": "Common stock dividends declared",
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK)."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r162"
     ]
    },
    "agle_TwoThousandAndFifteenEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "TwoThousandAndFifteenEquityIncentivePlanMember",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Thousand And Fifteen Equity Incentive Plan [Member]",
        "terseLabel": "2015 Equity Incentive Plan",
        "documentation": "Two thousand and fifteen equity incentive plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/IncomeTaxesSummaryOfDifferenceBetweenProvisionForIncomeTaxesAndAmountsComputedByApplyingStatutoryFederalIncomeTaxRateToIncomeBeforeIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/IncomeTaxesSummaryOfDifferenceBetweenProvisionForIncomeTaxesAndAmountsComputedByApplyingStatutoryFederalIncomeTaxRateToIncomeBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Change in the valuation allowance",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r894"
     ]
    },
    "agle_EmployeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "EmployeesMember",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityStockBasedCompensationExpenseDetails",
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquitySummaryOfEmployeeRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employees [Member]",
        "terseLabel": "Employees",
        "documentation": "Employees."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Liability, Current",
        "terseLabel": "CVR liability",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r218"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.spy.com/role/AssetAcquisitionNarrativeDetails",
      "http://www.spy.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.spy.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersDeficitEquity",
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.spy.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.spy.com/role/SeriesANonVotingConvertiblePreferredStockDetails",
      "http://www.spy.com/role/SubsequentEventsAdditionalInformationDetails",
      "http://www.spy.com/role/TheCompanyAndBasisOfPresentationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r202",
      "r213",
      "r214",
      "r215",
      "r238",
      "r263",
      "r264",
      "r266",
      "r268",
      "r274",
      "r275",
      "r327",
      "r363",
      "r365",
      "r366",
      "r367",
      "r370",
      "r371",
      "r377",
      "r378",
      "r382",
      "r385",
      "r392",
      "r516",
      "r641",
      "r642",
      "r643",
      "r644",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r663",
      "r680",
      "r702",
      "r724",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r810",
      "r835",
      "r842"
     ]
    },
    "us-gaap_ImpairmentOfLeasehold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOfLeasehold",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/RestructuringChargesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of Leasehold",
        "terseLabel": "Impairment on leasehold improvements",
        "documentation": "The adjustment to reduce the value of existing agreements that specify the lessee's rights to use the leased property. This expense is charged when the estimates of future profits generated by the leased property are reduced."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r60"
     ]
    },
    "agle_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Thousand Eighteen Equity Inducement Plan And Two Thousand Sixteen Employee Stock Purchase Plan [Member]",
        "terseLabel": "2018 Equity Inducement Plan and 2016 Employee Stock Purchase Plan",
        "documentation": "Two thousand eighteen equity inducement plan and two thousand sixteen employee stock purchase plan."
       }
      }
     },
     "auth_ref": []
    },
    "agle_RateOfRevenueShare": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "RateOfRevenueShare",
     "presentation": [
      "http://www.spy.com/role/StrategicLicenseAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rate Of Revenue Share",
        "terseLabel": "Rate of revenue share",
        "documentation": "Rate of revenue share."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/RestructuringChargesChargesRelatedToTheRestructuringActivitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.spy.com/role/RestructuringChargesChargesRelatedToTheRestructuringActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Costs",
        "totalLabel": "Total Restructuring Costs",
        "documentation": "Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedLabel": "Depreciable assets",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r898"
     ]
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.spy.com/role/SeriesANonVotingConvertiblePreferredStockDetails",
      "http://www.spy.com/role/TheCompanyAndBasisOfPresentationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement [Member]",
        "terseLabel": "Private Placement",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/LeasesScheduleOfOperatingAndFinancingLeasesPresentedInBalanceSheetDetails": {
       "parentTag": "agle_OperatingAndFinanceLeaseRightOfUseAsset",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/LeasesScheduleOfOperatingAndFinancingLeasesPresentedInBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization",
        "verboseLabel": "Finance",
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r528"
     ]
    },
    "agle_PeaceTrialAndBLAPackageMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "PeaceTrialAndBLAPackageMember",
     "presentation": [
      "http://www.spy.com/role/StrategicLicenseAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peace Trial And B L A Package [Member]",
        "terseLabel": "PEACE Trial and BLA Package",
        "documentation": "Peace Trial And BLA Package Member."
       }
      }
     },
     "auth_ref": []
    },
    "agle_PIPTrialMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "PIPTrialMember",
     "presentation": [
      "http://www.spy.com/role/StrategicLicenseAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "P I P Trial [Member]",
        "terseLabel": "PIP Trial",
        "documentation": "PIP trial."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 14.0
      },
      "http://www.spy.com/role/IncomeTaxesSummaryOfDifferenceBetweenProvisionForIncomeTaxesAndAmountsComputedByApplyingStatutoryFederalIncomeTaxRateToIncomeBeforeIncomeTaxesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://www.spy.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.spy.com/role/IncomeTaxesSummaryOfDifferenceBetweenProvisionForIncomeTaxesAndAmountsComputedByApplyingStatutoryFederalIncomeTaxRateToIncomeBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax (expense) benefit",
        "verboseLabel": "Provision or benefit from income taxes",
        "totalLabel": "Income tax (benefit) expense",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r201",
      "r257",
      "r258",
      "r281",
      "r467",
      "r482",
      "r623"
     ]
    },
    "agle_LicenseAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "LicenseAgreementsMember",
     "presentation": [
      "http://www.spy.com/role/StrategicLicenseAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License Agreements [Member]",
        "terseLabel": "License Agreements",
        "documentation": "License agreements."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale",
        "terseLabel": "Proceeds from maturities and sales of marketable securities",
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r231",
      "r232",
      "r846"
     ]
    },
    "agle_PeacePhase3TrialAndDrugSupplyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "PeacePhase3TrialAndDrugSupplyMember",
     "presentation": [
      "http://www.spy.com/role/StrategicLicenseAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peace Phase 3 Trial And Drug Supply [Member]",
        "terseLabel": "Peace Phase 3 Trial and Drug Supply",
        "documentation": "Peace phase 3 trial and drug supply."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "presentation": [
      "http://www.spy.com/role/LeasesScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid [Abstract]",
        "terseLabel": "Operating Leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiabilityCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/StrategicLicenseAgreementsChangesInContractLiabilitiesDetails",
      "http://www.spy.com/role/StrategicLicenseAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Contract liabilities",
        "periodStartLabel": "Beginning Balance",
        "periodEndLabel": "Ending Balance",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r395",
      "r396",
      "r400"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Deferred revenue, net of current portion",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r395",
      "r396",
      "r400"
     ]
    },
    "agle_CostsIncurredInPerformingTheTrial": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "CostsIncurredInPerformingTheTrial",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/StrategicLicenseAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs Incurred In Performing The Trial",
        "terseLabel": "Costs incurred in performing PIP Trial",
        "documentation": "Costs incurred in performing the pip trial."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://www.spy.com/role/StrategicLicenseAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Total revenue",
        "verboseLabel": "Revenue recognized",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r277",
      "r278",
      "r282",
      "r285",
      "r286",
      "r290",
      "r291",
      "r292",
      "r398",
      "r399",
      "r585"
     ]
    },
    "agle_NonRefundablePaymentReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "NonRefundablePaymentReceived",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/StrategicLicenseAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non Refundable Payment Received",
        "terseLabel": "Non refundable payment received",
        "documentation": "Non refundable payment received."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "presentation": [
      "http://www.spy.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.spy.com/role/PropertyAndEquipmentNetAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class",
        "documentation": "Class of asset."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_ContractWithCustomerAssetNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerAssetNet",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/StrategicLicenseAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss",
        "terseLabel": "Contract assets",
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time."
       }
      }
     },
     "auth_ref": [
      "r395",
      "r397",
      "r400"
     ]
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r207",
      "r238",
      "r327",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r491",
      "r494",
      "r495",
      "r516",
      "r793",
      "r858",
      "r912",
      "r913"
     ]
    },
    "us-gaap_ChangeInContractWithCustomerLiabilityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ChangeInContractWithCustomerLiabilityAbstract",
     "presentation": [
      "http://www.spy.com/role/StrategicLicenseAgreementsChangesInContractLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Contract with Customer, Liability [Abstract]",
        "terseLabel": "Change in Contract with Customer, Liability [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersDeficitEquity",
      "http://www.spy.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.spy.com/role/SeriesANonVotingConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of Series A non-voting convertible preferred stock",
        "verboseLabel": "Issuance of Series A non-voting convertible preferred stock",
        "documentation": "Value of new stock classified as temporary equity issued during the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquitySummaryOfEmployeeAndNonEmployeeStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Options exercisable",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperation",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/SaleOfPegzilarginaseToImmedicaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Assets",
        "terseLabel": "Carrying value of assets",
        "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r113",
      "r119",
      "r154",
      "r204",
      "r205"
     ]
    },
    "agle_RestructuringActivitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "RestructuringActivitiesMember",
     "presentation": [
      "http://www.spy.com/role/RestructuringChargesChargesRelatedToTheRestructuringActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Activities",
        "terseLabel": "Restructuring Activities",
        "documentation": "Restructuring activities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 31.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r234"
     ]
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfRestructuringDomain",
     "presentation": [
      "http://www.spy.com/role/RestructuringChargesChangesInAccruedRestructuringBalanceDetails",
      "http://www.spy.com/role/RestructuringChargesChargesRelatedToTheRestructuringActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Type of Restructuring [Domain]",
        "terseLabel": "Type of Restructuring [Domain]",
        "documentation": "Identification of the types of restructuring costs."
       }
      }
     },
     "auth_ref": [
      "r348",
      "r349",
      "r355",
      "r356"
     ]
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/IncomeTaxesSummaryOfDifferenceBetweenProvisionForIncomeTaxesAndAmountsComputedByApplyingStatutoryFederalIncomeTaxRateToIncomeBeforeIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/IncomeTaxesSummaryOfDifferenceBetweenProvisionForIncomeTaxesAndAmountsComputedByApplyingStatutoryFederalIncomeTaxRateToIncomeBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "terseLabel": "Effect of tax rate on foreign jurisdiction",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r894"
     ]
    },
    "agle_OtherCommitmentRightToTerminateAgreementOrWorkOrderPriorWrittenNoticePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "OtherCommitmentRightToTerminateAgreementOrWorkOrderPriorWrittenNoticePeriod",
     "presentation": [
      "http://www.spy.com/role/NovationOfManufacturingAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitment, Right To Terminate Agreement Or Work Order, Prior Written Notice Period",
        "terseLabel": "Right to terminate agreement or work order, prior written notice period",
        "documentation": "Other Commitment, Right To Terminate Agreement Or Work Order, Prior Written Notice Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 24.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash (used in) and provided by investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r234"
     ]
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "presentation": [
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "terseLabel": "Contractual Maturities of Marketable Securities at Estimated Fair Value",
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r146",
      "r147"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.spy.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r373",
      "r402",
      "r407",
      "r509",
      "r557",
      "r775",
      "r776",
      "r780",
      "r781",
      "r782"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "CURRENT LIABILITIES"
       }
      }
     },
     "auth_ref": []
    },
    "agle_OtherCommitmentRightToTerminateWorkOrderByCounterpartyReasonableCauseTerminationAmountPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "OtherCommitmentRightToTerminateWorkOrderByCounterpartyReasonableCauseTerminationAmountPayable",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/NovationOfManufacturingAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitment, Right To Terminate Work Order By Counterparty, Reasonable Cause, Termination Amount Payable",
        "terseLabel": "Right to terminate work order by counterparty, reasonable cause, termination amount payable",
        "documentation": "Other Commitment, Right To Terminate Work Order By Counterparty, Reasonable Cause, Termination Amount Payable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock",
     "presentation": [
      "http://www.spy.com/role/RestructuringChargesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Costs [Table Text Block]",
        "terseLabel": "Charges Related to the Restructuring Activities",
        "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r64",
      "r65"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES"
       }
      }
     },
     "auth_ref": []
    },
    "agle_OtherCommitmentRightToTerminateWorkOrderReasonableCausePriorWrittenNoticePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "OtherCommitmentRightToTerminateWorkOrderReasonableCausePriorWrittenNoticePeriod",
     "presentation": [
      "http://www.spy.com/role/NovationOfManufacturingAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitment, Right To Terminate Work Order, Reasonable Cause, Prior Written Notice Period",
        "terseLabel": "Right to terminate work order, reasonable cause, prior written notice period",
        "documentation": "Other Commitment, Right To Terminate Work Order, Reasonable Cause, Prior Written Notice Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "TOTAL LIABILITIES",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r238",
      "r327",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r491",
      "r494",
      "r495",
      "r516",
      "r678",
      "r771",
      "r806",
      "r858",
      "r912",
      "r913"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.spy.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r373",
      "r402",
      "r407",
      "r509",
      "r556",
      "r780",
      "r781",
      "r782"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/RestructuringChargesChargesRelatedToTheRestructuringActivitiesDetails": {
       "parentTag": "us-gaap_RestructuringCosts",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails",
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityStockBasedCompensationExpenseDetails",
      "http://www.spy.com/role/RestructuringChargesChargesRelatedToTheRestructuringActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expense",
        "presentationGuidance": "Stock-based compensation expense",
        "definitionGuidance": "Total stock-based compensation expense",
        "terseLabel": "Stock-based compensation expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r444",
      "r457"
     ]
    },
    "agle_OtherCommitmentRightToTerminateWorkOrderMaterialBreachUncuredPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "OtherCommitmentRightToTerminateWorkOrderMaterialBreachUncuredPeriod",
     "presentation": [
      "http://www.spy.com/role/NovationOfManufacturingAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitment, Right To Terminate Work Order, Material Breach, Uncured Period",
        "terseLabel": "Right to terminate work order, material breach, uncured period",
        "documentation": "Other Commitment, Right To Terminate Work Order, Material Breach, Uncured Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityAssumptionsUsedToEstimateTheFairValueOfStockOptionsGrantedDetails",
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Employee Service Share Based Compensation Allocation of Recognized Period Costs [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, issued (in shares)",
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r377"
     ]
    },
    "agle_OtherCommitmentRightToTerminateWorkOrderUnusualOrInfrequentCausePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "OtherCommitmentRightToTerminateWorkOrderUnusualOrInfrequentCausePeriod",
     "presentation": [
      "http://www.spy.com/role/NovationOfManufacturingAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitment, Right To Terminate Work Order, Unusual Or Infrequent Cause, Period",
        "terseLabel": "Right to terminate work order, unusual or infrequent cause, period",
        "documentation": "Other Commitment, Right To Terminate Work Order, Unusual Or Infrequent Cause, Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/IncomeTaxesIncomeLossBeforeIncomeTaxExpenseByJurisdictionDetails": {
       "parentTag": "us-gaap_IncomeLossFromEquityMethodInvestments",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/IncomeTaxesIncomeLossBeforeIncomeTaxExpenseByJurisdictionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "Domestic",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations."
       }
      }
     },
     "auth_ref": [
      "r239",
      "r483"
     ]
    },
    "agle_OtherCommitmentNonRefundableLicenseFeeAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "OtherCommitmentNonRefundableLicenseFeeAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/NovationOfManufacturingAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitment, Non-Refundable License Fee Amount",
        "terseLabel": "Non-refundable license fee amount",
        "documentation": "Other Commitment, Non-Refundable License Fee Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 29.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Debt Securities, Available-for-Sale",
        "negatedLabel": "Purchases of marketable securities",
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r231",
      "r293"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expense, Tax Benefit",
        "terseLabel": "Tax benefits recognized",
        "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r444"
     ]
    },
    "agle_OtherCommitmentRoyaltyPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "OtherCommitmentRoyaltyPercentage",
     "presentation": [
      "http://www.spy.com/role/NovationOfManufacturingAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitment, Royalty Percentage",
        "terseLabel": "Royalty percentage (less than)",
        "documentation": "Other Commitment, Royalty Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.spy.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.spy.com/role/FairValueMeasurementsSignificantInputsUsedToEstimateTheFairValueOfDerivativeLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r373",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r509",
      "r558",
      "r775",
      "r776",
      "r780",
      "r781",
      "r782"
     ]
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromEquityMethodInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/IncomeTaxesIncomeLossBeforeIncomeTaxExpenseByJurisdictionDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.spy.com/role/IncomeTaxesIncomeLossBeforeIncomeTaxExpenseByJurisdictionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Equity Method Investments",
        "totalLabel": "Loss before income tax expense",
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss)."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r135",
      "r182",
      "r280",
      "r326",
      "r616"
     ]
    },
    "agle_OtherCommitmentRightToTerminateAgreementPriorWrittenNoticePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "OtherCommitmentRightToTerminateAgreementPriorWrittenNoticePeriod",
     "presentation": [
      "http://www.spy.com/role/NovationOfManufacturingAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitment, Right To Terminate Agreement, Prior Written Notice Period",
        "terseLabel": "Right to terminate agreement, prior written notice period",
        "documentation": "Other Commitment, Right To Terminate Agreement, Prior Written Notice Period"
       }
      }
     },
     "auth_ref": []
    },
    "agle_OtherCommitmentRightToTerminateAgreementByCounterpartyMaterialBreachUncuredPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "OtherCommitmentRightToTerminateAgreementByCounterpartyMaterialBreachUncuredPeriod",
     "presentation": [
      "http://www.spy.com/role/NovationOfManufacturingAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitment, Right To Terminate Agreement By Counterparty, Material Breach, Uncured Period",
        "terseLabel": "Right to terminate agreement by counterparty, material breach, uncured period",
        "documentation": "Other Commitment, Right To Terminate Agreement By Counterparty, Material Breach, Uncured Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized stock-based compensation expense for options",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r891"
     ]
    },
    "agle_OtherCommitmentRightToTerminateAgreementByCounterpartyPaymentsNotReceivedPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "OtherCommitmentRightToTerminateAgreementByCounterpartyPaymentsNotReceivedPeriod",
     "presentation": [
      "http://www.spy.com/role/NovationOfManufacturingAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitment, Right To Terminate Agreement By Counterparty, Payments Not Received, Period",
        "terseLabel": "Right to terminate agreement by counterparty, payments not received, period",
        "documentation": "Other Commitment, Right To Terminate Agreement By Counterparty, Payments Not Received, Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://www.spy.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails",
      "http://www.spy.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation",
        "verboseLabel": "Stock compensation expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized stock-based compensation expense",
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r891"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.spy.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Authorized",
        "verboseLabel": "Preferred stock, authorized (in shares)",
        "terseLabel": "Preferred stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r680"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.spy.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Outstanding",
        "verboseLabel": "Preferred stock, outstanding (in shares)",
        "terseLabel": "Preferred stock, shares outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r680",
      "r699",
      "r927",
      "r928"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/IncomeTaxesIncomeLossBeforeIncomeTaxExpenseByJurisdictionDetails": {
       "parentTag": "us-gaap_IncomeLossFromEquityMethodInvestments",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/IncomeTaxesIncomeLossBeforeIncomeTaxExpenseByJurisdictionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "Foreign",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": [
      "r239",
      "r483"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "TOTAL LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' (DEFICIT) EQUITY",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r181",
      "r612",
      "r793",
      "r836",
      "r851",
      "r906"
     ]
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "presentation": [
      "http://www.spy.com/role/RestructuringChargesChangesInAccruedRestructuringBalanceDetails",
      "http://www.spy.com/role/RestructuringChargesChargesRelatedToTheRestructuringActivitiesDetails",
      "http://www.spy.com/role/RestructuringChargesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Restructuring and Related Costs [Table]",
        "terseLabel": "Schedule of Restructuring and Related Costs [Table]",
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring."
       }
      }
     },
     "auth_ref": [
      "r348",
      "r349",
      "r350",
      "r351",
      "r355",
      "r356",
      "r357"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesEstimatedFairValueOfCashEquivalentsAndMarketableSecuritiesAndTheGrossUnrealizedGainsAndLossesDetails",
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesNarrativeDetails",
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.spy.com/role/FairValueMeasurementsSignificantInputsUsedToEstimateTheFairValueOfDerivativeLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r336",
      "r340",
      "r341",
      "r375",
      "r390",
      "r502",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r620",
      "r774",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r847",
      "r848",
      "r849",
      "r850"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Loss",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.spy.com/role/StockholdersEquityAdditionalInformationDetails",
      "http://www.spy.com/role/TheCompanyAndBasisOfPresentationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)",
        "verboseLabel": "Preferred stock, par value",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r377"
     ]
    },
    "us-gaap_OptionIndexedToIssuersEquityTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OptionIndexedToIssuersEquityTypeDomain",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Indexed to Issuer's Equity, Type [Domain]",
        "terseLabel": "Option Indexed to Issuer's Equity, Type",
        "documentation": "Description of the type of freestanding contract issued by a Company that is indexed to, and potentially settled in, a Company's own stock. Specifically, the pertinent rights and privileges of the securities outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "terseLabel": "Impairments of long-lived assets",
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale)."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r60",
      "r153"
     ]
    },
    "us-gaap_StockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockOptionMember",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Option [Member]",
        "terseLabel": "Stock option",
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)."
       }
      }
     },
     "auth_ref": [
      "r798"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "terseLabel": "Tax credits",
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r83",
      "r898"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/LeasesScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/LeasesScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r540"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Intrinsic value of options exercised",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r434"
     ]
    },
    "us-gaap_FinanceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/LeasesScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/LeasesScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability",
        "terseLabel": "Total",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease."
       }
      }
     },
     "auth_ref": [
      "r529",
      "r540"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Less: Valuation allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r475"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityPreFundedWarrantsForCommonStockIssuedAndOutstandingDetails",
      "http://www.spy.com/role/StockholdersEquitySummaryOfPreFundedWarrantsForCommonStockIssuedAndOutstandingDetails",
      "http://www.spy.com/role/TheCompanyAndBasisOfPresentationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Outstanding",
        "terseLabel": "Number of shares sold in private placement",
        "presentationGuidance": "Number of shares sold in private placement",
        "definitionGuidance": "Number of Warrants Outstanding",
        "verboseLabel": "Number of Warrants Outstanding (in shares)",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockRedemptionPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockRedemptionPricePerShare",
     "presentation": [
      "http://www.spy.com/role/SeriesANonVotingConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Redemption Price Per Share",
        "terseLabel": "Preferred stock, redemption per share (in dollars per share)",
        "documentation": "The price per share at which the preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity is redeemed or may be called at. The redemption features of this preferred stock are solely within the control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r73",
      "r76"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/LeasesScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/LeasesScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2027",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r540"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "presentation": [
      "http://www.spy.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.spy.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.spy.com/role/FairValueMeasurementsSignificantInputsUsedToEstimateTheFairValueOfDerivativeLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value by Liability Class [Domain]",
        "terseLabel": "Fair Value by Liability Class [Domain]",
        "documentation": "Represents classes of liabilities measured and disclosed at fair value."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/LeasesScheduleOfOperatingAndFinancingLeasesPresentedInBalanceSheetDetails": {
       "parentTag": "agle_OperatingAndFinanceLeaseLiabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/LeasesScheduleOfOperatingAndFinancingLeasesPresentedInBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, Current",
        "verboseLabel": "Finance lease liabilities, current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r529"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/LeasesScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/LeasesScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r540"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.spy.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Components of Deferred Tax Assets and Liabilities",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r172"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/LeasesScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/LeasesScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r540"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/LeasesScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/LeasesScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r540"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating lease liabilities",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r813",
      "r832"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.spy.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Summary of Difference Between Provision for Income Taxes and Amounts Computed by Applying Statutory Federal Income Tax Rate to Income Before Income Taxes",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r171"
     ]
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "presentation": [
      "http://www.spy.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Schedule of Loss Income Before Income Tax Expense by Jurisdiction",
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions."
       }
      }
     },
     "auth_ref": [
      "r837"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/LeasesScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.spy.com/role/LeasesScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetailsAlternate1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.spy.com/role/LeasesScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease."
       }
      }
     },
     "auth_ref": [
      "r540"
     ]
    },
    "us-gaap_AssetAcquisitionTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionTableTextBlock",
     "presentation": [
      "http://www.spy.com/role/AssetAcquisitionTables",
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Table Text Block]",
        "verboseLabel": "Summary of Asset Acquisition Cost",
        "terseLabel": "Asset Acquisition Cost",
        "documentation": "Tabular disclosure of asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r899"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "STOCKHOLDERS' (DEFICIT) EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseImpairmentLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/RestructuringChargesChargesRelatedToTheRestructuringActivitiesDetails": {
       "parentTag": "us-gaap_RestructuringCosts",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/RestructuringChargesChargesRelatedToTheRestructuringActivitiesDetails",
      "http://www.spy.com/role/RestructuringChargesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Impairment Loss",
        "terseLabel": "Lease asset impairment",
        "verboseLabel": "Lease Asset Impairment",
        "documentation": "Amount of loss from impairment of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r907"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails",
      "http://www.spy.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "verboseLabel": "Warrants to purchase shares",
        "terseLabel": "Warrants to purchase shares (in shares)",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r393"
     ]
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue Recognition",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r703",
      "r761",
      "r768"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss",
        "terseLabel": "Debt securities, available-for-sale, allowance for credit loss",
        "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r298",
      "r335",
      "r342",
      "r343"
     ]
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.spy.com/role/StockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r237",
      "r376",
      "r378",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r391",
      "r394",
      "r503",
      "r727",
      "r729",
      "r758"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://www.spy.com/role/FairValueMeasurementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Financial Assets and Liabilities Measured at Fair Value on Recurring Basis",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r508",
      "r509"
     ]
    },
    "dei_ContactPersonnelName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ContactPersonnelName",
     "presentation": [
      "http://www.spy.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Name",
        "documentation": "Name of contact personnel"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r195"
     ]
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesAndOtherLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 15.0
      },
      "http://www.spy.com/role/AccruedAndOtherCurrentLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.spy.com/role/AccruedAndOtherCurrentLiabilitiesDetails",
      "http://www.spy.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities and Other Liabilities",
        "terseLabel": "Accrued and other current liabilities",
        "totalLabel": "Total accrued and other current liabilities",
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/LeasesScheduleOfOperatingAndFinancingLeasesPresentedInBalanceSheetDetails": {
       "parentTag": "agle_OperatingAndFinanceLeaseLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/LeasesScheduleOfOperatingAndFinancingLeasesPresentedInBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, Noncurrent",
        "verboseLabel": "Finance lease liabilities, noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r529"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.spy.com/role/AccruedAndOtherCurrentLiabilitiesTables",
      "http://www.spy.com/role/AccruedLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "verboseLabel": "Accrued and Other Current Liabilities",
        "terseLabel": "Accrued and Other Current Liabilities",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r276",
      "r283",
      "r287",
      "r289",
      "r772"
     ]
    },
    "us-gaap_AssetAcquisitionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityReverseStockSplit",
     "presentation": [
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.spy.com/role/ReverseStockSplitAdditionalInformationDetails",
      "http://www.spy.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Reverse Stock Split",
        "terseLabel": "Stockholders' equity, reverse stock split",
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements."
       }
      }
     },
     "auth_ref": [
      "r163"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesNetAbstract",
     "presentation": [
      "http://www.spy.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Net [Abstract]",
        "terseLabel": "Deferred tax liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetAcquisitionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionTable",
     "presentation": [
      "http://www.spy.com/role/AssetAcquisitionAssetAcquisitionCostDetails",
      "http://www.spy.com/role/AssetAcquisitionNarrativeDetails",
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesSummaryOfAssetAcquisitionCostDetails",
      "http://www.spy.com/role/ParapyreOptionObligationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Table]",
        "terseLabel": "Asset Acquisition [Table]",
        "documentation": "Disclosure of information about asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r899"
     ]
    },
    "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
     "presentation": [
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents and Investments [Table Text Block]",
        "terseLabel": "Estimated Fair Value of Cash Equivalents and Marketable Securities and the Gross Unrealized Gains and Losses",
        "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquitySummaryOfEmployeeRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Shares, Forfeited",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r432"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails",
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquitySummaryOfEmployeeRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Equity instruments other than options, granted (in shares)",
        "verboseLabel": "Shares, Granted",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r430"
     ]
    },
    "us-gaap_LicensingAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LicensingAgreementsMember",
     "presentation": [
      "http://www.spy.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Licensing Agreements [Member]",
        "terseLabel": "Licensing Agreements",
        "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory)."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r460",
      "r893"
     ]
    },
    "us-gaap_AssetAcquisitionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionDomain",
     "presentation": [
      "http://www.spy.com/role/AssetAcquisitionAssetAcquisitionCostDetails",
      "http://www.spy.com/role/AssetAcquisitionNarrativeDetails",
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesSummaryOfAssetAcquisitionCostDetails",
      "http://www.spy.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails",
      "http://www.spy.com/role/SubsequentEventsAdditionalInformationDetails",
      "http://www.spy.com/role/TheCompanyAndBasisOfPresentationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Domain]",
        "terseLabel": "Asset Acquisition [Domain]",
        "documentation": "Asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r899"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/LeasesScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetailsAlternate1": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/LeasesScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r540"
     ]
    },
    "us-gaap_DeferredRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredRevenue",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/StrategicLicenseAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Revenue",
        "terseLabel": "Total deferred revenue",
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r825"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "terseLabel": "Stock-based compensation",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r898"
     ]
    },
    "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
     "presentation": [
      "http://www.spy.com/role/NetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Weighted Average Number of Shares [Table Text Block]",
        "terseLabel": "Schedule of Reconciliation of Basic and Diluted Net Loss Per Share",
        "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit)."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquitySummaryOfEmployeeRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "definitionGuidance": "Weighted Average Grant Date Fair Value, Granted",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r430"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquitySummaryOfEmployeeRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodStartLabel": "Shares, Unvested restricted common stock, Beginning balance",
        "periodEndLabel": "Shares, Unvested restricted common stock, Ending balance",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r427",
      "r428"
     ]
    },
    "us-gaap_AssetAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionAxis",
     "presentation": [
      "http://www.spy.com/role/AssetAcquisitionAssetAcquisitionCostDetails",
      "http://www.spy.com/role/AssetAcquisitionNarrativeDetails",
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesSummaryOfAssetAcquisitionCostDetails",
      "http://www.spy.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails",
      "http://www.spy.com/role/SubsequentEventsAdditionalInformationDetails",
      "http://www.spy.com/role/TheCompanyAndBasisOfPresentationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Axis]",
        "terseLabel": "Asset Acquisition [Axis]",
        "documentation": "Information by asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r899"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquitySummaryOfEmployeeRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodStartLabel": "Weighted Average Grant Date Fair Value, Unvested restricted common stock, Beginning balance",
        "periodEndLabel": "Weighted Average Grant Date Fair Value, Unvested restricted common stock, Ending balance",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r427",
      "r428"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other non-current assets",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r211"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unamortized expense",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r447"
     ]
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NontradeReceivablesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NontradeReceivablesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nontrade Receivables, Current",
        "terseLabel": "Development receivables",
        "documentation": "The sum of amounts currently receivable other than from customers. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r826"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities",
        "terseLabel": "Accrued expense",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r898"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails",
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquitySummaryOfEmployeeRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "terseLabel": "Equity instruments other than options, vested (in shares)",
        "negatedLabel": "Shares, Vested",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r431"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquitySummaryOfEmployeeRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value, Forfeited",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r432"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://www.spy.com/role/PropertyAndEquipmentNetAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r279"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquitySummaryOfEmployeeRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value, Vested",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r431"
     ]
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "presentation": [
      "http://www.spy.com/role/DefinedContributionPlan"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation and Employee Benefit Plans [Text Block]",
        "terseLabel": "Defined Contribution Plan",
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r165",
      "r166",
      "r167"
     ]
    },
    "us-gaap_RevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenuesAbstract",
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenue:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.spy.com/role/LeasesSummaryOfWeightedAverageRemainingLeaseTermAndDiscountRatesForOperatingAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Operating leases, Weighted-average discount rate",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r539",
      "r792"
     ]
    },
    "us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionConsiderationTransferredTransactionCost",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/AssetAcquisitionAssetAcquisitionCostDetails",
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesSummaryOfAssetAcquisitionCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition, Consideration Transferred, Transaction Cost",
        "terseLabel": "Transaction costs incurred by Aeglea",
        "documentation": "Amount of transaction cost incurred as part of consideration transferred in asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r789",
      "r900",
      "r901",
      "r902"
     ]
    },
    "agle_CashEquivalentsAndMarketableSecuritiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "CashEquivalentsAndMarketableSecuritiesTable",
     "presentation": [
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Equivalents And Marketable Securities [Table]",
        "terseLabel": "Cash Equivalents And Marketable Securities [Table]",
        "documentation": "Cash equivalents and marketable securities."
       }
      }
     },
     "auth_ref": []
    },
    "agle_AccruedContractedResearchAndDevelopmentCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "AccruedContractedResearchAndDevelopmentCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/AccruedAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/AccruedAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Contracted Research And Development Costs",
        "terseLabel": "Accrued contracted research and development costs",
        "documentation": "Accrued contracted research and development costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "CURRENT ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other (expense) income:"
       }
      }
     },
     "auth_ref": []
    },
    "agle_OperatingAndFinanceLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "OperatingAndFinanceLeaseRightOfUseAsset",
     "calculation": {
      "http://www.spy.com/role/LeasesScheduleOfOperatingAndFinancingLeasesPresentedInBalanceSheetDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.spy.com/role/LeasesScheduleOfOperatingAndFinancingLeasesPresentedInBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating And Finance Lease Right Of Use Asset",
        "totalLabel": "Total leased assets",
        "documentation": "Operating and financing lease right of use asset."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OptionIndexedToIssuersEquityTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OptionIndexedToIssuersEquityTypeAxis",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Indexed to Issuer's Equity, Type [Axis]",
        "terseLabel": "Option Indexed to Issuer's Equity, Type",
        "documentation": "Information by type of freestanding contracts issued by an entity that are indexed to, and potentially settled in, an entity's own stock."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r99",
      "r100",
      "r175"
     ]
    },
    "us-gaap_DeferredRevenueCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredRevenueCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.spy.com/role/StrategicLicenseAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Revenue, Current",
        "verboseLabel": "Deferred revenue",
        "terseLabel": "Current deferred revenue",
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r824"
     ]
    },
    "us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionConsiderationTransferredContingentConsideration",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition, Consideration Transferred, Contingent Consideration",
        "terseLabel": "Fair value of contingent consideration assumed",
        "documentation": "Amount of contingent consideration recognized as part of consideration transferred in asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r900",
      "r901",
      "r902"
     ]
    },
    "us-gaap_AssetAcquisitionConsiderationTransferred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionConsiderationTransferred",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/AssetAcquisitionAssetAcquisitionCostDetails",
      "http://www.spy.com/role/AssetAcquisitionNarrativeDetails",
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesSummaryOfAssetAcquisitionCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition, Consideration Transferred",
        "totalLabel": "Cost to acquire asset",
        "terseLabel": "Cost to acquire asset",
        "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer."
       }
      }
     },
     "auth_ref": [
      "r789",
      "r900",
      "r901",
      "r902"
     ]
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.spy.com/role/LeasesSummaryOfWeightedAverageRemainingLeaseTermAndDiscountRatesForOperatingAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Finance leases, Weighted-average discount rate",
        "documentation": "Weighted average discount rate for finance lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r539",
      "r792"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/LeasesScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/LeasesScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r540"
     ]
    },
    "us-gaap_AssetAcquisitionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionLineItems",
     "presentation": [
      "http://www.spy.com/role/AssetAcquisitionAssetAcquisitionCostDetails",
      "http://www.spy.com/role/AssetAcquisitionNarrativeDetails",
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesSummaryOfAssetAcquisitionCostDetails",
      "http://www.spy.com/role/ParapyreOptionObligationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Line Items]",
        "terseLabel": "Asset Acquisition [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r899"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://www.spy.com/role/TheCompanyAndBasisOfPresentation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "The Company and Basis of Presentation",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r174",
      "r637",
      "r638"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Initial reserves of common stock",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValuePurchaseOfAssets",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Purchase of Assets",
        "terseLabel": "Issuance of common stock forward in connection with the asset acquisition of Spyre",
        "documentation": "Value of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/AssetAcquisitionAssetAcquisitionCostDetails",
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesSummaryOfAssetAcquisitionCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition, Consideration Transferred, Equity Interest Issued and Issuable",
        "terseLabel": "Consideration transferred in Series A Preferred Stock and common stock",
        "documentation": "Amount of acquirer's equity interest issued and issuable as part of consideration transferred in asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r900",
      "r901",
      "r902"
     ]
    },
    "agle_ScheduleOfOperatingAndFinanceLeasedAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "ScheduleOfOperatingAndFinanceLeasedAssetsLineItems",
     "presentation": [
      "http://www.spy.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Operating And Finance Leased Assets [Line Items]",
        "terseLabel": "Schedule Of Operating And Finance Leased Assets Line Items",
        "documentation": "Schedule of operating and finance leased assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other (expense) income",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r140"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Number of common stock available for issuance",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "agle_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesContractualMaturitiesOfMarketableSecuritiesAtEstimatedFairValueDetails": {
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesContractualMaturitiesOfMarketableSecuritiesAtEstimatedFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-For-Sale, Fair Value, Maturity, Allocated And Single Maturity Date, After Year One",
        "terseLabel": "Due thereafter",
        "documentation": "Debt Securities, Available-For-Sale, Fair Value, Maturity, Allocated And Single Maturity Date, After Year One"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 23.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r607",
      "r793"
     ]
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current",
        "totalLabel": "Total current assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r206",
      "r217",
      "r238",
      "r327",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r490",
      "r494",
      "r516",
      "r793",
      "r858",
      "r859",
      "r912"
     ]
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "terseLabel": "Intangible assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant date fair value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r433"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/LeasesScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.spy.com/role/LeasesScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetailsAlternate1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.spy.com/role/LeasesScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r540"
     ]
    },
    "agle_ScheduleOfOperatingAndFinanceLeasedAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "ScheduleOfOperatingAndFinanceLeasedAssetsTable",
     "presentation": [
      "http://www.spy.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Operating And Finance Leased Assets [Table]",
        "terseLabel": "Schedule Of Operating And Finance Leased Assets [Table]",
        "documentation": "Schedule of operating and finance leased assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquitySummaryOfEmployeeAndNonEmployeeStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Shares Issuable Under Options, Forfeited",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r425"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://www.spy.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.spy.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails",
      "http://www.spy.com/role/IncomeTaxesSummaryOfDifferenceBetweenProvisionForIncomeTaxesAndAmountsComputedByApplyingStatutoryFederalIncomeTaxRateToIncomeBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Domestic Tax Authority [Member]",
        "verboseLabel": "U.S",
        "terseLabel": "Federal Tax Credits",
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.spy.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
      "http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.spy.com/role/ParagonAgreementDetails",
      "http://www.spy.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r243",
      "r244",
      "r372",
      "r380",
      "r548",
      "r765",
      "r767"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract",
     "presentation": [
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesAvailableForSaleSecuritiesInAnUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position [Abstract]",
        "terseLabel": "Unrealized Losses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.spy.com/role/PropertyAndEquipmentNetAdditionalInformationDetails",
      "http://www.spy.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
      "http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property Plant And Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "terseLabel": "Accrued and other liabilities",
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other."
       }
      }
     },
     "auth_ref": [
      "r832"
     ]
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermDebtTypeAxis",
     "presentation": [
      "http://www.spy.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt, Type [Axis]",
        "terseLabel": "Short-term Debt, Type",
        "documentation": "Information by type of short-term debt arrangement."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.spy.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r807"
     ]
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "presentation": [
      "http://www.spy.com/role/RestructuringCharges"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "terseLabel": "Restructuring Charges",
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled."
       }
      }
     },
     "auth_ref": [
      "r346",
      "r347",
      "r349",
      "r352",
      "r358"
     ]
    },
    "us-gaap_RestructuringCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringCharges",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/RestructuringChargesChangesInAccruedRestructuringBalanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Charges",
        "terseLabel": "Charges",
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r353",
      "r355",
      "r855"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.spy.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r807"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.spy.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r807"
     ]
    },
    "us-gaap_CommonStockVotingRights": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockVotingRights",
     "presentation": [
      "http://www.spy.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Voting Rights",
        "terseLabel": "Common stock voting rights",
        "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "verboseLabel": "Common stock available for future issuance (in shares)",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 25.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesAvailableForSaleSecuritiesInAnUnrealizedLossPositionDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesAvailableForSaleSecuritiesInAnUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss",
        "negatedLabel": "Less Than 12 Months",
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r189",
      "r339"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Total comprehensive loss",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r222",
      "r224",
      "r229",
      "r598",
      "r621"
     ]
    },
    "us-gaap_RestructuringReserve": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringReserve",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/RestructuringChargesChangesInAccruedRestructuringBalanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Reserve",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan."
       }
      }
     },
     "auth_ref": [
      "r349",
      "r354"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.spy.com/role/AssetAcquisitionNarrativeDetails",
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersDeficitEquity",
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails",
      "http://www.spy.com/role/StockholdersEquityAdditionalInformationDetails",
      "http://www.spy.com/role/SubsequentEventsAdditionalInformationDetails",
      "http://www.spy.com/role/TheCompanyAndBasisOfPresentationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r796",
      "r797",
      "r798",
      "r800",
      "r801",
      "r802",
      "r803",
      "r838",
      "r839",
      "r904",
      "r926",
      "r927"
     ]
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressesAddressTypeAxis",
     "presentation": [
      "http://www.spy.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses, Address Type [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "srt_OwnershipAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "OwnershipAxis",
     "presentation": [
      "http://www.spy.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]",
        "terseLabel": "Ownership [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 34.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised",
        "terseLabel": "Proceeds from employee stock plan purchases and stock option exercises",
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r22"
     ]
    },
    "us-gaap_GainLossOnDerivativeInstrumentsNetPretax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnDerivativeInstrumentsNetPretax",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      },
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://www.spy.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain (Loss) on Derivative Instruments, Net, Pretax",
        "verboseLabel": "Change in fair value of forward contract liability",
        "negatedTerseLabel": "Change in fair value of forward contract liability",
        "documentation": "Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.spy.com/role/PropertyAndEquipmentNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment Net",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_InvestmentIncomeNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentIncomeNet",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Income, Net",
        "terseLabel": "Interest income",
        "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r141"
     ]
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://www.spy.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
      "http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer Equipment",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesAvailableForSaleSecuritiesInAnUnrealizedLossPositionDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesAvailableForSaleSecuritiesInAnUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months",
        "terseLabel": "Less Than 12 Months",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r189",
      "r339",
      "r774"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesAvailableForSaleSecuritiesInAnUnrealizedLossPositionDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesAvailableForSaleSecuritiesInAnUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position",
        "totalLabel": "Total, Fair Value",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss."
       }
      }
     },
     "auth_ref": [
      "r187",
      "r337",
      "r774"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction",
        "terseLabel": "Amortization of operating lease assets",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r833"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesAvailableForSaleSecuritiesInAnUnrealizedLossPositionDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesAvailableForSaleSecuritiesInAnUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss",
        "negatedTotalLabel": "Total, unrealized losses",
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r188",
      "r338"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesAvailableForSaleSecuritiesInAnUnrealizedLossPositionDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesAvailableForSaleSecuritiesInAnUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer",
        "terseLabel": "12 Months or Longer",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r189",
      "r339",
      "r774"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.spy.com/role/FairValueMeasurementsSignificantInputsUsedToEstimateTheFairValueOfDerivativeLiabilityDetails",
      "http://www.spy.com/role/LeasesAdditionalInformationDetails",
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails",
      "http://www.spy.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://www.spy.com/role/SeriesANonVotingConvertiblePreferredStockDetails",
      "http://www.spy.com/role/StrategicLicenseAgreementsNarrativeDetails",
      "http://www.spy.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "auth_ref": [
      "r359",
      "r360",
      "r361",
      "r362",
      "r409",
      "r583",
      "r630",
      "r670",
      "r671",
      "r733",
      "r735",
      "r737",
      "r738",
      "r747",
      "r759",
      "r760",
      "r773",
      "r777",
      "r785",
      "r795",
      "r860",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
     "presentation": [
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]",
        "terseLabel": "Available-for-Sale Securities in an Unrealized Loss Position",
        "documentation": "Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r186",
      "r774",
      "r852"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesAvailableForSaleSecuritiesInAnUnrealizedLossPositionDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesAvailableForSaleSecuritiesInAnUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss",
        "negatedLabel": "12 Months or Longer",
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r189",
      "r339"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://www.spy.com/role/StrategicLicenseAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "auth_ref": [
      "r290",
      "r585",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r762",
      "r779",
      "r794",
      "r814",
      "r856",
      "r857",
      "r862",
      "r925"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesContractualMaturitiesOfMarketableSecuritiesAtEstimatedFairValueDetails": {
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesContractualMaturitiesOfMarketableSecuritiesAtEstimatedFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Due in one year or less",
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r303",
      "r601"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesNarrativeDetails",
      "http://www.spy.com/role/FairValueMeasurementsSignificantInputsUsedToEstimateTheFairValueOfDerivativeLiabilityDetails",
      "http://www.spy.com/role/LeasesAdditionalInformationDetails",
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails",
      "http://www.spy.com/role/ParagonAgreementDetails",
      "http://www.spy.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://www.spy.com/role/SeriesANonVotingConvertiblePreferredStockDetails",
      "http://www.spy.com/role/StockholdersEquityAdditionalInformationDetails",
      "http://www.spy.com/role/StrategicLicenseAgreementsNarrativeDetails",
      "http://www.spy.com/role/SubsequentEventsAdditionalInformationDetails",
      "http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "auth_ref": [
      "r359",
      "r360",
      "r361",
      "r362",
      "r401",
      "r409",
      "r440",
      "r441",
      "r442",
      "r559",
      "r583",
      "r630",
      "r670",
      "r671",
      "r733",
      "r735",
      "r737",
      "r738",
      "r747",
      "r759",
      "r760",
      "r773",
      "r777",
      "r785",
      "r795",
      "r798",
      "r854",
      "r860",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919"
     ]
    },
    "us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember",
     "presentation": [
      "http://www.spy.com/role/SaleOfPegzilarginaseToImmedicaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]",
        "terseLabel": "Disposal Group, Disposed of by Sale, Not Discontinued Operations",
        "documentation": "Disposal group that has been sold. Excludes disposals classified as discontinued operations."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r23"
     ]
    },
    "srt_OwnershipDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "OwnershipDomain",
     "presentation": [
      "http://www.spy.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]",
        "terseLabel": "Ownership [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive (loss) income:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.spy.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r236"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.spy.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://www.spy.com/role/StrategicLicenseAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "auth_ref": [
      "r290",
      "r585",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r762",
      "r779",
      "r794",
      "r814",
      "r856",
      "r857",
      "r862",
      "r925"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://www.spy.com/role/AccruedLiabilitiesAdditionalInformationDetails",
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical",
      "http://www.spy.com/role/ParagonAgreementDetails",
      "http://www.spy.com/role/RelatedPartyTransactionsExpensesRelatedToRelatedPartyWhichWereSettledInCashDetails",
      "http://www.spy.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://www.spy.com/role/RelatedPartyTransactionsRelatedPartyAccountsPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party [Member]",
        "terseLabel": "Related Party",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r241",
      "r242",
      "r545",
      "r546",
      "r547",
      "r548",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r698",
      "r700",
      "r731"
     ]
    },
    "us-gaap_PreferredStockConvertibleConversionRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockConvertibleConversionRatio",
     "presentation": [
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.spy.com/role/SeriesANonVotingConvertiblePreferredStockDetails",
      "http://www.spy.com/role/TheCompanyAndBasisOfPresentationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Convertible, Conversion Ratio",
        "terseLabel": "Conversion basis",
        "documentation": "Number of common shares issuable upon conversion for each share of preferred stock to be converted."
       }
      }
     },
     "auth_ref": [
      "r379"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesNarrativeDetails",
      "http://www.spy.com/role/FairValueMeasurementsSignificantInputsUsedToEstimateTheFairValueOfDerivativeLiabilityDetails",
      "http://www.spy.com/role/LeasesAdditionalInformationDetails",
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails",
      "http://www.spy.com/role/ParagonAgreementDetails",
      "http://www.spy.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://www.spy.com/role/SeriesANonVotingConvertiblePreferredStockDetails",
      "http://www.spy.com/role/StockholdersEquityAdditionalInformationDetails",
      "http://www.spy.com/role/StrategicLicenseAgreementsNarrativeDetails",
      "http://www.spy.com/role/SubsequentEventsAdditionalInformationDetails",
      "http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum",
        "verboseLabel": "Maximum"
       }
      }
     },
     "auth_ref": [
      "r359",
      "r360",
      "r361",
      "r362",
      "r409",
      "r583",
      "r630",
      "r670",
      "r671",
      "r733",
      "r735",
      "r737",
      "r738",
      "r747",
      "r759",
      "r760",
      "r773",
      "r777",
      "r785",
      "r795",
      "r860",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesNarrativeDetails",
      "http://www.spy.com/role/FairValueMeasurementsSignificantInputsUsedToEstimateTheFairValueOfDerivativeLiabilityDetails",
      "http://www.spy.com/role/LeasesAdditionalInformationDetails",
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails",
      "http://www.spy.com/role/ParagonAgreementDetails",
      "http://www.spy.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://www.spy.com/role/SeriesANonVotingConvertiblePreferredStockDetails",
      "http://www.spy.com/role/StockholdersEquityAdditionalInformationDetails",
      "http://www.spy.com/role/StrategicLicenseAgreementsNarrativeDetails",
      "http://www.spy.com/role/SubsequentEventsAdditionalInformationDetails",
      "http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r359",
      "r360",
      "r361",
      "r362",
      "r401",
      "r409",
      "r440",
      "r441",
      "r442",
      "r559",
      "r583",
      "r630",
      "r670",
      "r671",
      "r733",
      "r735",
      "r737",
      "r738",
      "r747",
      "r759",
      "r760",
      "r773",
      "r777",
      "r785",
      "r795",
      "r798",
      "r854",
      "r860",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919"
     ]
    },
    "agle_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition Assets Acquired and Liabilities Assumed Net",
        "terseLabel": "Asset Acquisition, net liabilities assumed",
        "documentation": "Asset acquisition assets acquired and liabilities assumed net."
       }
      }
     },
     "auth_ref": []
    },
    "agle_AccruedOptionCostPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "AccruedOptionCostPayable",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/AccruedLiabilitiesAccruedAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/AccruedLiabilitiesAccruedAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Option Cost Payable",
        "terseLabel": "Accrued option cost payable to Paragon",
        "documentation": "Accrued option cost payable."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "presentation": [
      "http://www.spy.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents",
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r208"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails",
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquitySummaryOfEmployeeAndNonEmployeeStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "terseLabel": "Outstanding option awards",
        "periodStartLabel": "Shares Issuable Under Options, Outstanding, Beginning balance",
        "periodEndLabel": "Shares Issuable Under Options, Outstanding, Ending balance",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r419",
      "r420"
     ]
    },
    "agle_SummaryOfSignificantAccountingPoliciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "SummaryOfSignificantAccountingPoliciesTable",
     "presentation": [
      "http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary Of Significant Accounting Policies [Table]",
        "terseLabel": "Summary Of Significant Accounting Policies [Table]",
        "documentation": "Summary of significant accounting policies."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquitySummaryOfEmployeeAndNonEmployeeStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodStartLabel": "Weighted Average Exercise Price, Outstanding Beginning balance",
        "periodEndLabel": "Weighted Average Exercise Price, Outstanding Ending balance",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r419",
      "r420"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquitySummaryOfEmployeeAndNonEmployeeStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Outstanding",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.spy.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://www.spy.com/role/NetLossPerShareScheduleOfReconciliationOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average common shares outstanding, basic (in dollars per share)",
        "verboseLabel": "Total basic weighed average shares",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r261",
      "r268"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquitySummaryOfEmployeeAndNonEmployeeStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Shares Issuable Under Options, Options exercisable",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r421"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquitySummaryOfEmployeeAndNonEmployeeStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Options exercisable",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r421"
     ]
    },
    "agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodFairValue",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Granted In Period, Fair Value",
        "terseLabel": "Pro-rated estimated fair value of options",
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Granted In Period, Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "agle_CashEquivalentsUnrealizedGains": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "CashEquivalentsUnrealizedGains",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesEstimatedFairValueOfCashEquivalentsAndMarketableSecuritiesAndTheGrossUnrealizedGainsAndLossesDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesEstimatedFairValueOfCashEquivalentsAndMarketableSecuritiesAndTheGrossUnrealizedGainsAndLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Equivalents Unrealized Gains",
        "terseLabel": "Cash equivalents,Gross Unrealized Gains",
        "documentation": "Cash equivalents unrealized gains."
       }
      }
     },
     "auth_ref": []
    },
    "agle_MeasurementInputProabilityOfSuccessMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "MeasurementInputProabilityOfSuccessMember",
     "presentation": [
      "http://www.spy.com/role/FairValueMeasurementsSignificantInputsUsedToEstimateTheFairValueOfDerivativeLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Proability Of Success [Member]",
        "terseLabel": "Estimated probability of success",
        "documentation": "Measurement Input, Proability Of Success"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinued Operations and Disposal Groups [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityAssumptionsUsedToEstimateTheFairValueOfStockOptionsGrantedDetails",
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "verboseLabel": "Expected dividend yield",
        "terseLabel": "Dividend yield",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r441"
     ]
    },
    "agle_FairValueAssetsLevel1ToLevel2TransfersAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "FairValueAssetsLevel1ToLevel2TransfersAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Assets Level1 To Level2 Transfers Amount1",
        "terseLabel": "Fair value assets transferred from level 1 to level 2",
        "documentation": "Fair value assets level1 To level2 transfers amount1."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityAssumptionsUsedToEstimateTheFairValueOfStockOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r440"
     ]
    },
    "agle_USBankingInstitutionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "USBankingInstitutionMember",
     "presentation": [
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesNarrativeDetails",
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "U.S. Banking Institution [Member]",
        "terseLabel": "U.S. Banking Institution",
        "documentation": "U.S. Banking Institution [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.spy.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r240",
      "r462",
      "r469",
      "r471",
      "r477",
      "r481",
      "r484",
      "r485",
      "r486",
      "r646"
     ]
    },
    "agle_ParapyreOptionObligationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "ParapyreOptionObligationMember",
     "presentation": [
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.spy.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.spy.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails",
      "http://www.spy.com/role/ParagonAgreementDetails",
      "http://www.spy.com/role/ParapyreOptionObligationAdditionalInformationDetails",
      "http://www.spy.com/role/RelatedPartyTransactionsRelatedPartyAccountsPayableDetails",
      "http://www.spy.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Parapyre Option Obligation [Member]",
        "terseLabel": "Parapyre Option Obligation",
        "documentation": "Parapyre Option Obligation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "USGovernmentCorporationsAndAgenciesSecuritiesMember",
     "presentation": [
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesAvailableForSaleSecuritiesInAnUnrealizedLossPositionDetails",
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesEstimatedFairValueOfCashEquivalentsAndMarketableSecuritiesAndTheGrossUnrealizedGainsAndLossesDetails",
      "http://www.spy.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "US Government Corporations and Agencies Securities [Member]",
        "terseLabel": "U.S. government securities",
        "documentation": "This category includes information about debt issued by US Government Corporations and Agencies. Investments in such US Government Corporations may include debt securities issued by the Government National Mortgage Association (Ginnie Mae) and by the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac)."
       }
      }
     },
     "auth_ref": [
      "r921"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "presentation": [
      "http://www.spy.com/role/FairValueMeasurementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Changes in Derivative Liabilities",
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r103"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityAssumptionsUsedToEstimateTheFairValueOfStockOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r442"
     ]
    },
    "us-gaap_CommercialPaperMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommercialPaperMember",
     "presentation": [
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesAvailableForSaleSecuritiesInAnUnrealizedLossPositionDetails",
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesEstimatedFairValueOfCashEquivalentsAndMarketableSecuritiesAndTheGrossUnrealizedGainsAndLossesDetails",
      "http://www.spy.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper",
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r800",
      "r801",
      "r802",
      "r803"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "presentation": [
      "http://www.spy.com/role/FairValueMeasurementsChangesInDerivativeLiabilitiesDetails",
      "http://www.spy.com/role/FairValueMeasurementsSignificantInputsUsedToEstimateTheFairValueOfDerivativeLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r103"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "presentation": [
      "http://www.spy.com/role/FairValueMeasurementsChangesInDerivativeLiabilitiesDetails",
      "http://www.spy.com/role/FairValueMeasurementsSignificantInputsUsedToEstimateTheFairValueOfDerivativeLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityAssumptionsUsedToEstimateTheFairValueOfStockOptionsGrantedDetails",
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails",
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquitySummaryOfEmployeeRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r415",
      "r416",
      "r417",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "presentation": [
      "http://www.spy.com/role/FairValueMeasurementsChangesInDerivativeLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/FairValueMeasurementsChangesInDerivativeLiabilitiesDetails",
      "http://www.spy.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "verboseLabel": "Change in fair value of liability",
        "negatedTerseLabel": "Change in fair value",
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r513"
     ]
    },
    "agle_AccruedLiabilitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "AccruedLiabilitiesTable",
     "presentation": [
      "http://www.spy.com/role/AccruedLiabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities [Table]",
        "documentation": "Accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails",
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityPreFundedWarrantsForCommonStockIssuedAndOutstandingDetails",
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquitySummaryOfEmployeeRestrictedStockActivityDetails",
      "http://www.spy.com/role/StockholdersEquitySummaryOfPreFundedWarrantsForCommonStockIssuedAndOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r412",
      "r413",
      "r415",
      "r416",
      "r417",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443"
     ]
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentTypeCategorizationMember",
     "presentation": [
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesAvailableForSaleSecuritiesInAnUnrealizedLossPositionDetails",
      "http://www.spy.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments [Domain]",
        "terseLabel": "Investments",
        "documentation": "Asset obtained to generate income or appreciate in value."
       }
      }
     },
     "auth_ref": [
      "r664",
      "r665",
      "r666",
      "r667",
      "r669",
      "r732",
      "r734",
      "r736",
      "r739",
      "r740",
      "r745",
      "r746",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r798"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails",
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityPreFundedWarrantsForCommonStockIssuedAndOutstandingDetails",
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquitySummaryOfEmployeeRestrictedStockActivityDetails",
      "http://www.spy.com/role/StockholdersEquitySummaryOfPreFundedWarrantsForCommonStockIssuedAndOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r412",
      "r413",
      "r415",
      "r416",
      "r417",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r225",
      "r465",
      "r466",
      "r471",
      "r472",
      "r476",
      "r478",
      "r640"
     ]
    },
    "agle_AccruedLiabilitiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "AccruedLiabilitiesLineItems",
     "presentation": [
      "http://www.spy.com/role/AccruedLiabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities [Line Items]",
        "documentation": "Accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Period Increase (Decrease)",
        "terseLabel": "Number of common stock to option outstanding",
        "documentation": "The increase or decrease in number of shares reserved for issuance under stock option agreements awarded under the plan that validly exist and are outstanding, including vested options."
       }
      }
     },
     "auth_ref": [
      "r871"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Purchase Date",
        "terseLabel": "Percentage of fair market value of common stock",
        "documentation": "Discount rate from fair value on purchase date that participants pay for shares."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "dei_AddressTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AddressTypeDomain",
     "presentation": [
      "http://www.spy.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Address Type [Domain]",
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "auth_ref": []
    },
    "agle_ReimbursableResearchCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "ReimbursableResearchCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/AccruedLiabilitiesAdditionalInformationDetails",
      "http://www.spy.com/role/ParagonAgreementDetails",
      "http://www.spy.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reimbursable Research Costs",
        "terseLabel": "Reimbursable research costs",
        "documentation": "Reimbursable research costs."
       }
      }
     },
     "auth_ref": []
    },
    "agle_RelatedPartyExpensesIncurredPriorToAssetAcquisition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "RelatedPartyExpensesIncurredPriorToAssetAcquisition",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/AccruedLiabilitiesAdditionalInformationDetails",
      "http://www.spy.com/role/ParagonAgreementDetails",
      "http://www.spy.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Expenses Incurred Prior To Asset Acquisition",
        "terseLabel": "Related party expenses incurred prior to asset acquisition",
        "documentation": "Related party expenses incurred prior to asset acquisition."
       }
      }
     },
     "auth_ref": []
    },
    "agle_RelatedPartyExpensesUnpaidPriorToAssetAcquisition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "RelatedPartyExpensesUnpaidPriorToAssetAcquisition",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/AccruedLiabilitiesAdditionalInformationDetails",
      "http://www.spy.com/role/ParagonAgreementDetails",
      "http://www.spy.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Expenses Unpaid Prior To Asset Acquisition",
        "terseLabel": "Related party expenses unpaid prior to asset acquisition",
        "documentation": "Related party expenses unpaid prior to asset acquisition."
       }
      }
     },
     "auth_ref": []
    },
    "agle_ResearchInitiationFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "ResearchInitiationFees",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/AccruedLiabilitiesAdditionalInformationDetails",
      "http://www.spy.com/role/ParagonAgreementDetails",
      "http://www.spy.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research Initiation Fees",
        "terseLabel": "Research initiation fees",
        "documentation": "Research initiation fees."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.spy.com/role/AssetAcquisitionNarrativeDetails",
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.spy.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityAssumptionsUsedToEstimateTheFairValueOfStockOptionsGrantedDetails",
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails",
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityStockBasedCompensationExpenseDetails",
      "http://www.spy.com/role/ParagonAgreementDetails",
      "http://www.spy.com/role/ParapyreOptionObligationAdditionalInformationDetails",
      "http://www.spy.com/role/SubsequentEventsAdditionalInformationDetails",
      "http://www.spy.com/role/TheCompanyAndBasisOfPresentationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/IncomeTaxesSummaryOfDifferenceBetweenProvisionForIncomeTaxesAndAmountsComputedByApplyingStatutoryFederalIncomeTaxRateToIncomeBeforeIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/IncomeTaxesSummaryOfDifferenceBetweenProvisionForIncomeTaxesAndAmountsComputedByApplyingStatutoryFederalIncomeTaxRateToIncomeBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount",
        "verboseLabel": "Permanent differences and other",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates."
       }
      }
     },
     "auth_ref": [
      "r464",
      "r468"
     ]
    },
    "agle_PurchasedSoftwareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "PurchasedSoftwareMember",
     "presentation": [
      "http://www.spy.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
      "http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchased Software [Member]",
        "terseLabel": "Software",
        "documentation": "Purchased software."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityAssumptionsUsedToEstimateTheFairValueOfStockOptionsGrantedDetails",
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails",
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquitySummaryOfEmployeeRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r415",
      "r416",
      "r417",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443"
     ]
    },
    "agle_ParagonAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "ParagonAgreementMember",
     "presentation": [
      "http://www.spy.com/role/AccruedLiabilitiesAdditionalInformationDetails",
      "http://www.spy.com/role/ParagonAgreementDetails",
      "http://www.spy.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Paragon Agreement [Member]",
        "terseLabel": "Paragon Agreement",
        "documentation": "Paragon agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquitySummaryOfEmployeeAndNonEmployeeStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Shares Issuable Under Options, Options vested and expected to vest",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r435"
     ]
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermDebtTypeDomain",
     "presentation": [
      "http://www.spy.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt, Type [Domain]",
        "terseLabel": "Short-term Debt, Type",
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquitySummaryOfEmployeeAndNonEmployeeStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Options vested and expected to vest",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r435"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/IncomeTaxesSummaryOfDifferenceBetweenProvisionForIncomeTaxesAndAmountsComputedByApplyingStatutoryFederalIncomeTaxRateToIncomeBeforeIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/IncomeTaxesSummaryOfDifferenceBetweenProvisionForIncomeTaxesAndAmountsComputedByApplyingStatutoryFederalIncomeTaxRateToIncomeBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "Tax provision derived by applying the federal statutory rate to income before income taxes",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r468"
     ]
    },
    "agle_MarketableSecuritiesMaturityPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "MarketableSecuritiesMaturityPeriod",
     "presentation": [
      "http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities Maturity Period",
        "terseLabel": "Marketable securities stated maturity period",
        "documentation": "Marketable securities maturity period."
       }
      }
     },
     "auth_ref": []
    },
    "agle_SummaryOfSignificantAccountingPoliciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "SummaryOfSignificantAccountingPoliciesLineItems",
     "presentation": [
      "http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary Of Significant Accounting Policies [Line Items]",
        "terseLabel": "Summary Of Significant Accounting Policies [Line Items]",
        "documentation": "Summary of significant accounting policies."
       }
      }
     },
     "auth_ref": []
    },
    "agle_NumberOfSubsidiaryCorporationsOwned": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "NumberOfSubsidiaryCorporationsOwned",
     "presentation": [
      "http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number Of Subsidiary Corporations Owned",
        "terseLabel": "Number of subsidiary corporations owned",
        "documentation": "Number of subsidiary corporations owned."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.spy.com/role/AssetAcquisitionNarrativeDetails",
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.spy.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityAssumptionsUsedToEstimateTheFairValueOfStockOptionsGrantedDetails",
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityNarrativeDetails",
      "http://www.spy.com/role/LiabilitiesConvertiblePreferredStockAndStockholdersDeficitEquityStockBasedCompensationExpenseDetails",
      "http://www.spy.com/role/ParagonAgreementDetails",
      "http://www.spy.com/role/ParapyreOptionObligationAdditionalInformationDetails",
      "http://www.spy.com/role/SubsequentEventsAdditionalInformationDetails",
      "http://www.spy.com/role/TheCompanyAndBasisOfPresentationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890"
     ]
    },
    "agle_LaboratoryEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.spy.com/20230930",
     "localname": "LaboratoryEquipmentMember",
     "presentation": [
      "http://www.spy.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
      "http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Laboratory Equipment [Member]",
        "terseLabel": "Laboratory Equipment",
        "documentation": "Laboratory equipment."
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "940",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "SubTopic": "20",
   "Topic": "205",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-10"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a-c)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "SubTopic": "405",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481071/942-405-45-2"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-5"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "205",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c),(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Subparagraph": "(c)",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "60",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(27)",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "205",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-3"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-8"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.24)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.27(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-13"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-4"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "420",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "420",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "420",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "420",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB TOPIC 5.P.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "420",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "63",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481620/480-10-55-63"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(CFRR 211.02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-11"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "05",
   "Paragraph": "4",
   "Subparagraph": "(a)-(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479515/805-10-05-4"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "37",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479303/805-10-55-37"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-31"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-7"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "40",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-4"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "40",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "320",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-5"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205/tableOfContent"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205-20/tableOfContent"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-11"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-3A"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-4A"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-4B"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5A"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5D"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r136": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r137": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r138": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r139": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7(a),(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r140": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r141": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r142": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r143": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r144": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r145": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r146": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r147": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r148": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r149": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//275/tableOfContent"
  },
  "r150": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r151": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//360/tableOfContent"
  },
  "r152": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r153": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-2"
  },
  "r154": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r155": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3A"
  },
  "r156": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480091/360-10-S99-2"
  },
  "r157": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r158": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481573/470-10-45-12A"
  },
  "r159": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r160": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r161": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r162": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r163": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-4"
  },
  "r164": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "710",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//710/tableOfContent"
  },
  "r165": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "712",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//712/tableOfContent"
  },
  "r166": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//715/tableOfContent"
  },
  "r167": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r168": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r169": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r170": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r171": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r172": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r173": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1"
  },
  "r174": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//810/tableOfContent"
  },
  "r175": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-3"
  },
  "r176": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r177": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r178": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r179": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r180": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r181": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r182": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r183": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r184": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r185": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.14)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r186": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-6"
  },
  "r187": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-6"
  },
  "r188": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-6"
  },
  "r189": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-7"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "210",
   "Topic": "946",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-20"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "210",
   "Topic": "954",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-5"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-11"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(n))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//260/tableOfContent"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-2"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481664/323-10-45-1"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-5"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//420/tableOfContent"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-1"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-3"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.E.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-15"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481839/830-10-45-9"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482014/830-20-35-3"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-12"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-2"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//850/tableOfContent"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//855/tableOfContent"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482312/912-310-45-11"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-3A"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-21"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5D",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5D",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-8"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479908/805-50-55-1"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3"
  },
  "r813": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r814": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4H",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H"
  },
  "r815": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r816": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r817": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r818": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r819": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r820": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r821": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r822": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r823": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r824": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r825": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r826": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r827": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r828": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r829": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r830": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r831": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17"
  },
  "r832": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r834": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r835": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r836": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r837": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r838": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r839": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r840": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r841": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r842": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55"
  },
  "r843": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18"
  },
  "r844": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13"
  },
  "r845": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//320/tableOfContent"
  },
  "r846": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11"
  },
  "r847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-5"
  },
  "r854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r855": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482047/420-10-45-3"
  },
  "r856": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r859": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r860": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r861": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r863": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r864": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r865": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r889": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r890": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "15",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480123/805-50-15-3"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480060/805-50-25-1"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480027/805-50-30-1"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480027/805-50-30-2"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479365/842-20-25-6"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r909": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r910": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r911": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r912": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r913": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r915": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r916": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r917": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>167
<FILENAME>0001193125-23-302158-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-23-302158-xbrl.zip
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MRU"_,VBA:=U1^@S>YW9$!OJ@E=/W!7BBMV$RZ(VN_\Q(%,["<ETCIW/;AL0
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M&E"4@9S39$J^J:#,0E"G&Y7%+L8#@Q#*U23RN$FI&'-URW@]NP@9 $P8W[R
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M!,[I:^F73[D6I(>\7)V_%H#[6!RH->[4O-B&1)=IG7!_09?DK_\/4$L#!!0
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MHM;A^?IO("'Q?+?9\K)[$]UAW"C.Q)_/$8QM%YVC^!FA$.:H)Y]N>6%Y*Q0
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MM<:[$T7!@;"E@B'@RYB;I<]3#O:SIXE&0*(QETME+B\>H=%?Q<JEAD.8&(.
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MXTY=^7V&&F6'P% #.)8=614(G=Z7[/U?HKO1T*AA"$0V!F597A[%%#')KI*
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MVI=R*MM]4\Y6W;;395$G5.('AZ __QM02P,$%     @ \(.65^>Q@Q*,B@
MB=,( !4   !A9VQE+3(P,C,P.3,P7V1E9BYX;6SLO6MSXTC2+O;=$?X/X_'G
MV1%UU\99GZ"D5J^.U:(LL6?.L</!@(@B"0\)<'%1B^/P?W<6P M(5M8%J!LY
M$_&^.RVIJI!/9EVR,K,R_\M__9Q-?_H@:18E\;]^[OSCY.>?2#Q,PB@>_^OG
M(A_]<OWS?_W?_N?_Z;_\+[_\\I7$) UR$O[TOOCI_N'Q^:?_?OOZ]--CG.5!
M/"0_W2?#8D;B_*=??IKD^?R?O_[ZX\>/?X2C*,Z2:9'#![)_#)/9K_#WWZH/
M_O1Z]H\3^!'^=7KZRST9DMD[27\Y/3D]^^G_.KG\Y\7-/\\O_^^?_M^7;__?
M+[]0*J91_,=[D)&?@.HX^]?/M>]\OJ?3?R3I^-?3DY.S7U<-?ZY:_O,SB[9:
M_SA;M>W\^M^_/;T-)V06_!(MH:Q[T6%8_3HW-S>_EG^%IEGTSZSL_Y0,@[SD
MHY"NG] 6]*=?5LU^H;_ZI7/ZRUGG'Y]9N*8+VH3Y^C/U 2Y^K?[X,V57FDS)
M*QG]5%+ZSWPQ)__Z.8MF\RE%6/YNDI+1OWX.QE-2<OWDYNR$?NA_O4M@3KP$
M8VA(!_G^^K@%*ILO2E'2O_U::_MKVZ_&(8DS$L(_8,Y$(9UMM\&4RN1M0DB>
M29$C'L0XG2]!"BMA0O)H&$RU$+TSH@D$;SG\+UW!66_4F].U3M=L4^JQT>Q1
MKD4(4D.;QG0W">(QR1YC: "++8_>I^0%!B-I2ALFPS^Z<?7?23(-87.])Z-H
M&.5?_E-$^4(']+84&.=0D$T>ILD/+=.U-EA+NM>C]D;=+(-EW!T"0X!EP*VG
M*'B/IE$>D0S^!D=G*$&[ZH MZ>]/R%TRFP?Q L:_#;((N -BSX" <B$\!RE=
M$1_DGN1!-)7AOOJ0+3'<DVR81G,Z=F\$7[\MLB@F648G;#&;!>FB-WJ+QG$$
M$S:(\^YPF!1Q#@K0"\R-(3!SW:KD>,GP+*+#W259+@_<$AVNN=4-PY*H8/H8
MCY)T5@K5(I?XWV_)'?A<6I"ME=8.KNJ +>F'<RN8+U+2JQC\/HW&Y?@M430;
MMNW>:F,Z>C#G%#>'[QD9%=,GV$#+C34!G26G6RT]B>?TY- -OL&76W+D(8C2
MWX)I0;Z1("O2ZMA^B&+0EJ-@NCP7M\[#9<.PFZ_[]N)7,BS2%)"4IY \6\Q^
MW@1O&AS3DN.8H':M:]Z3-/HHOU?C94L(DH.;P%5;18_QO,@S6#!A/_F2Y1'L
M& 0.N\WL&.V3MVB)7-OGV^KRH%W3+>$CF%*R8*5\"](_8'"X4KS1-5%*8D56
M6"-*KB?\&K!\39,L^QZG))A&?Y+P:Q#%Y:*$WZK,(9^(M<+W[@=\C/[J(4G?
M@OI?'N-NO*&1TO:25/JG;G:VHL$*EQILJ$T';JOQ,<[A9Y)3BV=83 G[H(8&
M"LI?VR^80=A6I6TR:DLD3[!;M]98909I;=78V'DJ T];+5MQ0.WTKW78EY0\
M%'%(PM_I0J1Z79+>);-9$I>='K.L*&TM/3@_\R"F?I(V,+5\MR4W7LF4'EUP
MA\L7??AV%@Q+&V>#/4Y^*$,T?_F<4\M>MOQ[/ZDW_'T2#2>_DQ2VVSR?DO Q
MIGMR>W1M/FJ(#_7?+V]LV4NPH&=->[PR@[>UL^Q8N!K,1?$0FFEL9QU4&DV#
M%6@,GQBGA*A9!-">;7=DN&[ H?6<Q+\EU+: >AD4-EOE(=N>WIMK9",GB=&C
MQR5QCOG:8._0_TG'/%CK&5_@:\F" !E9GD;#?-47=O8/)1.#=8I<<Y#^X38H
MO88S>MZ7&NGRZ+?(-BDR'/.J]#Z6K@"NC:GL7[D,LJ]T4R&A/49JH+'U+81&
M4XVCX5,TI-);'ZI--&^5P=K2'927>C+^,YH&Z3B*83;VD\?9C(31,% @66Z<
MEM0^QO!!T@\^6U^LI4?21_%ZD[R/1C"O23PDMR3_04C\DB8?$8VA@W.X3E@<
M=F>E0DZWAX(&$2VZ\_ET ><Q#1TH\B1=/!!8#93T9;=7.NN3ZL=; GA(;<1&
M_/&);GW2H*0E<14B<K_<9^ /+(=/(ZXU&;\ENF>2ET94DKY-@I3\3J+Q!)C?
MA?TT&)-JIZ0!GFD9V0DWW>&T "7P(4UF=\%T6$R#RE%_'TVIT':&D^>")3I:
MW[9II"PISX2W.4BBY8ZB.%YKZBG_AGE!?8YWP)=Q(SNVW# &:%U[[I8Q$UMM
MEK&2[6 H?<$,0OJ?M1T)5)&M9DN=6&E_T?2=UC$,[QGY3P%K]\M'Z?UH&Y6A
M,IP6J_S&G;&, @4VQ>'2ZQ^/JT;+.#9JY:L'[ZH:[[5\R_$=H$_-@384^=6'
MM/L$I!'@737/O&]!OG03LF8&*9LW4D)T?<B,)T]:$(+^VF=(H[EA*1Y,?O8J
M#:=/FZ[^2=6T'=U]:<RX7?PWF(,9W 4;7],:?D*O3KU95:]DF, &/HV6RBJ-
M^QK"7-6L/+?^H)Y=:S6MRA_5?"'"$5K'.(^BN S_S]/HO7R:]@(GJ%1T,M)3
MW[J07KB,/F;XTCJBN\&H^OBIQDE-LU]ZDFOZGKRVM=5<[TK?N;6_DED0Q2M]
MM4_26;GU9.710FTWU(>$:1?JRHM9*LQH-LUU&N?Z_9[_!AH_)_'JIYK=W /?
MDCQM;<_^Y&-YUGX+XF(4K"[4:VN\PJDN/93KF5 V^!&DH7TO#N?;QKPS]:>0
MT&B8-[IRM1S?2I3KBH BF-9OA,R0W7P_!EIW;*PN<O2\ :/!#OF$I'=%2M\"
M-YH$\D,9?L>IX=VFI7NMMANMF3<>31]G6%K1VM:B^56D8_D8BZ]L$3VI/>ZP
M07"A]@C"!J&#]F(&=08+.M>V+"A5!G6G5HJ1X<B5UB$KNBV'ZJ8_(U[)ADY&
M\W<I'9<H]_D2%!0;C=\RH/M(VZ!XG:UH0=*4J@UG6B.2)EMZ)$/:D32AH@$T
M:TKR#$0Z&CL7%7S-HB'TGD'2A"']#)Q'"K,+[VP\'Q5<E5,R@3;T"3TP1DM>
MJOU!79]>-DXM]RBEIYRV+QG*\],BEX_V&+ &<5[Z(SB;1&D:R"+5*%.4 3I4
M50S].@4C(99V>VNCP95P40*R56K649"]E_E9B^R7<1#,?Z6 ?R73/*._H4-F
M)0]*_(2$LWTD>T.4<&C;7[]\YO1  .9_B8O9,D'E4Y2M5TN0#E=D+_]9'WF=
M/#:*\U_#:/;KLLVOP73ZLQ1.1AK;519:FK_VHH15CM:&'/@WA9G$OX1D%!33
M7"-QC+$UD9I0Y[,92I=#MR*T'..769EV62>5V^.V(7$"U*3#XIW\LH:ND5#F
MZ&W(C9.\JW7=K 8LB0II)$U4K>_XCZV/$+H+A#3C9_5;2HU,RN8RJW8RW!IK
M2O-8)REG1\O(\!_CY./7D$359@;_V&QA\,-@E0R\%ML#-)-'T&6SU<#3X)U,
MR\\-1%T&G9O3LR473)+;AQ$%Y-$F@\[)Z9Y,NNDV73 G5D,MIT?#%3E*DYD2
MFY94)#SBBPS(2>95!-;//R5I2-)__=PQR.,OH.CFBU>XO,*U#)3?YV"&\9K5
M%,B^.BB>XR#8O#\USGL:YY;.DTI%*"^6=_3ZD2[NDI O"FY/ '5]@)*1P,06
ME,F-J"*M'WP^AH"JO":6R4N*.@N8(D+Z )"; Q0.%PU;+.?&Q=(-PY1>YJO_
M4"@=KD@8[0>=SLD!B@-%PA;%A0-1G"J*XA0 =(Y"%$LD;%%<.A#%F:(HS@#
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M@$;KL!56+VJ<[,%647T AU,C?2.9(2B\J%S"/:N;ZC34V.'T;J%?;5E"\J*
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M?-%/@S@+AM5%;E'_B^!AIOP@P"TS]]TVCV J"2+^,S5D/CS:K%,F?/:WWQB
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MET1OBM509+*\^U]:)(HBW8/I1:B %9&Z-I39EJV- (2GX)W>HY)TL::"'WN
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M?\2Q6P.Q3DWHO&G..(IX('0\.<?<&]3NTI^0-)B3(H^&V6,\%'@RT!Y K-/
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MC<J#D^(6: U8E\'%Q5_$7B['"2]*%+%(%.[B>"= YLKB+L=T>4'5 7E1LLB
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M"HE#T96DPC0?YM#AGF3#-"II1%>^@6]1#AV2(\,@#Y!9HL,\9&!J]Y,[DN;
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M;5!:N*,C/Q6R=I<?WZ[.@JU99F-*HU,?@2$)"A%[D7N*'8 F%54KZDJYXC0
MP,'29.#WHD21)][ ,T,67X\GA"13!!FM3+H.D41>V3,EM0IHL>T-1$B2\?6)
MN@XN+UPY\C!&WRZV_B+MM%,8;W!YZL _)R<+D?--&:9??C9!?JAUR! GJ]Q6
M&\!HQKG2T"JI+IXM>2/XC#G#9,6!FKL8K8!D0X9ZJ=1S#/9Q>%PGV9@_RQ27
M7=L3V[#;1E$56&O!.(G[$Y(&<U+DT3![C(=\2PJO#]#M)-X?G;&,.Y:8?G.E
M4QZ"*)TE19S3"*OL6Q 'E2+Y-!4P7=AQ<.GF(9,*YR5!:/ C\:=[-Z:'3#!?
MI(1&R=*:B2+^BWL.3D_<N%\;S'TQ#!]<2?H3RU^>>15!U%(5DD;L0RD4,TG+
M+TU5@->2;;YDOI+,ZK!\J(YB3&JN%3/3XM-;,$7TF.<1;JXIR00%V)#F0*Y3
M>[K$4F"<9%PP.CQ@J--WG@#0WN@V"=)0Y.S=;PL$>IR&'^,VCL2@KVBEK,B5
M%V2W!B*=1C,T8S</BPXW$):#DK[OV#)UQ^$KR0A@GL _[\D'F2;S,O*R2D7+
METC#X0"FTU?\S436"JS!6B2O))J]%VGIWBU?L)>Y@=66ELH8 ,A)DI3V0F (
M51VXCDHC6-A+-(5C+HG)*G>P(."%W1S(=!HDW&QU<<&8*SBBH"D_14.J<\;C
M];3 Y2/L [B<ILU0%I(D(AT%3+"S:[XX.>E4WR>2^QJOS^#RW&F<4,-32(C(
M66$3^5)(E^?'9*5A8#-7_41K'9_+]4MDMP622IXA3*V3:JX0B6ZVNK9^-.&O
MR**AHYR(]MI(EV[2#S&GYSZ'&;2:*]$AXBUP1\C;>AN@UXDA0Y:W^[3J**AA
MRJ*Z<YHT\W$P!@'D9NP?7KH\4 ;H*-RA5?1*%O25TG?NN@R\*MO%PJM#\Z(&
MB 8AN3[=;4A+J W8O7W7B11>N_<; R*GF7VQ%2&62)U^<T4^!+K#'8WI(.F<
M$O0<S'BW/%93H-ZKTK<:+GPX3'-E/$27%#)?II!;VP5VJ>1&UTGW!YRN'E+S
M6<^XXJAATE&VPW_9N3Z^C I1=&Y9+NP!MY0DC?+%RHG-2 AYNWA.8AJ;#OR#
M3X^K)ISCK?&8@\L+'P,!GF3"_UN"UE%&!'7 ,5&MLO"7#O4W$N!IMJ4' "@^
MAA9PY=<$H8[J(JB/K>$THI6#'N/^)$HK&+A73M,'@!4^!C:(A:V9 SIJEDBL
MW*6_F$:*%[2.RDL:)6D_Z689R;O#_Q115@I 9@U+#@7P? R#4%O-2E@-UAE9
M!0$\4C:6D0%(86E.:R#2FTNBHD!P.#JJ@DA$GJQ(X-:30#L J3[&+,APGHO(
M8%4/UB+\'L^#2,?.Q1T(H/D8N]!LWY) JJ,4B+&G$N5KFZPWJOU.W:W &F5P
M>>EC>(3474$9IHZJ'>T3JPV')7TOP:(,1Z/G:9QSI,GN (B<YE1H(S@>(H,U
M,P37DY<T&:?!K%=^6U!AL-5X -1I>C!3]SL!8(.E*ZHE3^MGO, V7P9WKFU(
MF/1X?8#@@[.@2(+24:0"KURTO/CU1MTX+H)IE4GV:YD69;2<%YL2*+49PJB&
M@LE-[U> *8=I:S'!!D$="SOG8TG=NSA9S_MNLIY-LJVJI!/G2-7V#>#;P5EO
M##$!F3QVHW+8F9Y$,V&O R Z.)N-#")$1JL=T$6VJ=4-;?GW?E)O6.4Y)"EY
M(WD^)>%C?!=DDR/+2W5E4+?=>_BBJ,ON]1]<7GM^7[QB)UQ5 ^A%]14_$HA=
MFK$"M4P@MB]E#3 U)A"SJS,9R+!Q9>8"9".4YQ*=&T+$/A1Z,92KX<K0/4=/
MA@W*?"69U6'Y4.K%F-1<A_&8%I\HDD>W"\O.X^DK'Z^%]34C\'+)(?2A4LQC
M#'<,LJXE]40_(C[[.+T FIG+G]NS3XC8AU1A")'"793;#^"Y+DLG9+Z2S.JP
M?,@)9DQJOIQ]IL0G.OML)PEKDB)&H3= =AK_(;&<,"5&$IN.)&&']S3QRHQ)
MR,N[(LH +ZKUM'[U=F4HJ,#(TT3*=K'PZM!T9#GS04B^'(PFI25,O>C.+-/H
M:>*5-T$?]14AEDB=?D&",Q<.I*V)MAU8=&2.HIN_I/_AVHPANJ7_X09=.BU@
M^E7 Q&>-\]JK LWJ@FZM<5[C>5 .2Y>Y-F0H-:)P7J/E@S%HOCF4&LKH$/5-
M56%IK=/B7MV\]B:"J;X>Y-7-:]0D[2Z1C";?^O7A%O)2/KTVB'UP%AGRTEZ[
M*@,FS?Q&SMEKOPO(M)>:Y\=::_&)CC0E-Y$WOO5K']\EUM=,:]_Z-?H>44>L
MZ,NR9%3U1J#W/HW&I1]$7)<![P4W8A_C0@52D<'DA4M'VZ/!&V^,D*IV%1XB
M@>_%I%ER]S&QP^K)NZ3(6!W1/H.K$\OO8G<H$9D3F>UA.IBQ)W#-A0(F(O,9
MI_]@[8#5$[151IC'+"M(V$OI?RFXVT4?OBVX.,D. 9SR($J+)T2FU-7@^6#A
MXU-,Z17JX;)# &C7@5IJ\FDBXUVX/E@(+<O8EVN7;6'[96&L/?\5&ACWV@(<
MIZ%<:FN,+3H$E ]&QW6,VMTTR++>J"12<'*B?0"6F1NSV:-2@,<'<V*=,N$.
MN=\8U$-#EV;I\T[ 9&3A($A\L!5J$(DOQY-&V=@P!+Z1-")9]SF)?TOR*![?
M)?$'2?,(EOD+]",T;R#_M&DR#*!SF@<)6PL,:U,C9#X$AK],@YB3#Y[5#(@W
M8VDR>^;L0_#"_+<B2[BA;3<$!(;2&$F?+_L,Y3.^3K@7$=4M6._+.=)<!L(0
M7!VYFM^H!9[^>J73T[Q&T0>AY CK/@IZ @BGZ9U8TYIU,D@"\2(0>G=3%9P*
MK.: QH-J5LJG PY%1^%G[8(1;EGL#H#(=7TJG-%R@JD#T5')V2?1^'*JZ).1
M\)31D4BYW&+[$Y(&<U+DT9"F,I<X79@]@&BG&<1YTQT[73A #%9SWJ44KCQ9
M!,.77O;2 UQ=>UCFO&X<KNQY5<9"3%!:/P(L<1I>HN1+- 5?1W%I9$;4\E#"
MQ[_'Y!,.["A;WGR7:2LQ24MU'EQUG(:BJ$M0 9:YDM,M3C-LQBF<;]@0@-JI
M>4>+:Y\/SERY:Q6'0[GZJTWA)8V&Y(6DY>]X#@>L#^!R&F;42&@"-#J*9=LX
M)+?2^O;B;MS-EG9&$MX&&?.JYH *8*K3#-N.CUE)_@BJB-N,:]N'G^4''^)F
M>9/5$^)VU3%S/6\:XG:*ONOGT'^P(6Y:K%\=#QX \82C8/WJX 6+#]/"TG']
ME@?GLYIAI8-7ICI4R?AM^VHB(JTA859,7QVOS"/UR:YH^NJ@A@ZWMN&&BJ6&
MR[;@"W#4^WH7E]=!6F'W(>9,%E#M?0W5U35,CYT1@26^WO+;3P<F5@WQ;9@)
M@%*4T@(7+VDR)%G&SCB(WMWEN@,*7R_=^Q)3!^9#*E1:GV1%] ,P@%^94Z(7
M0',:P=!HE0GQF'O<"O06,Q(^1<%[-(4O<MU&.RV!-J=INQNL#P2#%U%K5MT$
MIT[3G1@]BRIP#M^X[CY3/ZZ\>E?G.OR:3]&0)@/>/.6/IJ!')C%95DY#MR%A
MQ\&5YX682P8R-B=)9#Y8]?S(=7AUZF.M)89X-< \MEI+QG(=7IT=;';M2M#,
MF:/* !\,F6WSZ%V='5!R[9+K8MG5H?GPJ%6#C'PQ,IL4EM:B2\YS'5Z=>9/5
MIKX>Q *IT^^#;5%_KL.KLX.M(ZA^>FT0^_ 2UDS6O*LSG^L(ELQ7DED=E@\&
M1&-2\_Q8:RT^K;64.)GSY+,:(MG]KLX\K@U8K@/&79Z'18>Q$7==GYQT]@P)
M(N<UV@<(]B8MLCSSQ8AT/)7%1$!#%.NEY+MQV*Q26)OA *;3?#,-!=<&K!>U
MBAH]_3_S(-V,=IUO'Z(7KW$;OT\_=YUZ9I^A?,;7"??BO6T+UONBC#67@?#1
MIHZZS48R%5^=.XUB8DUG1.$2@=#Q7):]"K(TKZT ^&DS^^&'P6L0C[$C8>OO
M0*<':6"TG04,;#H>SS:7 ;H0=EH K:XRP3!XAC"U3JJ.%ZAVV.IZ*V_"7^'F
MK>$]J8#/WX+/:%;,N)S>:@-T.PF$8D[/?0XS:#7WL%/ VSN:*)VD<[J7<91W
MK"E0[T%V%JV;-@Y3Q[O.9AL-F1=P#0QJ-_I=*E'%4JD_X'25SX7/>L8VI89)
M\#SR2&3GPP%C3(BBD^A4Z3;--]LJ/8'A]0'"G>1_:;!$<%,N!QDB"AUOD5;6
MKT?*M/)"\T#P$%UV:R#R, /B>' 0GNNX1=?I7=H9J<1I 16:Z2!)^\EN*"HN
M$.6A!E<7/E8&DI%60ZR(*'5DL:J7D5K-IK*<%"XPI .0ZM0,TD(L7$0(\W4\
MTF%-B._Q/(ATK"+N0 #-FPB7UFM( BDB1!UQVB]P X$S,QC#Q:(;QT4PK5[^
M?058>6^T3+;43UZ6IVPM-Q,C=0>J/6C]"C#%Z;NMQN(WP09D;NAP[S\G,?RY
MB,/ZWK)U6#\D:2\F+VDR3H/9"TSCQYB^=<*F0>,! :K35U^-)=X2,1+F:_?=
M$A:A,BOKS_5&M=\UB(ICC +8?0P)X4J[,4Q$Q%H2:94?[2>WA,ZKLL+F^I*$
M+5%>'R#8QV@1\2H4@T*DH".?]W,RB^+5:L=WQEHC(,EI/M46N]T>"H2Q>LP8
MY;.IWFC]D HW7NRV!.)\C)^14"$0* B?5Z>FR>>0TG4\[+^3K%<C>9)X',EL
M/[BZLAMVOC'UEX3<+DJRY-_8[?4:7%V:N2]Q7])QF,D^.X4(#C9+FM[Z95>7
M7CTBP(3%EC$?E0\O&EN7S+IT_21 P&2V9# D/CPUU" 2UVXC [*QDBS-416S
M2Z<W0&PM,!2R1LA\>&7X5KQG41@%Z>(M6&_CHC,)ZP.P/"@_W?1,XJ/RX25B
MC3#JTMRR(P@W1'%G .JZTK1 "(CD))'Y\/[0@@B].>/,R5)KY<[V(>]I] ''
M^<LT&/)?8O$[ #"GU@C99<06' ^3L7*=^B*R+[UZG2-U<#$0F,MPIC= ^,K5
M,QL&SQ"FUDDU5W-3-UM=[_U-^*NWGF:SN&O@DC#NNMX&Z'82*,*<GOL<9M!J
M[EV>_ICV*R=Q';*\W:?5BX=WMT46Q23+Y,LP(#T T^%:%KF8O*AZR:*PR@HK
M?C,I[ LX79L=N1*0%QH#EKF7?3Z)S_41;EJ.PN/>1(E-OEV2W1J(=6I^E%P5
M#&LD#X_!*I;;ELY70FG,UD4#:F%LFP@XU%>O/A3 <QHO(>WH; ?0BUJ7N]2'
M9#;?!#AQ+1^\CH#0J05$V5<M \>+2I88H;)5+:7Z UZG3U"TB8^!RMR+R,92
MK/F8JG_2<_V5!EY)"Q(?8G!U[?2!2DM9BH#I>"2)G(*W) :&#:-@.EW\.YG"
MP%GO1TQ"\:$G[@G$.WV?HG;&R>(Q^,BQ#RLZ28-T4878EX17I^Q]D5:G:Y2$
M55C],_E1_@E]-M1H,(#H])6*FLA:0-3Q/E+##ID,"0DS6E^EK%(5#TEOM.N;
MX.Z/,@, 8J=O3QKLCO*P=#RZ;"U(N8GX6S M"&_=MAD.N.'TN8FRD)N#-/@X
M4VN%:-D+?*N/ $N\"3L2[]@&H M>BYJ,(J_5;$)#J(#J\K^32J6X+W6,O,('
M+1\*^KG?@Y0^I\L>DK3V6(YUP;8?CU[R^C;(2+B5!9,2/"[WX=O%ILDRU+_[
M(TC#)XG@]?:##ZXOE/1@G9'N(N(SC'J%N/AVWQA<&TH:QHVBUR55]L&AF3F'
M'Z!?;2:4!4E,0<L&Z;/Z 4_,J!%-W6E:1,R>1V(^^!#:OT.=T&W#; ]P#&D)
MZ@'^.+O9<N( \B'.7YM\?'&EZ1>4UJ#_U@);*EO"N,>M=@##Z3MBSB)@"X-!
MO0\1_.76? \33'!(;;4#\LTXR_P[E!BX?8CE7Y,EW-YV6@($0TXRZ8.'P5(!
M[^ND^Q"&WXK[OAPK;<2@-8(>,?T\D/>TH.:H:#S)^S^2_B0I,KAT/P-F0@0Q
M&5*= 8E3CR-S?C.,- I@#!8!GZ?1M#^):+*!#0G]'["3X@7F)'O"[=*INU!6
M$+)(#%;O^18LJN_M$0"_X,M!HBN0[]1#*"L(:2CF8N\5CHNE27:I ?;25[J.
M:S9$SODAZ@HHG7H9S%J6Y-![4=2'2>J73]!FHXR4$2'K/V;+OV8=5<&+Q@-^
M.'4L.I@-<BP1/%_PV2?Q3!'ET0?YV].P.U<Z9]=VGVJ6!+V+:7[?I?G+YSRJ
M?&J5%U7$%QW?&'1.3=D8K>T&E801<[%F1FEP(2 Z6YF:DY#L]RB??$M2TI\$
M\0.LZ/]!@C3[C60TY4.?I+-E9!.FORD. ["NG9K(#,F_!2\TN ]0M;Q\UE7[
M\D.2K@CKDWA)QXIL7$57&@;X<^KT!FM2Q,UXX8,'HC%7ELE[M^/W88=ZC(<I
M@<;WI/JOB6-5]MO 9[=6$QO'B@4&^N!Y:8SUN: R6AK>LVZ13Y(T^I,(]1J=
MWP(^NDWPY.M$%##,!Z^3+FP?<".B'APX&<ISP,+\V_TD</7J&-4L2WS3X$Q#
M5++5OOL8UT+X[H)YE ?3BB::2SW]("&0]%#D14I6L<V8>M9B2,ICIP\,3:IJ
M[?GB@U>O,8<V%TIJNC:Q!VU_ 7AV<^A67R-;#I--YCR45?F-K8(<81A5'ZJF
M_>^3:#CY\A]HE?435OBP(#!=UP<&G?,3I^^(3.X^NKEDSH?:F L;0.H*D*4O
M4^8=HSINEWWF4K"I^+(TZ$N-QP)&=)P& Q@^W)HRQ M/MD;C2+4>[%BRJF]1
M1AZZ>]22Y6J+85[XUYOOP/1_ED;DRB#'<[OK_ QEG]N4K)[.-YQ7YM(,VIAJ
M2X_%E]E\FBP(H1F,AVE4HGDU=#$4?!+8>GK,AZEAOGF1F;$QQOLH&])$0O35
M_K<@_8/D56::96%(4[8*B<]2]A[C7<$B[[Q(1ME6XRAO/MGC,@[C:YID1B*&
M\*\!,\^<!KSZ.A&%+-.135.WE62YJ5?VH(<@2JLE5*:L  2KS5Z[C43RNY1S
M1VN$L\0\@TD_-=AX=BV1*[^(0:L<]DG*KV.\?%CBFXX\IYX=K[\3&A%-PNX'
M20%P^4>J4- U5ZXV:T>OD!(0POG?Q[)N=GJ1^[4M]%6\_QI]/\F#Z6.<IU&<
M14/3$UGF\Y3=QWC..^"A%]EO&^.M#/N5O_%1,O)?UW<H _^^8JLQRXLLO25]
M[V)@[\CJHG95LA-\9>*Y">=SE)U''Q)GAF<Z,@L[#(1:9@G,\K2@O\QZ^82D
M-%Z?J;@8B912(X&R_>]H=FU\U)&+N7T"J)51GZ0?T9"P6?!,WV+295BBS4H5
MI/[WNR3+GY/\?Y#\E0R3<4P#J#<C59UV6<*9S\YH L&X?=)O>(*[9JP7>:NE
MF- //JN4ZJ5WH?Z7+Y_TG[QKDYX/4)8=<P"&5BYYD4>[<<9[M0$&G1LW1?ML
MG<(J7-"135MGH6G9(B]8%PKKF%>] +<@';:EB$Y6ZHSU!80,85*6"2J"Z92$
MMXO=+!J\^,YV(U,F'?-3!CWL0>:0CC<,[!0[HQ$IMREV4A7,G=5D+(KP&.U4
M;1F"B-QVH396W8]:!#-G8Q#VI4"/\46<*@.0C 4ZDL6M2[-TQ_ _#X1D]-G+
M<O[12P^ZE,4]*?5'ZV"6AH\(3T?6&%KL*LTFT7SCI'Y(TEJ0]FKGZ">K^+!*
MH=R:9/WDEJP<+BR#FZE/ 7^.-_N,.7XA\TE'BAH#1/>3.Y+F((UE?3:+\VOW
MTY1_QWB:6.8?,O]T%--C*D.OY(-2PP"X<@WW@S_(%]AYAWEWE)/T.<DC_(&^
MSF]0CASM 6> 4<C4L6L)]2,-)^@&QWCVZ6 *,DL.)&Y=Z!6K7+M.'9S;) #;
M;_Y^ :2-C\CTM5S\85J.6_=1J;ESY :@D(_9=:C$!43P6@+/J7)6]ZK7M+,J
MESELMK<)C1\9W4<I'+Y)2G,)T^>3@+@7UW('=^?S-/D(IIB"9.);E$/':. W
MS3!D2NFPZI8?Q69T+][05_FVN;-%?AB*ZQB-^2UX@<CX0&*N5XZ*W7PZ=A(^
MXE^ES#UF!=L\ZY#LHSJ,SC6S1#<.O\=D97*H;Z6HI4BF,\5PO+8>!0X@4CS$
M@.65GKU^M"+,TF'@DY2M1Q\-:HYOR'2T&[PL6]%\<V!OM>#=FMJ-/#@].3GF
MF[@>]B!SR(<,,,JZ#H5TS!=H+FI$D';-P74??!6A-0VX<=KL#A32,>N;7-2(
M(.U:;(V%>;N(V:<1OL=X3[;%.&1&VC7"FGMXP+\F6?T^9?@Q1N>Y8"(R:^T&
M AL#O+P2).GR5[0=[PIGEQ J@F,^P)UP$YG0!Y(C97U[A7M+,5ME)IB3(3#H
M/OJ >TD<FLK:*/MMRNAC-'399B R4]VF=-]+@MH;/41IEE=UC&DQ.T$]0 N?
MIOP[VA@H>_Q#2B[IL+9K!?%*J%!H/03RX6(2<KY/.7F,IED73$2FHXZ@]29(
MLKW45B1<1I/1"@EH*)79#P*O+H_17&N%:\@,TUAI=3M[RBKJ.?P>AYN<D94I
M:_DG:M+")E&;,2GB8WR[K(LQR%2P;- ?3DA8E.]T1=S*,';UZ2SGW09T?6/0
M.3$4LAE,I^YT?<WLH2##_)_#!/:AS_S+M.SYKY\S,IY5ZLKR[],$!OG7SWE*
M\P(BDU&#4R)+\]I$A)\VDQ!^&+Q2;-W/B&71V_H[+49NQE(Q@9[IL'@GO\!O
M@>LUCQ9C,NB6UM:<8"%&1*/!S2 CFF];FRQ+.%4+"L>02V\EE%^J?7]?-BRN
M(7S=(A;AK 9SN7;.#H"G03'-37-X]14]+-Y0C;!:@XU7P.KE0<UE]E8;"LY)
MT"Y[CNXSF44MPEX-%D<1>X$_0O;6VU!8?K.702W"7KO!JM71 1] 3DMF.Y@?
MAEY_>G1J\I C990]2Y2+@MY BD-Z=W@.9N1^ZQAL8GYO\#G*>$,6=^'YSI-O
M0_MY<PX@$\JS<H,',J%<JS4>S2R1KG2IPT;TG,3_1Q%,HU&T[8E'SV^)7E0%
M\3MHI_EB9UA^I)B!B-"N;>>59'D:4<]?2>=W$$SV^O8=E;54/[HX_ Y\T25M
M%78@\E8RGV".@RIRH413Q2?P%RO6?M Y._7;8ZEUF0K8@ C,01+1:OL0+LJ]
MMA2ZWY$[NA<BQ@)$EI;S@A;O&?E/ 1"_4.>BQ#T-Z0$3],R,D=O#&QN?!XA@
M[08&,D@4Z\M8GT&G<V+()R9]B^+S7%I.6X 025F.>-,N*5^N)_I%)KQM6'Z(
MO4VL^#1DM8>=QG%>*L$JD1+4%A:V<*[L6J^6832"XZS6"N;EQ5_F"-O'C0C-
MKH5H299P ]QJ1X$:NLI+'T_[_.3R?8MPA/-VW]DVY[POQTUS$8B.E2N[%I#J
MLO 8A^239J<IJPFD697@2D)#E^D.#+H\^K"$!@Q!Y&_WE:N(7N$:E1N \LRU
M5J\@FF:RW8**2->N^<2F='W9FFV*6;B9.WI7JF U0_M0@$[-V$K+C2U*$3A$
M:N9C;OI13D\B $=?'!7!E!/?QVP+,]A0!02/#E41>D1\YF-Z]HCZ/<HGKV1:
M8J;IC_O)ESB'>8INL U&H5=D5U</D20DY"8%#I&H!E.+MQ)U?6[:$:WHI+S6
M\:!MM=W3BAO/2;S^D>\.Y/>B[FHG[VB;+R*&KT\*(R(9'6^[GLF/NTE$1E\^
MR;#(HP\ -8J&)!5$57![4<>R$V.F5LE(840DHRG>17*=L.9-QTV2*KT2P' A
M7+=KH-E-C28*;64TI^GSS;Q_]4A7E&  (D^[!I==^H17<'8'6CC#T!-3^6!3
MG-5RLMF"@DC'KL%$IW1<*W8FQ"14XY0,'LB1M/M]_K'$;DVI=9H_D3O7&:<0
M%P;";,MA'GF0E[MS98*A6W<2EX^[!5$\O'X4H!G#L(=GDPPG$%';C1/9H4^X
M"S+;4T"&WC')1_)(<!PQ'7(@(3*R&Q"B3T:^'%0FA"4ZL&[L!HK42NH)+?-[
M;2D@IQ9YWII@"P;#@ A#0P"(P,ZWGF-O0Q(':91P#._,MC2SK9E=S:,#2X0>
M$9^&*!*1^):T?(^S.1F6+TRX!EFT/07BTIC.XRY#%@(8B#PT6"JLRL/U0:1;
M,,+#QWSRD!6!#TE*AD&&QXWBC2D4)\>.S,S'1<($@<C!KI%A]:!#<&^J-Z.[
M]%_&A,< CLC-;GB%]&/@W1<['4,:@_P]B,%2/N^W2$>X;]?\T(;[K@\6'6(0
M'B8ZBO_U?R3]25)D01QVX_ M^LP)B5?E3FD:2)H0$FCCF^341J'>1Z=9\)AS
MGF&B:P0+$9:._,';]'RAM9)K!(7%L-R(5<4E'H<Z)9T^9V\F,&E@;)%U3G2$
M*&R3]!"-*$7P+]FYM==4E]BMD$*?%CM-2MYLYMCD#3;Y=$1AL*G'DG VV>/Y
M8P%$-[$T>G9Z*7"8_'3$:KS-%RFAOU8^D<4]:1T^IT\#964C#063A))5!)'$
M2Y &E(XJIKCW/HW&@=A5R>]%KZ@'H0=)P<"XKR/A!W-W;JFEBD:ASTV=)I%O
M=72)8&'2LISMHVF-T?5NG$9#TAO5O YX"0+S'Z4W/+_SR3@J"2O+.6Q6KLP^
MOVZX"A3_L<UG^ILM1A,XQ>-P4[9OB]4_?OSX1S9?_&.8S'XM6?P4!>_1%$8B
MV1TM?I3F$<U4#Q.]K$1:4DMU _K?23(%RK)[^/8P6GHOWXK9+$@7O=%*;=A)
MDM0=PD*DT8DD#Z)I]K-'F?&$LT*TFMI.N1/+@2V'E>&]8^@!NOD,[R=XXB+-
M[-&8X=UN4H*&*6P[A@X:5]Z!2HC,J<)"SI:<W:0&1Y%PM&,J85K3#+:E>#GJ
MAQD.L.>3#X7$#V\^^>)[\6!BB5PX=E\B["BDJDE/UT]EW+X2-[@+L&<'CPU(
M%OQ#>$Y^VCFNY^0,#4*$'LGS=K1OCYU6H^$)0D)L4N"0U^1'+%#7AZT=R0I?
M(>E\2R[Y>'QS#CBQ$C=?) P3,AL4$LG@EU*,G0HK SB<W45Y?/3R"4G[DR!>
M)J=?5SBO"A::,'&ITD#Y?O@EO#E&'\N,Q,S)1S*#R[JJV6.,%KVU30+=\_W.
MO^[K_&7R$9F^GI75:8SYMW+!.IV^VR10V?\]?;7Q$9F^GAEI&V-^2-(1B5S/
MX#TJ@/E_[\%:68G,8\^,P^U5I]])&;(8=C](&HQ)>23=!SEY"*+TMV!:<+V=
M'I!'<WP:RI!RY#-?F<?(DK!KSK:EC?FY+A1II'$]3F,-#W9Q-&,TLD(<A-=9
M4/C\7"&*-%+!.:G"?/ KI!FCD15BN429:6VR2$GFY_)0(1!$=@2!K0XO%2I<
M1A;&RC#L=0PL_<,>'[]\TG\2^X&OZP<\5>%+1,K3\N/PK][HE0R3<1S]"4(N
M][*[),NS)XDH6,U?HE7,+!>*6SOB]4"1#X_5^+U!Y^34C#..&RIK1OBBN%G]
M?#O8&-IF^34,E?YM&/]B0)S,"<1@@@_!M(V3/9R<N:[.QN HG_5;I/L0>=J&
M^:X#4'1(06N8IO@)(^]I^/8[<FTOMG5_DG+8JX?=Y5IB1+:8YX&Q$%"%!?P8
M@PI/UIG,GI:'A. \Y/0:=$[]*N%GZW@4\\18T&A[>0OW;VX_NHA<9Y@7LU])
M;%O C 6'>B$X7\YA<Q+4&@2JXS$% ?9,X.2X)Q]DFLPIV4M3A\S3"E%OBMFI
MQT9F3;%E*8_.AQ#3KR0F:3 %8KOA#-B<Y6E <R;(RE*J/YW[3A6FYM)4P6<N
MXM+"@Y@K,^^:/-5X1)PP%WWHYV.*DS-#S]I:O8ZADI"0FQ0X<P%YWDK4M59D
M1[0BS4@M5DWS^YB3,R=>]>;+A&%%8(/2$05EI$C?Z>7AE$G$6([B\B*R9GGN
MDI!]+"]5(X[2*#< 98_3HE8V75M*+!%$C_CL).]F63&KH@.^9[30^9<LCV8
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M'QE<7YMYG,5UTNN3K,@QKX<_!^N,IQ?ZWJ@&5V!<9[8''GCEG=<D4^;,X3#
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MG+'JK^@LRKUW6'W *$)S+.9)??KLI=7C0"ER42A"=$8R.(/5.$M)U:JWLZQ
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M;]DN2"2ER!?77U;*67Y,W$J^[I>&%H;.@N"<C7_ 8^'H_=O_ %!+ P04
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MC0)G%5J4R%9!!03D]8\K'XWK&@/"NI?6(6 H'I##('I.BB'!K$9%&\5J2)C
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MQ@?AB4FJ#ICB,8R=MB0, P<$]'<)/7C!]O++@48I98;,)GNA2>-4HT&_46]
M,3#CIHVGO!?)NPG[5'0DK<,TCFQ,8XK*;JG@*A9<^;EKP!-#8(J-!?K:\F,!
M/7B/DJDG"<^#-.PY0C*@!HB4YI$["#;"*AXJ[YEIG 0^,XWY 97M.?X@0-5=
M +&JH;N-B*JI\/NL2-4:1U^/HYT[1#"!/(24-J:'8 )DO<0'FF1O=VQ6,[8'
M< ^,L MOJ=YLT74#M5>T]'?W=-E\140'L:6771CP*9J%,HH-03^MZ(^6H-]D
MTUF.?EAC:E@8NE;4L"2 2/+FP$MB!M'S#?52>A\\OV2;W2=FV/&M4R/* _T
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MA&T:)UZC#Z9(&>*J+3:&H#(1#>\YI +O/_ST_@>!>?Z;OW1$KE]2>X!OUQT
M_9;\=%,RY]O,=;7-E-IYW=RF8(5A+L:"Z.R0,Y88;CM+>Y(068,0_S$B5N@
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M[ZD?/T?!WY@QL>5/"7>!5V99+C*UKZ-&95N92O^69N,VY'F^B+N7SS1K)F8
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MRJW H07FY,%CASJ>DY,^_RT(O>0YB-B9A60QN=[OZ3;P/61YGT48>A3 +)(
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MW#U]Y<LAXG8?#F$P' 2GZP$5_*:ENFL&B,9YE+)HCAWL-I5^M."V8;@T@MJ
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MY"1>+L\0FM]T9C%J>%%=E"$CGRH 4M@^14ND'"520H$4]I=#@91#&=],BT_
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M044H?US6RNAHKRG&#(NB)D;QKQ.'<L"Z%/ Q74VU.O=<5(;!1< &3"B/__]
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M\/[.G +M(*T]S2'@>=2I;.+RUD]7GL2U5\=USVIS%" \&.W/E-S\,W"2_[Y
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M 'B7F?N1 #99@P5 G!<D919=]G;YY4"CE*;7><+&NR2(D\>X';ZJ O>HH:!
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M*12M1\F4Y\YL65Z\E&X?XEWVV4O4(?#ZYF /GI7T=IQ514M2-$5]\FQ,=]$
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MMI.J:@Q@80HS>NG+Y5^/;,\-^?7V.COWDN0MB)Z'TJ@.=80LS3C$0^?=-.M
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M>$G $RN: +>G+2!N^RAMPZ!H@X]:*VK=P*P2"FW(*G$ ]R)[ *DX"-6M]:*
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MA?20S@T;S_6()#K3]IX.;$92C;Z+8A0FQV.09NA,O@3#]_=>@=V#@Q:4>T
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M+#EK?I9J=_ZF!&(#(+DU*X;P:77 F/1F788H:,VD>--.(SOB\@.RIRC0A7W
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M>S>]?NR$Z]?B1QB)19AD:\==Q;;N#<<Y$;D@ ^[TV\PTQO'1C/ZDW\QN+5A
M'&0N@IYDZ7!OM1:QHJ@W+CZ6CD'4+&B-&"9M?S&4CV;OW<A_D&&?4YS%C[UP
M;;%'&(M%A*XK2\\#82.*LVC+7L:$2?=NSKF@\+1.<F 1DV)F_DCP,@/0-I)<
M[_<INSK=9'U>D8XI$3EA9G$W'!=AR/I=ZT)UP S=")H69 C'2'X>(0BE45FF
M/77Y073V=@'1!)\&!3ZAHL>:+"U64.<"*"30FG29._^V[, V^/.QH5"B-#"2
M'V]GKD#GA!MP!31!S-H+L;1I1*TNJX.HK![8TQ[0F*@H;BIOV4[4#_53\V\$
MV=6WG'R"2ZLC35QH%61$_4M9KC/3%[AL-8.J8-FFK_EEBQ8^JT]:D.FMFJ3B
M4]?*14[YG8WJ05H(<D&U'&5!2X)A)H)LDQ]P^GH(8K%L/24QWQ=-5^['GH8E
M!!4&2'8"S[8H&UN0@1@=*">$E'YO0<MDI8,@:FBX$CD1R&^B(4K+Y;GZJ. *
M?802&J "^P 5-(9:2V<1E*&F<N&+4'%G=<I"PT.H^! +49=T_2U%!34++EKL
M3N2+KUH\'-MP1E,)[(6;S6(Q:&1\_$*&SC\3!-P'43K9V:%3\CZ$H;7Z'K/8
M#+22MQBIB-***+$31<;GM5D8\K7,!/??^XQYR?H?:HMBO"AXV+T8KP@+7Z$9
M8ZK*,3-9IJUI_!!KM?V7\;=@<UJUU;%@UNT0[Z(XHE3]<HE":D,7^NU,EQ3V
MZX^Z,QMHG."6BX&6:>%K!D^?FO>:84WCAU@S[+^,OS5#))7Z7S.FS20%^&:F
M:P6?Z6,N%0-M$MQ2,= @+7RIJ%2GG.<Z84?@AU@D++^)]X.8"SN$^,=<'$9^
M*].5X1_CA,?*"H$?_EB9()AE87O X>6(-[OBY7*<OD=;K)#%D9%!_K79O>!M
MLH^COQ-1L/7N-LGR[)6F'NNL_#3S01KMB22FL\&%;2U5<<6N:<69N$MT&YRC
M/#C2L5=H?4HNI/4?;&A/F<E@8A+SH,T.R9F0F(JO3ZAK'2NFH_W*"<4^!;$I
M50($-9A3XK-E_Z8$YX@L[<HKZ7?,>)9OI(>7+8,#?21]'8>5EE^B;ZRAY(0>
MOCP353\0-MJOQC<SOB>=$BI[?%JY=3U%+P=!<K[2#Y0S(CH((G.B6@<Q;07#
M['J%G)GW\ICB#BO+GW[X\=]5HJ/2(G__5ZVHO*79 V"UEK*_%* :I?_# S:7
M^,,2L)AK751JW5EJ75[MD G 8JF%['@;G:46TE[P=Q1^P3%QJX]$0NOP%,41
M\<B)Q-^Q<)9Z;Z(9]@?T-TTY:GY=T8]]N'I/Z3E.9T[)UN8MZ?<1W;/FQ]=U
MP4>@Y0/2Y;2"4-.%M,(/B$5PX\H^1C%^R/$IT]@.YS,!6AGW4II@/TN'1VQ\
M3YO:Z:4T: N;:+:P&IE!&I6)4-@T/Q-!<-ZU0(K(X3K++B=9"$!4/9FJ/*C!
MI$NH!6(BNPE.1\K /*I,O"I++RVPH.<049:EID@#]%T4HRL.TNQ[[V<4D^+0
M6=4/8Q#.^XA9Q\9?DB,9YDBVI"]!/LGYL<WL2S@<MI*F#]M6$H$H%0L[SQTE
MWD(&[T5+[Z8.!K'.SEKMX;H\X_<297_>IYC6<,+T'@FDZ>N>>ZF&3R%)0+-'
M*4"4!"1I^"A6SU"VM-FG'15 )!I^&).GP^FD!D\'4N"\D1><$9=]>UC'X6?\
MCH_)F5%>\B4KOK\F9(N]2]+3?9*R_!B+9)'QDWC)$'$@&V6^ POZ\.%9Q*PR
M03VN)N>@96;%+(C\AZ?C*9,<H+-$IA35IB*JM5I4I:1>2TG=]TK*3SJ(*]BI
M<T!<80[$'KV2L3>["G'K;Y$N5J]H#V@E5!0WM?@V.9)NB3BZJZHK._ZJ_%S)
MKZUW^H,.[0GAWMF$A*=6"YM(TZH@"&@J<V<$Y4])')2_>27_R@BZJ;O1>VQN
M/1(@T.RYG$(W/R?T 1Q/()RU"" !.E#CF] =J.XC4B ?3B<<1MO@F6P13L'Z
M1I^]J&H-E7BHI+:I5K(AXBW1&MWX3/(;3O>-MX0[O6;4<N4 U,(HS<V1F$?
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MXW]>TB@+(U:9JA>!O3T!L=C/15-K6 ^6$L?ZH&HG[]@<R(X?G Z5_4SP:@B
M)G(-M1\$PR*H9[IT=C<'1*N"7D7,%FK=-%)V2]*SRUL6A5&01NWGM"&57*<A
M3<W6J0>(.I/O_8S3* E[]N^-=H *W*2P]:H&T5C>P.L>W9Q,G[K9^;F;2MGY
MK6&UL7?7W6KI0R.5N]2J3GK=6=N0.@N]U.^>%5\=1#?O@O1(5I:<T/!7'*2]
M*[^B/:">JBANJH!LQQ9_VM+SNC^8;I\:K%6/IAYK=</-T=:CYBZ>IJV'(Z['
M_FM6XO#HT=>=LTE(]G'HU=(*U<'7-"IA>_AE(&=V (:.5,P1;>FJD/>#> KA
M(?Y+<+PP@I_3Z$1V%\?KYPM^38K$#WIBC74PLQP'$(*V''9\ _[ R$.,BD%0
M,0HBP]"+S\5 B(_D![S.F(UB=A6!<W0NF T)LWF"DH+98R>SD+ ?I,%-D^!/
M?4W-A:<O"W_L+EB)]Y05=B]FEZ1?@S34;=UUG0"]42WMS2]2-&86 ]6:^W%*
MK<A_PKG4%L("U1:TU;$ Z:CVZU#36^U7(*C@  ]A5TGHO66D[04;--!0W[4K
MY\UKNK_R>O/'GH4M9V$VNF^@0ATAAS[]&>%EJJ%U]^T<\=6&[A!5WJ5Y?RBO
MTH(C&Z./RMZ=6WT %W($9WWKP8HF[TKVKIXB&8,4LN8L>M%&(R?1B58:?#=7
MN\].JV-F$HRZ0ED#,SX,5[\9V(#A_'0MA?.!O86^U1 /K6Q&8'?ZD2:#^#,F
MO!-.]GBS(^M#S4+]ED='^K@3V;SN=AFF<6*:!LY#7BK@CQ@0RAR,X;GYO<JQ
M:$D(NL(V_ <Y(-VZ\R&1&%/<O/-@/Z830-QV,2X5 21< +D00-0I #!S,UKW
M:T9H'HIO9)KF]?U=F;(F)^LX;!M@983<M#>4D3+FILO+;]@@TK?+D_$1 1_%
M5D.S:"IG/J/]_0 MK%D0#RIH9"Y<?[.N[^7Q\AA]'3/>$B/%A%#\^HY?9+W!
M,=Y%^3H72><T"_1"J+F6_8.\_TE(9_/XN,[C2$*MS(G=#F_SZ+U:@P#1MJ@^
M(0IR)%/^B\&;??P&):<6%>7RG";O44;E0?H2J86TAFMP/A]96;+\@-%.""DK
MA)12:9*%5US0;EW7]INC.@D$E7>=7.+/IX6Z/1#-( [971QL<^*H#;5 JG'\
M6Q@EAT,MR KQ(>G1JAAT>L-A>/-CK R( WX*8EI(,XR(.%),H,?7V838!*_9
M:(,4V!"_>NUUD;U6GX^&<Y(LYXY/;S:;MB]X=IN>$\WEUL8ZS"*BI*O83/C,
M?K-CJ8RJ>4V$,=:K[GPX**6RRX\;I%QTVY;6E8OMY*AR?<>_U/>SV1)LJ!U=
MA_]U,2U<9#""_T6V@ZOARRL;#%5&FZ4[;LPR#64Q%:6\$MW<B<M=_U6Y]3?#
MA56EJ(9+JDI+Y^#L?L;$M4G9.L]+%1=I=NOC,?E*GUX8[@$;#>X?L7:R<.$K
MRYGXA4PV5R7#MIAMEF ?)ZU2!G1C7:9C!K+/#.$_ "N6SK8%4*"J@M?I><+Y
M^BW+4[(GT)@#?3?8BMXZ^CMJ5#?AN&)GCG_(3KZ>7!S(!UUC_9?1-]&BCG+9
MO2KD!P*#LK.M1O$)$*L$Z$Z\S"^I>QR3/5E]LP*6?=;W ,7T [M?DB3\&AV/
MZSA\(%OG>!^]'3'_DPWNM,/X!)Z>/R/DR2%8<+(<Q.OC,"/YK' QPW7,0"=[
M\6:@D'X )W^A3$<S[ND35BTNC)!4_'*B%#+3@G+#N4GQ.XXO7G=1AAK5BY!N
M=?(#"O(/^3MQKOF",YR^8YJTL=YNTTMPS-C_X_ Q"M[(!B^/.J\-NY_")\R&
MR\4(C_3?Q1_$!"LDI^#/L(I)5DA,@RKSS&3M<R<ER>,,JL&[QDBO/1@)D+D8
MCMOD1/^?1W?B4.1'9%\.08IO@HP^%54VH&<^XXS(@.GF95"&R&N$<:F.Q@R,
MG'"%V)2?V)SU9G36V9H:%_+[DB?;/S^],<ZWE>8SMS^#H3; %@W&F3>[9);$
M;3V"9^MAED&K- C^T[G',^<Y*V.@SIE@3J-PGH+"]&C7*O[+.W@-]0J:S:*Z
M7;ENOL*W"L([:?0;CZVJ17_HM:H3GJ*L:9+9Q5-Y!Z^14T&S68R4-O;S$)@Q
MX:]T-!3._!"OIBK]8<ZJGD#K=F47:'V K>KK1^.5G&B5O])K=N?9]AQ1/!S5
ML1U/H-#KF 8?>@7S")7GE!Y[YE?Z3'5.MC+TK;XS35RS!HYF).\PTG%I#BHY
MRHH][YZS@$$QDCN,_<PYC?$^R'$X#&5V#)]3O(V"V9V_V:BI&?9Z=104B46>
MF-TA0G<W#QA3T&\.*,=^6ATXKS;NFB$K'4[;S!8IG4ZI,*)3*#\[%*N\Y+DE
M'@_+E>W<R'2D"<]@G;'@ZA%GV?^JL#&+S-\1J;VSS]VM.YHVJ&GV](F8%A>F
M2;PSV?2;TU_N^U>T[LNL8-&M2[V0Z%8DF%?YM@<<7HYXLUO'>11&QPN]J_$%
M;R\IH^?NV_9X"7%(7R6G1S07?CUOL[L+TCB*]]DS3MDACNHU\:DF@GSSS[6,
M6N>'8@)Z_ZLZ!2KG0'(21-405::AG>1$]#$;?@[KYUET>(EM#"1VWY38QD9B
MH$\$3H+&UHN"DT 1Q%R-)/CFVCU S_MOD\X*:,BFE5XK&4N!2Y\/U<U" CXM
M# " FN8& #T>;<]3<,*]#_;U=_5N!6I\&"HRV4"07IY?^7/-SOS0V58Q,XBU
M]6M$?9HOF#XMN[Y-XG><YO0VQG,J]C$L_4WY)*!5;Z@:-<;<M!Q/UA&M4:4K
M*OHBUMG3"X*.&&LR\QU+]"1;[D];/BBM !=D4?:]MYHV=KI8JVKC01&-ZMI,
MJY#P-6U&+OJ/F@<<W4_A??$=)!=3?]LZ<O#HZZ7).0C)-%B@$9)_CV$XSAP[
M[RV0+<'X]#ZKY6C\Y9@=Y3M7CFR.WTH^(,+)2N'@FG"V=>%@*9PS$4Y&QU^P
M>=&_+N841B"&Y7<<[0_$ 5X33RO8XZ<+=<HV.T9.]I!E%QS>$-=XJ[$=YD,
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MIQA#;\]YG+<J2@+4CR1?"65>ZR%,R,!,3E!UE0D,50D$$%22C?2(WK("FCZ
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M06JA$8OSR#5Q5CI_FW#_(42"!^4 YM$G.J%IR>!0=!@,L;2.79/6^F$?M[_
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M"/$YY));:VK>3:WSRJTS&H=8O!:P0FR54DD,F=!5D!SRUJTC:&&N:+6D9=6
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M'+'R=79Q657V;'UXAX^#VMYG69EIC/^C2!Y<>-GK;K4;?03()#)\V%".%JA
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M#>L.N(EG7($8Y/+:Z;FMN.!6747;"NH.D(FG4Z$,,..%#AC:\-]8^(D@#3B
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M.)!]VX9S+ J_(^;S@]<):MLY5F70NS@W<A.PWGG,P"XMS[M-[$V@8!2Y=I*
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MF[4$[)'&@[2Z"-2"WIIOFANFPTTI6 #'BX@OC!D/&)7,&7]L%!?1P(O0J1_
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M);'12B$=Q%:% '$Q!.H+2WDT:-#;WQ/N:7J3Q.\LS4/0VJ=UKPH@<C=>PV:
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M@%KR@\V3/(BL^23N]GO/FHBZ(TIK#4[/B?W-&HM5&Z6;CJ98QTO3L+%4RVH
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M64()SF^O&2*?A@MB<T_#S6 -M'Z[ON PRQ SBV21B4_=%8L7_[7&X=?ZMT
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MZJ!$I.J/\<SU7 J]8W*+:S>W*K:H0C32%PO?-H*DG(?_O[TO6VX<5])^EWF
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M,P[-L.TF=@!"Y,^I@F<G&!OK=@#&L,T=4KH1(7"E;-AAU$(1\QEXTMH"X@$
MQK!U<RG=B! T]PE4K%Y\HG\? PR_JR#,?J4L7.SO:"<8)YOW_YQ'Z^*##[[W
MTP^*N$M(XHY3'W)/MI/.">4JY8$1);EA2W_NIX4%^25;K[WX?;+<)A[PAQ_Y
MU?HP#:$XS,?SU'_C(VY8ZOE!\A_=B3ATWPBB)(N+<)R=:#RS &R8>8C&B1J2
MC'\F:>S-9?W)F[UX-AKM$JE[;A'H1W.Z$77BKA5^6[[Y*^ 2;TS&)JQ-D1V2
M>G':%SW%J:8RY]2=D7HLNCA@8N$UME4UB_-H-V?MT$ C"Z"K_S*NU%"KYVT*
M7UT\Q+*E;P6[+&0K9"L@P;U-\2Z*E\R'%KRM5O;%O\;Y0-T!L<>;(@Z86'#U
M;5ZN"RZQ$OJ)NN9=CX46@PMI:EA/";T-'13:PI#-[\;;<E#3"'[5I2SK3H'S
MC+J&0H]%W!!%I"JO([;!IF =5#-I7;Q/O@7&O _]PA0N)+O_-Q'8PVR%:C>R
M2BYH-QJ'; ; K0\]Q Z(2'SJL$QD29-6?-:$W]XL..^H8\$H%X!U(!$'ECL5
M?IHB=M*1CVH-&$UD-OH\9.,>!9:(Q\25U@.-,1-8GJB6@N%4@($?9X)E-)'E
M,/@@>/=N!)_/B(-)AW CR$%$9-Z\HL^0#99$RZ'9Q#B#1\1Y3CU>)5:P11:/
M4_D%=@QK1"M$<P; +N*4F!XO!3,0$9EW)1&A:9H&OD'L*N]#(#TP+?."*8O7
MYRVFV]28#6?C^<"OT22 (NO"J02)QNE+!N<IAF?[V6DV)@E,'[ARU2><D<7E
ME'.Y 9[X"4VQBFK,!M@X\(!V$D"1=?$;^K#O.3Y^F/CS/&NV&QM5]9O D@^K
M5%W8$$EVI=Q6^^:(\6H5YW&LG4EZ[3EQEGX:N')$""NR4EQI2F+QL*S"TY'*
M<_118,K HY/:Q U)>VKN@78NF?B9[P&Q#_M!,?8CA?A$3G>U_SK:J>:O;)'E
M#:)J^Z.G(/JRC<G6-P >U\]<X"^R#UF&R5*J,%4QG9P<_H'Q+U^6WEMY#BBG
M+GYMF8MB61%1;2F[MJ^7"Q2M/1;A FIX/'IK=A.!3:&56";\<\ 'XG@ED5S8
M#C]2 M T%9=6$(]TE*(FK422A,\#$GWOWU:?P6*)D@'1-,FU!9%(XO1 '/A/
M>U'@/\RF?@J;^#V_K+[YB\P+D',(?78V.J?VQ[=[%JDHMY0E2LGSO_ST-=?L
MX)[WZF^FT6V8PH4%.UYJO 6P)?)5JSBHP6\MVDBS)I$:M=LK:8)N\*+'@" B
M^W=]^*MLE)#UFR8+/FSKQ;5A9WXX*$9W-NCSP#I4EA+Y7!-'92N71[#%@7V]
MO21LTSF 0% +MRVQLRS5-:&TE,#7[RS6VIA5\R%)5D!U"J Q#:%>*L4"$")I
M*VVOOQFL0^K+]HDZ4<]9X1<BV3A)S]FB8$J\RJQ'8OD_F05GW,?^;QG,QFE[
MPUT%O;P"?**NY^SL"A!#:2OSSL6T57W(CJ*)<V7RAJ_W77<9VL6AG!Y4EAM"
M<Q;2=:.+LJW$OM_B6MW/E64X1R@*1ES^TMGE50]J6TF"U&7>.[KR]7.5&<X1
M6#^$IL7T%@!=J(>0+=CF;1+*(O5S:9E,$*KY?5RJ.L/Y=TTU_*UN6X/HT=K[
MVQ8>3V*>[R@T8/0^^476H_XCXV67$7%V_K7;37(7!+-K:LCB-W_.D(43Y-/@
M_S=9/K-YM JA^WJAJ^6TZ6>_6/P>P.9X'G;.=V0+:Q$RM[-BMN'8BJ28P\>
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M+I0R6ZU;B'1P.V?4@T:"LN4OS4:?/OUV5N-V,'2\@4I)+UN(X2AU8XEDZKT
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M4.! 2:"N#)2/<QB<,(M\D]?@$5)E*0)@4P2 IUZ<4B_[XOZDO<R+QSD83AA
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M4>SD5N1(_G: CS@:OEM1TH*#M+N'GC0]1N$S6V;A G;2!W[*APE3=SLU> =
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M\=-?7FX'\$ 4EBH*PB+()L'_5JGB8]I[W OV'N_MX2C*#C*83-2XC*]4MW,
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MZ1O:)\&  ,("1;U*R'Q@W7%<Y3DJ%V^S+ (3R5'#NIU3E,-H6&R-WQZ=LG'
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M\ S#"G->S,!>1I@U*]FJTC.^!'.ME!+[QIFOJM@.W494[*$CH]0O ;$03'R
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MHS$=JY[K06[RG1(C@XTM! ,(EG0]5:1SUDYIY6[53JLQ1>93!M*N$2U ]7:
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M38#;O,$]6WQ9&PQ10/5+G59&DE(3<ONB7K=#FT.O!E.(R]'-&)*%P)!_4L_
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M?0489UY@@#:JQG'( 5PV)+CA.;P(A@L:NDJWEN<:J'LS.U+>*@R/L_31>9:
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MCA%!ZYI>CD*#--0-'">.1L#K'3(OTI,>AZF$I61)D6X)R^^V[FSZ%7',U$2
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M$KX!A_R3FQWR(/).#OZ #]]='!V^^O]02P,$%     @ \(.65Y2P+9MX2P
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M703X-$* J*\YUM#6X]J\P:XC@HF^,9*U=8#. $16(A&(^[R.8'\4:,!D0#S
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M&X2EKXU4>>'&/1//ETAUF"\*J=M@9DRX.4H$R&XZV@8@&\N@LE1MOW _&=C
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M/O5]=R+H5+#0%VS(&O=Z9(0IV,-DJ*(H0S^' $0DY;4>E7/FU:8XE ^O=>]
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M:9=MHEP:D[4AB'*#:S1!G('.!N)*RSCGB1<)-C&5B=% 1XIR^"L[(UD#[91
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M_"R@^]9>*W<V (.)5?FUI%"XI2%KOZ\[(WL0>14>8V7+@K!"%8/Z%EB,0;S
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M,!^^HN1(J8$0"Z<HJBL=.I=4%1>(I:(9[]K<JL21^:@L([Y!%_@@5K1M6DL
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M(GSN1-%+=[^'$SU\(0&%@G7U2'AU07"&D%9*[8ADWI"4QTL)-*NS?]I54$^
M]]9J%0+X95GK#O-&87\>PT&Q4VO.WE]:S='"><#>^.S/,U75T!<X+&N_NB7+
M*00YZH^EK3-3JF&36&_A%K7-AB&9>TJLG40@_)+21) S+NQ+V#D>*792<14&
MP\0JDX"/_3DGW!'<&19D<4H&%W%P,,@'VSB@I1.E(Z,7U-LUC]];E<_M@+6!
M.9+9>GEZ+0.:.O';ES)='#QVMF4 BC<091Y\T!*UV@<$ $/D.X<>:VH)/.2E
M*]B5*CDL^25?@/UY_&O<#(N#.VAUVC#DR*FF@=E:1]$_1R)>E^*(8V/6@29
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M+O)=\ADSC^A*A^_J*OPM]J^K^+ 0Q*BJ!%O1 ^C5+="\CRN((<<H?M.)INP
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MZRR3.>FD"MN6/:.V2+#%RC'C6Q> :<-P5Y>@6)6MJ7/.2YUAC[O,U\H0PI-
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MV-,[#)E2/Z'KXWWT'?BW]\;TZYY'W",*LU57]*8DWU%UH0)#C?GHN07FI5R
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M+] +&00\C_&Z*P51/IW0R-AO<&AVY$7,>R.X&5T-=."*C&?%L!J&4Y?5*H^
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M(>_&NLF*2\+)C\V L56)NUP%_JR3AI;JNGZ8.UT!GP!QU^7184@ER\!:)03
MW6SI]91,CNXS%WU6^+CXYYV7&MQC+DNTW5DD (NE?ZWW^0\6&X#:AE2.P#Q%
MDU%=D]^5\5\P+T!%RB<^$^/<,./W>9P@^UOFR@V553EL;YDL#VS'Q<7457>!
M=0^856%\,] Q(>$J>QN;SS70I28EQP-!P74-@?QQ?IP2$>[T;I 5$9DV_=O7
M8]+4L?#CN'2<->NSU=R\K3IQ+(++A=]]HH!)9G7U7G,]3YH2K[;X(9IK19-E
MRB_$+R']?K?D9^Q-)^?V1CAPYQBNSYH)Q#C)5VL:ZJJ+_\U#7X7?9[W)J;H<
M'R$%C^(EICIVF2:7.:@X[F9;K#2]4W&0D*VO0/[A8: 73/G<^S*3_+YM5>,Z
MY.K@VE6_39K"T.N2Z&T(=B3U(&H'04^NL[ I\>"(^,5?U<E\L/^WE_G34I.C
M;*XZ6W9<!H=DLJC-E?<5(I-%D9'3G4)<&-M21.JMO3MF7C4MX?M2%&Q.[K45
M-WZET@,J4U]U, >DQ*JKYU0DK/$.^HD^7.8RJ#LJV]Y?_DQ??78+YUOC;?VV
MQ!0+Y:K2X9K%9JBS-V]BHW>QT<MWNQD8'KRU>\E/-KBJ>0:B;_:<MF1;P:L8
M =6AL/FW<FJ%?)&&@2F'Q3.W]=6W.Y6O;FCFG-ET%C4W?4M2Z%GR$I2/F0%E
MW$./27;C#?U.PI3R :#JH,?[;9N3NMB DN6^T,W'?M-^M]:5%_-"SYR#/5)D
M[Y(3!BH"5'NGC_NY=4V8=LSE/?.S52# #J[86HVZO\-MVH.UYN(A8NY<6*\*
MYU\ ,T']BK]RG\&+,T'MILKS&[TWU4.L2@B'II_:)LRJ2$/:%@X>O&A=.JAN
MT:HD[J\T\0++4Z5U[_8.N;.!G\<YN,F1+4)*7+#.50A:A&R=L28ZMXE^IJK;
M_5<W$;2W2]G)2Q!AHR7QYVCINYJ0J&BLAXFJ$%MY5QGN8-0T"2NGA^_GN&E#
M(MC51G.*A-XA7^K%&0S6>([Z(0JV1II<P*%I3%50RDKL2@$KPJ3H%AVX'64:
M<>D$9MA3MB6ENGLD2"U'"/:2[0#QH-4! J:/.UI@<;&V[,.PS[H(9WCCR0%;
M7%M[A0;<'62$;<^[*]4'S( W%1#JM7)B]1(J;^2) ^.Y?)$HY9:7&M94D8Y;
M+18/?P*N\S[Y-R[A;0L'V2+J'](J=7 D;%F@^S?.6J7V*C:^,52$A>M>=X54
MFJH:)ENL*3'0 *N..\3%R^$.WS?>[K]NYL?!P=]*^6?<3NP*_.;WLY/D_.>3
MLZ,W)^_.3U^^39/35R]O+%WZ]LM,![2QP_W#1\G)_[P[/?\=9P([>?K;2?+F
MEZ-7">6?W,N\7L)'/[T^>W5ZE+Q]]^;-+R>_PKSNI[SKC<H/CC-GLUWMT=-I
MP2N5PTY!")58MB5/<H 53B?!6P^?'.P?[E0^A0,Q+ZJZS W&[IYN4>K'CNJ3
M=N?("J[19LU]S]&JHIP&E&GDQ(\#?M.)6E10P;"4BK<=X]W>ZEGU%MUY>TP
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MN8KA+SAD@.4,@+SO]2\ \%GY@(=QE&?NN<*'U6?I'<,\47P.AWIR<M"@N>:
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MVJKBW ;?;B"J)? PO0+.I(?&I^,HFR?,W'&,@V >Y<#$6/@YL+H(I[05V'/
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M!B;[',71=8.CX+X='+TJ,*+SO82;*]\V5N(*)D12]B1Q\,A4<R]EO; O]!"
MB8D&!*@5XNN=H![!ZZ=Y&E+5H)X7&=5ILJ!4QS'( $72<1AP1.8")3X-L":F
M;47&F^-_+[*<B@TJ;<0B!<AE5Q:(R59:<2"<G) RJ !5 YJ2E= TG%!:!)6W
MD& =1^AYCL<-^3N#<P&%-@W1U1*:#Q&W07RR6([^L,ZNROVA26(T6J1<H*;Q
MPF8B:$%X:S0=+%N^9-X@'9;X<.[]U_;6]O;VCM=%A1"?7ILY$X.*@R&_MRM"
M?BYA-%C%,-B(Z2&HK)[Q-K" C&K&T&5P-HW.:;S-!I]T85>68E&EW-G[&K5%
M4HZ52FLGZ" _,_*1S(6(S"Y/M.5Z3E:FCK)=K" D$5(;$*7"68PANP]ULB_@
M/S$;K1D&A+"27TMV":?0;MX"P@8"S14"H7<.*SQ^=/*\"WI4I?KQ&=K?8",2
M^Z-ODIC0J#B>ATM.< K'5V0GN.D%%+A>G5]P VQOEW!P$_M1R\1:,P;8]71+
M9NL*VEW%(QX=SO<44Z]N%%,?[R"D6BO\QS?[, QM=LS1\6L\N>X7J%D?</2Z
ME%$@^G_PC<2GMT)Z-BK%9[WVY^7GQ^NEYYW<IW]:=EX_RRK!6>1*_:"2LQJG
M';'YIY1:+'O_KF)SU8FM%IK7?G$[B5DHE7]=D7E]1MX*($G=P8\C,&\BV <W
M?BJC&$XTZ%6C0%GBVX9[F-DHI<:H2).1AU&548)1=Q4XT/$"0)NQQ#$DGJZC
M!TY>::7;UQ$N1GJ*652(X<S,S3@6675C..6=SLAJD $N)0. ,',I*@AL3)8V
M(MR#@+N6Z*X"Y;X[5Q?4LJ!>,R&(>Z&H)PYDU$_;+0I8T(V+<%?I#3FE\P18
M72QOF_.4\^GUT>]N1)NVD@ ,D-@%H!Z,@=$@5,*H7XC0)!T=M3,I8A78@":&
M;^=A'G$@&][#$B0**$7YDMP76018&J37 <HY;_<X>2OV]M\9I9A.9 CS1Z)1
M;E<U8CHC=3*98V,ZV-;Y(IKF-+5Z$B?3A+Q_%!X+.83.H"&'%1XVYUQ,TF Q
M1DB<A7_\,2T.;)(WC%1&?!D!!\!9\ #>!/0A1#O,@(DJUX]<C!LSA?%Y<,ZY
MA^=I KQU%F48ZEUP.DGQXF642!L= .D\ :+2/3I6DQ2YVB136*&U.OSI4E*/
M9KCZE)IC1/&_%VF4+%:57)$$TL-O><<@"2[1$1LG" C*/Y@$T721<MXE/6*\
MI58K8:C5BB UNB88P57F5[)O856+F(IXQDG,:70)'I8.Q/)CX08R#6F"=DD"
M;E8)#-T/!#->IU$X\71>J;-.\4;2></14+X2=E"47-$SE#I&.\-24!3^-."U
M%A>EE5ZG<^5,)7L8!Z3<A&,K(?N"!;T3#[=#X'FZ8,!3)HE=F<F#.ITZK@"P
M61)>BNB56N"T"+RY6H/E<=\T#92P2BH90=42QZD8SC1/[.09)W>F.HEE+4=H
MFXK8DZ+O-?M>YU/;[V%WBOYQL^>7LY+ZB[-_BT!;F3IR?;9#4;8-AD6AQ-.9
M:99@]JVCB(Y;0.BD(N@6G?#*K.@AHK/_..;$N=;2E<S\7'HL:58GTR=I%7]R
M?8E*:<-_X^L5>MJ0FO?%^E4X\TGUNRM A4BC&OP(I%#O\50BC[7L+#&+X7!J
MCCO+Y W5_*D@%3*)1B':(7,I$5+)^E5CKNA569$M;Z  93&5-H>]^.88;<_
M-@IUEB(;4$:S%P(TF6@CU6>L:F6.1)D8Q?V4#VH8)6NALM=;Z,W2E2K]@U[G
MDQ$%P#0K2L=<NFTE%><AL0)""HW9"7;UCI6UL)K N-RAX44J:QW 2VC@E G=
M'L@-SG+A@GUNIVI]A;^?<^:+P@:5[MM%%HQ6>1Y@B%S1)NX%UT'U.](#' $C
M[;A4NZV2!4BM=)>5EH/DHD>L9VYHM!RSMT>76#3*&U=!-!R]%$]#YYUW-@WB
M+YNZ?QSHP;!,S%@LB6.ELXU#B<3<E'?E9Z,TN?(J6VY@:CUV1=0]'.?S!#4!
M;M^![2LJ3J/H7*F@#T />18*;L,>J&/=5%ABH-JQ\(^<;;2@(+!ZI:B $BXH
MG15U#8NNQ0@RZ?UV4S];N]+=@@+S!M1Z):M\XK+BC-GP.97WX*DE.7-$,!H6
MV%QNN57"&VL :N9)<J1B9ND" ^(<M3=).M.FFJNZ;!2):7ST]&:1-ZO RTIE
MQAQ2U$U[<AB7%'38<1R>3Z/S4.7'2;<*TJC)9EA0A2HVX O2=(GDJEK0C!>Y
M:.WVX(89MQ+NZ,Q)-;^@VI$PSUGYSLTV$/7:.!DM2%)H4I5* ^#EE,.+^CGY
M#M)"C88-+3!/#H]#SR7*>S"^%%?(*%G$6<@-II*S<"D^OW%1* =OI'G)Q"8$
M0T15$"<3#'2W0+?B*[=7>.C@\<]6(4KS5^^@T^[[_S/TVP>%?@7(BAW_CSLG
MAZ!^#=OPO]3DM>\-CIL#Z\?3YF>O/SPZ@G\V#S_">[[GCHJ*7!-O#QB>4*<Q
MXW-)0*_7BOSSGG?8ZG<[_1;=,P"O#XY]4?_L9?7\+CSSVZ IZC*7TO)@3%H+
M3.T?>I]:@V-8"BX0%MOJPPNE+PY]_[3//S?W3WROU<8!VC[?>T CX(INM6 /
M8%94A)2F:L'&VQULNG;RN=7^0-T)X5M)SG^,/MVC6=@1' O"4!WU@6\S8"7
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MZ9"VI/[SH4UPH42V#TTJ! JD$T*<;QW!4F&-#GHK<EB%YHBH?9].%B#0:AN
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MUZ7[CW:[<[L&4\J/HPPTRR#E]JF<63O';CX82DA5!BK[1&V0#3GV5Y@XF'I
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MMS0L >*\*'L*:$?,.6P,X5*RE&ZL-ZI+X_ \@>WGG*^V)F>('6E*%F0MPT[
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MM,SS\@8!,+$030 ZQ:&WM^Z$$EFKF/"_#V,:W0[R'T/$>#A:A:0L:)Q.0]*
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M\<F190PHG=P*14#+2W'?]JP ]DX[D>)=C@'KD[S4+]:F]M'RT _1FPT4+L$
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M\)L_("/!7$E*XCY=RO]>/+MX??3JU2'\<'3Y\_GXV=?\.3J3'XY>N.]^DN\
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M#@,6%@8QZ&^90%4 ?EZ,)&S17D".!NP&)I6[L4$+D@(T1O@=6'4!!X0K"6;
MN$/D9"RP%R,U'*$3#C%,48V"\> H@>0R$#?ZJU$$S*Y(LQQWG$=P^@$R29 I
M":JIPW1$7(\4R>85>0\LR(#1LM1\+X:Y4"> -X<1Z3^A9I,9JE-I=ATDT7_D
MXVG6;O$HJ##!TR )F!4WG=JXNC!6P@&ZK'>CR0G\-R_P#<(W^# #0.!9\; 2
M0G.!8DX[%]D-3,'F&YPY'2NN7VX[$S,8'98=T.,5*,Y;\BO(W,7A7")O).K<
M4'5>(6M ^!PH )3"61"AA>^-2Z") .DB34J0U+[\F16G$?^DU2&2O 0^T+&D
M0+Z13]T"#L,CB"XBR9G0<2$,[;R<SE],>LN43NCL4+5MXX_+C(9ZPE:=!=X$
MH5D56$6('8L$!_RB3/!/LL_"N"1C4.J$@ 1 WF&8E;C*LI"/,@@+."WD#?[<
MS1%AQ,QOY'I8I#3M5B+7NY/>[R!0I$NQW?+H_P<S%M(NSHEI#>7P*TN*#P4H
M6B#%X]O@+D=A^FZ&DWSL>U>]_P$,WEA0XY++<^\?[^E_KIJ@A.1Q]WS0[?]P
M3D\4V^LK*)7GT4J#&E*5])>V$7 DL5YI*BO>I22*=LL]ZSUO\9LD4;8!"!EM
M39T&S$119@DZG\)T=L<,QWF(1C5XPT-5E%<R_ R;RJ4=&!5H[VITAU>.@ZG(
M8$\#H)H8I.WQ)!)C[V)&&C4@]P7+,S#XP-X[!DZ(YK]W5<!BP @^*J.X\-9V
M?.\*&+/PUE;7C_QVZTL0PW13W_O4\5;7-[<VO$4Q#:)XSULB^0T<$OT.P-"W
M]E97O=G4.QZ@ZZ3B5UI?)SMS8]];O%OR1BG *TD+#\V@KZ(*E5&9X7IQUWT!
M9)OCO\I>\BY%%H'I4!?^;)8N_D<>3(;K!."3I5(UJH1D4N@9RZ7A):T],EW:
M+;9=X.7*XA8-MV"GRQ7Z3-*$)]U:LK6<?()<2+$ G)6-"WPY-TC8:(GNO8+8
MF:];.AA(NX)%(VI:\N@:8'0-^-!D8P/J_W-[?<-?!1R9XVIHMSK3M'0<#<H:
MM]P1](A<PE!(CCS)4G0>YP&H!ZB^ /]-2H9M1)I&$,,?>0$O\7+0)QR"%C1R
M<4+N4*G"Y"-$Y0.VD:6XYRP-!6 G2CW]4I1$Z#C2L@. DH9AF2$5T)%'&:@W
M:@CTOUA8@ ]LKQY<?;X$[EHS-'>VX AAZZ2I+A-GW2/KJ)@<O(-W#F&XN\IH
M-:5;+Y078L$!E\K8+)!%!44X*6=Z'VBJ!P3N'$ *JU SS)@ M59+6V)7LCVS
M/A8'"$S@\//^#Z5616.;X\*+8!<(](;F"IW$B*$ 0M;RMAX#OTCCB+UJ%],D
M&I8YL%)05 K@6?!J2%HD>1Q#X"HJO@%RJ'=X?''4[QR\ZY&PT2@_A]00B*2Y
M,06DX[KI1N,!DHIIA+H7S#D4,,!8:;J68I5F[C=JB <VZY#'1*!L0-<7:-0Q
M^W*BG!A:'"2YI5>U6WJTN3,+P.X(W4 C =HDC@DCJ*<- VC@_E%2>48SZZ77
M0++PNYBH%Y?3&>K.EB[J_7-M>]=?W]Q>V=JM<,^^**1#^PBU>2>NEY .6V-R
M+/(()2QWL@D&/,6#K;S)B9!B?HW%?&65#8,W</G*7BI,WN5RXMLL<AV/4E-H
MM^JJ FKPL$505P2Z_VVEY01DL]%2-M:4EO+2SNW%T5RLJ4;L<+-QD!?$^Y47
M!OE0&9.:QYOVR0 J$S!YB#7-I&H33D" 2=L$?R.\D!3TH.=Z;7UY"KN8*)^U
MD@3.T536YM66)@\VFD[%""UL8+5#8)539G!WGEPRXAIHQ%D8Y>C#> U2%G,/
MA:Q+%[2+P1C1ZCJZH; BG1I"V=$/U^&@.9#G:(W -);86<5:JQ.A')/OXUN[
M1;#/GPQNG&X:W)&3C>$)JY8Z=EX"X<ECG*,46?P"Z+<2"#2AH)<]F?%\2<ZX
MS)1.+([8;8 640SV3Y+#OD%H1?DLS2/ET_( MJ*03B[T>R5Y$#)[@=\0GC,0
M3=;W:'K%9%>!;9@""*^+(+M!89\+RY74(#9C4))#8)VPPCB=(127X:C1,YN#
MX9&C58>1D'(Z)>8Z@[/)$(\L+KM!;&J3= 496$D3CD0GU<!8LY0)@WS"#B"I
M'A?I'OH_O;65U5_4PC$RH]UDY0P4OJ1 46Z'?6P#U)X80VV(6S;(?% ,8$)T
MC'JK*UMZGBS*ORX'HS]+HB<X!T_ZZ=P5L&YRC=^[:X#]40"I8BDW+\$-QF.^
MBQ0PDA%NK"(U:81';[=BLJ"$"S0(/(!8AK2N79_5>2J'6)W5I332J4%SGH+\
MR^ \ !N&,08T':!J#QM\F$9%(31<CI0+^<2XD"NN3= ^RVL KTKR("G'OB=T
M-!W,YOAH:G3KV82Z6XERO5CJUKI:^4_'V7,<9X_T(4N:<XA=IEJ,M&/$E6[&
MQ2Y3J%"ART2A>:$R*,T2(DOUM_RE0>ZZ$1S?B+$]'Q$E<O-M&NT$X[5&)W?=
MX?\S]/M@Z'?C+8=^E9<1D/1,1\%0[3J.@VB:OY'X[X?TP:P**RNCYMFTXR!U
MTK=?A/VBWR[D])7/A^J$/TN\7\=/MA\4F0P,&S,5WZ0Q\( @@_UYBPAE_6!#
M6B/#H1+7-1Z("&.H[#=/\<]@-(V2* =13'*06!IE>N5+*M$CX\/.53X*L@-4
M!\,)')7('XKU^JB<C(!+Y3G-"*+?^GL(((M@:\)QYBJ'B#*?<=;KE,P$#!7!
MT[PC%?Q$F'%\=!GCI10HEM'HW#>18M^*(T_)C,75 =-+Z"\94<<E!]?L3W$C
MH')%S#3U#D=H#^1IHH)_#2IL/> LU^_L%RPBM=]H5(866(H,53W.=&0+!)]?
MNC<%T6;J,A=7^P](',0VY583 >39WP9JVWRV:,:%1., UF#*\4R,<(<!AD8I
M*2M47@9\Z6M$89V8X&3KU HTZ2T"?Q+-U!LZP(U*'WQVA-,C\G@;WE%6&:;T
MRK41%,VK?B7@'Z C$^/@TRC/C?7">\#'0$V%$=LM\ER39<BFC[8^M*.W$O2<
M$_ZRF8E)JT"HPP%C?M9-E,;2V%+>>]*A.;@*MDC'>FDLD _%/GKD"S*OXC0D
MEV,1+2/I9I$!1L9?@]81*-=K'-PB[E^7L7X&E&]X [0 O]UR^5X'3+$3=TR=
M0TK'T@G)*;?V?GO'C@9AQL44/9=:;;] TO6^I-E7U.ME=!%CB@7S3AP)L'>
MP6+O]UY/J^T1&))>'XLY<FNV3?^>7]^#4B]9<@X?=]<T7.'#+C[#TVRN:W/F
M<T)Y'U<%)68<IR/CW^M,11:%2,.$@R?H@D':0@(V4Z[N>XM'2^S.E;P&G7C
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M D?1DQ:<DM_TLQ93MH"J)2-Z,B4@NK$.AY8BL<2"8YI9QV0)>TQ3 +P!X.1
MO/?HS_=J+R["Y$Y-T\ =)N+4"#P1$B84I$6FHX0O^3-16#)0P<C^%G$"'?X,
MD">N<.>-4H]^\?DC9DHC6P=\C](R7_'Z 9ZJ[]KB>02X)[.AF4?1D)B<(H]A
M+&WM^7Y ,Z!M>S_*9K"IQT( QAZ5/P-2N<Q$-2?'$%)PC8D?18,/5FF/Q)L
M96,X5<XE%Q+#$5!A41*GEM"CRC(; S"WB]/>.-F=+2[2+4=@)QX=#C[VKG0U
M7N_\^.SS2??*^]09#+K]*P_^Z?>./K-78'"!F?7>U07\?='W+CO]0:]SYIUW
M3\%,[9X?=[W%+Q^[F'SOG?8OKJ[@(4#SWJ?+L^X2OG!!/WWH?#X;^'(J+!"\
M@BF.!]Y9KW/4.^L-_O"Q*+!S_@?^@_,=7WRZQ(\T7_>*TJA>/N@U/Q[?L\)U
M'"XB^JZ0D<Y><%1,)G FE8QJ$3@R,T^%)?.P0LQ5^2+'3%701[,*Q;2UM>78
M0#)5*T?+\$\I/4CA\>%%B\N;?$L4-Z0P2GL _>V&2RE^YJSMK7IQ-WYZ<;_'
MBPN8H249;IORPHVR0^FZB/]DS)4%_5BM)OH@$VQ!X*"RH$..]%QFO&+:MO;Q
MT0D^4I=_LXSHU=9MR#!''X%4 SC"K#.=YE5'H2X'#%B%F9&SLB^+-FS;7*@;
M@-!%N22-U!LX@5%4-&1;+IF89I=B7I9-=S&;@50O$WR1 BQD)MMF2O?BV,ZN
MD.H#:!NXL*I=>LU%2AEY8Z(PFK'60RD9Y!- -A)=:\V#$LL$;0GS$,NP,%8D
MSOS8Z<(TU>F>4I,C3>&>"?=!P;]%'YBM"!!7(VRX+]\:@(M'HP[7U7JE,Q_S
M?O!7BEZ#*9,Q6,C#%&"X.\8D5<*3H*)U4M4V2-TR+K2+XRG L("*$?1RF(..
M3/D?B%[2L9-K(K@?M5,J R8-'O5DL([G([K'KD1V)&'J*:@C[,WQYQR2>S[\
M),<JR'96?K.NTL$,BO)S'\BR0E6I!]@#R[L#$X6,KQ3^[)3%),V(>ITX"1=2
M3&7Z%L'-5U4=^*!ZS5M$[N+;-?2G^E7TE\"+-8VVW;(2>E6^+]6:U'U>A#%.
M] ? 0B8%,K<H0=M?6CNJ2H',L-HJGE>K\=2L\\UG99WW+=\K.B;P0+\$&=9V
MX_GV22%%G# F B>A&RRSHFNL<69<&<Y*.EKZ4MTE-QK0*D>G[U=UG!+Y@,\)
M,%E0S<V?*:78&1..]5[":/R;?>:$5V";YR5YA1]4OXUEVH""VN(F[E5U+(0I
M4"MA9P;T2&Y^\O?"UFN&.F(L.S9]7CVM$Z0'%7LS-V-+DC<;9%B-S[+2 V[%
M>2&@_<N'DE"'1M/T*RIXH6CRDSX%^DWE+O<=<_VP@+,&Y+J[DZ$./E3.>#%E
MR92=,,9R-N1 P&_N* 8J35W)L]W!,2$E*Q@V3S"NZOZ2Y*[B,7D*4GM-.-UN
M/1ZII4'-34KD?L?D$2> XLY@;9*E.,JWZR$(>>4_RX*?&AO>>LNQ82N?[DID
M-]B@XXW$@X\$S)3(6$Y#:8".$'P0PZP$S4QZ8MYS=IFW:"4'$B'J)$+IF4*O
M8Y"! @=ZCM5B!I[48CI*'O#[;"V*)7;]5*)]E2Q&)]Y7#=':12CURF;I0*#J
M4%8J0Q[=2@I1H_'"32T%'WA#L1%I)DF*:FTFV#.ZNTJ^\AQ!YE&N)NC1[&$R
M!MD,9V# W*)FEURO>">FWJDAC[>R.:?+!3'U2)<X!J.;*$>-+Y<+MX\M0^V7
MG!></8/L%'>/_U+/ISM3\9S)>/+\%#.M:C0W,[%)I:%YTQ1T5-3(41NLG$!
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M-QTC7(N)Y"6F:31^C3SF)[2?">W/\CJCOQ?>U1#!T2EIM+\N_",,A1B/%U[
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MN?1&V-&U+,[J$;,2]K*<8W7&+>'=#@<B$TB2Y^X8.!P52/-DQ?<'/YZXRTY
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MVQC<.@NS$@@_@#/-[=[\YJ:M1=8A"^EN+[G6:%(;I45A$+WSU$A>OYP^VUQ
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M6E"K)9S7OJ \1]WP;9.<*7OS,AQ)S;M(9CBC,$WXW,Z;W1?;P&GL^D)S0(5
M(^R^LR74",KBZS2?YN=PPJ;1>TPCILFTW,;J7/)PCC*$I>:8LOGVT7T:@J5F
M/U'GF !EBG)!TF*7%!T"IJX>*>6)J(@23S)IP4P'AZB5!!7JM697# =\87-3
MW8)[B:673BN2H++K3/0J'MS6&:PLO.GWO)J8H#"O4-0,8)3/4V5 P2M?BJ8[
MMDWQ:]TR4S%&24A;G>!DU=XE5T93DQ+')+$NC,'1<.EC- ??8$2\\<X5YW<D
MR/*LEBX2L V3%.4#DUG5HM^S9;[!31CP^^XOB3_?(&H"-^*-3!H9H5)X2TJ$
M4&X[ 5?6'*$R(FM[S=CO84,,3P3U,[A;@:F1LWM%=V.IL+@T: (AR3[]A'7%
MU$S,XU9U:M>P,0JL9I&IQ8/1E+">L 27Z53IVG#Y:W25%Y\>Z/@N_&\E9XT^
MY*XA9LP]2ZC[!5A,V_%8D ^J7*:X*RTS+^SRA>FH=PL/DMUO/HA@*,""*)K'
MSI7H"3 Q2E0ITVB"D'Y&TV&M$K$*TYLQW*N*?F\,E_D()DEXLTDZHGR_@D.7
M+Q3A2$% YXJD5*I3Z=/X" ((3"MJQA#L:M K"LY+<8FHA(\\O\+?5 RVVWG1
M8@E1Q^E\ 1)ZUFAG=6<S1S_=9XZ^+G.DM?X0"Q(4U<"C<)-A%[L=DQA@  <G
M$0Y^OQN 2);S ;>^&24=#P&I0X)WN%UY/&S0QVE"D(?WJCA'QZ6CO<]CW:\-
M:PC=AFUQIY"#0U7"T9,GHT<2'8GX$])*_:O.T\3[,_S]W;N#I3J6W]:N73'E
MY"B8#>A"?9A!LWIWO6[>9-=R1_<^ZU:1TFANY]^BYMIU!A6A>E@=VVQ']""V
M=0A]O#;D)O@PXP?C_(KA/L29@/08!N:"2I>@O0Z=AG_CHL NX.#58^=:1@1Q
ME4O3 U_IQ_B+25W@9_AG$KUEMI?!Y<'UD%"^$74[CY&X27 $;5>(X(<G#&8P
M-#_&C.(RH F^$A='EX"9#"+[J%R]6+@7'=RC="V5W!4/"W.QXQYAG70CLR1;
MLM&RS_MF8BW6I1V'Q37>N!T90,6\]\$R]WNMZRRK@N,XY.O:! U@WN97[])D
MF(+AF?*]:XV(+[)>H_6-U^T@E=A^9<:2F&-$3*O FB,(IS"'#U'X<])]GE#?
MG EVYA/ZI )Y30B[![J)9KZ+L+T)=2^+=<,<PMAA&ZE"]+']_4H(&JSC@]Q6
MA6NZ"B0:')M&==JL'%%+$2\PA+\^KQ-JV:."SE9"/F(>4:8S;# HP]ZEBNKD
M,B^<8%6W.HL#*]235*N4B7RF2*FV#Y%1\*25'FGLG]2V4)B<9O@)#H GV%OJ
M]')I0AJD?Q 0S ;#G.-Q>LVM*"11M9@KNI $$4&4()?2O+6EO)4]<>M7N2K0
M>E:Q]WLG2N#^.HP8K!TMV$+:(5B#?>Y!ZFDY[IFUE5#WU[  PM[31Z4WJVTP
M9Z[A,7YTK'L#NN%K#FB+EW2I%L348\E*J K06R.^\I8%H760F^["Y>%L%#/I
MR&CCU>'5TQ)!1VFWP7-3%QY\<QM;.?3*@QK2Y86@VVG#VD/1RZ9R8Z%HSHF4
M7,&@.]JDE\E4$25BR;43I,6%[ 1M%>8RXGY<FK:GE*0'X[9A^T2/L96E:0OL
M9_R[(\6(ARMCWSZ,E0J[FNX FF-) [9E1DZ%6%^A>(N/I9<:I7+R*RPIH8N&
MIXK?&JI,35)6W]XDO7.TM8 ZJQON@ETJ+"Y #$N%="SY)YSK!=@/,!5M?J(D
M5/GH$UT.(!_,59:#H4%?L 5]O +VEYJB"LM&Q&75W<RDT[8P%U*G;>XR!7I*
M-Z8VWLT29>1YV@[1HB;'0F(OR1=XOEGWMJRZ-UM5&-H_!5_2P2<#BR0V 4U]
MCWHE?-]>["]9'D#M%IK:@Y:?MSPF6S)317F1SHU:AU6?*:QT]W]K#X%(B?.7
M"?N?'RD>Z!JB*PU(Z0A]%V-L3^]C;)M.?05>^_+<=ANDH*.-(EP_OC/ZU+"8
MA%RFS9#1JJ2^[4G-R<.NH1JW +^:9.<I7I1S_0FC"+?C)K.U@"?;=J6W@Z1S
MG4Q;1KOD:&_5WX=SY Z7FF'#4&'$I=<6^]8-7\9O$O/M*()]2L;BI[=B9WS>
MM6>BU#RU1-.JV5_UC]YEW!43;>-)WL:\-)?PSF!W$WF_I?9A;.-[?GY5-!IY
M<E\:#U^K)J-TB<,IW!AW9,KS:@-9WQ;KJ3WQV^_Q1[\B^QO;$K'6Q?VJ7 .V
M614/W=,C+7"NUAB*DPR*W21%OV>S%#*=1O:( \-O6N?F13+S4KF3#28JZ=LU
M9BN!)M.I />T+>W;E8#U^*0+/2,[:$Q=.*S0?@;[UJ17HN[LRC;PM[ODAYZH
MJBZR<H4+%>TX1I7WM<)C:*^X,[O6 *XW1>S+GJ.SE5OGLXGE"[R 6F,7*44K
MRYK9'TP&9<6J:(/,B<3"+$'2D/#7%R+>Z  3TN_9=TJ8G[U+^#!?9TZ<%]<0
MEJVH-'%ZHP)84PFW/?3;1TL^&S-$HEGN>.EBP@%K](8.B$3S*94W&RX#<9QA
M/N?R,X5!TV&M8]38>JB$:VD<NUH5 Q%D7).1G:_0LMHMM= B5VP[U-)6CJTX
MXX,W SQ%X-IM*4OQ&;EXK#?2S%'$!H*#3@P+<4P<R&S:F<B?X\CHIXC(,]Z8
MA'W%223:ZTP"+FG6%E;9?KKA,2'K,<\T-Z9=,^NTO5[P&X/:F[RW0=L'L?N$
MIDWO(!X0.L(D ?#0F($S_$GL40(W"<@4 @7@L,/)+">"M8=;F"A@VAI^P.O3
M@N<2=R7X[BXTZ^?[L-'-50VTG\DUTC;.-ZS"LC PWW9HR>U\V[#NKI1PM(S9
MY-G9"NE.Y39K #2,!SPPR[-O]  C0/'):.^#;B>"(2]<[@ZH#0I21OM[3ZC^
MX9*[Z<B/\--0P49P\R,?D*&32R&UEA,,><PE%=O)N*RS%1;RX-DGLB8N3VB;
M@4/,1Z <QU'+KJ2%F&7II3(TML2RA?]"WC:V/-'$TL/A3E*XMN,9\ZM)H@;F
M5$_PUD>JEV1\B=8 OP86[I.JZ)]C(F2#C:*OE,F4W,>Z;'2BYZ2T)KMP':IQ
M7>CMA=LAS<?T 6QIQ8Q7C7EN+9F&IP5W;UP3ELOU#MD"(E!=J:GUV] :*)UQ
M0TC60L. QT8,ZKI+'+&:T]()H3JMF3ZUS67KP.-TAVYB'7BH$0V&45-. J&-
M#3OES3\$XZP2X^YAQF[<WS])IAQDB<L?+&42X6V(.IYM",.D-@FLG;4""MLW
M/9]X2)?0VKPU<!=[$EK:3NGUI6W&IC0MT)C8:SQ%9B;M*O9/[# "Y7YF'\)\
MP[Y)?W31HGU7R]6._1M;I%;38EOT,44EI4:!%P!#$71HG*@29ECUX_EPP9,<
M5#F="#I!N_BQJXND4EB%RJ$(X@$614.M,J<+XJ_V4NKZ &#L@0[77C2 ESM)
M>^]BUJ@BAO@HTZ&E4.B#=UQE.W*D'5#K8#*!S\%P=Z.=1+_/TW'H)SKH4.ZT
M)B 9W,LX:H0L.1LW(I)(E2$O)$7;<,[AN2"]RL\3Z%2A!!)+ 1<?C]YU@@24
MOK?5:M?E@\-8$_U=N.-0T4W365HE-H9L+-EEYNB-(HW<G6_F#]JS!G$8OP\N
ME1?+2GB_H4GG*@[GP,F-TP(9V9;!XN>O6H]R3.?8'%ZCOK#,"BE.$K85]=_'
M& R:#75@KLY [,"J/"_R>LX*"Y-_H38%D?5?DM)[L-THM1E-!&+"#.Q(+QM@
MWL/AVX^U1?A#6X28/Y//B22OP<+$+IECOD](*Y.NEF]K:^D-C'1).SB-N9=Q
MP)FL"T'I6L--FOT$>1X&7<XEU@[?^>""YL->X_AEV%*\1SR7QVGZ>+0E,-&2
M@\'0IQ:OTE<&C5O")B$+C.!*YS/?R=&W!(L+N2Y(I4,A(Y#!<5X/J3'-PKB+
MU.%6!^(7S6&U2T"C33;%TR0U$D=^VV6YF7G>F#[3S>4YX(4GI^2XLVYS6V"!
MH_#@8C15_U[+&X'I/X\N,& >&<8_;TJ80PN^)"MF_*:Y:?8+[\*GP/\//^,M
M+U_^+5.+J%<IK+3N>J'3%/(*..6EG=22=RPI.M6S:X4YB&?OH(M'^;2>97)S
M(H%_5NH%T0:BXXA(X,><L*3Y$3</3P)(?HHV%I5.)(A/85P&Q#AV6HZ23;(6
ML?Q"TU$VI1&K[P_6&(:H$W(7Y=]KI45;G<M%QVA>W-70ZK/[T.H-D%%XVMJJ
M5".[NCT(.6%9BW"#?G%+RQJ6_--F>&29YG;?=PFK,YZR_Z(F$UV+*G41;&\:
MM]+7[MT.ZI%!P&\3B^>5Z1F%+):GOKWBJ)ZS/K"A;$^WMV6:N[$:]J)E.R;T
M-,)MLC0D.M@<)F!;D\0VOTA91_8$$(H?)(S9.<8X5U&7\%E5CHK\"C^DB]9L
M_X0 EV&7##Z-DH*/9X_3+(=H97\YB'J%UH.A;/[RM5N[H46-9BXUM$4]75KZ
M>WC +/FD]/59VDH>371@(JMEK!\/4I&<2WJ.5Y/_76*8@#O/B,4@Q4-%/L4:
MC0R+ %2EXK!BDQ@8%&(A*U \,?:BD?I3$@#\YZ5R%_G ;%:C@\$LP6>XH7G_
M N?P?KJ[#>*2I:%Y73+=W#Q?0+"']Q#D"J,UVZ #2MNFT93AN7@W[RCR#Q(\
M4@I_49HC1'\AX39_HJ:P=&B:D>/EJ8NVY,$8.TOD<Q;.;Y5):+/BMXF(%8LT
MJ WJLLI #Y"+BN5(5-HK':B]N!CK4=@'I!!%=3D!4:1V-7[)+QFI^2<ZT1.<
M")8'GM-N@ VO2NZ ,<3&,? 72A'%7EMV<IEQL\#\+)@#AQW<M2Q,MI#BK@Q.
MW)6&3+A3B*X5FA?,#T _Z!;<4D6D1K5QIL7)TAX@7N<M^$FZSUE;';EE;?+G
M.1X&]GBPL-)0Z@5%/9&_RL%JRMKQVA-5.Y5<\Q:47$!/OV,QGLU2VCX'_/.M
M0<Y.)<+RE%1+PJA1F=T1N8M7N?U\7QN4<Y '-.=:Q.?;LQ$&-NI/Z,'^GB%N
M!4;DQC<X#7/$>E@OBC%6KQ(V5-T+$@S@!A\@+J,+ZX\DL\'W-M6G=%AX'F<'
M2/1LCDD">&<Z\1M0ZKS+>7K)/7:Y&19LCLP*H8^Y[='K3X3!EF09V:=*8^M1
M/E_8* F^BLPD I_[\"$*EDB6(B08P2KGSI>+Q]_P!L3#U]4\+>E8A_K%GN/0
M ]G5Z*;Y7)A$VL=A.M"#)7NEJ'RYZ:&$-=;]7H"AJM (Y-B.IJ\Q8'<T%E59
M!?U#=Z2DJ:2T3V759V<6>KUI[PHV%8O(VZ?L.%![<#Y2>I_,+5MR'\AV7^93
MN%^X<D!G8Y6-/62Y<Z0:[S9:@ 4/9^"+'HHTK =)^\B8#5B9)5Z>\\:Q%GS;
MJM*N>T,!$=G@90KZH/LXF+;5QM> ;\$U58Q21//CDA@Z$>I!U2U5W0*^)Q*^
M9?WW%"ZIWU^M)"XYSK,'/ 5<5,U?XM(S;((IH37!+%\NZ]G,PRFX87@3",0/
M@CG W4>PHTN%/%P<!S /Q5"%G(TF!#ZT"NSA9R+=F'B\*)>)/IC3ZLTU>&Q1
MK=07LN:$HX_2P^%G-"X61"$$4UZY W"B'B2-'=#.O%XDE0E6PMJ="YI\5R-=
M<67E0 VG4LL-YM>4?L(<<N-A75WI),=!V!;V8$0':88N'9D,5CRQ&5,0-)2G
M=62R93GH>4[VM]^K,XI],Y5%E4YU+QU>*I:;B^12<?HJ'W+J?,^_?=>@HB;W
MACYA^MF1TC=Z2$W03*"/\ENLLI31K)4""RDL>97 \EA^=CN62FA#_$>:X;0[
M_T_ ^4]V"5)LK!+X]UV-+?]R'UO^.D;%.6I'AHYXI.TY(\NH<>M*.TB.@SXD
M%&0+@&?M41U[G-RC9.QV[[3C0W1;7HXS(T4OG_@O89\W=G/(S>,RB= (UKI?
M.\YH.Y+>NR7M8!62]V'HD+1XQ\#[/?,Q2=;)IK#.'IMDK([M8KS,8<Y?.-55
M2PIXM-]I:Z=\7)!+RJ;4)\Z#728I7SP%4B-)'9!G\;47%H0I78^^#.FGW=0A
M,M^-\I(73G%HYPM4OE%_\V3AR< 5]O*5=@)<CC;+,W:.Y7==H1='LFVJY"M$
MJ-]C&=)8$*S<D5H>3A_S!K=ME;00\-U]_&>9S'![!+A&9I:/DH&E+,E[E-H4
M!Y;79?"'IP8'^S6')F[X9J9<18R4#&>!5AKV+X9/3)K2[&#BS-8O.%GBPM_6
M^YXC4<+4-PG+W]J_IQ/T'FJ&8,/-7>OW.H()K9O9$;O1GSHO<K"<,AAB>JXA
MB5@GAE7:,ZJVU9%;7Y3EIR.9)5-PB.E(D#8XXA*26/.+,"">ER@K8U2)G]CO
M[2#&<2JH01L!V176JY'9J8X;96FM\5>K\+WH+#A%2=4:..7;B/MP.T:WU5E\
MD5G5\'7F'T9U:5NI*:8.P0L-)9D87*B)=KRY;&B@M"2N6T#)6[D/-6$X,6U9
M</W4H'834(?GWLO:EGR-EL[+KDV=3H8KIR6^(BY8&%2)O5'1I&6WT)_4PYZ5
M:GJII(AM:8Q&VT*4O=L^YOQGC':^4;1@:(*]KA?,$WP-_]WR&+9X\N9XS>!*
M5%/937*PB-\6Y6)J6IR&\+XRGXYCD^/737SP7Y7#BXO%_MS21ZJ-/3QW&Y[<
MP0<U1'X%\VE8GH1O<%(. E&RXP&9T^DJBJPTR)DO\BM,\#KDS)EH&$R4Q8[#
MK.?/N6"] L[T%R)>X(X9EH44'NXHN8FKY-Q+RU[)MK*]U?UL64T$-0WEE;9$
M&\X9:F9%*5@PJG3HMOVJ-&_]Y@#MX$@\HPI@7;JM.3OX3"PK;\8)#!$OFTA$
MR88?Y>..+9=$1;Y(IM7B 39M0DP$1@=6JC<$CCZHY[&)]N3%= R.GGF"%@IV
MOK!F[#(73PSLG;G".N]XO=B2H<TS;RMKV#E<#;IJ._B4J>7%5*BUJHN"@NC2
M;QA^D:JBW(WTWPW<SR^Z$&_"\FU57C6]B:[H\G02M\//\VF>5N%GM;6D>2#F
M=3'/RQ7U/C??SNXHVDH[NX-W'TZ/CG]=U4SO&QRTQ]S$3G0C'Z\SO%8$E] 2
MU/4;+CC?U%T6G*3+?)J,J,H0OX-0]X@=0; ,VYY"D'#W4>!MYA4"S.!(&Z0N
M(9 UH0U3:I]S^0X7$;$@TRU7@'\WXA;=<.[ ?"B1="F=47\3E=>E)H]G*]#-
M>!MEWK >OCWE0+!E^VPNT/@("Z!M].T1(@R6] PD/]RV<4?[6LAQ;3OWM_5?
M:71 M+#X*_P1M/0,IW:%M,7VFH4[DS1Z0G)A Q-,+4LE:A0_Z:@ZB&WFMA$C
M@M_E$Q,<LKAN-EB=8!E3*U#+'"_"<'=9$AX]O(^W;KK<;.F9$/7B1 0#DS5V
M!0OM3Q!M$XBX%45H7A9)ZBHU84OB!4&'*3L7;$I37Q(,^KA'BKXP;G%!\:+H
M]US*"?>5#D<,_OA:7G2:3)77 H=UNQ1?1N,:WRB)071=N$660PJZE3(XPF<9
M-J=^KZ5&XS%A5K9$9&3XKH\^1LX^.'[F-9=Y&^746%:UU8;.P67^N'F96Y?%
MTR#B_ 1:)8BGKJ=7=&GB+=,JB8@7 66GH (6FCC@6D9 2RXB*()XM/<(7K8%
M@/'0;0B[CA:[QIG2DK -0.XHU%YM!68@[-M"88XWI;A\4^_;3D+=+LU%3!F#
M,2>3X+@:)\XH,]98;XG_1E!>3*'2G@TQ64^32' 2H$XA@;6*',X%CG?K[IFT
MFXBW_I3E5U,U%@YAW7/<\"=(3S:>DHWKE;%@W*@E@CZ<2+>GB-):</X8)ZTJ
M[ED1]&WPVWI8DC8#190W:UHBBF1C=!9TM=?B#%]?@ 5DHHFNQZ)C6O!$S8XA
MAAC(>!F[05V7;E!3#!(8E/2E:44 _XVAL=@D>N-HGE\I>;"AL.6^:ECB(_>+
MC@E[#E4;T;3!CH;%7[).)H2IFUN8J#]_SX]1V6!>W/Z!KI4A;>41#.)O_*H/
M;X(MM:Q?-#]$1IAH&94GF4(ZGJ\3:]DR#/LQP["QD!X6 ^?@Q5\EU$K8OK2J
M=9.:A#^.LF0FMHSG4&08(Y9M6V6;?M9\AJ?)%:8Z#1VXU0T4R<$(+(LL>_)#
M'IPARM$I9A<[P710[M_DB<B/MA1U03T(J?^ +97G&@\OJTEU#)42=LZ ;;.1
M$V_OPCV1=#02*^MWN"7X,@[X3EA6;YG(^2B'6$K]!%T?DY1>MP6/F5>@* '\
M'91%ZK0Q-/C'-7.A8?^]UED9CG/$][<REM[)P,NC^\#+#47W_S#!_6MV OO*
M 9P<?CPY/(7U&IP=?3@^C0;';Z(_!R<G@^.SH\/3Z,/;:'#XZ[O#P:KAW8R&
M]Y6WAQ<:Z\:5I7>+-Y0WA>GQUVS'E=^^W9IW33WA',8'IPD63>;7/!]'IY(X
M]VZNE-!1I&,7;.Q+!RUTCW6-.W%^L8JDG#HRB$0F#V]R9JX#C:AQLUAD2%DJ
MLF!P6+/,C5- D96@$D'3%?.<D)D&I*XK@MUO)U-MD+EUSB/8N 4Z6VX3[8B*
MH:YT,:>#GX8%H&EC")X1/5@0E'O?I!B=0C2^+!1%UK55)I 9JFM$9\D)(C36
MJNUA.IO_5UVD)8@9@VU0*MD\EI$)3 5AH=HH-J@IOG"1QLQ]2"E/T7 FMM[*
MW)DK7_?^&+DK,EPMU+$5K-QQ31,SI@'L\_DYTK:@7^$$+O&R_CR7*XK>I7ND
M=4+%W5K;':Y 0-R+I,-TU9\F4^$& =0;5Y*F-B4E#$5'?^BT!E&RA<TZ6J"9
M-'E;-<P<!P08EBYP8[!U,C5&I+[F@G'DO%06NH5_^CU+<?ZGY#M$!_F8!/^M
M@J_".IRH\WJ::#='S&-#/<</"N KRFMMK2<"#S(5T.5NT(2D?2F)[.!+EA+K
M])VU1"V9%*,+K_":)A.N(@^&7J+._XWG%U0? C#D]6UP#BI7FDEYQDI<P$">
M^."1MIC>*$;6C1:[9,UJ$43ZPME<,36"\TOP@Y-%LX1GN+ $H(W$K^G_&]0"
MAQ"65J=(TO_6&[+L#BEEUQ)B;EQL.;?ZA'.K []F:&(GT@"@:'KK+J!H*OP4
MOJYG_X2\'%.E0P!P#EQXL8H6]Y)?RN$#&\,R#<YS-_Q )PN)+!();P7/:]^'
M:$<,;^)W895E<C".3^LE61![S;)!R^%XX:Y\>"T[I$#5MO @ATI$4C6P![YO
M7;G"Z4U3K!OY./Z;80TFQ1_;_'Y8WFXQX.ON+_S9LIPOVRR[<$RENDX-W9=/
MV2F@"@.:XJ<7N8#>EU@BAOI%J+!8.VN:U>NM%+BZAPX=O O8TU2%L88S4\QE
M21J?IP3OM?::A'"=P^-!^L-!!MP0#)<E-AL.1!F&6P*OU WNA Z\R'#A[)<T
MCQ<QK_)=CP_?"PY1=4*9=\PCYD6QP19Z@-!*T!)(IE5H%UO1?68%R,1RP?-2
M><+N_WF"ZH,40M-R,(62+L<4XV<HW"/@QJ99[+(;()%#4<^KT0)M*;]];8J\
MF)=XE\6(!DTJ6/(:"8N*I,8T JLT"=2R?.!%S7P[EN$G=H6W,0#BS*#H%/9G
M(]Q);M@C!/AVKC(T7Z9>YTLRCK#N6"]8RAP_QBXVBR!?1_'-1@B[8T7!S5QW
MV@D :5_\1Z-2)J3T6/>H3YA(@UAER([F1^*4*ISI[K93 T\XJ>F>+[XWZ? [
M-11.Z(ZN(%0"W/&SM0U6:?R6%>X:,OAV^6L8/RRU"O"\#R+AN)Z;IN6K_3[W
MO;*.;F?P FFP-5U83RT2/HH57IJ05O!D^[UVCTN/V*M_7NV&D1*[%B6]K0IO
MXPX2=[5L\>\\ETX<M])Z;JNV/.[WECMW%#I<Z>%%CH-W73<N<$6^Q@0/E?,2
M4[S?NU%;_.X&5??O@ZHWJ-TI\7N09Q.XWY%[^T!7IH,$>L1:6VR9,'"--ZKO
MG!N-9"KI';:?ME+ZC&I2)M<"!YN3Z1JWZS!ZQ8[Z7.H0N%Q;U_('K E)&T?F
M7,R\4V4]K72Q]V6:3_7+8^&"TS:G;?9A_F2?1;EY[\-C-4GPR3OR9Y,7T@0R
M!=S&<R&@@UVD9X(87.PZM70NK:\,EQ1QI%G49=5S)YW./186R U2PD]2.@L?
M.N?"AM)8&%)S.W%[E\3"M#$U=R88P6JJ;S]ZVG/;HY6VVV$?H=W-W%N7,"^K
MHCK#Q0,T371(A]G+D)R-V3^\"+#%OZ])?"?EFK[>?^$VB_4H9MN9-\.+":\*
MN()T$2G"M+@UM:WZLJ@#>HC8">N,N2[Y,K]04ZY\IW+O++QF.VCNW 8[K60R
M<"ASV$A: G<-/A1CZ2<"/[3SJ7BNS5JM3;YL<;[5"F#=6'KIK('ON6GC+*:N
M(*2AI,NUZ6L-*QCS0K+G;)\VA!6,W;B^UABQJV<*HRF,D;95"ZPI]OW>6@;9
MS<9&H^,OOY"B+[V/6*7?Y(5DKQ_:"PR%:]+UV3PO4_U>KK97%(-JDVC'AV!.
MJ(H*)%6VC:Y25 "PC@W"?;HZJ9N66RA,E&&F;90T@J*R<RR',3 V7I(R(,0B
MH)>35(GMP!Q:%CEJ3DJ-@$MXZ3+)R\:.+26AS</N;!H#;4>]DB#E"4.R+2D9
MW3)Z3^BI0<8A9J6(;1_-:>!-M68;<4[J#"D67%/8K4N0G'RQTT"^X_+X"N6R
MKAV[_2 5@]M\X=Q>!=TA'^.DF]_K)SKR7C3<1<2W160\&(=7.-!%7^2P^IJ*
MI?PJ*TTTC"(K)DC7>KZQF)H^/X)OF^9LI(G=UH,-)?W!_DV,=_?OR$^\-ATF
MC12A+-*=#/L).;08S"O,$#>!PQ(U+O5AU&71>= 7G?V-2Y410@;U$S%B* <5
M3!B];(*98%E"='KH^)=B,6&+[N;'4DQ\3+2+M()L[EK$H!>)PV^$'_))//L]
M:12INS&(RS3"'+C*SDE4&'5H(X$2(#<%X,U K;GE!;&WC#%=T@VKS6AW3 RU
M;@YJ2U?]F3M7$XKVFC(MZ67@]XYQ;A$7R2GN@R?'J97R!(SS?*YYG9*1]9%=
M+*=+R/'=0"@?WT?[-EW,XUT[\+-N\T;\TP:*C0&*J:H4%?MH/?^5U)??'O..
MQ4'8P/,H0X)4+.DV??.<O@IC&_#IP%/U>VL JJ)-XZEL"(=L.=B0U Y+<VR[
MWKP3\.C@[+,+<>J#M'SG'L,!;5\OFU^B3$Q2C+\$Y[7E(H@G>T_13G2&25T]
M6L9)C=:^N? F=/FL7D8OC(O4A]I+"_P_$1?[DWB 6(X\DF8;"&TC;]+</A)O
M[7 ^B&V>4'."F,.>)$&4*K#]6J= D; 5C:^W9 "TF>^I9[X_I0:ZG>:[V_*R
M:Q-7<X[&QO--N6P&08<Z3,!$0K9E,K/%K7KGQG8F-CX$VL[6;G&"\(+DT'/S
M*D^J?/LN(Q&U-7MNTM'?BM?HN$S516L[4(T?L[]I;?UH6V%<R\]*);E WE-K
MFSH0^!GW([ ]B6.3KY$J.!,P6A8<$OQ(LT,=6<P$"H@- (I$W@,UF9#%.KR@
MK9 PTV3E?TQ1*5(9Z6)Z P,TR"_;VJ*C:84%8[7."JN^L)R-IL%?('C1'ES1
M;DLJU;HNJS9RO7FG5 M;-.<.[H;M<6S]1X=LR7\(3$9'^3$?PGE$:PT9YL?N
M1IEQYR:8<:#W133WJ&;RD7148JK(, G)8" G_:CE31I7P&]MGA*SDC&')H,D
MI\RDDNHX)YE166CK<!U2V>;BMZU[U+KLWO?BUJ"P#*NTRX\@&^$\706(D9ES
M;_%-%3^$Y]OSHL=I.:>B4@D=<&!1I]LT]ZI9%GPRI@Y4QF#)9A]&2T39IB.7
MGA4G_;-&3$6_B1NC.-F+0#-T]-MT6;4YS(M-?]45Y[YAX73J>P8F&*FT)>T[
MZ? ND2&NA3)]ABFH0(7/NLOT&#18[K-O&O%R\GJR6XRZK*4,0_+I/(N,)@&2
MD1?NV&E&''U>ED3H$IFM&'O'><N^&?=07!SFVN9PH8X62H]("U>P\41FZL6R
ME((^2GU !9U1%2E;00;ZAYY7!4>V6OCWV9(,-#^0\CA(M83MCM?YI@3Y6L\R
M98[UM,^Y<M /4"4ZFLIYZ,:"(,"OUEYQ[(OP$<@AU2#4'#'$7/DBQB()7;R,
M !UCUAKW1%N6HL3 6@8Y)(;<NF!EKU?Q#L>\GMS'O#8=\_)NGX"4E_*=A$:2
M7K+ZR'C=XIMZN-^SBM@6W5NKAW@/3T<@VRB7?^;%)V$?IMH-UH5PKR#C['I]
M(8.2"5,NT8XWQR%<P4OE*$I*%"_0DMOS:A2NZ3J/&*H\'^O?:QYENA\T0><$
M@6 NAV))JQI\(^Q?;_D6X45HN*"9TMWCG@WH]FDEZ"E?YG@5>Q:0?@4E0V5"
M2UZQ?7_S&>/H)[JZS[%A%"(OSW0>[M:D,<]:;;[\G#?&Q @--7&#55AK;S?U
M$7)#QW21$HROR7"#5T1BLU"&ZP9$,QU*, 1,'/DQUK89,\B"""55F2O*UZ\)
MP&I"K@+K6Y,><PM"@Y67+)KF#='U(A[,WI2I,Y?/G))SF9K&NB646+ 8BRWK
M.1D/E&=,,_ NL!PFQ<:U.@C@-P0IHQUS&DGIM%;&AB))66A\&$6T#3J'JP.#
M%^C"6TUK@CTGU5A?_JP0E>#(HIW/EQ91B;Z4 %QV@CHC0V="IH":2S5P0J:H
M:;+)A81D,SK[%4<OCQSR]Z-7//&NB<K(Q2;UN]A9[@1CY I]0K/&%Q\@"5_N
MRIR6%%D%&4YT-V ;#Q%D''9C:3.!*.C@F5E;R)D@O&F#3!)=F(=G3@]0^ PV
M4I'(*@5&\-WIMFF2GNS]PH!X/_>"-6<OHG=P0-B.N W0$NMB7<N)-X>G#6-B
M/3)6?L8/:GK47@_X,(X(>^I"SZ,F$K6M0;(=E]<MN6.0+6T3W R:6HG!^845
M[[F;Y]".1ZRS(D[:A*O1?,A=A)#(?$%&$P.Y7+XW<EDRIFMJ5%PM+QJ+20=V
M!0TE>Y=V;\_Z&!+TW^M,8\\,@L1-__1[-O_C[EM88M"VSQVHM(9=T;J=+=&"
MKG7<'EC$[*1)-?NE?Y(NHSV5NUO/J9&8CG5C=2)WY29^G'3-Z:\M22/BMP@*
M=,%'J*?"X5:X&>8T"Q.&=*]M(U-OO#3J$]@ $QF4D6"*=,@0E^]32]QZ*?S9
MAA,-1"EWJH8[]4RHI+KU)0F ^!]T"HIA6E'!LQY8>S[5R(3CKM:5J78D<"GM
MVU]U9C"O_=Y8C0JE3(R]*U=+-&NZ+[=GE_A]R%;,BSLQ8-UEZC;ZMK8 >5MB
M!^SR1[U0EP%WQ11<-$!P-L.7EZ ZQ0]2LM!:DWJ'XS\_W<=_;I)0["%:=(*S
M02",->[^+F9<.VE&D AALVT%ZHA(*C3ZW%2M$<QI[W0O8J%@/_@]Z89"\3[\
M5S*;OY#?I6/PSS@D%3>_]P;4$Q8E4; MYS:A'PO*!%(]'WWAC<+\ALX!_Z:2
M*8X5/OE;#6L</OY-49]'AYQ!9L:6P3F34M"?WR(,&K],GQN,9^ *:SB$_HC
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M)C# V(-.R+$=+&W<TQ*[PU- )^3+:/"1K%B,LXMVGIAN%JDF@3WE%]&1LS&
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M'F:9W]K6$6A&XQ6J)/+LT$.* $L04Y.9(0 )XXR$U-X&=D/7>V7-!2R'#5]
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MB5F>S[A$V@I=)R(M;DWPB!<H96#,"L7MHKN'91=.#:BE69!MX0L/+/@.2;8
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M-$L]@J7*8Y#^Y/+>V3W+.[E?DQC?IC_YDB*XRZ-E;DSTF$BQU<N-!H2YRE2
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MLIC\12-(5HM9C>P5V11NX^&1?]%U*OPPUX E"::U/\I0HA+H)R%A,H2*8<)
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MGN]!*^TLTTIGA \?*Z.W6Z;JR!A'O]C65-(:]XN8Z])J%+V"2*2BO%\&GV=
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M8A197=#C=/Z;K36]<D4O)"GDW@3@3)IR>;.M"(^M\V]M%/9AN]62XZ>6"-2
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M*C?)*UCX8-C\#)P;E6VJX*/E.=PE$\>!X\[U7(OX&M)-$35- ^%94U(_Q).
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MVD=0E."P:"Y3>@A,VWI:?'=GXX4: ?FP%"QZ_&S\69A&..?C5Y4_[ZH[X@/
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M9/]___&/?_R?^$GTA^-);W0B^J<G!Z/!\&0RZAV)T<G!Z?BX-QF=T@_XP'
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M4'N)19CFL%%(+Q?*S  R5>'#EM4T<I1_0:#/4U!XC, %:$WZB,^^'!+*U-^
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MG,K[NKJV(^U@3QVMTVF=;97N:42!F#L7.2(!%IPBTYI.PZYJ=#5UKE%"?#6
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MP]&']*%ILO?5,=R80C=">57J2W':HJ(,=AFG4]@ 6WL'@QZK>D6+TN(6W?4
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MPNZ?5=.J>H]P,2D1&4WO1:%[P54B9*S+#9T()<>Q4(P,=XYO'U\':II<(4M
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M7!Z+?Q(#MH1$+@QG]&[G=D=IGG.649V&.4^IK,.G+/XK(JI':P/S-IZ%.E:
M!C3*J$/?)W-+@/RMK5Y(.>Y,&EM<9C/=TO8JRDVX;"5]K%:],+FIT7+$#XR
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MG=Q6D-6%%'AJY[B.Y&64LP'75I)5&?=$*_@--Y&<GU,_8 5LF@;;1VGRH)Z
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MG&/#/EZWJ(,SA<>Y@:INA3*7D8&;SXNRJXGU(<O(G2D]TZSP>IXNN ,9ZL?
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M2YUA3?M$P^ 6F8(;/JV" X'2Q5)2RIZK Q!+<@5Z;77"L>XJC]/MV*UM=BQ
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M,#,N:'1M[5MM<]I($OY.%?^ABU2VG"H98^QDL]BF2H!BLT? !4J<W-5]&,0
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M?7Z;"9Y^AR9XV@6<D5) J+.*  P$PR4(AN\<[ '>6IB+BCR\G>"[,"^ -?T
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M:JO.;:#CH<MC20Y,H][YR\>J=# TSPI?-ZDYRYB+WZY8JX$G!+NSA0/\E>
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M,'WKLH79-#0UJNA <QOSRL"WD?G8F@O52$I-TW]Z2 [Z&W=/NARADZ.NJ=@
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MN9C65R %86Q@[ 72( ,=7H)$DZ9*J78W^AN(NJ3>ZUFJ[T.'/\M=<:(T;)L
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MFE#HRX<G[U[_"S[\]>(?;X[^/U!+ P04    " #P@Y97)!VO5J]B  "(\P$
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M%D3I)%#3J1J7\9T*HB+(IL%0S4LU&ZF<C\#ALS X?'QX%.R4MRHPS>.<4@=
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MD,A<>8?]^L7.\I-EYUAN*Q"4,ZQ6K%[@01Y3Y;J@1]%Y&:TYW]\HB]0?+LJ
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MD+2)@S X?'QXQ/E_;5\]\9S,A&6T_(QIEN(!Y&N4JEP+Q)=)8"NPQ+"B1A3
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MYO+'7/Z8RQ]S^6,N?\SE-N;2\YZV.7]>_O3ZXN1/^/#M]=GIJ_\?4$L#!!0
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MSLJ/5NP'<4R"3;(TEZB41UNWM!U"QO]>K& 58MT ^W!HG2DMVV(MZ-XB(16
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MN+W #47PC??=$GO\M<C/9>]P]O"?PY.CTWT$Z-"+[<Q'1GQ@$%-V O^86;U
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M)RB@HBTE2-\$F%?O4(Q0F90T*('<Z+[-T"UL,O[7R,>5^, UXZ*3%!-O#)7
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MHL*W8-R!BV4:%WO;9BD1K%#3RA=EB4X9["^2GMS,IJ9"&Q^=(?RTI<A\.J;
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MSCSE0(D3C==_S_68IWI[" O'-[8I.I_ICXI,#+1A/"#E/ 4YZ3+BS(T8EIJ
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M!R^ 0C@^^!,^?'7VYO7>_P-02P,$%     @ \(.65Z01OAL* 0$ 6P4% !$
M  !D-3$X,CDX9&5X,3 W+FAT;>R]>7/;R)8G^K\B]!T0GNX)Z05*9=FNS:[K
M"%JB;4[+DJZ6JEMOHO\ 25#"+1)@ Z!D]:=_9\O,DXD$)2]BW=?AGIXNBP03
MN9P\^_F=7]]??#AZ_>O[X>#P]?;6KQ>CBZ/AZ^$_OMM_NO?3K]_SG_#Y]_)
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M\LD*#!ZP 1,P")I7";!?N*FBST_Y=HY>I_+Y=76+%\%]3!=T5F?"BI5PHVU
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MC+J)OL5X/I^H@*+09WKY^H0Y-"JKAWG&H8-#9,<412;C"?X_!1$XL#V:==Q
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MS*>-3W6H:#+CN1-?L$:WFPY'V@+$28/985X<* D1]DU2P],PT(S"PGZXU29
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M4)>E;E-:70-T=(>@$[>9P#!LRI&*'/1"WX@+!%ZC?2!G]B*])?CSLWRV:L0
M.[,+Z+H^6$/5V*HSG[/+W?9C]9A:16I)T3;Y?&8T=(Q4FCJ6G6:WK_[8VA"9
M'""BZM*L:YFUSG;$6^P=2:?@)B,P:0IEM=;_B84=TLN;(E)(><9'3)8SEJ1-
MV7?5!P4B5YOUC9Z9FF(+5=809#:!E=06V=RD01%HG1@.7M*3!^M6*D!QSWPA
M/9O3FXKY&D=2XO60S_15L5L;DCS%]#"MQN?EJ Q2,H(<<Z@&VO%@+?E=D,NN
M<M=5KG0G@<]6R#ZDJD.I3!M3+3Q-'VY+=?L*3&/TQ;L@=Z=T^0(L+VP?/,G%
M#O7!SK+80C6 6J@:VQP9_X ($8=<\71;/*/>NHIQ<^W87F-9YHY+.*I:B4D7
M'6/OKPJPQ'.F4OX*U').-0;F6]4-L\GQ/"O_5(:*U_R"/ 0MM4J^DG+&#L0N
M1<,QD)W3WFMMQMM5D@SS;-FP^\;50L54;W:^9>A4%VA[_A?N&D.>6(H,D7 Q
MW#?/)A;[6V\ZNU,CKG*O<X'%UNQD<&,8%G_,>@$FTJ/AKE.7C7EF;Y[+LP@]
M-T8"ZYP3CB%QP%3HIG,R4G.($UF7R)@U.H^<<B QP9QGY^HQ(G3N^S'TJRU+
M [O&WYK/AXN/WR3.*L;0-],\N6&L4H;)! UG(]^_0BZL=&OB(A*OZ6+<L^$7
M2DBHC\UW34*.SX?D$H(:N"AA)&KC<QEM IHE4M^0,'.J.Z9A)3&E7]-:K!NV
MBZ482G0HM::PCS,Y/@TUA^]XIZV\I>UPYVR_]GGN5_68I99\.[&Z)$.SN+"*
M:CA4T2A0R6^1D\^7LR_Z WM]\)D69;O/FVVH'*$][(@.#+F/92JC11D65A!2
M!WFX 49F6)36J&7C,R!LSM?K[W;VK3>0\TAW RVI\E(#I<"1*2MR>XO2\@U0
M!\9=4B_HHF?N>W:5%_GKQ5EB$98-Z7'[Y"(Z.#D[/3D;7 R3B[/!\?F G46;
M=1'M!Y!R6!/;%-8IR0'L Y?;WE4N^]H[V7HE1;_H071OB+X@C?AP7:FN$S]T
M16QF06#8.T8NZ&K&2^._?7LK\OH 4XW:W_3XEEFP)O@&ZN&$*9LE8B$25$/F
M@'ITQXZ(%!2';RKKT:VIP)3!;:),4EM68(R4CILM/DL'UF*-.>D18Q2&^PYE
M(_7(%^SZ!@MAY8?"(DL*-',LQ@NHCL,&DD3"7JJ[W0VTCL1B95Q)UC0KR7\(
M?/[^$MP<20M$.L>'>,*NRM!XE>X[*?)$2$D*%IHB""CW]&L8T0,&,S3NIIA:
M86-2=#BYVPLYO HJJEJ=QKZ,02D2UE5F''*2VT8!9D)?1<;LM[04C&_)E+,>
MLTQC6)('P8J1K"=7?GMK+>ZI6W V_>>*9(!O-4;@O%R;JXQ!4M>^82]YZZPC
M=/TX+$3?3T<IDD%.F#&S&)!EA0UTBUFJ ;PZO(Q)@3QDCI<YMQ>,.$.[VG-5
M.[NM-K[;U %'DJ0,.:LD7RQ@2F:G5.G* [B["7 Y*W+G]IJ]  U[IRW4*.L"
M2E>J*/4 S%>XRJ[TWN 6WGLUX%JP7[]1AFJP7,XG+WUNZ8&MD.(E=3,4#81;
M98;EFGARH&-YW^2ZDIA?$-JB<>Z6W:_P)TU>&N:@IHOU /_D5E,&6$<S%5[-
MKKNC:2)6J%B?)C#@OR[8Q/O9BX0=L1!$ROK(&4CYJ+. H1DGO0R&;EEF11&O
M4C1Z[(^'W@<[8.I)R2Y1L6_$+D]G''9;Z%+XM0<MUP/"!$-;PND1P'I$ %]W
M?5SR4BK3>\@N>JOVMU%*T^'H9EC,(H6M7)YNZM7Q M%$>L[=OQ.>(_B!)+$!
ME1EQ'2YH4U2SQ@?)S\\7FTDH-2E=RJ4<D^!I&+V.)P;2HJ ^GC:TQ#%K6S82
M40)V<BYY^"90U5B[CQ^YPDI_I"CR>HE_$1V=-AG;Y/.XXCQ*H0-:F^<,NN#C
MQ<823QY]$;E<"PM^;TT$7-:-:5@;)SXG=ZN:+1V,"DLD!A>N$M-W748'16#<
M/6!P-"VC0RE@--E  IA;)? AW7(\#W?#NO*X=LZH0LY''P:#'+/5>JLO$E4V
M*;L#,)),PXBW#GF]SS<+/3+!Z)05;[24&:R!L9,:2A?D7-,?M7.[O(+; )H*
M/;7 >-A;HM!UN3\ 6<T8I6AMWJ=I26# ?J7'BY3KD3LXTNT9?L;4(?9M,!LE
MZ<R5L1D\_78O6GL(1, @&2%HPT/M9OS>O+297.=33#5G8UHC%<^RFZJ6@KQ(
M^,H4:MH10A"6OEVRE\;O=X\&P'W*_][^CH!4QIM-$PLW %76W:'HS&P1]J_G
MO&O\B=D,E2ME&ZI0RC7UB61WHHS^S6?\9<@D%Q$N%'<9>>F-9>6SF VH4R-E
MO3F3\G-]<TR4-L+)*7H8R! E5_TD38RZXP&L*EZ=;F_)Q>+>V<P>4FL%DRHE
M2J#DPWMY, IY&VY6!C<+_3$F<WNR <V"G:HZ)V;@>8(\[X]-:.F&['5B;2P%
M%Y/Y\3:[[9 BUM7"VW-15&VB)BFY;%FS9"840PFU1P)NK%,;HC#*A/J]M=01
MP9:Q<@KZVN;7T*L-B>%LMK?"6$?8B3WV(L/U64/5F?BT:M'1*#.D*F\P!F.B
MYOP+H)4"57M@W5,FL+Z>S>)-M*5L/(B08";^%.G7S86>4Z^NKF?</="AB>-Z
M*ZVUJ] HT;I+D<Q&4A*M?F5O@3MW,SE/0N6J&3#?2#,].]^>]7NGC)MFUXH:
M&=7->$5&1J+0^!2_M8$!6_[.07V:+34"R[P-BQ"G.XAN9Q%UN+1Q=;[ ]+M5
MR?QU^J]@7FUO/<R^ND\!_*KF51"S<2?CX*6D5P-EYBLOR> ,H]"V'%[=/$;+
M(M_QDA>^UMQD,,K.X*),ZK1R3*SC6G!$6#7+_PN:U^\_H[#=X/##Z'AT?G%&
M?: V"Z2P_\P#OG4NM(%I1!^I\ @#RJ;4-J]C*!?B3GM3D:-WA@J* H #I9L0
ME^T/Z3GB;)Z?^(JQFZS^F][?'B@U^&5DJ!"LE\H$I?>$CL,@?85RQR@?U(#8
M2;U(C<%MLB-L*R)3%:++W?L&IY"BV6 8_^4Z'>VKQ<-0+6SK%7,IPH2 6]3Z
M^W77R6HUY=_,15T@%(V^:L(P$Y(,TX-\O DD/U#*,!^0%#=8QX)RO_./2TI7
M6E13+"+F'/IF4I1^#EU/R6:=SS.#'[31M4QV3>*/-*YN="Z\\4%LPJ/E=_G!
MU"7N%&X5F8U-)@\GTP%BBE?]:(&X'N=E0WB3_BJZ)CJH&U>(I#'+3&,T?5-S
MG2-CJV8#M<DH(8118?7LZ*N<>BZ.YTE1PYU&77]B$M.!]V63-CY=<KO9?)\-
MT,&5WD%C9\C!&G%D#AC!-;&-+Y=U6\\\KI,^1(,F7_#"Z8,ZI]Q7<7RFTDTC
MF\/[2D*DP(MHT'ODI:&JB[_1WSC6690(YR,=,CP@6 )9""I,1+N3P PJ,Z"@
M%V!EUW?!HYL@W.M=T=\8RM96Q_9(7C-[VJ--S*\(+Y;E4.*X2D-//('<N#17
M.4W?GOG+I-D_45C7J+ DIB_KA%1<0DL@\B!K3A!R,,NVG!3S7*J';6?JR5U0
M4&\/)2KK^4.K" ^TK"?$_DZ(TF*GVF<WP /^C/$ :WM:*'INA[N)XYKOLN=I
MZOF-I9'+.+^K")OW 2T]OF%M?\$I+$!MFH*IZ-2Y[RM!^YJN@J)ADJ33RCK1
MV/(>$R,../INH ABGL32:!>D'#N@(65>& <&(@0N0 $E/3/(0IU7$X%=(&[D
M9HKN-DQ%D+$P$8"N' 99-G#!2KQ@B,C4ZN+<[2T' L8H9*OQQ!HWPG.D $QG
M&0H@VPTELH!I73=^25B"Z8:8WFQ>2AO+&;6ND]4X:&KB@W-OXI97NZ9F-!H=
M<D(DR"F%<S5H!?,[DP019+=&>(-$L"@!>M7(JQO;JICL4Q9B=<L]5LVC$5Q*
MHU4LJWE!F"6:IF^K^D^[#K:#-("LJ/CX\:-3WA*+&__DXDBI:LY54\S&RRTG
M]$^))?:@XL;NYB;[S.\_\SSWSA> !R(8<[2SAS:(&_7<L_.$L'SLS60*4 N\
MT4X%VYS:F@1.Q<F44\*_MQEV+LNP]W:9"S2CYR^AJ+OX9+E/EO%T\GUM!6C(
MAM<[-W5W#]@9!4_YR&#F>!44'Y;N1[I-?8%)IZ)7*O7%HPV.7G>\3S'D #\W
MTD:](WC$8>1!KJO!XNL"(Z5>'*'7&[OW2V*;TK..YQIX<9D=MY#Q5VAF#&:=
ME$"K[%K/'\XMP"CW6SP(!J>X=#"F4L45==GO)1=>2&T-[XV5=%HB;:L@XUPD
M0&#MA ZQ[2W3VC<^O;[*9N:HE"['CG1^'V.I1.AY4TQ 5]D>PX9\!$6D*6YT
M\B4NJXN9(008ZBO.TM)>T]1$<L0XZ$13Z&L'1]$Y!@(@$@P;[&/(5IQ#Y_(A
MX%1N<4L=3#)QYIIJ/><*;0R%LD=5'P$E#K#BQN$75ZCH&<F"8RU)*0W&W6S%
M$9;8UD&141R E%S))GR(,1F%?*H+AI!_M7?&E'=J" 4IH@C!/'D]2=,+E(_P
MRC0? +'E[D_E <$3>!Z&+HU&A'BC&TC\8B+5)6KO;"_UH^QV30B <>#FSB_<
M$&/C';+I)0PBED\)BE0\]D(S/2#:!@09_WW>2K;T1?XQ:]RY7A7$T@2SCL@;
M+C]AE*%RC2-@:K? N1&Z>#F#K6[-UYO9V.=8)'+Y>OCV[?#@8O3;\'AX?IXF
M@P_#XT/J@8A-#\&B^C ZIOA/<O(VN7@_3$Z/!L>;+=UZ[H6"!E.'+\S6O@2,
M!\(@(HJ*9@UPUI+R9;/>.X#X1<MMO.!-00 HV<%_,C@OSF?T>FB'04L9F3V^
MDP%Z"8"J$Y4*"OK7,;X=XL@J\=V  D5=0+MI8ETL;=@KB*H2FWN;S+)-3O??
MMIOUEPB*DDD3][](U38ACV%1*>I=G\_JT^O+7SJUIZSB4577+YB*-HB5&UB0
M*"Z:%B"OG)[4&3_F@2/5!>5+8U%[.D& \,QYDRP?"N9K1"(;3\B_[0NL%^D!
M5&23;EYA1A"OJ&OFK=T7J8*PW0\5XJYN"NSR3@6 'M<E!^]Z2G++Z6N%@,@)
M/P<(>U@!5\^<C6G3;'U0Q*"7C+P5FY7&X5<G62E0KG:O.74M%U6]_U;9I =6
M]#J_MP%(#0JA :!DS(C8D6 ?.@$)-68JAV-RY2VF;,^.P<%^^9;U -;:'=O]
MRL0NR+SVQXV!Q;7/>B0<4AI:<+9MCM&[XTOXPJ-NX@-T#]O@<^BRWSC-V /?
M4-GU<\^Z1V\N@8+$-'DQ>O.LGA>Y!G A6)3P7@=:ME2C8TDP$JH-7"/4Q,[^
M4R'K.QA<NI=S>A3;E#"C'==HM2M,*K\3*\(=$1#4A'$K[B%" <V*4PISOMNL
MZ:6_;TG"7TJ!VK0<8-Z#B=CHX$*$*NEGO?4"RD%!$LYI&QK7TRH(CB11H5EP
M*$3E8@I*U)+"6,X-W[70^,<F*B<VZ<(Z5_V8E-_H9)S?DX?B0X?I!.,[:\>H
M1-?MK1"KE1+V,O0/-=7<9EO."^"54\_Y[Q)M@ZH2%7&$>P6&KNE'P"E*#L?/
MK)XS$'&O9JMR&O8SLD))W:C/QQ(2^4&Z.\@,'V7 5^'6:M-I'P4PF@&_4"1,
MHR!(0J6H-P712B"NA_ :E6!"HDDYT]D\\28%]'36B+=-)52P,@-CCLY/*#[?
MN&X405=&=@&8;$Q+OJVY/ZYLA(%WG9#4N+>F-XL*G,=@<?W8PH;$W(L]Q6,.
MAV]'QR.++.*Q$RQ0(:=C6*3BX-Q5R3GY=_VD./>M-)K81)L>;66JB@5C8J;2
M!&865-]TJNYQRLUF4ODD]P+8D.4\V >TON*L^VB;YXR]+D5+>)(NUU[U.O%^
M>E-Q@(LS;JUGS'S<J="35PFX))*WKAKHK?#'2:T6"[_0KF]M%O6/+QR7(6-J
M/GF2,#DG5CE8WXBG2-9\STLPQB'LUZ3?R"_"H7:)EZ7;6WIUSI[_E*4I\$*@
ML 9U1>EW#OQS5LQ@WF $DDZV\\/3?[<)V-S55@[%>E?Q$D8/*KH,O>*^8N78
MH7Z-=6\@G(T%.]1*N=M-*L1%$*8=EEKIJT 9D-_;D>Z[#N8TB:?9]HV?=:"Q
M&?6]UBO"P0B,1ID@U0GW)*_EEQ0.SJ?Z*3A[WW:#A7L)0<[C:^WH#L=AML(*
M3M;V>U4D?!%V'N-1.^7&W<43,D+%G1O-V0I07\9Y@":7-JE4*8@?G#*A,O-$
M016M%:P;OAS,9L6\H"I7K-O/3"U1*ITH[ALHFYANCIBK!1S+-I1^5-J?[#(/
MS# V0G" J49Z<]#AKH,:DP;MF30U=&1S'\4$,$IR4TCA4>F+*IDQ1KF&W.L
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MN;=?Q"B'W +1]'K+Y\C [UZZ7CKZ0G2@=/ W4_X-5LU8)!U"KC-Y&S=%QBI
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MP/WU;0&5*6%1)Y:1MK!GR^M*\N+@<E'FI??3YCI'C#/0/F>4[">-!&>KN;A
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M"=Z+_WR+T"2J4<UM9FT\>]=5F,:[3SNOE*S3(1;W;B_L05Z#$!5GI1)8<R&
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MZRN"VTWSQ+0 '&?;#FO TW)5&3)]87WF07\P'$6#WL')L/N)H&]+"72G5+/
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M7&"G;+,44C,:EP(_=$UXRV$-+P(.%Z@+3@H9 SFP@Z0DQL(QT =W++V)-L/
M3@FJM[F&_9>359U11'J1G,+1$9@L4RA-4:59'J^GZ[FPFT[B/">616V:F*ZU
MZ\5_N&/Q.2OD?P;-J]P(=8RDO/-D17%?Q;@TXB:,D):5U7!<,B3PFAG*L!+)
M!%IA0FO$5U6L:1=V \QNJ6Y7D!WBTAXG5Y(/G-KD('PB7U4:!DZS#?,_8G A
MKD14\ UMN]^R;V@-K-Q-8Q 9?$ZP:UX]'4R)BR'TDM.%*MHUTY3,$,Z()LD%
M3T%.50Z&D(8D/ !&NO;C7P8=H!X.H,Y<V(K5^]R!3/O2BS[U?NX=[C-I!%C
MQT\4/RTZ&H E/-P>_3*,S.NV^,3M?O6.N<L.8/AH*X@"V*B@=D(*L4H;8<"J
MYB*+.IV&)(C?=IU(H-<<1VFNDF?2\"I8;CF.#8,XZ<"B'PAE0XD&U)F87J-[
M=EPH5/U%$-CZ<*5U/R526QC$ZA+QF4)%W6RXG.5^DV+E=S@FD.934=,M_:4[
M>S:D@^WAM9ADB&S/P7165[QCV>);C3\;<C+7DC_^RE*<E.X'*9VAP7#+->H?
M'=7.VPUQJSO#R!M][&&P^&30'_5[!$@/YQ6-OOWH8V_0^_!K]+$+!_?P:!1]
MZ/4.D>JE/P23$/Y^<@A'-GQ =X\Z#W=_>OZ\39[N9SCP\.$6?$Z;3OR/&UOD
M:%#]2**9@6?N]0:C;O\0X3=&/9!:^-C0?_< ?CSY\/]Z,(;142U6HQ)8,'/-
ML/NI1__\W/U5IFD^B;.$4<&'P%&/>O_:ZQV/<%+'O<'G_FBT:0WPB=WCXT_]
MO>Z'3S!S&G0XJW9T?#(8GG0/9;RXM /BT<'7]O[5^\RD "/<BH/!T>=.U"=J
M@*/!,!I^/#J!4<%PN[_@S$<?NR/\Y*\T$_CUH/??)WV< CS[0Z_+PSSH'W8/
M]_K=3]&@/_PGK>OH8W\HST4L$Z0@@.'#;_9[\.D^#!OFVS_:I\_V/_=HY:/^
M<'B">ON@O _X?GEYLP%/.CJ&Q^"<8 ^/3@Z'O4_P<'S-9[X(3CX@HLH>/ /F
M/CR Y3L:_(JC=MXC/_4.#FAW<:[=PU^CX\'1\=$0YV@O$MU4FE6)M*ANK^!A
M=K^BRNW:PIV)H(TT0B)^\(XC'$7:*3P&_0,8)PPPD'@](:'D.U*NZ]2&M=G[
M=++?/_R97EAFHJ#CX742-QO22@RJX9,,R&P0?/QOL/9]"G -P7GL]5K#'3PM
MPQ[)%*P]#$TB7^8EBJ #$CKZ!16,_TCZ\0B& 6(+KZ5XF2-SM$J@9V"7CXF1
MYI>/_;V/>@"./N!JP-+QP0!A@3GWC^%!1P>P@#UYD+RN RL)WRVM%,[:+N?W
MK)MV8+=IOS[ P<)O.QJIUQN&D[K_I 4":6X6-;B6ZV6M6T)#<I:I8MNM]GZH
MVT]Q67C@R2>0=/@;B8,98=M[:7!;X T'CS\B/;7[YFFTW_T5GG8PDLN!U19:
MP/NXE,YE=GSR 70.C@AT[.'/*@>HMCX?F=5R!TKW\M&!B*N[Z* <OD6XMF!B
M>RV.0WCZ$ZU9!</1PE[46]T>DA9A613H:58CECI0%(RT4>$&MCU[D\Q!)A5T
M85*%J!+'JS$+):ITP3H0%P.IBG5*\2F]("434,+,0>[?1$#PB]GEPC&YX8ML
MJA,"LSL<<%AC\T93SI$8:'!]5IY@L&1;"8WG?C_BP/;_;VQ3]_PD<<6-9V)K
MA)T6YHQG.,ZRWPLWMT&VO05]E0+T9J,:)P'6Z2+-G.8I#_>Y/N_EX>G2L)*8
MT!MAQ3E$X42N-#W*82L_N'V1L<>%M+C3E)R)::&AI,T-ZU["54OQG8E[G0>/
M8>7;R?6+CE'.H^Z_0!&#P?K?)STP((6(:QBX\MCI'HWS-)D95'#+]]0SE3G[
M3K40 K2"H,X(*,24$(D7OHJ_^LRV68EIQHWQU()Q=]A>')Y\AIOZ5[P=#GLP
MB6%WT/_T*YHQ:!GW1KVVN6EQOE6DGB4[\V/W\&?P _@6[_74%\&U@ML3KE%\
M4G?_2W\(]]6''I@!/71G!GO](=Q.S09=Z\?JZ.SWAV#$T[5UX)@D'=@-4C!;
MJ=]XX<>#W'[\_O"HJB/.V0?F?4PE=+W ;[0YPV]">HN,JKK6&/'1G4:&4MA_
MW'",1C(^L4MH5\FR'<^Q ?+T3#Z$2-[VTI'/EAFF@Y3DPJ9//?%24HF IMYT
M4J/VXR;XF,:])( ;JBI,5\DYA5-E>LT&C#3)%\SHHZ36]"4,%&/<7R/#BAT4
M$I74/4#*"[!TU!W^=BI]7M0B-S0;A]E"96$JA7$UC%J^ !F@>&40+<F1!/'B
MZ"Z$J!,D0?V=A:N%L;TH&SOE.MQ%P5>GO*X%[Z/X>;S"=/(T77 [D1E+CDAI
M.SZQ^7:$M1-2)<;1A'*[=)D3)V]NJQ#]_)F/AA$&3O$>5EISC,Q;VFBG?-<N
M%17;S0D-PZ?#$IYL(^4.T'K\E?JUF'.:(K%8I,E$\&8MJ;0=BR>Q,EE-EJI=
M"EAP_7-R[Q;B"]]"O!E5R<BKLB_=A;@E7'E$(K[A\KO_6$V\@TB??5/&ZIYW
MFIAI)'6*4ZB%<J8 )5P#45>!76KA=1OMG><&_2@(IVQ//:L1#IOGID:%>C3<
M(6Q 853+Y>><\!3Q9% 7*6B,.?&B;]J(*@5#2*;4]:(T:O0\Y^YP-8G>%K2:
MI48<%[H$,[<\V6"B#OV4<]BP1:&UZTR:K/=P)4PS;N6\.>D7$"\$T[U&?T:A
M^B35&=YQ) ;V/3M6IZZ((%D^LBT5._*@EMWMQLO*4@HSBA^Z/[!Q7 <-LTRG
MAI.=+%^XM#"G3<+ZYCD&07MSMR%5%""L&35:3F+M%R).';DS"2BT8B?&M@YI
MPPI5X,/X:P)'7>; W&JZ,F:MEOE6X!Q@=4"M(3Y<C:GQ(U5/%&@>Y..^4XUA
MF1?Q@=LR^#SD&*F@=6ZNO^._W)]X+7U)OA'OYB]!D8-^7@O'V_4\%:4*@+:M
M_F1,+BF8YR82%]_2',3^@NSM.3SL(L$ZWV&24P%#B]C6X<@8YB"#%+Q,<DDG
MEXV7'4+&+H.3T;QET72U$+6"3Y:/O&-46[!V C0F(#=&"#VT:MX!8^)->2(F
M\VZ&[82 6#%8%![%,2'5(W8DE[%P"\=,W1]-5%=X3]43T.PWZ)T*];SP =MT
M-2K<@4EVNK#'2*X5O69<=%#ZHIU:N\Z]<AZPXU;1MK'I%..OINC\6V^;"OI6
M8Y^NL+)]PJP(O.:E#:_S3JN?OAWE\+(3_=P[[ VZGS 9^:4_Q(#)%NM87OIQ
M"SK!2RP>K/0ZNPZ;-CB2L9!'G#$\I_UB12#44%>"WK&T-6Z;KQ?IS@P)DQ!Q
MSZC@[R)-+@U0N-,DS36$9FPA3IE].W9#<K'86+JNLQ(;_':)06 +GGD]BCUP
M!W*G9KS2Q\$0(.M0,JL-EHQ4;554GJ/.I]Z=U-3<F/YG7# 3B<'U+>4\O->T
M311RTPN)HS1=K5=<RI3PM+S>>_(VL 8G3:K!R_62.H^QL%#9#)CF#/NSP=RG
M E&V$\F*7\6_$R>&J;)BWKGPZ0Q:Y#W^,?1].T%^U<&<9M]$NKMRG*0A)9T0
MH+4$0[+<8:^0@D\%)8JE+JODF%[?8C3V.)A,T>;8;;SEWE=MZ9<&?;?'J%C/
M9NF$ $^DDK6J'M90P,7Y/,4N(G4%-/S@M)P%D13#6R[%W%=T!^H/:&7!)/A#
M[Y "I.HQ:I;EV2*=X&&;I?FYT;Y:8YX6)A!7>@<<>FS1G[_SH"O\D5)F2&M:
MX0NS>$+F#U[_#)]LNQ:<@F:\FC'K9CZNJ,<6^U0T#Q9$6[21\VPJR*A7Q&?%
MD9M5 !6K&H-[X'8$&+9N":@Y%7OYJ=@5UFQYEDE9,:@-JE?WOEJ<)>C$@=O.
M3B$!CA0%UOY[JV$\/YFBB\@LL0';R(RP7#S%:4)^BY9<*K (62<+S/9A;^LZ
M3P5[X03;Y=%#(Z]>MB_57*$;;7#?I2X8QQ?DC?@X^P#">43!-^:/\R)94C@;
M\-?,$1N#TZ1C--Q(W#ML 14(*ONYOP1%L 82I.!7@Y/"DT29),!*KJ!,IOR;
M%FSV.K?M$^;-.QL7JD-Z2 3(68(KLP"EV1N=09 1>DS:CC0SHJ9NG:R%]R:,
MQLN;DJDY\$Q#I$_4]X"HFX &+,Q*H"S^9N&[P2(]):S$A$ LA548GHJ-I^XY
MM$%B/L>$T8 8VPL+=YZ7CZ6H,DZ2AS%MQB,D49*2W U/4H8A5QF@M\$=)S$;
M9RY?'YIA$[)%#)V?+*%HB))VL4>? #<#/%$_'(\U%JJ,\+1/TF6L!=98 "_"
MV1'+IH0HKI) H9VIE'9T5])B\3;:.\/$[8%B;"#F'SPF[TC!AS[5U9QLC!+J
MW3G88]CB0,HFY5B%JNOM&)^OJ1 (\[I8%$JEC%1^-RR77%#LG#H.M?H!%U7:
M^2HO2,L^YGP237L3:O#*H&TW0@T@.TA]*4P16JO6U!\;6"5)=:<++/Z1#78@
MU=C0)"6?Y6(XTCS#HU!J;2W1N1D<4)/DMTA-B)-WW3"]'$^8'4)?'^,6U$.3
MX3_C*?K=!+]!/S-V@N$7(M>\:-=,;CL"]@9\FY^/OO0&AYBA_]3]106K>M-.
MZ1IDYU!:AK%DJKYC,]68$[/Y2B1P)7&//8QP9G"OQD8QT>=B#64(X)#U$S0.
MXWQ3D&_@CV1NTUBD]9X-5VD)1"05<G+F5Y(R:#;L8RBD2L4Z:L16V+"I![Z-
M:Z#-/L2S(N\#G40;32Z/\%=Q2&9UEDA2P;[%&,#\06.NG<=?*60C07BX>!A9
M2%TZ4;C6Y*8'":H36$,P2]^F=D9"#NW]"]=/G>C@9(#U[:BV3@9=6V8S<NQ$
M:>#+M/V,5T@;DDW/E2@)E#?[LW8J>E\QW8J%3?(J&5:S8>G1$6T*6^Y,OYU7
MNL"=>E6MB%M8NV=/07/V1Y]ZK/4_]KI8^>DL'KCN<U0>DWAI6S//DMC0@X8-
M<@0'H'1R#$_%-[*M\6#B-\<IFZ8%QY'X@)LH$@5F<CW]'&3RE^B$@].V6D\\
MBPD9612:Q:0;2:R\OG L"JG1Y&BOT /1R/@/R5>"\2I*D'EUW]/FE."+I0;0
M[>SM+F\C_!,[)D:]P7%W,!I6:EZ17].8*3Q[EJ0&.P]Q5^ LX>5#D&,S!3T#
M=0/&:V:_SKZUFKUFF]G;)J*T]!1#<&T3&3 /,\UH?!DXX2-UUU9:O!IO=SF?
MP<7?^V):?[0"1SI]OTF=FWY4-*ISD!2ZNGF=%:[N?\";**9"A"X:?T$$U.U:
MU:_[)A&N]FTO 8G%G"6>EC(JE7$25QE=:MSD/>>LJG-C(%R!(8<S;RX-S4:&
MT9;"KEEQ,BL8L!.Y?PQJ1+458689$[P6O?#Z):R:PEF,W&)^KASGY'QO)UHD
MF%F@:EKL(HZ5.2,\^B&N,D>+<J(Q;&NQM\/FX4TNR$-C< 2>0P2[@2T[!I'7
M@@C;BT[H22"+*2E(QBC"W>##IV+*(9"X,%$3B;NA"<3Y]V\1WM#(%0.%#/W2
MY4PSX@/O2PAW8N94M.@T3R^24_"NN+3]_NMU-  [(1OP+^__;Z3_=PL:"!Q.
MT+MDE+R]+C=T)[V=?S]YWUTLDJ]1EVB(D8V3P-G<0@$;\W>2#U9>'V/I=R1I
MG!7J'A[V_A5U(Y,-NE\)J!@$=5QB8Y/;@B5EV3V)_',$P;1E.0-]E(.[D8-O
M6OT?)2K=OP\_=S]]>M_[^5,/- C_$'V0W_:/]%<C^0TX<-WCW@G,8:A_:D=]
M^>/AGO[NVKSX/4WGV=/=EU%/AO/?)V "FCG90<**][_TS!^.Y0^?NH?F=U6C
M=X:&MT4@0Z6Y_$7*7>C2@>>,I-^8GO6!8#">@,A_ZAX/>V_U'QLG'*[.7R)^
MS#_^\O0OT5[OTZ?C[CZZAN;GX7%W3W]VCQ./9\ '+_I']!?GO*9$V/66R)SE
M@_OZY1=P$K_(HL.\S0;P"4.IE]1X__W_502BH&KJ;Z-]?:C[9>^Q[AT=^<L<
MW59HWD45HSYY#Z>R1_<G#;*/ M#W)_1KMH[<.9D_P+>1JT4)&MR_]TF=!@^B
ML*Q+H GW\S'F$9XK#XO477 T%NVM;G(Z3^+H0YJ!NY_'RV0-7P07K[^8=%P@
M* ?!X\V[G8XS'"/0M 'P/P/\'Y3(^S5./KP_DM,E'43EXXB7%74?Z9_>LD?<
M?W],V#@F[>ME;,%H)VPO-H+'&+6Y H.W2.;@[+4$%TN6OO]>X[-F1?J*C(6_
M*>%OW,E)#P]@>$"]^\TYR'>K(0(5B?<F'_[W\@]SN%^#7B#I,'_0,\DSM2/6
M#_K??W[;!^R^N>T(7NKO2<#M7'5-:]1<]&UK^CX8'*FLP_@\>>N.*1RZZC/9
MUP]'H]'1Y[>[RZ\1 51'__64_H^5I?*C2.7ZXO$]CY$1R2<VO^[],,-D&7](
MT,6O^*=#BCO=Y9SO?N8D![X,.)OI[.7''@(Y_.,O;WS!LK^.X/S!:8:Q/+O3
MCU2,\!ZEM,OIX#^CH/:DS^M1..]5.-T1?KT#B?P32N+=/$"N,+72[CELY5EI
M-[#1R(C2?XK95FFR48&<M=0D)"J4J^,$+#G;Q#8E [L%C[$F;6C#E2PX_$49
M0>T_TX+[Z98&U+.G/\Z TJKESAT>GWM2KMN]L[VFS$TWVLU69W2U3,+X\-L_
MV9))U)M[1K!MB8J7WD9_O?7J_9__^NGUBQ=8+>;TY+6P^6WG3[:&]UB!/LJP
MK<_FK0MI39W5YV<JWKO[S>^M(&NR %%!DYTY&,>WO\]5:&P#>:OO"<S6KGF-
MC$HP^B;!F.TT.!V6A6$CMQ8F3"W:JISW%)$U+MFJ<#J3_QW]UHE:H[.D2/3I
M6%1&Q2:YMC0@OD]<L$BXJ.K'IO%<&SG9_I"RT9U[SRGR80GZX#[0%(^QP%BI
M$\*!@K;;E&F]D_">YAJ5QB%9$.'>-.*U^_?D+(&MP\0R07@1G,-ONH(;;+97
MC^'U<GA=M,C#BZ#OT2ZC'/XU:J,L"+R^QTZP*83MV/3T;ZG(J@Y7/^[U#]UK
M'RH;-_U&"ILZ0:W^U1HGJJ"9.BAJ0O.#!=C26N"T104,6!U5,P/N5"O,[2 4
MHAVC:^IDZ9YK0>16U32OS9@V&P/-NPH8*^.OV?PC_[=[N&]^I4_;^^?AT2^?
M>OL_>X_4;QP=F-_49%XJ7?</3.]@RC=O7CWB\*@HN0A#>3+3$G[65+D7V/#M
M(R_!UG-.IWB\#[XYW<K%HP]/2\#01@22_S.WRBU.I1 SBB?8X43D;;;MU[8(
M>%ST\.ES8;_3$KS0R*'F0Q_Y+%6:+M>BI^I5JEBMIS@SXAT63W%DPK WNW^R
M-50T8FZ)<$S2MM-8@Y/$-.4\/4]7AO#3IR$+*!BXFH$Y,ZWSP WE,9+OF:+@
M^!P9K:9E5B#\<$ &U+E>&SX>O>N.WK.'>_3ZA(Y!4MFGBN!W+B_PIQB^ZC1#
MZ<DT2IJK_N,\=\!^2N<2673T8)HN 8++JSRF,V([,L,B:*(K:A):4W?V7%"4
ML5Z7NVTCQ(\@$C^&\L-RZ9B+I^'@+@3D1N^8*Y'Y*798I6,"FQ K4H%8PR$Y
M2&'8+B"P5'3"?1)E^"V37.")JSUG_I=*)Z[OT,I$AJND-"AAX%MQA7(EX6TP
M.H*#P(86PF$RK17H_IZSCK)TNAX!M+3W.Q7;=8/"ZA;J@218J3$2+0<\\0(_
MM%+*4ML.3E3HU\\"]K<?96.LQZ;6@R4\FJ>D;$HMKI(^%T0)JJB>)!NY9*EQ
M9U7H(X0CQEN$M! :>88ZZ 0W%'[!H)LHGPM/8I%%EJ.=*0UYFM5KN&GF_#=+
M:N.3\]1IZS]SH>9_R!WR_.'>(8.@75:1WM]&@S4LPNZ+%WIO&'AW.&+SML>!
M:3N^!**QI(P5[:P$VEX^*>WP=R[SMRCI%VW#UPRC+(CR<ST7ZB?T3OBH6:PL
M,YOZ SI%4K9T3'"$&"1DI:_?$P6_$V6&Q$X:[RWZ9$"VU=$+]!)5)7Q)GZ4-
M'@RV4K"AB(@$:U T$[D F4+1/M&P0Q/%]M\/C@Y'YHB=P=>?%,MXDKP%E9;'
M($:+;/&$G_?WO^%G$80-=HL:/AQ[V:A5U<((UL-7K]C,.EAI(XQ:9?.6%>[;
MJ!4+TH0\I=E0E%Z96;F4+U"Y\46<SG$MWT6ML<-C+39!-H$'"NVYQ3-$:X0P
MXPC5TR-%,[L.0LA7[7D"9Z0U<9[M/EE;6N!J@JLD@S'3QK HC//L=Z:-0)/=
M(2I\Y_8<MJ;.LP7ETM])#EL3N<%T+8856ES@83PAL$:=B8&01E V&(8%:K%K
M7]29'([7XUA5M@D>-ME9'=<:89E(I7.PQ+>&2[D@>C6FK^"/7]'U67CO%:L+
M;YLBX7ZNV1IY)1\=DSNX5%X\W$NE2]@&*!Q]>^+?12=&3,4('Z3%[R@EUI&I
M"A^(+T)":B*$U/D<3XGR6]XE+86.BBG@:Q@B3,F0,RW@6>Z1L3  S82;Z2[/
MN.$544IH5"K%)4O/'(X^=222-8MDJ>M%RC2S,4R.X'!,J[:R8</)N43*&(/<
MHV?+!_#;$,)@EG=+>%P>7T?"*G3Y,&GDE>N:I8N2\B4%LYXS>J3S4:%EL1?5
M/ 45.\5IDNE=A#G5'/=56A#G"2SQ/"O,@ @402\1[GG$"</H9@:RQ<R7X&+4
MW6PV*OW->.%X*:H[!2< 8<,2YF=UAD)(V56K45[$1T5U:T7U\N$JJ@'CWX2P
M-N_*F#;%.X4_O=;T&J*&>P+F5D=,+]9IJ*H"I5:I5P3-(SA20<"P&HZGDMZU
MS"/<"H$7UPJS&@YFQT1#SV\X^4(G+W-'Y+2+!,XU+',+N7%6M"MN3IZS\=<_
MFJVP>3;Y_<EZJ1RC:MUBX+<&CL:QT.\^\%OOM#]JB!MKB%</5T-HY<,1<H,5
M9^FRUD();>1D@8WYL$*(HD:P,Z!%UG.ZAQG[[2(MR-)H-@PBA1K,],Y,WUD;
MVZ07X]4=F#/G2)DB4)@71GC!&#K+T#MWN=A@-.7'(M[G*E\7X(SW'30 PAF3
M\V%H_QPPA1N_LN(FM^\TLT*/A" UTU,"P,B3BTQ(5<S8YD56O17F;95$1R:*
MK(#UXL)1D8W'4-$M")(;=X[5ZPQD/*=1("\%?IB>[.&=KA?&DR6U0J&"9F.]
ML%^NY$$A-_31Z+@#E?+ZX:H4]G8TH@Q'>P2BL.>(PEVI&+ XC(Z)?!53Q4AW
M30:6W@^G$B_P1Q&] Q%]\W!%](A\8)3+SP3#;462[X)0&$VDBIST.)JNV05F
MA%%RN 464?,F<P*>PK2-T'OZG#IPG9WF\7G!T4X8Y8*^B%XLLAK Q H4<I<B
M+66?UX2IF705BX3F<0I^)^+O%/ZP>0#1APR<;J0Z()Q0PE!5,C&T5.>QX&$'
M;XMB\'/QN) ;CT=.4-DXZ5F>%5V0A+&#7G;>;C8JSKCS'"=\;0W.'4:-IZP?
MO]GCQWCQ]*>NF@LE[@_BRZ#H::K<0B[3#5704^$6V12K"'M\5C[A6YE4QW[)
MUC;8ZK" #T+FUFQ<@OHZ1;/;5GO1-G2B84KY/E-L5GYDSL%*N.&G3#R#1@(X
M'N-Y6IQAG-3&6GFD?''[>$K\Y#2OF-&EC[7$ U/T7T(,HX##$C/$"_X2/Q,!
MJR,D7%!L,:^(K<8#Y-5>9-'I.J8%H=QWDK+XH-MFCELMF0L)?5!B8X;%&??O
M/QFX5/MIGDP8T+3ZF*0ET\\=<+,1CC@NX%Y:%?:C=A5Q^5=9%LVSVISHXSWS
M#??,3P_WGADN,X1WVY,R3O^2 8<C27[79$8AB'>@'PO^E@<!YZ5]O$H6<*\$
M&<YD(PC=[5&V[J(P\>G#%2Y!1$$KYA?A^#0%BN35F2BS0Y!G"F.UKL\11]:;
M4[P/5P['.(I4LX%R!;9.6_D.V\)%9=F_81R7=AQ.58E#MZ1<8'@G&US!4V9I
M5+X]U+O5E9"4%:]@80MM^;9)<XROW#&UX<NHYTV?AQ]\;'NY?L$3WGJQ-5(B
M?3X^&HRZAZ-(X7QDKQE1YN3P2V\XZNU'QR>#O8_=(?R+^:=#UNM!3S\1??B5
M>*J10;M[^&LG.O[4PU\K__4O_=''Z->CDP'R8#<;2H0-?]X3&&W\-OU:$$D1
MENT _@5_ZAXJ!>(G>#&"A-'C\!M]K)XY['Z"H7SI'9[ Z'J#+P@;]LO'_M['
MZ//)<!1]Z.&#>OOT+>0P_]@?P/.1=8T5SG[W5YC: 3R)GFGFA,!P/&^8*SRE
M=W" [__2>V35N5VYOXG0&29 KBJI8*HC0QJ1(H5>A>/=1#)-J,31+C'D<8K>
ML#TQDC*1G_)C7+8_M*7G5T+Z=Y]$?]_(QE?M;GP//1\5(7X;/Y_)<2PK^>-J
MLK?5]G] $[HMHKYFHX*I[RI;WR%)7W50IT37%P5L?>7[P_#V?>.Z;XE&;W0F
M_% 8?I"31^0P!(E=N)#81?2-?3"VG:&0=1IGZP7M#;I,G+2_%TC!!P%3485+
M<2LLBA>O;@EF\>*Z[[M?NJ.A;ATVPZ($/&?/28$[?S[LCDX&&YN^KN]KOP7$
M32T83S#@?>UT&_4\_+_O0U/8?54-IP"_OQ8 Z5X_\XBDM"T!>ZCKL%WTCENL
M7\AE=!VRX8_9RAN(V _ UZA$?[]O3 _V&)J-7?)R8=M>/GU798\;KX2*%^YY
M9!78S/\>$JT<,GL1WBUZ#3<VKWY[1"B_X^WH_>MC_T-_%.W^(*AN1$B7N$<0
M!OEQ:.AF"">'H-@C?WQ'!Q1'N69D][1;I8C0WM%^;RLJ)G":FHU1_'497PG'
M,[I/J%? ^;M-.(#Z=]Z\:E,9#O=8,B6DM)=L<&\K'/69$\E8795:>*J(<ZEE
M2;U7Z<]8*KX.EI 3I3$]CP;II:7I,QQ7,2FO23SGHFF* KQ%CEE>C3PYQ31O
M=)ICR3'[].\L-VQ%!" ((3!]ZW/Y_#0M&(F,&'#=**_[@K:64U+FD$,592:6
M/X\[>@/4Q)L[AV;(M\57?/WC'$7"BK@M=&#W7\?=7WL#M@R'T6'W<^\/!['[
M0XWN;UQ@.#6#WG#XAUOC+;JVMX;D?9 +^)"%='BTUP<[!&RCDP$FM Y//G_H
M#?X ,EKI!=[)E?<G3N8_\ZZ-AY'$'[G&7=BT8E$AW>08U6T1QZ.:@B[P5#6$
M&6+9Y<T&VY1_?=IY^G375K61^;D)U XLKF@_F7.CW23+EYE@3I2@0R2-'F"&
M:-+_$E-$:J+FRBOH9OJIQ9#QM*_\O+RT:!>1FNP:TY$"K5S;Y=WQ,;1F=L[
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M6D"+5V5K4SZ#[A3W6^6 @D2Q@[CU[1S#]CWY@^YG[\8=A"OLWOW!AQA><"O
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MN'F7R9Q],E52%3<!7O,IX0=ZFKV#_"J.>SJKVH=2 Z;S;+BG=>",L4/EDZ"
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M3B8AM(:<VA$T[(Q3_,<-V-Z4UC"MJ8( S2NXTA)_3A5VKKH!LVMF2AVIVMU
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MOGLTFM?#HF'Q>XG2M_,RV\(GXK#_]@HEX^ -_78/GW(IVY2=\'/PY]??'Y#
MX#=>OMJF/X.$7!1- 0N7?+F=PN:&S.%T7H_^N*BK<=%D>S.4+I@/SN)Q]BZ?
ME7/0MO^"[\+ANFQAH^;9N)B ZH:G56UQC:_3E9\7G^<D+_H)^/TIOK">RD%[
MB4KJ^$U:8^^\?*#CM0MO^?3F].<]./G9Z:>W?X=3GYT=H<K<W$#%1&?MTYO'
M^%]WZ-.#>M$S)ISKHQ*6>#K_\=E_?LD8=T1A?WISN+@$84"Y.+V Y6NSO:N\
MK'(XL#C QWB(_@'+B/(NR]EFNX]?T-[N[KA#5\,>-%D^FU7E**?3CIJBQ8]O
M;N ^U9,![U,-FYI-X[>B-FBN1&9R'0+,I,GXD+"$M0LZ1*"A\%^B$E1%=628
MGHUBBX^.1185&FF32QS&5KZ=/=]].7CZXHD,"<[113FZP,^!MJL6+8JN'W )
M6J"DL^F&OIBB&,_U"!LQ[SFJ-"EY7C[&$R,J+AAX-BSFUT4QO?%)*P\4'OX<
MQ[JH2.-LE=M\+O!;JP\[_;Q5VB_P*A=717/>P-!X3?V>;VYT3M_C9ZJW<'$&
MV=90'H<K-1Z7^%$8ZK/!LY<[@YWGN[=8%Z\*>V?-M\+6R S]N"E!J&B'3@I0
MSU/4\+KE%5XL*,^ZRR!QW9VMIWAAS.A!\WJ /[1\3#8W8*3U8@YK-QWC@UFQ
M\U '-XT5%JW(0>1&>8LCGX#:R\[+*WP.:T]=A^B::7 CX$YM\=%9"V=P+E^
ML=>X$S/8R5#G[SYE=7A7<^/^NF?7Z9Z/^:PMQ@/9!Q@KKY8H'MZ!UNL?_NO
MGIKT_O"/N(WT%3C)955E^3G:)D.X=F_4+_ Y,$2F+,#P[?D%CJ,M_KG XR![
MJB]5]2-[ ^N#'P(KY4)&^2-J%Q'VIK S<B]<S. ]Q>>B&95L>,'SCF;T=ACA
MZ=X)C]),5=\*II(HJE$!8H-/'0;O(*U!CP)UQ,_"6>/J-/ -? /I;K"(PB'X
M+\H87IE#&\Y#5J1OC&1LX5?@Q9.B)*ELZ!=- :I\= $#'Z/%960;C$KZ48T@
MWFH\=*/BE3_1MQ@(G,EP)#3?:YPEVA7P<-".N,=P;NVVP3KBR6,1>X4CWAH'
M;VT:-',:>(^]C^ M^Y]A2M-SU#4U#.42[+I -N C--!8;F&4L[P<HP(A$<S;
M"WPM[P]H"K CP?)L<K]?JK=HV/3Y6;XDG8TBO[F!)I/H?'@@#'4Q$H.V>P6'
MI\*+9C!&=RX7+:ME>)],322'=DA$F&<)3\/EO2@J^D:;S\MVPM^:YY_Y;Z /
M<6#U$+R%G*V,IJC(<.0UY4?101X6H_JRB,8KIK98U+#I;5YU!_^AYI_RJ[H<
MT_1@H.-Z,03G1286B4CR90F5 9_+%_[@>//'N5'1?;B;M1=@/Y!52P;&N.C5
M>3PH;W+@RX)!^;>CM-.1:.?EG-RH;%31WSI7\@Z,@4VSE9;QU[L)GKJ;X!>8
MVR588I'%AO? 'BPT+-.<GF 5!"]?H\8 ^I%_%,7,K$H.ZP NWZC$ ]&5]U8>
M,40]],]%V10=^93?XXFBC<2/)Z[W'L6WKAOVF5O7O04\%N8SBDRG@^D(E;\L
M\=G-ZB A\9'R<FM9RK-A/T#X_IY/%WFS9)';&> +R,:!_X(1\LSYP_##RX'>
M 6B&\6#(+O]//55^D$=F$V3 M5A/[XN1,7:>[F3EY64Q1K<?3HX:;?2X,6I^
M>)B.F'2\7G&D4CNK,B[XSO#WU=L:1&!=._W<VU+E);C+I#EY4P_K[+)N"KXG
MG@^>//EA\'S'F=5^M]B""CVJ(C $#DZ/VG5-\(47Y?$_%NV<[C:W'3S3@U@X
M[ EM13@FJ#<NT1@F(SD,'N'-RU<V;6LNEO2XQ&#7=#S8W&A P4H\@A9Y8(WM
M0<H"QTMYB$]HZ>-PBPS1U* ?X&E5WK8EZ*9<#:P6-K#*&QF'AC7DK?#@9C&B
M&RX.>ZGE @9K"Z-MY!7PF:FW.Y,7OG-<@_L>SSA?IAJ?B@]Z,<=O@$W<=?)V
M!G*7F7,9^<>O/QP=GKG0^@58@X_:63XJ?IS6UTT^^^X-+-LCOK)@?_'#;W >
MC\#DH[%W7@@GE@:WKR)[C!8(JVN82V?:YG:U@L*F;LL7"5B[8%4%?N/*YY!%
MUKT8Q/T<F\=<YI_IINL\CJ[XRWQI#B7<4'CV5J[X<W^4T4*$3Z$C3;HNIQ.#
M#I89*MO]<MOE[."P)MO<(%66B8G4>C\UCK7R/8 ^TB5(.DD-^4@F_-,6HT4#
MY@I,K,JOVU<:.1[S/"=-+K$DW"6YG,BX0W/(K4#'+C$*Q ;L^C,,W[WAA1+M
M]?W[@U_?O/Y>DCR;&QG]_^L9S'99%:%2*RX[S\-?S?+SXM$0[HL_'@T+V)7B
MQ[RZSI?M=QC-F^%+?C[)3@_^#XSVZ7?Z7$I"_?@_?J#_^R[[[>#]V<__]=W.
MDR?_Z7((F+S8/_FW2T.A&E8[C?3P/@SWX.W!QX.SWWW:@,14A%>-H7I:49A\
M'X2D7A8%W"%[:#[161'#*?P*14_<QP<@;E-T77**YK\'B1W-ZX9#^3=JD<-Z
M^D@?I6K$/>(5QFA5(BD02[?]5WM?QIYB-H2CF4TP@8(JD;04F_^;&W&\@7Q?
M3$#0Z\F9@:-BCA7F6?1Z>-3D<,V@8P<+V?+1^B;1[F<4[=Y[_\O!X<'IV<G>
MV<'1(5_*-Z2SOE9H^YD);>.%7\[G!>NMNJ48XZL,;.*+&A9QJ<:O!@?$N02]
M"09>"9JS":(2\BQ0C];R(QT**Y^WX><>PR42!F'.BRG<SI6FUT#$.*V!^PN[
MSR%0[RYRF)3BNF*MDC21M3#Q[Q]$PZ-)7.17F,F"?\WJZX+LW1)DTT=S1WG3
M+"G.8-Y5?!X5,[!;+N [8,X,S"3YCL&0,#CH[85D7'#T$[DN7"HK!V%F9QW>
M>K]CPYY):F[DP^L^PHM^7"'LMQ&U'^XJ:NB7H,4%9IGXGB4J[%E3S,/MDQAD
MMH>!<K?^)F7B?@\+.:Y'"_HWF-^CQ;QCE\MS7]W77;_[=,'&PHSMJ"F'&)K&
M5 %/&W]98IYO44F6M2G.%Y6-X9!BLHF:V@1GUS 7,"3;HL*3J2EI&!V(7('9
M%+Z87MW;W;G[L,;;WKOD5'3=7+("2.B)@0:.T.QOYQSRF]N3&:1;Z&"J+.H-
MC<$?,LHQS0?WGWL/74>JD"0X-:!0,]II^.(*W4V*EPP2X3])]<$4R9JDJ5ZC
M0V*N_2O0)C2GH?\VV,H<RQ:[8$B!8=!X-H,.,@@#+>$ HM=4S.<5FK@X.WPD
MZ>+1"/:W<:[5=0X[2[:V!* 7%'J&PUN.9#')_KTL0*.$,: 5\4F18HF>PP?!
M%!Z6%2JDJCBG.-V8E8,8W>Y]^-7*^>MX8&!5:.!NBT2K.A=*CQ%N&:XYKXQ-
M&.$RD14SR<5L:5-7@Q.Q=8AX$8MXQPMRX>[ G>U&1-<Q^DD\^@]YV62_Y,T?
MH/1_S:L%>>WG-8C0)"=_B-PD?RT4Z01Y"+313"[A&$J][SNOHA1K;#2.R@8N
M$'1"1^I1PKV?C^;IX8*S/LG@ 47;YLUR#9KXW*XH* CK&J@UILH*[=MJ.1!C
MV053:.*4.D77N[CT/S?%K )30R)&E*7%''@%[\.O,G9I$/HC<>8J..,.](2_
M1M^WF+8\AAE]-O21Y:N,1C)@)/J+0R*M0XXOML5:8[U(\J>S9>WCM?\ZQE?&
MYTST^D#O"56S>%0TW^5 5.L8\3_0&&S0:J4]AZ-;C"@ ",=]R1)T6;:MJ'[X
M7#T=E9B@P-"CO\)'2P[[)<Q':S)Y6W(=<_TC=69=@NXBQ[QI@?<29O37,< J
M%I\^-\NA!M$]FG*^C/<D3N"N8QJ7VYRO+9P%0T-3ZX<5/ER9,[D7CXV)]"'7
M,,<W'_9T6^*.@<UV7N<57>Z)478-E3%(=^LO)A)^1,J ;;DFE5GCK.K9W+LY
MWQ,"J![!%J'=LN7#WG3/XX?EZJ9<Y6(X\\@4=\*W(P<)]GJF)@_9C1*)4%-V
MPG:JPDW SL6<!J6QXDQE58_R"F.OK"7]2#%*C1$HN:X^3<F./T6PEP@,!D5?
MSWKBB9VES>Q:O@PCKE\?':_(ZUT=^5]!W@<1^-DV//./@A/>I.)5IXKW$Y[.
M\17>RI(KY@/0E=RR9=%=@Z'Y3[P3T"L3!2_"CSM[7LOQ0[3 <.24D-S*Y/5-
MP+DB/4P950[.,!QT MXNJ+   )2A3L;<GKZ3L%>@Y6:X@/.Y)!F]*P"G-,B;
M*<X689!X>G>>_TU'_![TQ34ZX3])-/%=W<QJ6>6/^!Q\C^9:XG31L\=/7W$X
M^YMKT&8;U\:%"<9E.P*GR'DN/1>9IM'<XOA\IW>@!YK I[\[D!-L5X$?FCK7
M.<LOZ\6409J8+T.L%;Y0<?R@.M>"A'EF,)'^%CQ0S]'?!^_=J@DVAHQ-<RYA
M=*#:.S%K7#,*U<U,%I --I<]I&^"P)1P?[1U%6R18/$XH#/QL5[\I=JG [C<
M"#[+?BF<_"OTEOP=6'S&"&)+YI@-3CFW8X#OP4\B[HO#1FR?45@CG*<;]H3
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M "/J&'W0@;K"2JXB$^"@+1G%A$[2@V72V49?>4:$B7J^[2"V"-*.^$"THL-
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MN NR[B;]5S)PFEJ'EP0R9CV)"(C(_\*E4X]+?#$E.$+^'>^%,*M4Z*D0DFC
M+IFD!;Q7)N$3;@]&V!Y0O?5XZ<V<V%M[&!>-2?XH&Y!PU#0JL.1TR]114R7:
M#(89</+PD$&NMPV3LTNEI4D:H^%X_@2@03K&14NL;1$$VD,3A \(9C;XPH+-
MMB:UX:6)#2T%[1OL4#W$T+W3(:):I9PGV#\T@T>EQNCM6'U_(UK8=(#@E<:
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M#4/*"-#.L^YN5EI5<Q6*/C@"G5XB:G3?+<A[4A@^%DHBQ)TAC)W4(]5F>(&
M$Y[4)T>#$&0%[H(4+PD1@O_SL)A?8^.P>&,QNZ8G/\;J;&[TS"IF+:!H96#&
M,4&X-B#WY#V4H4:=H2M*3PF(Q%4G^2QW4=RPRG_BG,WN7SF;AT^1["93)#8G
M8HY!0!?)9+0==/$ 08YMS9R.WD!"FX-,J4 CY"%[*EVOBK*6%ZB#GF@?@Z40
M:+^U9>#Q!@\(*':(7XD)!5]YQ!F]/2@]CD$I%",TD<7@30QM-,8P38HZQWAV
M&YRZ*XS(E18%;(42;\\Q=RKLP\2(21%RJ_!JCN5A(_+IAI(\+L8!A6+/<\6]
M#6?6V%B\6H^6[J:4>)48."[4,70<2FZK=7"!PXD=&0U'OND4T+_\_(YP7W'5
MW&0Q.D*X3[V?Z'NJ7.D%G6R>4>XT6H)/Y,&")>116IOVD$R9[:6U:XI+Y"%8
M3-GS&W<#O-W"T7D'XYWF#%@9"SY='0M.T1XGO 8-Z-*U_L41W=YU)]^%O"S&
MH>0$LI;8='SFX+)W+(+N.!'@1;"%]4P-2\I9N@=)>$CW5&)MWKMP4>MPT1]O
M;IS&_ET8D3%U^!(X3P!9Q('^5\$=%'FB,2G\&@KE0?5[IO][\O:WK/F"CLHI
ML+&'&<<L3%C]4,;>.K&7]+AQ 8:&C?V(B?O^+4=DMWUD/W)XV]#_LR[V5M J
MB4+''%BQ).48_UE<7H;A6IZZ.O'S\E+ [+6DJ59P-IJ [+<I*-@->GWMO3\Z
M1O 'E1(0910V ]@_R?:.CT^.?MW[:.H\G8JV@ <I\U,XGD*_(]BDWK*F *<=
M$)<EM:N;"KHI) 1K!UW_FHT^NJU"+)BY>-ID+ZYOL[A/[>+^=/3K_LGAP>%/
MFQL?]W[KU";Y!>7"@,YIP /&6L<WZ"&PN=YR=)-A!:MXA:-1W8Q]M0;.79E:
M\=^G<P%)O"\JO.\*NMFDW!Z#18C5A0V@4TPUXW@]?V%Z[\Y+]RR0RU_V#]]3
M9]VCDPPL\U\.#O=(3H\^9,<?]PX3BZEQ40HV>_2L"6ZAU A#GS$2I6@9DV4I
M)MK-#0L2I>_;"UA)6V*^GMH6%XO-)&6"/?U][U+N:=H7P;T6HG'B(VC/7'0L
M!WWKP3 @-)MR5XK5&B*(J(:N,_0T#=2T-NO'(HW _X8S[B4,J>03[0G'3%2.
ML[)JZPCE'HZH0R%)M69TIOK;5"=/%-G(6/_F,)7.*L5 DX\?V*Y U@3+32>@
M0Q=.B8R9"#X&5UQ5^!\I^ C22'A@I^>8@<A7>M/CD7TV?KA7BZA6T=V:8G5/
M:[K.&HHD2^*[N;$W9G.,(SMU3.-[:G9^3X7,A">^LGYX;O7#X='A_G^_^_CI
M].#7@[/?42N<_;P?: 98(<="7_"-T-E5W7)I-R<^$7E-'0&H;SI,'*)W5:53
MP6=$/+IQM;I7X%A@CE%T-;R"U@D2^:443VU;F*'+B'/K4$8'72&%4U_2K]J^
M 6V/XA))O,O;$7'C:YWCC<8/%?-(/(#Z@=53RL'XJ"69_AU&'V>3!0,3499M
M.U<2=6L6U$&G'.*B1I^#VE"4(_*UOK 3WYWE,>#H.3@\/4"SZ>QDCUHI'1]]
M/'CW>^>6VL]#2B?B2Q!Z0,..SLJ):K:6ID ]V6C429_&="AG(4!X[1GAK7!'
M,AM;9AX( 0]6\QI1$MC-!J5="N_&SM(.Q?_;*(& FV3OXT>I^P8OZ-/;O^^_
M.\.NM5@ NW?X>_8.C*ZW>TB"BO6Q[XX^'9-!T;,U*:)TD^X8@3TTS+F5!I$9
MS.@6"[M?+,-3U_>=_H:Q_$E!C, ?T @32KW Y,6+@/)RMRPMTA:GG=R'XL;"
M\@7)Y5 I"N_^P(6JX9]&!.(7B!&0D(ZW2^&BL$&[+K]"\1DS1"V>>K2E..LS
MB/);7->E55.7X-'CZ;G*RXKC)FPS4\I2UKK36'EU2R_&!JR"!O@*9+>O6@^*
MB2CX/1(X%UVVTD1/3C/2;Z2[ G*%]_L?#@X/? E <"K:;-$J8W6@O@O73;*H
MVH*I$,;%A)+1&AF8!^ANCK_YRI;@KYL;ET6.%<3MCW_>9,?3OY(=#QWQ>OEX
MAZL0+0EC8*B&](L9BE&;'8%^&H)3P*G.YX-L]\GN4T6)8W\P$S@@8][+=LM.
MBC"R(1\24RNA<?]@@84'6)?=Q+IHECNY)H0DYH1XYN&--'_6Z!7SZT_=3]JC
MR19M4.,55+G<+D49Y[@#F?NYHD727[)"'G%'*JT'[Q3L6O(_4J2"(D!L[Q2Q
MCS#Y_!S_RKU\G6V2&;.DX^%*H^C-#8K#1XWJE/R!T=0F:-#EL47K7CY+7[?E
M,*3Z9>TI#-X*R /ACQU('DL;Z<K2V]5TI?-FR@K)YFV%3-I4E%EQ9Q-5F0X;
M0QHV> A55 Z7\BR4:/YS[Y8(BRD=A$6;N,#(%(VD:" BQDY*"_-L:6)IN1KH
M>-F?P0)]^@L7D"Y:OAKX=Z:ZD;:_\":4@'85FA0.:'-#<Y JQ)2-N@9!HOIJ
M^.(5,\U;"##5#7" >S0/LI#K.N5/$Z<<+8C^$YX'Z3C?)<$>K2-)NW0YT+E?
MW%OTXP9<9W!R^HF.Q[&IRC; \6^_),]ZEF1SPX7?4JO3PREM[%#E3 H0>K?
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M1&=)/1F4$(NK6"[1Y_2@[:@0'U<!0X5<.)!D.9)5*1#@P ,@8QN'IP._*NN
M:-)&)U<0VB/9D.P@;2_M"V<P.71,Y(E%H&%G>(#!'%P0Q4,V;A;G$3^\]0ZZ
MO0B], G-M[N"E2%OGPH>]]T[-S>.C$% %[7X@^\+=.8U6OHQ'^+>?ZBY!V'V
M'H:6[8W!JS:T=*<A@>2^UF/YQ_)W@R?_?='.!9FW57YV6L57]!DA$;8IUS(7
M?']^&T7;.3E#Y!2&437F$=3G;6XX5M1(.[V[*(L)HM4DL'XDH0NTB%,->&[W
M]8&W*[9?97!KAP6*>'T'_:FP+>[0E!+0FR.J6)C2#4U')DX7D9' :@AC\L%Y
MZ'E;GCVEIB0^KJ+QX>19@M6?>0)J&2(>;>6H)NP5MF]A=Z,IS['!B1G>0-1D
MW[UQOYV!^_OFK<'NQQJ_F1"^/PP?::C"KAYIVP55#H-ZH)DPBCO\:B[-'/@!
M>4Q?QF$HCQN@O:.'>8]/:W3/\1R"(,.4H]RB[YXZU G0_6VH-2)KC(>*>NN\
MQD_X:%<VK@NF^#5T>\R_E]@<+=P/^/22L(XP[44PO4KH*].T>D'9'XPEK(YY
MHI6 :E;BZS<W1*[\($FPU'.&S\S -&.UR3JUN U=($>=;=OF]4167I(;H+,4
M/Z >I\/)7;OB !< A>,$#^6"L<1X=G=^>/G"1M8M@:^G^T6^\45U3F(Z=]BW
M/W'MR[._TD$/+Z,_)%Q5#07TRND[FY;WP0UUP5SN';PW;HO<NBXYR.L8F"1J
M4W-<M0X[1_ ON7X0KE2-2A&Z)^@&2@UOUW/*=YXDCSEE BC\V[N,DBY@V,\#
MP#\>8C*)]* K?$I,XW2V1#,-;J<FGY%-#.;OP73TV#D<OM0\*%!?T_026;YW
M?+?EZ3"WR<^$47\PT)!HFDOH<52$,9S.7;X#;?%B>IZ?=\%%M9@6-W'>"IN^
M"^:X2DF*X:TMO+63R*(D:Q1Z)5\*I9F1UOBEQGSEIMR&%)VR,?S*8]H/3>CE
M;1AD4H2%6"!MMO,4^8WPCMQYAO^2=SG?9V\TWY8*!AX>OV583,',HI@J);K,
M^TP<ZP1)1FXLLMAY.G[T5!,&J?>O2NZE>'54E()>3911)HC@\[C"7[)SG")T
M7^J(IO-/+HKI(QMK[F3W?%7R(*+3F:3RL^UB*.7U;D,)2!K6+GK 93!G0N<O
M*6_.6Z^-D90^A$U$+&Z_[1(HFKMW86UK!_.:GFJ<5[[.<9XH:^'43J6116J=
M9.C9G%Z@*I[-#>75\$FCJJ\$!-SL @GWMD8K7I_#T6ND427^K:[*<3 V/VD!
M1VK!G]/8 _D5UY[U/L_F-T#$0*]J$#N1'@[>'7*$EI>$B>!*.RX8DG2=!!VD
MC[V3Y&Q+<*[#I50<DB=E*^_I;^S!"9,)G6#NHIT>6[L S7MER!4#\JIM]'^0
MXF!^]_/&?U]ULNM&N5I6C2'K6S6.M] 3>C8+A&;L=:ONKR'^X\V41@8%(9US
M!X?00V"^( J28Z9Q3:0MB-S<V%*/Y0SC>QC2/+G1==GF#D$B3ZN@X^?4A65F
MCDW9*&T N97(AQT"=UU5JBN]\IIIX,ZN;]@YT49GO0?5;HS0$FH;8<_1T<![
M?3PM:#[NJ3(43Q+-DI0MW:1MU R:&.,O\W\P:Q%\C1$^;IW80*>0LW2C$X .
M/E:KPUS'Z67ZZ]=DW(.;7<.2:J" $OV"V4'EZ1KZ#1%*$8R)4UZ)!P<%@DI$
M2UN2?E> "$I=.,C-Q31S>GUTKHZAH;/H7_)!+!GAG=7S+00,^>2^7F!WNEYN
M 7HZ%B_+5D($\\,GX1;C(3YO:C@>'(KGQCL,Y>'+PM) D3"1#]NRKE3=/PB5
MR<#T%&R$R,IP$C :QE"-:/HA5#A13+%;0CNW8;"85X0%'P-LS)A/Q2"4"N>0
M&5/C!9CRR)A;2<FW+?=:Q*+OJS$V-[0,AI,6*ZMW.?\IU/ZVAE:?R]48$Q^5
M#>?3\V 9(]%/L.9>9E&/!8/::F[6,N2KA)HI@'WE1 :H*C"FT&?SI'.,*+%I
MEEX*4VT6'+Y"\:[.E@RDXL9%!0S_H4)-NXP<#A"$4<%:DFX<>TU>0?CQ@Y/3
M['Q1<@FHR]GA.S<W[!6%6$Y^?_KBZ@YG;?YO NREZ(FT]RLJ.HSMK&WX"9#.
M>T='FYQ !(_"&K\!A8[RJ98ULL$V]K2V@4[8W @CV;MPG6P]#?@=Z"G1B]B:
M4DH\3W41YA,64U<C0I$"#>+;$X4%$)@_QO-]A<,+]0N66X#1Q]1W+IF!3YU=
M+%O*4:)\%M1/BXM"+YVR'.53KJ2=,8DW6=1BM6,Y6SZ_8!1IYV,56KW,HB<6
M>;UH#:$>)3U)OZ/#X"K.UR8Y"721)SVP<L.5$WUQ'UN^Y7%'KIPG&>FY.6'A
MBRNU\(=4MCZ?BA]-\]C<P;/5"YP41?QFWWD>AUQ*V;2[0@J-I?A$CYR;\#EK
MV[ $ALH&3&Z90S'I;OWVYL8>E^3O_/#TF4VCK&VJ+U=,=27HT$$.;?D3>VV^
MEZ!W0V#F4FW5F&:=&,#Q?,=H$GQ6IIY)W0C=LS-?Y\N9P9G2^1^7$^IZ/5<^
M:7(T?2<@@<1L!VQ0;+8%Q.YU#T\X\3%B+:_<VM*%YT^<R7K^5R;K*QRC1"HK
MI#.Z'8P=9%#Q_&3Q2->!N?;$4 (%:L6B/@^*\PU\4Q/_Y$R;I@7OY?H ?%+T
M2GKXW@D>!,_L0[^5H<@)6UM"8/=)=^D[1-CIU<]=#\PQ,T5B;,SQ9G/@I"?T
M:7-L 1$[PM4ICZ#%CW?J42._0CFF];C7^B 36.GZL/CQ4@?IQ; J1PCS0QPJ
M8[:X+\W4=<G%6"NKT;RR\4G5T8/-#6*:J6IJ(BV*-.R'&]56*>LMZ%2P0ZN5
MCW<57;K^P01\*U],Z<Y5+F$V$FAH"G0'V;4&D4 ,RV_HZ9[.FP+$XN_U O$-
M*!@NVBGUS_ 7MH+TO9QA1H*%EHAE2VY?N^[M'=Y^>Q$*B%$QL?1D\:8]JQ?L
M?! F=EO/#C9BN\_=$5%!&);2'[G]@^F("0N^2BYNO5T$@[O#=F7A;MVQ8]3#
M;M=H._;3O$ZNJ1&,L-,1B&LUBZQ5U3,FE6J,TG8A7[Y%5NBN[)H@]!C((R>.
M,/QB?5'@690]"U1/PHX"#0@]Y$ =?40>J5^DYQH:ZU5#"@G;@Q;0!*,E5P2\
M%TL C5V2'5Z:W&8563"X"7&][M,ZIM,ZI?I;S3<KI"Y@;1AT:"1"P0[@?>N[
M=A-@C9]P6"<4'H@NW+_*3%R9R>W[[6UU:RCP^HE:MR:>X)KR<LO7MM38$M.^
MM*.:_2C77"(L O&OP/2+RVGO//E/?&?B?<B%CMH"0PM;0:K6/RI) 13VNO4!
MCB@,3 #5TC[#N80446WT$M'\F:U=' C[E<X/;H1Z%**_NC/R%LIUW?S!#2>"
MQ7CZ/(/344AM8@IDC984 TWFF72LF!@YYJP*JU:7/-*D48DUVYF&#,IIO)$!
M#:KOSTWYN&QK3V:*_2(J# US'4<4_E.H6Y[!OG&*]AP.Y[]<^<36V_1S.$UC
M^O3.M5=-?+[FCA")_L28EGEK.:3\B:>HDP0 .;3O&Q? K\&_\XAUHV@&-NWI
M$3Q!HWM%KV/>I9V4Q?C';&O'Q (Z2'?M<NDQZA%2PK2QQIRNW%4MJ*2Y'9SF
M%EX03-[)M=Z-1)VK0"1#S+"YH1:5KU,--*;++[:6]HUKXTG47V5;N]O=D!QQ
MM3R5P6S-'=HHP-IE[Q"/?TS1U%"-;V>N)"+HT>F7B1A\EN'8\?@.A&J; .-M
MW>4*(@HSL4YQT<9-?FU7V4I K3_R]3^MG60Q*\+64X,LB*@=#+3<2*$G=J/M
MYW.DA*7AWAG&O;#-G%ULLX(XVJ@J(ZXK$6[&<NX3LS0V["D>U$?X);V;-#S.
M3B\H,V?'F-XJ*VB$FM=+<IIJ]VK)<!L,-%#KCN3N)D['Y@9]/&CBZ\]R4O89
M@[$VFI8$@E.*V7O@FSVT)@$2PU7'S4VQ- ,<;D'V%EC.'%M--WG;>9'"_JW/
M?DS@.'MZU2375G2%!_2%Y_S4L*2AK<5U,H@.<%'@X%+!(ZG?B6Z8M4E;(E]Z
M<'+ZA04<Z!/1]-8V'<F?XD1D^#JK>]&$]V0G],]('E,K(LCVCDI #6Z3+%O3
MXB52B!PZZ%$\RATC>8V9=I-R06,)&/=V$GB^MJDFDF\]49#4W)4.;)F"<79A
M72YT,2=2X*\;LZ!K_IHR_'!A8YC%(V#$YS_=?_<GSBV]^"NW]!4.1")%>V02
ME7R25V8XE%47P988V.!#TBZ([CS Q*.E]PBS2)(3J#LO&H1YU$[##9>""IG1
MB[@3=O#H&V^ 65,\FN!A':O^OR:^829.TM:5,@2&ADSK2](9^E[)IC$:*X"L
MWWX.C-U6"NAX%C[L.H7/U7.#]J9V.S )P0$2)G%]ME<B6\D77V\5DH5EVA"/
MT8O;TLUN,1TV]1\8_;A ZQ[#&O[+R#Q :X6&66@&@X>HG"/2:<-\*_U*1 -*
M)PK'50?/)D!\Z*DPSHJ1 ;#^<3D&<317Z**T#C)*<$4?K>U4);0NQ$<37=MN
M/DTD0(WSU8?>\+4LF,@UC-6=+E7KFI=$F&$Z,C6<"4\OYJ_32<IG7[ZB1)'.
ME?J%8^"3MC7LR=5K ('?K_F3]34)@E5(^)QV^A^HVJ_ML#O!QS+]I3_&&B?+
MI<$.P=A37&$4<O6W!I_L*$@_4!)-5[9P50M@%3-\]6*(,6^TQ$SYO+Z:<($(
M?552GU3VSM31#]3C\\TRL4 MK\C-01-*J]>4O'OH6IV:GFQ!6!EE PZ <-'#
M;Q08OKF!?">4E7-^P&T&,.@; 654?]K;.Z9,U$V7'9+\X8?UJAOF;=GRO25K
M-H[AYP&3/C52&[;@2X.A2U_FF)E0C9*)>@NN0;QSD3(7C.'VPE^\<PP7SVD
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M^ +P1+_:X,?Y DY1W_!OT:/TQ@\,FU7+?QM+\.8%0J" OB%Z@6DJP*W1KHJ
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M S_T>^0LPRYJW\@?.*J&^;=(80_H3*)!EH# 0WN?^)'_'H[E@,#&>TJ6Z,8
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M%3%J<(?A$$C)JK](FE@S4<GW"+/W"#)854TP2(QH[98W@,GB!@45R -#!1>
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M1AK7(-@F=*VL"%.1=/"9#90NQ33(&NX2,)9R9[H;P_86;ACDU6#*Q*3=#;R
M:^?N/1$U^B<0V3%!'$XOVKDO&7+Q9USR!Y$*<)H;,Y,;6[U(U(38(!#6)[7*
M(6=F!GN AHIP>U5B0P'O-'X;B$ *SG$6G>>\]I)EW;F#+JBNB<I:>-A0D9IN
MYMB1@J 63C\[![&+.,'!/G#S]<?3R^-?@9-WW4/0Q\2YZ??[.U<[E8BQBK.9
M1*U.[:IAC7Z;><*Q67@"PDU2#Q-N6]=9FR+\$D)^JG?^^^$0P1+ZLI1PIPWA
M,ET.A@JDH*5#R" .7#;UR.)?E;)CD6)9\NY(3+=&5^?9>%:927:Z9N%MF8,
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MC<E!]7&G"7ANUFZEY::O]_85$G?K2XL[WD("60&@GR5*J+_(]\@2.3R[E*;
MQA*X0QV3].2K]H(,^MT^*!E3I?:O6L%T$4],B=#SN<*0@CHRT@7O!;$2QIQU
M/8278G0F1IG\P$!2N]:')0R="O+6_;R#ANN: 7#X0J+$0T2I&]!TR4.H'?>S
MNX_,1KPU#3"8FA(FN,Q -AR!7F!6B(4'O\>;<>M:VW_&DG_,4CG<CTY'E&91
MZ*CWH[/1A_')^/CRMQUB2;_XT=,-G3)#@]9XZA*%T!JT/,4PU) NKD>>4CVS
MS'VR$CH4Y\$HI8I4;6QVX^MO)\&O!'G@^P0W,AH^]EL<$9*5;6*=00%N2#@0
M#6H1!-H=:-D9X79:72+%P,$(E91PZ5(%W5XKB*6B=>VJC&>F48<MHWTHT4CW
M[.R34RUS3&J]!8:PY!MFSH0?).#523F9'_1'23?V.("4&9UV"^,7FXHPA7%J
M,2B=>NZT^6QC0(F'\^R6;$LS4_U>!G30)6J0K8*7T#?I)IA\Z'1% Z! 42?8
M#IY:5I<Z",DZ+Q1T-$AKSM&@65('/K@;EPR\^Y/SLU.*U%_U>U\N<-2I3/=
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M@+N%W@'5/)SZ(54[G_#7]4$-8CU))9:0P%]J > 8YLEQ?G/P[5?V>#NX5,.
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MF= 4*AD=HX=,^5T<*;?#*ASIU#8!&*W&0V^6VG>%QNQH6*F.1S,8T&0\0+*
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MO+YT*QV4XWO=62@/N7%._@_9> $.&A-I1:K<EI2#!U0EQRK-;O%:?C'.L+"
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MF"J2-$SX2URN*C6:6<,^>.X1?63R0<VPI\V5,#,,-H-2O6-HB@]XD(P?]P6
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M(V3L(3X)3E>TOB=Q@.DSDO>GGYX]L+:'<2C,-8,\FY6(B#..!#_0:Y[!H8&
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MW 7E*6EQ-1D94**!J-O;L<7<P9-_]7KG]6'=EZ>P>H.>[M#(PU/4KW9V=[<
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MX"-";>!#Y><]L!0M@(<16)X9- =77CAD7S,(BM_$WD_04'$JJTJ[=TJ>='7
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M_FV+4PA% ;Z; 95881%U9!J)*4 51?Z?.-O$C8/2"OM&W7@*\8 "GF'YQ2&
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MT!\H.AV82LFYA<1* .XM;COEMP$;<IGFMZ/\5MGGMWGQ!>KJIA!_P1JT+^J
M#GD137V)G@PP.B>(G,%)&>97&7_N5KBI72[H*KF%C;Y&"PB* TH77QMRCEJ?
ME"ND\\G]34S2OGC::9/#&H5SJ;'KI'V6D$J]/FX9%RDNSC[-_ZGWH$&\N T3
MY*^%FZ:6'+B*G:(>!'T+'!:$[(N(Z6NH57H5I;J3%#8L$[=7AOH4-B?40"<P
MJC$<%\T#GL1<?X1]IXD$ HY(92E<Z8:M1M^7T3BNB,Q.0]1%:SNT.02F.("
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M*]YA4:6OC +45X]/S?20-^]Z=8-G4=8OXD2[P>89(FUARMXVMD+:R<#(4!I
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MO/S-QW;>$T/]&%&F NYX[(G?$,[DWL6W/KV"1O'-D#B(XVG+_YW'K0_NW("
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MBS6):..C:K$R8+!M[2*5-=-$5/#?>?4FI_Z*#4 %(5RZ?^ ]5UZ//%\JW-"
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MC[3UY!2'A61C]P98#@P-%P?@VKQTWW YT*#S4I^\)?WCQ--2L*,CE)]U:5.
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MZQX\^?PQ^?B+.[=/Z0/W&F>G;_Z>?#H]__Q?"185OO>3?VZV6X7=(P;?;-"
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MF>)38>Z[$+U;$KQ#BN?OC^AY=2!M1F"**P,S.7'^\08\#-A<]8EVR]=@^L^
M?Z,JE^Z%$*7%3-?A*6\F77'8S(W-A4D(KKXB7S*(PIKVY]3,'C/U^P"N39VD
M#<-.V#-ZK2QXDGH#NB+YC #ZE$(T-X"OX-J5-!4P)92V+H-H:M2%O2Y)/D%8
M1$G30?-=S)/:I/B4!"BI_G">Q,/J(&>RG1O"4*@Y@<:)T#R.,'C%ZFO/#$/
M "EV6\$+M=8AT&CS%Y"W1O<:<*20#": $W4Y=0;5;)IL:0YGGZ0-[)?-/ ,9
MCRRP.D/E/UD\!\$J%F_3[_Z;(B,R&5K,UT ^9T@(5[.YF#OS+<H/P@&-'0YW
MPC=(LQ[PAYX!Q!O[(=SC/WOZ]*E[\X/+@S2YO;T]@"PN7.O 76;LP9EKLZ.2
MZ]SY<#.U1F80H;O OTB7<<>J,B6XW"6<XU?,4%-3?@=_=;_"#Z+L) HOPOY@
MAK.=^&;2\G0:8)-/DO]E(*J=P84.RB7B73'=DTH'$BR15EH= CZ_9V4^A5YB
MWD"PE\#M<NFB$.)FG/M?$(<NG%RF7$*W;_+*.,NSG!:K!:4EH5+N/J&:. @#
M'H"@3$B?:!@N0XMCX=@M8M15OF".CD82(A"BV;HOE&]%8@B%,\<WY90*N6@\
M0X+I*>D'U%+^1>TL!:*[S5;#>FN@CMV)N,G]@S&V^<T5S)17CV_@8EM@[JQ<
M U>8E3GA+7![A&9XM&>?@=9!")1X6U [#S^.U)KUS_V/@8MCF1?D7$:J$_1\
M->)!FH]QL4'@1^7'H?7=#:,]'FB\(+V >T14P!0P;>M+-\]5+CEP(\6KT[:X
M:SLBW,V@J5"IV,2-'$@WD=(,\<*CSU73VL1)8GH&%ZK X]'B*)8F F]["R'I
MHL$]&>TIE7S[];65BV>#R >(-];=LLB)-G%SC<64TJ^D$&A_PZD!]"7=^^0M
MDP(L8DR)CP_L+ G2_(?2%_VOYYD^U6P7<X&#B%N)7F@\0T,S\<JCRZRY8&F*
M.;_/T,[G0<:*"QI%V! 5Q&K.BW1#=O<#9PV/?F8-'_>L5U4A42V,^.,P>1;^
M+?DU#P@1@O/2[;$%*\V T#OF,8@'%DFE_A][[]K41I:E"W\G@O^0T6?F!$2D
M:8-O5:X^%2-C[&*&LGD!5TW%Q(DW4E(*LBPIU9D2-OWKS[KNO79>) $"03<3
MTV4DY65?UU[7YV%5MWX:NL5:.@N_4NW$&5\I4N])'2KOU<H^I9=N4<J<DYOD
M"UQ0I[-MMK4!\$44#I0K(0D*S.FBD,K""T!/>)8/GDWRWM=T*D$7ET/70"'I
M=?(I(U<[^H=>7DZ565EHEAW)9/, K46K5,:9#O&_";'H8C6RFW'6 HKIN82&
M$C%&$P%3TX8N3< 2(I);VZEL8\]EV$0$2+P/KEA/>.N6M1%5Y:BL];%7_2K^
M:5W^8>6_!]I7KWVIKMX"38KT7(M8S!%FG=!D:5LB#J:5TA2'J<.GBYW!@WK9
M:.+[K)M47I<UD1@9E9;A:QI[T]Y,TQ =$/815!ON9O\R%^LIQ\-W98'@&ZSL
M'UQ!(Y&+^37=,8QC'G2^PH7B9]B&N=6O'RSX5CO3V9:<^>D"]X:FP6F%8+B_
M RURC+K/^T2Q?;LIJ3:B:L'J_3X-+Y-7P#(A:40@45D_)FL> ?LG,\XD11C5
M8JRLSV2$D1*"\C?#3K(&%GNEF10P?;SC<4_8I>R^AZ4#1DB?.2][KC.<V$&F
MHC>PY1F,OFX? GI:*=&AE/T.7+;O5AE"KWFG UJ'6>%YN_0YVSX%[M7;Y\^C
MR<X(TS;9V\B18V^(2AMI1(6V$H?:#F[L*#:IVR*W' ,&3&<V(2TX0,?MIL/\
MVUM4A*Z;4W<K)  80X\'"(-@PO=SJXG;%)A;-::3G@_3)'J7T7@GDW0&NPVT
MA<-Q;YYC]T[:\L/S5YL;1S!%^]D(_@LC]!5TR?MNQ2F<[VD$VNC]S\4,J9/B
MZ.R_HS<_O'GY^KY[WL$=C%L5]L1_@O2AJM7.$-2NV?G%?3?F@,1+AV':WJ+E
M]V<B3?F/A!8M>B#)WKO)B76KMHG,Z^43TI&VK(L7;6OCYN73:S[>R-TT<C\'
M)>Z*Q?S1T?%]S]^K5]$OLS[R./^!B0_SI.R=O!___",OOL;1IS]P-S_?O?_]
M[/93]'LV'&;)*#K-BP2.G6'R$_%X7<#%I]GPDB 8[KU]E2WVK=3&_4>/U@YN
M,'A%J0TT7]__<N93TZ3 W2@I_'8GP^0*"W'/UGY0[NWM1OLP:3U*^YR"!3&-
M01_*N )N]TT<Z2&V]^[>5]7OR1 .CE$<_=J)GN^]5(_3>HZQ@TO85V<7L&)0
M$JWW"$.BK)VIM.4_)DF1G,/=9C&M9V,]BL/L8]8MT7WQ?C:66L3_G8PF/\$N
MF$U[:!/J"7>?*_T5G'&_2LCS=+JCN^[%<]$=[U-I3<:;&Q\*Q#4I>WD<[7>B
M'U_N/G^UOKT7G5S!UOMU5A0@FJ!A?3 .WX$M"R)S_Z+(2JPW+=%P7O.I5XR@
MB?]Q3NNK#ZN+#[UN%YM:^_J^VPIV- U2I2&/-_SP\BG\L%K7V8]+LG%H#"\W
MC!R8.]-.QK&YP0F;O=DTA#(G!Z2F&)JBOC 7JI*:5$V-4K)$>AB_V8 HSR/T
MD%HGVUIL*-/S2;X=T=354@-"<"Y%?TT*#,N+%Y5<1E-V EJ2O":0U_M->7-<
M9:>4FE3U_G<P$1RT= FU<EU_@Y>9F<DPP,'9,\3 8.( FQL:OH4CG_UV\D40
M*_;J0>*K;NF)&?-/NT=2.WT!VTBPZ#RN;HA"T!S96OSD')K!<8[Z*$@')(W/
M]8MJ7_PO81X%XY1' \KF^G/6/]<ZN(6!,-@GO2&SS5]HAOX2$S-G3N(P3P9O
M\6ETW!K!J&-P $NG:LO1R*6+::J4D9"-LJFD4M3:%POB0#HU6:#?<BI@@,LN
MBH3V1<$1/G83,[1LK:>B7M9_T)5HLKA,."I16FJ$@B\C1(=!DG82291#JV6*
MO&/=F*:MHUAO@L \--8WA>EEMF$(W!"-\CX5:%+TEI)E+MM2=FP2M@P_(<I+
M+NC4.=O)(X[>=91CC7->&>SE>ZJSX+JTN3'_>AIZ IJ#(R2#SM4P.'.8 K<V
MD2XN'V6]..JJ5]Z':ZP<O6:[UQ*-<O1PGZGY)Q@R@DGX*3K5G7#L^:+,8<O)
MTXFE/=8P9Z0\?(JZ+4FL]&#YT22'8]B$LH4W-RBVD[AX7Q#&@I.7@%HNE5F/
M"7!-=EJ0["]IZ.[A0@5. 2$X5#GK0),-*DD]GC['+6=?(.1>,W9X)HY-V14H
M!/<VM"L@V82-Z:4<INN@M8PKI)^,0.6C"!O;J2-X*2%/\B^8\$?)0_ "S'1@
M\<F,R@[N,TKZT$M&YL97ZP5YKS<K=#LJQ[*(<.ZHV]0&:7[^ 6;R<@>2>1&H
M/B%SA(,9HJ LR 8??ZP"U=NW;+<E/'O )3YO+19VA'HSV,ZE5)RX7H R08_"
M2I6KBASJ?1WGWX9I_SSU">Z1Q;<Q%*F53!!*2%. V=@=*YL;EGW-2PU:AS3G
M"%>;#BSSM6MY?;P=^QHGRNA;**\+F]BH=W#R.@,G]#D1C%M<V3J6E)X9YUT'
M7=J.3]@),?<#4<ZZ >A:4[]3\@GQT^&U=#X(Y7G+L 6<=2X+NS9HRFZ=E)G1
M1ZSNC)F;]2UA^N/N(AY($N)-;<AX8^"C#+NS@3?"1[!"'V'7ZZ/5<=NL3-.O
M'+NO8!+[3^62ZR&H)7";B^YEDD%L5C=GI'G1$!G(]*H)'M4E-C(N<M"D]1Q6
M>QX,^NPB*_K/> C?4<Y.+TN*H-+\$W11,DRK%5)R_%"?D (!R6E)*94@.HQ9
M7O@Z!B3DYL,)IXTH=3<WMJ080.%N*XE"T7ORVGT&I:F?CL8LF?2:4+_@71-F
M%DE*S/+(5B\Y-7>;UQY79KED)K>KY3"2ZHAOL-S+'&TL27WGTU%6;HLI>-^3
M[E&S/%_ZNMD7'4$8324#]B$<LJ+P\3?]? C&D6.E+^3K?S,\R7 WE:/(I>LJ
M0?R0%W-< * S7,!*NA2X&0)$_CYUQ<YON:X'MMH,>3"$58PW#VL$8@\,9UR2
MA94#F/X,#RR3GSC-;I24O1FH#' @I":_R=X_2)&^24J)QND,':I\<?E3>$'K
M(_Q;FI[A6!/M]Y6GA$^HO/$QDT&]>O)6KG9;];:MEL]>":J#[F43\M#]B9!#
M0Y?$-D[/\VF6N$2^?I$,5#$*]R.;\D8?)9&/W#U<I.3$I#MGU&^%UXZZV?E,
MV&,*A=(DM"4J,CY/T'W)F7+: EN>;(MK??9<\%;2%+ (#H'RFS- 764[GL.S
MT43OZ\X*#)YPQ44^D'=BN13(B$%RF1=,[A#U$>!+/GJ;!0ZORZR8^J(D!GHJ
M+[*)'GUS_%+K !3H;T>=,IJ532 VDH',OB@^.T0,Z0D"8VB_1X R\]-E@HHI
M*Y"J]@>3Z%-$NVHM8&4;>LL$7JT[ SF?L*I83RSM*N2==U7;QFK*KG_@JNAK
M;C#0Z7:CUP(3QM&+CX2(Y*=P!WN]<MD=]:*&E>%Q?R"5TK7)49AG^06V;Y$&
MNB:]%?_0![<8>_H&^N">6B\9C(TF.;Q:Q[(>;).)XX:3(.F&R$LV= YIL3J#
M#4D8V^:R\/#%7]D;V9/UZ6!9XL789D7Z+!TGO2G#W7#QA-L7P8LOC:.#T7 I
M)T!*O_$T\XXMKI+WA)&EU!T0F61>7&&0P8>#A Y&"SX-A;'I=;F.&3OGXZJ;
M#_MP48]<9@G5UK->Q#@* ];^L"OST+?(O8.&L"O*X]QJOQX0*&N>-$H<S$G#
M/J@8N@':0!O)QW5.I[6HX1<\ ;36[7;(")[;A:=,5EC4 "5OZ'B;?FT:</*(
M:#D[EG]XSY>*/09)!XN;9H53T*6: L11.F1@!*FDJ1W"09?$*[ZZ/M68;'V)
M:/":,G")0/<]EC\=LW?2@&DZ8C4+/9E45EDAQZ9X,>PFS(C/^NS"B,EG.A;X
MG8L<G^E;L.P=C>BA1;5QFQN"WEC.AC(:B6O<K]KH3A]MM50 Y:A\1YO3<DW@
MXK:Z:A.&=-.05X@AVQ<S"@N$#CQ7- L3\T;9K9][>8&G8BZ14\$U9FM5<!:&
M*1:9(UA#^T-:A1[WN._:6;KBX-34TW7=I\5#( 'AA2/P]QG8.8,K[])K;KNT
MV**^A'XH!KHI4.P/B6Q.RC:8 Q4/!:9.2/@:-4ULI\WR,E]F987@VF1"M#5W
M+3(XVW9^;''A:)E0U8F#X&\^["*_CM($S_\JG S.;X!B+R+"L56X J'=W;>O
M?J0*H<V-+5LCM*W>[3Y'1#B<//V6!Z5!912@;?<=.5D8IE$Z>TF$5*'L1!2Z
MR:E<;)*74PUH]*.PRS8F)N^K)-70JK&PH)>J5:>V;@I:"0LJST?H!,IT>VGQ
MGZPB;X5B1=<[Z4#8;.BD7.WM4H6+/=B/'*:W,+YY1C?XL3YN!O!G,NO"VH4M
M41D!F1*X7ZL0#>S2>^S61S*=L/&=<3*\PL $/O DG8+41I"_\@I&&'J.O7*\
M%[XVK4O]#1"P$C\.3>/;A)?#H8<+C&C0A%,T+^@QISX]'%WHS^WH=^MR'";E
M%*;%<T=4HZL!!IF*).CQN;NB/\, 4*5\<H#_D;#S*?K$^UA?=PJ7)%>*H[:Y
MP?M(X<"ZR?@KK>-34)QL&BH*X;P89TG,H!2&><,5MO*<(E2DH/#3:O6!1XQ1
M7;KLEJ!7U $\R%W?&ZYQO>;-@[>TE!3B: J^64D2G;VW5ISL2"'+8W1GOGYR
M9ZXX#N-PZ 0W8'XVB$_P<'DA#?ZM!/':&X$(ZF9</?0]-^51\T>P\-A@QE.H
M$U_C-IF^_F:"[C:+=.MOAS^?4)9@G^&&<)7Y)"^*X^-<1]TAR!R$"]A^O/&%
M-T\;<LZ&O FB_.$GZ,'9)V07__V7@Y.#SQ]BHAFPP6@R[GH)^9?KWDP+!&@(
M,>B\&Q"">-+-+QW12\TM95J\YY=>ZTJT*X^&5,:<HM4TY'\[0Y+S"('Q3X\[
M^X>?/OZ?OSS_"WT^[KQ_KY]EXE[BO+W[?/+^X(2^EE;Q-\]@LH\ZQZ<';_6/
MN2-:'7Z<3EZ59R<_RQ_OW8K9^W>8@;^>O?>__"9]X=[ZM:47A@_XX8U^#_\Y
M,:_2/ICEG8W!S(?E31 6U^Q#2^-@1&!X/^'6P(74.?AX=-")WATBL?U)Y_C@
MR]GA_FD<'7[:WV$V FUHV$CS-O.R7PX./_YR!EU_'7;=?.\;L/>7UJ??Z1#\
M_.[JK6U<]6==J.U7++W7=_&K+N70^*^^H[,,.O._GM/_77/S_[7\:U0K6J==
MM9:Q_)2,TEN.9D-OUM&3,TQPNV57CI&?J*]*ROX%IJ8)#3<8?)^92.;&6RK<
MN^L8I)KT.#T^^!3]>G#R\0 :\.5==/@D.9XDQY/DN'Y76%8<L"\&U*Y_/EEQ
M>O#_??E\V FD!8B+HZ/])VGQ)"V>I,63M BDQ?$?)P?1DTWR:&3%?^U$ 0C)
MHQ85]<X\5DGA+!+K<8!_T-?R,SOCHB>OW J<G""S#O[[E\-WAV=19Q&/8QO<
MXBW?OW]P<M8Y_!2]/_AP^.GP+&"4O$5"V;7]DTB4-;^JP)8+,O0\C!XG.$8=
M;/+VO2,/<&@?PQR'/W?VS]#CC@V1Z/Z%9-1@E)_Q3SVMT>9BOMT?=AR W]KZ
M!"K"$&O5*CWCL#+5-7$.@ZV<XZ\IY8#9_(97E"6&F;/\$<.718ZXB5@5BSQ_
MN22X%ECU*QE*F#I3Y,.2*JWDPU 8/S!"74H-$B+>YF.]0@@_N#J7FL)Y-E0^
M+84W?*7T)5A5FM4<7,@OK67IMKZ=K]SFD>&L(:P(3TM&#S"#$MDQD=P8!T+
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MP]-.U!:_,3IE7DSRPD-L%%BQ2+@ZXNC:TN !\O;E4^)-YEO2_K8O"-O"A2#
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M\MA%872GT,DBV[KIECP@>S>-XDTN)VZ0[!/FX0AZ?FW[-(!CD%B9#47)L[S
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MS)VHZ&9*79</@NNV'8"P!D'5H1FK&Y+*KCCS/VX2??\C@B_Z8>>'_ZN'=!O
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M]G*D:<+BEN6(<+(4_8LNLR3"D-^0TM_XU"-UK1_U9P5#8Y\3*HQFQ&UN@#E
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M0+D[DT:_DI86M^0M+9.NM)(([\JRE1I*VBF6[J:^(=>O+4[OD/24J%M,C)C
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MW8E(^C?8GC?;E-OB!QY8,KFFL0B.V3+(PD/#@6/<F(A,I2V(TZOY[EODYXO
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M6^5\0TJ[Q#/Y>=T2W8OCZ1+J[LH"'J7U.C;Y@0C_!92[F?/V5AU%M?*"V%.
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MQQU$MASG$\2O:Z3_?0(Y+*X)]@I\A=45+JK!N?TY%4RA@S0JIF VQ'!$BO/
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M&JL>=*E"N^7C5YA<F&*BPM9[<S+-,VU!L5G,8/-3Q][;2.F'621*/&OGB)F
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M/YSBQ;^,;4<*1MS#ZB75%8M0>6TN31R)# '&>9DS/G>4E9]2\N\JP$B1)LU
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M\S^^QJ>9F[7!(KILRO6)4$X(B6T 3;1I<Q^>%_&]>!$#OH+,H@W(<X*%(\_
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MV<1XK(TMUUASPUG7A!(F4I73)<[A-1[D3]HW>M!FFD5]77.WYZA_/KY6X4)
M&U^WO"!J&YU*O!;-C7)\P5%+OPVWD.J%S[!PK"ZJ'C*/L WIZA8.WW X[=EC
M..U+7Z$7G5?H5B$=:BK+?(+9LIC-Y.E6(+3^_-M&J2:PM C9@V[-&CJ0$+DD
M(?0H[T<[++95J E+SB[2$$P*E_T+#\@<[(VW5B>N_8*YPYY49T^HZ;+M7T"J
M,Y)"G!0-CI94A&XV3<ZC;2&56E:(U.LSE63FIQ->#._F2R)-I_R4IZS[#2](
MM;^*^Q<X%(">E'91H"Y</4U#D.]:KII(D24%\6ZN;J&VYG,U*]#^ZI78QK%'
M" 6:=+7])MMT4RLLACFPH&3-^28\(NXQR4T.,\8^5\D_$A[;WXN?W<$#.\VN
MP#ZSV;SX&GA113/U?'KF<QTW=JY!)I2X9LT+G*'3CIC<AM;DYC=_*BEL&S\&
MYJ]E*5T:UELU7C%5;"/"C)JJ9RILQ\#B"_0'_*S;H["L:':Y(_$ILH^$NK@U
M2V"] Y5&C<"+YA.)_E7)_%">]TG1. RP2<<VXXUI?IS(45)%%J$28C?!TU_^
M+US*DKWA CZ76#N#AT'#^E6L=NS9!%B2%KEU2)E2TUKY#",T\ZX\JI^&2X=L
M>!^Q^TPYM=AA/M>OO.-_K 4RC')5MY BU#D(2& $BLSDE* '[%@@R9FK*+S
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M>'U7Z?^-),0/R" >M<$C9^O N3Z+SGYX0N9L+=G3VU&(>L.I@VA(?1;V2ZQ
MI>,:6YQ$:S4^#RV!MQ=DX9TMZ5E9=0[.)#R2NTU/($PMW;J-%7>I_BW'%'>B
ML;*^;66FW]-U0A^X.13BO\ZFW+;.+K2=*M&7T\)F:IBJZ6PQ<6 BYS=[I17
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MW(W%XOKCJ#*;+VLHCUI@[4Y0'^1:5J>P&'EJYFU,36C#7B_.S:E*%>3(W!2
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MR&I2,2/O$9326\*>TQAU!23@K@-T:^+B$!%+5VSI?B^,2RB&+>ZHT_I<T4+
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MDH=+85R)A"S:W/N6;!S3K[!.5!V)5\[8_*4TPQ_;?6>B'?HCS-LL@I0-84]
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M6Q6OT2Z1[TOM)$(>6&5Y<'E!^Y=8:Y2>&T2?^^!'7NC2^3C\P&L+6,7W-1V
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M'-?0!/8KW$SKR:$THD-AY+'=JNN$ND>*J)XDI!-K!7BL-:*C!]+3_^C1O#'
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M"JJV^-A/264]WB;F/*FZ!U]QYW#)_/9QV8"E"3ID$9.?<Z2H<=1M^ST^Q*"
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M ^-U(#/P5: //"\44+E()Q!30AK5%*DMUSLEJ\GEARUDT/EW@6+DDMGUPT>
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M-76-&E2S[G!C]H[R!P\>[$>L\[PFC#4KO8BV0;?1"!V&1>U5J]L<26947UX
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M<!]NY\_/K4/?67Z-E-PQN5D!O@V^>H[5U2@D$?#KU]K"\/#1\;ZSD*VHHCH
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M+XEK?9PV9$?<@/,U^B)\>64BDWY]Y9?U?!-E4C@/K\_<H(KFG0RXI9>-*=A
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M+V.H[DDB2D<D9,LN-+Z2X1N*[40=Y2-&%GC[[\[)/@'L&9L'700>6<6<<"
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M3L<CI")E=1)4T85)WO9#?=7B@&28 "W]]N$+'H?B4)&Y,(8LN!UY&HNTZD&
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ME?!C<Q01"ME_UDV[7CS=W7%^DGMT"&%*B%5.*'V$*;?V1S+T(72SL*09<[!
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M!QUT(P@&H\EI58MMT4=??< 0.BQJ"7H$E1]H2WB>D3/DK>+>8[XS@UH*4;<
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MA]WSR^-WQX>=RVYP]BXXZE[ )SJ7QV>G^./'\^Z[[GGW]+ +RURPPE4>OK7
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M/+)%=ZCCN<$%.99^2Z8/W@&:9=>QTLO&#;7/Q(0&*9)FHL7J;IBOW2FV5/=
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MAR>VT /T(E,L]]6JMQ99WT3RA*9KD[5(5KE(W"5<4?M@B"]'R1"-;O/KD X
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M7T9PXD\4Y[>P2#4875\Z0-J_VWD*),3P$<4LT>STS;S\I@8L/YE6#@M#U\Z
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M[+F,;DLQY>[=5ZV'6;!MHY/('#?; =$NT7J/(Y744+!:Z]M4\&!7*30G/3[
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MX/0,5%8W.'L'JN7T<_?\XOCL]%L"#W=9P\;E67#075_K_JM[^.FR>Q0<_!:
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MI$=AWXH0C3.R77%59:T"0JZY=S(<)FEB=X]C?<E]$D#IY0:6$S5R+ UI8[Z
MD,9[R]-3N25$*:N>?WF]K?++G0$U+G _?:-.WNG>892;H9V_!X=5$L?FJ<W$
MN&66@"/L#"5RF^HCE+Y7N=N2@-'D]>V(0\3E$J&;RZ],!^!/Z&S4N[GL@C!3
M1'7)M="ME$0\!5V^]*VX\!*IP_ GF^C.XEVDV)(4Z J';?,>%8F"R^ AB48O
MX$'PY5]AZTO:VFQ4M[K^N?=:2NC('XV+[.1KV+C"5K\BA:-@\9Z48M=-HD$,
M)C\B&L5U_[(*L5RD9A'7J+9S(H9SDWP:(!@&L\Q$L#?K+2SC&2VNMK=:6(?5
MR,ZI[ .\KZ*/$4IJV5+?TRQ3?Y<6+59>SN@5(_@LG*$''KGC"HY-0LX1D!$5
M!:BB<M<&8BRE4^L-T[E7VW+"A!;)'I0A!&8TA7-![5)A(Q*A;0E?0G=5;H/U
M&[13.*:GS"]3,.LKSF[@4VV5((W2X0HLT\6O6!=[L_XF\F%Z]WF@;S[=XRJ:
MX*%Z1OV6@]JL)<R28;=JS58[Z/JWF 'D"_6^I)CTZ</)QP;NS.^JU&E<&""U
M2VO=<K>I_L;B ON:GZY)MN_YR:^?W+&]M3[/^;3]ZM<I:8+ZC*+QUU:YV'UM
MW&-,LX@1_BQNYSK/(=E1118J9I*7%<4G3-Q2IRV.C$YKB0+;OYZ"S,X'H*M)
M@&88HT<3&-;BE!OI&UQ*=JZ,I5 N-*HGX@;_ZLFS'AP69EFR'/0,HZ!\22_)
M)V/Q\\#_5EC;SIGW)1)R]SRV/8]5"X([6 2\VY44B,A"EIH6]6S*/E4-<61'
M@0JQ.(&B.A:P;(=M$JDWA"U0B'2WQ<,-5PSWH0C#Z05),4%NP05(#,%Q@YQW
MZ_CL[M?N^(++2) O0M[Y6@QN!1UUY]96'W(N+5K:E',^7&RVV/[.AH/ 8IF'
M'NNDU?!/4 /KG&%4&F^+GK 6'7%:$#4CYLN7SJU^P(5BBSK^IAG&6QJX:;8(
MQT(U(#CIYUY,*E)"\X,$5'*L3$L;=MR+J_L8..G@+R3(#W_<__$OZKQ\/*C$
M@L&$6A2QNVRWL [^WIYRT4+$.OYN@:\#KO=R9P?<8R=$8LJ2W3>MJI=:L>^-
M"K^40O4Z_BY*$ATI_'M2U:(1"5]B[WY-Z5R"F(&E3K8/TV%%"*RB:!'A30@,
M3C*Q%)FC29&_5LD3 ZU13V!7;8JBCI,1NC7FXY B;O W<0"("?7,I@P'0Y6Q
M1BJC)V+EUQ@Y27B<Y$LUWX/;!7=OY\UA6>U2UT9F1+K'M>W2.*@:',[9NXQ"
MV30!4NR_87]J=M.\071])4%)O@A+I/8#<^O7Q9L7&MJU8_U\TJ2C>2?Z*'3W
M=[[L/K@J:5&Q!Q%951@D?@ V2+:2EJW1&J*(X<S!%LF R:U7BA1TY,R&8S%A
M#6&2H.8OXKB&G?2!43 AN\:JK:#J)EK=4C$U]Y3)S-W"DH%:J<Y2IK;D9C\E
M:!6(BI:KO,H#5=N0'M8-%XPH4 MLA!H4 I9ONPL504]A,INH.^(VOEI5P"^5
MGI%!,5EP)5VXTE[ Z>#"<-/W$97_98/GNI,/FV_+*.87&Q126RK8Z=JQ&%-S
M6.(5$.SVKDUF^T$K(4VZO>7.-ES]H!S85%D5,\PR4^ZNK\ 0"2(C\" DZ"+-
M#+'O)W=5X.7/^(KB3:RX;=0R:DAZS,2;5'"EQ:JAJNAT+MR$-]MJ&+]>"-U;
M!LR%(NT9CT^S OBKE*0');*D]-Y8XZNE0ZCSSE)Y=/@FVCO<B79W#G?=I@O4
MPDX'9IXDH_X:V>NG&%>1]$O7TMI0%?%70'%?<QVQ0B31LFR\:1%TS/B4"]$4
MO%R2[):UB*S!2IS:-[:[K$8%&7O91N\1)D7&SMBR2_SIYN2ZZ7A>$E["1:.$
M2]= :(^I-T(AMZ(-Z/+OAV_QM#ZFY+@^>@\XK"WQ'B<HBX\"N&I,6S$80^I>
MPKAGE@W:WM4Y8P4VA66J%)GW ,EY-?^LM3URW<4F\H_)]HU[G^E( ,:N>LK"
MS$STC-2T P$DQ%29*]ZN)XNQ<ES?/Y*O.I!%3.?9^%S CKHB^8%01UPM8QFI
M1+*^G0R<!#_JJ59[T#A/@SJO[T$5RSG.$O<7'22B9WMSGL6TD+JA<S758VL4
M7?R6L)[X4'&,.=M,GDO4]A.OP\[MXLES+_L)5D[ABKT47<5_=@PF#EEPGH#1
M_R+OE%>W['@\!3IPOZV!6O4'EE)D5DO\)@H[&-\Q7L1?UPH"K*+P534KLGKT
MDC)]2AIO,A]K$V&1>\ZU _:26M?=M'WGKF'F4-JI,6'6DUPT/<^&,C5-O);Z
MNL!N4F?=X; I1A^K&^XLDZD&W)6)"Y^DTZ<EAGT&^O=\V49-O!=HXEWW8!',
MCB<]ZF0F=MRM28VOY@#!-=C>LA+JGD(\6Z!%?FFV#NKLM0+/M61W<K,WC'%B
MD2*/(N?+T:)F/ B:S=Z %69!\;A1.0]:,\$S5,L+$)V%U2M*1($JP<7HK6DX
MJ0,JJ%6P(XJD&+!-&]>WD^-?2%:@5 T*;$0.J7/3]MB>2 MB*5<N C[L]]E@
MQ/#3480>/7THF#EQ]LQ(U.9Z],#-*A]2]HH&.?;3*"$9!?^><O]C&YM1!!9*
M2#\#KS?V<\!VT-AS>* ^:8&+5!:Z3YDP+@=Y\HKXR[LD3\T'\B[KPR$5!2Y_
MJTP[\)RL(/63HC^;8" (V8:3=G2KC)H@JD@?"[-T#URGV7T%SC[CRV8U)'-2
M)%[+\NL$1? T<D+,0C8W:FA;,E_ >',1MGRB"DNT\<BM?20J\ C?0T?)DD ]
M"CV*P4!WP0JJ._R$K8K4<"U.]$4*QBKY=/LW"&;IQ=C:-LY&T4C"4BY'$_,"
M9XZ*F-/VN8G:,%MB9!295]J]43SW=Q!7]'NJJ8SP'A<5C;(U)BHO(N3&WZK]
M'D<?XPPG?1D/UVYM@W$AJ[O  XX$:^0:,]";AAP!BY!,X)#-D#F1?Q>6:_J&
MSDQS#%%$V#TSQKFO>>9M;EZ[E.0Q3)2C=OCZ0"=%]8 >OQ*S!C]JE+*.%HB+
MLD%C68_EMNXU;<6P@DJDT<Y5'3(U($E4"-E*HDD9F3KWHI=43,CG*>A 5ZY9
MX<Q!4DZ5QJP(59=C_-\DTJT2.=T=T16%;H(V4;F>4FLV0CC0P9A2G<9>6W ;
MY5/(2E#=7R4LR5YJL8\B:IZ.9)<;;8/X'QY(_2I[EHN3HA(;L\55E4KS+#1F
ML<&I[0*;6&,<%6G"X2)O6A";PSYI<L_F(MU_2ENPN:7&J#'; M^=+"-_E(-J
M(3A AWJN"8OR_VS7":0L"[I\!1=*K,+ID,5IWIV7Q6#7KD0$/UP?CB?Z4FOW
MQ7$.*PIJ31@R?1F((B3C-?P JYD+SFG02$MRR\GD5I6OTG=0Q+[*@NM&[2V&
MI)O?7[%?X/:6G1.C[?O;S?5F5>A2T=]?[,&-D7<Y.&S, 2OV,*:9Y"2IX@9P
M>)F11R/@OLH;5+(W4N$3#;\S:PNI63&>?:V=,G[E/<X5IY&&OGD02OJC%E(Q
M%Q7O,A87/%[-!>G%#+MI[73$?2@,9@$[=?&:G2 P5;P7L8YA+W2 ':GA#,-P
M<H&+*E5[I!3AB[.D'*O@N=J7-!165+5(UDX?JWP[&/-,)F/7FDT;A<T=[BBD
M98PRHF7-N6J!;]3KZNCWVI+SM.&S:YN]E%D"W?%#CE=AY9>&E3DW8RAJ"K'J
MW;J&R1=EYNOI.[HN(2*@KR  S]*\Q"._C6@8)FU,U2&TS)/-5YBW&NFTL5TB
M;N7B,8KP2%0F>>+IX"<J:4QP7K8) BO)7RO$6"'=+X=C=6K3_7_JOCO+&W2/
MMK=6ZZ:#UHFEEIO6U[^3HMK>\H,W_BB*RJ -!M3Y*; G93F,L9PGWI@+FT;8
M6 =1NB1:Z)YY-P'+EA=;BK!V[:BXX8D,:J[<GLWW+J@ ZKUATRZSJ5A8SFRU
M4EG<ZUFO-7-@40J*>4-5>->MS%J.252FSR+\&GO4N7YPJ1OW[[&NW1I6H<WE
MH1I':L%/?;1PM&?I@-70(>!4,&)$J9@ S;&I@'BP\@\M)QHVSI.ZV7\PX6@=
MG]S5DZ]K'6K=QUO3).4E9=A:?V#8"7&8L.MRJ-Z,/DB)&JX>>VV+FEA8>P7P
MPRED)B^+5@GW]?-!!WBPGE5AX:-TK?//4C>1[Y^>P]L$8K0U!-:E/VC:8H 7
ME6"]]B,Q-7"JHD)%];@+'+A56KUQ(IQ<P084<M>.56%*FDBI>X-["NRK'!&)
MFHVF9(74RD@-8_1U#5"YJP-G;24DN7[LX'O2\ %%=HR>M3JO2TQM,.N3 [5S
M:)L"J]?'-Z+7M6NFNV=J5\BZ981=QM 4#NQ-<$HO&SXO[+505=#V%MU^YBQL
M,J[-S#*F2/+ E(8426D" YHIK20*+5&-75N-39UB[$8#/6O_H4"G$ 5+6R/X
M#XTHH.3X[J-FY!UGUW=V&VX>(!4OM80_&D/&+G BLOYEN8,@ VM0CG'N5&/:
MIC$RC@;*V)99S^(Y<:-5D=BB!]%I*%>:'*@M!79*XB\1*GV:H*I-':W4VJX'
MK)\XRR\B<>=_/CP,#PX.N!_,'8'EUE,DGA2OOQ_+HS&"O^N#N;R!=7?-=4.T
M3>M]6^<J*^+"KOY\>$#$Y/-5101*>XJQ8 /*6V9)^<NPM"E5\40LF[/_3*?(
M-5QU\)":+U#K\^8@O4PA*!5][+Q<C*MUQYZLS#*A.D(<7=>/#(2P/F:JD5-6
MQZNDW7H\BLG8$8^?X[D*EGO Y8MJD@,FY.A[,0T^ZRNOFV9S-3"43NC@*G=:
M3#'Y.8T>M:5;R'&(/<92X-A*\ @*T&4DX7V]@35;Z\'?]K1FK!FGDBD.HE$;
MS*2/!5OD/^ V)5^J,D\XTQE$5SST3HU9*_+0CK%M*RKP-YYY+*4564Y*O4K3
M0=*(J5@/ =&1S=?U\BGRXXE;AH%N/]EHX>4B.[>WP!X;FS"-;$)"1?5LTC?6
MP69D3CT_@B*32JJ82\9YEA=2:&("0G;/\W]#A?TTA194 '(#MZNXTYZ]N*,7
MJCU1K:;"GH1A"(2&0!;IF8'X/\"!%;TSD0D[!;V'\^.?XWAJ!-;VEDS_1')&
M,Q!&!6QB(-@S.98%DY:(6_,TUC$X?)3BYL=O2A6"JQ"+OS!%J,K4F7!OXU5,
MQP!\'AR<%<M0WQ\*)*L,K'B/N=UM$RP?M@.JE.&<6:2*(Q?Z5(U(?%0;W2$E
MY]%G;NB,9I[ _LFP,,TBZ7&++\H/5&_>5C)!R)Q5)DP_K&QT&<^GK=/ V.44
MXH!CF!L"27Z0=D:,'E*)"A;4F(L0(N(F&6!8C^Y"*%-E:9PF7I*EV\M@>SA>
MM"SQK?LZHO,40N<-'O;[@@-E")PGHJF"4[A&^B_+NG2(9%CMAC],Y^,-:42"
ML<?35"/2Z-(T5]\8#P3GA<\BF\"9U+OX0?LT7'XY=63LL0XW;K1X6G2F"9*V
M3',V^2DE1 9FQO#R/;0-ZJ-&I3P;0Y(;[?3>WBKR&67[9U,=8(CQ*QB,R5,Q
M</:#7V7,-% ?I6#SB1K$YK;LJYLION8Q(J]Z49EHJ<F^WZ/%.E171LL>Q!Z9
M;" 2 ,DJ=R.Y[)OCODY$;2%9GLJT^0&EC.[VWXV^*!'3K4&+&Q5&"W3<MY T
MAH\T4@.M([ 1BI&>%FCU;>6!R?T95=F#%0IJ<#)EZ)@T!\2]LUB0/DO*:7:]
MY$H($UOA,-.@U@5SN0TV&I$"QP&I!R$("!=]66%%]$UUA#2 _L[T'M-G:%55
MZ$J 1BE9_>2H!C[#:?&.D15I2EB3TIC86&+KUI1M7+CZL+NMI*P?5?.8% R*
M&FPJ<*LIAU!6IL0H5&1%T[42)]9"(JL![HT#M_(OBD9XQ+F#8X:7P"$S@$<$
M<CUG5M^]"=;CXQ1FG-;Q)!7S;Q@_4T75C 9[6;EUJP*=*CT:Q>-.%Z%O,O5A
MR?RSUC9_]98_:N3N"H/-G'<_1OB@;3S::A/1FL*^/HW-I0/59'R?QK7>-*Z-
M>ET7&&^6JAE>\X9]7V?JKTR$\#1C6P8+^EXAVBIH?UQ7SOZP3VAZ.!1DSA,3
M*=A0K&QMP?\#MR1A5CA/*- _X-@_?W8[39.J%7WDXO^!2].8;^Y&VW*@AV&B
M($<.!H.J?[@X6U;O"JY)]!DS" AM,ZTAT;:P_EW:5EK+->%^GMS1V >(--:,
MM)CGG-H"Q\*;.O$;XLE&B^1VO7F,JM9RM&7I;TWNO9SUF.;.\;0*&IECEZ*U
M7S1\K[=.#UI0"SW$;MN0 (2_1&P'P]J1/FI*9XD\NKM*^TY90SG!@M+F(ASD
MCSMHQW)>'(!$I-UJ B>:?"L\.X8SS:U6%&U( )?1S,1P]A+ (I@5\X;SIEEF
M=TF73M+,4IR)M\->)-R7G*R,M9?IG+C]4NF 8;UU_1UQ1,B:ND,.XYK-/'\0
M<*':5ZTEHK\9(Q9#%P.&4"O;P!V7@*Y1:=2D'V'#C1DM@>2('WMF\TJK,G^G
MA35*@N0F*L0'WQZWO<,WU2G4 Z&E0YZ_=,RC.C9A 6%9@#.&LZUSMY"XI!7!
MQ1V9TOT\!6'?YL:1)"5;F,QIM]Q=@IXLHR(*^H5:.YE)?-9Q6?).)Z\#-W<-
MGFLQBK+D7_()L%PTA;^G^I,58C7E%$X<>P$HPM%=1$>#^[91"'@<3YB_<$K$
MB+)_NPLW;,-X.='B8%83M];!$#'A@B80"G>,-6'*X^A@ZB^,%VRNA[O4JR2H
MRY LG$+-<.1%W2&L#]L(.4Q-57!8<5G-=ZG/>F-M-E_@&89!BBY::,(W!$B"
M0ROQ?J9)/\[D6G)9-=Q-9#_IW&SY(YBUJ*B^#^O+:^!>N--\#>#+!(!%^6*^
M NLW_=HSU>\%-9!9D9PD?;(C8SQ;^KB[Y[B+5#43)VVQ*_T1<DJMPRE;I=/.
ML5 Q4)QZ+1SEFPK3)*5[>L'7'%Y(9[YSOL+EAON2 NG9K71NM:W="AER-IG.
MTC)7RLJ051/%@:Z7=#]+,!!8+BL-$"Z0T PU8V-B)86VZ^"Z:NE_I*92%NF\
M0<BB3NNEE!4@N@H\$NN[6.M6.>\!54L^D)_7*S$^EU4KF+L/##S;.68K;.<+
MI% ["S#N9CI<6H^T- #NH1Z[V/A;.QRC/=O27MCE(LWH=PO;T&+SE^ SE;#C
M_YHHYJ+SCAC74%NRS\C12>O5UX40% 1P10-Z;%@# ,I>N5)QX=9,< Z%9ZDF
M#[J6=#5V>S">I-C=&BTH.*<2;F;AZ;:_VRPOU.SOY=G0:R0N<2(B#*[ AL72
M(TM7D$P(R#,AM98UF^XE;H"Z[>N:Y=P\1#OQDFP)@[6']'DW?@)0=D+#"&-I
MUHL%($,:.2VA>J[YN+,:<E R*!E2_65%@AG6+A +_$7+QBEH,3;P$C<,"OL>
MP5ND!<PX)T1[J4/XBZX)EQSK";:TKT4<FWF$$*9R^?WZMC86T7J@E7IY:63J
MX\8-K$[8BUAC/^@ZS3ZR&/O280+/:<;,[5+,6$!3/1JJ"X>_R]M*MXRU*/;A
M$HX5FN,0'$R0@;O2=Z/+ Q-=+DU FDZ%H]+(\;I=&/^34U5.,\"2GCW5I"M5
M*+;$K!OBHNP)]XW-TV,%<*MN@SR8 ]/-F:6,R*Z]D/1]ZZ7HVJ%VZAZF.Q$Y
MH/&:E1Y1DR VQ9MF8>L%(#>,3UZG;O0@1EH%I_]4A$!DK3I_WV%[4@=K]QC_
M@0>L\D%F)<])E[3OIFZ.PBRHJ:BTM2*>II',:Q(A,]]E*&%/C[ZSU8+/:+(=
MABB+TGR4STHN_FR_F%YY[6TA3)?5C)(A;QV]%JIXCP:#@KI2D:T@4G\ZC:-"
M&P42) EZ>?[9/R.HUEY5&+&-A3#M%..[7QS@F#TPJN%E XS_+JA]7VR*H.,Q
M99ZDS==",6BFIV "+)B@7+FCD[>W.'76VCH1&RGE9:),A+[D <03=.-;L&'U
M]S,-JI3N#S><ICS1EW80F48!_V>6SH7!0Z#6BY<4ILP&>AI0_6+CWTXFP.W]
M2&E&!2_AY_PUFDS?PF>HU<^X\7487%Z>45DPXQS ;)EP6WTN+J,1 @Q_MV/C
MU,5?C2-H9=/O^:8-QN*D?Q,/ID3IR &X$[KXYE.!=:\B-O%?5L<O->W(AJ'U
MI:>=_=GA<R A!H\H8HE&IV_:W5?-$_S!M E8&KAVIBE8R$4[B,X7*1+CD&2*
ML=@X5#51,NTQ OK^93T8%[)VNO)O^X0*N8D'!/VV,?*/"8+0F" \*W03%M>&
M6*.E]<^YUHA\HUZ2HL7@P^#D5B&;TQ<ZIJE$F0.B<%O86=7T>MH82G\E:^?<
MX3'3B15WI69]7@#*JC46+S>3-UZ;,7[<MT&((E'LL3>FUYF3!-TDKZ@R-LN@
M=N8R""E-+9)2SBHP28<[=D<.B3HOK;F?%L>\K<$#&;^E<7PE=WS%,AK3A-BJ
MK[.&)@)SE&WV&#QDE.<#!*#8-4T#GJ8LA6J>Z0_4IM1\@P96('2?0-<\= G+
M-$IQW8%&97T*FI1B._V<]3.DT$,9'>@5.]#)A";T<.$#/4"PF_0G-B8E?LB1
M6!/#V2A:@.<>U0L5*<Y>2">0?E0@HE+.FR8"<7*4&0B1?.Q2K*>&?C3B43%%
MK W;QRK9TWJX-D!^Z; GIW-?9:TY+ZR64SS;8.BR^A-(G,.#?:;^Y@3(C0!A
M_85?3%=$X[.-7O%<1M/)B^\*]Z0"0E,7J<*^*?PQY1+ =N][51![4,BR*OQ
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MA 'Q"E'>:,&! C;=IU.V/T[Q7JOETO1:O=$Y!,N;ZVJ3CJ5)K?F3M5*%B5K
MYB+I,CWZ&KB$<3G4AG9A_!;+&OG!:::>@>LFUNUYLXS8=V1LO]ETS(/[=,S-
MJ.K<T7P:'%OO38=6L)=NC; 9@STD_>+>[DP=@%9\*L5Z*- ^1Z =T)E08GE:
M._']0-?7!M^#18'TGD#)D4YTE'>,O73W"U87.#Z9!HF,XORC)LR?G5A^$HV
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M3=;76+D@QH>TG%U# OO@N:58.^4+1L3(BH\EM)2B-Y6%UKR[#)0*SIA3)>Q
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M3'&_/J1/W&SH[%[>_KSR!HKLDANT&<_)&I'W G0O0$,"5*5U/75-A*KS KE
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MN2_>N@T_2R0OJ!XZ+RC-][FV!0\)]66IYJ=_" UP V]F-)\SD!HAV^X-UZX
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M,>[;_$OB=!8<;@]SYFZ[.+2X,RQMS[I>G\@XR6:<TD;&@05E[*"!9!(J0*'
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MJ[J>T$=H$M+2!,]@"=0#@19Q L=!,::I9I, [49<:)S$\7NP2F?EY I=2[N
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M$)MB6:XZ JJ^>7/,BIJWK>Y28I';?'=FMV XJ+(A<F",SUH7#N;\QFYWK4;
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MEV4V;[6V'H#(QJW#092S$=>BLOW?L8J)>1RY%#%'ULUJ0BI((GIB6(3^BX_
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M:9KYH-HKGM8-^>(%]P -6Z$OUIL4]G%7J&_Y-R0#XL3.M7DWOV+KFYC5HZY
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MM%*;HBE WRSWD.L]0+@;#H)(1A^]&:HF8U]A@L@ZJ4/%O6WSL FQ!+&RFY)
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MW4_<,"RG%>STB$FM\DQJ=&Y9*K7=>+_O77;O#2SQ58A4)=PF^J"\KU&(D'C
M*S>V;6Z0BU/<*;*"Z(L\'8;9WS/A"\_ZA=S:()J4D.ZS[N2#UH(W)'K9QY"X
M2<P@$:Q_"G\H9]5OA.]J;6V$YN4;FX=VM- QSY6]Q_Y>>)-[5 F*[I1H"J<V
M?J>%R3YB75)^HRX(';];K0CO)]KKA.WH/%"W0#C4M+BIF?T=G*"*$X/;\:^!
M.\_&YR<7O?_A,/*9VY@GY)N2"P1#1. !;= ?\=NOB<;'1T&*$3N"2]3.Q%S9
M;K?B56N7VAZ0SL 6D3>N<B_J,[1+S0J[E=N4D_",+VN6QD+3XT!++)HQV%<X
M2N:EEB,4,G^K!6U:4A2,1?#Y<OVQWHP!K;!OKZME %A2M36Y=W##,*?@S&<>
MS 666G,E%7:%;YE^N6EQL5=[SQ^$$;PO[SST.4(6]^<O5Z(V.=K"A';>P_:'
MCC3XY,XW]0+MO7%J=(3;!:X&59RKNRG'.1Z;,#L=0X=,%P];W;-5@0-%6[J*
M#SH*QN_O&88<79C.\N($\9A>'1%F=&JP,@L*R&:DKO1=P4)%7#>NIH!#-BV6
M9%G!/$/\N)FK6EI>L!QN7$_7R=G!'=8CBF67.YK<=: D]!ZO:LI5LT;2N&D>
M  US_3KC[L2;M? V/"9;*0;K&%4*WM(\"=*#KL'^X%>_/KQXJ.7&@@A&-J6Q
M5NY*SQ#BI(LS(Y:CSJP?Y4#]GRX/G$M04-@M.1Y/VC7Z\2U8FGS9-4:)'F9'
M6"ZGZWU&@4,'/V$'R$D#!AA)JXU P4_!=J4XHTE[]3-;H5]UP(FWD_/3BR,>
M#>GT@NC7.P9CPOO.RY(E+20)B'&/8;OY1X\/BD.OQB=EU 1M4@8AO<;U@>P!
M\4ZU[?$YUBBO,*;%<=C:<1]W"!!$D) W<AJ$@6L1G7BU1,F-.XT#LOB>GBB6
M8V:;7L(#7*3=,W)R\:U*)BNA<6M1.T+;$,)9?'"0QK"_4N\)N3&N%.@+>X<Z
M8:.G0_XV=S%)Q1?BC:7; 0,%O)WP7SH?\9*J_QL(H!K)\!+ZCD0,9=! 9BYV
M9%K-?86>>'@P.(6;/->,+O)0G!&D3;)_]PUDLMKI'8EZ$C*_6D@E1S>)"G9/
MH\YH2)ZSIOB9'Q*4Z7%1&GP35PGU#3C\\X7T6E-V*TO&P3'ZIN/SAGG.0BG<
M9I[,N5-9)BR>,9T1FJ-X"CFNJS3$6YB>3HD4DAW4B$/X,-=-/?PZ?'0RD9 =
MW%Z7'5.FR'E+X0AY"4M1>(W8=LH!4Q)CPG0E/K8S(#$QE1IIP$:[OWON-4.H
MQFQK0MVB^(1!BK-TPO9C;%<EX4U1T8<\BDESPJ5?$=^WK-N6RKX,\9EU)&"N
MM\9!;?04U]D2?[=LF$JT(L7B)FI@WJ(+K(_]/4G+#KU_PP5& 3RX2=8*:'M2
MK-#>QI)LQ M$%V =LT?O:*#(L_2V%=(IK+1HQ8ZP6%V761W=Z?AX%?;W<$K:
M4NKR5AB:VX*4!->=\NLH2E[3M1%5$5M"##IVY9:2UB9V(_ 7"FI9Z-2YLOWA
M4WPE0ACI"R,6*KXE]8KS%D/<( $S-%]HENGQGUFF3\LR#?7&<,HLV7M I9PS
M.^O$'%6A2/G6-(_W"GCM[\4HG$VJGP9M?$?FO="#%K%R#58"+!S'[C3(B,4D
MWMRWVR79ZTE@9?K\EY^E!&T9S]&.3,J%,RDOJX[/US//;TMTB)08$DNR'[5*
M'<'8,X0C+CB_5#]-7424<!#Q]]((A=1JKRJ<8S7]")C('G.P@H\ OT$6-N$<
M7G%OEJ_)SRH;MPX^^, ]57P7%HS=8.DL10EF,VMHD(,\7%K@:7'2LW#7*["A
MJ?@PGH%BOH$W]J^R?HB4R<+/D#N"/%8,WV3:=@>WU!66O"N*2&?%E+YW%.&A
M615:YK+M!4F2#Z^;Q+,?@F7ORK3S>P\=*1]2##HPSY9!QV(XSER!CKVB?R(/
M K59'G7.J!$29P"1C8_M2I'^/%5#%+Z8;@R%&3&A7O]%6P(Y$A:Y6%RA0<@J
M5VZ!)KM\[CH!X3N [<0026KZ@WNHG#$[%O4<6@R?]9D5?%:_F')N?.V.Z^7C
M;;AY[JMJ?\C 3Q?,LQFV#@^<L!EK:RD\W0"/RZC+P,'(W%(6=?#&2I-.D'TI
M;DK"\EMIMY/J3K3&JW(=CX3XSS5@TK9+0VOO<*K\Y[H'1D[B-F116\CZ+G*L
MM6>-@_6E8#XB0<YT@S,UJLNZ^A!\TCR&*98S ?T:H50T+4YL Q/14RV38N!4
M8U)P(00&R\(V@@H^Q*!D4TQ*W-KZ;VIEBD@"":G)G]A6F)6D7M=2MV!+C%#9
M]W:*+6X<!BMN$&61;'JMJV)#0%\?A>PWXQG[Z,Y'&/9U$WXSV (MJK:WV-WD
M>B? O Q5VG*\+K ?]$NH%E,L7L28>]5:_\?B.WQ7!>'!C8]D"8"KQ>7IE^@6
M[1:Y)D(S6K,A0$_T2UK@'.M''F+L!*_%X HD^SS65QR5B9-R.N95.Y0Y3*Y:
M[N<]:DVQW<RS[U^RG*?U0#]EA*:BY/A;3O*W G)7 +ZSJ3U#&.K8IF.:U:VB
M!-MD^)-U6_ *5Q'!I\\,8;R@+-^SF;^_-T8ZN'+!/2KXOII NY_,#,:JPJ!+
MFM?4QH^H"KSPGE0I=;93Z^309 ]:[.LPK.H/89W<G7&$- Z)OQ/)X>!>(#WB
MU 2BEA;,WB8-@FC^)>). 7T?D<^'SQ([V]^SB;CUXTZ9'FFVVJVB7OCSM0]T
MQ\@V05!Z/P8GXM::8"R6- X?N(06,"<N]5>@EH^E>-VXCYU\.MS.O= X=H>N
MP?NP6&G/K3;3':<12X]R K& 4[L,G.MU4[;%_MK?^]@-YO5"++:QXC/J+G<O
M_#%B3?73R<+\3:'@A!X@0K+ML!R8,B&:+G4=E&_-V6E!W4>RK'.3#O#@A25#
M'JD:JB/$I.:&8YJ6N,@[X!RQK]R5X^M%/:NO[BA]E1[+*FW9]^=FC0]FJ72=
MC<OA##8*4P])1=B5A@U':*N^M _@8EN5[G=J+\P2*9^4^:98M]Q@X'!A>F5'
M9"ND6#+#%>:UW17%Z=(X-.V*7*M[-FIFV "">X3%95Q?+9AZV-4A(CJ7=@L[
ML,M5)\UJN;\7[ASDF,>Z^GJ&?+$D4JPY"&UM2O0D)X?V(GK,"K:X86IXL77;
M]^0,X-@\%? $-R.,80)[IA#(\WC5PF0:5P,6VTBNX>P?K3HZ/;0)($9&W&C=
M\RF4)]F,EI*L/G04]C'NM=Y+SZZWXZ:8-2SFTAL,NWG)"5)(W>8-W $.AG8N
MH1]0 _"B[V6*^F/=N+13-DS)D_%@(M'5[,!7BVI,Q55<N1E>D^(L]74:F#\-
M"C76P@Y]94&F:4^7; :W#J2:RO"TPW>ETLROB^W@"A$BY EC.(C."!P;E4+-
M]9[2802A1@4C5MV-".JAM+96A@U7CW=AZR;(89$!G<JJ]CPEBJAUA!IL!<4R
M_ER8JH^IY&+.XG)126 U,<4.3H_7MUBF3HLZ5>\>/43NC<[T.%]N%ZK'3_[,
MM7WNL^B?/O-B4?2D]8^FR$!6*/>3(I765?/W#O>!OD=APZJUG ^/E?-AF-40
M_A>R5C_^1EFK$;M+]5 6T)6M)0-B4I"^?61KD4_A/;)GCYX14/]^'!:N_5:"
M 0(LQ]W$6!N#Z0K6SS!/7-RU\-8#<=;!I,?<'8;O2ZQ%Y69,72JZSLF0BGC'
MT/!OZ8'LZ0LND>S1&FS1FX@V!Y<,!YDHTVTWK\KCI\6#Q]_8+@O;<*]],S$_
M2C.2'$9L_%(-;YVZHE65CE+Y@ZF@LQM24(_4$SS%/ 4K67 D1%=.FT.C.ZA=
MG8NP:[UI#QH]BUH7($B*2K,"L <GBH5+S]G80PQ9DMMT@&AO&<(;@+M*3KD3
M,</7Y0\L=:M^79 -2$K$=;Q7>=&[J#%$3C)E2Y[;RCI\:,N)5E=IZ(GWZ@56
MC7Z^V;TQM9!^/H<&BF-ATT?5G+.L-$746<&A38$= MEJ,?:.U%Y56@F>@J)/
MJJE0/\(,<8K,#I=N7CC>N8* Z?_;(7P)G^W8Q<[=SGL#,K\JKI0>M[P_WV1(
MJ==*Y,$7*R!=>NE;]"01Z*Y,<)CIL0O90UTIBJ/IN5I5B-M:E&V25-)S1/Y!
M49.+08YJJK=="S4Q*!/X**=JI,T!0/6R<_6\<^=KY\R,A=\5CKV+@YR^J][-
M4+1W"/02^._"NN8"%[V:;T\?@44)J %RCJ8KR)="^!H#1K<H1_BZ)#0$6T,H
M4*Q.P 5J7,-SHXUPS/BNK)E<N0'%T2;,5,%<@QC2D62Z(Q_<]/K.\S5A#G?,
MF4'(B=>:!/G]YH "; :[NWE5M"@7Y%<+/?FDVC UNS%=6D]X'S":/=_?,YSW
MQS*-?<K[1'G+/1BIZ4!O+25M@L@-OGGRZ-$37]&PD1&L,ZQ>=K#KS:/]O83@
M8-P"/ Q6-24%C5@0',K"<*EZ91N#S#;0)+1,[H);=3$0DI?#G=A>XNHKO:N_
MQO!IR34^-.\*;FI,E5!X5N$P#N?!\8W@A08H/_MA4&U-H#$2]#QRUWR@92SO
MB""% T1TU"N3#WQ1&+ =)QB*G\,><)V'G*MA2HB(B%R)6<6V,#G^=0>7-&#P
MBL+)  6CG-X:% D*T=A)J]A@GZ]FC@,76;Q7"R'%3:^T-Y?$C#.1&.ZOI<TC
MM"*Y-5K8+90O87RXOQ='M;!9O')$AXZ#J7P<>O_(2PB6[EXN [4TC+V&C3X#
M_,K]3-$6(4VE+ _S6VSQ0M$ZWFM')_<N@T7ON)9-"LW3&S#3_4<]EN @ %E!
M,PX&IF<J2[/G?DB)3+]CTO[>MBV3^NS^N4]UJ"G8#XQ:$?IH#_,39&>:D)TM
M/$[XG?OA)I<RM&U  ERT./#9_-LY O8MW#L476R:1_/F>&4&:9$O^ZONI0R;
M0HJ8D3E<(DN,'H7:#/6F3" :]%Y;[)(H#>O;2&V]]L-8I?@F?=)!-_"2V!M8
MG<O64 )N.8L^OG]8=L"Y&G(Y\$L[QA.>5.+E@ MZ[43L!A%CGH7\TWJ:*9J,
M4,=L*0EB*Z%DBI%2L/<674ZG:)XQ*^[ H&!/E^XE6S/GT:O;\&7TE2<<5400
M,FF"/B;L/!QI_&*:@-TD3-NF/K&A!_DG" 2HE6B%DP^VLM37DVY\L$=-!._B
M#H?;LGCO<FZ?N#&B(CZLNYK@B3\YC(*%QH)5_)V6ZX?QG(PJ,)'BUANZQKR-
MSW]MC5ZNZ^^@"F!#2QDKO%]PNN3IG^F2S^UL=L[9_'_/I2OK_\<NY4Z0!"L?
MMA?"Y5<N/_.V[D-8:+MQA1,:YIJW5'C*((\2'4MAZR?<RP2)VM\3[E!7%>+B
M#9I(1YC7,H$5R<Z$>];WLQ^;[B73TK0T#5E>32J&C&8S+M\.D.%EIE]@%C"5
MCF@0B&8IKXO9-#(K C@\?GXV*Z1%Y1$2OREX(L(7U1A5)3V#?'<N)N"I00_8
M!%ZZNQ5$(S<M!=8A1BM2U(:.J9S/;LI:VR(8.U%Z>$XJWCL5F$SJ.T$7D!>0
MF!6>"*: (ZMO?V\J!$9%UMTMRU!8M'-TCUAP=:C>R1UWS2ZS(4[@]9(X0#$6
M&C \.[B[YG!T4P=8X7B@^AA*6'GYNRZ:.5$.BLRR@#MS.1>J6'AUHJIM2]-U
MB1D178FS!N!@GS>+\J[ETU16>!LG<>,%\*@']?3!LAZ_+SMQ!=0CD.&U8' V
M5<NPC-X<APCUQ-;=D3Z[<?KLK*EN,&#@=IUVRFI7<Q.J!3=G[,#3?FO(E-N0
MM%8\2V]6W(H6N =^5RBN3S(ER#1*CZ T)J$]1/[+\1\)8ZB'OU$U1($HT2AF
MP_O'I2GVK$B:+DV!VJ6@NLP@IJXW=R2WO7N/?5-=:9[N%'O8;Y=&'G44%PWF
M[K=F*ESX\][OM$V3=>[W_'G>*:AK +E =V5-D-=3)-*!] O5_NUHM]W&27^P
M&; L1GU&^%+K<) *41C'Z$IU'>'[A^P^TJVBN#IEQH(R&XK,S,4W('>FPV:M
ME =:DB&BO09TUUS8%L<FA*O-4!ABYEJ2N(&.O2OSE^=FY_3?14/TC[]_]HCM
M(FZ.N:-5^>!6)<#.V"HWTYW+]M?TFH(TE>%LI8)G;=T\+K!V)](TCK>)4O_;
MJ#AY:%^KT>'BKXTS8=:JJENY0>ONT)J:-$LQY5K?4'<4'QP(%7)K$488HTCA
MA7:TL'>&*[9UP;9?"N+_(F5T;GS17J)*G?* ,X3.&=,5R)O%88^:)P>C0[)>
MXH^O#E-.;[]BP=/*.]K4((N@#&.B^^R:I+A.AB*Y*7:B@!D!"X$<NX'-9SHL
M6"-Z6A-)HFKW]UC7,LI"+4HZ-)0<S4&9@]%CX20M5YPVE,[ 1IM-:\QM.)@O
M,W2S\ANENPU%Y?Y*%I,*2O3>R!T><5S; ^7V]QSC3:*EN3[-5+#V@,IS?RIZ
MD8C/2TL#$*Q63><U'7P$X)71)*O^[2A2GM4FEM\=[>I_N5WML\W])#/1<S9S
MGU+4Z9+H_61+=DMM8T<]6C1DBOO:UT4X2+'QVFC'<KU&Y:B8$77//MXF5R;E
M_A[2*X3#-^^E6"@)X,>_-HD+]K2\)R:U+@8645PI]S-&_]IRYIP8!&OY!)?.
MK=*C$T\T <4)A\A1SWP[FE-NL*9.E7V*ZW#4UM.BT=P30;5*H@XSD !:4VU9
M,VRW^Z2+5NA:6?>VL)8ZZ]]$P^C>L9>]9=J'>JI59:R'UF:^Q<0E8!>53% 1
M=^2 A\2-#Y^Y7B56XGW@Q5%SFAT0.38T-**1%,/;U<&B-1(Z<94[_%%+V8G"
M\I4ANV,WV)2B<-KA;4VU9U<,A7N'1@^\P!JO%C-BG^S6QD&8)V%+<Q?KZL%V
M%UN55IK2!0,6%P645#VB<>!]M)9+"9;TKWQ_#RLPT"Q%)(1!1E#_S[;ZD!U\
MJ\@56(!KA&%I8R$Q)NM&;$DQ1UU,B,6#:SBI$L4QUO /,2RXNLN":WFO#;*^
M.;QNB2K3F4#%35'-3+*5E012>N+>I].P;V=S6BPTM"V>PR#-7^9#P;/((H]+
M"7N^=KS#A30_J,SQ/D,MDINX4=RL*ZWL&'Y3^;W A@IW0-*[]X(ATSIL74)1
M7V,X8<LBP]6(ZVN\_T*\?Z.;S;2F#SUOH@YZ\CB(T!A#,1?_Q<_UL#-$2&LT
MPQ@".1$FTB^Z2.?9GUFGSWV,C$:^2J?X$+0QV)Y]BMPJ1ET)O(;CX\J:#,+=
MK1HY3CQ+DJ>@-Y>P^BO[M=#L>K#VB(WX2O$!(;\9DR&1[6(?07<?UPT>"HH[
M6]_96-P0S71;"+A>BV6 :QTP&L^%#S.RL:=8 L\?:#K04ZR%\UV.9XX&H.F4
M(OL9G:H%JC]$=PN+YAV7"_X&JJ&=5*+#'=7A%B75+O!(<8[>\H1W81J-@1I[
M&U<M/IC&GG ;.SY>*M-;D,N$4:D1Z_9$FE"S#YS@I!@4SAX)\#5BT6IFV?&O
M=FC65V09,V6\"U8+RIKQ4*)RM/5/GS+_(2$N#_#?=<-KWK%E>YB5KMZ=RG/C
M9GWU5HTZL>L8OIR!<Z!\B8L$=E^SPFH.'(U$ON1EO$6W'>79P_V]/["3:- N
MWG24M14NLBC2M9'LB/4M&VTUO^D0[_O <Q&Y(+P8@!XA33#0,RO:EO&SE.^&
ML8,IO<2P\7%F>,%IC+9G <F<VAN[\1W&XR \;Y76R>*F:FI5*,@126>!KGJZ
M4F3KO7A=M!*GTCJD2$FF^SIPS;&V=0C0ILMZ-ELYHE'?A!*>?KV"%P:3LYBA
M=+/@E?[U3&@"U,V(RNB*JL%44#,M<#Y0WL!EN&J(ZX#_!',0K5^YA-':^A<9
MW,5A7$X!!F1$]QVVH>#H8IO['LJ4CR ?60(JCF7&?SS-7A?_*II)O6I=>0^3
MKWCYCF&Y,!\KQ("MFM)!Q\E(M0UJB684JWGPH9R;A.W0,$]!U8+84JH+#7 "
MYE%8=3&9B>&>&%78-3DE80%8,!<S-ZB;H+HOCH<88M&^ X+RI)R\GN7NRIZ2
M$8FO,S/$33+2V!^J-Q>JH.HKW2BDTPZ-AC^'/ Y/-CPJH]CMQ_1C48: M7Q0
MZX@$/"G4QS )N+ALNT9'X UB[F$#P!'</R[J 8*YFTJ+@6S#<SW*R<<=,GYR
M<*@[T(:P +AUE[GII!1T5,2I)E.UO"J3ELW@6W,",AEU7]SUQ89"F%O3PG.W
MSU14 (-R8'O>" ")H!53ZL@VP*07O$)(VRD!GZW&K^+'1/$1>S:9UT:BZ8YW
M6Q-BKVT5M'["3$$SSI?8-<Z*0H*6A@#!##H6WA:A:V$*-X2>SN[#KQH(?/Z9
M)#XXT(;X96SD:GMVUM]CSV3!EF&NL(');SY]1]7:IT/,P+YTZO11!2I3P5B&
M9A]J^A@3=,#RU*AY8CP[RA9-)C8@_+,4D5]P*-)T#QW0\%N&9)=QY#5 .'H+
M>5T4ED-Q+-RNN7T_YE<W_7Q@ODUX=>,]_.*M:;A!5L&6F"RM.@B?G,QH6NM0
MR.:(C0_>7PO_6[-F>!_]G%H_=82\VXW?4)8D8B#:+WXZ6G35@^.ZP;;:%7G3
MDXP^>X'$P>!\.=_AWC:%?I<H%3?,;-N3?G+N?ROQIGQ@[C,.7F.SX&,9;%+R
M!X;11NK$LV\[UY0L5<UDU_R.]N[YMK=WAR$Q\'%J6 @2X.3&9)G:GZL%^"33
ME11?.+O_JD).,@I7(NI-<<[T_OM[[D<* XW],)![:L*'F550D98#A.)5Y*LC
MS(,FFIF.IZL&[ZYX.6Q3AMN9O),Y'3A4#AXTE)@:X;":Q;^6 KUJ#)=Q4SV!
M(V^5H$5O7=.SE "OYUBJ/C9N!$MDQ;ZIYR_P6UM&Z7_QP)WGQNP0[#PE(# I
MK&4Q J:P_;U<_TL_T]*[DDDL=4#,OXF@=(K.<+LF_07OHX"VQ)VM=1-WUJ(T
MH=A.G-IPP1Z,9[P2EUR40':FQ?H>]?;==Q;UEAW@;ZTO^.KX[*CG_=$#_IJI
M'L&;/7GT^%'4 -2X:9B<?#"2R^DB^'OL51-HHN><<[HQ\NB.H=P@"G),"A,S
M ;,T.XD=%%BSFV@(Z+J/R$,#*80G$ OU;$7$)"*7>?:^&K\?%=CG3=7+&MG=
MHC'3UNY%_*U/K>[OD37N^>JZ-0R@"3,-;X[+Z4/E2J4755%[GKZ-E>."\'2@
MO0&2$UODI3_T?5H#WQK6&T?[!>? OODS!_:YS9KIU%G.O]2+$DT7LO28>NC6
M9,-L\Y'-7*I@+#1EE#HR?) =MTZA$:4B"28J:LHBL?00Z<X4Y.D+)5/(OE\O
MCK*S LYX\*THX8\?OB@6[]%4A9L9A/)W 4*9KYS3=,S\=$@_PU9#;3:%T^8^
MI8T^=YC3-M@BR@(2^M*=/$J_F>ZWYUF3<FDGEX=%F52&1E3?CL$Y#/F!60?O
M&M58QZ?1P.('QQ,16GF@*C-@DY5@*+\Y2<G[20RQ%4=*$Z-RQP\; J-ZXJR\
MHAE5Z'L0G]!VMHM]@*, ,&G!FWIV$Y/%U@D*Z!1,,CD_U.WH(TG3=^/%7%VY
M[?[NU='Q>A]ET#D1ER\\(OUQ:NBDG?MR;T=D@[NS(=]*2"/0&Y)C7K-?\+[O
M:(SX%+7KN"^:TAOM[P51?)ZYD(; 90(MF=XE'MHK,,Q>8LY<$@K.AO0?XJ\O
M.L<M(#=Y*TK@0A%3Q_4*-*&4#YVL,,X#QMFO"]J+KRO,.OP&UIN;5O?XP'C$
M-,H-PHG,_.@F>1X#U+$:4VI,T@&-3 %,H@*<]HT!30:MDX!%Y1SL0U/.^651
MJQ)DO%3XUZQTL2Y^J"ZYZ=#V6PTV5X;Q8@S.XE1+5&Z AUXK8R0]20Z '#X.
M0DC>7>6A4G(31LARAJ;#)!:MZ';RQR!MTP*4,QZITD(JTA>.L[)I*NH>FGZV
M7/H@N/;!+6:)47K-V Y<-4B>G8)M#U[ Q5U3%7EVO!K!_WU+"?*_PKXHQ(IN
M0+$46^!]V_H!4PNJ+GX).K1KWV=G9;V<E9[*EOT_-GCO?]<WJ^MB,7A7"F*)
MS?+K^P:9[PYW%*2\OO:Z=SJ-, Q'OK[:VURN,8?!XP:EV#[G*0$)>-/K:@G'
M;W=+8 ZC- ]8"Y@0^=VAF"/@@2$8 'R3B1HE?%/8Q-E(QMG2.&W3!EN-N9G]
M*^BBQ722!$FIS:_(Y:$8Y.8>+UN1@^]DH:O*+?316%D62<^?.]X@ASY6@=4/
MZ"QPNC(!1G-W%"^2BO0E?AM67Y-Y(C$[6%R$];C^=["G*FWN!!(UUV%@TQ/$
M@KBZ@;XQ9&MWW7G!\K(>A[^IU$0OY .!_Y"\I*_"IYT<59EK;!J;6M]S:)C$
M0VR9M#I B:2#(YQTB7R$DT^#PX) -PX_W02+\:Y+,;FI6K9DIQ7X0$Q5N77C
MI@,^$^B$$V=!5_!0<+Z[6B$2R0EUWKM"3B%&Y@5E)^:M0C)3:2QC.(TCT/7P
M>^SO?;X7(::VLN'M,:XF[*!H.JVW49=FHX9YC[3,N'=F.KE0<N/$NV/=$@(_
M#NMTW*Q0R([2;^[:&C!OD^QW ;:A-D,_!>?1$SD-M;>*5FDWGLIOO]F4WED#
M$@9'%_,[^_;*OQ2+:BGN\O,L!G097/\O'Y>.<?69PPD]B>C'E9NU+.Z<ZH,9
MZ$_GF9Y:;?PN<_,N*ES+AAT3SN/[.HM0=<#CIJ -9I@W8VN<BX;I<6DF@%1R
M,$IW:_EA7)]JFVD-. 7:5M NP$!QZH[.Z/?O/0Q0.[^\1$)N?&L9-IK77J3\
M40R[PW>+P5[ >=0]QL*OVFXU(1T>Q%_V]ZQ#*=?$/J7KC&5;DN::765):GTA
M&D>)A48!@>%28F@-+X)_4\2\ @>EJP@QMN!J#4^3$_2P3(/"TP3@A$*LQ\2K
M'!$$*GW:_I[;)8Y?_4;H/$CAZH3Y+DE*6(85P6,YJ%OB_B=^>-151:/>(#U1
M>C[QO"WMAC*S%CRM,BT4MH?%IZC5B=8=@T3T5M1?A^A&Y4G]&O!D5D/IAWHD
MW:%4#0I"#]X;P2/'7*4 8J)<U'EP,R]RI$6L5,5"E<S11'V2Z76XG$RK$C!:
MA!5)M%64D]Q]JZ5%MA&1<S;DW'JEK;Y?-JLK,/W9R0[+XQ.1EM>,BL4?OB:8
M[ 6W#G:0L2\V/_+MG_F13YC.GZB,A7I6E I?)8N=P&-NZY%$;1N2MNETFT%O
ML@G*+)[ZHM0F)1G1C3]Z-$2.(&,6V3'N;#GIL9VH:]<%OS^'WY>W^WLO:E25
M&Z+]YH##PO%Q__#Y1#1LL3#-93DMCS5'[;+&,WO,C<?8=HK'<B?[7*-NCD>"
M,PXM C#48JHGCK7")>SCHSAQBGZ<2DLH: ;[4V),:;P=MPIKX>T9\*-J@$0V
MJ+"M[Q1TEEC*W1CLLYDUV(\\+89SX1+1#%=LQ7#8A>$<Q%4*:09]T0*<IAC*
MA ,:*_8.?8CT;$W<XF/Y[RRW3M'GCA\BS=N)63N?VT5X6;7_7('^=,PN)S=^
M&>![5@FC@CKXUHV0.DWT5\0@S(AK:X$2'7?VS:-O#R:'!X\/#ZK#!P<W"*IQ
M,ADA! ^*0/FD1Q4;OU78)29NBKPE9%-_<"Q$T%(\;\G&1^6LOCT,ZQ0&9HY8
M*6JQLG 6]O=D&IX<8M3O :)L"&T#'ST]S,.7>!C,0GIDX2S X5!@:CDERTXY
M69XNS _K,L:EW;IJ04.,(51G 'B52FH%PE>P(_?WD,;\"LZY:WMOEHB 20M_
M$M.4A+ ^"00'?=%UG>S6&UQ.\91\:][&D7)0Z>)!VDL]1#KEU:(TM6HA^G3J
MPZ M<1FF: &&_>LN!8&-JOEMA*O/.*3E8D[8D18>Q=#)E,@&GDZ&J-U&2WF%
MW0)A)8DZ]MIYPQ'D].ADL&'G\LX=K?X1GJ+&@!MV<^XL%KY3C<1'I.UOOZ'4
M]O48^WMA*J%?Z!=;!%)4$C#G^,;4VFH,*P3!NEER]@87>-51=IS9N#%-7G:W
M=?.>NKPW$]P4\&4][?A?M^4(21C1C?3$3N)4HN<YH@JY-83ZIY?2<;#/I(^L
M":ZC,,%QR3=C\X:MC[(AP+98,MX7-IF@(?H,A0_I9O%EJ=MT9FZ-9>7"$Q*"
M1J,8]A#;7[.R:!2AXRRMRZ;^#>LA:UA0U#Y41U+/1\1Q,KOE-W<A&_@(M "6
M\8WK2;FM+5AAP "7-<+\,0QO7C;2/=HTE%A>W[5HJN8L*2ZX41A7]L;T7;#Q
M1<_HSDC"KO0= :84Q(;'474+<X+0/RU["D9HJAMBQ*& BHDMDA>.9C8^/@_N
M:*HY2Y:XL,+QV%Z+ ;58RE92@&2F)RTQ8?=J'.*9]J'&^_HXRL#[*0P2U]$)
M'QK4$U!68(\/O+??'WI>!X^U!S,?AXZ<CB:#7F]@"T2FRAHE$KVXZTEORC\]
MF-J4@A49.$HK3&;QT:V/6A1SU"(=[!*L^IM,D(L*I6Y6+J^1N&BQPBZO6R3U
MRP>P<!Y=I7>"NW0UF0.HK+BCB4XLW]LGE;$&G$7$65?Z^ E&S5RF!78A44+K
MMTM0HE1VJQ^,83$K#*Z#QZN?C1#@%[!U(4"-R]HE'\7=#N07%JK?9SV384I5
M,H%ZL%=AS21AX6E"2X_N)/\(=86I90W[95)*W/80TKQP\!O7Q4=B!& NH*.'
M_?$H1X46GJ@07WJ;FZB"J62FF$-57"WJMFHY2V>C"J!!IBQ9/-0;-]+$>.2'
MOFLV>:5VI1&(0PY#,[34C!ZO_HELY3K+#<^A'1P]HVR">96,E@S*8>.#!EM8
MK9(:NJ5#Y/.".-IE9N'-;P:6R&8]Q#W"4XE5A.A?2B_*L-TO>U2Y$G\\=;-W
M!C*M2HM*B<)6I@ZE^OVW046!^*SN=NZ)^WN7WO! L_8$A*.>8RM5N+M+=\@/
MR4,;MA=>GYX=Q74*.$W586_2UT^1:E%4D[E,2O15?]8.##X6 T&'9A[/^/@B
M)*;KM1IL,4%Z526#^WK;NYB![I/HU'Q$9Q&77=+O8LJ_^E9ZIX8"K9F$4/-R
MV*YJ.7J'[6?0@J5/M42?#VN>=U;H!4S"'6Y/M;?Q1%&D,$'<_%[A/EY&QWNR
MA[;\L"+M4"F9W<9RXF1W'@S]CJ^I\'#5%5?LU:P6AH-R);XE:U4^L,27\.=H
MGO6,@KQ_GF]3Z8%FFN1:9HH_8"2Y<,>0?X YKMS2$VVDAT5R YPW!7@K5=-O
M*\;M2)*BF5"[MLJ1UI@9S>T-]9*U#&<.%QTBG0.4=$TDWCXB[$N6Q?BI&M]-
M**@M8=;T<4>"X-W!G$.6,3G&F>'#$*LPBXVC8+58D_2757+6R1MXB7"F6TA:
M0MOH]!(!B/<0'([/QV*9BT#"65FUOE5B(G#\!=?#?/=GON=S1Q/J>I >B(3-
M'CIIIKB4VLK9U_@<RHK(@3CY+)Q*=$HD-]U,65NL^@E[%_H#B+EO/-]-4V*L
MB;[P<1\AOZ$R54^($^#+/;<.G,?6K@C,"M$X4;P3;I2XB A=>W#[R!OTY:=D
ML4B\!HV0NEE4!:J2=H4>@*Y@P,<>HND=@X LN5-2!L]R</(KEF9^^_6WWWU_
MV$-WQ FW4&SB_H"NRVBJL-#^-!V%:ONQB 5W0LH=(PDA .AM"4;/,N7ZQX*Z
M78*76.)L(S2Q2XUH8P/G"BN!!@H<[8DS*+!^/?S*;WGT].MK==XN7&?-M8T9
M!P,[R<[TH>O'W8LX(K69O6@C^4L>UL<-\ZSX(*S#KKBD*[U,?PYP, M/]LP$
MDLCH5G%@7DMN2-0J\*NYPOH&7(Z:VTF$U-&$#WPKW,?<(],$B;7V':T1%^NA
M^'Y_8-[T-$1^U4+?C [R65DP5HGX-0F@D\LD.[%T)=PNEV V4!JBR0TS*X?I
ME<QWU44)[Q#48N(N0>[;+X%  U?BJM>=""PYG;EM,>\+Z'(+ 3!U=5@?$S&P
MU(W=5JR&$T^S$^*XI?N:12W&UGH<E,Y;MQD91Q@;:7636&&?>$CAFARSDPMD
M9 $ER19E  NIIN$%" ([B?"Q3.JRH#0GA;NIDW+-R$F,(*#LY^+F8GL;L:)S
MUX=3PRU*;$2TJL2MS^=%W%#/S+@+X,&E4J%OAUO(QI,?DN^1(RRX*848PN7)
M.5(UYT0?7>Q;UB6D)AK'IR>JGWV$G?7TX1/?CJ=/N_YW3[O>8VN7Y$[49TX@
MZ5,N#2QG4S:1ZH9Z^-'RN*MS@\EFPTQHWMM$<I7CN[#9AVW[;W\WGGM?,&38
M,)Y[ZBJ>BXL ITY)YX46ZDQ6= S1K_%XHMZ2LSL\L4RW'!#\*P33.:B%C[(0
M\Y\L0D"JJ^TRS,B\T=*X;F&>AX5VV#1"U;OLK^4-S:6ZCVOVL*(I9PYQV/)>
MG,>^<*)'B[&L;[78VA4 =S6\M<?2%PLE4 "[<*[ Z8T0$?.0X1($C[.DQE -
M5GNL.IXODYL-R\)M(O62DKU@%KE )1:!WY1:-A)41F@5H9]4DZLCTVT$"QY=
M4M^[.:DYH4FJC,.-$5LL$W4&Y&Y6?5:]+UUQ.L=G6(D[X\2-0#1(:@D]Q*.B
M&C=5Q0Y?0&_/JV-J.(UZ8>8.O)(7+775$(*:R325/%,;.6LO$KR"MC ]8P86
M)5I)+B1E%/\T7O%<RTZ9-T9ZR%9=:B 4GL2!6..7;N?NP:LAR%Q=IE'0/0!3
M,<A#@R#&\@/H.;>LV.5E=L/P1GC1@.IG7E,LK%K-<?E!C4Q\[P&)!)-?VS-]
MM'O)_IZ0ALUXQ\J0!?ZK6:/:]_V@%G#B)^.YSH'.D3JTJ,HZUBK<*THZ8#AJ
M,I]2V T"8N29R=[69([!>"S:SFF2W*N1OHJ(!;2O:-0[2W302USE-*N4&MU7
M 24JM;08?7_/F=ZV##0P_0ET8"0+(R4>TA?K@]QVY9 9]+AYLP,1VS\M\)%<
M4"N&J_8"ZJXSSW<Y*Y92)X:  R*XZ#1!,BJI0X"[G60VZ'%824<U1/C>ILU@
MR\P+%A!+R2!IT3P>E[/2]U<;X[K.(M/?M'1FD2.\4$.$14VD_OHZNU#>K=!>
M'5P#?")QP&(DW()9<[5H-<1.Z4FR;BTWM>4.EW0]A;\,F0#J@L,(*MA3?-I;
MBN52BO? "Z/\Q8')&4WXM;)B5*/G[XI25"20VX+7"S/"LB:-?^DV2()1H\[-
M 8%-H*3]/=\;0 (%XKU+#L+TPXG6K*L]9F?(^-@1#[NS;4WK4*3/UY[$%U0U
M$Q7Y2N<K5S9I^^V (!_XVIH8=R>(P$.)$6%;YJ:B>?;")%%(5VD:=OS1D@ I
MS>G8&#!](H<I,H72Q@LI"79*EMD<1[=D;$'P85^AI>M9*/X.4LXZ7(/6,7/T
M.,.R #TCIP0"4+YS=H#1$9K-7)=&VU-]",1XJ&]$MI7.BZ7/2R B-TX$)KND
MNBG<WGGVX^E/&NK"(!Y]< TF/@R+_R:!&*$]\EZG+&[GA:.LU,CT8N40Z*09
M:=/=CY;5,4LB9FN^FDO+"Z?VV:Z 1]UHO18W!P^[+A.'DO:W^\B3-XH;HB(L
M9[.P[HN#]J6BG>PZJO;8]+YA4&-SR]@UVP*9-=G]B9MX]3N&BI^ZABK,GA:Y
M290DA2KI-@_M.>^HB?9.M-F@-FR"V_J"<XI_^3.G^#EC71<#VL;!&!*5+SDF
M;Q:]^I>@!!U;=/H:=%__(H1$M5?S9-Z)O2 @;L=[ZXI*>YI.V&+LKO'%I53=
M*A0.G?;RT9KWIEY=7=OR@=I1+,4GA&8PPZWY?"A8H"VTV:%NZO=E\V!2PM&L
M#"!A%^9O]+5LN7DF1CL/J%Q<@7QR5L(#DA-4V,RB"]996]L3GV@^@I'LB@#=
M65-^VC#ROA(O\(C-)3J0HMF]+5I'2AX* ?:OQ*\=TJ:[EKY'>N)WTJ]9R]FQ
MV5+)G9 X8NZ*BDS!C:\@>GQ0' X>#SNB^783.<PB'UNF(I]2+)(VV0I-5&A:
M2/C,]>"&?X]GU(EX?;,$F[L/>D2"94^E')((692W[;)8HO<S+ZZ*?U6+TD90
M*'U!'FE3%Y,Q=GY"W!$A@I7N&$S#8E+1KA9M1<R=2D6!/JCG=Z'!QF3MIJQE
MF#4E$1K0;L=D8'O&>Z:6-!J&THYAJ9&M$ L16HIY8W+Q=/?E'>U>S\%Z\@&M
MQU(8EL/#(Q7L!]^6<Y4$9:3IJ:^XYX4+Y$7IVIRFEV;<)>'R_;VV7B((UF)C
M2S\8D"JG'BFQXJB-YMPU$15CH5U(D9QHQ&51RC8C(CN'&VJLK6K?N\P"&+^.
M2++R_J!6YAJ5I#E$>)[<6_16ZM;2NEGOE[#Y0)HE:##"PA&*%RI:%F\C#%GK
MQK0C)D_#,3:F4ZNV&.!D9LC25R%&Q?=,OR[$Y5TBP!X4#J<>FY*]QXA%1->
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M W"J?TW-0>VJ<]HXQMG@.WM0N*8^X?[V4*XQOT #?VD-^;3T;8HQM2U!4#=
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M8*IKWLEZF.*8K2^$JCFE]2*FFRIE'K(9>VN*5 ;,'5@%EIZ[6PV'&1G6DJ;
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M]7!+\WVVH((?7;%OE<&!M2Q8%V E6[?M&GP=MI]5Q>\DTX5, H#I#).Q44L
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MA2F/1%T>)(J,I*=YTBN%Z48R+3@:,*841TV,"PL.=L^47"F?,0=B-SG KWX
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MW8AP=IK1,D4(QJHP-\XDL^K@1NQ)=K5\SB=Z<4A-H B@/^DEM@'NT%150YI
MKD;>L'F-?\8ZEZ<(]YU!C<F458=%^:;^T5U_WI_@%M-6G;\B-YR+'L89CH9A
MK$=5%QI*>!/=RU-+B[4'UG!$N/09;RUP<1<5VEN-YQ-D$W :G5WDA'^G*J?[
M4&],2H\?DO0!W7[D]02YBKL(A%GD)!0XJ=M$[Z"BRKX^].L6A8YM@!%=N[JQ
M1W:7I'H 0S4<$K"""[H$'(9PHIIY'Q)> N4\##JH3U!2K)KKB3(_.12A0SBD
M?%H3Y% =-XEUI,C"!S;UT2G?H2(3+B_Q#.[*'>T1Z\STEU4*A'4&S2)%VWBS
MF3HV&-TO4]9HENL;S48N<QW2L+:E5MDE9^-4U9 J?4$R2?*W+& 4JB,EC884
MZ1'%19@@M4;[?B0(,S]#2Y ,X]XW:GQC";";+"GO&*N)_=AA$>M(V\0B ?P;
M#7T)RQ_DJ\A;;W)#*DDYA"=QTNFIV'6*F)/+S34[PF"CQ?,A9X0=" FQ!%:J
M>C-3=&KF?P1MA))9 /.X,OJVVM(->*V^F%@T"47^*];U 2*N954%F"P L Z5
M"80>E)0993!K.RFKE  V7TE]J&?CR.TK&1&L!&SU" SH?D8&RP"RP0BF]3,3
M.?&.EH>U Z9ZHUW7%C.U\TZP&4IM?,G;R;6T^+RTX-#B)45C!UD@C=,:\)06
M1/^:0H!(G=1I?*LV#SGVZ*17AF\P M;J5-WB2\L?V-7UI$ST2HD>3&E!CA(+
M)U;.PAK/\2(\Y,9%S>!*)]*')I0KU33 MZKE;P/BL;S7F4GHA.7:'')#<]4Y
MWC8((+CFU7(MTDN3W+"B8IJ/.(<GJ53XV.1,<EQ[29KN*G8I6OU+?& WR%8%
MG-<B-"$EN88+%,6/;C=N*V@A*%$-&-[KI0KWIMXC>+'T%_/<QK.FGI-0C2I1
M92FH9_-<0H97!/278Z DG:02_BX^XPJP49,N4I(WPB&G+B7596*FT\I>MXC?
M*&+(J\.BK%QD'<I&K<Z31H4/6T$X(6;Y\/114I-!??:8SST9C5$])QRR+&5)
M79/:RD<RH"=Q>@NBL]917J-H:B\8GVYBPQZL1?<?)B!%Z7RW2*2;^F*(317'
M" +B'+-2K)<ZNT631KH3:J</X)I'&TY=)R.L.V=\CUN"?DOQT"]) 452D":J
M[3D'.FM:'!XV&6)DG*Q%<(\@!K(S@PL0/HWD#*/$C9KP#/?1]MN O]!>VU-Y
M[A9LE29. ]^J[9<SX2O'^?QP5R)R"+*$YSVM'J$5X"U;LV=E!G1.&/0;XR"D
M[SG=9:1]O#<1</ZP)X%]]%820!"# 139-6[V&4UQ;,>,?1R >**,\O^][)RV
MNF?'G4L@*+EHO>\$W3,@1>F>G[5.3H#3Y-UU<'32.OO]_QF5Y56,S>TVL;EG
MOCBZOUZ=JC7RV]FOO] _@C_X-]WKL\[55>770&!S_DY^C:M)_DG_#0E(>HR0
M>$QA.*6O7=B"^>4TLPDTT>+J3X;WACR%=J"GH&UL,J*,R'+V<?#IBSG-@R1'
MNG^D% /P>I-]B:M;]0F:ACBY//MH__WCX3*'^]]2S&FF>M/N4]6;7BY-UM#H
MLNSA>K[BU7CQYV5'K]UKLW9;%YV/U]WVE5FM>@>TY7=;=$8^1C]FY[!>0$;]
M?HD*,B(+<S13\U':P&OPQ='Y]?7YJ>KF7W!#JD;\VS;^GUGW<Q\U]TF_%+]P
M3F8[4H!/W;/7D[P<,CGV<D;I3+5D 76=69]P.[.<;EQ#6N-3^X&2B<QQI8[;
MBFRB4?NA^SAH+N;F8FXNYN9B=B_F;V<BP%:YX(7^\;+]H775N90%_T;;.E.7
M4C"W.?9BFF+7/4L_6MW@*(&$\[LT&V:W]\')2?O;6E<*#H";$AP-W;0_@1)(
M]??3*%5K@KRHW(3%N[WSX#9T2WEECMOU;X2Z4&3O^T&NL_,_%+I]!/)J#>-_
M1FD_SX)3==.FV8IC+[\[JXN^#.[Z!-GQ%^IZA9+E<@;\:N[,G?VGWID'2[LS
M[?GS;J:@]KCG7P%"?;.SM8W8V0:>+^27#[P7WNBS^-N=6P@2%CVM?HR!,6?F
MU>1?<:D ['$\#-XG2,8GQ^;T2^QOOW#X])ZY=.:LB!^D)S7S^U//K%QG?X.I
MG7ZK7OPVXV9M'!N-8Z-Q;#2.C9_<L?%P"_]= LF^)1!]0AUI<)'EY4"ANZQX
M$UP BVO4BR=8?5>8OS6^@.7X MIW>0(.F3M2+%]A-X#5D]7U +3,97/%E\U]
M@U$:C-)@E :C-!CE^V 4-RK3()0&H30(I4$H*XY00CN%WD8CZVO/"T?@%G@6
M2-*$MAI$\C,BDA:5IJBMB!OF4[?[)JC\T<4H[R9IOX$G#3QIX$D#3U83GC0.
ME :N-'!E%>'*:;D5?(KS%!4JU+8K@VL0>K$P"P.9]WGVM;S3]90-9FDP2X-9
M&LS28)8&LS28I<$L/Q9F:<!* U8:L-* E0:L-&"E 2L-6/G^Y<'3H BH@0++
MH-H=%UDV?%#%\,,AD\('!A292F$@F%. R9+W+0A"Q3.K9AJ8U,"D!B8U,*F!
M20U,:F!2 Y.^@T\GF.[4^?VP\>LT@*4!+ U@:0!+ U@:P-( EN_AU_G4.;L\
M;_^NP$+KY/I#NW6IEF?KHGO=.@DN6I=JRU]>!9WW87"R=;&U*B ,O$2?/K0O
M+ \1]>&D'2)I^FV<QCEKCZ<-\=NR(->5N@M4?X*K;%*N/NSR>M- KP9Z-="K
M@5X-]&J@U^.A5[?;72;V>GBGZK 7=6(&^%H94'E)%6^@B:;[,VK8@QL0V8#(
M!D0V(+(!D0V(;$#D]P61@+7FZERVSU]TSSYUKJY/U4DF&I<?SD]@R5YI?+8J
M?9Z/,2U,]HVST7Q(N+[68,(&$S:8L,&$#29L,&&#"1M,^/U=51>=RW;GXKK[
MJ1.<=-]U@JMVMW/6[EP%IZTK=68%[SZ>'2NT<GV\U0"4Y0"4_XZ@7Q^V ,&F
MR5\K#E"\WJPN0"&YT?-QG$<EZ-XW<J,-1FDP2H-1&HSR_#Z<RU;W^ ^U $VL
MTT(GP<G%JH M< *!RZ>;?HF+$@\-<DOE87"41TG_:SP<<G\:J+6$O'[UAS0X
MBLLR*;)TQ9&6VYG5!5H?XJ@/-^.[)(W27DQ?^,]H-'XKZ"M+BV:W?/_=HHZN
MI+@+?E=8/BFCX8IO%Z\W2YCR;VB5V)OF/>?4M+-)6L3#7QN#I3%8&H.E,5@:
M@^79</[E]1^-__1'@2G'45[<16EPH4ZE50<I3E]6%](?)[FZ6K*IX>FYV\$Y
MD+[_LG=>#YN]>W9V_JEUW3T_J]OWS9Y_X)[',5[!G8[#\X1MCM]?XAY_LAE"
M'?@[[>YOB';@X#CJGE]WVA^"\XN+\\OKCV?=ZV[G"HZ-;Y^.MKZ&)Y=V11;J
MN+H(I_@G&_#R/0^RRZP?YTGO<_!'EMZ&P>G6\=;*'F<U?5G%0PWW 7A4+J04
MJ7&;-&Z3QFW2N$V6#R3^+FZ3=ZWNY>GYQ[-KN\P50[S=KBYL;5#(]W>A7,3J
MD@@^1/G79-6CHG975M>!HM'(:3RZ:<!( T8:,-* D0:,/*N'Y/Q_.I="LJ%+
M'AOT\?W11RO*LS0XCKXDQ8J##ZLGJXL]*,6D@Y<-W"Q-XGN#01H,TF"0!H,\
M>S_:63[*\DAML??#["8:!A_B:%C>]:(\#DZC BQ9H($/JRGPWR)SW6_-^IK5
MG/<7#49:(D8Z2NXF4="^BU?=/V,ZLKH(J?'.-,BH048-,FJ0T3?#(\=Q/ ZN
M\ZCW.3A*LC+NW:79,+N]]V!1V6]B1DM")&?JA#N-BR(:)"L.2:R>K"XFL?B4
M+N+<*0AL4$F#2AI4TJ"2!I4\F:C@I-7^_>KZ_*P3M,[..O_CTA2L&#/[T5"A
MJZ+,4G5T#-49J_8_' JMHHC+;^QMLK@ZU>NR7J(.ED(S=JZO-9H\/P3$^V^
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MM;M"^WU%MOINN+W_*GRY][2=_O->Y[/VOGO/-SO_4>W<VPOW]O:;C?_<&_\
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M%/8)(#[\D%&4O2=3!L0BJ<CPM7J*OH<B@#/Z=UZ\)VF*%M5E7I!"A0<6<,.
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MN08BC020I6H]@\%Z1Y"4K<([=>D8$,SAH$59;PEG6>U*<P6C)$[$]30!H40
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M^'@=L9#3D!>K!(2 C3K,9.",1:>6-\Q:JXFI)XNX%JV5?03-9JK*HEI)BV>
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M>)9]]PJY%2ZPHT)H-+-HU[X[S9BC8JW%66Z"$K:ILZDM,1]"1CM[,^D.%10
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M9V>_M5QJ/SR&6_D*H0;C*-VAY7I" K+_[#OXPO-;(S)O3)7Y.X?K./ :&ZH
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MZ6/N[XUV'AOOLG4'-2^9J/5'K3'O)H'9)N1V%UJ3>&U;U"999XD-EBI2.?:
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M='(/I".@0"MR#N3IB9O!HY$"\\!G/KBU8ZJN.V1+!Z$?#CJ-06XW!4LQ H?
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M*ES@KQ3"M%J81=PJ8D[O>XK8-YMUPT+!#!@CP;L*I:<@5PA.DLI=BGV7DSD
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MW$&>S?N_-)@,O>6FP$3(C7&!_KF(2_Q=!M.,=S^Y=+^ V8!<X_*I6(B2]^$
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MT]O?&#@!S\V-T7RP!E[XR?R<\OSN568.'2"(X(9S:!_<\U?('?+DBPJQWW5
M#T-;>N'K2V#DKOL3CCUC."#ZC&]YP>XN,FH77B2[MZ_[MZPD'CV^K9)8]?VV
M+ZU\:>N;'MZK.KK=.;WE*5\^N=T#UC8#]O%'H[R .]S]Z /:Q["0?]NC_]W4
MW[/GPFW>7V7C3J)9?,NM^^LMVCE&O.]LU5J5^YV[.8B7?'-T>'84O#[\S^ P
M>/GVW;\#L(C/?X%+X.VO\+OSHU?!X<FKX.@_CU[^AO\X>7M^_/*(?O;/WX[.
MSH_?GIP<'I\>A?2CTZ/SWTY/Z/MO3X]_/CXY?!.\@$?^Z^CTY/CG7\Z#7P^/
MWX3!^=LGCN?JAA/4T(?]AS?%/KS,%T65Q<O@?'F!Y9C9;3NA?,P0\A0& %=J
MCQO[:5Z]O[\7G.P&O\W!!0E^C\;OXV(X>%7LAL'9(JGBX-'!WEX8O+Q,QM%%
M'@;';X+O]^#_/OLXS^,TGE_F61R<Y+M/@JV'^P?;JR-L/_ZXO_/]X[T]$V;[
M[#M[6%68^4+ <;N<?<XUY.4:#GH6[&@'<X=/S'J]-&/]7V,2T=UQ/NN)-,#Y
M??OJW_##7\Y_??/\_P-02P,$%     @ \(.65Y6>NOKX-@  _>0  !    !D
M-3$X,CDX9&5X-#4N:'1M[7WY;]O8U>CO!OP_$.DWA03(CIUEIG$R!F192=0Z
MMC])GC2O* I*HBPV%*F2E!WUKW]GNRM)V9Z)_=J'&0R22"+O<NZY9U_>?1Q_
M.CM^]['?/3W>W7DW'HS/^L?]O^Z]VG_][CE_@J^?R^_!NY.+TR_!R8?>Q=G%
M\.=GGS\.QOUGP6C\Y:S_\[,D3J.]111?+\JC\RQ?ALFSXV!W!][O16D9Y<?O
M3@>_J(=OXUFY./K3_NLX?1:$27R=P@#1O'Q&TURJQY9A?AVG>V6V.CI8E6\#
M^3S)RC);\E?S+"WWBOC?T=&A^3P/EW&R.1K'RZ@(SJ/;8)@M0YBI>S;X</[S
MLQP7^>SXW<EQ_]LBGL1E !L.WCT_.7[W_!)W7+> PQ??<053 @DMH=O_<-;O
M!B>#B_''_K![V;\:#WJC3C X[^W?M:8?'V=)G[O#8?=\'(PO@LNK8>]C=]0/
M>A>?/EV<PQHN>G]Y4E#)89VOEY,H#[)Y,%J$>50<!7_[8SHI5F^K?_X]V+*V
M1\"C5K&>_#.:ED&9!>'LG^NB7 (LV[2* *]5]^0, -@_.QM==GN#\P\_/SMX
M1I\ONZ>GZO/GP>GXX\_/#@\.?G@6G%P,3_M#^EZVP-_LP=4[ZUZ.^D?J'UM7
MZF^K<MAX/VF)PV/YQZE:R.O#'P 9GH]/S2^_R-L,-[-D]: [P*L_J>_ACZ$U
ME=K2*KR.]B9Y%'[=B],BGD5'X4T6SX*';>G86QP<,GQGSCYP#S^H/7WY"DG0
MT>'^P4&T?!N4T;<2%C8#4!WMJ2\?@B;'G\,\#],R.,_VMV KHHD-/@_*Q_;#
M6YX+SB\^ _GP</,"_H[3, D&1;&.@M.PC+;=G$[PXN#%MJ6:TX2_$*^/Z\GU
M=R$!Q]WH.HG"X"3.QHLH#U?1NHRG!=#&=+K?"<+@-$K"6Z &P33+5UD>EG&6
M!JUR$05__,/AJY_> BWK9<M5F&Z08N%W?WK;[@0P5C39!-,H+^-Y#%.6B[#L
MP%+RX#K+9D&8SG9W;L)D'4X2')N0DT?O!#AZ'DVC&' )'@R*]7P>3^,HG6Z0
M.MTNXNDBP#7)+.'T:YK=)M'L.IIUMA$MF#TN"QC[.B[@<D:PCJ( SEAX._J8
M); :9T-Q$0"6QF6"4UC4"-^#H99%4$0E[J]<!),HR6X[^.MJG4\781$%\SQ;
MXK.[.P*M8+TB8@9_E( [L*TMZRZ('N-#TVRYA ,HRFSZM1/\SP'<F8/#8!7F
M 0(S"E9 P.GIZAGA>R-\S]D7C(D/JE6UHA!@6ZSQ#QP&44 /HBX;L0<S"IU1
MF"36:T6'-UO_:F&M( CQC(/H6Y1/8P#4*H^G]C:B?ZT!/  IO5>SP[ 09@ '
MR0 &[*9#P;_AUU6>W0!>S8(8M@X'!MC%('U#J!,+KNE5]M4J+G$5]BK7*X3Z
M.L\CH%8Y0PU00FT+YKR4HZ83UK .6G$Z3=:S.+T.$+[R0F&_$3@OQ$A%:,71
M-_@YO88S*.&=8H[SYH"\JR2<1LC_:!/9W-N$3%&!\4; DM8!"Z:'L<,YH#*-
M-@,J)L-[F.22N]T=I'<.1GF78YXE<!MP_WQ-<'ZX[[,83P-D#&+ACR9Z'1_N
MOQL< Q6;QRG/^.[YX'@_> ^[A<NYR@J^5_9I=FK7#3@'*+X(;R)&;?/[,@I3
M^/OQ]](*V^8<ND 3D]@!/JVDH*.^C/("SG06 QTMDPU1OE1_ OB7.:P?\&RR
MZ>B/N!EX<$TH+I1&?@MNXW(!Q&!WAVEC!Z\7W7<Y5;B/ZX+Q5DZX*'-$9!YM
MN 8R_^K@M7Q$ ,.%7.=P)K#'[A2 /EF7@(:P.F02118D&=X9F44M@T\!/\7I
M.MK? O'OPQY;D[9%Q?"BPOT$-*H '7=T!2@&.QZ5<"J%O3^$2%]N<V &>8+E
M3RV,Z259@4<\"I,*A>-=,(,&_-G=*7CU&SP!N!^(4T@3^&XD85$B49HI>DU'
M1M1?O0:H@T_"-.DT7@&Y&,/C./NG,/_*G-)]@S *B!MP4$++X"3),E1(KH.S
M_4N013) NGC.+S4..P'6GA)US58H3Q!E(_Y2(N6>!8MLG1?!)"QB/I99!A!+
MLW)W9Q:A*("OU&V1-I[6[SZ;>YN'KV%[L(A71P<'P>7^)U@^GLJ7+/\:]/ )
M)+KWV#%N&*?4(\>TV"")F>GA+ ( W&>0D@0%8"D,\BDV@L-E,)AY94DPV]V1
ML\JC)+I!;N8=]+_6&2T0] 9SVNZJ>(!W[R] I57VAP5<AKUB!;SJ"*0S$"U!
M5;GK@>PFRO=@J+UIMD;UZ=US?.-8_I(%!W7K]6%Y,>X)3A3!ASP#:0LEVJ"%
M^!T4,5R7,(>=Y]= N__-4BW^=$U")ISF-(H(1G"(*#+.URF)#W09>![\E>!1
MM/>#@8A1E2L63,,43VR"_TJFZR14!Q<ZER5$(0Y$;W@@YPT1XFZ4@ 9O1-<9
MC@VX*_)5W7057"2Y!;Z@,9E\3H!]T9AAG"N8LO@(0%RN2Y"X@ S/(B3M<<KP
MM(5$O#?XF5F!V7SMS\P:4I+S4>"]SJ.(Q:GZ)?@;L"[>21;F,WS@E!A9EA>^
M^,K[ T9$AT::!LP (OD_U[-K%)E@XYG96?T2]H-Q[61(*7]\J]]FI%$0A>N1
M$L+0UO [.D\D_I,"9;59M"2>2("(\CP#P'65T.R,69A!PQ6(L(!D<'9P(D;8
M92K-:@ P>11R4]1+Z'.Q2N)2/NSN !^?J,5J"B 7@ 7+D# [F &X$>$7-&T2
M3UDU$Z3%)X"BQMGL";C6S.):3:2^E@,K^J?YUWT((%X1UBD%E6QA'*\X/ ;K
M5$0W8PE'J*)%@CL\2D=8)@Y68QOHF-/%)\[#8A;^*_B09!-XC+>VO\VZ]IU
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MX.RLUZDC*MK:@=(86P!SH3.YECUMC.FP!2H5P:TH\%16*Y"62M9(684,@8P
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MR1IK(F"WWE3(*404O?-LX\TF(""%2@[?W0$>LXI8Q?+70U3<,EXMF+,Y;QA
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MC @G7M'3"(2ZN,S@I,FX:^BN9GZGXYZM]@#XLO7U@J:1MX//,-PL#V^!Y+"
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MZ)JPW4)D9JO<C'-SB O,E(6^:6691Q)('Q%UT*B)KH>+*:VQ@8&B$P.5D4!
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M&X-/H6V%SE_18;OXC IJ:TBWUYG^XN7U<9R0V%0/;^1A%/U#!B(WVHM"Q:G
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M P3.^[PL_(E@"[_0W_C>&$YLU.4'X-EQ_]/E&2S[5.T>GH6A>U>CD7P'8[8
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MZ@@05@7S:9!;1UYB]KG;??$][7__/<:^P]]J[?O3_SMKWX,YH'R%+.WH</^
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MT^295&Q7\%T@$,T;Q'\!4$L#!!0    ( /"#EE<7VC@00 @  $AL   8
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M,X5<K"]=-S >882&M%F4VQB]J &WTK!^[WN_^Q$<%RY\F'@0L:9+'P/:HD%
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M"*PB[:JGSSY\%KORJ1')JRO]7SV=/-),7#O/75FYQBL& JO:E3&25C>:?%R
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M?=<EO1#&H3Y-PZXZU^ TE+< ]-!W150YF93N[])/($>0F?,.GT>0LTSIK\Z
M;^*P6MNOUH[X[[]\BISL13QATR:N HF@23K4_=K!X<%IP<WRHH.SH_WCPVIZ
M$?PKR(ZT&5#R8X]Y(7-@L.359\Y43B\A='9&CQT \>6+AOBY 'Y*Z3IZ;\*
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M2,.5V-LF,I;B1II)*,_B()NS-O]_\UWW4+E?!_V[QL4[=Y_9!)BPF .3]&T
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MDT03*[>4_!R L"</CHF(!A7 CM5R%D8_2<?PATX8V2U*YV.LK>@'D>[VS1!
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M-IAU/ZJ@&<EE?&9)\+*J6YNO3'TNMAUL#A-HMCG&Y<=G\NHS)Y\3T+BC)I5
M;8!9_OXEIXB5Q3_^NH/\L".*@!X7/Z.:^XR<-^M/+>!J?F<Q\UK%\)R0!@/6
MQ)VOU9/=P],J_']FB\/D6O:7E.^W27(;T,X;M$NTDAG,&LS.!;,'NY5:86 A
M>B(#/+&A"LW!BPGQLJ](S,,\C_(C]@P^#3[G@L_#W;/CT]VCD]-9,9H;< K
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M.-]2E:O=:(Z0NAT&*T%Y'.Y=?!=+VG=-3/B*BI:ZXY/")'36D0R20AE;&V1
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MGQY*GK3++*(()$T>!OT?@T_&;>;DHS#]K"5K$&?W'?$6U^ZXBJ2EO;;LT$>
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MTATAKA JU2B-%W6PR,XTUU;2T<F634YD%X'8*WCG(@_$"/(G%;AE/;845X%
MV>Q9P4J":=J'=(#G0:!+5Q1R02+[()U48W\Q(%V8 \0+!(N9?+E#S8TQ'<3L
M_OT74QM6XLJ&8L.MC:)&0H:L6RIW=<<90 K2/L&ZRB0/)Z@&<2:1F<M$,!2'
MY!5%:/L=10-30#(R(HU9O?$0 G%5V=(_'@BKP<FA0Z%YF4RWA9)\?>?1KX*O
M=X)6 %MB;1L#U/O1NF0U#2IXW-UY':(\<F1GYU:1UM.6V?"\4S\W#[*>+7^*
M/1!>D>,6/VO2 )CW ']!\C-(Z<$$^UX[!$H:$:)J6)\=X H7VQ&S1C38@M,J
M7OCK']YR+Q^,O-5?PP7X8E%(GZ:58$G5$ZP9Q41-ZF$P7CB'L'K3!.9DA1F+
M/G:0?L1#N H0M%7"76A12A6O%N4C/I$H-VAF):L'W\D3<^J#<K <,,?KQL?$
MJ%5D8C4W($2[F+ <FP>/8M2ILZB!H-#UH7;1<FSE^;"+<@=LRV;08U,0Q'!/
M8.QH:NCQZ1#"-)E?0#H^P4W<;*[">B<Z_TVS!31+RBK,\AY;H.7(XE-7&],C
M5ITA#H_C$\J# 2V& 91^D.=Y_80)Z,->J)C,724F 15**UAJ$TX';!M<E:QL
MW,+_XYB7\QO'T>#%'K<@[VONX,^-W2(#A%K'+/J<MJ6,6&P.Z%.L?W[]SLO_
M*/=$U-I,%0@N[#%XSK"96L<T[;GOOGEEB[ >:ID6@-_]:!V) =K&1H^L/IS3
M*$LNLCH(_;!(>E9EXFJE''*<R<F[8E':W6BY<V%;%@82(]FJ%E_:5.,POTO!
MP>I0B/3"PT9BFG_02H;WK[+'$ @*'TE:D&0'(Z=7>64?TNT./SOU1]XI<@K
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M.-^")B&*#,#)#_=FA+80]%G0]AF06@+TYC>.1K%AM]3@$R+TVTWP*,_*ZWF
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M)(8/?,'\Y=4<E'#XVK^^?]/S^']]TM]^AV37)Z.#)9!;[MAB>NT<X8J; R3
MC2QEC\Z'B68L&+= *C(*PMEH!L ;+'H1)BLE.DOEJ>G<MA4R5@B<U$>.*?QI
M[&9*U25K,S1(0))?@!^6<$\ANUC6U$*0(P2,IV^=@Q297&'C."PO\3H];51
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M")3)N"IMQM8Q@CH--)CCG4POZ./6#Z6\ MHYA/X&IT>')]/>^P]-(I7Z!&^
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M H:?&8I^G]3%Y LP;WUI3![]O<D-OQ=S$R1U\:+V;9*P0)Z_JD +UW7&UZ#
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M_BT1-?FIX+ /[T+7IN&J-ODB*RK0+/G]ZV\:]TB?-WFNG\9C-_8NB!S:KKC
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M-;9QC8\2X7"\-2#% ;D1AW8C4]@LX+!9 #+T3+XE@RZ"\ (B!JERC>!#C'4
M$I8S<NYE:;+(5_-ZXJA$X6BTVEQ;_1#IAH;R8#F,FYE6GQU18/3D$B,_]3]P
MRC[K)L5*@(2E\%TZ,TE8_;0&G6-\[:5S/GV[LZEV.N&&S']?+M.UG(%7N#_4
M@=P_=JK9]M>:G2RYR, \P]T& K.*X<P[R=Q)YI=+9B" REFKT+? <EK"]%J%
MR#R'0 R"+'RA:!4[ %3C#IV<?$_J!^WW_&=I];B)^-B_6J3OO.3];8 /8!R/
M_? \0.3=3>W[6^/QX)2KZ^ I':/B6("5G@XTSAM:>*XTY?0MAR16FA,.HA+
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MHN.0?QX033C-[#@W7'<1.2QA8]34U:Q-I!N,M*V8Y^6$S876+5H;P9X<S<:
M<W<-8HSXQ-$W8&Y+KE+)FSP!;G!U!6P94E915]&FZ^ZY$D'_&D6VCH#ZMZH*
M5WF@(JR-/39&(#!<+C&7BT3;TO2_/\Z@.J" F%%ZD7U@J<_'7+UV!][4CQJ
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MG>!:*$/( WO%I$'+  <WX#I?)30/%1J;JELB)ZZ% #9/>[^8PG/UV3'!AEB
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M'4T*#:Y$STKZ.>PX,,"3[K&8ML"^.C]!;5?K_00// QN_I3IM%P)$&"A>)G
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MP$;S3!1<*Y'E.##V\O1$&YD-#7L=1:.-F,D>[K_FI8A_I] 5\<4F#I(CG[T
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MJE!L:\6=Y1Z&A3MM:PQSWF]C$VXO>:T8Y[MCT6X,0D/]M!Z1Q]A.^K%?5-8
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MWZ(<RV;_-G;O!X2&I[F^KV,@'GFU^?R[W\B_\Q%QX4W\"*_D.<LV2J'O#;&
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M8<\#;JONNVZ!Q_<0U9WCA)];F!^8OPBF5Q)QN9XZ\9U0'C"N0RN2C;G\=O_
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M"HB)WH- R='[UX<'H*YRX>ZMXA,<8B<BZD5K,5!,MQN3=T2.<<SOCL:<U-
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MV!EAI]+U3;,^TYB47'TL25Y9$'T\7D+1]W?10.FK%_*5Q9U02\9;O8J[NM,
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MJP(>B]#) 3P;51';J6%!'261!=5G6J73*/'HSSAGL6;,U*2$HFHX(/K6'KW
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MCY\\U6N4FNC@?0@#:I_KGTFFW%.K "G4XCOQ+[JO5FJ-%2*=K!8R_S%VX;G
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M69YB7YTW61'LI:?Q'/7*/2U$PSRX;,X&E-[TVPW UO?D:W4Y](-+LVC<#(N
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M[SML0) 4O"S0>U#TP V(8)ZD<*'K)X'O53!RPCL-7X+C@.FRS0@TB=_'PYC
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MD1'9?=UV4RHE;&1./( N*(@]$157TG)<>=<K.M^HZ.S!!<S25?!J$/QWE:1
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M5%E=*TT7D)IRW1C;B(<5BGGBR_X -E;ZA@.(8'3J"J*:)=C651(3C$+ASJ_
MQ,&@%&8F+G;1=4"IH*.-0P>$M"6^H\2BPN7C) QE-"W)9&K"0*C"BH/2$92,
MWG:[C8=8M&?.W>&?P/63Z/!,A!06"IJ%@O(3&*Y5FACW@I76T018L1O%9'/
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M@#KHO3!0/12]VC5ZK85>[1J]'H)>G1J]UD*OSLM&KZ,;ZAS+0'@(KJWEC09
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MQ$03/P9<F[GYU>JE? R\R94(K^UT=7\X0$/^W+D#(LLL6R4:\L(]3!>;W/G
MDL;6F+QE4<,Z$R'FB&'>R:$\%Y,#.(J48+>?@:,)Z]@)O< DIKB(Z;B* N(H
MO""+D<G(X'3I@!H[DL6$.-TB#*Z<*XT%0/ZNN*&DF++EGU_\RW+0;EV3CZ;9
M(GQBR#5%&;=DZJ:7@?N#D;M(YV9.NJA>3,H9[X]WS"D?P1CITXD D!%+GP$'
MQH,5%NS&G;L18<.8=NHL -HWF!T%8R*D=*HS3)?X$O:3)7F#NUF[8537;GC9
MM1OZSU])/$[F)$=O5#H>,2Q0^0":(#OB)/2M U4<X>)<)M2]MI# #;T1M:,;
M=Z*Y7C)7?&2<3I F1=++Q+:-/,8Y2+V$$Q.1Z[G!Q$[9H_H"UN12< J^QM(Z
MU9T$,IPK$=\*X9.VF.&^L<G7<HF3Q;GUT%<" .[+"^CR=8+@!RD[!Q%J=4#!
M ,G4?*T4UI(EK#%BG4/]]F#P_*EG60YU+F%:X[X/4AX$8  6P0$8"=%KE4?,
MSG#$&2>9N%3E1%=N  $=RY3=Y=G*SS+M],AWO+O(Y71CG]09TLK.&$"\<832
MF7-G_2G"*(E,)4QF!U5+</)4/'(C/[TMR9?>4&[TK2"U![6@E$>FR=*<12PU
M9,D20B&MFYF[B#1/<PW@+=8$'K,+RDIN+(/A<!,P+*;6T;_?N"!:W''N.6$*
MF#M!2#MZD_C A#S7%R"6*IVOQ)?QL>/?62"1+)VJ)_^SL2SE]77.,IQ'U0HX
MESN_MJ)P_,^?KGNM87LTO&ZV_AYT&O]97".[B__YTZ>O'[^B+H9*+FN+.ZGL
MMIJULENB[&[K#)Z,TKZ M#IE:;64T#;.C2\S+!*,Y<4,_6H+#[" A&1UU0=Z
MY(1"5]1(16Z! SX_!C'J)H/!$@:Q19@?>5Y.Q*# 0CL=I8=%6$.B9J7TDQ8#
MB*1#%DF'ADB21H22CC/AD%"\=6%ZK*MR93H6KLA=$(0+Q%TV-4!?DKJ^Z\,;
M* A :E)E(A>0^CHR5GHAQF!AQ"YL%) ;G<'XZ\EW]E7A;[9U.Q/D3*8:)<QN
M\$5G&LM!R&4#;PAT9@!1N"'(7G0QHE5#O]U9U\(7H>,9BT4(>C!+XG (&;XE
M"XO@*FU+?!\+X.&R*@I@""J+H"O@T.0-1(0V-A_QY^8)F=!H[+8 :=4"Y D%
MR#IZN^5.8)/?F2_]3ZL#2NW)\;_.3R__;7W]Z\O)^<5OIV?6UP_6\<GYY='I
M%^O=R9>3#Z?'IT>?Y'/KZ,M[Z_/1EZ./)Y]/OES2G^<GGXXN3]Y;%Y=?C__X
M[>LGL%[AE<M+?/UI98JTHP7;5'&&L.P<57X#QD;4!LHULH9H#*:G ^8955W"
M^Z!%<@5R5W$@F^T'R2;48%? (X"NT:"#X8 O@G*O6!?(X3D0-%_:L1M6.168
M)%OL6>C *MY42['^R[RS[;U:=F,O2]JL]CF09.I7C]$J':-DYJUZ*]8\@X*W
M@KP&$MTF;@B(&831KZM=!C5VU=AU/^S"DK?&72/\3*4A:V2KD6TSR :J<8&3
MD6I>Q#FCX-_2"K8U"M8H>&]^MP $0VT1=$(N*8G6X!250(XRH,>H#<X"O#(S
MU4BR;94^"(8>:80<&" <MCS!QNYAX$R)BG@_3__FU&=9%A9T8C?&X'QIZ%_,
M'-!UK7?FAK["AG0%3MA\&J$CKQHQKJ9O8VWB9G-@13Q$F3I<C% H5XV7^K<W
M H)W91H\[$W7)2TM4TL._02CZ"BZ2-\B:&\_V%7L6.# B,BZ"6(9NY;>=EJ+
MX!;0(F]8%#'CHAJ247+U'_6=O'"@0!"*7TG"D$.%@(F&8S<B1H:W3<:?.#OL
ML-^T)N2(J[12:,2 6 UZXH)<A8$"ZI-G)^: %Z 9"Z^@U56)6NI4NF]D=?RR
MXOCP-5JOU%' -+%HEW+HJR0F/],CAB.?$SF->,R&]3[1]6UAV\"=(O+_N',W
M5F?M2X]42-XHO/V:BC#45180+/+AN_Q#VR /=M[><?Z+<;84@G.%UT1<UE9%
M*I9:G6#V2JOW2H ]W$"7&#JCD+QP7[<N  2 )":V<2I2QB+QNQR@!M@024N:
MYH\"^)?$7L;H&YFK4XZ]4I!3T$ UVE9BR]PV47H,WR0^AG0MP@!6#/_PG%MB
MOQBME-[WEV_7!?0<.\:-&N^+ &1;(&IA>;(G RNX!<C*Z"9 HY"30A=W\ _@
MFZ&S$*"6C&$MI_ZX 332;EG',!YB%VPR%"*VK7>)RTC?[MC61>+&PFHU>[;U
ME^,!_L)>/Q]9S7:W5V1T.U6-=Z2+\0[ZCZG%VWY(+=[!MDKFWFO@;238#!J]
M'U<TM__D95I9RO&23/[ OQ"3>'05UQ]V0F4]OU8!Y OP) ZQ9$Z%#"C/H1X(
MD6=5G_=+@NK&$]4D?E8[/]/:R'.L3SQZ_JG0HP=<JV=.0,%]Q5LK[N9[KUBO
MX3#+Z$WN9GV]);R0),1GL^9M"(31LTF)74T9)TKK=Z(H&+-_@[1Y+!W T8T?
M$@SI_>SX !>T6/]Q%5J_O/WTZ=@Z:+W>EW3\CCUL=>Q1<V.%"7<<'JUFXW&=
M=%]M6>O:"[E437V?SRVBL \ &DQG>FT=M/>(V :=KCUL[VBOYFT0V^.J CT!
ML>T,39$ZO:#+HD^8*'HQ=C&."B58A YX%&>V]2F>-"QJP[H?)-6V^\V^W1_\
MB'(*SQ$>@\;CB@;6XNLQXNM/X8?HX?U-H(^3_*;'S@(-)58>SYPP)L\JM53<
M%PKL#-KVH/4X3KX_%-A__@KD[A/:^>5?UJF^2XQ KIU95,5D7VBJW0&:ZC=K
MFI(T54NUK1/;>R$6UF4(V[#>N4$LQC.?^X*6*)#]O2&UECWJU:1FU&JM3;*-
M413=^D^"5 M4I(32:K!')#2D<N6U!JA(Z''>U!4D9$1'%&E!YOOT\4G)(HS'
MZ=5?]_ZOUD+T1]ZX?:%XG1,='/Q5!P?[$^N]BB"N+^)V8<TO74;^'O@.Q0:K
M4FS6P7!O)&.G.;#[W5XM%PD:_V=3RZFE3Q4QP6)# 19;PU)5$/>%E)Y'S?3G
M")GG3E:[0SWNW#(JA=:44U-.+9 >1U)'?CP+_#OK8\-2Q5P;[ZSC6>.=;9W-
M&N\;UL%H;[2]?M_N]#?6L6S'@?'<:6MG2.B3B#Q76%3[6!+-OA!,+9EVE7IV
M7S*=)U$D/,_ZO6$=!]^M@U9S;^10KVLWF\.:DG:"DG:&8)1OX:^&=>1=41!3
M:X_BX =VJU/K;KM!,[LO?3XY28A*72R\_XH0*&E_@MS;]F!0$])N$-+.T,N1
MYV*MBT_.;0S_.6CM3P![KVD/:F5M1^AE]P7/&9;VL7YSPEL7Z>CU06M_(M$[
M]K WLKMU+F.:7O4X05S'\AGEPN _D?6'&PG/^<:4LS_QYC7E[![E[+XL^NR.
M9X[PK-\$U@"CRH.?Z4JHM3_AY=V>W6O6L>6[H=[M#.4<.W,1@B%TF82Q)VSK
M_=G,]8!N]BFFO-EN@T2J/0G2J])XG(U8"Z2UO R>JAM:6GK9GYCUF74A9L[M
M/6@U55W)UT"*^Q/$VK-;K8'=[=1."LF:NIO.1H1QB@6/L:'5H4S"&#:,PI?E
M=3#;NK*V+M6V^)ZKTR8+5;>,@MA[4^5[G2:<&?W#?+))SG2/"LS%,MSGJLUF
M5-E>A9J44\1\X.N2OOO6;;K5KOLGE?1/>CFD2B76GCFQOE,EX+'"<XC]"">L
M)%!5^(OQ3$P2.*M6Y_TO1]A*B>L\5Q>8X\I7L@:]?DTWJ891*ZJ3Z[+L%R?'
M#<O@(6D1ZFQM;>'EEF(4+,%548)J?B'6J5J*O>3+T].*C_77!*+2 58VXCL.
M#KGJ@^JVAU/%P35WO,O5[SO-371ZRL6_"TNC<TCW!A./9X L=R6M^UC]\^XJ
M:GCK,1O&O)$(;ZB$A5G]?DZG'EJZ_[$L&Y['#MQ"=BE.03+H$NY<:SQ*FP3"
M+^JLETS2P)K>NN7?@FO4X+OI>VZT#&\_GI6C+CQ08&U81Q%O&BN"SPF+H^P<
M'\]L*W,]@7O/NEVSD"@6+*\$Q,KC0@@8E88S.V\WF]8[)Z1U :^TWH=@%JB2
MYMUFT[;^@F,%$O.C63 # A,8J'EDM4;=]K#N??Z6*OCM,"\O;2**Z".+%98V
M\>BJ)A[W8,>RYJ%U(;"#NG46A/$4%/@@>F.=P:=S8(4)@2E*G]E+/\L6\BC[
MZ&ARXT: U+)7PY^GIV^*#[/#<"$0_=)G()\_1>C3?K#TOW49)E'\QEP8C?TQ
M#&Z!0ZMVU_<>9OGWN:<(8<!O%+IG0>#9+ P>/-D??9J/&$4DK*EFSM@=)<'#
M10'&7)T.DR4%]SR1_XZ2*R GUPDE:Y;X ZSQRKUV7,\Z:UB_!S,?(QU<]"ZH
M5&Z66\<S9$H.\T7^P1738AIX9NC/*:?%3]3P3!:V;-&"++FX!INV1.TR0C$)
M )H.\$/FM+:E)2&U'0D#S-R-$8;P#'M%J-8?LGO&F!$^I0"Y0AN(3=('OM8=
MO5)+E1]RHPUS2Y>%?<AN170<V(&#M &] II3%J?FMAZDGE-C#.S9D7F!0M('
MO^JF']>A8!G'37A9-\!)EF^0NO]>T2:JF^C,G?\$(>(:OK42:( F- 8B]9V=
MPAPLE#!K(9:N2"&-]&LAIS,:E:S8O6U*["(>9>6R;30L3FMT:4JBQL53%(Y-
MZDN*O!4.80S<.@P\C_MCXW'FFZMD$,"0U7$51:+H[O9 3L_GB ^J+4D0Q735
MA-U'VJUF+:#?4CW0/130:Y=$U:JK\04^3$V6#8GXW/@%7,X]1Q3NM4!U!B%@
MG7D@_VVKU40KQPM0+""\_AV$W^!?_X8'S6:GQN:W5%MS_["YNK:HI<N*GJ*-
M:YC??_YV?(8_5N"QU6K?'X75F+;^EZ7-<F+TOW&O,[4:PS T/L@X ];9VLE'
M&*L!VDEFL)./J8%)/QA6:>GTG_7$V.EK)EM\E=B^>JU*<-*+RFPW7S@.BG/3
M:O-3&ZM=:_:3CPVP-1L@L4 F_A',:"E?W+D;S; KWDSK9U)<&S*:YR/8RID+
MK,9P"$15'=$B:V"]"^]0[X.# #;3[H23*N;3JFU=8#Z]O60^Y057)7+GGE4R
MF\[]F4UNZ (2YYXCQG:;+"*/;H2?@+PD;+4&)?C:K?'U+57RW$-\O4\Q4XG&
MZ2?+U;X'H'$Z-'!T!Q9I_1$&KJ^D0(9_\XSI^SF,EUT_-9^^4Q[*CV#>^+=H
MGBK,-WBU?FA;QY=6LS_LU'8/(/]@AY!_3<1?6G-48GKAG8W;.849&B4+@Q5)
M BBY& &#O_A%\3:DI.^TV7YUR7I4].D?H0-G]E\:^SR 78/V!AJ9=11_<\G'
MH;0L?7NQ4#JIVGU^5[)U.[89SNQMXD;C4-"1Y9T;K(4I3T^.YBLG67;8* J[
M7?AA0JE3FBGTJLW'=KMF"F^I_. S9PH&(1ZXKT&Y:?>ZJTCR<]A@>M:%%A&#
M#ESW-?^LVE*;_;'Q=K+3;-J=4:MJ^'5;:.]=A$JGCE!YV1$JHYWC$]WA:*6F
MJK@$E>M:DT5PX:LM<H@7@U-4A6:WD*H];*XM>K#2SGHHU>O8@_:P1JD-H-0.
M1-+E4*K3!7ZR$JLN0#LFW*%KY$?%;1FZT17=;J^'I%3JHL;1#>#H#D0(&3A:
MX\.V\6$'+J37P >N[5$CQ 808@?N=/-"3'76SONBRL)\XYD3EXJN%?+*B)1=
M+:XX%[E&QPV@XP[<\OT(=%1QVC4^/C$^[L MWAKRLD:(C2'$#MQLY9W8W3Z<
M?J7Z7'!0<>V#=2VU00]X7XU:FT"MW;L?Z=J]4<]N=BM5\35]4NVVW1EM$XEV
M\R:D6]^$E-R$;.T,Z)G1NZ_D4"QW IO\WFL-VZ/A_[2Z/[T]/CF_/#K]8IV?
M?#JZ//WZY>*WT[,+Z^C+>_[EY+UU>7[TY>+HF!Y:U5C4:C]^"S^]/8KH,AQK
ML%-ZA)&7>0X:)"9-8.3G'0;!^)$S)H*440J8UZ<2&# BB%)@CWP_P7#1,/A^
M9X.:Z@6WUBTJK]$X=*_X C\VQD)]EAV&\-:M"$&0T+W^G16YF*3QNP/CA7>2
M<HEP6Y@N(S_"X1R9(.C?!-Z-P!O_L1 8A8$/,4N?8WE^;K6;=A-D#S*9EDYO
M<8!) J:K3<0!Q3? 1YA*%*].A;T33G@H_(G*A)T&H<S5<?%?MP'F?RP\@:"<
M JAA=/R$XT?T/G!J7=+$+BEZ8E-^ALB\)7\I>UF]9?F8+R1DWHE*OH&]S@.*
MIH"]]5ZIO9M<U,9\(D[@T2&ID3)%0O%WXH;:&$$,\@+$H$421@E&J<*#TUC,
MK6ZS2^&!XCKQ.$9F)4 O#O^P%3!G#N;9EJ1PS0$U0TPX=2F%"#/&<J22DD%_
M5<F.9HYK[X<2T7NUK.8*O=)90\\@8N]7C]$J':-DYJTJ*&N>04%!^>I;GQW)
M77K$7=HV<J)<9MH"4SXH= A.@/Y7I:-1_-#O@2\BX)"4P'?J1[$;4VJ70^EI
M-RZFNM#E")!0;BC,NT/*@ ]IIE!<NQ'/K=!^.@54A^>45 U?P=S7#B>J=3M-
MNY71U?-TC#P,UI]<>>X8R7,\<R)B3F,:X.=NL]&D>DD\!K&)E20*2MTAYGD)
MS?5NG1"8>DSL7,^2+/#/_JAK#T?M1ZRQ,VJ,1K3&AZ^,#PH^UO%@Z?@(@G8O
M!0+&?;G1LJ.0["XPL&?$V-.PS@P>&.,XZBL;WT?1@%_C*!,XQ3=52FC-R0QS
M:"4GZZW!R=S&L[>7WCG?  G?A21XHVRRG$R[00+M]P<J"4<5W<B4U.!A,N4T
M-%U-K':O97=Z+1JI/0+:'&Z,XK,:A RK!,T$$V51,<KPKR*E.XL%Z(TN"G?O
M#A2V5J/-YP[0\X"?_EH3RY,1RPY0RQ&L /.["ZD$-C%ZCLIW0"?V7+)D2 1<
M)#>AB&/'SE $6P;;((.'X#T(I!S>DUBN<?^I<'\'D/]$)0?F$?P+H*,S<SS'
M0/!6IVTW!ZWG@N"]1B>#WY6>N!JW:W/NWN8<()]T%_65OZAHT;%R'[)/@ER&
MD6'5'124J?/S(ZU*Z<(AAIYE9WP?J7/*>(426$@J>>PZ&0.X'!<SBB+'$Z5+
MRJ>G+#&BS'MD<]:2O<B)D"8N=&VN-('[7[ILB-X[JF^>%]Q2-1+R_V"EK>)L
M!&K<9P#&W#4Q)2PMXN(%4>D^HQA>(IC#'Q^P!,D:#J*.=A!I)Q5Q&. WR'_0
M+V9;X^"&C;5EFZ[8;.'DO"C@DC7XA,X&]\4&+OKXJ-+*+8P9"U]9LLKNBW"5
M5QZ>$<P_@>-#2Q/(1/@3)R1OH&U=);'E!X9;+IX!,JX8E_*;:#&9X=&/BVY,
M*NLBX&W$'<S%0N@'Z$($0+A79O49-UP*)AMK)OU'X2 @HSMUI:>5[V@0W/[$
M99<N+LMSYVY,1RS3J#1T&9A<\ @6.TXBH'TGO$/GGIC[,/*844.B$ T)6X()
M?.EPEE21HE%$TR?C..>#S!PKKT,2EO3^FH><%#'! IZ!]98 J? ^ =/\QA1R
MD2RD+0^'Y[F<)A>, 5QJX)1<Q W>?[W!"S!F2UBU:!FP&7-%CIAQ-82!5P)0
M(0J\[$Y1X:631C]P.87]:ERM;64-YU1EL]LU(&F,B/6&=*:Z?#,M]J@).0+$
M\8 L0GB%5JR7'%--P1AD N@\<>:H4OX*-.0%/I6&@,/0NI%M/7S'VNE-&R[A
ML(B. ="O@?/HZ0.(W 1>,B>: _$E2TH0%9:![5=\[\"]D?M%BL<\!'5=H+<\
MD<Z_''*O5*$V?GETZF-R)!&]+4]/LBY1O)3(5&VG.Q'A1XRAI&%RP0[S.LJY
M@A.1N"3Q)JVQ=FP,8*L+J<=?-YGPK;C3JN^>ZKNG[-U3H[Y[JHV5^QLKIT6=
M!HGW".D?I"6@>21Y*^K4493,)5]1Y@H6(#!T),#UE0A^!O;]9Q&"?%1H?K&X
M"X4AL<\<8$F8IZZ,(5-%+CPLU_<U=T^_H%+<?R? :D6(Z3].Y$;$KUPL8J N
MR8#<B;%,Y(*H-A)&$*%1A^45KD-GCA_SY0OQT'&,S'D<1%AVQJ>V(=(3LA(:
M<*+?#I.% @6/D=<?4074^F()=([T0U,PEYSBGD4;]>IHH[W-NQXMX]]/S#@1
MK _F:RC$-5-@_4I\1][$3I2?6Z.<JWT9)Y0Z(O[/@DF:K-B(U1_@;S]W\J-I
MWN7ZP 58"YD*P8']MZ#53!+!QF0$L)2W_.63([O_N=7/SP#OA\*=7P'7(KS3
MVUNV$62\,Q>K6>)!YIDGUL?D3TSNYJ2\C#B=708]W%+B+QQW0NO%/Y7D@E&3
MR"R76^21#3"H0M3[4$,T74YDR\'*)QH2J'=ISU$5R%"AA*,R8C_;?$W?*9=;
MLGZ/=LRAJAEC56/E ,<I"*_R0D(_^$J887W5<KF!7BUM)P&P)R+&^L[H*Z<B
MPKPYTP0BX:5V@YM5H]L@*=E&D:%WL"CV)DK[*$,G3$;X[S=8DL8= YGD022I
M11E0.-F:0WU-T))FQ9H*'E>N6L[14)/4OOY:?=Z,^OQ[ JHDF>B(;[K H29P
M%>LS(1KC<'(PNH'\"$>6<<B2NE#6Q=F_FTV.FZ!_M@NJ:90/>N *5&H04CKX
M!L(8[Q.HOL"Q<ZQ>O] NOM"POFYL/YUT/UV]#7AS#@P0>;F&(3(RQ8\+!<S-
MKB9+MU6U)7E>:GE7><[L:)DDO>X_M]L%T;W0-L',%3=:.$B']1A8+YQ*L-"+
M&7L@EE$ P@@"JY&+2/M0IFX8Q0@0="N;YLCC=IE%#U(#Y&K!#$I@^-2[GBZJ
MOA^M>>8V70Z_ YDS'S7#_(DD7=#>F 33W%1*8QT,[6Z[LAH9Q9;U>W:[WS%>
MD7T5CBQ0UZ>"=$U^'76M[^,9JD!$@.DG#];\M9/  5+^SJY9GH#N17#L9J/7
M'76[PR%NKU70Z0KJJ4Y/LMJ]@=WOM];9&L>VZEC3]JC5: Z-@-O\K.E9G)V>
MG0"G]^DGJ;ZV3?45[]$>?*V=SE-ZM9T^YK*^Y/1-NY1H9*BZ]R[Y_HGNOXF+
MNFK2U>KW,@) =7M=U3H,:)5@XV"C"[S0I"X>H/">"W0W@'ZBI4_4R"G>-7^O
M^?OV^'M&,R:^4LG;6WU@;(,B8WNWBK'UF]E, N)<V<3+P5+F55PH7KY6[.%A
M3*EBC&?,F(HGIXV# JRVR*X>[B8X=Z-O<#!T:T@3M'_]D,1)R-$H!# ).NR-
M^!W@C%N/$'#JQG <) # L9. )DWM! FJC'D ^8E -5YY&?1=L*EHW_-R?+B%
MY%#,A;YQQ:UM'6&DT@WV2@RM<\"I--YEFI$^C&)F%B;28;6CO[^)*WVT*Z\"
M0$!<3=IC?89^O D8G-3W4L4CA7)MLA1ZYIY]$<#QWZ5W1Z[ZR:8S7'9O#/_4
M-\?4EM.3_(PZO4]T+[;2MI.K[Y:I-95_E^^DY<[G8L+A8]Q+B]*M^-6*4'+9
MXI+#?8!N RI*S3?6MHQ&B?&'.<)KDO, ..E%<C4@>:(DC3&A^S_")%Z=1B;>
MJ@.<,*:.8SBEH)MT)_V;;N;HMAP;GO F,>QJ(>!_J#"V.G&9"TS!2Y9+[3==
M/Q=D5S8C;E*NC_B=N1?T==/&049- 1=BGEY=HF-T%N.(<L3* C@(9Q5RB-,F
M40&4!9!QIE<6QVP#>22&W0O!UL$O!'@..=RPB%P:^8P8I6B=T))(QY+0V?[X
M6!);]]B3I1X8T<M0 X<,)1<$%$"-3PI5$Y4;%L85T1_D'<=O,/200D]]*481
M#X,(0QS+)J(5J1DDR7CB!O6!*2 )7YV/W7"<S*/8H4YDJ1>-XI2XUI+^2JHG
M!>K2NH<*X)1!8 0#K(0I9%14)@H)B0G)G"Z6,6 -R\M/0??EF#2.H:*'LB,1
M($RZ/@[V2WR#&P%[!8[-<4RI$S!R./1,1=3E-JS[$,;&'4J6$\DVA)$F4L46
MC,TTU#7P;MYB]^M;[.==,Z/WT]N+DT^?3K]\M"XNOQ[_\=O73V"];K\R!J4
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MEN/C>ZJ#EK4(;D7(T9>AB!9X)1T'.(H+1S%SX#<KF%(Y;(J4#\;?&M:_>%&
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MBKGE=(-54U;WX7T,L115MQRQE*HN>;HI:!0/HQ!YP[>;%Y3M^H*RY()R6V>
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MV7EX(81$VC^CEF;%SC>!'62PWTTNQE>J%$NS?"9B[%%3B]3)J23XR?&*$YF
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M.P.[V1D4F[,4R^&7 &]9+Q=0LY2_^VDN ]-J3'"2X]!E:SU*YC X#,-N@WF
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M++*-7OQ]<M6'2I$MOE]-9,G6>6Y7$E^SII/XMC:)[V0:$UPR]T&P)H6;)/?
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MA>@\HLWP,EX/QQX&SC/W*J4]3\D[SHCQ/ 9^C)XS,<3JD?4MM_=9B4G2#*I
M^+3Q^H%N@4=V[+CK6+!%.XY&$[_0=2UGD,QMQVR=P*%\1'4N7R3\?G/T4!!A
M8NY%^RS[U,[S8JYRA<83YG6/I]][Z,KO]2P'4TO];A30G,A,<J@_%HS)1-DI
MY,)L*@[GP[:ZE%@>I',DOGO4'8 P&4KT%6%-)%(FK9)X@RRJZH/#1-E34G,
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M_B'.[06X.U@JT$.%3F36/)&0"'TNE+"HW<<X%8X^0-<GMZIX&^M(]J"EG,_
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MG?ZXI!%17>L6EAE8G:^J$'H8#>$]'11.O+4:L79,,.5K8KK3CV&,K[=9UQF
M0?_'WN'>E]I!HU5+9+4\P?R(DF[YT2D'S7LP=3@N!Q:Z@)UN-XB9K<0)@,@(
M?<I';[Z0I9YS7!XL="/?<\ZQ&YIH7Y190XDU=$7#2\I*SG/"UKB>.8:AL?O&
MLYK5&W=Y?0$:T5']L%8_G'3IYMWD35H25;#3Z>I0.3M=X-JDS.,]-Z<^U6Z;
MBY<IEZ0$/EWN^0#6[Q9!BYROB&%?4S+>3>\*% ,/Q$\R:"V_V\-QOHV[!<9-
MNZT?C]^QJ\O3\^O[\\Z?=^?GW\ZO']3;5MO[4L_?LM^R]G]:JO#E=]?Q?GX*
MNWTVL. -QBO]'H$0^&,O='#@Q)[XK!_@!O!H^U(7.7@-;7)"_#:VZ&^*ZX'[
M3.0_6?>&$3P]?JB9!O[?QZQOQOB?,>_,_ZB^' ,%6#R0'U'ZMN&A%] 5GZ%?
M'>RK?==YLB+L%S+A[UUK./XG$:(Q#FNUSX;+,*ZZ+]+WTR?]8-BW//AJX[-!
M?B.'PH^?C-KP57S"TSWA>>Z1^6R\.+;_PK_RX@=VNBA]!][[^-.!K^%WPRCP
M?[)][NSA?U<]M,DVQB(66%/6_>G1$"9*:RUZ1H!KXM\%;K)_YVXQ@_O%/A>%
MW0P>=\L\3I$W(Q]Z,_*Q-[DF$@?"\G6OP+-F%+CYC#$_GY%W]!G_YS^Q'WT>
MNU'\PSG.EPO<24^;XV%PJ.CIN5Z<V_/X9>-WB9_[]7/^M9WS/Z_..\;7RYN'
M?Y[?=6[/OS]<GMZ;QN7UZ8'JK$R)<"S 6"\$<D&F[0X#^?+Z[/S_&0\WQNG-
M]?W-U>59Y^'\#".QG>O3R\Z5<?\ 'R ?OI\ \ESQDI$)]TR]UP6G5I=8]"S2
MBZ[ZL459U(RB);D%7O"$/,(%S@D;D3\M<AER.)$<I'Z$!Q!%5?PT'"CTB^ =
M8@N90^]]R=14*2](_SI6XV0<'Q\>'#;;]'<JG9A61FQPK"1;K1\=-.N-UMB7
MI_U(A1F976:*O@RJ^EI("+;I@LRU:X'9]&X=M.C+2D57">OD5H/+@?'#/_8:
MXQ=(+E ?1M11RQ[3!29L(!^C&2.112EB,19T:SVQ+)67 [B*+DB]-O<-R4)B
M+I&;$>L4\\HH0OOTT3M$!L)\7T2^I,)3Q ^SVM^[+X!:#)A__-2GD; VQ?P3
MNR1-.PQ+2F MD"7SWK6)U#CCBKZ)?]<69)\;\9+54")<TG>387-E9+@<9>QW
MR^"&Z"\]QY-:; ,'RE.2+-65IKF@=VDNZ"W/!>VDN: 7F.;YX?+,:#3;4Q),
M/_[^FU4-'8X9=)AS,U'N39;4BZRB2D\RO<8-N:*U%D71Q7YC$J#>?&)-D!M%
MD,TQ.?G5<BFC_;[/6!1J@EJ4H XU0>TV01V.$=1]IO)*)&Q1:SI-6HN15DN3
MUFZ35FLJ:6$25L#Z&&QZ9L:5'VH26YC$CC2)[3:)'4TGL73JJC+D*!19Y09/
MAM14MRC5'6NJVVVJ.YY.=5;8-RY<_T4+M(5)JZU):[=)JXUS+R(^\V5F0$#3
MUZ+T=5(-?<FF>)D\))=9P2?X2O_SP'J5MTY$WG,A?)4\&H<Z2Z(H2R))AS!N
M+HS._?WYP[W1.?W?[Y=WYV=&Y_K,N+KL?+V\NGRX/+_'OW__AMD4=S??C/O;
MO^_.C7PFB_'U;^,-F2XZ[6)=TRY:!_7V&],NV@?UUI%.N]!I%YN>=E&&[K4K
M.1?+[^DTL:633LO0:1G:2IK/2CK1:1EK958UF]IOL=,4V:RM0I9J0EV84'50
M>L<)M:XX&#7%;@#%5A3CUB[+9;@LOU]WOI]=8E77Z0U\=GW/?]+%7MKKJ+V.
MVNNHO8X[Z77\[LF>\J<^'C3D/\U1_956?:%ZYL%RQ@#>UP]%Q=<]&T9JR5=-
M^Q97_I+-I<>=-) :E-Q41)6ZUN2=M29U[7S8;=IJ3J0M7792&I7I&LD=I[+#
M.:E,5Z"40&TZ\K7CU-::E]K28A1XBL"/_K);ZFX7T.,X-1;MNJ)BE0]GK.=T
MG>BC+EMY*ZGJ6N<=)]6C>4E55["\G<IT3>:.4]FQ$F%^DZ=3$]W"1%=126:Y
M0>)Y.JRVIP4KV^7$*M^SOP)R+6 U\T6NET.C%_OU(O?_.""VKVVR@'\864&T
M]9V4U7M<,"3,H"EAF0%A-#,LI=E^4'@W-=+7&.D*S=9;3=.0_P#E2@VA21L4
MC67;AW4,2_VV(.'/P9]*0[U&=!&B52'0/&BTTX060?$'1\<%1"\^SHP'-B@C
M057=(K^[]^6!DG?(*0CB*JN$;;64V-Y+L_SF^IG&F25J6%N:)?C&$I;I>ER&
M+13,_GV;1KLR&#WP<;5??2NP$5)G3L"ZD1^$.4<IY3!/33V> V#M\B_HNR_C
M<G.3;H; 0/CP:@1\L7T^VYPH8>C#&MU".?Y:.C,0,A90Y6!H>2.DRZ[JTW@4
M>2(AY8G,NI=\[#<\%\:/H6,[(.#@#!_P%>C[;]0^G_+WT&_USQ]%!6EQ<V]:
M#0<MF6(&-.,SM9F=W6.8<7CZ2;S=I/'IF<"@ZX?BXS2"$19$*!C%)>BU^##Z
M4'OH0S7*:5MNXE!T-[9I.KAR+(]\31\P?Q@X VS8%>/2 QK4CM!28)D!0B^Y
MW"DX))0/ #DT:]KG!&'*>=?3OVX X$*:E6TY@3O"3=- <3FC'K9&$\!#OEZZ
MQ%#,GY) $DA?'-EA['*DXIU*$9M<L](1@X\"7%!C0OS3/'<K%5G# /#F#%U
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M[P9.:_%86N3+97F$6=Q?6GGAI07A><1R;1%5#"W\AHPK@LZ.9\/E'$JF%5R
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MU(<SU'[=^RWS?D6)/6AC;F>Z(0/TVH.CX_0SOJGT8_KNB]!B'WW71GYC&?T
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MVMIZ<Q9QP(86P$4$=[E?PT?7EW!T[+(X$\ Y8ST6!,P6_K^.QV?4= @^2Z^
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M=\KYJKH/&ZUYSFM/;# '-^HG([L.R!=L6.JS6MAW;A:Z"Y*_OB6+WR=KYU+
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M$JA7M$]2E3OWI^7G\31JK?W#FBE<%G_ZB&8P  %^WKC #X'U6&Y,$'[I,\(
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M2$>& SL4#L0CXK*N'^*05K*X,OOCOG9@P$@K^,^0RS/<-'L= G=*>&&2.:X
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MHD?Z8NJS0N*,/>)?R$1L*[!1G<\H- ;1DGPCWZS*]I'3BRVJF\/=FGP'PHP
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MHK K)P-]^V?<_A1T1@J[52=ID*F7WNK4GNNZ("5 OO$\J=(#%*4O:#U;CHO
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M;*XE[N[]7H3M\C868[<BA].6)]EVC-$H!\I/%=KR@#MIUPQ_5.A\T_L7)?N
MFCM?AFMRN$OE;(MB],M]WY>M4D!C%ZT">%P*\XFI?CYOQO18/@*3:[J=>V(!
M0SY-9KD)Y'3-F]Z5[SVA'B_&=VBC?C&C7LD0 G0C,/<)F@8'YXJM>]J/2_N1
M)BB9D<\.>Q$)5B)%BSL;>YC &5*NCI,>#'-VJ/\<;^\D+$G*.T,_IEH'EV1\
M)4UOTJ*VM$8ML:_1&8BV^&.2I8G7'.UW\0N/Z5+"C\4]@X^B VW@A&FON;%W
M)/EPHD</-KP(R:TGO7T\2VP\F4MT&A-.A(ZG D':TTJ^C'B)R-]+#H5QI"%O
M*1*IQTI;#8V#A+M!>3:@6O7#6P6^X#_36U(JI#U.T/]DKGWA!R#/*ATLD>L-
M6^&&2YF<L,P-ES**);=ASR\8]##K ^5*$[V[.0XA4R=(V3"8AQE*DWK#XHWA
MUQI1L9![F3Q+'5Y<>B=J2W',<UI9>LX=;R5(I%EM  Z;A[7=$EL"\,:=6M6K
MP-XXI:K>]2GVY$G!8>)>I31C'[VEV)>0>HK+HZBM2L,HMK/-3",L.$ZZTGDQ
MID+&U&@NTP=5]?4^B&$BH9"?5J9K:29ALBCG:&+EM*S.-OD!K$QK.*P.FM)-
MM?3<1=_;ITYJ(G-BXJ;3+DV4-AY3N(GB5TY@[^/\%0RS!L_H3T$=FO+<LRW'
M,.A)W7.55V11X2N#"593LZ/>/5X"SSFCQ)G(R:3*>>I,F$]5DQEJHGPO?^[,
M*9->0:=W-Z'L%62FWYH"H/2KW]2OIAU3_3A"BS"/%SH2KSH86B/"+]>,9&F%
M%75YC[4AU0F&/!##OR&K]TDA%$MS A'K)QJ2 "3U>PQB_(8EZG(HSS])5%7Z
M//32%>$YQ@44>M][L.6()_B3:!K& 38XY-UY4Y##4J!S.6%?L@<$JVD@A.:"
MC*1ZENF;$(V&HC0BV;-$$$M'V5G#H>NDI\?H04K,V#X=H2DG&Q!Y*:TB>>,^
MR[/<$>:'\S:;F%R$Q>OP/=!Z/>:*[@[BXSQ>K5!Y^Q.U(40DT3@'T=P7&(3"
M7R2TLY'L-#(T(T=O[3,@+_;K=6-2&MFX13TYK6R^/$C2)^9+Q,)'91[D8JE>
MAXND>K4V*].RM<C9CM8MT_)HD=T?;V2F9>Z3]4Z+/%X$(^T%WY"0<&4,;>\+
M]F4*,VHG-A!*6RFE8HK:#G!Y(C,J+"YUDVP!G")N=?NB:Q,U1B3I3N6+:7Z2
M93_3XT(S$!E1ELUX'B (5)*G5+,[28Z:HM7J2"I"LFY7B'XJ.:)F5HXP0(5R
M(9],BZ8LJ?PG\C:K<TB1ROO'\ZY#7&=_9%16\Q-4X['"9-ZI.)2)7Z2;(!2&
M<41)>ZB<AAGYF+Z'KY2. QC"3>&JAQ=@S9MMRE%+:(2,##OF"1<F>;V>L:5;
MDL<QKMTGZ#05/1,KKM7.ROY,RX**J;@+3.AO!\9IZKF+QC0<WIB=UZ(Y7J+?
MC1>9YII42Z4NWZXU[1168!05E33],VGNA1W!QYO[HDJJ4EG.B%%3 SDGXQTU
MQ$$ 1(Y0F64AJ6QOQ?N1R595T^VUC)\C)RLF^M^OL/J=48A!N]D7'95$4%LC
M?X32&L;A#NT@0"KA9<_(U7C QXK2UO0'&U#">$>I=WYO/PZSQ8O2QKR[^:YT
MQ26/8<!D*78AI5/S=^ =,4WQX-:QR]W?Q/"EPU&)D%%Q*/VJ=F:?_I[4 D\:
M&?(E%/G%&X$G;)?^+NHH<_U\BM[A\FL(K"B=(P"[EV,!Y)_3,EA<Q,%6>-AY
MC(<PDJ(UI4V>DK\H?5H 9S5M, \-)U3-R$@!(;76]KJBAQ&LQH^HOA\]OT4K
M9FI&<P7V0I:,@37)S4P12#)X"@"%>T%H"33!%PQ2FK\5B!DA*:G%L@TD$!+?
M/NHR?A#X+PA_2K3/[-OQN-N<TB:3ICO3052D-\UW?@"NG[(#L8%)&RTX6;*I
M?7[UU293HN=/%!#J1CR9FX\)Y*J ".(IM92\NW3/Y<?G4X7@M(_D7J [*?IC
M8<&"TK ^X!T7\:(D5R]W(\:N4 I/-YG)2(+4#7U9WASR'/WLE2$M$@[I\[E)
M :Y?@!CNY!#+\+\[5#3A/(NR<4E;MA.@IL'U/>FY-4F]1&=,EX<5'S*7-"1%
M3';B]F4K4%]F!N/F"*ER;@S_*G4PX#UJDKZ@HZ2J0T4O']SUBEWN0SX9@S1*
M\2:,<BJJVL0:V'1@":>=; R2!GQE4Z9%+XM"JE0SBL??G*)]W+5.XTZR/&[1
M7?#$!_7*</3!YZ" )GMYRYO51.@)ES+-+F>DDF+O@N3=(L4\<]'3_(S)M+QR
MOS2JQ *68[[F%,*5-)2@Y85>D(0_Q. NS(6F85SH W_PAZ &MP]S8R3!Q'&3
M!BTH"D+>SYBM9NM$ PF?HE(RWWTF1#/L,TRE$(69HEQQX![K5%R;:E\/,ZTI
MRJHZRSXD[0DIP57$(/]COM**>/@8DI"7CD1'BE1W45NT !02G..W!#Q%?$LR
M@7HCUW)53!#)0?--)4L7EA-@YA=3!E=?IL6.;V]!,4<@N;%;AAF"VOB75)#2
MVE(%W&MDM9'"I33G4?09X5!!OU2F"5O6XR+%?%JI5QD1)Z^0?5$58V!L7%6D
M*J#*YNUD1+LRVVM\?) 8;)+INI-$S["S1@"T15$K:E].$",K2GF>FS-\HJ?R
M4M':? + #XR+3*<S.6!%>-RH<2OW2;W(B41)*)!,.&P&16:DS+S")J_H2$1'
M%<X^Z5''D%0-X#T+J:H%^5@Z'B5Q!\FFL1;FH3IP9Z*D:ZNJ^W*CZB_4!,>-
MADFWBSA<,0K5+H89YVB4 ;( BARD#;C ,C/RTF)<#]O>B^W#.;D7-:.-$A#E
MH7/-25.;M: Q?AXH?+58ZL.RMVY2A$><70(^=:4Z'J:T>;P<UDRQI-8\B^N$
M];+ 4H 4A)F+"M[*=*X"RB&4*NA.0\XA-:1)VP@ZH,('W?Y(U3&Q[[B+SD42
M=HYP.?,J8.R6&;WXZ1R!,63YC^B.YE:M+&&TX#NQE_Y%SMF4<Q[@XJ/AQ*=A
M#;"3+YR>OAKS\1;*HGPW/"\#;O;XD^IKY+.\HUT!<P"M<*RNF8L%I7P]8D]^
M(*T2.<LP2THI"!.3-)F-B0HG')Z F<!2M K-QDQD5F@AB<ZX6FL?X1[K\=.8
MK\=/.='N>7O+X*-OBW:W%XG@G6Q6M/MDH9Y)M74+=]?GS77@3T]I^K1) 6_=
M; A1N0CB&XO'U1MOB*N_6]07RV:I"F%;:3X_!^4H%Q\9@T$7A<]7%%YN3?A)
M;0UJPO'*<&35/U58$7<SKGVE^K7P[8NA%XX8JLJ$"L^M$-X!%'.AA3VBJ.K8
M9&@"%!5PY* A^-L1_D$Y W WN)+>'WN-O8E/K@6Z&DM%E\@]I:;>ZIT1:)N$
M375@22'FS+0AN<JSJ$%3N@<,%UD>[XH=!#Y5_O,4;N4A8?*!G6OQ]Z:9Z<(#
MV(NQW;[BU=>72>"Q6>5E2@I:E<A<D3TF3)UG^;B(<H"Z\312)M!2W0,BF7MJ
M%C3]G5F&?S:H\HAF6G%P=L)8O8."$MAE6O[%O?*4R41JKWX12"RK[UVNII'W
M7N(_#ZU18O[+%*:,5Q"CR*\4PLHX!&-9YRA[$(%PP&9_6+&<:33WI@RG.SX
M\"X-#BRG>*NY6SYW 69#@?.*?>S?B7P[]Z<B^G-4.S(-F3 D=DLNVU.1O2E"
M0J=Q"!M@@:Q:2;*,DF74<A;IP$K"OV$R<E($Y7%,$E]1S+T/>;ZH3XXA((F!
M@_SHR:=2EK1JQ12N85&/*SQG/9>&R8NL4W*^B?PB6=LL-L2G3<@( N/19<Q<
MH,1)$?7#T9:Y%X\ECQ1,T.2.XS2Y3 KU!!I*)AI*>L5_%G;](4M#<H049=?"
MK2K*CLE>(=<=;C^,V!",EP_.1RZ<1-?X428%]T/X44;V)-@!@T[A=Q0?;J96
M*AT82TO2]^4"V:0:U5U/&I%:5(9S7[E9I")*C@_ 59_%HAB@[LJ,CMR:2=7,
MO-M%!OQ!KIU<S.R]_$"N_X\J[$-8+^P1IY[PKI5G%R3CFI"L@$_Q_ SU(DZ]
M:G*\;&#SB2<\&PZ'X";QI.EFLGK8 B:^> [])#8LO#+ORKU4UA-</9_"*D H
MK\;Z1$5S@[D0HSE6E;)/@7>J(4CJ$RT>^@-)S=O<*M2/G"^Q1"90%NH\X[.#
M, <#JQYX[UQD2Y(C*)/RI@VR5FHDDAG+V*#BV;$QT7NR/*"5)32X-88-,2E'
M!;E,DD'*K2TKY/Q?=J,0,.')Y#P3+^P[0ZJOX"=$GB77M[(;4?9!45$!TZ1[
M1,"GFDWB&]E,FW32E!SYHA8UR$QW,ZT,5//=93(5O[AHA_I8[VN.U:+REL>#
M >:YX8@7+B-!@TO540D8*9R3*4S< ."V0CX'EM+Y(X=;&G0IF4=)CER7!OKJ
MC@W/I*R5['@M/F(.+5SX<L^)QK%$C&I!I,AL)>Q8+.:II/>"WPGQ]9S(H#E9
MTU?'5)L4[2HZG6RP6.1U<N(:7XB//5;W4G31^0Q.3&<4YR"1] CV&'>5Y[\A
M VMRAP=&)Z>=2%N(',RD%Z&G$N\%(&_"DKS7*B5+RGS=5*](HH6871"PI".J
MN!#N*!,>'28LI4B<]43AB\SX3+*0TT*1)&<]=VOAVZ%/2!F-1V4G<K85"?*\
M<N-D1N;R3%VN#27%RLDUF'@>;O4G)<V).4EA\7W,(V!)9H;P7$FM_O[^-JD=
MH)11:8(:\!<YB!%_5/..%=^&G.7;FZJCX2![TKN(U8GO(*Z0KM0 .=TXF>C)
M;XOX5:3DXU;4'.%Q'HJ,& QV!)^0ZKPYDD]S[516BNW.:;Z5:<A61#SCVD18
M/F8Y)>OV>:\*+M^>L#\P-AJ%U\)1DB;SBJ*;;DDX;)2)?I1$35KGOAP"E9E7
MF/2C5QTO6;9#/=N5W+^0RT^1.!N-I[\CV-!9D>=MO>3O3JB2CNBDGVCQ\)W8
M$QO+DO$S2!A;5*OQE= ^FG05MJI^O;G,^O5Y!XG@HV^+Z-<7&DA3GS*19AUC
M^O6%)K'4#]<NJ+]0>X'ZE/X"FQ347]MXNR"S!6ART6B[Q.,B6#^JMNC],9G6
MJVKFW4P!L_&3C3)A"QF:SXLD*L?I6\_C#9QX28@,4@B-2&@ :E5GU@>89(QB
M=?;0G6+8KD#]NTQ,'&7'B16 !H]J_L@ZK53^<C_HV.!DI4Z<*<T<QURC<HJQ
M,J6;M ^7OSCK%!7IGT%:<3?14.&SAX0JGM4)% ]H=FO%7D$,=2H%07)2L$P(
MY/,FN!.$,FS%$'*QK!R8J6X@ 6'V]6D1T82-B"L\T0LI)T.+J>=.*)1%5_I3
M,O<85= @M,C5+:9*H&H]YE/^+SEP #&D#7>[,0"S([W9-FT;_3H8\ 5+DU)U
MQ]I$9*]%Z;GO =M/9G2+S*IL1=9$8*;C5(NA2@:/EXZUQN]CS9HGG"N@GGH,
M-6PKP!G72F\(^7)I>E!+3XQ_C[^#S^#@RKA2.9!I=T66CX*@TB'8Q:Y=^_%0
M0$_,FO>DT>3XA.9T?ZMB4>-5\Y**%,/)5.T?,JVDG\F 90$M:&W*LM)Y!KTG
MWPK'S7=!Y@"91R8JOW#NR5A[%87">;;^[&N7\IHI[ 3 ,9O""ZE:$#V/RB=$
M;8[[TE)P)047,[=^8'S+ 3EUUN"[E!! ?M2J"+P%JA>1C?\]S791,$WAZV?>
MIS'CY<%W3L$98 R'DMG"K<5=S\EBD@RIA&0UESY?+U(0UE)OL>1"65XGZPBY
MZI)X1-#+D%:K\\&\3O(G:E;02Q$I_%Z90OVD$Z5RZQ2_:5(N/B: ?<:]EMS)
MICA1$RVC+XH/TV73TO.T@Z;8+)?)(D<DRJ@JO),&^6!C*G 1D5C!UZ16)KL9
MBL%J\O(ECN>D\"2=\#-%\5"72)L8(55@DUQ9Q'A@7(R':GDQ+O^FR"6-F(OJ
MM(@_\+%"&9\ICI$*][G[*_!'ELOS1-)89Y[Q9=-LDD((6BD1;<HAN".0#9*2
M(PX"9OL86T$\1&R0JG+D])$[$=(S>TO5B#P].$H8%+Y=/9+*@$5'!DLTRT^B
MS>2]XZXF+JEI <G8 ,AID#EYM%C]+CH$KV]]I.X_B?LS^4A&9E?#(!Z*@6JE
MF0Y9%7."^BA<]#GO;L H4H4"9 *\,@%KT@0G/(@4*$'%??5#WR$ISMD0IB)2
M\3_\DMQ!Y1,UQ6&\S82H,\):O3C"8AY?9#2.CZM?$6JR,HS2641B^,"WN?.\
MY^<LU5PL0RF<#DD#2)N]TC*R+3^*+<H"&8^A$&WE@BA)%#:)4K)7^BCMO6L*
M=21]2]IPK2L;Y?.*18,Y@I<G)?K)-O$!0XG(RAM9\#Z;H>^ 1)"74<BF!H8R
M.3A@PZ_2F)ZZT:Q)G0&L5)7F10N/*^70P#GXB$\#P'S,Q!8)'#@N-;N3$<:'
M1#7(!3LS6_.G64IT0T1] T^>XGUDI>XQB^%B+Q]BW^,M.RPJ1DS-#YXVQ;G;
M2FPCD6^YO+<J9\<XB.5VQ0A(;BI@DZRAS;7V @2,M1<.8TK!_E 7$I'S>3EV
M)JLWY@0")?;R><\),Y^ 6,IT:F1>(B2\"Z:2/3+&N[+@0.D)J4T/_4*_!!74
MQMG=%.=FY(DI/?+$N*704=V(!2R9_*P2Q"SVL@UI2*?8*HJ2_O&F9[35-<I(
MPO;7_YV6>X;NP*RQ(=)TE&=$!I'Q;U),TD9*2@O[M(,:7 <B!E62PMGZLH(F
MDP(O)+JR$&]5E0Q]SOCEJ ?75A47'TXL+EZD;'+A ,@"9<;-'\TW!4 6ZMU<
MG]*\>2V#D@OU0:ZWURXHN5 5>'U*&?@F!25UI3&B<@'$-VIOB:Y.+B(I)9C)
M<WE>1,<=&E[A)4%'Q:TMDGS(?T,2+2MCT@30HNSKM *C76N;1E;69]+TLH46
M\+1,S"I(Q%7%I!A0(;-I^>1T82 IOOQT/$;6!D8'!&JD:KX3!E*DZ)6"-5UJ
M@E>M..\<SL&E-Z(>DYJ2Z"Q@O2!&P%NM*/%#;KK(AU/K*8&C,.@RWK/I^^&I
MQ/,M._#)0TU&+Z*,LJA 3;;]8#])0U13BN>X$TE&/H>DNHGQ#>2*3'*&J#IM
M1;EH:,\I?4M5WXX(J!:D'@HSABR4$+DDMOP6WH9'K@-BL2)J>C&L$3B1T%G3
M5CQPB5"I(PN)?PFSU$C'2YMS<G.6'Y(&*V%)FB'9 (<*CQ2,(TB]T7,#)"FS
M2919.J@HLX$#[&-Q#=H=##N2A]W >63V]+[F@*1GT=#OS:5Y,T>LZ2;D,^ON
MUGA8VMVDKO7IW#+19-7.3C>;\441EC"-QS@-^[G.P.%>!!-]\U9 (0H1* JI
MKQ>L@V4%?O>G</QCE =>+XH4D.K%7 .1+INXJ)+^^S)M5#S@)E/J03(*FL(]
M]P!]L@ ^]7-E2A3$"CQO-J3Z6=XF3E;B.X&=-?^Z?+;97'/0_.( Z"/K6VZ/
MFN[&GM*6F(:FXA2GKG"\IC$BM9$K\1JED3)];]9L@I4X2#OC@T*0,18&TJB[
MG<=CM[+)%^^IC5\1)>7S@#R34%$P1$28X\EU5X-)PG=.4APG7U+)@)C4,6&B
MR!MZD-[W88VO>/-/E8M_0^%+8,*7LH\U3I)^1T?2G6+ ]\1."*B&"M4U\EPI
M03NNXH7D@U<9H<6-@"?0+80GE@V&KC]B@I]5TDTT>47J^"[J=DV;VK>S;0-2
M?8AVSMVW8W^F R8E-9G*"OD66R10T3N4K)BO+EBI^_?=OD]!WF$2AZ!@-ZI)
MA6]4FB;PE^-8W=2PN;O_'J:#*H*Q$0%*3X0)HQ[0)(.'Q;FR)\"?Z11\8YEU
M"$;YB(<J_9)NY[/;IE.(,(0[D$Y6$J.:0&OM@;+,VZP&V?0^$1,?R8BYG-<X
M4J;[2 ]^DC&H;E"*?C4-4$Z M&3!N/I^!T7/:=$9:6BFN'S57V]QNT-DOH+<
M9"J((#L2MVJ(0"F5R6*M,+4@>5K)H9 I6V^2$R (P*I[L%[U2*#%T,X!9P#D
MV*IU[VSHPJ:H1?$X<9IZ?4TSPVYZ]T!<CNU8P>C4#X;"# ]O7L!"'L-^)[SQ
M)D\0O__^]?[RK'/WMSI'O):,$:]-'R,.EG=^2O@+,&-,K,.]$!/@^\264<E&
M25\3689"Y4H;_\@\ZIYJKE/W,8ZV"-%V8'P7?7^ F/@W,%, ,\)1,%JO$YM>
M![FX82:76RB5N (:&L3!9.4@L HX 9S%=GH];$:,?Y!Y8]Q&ETU_J.U_.F2/
M8N6PY*.5:_B?Z7EE=))4 71I4!UVZ@9+ 0 6S0L_BS, /N+P@F+E7()-\R2S
MGL$\0,_*$G8[2C,IFO+ 9PEF1^U:3]ATA?L&BQ!)H7XPK.CB.$':Y(C+4/3U
M9+NPX,5 SY;(]*2>:6B!2F,""\YE\>:\-T?.>N*2&<>%BSD[8X.;I,%0<.X#
MXTQLUT#MA:?-!QA^#HT^S; 3X^L\[*)6L"^J0Z&$,Q[P]GL])")T816_;WV2
MT:29SUM!)X-OX&Q#/Y225*8S%R,/,<NK<Y-OR/RC, YQ/=G@F;U:2781E^<A
MJ(D(,)&[DA3+HG E(U^,5 )@8+^Q-%<NV?<"%ROM,HW."BH! #1%KG!-%^6$
M"?^BDPP4X!UADG$S>"-!-<ID4R;Y&+&GD#_Q&KEI,G(SL^851B*4+=[O1AEX
MU"$DG;$N0XDCVM/530.E"&T$?JB/SV:Q)\@NJ;%\5_8(TO>KV.%"(NO[_=F;
MA%7I.ZN7M3//STG1O%B=@E[IQ^<)7M//F>B,YREUW,HK1<X%?M>$>W=.57(9
M&"IIYW5EYZ5A<"D[KRD[KRWS[N4O8\*1J(!>,J3$2RGRH](:MT07P1&WZ'<K
MYBNF8"JP*IYQHE&T'9DPK7DS8=Z8]R(#VHN$OZ=T6%_'K)3&0FW$&XUURTII
M+-3(H#&ED<'Z9J6L=WJ(A.E$)PLRL8#U@3$[SXQS<NYNJ=+I4L" -MWGDH&C
M<>6'J_:\9#?DXH8<X7GG9>:.<.'V 3ZBSRAHZ=29-Y(#V-/T=ZZ'\: @IB?_
M?_;>O+EM'&D<_BJHS$Y54B5K=%M.YG&5X]CSY/GE>F//;NU?*5J"+.Y0I(:'
M'>^G?[L;( F*I Z;E$@*4[N)(U,@T-WH^Y"*6:(UCMJ]6Z0-Q"/::3W3?N!A
MX2\(4?7U4>ZR:]X%XH68+*H\D6U3B%=.$H>5ZO]K//0;RB,75BSUPH('J9P-
M';NQZP'53VG7X+=DO(%,=K2GJC^=.FH8?0*"Z02KPA)Y<7%?91$8!N$%O$<"
M9B(G?LG)N&IY=IAQ(P,22B5 7$6A@#'J82 F\29\1_*5HN%2A+\9V,DR_23:
M3.A1BLOKPU_EJDR[I7Q$4Q _Q!/9FNM>[LMQ<F(6X6=U]%H5W,*RD"/L68DH
M]S*F":IMQ@TOUXF5:#PN.ZDA]2 5R9*6]<%IK&P/+)R/&1+)!;T*#)E/\8LD
M%*=?[>_A\N]Q=5(D2FWJW3\;]P4 X\;$U#L=>R^*# /II-L<R5-F-3X7G,G@
M(0V(.8&ONMDCREZ3K>0$'KS(>X.];5?O\0Z]N 0D&C$_YJQ7X/B847_G^3&#
MQ#<V_GB,2Y8P0&.\:7X&DWMEDAQC"=(> NW$]+OAR%NNDUHM&BR"/<_DTH),
MPQ6Z[0YZ(3PP%J;LEP[]]RX;X"GK:$60O;BZ:ZT0S/;()%7T8J"HJ:57=V)1
M1P^51B(:!5NBH+Q;JE&P)0KZ&@4'0<&MXX=3SNLAI$BG3=76_3*9<#Z;;3$L
M;&>/8<)Q2HY[U3!E)_31\VUMII8.AH7HZO0K81QNB9QG#3<+OW3 !_5^CV>_
MAQL4^+*[W]_7W?],S>-D-_D9,+EB;[_J#9;.X)QU_O'\+ZMBC2),[S8%^06?
MRW"<KDUN^1%]X2,-7R25HON9++' PX6C!]X_13_^;^@OHL<O?II>O([JOHQ<
M;SD+*L]>NR+3\8E6(Q1^)@Q>(P+5[U\:'I8"XE]7\9!"_-J&G(23?I24T$\D
M)6!"PLG4\4_DLZ_.N\-6;]C)2$1X/C'LR#PJ2H/DF>R]*VIW&BB-!4JYW$IS
MF8VTTSCC86\*Q&7<TF)I++E[(/7AI2LTEU65 9E2^%5,2=^0D'(8%"U^B9G]
M255*4<EZAU;)BN-ZO7YK-.@V0;?2%_3(+^@Q72SM=MB@-?S9OFFS>RQ_MJEH
M-\[HTOJ#9D_%>6<.K@H B_HC(G.U_!?LI8M[> I(_B8B_GT;58-6K]\(SXV^
MOLVYOOK:55'W. I7AJ 3; A]N$"(9F6U9V41(;T'.LIF,Q^CXI';IR4_!E=&
MOW7:[VE=0U_0^E_0([I8:6U"40N6/]<+_SVECNRJ7<CT.5'2M/PI,^?<^[O7
MG1;#_[W)TQ 2Y>BUV5^Q[*"JIZSZ_C06JK _C84J[*\)OO*]I>=2VG2JNE&G
MZ=4K3:\NF3":F&H052C0>.BV1IV^)J:&6N2UNF'5NAF#46L\+.UF--VN[H.6
M.'4"[$!0336VD U6WYK0>-!XT'@X9CR0I($_L!N,[B^CRFW17V:@^\L4OV0)
M3IWZ= QI:'^9\IJ''#6UU+ZM@^XO4R44Z/XR!T>![B]S&!3H_C+5#&#I_C)Z
MOPW=;UV#U[J_3/4B(=UJ!JX/WOEAW!J/QSI"J2.4&BB59%::R>B2+-U=YD@Y
M54U*/KJZNTP&TQL-6X.NKLG2%[3^%_28+I9V.NA";LV3]L.3="%WNOZ@UQJ>
M#K36H&]H_6_H,=VLIJ><'UOAI,:"QH+&@L9"=;#0.#^WKO&NJMY7R5!Y3<)1
MFI8VTU*#[/73T];9>*2)J:&F>JUN6+5NQGC4&FM[^[G:X_&54FH\:#QH/&@\
M5&&#^27>*,Y0&)MV8 AYEKU9JOI>V2SM535X![^FK/%UICM8LG/.+IW%TK"?
MV$)(<(_Y\.$,)#M[0-'.G!E;I/+"&2@;:"/S*5NZY@2^9=H,)?(#E\]Y*,V9
MB?M"E @CF<%'EFG<F18Y_ML,-Z#6PTE;&E:;6,&4L]71(P:V@W]2)I"T0)5)
M9ITQP\8ZJ410N44?&BX79YJR.\.#/U.'P"U[)L#*<..=K)X+ES+)^& .P,H%
M@!FK"\%'/KT/Z B^.V4SUUDPY\[C[@-5XDM@3@W?:#-)+H?"/$>@ *Q@VZYA
M>S/N>NR.^X^<V\Q"Y,"9?2(+#D<'>N#&9,Y<#A &NKUG '33F1(RX<2/^$>V
M8FK<6_QMI#0*]50X VX=8<C=AANX6#B![7?7:JH;=,M.I%IV$JKE"5 /JI>/
M<,L];N=IT<5NME?49FTG0P5>^2 #CVK=+U%PXM9- U3M"<4"F1X0,O>P*G :
MD:=\RY< KILY":$F_[EB>F#Z[VH*L#T5*<-(_W'P[Q;@]=YR)G^M0*_3_=$1
MD+MU5"AR -,2WN2[@;1C@'7RZ06 "Y>ZX18G(/PX&YZ.^F?#<3[_[X[S!,#S
M78:[ED$.V@SAQ!1 $7IB4+$85BQ1+[D._C>3.9\&%O\ZR\;$S1SN[BUW%W&\
MU;O%MY6,CM$H%QVCLMC<S+$LYY'H&T_H,2]8P'M@!<'3/!_N(/+NI-#S8PY)
MOH?3=QZ;(*KX"JH6,:IBN42_P27N7<?SX.Z[')22_\);[@W3%K\&8]R#)U^#
MB/'G3N#!9]Z;MQG20#=_P<6&ISLW?QD5WU:E:4N6$ :J3SN/AC9_*:^MQ%%3
M2^U[+H">"IL"(?3[G?O;.4@WS]?=+PZ"B3]0*Q!8^#-2#<2__T#]0*.E:FCY
M1,J:QLM!\'(5ZN@"%VB5BY_(-J^3M#N2%)G+%4/IK6XCH_?;D/WJBB[=1B8C
MVV+5R>9?&J[[!!*&9-3ZKOKK&BI$#;D^VI[O!NBJTR-*=,J1!DJ%@+*9,Z1;
MHNP\>J/!3*)QBK;NN5)E<;NN>T'9%^FT1<VYZR]L]X=RBL2OX#MVSY"_K+KX
MUKC.P?7KYR!;>.&JB^UBVXB\:1"Z]Z(B'9JQUTU!:HX>M)HH&&=B:(UH"XWH
MSYL_(MB%71K@#9@J=($IEP#'['X-I5^K?NNTWXAZJ#((HAG&>*VTB^K>E&(U
M3:U[[*A[5)<PD(4.=>'<\^H_CJTMA,:"QH+&@L9"=;#0N.# GAO5K!8M:(-X
MLT%<H$=PU.IT3K4!NT^'?U5MJ@8AKBS[ND"K1YO#!S2'"V:@VGS5RJ)6V2N]
M/XV%*NQ/8Z$*^\OO]Y*]L\PR;I:JDDR\+'^EK"KZ':KFT[4^0F7@/ZDGR_GU
M25<$Y,(/\AI$I/Z=;%Z@MKUAYC2W8<":K@(7RR6WI]&C/[JOME]Y.-YZY>$X
M7#D\<EZO%C3C5Z#/J=8H<EC<<=!V^%O#>C2>O%?G"NBBM=,]@3:>*;W='<[6
M6SG;/-*%I%_DC/Y[)XF_O_PIJ\R[G<ZOKWXK?O>]77;?S\>,XE!ICS$5(485
M@XO>'IW&GPETQ1^K16F,JM+@/0:;NZC2_N([DU?GU# #6T5<HAY,GA5C2X1F
M?*+6L.&?[/?PFB<+[10V)+E0RI%%FG!41<<RB^ZR+KGR:X'@<7MH)O@!.K#>
M)9Q9V,PA_,05T!+]'79'>W\7M ]V?H/@#\B?F]$.8[1S.XS3XAM--&W)$IS-
M]6EPH-MA[(B-HZ:6VE>5ZW885<&$;H=1-[3H=AC5:H<A3JO;850S$/\YJT6@
M[HFA]]N4_>KZ%%VGFS.$Y,$P+>1\UXY[8UC\ [_SXSSH2 5'Y?N]X9D5KNWK
MCEJC@1ZE6P853";!(K!0HR&5,YGK\YX\YK?&S^J21FG3X^M.%3EI0B\E"[0^
MZD 6Q::M'$\.TBI=Q#21I)#+P'4!:]6E )09Y;5[:)Q!MD=U+#$?1&MCS]3&
M-LYSWTMQ6R.&;^KZX&-33 Y_>8HMK-?ZR3/UD\,3 G+1THP8[1S2S4OVJYA4
MMQ9_<%9:*4/="40K*QHR%1;31\E3='E4LXH1-!8T%C06-!:J@X7&^;#WW-TC
M<_KH,<S;*-1B+##FUVF-3QO1[Z-*V"P@04!'^\O$[L']Z07Z0IO12/.@U_<E
MEG:QO'A06G"PZ;9Q'S2]J1.@9E%-5;20#5;?(M!XT'C0>#AF//R>UT)$$3B]
MN(5(;D>1Y+OP-<VHA#_=N1)^5'R->=.6+,$Q4Y_:YH96PG?K5!M8'VJI?4&I
MKH2O"B9T)7S=T*(KX74EO Y:;5UXL=*,7A?!Z_TV9;\ZSWE3&PR<8"XCUFP6
M'*[P:N_CWY\WAJ)[V)GOX]9XW(C2JH+1W8QTW+W<@9?.@]CO#9B9/_GTY+_<
M=2(DI\A?8WTWSO?B41)-9H)-#R$?6S*CQH+&@L:"QD)UL* ]57IXXKZMUIHH
M7W7'7S/,T/U1]HMM46U75@&-Q1J7->%5VE!LEEJFL:"QH+&@L5 =+-0U>*E[
M^!]+>%WOMY;I"T?1358W]W]Q#7[WH(V:1\/68-#7KJ9*UNX?EC0T5>10Q:%K
M_@],%L6. M'-<Y_1*^#P,J.KN^;J'OZ5$K<[*UV'[S[=[;6&X]*F9-2=&G2<
MK\H*R.%O3['-QK0>\DP]Y/"$@&STM+0!=3H$V2R'O\:"QH+&@L9"=;#0N "$
M;@5<0XNX0,5\W.KT&C$PN$K8+""<H&,#96+WX%9Y@9-5="O@@YK5!?+BT];9
MN-AQAT=D&Q]?RTV-!XT'C0>-ARIL,"5I?@]; :,X0_%IVH$AY)F0;U^"!7?-
MR8ID7M&T5N1T4M/ZYG@FKAC5T]SBH[<@I]];SN2O%:G=Z?[HB.;]MX[:R)^#
M=%["#GPWX+F0I-;%*Y D0*J6\^#7E%F_S@< )O&<PP.6Y3R:]CV35G&P@-?
M A[SX=?J?E2QSZ3<9R_I75?(@D:(HQ-0;DX\P)+:TDZQ\IEI,\,&;2G$(;,
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MIZ,"^U6.L[M/YCBK1$_*XAM,#G2#2=W*L2CX:3II0J.\2O<H;"K0=7?"ZB4
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M^WSU8-=JKG&;J1"25<5,0(HEJKRR3S$JJ_)9UCDST\/BW+F#8WVF.+O']+R
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M$/4 <T<!<Z>J8.Z>9H/9Y1[R<AI#WRYY?EBJ>OD61X>OC:?LE5ML-2B,S$.
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MQ%EP?Y'8]T(IB$S$GQM^YCS&-&$RX!^KW$IA:40Z)$4E24R!>$/"]TRX^$!
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M:E#%$QI!'Q2KJZ,B2L.3/L-> HJ[X \8(7HR'':XL3!_+Q/<]-,\L#',?D:
M2Q0,OV:F=^\B.)!(A]MHWG$W(?(2)JXE^0C"14!"PA_.$PJN@%!-@DNW-?C1
MZ62"3WV_^2PC3YUT8^BI[E9TYE8WC3ZE $-WPA]4P/OUN!/[Y>+KFTLWX]&
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MM.3?4.\,"JN9:V![REKV%'&3#]MZN]=3E_GKE/7Q36:LVG5^?!RH7N"@<;@
M7R\FGRZ^7MQ>G-]HDV^?M9O;R[/__L?EU\_GUS<"MDT[_[_?+V[_1W5IE[!2
M9<+NC!T@2:X2S1J+YC&TGTU,DW"XM)FQP$:>HW"]Q)ZO^)9OL96IY)XS?3 L
MK,"OB=[87APK)-@Z+*PRK;8W:XDP)_^Z3A!/CR83])GY]I.!,Z&D63KE*JJA
MWF\7EGUM:E)H3[[EH*X.5/>@#*_\ZIJD.;Y'H^"6ZTMV&;^L2H3JSL)B&F84
M', A$4S$A"8<+>3.#^5"'N*>YQN_YOM6:JN!K"M"7?7;M?,EC\$BFYBF/Q?#
M2Y?13([1-A/4D#R8"!=#>JFL<%E?'PW2L]B4CBN$@X6T"7;T4;=V6J]!RDW,
M9J?II O-J$;4_R!G0@XDTVDH.?0_UD<=A3A7*-^:%%%K5JW6L17^5JU2Z]CH
MWSQ_Z% 03<?H QTL[=;KZ:/B< ";:B24E6U+VW0]?= ?*._F8)5WN7>A?DMU
MH:H2A/APE=Z6VFGI@[$J0RB<=TWRF^INYS5*>7JJV&%=IKQH9:H2AP?G8A$F
M9T]OM4KL&%06YY:B!P+6P]GLD;\\\WQDR=&HMS.:"6*&_[;#A[-Y ,](\DQ*
MR1T++PN97:6WAX4!TZB >[,"OBK@K@+N=;4I. 1*4=VC5;YPRB\I&O3U_D!%
MV'/E4U&#*[OJ]E>WC[K]*[H^%3C8KY75>WRT0\0PYW,3T=>RW7OFFJ!4M7??
MO)!Q@K;;[ZN%'K'%98RWA5/=Y4WM?Z._!/8'UW;^ZZ?0GS-<XE;MGX]JKC;1
MMERO^1)-V?&O/^(WS,>S/"D&'/G)0RD1B140$J(4(EO-_"@F&82>^9>N_7VS
M]-VRQYGG&_X"IRJ$BRO#O_1O0JP2_I?AS-D5\V\>#)]ME,0??*^3;Y[[+UK7
M6;*@JV@]-[B</]CC'?/G 7XU?0N*_9EC!,'EE-XP>;&##,'^,6/^#[&0Q(*\
M^/8E-B%;6TS(HJB0*+$Z4*%UVFJULGHH5E[ "G'M";?^4=N+<K2Z8#(/'SP?
M3I-U2(H%M);7DJJMMT8#O=M+4XMN[+RI4MIIVH<J)P$SD3+/8"T&S$75DZ8&
M?Z!FQ+O3C !S(#=L%M("^;7:!:L2F4[4^\Q,^4]M^E-'U^!!,V9BM8*S>)7D
M7<[#((1O ++55_1>L>^+()@WX+1E.ODY';_-HE&/\Y>G9-1CQQD:9ZT*LFFK
MO'4S879.ZNAHPK K4G1F^/X"R#AYQ-Z;21CZ]MT\)  N#^RD;=G<XJVBUXZ4
M&0WU=JOF:-CUE(XR/8=*EPZH2-EV-SH#\/?=Y_,O%V<7M^\5]&]Y*VU>+*B\
MONNK/8,RRZKO53&9 P117KWJC8'@*@8]EG>Z5\PC7[=II(_;77W03[M-L5N^
MU5G:>S/KA>R-/F!+!T;A_V?X?&^/+KR&J3LX3R7Z=UDKW#7@4>EE5H::.X11
M2O=N#^;_'HW'NRP)=%NI"N7&\$WULS48T0B3YR 7NYG5_,VULJE?M^3:&=32
M-@]H@.:YQJ(L_LYZ([G(U-S>#"S#+GTS!PLV]S(;]GHC?3#* L%[M0.W)^TK
M<GH*=JVR.H@&;:!_.ZMA4B64"FTDBUE?H&V=GEJA4CNY\ZD0W/:Z-3 ?0\1Z
M8EDV\L)P\J]?G!FV!1N(BA>-F1T:SM%HPX2R5T"'"_>,[U\Z?&7!B_7[^KBO
MM&09_"L$_&$(_!L6!HBM@@^[8,7/'^<<4EE@Q7N/,Y\],"#/$]-L%WYGVCO'
M"X)\VS@.>T#>;87IC<C"(7IEHEP03;X"1;ZQ\')Z:[SDI^X"6"2\MBW-U,VW
MX_-](Y1>X3Q]I0K<C:>]?.=HOE=69.X*TF)3V[3#XU&#URPT@"K6N>&[8!<'
M$C$^<UJ4K?F&K;;>Z>8+&'44VN]5K"Q6X77Z^J!3'"M53WRS>K)53[SJB7^5
ML5 V\$WI];Z5OG@HGO#@.2"7 2^X+]MFZ/3Z>J^E/*9]PT0[<:Z0N8(MO5M<
M6XNR"YIU+RF[H)EVP3$@;*20\G3M[/+;O\ZO;R\^?3W7KJ[/OYQ?7Y]_YC:%
M-OGVN<K6Q=\/!.$V<:TBK8PMQ4Q#O3.H>0]FU1E7A)$Q;.OM7HG(X\TR,KIP
MB5C>'.%ZJGG+Y;+ *IL9Q\<!.E/P#[9FKUM:NY->6BN^J?GQ:ZW>W*N6B*32
M3+C^F0\7]0.C8;./,\/%9G%8=XB5C3Z\[&HVO.G>-QR:2HN%=>$#"QCJ,3 ?
M F;A3V1R41IA:KN&:]KP]B#J @].-;'S[&WADE.;TN1=C3"0LD3#]4\J@#Y?
M3GKM: OI?[-?D!8HBX20B)3U1WHX+L71XEJ<=9* %MO*1O$ER3B]8W!#@''J
M/!N+X*=H;0^QRA96YYC^^RB6!V+]\=FVP@<@5.OGGWY9^G[)0CP=89(J69 &
M=N7I8)B\QA>5O$R??1;'X@YN1-R;H3WX>-G]#:Y)D$(4?90OA-A#L?GU%R.+
MWKPLZ=="29TA!$ME5D2BT6G?7I(7-+ _+AG;QCSTHE=\OGE\:2U?"Q+@";MW
MF*%]LCTXZG#'LSDHQ$#7+EQSZ6S:%G#9=OOM46<\^M%%>Z.L)9[%ZN1,5B<Q
ME 25](JY+O"&[1JE@#6^^^X:<PNDQ])!;$ />O/ <"T@)'LQ&>@L*DNF F-8
M:/0;(6\$[S-6+"VGD^C M2IQ607B#4(GQF2.,S,LK'RF(FO\7=3ZT>_BRSY=
M7H-7=7)V^?7KY.KF_$/TP\Y^*Y$L40X?^77XH246^J$E1'N-84C%ABNF(7]:
M?_SSSN:@6$!WZ1-;?SS&1Q80N1AMRV=H8JV:D,?$?J*(PLXVY([/23T-%#Q(
MOOM?/PUBL1=&FWA ^[2%M@6/$/VM1?]M=_WX^<>(!MQ73/L#"/(0:.>@L*Q?
M[_Q??LMH-<AKBP4\IV@B?8/KM'P:';6X=XKA) :3ZB#(Q6V_<]S;5]ROMH8B
MDZS*F82TF?V:1,(UG][W0>&(J976<J4%'?TJ5"+G<\)_154>K1-1>$[LEY,'
MVX(O_<#_9]P?#GKM3F^/]_;W>.]@C_<.<;#H$W.\&08FM"GC+K_O+8Q??\&'
M_.:(_PW%_R[$_QY#ZE(HZR^^]Y@UH?+\Q73F>%5.@H#!_UGI;H36\$>+$F+=
M6T^!^C23M1V)M3GF/=O#PI*>BI]9_&SG>E33^(FCPKK/%3\W\;.@\]G1VX,2
M.V*;599P;+5W52M*4/17]%?T/Q[Z-RY@UR_+G;_U0L/1?&Z.-*@;2'F^U;&L
M:\U?Y?XVB*G*!VXP4YOA"-<CW5!:0E'4$;KW&GN98=5AH+WC8%#O59)1K;2>
M*VV<NU):]O&:!<SPS0=*XUE2:B^[6'?8__FCEM[N*I#F1ZF2[+2+\<=W[??+
ME>Q'X!)QRDY<2TJ9GG.EFUS#YG_FML^L"_?*]TRXD<^\8!6Q)V?7* -'01\,
MLC#;E:%5+G^+<HW:^GBHP%0/Q]^"O:1^7Q]U\H5!4?Q]#7\+.K^]GM[MY(LB
MV0"/J303Z7?F,NP!10O)L!YMUPY"=*&>CB>\*T@ 1V6R1 !Q6DJV5T9Z?Z2"
M?>6PL""5-M#'?75C%<O"@JV.#E@=*N9>$@^+"L5V]5YQYU!%95X/3LVMSOP'
MG,!>9MR0%6 "_IH 4(-LFS5 EL:]PSZD[/MLMR!_"V='B,MQ<>CQ35.Q>? S
M'SVKB@\.SM""C9]VMZ6W1X7YY(J319E S1F7W+ @BV&[&DY+-C@0TN$,'\T(
M G8$YD_DD7P&2GE ]M_!HIY]\T+X'0^@[<Z9%8,.(7MPB,ZE&[V]Y)A/NZ</
M6F-E"^WI;N;,W%KKX/KRN)P37+3)I$[P 4]P0ZTHU>56YRX3U>6CZ*_HK^BO
MNMQR<M=+[G+S4K7D#7*;-YME<1F]2-P%9?O#([W;535]17&MJ$K,D3[NY.L#
M*:X5[[F.AWIG6/-1,!5F6U$U1D-]."JLK%WYHLVR!94MKNBOZ*_HWS!?M#F-
MRQC?UJ:^]QBYG9[;)'=S2XXG-J8NJ%<;B7&HFK0"7,]F)'+R8^'K+>*=63CL
MY^O0*!;FY8ONR,+Q0.^.5#ZU2!X6?0P'?7W0+HZ%C0MOEP>2$CXP7WLGHMKO
M-0Z0HO!1U$KKN=*Z.A>EE9]>X.0;%H3BI#?(K]A\&5ZX3[!K+'OEM^$W5C;X
M2%OO] M# ZNO$9,;VXKJ'%3-#P4PK>B67;W546>M.+85A?_1*2S1WS@7H32+
MX>S!<.\9SD*>&K:O/1G.G!I7@)//AD^3X0E\$SYNW-F.'2X:9%1L<;&E<F3F
MVT_4X'[A!J$_IW'6<(*N?!;N" ']XPNG:(1F&OQ!HU3G 7Y5UO.O[>"OR8L=
M%-&.V]>[.2.E-2/F4JP\+.G5<N2A M7N]96&@M1#IG54)?4PZNK]KE(/9:F'
M3+/K:-2#BNGL%,3E 1U=<QO5T[LEQ8$[_^:YWG*JXS!H;1V]VU-07Z5PL*A8
MCT+Y*I1]A4=].@-U $OA8%$'L+#:<U7%W*PJ0E7%J>BOZ*_HW[ JYN/IJ,TL
M/&J0X[HE-%BBT[ICQ+^M#P>JV'E?\[DJKFNWK3R?PLY@6:7.P['>Z:DS6-@9
M++I\H4R$<>6^UME\5.:[HK^BOZ)_P]S7YC3&4!/N'8/[G@G?5 N-EPC^Z7C\
MU*1W+!JT;;MSL+-B1,[@$Q&)O^_6>&'!^4OH&R"[MFOXBXN0/09@H%&5H.<X
M9*+Q%H1#>;J]EMYNY9OI:X:573U1**$]N-?K*E&HL"B4Y7MWAGU]T!TH6:B!
M+)30KMPN,!;:N-Q!B=V+L266I [NF,NF=I.*WG8Z<7"21)CK$R= R>5NZMK<
MO\%J+[X5K>4Z.0\I4!PLW6;)UUQ1#"S;T&@7-U=690R:%;%3$5-%?T5_17^5
M,:AHQN ;"S7'"PX%U?GW<DMG6'AX?$X*Y->]7*:"?"LAZM[IUCT!4R&^E1HB
M;]>][;N"C"L\GMW3Q^/BXG7*U6R6J:=,;45_17]%_X:YFD< YQSYH-J, >T>
M#)_IVIT1V*9FN)9FV<X\9-91.*CGAN_:[GUPQ?P;I,-GOO?7NJH_@* _Z$&R
M+=:)3;'6KJ;8?JO^A+P[^)K'IYG>FO("BI+&;?Y %:6QM#7W3D=*&LN0QEW#
M"E62QM+7/!B?]K-"D$H<BQ+'.BG'TM?<:9VV2Q1'E13:8I#_FUY@UHD!FP#2
M@'P\/H(LD6T>:-X\#$(PS4&0JF.HEU^5$U%IPHGT;8Y EI=3H0CH7 27":E>
M91!SBLO'JR4?KS=H@C6K3RW[]<;\6];>TSOCKC[*A =0M6,'D-*-=T'%I;2P
MM7<1?$0?M[-F;2@I+5%*=S*@*RJEA:^]JX\';;W?RRJ[55)Z "FMHRXM?.U=
MO=/IZ.-1P7[ JAL _QAW#ENRS"6SO@/FM&2HMY)?A9E.=K^<',!UX1,UDSG.
MS+"0HK1[_!U7&/TNONS3Y?7G\^N3L\NO7R=7-^<?HA_V3!)08N-#Z^.S;84/
M\%KKYY]V<G%6G!;^\=[/J^2#S<O'!?T1=)';[[>>]^Q/[NT(O<''D;Y=HZ]?
MWZ;ES"UXPM\WGZ-K%C##-Q\FKO69/3''FR%.O2C-/W_!AP"/)^9_YK;/K OW
MRO=,%@1GWH[-XS^NF6/ .;TR_' AP^/+K]_ZAAOPY06?%O)?=@'+[\?'<K!U
MCNUI.F[)Y1U([R!UT/<KCV394R:J1+).ZS1M$"Z3S'8UGW^_-L,%1 @- 3Y9
M"Q\8_+_/&)'6!6'5P/L.'P*-@=]O:3=L%M(>^4.[+5U#(NCPS&#&3)R?X"SH
MLZ5S97G60^%<67>]G 3,1,8\@UH,F+OM9BS@1%>5$*ZW_7[-7S8[IYH4%EI[
M\4HW =V\6NJN35U\&V])2?.;#+NS?_KM%M9OF*;W.#/<!3 5U'\(GP&[!38$
MYS)D][[AT,YQ7!AL-\#P%\;; D9CPZAF@,@SM5W#-6UX.YA.L&N<AA)O-'M;
MF0:$)N]JM&I0;'A2 ?3Y<M+KQ+R2_EW#)0P_KBP"7Y*,#8Y&\\%PGHU%\%/T
MN(?8+A$U#6/Z[Z.XE+NS%]F2^66->::=CK").UF0!M;!Z6"8O,87E;Q,GWT6
M-_^=YUAHBQ@:"#0<K+^%G@D20M8;\!Y! 9"EO_YB_)9!$?I7^S6BSM(290-#
MV!>I,@ZR63]:=C!S##!A;!<_M&(:93!(_C,GT>BT;[LI&VLI<FS,0R]ZQ>>;
MQY?6VF$%"=>$W3O,T#[9'AQ#,-+9'"S%0-? \EHZ-[8%7+;=?GO4&8]^='L_
ME;?$L_BHG\E'_28^X%PR'F<^>X#WP56K$>C2(<[JN^^N 3<3K$]'BR)\\.8!
M:.7@?<9J:NC3) H@<6_X0C^TA/BN*=\%E^'E8Z9G,^C^O'/1KEA 9^D36W\\
MQD<6D% ;;<NG:6*MFI#'Q%T\[<_"CSO'HW9\3NIIH,1!\EUR!\23176A>$#[
MM(5W.R\Q_%N+_ML>B.)G&P''R<CZ@]M6YVA;_7KG__);AH&5UQ8+>$[11/J&
M]F?I-#IJ<>\4PTET8.L@R,5MOW/<VU?<K[:&.K):]*,H-U?]T/6L/53]T WD
MF^J'KCGC&M</K:IB,P96FTNQOW=H*T1SP#[D:C2\M>,\_S>JE39UI8WS%TK#
M]OWB^?"2JYESWV>NN=!"3.,Z!"&M&=:?\R#$M$&#BN*W7)6D)9<2)/SF%(0Z
M$W22LMT3U[I-B/:[8;MXRTY\.P O]_/<AW^OF&][%MS"E]-;X^5@PP;S19YM
M!GAP=<6A:'NLFU7VK<2A:N)0EE_55M)0(VDH6CEDUC$?MZ-6FDWVW052./!
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M[Q5I]R/M9S:U33M49-M(MELOC-2$G+BE^N3A1_X'GL4M;--':]84Q%)>%5G
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M>J;'9VX=GYMS9G5[.C=:"SBM8%1T?]H?L;(><34<\F";P7Y:(]-[8D: V1/
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MH#E #).D58<_'#H6/^6_3#<:F>,:P"8,36L$Y!8MU8X*;_V;KMJM9_1ACZY
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M "/8E-&,#7& ( 9^'.5>$%D5!E)*VA$\29BS&HL?A4#N8!46,]#?:9C#2)2
MH5K!]Z+6>Z]1RRTNOCP4*(?_&YL!+ ^L_IY1_8J9)&EDO"S)(0IC$FG$1JC4
M6$M%E3&,_9EA0ES0HW(M6*:5)&3)2U?X%H)=&B69]P31-D@#'5&20B8L(DYA
MC!G7#:EN9S!V1-D."!@"M4\B(!-/$5MU9O)TR9:9#[LY,^Q[Z& ,)>$O#ZF#
M#FE.YC#CXV. O7JA'JXNE3@7>CFQZNF9S(V?TQ2UBD !)1R('SY"&8ZRBIN
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M,6V"ZR(B"4.$B96XKFHC_#NV>6-A=>\RE0AU$BN3KEZ,<RIT2^G&64AFWNQ
M&(F@'5B'&4:19-S, ; @\3"8O5]Q*+^O'G$,0.+%LJF=(_&6Y"$EHFVF4\:
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MNB_F-'SW43E0LO:\3;CT3//;7>-LK9FSC1(?J"A".*?_7 AC%RSBBQ?'CD:
MX,;[=[^5O_O6.KMO%V-&"9W7>UCBD*+*^& TZ]VS]#..KO1C^NZ+,.\'OFNC
ML#&-48 \XR]P=4&O([T,+BY*$W22_^TW<T6$*IO,NP.J9DR0[M4[3N:Z8,Z
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M!1I^$:[:7S$NXH\39R"J)Y@Z2ZI *"\2B59_(HQ(<C+G^18L\D'C7]>1FHE
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M14.=AB9<APEY@S-0DRS&[% ^FQA\TH B=T*^-I[;@N0A/970EO(U[7RQ33
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M)EIR$PI>5#(25#279$%ZS87MA!/7G'XP' ^_=)&%> &NR6<Q@VM&(^\2)\R
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M]53$GJ@246@]9<_"H(>JC<P;CZ_H=%02C:W=JJ/ F*Q,:\TM[6_''5TT%MZ
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MT$]FQ210_"%0)<,A/HF2@8?R#!QB %H0 HDWW4\4$CSS,X/S\W%"-' $)_#
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MSY1E+C#FGI+M&-C4-3C)I,VDMN;>676$S?*GL^S7"4,<VKRH[^.,:+STR2/
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M*\2]#U=F@WW7M-A[M=@3!40R%]EAX0'=IR5I5WCR+^G!]^$2M<H.3/QZ1#X
M[37=#SU".T>U<U0[1[5SM.*-E7C9.M7G))TG-MU4J;?AIDJ]>LY8NNTW5;KQ
MC*_F5%3B\?)U<J,QT<0F?WP>5</(C]6I?U2XDRVBD$U;;I5!>LQ>/*TP;7,C
MJD5YP>+$G"IO->+),("S\7I#DW=N\8=%N;1B(#'W@]Q@61SM[YJMJH]6MTW^
MVTS#; 6-XZ5N,R>!DC$$,,U4914@*1FDE6*6YH/^)X;C8+DH3^HGNG BK+ ,
MGAT+J'+" NJ+(6F#1@PF>YD$/I#..#OZT.3=?69R5X@Z2_<NXCC2DW@BJW3I
ME;,-QC(-<^;HFF9KBC_2@$7966=^!BB'[<BTTU-%I$*)R63A<D)/24@,I$8U
M@9:Z"QP_>/1GU83CN07-\Z778 %[PAI)"PNS+3;AV.)59TY:E<LT$WH3$RK@
M0(M*)01DT_DF$LJY ^8/%[C-[E+H8MLT)XS\ )5'@+4RG"EE+R^<FR>=SSCK
MRFO N"X;^NYAPX/5F-!,0<M!(&@Y\T&9&A.4> -',TSZ#XGAUY=)#[[ CY]>
M5YF\;]V&>IOK-M1;O:=-;[^Z#?76Z3;4JUJWH=XZW89Z^]EM2"58KEO^35ZU
MS E4 US8WW-1$U)T$]752'372K<TZKVBI=%:-NYU'&"3D[$?L%J!2@?6Q;,C
M&AA1HY3%(]A7[+1WQP($,=SXVV&?5N0E&[_C>K=#T6KOT;\3:RF=^7**S/-$
M8T<TPU]M<)3:AF]6H,%Y"BI<3UK+)-J<.'LO31OXGU<PH#[;X25;:DP&XS#&
M7C.VX\9H69+16).&7_%,>BL[B-Z.@[RY\SD^!]$Y@WI"H*T'LI2WAE#Z:PCI
M._"QO1 LQ7O9^D%ZH)UT ^EC'A^ -7:C!39EIE&V4"?P,]$Z%S6-M#=7>J+%
MGAIN]$@0+QJ0/=LQ.F<Q0GNB^Y=NP6^@83+Y)$X&TQ.YZPPC5WP6Y/!0VT@/
M'0\XZW\SB9NILP,N*K$BZ0,1U<US[I#9_KOP@,BNFG67P2$]$%B 3!)5:$UA
MAQMTG2UQ)7Q3OYAKNU[[P:W'[OB6[D!MO?$PA6(UHZM*NGDC9W)+1C6O&]?"
MG0F:MS!(/>Q[!,PK&H4&[PDZ/ZXYIU=]XMA94OM?9->0OQ,DA/+9+,#/\ESA
M)0#\!\FC2^GHP]UX=GZ*F3#Z5C342K6RYCN\9JVL%?HNO 'VN6&(XX!]:^DU
MRG9LJ/%>6^A0S3@C4O>#=+%1MS^UL]-]089GZL@0'<@P)H$!?_)2A[)I2,B5
M.A&J"'<BO$MC*&/39LCS9?.X".0+")M%K/T+[W27^E,<EX$*!KQ<++,:1Q%8
MR@U)AT%TB;>%!331K$C]?#VUE7F\_$N[T^,5Y"$MY&RJWVX'%)UI\]G,'=22
MMC#'$)#0%LUGTW'IYB_ROE-T1["/I(OIW?\U&LWY8!'>)N0$HA$MF;L\KFG*
M[\AFCV;R K7+I'A($%*ZBW10B-*)+S%FRCD/ ([^O\T[H.*/I_)DR"G'IN.%
M:COX';$O5:N%O5BQJM(6 3!+#B] N,: %4=[XPE^LHB5<9G\Z']BJ(#2#(OD
M97F6\]F/IE! OYH_G7$\3N[S/792+<EMC+DZ</XY1K1UD=Q:'O&:)$'5D0.2
ME(@3L(B$Z0P=*R->J2V'&!6#O80X6PV38/^0AN3PIIJ10OY%Y, [5XHW8[M9
MN,3BQ4 ,Z0OJQG?<YBO)3&$%6=MHL?DS%JU7P=*9EX?-Q*1)*>IPZ*99[RPA
M&S0D$>M> B;J-9RAEJ0I;"WIT9R#DMG[/S;_9.0&(N]=2@12QUEFMPHA?SM,
MQ/ZQ8:^U%'O)I><7UO9#:H&+"!S%P-\!UI%#O<?QFMR1P[-I1(%CNG6<5O5O
M16C-74HA!E<0<$ _0K[-BO"P\ ;GDHML+9RHP71 )+IAL9R:4P'"W#W#_\)Y
M#TQ8T'UNO9&!V0:'&\YM:Y]M.+?MO)XV="K=Z?;-]TYX@TCA95/Z1,ZUCZKD
ME$+L<(UC B]QUR!912K09Q8Z3RD+Y4=AGH6]K.]3'^T7'/:7^F@7=[!/>]Q;
M 8O$)#SJF9E\-TI>+Z8)JOIO\1:3SNNK]LE.6/_=S=W53E3560]T\>%J<A;3
MPE[#)D^6_/_;^[+EQHTLT?>)F'] N,<W5!,4S46K[5L1VLI6=U5)5Y+;,T\.
MD$B*:(, #1!2L;_^GB4SD=BX2. FH<-M2Q28R#Q;GOVX-"" YEST!3IIJ9<[
M&.[4_7V!GL7B+VK\'C16U5CW'2YH1_ON(&DG#%2USR&F_50;N5SL58:9>(@C
M3Z7 :8QXS5HV_"'!+><>>E.+\C12F)X_FN/J&R:/H0=+1Q[EZV8)A1"_$* V
M].S2521]_;VI!;S;F"T+G  ^QL[Y0QMH](DDJ(S]-*U?@V?0UT*:]>#A&%1,
M.<'6^O.I%[G B/ 5&';PT@8)!GB,+8P!J!N@MKB\$2V+#*:S@?O_%=!8M/FA
MQ%GG_M':LV7IE>VA^0]0Q'D(C[ -!XX<X;@(GE'P#+\U "%:[N*S,CKV"'OU
MYPU-H?$"^BTV3@B;*VCX*7R1& L<^P)0(YJ(^![@-1TG\P>4%D5DEGG5M6^.
M2I49M^=3H):(%L:KB%:VL93 8W#2EMAZZJ>7<Y*=IR'5X!FT\EJB<0ZHX%+(
MB@%( TBFF.WK\EMRL',';/=)3?XYB#W'P%$6>X0S<P?\(MP6\*@G'AE_C%8%
M2&R4"-H7;S,5]*>XKO#%P)W,(RG4^![MT/$P]@S//@\%62AX/C46)8!' AK9
M)U^F7!S JR-A^VE E]Q(.>S1EWGP;.+0EOYT.3=(AA3I$VR)S<O1)RP-([F6
MEB,-:Z\G.82G,2F+:P'F1XKR<4@)3F,-T4KAG_>"9*Q,;VJ\^0.=$RP5.=W5
MCD$LA'"!+S;5::\O=SK&]$$%-A*J+#PL>XQHM?6 &O/0<[0E<@PFN^#4"_VW
MW#S5KW;DV'\MHFCN6J;=Z<HR[<#T6#2?JWN\4YEVM-TESK9=F7:TH25VOY.9
M=EN<!"=!NL(DN"^<TG07XR6?,O$2 7D;!N,@LCUMVZ'J,:%[;0+K81 6U84)
M:..8?S7+]Y;R9]QQK$)W*#;RW)(4N74.AZ@P^:V;]ZOK[#>XV!XQS<?3H[%+
M[QX5SC%&V:64:KSNX]$(%8.];TJ?!;Q\PKP</"+<>&8[WSU0X&G\VR*6!2%Z
M;VHLRUH&:5NFGI$Q;O@>#%1(S>=+GV?5$^V@PD?' Z(2;.%*Q:-PU!SNE /]
M01R:MSK 9302#@[NP_HQDN:L+$Z,,SL!VS>!YR1$FC8D<%TU8)%W9BYL#U#%
MS*V+P'$D<,P0(JK-I6&\(F60HX4+6FBVH=TJ-R8.M@.;3RE]8/4";F*UR<J-
MZ&>7J"^I>DNC?^.3SVC<)&* W"^,]Q392+.(1B*2ZS? 87%@J&3F8@!?39#*
M<" IEB2:E">- S=,U[6"7>E*FB"3-J-V%DA5]BKLN>IK+MI3 K,P?8$]NL@[
M)Q584&^133/5'G,< ))=:>8E6X?FKC"K>2E[ XE8:>< -K#9^Q0**!D*I8RH
M911N%G;9*DK3:6@43UX7.AH!#!)[14[6Q %Z=4%!*1Z(R8,"OTV33""6N"29
MP'(53[@=E+88Z8B8;TTK0Q$44B!-(^S+9#Y;&C"%^3IS^-\UIM:A\ =:HP!L
M 4'OX4GZ[N2#2E'O@?T7HRWG#DP,<#UN@B27M\MTD20TFZ^8XT92=BS.=X4[
MJ\<* =UV8_.*,-F'LDR5EY.)Q.-($W<HU:::L=-D/E*6T(RILW.<,4:N.# %
M.8TP53QE._(^M?_$&%N+W"4B7;4[,P?+^%IJGF#6/6/ZKV;.G9V3F)C5K]3;
M.0NB2)5*TIE6JTJ]/%IYV.TTNW/BE:GJ;T5$DF!,4IHY0AJ-^F)DS@@ISX/\
MW+%<:T3 :V>6M3O-3CYRG+!D>BCLD%3-HAFD6@RQ0S [$'I^_$IJ=/*>LWKN
M( YEKV-Z:>@^D9-Q4YF;2G^8Y8 JU 0HKU^+M]G"%@U*=);WR9"0(0U609<A
M58/*DBW=(3"WR?)J+4RD!PO/JVR@TJ<R%="CC8.##7]UNHH%#5YY*\S$C4L.
MY*';<S$!81 &(X6;3)W3@N[&]#T]:'!W[J2JA\R2A*<:_ %O%"ZAX)&=T*3Q
MH!*+018/M4@X'_O2V;W=YQG>.!\.*^(L.?H[R;8::Y/<VH/[#ZYX-QHFNH($
M34],GH7P9SD!SHWW_<KJP,TSB(A2F[^D0N0+Z&S%"7I;ZQ4H<@K,&6):&;1*
MTQG7"ZV#)0H(3YNG^4&DWW_0H3]J?9($#<J8IM!W4F#A/[I/^ <Q&$BAD.&M
MS65-Z\21HZ+$$6RM S8\)8^,Z>X36"K6U[F:,\CK 2Y?L.S"*9>@$AK9(7=)
M)9) 9F[@<-DI[(K^5-0VX\B@N*-UW!#Y*;>+WQ''G7;CX##?K6XQ\6R);S+6
MB$;,8QA$$<^7%\ZL_CO)]<N/8@=AFLGF]\7-X);Q=JO0MAB(L]]*03+N@:GH
M FKO 2BI$;A;JNEW"J>^92J$,*=43)8!^&(D_D^TS[:*PE]3Y78\SV1J2)GG
M"$S%)IM;2PRX4U*>CP $(I5+4S'6YFM'C@OK)EG*;VH<^/$?\(_.&98__Y%]
MI4D'Y]+3G>G(N<5BLWMTT#@Y*1BYO$@Z$,A(.Z3;"+70="_ S-3/Q?(&225'
M6Y\M_WQVI8P9P/<X$X_\,91>C<=\QEI]Y1;5[;>G7,FKNMF!>N'Z#!/6K86P
MOF)F4G=37'#3GP3:/]$IY 251SK#JYGR?Z*B$WCH-ES073W"3# 6#=K'2N81
M&0M8^2'=H!DOI4S/'@J/,/8U>#)\+7 E2V?HBS*E+]T(:0&436J.H:M@94(]
M=?LBSCU'5Y$J]%MUM]#RX&TI@2Q%$'!A6D8#]<;,I&<J%RMR&E\JIS%+OCF4
M74DJ>#XS '_6'61?E2AJK$>93_W\XW?BT8VXG>DE]>JP;M0=5Y "NI&^JYW"
MZPUQ&&% :[;*\S(U_E 2?0>(7G60Z?QAM)HIO'&8:'"?@8\\5?6M<]!M-=JM
MF;=.RMRCS(1$9]'^WSE:HJ$DS_795@N<"CRS!Z X%_B]DF ).1FJ[W,B]K$!
MB!H!8\&=BBV,THV0N$9SSF05UEI^Y^_?A%37\)4,>\")Z ,-HWR[L#VXVLZG
M\KE(/I@EY#2.JJ3%HU/0@$YG&HZOH4524PMAH<03D:;^X\L 4$IO!XMK@NB9
M.2Z)!4@JL/9",<:R*'^B8G)\_O(0'DDVF9:B@3:"*S:BC^9P<"'@KF05= G@
MVNN&'#)J41!%56L;,))P_,!%=F%R97%[*8.LC$ Y*&&@7PWDXU*_3A0_^.43
MUBQ4+@ON][M-*04P")0RT556@=)/T2<^&;I1<@)JX$'*YS=WQ"ZY%WE1RMNB
M%5]NU9G<!YUFWE6YI,6-S;39[$X9W',+6M4R9[@*]@S&7#JY1&&;VQ7#HM/,
MMW[+M$MZ2WG11ZW5=2#M+M[GLKM3>=&TW27.MEUYT;2A)7:_DWG1[[X#*>)M
M"20?K#93>\,F<^4:PRU8#Y],ZT'I9ILWP3^)7AACWF6GU3YM6&>@DWEHD[?H
M=IYIH&_(R)J;W.3*V07/8$F!'(!O]@#-6M.(=+9>SE;)IN U+"IP>^L*>6*E
M9%1SU5%6XH&3GC12<JWH; K/DO6_<-8FNF==W_1"5T]6MNL BZBQ)3+W'<F;
MLLS] 'MJN-)^P!XM3>M6-NM)33-1QE[2)(/9PHRT%U)LB<4\ N;"W*Z>,)N!
MF;FC2=+DLP] '+KCA;+[.-<%KCLQ.TITHU9-$BRPCVER'$6Q27_F@J;,V'!*
M47IN?%N'U>_VZ2SU^Q5Y$P>%:1/6GJSLD9D@ECZIE1Q5E?A0G'6]4'H(+C@'
M2V:YK!MJQ<DFG*@LD\,DWS:M<^!1*4B!6%$JI&U<F<FGLL+M:7$Y+'YC%C9T
MP0C%6LP$+&01SD20Q<9;2-'E*4>KSQ'290=FE0^E\RAA)'OTA>*)1,Q,-*@\
M.9D:A!&U\H%TA;?>';^F !7LF7\('NP_Q14M?X9N@J]$5@OR@ &A_4CT?W3B
MT+&GWWT\:F>M4$QTCZ0C@BJNF7JYQ "[E&1'B6A3?5;P[;X_%$Z,_G/<-EY8
MNA6N06:7.B_W-N 8;D36R:N"<&OOJ#XOY3^I'EJC*DA"*G7;H1I2G/CV8X'S
MQ0!")W&^E/IBTKX7G.U(5F9?>-X8E1;_D?0N_%T>CIWL_++SF[O+J[O]BYO/
MG\]N[Z]^5#\L-QI<FH. 0IY3^6-+[O/'EC3W2N:%$G S$T-YL8.3[Q>>$JJ]
M"ZFOS/UQ!]9<P=#BDWDSBRVY64N23S*(M'DXQCFZ%+"T+D$/G7ONN6N5C'?M
M!TBL/H?=>&4Y 54NT 9+83R1 Z+_UJ+_S9\$S*X,>.V5UJ?YU54>9H>!PAH%
MOYALPG</$XY[\FN# ?]7J6@_]\(?/EK&I5HIM%8TKSSO#OQ;'\RPP6#E@\S;
MZQIDKCQ&#,R3!GF.-C3"_+4K%,TQ_QKX!8SY^CV]I6GNE;F[DI) 1597^/##
M<_ P#.((&/^K"]\1J732,TQHQ#N%DDCE>ZK/27FU8VT'J6@5#/4"4C*D_I92
M33ZUYOKKIS*"&;C?A+/_;Q$&".&33KOS4TG4N%(,KNB.>SM7&44[4I9MJ[[(
M-BV"=OTB(Z)Z&+K8UCP12 _/0,C3^A;;66Y:Y2VV&9)YQU?8.S#3OMC20NOP
MS=:I;[9-BZ5=O]F I%@FY804?%!?;3O+3JN\VC9$,TO=;?FLWL-6HU509;*R
M2\VXG<;?9M]!:KV**.^UJU?_X/O8[[)*A'2[TT- (]+C'C[V]N!ZQW\^E"D"
MJ=SQG=G?6_!C=->EZSU0=YCU!>$K527?"D=OZW[?KFY1*PDUR;_I_;[F$N["
M)>P$,28K;:>64,D&<QP#_\($K7Q-VAMN\4!)J_O4[<,R&X*\OKIDEZ#0:;6/
M5%N/:Q]33#!Y]=:S*X##J_NUS]B<RE6G1_ 3/7M"3F?BG$=L4:G:H"8IUK*"
M/-<8$(O1PR<YV,F51</X:"AX%#&V$;+])(_#!$@.M.VD^3TE>T^%'>JT8Y[;
M0'7O(ARI H4Q'6TR#(/X<8C^QY,/2?_K/?O#S.Y5/FS,2_*&;P9GNCR$T[5_
MQW9'5[A<]! 4#=4H[EPELVS;1P]!N\,YQ>VC/PS/!"QR#Y>]$+[JC"51A7@Q
M]0S\O6S2?3;%N[M,.<.,61H)DDO:/);4F< /EZ)O9O&VU9)F8\@QID73.HA>
MJHK04[%L*H3"UKZ4[$S%/ID&ZN<!=IG2Y$$]P\WFK50%KZ>W-7($*'LBT:$*
M_M!I$ <894+E]),T/S*EX1DJBX^D')Y/<_V1R/V4D)ENR$$@/5-C[#\%X2^H
M<A;II3J%NW*">DT;CW;KH'%X5- P94XOULW"L+-5,#P^:9P>G91U0DE//V[0
M'(*1L&QUWK0(3@;!:WF_D?YJU]QED'(>TM6=CXB<3'EG_FZ>W6#HI<2C$!Q-
MPI@J[&[PRGH8VCY/THZ(<J)KGTM)"CH3$OFTJ#,AUXRT_KB3$P]E+T$DA^CN
M_K><\_EA.F;G\S;1WFFCW<F3GKR/0WTR2PV&P(Z#2J. 0T9:F3 :?XO1V NF
M@MIB8W>\)UA&W=^1V2D\%(^Q9T^"<-J@*P6#1VJ*2Q\H 4V"9"H]=1'7(EIV
M: $M!*MN $_\\=Q9$EM)=O^$$PIG$;)+O!,[1'94206D]PSF621 .O@48"TF
M.E8=0/=$\K*&MD/T(]41V_/X<ZK*@5<,!#6'CURI?V)I'[T9?T](AY_'4K^1
MF*BB8-8NY8 ?&K\V".&LS=?0R)GG!3CLQRDFEJMO^&.N&*VP/&OS&,[TK5D8
MO5^#,N22&-GG&2-]TY04#!B:S((UWX\^32SE.23P.0Y.=S;8,#<_;QXP2!.)
MS!Z@:EZ*5']SG58;ABJK%=S4V"CY37UYHY@3.$G!QU;D^*?JW?#P\)BF$[MP
M04\DIFPRDACN/,HA2DW;PQ8H#H\%HZ;ITP0*:#?I00>*&8N1CC.ZJ:T6P F>
MQ,$*.#JFG]3VM(\Z>R/=IYY:":-Z?B>>A!^C5N$(NA<\].>HQ^2D9U6HFKPG
M.PCKP?YF7<03[A7U]Z 7 ;9H%4# ,0W$4O=-6HG1R'N!J&#]%QG!5#J,JFU9
MY7LS($*Y&7!?S2",+JB!"K:FNO&-]J-GLM7L8M,+MDG[Z#2.03UL=?,=MM5E
MP!"2K6,>9=^UPF$PA@(R8@ J:B P8J^-1[L_M<X$P-].E!36-G#XHS>A"M!"
M%?K!D$(TD#U5,DX3OM@Z7EPOES-[>/!.X9'D&,:>0)DB]690<&A*,GR$UL"K
MZ*_L>KKQ$TJC&Z:P*^+J2.JE]XY?>N^HZP4G*?5PJ$K1'6,0F42T5BNFA//Y
M5+B1"VJ!4NJ$Z%"A>H5^8[0QN.!.)VQ^WTF'(%C?GV(</:4Z"<X.L6V5,#KM
M-@Y.\]UQE>I2Q-\#.JMF\S?6C:]=VHVOO+W9THW!#I9I#':X6WWY#I<YV]&V
M]>4[6F;WQ[O8EV^[6^8=+P/_DS?=,@_NKY,DON7$LMGK%D3?N"D\!U!@KQ;<
MCI-A9+%Q-/-.SIN!26>CP4;\5,JCG@V'G:DAQ3G75+'C(GVK4^VD<:TK[*W/
MR#AIE:72T,V^9) S4!I5*46B8K])-W>A,_L7G*ZUB_CK-@Y/NHV3DQGXT^"7
M>CO@R <6'8)E)4=+$SKVL?N>-;#=,#5#F.+<V262*<S:4 #;0=D1.!YU%0F1
MP7YH3VQYKIX=86?O)VDX*C?ZF-"YL='P$C[4V]#VLRT=4S.H">C4\K!X'/6L
M+H,-.J^%X.CA,$V$PB*\5-)6Z\7A1OS7/QGRS$?9(I85\E!!,S)MZPZ".*1(
M>%3<'KN1=*!< :6^$A.]^9CHY8(HNNE/<91D,V@ A7,?L3"K1[G!([1SU;;?
M9)!Y[/PF\LC&TU!P%L8VYE&5^/D7G:*6<1"#NC"2H]+.1JP-(D-B3(?FILT%
MQAY^549:^6'Y7"J'"]<DU[R1IX.?P4%TSU>9IL-*04/.<J. F!RGS&Y\Y6LU
M6\N^U+UHI$H!V_V6;,;T>R_FKYXU^"_[-Y[ZA\#"KV[.J=T]F.-%@@M0^J'-
M.X]5%3LY3[G"\BA[)!=J*;:_0XK*6Y!LMS: $5F4*=NZZ7GN8T4YLMLITV:<
MF.6+3"YU='(IQQ-E6VZ^^(":"X7.!E(WBV6/.B4?,CGC2U,UEYAOGI_[HA,U
MX?]^26(FR;X2?9I$P2#&Z*WC>C%*?6+<AHR 6)X-"G=/SE+%]K8Z(1?W[#LV
M*YR6D[@\S)1<!-8C+'6F^I<W5"=\$F! VG\"=;$<<P1^$UZD\SM[Y V!I1P5
M[=3G*<CU+)YB.I,L 4@@*Y5#C2Y)_33_#;L2PU]YQ&F@VOC2NDBV3PB$B0%L
MDS<T#T68G$>93G-3D583S6?1K&OJ4!:/>%)K]AHQF:\GM,>B()]7[?A9)>8N
M.EOJQ=I^86+4)S@!#9?.VF JVQK9-_EY:?;]XQ[$B@UO^A0 \H$;=+]M7?>E
MGJAVRG1W@6'= RE8YT!\T=',280W]<1ZY.++(=6:-Q KFT%D3$LF&9>,>-7W
M6?G]QR.,6>:"4".AL827=Q'FR#DERK+_TG;MYC#0:>9#I&D,()0J.7JQ2;_)
MH\\=3)?.U<[3(MMBA:EO:J*V=)Z57V4+72PQ #P()_3>I=] &Y^#PBN90'//
M*;C%&/V*!B:*<$XCH4)R\^\X4^]K,/E? ?A18)J=,;!)["\ZBV^Q!O]5N_?A
M-^QO<NU/0FQ:T*>;<M?& CRD^OYS,WR0TO :6" J]!K+^;#LEE9*#.=;H5:'
ME6)<XD:JK*H?(Z!%Z/AW*5]W]WOYG^A6_I@04%TO_^[!TKW\.]6WW:^7K)?<
MJ3D+ZVJ=WSY83>_\!])XO["B>U6BZ.[.A(%5@>DKF@/KA-*[)O:CU2 1U9[=
M(>75 :%3 Z&FA!50PKN662N:;?.+;)6V*[2Z(C#\3KG!PN%Q/F?P1: L_H4@
MQ#^B86RA^YA_)=/XW8.NIJ":@FH*JBFHIJ"-@V%+*&A%G7#?P3B$>S/'[@V-
M0MAXA4)A^+/:3JOM1NO@H'%T5%3Z63TVWM(0B+GXCY8B "4%I?Q+39-X$5V4
MCG;H+$X<!\W#E37AK:5#1=*A8U!!IUKI<-AJG+2.W@(%O#?1,),HJA -1\WC
M>NC+MHJ&DMR&*D5#MW%R=-SH'M7288>DPT)T48%T.&T>U<)AVX7#"O6&]F&W
M<712BX8=% VK5AP..RNT*=[MF +N@2^S4BUVR-RJFJ(MJ"_]3;> RV8PSM]Y
MJHG_U?WMK2H 35=H&8W;H\ K:\#]:CG+)51<7%76M':1<FS5[TME$N/!U;G7
M5ZUY<)H7TJK*AXK7'A]#\4A-#.R("MOZ0CB4@8U=ZP$!@* YR=*W\DN?PF#$
MQ\2LU$W";)4E&,X+>N)0[6LHN"YY"^@V=0=L(=T>-5K'^;:9BFZS@B#3?A(E
MR#S:KI2BUP'-UU!TIWJ*[KRQ9H"=%S0#?&%+P)-E&I^=LJ+P<<Z&EM[$Z3*;
M:+?4+@P4F9$BJ0/E F&DXFE=QDKU5EA+E\/J.@YN>_>_^41B:116A\?M;C&H
MZ'8U4F7C)L&]T6X^-;E,-CHNL@@6*][*%K%]"L*\SF'8K'(N ):LE11^X2I@
MVN(-M[JBK=4,(*/QL'-;^QO5ATE=%E641[+D*[+VJ!<?JP;1A]VOR2+H,6.?
M=BJLR3I:OB;KH/H*G;>VY+M.4UY1+CF5$?%;N4J&?Z92&4YCVN6JHA4!+5=4
MM!9(O6OR7U%BWV[5DZP."#M46513P@Y10IVQ^M*,59S888?](3D)'?$DO&!,
M#9"+M>WC0S +\L?-VEP_&;*_V<4Y\GOM#VDKZRT'+U\V_JVXQ8]"T)GO7";H
MD4N83M%K'^PMH5M4?9:&YB(^TF1V<'=NG.3T;>0S[! ]I+WFVT4/1]U\+Z2:
M&M8Z''*+J.&@T>[6J2[KI8=ME@Z=1JN;CQ)7F>%2O<[W=E2[7X0O0AS>B1-S
MG9'KN]$$VSL^B7=3F52E(B;!"9QUE@+FIIBKW3CIU"4I&]?'MHTL3CMOX@;>
M%:(H5LNVC2@.&IVC-Z&H[QI9;+>LZ#:.#HN&+J](/S,4+70)+4(W%1%8V>K+
M*G+2"TH/P1FD S1\[.VU&A;^\Z%,&4LE<.W,_JIE\VT]Y;;OK\;"-NROQL(V
M[.]-1WVZZW(-+):K58=JEO(05*FN'Y_4498-6O55>FD.ZX#9)FWQZE!YTCAH
MU:C<H/U<'2H/&T<G1<,9:\-W 36N"VJ<$\280+V=>F8E&]Q^=;_&0XV'&@_O
M&0\_IYH\['9YC"Z*,6H+%S+N"RMC#K[/7M28I9BMIRNJ)*LFRW%!NI^_J86(
M[!7^ >/M%KV^A!CK"8CU!,3MFX#XRF81BT7MJH;S40F<]R/11U@_@R2,A/^R
M#DF+)2UL[$A^4&!UY;I7Q/VAH@9NOO(RR9/T7IC?$6G988VIAB)(RVI4L>UQ
MU?49CI7ES][@],5GV4]KW^:&6M:Y9_?_W =(!1Z.Q696'0,L<8E1X B/!^W*
M6=-QQ RNYE(G \+U:.K([*6=F>A8VCX)B;9!1$)3N+D-BAPI3^<H:H%BM/50
M R''\#VL5GD# R%75GQ\O'3Q\5'U9;V';VS)=UU]61<?+[+..LJ.-PFM=\T"
M[ZCL=+W'W[K2XQK[.XO]-Y=XLK::%*VD5YI;\MH86O4/UCM]JSM=$>^_G=PR
MC.CWR7\GPA&U\IH*.XP^O+VBLQ)O$3H=>O/[TO:R;B0<Z4;#W S7D0+F \"R
MO9A'O+BMZE^Q.YE>^W@GND]S&JIF'7A.'"(*O_MXU&R=Y#QGZ\Y_J8EA)C$L
MTF.W*F+HU,2PG<2P3 OQJHCAH":&[2:&M4F&PV;22[]B8GASEM?ZU;*GP -2
M\P#/;T\CJWI4P"Q>^Z>&XYT]6;"'P.N9+AV''<=EPV?V._,2TUO5=N;X_BV)
M[.VCHZJ%=V5T5'&A2DU&*R&C52F$U8FC=BV.=HB.ME<<5=O/X/O5ZYYO1\6\
M<Z,_]P>8I>5BY$5$DUK#? DK(AP_ 1BO)12W1[\\6)P1#YJ=DUJB[PH9K5>>
M+T%&W6:[VGY6-1FM@(PVHUXN)8U:^6S]FHRVE(RV5AIUF@<[IU^^ ]_FI?L$
MP/$=:^H*SZF5SM?8?PJ6VZ-TMDKY<^!^$\[^OT48(/A/.NW.3R5U2:M#;RWO
M7T]/ZY7W-3V]57K:C!I:T]-;IZ=W+I]VU?&YWJQF+"6LLYKKG>[D3FO;LTYW
MWO8\MF6LS]'8"Z9"4&7^+9=_OS2;K=4\;-6IC=M-$HLH:#5)O N26,8&K)0D
M#DYKDMANDEB[E%@92>RJ159G.^^JFZ2Z;.?E.:RRY+!.IU,'@7>'FE8CKRNC
MIM,Z\WD'B&FU^F!U^<\G=?[S#E'3EHNFBIO;UUDJ=7KT]G!JU>G15?/I$OED
MA\W.%HSEK&FILASI#=)2M[D-DW]K6JHL47J#M'30/*U6+M7JZ(;3I3=(3.WF
M"BWEVA-:YT9O1:[8)C7.K<L8JT7\!C*D:ZJJJ:KZ/.F:JFJJJCY;^LU3U<\S
MI\W@[P@\U^=A,<69$O:C)WZ\GX0 ZT>W_]GMXT"<LT>P"A!7KQHH8\FW"^<,
MX(1+W0M/$#3^.#T\/NJ>'!R43YTY*9DZL]24F7:[:>G#6?)TECY>5#!X9>63
M;VY\ZXL-U,B([+1IC!#\VY@W8U%7<>&@$S>P;!Q;U??BR'T2H(#S&7#\3!2/
MQ][4LM5QK&=W,K2N1R/A .%8>[@BDF.G]9/^4)^=_M#^Z4/3.I?OP_DT],+)
MT(V25=,[HX]IK,XX#)!/D_=-4B-]'@.<<4/;%.$3[#J:/>;F:$>FW&QFAJ#;
MG'N/[,Z<OTOA 2F'*<)N #7WF+@1IXT4H9N',"6E)44EO&T"!+POD<X#A2QY
MSF\_96<J?O?Q3_CB_C!X9D)*<8H4$HH]D-(=\22\8$Q;Z0= [F'?A6/^&T<Y
M/?[;]0B*<+FDUKD- R?N:S8#SN()8R(,W4D03FDN7>A&:BK4B&XE'%H'TBK"
MX53XZ54<!F,!@+H"81J,0(B= 6%9>_(E5U=GZ@4-"R\M8,U_P(I.,-+/_/:/
MY)%[D!!P3<&EYS0LN"H#N*D;UI? M_L!_-4FT>3Z\/,_;:0MW[IP)].&]1"'
M?XHI/A$[+FS![KFV?B'^:EV-7!2S4</Z?_;$#AO6/^)GVP7A<6X/0]N5 [-N
M@%I24'I0X%![_*E\G%HM-I87&V]*;N =!)S.@]P>O:!G>];8?0HF\-_;J[.+
M*VOO-LV05X,!*!P6Z*UGZJ.V=2D&;M\5?G]J7<"+$!36E>^, [C\H@_6+>J)
M5M>:A,#DFHMX_0?\3+,T4K0:)'GN!EX 2D:4:!EP.</:I#6K5<X_:WZU@-+^
MQ*EV(& &+I C7=YXLD^79PT+Q%Q_")]YGM6#6Q\D$([ <ZS>-+EP0:0$O0DP
MEY(AOH!K-K)!N(3B,8:-H9RQQWA3@P:K1)#FN9]8N-;\5B&_O2F&NQ4AFCF6
M;=T"Q=D3-!NN_2<<J,BS/&G,2I93KF\S?()TBMB@,9N)NA@@91-EP(\AD"[J
MMWV %5!T,0$CBV2)>,;\S75J]=>^A:2-0,DHS,!B^LP(39Q-:_T=A0V8)H+5
M;GAXY((*(S04_WY_8:H@2MD.@)8BQ)*:7(O6Y1.\%D=0,K92 RRU%O^3!>H.
M2A'>'2A;H&CX?:$4C>RDR[&--.N.&<T2Z+ I!6VP)4EW<TKA7"@:+!.L)UE1
M,6.E5YJ"^9E-WWW\M'_4U<1CGB=G2?,CZMRF46VY3JEI.\/^A;M!^(Y^](_V
M=XM E((W&3@(FB:E)5E/  F )/.>[6GTW<>RT^7\ K//E-_N$F?K9,XVU!)8
MYF"=TO]^DM*G"PJ[(;-_J'[WG65VWRW'C"& FR<8:TM098%,;AX=)Y\QNI*/
MZ;O/4M[V L_!&\"VAB&Z5_XV"?K??:2)OLB>%^AY =7DYQ_L!1%J;+* [E/6
M%$'ZI'GH^KD[*15+Q &NZI.0M\TS79>'?W<9^)=[B"J0"M]]=%P'KKL)7#=R
M&B\:I4J0HWH9@M&%<X2E$Z-A]6)XV@9I")+4M@@4&1DJY?4$-4]W J;<LZ^S
M\;029B<^TN8FO%"?XI#/4.S<D:XE^$G=78WT36;X@:1KU1H K,SE&NJ6F8 R
M@'XJT&43\QE _E?LAM(/)R$HC68:ND[%SOHOB9-+H4Q=B:A4"!</8^VY'_@Z
M 23*\=#&"5*;-=Z6V[AE QG >Z)^$/O&G_$LCNT%/OP(NBM>W#A]&I@47ZW>
M/0)]?!2/DE?]%2,(\(IN)GO!:?5"EW6C*F2;^R=0(;D@T%-CRG%_TB%!X("/
M3)\$\V :G#G%'Q'S+R1/J40HDR5Q,Y9I!8H=\MZ]9'HWZ#<]T%/HKPE8TD<:
M"/B&'44![!HA0,:/C32'4,5S%BB \XZU$49Z,.A&*K&HX%7NL@*%9!]N!U#M
M\%Z0CJLQAU00,/]5'*DA__[7P+_37Y5AF#NYUZQGO_M'ASS[[8<@^?D/1;=@
M'(-M<'9NQE >IF-Q,S""/D7!E-_N+\U8ROZA#J8<S2NH:C?SJ3V*U8 +X:AE
MDDE*" -*,X $Q@[>D*!+W0PDC#X%X060[+7?C\-0.-<^V#9DVJP):*_(SD^*
MQS7,OB_C:F9+5YX2V4J:$LJOH$TZ*QXC8&W@HF\DY.80'D(O,L"GEP6N624@
M__C"^^,'HW!RAW^MEB[;S7SOZ119@K0O,PJ'ML.W6H^J0$P#V)1[*7^S!<N"
M!H&WCR3HB.])M2A>*7"( *,Y[L1C'M#+!E/;(S-12LW*!=3(=?8[K>^E9")T
MH./-%Q,K H!F[_@"Z0W@^GL,BD(^'C8*''?@"B>C"J3C70;'*R^"H<GI>XJ<
M"YZMM /:4N+<(Z"??S[3[CG)"FPK]SSE^' I=C&D4^)UA<N$PAWUXC 22MHP
MMY0PB(JAWYG?^@07[&=WA'[U6[# ?2#>H3MFGPO^O2QW!_GE^(_NYJ5UMYD7
M/&EAK12Z_B2VO0+98R(GBOM#_".KB086-W[5 QK(_$*2!'51$^$(R!V/YX@!
MZ('J'.CHZI,V"5\@+0Y8U>K'P,[ W?#GOAU+I=3D9H<#93(P"RJG8*"-,2@4
M3EA"!*3Z:O(V?&19.<]^/=@Z4AOBH0?*GB^BJ(%P9X\S?H]\/ZB?A8(T[7^A
MLPKX,AK:H;H20C?Z,Y(><$SH8%D4DOLAS;L92-$+6(TLT!D3.VP"!!HQ 452
M/4P 9AP2E/0Q'>;L_L(Z:AVE9:(CT(J 0QIO3V+4>A_):T&L@67:G^0LOX@-
MH$ERR&+)$/V8J/&&;MTP5.$Y(J>A-.?4\^H*W@CEWX.A @*XCW8<$<O(_E-2
M0B0TD/G\.>RC;SV4LCN!_0!P&X1U4D!!M.'P^QFY7/1$=\%X!+F0CTJ7:1<M
MLW#B6I5QC(7"%KF(QZ)QC#-2/H"MQ=@TCTM27% YZ\M0(U,MAP3;/W2LO@H8
M<LQ#1?^4'B%5&^1?E-] _/B[5J,3GF]:9W ?A$B=R%%9P2_]&R-*#VC@0:2S
M@'Y%14=%9A(%!P48YA71VTT/@1DB ,F/W@@=/="J%$G'YR#V'.5,B0"LQ/,D
M^TD#@YVR",;<AP#O+9._AP!U>))<78Y -Y[T3] G"E0DRM-Y$XN%<&JI4$N%
M2J7"@^'YT@H ZF>QWY<\5:QU/8)2QLI'\BA:<5*LJ#45(YMN/FDQ9!RCJ S"
MZV-/NY+[&=4M\!\#%",)+]=,4S/-AIA&VQI)O@F2MIF=8UQUC90YC9=3XD[J
MTX4SM$'S[PGA&R'LWE0:-M(8V9(P_R^2]4V33_&YM $R41%R7\B0@#VB@ )<
MB4E, #E>Z@TJ-$^AE^1C,A@-/Q!9BD'Z_::=P^:FCH"821<-&;K"$_@@=$J<
M&YEX%AP6O0YHSAM*%"DY,C\I;=RZ _[C4*"3!'<-=E3:+B,_5=8X4[M,I)Z.
MX13&;50DJ ^R .@.O9*8QHRZ$(7E "[XN):_&*PA6YKQE8KR;-RA4&2IQN-!
M&& $"NL+M!M;4=%LU^MO_%WIR7X+7OYH2-*BA[U-I$=!)=4FO@*.R(%ZK17C
MK'YM -J>%!@%R0D9$77(@#TV/=(%,/=K1$*./7<L;<K\=^G@@?C6%P+15H<,
M9D6RW,1?AAJFYV4<RXOQ_X64V+^#O74A_6:?8+&4N_EFH,!-;_SLRH!$!L9G
MT8W_*MA*E5C#5DKPF_">58EU@[E<;OPV1DD#ZKGX*T9@5QXF"<6^>+(]3I:1
MP1(G%MHX4+XQ=J[VW; ?CSA5+RJ58S,Y]!F,<]AE%/&E3[4&,GIGHS..OI2A
M,!]#V.,@- 7CDPW<1^: -/F9RZ6?(YI@EK]P5.:RNIO5E8R. =AW?R(C):!&
MQ?C??O#HL_^7-*%[$,9$)(RO;HNJH[I9>1XCEN@D%!CJVX5NG;>5JWA0FJN8
M3OY:*ELQGVZU1&[6X6YE+1XN<[:C;<M:/%IF]\>[F+5H$B[+Q9\5HZ5.8!JF
MTB[--?8C4:V%KZ6E[Y:G1AXO@^23U:9&NJ71^")399:"J)S5))P+(O)9+_J,
M:+Q6(1>YQLHUI'<:>R^-T6J5$TLR-0(G5%FU"!0Y\G#F.Y=)W,$XIM)%'P*I
MSH.5=(-^B"BE[?\2!E&T U#.M\!+:Y<<2T&O3"QF6D2-M)\L2^QE6JI,#$J%
MU=T)NC4T%])GMAG#(9TKC "AY+0AAU4?X*[>,H@G8#I2$@[AO6'H5_B2W"8*
MW4YS*84X'=EK^I"L>$86370S,#[;>CKH'#;S[90S[+9AGQ(*QCZQ\BQ+\4P]
MQ6A(8>$64;TB5/QQ*\"2(MH'R0&$?\MT;W[Q%:+E?(IOK1;GIW-Y'UES.X$M
M_5!;#-WN7!>@M/!F2*4%=(AT"*(DBZ>! 3F*N -<P.*D"3&6M#JI$&"_H!(@
MTO5[]_>W2=F]+.9%0SRU3DY78JD]&;JALX^!CZD,R?<!S7PA&)FYE!RGE2BD
MO=3&X$VNS!"%S>@D13,Z">^'V\*-A@OX0F/J5$!Q2M?!<"@Z,03GYMMH\,<:
M^$ /Z#Q!ET/ H0 /0(\_!SW<+]U0CCVQLYJ?SI7BV,)D&,1TB\GL(_@8CO;(
M!1DR72W 5"14_#PWI7XR F-OPLES5-;#K"?/MP"3*I9\P/MPZ^^C=F>^^K>A
M^V@<H"G("3,ZNSF?SIQ8$V8N#&#VT<U4"1,K25/220IT<N*@H6) R<O8>RK=
M8NA=G9KNJS1_LCKEJN ^D+D+8I(SAB+DEO3:*4L&N!.#H_ &\WNXS*P29R4K
M1A3 0B4M"8[*99SY&8Y)LO?<%'*]Y3$HX $F\5&ZCV1(U82%LJ?*$E!U2J01
MH5D -T:5,N6'[V-<-([(*T1(X%-,R>9CL<3?*$STQ.WY3L1$(AVLHHPHV-PA
M>49520GZ)74T+ E);&H*AQ<HX4)!'E&4]2)T X?=I!'L2F$4O9H3SIL%X1-X
M6 H$A^) -J=^4/YYRJO+:GC6'M.GL9U_Q1$7$BK9IL1S@6%@Q.33\#$\K<M2
MB!UI?RV%=.EF2$JW9')_GVVXANJ* 3CP9>:_Q.=D"$ 9!IXCF6\D)@5!85@9
M]J]2_8T+*)WL7V "I<V= 9(RA7LQ,0$.A,F]@5 I.6ZT^9"O@1,%X$1CSY3F
ME43JZ=C4N83L.'@;08;]XT@> Z"\=%Y2&N;I1,?L5U;=>"E)(,FWAO#%P#6*
M+Q4@X)@Z2$"^*4EP&I1S35""-#I[BD)D5]^D:#B3=/A@?\M>_:?&U:^:W[TB
M*I:TH]MBW7R^=H$TH\E8QLZ1()G>S(34@2@@] 4SADK4=71^&#2 ;3*8&Z3:
MBB&_,2B3('.& 8GT3.%)1A,M><TVBHQ%_'.O)OGB;JXO-/DIG;JK#/_+,'Z\
MIYRG+2;_5C,_JR!-_8DVD^^UJ(TO'Z0@6*_^9!BA:@%8+ UXDJ>6%."5([>X
MK?B.(S?IUMK*ST\%_#X'H1,)'PNK<YAETUHQF$(>ZB]+8$^ZS]4JCW"AA21B
MI,-U85K@PL[))'1[\43U2TI$INI7IN0D52: !NL Z&4RH53*M,Y'ERJZ^NT0
MTX_)4$&=_C&T1[@] (2/R1"?4B?'-1;==">MSVY*;!6W-G\/GLI6,S^&=&%/
MY0HNCO>'@<X\#&1=C$N$08O5DZ;%A4Z7H%4;'-DNX\@0^=<1 R$UH$49LX@6
M9J6.M3O2/_8"Q*\S;I?M1U)\F3<00NRE>0V<+E#OS 65MP=<G69^OF,:7)3Y
MY0'0V!>/O_&9%E=>7@BAUV@I:U,;%J.F>7EOFVE0CHD?LC_Y,>\DV]30#]#M
ME02?L6@RV[7<J"X,*$Y":\C&K90I(]-#4CU;S=(&Y>5A2D"_I"PTEOZ*/#R;
MUIT8R9:H.='V;*>L1)O;'"IGQR.Z\(!$T6D11$F[(?1(3>::?I7TJ\\G:N'/
MNOQF:7=+R7HN**9N/_^X8D?KW/;8-TF:HN),2_\]GZM5 I:C51G$8-PCB@V?
M@T0L-UOIN125D^Y-.QH"&7DRCRJ2D2%VQ:HC,985Q?%GGA1%+L?7# [0)2H]
MAI05#87(-F31I!:ENIF;KA .:*!2'R6A!]Q\JO$ WS;H5L9*6TV_Y.5+I3PU
MK=_10YO.T&77"#5[:J [FJ14[A%@Y\!/<FPQGM>0AD+2=V$<NF@2!-I1&":M
M_@.C"8548?3W$N-8-W6S-9@;QL\:Y%/ET4$EI9E0GHD2]K.;[*QE[V""'G?\
M4J#Y.+]->(4^2*)XZ5V3?]_SBBC,ZH<N)38;\1GR9[^IE./#=:0<GRR3\WBZ
M6RG'ITLU@6UM6\YQN[74_F=TL=W>K./M3@A6,,W-[9FE0:,Y/@$K6&O2!)Y7
MS?)95O:\^GY/&L6PRTN6YT=F&+7H/BZ\NY4'C^.VD974^N_1,CPZ*OHPNQD-
M:=N[4$+/A'K:^3XIIN=]_MB2A)BJIS=X$[7(XCKZSO??+3K24[[_)/6-N3^^
MQR57,%CV9-Y<64ONU9+DF'00:!Z.L>O 5W3Q?F$7[]4LO_1<J,Q]5<E,-+CM
M@#=\+E[EE9F0U0+M9@N5I2CP #1_:]'_YH^T8YE.\X<R_K&?>^$/'\E)5M69
M=A8VJLXN>O>0N!34NZD&Q7<?\P) <TQE4F"5D[;S]6%_Z_>%& Q6/H*[O:X1
MW$4&\H^53N(N^=(&'ZSW^W[VNR+)L'(!T%V7 +C,.+LKY?W%Q]/^USK'#[\\
M$#DO3M;58:#NO#A9X^@T'UA<^]SH'<%<:6L2C3:M@"[HIJ@*CX?'^>*C&HM[
MKV# :^S;;4<"S"WZ+[5&XN?/^C3[Q;GVSV4+ZHM@U),=A*M'/.:%PV?S$@0:
MG>-\1>=KD/'A;1!!M4*X N9=9-[Z6F:L;RH-&*/MRV.%_,)?Q>R,BJKR(U:S
MO7D7]VO2-_+Y'-G@L!/K_O>+9V]B%!%WWC2#:;G 3*F#_U)F(_P"YNM8=NJ"
M35QBWT(9F;D9RSANA)]Z012'J_'V5Y/DT 90W-L<K[DMS_U8?U[!9A-?&ERE
M8$Q7I3;CPIZD4LA#FTNG[%[@ ;$X;H1W:_%\XT8*H+C"G(RUVS# _BH19GPB
MBFX&U_X$FY*!]"/V+&C/T3E6Y*1__B-%M/P+D.G@?(J+?@TFQ=1KYFZE5KB0
M669<DTOYH+\0,.\(EIC/:4+27 <8!F3+/0Y51S#*Q)9[S-8X\YVDJUC".='Y
M="F>J[C.YG!NG8WKZ\:@E-DREDB3E5\S1LZ0]ITZW.RS7= GCYPZFZ2+% GH
M&O<5X+[56@3Y?8V5TI%0D12O,U+KHAA.$0EN^N-D$^O&H7AR@]A(7-(BK2<F
MST+X&;&8#&!K6C/D:-\.0QKQQ]T#S R[!=)%603=#)8@X9I6EZ'5HQ):S:E/
MJ'OG]25 H,MXI)$/,I&,T]TPB\N8>5%6'F+/NZ)29RY#T2^VZW\.(D"V>KR^
MMU8LNP[FIM=3?JV<W!3P-D 0J.&F*LO1C9*^M[6VLNU8?[FVTJ#)@'@!&%T,
MD@&QDZ&1[*IZMF2N,U4P R^7U?Y8*I/D\1JAL(T5[A;U4PB%>8=SB_Z1G6WS
MC$".*%VY-[5\91#8\608A*Z:Y/BGF%I7,7;CL'$H5_BG.GL&5'J$;H\E[Z?+
MLP8VN\ 4:NI.P:TK6'M0^-(-YV5.=*G2@1W_Q[;K:)SJB<640DL=+.C!AIX8
M@'/6J*"1\VZQ+02H(S3'38"6FLP N/CG76YL$7Z65% D?7YTLP#B?HN\C)$[
M,5O?9#TXLTSO*SO$.H+H5H3W0_N5-O6,1$I*]SLX.>BNVO#N-N'7B84W(UC>
MH46GVH"AG6U  500$>EXN+-4J>M8\.P+[,H] = SH<BR_I6TJ)@\!_M4UB1[
M5,B6 7)<.4^XH*$D?7?,5Q@H1W$HQ4SZ:&PT458BN1KA1$W4K66HCDXD.R>6
M+WDMFX4]Z9$$INZ$?&=AGRS-4=R^S. HX^VYEW-_L>3ENNNDN=S&I.>ZD.M&
MLAR:^-W:0SK\8#8,D\]Q'0,K*MFGD5(C8BA8#:[/?LRWDYK>HBB8Q7,1MA.*
MX59KQ0]IR9@XDF!;ACC-'8/D,Q8R4.5']L_HP*+Z!7,-P]/)2;-,V091W</'
M@+ SZU93U#T=SPF2OE4XA29I5@,[Q2'DQ.5"7_.R=Q2^JG1-Z@.6:RFE@"RU
M VQXUT_$B,9'ME%4>G;(@HLTC!L0>]E'<"%Q,WS&+#Z3ZV2<NX;,2:]3?1?B
M8I)0_"!3F6.TU4O_P?9"83L8"GA"3!$&(_A3I(HQMZRJ\)P 2_5/KD<TE@<R
M<0[?!S0!"O;G.MKCKAZ7*@Q7! AG'P@MQ*)HT$Y[W+HHQVZ5RQ$0H_M(R\*1
M@N296E4!.X(HIBZ,5("8Y:*&[FJ81B;JMKI''L$'N]QE[Y4UGH*0D>44PLQ<
M3DG&+O'D)]F:#(<N@68G>_E)WI_2B[@+'SJ^I3-*?M6FZQ*;4*C$_=288L71
M26<-6V\GT[!<]?V21V*,:(#+P11PI@+0XSO+*58W&$S6F-!,7,#.*.)[9>+N
MJW73HF@(WRW:/$^(]KQ\O4+#$)BSV8C;ZHT(&Z682GH8$F"B+"FB]Z8 (L^J
MRU_F;&^J]NVHM/;--!^6JGQ+]/S%JJKPT3]F%%5M6<6;W.X29^ML4<&;W- 2
MN^_N8KG;^QZR8>*MU.R_[P^%$Z,[\0R65>+M7LN_*ZF(<EL<?2?>#"KU%VRP
MXBZG6:'IBQ79V"<U9H]/20?>C#8]XXXR-&$WM,1@ ,B2-XO1\M:\8,K+^.JZ
MO=*ZO8.EZ_8ZU5?$O;4EM[)N;UTU1D>KJ3%ZH!YS9MTAUQ@5U![M3#G6BD"5
MJ]!<"Z3>-=&OJ+"N\@*Z'05"77=;4\(J**&N)WUI.=G-F%MEF;/73;?JALK+
M7KO"\N4-K[0!><S38AV7KT9C+Y@*03$/1H"9'/+*G9Q/BQ<HR@CA<,8BB?5%
M933M[F'CZ#C?_70'RZG>&+VEN_"^$7H[;#<.N]V:VK:&VHJ'!;P-:FLW#CI'
MC4XGWQRWIK=-T]N;E&YPEW9/5U::O*MM%=:F!__FR[@T8' 2NOV)SIQ"'$>U
M&ER]&GRG(4VLBRP4W=W_MOW,NTA9\JHIH":\E^O#.TMXN5OCJ-%JY1/S:WK;
MM(;R1@1=P2STVMK?/FI[J]+MN-%M[YI&_ Y<QJ79VWLT;:KZ]%4[VI>E#3J!
ME8:>?ZBU\NJU<L;NV4522Z+13%C>03ERT&D<MMJ-HY-JNS[5EU?UJOGN4U]M
M'.X*!18KZ[M/@04U^XV3PW;CX."XEG];1WVU_%M#_[[E6K&1!17W)U35=>8[
M=USM=X83/ E$%;5?FULJWNJ<KKI4_  'Z1G'M2X U3AWY475XKLT!.]>8-8[
M%D9A*1I;,,@PPH\XKWVSP^]N?.ML'+H>TWB[H[HKZ>EQU"1./+GP%=E>R<71
M;E3?]22X,X\[TC/P=.I^=I(.SY5N_]"Q^@ 9Y#(>+2T;<4SL\,GU7'Q&#\C6
MS>JP!I.ZH."WAL$HZ$\CI&@<F(90Y9X3/=G[-5T,&2W2<<_%IB"R;(XZBD24
MJB2^C3VLC0/"A3\^8L&I1XV(4)31$R/[FSL"4*>Z"7 S*JH\]!_!VG>X%9\C
ML' $ST.%#@0^H]&(\^1&/ T/IVP'(=;ENY':SD:*;,\B@ =C-@U%=S3VJ%L&
M02Q,<3:0OV\TT7#)6*>&(0 J[ @P;TATH52\"*+)5ZK(O1G<!ES^'%UYKNPR
M=DLU'/#O?G[$:^O $))'98U)QR!FS9NGHV^>_<X<Q6>C!SI8P8%.BM)?,A]\
M#SB6$TV48,BRO( KGFA@*&RGC]H)%EO_/?9%MH"\<,REDR$LW06&^)M71LF
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MJVU5\%(;>H%Y)!=8T&+=HO)]C3:SS4G-E_;$MCZYGK#V,!W6GLC(O$DGU.4
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M?-A6"4!#@388BIX@._=4R0:2F*[?T&7+FK11EF1FB-H3%AW \*)D/RPMX7'
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MEE>T+X*YGCT! *Z; 0 1    9S4Q.#(Y.&<P,7$W,RYJ<&?LO0=<4UVS/AI
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M;C]. ^3?.Q]P#B1:K@Z<_R^,G\@#[?+;R>27X/^1HX=Q@/V!0P)VP9J '?[
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MSN_0  @)\=X>._3I. FQY*$+7**TQ_ >N'.?(A:[$4UWX,$SH^X/XCSVD^C
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MGO16I:YK:)V>C-BNDL([U+N0CW,Q1MM\27G]V VVW3::SO.DYY3B<#XL#-Z
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M3,@OZ"8F^68ZI"D[4JD-V?2 PKEL'Y!=GPY -2&^LDQNO(@4VC@;PK2\R5:
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ME,D^H*RWN(IN>?,)EH]=;5P.TU%!^KB!Z21;6*.@S6!VVK0B5^P[<:F,90+
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M/A\B)2FVJTQ\G_5LJYKLT'Y7E/FY5 Y>U\'+#0PQ*%RFT,C#S&4W5/W0F_'
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MCM_EF20-B<E]%S^_/H9U^B7.;"[\%3IR"1/1?:O!HNQ_H)[](>\^=V**6>N
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M)'_*<BMN]D#\V]S+]*B2HL&O5B7X(%(ETCG[>VXJTQONJCHX_J0"W2XA-_M
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M '-QNLQ6JV[WDV(76/1:H-\HNBUVF<NP;+AH U]EM.B=?;966*V;4^+GI.6
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M'F>3ENY5-JE5ZLV(1,*XZ*)W=;&^2)&W.2GDP$3=]_68'71%P__V_>$X>?-
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M)[I7&9@2OY; =MMQPMA8<S ")^=B#(SJ!'TK!FM"'_$Q2#;JLF2=K_Y 323
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M[;DM2L7V*C 0F@-3-[FOEQVKR;Q5.NM1 1TF<A!S%94I$0,N31LY2$PS'-C
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MF&HGG4%<]WZ/Q,$!9<(IU'V9TEK/M]";&Q]KT?!:"K?==AX-"O_?\KC/Y!0
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MN_OP?M_<^3%WYKGW_NVNY_2JZK76V7N?.KM*6R=:EPCO7DFCE9L4^*(DH?Y
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M6&0E+C I+/Q+P.U56.'(7O:IU(!^TH[Z?L=XJJ(G4FDW6;LJ>>N%[Q([,\V
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MNG+?>'RCO\0EU=2QY\W;P50F<TKES&,3YD[NC::'-G/)IA[#1[EKDL<RKKM
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MVIPI^0 $M-U#SK4GJUZDM8N-ZA+/Z29:"Y0O=XL$L S=-E[4SIJ7Q'CP[3\
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M@/_?+,+FT/'&?7]R#:F':A9VV"\IJ5^:LXMK%"#F+Q=K'GNM[;H)6_'\E_0
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M- O>XQ61A1J/?NK6OF(1/EAXZS.==>6G^QD![3+<0<>9B8^%UXS_!U?\V.=
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M+_WW[L)2-^G5)G>V%SZLHM+FK*J_AAF_TJK?#1D#1SO1QAH//WR72YT=GEO
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MS+N'V%$2F-N(Z%-V[F<@-\LX6RXBCTASYE@@KW/]/[C"[8^!;IC"+7LW#L3
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M)UYP!'M]N;/ & ?13>+KX/,[J:KGS/X*B\(DAI9H:8$Y+1V7DF]!M4U]*SE
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MYBR]'_R]LH1V*"ZRM('J'G*Y> XER6.SXAWYZJH+\D[R4;-5"GWR*4V_!%A
MT-40*N03PVIT^9G@R(H;7&IL8\E3]NV0@"(/%M']A&(ALV@53G:=66%F*7]%
MOZ>A-&M8P<KZ-OE7PG!U0O[V[$L5KI+16/L23U%-\)E"H>"A>T)!)']@E8?,
M6##3;+KL'7,= )";L "_IWY9*8EPJ&JT>'MV4GFI,B#FF*I&7AZ<7JB5SW:W
ME/?FP5=-S_>5"LV,9"9,)PVE69OS0^N&:K<2+*M2U=!LFW*[LOLQ4-5"U<G@
M!<JT(M:6,_+-A9TKQ_).R;^:&>0?8#IJ*$V$O.]U\+94_*DJBZ89H-&R<[5O
M8U86]U8A@VXHC2JSMRADE\I.KSR2%R=_:*:?]XCI  "D>UB FM/[,#L8=K?S
M8W;-X6NMWN!5^Y8WG */!-!K%!"*JT ]*\=W:4C%JIRV*7O4!KD6FF.9:"BK
M7CW$&EA'IR'\TN':EDWPZKT?ZJO@K0&[JM/AKURC*D81WDN=RXXC<%.4%6N0
M,9ICM6(!RJWN=_BGL)CVG[@/AP\VV^#6[!77<; M_I^J=F#!KO/*J[&I2V>6
MXK#"*;?+"#@;#96BH21''M.E,*VVCS3+Y,=-BRF7]MK5XLA7_(5J3_+J]6?+
M"DBC2]Z5["//,;8H-2 %:RA;#;7ER!3^(6AIVVQN3#*QT9-=%ME7HV"M]7>O
M#&3.7\\IK6:(EUQ1A3.W& >H.BC% $!\BP7(M[MB\D.A0:V)DLO)+@U4D3P2
M4GU;T+WM:P63OWO]@9*+O&-+!HI3>$^,P<5"2J^&ZM=0E,Y;Q5%0HY8Q95S2
MQ_K7\MK(#=5;\E.V]9>_D%Y?OZ'$3JI>TEDD%:N,Y45"RC4-E:^A=G;&J$6Y
MHRU[RZV2CM6GJ#Y%3JMJ*HK?EE]^4/EP_2Q5F7+*$G7A#^D"X[["9LH[#870
M4*:=,YJVY/8U?ZG;D-16][Z*L.=CU9**BFW4LN[R#>MG%O\LF;:DO_"0=+7Q
MV\(%U)D:*AH+(-*''4$_T_*&6K/71^WIPV3G!V5WX<'+/12MM\'#]EN;%D'B
M+/4;OD!2=#+J=^;2 ("P5$,EG?* 4].J!OOA,Z(.]J; K@5E=OK#QCSR6BAP
M4_N0A@IXN*5?O2,\2M>XUA[IJZ$6:RC023/<M33)@ )[-<JO9S-V6E!@AS&F
MT /5[(9)LP^J]\/D6J)J^9@J74FU/Q:BH31S&9%Y_ EM5AJJ/YNBB++HGD%.
M#%K6=HE$\CC8I$72M@^HTR;>MJRI64 BZIFI981T#;500^T[]H(;GQ9_-).-
M/?CKB"[S29!V:S^CU&-7PVWZ6?N@FAOT:LO;5><8#GJXRJ6$#@UEI:$V'%LF
M>9 6UI<OXA[\W+50P [2:1GE??+85?^*^\(^NOH"3VN^N;J,:ZSWH/PNX;N&
M6J"A+(:(2DB:7^\S>=/!SYV'\OV"IK282!,\]M4ODQRPAU4#$MC\[94JP2+]
MC65GB.M_4_!/0_KE#FGNO?M4/P_^Z#A:9!<TNSE:.<LCL0ZBB+1G587++\Z'
M5MP1>.A32I\3#VNH^1KJQF!!W9:T+3UWJP111AVN%?N"5C:-E*WU(-5>*3EC
MWZ&N+]PZOZG"49"H?Z+4ERC^33U:F).9/>><9>[V[+<=6.A"\$CQ2N@S2!U]
M*:PQIR@K%H[)5460$;N@RHWV2$>8>'8!:A'LR8-I8 HZZ4P*A(:V;/N6@T0]
M+!S.C4>=HMZ$;D>=SEP#6XMZ$+X/;H[ZZF8 ?XTV,[=&A*&.WG,$O:%=&,D'
M:U/C6J,@4RAF2M^<*:2?%'2N(6E&^GNH/M%K]Q;H)P+,]2ML$#\X<Q VBC>^
MDYPE$+F>.@VJY?<VR[/[N*D%#>#S[!WD&9!'S)RTQIQ/]/ZPE;GO:(O6_X(V
M4MK,A% &Z<6MDYF0PH*33EG\ OLF;5!5WF/YJNPA\2BQ%OQ0\"45F6/ 2PY=
MDFO,_K;>/+>+^6L&)S>+YGXS-4-:;7K\6F9S>6>#.FM8A<F_#GJBA!-RP=-D
MS2E[("[2M2%K<CQ%T]9YY=SE#TUOSB$RMM\(3'_>QCQV-%.W<5\](\N\QC&O
M!^10L0D/RCZ@RC\, M.5.X+W0H0RB LG9UG>LFF_(+WT<]<STM,&K(8>9N"Z
MS>M4F=0V7>EPEJQA"8X$.EE5G5R2_;.L-:@.8E2,</X (2E:IAV&+*2GC@VG
M6YXY-N2387O\0>WSS$5][R7C6<L[UV&[0+N:?B0]SR;4HH*F@-EJ?^=8\$_5
MBJD?P$KZ_,OFF*E9K4<?8J:#3E5_P"S(/BM9B'$!G\=",.&0FTFO,-2<3T&.
MF+-00^=\;"3,8-H>W#O8IDM,5# 2T]>(RD;"J\Z@)$BDZ!>J#\G!A*+>(SL2
M+Z+7(S_OLD*S4,YKN1@S%&BJ)W8;BG 10%R@!/4:(+7)7FI/Y%J2CQ"'S")F
MH'XANPC="<4H<X)-H#$J!R]U$J!>XI>9[D!?P!'.I\/)_#G=\? CW+D51?#/
M; >!*<*#F8Q4(XKH-^.A2!,::*<1,H>ZR+$&>8MB90)%L8@_SKZ'@>1/NU[#
MU/G&Y:MA+R6>O!*XNU"*2("7\N?'[4,LYCS>,1<A8-UUN(%XQL08]R-S*>_/
M-$%EY1<ZFZ"72A:6OH.9%V9Q0;##\D?P -CE/%YL.#Q43-R^!3XB>.2P"&'.
MQQO;(E@4QNG:W+>-%SOJH2MK TN>0>,K>SFIT([2,-A>F%V1<PP)5EN0%4"$
M+\K?;D^ [Y>"IJCAPY1U(P]RL[O?MM_/5;<7EDS/O='DPF9 E]<\A^*@LDJC
MZ$'8\I(V_X<P>5'*FA^PHP6!4[S@J\EO1G;G6IW<TAZ0&SRP1!65FWOD#FLX
MMZ6U/_<$=&F#?;0UM+X:X1\&6U[Q;@T*YJG,,'H#JR.W'T-3YV32FWY0UF;U
M%/+)(- 8TY)T/OM53AO)#V)\:#_Q1H[+MF:B(G?WZB'B!VB(X0WR+MBA(5\R
M%M[>^(S4!7^FS":9("P9!D0((@*B)GQ%E$?M(\B11GZ=A"1DLMU50B.RS]">
MJ$9!!LU(4XE?&RJ(^XF.BBA"$P%$NT:PPU\ 4_"=^+"#P?@4W'O?XW@?G'+5
M=SP)EVX@)6S &??7$(YS5M8[$F:S6/*3>"3C,S4+#]"1V5ZX"MJZ RZX%*K9
MUE%< &7F*CL<E(PVF(7[0EQQ- S?G1==>Q5O*OXI@^#@P@**+4Z/'PRRQ-9S
M5^]WP1+985L!;!+SR$HHEL@TTE=A'Q%1?0ZXEZJ>FG:<1Z$X/P);51!'GH5U
MS=^:-1_S6+)W7S"F5=COXX,IXC?;7L'4\V?J^V!^$3?W^N#\:]=7#V.5ZL"\
M.*Q>V7:2-89=O"]S,\9'T;Z7CYDCPWN7H3_E+;8-1G^1>.E]PK@3#7NXV#/M
M8]73L3;-3M(\#+'N$#$0HZU69F2CV\H"(Z^B1<65WB;HW,+,%;?1!V5XO5:T
MBG"C9Q86.G"T"H^YV!,K>8%9VGZ4($ +FES2CZ$]:OTCMZ*MU=E> K1!N<,*
M&.J1[* > 6U#Z&S;SXO(:"ASX2@R7PH7L>>#S+ ?F">SUZ0.,Z3@L @!700A
M>[RFW<DIL<'1-^;B=%9JKN7=K7LX=V&AI=YL/YA"8,6\!'N*^<J@P-U3+M.C
MX)7A:EH"8JG'%&H+0KJLD?H-\4'[.I6(2F[Q9S/PSTI,6-KX WP=!A]W$7V%
M'HI+/CQ"6X^;N[N+&H"][[Z.HL!V+OU&.8-MUQ919F.+F^U8.YFBXDN,8<86
M;BO],.T)JH.VDMJ<W$U=2*D..T/90CZ^)84L)9LN#2*WDAYI1Y*NX<1->LSM
M8O^B?OJPT)4CIV7P5R,95#?N^J1ZBB,[)?0V.9KY<',IJ9M1MZ2)-,CHT%Y&
M/(7+;M1GD H7%O;0C0HBV5)J=3X'P:? )&.)I\A9HGVA9B2IP''3+^)G7NT2
M.^(+WB*MKX2'N/ &%_I3]53E<UI6F9C51YVF,H4?(5]3%B3JD4;EB)##Q)]Y
MES9!B '2+8O[B ZB JU1PG+<YGH^'=2\7.E!_56OS3*BB*MZX-KD\'))0C I
M2'4W^!B14/AAXQO"&674XFB"4.*NU8YGX6SKK>GS>AB*(U1U1S\SG;*Q^1CL
M .EUW:OX#N*]JKY@'^+,BD<;,82X4L=%XX3%XA]:A7@SW-P*6?[3#$,I6YJ=
MZ4DI%6_*2H;4"S>!F#$M_*3LMD ^=Q3\V/42IQ_RP4K%)><0-:M1$&)K^:F\
M NARR07)9BB6?$4T%7H3_$!@"O.+?L[;"!O:>8Y3#0]RG<L6P4>L]#DN$[]7
M4J^A!66OI1&XC>+S8B/L*=)3P75L?/9+WD/L_&@][@+,VYU:;"GF]OI8%@YS
M>4$NZQ?FO69U \("I1\EZ^@>HG[A,]I"XC'^<:HIZ!/W-&7:(4O.3++GC@TL
M,4FTKH^))EG._\&\24K0K (V:BAC\1I!EO",X 5/11CFG>/<R_K$N<%>&^7+
MGLULVHYFEC)0ZU8RF/3:^1S&.?I]S9.Y Q8H<19ER(\)307V^<&$*;RIDEM9
M2SGS1.2#N:R]@J2 4XS;O%H7*7V(>WS^$OH[#D_S!+L+"ZAPPK&R-8(0OD(U
M%Q_ A2N_92:Q<?(?!TXR!_)# ]8Q?*7N+LOHLR5"R_-T._Y9S1.1" L4OQ4F
MUW7QN_F.U<:X*JY!A6_&<;9N2?F!U4R?(KI_&?VL,LZYF28MN&;)H%'X2@#
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M153L3&'_A=_2X\16$!2&+6P@,9>WGIU,<D8^8,>2;A:@V>GDSE@=FTPI7!S
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M+<M1VQ>4UM]#%]KG-PR@/:QJ6M=;-(APJ_TR)A'4W_((ZY?/:?+&S5H;:-F
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M5+^Y^O,6G6A1S=V-:5AG\-\]N.(2Z(&.5?$R>%CK*M\C<("E>P("/4U8MF<
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MCGD_/-KFMJD%ON<_BG66\KUE-92&:&X<@=TM#[&P$*LS=M25(/6Q8TQLU/G
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MS!LWA43B0;N=P=<+UIFJH#W% Z(S<%C90^(BI'OEZRH@Z@3PQGH6I@S<%;D
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M)&:O/B2SB&(*A[Q$^>C(<OU0<_G8)#^^3_)RS"'B3.H!+"2_,WT;]@< D)F
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MNYB3B(UV:,C%8*_NS,MUPJW5TH27X^9M-E)-QF9R0J$CT(E<!KR=K4_NC"T
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M+*#!_Y>J^AYU/>2Z^'3<TLC-%/7$';'A^<DI9HF9*8V #:D1@:,9!S*T'>#
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MA3>\;X=>$QRT/A&V7J"O;QW=S3^G=IKPDVHGLW585=G/..(R4[X$!??P5+%
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M -H^YZTP\HK!S2E?,B*A&( TUB%W9Z:V_U1>91;$>1?L#HAC7)9?#7%<>ZJ
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MG5>0/J:_AS<GT^-2"M^DZ06]0>JD2_9:%JW*G+3Z5O0DZ](V*@H#VK*<@/4
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M)B:KP]G7D^8J'2#V<^NU,0Y##HTBA##(UV-YGE@*( 'N8$9YGZR_>PUU?VK
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M"  5IU&R/. :/DAB:QM".,X!/WV*K#@%O]Q39#3Z9GAUT?%#^ 9'%&V_J1"
MAK?.HLHQ]+JNM!EL6]F/@%3<9]FPS0\"DBMX:H2,N>)QZ3/RYIGRH> BZ-'?
M]3"4P2&*H Z]IF=MT4>,:3,G#8I-JA+Y?\7M5WRS&2$X\*@/2AG:&/T+0CH3
M@SFTB;X2<[]N#ZT="Q0LHR7CEA>-T+;B;J91J._P)P)BJ \(KVP)-'52T3_W
M:2):Z_EDFA[UR8 .M8^ZMW8W-8MRC/><:DK)0=90EU&<4A&47Y0-_D74M92M
M-O]0$RD!]R*H'D*/L\<H-_FP \44&O=0]3@EA./.[:58L-XA%!1CYI$4,<6>
MP?,;H@#I\3:QE%':DCNCE-TEXV<,R:<4'_O5R 299U4R.5P\R$&2@X2P0C8Y
MF6^=/$ F<Q[ZK2&/LY#6=RAV]([;WF3/.H]3?:0'5?C>,E)-V97*)21*22#;
M@T23WX%S26T2>=);TC_";;YXLA,WSQI)'F):37\C23J.G$22K%O4]V<2W]3'
MES\D7JT:9[D1[Y7Y%U21EBLO)3F18J4./A])QP4NUOKD");HYC/2P@&;\5QB
MPWY23S(QM?U4V2.B5]-V9BHQL4::_X0H*YM)K"+>5^KY4$G)HLM6ETA?V2=N
MKB"6'%.-%1.=AQYTDPFO^]>5:1 N=(8PI(2G3>7Y3D3SZLG$C42VZH3/=M)2
MJ:F5G-3-F9C*)@:>>W/B#>'-F%'7.$$U8E_J3<CO=Z'_0^!TQ,.:"-<;  D=
M1)<*7>^KQ--R-ZM,$I+;>>6MX"7JYJB,3T#'M1_FF:/OE*1Q?F$(M%;V$ZQ7
MWF7679Q=PGKF7;RO-Y[QGE!KE<C82,JY7,174(X= ?+L*:YM]9R/Y,O%B>SK
M9!:UFW6%G)7[C/F0#(K?Q_A)QGN=9YB1ARS?T&$4DTN[>-&\P</KN(NY]JUT
M]AGV6:4=:Y0EIY0S+S'I.>\97QG2N#R&&;W.RY2.IHU:"FG7J%<F)KB>BL;A
M?O:LS+%E-6M"_$#^G'E.V$=&,3[Q^Z'?&+;<X[%M= +[A&<E[1:SV]*)%D1/
MN4#E0*H80V#VCG*[IC.L!27?9+U,#<5-$I!A+9V KJ,S1=,QWVAW^6.>6VGA
M'*S%>^I5QLGS2>PC+9#!8!:NP:&QGQE7LTS:P<@H?TW$TI4E]R!^M.?RB9@4
M6K2XPJ.7.L77L^BCYK*TSF6S;7N]#Z4R9SJ-&DXQ)II_2\[0I^ON$7KI>I5G
MP0TTA*HF^B;UCMS-(XY:*"194*CKV$9G:UBG1E8-5#!Y!]4:%C RNZ]+U.G0
MUEK\#UI;/1JL1=.MM(F&4-G%C1Y:U"WB9HM8R@1GXUE-5M'XA8%%3-<C1^L3
M&*L'B.($NDZ/(3Z#%M%R#22D'JT%1VM0]Y;V[!NGW)=R+.PH2LZC$\/*V:*[
M^\_*>U&%U?E2"7JU0"&6HL]@DX6MF+:L7_QSV$.1Y[@O<2_VCG%6$'+,(2P#
M$N X07&,;-=S248G354Q)'DD.?^@"$<JQ# %=21LECWO)JDQ4I>[BO1TKPO;
MCYQD;LI$4I8?2Y#7<<C===)\]KY*O#B1I</K%J*9^NAB?@_#&YC%_4'G18 Y
MOK1)]V,L!<W!["-CDEIYU$<FETYU$22YXJ&*(%&6L(W;+"#R3Z&J>.=Y*S*E
M7&-.1OAQ-IO5[1[.?,N8,1MG!-%7CQI)CY3OZD2*52KK<E=AB3*"P^<?E7&+
M6G@KQ9,9XQR*T#[<F/6:AW)[S02R)685]"N,C"-&4OT&1 =*-%O37N8IF*UX
MQJ[E&Y;:(R>Y&"4_0X?]5'H[K(F5(5KI5LIXR?UEAJ7G,$6'0R6JSJ[V1A&F
M=44I0H!J +"F>0W5!Y&[.;_*==*9;$1Q?)@3\[DTURV&01/8FR73U[)D(]42
MZX,WV[Z)UNR/4YT0K&X_P#+G.34M07 XQ36)@-]LO3)%Z"VFXH_@UV>8B2S,
M?&@3[(*1#>)[HU_:"H4G!UDJ"_[1WEO,8N[C#CV$&L>C,0H@9YVL0H:RF&$E
M,:[WZ1_$]\QL:$J.T8&5U6Y%-@V9%;N+)N09I8XH'/5]<1;:I\!,7H]Q3O65
MW,>F!E>*M'$M+@Y\,X*W22=G"RFZ?TF5,?%'?7VY+G% UJ4R(HJHWLHD(B^?
M)&L@]J;4BV=(:L&:0AL2U/D:#T#6,JED9Y'?]&VNU&.-U'66K6#62"^7;&/4
M4("*#/IE6*]TD&Z<_$&\@58=1!) :%N=B=Q6ZK")F'6,FM-K7&$LSJAM*S44
MDB7'BSWX(V2\G,33S;LC><2I2/811;#- W_R]S-'G*VYZHQ $SK+FG9Z?W!Y
MD&IKS;@J0HD43RI1L@<DL6Q8DI&G)]$5?D^J$2KXC8%,_B+N'J=7G%Q6KPF6
MV<]8U(,L:Z^9KM$HZ:G,$F]67"G]1IR0;2BNS<T04^2129J"'^+?@?H\M$#J
MU,-^RYDQ*6 &,M=W#Y=9M&*K(TKL&YU%$$5,S0>BH;2RHC=G0KQ,590H%W 5
MNP+&N3_%'4XT-H/WU03"F&$M[=Y>.K'_5]7AXFL=+X77Y#/-1PARJ4,=)\=?
MU% 9G;A38*%:$H#C-LK83DEL4\&822:CC76EJZV4.H2J\BWF]%.%T?+ZK@2"
MCN1ARR;HI"B\]G[".?Z=<E&  S==J>EDQ9H1!9BD,@K8F&:UEB'DL1)2P^VB
M)/:AVBVHY>CRRB+4 Y!3Z03Z2>Q8\0;L)M]:F0\.X_"/R)M@LMN2^XODWV33
M/$;4+/Y0_P_A(MNA9C-A +VQ D$XDWU =9FH%1N@-")B?!VEJ20UAQ9A'NGT
M[B#N'O+E1G+3*-.MV+;N$<.9):S>0H]'0<L)M(YLW9*'-).88PH_ZEF?RQ(!
M%>> $;13@W<#.3RJ2\/)QHO")&5V[0]^%7-_E3MO05%;62E'E 4J6<GVC7&4
M$UFK?>#B2XQ;#L'\W_3NW3CV#(W9H-ZHK80JFFKWRF89;RJ9DD;DT]*'(CCP
M='&@(#!Z4'::Y^*S66S(6>^PFP]DOM@M9!?0V^LS&S(KQ8HE-:HR ".LXFZ)
M%S*TU%7A!'15-DD=HP-E&T1[O*^)Z'PCAZ6\F^Q/NRO8:HR.NHOUCQN+Y;P:
MO=H&^K6*V,I^Q$55=^E$YDGE#N5,U&MIM6R9=XEHH6B!_5L>B'MQ=RNKB<FM
M"ZWG=.+DVM4#+4?I*>4S]9\0*2K?:M/,-,50&2A*)?502KP!PF9)L?TMGA8?
MMKN?E<3RK'U6O_? _\=@685%N6AAV&[==C<E)2$*TMV-B(C27=/]S_P]W3T,
M0W>#@-W='F,;V%W;VG:>?;DNWHOU?.OYUANI[JDM[=V%?#;7M_\A?S5\:/+/
MFZPMJ!&DI"G?& ^&KI-EJ:^O/R:Z*#VS9A]_!?^FJ6N@G%HB\>T^2?T.6-J]
M:=T5!YIVT*69?76+&9:$!G,V\V'@;SV=G>!^6Q4*S+7Y+-G)\S4M[I< ON(G
M7;>!T4!T6S#G8T5)8S^P,'-S[0* G)!4E0?\"#RH@[B-[O]39O"DMK[B1^"P
ML;Y/A+X4;^]\B'SF7&X-1AS*GS<,PI;M#VI6PO[Q_YH8\(1 1%L+/70_J1!#
MSVS98GMXIG%UKU["$9WN^"@:X:QMV2K,+4^O/RE8LCW7$L ?&Z\VUN.C R,T
M5[$)[@?EE]$5MKTB(1)A,/9<T(P5^7:X*/>PJYL-<D/9R?H)4OVV?ZIIXOYX
M;\-CX8/ .9I5@HGNN^1K<1?;V\+?:(9A9L_Z*K[P0+O&H&1;-7W1#I:EUA6H
M/FX3F*\J@N/>&=9+50$OU5S1#?<=LAK!3+LQ0C$6H^_L;JY_)]S:/J$FC'6D
MJ;2JK?1;[0W#LFU>YFB-*6Z7OD<Y->"\ZJFTU+U/ME2XQVZ5T %?H(_H#F_W
M%"YNJVLZQ^(W?JI++QVJ33*_S_A4=<1@BN/IO35> 9TJ5'[8O5>Z5^QNYR.X
MC1_1?>SZV9<CN-06UVG/\FNL;KY:2JKY5,?/.%A58$Z*VZJ[JY\;8%1Y*$_^
M1[$DY78) @L_5C9K7S)U*=@P_(A:1Y[?C]&2\O.[%M ]-U>W@(Q-D:_J>IB=
M/ONJC&P'%U>M%3#&>K0LBN<J/;B7R4% [O!H3C#I79^,XY._L7,ZA["YHKF<
M<R_R1*T%P'TZ31)NK$NRQHJ79ETIS0=KI-B>2F0 7#OX!SY):N_%X&EY+SK&
M0%6;;9ORH.V1VIIJ*,[':-1!FUR(Z@!(:GU>8H%>2(-VEXL.\*X-CA:N)P7T
MB/FW\N3M8_ ]J=<;*[%+D5F6 6RT#V[8B0:XB%4TI-IFA?@],DOR=I=.>8"'
M['"0&XG/N@>D=7GN;8[BRZG:!J5H3:1;]2.!T8>N_\B?X-*@/(&A-OGB+'2>
MQ+#SO6$7SV, U+XCUG>/5L?D_MO*5)Q.S:B_*\N,G%%M+_[C4ZJ/$%:[#"N=
M^;XVM:+'Z&=)V$YBC93[;_\7\Q)B21?!<"#W8,M]+9CJ6A^KVASQT5PM=_0I
MT/6*O[B<4K0)CMI<$('8H&3F\.=F=^[Q?J#^+V) Y_OJS[GFEBSCOZDSZ\[K
MQD;<,MNKIOMLT_G*9KK<5*P7S;'Y)'+&D\57AULZ]W/[^Y>W7"&Z=<+UMW+Q
MYI'J[ZECZ@*,(1$WJ^HU2I]2[17Y79=W\E=B%]NYPE?X_^#I)_(IGZGB0Q[4
M_*+?>\;3IF:4[.BB_1M_NWLB8W$PTC*5"6XX6C/(GN%X1O^$\VEUF'R89P-/
M/ ZROU%-!Q/8K<7C=D]@UV04#:C8(_$W.F]S,H,E3;>!91L>603<44Z+=:=Y
M#JNORPZ! GCFL6RXCRHXX ,=+GJW\S4T/2.ZOP+LCS_:,0PJ@T6-!\#F#;^K
MJ>#?3MG:\Y"/5:KT)70<_NMHJ-"32MR_DK^GZ,3P99R:8=^7B%'CN]H;T,%@
MO&$G.L]SOIF+B)UJ-.\0&ZM#TG7P/>C'D11Y+S5CGX.TL:AOZ+KX8L:TWLTB
MY_BZMA;![F!1_7E^@:=+51.^T.EOC2OZU'JIQ(C\#=T^K-6MH,;LS5;SBCJ&
MQBDG9TSO@65'XNM:_Y88@[5U/T6H9[3IJ8#F/%$MQ3G6Q9+Y: >T_] W<RXU
M<,\>HU51QV"*;GS&G.X+ZIGQ[:V.BO7!375;I?F>!:80D<%YG7HT_XYUJ[@+
MVP;5'N+5DZD;]ZRS2(MZ=QPQ[<U8VKU>/R-^1XM!#0</U%Z7?_<$C&<D+.<M
M*J5PAO4M<2KV%A(<6M2:2/7:?:AA1]&>':$URS.<NP9,@_&G6^;IR,$7:[>K
M_#RKC'FR.<Y,E9]HDLT8\2R\X.E.>C^E^'^I#,U_N_&91)I'LS<KDNX@KV=;
M,S8RWG+^8A;D) !_L3JB+W+].&L\>GE[@3^/AZC7>92+.V@/>(Y[_J+?YWYO
M_(<QPGTF(S)'N!_IMU@O>8NS4S@S>-%17X LGMYC O<'[^?#)Y0XD?C\>VJ)
M</$NG ;RCS5PZ3J\3>K(V('UT@XR'Z)GL_+9MLC#* ^.#OZTCLB-A1X_6$/Z
MJ96=6T>Q4D\:ODH-5S37_:*19&7B&_0N22FUCO%%1,GDLM($)9$0^P'NZ_X:
MZ$4&[FF)SVO99UK(<\S_#L50@HS"6BF5J0L6*6C'U LH$H:#8LKV!F:#Y%K$
M"#M$F.7.!JRQS+M!Q#D=J:?320'-UP?'D"OK<VKB*5V6"4(B;9SQ$%E 9VB!
M;=>9$Y0+(\)9^R2;W1=QNO%'=QP)%4.+3D43C;W- V])1SI66H(H8YK:!2"U
MH#:"M)?VU'1MFQT#UMJ$GV)%R^>YG>9$"'QN)U?^>W#/23IQR>ZX@5DD_X'A
MZFUD5M<B?A/E0;.<-)9&K/F04<58:!P5OHWY2JEUX[/_%1:.[*AL/F-UXA;A
MQ)&!_ASBG;UCS-7D&3M\\)<46B>/F$V;TMB:,8>^W\P(^\*L5I]P2V+WBG*N
MKP3GD1<?K0(743;V0N ::GS5:3"05HQW@/ET S$7U#.>9*P#;[#BPY=#_NQ/
M;CSH+O#K6B.W$# =(7,E0%5/,7<'T&C:Q7T(',9J>,N!'X027@4W86L2[W_<
M@;!"<#O/TVT4M(KW^*H5YU_!W$/7@37\<5W_ -GX&&,RT(ZM00NXH]&RRFU<
M(G(DG<1]CRP,W<4SPD17%4B#!B_7L =4U(.A[+>*DLYLSGI9I?X31RJ1(FN!
MT:*K%:F 2&BSI99KPR\,7<9]ADE<77BWD:+_K66UF4_LO\-Z:3S?_IN]47='
MU\"VJ'_"XSG+E,[E&9Q#,FK:'8 B-H0HN;$"V.46+Q7]<O$;\V;+['U=K&4-
MKFV7614UP5J4=:-J*S2&G:_GEC$X,]75:<Z<F_*:D#G *7&4BYK[$,^Y\(NY
MOB]V[PXFNY/;>IUYLD6JD;,\ZK6@'>ML=4OI839F:-YLY&Q65P1W FG2FRYI
M7)A?>V$C8]^>XCUOF:,&.UHG,2-Z>M3[F+UM9EX.*Z9!7KJ(/:>Z8O-"]GO]
MN.!DSG>%O8LMUU70?[Z747HL<\\V1M?^EI8LQO-AK7H2,ZQW*W<W\WZ;=8F(
MU5OW=VH3N\KD&_2'TZ=:N_8/\%:H.S59<)DT?MB;_YP<WKB3OX)"5])Q K7U
MO\0NT-X5W\-\&-M2;=!^YLL@ 1K"WK>6@WP#OIVXS8]@/QGRP'F<%0VMV&G.
M5@45L^<T<\ZC9F!*\6AT%2#9E(4,<E<&OD$*N;?7VB'>O+/'=V /L#.#HS!G
M;$Q] PJCP?*MR">DAGT<82&+BY8@"^"NE%KX#!P:F -;H*?.=V$YA![;BC;+
MY0,FY*/T<=UJ)%WB*YL&WQ:ULFIA4+BAT [VXE](?@B/Q3,#[D)OT!O.%N@S
MLOSH#*3)&-@?#W_6':BY#Q=H-DA&H _*/J8.JI%O*(B!2)(KR3Y0DB@YH )*
MX=<Y%T(D5'?X$SQ2_ZG/!W:O,5LN0PUF:_$(Y&%H8O2!+[3V^4+PD+(GJ1W<
M*5L2,!F\(/)V]@3_8(\/SX;].LV]Z9"Q-;?Z'VA<PV?1-]!00Z(_ ]-,'_*>
M@-ZZ@J2UX#IEM_].,%-B<9X)UO$G'\J'3@PY]+1 -GW3JYU!24>]: ,XOWDR
MW9UWLY:9%\$[9[J>N(MW63O*GPB.D1UQ>@<F"<8=_ >B'JCO60Y>VV4TBT&W
M@<5"$:^W,XNFYQ&:>G//\$HL'Q(S>%S]3W]WWEZ%Q>DZ.%MP;3=#V4,,;Y\M
M?TI2&[[*8LF7^,LE5ZFS*/\3E] J<[:*)M(_)"P2-#/-?F/YB6R%8PL^$?AW
M%T\1RM*U.<FJ62\-XZ5SV2&XI[B5W4/^(HKF;,C6"7YR[L27\_N *E\13N,*
M'7E8"&]@)UOV#3G;.DZ:AP3H?H@?P,.8DPB'8\A3A3[0MZSS@G'0@;AS^"5(
MZKL,ZX%*';>B&FC3<+'TN'14\XADH]BB/2HZ)=J V@J)@A>DQ0(__G#6!/YB
M7!'G@?W!<GWVHM]0)T=OY!M\?2A><DYGVW1='*+^K-DKO*D\C,P6*.0*HA,_
M7UJ<Z8]GB!-BZ[!DX3*?'#03/^6X$J&@&P:W2J;71#7>%XG,<>I3PI7&C; S
M?T2WE)"-#ZM';]=BW?('L=;H3DF[SSSDIM##<3(R"JO8H1;36U,;%PJ_- I4
M?P326BE4R@\W Y4#N+VA=/MDS%X3'G,0=9=_][Z!%(J+'3[#]3@P\%D\IB^R
M@2$4=C:I-@D6M>P&#^'GZELJYV+]U:IM$'K(4!2S';FLGNK=@$R29CH\@Y/Y
MN0-"4<_N5?7?A5X[:I5'^$>Z=X#V>'FKHD*.Q=>7;IN/YIA=8R8CL/:8=QE\
M3#[5X18\1["B<ZOI$&%OM97!D31%&J\]24[B7%;#E(;25\H0VJST>_(Q]/:H
MQ9)A9J%7E2B?3;&?(!@+O.[0&$$F;";I1S.?212:5M86SF)5 >MNJ;?"A8VE
M!TE_<V(BM>(C@)-7I!#C!MM/Y*_GF=J/&D)@IRI0>P,Z(!Y0(U FVUN9 "TN
M(<OMP7^WF*13P2>1LT6/P(>>OP5[P&_VDW 0LFN[IG<4#9H@S7&A0-2L8@L*
M6!F*2'Y"<:ML YZ>]D7B@)5%U(CFHUS/@X*QB-Q^,G8/UK1^UCFJ8XQF]27E
M=N%^I4).8E+EA5*LZ*TT0=R2EBU.%UZ+6"_<PO_@*>1OQ[[93\%2D=NM#EIR
MU3W#$_5BHYMPJN*ZCLC8*>M3MQ?Y2AH5CS=?$G7+EH5?%.P3!WDFX5<%7O93
MT/OH[Q90\Z QQ;!!I:A])-BJB*J.8LR0K31:"ELEB[1O-F\1V:O<PGF"];)D
MSS5XILC??BH*8E^:OVBHG<WZ#I5-:SG_I'RDX0.=*^VLV52X4MQB&DA](CRL
M_1GNPK^L7.DY'OLEF?0?Y8*?:=9IK';<U?LJK_?\S8^2"]I+:3^E\8UG"GK%
MH35VJ3)AKI$2]HH/JTT;1K#=4HG]5.0MGV$YWSB5D*%HKATB-D+?JB6D-Z0C
M)@HE.M=#GT(]F:S26-&)(=&*&TQ_CV(IB9UEVR!\ #RV;*C_R&A4V-5T,&=
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ME&^ZY(3QZ,XV'C&8OKQ)1I(7+ZFK(G],OU4MIH(Q1F,:?:/?&<TWYF)75%'
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M!"]SB)VI>!1Q5*LO)LZ/:)R$7MFRO688M8ME5T4CQL!#NHO(BO4[5?9PEZ-
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MI?*M?:SQXN3H<6Q/X<2-^SAF7.KPGU,BE[ILJ7-K5E3W4\^9RZ0*&M=8SGE
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M_)2(\9$@&7B0(P4Y@=F8$'A6 Q\NA?[4.XI:H(L6,RT+VFS>5W0+VFE\G4I
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M5D8&=EZ^/68EUJN,".S"C*I+[I%8O;K5+A-;"[&5(S [Y7Q>'?I=1:-VHT>
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M6"-2/VY!&D=-J,7[L<%C(Y &^@)E8-2CFJ",F]K@LO.Z<.();1SG@#I=-J&
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M5I:SND1HL9-+4ML8#*.)RJ_5D*1V)5[CD.%JF\18I[,*YVP2X%L:^?B6AH4
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M3*2L0:I$"KR!(ZFPTJJY=I)0[, )-$Z,H-:)YCN=.(ZS"<]N=BS$SPWRG=\
MW?;5P+IC,VATVW6OW=/C:G^ SYG)*+_9T=CXP=X42$MK)J:V,9]14UM2)3;"
M%5PM5D]342Q$!:L>(ZMJ1$A53>42BQ,J<3;!JYH=2$%+XT( @:M!X&I0;O\:
M&+:N K9M&Y\U[]QVN\=]UZ6QP-TG9\-])R?VQ74/)N4W=F6@#2UY-%ECD8!?
M5RZGF]%:HH%D0ND8=>4:@;VD1M%86&-R0&J:'<7REL8R24O#0@"AJZ%JVR=
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M#;C+2/._RTY?B/[>-]]HVO_'-PS7__2F!'SP'AM\]2D)K%Z&!-O6%0//K=G
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M_B#N5.(QW*'DD[@#*?._Z+>&GQK*7 U05P-L]\>N7Z6O 25X#:!&;0>4!&]
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MZ*V<[+#;V5EA=S(SPN]F_ V(-TE#U(XYD*6"]EZ=Y5!CL ::C#=]:K/8]OJ
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M>5ZBO_,ZY_9GP-DJ#:P]LN"G,1_"T7X1:[(>$FRW0X*S"L22]T$$RP2"/&S
M+P#[TSN:^$V02OG"R7.;9I6S/C+J.!_H;;QWU![!6TJ_YVOR!:\)\CVO<?*$
MUP/J&^_K]$F?BVYOA:<9;X4GF&]]_P2X: ;.+ED(4)L/4=K+(-%X':3:;(-4
M[!Y(<M&&.#>C7Q$\JV]!?HZ?1.'$#SZ)E$F/+,9K;K'[!+N*]X+9Y#'F=L#K
M*?VH]RCMK,\3VBWA??H+X36W-[[G&:]%@ZS7HF/L5_Y'W/\,>&@&_DY9"%:9
M!W%:2R'5:"UD6F^!3,==D$'<^RN%9O EGF/Y,<(;\S8XF##A'TL9%Z8QGWKF
M<Q[SR@4/.'5>=]GMPEO,PW[#C$'1-<95_\N,9P%G61,! ^P)<2_GI?@@]Z7X
M ._/@+]%&CR59"#LW_ZON00R#== KJ4"Y&%VS.3BU;]D4?0^I++,7L=[V#^/
M$N-'0R(I#P*2F+>%V;QAKV+/*X(JX25>D^@"YT# 6?>C@:?9YX-.LA\$'^.\
M".[A/@_NY#T/;A4\#VX6O/BC_S+X*,I I/)<2-5<#+D&JZ 0?3:*[16_%>%4
M/A:X:K_.<3,>3^/;/$X0.=V)#*5<#XEC#06D\<_[YGF?]B[S&_2L#>@7M 8=
MY1\*.<([&7J(-QS6S1\+:Q.,A35YCH75>8V'UOP%"/X]C]HF S%H]\[8NP@*
M]%="J?GZF7+;K9_*L<IO2XE[GQ?1])_D<BUOI_HX78D/HER(C&*="DD2#(BS
M?/I$1?Z'A96!W=Z-(9U>!\+;/8]'M'H,139[/HVL\WX64>7S+*)"^"R\3#CV
M1^"Q60I$6V7^^S=SV1H+H5A_.528K?V^WTKA0Y6#TD053F6TDJ)]MY!E<37+
M$WL^Q9\\&!?&/AH9)S@4FB;L"LH+: \H"V[VJPUK\&V+K!4>B:KV.1>]7_@P
MNMQW-*K$[VE4D>AI9('H6<2?_)=!C.Y'X@YYR%5? &5Z2Z'*>-7G6HL-;^OM
MMH[7.^U\6..B=;V,87XA7X =S/ C]R4'LP[&10LZHI*$+6%9 ?7!12'5@?O#
M*P.:H\K\>V**12=CB_QOQ>8'C,3DBD>C<\2C4=GBIY%_ IYHAB %:4A6DH,"
M]/FLU%TR4VNX8JK!=.VK9NM-HZV8[;?K"9I#E72S4\5<QV.Y/JX'TP-9[4D1
M@J:X>&%M=+JX,B(_I#2T/*(PN"$Z+^A ;$[00%Q6T+6XS. GL>G!(S%I(:/1
MJ*@_0=_RI2 $[3BIBG)0I#8/JO8M^E&OM^Q]B_&J%QV6:Q]UVFV[WHS?>[Z&
M9CI0SL$<*O1R[<CV9S:EAPIJDF.%Y?$IXN*8G)"\J-*(K @T45A'7$K8L?CD
ML,OQ2>%/XA+#G\0FAH_$)(:/1O\)>*$9PC9*0[JB+)2HSH4:K05?FW06O^TP
M6#9VT&SE/]W66R^WX31.-5!,^JK8#EVE'B[-!7[,FNQ@?GEZE+ H)2D@-S$K
M)".N*"(EIBHF(;HU+C:Z-SXF^F)"=,SC^.CH)['1T2,Q,5&CT7\"WFB&B/52
MD+E=%LI4YD#=WGF?6C47O.K67332:[STYB&K+1<ZG=0'FLG&/;5,^[9*/JFN
M1,BH* CD%^5$^.1DQ@>DIZ6')*441,0F5<9$)33'A2<<C@]-.)<0DO@8_?5)
M;%C\2$Q8W&CTGX#/)BF(6H?V7O3YK-PM][M1;<Z'3O5YSX]HS7O8K[OD6J^E
MPIF#6+6^=A>C TT,N\8:+G%_I;=;<6D +Z<PS#LM+]8_,2<U."8S-R(\O3PZ
M.*TA3IQZ,-X_]72\?]J#^(#4)['BY)&8P*31Z#\!7[3[QZ 9\M#7[.I=LC]:
M=LM-'MPM]ZQ?7>[.2>W%EXZ;;SIQ!*-RJ(MDT-I&MZUIY!!*:SWIN?M%W+3R
M$*^$DFA1=%%24&A^=EA@;DF4**<N5IAS(,X[9S#>*_=.G$_VDUC?S)$8O_31
MZ#\!$;H/\6LDH1!]/NIVRGSI4)*9Z%64?G)&66KXC-;"LX.F&XX><]C3>9B@
MW]!%M2YO9^/RFSVHZ0V^[HFU09Y151&^(14)XH"RC%#?TJ((K^*::$%Q1PRO
MN#^66W(CAE<T$BW('XWRS'WZ1Q"X5A*25TM""7I?-&Z7FCJH(#5^8J/D/Y>V
M2 Y=V+O@Q!F3]3V#=KM:CN%UJXY0+(L.LIPR#_#)B>T^S*@6,3^D,<S'OS[.
MWZ<V+4A04Q#*J:Z*8%6U13&JCZ&N13&JGD:RRY]&NI<\B_@3"$'GIZ^2@,H-
MDC-M&R7?]JV2>')Q"7+]ZB;)LU?4YO5=-%K3<<YF1]TI9^V2 5>S[*,,3-(1
M+BFZQXL>TNW/\3\0ZN'=$2/DMZ?ZLUOS ADME2&TEM8P2LO1,'+KE3#7EO$P
M:OUX&+UF//1/('*%).2@_;]FM<27[N7(_5/SD)O7YR$7;ZZ7Z+^A,J?[FOZJ
MQLM6VRLN8O?FGB49IYRBV\8,NN-"^CW)HF-^#*^CP1Q>;[0'ZTBR#_UPKA_Y
M<(4_Z5"+F'"H3XP_?!DU+B9TO0PDM?\9Q"^5@*(E"#0O0>[WS46NG9V#7+@Y
M%QF\OT;BT+U=<BUW=9=7W;+84C",44V[2M"/':):A%QD8T07//!>YWS)W+-!
M;LPS46S:Z62>ZZE< ?%4A1?N5+.WTZE>'^SI(=2X-W;@K=#IZ%O?/X'4Q>@^
M+$0>')!'KAZ71\Y>D$/Z[\Y#>D;62K2.[)*K?J*[M.BQ^<:,!_;*<??P6J%W
M*,:B6RPKSYL"!^X-7QQS.(A$'8ZBN%Q/IN.OYS*<KE>P'*^WN#M<[W.W'[[L
M[C#\G&UW;8IK?W&*]R>0MP!YTBB-7#LDBYP>E$6.7I%'NA[/1YJ>;Y#:_WS/
MO(+GNBO3QLT48L?LE(.?.>WU?>JJ[S'*,'4?Y5FYC0CM*".!CJ212&?<2!(>
M.Y)#PHR4N]B/-KG:CAXFVSP]CQHA6X]\(%L]^DS]D\D*:>1&AS1RND\&Z3TC
M@W3<D$?J)Q=+E$\JR.1-JBQ,?:NW.N:M^>:@MW;*PK=.ZKPWI'W,-S0#ZAN.
MB<L;+W/\&W\KIS=AMIBW\?9V;S,P-F^+'"TG:YS,)SN=S=[U.YN^OX(S??\<
M9S+YT?E/;C<@R-F#4LB1?BFD[9(,4GU/'BG^M$PB^_,VN>3/ZHNBONBO%G\Q
M4_#^8J/$_8+=X_:5J$[^2M4B?F7K.'\5Z&.^^1K:?0LRMOX696KQ/=G<['NN
MI<F/<BNC'XW6!C^[;?1_GK#5^W7=5O?7V!]=Z$"0WEY)I/6,)+)_6!K)'YN#
M9,RLEDSXK207CG9N?]!9Z0$FZ]E@M84&&$42X)5Q0-[C" PU.^!J6(.7I@6(
MM$PA=)\QQ.H80)J>'N3KZT"E@38T&6I!MY$FG##:"T/&?])W$$%:!Q"D<@A!
M<N])(BD_%TA$PQK)(-@F*X0]\WF@M90!!JM<P7P='FPW.@)VLQT0MUD!5=$<
MF$HFP-MI!%[*^N"_2Q="]VA#K(HFI*FJHQ]&U*!"704:-/; @;V[H?>/VOH0
M9/\Y!,FYB2#QHP@2"8LD_&&EI  V2K- 29X"JO,)L&^Q(Q@MLP6+E99@M]H4
ML&N,@+A.'\CK=8&Q01LX&S7!8Y,&^"FH0O#F/1"]91<D;]WQW_E"Z79%J%'<
M#DU_5'42O?ZKZ/R'"!+R11+QA042'%@J28,U4@10D'8$)5D;4)4W!^VYQF P
MWP#,%NJ ]2(M<%B\%YR7J %IJ0I0ENT&QG)EX"[? 5XK%$&T<BN$KMH"L:L5
M('7U1LA=LP&*_PA(2M+@K"$#)"TY8!@N!([E2N Y;@*.JQ*PV*K@)M0"2J@^
MN"08 R';')Q+K !;;0..37: Z;0'A\,.8-^/ ;NSCF![#0NV3[!@\\H);*:<
M?ME^<?IJ_]WIH\,/[!O'GTZOL;/[OQE<->6 K;\0^!8KP0.S"?@D)7!GJ@+3
M2PMHP?K@&F<"Q$P+P!=9@U.5+6 ;[<&Q P.80X[@T(\%^W-.8'?=&6Q'46^<
M?]M.X;[;?\5-8[X[3V)_.+]P^H%[_@?@HB0%.'49H&C( 4=O(7B:K01O^TW@
M25 "OILJL 7:X"8V $J,*;BD6P*AT 9PE7;@U.  V Y'<#R$!4R_,SB<<P;[
M&SBP>X;>NI/XG_;3^,\.7_'OL-_P$T[?\4]Q/PBCN!_$V8"KHA00U&2 KBX'
M?)V%X&.R$GQM-X(0IP2>-%7@\K2!)3( >J0ID%.L@)1G"X0*!\#5.X)3FQ-@
M>YS!\3@.,&?Q@+E.^.TP2OSI\(;XS>$3\0/V*_&5\S?B,]PWTD/"=Y?[?P!D
M-(.+B@PP5>7 \_\[BPFPV0C^SHK@2U$!3W=MX H-@!5F!O1$:Z!DVX%+"0:(
MU4Y :,;]QAW SSCW$G\YG23]P%XF?<,^<OF,?>4RA9UV>8W[XO(4_]7U ?$;
M^0;I&^7Z'_R7@;);!CA[Y$"X=P$$&JZ $*L-$(S=#F+7/>#'U )/3P/@!9D!
M.];ZMUNZ_4]J ?8[N1+WS:6>\(743OI,..0RC>]WG<)?('_ W:&\Q;V@O,)/
MD9\2/E/_(7VA77?Y2K](_D:_\ = V2X%=&49X"O+@K_&? A%NUZ$Y7J(P&R#
M,.)N"'33!%^^P2]/?[/OO$B;+^[)#M.,'*>/]%+\>VH-:9+<[/K&M8ORVN4H
M=8)TAO:"=(,V1AJGC9 ^T.^X?&9<(7]AGJ=\89ZD?F&=H,T.J&@&Y@X9\-HA
M"\'_?A=#;QG$FJ^%./LM$(U7AG#JWN]!'+W/?D+3C]ZA-I.">,QK3H;S2U8A
M\3FCTG6,WD!Y2NV@/:$<<7M$/LEX0+[&O$-^QKQ!?L\:HGQBGZ9]<N^G?^+T
MNDUSCC!F![1M4N"NB'9OM/^'J\Z#.-TED&2Z&I)M%2#1><>W.++:5"139S+8
MTV3"/]!Z7!B->>J1@GO,RW6Y[UY*N<.LH=]D-#.OT[O95VG'W2_3+G NT1YR
MS]'?< ?I4[P^QD=^#_,C_P#K([^3/3N@HQEXVZ3!'^T742IS(7G?8D@W7@D9
MUAN^IV.W3Z60]KR-IVN_B.(;C8:(K!X&A&/N"./QPYX9KE?X!?1+W KF>?<Z
M]S.L=NXIYF'^(..48( Q['&,^<+C,.N]YP'V>\\V]_>>39SW'HW<#[,"MZU2
MX('V[B"T7\3MG@/IVO_^7['+9W(MUWW*==@RF857?I%&T1A)Y.K_$^5C.1P2
MA+DLCB:<]TNFG/;.=AOT*&8?YU=Q^[A-@B.<+L\>]^->W>Y#W@?<GWJW<29]
M&GF3WG7\2>]JP3NOJC\ !IKAW\X9^F__WR4/69KS(=]@Z;<B\]7OB^PVOBQT
M4AS-=57Y)XVE=RW!T_)B5 #F=&@X\41@//6H*)UY6)C'.>A=QC_@6>?9+FCW
M;N$?$3;QS_HV\!_XU@K>^.[W>.M;[OE66.HUZ5/R!_]E$*)=*WRS-*0HRT&N
MQCPHUEOTJ<QTQ9MRZ[5CY9C-#XJ(>ZYGN^E>3.5;G(KWQ1R/"B8>"8VF=@<E
M,SL"LKDM?D6"1F&5=YUWL[#:ZZ!?I==)48773?\R[U>B8I_7?@4^;_SRA&]]
M4<+9  OM5WX;T,Z)KD7Z3EDH5)_SLUQGP8?]1DM>5ENL'*FVVW"K#+=K*)^F
M<SJ38WX\V0=S*$Y,.! 506T-2V U!J=S:\7Y'OO]RWW*_.K]BGT/^!?Z]@?D
M^UX-R/-[$9#C]\H_2_1:E"EZXY?Q!^".SO9'^V8,VGVSE&2@6%7^VW[M>9.U
M^@O'&TR6/JBW6G]MO[/RN6+*OH%<MMGA#$^' \G^A):X4&I]= RS*B*%6QZ:
MXUD<7.*3'UCCEQ/0'I 9T"=.#[@4F"9^)DX53P2D!+[R3PY\+4+YS0:XZ&PQ
MVO?B-Z)=!WU&R_;(?JK1G/.J<=^\T5;#A;>;+-9=JL'N/%GNJMU7R#3KRA'8
MMZ3[XNN2@RC[XZ.8I3&)W(+(3,^<\")A1FB5*#6D)2 I^'!@0O"YH/B0D<#X
MD EQ7,BK@+B0UZ(_ 3ZZ#\%HYTU<+PGYZ'-:N4OF8[V:[(O6O?*/.O?-O]YJ
MOO9<@^.._BH7K9Y2AFE; <^N/L<'OS]=3"E)"6?F)\9SL^+2/=-B\H5)416B
MN,@F<71$3V!DQ)F@B,B'J EQ9,1$0&3$*__(B->BV8 '.CL4[9S)Z]#NO57J
M9_5.Z7?-NZ7'#JC*_'-0<][E#M,UIYH=E'KKB)H'*NDF3:4<VZH"+UQICC\Y
M/S.4D946PTE-3O%(2,SUB8DO$T7$U8M#8[N#@F-/!@7%WD6]% ?'3@2$Q+SR
M#XE^+9H->*&SPU=)0MI:"2C9+/FM3E'J=;N2U,BAG5(W#VO,O=!ELKJ_W5ZQ
MIPF_M[66:E1;Z6Y35NKA7%#HYYJ5%^R6DAW%B<],\HA*R_()2RT1!277!@0D
M=0:*D@:"?)-O!ODE3XA%B1,!_@FO_ ,27HMF S[H/D2ME(#,U1)0OE'B4],6
MR1=="A(/CFV6N-JG/N?T(:-5?5VVVSK;<.H-C13#REJ6=>%^ 3:K7.B24A)(
MCRN,<(_,3Q"$Y&1XB[,+_?PRJ_U],MK%GAG' STRKZ$FQ%[IKP)\4E^+?%)F
M!W[H&L2ND( <-,?^M1(?VM9)/#NR$KDUL$'BXG%5^8$^@Q4]AZRWMG0YJ56W
MN>J7-#,L<^IYCJDUWL2X_0'4R(HP5G!I+,^_.,U36)0O]"S8+^(5M 9P\OL"
MW LNHU[X<_->B_C9K_WX6;.# +3[)RZ3@(+ER*^Z%<CKKJ7(_1/SD:NGUDF<
M/KE'KF] ;UGG4:O-]8>Q>\JZ2;IYG6[F:6T<A_AF3WQ$@X@<5!?"$-5$NWM7
M)0L$^W.].)450F9%LY];Q1$1O>(2:MS/K>R-'[/HC2^K\.VL(!CM_JE+)*!T
M"3+=O!#YY_!<Y/JIN<CY<ZN1_K/*,@=/ZRQI&K38N/\X9E=!'U$[_3#-).$@
MVS;B@(=34(<OR:\MB.K5&LGD-2=QV$W9?+?&,D]J0Z.W:\-A'Y?&"ZAGWB[U
MD]Z4*M3^V4$$VOVS%B-?]B] [G7,0:[VS4$NG)5'3@PM1PX/*4FW7=1>5'/.
M=%WQ:?L=F8/XO8D#%(/(8RS+H#Z^O5^OC[/G83&)>RB"RCR8P*!U9[%=NTNY
MQ*X&'KZKAX_K/H]ZRG<^\%& ;_T@(+3,#N(6(E P'WG8((M<ZY9#SAV70P8N
MR"&'AQ<C[<-;I>JN[YU?>M5X=?:0S;:DB\XJD>===8+.,HQ]3_.L/$YYVW-.
M!C@Q!L,)U!,)KBX#F53"0 G=N;^>@>WO86(&SC$Q\ S UMR<X83#6MDZ6")2
M<P9&&0[]'UB8WL]LS)'90>H\Y&F%%#+<*H.<.RR#'!^41@Y>ED?:[BU ZNXK
M2);=4YV3<]=@>?)MJTU1-[$[@X9)&K[7W70%5SG&[E>\+-RN!-A2+H<YD(;B
ML;BA3!QVJ(2 &6H@V0_UN-A=/N=B>WF49'OI@ZOUA1]DFW,_*;/YFBN-W*Z5
M1"X<D$:.'95"NL[*($W#<Y"JIXN1DJ>;I;)'U>8DC>HOC1RQ6!?X!+--^)BX
MB_^(IL%^R-E'?^BE3W[@;TQ\$&:.>Q!OZ?@@T\;A08F=[8,&>YN'/0[6C\XZ
M6#UZXF#U8-+!XMYWK/F]G[-Z6(8@0RV2R/$>2:1K0 IIN"2#E-^=@Q1,+)?(
M>+5=.F%B[[SP"8/E 1,6Z[PF[+=P7N)VN+TD[R&_9&H07PJT<"]]=; O@_4=
M7L88VKY,-;:>*#"UF*@R,WO5;F[ZZIB%R>NKJ'$+DXG/%B8OOYG/YFH=@@QT
M2B!=?1)(_5E)I'18!LE^.A=)_;A6(O;C#IF0*8WY?E/ZRSRFS->PI^PVT::=
MMI*F791PTVZ[L-/</0Z?O-5L/P5H6'T*US3_E*!M^CEKG]'G4EW#+_5Z^E^Z
M]/6^#AKH?KMNH/-U O5V5H.M"-+=@R#U@PA2,B2!9-R31A)^+$0B?JZ3%/]4
ME/'^I3:7^TMGL=N,R0K7W]9K\+\Q&[! 4+ 'RA8;8&VW!+ZB&?CL,(% 94.(
MW*4'27MT(%=%&\I5-:%1;2\<5-> $QKJ,(RZ.ZN#!Q"DX1@Z_SR"I-]$D.@1
M2204EDCXPAI)/FR19L)N.0IHSB> P2(LF"^S ]L5UH!=90[$-29 76<$K/7Z
MP-NH"SZ;M$&LH F1F]4A::LJY&[; ^7;=T.#XBXXH*@,QY5VPHE9-1Y!YY]&
MYU]#D*B'"!+X70[Q@D42;%@I286-4@10E'$$%5E;T)*W!(-YIF"^P AL%NJ#
MXV(=P"_1 M>E>\%MF3IPEJ-5<<5N\%^I#&&KE"!^]7;(6K,-2M9NA>JU6Z!U
MW6;HF%79"73^$#K_'P3Q&T,0/D@C;K  (<%2"2RZ%K:@(&4.2M+&H"*C!YJR
M^T!/;B\8RZF!A;P*V,[9#8YS=@)^KA*XSMT.;O.V F?>9O">OPG$"S9 Y,)U
MD+QP#60O6@VEJ/+%LP$'92FPV2L#6$U9(.R3!XKI0J#9K00*80.X,+<!P4L9
MG$)4 9.P%^RRM<&Z5!>L:O3!LL4 ++J,P+S7&,Q.HBZ9@.D=4S =1[TS ],O
MJ!DS0'_^;@&FGZS [+WU[ "S4PKL-/X]&9$%%VUYH!DO!#?;E4#';P"*VS9P
M\5 &?* J.,5J B9S']@5ZX%-E0%8-QF"5:<Q6!XV 8L!4[ X;P;F-U#/S,'\
M+>HSZI?Y+POT=]9@_MX&+-[8SNZ_# YJTD!0EP&RIOQ_)T0LZY7 Q&T .FT;
M4/B[@!2@!OAH3<"FZ0"F0!_L*PW!KMX8;-I-P*;'%*R/FX'5&7.PNF8!EB.H
MUY8SEM.6/]$?7ZW XH,M^B=V8/7<'JQG XYH!JR*]'^G$G0-.7#77PA<JY7
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MJXM.8'7:&:Q/S@(PVR7!!>V93+3["]"U$*K(@+_.7/ W73SC9[_JJP]APY3
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MYZ!=TV^-!(1ND("8K9+?DI2E)E,U9,?3].<^2K%<>B/.:?U0)$7Q;(B[ZHD
M[WU'?<6&A[TCS YZ)EAU\C/LVKCYF&9..;:!78^K8W42:EA'B56LBZ1*UE-2
M.?LCL90]0RQV!T(A!P@%',#_OX""7C\?[=T!:([(=6CO5)"83E.4G,A2D1[)
MT9:[G6&ZY'(R9MW9.!?%@4BF:F^(A_9!L<BP4Q1BUBJ,L6[T3K&K\\QVK!:4
M.%?RJ_%EO%9B"?>P2R'WK&L!]Z%K'N^]2R[OETLV_S<IB_^;F"GXWX"&=GX/
MM&\&H;TS9HW$3,K_8=LNPZ,ZM[>!KYF)N[N[N[N[N[N[N[N["R%" B3!@@1W
MITB!%EJTN!5W6>_#.>?_7C3TP^^:X4OOO==Z=B;W0,4ISSMD*'=[E:E_]&DS
MG.VRY#S6ZBJRK\%??D=UA,;F\@2#A>(,L[F"?)OIW'+'B:PZU[&,-H^AM#Z?
M_M1QOYZ4N<"NY"W![<D'0MJ2+X>TI#P-;DGY%-2<^C6P,?5K0&/JMY]@!+G_
M--+WBDCOK!6$CZTB\*1'G')K2)9R<4B3_E2?.<?!3F?AG2V^<EL:0M47JN/T
M9RM2S29+<FS&"TL<A_.K7?MSFSV[L[M].C)'_%LS9H*:TC>&-*3O#:U+/Q]:
MF_$HI#;C0W!-YI>@FLRO@?\&H\@>,KA)[^4E?8L/WG4*P(,!(?AS3 S.C:K3
M'1TT9=_3ZRBTM<-;=K$E6&VN(5IOLB;9=*PRRWJPK-"AM[C"M;.PP;,UO\.G
M*7?0ORYG,J@F>R&D,GM76$7VF;#RG >AY3GO0LIRO@03@64Y7W^",>3^L\DU
ME',#-O' JQX>N#/" Y<GA.'4*E6Z@Z/&;,N#]H*;>CQEUG4$J4ZU1.J.-22:
M#-9F6/54Y=NW5Y2Y-)?5>=27M/G4%/4'5!1.!)46K \MSE\.*\P_%598<"^L
ML/!M2&'!Y^#"@B]!1.!*&$?VD$MZ=Q71R@7/^SG@YBIV.#\E",<FE6E[5QFR
M;AVQ%5@8<)>:Z0E0&>^(T!ELC3?N:4JS:J_/M6^J+7&IJZKVJ*IL\2DK[_4O
M*AL/RB]=&YI;LCTLN^0X\5=8=NGKD.S2S\$Y)5^"_@TFDAGDD]Y=RP%O.MCA
MSV$6N#3)"F=F^.'0C")M><J 9=,J&_ZY$3?)U8-^RL.]8=J]7;%&[>TIEDTM
MV7:U347.%0V5[B5U3=X%-=W^N=6C09E5LR'IE5O#4BN/AJ56W21>A:16?0Y.
MJ_@2E/XO,)ET_R+2O>O9X*\>TKU'F>'L-#,<7\L#>]?*4[?.ZC'/3UGQ3D^X
M2(R.^BCV#85H=?1'&S;U))G7=&7:5G04.!6WE;OEM]1[93=U^*4W#@>F-,P$
M)]9O#HVO/T1<(UZ$)-1_#DZL_1)$!*Z$:22_E U>-3/#U7X&.+>*"4[.,L'!
M>2Y8GI>A;EROPS0[9\&S:L9);&#26[YS59!&TVBD?LUP@EGY0+IU45^>0VY/
MJ6MF5ZUG:F>;3V+'@']<^U10=-O&X,BV R&1;5?)Z]_$YZ#HEJ^!T<T_PTPV
MP$IFN-E.@U^'&.#4% ,<6L< NS9RP)9-4I1U&S09)A?,N(;6.8ATSWG*-L\$
MJ-5.A>N63\09%XZG6N:,9MMEC!0[)0]5N\4/MGA%]_?Y1O2O]@_M6PP,Z=L;
M%-QW*3"X[VE@<._'@-#N;_ZA73_#7&9X6T<'5[II<&:,GG1/>MB]2/K_$AO,
M;Q.C3&]5HQ_=8LS1L\E.L&717:IVWD^Y?%V85N%<C$'VFF2SM)E,ZZ2I0ONX
MR4KGR(DFM[!5/9Y!JU;Y!(S/^_J-[_'S';] //'U'?O@ZS>"OG[#/\,B!KC=
M#'!^@$J> QKL64?Z_R8*S"\SP<PN(1C;I4SKVVG VK;#FJ]NFXMXV9*/?,'F
M$+6LC5$ZJ1L2C1(6,\QBYO.M(M:7VX6L:W *6-OMXKMVW-U[;KV'Y]I=GAYK
MSWEZS#WR=)]][^F^!CT]9G[VJ1+@2@? R5$*[%M#A:V+)'\;P.1^.A@]R =]
M!^6I;0=TF>KV6W"7[742SM_C)9VY*T@Q96>D>OQRO$[4CC2#L.UY)D';RBS\
MM]9;>V_MLO-8&G-P6UKGY+*TT\EYZUDGYZ5'3DZ;WSD[;4*7?_-7 \#9/H!#
MI']O7T?Z[V:2OXL"0X?IH>LD%[2<E*+4GM2D+SUARIYWW)XOXYB':-+1 .G8
M(^&*$8?C5$,.I6H&',S1]3U8:N!YH,[8[4"GF<N!40O' VLM'0XL6]D?^(5X
M:&FW[YVU[5ZTL=V#MBO]U@YP;!1@>0W X@: J>]_![^?"NTG&*#V BM4_BH"
MQ;^JT')^-61*NV##F7#!E3_ZO*](V+E0R:!S,;)^9Y,5O<]FJ[B?+5%W.5NK
MY72V0\?^[(B>[=FU^C9GEPVLS_VB;WWVH;[5+V\-+4]_,[8XC3\Y-0"P9PI@
MXWJ Z2623_IG^S$:U)QCA**KK)![0P@R;BA0DV[HTL?<L& )O^'$&7S#B\__
M1I"@]XTH48\;B1*NUS.EG&X4R3K<J):WO=&F:'UC2-GRQJR*Q<UM*N:W3JB8
MW[RC8G;]I:KIM<_J)M>^:JQT8 )@\QS S":2OXOD'P:H_H4*!;\S0L9#3DA^
M*$J)?:A(C7BD0Q_TR)3)[Y$=F^=C-TZWQ[X\SH]#^1T>QPC:/4D1MGZ2(VKY
MI%3<[$F#A,G3;BFCIZND#9\MR!@\VRVK__<Y6;V_[\OJ/7E+?/C)$MG!["+
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MN@DMAW6+.O;K]NO8K?]#QV[M<QW;N<^ZMK.H:[L&]7YTGLS@8 ? -K*#=1,
MJ]:0_DWRFT@'+=M)A8)=W)"S6QHR=FM0DW:;,,3MLF6)W.7&$;K3ER=P.43
M;SE:V'M'LIC'CFQ)U^TE,D[;Z^3MMW<IVFX;5[;>MJ!BM7V?BN7V*RJ66_]6
ML5CZI&:^!=7--__3\69R#OL!%L9)_YXA_7>>]$^27TDZ8.Y^&J0<88/$HR(0
M>U2)$GE4GQ9ZU)(^\*@3L]\1+S:O(T&<[D<B>5P.)_ ['<X0M#]<)&)SN$;,
MZG"'A,7A,4FSP_-2IH?W2)L<OBQM>NAO:>,#'V6,]J/<2M_/X:91@!ER!H?6
M [1M!JC:"9"_'R#E&!U$G&&"X',\$'A>&OS/:U"\SQM3/<[;TKF>=V-P/N_+
MY' ^E-7V?"R[]?E43HOS^=QF%ZIX32ZT\1E=&!$PN+!.4/_";D&]7W\5U#__
M5$#OW'LAW;,HLM+2,#D#Y R.K /H(/G5W_,/D/SC !&_T,#O$A.X76<'E^M"
MX'1# 1QNZ%#L;II1;6[:TRQONM.9W_*G-[T5SF!\*X')\%8FL_[M$A;=VPUL
MVK?[V+7^FN;0^&N)0^/.<0[U.W<XU&^]XE"[^9E3[>97KA^M_7X&YP Z-P'4
MDOD7'"3Y)TG^.0#?RQ1POL8 ]H\XP>:1,%@]E@/SQQI@\L2 8O34@F+PU(&J
M^\R=IOW,GZ;Y=SB=^M_Q]*I_9]$K/R]E4'K>S*CP8I!1_L4<D]S+92;9EV>8
M9%[=8Y)Y\9I)YOG;?UCU_1G8"%!'\@O_EQ]^'L#[=P"'ZP"6C^G![!T'&+\3
M!(/W4J#[7@FT/VB!QD<#BNI'<XKR)SN*XB<7JOQG'ZKLYQ"JU)=8FL27#)K8
MUU*:Z+=F.N%O0W1"N)9.$'?0"> )XA9Q]Q]Z-P#4[P H.O"__%\!O*X"V-T$
M,+D+H/^>!CK(!AK( ZHH DHH#0JH"+*H#E*H"Q)H3!%#2XHPVE,$T9W"C_X4
M7HRD<&,*E0N+J!S82 Q0V7&&RH:;B'W$H7]HW Y03,Y?ZO?Y7R3Y?P+8W@(P
MN@>@^0)(+H B,H$<<H T\I),81!%"1!"6>!')> EU\*-.L"%1L"!EL"&#A06
M]*0P8C"%#N,I%,RA %83G<0H,4>L^P=4TZ2@EAH%==2HJ*M%16T#&FI9TU#3
MG0[50QA0-8$1E7.94*F"!16;6%&QFPT5A]E188)8PX$*\\1F3E18)@X0)XG?
MB?O$"\YO"A\Y/RLBY\?O%)#[PW_Q_ @U2+ZN,@7U5:AHH$[H45'?DH:ZKG2H
M$\B 6G&,J)'%C&JE+*A6SX:J'>RH.L"!*N.<J#)-K.-"E8U<J+R=V,N-RL>)
MB]S?E.]P?U9YSOU!Y0/7.U7D>J."/ 3O:Q7D>ZW\3ZA-\@T4*&A,F"A__SZ(
M,*>AL1,]&OHQH'X4(^JF,:-.(1MJU;"C5BL':O9RHN8(%VJLYD:-66*!W,L2
MSS>-73Q?-8[P?-8XQ_M!XS;/6XUG/"\UW_,\UT3>OS60_YD&"CS50,&54.][
M/NG_YH2% A6MO__;%&,:6MK3H;D7 YJ&,:%Q$@L:YK*C004'ZC=R?=7KY/ZB
M-\#S27><]Z/N-.\'W75\[W4W\;W3W<'W1O< WVO=,WPO=&_P/=-]PO=([QW_
M UT4O*^+0G=U4/BN+HK<T?DG-/J>3_J_M20%[;]_%T'.A2,Y$PY6=&CGQH#6
M04QH&<?ZV2*3XZ-9,=<[TUKN-R:MO*^->_E>&@_SO3!:S?^WT:S ,Z-%@:=&
M6P4>&^T5>&1T4N"!T9\"=XP?"]PR>BMTW0A%_C1$L:N&*/X[\9LA2OP(3;_G
MBY%\TK]=R7MW)0IZD'VXF]&ABR/#)R=?IG<.D:RO[%(XGMOD<3^UKN!];-7(
M]]"R@_^^Q8# /8LQP3OFTT)_F:\7NF6^1>BF^6[AZ^;'A/\TOR+RF_DCD5_-
MWXJ?-?\F><8,I4Z;H?3)?X&6W_-)]W8EO,0IZ"M'03]R-GT-:>^];>A?>K@S
M/74+87WH$L]YSRF3^R_'8KZ;]C4"U^U:!/^P[1:^8C,L<MEF0O2B]:S8!>L-
MXN>L=TB<M3XH<<;ZO.1)FWN21VU>2Q^R_B9[P!KE]A%[K5%^);01HJ S+Z 7
MZ=P!PH#!9!8A2I3W(3K4YT'F= _]G1GO^/JSW/".XKCJD<)SR2U/X+QKF=!9
MYSK1,TYM8J<<>R5..(Y('G.8E#[BL$[FD/UFV8/V>V3WVY^4V^MP4WZGPW.%
M[0Z?%;<ZH-(2L878O (Z\ .ZD][K3[I_J !@A"A\C)*E/(]2H]R/,*#=#+.C
MOQ+LQ7(A,)3SC%\\WPF?#*&C7H6BASTKQ0]X-$CN<^^0WN/6+[O+=4QNV65&
M8;O+@N)6E^U*2\Z'E3<[_Z:\P>6QRKS+!]5U+JBZUA55Y_X%.I-L+](YOW\'
M$4G>QPK JWAQ>! O#S?BM"F78BSI?XER93D>'L!Y*"2*?U]0LO#N@&RQ9;]B
MR>V^U3)+/DURF[VZ%#9Z#2HM>DXHSWNL55WGL45MSF.?^JS'68UIC_L:DYYO
M-28\46,5,?Z=US^A&\GV(]T_G%Q'+"=\3.2&)\G\<#-%#"ZFJ%%.)YG2'8UW
M9-X?X\.Y*RJ,?WMXO/"6T'3QC<'YT@M!9;+K VH5YOQ;E=;X]:I,^XZJ3?I.
M:TSX+&J.^^S4&O4YJ3WL\Y?VH.\K[0%?U.[W0^T^/]1:"3U)=A#IW5&L\#F!
M#5ZDLL/== [X+4, SF0J48ZD&]+M3;5CWI'DR;DE/HA_0TRTR/JH9(FYB"SI
MF? B^<G02L6)D$:5L> .M9&@08VAP-5:_0'K=7H#MNEV!QS5ZPJXKM<1^$*O
M/?"K;EL0?J=#:/\(O4GO#F4F,V"")RF,<#V#":YDL\"Y'%XXEBM/V9>C1]N1
M9<VT.=V-8R'%GV\N,4)X.CY>8G5LNLQ8=)[\2%2ITF!$K6I?>*MZ3UBO5F?H
MF$Y[R*Q>:\@6_>:0@P:-(;\9-(0^,Z@/_:Q?'X9Z=6&HNQ+ZDMX=S@!O$^C@
M9CH-+N<PP/E\9CA9P T'"F5@N4";MCG/@G$^VYEC-L.';S(M5'@\.49\.#%%
M9B A6[XWKDBI*[92M3VZ4:,EJDNK*7)8MSYR6K\V8J-!=<0^HZJ("T:5D8\-
M*R(_&51$H3ZAMQ+ZD]X=10</DP'^R**1?'HX542Z?PDG["Z5A*423>I"D1GC
M;+X#^V2N%^]85I#08$:4>&]JHG172H9\>U*^4DMBF6IC0IU&75R[=G7L@%YE
M[*1!6<RB84G,;N/BF+/&1;$/C8IB/Q@6Q:$!H;\2!M(#QE#@=AKI_KE4.%U$
M!T=+Z6%?.3MLKQ"'C15JU+5EQ@R3Q79L8X4>/(-Y 4(].>%B'5EQ4BT9J7*-
M:3E*=:DEJM4I-1H5R2W:I4E]>D6)$P8%">N-\A)V&N<FG#;)2;AOG)/XWB@G
M$0USDM" T/\1!E/A73R0<T#Z5@$%CI?2X$ EZ?Y5I/O7B,#Z&A7J=)4A_7BY
M#>M@J2MW3Y&?8'M!J&AS7HQ4?4ZR7'5VEF)%9J%J:4:E1E%ZDW9!6H]>;NJ8
M05;*6J.,E!TFZ2DG3=)2[IJDI[XU2D]%0\)@)0P%>$*Z]U72_\\4 QRNH,+N
M&AILK6.&Q7HAF*U7HDS4Z=,/UUBQ]%8Z<[67^P@TEP:+UA5'2585)LJ6Y6<H
M%N?EJQ3DEFODYC1H9V5WZ:5GC1JD9LX9)6=N,TG*/&Z2F/D7\<8H*1,-"8.5
M, +@+NG>%TGO/$&Z[W[R:]>.>@IL;&2$M<W\,-DL3QEMTJ7K:[!@[JASY&RN
M]N*OJPP4J:R(D"@MBY<I*DE3R"O.5<DN*E7/**S32BWHT$W*'S9(R%MC%)>[
M9!R3>\0D)O<6\=HH-A<-"8.5,!K@5CK90R' D4J W?4 2Z1[K6^EP70;+XRU
MRU(&VK1H7:UF3"W-]AQUC1Z\E?7^0J6U8>*%-;'2N54I\IF5V<IIY<5JR64U
MF@FEK3JQ)8/Z4<73AA'%FXW"BP\9AQ5?-PXO?FD47O3-,*((#0C]'[V- [B6
M!7"*=-\#M0#;2?Z&=M*[.@'&N[E@L$<*NKLU:"U=QHQU';9LE>UN/"6MOH+Y
MS2&BV4W14AD-2;(I]9F*B76%JK&UE1I1-<W:X=5]NJ%5DP;!E1L- RL/& 56
M_D%>7Q@&57PU"*I _94>)9'G@>SA6 69 >G?6TC^6M+_5O61[CG  =V#8M Z
MJ$JM'S"DK^RS9BGN=>;*Z_'FS^H*$D[KC!1/ZDB0CF]+EX]NS5.*:"E7"VUN
MU QJZM'V;YS0]6U<U/=IW*?OW?B;OG?#W_H^]9_U?.KQ.]T?W2'/Y%ER%@]^
MGT$KZ;XD?XITX$'2 3M'6:%E7 CJQA4I%6-Z=,6C%DRY(X[LF<.>/"E# 8()
M@^&BL?VQ$I%]*3)AO3GRP3VE2O[=]:H^W5T:7EWC6AY=\]IN77MTW+HNZKAU
M/M-QZ_BDX]:.VFYM_W2-/ \GOL^@"6 SR9\=(-UO!*!K J!QB@&JI_F@;$:6
M4CBC1<N9-F5(G[)C39ITXXQ;[<<;-1$B&+XJ6C1X/$DB8#Q+VG>L6,YKM%;1
M?:1#V65D5,UI9)VZX_ N=8>1\^H.0T_4'08_:C@,X$\ND+-XL([,H(.<0W+_
MJTD'[R?Y+3, Y:0'%\YS0>Z\!&0NJ%%2Y@WIXN>M&:/7.[.&K_/F#%D7Q!NX
M-E+ =RY!V&LN0\Q]MD#294VUM-.:-CG[-<,*MC-K%6UFEI6L9\XJ6D\_5K2:
M^J!D-8G*5JO_Z229P2ZR@XUD_]/D_H=(!VY? U"SGO1OTH/3EM@@>:L0Q&]5
MI$1OU:5&;#6G"]GJP!BPY,'BN^3/[K44QN6^)9;794NJ@./F/"'[S14B-IM:
MQ*TV#4I8;)J5,MNT@S@C9;;QH93IAO?2)HLH8[* LC\ZT$">Q1Z .;+_,7+_
M7:0#URV0_K<9()WTT.@]]!"^EP="]DE!T#YUBM\^(ZKW/ALZCWTN#&[[?)B<
M]P6S..R+8K/;E\1AO3>;VW)O&:_9WB9^D[W] D9[9P0-]VX3,MA[2LAPSP-!
M_=WOA/5WH8C>3A3]T3)Y!M</ 4R0_%Z2WTCR2Y< ,G<"Q.X#"#I"!UXGV,#]
MA""XG90'EU/:X'C*E&)_RHYJ>\J-9GW*C\[B5!B#V:DX1I/3&<Q&IXM8#$[7
ML^F=[F'7.3W%H7UZ"Z?6F>.<6J?O<6B>?,NI<>(KM\9QY/G1AD& R57D#)#Y
M-R\"E&T%R-H-$'<0(/@8@,=I&MB?9P*+RQQ@?ED$S'Y3 -/?M<'XBBD87;6G
M&%QUI^A?#:#J_A%!U?XCB:;U9RZ=QI^5]&I_MM.K7!MG4+ZVR*!T_2!Q@T'Q
MS^>,"E<_,BE<^<;\HYEQ<@9(?BO)KR#YV7L X@^3?-+#W7\A'?PB!4RN,H#^
M77;0O2L VG>E0.N>"FC<UP7U^V:@^L .5!ZX490>^E$4'X93Y!\E4F4?Y5)E
M'E=3I1YWTR2?3-+$GVRAB3T]3MRFB3Y^21-]]/$?1LCY;R?SK]P&D+.7Y!\E
M^:<!W,X#6%\&,+H&H'F;"NHOV4'U)2\HO1(#A5=R(/=:%63>Z(#T&V.0?&L-
MXF^=0?2=-PB_#Z$(OH^G\'_(H?!]K*;P?NRA\'R:HG)_6J)R?3Y&7"<>_4/G
M/$ UN?]<DI] 9A],[MWU(H#550#]&P!J=P 47@+(?6,!:>0"210 ,10#890!
M050"?M0 7M0''C0#+K0%#G0#=@P 5HP!9LP$)JRD,&(7A1Y74^AP [&'0L/C
M_U!+\O-)?B+)#SE'\LF]6Y)[U[T-H'P/0/HI@,17 !&D)YEL)).+Y/&1/&&2
M)T'R9$F>$LG2 %+2@8;F .A >!/A1"I12I ? $@>/B2+QX5_0$4U"JJH4%"5
M4-&@H((>%>4MJ2CK2D/I(!I*Q=&A1!8=BI<2]?0HWD$,$&,,*#[%@&)KB0V,
M*+:5V$T<)LXRHOA-X@GC%_&WC!_%OS&\ET#&]^+(]$X<F5="99*MIDA!#4+]
M^WL=<CWF5%1VIJ&B/PWEH^E0-IT.98KH4::&'J5;&5"ZEQAA1.G5Q!IBG@FE
M-Q/+Q$'B--,7Z6M,'Z4?,;V3?L/T6N8KXRL99'XI@RPOI9'UQ0JHID!!+=)S
MM4GOUR;O=33)JPD5-1UHJ.Y#0]4(.E1.ID>E?'I4K&1 Q29&5.@B!IA089SI
MF\(T\U>%=<Q?%#8R?U;8SOQ)81_S!X43S.\4KC*_4GC(_%SQ-?,SQ:\L3Q20
M];$"LC\B'BH@QX]0DV3KDIZK+TE!0_+>B.S&R)"*!C94U/.@H4X('6K%TZ-&
M%L,W]5+&+^IU3)_4VI@_J/4ROU<;9GFGNIKEC>HLRVO5!=97JDNL+U5WLSY7
M/<;ZM]HEUL=J]UGOJ[UBO:OVA?TO->2\K89<MXB;:LC](]3]GBU*01.1_WX7
M8JE$D'V86U#1E.S#V)_NLV$TPWO]-,:W>@5,KW0KF5_H-+(\U^ED?:8SP/I4
M>XSML?84VR/M=6P/M3>QW]?>R7Y/^S#['9T+[#=U[K%=TWG)>47["_=E;>3Y
M51MY+V@CW_D5_I-O*@AH23JWK1@YTF0O#N1LVAE3O]C8T=Y9>M&]- ]C>&:6
MR/C8-)OYH4D)RSWC6M8[1JUL?QGUL-\R'&:_:3C!<=UPEN-/PT7.JP;;N7XW
M.,AUV> LUP7#.]R_&+[D/67XF?^$(0H<,T3!HX8H=&2%_^1;\0+:$\Y"@&Y2
MA#+EDZLNY963!?6I@PO= [L ACNV,4PWK=-8KEGELUVUK&"_;-' >=&\G>N"
M>1_W.;-1GE_,IGC/F*WC.V6ZF>^$Z6[^XZ8G!(Z:71,X:/9,<)_91^'=9BBR
MRPQ%=Q++*Z %'Z =Z=XNW(">Y+VW*'SVD867WNJ41YY&E+_<[6G77+WI?W,.
M8[K@F,!ZUB&+X[1]$=<)NRJ>8[:-?$=L.O@/V_0+'+0>$]QO/2.TUVI!>(_5
M=I%=5H=$EJU^%=UF_5!TB_4[\4W6*+&!6"065D ;DNU(NO_W_NU+W@?PP^M
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M%3V6MBA/ZN]6=>E?JN;4OTE]8O\1XFOUB8L?:TQ<]+?&A(6<YH2^?SDTA6I
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M#YKP]CSHC4HX7B@GX:E2+OY0*L-O2K5XI-2,!TKMN*<T&[\J]>*NTF+<5AS
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M]\I[YZV2>.7M4/#,.TW\J."9^U3!*Y>3>.7\RS&JP0[26T<V8&$!C86"=V=
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M&G2GJ7.=IN1.KR<.T]?)T)^Z33QZ2SO5NW[X/1S*.64#M0'EZ[V+]/>2_@'
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M7/@_[*&!XIA\Q$1_=(RP<Q\]-8/B.IR:DQR#\T B^QO"_KI3UYJZA@Q5YP5
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M.1I=ZU#OVH8ZUW[4N"U M=L*5+EO087'(91[7$2YY_,H\_P$I9Z_$/G?/!/
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M,\4-NW<X)G<XT5YGDE_?0MCXG<OD:10QWVD;N!9LYSK '+L<!2RI:\#IJ_E
M\^'K4%Z8W0M1\,I#>R+_F+T^Y"V.S[N<)W<-@ \LE=_3^DDX\"E/")]Q3#[G
MH'_!"?8%D_PEQ;X\/[O_H#V+Y.][0)3?"2*#XGZ8W^EU?T$Y?6D]'6L;O7D/
MOJ6__)H^]TN,XPLLP6?TF)]B&A_367Y(GWF/3O<_=-KOXPF\R\"5WP?Z\]_W
MGOQSEG_\O?^@,HONS/4H?\$!O\&;OQ&.^_2ZW])C?H4B^N(J?$)_^2']Y3WZ
MR[N,XSW&\2[C>!M+J;$2;V =??,V^O:]3--QINLB(WB:/OI=IO$[W*+"LP]Q
MZW_V'Q3[,;_,7(-AS?ZYL6^!C%Y&O12VD$N-4FK4,/5-'()VO,PX7F0<SS..
MYQC'+<:AO YC(X=O)Z?,(0[E66;BZLQNS&5F[!*S^BB5'N;A_8<?H$I=/>;0
ME/URH)X/^Q-&K3CJI%,CGSTJPTW&<9UQ7&,<5S@N3V"0TW6$[2]DF\OH]-=P
M&F^A^EX>1L=QBC\YP2P<PP<XBA__O@;CP748"OV_R'=0?@7O/YF+EYB+6\S%
M3<Z+)Q% G4CV(Y$M9;+] K9?QL.RAJ/=R/;;<))Q'&<<QQC'$4RPW2D<Y)CL
MQPY&<0B[^1N[F)D=> O;\0U'ZD]LI?(#%/W_%LK;O5Z;V7)48>9TJ6>""[!G
M7[RH$\)^1+,/R6P_B^T7X@#CV,<X]C*.W8QC%[JI,42-4;:[F#-S%9?3S=C
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MN8,5FCM&(7F/*3AOIH+R5H#="LP["W[#\S\K./>V?4_4:'0.A))TSW'4@-J
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M*9=*%KPJ%I3J ,?$;A26Z_!%';ZHXTMU<*LZ8U,!Y+4.3E$+@:F%N-20M=5
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M\K-9Y6L+ED]@)$B0=V"&O((*Y1%4(_?@3G(+[B_7X-%R"7[<<7A^,,E8T'X
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MO3 >=9*7R3O&*=+5<[#.&)?LKN,P/!$6RQ>FL0.U9&XH1!#4!DO+(P&,)!I
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MWUJNQ[675>([*5KB<;R&VHW1E'6CM<+C:)VR$ZW5=6"4^M;1!FRO/ 'L[TP
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M D-ZO)2M.H86Z-J0HJI6N,S47**J;BK26AL+JVP-!69[0[[=T9#G=40+?(X
ME*?PX0'>2V-!.600008!9.! !DY\W!U.8M)-=EK^958>]BP321^@$00]9)J\
MDU"F:2_E5;6@R\U-2*FU$:ZT0_^%.>N+]:Y88;4[5N!T1PIKW(&B&G<-E*/X
MX0$^9!#];1"N_1)P=ZT O'UQ=W@'DVYRD_,OL[-+AU@P9C\#5WZ<1E5VD%B5
MK7BNJ0DKM#:@)8X84N&J@VMJHB55WFB1Q1LM='D#Q6Z/!\I1[*ZQEM0\-""
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M,[I+V*G'T=SD3CP_\1A5>*B#57Z@G2]*:)>*X]O5DOWM1LF^=J?X80'C"V.
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MP[O!EGQC=5.NQQ+.#UAJ"@)6:V' :BP*6/3%08NV)&2N>$B !OTLQX0,+,C
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MHUP^,::FIASK<0FP7B>_U.?@E?KLW%*_[4$!)F1@0P8.9! M_1 HE@Z_8%L
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MK;S+V;WBS_(]R_]4[%UVIW+?TCNF!];D'CO&%7E\3&77V#&B:T\^Q@(O/TL
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M2<]WING)GRSS@Z,NEGM&7:UWC(P)Z80\6DO(I59"CF[G(;MI]]MZDI=LO"Q
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M]??4,(5_C&I#:4@/*F_UH?K*$*J]1O\%4YK!@&8PI:RE^& GQP\'-2$PC:;
MP6X6[-@+81VT%!;Q8C#-7@.C<FD8ULM"OU4!>IV*T-NG#-UC*M"YJ J=A]2
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M*/O)XI3^=/XW!-%]2*'=F_;_JW6$G&GC)8<[&&3O7AZR_>@$TGY,E*?IJ(Q
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M6^N56;O'.[WN"O'<*Z,.9V?6HGM6-;IF5Z+SUV <!_[,^=R'B\WDG5WD??T
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M?RU@1-YM8(3?G2*>,$)OD1%Z3;SZDL4T_SV47T_Y!8<HG_8>>A' XRJ W34
MDU\ M.\ J#P"4/R;&^3(^V50 B3)^<51#411%X31%(30#@30'?@P$+CI0LS!
M?&!A,S#_<?Y-!&T*GQ/X7_31_#50?B'U/OD,Y5/=W7\$L+D)5', ]?L <I0O
M]0XH$RB3ES*%01#%*$^:\A2!Q)A^ECYA0<PB?(@H@FZ*D"X .$S01O$T\3OQ
M_@N:*;^8\E/.4C[5W?UGZOUM #W*5I[.?DJY?P'E NT3@)?@(#?]77Y"F! C
MI @%0H,P(*P)=X)N#*9_,8'T 8!T\N$:8@]Q^0M0T81!54,&U0AE8P;E+1B4
M=&10Q)-!H7 6"J2PD*^(J",ZB$%B,;&<6$ML(G80!QCD.TE\0Z]_(YX1[QCD
MQW]A_0\"R/X"%2,&-?08U"34R76531F4M:5UN#,H%LQ"T406"N<1540KT4<,
M$V/$*F(#L8W82QPE+A*WB#^(OPC\C AE?8:#HE^AH<^@-OF_+CF_#KFNQO0Z
MJ!8*+@S*!;!0.I:%DEDLE"@C&HFY;)08(A835 N)M73<3.PD#A%GB>MLE'S(
M_B3YEOVW)++?2?T'SE]2R$5P?\U_\O7)<0U5J95TU*7W.E0+3>J'N@\+52)8
MJ)3*0H5"-BK4LE&^C>@CAHFE')1?R4&%#<1V8A]QDO-!X5O..X4'G#>*KSDO
M%9'KA2)R/U=$GF=*R$OP/5-$OJ<S^$^^L1*@J0*A2*@3-!O&-@Q=U5BH&\)"
M[00V:N:P4:."ZM;$^:31Q?FH,<3UM\8(UWN-Y5Q_::SE_E-C,_<;C=W<KS6.
M<K_4O,S]5/,N]R.ME]R_:WWBO:^)_'>U4. W+13\31,%[Q"W-5'H7]!8F4XI
M64 K:8*<VY;68TL]L:%^6#HS:.['0I-H]M_&Z9R_C(HX;PQKN5X9MG*_,.SE
M?F:X@.>)X5+>/PQ7\CXRW,C[T'"*]X'A(;[[AA?X[AC=X?W%Z 7_SX:?!'\P
M0N'O#%'DJB&*?D-<)BX9_2]H+@=H0^YM3^[K* [H3.]=J!9.-*N.=LQ[>P_6
M:]M0]G.;1,X?UKE<#ZW*N>];-?+>M>SDO6,YR/>KY0C_+Y;C_#<LU@I<M]@J
M>,UBO^#W%F>%KEK>$KID^5SDG.5'\=.6*''2$B6/6Z+4<0N4.D+'P_3^7]":
M]NY WNLD1*>T"* GK<>3>N*I#6]GFS//W)R9AR[^[+O.,9Q;3NG</\\JXKWF
M6,/_G>,<P6\<>H0N.\P7N6@_*GK>?H786?N-XF?L=TJ<LC\F<<+^>\DC#H^E
M#MC_+;/7'F5WVZ/<+F(GO=[N@++;9H!VTWN?SB?G\R;W]*/U^$O!&W\5>.RK
M#W=];)B;/IZL[[W".%<\DW@O>.0(G)U=)G3*O5[TN%N;^%&W7HG#KL-2!UW'
MI/>[K)'9Y[)5=H_+ ;E=+A?DIUSORV]Q_5-QDRLJ;236NZ+B-&M<46'U#' 6
M9;I-YY-[!_ "!@O NQ 1>!PL!;>#5.%:L!E<#G9EG0T*Y#H1&,MWQ#]=Z*!?
M@>@^WTJ)W3Z-4CN].V6FO ;DMGDM4MCBN5QQD^<&Y8T>NU36>YQ26>OYJ^HJ
MS]>J$YZH-NZ%JLL^H[+$"Y5'9X N5 -/\CU_@+]"6?![! =N1_#"G0@A^#Y"
M#BY$&<+)*$?6X4A?[GT1$?R[PI*$MX=FBV\)+I&:#*J1W1#8(K\NH%MIM?\\
ME97^2U4G_-:HC_MMTQCS.Z*YQ.^:UF*_YUH+_5%SF%C@CQKS_5%]* #59H)N
M_)\O,2'D.G29N1G'P/?Q7' UC@_.QTO"\41=.)!HR]J5X,F]+2Z$?U-,G,CZ
MZ'2)-9'Y,BLCRN67AS<H+0MK5UD2VJ^^.&21YJ+@">WAX$TZ\X(/Z X%7]'M
M#_Y#MR_DDTY/"&H36MVAJ#DW%#6Z9H >Y-U^ ,\C &[% 7Q+OG$AA0UG4KCA
M>(H8[$_7A)WIEJPM:6Y<&U("^5<G18E,)"1++HO/EET25ZPP$E.M/!S=HC8_
MJEMS,'*^=G_$,MV>B/7Z<\-W&W2&GS=HCWAHT!;Q0;\U$G4)G3F1J-42B9HS
M02\V8!#  W*^GRC_8CK J4P&CF9R8'^F,.S(487-.6:L==G.7"LS??G',\)%
M1M,2)!>E9,C.3RY0'$RL4.E/:%#OB>_0ZHH;U&V/'=5OC5ECV!RSPZ@IYK1Q
M0\Q]H_K8]X9UL:A?%X>ZA Z]UJZ-1:U_F>[#WZ$ OY'S74TCW\HFYR/GV)?'
M@IUY0K"Y0 G6%1HS*PL<N<;RO/D7YX:(+,B.E1S,3)7MR\A5[$XK5>U,K=5H
M2VG5;DGNU6M,6F10E[C2J"9QFTE5P@F3BL0[Q#NCBB0T(/0(W8I$U)[)OWWX
MA?S_8A:Y1C[=ZQ>1^Q<#;"GBAW4E\K"RU( 9*[7CC!1[\,TO#!(>*(B6[,E+
MENW,R5)LRRY2;<FJTFC(;-:N3>_6JTI;8%B1-F%<FKK%I#CUJ&E1ZBW3PK0_
MC8O2T)#0)W2+4E%G)M._;GD\W0>JP5ERW\.4O9O<;VLYP/IR'EA9*0/+JG29
MD4H;SOP*-][^,G_AN241$NW%";(MA1F*C07Y*G7YY1K5N0W:Y3F=>B79\PP+
MLY89YV=-FN9F'3++R;IAFI/UQC@G"PT)_=PLU,O-1%U"YU\PF&9A>A;)_T^2
M^^ZG_*DJ<G_ROU75;!BKE821.BUF?ITEN[_6A6=NM:]06V68>'-%G$Q]6:I"
M=6FN2D5)J7II49UV46&[7G[!H&%._E+CS/P-INGY!\S2\G\R3<M_;9*6CT;I
M^6B0GH=Z&;FH.Y./=+OU&_7A$MWZ'2VA&E#^ECJ M0WD',1(HQC,;U:'_F8S
MUMPF)^ZV!F_!IOH0L;K:&.FJFF3YLJILY:+*8K7\BFJMG/(YNIEE_09II:/&
MR27K3!)+]IDFE'Q'O#1.+$'#Q&(T2"I&O>0BU$TN_%]>3,]"*GEO <#!"JH!
MY6\D_UPQA_);R'M:1:"O706ZVHU9K6T.7(VM'ORU+8$B%<V1DB5-B;*%#9F*
MN?4%JEEUE1IIM<TZR34]^@G5(X:Q56N,HZOVF$15?4.\,(ZN1$-"/Z8"]6++
M49?0^9<G,0 _3O>!:K"7;CVW4/Z:-H"Q#LKO!.B>*P@=W0HPI\> :>BVY53/
M=>,M[_(7*NH,%\]OCY/.;DN33V_-4TZ94ZZ6T-*@&=L\5S>J::%^1.,JP]#&
M748AC9>,0AJ>&88VH$%H/>J%U:%N>"WJS.3W1( K="X>J23OI-OPC>T $W/)
M?7O(O<D#6P=XH7%0!NJ&=)C*(4MVZ: S=\& CT!.?XA(1E^,1&IOLDQB3[9"
M7'>)<M3<.K7PK@[-D,X%.D$=*_0".G;H^W5<T/=K?ZKGWX9Z_JVH2^@$M*!V
MX QN3Y\/="[LIQYLI?VOZ2;W[:<:T*UXVWQRKV$65"P2A](1=2@:,67E+G+@
M9"[RX$U=&"B8-!PI$K<@02)Z?H9,Q/Q"^9!YU4J!0VVJ?H-#&CZ#$YI>@]NU
M/0;/:7L,/-'RZ$,MCU[4\NQ!3<_N+[E&LWB\\O.SP.GG8.,#T\^@J >D1XVC
MY![D@GGCPI ]K@B9R_69U.4VK*1Q5ZZX<5_>Z&6A N'+8H5#QE+% Y?F2?DM
MK9#U7M(B[[%D0,EM=%S%972KJO/H&57GQ8]5G$=0U6DAJCD-HYKS@B^Y2#4X
M0/._M8O.1<I?O "@?X1Z0-E5RP%RR$63U_)"PCI)B%NO"3'KS9C(]8ZLL/4>
MG.!U@=P!ZZ+X?-<E"7JMS1:>O;9,S'5-DZ33FCYIQS5C,O9KMLC:K3DM:[?Z
MD:SM2I2WF4 %F^6H:#/^)2>JJ08T ^LI?XR4;![MO6.<>D >6K@.()44+6(K
M0/!V80C<K@ !4[K@-V4%/E/.C.>4#VOV5"C'=2J.VWDJG==QJHC??JI.T&:J
M6]AJ^ZB(Q=0F4?.IDZ+FVQ^*FFW])&ZZ&25--J&4R21*SV3Z>>1FZO\$Y2^D
M_+FT]P92LA+RT(PM #$[  )WDP,>X *7@V+@?% 9G X9@.,A:W X[ IVA_T8
MF\/A+*LC22R+([D<LR-57"9'.KB-CBSB,3BR@5?_Z#%>_2,/>/0.?N37/8""
M.OM02&<O"L]D>R_ :JK_8LKOFP!H6@M02IJ<.0402VH8M!]@-OFH_0D6F)[E
M!>-S8F!T3@D,S^N!P7DK,+C@ OH7?4'W8B3H7$H![4M%C.:E)D;C\A!+[?)J
MENJ5@RS5RW=9*A??LY7/(T?Y''(IG47NF:RC_*64/TCY<ZCVY;3WK%T <0=H
M_T=H_\<![$B732X Z%SA@,H/_*!P7104?I8'^9^U0?Z&&<C== 39F]X@^TL$
MR-Q*!>E?2T'JUW:0O#T*$G>V@?AOET'\U]<@_@LR8C>)GY$UDV64/X_RV]9_
M?@:537N/HWT'G@!P.P-@0]E&5P TOP=0)">7NL4%D@^%0?R1)(@]5@+1Q]H@
M_(<I"#^Q!Z&GGB#P- SXGZ4"W_-RX'TQ%WA>+@>NE_N \^(NL%Y\!-8S!/:3
M+QFF_([UGY]!Y>RC_&,  93M0MF6WP#H_P"@1MEROP*(WP40><Z T#M^$'@O
M GQ_2P'/WXK ^: )S =#@ \VA!M!%\(/*0 ?Z</_ S7[ YU<'XX2CPFD?_\E
M<RF_AO)SJ>_QM/= RG:F;/,?J?8W 91NT][O 0C_#L#_ H#W(P 7LH$D_Y_G
M#^*$#*%"Z!!FA-,_W\&@BR'2.K#OGV</M$%\0'SXXCE,/<U>/O4^X13E7Z9\
MVK<996O= 9"_#R#V"$#P*>6^!/KS7\,UXUG(]%ID";5_GH/8$;Y$ D$W!$CU
M0*H'[B6^(W[Y'U#6$%!.C] %E#( %#4%%+!ED#V;00@A$HE\HIJ80_02"XBE
MM(P5Q#IB"[&+.$2<(7XD'A"OB(_$_^<?!<I7T@94U*)UZ !*T)J$+6D=+@SR
M!C+(%4?KR6:054XT$5W$$#%"C#/(K 9D)HGMQ#[B!/$-_>2[Q OB WR@%7]@
M$6R"@\P'KB]!%<I7(\=550-4UJ"Z3*^#:B'FR*"P+X-"40P*I#'(7T34$FU$
M'T&UX%]"K"#6$5N(W<01:L\%XE?XF_\9_,G_'MX((/-&$)G70O^!]36H3OF:
MY/N:Y+GJ=%2F]XK3_;$%E/9@4"*407'JAV@N44%0+42I%J*#Q")B&;&:^2@Z
MR7P0G6+>BQYDWHF=9=Z(W61>B#UAGHJ]8_X01]9C"60]DD#VP_\#U*9<75E"
M&E![&GJO3;.A0?U0=:$^!3"H$,.@7 ;S2:Z8^2!;R[R3;67^E.UEWLK.9U[+
MCC*O9">8%W+KF.=R6UE/Y?:QGLB=8CV2_XEU7_XQ<T?A'>M7!63_HHB<FXK(
M=>,??IX!ZLL!&DD08I\QGGY/M3 T!M2SI_5X,>\UPYFW&LG,2_4\YIEZ!>N)
M>B/KL7HGZZ'Z .N!^D+6/?5EK+OJJUEWU#>Q;FOL9MW2.,ZZJ?$#ZYKF(_95
MS7=<E[60^Z(6\IS70MYSTVA^"1I+TBE-[FU.[FLI#&A%[ZVH+Q8Z\-[,$EZ9
MN,)3HT#FH6$L<\\P@W7'L)AURZ"&==-@#ONZ00_[FL$\SO<&HYQO#59POC'8
MP'798(KKHL%A[@N&E[G/&#W@.6'T)]]1(^0_;(0"!XU0\, TABBX?P9H1GNW
M$@2T)N^T%P!TI/4X2,%?=BKPS,8 'EC;P6TK+[AA%<Y\;Y7,^L8JEWW)LHQS
MP;*>ZYQE._<9RSZ>4Q8+>$]8+.4[9K&:[ZC%9O[#%GL%#EJ<$=AO>5M@M^4K
MH1V6*+*-V&J)HEN(S?1Z)FA%>[>E?$<6H LWH*L O'<5@2?.TO";HSI<GV4&
M5YU<X8)3$.N,4RS[Q*QTKJ.S"GD..U;R'G!LY-_GT"FPQV% <+?#(J&=]N/"
M4_;K1;;9[Q#=8G],;+/]3V(;')Z)KW5 B=4.*+F*CBN)%9\1_Q>T)?=W_/P5
MMS<>Y/^>++A-+OZ;FQ!\[RX'%SP,X927(W/4RX=UP#."L]<CB7OG[&R^*?<2
M@:WN-4*;W5I$)MWFBFYP'1)?YSHJL=9EE>1JERU2*UT.2$^X7)%>YOI(9JGK
M!YE15Y09^8ST(E>4F@DZT-Z= =YY MPC][P12,X5P(%O?/G@G*\D' O0@0.!
M-LSN0 _6]H!@KBW^L;P;_=+XU_GF"ZWQ*1=9Y5,O-N'=)C'NU2LUYC4LL\1S
M7':QYP:Y19Y[Y!=ZGE.8[WE?8<CKG<* %\KW>Z$<(=OW&9E_02?6?QYO/Z;\
MFR$ WX23[X0S<"J4"XZ&B,'>,'68BK!@-H>[LC:$^W.M"8OD71&2)#@>G"4R
M%E0D-AI8)3D2V"2],*!+=K[_D-R0_Q*% ;\U2GU^4\H]?B>5Y_K=4>[T_U.Y
MPQ^5VOU1L3T Y>DH-Q-TH<NI%]6 +K??1U(^.<^Q6'*N:#;LB1*&;3'*,!EK
MPJR-G<5:$>/#M2PZC&])5)S@HLATT>&(//%YX652 V%U,GVA;?(](7V*72&+
ME#N"5ZJT!6]5G1-\5*TY^*9:8\AKU8805"&4"$5"@9#_%Z3+_7.ZO-VB_5^B
M[!/D/ ?HDKN+CMOB!6!CHCRL3C: Y<GVK*5)'ER+$H/Y%L1'"P[&)8OVQ69+
M],042W=%5\FV1S4KM$;.56J.7*#2&#&N5A>Q2;TF_*!&=<2/&E41+]4K(U&5
M4"&4"$5"X5^0YO /FH'KY/]G*?<PN>?N=,HG]]F8P@NKTF1@/%T71C-L6 O3
MW;F&T@)X^U,B!+N3$T0[DS(DVA+SI5L2RN4:XQL4Z^,ZE&MBAU2K8L?4RV,V
M:);&[-,JB;FJ51S[7*,H%M4)U>)85":4",5_F?[JZ8-0FD/R_Y.4OY_<<RH;
M8))8G<D%XUF2,)JC!<,YEJS!;!=.;Y8O;U=FF&!;1IQH2WJJ1&-:KG1=:JE<
M=4JM8F5RFW)94K]:<>*H1F'B.JW\A#U:N8F7M',2GVKF)*)Z;B*J$BJ$,J'T
M+^^H#[^1>U^F^A_-H!KDDO?FD_L3X[D,+,X3@P4%ZC!8:,;T%,SB=.9[\;3F
M!0LTY4:+U&<G2U1G94E79A7)E656*Q9GM"@7I/>JY::-:&2GKM'*3-VEG9YZ
M@?A#*ST5-0BUC%14(90)I7]YZ4^S0'TX1S4X2-XW54@](/=:02RFU_.+16&@
M5 6Z2XV9CE(']IP2#YZ&XD"!VL)(X<J"1/&R_ RIXKP"V8+<"H7<G";EK)QN
MM8SLA1JI6:NTDK-V:"=EG=5.S'JDE9CU22,I"]62,E$E.1.59_(LB&8A'N 4
MU6!? 3E?*=6 ;@''R@$6T"U87[D0S*U4A/8J Z:ERI9=7^G.75WASU=>'BY4
M4A8G5EB:)IE7DB>375PFGU%4KY1:V*F:5+! /2%_A69L_G:MF/S36M'YO]/Q
MHT9,'JK%YJ%*7!XJQ^7^+X_#/C^3/$8UV%5"<T#^N[*&:D#T50%TU@A :YTL
M--7K0EV]%:NJSH6KK-:'MZ@F1#"_.D8DNRI%(J,R6SJUHE@NJ;Q6,;Z\726V
M;$@MJG2Y1D3I5LVPTI/$ \VPD@_JX26H&EZ,*A'%J!Q1A$K_<B_J\S/)0U2#
M[;3_=74T!XW4 _+@3J*YB0?JFZ6@ND43*N:8,R4MLS@%S9X\.<U!_)E-D4)I
MC8EBR0V9D@GUA3*Q=57R4;5SE,)K!U1":L;4@FHVJP?6'%</J+ZG'E#UMUI@
M%:H$5J)R4 4JS>06]>$,G0-[J0>;:^E<: 88G4/N332WTGU_.PO*.\2@I$L5
M"KN,F=PN.U96ISM76J<_;W)'F$!">YQP;%N:6%1;GF1X:X5,R)QF^<"6/D6_
MEB7*/BV3*M[-1U6]FG]3\6IZK^S=B,K>#:CD4X^*,_F!5.08S=X.\N\-E#].
M#KZ@$Z"+J)L+4$RWY'G]0I ]( ^9 WJ0.FC%) TXL^,'O+EB^H-Y(_NC!<+Z
MDH6#>[-% WI+)7Q[&J2]N[ME/;H7R[MW;U!PZSZLX-I]6\&UZYV":P<JN+:C
M@EL[RKNU_2_3ST4/T/QMH?JO[J :=%,-*'<.:4G%(+DG^6C*,"\D+I*$^$4:
M$#MB E$C]DSXR&QVZ")_KJ!%X3S^B^+Y?!9F"'HM+!*>/5PKYCK<)>&\8)'4
MK 7KI!T6'"1N2=O/^TO&?A!E[ >(_B^9?B:YBV9@ ^U_60_58(!J,(]J0-F%
MBP!2EP!$+0,(72X,(<L5(&A"%P(F+,%OPHGQF?!B>4T$LV=/1'.Y3:3P."_/
MXYNUO$K ?GF[D.WR!<+6R]>(6"W?+VJY_*:(Y=B?HA9+4=QBE%B,$C,Y./T\
MDOJ^DO)'ANA<& 9H60Q0MI1J,$[^N8+\GS3-:STOS-X@#NX;5,!UHP&X;+0!
MYTE7F#7IRSA,AK'L)N/9-I-9'*O),B[SR19NT\DA'N/)E;Q&DWOX#"=_XC7<
M\(;?8!T*Z*]!0?W5*#23G30#ZRA_*>4/+01HI^SJY30#JP&2U@&$30)X;P&8
M14YJO5, +'=*@<4N-3#?90AFNVW =+<KF.SQ ^,]$6"X)YG1WU/ Z.VM8^GL
M[6-I[1UG:^[=P=;8>Y6ML?LU1WTG<JGM0&ZU*>11V_Z_;*+^+Y_^+A;5O6N,
M>O#/,Z"430 1VP!\=Y"#[B8')R<V.,0&S6."H'Y,$M2/JX#:<7U0/6$)*B><
M0?FD+RB=B@3%4VF@<+H,Y$^W@]SIQ2![9C/(G#D/,J=>,#(GD)$^CBSIH\B>
MR<JAS]^%ZJ&>-]#>BS?2#%!VY"[*)SUU.DCY1P#TR<G5SP#(7>" Q!5^$+LJ
M!J)7Y4'T6RT0^=84A+]S)+Q!B&Y"A+[/ ,$?JHD^$+BV"OBO'0*^G^X#_P^?
M0. [!(&K_X'YEU'*[Z>^-Z_Y_ PHG?8=M0_ YS#5GU3=G'Q<]RR RD4 F6_(
MP\G+!7_F MY?!(#[EAAPW9('SJ^:P+IM#,P=>[H T@W17;H9NDLGW#T:]OLT
MX/<WT,69-O#@.<#O^%\,4?Z<M9^? 650S:,.4?YQ ,?3 *;G ;0N RB2JDO^
M!"!\$X#O-@#K'GG_0VY"B! #>$3._YB<_PDY_S,;@!=T4_*2UO&*/OQ>T4G_
MFAK]9BO VRL ?[XB\ O:*;^2_G/F'H#HH]/? 0)PN !@3'O6H#W+W:"]_TI[
M_PV \X"R'Q%OB-?31RY"@'ZV""$)\)<2P'L=NCFT_.<[&!'_?!>DA1@EMO_S
MO8LGQ+O_H9KRLZGV,;1W/]JW V4;70-0HSU+WZ&]WP?@G<ZEOP942OCK_WH6
M,OV]$$%"])_G(-/?33$E7/[Y+LB_ZZ"3'K?\\__ ?/\_H 3YK806N3XA1-[/
M;40_UHIP)8*(>"*'*"<:B2YBD%A$C!&KB W$5F(W0>X/Y/YPB_B#^.O__PQ$
MFK*ER7$EU6@;&H#\M"8P)681?D0TD4X4$[5$&]%+S"=&B>7$&F(3L8,X )_@
M#'R$G^!O> COX2V\^V<E,WDW Y2G?'EE*B$YOP0=A>D]OR$@CQT@VY/^1!B1
M3.01E433/[48(!;^4XN5E+L>/E MWL->^!-.T,A<A5=P'U[2X$P_C7E./)O!
M\QF@\O1S#_)]11E &=G/ZQ#3_?P\2)#ZP1\(R!M':\JD/I405 ON5OC$W0,?
MN.?!>^[%\!?W.+SE7@.ON3?!2^Z=\)SK"#SAN@2/N>[2Z4,KX46XQX]P5^ _
M,%^#:I2K)@&H2OZM(/[_^'H+\*J.]?M_[7TD?N)&T&!!DA!(0HB[N[N["X2$
M$!(@)$" 0-#@[FY%BY1"2Z'>WMJMNPMM;W7_U\X)+;>_^_T_?3X]DC#KG7=F
MS\P:9F\8RS#F91S;QYGQ>#.>"+91"G[7%. 7315^TLS! \T"?*_IQK>:5?A:
MLQY?:;;@"\UN?*XYC$\U9_"Q\55\9'P/[QE_@'^;_(#7327A53-)>-E<$EXR
ME\07_X$TGOKCZ??'&4$:2P\^UH+=FKD8-8GQN.$7VR \L(G#-]99^-*Z%)]9
MU^-CZU9\:+T0[ULOP[O6:_".]2;\VWH'WK0^@-=M3N%5F\MXV?8NGA_VGG#/
M[@?AZ>&2>)O<&BXIGO@?2 [4GV0 R8'>=PI?I\B?K?''!'L\&.N$+\=XX>/1
M$7A_= K>'IV/-\94XM4QL_'2F/G"\V.ZA.?L5PCW[=<*S]AO$9ZVWR,\-?:H
M>'OL>?'6V%OBS7%OBH^/_UIQ>?R?R@OC)=5Y<FZ\I!Y"]1!I*NOOJ(+D)$!R
MX:N+ ?YP-L%W4VSPR:3Q>,=A!EYS",0+D^-P?THFGIY2(MR94BO<FMHLWIRZ
M0+P^M5OQ^-15BJM3-R@N3]VNO#CU@/+"U%.J\U.OJ<XYOJ ZY?BY^KC3;SI'
MG"3=0^2@C.-_(SGK:K=WW3C4<9C]W%W$)S-T\:&S,5YWLL-S+E/Q] QOW'*-
MP'6W%.&*6YYXR:U<?,RM7G'.M45YQK53=<IUJ?JDZVKU<=<!G:.NNW6/N![5
M.^1Z4>^ ZUW]?6X?Z>]R^X_!#C?)<)L6@ZW_0)HA:O4YW7SD"[S%H>UE'R5>
MG*F'9SPL\83G!%SU<<<%WV#AK&^\<,HG4W'<ITAYU*=*=<B[27W NTUWO_=B
MO;U>O?J[O=89[/3:9KC=ZZ#1-J^SFBU>3VH&O-[5;/!Z8+S.6S+NUZ)9XRT9
M/8JL+V\M?QX _#L4>)[3WM-\O1V@PG5_4UP,'(,SP=-Q(L1?.!(2)1X(25'L
M#<Y5[0HNU=D15*N[+:A9?TO@ H.!P&ZCC0%]FO4! \9K _::K@DX:;8ZX+K9
MJH#7S7H#OC-;%BB9+0V43(E)CQ;CAT@>G-I\M%/NB_1]3]&#7X^A]XT4<3Y,
M@Y,1(W DRA'[H[V$W=%AXO:H!.66J$SU0&2A[H:(2OUU$0V&_>&MFK[P1<8K
MPWI->\/6FRT+W6G1$WK4<DGH9:NNT!>L%H5];=49)EEVA$D6Q(R8/HKD!7S-
M*>XMZM]+H.]-IM<@9_G^>(P!#L;98D_")&Q/G"EL3@P2-R;$*M<EI*K7Q.?J
MK8HK-5@16V.T+':.<4_, M,E,3WFBZ+76'9&;[5:$'7(>G[4!9NVJ/LVK=%?
MV+1$_VD]-UJR)!;$G)@]1/ZKAD^9@U?BF7].^5?H?\]F ,?X_D"2#G8E6V)K
MZGAL2G,5UJ7YBZO3(I4K4Y/4RU.R]'J2BPRZDBLUBY(:33H3YYFU)RZV:$M8
M9=42/V#3'+_?=G;\N6%-\4\/:XC_=%A]PN\V]0F2-;$D%@WQDOE#?F0?_#"*
MWI]UOY%)[Y_#=78N];. 7>D*;,DPPX8L>_1GNPBKLGW$Y=EARIZL>/7BS'2]
MA1GYA@LRRC1MZ74FK6ESS9M3.RUGI_9:-Z9LL*U+V3.L)OFT777R;;O*E(_)
M;[:5*9(UL2*652F2Q4.^9SN\0^_]#.M_E?IGZ+N.%-+[TP=OH0]<GVN"U?FC
ML*+ "4L+/,6N_!#EPOQ8]8*\5+VVW!R#EIP237-VM4E3]FSS^JQVR]K,I=95
MF>ML*S)VV95EG!Q>DO'$\.*,#\BOPXHS)!MB79(A61*+AWS#:^"-1+8#ZWV)
M^B=+@/VE]/Y%U.?GOD(->HN'HZ=D"A:7S!0Z2@(5\XNCU"U%2;ISBK(,F@H+
M-?4%E28U^8WF5?EMEN5YW=:EN6MLBW)WV!7D'!^>GW-C>%[.>^0_P_)R)!MB
MG9\C61'+AWP1R?& ;?\$\W^>^D>YY-E--G%)VL?/RTH-L:3<%@LK'+"@TDV8
M5^&G:*Z(4#65)^C6EV7HUY3E&U65EIF4E]2;E12W6A85+[;.+^JSS2W<9I==
M>'1X9N&UX1F%[Y"?AV462K:9!9)U5H%D12P?\@FOP^<RM'MA\C[4H1IZ/K*V
MBOJ,97&5'CIJ+#&_=CQ::J<+<VI]Q(;:4&5M39Q.576J7GEUKF%)58EQ466-
M:7Y%LT5.Q4*KK/*5-NEE6X:EEAVV2RF[.CRY["WRT[#D4LDFI52R3BF1K%)+
M),N'O,]K\&Z.=B],WH?:WP ,U'.]7T=]>M'V>A5:&LTPIVD,&IN<A;HF3[&Z
M*5A9T1BM+FU,UBUJR#+(KR\RRJFO,LFJFVV>7MMAF5+;:YU4,V";4'-P6%S-
M9;O8FM>'Q58_L(VKDFR(=7RE9$4L'_)O+GV?+-#NA1VE_NXY]+WTX<O(_":N
MN?FY8:X)ZEI&H+IU"BI:9PJEK?Z*HM8(57Y+@D[.W'2]K+GYANG-Y9J4.0VF
MB7/FF\?/7FH5,WNC=533?IN(IHNVX4VOV$8T_F 3T2!91S9(5I'UDF54O63Q
MD)=Y/5Z7]P-9[X/-[(NM[ <M0!>9R_=U\X'*=B.4+;!%<<<$%'9.%_(Z?<3L
MSE!%9D>L*JTC12=Y08Y>8GN)85Q[G29Z?JMIY/QN\["V=98A;7NM@ML>LPIJ
M>]$J:-[W5D&MDF50BV01/)<T2^8/N9_'=F#;'V>]]U)O(RW)\G:@@Z^-'?0=
M].0%7;K([39'=L\89/8X(;W'0TCI"123>B(5\3V)JMCN3)VH[D*]B"75!J%+
MYAH%=2TV#NCJ-_7KVFWFTW7.W+OK.7/O1=^:>2^4S'PZ20=9()D^Y$GFX!S;
MX+"\#[4(Z"=+2"NU:[KIO>F)TU<*2%YEC,0^.\3W343<ZAF(6>TC1*T.$2-6
MQRI"5Z<J@_OR5(%]Y3I^?4UZ/JLZ#3Q7]1EZK-II-'/5&8W[JGL:]Y7?:-QZ
M)8W;,LG8;:ED[-[S-_)>V$GF?!]U!WJ %4N9 ])([=*50"8]<?QZ^K^->@C;
M9(Z03:,1/# %00/N"-CL#__-X8+OY@31>W.FZ+FY6#%S<YW*;:!=/6-@A8[+
MP#9=YX&3NDX#=W6=-GVEZ[1!TG=<1]9*!H[]?W.>?>XP+=!VZJZE9O<JH*4/
MJ*)5S:-V,JU1Q#; ?R?@N=L('GNL,7.//=SW.L)M[TRX[@W C'U1<-F7+$S;
MERLX[:L4INYK$2?O6ZIPV+=9,7'?,>6$?;<5$_9^H1R_6U*-WRFIQ^T@VR6=
MA\C[4'NHOY':*]<""ZA;3R]>).\!T0]'[P8"Z<D]#@'.1Q68?%R#2<=MX'!B
M+":><,2$DS,Q_F0 QIV,PMA3J; _580QIQHPZM0BC#R]3AA^^I!@=_J&8'?J
M$\'NQ)_BL&.2..RHI!AVY&\.4G\+Z[UF':\%VM)FZI93-VL?$$?=X&/ +'I2
MYS/ A// R(LJV%S6P/JR%:ROC(;5E<FPO.H&BZO^,'\\"F:/IY,RF%YK@<FU
M%3"YOAN:ZY?(>S"^^AN,KT@PN20)CR*?15K'NO>PWJV[V ;TX;E'@<130,A9
MYI^ZSA>!\5> $=< 2]I5X]LJ&-PU@MY="^C>'0&=NQ/)=*B?\87JF2@H[V5"
M<:\2XKT%$.ZQ<O>. /=IZ._1.-^C27Y&@G#W;S9NX+6XE>.1O =T&,AGG1.I
M&T+=6=1UHNY8ZMK=!LSO D;WZ</IS867]3C1:+CPL 1>'0F\1L__.A?';\J+
M4ODOIC@)OBT_B+B+$S,K^ XK]/;K?/V92/_%2O:W#GD/B'4O8+Z3+E&?NAXW
M@:G4'?,T8$-=$^H:T*HKWZ#7?YN\*P#O,8[W&<>'YEP0VP&?C ,^<P:^\ :^
M8AQ?<Q+XFA?^-\N ;]G W[)2WW[ S[_P5?J+A?NT>T!%YW@-7 5";P$SF;;)
M]X!1SS/WU-505T?6?9]\+._!#.V%?$F^5K%,0^ [$RY,K8$?1P/_F0+\QH7R
M'YR4_^2$+,U^Y"S(=?(>^?$O9A_7[@&E\D=AU/9@G2>_R+9_C;G_-V!(7<5#
MW2^']D%^&-J'^6EH3^17\H<.RS,:.@\BWQ?C .VS0>2S('(<G BDOJ$XY&>"
MO/ 7DO$XK=\W&$.OS_>@S\1TXDNB208I^1_[#_UD@.P@^\@1<II<(D^2EX;.
M@CP8W.?X<VB_X\__@60J[WW0XQJ-H+\?Q6_&$GDOQI.$DQ120*H?V7_H(:O(
M>K*%["('6-YQ_('S^!W7\1ONXQ<VWG^8N)_YS4_\C1__#R1+>>^#?M_$EKD@
M&#&4"W<21.*AW0\J(PV#N?@3BUGJ<C;!&NILI,XVZNQA>8=9Z]/X'I?Q'9["
M-W@+7[,!O^)O?L$_^?G_@61#72M+QF'.-B$&C$>';2).&VH/>3\HC112MYIZ
M<ZBU@#I+J+.".FNI,T"EG=39SVYSG"WP&+ON$_@0+S,3G^$]1BCO3OW[_T"R
MH^XP^GTK#;N3#.,Q9IL83H&DYP%)'8+?% GX6<S&]V(IOA;K\;G8@D_$3GRL
MZ,&'BE5X7[$>[RFVXAWE'OQ;>01O*L_B-=5UO*IZ'B^I/\'SNO_!L_H2[AE(
M>,9P"(._D491?Z0!X]"!9,M7&U/&P]R8C<.O)M/P@\877QM%XC/#5'QD6(#W
M#2OQME$3WC1JP^M&B_&JT7*\;+0&+QH-X'G-3CRG.83[FC-X1G,-=XV?QVW3
MSW#3[!=<,Y=PU5P2KCS"Y2$D>T-(8Y3:Q^V,43$F?AYNBI]LAN-+2P=\9.Z.
M=\R"\+IY'%ZRR,3SEL6X;U6#9ZSFX&GK=MRQ7H(G;5;@ELTZW+3=BNNV^_"X
M[0E<'789EX<]@PMV'PEGA_\DG!XAB2?)"7+\'T@3U)#&8_!Q/[]QN/UNO +?
MCC' I\/-\+;M"+QLYXC[([SQU*@(/#DZ!3?&Y.&:?3FNV-?CTM@67!S;(3PV
MMD<X-[9/.#MNHW!ZW$[AU+C#XHEQY\5CXV^+1\:_(QZ<\(-BWP1)L8?LGB I
M=_'U4:1)VN'D)T<.M=,X?'.H?7V*$J_:Z^/9L5:X/6$BKCNXX_+D8%R8$H=S
M4S-P>FJA<')JI7#<L5$XZCA//.RX4#SDN%P\X-BOV.>X1;'7<9]RM^,IY4['
MZ\H=CJ\IMSI]HQIPDM0;G27U!K+>25(]BC05@X\[^MR-TPR'UQ?(77?@CK,:
M-QQ-<6G:&)R=[H*3KKXXZA:)0V[)P@&W'&&O6XFXVZU&W.DV6['#;;YRFUN7
M<HO;2M5FUXWJ3:Z[U!M<C^FL<[NLN];M>=W5;E_JKG+_4W>%NZ3;JT5GN=O?
M2*SW]ZZ<"CC-O!A [4"NL^F#+WL*..^NP<E9PW'8:RKV>WMBCT\H=OC$"]M\
M,L3-/@6*33[ER@W>]:IUWG/5_=Z=.FN\E^KT>?7KKO3:IM?K=4A_F==C!DN]
M[AHL\?[48+'W;P:+O"7]A5KTB.Y#Y%LNO_2DYZ3WO1M&OQ5!K\'74XSEF*\^
M]OM;8W?@1&P/<L/FX$!A8W"TL"XX15P3E*/H"RI6K0RJ4O<&-NDL"VS3[0GL
MTE\2L,I@<<" X<* ?48= 6<T"P)N:^8'?*B9%_B+46N@9-@2*!D,H=\2H.4G
MYOUCUON%<'I.^KZ+L=3GZR'&LC=$C1VAYM@</A8;(J:C/])7Z(L,%U=$)BB6
M1V0H>R+R54LBRG46A]?I+@R?J]\1UFG0'K;<:%[8>DU+Z&[CYM"3)G-";YHT
MA;YKTACVLW%#F*0A1L20&#2$:OF![?]N,)<WT<#C]'UGD[C&I0_?S5BV10K8
M&&6*M3&CT1?GA!5QGL+2N!!Q25RL8G%<JK(S-D>](+989WY,M5YKS&R#N='M
MAG.B>S1-T?W&#5$[3.NBCIG51%TSJXYZRZPJ^D?3RFC)F&@JHR0C8OB0;WVX
M]&$.[L33^]/WG4SG.I\^?"MCV1C'=6:\!BL2AV-9\A0L29Z)1<F!0D=RE&)^
M<I)R7E*FNB6I4'=.8H5>4V*#04/"/*/:A"[CZOC5)I7Q6\W*XX^8E\9?,2^)
M?\V\./X'L^)XR808$TU)G&1$#&6^9#]\F3EX(IG>G_[[:#:PD_YO8QKU^5UO
MBB&ZTVRQ.'TB.C-<T9[A)\S+"%?,38]7SDY/5S>FY>G4I97JU:36&E2ESC4J
M3UEH7)JRTK0X>;-98?(A\_SD2Q9YR2]9Y"9_;YZ;+)GF)4O&1).7)!D]Y!.V
MPW/,P376_PR77@?I_;;RM9_+P5Y^MR13'PNSK-">/0[S<EPP-\=;F)T3*C;D
MQ"KKLE-4U=DY.I79Q7KE6=4&)9ESC(HR.XP+,GI-<S,VF66G'[#(2K]@D9'Q
MO$5&^K?F&>F2:6:Z9$(TF6F2T4,^8#L\P[Q?IN9)^N^]A<P!7U<QEB7,24>N
M#MKRS-%2, 9S"IW06#A+J"L,$JL+HA25!4FJLH),G9+\0KVB_$J#_+PFH]S<
M=N.LW&6F&3D;S-)R]IFGY)RW2,YYEGQMGIPCF:9D2R9$DY(E:5*S)".9M]D.
M=]C^%ZAYK)CM4$*_Q==E1=1G+*V%"LPI-D5CR4C4E4Y!==E,H;+,7RPKC5"4
ME"8H"TO2U?DE^;HYQ67Z6<7UAAE%;9K4HFZ3Y,)U9HF%>\SC"\^:QQ7>(U^9
MQ15(IL0D/E_2#&$D\SK[W1-L_[/4/%1!OU-.[U]&OT-:&4\37^LJ-*BNM$-%
ME0/*JEU17.TC%%:'BGE5L<J<JE159F6.3GIEB5YJ1:U!4D6+44)YEW%L>;])
M=-DNLZBRTV8194^3+\PB2B63R%+).+)$TD252$91Q5KDLVF/R^>QJ+6?_G=C
M-?U&%7- FD@-ORNO-41)O34*&\8AOV$:<AL\A>R&(#&C(4J1UI"D3*G/5"?6
M%^K$UU?IQ=;-,8BJ6V044=MG'%:[PR2D]J1I<.T=TZ":STV"JR7CX"I)$U(E
M&854_HV\)WB).3A&[5VT OWU[ =UP#Q2R_<E3?0]<W20TVR&K+FCD-$R!6DM
M[DAI\1.26L+%A)8X1=S<-&7TW#Q5Y-QRG?#F)KV0Y@Z#H#DK#0/F;-/XS3FN
M\9WSI,9GSJ<:WZ8_C'P;)2/?!LG03Z9>RY/,P3FVP2'J;YTCGP,".LD<4L'E
M>&XKD#Y?0'*[!HD+AB&A8P+B.EP0T^F%Z,X@(;(S2@SO2!9#.[*501TEJH".
M>K7?@OFZW@N6ZWDNV*P_:\%1@YD+GC"8V?ZQP<RVWPUFSI,,9K9*^AXM?_,X
M^]])UGE?"["A53X'!+21^GE \7SJ=P+QBX&H)?H([[9 6,]HA"R=@N"E;@A:
MZHN 96&"_[(XP7=INNB]M$#AN;1:.7-IB\IM:8]ZQM)-.M-[#NM,6WI=9UK/
MASK3EORF.VVQI#MM$5GX-X^QS0^SOCL[@-4+@$6DF>\KJ9U+[:0>(+(7"%@E
MPF>U!EZK;>"Y9BQFK7&$1_],S.SWAWM_!%S7)F+&VFS!96V9X+QVMNC8OU@Q
MI7^=8G+_ 85#_U6E0_][BHFK?U5.7"6I)JXD*_[F%'.^C[H#2]@7:4_;21W?
M%RUE#J@=0VL4M);^>R,P?;,.G+:8P''+,$S=.@Y3MCIA\C8/3-H6 (=M49BX
M/043MA=@_/9:C-V^0+#?OEH8O7V/,&K[16'D]G\+([?^1QRY61)'#DB*D1O_
MYK!\3QPUUU)OR7+V [Z6KP*RAO: 0@< +_KBZ3OI >G-[??K8=0!4XP\, PC
M#H[#\(..L#LX$\,.!<#V4#1L#J7#^G IK)A<R\/+8'%X.\R/G(79D9=@=O!'
MF!^0!/-]0^S5LJ>;U^,*]D5JMO?S6J1N_B;ZWZU .'5]]P*N!ZA_A!Z<WM3V
M%&!V1@?&YTR@.6=-QL#HW!3B#L/S 3 X'PO]\]G0.U\-W?,=T#F_#NKSAZ$Z
M_R1?/X?..0FZ9\D9"7JGM6RF'5[-7'=1=S9U2ZB;1MVH@X#_4<#M)/7/4)^^
MW.8"8'J9/OAQ$>KK!A"OFT*X80O<L =NTFO?Y&+D"2Y^GN $=(L#[RU>;+?8
MH6XQD;=8P"T:^%LTRD](_\7:=;P6-FO/X532$F=3-XYU#> ?<:,?GT2+/.HJ
M8$5?;O($H'^;/OPN??8]>OY[]/SW38%G;<@8X/G)7 QQ8?H2%V4O<Q'R,@>>
M5WC!O<).]0J3^>I-0@/_ZA]$^HOE6W@M[@:J#_$ZD._#.@\$4M>5N@XW@!&W
M (L[@-$S@/I9:K](_D5>)V\PCK<,N!@VX8+<$GAO!/ !#<)'7"!^PGQ\RD'X
M4P[ G['3?\9._?D)PD*^^(;\2:1!VN4](+9UWFD@@=J!K*\KZSN1NG;4-7L.
M,'@)$%^CYK_)>^1#(I]'^61H7^(+'> K(^ ;YN0[MLV#<<#/+L O7)S\RH71
MKY4T+[S@?F.;_,Y*_LZ*_/$5>3!(@[P'Q+PGLM[!K+/KT\"$^\ P_IH)=74?
MZLJ:GP[M@[ :-+S:O1#Y7,K/Y!>!&KK GYJAYX/(]\0X:P^/RP_K&GPV*ON&
MQ$:7&,?@<U)>'D0R&$V?/7+(\_,]QA,GXD4B2.J@YY90\S_V'];]CW,8YZ"]
M)^89\M[@"8<_\<?@'3&/\CL>.8,A[WW(?E\I[SWP%?(^R&0RDX20!))+RDGC
MT%[,(K(,VC,I\CF,K=39S7(/X3><9+D7\1_<QD_L-#_B"SS@-_*=.=]#>X?.
M/QG<^]#0[^M:\).,[5 NY/T@?_R]'U1$G1KJS,&O:&>I76R"7NJLH<9&EK6=
M&GM9ZZ/X&F?Q%:Y3_3EVEX_9A#_R_]J=(?GUHW\@F5'7A/[?T!B2@J^P'&J3
MJ4/[06'43*)>+K7*V WJV1U:J-%!C6Y\CA746,OR!UC>3GR  VR!DW@'E]B%
MG\:;>!>O,;)_L0:OL#2V_N!.U:-(EM0UH]_7Z+%-^*IGQECD-IG =IM!77]J
MQE OG5H%U*G$^VR3=]DF;Z,3;[%OO,&^\1K6L_RMO'3WX'GFXEF<QSW<PEVV
MQU.,^ Y;2=XINR5(>$+0OCY$LC%@'"KMT283-21C(^;$ K_KC,)WBBFLWRQJ
MAN)M(0%OB%EX12S&BXIJ/*>8C?O*-CRC7(2[RF5X2K4:MU6;<$NU$S?5AW!#
M?1;7U#=P5?<57-;[$A<,_L!Y0_98(PEG_X%DI](>JY)O=[/BY66NQJ\F&GQM
M:(4/].SQAMXTO*3OBV<-(G'7, 5WC'+QI%$9;FKJ<$/3C&N:!;AJO 17C%?B
MDLEZ7##9AL=,#N"<Z6F<,;V.TZ:OX+CYUSAB\2<.64HX,,1^"TEXR.!M=L,Y
MC(SD4$,^&"X/>2J\K3'"2QH;/&/J@"?-9^*Z13"N6,7AHG4&'K,NP%F;"IRQ
M;< IVQ:<&-:)X\.6XJC=:ARQ&\ ANSTX,/PX]@^_@KTCGL.ND9\+VT?^+FP=
M)0E;R&:9D9(P,,3@L3(.)U]RB'V7P_W+DS@%<)B[.UP7MVS-<'6X/1X;Z8(S
MHWUQ8DP$CMDGX?#8;!P<5XS]XZJQ=UP3]HR;AUWC%PD[Q_<*V\>O$[:-WRYL
MF7!8&)CPF+!IPM/B^HD?B_T3?Q%7.TAB'UDU\;^1]X"^I^X''%I?= 6>(M>G
MT?-,$G%AK :G)@S'48<I.#C9 WNG!&/7U%CL<$S#-L<\;'$L$P8<:X5-3G.$
M#4[MXCJG;G&MTVIQC=-F19_3?L5*IS.*%4Y/*I8[OZ?L<?Y)N<194G8Y2PJ9
MQ8_P&_6_H/[K'L#3WO1\Y#R]^,GI])Z.!CC@;(W=+A.P?88K-KOZ8Y-;)-:[
M)6&M6Y:PQJU0Z'.K$%>Z-8@KW%H5R]T6*9:Z]2J[W38HN]QVJQ:YG5 M=+NN
M[G!_2]WN_D#=YBZI9.:Y2\I!W+3\Z,@I:":G73]._YQR'Z/_/.8/'/ $]KBK
ML6VF.09FV6.]IS/ZO;W0YQV*%=YQPG+O-&&I=Z[8[5TB=GG7*!9YSU%V>K<K
M.[Q[5.W>_>HVK^TZK5Y'=>9Z7=%M]GY%=[;W=[I-WI).H[>D)JI!O+1\Q_J^
M3?__-+6OT'N>C*#7"05V<*K9XB-@O8\)UOB-P,J *5@>Z(&>H$!T!44)BX*2
MA,Z@+'%!8*%B?F"%<EY@@ZHE<)ZZ.:!+9W9 GVYCP!;=^H!#>G4!%_5K I[7
MKP[X6J\J4-*M#)1T*@,D]1 JF:^8@U<YU=^2]X!B@"-D9R2P*8QK3'Z_*L@(
MRT*&H3O4 8O#7-$9[H<%X>%"6WB\V!J>)LX-SU/,"2]5-H75JAK"FM5U89TZ
M-:$K]*I"-^E7A.XW* L];U :>L^@)/1+@^(P2:\X5-(E.D1='*+E4R^V ^M]
MC=IG$KC&)IMCZ;>BN,9D'#WA!E@<:86.J'%HCW;!O!AOS(T)$>;$Q(A-,2EB
M0TRVHBZF2%D37:6JBF[2J8AJURV-6J97'+5!OS!JKT%!U%G#O*B[AKE1GQOD
M1OVIGQLEZ>5&2KI$YR$?L!\\PQQ<H?9)+C=V<>FS@<NPE5P2]M"3+XS117N<
M.>;%C\'<!"?,3IR%QL1 H2XQ2JA)3!2K$C(4%0D%RK*$<G5)?(-.47R;;D%\
MMWY>W%J#G+A=AEEQIXTRXNZ03PW3X_XP2(^3]#+B)-V,6$GG(>^P']YA#BY0
M^V@&L$W>?V$L2_EY(>-H2U1B;I(I9B>/1$/*%-2ENJ,ZU5^H3 T7RE/CQ=+4
M-$5Q:JZR,*54E9]2IY.3TJ*;E=REGY&\QB M>:=A2M))H^2D)XV2DCXV3$KZ
MW2 I2=)+3I1TA]"1>2-4NPP^1^][,(M>)Y,YX/LNQM+&.)I3!32D&:,VPP[5
MF0ZHR)R!LBP?H20K1"C*BA$+,E,4>9G9RIS,8E561K4Z/:-9-S5CD5YR>I]!
M8OIVP_CTXT9QZ4\8Q:9_:!B;_IM!7)JD1W3C4B7=^%1)1^8E]K_KU#J=S6N1
M_G=]#K!,WG]A/,W,2SUCJLHV0GF.#4ISQZ$X;QH*\SR1GQ<DY.9%B=EYB6)F
M7J8B/:] E9);J4[*G:V3D-.A%Y>S4C\F9ZM!5,Y1P\B<&X81.1\81F3_JA^1
M)>E%9DFZD9F#Z,@\&ZL]$W4\G]=C =N!KTMH#=I(/>.IY&M)@3X*"RV07S0&
MN<6.R"Z>B<QB?R&].%Q(+8X7DXO3%(G%><KXXC)5;%&#.KJH73>BL%<OK'"S
M?FCA88/@PFOD/8/@@E_T@_,E/:(;DB?I/.0I]K\+K/<1^N\M9 4M02=I)I6%
M])W\+J]4C:PR4V24CT!:Q22D5LY <J4W$BM#A/C*:"&V,EF,KLQ61%:6*,,K
MZE2A%?-T@BN6Z@:6;]+S+S^D[U=^5=^W_&T]W[*?]7Q+)5V_$DEGD&(M3Z1I
MST0=J.#U4,YK@7:@C320$G[.YK(\O5I <JT&B74VB*\;A]AZ)\34>R"J(0"1
M#1%">$."$-J0(0;7%RH"ZZN5_O4M*M_Z;K5WW7H=S[K]NAYUE\F;.AZU/^EX
MU$@Z'M62>E85J=1RE3DX40KLYM)[336]?Q4PEU3S?4$M?5\]?4\3$#U''Q'-
MY@B;.PJA<R<AI&4&@EJ\$=@2C("6&,&O)47P:<D5O5K*Q5DMLQ4S6Q8IW5K6
MJF;,W:N:/O>BRJ7E7RJ7YA]5+K,EE4L3:914TX=XC#D_3/VMM(:]]?(Y(*"1
ME/%S-K43Y@*1\^A]VA7P6Z"!3X<-O#O&PJO3$9Z=[IBUT \>"\/AS@O9;6&F
M,&-AL>"RL%YP7M@A.B[L4TQ=N$LQ>>%YQ:2%+RHF=?R@F-0N*2;-)VU_<XJY
MWC>;UT,S^^(<^DY20PJHG4;M:-JTH(7T_TOH/Y?J8?HR4[@LL\.T9>/AO-P9
M3LL]X-@;@*F]D9C<FXQ)O7EPZ*W"A-YYPKC>7F%L[W;!OO>,,&;%L\*8Y=\)
MHY=*XNANLD02QPQQI)%CXWR@KXU]D9I-I)2?LSK8!HN T&[ >SG]%_WYU#7T
M8&L-,6Z=.<:N&P[[]1,P9KTS1J_WP*@-@1BY(1HC-J1C^(9B#-LX&[8;NV&S
M<0#6&X_#<N/3L%K_-:S62H)5/UE#5FO91^V!Q1P36->V3O8#ZN;1&B8O!2)Z
M ;_5K#^]N2,MZWCZ\Q';!5CM-(3%+C-B!_-=XV&VRPFFNSU($$QVQ\%X=S8T
M>ZI@M*>=],-PSP'H[[X.@]T?PW#GGS#:(<%H.]FF93OU^I<!BZG91$JHF[Z*
M;=!/_T_=F?3E3MN!<?3FP_<!E@<!XR-*Z!\WA,XQ,ZB/V4%U;!R4QYT@'I\%
MX7@(!QM>\,=YL1UGASI.CWF<7O?X6?(*%R?TN<?HMX^2(UHV4',%Z]JV6GL.
M)V<#VX#U#=X!S*(G=S[ ^M.7<XD*BU. AD7I/08(%_0XL-#?7K0@7 A?&D^<
MY;^$XJ#'"?>*?"!4OOF+B;["1KQRB-!47_F"OT/??UGZB]747;R).6!]BZB;
M0MTPUM7K&#"-FN.I:4=-LTN (;VYZAH]]A/DE@@\J4\8QVW&<<>.BU%Y,>P$
MW&,<]SD9W^=@?Y\7^;-L[&<I<)\&_]DWR$]\+_U%]\#0\W#V YE'V0:G 5]:
M\VD7F?\K@"TU36\"^D\"XM/R_@MYGKP@[X?0[[]$O_^*$? O4^ -&I6WN$A_
M9RKP'N-X7[Y!E0/^A^SX'S+A'[$Q/[I./B;_(=(@\^1S.$Q3]@D@AMI^U)TV
M= ;&^@[;_BZ@\^R0YJOD+?*.?!9EZ%R(O!_RL0+XE&WS&7/RI27P-8W*=U.
M!XSC1RX,?F+?^+D5^,]:P@3_<IOP#_[RPR UAX%<UCV.N?:_ ;BPOO:LKQ5U
MC5X$E/_<?Y'W0;X8NC?FT;V0P3,AC.57 ^ /TZ&S(/)?X'*A)C\\3N)@+'7\
MXWZ85P>1E,.'_+Z,_-Z>3"$>Y.$](/+^0\7_V'^0[P-Y]!S&PV>#7(3V+,CK
M=-M?TCO_QO^DO_@5VM,A?]T#HF,#2; <VGNP(G:#GEN"*PDDL203VOMAY+V8
M.:0=VC,IRUG^:OR.#2QW&WZAY_X/CN!GG,6/N$:=9P?O1?F.27KT/I2OA_CK
M#(8!M=6F?&<RA-50+N3](&]H]X.269\\UJ&<.O74:*%&!\M?@N_1R_+[6?8F
M-L\.UGH_RSW.)KM(SWX''^%M?,#?>)\EO,N2WAW:(7H4R8BZ>O3[@B$_R9@-
MM8D#Z^=.S2#6(I9:&=0II$85-1JIT<H:=K*+=+/\%2QK+;OJ9G:=77@3A_$:
M<_$*KN-%O,3+Z'-FY%?<9ZD/N?<(D@EU#74@*41^TB6:P5S\Q%Q\"V=J>N,S
MA+,^2=3)9JU*J%&-?Z$)+[-OO,@XGD</-5:QO/6XRS9Y"OMPF_WB%B[C)IYA
M)!_A<6;N*N2[EOY?)%.5]C$W\N-N= 7V47VVJ0EUAS&'#M1T8\\*8&VB\1Q2
M66(>GD8I-6JI,9L:;;C!/GJ-??0J^\85MLDEYN("^\5Y/,9LW,%IML IX7N<
M$"4<5T@XIOQO)(NAV\N,Z;\YU'S.6#Y3Z#&G9JSG*-P7'/&4Z(E;BA!<5\3C
MJC(#EU4%N*@JQV/J.IQ3-^.L3CM.ZW3AE.X*G-!=CV-ZVW%$[R .ZY_#00YN
M^PW>P5ZC!]BMD;"3[/@'@_LOYKS4.<1]: N\:<7AST3$<WH&>$K7"C?TQ^&*
MX70\9N2+LYH(G-(DX81)%HZ9%.&(224.F3;@H&D+]IMV8I_I4NPQ6X-=9ENP
MTWP_MIN?P5;S)[#%XFULM'J ]582UEE+6$OZ9:RTR/_TU(,1'#+'<LCEM'.7
M0_Y-?G[<2HG+)B8X:SX")RRGX(B5!P[8!&&?;0QVVZ9BY[ <;+<KP3:[:FP9
MWH3-P]NP:?AB;!RQ$NM';,3:D;O1/_($5H^\AKY1KV'%Z.^$9:,E82GI&:)[
MB,$]H D<ZAVI/XW:G'+..=#WV7.JM3/$P1'6V#-J G:,F8&M]KX8&!N.C>,2
ML'Y<!M:.ST?_^#*LGE"+51.:L7)"!WHG+!663UPK+)VX7>B>>$3HFGA96.SP
M@M#I\+6P8)(DM)/Y#O_-CZSW!]1]S@VXX0&<=>>4[L+U':>=W1/4V#[!' ,.
M8[!^LA/ZI\Q"W]1@K'2,1J]C,I8Y9:/'J0C=3I5"EU.CL,AIGK#0N4OH<.X3
MVYTWBVW.!\1YSH^)+<[WQ.9IGXMSIOTI-DV3M#C_S;>3.0U1_PZ']4OTOT>]
MJ<U8MLZ@_^=R8+V3"59/&XX5TR=AV0PW=+OZH<LM HO<$M#IEHX%;GE"NUNI
MT.9>*[2Z-8LM;IUBLUNO8K;;1D6C^UY%O?M999W[4\H:]T^4U>Z_*ZK<)1FQ
M4L9-R^?,_TN<WFX&T&?0_^Z3]SY\J<WO5C,G*]R,L'2F#;H\QF.AIPLZO+PQ
MWRL$\[QCT.*=(LSUSA;F>!<)3=Z58H-WDUCO/5]1Z]6CJ/9:IZSTVJ4L]SJE
M*O-^4E7B_9&JV/M79;&WI"CR^@M1YB/FX#[K?Y7>]SB7/SNX%%O/6%;Y<XW)
MG'1YZZ/3QP+MOO:8Y^>$%G\/S D(1%- )!H#$H3Z@ RA-B!?K XH$RL#ZA7E
M :V*LH N94G &E51P Y50<!Q=7[ 375NP/OD%U5.@*3,\9<4C_+.+"Y_J'F1
MRXU#4<P!ES^K&<O28*ZOF),% 6K,"S1%<]!(S Z9C(80-]2%^J$F- Q5H7%"
M96BJ4!Z:(Y:&EHC%H36*PM!F97[H(F5NZ"I5=LA6=5;(475&Z#6=]-!WU.FA
M/ZO20B3E(,&2(GV(-WRX+*/F.7K?O83+<_0REL6,I9TY:0D5,3O,!/7A=JB-
MF(BJR.FHC/)&>50P2J.BA>*H)*$P*E/,CRH4\Z(J%3E1LY59D1VJC,@5JK3(
MS>J4R,,ZR9%7=9(BW]))C/Q)G1@IJ1(C)"51)(9+BB3R,NMZG9JG$X"=\5QC
M<[G1PU@6,):6<'HNYJ<VR@A5,38HCQV'TEAG%,?-0F%<( KB(X2\^ 0A)SY=
MS(K+%S/BRA5I<8W*E+AV55+<<E5B["9U?.Q!G=C8RSHQL:^3']4QL9(J)D92
MRL1&2PJ99^7].&H>3]:>PUG%9?EBQC./\31R&5;-F,KC#5"28(FBQ#$H2)J*
MO"1WY"3[(2LY#)G)L4)Z<JJ0FIPC)B>7*A*3ZA3Q26W*V*2EJNBDC>JHI ,Z
M$4F7=,*37M$)3_Q!'9XHJ<(3)&6$3+RDD+G+NEZD[F'Z[TU<CB]/ 3KD_1?&
M4\U8ROA:F*R+O%0SY*2-1%;:)&2DST!ZNC=2,X*1DA$M)&4D"0D966)<>K$8
MDUZCB$IO44:D=ZO"TM:K0]+VJ8/3+JB#TE]4!Z5]KPY*E51!*9(R6"994LC<
M9L[/47M?)K".2_'N='H-TL"82OE] =_G9"B1D6F"M"P[I&1/0%+.-"3FS$)"
M;@#B<B,0DYL@1.>F"Y&Y!6)X3I4B-*=9$9RS6!F8TZ_RS]FC]LLYK_;->5[M
MD_V=RC=+4OIF#J+PS9 4?N0&<WZ*^KNX!%^=3>\O[P&1&E) LOA]:BZ0F&^$
M^ )KQ!;:(Z9P*J*+W!!9Y(N(HE"$%<4BM"A5""[*%0*+RD7_HB:%;]%"A7?1
M:J5GX2[EK,*S*H^B^RJ/PF^4'@62TB-?4GCD28I9N5JN,/?'Y/-(^;P>^-I.
M&DDYR>%W*85<<Q<#4:7ZB"@S0UCY"(243T1PA0N"*F8AL#(0_I61\*M,A$]E
MEN!=62)X5M:+'I4+1/>*E0K7BAV*&16G%2X5SRA<RK]2N)1)"I=223&]A!1K
M>8QU/40-6F5T%_%:(#6DF)\S2NC[RNE]J^C_:Y3PK]7 M\X&/G7V\*Z? L]Z
M5\QJ\(%'0PAF-L3"G0WHVE @3&^H$5P:Y@G.#<M%QX:MXI2&$^+DAJ?$R?5?
MB)/K)'%R#:F6Q"E#G)+/1%6P':C527LXFU20/'Y.H794+?4;Z/]GT_\VZ\-U
MKAEFM S']);Q<&EUPK36F7!N]8-3:SBFSDO$E'G9F#RO' [SFC%A7H\P?MZ
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MQN^3PLZ4+(<EGW/AP!<@^Q)P&<"T.HX>5V"/*[''U>AQ#4'@M>AQ/<'']4S
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MS_LCX;[HM#T(6#RTS6^>-OF':[U_HM;.R])J2Y%66JJTPM*@90'M6AK0J]F
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M&4JO.Z;4NMN44O<S)=>]J>3:;Y5BM2FUQH%K*/OL:L8BPM^58!H,@U[0#AI
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M>2VASCG#\/\Q^"]%A)K\SRP<>)GDL9) ;RU8YR:MAU=N(-C92*"QF4E^"X'
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M,^==U;A_JQH/FZS ' 5V-)"V-VM/@AWK/DSN8YAK R9<19<^7W?U>?FJUS-
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M.-:9537M48EG5>#AY?2N,OI'*2-;*2.".96I#%R&O /^CB6Q2P(<(=D [WM
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M=4[ Q/]@R6;R'DZ$_0P0)@_Q&\>4&-F-'//+99DC%\H<05(05Z6@39(1VR7
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MPLU;T!Y;F ?_FA&R"7U#NX"S+^@#ZVR693#?N<PZG)GLO6#C 'F\E]1@UO]
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MWLS9%^Z<' 3SI&'F.%LF]\&L03C):>9&EIEQD6K$=Q5HDTK$_96(MTL0N12
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M- 3( =M6X EK!=PTSNC'Z(#) 1V$"[*-F^T2,;F/Q7C-N$Z,ZX89#Z7S 4*
M*&2( U*0(P<YBI"A@K(FH\P99"K8,"M#)D-CDZ!15;3L1+3R!%CZ>-83AX[B
MV[=8HR]S(M($0EE+08]@6MF-(7TCW+&5@G#9!-FNJCJN38=+H@9.TP@/RA=
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M/.+6A$L<SJ X8MZ1\.'$X.R(P6,1PYP!^9L@3Q-NSCQ.#D@54,9[!4 >G\D
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MPRRFW7E8#MA_&\/_X?W_Y?HB7%S<W#P\O- !OX" H* 0]" L(B(*58P4%Y>
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MP+NRNI_57-O-Z*QKIG;6U=%[RZL8YPK*O2YD_0W_QT&$-DXJZI"KO )*M#=
ME>%>J+%6_EZ%,YRJ(&/?E#!IS_*XO/NIPJCKL1%I(Z%Q^0-!J:5G_'.J3G-*
M:SM\ZNI;V1T-U8R.AG)F=U6Q=W]1(?M\SM\ $:A#*.H0C39.FOP"R%=>#N5:
M&Z 6=:BW4OY2[VCXKI:$?5GI27]8Z,._GAX0-YP0DGXV*KJ@*R2QK)V?4=W$
M*ZRKXU8V5ONU-)5XMS<5L$_7YOKVE63[#>3]#?_'(?;W5SJH0^'QY5"IN1[J
M#?;\;+94_M2,-7S3Z.HX7D/SO%/,$ES,YL:=31:D=\5&%+1&Q)?7AZ365 7E
MUI<%EC45!S0TYW+;6C+]3M6G^_>6I?'.%?P-$(DZA&V3A?C?7\@<F@_%QY=!
M->K09+#G>YO%\0_M&,.7;2Y.#^LIC*OE#,%@GF]<=WI@>JLXM* N.KJ\(B*I
MIC@DJR%/6-2<+:AI2>>WMB8%=#0F\GLJQ/RSA7\#1**=%;95%A)VR4$VZE!Z
M;!G4:JZ#%OW=7SK-CD^>MC=\UHEWNMOLQKQ8Y2GH*V+'MF?QTNM3A 45"5'E
MA=$)-3F1Z0WI8?G-*:&5K8FA+:VQ@O:FV.#NRIC@_N*_X5^'<-0A$77(11W*
MCRV%>HVUT*Z_ZU./Z;'79VP-GG3C'&^TDQCGZSR"NLI8L4UYW/3*C*""HN3P
M\NR$V)K4V)0&L2BW.2ZJO#4ZJJDM(JRM.2*\JRHBO*_D;X"H_W5(0AWRT;6R
M\M@2:-)8^^.4WLZ/?29*KP9L#![T.3E>Z21Z]C=2@]HKF3&U1;YI)3F!^3D9
M(66I*=$U"8E)#=$)6<T1<26MH7'U;<+HUA9A=%=U<'1?R=_PKT,$ZI"R<S84
MH@[52DN@1?V?;UUZ.]X-F!Q]-FRM=W< BQWN)GAVM[KSF^H8T>7E[-2\0O^\
MM%QA64)F9'54NK@A-"6C69!<U!J87-OJ+VYM"4@X71,0?Z;T;P 1ZA").J2A
M#L7H>EV'WK_;U5=_.:.[_<V0L>*3RU8ZUX<<' ;Z7.@=I\B!-4UT46$-*R6C
MG)LK+@XJB<H/KPK)C:L/S$YKXF;EMW RJUK8&:TMOFFG:S@I9TK_!HA&FS<*
M[>X,]-Y9>F .-!Y=^./TB54?SNEL>7G92/[!=8N3ER[98WH'G6E-/21>60<M
M*KO)*SFICI,CJ@HL#BX+K0@HB:[E%"4W>!?F-C$+*YH]B]J;&'E=U5[99TK_
MAG\=HC?+0C;J4+%?#EJ.+/C<J[;B];#.QB<W#???NFNF??Z:G=VI$2=JS3DB
MMZ"'$I%ZBB&.:65GAC3R"@+J@\M\:J.JF-6)M1[5V?64ZO(&]^K6>DIY=Q6U
MI*_D;X"859(0MU$&\K;+0LV^V3]/*<Y[-Z"Z=/RJ]MI[#_3V77YHJGGFCHU-
MTU5'<ND(@9,Q2 Z-ZZ/'A?9XIP6<YN;X= B*&.V19=0V<85;:U85L:VLFM#6
M4NW:W%M.K#M;]#= +-K=B1NDH6B;##3NE?W<JR#W_*+*PKMCZJLOC^OM'Q@W
MUFQ_8&U5=<>!F'L=[RV^3!*$C]!$@1>\$GT&_=(]SPER*&<C"XAGQ44N_=DE
MN/[24L?^IE*GOOXBW.G!O+\!XE&'M'724+Y%&MIW2;\9/"1[[_;A.9>?:/QS
M[I7N_LZ71AIU3RTM"A]C\*D/\/3H>V0_X1VZD'N+'>EUG1=''14F$B]%I#J/
MQ&5@AU.S,$-YV79#E=FV0QW9]L/#Z7\#B-'VST;WE+4;)3_U;)-\='6KU.7'
M\O/.3JBOZWBG>Z#NK>&)XM?F)AFO,)BXER[$T.<4>L S+S;[,<??\T%@D/N]
MD!#7.U'ASK<2(AUOIHDP-_)B[&Z4Q=I<;XJUNM[[5T#2<DDH6BT)K6LE7@RM
MD+CR<)WDV8E#"SJFU-?7?#ZYOW#*0"7CHYE>_ >,9=@'@D/@>YJ+[SL6F?F&
MZT%[%<1P>Q'&(CR+]G%^*N8X/DGC8A[G^-L]+@ZP>50;:/6P[:^ M*424+U,
MXD/?0F3TYERD?V*]=-NG0XNK?ZJM+_BIM2?UA][1V!^F&J$_[/4#?A#,?']X
MV#"^>V.H7[E.Y,\"O.M4. '_(8:(>Y_HYO@NG8R9S'&W>UM,M7E;3;-ZT^3Q
M-T#A(N1=^SSDXGDYI/_^7*3E\P;9*I!?D@?*ZY) 8T<4Z!X2@,DQ+MB=8('+
M23K0]-V!940"KBD!@LR=(<S2":*ML""VQOQ*L[7_F6UG^Z/(WOI[)<;J>[W#
MWS!9.QL9Z9Z%](S,1IK>+) LATVS<^'08C$<71,.:IL#X.0N-A@?I(.UHCLX
M'R,"104/3#4<^*IC(5 3 R%:]A"I;0MQ)VT@2<<:,G0M(4_/ DKUS:':X&^X
MU":-=/7)( W79)&27XNDLF#+['C8MS $%%;X@?):!FAM=@>#'2Y@L=L1L/LP
M0#QH!QZ';("E8 5^ARTA4-$"0HZ80>114XA5,H%$)6-(/V8$><<-H>2OZ.Z4
M0NHN2"&%=Z4DTF&)5!QLGBV$G?-]X, 2#SBZD@@G_G$"W?5V8++)"FRWF -N
MFPD0MQL#;8<A,'<:@,\N??#?K0=!NW4A=(\.1.Y!PVRO-B3MU8*,?7]#_1D)
MI' 409)?24E$PU*I(%@KZPU;YKC#[@7.Z'EA#\>76X+F2A/07VT(YFOTP&ZM
M#CBNTP;".BUP6Z\!M WJP-AP KPWJ@%GHRKP-JJ 8),RA*-$;_X;@+M."GQV
MRH*7PES@'5T((2>60X3>.A!9[H!(YT,0YJ$,0C]M" PS O\$2_#-L /O L<?
MS#+\-WJ-ZQ=JD]MG]P[W*7(O]0-IT.,M8<1S G^5\0QWC_G(<9QUS^'I'_E_
M#O\W.:#W"M\=LN M/Q?X1Q9"F.IR$.FN@UCS'1#M= @BJ2H0ZJL#@F 3"(BS
M ;\T[ ]V'OZK5PGQLV>U^Q2MD?:!TN[YGMS#G"0-LB9<1]C/\==\'N/&?.\X
M/O:[[CCN\R? _W\=? _. :'B HA260YQ.NM ;+H#$K#R$$M6A2AO/0@+L@"!
M"/,C(!G_A9/M-N5=Y/&>6<&<I-=YOZ&V^$ZX=W%?N@T$/"->Y#]RN1%T"W=/
M<!GW('#8^;'_GP >ZL!!]R]<=!_W^UV0&.5E(-9>"RDF.R 9(P]BHAK$,@T@
M*L#Z5VB$T]<@L=M'_PSZI$\^Z[57*>>E9TW <UI3T%/WSN G;N?"'J(W\ELN
M_XFZA+\5,>AR3]A/>,#_$Q" MK\?ZL#;/^??=T'BT<Y*UEH+&48[(-U. 5((
M)T!,-X)8KNV/R%"7J9 XZF1@*FO"+X?[W+LX:)Q1&?J(UACY@'(J>HQ\+NXV
MZ8KXHLL5\8#K]>A>XIVPTZ1[PC_QKP,7=>"CW2U"&R?Q^-)_WXG)-MP.V38*
MD(E7AU2:\7>Q#^9SC(#T/B*:,2%,\GOFGREXS"Z(N,\LC[WK42^^13V5\A_W
MP?1AUZ',L\2+J3UNHPD=Y)M1+>YWPOX$!*(._JB#8(\<Q* .R6AG96K^ WD&
MVR'?2@%R<1K?L]Q-/Z6R'-^) RD3T1'L9Z$)08\"TR+O<?(2;GJ5IHYZU&9?
MHK7G#E//YO6Y#>1UDH<R6RF7DQIHUV-J:;<B_P0$HLWKCS9O\&XYB$,;)PUM
MG!R-?Z!0?SN46"C\+'+4^)SO9O8NBXE[E>KO,1X7S!T+%X5=#Q0G7.*DIU[P
MSL\:8%;D]GDVYO?2NPL[J&<+&ZF#N;4>(VF5GJ,)Y8P;T7\"^*@##W4(VS4;
MQ ?F02;JD*^^!DKUMD&%N?S7<@>-#R6NYA,%=/QXA@_C;D(@?S0R3#0DC$D\
M&Y"<WL/)SNED%^>WLVJ*6KS:BQL8?265GN<*RIA#F46LRXD%WM=B_P0$_:_#
M[_>TDM#.RCZZ&(I.K(8*W:T_:TSE/U7;:[RM=+%X5D)U&<OQ8HTF<P478H2B
MOO"HQ-."A(S6@/3<1K_\PEK?BI(JGZ;2"I_>LD)67W$>^WQ.CN^EE"S?T80_
M\:]# .KP^_VDE/US(??((B@]L0JJ=;=\;S Y]*'!5N-5O;/%HPJRZXT"AO=P
MNJ^@3\P7=8K"DIK#8C-J!<EY%8'9127^):6%W+KR?+_.\DS?WK)TOX&\-.Y(
M6JK_E<0_ 0+4(1#MS=_OQ*2AUV<!ZE"NM@IJ=;9\:38^.-EJH_ZLV<GB7@W)
M]7(QG74NFQUT.H4G:HX/3JJ)$F66A8GS"H49Q;G\PK+,P.J*M(#VRB3_GHK$
M@',%XL#A] 3^Y:0_ 8+5_^/P^WV4C'USH$AQ(52IKOS5<'+SIS:C@Z\[K=2?
MM#F:_Z?!E3!43F/UY+."6C.XHMJDH,2RN(C,@JBXO*SPU.+4D+RR)&%Y18*P
MN3)&T(URMBA:.)09+;R4_"= B#KP48??[T!D[9.#$G2]KE%=\:/YY*8/G8;[
M7_9:G'C0Z6!^I9E .%=-\3I5S.0WY/A&E:<%)A8DAF9DQL7DI40G%R=$9I?%
MA)=61H4W5(6'=U>%A?47AX==R H/NYCZ)_YU"-HB PGH.9&S5P[*#L^'>I7E
MW]JT-TQV&^Y[=M9<]6X/QFRD#>_26T=FMI1[!E85L".+LGGBK#1A1G)25%Y<
M@K@X*A:=EICBRN#HNBI!3%=5D*BO1" ZGRT0C:3]"0A&'82;92 1/19Y>V=#
MI<)\:%)9]KE3:_V;?H,]3\Z;*U_OMS,=['3&=S:Y,>JK/0)*2UF1.05^XI3L
MH/2XC(C<R-3XHN"DM#)^8D$%3UQ=R16?JN(F])7XQY_/X<6-I/T)"$:[.V23
M#"2C#@5[9D.UPMQ?K<I+/O9HKGUY7G_G@Q'38Y<';$WZ>IR<6]N(GI4-5%Y^
M%3,\K903'U^(+I9YH3G"[)C"@,R44DYZ7CD[O;*"E=Y6R4KK*V&GG,_Q21Y)
M_Q,0@CJ$H^V?BLY'\>Y94"\_Y_NIXXO>G=58_>R2WK8[H\9*0T/61J?['9WJ
MNPCTXC:*?V:#9YBXQB<NLH*7(BP-SO(O$N7[%"05,_.S2^EYY>6T_)9RC_R^
M$L_L\SF,K)&T/P&AJ$/4>FG(V"P-9;MDH?G@[$\]2@M>#:DO?WA39^/5FX9'
MSEZV,FP][X"M['.AY7:1.4GM]&!1,RLZN(&;Z%\K2&=71^9X5HH+J!591>2*
MTF)215,)J?)L$;GD0I9[T4CJGX PM/UCUDI#SB9IJ-HA\[/C@.S;@2-S'E]3
M6W3SOM:&H3&#PUTW+/3J+F,P11><W=/.D7QB>FE!(5U>D?ZG./'>[?QD>FMX
MAGM+?#:Q.3//I:DDW[FY,1_7<C8/7S^<X5)S*?E/0#CJ\/O]I(*-4M"P36JJ
M9X_TTTN'9&^.*2T<'M?:V/=(7Z%ES%RG_*:=;=:H$S'^HJM7V!"%QQMDA'B?
M\XVB]P?&D?O"DPAGXE-QO9GIV-Z2#(<SC9F8OK,9#EV7DK$=HPE_ B)72$(*
MVOYEZR1_M6V2G#B_6?+6O6W2P^-'%Y]YJ;6Y]9F>0M434^V\!S:62?<<G2-N
M$ZB!-RAL]C5& 'W4-]CM"C_"Y7*XR.ER0BSF<E:\W>72!)O+S6+KT8$$FY%K
ML3:#-T1_ D3+)2%[I034KI;XV+M*XM[-Q<CP^':9WC='E[:\U=Q2^5I7/O^5
MD7K*"VMCT3-'.^%3(M[O"<W=ZXFW)^TQS]OM40C'Y5&,O].CY$"'!SE!=O=+
MA=9C]<&68UW!%F.CP>:W[@K_!,0ME82BI1*_VI8@-X;G(L-/%DOTO-T^JWE*
M:7G%1_7-N1]T#B:_-U2)?F>E(YQT-.5.DFR\)^E8^EL?O/O;0%?BVS R_FTL
MQ>E-BH?#ZQQ/NU?%#)M7-4RKEVU>%B\'6.8OKO\12%LD 34+D&N]<LCY2W)(
MU^02R<:O.^:4?U=:GO-=;5/B=^V]D=\,% 7?+-7\OCF>]/I&,O#XYFE"_N9C
MX?HMT!K_+<P6]ST6@_V6XH#YFNUH^Z78R?ISE;/EYV:\Q:=>O-FG"RY_ @KG
M(C?:9)%S_;.04]?DD+H?RZ1*8-?<+%!<'@_*Z\- <WL Z.]G@_EA3W X[@Y$
M-2+0-5R K8T#G@X6@O4P(-*W@T1#&\@TLH8"8TLH-S&'>E,S.&5F"GWF?^)V
MK21RKE,&:3\O@U3?F8T4PDKI#-@S-Q8.+0D&I35^H+Z1 ;K;W<%T#P'L#N#
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M@T>#YSM*!^LMN<_G%7&8\]3E.G<,=Y]WU?&Q_PCNJ<^ \TO&.><)^DR -^K
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MG<0^<7R)>>7TU/X=[A%FRN&NPU?;F0!W=._BBCI0]\T";W1/[7]T ? UEH/
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MO;#.M[G.#K>"76UO1;M9WDJEF-TJI)G<JO<POGW&P^C.79KQS0F*R:5)MYF
MN+G(BR)IY$J3+'*V6Q;I_/T=QHL%$A5O-LL4O%%8D/I:>77,A.;6X%?Z^_U?
M6AYAO<"JT5ZX:KN]H.F[//<V=GK.,\<\#[6R>1YK8_DBS=[\12'&Y$4=UOAE
M%];HU:BCX<L7C@://V!GXFNZ%'*M2A(YVRJ-M/?)('6CLY'23XLE<J:VRB9/
MR2^(FCJ^4C"EL9$SI;>#,66VG_(1<YCXD:#D_)&JXCCE?<)^BJ=I.Q6B;345
MHV/^*57/]%.^@?&G*D/#S^U&!I\'C?6_/##6^_P!Y>.TW"Y$D(%Z2:3ME!12
M?5X:*;PU"\GXN4Q2_'/'K/!?!^8'_#JZS!M._$,#W8TD,-GF#+:[L."\SQ[<
M#]J@06()G,/F$'3$%"*/&H/XF"%D'=>'$F4]J%?1@=.J)V%851N>JFG#LVD9
MJD*0]A8)I.J,!))W61))'I^%Q,(JJ1#8*LN%O7,9<'@1&526XT%[M0,8KK,!
MRXV6X+#9# A;C8&ZW1!8._2!NTL/W8SJ0-2>W]]^:$+./@THW:\.]?M/0.<!
M-1@Y.!.GZA&DJA-!<L\C2.(M!(G\,5<B"%9*^L!&&1KLE'.%@_,=06F1+:@O
M-0?=%<9@LLH ;%;K G:--A#6:H+[.G5@K#\!G/6J$+1!&2(V'H>$34J0N?DH
M%&T^ M5;%*$-I7U:JEO0\?L11#R*("$/$20 YDMXP5)),OPCC8,MLG:P1\X<
M%.8:P?'YNJ"Q4 OT%JN#R1)5L%JJ#)AEQP"W["@0ERL"=84">*TX!-R5!]#%
M?S^(5NV%Q%5[(&OU;BB=D?QN=/QA=/R[",+YC"!TF"-!@$62&%@N90'KI W1
M.=&!O;,U0$%.!8[/.0;J<Q7AY#QY,)A_$,SF[P>K!7O!?L%N<%JX$UP7;@?*
MPFW 7+0%.(LV0]#BC1"Q> ,DS A@T?NU[3X9L%.8!;@C<D!0G0]$G25 ,EL)
M1*>UX$K?#'C>#L!%[0&GE/V S3\$#A4*@&E0!/N.(V#7=Q3L1HZ![<UC8//@
M.%@_50:K"16P?*?RPV)*]8O%5]4I\Y^J'\QA6O['8:\,8.1G 5Y1#H@J\\'M
MY!(@FZX$,G8=D#PV \%_)^ C]@(NZ0 XY<J#8[DB.-0?!4R[$F!ZCX/]D#+8
M75<!V_NJ8/-4#:Q?J?VTFCSQU7+JQ">+K^H?+'ZJ3UJ VG2 XR8IL$,=L =G
M@:N"')"/SP>JUA*@F:P$&F8=4"A;P8VS"UQ#]X-+@CS@LXX KD0)G&J.@V.+
M"F"[U,!A\ 1@1C7 _IXFV(YK_;1YJ?W5>E)[RFKJY#NK;R??6/W2GK "S>D
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MCW_ QG\#6$=N!LOD;6"1MP/,RW:!6?UN,&O; Z:]>\'TPCXPN;$?3)Z@O#X
M)A\.@/&7@V#\XR 8P<$?*%^-X,"7:0#+K?_C8'50!NP/SP+'XW, I[4 G$R6
M@B-F%3A0U@+&;Q/8A6T%&_$.L,[>!58E>\"R9A]8M.P'BZX#8#YP$,Q'#X'9
M0WDP>R4/IN\5P/2S IC\./S=! Y_,8;#4R8@_W$:_G4PV2\--@=D "L_"YR5
MYH"+Q@)P,5H*SG:K $=>!XX^F\$A>#O8Q^T"NXR]8%.X'ZRK#H)UXR&P.J4
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MQZ.!Z2M5L8!7&:OY%'$=OP+V\\OCQ"HYW+E*%H\39Y8U0LZ@BYQ!S06 _%L
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M.^S*4_H=2Y(GG N3]KH4),VYYB<_<2I,^VI3G('F)9EH7)J%!DMA$-G_>";
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M.[^V*7N?M@,.WFW7''S6O;7U7_?3(K =38+:T7 I3 :X7TSV@+3OR4Z V8T
M.X9)_Y/V&9IFA]YM(I2.:16&QBV&'%63-OS%X\["N:/>DNDC00I)FR)5XX82
MM"(',O1"^PN, C=6F?KUM5AX]?99>_1.VKKUSMJZ]EXECV^L/'I_F'GUHI%W
M+QHL]3Z3W$72_V=; 0Z3_MY)^G=R;'$^Z<_=3+!NCP T[E:@5>W292V>L>#)
MV>XHD#;M*9JX-4 Z9BI<(7PR3C5X(DW3?SQ?UWNLPL!CM-G8=;37S&GSA+G#
MYED+A]&K%@Z;7YLZ;?YAY#R"^BXCJ+O4(W(.E^L CI,]V#, L(6<P:8MI#])
M_S4?H$+MH950<4B:4GA0DRG[@.F*E%D[OOA];H)1>_U$0_>$2@7NCI'WW96B
MY+DS5\UM9[FFTTR3COW,!CWZCG$#FYG]!M8S5PUL=KS6M]W^0\=V.VK1MZ'F
M4K?)73Q#]N! '\ T.8.12=*?I/]:]@-4'J5!P>D5D'MZ+62<5J$EG3)@B3EI
MS1E^PIDWZ(2W@-_Q8!&O8]'B;L>2I9R/YL@Y'"U3I!]I5+8^LD'5\LBXNOF1
M677SH[^IFQ]^HV9^Z*>J^4%4(927NE0/<*2;W(%!@-%Q@-[M *W[ *J. .2?
M88"4RZR0<)4?8J[*4"*N:C$$7S%C\;MBS^%UV8/;[7( G_/E" &'2PE"]$M9
M:ZTOE8A97&J4,+O4(V5R:5S&Z-*LC-'EZS)&%]]*&U[X+FUX'J4-S_W;B7:
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M#T2YI="5[($?Z;T((H&L(Y4;/F?RPK-L0;B3(TVYFJW#<#;=BN-8LBO?@80
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MY6DV)Y3I-,35&=3&KC.JBNDS+8\>,R^-WF59''W*JC#Z@65Q[&>CDGC4+4U
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ME\K$)E]J$C>YU,.>],,&MO$/!R2,?[C!-KKX4L+P^\^2!N<)Q^ <X4YD<P_
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M#93ZB1Y*[<00I7KR,*5ZXBZE<NPM3?D(H2L?_@O&-]8N_OHL5#] +=8]?S-
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MO-+#3;HYP#O<J+['F_('O!E]''\F!3]P/JT!^+P+P<F1&_^E>/P,"FL?=AC
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M]]2!U)YNX.T9!NZ>8\#=_0!XNSX ;R<!WHZ_68&U[\"Z-V"]2\>?S,'LJ"$
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M\\#]XS\9A?DG (QQONJ8*X>Y4E=Q[N.Y-\9/9)![7T]''E*X(1?##2D7X*D
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MAR[]0=T_@?XPFL:V<8"HZXL_M:+PJT8:?E04XEM%->XKFG%/WHF[BCY\JAC
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MR>PP+I@]@7.3G\$3D]_&J2G?",?-'PI'+43AL!J''L/8,.8T^Y<#ASWQN9V
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M S(SX/\H%MYC</Z!M%%;.L+-Q? CMLE'[/ ?L8$_HB,_?(&XQ]<_CJ&;;=U
MGQ>RWLGD#F5=W=1[8,QNLNUOT_=2_N45=?[E76D?"O&!.B\QE@]1,C"F3^[1
M)U^8 /<I6+YQI&BA/Z3CN]^Q;WS/R>X'MLD/=/8/=.P/=XA/QM!(]Q2S[JF7
M@+#K@/NSY"?O)/(:O$K?/YY_^?2Q_2#WU;F0;]6YD.^E&T0T@)_U@-_HDX?F
MZAM3I:/]2>H3,M(OQCSZY1KIEI"GQR!JFE'?3J(:G:36_=(>#$?";TQSB\B$
MZE1(/=&NSC](>T%6CN4?5*=DMA*[H3HE<Q*JO2#/XB^\1=U\'W_@UW_G/WY5
MXV>H3J5(>S)$76I]I3%?29B@MD/:C^))A!,I1 %4^U&:H-H+(IU.64J.0?R)
M87*,DF,[R]Z+7W"4Y9^E7K]&CA?',@\/^$K*=7P#U;TE7ZF?CUZ+^M3ZVH9\
M-8Z0GE(^QI)PA>J4CI0/RB)7*7GJR--*CFYR]+'D 7*L(L<Z<FQBF3M9Y@$V
MU0E\3E]\1M7_3S;D)V3_B)9^R)(^^!\0QU'KZ^E"E&OSG9XZ%R/M1YG);_F0
M,Q(_(97-G4^>"O(TD*.='//(L9 < ^1818[U+&\SWF>;O(O#;(4S>)V^>)4#
MZ&5VHA=I^?,L]?FQ3)6(VX]!--*B+V3L%^P>2KZ&P9@O?J$O'F 6ZQ6$+Q"'
MN^P7'Z.(/%7D:"1'.SGFD6,A.9:18S7+W\ RM^(6]K$W',<S],53> Y7:>$5
M>NPR6^^2NK<\CK'<!Z>[L8N V:5%36W\*AB2=S+K:$].;[S#?O$ZDLB50YX2
MEEI-+S?B!N9PNIJ'ZUA$GN7D6$N.45Q@FYQC_SS+_YVF)2=9P@G9-S@F_P-'
ME2*.:(@X_!A$$]7%.[\07QMQZ'&Z^4Q#"Q_(Q^--^72\I'#&;84_;BBC<5V9
MBBL:N;BD48H+FC4XI]F$LYH=.*W5@Y-:_3BAO1+'M-?AB/96'-+9CP,ZI[!?
M]SKVZKV)W?K?8*?!7]ANP#5J'$?28Y N/_Z%T]O]J9QRB+?X_E5C&5YF'WE.
MUP1/Z=O@20-WG#<(P9EQ<3AIF(YCAODX8EB&0T:U.&#4C'U&<['':#YV&RW%
MSO%KL'W\*+:-WX,MQL>QR?@*1B>\B@T3O\8ZDS\Q-(GK ['F,?S.Y>9;*_+;
MD]L!>,Z.R\$,X*J9$I?&&^+,Q*DX;N*$0Y-\L<\T KO-$K'3+!/;)A=BR^1R
M;)Y<A]$I+=@XI1,;IO1AG?ER#)FOPUKS[5AM<1B#%A>P<NKS6#[M<PQ,_QU+
MIHO"8C7ZU?B)R\QG3JIMA[<\@"M\GN=T?XK+X#$+/1R8:HK=TVVQ;88[-EL&
M8:-E#-9;I6#8*AMKK8JPVKH2@]8-6&'=AN76\S!@O1A+;%9CL<TF89'-/F&A
M[1EA@>U-8;[=IT*/W2]"M[TH=/T7'G!:_X#<SW.)N1; .)]3ZW%OX "7X=WV
MFMAJ9XP1^^D8GNF,-0Z^&'0,QW+'> PXIF.)8R[ZG4JPT*D:?4Z-F._4@1ZG
M!<(\I^5"E],&8:[S+J'#^81LCO-3LC:7#V2M+C_*6EQ%6;,*0I,:7[#>;Y#W
M1@B7=FKP$\2!8,9WOM2=;@*&70RQRM4<RV?98XF;!Q:Y!Z'//1KSW9/0XYZ)
M;O<"=+J7H<.]3ICCWB*TN7<++1Y+A&:/(5FCQW;9;(^CLGK/*[(ZS[?DM5[?
MR6J\Q#%4/X*G*/N4=7Z1_%>IO\]PR3\4(^W_8'S'SX;HF^6>^ECL-0E]WM;H
M]7%%MX\?.GW#,<<W#FV^J6CUS4&S;S$:?:N$V;Z-0KUOAU#KNU!6X[M*5N6[
M65[I=TA>[G=)7N;_JKS4_UM"E)?XB[+'\0']_UP$<(E+_0DNL_L2J77B@751
MC'%IQR)_;?3X3T!GP'3,"71$6Z 7FH."T1@4C8:@)-0%9: V*!_5065"95"=
M4!'4)I0%S9>5!JV0%0>-R(N"]\L+@L\K\H-?5.2'?*W("_E+GA<B2I"-(5B4
MO4V>&ZS[N415#F87,9K"&)?V+*$=\T(UT!%BA-90<S2&VJ,AS!UU80&H"0M'
M55@<*L)241:6@]*P8J$XK%HH"F^6%83/D^6'#\ASPS?(<\+W*K(BSBHR(^X0
M7RHR(OZ49T2(\DP59!)>#:?V9[W/D/M@!K4.P\ -?*[D^SY^WA$E0U.$ 1HB
MS5 398VJ*!>41_F@+"H$)5'1*(I*0D%4)O*C"X2\Z HA)WJV+#NZ4Y89O5B>
M$3TL3XO>K4B-.:U(B7E.D1SS.?$'(<HEI*CQ(L//R]3_)\F]+T>=@^%S@.][
M^'D+[:B+U4=5K G*XV:@),X117&>*(@+1%Y<!'+BXI$=EXZL^#PA,[Y,2(^O
M%]+B.V0I\8ODR?%KY8D).Q4)":<4\0DW%7$)]XC?"5$>_QANLQ]<3.-<0-[=
MU+^;"MD.Q.(\8"[]T4 [*I-T4))HC,*DJ<A/LD=NDANRD_R1F12&C.18I">G
M(#4Y1TA)+A&2DFN%Q.1V67Q*GRPN9;4\)F6[(CKEA"(JY88B,O6N(C+E-[X6
MY6-(5N%9]H-STGXD\N]DV+>1&GB06,C7;;2KAG84IVDB+\T(.6E3D)EF@_1T
M5Z2E^R E/03)Z=%(RDA"8D86XC.*A+B,:B$FHT46E3%?%IDQ* _/V"H/RSRF
M",U\6A&2^2GQJSPT0_P;Z:+\*;;[&?K_ #FW,>1;5\7Q2,SGZR;ZHX+^R,N6
M(S/; &G9IDC)MD12CA,2<SP1GQ.(N-Q(Q.8F("8W U&Y!4)D;J40GMLDA.;V
MR$)R5\B"<C?+ W./R /RKLO]\SZ6^^?^0HCR@)R_<87M?H)<>RND&V(X)U .
M+"6Z^;J!=I32)UE%C+D+])!0, %QA=,04VB/Z"(W1!7Y(:(H#.%%L0@K3D5H
M<2Z"B\N$P.+90D!QE\RO>)G,IWA4YEU\6.Y5?%7N6?*!W+/X)[E7D2@;0Z$*
M%UG/(V4<D^0<H09?12FPB)C+US6TI;":VIMR*;9<&Y'E1@@OGX*P"FN$5#@C
MN,(+095!"*R,0D!E$OPJL^!;60+ORCK!JW*NX%&Y5'"KVBB;5750YEIU6>92
M]9[,I?)'F4N%*'.54*["V6+533W;&JF]6U4WM,PGVMK8%UNHNVA/$NT)KY<C
ML,X _O4F\*N?#M]Z>W@WN,&KP0^>#6'PF!T']]GI<)M="-?9U7"9W0ZGV?V"
MP^SUPLS9^P7[V9<$N\:W!;N&[P6[>G$,]G6B3,()UG$O.39+M]10&BZA!.CN
MIO;EL[03R.!GL1W4?OR[9YL.W-J-,*M],ES;K>#2[@CG.9YPFA,(QSF1F#DG
M"?8=.;#KJ(!-1S.L._I@V3&$&1U[,+WC J9UO(YI<[[#M'91F-8F"M-;53C<
MP/6)Y6_HEF[IY7A80.W9QW8@\HDDOH\@?"D97>?+8#]?'[;S)\!ZOCFL%MC
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M]5KJWV'.!^N!T(V YPA@3TRE/I^XB?Q; )VMU*';&/QN8R"\S9B83# (W,[
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MOUR Q@H=""O& 2LF<$!/(1CXK& @L(*+X I.:LN350-]>2-!S;V,.G,9!?P
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MUP^)D4_PRZ<D8I^1G'T^0?IB,4+P?4&EO\!X7Q@V[N.<=S#S$&8]AMD38_:
MF#-!AO?#F/,XS/-IS5X4<R[I(CM3^C?,YI^PG>_@5-_"[LR9'/^ E7T%^_P"
M5OTYK/OO*/XI3/IOW#5\'NE;SOF/9YSS #^LO[AX#88Y$\2L1S%GDM;H7VH&
M8QSE3Z+L =CS7,I=I$_0PSP;Y2/T^"LL[ ,8X/LPPG?A=V_#AM\B>-[ ::_S
M[U5^:>8^S-J3%YW89B_(@_\U!R+[G- _%0)>/+_*!J^,.C10_EB]!\]]&][_
MIF9@]KEZ#3W^B!Y_0(^7T>,WZ/$2S/ %N.YSL/QGX)E/$TA/ZGG<^:$NV$]+
M<<Q_W.><@[C]1SI\(W/4K2=W!X(713U2P2H ITJ_A?>_B$^>4P]E3Z'L&90]
ME[*'J.ERREY+O;800GNHVR'=3P=RKWT'R$_LYX'>@>:WV4^.=3S1V)QD:\[#
MN.8B';[\CSD(?_!"]"ML\92R**$$C#K*'TVM.JA#+V5/H>P!$.90_D+*7T;Y
M:^'K6W4CC/\\;/DZ?'(-5\[RJRNQSADL:G90F=-D+G>*V57U+^?\R[O.\'[>
MWMP\J5,@=8D$*QF<7&Q63FGUE-^LZ]'C'/:X!K]<K>FZ"KY]!7J<08]3Z&%6
M/1RG,[\,GQSFSH.4< "+[<.3EV#MB]=?&/G<.:UHFMJ3<DR%WF?OCORP5S!X
ML6"E4X\","JHPPA*;J8%M(/1#<8D,*:!,0O4A6 LI]SUM)2=VL&W6]%N"]IO
MPHH;]#O[3-XZ.686A^5]+_ 9=GY!-_L KW=X.Z:DS\F#7P=0IS#P$O!P)CA%
M8%2!T0!&,QCMU+@;G#YM1H^-Z+&!^%BGE5K#E55VC4Y@G>NUA YU$=X=H@4M
M).K-+.>P_)%N]:E0\,/AG6;Y8;!C:^CEZ':$OF._K$1[I+8KB?ID@U-,+:O0
MOT&KT6,E>JS0>'#ZP)FNQ<3'$.\6<,<\;#$':\W"8S-U)U'\!!'TC@9<OM9T
M5]OW\@+=Z<_B',=@G2<-N2)6.D9*<H"A9Q=VV>+N!V8P>#%@I0C6HL4N)1IR
MJ=8"UP;-<VO67+=VS7;OUBSWR1ITGZ$!CP6:[K%24SVW:HKG04WVNE)]WK=K
MHO?CFN#SEGK]OD)LW\M3X-Z7QO"5">]%CO/^ *G(SAA2#^RS*L!-2WPL6N =
MJKD^<9KMFZ:9OGF:X5>JZ7[5FN;7H'[_%DWQ[] D_U[U6:9J@F6V>BU+U6W9
MJ'$!^]45<$:= ;>I/?#G:K>^K3;K-XA-;4$V^^MCI%\_,7,P!0SQ!8XS0/:0
M"FUFR%L53]J%3>8$>6D@P*JI@1&:8DW0)&N&)EKSU6LM4X^U1MU!(S4NJ%5=
M0>/4&=2G]N 9:@L>TIC@=6H-V:OFD),:'7JS1H4^JJ:P-]04_C5B^UX>RG$,
M\]>0?IU@F#W ZW8^K\MQI(=S\='T*!?UA5K4&QJB\:$QZ@I+46=8MMK#BM06
M7J$QX?5J#1^EEHAVC8[HU:B(:6J*G*?&R%5JB-JI$=''51=]@VIC'E9-S*NJ
MB?U*M;&V[^5>4M";X-57,KQ>1BJZMYH8@-^N+(;O89-!AM[)^&9\C(_:HZP:
M&QVAUN@$-4>G:W1,GIIB2C0RIEJ-L8UJB&U5?>PXU<5-5FW\;-7$+U=5PC95
MDHQ5)%ZO\L0'5);T>^0+E27;>+6I'/DI];X>W-/U^('A=3>R$9Z]C'1P'GI,
M0X]>XJ0]V4/-"0%J2@A58T*,1B0DJSXQ2W6)A:I)+%=U4IVJDD:K,KE#%<E]
M*D^9J=*4)2I)W:+BU,,J2CNG@K3[5)#^&^0SQ*9"I]P)UCGP+X=;7]HD[4#6
MD7XM(16<Q7=32K !J6%KIHL:4OU5EQ*DFM1(5:4FJ#(U7>6IN2I+*U%I6K5*
MTD>J.'VLBC)Z59@QH(+,1<K/W*C<K(/*R;Y&V=GW*"O[167E?*KL'!N?;5RW
MZ3;J?#7XQTF!]Y-R;4/6C"86N3:('GWHT8D>H]"C-LM'%9E6E66&J20S5L69
M*2K,S%)!5J$*LBN4GSU">3FMRLWI5D[N-&7G+E1FWGIEY!U0>OY9I>7?K=2"
MYY&_*:W 9I?T?)MNQO97@7ETC',O$/1HE3F+!%VFHT<O>K01*XWXK++ 4\5Y
M%A7FA2@_+TIY>8G*R<M0=GZ^LO++E%50I\R"9F44=BFML%^I1?.54K16R<7[
ME%1\E1)*[E)\R;/(Q[RW*1%)*K;I!FQ_9HSCSZ%[NJ G9AT*K_/;S5DD\"V^
M'X.>(XC7\G)7Y1?[*Z<X2%G%$<HLCE=Z<:K22G*46E*LE-)J)9<V*:FL0XF0
MY(3R.8HO7ZW8BKV*J;A"T15W*JKRE\B'BJZT<<TAUU'?4^ ?@MOO(@7?"#U;
MSNM<=)F"'N/0KP4[U1$C)=@DN\I':14!2JD(57)EC)(JDY58F:F$RD+%5U4J
MKJI1L=5MBJZ>J*B:68JL6:'PFMT*JSVMT-K;%5+W%/(![__%-1O?D4-@_Q/@
M'R#=W &_7S^9>.1U-O1H$M<[L<EH[JE&UT)LDM'@H<1ZB^+J@Q1;'Z&8^GA%
MUZ<IJCY/D2/*%#ZB7F$C6A7:T*.0AAD*;ERFH,8=LC:>5&#C;0H8^03R/N__
MR36;K TV745]CQDZ!D7>!J]? R5:-,VQ%V=B'VT2W1K1I1SJF(LN*:U2S&@?
M18P*5-BH4(6.CE'(Z&0%C\Y2T.@BI$;6YM$*;!ZG@);ILK0LEG_+5OFU')-/
MRXWR;GD4>9/W7\FWF<P1.0/&$?#VSG"<2;MR%O$XT[$7IP=]6M"M%EV*N2^S
M&^Z%SA&=[@IJ]U=@>Y "VB.0>%DZTN3?D2^_C@KY=HR43T>'O#JGR+-S@=P[
M-\JU\[!<.N'^'0\AK\JEXS/$)M=V\BGP#X*Y:RZT>+YC'<I\<R8LU*P+2C(2
M72H&X%Y3L0'Z1..GX#X762;ZR&="@+PFA,AS0K3<)R3+;4*V7"?0@";0X4P8
MZS#DQ#F\7XO -2? _2>0(?5"3'K)WGK(XGK(Y\#?#_:V1=#Q)8P1T/19O$[D
M\YB%Q"+?%:-?!D7%8:,P[@] +Y\9WG*;0>(SP" _P, VP  WP  SP, W0,<[
M0" /$-P#W#P=CC<=XCX-0C<-$C7U102NV8\._38= 6</N)NY;?4J_+":VWCM
M@B:/Y%KY,O@WWR>B5P04R8INOHCK$#QJ"&ZY$$ZWD$%^(7Q[(0/+ CC5 FRQ
MH $AB!9@P 7\<#X$?SZD=AZD=>ZO&(P_1OY)\-MT8+EC+]"&]8YU*#.1"4CK
M!JD&*4!2^"YJG12$27T1-T1KX=IK2?S68(LU5N>:%)*.-?#M-72JJ['%ZA;'
M9.=JC+G*;/8Y2L!!*E= 4I=_ .!WB,U^'LO6S?QL*VINIT] W79DQ$Y\L$M*
MXS4:"4)\=YHU*.!SG02/5S>2'?38B1X[T6,G>NPB$=N%3W8QX.VB<]M)X]Y)
MP.]8[7@ \7;B<AN9\U8RZ2TPFBTV[=CFF*99M >7047'[<<'A$\9%#T#B4&"
M#H&/R*Q!N0PY>K&X("2?1TG\CJ+',?0X1G)XW"1E) 7'B8MCQ.:Q(<>#@(X2
M$Y<1ET=>H3RR^L,V^UZ@9> .@M5SA/[H&.W@A)1UN11[$GQ<Z#.\!H6?0UA(
M>'XD9F[D6G<&8!_I.A+BZXF/\^AQ [%Q SZY@0[W/+8XCT//H_CUMR'P_NM@
M5>>^U4KJ-YNZ302W!:PJ<++!B:/L(,KV'IYWN5'FCYZ"4#GF0H9E>&_.\-S(
MW<3JO?CF_A#I0=K*@\3&0\3G0PP"#], 'L*)#U+P@P_S_D^\?J9Y8$\">RRX
M->?H"V\ WWD6K==M3HR[G/,MPW,2CSCE4>?\Q 4YSB@9G@_YI9OCK-87(0J_
M)AG\-;'Q&P; W](!OTP#>!E;_.Y6A!^\_&?U7T4,@EU'/0O 3  S"$RO>R_"
M?-2),;P>Y#E=M/9$/YS5^HIS+L2L"[$_0P8]/L0>'Y$@?TPB\C?:ZB=T?I\2
M%Y]B\$\QW-_-:@0WYQR$NW,^Q.R-,<^G-6>2FOTPYCP.\WP8<S:J60LR XXZ
M#Z:T6'@2]KA>7\.TOJ*A?*E+X8['[2<L?(KS_@9;_0CC? B3_BMW#9]#:N8A
MS%Z0GSOG(/Y[_L',Q9@S0<QS87/T;SCFMQH)1AMEF[TH_90]2-GS*'>Q_F)_
M-LIZ./-6Y[-1#F&&R_4ZP?HJP?,*AGP9-OM;?FG.X##[7W[IQ#9S$#_]'SK\
M2][Z!_SN<T7K$[CNQW#,OZB&\D?K3?CV:YI /?KU>_3X+7K\&A;Y(@SL>5CF
ML^CQ#+S_:5CBDS#D7Q#,%T!YE$^/H.5#^LZ^]N-^Y_R'67]Q_B(=_NV<@_@(
MW[PK"W4)TQ^QQ<MPS)=41OGUZ-]":9W8< )E]U/V(&7/I>Q%E+V">JW3O;#@
MN^&Z=]%YW$%#ODVW@&56A/Q.-U"SX;- S1-]S!D8IYPZT&/:'S?TKC.L7B N
MGE806-'@I%)"/KI7TC0:*+N5LCLINY?2IU#^ )Z?0WV&*'\Y?'T=7M@.^@&Z
MD\MU&L23V.)R2CR&18]26W.JKGG"D%E_84[9_<8Y_V*V?+WH;%J/$)_W.M=@
MW*9XZI )1A'E5\&@&XFX5NK02?D]E#^9\J<3B;,I?R%E+R<B-A"=.^'LA[&(
M615R"]W[(]J!)[<36=OTP_J++?:Y.L=2JV><3? ^9]=S([:XEKBXDC9R2LDZ
M@4^.PON/J!K]&]&_1?N(C[WJ!F,2&-/ F W&$&6OU&;^;42#=?QR#;98C157
MTJ"7$V'+P+U8WO"@R?M2=YKR772U-[D[NMXKB(OCM)'#"J$^,6"E@I,+1@D8
MU2 T@M%"BVC76O18HSZM0H\5Z+&,]K*4*XO0:B$E+,!R\ZC9'*)TMM[1+%J:
M>1*V6?%E7E^B>W^,[NRG="4W\GH5P\X)]#E,5[=/7I02@+W"L&X\I::!DT==
M2L&HUA+B8Y&:P6D'IQN<243H #CS*'\Y/<DFO+1/4[%D/Y$S&7],PA]FEM.<
M0-3GE*?"L;\Y HLAYFJ&W1-1Y'8,.;M)3;9@E[4NOM3-"EX$6 F:KPSJDP].
M*3@UX#2 VHP%VL'J(4JG4/Y,REY$ZUG+E=UH=USC7,ZKR^4!=;K^1AWNGZK#
MP_:]/&;F8)(9PM+@O<AAWN_FVN9(4@_LLL3BJGF>_IKE%J0!URA-<TM2OWNF
M)KL7J,^C3!,]:M3KV:@>SQ:-]^S4.*\)ZO2:K@[O>6KS7JDQ/MO5ZG-4+;[7
M:;3O?1KE]Y)&^7^B)HO-+J.0!^G*;\EB2,YEJ#=_?F&XW48*LI:T; EIT5QL
M,A#HH<E^%DWP#5&/7XS&^R6KRS]+'?X%:O<O5YNE5F,L(]5J&:-FRWB-#IBB
M40&S-3)@F1H"MFI$X!'56\^IUGJ?:JR_5DW0WQ&;76J1>[(<VV_/%#N6P>XI
M@N^9/3"D( M(RP:QR63\-3[(6^V!5HVUAJO5&J=F:ZI&6W/4%%2DD4$5:@RJ
M5T/0:-4'=Z@N>*)J@P=5';)852&;5!%Z4.6A5ZLL[&Z5ACVODO"_J33<]KW<
MR?!^CA3T9 7<GZ%M!ZG/.CXOX?H<;#(5._62!K1'NJLYU**1H<%J"(W2B-!$
MU85EJ#8L3S5AI:H*KU9E^$A5A(]5>42/RB*FJR1RH8JCUJLP:K\*HJ]2?O1=
MRHOY%?*1\F)MRH]QR&UF+0[8Q^&T^VOQ [(&GCV$'C,+'&M QA$G+0E20[2O
M:J.LJHX*5V54G,JC4U06G:72Z$*51%>H.*9>13$M*H@=I_RX?N7%S5-N_!IE
MQU^BK(0KE)EPAS(2GU9ZXE]Y_;<R$VUVN9EZ7P7N4=+/O8V.LUA705$6&(I0
M1GY5""W*D4:A1TVBE\KC U02'Z+B^"@5QB>J(#Y=^0EYRDLH56YBC7(21RD[
MJ5-929.4D3Q'Z<FKE):R6RDIIY6<>KN24I]44MI?E)SV+S[;E(*8=.\,^(?A
ML[M)/S>.(A9X/X]KT_BN!QW'$B.-Q&MENIN*4OR5GQRDW.1P92?'*2LY19DI
MV<I(*5)Z:I72TAJ5FM:FE/2)2DZ?I:2,%4K(V*GXS).*R[Q5,5F_0-Y3;-9W
MBLNR<9TQC#J? O,@5& G/'^#68?"^[GH,@4]QN.C%F*E'I^5$:NYF3[*S A4
M1D:HTC*BE9J1I)3,#"5GYBLIJUR)62.4D#U&\=F]BLN9H1@(4G3N=D7EGE!$
MWLT*SWL<>8?WWRHRSZ8HY%KL?P+, W#J'1W$HUF'8OY4C2Z31IFS2*3F.G(]
M8J:$&,DN\%1JKD5)N<%*S(U40EZ\XO/2%)>7J]C\4L7DURJZH%F1!>,543A=
MX86+%5:T52%%QQ1<=)."BA]#_JS@XF^X9K/+69/^@[\/*K(-CK\&;KT8;CV3
MU&\B>G20BH["3C78I C?9)2[*:'83['%5L44ARFJ.$:1Q<F**,E2>$F1PDJK
M%5HZ2B&E70HNFZJ@LB%9RS<KL/PR!93?($O%(\CKLI1_Q6<R1^0*<"X#?R_T
M=,M$YSH4>/X,/D_@>CLV&<D]E>B:C\U2L4ELM;?"*P,45AFLT,I(A50E*+@J
M74%5^;)652BPNE$!U>VRU$Q&YLL/TNA;<U ^M>?D5?L \CMYUWXJGQH;U\EC
MJ.\A4O_=</I-_8YU*//A^-/YW(,N8[!+/?>48JML?):$?R)'NBFXP4_6$58%
MC A#8F5I2)%_0X[\&DKEVU OG\:Q\FJ<*,_&.7)O7".WQOUR:;R:X(8D-+[$
M^[\A_Y1K@\U^-O"E9C_2=&G]#,<ZE+G(-#Z/1Y_1T+1J[L&]2L,NL=@E="S\
MO]5;?BT!\FX)EE=+E#Q;$N71FBFWUB*YMA+(K2C<VF,>:H- XELADZV0M5:(
M0PO$H 7>W4(&UV+34>J\#\QMLQ@CYA"/<^D?YSKVXK1SO0%:4H8NV>B9B#X1
MV,9*T7[=7O(8;Y'+N" Z,3KS<7&.SFP<'>PX G@<032.P!I'9<8M12#+71#'
M+C*D3C*F3K*W#G3HL#G.A %S\P+'.A3S;.)!Z&D/GYNA(]7H4H!^J=P7/2 %
M4Z3_5,ES*IRNGT1C"H/\%)*/*5&.B>W)#$"32Q"">'*[8V'/Y"''HHI)QZ4^
M^%7?DP0\W'\".DRPZ=+YCKU &X;7H2!3EF,#/H]80GODNTR*B(,JAG*O!;V\
M$,TER9E+@C''8OZX0&,.,XL<$0:8V=AB-HUH%OZ8A>%FF44^&VALD.I!"-V,
MQ^F$WT.^)?!LVHN9MJYRK$-98M:A(-V\'XU40@USD$2^#\>E 8@7.FI8EI,(
M+B<17$XRMBS(L29E&0/<L@P$6RRE<UF*/Y;BU"44LN0 #1]BN0BR.@097/@U
M@X)-.]<ZSJ0=7H?2MY6V@-0B!=ND9%XCN!Z(>"$DDS^(^;P%/;:@QQ;LL04]
MMJ#'%GCN%@:9S0Q^FUL1@FD3!MVTRW$^R@8RY_5DTNM@-&MMVF;.I(6"+B!D
M^J'E'83O"/-,GGW$ !*)!")>9NT)U2!IIV-WRJ7#@E\N]>8:>AQ$CX/H<8B$
M[! #[R'BXB"V.$A@74IE+X7H'R N]S]/8_@$L6DCN(O!G [&.,H=>9B^X#(I
M'7H>=0S[?W\.BASK3\XXYT-^+&9^Y"IL<A5Q>I;$^&KTN";5\0>B:^ALK\$6
M5Q-D5P-T]CP"D;_J+_8].<NHQR"X/6". J?\-/TQ94919N!5DL>/UZ#<Y)P+
M&1;[GASGW(@YK^0.%Q)4'^<9)22E]Q ;]^"3>QF([L$6]^# NZG(W?15=_\.
M^52SJ>N$DW05X%:"ET7(1%]/_6^0W&]REG^[<Z[E'B<)>D _VHLCQQ^(A^=#
MS)J-)[T@3NCQ*Y+V9QGXGR,^GV<@>(%&\#Q.?8["G\,6S_U9D\ ><PW] '7,
MI5ZQ8 ;B+O?AN9?A_3B/ZH?U(+]TBID/&3Z;Y,6+YD*&STY]"]^\AQ[OTU;^
MPN#_ ?'Y5]K(A\3%AU3\(X ^^OF/N+]9#V+V@)AGQ9@S2<U^&',>1Y/,6A#'
M7I1^6-),?0W3^ K6\26LYPL8T&>PR+_#QCZ!5WT,"_T0!WZ  =_'0._"I-^!
M<P^?P_&2<PW&(\XYB/^> S%S,8[U*/^"SWP#Q_Q2=93?3-E=E#T1]CQ5[Z''
M.^CQ-GJ\!9-\ ];W.GK\$8[Y"LSZ9?M>E!LPSSVPS&?X]X%][L.L?GG<.0=A
MGN1[Z__0X6MY4*< _0U>]5>X[GO8XBU54'X#98_1;S6.>DS4"^CQ''K\"E[W
M2_CE4^CQ!'K\'$9Z 8;Z*-SJ$5CZ@P3K?7RZAQ+NMN\4<LQ_F#48YCDD9R_2
MP<P!T%KM6YO>D)]^KV"P8L%)!Z.0\JLI>R26':N'T>,!]+@/O]RK0<J>2]F+
M*'L%S'8#J#MH,I?"W4_1E,[3I.[1-03.U=1L^"Q0LQ;#G(=QF5,'<P[(7R^:
M@WB:N+B@0+ BL%DB&-F47X)W:VB*390]AI*[*'L"=9E"^0/49P[E#^&!%92_
MD8C8#<81'>7J$;0Z1*.YE(@X0#29$V6,F/47YJG+7\BQG.EE9ZB;YG6O7.QK
M,&[&%N?MYV"D@)%+^:74K);NJHGRQU!^)^7W4/YDNLWIE#^;LH>(S)5HL)GR
M+\$S)^C6K^?3O6CV(M[Z^W^LP5@MFWW^Y]?.9F>:_)W.;N@:;'&&N#A!&[D,
MWG\(GQR ]U^B,O2OU2[\LD,M1&$'&-U@3 )C.AASP%BL-?Q;:=^5<DA+L<5B
M:K4(CRZDI2P@VN>#;60!8HX9^H67XPR06ST=1T.9KO>X?4CP!=-*?2+!2=0F
MVLD&>/]:]%B-7U:I$<NW:!GM=BEZ+$:/(?RR@/B8Q]4Y]I4AEQ"Y)S7#OH/H
M84W3:T3S5_:G0/4[Y1F&F0?IWF]CJ+F6UY-\/HP^#"'4TX-2+& &4Z=H<)*H
M2R9U*: .9>#4@-,(3C,X[>!TH\%D< 8I>R'O5JN/4B9@R5[[*IY[-1Y_C"/Z
MS>Z[87DLU/$XM.O-LD=2H<.D97O19RNZK,4NR^5-W0+ "\7;,92>3'VRP"D
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M4(;G0JYWSH4,O]KWX\BQ3F1X?N06=\<9)7>@QQTD07<0GW?0\=^!+>X@Z.X
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M9*%_H;:BQV;TV$B<KJ>]K(-OKX$%KR)65Z#'<N)C*0B+N,/LCIE/#>82@7-
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M_$G2_9)/RS?Y#ODD/XV\S_OOY)=DLY]+8_8C[83'KH=;+T/F-?]P'NL8;-2
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MCS[N^(G!FZ"%]W=@BW9LT<;@UH8MQC+PCF40'(L_QA(38\T")WX\9CZRQ7'
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M7"3V[_#-(7]'@GH8GQRB4SN$+0Z90WDP[L$CW NI/_ "97ZN^6!. :/M #'
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M_-R' OZW!OFD"=!%BQ^D(2 DE0+M)0+22 1H&P[0-DRT>-!N:B*(BI(4R**
M*'900^24=.!BAL@H#T"D5((0"94D]-=.%8AXIR%$1&T/;:/VAPBH+T!XNU"!
M$HAGJ9^#:QY<7Z%+H.X10':(],8^%!=P'4.=QXKZ3E[ 4P!M(PG:1ABTS4%@
M$W;@KTP@O::EQX<H:;9#9-04$ GU3FC[KMW07[OV0<0T'! 1#1^TC58"(J!5
M@O!V@Z1U-TA"]OANO+"^!P2;>U!?X@=RO=T@O]C]%8J1V#@6\+C<QGDH3N"R
M K\;@<\T@&[RP$:'0;HD!&QR$-B$#:2S>X&_4N_#A\CW;H>VTY%#1'14T#8Z
M6@B?CA'"HP=,>N#<>X$Q]RJ )!$DA@S'0*#NO1&L,X G$@/(>1E E+ 7Z+#W
M&W11>F,)-$AI8Q^*$[@L4>_B@-O5CP =@$T. SV%@"[<P&>90?&[@1Z4[/@0
M*<MVB)"9',+;!SK-/M!Y]@'G90:&8@:.M!\8<;\LN$ LO1_D6"P@@6-!;5X'
MP?)^$)SN!\$F,]!AWS<H"L@_">0&JF_L0W$ (:<%^-U %>1\0!<YP)< NO !
MF[ #/1B _U #?R4_B \1<_T%X7&"@9T##"#LH--P@ &7 S@P!U"2 P Y@3$Y
M08&<(+'F!#D6YVEP@2<C!WA*LH,G-COP![8UZ#R0'P9D^^N ?@G,9@_24W/P
MOSY07PU\+@MT$0$VX0%Z[ ?ITF[@)Y2@BB2">! !/QA ^<#@Q0MT0(!!%0$Z
M, (X"P(X,0(X$@(8$0%R?P1(D!$@F4: A.H@2%0.@DB!IPT8%NC _1T*!VJ&
M KE^AJ!?&H-^"2XSHXWS2)2!+H<!GQ_HP0YLP@!L0@VJ1@Z*)@+M P9.D)R#
M!Z\H&-!%P,-.&+2',&@/8> 3PBA'!B!AD/L+@T*%06XC#!)#(9!,"(*$1 #D
MW0) !_YUZ SJ7%R0COJ U,,%=28LN,S I0WR>SF@BRC0CQO8A!G8A!;H0@&*
M_ O8!3P2@)'  TT&V$(:V$(*V$**:F-"5Q*TAR3P"4G0>)( + F$2-IO'.PI
M 9(W"1"MB3\!=0#^(+8.G4)]/S-P&2]K\)P N;R-'>B7H"NIHEXG GKQ ?W8
M@$WH0#&4P"XD0!\\8!OP( 6-!2Y5D%NJ@'Q;&?B%$K"%$K"%(G@0*H+V4!1"
M?=DTN$!#*P !"B JD0?)I!Q(V&1!(G3D':C#.G0"L/R!BA[ 5$XNP!]!"J0-
M @<YH(LPX!VPVOA.G)U 'U+0K/BH>0^CG]>//2G@T@-ZZ((VT0%MH@/ZB#:P
MA3;H']J@/;2!$VFK_]R/ OJG)DAL-4#4J Z2,M49H/_ZC^]&1NU#07TWL1VX
M#('[*H._Q8$^!P&/V1&"=@$=R8%.!#_F.\!E_2.X 0,)]'-/"KC,@1[F0 \S
MH(<9Z"-FP!:FX.%G"AS8%#C34:#\45"X">B?QF"L- ))HB'(*/2_;^Q# 4.8
MLQ^X#?ROX0.:%US\0&56+^ #0"]RU'LXX'9H\X5:: *NCK8WQ1GXA]/VC0#(
MB0:"'(%?./)M' 3E !S+ 77X3!BH+$BJ;4'R:C,&ZO,-"@@$10)7L0*7#KCD
MP"5T'/0#<.T!OU,$ ?D_WKOY>6U^'R?PYQ6P^<+;.#,V .@1 -HD@&/C8>@/
M'-H/&,XO8.,[BWU __3N!HZX#'F! -86J&8 NJXB&$)$SP ?. N&6W!1@-^W
MH<Z!_746; 3T9SX$XWT<"/U=G?.@OT12;BR218)!_CRPQ7G@W.>!$<^! B)
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MA][ZF;WHC4T,RUCCX1X)744'W,( P#*080R +$P'C.R $080QRCB#3K@& 8
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M  ?@PPS%C5$$++/&U!+FM[X8 -CK*BD8 -AR4@,Q'%"(#GB/,4A=@U7#$0Z
M)Q@WX0#X>M,$?)K$' 98CR-"!\ #QO59*W0 /&!<7V]51T=@ -;;0*9$MH=-
M0$;KF.^%;*SO2/5/PT=''/TW:+:GO?G1_>J*DKN%N3GPS0?#)_1E^%GIJ+;_
M'O'1%_;\,7P:0M]CB;%[ 8+\T$5@.#VDA [0P@#0HP,N8LI 7R1YB E K\8B
M'08 -CL [Q40= L=X(H!@,T&QV$ 8+E]!08 EMN_V@\'Z*,#UN'/=D@&!@B
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M@0'010<TL\(!DC!+J\,!G.@ S'D42AC@)L92#@SP0N,? -;/PZ>#X8 V_7\
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MD(\7?1ZEBYT*8Q$$O7PL\RCH@-!_!+B+D6C!HIQAS+TBL,,N;#  L V0D1@
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MN8-'4V"%?PJ=L?0+B[62^?0A[:OSDC4Q=P;$J*RI0QI/3NE^V<>7:KYSN9-
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MG9\E.<_%3OVPO8/'?2W$W&W6Z_M<%W9\,>'\P#E*'1<K=*:9J\<[W6AR+N$
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MW$^G9Z03SL8CM<.*Y[O'M"H(%@^XMD@]V"V.9Z%XJOZX1]727BWV6+-TR\C
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M9E/\SH]>XUQ9MRC8@LG,9T?D3%?N/J,6H%"^:&<QRU@IB; H%YTRO?SY_KD
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M^I9);*#"HM(M?2<,ZQ,^,UDL>\DKP7\=!]U1??@]@2@:A<$1X" (A4,@@ "
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MN&LY29)V1"1AMG(QV\\(UVV2PR6&.+4W$5KY1#P\$ B$#P(AXB&TP$:(3"H
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MH8Z?2=C&2.,?[_Z0]U-+Z%P9ZCWR_P_-?,'*.SIW7T]4O080*:0#AD-;?&@
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M-IVW%D/7&6.T17N,T'6^O.A7>O"TBR^A'YD=1DI*#J I$);]BB0F%A4[[P+
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MK0\UTX6"G:*=I]G4^RNA+Y4_EIJ4O AXJ_T^4QMS0-6ZHW/?20D3@31E"E<
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MD_0#Q7SI3N+ZW@Z1^)C]XEL!W.Q''[A\N*DINP7<HH.VB24N,QUQC2)DV6:
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MB\2@X1 9MNQ$:#0$3%^"C5B/4"0TB!!0:8"XU%-CQ*.*2]5ZM#!)#>6M#18
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M)L' G$5=:%>-'I.0<WG>4)6ITR[I7O&3/UC#-S_I3[R-SKH>%@YSQ(?^+[+
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MAR*:4:"'X@ #/)0VM#(Z?%:%_U_3KG06 .VGE:@W+%7;S763L"K^LGG]DH;
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M%B)$.<F?5PJ_GH*-6YK6S(IW4+ZC$F<!,6%CRX(NV]#2(=":_ZA:^C^-"VB
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M0N>QU/Q7RZ;B!J^0B0!L .VR"7+5];6^J]!_U+4J&^B_JJZY"5-O.)CMLN)
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M85-6K0/;CRVNA3]4M/J5>%=F-7<FD!%SFDZZT<! /W[@K3DSZ5W7F@P.BDW
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MH2B.-P_,BU4:@]G!X?Q+MJ2OQ<I EA'8+>^B[T>6!?G)J*@W=#?[,UJPUA@
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MF[N[M!SB$]#K^X<2:A+<Z^1B\@R.'A,\YZLK@<?.&@GU4[6F$;$/BG(T>4]
MHP.V1/NP\@DWU(G#KZNH3VI-_*VL@/X3D*9+@,6-\ KKS&/USM.%]'R%OL!Y
M#GJS^N %=;G<B2:66AFZIP@\X:%NSXM2Z/#%X8ZU;\I'H:GL48:#;IJ@[/?&
M&W'YV*X?*ML06PKK\HV-."!=.S^DNW)O]_6)>HZ4N_N7$SOXM#&$9Q@R94=_
MM,_T%&MJRN;O>];D%2'#QDJJ8^'R_G@^RJ18G%[5YVTE0Z8YF@6,?1B';U,C
M&D)_\'D&G;[G:+MC+DG&EYMGX3_2G 7=$!$B+#;E_Q(CMTI-E[$3<AQ!3QP:
M&#IUNV1-4SW XCX/OSV.7MX:$_CCJ$IZOJ@>%3JZ7,XLW<R>GOI@RNP;F&<A
M.K;"O[FQV)3]C/5^"Q:$VZWB1(C.A=+K!AEK]LPQAI,R38=(Y[%*WD<[S&>T
MF%/G?>UN* >=,>48)Z=N-_M*AI9MJ:]&+XYV#]O[#O.$^_CW!HY'XBU_Q%A,
MOK_?0PI^?]9@GSTY(/I+#R5X42R2$VJ!TI:NB/R:C-]K2W9F.*/OZVS&LT6\
M)R4)O=D.^.L$H_4;HIZC,8=1\\3QQY=))?>OWT-*&ED4-I:X+MW./C:9'W[$
M<+LJS0+W=/V@972=DDR8DE23&]4F^"X9_C-T! =@I73KAL$V0_W7B#IH4_B-
M.YN\X7J9%N!YW^(E; 1^+DVS^F6#2:U&0#:#4!DYUG646!J>PO65K+-,OFDZ
MQ?KD]5VFYNV@;7IBNTIA;N;W>696*$,KG!+QSXJ*Q,AI)M,5-T("SL;NN+@4
M"ZKBS+0DV^LMD]<8'Y5?,YM!U8T4.=0R<T)CB1\^4,++IVM5[6P)O%)?%VQ4
M0Z_';07) 5$Y>;E!CGWH"(,P@0U"5*SK.:P9(R*.@SI3.%Y@<SEW]1#)6D0R
MPR-]A)Q2%DGQ QT'(4DUAG9Z#X3+V65Y,V;@+FLVFEP\&#("@J$TC"J3']5.
M?5^Q7$*.O*^2& K@Y\>/":X9G6./D::R'N3U$ACX*AYMS+CV-N7[2?MA6G<Y
M7. <J#<L'_%O4'W13TB*Q^G\A8"N&60*?Z]_YI39OI#J&TH?@LDSI-_];E7H
MQ-S[E=RUL\LOP (1J[?<T )%>.IQ H6!D-84LR,D4*1^AA_W9.8EW/R2L,B*
ME>,5?Q*V8.V9_8]OT6B.PE=N1Q$322]TFV\3<:MJ#/BH]AA^T;+BL[RFW2P4
M^4,9Q?,]YKX,L"32]B/6;ZB'ET-$+!TY,=>X.(9GPTBBQIC>.MRB:L?=<KO2
M=I[";5K?4AZ114$O))>616GXLZWJ2+\C1PHYF_V- BL2Y_"LO"'],MM$7V)[
MR6)(W^3# #7B&QX3C29ZJ.YG6C4T1 B,IC;*C"(8\MGITOU%0O]YD/TYQDSB
M/SP!K1P>ZW>-L@RI&SQ2 T2(()9T$ V$*T;X'2'IDF(<00#_+;YH^R1 6+X"
M>/KI+5.:Q 7^F:P3,JE (/>TWN[TU8^T%*8UY_H36L]8I!"L<+_6*F-RU]2(
MC"Q[7GA%NQH7!Q,XCB/#HK0P^K;%L*UZ@,_Q(B7H9I06P7<9@1(44(09(+!Q
M*-#>G?6*3<8W)=7YM$6FXLU$^3+^96HJK4&2M  IU&<[;E/:22:1R\DDEWI4
M^/<2_WOGYZ _N;#6VF02<;1S/BJL=G?B>=PQ_KDAA_0>]#-_3M#P$<> <,3Y
M<'E\1([_=_XB"BGI*B:.DX))5@Z<W]G\[=;2,'G[I-"SVR$Z^+.S0>-&N),S
M$,\<./@/'%P9NU1]E8)7^O35>+'XVFKXQL@MGD,$*11TG"XPXO.C5[2X(U_N
MDN(3I7Q*4QQIC;VV\AS>,TK99TUYD"\OD]VL"11F!&ZDKZA,93N?TJRN/ <2
M52=0#=_X=GV]NS2(-/C/Z"IWG\CHMXG([I,,Q24#G1:1P+PSW\Q6QR> [2B5
M@2'J4FE,L J4[I(-]^U83*RCF>D Z\UF1-#-1BM[4S80=7-O+G[;!_@@QT?:
MZ#^<=P7^S)Y#MT_H\KWW=T^2.*,XS4 @%#;9V!YL3'OTJ]TR?X8OH9'5UK9\
M=QG8\\-$[EM%YUX\.P:6BYOG4&OY8[3FU8QHHDA3HP.RQ*/:"'\? R'#*"S;
M452TF;7S^%E32B?AMV1W!NYB2?['&4E.PJTCEU'1&VG-3CE6R[>O1(E."GF?
M!W@GX1-X:> NC<POG/SM04#DDFG%9KFTF.=9N@W1,0.M7KFK9XB%&W$^ST @
MQ47=N"!C\GL =89VYIG^7FV5]NBK=Y?M!0Z3\YRC%.6.8X6L*B<G;_$",[Z,
M>3&,7,I56'Y[&#<0&*59'$SUD>8\S[AT?&8"PG-_IL*:=QYF_(?W_L9T\G&#
M#X?1]FP^YY<^VRMKV235D1:]A19-9!0G]V]/_X[S"4"UCVE?-7"7L;OYG:=$
M^3+U:I1_/"HTIDR[QH">R ",@9P"C0B][44;K7>70-D7*$Q'L>,0/DUW)9S/
M![_[Q>XQV75:0(#/37,6>D/K(-'&%N7@V(\OT<^ 4L^/(E)CDI_E)5U%:-#1
M\66=V3<@#PKZR)YU,GSM8GI%[BJ<P2;*H*GUIZ^,7;HF@V1.*8]V6*8";\+?
MA6^<9LUWF=P?A]G?3NP>F8YF7*"-7/2KNNV<PS=5-NHF;_X\ [:+-A_=(]X]
M\,\(NUQU?#I;$SC&70! EAV%B/CKH-F_I[QE08F_;C'?D97$"9R2Q(T/JBWM
M,:*$F]KXI,A?)J ]E5NP!:9[F\8\K?W?K+J_$HT@^XGZEX,UF P:/B8.J:N5
MR0=E2'[BRB6.4TA12V8:&U<I#"T<RVS8&*GK_)6D+#DDN>W:(&4%_J&.E"(D
MC*%7.GQ96\P@G+EMDSH:(O72:U.Z#+(UM7<AR^,1RWPAP#%?U(E]*X>7K6VH
MMHI6D@0'SGWW4(Z2X\5#Q82.DI.Y991HFT.:<STA[<Y" =T7Q-#TF@I-MZR'
M9.)N?'1 @B70LE*)LPI<JW'!H53V3Q5MJ.BI+2RSI5[0FTU3]C@50V[RT$UE
M92^+FJ!>0]K6</(T,^2A@V6WB$#M14*F:SE&:XM73"[IR2BU,];-CC6)PJYU
M?_FLK=:U&>E2//-[ZZ!:N^]KN?1KWY6M/G-^5]^+KP]/RQN?*#CZ^4YB$J9#
M>RNCS[E)R>L[GL' :V''Z1/&6_^2"XZ(XI7G3*5VV96M*T'<VT9KH<KZ-X.*
M>^^CS8M?'NWA"V+Y?AW)*E1<O-S>[TQ05Q-0HGX]7$_V178+5%A/(F(]Y(.L
ME%?W,H=[XF#BU(3E]PK7"#OO\.:OJR%$'>-LA_'LLN,,W&AK?JL7B<D/DKHO
M!%@F0SRQJ^GZB*4B+*8-8/-*DK!3J0+(K^:[^\75BU>.2QLP/]6>>_)JUO_L
M721 =5]A,2_DR1<OU?YTK9<.T'-S]<L73)'-Z?C(XM4$V9HA5975*2VL2<()
M6%ABWF%4D3*_)1<M3W*5:?LVP86TLD9]KOWC"<!)884/2BG+;TZQ1E_PJ@A'
M<'^3\FOIDPWSJE1XX?=%NRRN$E*WNBUZ*<6&Q?>Y(&GQ^% M2P4I&]1*XIMN
MIXV7F.99R$>>^CV_N6N<ON+'J=0S=_X@,^(=6=/A ZF3ZPU@_62=?5?(EO\V
MKWE38#+Q\XY;>C*/R%ZJF()ZU-Z2HR23KQW!A)[Y5O*VN% .=R0]67KL$#G-
ME].@,X7U#X<==^6'Y],Z;F$O'0X^J#=5T3;65DM'>JEDJ[,UQ%AQ44_&676F
MUXOZ1RJ[O1[;4@BF2M2_0$]08N>HQX \!HPJJ5AE;V$K46.Z[V>0KR\L8;"=
MJ'=@S[?9IL3\A.3EE21C=<%7?43]V*)TZ05MM/C^AJC23.+K-YB5O%\6MBH$
M9W_9-CUBQ((>(3*L[#T3*_(ZQ>#4GQ\"9MA-<HU,RM8NQ#7H+=0.JN/,:H6V
M"L&<-0U>I%\X@_+,WCG0%M8GB^ 2LC8NQ$]^TZ;+:'8GUP6QN:3.*<HT>^I^
M=*IUE].$0+ZC@V/Q(-[0  <GN/[#?@K#J6+U_V0Z:?,IT&EIT@!%HM>*#BY9
M_QK-[9]_:(D]%)UKLD-'% !]/UV27HR_UU:7IF'KQ\+.>)\WM2M'R<B H#\X
MKL/,"R45V:2#2/R291L4S'H+VQ+[8W-H4/@8VI*\(YJX<T!39W,G2L]&V;.R
MSU'W+H%)*P47OV76</T;>+$&U=B5NM7;?XUUG74HP3[O<$T.'>$HR?/%A!+L
M9A^@)8<; 381RAWGO5Y9Z!,R(*"&4BRM580\ 4?0@1^P40-+"AGR86R8<Y6-
M=QD&*7ET?;/0BR.J!,SW[2G#8G_D/<)1<H6NFTQ27<AZFZ-E*5/]EDAO,&&9
M3IZ;)JD7R#^/IPR/@OW*,>G7PHZ(YX4YD7736?RSC\U#>3FN;2,;ER1?3AT@
MI> $(AA7$R#6N0'$(-Q'ZB:RN^61DAL[GNU^AN71C:@YX;N^>L)1(A&$*IB2
M2LA(MZN'6W5T!:<[MO?9^H/!'0^=$.\ B/RX8I[J;,ZH*P7-,%8NZY1]G?9Z
M97B)D#9CGN"TO8,R+GE$Z)).W->3X4>;BDWVO2CJK["]BJ&PT0+VQU@TO^'<
MPEO1*_O[2"AL9<F&3:]KI/.A<+6; .BA>!8S<M"@NO4H;K?"^4=2,B1K1A$O
M1H<0$1[>.8 KPQT!QP5YQ+9ZC9P&";<;=";+T3/$LQ3?+-KNS2O691/VQZ!P
MYP:QPG\.RE/N2]UFJ(]KC>]U':H04C)KY8H^;%Q82Y"SEP;)YU60SE9.OJ3'
M74Y@LZDWB&.6"H>$I_O.DJJ(GD7)S@Y>W7-^JC]L$$>$LE9;=L$/P!'NB\,%
MF%:$PG,1E'>)SA[\T:&H39\\^ I@DB4M8*?,GT#^[EAHD='5&!F%Y%)245(!
M=$RRLC@ 7/%XXYYF^>1_LS_R_U<THYOU;&D6%RT^U+U.W%S\_HG;R\TIUUDF
M_$Z%(G\Q7J=7]?+GA46JG YZ[<(+9CNFG*!;8GE+;&;P[5'T*,MB6^N"A2HW
MES_"GP_!YM?X&QC65C[OQ^K1;[[](/B]JNLFNT16$^BP3*+IZ"WD=>R:8&$K
M,FGUP?VE,Y4=&7J^C!N^GWJI>G/F-QS=@JEU+\U8TBB"%5<1)8V8*PL<:G#7
M53"^?5@LJE!./\EB0 XZ@!E*&FRPX5@"K'7P5#*2^&\0\E@LG-O)E]&HWZ&S
MGG\HG3IB4F4F6'ZH'V@Q'"\)__2N,75*B.#<K[!Z.N([@FJNZG[)O/N!Y9'2
MNTF(6IK]Z@\511+:HP#<1&5*LIVO,#Y9>#F;O)U^$$-#]>:(V0B4K'(X9^'A
MD4>OLM"@8,EKMIJO;$YW5H'ZAIT^$'F_WM9W+MIC6<T[_&AIN;-QGXL9G[@'
M?YNXKH"@!U=*[:>4\L<WC3X>;W943J).EKOB&>%AL1)"F61C XCXR'2*=%^8
M52T#TM9>$<,KE! VP6%VR1[PJ9JYY_Q)7!89K& %AS0(E4I5\+(U.?:FG'/'
ML+QN7(D:'G7G)JK7BJ6?NR1\;%+R'6H#)ZG$UK6\K** ?-88;>";@.6IP&.$
ME,#V&DL ;,EOW[YGZWP]2IFK_@';NI<1,N6M.YAC,!HM.3BTNJM97BC_,8TM
M I]F*U\ZOY=C1[ZI1C=&NS@ME%" 6G>-/5^^$#5#V_T)?WYHDDE,J&(ROO\[
M@>8T>Q4?C@00.15&5 F\DN=?9EE+1%59EK4F&?'DWBHT/+0)WK,4);Y7U.6=
MKK6![+JY8CU$U*0U\"[SQ:?$5O(&-];3;X.72?P6:ZUKF'\6PCVT5K*6MLU?
M%[O"\5(,\:24!22')(LX.>->MP2LZ10DT50$ +;SOSA@TN<!:N_#L+&423M"
M1\AZ%B1FM-&U17NT79D3S*?KK"[#A0>]RM7K=Z:92]N4==T9QO94"\=S%;-'
MG"A?:')]8YHUDM,UI"G\39 GD\TT^\ZVN72EJ=G=4\!F1%=)4$.B9.*?_*WY
M;EUZ/L7]4-TN^'W=:TU723-)S+R"F<,NV3J[=_6*L##] IU1W< ]VOF+WA2I
M84C19P7>@IP2P=@P&%G^"=EDAN@54AFUTC?<<T1DRZ %K13-,$82Z]9Z5K\Q
MOSCYHD5.QL45Q:+N);+^19%L:P<Z".D"26*DMMM]9=U>H?TBCY1BL=KN"^.9
MI9"AWEFE_#8"X3<RX:$,C(;O2K"JX+EHW[^:L2C^92=!)*H04T%#I</@T$RO
ME#5_-5!51E(XW)[24KFU/*N7.EZ[-5#)M_ $U._>'2OE0]:;;S\2+/-.)3%O
MY0D/2V;1)SF+>ZU"9G7<WL]CO1F-]NTI\4C.C6@Y"TN_"[C&BMO6>E[A5O/I
M\>Z7?B!@FQ=!3G"SH_ATVY+F/8G_5KVPKDYZ?N8CE_UKY@])+N(%Q+9M]O.S
MKDL]O"R,E65,]4."2D6"YR-)F&-&%WYL;U%\(J#+!5@C4C$CI#\^6C0G=QTJ
M1*YH)S29+6A,5R/8;&LW,4DNB'3\*!=0F,3>[#=OLY8IFV)\R4H<><J5>4'L
MVJ9JOM)<ALJB[HN\VB1B;>["H)Q-9#C;QAT7P1WWK9\X("+VRI)!(BTR\\=+
M>NNY=*S#UZU=)\?&BZ^F*PE&2\=,%*.FVPC .>&NG$E+[WB%1IC)1/K((K$8
MPY,H\CM];:HFIM$9E(W@,H^.V46V0WBT8H]&[!%86M_^:E'Y>^7,OX_B^I2'
M^*]U,;0I+:G:_6GOTZS3"16-SFCY9)$:-T?F/5OUE>X=?\1A9D$5P18E]#UM
MHV0@"+W^G @79=\^TS"PV@A_'7AP6(:47BT32B$8CL@Z]#I[W7Q]&8NVAP)X
M%QTN!J' -J-_P>"H9.(N1++D.MMI,!E0*[$#</W6$@&I "YJPH#I6TYO0<>Z
MUI&QY7HDPBRZQD5DQ!]ROU((7VAR!JG&.@"CFH8H#*3.[0/"Y(X#Q/M&Z["0
M@G5_>#DS 0ZR947:B&-"VBY-KBO?5%99#6J\G$(Y.ODNN@G36,B>P]:[.&;K
M)G%:QRD9>^$3QY5&;[^85.^^P-8&Y,.TWU%+<*SLB8;<S82IKB0<Z?6@+RM2
M-2@.+.0']@M4@^):U]'*[:O8Y<4,(OH6OW8[1I-D!P1-[(W6<GV-/R_]LCU#
MP%%[7R?)FE@YT]$SS\')F015SJ'S^,34LS<%B]PV))#40L1I_ZVCLG.,^8N0
M#]2#O=I;4])+GC->6$6E^&P:+EORV3KQ??&O>+D'( 33D&PM&6W+?DWM0G17
MT<_5.U_(?]1=G+G1%KXS RN>@/E22R)7"5V_RP$).-VR2.'6OW\M/U"Z&$BM
MK:?B&ZV54@:DI:Y2O3.HS:'%9"U$IRUELD!#74;D &8/BJU*T#5F#DLCZUUX
M!MWBS!:F2/33?XS^H#8H'"^L9"K@HO!((H75]&*#72TFVI@4FW=5!U7$.!<X
M$VIL"1<EV]'[>GMZ55%7>K0K\7WJX[W_IB$(O=6Q,9"]*)>[B*)=MWV@JK.-
M,&.2\K9:<.2,'X3$YX('?C$SJP_0MM@H.,Q*_D^?=O_?2VG#H!*=G&O>,GC1
M,2&WF\Y253& S%)"_!/O*ECJ,V6N(9#I\"97PBP!'F\2C,1&&[2 RN0I89<3
M)"!?#*>(T#D%GQ#+7;2MFI30S#41?\%B)C-6.[51Z&LQGOW:LX9W@5RE5VV/
MQ#*'KBLA%ZL.)JD,PW;EM=MP_)D 2;'5TY.5V"=[O0=6TG;(N2BF^47&K-S1
MWQG/&>1,NF])>GE&CI>?;5]<GD5FPE">*R)%22=33'0 KR02@!*8G68)@01)
MAD/4$G 3<-# X6 YE 85:8CL=C[E:6^4N;V?\*X:\@?P Z5E3@F07A&"!.#B
MHBC#B;NL45K 40*<15O?!C]N-3-INOXG@[T:08IH'&OFK<K$D7+<[LO)R8G?
M,JV"<HKX,1..BV".B>L-R44K)&;;YS5##EX\;= G(($RB .2DTLE)XP#T "6
MTL0.1Q-96&^B,Q<_;O5X?P;[;J>R-9<!6[-RCEW+=KBU9F_3F"")*6"<!1U)
MY3%92S1)21)4,D9464)Q\34J2I<H9.3X(CVCL#$=S\1TF\N@,!VISU13K/EP
MX ZYB\C&#>N-%:D(R:J$ GSFJOBXV/BXB9S- "5P_VM%V5MF)CGE@^\QJ:N6
MX.+_XG3]8B]7&*:+UZN[AY>]IXZ++ENXHNL7]< OF)2_#TD2O>MJ&&VN15,0
M'I,OMNW,<0E0XZJ&2;>$&>VZ7M@AHZN$$N1!HC_F (Y\73")0_ANTN P_(MH
M8U&8X\/7KFY%>&GJDZ3(4%S'Z> F$JXEO U[7$4<V;LWU0VT.1JI2OW5=9]1
MI5(6W<(>")GEXQN922\"@!Q&U!^6/2\F((F-$*=X: Z#WN6=9NUZ;D)UT#?G
MF?58<42,1([BFOD SB.Q\M:XCD7PPPHZ'B"^4)<V,O+Z9^_<!/(N+?Q\*.4*
M!77O$@YH.?QX0*2'/F&)] D(A%>]W""K;M\HO56*HBF6!6+XBT@#G;',ASZ/
M-&'<NN[RK!L;8T5CS>2RU"V& X@)NK;T/=]R^A @HN]L&WK]#MP]2<_/W[&3
MFT8?2<2DDMXXB9]1'4J/]57$WESFIRJD"#F_^""FJ$=/LS3>3E9-/FMRIR@>
M:\!ML]=^@V>#)&O65Q]ZY1IP(_HEF8PU/K$Z_A/3"V5=.)IGPRW/2?=IXF^=
M.21LD.O<@Y=TZ$0/%8RH NNEB)HMO0_?MQ5[WT)7LU;*-#\>HA8KV7*.AZN6
MT,ZT4.6@%1$F5+:]U]ONX5OI(S3W)@*Y*Y=:F/]]P?2^8C6Q"+A%_8+U^SN-
MG(*2NOH$GHL61J2$K PP@DEF<+GFPA74-A]OG66 -N28*1;[U()+EA;>'D &
MX,[L4G</Z_/K$FQ)-*BA<6%A,\9,C!CZS%.+?[Z&^8*[G8:(:JPN,- 8S7**
M<TIXHZH"0PI]:4K%#1UR3:'0#3W# ](?AL=E?JZKXI0*3T!$>+6 [O2R=LU_
MDRG@?RH)7Y;>_.PQYBM6.6J,K&9E+P3[(8*Q)"86U+Q4=HH<5L 0")S =3O=
M:PR:8K63(U:"KVP8%!HVRYM+[3016M$(HB"MT4KOP/O3V<?R 1*,!X-M2*TN
MTD)2IT9.L=>12R&S)D35]M!)O#-<%LUM 3(1(-'^89^P,UX]=89^-MC8CA5K
MR'T@/.P5)H>R.#7::PO*Y?"-SP@-ZMWSUZ>R3+]T(G4=%$KKNV-Z\:K"J748
M8/CC8^A1RB'Y .$W EY#'3TT@?G#7RZ<N"L.9+0$Q$VU(SZ$^C_DJOF G!?-
M[L!/":*:$I8SX2< AS3FDJ(F_3:$D^;+9=R-2@<,\/.\WEKK3.\Y0CGO,Z X
ME^[\\^!V<[;1UA?7B\_L&[$$VHY:??P\9[#W&+?CYY+_#RF7*,9),"Z> )0G
MX,;7"_+/R@[^;VW8A/PCG@#[_;LW1?<H&2/_U6K7;>L;4/WEU50Z.46&F*12
MN^?][H'^JK^P.\K%<Y=/P, 3$/;0IE%R2Y&>(8K/:-/2_NBQO_'X<<[_<DQL
MG\+\;^<%5^P.SH\'KG^3SI. ]IZ SV*+(DW&BME=Y_GN?=M*QM<(-QL-8@K9
M1O[3]M'U3T!7I+:[CY_O$Q"O=O>J@6*4K./JCL;(KWSI"7C()_?<!JMYOVH0
M&Z7K>'A1T3;]!$3?G,:L0#P\_%R]PS)&\N>:GH!1C^+MC&$2C/JN:['M7K]1
M5NVT%8IT__$BD?"_JFE;)%W@?;5[:!\%ZOI;T:60]Z]4ZD_ 3N2G!__/HOR'
MHY?&DTT;YZ.W/$A)_C?'^#X9T56\KQ;[-I^ OHTTYFN$X2< GEDD8@G3OXG,
M7_C\(/)3ZG;;(3(_J7^&8%S!R?W%S4GA\HH8[]E?Y8\>]#D8/@'AO*#91_;S
MK95!LIOI7*5_VE[?_+.Z9I/A'DNLE$"@D>>!DCSJ,F,E-9#K]!G\8PZ?@/W'
MS#?L<>YA]^_^-;EMS[*W"MRO_'%\\*KU#DN]N2<N3>%S.'-LYB. H_23/7P"
M:%!B_GSV?] Z7B3+V1,&C6ZI_/&:>7BXZM?A%5TK?@)89@D1XZ)-2]C=Q7"3
M"5>Q 24@2!KN=^W@M4_VNA5/>>GAB$^.^JF9'2I MMF AH#X/ GGBW%_ A[\
M_'RV(:Z@P1-$3XXUS1D_5^K!)9#(1@/H?KRBX?"1_0FH4_+CM!B[W_W7Y'*/
MGDAW]NU=^0\>/@@J^;-W/ '$JG/_,)8G8)P$='DJ3OQ79WMM<-OG^?]RR;8!
M$M 3T""V."I8R_1OJP-W/@&:;8O1Y<Q_C>"O;:P\&__A*,6/9R7=ALU^$XS&
M;/:Y+_Q7QW]'U(KH9W_CX+=2'&CY;UO[SDL@\P18]-_Y%Q,K9=T\3S2Y_ZM_
M.0FY0<<_O>3^"9C;%0W;!F?.IX2-\(6N'?D'"?EYG-&<XJSZ^J3S'^=[M!&2
MVF^MR:P^1K^P3_A=<TCPLR7YET*/JTZ;"U+1X,))A:T.$BM4\QJ_YVXWIR"7
M#2<S4T<<K"$+/@EY_37K'1HS"VJ8"J@1,PSQ7;T41\2K5[_0,T 8QEW@N'G^
M@GFYUQH[<I"95!GMSX>%TE+">' Z.%I)'CL,;D6?Q"GA;45:(>V$#Z??"Q),
MSZ?4Y$1\KF<)NR;))(]&$/:H^5^T"ZU\7EU/L$^+1*S.F!\,8Q>I9N)#ZFKF
MYIDTUY\7J[JT . %;>41X84".-]N! $HH\'3L4JZ!YFQ7ANTL6B(L=<5H&(.
M3>^9%$*9)KI:1?1NM&6R^E#SGQ[)&2;L?IQ-E\WXAAEF=4\ PFJ)3Z]C^Y$3
MVF%T;H&;.,7ABI"E,>67L585D!JF3YTAN9A+<^1B2448GSL;VA?U+-]5AJ,.
MO5XXBC@2_XX-X'<X<'QR[>!!?CH3BMYN5%/:=HIK0D5-R<$);VZDR%5>%4S5
MVB.1+#;TK>5(5S]'^]7*:Y(>/0Q*JK>+!#C:L7$PP58S(C@&)O#G/^X"8ZOL
MCT;F<F39*:=$+V!$%53[4N4-\^TLB$;&",2\M#J:H7'JW@Q^4+CFV@, ^:7M
M7,#?FZ(8ET][@56$7LZDIL(GH.:UU((J 5]3)%9&1#B%QRC<\$I1MSLK725"
M.CP[O()2E?NM\QW7$@H4NNC&\ TEYIQS5X"_HR_C6-(9>:3N<:P>ISM=4;>2
MZIA-_^3\V17[W6'2Q+^WLNR_81& + .M[. 82 8<8AW[JC4("4>[QQW2A2NW
M%I7<=!_'RK9(&YR(.)-:)!U_.:!Z(!1K$6<<2YTZK2)C,JM;'@&T6%L-W%&@
M:@T"M%X/,>X744O%9)>^RYK7GVHWDRI8:0*0Z5:X%$1/-KT;N%@_?9X5@&J]
M@B;;=!SDK3JG;95#TSEMM3QH@&T*KE7W$8ZX*,Y%N.JBQY.2CL/7>K18$K@C
MLX%"$O[S]QQ)\//&""7??%:!*\@3\.AI!SPC$7T)=Y]Q&>-\KS=<_P%R?A,[
M:Y:AQ%UW&IO<J/(\IWGV(<J]\.*U5H $(@%A=&*95$.R-X-_ &@Y:IV!AK^N
M1)?<2>)>9;$?!SCOY9E#-42^J\ V_I#S@UXZ=.N@,XO_"=A<><\3^N/1T=K2
MECK+R@Y%K!J_(\HQQ;SGMH++DH$A788&YI!*WJC"-TFY8"JEF$W_TO-JZ[%?
M9+'8P 7S_>^EM4B)FN/[ K+?Y<&QJ 33H8**2C;C#AS"58YSSD$>V'"T,35,
ME+'BSG#O.\62^#]&6OO7X(AV_(&RR#6WWLDWF&1KH0=:&?P1J^;QO^4QNMX.
M\C/GWTBU2 T0+3S:XSQ^#3^B)L?MKE"[9@&".T:X%SKO[/;CZ[;'$@>I>S/Y
M0;<]7V]IT9 /:S6(?O@=E4K!&?@;==.Z*CZ'CK( %T:F1!L 1T_\/IUM-O5Q
MW#%(,3*D3'D_A=]]*'7O7:D?)D436;LGV6'*J[:,Z\P@%*)5TVTH.=N>,U.3
M1)0Y<M6"%&K^(<4FT[I@[N];EB"QW$^Z[[)]FJ9"W8O65)]Y<MY\A89RN<N+
M3RJ257&=@2H# Z2KZ1P )&TJ;2<15__@H#T P-%7L"_LD92FGJC3P<&+10PS
M;2=GIC]W$S([PA&G<-.)+F2$^U![P-LK+:$"^7B/ZX2*!*; $1?<PA!'&L-(
MF@HS;_SP0P:Y#%-7^+WFWNFK4*W AF[A,+L94RE36JT5N\$E)>F5@P''%V.I
M?G):Z Q1H ]9"8RI($\PW0>DM['?^2,'Q9TZAP51\?MA.;E,*LP0"/R7H%P
MCGY(#G'+:Q.#W<&!N]D=V>?\XYP!]AP>O-!UAT@#_U2I\OP_4=37();W%>F#
MVQ-@='OZ6S&^\)E=B*4+!=_2&/E?H_B+A2WFW%*D_64B9[^$ OR'25"W#^\S
MG@!>X;O3D*T3_^Y_\!ZQ:C+_YQJG*X^4%)K^8;-_ZPBUB@G^$U/\ZW]'A@UL
M9"R BBO^9!3C>NB\O[?M&BD^(??_]QO/E9^ :Y0[7WVW7)E_ M83\)WWU73?
MD?_A<?H3H!'_%T^VF__)E-+]G;<'[[M&!9_19N*_B!?[I?\_Z,?SJ\'_:H&
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MXJ?K;?&5982-C@#- PFJ9: 09AM&A,+F?58Z1^"&3W$V_^/YPB84 0K2%*D
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MT5%J_ZC<*I??Z*,\A;IB2[S0N?3E?81+ZAP9)7=+VBV+^:=<:=\5]>^^$O2
M K $LTJW5#*RS[PK33[SM'R@M@"RB#TT>V/(*)L#_1AK5;_SK[%SYU'#+T*K
MUE["X5PF%8[BRUOJO@])GO?/JV/0;6U\3MU"TPIOO=8D%=&\)E<-P03*R'>1
M=;61-<RJH)[T914Z\I /4IC.3U ]Y.TP4'ET3PLL.# QI&#IUM^D"E$_O:U]
MQ+9JE92P22VL^3M#N]8&IP6S)NKX4!L3+Q&YS<G3E@(L0:5!MVX!.Y)&:YYE
M/B-$)7M*MT@]C;C]G3,_D8[N[XA/"M'</TMTLXNOM#!5_EA\T@8_2'?LF:%)
M^R/4.Z+2?.QTC;?ZOA6Y:%^^U?-$W8M"%='$;I<T)=&Z('C7D54G:M-H&7?/
M!#VQ"G&@ZRCZ+=1\LU?1>2UW]<,YG/M)!JVL]Z,(=)DFRHU_LN> W99'QW%<
M*+OII#7RWO/"+DPW0\C83T9S2Z+=0K[Y1M:V0I N?PD6P8RKEX2+3P6VG-GX
M(Q(ID<)\L9BW<%QR.@?.3=]<9AORFZHHC A*D+(T6LWDGSR#GO[=I7/OR!DS
M%64IQ=+#MRG3>8*QZ#9>;^YL62R2R.5_]6HT/EXAUGA'KG32+AE/UJ\P6=EJ
M9IY7I%MG_I9,S25,OY1;1<V6/U%M^)3VD3( 9$]V5O L[=#&C[,VEBA$-L!\
M$T*6L*E@<N#ZH=Y'.LM,C[,7+EBQT]A(U/JUA=WTGT^6G5IE4,L"ET_$#3;C
MPIYHBDD<W%SF8"#)6:F0QW%FX8/&3_^1H/<*>OYZ">DIQ,6WH._SH#W;<1K
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MIU)9M8'+(9V$B%'T7XD>CHU.Q^XW.'\SX^%^UMI#H(<#X- 0/>,$\GD4UJZ
M0 CSF#0..-;LY X5(1P+_O%;6770\V0SAE^]QNRT$!HS,6?:6W6"G"'0-@54
M'K2;GNDHL=LL;+*E@Z$1RK+TBUCF4-C)P.-#2"E.=%^@0P1TJUSK.VE\T[)H
M2QI&S?I 1Q47&H:P-Q<J*JHX "M.^ KT DAM=CV.>\PZ/RWU%"+M.ISOEN,O
M-2<E[J'3-EN8_958,1-(87_Y:(HGL+5Q'6408\\=7](B]E/1;ODMFSPBZ( J
M2VLSY<$EC&/%4)#\A-\L#I./!$3A;'X68V".5J&]"R(0;/LGAD61B>.\HG1)
MZN#5'%_P J#Z@":SN5-G9/:M7*VNVO8W)^TR>$PU2PY7Q<5<Y"/]-('(#@$/
MK('+^^&F/QA*[H>'7.O?C!8IA%FU><YI+\CW%A<?HBDX"\W-)OI1()5?C8:%
MB8B3)URJ?A$W_?5JNT QM?L=*7BGA%2>#4I8P!0GSM^U'G-'E+3DK1%FLZL.
MYP&@(\-'!P/7[:]"&7!&P_L@<FRP?>1WFA?[[$O-G\A)*FO]P'[!AP>VF[J9
MX+*QX<8*,MR)]S 9$4G<SSI'&0($V2/QQ#P]TZJY,[\<I<U*HYU9ZDD5FQI)
M*'>NO2^7*?^X'Y/3ZIQKS)?CJ:M'@?+P+?S:M .'#%+,[6FH1\44J.!',-^1
M>F<Z!U117O2O. >SZ9_>,YIK+@6JYYT"H_*AV8G(*&U1[]&0KL+))-M)<H?A
M5^P% Y.(ZA?3^=?\]2 79L4R##!D2)@UPS.(,#L(9<B ,9R7/GPWIW(D-82U
M7Y.!3!(Q@@;LKU#I08,W18-XAT; VF2-!S/8I45'$[D@0!CW&/=Z\MSZ+6%P
MCU$)^3^E*"49!&IT#;2_ +[<QV;BVK'AR<@TS=Q.O+M#]1-529RN+H-*$0Z+
MJ.8WE<6M\+X?+JO61K ;O@;&?L;?I"_P49+W^/,IL6C588<HJ[M$5F\?)[]@
M.YF+)H'3T((S$=AH9<0"3"L!V16#&>3D=:JFRV6JCY*<5&83OKTS_K?=S**Y
M@EI_R3'5GV:OL6<MI6_LN"-3H.V\/%8A>N$:UJ*:F=^L4F<W>%&"OQ]_?.\(
MJK(:E35U^O)1!%TK3K$[%[&SUQ2WA4 R$B_CZAV?>B Z<IQ!2H*8^-)3RJ)K
M%!9V#J1/23<T_2/2+,II9=D*DTUZ46F(JP/^#\TD.[M3.Z(%D@&<_84MV0QK
MZ^.V'Y]UB(BQ0?-VOWH9F37N8 JR\'WE,N7<)=R/&ARQ\N4L:6#N3$^NTAH%
MCJRN<D?&O C#>;RJWS--(*(3<.B^40$B8F,A @"*1N<3MW<C21)50)@4)2E8
MW1%3_9&&EVSQ%+F!YHN*).0+@@DC-16?G=8)^072F<UR$G$SCGJ991C.7S/%
M#5W"+[H(UB=(=F+&(E(1S.I2SJV.*NG-5CCW=0OPO+9'9")@;V:L&J"/!1+@
M2-)2V*MJBY>?)&N*VX%N# X=J/%"_0O4"=<1@N@H H'^3*=V8&T,^54F#/BJ
M=L^J)AFZ5%#*U*/%FLIR&DNSL<JW.F;V69KQ=EK]6@8XT4@R?+',ROT 5T2B
M<)$A?(>X_E-%HVUGZ51!2Y@6_@ =;R$\/-K@")FI@(56GLD!A%R)+X>,[Y@$
M2J"QXZ+E_0WV8IYZ,CJ;"L^M;LK-[.J1H>)EH,/+_H*I$Y?^KB#)&!]%Z@U1
MT1LK\L:!K[MSS',821U]:3)!\@W"T@Q6^&7OK!Q+YU9J:X]; V<]$QB*Y,(/
M57ZC'3AJD&)&$\WQ[*7KRCNC3BW)RM)BJ:=_9'*!T"RZ_% EKP$(Y1,QWX;N
MN1G-)7DQAR:5N: 8>Q,2AC.SF"0K B#=VG;O\61752QA&KB4))\%?0XI(QG"
M-(SF"D^,<M6V5FXQ;'<4E^_?8[2UA+BF[D"/.8AP]M1O2A*_<)LH0'8;+HR$
MF++D8L3*WBX)'9BZ6&*L6'_ TB ,9JQO(TQV5,]# 2<>ZZ$MB>S@R>R11X)R
MT'M4B0L"0J'IA!6L4J *"6F\_%"U8/JBRG_K<$Q!2)+#<1]"G\JI4.!"2T;!
MF@:CT<!'CGB#V1*HA<IJP8"KE9T"G/1LN\(^KV4].V= %_)$KG+U.TI"\8*X
MO2<D)!PJCCU/(8M\@E@$5(S;R.0++$OX?F-EUMW%*J\LW]FC3 N4CMZN4%!5
M+T=3B^(2IXW#&.E@-#^0%BB)5S0R(IXI\4G6ARS9-PU##]\XLZ<(5=2#)6S*
M6J8EJ]"WNN-4Y6@"H1+( #T]/&NC"??*3!LF(']JN!&?>GY-*MZPJG8=OX5U
ME[%^I.6!3;T?*;J6R)V<\',[9), C59C7_._LJR+V1LT9I4#<S.AN8E)SM<N
MSMM15]=>B\=S$S[,FK.A75HM:V"P<8'H&0(3I10@';1NLE7TYDAN#CEJ&=?M
M^O$ #T>\&==BV,7PHMZ9\!<V'<S,B5";;7I*_;?&"?-S0&C<S)PG_(X(HU["
MIHY@*5Y4+RP?XIW/__"[8G>^4;W&&;.V%@! W?F%CDP<M>Z^0$K^NT\\B4@
M$#SD2L!FUAO$R'(Z/>J2$TAF*F>5,R^&'),\2\Z>TQ\JAIH]'6G!W*5@R80,
MBB\7&ENU??:X_"T^2OHS  MH_TA6BL65R+O\Y3OOI/5[_V5$,JP7@"5V/DXB
MZI_5;O&]IY/WI3V0Q+II=&:;.FAP T0Y#H*GJ1SD_RXXA8)9?@-L18-88"I#
M_'TZ;[)VOOZ>N 7.3D*R-S6_8;(#K3=F8:?280$U>"CB).:I+!JB6X22FM;Y
M$\ ^Y]2!P!\-P&_DY! L5?T!AM+%CO+320[,$()$6EIF.72(*J)J8KX!F,8
M\)^/@07DO^[<U(S$*J/\5.>IKIG>$#1=<_"-A92"J2-86%V (X?#O((FA"5[
MQI!5S@:!@XB$ "\S!2.44),[A B ^*,VCLOQ?1XVIV?@#$1'3\TF!0\636N*
MSJJ@F#Q[:*%"*6_3]W[* 1!<7K>D#$;O3M*">/ZX5YL51]&FE&8LRR<RYE?2
M.>,)F"_WH4]BR9*<A[2_]8'8"Q<X,X)G<]C!TP[035V(+J;HF:2JOZ<X J3D
M/YEAEL2+2Z2E 3-#Q%^9 J!#Q/^3']3W!>H )( !#H#2_]__W!ST+W*+=?NA
MZ5'K7VXSIP['YG3%J_[I-ZK7]R98S;+@M&V>C WY87K\E+<Y(S>TP( XS<V$
M=H)PQ:;:.03%L)G157^H;V.KJS9KWO-@&Z$6I#_I[KT ]C&OK+"UI8T:R,Z5
M$3$5;P;;_VHNU$8O=-'@S>#,7W;>$7%.$BC>ZS)_1<<F%\Q-P1$-AXA8$P@U
MH-GG3(N27<!DZR-[)=!P\0%O&$^:Y"<J =)5(U[:]S@D,]4],,G$=/VQ=2G*
M38D!E*)"!%=$MLTM5LL[0CX4Z;*3'5NL8FK/L5(L%X)RX_GJOQX4B#@274A
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M)S2%ZV(O1'((UH9I%.08:AMZ AIZ2B57WL@YV.1\YFU$E-5)LU$4+IPL,"G
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M("H,1EQ0:2L;*]ETM(1GE?2K+7&V=+Q95+V@%2)%G-"R'8>YZ+_F+L3]D$^
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MO3\6>D>(%DE@2*JCT\K+(T<1O$$FX$HG$*#/-S@/@$'J-?\7M!V:&+Z:H1]
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MD4ZE7 ?:ETMJN2>*W5B.7M] 7T99]:="QK<=YGSATU^V%18A45Z%^'1(ZW*
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M^C$P0$W-&9I9^<]<<>'>&[<R:/9^=2/K%/LG''=%W]EI=W5X7+1CS>R]7<;
M[\-I%Q*[%E^_%+( 'OM_CU)F3ED;^NX>'@DFYS<4WD('ASWA5UXERQO=N)D_
M[ZM&_I-1W\C?+5X^R:_?.- T:Z?(+!A[D_#O!:"3I0OGB>WE-?.*'1X^O?X[
MO'ZYN'Z[?AE6=N_K)^C:Y$Y%,I/RMXO3?OQ5ID%90C6M][B\RB=BXJ*6 WP[
ME948M<5GPOR/^X=>81.;Y#RQY[];?/^OYKXZ**[OV?/B&C1!PN 0 @$"(0GN
M), @ X.[0W &@KL$"3YX< M.@@\6-+@%"VZ#N[L\OF_?;U]M[5;MVZKWQU;_
M=\^M[KZGNS^?<^N>OF?.YX/3F4G+53Z+\A($J61N1P$:L5E8T%!S.QEN[V,!
MT;X.\8I4/UU9%(V*L5+,?@ .4T\\80<%Y7:TQT]2(TQ]U/Y6S9D$FFX@,QQ%
ML-*%=7')QWVK[]''_O(27F$.[D+VRQL$36YE#P);][W\V\8FNLLL_KBDOOKD
M8[]Z^]+<CI8VU&91Z%[M;Y,?B[_IR=R2>QI*W/3V2GHY#58(V=FR2#W"M^>]
MQ=\K#;W+C(ZI#-_9GDAA78^QX?J9Y27/D_LF-OS!CGOQ*A'&X_(F7RTRB.^?
MX0Z5B3NWL9KWRU@;)V4?I!QOJ;H1^2[SR5";YC+EEPWE(#/GNRZ5O+/I+VF%
MUQ_@,PYJ!P)<N@)+X+^_\F)D%KFVS3_[9>VC&*\SR>S.&NEDH3,9%8/C@^P.
MBI1R<N"XX40X[)I)3%AE&<A&_XAPGV':0!PV<K-V;%FL0C-U11D*W/Z@&/=N
M1T%#9O%X^60@+YPKTC04%20Y#FY7:X(^"8_@;D:G2GSQ>U5.7SNOKR4 &FNG
MM<H"NH$XI.7EF<;M:FZS#$0U7>#P#V5SH$CQ7I<.-Z#A^X'>!$QTYM2P@G'$
M<9GZGFZXU3-A9Q",#KU62D& S.>JJB+NM\HY[S1%6W.C4)B9KB)(/CLNNC5M
MM*Y*'B/SU#WM+Y3O?T><$3!R'0NQ3:<BP'SG5B.7]UMVA.RP<9LL[M[5* <^
MD7,^G"X,>:AD8IJT19B+CQA:' Z@[NO/\!J119LP*RO*RN.*%[L[G^45O<;A
M!7)9UN\R3;/HWV/DGS2@3G43:;%,^";IVAC+H5%W6^A"#FX\\QK&;IPP-E_R
MC[9@1_KQ\PIWK#I@"G]5%L(_=!/*N-Y%U10(_TDDD]@4+I+?.I&1M<,#QK3X
M636_S'70MHT_V,9',Z2UX0_GM [%OS)DZ\<"3(F[^!CI3%1ISX@7[#,/4R]N
MH\-O"S<0+2ST4Q9HX$>LP ?IN+@-8QUG++-@,:9I21:NNH,BOJ Z**9$_27E
MGR&0N)())I(Y\Y-0+IC3R^0Z,>K;-WNL<,KNJD070G[R=YV")%R^#%6GT@W<
M<X%M/2-DZ<C>RR>2>@=S>XPMC,YH42M+BD$D-H,+:#\]UI<"(%6)(5XPISD6
M1N1-."40Y=;;2F>"I2!H<*89WH.YU $CF?!TFE:4W.<4/^B)[OK]6'\!3R%5
MM;[H0/9G7:8ETL";</1#X$(:G6!9#!!(-[IJ;,-8:T2HWB@0#]![488'4&"R
M\U77B"?XIA7.NL"8,KP+$/ZBOS:.F> >5;T VC@?[K8J+J>@%)XXYR2(3O\
M]46([Y5#K[M@>(H/;Z(GS4;<*P<"7Q;V?:P-X4[!BZW;,.I[1EP@-E+)XH!L
MX,"L-SPIV8'!J<#^2AES]BOU4HLK<7[QC)E!$3/J7#4J^&N/VIC!D[,O:!.C
M[.5I"8!$P@$L+<),ZY4X.[B7  <1#*#:\$8XU-;TX<A0A8&?ZO7(HE4OP?^R
MX:_&C!XDM-\OOS12/XM7B8C=,^OTC/ F- [=;J.+@IA$<WQ +T+&<B3_VL%<
M/=36+W;-]0ZM""@<4KUNY:T*8XP)\PPBB7E)9HC""GAJZ,N 3  J.B), *O'
M%4V,3GN::/)T J]^WAPC,"^T#]U-;$TM)34(FY9KNBG-9[ND .0_IZ79/>D@
M^M'A[\;63=%,& W6QI'5?Y#%M8;^)?*$9>_XDJ:;?OMT[SVDY_KX/W M^DI-
M_]*BKL* < ?9\KRLO]-J :%0] C#&1Y;&^2/-]'P//+?1F9?P\$9H7'5_9P%
M1(-Z,7/YD0Z<>J[/"%5V4O\=8GONMW>:HAZ %+VCM0"GMHWG7F<TC7N*X[-!
MM)!V*V%[AY,;27.3NOWRQFM1?[U?+#&"&TC6F7%>QD/?+0^/]178MR<I4W'A
MY4VP5B$?J8@+4;0N@(6.:NSK(]A3N2V&]#VFK=OP(S&=5C9 O B$PX;M(+2Y
MH.W#C>3+V18!EQ1DZP-@\#H=?;"C[46@N0O(4TM?*,WBDH1 I.T<B?7Q%#GY
M2V/P$4E][+^7":@^LM@#0#>=.=JWL76/<9^[L0C]81WB?Q5-AE3>20WE>TO%
M<ZJ7,"IT3R9+8T#[IV?B#+:X@U2IZ6@]0NZT$J4@3)'K5#RBQ\7-45A'D7 L
MGT5:SKG4L6B]N1N_DB^G&FO'2,@CXXL23:=%/S*I@PC-;UCFC]W5"^L3K.L+
ME9K[3+2=[NOAQQB(AMH,B7;]0[9A&Z<N#P#/2.S&YC^&+GP\5!^7%?^0[>+0
M3OF=OGD?Y<&9EZ<%H09FH&>(_W*GQX%%N1WYHX*%R[L)C1;IPU=G:28[QW]^
MN=)D?KE4J6G?,SDYJ7O^J"3JE(J' NMQ=B%,)M'&[B?#=%&K)@*^<M$*6RMQ
MA8?OCUH(MR1Y'+HO@@>Z8\_+FQ2E._%8_&>QA$ZBYOS65K"Z1[+9EC,/2PZ]
M;O.$A9T<CC*3;8:C]\N;9]'OS2R$7+H\"5;1_CU8H@Q"#T ^-*5N4YOT1;@U
MV>06'G>YP)4V$8$$-&\ZB[A+F.$K:B7A'_Z)*RMA1\*N#RP\@W#WMC$6E"O*
MTD'XLF7.,=%L?C6YTFRX>S4?5& D),TRB5I"+2:)K%].6PSZS0;N+VRM?;:U
MO?X_]W3\'P38Y9Z[ASM"MH0R?_R_+E8[,BD?@)<?-I9-?@M/&\WJ^-KK1JK7
M%M@4#XY;36A]SF>0X[5;>;.CG\'*"7I?>LJJB84K:0B\V[@6S/XX7U4 XG/F
MP*4/?%J**OJY9=E,\&Z=)7K\+OR<R//C>[/*GDY'5W22FF7#RA;3+HR&UJR;
M 5=9]BT11U&.X,U:U=BJ6G44I2UR;ST%>(: 4BE!-8H?//ZF=Q60[4Z6KK34
MC9 W?T+G[Y(Q":1_./$;/AM[ *8O? 'CK#WF43QX[N=G_#B;KO0GS*%#$^ZB
M'%$;IUEW767$IXX8TYHX:+12L*C85C1*1M"&0'MSD@PT1"<TZRGTIM=1G!.R
M>S#8TSC3L%CX-@^]2$<N&.SGTQ=$1JO:B"&&ODG%EMFBU_"59G](2[:');6]
M8F+8)L"-SI!(?(-OZWAXL]UBC_OY ^#)TG-3?QDSTUNP_8QVL$;K_J0I78"Z
MHPW!@ *3/)ZR"^6[B9Q>DQ;"JZV(NA2*C8J=HRTE$6L3#KJA>XJR V.F.Z1J
MI3K#F'6S.J3N*;H.;K=OJ4&Q7M^7O(-2B_$2:&1=V?!*^6$.:0,1#P >&S*N
MI[<[0VPUC>9RM?@^9'&/6^&XI_L6L30PR/V65FS*_J(V1X8RSH=6]<H_Q010
M];Z^^W-P :I6E$6_T=+8Q081I 7VMAY?7SW?*9G^G"\%DM=D L-'\(=0,+L$
MTW<,"E6Y7M=P6SHZ\Y^J4)SXOQ/UZ?[L=(],#*&S(-?3]9Q>C<A#[J MB0,.
M6--!_#?R8H;$3:G6=VGZ^YB&>.-W$D:-]K;,66!$\ -0F5_%W+\NITJ8V/'9
M_2YXCV9J?:\D F11)]NVU^T4&T7P]HY<2N3%R^&#_!-,[P7-*/&U[S^VB<E>
MS4A2RR=5W4&/LL;-]3,?'9#&LN# S^B8F>GRNKKF$ZZ*<"?AXJ/?;<"CJ2+^
MYFFY;#\]Y>3:).ZZ38K?HS^VHL/0>:>2/QVY^#[V,0 AOHCYW*/U_9(8'\"S
MGNZ<B8" R_%CP6:E9D8=B>@DU@.PT^TIU5JP34Q98DF][158L9F6]HD%G-FB
MTY",;K,6+^UCC]NMD8(BVPH@:0E_H/L7;#;83AJ3NPBV?7M#)5#/9WE(>H8=
M9K:G/AZ+?W(F?D0P0?OHM-"YW4C/P9C+)!>$L@M:SL_DRD?)M&IYS1ERMT[G
M:C>U3.K';BSC X.,OZ"X%RX\>7%X+/ 2,^W4*KK%I($Z>'#&X/M>R2JR_IJR
ME04KXOP$2^-4CW^EE*+A,?]O]V*3W,8G1,62[3P]%9,86^[[/C'8)S?B!A[_
MM?LZ%K\[D=)].:^.?M&K47]F9@"*\%-\UP0QF8S@_LJ[QFQ4%V8[F@/9#3,A
M%9!M=B#,RB/X6:0CCO.*L=H4]5SXV>UWNA!_4@/Y6]3+;D23WLC!U_QNRS\<
M&K96 V!/_-%7*FS,JSU1,PT9\AD!N*I.?L+/X\NA.<0_M&=K>7ZN,%.7(9NP
M5>,:<G#BZ?*X$*0,V R_Q/>&*V7.+<@)<=@Z!?LZQ?" P/JPJ*=ERU5+W"@
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MS-J-LPZJIO[H-%;]6D8\K;Q8\$$DRH/UX,UAJ!@X'UN)'0H.J#,DIV,67):
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MUP[<SVS*Q:B$H_NO=_:L4MF-^I'D8<G@*$/)FY8 @UH\^/X5-_U"1OK"/(0
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M%YO:T'SU?Z&C[_]W\7V8_C=02P,$%     @ \(.65VZA KSW.P  OX@  !$
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M+<L_\?7=8:A3OJXW[ KRR4\VH2<4@D(@E< H\*_ZT+77=?]9'R?7/\Z*ITF
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MOUH%*Y_7>&[D'-S<IEA=6C'+OMHWH:@T+#20$,2CT2"T,\8G\>;!"PS]9V5
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MCTI-EK#Z^2*M(OUH.\;9I=6 CZ=H"@]RF53PC%X:%.SQO:G0/M>'43.IC0J
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M091"Y>2]NTK6P#RR_LE[();*Y^AM7(S[R\6(2X4<%!(6,U_X^?Q+-6D:<BV
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M@XT%.@OA,C\YYDD$KLP7L 3\'U*<1O!<9_"](*OU6\3=:%E=2ANDT <V[-,
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MQD:/U2/Q8\"=;_SHY;MN+16-&/=B&]VD!US=;':BIN=.NMER1/+YY6=]LF,
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MZ0]BEL(_V5]#V-J)Z\@I_(%WTI)D_J-C'AX>/!Z"/'"$/2^_F)@8+Y\ KX
M\$0#B+P%0UEY F%(EN].?OB1 R-M$)"SUU.83MM6UG WE"0S,S[3+_0=R.47
MH+]D\$1PDD%!WM\9G73\]T8_TOXO1NKJ_[49%/I;2R1*WAWU7ULB3[_VY-4!
M(^%N"!NPO#L8AF+YO2L=\+]T^/>N3M1_Z\C6YJ<7%S>$\]GHV-KP@IW!T!-L
MY(DG_M_V!06Q^Q?\4\F_)@_L"?D7LU/)OYJY_'A%[%_&^(?XNP.I/SU<.QE^
M<2T$W-;-!HR04H?8(.!(N!VJM93)$(ZP/2EG?K%KO'_1^<7V9*3%91%@*Q0<
MH0>'._^;^=_5?N<!+'>R29W.'B"_P,G4T>,'B?,)B//S<?&!Q 7Y?G'R7?-O
M/M3AMA"[6[_QP2\L+B3ZJX]?-/_NXV2ZVUJAK/Y;7G[5_:L?=75Q.;B-VVEU
M*,M)?5],;.$V$-L_!TE<5%C8"B3$9PWD$Q,3!0K;"0D#1>U @D !?A$!81$A
M01 ?O^T9T%^=_0-(&89$6<%.W^B0.F'P0$Y 1$$VUG9B(J) 6T%! 2"?G9 8
MT$J4CP\H:,,O !85X .+VEC]</V+^3]<?W_?P\KY%W@WMQ/_"@(@63DQ$6&@
M@!@?""@D**0 %)61%P(*RLL)R8D(@D3X^(1^^/^-CW_@*$&0)W5Q2^HO17VV
MN.F"7?_*_2%PAIPM=BY6".39FR:2S#\F,?,_#$YMSI85<2N;TV52"FGE#C[)
M[5]X_VX$^6>"A<1$1:V%A?F!5H(VHD A42%^H#6?G=W)I4!(@%_03L#&5ECD
MAW_([Q+\=PP/!S#LG_4F\+/R?]'Z=R>GL\[#"@&6MC_)L]3W*]6?[XT*@'@$
MF:X:0F"V< \DQP^7?[7Y=]\V#E8P>["M%.\/PQ^,?XP.[_?A^?_BL-F("@J!
M^06L@2!A:S!06$C("BC*=S* HD+"(F)BM@+"0E9"_PO#]N<R<3YL)T-D X>=
MOO;T'PS="8[5R8T7&(&4LD/ H4Q6+B[.$!NK4RM>=YCM'Q>UGTLI$PK.!(%:
MV8-YP2Y(NQ\HOSCYO]A96S "\I]4Z2]1_LP3T__?.OT_GIC_O0O6^<3\&_>O
M5\<?5]Q_7DU_W))\KTV%T^KZ[PWVM;-;Z/_)4OHW\]]YM_T_NKOXA^WO7,/_
M1S<P_^KCGSG_);6_2FUMQ&V^W_3^9_<V4F?_8^,_&?K?(IWBV\$14"N4U*]+
MQ9_<7U1/GTA.;]9.>GBVYDCQ7^/]!^_O^D:G=>/L=B83$^8[(5[^T_T?IK^*
M_VYJ_%^;&O\7IG^*]&$0E)3 'R9_8_]B=?K8)'[VPJRNBY4-6$H8!!($7>/]
M._OO%EH03["SD1SD9-21IW$("?PP^KODMY;&?\H%A05^M33^K>6?CP9G,9T\
MI("E3JKP=^P?S_^\?_L X/NG"[Q_?+P@A7]2GC\^V_C=6O2_3^<@YR#G(.<@
MYR#G(.<@YR#G(.<@YR#G(.<@YR#G(.<@YR#G(.<@YR#G(.<@YR#G(.<@YR#G
M(.<@YR#G(.<@YR#G(.<@YR#G(.<@YR#G(.<@YR#G(.<@YR#G(.<@_\L@^'_^
M6@ 89BO)[,%\7>IX"B +0/L?TJF3_ZD/M+.?FT9S1"O 0"/[\7/3[8!+ #0
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MYW-Y8L7<@NU :X:@/'1T8[^G0WK@/*Q&F2WK#%6=KFK'CQ0']AZ)G_!QGMW
MABUE]RWKNTXU%L!X<N+<2^",F\MN @&&]Q13"T4*79RN/AYG$5Z-[-8I[[G,
MAA="]FC#L>%MFTJVVPWD<P.5K"MCH.U GYC+O$X/C065M^Z*5IM&UQJ:I*,<
M*RHIJ:I2,WQ'C7D0[_4XR2]CUJ80[U7FF?/;M(=LW6NU:3)Y<A]ST!\+&8V\
M*6WX1"5#%@-'9",@G;MMU. QAJ8*%:U8#_Y7L(BJU954^7IUWU</KY.GR^3W
MZ8W247"")&%%Q9L5[TT'&5S"E<FWS=_8U2?*)ULK%,KZM@9IFF&I7R#&F[P[
MS2M&FSU]K5L[=>EBE%*$6S?5LF?+T[U06)%"KLJT0OO73:M!$R==V[?Z;%K6
M]:8:CY$7K>_F\[-3I#O$> DRJD5GDW&:+M:3JU@00M)?D_.3?HH3ZZ_K9\-&
M2EM>&7)#"Q'(H'=K6BJ*YO)BF;W' H. EBC--[>!QEW8)<JY!IESLO8$5JYO
MLLC"^"G?TOF_JJ)UX##KR43)W(\MUE@\!A@O=K-<$CL(\NN*$E!)YKVWGV5"
M '1[<BT5",?C4E5S[2K1@GQ:R9'7AA3(]^*162<^:%W\$&?'H$8A\\Z-PZ3T
MENB3F/8.G)QLGZ0VA?N!E<,AW-EY%[>@"UE97YTD[-X!8X:F9O:!6:EY!H4*
MV3>*ZTSO#G:!]L+*<>-"EQTX[5T,DA*MU90KLWNG:UE-C2^:3E&B:=M,B>,)
M$EM/9UUL-W#$MQT::+48A F;F\8T&L155O(Z/2/G KV@?"SAGM4"K>4A-"0W
M>[\)?/'(KIXM9[K,9)#-JD^IA/3FR)M"=/!K:F9KRA*SC>F^)HV,'/VEM\'E
M1<HYNNP*Q/!WGO'O%(7[-8C#QF&TFH5LS2B#Q?Q2$0RR(^2;0R_F4#UA8&'H
MD-\V4LTP-ECK00CO;;IF1YT%BARY=17"9V:Z+TTD);[8D3V2=& M\ZS+[O!C
MY:5<O)T<2\_KMC5L0I'=HS$D;%EZA<LK2>N O8:S>*QIJJ!O.((6LN8LH8_[
MKC5J/0&;U8;\LJ91>)#//AL'Y?(U!(-H-:WUDX,,B@"#AY N&UT.35EWH'YA
MH?=SA#Q;A)KY:-E6?QMH&CQ4<S/T9HL#2(]%5A=77DT?5S64/&;8<GDI_(.P
M\_0MA%W#(P[ZX!371M;-1OER&>0S*U-1ZH>#.^#GH704>8+-LVN0R8(&C 'S
M:+ %^;XPE_J[QCM4C%(J9L^=Y",$J>@N\XA*W?;]%I7L9R&FNC*L<)^MA+2N
M;4:0IZ1JV6"+OF29):)LI(;ZXCOU2B\R%:\LML>!B[S"*F\Z Q(UQ@)RBQ?L
M%1+N^ZAQM%/(A0CG=^L9N@\_O38:M!.CCD/SRN RN.F1)U*GXA/+1[N,+.>;
MCZP@,EW(1Y@%+-W^W<MT_#N1S!*C&$X\JDV"ACP4 >#I$?W_SIW(+P>MT?5J
MX/JV T]'O%>? 1.(YY!R'#K]P8&2!%S4!K]F^C"%AU7+)E@UA#NGMU]>9:3.
M2=(QT?(&%YY1=7J#=KH)-VS9[TN9>/A$[MH!^Z7IE@/)&Y>"&O,'O.(^=]8T
M,;S9K_CR'//#\PT^$FCV5ZM->^[;'$Z^TE*)+VK =0:^!KW<"G3*,&[<D0]+
MN]=/K=\+?)NY'B)65S,>$&[SF7I 0%.4"2W<=EGS0U#ULZ,,SV]H58E?!_+H
M(O&)XGNY31ZH+I./-H)O&>^6/9.WF#YBI#1-,JD@IL\V36O8Z9P.R/7 :WE=
M3!G_R%!GD;F%2%B"G!1C-B0VOSTP=S>/]KX5Q;V+V9,7)Z<\FUB(YUP>!B_L
MNSOCM@I[YZ8[O/;#N?7!VC4,A>-Q(%&&YN^!H<CV@4\XBC/ND4C\6-4V-*M^
MS&H7*"C>VZB6@$$TS'*U(O0AO'&%GUXP[0D^SMA!77FPY3LLU"YZ8#O=>HUH
M)!__C2!G^41^%VL\9SFY1$"BT5>VS W:/CX$7GE)N]8]O'INIXDC6(Y1E'>5
M8QQV4?S+IU.:8NQRCG0C'ZH2Y#/=Z"C'4Q0(.F'TN1=@->;7IK%NA, OCY )
MO \B(B](S*62$)]ZMR-48@'.[WL4FJ;?B ,52^0$%6TH)%SG>Q_!\TV?TVJO
MEF(]*+.XFFF<L?;K%E;/,D!243J"XC"(F($OWR47G5V\%>\^T4&U]4@E0OJQ
MIJ']+<QZ#WZM[ 2+%V8:3M'S]B.%UHY=,Q+7FY>JNXI#U9G-^;X!G]A(;I@
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MLE$D$;U?>??7M9<O:,)2P.*)/4#I#N.]8X#KV,';3O?!&$-5CM;>>L[*4O:
M32%\D%V$BU65"8G^*]+HM2C6I0C*O#U(9\"6\[LA9N]^'JL\SB/'Q<B/=!OS
M;]<?O7(#<KI&T^RZ4L1C1R22]WZH-WUD.YFB];Z1N,=-AI&Q0'P^6IY8HZE-
MW:XL;R&-2X<)QL[2BMFD5!0>6,A=L931)[,;R,F $=CQY!-%P<=;Q(P+?$7*
MS9]-!%P6=%UR3:J[:JMP.K"G1LVKE!5'W6K>>-5,78@I4+?(F'/B,<'(;4._
MA-D22_D9-XHTRN!!M9RBS@5*/JV/=!H!&X+)K%74&7U'O5HBA1_2#2,2^ZM)
MN)YQ::G69_0XU5O$L54^OAIW;]1AD\.ADO@"9U6[0/DH+S&A0\S%/'&EJQAC
M;3KM+*+*B6'(];B1:-5&>9,=%]E>>3-Z4T9;CS8X9YR*A)1\D!O5?KZ9M[>S
M3Y^ P2H/IW/'2'7I8<-+%,\UD7:%._4=T2\1E)J%V537]:J$#KDU$A]274C3
MJ\^(+]!;F^Z7$Q/^XN)VE:CE1;^XK9%>RAW7-0\V(L>4;]4PR ?@P7J_^VU#
MT]2\EZ6BCR7W_+H"+KLLT?&D%W6O>74%2<7WR2NH-4%NY4-*#QHUP5'DVV8C
MCJ_-L-\YJ X&"LH)'NBM;ZK>,F&?6:HJZ=J<RA2'E#M"QX9E8F=SFHJ4P^_A
M8KE:ED[=[G5N]\O)U=;Z7##\  W/6)F56H,1Z>7EN*JVMHU6R3<Y0IO/^:6:
M6B; $Y@MO K2-O*;O"V245=P\8-NG'R14F\A75GRUX)PGV0^'7Q]W R_8+!<
MN\S=88GMIX1%!DY*3^OW" H,Y77_@ZOUZ3<,MI+)'V%+,0^?" JP@1G5NS"@
MNC?OYK -8^GT[D*>KQT#;#$)%V49/.]%WGD"]0UCJ"A/0KSAZ\9/5S2Y<?&N
MJF7 YX]W/L2D>]#=)$XC86&]&1"3?IW1Z_51J>?'N89'D<-MPH%H&U^ (S<<
M3((^&XE\P#+?=Y6X_VRY.: <1T"9-2HC>ORF[[6YA;39;="=J\0*HC@7Q<18
MGGK['Y4>WDB:>+;K_8UQ*6U__W9(!A @27GI/C:IJ0,)@VB8I-*E- !;3@((
MQ%I<-M&5'5=0^;@Q]<N-NM+:1\/E%36M[Z;UOGC=#+PG%K^B)X?+I1.B)D\C
MQX'&QLZNO8>OD/(Y[(,&K_/-%M>-.]QOVA?PNH(88,YE-0R>[A)\Q%OH>)>3
M,:(!RYZ\-NDX57,T_C@$:('6+9]#9O?O?[O21NS$C7M3IB_E@X,#?4!YK6-W
M?5[>NZE]V)3DYJ9))G-%:*ZX_OQ<$E0A@KMTMIS4;K[CW5M5&:M'A,5KLR2T
MMR5NX%U^9%W$^)5F5JZ,58EX8[Y1N*W#^OWG^]RL5>AX+C?<9P'DFDUO7F ^
MD$9D304X;D/'JG>$PY[/=\>X5Z4*^^QROH/VB($+$M">.VS)FBQVFMZKQM*F
M&G%^:BWT1EF]0JZ_A337!NBRQI_5PVYL(S/!&[<"$^Q><K+_>"_"K3]@8#1L
MULO@Z2L='@K#=[LR&D^DDPM+(]]YPHXDHK_2RV1DCPI2DF$;6RG=&];6X1&Y
MD:98P/[4KAEC;C [5(*J9]#)5%Q">Z*U+'V*"=$$0S9,C+*NQ!07%3F(/-,L
M-,,463>VN>(JTCE\C?9]<B@GGVQ_X-W51X$YB@E**_?(6>5ZO594<EQV5I[G
MC1"AL'F)2C5-PF@\[KL!VU^O%V9S63Q 2-#H&PT^R::;+T]% A4QVR:UHP=G
M"0P]6J?$\FP:L[N#'0C?M\5%]B4$H;,.WD.RY[:_#=.DJ<+OMF)R$^?/Q;\N
M7(3QT;N6<^*K&#3T6:92B?IZA+2S_E*^R-M:O;30L=!C@/7HB@AXJJ[PD_33
MI<HGX)+PK<=3D+ /W+D:2BTU4:/8E?,S,E'D ],3Z^ZA7&,M$]/H7SEIQ!GJ
M0U@47%/V?=_%=_)PTX5UEEQ<KEX3A._5;$RY<:(67+O,5:Q@S 'VX1P/'NM.
M7K.FY>72J6Y5)KO<=\.=DZZO;K=G)-&]"<44A*%6YV^@-2W)M%LYZ%%H2NBF
MMZH[@G^O-4OMN>E!([(@CJ;*<Y!SI' XP;Y<.(@V/S;X?49F-KFQ]A8A*-/W
M649;]0>V):86:E96R\"7&";=(LYKD1>ERS($(!ZN]A*E'_.X#&L5.[)L9GM,
MS;M'<^HL=_;H:"GQ?21&7TU2=D:$VQN_6>13L2J]HF80?B6A:)5?/(OF_R'F
M+:/B;*(M81(([N[NT+A[<'=M++@V[@1(@KN[NT/0;C0XP=W=W1T"&=[W_OKN
MNM^:N3.SUORJ'T_U4Z?VWN<\YU15EP(&'B:E4GHDZLAW"9+?2]$[N@#QY3DI
MY>I8[2+&V& ]HF#4=5XR9B0"&2W8-DW( P>-P,G9_';YAIU!1,RU7XE)5Y^^
M #8/R;P9_.V>P8@?'2LJ<Q\YA7B:!<NEO[@"C\4A@R3>J*RP"^KS!Z<]CW5?
M:2^^8]10Y,J,19[*F('@-BFI#K&F<0%.&L<7G19/AYW-<0EUH^%(0I1A3T%#
M]0<1_KOX?5KX%@3$3'4*V*\FN<%[%08AA?N)R8TCLGX,5>@ 0N6!\R(ZYB#O
MMFK''?GA#4[_?9.A%3P 90,*XSIH;<W$EF$2/*OKX(7U\5#"0N%S-"HBX!2W
M4:]%UY5R6SG<C-2DJ[S<:=W "),11GL>I9 P&@:S;:ZZ6!,XO][ ?))6N2K
MP>RZ/R&=M[QL+OX8JN^QX:5BV99>/?TES1GTI]'+@I+Q^P]@6!3$60U%U;1A
M<S5[9Z)\3&Q"G#K>54)O>R"*LFL<;:R]G05WU*#-IU*0:-*!ILMTODR%-TE
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M+$GRNA=X]J??:TES3!IVF[%KIODTAIP,&UX70NSC+X1R!4.N?^Q(?9UOSH<
M5[-M@98=<EKN6GB?M+.N%!(X3G!\/?:7EJMN]3&/0SB"I? Z[ *PQ>6:KP;+
M6T>.V[YAIUU#)X<"K3PK^%J094W4Y5R0]J9M/BAJTXZOG5 /=;K=GU&4(HP8
M(Q.N-2>@2E6DHMQ&4O=;"/GM!94Q4= <+T1<ERGV&M!?-"J+1Q.HK]>Q?ZS%
MMIH9'0V]'B+7?O/6"$1>*I9T%RY;/W%6:V]L0SV2 N6[$\P33'&U%>P;LH#U
MVK7]AF=3O9O6$,U_=@ S]$/J099[K6UHGT],"_/-Q=74$&QR-&CM=\ZSMFWA
M[RSW\9*NE@'=^B$-3NDIQXL<3.X*?I9C%/4.9CDM0'N=,^G+-<$0CT8302I.
M&&Y.!RJ*G7/5.#FIUN8>;'U]!AIN&^SD =Y$7/O?UI1KC*H6>E1)<^72S_BD
MPE3VF7FI+@V3+78!# 0-$#CNN<)9ZO/,<G>@5KN[8\G)VH.KEMK()X[)&<PA
M(>#\&PRLYBQ_..2G+7I-G@$_DU.Y]7HT-FEH"-#H8".@8$=O1;^IUGZ[O]6=
M_'>!AGWF52SEF57Q[^M:;I;>7E=&#V JEG/1]+>R<TC<J'309$B20C_&5D]*
M3)F3#MNG9Q_1]  9"I7TB^$>V^EZQO,EA7AG'G;7:O,U_LJ/]VO[A@X6@X@
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MR\QP]?%HCQ'SN11D/-G?8:YRFM+"L>!)QV84C.-1;9K?5=UX#[]7-C2M.RX
MW*KU:,OR.EL^GBPF3N2MMS2>7U'QD-C&P(RGE-:]<T4OR>^5FWSE?YY);E+B
M]",J<15RLV]8.M]:)XI,=FNU<VWVXXKP T32H.2-E[>*-%=K;-N@>I?VU_Q2
M G.Y]9<*Z5H2:1M\"[=@*48Y+NJ]<RK6(@QWH21X4S&#<69FU#7Y[M.A/[SY
M>9,XZV903?._'\C^?QKC*"ER4HW$ 6\JN"@K:+B?$V'$.W":<%L^/MH@JU#5
ME-N.E_C$Y"UXU:VH&LT\JQ]4#'[4.<[!.WP$XT[%GA??ED^O0$[-##A#14Z5
MJ(38@J)P#:RA)*-1@MHMR+MWV[8C"?'4TL)ZVK[)C!Q?8[^(1DG+"4.(K[FO
MEQY-&O)FY5 ,KK#^]#$KLZ*$M;":G9\QP"E^.S8:F?T!L2,SC]H!JX=W_1ZB
MH2(XYY"C)D78T=OI;E-7=K.UWNMM#YW6EK!Y2GB^$X+"#GZYP^C: 8>)BK(2
M[_Z%RB1\RC+74%(B[85\H:]X;;K[OX#4_[M&"L;X)..JD:?E_2MM"1Q>VZT"
M'^W[$S%&'($X395ZQ%W1BW^?QL(:?0S5%OAA1E^44Z8ZCEE29VP(=UAG8\4?
MD[0N=([\4Y=CX[9(KU1A>$Q]=\41R"UPIGX?%CYT0$-IF@VTUGGH6V\]'T%=
M3LN##T;([*\P:.KOV:HQWL"UURQQP(^%U0X!W%6N'2U654A 4VNVJ37>C=M\
M\# 0B2^J7_1=]C:HAAC1*BF8WQXCI6_./4NOS9L*Z\;,M\-EJHU.N0]U;G+D
M]X>J)&<$.F6H'9,NR.LFPW..A.,B%C9%8<B2]R^M3#^H96>0WZ)>*80V,^G9
MGX=JAP*+IBNL9>49DPXUAF0G$"+"&+OX3X4=-U:R8?UN1949.\*L8)\P4DD5
MEJ;^*X=P*Z%5;&^T">HV6%)1.TR"ZM.5]W7Y-0QE1B%YCT]8UQMUO9#Y*?(G
M%PL(%U.QT9@66)U\FR@W?<S2['O?^TL7+[VM)8)E>0\_&8SDT");S4_B07[.
M_LM0HK\0USDMW#HEF"D6ER!+TPL+'>N#<T$R0#:6),+Y/*'2N]>O,[FU'9@3
M)\"TMM90W&3O-UVQ='94MRT  &VE5:P$*TR=T#=II#H#Z#@5.W>$BPHEK7FW
MQ<*Y895-_%]IL&=0^<5IW8@Y*UU&75QNQ9]^#_UV+>,DYAPJ'FL\]V_QRP9O
MA>TUU$;R.WD\/N6SKP-"06HE)\\RZP,2RL?-)38QTH(E>3/ @L:UZ^]..KRX
MS/CQZ(4DUHJR6'![&HI-5EL"A9P*-P>9PH>;'W%MK"O^5V[(1*RYI7=9&?S>
M -2"Q=Q0,)]TX(AV[T>IU'9N/#"DMQO3J3;SMW%USE57I ^QI.DW*++!9R-O
MS+Z,*I)UL2362)M)WE!AR(2JPPYK<@L-^51)HAD*-AQ3KRT6=;I#2*FV"89V
M% R&>."65<R>-ED*&W'7.3;1'J.FV3@H2HLE9FMDE<D'XE)2=+\H1(CCH0ZY
M+/W\[13O"M6O]@U*!9?3,E#;=G:2F?#+LP$HNNM'?_$,J FHM^!10:1OF&HW
M:S>%&RH%[3YPIEA'//X (_W5&L0ERPUB:G;8)C .H)SIXQ)+88S$Y!HNS?3V
M$!ROB]!<'F3-;!_[9GBB=N15#[;HM2Q>'I.Q!AG,@OC!FDY:='+EW&3Z[46&
MY2?RBQD.Y$$$X9RVLZFW:KB(Q7$/EH.2"(UA)3BO:$0*36TV/@M)@K" +E$"
M_<3_?,F#F?0^ +KG66^YO];"$+_9Q7T6XC).)P2+9'(=D6@KY/5]<EY#;;V.
MV43(1"H<EMFEN#_T X;/<($T0TP$;K7=/?^?>>KU,ZB<%->\&*@J"=(8VLJ4
MB\8+HN=#/J-:1"D5>T>%1/4'AY!%J7Z(KX+6*F[UJ,4*??*/54795#%)", :
MO: K#7G?OAUG)$\FDL?6:7X2[BC1J?%3E<(O?='Y4\>!_)^"*=<_V\!UJ8YN
M[IFA#*WIB*\<_A   &RKJ5?I72 $)SG+%QV&/G\?86,'8@=4R539+#8/K#1F
M) U9)[(7FX;W&FS$>!:^M08Y7S<H\-;2?8U8T@!FLDOD3=,G:H3GIA=.'V$?
M)FY+'/:-PC,H$I>0:F8E]4+U?N[6QLRC[#.J2;P/&7=5[]0FGYU;9EP/>?BO
M-U4-^7<'-:O<AF4DVP?E&,**@H/B^(=5PO&[+U9@G*2&CM8+GLNL]3.=Q@="
M"^9P>*>F+\NGR^L71%W.D4KNK8W)PG@XYSTF])L9;5@+EKTY#?M70]RX1H3B
MGFT,'B^3RI/%#0KT1DW@B^V]G"S-+#:0<WZY>?FX@HOIP#J&S8L-->,"5>9$
M.I#6#L1QT/P$]ZDOQ^SLF2MC"R>_M"/OEQZ/A?V:*$UIG^YLR'@%$HO+CH+^
MC0.&0'.%Q=SQCZV^6'@?W&TEDVM(/CF"9\O3)9Q1.V1*Z<5HY6RB3KUV$8_V
M=<YQ]&5NNM0 L>@.#/88<_,Y7>4O8Y&=1*+4)M8!EE!()O]H 8_RE\69-!-A
MUD\AI'+*,*[VS=Z))+I@ ^(*E4.B0!HC/T9?I1+^DW]'0O%^Z" $1'4VRSCB
MP-X"V\Y?9HA=1_DS]GP,@Z4]:"I12&?GK" EYE2]'NM8!.A!2'XG:9,%"JTT
MVG26& G&++;: <:Z$&OR7X(^/1=WD1"D(X-ZP,":? R5AF/'YXBM<%4#28%#
M?==?OU!3M6VY\&FQ+8?-1 HDF#$P+<F:%2@9^V0_B-10MO\R!,RHQ@%HX62A
M ?0"U7'_.2YU(_4W^ !>.G%=3@SHN/2>#</\-6K\V@I@'[74JMZ^-3N).;0F
MA:GE-VT75[)!K@^_Y97%,'XWT#5A(,1S>3WH>ZO6B?E40!?9[-D(RU8]L#ZV
MZG&LMT-E6ZL?\1WSS%&$Y91E%6%@AM(RZBBOK81&P[VJ"A]#-]$&>:'0")E/
M=0Z#=K<['4G3MQB3$!WB.?6(3XD<-P!PH9&_^1"UZP9+^XH8GNX?H?"QIP3L
M'^@L9"((R%9PG)F/'E0-8[RQ?R:=H>S LEEQSE,H5W#YK)@\[]98X[*M]#FC
M)6$&2DE!;O1S5_:#B'-RULQ(CB.Q ):31>J1HS#VBE/37*4P08IA0B.3,L^0
M)C;\"9#&L%:IN-EA17ZFS2#Q*!07LP0'X&DP G&:3K.M&+327P^2"^/FZHAZ
M]6YO@JRZ)M$:WW[H[1K)@]G%7;K5 CI8-G@?B55P&V++2X0W&)969&KE+5!3
M:-//^<B'(!.$8<25*2 I2GQ'EV+0E9]$@(^L9%[2X;>>3]&]'&8<I3=P)H^\
M25/9[+6&%FT1!<']\B6R&_CZO5?F^\Z RD:1M_?=\Z7VUQNP\J*2QN:@-2F1
MZHK*R!6178B@Z\LT'UW\-AM<>M]%3(COK4I _L78I5DCUH;-BPV9>W33@9#7
M7N$^G.-'E6^$U ^#H0YN#.^/D<VV1$%DHGV@VNN_4 6ZY[*G? =]T9AN)_=:
M1.S+<#&S'G.#CGT6-2)PHD/L,2I'76>_65ZYG_P2-X[6(P(M!<6@T()1&A^&
M_D@#S]ED[+G$Z,C(O<E)^XPD)HX#8TOET20?V9=A [I%0=#QRP/+;^P;9#]$
M1#D?,,I'%DX<Y^BF;\<*%X9$D'D" U^2>*95A/RDET^M2/T/'[.P!IT$8[C-
M6 T>K_<=&81S7X7>)O\9\6K9?]G).?Z.R.XW24-L-[JR<XY*  M;R$*'O[%Y
M9Y:_THW6(_O27Z@GNK,B=*_^J*97R!5 !/X:^O9),EO@-94L$"7O$G:69V8E
MP1Y4 S="UH%L-OAS-X>]<L-U)*1<.!LU"VV1O;8[9A+J+]0GE,8$A-W%$0/.
M&VHNB*C3*YU&YT$N$?61P=E,^\P[!4+^>R1-7N:O[V8?Q"D+3W53N_BZ=G5=
MF,62U=6KH'YU^\5:C3K*\_WW.U7*J.R/44V]\1NQ;IJPTM[\!U!F0LI&#0>'
M0YQ[*WY:_L@\W\<]<IMS5OVI -X37T03A#PN)^CP!]C-+GQ/-BK\)W"G7@[?
M\40C:Y$!Z9[]@5T^%_3+$Y[:?<#?-'N.3[X[ GH?)^[E9C/M%9"D@:#NET.6
M76/W.18\=P;7L&X.R%Z-T6\N)%;H4GUB5DO?)Q@P) &B@XY:7#&<&-TJO/<Z
M.+V*@Q5RYW?-K?2F?FU#V\^%%?S\%XH&I?%@Y)AG8?/U8(WX)HKX0S??*;=9
MG?Q)[X7;T<)?*)4IU%&/[P,\N<T)[!/;/ M/!_@H6/$/7W9SX^%W!N_.$GQ%
M'8N5@T60/0(GSE56Q'9WWB7[XF5U*1-%%C_X-;'(0^3AEPF=\B\[%Y5W<CP>
M55>TV;R?HYJ6X';?$?V]>=#;E4UQ1'R[$/VTFU)UO:",NY?YCCVU:].[93'S
M/ NY+!Q X;;$@<]74%?\/G>U*Y*YHB59_@UH[Z]SSBX[*_L>/Q;5M!J+O%7$
M/O%M@ U-H.[HX9>/G@CXR.%.ZS\D*@&B1OW,P[%@Q2_TA0M"?, _'B!'?W$G
M=W&K^<BV#/</YD;\9&HI;<0';[(WXW"AQ(]?"B\$;)<>)%\+#<E8CM\=!NW=
M86:_WIB!/*EB4 FIP'PO+S==31TB!S\Y&82\7]EBD_]Q6ZI_?)LZ5Y#([M+K
MBJ)P6^Y5+&87QO,(B&0LC$7J>B!WK2G(MHSQ%^K'.W]1 1^:VVZO@7 '6X&[
MG#V"_LF-MP1%]P&WZV_RO_ZEA_JU$57&[AU1-+3UU%#\JZ=8_,12X%7,OW:C
MPIV_QXB8 (SFMF:V=T5E>7WYD&4>K3LR3SLC]';TCUOY)^((OIN._X]:MOT+
M04YTL:)N*J-.<&3^T)W$='-T;5>Q*C3&@21YGO\PX_IG '@^")7U4ISU?1$5
M 0HK9D;D+4 S<Q A@$;EO9,YV7M$B'$1JTMI(RL$,&<]"!7MHKI==#X7W?L/
MY\(2?3[ER6_.37^.;EHZ%]T-08,6#2"5U$&3/;A[6K1-S$W["S5RW?*;\0_^
M&=R?Q/NIE:?HIM<_ 0DBPK$C/^%D+T*)7^J5LP-N-]IGFT<LZJO;? PK'9>J
M0Z@<,F*7 25FEF$;>=/MF.F6-Y;$C? F!N[P;+$4C,-.!1CW$YEN,9RZ9!I5
M;%1B!DVKZ<3S] XGEDIKVVKZ52L)!UG?07L5MX3]WBDE>YAM;!4K>BR0Z >%
MST-<R8KL.3]-^0NQ!2TDM6B)Z='[J*5>$$*C"0(-9F^_+?/Q"%KT;R*AL5DF
M]&>[5X7T@@Q#.KB)QA?3JQ0G$"T.B[@.<>#7N#R"B9P6%L\)C\030\HB*318
MFVB%H'$D"XPP3:IP).5"#C9J2S_967J4E2TP12R$?;W[+RNO__N-L:#^6<=I
M^%C7/+Z*=/2A_\R2;:'LK'GF>A(2T\]EJL_.R\->/6'+38AK)%40UH_OF1&M
MQ8.+!BNV-()292SN@A0G^U:+)W?"FFL^BW@6QPB5'9+WK-BJPQK-UHB>KZ_(
MAI>!3(/W[\4\ 2".8,FA1/4.^9H'#W6I-;8G42>QW.)Y65S!X#>3MM*=3C-E
M1NH^+24EA0+LS7:FJ0*DJP-R.)D$!@7M^<KOADA3,8K_9BX ,6._66,FX8X7
MD/WJ<$X>:/U,=BHCQ>]RO5C5R$UNY<V@6DXVI>1/OIS&]0;#;2B'^5GA-N:F
MOJ:,9SV,E_]\VJ:&05JBDX"GE2K\IQRV#1W/_)D<.WA=P=?U/ATSQA'#<)\=
MP]W3-GW81EY0OZ@C4?7S:W2;IT6EY]I+5/,8#NQ76*HY]&W@OKF='GY?2YZ^
M;S\3CXZKY9>NF'3_EU>L\:;;K=5:.$?29*4Q(X'U9<9S0A+*%))Q%6D-]MV)
M%$<6'/XE/ ]0QU!DM:O)*+ED-*P<F7:TY]A/2?J<$N(V6^9V6?:\<1E)*5D/
M.D8$;ZNG7MA6M:6!0MFY56NYP\Z<]T1#&4S<H!RN[J0L4:4D5C3$:&F)@OG=
MR%-K80I%GB%HV5Y!47FL*@\GUBKXAXM3$-T\XO;SJPOMLH4[XY>I+&]+J.K'
M)?$-G)0=@@<9YPV*2]^VJES1*X+OL:@%G%L3A&$'K.S7_O[*Y5?Z#J)<O&0W
MKX-MK6^U?98J\3N_1K(QQHU<C7[G,+=\U5KQ%X4!D_R%JCL_G\@1U.UQDAVT
MCT'EG\FM!?K=RHC.[#,-/3\Q?M76CQU#&=SY9S5ZS1OKS\#C#O'C#C5T-J9+
ML^>(*&M!^9HA^  %,(C)_A<*>FSMV]=+I2B23J^)$#<9?M3.^./A7)R4U3CA
MJ=4 OMW3!T\QY%RR/DLOXL0H-,X"_EC/4>F.D\*%[?J5-^MST=XWN,S6J[]0
M#P1;.XM?7\R#<H_\ XRTM8@JFQ_IU@"#R!YD<&UM0W^A7@E>_5HNNKOI6(49
MYCG:EC3>7W#U2 5Y\WW;&5MS?GBC"E AV!&A(J3*RLPE$?2G]]0#A5XK.!]D
M?;&_\?2^Z-X?^!#ENB$*>,?#;Q"D33*WXOPG8=7Y+]3D@Z>1UYL9 K'K;VA2
M_AW)K/97ANN8;[QZH(GWWZ_]\?!NZUR"%NVRBG&-$23>B8H?-_)YI4WO)WV?
MYD9W(>0ZX%IH;?%RPM4,;FWE'7#^Y]?W,<S.%@4$M^M7/_1*.!_\A9)86_-;
MVA\XN(N*GQB11$MTS95^3WTJP02B/P1C^*Z(A-?FT0@&>=C(4LW&WV'TCF5M
M\V.XT@,]_L%8#;#/77VW0<2XRXKO:L!KU_RJ0%EC<'R#\Q\FFJ%#<G9B1S9O
M/'-$_:+>5K^VX$\AC0H3VN7":A)5-;\!2 9C<[OWSV.%GG3'_?]"B:8*4&4U
M_%K^ R>G]5C5_$3V0S^V^^I1:&V#V"NV;#268N-\4,#5_Q?;MZS,M(LSSZ#W
M3G^A,@1CH G^9?N@DTVL+C078^N&>#,FH%0PQO!K@T1KFP/G(PUD)X9OZ?S\
M292US]@QU_Y/R]R^T%O8 7,ML3<)UCM=-^]=SCFC3F\\S?BN_TCEO!$,_JM>
MOEO/W>6*=]D%C)$,FC]^)3V_.-BY(XC]\#PX(>DRNWMSN&[S#L4?0L%8X;]0
MF[YM^5W"3W6!_!??)Z@&R3'&52;.UFT+W5,VJ'%3=D*$_-%X/5QOWJ"%1&M[
M!=H'<Z=D^E]%S#H/_Z$KMYMD\&JO86V-C#B /?!B1\B3?T>-#._V*5@E8L0Q
MZJ40<G4M*+2V[ONU2@^?+F;G?""BQ5999?\OE(5Q1)OC.*%^S,Z$55L;P=F!
MF="XZ&?A4!;_7Y*NJ6E[#T.UB.\C[-S(. _^2_=7R!NTZ^![6K%#?IAP&R/\
MUBI?VV\('H=6<%Z]%WT7-?2OV&W.6!%_O>Y-?K!Q'"-6Y//G@[L/(HQGO_93
M=G[="Z]MQ/&1A8VK.._%#Q$0,/%;^:?\XE&): ,]%4/.72?>2?TC]!<*(YW@
M<O,OU.R[:%YS1\[>Y^$\N!FS$Q+PBN;I.0AU$XG[]0_G;W+7?W7K5#C@0]=O
M ?DSN1KP]AXF7D6W>7L/HF))_D'QUX+</RAL3JUZKGKXMM7M?!/]-FI%G.-%
MR@\'\ZX9]UBAXG<>GOZ1)*F^\-K4]3C:K -:@(B8"!],C,O--<;Q!C<SAQ$F
M*\]JM(^TUH)R<M9WO *YY5$WCDKYHVY@">$$ 3^=_2>H*FJI'YA5I DUB1%T
M^ZSS@8SE:2]]Q[MQ@LE;AB,9&PT\.;MK#US%#D6+S<R>./W.OWG+ZYBX#V=Q
M+3XR17BN5<!P%+)SHQJI*00BB!,&65O-LP9)B=T-+W0\V29[!'I/$Q9F E/Q
MK3B/8"P5SH9#6QPK!^UR%EM9]EJ:0)[0[$,@)J6#KTS5KLO:[M6NP!H;S]%V
M41?<*_?;&L)$S$T:U>E")7&3>$SGB5\40_HI0CZ2SA2'YDH?V\LRSYO<QR99
M01RWK4,U2!4O=5S@<#%]_T)W/6V*3,B"A#IB%#L.+33*%"&OG*:LJ44==S #
M4HB&@X2+@%V._7J$WKI;88XZ\<;QTTG9?]RYCC>"5TQ;'P[::=I<#=5L##;*
M"CE5(+1)]9Q2',6.@!6V9@FIN4QWQ=MFUY^]HYMC$?X9YO1Q5KX!F7-N1R9#
M/=Y/,NZ',=.(#0F@W%@^9;$]V4'7#J+!)0<^!J)TW>8XWODA8 Q;Q_6&,#DE
M0,)_M.P.&"";8GP3CV-/0MJ8*9TSPYR0;K=<[OLN3BV>X*;WSP+#CPH>W*FY
M&NSH\?+Z,L[:"FR<OI+Y[>%$0B-3(1NO<*<XTWPV0SDE1!@&3]N$\%D)<9/N
MM##,!&;1+_Q34<@M(<U41[SD=IC FIEXUT.EQ1,55= $EV5U@SJ53]Z!QG8A
M>2OSAS.5X#CMT[L\B:A29Z )0'D*>X(YGS^FJ/2>W18>:E%_(3XO7&YXW6%T
M@QVOX-+\E*:H=#X#-0-09S$\N\@E_:(6+$JYF#]MUGBH)+YOSV6BNM.?F(%N
M\C.C5J>HN#V0"4I^IBA')8S#: 3AC L'T .'8 N)Z=<:9V);5W34N=&#*RC_
M/[]3OFYX4S<#:VJ*R65S7$??TZ1UL;HYG17!"BN?BZ=G1Z$E'F6XS8SE/*C;
M>P##X,96DW>V:$$=F;QII(CR0X-!BTYHB4HBLZ)DZHA"BQ MTICB%X#HE,MB
MR;)@I5UF*D_.6*"'I[/C@^VN!$E:A"!CMG$36*KD*L&Q,?WS24@60\^ 73=$
M0[607G$PG)"8FI%"I *!&Z^QOW50I#'M:_HU6OH65T&VC2!2\RS*XLBYLE&=
MD&6>$5.TWY&2A$I0TG3MIZF5$TY'EN=MNY/7!HQ:MEY;R6A4:6*:O%_96(EV
M&9+6-BG *W_PD5U61<HFYQ'W^)?>^L64B))_5\OV>0-N0.6 B05@<\>4[P'K
MV"CD%O97;W];/9%Y*SO+1S5[@IJ38E=*@0O8N1J[K:(1L"*>OJ+28"B[J\GS
MXY<1H+MXY#V5\SRP*,URYD0S/B7NU>?P3\J;QQK74KFN BO/0)%66=7>RO]@
M[2VCX@J:M='!(<$)! CN3@@>+ 1W=R>XNSO!'8);<(=@@UMP'630P6UP=[WD
M/>>L]:U[O[ON]^/^FEE[>G=5/?5T377OVMWJDK;*%5>STPQ7K=B9RL.)LA[O
M).G35.%8YP+>>46F($M/JB1WZ3^RF[+>% 1_=[U'M%29^/_#M_\O'_,KAY#B
M=8:/L%4N7-<.;J#O-?R$##\$MNPP;!Q.G(.,6B4J92PKKXP%C[T[WW]G0&9+
M.[V;QY9R1J22I $HD[_/LXQ$/&'GGC7>S%MO2/5ET;?H;L;$D]+&8QQ99:-S
M^?B^3NQ2XU<QPD!6HC50$[751M+I0);F4:ENYN=OL'6O,K513R")Y2DN2@@>
ME50R-:9B*=](R/TS&:]J;29O.EMEO6@$NFFWRG]Y:2IT.].=MW:?N=&=.D2X
M>LULYF_<MQ]"3(?9C;KYS;9HN)6'#:'4EY#CN9]):#:+GP_"T _^/*B]HX [
M+%)2<S2FBUE\\3TDBG<!9N\U9C:]9VR=Z\=>'14D:$*OLMX^>044Y/4[,DRH
M]T8MX1KB90_V>R[P/<U&]BMYKJZT"V39(M]:WOTJ8\#$5Z*@6 B7P(GJK6^[
MJE@R+U=_2<T[P;T&9G+O _([W>Q)H$IV#*LQ=X*1>QRW"&["O5BV,H13P+;F
MX-;=BCS(!WH&W[\Z>6W,;N3]L6P$NSUAV$2F.XH6EVA_S0/O%<MR!02WN$><
M_"M]<=6WXGEPOY<_-K)*ISGF"RO1(U>F_8VUBGB'^;/G)ZHC*J:3HH34WCOZ
MD8FR2"?$*O,BCUA%U4H2L^YIQJJ&<>&7Q7:,\16@O^Q)P"M@661C \3_]%--
MH-Z#-!-B(W2_XSSXLDGR"IB%Y#Q0>)N="7$#%Y=? 4S58?;H GWK]UFY;:+"
MO.T8>#<0(9$1Z%/7-FT8_]UY]Q0.A#OPO@T(VD^>? 7\"7YZ!;B%5QQG=CVM
M0.S#+D:@+[G;I =3N&^"B/PP;.NA=Z;.KX#2QW _/\+_DN.V^/RE9:O[QSVR
MCW.N((>8@<W*BY!WFRU2[]D(-.&AHX^$5.BA04S!9A5I]P3"_@J0K0[<.KG%
M=-L:S$T)SUG\CTZ"!J'<(H^^_:\ [E< +,.CV>G;M[>>V5M> 3<8#Z^ "E'5
MF_%U/[OC^H=_"AR17O\KA?IW]_CQ&RC5_J"7[[[+ST]H6!H0;O_[#N#:?C+H
MWOP>Z?;^]FP*%W[WC%\'8O.,P9CW"C 2FKDZ$_W7G;WMO^[>;-ZC3;W>BSC.
M['Y:A1B] D",O_F%]LC/SRZ([]?_78:>>=NFGSU]:<5_%@H(>^@\.D_\9^@K
M8/<&XE^L(73M=R[XXE\1*YFSV/8*>//3FYDG?MXD0AY^'M#3K1SD4EKNP,TW
M2*_>L+]_WG3>&"3U^ _VZRL0\]$WI.Z=GWY>OM2T)?Z/\4L>3Y<M6[E[!/\!
M_\W+MJ3W6\Z@E\W8-[]JC%E$YCN[OS"O %_"DD&O #[,O<C_1L/MZ:+EGG;P
M'AD VG]+4_\#_)O7BS6^.3_#"U4\7(GBO!GT=N>/WC<X!@6% K+.;YWS:8'V
M<#T=_X@ .GZ&?[SZ7P!ZPYOL?B^R\S^V'0/-7])UWR[=XH"@@W[>%O\CUW?U
M7@_C^!8G%\SQ3\+YV[T\9YYZL/P^ OVDK ^/AI'%;QJCK0"?+BY:GKM^^WC<
MWS_]%S&$@MML^!WOS)T?7P'"0C.D@LA%N_SNT;UN<O8MXMM)\=3?\Q"JN#D%
M))#@GF-4''X/ON.'AA@&!V']/92,;%"165E?G/L\(#:<A[K[VTR 5L=O?P6O
M/PT(>@0^IV64U!]G,H^]N"FH;']4B9"VX_ATKH<NN7]MR1CQ**W.L%%X54S^
M,SC-$L$!#!WD*M&C&?[JJ9>SDY7:P;)Q5G2]C_$# D'07N'X1.^WZA98&88@
M7?2UNT2'X6&\S;*:8H4;J-;=-I<BDAV&J*V);*Q?W/00:?:+KCD"L]AR)5=E
MU2IZ5&MQ<?2AXU,EXT-4IS?=3E=BID^A?*N85_Y%S=*#2! SO53>+ N.] !'
MTX<=X)_\O@B4E5.;QG37OS[4%*JBWP+4?XA'"F10[GO=3V3_LJN^":LB7O7(
M[*T\_N^E'9]^+^6%3*$PSWFGHCR=D:H-![X*FXK&[YW@4TDJ;6:W:I"MUD)(
MWSR?;4 ALBR>3%D%@@QF?S.V/0?KDA$(.2J8\W%JK6!ZQ,+)#XF+8[H)VF%;
M.*IBV:8-L?T2IQ=E4#!C@UM0/%5Q;J+KHJIAX00\;J&GVQ6#6:?15Q[*"D&$
M-QGM@&6(Q_EX<Y$WH/U3-D1P;*=//34BJXC%V^*KI4>!29W__TE!C%CQ4BCT
MEBCF3#>FA'\9ZRB++QSL(+J8=*"7L]0R-[%)6MZDZ]KCVO>S60'/=[<)A'<T
M>L_$#=[^:MO3)-LT0HV%L;B1[@$%(T%GOO(D(U_BK%P4AOHDQ^AU0KIJ/[F[
M"%G/[X:YETM>A2P>MRN2-/+1?[.D*+#<9:TJ@%0M_Q*QK6[H%QG0.R0YZ@LX
M^VQ'U$[@UD[)S(S")J#-%$O6-!S!8@+F"IDNMA Y[(/!4A2.P9-N/MFY,WH0
M98HIJFJQ3K"I>F[@]G*33U5I0E-<%>MIQ,JP"RW"RG9<PBI>C==GMRFM88@9
M36TAY[JP,EA<UR%']U7:R>/I\475"%Z(WF#2Y-MQOBH@C=?A^C]9M!.+UN#J
M'Q&JF#Q1H]]WR*B)9"1I!]LJYPN<.-:MJ$@ZBJ"_3S>BRIV[#W-/92%BHRB'
M>R":-DYSRB<:0U;>_:)W*V=]0&.A[;)KW2=9YJO>FM$9^S[)NO+Q85;S$&)]
M="D-/3$=]\T"MG89K6B8#2OKQ#^'CRS=U']'.VSR@]:78T2B?@IQV$\\WZRE
M>2Y&* A6B+!*$&)Y3JE./,<MHMCU8E0>!VE=;ERJL#-.041M3XK:F@^R!W,=
M\J,\[$@VD[[)F&F'O?.[T".NJ^.:.ZD84&75@>?(9U]*("7)QS(0&W61+Q7_
MV>(B,FNS$RNBGBL%5JVT=22 ?+[8+/[RWC*#*4E4GZG#.)5/B%,FI71D3$'*
ME!/EP]:<")7A=6%P$#ILXKM!?'5T*;C*0&O/;F<U#/J*E^3"3PC'%N73Q;=$
MN5B949:V%#UVFUW6MQAVVO:I6Q>+]:<"8[5JT@,6:!HJ)-A9:(RDCO^6%!]5
MV7E&/F(3>7O;K;X"M!UM.4?#6,EI80A&%4BG(K.$V=$0<Y0W[J?5QRH9Y:8'
MZH">OQ]+(T>/2VS3QDO&U3C#<!(%Y,86;(2#MK*"=EV\;JV+M=GSV';)9>5%
M9:<W!J2-R7!EOT59T,W;16^*@?0QB%?U5K*X3%8.)L2UVA2^_N<-7,U%O673
MW_FZ:2GYKD>%'47;93B-TOQ1:C.J$6(!.S',3,N1.TX]\9$3%GTQI^_]F"+U
M+['+8B/"&5$B#LG[ SAP]&B\O0-X4@)XV11->[$,R(OCLM[;^U)Z"[?$'UR.
M6R?N94<)5T B3;Q<M4<,N$*LRC3;ZM'G^LM2+8 K-S??C?;1+H!)@WO[H1\;
MRJQM!F_"I4)P+?!*>-M2<^ $>2U^5_!$(L9R0N6+I4I.&6U.1F;;\KA.JM"[
M!-SVN2Y:AR+(K ^*U4VJ(:Y'^XW6Z/2>KM^M>WV&E^9_KGS1,V.2W*EE1V=J
MX$W^*1%[539\9:6V[YXJ'O:99)M3WE,"V30MX__MJ-B+<C4";9N:!GG9D>%1
M0SALQ^^$,*"( Y0+,G?:/FS.P?-/1K6+66*E5KL_-6$MK":UB&") FZ-O;?D
MJVM#$?[\P>8F=#N0&6Z:OLH0I0LO&V_NZRZ:WPEN+NL5MI&(._%VG>721X_3
MO4A-3<G*8*$O\PP_IR[!063%Z/66,.ZS-V$U\(GO-7,(D&Q96:'PW3R(!S<2
M#P/X\(P1=(.T>NN.-)C]5E?&(CGKG)06U1!%U!967+A+&:I=>PIYM:M%.Y:J
M/7RQXK&/ LXDW86CE8T9+#]OB6*=-8IVK?+AP.%]&N+)#K2_<S*=(-WY(<$L
MS\^RED8]S 2O_"TR49,#*4C+ZUC<-,Z"5[>&"YRI+S:E6\E#S"D%GL.N1P3>
M2,O$#*B6SJ#8,4-/QNB2<+[L$IK)UOVD0LYI1?'WM$D+C$.A3L,)Y[,G];SQ
M<+=@T>K=97L:HPX8#,D*=(1/3UO]T;IK_'[BVZC"B*JIZ%C64&;@>@MGB*MS
MP/=$<8_A?:GCK.W 6+=>ZV#;GT0\@>GN:-19F/@I;%SJ612#T[IRP<([:YJ/
M/%#\ 6>08^#E\24_ZMTA\V\?VMFEK>OH&E&L6X/B^O_#)PR:.RWE49O!1M6F
MWU=U6ALA[C,Z#A\EFYAIEYB# S=%QV#T[12)IS3P.6DIN;%(F'X-:I^U?T"0
MZ!-#G=.?9R\UOL#C&*7_'>3\!Y8B+@.L/FXKP#;OHZ,6N!?>"&',^4T^J%AF
M1[AR@@V>9ZG0ZL42EK)M6ZJ\8:HXE_:#%U4*<: AIU;$^5"&98PO_3YC7^ !
M;E@CR@ON;Q=_ZB1>9)6R?DS ]$G'=54G;F?VB58)X]0@.I2[2BV[P^T\=CQ!
MQRAEIF$B[#U;+;O=ZD1S+=Y4*/FXA)R8(KFH^R.3RZAXFD3]U]GM=KV[=$1"
M.-$> LPYI!$%&8A<"(1&^GBGQ1!R=^+U.&<:"K('/E^YR4>VS<YC-2^G_);E
MS:JG3PU-F_"*-F%@%J=CBQZSF)(&JQ>@8V5\*4'W>61#\<1-M*4^F"_JOU .
M_4\DT<[LR!3R;[Y=-'>7LB%7MF6V+$SC@&2Z9-8@$:(=-XCS*;$#I4]U>&"^
MU(@)QYS:S'9&IRTF9S"))8N$]_U*4;QJO/+SRY%&(95YKZFC4'[#ZC=YPCQ5
MHWB2I7WHTY7^N-G %VFGR("+D!^CUJ@>4X ]RVGK(P$[DM]]&+3GH1N.V<?I
MLCRO_0OY)WD(;1BQY1SXFQACM0_:THO3'V?[E]#1*'-&/,3OG./VZA#UZ]X_
M[^,?*GMN ]1?_G IKRPKZS;@_?UAAF\AI*\A7,*&_F[3:\%IAO458,!06H])
MCG1H*T'T2'[X3.?RZ+C=&74E9M=2>GX(?M=((=^H:C<.&F90)G:+;*"IE0O/
M T=$:(9@?8M!+:7G(?@+%I;44$\^[ 7-2DL1..ZN,:L2G+V<0C^5+:?N9]<)
M&MS%\+P"1++VB>,Z#>34<D 0H>J(LY>SP3O5$QE!H2:;\+/!D)A7P.?+TT+K
MU;AKY7\%$'@PJ^R/Y=P4XE+#V76\QSO7Q(%; QXGO -8G-?W@]2*"TB!KX 0
M^>VVK%R;.L!6+T!SV>ULZU2@/\;+%YP+SBW\#7GLBCXI<=(E18%0>#R^%(1Z
MGEV<'W%2LJ^QWTK-U"P*DJ[<@_KEMUNV'B^&T'FV,4J/X-: @N9)/ZW7!$E\
MCF[\EKW9^FR?-P+0#[BIMQ6:M"A\>$G#>T#.ZR@ -WY*@RYMMV&!3)>+2[5/
M_N[GC^7NM.L*QZ/DESR#8'?*7GYLWA.8J= .*+\^L"II\9'%0!']Q=]5?+N%
MY^6I3BAI%PGL!MM5\\*54,7_<']/+^B9X5*=8Y6+<7+Y"GB7/8R^'#%*^9RK
MM##AIQO OAR#3/A@0'OR2Z.UU?<;/X\0[J?$H<%'X-#6U0NEY]D)[S!HG/ 6
M-)H,?H.W/4_C &9MJS5[V/,5X+N(D8N/QX.*#A"X!SF@1][J/T;2V1WI('U2
M*Q/0J-*'M+[\4GV0M.=7LYN5T.3?I""<.Y&GDX8AYY6B+=VAYS]4>Q)NXA/X
M1:0L(H\'[R>3:B/*=8V.22HN9<-BV -0B_# []@DC/%*UYR:"0;##!^0X=SK
M!L9+ *X2OVV5_LAQKN%]N1P,PQ&4.P,;E9SMN0;4M05+\12J'; C!)+NQN-W
M\0<&B3L/D]W<7P"&^$DII(@8-?T]CU'8D__4A]*^5!4;<B1Q(I6M]8NS]@EL
MI@M':H=_\/[P_"LIULE'2KD6&IQ%E(/S]]LL"7A)T%/Y?0OMK6%MO$@;YG;\
MP:GQR)0[$SY/,#; )K1%R/98)KUOJF"^[';ZFKW(W BAJ',RSG9#:5^DS/ G
M];P=]$,A%16VY#NJV%]$<#52-RQK>&P='5$N2>T 5'Q;%.>3#?.RU DMMVAM
M8>J+C_&.^$D?G(XFQYG>'.(X<.!.J& H?61N<T-YP(_J%]<&;=B\#?[XT?%D
M-.PS7#?N9[,#EXX00GC.]SD(P>PEO8]=3V^,V7HYJA/B]P^_?+'Q.<^G!</U
M/I5S4WWK_D?Z]1S'ZT]!WN[\V\'=A.)=?@W'OQZ@:Z)W_NZO@&3Y[6:DYT43
M[[=9.-;R+24M#\!Q6Z/U=B7YC=9/+P?9P]#<6]L$4J'WQ(/\#CRD%9+S]0/>
MR+D8IZB8W"HM+,XOQW4$]_[A,[%LH!SO6QK"PTEEOW1PV4(.Y]$][9MR0AM*
M+6^QH:K.H""N](CH#DKEF4W)+KSB<V"75&)05_HVN@9=^1+?YMQ^BSB#+P5A
M]JQS+E%"0N#R7$7TR[6WG\Z/>4WXL%X!X1L76T3N2 (KMX+^J@IAMV'WJB>2
MT$YSFS B#S]*GS/VG@$%/Q3<-[U? 3LJ+?S^#\<)H%BA/O>5'.==>5[QCLLM
M?E[:^IN-A8SLKK:G_VB?"P%*@,BB%V9 0X8>3AP126L\.VIO;7)V$ +<[TX*
MG$2B_?VT<!X\:WMSKXX'$LRA#\DJ&\^K2/^)25EU0D*DI5M;<5.WAFT@Z J6
MQL;SVN!)V7*N_ULH<.L!O )@EG,6D:+OLE 35 Y@5MG>!C?U8-9.//\E]$>L
MA* 0"P\^K>MI)_TUX T AIAA1\C-3L+V+?2<&'I[QH-/9;GFO((C5&.[J/KF
MK<NWNVE\ZOE,_,SO8[:Z'7/XGJ:JNRPO?N86/A>,J]H^KPMMJ+10. :F0RAW
M_7>YB6LG4+:(+_)CO*&Y;O^JP91'\<(4[2>I2V=+/N6M"9 E(\SK1=KU50U2
M!54W<E'OD+LZ\7Z65?Z<JRDA[>IA#EFL +>%X&/K:QNOVCWAD]1,MJ22%UC8
M;KWL"S&4YK$=.YL./'BK=_PJ)Z:OF\T3=6DV \,(:":E1GTN+!)34E#]7%T[
M%^9,B%H"/D0I!B+2R9&@5_8< #1C[]?DZGYHEJ!O,J3L7L\Q;W&YM2'THJ2,
MA%[J5J%KL;,1N:-3+-F5#7A7Q;"\*R!8]+R;^0RF^=&3\CU%VL1,)QAG+L?Y
M!P-(W^:ER@*F7$3N47I5+:URK;:I7$ZYO&G1N3FM<PT[E71/;5D\IMY<7X.S
MX:814.-#S718U7K_984:5OUKA+YAN3[#F9C?[A?SKR@F#5U,>6$X, >[[\;T
M<#6SVYJO)3_9MEK^7CEXCJB2XT;XFN[V:5KY.A5'3J8*&27-5H9GDP*^MYP*
MMEEQZDO:")9R<A%^\#L.MA.FJ?G6U@SG,?6XO W3LAJ)\\6BEI4?(Q!MB6/!
M\[67<#GK\1;S8RR00^Z\&@@%V.3B;<G<[!ZSWVQ&.6 PVYO5?.3MEN9V[ ?M
MU=7V*=QF8S$Q+65:MD_GUV$HBG*PBB@(+?9T8=S345,K8+Z;(TV5WU.N,CXB
M+6PML*@:D_Z;7?^H$0]AAFGR3MS_.>'2. ^[S\_JVMXEN^N-3>?10"/0E]94
MCT533-$3I9J6$DQ7ZEA\/IYUWM& ]DZPX%#\WA.WCKE%13?^N(B^7Z>LC4QQ
MS264_?QGM\_$6#,I,*9YO:D*,\KXQOUK3HUG6.; ^ZY5NAF6?CF6#Y(S6/NK
MG52\)O(32OVYPX>>0TB5L&.8L;A<52[\>LV1E17_!W/J'YU;#LS@$Y67>V4>
M@;O(6  /B4@648QU5WC72OUM;];S<7:NGD3YO:T@*C.2AV[W2M^6?LVN>.<=
M+7P.%(F2=SLK1V4-L'[[^&W]<MM;(?H,0'HOHBFAP-G?=]H3 ?O%#8<_]S.S
MLO.3_5T9RH2"P(-SK)-C<'0TP%6A0W>S4F$ZMC\D&ZRKDL.V-DIP"87_ 0?(
MV;Z0=W"D0*U?&QMBES#*Y,FS$;*_P^NH#9RP#LB!$?J)\Q,:X!\S]-@#1=*O
M.F+]B9+]E+DY*!G?C9H^[/#1&!F?Z#T[CYL/;.V7XQ\("I%'_A(W,38[2^^5
M/4M;K/(M(O&;-3(@VN'8[*EH$$D[BC\A?XNKJ3Q&8I2CT(V5/U@X[(6+>A0Y
M;#9_<MB,-6;@B]6H 1?DL]7<3/8MME\PXD5UH 10'Z!8I>-F;6AC<DL9,7PL
MUK!O@&1_RVS'?8?L)%-/E<+@+/ZS^$ /TWI$666,(!0D:^$H:IQ6&AE 7D-6
M+M"\]@<4WPJXN"XMO6P3C@2+L!+<M@O4Z5B[B[1C6 ,7\W1*B'VX( HHX<F!
MXJ[SD31>U)E1@>@4>DI?][ V\JDBS11_R8CNIY/\R3<^_Q/[]D>BFDT,+=J9
M4.'@TA*2RTPNDY0&4W^[\=QS@)(G+3],XGUP\. ]A08A;\=(;)$YX]TS  3T
MKQ%U,JXX_O='//XP!=?5KLW6'1=V$KL\C#.''UC.,&]?!C%4.E?7[=FW4J/J
MU-@D8"SJ8[X"4. ])O/[L01D>:21-<J&FWQR)KX0>,:817T,X)&I]4K09/[&
M;FYE+9RY-^[!;4-\MM1*4Q7I=MN,U+'BY*N@9FYG:Q<,I&.YBXBPB5TE^LZ$
MG&"D ZT,]\W+1-=>'*EFTA3_3MW.$ 4_=G4%8@6;C73P:++O9Z]:](_"%HT:
M[:TE&9UDM_C$].56<6=\++MMUC9)=BFG!#:\ KR.Q9(;;CG<B98V>F3!69)R
M@^PK[+#XPCF>#("==XIRLM=)*IKM%TD_0H>+)V'"&S$60H"VN$JNXQ;RR^]]
MCDQ'\N64=#_T*T^'8873(Q+&*7?8MQW*3BN^4P'G%);^^@WO$BM18R!X/"[L
MUO29<-)O8Q"A6JY5.Z9?YW[4URZS30 BN'1,75G*0UMFS^6VSV*[$T<@GU;O
M2(Q[LU*15@M<-5JX]=RU=5;0B7+TS5>FK#;FD'3'R>?'KQ8U>?@D-2>OPA0+
MSY?[9QUN)B($.(YK(+B:Y)M=GP52C]EN]":!9-\US[-H#7)[G.#.0:I&EXF]
MS(S2ELW_6H^)!EJ2'/&VJ/682O,9"Z?$". 9[^#54X @EOYV_G'J(ZU=1;:$
MFO1K/LM..O9+R;RJSS7'?Y,$EV3$G;(-JZABI'Z'SBIE:3MC,H^*ZYO^T8X<
M28\L8D:)#^\/%Y42$PZ#WV5J4/XS0QOQH3'L7<!N/T9F0Q"A']CAZ>]PU;\]
MP,6JS?$>Z(Z/=T9L+GQ;*$4=QNLL4BG2]7SX=M/.<]#ZU>-3O6QM *-9%IU;
M.NO-,QJ$'Q@3&$E0*]3FF:A0I4S*F1QK7*8;,W38"5*WO,ZV*578D!M]Z>>
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MW6AZ+*VH/RS5O,/]TR736N6=Y-&D BR.$1.26OR4:DTP]^X4;:#-=P.R,M&
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M?00\F8Q6[=%P*Y 2GR1=8S'0#FRO\[MSFQL/+A]PS-3VF'TD?V52>E><_'Y
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MLW1[)?IV1954+,GG[NG<J87N2G W:2XI&+I'\?2.(8#V] 4 ;H8]X;0]!KX
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M_R#.T)0/V-/^/[).\Q%H. 1:8:DA;[;-?#0IL'2YT5-0-T'4$&.;8%Q>YHO
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M#EYNWAEOZCO5T63L<]\GO(X";KM^&^29::7IA5139TX)E5FE/L#.GX7:DEX
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M.?./-G3#XOV!H^!I#%0O=X'Y%X"';YLCT%DB/AP#3NEE6]?"]P"UVEP3!$&
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MZ<HU<&02 I>ZN1CMBW/3DO]QMC QIMKA.;(@(A.>;\P&OQXPD#GV]1@%HZ-
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M!D4 V8VH2*O$%)EUZ"R=N:GOR%9NQ.[*)HA6/E_Q.!6="H:5.D(LL,?^2D4
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M.=YO/QL;M-6?H8QX,"1P#H;[CN0-3SA*7":J[A8%:!O7?>SX;NU:=LQ5>>Y
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M=6<S;^W$.Q]IWH\ZTRCFXC176(4\[L6':3' J5A K\[>QPB-W7-,PMSZU/D
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M=*>5$UG@PT\ZD)0P&ULUP"):]$'L&I)QWD[^"A8K^1X'N@#FK:G"BOU,X$2
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M.SJ<0_D8M5 I(EK)K(E8E9;-+BZ"T._<8O-GT,%JUXT;8W77RIV'9B8352K
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M;>OW=H20PAJ3%'G,ZE;>UE:#C*C8'AH1W=M6322N;I8A6S?\J'%;$EJ:\GP
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MQQ$=RVYT;\YHP$!H,CL.?$RV3_-NNAMK2O-'\Y!K&IG:\/!:-M.TFM).M*_
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MS*8L='Z-U!^. [+2ETPO #\0"'ZG]MT4\=;5P@?#]"8G7)VF/-/RW4R;-IG
M<U6V\YUKO^6WQZV7T'L','N24$N(+W+)O(1UG9EN01X\QMKI.7\V%3%E$T=@
M(P%B8/;H;\HL-^KD7E"1&M-(!_:*4.4%JB-(VH%@21R4N=^QG8XUXJIL376
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M<38)C!TFR[ M,DI<5@QEQ"+D^AWX 44N\QB1]'&>7#A A_H[H,Z_U[K.+N2
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M*WOZXI^>"TE=,NP?BK.'*#"N/+? V[! ?\X^_PWNKY'K;1)T=>Q.JY@.*D9
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MW:7([Z5_L/M9S"()(+)V;RF<Q*H:=I$-/36"AY7*S([7FE/C^C^3>+X'_;X
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M,#(S,#DS,%]D968N>&UL4$L! A0#%     @ \(.65X^B)V]QR0  < H, !4
M             ( !4<0  &%G;&4M,C R,S Y,S!?;&%B+GAM;%!+ 0(4 Q0
M   ( /"#EE=2JU9A%:8  #@L"P 5              "  ?6- 0!A9VQE+3(P
M,C,P.3,P7W!R92YX;6Q02P$"% ,4    " #P@Y97COFU^LY:  #1? ( $0
M            @ $]- ( 9#4Q.#(Y.&1E>#$P,2YH=&U02P$"% ,4    " #P
M@Y97E+ MFWA+   %F $ $@              @ $ZCP( 9#4Q.#(Y.&1E>#$P
M,3 N:'1M4$L! A0#%     @ \(.65PC1!L!F(0  SI4  !(
M ( !XMH" &0U,3@R.3AD97@Q,#$Q+FAT;5!+ 0(4 Q0    ( /"#EE=.X8SK
M13P  +H, 0 2              "  7C\ @!D-3$X,CDX9&5X,3 Q,BYH=&U0
M2P$"% ,4    " #P@Y97S"\F41XR  ">]0  $@              @ 'M. ,
M9#4Q.#(Y.&1E>#$P,3,N:'1M4$L! A0#%     @ \(.65W2"B</F*@  2-
M !(              ( !.VL# &0U,3@R.3AD97@Q,#$T+FAT;5!+ 0(4 Q0
M   ( /"#EE=F[QW0"BP  !//   2              "  5&6 P!D-3$X,CDX
M9&5X,3 Q-2YH=&U02P$"% ,4    " #P@Y97"^W+"^XU  #6$P$ $@
M        @ &+P@, 9#4Q.#(Y.&1E>#$P,38N:'1M4$L! A0#%     @ \(.6
M5].Z*=(TQ   6$$$ !(              ( !J?@# &0U,3@R.3AD97@Q,#$W
M+FAT;5!+ 0(4 Q0    ( /"#EE>!O@C#72(   6N   2              "
M 0V]! !D-3$X,CDX9&5X,3 Q."YH=&U02P$"% ,4    " #P@Y97 "]"_KHR
M  "_- $ $0              @ &:WP0 9#4Q.#(Y.&1E>#$P,BYH=&U02P$"
M% ,4    " #P@Y97*^%Z'E4+  !+-@  $0              @ &#$@4 9#4Q
M.#(Y.&1E>#$P,RYH=&U02P$"% ,4    " #P@Y97PU_O_Z0S   A @$ $0
M            @ $''@4 9#4Q.#(Y.&1E>#$P-"YH=&U02P$"% ,4    " #P
M@Y97)!VO5J]B  "(\P$ $0              @ ':404 9#4Q.#(Y.&1E>#$P
M-2YH=&U02P$"% ,4    " #P@Y97(#$@PIDP  "TTP  $0
M@ &XM 4 9#4Q.#(Y.&1E>#$P-BYH=&U02P$"% ,4    " #P@Y97I!&^&PH!
M 0!;!04 $0              @ & Y04 9#4Q.#(Y.&1E>#$P-RYH=&U02P$"
M% ,4    " #P@Y97OB:XL*5B   %T@$ $0              @ &YY@8 9#4Q
M.#(Y.&1E>#$P."YH=&U02P$"% ,4    " #P@Y97+37*"J0W   U\0  $0
M            @ &-20< 9#4Q.#(Y.&1E>#$P.2YH=&U02P$"% ,4    " #P
M@Y97+@D7>17W 0"N. L $               @ %@@0< 9#4Q.#(Y.&1E>#(Q
M+FAT;5!+ 0(4 Q0    ( /"#EE>4#+Y[\P(  "<>   1              "
M :-X"0!D-3$X,CDX9&5X,C$Q+FAT;5!+ 0(4 Q0    ( /"#EE<Y'O63-@,
M ,4(   1              "  <5["0!D-3$X,CDX9&5X,C,Q+FAT;5!+ 0(4
M Q0    ( /"#EE>$B;X>!P,  &((   1              "  2I_"0!D-3$X
M,CDX9&5X,C,R+FAT;5!+ 0(4 Q0    ( /"#EE?@LYN1E!H  $=W   0
M          "  6"""0!D-3$X,CDX9&5X,S$N:'1M4$L! A0#%     @ \(.6
M5_/_;/;*7   DK<! !               ( !(IT) &0U,3@R.3AD97@S,BYH
M=&U02P$"% ,4    " #P@Y97[IGT?8D]  ",.0$ $               @ $:
M^@D 9#4Q.#(Y.&1E>#,S+FAT;5!+ 0(4 Q0    ( /"#EE<X6PQQR#L  #TO
M 0 0              "  =$W"@!D-3$X,CDX9&5X,S0N:'1M4$L! A0#%
M  @ \(.65\ZTP97\90  LAP" !               ( !QW,* &0U,3@R.3AD
M97@T,2YH=&U02P$"% ,4    " #P@Y97MBU2S]$&  "C#0  $
M    @ 'QV0H 9#4Q.#(Y.&1E>#0R+FAT;5!+ 0(4 Q0    ( /"#EE<9N<LR
MM,<  &C*!  0              "  ?#@"@!D-3$X,CDX9&5X-#,N:'1M4$L!
M A0#%     @ \(.65R8L9R6D:0  ")X" !               ( !TJ@+ &0U
M,3@R.3AD97@T-"YH=&U02P$"% ,4    " #P@Y97E9ZZ^O@V  #]Y   $
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M:3<Y+FIP9U!+ 0(4 Q0    ( /"#EE=W&)^' CH! "B2 0 1
M  "  = !&@!G-3$X,CDX9SDT=3<W+FIP9U!+!08     *P K *<*   !/!L
"   !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
